DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

42 CFR Parts 411, 412, 419, 488, 489, and 495

[CMS–1785–F and CMS–1786–F]

RINs 0938–AV08 and 0938–AV17

Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2024 Rates; Quality Programs and Medicare Promoting Interoperability Program Requirements for Eligible Hospitals and Critical Access Hospitals; Rural Hospital and Physician-Owned Hospital Requirements; and Provider and Supplier Disclosure of Ownership; and Medicare Disproportionate Share Hospital (DSH) Payments: Counting Certain Days Associated With Section 1115 Demonstrations In the Medicaid Fraction

AGENCY: Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services (HHS).

ACTION: Final rules.

SUMMARY: This final rule will: revise the Medicare hospital inpatient prospective payment systems (IPPS) for operating and capital-related costs of acute care hospitals; make changes relating to Medicare graduate medical education (GME) for teaching hospitals; update the payment policies and the annual payment rates for the Medicare prospective payment system (PPS) for inpatient hospital services provided by long-term care hospitals (LTCHs); and make other policy-related changes. This final rule also revises our regulations on the counting of days associated with individuals eligible for certain benefits provided by section 1115 demonstrations in the Medicaid fraction.

DATES: This final rule is effective October 1, 2023. The amendments to 42 CFR 488.18(d), published at 59 FR 32120, June 22, 1994, is effective August 1, 2023.

FOR FURTHER INFORMATION CONTACT:
Donald Thompson, and Michele Hudson, (410) 786–4497 or DAC@cms.hhs.gov, Operating Prospective Payment, MS–DRG Relative Weights, Wage Index, Hospital Geographic Reclassifications, Graduate Medical Education, Capital Prospective Payment, Excluded Hospitals, Medicare Disproportionate Share Hospital (DSH) Payment Adjustment, Sole Community Hospitals (SCHs), Medicare-Dependent Small Rural Hospital (MDH) Program, Low-Volume Hospital Payment Adjustment, and Inpatient Critical Access Hospital (CAH) Issues.

Emily Lipkin, and Jim Mildenberger, DAC@cms.hhs.gov, Long-Term Care Hospital Prospective Payment System and MS–LTC–DRG Relative Weights Issues.


Mady Hue, marilu.hue@cms.hhs.gov, and Andrea Hazeley, andrea.hazeley@cms.hhs.gov, MS–DRG Classifications Issues.

Siddhartha Mazumdar, siddhartha.mazumdar@cms.hhs.gov, Rural Community Hospital Demonstration Program Issues.

Jenis Smith, jenis.smith@cms.hhs.gov, Frontier Community Health Integration Project (FCHIP) Demonstration Issues.

Lang Le, lang.le@cms.hhs.gov, Hospital Readmissions Reduction Program—Administration Issues.

Ngozi Uzokwe, ngozi.uzokwe@cms.hhs.gov, Hospital Readmissions Reduction Program—Measures Issues.

Jennifer Tate, jennifer.tate@cms.hhs.gov, Hospital-Acquired Condition Reduction Program—Administration Issues.

Ngozi Uzokwe, ngozi.uzokwe@cms.hhs.gov, Hospital-Acquired Condition Reduction Program—Measures Issues.

Julia Venanzi, julia.venanzi@cms.hhs.gov, Hospital Inpatient Quality Reporting Program and Hospital Value-Based Purchasing Program—Administration Issues.

Melissa Hager, melissa.hager@cms.hhs.gov and Ngozi Uzokwe, ngozi.uzokwe@cms.hhs.gov—Hospital Inpatient Quality Reporting Program and Hospital Value-Based Purchasing Program—Measures Issues Except Hospital Consumer Assessment of Healthcare Providers and Systems Issues.

Elizabeth Goldstein, elizabeth.goldstein@cms.hhs.gov, Hospital Inpatient Quality Reporting and Hospital Value-Based Purchasing—Hospital Consumer Assessment of Healthcare Providers and Systems Measures Issues.

Ora Dawedeit, ora.dawedeit@cms.hhs.gov, PPS-Exempt Cancer Hospital Quality Reporting—Administration Issues.

Leah Domino, leah.domino@cms.hhs.gov, PPS-Exempt Cancer Hospital Quality Reporting Program—Measure Issues.

Ariel Cress, ariel.cress@cms.hhs.gov, Lorraine Wickiser, Lorraine, Wickiser@cms.hhs.gov, Long-Term Care Hospital Quality Reporting Program—Data Reporting Issues.

Jessica Warren, jessica.warren@cms.hhs.gov and Elizabeth Holland, elizabeth.holland@cms.hhs.gov, Medicare Promoting Interoperability Program.

Jennifer Milby, jennifer.milby@cms.hhs.gov and Sara Brice-Payne, sara.brice-payne@cms.hhs.gov, Special Requirements for Rural Emergency Hospitals (REHs).

Lisa O. Wilson, Lisa.Wilson2@cms.hhs.gov, Physician-Owned Hospital Issues.

Frank Whelan, Frank.Whelan@cms.hhs.gov, Disclosure of Ownership.

SUPPLEMENTARY INFORMATION:

Tables Available on the CMS Website

The IPPS tables for this fiscal year (FY) 2024 final rule are available on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html. Click on the link on the left side of the screen titled “FY 2024 IPPS Final Rule Home Page” or “Acute Inpatient—Files for Download.” The LTCH PPS tables for this FY 2024 final rule are available on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/LongTermCareHospitalPPS/index.html under the list item for Regulation Number CMS–1785–F. For further details on the contents of the tables referenced in this final rule, we refer readers to section VI. of the Addendum to this FY 2024 IPPS/LTCH PPS final rule.

Readers who experience any problems accessing any of the tables that are posted on the CMS websites, as previously identified, should contact Michael Treitel, DAC@cms.hhs.gov.

Table of Contents

I. Executive Summary and Background
A. Executive Summary
B. Background Summary
C. Summary of Provisions of Recent Legislation That Would Be Implemented in This Final Rule
D. Issuance of a Notice Proposed Rulemaking and Summary of the Proposed Provisions
E. Use of the Best Available Data in the FY 2024 IPPS and LTCH PPS Ratesetting
F. Potential Payment Under the IPPS for Establishing and Maintaining Access to Essential Medicines
II. Changes to Medicare Severity Diagnosis-Related Group (MS–DRG) Classifications and Relative Weights
Federal Register / Vol. 88, No. 165 / Monday, August 28, 2023 / Rules and Regulations 58641

A. Background
B. Adoption of the MS–DRGs and MS–DRG Reclassifications
C. Changes to Specific MS–DRG Classifications
D. Recalibration of the FY 2024 MS–DRG Relative Weights
E. Add-On Payments for New Services and Technologies for FY 2024

III. Changes to the Hospital Wage Index for Acute Care Hospitals
A. Background
B. Worksheet S–3 Wage Data for the FY 2024 Wage Index
C. Verification of Worksheet S–3 Wage Data
D. Method for Computing the FY 2024 Unadjusted Wage Index
E. Occupational Mix Adjustment to the FY 2024 Wage Index
F. Analysis and Implementation of the Occupational Mix Adjustment and the FY 2024 Occupational Mix Adjusted Wage Index

G. Application of the Rural Floor, Application of the State Frontier Floor, Continuation of the Low Wage Index Hospital Policy, and Permanent Transition to Cap Wage Index Losses

H. FY 2024 Wage Index Tables
I. Revisions to the Wage Index Based on Hospital Redesignations and Reclassifications
J. Out-Migration Adjustment Based on Commuting Patterns of Hospital Employees
K. Reclassification From Urban to Rural Under Section 1886(d)(8)(E) of the Act Implemented at 42 CFR 412.103
L. Process for Requests for Wage Index Data Corrections
M. Labor-Related Share for the FY 2024 Wage Index

IV. Payment Adjustment for Medicare Disproportionate Share Hospitals (DSHs) for FY 2024 (§ 412.106)
A. General Discussion
B. Eligibility for Empirically Justified Medicare DSH Payments and Uncompensated Care Payments
C. Empirically Justified Medicare DSH Payments
D. Supplemental Payment for Indian Health Service (IHS) and Tribal Hospitals and Puerto Rico Hospitals
E. Uncompensated Care Payments
F. Counting Certain Days Associated With Section 1115 Demonstrations in the Medicaid Fraction

V. Other Decisions and Changes to the IPPS
A. Changes to MS–DRGs Subject to Postacute Care Transfer Policy and MS–DRG Special Payments Policies (§ 412.4)
B. Changes in the Inpatient Hospital Update for FY 2024 (§ 412.64(d))
C. Sole Community Hospitals—Effective Date of Status in the Case of a Merger (§ 412.92)
D. Rural Referral Centers (RRCs) Annual Updates (§ 412.96)
E. Payment Adjustment for Low-Volume Hospitals (§ 412.101)
F. Medicare-Dependent, Small Rural Hospital (MDH) Program (§ 412.108)
G. Payments for Indirect and Direct Graduate Medical Education Costs (§§ 412.105 and 413.75 through 413.83)
H. Reasonable Cost Payment for Nursing and Allied Health Education Programs (§§ 413.85 and 413.87)
I. Payment Adjustment for Certain Clinical Trial and Expanded Access Use Immunotherapy Cases (§§ 412.85 and 412.312)
J. Hospital Readmissions Reduction Program (§§ 412.150 Through 412.154)
K. Hospital Value-Based Purchasing (VBP) Program: Policy Changes (§§ 412.160 Through 412.167)
L. Hospital-Acquired Condition (HAC) Reduction Program
M. Rural Community Hospital Demonstration Program

VI. Changes to the IPPS for Capital-Related Costs
A. Overview
B. Additional Provisions
C. Annual Update for FY 2024
D. Treatment of Rural Reclassifications for Capital DSH Payments

VII. Changes for Hospitals Excluded From the IPPS
A. Rate-of-Increase in Payments to Excluded Hospitals for FY 2024
B. Report on Adjustment (Exception) Payments
C. Critical Access Hospitals (CAHs)

VIII. Changes to the Long-Term Care Hospital Prospective Payment System (LTCH PPS) for FY 2024
A. Background of the LTCH PPS
B. Medicare Severity Long-Term Care Diagnosis-Related Group (MS–LTCDRG) Classifications and Relative Weights for FY 2024

IX. Quality Data Reporting Requirements for Specific Providers and Suppliers
A. Overview
B. Crosscutting Quality Program Proposal To Adopt the Up-to-Date COVID–19 Vaccination Coverage Among Healthcare Personnel Measure
C. Changes to the Hospital Inpatient Quality Reporting (IQR) Program
D. Changes to the PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program
E. Changes to the Long-Term Care Hospital Quality Reporting Program (LTCH QRP)
F. Changes to the Medicare Promoting Interoperability Program

X. Other Provisions Included in This Final Rule
A. Rural Emergency Hospitals (REHs)
B. Physician Self-Referral and Physician-Owned Hospitals
C. Technical Corrections to 42 CFR 411.353 and 411.357
D. Safety Net Hospitals RFI
E. Disclosures of Ownership and Additional Disclosable Parties Information

XI. MedPAC Recommendations and Publicly Available Files
A. MedPAC Recommendations
B. Publicly Available Files

XII. Collection of Information Requirements
A. Statutory Requirements for Solicitation of Comments
B. Collection of Information Requirements

I. Executive Summary and Background
A. Executive Summary
1. Purpose and Legal Authority

This FY 2024 IPPS/LTCH PPS final rule makes payment and policy changes under the Medicare inpatient prospective payment system (IPPS) for operating and capital-related costs of acute care hospitals as well as for certain hospitals and hospital units excluded from the IPPS. In addition, it makes payment and policy changes for inpatient hospital services provided by long-term care hospitals (LTCHs) under the long-term care hospital prospective payment system (LTCH PPS). This final rule also makes policy changes to programs associated with Medicare IPPS hospitals, IPPS-excluded hospitals, and LTCHs. In this FY 2024 final rule, we are finalizing our proposal to continue policies to address wage index disparities impacting low wage index hospitals. We are also finalizing our proposed changes relating to Medicare graduate medical education (GME) for teaching hospitals and new technology add-on payments.

In this FY 2024 final rule, we are finalizing our changes to the regulation governing the counting of days associated with individuals eligible for certain benefits provided by section 1115 demonstrations in the Medicaid fraction of a hospital’s DPP that were proposed in CMS 1788–P, Medicare Program: Medicare Disproportionate Share Hospital (DSH) Payments: Counting Certain Days Associated With Section 1115 Demonstrations in the Medicaid Fraction (88 FR 12623).

We are finalizing our proposals to establish new requirements and revise existing requirements for eligible hospitals and CAHs participating in the Medicare Promoting Interoperability Program.

In the Hospital VBP Program, we are finalizing our proposals to add one new measure, substantively modify two existing measures, add technical changes to the administration of the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Survey, change the scoring policy to include a health equity scoring adjustment, and modify the Total Performance Score (TPS) maximum to be 110, resulting in a numeric score range of 0 to 110. We are also providing estimated and newly established performance standards for the FY 2026 through FY 2029 program years for the Hospital VBP Program.
In the HAC Reduction Program, we are finalizing our proposals to establish a validation reconsideration process for data validation and to add an additional targeting criterion for validation. We did not propose any changes and are not finalizing any changes for the Hospital Readmissions Reduction Program.

In the Hospital IQR Program, we are finalizing our proposals to add three new measures, to modify three existing measures, and to remove three measures. We are also finalizing our proposed changes to add technical changes to the administration of the HCAHPS Survey and to add an additional targeting criterion for validation.

In the PPS-Exempt Cancer Hospital Quality Reporting Program (PCHQR), we are finalizing our proposals to add four new measures and to modify an existing measure. We are also finalizing our proposed changes to add technical changes to the administration of the HCAHPS Survey and to begin public reporting of one measure.

In the LTCH QRP, we are finalizing our proposals to add two new measures, modify an existing measure, remove two measures, and increase the LTCH QRP data completion thresholds for LTCH Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) items. Additionally, we provide a summary of the comments received to our request for information on principles for selecting and prioritizing LTCH QRP quality measures and concepts under consideration for future years and our update on CMS' continued efforts to close the health equity gap.

Under various statutory authorities, we either discuss continued program implementation or make changes to the Medicare IPPS, the LTCH PPS, other related payment methodologies and programs for FY 2024 and subsequent fiscal years, and other policies and provisions included in this rule. These statutory authorities include, but are not limited to, the following:

• Section 1886(d) of the Social Security Act (the Act), which sets forth a system of payment for the operating costs of acute care hospital inpatient stays under Medicare Part A (Hospital Insurance) based on prospectively set rates. Section 1886(g) of the Act requires that, instead of paying for capital-related costs of inpatient hospital services on a reasonable cost basis, the Secretary use a prospective payment system (PPS).

• Section 1886(d)(1)(B) of the Act, which specifies that certain hospitals and hospital units are excluded from the IPPS. These hospitals and units are: rehabilitation hospitals and units; LTCHs; psychiatric hospitals and units; children’s hospitals; cancer hospitals; extended neoplastic disease care hospitals; and hospitals located outside the 50 States, the District of Columbia, and Puerto Rico (that is, hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa). Religious nonmedical health care institutions (RNHHCs) are also excluded from the IPPS.

• Sections 123(a) and (c) of the Balanced Budget Refinement Act of 1999 (BBRA) (Public Law (Pub. L.) 106–113) and section 307(b)(1) of the Benefits Improvement and Protection Act of 2000 (BIPA) (Pub. L. 106–554) (as codified under section 1886(m)(1) of the Act), which provide for the development and implementation of a prospective payment system for payment for inpatient hospital services of LTCHs described in section 1886(d)(1)(B)(iv) of the Act.

• Section 1814(l)(4) of the Act requires downward adjustments to the applicable percentage increase, beginning with FY 2015, for CAHs that do not successfully demonstrate meaningful use of certified electronic health record technology (CEHRT) for an EHR reporting payment for a payment adjustment year.

• Section 1814(l)(4) of the Act, which requires downward adjustments to the applicable percentage increase, beginning with FY 2015, for CAHs that do not successfully demonstrate meaningful use of certified electronic health record technology (CEHRT) for an electronic health record (EHR) reporting payment for a payment adjustment year.

• Section 1886(a)(4) of the Act, which specifies that costs of approved educational activities are excluded from the operating costs of inpatient hospital services. Hospitals with approved graduate medical education (GME) programs are paid for the direct costs of GME in accordance with section 1886(h) of the Act. Hospitals paid under the IPPS with approved GME programs are paid for the indirect costs of training residents in accordance with section 1886(d)(5)(B) of the Act.

• Section 1886(d)(5)(F) of the Act provides for additional Medicare IPPS payments to subsection (d) hospitals that serve a significantly disproportionate number of low-income patients. These payments are known as the Medicare disproportionate share hospital (DSH) adjustment. Section 1886(d)(5)(F) of the Act specifies the applicable percentage that a hospital may qualify for the DSH payment adjustment.

• Section 1886(b)(3)[B](viii) of the Act, which requires the Secretary to reduce the applicable percentage increase that would otherwise apply to the standardized amount applicable to a subsection (d) hospital for discharges occurring in a fiscal year if the hospital does not submit data on measures in a form and manner, and at a time, specified by the Secretary.

• Section 1886(b)(3)[B](ix) of the Act, which requires downward adjustments to the applicable percentage increase, beginning with FY 2015 (and beginning with FY 2022 for subsection (d) Puerto Rico hospitals), for eligible hospitals that do not successfully demonstrate meaningful use of CEHRT for an EHR reporting period for a payment adjustment year.

• Section 1886(k) of the Act, which provides for the establishment of a quality reporting program for hospitals described in section 1886(d)(1)(B)(v) of the Act, referred to as “PPS-exempt cancer hospitals.”

• Section 1886(n) of the Act, which establishes the requirements for an eligible hospital to be treated as a meaningful EHR user of CEHRT for an EHR reporting period for a payment year or, for purposes of subsection (b)(3)[B](ix) of the Act, for a fiscal year.

• Section 1886(o) of the Act, which requires the Secretary to establish a Hospital Value-Based Purchasing (VBP) Program, under which value-based incentive payments are made in a fiscal year to hospitals meeting performance standards established for a performance period for such fiscal year.

• Section 1886(p) of the Act, which establishes a Hospital-Acquired Condition (HAC) Reduction Program, under which payments to applicable hospitals are adjusted to provide an incentive to reduce hospital-acquired conditions.

• Section 1886(q) of the Act, as amended by section 15002 of the 21st Century Cures Act, which establishes the Hospital Readmissions Reduction Program. Under the program, payments for discharges from an applicable hospital as defined under section 1886(d) of the Act will be reduced to account for certain excess readmissions. Section 15002 of the 21st Century Cures Act directs the Secretary to compare hospitals with respect to the number of their Medicare-Medicaid dual-eligible beneficiaries in determining the extent of excess readmissions.

• Section 1886(r) of the Act, as added by section 3133 of the Affordable Care Act, which provides for a reduction to disproportionate share hospital (DSH) payments under section 1886(d)(5)(F) of the Act and for an additional...
uncompensated care payment to eligible hospitals. Specifically, section 1886(r) of the Act requires that, for fiscal year 2014 and each subsequent fiscal year, subsection (d) hospitals that would otherwise receive a DSH payment made under section 1886(d)(5)(F) of the Act will receive two separate payments: (1) 25 percent of the amount they previously would have received under the statutory formula for Medicare DSH payments in section 1886(d)(5)(F) of the Act (“the empirically justified amount”), and (2) an additional payment for the DSH hospital’s proportion of uncompensated care, determined as the product of three factors. These three factors are: (1) 75 percent of the payments that would otherwise be made under section 1886(d)(5)(F) of the Act, in the absence of section 1886(r) of the Act; (2) 1 minus the percent change in the percent of individuals who are uninsured; and (3) the hospital’s uncompensated care amount relative to the uncompensated care amount of all DSH hospitals expressed as a percentage.

• Section 1886(m)(5) of the Act, which requires the Secretary to reduce by two percentage points the annual update to the standard Federal rate for discharges for a long-term care hospital (LTCH) during the rate year for LTCHs that do not submit data in the form, manner, and at a time, specified by the Secretary.

• Section 1886(m)(6) of the Act, as added by section 1206(a)(1) of the Pathway for Sustainable Growth Rate (SGR) Reform Act of 2013 (Pub. L. 113–67) and amended by section 51005(a) of the Bipartisan Budget Act of 2018 (Pub. L. 115–123), which provided for the establishment of site neutral payment rate criteria under the LTCH PPS, with implementation beginning in FY 2016. Section 51005(b) of the Bipartisan Budget Act of 2018 amended section 1886(m)(6) by adding new clause (iv), which specifies that the IPPS comparable amount defined in clause (iii) shall be reduced by 4.6 percent for FY 2018 through 2026.

• Section 1899B of the Act, as added by section 2(a) of the Improving Medicare Post-Acute Care Transformation Act of 2014 (IMPACT Act) (Pub. L. 113–185), which provides for the establishment of standardized data reporting for certain post-acute care providers, including LTCHs.

• Section 1861(3)(k) of the Act requires the Secretary to establish the conditions REHs must meet in order to participate in the Medicare program and which are consistent and necessary to ensure the health and safety of patients receiving services at these entities.

• Section 1877(i) of the Act, as added by section 6001(a)(3) of the Patient Protection and Affordable Care Act of 2010 (Affordable Care Act) (Pub. L. 111–148) and amended by section 1106 of the Health Care and Education Reconciliation Act of 2010 (HCERA) (Pub. L. 111–152), which requires the Secretary to establish and implement a process under which a hospital that is an “applicable hospital” or a “high Medicaid facility” may apply for an exception from the prohibition on expansion of facility capacity.


The following is a summary of the major provisions in this final rule. In general, these major provisions are being finalized as part of the annual update to the payment policies and payment rates, consistent with the applicable statutory provisions. A general summary of the changes in this final rule is presented in section I.D. of the preamble of this final rule.

a. Modification to the Rural Wage Index Calculation Methodology

As discussed in section III.G.1. of this final rule, CMS has taken the opportunity to revisit the case law, prior public comments, and the relevant statutory language with regard to its policies involving the treatment of hospitals that have reclassified as rural under section 1886(d)(8)(E) of the Act, as implemented in the regulations under 42 CFR 412.103. After doing so, CMS now agrees that the best reading of section 1886(d)(8)(E) is that it instructs CMS to treat § 412.103 hospitals the same as geographically rural hospitals. Therefore, we believe it is proper to include these hospitals in all iterations of the rural wage index calculation methodology included in section 1886(d) of the Act, including all hold harmless calculations in that provision. Beginning with FY 2024, we will include hospitals with § 412.103 reclassification along with geographically rural hospitals in all rural wage index calculations and only exclude “dual reclass” hospitals (hospitals with simultaneous § 412.103 and Medicare Geographic Classification Review Board (MGCRB) reclassifications) in accordance with the hold harmless provision at section 1886(d)(8)(C)(ii) of the Act.

b. Continuation of the Low Wage Index Hospital Policy

To help mitigate growing wage index disparities between high wage and low wage hospitals, in the FY 2020 IPPS/LTCH PPS rule (84 FR 42326 through 42332), we adopted a policy to increase the wage index values for certain hospitals with low wage index values (the low wage index hospital policy). This policy was adopted in a budget neutral manner through an adjustment applied to the standardized amounts for all hospitals. We also indicated our intention that this policy would be effective for at least 4 years, beginning in FY 2020, in order to allow employee compensation increases implemented by these hospitals sufficient time to be reflected in the wage index calculation. As discussed in section III.G.4. of the preamble of this final rule, as we only have 1 year of relevant data at this time that we could use to evaluate any potential impacts of this policy, we believe it is necessary to wait until we have useable data from additional fiscal years before making any decision to modify or discontinue the policy. Therefore, for FY 2024, we are finalizing our proposal to continue the low wage index hospital policy and the related budget neutrality adjustment.

c. DSH Payment Adjustment and Additional Payment for Uncompensated Care

Under section 1886(r) of the Act, which was added by section 3133 of the Affordable Care Act, starting in FY 2014, Medicare disproportionate share hospitals (DSHs) receive 25 percent of the amount they previously would have received under the statutory formula for Medicare DSH payments in section 1886(d)(5)(F) of the Act. The remaining amount, equal to 75 percent of the amount that otherwise would have been paid as Medicare DSH payments, is paid as additional payments after the amount is reduced for changes in the percentage of individuals that are uninsured. Each Medicare DSH will receive an additional payment based on its share of the total amount of uncompensated care for all Medicare DSHs for a given time period.

In this final rule, we are finalizing our proposal to update our estimates of the three factors used to determine uncompensated care payments for FY 2024. We are also finalizing our proposal to continue to use uninsured estimates produced by CMS’ Office of the Actuary (OACT) as part of the development of the National Health Expenditure Accounts (NHEA) in conjunction with more recently available data in the calculation of Factor 2. Consistent with the regulation at § 412.106(g)(1)(iii)(C)(iv), which was
adopted in the FY 2023 IPPS/LTCH PPS final rule, for FY 2024, we will use the 3 most recent years of audited data on uncompensated care costs from Worksheet S–10 of the FY 2018, FY 2019, and FY 2020 cost reports to calculate Factor 3 in the uncompensated care payment methodology for all eligible hospitals.

Beginning with FY 2023, we established a supplemental payment for IHS and Tribal hospitals and hospitals located in Puerto Rico, to help prevent undue long-term financial disruption to these hospitals due to the decision to discontinue use of the low-income insured days proxy in the uncompensated care payment methodology for these providers.

In this final rule we are also finalizing our proposal (88 FR 12623) on counting of days associated with individuals eligible for certain benefits provided by section 1115 demonstrations in the Medicaid fraction of a hospital’s disproportionate patient percentage for the purposes of determining Medicare DSH payments to subsection (d) hospitals under section 1886(d)(5)(F) of the Act. Specifically, under our finalized policy, for purposes of the Medicare DSH calculation in section 1886(d)(5)(F)(vi) of the Act we will "regard as" eligible for medical assistance under a State plan approved under title XIX” patients who (1) receive health insurance authorized by a section 1115 demonstration or (2) buy health insurance with premium assistance provided to them under a section 1115 demonstration, where State expenditures to provide the health insurance or premium assistance is matched with funds from title XIX. Furthermore, of these expansion groups we regard as eligible for Medicaid, we include in the disproportionate patient percentage (DPP) Medicaid fraction numerator only the days of those patients who receive from the demonstration (1) health insurance that covers inpatient hospital services or (2) premium assistance that covers 100 percent of the premium cost to the patient, which the patient uses to buy health insurance that covers inpatient hospital services, provided in either case that the patient is not also entitled to Medicare Part A. Finally, patients whose inpatient hospital costs are paid for with funds from an uncompensated/ uncompensated care pool authorized by a section 1115 demonstration will not be patients “regarded as” eligible for Medicaid of such patients may not be included in the DPP Medicaid fraction numerator.

d. Hospital Readmissions Reduction Program

We did not propose any changes to the Hospital Readmissions Reduction Program. We note that all previously finalized policies under this program will continue to apply and refer readers to the FY 2023 IPPS/LTCH PPS final rule (87 FR 49081 through 49094) for information on these policies.

e. Hospital Value-Based Purchasing (VBP) Program

Section 1886(o) of the Act requires the Secretary to establish a Hospital VBP Program under which value-based incentive payments are made in a fiscal year to hospitals based on their performance on measures established for a performance period for such fiscal year. In this final rule, we are finalizing our proposal to adopt modified versions of: (1) the Medicare Spending Per Beneficiary (MSPB) Hospital measure beginning with the FY 2028 program year; and (2) the Hospital-level Risk-Standardized Complication Rate (RSCR) Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA) measure beginning with the FY 2030 program year. In addition, we are finalizing our proposal to adopt the Severe Sepsis and Septic Shock: Management Bundle measure in the Safety Domain beginning with the FY 2026 program year.

We are finalizing our proposal to make technical changes to the form and manner of the administration of the HCAHPS Survey measure under the Hospital VBP Program beginning with the FY 2027 program year in alignment with the Hospital IQR Program. Additionally, we are finalizing our proposal to adopt a health equity scoring change for rewarding excellent care in underserved populations beginning with the FY 2026 program year, as well as the proposal to modify the Total Performance Score (TPS) maximum to be 110, such that the TPS numeric score range would be 0 to 110 in order to afford even top-performing hospitals the opportunity to receive the additional health equity bonus points under the health equity scoring change.

f. Hospital-Acquired Condition Reduction Program

Section 1886(p) of the Act establishes the HAC Reduction Program under which payments to applicable hospitals are adjusted to provide an incentive to reduce hospital-acquired conditions. In this final rule, we are finalizing our proposal to establish a validation reconsideration process for hospitals who fail data validation beginning with the FY 2025 program year, affecting calendar year 2022 discharges. We are also finalizing modification of the validation targeting criteria to include hospitals granted an extraordinary circumstances exceptions (ECEs) beginning with the FY 2027 program year, affecting calendar year 2024 discharges.

g. Modification of the COVID–19 Vaccination Coverage Among Healthcare Personnel (HCP) Measure in the Hospital IQR Program, PCHQR Program, and LTCH QRP

In the FY 2024 IPPS/LTCH PPS final rule, we are finalizing our proposal to modify the COVID–19 Vaccination Coverage among HCP measure to replace the term "complete vaccination course" with the term “up to date” with regard to recommended COVID–19 vaccines beginning with the Quarter 4 (Q4) calendar year (CY) 2023 reporting period/FY 2024 payment determination for the Hospital IQR Program, and the FY 2025 program year for the LTCH QRP and the PCHQR Program.

h. Hospital Inpatient Quality Reporting (IQR) Program

Under section 1886(b)(3)(B)(viii) of the Act, subsection (d) hospitals are required to report data on measures selected by the Secretary for a fiscal year in order to receive the full annual percentage increase.

In the FY 2024 IPPS/LTCH PPS final rule, we are finalizing several changes to the Hospital IQR Program. We are finalizing the adoption of three new measures: (1) Hospital Harm—Pressure Injury electronic clinical quality measure (eCQM) beginning with the CY 2025 reporting period/FY 2027 payment determination; (2) Hospital Harm—Acute Kidney Injury eCQM beginning with the CY 2025 reporting period/FY 2027 payment determination; and (3) Excessive Radiation eCQM beginning with the CY 2025 reporting period/FY 2027 payment determination. We are also finalizing the modification of three current measures: (1) Hybrid Hospital-Wide All-Cause Risk Standardized Mortality (HWM) measure beginning with the FY 2027 payment determination; (2) Hybrid Hospital-Wide All-Cause Readmission (HWR) measure beginning with the FY 2027 payment determination; and (3) COVID–19 Vaccination Coverage among HCP measure beginning with the Q4 CY 2023 reporting period/FY 2023 payment determination. We are also finalizing the removal of three current measures: (1) Hospital-level Risk-standardized Complication Rate (RSCR) Following Elective Primary Total Hip Arthroplasty
with the FY 2027 program year.

...manner of the administration of the

...and technical changes to the form

...Complications for Localized Prostate

...report the Surgical Treatment

...FY 2025 program year. We are also

...COVID–19 Vaccination Coverage

...proposal to adopt a modified version of

...Discussions Among Cancer Patients

...Documentation of Goals of Care

...and the Screen Positive Rate for Social

...Health Equity measure, the Screening

...measures: the Facility Commitment to

...beginning with the FY 2027 payment

...payment if a PCH does not participate.

...to such fiscal year. There is no

...described in section 1886(d)(1)(B)(v) of

...subsequent fiscal year, that a hospital

...Adjustment year’’ at § 495.4 for eligible

...Interoperability Program, to define the

...eligible hospitals and CAHs

...percent in CY 2025 as a minimum of any

...Interoperability Program, to define the

...are: (1) amend the definition of

...CMS is recognizing homelessness as an

...indicator of increased resource

...utilization in the acute inpatient

...hospital setting.

...Consistent with the Administration’s

...goal of advancing health equity for all,

...including members of historically

...underserved and under-resourced

...communities, as described in the

...President’s January 20, 2021 Executive

...Order 13985 on “Advancing Racial

...Equity and Support for Underserved

...Communities Through the Federal

...Government.” 1 we also continue to be

...interested in receiving feedback on how

...we might otherwise foster the

...documentation and reporting of the
diagnosis codes describing social and
economic circumstances to more
accurately reflect each health care
encounter and improve the reliability
and validity of the coded data including
in support of efforts to advance health
equity.

3. Summary of Costs and Benefits

The following table provides a
summary of the costs, savings, and
benefits associated with the major

1 Available at 86 FR 7099 [January 25, 2021]
(https://www.federalregister.gov/documents/2021/
01/25/2021-01753/advancing-racial-equity-and-
support-for-underserved-communities-through-the-
federal-government).
<table>
<thead>
<tr>
<th>Provision Description</th>
<th>Description of Costs, Transfers, Savings, and Benefits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modification to the Rural Wage Index Calculation Methodology</td>
<td>Beginning with FY 2024, we are including hospitals with § 412.103 reclassification along with geographically rural hospitals in all rural wage index calculations and only excluding “dual reclass” hospitals (hospitals with simultaneous § 412.103 and MGRB reclassifications) in accordance with the hold-harmless provision at section 1866(d)(8)(C)(ii) of the Act. Changes to the rural wage index, which affect the rural floor, are generally implemented in a budget neutral manner.</td>
</tr>
<tr>
<td>Continuation of the Low Wage Index Hospital Policy</td>
<td>For FY 2024, we are continuing the low wage index hospital policy and the related budget neutrality adjustment.</td>
</tr>
<tr>
<td>Medicare DSH Payment Adjustment and Additional Payment for Uncompensated Care and Supplemental Payment</td>
<td>For FY 2024, we are updating our estimates of the three factors used to determine uncompensated care payments. We are continuing to use uninsured estimates produced by OACT as part of the development of the NHEA in conjunction with more recently available data in the calculation of Factor 2. As provided in the regulation at § 412.106(g)(1)(iii)(C)(1), for FY 2024, we are using the 3 most recent years of audited data on uncompensated care costs from Worksheet S–10 of the FY 2018, FY 2019, and FY 2020 cost reports to calculate Factor 3 in the uncompensated care payment methodology for all eligible hospitals.</td>
</tr>
<tr>
<td>Update to the IPPS Payment Rates and Other Payment Policies</td>
<td>As discussed in appendix A of this final rule, acute care hospitals are estimated to experience an increase of approximately $2.2 billion in FY 2024, primarily driven by: (1) a combined $2.6 billion increase in FY 2024 operating payments and capital payments, as well as changes in DSH and uncompensated care payments, and (2) a decrease of $364 million resulting from estimated changes in new technology add-on payments, as projected for this final rule.</td>
</tr>
<tr>
<td>Update to the LTCH PPS Payment Rates and Other Payment Policies</td>
<td>As discussed in appendix A of this final rule, based on the best available data for the 333 LTCHs in our database, we estimate that the changes to the payment rates and factors that we present in the preamble of and Addendum of the final rule, which reflect the update to the LTCH PPS standard Federal payment rate for FY 2024, will result in an estimated increase in payments in FY 2024 of approximately $6 million.</td>
</tr>
<tr>
<td>Changes to the Value-Based Incentive Payments under the Hospital VBP Program</td>
<td>We estimate that there would be no net financial impact to the Hospital VBP Program for the FY 2024 program year in the aggregate because, by law, the amount available for value-based incentive payments under the program in a given year must be equal to the total amount of base operating MS-DRG payment amount reductions for that year, as estimated by the Secretary. The estimated amount of base operating MS-DRG payment amount reductions for the FY 2024 program year and, therefore, the estimated amount available for value-based incentive payments for FY 2024 discharges is approximately $1.7 billion.</td>
</tr>
<tr>
<td>Modification of the COVID-19 Vaccination Coverage among Healthcare Personnel Measure in the Hospital IQR Program, PCHQR Program, and LTCH QRP</td>
<td>We estimate that the modified version of this measure will have no financial impact on the LTCH QRP, PCHQR Program, or Hospital IQR Program</td>
</tr>
<tr>
<td>Changes to the Hospital-Acquired Condition (HAC) Reduction Program</td>
<td>Across the 400 subsection (d) hospitals selected for validation each year from the HAC Reduction Program, we estimate that our changes in this final rule will not result in a change in information collection burden for the FY 2025 program year and subsequent years.</td>
</tr>
<tr>
<td>Changes to the Hospital IQR Program</td>
<td>Across 3,150 IPPS hospitals, we estimate that our changes for the Hospital IQR Program in this final rule will result in a total information collection burden decrease of 144,836 hours associated with our finalized policies,</td>
</tr>
<tr>
<td>Provision Description</td>
<td>Description of Costs, Transfers, Savings, and Benefits</td>
</tr>
<tr>
<td>------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>and updated burden estimates and a total cost decrease of approximately $6,834,886 across a 4-year period from the CY 2024 reporting period/FY 2026 payment determination through the CY 2027 reporting period/FY 2029 payment determination.</td>
<td></td>
</tr>
<tr>
<td>Changes to the PCHQR Program</td>
<td>Across 11 PCHs, we estimate that our changes for the PCHQR Program in this final rule will result in a total information collection burden increase of 187.2 hours at a cost increase of $6,232. We estimate additional costs of $416,815 annually associated with our adoption of the Documentation of Goals of Care Discussions Among Cancer Patients measure beginning with the FY 2026 program year.</td>
</tr>
<tr>
<td>Changes to the LTCH QRP</td>
<td>Across 330 LTCHs, we estimate that our changes for the LTCH QRP in this final rule will result in a total information collection burden decrease of 1,292 hours associated with our policies and updated burden estimates and a total cost decrease of approximately $127,421 across the FY 2025 and FY 2026 LTCH QRP program years.</td>
</tr>
<tr>
<td>Changes to the Medicare Promoting Interoperability Program</td>
<td>Across 4,500 eligible hospitals and CAHs, we estimate that our changes for the Medicare Promoting Interoperability Program in this final rule would not result in a change to the information collection burden for the CY 2024 EHR Reporting Period and subsequent years. We estimate additional annual costs associated with our finalized modification to the SAFER Guides measure to range from a minimum of $8,916,278 to a maximum of $108,976,725 beginning with the CY 2024 EHR Reporting Period.</td>
</tr>
</tbody>
</table>
B. Background Summary

1. Acute Care Hospital Inpatient Prospective Payment System (IPPS)

Section 1886(d) of the Act sets forth a system of payment for the operating costs of acute care hospital inpatient stays under Medicare Part A (Hospital Insurance) based on prospectively set rates. Section 1886(g) of the Act requires the Secretary to use a prospective payment system (PPS) to pay for the capital-related costs of inpatient hospital services for these “subsection (d) hospitals.” Under these PPSs, Medicare payment for hospital inpatient operating and capital-related costs is made at predetermined, specific rates for each hospital discharge. Discharges are classified according to a list of diagnosis-related groups (DRGs).

The base payment rate is comprised of a standardized amount that is divided into a labor-related share and a nonlabor-related share. The labor-related share is adjusted by the wage index applicable to the area where the hospital is located. If the hospital is located in Alaska or Hawaii, the nonlabor-related share is adjusted by a cost-of-living adjustment factor. This base payment rate is multiplied by the DRG relative weight.

If the hospital treats a high percentage of certain low-income patients, it receives a percentage add-on payment applied to the DRG-adjusted base payment rate. This add-on payment, known as the disproportionate share hospital (DSH) adjustment, provides for a percentage increase in Medicare payments to hospitals that qualify under either of two statutory formulas designed to identify hospitals that serve a disproportionate share of low-income patients. For qualifying hospitals, the amount of this adjustment varies based on the outcome of the statutory calculations. The Affordable Care Act revised the Medicare DSH payment methodology and provides for an additional Medicare payment beginning on October 1, 2013, that considers the amount of uncompensated care furnished by the hospital relative to all other qualifying hospitals.

If the hospital is training residents in an approved residency program(s), it receives a percentage add-on payment for each case paid under the IPPS, known as the indirect medical education (IME) adjustment. This percentage varies, depending on the ratio of residents to beds.

Additional payments may be made for cases that involve new technologies or medical services that have been approved for special add-on payments. In general, to qualify, a new technology or medical service must demonstrate that it is a substantial clinical improvement over technologies or services otherwise available, and that, absent an add-on payment, it would be inadequately paid under the regular DRG payment. In addition, certain transformative new devices and certain antimicrobial products may qualify under an alternative inpatient new technology add-on payment pathway by demonstrating that, absent an add-on payment, they would be inadequately paid under the regular DRG payment.

The costs incurred by the hospital for a case are evaluated to determine whether the hospital is eligible for an additional payment as an outlier case. This additional payment is designed to protect the hospital from large financial losses due to unusually expensive cases. Any eligible outlier payment is added to the DRG-adjusted base payment rate, plus any DSH, IME, and new technology or medical service add-on adjustments and, beginning in FY 2023 for IHS and Tribal hospitals and hospitals located in Puerto Rico, the new supplemental payment.

Although payments to most hospitals under the IPPS are made on the basis of the standardized amounts, some categories of hospitals are paid in whole or in part based on their hospital-specific rate, which is determined from their costs in a base year. For example, sole community hospitals (SCHs) receive the higher of a hospital-specific rate based on their costs in a base year (the highest of FY 1992, FY 1987, FY 1996, or FY 2006) or the IPPS Federal rate based on the standardized amount. SCHs are the sole source of care in their areas. Specifically, section 1886(d)(5)(D)(iii) of the Act defines an SCH as a hospital that is located more than 35 road miles from another hospital or that, by reason of factors such as an isolated location, weather conditions, travel conditions, or absence of other like hospitals (as determined by the Secretary), is the sole source of hospital inpatient services reasonably available to Medicare beneficiaries. In addition, certain rural hospitals previously designated by the Secretary as essential access community hospitals are considered SCHs.

Under current law, the Medicare-dependent, small rural hospital (MDH) program is effective through FY 2024. For discharges occurring on or after October 1, 2007, but before October 1, 2024, an MDH receives the higher of the Federal rate or the Federal rate plus 75 percent of the amount by which the Federal rate exceeds the highest of its FY 1982, FY 1987, or FY 2002 hospital-specific rate. MDHs are a major source of care for Medicare beneficiaries in their areas. Section 1886(d)(5)(G)(iv) of the Act defines an MDH as a hospital that is located in a rural area (or, as amended by the Bipartisan Budget Act of 2018, a hospital located in a State with no rural area that meets certain statutory criteria), has not more than 100 beds, is not an SCH, and has a high percentage of Medicare discharges (not less than 60 percent of its inpatient days or discharges in its cost reporting year beginning in FY 1987 or in two of its three most recently settled Medicare cost reporting years).

Section 1886(g) of the Act requires the Secretary to pay for the capital-related costs of inpatient hospital services in accordance with a prospective payment system established by the Secretary. The basic methodology for determining capital prospective payments is set forth in our regulations at 42 CFR 412.308 and 412.312. Under the capital IPPS, payments are adjusted by the same DRG for the case as they are under the operating IPPS. Capital IPPS payments are also adjusted for IME and DSH, similar to the adjustments made under the operating IPPS. In addition, hospitals may receive outlier payments for those cases that have unusually high costs.

The existing regulations governing payments to hospitals under the IPPS are located in 42 CFR part 412, subparts A through M.

2. Hospitals and Hospital Units

Excluded From the IPPS

Under section 1886(d)(1)(B) of the Act, as amended, certain hospitals and hospital units are excluded from the IPPS. These hospitals and units are: Inpatient rehabilitation facility (IRF) hospitals and units; long-term care hospitals (LTCHs); psychiatric hospitals and units; children’s hospitals; cancer hospitals; extended neoplastic disease care hospitals, and hospitals located outside the 50 States, the District of Columbia, and Puerto Rico (that is, hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa). Religious nonmedical health care institutions (RNHCIs) are also excluded from the IPPS. Various sections of the Balanced Budget Act of 1997 (BBA) (Pub. L. 105–33), the Medicare, Medicaid and SCHIP [State Children’s Health Insurance Program] Balanced Budget Refinement Act of 1999 (BBRA, Pub. L. 106–113), and the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 [BIPA, Pub. L. 106–534] provide for the implementation of PPSs for IRF hospitals and units, LTCHs, and
psychiatric hospitals and units (referred to as inpatient psychiatric facilities (IPFs)). (We note that the annual updates to the LTCH PPS are included along with the IPPS annual update in this document. Updates to the IRF PPS and IPF PPS are issued as separate documents.) Children’s hospitals, cancer hospitals, hospitals located outside the 50 States, the District of Columbia, and Puerto Rico (that is, hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa), and RHNCIs continue to be paid solely under a reasonable cost-based system, subject to a rate-of-increase ceiling on inpatient operating costs. Similarly, extended neoplastic disease care hospitals are paid on a reasonable cost basis, subject to a rate-of-increase ceiling on inpatient operating costs.

The existing regulations governing payments to excluded hospitals and hospital units are located in 42 CFR parts 412 and 413.

3. Long-Term Care Hospital Prospective Payment System (LTCH PPS)

The Medicare prospective payment system (PPS) for LTCHs applies to hospitals described in section 1886(d)(1)[B][iv] of the Act, effective for cost reporting periods beginning on or after October 1, 2002. The LTCH PPS was established under the authority of sections 123 of the BBRA and section 307(b) of the BIPA (as codified under section 1886(m)(1) of the Act). Section 1206(a) of the Pathway for SGR Reform Act of 2013 (Pub. L. 113–67) established the site neutral payment rate under the LTCH PPS, which made the LTCH PPS a dual rate payment system beginning in FY 2016. Under this statute, effective for LTCH’s cost reporting periods beginning in FY 2016 cost reporting period, LTCHs are generally paid for discharges at the site neutral payment rate unless the discharge meets the patient criteria for payment at the LTCH PPS standard Federal payment rate. The existing regulations governing payment under the LTCH PPS are located in 42 CFR part 412. Beginning October 1, 2009, we issue the annual updates to the LTCH PPS in the same documents that update the IPPS.

4. Critical Access Hospitals (CAHs)

Under sections 1814(l), 1820, and 1834(g) of the Act, payments made to critical access hospitals (CAHs) (that is, rural hospitals or facilities that meet certain statutory requirements) for inpatient and outpatient services are generally paid at 101 percent of reasonable cost. Reasonable cost is determined under the provisions of section 1861(v) of the Act and existing regulations under 42 CFR part 413.

5. Payments for Graduate Medical Education (GME)

Under section 1886(a)(4) of the Act, costs of approved educational activities are excluded from the operating costs of inpatient hospital services. Hospitals with approved graduate medical education (GME) programs are paid for the direct costs of GME in accordance with section 1886(h) of the Act. The amount of payment for direct GME (DGME) costs for a cost reporting period is based on the hospital’s number of residents in that period and the hospital’s costs per resident in a base year. The existing regulations governing payments to the various types of hospitals are located in 42 CFR part 413. Section 1886(d)(5)[B] of the Act provides that prospective payment hospitals that have residents in an approved GME program receive an additional payment for each Medicare discharge to reflect the higher patient care costs of teaching hospitals relative to non-teaching hospitals. The additional payment is based on the indirect medical education (IME) adjustment factor, which is calculated using a hospital’s ratio of residents to beds and a multiplier, which is set by Congress. Section 1886(d)(5)[B][ii][XII] of the Act provides that, for discharges occurring during FY 2008 and fiscal years thereafter, the IME formula multiplier is 1.35. The regulations regarding the indirect medical education (IME) adjustment are located at 42 CFR 412.105.

C. Summary of Provisions of Recent Legislation That Will Be Implemented in This Final Rule

1. The Consolidated Appropriations Act, 2023 (CAA 2023; Pub. L. 117–328)

Section 4101 of the CAA 2023 extended through FY 2024 the modified definition of a low-volume hospital and the methodology for calculating the payment adjustment for low-volume hospitals in effect for FYs 2019 through 2022. Specifically, under section 1886(d)[12][C][i] of the Act, as amended, for FYs 2019 through 2024, a subsection (d) hospital qualifies as a low-volume hospital if it is more than 12 road miles from another subsection (d) hospital and has less than 3,800 total discharges during the fiscal year. Under section 1886(d)[12][D] of the Act, as amended, for discharges occurring in FYs 2019 through 2024, the Secretary determines the applicable percentage increase using a continuous, linear sliding scale ranging from an additional 25 percent payment adjustment for low-volume hospitals with 500 or fewer discharges to a zero percent additional payment for low-volume hospitals with more than 3,800 discharges in the fiscal year.

Section 4102 of the CAA 2023 amended sections 1886(d)[5][G][i] and 1886(d)[5][G][ii][III] of the Act to provide for an extension of the MDH program through FY 2024.

Section 4143 of the CAA 2023 amended section 1886(l)[2][B] of the Act to specify that for portions of cost reporting periods occurring in each of calendar years (CYs) 2010 through 2019, the $60 million payment limit specified in that subparagraph is not to apply to the total amount of additional payments for nursing and allied health education to be distributed to hospitals that, as of December 29, 2022, were operating a school of nursing, a school of allied health, or a school of nursing and allied health. In addition, section 4143 of the CAA 2023 provides that in addition to not applying the $60 million limit for each of years 2010 through 2019, the Secretary shall not reduce direct GME payments by such additional payment amounts for such nursing and allied health education for portions of cost reporting periods occurring in the year.

D. Issuance of the Notices of Proposed Rulemaking and Summary of the Proposed Provisions

1. FY 2024 IPPS/LTCH PPS Proposed Rule

In the proposed rule that appeared in the Federal Register on May 1, 2023 (88 FR 26658), we set forth proposed payment and policy changes to the Medicare IPPS for FY 2024 operating costs and capital-related costs of acute care hospitals and certain hospitals and hospital units that are excluded from IPPS. In addition, we set forth proposed changes to the payment rates, factors, and other payment and policy-related changes to programs associated with payment rate policies under the LTCH PPS for FY 2024.

The following is a general summary of the changes that we proposed to make:

a. Proposed Changes to MS–DRG Classifications and Recalibrations of Relative Weights

In section II of the preamble of the proposed rule, we included the following:

• Proposed changes to MS–DRG classifications based on our yearly review for FY 2024.
• Proposed recalibration of the MS–DRG relative weights.
• A discussion of the proposed FY 2024 status of new technologies.
approved for add-on payments for FY 2023, a presentation of our evaluation and analysis of the FY 2024 applicants for add-on payments for high-cost new medical services and technologies (including public input, as directed by Pub. L. 108–173, obtained in a town hall meeting) for applications not submitted under an alternative pathway, and a discussion of the proposed status of FY 2024 new technology applicants under the alternative pathways for certain medical devices and certain antimicrobial products.

- Proposed modifications to the new technology add-on payment application eligibility requirements for technologies that are not already Food and Drug Administration (FDA) market authorized to require such applicants to have a complete and active FDA market authorization request at the time of new technology add-on payment application submission, to provide documentation of FDA acceptance or filing, and to move the deadline for FDA marketing authorization from July 1 to May 1 of the year before the fiscal year for which the applicant applied for new technology add-on payments, beginning with applications for FY 2025 (as discussed in section II.E.9. of the preamble of the proposed rule).

b. Proposed Changes to the Hospital Wage Index for Acute Care Hospitals

In section III. of the preamble of the proposed rule, we proposed revisions to the wage index for acute care hospitals and the annual update of the wage data. Specific issues addressed include, but are not limited to, the following:

- The proposed FY 2024 wage index update using wage data from cost reporting periods beginning in FY 2019.
- Calculation, analysis, and implementation of the proposed occupational mix adjustment to the wage index for acute care hospitals for FY 2024 based on the 2019 Occupational Mix Survey.
- Proposed application of the rural, imputed and frontier State floors, and continuation of the low wage index hospital policy.
- Proposed revisions to the wage index for acute care hospitals, based on hospital redesignations and reclassifications under sections 1886(d)(8)(B), (d)(8)(E), and (d)(10) of the Act.
- Proposed adjustment to the wage index for acute care hospitals for FY 2024 based on commuting patterns of hospital employees who reside in a county and work in a different area with a higher wage index.
- Proposed labor-related share for the proposed FY 2024 wage index.

c. Payment Adjustment for Medicare Disproportionate Share Hospitals (DSHs) for FY 2024

In section IV. of the preamble of the proposed rule, we discuss the following:

- Proposed calculation of Factor 1 and Factor 2 of the uncompensated care payment methodology.
- Proposed methodological approach for determining the additional payments for uncompensated care for FY 2024, which is the same overall approach as was for FY 2023.

d. Other Decisions and Proposed Changes to the IPPS for Operating Costs

In section V. of the preamble of the proposed rule, we discuss proposed changes or clarifications of a number of the provisions of the regulations in 42 CFR parts 412 and 413, including the following:

- Proposed inpatient hospital update for FY 2024.
- Proposed change related to the effective date of sole community hospital (SCH) classification in cases that involve a merger.
- Proposed updated national and regional case-mix values and discharges for purposes of determining RRC status.
- Proposed payment adjustment for low-volume hospitals for FY 2024.
- Discussion of statutory extension of the MDH program through FY 2024.
- Proposed to establish a validation reconsideration process and update the data validation targeting criteria under the HAC Reduction Program for FY 2024.

- Proposed to update the MSPB Hospital and THA/TKA Complications measures, to adopt the new Severe Sepsis and Septic Shock: Management Bundle measure, to update the changes to the data collection and submission requirements for the HCAHPS Survey measure, to revise the scoring methodology to include a health equity scoring adjustment, to modify the Total Performance Score numeric score range to be 0–110, and to codify the measure removal factors, the revised scoring methodology and TPS numeric score range, and the minimum numbers of cases.
- Proposed changes to the regulations for GME payments when training occurs in REHs.
- Discussion of and proposed changes relating to the implementation of the Rural Community Hospital Demonstration Program in FY 2024.
- Proposed nursing and allied health education program Medicare Advantage (MA) add-on rates and direct GME MA percentage reductions for FY 2022.
- Proposed to implement section 4143 of the CAA 2023 which waives the $60 million limit on annual nursing and allied health education program MA payments.
- Proposed update to the payment adjustment for certain clinical trial and expanded access use immunotherapy cases.

- Proposed FY 2024 Policy Governing the IPPS for Capital-Related Costs

In section VI. of the preamble of the proposed rule, we discuss the proposed payment policy requirements for capital-related costs and capital payments to hospitals for FY 2024. In addition, we discuss a proposed change to how hospitals with a rural recategorization are treated for capital DSH payments.

f. Proposed Changes to the Payment Rates for Certain Excluded Hospitals: Rate-of-Increase Percentages

In section VII. of the preamble of the proposed rule, we discuss the following:

- Proposed changes to payments to certain excluded hospitals for FY 2024.
- Proposed continued implementation of the Frontier Community Health Integration Project (FCHIP) Demonstration.

g. Proposed Changes to the LTCH PPS

In section VIII. of the preamble of the proposed rule, we set forth proposed changes to the LTCH PPS Federal payment rates, factors, and other payment rate policies under the LTCH PPS for FY 2024.

- Proposed Changes Relating to Quality Data Reporting for Specific Providers and Suppliers

In section IX. of the preamble of the proposed rule, we addressed the following:

- Proposed adoption of a modified version of the COVID–19 Vaccination Coverage among Healthcare Personnel Measure in the Hospital IQR Program, PCHQR Program, and LTCH QRP.
- Proposed requirements for the Hospital Inpatient Quality Reporting (IQR) Program.
- Proposed changes to the requirements for the PPS-Exempt Cancer Hospital Quality Reporting Program (PCHQR Program).
- Proposed changes to the requirements for the Long-Term Care Hospital Quality Reporting Program (LTCH QRP), and a request for information on principles for selecting and prioritizing LTCH QRP quality measures and concepts under consideration for future years. We also provide an update on health equity.
- Proposed changes to requirements pertaining to eligible hospitals and
CAHs participating in the Medicare Promoting Interoperability Program.

i. Other Proposals and Comment Solicitations Included in the Proposed Rule

Section X. of the preamble of the proposed rule included the following:
- Proposals to establish requirements for additional information that an eligible facility would be required to submit when applying for enrollment as an REH.
- Proposed changes pertaining to the process for hospitals requesting an exception from the prohibition against facility expansion and program integrity restrictions on approved facility expansion.
- Solicitation of comments on potential approaches to address the challenges faced by safety-net hospitals, including an appropriate mechanism for identifying safety-net hospitals for Medicare policy purposes.
- Proposals to apply certain definitions included in the Disclosures of Ownership and Additional Disclosable Parties Information for Skilled Nursing Facilities proposed rule published in the February 15, 2023 Federal Register (88 FR 9820) to all provider types that complete the Form CMS–855–A enrollment application.

j. Other Provisions of the Proposed Rule

Section XI.A. of the preamble of the proposed rule includes our discussion of the MedPAC Recommendations.

Section XI.B. of the preamble of the proposed rule includes a descriptive listing of the public use files associated with the proposed rule.

Section XII. of the preamble of the proposed rule includes the collection of information requirements for entities based on our proposals.

Section XIII. of the preamble of the proposed rule includes information regarding our responses to public comments.

k. Determining Prospective Payment Rates for Acute Care Hospitals

In sections II. and III. of the Addendum of the proposed rule, we set forth proposed changes to the amounts and factors for determining the proposed FY 2024 prospective payment rates for operating costs and capital-related costs for acute care hospitals. We proposed to establish the threshold amounts for outlier cases. In addition, in section IV. of the Addendum of the proposed rule, we address the proposed update factors for determining the rate-of-increase limits for cost reporting periods beginning in FY 2024 for certain hospitals excluded from the IPPS.

l. Determining Prospective Payment Rates for LTCHs

In section V. of the Addendum of the proposed rule, we set forth proposed changes to the amounts and factors for determining the proposed FY 2024 LTCH PPS standard Federal payment rate and other factors used to determine LTCH PPS payments under both the LTCH PPS standard Federal payment rate and the site neutral payment rate in FY 2024. We are proposing to establish the adjustments for the wage index, labor-related share, the cost-of-living adjustment, and high-cost outliers, including the applicable fixed-loss amounts and the LTCH cost-to-charge ratios (CCRs) for both payment rates.

m. Impact Analysis

In appendix A of the proposed rule, we set forth an analysis of the impact the proposed changes would have on affected acute care hospitals, CAHs, LTCHs and other entities.

n. Recommendation of Update Factors for Operating Cost Rates of Payment for Hospital Inpatient Services

In appendix B of the proposed rule, as required by sections 1886(e)(4) and (e)(5) of the Act, we provide our recommendations of the appropriate percentage changes for FY 2024 for the following:
- A single average standardized amount for all areas for hospital inpatient services paid under the IPPS for operating costs of acute care hospitals (and hospital-specific rates applicable to SCHs and MDHs).
- Target rate-of-increase limits to the allowable operating costs of hospital inpatient services furnished by certain hospitals excluded from the IPPS.
- The LTCH PPS standard Federal payment rate and the site neutral payment rate for hospital inpatient services provided for LTCH PPS discharges.

o. Discussion of Medicare Payment Advisory Commission Recommendations

Under section 1805(b) of the Act, MedPAC is required to submit a report to Congress, no later than March 15 of each year, in which MedPAC reviews and makes recommendations on Medicare payment policies. MedPAC’s March 2023 recommendations concerning hospital inpatient payment policies address the update factor for hospital inpatient operating costs and capital-related costs for hospitals under the IPPS. We address these recommendations in appendix B of the proposed rule. For further information relating specifically to the MedPAC March 2023 report or to obtain a copy of the report, contact MedPAC at (202) 220–3700 or visit MedPAC’s website at https://www.medpac.gov.

2. Section 1115 Demonstration Disproportionate Share Hospital Proposed Rule

In addition, in the proposed rule that appeared in the Federal Register on February 28, 2023 (88 FR 12623), we set forth proposed revisions to the regulations on the counting of days associated with individuals eligible for certain benefits provided by section 1115 demonstrations in the Medicaid fraction of a hospital’s disproportionate patient percentage for the purposes of determining Medicare DSH payments to subsection (d) hospitals under section 1886(d)(5)(P) of the Act. Specifically, we proposed for purposes of the Medicare DSH calculation in section 1886(d)(5)(P)(vi) of the Act to “regard as” “eligible for medical assistance under a State plan approved under title XIX” patients who (1) receive health insurance authorized by a section 1115 demonstration or (2) buy health insurance with premium assistance provided to them under a section 1115 demonstration, where State expenditures to provide the health insurance or premium assistance is matched with funds from title XIX. Furthermore, of these expansion groups we proposed to regard as eligible for Medicaid, we proposed to include in the disproportionate patient percentage (DPP) Medicaid fraction numerator only the days of those patients who receive from the demonstration (1) health insurance that covers inpatient hospital services or (2) premium assistance that covers 100 percent of the premium cost to the patient, which the patient uses to buy health insurance that covers inpatient hospital services, provided in either case that the patient is not also entitled to Medicare Part A. Finally, we proposed specifically that patients whose inpatient hospital costs are paid for with funds from an uncompensated/undercompensated care pool authorized by a section 1115 demonstration would not be patients “regarded as” eligible for Medicaid, and the days of such patients may not be included in the DPP Medicaid fraction numerator.

E. Use of the Best Available Data for the FY 2024 IPPS and LTCH PPS Ratesetting

We primarily use two data sources in the IPPS and LTCH PPS ratesetting: claims data and cost report data. The
would be fewer COVID–19 hospitalizations for Medicare beneficiaries in FY 2022 than there were in FY 2020. Therefore, we finalized our proposal to use FY 2019 data for the FY 2022 ratesetting for circumstances where the FY 2020 data was significantly impacted by the COVID–19 PHE, based on the belief that FY 2019 data from before the COVID–19 PHE would be a better overall approximation of the FY 2022 inpatient experience at both IPPS hospitals and LTCHs. As discussed in the FY 2023 IPPS/LTCH PPS final rule (87 FR 48795 through 48798), we discussed that the FY 2021 MedPAR claims file and the FY 2020 HCRIS dataset (the most recently available data at the time of rulemaking) both contain data that was significantly impacted by the COVID–19 PHE, primarily in that the utilization of services at IPPS hospitals and LTCHs was again generally markedly different for certain types of services in FY 2021 than would have been expected in the absence of the virus that causes COVID–19. Based on review of the most recent hospitalization data and information available from the CDC at the time of rulemaking, we also stated our belief that it would be reasonable to assume that some Medicare beneficiaries would continue to be hospitalized with COVID–19 at IPPS hospitals and LTCHs in FY 2023. However, we also stated our belief that it would be reasonable to assume based on the information available at the time that there would be fewer COVID–19 hospitalizations in FY 2023 than in FY 2021. Accordingly, because we anticipated Medicare inpatient hospitalizations for COVID–19 would continue in FY 2023 but at a lower level, we finalized our proposal to use FY 2021 data for purposes of the FY 2023 IPPS and LTCH PPS ratesetting but with several modifications to our usual ratesetting methodologies to account for the anticipated decline in COVID–19 hospitalizations of Medicare beneficiaries at IPPS hospitals and LTCHs as compared to FY 2021.

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26671), we analyzed the FY 2022 MedPAR claims file and the FY 2021 HCRIS dataset, which are the most recently available data for FY 2024 ratesetting. We observed that certain shifts in inpatient utilization and costs that occurred in FY 2020 continued to persist in FY 2022. Specifically, the share of admissions at IPPS hospitals and LTCHs for MS–DRGs and MS–LTC–DRGs that are associated with the treatment of COVID–19 continued to remain at levels higher than those observed in the pre-pandemic data.

For example, in FY 2019, the share of IPPS cases grouped to MS–DRG 177 (Respiratory Infections and Inflammations with major complication or comorbidity (MCC)) was approximately 1 percent, while in FY 2022 the share of IPPS cases grouped to MS–DRG 177 was approximately 4 percent. Similarly, in FY 2019, the share of LTCH PPS standard Federal payment rate cases grouped to MS–LTC–DRG 207 (Respiratory System Diagnosis with Ventilator Support >96 Hours) was approximately 18 percent, while in FY 2022 the share of LTCH PPS standard Federal payment rate cases grouped to MS–LTC–DRG 207 was approximately 22 percent.

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26671), we also reviewed the most recent COVID–19 related data and information released by the CDC. We presented this CDC graph which illustrates new inpatient hospital admissions of patients with confirmed COVID–19 from August 1, 2020 through January 20, 2023. (https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/01202023/images/hospitalizations.png?_2=4630, accessed January 20, 2023).
We stated that the graph shows that in the United States, patients continue to be hospitalized with the virus that causes COVID–19. We also noted that the CDC has stated that new variants will continue to emerge. Viruses constantly change through mutation and sometimes these mutations result in a new variant of the virus. Some variants spread more easily and quickly than other variants, which may lead to more cases of COVID–19. Even if a variant causes less severe disease in general, an increase in the overall number of cases could cause an increase in hospitalizations.2 In the proposed rule, we concluded that based on the information available at the time, we believe there will continue to be COVID–19 cases treated at IPPS hospitals and LTCHs in FY 2024, such that it is appropriate to use the FY 2022 data, as the most recent available data, for purposes of the FY 2024 IPPS and LTCH PPS ratesetting. We also stated that based on the information available at the time, we do not believe there is a reasonable basis for us to assume that there will be a meaningful difference in the number of COVID–19 cases treated at IPPS hospitals and LTCHs in FY 2024 relative to FY 2022 to the extent that modifications to our usual ratesetting methodologies would be warranted. As such, we stated our belief that FY 2022 data, as the most recent available data, is the best available data for approximating the inpatient experience at IPPS hospitals and LTCHs in FY 2024. Therefore, we proposed to use the FY 2022 MedPAR claims file and the FY 2021 HCRIS dataset (which contains data from many cost reports ending in FY 2022 based on each hospital’s cost reporting period) for purposes of the FY 2024 IPPS and LTCH PPS ratesetting. For the reasons discussed, we did not propose any modifications to our usual ratesetting methodologies to account for the impact of COVID–19 on the ratesetting data.

The comments we received on our proposal to use FY 2022 data for purposes of the FY 2024 IPPS and LTCH PPS ratesetting were focused on the specific use of FY 2022 data when determining the FY 2024 outlier fixed-loss amounts. Therefore, we refer the reader to section II.A.4. of the addendum to this final rule for our summary and response to comments received on our proposal to use FY 2022 data and our usual methodology when determining the FY 2024 outlier fixed-loss amounts for IPPS cases. We refer the reader to section V.D.3. of the Addendum to this final rule for our summary and response to comments received on our proposal to use FY 2022 data and our usual methodology when determining the FY 2024 outlier fixed-loss amounts for LTCH PPS standard Federal payment rate cases.

For the reasons discussed in those sections, we are finalizing our proposal to use FY 2022 data for purposes of the FY 2024 IPPS and LTCH PPS ratesetting. (That is, the FY 2022 MedPAR claims file and the FY 2021 HCRIS dataset (which contains data from many cost reports ending in FY 2022 based on each hospital’s cost reporting period).) We also are finalizing, with modification, our proposal to use our usual ratesetting methodologies for purposes of the FY 2024 IPPS and LTCH PPS ratesetting. As discussed in section V.D.3. of the addendum to this final rule, after consideration of the comments received, we are modifying our proposed methodology for establishing the FY 2024 outlier fixed-loss amount for LTCH PPS standard Federal payment rate cases.

F. Potential Payment Under the IPPS for Establishing and Maintaining Access to Essential Medicines

In the CY 2024 Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Proposed Rule (CMS 1786–P) issued on July 13, 2023, we included a request for public comments on potential payment under the IPPS for establishing and maintaining access to essential medicines. As discussed in that rule, we are seeking comment on, and may consider finalizing based on the review of comments received, as early as for cost reporting periods beginning on or after January 1, 2024, separate payment under IPPS, for establishing and maintaining access to a buffer stock of essential medicines to foster a more reliable, resilient supply of these medicines. Public comments are being accepted through September 11, 2023.

II. Changes to Medicare Severity Diagnosis-Related Group (MS-DRG) Classifications and Relative Weights

A. Background

Section 1886(d) of the Act specifies that the Secretary shall establish a classification system (referred to as diagnosis-related groups (DRGs)) for inpatient discharges and adjust payments under the IPPS based on appropriate weighting factors assigned to each DRG. Therefore, under the IPPS, Medicare pays for inpatient hospital services on a rate per discharge basis that varies according to the DRG to which a beneficiary’s stay is assigned. The formula used to calculate payment for a specific case multiplies an

---

individual hospital’s payment rate per case by the weight of the DRG to which the case is assigned. Each DRG weight represents the average resources required to care for cases in that particular DRG, relative to the average resources used to treat cases in all DRGs.

Section 1886(d)(4)(C) of the Act requires that the Secretary adjust the DRG classifications and relative weights at least annually to account for changes in resource consumption. These adjustments are made to reflect changes in treatment patterns, technology, and any other factors that may change the relative use of hospital resources.

B. Adoption of the MS–DRGs and MS–DRG Reclassifications

For information on the adoption of the MS–DRGs in FY 2008, we refer readers to the FY 2008 IPPS final rule with comment period (72 FR 47140 through 471889). For general information about the MS–DRG system, including yearly reviews and changes to the MS–DRGs, we refer readers to the previous discussions in the FY 2010 IPPS/rate year (FY 2010 LTCH PPS final rule (74 FR 43764 through 43766) and the FYs 2011 through 2023 IPPS/LTCH PPS final rules (75 FR 50053 through 50055; 76 FR 51485 through 51487; 77 FR 53273; 78 FR 50512; 79 FR 49871; 80 FR 49342; 81 FR 56787 through 56789; 82 FR 38010 through 38005; 83 FR 41158 through 41258; 84 FR 42058 through 42165; 85 FR 58444 through 58596; 86 FR 44795 through 44961; and 87 FR 48800 through 48891).

For discussion regarding our previously finalized policies (including our historical adjustments to the payment rates) relating to the effect of changes in documentation and coding that do not reflect real changes in case mix, we refer readers to the FY 2023 IPPS/LTCH PPS final rule (87 FR 48799 through 48800).

Comment: Several commenters requested that CMS make a positive adjustment to restore the full amount of the documentation and coding recoupment adjustments in the FY 2024 IPPS final rule which they asserted is required under section (7)(B)(2) and (4) of the TMA [Transitional Medical Assistance], Abstinence Education, and QI [Qualifying Individuals] Programs Extension Act of 2007 (Pub. L. 110–90). Commenters stated that the statute is explicit that CMS may not carry forward any documentation and coding adjustments applied in fiscal years 2010 through 2017 into IPPS rates after FY 2023. Commenters contended that CMS, by its own admission, has restored only 2.9588 percentage points of a total 3.9 percentage point reduction. By not fully restoring the total reductions, commenters believe that CMS is improperly extending payment adjustments beyond the FY 2023 statutory limit. A commenter stated that, even if CMS disputes it is required to make such an adjustment, CMS should use its special exceptions and adjustments authority to address the shortfall.

Response: As of FY 2023, CMS completed the statutory requirements of section 7(b)(1)(B) of Pub. L. 110–90 as amended by section 631 of the American Taxpayer Relief Act of 2012 (ATRA, Pub. L. 112–240), section 404 of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), and section 15005 of the 21st Century Cures Act (Pub. L. 114–255). As we discussed in the FY 2022 IPPS/LTCH PPS final rule (86 FR 44794 through 44795), the FY 2021 IPPS/LTCH PPS final rule (85 FR 58444 through 58445) and in prior rules, we believe section 414 of the MACRA and section 15005 of the 21st Century Cures Act set forth the levels of positive adjustments for FYs 2018 through 2023. We are not convinced that the adjustments prescribed by MACRA were predicated on a specific adjustment level estimated or implemented by CMS in previous rulemaking. We see no evidence that Congress enacted these adjustments with the intent that CMS would make an additional +0.7 percentage point adjustment in FY 2018 to compensate for the higher than expected final ATRA adjustment made in FY 2017, nor are we persuaded that it would be appropriate to use the Secretary’s exceptions and adjustments authority under section 1886(d)(5)(I) of the Act to adjust payments in FY 2024 restore any additional amount of the original 3.9 percentage point reduction, given Congress’ directive regarding prescriptive adjustment levels under section 414 of the MACRA and section 15005 of the 21st Century Cures Act. Accordingly, in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38009), we implemented the required +0.4588 percentage point adjustment to the standardized amount for FY 2018. In the FY 2019 IPPS/LTCH PPS final rule (FY 2019 final rule) (83 FR 41157), the FY 2020 IPPS/LTCH PPS final rule (FY 2020 final rule) (84 FR 42057), the FY 2021 IPPS/LTCH PPS final rule (FY 2021 final rule) (85 FR 58444 and 58445), the FY 2022 IPPS/LTCH PPS final rule (FY 2022 final rule) (86 FR 44794 and 44795), and the FY 2023 IPPS/LTCH PPS final rule (FY 2023 final rule) (87 FR 48800), consistent with the requirements of section 414 of the MACRA, we implemented 0.5 percentage point positive adjustments to the standardized amount for FY 2019, FY 2020, FY 2021, FY 2022 and FY 2023, respectively. As discussed in the FY 2023 final rule, the finalized 0.5 percentage point positive adjustment for FY 2023 is the final adjustment prescribed by section 414 of the MACRA.

C. Changes to Specific MS–DRG Classifications

1. Discussion of Changes to Coding System and Basis for FY 2024 MS–DRG Updates
   a. Conversion of MS–DRGs to the International Classification of Diseases, 10th Revision (ICD–10)

As of October 1, 2015, providers use the International Classification of Diseases, 10th Revision (ICD–10) coding system to report diagnoses and procedures for Medicare hospital inpatient services under the MS–DRG system instead of the ICD–9–CM coding system, which was used through September 30, 2015. The ICD–10 coding system includes the International Classification of Diseases, 10th Revision, Clinical Modification (ICD–10–CM) for diagnosis coding and the International Classification of Diseases, 10th Revision, Procedure Coding System (ICD–10–PCS) for inpatient hospital procedure coding, as well as the ICD–10–CM and ICD–10–PCS Official Guidelines for Coding and Reporting. For a detailed discussion of the conversion of the MS–DRGs to ICD–10, we refer readers to the FY 2017 IPPS/LTCH PPS final rule (81 FR 56787 through 56789).

b. Basis for FY 2024 MS–DRG Updates

As discussed in the FY 2023 IPPS/ LTCH PPS proposed rule (87 FR 28127) and final rule (87 FR 48800 through 48801), beginning with FY 2024 MS–DRG classification change requests, we changed the deadline to request changes to the MS–DRGs to October 20 of each year to allow for additional time for the review and consideration of any proposed updates. We also described the new process for submitting requested changes to the MS–DRGs via a new electronic application intake system, Medicare Electronic Application Request Information SystemTM (MEARISTM), accessed at https://mearis.cms.gov. We stated that beginning with FY 2024 MS–DRG classification change requests, CMS will only accept requests submitted via MEARISTM and will no longer consider...
requests sent via email. Additionally, we noted that within MEARISTM, we have built in several resources to support users, including a “Resources” section available at https://mearis.cms.gov/public/resources with technical support available under “Useful Links” at the bottom of the MEARISTM site. Questions regarding the MEARISTM system can be submitted to CMS using the form available under “Contact”, also at the bottom of the MEARISTM site.

We note that the burden associated with this information collection requirement is the time and effort required to collect and submit the data in the request for MS–DRG classification changes to CMS. The aforementioned burden is subject to the Paperwork Reduction Act (PRA) of 1995 and approved under Office of Management and Budget (OMB) control number 0938–1431 and has an expiration date of 09/30/2025.

As noted previously, interested parties had to submit MS–DRG classification change requests for FY 2024 by October 20, 2022. As we have discussed in prior rulemaking, we may not be able to fully consider all of the requests that we receive for the upcoming fiscal year. We have found that, with the implementation of ICD–10, some types of requested changes to the MS–DRG classifications require more extensive research to identify and analyze all of the data that are relevant to evaluating the potential change. We note in the discussion that follows those topics for which further research and analysis are required, and which we will continue to consider in connection with future rulemaking. Interested parties should submit any comments and suggestions for FY 2025 by October 20, 2023 via MEARISTM at: https://mearis.cms.gov/public/home.

As we did for the FY 2023 IPPS/LTCH PPS proposed rule, for the FY 2024 IPPS/LTCH PPS proposed rule we provided a test version of the ICD–10 MS–DRG GROUPER Software, Version 41, so that the public can better analyze and understand the impact of the proposals included in the proposed rule. We noted that this test software reflected the proposed GROUPER logic for FY 2024. Therefore, it included the new diagnosis and procedure codes that are effective for FY 2024 as reflected in Table 6A.—New Diagnosis Codes—FY 2024 and Table 6B.—New Procedure Codes—FY 2024 that were associated with the proposed rule and does not include the diagnosis codes that are invalid for FY 2024 as reflected in Table 6C.—Invalid Diagnosis Codes—FY 2024 associated with the proposed rule. We noted that at the time of the development of the proposed rule there were no procedure codes designated as invalid for FY 2024, and therefore, there was no Table 6D—Invalid Procedure Codes—FY 2024 associated with the proposed rule.

Those tables were not published in the Addendum to the proposed rule, but are available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/Acute InpatientPPS/index.html as described in section VI. of the Addendum to the proposed rule. Because the diagnosis codes no longer valid for FY 2024 are not reflected in the test software, we made available a supplemental file in Table 6P.1a that includes the mapped Version 41 FY 2024 ICD–10–CM codes and the deleted Version 40.1 FY 2023 ICD–10–CM codes that should be used for testing purposes with users’ available claims data. Therefore, users had access to the test software allowing them to build case examples that reflect the proposals that were included in the proposed rule. In addition, users were able to view the draft version of the ICD–10 MS–DRG Definitions Manual, Version 41.


Following are the changes that we proposed to the MS–DRGs for FY 2024. We invited public comments on each of the MS–DRG classification proposed changes, as well as our proposals to maintain certain existing MS–DRG classifications discussed in the proposed rule. In some cases, we proposed changes to the MS–DRG classifications based on our analysis of claims data and clinical appropriateness. In other cases, we proposed to maintain the existing MS–DRG classifications based on our analysis of claims data and clinical appropriateness. As discussed in the FY 2024 IPPS/LTCH PPS proposed rule, our initial MS–DRG analysis was based on ICD–10 claims data from the September 2022 update of the FY 2022 MedPAR file, which contains hospital bills received from October 1, 2021, through September 30, 2022. In our discussion of the proposed MS–DRG reclassification MS–DRG for FY 2024 as reflected in the proposed rule and in this section, we referred to those claims data as the “September 2022 update of the FY 2022 MedPAR file.” Separately, where otherwise indicated, additional analysis was based on ICD–10 claims data from the December 2022 update of the FY 2022 MedPAR file, which contains hospital bills received by CMS through December 31, 2022, for discharges occurring from October 1, 2021, through September 30, 2022. In our discussion of the proposed MS–DRG reclassification changes, we referred to those claims data as the “December 2022 update of the FY 2022 MedPAR file.” Specifically, as discussed further in the proposed rule and in this section, we used the additional claims data available in the December 2022 update of the FY 2022 MedPAR file to assess the application of the NonCC subgroup criteria to existing MS–DRGs with a three-way severity level split, as well as to simulate restructuring of any proposed MS–DRGs, to assess the case counts and other criteria for determining whether a proposed new base MS–DRG would satisfy the criteria to create subgroups.

As explained in previous rulemaking (76 FR 51487), in deciding whether to propose to make further modifications to the MS–DRGs for particular circumstances brought to our attention, we consider whether the resource consumption and clinical characteristics of the patients with a given set of conditions are significantly different than the remaining patients represented in the MS–DRG. We evaluate patient care costs using average costs and lengths of stay and rely on clinical factors to determine whether patients are clinically distinct or similar to other patients represented in the MS–DRG. In evaluating resource costs, we consider both the absolute and percentage differences in average costs between the cases we select for review and the remainder of cases in the MS–DRG. We also consider variation in costs within these groups; that is, whether observed average differences are consistent across patients or attributable to cases that are extreme in terms of costs or length of stay, or both. Further, we consider the number of patients who will have a given set of characteristics and generally prefer not to create a new MS–DRG unless it would include a substantial number of cases.

In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58448), we finalized our proposal to expand our existing criteria to create a new complication or comorbidity (CC) or major complication or comorbidity (MCC) subgroup within a base MS–DRG. Specifically, we finalized the criteria to include the NonCC subgroup for a three-way severity level split. We stated we
believed that applying these criteria to the NonCC subgroup would better reflect resource stratification as well as promote stability in the relative weights by avoiding low volume counts for the NonCC level MS–DRGs. We noted that in our analysis of MS–DRG classification requests for FY 2021 that were received by November 1, 2019, as well as any additional analyses that were conducted in connection with those requests, we applied these criteria to each of the MCC, CC, and NonCC subgroups. We also noted that the application of the NonCC subgroup criteria going forward may result in modifications to certain MS–DRGs that are currently split into three severity levels and result in MS–DRGs that are split into two severity levels. We stated that any proposed modifications to the MS–DRGs would be addressed in future rulemaking consistent with our annual process and reflected in Table 5.—List of Medicare Severity Diagnosis-Related Groups (MS–DRGs), Relative Weighting Factors, and Geometric and Arithmetic Mean Length of Stay for the applicable fiscal year.

In the FY 2022 IPPS/LTCH PPS final rule (86 FR 44798), we finalized a delay in applying this technical criterion to existing MS–DRGs until FY 2023 or future rulemaking, in light of the PHE. Interested parties recommended that a complete analysis of the MS–DRG changes to be proposed for future rulemaking in connection with the expanded three-way severity split criteria be conducted and made available to enable the public an opportunity to review and consider the redistribution of cases, the impact to the relative weights, payment rates, and hospital case mix to allow meaningful comment prior to implementation.

In the FY 2023 IPPS/LTCH PPS final rule (87 FR 48803), we also finalized a delay in application of the NonCC subgroup criteria to existing MS–DRGs with a three-way severity level split in light of the ongoing PHE and until such time additional analyses can be performed to assess impacts, as discussed in response to public comments in the FY 2022 and FY 2023 IPPS/LTCH PPS final rules.

In our analysis of the MS–DRG classification requests for FY 2024 that we received by October 20, 2022, as well as any additional analyses that were conducted in connection with those requests, we applied these criteria to each of the MCC, CC, and NonCC subgroups, as described in the following table.

<table>
<thead>
<tr>
<th>Criteria Number and Description</th>
<th>Three-Way Split 123 (MCC vs CC vs NonCC)</th>
<th>Two-Way Split 1,23 (MCC vs (CC+NonCC))</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. At least 500 cases in the MCC/CC/NonCC group</td>
<td>500+ cases for MCC group; and 500+ cases for CC group; and 500+ cases for NonCC group</td>
<td>500+ cases for MCC group; and 500+ cases for (CC+NonCC) group</td>
</tr>
<tr>
<td>2. At least 5% of the patients are in the MCC/CC/NonCC group</td>
<td>5%+ cases for MCC group; and 5%+ cases for CC group; and 5%+ cases for NonCC group</td>
<td>5%+ cases for MCC group; and 5%+ cases for (CC+NonCC) group</td>
</tr>
<tr>
<td>3. There is at least a 20% difference in average cost between subgroups</td>
<td>20%+ difference in average cost between MCC group and CC group; and 20%+ difference in average cost between CC group and NonCC group</td>
<td>20%+ difference in average cost between MCC group and (CC+NonCC) group</td>
</tr>
<tr>
<td>4. There is at least a $2,000 difference in average cost between subgroups</td>
<td>$2,000+ difference in average cost between MCC group and CC group; and $2,000+ difference in average cost between CC group and NonCC group</td>
<td>$2,000+ difference in average cost between MCC group and (CC+NonCC) group</td>
</tr>
<tr>
<td>5. The R2 of the split groups is greater than or equal to 3</td>
<td>R2 &gt; 3.0 for the three way split within the base MS-DRG</td>
<td>R2 &gt; 3.0 for the two way 1,23 split within the base MS-DRG</td>
</tr>
</tbody>
</table>

In general, once the decision has been made to propose to make further modifications to the MS–DRGs as described previously, such as creating a new base MS–DRG, or in our evaluation of a specific MS–DRG classification request to split (or subdivide) an existing base MS–DRG into severity levels, all five criteria must be met for the base MS–DRG to be split (or subdivided) by a CC subgroup. We note that in our analysis of requests to create a new MS–DRG, we typically evaluate the most recent year of MedPAR claims data available. For example, we stated earlier that for the FY 2024 IPPS/LTCH PPS proposed rule, our initial MS–DRG analysis was generally based on ICD–10 claims data from the September 2022 update of the FY 2022 MedPAR file, with the additional claims data...
available in the December 2022 update of the FY 2022 MedPAR file used to assess the case counts and other criteria for determining whether a proposed new base MS–DRG would satisfy the criteria to create subgroups. However, in our evaluation of requests to split an existing base MS–DRG into severity levels, as noted in prior rulemaking (80 FR 49368), we typically analyze the most recent two years of data. This analysis includes 2 years of MedPAR claims data to compare the data results from 1 year to the next to avoid making determinations about whether additional severity levels are warranted based on an isolated year’s data fluctuation and also to validate that the established severity levels within a base MS–DRG are supported. The first step in our process of evaluating if the creation of a new CC subgroup within a base MS–DRG is warranted is to determine if all the criteria is satisfied for a three-way split. In applying the criteria for a three-way split, a base MS–DRG is initially subdivided into the three subgroups: MCC, CC, and NonCC. Each subgroup is then analyzed in relation to the other two subgroups using the volume (Criteria 1 and 2), average cost (Criteria 3 and 4), and reduction in variance (Criteria 5). If the criteria fail, the next step is to determine if the criteria are satisfied for a two-way split. In applying the criteria for a two-way split, a base MS–DRG is initially subdivided into two subgroups: “with MCC” and “without MCC” (1_23) or “with CC/MCC” and “without CC/MCC” (12_3). Each subgroup is then analyzed in relation to the other using the volume (Criteria 1 and 2), average cost (Criteria 3 and 4), and reduction in variance (Criteria 5). If the criteria for both of the two-way splits fail, then a split (or CC subgroup) would generally not be warranted for that base MS–DRG.

If the three-way split fails on any one of the five criteria and all five criteria for both two-way splits (1_23 and 12_3) are met, we would apply the two-way split with the highest R^2 value. We note that if the request to split (or subdivide) an existing base MS–DRG into severity levels specifies the request is for either one of the two-way splits (1_23 or 12_3), in response to the specific request, we will evaluate the criteria for both of the two-way splits, however we do not also evaluate the criteria for a three-way split.

As previously noted, to validate whether the established severity levels within a base MS–DRG are supported, we typically analyze the most recent two years of MedPAR claims data. For the FY 2024 IPPS/LTCH PPS proposed rule, using the December 2022 update of the FY 2022 MedPAR file and the March 2022 update of the FY 2021 MedPAR file, we also analyzed how applying the NonCC subgroup criteria to all MS–DRGs currently split into three severity levels would potentially affect the MS–DRG structure in connection with the proposed FY 2024 MS–DRG classification changes. While, as previously noted, our MS–DRG analysis for the FY 2024 IPPS/LTCH PPS proposed rule was otherwise based on ICD–10 claims data from the September 2022 update of the FY 2022 MedPAR file, we utilized the additional claims data available from the December 2022 update of the FY 2022 MedPAR file for purposes of assessing the application of the NonCC subgroup criteria to these existing MS–DRGs as well as to determine whether a proposed new base MS–DRG satisfies the criteria to create subgroups. In the FY 2024 IPPS/LTCH PPS proposed rule, we noted that findings from our analysis indicated that approximately 45 base MS–DRGs would be subject to change based on the three-way severity level split criterion finalized in FY 2021. Specifically, we found that applying the NonCC subgroup criteria to all MS–DRGs currently split into three severity levels would result in the potential deletion of 135 MS–DRGs (45 MS–DRGs × 3 severity levels =135) and the potential creation of 86 new MS–DRGs.

We referred the reader to Table 6P.10—Potential MS–DRG Changes with Application of the NonCC Subgroup Criteria and Detailed Data Analysis—FY 2024 associated with the proposed rule and available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS for detailed information, including the criteria to create subgroups in Table 6P.10a (as also set forth in the preceding table) and the list of the 135 MS–DRGs that would potentially be subject to deletion and the list of the 86 MS–DRGs that would potentially be created in Table 6P.10b. We noted that we also identified an additional 12 obstetric MS–DRGs (4 base MS–DRGs × 3 severity levels=12) that would be subject to change based on the application of the three-way severity level split criterion, as reflected in our data analysis in Table 6P.10c associated with the proposed rule. However, in response to prior public comments expressing concern about the historical low volume of the obstetric related MS–DRGs being subject to application of the NonCC subgroup criteria and consistent with our discussion in prior rulemaking regarding this population in our Medicare claims data and the development of these MS–DRGs (83 FR 41210), we stated we believed it may be appropriate to exclude these MS–DRGs from application of the NonCC subgroup criteria. The list of 12 obstetric MS–DRGs is shown in the following table.

<table>
<thead>
<tr>
<th>List of 12 Obstetric MS–DRGs to Potentially Exclude from Application of the NonCC Subgroup Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MS–DRG</strong></td>
</tr>
<tr>
<td>783</td>
</tr>
<tr>
<td>784</td>
</tr>
<tr>
<td>785</td>
</tr>
<tr>
<td>796</td>
</tr>
<tr>
<td>797</td>
</tr>
<tr>
<td>798</td>
</tr>
<tr>
<td>817</td>
</tr>
<tr>
<td>818</td>
</tr>
<tr>
<td>819</td>
</tr>
<tr>
<td>831</td>
</tr>
<tr>
<td>832</td>
</tr>
<tr>
<td>833</td>
</tr>
</tbody>
</table>
We also referred the reader to Table 6P.10d for the data analysis of all 49 base MS–DRGs that would be subject to change based on the application of the three-way severity level split criterion and to Table 6P.10e for the corresponding data dictionary that describes the meaning of the data elements and assists with interpretation of the data related to our analysis with application of the NonCC subgroup criteria. We noted, in our analysis of the claims data and as reflected in Table 6P.10d, we identified four base MS–DRGs currently subdivided with a three-way severity level split (4 base MS–DRGs × 3 severity levels=12 MS–DRGs) that result in the potential creation of a single, base MS–DRG when grouped under the proposed V41 GROUPER software with application of the NonCC subgroup criteria. As shown in Table 6P.10d, the four current base MS–DRGs (excluding the 4 obstetric related base DRGs) are base MS–DRGs 283, 296, 411, and 799. In addition to not satisfying the criterion that there be at least 500 cases in the NonCC subgroup for a three-way severity level split, these four base MS–DRGs also failed one or more of the other criteria to create subgroups. For example, our review of base MS–DRGs 283 and 296 showed they failed the criterion that there be at least 5% or more of the patient cases in the NonCC subgroup. For base MS–DRG 411, we found the criterion that there be at least 500 cases in each subgroup for a three-way severity level split, as well as in each subgroup for both of the two-way severity level splits, was not met. Lastly, for base MS–DRG 799, we found less than 500 cases in at least two of three subgroups for a three-way severity level split, as well as for at least one of the two subgroups for a two-way severity level split, and the R2 value was less than 3.0 for the two-way severity level split.

We also referred the reader to Table 6P.10f for the alternate cost weight analysis with application of the NonCC subgroup criteria that includes transfer-adjusted cases from the December 2022 update of the FY 2022 MedPAR file under the proposed V41 ICD–10–MS–DRG GROUPER Software, the MS–DRG relative weights calculated under the proposed V41 ICD–10–MS–DRG GROUPER Software, and the changes in MS–DRG relative weights between those calculated under the proposed V41 GROUPER Software and those calculated under the alternate V41.A GROUPER Software. We noted that to facilitate the structural comparison between the proposed V41 GROUPER and the alternate V41.A GROUPER, the relative weights calculated using the proposed V41 GROUPER Software (column F) did not reflect application of the 10-percent cap. We further noted that changes in the status for transfer adjusted cases were reflected for the relative weights calculated using the proposed V41 GROUPER Software only and were not reflected for the alternate MS–DRG weights with application of the NonCC subgroup criteria. We noted, as shown in Table 6P.10f, that we found five MS–DRGs for which there appears to be a greater than negative 10% change between the relative weight calculated under the proposed V41 GROUPER Software and the calculated alternate relative weight under the V41.A GROUPER Software with application of the NonCC subgroup criteria. As shown in Table 6P.10f, the five MS–DRGs are existing MS–DRG 021 (potential new MS–DRG 105), existing MS–DRG 411 (potential new MS–DRG 426), existing MS–DRG 573 (potential new MS–DRG 589), existing MS–DRG 574 (potential new MS–DRG 583), and existing MS–DRG 799 (potential new MS–DRG 649). Of the five existing MS–DRGs, two of the MS–DRGs are those for which a new single, base MS–DRG would potentially be created from the current three-way split, as previously described: MS–DRG 411 (potential new MS–DRG 426) and MS–DRG 799 (potential new MS–DRG 649). In the proposed rule, we stated that the findings were consistent with what we would expect given the low volume of cases in the NonCC subgroups compared to the volume of cases in the CC subgroups for these MS–DRGs.

As noted in prior rulemaking, any potential MS–DRG updates to be considered for a future proposal in connection with application of the NonCC subgroup criteria would also involve a redistribution of cases, which would impact the relative weights, and, thus, the payment rates proposed for particular types of cases. As such, and in response to prior public comments requesting that further analysis of the application of the NonCC subgroup criteria be made available, in addition to Table 6P.10f, we made available additional files reflecting application of the NonCC subgroup criteria in connection with the proposed FY 2024 MS–DRG changes, using the December 2022 update of the FY 2022 MedPAR file. These additional files included an alternate Table 5—Alternate List of Medicare Severity Diagnosis Related Groups (MS–DRGs), Relative Weighting Factors, and Geometric and Arithmetical Mean Length of Stay, an alternate Length of Stay (LOS) Statistics file, an alternate Case Mix Index (CMI) file, and an alternate After Outliers Removed and Before Outliers Removed (AOR_BOR) file. The files are available in association with the proposed rule on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/Acute InpatientPPS.

For the FY 2024 IPPS/LTCH PPS proposed rule we also provided an alternate test version of the ICD–10 MS–DRG GROUPER Software, Version 41.A, so that the public can better analyze and understand the impact on the proposals included in the proposed rule if the NonCC subgroup criteria were to be applied to existing MS–DRGs with a three-way severity level split. We noted that this alternate test software reflected the proposed GROUPER logic for FY 2024 as modified by the application of the NonCC subgroup criteria. Therefore, it included the new diagnosis and procedure codes that are effective for FY 2024 as reflected in Table 6A.—New Diagnosis Codes—FY 2024 and Table 6B.—New Procedure Codes—FY 2024 associated with the proposed rule and did not include the diagnosis codes that are invalid beginning in FY 2024 as reflected in Table 6C.—Invalid Diagnosis Codes—FY 2024 associated with the proposed rule. As previously noted, at the time of the development of the proposed rule there were no procedure codes designated as invalid for FY 2024, and therefore, there was no Table 6D—Invalid Procedure Codes—FY 2024 associated with the proposed rule. These tables were not published in the Addendum to the proposed rule, but are available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/Acute InpatientPPS/index.html as described in section VI. of the Addendum to the proposed rule. Because the diagnosis codes no longer valid for FY 2024 are not reflected in the alternate test software, we made available a supplemental file in Table 6P.1a that includes the mapped Version 41 FY 2024 ICD–10–CM codes and the deleted Version 40.1 FY 2023 ICD–10–CM codes that should be used for testing purposes with users’ available claims data.

Therefore, users had access to the alternate test software allowing them to build case examples that reflect the proposals included in the proposed rule.
with application of the NonCC subgroup criteria. Because the potential MS–DRG changes with application of the NonCC subgroup criteria are available in Table 6P.10b associated with the proposed rule, an alternate version of the ICD–10 MS–DRG Definitions Manual was not developed.

The alternate test version of the ICD–10 MS–DRG GROUPER Software, Version 41.A, and the supplemental mapping files in Table 6P.1a of the FY 2023 and FY 2024 ICD–10–CM diagnosis codes are available at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/Acute InpatientPPS/MS-DRG-Classifications-and-Software.

After delaying the application of the NonCC subgroup criteria for two years, and in response to prior public comments, we made available these additional analyses reflecting application of the criteria in connection with the proposed FY 2024 MS–DRG changes for public review and comment, to inform application of the NonCC subgroup criteria for FY 2025 rulemaking.

We proposed to continue to delay application of the NonCC subgroup criteria to existing MS–DRGs with a three-way severity level split for FY 2024. We stated that we were interested in hearing feedback regarding the experience of large urban hospitals, rural hospitals, and other hospital types and will take commenters’ feedback into consideration for our development of the FY 2025 proposed rule.

Comment: Commenters expressed appreciation that CMS provided additional files for review and consideration that reflect application of the NonCC subgroup criteria in connection with the FY 2024 proposed MS–DRG changes.

Response: We thank the commenters for their feedback.

Comment: Commenters supported the proposal to delay application of the NonCC subgroup criteria to existing MS–DRGs with a three-way severity level split for FY 2024 and to maintain the current structure of the 45 MS–DRGs that currently have a three-way split (total of 135 MS–DRGs). The commenters also expressed support for the proposal to exclude the 12 obstetric related MS–DRGs from application of the NonCC subgroup criteria in the future. Some commenters stated they agreed with the methodology for creating subgroups and viewed the consolidation as a positive change, however, the commenters also recommended that CMS continue to collect data and identify any unintended impacts to the MS–DRG relative weights because of the redistribution of cases from application of the NonCC subgroup criteria. Other commenters stated that although the COVID–19 PHE has ended, several hospitals are still recovering and further assessment of the impacts for low volume procedures in connection with the potential MS–DRG changes with application of the NonCC subgroup criteria is needed.

A couple commenters specifically requested that CMS provide additional analysis by hospital type for FY 2025 rulemaking to afford organizations additional time to review and forecast impacts, as well as to facilitate more informed comments in response to the CMS request for comments related to experiences of large urban hospitals, rural hospitals, and other hospital types.

Response: We appreciate the commenters’ support. We will continue to review and consider the feedback we have received for our development of the FY 2025 proposed rule.

Some commenters who expressed support for the proposed delay in application of the NonCC subgroup criteria for FY 2024 and for the additional analysis files that were made available stated that deleting and adding a large volume of MS–DRGs may create additional administrative burden. The commenters stated providers will need more time than is typically provided for implementation of finalized policies under the IPPS. The commenters urged CMS to work with interested parties in developing an appropriate implementation timeline. A commenter suggested that CMS consider implementing application of the NonCC subgroup criteria using a phased approach, over several years, to assist in the transition. This commenter encouraged CMS to continue to provide additional analysis files as was done with the proposed rule and to include the potential effects of a multi-year implementation plan.

Response: We thank the commenters for their support and feedback. We will continue to review and consider the feedback we have received for our development of the FY 2025 proposed rule.

Comment: A commenter who agreed it is appropriate to defer implementation of MS–DRG consolidation based on the three-way severity criteria specifically expressed concern that the policy may result in additional reductions to relative weights for important procedures, including intracranial vascular procedures. According to the commenter, intracranial vascular procedures have already experienced significant cuts in recent years. The commenter stated that based on the data that was made available in connection with the proposed rule, the estimates show that consolidation for five MS–DRGs, including potential new MS–DRG 105 (Intracranial Vascular Procedures with Principal Diagnosis Hemorrhage without MCC) would result in a more than 10 percent relative weight reduction (prior to the application of the current 10-percent cap). To the extent that CMS does adopt such MS–DRG consolidation in the future, the commenter recommended that CMS limit the single-year relative weight reductions resulting from cumulative policy changes to 5 percent.

The commenter also suggested that CMS consider building more flexibility into its assessment of severity level subdivisions for both new and existing MS–DRGs. According to the commenter, the requirement to meet multiple, rigid cost and volume cut-offs may detract from the assessment of important clinical and resource distinctions in patient populations within the MS–DRGs.

A few commenters expressed concern that the criterion of a 500-case volume may be too high, particularly for low volume services and MS–DRGs. The commenters stated that there has been tremendous growth in Medicare Advantage claims with a decrease in fee-for-service (FFS) claims flowing into rate-setting. The commenters stated additional analysis of this criterion is warranted and requested that CMS provide further information about the benefits.

Response: We appreciate the commenters’ feedback. We acknowledge the growth in Medicare Advantage claims and will continue to review and consider the feedback we have received for our development of the FY 2025 proposed rule.

In response to the commenter’s recommendation that CMS limit the single-year relative weight reductions to 5 percent, we note that there was extensive discussion in the FY 2023 IPPS/LTCH PPS final rule (87 FR 48897 through 48900) regarding the cap for relative weight reductions and refer the reader to that discussion for detailed information. We also refer the reader to the additional discussion in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26774 through 26775) and in section II.D.2.c. of the preamble of this final rule.

With regard to the commenter’s suggestion that more flexibility should be built into CMS’ assessment of severity level subdivisions for both new
and existing MS–DRGs, we note that currently, the minimum case volume requirements were established to avoid overly fragmenting the MS–DRG classification system. With smaller volumes they will be subject to stochastic (unpredictable) effects that may indicate a cost difference within the data sample. Reevaluation in subsequent years may result in those cost differences being insufficient to support the split.

We do not believe it is in the interest of the Medicare program or providers to establish and then remove MS–DRG splits. We believe that stability of MS–DRG payment is an important objective and therefore, that a volume requirement is a necessary adjunct to cost differentiation. We established a 500-case limit to meet this stability requirement. With this case limit, an MS–DRG split not meeting this minimum volume threshold will have fewer than 0.007% cases from which the MS–DRG RW is constructed. Under application of the NonCC subgroup criteria, hospitals would receive a payment weight that averages the two comorbidity split levels (CC and NonCC) and will thus only experience any potential negative impact to the extent that their case mix is comprised of cases with the (potentially) higher weight. We note, as discussed in prior rulemaking (86 FR 44878), the MS–DRG system is a system of averages and it is expected that within the diagnostic related groups, some cases may demonstrate higher than average costs, while other cases may demonstrate lower than average costs. We also provide outlier payments to mitigate extreme loss on individual cases.

**Comment:** A couple commenters requested clarification on how the policy to cap the reductions for MS–DRG relative weights to 10-percent would apply as CMS considers implementation of the NonCC subgroup criteria.

**Response:** As stated in the FY 2023 IPPS/LTCF PPS final rule (87 FR 48900), the 10-percent cap on reductions to an MS–DRG’s relative weight applies to new or modified MS–DRGs after the first fiscal year that the new or modified MS–DRGs take effect. Therefore, the 10-percent cap would not apply to the relative weight for any new or renumbered MS–DRGs for the first fiscal year. However, we recognize that application of the NonCC subgroup criteria may warrant special consideration with respect to the 10-percent cap on reductions to an MS–DRG’s relative weight and will continue to consider this issue in connection with our efforts to promote predictability and mitigate financial impacts resulting from significant fluctuations in the relative weights.

**Comment:** A couple commenters expressed concern that the additional files made available in connection with the proposed rule did not demonstrate how the explanatory power of the potential new MS–DRGs with application of the NonCC subgroup criteria is resulting in fewer MS–DRGs split into three severity levels, as well as when the criteria were applied to proposed new MS–DRG classification requests, none of the proposed new MS–DRGs with a two-way severity level split involved a “with CC/MCC” and “without CC/MCC” split.

**Response:** As discussed in the FY 2024 IPPS/LTCF proposed rule, we provided both a test version of the ICD–10 MS–DRG GROUPER Software, Version 41 and an alternate version of the ICD–10 MS–DRG GROUPER Software, Version 41.A so that the public could better analyze and understand the impact on the proposals included in the proposed rule if the NonCC subgroup criteria were to be applied to existing MS–DRGs with a three-way severity level split. We noted that this alternate test software reflected the proposed GROUPER logic for FY 2024 as modified by the application of the NonCC subgroup criteria. Overall, we believe the explanatory power (R2) for the V41.A alternate GROUPER yields similar results to the proposed V41 GROUPER. Based on our review, the explanatory power (R2) goes down by 0.04 percent with the V41.A alternate GROUPER, explaining less variation when compared to the V41 notice of proposed rulemaking (NPRM) GROUPER, however this result is as we would expect since the MS–DRGs subject to the NonCC subgroup criteria considered for potential adjustment are low volume to begin with.

<table>
<thead>
<tr>
<th>GROUPER Version</th>
<th>Number of Cases in Relative Weights Calculation</th>
<th>R2</th>
</tr>
</thead>
<tbody>
<tr>
<td>V41 NPRM</td>
<td></td>
<td>6,916,080</td>
</tr>
<tr>
<td>V41.A</td>
<td></td>
<td>6,916,081</td>
</tr>
</tbody>
</table>

In response to the concerns expressed that application of the NonCC subgroup criteria to existing MS–DRGs with a three-way severity level split appears to result in fewer MS–DRGs split by the presence of a CC, we note that the criteria for the two-way split of “with CC/MCC” and “without CC/MCC” requires that there be at least 500 cases in the NonCC group, and as discussed in the proposed rule, in applying the criteria for proposed new MS–DRGs, that volume requirement was not met. Alternatively, the criteria for the two-way split of “with MCC” and “without MCC” was met for specific proposals, and therefore, proposed.

We recognize and acknowledge the concerns raised by the commenters regarding the impact the application of the NonCC subgroup criteria to existing MS–DRGs with a three-way split appears to have on the presence of a CC for MS–DRG assignment. We will continue to examine this issue with respect to the criteria and how it also relates to the comprehensive CC/MCC analysis. We refer the reader to section II.C.12.b. of the preamble of this final rule for additional discussion related to the comprehensive CC/MCC analysis. Comments made available in connection with the proposed MS–DRG changes for FY 2024 if the intent is to delay application of the NonCC subgroup criteria until future rulemaking.

**Response:** As discussed in prior rulemaking, in general, once the decision has been made to propose to make further modifications to the MS–DRGs, such as creating a new base MS–DRG, all five criteria must be met for the base MS–DRG to be split (or subdivided) by a CC subgroup. We note that we have applied the criteria to create subgroups, including the application of the NonCC subgroup criteria, in our annual analysis of the MS–DRG classification requests.
DRG classification requests, consistent criteria, in our annual analysis of MS–
criteria to create subgroups, including application of the NonCC subgroup
subgroup criteria to existing MS–DRGs. For example, we applied the
criteria to create subgroups, including application of the NonCC subgroup
as discussed in our finalization of new base MS–DRG as discussed in our finalization of new base MS–DRG 018 (Chimeric
Antigen Receptor (CAR) T-cell
Immunotherapy), new base MS–DRG
019 (Simultaneous Pancreas and Kidney
Transplant with Hemodialysis), new
base MS–DRG 140 (Major Head and
Neck Procedures), new base MS–DRG
143 (Other Ear, Nose, Mouth and Throat
O.R. Procedures), new base MS–DRG
521 (Hip Replacement with Principal
Diagnosis of Hip Fracture) and new base
MS–DRG 650 (Kidney Transplant with
Hemodialysis) for FY 2021. In the FY
2021 IPPS/LTCH PPS final rule (85 FR
58448), we finalized our proposal to expand our existing criteria to create a
new CC or MCC subgroup within a base
MS–DRG. Specifically, we finalized the expansion of the criteria to include the NonCC subgroup for a three-way
severity level split.

Similarly, we applied the criteria to create subgroups including application of the NonCC subgroup criteria for MS–
DRG classification requests for FY 2022 that we received by November 1, 2020
(86 FR 44799 through 447998), for MS–
DRG classification requests for FY 2023
that we received by November 1, 2021
(87 FR 48801 through 48804), and for MS–DRG classification requests for FY
2024 that we received by October 20,
2022 (88 FR 26673 through 26676), as well as any additional analyses that were conducted in connection with those requests.

In the FY 2022 IPPS/LTCH PPS final rule (86 FR 44799) and FY 2023 IPPS/
LTCH PPS final rule (87 FR 48803), we finalized a delay in applying this
technical criterion to existing MS–DRGs
in light of the PHE. We take this
opportunity to clarify that the delay referenced in applying this
technical criterion to existing MS–DRGs
with a three-way severity level split.
Therefore, while we have made analyses for potential MS–DRG changes with application of the NonCC subgroup criteria publicly available, we have not
yet proposed application of the NonCC subgroup criteria to existing MS–DRGs
with a three-way severity level split. We
note that we will continue to apply the
criteria to create subgroups, including application of the NonCC subgroup
criteria, in our annual analysis of MS–
DRG classification requests, consistent
with our approach since FY 2021 when we finalized the expansion of the criteria to include the NonCC subgroup
for a three-way severity level split.

**Comment:** A few commenters expressed concerns about the fluctuations in potential MS–DRG restructuring with application of the NonCC subgroup criteria from FY 2021 through FY 2024 based on different sets of claims data.

**Response:** We note that we addressed similar comments in detail in the FY 2023 IPPS/LTCH PPS final rule (87 FR 48803 through 48804) and refer the reader to that discussion.

After consideration of the public comments we received, and for the reasons discussed, we are finalizing our proposal to delay the application of the NonCC subgroup criteria to existing MS–DRGs with a three-way severity level split until FY 2025 or later, and are finalizing for FY 2024 our proposal to maintain the current structure of the 45
MS–DRGs that currently have a three-way severity level split.

We are making the FY 2024 ICD–10
MS–DRG GROUPER and Medicare Code
Editor (MCE) Software Version 41; the
ICD–10 MS–DRG Definitions Manual
files Version 41 and the Definitions of
Medicare Code Edits Manual Version 41 available to the public on our CMS
website at: https://www.cms.gov/
Medicare/Medicare-Fee-for-Service/
Payment/ICD-10-CM/ICD-10-CM-Pro
tocols/ICD-10-CM-Grouped-Codes-and-
Software.

2. Major Diagnostic Category (MDC) 01:
(Diseases and Disorders of the Nervous
System): Epilepsy With Neurostimulator

The Responsive Neurostimulator (RNS®) System is a cranially implanted neurostimulator and is a treatment option for persons diagnosed with medically intractable epilepsy, a brain disorder characterized by persistent
seizure activity which despite maximal medical treatment, remains sufficiently
debilitating. In the FY 2024 IPPS/LTCH
PPS proposed rule (88 FR 26676 through 26681), we stated that cases involving the use of the RNS® System are identified by the reporting of an
ICD–10–PCS code combination
capturing a neurostimulator generator inserted into the skull with the insertion of a neurostimulator lead into the brain
(including cases involving the use of the RNS® neurostimulator) to MS–DRG 023
even if there is no MCC reported:
• 0NH00NZ (Insertion of
neurostimulator generator into skull,
open approach), in combination with
0H00MZ (Insertion of neurostimulator
lead into brain, open approach);
• 0NH00NZ (Insertion of
neurostimulator generator into skull,
open approach), in combination with
0H03MZ (Insertion of neurostimulator
lead into brain, percutaneous approach);
and
• 0NH00NZ (Insertion of
neurostimulator generator into skull,
open approach), in combination with
0H04MZ (Insertion of neurostimulator
lead into brain, percutaneous endoscopic approach).

We also finalized our proposed change to the title of MS–DRG 023 from
“Craniotomy with Major Device Implant
or Acute Complex Central Nervous
System (CNS) Principal Diagnosis (PDX)
with MCC or Chemo Implant” to
“Craniotomy with Major Device Implant
or Acute Complex Central Nervous
System (CNS) Principal Diagnosis (PDX)
with MCC or Chemotherapy Implant or
Epilepsy with Neurostimulator” to reflect the modifications to the MS–DRG
structure.

In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58459 through 58462), we discussed a request to reassign cases describing the insertion of a neurostimulator generator into the skull in combination with the insertion of a
neurostimulator lead into the brain from
MS–DRG 023 to MS–DRG 021
(Intracranial Vascular Procedures with
Principal Diagnosis Hemorrhage with
CC) or to reassign these cases to another
MS–DRG for more appropriate payment.
We stated that while the results of our
claims analysis indicated that the average costs of cases reporting a
neurostimulator generator inserted into
the skull with the insertion of a
neurostimulator lead into the brain
(including cases involving the use of the
RNS® neurostimulator), and a principal
diagnosis of epilepsy are higher
compared to the average costs for all
cases in their assigned MS–DRG, we
could not ascertain from the claims data
the resource use specifically attributable to the procedure during a hospital stay. We stated that we believed that further analysis of cases reporting a neurostimulator generator inserted into the skull with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator), and a principal diagnosis of epilepsy was needed prior to proposing any further reassignment of these cases to ensure clinical coherence between these cases and the other cases with which they may potentially be grouped and therefore did not propose to reassign cases describing a neurostimulator generator inserted into the skull with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator) from MS–DRG 023 to MS–DRG 021. We also did not propose to reassign Responsive Neurostimulator (RNS®) System cases to another MS–DRG. We stated we expected that, in future years, we would have additional data that could be used to evaluate the potential reassignment of cases reporting a neurostimulator generator inserted into the skull with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator), and a principal diagnosis of epilepsy.

In the FY 2024 IPPS/LTCH PPS proposed rule, we stated we received a similar request to reassign a neurostimulator generator inserted into the skull in combination with the insertion of a neurostimulator lead into the brain from MS–DRG 023 to MS–DRG 021 or reassign all cases currently assigned to MS–DRG 023 that involve a craniectomy or a craniotomy with the insertion of device implant and create a new MS–DRG for these cases. The requestor acknowledged both the refinements made to MS–DRG 023 effective for FY 2018 and the discussion in FY 2021 rulemaking, but stated that cases describing the insertion of a neurostimulator generator into the skull in combination with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator) are negatively impacted from a payment perspective in their current MS–DRG assignment due to the large number of cases, with a wide range of principal diagnoses, procedures, and procedure approaches, also assigned to MS–DRG 023 and MS–DRG 024 (Craniotomy with Major Device Implant or Acute Complex CNS Principal Diagnosis without MCC) and therefore continue to be underpaid. We stated in the FY 2024 IPPS/LTCH PPS proposed rule that the requestor performed its own analysis of Medicare claims data and stated that it found that the average costs of cases describing the insertion of the RNS® neurostimulator were significantly higher than the average costs of all cases in their current assignment to MS–DRG 023, and as a result, cases describing the insertion of the RNS® neurostimulator are not being adequately reimbursed.

The requestor suggested the following two options for MS–DRG assignment updates: (1) reassign cases describing the insertion of a neurostimulator generator into the skull in combination with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator) from MS–DRG 023 to MS–DRG 021 with a change in title to “Intracranial Vascular Procedures with PDx Hemorrhage with CC or Cranietomy with Neurostimulator;” or (2) extract all cases from MS–DRG 023 involving a craniectomy/craniotomy with device implant and create a new MS–DRG for these cases.

The requestor acknowledged that the relatively low volume of cases that only involve the insertion of a neurostimulator generator into the skull in combination with the insertion of a neurostimulator lead into the brain in the claims data is likely not sufficient to warrant the creation of a new MS–DRG. The requestor further stated given the limited options within the existing MS–DRG structure that fit from both a cost and clinical cohesiveness perspective, they believe that MS–DRG 021 is the most logical fit in terms of average costs and clinical coherence for reassignment of RNS® System cases even though, according to the requestor, the insertion of a neurostimulator generator into the skull in combination with the insertion of a neurostimulator lead into the brain is technically more complex and involves a higher level of training, extreme precision and sophisticated technology than performing a craniectomy for hemorrhage.

As another option, the requestor identified procedures involving a craniectomy or craniotomy by searching for ICD–10–PCS codes that describe the root operations “Destruction”, “Division”, “Drainage”, “Excision”, “Extrication”, or “Insertion” performed related to the brain or specific brain anatomy (for example, cerebral ventricle, cerebellum) with an “Open Approach” in the claims data. The requestor also said they identified claims involving a device implant by searching for ICD–10–PCS codes that describe the root operation “Insertion” and stated that they found that the claims they identified had average costs comparable to the average costs of RNS® cases and therefore creating a new MS–DRG for all cases involving a craniectomy/craniotomy with device implant was a reasonable alternative option.

We stated in the proposed rule that to begin our analysis, we identified the ICD–10–CM diagnosis codes that describe a diagnosis of epilepsy. We referred the reader to Table 6P.2a associated with the proposed rule (and available at: https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps for the list of the ICD–10–CM codes that we identified.

We stated in the proposed rule that we then examined the claims data from the September 2022 update of the FY 2022 MedPAR file for all cases in MS–DRG 023 and compared the results to cases reporting a neurostimulator generator inserted into the skull with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator) that had a principal diagnosis of epilepsy in MS–DRG 023. The following table shows our findings:

<table>
<thead>
<tr>
<th>MS-DRG 023</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>All cases</td>
<td>11,602</td>
<td>10.4</td>
<td>$47,321</td>
</tr>
<tr>
<td>Cases with principal diagnosis of epilepsy with neurostimulator generator inserted into the skull and insertion of a neurostimulator lead into brain</td>
<td>57</td>
<td>3.1</td>
<td>$58,676</td>
</tr>
</tbody>
</table>

BILLING CODE 4120–01–P
As shown in the table, for MS–DRG 023, we identified a total of 11,602 cases, with an average length of stay of 10.4 days and average costs of $47,321. Of those 11,602 cases in MS–DRG 023, there were 57 cases describing a neurostimulator generator inserted into the skull with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator) that had a principal diagnosis of epilepsy. We noted that the 57 cases describing a neurostimulator generator inserted into the skull with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator) and a principal diagnosis of epilepsy had an average length of stay of 3.1 days and average costs of $58,676, as compared to the average length of stay of 10.4 days and average costs of $47,321 for all cases in MS–DRG 023. We stated that while these neurostimulator cases had average costs that were $11,355 higher than the average costs of all cases in MS–DRG 023, there were only a total of 57 cases. We stated we reviewed these data, and agreed with the requestor that the number of cases continued to be too small to warrant the creation of a new MS–DRG for these cases, for the reasons discussed in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38015 through 38019) and the FY 2021 IPPS/LTCH PPS final rule (85 FR 58459 through 58462).

As stated in the proposed rule, we examined the reassignment of cases describing a neurostimulator generator inserted into the skull with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator) to MS–DRGs 020, 021, and 022 (Intracranial Vascular Procedures with PDX Hemorrhage with MCC, with CC, and without CC/MCC, respectively). While the request was to reassign these cases to MS–DRG 021, we noted that MS–DRG 021 is specifically differentiated according to the presence of a secondary diagnosis with a severity level designation of a complication or comorbidity (CC). Cases with a neurostimulator generator inserted into the skull with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator) do not always involve the presence of a secondary diagnosis with a severity level designation of a complication or comorbidity (CC), and therefore we reviewed data for all three MS–DRGs. The following table shows our findings:

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>020</td>
<td>2,016</td>
<td>13.9</td>
<td>$72,776</td>
</tr>
<tr>
<td>021</td>
<td>548</td>
<td>9.1</td>
<td>$53,973</td>
</tr>
<tr>
<td>022</td>
<td>270</td>
<td>3.9</td>
<td>$31,248</td>
</tr>
</tbody>
</table>

As shown in the table, for MS–DRG 020, there were a total of 2,016 cases with an average length of stay of 13.9 days and average costs of $72,776. For MS–DRG 021, there were a total of 548 cases with an average length of stay of 9.1 days and average costs of $53,973. For MS–DRG 022, there were a total of 270 cases with an average length of stay of 3.9 days and average costs of $31,248. Because all cases describing a neurostimulator generator inserted into the skull with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator) with a principal diagnosis of epilepsy are assigned MS–DRG 023 even if there is no MCC reported and there is a three-way split within MS–DRGs 020, 021, and 022, in the proposed rule we stated we also analyzed the cases reporting a neurostimulator generator inserted into the skull with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator) with a principal diagnosis of epilepsy for the presence or absence of a secondary diagnosis designated as a complication or comorbidity (CC) or a major complication or comorbidity (MCC). The following table shows our findings:

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>023</td>
<td>8</td>
<td>8.4</td>
<td>$68,486</td>
</tr>
<tr>
<td>020</td>
<td>14</td>
<td>2.4</td>
<td>$60,799</td>
</tr>
<tr>
<td>022</td>
<td>35</td>
<td>2.1</td>
<td>$55,585</td>
</tr>
</tbody>
</table>
As noted in the proposed rule, this data analysis shows that, similar to our findings as summarized in the FY 2018 and FY 2021 IPPS/LTCH PPS final rules, on average, the cases in MS–DRG 023 describing a neurostimulator generator inserted into the skull with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator) and a principal diagnosis of epilepsy have average costs that are relatively more similar to the average costs of cases in MS–DRG 021 ($58,676 compared to $53,973), while the average length of stay is shorter (3.1 days compared to 9.1 days). However, when distributed based on the presence or absence of a secondary diagnosis designated as a CC or an MCC, the 57 cases in MS–DRG 023 reporting a principal diagnosis of epilepsy with a neurostimulator generator inserted into the skull and insertion of a neurostimulator lead into brain have higher average costs and shorter lengths of stay than the cases in MS–DRG 020. We stated that we then explored reassigning the cases describing a neurostimulator generator inserted into the skull with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator) and a principal diagnosis of epilepsy from MS–DRG 023 to MS–DRGs 020, 021, or 022. We noted in the proposed rule that as also discussed in the FY 2018 and FY 2021 IPPS/LTCH PPS final rules, the cases in MS–DRGs 020, 021, and 022 have a principal diagnosis of a hemorrhage. The RNS® neurostimulator generators are not used to treat patients with diagnosis of a hemorrhage. We continued to believe that it is inappropriate to reassign cases representing a principal diagnosis of epilepsy to a MS–DRG that contains diagnosis of a hemorrhage. We stated we further analyzed the data to find cases comparable to cases involving the use of the RNS® System as these root operations all describe procedures performed for distinct and differing objectives. Instead, to review for similar utilization of resources, we stated we further analyzed the data to identify those cases currently reporting a procedure code combination representing neurostimulator generator and lead code combinations that are captured under the list referred to as “Major Device Implant” in the GROUPER logic for MS–DRGs 023 and 024 since the ICD–10–PCS codes that describe the root operations “Destruction”, “Division”, “Drainage”, “Excision”, “Exteripation”, or “Insertion” performed related to the brain or specific brain anatomy as suggested by the requestor was a reasonable approach to find cases comparable to cases involving the use of the RNS® System and average costs based on the more recent data continued to support this recommendation.

We noted, as discussed in section II.C.1.b of the proposed rule, using the December 2022 update of the FY 2022 MedPAR file, we analyzed how applying the NonCC subgroup criteria to all MS–DRGs currently split into three severity levels would affect the MS–DRG structure beginning in FY 2024. As stated in the proposed rule, findings from our analysis indicated that MS–DRGs 020, 021, and 022 as well as approximately 44 other base MS–DRGs would potentially be subject to change based on the three-way severity level split criterion finalized in FY 2021. We referred the reader to Table 6P.10b associated with the proposed rule (which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS) for the list of the 135 MS–DRGs that would be subject to deletion and the list of the 86 new MS–DRGs that would potentially be created if the NonCC subgroup criteria were applied.

We stated that we then explored alternative options, as was requested. As stated in the proposed rule, we did not agree that searching for ICD–10–PCS codes that describe the root operations “Destruction”, “Division”, “Drainage”, “Excision”, “Exteripation”, or “Insertion” performed related to the brain or specific brain anatomy as suggested by the requestor was a reasonable approach to find cases comparable to cases involving the use of the RNS® System as these root operations all describe procedures performed for distinct and differing objectives. Instead, to review for similar utilization of resources, we stated we further analyzed the data to identify those cases currently reporting a procedure code combination representing neurostimulator generator and lead code combinations that are captured under the list referred to as “Major Device Implant” in the GROUPER logic for MS–DRGs 023 and 024 since the ICD–10–PCS code combinations that capture the use of the RNS® neurostimulator generator and leads that would determine an assignment of a case to MS–DRGs 023 are also found on the “Major Device Implant” list. The neurostimulator generators on this list are inserted into the skull, as well as into the subcutaneous areas of the chest, back, or abdomen. The leads are all inserted into the brain. The following table shows our findings:
We noted that the 90 Major Device Implant list cases involving a neurostimulator generator (including cases involving the use of the RNS® neurostimulator and a principal diagnosis of epilepsy) have an average length of stay of 7.3 days and average costs of $59,733 as compared to all 11,602 cases in MS–DRG 023, which have an average length of stay of 10.4 days and average costs of $47,321. In MS–DRG 024, we noted that the 395 Major Device Implant list cases involving a neurostimulator generator have an average length of stay of 1.6 days and average costs of $36,147 as compared to all 4,378 cases in MS–DRG 024, which have an average length of stay of 5.2 days and average costs of $32,613. In the proposed rule, we stated that we were unable to identify another MS–DRG in MDC 01 that would be a more appropriate MS–DRG assignment for these cases based on the indication for and complexity of the procedure.

We noted that while our data findings demonstrated the average costs are higher for the 57 cases with a principal diagnosis of epilepsy with neurostimulator generator inserted into the skull and insertion of a neurostimulator lead into brain when compared to all cases in MS–DRG 023, these cases represent a small percentage of the total number of cases reported in this MS–DRG. We stated that while we appreciated the requestor’s concerns regarding the differential in average costs for cases describing the insertion of a neurostimulator generator into the skull in combination with the insertion of a neurostimulator lead into the brain when compared to all cases in their assigned MS–DRG, we believe additional time is needed to evaluate these cases as part of our ongoing examination of the case logic for MS–DRGs 023 through 027. As discussed in the FY 2023 IPPS/LTCH PPS final rule (87 FR 48808 through 48820), in connection with our analysis of cases reporting LITT procedures performed on the brain or brain stem in MDC 01, we have started to examine the logic for case assignment to MS–DRGs 023 through 027 to determine where further refinements could potentially be made to better account for differences in the technical complexity and resource utilization among the procedures that are currently assigned to those MS–DRGs. In the proposed rule, we stated that specifically, we are in the process of evaluating procedures that are performed using an open craniotomy (where it is necessary to surgically remove a portion of the skull) versus a percutaneous burr hole (where a hole approximately the size of a pencil is drilled) to obtain access to the brain in the performance of a procedure. We are also reviewing the indications for these procedures, for example, malignant neoplasms versus epilepsy to consider if there may be merit in considering restructuring the current MS–DRGs to better recognize the clinical distinctions.
of these patient populations in the MS–DRGs. As part of this evaluation, as discussed in the proposed rule, we have begun to analyze the ICD–10 coded claims data from the September 2022 update of the FY 2022 MedPAR file to determine if the patients’ diagnoses, the objective of the procedure performed, the specific anatomical site where the procedure is performed or the surgical approach used (for example, open, percutaneous, percutaneous endoscopic, among others) demonstrates a greater severity of illness and/or increased treatment difficulty as we consider restructuring MS–DRGs 023 through 027, including how to better align the clinical indications with the performance of specific intracranial procedures. We refer the reader to Tables 6P.2b through 6P.2f associated with the proposed rule (which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPSI) for data analysis findings of cases assigned to MS–DRGs 023 through 027 as we continue to look for patterns of complexity and resource intensity.

In summary, in the proposed rule, we stated we believe that further analysis of cases reporting a neurostimulator generator inserted into the skull with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator) and a principal diagnosis of epilepsy is needed in connection with our analysis of the claims data for MS–DRGs 023 through 027 prior to proposing any further reassignment of these cases, to ensure clinical coherence between these cases and the other cases with which they may potentially be grouped. Therefore, we did not propose to reassign cases describing a neurostimulator generator inserted into the skull with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator) and a principal diagnosis of epilepsy with neurostimulator generator inserted into the skull and insertion of a neurostimulator lead into brain. The commenter stated this refinement would result in a much better alignment of the average costs of these cases compared to their current MS–DRG assignment.

Response: We thank the commenter for their feedback. We continue to be receptive to concerns about payment for cases reporting procedure codes that describe a neurostimulator generator inserted into the skull with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator) and a principal diagnosis of epilepsy with neurostimulator generator inserted into the skull and insertion of a neurostimulator lead into brain. The commenter stated this refinement would result in a much better alignment of the average costs of these cases compared to their current MS–DRG assignment.

Response: We thank the commenter for their feedback. We continue to be receptive to concerns about payment for cases reporting procedure codes that describe a neurostimulator generator inserted into the skull with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator) and a principal diagnosis of epilepsy with neurostimulator generator inserted into the skull and insertion of a neurostimulator lead into brain. The commenter stated this refinement would result in a much better alignment of the average costs of these cases compared to their current MS–DRG assignment.

Comment: Some commenters expressed support for CMS’ proposal to maintain the assignment of cases reporting procedure codes that describe a neurostimulator generator inserted into the skull with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator) in MS–DRG 023 and to not propose to create a new MS–DRG for cases involving a craniectomy/ craniotomy with device implant. A commenter stated they agreed that it was inappropriate to reassign cases that involve craniectomy or craniotomy with the insertion of neurostimulator into the skull in combination with the insertion of a neurostimulator lead into the brain from MS–DRG 023 (Cranioemty with Major Device Implant or Acute Complex CNS Principal Diagnosis with MCC or Chemotherapy Implant or Epilepsy with Neurostimulator) to MS–DRG 021 (Intracranial Vascular Procedures with Principal Diagnosis Hemorrhage with CC). This commenter also stated that due to the low volume of total cases, they agreed that creation of a new MS–DRG was not warranted.

Response: We appreciate the commenters’ support.

Comment: Another commenter opposed CMS’ proposal. The commenter stated CMS’ data analysis demonstrated that the average costs of RNS® System cases continue to be substantially higher than the average costs of all cases assigned to MS–DRG 023. This commenter further stated that they believed the data analysis supports extracting cases reporting procedure codes that describe a neurostimulator generator inserted into the skull with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator) (e.g., Major Device Implant list) from MS–DRGs 023 and 024 and creating new MS–DRGs with logic maintained for cases with a principal diagnosis of epilepsy with neurostimulator generator inserted into the skull and insertion of a neurostimulator lead into brain. The commenter stated this refinement would result in a much better alignment of the average costs of these cases compared to their current MS–DRG assignment.

Response: We appreciate the commenter’s statement that they agreed that it was inappropriate to reassign cases that involve craniectomy or craniotomy with the insertion of neurostimulator into the skull in combination with the insertion of a neurostimulator lead into the brain from MS–DRG 023 (Cranioemty with Major Device Implant or Acute Complex CNS Principal Diagnosis with MCC or Chemotherapy Implant or Epilepsy with Neurostimulator) to MS–DRG 021 (Intracranial Vascular Procedures with Principal Diagnosis Hemorrhage with CC). This commenter also stated that due to the low volume of total cases, they agreed that creation of a new MS–DRG was not warranted.

Response: We appreciate the commenters’ support.

Comment: Another commenter opposed CMS’ proposal. The commenter stated CMS’ data analysis demonstrated that the average costs of RNS® System cases continue to be substantially higher than the average costs of all cases assigned to MS–DRG 023. This commenter further stated that they believed the data analysis supports extracting cases reporting procedure codes that describe a neurostimulator generator inserted into the skull with the insertion of a neurostimulator lead into the brain (including cases involving the use of the RNS® neurostimulator) (e.g., Major Device Implant list) from MS–DRGs 023 and 024 and creating new MS–DRGs with logic maintained for cases with a principal diagnosis of epilepsy with neurostimulator generator inserted into the skull and insertion of a neurostimulator lead into brain. The commenter stated this refinement would result in a much better alignment of the average costs of these cases compared to their current MS–DRG assignment.

Response: We appreciate the commenter’s statement that they agreed that it was inappropriate to reassign cases that involve craniectomy or craniotomy with the insertion of neurostimulator into the skull in combination with the insertion of a neurostimulator lead into the brain from MS–DRG 023 (Cranioemty with Major Device Implant or Acute Complex CNS Principal Diagnosis with MCC or Chemotherapy Implant or Epilepsy with Neurostimulator) to MS–DRG 021 (Intracranial Vascular Procedures with Principal Diagnosis Hemorrhage with CC). This commenter also stated that due to the low volume of total cases, they agreed that creation of a new MS–DRG was not warranted.

Response: We appreciate the commenter’s statement that they agreed that it was inappropriate to reassign cases that involve craniectomy or craniotomy with the insertion of neurostimulator into the skull in combination with the insertion of a neurostimulator lead into the brain from MS–DRG 023 (Cranioemty with Major Device Implant or Acute Complex CNS Principal Diagnosis with MCC or Chemotherapy Implant or Epilepsy with Neurostimulator) to MS–DRG 021 (Intracranial Vascular Procedures with Principal Diagnosis Hemorrhage with CC). This commenter also stated that due to the low volume of total cases, they agreed that creation of a new MS–DRG was not warranted.
CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software for complete documentation of the GROUPER logic for MS–DRGs 023 through 027. Feedback and other suggestions may be submitted by October 20, 2023 and directed to the new electronic intake system, Medicare Electronic Application Request Information System™ (MEARISTM), discussed in section II.C.1.b. of the preamble of the proposed rule and this final rule at: https://mearis.cms.gov/public/home.

Comment: In response to CMS’ request for public comment and feedback on the potential restructuring of the craniotomy MS–DRGs for future consideration, a commenter stated they do not believe there is a need for CMS to re-evaluate the assignment of neurosurgical procedures within the craniotomy MS–DRGs 023 through 027. This commenter stated that the procedures in these MS–DRGs have been well established from a clinical homogeneity perspective, as well as a resource utilization perspective, and the procedures costs have been stable. Another commenter stated they appreciate CMS’ willingness to review the craniotomy/craniectomy MS–DRGs to ensure proper alignment of procedures, indications, technical complexity, and resource utilization. This commenter further noted there are a wide array of diagnoses and procedures that fall within this range of MS–DRG and stated they believe there are a variety of ways these MS–DRGs can be classified.

A commenter mentioned that CMS referred the reader to Tables 6P.2b through 6P.2f associated with the proposed rule (which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS) for the data analysis findings of cases assigned to MS–DRGs 023 through 027 and expressed concern that there was no discussion of these findings or their significance in the proposed rule. This commenter suggested that CMS comment on the following:

• How is CMS defining technical complexity and what factors are being considered in the analysis?
• Are there other data not included in Tables 6P.2b through 6P.2f that CMS is analyzing?
• What is the timing for completion of the full analysis of MS–DRGs 023–027?

Response: We thank the commenters for their feedback and will take these recommendations into consideration as we further examine the logic for case assignment. The data analysis as displayed in Tables 6P.2b through 6P.2f associated with the proposed rule was displayed to provide the public an opportunity to review our examination of the procedures by their approach (open versus percutaneous), clinical indications, and procedures that involve the insertion or implantation of a device and to reflect on what factors should be considered in the potential restructuring of these MS–DRGs. We welcome further feedback on how CMS should define technical complexity, what factors should be considered in the analysis, and whether there are other data not included in Tables 6P.2b through 6P.2f that CMS should analyze.

As discussed in the proposed rule, and earlier in this section, as we continue the analysis of the claims data with respect to MS–DRGs 023 through 027, we are interested in receiving feedback on where further refinements could potentially be made to better account for differences in the technical complexity and resource utilization among these procedures that are currently assigned to these MS–DRGs. Feedback and other suggestions may be submitted by October 20, 2023 and directed to the new electronic intake system, Medicare Electronic Application Request Information System™ (MEARISTM) at https://mearis.cms.gov/public/home. We note that we would address any proposed modifications to the existing logic in future rulemaking.

3. MDC 02 (Diseases and Disorders of the Eye): Retinal Artery Occlusion

In the FY 2023 IPPS/LTCH PPS final rule (88 FR 48830 through 48835), we discussed a request we received to reassign cases reporting diagnosis codes describing central retinal artery occlusion, and the closely allied condition, branch retinal artery occlusion, from MS–DRG 123 (Neurological Eye Disorders) in MDC 02 (Diseases and Disorders of the Eye) to MS–DRGs 061, 062, and 063 (Ischemic Stroke Precerebral Occlusion or Transient Ischemia with Thrombolytic Agent with MCC, with CC, and without CC/MCC, respectively) in MDC 01 (Diseases and Disorders of the Nervous System). Retinal artery occlusion refers to blockage of the retinal artery that carries oxygen to the nerve cells in the retina at the back of the eye, often by an embolus or thrombus. A blockage in the main artery in the retina is called central retinal artery occlusion (CRAO). A blockage in a smaller artery is called branch retinal artery occlusion (BRAO).

Based on the various data analyses we performed to explore the possible reassignment of cases with a principal diagnosis of CRAO or BRAO with a procedure code describing the administration of a thrombolytic agent or a procedure code describing hyperbaric oxygen therapy, and the clinical analysis discussed, for FY 2023 we did not propose any MS–DRG changes for cases with a principal diagnosis of CRAO or BRAO with a procedure code describing the administration of a thrombolytic agent or a procedure code describing hyperbaric oxygen therapy.

In response to this final policy, as discussed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26681 through 26684), we received a request to again review the MS–DRG assignment of cases involving CRAO. According to the requestor, CRAO is a form of acute ischemic stroke which occurs when a vessel supplying blood to the brain is obstructed and there is growing recognition of this diagnosis as a vascular neurological problem. The requestor stated new evidence outlines treatment of patients with CRAO with acute stroke protocols, specifically with intravenous thrombolysis (IV tPA) or hyperbaric oxygen therapy (HBOT), to improve outcomes. We stated in the proposed rule that the requestor stated they performed an internal analysis of their claims data and found that the average costs of cases reporting a procedure code describing the administration of a thrombolytic agent with a principal diagnosis of CRAO were 2.5 times higher than the average costs of cases with a principal diagnosis of CRAO that did not report the administration of a thrombolytic agent. The requestor further stated the increased utilization of resources of these cases was isolated to be almost entirely due to the cost of the tPA itself based on this review of their internal cost level data. Consequently, the requestor stated the continued assignment of these conditions to MS–DRG 123 does not properly recognize disease complexity and underestimates the resource utilization associated with administering critical (potentially vision-saving) treatments for these cases.

The requestor suggested that the following three MS–DRGs be created to reflect current standard of care for these patients:

• Suggested New MS–DRG XXX—Neurological Eye Disorders with Thrombolytic Agent with MCC.
• Suggested New MS–DRG XXX—Neurological Eye Disorders with Thrombolytic Agent with CC.
• Suggested New MS–DRG XXX—Neurological Eye Disorders with Thrombolytic Agent without CC/MCC.

We stated in the proposed rule that in reviewing this issue, it was unclear why the requestor did not include branch retinal artery occlusion (BRAO) in their request for FY 2024 rulemaking. As discussed in the FY 2023 IPPS/LTCH PPS final rule, BRAO is a closely allied condition. Therefore, we identified the ICD–10–CM codes found in the following table that describe CRAO and BRAO.

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>H34.10</td>
<td>Central retinal artery occlusion, unspecified eye</td>
</tr>
<tr>
<td>H34.11</td>
<td>Central retinal artery occlusion, right eye</td>
</tr>
<tr>
<td>H34.12</td>
<td>Central retinal artery occlusion, left eye</td>
</tr>
<tr>
<td>H34.13</td>
<td>Central retinal artery occlusion, bilateral</td>
</tr>
<tr>
<td>H34.231</td>
<td>Retinal artery branch occlusion, right eye</td>
</tr>
<tr>
<td>H34.232</td>
<td>Retinal artery branch occlusion, left eye</td>
</tr>
<tr>
<td>H34.233</td>
<td>Retinal artery branch occlusion, bilateral</td>
</tr>
<tr>
<td>H34.239</td>
<td>Retinal artery branch occlusion, unspecified eye</td>
</tr>
</tbody>
</table>

We stated in the proposed rule that thrombolytic therapy is identified with the following ICD–10–PCS procedure codes.

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3E03017</td>
<td>Introduction of other thrombolytic into peripheral vein, open approach</td>
</tr>
<tr>
<td>3E03317</td>
<td>Introduction of other thrombolytic into peripheral vein, percutaneous approach</td>
</tr>
<tr>
<td>3E04017</td>
<td>Introduction of other thrombolytic into central vein, open approach</td>
</tr>
<tr>
<td>3E04317</td>
<td>Introduction of other thrombolytic into central vein, percutaneous approach</td>
</tr>
<tr>
<td>3E05017</td>
<td>Introduction of other thrombolytic into peripheral artery, open approach</td>
</tr>
<tr>
<td>3E05317</td>
<td>Introduction of other thrombolytic into peripheral artery, percutaneous approach</td>
</tr>
<tr>
<td>3E06017</td>
<td>Introduction of other thrombolytic into central artery, open approach</td>
</tr>
<tr>
<td>3E06317</td>
<td>Introduction of other thrombolytic into central artery, percutaneous approach</td>
</tr>
</tbody>
</table>

In this final rule, we would like to correct the statement in the proposed rule and add that thrombolytic therapy is also identified with the following two ICD–10–PCS procedure codes.

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3E08017</td>
<td>Introduction of other thrombolytic into heart, open approach</td>
</tr>
<tr>
<td>3E08317</td>
<td>Introduction of other thrombolytic into heart, percutaneous approach</td>
</tr>
</tbody>
</table>

We stated in the proposed rule that our analysis of this grouping issue again confirmed that, when a procedure code describing the administration of a thrombolytic agent is reported with principal diagnosis code describing CRAO or BRAO, these cases group to medical MS–DRG 123. We refer the reader to the ICD–10 MS–DRG Definitions Manual Version 40.1, which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software for complete documentation of the GROUPER logic for MS–DRG 123.

To begin our analysis, as discussed in the proposed rule, we examined claims data from the September 2022 update of the FY 2022 MedPAR file for MS–DRG 123 to (1) identify cases reporting a principal diagnosis code describing CRAO or BRAO without a procedure code describing the administration of a thrombolytic agent and (2) identify cases reporting diagnosis codes describing CRAO or BRAO with a procedure code describing the administration of a thrombolytic agent.

Our findings are shown in the following table:
As shown in the table, we identified a total of 2,771 cases within MS–DRG 123 with an average length of stay of 2.5 days and average costs of $6,720. Of these 2,771 cases, there are 839 cases that reported a principal diagnosis code describing CRAO or BRAO without a procedure code describing the administration of a thrombolytic agent with an average length of stay of 2.2 days and average costs of $5,842. There are 38 cases that reported a principal diagnosis code describing CRAO or BRAO with a procedure code describing the administration of a thrombolytic agent with an average length of stay of 3.3 days and average costs of $13,302.

We stated in the proposed rule that the data analysis showed that the 839 cases in MS–DRG 123 reporting a principal diagnosis code describing CRAO or BRAO without a procedure code describing the administration of a thrombolytic agent have lower average costs as compared to all cases in MS–DRG 123 ($5,842 compared to $6,720), and a shorter average length of stay (2.2 days compared to 2.5 days). For the 38 cases in MS–DRG 123 reporting a principal diagnosis code describing CRAO or BRAO with a procedure code describing the administration of a thrombolytic agent, however, the average length of stay is longer (3.3 days compared to 2.5 days) and the average costs are higher ($13,302 compared to $6,720) than the average length of stay and average costs compared to all cases in that MS–DRG.

We stated in the proposed rule that we reviewed these data and did not believe that the small subset of cases reporting a principal diagnosis code describing CRAO or BRAO with a procedure code describing the administration of a thrombolytic agent warranted the creation of new MS–DRGs at this time. As stated in prior rulemaking, the MS–DRGs are a classification system intended to group together diagnoses and procedures with similar clinical characteristics and utilization of resources. We generally seek to identify sufficiently large sets of claims data with a resource/cost similarity and clinical similarity in developing diagnostic-related groups rather than smaller subsets. Moreover, in response to the specific request to create new MS–DRGs subdivided into severity levels for the cases reporting a principal diagnosis code describing CRAO or BRAO with a procedure code describing the administration of a thrombolytic agent, we only identified a total of 38 cases, so the criterion that there are at least 500 or more cases in each subgroup cannot be met. Therefore, for FY 2024, we did not propose to create new MS–DRGs subdivided into severity levels for cases reporting a principal diagnosis code describing CRAO or BRAO with a procedure code describing the administration of a thrombolytic agent.

We stated however, that the average costs of the small number of cases reporting a principal diagnosis code describing CRAO or BRAO with a procedure code describing the administration of a thrombolytic agent are greater when compared to the average costs of all cases in MS–DRG 123. To explore other mechanisms to address this request, we then reexamined the MS–DRGs within MDC 02 to consider the possibility of reassigning the cases with a principal diagnosis of CRAO or BRAO that receive the administration of a thrombolytic agent to other MS–DRGs within MDC 02. As discussed in the proposed rule, after further consideration, in reviewing the claims data from the September 2022 update of the FY 2022 MedPAR file and examining the clinical considerations, we stated that we believe that the cases reporting a principal diagnosis code describing CRAO or BRAO could more suitably group to MS–DRGs 124 and 125 (Other Disorders of the Eye with MCC, and without MCC, respectively), which contain diagnoses other than neurological conditions that affect the eye, noting the vascular involvement inherent to a diagnosis of CRAO or BRAO. We refer the reader to the ICD–10 MS–DRG Definitions Manual Version 40.1, which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare–Fee-for–Service–Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software for complete documentation of the GROUPER logic for MS–DRGs 124 and 125.

To determine how the resources for this subset of cases compared to cases in MS–DRGs 124 and 125 as a whole, we stated we examined the average costs and length of stay for cases in MS–DRGs 124 and 125. Our findings are shown in this table.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>All cases</td>
<td>2,771</td>
<td>2.5</td>
<td>$6,720</td>
</tr>
<tr>
<td>Cases reporting a principal diagnosis of CRAO or BRAO without a procedure code describing the administration of a thrombolytic agent</td>
<td>839</td>
<td>2.2</td>
<td>$5,842</td>
</tr>
<tr>
<td>Cases reporting a principal diagnosis of CRAO or BRAO with a procedure code describing the administration of a thrombolytic agent</td>
<td>38</td>
<td>3.3</td>
<td>$13,302</td>
</tr>
<tr>
<td>All other cases</td>
<td>1,894</td>
<td>2.6</td>
<td>$6,977</td>
</tr>
</tbody>
</table>
For this subset of cases, the average costs of the 38 cases reporting a principal diagnosis code describing CRAO or BRAO without a procedure code describing the administration of a thrombolytic agent have lower average costs ($5,842 compared to $7,425) and a shorter average length of stay (2.2 compared to 3.3 days) than for cases in MS–DRG 125.

We stated in the proposed rule that our analysis demonstrated that while the volume of cases is small, the average costs for the cases reporting a principal diagnosis code describing CRAO or BRAO without a procedure code describing the administration of a thrombolytic agent currently grouping to MS–DRG 123 are more aligned with the average costs of the cases currently grouping to MS–DRG 124. We stated we reviewed these data and supported the addition of the ten diagnosis codes listed previously to the GROUPER logic list for MS–DRG 124. In the proposed rule, we believed reassigning these diagnosis codes to MS–DRGs 124 and 125 would better account for the subset of patients who are treated with a thrombolytic agent, and would more appropriately reflect the resources involved in evaluating and treating these patients. We also stated we supported the assignment of the cases reporting procedure codes describing the administration of a thrombolytic agent to the higher (MCC) severity level MS–DRG 124 as an enhancement to better reflect the clinical severity and resource use involved in these cases.

For this subset of cases, the average costs of the 38 cases reporting a principal diagnosis code describing CRAO or BRAO with a procedure code describing the administration of a thrombolytic agent are slightly higher ($13,302 compared to $11,922) and the average length of stay is shorter (3.3 days compared to 5.4 days) than for all cases in MS–DRGs 124. The 839 cases reporting a principal diagnosis code describing CRAO or BRAO without a procedure code describing the administration of a thrombolytic agent have lower average costs ($5,842 compared to $7,425) and a shorter average length of stay (2.2 compared to 3.3 days) than for cases in MS–DRG 125.

We stated in the proposed rule that our analysis demonstrated that while the volume of cases is small, the average costs for the cases reporting a principal diagnosis code describing CRAO or BRAO with a procedure code describing the administration of a thrombolytic agent currently grouping to MS–DRG 123 are more aligned with the average costs of the cases currently grouping to MS–DRG 124. We stated we reviewed these data and supported the addition of the ten diagnosis codes listed previously to the GROUPER logic list for MS–DRG 124. In the proposed rule, we believed reassigning these diagnosis codes to MS–DRGs 124 and 125 would better account for the subset of patients who are treated with a thrombolytic agent, and would more appropriately reflect the resources involved in evaluating and treating these patients. We also stated we supported the assignment of the cases reporting procedure codes describing the administration of a thrombolytic agent to the higher (MCC) severity level MS–DRG 124 as an enhancement to better reflect the clinical severity and resource use involved in these cases.

Therefore, we proposed to reassign ICD–10–CM diagnosis codes H34.10, H34.11, H34.12, H34.13, H34.231, H34.232, H34.233, and H34.239 from MDC 02 MS–DRG 123 to MS–DRGs 124 and 125, effective October 1, 2023, for FY 2024. We also proposed to add the procedure codes describing the administration of a thrombolytic agent listed previously to MS–DRG 124. In the proposed rule, we noted that the procedure codes describing the administration of a thrombolytic agent are not designated as operating room procedures for purposes of MS–DRG assignment (“non-O.R. procedures”), therefore, as part of the logic for MS–DRG 124, we also proposed to designate these codes as non-O.R. procedures affecting the MS–DRG. Lastly, for consistency, we also proposed to change the titles of MS–DRGs 124 and 125 from “Other Disorders of the Eye, with and without MCC, respectively” to “Other Disorders of the Eye with MCC or Thrombolytic Agent, and without MCC, respectively” to better reflect the assigned procedures.

Comment: Commenters agreed with our proposal to reassign ICD–10–CM diagnosis codes H34.10, H34.11, H34.12, H34.13, H34.231, H34.232, H34.233, and H34.239 from MDC 02 MS–DRG 123 to MS–DRGs 124 and 125. A commenter stated that this proposal better aligns with the resource consumption of these cases. Another commenter stated that the proposed MS–DRG assignment of cases reporting a principal diagnosis code describing CRAO or BRAO with a procedure code describing the administration of a thrombolytic agent would more accurately capture the complexity of the condition and the necessary resources associated with administering critical treatments.

Response: We thank the commenters for their support.

After consideration of the public comments we received, we are finalizing our proposal to reassign ICD–10–CM diagnosis codes H34.10, H34.11, H34.12, H34.13, H34.231, H34.232, H34.233, and H34.239 from MDC 02 MS–DRG 123 to MS–DRGs 124 and 125, effective October 1, 2023, for FY 2024. In addition, we are finalizing our proposal to add the procedure codes describing the administration of a thrombolytic agent listed previously to MS–DRG 124. As part of the logic for MS–DRG 124, we are also finalizing our proposal to designate the 10 ICD–10–PCS procedure codes describing the administration of a thrombolytic agent listed previously as non-O.R. procedures affecting the MS–DRG. Lastly, we are finalizing our proposal to change the titles of MS–DRGs 124 and 125 from “Other Disorders of the Eye, with and without MCC, respectively” to “Other Disorders of the Eye with MCC or Thrombolytic Agent, and without MCC, respectively” to better reflect the assigned procedures for FY 2024.

4. MDC 04 (Diseases and Disorders of the Respiratory System)

a. Ultrasound Accelerated Thrombolysis for Pulmonary Embolism

As discussed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26684 through 26691), we received a request to reassign cases reporting ultrasound accelerated thrombolysis (USAT) with the administration of thrombolytic(s) for the treatment of pulmonary embolism (PE) from MS–DRGs 166, 167, and 168 (Other Respiratory System O.R. Procedures with MCC, with CC, and without CC/MCC, respectively) to MS–DRGs 163, 164, and 165 (Major Chest Procedures with MCC, with CC, and without CC/MCC, respectively).

A pulmonary embolism is an obstruction of pulmonary vasculature most commonly caused by a venous thrombus, and less commonly by fat or tumor tissue or air bubbles or both. Risk factors for a pulmonary embolism include prolonged immobilization from any cause, obesity, cancer, fractured hip or leg, use of certain medications such as oral contraceptives, presence of certain medical conditions such as heart failure, sickle cell anemia, or certain congenital heart defects. Common symptoms of pulmonary embolism include shortness of breath with or without chest pain, tachycardia, hemoptysis, low grade fever, pleural effusion, and depending on the etiology of the embolus, might include lower extremity pain or swelling, syncope, jugular venous distention. Alternatively, a pulmonary embolus could be asymptomatic.

Thrombolysis is a type of treatment where the infusion of thrombolytics (fibrinolytic or “clot-busting” drugs) is used to dissolve blood clots that form in the arteries or veins with the goal of

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG 124--All cases</td>
<td>889</td>
<td>5.4</td>
<td>$11,922</td>
</tr>
<tr>
<td>MS-DRG 125--All cases</td>
<td>2,424</td>
<td>3.3</td>
<td>$7,425</td>
</tr>
</tbody>
</table>
improving blood flow and preventing long-term damage to tissues and organs. When a clot forms in the arteries of the lungs it is known as a pulmonary embolism. In addition, clots in the veins of the legs causing deep venous thrombosis (DVT) may also result in pulmonary embolism if a piece of the clot breaks off and travels to an artery in the lungs. Conventional catheter-directed thrombolysis (CDT) procedures generally rely on a multi-sidehole catheter placed adjacent to the thrombus through which thrombolytics are delivered directly to the thrombus, however, the EKOSTM EkoSonic® Endovascular System (EKOSTM System) employs ultrasound to assist in thrombolysis. The ultrasound does not itself dissolve the thrombus, but pulses of ultrasonic energy temporarily make the fibrin in the thrombus more porous and increase fluid flow within the thrombus. High frequency, low-intensity ultrasonic waves create a pressure gradient that drives the thrombolytic into the thrombus and keeps it in close proximity to the binding sites. USAT is also referred to as ultrasound-assisted thrombolysis or ultrasound-enhanced thrombolysis. As discussed in the proposed rule, according to the requestor (the manufacturer of the EKOSTM device), USAT with the administration of thrombolytic(s) for the treatment of PE performed using the EKOSTM device utilizes more resources in comparison to other procedures that are currently assigned to MS–DRGs 166, 167, and 168 and is not clinically coherent with the other procedures assigned to those MS–DRGs. The requestor stated that the cases reporting USAT with the administration of thrombolytic(s) for PE are more comparable with and more clinically aligned with the procedures assigned to MS–DRGs 163, 164, and 165. The requestor stated they performed an analysis of cases reporting USAT for PE with the following ICD–10–PCS procedure codes.

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02FP3Z0</td>
<td>Fragmentation of pulmonary trunk, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>02FQ3Z0</td>
<td>Fragmentation of right pulmonary artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>02FR3Z0</td>
<td>Fragmentation of left pulmonary artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>02FS3Z0</td>
<td>Fragmentation of right pulmonary vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>02FT3Z0</td>
<td>Fragmentation of left pulmonary vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>03F23Z0</td>
<td>Fragmentation of innominate artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>03F33Z0</td>
<td>Fragmentation of right subclavian artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>03F43Z0</td>
<td>Fragmentation of left subclavian artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>03F53Z0</td>
<td>Fragmentation of right axillary artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>03F63Z0</td>
<td>Fragmentation of left axillary artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>03F73Z0</td>
<td>Fragmentation of right brachial artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>03F83Z0</td>
<td>Fragmentation of left brachial artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>03F93Z0</td>
<td>Fragmentation of right ulnar artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>03FA3Z0</td>
<td>Fragmentation of left ulnar artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>03FB3Z0</td>
<td>Fragmentation of right radial artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>03FC3Z0</td>
<td>Fragmentation of left radial artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>03FY3Z0</td>
<td>Fragmentation of upper artery, percutaneous approach, ultrasonic</td>
</tr>
</tbody>
</table>

We noted in the proposed rule that the requestor did not include a list of diagnosis codes describing PE or a list of procedure codes describing the administration of thrombolytic(s) in connection with its analysis. In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58561 through 85 FR 58579), we summarized and responded to public comments expressing concern with the proposed MS–DRG assignments for the newly created procedure codes describing USAT of several anatomic sites that were effective with discharges on and after October 1, 2020 (FY 2021). We noted in the proposed rule that similar to the current request for FY 2024, for FY 2021, the commenters recommended that USAT procedures performed with the EKOSTM device for the treatment of pulmonary embolism be assigned to MS–DRGs 163, 164, and 165 instead of MS–DRGs 166, 167, and 168. We refer the reader to the FY 2021 IPPS/LTCH PPS final rule (85 FR 58561 through 85 FR 58579), available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS for the detailed discussion. As discussed in the proposed rule, we analyzed claims data from the September 2022 update of the FY 2022 MedPAR file for MS–DRGs 166, 167, and 168 for all cases reporting a principal diagnosis of PE and USAT procedure with and without the administration of thrombolytic(s). We identified claims reporting an USAT procedure, the administration of thrombolytic(s), and a diagnosis of PE with the listed codes shown in the following tables.
We noted that the listed procedure codes describing USAT identified for our claims analysis differ from the procedure codes identified by the requestor for its analysis. Clinically, we did not agree that thrombolysis of non-pulmonary anatomic sites (for example, subclavian artery, axillary artery, etc.) would be performed for the treatment of a PE. We also noted that the procedure codes describing thrombolysis of non-pulmonary anatomic sites provided by the requestor are assigned to MDC 05 (Diseases and Disorders of the Circulatory System) and not to MDC 04 (Diseases and Disorders of the Respiratory System) where MS–DRGs 163, 164, 165, 166, 167, and 168 are assigned. The findings from our analysis are shown in the following table.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>166 – All cases</td>
<td>8,318</td>
<td>11</td>
<td>$31,910</td>
</tr>
<tr>
<td>166 – Cases reporting a principal diagnosis of PE and USAT with thrombolytic(s)</td>
<td>826</td>
<td>5.4</td>
<td>$28,912</td>
</tr>
<tr>
<td>166 – Cases reporting principal diagnosis of PE and USAT without thrombolytic(s)</td>
<td>161</td>
<td>5.4</td>
<td>$27,897</td>
</tr>
<tr>
<td>167 – All cases</td>
<td>4,306</td>
<td>4.7</td>
<td>$16,290</td>
</tr>
<tr>
<td>167 – Cases reporting a principal diagnosis of PE and USAT with thrombolytic(s)</td>
<td>316</td>
<td>3.9</td>
<td>$23,240</td>
</tr>
<tr>
<td>167 – Cases reporting principal diagnosis of PE and USAT without thrombolytic(s)</td>
<td>52</td>
<td>3.7</td>
<td>$23,608</td>
</tr>
<tr>
<td>168 – All cases</td>
<td>1,441</td>
<td>2.3</td>
<td>$12,379</td>
</tr>
<tr>
<td>168 – Cases reporting a principal diagnosis of PE and USAT with thrombolytic(s)</td>
<td>65</td>
<td>2.8</td>
<td>$20,156</td>
</tr>
<tr>
<td>168 – Cases reporting principal diagnosis of PE and USAT without thrombolytic(s)</td>
<td>15</td>
<td>2.7</td>
<td>$20,112</td>
</tr>
</tbody>
</table>

As shown in the table, we identified a total of 8,318 cases in MS–DRG 166 with an average length of stay of 11 days and average costs of $31,910. Of the 8,318 cases, we found 826 cases reporting a principal diagnosis of PE and USAT with thrombolytic(s) with an average length of stay of 5.4 days and average costs of $28,912 and 161 cases reporting a principal diagnosis of PE and USAT without thrombolytic(s) with an average length of stay of 5.4 days and average costs of $20,156.
average costs of $27,897. The data demonstrate that the cases reporting a principal diagnosis of PE and USAT with or without thrombolytic(s) have a shorter average length of stay compared to the average length of stay of all the cases in MS–DRG 166 (5.4 days and 5.4 days, respectively versus 11 days).

Similarly, the average costs for the cases reporting a principal diagnosis of PE and USAT with or without thrombolytic(s) appear to be grouped and paid appropriately, despite the fact the logic for case assignment to MS–DRG 166 requires the reporting of at least one or more secondary MCC diagnoses, and it would not be unreasonable to expect these cases to be more expensive in comparison to all the cases in MS–DRG 166. As the average costs for these cases are lower than the average costs of all the cases in MS–DRG 166 ($28,912 and $27,897, respectively versus $31,910). The data indicate that the cases reporting a principal diagnosis of PE and USAT with or without thrombolytic(s) appear to be grouped and paid appropriately.

For MS–DRG 168, we identified a total of 1,441 cases with an average length of stay of 2.3 days and average costs of $12,379. Of the 1,441 cases, we found 65 cases reporting a principal diagnosis of PE and USAT with thrombolytic(s) with an average length of stay of 2.8 days and average costs of $20,156 and 15 cases reporting a principal diagnosis of PE and USAT without thrombolytic(s) with an average length of stay of 2.7 days and average costs of $20,112. The data demonstrate that the cases reporting a principal diagnosis of PE and USAT with or without thrombolytic(s) have a longer average length of stay compared to the average length of stay of all the cases in MS–DRG 168 (2.8 days and 2.7 days, respectively versus 2.3 days). Additionally, the average costs for the cases reporting a principal diagnosis of PE and USAT with or without thrombolytic(s) are higher than the average costs of all the cases in MS–DRG 168 ($20,156 and $20,112, respectively versus $12,379) with a corresponding difference in average costs of $7,777 and $7,733, respectively. Similar to our findings for MS–DRG 167, the data for MS–DRG 168 indicate the cases reporting a principal diagnosis of PE and USAT with or without thrombolytic(s) appear to consume more resources in comparison to the other cases in MS–DRG 168. However, it is unclear if the higher resource consumption is a direct result of the EKOST™ device technology utilized in the performance of the thrombolysis procedure alone, or if there are other contributing factors, since cases grouping to MS–DRG 168 do not include the reporting of at least one or more secondary CC or MCC diagnoses.

We stated in the proposed rule that based on our review of the data for MS–DRGs 166, 167, and 168 and our initial analysis for cases reporting a principal diagnosis of PE and USAT procedure with and without the administration of thrombolytic(s), the findings also suggest that the administration of thrombolytic(s) is not a significant factor in the consumption of resources for these cases in MS–DRGs 166, 167, and 168 where USAT is performed in the treatment of a PE. For example, in MS–DRG 166, there are 926 cases reporting a principal diagnosis of PE and USAT procedure with the administration of thrombolytic(s) and 161 cases reporting a principal diagnosis of PE and USAT procedure without the administration of thrombolytic(s), however, both subsets of cases have an equivalent average length of stay of 5.4 days and a difference in average costs of $1,015 ($28,912 – $27,897 = $1,015). For MS–DRG 167, there are 316 cases reporting a principal diagnosis of PE and USAT with the administration of thrombolytic(s) and 52 cases reporting a principal diagnosis of PE and USAT without the administration of thrombolytic(s), however, both subsets of cases have a similar average length of stay (3.9 days and 3.7 days, respectively) with a difference in average costs of $368 ($23,608 – $23,240 = $368). For MS–DRG 168, there are 65 cases reporting a principal diagnosis of PE and USAT with the administration of thrombolytic(s) and 15 cases reporting a principal diagnosis of PE and USAT procedure without the administration of thrombolytic(s), however, both subsets of cases have a similar average length of stay (2.8 days and 2.7 days, respectively) with a difference in average costs of $44 ($20,156 – $20,112 = $44). Because the administration of thrombolytic(s) would be expected to increase resource consumption, the small difference in average costs between these two sets of cases could also suggest that the administration of thrombolytic(s) was not consistently reported.

We noted in the proposed rule that while the request we received was to reassign cases reporting ultrasound accelerated thrombolysis (USAT) with the administration of thrombolytic(s) for the treatment of pulmonary embolism (PE) from MS–DRGs 166, 167, and 168 to MS–DRGs 163, 164, and 165, based on our findings that suggest the administration of thrombolytic(s) is not a significant factor in the consumption of resources for those cases or that a code describing the administration of thrombolytic(s) may not have been consistently reported on a subset of claims that also reported a code identifying USAT was performed, we then analyzed claims data from the September 2022 update of the FY 2022 MedPAR file for all cases in MS–DRGs 163, 164, and 165 and compared it to the cases reporting a principal diagnosis of PE and USAT procedure with or without thrombolytic(s) in MS–DRGs 166, 167, and 168. The findings from our analysis are shown in the following tables.
The average costs of the 987 cases reporting a principal diagnosis of PE and USAT with or without thrombolytic(s) in MS–DRG 166 are $10,380 less than the average costs of all cases in MS–DRG 163 ($39,126-$28,746=$10,380) and have an average length of stay that is approximately half the average length of stay of all cases in MS–DRG 163 (5.4 days versus 10.3 days). As stated previously, our analysis of these cases demonstrates they appear to be grouped and paid appropriately in MS–DRG 166. The 368 cases reporting a principal diagnosis of PE and USAT with or without thrombolytic(s) in MS–DRG 167 have a shorter average length of stay (3.9 days versus 4.7 days) in comparison to all the cases in MS–DRG 164, however, the average costs of the 368 cases reporting a principal diagnosis of PE and USAT with or without thrombolytic(s) in MS–DRG 167 are more comparable to the average costs of all the cases in MS–DRG 164 ($23,292 versus $22,040). Finally, the 80 cases reporting a principal diagnosis of PE and USAT with or without thrombolytic(s) in MS–DRG 165 have an average length of stay that is more comparable to all the cases in MS–DRG 165 (2.8 days versus 2.7 days), however, the average costs for the 80 cases continue to be higher in comparison to all the cases in MS–DRG 165 ($20,148 versus $16,404).

We stated in the proposed rule that upon analysis of the claims data and our review of the request, we do not agree with reassigning cases reporting an USAT procedure with the administration of thrombolytic(s) and a principal diagnosis of PE from MS–DRGs 166, 167, and 168 to MS–DRGs 163, 164, and 165. As previously noted, the data do not support that cases reporting USAT (with or without thrombolytic(s)) for PE utilize similar resources when compared to other procedures currently assigned to MS–DRGs 163 and 165. Costs were only comparable with procedures currently assigned to MS–DRG 164. Further, we stated we do not agree that cases reporting USAT (with or without thrombolytic(s)) are more comparable with and more clinically aligned with the procedures assigned to MS–DRGs 163, 164, and 165. The vast majority of procedures in these MS–DRGs describe procedures performed on the trachea, bronchus or lungs with either an open approach or a percutaneous endoscopic approach in contrast to the USAT endovascular (percutaneous) procedure performed on the pulmonary trunk, arteries or veins. In addition, the majority of procedures in MS–DRGs 163, 164, and 165 are performed on patients who are not clinically similar to patients who undergo USAT for PE since they describe procedures such as destruction (ablation) or excision performed for patients with conditions other than a PE, such as malignant neoplasm, pneumonia, or pulmonary fibrosis. Lastly, a number of procedures in these MS–DRGs also involve the use of a permanently implanted device while the procedures utilizing USAT do not. Therefore, we stated in the proposed rule that we do not consider USAT procedures to be major chest procedures, nor do we believe the cases reporting USAT with (or without thrombolytic(s)) do not a significant factor in the consumption of resources for cases in MS–DRGs 166, 167, and 168 reporting an USAT procedure performed for the treatment of a PE or that a code describing the administration of thrombolytic(s) may not have been consistently reported on a subset of claims that also reported a code identifying USAT was performed, or a combination of both factors. Based on these findings related to the administration of thrombolytic(s), we stated we believed it would also be beneficial to examine cases reporting standard CDT procedures with or without thrombolytic(s) for the treatment of PE in MS–DRGs 166, 167, and 168, and compare the findings to the cases reporting USAT with or without thrombolytic(s) for the treatment of PE.

Therefore, as discussed in the proposed rule, we conducted additional analyses to determine if there were significant differences in resource utilization for cases reporting standard CDT with or without thrombolytic(s) versus USAT procedures with or without thrombolytic(s) in the treatment of PE, since claims data to compare the two modalities is now available and studies have reported similar clinical outcomes in reducing PE regardless of which thrombolytic modality is utilized.3,4

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>163 – All cases</td>
<td>10,697</td>
<td>10.3</td>
<td>$39,126</td>
</tr>
<tr>
<td>164 – All cases</td>
<td>13,384</td>
<td>4.7</td>
<td>$22,040</td>
</tr>
<tr>
<td>165 – All cases</td>
<td>6,301</td>
<td>2.7</td>
<td>$16,404</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>166 – All cases</td>
<td>8,318</td>
<td>11</td>
<td>$31,910</td>
</tr>
<tr>
<td>166 – Cases with principal diagnosis of PE and USAT with or without thrombolytic(s)</td>
<td>987</td>
<td>5.4</td>
<td>$28,746</td>
</tr>
<tr>
<td>167 – All cases</td>
<td>4,306</td>
<td>4.7</td>
<td>$16,290</td>
</tr>
<tr>
<td>167 – Cases with principal diagnosis of PE and USAT with or without thrombolytic(s)</td>
<td>368</td>
<td>3.9</td>
<td>$23,292</td>
</tr>
<tr>
<td>168 – All cases</td>
<td>1,441</td>
<td>2.3</td>
<td>$12,379</td>
</tr>
<tr>
<td>168 – Cases with principal diagnosis of PE and USAT with or without thrombolytic(s)</td>
<td>80</td>
<td>2.8</td>
<td>$20,148</td>
</tr>
</tbody>
</table>


In the proposed rule, we stated that we analyzed claims data from the September 2022 update of the FY 2022 MedPAR file for all cases in MS–DRGs 166, 167, and 168 and cases reporting a standard CDT procedure with or without the administration of thrombolytic(s) and a principal diagnosis of PE. We utilized the previously listed procedure codes for the administration of thrombolytic(s) and the previously listed diagnosis codes for a principal diagnosis of PE. We identified cases describing standard CDT procedures performed in the treatment of PE with the following procedure codes.

The findings from our analysis are shown in the following table. We noted that there were no cases found to report a principal diagnosis of PE and standard CDT with or without thrombolytic(s) in MS–DRGs 168.

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02FP3ZZ</td>
<td>Fragmentation of pulmonary trunk, percutaneous approach</td>
</tr>
<tr>
<td>02F03ZZ</td>
<td>Fragmentation of right pulmonary artery, percutaneous approach</td>
</tr>
<tr>
<td>02FR3ZZ</td>
<td>Fragmentation of left pulmonary artery, percutaneous approach</td>
</tr>
<tr>
<td>02FS3ZZ</td>
<td>Fragmentation of right pulmonary vein, percutaneous approach</td>
</tr>
<tr>
<td>02FT3ZZ</td>
<td>Fragmentation of left pulmonary vein, percutaneous approach</td>
</tr>
</tbody>
</table>

The data shows that the 7 cases reporting a principal diagnosis of PE and CDT with or without thrombolytic(s) in MS–DRG 166 have a shorter average length of stay compared to all cases in MS–DRG 166 (3.3 days versus 11 days) and lower average costs ($18,472 versus $31,910). For MS–DRG 167, the data shows that the 6 cases reporting a principal diagnosis of PE and CDT with or without thrombolytic(s) have a shorter average length of stay compared to all cases in MS–DRG 167 (3.5 days versus 4.7 days), however the average costs are higher ($30,928 versus $16,290).

As discussed in the proposed rule, based on our review and the claims data analysis for cases in MS–DRGs 163, 164, and 165, and for MS–DRGs 166, 167, and 168 and cases reporting standard CDT or USAT with or without thrombolytic(s) and a principal diagnosis of PE, we believe that while this subset of cases for patients undergoing a thrombolysis (CDT or USAT) procedure for PE does not clinically align with patients undergoing surgery for malignancy or treatment for infection and does not involve the same level of complexity, monitoring or support as cases grouping to MS–DRGs 163, 164, and 165, the differences in resource consumption warrant proposed reassignment of these cases. Specifically, we believe the clinical and data analyses support creating a new base MS–DRG to distinguish cases reporting a principal diagnosis of PE and USAT or standard CDT procedure with or without thrombolytic(s) from other cases currently grouping to MS–DRGs 166, 167, and 168. We believe a new MS–DRG would reflect more appropriate payment for USAT and standard CDT procedures in the treatment of PE.

We stated in the proposed rule that to compare and analyze the impact of our suggested modifications, we ran a simulation using the most recent claims data from the December 2022 update of the FY 2022 MedPAR file. The following table illustrates our findings for all 1,534 cases reporting procedure codes describing an USAT or CDT procedure with a principal diagnosis of PE.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>166 – All cases</td>
<td>8,318</td>
<td>11</td>
<td>$31,910</td>
</tr>
<tr>
<td>166 – Cases with principal diagnosis of PE and CDT with or without thrombolytic(s)</td>
<td>7</td>
<td>3.3</td>
<td>$18,472</td>
</tr>
<tr>
<td>167 – All cases</td>
<td>4,306</td>
<td>4.7</td>
<td>$16,290</td>
</tr>
<tr>
<td>167 – Cases with principal diagnosis of PE and CDT with or without thrombolytic(s)</td>
<td>6</td>
<td>3.5</td>
<td>$30,928</td>
</tr>
<tr>
<td>168 – All cases</td>
<td>1,441</td>
<td>2.3</td>
<td>$12,379</td>
</tr>
</tbody>
</table>

Consistent with our established process as discussed in section II.C.1.b. of the preamble of the proposed rule and this final rule, once the decision has been made to propose to make further modifications to the MS–DRGs, such as creating a new base MS–DRG, all five criteria to create subgroups must be met for the base MS–DRG to be split (or subdivided) by a CC subgroup. Therefore, we applied the criteria to create subgroups in a base MS–DRG. We noted that, as shown in the table that follows, a three-way split of this base MS–DRG failed to meet the criterion that there be at least 500 cases in both the CC and the NonCC (without CC/ MCC) subgroup and it also failed to...
meet the criterion that there be a 20% difference in average costs between the CG and NonCC subgroup.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>With MCC</td>
<td>1,058</td>
<td>5.31</td>
<td>$28,618</td>
</tr>
<tr>
<td>With CC</td>
<td>393</td>
<td>3.85</td>
<td>$23,164</td>
</tr>
<tr>
<td>Without CC/MCC</td>
<td>83</td>
<td>2.88</td>
<td>$20,886</td>
</tr>
</tbody>
</table>

As also discussed in section II.C.1.b. of the preamble of the proposed rule and this final rule, if the criteria for a three-way split fail, the next step is to determine if the criteria are satisfied for a two-way split. We therefore applied the criteria for a two-way split for the “with MCC and without MCC” subgroups. We noted that, as shown in the table that follows, a two-way split of this base MS–DRG failed to meet the criterion that there be at least 500 cases in the without MCC (CC+NonCC) subgroup. The following table illustrates our findings.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>With MCC</td>
<td>1,058</td>
<td>5.31</td>
<td>$28,618</td>
</tr>
<tr>
<td>Without MCC</td>
<td>476</td>
<td>3.7</td>
<td>$22,767</td>
</tr>
</tbody>
</table>

We then applied the criteria for a two-way split for the “with CC/MCC and without CC/MCC” subgroups. As with the analysis of the three-way severity split as described previously, and as shown in the table that follows, a two-way split of this base MS–DRG failed to meet the criterion that there be at least 500 cases in the without CC/MCC (NonCC) subgroup.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>With CC/MCC</td>
<td>1,451</td>
<td>4.9</td>
<td>$27,141</td>
</tr>
<tr>
<td>Without CC/MCC</td>
<td>83</td>
<td>2.88</td>
<td>$20,886</td>
</tr>
</tbody>
</table>

We noted that because the criteria for both of the two-way splits failed, a split (or CC subgroup) is not warranted for the proposed new base MS–DRG. As a result, for FY 2024, we proposed to create new base MS–DRG 173 (Ultrasound Accelerated and Other Thrombolysis with Principal Diagnosis Pulmonary Embolism). The following table reflects a simulation of the proposed new base MS–DRG.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proposed MS-DRG 173</td>
<td>1,534</td>
<td>4.8</td>
<td>$26,802</td>
</tr>
</tbody>
</table>

Comment: Commenters supported the proposal to create new MS–DRG 173 (Ultrasound Accelerated and Other Thrombolysis with Principal Diagnosis Pulmonary Embolism) given the data and information provided. A commenter expressed appreciation that CMS has acted to correct payment disparities for these procedures and recommended that CMS also utilize this approach to address other, similar MS–DRG reassignment requests that may involve a component with a lower volume of cases. Another commenter stated the proposal aligns more closely with the resources used, as opposed to the current MS–DRGs 166, 167, and 168. The commenter requested that CMS continue to analyze the data for these cases and consider creating an additional MS–DRG to reflect major complications and comorbidities, if warranted by further analysis. Other commenters who supported the proposal to reassign the cases from their current MS–DRG assignment expressed concern about the proposed single base MS–DRG. Specifically, the commenters stated the proposal does not acknowledge the secondary diagnosis.
impact that the CMS analysis recognized may or may not be a contributing factor for the higher average costs of the cases reporting USAT procedures. The commenters also stated that the proposal demonstrates that application of the NonCC Subgroup may not be appropriate for some MS–DRGs since the result in this instance is for a base MS–DRG with a lower relative weight because severity of illness is unable to be recognized. 

Response: We thank the commenters for their support. In response to the concerns raised by the commenters regarding the impact application of the NonCC subgroup criteria has on proposed new MS–DRG 173, we note that, as discussed in the proposed rule and in this final rule, we apply the NonCC subgroup criteria once the decision is made to propose to make further modifications to the MS–DRGs. While application of the criteria did not support a severity level split for proposed MS–DRG 173 for FY 2024, we intend to reevaluate for future rulemakings whether the criteria for a potential “with MCC” and “without MCC” two-way split would be met. 

Comment: A couple commenters suggested that the proposal to create new MS–DRG 173 should be delayed until more data can be collected. The commenters stated their belief that it is premature to create this new MS–DRG at this time and that in developing this proposed MS–DRG, CMS relied on recently implemented ICD–10–PCS data. According to the commenters, due to the lengthy processes for hospitals to adopt and accurately implement new coding, and conflicting coding advice for utilization of the ICD–10–PCS procedure codes for CDT and USAT, the number of cases is currently insufficient to support development of a new MS–DRG. The commenters stated that the low volume of cases and related data selected by CMS for analysis, CDT for the treatment of PE, cannot adequately compare to the costs, complexity, and utilization of USAT with a high confidence interval.

Response: We appreciate the commenters’ feedback. We disagree with the commenters that it is premature to propose the creation of new MS–DRG 173 based on our review and claims data analysis as discussed in the proposed rule. In response to the commenters’ statement that CMS relied on recently implemented ICD–10–PCS data, it is not clear to us what specific ICD–10–PCS data the commenters are referring to since a specific list was not provided. However, we believe the commenters may be suggesting the codes for USAT that were finalized October 1, 2020 (FY 2021), and listed previously in connection with the analysis discussed in the proposed rule. As discussed in the proposed rule and prior rulemaking, our goal is always to use the best available data. We noted in the proposed rule that our initial MS–DRG analysis was based on ICD–10 claims data from the September 2022 update of the FY 2022 MedPAR file, which contains hospital bills received from October 1, 2021, through September 30, 2022, and where otherwise indicated, additional analysis was based on ICD–10 claims data from the December 2022 update of the FY 2022 MedPAR file, which contains hospital bills received by CMS through December 31, 2022, for discharges occurring from October 1, 2021, through September 30, 2022. Therefore, we believe our analysis of claims data in consideration of the MS–DRG request to reassign cases reporting USAT procedures for PE is consistent with our standard process, regardless of the effective date of the coded claims data. We also do not agree with the commenters’ assertion that it is a lengthy process for hospitals to adopt and accurately implement new coding. We note that procedure code proposals discussed at the September ICD–10 Coordination and Maintenance Committee meeting and subsequently finalized are typically included in Table 6B—New Procedure Codes in association with the proposed rule that is made publicly available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS. This table (Table 6B) lists the new procedure codes that have been approved to date that will be effective with discharges on and after October 1 of the upcoming fiscal year. Therefore, information regarding the finalized codes from the September meeting is made publicly available approximately 4–5 months in advance of the implementation date, affording the ability for users of the code set to gain familiarity with the updates. In addition, there are extensive industry-sponsored educational opportunities through various professional associations that introduce and discuss the annual code updates. For example, the American Hospital Association (AHA), American Health Information Management Association (AHIMA), and the American Academy of Professional Coders (AAPC) generally take lead roles in developing detailed technical training materials for coders and other users of the code set. The AHA also includes updates to ICD–10 in its Coding Clinic® for ICD–10–CM/ICD–10–PCS publication. Because the codes describing USAT were finalized for implementation October 1, 2020 (FY 2021), we believe sufficient time has elapsed and that providers are successfully coding and reporting the procedure as demonstrated in our claims analysis.

It is also not clear what conflicting coding advice for utilization of the ICD–10–PCS procedure codes for CDT and USAT the commenters are referring to since the commenters did not provide examples or supplemental information for what they believed to be conflicting advice to enable further evaluation.

Comment: A few commenters expressed concern that the inclusion of both conventional CDT, also known as “standard infusion catheters,” and USAT in the proposed new MS–DRG disregards fundamental clinical differences between the procedures. According to the commenters, CDT generally relies on a multi-sidehole infusion catheter placed adjacent to the thrombus through which thrombolytics are delivered, typically over the course of 24 hours with the catheter indwelling, whereas USAT employs ultrasound to assist in thrombolysis, and the pulses of ultrasonic energy temporarily make the fibrin in the thrombus more porous and increase fluid flow within the thrombus. The commenters stated standard CDT is the simple infusion of liquids into the vessel and should not map to the same root operation fragmentation codes as does USAT. The commenters also stated CDT procedures are generally less complex clinically and consume significantly lower level of hospital resources as a result. The commenters recommended CMS should delay implementation, not finalize the proposed MS–DRG at this time and reconsider at a later date when utilization volumes reach a threshold of significance.

A commenter also indicated that an analysis of cost data was being submitted to CMS to demonstrate that USAT PE cases have total costs that are more than three times the cost of CDT procedures for the sickest patients. 

Response: We disagree with the commenters that inclusion of both conventional CDT and USAT in the proposed new MS–DRG disregards fundamental clinical differences between the procedures. We note that while USAT procedures performed utilizing the EKOSTM device employ ultrasound, the objective of both CDT and USAT procedures is to effectuate thrombolysis and reduce clot burden. In both CDT and USAT procedures for the sickest patients, USAT PE cases have total costs that are more than three times the cost of CDT and the commenters are referring to since the commenters did not provide examples or supplemental information for what they believed to be conflicting advice to enable further evaluation.
of liquids into the vessel and should not map to the same root operation. Fragmentation codes as does USAT, we note that under ICD–10–PCS, both USAT and CDT are reported with the root operation fragmentation, defined as breaking solid matter in a body part into pieces. The procedure may be accomplished by physical force (e.g., manual, ultrasonic) applied directly or indirectly that is used to break the solid matter into pieces. The solid matter may be an abnormal byproduct of a biological function or a foreign body. The pieces of solid matter are not taken out. With respect to the commenters’ statement that CDT procedures are generally less complex clinically and consume significantly lower level of hospital resources, we note that any procedure that places a catheter inside a blood vessel carries certain risks, including damage to the blood vessel, bruising or bleeding at the puncture site, and infection. In the treatment of a significant pulmonary embolism, both procedures (USAT and CDT) require a right heart catheterization by either an interventional cardiologist or an interventional radiologist, utilizing the same level of facility resources. In response to the commenters’ recommendation that CMS should delay finalization for the proposed MS–DRG, and reconsider in the future when utilization volumes reach a threshold of significance, as discussed in the proposed rule, once the decision was made to propose a new base MS–DRG, we applied the criteria to create subgroups and the criteria for both a three-way split and for a two-way split failed, however, we believe the simulated volume of 1,534 cases is sufficient for creation of the proposed new MS–DRG for these procedures.

Finally, in response to the cost data that was submitted by a commenter, we note that it was the same data analysis as reflected and discussed in the proposed rule, and therefore we refer readers to that prior discussion.

Response: We appreciate the commenter’s feedback, however, based on our review of the procedures and claims data analysis as discussed in the proposed rule, we believe that USAT and CDT procedures performed for PE are clinically distinct and utilize a different pattern of resources than the other procedures in MS–DRGs 166, 167, and 168. We stated in the proposed rule that while we did not agree with the request to reassign cases reporting USAT or CDT for PE from MS–DRGs 166, 167, and 168 to MS–DRGs 163, 164, and 165, we believed the findings from our analysis warranted proposed reassignment of these cases. While we described the findings from our review of the procedures currently assigned to MS–DRGs 163, 164, and 165 to specifically address the MS–DRG request (86 FR 20669), we note that in our review of cases assigned to MS–DRGs 166, 167, and 168, we identified similar findings; the majority of procedures reported are for malignant neoplasms of the trachea, bronchus, and lung, as well as for pneumonia and respiratory failure with either an open or percutaneous endoscopic approach in contrast to the USAT endovascular (percutaneous) procedure performed on the pulmonary trunk, arteries or veins. In addition, the majority of procedures in MS–DRGs 166, 167, and 168 are performed on patients who are not clinically similar to patients who undergo USAT or CDT for PE since they describe procedures such as destruction (ablation) or excision performed for patients with conditions other than a PE, such as malignant neoplasm, pneumonia, or pulmonary fibrosis. Lastly, a number of procedures in these MS–DRGs also involve the use of a permanently implanted device while the procedures utilizing USAT or CDT do not.

As we have also stated in prior rulemaking (86 FR 44808), the “other” surgical category contains surgical procedures which, while infrequent, could still reasonably be expected to be performed for a patient in the particular MDC. We note that because MS–DRGs 166, 167, and 168 are classified as an “other” surgical category, they are not as precisely defined from a clinical perspective and contain surgical procedures that are not based on any particular organizing principle (e.g., anatomy, surgical approach, diagnostic approach, pathology, etiology, or treatment process). However, we also note that the classification of patient cases into the MS–DRGs is a constantly evolving process, therefore, as coding, medical technologies or treatments change and more comprehensive data is collected, the MS–DRG definitions are reviewed, and revisions are proposed.

As discussed in the FY 2022 IPPS/LTCH PPS final rule (86 FR 44820), we stated we believed further analysis of the procedures assigned to MS–DRGs 163, 164, 165, 166, 167, and 168 was warranted based on the creation of new procedure codes that have been assigned to these MS–DRGs in recent years for which claims data were not yet available and the additional time to examine the procedures currently assigned to those MS–DRGs by clinical intensity, complexity of service and resource utilization. We stated we would continue to evaluate the procedures assigned to these MS–DRGs as additional claims data became available.

We also do not agree that the proposed new MS–DRG would create an unnecessary administrative burden for the established procedure codes since providers are accustomed to proposed and finalized changes to the MS–DRG classifications each fiscal year and software vendors incorporate the finalized changes into their products. With respect to the commenter’s assertion that a low volume of procedures would be assigned to their own MS–DRG based on the proposal, as previously discussed, once the decision was made to propose a new base MS–DRG, we applied the criteria to create subgroups and the criteria for both a three-way split and for a two-way split failed, however, we believe the simulated volume of 1,534 cases is...
sufficient for creation of the proposed new MS–DRG.

Comment: A commenter stated they could not fully understand or evaluate CMS’ proposal for proposed new MS–DRG 173 or determine how the data presented in the preamble of the proposed rule related to the proposed reassignment of cases because of inconsistencies in the materials supporting the proposed rule. According to the commenter, CMS referred to one set of ICD–10–PCS codes in the proposed rule and cited a different set of ICD–10–PCS codes mapping to proposed MS–DRG 173 in the proposed ICD–10 MS–DRG V41 Definitions Manual. The commenter stated interested parties are unable to evaluate and comment on proposals complicated by such an important inconsistency.

Response: We appreciate the commenter’s feedback, however, it is not clear what inconsistencies in the materials the commenter is specifically referring to. The commenter did not provide a list of codes for evaluation. Upon review of the proposed rule and the proposed ICD–10 MS–DRG V41 Definitions Manual, we did not find discrepancies.

After consideration of the public comments we received, we are finalizing our proposal to create new MS–DRG 173 (Ultrasound Accelerated and Other Thrombolysis with Principal Diagnosis Pulmonary Embolism), without modification, for FY 2024. We are also finalizing our proposal to define the logic for the new MS–DRG using the previously listed diagnosis codes for PE and the previously listed procedure codes for USAT and CDT, as identified and discussed in our analysis of the claims data in association with the proposed rule. We will continue to monitor the claims data for this new MS–DRG after implementation to determine if additional refinements are warranted.

b. Respiratory Infections and Inflammations Logic

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26691), we stated that the logic for case assignment to MS–DRGs 177, 178, and 179 (Respiratory Infections and Inflammations with MCC, with CC, and without CC/MCC, respectively) as displayed in the ICD–10 MS–DRG V40.1 Definitions Manual (which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software) is comprised of two logic lists. The first logic list is entitled “Principal Diagnosis with Secondary Diagnosis” and is defined by a list of five ICD–10–CM diagnosis codes describing influenza due to other or unidentified influenza virus with pneumonia in combination with a separate list of ten diagnosis codes describing the specific pneumonia infection. When any one of the five listed diagnosis codes from the “Principal Diagnosis” logic list is reported as a principal diagnosis in combination with any one of the ten listed diagnosis code from the “with Secondary Diagnosis” logic list as a secondary diagnosis, the case results in assignment to MS–DRG 177, 178, or 179 depending on the presence of any additional MCC or CC secondary diagnoses. All 15 of the diagnosis codes included on the first logic list “Principal Diagnosis with Secondary Diagnosis” are designated as MCCs.

The second logic list is entitled “or Principal Diagnosis” and is defined by a list of 57 diagnosis codes describing various pulmonary infections. When any one of the 57 diagnosis codes from this list is reported as a principal diagnosis, the case results in assignment to MS–DRG 177, 178, or 179 depending on the presence of any additional MCC or CC secondary diagnoses. We noted in the proposed rule that currently, when a diagnosis code from the second logic list “or Principal Diagnosis” is reported as the principal diagnosis and a diagnosis code from the first logic list “Principal Diagnosis with Secondary Diagnosis” is reported as a secondary diagnosis, the case is grouping to MS–DRG 177 (Respiratory Infections and Inflammations with MCC). Consistent with how other similar logic lists function in the ICD–10 Grouper software for case assignment to the “with MCC” MS–DRG, the logic for case assignment to MS–DRG 177 is intended to require any other diagnosis designated as an MCC and reported as a secondary diagnosis for appropriate assignment, and not the diagnoses currently listed in the logic for the definition of the MS–DRG.

Therefore, for FY 2024, we proposed to correct the logic for case assignment to MS–DRG 177 by excluding the 15 diagnosis codes from the first logic list “Principal Diagnosis with Secondary Diagnosis” from acting as an MCC when any one of the listed codes is reported as a secondary diagnosis with a diagnosis code from the second logic list “or Principal Diagnosis” reported as the principal diagnosis.

Comment: Several commenters expressed support for the proposal to correct the logic for case assignment to MS–DRG 177. However, some commenters stated it was not specifically clear what was changing and requested that CMS provide more transparency with examples.

A couple commenters recommended that when any one of the five influenza codes (J10.00, J10.01, J10.08, J11.00, or J11.08) from the first logic list entitled “Principal Diagnosis” in MS–DRGs 177, 178, and 179 is reported as a secondary diagnosis with a principal diagnosis from the second logic list (“or Principal Diagnosis”), that the influenza diagnosis code continue to be allowed to act as an MCC for assignment to MS–DRG 177.

According to the commenters, influenza is not inherently related to the principal diagnoses on the second logic list, and, in combination, they have the potential to be more complicated and resource intensive to treat than any of the diagnoses occurring alone. The commenters supported excluding the 10 secondary diagnoses from the first logic list entitled “with Secondary Diagnosis” from acting as an MCC when any one of the codes is reported as a secondary diagnosis with a principal diagnosis code from the second logic list.

Response: We thank the commenters for their support. In response to the commenters who requested additional clarification for the proposed changes, we are providing the following case example to demonstrate the intent of the proposed logic changes with application of the V41 ICD–10 MS–DRG test GROUPER that was made publicly available in association with the proposed rule at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software.

Case Example: A patient who is admitted with COVID–19 develops influenza due to an unidentified flu virus along with an unspecified type of pneumonia. The principal diagnosis in this case is reported as the COVID–19 (diagnosis code U07.1) and the secondary diagnosis in this case is reported as influenza due to an unidentified flu virus with unspecified type of pneumonia (diagnosis code J11.00). The diagnosis code for COVID–19 (U07.1) is listed as one of the 58 diagnoses in the second logic list entitled “or Principal Diagnosis” and the diagnosis code for influenza due to an unidentified flu virus with unspecified type of pneumonia (J11.00) is listed as one of the five diagnoses in the first logic list entitled “Principal Diagnosis”. When these diagnoses are entered in the V41 ICD–10 MS–DRG test GROUPER, the resulting MS–DRG is 177 (Respiratory infections and inflammations with MCC).
Principal Diagnosis: U07.1 COVID–19 (DRG)
Secondary Diagnoses: J11.00 Flu due to unidentified flu virus w unsp type of pneumonia (MCC)

Additionally, when any one of the other four influenza diagnosis codes (J10.00, J10.01, J10.08, or J11.08) in that first logic list is reported as a secondary diagnosis with a principal diagnosis of U07.1, the resulting MS–DRG is also MS–DRG 177. Therefore, we agree with the commenters that the five influenza codes (J10.00, J10.01, J10.08, J11.00, or J11.08) should continue to be allowed to act as a MCC with a principal diagnosis from the second logic list in specific clinical scenarios.

The following tables illustrate additional examples when the reporting of any one of the five influenza codes (J10.00, J10.01, J10.08, J11.00, or J11.08) from the first logic list entitled “Principal Diagnosis” in MS–DRGs 177, 178, and 179 continues to act as a MCC when reported as a secondary diagnosis with certain principal diagnoses from the second logic list (“or Principal Diagnosis”) and to illustrate when any one of the five influenza diagnosis codes is excluded from acting as an MCC when reported as a secondary diagnosis with certain principal diagnoses from the second logic list.

BILLING CODE 4120–01–P

We note that in the preamble of the proposed rule we stated that we were proposing to exclude the 15 diagnosis codes from the first logic list “Principal Diagnosis with Secondary Diagnosis” from acting as an MCC when any one of the listed codes is reported as a secondary diagnosis with a diagnosis code from the second logic list “or Principal Diagnosis” reported as the principal diagnosis, however, the proposal was intended to exclude the 11 secondary diagnoses from the first logic list entitled “with Secondary Diagnosis” when one of the codes is reported as a secondary diagnosis with a principal diagnosis code from the second logic list, (as reflected in the case example when a diagnosis from each logic list is entered in the V41 ICD–10 MS–DRG test GROUPER).

After consideration of the public comments we received, we are finalizing our proposal to correct the logic for case assignment to MS–DRG 177, with modification, for FY 2024. We are finalizing the exclusion of the following 11 diagnosis codes listed in the first logic list entitled “with Secondary Diagnosis” from acting as an MCC when any one of the listed codes is reported as a secondary diagnosis with a diagnosis code from the second logic list entitled “or Principal Diagnosis” when reported as the principal diagnosis.

<p>| Influenza Codes (J10.00, J10.01, J10.08, J11.00, or J11.08) Acting as an MCC with Certain Principal Diagnoses from Second Logic List in ICD-10 MS-DRG GROUPER Version 41 |
|-----------------|--------------------------------|-----------------|-----------------|</p>
<table>
<thead>
<tr>
<th>Principal Diagnosis</th>
<th>Secondary Diagnosis Influenza Code</th>
<th>MCC</th>
<th>MS-DRG</th>
</tr>
</thead>
<tbody>
<tr>
<td>A06.5 Amoeba lung disease</td>
<td>J10.00 Influenza due to other identified influenza virus with unspecified type of pneumonia</td>
<td>Yes</td>
<td>177</td>
</tr>
<tr>
<td>A15.7 Primary respiratory tuberculosis</td>
<td>J10.01 Influenza due to other identified influenza virus with the same other identified influenza virus pneumonia</td>
<td>Yes</td>
<td>177</td>
</tr>
<tr>
<td>B01.2 Varicella pneumonia</td>
<td>J10.08 Influenza due to other identified influenza virus with other specified pneumonia</td>
<td>Yes</td>
<td>177</td>
</tr>
<tr>
<td>J85.0 Gangrene and necrosis of lung</td>
<td>J11.00 Influenza due to unidentified influenza virus with unspecified type of pneumonia</td>
<td>Yes</td>
<td>177</td>
</tr>
<tr>
<td>J86.0 Pyothorax with fistula</td>
<td>J11.08 Influenza due to unidentified influenza virus with specified pneumonia</td>
<td>Yes</td>
<td>177</td>
</tr>
</tbody>
</table>

<p>| Influenza Codes (J10.00, J10.01, J10.08, J11.00 or J11.08) Excluded from Acting as an MCC with Certain Principal Diagnoses from Second Logic List in ICD-10 MS-DRG GROUPER Version 41 |
|-----------------|--------------------------------|-----------------|-----------------|</p>
<table>
<thead>
<tr>
<th>Principal Diagnosis</th>
<th>Secondary Diagnosis Influenza Code</th>
<th>MCC</th>
<th>MS-DRG</th>
</tr>
</thead>
<tbody>
<tr>
<td>A15.0 Tuberculosis of lung</td>
<td>J10.00 Influenza due to other identified influenza virus with unspecified type of pneumonia</td>
<td>No</td>
<td>179</td>
</tr>
<tr>
<td>A15.8 Other respiratory tuberculosis</td>
<td>J10.01 Influenza due to other identified influenza virus with the same other identified influenza virus pneumonia</td>
<td>No</td>
<td>179</td>
</tr>
<tr>
<td>B25.0 Cytomegaloviral pneumonia</td>
<td>J10.08 Influenza due to other identified influenza virus with other specified pneumonia</td>
<td>No</td>
<td>179</td>
</tr>
<tr>
<td>B39.0 Acute pulmonary histoplasmosis capsulati</td>
<td>J11.00 Influenza due to unidentified influenza virus with unspecified type of pneumonia</td>
<td>No</td>
<td>179</td>
</tr>
<tr>
<td>B39.1 Chronic pulmonary histoplasmosis capsulati</td>
<td>J11.08 Influenza due to unidentified influenza virus with specified pneumonia</td>
<td>No</td>
<td>179</td>
</tr>
</tbody>
</table>
### Diagnoses Excluded from Acting as an MCC for MS-DRG 177

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A48.1</td>
<td>Legionnaires’ disease</td>
</tr>
<tr>
<td>J15.0</td>
<td>Pneumonia due to Klebsiella pneumoniae</td>
</tr>
<tr>
<td>J15.1</td>
<td>Pneumonia due to Pseudomonas</td>
</tr>
<tr>
<td>J15.20</td>
<td>Pneumonia due to staphylococcus, unspecified</td>
</tr>
<tr>
<td>J15.211</td>
<td>Pneumonia due to Methicillin susceptible Staphylococcus aureus</td>
</tr>
<tr>
<td>J15.212</td>
<td>Pneumonia due to Methicillin resistant Staphylococcus aureus</td>
</tr>
<tr>
<td>J15.29</td>
<td>Pneumonia due to other staphylococcus</td>
</tr>
<tr>
<td>J15.5</td>
<td>Pneumonia due to Escherichia coli</td>
</tr>
<tr>
<td>J15.61</td>
<td>Pneumonia due to Acinetobacter baumannii</td>
</tr>
<tr>
<td>J15.69</td>
<td>Pneumonia due to other Gram-negative bacteria</td>
</tr>
<tr>
<td>J15.8</td>
<td>Pneumonia due to other specified bacteria</td>
</tr>
</tbody>
</table>

#### BILLING CODE 4120–01–C

5. MDC 05 (Diseases and Disorders of the Circulatory System)

a. Surgical Ablation

In the FY 2022 IPPS/LTCH PPS final rule (86 FR 44836 through 44848), we discussed a two-part request we received to review the MS–DRG assignments for cases involving the surgical ablation procedure for atrial fibrillation. The first part of the request was to create a new classification of surgical ablation MS–DRGs to better accommodate the costs of open concomitant surgical ablation. The second part of the request was to reassign cases describing standalone percutaneous endoscopic surgical ablation. In the part of the request relating to the costs of open concomitant surgical ablations, the requestor identified the following potential procedure combinations that would comprise an “open concomitant surgical ablation” procedure.

- Open CABG + open surgical ablation
- Open MVR + open surgical ablation
- Open AVR + open surgical ablation
- Open MVR + open AVR + open surgical ablation
- Open MVR + open CABG + open surgical ablation
- Open MVR + open AVR + open CABG + open surgical ablation
- Open AVR + open CABG + open surgical ablation

As discussed in the FY 2022 IPPS/LTCH PPS final rule, we examined claims data from the March 2020 update of the FY 2019 MedPAR file and the September 2020 update of the FY 2020 MedPAR file for cases reporting procedure code combinations describing open concomitant surgical ablations. We refer the reader to Table 6P.10 associated with the FY 2022 final rule (which is available on the CMS website at: [https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS](https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS)) for data analysis findings of cases reporting procedure code combinations describing open concomitant surgical ablations. We stated our analysis showed while the average lengths of stay and average costs of cases reporting procedure code combinations describing open concomitant surgical ablations are higher than all cases in their respective MS–DRG, we found variation in the volume, length of stay, and average costs of the cases. We also stated findings from our analysis indicated that MS–DRGs 216, 217, and 218 (Cardiac Valve and Other Major Cardiothoracic Procedures with Cardiac Catheterization with MCC, with CC, and with CC/MCC, respectively) as well as approximately 31 other MS–DRGs would be subject to change based on the three-way severity level split criterion finalized in FY 2021.

In the FY 2022 final rule, we finalized our proposal to revise the surgical hierarchy for the MS–DRGs in MDC 05 (Diseases and Disorders of the Circulatory System) to sequence MS–DRGs 231–236 (Coronary Bypass, with or without PTCA, with or without Cardiac Catheterization or Open Ablation, with and without MCC, respectively) above MS–DRGs 216 and 217 (Cardiac Valve and Other Major Cardiothoracic Procedures with Cardiac Catheterization with MCC and with CC, respectively) similar to what CMS did with CABG and open ablation procedures in the FY 2022 rulemaking to better accommodate the added cost of open concomitant surgical ablation.

We stated our analysis using the September 2021 update of the FY 2021 MedPAR file reflected that the cases reporting an open concomitant surgical ablation code combination are predominately found in the higher (CC or MCC) severity level MS–DRGs of their current base MS–DRG assignment, suggesting that the patient’s co-morbid conditions may also be contributing to the higher costs of these cases. Secondly, for the numerous procedure combinations that would comprise an “open concomitant surgical ablation” procedure, the increase in average costs appeared to directly correlate with the number of procedures performed. For example, cases that describe “Open MVR + Open surgical ablation” generally demonstrated costs that were lower than cases that describe “Open MVR + Open AVR + Open CABG + Open surgical ablation.” We also noted using the September 2021 update of the FY 2021 MedPAR file, we analyzed how applying the NonCC subgroup criteria to all MS–DRGs currently split into three severity levels would affect the MS–DRG structure beginning in FY 2022. Similar to our findings discussed in the FY 2022 IPPS/LTCH final rule, findings
from our analysis using the September 2021 update of the FY 2021 MedPAR file indicated that MS–DRGs 216, 217, 218 as well as approximately 40 other MS–DRGs would be subject to change based on the three-way severity level split criterion finalized in FY 2021.

Therefore, we stated we believe that additional time was needed to allow for further analysis of the claims data to determine to what extent the patient’s co-morbid conditions are also contributing to higher costs and to identify other contributing factors that might exist with respect to the increased length of stay and costs of these cases in these MS–DRGs. For the reasons summarized, and after consideration of the public comments we received, we did not make any MS–DRG changes for cases involving the open concomitant surgical ablation procedures for FY 2023.

As discussed in the FY 2024 IPPS/ LTCH PPS proposed rule (88 FR 26691 through 26695), we again received a request to CMS to reassign MS–DRG assignment of cases involving open concomitant surgical ablation procedures. The requestor recommended that CMS reassigned open concomitant surgical ablation procedures for atrial fibrillation (AF) from MS–DRGs 219, 220, and 221 (Cardiac Valve and Other Major Cardiothoracic Procedures without Cardiac Catheterization with MCC, with CC, and without CC/MCC, respectively) to MS–DRGs 216, 217, and 218. The requestor further recommended that if CMS does not reassigned cases involving open concomitant surgical ablation procedures to MS–DRGs 216, 217, and 218, in the alternative, CMS should create new MS–DRGs for all open mitral or aortic valve repair or replacement procedures with concomitant surgical ablation for AF to improve clinical coherence when three to four open heart procedures are performed in one setting.

The requestor suggested that the following three MS–DRGs be created to reflect current standard of care for these patients:

- **Suggested New MS–DRG XXX—2 procedures**;
- **Suggested New MS–DRG XXX—3 procedures**; and
- **Suggested New MS–DRG XXX—4+ procedures**.

The requestor stated that cases reporting open surgical ablation procedures for AF performed during open valve repair/replacement procedures are typically assigned to MS–DRGs 216, 217, 218, 219, 220, and 221, with the majority of the cases being assigned to MS–DRGs 219, 220 and 221 because of the surgical hierarchy in MDC 05 and because there is less of a need for cardiac catheterization in these cases. We stated in the proposed rule that the requestor performed its own data analysis, and stated their analysis showed that the data continues to demonstrate that claims with open surgical ablation procedures for AF are not clinically similar to the remaining cases in MS–DRGs 219, 220, and 221, and there are significant differences in resource utilization that reflect those clinical differences.

To explore mechanisms to address this request, we began our analysis by examining claims data from the September 2022 update of the FY 2022 MedPAR file for cases reporting procedure code combinations describing open concomitant surgical ablations assigned to MS–DRGs 216, 217, 218, 219, 220, and 221. We referred readers to Tables 6P.3a and 6P.3b associated with the proposed rule (which are available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/Acute InpatientPPS) for the data analysis of cases reporting procedure code combinations describing open concomitant surgical ablations in the September 2022 update of the FY 2022 MedPAR file. Table 6P.3a associated with the proposed rule sets forth the list of ICD–10–PCS procedure codes reflecting mitral valve repair or replacement (MVR), aortic valve repair or replacement (AVR), coronary artery bypass grafting (CABG) and surgical ablation procedures that we examined in this analysis. Table 6P.3b associated with the proposed rule shows the data analysis findings of cases reporting procedure code combinations describing open concomitant surgical ablations assigned to MS–DRGs 216, 217, 218, 219, 220, and 221 from the September 2022 update of the FY 2022 MedPAR file.

As shown in Table 6P.3b associated with the proposed rule, while the average lengths of stay and average costs of cases reporting procedure code combinations describing open concomitant surgical ablations are higher than all cases in their respective MS–DRG, we found there is variation in the volume, length of stay, and average costs of the cases. For MS–DRG 216, we found 439 cases reporting procedure code combinations describing open concomitant surgical ablations with the average length of stay ranging from 5.8 days to 9.6 days and average costs ranging from $49,900 to $84,293 for these cases. For MS–DRG 217, we found 38 cases reporting procedure code combinations describing open concomitant surgical ablations with the average length of stay ranging from 6.7 days to 9.6 days and average costs ranging from $43,221 to $98,001 for these cases. For MS–DRG 219, we found 2 cases reporting procedure code combinations describing open concomitant surgical ablations with the average length of stay of 6.5 days and average cost of $38,519 for these cases. For MS–DRG 220, we found 770 cases reporting procedure code combinations describing open concomitant surgical ablations with the average length of stay ranging from 4.3 days to 5.8 days and average costs ranging from $30,725 to $59,024 for these cases.

We stated in the proposed rule that similar to our analysis of the data as discussed in the FY 2023 IPPS/LTCH PPS final rule, this data analysis also shows for the numerous procedure combinations that would comprise an “open concomitant surgical ablation” procedure, the increase in average costs appears to directly correlate with the number of procedures performed. We stated the data analysis reflects that cases that describe “Open MVR + Open AVR” in addition to other concomitant procedures generally demonstrate higher average costs in their respective MS–DRGs. In MS–DRG 216, we identified a total of 439 cases reporting procedure code combinations describing open concomitant surgical ablations with an average length of stay of 17.7 days and average costs of $89,877. Of those 439 cases, there were 40 cases reporting an aortic valve repair/replacement procedure, a mitral valve repair/replacement procedure, and another concomitant procedure with average costs of $106,301 and an average length of stay of 17.9 days. In MS–DRG 217, we identified a total of 92 cases reporting procedure code combinations describing open concomitant surgical ablations with an average length of stay of 10 days and average costs of $86,975. Of those 92 cases, there were 9 cases reporting an aortic valve repair/replacement procedure, a mitral valve repair/
replacement procedure, and another concomitant procedure with average costs of $82,514 and an average length of stay of 12.5 days. In MS–DRG 219, we identified a total of 1,136 cases reporting procedure code combinations describing open concomitant surgical ablations with an average length of stay of 11.2 days and average costs of $70,693. Of those 1,136 cases, there were 102 cases reporting an aortic valve repair/replacement procedure, a mitral valve repair/replacement procedure, and another concomitant procedure with average costs of $85,337 and an average length of stay of 12.8 days. In MS–DRG 220, we identified a total of 770 cases reporting procedure code combinations describing open concomitant surgical ablations with an average length of stay of 7.3 days and average costs of $52,456. Of those 770 cases, there were 48 cases reporting an aortic valve repair/replacement procedure, a mitral valve repair/replacement procedure, and another concomitant procedure with average costs of $67,344 and an average length of stay of 6.4 days. For MS–DRG 218 and MS–DRG 221, we did not identify any cases reporting procedure code combinations describing open concomitant surgical ablations with an aortic valve repair/replacement procedure, a mitral valve repair/replacement procedure, and another concomitant procedure.

In examining this request, we noted in the proposed rule that the requestor suggested that CMS reassign open concomitant surgical ablation procedures for atrial fibrillation (AF) from MS–DRGs 219, 220, and 221 (Cardiac Valve and Other Major Cardiothoracic Procedures without Cardiac Catheterization with MCC, with CC, and without CC/MCC, respectively) to MS–DRGs 216, 217 and 218 for FY 2024, however, as discussed in the FY 2023 IPPS/LTCH PPS final rule, MS–DRGs 216, 217 and 218 are defined by the performance of cardiac catheterization. We stated we continue to be concerned about the effect on clinical coherence of assigning cases reporting procedure code combinations describing open concomitant surgical ablations that do not also have a cardiac catheterization procedure reported to MS–DRGs that are defined by the performance of that procedure. We also noted, as discussed in section II.C.1.b of the proposed rule, using the December 2022 update of the FY 2022 MedPAR file, we analyzed how applying the NonCC subgroup criteria to all MS–DRGs currently split into three severity levels would affect the MS–DRG structure beginning in FY 2024. Similar to our findings discussed in the FY 2022 and FY 2023 IPPS/LTCH PPS final rules, findings from our analysis indicate that MS–DRGs 216, 217, 218 as well as approximately 44 other base MS–DRGs would be subject to change based on the three-way severity level split criterion finalized in FY 2021. Specifically, we noted that the total number of cases in MS–DRG 218 is again below 500. We refer the reader to Table 6P.10b associated with the proposed rule (which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS) for the list of the 135 MS–DRGs that would potentially be subject to deletion and the list of the 86 new MS–DRGs that would potentially be created under this policy if the NonCC subgroup criteria was applied.

As discussed in the proposed rule, to further analyze the claims data to determine to what extent the performance of multiple procedures is contributing to higher costs and to identify other contributing factors that might exist with respect to the increased length of stay and costs of these cases in these MS–DRGs, we analyzed the cases reporting a concomitant procedure code combination without reporting a procedure code describing open surgical ablation assigned to MS–DRGs 216, 217, 218, 219, 220, and 221. We refer readers to Tables 6P.3c associated with the proposed rule (which are available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS) for the data analysis of cases reporting a concomitant procedure code combination without reporting a procedure code describing open surgical ablation assigned to MS–DRGs 216, 217, 218, 219, 220, and 221 from the September 2022 update of the FY 2022 MedPAR file.

We stated that the data analysis as shown in Table 6P.3c associated with the proposed rule, similarly, reflects that cases that report “Open MVR + Open AVR” in addition to other concomitant procedures generally demonstrate higher average costs in their respective MS–DRGs, even in instances where an open surgical ablation was not reported. In MS–DRG 216, we identified a total of 2,759 cases reporting a concomitant procedure code combination without reporting a procedure code describing open surgical ablation with an average length of stay of 17.5 days and average costs of $52,031. Of those 2,759 cases, there were 240 cases reporting an aortic valve repair/replacement procedure, a mitral valve repair/replacement procedure, and another concomitant procedure with average costs of $116,611 and an average length of stay of 22.7 days. In MS–DRG 217, we identified a total of 852 cases reporting a concomitant procedure code combination without reporting a procedure code describing open surgical ablation with an average length of stay of 10.7 days and average costs of $56,208. Of those 852 cases, there were 31 cases reporting an aortic valve repair/replacement procedure, a mitral valve repair/replacement procedure, and another concomitant procedure with average costs of $70,831 and an average length of stay of 12.6 days. In MS–DRG 218, we identified a total of 64 cases reporting a concomitant procedure code combination without reporting a procedure code describing open surgical ablation with an average length of stay of 11.1 days and average costs of $66,412. Of those 64 cases, there were 579 cases reporting an aortic valve repair/replacement procedure, a mitral valve repair/replacement procedure, and another concomitant procedure with average costs of $85,890 and an average length of stay of 13.7 days. In MS–DRG 220, we identified a total of 6,430 cases reporting a concomitant procedure code combination without reporting a procedure code describing open surgical ablation with an average length of stay of 6.5 days and average costs of $39,924, none of which reported an aortic valve repair/replacement procedure, a mitral valve repair/replacement procedure, and another concomitant procedure. In MS–DRG 219, we identified a total of 7,604 cases reporting a concomitant procedure code combination without reporting a procedure code describing open surgical ablation with an average length of stay of 12.6 days and average costs of $66,412. Of those 7,604 cases, there were 31 cases reporting an aortic valve repair/replacement procedure, a mitral valve repair/replacement procedure, and another concomitant procedure with average costs of $56,208. Of those 852 cases, there were 31 cases reporting an aortic valve repair/replacement procedure, a mitral valve repair/replacement procedure, and another concomitant procedure with average costs of $56,208 and an average length of stay of 5.0 days and average costs of $39,777. Of those 66 cases, there were 9 cases reporting an aortic valve repair/replacement procedure, a mitral valve repair/replacement procedure, and another concomitant procedure with average costs of $89,337 and an average length of stay of 7.8 days. In MS–DRG 221, we identified a total of 66 cases reporting a concomitant procedure code combination without reporting a procedure code describing open surgical ablation with an average length of stay of 12.6 days and average costs of $36,791 and an average length of stay of 7.8 days. In MS–DRG 221, we identified a total of 9 cases reporting an aortic valve repair/replacement procedure, a mitral valve repair/replacement procedure, and another concomitant procedure with average costs of $89,337 and an average length of stay of 7.8 days.
We noted in the proposed rule that analysis of the claims data suggested that it is the performance of an aortic valve repair or replacement procedure, a mitral valve repair or replacement procedure plus another concomitant procedure that is associated with increased hospital resource utilization, not solely the performance of open surgical ablation as suggested by the requester, when compared to other cases in their respective MS–DRGs. We stated we reviewed these data and noted, clinically, the management of mixed valve disease is challenging because patients with mixed valve disease are often frail, elderly, and present with multiple comorbidities. The combination of conditions in mixed valve disease, such as aortic stenosis and mitral stenosis, can result in a greater reduction of cardiac output than in isolated valvular stenosis. Patients requiring an aortic valve procedure and a mitral valve procedure in the same operative session are more complex cases and can be at significant risk for adverse events if there is moderate or severe disease of one or more cardiac valves. In the proposed rule, we stated that the data analysis clearly showed that cases reporting aortic valve repair or replacement procedure, a mitral valve repair or replacement procedure and another concomitant procedure have higher average costs and generally longer lengths of stay compared to all the cases in their assigned MS–DRG. For these reasons, we proposed to create a new MS–DRG for cases reporting an aortic valve repair or replacement procedure, a mitral valve repair or replacement procedure, and another concomitant procedure.

As discussed in the proposed rule, to compare and analyze the impact of our suggested modifications, we ran a simulation using the most recent claims data from the December 2022 update of the FY 2022 MedPAR file. The following table illustrates our findings for all 892 cases reporting procedure codes describing an aortic valve repair or replacement procedure, a mitral valve repair or replacement procedure, and another concomitant procedure. We stated we believed that the resulting proposed MS–DRG assignment is more clinically homogeneous, coherent and better reflects hospital resource use.

<table>
<thead>
<tr>
<th>Proposed new MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proposed new MS-DRG XXX Concomitant Aortic and Mitral Valve Procedures</td>
<td>892</td>
<td>15.7</td>
<td>$93,764</td>
</tr>
</tbody>
</table>

We applied the criteria to create subgroups in a base MS–DRG as discussed in section II.C.1.b. of the FY 2024 IPPS/LTCH PPS proposed rule. As shown in the table that follows, a three-way split of the proposed new MS–DRG failed to meet the criterion that there be at least 500 or more cases in each subgroup.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>With MCC</td>
<td>679</td>
<td>17.7</td>
<td>$102,194</td>
</tr>
<tr>
<td>With CC</td>
<td>207</td>
<td>9.4</td>
<td>$67,682</td>
</tr>
<tr>
<td>Without CC/MCC</td>
<td>6</td>
<td>5</td>
<td>$39,567</td>
</tr>
</tbody>
</table>

We then applied the criteria for a two-way split for the “with CC/MCC” and “without CC/MCC” subgroups and again found that the criterion that there be at least 500 or more cases in each subgroup could also not be met. The following table illustrates our findings.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>With CC/MCC</td>
<td>886</td>
<td>15.7</td>
<td>$94,131</td>
</tr>
<tr>
<td>Without CC/MCC</td>
<td>6</td>
<td>5</td>
<td>$39,567</td>
</tr>
</tbody>
</table>

We also applied the criteria for a two-way split for the “with MCC” and “without MCC” subgroups and found that the criterion that there be at least 500 or more cases in each subgroup similarly could not be met. The following table illustrates our findings.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>With MCC</td>
<td>679</td>
<td>17.7</td>
<td>$102,194</td>
</tr>
<tr>
<td>Without MCC</td>
<td>213</td>
<td>9.2</td>
<td>$66,890</td>
</tr>
</tbody>
</table>
Therefore, for FY 2024, we did not propose to subdivide the proposed new MS–DRG for cases reporting procedure codes describing an aortic valve repair or replacement procedure, a mitral valve repair or replacement procedure, and another concomitant procedure into severity levels.

In summary, for FY 2024, taking into consideration that it clinically requires greater resources to perform an aortic valve repair or replacement procedure, a mitral valve repair or replacement procedure, and another concomitant procedure, we proposed to create a new base MS–DRG for cases reporting an aortic valve repair or replacement procedure, a mitral valve repair or replacement procedure, and another concomitant procedure in MDC 05. The proposed new MS–DRG is proposed new MS–DRG 212 (Concomitant Aortic and Mitral Valve Procedures). We referred the reader to Table 6P.4a associated with the proposed rule (which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index for the list of procedure codes we proposed to define in the logic for the proposed new MS–DRG. We refer the reader to section II.C.15. of the preamble of this final rule for the discussion of the surgical hierarchy and the complete list of our proposed modifications to the surgical hierarchy as well as our finalization of those proposals.

Comment: Commenters expressed support for the proposal to create new base MS–DRG 212 (Concomitant Aortic and Mitral Valve Procedures) for cases reporting an aortic valve repair or replacement procedure, a mitral valve repair or replacement procedure, and another concomitant procedure in MDC 05. Many commenters stated that the proposal would provide the resources necessary to continue offering these concomitant procedures to Medicare patients with extremely serious, complicated heart conditions, which avoids a future additional surgery down the line. Other commenters stated they agreed with CMS that this proposal would result in more clinically homogenous assignments that better reflect hospital resources. A commenter stated they thank CMS for recognizing the importance of adequate payment for multiple concomitant open valvular procedures. Another commenter stated that without an MS–DRG reflecting the additional costs of performing concomitant procedures, hospitals will continue to be incentivized for multiple admissions for separate cardiac procedures in order to cover the cost of care.

Response: We appreciate the commenters’ support.

Comment: Many commenters stated that the proposal to create MS–DRG 212 is a good first step, but urged CMS go a step further and also assign cases reporting a single AVR or MVR procedure and another concomitant procedure in MDC 05 to the proposed new MS–DRG. Commenters stated that this modification to the proposal would better align with the clinical literature and the clinical needs of Medicare beneficiaries by allowing patients to receive lifesaving therapies in one visit, while not incentivizing hospitals to send patients with AF home to return for future procedures. Some commenters stated, based on their analysis, more patients require an open concomitant single AVR or MVR procedure than multiple open valvular procedures with open surgical ablation. These commenters stated that new MS–DRG 212 would apply to roughly 10 percent of Medicare beneficiaries, while excluding the majority of Medicare beneficiaries who require open heart valve procedures in combination with open surgical ablation treatment for AF. A commenter stated that AF is a complex arrhythmia that is present in more than 40 percent of patients undergoing open single or multiple valve procedures and stated that these patients have a two to three times greater risk for hospitalizations and multiple admissions if their AF goes untreated. Commenters stated that treating atrial fibrillation during the same surgical session as a single open valve procedure requires significant device costs, additional operating room time, and specialized staff. Some commenters expressed concern that given the added costs of performing multiple procedures at the same time, hospitals may more likely schedule the patient for separate procedures even though guidelines of the Society for Thoracic Surgeons and the Heart Rhythm Society recommend performing surgical ablation for atrial fibrillation at the time of open-heart procedures when indicated. These commenters further stated a delay in addressing the biggest patient segment with single open valve replacement (MVR or AVR) and other concomitant procedures risks limiting lifesaving access to therapies for CMS beneficiaries. Many commenters stated the proposal would be even more impactful for patients if cases reporting single open valve procedures were included.

Some commenters urged CMS to either (1) assign all cases reporting a single AVR or MVR procedure and another concomitant procedure for the treatment of atrial fibrillation to new proposed MS–DRG 212. (2) create a new MS–DRG for cases reporting a single AVR or MVR procedure for the treatment of atrial fibrillation, or (3) assign cases reporting a single AVR or MVR procedure and a concomitant surgical ablation procedure for the treatment of atrial fibrillation to MS–DRGs 216, 217, and 218 (Cardiac Valve and Other Major Cardiothoracic Procedures with Cardiac Catheterization with MCC, with CC, and without CC/ MCC, respectively) and change the title of the MS–DRGs, while maintaining the relative weight, and then monitor the claims data for two years.

However, other commenters were not supportive of assigning cases reporting a single AVR or MVR procedure and another concomitant procedure to the proposed new MS–DRG 212. These commenters noted that the focus and clinical rationale for CMS’ proposal was based on the complex, multiple valve procedures. Commenters stated that assigning cases reporting a single AVR or MVR procedure and another concomitant procedure to new MS–DRG 212 would have a significant negative impact on the remaining MS–DRGs, notably MS–DRG 216. The commenters recommended that CMS continue to carefully review the impacts on the relative weights in these MS–DRGs if CMS finalizes the proposal to move approximately 900 cases out of MS–DRGs 216, 217, 218, 219, 220, and 221. Another commenter requested that CMS delay implementation of proposed new MS–DRG 212 for a year to allow interested parties to fully assess the impact of the proposed changes to MS–DRGs 216, 217, 218, 219, 220, and 221 and to analyze other options to address payment adequacy more broadly across concomitant procedures, particularly given that findings from CMS’ analysis indicate that MS–DRGs 216, 217, and 218 as well as approximately 44 other base MS–DRGs would be subject to change based on the NonCC subgroup criteria finalized in FY 2021. This commenter further stated given the relatively small number of cases impacted by the newly proposed MS–DRG 212, additional time would give CMS an opportunity to work with interested parties to consider other concomitant procedures that have similar clinical and cost coherence as the procedures currently proposed for MS–DRG 212, such as concomitant procedures involving the tricuspid and pulmonary valves.

Response: We appreciate the commenters sharing their concerns and
feedback on this proposal. To examine the recommendation that CMS expand MS–DRG 212 to allow cases reporting a single aortic valve repair or replacement procedure or a mitral valve repair or replacement procedure with an open concomitant surgical ablation to be grouped into the proposed new MS–DRG, we further analyzed the September 2022 update of the FY 2022 MedPAR file for cases reporting procedure code combinations describing a single AVR or MVR procedure and a concomitant procedure assigned to MS–DRGs 216, 217, 218, 219, 220 and 221. We also analyzed the September 2022 update of the FY 2022 MedPAR file for cases reporting procedure code combinations describing a single AVR or MVR procedure and a concomitant procedure and a diagnosis of AF. We identified cases reporting AF as a principal or secondary diagnosis with the following ICD–10–CM codes.

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I48.0</td>
<td>Paroxysmal atrial fibrillation</td>
</tr>
<tr>
<td>I48.11</td>
<td>Longstanding persistent atrial fibrillation</td>
</tr>
<tr>
<td>I48.19</td>
<td>Other persistent atrial fibrillation</td>
</tr>
<tr>
<td>I48.20</td>
<td>Chronic atrial fibrillation, unspecified</td>
</tr>
<tr>
<td>I48.21</td>
<td>Permanent atrial fibrillation</td>
</tr>
<tr>
<td>I48.91</td>
<td>Unspecified atrial fibrillation</td>
</tr>
</tbody>
</table>

| MS-DRGs 216 – 221: Cases Reporting Procedures Describing Concomitant Single Open Valve Procedures |
|---------------------------------------------------------------|-----------------|-----------------|-----------------|
| MS-DRG                                                | Number of Cases | Average Length of Stay | Average Costs |
| 216 Cardiac Valve and Other Major Cardiothoracic Procedures with Cardiac Catheterization with MCC - ALL CASES | 5,311            | 14.9             | $84,327         |

BILLING CODE 4120–01–P
As shown in the table, in MS–DRG 216, we identified a total of 2,590 cases reporting procedure code combinations describing a single AVR or MVR procedure and a concomitant procedure with an average length of stay of 17.1 days and average costs of $87,374. Of those 2,590 cases, there were 1,511 cases reporting procedure code combinations describing a single AVR or MVR procedure and a concomitant procedure, with a diagnosis of AF with average costs of $85,840 and an average length of stay of 17 days. The data analysis performed indicates that the 1,511 cases in MS–DRG 216 reporting procedure code combinations describing a single AVR or MVR procedure and a concomitant procedure with a diagnosis of AF have an average length of stay that is longer than the average length of stay for all the cases in MS–DRG 216 (17.1 days versus 14.9 days) and slightly higher average costs when compared to all the cases in MS–DRG 216 ($85,840 versus $84,327).

In MS–DRG 217, we identified a total of 808 cases reporting procedure code combinations describing a single AVR or MVR procedure and a concomitant procedure with an average length of stay of 9.4 days and average costs of $55,593. Of those 808 cases, there were 462 cases reporting procedure code combinations describing a single AVR or MVR procedure and a concomitant procedure, with a diagnosis of AF with average costs of $56,104 and an average length of stay of 9.8 days. The data analysis performed indicates that the 462 cases in MS–DRG 217 reporting procedure code combinations describing a single AVR or MVR procedure and a concomitant procedure with a diagnosis of AF have an average length of stay that is longer than the average length of stay for all the cases in MS–DRG 217 (9.4 days versus 9.0 days) and slightly higher average costs when compared to all the cases in MS–DRG 217 ($56,104 versus $55,593).
AVR or MVR procedure and a concomitant procedure with a diagnosis of AF have an average length of stay that is longer than the average length of stay for all the cases in MS–DRG 217 (9.8 days versus 7.3 days) and similar average costs when compared to all the cases in MS–DRG 217 ($56,104 versus $56,143).

In MS–DRG 218, we identified a total of 62 cases reporting procedure code combinations describing a single AVR or MVR procedure and a concomitant procedure with an average length of stay of 6.6 days and average costs of $38,013. Of those 62 cases, there were 18 cases reporting procedure code combinations describing a single AVR or MVR procedure and a concomitant procedure, with a diagnosis of AF with average costs of $37,053 and an average length of stay of 6.2 days. The data analysis performed indicates that the 18 cases in MS–DRG 218 reporting procedure code combinations describing a single AVR or MVR procedure and a concomitant procedure with a diagnosis of AF have an average length of stay that is longer than the average length of stay for all the cases in MS–DRG 218 (6.2 days versus 3.1 days) and lower average costs when compared to all the cases in MS–DRG 218 ($37,053 versus $50,208). In MS–DRG 219, we identified a total of 7,400 cases reporting procedure code combinations describing a single AVR or MVR procedure and a concomitant procedure with an average length of stay of 10.9 days and average costs of $66,489. Of those 7,400 cases, there were 4,485 cases reporting procedure code combinations describing a single AVR or MVR procedure and a concomitant procedure, with a diagnosis of AF with average costs of $41,903 and an average length of stay of 5.6 days. The data analysis performed indicates that the 239 cases in MS–DRG 221 reporting procedure code combinations describing a single AVR or MVR procedure and a concomitant procedure, with a diagnosis of AF with average costs of $41,903 and an average length of stay of 5.6 days and average costs of $39,688. Of those 650 cases, there were 239 cases reporting procedure code combinations describing a single AVR or MVR procedure and a concomitant procedure, with a diagnosis of AF with average costs of $41,903 and an average length of stay of 5.6 days. The data analysis performed also indicates that the 239 cases in MS–DRG 221 reporting procedure code combinations describing a single AVR or MVR procedure and a concomitant procedure, with a diagnosis of AF have an average length of stay that is longer than the average length of stay for all the cases in MS–DRG 221 (5.6 days versus 4 days) and slightly higher average costs when compared to all the cases in MS–DRG 221 ($41,903 versus $40,694).

The data analysis performed also indicates that the cases in MS–DRGs 219, 220, and 221 reporting procedure code combinations describing a single AVR or MVR procedure and a concomitant procedure have a similar average length of stay and generally lower average costs when compared to all the cases in MS–DRGs 216, 217, 218, 219, 220, and 221 where they are currently assigned based on the similarities in resource utilization compared to all the cases in their respective MS–DRG.

In response to comments that urged CMS to assign cases reporting procedure code combinations describing open concomitant surgical ablations currently assigned to MS–DRGs 216, 217, 218, 219, 220, and 221 where they are currently assigned based on the similarities in resource utilization compared to all the cases in their respective MS–DRG.

In response to comments that urged CMS delay implementation of proposed MS–DRG for cases reporting a single AVR or MVR procedure for the treatment of atrial fibrillation and instead suggest that cases reporting a single AVR or MVR procedure for the treatment of atrial fibrillation are suitably grouped to MS–DRGs 216, 217, 218, 219, 220, and 221 where they are currently assigned based on the similarities in resource utilization compared to all the cases in their respective MS–DRG.
available is sufficient to create a new MS–DRG for cases reporting an aortic valve repair or replacement procedure, a mitral valve repair or replacement procedure, and another concomitant procedure. As discussed in the proposed rule, and earlier in this section, the data demonstrate that cases reporting aortic valve repair or replacement procedure, a mitral valve repair or replacement procedure, and another concomitant procedure have higher average costs and generally longer lengths of stay compared to all the cases in their assigned MS–DRG.

We appreciate the public comments we received and will continue to monitor for impacts in MDC 05 and across the MS–DRGs to avoid unintended consequences or missed opportunities in most appropriately capturing the resource utilization and clinical coherence for this subset of procedures.

Comment: Some commenters stated the title of proposed new MS–DRG 212 (Concomitant Aortic and Mitral Valve Procedures) is not clear. These commenters stated it was not clear if the logic intent is for cases reporting both a mitral and aortic valve procedure with a concomitant procedure to be assigned to new MS–DRG 212 or if the logic intent is to have cases reporting a mitral valve or an aortic valve procedure with a concomitant procedure to be assigned to new MS–DRG 212. A few commenters suggested that consideration be given to revising the title of the proposed new MS–DRG as it is not clear if the logic intent is for cases reporting both a mitral and aortic valve procedure with a concomitant procedure to be assigned to new MS–DRG 212 or if the logic intent is to have cases reporting a mitral valve or an aortic valve procedure with a concomitant procedure to be assigned to new MS–DRG 212. Few commenters suggested that the list of procedure codes within the GROUPER logic list for MS–DRG 212 includes both surgical ablation and CABG procedures. Another commenter stated that the display in the draft Definition Manual, Version 41 for MS–DRG 212 is unclear and observed there are no instructional notes included in the draft Definition Manual to explain the intent of the various lists of procedures.

Response: We appreciate the commenters’ feedback. As discussed in the final ICD–10 MS–DRG Definitions Manual, Version 41, available at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software, that was provided so the public can better analyze and understand the impact of the proposals included in the FY 2024 IPPS/LTCH PPS proposed rule, we agree refinements to the display would be helpful to clarify the GROUPER logic for MS–DRG 212. In the final ICD–10 MS–DRG Definitions Manual, Version 41, we will refine the display by adding headers above each of the respective logic lists as follows:

- Select ONE procedure from aortic valve procedures
- Select ONE procedure from mitral valve procedures
- Select at least ONE procedure from concomitant procedures

Comment: Some commenters noted that the list of procedure codes we proposed to define aortic valve procedures and mitral valve procedures in the logic for the proposed new MS–DRG is limited to the root operations “Repair” and “Replacement,” however there are other valve procedures listed under the “Concomitant Procedures” logic list. These commenters suggested that CMS consider moving the aortic and mitral valve procedure codes with the root operations of “Creation”, “Release”, “Restriction”, and “Supplement,” that are currently listed under the Concomitant Procedures list in Table 6P.4a and in the draft version of the ICD–10 MS–DRG Definitions Manual to the appropriate logic list of aortic valve or mitral valve procedures. The commenters stated that procedure codes with these other root operations also represent types of valvular repairs and should be included on the aortic valve procedures and mitral valve procedures logic lists rather than the “Concomitant Procedures” logic list. A commenter stated that this change would ensure that all of the aortic valve and mitral valve procedure codes are captured as valve procedures instead of concomitant procedures when performed.

Response: We appreciate the feedback and will take these suggestions under consideration. We note that the requestor originally requested that CMS review the MS–DRG assignments for cases involving open surgical ablation performed during another open heart surgical procedure such as mitral valve repair or replacement (MVR), aortic valve repair or replacement (AVR), or coronary artery bypass grafting (CABG). Table 6P.3a associated with the proposed rule sets forth the list of ICD–10–PCS procedure codes reflecting MVR, AVR, CABG, and surgical ablation procedures that we examined in our analysis. We agree with the commenters that there are other valve procedures listed under the “Concomitant Procedure” logic list in Table 6P.3a, however, each of these procedures are defined by clinically distinct definitions and objectives, which is why there are separate and unique ICD–10–PCS procedure codes within the classification for reporting purposes. Additional claims analysis is needed to determine if the technical complexity and resource utilization of all, or a subset, of the aortic and mitral valve procedure codes with the root operations of “Creation”, “Release”, “Restriction”, and “Supplement” in the “Concomitant Procedures” logic list warrant any modifications to the GROUPER logic of proposed new MS–DRGs. We believe there may be an opportunity to further refine this MS–DRG as we continue to monitor the claims data and perform additional analysis. We note that we would address any proposed modifications to the logic in future rulemaking.

Comment: Commenters stated they appreciated CMS’ willingness to examine how the performance of multiple procedures during the same
operative session contributes to higher hospital costs and patient length of stay. Commenters encouraged CMS to continue to consider options in the MS–DRGs for concomitant procedures with higher hospital resource utilization, given the important patient care benefits and efficiencies associated with performing certain procedures concomitantly in a single encounter rather than staging separate procedures. A commenter stated they recognize that clinical services across many medical specialties may be performed concomitantly to optimize patient outcomes and noted, for example, studies indicate when left atrial appendage closure (LAAC) is performed concomitantly with ablation, the outcomes are at least as comparable as for patients who have undergone these procedures separately. This commenter suggested that CMS conduct a comprehensive analysis of all concomitant procedures, similar to the analysis of concomitant aortic and mitral valve procedures, to inform whether CMS should establish a more holistic policy to provide adequate payment for clinical practices that lead to better efficiency and patient outcomes. Another commenter recommended that CMS devise a broader, more inclusive, supplemental mechanism to facilitate incremental payment when two major procedures are performed during the same hospital admission and urged CMS to ensure that the incurred costs are adequately addressed so as not to disincentivize concomitant procedures which can be more cost efficient, more convenient, and provide a better prognosis for the patient than the procedures being performed during different hospital stays.

Response: We appreciate the commenters’ support. We also thank the commenters for their recommendations to conduct a comprehensive analysis of all concomitant procedures as we agree that the performance of “concomitant procedures” may affect the consumption of resources in other clinical scenarios, especially when the use of devices is involved. We continue to be interested in receiving feedback on possible mechanisms through which we can address concomitant procedures. We are also interested in receiving feedback on how CMS can mitigate any unintended negative payment impacts to providers providing concomitant procedures. Commenters can continue to submit their recommendations via the Medicare Electronic Application Request Information System™ (MEARIS™) at: https://mearis.cms.gov/

public/home. We will consider these public comments for possible proposals in future rulemaking as part of our annual review process.

Comment: While supporting the proposal, a commenter suggested that proposed new MS–DRG 212 be split into two severity levels (with and without MCC). The commenter stated they believe it is mathematically impossible for the proposed new MS–DRG to ever be more than a base MS–DRG, however in their opinion, a base MS–DRG does not take into account the variation in the average costs between cases reporting a secondary diagnosis designated as a MCC compared to cases reporting a secondary diagnosis designated as a CC.

Response: We thank the commenter for their feedback. In response to the suggestion that proposed new MS–DRG 212 for cases describing concomitant aortic and mitral valve procedures be subdivided with a two-way severity level split, we note as discussed in the proposed rule and earlier in this section, in the analysis of the cases describing concomitant aortic and mitral valve procedures, we applied the criteria for a two-way split for the “with MCC” and “without MCC” subgroups and found that the criterion that there be at least 500 or more cases in each subgroup could not be met and therefore did not propose to subdivide the proposed new MS–DRG for concomitant aortic and mitral valve procedures into severity levels for FY 2024. In response to the concern about variation of costs between cases reporting a secondary diagnosis designated as a MCC compared to cases reporting a secondary diagnosis designated as a CC in a base MS–DRG, we note the MS–DRG system is a system of averages, and it is expected that within the diagnostic related groups, some cases may demonstrate higher than average costs, while other cases may demonstrate lower than average costs.

Therefore, after consideration of the public comments we received, and for the reasons discussed, we are finalizing our proposal to create a new MS–DRG 212 [Concomitant Aortic and Mitral Valve Procedures] in MDC 05, without modification, effective October 1, 2023, for FY 2024. We are also finalizing the list of procedure codes to define the logic for the new MS–DRGs as displayed in Table 6P.4a associated with the proposed rule (which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index)

b. External Heart Assist Device

Impella® Ventricular Support Systems are temporary heart assist devices intended to support blood pressure and provide increased blood flow to critical organs in patients with cardiogenic shock, by drawing blood out of the heart and pumping it into the aorta, partially or fully bypassing the left ventricle to provide adequate circulation of blood (replace or supplement left ventricle pumping) while also allowing damaged heart muscle the opportunity to rest and recover in patients who need short-term support.

In the FY 2022 IPPS/LTCH PPS final rule (86 FR 44820 through 44831), we discussed a request to reassign certain cases reporting procedure codes describing the insertion of a percutaneous short-term external heart assist device from MS–DRG 215 (Other Heart Assist System Implant) to MS–DRGs 216, 217, and 218 (Cardiac Valve and Other Major Cardiothoracic Procedures with Cardiac Catheterization with MCC, with CC, and without CC/ MCC, respectively). We stated that our clinical advisors reviewed the clinical issues and the claims data and agreed that cases reporting a procedure code that describes the intraoperative insertion of a short-term external heart assist device are generally less resource intensive and are clinically distinct from other cases reporting procedure codes describing the insertion of other types of heart assist devices currently assigned to MS–DRG 215. We also stated that critically ill patients who are experiencing or at risk for cardiogenic shock from an emergent event such as heart attack or virus that impacts the functioning of the heart and requires longer heart pump support are different from those patients who require intraoperative support only. Patients receiving a short-term external heart assist device intraoperatively during coronary interventions often have an underlying disease pathology such as heart failure related to occluded coronary vessels that is broadly similar in kind to other patients also receiving these interventions without the need for an insertion of a short-term external heart assist device. In the post-operative period, these patients can recover and can be sufficiently rehabilitated prior to discharge. For these reasons, we finalized our proposal to assign ICD–10–PCS codes 02HA0R, 02HA3R, or 02HA4R that describe the intraoperative insertion of a short-term external heart assist device to MS–DRGs 216, 217, 218, 219, 220, 221, and 222.

As discussed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 6695
we received a request to reassign certain cases reporting procedure codes describing the insertion of a short-term external heart assist device using an axillary artery conduit from MS–DRG 215 to MS–DRGs 001 and 002 (Heart Transplant or Implant of Heart Assist System with MCC and without MCC, respectively) and MS–DRG 003 (ECMO or Tracheostomy with MV >96 Hours or Principal Diagnosis Except Face, Mouth and Neck with Major O.R. Procedures). During our review of this request, we noted in the proposed rule that we agreed with the requestor that the insertion of a short-term external heart assist device using an axillary artery conduit is not separately identifiable in the claims data. Therefore, in this section, we address the assignment of the existing procedure codes describing the insertion of short-term external heart assist devices, including our proposed reassignment of a subset of these cases for FY 2024.

The following ICD–10–PCS procedure codes describe the insertion of a short-term external heart assist device.

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02HA0RZ</td>
<td>Insertion of short-term external heart assist system into heart, open approach</td>
</tr>
<tr>
<td>02HA3RZ</td>
<td>Insertion of short-term external heart assist system into heart, percutaneous approach</td>
</tr>
<tr>
<td>02HA4RZ</td>
<td>Insertion of short-term external heart assist system into heart, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

In the ICD–10 MS–DRG Definitions Manual Version 40.1, procedure codes 02HA0RZ, 02HA3RZ, and 02HA4RZ are currently recognized as extensive O.R. procedures assigned to MS–DRG 215 (Other Respiratory System O.R. Procedures with MCC, with CC, and without CC/MCC, respectively) in MDC 05.

As stated previously and discussed in the proposed rule, the request for FY 2024 rulemaking was to reassign certain cases reporting procedure codes describing the insertion of a short-term external heart assist device using an axillary artery conduit from MS–DRG 215 to MS–DRGs 001 and 002 (Heart Transplant or Implant of Heart Assist System with MCC and without MCC, respectively) and MS–DRG 003 (ECMO or Tracheostomy with MV >96 Hours or Principal Diagnosis Except Face, Mouth and Neck with Major O.R. Procedures).

According to the requestor, the Impella 5.5® with SmartAssist® System is designed for longer-duration support (up to 14 days) than other femoral access percutaneous ventricular assist devices (pVADs) that treat cardiogenic shock (up to 4 days) providing full cardiac and hemodynamic support with 5.5 liters of blood flow per minute. The Impella 5.5® with SmartAssist® System is considered a hybrid procedure of an open vascular exposure and an endovascular procedure. The Impella 5.5® with SmartAssist® System surgical pump can be inserted through an open chest for direct aortic access or a surgical incision that exposes the axillary artery. In the axillary artery approach, a surgical graft conduit is anastomosed to the axillary artery by a surgeon in the operating room. The device is positioned across the aortic valve, with the inlet located in the left ventricle and the outlet in the ascending aorta to allow the device to directly unload via the native pathway and to support coronary perfusion.

We noted in the proposed rule that the Impella 5.5® with SmartAssist® System is reassignment of a subset of cases reporting procedure codes describing the insertion of a short-term external heart assist device using an axillary artery conduit must be performed by a surgeon in the operating room. We stated in the proposed rule that the requestor performed its own data analysis, and stated their analysis showed a significant variation in the resource utilization for patients treated with the Impella 5.5® with SmartAssist® System compared to patients treated with other femoral access pVADs assigned to MS–DRG 215.

In the proposed rule, we also noted that following the submission of the FY 2024 MS–DRG classification change request for certain cases reporting procedure codes describing the insertion of a short-term external heart assist device using an axillary artery conduit, this same requestor (the manufacturer of the Impella® Ventricular Support Systems) submitted a code proposal requesting a new ICD–10–PCS procedure code to describe the Impella 5.5® with SmartAssist® System for consideration as an agenda topic to be discussed at the March 7–8, 2023 ICD–10 Coordination and Maintenance Committee meeting. The proposal was presented and discussed at the March 7–8, 2023 ICD–10 Coordination and Maintenance Committee Meeting. We refer the reader to the CMS website at: https://www.cms.gov/Medicare/Coding/ICD10-C-and-M-Meeting-Materials for additional detailed information regarding the request, including a recording of the discussion and the related meeting materials. Public comments in response to the code proposal were due by April 7, 2023.

In reviewing this MS–DRG reclassification request, in the proposed rule we noted that we agreed with the requestor that the insertion of a short-term external heart assist device using an axillary artery conduit (such as the Impella 5.5® with SmartAssist® System) is not separately identifiable in the claims data. Therefore, in this section, we address the assignment of the following procedure codes describing the insertion of short-term external heart assist devices, including our proposed reassignment of a subset of these cases for FY 2024.

The following ICD–10–PCS procedure codes describe the insertion of a short-term external heart assist device.
As procedure codes describing the insertion of a short-term external heart assist device are classified as extensive procedures in Version 40.1, specific assignment of these procedure codes to MS–DRG 003 is not required. When the other parameters of the GROUPER logic are met and procedure codes describing the insertion of a short-term external heart assist device are also reported, MS–DRG 003 will be assigned, therefore in the proposed rule we stated we did not include MS–DRG 003 in our analysis. We refer the reader to the ICD–10 MS–DRG Version 40.1 Definitions Manual (which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software for complete documentation of the GROUPER logic for the listed MS–DRGs and for Appendix E—Operating Room Procedures and Procedure Code/MS–DRG Index.

In the proposed rule, we stated that to begin our analysis, we examined claims data from the September 2022 update of the FY 2022 MedPAR file for MS–DRG 215 to identify cases reporting ICD–10–PCS codes 02HA0RZ, 02HA3RZ, and 02HA4RZ. Our findings are shown in the following table:

<table>
<thead>
<tr>
<th>ECMO</th>
<th>Tracheostomy</th>
<th>MV &gt;96</th>
<th>PDx Except Face, Mouth, Neck</th>
<th>Major O.R. Procedure</th>
<th>MS-DRG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>003 (ECMO or Tracheostomy with MV &gt;96 Hours or Principal Diagnosis Except Face, Mouth and Neck with Major O.R. Procedures)</td>
</tr>
<tr>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>003 (ECMO or Tracheostomy with MV &gt;96 Hours or Principal Diagnosis Except Face, Mouth and Neck with Major O.R. Procedures)</td>
</tr>
<tr>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>003 (ECMO or Tracheostomy with MV &gt;96 Hours or Principal Diagnosis Except Face, Mouth and Neck with Major O.R. Procedures)</td>
</tr>
<tr>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>004 (Tracheostomy with MV &gt;96 Hours or Principal Diagnosis Except Face, Mouth and Neck without Major O.R. Procedures)</td>
</tr>
</tbody>
</table>

As shown in the table, we identified a total of 3,587 cases within MS–DRG 215 with an average length of stay of 9 days and average costs of $86,774. Of these 3,587 cases, there are 60 cases reporting a procedure code describing the open insertion of a short-term external heart assist device with an average length of stay of 9.2 days and average costs of $130,153. There are 3,424 cases reporting a procedure code describing a percutaneous insertion of a short-term external heart assist device with an average length of stay of 8.9 days and average costs of $86,640. There are 6 cases reporting a procedure code describing a percutaneous endoscopic insertion of a short-term external heart assist device with an average length of stay of 6.7 days and average costs of $63,923. The data analysis shows that the average length of stay is longer and the average costs are higher for the cases reporting a procedure code describing the open insertion of a short-term external heart assist device compared to all cases in MS–DRG 215, while the average length of stay is shorter and the average costs are lower for the cases reporting a procedure code describing the percutaneous or percutaneous endoscopic insertion of a short-term external heart assist device.
external heart assist device compared to all cases in that MS–DRG.

We stated in the proposed rule that we then examined claims data from the September 2022 update of the FY 2022 MedPAR for MS–DRGs 001 and 002. Our findings are shown in the following table.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>001</td>
<td>1,553</td>
<td>40.4</td>
<td>$235,135</td>
</tr>
<tr>
<td>002</td>
<td>28</td>
<td>18.3</td>
<td>$108,476</td>
</tr>
</tbody>
</table>

We stated that while the average costs for all cases in MS–DRG 001 are higher than the average costs of the cases reporting a procedure code describing the open insertion of a short-term external heart assist device, the data suggested that overall, cases reporting a procedure code describing the open insertion of a short-term external heart assist device may be more appropriately aligned with the average costs of the cases in MS–DRGs 001 and 002 in comparison to MS–DRG 215, even though the average length of stay is shorter.

In the proposed rule, we stated that we then reviewed the clinical considerations along with this data analysis and agreed that cases reporting a procedure code that describes the open insertion of a short-term external heart assist device are generally more resource intensive and are clinically distinct from other cases reporting procedure codes describing the insertion of short-term external heart devices by other approaches currently assigned to MS–DRG 215. The availability of mechanical circulatory support devices to provide acute hemodynamic support for cardiogenic shock or to support percutaneous coronary intervention (PCI) has expanded over the past decade. We noted that there is now a portfolio of short-term external heart assist devices available that each have different indications for use and techniques for implantation.

We also noted that the percutaneous or percutaneous endoscopic insertion of a short-term external heart assist device involves standard catheterization techniques except for the requirement of a large-bore 13 or 14 Fr sheath. Short-term external heart assist devices inserted in this manner generally provide blood flow up to 2.5 L/min for systemic perfusion and are intended for temporary (≤4 days) use to maintain stable heart function. In contrast, the open insertion of a short-term external heart assist device or the insertion of short-term external heart assist devices using an axillary artery conduit requires a surgical cutdown of the axillary artery to place the larger 23 Fr sheaths of these devices. Short-term external heart assist devices that are inserted via an open approach or using an axillary artery conduit can provide blood flow up to 5.5 L/min for systemic perfusion and are intended for longer use (≤14 days). They are indicated for the treatment of ongoing cardiogenic shock that occurs less than 48 hours following acute myocardial infarction or open-heart surgery or in the setting of cardiomyopathy, including peripartum cardiomyopathy, or myocarditis as a result of isolated left ventricular failure that is not responsive to medical management and conventional treatment measures. We noted in the proposed rule that the indications for the open insertion of a short-term external heart assist device or the insertion of short-term external heart assist devices using an axillary artery conduit are more closely aligned with MS–DRGs 001 and 002 as compared to MS–DRG 215. For these reasons, we stated we believed reassigning ICD–10–PCS code 02HA0RZ that describes the open insertion of a short-term external heart assist device to Pre-MDC MS–DRGs 001 and 002 would improve clinical coherence in these MS–DRGs.

As discussed in the proposed rule, to compare and analyze the impact of these potential modifications, we ran a simulation using the claims data from the September 2022 update of the FY 2022 MedPAR file. The following table reflects our simulation for ICD–10–PCS procedure code 02HA0RZ that describes the open insertion of a short-term external heart assist device if it was moved to MS–DRGs 001 and 002.
costs of the cases remaining in MS–DRG 215 by about $3,000, while similarly having a limited effect on the average costs of MS–DRGs 001 and 002. Therefore, for FY 2024, we proposed to reassign ICD–10–PCS code 02HA0RZ when reported as a standalone procedure from MDC 05 in MS–DRG 215 to Pre-MDC MS–DRGs 001 and 002. We noted that under this proposal, procedure code 02HA0RZ would no longer need to be reported as part of a procedure code combination or procedure code “cluster” to satisfy the logic for assignment to MS–DRGs 001 and 002.

As discussed in the proposed rule, we will continue to monitor the clinical cohesiveness of the procedures assigned to MS–DRGs 001 and 002 to assess whether they continue to be aligned on resource use, as well as current shifts in treatment practices, to determine if additional refinements may be warranted in the future. The increased availability of short-term external heart assist devices and their development into low profile, high output pumps has shifted the management of cardiogenic shock that is unresponsive to other interventions in the years since these MS–DRGs were created. These short-term devices can now be used as a bridge to provide the time needed for clinical decision making, native heart recovery, or until another procedure can be performed, such as the insertion of a left ventricular assist device (LVAD) or cardiac transplantation.

As noted previously, this same request for the manufacturer of the Impella® Ventricular Support Systems submitted a code proposal to be discussed at the March 7–8, 2023 ICD–10 Coordination and Maintenance Committee meeting to request a change to how the Impella 5.5® with SmartAssist® System is coded within the ICD–10–PCS classification as there are no unique ICD–10–PCS codes to describe the insertion of a short-term external heart assist system using an axillary artery conduit, the procedure will be reported with current coding that is applicable within the classification as displayed in the ICD–10 Coordination and Maintenance Committee meeting materials (available on our CMS website at: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials). We refer the reader to section ILC.13. of the preamble of the proposed rule and this final rule for further information regarding Table 6B.

As discussed in prior rulemaking, interested parties may use current coding information to consider the potential MS–DRG assignments for procedure codes that may be finalized after the March meeting and submit public comments for consideration. Specifically, in the ICD–10 Coordination and Maintenance Committee meeting materials (available on our CMS website at: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials), for each procedure code proposal we provide the current coding that is applicable within the classification and that should be reported in the absence of a more unique code, or until such time a new code is created and becomes effective. The procedure code(s) listed in current coding are generally, but not always, the same code(s) that are considered as the predecessor code(s) for purposes of MS–DRG assignment. As previously noted, our process for determining the MS–DRG assignment for a new procedure code does not automatically result in the new procedure code being assigned to the same MS–DRG or having the same designation (O.R. versus Non-O.R.) as the predecessor code. However, this current coding information can be used in conjunction with the GROUPER logic, as set forth in the ICD–10 MS–DRG Definitions Manual and publicly available on our CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software to review the MS–DRG assignment of the current code(s) and examine the potential MS–DRG assignment of the proposed code(s), to assist in formulating any public comments for submission to CMS for consideration.

In summary, we proposed to reassign ICD–10–PCS code 02HA0RZ (Insertion of short-term external heart assist system into heart, open approach) from MDC 05 in MS–DRG 215 to Pre-MDC MS–DRGs 001 and 002 for FY 2024. Separately, and as previously discussed, a code proposal was discussed at the March 7–8, 2023 ICD–10 Coordination and Maintenance Committee meeting to request a change to how the Impella 5.5® with SmartAssist® System is coded within the ICD–10–PCS classification. In the proposed rule, we noted that if finalized, the new procedure code would be included in the FY 2024 code update files that are made available in late May/early June on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS. In addition, using our established process, if finalized, the MS–DRG assignment for any new procedure codes describing the Impella 5.5® with SmartAssist® System will be displayed in Table 6B.—New Procedure Codes associated with the final rule for FY 2024. In the event there is no support for the new procedure code as presented at the March 7–8, 2023 ICD–10 Coordination and Maintenance Committee meeting to describe the insertion of a short-term external heart assist system using an axillary artery conduit, the procedure will be reported with current coding that is applicable within the classification as displayed in the ICD–10 Coordination and Maintenance Committee meeting materials (available on the CMS website at: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials). We refer the reader to section ILC.13. of the preamble of the proposed rule and this final rule for further information regarding Table 6B.

As discussed in prior rulemaking, interested parties may use current coding information to consider the potential MS–DRG assignments for procedure codes that may be finalized after the March meeting and submit public comments for consideration. Specifically, in the ICD–10 Coordination and Maintenance Committee meeting materials (available on our CMS website at: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials), for each procedure code proposal we provide the current coding that is applicable within the classification and that should be reported in the absence of a more unique code, or until such time a new code is created and becomes effective. The procedure code(s) listed in current coding are generally, but not always, the same code(s) that are considered as the predecessor code(s) for purposes of MS–DRG assignment. As previously noted, our process for determining the MS–DRG assignment for a new procedure code does not automatically result in the new procedure code being assigned to the same MS–DRG or having the same designation (O.R. versus Non-O.R.) as the predecessor code. However, this current coding information can be used in conjunction with the GROUPER logic, as set forth in the ICD–10 MS–DRG Definitions Manual and publicly available on our CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software to review the MS–DRG assignment of the current code(s) and examine the potential MS–DRG assignment of the proposed code(s), to assist in formulating any public comments for submission to CMS for consideration.
short-term heart assist devices and to improve clinical consistency and predictability for providers as short-term heart assist devices have evolved with different access procedures to treat hemodynamically compromised patients. Some commenters also stated that streamlining the GROUPER logic so that ICD–10–PCS code 02HA0RZ will no longer need to be reported as part of a procedure code combination or procedure code “cluster” to satisfy the logic for assignment to MS–DRGs 001 and 002 will ensure that the cases in these MS–DRGs are more clinically homogeneous and better reflect hospital resource use.

Response: We thank the commenters for their support.

After consideration of the public comments we received, we are finalizing our proposal to reassign ICD–10–PCS code 02HA0RZ (Insertion of short-term external heart assist system into heart, open approach) from MDC 05 in MS–DRG 215 to Pre-MDC MS–DRGs 001 and 002 when reported as a standalone procedure, without modification, effective October 1, 2023, for FY 2024. Under this finalization, procedure code 02HA0RZ will no longer need to be reported as part of a procedure code combination or procedure code “cluster” to satisfy the logic for assignment to MS–DRGs 001 and 002.

Comment: Many commenters stated that if new ICD–10–PCS procedure codes describing the Impella 5.5 with SmartAssist® System were made publicly available on the CMS website, we note that the new procedure codes are also reflected in Table 6B.—New Procedure Codes, in association with this final rule and available on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS, including the MS–DRG assignments for these new codes for FY 2024. We refer the reader to section II.C.13. of the preamble of this final rule for further information regarding the table.

Specifically, using our established process, we examined the MS–DRG assignment for the predecessor code to determine the most appropriate MS–DRG assignment. We reviewed the predecessor code and MS–DRG assignment most closely associated with the new procedure codes, and in the absence of claims data, we considered other factors that may be relevant to the MS–DRG assignment, including the severity of illness, treatment difficulty, complexity of service and the resources utilized in the diagnosis and/or treatment of the condition. ICD–10–PCS procedure code 03HY0YZ (Insertion of other device into upper artery, open approach) is the predecessor code that we utilized to inform this analysis.

The MS–DRG assignment for the predecessor code 03HY0YZ and the new procedure codes describing the insertion of a short-term external heart assist system using a conduit attached to the right axillary artery or to the ascending aorta under MDC 05 are identified as follows.

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Description</th>
<th>MS-DRG</th>
</tr>
</thead>
<tbody>
<tr>
<td>X2HL0F9</td>
<td>Insertion of conduit to short-term external heart assist system into right axillary artery, open approach, new technology group 9</td>
<td>252-254 (Other Vascular Procedures with MCC, with CC, without MCC respectively)</td>
</tr>
<tr>
<td>X2HM0F9</td>
<td>Insertion of conduit to short-term external heart assist system into left axillary artery, open approach, new technology group 9</td>
<td></td>
</tr>
<tr>
<td>X2HX0F9</td>
<td>Insertion of conduit to short-term external heart assist system into thoracic aorta, ascending, open approach, new technology group 9</td>
<td></td>
</tr>
</tbody>
</table>

While the new procedure codes are being assigned to the same MS–DRG as the predecessor code in this instance, as we have noted in prior rulemaking, and earlier in this section, this process does not automatically result in the new procedure code being assigned to the same MS–DRG or to have the same designation (O.R. versus Non-O.R.) as the predecessor code.

We also note that the finalized procedure codes describing the Impella 5.5 with SmartAssist® System identify the insertion of short-term external heart assist system using a conduit attached to the right axillary artery or to the ascending aorta. To fully describe the procedure, a separate code will continue to be reported for the insertion of the external heart assist system. In addition to the MDC and MS–DRG assignments as reflected in the previous table and in Table 6B.—New Procedure Codes, in association with this final rule, we note the procedure code combinations reflected in the table that follows are assigned to MS–DRGs 001 and 002, for FY 2024. This assignment is also reflected in the final Version 41 ICD–10 MS–DRG GROUPER logic.
The public may provide feedback on these MS–DRG assignments for FY 2024, which will then be taken into consideration for the following fiscal year.

c. Ultrasound Accelerated Thrombolysis for Deep Venous Thrombosis

As discussed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27000 through 26706), we received a request to reassign cases reporting ultrasound accelerated thrombosis (USAT) of peripheral vascular structures procedures with the administration of thrombolytic(s) for deep venous thrombosis from MS–DRGs 252, 253, and 254 (Other Vascular Procedures with MCC, with CC, and without CC/MCC, respectively) to MS–DRGs 270, 271, and 272 (Other Major Cardiovascular Procedures with MCC, with CC, and without CC/MCC, respectively).

Deep venous thrombosis (DVT) is caused when a blood clot (or thrombus) forms in a vein, primarily in large veins of the lower leg and thigh, but may also occur in the deep veins of the pelvis and less commonly, in the upper extremities. Risk factors for DVT are similar to those of pulmonary embolism as discussed in section II.C.4.a. of the proposed rule and this final rule, and include prolonged immobilization from any cause, obesity, cancer, fractured hip or leg, use of certain medications such as oral contraceptives, and the presence of certain medical conditions such as heart failure. Common symptoms of DVT include leg (or arm) swelling, pain, cramping, or heaviness, skin discoloration, the feeling of warmth in the affected area, or there may not be any noticeable symptoms.

Thrombolysis is a type of treatment where the infusion of thrombolytics (fibrinolytic or "clot-busting" drugs) is used to dissolve blood clots that form in the arteries or veins with the goal of improving blood flow and preventing long-term damage to tissues and organs. Conventional catheter-directed thrombolysis (CDT) procedures generally rely on a multi-sidehole catheter placed adjacent to the thrombus through which thrombolytics are delivered directly to the thrombus, however, the EKOSTM EkoSonic® Endovascular System (EKOSTM System) employs ultrasound to assist in thrombolysis. The ultrasound does not itself dissolve the thrombus, but pulses of ultrasonic energy temporarily make the fibrin in the thrombus more porous and increase fluid flow within the thrombus. High frequency, low-intensity ultrasonic waves create a pressure gradient that drives the thrombolytic into the thrombus and keeps it in close proximity to the binding sites. USAT is also referred to as ultrasound-assisted thrombolysis or ultrasound-enhanced thrombolysis.

We stated in the proposed rule that, according to the requestor (the manufacturer of the EKOSTM device), USAT of peripheral vascular structures with the administration of thrombolytic(s) for the treatment of DVT performed using the EKOSTM device utilizes more resources in comparison to other procedures that are currently assigned to MS–DRGs 252, 253, and 254 and is not clinically coherent with the other procedures assigned to those MS–DRGs. The requestor stated they performed an analysis of cases reporting USAT of peripheral vascular structures...
We noted in the proposed rule that the requestor did not include a list of diagnosis codes describing DVT or a list of procedure codes describing the administration of thrombolytic(s) in connection with its analysis.

In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58561 through 85 FR 58579), we summarized and responded to public comments expressing concern with the proposed MS–DRG assignments for the newly created procedure codes describing USAT of several anatomic sites that were effective with discharges on and after October 1, 2020 (FY 2021). Similar to the current request for FY 2024, for FY 2021, the commenters recommended that USAT procedures performed with the EKOS™ device for the treatment of DVT be assigned to MS–DRGs 270, 271, and 272 instead of MS–DRGs 252, 253, and 254. We refer the reader to the FY 2021 IPPS/LTCH PPS final rule (85 FR

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>04FC3Z0</td>
<td>Fragmentation of right common iliac artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>04FD3Z0</td>
<td>Fragmentation of left common iliac artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>04FE3Z0</td>
<td>Fragmentation of right internal iliac artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>04FF3Z0</td>
<td>Fragmentation of left internal iliac artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>04FH3Z0</td>
<td>Fragmentation of right external iliac artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>04FJ3Z0</td>
<td>Fragmentation of left external iliac artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>04FK3Z0</td>
<td>Fragmentation of right femoral artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>04FL3Z0</td>
<td>Fragmentation of left femoral artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>04FM3Z0</td>
<td>Fragmentation of right popliteal artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>04FN3Z0</td>
<td>Fragmentation of left popliteal artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>04FP3Z0</td>
<td>Fragmentation of right anterior tibial artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>04FQ3Z0</td>
<td>Fragmentation of left anterior tibial artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>04FR3Z0</td>
<td>Fragmentation of right posterior tibial artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>04FS3Z0</td>
<td>Fragmentation of left posterior tibial artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>04FT3Z0</td>
<td>Fragmentation of right peroneal artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>04FU3Z0</td>
<td>Fragmentation of left peroneal artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>04FY3Z0</td>
<td>Fragmentation of lower artery, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>05F33Z0</td>
<td>Fragmentation of right innominate vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>05F43Z0</td>
<td>Fragmentation of left innominate vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>05F53Z0</td>
<td>Fragmentation of right subclavian vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>05F63Z0</td>
<td>Fragmentation of left subclavian vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>05F73Z0</td>
<td>Fragmentation of right axillary vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>05F83Z0</td>
<td>Fragmentation of left axillary vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>05F93Z0</td>
<td>Fragmentation of right brachial vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>05FA3Z0</td>
<td>Fragmentation of left brachial vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>05FB3Z0</td>
<td>Fragmentation of right basilic vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>05FC3Z0</td>
<td>Fragmentation of left basilic vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>05FD3Z0</td>
<td>Fragmentation of right cephalic vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>05FF3Z0</td>
<td>Fragmentation of left cephalic vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>06FC3Z0</td>
<td>Fragmentation of right common iliac vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>06FD3Z0</td>
<td>Fragmentation of left common iliac vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>06FF3Z0</td>
<td>Fragmentation of right external iliac vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>06FG3Z0</td>
<td>Fragmentation of left external iliac vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>06FH3Z0</td>
<td>Fragmentation of right hypogastric vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>06FJ3Z0</td>
<td>Fragmentation of left hypogastric vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>06FM3Z0</td>
<td>Fragmentation of right femoral vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>06FN3Z0</td>
<td>Fragmentation of left femoral vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>06FP3Z0</td>
<td>Fragmentation of right saphenous vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>06FQ3Z0</td>
<td>Fragmentation of left saphenous vein, percutaneous approach, ultrasonic</td>
</tr>
<tr>
<td>06FY3Z0</td>
<td>Fragmentation of lower vein, percutaneous approach, ultrasonic</td>
</tr>
</tbody>
</table>
and 254 and cases reporting a principal diagnosis of DVT and USAT of peripheral vascular structures procedure with and without the administration of thrombolytic(s). We noted that we identified claims reporting an USAT of peripheral vascular structures procedure, the administration of thrombolytic(s), and a diagnosis of DVT with the listed codes as shown in Table 6P.5a associated with the proposed rule (and available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS). The findings from our analysis are shown in the following table.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>252 – All cases</td>
<td>20,939</td>
<td>8</td>
<td>$29,307</td>
</tr>
<tr>
<td>252 – Cases reporting a principal diagnosis of DVT and USAT with thrombolytic(s)</td>
<td>51</td>
<td>6.4</td>
<td>$36,660</td>
</tr>
<tr>
<td>252 – Cases reporting principal diagnosis of DVT and USAT without thrombolytic(s)</td>
<td>10</td>
<td>6.7</td>
<td>$21,538</td>
</tr>
<tr>
<td>253 – All cases</td>
<td>16,650</td>
<td>5.2</td>
<td>$22,685</td>
</tr>
<tr>
<td>253 – Cases reporting a principal diagnosis of DVT and USAT with thrombolytic(s)</td>
<td>80</td>
<td>5.2</td>
<td>$26,471</td>
</tr>
<tr>
<td>253 – Cases reporting principal diagnosis of DVT and USAT without thrombolytic(s)</td>
<td>11</td>
<td>3.8</td>
<td>$20,126</td>
</tr>
<tr>
<td>254 – All cases</td>
<td>6,707</td>
<td>2.4</td>
<td>$15,438</td>
</tr>
<tr>
<td>254 – Cases reporting a principal diagnosis of DVT and USAT with thrombolytic(s)</td>
<td>22</td>
<td>3</td>
<td>$21,867</td>
</tr>
<tr>
<td>254 – Cases reporting principal diagnosis of DVT and USAT without thrombolytic(s)</td>
<td>9</td>
<td>2</td>
<td>$17,750</td>
</tr>
</tbody>
</table>

As shown in the table, we identified a total of 20,939 cases in MS–DRG 252 with an average length of stay of 8 days and average costs of $29,307. Of the 20,939 cases, we found 51 cases reporting a principal diagnosis of DVT and USAT with thrombolytic(s) with an average length of stay of 6.4 days and average costs of $36,660 and 10 cases reporting a principal diagnosis of DVT and USAT without thrombolytic(s) with an average length of stay of 6.7 days and average costs of $21,538. The data demonstrate that the cases reporting a principal diagnosis of DVT and USAT with or without thrombolytic(s) have a shorter average length of stay compared to the average length of stay of all the cases in MS–DRG 252 (6.4 days and 6.7 days, respectively versus 8 days).

However, the average costs for the cases reporting a principal diagnosis of DVT and USAT with thrombolytic(s) are higher than the average costs of all the cases in MS–DRG 252 ($36,660 versus $29,307) and the average costs for the cases reporting a principal diagnosis of DVT and USAT without thrombolytic(s) are lower than the average costs of all the cases in MS–DRG 252 ($21,538 versus $29,307). The data indicate that the cases reporting use of the EKOS™ device technology may have an impact on the consumption of resources when compared to all the cases in MS–DRG 252.

For MS–DRG 253, we identified a total of 16,650 cases with an average length of stay of 5.2 days and average costs of $22,685. Of the 16,650 cases, we found 80 cases reporting a principal diagnosis of DVT and USAT with thrombolytic(s) with an average length of stay of 5.2 days and average costs of $26,471 and 11 cases reporting a principal diagnosis of DVT and USAT without thrombolytic(s) with an average length of stay of 3.8 days and average costs of $20,126. The data demonstrate that the average length of stay for cases reporting a principal diagnosis of DVT and USAT with thrombolytic(s) is the same as the average length of stay for all the cases in MS–DRG 253 (5.2 days). Conversely, the average length of stay for the cases reporting a principal diagnosis of DVT and USAT without thrombolytic(s) is shorter than the average length of stay of all the cases in MS–DRG 253 (3.8 days versus 5.2 days).

Similar to MS–DRG 252, the average costs for the cases reporting a principal diagnosis of DVT and USAT with thrombolytic(s) are higher than the average costs of all the cases in MS–DRG 253 ($26,471 versus $22,685) and the average costs for the cases reporting a principal diagnosis of DVT and USAT without thrombolytic(s) are lower than the average costs of all the cases in MS–DRG 253 ($20,126 versus $22,685). The data indicate that the cases reporting a principal diagnosis of DVT and USAT with thrombolytic(s) appear to consume more resources in comparison to the other cases in MS–DRG 253, although it is unclear if the higher resource consumption is a direct result of the EKOS™ device technology utilized in the performance of the thrombolysis procedure, or the fact that these cases also include the reporting of at least one or more secondary MCC diagnoses, or a combination of both factors. Conversely, the data indicate that the cases reporting a principal diagnosis of DVT and USAT without thrombolytic(s) appear to be less resource intensive with a difference in average costs of $7,769 ($29,307 – $21,538 = $7,769). Accordingly, the data appear to reflect that the cases reporting use of the EKOS™ device technology with thrombolytic(s) may have an impact on the consumption of resources when compared to all the cases in MS–DRG 252.

For MS–DRG 254, we identified a total of 6,707 cases with an average length of stay of 2.4 days and average costs of $15,438. Of the 6,707 cases, we found 22 cases reporting a principal diagnosis of DVT and USAT with thrombolytic(s) with an average length of stay of 3 days and average costs of $21,867 and 9 cases reporting a principal diagnosis of DVT and USAT without thrombolytic(s) with an average length of stay of 2 days and average costs of $17,750. The data demonstrate that the cases reporting a principal diagnosis of DVT and USAT with thrombolytic(s) have a longer average length of stay compared to the average...
length of stay of all the cases in MS–DRG 254 (3 days versus 2.4 days), however, the cases reporting a principal diagnosis of DVT and USAT without thrombolytic(s) have a shorter but comparable average length of stay compared to the average length of stay of all the cases in MS–DRG 254 (2 days versus 2.4 days). Additionally, the average costs for the cases reporting a principal diagnosis of DVT and USAT with or without thrombolytic(s) are higher than the average costs of all the cases in MS–DRG 254 ($21,867 and $17,750 respectively versus $15,438) with a corresponding difference in average costs of $6,429 and $2,312 respectively. Similar to our findings for MS–DRGs 252 and 253, the data for MS–DRG 254 indicate the cases reporting a principal diagnosis of DVT and USAT with thrombolytic(s) appear to consume more resources in comparison to the other cases in their respective MS–DRG. In addition, as noted, for MS–DRG 254, the average costs of cases reporting a principal diagnosis of DVT and USAT without thrombolytic(s) are also higher than the average costs of all the cases in MS–DRG 254. However, it is unclear if the higher resource consumption is a direct result of the EKOS™ device technology utilized in the performance of the thrombolysis procedure alone, or if there are other contributing factors, since cases grouping to MS–DRG 254 do not include the reporting of at least one or more secondary CC or MCC diagnoses.

We stated in the proposed rule that our review of the data for MS–DRGs 252, 253, and 254 and our initial analysis for cases reporting a principal diagnosis of DVT and USAT procedure with and without the administration of thrombolytic(s) suggests that the administration of thrombolytic(s) may be considered a factor in the consumption of resources for these cases in MS–DRGs 252, 253, and 254 where USAT is performed in the treatment of a DVT. For example, in MS–DRG 252, there are 51 cases reporting a principal diagnosis of DVT and USAT procedure with the administration of thrombolytic(s) and 10 cases reporting a principal diagnosis of DVT and USAT procedure without the administration of thrombolytic(s), with both subsets of cases showing a comparable average length of stay (5.2 days and 3.8 days, respectively) and a difference in average costs of $6,345 ($26,471 – $20,126 = $6,345). For MS–DRG 254, there are 22 cases reporting a principal diagnosis of DVT and USAT procedure with the administration of thrombolytic(s) and 9 cases reporting a principal diagnosis of DVT and USAT procedure without the administration of thrombolytic(s), however, both subsets of cases have a similar average length of stay (3 days and 2 days, respectively) with a difference in average costs of $4,117 ($21,867 – $17,750 = $4,117).

In the proposed rule, we noted that since the request we received was to reassess cases reporting ultrasound accelerated thrombolysis (USAT) with the administration of thrombolytic(s) for the treatment of deep venous thrombosis (DVT) from MS–DRGs 252, 253, and 254 to MS–DRGs 270, 271, and 272, based on our approach utilized in our initial analysis of claims reporting USAT with a principal diagnosis of DVT in MS–DRGs 252, 253, and 254, we then analyzed claims data from the September 2022 update of the FY 2022 MedPAR file for all cases in MS–DRGs 270, 271, and 272 and compared it to the cases reporting a principal diagnosis of DVT and USAT procedure with or without thrombolytic(s) in MS–DRGs 252, 253, and 254. The findings from our analysis are shown in the following tables.

<table>
<thead>
<tr>
<th>MS–DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>270 – All cases</td>
<td>15,879</td>
<td>9.5</td>
<td>$42,517</td>
</tr>
<tr>
<td>271 – All cases</td>
<td>11,449</td>
<td>5.4</td>
<td>$30,030</td>
</tr>
<tr>
<td>272 – All cases</td>
<td>3,832</td>
<td>2.4</td>
<td>$21,556</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MS–DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>252 – All cases</td>
<td>20,939</td>
<td>8</td>
<td>$29,307</td>
</tr>
<tr>
<td>252 – Cases with principal diagnosis of DVT and USAT with or without thrombolytic(s)</td>
<td>61</td>
<td>6.4</td>
<td>$34,181</td>
</tr>
<tr>
<td>253 – All cases</td>
<td>16,650</td>
<td>5.2</td>
<td>$22,685</td>
</tr>
<tr>
<td>253 – Cases with principal diagnosis of DVT and USAT with or without thrombolytic(s)</td>
<td>91</td>
<td>5</td>
<td>$25,704</td>
</tr>
<tr>
<td>254 – All cases</td>
<td>6,707</td>
<td>2.4</td>
<td>$15,438</td>
</tr>
<tr>
<td>254 – Cases with principal diagnosis of DVT and USAT with or without thrombolytic(s)</td>
<td>31</td>
<td>2.7</td>
<td>$20,672</td>
</tr>
</tbody>
</table>

The claims data show that the 61 cases reporting a principal diagnosis of DVT and USAT with or without thrombolytic(s) in MS–DRG 252 have average costs that are lower than the average costs of all cases in MS–DRG 270 ($34,181 versus $42,517) and have a shorter average length of stay compared to all the cases in MS–DRG 270 (6.4 days versus 9.5 days). The 91 cases reporting a principal diagnosis of DVT and USAT with or without thrombolytic(s) in MS–DRG 253 have a comparable average length of stay (5 days versus 5.4 days) in comparison to all the cases in MS–DRG 271 and lower average costs in comparison to all the cases in MS–DRG 271 ($25,704 versus $30,030) with a difference of $4,326. Finally, the 31 cases reporting a principal diagnosis of DVT and USAT with or without thrombolytic(s) in MS–DRG 254 have an average length of stay that is comparable to all the cases in the
MS–DRG 272 (2.7 days versus 2.4 days) and comparable average costs ($20,672 versus $21,556) with a difference of $884.

We stated in the proposed rule that upon analysis of the claims data and our review of the request, we do not agree with reassigning cases reporting an USAT procedure with the administration of thrombolytic(s) and a principal diagnosis of DVT from MS–DRGs 252, 253, and 254 to MS–DRGs 270, 271, and 272. As stated in the proposed rule, the data do not support that cases reporting USAT (with or without thrombolytic(s)) for DVT utilize similar resources when compared to other procedures currently assigned to MS–DRGs 270, 271, and 272. We do not agree that cases reporting USAT (with or without thrombolytic(s)) are more comparable with and more clinically aligned with the procedures assigned to MS–DRGs 270, 271, and 272 because the majority of procedures in these MS–DRGs describe procedures performed on the heart and great vessels with either an open or an endoscopic approach in contrast to the USAT endovascular (percutaneous) procedure performed on the peripheral vascular structures. In addition, the majority of procedures in MS–DRGs 270, 271, and 272 are performed on patients who are not clinically similar to patients who undergo USAT for DVT since they describe procedures such as bypass, occlusion, and restriction that are typically performed for patients with conditions other than a DVT, such as atherosclerosis, aneurysm, and acute myocardial infarction (AMI). Lastly, a number of procedures in these MS–DRGs also involve the use of a permanently implanted device while the procedures utilizing USAT do not. Therefore, we do not consider USAT to be major cardiovascular procedures, nor do we believe the cases reporting USAT with (or without thrombolytic(s)) for DVT demonstrate a similar level of technical complexity when compared to other procedures currently assigned to MS–DRGs 270, 271, and 272.

As noted in the proposed rule, while the average costs are higher for cases reporting the administration of a thrombolytic, we questioned whether the higher average costs may also reflect other factors, such as the use of the EKOSTM device or the performance of other O.R. procedures that also group to MS–DRGs 252, 253, and 254. Consistent with the analysis discussed in section II.C.4.a. of the proposed rule and this final rule for a similar, but separate request related to thrombolysis procedures, we believed it would also be beneficial to examine cases reporting standard CDT procedures with or without thrombolytic(s) for the treatment of DVT in MS–DRGs 252, 253, and 254, and compare the findings to the cases reporting USAT with or without thrombolytic(s) for the treatment of DVT.

Therefore, as discussed in the proposed rule, we conducted additional analyses to determine if there were significant differences in resource utilization for cases reporting standard CDT with or without thrombolytic(s) versus USAT procedures with or without thrombolytic(s) in the treatment of DVT, since claims data to compare the two modalities is now available and studies have reported similar clinical outcomes in reducing DVT regardless of which thrombolytic modality is utilized.5

We analyzed claims data from the September 2022 update of the FY 2022 MedPAR file for all cases in MS–DRGs 252, 253, and 254 and cases reporting a standard CDT procedure with or without the administration of thrombolytic(s) and a principal diagnosis of DVT. We utilized the previously listed procedure codes for the administration of thrombolytic(s) and the previously listed diagnosis codes for a principal diagnosis of DVT. We identified cases describing standard CDT procedures performed in the treatment of DVT with the procedure codes listed in Table 6P.5a, associated with the proposed rule and available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS. The findings from our analysis are shown in the following table. We note there were no cases found to report a standard CDT procedure with or without thrombolytic(s) and a principal diagnosis of DVT in MS–DRGs 253 or 254.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>252 – All cases</td>
<td>20,939</td>
<td>8</td>
<td>$29,307</td>
</tr>
<tr>
<td>252 – Cases with principal diagnosis of DVT and CDT with or without thrombolytic(s)</td>
<td>3</td>
<td>2.3</td>
<td>$10,603</td>
</tr>
<tr>
<td>253 – All cases</td>
<td>16,650</td>
<td>5.2</td>
<td>$22,685</td>
</tr>
<tr>
<td>254 – All cases</td>
<td>6,707</td>
<td>2.4</td>
<td>$15,438</td>
</tr>
</tbody>
</table>

The data shows that the 3 cases reporting a principal diagnosis of DVT and standard CDT with or without thrombolytic(s) in MS–DRG 252 have a shorter average length of stay compared to all cases in MS–DRG 252 (2.3 days versus 8 days) and lower average costs ($10,603 versus $29,307).

We noted in the proposed rule that, overall, our analysis of the claims data for cases reporting a principal diagnosis of DVT and USAT or standard CDT, with or without thrombolytic(s), demonstrate a low volume of cases, however, the average costs of the cases reporting USAT with thrombolytic(s) reflect a significantly higher consumption of resources than all cases in MS–DRGs 252, 253, and 254. We further noted that because it is also possible that a patient may be admitted to a hospital and receive thrombolysis (USAT or CDT) with a principal diagnosis other than a DVT or the DVT condition may be reported as a secondary diagnosis, we believed additional analysis for cases reporting either USAT or CDT, regardless of the principal diagnosis, would provide us with more beneficial information in our review of these cases.

Therefore, using the September 2022 update of the FY 2022 MedPAR file, we conducted an analysis of MS–DRGs 252, 253, and 254 for cases reporting either USAT or CDT with and without thrombolytic(s) with any principal diagnosis of DVT.

The findings from our analysis show a larger volume of cases for each respective MS–DRG (252, 253, and 254) for cases reporting USAT or CDT procedures with any MDC 05 principal diagnosis versus the findings from our earlier analysis involving cases specifically reporting a principal diagnosis of DVT. The claims data also show that the 468 cases reporting any principal diagnosis from MDC 05 and USAT or CDT with or without thrombolytic(s) in MS–DRG 252 have higher average costs than the average costs of all cases in MS–DRG 252 ($39,181 versus $29,307) and have a comparable average length of stay (8.6 days versus 8.0 days). The 722 cases reporting any principal diagnosis from MDC 05 and USAT or CDT with or without thrombolytic(s) in MS–DRG 253 have a shorter average length of stay (4.9 days versus 5.2 days) in comparison to all the cases in MS–DRG 253 and higher average costs ($29,663 versus $22,685) with a difference of $6,978. Finally, the 195 cases reporting any principal diagnosis from MDC 05 and USAT or CDT with or without thrombolytic(s) in MS–DRG 254 have an average length of stay that is comparable to all the cases in MS–DRG 272 (2.6 days versus 2.4 days) and higher average costs ($22,487 versus $15,438) with a difference of $7,049.

As discussed in the proposed rule, based on our review and the claims data analysis for cases in MS–DRGs 252, 253, and 254 and MS–DRGs 270, 271, and 272, and for cases reporting standard CDT or USAT with or without thrombolytic(s) regardless of the principal diagnosis reported from MDC 05, we believe that while the subset of cases for patients undergoing a thrombolysis (CDT or USAT) procedure for DVT does not clinically align with patients undergoing surgery for acute myocardial infarction (AMI) and does not involve the same level of complexity as cases grouping to MS–DRGs 270, 271, and 272, the differences in resource consumption warrant realignment of these cases. Specifically, we believe the clinical and data analyses support creating a new base MS–DRG to distinguish cases reporting USAT or standard CDT procedure of peripheral vascular structures with or without thrombolytic(s) from other cases currently grouping to MS–DRGs 252, 253, and 254. We stated we believe a new MS–DRG would reflect more appropriate payment for USAT and standard CDT procedures of peripheral vascular structures.

In the proposed rule, we also noted that to compare and analyze the impact of our suggested modifications, we ran a simulation using the most recent claims data from the December 2022 update of the FY 2022 MedPAR file. The following table illustrates our findings for all 1,487 cases reporting procedure codes describing an USAT or CDT procedure with any principal diagnosis from MDC 05.

<table>
<thead>
<tr>
<th>Proposed new MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proposed new MS-DRG XXX</td>
<td>1,487</td>
<td>5.8</td>
<td>$31,794</td>
</tr>
</tbody>
</table>

Consistent with our established process as discussed in section II.C.1.b. of the preamble of the proposed rule and this final rule, once the decision has been made to propose to make further modifications to the MS–DRGs, such as creating a new base MS–DRG, all five criteria to create subgroups must be met for the base MS–DRG to be split (or subdivided) by a CC subgroup. Therefore, we applied the criteria to create subgroups in a base MS–DRG. We noted in the proposed rule that, as shown in the table that follows, a three-way split of this base MS–DRG failed to meet the criterion that there be at least 500 cases in the NonCC (without CC/MCC) subgroup.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>With MCC</td>
<td>516</td>
<td>8.5</td>
<td>$38,904</td>
</tr>
<tr>
<td>With CC</td>
<td>768</td>
<td>4.8</td>
<td>$29,555</td>
</tr>
<tr>
<td>Without CC/MCC</td>
<td>203</td>
<td>2.5</td>
<td>$22,188</td>
</tr>
</tbody>
</table>

As discussed in section II.C.1.b. of the preamble of the proposed rule and this final rule, if the criteria for a three-way split fail, the next step is to determine if the criteria are satisfied for a two-way split. We applied the criteria for a two-way split for the “with MCC and without MCC” subgroups. We noted that, as shown in the table that follows, a two-way split of this base MS–DRG met all five criteria. For the proposed MS–DRGs, there is at least (1) 500 or more cases in the MCC group and in the without MCC subgroup; (2) 5 percent or more of the cases in the MCC group and...
in the without MCC subgroup; (3) a 20 percent difference in average costs between the MCC group and the without MCC group; (4) a $2,000 difference in average costs between the MCC group and the without MCC group; and (5) a 3-percent reduction in cost variance, indicating that the proposed severity level splits increase the explanatory power of the base MS–DRG in capturing differences in expected cost between the proposed MS–DRG severity level splits by at least 3 percent and thus improve the overall accuracy of the IPPS payment system. The following table illustrates our findings for the suggested MS–DRGs with a two-way severity level split.

<table>
<thead>
<tr>
<th>MS–DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>With MCC</td>
<td>516</td>
<td>8.5</td>
<td>$38,904</td>
</tr>
<tr>
<td>Without MCC</td>
<td>971</td>
<td>4.3</td>
<td>$28,015</td>
</tr>
</tbody>
</table>

Accordingly, because the criteria for the two-way split were met, we stated we believed a split (or CC subgroup) is warranted for the proposed new base MS–DRG. As a result, for FY 2024, we proposed to create new MS–DRG 278 (Ultrasound Accelerated and Other Thrombolysis of Peripheral Vascular Structures with MCC) and new MS–DRG 279 (Ultrasound Accelerated and Other Thrombolysis of Peripheral Vascular Structures without MCC).

We proposed to define the logic for the proposed new MS–DRGs using the previously listed procedure codes for USAT and CDT, as identified and discussed in our analysis of the claims data in Table 6P.5a associated with the proposed rule.

Comment: Commenters supported the proposal to create new MS–DRGs 278 and 279 (Ultrasound Accelerated and Other Thrombolysis of Peripheral Vascular Structures with and without MCC, respectively) given the data and information provided. A commenter stated the new MS–DRGs will generate more appropriate payment for cases reporting these procedures.

Response: We thank the commenters for their support.

Comment: A couple commenters suggested that the proposal to create the two new MS–DRGs should be delayed until more data can be collected. The commenters stated their belief that it is premature to create these new MS–DRGs at this time and that in developing these proposed MS–DRGs, CMS relied on recently implemented ICD-10-PCS data. According to the commenters, due to the lengthy processes for hospitals to adopt and accurately implement new coding, and conflicting coding advice for utilization of the ICD-10–PCS procedure codes for CDT and USAT, the number of cases is currently insufficient to support development of new MS–DRGs. The commenter stated that the low volume of cases and related data selected by CMS for analysis, CDT for the treatment of DVT, cannot adequately compare to the costs, complexity, and utilization of USAT with a high confidence interval.

Response: We appreciate the commenters’ feedback. We disagree with the commenters that it is premature to propose the creation of new MS–DRGs 278 and 279 based on our review and claims data analysis as discussed in the proposed rule. In response to the commenters’ statement that CMS relied on recently implemented ICD–10–PCS data, it is not clear to us what specific ICD–10–PCS data the commenters are referring to since a specific list was not provided, however, we believe the commenters may be suggesting the codes for USAT that were finalized October 1, 2020 (FY 2021), and listed previously in connection with the analysis discussed in the proposed rule. As discussed in the proposed rule and prior rulemaking, our goal is always to use the best available data. We noted in the proposed rule that our initial MS–DRG analysis was based on ICD–10 claims data from the September 2022 update of the FY 2022 MedPAR file, which contains hospital bills received from October 1, 2021, through September 30, 2022, and where otherwise indicated, additional analysis was based on ICD–10 claims data from the December 2022 update of the FY 2022 MedPAR file, which contains hospital bills received by CMS through December 31, 2022, for discharges occurring from October 1, 2021, through September 30, 2022. Therefore, we believe our analysis of claims data in consideration of the MS–DRG request to reassign cases reporting USAT of peripheral vascular structures procedures with the administration of thrombolytic[s] for DVT is consistent with our standard process, regardless of the effective date of the coded claims data. We also do not agree with the commenters’ assertion that it is a lengthy process for hospitals to adopt and accurately implement new coding. We note that procedure code proposals discussed at the September ICD–10 Coordination and Maintenance Committee meeting and subsequently finalized are typically included in Table 6B.—New Procedure Codes in association with the proposed rule that is made publicly available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcutelnpatientPPS. This table (Table 6B) lists the new procedure codes that have been approved to date that will be effective with discharges on and after October 1 of the upcoming fiscal year. Therefore, information regarding the finalized codes from the September meeting is made publicly available approximately 4–5 months in advance of the implementation date, allowing the ability for users of the code set to gain familiarity with the updates. In addition, there are extensive industry-sponsored educational opportunities through various professional associations that introduce and discuss the annual code updates. For example, the American Hospital Association (AHA), American Health Information Management Association (AHIMA), and the American Academy of Professional Coders (AAPC) generally take lead roles in developing detailed technical training materials for coders and other users of the ICD–10 code set. The AHA also includes updates to ICD–10 in its Coding Clinic® for ICD–10–CM/ICD–10–PCS publication. Because the codes describing USAT were finalized for implementation October 1, 2020 (FY 2021), we believe sufficient time has elapsed and that providers are successfully coding and reporting the procedure as demonstrated in our claims analysis.

It is also not clear what conflicting coding advice for utilization of the ICD–10–PCS procedure codes for CDT and USAT the commenters are referring to since the commenters did not provide examples or supplemental information for what they believed to be conflicting advice to enable further evaluation.

Comment: A couple commenters expressed concern that the inclusion of both conventional CDT, also known as
“standard infusion catheters,” and USAT in the proposed new MS–DRGs disdards fundamental clinical differences between the procedures. According to the commenters, CDT generally relies on a multi-sidehole infusion catheter placed adjacent to the thrombus through which thrombolytics are delivered, typically over the course of 24 hours with the catheter indwelling, whereas USAT employs ultrasound to assist in thrombolysis, and the pulses of ultrasonic energy temporarily make the fibrin in the thrombus more porous and increase fluid flow within the thrombus. The commenters stated standard CDT is the simple infusion of liquids into the vessel and should not map to the same root operation fragmentation codes as does USAT. The commenters also stated CDT procedures are generally less complex clinically and consume significantly lower level of hospital resources, we note that any procedure that places a catheter inside a blood vessel carries certain risks, including damage to the blood vessel, bruising or bleeding at the puncture site, and infection. In response to the commenters’ recommendation that CMS should delay finalization for the proposed MS–DRGs and reconsider in the future when utilization volumes reach a threshold of significance, as discussed in the proposed rule, once the decision was made to propose a new base MS–DRG, we applied the criteria to create subgroups and the criteria for a two-way split was met, therefore, we believe sufficient volume does exist for the proposed new MS–DRGs.

Finally, in response to the cost data that was submitted by a commenter, we note that it was the same data analysis as reflected and discussed in the proposed rule, therefore we refer readers to that prior discussion.

Comment: A commenter stated they agreed that fragmentation procedures with or without USAT do not belong in the requested MS–DRGs 270, 271, and 272, and suggested they remain in their current MS–DRGs 252, 253, and 254 based on clinical coherence and resource utilization.

Response: We appreciate the commenter’s feedback and agree that fragmentation procedures with or without USAT do not belong in the requested MS–DRGs 270, 271, and 272. However, for reasons discussed in the proposed rule, we believe our review of these procedures and data analysis findings support the proposal to create new MS–DRGs 278 and 279 for grouping cases reporting the performance of USAT or CDT with any principal diagnosis from MDC 05.

Comment: A couple commenters disagreed with the proposal to create new MS–DRGs 278 and 279. A commenter stated USAT procedures have been receiving appropriate payment since FY 2021 and the proposed new MS–DRGs would create unnecessary administrative burden for established procedure codes that already have appropriate payment. Another commenter stated that fragmentation procedures, with or without ultrasonic assistance to break up blood clots in the peripheral vasculature, should stay assigned to the current MS–DRGs 252, 253, and 254, respectively. The commenter stated that the costs and resources for these procedures are consistent with current payment levels when compared to the rest of the procedures assigned to the current MS–DRGs and CDT procedure is not needed or necessary, and that over time may result in overall reduced payment, given that such a low number of procedures would be assigned to their own MS–DRGs.

Response: We appreciate the commenters’ feedback, however, based on our review of the procedures and claims data analysis as discussed in the proposed rule, we believe that USAT and CDT procedures performed on peripheral vascular structures are clinically distinct and utilize a different pattern of resources than other procedures in MS–DRGs 252, 253, and 254. We stated in the proposed rule that while we did not agree with the request to reassign cases reporting USAT or CDT for peripheral vascular structures from MS–DRGs 252, 253, and 254 to MS–DRGs 270, 271, and 272, we believed the findings from our analysis warranted proposed reassignment of these cases. While we described the findings from our review of the procedures currently assigned to MS–DRGs 270, 271, and 272 to specifically address the MS–DRG request (88 FR 26704), we note that in our review of cases assigned to MS–DRGs 252, 253, and 254 we identified the majority of procedures reported are for procedures that involve a bypass or dilation procedure that alters the diameter or route of a tubular body part with either an open or percutaneous endoscopic approach in contrast to the USAT endovascular (percutaneous) procedure performed on the peripheral vascular structures. In addition, a number of procedures in these MS–DRGs also involve the use of a permanently implanted device while the procedures utilizing USAT or CDT do not. We also do not agree that the proposed new MS–DRGs would create an unnecessary administrative burden for the established procedure codes since providers are accustomed to proposed and finalized changes to the MS–DRG classifications each fiscal year and software vendors incorporate the finalized changes into their products. With respect to the commenter’s assertion that a low volume of procedures would be assigned to their own MS–DRGs based on the proposal, as previously discussed, once the decision was made to propose a new base MS–DRG, we applied the criteria to create subgroups and the criteria for a two-way split was met, therefore, we believe sufficient volume does exist for the proposed new MS–DRGs.

After consideration of the public comments we received, we are finalizing our proposal to create new MS–DRG 278 (Ultrasound Accelerated Thrombectomy of Peripheral Vascular Structures with MCC) and new MS–DRG 279 (Ultrasound Accelerated
and Other Thrombolysis of Peripheral Vascular Structures without MCC), without modification, for FY 2024. We are also finalizing our proposal to define the logic for the new MS–DRGs using the previously listed procedure codes for USAT and CDT, as identified in our analysis of the claims data in Table 6P.5a associated with the proposed rule. We will continue to monitor the claims data for these new MS–DRGs after implementation to determine if additional refinements are warranted.

d. Coronary Intravascular Lithotripsy

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26706 through 26712), we discussed a request we received to review the MS–DRG assignment of cases describing percutaneous coronary intravascular lithotripsy (IVL) involving the insertion of a coronary drug-eluting stent. Coronary IVL is utilized in a subset of percutaneous coronary interventions (PCI) procedures when the artery is severely calcified. The presence of calcium can create various challenges in PCI procedures as it can prevent the optimal deployment of coronary stents and can negatively impact patient outcomes. To fully optimize the PCI for severely calcified arteries, advanced techniques, such as coronary IVL, that utilize specialty devices are often required. In coronary IVL, a lithotripsy device catheter is delivered from a small incision in the patient’s arm or leg through to the coronary arterial system of the heart to reach the site of a severely calcified lesion. The lithotripsy emitters at the end of the catheter create acoustic pressure waves that are intended to break up the calcification that is restricting the blood flow in the vessels of the heart to help open the blood vessels when an angioplasty balloon is inflated. After the lithotripsy is performed, the provider can implant an intraluminal device, also called a stent, to keep the vessel open.

According to the requestor, PCIs involving coronary IVL are clinically more complex because coronary IVL is a therapy deployed exclusively in severely calcified coronary lesions, and these lesion types are associated with longer procedure times and increased utilization of hospital resources. The requestor performed its own analysis of claims data for cases reporting procedure codes describing coronary IVL in MS–DRGs 246 and 247. We stated in the proposed rule that coronary IVL is a vessel preparation technique and that there may be instances where an intraluminal device is unable to be inserted after the application of the IVL pulses. Therefore, in our analysis of cases reporting procedure codes describing percutaneous coronary IVL involving the insertion of a drug-eluting intraluminal device to the higher severity level MS–DRG 247 to the higher severity level MS–DRG 249 would be reasonable. The requestor also asked that CMS analyze the cases reporting procedure codes describing percutaneous coronary IVL involving the insertion of a therapy deployed exclusively in severely calcified coronary lesions, and these lesion types are associated with longer procedure times and increased utilization of hospital resources. The requestor performed its own analysis of claims data for cases reporting procedure codes describing coronary IVL in MS–DRGs 246 and 247.

The four ICD–10–PCS procedure codes that describe percutaneous coronary IVL are shown in the following table.

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02F03ZZ</td>
<td>Fragmentation in coronary artery, one artery, percutaneous approach</td>
</tr>
<tr>
<td>02F13ZZ</td>
<td>Fragmentation in coronary artery, two arteries, percutaneous approach</td>
</tr>
<tr>
<td>02F23ZZ</td>
<td>Fragmentation in coronary artery, three arteries, percutaneous approach</td>
</tr>
<tr>
<td>02F33ZZ</td>
<td>Fragmentation in coronary artery, four or more arteries, percutaneous approach</td>
</tr>
</tbody>
</table>

We stated in the proposed rule that the requestor is correct that cases reporting procedure codes that describe percutaneous coronary IVL involving the insertion of a drug-eluting intraluminal device group to MS–DRGs 246 and 247. We also stated the requestor is correct that cases reporting procedure codes that describe percutaneous coronary IVL involving the insertion of a non-drug-eluting intraluminal device group to MS–DRGs 246 and 249. We referred the reader to the ICD–10 MS–DRG Definitions Manual Version 40.1, which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/InpatientPPS/MS-DRG-Classifications-and-Software for complete documentation of the GROUPER logic for MS–DRGs 246, 247, 248, and 249.

In analyzing this request, we noted in the proposed rule that coronary IVL is a vessel preparation technique and that there may be instances where an intraluminal device is unable to be inserted after the application of the IVL pulses. Therefore, in our analysis of cases reporting procedure codes describing percutaneous coronary IVL involving the insertion of a therapy deployed exclusively in severely calcified coronary lesions, and these lesion types are associated with longer procedure times and increased utilization of hospital resources. The requestor performed its own analysis of claims data for cases reporting procedure codes describing coronary IVL in MS–DRGs 246 and 247.

The four ICD–10–PCS procedure codes that describe percutaneous coronary IVL are shown in the following table.
update of the FY 2022 MedPAR file for cases reporting percutaneous coronary IVL and compared the results to all cases in their respective MS–DRG.

The following table shows our findings:

<table>
<thead>
<tr>
<th>MS–DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>246</td>
<td>All cases</td>
<td>40,647</td>
<td>5.2</td>
</tr>
<tr>
<td></td>
<td>Cases reporting coronary IVL</td>
<td>2,359</td>
<td>5.7</td>
</tr>
<tr>
<td></td>
<td>All other cases</td>
<td>38,288</td>
<td>5.2</td>
</tr>
<tr>
<td>247</td>
<td>All cases</td>
<td>54,671</td>
<td>2.4</td>
</tr>
<tr>
<td></td>
<td>Cases reporting coronary IVL</td>
<td>1,505</td>
<td>2.7</td>
</tr>
<tr>
<td></td>
<td>All other cases</td>
<td>53,166</td>
<td>2.4</td>
</tr>
<tr>
<td>248</td>
<td>All cases</td>
<td>555</td>
<td>5.9</td>
</tr>
<tr>
<td></td>
<td>Cases reporting coronary IVL</td>
<td>13</td>
<td>7.2</td>
</tr>
<tr>
<td></td>
<td>All other cases</td>
<td>542</td>
<td>5.9</td>
</tr>
<tr>
<td>249</td>
<td>All cases</td>
<td>604</td>
<td>2.5</td>
</tr>
<tr>
<td></td>
<td>Cases reporting coronary IVL</td>
<td>11</td>
<td>2.8</td>
</tr>
<tr>
<td></td>
<td>All other cases</td>
<td>593</td>
<td>2.5</td>
</tr>
<tr>
<td>250</td>
<td>All cases</td>
<td>3,483</td>
<td>4.8</td>
</tr>
<tr>
<td></td>
<td>Cases reporting coronary IVL</td>
<td>201</td>
<td>4.4</td>
</tr>
<tr>
<td></td>
<td>All other cases</td>
<td>3,282</td>
<td>4.8</td>
</tr>
<tr>
<td>251</td>
<td>All cases</td>
<td>3,199</td>
<td>2.5</td>
</tr>
<tr>
<td></td>
<td>Cases reporting coronary IVL</td>
<td>185</td>
<td>2.4</td>
</tr>
<tr>
<td></td>
<td>All other cases</td>
<td>3,014</td>
<td>2.5</td>
</tr>
</tbody>
</table>

As shown by the table, in MS–DRG 246, we identified a total of 40,647 cases, with an average length of stay of 5.2 days and average costs of $25,630. Of those 40,647 cases, there were 2,359 cases reporting percutaneous coronary IVL, with higher average costs as compared to all cases in MS–DRG 246 ($35,503 compared to $25,630), and a longer average length of stay (5.7 days compared to 5.2 days). In MS–DRG 247, we identified a total of 54,671 cases with an average length of stay of 2.4 days and average costs of $16,241. Of those 54,671 cases, there were 1,505 cases reporting percutaneous coronary IVL, with higher average costs as compared to all cases in MS–DRG 247 ($34,492 compared to $16,241), and a longer average length of stay (2.7 days compared to 2.4 days). In MS–DRG 248, we identified a total of 555 cases with an average length of stay of 5.9 days and average costs of $25,740. Of those 555 cases, there were 13 cases reporting percutaneous coronary IVL, with higher average costs as compared to all cases in MS–DRG 248 ($34,492 compared to $25,740), and a longer average length of stay (7.2 days compared to 5.9 days). In MS–DRG 249, we identified a total of 604 cases with an average length of stay of 2.5 days and average costs of $14,909. Of those 604 cases, there were 11 cases reporting percutaneous coronary IVL, with higher average costs as compared to all cases in MS–DRG 249 ($18,648 compared to $14,909), and a longer average length of stay (4.8 days compared to 2.5 days). In MS–DRG 250, we identified a total of 3,483 cases with an average length of stay of 4.4 days and average costs of $20,634. Of those 3,483 cases, there were 201 cases reporting percutaneous coronary IVL, with higher average costs as compared to all cases in MS–DRG 250 ($25,628 compared to $20,634), and a shorter average length of stay (4.4 days compared to 4.8 days). In MS–DRG 251, we identified a total of 3,199 cases with an average length of stay of 2.5 days and average costs of $14,273. Of those 3,199 cases, there were 185 cases reporting percutaneous coronary IVL, with higher average costs as compared to all cases in MS–DRG 251 ($20,289 compared to $14,273), and a shorter average length of stay (2.4 days compared to 2.5 days). We stated in the proposed rule that the data analysis shows that the average costs of cases reporting percutaneous coronary IVL, with or without involving the insertion of intraluminal device, are higher than for all cases in their respective MS–DRG.

We also stated that the data analysis also shows that when the insertion of an intraluminal device was reported with percutaneous coronary IVL, average costs are generally similar without regard as to whether a drug-eluting or a non-drug-eluting intraluminal device was placed. In MS–DRG 246, there were 2,359 cases reporting percutaneous coronary IVL involving the insertion of a drug-eluting intraluminal device with average costs of $35,503 compared to 12 cases reporting percutaneous coronary IVL involving the insertion of a non-drug-eluting intraluminal device with average costs of $18,648 in MS–DRG 248. In MS–DRG 247, there were 1,505 cases reporting percutaneous coronary IVL involving the insertion of a drug-eluting intraluminal device with average costs of $34,492 in MS–DRG 249.

In the proposed rule, we stated we reviewed this data analysis and agreed
that the performance of percutaneous coronary IVL contributes to increased resource consumption for these PCI procedures. We also stated that we agreed that clinically, the presence of severe calcification can increase the treatment difficulty and complexity of service. The data analysis clearly shows that cases reporting percutaneous coronary IVL, with or without involving the insertion of an intraluminal device, have higher average costs and generally longer lengths of stay compared to all the cases in their assigned MS–DRG. For these reasons, we proposed to create new MS–DRGs for percutaneous coronary IVL involving the insertion of an intraluminal device. While there is not a large number of cases reporting percutaneous coronary IVL without the insertion of an intraluminal device represented in the Medicare data, and we generally prefer not to create a new MS–DRG unless it would include a substantial number of cases, we stated in the proposed rule that we believed creating a separate MS–DRG for these cases as well would appropriately address the differential in resource consumption. Therefore, we also proposed to create a new MS–DRG for cases describing percutaneous coronary IVL involving the insertion of an intraluminal device.

<table>
<thead>
<tr>
<th>Proposed new MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proposed new MS-DRG XXX Coronary Intravascular Lithotripsy with Intraluminal Device</td>
<td>4,238</td>
<td>4.6</td>
<td>$31,115</td>
</tr>
</tbody>
</table>

We stated we applied the criteria to create subgroups in a base MS–DRG as discussed in section II.C.1.b. of the proposed rule and this FY 2024 IPPS/LTCH PPS final rule. As shown, a three-way split of the proposed new MS–DRG failed to meet the criterion that there be at least a 20% difference in average costs between the CC and NonCC subgroup and also failed to meet the criterion that there be at least a $2,000 difference in average costs between the CC and NonCC subgroup.

<table>
<thead>
<tr>
<th>Proposed new MS-DRGs</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>With MCC</td>
<td>2,079</td>
<td>6.3</td>
<td>$36,325</td>
</tr>
<tr>
<td>With CC</td>
<td>1,423</td>
<td>3.2</td>
<td>$26,707</td>
</tr>
<tr>
<td>Without CC/MCC</td>
<td>736</td>
<td>2.3</td>
<td>$24,924</td>
</tr>
</tbody>
</table>

We then applied the criteria for a two-way split for the “with MCC” and “without MCC” subgroups and found that all five criteria were met. The following table illustrates our findings.

<table>
<thead>
<tr>
<th>Proposed new MS-DRGs</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>With MCC</td>
<td>2,079</td>
<td>6.3</td>
<td>$36,325</td>
</tr>
<tr>
<td>Without MCC</td>
<td>2,159</td>
<td>2.9</td>
<td>$26,099</td>
</tr>
</tbody>
</table>

As discussed in the proposed rule, for the proposed new MS–DRGs for cases reporting procedure codes describing percutaneous coronary IVL involving the insertion of an intraluminal device, there is at least (1) 500 cases in the MCC subgroup and 500 cases in the without MCC subgroup; (2) 5 percent of the cases in the MCC group and 5 percent in the without MCC subgroup; (3) a 20 percent difference in average costs between the MCC group and the without MCC group; (4) a $2,000 difference in average costs between the MCC group and the without MCC group and the without MCC group; and (5) a 3-percent reduction in cost variance, indicating that the proposed severity level splits increase the explanatory power of the base MS–DRG in capturing differences in expected cost between the proposed MS–DRG severity level splits by at least 3 percent and thus improve the overall accuracy of the IPPS payment system.

For the cases describing coronary intravascular lithotripsy without the insertion of an intraluminal device, we identified a total of 404 cases using the most recent claims data from the December 2022 update of the FY 2022 MedPAR file, so the criterion that there are at least 500 or more cases in each subgroup could not be met. Therefore, for FY 2024, we did not propose to subdivide the proposed new MS–DRG for coronary intravascular lithotripsy.
Comment: While supporting the proposal, some commenters suggested that proposed new MS–DRG 325 (Coronary Intravascular Lithotripsy without Intraluminal Device) be split into two severity levels (with and without MCC) to recognize the increased resource utilization when a secondary diagnosis designated as an MCC is present. Another commenter stated that CMS proposed to delay application of the NonCC subgroup criteria to existing MS–DRGs with a three-way severity level split for FY 2024 and questioned CMS’ application of the methodology to the proposed new MS–DRGs. This commenter stated that the presence of a secondary diagnosis designated as CC and a MCC impacts the length of stay and costs and therefore distinct tiers within these proposed MS–DRGs are necessary to reflect the differences in resource utilization.

Response: We thank the commenters for their feedback.

In response to the suggestion that proposed new MS–DRG 325 for cases describing coronary intravascular lithotripsy without intraluminal device be subdivided with a two-way severity level split, as discussed in the proposed rule and earlier in this section, in the analysis of the cases describing coronary intravascular lithotripsy without the insertion of an intraluminal device, we note we identified a total of 404 cases using the most recent claims data from the December 2022 update of the FY 2022 MedPAR file. Therefore, the criterion that there are at least 500 or more cases in each subgroup could not be met so we did not propose to subdivide the proposed new MS–DRG for coronary intravascular lithotripsy without an intraluminal device into severity levels for FY 2024.

In response to the concern regarding the application of the NonCC subgroup criteria to the proposed new MS–DRGs, we note in the FY 2021 IPPS/LTC PPS final rule (85 FR 58448), we finalized our proposal to expand our existing criteria to create a new CC or MCC subgroup within a base MS–DRG. Specifically, we finalized the expansion of the criteria to include the NonCC subgroup for a three-way severity level split. In the FY 2022 IPPS/LTC PPS final rule (86 FR 44798) and FY 2023 IPPS/LTC PPS final rule (87 FR 48803), we finalized a delay in applying this technical criterion to existing MS–DRGs in light of the PHE. We note that this delay relates to applying this technical criterion to existing MS–DRGs with a three-way severity level split. As discussed in prior rulemaking, in general, once the decision has been made to propose to make further modifications to the MS–DRGs, such as creating a new base MS–DRG, all five criteria must be met for the base MS–DRG to be split (or subdivided) by a CC subgroup. We note that we have applied the criteria to create subgroups, including application of the NonCC subgroup criteria, in our annual analysis of the MS–DRG classification requests effective FY 2021 (85 FR 58446 through 58448). For example, we applied the criteria to create subgroups, including application of the NonCC subgroup criteria, for a proposed new base MS–DRG as discussed in our finalization of new base MS–DRG 018 (Chimeric Antigen Receptor (CAR) T-cell Immunotherapy), new base MS–DRG 019 (Simultaneous Pancreas and Kidney Transplant with Hemodialysis), new base MS–DRG 140 (Major Head and Neck Procedures), new base MS–DRG 143 (Other Ear, Nose, Mouth and Throat O.R. Procedures), new base MS–DRG 521 (Hip Replacement with Principal Diagnosis of Hip Fracture) and new base MS–DRG 650 (Kidney Transplant with Hemodialysis) for FY 2021. Similarly, we applied the criteria to create subgroups including application of the NonCC subgroup criteria for MS–DRG classification requests for FY 2022 that we received by November 1, 2020 (86 FR 44796 through 44798), for MS–DRG classification requests for FY 2023 that we received by November 1, 2021 (87 FR 48801 through 48804), and for MS–DRG classification requests for FY 2024 that we received by October 20, 2022 (88 FR 26673 through 26676), as well as any additional analyses that were conducted in connection with those requests. We refer the reader to section I.I.C.1.b. of the preamble of this final rule for related discussion regarding our finalization of the criteria to include the NonCC subgroup in the FY 2021 final rule and our finalization of the proposal to continue to delay application of the NonCC subgroup criteria to existing MS–DRGs with a three-way severity level split for FY 2024.

Comment: Some commenters expressed concern with CMS’ proposal and stated that the proposed MS–DRGs may not reflect the full range of treatment options for severely calcified coronary lesions that may demonstrate similar increased costs and acuity. These commenters stated that the presence of severe calcification can increase treatment difficulty and complexity of service, which lead to higher average costs and generally longer lengths of stay. These commenters stated that CMS should
consider other well-established advanced vessel preparation techniques, such as percutaneous coronary rotational and orbital atherectomy, that also use specialty devices to fully optimize PCI for severely calcified arteries. A commenter stated that they agreed that there is a subset of clinically complex PCI cases with higher average costs however, they do not believe it serves the integrity of the IPPS to create new MS–DRGs for a single technology serving a relatively low volume of patient cases and suggested that CMS refine the proposed new MS–DRGs 323, 324 and 325 to include coronary atherectomy procedures. Another commenter stated that its own analysis demonstrated that resource requirements for orbital atherectomy are virtually the same as those for coronary IVL. This commenter noted CMS proposed to create MS–DRG 325 for cases describing coronary intravascular lithotripsy without intraluminal device and stated that this is inconsistent with the labeled indications for use of these high-resource devices. The commenter stated that coronary IVL and other complex vessel preparation technologies focus on treating severe calcium to facilitate placement and technical success of intraluminal devices and expressed concern with the precedent of establishing a device-specific MS–DRG that is inconsistent with a technology’s indications for use.

Other commenters opposed these recommendations and stated they believed that CMS’ proposal correctly differentiated coronary IVL from other PCI procedures, given the significant resource variance when IVL is utilized, and the more clinically complex patients being treated. A commenter stated that atherectomy is distinct from coronary IVL in terms of mechanism of action and technique, and further noted that, the clinical utilization is different in that atherectomy is not a therapy that is exclusively utilized in heavily calcified lesions. This commenter stated that in its own analysis of the claims data, the costs of atherectomy cases are half the cost of coronary IVL cases. These commenters all encouraged CMS to evaluate these and any other PCI-related procedures in future rulemaking to allow for all options to be considered appropriately.

Response: We thank the commenters for their feedback. Although we note that the initial request was to review the MS–DRG assignment of cases describing percutaneous coronary intravascular lithotripsy, and not cases describing other PCI techniques, the commenters are correct in that there are different types of treatment options available in the treatment of calcified coronary lesions. Under the ICD–10–PCS procedure classification system there are two root operations, Extirpation and Fragmentation, specifically defined as:

Extirpation: Taking or cutting out solid matter from a body part; and

Fragmentation: Breaking solid matter in a body part into pieces that are reported to describe the respective procedure that was performed.

In coronary IVL, emitters at the end of the catheter create acoustic pressure waves that are intended to break up the calcification that is restricting the blood flow in the vessels of the heart to help open the blood vessels when an angioplasty balloon is inflated. Because the technique fragments matter, procedures performed utilizing devices such as the Shockwave C2 Intravascular Lithotripsy System are identified and described by the root operation Fragmentation. In contrast, procedures such as rotational and orbital atherectomy are performed with the root operation Extirpation because both techniques cut up the calcified material into small particles that are removed from the blood stream by the normal hemofiltration process.

In response to the commenter’s statement that both coronary IVL and coronary atherectomy are procedures intended to treat calcified coronary arteries, we agree, however, as shown, each of these procedures are defined by clinically distinct definitions and objectives, and there are separate and unique ICD–10–PCS procedure codes within the classification for reporting purposes. We do not believe it is appropriate to specifically compare the devices being utilized in the performance of these distinct procedures in consideration of MS–DRG assignment, rather, the emphasis is on the fragmentation and extirpation procedures performed and evaluating the treatment difficulty, resource utilization, and complexity of service.

In response to the commenter’s statement regarding the labeled indications for coronary IVL, as discussed in the proposed rule, there may be instances where an intraluminal device is unable to be inserted after the application of the IVL pulses. Accordingly, we identified a total of 386 cases describing coronary intravascular lithotripsy without the insertion of an intraluminal device using the September 2022 update of the FY 2022 MedPAR file and 404 cases describing coronary intravascular lithotripsy without the insertion of an intraluminal device using the more recent claim data from the December 2022 update of the FY 2022 MedPAR file. We continue to believe creating a MS–DRG for these cases as well would appropriately address the differential in resource consumption.

As discussed in the proposed rule, the data analysis clearly shows that cases reporting percutaneous coronary IVL, with or without involving the insertion of an intraluminal device, have higher average costs and generally longer lengths of stay compared to all the cases in their assigned MS–DRG. We appreciate the commenters’ feedback and suggestions, however, we believe that continued monitoring of the data and further analysis is needed prior to proposing any modifications to the proposed new MS–DRGs for percutaneous coronary IVL. We will continue to evaluate the claims data to determine if further modifications to the MS–DRG assignment of cases reporting percutaneous coronary intervention procedures are warranted and address any proposed modifications to the existing logic in future rulemaking.

Therefore, after consideration of the public comments we received, and for the reasons discussed, we are finalizing our proposal to create new MS–DRG 323 (Coronary Intravascular Lithotripsy with Intraluminal Device) new MS–DRG 324 (Coronary Intravascular Lithotripsy with Intraluminal Device without MCC) and new MS–DRG 325 (Coronary Intravascular Lithotripsy without Intraluminal Device) in MDC 05, without modification, effective October 1, 2023 for FY 2024. We are also finalizing the logic in the list of procedure codes to define the logic for each of the new MS–DRGs as displayed in Table 6P.6a associated with the proposed rule (which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index).

In reviewing this issue, we noted in the FY 2024 proposed rule that we received a separate but related request in FY 2022 rulemaking. In the FY 2022 IPPS/LTC PPS final rule (86 FR 44848 through 44850), we discussed a request to review the MS–DRG assignments of claims involving the insertion of coronary stents in PCI. The requestor suggested that CMS eliminate the distinction between drug-eluting and bare-metal coronary stents in the MS–DRG classification. According to the requestor, coated stents have a clinical performance comparable to drug-eluting stents, however, they are grouped with bare-metal stents because they do not contain a drug. The requestor asserted that this conflation muddies the existing claims to the MS–DRG structure, as one cannot infer distinctions in clinical performance or
benefits among the groups and potentially creates a barrier (based on hospital decision-making) to patient access to modern coated stents. In response, we stated that based on a review of the procedure codes that are currently assigned to MS–DRGs 246, 247, 248, and 249, our clinical advisors agreed that further refinement of these MS–DRGs may be warranted. We noted that in the FY 2003 IPPS/LTCH PPS final rule (67 FR 50003 through 50005), although the FDA had not yet approved the technology for use, we created two new temporary CMS DRGs to reflect cases involving the insertion of a drug-eluting coronary artery stent as signified by the presence of ICD–9–CM procedure code 36.07 (Insertion of drug-eluting coronary artery stent) in recognition of the potentially significant impact this technology could have on the treatment of coronary artery blockages, the predictions of its rapid, widespread use, and that the higher costs of this technology could create undue financial hardships for hospitals due to the high volume of stent cases. In the FY 2022 final rule, we noted that the distinction between drug-eluting and non-drug-eluting stents is found elsewhere in the ICD–10–PCS procedure code classification and stated evaluating this request required a more extensive analysis to assess potential impacts across the MS–DRGs. We also stated that we believed it would be more appropriate to consider this request further in future rulemaking.

As discussed in the proposed rule and this section of the final rule, our analysis of claims data from the September 2022 update of the FY 2022 MedPAR file indicates that in cases reporting percutaneous coronary IVL involving the insertion of an intraluminal device, average costs are generally similar without regard as to whether a drug-eluting or non-drug-eluting intraluminal device was inserted. Therefore, in consideration of the prior request discussed in FY 2022 rulemaking and to further explore this current finding, we stated we examined claims data from the September 2022 update of the FY 2022 MedPAR file for MS–DRGs 246, 247, 248, and 249 for “all other cases” assigned to MS–DRGs 246, 247, 248, and 249 that did not report percutaneous coronary IVL as reflected in the previous table.

In the proposed rule, we again noted that the data analysis shows that in percutaneous cardiovascular procedures involving the insertion of an intraluminal device, the average costs are generally similar without regard as to whether a drug-eluting or non-drug-eluting intraluminal device(s) was inserted. In MS–DRG 246, there were 38,288 cases reporting percutaneous cardiovascular procedures involving the insertion of a drug-eluting intraluminal device with an MCC or procedures involving four or more arteries or intraluminal devices with average costs of $25,022 compared to 542 cases reporting percutaneous cardiovascular procedures involving the insertion of a non-drug-eluting intraluminal device with an MCC or procedures involving four or more arteries or intraluminal devices with average costs of $25,022 compared to 542 cases reporting percutaneous cardiovascular procedures involving the insertion of a non-drug-eluting intraluminal device with an MCC or procedures involving four or more arteries or intraluminal devices with average costs of $25,022 compared to 542 cases reporting percutaneous cardiovascular procedures involving the insertion of a non-drug-eluting intraluminal device with an MCC or procedures involving four or more arteries or intraluminal devices with average costs of $25,022 compared to 542 cases reporting percutaneous cardiovascular procedures involving the insertion of a non-drug-eluting intraluminal device with an MCC or procedures involving four or more arteries or intraluminal devices with average costs of $25,022 compared to 542 cases reporting percutaneous cardiovascular procedures involving the insertion of a non-drug-eluting intraluminal device with an MCC or procedures involving four or more arteries or intraluminal devices with average costs of $25,022 compared to 542 cases reporting percutaneous cardiovascular procedures involving the insertion of a non-drug-eluting intraluminal device with an MCC or procedures involving four or more arteries or intraluminal devices with average costs of $25,022 compared to 542 cases reporting percutaneous cardiovascular procedures involving the insertion of a non-drug-eluting intraluminal device with an MCC or procedures involving four or more arteries or intraluminal devices with average costs of $25,022 compared to 542 cases reporting percutaneous cardiovascular procedures involving the insertion of a non-drug-eluting intraluminal device with an MCC or procedures involving four or more arteries or intraluminal devices with average costs of $25,022 compared to 542 cases reporting percutaneous cardiovascular procedures involving the insertion of a non-drug-eluting intraluminal device with an MCC or procedures involving four or more arteries or intraluminal devices with average costs of $25,022 compared to 542 cases reporting percutaneous cardiovascular procedures involving the insertion of a non-drug-eluting intraluminal device with an MCC or procedures involving four or more arteries or intraluminal devices with average costs of $25,022.
As discussed in the proposed rule, in MS–DRG 246, we identified a total of 40,647 cases with an average length of stay of 5.2 days and average costs of $25,630. Of those 40,647 cases, there were 3,430 cases reporting percutaneous cardiovascular procedures involving four or more arteries or intraluminal devices, with higher average costs as compared to all cases in MS–DRG 246 ($27,397 compared to $25,630), and a shorter average length of stay (3.2 days compared to 5.2 days). We stated this analysis demonstrates that cases reporting percutaneous procedures involving four or more arteries or intraluminal devices continue to be more comparable in average costs and resource consumption to the cases in the higher weighted MS–DRG in the group and indicates that maintaining the logic that recognizes the performance of percutaneous cardiovascular procedures involving four or more arteries or intraluminal devices that exists currently in MS–DRGs 246 and 248 in the proposed new MS–DRGs was warranted.

We noted presently, MS–DRGs 246 and 248 are defined as base MS–DRGs, each of which is split by a two-way severity level subgroup. Our proposal includes the creation of one base MS–DRG split also by a two-way severity level subgroup. To compare and analyze the impact of our suggested modifications, we stated we ran a simulation using the most recent claims data from the December 2022 update of the FY 2022 MedPAR file. The following table illustrates our findings for all 97,338 cases reporting percutaneous cardiovascular procedures involving intraluminal devices.

<table>
<thead>
<tr>
<th>MS–DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>246 All cases</td>
<td>40,647</td>
<td>5.2</td>
<td>$25,630</td>
</tr>
<tr>
<td>246 Cases reporting percutaneous cardiovascular procedures involving four or more arteries or intraluminal devices</td>
<td>3,430</td>
<td>3.2</td>
<td>$27,397</td>
</tr>
<tr>
<td>248 All cases</td>
<td>555</td>
<td>5.9</td>
<td>$25,740</td>
</tr>
<tr>
<td>248 Cases reporting percutaneous cardiovascular procedures involving four or more arteries or intraluminal devices</td>
<td>21</td>
<td>3.4</td>
<td>$28,251</td>
</tr>
</tbody>
</table>

We applied the criteria to create subgroups in a base MS–DRG as discussed in section II.C.1.b. of the proposed rule and this FY 2024 IPPS/LTCH PPS final rule. As shown in the table that follows, a three-way split of the proposed new MS–DRGs failed to meet the criterion that there be at least a 20% difference in average costs between the CC and NonCC subgroup and also failed to meet the criterion that there be at least a $2,000 difference in average costs between the CC and NonCC subgroup.

<table>
<thead>
<tr>
<th>Proposed new MS–DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proposed new MS–DRG XXX Percutaneous Cardiovascular Procedures with Intraluminal Device</td>
<td>97,338</td>
<td>3.5</td>
<td>$19,766</td>
</tr>
</tbody>
</table>

We then applied the criteria for a two-way split for the “with MCC” and “without MCC” subgroups for the proposed new MS–DRGs and found that all five criteria were met. The following table illustrates our findings.

<table>
<thead>
<tr>
<th>MS–DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>With MCC</td>
<td>37,604</td>
<td>5.3</td>
<td>$24,871</td>
</tr>
<tr>
<td>With CC</td>
<td>33,088</td>
<td>2.7</td>
<td>$17,407</td>
</tr>
<tr>
<td>Without CC/MCC</td>
<td>26,646</td>
<td>2</td>
<td>$15,492</td>
</tr>
</tbody>
</table>
For the proposed new MS–DRGs, there is (1) at least 500 cases in the MCC subgroup and in the without MCC subgroup; (2) at least 5 percent of the cases are in the MCC subgroup and in the without MCC subgroup; (3) at least a 20 percent difference in average costs between the MCC subgroup and the without MCC subgroup; (4) at least a $2,000 difference in average costs between the MCC subgroup and the without MCC subgroup; and (5) at least a 3-percent reduction in cost variance, indicating that the proposed severity level splits increase the explanatory power of the base MS–DRG in capturing differences in expected cost between the proposed MS–DRG severity level splits by at least 3 percent and thus improve the overall accuracy of the IPPS payment system. We noted in that proposed rule that proposed refinements for cases reporting percutaneous cardiovascular procedures with intraluminal devices represented the first step in investigating how we may evaluate the distinctions between drug-eluting and non-drug-eluting intraluminal devices found elsewhere in the ICD–10–PCS procedure code classification. We stated that we are making concerted efforts to continue refining the ICD–10 MS–DRGs and we believed the resulting MS–DRG assignments in our current proposal would be more clinically homogeneous, coherent and better reflect current trends and hospital resource use. In summary, for FY 2024, taking into consideration it appears to no longer be necessary to subdivide the MS–DRGs for percutaneous cardiovascular procedures based on the type of coronary intraluminal device inserted, we proposed to delete MS–DRGs 246, 247, 248, and 249 and create a new base MS–DRG with a two-way severity level split for cases describing percutaneous intraluminal device in MDC 05. These proposed new MS–DRGs are proposed new MS–DRG 321 (Percutaneous Cardiovascular Procedures with Intraluminal Device with MCC or 4+ Arteries/Intraluminal Devices) and proposed new MS–DRG 322 (Percutaneous Cardiovascular Procedures with Intraluminal Device without MCC). We proposed to add the procedure codes from current MS–DRGs 246, 247, 248, and 249 to the proposed new MS–DRGs 321 and 322. We also proposed to revise the titles for MS–DRGs 250 and 251 from “Percutaneous Cardiovascular Procedures without Coronary Artery Stent with MCC, and without MCC, respectively” to “Percutaneous Cardiovascular Procedures Without Intraluminal Device with MCC, and without MCC, respectively” to better reflect the ICD–10–PCS terminology of “intraluminal devices” versus “stents” as used in the procedure code titles within the classification. We refer the reader to section II.C.15. of the preamble of this final rule for the discussion of the surgical hierarchy and the complete list of our proposed modifications to the surgical hierarchy as well as our finalization of those proposals.

**Comment:** Commenters supported CMS’ proposals. These commenters stated that they agreed with CMS that the distinction between drug-eluting and bare metal stents is no longer required given the evolution of these technologies. A commenter stated they appreciated the simplification of MS–DRGs involving percutaneous intraluminal devices by omitting the distinction between drug-eluting versus non-drug-eluting devices with the proposed creation of MS–DRGs 321 and 322. Another commenter stated that they appreciate CMS periodically reviewing the MS–DRGs for percutaneous coronary interventions to ensure they appropriately reflect current clinical practice and appropriately reflect the hospital resources associated with these procedures. A commenter supported the proposal, but suggested that there be consideration to split the new base MS–DRG for cases describing percutaneous cardiovascular procedures with intraluminal device with a three-way severity level split, instead of a two-way severity level split as proposed.

**Response:** We appreciate the commenters’ feedback and concern. We note that each year, we calculate the relative weights by dividing the average cost for cases within each MS–DRG by the average cost for cases across all MS–DRGs. It is to be expected that when MS–DRGs are restructured, such as when procedure codes are reassigned or the hierarchy within an MDC is revised, resulting in a different case-mix within the MS–DRGs, the relative weights of the MS–DRGs will change as a result. As discussed in the FY 2024 IPPS/LTCH PPS proposed rule, and earlier in this section, upon application of the criteria to create subgroups, we proposed to create a base MS–DRG split by a two-way severity level subgroup for cases describing coronary intravascular lithotripsy involving the insertion of an intraluminal device in MDC 05 for FY

### Proposed new MS–DRGs

<table>
<thead>
<tr>
<th>Proposed new MS–DRGs</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>With MCC or 4+ Arteries/Intraluminal Devices</td>
<td>37,604</td>
<td>5.3</td>
<td>$24,871</td>
</tr>
<tr>
<td>Without MCC</td>
<td>59,734</td>
<td>2.4</td>
<td>$16,553</td>
</tr>
</tbody>
</table>

For the proposed new MS–DRGs, there is (1) at least 500 cases in the MCC subgroup and in the without MCC subgroup; (2) at least 5 percent of the cases are in the MCC subgroup and in the without MCC subgroup; (3) at least a 20 percent difference in average costs between the MCC subgroup and the without MCC subgroup; (4) at least a $2,000 difference in average costs between the MCC subgroup and the without MCC subgroup; and (5) at least a 3-percent reduction in cost variance, indicating that the proposed severity level splits increase the explanatory power of the base MS–DRG in capturing differences in expected cost between the proposed MS–DRG severity level splits by at least 3 percent and thus improve the overall accuracy of the IPPS payment system.

We noted in that proposed rule that proposed refinements for cases reporting percutaneous cardiovascular procedures with intraluminal devices represented the first step in investigating how we may evaluate the distinctions between drug-eluting and non-drug-eluting intraluminal devices found elsewhere in the ICD–10–PCS procedure code classification. We stated that we are making concerted efforts to continue refining the ICD–10 MS–DRGs and we believed the resulting MS–DRG assignments in our current proposal would be more clinically homogeneous, coherent and better reflect current trends and hospital resource use.

In summary, for FY 2024, taking into consideration it appears to no longer be necessary to subdivide the MS–DRGs for percutaneous cardiovascular procedures based on the type of coronary intraluminal device inserted, we proposed to delete MS–DRGs 246, 247, 248, and 249 and create a new base MS–DRG with a two-way severity level split for cases describing percutaneous cardiovascular procedures with intraluminal device in MDC 05. These proposed new MS–DRGs are proposed new MS–DRG 321 (Percutaneous Cardiovascular Procedures with Intraluminal Device with MCC or 4+ Arteries/Intraluminal Devices) and proposed new MS–DRG 322 (Percutaneous Cardiovascular Procedures with Intraluminal Device without MCC). We proposed to add the procedure codes from current MS–DRGs 246, 247, 248, and 249 to the proposed new MS–DRGs 321 and 322. We also proposed to revise the titles for MS–DRGs 250 and 251 from “Percutaneous Cardiovascular Procedures without Coronary Artery Stent with MCC, and without MCC, respectively” to “Percutaneous Cardiovascular Procedures Without Intraluminal Device with MCC, and without MCC, respectively” to better reflect the ICD–10–PCS terminology of “intraluminal devices” versus “stents” as used in the procedure code titles within the classification. We refer the reader to section II.C.15. of the preamble of this final rule for the discussion of the surgical hierarchy and the complete list of our proposed modifications to the surgical hierarchy as well as our finalization of those proposals.

**Comment:** Commenters supported CMS’ proposals. These commenters stated that they agreed with CMS that the distinction between drug-eluting and bare metal stents is no longer required given the evolution of these technologies. A commenter stated they appreciated the simplification of MS–DRGs involving percutaneous intraluminal devices by omitting the distinction between drug-eluting versus non-drug-eluting devices with the proposed creation of MS–DRGs 321 and 322. Another commenter stated that they appreciate CMS periodically reviewing the MS–DRGs for percutaneous coronary interventions to ensure they appropriately reflect current clinical practice and appropriately reflect the hospital resources associated with these procedures. A commenter supported the proposal, but suggested that there be consideration to split the new base MS–DRG for cases describing percutaneous cardiovascular procedures with intraluminal device with a three-way severity level split, instead of a two-way severity level split as proposed.

**Response:** We appreciate the commenters’ feedback and concern. We note that each year, we calculate the relative weights by dividing the average cost for cases within each MS–DRG by the average cost for cases across all MS–DRGs. It is to be expected that when MS–DRGs are restructured, such as when procedure codes are reassigned or the hierarchy within an MDC is revised, resulting in a different case-mix within the MS–DRGs, the relative weights of the MS–DRGs will change as a result. As discussed in the FY 2024 IPPS/LTCH PPS proposed rule, and earlier in this section, upon application of the criteria to create subgroups, we proposed to create a base MS–DRG split by a two-way severity level subgroup for cases describing coronary intravascular lithotripsy involving the insertion of an intraluminal device in MDC 05 for FY
2024. Therefore, the data appear to reflect that the difference in the relative weights reflected in Table 5—List of Medicare Severity Diagnosis-Related Groups (MS-DRGs), Relative Weighting Factors, and Geometric and Arithmetic Mean Length of Stay—FY 2024, associated with the proposed rule, can be attributed to the fact that these proposals resulted in a different case-mix within the MS-DRGs which is then being reflected in the relative weights. We refer the reader to section I.D. of the preamble of this FY 2024 IPPS/LTC PP final rule for a complete discussion of the relative weight calculations.

After consideration of the public comments we received, and for the reasons discussed, we are finalizing our proposal, without modification, to delete MS-DRGs 246, 247, 248, and 249 for FY 2024. We are also finalizing our proposal to create new MS-DRG 321 (Percutaneous Cardiovascular Procedures with Intraluminal Device with MCC or 4+ Arteries/Intraluminal Devices) and new MS-DRG 322 (Percutaneous Cardiovascular Procedures with Intraluminal Device without MCC). Accordingly, we are finalizing our proposal to assign the procedure codes from current MS-DRGs 246, 247, 248, and 249 to the new MS-DRGs 321 and 322. Lastly, we are also finalizing our proposal to revise the titles of MS-DRGs 250 and 251 from “Percutaneous Cardiovascular Procedures without Coronary Artery Stent with MCC, and without MCC, respectively” to “Percutaneous Cardiovascular Procedures without Intraluminal Device with MCC, and without MCC, respectively” effective October 1, 2023 for FY 2024.

e. Shock

In the FY 2022 IPPS/LTC PP final rule (86 FR 44831 through 44833), we discussed a request we received to review the MS-DRG assignment of ICD-10-CM diagnosis code I21.A1 (Myocardial infarction type 2). The requestor stated that when a type 2 myocardial infarction is documented, per coding guidelines, it is to be coded as a secondary diagnosis since it is due to an underlying cause. This requestor also noted that when a type 2 myocardial infarction is coded with a principal diagnosis in MDC 05 (Diseases and Disorders of the Circulatory System), the GROUPER logic assigns MS-DRGs 280 through 282 (Acute Myocardial Infarction, Discharged Alive with MCC, with CC, and without CC/ MCC, respectively). The requestor questioned if this GROUPER logic was correct or if the logic should be changed so that a type 2 myocardial infarction, coded as a secondary diagnosis, does not result in the assignment of a MS-DRG that describes an acute myocardial infarction. During our review of this issue, we also noted that ICD-10-CM diagnosis code I21.A1 (Myocardial infarction type 2) was one of the listed principal diagnoses in the GROUPER logic for MS-DRGs 222 and 223 (Cardiac Defibrillator Implant with Cardiac Catheterization with Acute Myocardial Infarction (AMI), Heart Failure (HF), or Shock with and without MCC, respectively). However, code I21.A1 was not recognized in these same MS-DRGs when coded as a secondary diagnosis. Acknowledging that coding guidelines instruct to code I21.A1 after the diagnosis code that describes the underlying cause, we indicated our clinical advisors recommended adding special logic in MS-DRGs 222 and 223 to have code I21.A1 also qualify when coded as a secondary diagnosis in combination with a principal diagnosis in MDC 05 since these diagnosis code combinations also describe acute myocardial infarctions. In the FY 2022 final rule, after consideration of the public comments, we finalized our proposal to maintain the structure of MS-DRGs 280 through 285, without modification, for FY 2022. We also finalized our proposal to modify the GROUPER logic to allow cases reporting diagnosis code I21.A1 (Myocardial infarction type 2) as a secondary diagnosis to group to MS-DRGs 222 and 223 when reported with qualifying procedures, effective October 1, 2021. Under this finalization, code I21.A1, as a secondary diagnosis, is used in the definition of the logic for assignment to MS-DRGs 222 and 223, and therefore does not act as an MCC in these MS-DRGs.

In response to this final policy, in the FY 2024 IPPS/LTC PP proposed rule (88 FR 26712 through 26717), we discussed a related request we received to also add ICD-10-CM diagnosis code R57.0 (Cardiogenic shock) to the list of “secondary diagnoses” that group to MS-DRGs 222 and 223. Cardiogenic shock occurs when the heart cannot pump enough oxygen-rich blood to the brain and other vital organs resulting in inadequate tissue perfusion. The most common cause of cardiogenic shock is acute myocardial infarction. Other causes include myocarditis, endocarditis, papillary muscle rupture, left ventricular free wall rupture, acute ventricular septal defect, severe congestive heart failure, end-stage cardiomyopathy, severe valvular dysfunction, acute cardiac tamponade, cardiac contusion, massive pulmonary embolus, or the overdose of drugs such as beta blockers or calcium channel blockers.

As discussed in the proposed rule, since the MS-DRG titles contain the word “shock”, the requestor indicated that it seemed reasonable for the GROUPER logic to recognize cardiogenic shock when coded as a secondary diagnosis because, according to the requestor, the specific underlying cardiac condition responsible for causing the cardiogenic shock must always be sequenced first. The requestor further asserted that ICD-10-CM coding guidelines require codes from Chapter 18 (Symptoms, Signs, and Abnormal Clinical and Laboratory Findings) to be sequenced first, therefore when coding guidelines are followed, this code can never be an appropriate principal diagnosis. The requestor acknowledged that if code R57.0 were to be added to the list of “secondary diagnoses” that group to MS-DRGs 222 and 223, and therefore used in the definition of the logic for assignment, the code would no longer act as an MCC in MS-DRGs 222 and 223.

To begin our analysis, we stated we reviewed the GROUPER logic. In the proposed rule, we noted that ICD-10-CM diagnosis code R57.0 (Cardiogenic shock) is currently one of the listed principal diagnoses in the GROUPER logic for MS-DRGs 222 and 223. We stated that requestor was correct that diagnosis code R57.0 is not currently recognized in these same MS-DRGs when coded as a secondary diagnosis. We refer the reader to the ICD-10-MS-DRG Definitions Manual Version 40.1, which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software for complete documentation of the GROUPER logic for MS-DRGs 222 and 223.

We also stated that the requestor was also correct that the diagnosis code R57.0 is found in Chapter 18 (Symptoms, Signs and Abnormal Clinical and Laboratory Findings) of ICD-10-CM and that diagnosis code R57.0 has a current severity designation of MCC when reported as a secondary diagnosis. We disagreed, however, that this code can never be an appropriate principal diagnosis. We noted that according to the ICD-10-CM Official Guidelines for Coding and Reporting, diagnoses described by codes from Chapter 18 of ICD-10-CM, such as R57.0, are acceptable for reporting when a related definitive code has not been established (confirmed) by the provider. We also pointed out that a
"code first" note appears at ICD–10–CM diagnosis code I21.A1 (Myocardial infarction type 2). The "code first" note is an etiology/manifestation coding convention (additional detail can be found in the ICD–10–CM Official Guidelines for Coding and Reporting), indicating that the condition has both an underlying etiology and manifestation due to the underlying etiology. No such "code first" notes appear at ICD–10–CM diagnosis code R57.0 (Cardiogenic shock). If providers have cases involving cardiogenic shock which they need ICD–10 coding assistance, we encourage them to submit their questions to the American Hospital Association’s Central Office on ICD–10 at https://www.codingclinicadvisor.com/.

As discussed in the proposed rule, we then examined claims data from the September 2022 update of the FY 2022 MedPAR file for all cases in MS–DRGs 222 and 223 (Cardiac Defibrillator Implant with Cardiac Catheterization with AMI, HF or Shock, with and without MCC, respectively) and compared the results to cases that had a principal diagnosis or a secondary diagnosis of cardiogenic shock in those MS–DRGs. We also included MS–DRGs 224 and 225 (Cardiac Defibrillator Implant with Cardiac Catheterization without AMI, HF or Shock with and without MCC, respectively) and MS–DRGs 226 and 227 (Cardiac Defibrillator Implant without Cardiac Catheterization with and without MCC, respectively) in our analysis as the logic for these MS–DRGs is similar, differing only in the reporting of a diagnosis that describes acute myocardial infarction, heart failure or shock, or the performance of cardiac catheterization. The following table shows our findings:

<table>
<thead>
<tr>
<th>MS–DRGs 222-227: All Cases and Cases with Principal or Secondary Diagnosis of Cardiogenic Shock</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MS-DRG</strong></td>
</tr>
<tr>
<td>All cases</td>
</tr>
<tr>
<td>Cases with principal diagnosis of R57.0</td>
</tr>
<tr>
<td>Cases with secondary diagnosis of R57.0</td>
</tr>
<tr>
<td>All cases</td>
</tr>
<tr>
<td>Cases with principal diagnosis of R57.0</td>
</tr>
<tr>
<td>Cases with secondary diagnosis of R57.0</td>
</tr>
<tr>
<td>All cases</td>
</tr>
<tr>
<td>Cases with principal diagnosis of R57.0</td>
</tr>
<tr>
<td>Cases with secondary diagnosis of R57.0</td>
</tr>
<tr>
<td>All cases</td>
</tr>
<tr>
<td>Cases with principal diagnosis of R57.0</td>
</tr>
<tr>
<td>Cases with secondary diagnosis of R57.0</td>
</tr>
<tr>
<td>All cases</td>
</tr>
<tr>
<td>Cases with principal diagnosis of R57.0</td>
</tr>
<tr>
<td>Cases with secondary diagnosis of R57.0</td>
</tr>
<tr>
<td>All cases</td>
</tr>
<tr>
<td>Cases with principal diagnosis of R57.0</td>
</tr>
<tr>
<td>Cases with secondary diagnosis of R57.0</td>
</tr>
</tbody>
</table>

In MS–DRG 222, we identified a total of 1,488 cases with an average length of stay of 11 days and average costs of $64,794. Of those 1,488 cases, there were six cases reporting a principal diagnosis of R57.0, with higher average costs as compared to all cases in MS–DRG 222 ($88,486 compared to $64,794), and a longer average length of stay (13.5 days compared to 11 days). There were 322 cases reporting a secondary diagnosis of R57.0, with higher average costs as compared to all cases in MS–DRG 222 ($77,451 compared to $64,794), and a longer average length of stay (15.1 days compared to 11 days). In MS–DRG 224, we identified a total of 1,606 cases with an average length of stay of 9.4 days and average costs of $60,583. Of those 1,606 cases, there were zero cases reporting a principal diagnosis of R57.0. There were 268 cases reporting a secondary diagnosis of R57.0, with higher average costs as compared to all cases in MS–DRG 224 ($77,334 compared to $60,583), and a longer average length of stay (12.9 days compared to 9.4 days). In MS–DRG 226, we identified a total of 3,595 cases with an average length of stay of 8.3 days and average costs of $53,706. Of those 3,595 cases, there were four cases reporting a principal diagnosis of R57.0, with higher average costs as compared to all cases in MS–DRG 226 ($72,349 compared to $53,706), and a longer average length of stay (14.3 days compared to 8.3 days). There were 325 cases reporting a secondary diagnosis of R57.0, with higher average costs as compared to all cases in MS–DRG 226 ($65,266 compared to $53,706), and a longer average length of stay (12.5 days compared to 8.3 days). We found zero cases across MS–DRGs 223, 225, and 227 reporting R57.0 as principal or as a secondary diagnosis. Our analysis
clearly shows that the cases reporting a secondary diagnosis of cardiogenic shock in MS–DRGs 222, 224 and 226 had higher average costs and longer average length of stay compared to all cases in their respective MS–DRGs.

We stated in the proposed rule that we reviewed these data and did not recommend modifying the GROUPER logic to allow cases reporting diagnosis code R57.0 (Cardiogenic shock) as a secondary diagnosis to group to MS–DRGs 222 and 223 when reported with qualifying procedures. As noted by the requestor, and as discussed in FY 2004 IPPS/LTCPPS final rule, (68 FR 45356 through 45358), a diagnosis code may define the logic for a specific MS–DRG assignment in three different ways. Whenever there is a secondary diagnosis component to the MS–DRG logic, the diagnosis code can either be used in the logic for assignment to the MS–DRG or to act as a CC/MCC.

We stated we believed that patients with cardiogenic shock as a secondary diagnosis are more severely ill and these inpatient admissions are associated with greater resource utilization. Cardiogenic shock represents a life-threatening emergency that requires urgent treatment that focuses on getting blood flowing properly to prevent, and protect against, organ failure, brain injury or death. For clinical consistency, we stated it was more appropriate for ICD–10–CM diagnosis code R57.0 to act as an MCC when cardiogenic shock is documented in the medical record and coded as a secondary diagnosis. Therefore, we did not propose to modify the GROUPER logic to allow cases reporting diagnosis code R57.0 (Cardiogenic shock) as a secondary diagnosis to group to MS–DRGs 222 and 223 when reported with qualifying procedures.

Comment: Commenters expressed support for CMS’ proposal to not modify the GROUPER logic to allow cases reporting diagnosis code R57.0 (Cardiogenic shock) as a secondary diagnosis to group to MS–DRGs 222 and 223 when reported with qualifying procedures.

Response: We thank the commenters for their support.

During our review of this issue, we noted in the proposed rule that the data analysis showed that in procedures involving a cardiac defibrillator implant, the average costs and length of stay are generally similar without regard to the presence of diagnosis codes describing AMI, HF or shock. In MS–DRG 222, there were 1,488 cases reporting a cardiac defibrillator implant with cardiac catheterization with AMI, HF, or Shock with an MCC with average costs of $64,794 and an average length of stay of 11 days compared to 1,606 cases reporting cardiac defibrillator implant with cardiac catheterization without AMI, HF, or Shock with an MCC with average costs of $60,583 and an average length of stay of 9.4 days in MS–DRG 224. In MS–DRG 223, there were 270 cases reporting cardiac defibrillator implant with cardiac catheterization with AMI, HF or Shock without an MCC with average costs of $43,500 and an average length of stay of 5.7 days compared to 1,167 cases reporting cardiac defibrillator implant with cardiac catheterization without AMI, HF, or Shock without an MCC with average costs of $42,442 and an average length of stay of 4.6 days in MS–DRG 225.

We stated that the analysis of MS–DRGs 222, 223, 224, 225, and 227 further demonstrated that the average length of stay and average costs for all cases are similar for each of the “without MCC” subgroups. As stated previously, for all of the cases in MS–DRG 223, we found that the average length of stay was 5.7 days with average costs of $43,500, and for all of the cases in MS–DRG 225, the average length of stay was 4.6 days with average costs of $42,442. Likewise, for all of the cases in MS–DRG 227, we found that the average length of stay was 3.9 days with average costs of $41,636.

We reviewed these findings and stated we believed that it may no longer be necessary to subdivide these MS–DRGs based on the diagnosis codes reported. We noted that in the FY 2004 IPPS/LTCPPS final rule (68 FR 45356 through 45358), we stated that we found that patients who are admitted with acute myocardial infarction, heart failure, or shock and have a cardiac catheterization are generally acute patients who require emergency implantation of the defibrillator. Thus, we stated there were very high costs associated with these patients. Therefore, we finalized the creation of new DRGs for patients receiving a cardiac defibrillator implant with cardiac catheterization and with a principal diagnosis of acute myocardial infarction, heart failure, or shock. As discussed in the proposed rule, our analysis of claims data from the September 2022 update of the FY 2022 MedPAR file clearly shows that in the 20 years since the DRGs for cases involving a cardiac defibrillator implant with cardiac catheterization split based on the presence or absence of diagnosis codes describing acute myocardial infarction, heart failure, or shock were created, cases reporting a cardiac defibrillator implant with cardiac catheterization continue to demonstrate higher average costs and longer lengths of stays, however these increased costs appear to be more related to the procedures performed than to the diagnoses reported on the claim, and therefore we stated that we believed it was time to restructure these MS–DRGs accordingly.

In the proposed rule, we did note that when reviewing consumption of hospital resources for the cases reporting cardiac defibrillator implant with cardiac catheterization during a hospital stay, the claims data clearly shows that the cases reporting secondary diagnoses designated as MCCs are more resource intensive as compared to other cases reporting cardiac defibrillator implant. As noted previously, in MS–DRG 222, there were 1,488 cases reporting cardiac defibrillator implant with cardiac catheterization with AMI, HF, or Shock with an MCC with average costs of $64,794 and an average length of stay of 11 days. Similarly, in MS–DRG 224, there were 1,606 cases reporting cardiac defibrillator implant with cardiac catheterization without AMI, HF, or Shock with an MCC with average costs of $60,583 and an average length of stay of 9.4 days in MS–DRG 224. In comparison, there were 270 cases reporting cardiac defibrillator implant with cardiac catheterization with AMI, HF, or Shock without an MCC with average costs of $43,500 and an average length of stay of 5.7 days in MS–DRG 223. 1,167 cases reporting cardiac defibrillator implant without cardiac catheterization with AMI, HF, or Shock without an MCC with average costs of $42,442 and an average length of stay of 4.6 days in MS–DRG 225, 3,595 cases reporting cardiac defibrillator implant without cardiac catheterization with an MCC with average costs of $53,706 and an average length of stay of 8.3 days in MS–DRG 226, and 2,522 cases reporting cardiac defibrillator implant without cardiac catheterization without an MCC with average costs of $41,636 and an average length of stay of 3.9 days in MS–DRG 227.

Therefore, we stated we supported the removal of the special logic defined as “Principal Diagnosis AMI/HF/SHOCK” from the definition for assignment to any proposed modifications to the MS–DRGs, noting the cases can be appropriately grouped along with cases reporting any MDC 05 diagnosis when reported with qualifying procedures, in any restructured proposed MS–DRGs. For these reasons, we proposed the deletion of MS–DRGs 222, 223, 224, 225, 226, and 227, and the creation of three new MS–DRGs. Our proposal
included the creation of one new base MS–DRG for cases reporting a cardiac defibrillator implant with cardiac catheterization and a secondary diagnosis designated as an MCC and another new base MS–DRG split by a two-way severity level subgroup for cases reporting a cardiac defibrillator implant without cardiac catheterization.

We stated in the proposed rule that to compare and analyze the impact of our suggested modifications, we ran a simulation using the most recent claims data from the December 2022 update of the FY 2022 MedPAR file. The following table illustrates our findings for all 3,467 cases reporting a cardiac defibrillator implant with cardiac catheterization and a secondary diagnosis designated as an MCC. We note that as discussed in prior rulemaking (86 FR 44831 through 44833), a diagnosis code may define the logic for a specific MS–DRG assignment in three different ways. The diagnosis code may be listed as principal or as any one of the secondary diagnoses, as a secondary diagnosis, or only as a secondary diagnosis. For this specific scenario, we proposed that secondary diagnosis codes with a severity designation of MCC be used in the definition of the logic for assignment to the proposed base MS–DRG for cases reporting a cardiac defibrillator implant with cardiac catheterization and a secondary diagnosis designated as an MCC. Therefore, we did not apply the criteria to create further subgroups in a base MS–DRG for cases reporting a cardiac defibrillator implant with cardiac catheterization and a secondary diagnosis designated as an MCC as discussed in section II.C.1.b. of the FY 2024 IPPS/LTCH PPS proposed rule. We stated that we believed the resulting proposed MS–DRG assignment is more clinically homogeneous, coherent and better reflects hospital resource use.

<table>
<thead>
<tr>
<th>Proposed new MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proposed new MS-DRG XXX Cardiac Defibrillator Implant with Cardiac Catheterization and MCC</td>
<td>3,467</td>
<td>10</td>
<td>$61,744</td>
</tr>
</tbody>
</table>

To further compare and analyze the impact of our suggested modifications, we stated we then ran a simulation using the most recent claims data from the December 2022 update of the FY 2022 MedPAR file for cases reporting a cardiac defibrillator implant without additionally reporting both a cardiac catheterization and a secondary diagnosis designated as an MCC. The following table illustrates our findings for all 7,935 cases.

<table>
<thead>
<tr>
<th>Proposed new MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proposed new MS-DRG XXX Cardiac Defibrillator Implant</td>
<td>7,935</td>
<td>6.2</td>
<td>$47,822</td>
</tr>
</tbody>
</table>

We applied the criteria to create subgroups in a base MS–DRG as discussed in section II.C.1.b. of the FY 2024 IPPS/LTCH PPS proposed rule. As shown in the table that follows, a three-way split of the proposed new MS–DRGs failed the criterion that there be at least 500 cases for each subgroup due to low volume. Specifically, for the "without CC/MCC" (NonCC) split, there were only 452 cases in the subgroup. The criterion that there be at least a 20% difference in average costs between the CC and NonCC subgroup also failed to be met.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>With MCC</td>
<td>3,830</td>
<td>8.4</td>
<td>$53,924</td>
</tr>
<tr>
<td>With CC</td>
<td>3,653</td>
<td>4.3</td>
<td>$42,466</td>
</tr>
<tr>
<td>Without CC/MCC</td>
<td>452</td>
<td>3.2</td>
<td>$39,394</td>
</tr>
</tbody>
</table>

We then applied the criteria for a two-way split for the “with MCC” and “without MCC” subgroups for the proposed new MS–DRGs and found that all five criteria were met. The following table illustrates our findings.

<table>
<thead>
<tr>
<th>Proposed new MS-DRGs</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>With MCC</td>
<td>3,830</td>
<td>8.4</td>
<td>$53,924</td>
</tr>
<tr>
<td>Without MCC</td>
<td>4,105</td>
<td>4.2</td>
<td>$42,128</td>
</tr>
</tbody>
</table>
For the proposed new MS–DRGs, there is (1) at least 500 cases in the MCC subgroup and in the without MCC subgroup; (2) at least 5 percent of the cases are in the MCC subgroup and in the without MCC subgroup; (3) at least a 20 percent difference in average costs between the MCC subgroup and the without MCC subgroup; (4) at least a $2,000 difference in average costs between the MCC subgroup and the without MCC subgroup; and (5) at least a 3-percent reduction in cost variance, indicating that the proposed severity level splits increase the explanatory power of the base MS–DRG in capturing differences in expected cost between the proposed MS–DRG severity level splits by at least 3 percent and thus improve the overall accuracy of the IPPS payment system.

In summary, for FY 2024, taking into consideration that it appears to no longer be necessary to subdivide the MS–DRGs for cases reporting a cardiac defibrillator implant based on the diagnosis code reported, we proposed to delete MS–DRGs 222, 223, 224, 225, 226, and 227, and create a new MS–DRG for cases reporting a cardiac defibrillator implant with cardiac catheterization and a secondary diagnosis designated as an MCC in MDC 05. We also proposed to create two new MS–DRGs with a two-way severity level split for cases reporting a cardiac defibrillator implant without additionally reporting both a cardiac catheterization and a secondary diagnosis designated as an MCC. These proposed new MS–DRGs are proposed new MS–DRG 275 (Cardiac Defibrillator Implant with Catheterization and MCC), proposed new MS–DRG 276 (Cardiac Defibrillator Implant with MCC) and proposed new MS–DRG 277 (Cardiac Defibrillator Implant without MCC).

In the proposed rule, we noted that the procedure codes describing cardiac catheterization are designated as non-O.R. procedures, therefore, as part of the logic for MS–DRG 275, we also proposed to designate these codes as non-O.R. procedures affecting the MS–DRG. We referred the reader to Table 6P.7a and Table 6P.7b associated with the proposed rule (which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index) for the list of procedure codes we proposed to define in the logic for each of the proposed new MS–DRGs. We refer the reader to section II.C.15. of the preamble of this final rule for the discussion of the surgical hierarchy and the complete list of our proposed modifications to the surgical hierarchy as well as our finalization of those proposals.

Comment: Most commenters supported the proposal to delete MS–DRGs 222, 223, 224, 225, 226, and 227, and to create three new MS–DRGs in MDC 05. These commenters stated that they agreed with CMS that it is no longer necessary to subdivide the MS–DRGs for cases reporting a cardiac defibrillator implant based on the diagnosis code reported. A few commenters stated that while they found the proposal reasonable based on the data and rationale provided, they urged CMS to monitor for any unintended consequences. However, a commenter opposed the proposal. This commenter stated that the proposed change will have a notable negative impact based on its own analysis of claims data at its organization. The commenter further noted claims at its organization demonstrate significant length of stay and cost variations across the current MS–DRGs which they asserted further supports that revising the MS–DRG is not appropriate from a resource utilization perspective.

Response: We appreciate the commenters’ support and appreciate the additional feedback. With regard to the commenter’s concern that the proposal might have a negative impact based on its own analysis of claims data at its organization, the examination of claims data from the September 2022 update of the FY 2022 MedPAR file for MS–DRGs 222, 223, 224, 225, 226, and 227 showed that in procedures involving a cardiac defibrillator implant, the average costs and length of stay are generally similar without regard to the presence of diagnosis codes describing AMI, HF or shock. We note that the commenter did not provide any clinical rationale as to why the distinction based on the presence of diagnosis codes should be maintained in these MS–DRGs. As noted in prior rulemaking, the goals of reviewing the MS–DRG assignments of particular procedures are to better clinically represent the resources involved in caring for these patients and to enhance the overall accuracy of the system. Our analysis of the claims data demonstrated that for cases involving a cardiac defibrillator implant the increased costs appear to be more related to the procedures performed than to the diagnoses reported on the claim, and we continue to believe it is time to restructure these MS–DRGs accordingly, noting that cases reporting any MDC 05 diagnosis when reported with qualifying procedures will group to the proposed new MS–DRG. CMS will continue to monitor the claims data for these procedures for unintended consequences as a result of the deletion of the six MS–DRGs from the GROUPER logic as we continue our comprehensive analysis in future rulemaking.

Comment: While supporting the proposal, other commenters noted that CMS proposed to create new MS–DRG 275 (Cardiac Defibrillator Implant with Cardiac Catheterization and MCC) for cases reporting a cardiac defibrillator implant with cardiac catheterization and a secondary diagnosis designated as an MCC in MDC 05. These commenters recommended that an additional MS–DRG be created for cardiac defibrillator implant without cardiac catheterization without MCC. A few commenters stated that it was not clear where cases reporting a cardiac defibrillator implant with a cardiac catheterization without MCC would be assigned. A commenter noted that the draft HTML version of the ICD–10 MS–DRG Definitions Manual for Version 41 available on the CMS website does not show “MCC” as part of the logic for MS–DRGs 275 and 276. Another commenter noted that CMS proposed to delay application of the NonCC subgroup criteria to existing MS–DRGs with a three-way severity level split for FY 2024 and questioned CMS’ application of the methodology to the proposed new MS–DRGs.

Response: We thank the commenters for their feedback. We note to commenters that when reviewing consumption of hospital resources for the cases reporting cardiac defibrillator implant with cardiac catheterization during a hospital stay, as discussed earlier in this section, the claims data clearly showed that the cases reporting secondary diagnoses designated as MCCs are more resource intensive as compared to other cases reporting cardiac defibrillator implant. Accordingly, our proposal included the creation of one base MS–DRG for cases reporting a cardiac defibrillator implant with cardiac catheterization and a secondary diagnosis designated as an MCC and another base MS–DRG split by a two-way severity level subgroup for cases reporting a cardiac defibrillator implant without cardiac catheterization.

As discussed in the proposed rule, we examined claims data from the September 2022 update of the FY 2022 MedPAR file for all cases in MS–DRGs 222, 223, 224, 225, 226, and 227. In MS–DRGs 222 and 224, there were 3,094 cases reporting cardiac defibrillator implant with cardiac catheterization, or without a diagnosis of AMI, HF, or Shock, and a secondary diagnosis designated as an MCC with an average length of stay of 10.2 days. In comparison, there were 3,959 cases reporting cardiac
defibrillator implant, with or without cardiac catheterization, with or without a diagnosis of AMI, HF, or Shock, without an MCC with average costs of $42,001 and an average length of stay of 4.2 days in MS–DRG 223, 225 and 227. We did not propose to subdivide the proposed new base MS–DRG 275 for cases reporting a cardiac defibrillator implant with cardiac catheterization and a secondary diagnosis designated as an MCC into severity levels as the cases reporting a cardiac defibrillator implant with cardiac catheterization without a secondary diagnosis designated as an MCC (that are currently assigned to MS–DRGs 223 and 225) have average costs and an average lengths of stay comparable to other cases reporting cardiac defibrillator implant, without cardiac catheterization, with or without a diagnosis of AMI, HF, or Shock, also without a secondary diagnosis designated as an MCC. Instead, for this specific scenario, we proposed that secondary diagnosis codes with a severity designation of MCC be used in the definition of the logic for assignment to the proposed base MS–DRG for cases reporting a cardiac defibrillator implant with cardiac catheterization and a secondary diagnosis designated as an MCC. We continue to believe the resulting proposed MS–DRG assignment is more clinically homogeneous, coherent and better reflects hospital resource use.

In response to commenters who stated that it was not clear where cases reporting a cardiac defibrillator implant with a cardiac catheterization without a secondary diagnosis designated as an MCC would be assigned, we note that these cases would be assigned to proposed new MS–DRG 277 (Cardiac Defibrillator Implant without MCC), as reflected in the test version of the ICD–10 MS–DRG GROUPER Software, Version 41.

In response to the comment regarding the draft version of the ICD–10 MS–DRG Definitions Manual, Version 41, available at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software, we agree there was an inadvertent error in the logic table for MS–DRGs 275, 276 and 277. We are correcting the display as reflected in the following logic table:

<table>
<thead>
<tr>
<th>Cardiac Catheterization</th>
<th>MCC</th>
<th>MS-DRG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>275</td>
</tr>
<tr>
<td>No</td>
<td>Yes</td>
<td>276</td>
</tr>
<tr>
<td>No</td>
<td>No</td>
<td>277</td>
</tr>
</tbody>
</table>

This correction will also be reflected in the final ICD–10 MS–DRG Definitions Manual, Version 41.

In response to the concern regarding the application of the NonCC subgroup criteria to the proposed new MS–DRGs, we note that in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58448), we finalized our proposal to expand our existing criteria to create a new complication or comorbidity (CC) or major complication or comorbidity (MCC) subgroup within a base MS–DRG. Specifically, we finalized the expansion of the criteria to include the NonCC subgroup for a three-way severity level split. In the FY 2022 IPPS/LTCH PPS final rule (86 FR 44798) and FY 2023 IPPS/LTCH PPS final rule (87 FR 48803), we finalized a delay in applying this technical criterion to existing MS–DRGs in light of the PHE. We note that this delay relates to applying this technical criterion to existing MS–DRGs with a three-way severity level split. As discussed in prior rulemaking, in general, once the decision has been made to propose to make further modifications to the MS–DRGs, such as creating a new base MS–DRG, all five criteria must be met for the base MS–DRG to be split (or subdivided) by a CC subgroup. We note that we have applied the criteria to create subgroups, including application of the NonCC subgroup criteria, in our annual analysis of the MS–DRG classification requests effective FY 2021 (85 FR 58446 through 58448). For example, we applied the criteria to create subgroups, including application of the NonCC subgroup criteria, for a proposed new base MS–DRG as discussed in our finalization of new base MS–DRG 018 (Chimeric Antigen Receptor (CAR) T-cell Immunotherapy), new base MS–DRG 019 (Simultaneous Pancreas and Kidney Transplant with Hemodialysis), new base MS–DRG 140 (Major Head and Neck Procedures), new base MS–DRG 143 (Other Ear, Nose, Mouth and Throat O.R. Procedures), new base MS–DRG 521 (Hip Replacement with Principal Diagnosis of Hip Fracture), and new base MS–DRG 650 (Kidney Transplant with Hemodialysis) for FY 2021.

Similarly, we applied the criteria to create subgroups including application of the NonCC subgroup criteria for MS–DRG classification requests for FY 2022 that we received by November 1, 2020 (86 FR 44796 through 44798), for MS–DRG classification requests for FY 2023 (87 FR 48801 through 48804) that we received by November 1, 2021, and for MS–DRG classification requests for FY 2024 that we received by October 20, 2022 (88 FR 26673 through 26676), as well as any additional analyses that were conducted in connection with those requests. We refer the reader to section II.C.1.b. of the preamble of this final rule for related discussion regarding our finalization of the expansion of the criteria to include the NonCC subgroup in the FY 2021 final rule and our finalization of the proposal to continue to delay application of the NonCC subgroup criteria to existing MS–DRGs with a three-way severity level split for FY 2024.

Comment: A commenter stated that while they agreed that it appears to no longer be necessary to subdivide the MS–DRGs for cases reporting a cardiac defibrillator implant based on the diagnosis code reported, they did not think it was necessary to delete MS–DRGs 226 and 227 (Cardiac Defibrillator Implant without Cardiac Catheterization with and without MCC, respectively) and create new MS–DRGs 275 and 277 (Cardiac Defibrillator Implant with and without MCC, respectively). This commenter stated that the proposed new MS–DRG 276 has the same GROUPER logic as the existing MS–DRG 226 and therefore will capture the same cases. This commenter further stated they believed that the current title of MS–DRG 226 better identifies the cases assigned. This commenter also suggested keeping existing MS–DRG 227 and revising the title to “Cardiac Defibrillator Implant with or without Cardiac Catheterization without MCC” instead of creating new MS–DRG 277.

Response: We appreciate the commenter’s feedback. The commenter is correct that proposed new MS–DRG 276 has the same GROUPER logic as current MS–DRG 226. In response to the
commenter’s concern regarding why new MS–DRG numbers would be considered, as discussed in prior rulemaking (87 FR 48804), we note that new MS–DRG numbers are preferred because we anticipate that individuals, payers, and organizations conducting analysis would need to be aware if proposed changes to base DRG concepts are made to allow them time to adjust their programs, analyses, or queries that may have hard coded the DRG numbers. To minimize confusion for those who rely on MS–DRG concepts year to year and to avoid unintended consequences from maintaining the existing MS–DRG number, we believe it is appropriate to finalize the revision to both the MS–DRG number and corresponding description for cases reporting a cardiac defibrillator implant without cardiac catheterization with a secondary diagnosis designated as an MCC.

Therefore, after consideration of the public comments received, and for the reasons previously stated, we are finalizing our proposal to delete MS–DRGs 222, 223, 224, 225, 226, and 227. We are also finalizing our proposal to create new MS–DRG 275 (Cardiac Defibrillator Implant with Cardiac Catheterization and MCC), new MS–DRG 276 (Cardiac Defibrillator Implant with MCC), and new MS–DRG 277 (Cardiac Defibrillator Implant without MCC) in MDC 05, without modification, effective October 1, 2023, for FY 2024. Accordingly, we are also finalizing our proposal to designate the procedure codes describing cardiac catheterization as non-O.R. procedures affecting the MS–DRG.

Comment: Another commenter stated that a code proposal requesting new procedure codes to describe the implantation, removal and revision of extravascular implantable defibrillator (EV ICD) leads was presented and discussed at the March 7–8, 2023 ICD–10 Coordination and Maintenance Committee meeting. The commenter further stated that CMS has proposed to create new MS–DRGs 275, 276, and 277 for cases reporting cardiac defibrillator implant procedures, which includes procedures describing the insertion of implantable cardioverter-defibrillators (ICDs) for FY 2024, while cases reporting cardiac defibrillator lead removal and revision procedures are assigned to MS–DRG 265 (AICD Lead Procedures). This commenter suggested that any new procedure codes finalized after the March 7–8, 2023 ICD–10 Coordination and Maintenance Committee meeting that describe EV ICD procedures should be assigned to MS–DRG 265 and MS–DRGs 275–277 as well and stated that alignment of these new ICD–10–PCS codes with existing defibrillator procedure codes in terms of MS–DRG assignment will ensure clinical coherence and facilitate patient access and provider choice among ICD technologies.

Response: We thank the commenter for their feedback. We note that the proposal requesting new procedure codes to identify procedures involving extravascular implantable defibrillator leads that was discussed at the March 7–8, 2023 ICD–10 Coordination and Maintenance Committee meeting was approved and 11 new procedure codes to identify procedures involving EV ICD leads were finalized as reflected in the FY 2024 ICD–10–PCS Code Update files that were made publicly available on the CMS website at https://www.cms.gov/Medicare/Coding/ICD10AcuteInpatientPPS, including the MS–DRG assignments for these new codes for FY 2024. We refer the reader to section II.C.13. of the preamble of this final rule for further information regarding the table.

As we have noted in prior rulemaking (86 FR 44805), we used our established process to determine the most appropriate MS–DRG assignment for the new procedure codes approved after March 7–8, 2023 ICD–10 Coordination and Maintenance Committee meeting to identify procedures involving EV ICD leads. Specifically, we reviewed the predecessor codes and MS–DRG assignments most closely associated with the new procedure codes, and in the absence of claims data, we considered other factors that may be relevant to the MS–DRG assignment, including the severity of illness, treatment difficulty, complexity of service and the resources utilized in the diagnosis and/or treatment of the condition. The MS–DRG assignments for the predecessor codes that we utilized to inform this analysis and the new procedure codes to identify procedures involving extravascular implantable defibrillator leads under MDC 05 are identified as follows.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0WHC0GZ</td>
<td>Insertion of Defibrillator Lead into Mediastinum, Open Approach</td>
<td>Y</td>
<td>02HN0KZ</td>
<td>Insertion of defibrillator lead into pericardium, open approach</td>
<td>265 (AICD Lead Procedures)</td>
</tr>
<tr>
<td>0WHC3GZ</td>
<td>Insertion of Defibrillator Lead into Mediastinum, Percutaneous Approach</td>
<td>Y</td>
<td>02HN3KZ</td>
<td>Insertion of defibrillator lead into pericardium, percutaneous approach</td>
<td>265 (AICD Lead Procedures)</td>
</tr>
<tr>
<td>0WHC4GZ</td>
<td>Insertion of Defibrillator Lead into Mediastinum, Percutaneous Endoscopic Approach</td>
<td>Y</td>
<td>02HN4KZ</td>
<td>Insertion of defibrillator lead into pericardium, percutaneous endoscopic approach</td>
<td>265 (AICD Lead Procedures)</td>
</tr>
<tr>
<td>0WPC0GZ</td>
<td>Removal of Defibrillator Lead from Mediastinum, Open Approach</td>
<td>Y</td>
<td>0JPT0FZ</td>
<td>Removal of subcutaneous defibrillator lead from trunk subcutaneous tissue and fascia, open approach</td>
<td>265 (AICD Lead Procedures)</td>
</tr>
<tr>
<td>0WPC3GZ</td>
<td>Removal of Defibrillator Lead from Mediastinum, Percutaneous Approach</td>
<td>Y</td>
<td>0JPT3FZ</td>
<td>Removal of subcutaneous defibrillator lead from trunk subcutaneous tissue and fascia, percutaneous approach</td>
<td>265 (AICD Lead Procedures)</td>
</tr>
<tr>
<td>0WPC4GZ</td>
<td>Removal of Defibrillator Lead from Mediastinum, Percutaneous Endoscopic Approach</td>
<td>Y</td>
<td>0JPT0FZ</td>
<td>Removal of subcutaneous defibrillator lead from trunk subcutaneous tissue and fascia, open approach</td>
<td>265 (AICD Lead Procedures)</td>
</tr>
<tr>
<td>0WPCXGZ</td>
<td>Removal of Defibrillator Lead from Mediastinum, External Approach</td>
<td>N</td>
<td>0WPCXYZ</td>
<td>Removal of other device from mediastinum, external approach</td>
<td></td>
</tr>
<tr>
<td>0WWC0GZ</td>
<td>Revision of Defibrillator Lead in Mediastinum, Open Approach</td>
<td>Y</td>
<td>0JWT0FZ</td>
<td>Revision of subcutaneous defibrillator lead in trunk subcutaneous tissue and fascia, open approach</td>
<td>265 (AICD Lead Procedures)</td>
</tr>
<tr>
<td>0WWC3GZ</td>
<td>Revision of Defibrillator Lead in Mediastinum, Percutaneous Approach</td>
<td>Y</td>
<td>0JWT3FZ</td>
<td>Revision of subcutaneous defibrillator lead in trunk subcutaneous tissue and fascia, percutaneous approach</td>
<td>265 (AICD Lead Procedures)</td>
</tr>
<tr>
<td>0WWC4GZ</td>
<td>Revision of Defibrillator Lead in Mediastinum, Percutaneous Endoscopic Approach</td>
<td>Y</td>
<td>0JWT0FZ</td>
<td>Revision of subcutaneous defibrillator lead in trunk subcutaneous tissue and fascia, open approach</td>
<td>265 (AICD Lead Procedures)</td>
</tr>
<tr>
<td>0WWCXGZ</td>
<td>Revision of Defibrillator Lead in Mediastinum, External Approach</td>
<td>N</td>
<td>0WWCXYZ</td>
<td>Revision of other device in mediastinum, external approach</td>
<td></td>
</tr>
</tbody>
</table>

While the new procedure codes are being assigned to the same MS–DRG as the predecessor codes in this instance, as we have noted in prior rulemaking, and earlier in this section, this process does not automatically result in the new procedure code being assigned to the same MS–DRG or to have the same designation (O.R. versus Non-O.R.) as the predecessor code.

In addition to the MDC and MS–DRG assignments as reflected in Table 6B.—
New Procedure Codes, in association with this final rule, we note that the procedure code combinations describing the insertion of an EV ICD lead with the insertion of a defibrillator generator, are assigned to new MS–DRGs 275, 276, and 277 for FY 2024. This assignment is reflected in the final V41 GROUPER logic. The public may provide feedback on the MS–DRG assignments for FY 2024, which will then be taken into consideration for the following fiscal year.

6. MDC 06 (Diseases and Disorders of the Digestive System): Appendicitis

In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28163 through 87 FR 28165) and final rule (87 FR 48849 through 87 FR 48850), we discussed a request related to the MS–DRG assignment of diagnosis codes describing acute appendicitis with generalized peritonitis, with and without perforation or abscess when reported with an appendectomy procedure. In that discussion, we stated that any future proposed changes to the MS–DRGs for appendectomy procedures would be dependent on the diagnosis code revisions that are finalized by the CDC/National Center for Health Statistics (NCHS) since the CDC/NCHS staff presented a proposal for further revisions to the diagnosis codes describing acute appendicitis with generalized peritonitis at the March 8–9, 2022 ICD–10 Coordination and Maintenance Committee meeting. Specifically, the CDC/NCHS staff proposed to expand diagnosis codes K35.20 (Acute appendicitis with generalized peritonitis, without abscess) and K35.21 (Acute appendicitis with generalized peritonitis, with abscess), making them sub-categories and creating new diagnosis codes to identify and describe acute appendicitis with generalized peritonitis, with perforation and without perforation, and unspecified as to perforation. We noted that the deadline for submitting public comments on the diagnosis code proposals discussed at the March 8–9, 2022 ICD–10 Coordination and Maintenance Committee meeting was May 9, 2022, and according to the CDC/NCHS staff, the diagnosis code proposals were being considered for an October 1, 2023, implementation (FY 2024). We refer the reader to the CDC website at https://www.cdc.gov/nchs/ icd/icd10cm_maintenance.htm for additional detailed information regarding the proposal, including a recording of the discussion and the related meeting materials.

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26717), we stated that, as shown in Appendix B—Diagnosis Code/MDC/MS–DRG Index of the ICD–10 MS–DRG Definitions Manual V40.1 (available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software), diagnosis codes K35.20 and K35.21 are currently assigned to medical MS–DRGs 371, 372, and 373 (Major Gastrointestinal Disorders and Peritoneal Infections with MCC, with CC, and without CC/MCC, respectively) in MDC 06. Diagnosis code K35.21 is also assigned to surgical MS–DRGs 338, 339, and 340 (Appendectomy with Complicated Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively) in MDC 06 because diagnosis code K35.21 is defined as a complicated diagnosis in the GROUPEPER logic. Therefore, when a procedure code describing an appendectomy is reported with principal diagnosis code K35.21, the logic for case assignment to MS–DRGs 338, 339, or 340 is satisfied.

As discussed in section II.C.13. of the preamble of the proposed rule, Table 6C—Invalid Diagnosis Codes (available on the CMS website at: https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps) lists the diagnosis codes that are no longer effective starting October 1, 2023. Included in this table are diagnosis codes K35.20 and K35.21. In addition, we noted that as shown in the following table and in Table 6A—New Diagnosis Codes associated with the proposed rule (and available on the CMS website at: https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps), six new diagnosis codes describing acute appendicitis with generalized peritonitis, with and without perforation or abscess were finalized and are effective with discharges on and after October 1, 2023. We stated in the proposed rule that consistent with our established process for assigning new diagnosis and procedure codes, we reviewed the predecessor codes (K35.20 and K35.21) to determine the MS–DRG assignment most closely associated with the new diagnosis codes. In addition, we noted that the proposed severity level designations for the new diagnosis codes are set forth in Table 6A. As shown, the new codes are proposed for assignment to medical MS–DRGs 371, 372, and 373 (Major Gastrointestinal Disorders and Peritoneal Infections with MCC, with CC, and without CC/MCC, respectively), in accordance with the assignment of predecessor codes K35.20 and K35.21.

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
<th>Proposed MS-DRGs</th>
</tr>
</thead>
<tbody>
<tr>
<td>K35.200</td>
<td>Acute appendicitis with generalized peritonitis, without perforation or abscess</td>
<td>371, 372, 373</td>
</tr>
<tr>
<td>K35.201</td>
<td>Acute appendicitis with generalized peritonitis, with perforation, without abscess</td>
<td>371, 372, 373</td>
</tr>
<tr>
<td>K35.209</td>
<td>Acute appendicitis with generalized peritonitis, without abscess, unspecified as to perforation</td>
<td>371, 372, 373</td>
</tr>
<tr>
<td>K35.210</td>
<td>Acute appendicitis with generalized peritonitis, without perforation, with abscess</td>
<td>371, 372, 373</td>
</tr>
<tr>
<td>K35.211</td>
<td>Acute appendicitis with generalized peritonitis, with perforation and abscess</td>
<td>371, 372, 373</td>
</tr>
<tr>
<td>K35.219</td>
<td>Acute appendicitis with generalized peritonitis, with abscess, unspecified as to perforation</td>
<td>371, 372, 373</td>
</tr>
</tbody>
</table>

We stated in the proposed rule that because the acute appendicitis diagnosis code revisions have been finalized by the CDC/NCHS, we believed it is now appropriate to address the MS–DRG request for diagnosis code K35.20 describing acute appendicitis with generalized peritonitis when an appendectomy procedure is performed. We referred the reader to the ICD–10 MS–DRG Definitions Manual Version 40.1, which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software for complete documentation of the GROUPER logic for MS–DRGs 338, 339, and 340 (Appendectomy with Complicated Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively) and MS–DRGs 341, 342, and 343 (Appendectomy without Complicated Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively) that includes the procedure codes defined in the logic for an appendectomy.

As stated in the proposed rule, we first analyzed claims data from the September 2022 update of the FY 2022 MedPAR file for MS–DRGs 338, 339, and 340 and cases reporting any one of
the following diagnosis codes currently defined in the logic as a complicated principal diagnosis when reported as a principal diagnosis.

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C18.1</td>
<td>Malignant neoplasm of appendix</td>
</tr>
<tr>
<td>C7A.020</td>
<td>Malignant carcinoid tumor of the appendix</td>
</tr>
<tr>
<td>K35.21</td>
<td>Acute appendicitis with generalized peritonitis, with abscess</td>
</tr>
<tr>
<td>K35.32</td>
<td>Acute appendicitis with perforation and localized peritonitis, without abscess</td>
</tr>
<tr>
<td>K35.33</td>
<td>Acute appendicitis with perforation and localized peritonitis, with abscess</td>
</tr>
</tbody>
</table>

Our findings are shown in the following table. We note that if a diagnosis is not listed it is because there were no cases found.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>ICD-10-CM Code</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>338</td>
<td>All Cases</td>
<td>579</td>
<td>7</td>
<td>$20,311</td>
</tr>
<tr>
<td></td>
<td>C18.1</td>
<td>30</td>
<td>6.7</td>
<td>$20,285</td>
</tr>
<tr>
<td></td>
<td>C7A.020</td>
<td>1</td>
<td>3</td>
<td>$20,984</td>
</tr>
<tr>
<td></td>
<td>K35.21</td>
<td>20</td>
<td>8.5</td>
<td>$23,290</td>
</tr>
<tr>
<td></td>
<td>K35.32</td>
<td>294</td>
<td>6.4</td>
<td>$19,743</td>
</tr>
<tr>
<td></td>
<td>K35.33</td>
<td>234</td>
<td>7.7</td>
<td>$20,772</td>
</tr>
<tr>
<td>339</td>
<td>All Cases</td>
<td>2,018</td>
<td>4.7</td>
<td>$14,068</td>
</tr>
<tr>
<td></td>
<td>C18.1</td>
<td>35</td>
<td>4</td>
<td>$13,855</td>
</tr>
<tr>
<td></td>
<td>K35.21</td>
<td>47</td>
<td>6.4</td>
<td>$14,857</td>
</tr>
<tr>
<td></td>
<td>K35.32</td>
<td>1,105</td>
<td>4.4</td>
<td>$13,370</td>
</tr>
<tr>
<td></td>
<td>K35.33</td>
<td>831</td>
<td>5.1</td>
<td>$14,960</td>
</tr>
<tr>
<td>340</td>
<td>All Cases</td>
<td>1,437</td>
<td>2.7</td>
<td>$9,988</td>
</tr>
<tr>
<td></td>
<td>C18.1</td>
<td>8</td>
<td>1.4</td>
<td>$11,529</td>
</tr>
<tr>
<td></td>
<td>K35.21</td>
<td>26</td>
<td>4.1</td>
<td>$10,187</td>
</tr>
<tr>
<td></td>
<td>K35.32</td>
<td>815</td>
<td>2.5</td>
<td>$9,670</td>
</tr>
<tr>
<td></td>
<td>K35.33</td>
<td>588</td>
<td>2.9</td>
<td>$10,399</td>
</tr>
</tbody>
</table>

The data shows that overall, each of the “complicated” diagnoses appears to have a comparable average length of stay and similar average costs when compared to the average length of stay and average costs of all the cases in the respective MS–DRG, as well as, to each other.

Next, we analyzed claims data from the September 2022 update of the FY 2022 MedPAR file for MS–DRGs 341, 342, and 343 and cases reporting any one of the following diagnosis codes describing acute appendicitis.
Our findings are shown in the following table.

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>K35.20</td>
<td>Acute appendicitis with generalized peritonitis, without abscess</td>
</tr>
<tr>
<td>K35.30</td>
<td>Acute appendicitis with localized peritonitis, without perforation or gangrene</td>
</tr>
<tr>
<td>K35.31</td>
<td>Acute appendicitis with localized peritonitis and gangrene, without perforation</td>
</tr>
<tr>
<td>K35.80</td>
<td>Unspecified acute appendicitis</td>
</tr>
<tr>
<td>K35.890</td>
<td>Other acute appendicitis without perforation or gangrene</td>
</tr>
<tr>
<td>K35.891</td>
<td>Other acute appendicitis without perforation, with gangrene</td>
</tr>
</tbody>
</table>

Similar to the findings for the “complicated” diagnoses, the “uncomplicated” diagnoses also have a comparable average length of stay and similar average costs when compared to the average length of stay and average costs of all the cases in the respective MS–DRG.

We stated in the proposed rule that based on our analysis for both the “complicated” and “uncomplicated” diagnoses combined with our review of all the cases in the MS–DRGs, we believed the findings support a prior comment, as summarized in the FY 2023 IPPS/LTCH PPS final rule (87 FR 48849), that clinically, both localized and generalized peritonitis in association with an appendectomy require the same level of patient care, including extensive intraoperative irrigation at the surgical site, direct inspection or imaging of the abdomen to identify possible abscess, use of intravenous antibiotics, and prolonged monitoring. In addition, localized peritonitis progresses to generalized peritonitis. In our direct comparison of the “complicated” versus “uncomplicated” MS–DRGs, we believe the distinction is no longer meaningful with regard to resource consumption. As shown in the following table, we
found the “with MCC” MS–DRGs, the “with CC” MS–DRGs, and the “without CC/MCC” MS–DRGs all have a comparable average length of stay and similar average costs. For example, MS–DRG 338 has an average length of stay of 7 days with average costs of $20,311 and MS–DRG 341 has an average length of stay of 5.8 days and average costs of $19,080. The volume of cases for this MS–DRG pair is also similar with 579 cases in MS–DRG 338 and 533 cases in MS–DRG 341.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Description</th>
<th>Number of cases</th>
<th>Average Length of Stay</th>
<th>Average costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>338</td>
<td>Appendectomy with Complicated Principal Diagnosis with MCC</td>
<td>579</td>
<td>7</td>
<td>$20,311</td>
</tr>
<tr>
<td>339</td>
<td>Appendectomy with Complicated Principal Diagnosis with CC</td>
<td>2,018</td>
<td>4.7</td>
<td>$14,068</td>
</tr>
<tr>
<td>340</td>
<td>Appendectomy with Complicated Principal Diagnosis without CC/ MCC</td>
<td>1,437</td>
<td>2.7</td>
<td>$9,988</td>
</tr>
<tr>
<td>341</td>
<td>Appendectomy without Complicated Principal Diagnosis with MCC</td>
<td>533</td>
<td>5.8</td>
<td>$19,080</td>
</tr>
<tr>
<td>342</td>
<td>Appendectomy without Complicated Principal Diagnosis with CC</td>
<td>1,581</td>
<td>3.2</td>
<td>$12,309</td>
</tr>
<tr>
<td>343</td>
<td>Appendectomy without Complicated Principal Diagnosis without CC/ MCC</td>
<td>1,482</td>
<td>1.9</td>
<td>$9,596</td>
</tr>
</tbody>
</table>

As a result of our analysis and review of this issue, we stated in the proposed rule that we believed the findings support eliminating the logic for “complicated” and “uncomplicated” diagnoses and restructuring the six MS–DRGs. We also noted that in our review of the logic for the appendectomy procedures, we identified procedures listed in the current logic that we did not agree reflect an actual appendectomy as suggested in the title of the current MS–DRGs, rather the logic describes various procedures performed on the appendix.

To compare and analyze the impact of our suggested modifications, we ran a simulation using the most recent claims data from the December 2022 update of the FY 2022 MedPAR file. The following table illustrates our findings for all 8,060 cases reporting procedure codes describing a procedure performed on the appendix.

<table>
<thead>
<tr>
<th>Proposed new MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proposed new MS-DRG XXX</td>
<td>8,060</td>
<td>3.7</td>
<td>$12,838</td>
</tr>
</tbody>
</table>

Consistent with our established process as discussed in section II.C.1.b. of the preamble of the proposed rule, once the decision has been made to propose to make further modifications to the MS–DRGs, all five criteria to create subgroups must be met for the base MS–DRG to be split (or subdivided) by a CC subgroup. Therefore, we applied the criteria to create subgroups in a base MS–DRG. We noted that, as shown in the table that follows, a three-way split of this proposed new base MS–DRG was met. The following table illustrates our findings.

<table>
<thead>
<tr>
<th>Proposed new MS-DRGs</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>With MCC</td>
<td>1,186</td>
<td>6.4</td>
<td>$19,584</td>
</tr>
<tr>
<td>With CC</td>
<td>3,813</td>
<td>4.0</td>
<td>$13,223</td>
</tr>
<tr>
<td>Without CC/MCC</td>
<td>3,061</td>
<td>2.3</td>
<td>$9,745</td>
</tr>
</tbody>
</table>

For the proposed new MS–DRGs, there is (1) at least 500 cases in the MCC subgroup, the CC subgroup, and the without CC/MCC subgroup; (2) at least 5 percent of the cases are in the MCC subgroup, the CC subgroup, and the without CC/MCC subgroup; (3) at least a 20 percent difference in average costs between the MCC subgroup and the CC subgroup and between the CC group and NonCC subgroup; (4) at least a $2,000 difference in average costs between the MCC subgroup and the CC subgroup and between the CC subgroup and NonCC subgroup; and (5) at least a 3-percent reduction in cost variance, indicating that the proposed severity level splits increase the explanatory
power of the base MS–DRG in capturing differences in expected cost between the proposed MS–DRG severity level splits by at least 3 percent and thus improve the overall accuracy of the IPPS payment system.

Therefore, we proposed to delete MS–DRGs 338, 339, 340, 341, 342, and 343 and proposed to create new MS–DRG 397 Appendix Procedures with MCC, MS–DRG 398 Appendix Procedures with CC, and MS–DRG 399 Appendix Procedures without CC/MCC for FY 2024. These proposed new MS–DRGs would no longer require a diagnosis in the definition of the logic for case assignment. We also proposed to include the current list of appendectomy procedures in the logic for case assignment of appendix procedures for the proposed new MS–DRGs.

Comment: Several commenters expressed support for the proposed changes to the MS–DRGs for appendectomy with and without a complicated principal diagnosis. A commenter who agreed with CMS that the average length of stay and average costs were comparable among the appendectomy MS–DRGs with and without a complicated principal diagnosis stated that the data for diagnosis code K35.21 (Acute appendicitis with generalized peritonitis, with abscess) specifically reflected a longer length of stay and higher average costs among all the MS–DRGs for appendectomy with complicated principal diagnosis (MS–DRGs 338, 339, and 340). The commenter requested that CMS continue to monitor this diagnosis code.

Response: We appreciate the commenters’ support and feedback. CMS will continue to monitor and analyze the claims data for diagnosis code K35.21.

Comment: A commenter expressed concerns about the proposed new MS–DRGs 397, 398, and 399 no longer reflecting the differences in complexity and costs associated with treating appendicitis, including concerns about the potential decrease in case weight. The commenter stated that some operations on patients with complicated appendicitis should group to a complicated diagnosis, as a result, these patients may have up to 30% of patients with complicated appendicitis and that the treatment of appendicitis with a complicated principal diagnosis utilizes substantially more resources. This commenter also stated specifically, that patients with more complicated disease frequently have perforated disease which contaminates the peritoneal cavity and wounds. According to the commenter, as a result, these patients face significantly higher risk of surgical site infections and require longer hospitalizations in order to receive longer duration IV antibiotics. Finally, the commenter stated that operations on complex patients take much longer and suggested there is little parity with regard to these populations between major referral centers and smaller centers of care.

Another commenter stated their belief that CMS failed to recognize clinical best practice for treatment of patients with complicated disease including perforation. The commenter stated that the proposed MS–DRG changes demonstrated a lack of understanding about the complexities of appendectomy procedures and urged CMS to maintain the existing MS–DRGs and reassign code K35.20 to MS–DRGs 338, 339, and 340, due to the risk of postoperative abscess formation and extended length of hospital stay, thereby warranting classification as a complicated diagnosis.

Another commenter who disagreed with CMS’ proposal agreed that clinically, both localized and generalized peritonitis in association with an appendectomy requires increased levels of care, inclusive of extensive intraoperative irrigation at the surgical site, direct inspection or imaging of the abdomen, use of antibiotics and prolonged monitoring, however, the commenter stated that localized and general peritonitis are complicated appendicitis diagnoses and are clinically different than uncomplicated appendicitis diagnoses.

Comment: Several commenters expressed support for the proposed new MS–DRGs 338, 339, 340, 341, 342, and 343 and proposed to create new MS–DRG 397 Appendix Procedures with MCC, MS–DRG 398 Appendix Procedures with CC, and MS–DRG 399 Appendix Procedures without CC/MCC for FY 2024. These proposed new MS–DRGs would no longer require a diagnosis in the definition of the logic for case assignment. We also proposed to include the current list of appendectomy procedures in the logic for case assignment of appendix procedures for the proposed new MS–DRGs.

Comment: Several commenters expressed support for the proposed changes to the MS–DRGs for appendectomy with and without a complicated principal diagnosis. A commenter who agreed with CMS that the average length of stay and average costs were comparable among the appendectomy MS–DRGs with and without a complicated principal diagnosis stated that the data for diagnosis code K35.21 (Acute appendicitis with generalized peritonitis, with abscess) specifically reflected a longer length of stay and higher average costs among all the MS–DRGs for appendectomy with complicated principal diagnosis (MS–DRGs 338, 339, and 340). The commenter requested that CMS continue to monitor this diagnosis code.

Response: We appreciate the commenters’ support and feedback. CMS will continue to monitor and analyze the claims data for diagnosis code K35.21.

Comment: A commenter expressed concerns about the proposed new MS–DRGs 397, 398, and 399 no longer reflecting the differences in complexity and costs associated with treating appendicitis, including concerns about the potential decrease in case weight. The commenter stated that some operations on patients with complicated appendicitis should group to a complicated diagnosis, as a result, these patients may have up to 30% of patients with complicated appendicitis and that the treatment of appendicitis with a complicated principal diagnosis utilizes substantially more resources. This commenter also stated specifically, that patients with more complicated disease frequently have perforated disease which contaminates the peritoneal cavity and wounds. According to the commenter, as a result, these patients face significantly higher risk of surgical site infections and require longer hospitalizations in order to receive longer duration IV antibiotics. Finally, the commenter stated that operations on complex patients take much longer and suggested there is little parity with regard to these populations between major referral centers and smaller centers of care.

Another commenter stated their belief that CMS failed to recognize clinical best practice for treatment of patients with complicated disease including perforation. The commenter stated that the proposed MS–DRG changes demonstrated a lack of understanding about the complexities of appendectomy procedures and urged CMS to maintain the existing MS–DRGs and reassign code K35.20 to MS–DRGs 338, 339, and 340, due to the risk of postoperative abscess formation and extended length of hospital stay, thereby warranting classification as a complicated diagnosis.

Another commenter who disagreed with CMS’ proposal agreed that clinically, both localized and generalized peritonitis in association with an appendectomy requires increased levels of care, inclusive of extensive intraoperative irrigation at the surgical site, direct inspection or imaging of the abdomen, use of antibiotics and prolonged monitoring, however, the commenter stated that localized and general peritonitis are complicated appendicitis diagnoses and are clinically different than uncomplicated appendicitis diagnoses.

Response: We thank the commenters for their feedback. In response to the commenter who expressed concerns about the potential decrease in case weight for the proposed new MS–DRGs, we note that the relative weights (RW) and geometric mean length of stay (GMLOS) for existing MS–DRGs 338, 339, 340, 341, 342, and 343 have been trending downward over the past few years as shown in the following table.
In association with the proposed rule, we made available the proposed FY 2024 relative weights and GMLOS for proposed new MS–DRGs 397, 398, and 399 as reflected in Table 5—List of Medicare Severity Diagnosis-Related Groups (MS–DRGs), Relative Weighting Factors, and Geometric and Arithmetic Mean Length of Stay—FY 2024 Proposed Rule available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS.

<table>
<thead>
<tr>
<th>Proposed new MS-DRGs</th>
<th>Proposed Relative Weight</th>
<th>Proposed GMLOS</th>
</tr>
</thead>
<tbody>
<tr>
<td>397 - Appendix Procedures with MCC</td>
<td>2.2479</td>
<td>4.7</td>
</tr>
<tr>
<td>398 - Appendix Procedures with CC</td>
<td>1.5111</td>
<td>3.1</td>
</tr>
<tr>
<td>399 - Appendix Procedures without CC/MCC</td>
<td>1.1126</td>
<td>1.9</td>
</tr>
</tbody>
</table>

We believe the proposed relative weight and GMLOS for the proposed new MS–DRGs appear to be appropriately driven by the underlying data.

While we recognize the commenter’s statement that tertiary care centers may provide treatment for up to 30% of patients with complicated appendicitis, we note that we do not propose MS–DRG modifications based on provider type. We also do not agree with the commenter’s statement that complicated appendicitis utilizes substantially more resources since, as discussed in the proposed rule, our findings reflect that cases in the complicated appendectomy MS–DRGs are comparable to cases in the uncomplicated MS–DRGs with regard to volume, average length of stay, and average costs.

In response to the commenter who indicated that CMS failed to recognize clinical best practice for treatment of patients with complicated disease including perforation, we note that our proposed MS–DRG classification changes are not a reflection of, nor intended to define, how providers render care for patients diagnosed with acute appendicitis, rather, our proposals are based on a combination of data analysis and clinical judgement. With respect to the commenter’s request that CMS reassign diagnosis code K35.20 (Acute appendicitis with generalized peritonitis, without abscess), we note that, as discussed in the preamble of the proposed rule and this final rule, diagnosis code K35.20 has been expanded and is no longer valid effective October 1, 2023, as reflected in Table 6C.—Invalid Diagnosis Codes.

In response to the commenter who disagreed with CMS’ proposal but agreed that clinically, both localized and generalized peritonitis in association with an appendectomy are complicated appendicitis diagnoses and should group to a complicated appendicitis MS–DRG, we note that our proposal reflects that both localized and generalized peritonitis in association with an appendectomy are comparable, clinically coherent diagnoses and should be grouped together. The MS–DRGs are a classification system intended to group together those diagnoses and procedures with similar...
clinical characteristics and utilization of resources. Our proposal also essentially reflects the commenter’s suggestion to group the four diagnoses (K35.20, K35.30, K35.31, and K35.891) that are currently assigned to the appendectomy without complicated principal diagnosis MS–DRGs (MS–DRGs 341, 342, and 342) together with the diagnoses that are currently assigned to the appendectomy with complicated principal diagnosis MS–DRGs (MS–DRGs 338, 338, and 340). Additionally, as previously discussed, we believe our data findings and clinical review no longer support the distinction of complicated versus uncomplicated MS–DRGs with respect to resource utilization for acute appendicitis and therefore, disagree with the commenter’s suggestion to retain the existing MS–DRGs and to only reflect diagnosis codes K35.80, K35.890, and K36 in an uncomplicated MS–DRG. We note that diagnosis code K36 (Other appendicitis) is currently assigned to MS–DRGs 393, 394, and 395 (Other Digestive System Diagnoses with MCC, with CC, and without CC/MCC, respectively), and was not specifically included or addressed in our analysis, nor our proposal.

After consideration of the public comments we received, and for the reasons discussed, we are finalizing our proposal to delete MS–DRGs 338, 339, 340, 341, 342, and 343 and to create MS–DRGs 397, 398, and 399 (Appendix Procedures with MCC, with CC, and without CC/MCC, respectively), without modification, for FY 2024. These finalized new MS–DRGs no longer require a diagnosis in the definition of the logic for case assignment. We are also finalizing our proposal to include the current list of appendectomy procedures in the logic for case assignment of appendectomy procedures for the finalized new MS–DRGs.

7. MDC 07 (Diseases and Disorders of the Hepatobiliary System and Pancreas):
   Alcoholic Hepatitis

   As stated in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26721 through 26726), we received a request to create new MS–DRGs with a two-way split (with MCC and without MCC) for cases reporting alcoholic hepatitis. Alcoholic hepatitis is identified with ICD–10–CM diagnosis codes K70.10 (Alcoholic hepatitis without ascites) and K70.11 (Alcoholic hepatitis with ascites) which are currently assigned to MS–DRGs 432, 433, and 434 (Cirrhosis and Alcoholic Hepatitis with MCC, with CC, and without CC/MCC, respectively) when reported as a principal diagnosis.

   Alcoholic hepatitis is characterized as an inflammatory condition due to chronic, excessive alcohol use and is considered an acute form of alcohol-associated liver disease (ALD). Data suggests that ALD was responsible for over 100,000 hospitalizations in 2017 and admissions for ALD continued to increase during the COVID–19 public health emergency. Data also suggest that ALD may be one of the leading causes of liver transplants in the U.S.

   As discussed in the proposed rule, the requestor stated that currently there are no effective therapies available to treat alcoholic hepatitis and current treatment guidelines suggest corticosteroids, despite increased risk of infection and minimal impact on survival beyond 28 days. However, the requestor (manufacturer of Larsucosterol) also indicated that epigenetic therapy is currently being studied to address various types of acute and chronic organ injury and provided information related to its AHFIRM (Alcohol-associated Hepatitis to evaluate safety and efficacy of Larsucosterol (DUR–928) treatment) Phase 2b study for patients diagnosed with alcoholic hepatitis. The FDA granted Fast Track Designation to DUR–928 for the treatment of alcoholic hepatitis in 2020.

   The requestor stated it performed its own analysis using 2 years of claims data, (calendar years 2018 and 2019), and its findings showed that the patients with alcoholic hepatitis are distinct from the typical Medicare beneficiary and that the condition disproportionately affects younger patients that represent a small proportion of the cases currently grouping to MS–DRGs 432, 433, and 434. According to the requestor, the low volume of cases reporting alcoholic hepatitis have little to no impact on the annual recalibration of the MS–DRG relative payment weights for MS–DRGs 432, 433, and 434, resulting in underpayments. The requestor stated its analysis of cases reporting alcoholic hepatitis showed higher resource utilization and a longer length of stay when compared to all cases in MS–DRGs 432, 433, and 434. The requestor stated it applied the criteria to create subgroups for the cases reporting alcoholic hepatitis currently grouping to MS–DRGs 432, 433, and 434 and found that the criteria for a two-way split (with MCC and without MCC) was met. The requestor further stated that splitting out the cases reporting alcoholic hepatitis from MS–DRGs 432, 433, and 434 would enable more accurate payment of these cases and support research that is specific to alcoholic hepatitis distinct from cirrhosis.

   The logic for case assignment to MS–DRGs 432, 433, and 434 is comprised of the following diagnosis codes.
As stated in the proposed rule, we analyzed claims data from the September 2022 update of the FY 2022 MedPAR file for MS–DRGs 432, 433, and 434 and cases reporting any one of the listed diagnoses as a principal diagnosis. We noted that if a diagnosis code is not listed it is because there were no cases found reporting that code in the respective MS–DRG. The findings from our analysis are shown in the following table.

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>K70.10</td>
<td>Alcoholic hepatitis without ascites</td>
</tr>
<tr>
<td>K70.11</td>
<td>Alcoholic hepatitis with ascites</td>
</tr>
<tr>
<td>K70.2</td>
<td>Alcoholic fibrosis and sclerosis of liver</td>
</tr>
<tr>
<td>K70.30</td>
<td>Alcoholic cirrhosis of liver without ascites</td>
</tr>
<tr>
<td>K70.31</td>
<td>Alcoholic cirrhosis of liver with ascites</td>
</tr>
<tr>
<td>K70.40</td>
<td>Alcoholic hepatic failure without coma</td>
</tr>
<tr>
<td>K70.41</td>
<td>Alcoholic hepatic failure with coma</td>
</tr>
<tr>
<td>K70.9</td>
<td>Alcoholic liver disease, unspecified</td>
</tr>
<tr>
<td>K74.00</td>
<td>Hepatic fibrosis, unspecified</td>
</tr>
<tr>
<td>K74.01</td>
<td>Hepatic fibrosis, early fibrosis</td>
</tr>
<tr>
<td>K74.02</td>
<td>Hepatic fibrosis, advanced fibrosis</td>
</tr>
<tr>
<td>K74.3</td>
<td>Primary biliary cirrhosis</td>
</tr>
<tr>
<td>K74.4</td>
<td>Secondary biliary cirrhosis</td>
</tr>
<tr>
<td>K74.5</td>
<td>Biliary cirrhosis, unspecified</td>
</tr>
<tr>
<td>K74.60</td>
<td>Unspecified cirrhosis of liver</td>
</tr>
<tr>
<td>K74.69</td>
<td>Other cirrhosis of liver</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>432 – All cases</td>
<td>16,836</td>
<td>6.8</td>
<td>$16,532</td>
</tr>
<tr>
<td>432 – Cases reporting a principal diagnosis of K70.10 (Alcoholic hepatitis without ascites)</td>
<td>269</td>
<td>7.4</td>
<td>$14,710</td>
</tr>
<tr>
<td>432 – Cases reporting a principal diagnosis of K70.11 (Alcoholic hepatitis with ascites)</td>
<td>244</td>
<td>9.1</td>
<td>$20,727</td>
</tr>
<tr>
<td>MS-DRG</td>
<td>Number of Cases</td>
<td>Average Length of Stay</td>
<td>Average Costs</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>----------------</td>
<td>------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>432 – Cases reporting a principal diagnosis of K70.30 (Alcoholic cirrhosis of liver without ascites)</td>
<td>1,241</td>
<td>5.4</td>
<td>$14,136</td>
</tr>
<tr>
<td>432 – Cases reporting a principal diagnosis of K70.31 (Alcoholic cirrhosis of liver with ascites)</td>
<td>5,687</td>
<td>7.5</td>
<td>$17,694</td>
</tr>
<tr>
<td>432 – Cases reporting a principal diagnosis of K70.40 (Alcoholic hepatic failure without coma)</td>
<td>1,179</td>
<td>8.1</td>
<td>$19,277</td>
</tr>
<tr>
<td>432 – Cases reporting a principal diagnosis of K70.41 (Alcoholic hepatic failure with coma)</td>
<td>33</td>
<td>8.7</td>
<td>$22,530</td>
</tr>
<tr>
<td>432 – Cases reporting a principal diagnosis of K70.9 (Alcoholic liver disease, unspecified)</td>
<td>28</td>
<td>4.8</td>
<td>$12,708</td>
</tr>
<tr>
<td>432 – Cases reporting a principal diagnosis of K74.3 (Primary biliary cirrhosis)</td>
<td>244</td>
<td>7.3</td>
<td>$18,020</td>
</tr>
<tr>
<td>432 – Cases reporting a principal diagnosis of K74.4 (Secondary biliary cirrhosis)</td>
<td>11</td>
<td>7.5</td>
<td>$15,324</td>
</tr>
<tr>
<td>432 – Cases reporting a principal diagnosis of K74.5 (Biliary cirrhosis, unspecified)</td>
<td>15</td>
<td>8.2</td>
<td>$16,569</td>
</tr>
<tr>
<td>432 – Cases reporting a principal diagnosis of K74.60 (Unspecified cirrhosis of liver)</td>
<td>5,501</td>
<td>6</td>
<td>$15,120</td>
</tr>
<tr>
<td>432 – Cases reporting a principal diagnosis of K74.69 (Other cirrhosis of liver)</td>
<td>2,384</td>
<td>6.9</td>
<td>$16,501</td>
</tr>
<tr>
<td>433 – All cases</td>
<td>8,436</td>
<td>4.3</td>
<td>$9,007</td>
</tr>
<tr>
<td>433 – Cases reporting a principal diagnosis of K70.10 (Alcoholic hepatitis without ascites)</td>
<td>309</td>
<td>4.8</td>
<td>$8,436</td>
</tr>
<tr>
<td>433 – Cases reporting a principal diagnosis of K70.11 (Alcoholic hepatitis with ascites)</td>
<td>173</td>
<td>5</td>
<td>$10,085</td>
</tr>
<tr>
<td>433 – Cases reporting a principal diagnosis of K70.30 (Alcoholic cirrhosis of liver without ascites)</td>
<td>433</td>
<td>4.5</td>
<td>$9,343</td>
</tr>
<tr>
<td>433 – Cases reporting a principal diagnosis of K70.31 (Alcoholic cirrhosis of liver with ascites)</td>
<td>2,825</td>
<td>4.4</td>
<td>$9,548</td>
</tr>
<tr>
<td>433 – Cases reporting a principal diagnosis of K70.40 (Alcoholic hepatic failure without coma)</td>
<td>815</td>
<td>4.6</td>
<td>$9,066</td>
</tr>
<tr>
<td>433 – Cases reporting a principal diagnosis of K70.41 (Alcoholic hepatic failure with coma)</td>
<td>6</td>
<td>3.2</td>
<td>$5,853</td>
</tr>
<tr>
<td>433 – Cases reporting a principal diagnosis of K70.9 (Alcoholic liver disease, unspecified)</td>
<td>24</td>
<td>4.8</td>
<td>$11,893</td>
</tr>
<tr>
<td>433 – Cases reporting a principal diagnosis of K74.3 (Primary biliary cirrhosis)</td>
<td>121</td>
<td>4</td>
<td>$7,757</td>
</tr>
<tr>
<td>433 – Cases reporting a principal diagnosis of K74.4 (Secondary biliary cirrhosis)</td>
<td>4</td>
<td>3.3</td>
<td>$5,687</td>
</tr>
<tr>
<td>433 – Cases reporting a principal diagnosis of K74.5 (Biliary cirrhosis, unspecified)</td>
<td>12</td>
<td>2.2</td>
<td>$4,784</td>
</tr>
<tr>
<td>433 – Cases reporting a principal diagnosis of K74.60 (Unspecified cirrhosis of liver)</td>
<td>2,679</td>
<td>3.9</td>
<td>$8,482</td>
</tr>
<tr>
<td>433 – Cases reporting a principal diagnosis of K74.69 (Other cirrhosis of liver)</td>
<td>1,035</td>
<td>4.3</td>
<td>$8,855</td>
</tr>
<tr>
<td>434 – All cases</td>
<td>358</td>
<td>2.8</td>
<td>$5,825</td>
</tr>
<tr>
<td>434 – Cases reporting a principal diagnosis of K70.10 (Alcoholic hepatitis without ascites)</td>
<td>41</td>
<td>2.4</td>
<td>$5,784</td>
</tr>
</tbody>
</table>
Based on our initial analysis for cases in MS–DRGs 432, 433, and 434, the data clearly demonstrate that there are several diagnoses, other than the two diagnoses identified by the requestor (codes K70.10 and K70.11) with increased resource utilization when compared to the average length of stay and average costs of all cases in MS–DRGs 432, 433, and 434.

We stated in the proposed rule that the data show cases in MS–DRG 432 reporting diagnosis codes K70.11, K70.30, K70.40, K70.41, K74.3, or K74.5 as a principal diagnosis have a longer average length of stay (9.1 days, 7.5 days, 8.1 days, 8.7 days, 7.3 days, and 8.2 days, respectively versus 6.8 days) and higher average costs ($20,727, $17,694, $19,277, $22,530, $18,020, and $16,569, respectively versus $16,532) compared to the average length of stay and the average costs for all the cases in MS–DRG 432. We noted that the cases reporting diagnosis code K70.10, K74.4, or K74.69 as a principal diagnosis also have a longer average length of stay (7.4 days, 6.9 days, respectively versus 6.8 days) compared to the average length of stay and the average costs for all the cases in MS–DRG 432. We noted that the cases reporting diagnosis code K70.10 as a principal diagnosis also have a longer average length of stay (4.8 days versus 4.3 days) compared to all the cases in MS–DRG 433, however, the average costs of these cases are lower ($8,436 versus $9,007) compared to the average costs for all the cases in the MS–DRG.

Lastly, for MS–DRG 434, the cases reporting diagnosis codes K70.31, K74.3, or K74.60 as a principal diagnosis have a longer average length of stay (3 days, 4.2 days, and 2.6 days, respectively versus 2.8 days) and higher average costs ($6,348, $8,485, and $5,862, respectively versus $5,825) compared to the average length of stay and the average costs for all the cases in MS–DRG 434.

The data also show that there is significantly more case volume for several of the other diagnoses compared to the case volume of the two diagnoses (K70.10 and K70.11) associated with the request to create new MS–DRGs. We identified diagnosis code K70.31 (Alcoholic cirrhosis of liver with ascites) to be the most prevalent diagnosis with respect to case volume reported across MS–DRGs 432, 433, and 434. For example, as shown in the table, we found 5,687 cases in MS–DRG 432 reporting diagnosis code K70.31 as a principal diagnosis compared to 269 cases reporting diagnosis code K70.10 and 244 cases reporting diagnosis code K70.11. For MS–DRG 433, we found 2,825 cases reporting diagnosis code K70.31 as a principal diagnosis compared to 309 cases reporting diagnosis code K70.10 and 173 cases reporting diagnosis code K70.11. Lastly, for MS–DRG 434, we found 179 cases reporting diagnosis code K70.31 as a principal diagnosis compared to 41 cases reporting diagnosis code K70.10 and 8 cases reporting diagnosis code K70.11.

As discussed in the proposed rule, following our initial review of the claims data for the cases reporting any one of the listed diagnoses as a principal diagnosis that are included in the logic for case assignment to MS–DRGs 432, 433, and 434, we performed additional analyses to focus on the cases specifically reporting diagnosis code K70.10 or K70.11 as a principal diagnosis in response to the request to create new MS–DRGs with a two-way split (with and without MCC). The findings from our analysis are shown in the following table.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>434 – Cases reporting a principal diagnosis of K70.11 (Alcoholic hepatitis with ascites)</td>
<td>8</td>
<td>2.1</td>
<td>$4,316</td>
</tr>
<tr>
<td>434 – Cases reporting a principal diagnosis of K70.30 (Alcoholic cirrhosis of liver without ascites)</td>
<td>27</td>
<td>2.3</td>
<td>$4,624</td>
</tr>
<tr>
<td>434 – Cases reporting a principal diagnosis of K70.31 (Alcoholic cirrhosis of liver with ascites)</td>
<td>179</td>
<td>3</td>
<td>$6,348</td>
</tr>
<tr>
<td>434 – Cases reporting a principal diagnosis of K70.40 (Alcoholic hepatic failure with coma)</td>
<td>54</td>
<td>2.6</td>
<td>$4,803</td>
</tr>
<tr>
<td>434 – Cases reporting a principal diagnosis of K70.9 (Alcoholic liver disease, unspecified)</td>
<td>2</td>
<td>2.5</td>
<td>$5,351</td>
</tr>
<tr>
<td>434 – Cases reporting a principal diagnosis of K74.3 (Primary biliary cirrhosis)</td>
<td>6</td>
<td>4.2</td>
<td>$8,485</td>
</tr>
<tr>
<td>434 – Cases reporting a principal diagnosis of K74.60 (Unspecified cirrhosis of liver)</td>
<td>36</td>
<td>2.6</td>
<td>$5,862</td>
</tr>
<tr>
<td>434 – Cases reporting a principal diagnosis of K74.69 (Other cirrhosis of liver)</td>
<td>5</td>
<td>3</td>
<td>$4,122</td>
</tr>
</tbody>
</table>
The data show that the 513 cases reporting alcoholic hepatitis without or with ascites in MS–DRG 432 have a longer average length of stay (8.2 days versus 6.8 days) and higher average costs ($17,572 versus $16,532). For MS–DRG 433, the data show that the 482 cases reporting alcoholic hepatitis without or with ascites have a longer average length of stay (4.9 days versus 4.3 days) and a difference in average costs of $21 ($9,028 versus $9,007). For MS–DRG 434, the 49 cases reporting alcoholic hepatitis without or with ascites have a shorter length of stay (2.4 days versus 2.8 days) and lower average costs ($5,544 versus $5,825).

We stated in the proposed rule that, based on the results of our review and our analysis of the claims data for cases reporting a principal diagnosis of alcoholic hepatitis without or with ascites (codes K70.10 or K70.11), we believe the cases demonstrate similar patterns of resource intensity in comparison to the other cases in MS–DRGs 432, 433, and 434. We also stated that the diagnosis of alcoholic hepatitis without or with ascites is driven by the reporting of any one of the listed diagnoses as a principal diagnosis. The commenter stated that while the logic for case assignment to MS–DRG 432, 433, and 434 includes clinically related diagnoses that differ in severity and resource intensity with alcoholic hepatitis being at the lowest end of the severity spectrum. Therefore, we proposed to maintain the structure of MS–DRGs 432, 433, and 434 for FY 2024.

Response: We thank the commenters for their support.

Comment: A commenter (the requestor) who disagreed with the proposal stated that alcoholic hepatitis (AH) is a distinct clinical pathological entity that is different from common forms of alcoholic-liver disease (ALD) and that liver failure in severe AH is driven by loss of hepatocyte nuclear factor 4 alpha (HNF4a) function and liver-specific changes distinct from those seen in other forms of ALD. The commenter expressed concerns regarding both the analysis conducted by CMS and the interpretation of the findings. Specifically, the commenter stated that analyses by principal diagnoses comparing average length of stay and average costs should not be used as the primary determinant in assessing resource use differences, although the commenter acknowledged some principal diagnoses findings will be above, and some will be below, when compared to an average. According to the commenter, the CMS analyses also did not account for the differences between AH and non-AH cases and masked resource use differences. Using data from calendar years 2018 through 2022, the commenter provided an updated analysis for MS–DRG 432 while combining its analyses for MS–DRGs 433 and 434, separating AH cases from non-AH and comparing average length of stay among the cases.

Response: The MS–DRGs were developed as a patient classification scheme consisting of patients who are similar clinically and with regard to their consumption of hospital resources. The concept of clinical coherence requires that the patient characteristics included in the definition of each MS–DRG relate to a common organ system or etiology and that a specific medical specialty should typically provide care to the patients in the MS–DRG. While all patients are unique, groups of patients have diagnostic and therapeutic attributes in common that determine their level of resource intensity. Similar resource intensity means that the resources used are relatively consistent across the patients in each MS–DRG. However, some variation in resource intensity will remain among the patients in each MS–DRG. In other words, the definition of a MS–DRG will not be so specific that every patient is identical, rather the level of variation is relatively understood and predictable. We continue to believe, as stated previously, that AH diagnoses are clinically coherent with the other diagnoses currently assigned to MS–DRGs 432, 433, and 434.

With respect to the updated analyses that was submitted, we appreciate the commenter’s feedback. However, we note that the commenter did not uniquely identify and distinguish the AH cases from non-AH cases with specific ICD–10–CM codes that it was considering under its analyses, nor did the analysis include any case counts. As such, it was not clear specifically what diagnoses were included in the commenter’s data analysis.

With respect to the commenter’s assertion that the CMS analyses by principal diagnoses comparing average length of stay and average costs was used as the primary determinant in assessing resource use differences, we note that while the logic for case assignment to MS–DRGs 432, 433, and 434 is driven by the reporting of any one of the listed diagnoses as a principal diagnosis, we also consider other factors in deciding whether to propose to make further modifications to the MS–DRGs for particular circumstances brought to
our attention, as described in the preamble of the proposed rule (88 FR 26673) and discussed in prior rulemaking (for example, severity of illness, treatment difficulty, complexity of service, etc.).

In response to the commenter’s statement that the CMS analyses did not account for the differences between AH and non-AH cases masking resource use differences, we note that the analysis we performed and made available in the proposed rule to address the MS–DRG request listed the number of cases (volume), average length of stay and average costs of all cases, as well as detailed data for each diagnosis code defined in the logic for case assignment to MS–DRGs 432, 433, and 434 when reported as the principal diagnosis. Therefore, the data findings for what we believe the commenter is referring to as non-AH cases were reflected and the ability to perform a comparison between AH and non-AH was made available.

Specifically, in review of the findings for MS–DRG 432, as displayed in the proposed rule and this final rule, the number of non-AH cases (e.g., cases reporting a principal diagnosis other than diagnosis code K70.10 or K70.11) can be calculated by subtracting the total number of cases reporting AH from the total number of all cases in the MS–DRG. For example, the total number of cases found in MS–DRG 432 is 16,836 and the total number of cases reporting AH is 513, therefore, the number of non-AH cases is 16,323 (16,836 – 513 = 16,323), with an average length of stay of 6.8 days and average costs of $16,499, resulting in a difference of 1.4 days for the average length of stay and a difference in average costs of $1,073 for AH and non-AH cases. For MS–DRG 433, the number of non-AH cases can be calculated as 7,954 (8,436 – 482 = 7,954) with an average length of stay of 4.3 days and average costs of $9,006, resulting in a difference of .6 days for the average length of stay and a difference in average costs of $22 for AH and non-AH cases. Lastly, for MS–DRG 434, the number of non-AH cases can be calculated as 309 (358 – 49 = 309) with an average length of stay of 2.9 days and average costs of $5,870, resulting in a difference of .5 days for the average length of stay and a difference in average costs of $326 for AH and non-AH cases. We illustrate these findings in the following table.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>432 – All cases</td>
<td>16,836</td>
<td>6.8</td>
<td>$16,532</td>
</tr>
<tr>
<td>432 – Cases reporting a principal diagnosis of alcoholic hepatitis without or with ascites (K70.10 or K70.11)</td>
<td>513</td>
<td>8.2</td>
<td>$17,572</td>
</tr>
<tr>
<td>432 – All other cases</td>
<td>16,323</td>
<td>6.8</td>
<td>$16,499</td>
</tr>
<tr>
<td>433 – All cases</td>
<td>8,436</td>
<td>4.3</td>
<td>$9,007</td>
</tr>
<tr>
<td>433 – Cases reporting a principal diagnosis of alcoholic hepatitis without or with ascites (K70.10 or K70.11)</td>
<td>482</td>
<td>4.9</td>
<td>$9,028</td>
</tr>
<tr>
<td>433 – All other cases</td>
<td>7,954</td>
<td>4.3</td>
<td>$9,006</td>
</tr>
<tr>
<td>434 – All cases</td>
<td>358</td>
<td>2.8</td>
<td>$5,825</td>
</tr>
<tr>
<td>434 – Cases reporting a principal diagnosis of alcoholic hepatitis without or with ascites (K70.10 or K70.11)</td>
<td>49</td>
<td>2.4</td>
<td>$5,544</td>
</tr>
<tr>
<td>434 – All other cases</td>
<td>309</td>
<td>2.9</td>
<td>$5,870</td>
</tr>
</tbody>
</table>

After consideration of the public comments we received, and for the reasons discussed, we are finalizing our proposal to maintain the structure of MS–DRGs 432, 433, and 434, without modification, for FY 2024.

We also note, as discussed in section II.C.1.b. of the preamble of proposed rule, using the December 2022 update of the FY 2022 MedPAR file, we analyzed how applying the NonCC subgroup criteria to all MS–DRGs currently split into three severity levels would affect the MS–DRG structure beginning in FY 2024. Findings from our analysis indicated that MS–DRGs 432, 433, and 434, as well as approximately 44 other base MS–DRGs, would potentially be subject to change based on the three-way severity level split criterion finalized in FY 2021. We referred the reader to Table 6P.10b associated with the proposed rule (which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS) for the list of the 135 MS–DRGs that would potentially be subject to deletion and the list of the 86 new MS–DRGs that would potentially be created under this policy if the NonCC subgroup criteria was applied.

Comment: A commenter expressed support for the analysis CMS performed to determine how applying the NonCC subgroup criteria would potentially impact MS–DRGs currently split into three severity levels. Specifically, the commenter stated application of the NonCC subgroup criteria for MS–DRGs 432, 433, and 434 is reflective of the MS–DRG structure that was requested for AH.

Response: We thank the commenter for their support. We refer the reader to section II.C.1.b. of the preamble of this final rule for related discussion regarding our finalization of the expansion of the criteria to include the NonCC subgroup and our finalization of the proposal to continue to delay application of the NonCC subgroup criteria to existing MS–DRGs with a three-way severity level split for FY 2024.

8. MDC 08 (Diseases and Disorders of the Musculoskeletal System and Connective Tissue): Spinal Fusion

As discussed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26726 through 26729), we received a request to
reassign cases reporting spinal fusion procedures utilizing an aprevo™ customized interbody fusion device from the lower severity MS–DRG 455 (Combined Anterior and Posterior Spinal Fusion without CC/MCC) to the higher severity MS–DRG 453 (Combined Anterior and Posterior Spinal Fusion with MCC), from the lower severity MS–DRG 458 (Spinal Fusion Except Cervical with Spinal Curvature, Infection or Extensive Fusions without CC/MCC) to the higher severity level MS–DRG 456 (Spinal Fusion Except Cervical with Spinal Curvature, Malignancy, Infection or Extensive Fusions with MCC) when a diagnosis of malalignment is reported, and from MS–DRGs 459 and 460 (Spinal Fusion Except Cervical with MCC and without MCC, respectively) to MS–DRG 456.

We noted that the Aprevo™ Intervertebral Body Fusion Device technology was discussed in the FY 2022 IPPS/LTCH PPS proposed (86 FR 25361 through 25365) and final rules (86 FR 45127 through 45133) with respect to a new technology add-on payment application and was approved for add-on payments for FY 2022. We also noted that, as discussed in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49468 through 49469), CMS finalized the continuation of the new technology add-on payments for this technology for FY 2023.

In support of the new technology add-on payment application that was submitted for FY 2022 consideration, we received a request and proposal to create new ICD–10–PCS codes to differentiate spinal fusion procedures that utilize an aprevo™ customized interbody fusion device, which was discussed at the March 9–10, 2021 ICD–10 Coordination and Maintenance Committee meeting. As a result, effective October 1, 2021 (FY 2022), we implemented 12 new ICD–10–PCS procedure codes to identify and describe spinal fusion procedures utilizing the aprevo™ customized interbody fusion device as shown in the following table.

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>XRGAG0R7</td>
<td>Fusion of thoracolumbar vertebral joint using customizable interbody fusion device, open approach, new technology group 7</td>
</tr>
<tr>
<td>XRGAG3R7</td>
<td>Fusion of thoracolumbar vertebral joint using customizable interbody fusion device, percutaneous approach, new technology group 7</td>
</tr>
<tr>
<td>XRGAG4R7</td>
<td>Fusion of thoracolumbar vertebral joint using customizable interbody fusion device, percutaneous endoscopic approach, new technology group 7</td>
</tr>
<tr>
<td>XRGB0R7</td>
<td>Fusion of lumbar vertebral joint using customizable interbody fusion device, open approach, new technology group 7</td>
</tr>
<tr>
<td>XRGB3R7</td>
<td>Fusion of lumbar vertebral joint using customizable interbody fusion device, percutaneous approach, new technology group 7</td>
</tr>
<tr>
<td>XRGB4R7</td>
<td>Fusion of lumbar vertebral joint using customizable interbody fusion device, percutaneous endoscopic approach, new technology group 7</td>
</tr>
<tr>
<td>XRGCO1R7</td>
<td>Fusion of 2 or more lumbar vertebral joints using customizable interbody fusion device, open approach, new technology group 7</td>
</tr>
<tr>
<td>XRGCO3R7</td>
<td>Fusion of 2 or more lumbar vertebral joints using customizable interbody fusion device, percutaneous approach, new technology group 7</td>
</tr>
<tr>
<td>XRGCO4R7</td>
<td>Fusion of 2 or more lumbar vertebral joints using customizable interbody fusion device, percutaneous endoscopic approach, new technology group 7</td>
</tr>
<tr>
<td>XRGD0R7</td>
<td>Fusion of lumbosacral joint using customizable interbody fusion device, open approach, new technology group 7</td>
</tr>
<tr>
<td>XRGD3R7</td>
<td>Fusion of lumbosacral joint using customizable interbody fusion device, percutaneous approach, new technology group 7</td>
</tr>
<tr>
<td>XRGD4R7</td>
<td>Fusion of lumbosacral joint using customizable interbody fusion device, percutaneous endoscopic approach, new technology group 7</td>
</tr>
</tbody>
</table>

Each of the listed procedure codes are assigned to MDC 01 (Diseases and Disorders of the Nervous System) in MS–DRGs 028, 029, and 030 (Spinal Procedures with MCC, with CC or Spinal Neurostimulators, and without CC/MCC, respectively) and to MDC 08 (Diseases and Disorders of the Musculoskeletal System and Connective Tissue) in MS–DRGs 453, 454, and 455 (Combined Anterior and Posterior Spinal Fusion with MCC, with CC, and without CC/MCC, respectively), MS–DRGs 456, 457, and 458 (Spinal Fusion Except Cervical With Spinal Curvature, Malignancy, Infection or Extensive Fusions with MCC, with CC, and without CC/MCC, respectively), and MS–DRGs 459 and 460 (Spinal Fusion Except Cervical with MCC and without MCC, respectively).

As stated in the proposed rule, the requestor (the manufacturer of aprevo™ custom-made device) expressed concerns that findings from its analysis of claims data for spinal fusion MS–DRGs 453, 454, 455, 456, 457, 458, 459, and 460 from the first half of FY 2022 indicate there may be unintentional miscoded claims from providers with whom they do not have an explicit relationship. Specifically, the requestor stated that a subset of the facilities identified in its analysis are not customers to whom the aprevo™ custom-made device was provided. The volume of cases initially identified by the requestor in its analysis totaled 89 cases, however, upon
eliminating the provider claims from the facilities that are not a current client, the resulting volume was 14 cases. The requestor stated that subsequently, after another quarter’s data became available from current clients for cases reporting the performance of a spinal fusion procedure utilizing an aprevo™ customized interbody spinal fusion device, they identified an additional 16 cases for a total of 30 cases, all of which were assigned to MS–DRGs 453, 454, and 455.

Upon further review of the data, the requestor stated it found that cases reporting the performance of a spinal fusion procedure utilizing an aprevo™ customized interbody spinal fusion device had higher average costs in comparison to the average costs of all the cases in the highest severity level “with MCC” MS–DRGs 453 and 456. According to the requestor, this finding suggested that the use of the device impacts intensity of resources such that the cases reporting the performance of a spinal fusion procedure utilizing an aprevo™ customized interbody spinal fusion device merit reassignment to the highest severity level “with MCC” MS–DRGs (MS–DRGs 453 and 456). The requestor asserted that while spinal disorders impact approximately 65 million patients in the U.S., the patients undergoing spine surgery with an aprevo™ customized interbody spinal fusion device are those with irreversible, debilitating conditions. In addition, the requestor stated that since the cases reporting the performance of a spinal fusion procedure utilizing an aprevo™ customized interbody spinal fusion device already appear to map to the most resource intensive MS–DRGs for spinal procedures, there is no other alternative assignment for these procedures, with the exception of a new MS–DRG. Lastly, the requestor maintained that reassigning cases reporting the performance of a spinal fusion procedure utilizing an aprevo™ customized interbody spinal fusion device to the “with MCC” level aligns with CMS’s factors that are considered in review of MS–DRG classification change requests, including treatment difficulty, complexity of service, and utilization of resources.

As discussed in the proposed rule, we analyzed data from the September 2022 update of the FY 2022 MedPAR file for MS–DRGs 453, 454, 455, 456, 457, 458, 459, and 460 and cases reporting any one of the previously listed procedure codes describing utilization of an aprevo™ customized interbody spinal fusion device. Our findings are shown in the following table.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG 453 All cases</td>
<td>3,779</td>
<td>9.4</td>
<td>$77,856</td>
</tr>
<tr>
<td>MS-DRG 453 Cases reporting customized interbody spinal fusion</td>
<td>17</td>
<td>8.4</td>
<td>$79,080</td>
</tr>
<tr>
<td>MS-DRG 454 All cases</td>
<td>19,246</td>
<td>4.4</td>
<td>$54,227</td>
</tr>
<tr>
<td>MS-DRG 454 Cases reporting customized interbody spinal fusion</td>
<td>75</td>
<td>4.4</td>
<td>$75,294</td>
</tr>
<tr>
<td>MS-DRG 455 All cases</td>
<td>16,564</td>
<td>2.7</td>
<td>$40,683</td>
</tr>
<tr>
<td>MS-DRG 455 Cases reporting customized interbody spinal fusion</td>
<td>67</td>
<td>2.7</td>
<td>$54,287</td>
</tr>
<tr>
<td>MS-DRG 456 All cases</td>
<td>1,276</td>
<td>13.2</td>
<td>$73,399</td>
</tr>
<tr>
<td>MS-DRG 456 Cases reporting customized interbody spinal fusion</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>MS-DRG 457 All cases</td>
<td>2,973</td>
<td>6.4</td>
<td>$53,750</td>
</tr>
<tr>
<td>MS-DRG 457 Cases reporting customized interbody spinal fusion</td>
<td>2</td>
<td>3.5</td>
<td>$185,782</td>
</tr>
<tr>
<td>MS-DRG 458 All cases</td>
<td>777</td>
<td>3.5</td>
<td>$40,343</td>
</tr>
<tr>
<td>MS-DRG 458 Cases reporting customized interbody spinal fusion</td>
<td>1</td>
<td>12</td>
<td>$91,672</td>
</tr>
<tr>
<td>MS-DRG 459 All cases</td>
<td>3,128</td>
<td>9.8</td>
<td>$53,342</td>
</tr>
<tr>
<td>MS-DRG 459 Cases reporting customized interbody spinal fusion</td>
<td>2</td>
<td>5</td>
<td>$57,039</td>
</tr>
<tr>
<td>MS-DRG 460 All cases</td>
<td>30,310</td>
<td>3.5</td>
<td>$31,921</td>
</tr>
<tr>
<td>MS-DRG 460 Cases reporting customized interbody spinal fusion</td>
<td>30</td>
<td>4.5</td>
<td>$46,683</td>
</tr>
</tbody>
</table>

We found the majority of cases reporting the performance of a spinal fusion procedure utilizing an aprevo™ customized interbody spinal fusion device in MS–DRGs 453, 454, and 455 with a total of 159 cases (17 + 75 + 67 = 159) with an average length of stay of 4.1 days and average costs of $66,847. The 17 cases identified in MS–DRG 453 appear to have a comparable average length of stay and comparable average costs compared to all the cases in MS–DRG 453 with a difference of 1.0 day and a difference in average costs of $1,383 for the cases reporting the performance of a spinal fusion procedure utilizing an aprevo™ customized interbody spinal fusion device. The 75 cases found in MS–DRG 454 have an identical average length of stay of 4.4 days in comparison to all the cases in MS–DRG 454, however, the difference in average costs is $21,067 ($75,294 – $54,227 = $21,067) for the cases reporting the performance of a spinal fusion procedure utilizing an aprevo™ customized interbody spinal fusion device. The 67 cases found in MS–DRG 455 also have an identical average length of stay of 2.7 days in comparison to all the cases in MS–DRG 455; however, the difference in average costs is $13,604 ($54,287 – $40,683 = $13,604) for the cases reporting the performance of a spinal fusion procedure utilizing an aprevo™ customized interbody spinal fusion device. As shown in the table, there were no cases found to report utilization of an aprevo™ customized interbody spinal fusion device in MS–DRG 456. For MS–DRG 457, the 2 cases found to report utilization of an aprevo™ customized interbody spinal fusion device appear to be outliers with a difference in average costs of $105,032 ($158,782 – $53,750 = $105,032) and a shorter average length of stay (3.5 days versus 6.4 days) in comparison to all the cases in MS–DRG 457. For MS–DRG 458, we found 1 case reporting utilization of an aprevo™ customized interbody spinal fusion device with an average length of stay almost three times the average length of stay of all the cases in MS–DRG 458 (12 days versus 3.5 days) and average costs that are twice as


high ($91,672 versus $40,343) compared to the average costs of all the cases in MS–DRG 458. For MS–DRG 459, the 2 cases reporting utilization of an aprevo™ customized interbody spinal fusion device had a shorter average length of stay (5 days versus 9.8 days) compared to the average length of stay of all the cases in MS–DRG 459 with a difference in average costs of $3,697 ($57,039 – $53,342 = $3,697). For MS–DRG 460, the 30 cases reporting utilization of an aprevo™ customized interbody spinal fusion device had a longer average length of stay (4.5 days versus 3.5 days) compared to the average length of stay of all the cases in MS–DRG 460 with a difference in average costs of $14,762 ($46,683 – $31,921 = $14,762).

As discussed in the proposed rule, the requestor expressed concerns that there may be unintentional miscoded claims from providers with whom they do not have an explicit relationship. In the proposed rule, we noted that following the submission of the request for the FY 2024 MS–DRG classification change for cases reporting the performance of a spinal fusion procedure utilizing an aprevo™ customized interbody spinal fusion device, this same requestor (the manufacturer of aprevo™ customized interbody spinal fusion devices) submitted a code proposal requesting a revision to the title of the current procedure codes that identify and describe a spinal fusion procedure utilizing an aprevo™ customized interbody spinal fusion device for consideration as an agenda topic to be discussed at the March 7–8, 2023 ICD–10 Coordination and Maintenance Committee meeting. The requestor stated its belief that the term “customizable” as currently reflected in Table 6F.—Revised Procedure Code Titles associated with the final rule for October 1 implementation (upcoming FY) are not finalized in time to include in Table 6A.—New Diagnosis Codes, Table 6B.—New Procedure Codes, Table 6C.—Invalid Diagnosis Codes, Table 6D.—Invalid Procedure Codes, Table 6E.—Revised Diagnosis Code Titles or Table 6F.—Revised Procedure Code Titles in association with the proposed rule. Accordingly, we stated that any update to the title of the procedure codes describing utilization of an aprevo™ customized interbody spinal fusion device, if finalized following the March meeting, would be reflected in Table 6F.—Revised Procedure Code Titles associated with the final rule for FY 2024.

As discussed in the proposed rule, based on our review of this issue and our analysis of the claims data, we agreed that the findings appear to indicate that cases reporting the performance of a procedure utilizing an aprevo™ customized interbody spinal fusion device reflect a higher consumption of resources. However, due to the concerns expressed with respect to suspected inaccuracies of the coding and therefore, reliability of the claims data, we stated we believed further review is warranted. In addition, as previously discussed in the proposed rule and this final rule, the proposal to revise the current code descriptions was presented at the March 2023 ICD–10 Coordination and Maintenance Committee meeting and if finalized, the revised coding may improve the reporting of procedures where an aprevo™ customized interbody spinal fusion device is utilized. In the proposed rule, we also stated we believe the technology is currently receiving new technology add-on payments, it would be advantageous to allow for more claims data to be analyzed under the application of the policy in consideration of any future modifications to the MS–DRGs for which the technology is utilized in the performance of a spinal fusion procedure.

In the proposed rule, we noted that with regard to possible future action, we will continue to monitor the claims data for resolution of the potential coding issues identified by the requestor. We also noted that because the procedure codes that we analyzed and presented findings for in the FY 2024 IPPS/LTCH PPS proposed rule may be revised based on the proposal as discussed at the March 2023 ICD–10 Coordination and Maintenance Committee meeting, the claims data that we examine in the future may change. Additionally, we stated that we will continue to collaborate with the AHA as one of the four Cooperating Parties through the AHA’s Coding Clinic for ICD–10–CM/PCS and provide further education on spinal fusion procedures utilizing an aprevo™ customized interbody spinal fusion device and the proper reporting of the ICD–10–PCS spinal fusion procedure codes. Until these potential coding inaccuracies are addressed and additional, future analysis of the procedures being reported in the claims data can occur, we stated we believed it would be premature to propose any MS–DRG modifications for spinal fusion procedures utilizing an aprevo™ customized interbody spinal fusion device at this time. For these reasons, we proposed to maintain the current structure of MS–DRGs 453, 454, 455, 456, 457, 458, 459, and 460 for FY 2024.

Comment: Comments supported our proposal to maintain the current structure of MS–DRGs 453, 454, 455, 456, 457, 458, 459, and 460 for FY 2024.

Response: We thank the commenters for their support.

Comment: Several commenters (orthopedic surgeons) who expressed support for the requested reassignment of cases reporting the utilization of an aprevo™ customized interbody spinal fusion device stated how important these devices are for their patients because it optimizes patient alignment, is patient-specific, and therefore, beneficial for situations where a patient’s normal anatomy does not allow for traditional implants. These commenters stated that without reassignment to the higher severity MS–DRGs their facilities would not allow use of the technology on the population of Medicare patients they serve.

Response: We appreciate the commenters’ feedback. As discussed in the proposed rule, based on our review...
and analysis of the claims data, we agreed that the findings appear to indicate that cases reporting the performance of a procedure utilizing an aprovo™ customized interbody spinal fusion device reflect a higher consumption of resources. We also note that the proposal to revise the current code descriptions that was presented at the March 2023 ICD–10 Coordination and Maintenance Committee meeting was finalized, as reflected in the FY 2024 ICD–10–PCS Code Update files available via the CMS website at: https://www.cms.gov/medicare/icd-10/2024-icd-10-pscs as well as in Table 6F.—Revised Procedure Code Titles—FY 2024 associated with this final rule and available via the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS.

As also previously discussed, because of the concerns with respect to suspected inaccuracies of the current coding, we continue to believe additional review of claims data is warranted and would be informative as we continue to consider this technology for future rulemaking. Accurate and complete documentation within the medical record is important for patient management, outcome measurement, and quality improvement, as well as payment accuracy. We anticipate that the revisions to the code title for the aprovo™ customized interbody spinal fusion device will encourage more accurate reporting of procedures and improve the quality and reliability of the data. We also continue to believe that because this technology is currently receiving new technology add-on payments and will continue to receive new technology add-on payments, additional claims data analysis of the cases under the application of the policy in consideration of any future modifications to the MS–DRGs for which the technology is utilized in the performance of a spinal fusion procedure would be beneficial. As we have stated in prior rulemaking, we rely on providers to assess the needs of their patients and provide the most appropriate treatment. It is not appropriate for facilities to deny treatment to beneficiaries needing a specific type of therapy or treatment that potentially involves increased costs (86 FR 44947). It would also not be appropriate to consider modifications to the MS–DRG assignment of cases reporting the performance of a procedure that identifies and describes a specific technology solely as an incentive for providers to purchase and utilize one technology over another.

After consideration of the public comments we received, and for the reasons discussed, we are finalizing our proposal to maintain the structure of MS–DRGs 453, 454, 455, 456, 457, 458, 459, and 460, without modification, for FY 2024.

9. MDC 11 (Diseases and Disorders of the Kidney and Urinary Tract): Complications of Arteriovenous Fistulas and Shunts

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26729 through 26733), we discussed a request we received to add eight ICD–10–CM diagnosis codes to the list of principal diagnoses assigned to MS–DRGs 673, 674, and 675 (Other Kidney and Urinary Tract Procedures with MCC, with CC, and without CC/MCC, respectively) in MDC 11 (Diseases and Disorders of the Kidney and Urinary Tract) when reported with procedure codes describing the insertion of totally implantable vascular access devices (TIVADs) and tunneled vascular access devices. The list of eight ICD–10–CM diagnosis codes submitted by the requestor, as well as their current MDC assignments, are found in the table:

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
<th>MDC</th>
</tr>
</thead>
<tbody>
<tr>
<td>T82.510A</td>
<td>Breakdown (mechanical) of surgically created arteriovenous fistula, initial encounter</td>
<td>05</td>
</tr>
<tr>
<td>T82.511A</td>
<td>Breakdown (mechanical) of surgically created arteriovenous shunt, initial encounter</td>
<td>05</td>
</tr>
<tr>
<td>T82.520A</td>
<td>Displacement of surgically created arteriovenous fistula, initial encounter</td>
<td>05</td>
</tr>
<tr>
<td>T82.521A</td>
<td>Displacement of surgically created arteriovenous shunt, initial encounter</td>
<td>05</td>
</tr>
<tr>
<td>T82.530A</td>
<td>Leakage of surgically created arteriovenous fistula, initial encounter</td>
<td>05</td>
</tr>
<tr>
<td>T82.531A</td>
<td>Leakage of surgically created arteriovenous shunt, initial encounter</td>
<td>05</td>
</tr>
<tr>
<td>T82.590A</td>
<td>Other mechanical complication of surgically created arteriovenous fistula, initial encounter</td>
<td>05</td>
</tr>
<tr>
<td>T82.591A</td>
<td>Other mechanical complication of surgically created arteriovenous shunt, initial encounter</td>
<td>05</td>
</tr>
</tbody>
</table>

As noted in the proposed rule, in order to be treated with dialysis, a procedure that replaces kidney function when the organs fail, a connection must be established between the dialysis equipment and the patient’s bloodstream. To establish long-term hemodialysis access, an arteriovenous (AV) fistula or an AV shunt can be surgically created. An AV fistula is created by suturing an artery directly to a vein, generally in the wrist, forearm, inner elbow or upper arm. AV fistulas usually require from 8 to 12 weeks for maturation prior to initial use. AV shunts, also called AV grafts, are created by connecting an artery and a vein using a graft made of synthetic material. AV shunts do not require maturation, as AV fistulas do, and they can be used for hemodialysis in as little as 24 hours after creation depending upon the type of graft that is used. The requester noted that diagnosis codes that describe complications of dialysis catheters currently are in the list of qualifying principal diagnoses in MS–DRGs 673, 674, and 675 when reported with procedure codes describing the insertion of TIVADs or tunneled vascular access devices; therefore, according to the requester, diagnosis codes that describe complications of arteriovenous fistulas and shunts should reasonably be added.

We stated in the proposed rule that to begin our analysis, we reviewed the GROUPER logic for MS–DRGs 673, 674, and 675 including the special logic in MS–DRGs 673, 674, and 675 for certain MDC 11 diagnoses reported with procedure codes for the insertion of tunneled or totally implantable vascular access devices. We refer the reader to the ICD–10 MS–DRG Definitions Manual Version 40.1, which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software for complete documentation of the GROUPER logic for MS–DRGs 673, 674, and 675.

As discussed in the FY 2003 IPPS/LTCH PPS final rule (68 FR 49993 through 49994), the procedure code for the insertion of totally implantable
vascular access devices was added to the GROUPER logic of DRG 315 (Other Kidney and Urinary Tract O.R. Procedures), the predecessor DRG of MS–DRGs 673, 674, and 675, when combined with principal diagnoses specifically describing renal failure, recognizing that inserting these devices as an inpatient procedure for the purposes of hemodialysis can lead to higher average charges and longer lengths of stay for those cases. In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58511 through 58517), we discussed a similar request to add 29 ICD–10–CM diagnosis codes to the list of principal diagnoses assigned to MS–DRGs 673, 674, and 675. In the FY 2021 IPPS/LTCH PPS final rule, we finalized the assignment of diagnosis codes that describe diabetes mellitus with diabetic chronic kidney disease, codes that describe complications of kidney transplant and codes that describe mechanical complications of vascular dialysis catheters to the list of qualifying principal diagnoses in MS–DRGs 673, 674, and 675 and stated that we believed the insertion of TIVADs or tunneled vascular access devices for the purposes of hemodialysis was clinically related to these diagnosis codes. We stated that for clinical coherence, the cases reporting these diagnoses should be grouped with the subset of cases that report the insertion of totally implantable vascular access devices or tunneled vascular access devices as an inpatient procedure for the purposes of hemodialysis for renal failure.

As discussed in the FY 2024 IPPS/LTCH proposed rule, we reviewed the eight diagnosis codes submitted by the requestor. Diagnosis codes T82.510A, T82.511A, T82.520A, T82.521A, T82.530A, T82.531A, T82.590A, and T82.591A describe mechanical complications of arteriovenous fistulas and shunts and are currently assigned to MDC 05 (Diseases and Disorders of the Circulatory System). The eight diagnosis codes would require reassignment to MDC 11 in MS–DRGs 673, 674, and 675 to group with the subset of cases that report the insertion of totally implantable vascular access devices or tunneled vascular access devices as an inpatient procedure for the purposes of hemodialysis for renal failure. We examined claims data from the September 2022 update of the FY 2022 MedPAR file for all cases reporting procedures describing the insertion of TIVADs or tunneled vascular access devices with a principal diagnosis describing mechanical complications of arteriovenous fistulas and shunts and compared these data to cases in MS–DRGs 673, 674 and 675. The following table shows our findings:

| MS-DRGs 673, 674 and 675 Compared to Cases Reporting Procedures Describing the Insertion of TIVADs or Tunneled Vascular Access Devices with a Principal Diagnosis Code Describing Mechanical Complications of Complications of Arteriovenous Fistulas and Shunts |
|---------------------------------|----------------|----------------|----------------|
|                                 | MS-DRG         | Number of Cases | Average Length of Stay | Average Costs |
| All cases                       |                | 13,904          | 12.1                   | $31,946       |
| Cases reporting procedures describing the insertion of TIVADs or tunneled vascular access devices with a principal diagnosis of T82.510A, T82.511A, T82.520A, T82.521A, T82.530A, T82.531A, T82.590A or T82.591A with secondary diagnosis designated as MCC | 748            | 6               | $24,467       |
| All cases                       |                | 5,532           | 7.8                    | $20,702       |
| Cases reporting procedures describing the insertion of TIVADs or tunneled vascular access devices with a principal diagnosis T82.510A, T82.511A, T82.520A, T82.521A, T82.530A, T82.531A, T82.590A or T82.591A with secondary diagnosis designated as CC | 1              | 3               | $6,418        |
| All cases                       |                | 303             | 3.6                    | $13,343       |
| Cases reporting procedures describing the insertion of TIVADs or tunneled vascular access devices with a principal diagnosis T82.510A, T82.511A, T82.520A, T82.521A, T82.530A, T82.531A, T82.590A or T82.591A without secondary diagnosis designated as CC or MCC | 0              | 0               | $0            |

As shown in the table, there were 13,904 cases in MS–DRG 673 with an average length of stay of 12.1 days and average costs of $31,946. There were 748 cases reporting a principal diagnosis describing mechanical complications of arteriovenous fistulas and shunts, with a secondary diagnosis of MCC, and a procedure code for the insertion of a TIVAD or tunneled vascular access device with an average length of stay of 6 days and average costs of $24,467. There were 5,532 cases in MS–DRG 674 with an average length of stay of 7.8 days and average costs of $20,702. There was one case reporting a principal diagnosis describing mechanical complications of arteriovenous fistulas and shunts, with a secondary diagnosis of CC, and a procedure code for the insertion of a TIVAD or tunneled vascular access device with a length of stay of 3 days and costs of $6,418. There were 303 cases in MS–DRG 675 with an average length of stay of 3.6 days and average costs of $13,343. There were zero cases reporting a principal diagnosis describing mechanical complications of arteriovenous fistulas and shunts, without a secondary diagnosis of CC or MCC, and a procedure code for the insertion of a TIVAD or tunneled vascular access device. We note that the average length of stay and average costs of cases reporting a principal diagnosis describing mechanical complications of arteriovenous fistulas and shunts and the insertion of a TIVAD or a tunneled
vascular access device are lower than for all cases in MS–DRGs 673 and 674, respectively.

To further examine the impact of moving the eight MDC 05 diagnoses into MDC 11, in the proposed rule, we stated we analyzed claims data for cases reporting an O.R. procedure assigned to MDC 05 and a principal diagnosis describing mechanical complications of arteriovenous fistulas and shunts. Our findings are reflected in the following table:

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Description</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>215</td>
<td>Other Heart Assist System Implant</td>
<td>1</td>
<td>1</td>
<td>$68,682</td>
</tr>
<tr>
<td>219</td>
<td>Cardiac Valve and Other Major Cardiothoracic Procedures without Cardiac Catheterization with MCC</td>
<td>1</td>
<td>13</td>
<td>$207,909</td>
</tr>
<tr>
<td>228</td>
<td>Other Cardiothoracic Procedures with MCC</td>
<td>3</td>
<td>5</td>
<td>$61,681</td>
</tr>
<tr>
<td>233</td>
<td>Coronary Bypass with Cardiac Catheterization or Open Ablation with MCC</td>
<td>1</td>
<td>13</td>
<td>$143,481</td>
</tr>
<tr>
<td>239</td>
<td>Amputation for Circulatory System Disorders Except Upper Limb and Toe with MCC</td>
<td>6</td>
<td>19.5</td>
<td>$71,860</td>
</tr>
<tr>
<td>242</td>
<td>Permanent Cardiac Pacemaker Implant with MCC</td>
<td>2</td>
<td>16.5</td>
<td>$94,850</td>
</tr>
<tr>
<td>246</td>
<td>Percutaneous Cardiovascular Procedures with Drug-Eluting Stent with MCC or + Arteries or Stents</td>
<td>7</td>
<td>12.7</td>
<td>$56,048</td>
</tr>
<tr>
<td>252</td>
<td>Other Vascular Procedures with MCC</td>
<td>1,323</td>
<td>5.2</td>
<td>$22,734</td>
</tr>
<tr>
<td>253</td>
<td>Other Vascular Procedures with CC</td>
<td>42</td>
<td>4</td>
<td>$13,092</td>
</tr>
<tr>
<td>254</td>
<td>Other Vascular Procedures without CC/MCC</td>
<td>4</td>
<td>2.5</td>
<td>$9,344</td>
</tr>
<tr>
<td>255</td>
<td>Upper Limb and Toe Amputation for Circulatory System Disorders with MCC</td>
<td>2</td>
<td>6</td>
<td>$21,121</td>
</tr>
<tr>
<td>263</td>
<td>Vein Ligation and Stripping</td>
<td>9</td>
<td>4.6</td>
<td>$19,576</td>
</tr>
<tr>
<td>264</td>
<td>Other Circulatory System O.R. Procedures</td>
<td>102</td>
<td>6</td>
<td>$23,393</td>
</tr>
<tr>
<td>268</td>
<td>Aortic and Heart Assist Procedures Except Pulsation Balloon with MCC</td>
<td>1</td>
<td>8</td>
<td>$49,865</td>
</tr>
<tr>
<td>270</td>
<td>Other Major Cardiovascular Procedures with MCC</td>
<td>75</td>
<td>4.9</td>
<td>$26,697</td>
</tr>
<tr>
<td>271</td>
<td>Other Major Cardiovascular Procedures with CC</td>
<td>2</td>
<td>3</td>
<td>$37,375</td>
</tr>
</tbody>
</table>

Total Cases: 1,581  5.3  $23,643

We noted in the proposed rule that whenever there is a surgical procedure reported on the claim that is unrelated to the MDC to which the case was assigned based on the principal diagnosis, it results in an MS–DRG assignment to a surgical class referred to as “unrelated operating room procedures”. As shown in the table, if we were to move the eight diagnosis codes describing mechanical complications of arteriovenous fistulas and shunts from MDC 05 to MDC 11, 1,581 cases would be assigned to the surgical class referred to as “unrelated operating room procedures” as an unintended consequence. We stated that the data also indicates that there were more cases that reported an O.R. procedure assigned to MDC 05 with a principal diagnosis describing mechanical complications of arteriovenous fistulas and shunts than there were cases reporting a principal diagnosis describing mechanical complications of arteriovenous fistulas and shunts and a procedure code for the insertion of a TIVAD or tunneled vascular access device (1,581 cases versus 749 cases) demonstrating that inpatient admissions for mechanical complications of arteriovenous fistulas and shunts more typically have an O.R. procedure assigned to MDC 05 performed.

We further stated we also reviewed the cases reporting an O.R. procedure assigned to MDC 05 and a principal diagnosis describing mechanical complications of arteriovenous fistulas and shunts to identify the top 10 O.R. procedures assigned to MDC 05 that were reported within the claims data for these cases. Our findings are shown in the following table:
As noted previously, if we were to move the eight diagnosis codes describing mechanical complications of arteriovenous fistulas and shunts to MDC 11, cases reporting one of the O.R. procedures assigned to MDC 05 shown in the table would be assigned to the surgical class referred to as “unrelated operating room procedures” as an unintended consequence.

Based on the results of our analysis, we stated we did not support adding the eight diagnosis codes that describe mechanical complications of arteriovenous fistulas and shunts to the special logic in MS–DRGs 673, 674, and 675. As discussed previously, these diagnosis codes are assigned to MDC 05 (Diseases and Disorders of the Circulatory System). In the proposed rule, we noted that patients can sometimes require the insertion of tunneled or totally implantable vascular access devices for hemodialysis while surgically created AV fistulas or AV shunts are unable to be accessed due to mechanical complications, however, more often these mechanical complications related to AV fistulas or AV shunts require inpatient admission for vascular surgery to be effectively treated. We stated that while patients can sometimes require the insertion of tunneled or totally implantable vascular access devices, these MS–DRGs into one of the surgical MS–DRGs for the MDC into which the primary diagnosis falls. The data are arrayed in two ways for comparison purposes. We look at a frequency count of each major operative procedure code. We also compare procedures across MDCs by volume of procedure codes within each MDC. We use this information to determine which procedure codes and diagnosis codes to examine.

We identify those procedures occurring in conjunction with certain principal diagnoses with sufficient frequency to justify adding them to one of the surgical MS–DRGs for the MDC in which the diagnosis falls. We also consider whether it would be more appropriate to move cases reporting these procedure codes out of these MS–DRGs into one of the surgical MS–DRGs for the MDC into which the principal diagnosis falls. The data are arrayed in two ways for comparison purposes. We look at a frequency count of each major operative procedure code. We also compare procedures across MDCs by volume of procedure codes within each MDC. We use this information to determine which procedure codes and diagnosis codes to examine.

We identify those procedures occurring in conjunction with certain principal diagnoses with sufficient frequency to justify adding them to one of the surgical MS–DRGs for the MDC in which the diagnosis falls. We also consider whether it would be more appropriate to move cases reporting these procedure codes out of these MS–DRGs into one of the surgical MS–DRGs for the MDC into which the principal diagnosis falls. The data are arrayed in two ways for comparison purposes. We look at a frequency count of each major operative procedure code. We also compare procedures across MDCs by volume of procedure codes within each MDC. We use this information to determine which procedure codes and diagnosis codes to examine.

We annually conduct a review of procedures producing assignment to MS–DRGs 981 through 983 (Extensive O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively) or MS–DRGs 987 through 989 (Non-Extensive O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively) on the basis of volume, by procedure, to see if it would be appropriate to move cases reporting these procedure codes out of these MS–DRGs into one of the surgical MS–DRGs for the MDC into which the principal diagnosis falls. The data are arrayed in two ways for comparison purposes. We look at a frequency count of each major operative procedure code. We also compare procedures across MDCs by volume of procedure codes within each MDC. We use this information to determine which procedure codes and diagnosis codes to examine.

We identify those procedures occurring in conjunction with certain principal diagnoses with sufficient frequency to justify adding them to one of the surgical MS–DRGs for the MDC in which the diagnosis falls. We also consider whether it would be more appropriate to move cases reporting these procedure codes out of these MS–DRGs into one of the surgical MS–DRGs for the MDC into which the principal diagnosis falls. The data are arrayed in two ways for comparison purposes. We look at a frequency count of each major operative procedure code. We also compare procedures across MDCs by volume of procedure codes within each MDC. We use this information to determine which procedure codes and diagnosis codes to examine.
this section of this rule from MS–DRGs 981 through 983 or MS–DRGs 987 through 989 into one of the surgical MS–DRGs for the MDC into which the principal diagnosis or procedure is assigned.

a. Percutaneous Endoscopic Resection of Colon

As discussed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26733 through 26735), during our review of the cases that group to MS–DRGs 981 through 983, we noted that when ICD–10–PCS procedure code 0DTN4ZZ (Resection of sigmoid colon, percutaneous endoscopic approach) is reported with a principal diagnosis in MDC 11 (Diseases and Disorders of the Kidney and Urinary Tract), the cases group to MS–DRGs 981 through 983. We stated in the proposed rule that the principal diagnosis most frequently reported with ICD–10–PCS procedure code 0DTN4ZZ in MDC 11 is ICD–10–CM code N32.1 (Vesicointestinal fistula). ICD–10–PCS procedure code 0DTN4ZZ currently groups to several MDCs, which are listed in the following table.

<table>
<thead>
<tr>
<th>MDC</th>
<th>MS-DRG</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>06</td>
<td>329-331</td>
<td>Major Small and Large Bowel Procedures</td>
</tr>
<tr>
<td>17</td>
<td>820-822</td>
<td>Lymphoma and Leukemia with Major Procedure</td>
</tr>
<tr>
<td>17</td>
<td>826-828</td>
<td>Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major Procedure</td>
</tr>
<tr>
<td>21</td>
<td>907-909</td>
<td>Other O.R. Procedures for Injuries</td>
</tr>
<tr>
<td>24</td>
<td>957-959</td>
<td>Other Procedures for Multiple Significant Trauma</td>
</tr>
</tbody>
</table>

As noted in the proposed rule, we examined claims data from the September 2022 update of the FY 2022 MedPAR file to identify the average length of stay and average costs for cases reporting procedure code 0DTN4ZZ with a principal diagnosis in MDC 11, which are currently grouping to MS–DRGs 981 through 983, as well as all cases in MS–DRGs 981 through 983. Our findings are shown in the following table.

<table>
<thead>
<tr>
<th>MS-DRGs 981-983: All Cases and Cases with Principal Diagnosis in MDC 11 and Procedure Code 0DTN4ZZ</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG 981--All cases</td>
<td>21,139</td>
<td>12.6</td>
<td>$37,872</td>
</tr>
<tr>
<td>MS-DRG 981--Cases reporting procedure code 0DTN4ZZ and a principal diagnosis in MDC 11</td>
<td>12</td>
<td>11.5</td>
<td>$36,596</td>
</tr>
<tr>
<td>MS-DRG 982--All cases</td>
<td>9,386</td>
<td>5.9</td>
<td>$20,819</td>
</tr>
<tr>
<td>MS-DRG 982--Cases reporting procedure code 0DTN4ZZ and a principal diagnosis in MDC 11</td>
<td>38</td>
<td>5.2</td>
<td>$23,624</td>
</tr>
<tr>
<td>MS-DRG 983--All cases</td>
<td>1,782</td>
<td>2.6</td>
<td>$14,541</td>
</tr>
<tr>
<td>MS-DRG 983--Cases reporting procedure code 0DTN4ZZ and a principal diagnosis in MDC 11</td>
<td>12</td>
<td>2.8</td>
<td>$25,172</td>
</tr>
</tbody>
</table>

We then examined the MS–DRGs within MDC 11 and determined that the cases reporting procedure code 0DTN4ZZ with a principal diagnosis in MDC 11 would most suitably group to MS–DRGs 673, 674, and 675 (Other Kidney and Urinary Tract Procedures with MCC, with CC, and without CC/MCC, respectively), which contain procedures performed on structures other than kidney and urinary tract anatomy.

To determine how the resources for this subset of cases compared to cases in MS–DRGs 673, 674, and 675 as a whole, we stated in the proposed rule we examined the average costs and length of stay for cases in MS–DRGs 673, 674, and 675. Our findings are shown in this table.
We reviewed the data and noted in the proposed rule that for this subset of cases, the average costs are higher and the average length of stays are shorter than for cases in MS–DRGs 673, 674, and 675. However, we stated we believed that when ICD–10–PCS procedure code 0DTN4ZZ is reported with a principal diagnosis in MDC 11 (typically vesicointestinal fistula), the procedure is related to the principal diagnosis. Because vesicointestinal fistulas involve both the bladder and the bowel, we stated some procedures in both MDC 06 (Diseases and Disorders of the Digestive System) and MDC 11 (Diseases and Disorders of the Kidney and Urinary Tract) would be expected to be related to a principal diagnosis of vesicointestinal fistula (ICD–10–CM code N32.1). Therefore, we proposed to add ICD–10–PCS procedure code 0DTN4ZZ to MDC 11. Under this proposal, cases reporting procedure code 0DTN4ZZ with a principal diagnosis of vesicointestinal fistula (diagnosis code N32.1) in MDC 11 would group to MS–DRGs 673, 674, and 675.

Comment: Commenters supported the proposal to add ICD–10–PCS procedure code 0DTN4ZZ (Resection of sigmoid colon, percutaneous endoscopic approach) to MDC 11 (Diseases and Disorders of the Kidney and Urinary Tract), without modification, effective October 1, 2023 for FY 2024.

b. Open Excision of Muscle

As discussed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26735 through 26737), during the review of the cases that group to MS–DRGs 981 through 983, we noted that when ICD–10–PCS procedure codes describing the open excision of muscle are reported in conjunction with ICD–10–CM diagnosis codes in MDC 05 (Diseases and Disorders of the Circulatory System), the cases group to MS–DRGs 981 through 983. The list of 28 ICD–10–CM procedure codes reviewed, as well as their current MDC assignments, are found in the table:

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG 673--All cases</td>
<td>13,904</td>
<td>12.1</td>
<td>$31,946</td>
</tr>
<tr>
<td>MS-DRG 674--All cases</td>
<td>5,532</td>
<td>7.8</td>
<td>$20,702</td>
</tr>
<tr>
<td>MS-DRG 675--All cases</td>
<td>303</td>
<td>3.6</td>
<td>$13,343</td>
</tr>
</tbody>
</table>
We refer the reader to Appendix E of the ICD–10 MS–DRG Version 40.1 Definitions Manual (which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRGClassifications-and-Software) for the MS–DRG assignment for each procedure code listed and further discussion of how each procedure code may be assigned to multiple MDCs and MS–DRGs under the IPPS.

As discussed in the proposed rule, the principal diagnosis most frequently reported with the 28 ICD–10–PCS procedure codes describing the open excision of muscle in MDC 05 is ICD–10–CM code I96 (Gangrene, not elsewhere classified). Gangrene is a condition in which body tissue dies from not getting enough blood. It can cause changes in skin color, numbness or pain, swelling, and other symptoms. The combination of a procedure code describing the open excision of muscle and ICD–10–CM diagnosis code I96 indicates open debridement of muscle for gangrene was performed.

We stated we examined claims data from the September 2022 update of the FY 2022 MedPAR file to identify the average length of stay and average costs for cases reporting a procedure code describing the open excision of muscle with a principal diagnosis in MDC 05, which are currently grouping to MS–DRGs 981 through 983, as well as all cases in MS–DRGs 981 through 983. Our findings are shown in the following table.
We then examined the MS–DRGs within MDC 05 and stated we determined that the cases reporting procedure codes describing the open excision of muscle with a principal diagnosis in MDC 05 would most suitably group to MS–DRG 264 (Other Circulatory System O.R. Procedures), which contains procedures performed on structures other than circulatory anatomy.

To determine how the resources for this subset of cases compared to cases in MS–DRG 264 as a whole, we examined the average costs and length of stay for cases in MS–DRG 264. Our findings are shown in this table.

<table>
<thead>
<tr>
<th>MS–DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS–DRG 981--All cases</td>
<td>21,139</td>
<td>12.6</td>
<td>$37,872</td>
</tr>
<tr>
<td>MS–DRG 981--Cases reporting procedure code describing the open excision of muscle and a principal diagnosis in MDC 05</td>
<td>362</td>
<td>11.7</td>
<td>$27,392</td>
</tr>
<tr>
<td>MS–DRG 982--All cases</td>
<td>9,386</td>
<td>5.9</td>
<td>$20,819</td>
</tr>
<tr>
<td>MS–DRG 982--Cases reporting procedure code describing the open excision of muscle and a principal diagnosis in MDC 05</td>
<td>121</td>
<td>7.9</td>
<td>$16,989</td>
</tr>
<tr>
<td>MS–DRG 983--All cases</td>
<td>1,782</td>
<td>2.6</td>
<td>$14,541</td>
</tr>
<tr>
<td>MS–DRG 983--Cases reporting procedure code describing the open excision of muscle and a principal diagnosis in MDC 05</td>
<td>6</td>
<td>4.7</td>
<td>$7,140</td>
</tr>
</tbody>
</table>

As discussed in the proposed rule, we reviewed the data and noted for this subset of cases, in the “with MCC” subgroup the average costs of the cases reporting procedure codes describing the open excision of muscle with a principal diagnosis in MDC 05 are slightly higher ($27,392 compared to $27,237) and the average length of stay is longer (11.7 days compared to 9.9 days) than for all cases in MS–DRG 264, while the cases in the “with CC” and the “without CC/MCC” subgroups have lower average costs ($16,989 and $7,140 respectively compared to $27,237) and a shorter average length of stay (7.9 days and 4.7 days respectively compared to 9.9 days) than for cases in MS–DRG 264. However, we stated that when a procedure code describing the open excision of muscle is reported with a principal diagnosis in MDC 05 (typically gangrene, not elsewhere classified), the procedure is related to the principal diagnosis. Because debridement, or the cutting away of dead and dying tissue, can be performed to keep gangrene from spreading, we stated a procedure code describing the open excision of muscle would be expected to be related to a principal diagnosis of gangrene, not elsewhere classified (diagnosis code I96), and it would be clinically appropriate for the procedures to group to the same MS–DRGs as the principal diagnoses. Therefore, we proposed to add the 28 procedure codes listed previously to MDC 05. Under this proposal, cases reporting a procedure code describing the open excision of muscle with a principal diagnosis of gangrene, not elsewhere classified (diagnosis code I96) in MDC 05 would group to MS–DRG 264.

As discussed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26737 through 26739), during our review of the cases that group to MS–DRGs 981 through 983, we noted that when ICD–10–PCS procedure code ONR00JZ (Replacement of skull with synthetic substitute, open approach) is reported with a principal diagnosis in MDC 09 (Diseases and Disorders of the Skin, Subcutaneous Tissue and Breast), the cases group to MS–DRGs 981 through 983. The principal diagnosis most frequently reported with ICD–10–PCS procedure code ONR00JZ is ICD–10–CM code Z42.8 (Encounter for other plastic and reconstructive surgery, without debridement or amputation).
following medical procedure or healed injury). ICD–10–PCS procedure code 0NR00JZ currently groups to several MDCs, which are listed in the following table.

<table>
<thead>
<tr>
<th>MDC</th>
<th>MS-DRG</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>023-024</td>
<td>Craniotomy with Major Device Implant or Acute Complex CNS Principal Diagnosis</td>
</tr>
<tr>
<td></td>
<td>025-027</td>
<td>Craniotomy and Endovascular Intracranial Procedures</td>
</tr>
<tr>
<td>03</td>
<td>143-145</td>
<td>Other Ear, Nose, Mouth and Throat O.R. Procedures</td>
</tr>
<tr>
<td>08</td>
<td>515-517</td>
<td>Other Musculoskeletal System and Connective Tissue O.R. Procedures</td>
</tr>
<tr>
<td>21</td>
<td>907-909</td>
<td>Other O.R. Procedures for Injuries</td>
</tr>
<tr>
<td>24</td>
<td>955</td>
<td>Craniotomy for Multiple Significant Trauma</td>
</tr>
</tbody>
</table>

As discussed in the proposed rule, we examined claims data from the September 2022 update of the FY 2022 MedPAR file to identify the average length of stay and average costs for cases reporting procedure code 0NR00JZ with a principal diagnosis in MDC 09, which are currently grouping to MS–DRGs 981 through 983, as well as all cases in MS–DRGs 981 through 983. Our findings are shown in the following table.

| MS-DRGs 981–983: All Cases and Cases with Principal Diagnosis in MDC 09 and Procedure Code 0NR00JZ |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| MS-DRG                                          | Number of Cases | Average Length of Stay | Average Costs |
| MS-DRG 981--All cases                          | 21,139           | 12.6                  | $37,872       |
| MS-DRG 981--Cases reporting procedure code 0NR00JZ and a principal diagnosis in MDC 09 | 10               | 5.4                   | $34,627       |
| MS-DRG 982--All cases                          | 9,386            | 5.9                   | $20,819       |
| MS-DRG 982--Cases reporting procedure code 0NR00JZ and a principal diagnosis in MDC 09 | 28               | 3.3                   | $21,776       |
| MS-DRG 983--All cases                          | 1,782            | 2.6                   | $14,541       |
| MS-DRG 983--Cases reporting procedure code 0NR00JZ and a principal diagnosis in MDC 09 | 21               | 2.1                   | $23,709       |

We then examined the MS–DRGs within MDC 09 and determined that the cases reporting procedure code 0NR00JZ with a principal diagnosis in MDC 09 would most suitably group to MS–DRGs 579, 580, and 581 (Other Skin, Subcutaneous Tissue and Breast Procedures with MCC, with CC, and without CC/MCC, respectively) given the nature of the procedure. MS–DRGs 579, 580, and 581 contain procedures assigned to MDC 09 that do not fit within the specific surgical MS–DRGs in MDC 09, which are: skin graft; skin debridement; mastectomy for malignancy; and breast biopsy, local excision, and other breast procedures.

To determine how the resources for this subset of cases compared to cases in MS–DRGs 579, 580, and 581 as a whole, we stated we examined the average costs and length of stay for cases in MS–DRGs 579, 580, and 581. Our findings are shown in this table.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG 579--All cases</td>
<td>3,391</td>
<td>11</td>
<td>$26,423</td>
</tr>
<tr>
<td>MS-DRG 580--All cases</td>
<td>5,896</td>
<td>5.7</td>
<td>$14,628</td>
</tr>
<tr>
<td>MS-DRG 581--All cases</td>
<td>1,831</td>
<td>2.6</td>
<td>$11,784</td>
</tr>
</tbody>
</table>

We reviewed the data and noted for this subset of cases, the average costs are higher and the average length of stays are shorter than for cases in MS–DRGs 579, 580, and 581. However, we stated we believed that when ICD–10–PCS procedure code 0NR00JZ is reported with a principal diagnosis in MDC 09 (typically encounter for other plastic and reconstructive surgery following medical procedure or healed injury), the
procedure is related to the principal diagnosis.

We noted in the proposed rule that open brain surgeries that require removing a portion of the skull, for indications such as brain tumor resection, hydrocephalus shunt implantation, cerebral aneurysm clipping, evacuation of a brain hemorrhage, microvascular decompression, and lobectomy, can sometimes result in a residual cranial defect. We stated we believed that would be clinically appropriate for the procedures to group to the same MS–DRGs as the principal diagnosis as procedure code 0NR00JZ can be used to describe cranial reconstruction procedures that involve applying a cranial prosthetic device to address the residual bony void and/or defect to restore the natural contours of the skull.

Therefore, we proposed to add ICD–10–PCS procedure code 0NR00JZ to MDC 09. Under this proposal, cases reporting procedure code 0NR00JZ with a principal diagnosis in MDC 09 (such as encounter for other plastic and reconstructive surgery following medical procedure or healed injury) would group to MS–DRGs 579, 580, and 581.

Comment: Most commenters supported the proposal to add ICD–10–PCS procedure code 0NR00JZ to MDC 09 (Diseases and Disorders of the Skin, Subcutaneous Tissue and Breast). However, a commenter opposed CMS’ proposal. The commenter stated they did not agree and stated MS–DRGs 579, 580, and 581 are not reflective of the clinical nature of skull procedures which are more in line with cranial procedures in MDC 01 (Diseases and Disorders of the Nervous System). This commenter further requested the creation of new MS–DRGs in MDC 01 to reflect the resources utilized in the performance of these procedures.

Response: We thank the commenters for their support and feedback. In response to the commenter that opposed the proposal, we note that ICD–10–PCS procedure code 0NR00JZ currently groups to several MDCs, which are listed in the previous table. In MDC 01 specifically, ICD–10–PCS procedure code 0NR00JZ is assigned to MS–DRG 023 (Craniotomy with Major Device Implant or Acute Complex CNS Principal Diagnosis with MCC or Chemotherapy Implant or Epilepsy with Neurostimulator), MS–DRG 024 (Craniotomy with Major Device Implant or Acute Complex CNS Principal Diagnosis without MCC), and MS–DRGs 025, 026, and 027 (Craniotomy and Endovascular Intracranial Procedures with MCC, with CC, and without CC/ MCC, respectively). When ICD–10–PCS procedure code 0NR00JZ is reported with an ICD–10–CM diagnosis code assigned to MDC 01, the cases group MS–DRGs 023 through 027 depending on the circumstances of the admission. ICD–10–CM diagnosis code Z42.8 (Encounter for other plastic and reconstructive surgery following medical procedure or healed injury), however, is currently assigned to MDC 09 and would require reassignment to MDC 01 in order for these cases to group to MS–DRGs in MDC 01 as suggested by the commenter. We believe that diagnosis code Z42.8 is appropriately assigned to MDC 09 (Diseases and Disorders of the Circulatory System) as it describes encounters for other plastic and reconstructive surgery following medical procedure or healed injury. In reviewing the commenter’s concerns, we note that diagnosis code Z42.8 does not describe a diagnosis or circumstance limited to affecting the nervous system. It would not be appropriate to move this diagnosis code into another MDC because it could inadvertently cause cases reporting this MDC 09 diagnosis with reconstructive procedures to be assigned to an unrelated MS–DRG. We note that whenever there is a surgical procedure reported on the claim that is unrelated to the MDC to which the case was assigned based on the principal diagnosis, it results in a MS–DRG assignment to a surgical class referred to as “unrelated operating room procedures”.

As discussed in the proposed rule, we note that MS–DRGs 579, 580, and 581 contain procedures assigned to MDC 09 that do not fit within the specific surgical MS–DRGs in MDC 09. We continue to believe that when ICD–10–PCS procedure code 0NR00JZ is reported with a principal diagnosis in MDC 09 (typically encounter for other plastic and reconstructive surgery following medical procedure or healed injury), the procedure is related to the principal diagnosis and that it would be clinically appropriate for the procedure to group to the same MS–DRGs as the principal diagnosis. We also continue to believe that cases reporting procedure code 0NR00JZ with a principal diagnosis in MDC 09 would most suitably group to MS–DRGs 579, 580, and 581 (Other Skin, Subcutaneous Tissue and Breast Procedures with MCC, with CC, and without CC/MCC, respectively) given the nature of the procedure.

Therefore, after consideration of the public comments we received, and for the reasons discussed, we are finalizing our proposal to add ICD–10–PCS procedure code 0NR00JZ to MDC 09 (Diseases and Disorders of the Circulatory System), without modification, effective October 1, 2023 for FY 2024.

d. Endoscopic Dilation of Ureters With Intraluminal Device

As discussed in the FY 2024 IPPS/ LTCH PPS proposed rule (88 FR 26739 through 26740), during the review of the cases that group to MS–DRGs 987 through 989, we noted that when ICD–10–PCS procedure codes describing the endoscopic dilation of ureters with an intraluminal device are reported in conjunction with ICD–10–CM diagnosis codes in MDC 05 (Diseases and Disorders of the Circulatory System), the cases group to MS–DRGs 987 through 989. The principal diagnosis most frequently reported with ICD–10–PCS procedure codes describing the endoscopic dilation of ureters with an intraluminal device in MDC 05 is ICD–10–CM code I13.0 (Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease).

In the following tables, the ICD–10–PCS procedure codes describing the endoscopic dilation of ureters with an intraluminal device are listed, as well as their MDC and MS–DRG assignments.

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>01768DZ</td>
<td>Dilation of right ureter with intraluminal device, via natural or artificial opening endoscopic</td>
</tr>
<tr>
<td>01778DZ</td>
<td>Dilation of left ureter with intraluminal device, via natural or artificial opening endoscopic</td>
</tr>
<tr>
<td>0T788DZ</td>
<td>Dilation of bilateral ureters with intraluminal device, via natural or artificial opening endoscopic</td>
</tr>
</tbody>
</table>
As discussed in the proposed rule, we examined claims data from the September 2022 update of the FY 2022 MedPAR file to identify the average length of stay and average costs for cases reporting procedure code 0T768DZ, 0T778DZ, or 0T888DZ with a principal diagnosis in MDC 05, which are currently grouping to MS–DRGs 987 through 989, as well as all cases in MS–DRGs 987 through 989. Our findings are shown in the following table.

### MS-DRGs 987-989: All Cases and Cases with Principal Diagnosis in MDC 05 and Procedure Code 0T768DZ, 0T778DZ or 0T788DZ

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG 987--All cases</td>
<td>7,305</td>
<td>11.2</td>
<td>$28,127</td>
</tr>
<tr>
<td>MS-DRG 987--Cases reporting procedure code 0T768DZ, 0T778DZ or 0T788DZ and a principal diagnosis in MDC 05</td>
<td>358</td>
<td>10.3</td>
<td>$24,657</td>
</tr>
<tr>
<td>MS-DRG 988--All cases</td>
<td>5,001</td>
<td>5.7</td>
<td>$14,402</td>
</tr>
<tr>
<td>MS-DRG 988--Cases reporting procedure code 0T768DZ, 0T778DZ or 0T788DZ and a principal diagnosis in MDC 05</td>
<td>134</td>
<td>4.6</td>
<td>$13,704</td>
</tr>
<tr>
<td>MS-DRG 989--All cases</td>
<td>681</td>
<td>3.0</td>
<td>$9,570</td>
</tr>
<tr>
<td>MS-DRG 989--Cases reporting procedure code 0T768DZ, 0T778DZ or 0T788DZ and a principal diagnosis in MDC 05</td>
<td>7</td>
<td>1.4</td>
<td>$8,729</td>
</tr>
</tbody>
</table>

We stated we then examined the MS–DRGs within MDC 05 and determined that the cases reporting procedure codes describing the endoscopic dilation of ureters with an intraluminal device with a principal diagnosis in MDC 05 would most suitably group to MS–DRG 264 (Other Circulatory System O.R. Procedures), which contains procedures performed on structures other than circulatory anatomy. To determine how the resources for this subset of cases compared to cases in MS–DRG 264 as a whole, we stated we examined the average costs and length of stay for cases in MS–DRG 264. Our findings are shown in this table.

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG 264--All cases</td>
<td>6,774</td>
<td>9.9</td>
<td>$27,237</td>
</tr>
</tbody>
</table>

As discussed in the proposed rule, we reviewed these data and noted that the average costs for this subset of cases, most of which group to MS–DRG 987, are lower than the average costs than for cases in MS–DRG 264. However, we stated we believed that when a procedure code describing the endoscopic dilation of ureters with an intraluminal device is reported with a principal diagnosis in MDC 05 (typically hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease), the procedure is related to the principal diagnosis. We noted in the proposed rule that ureteral intraluminal devices are used to relieve ureteral obstruction by passively dilating the ureter to allow urine to drain through the center of the hollow intraluminal device as well as around the device. Indications for endoscopic
ureteral intraluminal device placement include the uncomplicated ureteral obstruction due to causes such as nephrolithiasis, tumor, or retroperitoneal fibrosis, or obstruction complicated by urinary tract infection, renal insufficiency, or renal failure. As the endoscopic dilation of ureters with an intraluminal device would be expected to be related to a principal diagnosis of hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease, not elsewhere classified (diagnosis code I13.0), we stated it would be clinically appropriate for the procedures to group to the same MS–DRGs as the principal diagnoses.

Therefore, we proposed to add ICD–10–PCS procedure codes 0T768DZ, 0T778DZ, and 0T788DZ to MDC 05. Under this proposal, cases reporting procedure code 0T768DZ, 0T778DZ, or 0T788DZ with a principal diagnosis of hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease (I13.0) in MDC 05 would group to MS–DRG 264.

Comment: Most commenters supported the proposal to add ICD–10–PCS procedure codes 0T768DZ, 0T778DZ and 0T788DZ to MDC 05 (Diseases and Disorders of the Circulatory System). However, a commenter opposed CMS’ proposal. The commenter stated they did not agree and stated these cases would most appropriately group to MDC 11 (Diseases and Disorders of the Kidney and Urinary Tract).

Response: We thank the commenters for their support and feedback. In response to the commenter that opposed the proposal, we note that ICD–10–CM diagnosis code I13.0 (Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease) is currently assigned to MDC 05 and would require reassignment to MDC 11 in order for these cases to group to MDC 11 as suggested by the commenter. As discussed in prior rulemaking (85 FR 58504), we believe that this diagnosis code is appropriately assigned to MDC 05 (Diseases and Disorders of the Circulatory System) as it describes heart failure. We continue to believe it would not be appropriate to move this diagnosis into another MDC because it could inadvertently cause cases reporting this MDC 05 diagnosis with a circulatory system procedure to be assigned to an unrelated MS–DRG. We note that whenever there is a surgical procedure reported on the claim that is unrelated to the MDC to which the case was assigned based on the principal diagnosis, it results in a MS–DRG assignment to a surgical class referred to as “unrelated operating room procedures”.

Therefore, after consideration of the public comments we received, and for the reasons discussed, we are finalizing our proposal to add ICD–10–PCS procedure codes 0T768DZ, 0T778DZ, and 0T788DZ to MDC 05 (Diseases and Disorders of the Circulatory System), without modification, effective October 1, 2023, for FY 2024.

e. Occlusion of Splenic Artery

As discussed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26740 through 26742), during our review of the cases currently grouping to MS–DRGs 987 through 989, we noted that when ICD–10–PCS procedure codes describing the occlusion of the splenic artery are reported in conjunction with ICD–10–CM diagnosis codes in MDC 16 (Diseases and Disorders of Blood, Blood Forming Organs and Immunologic Disorders), the cases group to MS–DRGs 987 through 989. The principal diagnosis most frequently reported with ICD–10–PCS procedure codes describing the occlusion of the splenic artery in MDC 16 is ICD–10–CM code S36.032A (Major laceration of spleen, initial encounter).

In the following tables, the ICD–10–PCS procedure codes describing the occlusion of the splenic artery are listed, as well as their MDC and MS–DRG assignments.

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>04L40CZ</td>
<td>Occlusion of splenic artery with extraluminal device, open approach</td>
</tr>
<tr>
<td>04L40DZ</td>
<td>Occlusion of splenic artery with intraluminal device, open approach</td>
</tr>
<tr>
<td>04L40ZZ</td>
<td>Occlusion of splenic artery, open approach</td>
</tr>
<tr>
<td>04L43CZ</td>
<td>Occlusion of splenic artery with extraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>04L43DZ</td>
<td>Occlusion of splenic artery with intraluminal device, percutaneous approach</td>
</tr>
<tr>
<td>04L43ZZ</td>
<td>Occlusion of splenic artery, percutaneous approach</td>
</tr>
<tr>
<td>04L44CZ</td>
<td>Occlusion of splenic artery with extraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04L44DZ</td>
<td>Occlusion of splenic artery with intraluminal device, percutaneous endoscopic approach</td>
</tr>
<tr>
<td>04L44ZZ</td>
<td>Occlusion of splenic artery, percutaneous endoscopic approach</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MS-DRG Assignments of the ICD-10-PCS Procedure Codes Describing the Occlusion of the Splenic Artery</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDC</td>
</tr>
<tr>
<td>-----</td>
</tr>
<tr>
<td>05</td>
</tr>
<tr>
<td>06</td>
</tr>
<tr>
<td>21</td>
</tr>
<tr>
<td>24</td>
</tr>
</tbody>
</table>
As discussed in the proposed rule, we examined claims data from the September 2022 update of the FY 2022 MedPAR file to identify the average length of stay and average costs for cases reporting procedure codes describing the occlusion of the splenic artery with a principal diagnosis in MDC 16, which are currently grouping to MS–DRGs 987 through 989, as well as all cases in MS–DRGs 987 through 989. Our findings are shown in the following table.

### MS–DRGs 987-989: All Cases and Cases with Principal Diagnosis in MDC 16 and Procedure Code Describing the Occlusion of the Splenic Artery

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG 987--All cases</td>
<td>7,305</td>
<td>11.2</td>
<td>$28,127</td>
</tr>
<tr>
<td>MS-DRG 987--Cases reporting procedure code describing the occlusion of the splenic artery and a principal diagnosis in MDC 16</td>
<td>118</td>
<td>9.1</td>
<td>$36,334</td>
</tr>
<tr>
<td>MS-DRG 988--All cases</td>
<td>5,001</td>
<td>5.7</td>
<td>$14,402</td>
</tr>
<tr>
<td>MS-DRG 988--Cases reporting procedure code describing the occlusion of the splenic artery and a principal diagnosis in MDC 16</td>
<td>76</td>
<td>4.8</td>
<td>$21,845</td>
</tr>
<tr>
<td>MS-DRG 989--All cases</td>
<td>681</td>
<td>3.0</td>
<td>$9,570</td>
</tr>
<tr>
<td>MS-DRG 989--Cases reporting procedure code describing the occlusion of the splenic artery and a principal diagnosis in MDC 16</td>
<td>4</td>
<td>3.3</td>
<td>$25,768</td>
</tr>
</tbody>
</table>

We stated that the cases reporting a procedure code describing the occlusion of the splenic artery with a principal diagnosis in MDC 16 would most suitably group to MS–DRGs 799, 800, and 801 (Splenectomy with MCC, with CC, and without CC/MCC, respectively) given the nature of the procedure.

We noted that the average length of stay and average costs of the subset of cases reporting a procedure code describing the occlusion of the splenic artery with a principal diagnosis in MDC 16 are more similar to those of cases in MS–DRGs 799, 800, and 801. In the proposed rule, we also noted that in cases of splenic injury, the diagnosis and prompt management of potentially life-threatening hemorrhage is the primary goal. Procedures to occlude the splenic artery, such as splenic embolization, can be performed for spleen injuries, such as lacerations, in order to manage bleeding prior to or instead of more invasive splenic procedures. We stated a procedure code describing the occlusion of the splenic artery would be expected to be related to a principal diagnosis of a major laceration of spleen, initial encounter.
(diagnosis code S36.032A) and would be clinically appropriate for the procedures to group to the same MS–DRGs as the principal diagnoses.

Given the similarity in resource use between this subset of cases and cases in MS–DRGs 799, 800, and 801, and that we believed that procedure codes describing the occlusion of the splenic artery are related to principal diagnoses in MDC 16 (typically major laceration of spleen, initial encounter), we stated these cases would be more appropriately assigned to MS–DRGs 799, 800, and 801 in MDC 16 than their current assignment in MS–DRGs 987 through 989. Therefore, we proposed to add the nine procedure codes listed in the previous table that describe the occlusion of the splenic artery to MDC 16 (Diseases and Disorders of Blood, Blood Forming Organs and Immunologic Disorders) in MS–DRGs 799, 800, and 801. Under this proposal, cases reporting a principal diagnosis of a major laceration of spleen, initial encounter (S36.032A) with a procedure describing the occlusion of the splenic artery would group to MS–DRGs 799, 800, and 801.

As discussed in the proposed rule, during the review of this issue, we noted that a splenectomy is a surgical operation involving removal of the spleen, however the GROUPER logic list for MS–DRGs 799, 800, and 801 does not exclusively contain procedure codes that describe the removal of the spleen. We refer the reader to the ICD–10 MS–DRG Version 40.1 Definitions Manual (which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/AcuteInpatientPPS/MS-DRGClassifications-and-Software) for complete documentation of the GROUPER logic for MS–DRGs 799, 800, and 801. Therefore, we also proposed to revise the titles of MDC 16 MS–DRGs 799, 800, and 801 from “Splenectomy with MCC, with CC, and without CC/MCC, respectively” to “Splenectomy with MCC, with CC, and without CC/MCC, respectively” to better reflect the assigned procedures.

Response: We appreciate the commenters’ support. We note that consistent with our process as described previously in this section, we do conduct an annual review of procedures producing assignment to MS–DRGs 981 through 983 (Extensive O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively) or MS–DRGs 987 through 989 (Non-Extensive O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively) on the basis of volume, by procedure, to see if it would be appropriate to move cases reporting these procedure codes out of these MS–DRGs into one of the surgical MS–DRGs for the MDC into which the principal diagnosis falls.

After consideration of the public comments we received, we are finalizing our proposal to add the nine procedure codes listed in the previous table that describe the occlusion of the splenic artery to MDC 16 (Diseases and Disorders of Blood, Blood Forming Organs and Immunologic Disorders) in MS–DRGs 799, 800, and 801, without modification, effective October 1, 2023, for FY 2024. We are also finalizing our proposal to revise the titles of MDC 16 MS–DRGs 799, 800, and 801 from “Splenectomy with MCC, with CC, and without CC/MCC, respectively” to “Splenectomy with MCC, with CC, and without CC/MCC, respectively” to better reflect the assigned procedures for FY 2024.

In addition to the internal review of procedures producing assignment to MS–DRGs 981 through 983 or MS–DRGs 987 through 989, as discussed in the proposed rule, we also consider requests that we receive to examine cases found to group to MS–DRGs 981 through 983 or MS–DRGs 987 through 989 to determine if it would be appropriate to add procedure codes to one of the surgical MS–DRGs for the MDC into which the principal diagnosis falls or to move the principal diagnosis to the surgical MS–DRGs to which the procedure codes are assigned. We stated we did not receive any requests suggesting reassignment. Therefore, for FY 2024 we did not propose to move any cases reporting procedure codes from MS–DRGs 981 through 983 to MS–DRGs 987 through 989 or vice versa.

Comment: Commenters expressed support for CMS’ proposal to not move any cases reporting procedure codes from MS–DRGs 981 through 983 to MS–DRGs 987 through 989 or vice versa.

Response: We appreciate the commenters’ support.

After consideration of the public comments we received, we are finalizing, without modification, our proposal to not move any cases reporting procedure codes from MS–DRGs 981 through 983 to MS–DRGs 987 through 989 or vice versa.

11. Operating Room (O.R.) and Non-O.R. Procedures

a. Background

Under the IPPS MS–DRGs (and former CMS DRGs), we have a list of procedure codes that are considered operating room (O.R.) procedures. Historically, we developed this list using physician panels that classified each procedure code based on the procedure and its effect on consumption of hospital resources. For example, generally the presence of a surgical procedure which required the use of the operating room would be expected to have a significant effect on the type of hospital resources (for example, operating room, recovery room, and anesthesia) used by a patient, and therefore, these patients were considered surgical. Because the claims data generally available do not precisely indicate whether a patient was taken to the operating room, surgical patients were identified based on the procedures that were performed. Generally, if the procedure was not expected to require the use of the operating room, the
patient would be considered medical (non-O.R.).

Currently, each ICD–10–PCS procedure code has designations that determine whether and in what way the presence of that procedure on a claim impacts the MS–DRG assignment. First, each ICD–10–PCS procedure code is either designated as an O.R. procedure for purposes of MS–DRG assignment (“O.R. procedures”) or is not designated as an O.R. procedure for purposes of MS–DRG assignment (“non-O.R. procedures”). Second, for each procedure that is designated as an O.R. procedure, that O.R. procedure is further classified as either extensive or non-extensive. Third, for each procedure that is designated as a non-O.R. procedure, that non-O.R. procedure is further classified as either affecting the MS–DRG assignment or not affecting the MS–DRG assignment. We refer to these designations that do affect MS–DRG assignment as “non O.R. affecting the MS–DRG.” For new procedure codes that have been finalized through the ICD–10 Coordination and Maintenance Committee meeting process and are proposed to be classified as O.R. procedures or non-O.R. procedures affecting the MS–DRG, we recommend the MS–DRG assignment which is then made available in association with the proposed rule (Table 6B.—New Procedure Codes) and subject to public comment. These proposed assignments are generally based on the assignment of predecessor codes or the assignment of similar codes. For example, we generally examine the MS–DRG assignment for similar procedures, such as the other approaches for that procedure, to determine the most appropriate MS–DRG assignment for procedures proposed to be newly designated as O.R. procedures. As discussed in section II.C.13 of the preamble of this final rule, we are making Table 6B.—New Procedure Codes—FY 2024 available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html. In this Manual, we refer readers to the ICD–10 MS–DRG Version 40.1 Definitions Manual at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software.html for detailed information regarding the designation of procedures as O.R. or non-O.R. (affecting the MS–DRG) in Appendix E—Operating Room Procedures and Procedure Code/MS–DRG Index.

In the FY 2020 IPPS/LTCH PPS proposed rule, we stated that, given the long period of time that has elapsed since the original O.R. (extensive and non-extensive) and non-O.R. designations were established, the incremental changes that have occurred to these O.R. and non-O.R. procedure code lists, and changes in the way inpatient care is delivered, we plan to conduct a comprehensive, systematic review of the ICD–10–PCS procedure codes. This will be a multiyear project during which we will also review the process for determining when a procedure is considered an operating room procedure. For example, we may restructure the current O.R. and non-O.R. designations for procedures by leveraging the detail that is now available in the ICD–10 claims data. We refer readers to the discussion regarding the designation of procedure codes in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38066) where we stated that the determination of when a procedure code should be designated as an O.R. procedure has become a much more complex task. This is, in part, due to the number of various approaches available in the ICD–10–PCS classification, as well as changes in medical practice. While we have typically evaluated procedures on the basis of whether or not they would be performed in an operating room, we believe that there may be other factors to consider with regard to resource utilization, particularly with the implementation of ICD–10.

We discussed in the FY 2020 IPPS/LTCH PPS proposed rule that as a result of this planned review and potential restructuring procedures that are currently designated as O.R. procedures may no longer warrant that designation, and conversely, procedures that are currently designated as non-O.R. procedures may warrant an O.R. type of designation. We intend to consider the resources used and how a procedure should affect the MS–DRG assignment. We may also consider the effect of specific surgical approaches to evaluate whether to subdivide specific MS–DRGs based on a specific surgical approach. We stated we plan to utilize our available claims data as a basis for this review and the input of our clinical advisors. As part of this comprehensive review of the procedure codes, we also intend to evaluate the MS–DRG assignment of the procedures and the current surgical hierarchy because both of these factor into the process of refining the ICD–10 MS–DRGs to better recognize complexity of service and resource utilization.

In the FY 2021 IPPS/LTCH PPS final rule (85 FR 85444 through 85451), we provided a summary of the comments we had received in response to our request for feedback on what factors or criteria to consider in determining whether a procedure is designated as an O.R. procedure in the ICD–10–PCS classification system for future consideration. In the FY 2022 IPPS/LTCH PPS proposed rule (86 FR 25158) and final rule (86 FR 44891), and FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28174) and final rule (87 FR 48862), we stated that in consideration of the ongoing PHE, we believed it may be appropriate to allow additional time for the claims data to stabilize prior to selecting the timeframe to analyze for this review.

We stated in the FY 2024 IPPS/LTCH PPS proposed rule, we continue to believe additional time is necessary as we continue to develop our process and methodology. Therefore, we stated we will provide more detail on this analysis and the methodology for conducting this review in future rulemaking. Comment: Commenters supported CMS’ plan to continue to conduct a comprehensive, systematic review of the ICD–10–PCS codes and to evaluate their current O.R. and non-O.R. designations. These commenters expressed that they were supportive of CMS’ decision to continue to develop the processes and methodology over the upcoming years and to allow the claims data to become more stable. Other commenters stated they agreed that a restructuring of these designations may be warranted as a result of the expanded detail in the ICD–10–PCS classification and changes in medical practice and that they look forward to commenting on CMS’ data analysis and methodology in the future.

Response: We thank the commenters for their support.

Comment: Other commenters stated that designation of O.R. versus non-O.R. may no longer be the most critical differentiator between resource-intensive procedures for MS–DRG purposes. These commenters stated presently, there are increasingly complex and resource-intensive procedures performed by hospitals that do not involve the use of an operating room. A commenter stated that the administration of certain complex biologics or radiotherapies are not surgical procedures at all, yet these procedures represent significant resource utilization by hospitals. Another commenter stated that biplane radiology interventional suites and cardiac catheterization labs used for procedures such as mechanical thrombectomy or endovascular coiling for aneurysms can utilize more advanced equipment than a basic operating room with minimal installed equipment. This commenter
encouraged CMS to recognize that the revolution in medical procedures in recent years may render O.R. vs. non-O.R. a less critical distinction in driving payment policy.

As part of the broader and continuing conversation about future MS–DRG assignments and designations for these procedures and therapies, a commenter encouraged CMS to consider how other factors influence resource utilization, and recommended CMS consider questions such as whether:

• Certain types of procedures and therapies make up a substantial percentage of the costs within a particular MS–DRG?
• There is an average amount of cost within the relative weight of a MS–DRG that represents significant resource utilization and complexity?
• Certain types of interventions, such as the administration of certain complex drugs/biologics or therapies (for example, radiation therapy), that demonstrate higher costs and resource utilization, warrant consideration of a designation as an O.R. procedure or another equivalent designation? Should these therapies be considered for another type of distinction apart from medical and surgical MS–DRGs—for example, a third category, or be treated like CCs/MCCs?
• What percentage of cases within an MS–DRG receive outlier payment?

Response: CMS appreciates the commenters’ feedback and recommendations as to what factors to consider in evaluating O.R. versus non-O.R. designations. As stated previously, we have typically evaluated procedures on the basis of whether or not they would be performed in an operating room. We agree with commenters and believe that there may be other factors to consider with regard to resource utilization, particularly with the implementation of ICD–10. As discussed in the proposed rule, we are exploring alternatives on how we may restructure the current O.R. and non-O.R. designations for procedures by leveraging the detail that is available in the ICD–10 claims data. As we continue to consider the feedback we have received to help inform the development of our process and methodology, we will provide more detail in future rulemaking. We encourage the public to continue to submit comments on any other factors to consider in our refinement efforts to recognize and differentiate consumption of resources for the ICD–10 MS–DRGs for consideration.

As discussed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26744 through 26746), we received the following requests regarding changing the designation of specific ICD–10–PCS procedure codes from non-O.R. to O.R. procedures. In this section of this rule, as we did in the proposed rule, we summarize these requests and address why we are not considering a change to the designation of these codes at this time and, further, respond to the public comments we received regarding these requests.

In the FY 2023 IPPS/LTCH PPS final rule (87 FR 48863), we discussed a request we received to change the designation of all ICD–10–PCS codes that describe diagnostic and therapeutic percutaneous endoscopic procedures performed on thoracic and abdominal organs, from non-O.R. to O.R. In the FY 2023 final rule, we stated that we believed additional time was needed to fully examine the numerous ICD–10–PCS codes in the classification that describe diagnostic and therapeutic percutaneous endoscopic procedures performed on thoracic and abdominal organs. We stated that rather than evaluating these codes describing diagnostic and therapeutic percutaneous endoscopic procedures performed on thoracic and abdominal organs in isolation, analysis should be performed for this subset of procedure codes across the MS–DRGs, as part of the comprehensive procedure code review. We also stated that as a component of our broader comprehensive procedure code review, we are also reviewing the process for determining when a procedure is considered an operating room procedure.

As discussed in the FY 2024 IPPS/LTCH PPS proposed rule, we again received a request to change the designation of all ICD–10–PCS procedure codes that describe diagnostic and therapeutic percutaneous endoscopic procedures performed on thoracic and abdominal organs, from non-O.R. to O.R. from the same requestor. According to the requestor, diagnostic and therapeutic thorascopic and laparoscopic procedures on thoracic and abdominal organs are always performed in the operating room under complex general anesthesia. The requestor did not provide a specific list of the procedure codes that describe diagnostic and therapeutic percutaneous endoscopic procedures performed on thoracic and abdominal organs and are currently designated as non-O.R. for CMS for review, to narrow the scope of this repeat request.

As we have signaled in prior rulemaking, the designation of an O.R. procedure encompasses more than the physical location of the hospital in which the procedure may be performed; in other words, the performance of a procedure in an operating room is not the sole determining factor we consider as we examine the designation of a procedure in the ICD–10–PCS classification system. We also examine if, and in what way, the performance of the procedure affects the resource expenditure in those admissions in the inpatient setting, in addition to examining other clinical factors such as procedure complexity, and need for anesthesia administration as well as other types of sedation. As also stated in prior rulemaking, we plan to conduct a comprehensive, systematic review of the ICD–10–PCS procedure codes. We stated in the proposed rule that rather than evaluating this subset of procedure codes in isolation, as any potential change to the designation of these codes requires significant review, we continue to believe that analysis of the designation of the procedure codes describing diagnostic and therapeutic percutaneous endoscopic procedures performed on thoracic and abdominal organs should be performed across the MS–DRGs, as part of the comprehensive procedure code review. Therefore, for the reasons discussed, we did not propose any changes to the designation of all ICD–10–PCS procedure codes that describe diagnostic and therapeutic percutaneous endoscopic procedures performed on thoracic and abdominal organs, from non-O.R. to O.R. for FY 2024. As diagnostic and therapeutic percutaneous endoscopic procedures performed on thoracic and abdominal organs differ greatly in terms of clinical factors such as procedure complexity and resource utilization, we invited feedback on what factors or criteria to consider in determining whether a procedure should be designated as an O.R. procedure in the ICD–10–PCS classification system when evaluating this subset of procedure codes as part of the comprehensive procedure code review. Feedback and other suggestions may be submitted by October 20, 2023, and directed to the Medicare Electronic Application Request Information System™ (MEARIS™), discussed in section II.C.1.b of the preamble of the proposed rule at: https://mearis.cms.gov/public/home.

We will provide more detail on the comprehensive procedure code review and the methodology for conducting this review in future rulemaking.

Comment: Most commenters agreed with CMS’ proposal to maintain the designation of all ICD–10–PCS procedure codes that describe
diagnostic and therapeutic percutaneous endoscopic procedures performed on thoracic and abdominal organs for FY 2024.

Response: We appreciate the commenters’ support.

Comment: A commenter stated that while they did not dispute that there may be numerous ICD–10–PCS codes that describe procedures performed using a percutaneous endoscopic approach, they believed that this list could be narrowed down substantially by considering only codes describing procedures performed on thoracic and abdominal organs. This commenter stated that even with a smaller list utilizing the criteria they suggested, they were unable to envision a thorascopic or laparoscopic procedure that would not require general anesthesia and be performed in an operating room and urged CMS to designate any ICD–10–PCS procedure code that describes a thoracic or abdominal procedure using a percutaneous endoscopic approach as an operating room procedure.

Response: We thank the commenter for their feedback. We also appreciate the commenter’s suggestion, however, as stated in the proposed rule, and in prior rulemaking, we plan to conduct a comprehensive, systematic review of the ICD–10–PCS procedure codes. We continue to believe that rather than evaluating the procedure codes describing diagnostic and therapeutic percutaneous endoscopic procedures performed on thoracic and abdominal organs in isolation, analysis should be performed for this subset of procedure codes across the MS–DRGs, as part of the comprehensive procedure code review. As a component of our broader comprehensive procedure code review, we are also reviewing the process for determining when a procedure is considered an operating room procedure. For example, we may restructure the current O.R. and non-O.R. designations for procedures by leveraging the detail that is available in the ICD–10 claims data. Therefore, after consideration of the public comments we received, and for the reasons discussed, we are not making changes in this final rule to the designation of all ICD–10–PCS procedure codes that describe diagnostic and therapeutic percutaneous endoscopic procedures performed on thoracic and abdominal organs, from non-O.R. to O.R.

In the FY 2022 IPPS/LTCH PPS final rule (86 FR 44892 through 44895), CMS finalized the proposal to remove the 22 codes that describe the open drainage of subcutaneous tissue and fascia listed in the following table from the ICD–10 MS–DRGs Version 39 Definitions Manual in Appendix E—Operating Room Procedures and Procedure Code/MS–DRG Index as O.R. procedures. Under this finalization, these procedures no longer impact MS–DRG assignment.

<table>
<thead>
<tr>
<th>ICD-10-PCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>OJ900ZZ</td>
<td>Drainage of scalp subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ910ZZ</td>
<td>Drainage of face subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ940ZZ</td>
<td>Drainage of right neck subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ950ZZ</td>
<td>Drainage of left neck subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ960ZZ</td>
<td>Drainage of chest subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ970ZZ</td>
<td>Drainage of back subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ980ZZ</td>
<td>Drainage of abdomen subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ990ZZ</td>
<td>Drainage of buttock subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ9B0ZZ</td>
<td>Drainage of perineum subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ9C0ZZ</td>
<td>Drainage of pelvic region subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ9D0ZZ</td>
<td>Drainage of right upper arm subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ9F0ZZ</td>
<td>Drainage of left upper arm subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ9G0ZZ</td>
<td>Drainage of right lower arm subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ9H0ZZ</td>
<td>Drainage of left lower arm subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ9J0ZZ</td>
<td>Drainage of right hand subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ9K0ZZ</td>
<td>Drainage of left hand subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ9L0ZZ</td>
<td>Drainage of right upper leg subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ9M0ZZ</td>
<td>Drainage of left upper leg subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ9N0ZZ</td>
<td>Drainage of right lower leg subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ9P0ZZ</td>
<td>Drainage of left lower leg subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ9Q0ZZ</td>
<td>Drainage of right foot subcutaneous tissue and fascia, open approach</td>
</tr>
<tr>
<td>OJ9R0ZZ</td>
<td>Drainage of left foot subcutaneous tissue and fascia, open approach</td>
</tr>
</tbody>
</table>

In the FY 2022 final rule, we noted that the designation of the 22 procedure codes that describe the open drainage of subcutaneous tissue and fascia as O.R. procedures was a result of a replication error in transitioning to ICD–10. This replication error led to ICD–10–PCS procedure codes that describe the open drainage of subcutaneous tissue and fascia being listed as comparable translations for ICD–9–CM code 86.04 (Other incision with drainage of skin and subcutaneous tissue), which was designated as a non-O.R. procedure under the ICD–9–CM MS–DRGs Version 32. We stated in the FY 2022 final rule that designating the 22 procedure codes that describe the open drainage of subcutaneous tissue...
and fascia as non-O.R. procedures would result in a more accurate replication of the comparable procedure, under the ICD–9–CM MS–DRGs Version 32 which was 86.04, not 83.09 and is more aligned with current shifts in treatment practices.

In the FY 2023 IPPS/LTCH PPS final rule (87 FR 48863 through 48865), we discussed a request we received to re-examine this change in designation. In the FY 2023 final rule, we did not make changes to the designation of these codes and stated that procedure codes that describe the open drainage of subcutaneous tissue and fascia do not reflect the technical complexity or resource intensity in comparison to other procedures that are designated as O.R. procedures. We stated that our analysis of the September 2021 update of the FY 2021 MedPAR file reflected that when the procedure codes that describe the open drainage of the subcutaneous tissue and fascia are reported, approximately 70% of the MS–DRGs assigned are classified as surgical MS–DRGs which indicated at least one procedure code designated as an O.R. procedure was also reported in these cases. We also stated that the non-O.R. designation of the 22 procedure codes that describe the open drainage of subcutaneous tissue and fascia as finalized in the FY 2022 final rule better reflects the associated technical complexity and hospital resource use of these procedures.

As discussed in the FY 2024 IPPS/LTCH PPS proposed rule, we again received a request to re-examine the designation of the 22 procedure codes that describe the open drainage of subcutaneous tissue and fascia as non-O.R. procedures from the same requestor. The requestor stated that CMS should return the designation of these procedure codes to O.R. procedures to reflect the operating room resources utilized in the performance of these procedures and suggested that CMS analyze claims containing the 22 ICD–9–CM codes to determine the percentage that contained timed O.R. charges billed under revenue code 360. The requestor also indicated that there was confusion about the codes claims data as presented in the FY 2023 final rule. The requestor noted that the 22 procedure codes that describe the open drainage of subcutaneous tissue and fascia were designated as O.R. procedures in FY 2021 so it was unclear to the requestor why the table displayed by CMS associated with the FY 2023 final rule contained assignment to medical MS–DRGs.

First, in response to the question about the coded claims data as presented in the FY 2023 final rule, in the proposed rule we noted as generally stated in the preamble of the proposed rule each year, the diagnosis and procedure codes from the specified FY MedPAR claims data are grouped through the applicable version of the proposed FY GROUPER. The FY 2021 MedPAR claims data presented in the FY 2023 final rule were regrouped using the proposed FY 2023 MS–DRG classifications. In the proposed FY 2023 GROUPER, the procedure codes that describe the open drainage of subcutaneous tissue and fascia no longer impacted MS–DRG assignment and that is the reason why assignments to medical DRGs were displayed in Table 6P.1f associated with the FY 2023 final rule.

Next, we referred the reader to Table 6P.8a associated with the proposed rule (which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ AcuteInpatientPPS) for the data analysis of cases reporting the 22 procedure codes that describe the open drainage of subcutaneous tissue and fascia in the September 2022 update of the FY 2022 MedPAR file. We noted that within each MDC, the MS–DRGs are divided into medical and surgical categories. In general, surgical MS–DRGs are further defined based on the precise surgical procedure performed while the medical MS–DRGs are further defined based on the precise principal diagnosis for which a patient was admitted to the hospital. In Table 6P.8a associated with the proposed rule, column B displays the category of each MS–DRG in MS–DRG GROUPER Version 40.1. The letter M is used to designate a medical MS–DRG and the letter P is used to designate a surgical MS–DRG. In the proposed rule, we stated that overall, the data continues to indicate that the open drainage of subcutaneous tissue and fascia was not the underlying reason for, or main driver of, resource utilization for those cases. As shown in the table, when the procedure codes that describe the open drainage of the subcutaneous tissue and fascia are reported, approximately 55% of the MS–DRGs assigned are classified as surgical MS–DRGs, which indicates at least one procedure code designated as an O.R. procedure was also reported in these cases. We referred the reader to the ICD–10 MS–DRG Version 40.1 Definitions Manual (which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRGClassifications-and-Software) for complete documentation of the GROUPER logic for the listed MS–DRGs.

We stated we reviewed these data and continued to believe that procedure codes that describe the open drainage of subcutaneous tissue and fascia do not reflect the technical complexity or resource intensity in comparison to other procedures that are designated as O.R. procedures. As stated in prior rulemaking, procedures describing the open drainage of subcutaneous tissue and fascia can now be safely performed in the outpatient setting and when performed during a hospitalization, it is typically in conjunction with another O.R. procedure. In cases where procedures describing open drainage of subcutaneous tissue and fascia are the only procedures performed in an admission, the admission is quite likely due to need for IV antibiotics as opposed to the need for operating room resources in an inpatient setting.

We also noted that, as stated in prior rulemaking (84 FR 42069), in deciding whether to propose modifications to the MS–DRGs for particular circumstances brought to our attention, we do not consider the reported revenue codes. Rather, as stated previously, we consider whether the resource consumption and clinical characteristics of the patients with a given set of conditions are significantly different than the remaining patients represented in the MS–DRG. We stated we do this by evaluating the ICD–10–CM diagnosis and/or ICD–10–PCS procedure codes that identify the patient conditions, procedures, and the relevant MS–DRG(s) that are the subject of a request. Specifically, for this request, we analyzed the cases reporting the ICD–10–PCS procedure codes that describe the open drainage of subcutaneous tissue and fascia. We then evaluated patient care costs using average costs and average lengths of stay (based on the MedPAR data) to detect if, and in what way, the performance of these procedures affects the resource expenditure in those admissions in the inpatient setting. In addition to examining other clinical factors such as procedure complexity and need for anesthesia administration as well as other types of sedation.

We stated in the proposed rule, we continue to believe that the non-O.R. designation of the 22 procedure codes that describe the open drainage of subcutaneous tissue and fascia as finalized in the FY 2022 final rule better reflects the associated technical complexity and hospital resource use of these procedures. The reasons discussed, we did not propose changes to the designation of the 22

codes that describe the open drainage of subcutaneous tissue and fascia listed in the previous table for FY 2024.

Comment: Most commenters agreed with CMS’ proposal to maintain the designation of the 22 codes that describe the open drainage of subcutaneous tissue and fascia for FY 2024.

Response: We appreciate the commenters’ support.

Comment: A commenter opposed the non-O.R. designation of the 22 procedure codes that describe the open drainage of subcutaneous tissue and fascia as finalized in the FY 2022 final rule. This commenter stated that they disagree that these 22 ICD–10–PCS procedures do not typically require the resources of an O.R. when occurring in the inpatient setting and stated they do not believe these procedures can be safely performed in a non-O.R. setting. The commenter stated in the FY 2018 IPPS proposed rule, these same 22 ICD–10–PCS codes were identified, and a commenter in the proposal to redesignate these codes at that time. In response to the issues raised by this commenter, CMS determined in the FY 2018 IPPS final rule that it was appropriate to maintain the designation of the 22 procedure codes. This commenter further stated they find CMS’ rulemaking on this issue between FY 2018 and FY 2024 to be contradictory and believe that the rationale to maintain these 22 codes as O.R. procedures remains the same and that there is no safe way to effectively drain an infection involving the subfascial plane without the resources of an operating room.

Response: We thank the commenter for their feedback. We reviewed the commenters’ concerns and continue to state that treatment practices have continued to shift since FY 2018 rulemaking. As stated in the proposed rule, and in prior rulemaking, in response to similar comments, we believe procedures describing the open drainage of subcutaneous tissue and fascia can now be safely performed in the outpatient setting and when performed during a hospitalization, it is typically in conjunction with another O.R. procedure. In cases where procedures describing open drainage of subcutaneous tissue and fascia are the only procedures performed in an admission, the admission is quite likely due to need for IV antibiotics as opposed to the need for operating room resources in an inpatient setting. As shown in Table 6P.8a associated with the proposed rule (which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS), when the procedure codes that describe the open drainage of the subcutaneous tissue and fascia are reported, approximately 55% of the MS–DRGs assigned are classified as surgical MS–DRGs which indicates at least one procedure code designated as an O.R. procedure was also reported in these cases.

As discussed in the proposed rule and earlier in this section, we have signaled in prior rulemaking that the designation of an O.R. procedure encompasses more than the physical location of the hospital room in which the procedure may be performed; in other words, the performance of a procedure in an operating room is not the sole determining factor we consider as we examine the designation of a procedure in the ICD–10–PCS classification system. We continue to believe that procedure codes that describe the open drainage of subcutaneous tissue and fascia do not reflect the technical complexity or resource intensity in comparison to other procedures that are designated as O.R. procedures. The non-O.R. designation of the 22 procedure codes that describe the open drainage of subcutaneous tissue and fascia as finalized in the FY 2022 final rule better reflects the associated technical complexity and hospital resource use of these procedures.

Therefore, after consideration of the public comments we received, and for the reasons discussed, we are not making changes in this final rule to the designation of the 22 codes that describe the open drainage of subcutaneous tissue and fascia listed in the previous table for FY 2024.

12. Changes to the MS–DRG Diagnosis Codes for FY 2024

a. Background of the CC List and the CC Exclusions List

Under the IPPS MS–DRG classification system, we have developed a standard list of diagnoses that are considered CCs. Historically, we developed this list using physician panels that classified each diagnosis code based on whether the diagnosis, when present as a secondary condition, would be considered a substantial complication or comorbidity. A substantial complication or comorbidity was defined as a condition that, because of its presence with a specific principal diagnosis, would cause an increase in the length-of-stay by at least 1 day in at least 75 percent of the patients. However, depending on the principal diagnosis of the patient, some diagnoses on the basic list of complications and comorbidities may be excluded if they are closely related to the principal diagnosis. In FY 2008, we evaluated each diagnosis code to determine its impact on resource use and to determine the most appropriate CC subclassification (NonCC, CC, or MCC) assignment. We refer readers to sections II.D.2. and 3. of the preamble of the FY 2008 IPPS final rule with comment period for a discussion of the refinement of CCs in relation to the MS–DRGs we adopted for FY 2008 (72 FR 47152 through 47171).

b. Overview of Comprehensive CC/MCC Analysis

In the FY 2008 IPPS/LTCH PPS final rule (72 FR 47159), we described our process for establishing three different levels of CC severity into which we would subdivide the diagnosis codes.

The categorization of diagnoses as a MCC, a CC, or a NonCC was accomplished using an iterative approach in which each diagnosis was evaluated to determine the extent to which its presence as a secondary diagnosis resulted in increased hospital resource use. We refer readers to the FY 2008 IPPS/LTCH PPS final rule (72 FR 47159) for a complete discussion of our approach. Since the comprehensive analysis was completed for FY 2008, we have evaluated diagnosis codes individually when assigning severity levels to new codes and when receiving requests to change the severity level of specific diagnosis codes.

We noted in the FY 2020 IPPS/LTCH PPS proposed rule (84 FR 19235 through 19246) that with the transition to ICD–10–CM and the significant changes that have occurred to diagnosis codes since the FY 2008 review, we believed it was necessary to conduct a comprehensive analysis once again. Based on this analysis, we proposed changes to the severity level designations for 1,492 ICD–10–CM diagnosis codes and invited public comments on those proposals. As summarized in the FY 2020 IPPS/LTCH PPS final rule, many commenters expressed concern with the proposed severity level designation changes overall and recommended that CMS conduct further analysis prior to finalizing any proposals. After careful consideration of the public comments we received, as discussed further in the FY 2020 final rule, we generally did not finalize our proposed changes to the severity designations for the ICD–10–CM diagnosis codes, other than the changes to the severity level designations for the diagnosis codes in category Z16 (Resistance to antimicrobial drugs) from NonCC to a CC. We stated that postponing adoption
of the proposed comprehensive changes in the severity level designations would allow further opportunity to provide additional background to the public on the methodology utilized and clinical rationale applied across diagnostic categories to assist the public in its review. We refer readers to the FY 2020 IPPS/LTCH PPS final rule (84 FR 42150 through 42152) for a complete discussion of our response to public comments regarding the proposed severity level designation changes for FY 2020.

As discussed in the FY 2021 IPPS/LTCH PPS proposed rule (85 FR 32550), to provide the public with more information on the CC/MCC comprehensive analysis discussed in the FY 2020 IPPS/LTCH PPS proposed and final rules, CMS hosted a listening session on October 8, 2019. The listening session included a review of this methodology utilized to mathematically measure the impact on resource use. We refer readers to https://www.cms.gov/Outreach-and-Education/Outreach/OpenDoorForums/Downloads/10082019ListingSessionTranscriptandQandAsandAudioFile.zip for the transcript and audio file of the listening session. We also refer readers to https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software.html for the supplementary file containing the mathematical data generated using claims from the FY 2018 MedPAR file describing the impact on resource use of specific ICD–10–CM diagnosis codes when reported as a secondary diagnosis that was made available for the listening session.

In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58550 through 58554), we discussed our plan to continue a comprehensive CC/MCC analysis, using a combination of mathematical analysis of claims data as discussed in the FY 2020 IPPS/LTCH PPS proposed rule (84 FR 19235) and the application of nine guiding principles and plan to present the findings and proposals in future rulemaking. The nine guiding principles are as follows:

- Represents end of life/near death or has reached an advanced stage associated with systemic physiologic decompensation and debility.
- Denotes organ system instability or failure.
- Involves a chronic illness with susceptibility to exacerbations or abrupt decline.
- Serves as a marker for advanced disease states across multiple different comorbid conditions.
- Reflects systemic impact.
- Post-operative/post-procedure condition/complication impacting recovery.
- Typically requires higher level of care (that is, intensive monitoring, greater number of caregivers, additional testing, intensive care unit care, extended length of stay).
- Impedes patient cooperation or management of care or both.
- Recent (last 10 years) change in best practice, or in practice guidelines and review of the extent to which these changes have led to concomitant changes in expected resource use.

We refer readers to the FY 2021 IPPS/LTCH PPS final rule for a complete discussion of our response to public comments regarding the nine guiding principles.

In the FY 2022 IPPS/LTCH PPS proposed rule (86 FR 25175 through 25180), as another interval step in our comprehensive review of the severity designations of ICD–10–CM diagnosis codes, we requested public comments on a potential change to the severity level designations for “unspecified” ICD–10–CM diagnosis codes that we were considering adopting for FY 2022. Specifically, we noted we were considering changing the severity level designation of “unspecified” diagnosis codes to a NonCC where there are other codes available in that code subcategory that further specify the anatomic site. As summarized in the FY 2022 IPPS/LTCH PPS final rule, many commenters expressed concern with the potential severity level designation changes overall and recommended that CMS delay any possible change to the designation of these codes to give hospitals and their physicians time to prepare. After careful consideration of the public comments we received, we maintained the severity level designation of the “unspecified” diagnosis codes currently designated as a CC or MCC where there are other codes available in the code subcategory that further specify the anatomic site for FY 2022. We refer readers to the FY 2022 IPPS/LTCH PPS final rule (86 FR 44916 through 44926) for a complete discussion of our response to public comments regarding the potential severity level designation changes. Instead, for FY 2022, we finalized a new Medicare Code Editor (MCE) code edit for “unspecified” codes, effective with discharges on and after April 1, 2022. We stated we believe finalizing this new edit would provide additional time for providers to be educated while not affecting the payment the provider is eligible to receive. We refer the reader to section II.D.14.e. of the FY 2022 IPPS/LTCH PPS final rule (86 FR 44940 through 44943) for the complete discussion.

As discussed in the FY 2023 IPPS/LTCH PPS final rule (87 FR 48866), we stated that as the new unspecified code edit became effective beginning with discharges on and after April 1, 2022, we believed it was appropriate to not propose to change the designation of any ICD–10–CM diagnosis codes, including the unspecified codes that are subject to the “Unspecified Code” edit, as we continue our comprehensive CC/MCC analysis to allow interested parties the time needed to become acclimated to the new edit.

In the FY 2023 IPPS/LTCH proposed rule (87 FR 28177 through 28181), we also requested public comments on how the reporting of diagnosis codes in categories Z55–Z65 might improve our ability to recognize severity of illness, complexity of illness, and/or utilization of resources under the MS–DRGs. Consistent with the Administration’s goal of advancing health equity for all, including members of historically underserved and under-resourced communities, as described in the President’s January 20, 2021 Executive Order 13985 on “Advancing Racial Equity and Support for Underserved Communities Through the Federal Government,” we stated we were also interested in receiving feedback on how we might otherwise foster the documentation and reporting of the diagnosis codes describing social and economic circumstances to more accurately reflect our health care encounter and improve the reliability and validity of the coded data in support of efforts to advance health equity.

We noted that social determinants of health (SDOH) are the conditions in the environments where people are born, live, learn, work, play, worship, and age that affect a wide range of health, functioning, and quality-of-life outcomes and risks. The subset of Z codes that describe the social determinants of health are found in categories Z55–Z65 (Persons with potential health hazards related to socioeconomic and psychosocial circumstances). These codes describe a range of issues related—but not limited—to education and literacy, employment, housing, ability to obtain adequate amounts of food or safe drinking water, and occupational


8 Available at: https://health.gov/healthypeople/objectives-and-data/social-determinants-health.
exposure to toxic agents, dust, or radiation.

We received numerous public comments that expressed a variety of views on our comment solicitation, including many comments that were supportive, and others that offered specific suggestions for our consideration in future rulemaking. Many commenters applauded CMS’ efforts to encourage documentation and reporting of SDOH diagnosis codes given the impact that social risks can have on health outcomes. These commenters stated that it is critical that physicians, other health care professionals, and facilities recognize the impact SDOH have on the health of their patients. Many commenters also stated that the most immediate and important action CMS could take to increase the use of SDOH Z codes is to finalize the evidence-based “Screening for Social Drivers of Health” and “Screen Positive Rate for Social Drivers of Health” measures proposed to be adopted in the Hospital Inpatient Quality Reporting (IQR) Program. In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49202 through 49220), CMS finalized the “Screening for Social Drivers of Health” and “Screen Positive Rate for Social Drivers of Health” measures in the Hospital Inpatient Quality Reporting (IQR) Program. We refer readers to the FY 2023 IPPS/LTCH PPS final rule (87 FR 48867 through 48872) for the complete discussion of the public comments received regarding the request for information on SDOH diagnosis codes as well as the following section of this final rule for our proposed changes to the severity level designation for certain diagnosis codes that describe homelessness for FY 2024, as well as our finalization of that proposal.

As discussed in the FY 2024 IPPS/LTCH PPS proposed rule, we continue to solicit feedback regarding the guiding principles, as well as other possible ways we can incorporate meaningful indicators of clinical severity. We have made available on the CMS website updated impact on resource use files so that the public can review the mathematical data for the impact on resource use generated using claims from the FY 2019 through the FY 2022 MedPAR files. The link to these files is posted on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/Acute InpatientPPS/MS-DRG-Classifications-and-Software. When providing additional feedback or comments, we encourage the public to provide a detailed explanation of how applying a suggested concept or principle would ensure that the severity designation appropriately reflects resource use for any diagnosis code. We also continue to be interested in receiving feedback on how we might otherwise foster the documentation and reporting of the most specific diagnosis codes supported by the available medical record documentation and clinical knowledge of the patient’s health condition to more accurately reflect each health care encounter and improve the reliability and validity of the coded data.

As discussed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26748), for new diagnosis codes approved for FY 2024, consistent with our annual process for designating a severity level (MCC, CC, or NonCC) for new diagnosis codes, we first review the predecessor code designation, followed by review and consideration of other factors that may be relevant to the severity level designation, including the severity of illness, treatment difficulty, complexity of service and the resources utilized in the diagnosis or treatment of the condition. We noted that this process does not automatically result in the new diagnosis code having the same designation as the predecessor code. We refer the reader to section IIC.13 of this final rule for the discussion of the finalized changes to the ICD–10–CM and ICD–10–PCS coding systems for FY 2024.

c. Changes to Severity Levels

As discussed earlier in this section, in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28177 through 28181), we reviewed public comments on how the reporting of diagnosis codes in categories Z55–Z65 might improve our ability to recognize severity of illness, complexity of illness, and/or utilization of resources under the MS–DRGs. We sought comment on which specific SDOH Z codes were most likely to influence (that is, increase) hospital resource utilization related to inpatient care, including any supporting information that correlates inpatient hospital resource use to specific SDOH Z codes. In the FY 2023 proposed rule, we stated CMS believed a potential starting point for discussion was consideration of the SDOH Z diagnosis codes describing homelessness as homelessness can be reasonably expected to have an impact on hospital utilization.

To further examine the diagnosis codes that describe SDOH, in the FY 2023 proposed rule, we stated we reviewed the data on the impact on resource use for diagnosis code Z59.0 (Homelessness) when reported as a secondary diagnosis to facilitate discussion for the purposes of the comment solicitation. We noted that prior to FY 2022, homelessness was one of the more frequently reported codes that describe social determinants of health. We also noted that effective FY 2022, the subcategory was expanded and now included codes Z59.00 (Homelessness, unspecified), Z59.01 (Sheltered homelessness), and code Z59.02 (Unsheltered homelessness).

We also displayed the impact on resource use data generated using claims from the FY 2019 MedPAR file, FY 2020 MedPAR file and the FY 2021 MedPAR file, respectively, for the diagnosis code that describes homelessness as a NonCC. We noted there was no data for codes Z59.01 (Sheltered homelessness) and Z59.02 (Unsheltered homelessness) as these codes became effective on October 1, 2021. We stated that when examining diagnosis code Z59.0 (Homelessness) in FY 2019 and FY 2020, the data suggested that when homelessness is reported as a secondary diagnosis, the resources involved in caring for these patients are more aligned with a CC than a NonCC or an MCC. However, in FY 2021, the data suggested that the resources involved in caring for patients experiencing homelessness are more aligned with a NonCC severity level than a CC or an MCC severity level. We stated we were uncertain if the data from FY 2021, in particular, reflected fluctuations that may be a result of the public health emergency or even reduced hospitalizations of certain conditions. We also stated we were uncertain if homelessness may be underreported when there is not an available field on the claim when other diagnoses are reported instead.
The table shows that the C1 is 1.75 for ICD–10–CM diagnosis code Z59.00, 2.00 for ICD–10–CM diagnosis code Z59.01, and 2.12 for ICD–10–CM diagnosis code Z59.02. A value close to 2.0 in column C1 suggests that the secondary diagnosis is more aligned with a CC than a NonCC. Because the C1 values in the table are generally close to 2, the data suggest that when these three SDOH Z codes are reported as a secondary diagnosis, the resources involved in caring for a patient experiencing homelessness support increasing the severity level from a NonCC to a CC.

In the proposed rule, we noted the table also shows that the C2 finding was 2.19 for ICD–10–CM diagnosis code Z59.00, 2.24 for ICD–10–CM diagnosis code Z59.01, and 2.35 for ICD–10–CM diagnosis code Z59.02. A C2 value close to 2.0 suggests the condition is more like a CC than a NonCC, but not as significant in resource usage as an MCC when there is at least one other secondary diagnosis that is a CC but none that is an MCC. Because the C2 values in the table are generally close to 2, we stated that the data again suggested that when these three SDOH Z codes are reported as a secondary diagnosis, the resources involved in caring for a patient experiencing homelessness support increasing the severity level from a NonCC to a CC.

As discussed in the FY 2023 IPPS/LTCH PPS proposed rule (85 FR 58550 through 58554), following the listening session on October 8, 2019, we reconvened an internal workgroup comprised of clinicians, consultants, coding specialists and other policy analysts to identify guiding principles to apply in evaluating whether changes to the severity level designations of diagnoses are needed and to ensure the severity designations appropriately reflect resource use based on review of the claims data, as well as consideration of relevant experts (for example, the clinical nature of each of the secondary diagnoses and the severity level of clinically similar diagnoses) and improve the overall accuracy of the IPPS payments. In considering the nine guiding principles identified by the workgroup, as summarized previously, to illustrate how they might be applied in evaluating changes to the severity designations of diagnosis codes, in the FY 2024 IPPS/LTCH PPS proposed rule we noted that homelessness is a circumstance that can impede patient cooperation or management of care or both. In addition, patients experiencing homelessness can require a higher level of care by needing an extended length of stay. As discussed in the FY 2023 proposed rule, healthcare needs for patients experiencing homelessness (sheltered, unsheltered, or unspecified) may be associated with increased resource utilization.

Healthcare needs for patients experiencing homelessness may be associated with increased resource utilization compared to other patients due to difficulty finding discharge destinations to meet the patient’s multifaceted needs which can result in longer inpatient stays and can have financial impacts for hospitals. Longer hospital stays for these patients can also be associated with increased costs because patients experiencing homelessness are less able to access care at early stages of illness, and also may be exposed to communicable disease and harsh climate conditions, resulting in more severe and complex symptoms by the time they are admitted to hospitals, potentially leading to worse health outcomes. Patients experiencing homelessness can also be disproportionately affected by mental health diagnoses and issues with substance use disorders. In addition, patients experiencing homelessness may have limited or no access to prescription medicines or over-the-counter medicines, including adequate locations to store medications away from the heat or cold, and studies have shown difficulties adhering to medication regimens among persons experiencing homelessness.

Therefore, after considering the C1 and C2 ratings of the three ICD–10–CM diagnosis codes that describe

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
<th>Total Count</th>
<th>Cnt1</th>
<th>C1</th>
<th>Cnt2</th>
<th>C2</th>
<th>Cnt3</th>
<th>C3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z59.00</td>
<td>Homelessness, unspecified</td>
<td>27,148</td>
<td>1,130</td>
<td>2.19</td>
<td>11,055</td>
<td>3.10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Z59.01</td>
<td>Sheltered homelessness</td>
<td>6,862</td>
<td>3,027</td>
<td>2.00</td>
<td>3,014</td>
<td>3.08</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Z59.02</td>
<td>Unsheltered homelessness</td>
<td>4,394</td>
<td>3,948</td>
<td>2.12</td>
<td>1,993</td>
<td>3.10</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 This column is the secondary diagnosis code (SDX).  
2 This column is the title of the SDX.  
3 The total count of discharge claims with the SDX.  
4 Count of discharge claims with the SDX but with no other SDX or with all other SDX a NonCC.  
5 “C1” impact on resource use of the SDX for discharge claims in “Cnt1”.  
6 Count of discharge claims with the SDX and with at least one other SDX that is a CC but none that is a MCC.  
7 “C2” impact on resource use of the SDX for discharge claims in “Cnt2”.  
8 Count of discharge claims with the SDX and with at least one other SDX that is a MCC.  
9 “C3” impact on resource use of the SDX for discharge claims in “Cnt3”.  
10 Sheltered homelessness: refers to people experiencing homelessness who were found in emergency shelters, safe havens, transitional housing, or other temporary settings. Department of Housing and Urban Development (HUD) Press Release No. 22–022, https://www.hud.gov/press/releases/media_advocaries/hud_no_22_022.  
11 Unsheltered homelessness refers to “a primary nighttime residence that is a public or private place not designed for or ordinarily used as a regularly sleeping accommodation for human beings, including a car, park, abandoned building, bus or train station, airport, or camping ground.” HUD.  

homelessness and consideration of the nine guiding principles, we proposed to change the severity level designation for diagnosis codes Z59.00 (Homelessness, unspecified), Z59.01 (Sheltered homelessness), and Z59.02 (Unsheltered homelessness) from NonCC to CC for FY 2024. As discussed in the FY 2023 IPPS/LTCH PPS final rule, if SDOH Z codes are not consistently reported in inpatient claims data, our methodology utilized to mathematically measure the impact on resource use, as described previously, may not adequately reflect what additional resources were expended by the hospital to address these SDOH circumstances in terms of requiring clinical evaluation, extended length of hospital stay, increased nursing care or monitoring or both, and comprehensive discharge planning. In the proposed rule, we stated we also expect that SDOH Z code reporting may continue to increase for a number of reasons, for example, newer SDOH screening performed as a result of new quality measures in the Hospital Inpatient Quality Reporting program. We may consider proposed changes for other SDOH codes in the future based on our analysis of the impact on resource use, per our methodology, as previously described, and consideration of the guiding principles. We further stated we also continue to be interested in receiving feedback on how we might otherwise foster the documentation and reporting of the diagnosis codes describing social and economic circumstances to more accurately reflect each health care encounter and improve the reliability and validity of the coded data including in support of efforts to advance health equity.

Feedback and other suggestions may be submitted by October 20, 2023 and directed to the electronic intake system, Medicare Electronic Application Request Information System™ (MPEARSTM) at: https://mearis.cms.gov/public/home.

Comment: Commenters expressed overwhelming support for our proposal to change the severity level designation for diagnosis codes Z59.00 (Homelessness, unspecified), Z59.01 (Sheltered homelessness), and Z59.02 (Unsheltered homelessness) from NonCC to CC for FY 2024. These commenters stated this proposal acknowledges the impact of homelessness as a social determinant of health, its implications for resource utilization, and its costs to healthcare providers in effectively addressing the healthcare needs of Medicare beneficiaries experiencing homelessness. A commenter stated they especially appreciate thoughtful policies that are data-driven and intended to bridge the gap of compensation for providers who have been tirelessly caring for underserved populations. Another commenter stated that this change will confer enhanced financial resources to safety net hospitals, which care for a disproportionate number of patients impacted by health-related social risk factors. A commenter specifically stated that they see this proposal as a watershed moment as it is the first time CMS will be linking social determinants of health to payment in traditional Medicare. Commenters stated that a change to the severity level designation of the three diagnosis codes that describe homelessness from NonCC to CC may increase voluntary reporting of these circumstances, incentivize treating the whole patient, while enabling CMS to assess homelessness-related impacts on illness severity, care complexity, and hospital utilization to drive meaningful evaluation of the association between these Z codes and outcomes. A few commenters stated that based on their own analysis, homelessness has an effect on resource utilization on par with other diagnoses currently designated as MCCs but stated changing the designation to a CC is a logical and necessary step.

Response: We thank the commenters for their support.

Comment: While commending CMS' efforts, many commenters noted an operational concern in that currently only 25 diagnoses are captured on the institutional claim form. Commenters stated that deciding which SDOH factors to screen and reporting the social and economic circumstances patients may be experiencing may require a substantial number of SDOH Z codes and stated that this could lead to the crowding out of other diagnosis codes that also need to be captured on the institutional claim form for both payment and quality measures. A commenter stated that the "Screening for Social Drivers of Health" and "Screen Positive Rate for Social Drivers of Health" measures in the Hospital Inpatient Quality Reporting (IQR) Program, finalized in the FY 2023 IPPS/LTCH final rule, will result in the need to include additional Z codes on the claim to represent the findings of the SDOH screenings, further limiting the space available. Commenters stated that given the number of fields available to report diagnosis codes, it would be helpful if CMS would instruct hospitals on how to prioritize the use of SDOH diagnosis codes to ensure that all the medical diagnoses that govern mortality and readmission rates are also captured. A few commenters suggested that CMS evaluate the potential to expand the number of diagnosis codes that can be submitted, or alternatively, design a separate way to report the Z codes on the claim form, separate and distinct from the fields for the diagnosis codes.

Response: We thank the commenters for their feedback. We note that any proposed changes to the institutional claim form would need to be submitted to the National Uniform Billing Committee (NUBC) for consideration as the NUBC develops and maintains the Uniform Billing (UB) 04 data set and form. The NUBC is a Data Content Committee named in the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and is composed of a diverse group of interested parties representing providers, health plans, designated standards maintenance organizations, public health organizations, and vendors.

Comment: Some commenters requested that CMS further explore other SDOH diagnosis codes that could impact hospital resource use. These commenters encouraged CMS to examine other SDOH Z codes that describe circumstances such as food insecurity, lack of adequate food and drinking water, extreme poverty, lack of transportation, inadequate housing, environmental temperature, and problems related to employment, physical environment, social environment, upbringing, primary support group, literacy, economic circumstances, and psychosocial circumstances to determine the hospital resource utilization related to addressing these factors and to analyze whether these SDOH Z codes should be considered for severity designation changes in future rulemaking as well. Other commenters also pointed to conditions outside of the SDOH Z codes in categories Z55–Z65 such as: medical debt, malnutrition, delirium due to a known physiological condition, elder abuse and neglect, contact with and (suspected) exposure to hazards in the physical environment, personal history of failing, personal history of adult physical and sexual abuse, awaiting organ transplant status, and underdosing of medication regimens as examples of other areas where fostering better documentation and reporting, and considering severity designation changes in future rulemaking, could improve health outcomes.

Response: We appreciate the feedback. We will examine these suggestions and determine if there are other diagnoses codes, including diagnosis codes that describe SDOH, that should also be considered further. We will consider these diagnosis codes...
for changes to severity level designations, using a combination of mathematical analysis of claims data and the application of nine guiding principles, as we continue our comprehensive CC/MCC analysis and will provide more detail in future rulemaking.

Comment: While supporting the proposal to designate the three ICD–10–CM diagnosis codes describing homelessness as CCs, some commenters expressed concern with the perceived diminished value that designating homelessness as a CC when reported as a secondary diagnosis may have, due to the expansion of the criteria for subdividing a base MS–DRG into a three-way split. These commenters stated the application of the NonCC subgroup criteria as demonstrated by the MS–DRG changes associated with Table 6P.10—Potential MS–DRG Changes with Application of the NonCC Subgroup Criteria and Detailed Data Analysis—FY 2024, associated with the proposed rule, appears to frequently not recognize the need for a severity level of CC by eliminating many “with CC” and “without CC/MCC” MS–DRGs, meaning there is a potential for fewer MS–DRGs to be impacted by the presence of homelessness as a CC. The commenters further stated that if there are a limited number of MS–DRGs impacted by the presence of a CC, the change of the severity designation of these three diagnosis codes will not accomplish the desired documentation and reporting goals.

Response: We appreciate the commenters’ feedback and concern. We concur with commenters that the application of the NonCC subgroup criteria to existing MS–DRGs currently subdivided by a three-way severity level split going forward may result in modifications to certain MS–DRGs that are currently split into three severity levels and potentially result in MS–DRGs that are subdivided to split into two severity levels. As discussed in section II.C.1.b of the preamble of this final rule for related discussion regarding our finalization of the expansion of the criteria to include the NonCC subgroup and our finalization of the proposal to continue to delay application of the NonCC subgroup criteria to existing MS–DRGs with a three-way severity level split.

Comment: A commenter stated that even though they applauded CMS’ efforts to recognize the underreporting of SDOH, they recommended only changing the designation of diagnosis codes Z59.01 (Sheltered homelessness) and Z59.02 (Unsheltered homelessness) from NonCC to CC. This commenter stated that if the proposed change to the severity designation of diagnosis code Z59.00 (Homelessness, unspecified) is finalized, they envisioned payment oversight agencies would question its significance and effect on resource utilization due to the “unspecified” code description, especially if code Z59.00 is the only secondary diagnosis code designated as a CC on the claim.

Response: We thank the commenter for their feedback. We reviewed the commenter’s concern and note that whether the patient is experiencing sheltered, unsheltered, or unspecified homelessness, the patient may still have limited or no access to prescription medicines or over-the-counter medicines, including adequate locations to store medications away from the heat or cold, and have difficulties adhering to medication regimens. We continue to believe that patients experiencing homelessness (regardless of type) may be less able to access care at early stages of illness, and also may be exposed to communicable disease and harsh climate conditions, resulting in more severe and complex symptoms by the time they are admitted to hospitals, potentially leading to worse health outcomes. If SDOH Z codes are consistently reported in inpatient claims data, our methodology utilized to mathematically measure the impact on resource use may more adequately reflect what additional resources were expended by the hospital to address these SDOH circumstances in terms of requiring clinical evaluation, extended length of hospital stay, increased nursing care or monitoring or both, and comprehensive discharge planning and we can reexamine these severity designations in future rulemaking.

Comment: Some commenters thanked CMS for its continued interest in receiving feedback on documentation and reporting of the ICD–10–CM diagnosis SDOH Z codes, yet stated there continue to be many challenges for clinicians in documenting SDOH, such as the lack of knowledge surrounding these codes, the time and burden associated with adding them to a patient’s problem list, and the perceived inability to do anything with the information. Other commenters stated assigning codes for SDOH can be a time-consuming and labor-intensive process, as many electronic health records (EHRs) do not have pathways to add a Z code to the problem or diagnosis list. These commenters stated prioritizing provider education on the reporting of Z codes and offering support mechanisms, including the use of incentives, would significantly improve the acquisition of SDOH data, as such data is essential in helping health systems better anticipate needs and help vulnerable patients receive support at both the individual and population levels. Another commenter stated that given the administrative and operational challenges for providers associated with capturing SDOH data, they recommended CMS delay implementation of the change in severity level designation of diagnosis codes Z59.00, Z59.01, and Z59.02 by one year so that providers may continue to adapt their processes and workflows to properly capture the homelessness Z codes. This commenter stated that although the proposed change would not require additional work for providers beyond reporting the codes, the act of reporting itself is still a broad change to hospital coding practices and electronic health record (EHR) use that
they believe deserves additional time for provider adoption.

Response: We appreciate the feedback. We note that the ICD–10–CM Official Guidelines for Coding and Reporting have been regularly revised to provide additional guidance as it relates to diagnosis codes describing social determinants of health diagnosis. Specifically, Section I.C.21.c.17 of the ICD–10–CM Official Guidelines for Coding and Reporting were updated:

- Effective October 1, 2021, to clarify that code assignment may be based on medical record documentation from clinicians involved in the care of the patient who are not the patient’s provider and that patient self-reported documentation may be used to assign codes for social determinants of health, as long as the patient self-reported information is signed-off by and incorporated into the medical record by either a clinician or provider;
- Effective October 1, 2022, to clarify that SDOH codes should be assigned only when the documentation specifies that the patient has an associated problem or risk factor; and
- Effective April 1, 2023, to provide more guidance on reporting SDOH and to provide more examples to facilitate the capture of these data.

We encourage the commenters to review the Official ICD–10–CM Coding Guidelines, which can be found on the CDC website at: https://www.cdc.gov/nchs/icd/icd10.htm.

The American Hospital Association (AHA)’s Coding Clinic for ICD–10–CM/PCS publication has provided further clarification on the appropriate documentation and use of Z codes to enable hospitals to incorporate these into their processes. The AHA also offers a range of tools and resources for hospitals, health systems and clinicians to address the social needs of their patients. We believe these updates and resources will help alleviate the concerns expressed by these commenters. As one of the four Cooperating Parties for ICD–10, we will continue to collaborate with the AHA to provide guidance for coding problems or risk factors related to SDOH through the AHA’s Coding Clinic for ICD–10–CM/PCS publication and to review the ICD–10–CM Coding Guidelines to determine where further clarifications may be made.

In response to commenters that state there continue to be many challenges for clinicians in documenting SDOH, such as the time and burden associated with adding them to a patient’s problem list, and state that many electronic health records (EHRs) do not have pathways to add a Z code to the problem or diagnosis list, the Office of the Assistant Secretary for Planning and Evaluation (ASPE), the principal advisor to the Secretary of the U.S. Department of Health and Human Services, conducted interviews with six electronic health records (EHRs) vendors with large market shares in both ambulatory and inpatient settings to investigate the development of software products that allow health care providers to identify and address patients SDOH in health care settings. The findings of the study indicate commercial vendors appear to be ready to collaboratively discuss policy solutions, such as standards or guidelines with each other, health care systems, and government agencies in order to further promote integration of SDOH data into the standard of care for all health systems. We further note that on April 18, 2023, the Office of the National Coordinator proposed updated certification standards (USCDI v3) that would, if finalized, require certified EHR vendors to include four SDOH data elements: SDOH Assessment, Goals, Interventions, Problems/Health Concerns.

In response to the suggestion that CMS delay implementation of the change to the severity level designation of diagnosis codes Z59.00, Z59.01, and Z59.02 by one year so that providers may continue to adapt their processes and workflows to properly capture the diagnosis codes describing homelessness, we reviewed the commenters’ concern and do not agree that a delay is necessary or appropriate. As discussed in the proposed rule, and previously in this section, when examining the data on the impact on resource use for the ICD–10–CM SDOH Z codes that describe homelessness from the FY 2019, FY 2020, and FY 2022 MedPAR files, the data suggested that when homelessness is reported as a secondary diagnosis, the resources involved in caring for these patients are more aligned with a CC than a NonCC. After considering the C1 and C2 ratings of the three ICD–10–CM diagnosis codes that describe homelessness and consideration of the nine guiding principles, we changed the severity level designation for diagnosis codes Z59.00 (Homelessness, unspecified), Z59.01 (Sheltered homelessness), and Z59.02 (Unsheltered homelessness) from NonCC to CC at this time to be prudent, without the need for further delay.

Therefore, after consideration of the public comments received, we are finalizing changes to the severity levels for diagnosis codes Z59.00 (Homelessness, unspecified), Z59.01 (Sheltered homelessness), and Z59.02 (Unsheltered homelessness), from NonCC to CC for FY 2024, without modification. In addition, the proposed diagnosis codes are reflected in Table 61.1—Additions to the CC List—FY 2024 associated with this final rule and available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS. We refer the reader to section I.C.13 of the preamble of the proposed rule and this final rule for further information regarding Table 61.1.

We again thank commenters for sharing their views and their willingness to support CMS in these efforts. We will take the commenters’ feedback into consideration in future policy development. We hope and expect that this finalization will foster the increased documentation and reporting of the diagnosis codes describing social and economic circumstances and serve as an example for providers that when they document and report Z codes, CMS can further examine the claims data and consider future changes to the designation of these codes when reported as a secondary diagnoses. CMS will continue to monitor and evaluate the reporting of these diagnosis codes describing social and economic circumstances, including diagnosis codes Z59.00 (Homelessness, unspecified), Z59.01 (Sheltered homelessness), and Z59.02 (Unsheltered homelessness).

Additionally, as discussed in the FY 2024 IPPS/LTC PPS proposed rule, we received a request to change the severity level designations of three ICD–10–CM diagnosis codes. The requestor suggested the severity level of ICD–10–CM diagnosis code K76.72 (Hepatic encephalopathy) be changed from NonCC to CC at this time to be prudent, without the need for further delay.

In the proposed rule, we noted that these three diagnosis codes became effective with discharges on and after October 1, 2022 (FY 2023), and the current claims data from the September 2022 update of the FY 2022 MedPAR file did not yet reflect these new diagnosis codes. The proposed and finalized severity level designations for

---


these ICD–10–CM diagnosis codes were displayed in Table 6A– New Diagnosis Codes (associated with the FY 2023 proposed rule and final rule and are available on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS). As discussed earlier in this section, for new diagnosis codes approved for each fiscal year, consistent with our annual process for designating a severity level (MCC, CC, or NonCC) for new diagnosis codes, in establishing the severity level of these codes, we first reviewed the predecessor code designation, followed by review and consideration of other factors that may be relevant to the severity level designation, including the severity of illness, treatment difficulty, complexity of service and the resources utilized in the diagnosis or treatment of the condition.

Specifically, the predecessor code for K76.72 (Hepatic encephalopathy) was diagnosis code K72.90 (Hepatic failure, unspecified without coma), which is designated as a NonCC. We stated when we reviewed and considered the factors as described previously, we did not believe that the resources required for hepatic encephalopathy exceeded the resources required for patients with hepatic failure, unspecified without coma as both conditions require treatment to rid the body of toxins. Therefore, our proposed and finalized severity level designation for hepatic encephalopathy was also a NonCC for FY 2023. Similarly, the predecessor code for N14.11 (Contrast-induced nephropathy) was diagnosis code N14.1 (Nephropathy induced by other drugs, medicaments and biological substances), which was designated as a NonCC. After review and consideration of the factors as described previously, we did not believe that the resources required for contrast-induced nephropathy exceeded the resources required for patients with hepatic failure, unspecified without coma as both conditions require treatment to rid the body of toxins. Therefore, our proposed and finalized severity level designation for contrast-induced nephropathy was also a NonCC.

We further stated we believed that claims data reflecting the reporting of these new diagnosis codes are needed for analysis prior to proposing changes to these three diagnosis codes. As stated earlier in this section, we plan to continue a comprehensive CC/MCC analysis, using a combination of mathematical analysis of claims data and the application of nine guiding principles. We stated we believed it was appropriate to consider these requests in connection with our continued comprehensive CC/MCC analysis in future rulemaking, using the available claims data, rather than proposing to change the designation of these individual ICD–10–CM diagnosis codes in the absence of such data at this time. We will consider these individual requests received for changes to severity level designations as we continue our comprehensive CC/MCC analysis and will provide more detail in future rulemaking.

Comment: Commenters stated that they support CMS’ decision not to propose to change the severity level designation of diagnosis code K76.72 (Hepatic encephalopathy), N14.11 (Contrast-induced nephropathy) and S06.2XXA (Diffuse traumatic brain injury with loss of consciousness status unknown, initial encounter) at this time and to consider these requests in connection with our continued comprehensive CC/MCC analysis in future rulemaking. A commenter specifically stated they appreciate CMS moving cautiously with changes that could cause considerable upheaval during this time of unprecedented stress on hospitals and encouraged CMS to continue careful assessment of significant changes in the future.

However, another commenter expressed concern that CMS continues to not be able to undertake a comprehensive analysis of the severity designation of the diagnosis codes in the ICD–10–CM classification. The commenter stated they believed that the nation is being negatively impacted since, in their opinion, some diagnoses currently designated as an MCC (for example severe malnutrition) do not require the resources inherent to a MCC whereas others that do (for example cardiac tamponade) are not designated as such. This commenter further stated it would be helpful if CMS made a proposed list of severity level designation changes available along with the impact on resource use files generated using claims from the FY 2019 through the FY 2022 MedPAR files that have been made publicly available on the CMS website.

Response: We thank the commenters for their support and appreciate the feedback. With respect to CMS not being able to undertake a comprehensive analysis, we note that in the FY 2020 IPPS/LTCH PPS proposed rule (84 FR 19235 through 19246) we stated that with the transition to ICD–10–CM and the significant changes that have occurred to diagnosis codes since the FY 2008 review, we believed it was necessary to conduct a comprehensive analysis once again and therefore proposed changes to the severity level designations for 1,492 ICD–10–CM diagnosis codes. As summarized in the FY 2020 IPPS/LTCH PPS final rule, after careful consideration of the public comments we received in response, we generally did not finalize our proposed changes to the severity designations for the ICD–10–CM diagnosis codes, other than the changes to the severity level designations for the diagnosis codes in category Z16– Resistance to antimicrobial drugs from a NonCC to a CC. We stated that postponing adoption of the proposed comprehensive changes in the severity level designations would allow further development to provide additional background to the public on the methodology utilized and clinical
rationale applied across diagnostic categories to assist the public in its review. Since that time, CMS has taken interval steps to continue a comprehensive CC/MCC analysis. First, CMS hosted a listening session on October 8, 2019, to review the methodology utilized to mathematically measure the impact on resource use. In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58550 through 58554), we discussed our plan to continue a comprehensive CC/MCC analysis, using a combination of mathematical analysis of claims data and the application of nine guiding principles. In the FY 2022 IPPS/LTCH PPS proposed rule (86 FR 25175 through 25180), as another interval step in our comprehensive review of the severity designations of ICD–10–CM diagnosis codes, we requested public comments on a potential change to the severity level designations for nine unspecified ICD–10–CM diagnosis codes that were considering adopting for FY 2022. In the FY 2022 IPPS/LTCH PPS final rule (86 FR 44940 through 44943), instead of changing the severity level designations of the unspecified ICD–10–CM diagnosis codes identified, we finalized a new Medicare Code Editor (MCE) code edit for “unspecified” ICD–10–CM diagnosis codes, effective with discharges on and after April 1, 2022. We stated we believed finalizing this new edit would provide additional time for providers to be educated while not affecting the payment the provider is eligible to receive. As discussed in the FY 2022 IPPS/LTCH PPS final rule (87 FR 48866), as the new unspecified edit became effective beginning with discharges on and after April 1, 2022, we believed it was appropriate to not propose to change the designation of any ICD–10–CM diagnosis codes, including the unspecified codes that are subject to the “Unspecified Code” edit, to allow interested parties the time needed to become acclimated to the new edit.

In the FY 2023 IPPS/LTCH proposed rule (87 FR 28177 through 28181), we requested public comments on how the reporting of diagnosis codes in categories Z55–Z65 might improve our ability to recognize severity of illness, complexity of illness, and/or utilization of resources under the MS–DRGs. In addition, we have provided updated impact on resource use files so that the public can review the mathematical data for the impact on resource use generated using claims from the FY 2018, FY 2019, FY 2020, FY 2021 and the FY 2022, FY 2023, FY 2024, respectively at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software.html.

Considering the potential impact of implementing a significant number of severity designation changes, and in light of the public health emergency (PHE) that was occurring concurrently during much of this timeframe, we believe these interval steps were appropriate as we plan to continue a comprehensive CC/MCC analysis, using a combination of mathematical analysis of claims data and the application of nine guiding principles. We continue to solicit comments regarding the nine guiding principles, as well as other possible ways we can incorporate meaningful indicators of clinical severity. We encourage commenters to provide a detailed explanation of how applying a suggested concept or principle would ensure that the severity designation appropriately reflects resource use for ICD–10–CM codes when reported as secondary diagnoses. Commenters should submit their recommendations by October 20, 2023 via the electronic intake system, Medicare Electronic Application Request Information System™ (MEARIS™) at: https://mearis.cms.gov/public/home. With respect to the suggestion that CMS make a proposed list of severity level designation changes available along with the impact on resource use files generated using claims from the fiscal year MedPAR files, we appreciate the feedback and will take this suggestion under consideration.

After consideration of the public comments we received, and for the reasons discussed, we are finalizing our proposal, without modification, to maintain the current severity level designation of diagnosis codes K76.72 (Hepatic encephalopathy), N14.11 (Contrast-induced nephropathy), and S06.2XXA (Diffuse traumatic brain injury with loss of consciousness status unknown, initial encounter) for FY 2024.

d. Additions and Deletions to the Diagnosis Code Severity Levels for FY 2024

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26750), we noted the following tables identifying the proposed additions and deletions to the diagnosis code MCC severity levels list and the proposed additions and deletions to the diagnosis code CC severity levels list for FY 2024 and are available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html.

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>6J.1</td>
<td>Proposed Additions to the MCC List FY 2024</td>
</tr>
<tr>
<td>6J.2</td>
<td>Proposed Deletions to the MCC List FY 2024</td>
</tr>
<tr>
<td>6L.1</td>
<td>Proposed Additions to the CC List FY 2024</td>
</tr>
<tr>
<td>6L.2</td>
<td>Proposed Deletions to the CC List FY 2024</td>
</tr>
<tr>
<td>6I.1</td>
<td>Additions to the MCC List FY 2024</td>
</tr>
<tr>
<td>6I.2</td>
<td>Deletions to the MCC List FY 2024</td>
</tr>
<tr>
<td>6J.1</td>
<td>Additions to the CC List FY 2024</td>
</tr>
<tr>
<td>6J.2</td>
<td>Deletions to the CC List FY 2024</td>
</tr>
<tr>
<td>6I</td>
<td>CC Exclusions List for FY 2024</td>
</tr>
</tbody>
</table>

In the September 1, 1987 final notice (52 FR 33143) concerning changes to the DRG classification system, we modified the GROUPER logic so that certain diagnoses included on the standard list of CCs would not be considered valid CCs in combination with a particular principal diagnosis. We created the CC Exclusions List for the following reasons: (1) to preclude coding of CCs for closely related conditions; (2) to preclude duplicative or inconsistent coding from being treated as CCs; and (3) to ensure that cases are appropriately classified between the complicated and uncomplicated DRGs in a pair.

In the May 19, 1987 proposed notice (52 FR 18877) and the September 1, 1987 final notice (52 FR 33154), we explained that the excluded secondary diagnoses were established using the following five principles:

- Chronic and acute manifestations of the same condition should not be considered CCs for one another;
- Specific and nonspecific (that is, not otherwise specified (NOS)) diagnosis codes for the same condition should not be considered CCs for one another;
- Codes for the same condition that cannot coexist, such as partial/total, unilateral/bilateral, obstructed/unobstructed, and benign/malignant, should not be considered CCs for one another;
Codes for the same condition in anatomically proximal sites should not be considered CCs for one another; and

- Closely related conditions should not be considered CCs for one another.

The creation of the CC Exclusions List was a major project involving hundreds of codes. We have continued to review the remaining CCs to identify additional exclusions and to remove diagnoses from the master list that have been shown not to meet the definition of a CC. We refer readers to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50541 through 50544) for detailed information regarding revisions that were made to the CC and CC Exclusion Lists under the ICD−9−CM MS−DRGs.

The ICD−10 MS−DRGs Version 40.1 CC Exclusion List is included as Appendix C in the ICD−10 MS−DRG Definitions Manual, which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html, and includes two lists identified as Part 1 and Part 2. Part 1 is the list of all diagnosis codes that are defined as a CC or MCC when reported as a secondary diagnosis. For all diagnosis codes on the list, a link is provided to a collection of diagnosis codes which, when reported as the principal diagnosis, would cause the CC or MCC diagnosis to be considered as a NonCC. Part 2 is the list of diagnosis codes designated as an MCC only for patients discharged alive; otherwise, they are assigned as a NonCC.

In the FY 2024 IPPS/LTCH PPS proposed rule, we proposed additional changes to the ICD−10 MS−DRGs Version 41 CC Exclusion List based on the diagnosis and procedure code updates as discussed in section II.C.13. of the proposed rule and set forth in Tables 6G.1, 6G.2, 6H.1, and 6H.2 associated with the proposed rule and available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html.

As discussed in section II.C.13. of the preamble of this final rule, we are finalizing, without modification, the proposed assignments and designations for the diagnosis codes after consideration of the public comments received. Therefore, the finalized CC Exclusions List as displayed in Tables 6G.1, 6G.2, 6H.1, 6H.2, and 6K, associated with this final rule reflect the severity levels under V41 of the ICD−10 MS−DRGs. We have developed Table 6G.1.—Secondary Diagnosis Order Additions to the CC Exclusions List—FY 2024; Table 6G.2.—Principal Diagnosis Order Additions to the CC Exclusions List—FY 2024; and Table 6H.2.—Principal Diagnosis Order Deletions to the CC Exclusions List—FY 2024; and Table 6K. Complete List of CC Exclusions—FY 2024.

For Table 6G.1, each secondary diagnosis code finalized for addition to the CC Exclusion List is shown with an asterisk and the principal diagnoses finalized to exclude the secondary diagnosis code are provided in the indented column immediately following it. For Table 6G.2, each of the principal diagnosis codes for which there is a CC exclusion is shown with an asterisk and the conditions finalized for addition to the CC Exclusion List that will not count as a CC are provided in an indented column immediately following the affected principal diagnosis. Table 6H.1, each secondary diagnosis code finalized for deletion from the CC Exclusion List is shown with an asterisk followed by the principal diagnosis codes that currently exclude it. For Table 6H.2, each of the principal diagnosis codes is shown with an asterisk and the final deletions to the CC Exclusions List are provided in an indented column immediately following the affected principal diagnosis. Tables 6G.1., 6G.2., 6H.1., and 6H.2. associated with this final rule are available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html.

As discussed in the proposed rule, we also noted that in our review of the CC Exclusion List that we identified a total of 668 diagnosis codes currently listed on various principal diagnosis collection lists that are not able to be reported as a principal diagnosis based on the ICD−10−CM Official Guidelines for Coding and Reporting. In addition, these codes are listed on the Medicare Code Editor (MCE) code edit lists for Unacceptable Principal Diagnosis or Manifestations not allowed as Principal Diagnosis. Therefore, we stated we believed it was appropriate to remove these codes from the affected principal diagnosis collection lists for V41 of the GROUPER. Because we were unable to reflect these changes in Table 6G.1., 6G.2., 6H.1., or 6H.2 at the time of the development of the proposed rule, we provided a supplementary table, Table 6H.3—Principal Diagnosis Codes for Removal from CC Exclusion List—FY 2024 listing each of these 668 diagnosis codes, including the code descriptions, the applicable MCE edit, and the current principal diagnosis collection list(s) where they are listed and from which the code would be removed for the final FY 2024 V41 GROUPER.

Table 6H.3 associated with the proposed rule is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html.

The ICD−10 MS−DRGs Version 41 CC Exclusion List is included as Appendix C of the Definitions Manual (available in two formats; text and HTML). The manuals are available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRGs-Classifications-and-Software and each format includes two lists identified as Part 1 and Part 2. Part 1 is the list of all diagnosis codes that are defined as a CC or MCC when reported as a secondary diagnosis. For all diagnosis codes on the list, a link (HTML version) is provided to a collection of diagnosis codes which, when used as the principal diagnosis, would cause the CC or MCC diagnosis to be considered as a NonCC. Part 2 is the list of diagnosis codes designated as a MCC only for patients discharged alive; otherwise, they are assigned as a NonCC.

13. Changes to the ICD−10−CM and ICD−10−PCS Coding Systems

To identify new, revised and deleted diagnosis and procedure codes, for FY 2024, we have developed Table 6A.—New Diagnosis Codes, Table 6B.—New Procedure Codes, Table 6C.—Invalid Diagnosis Codes, Table 6D.—Invalid Procedure Codes, Table 6E.—Revised Diagnosis Code Titles and Table 6F.—Revised Procedure Code Titles for this final rule.

These tables are not published in the Addendum to the proposed rule or final rule, but are available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html as described in section VI. of the Addendum to this final rule. As discussed in section II.C.16. of the preamble of the proposed rule and this final rule, the code titles are adopted as part of the ICD−10 Coordination and Maintenance Committee meeting process. Therefore, although we publish the code titles in the IPPS proposed and final rules, they are not subject to comment in the proposed or final rules.

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26752), we proposed the MDC and MS−DRG assignments for the new diagnosis codes and procedure codes as set forth in Table 6A.—New Diagnosis Codes and Table 6B.—New Procedure Codes. We also stated that the proposed severity level designations for these diagnosis codes are set forth in Table 6A. and the proposed O.R. status for the new
In this section of this rule, we summarize the public comments received for Table 6A and Table 6B and provide our responses.

**Comment:** A commenter applauded the addition of diagnosis code Z29.81 (Encounter for HIV pre-exposure prophylaxis) (PrEP) and encouraged ongoing monitoring of the code to ensure appropriate billing. The commenter stated a diagnostic code for PrEP has the opportunity to improve HIV prevention efforts for patients at the point of care. According to the commenter, HIV remains an issue in every region of the United States (U.S.) and significant gaps persist in ongoing HIV preventive care in clinical practice, including early detection of HIV and linking patients to appropriate prevention services, such as PrEP.

**Response:** We thank the commenter for their feedback.

**Comment:** A commenter stated that CMS proposed the severity level designation for diagnosis code O90.41 (Hepatorenal syndrome following labor and delivery) to the MCC list, proposed the removal of diagnosis code O90.4 (Postpartum acute kidney failure) from the MCC list (since the code will no longer be valid), and proposed to add several diagnosis codes describing osteoporosis and intrahepatic cholestasis of pregnancy codes to the CC list. However, according to the commenter, CMS did not include a proposal to add diagnosis code O26.649 (Intrahepatic cholestasis of pregnancy, unspecified trimester) to the CC list. The commenter stated that in FY 2022, CMS finalized the severity level designation of “unspecified” diagnosis codes as CC or MCC where there are other codes available in the code subcategory that further specify the anatomic site for purposes of a new Medicare Code Editor (MCE) “Unspecified code edit” effective with discharges on or after April 1, 2022. As such, the commenter requested consideration for the addition of diagnosis code O26.649 (Intrahepatic cholestasis of pregnancy, unspecified trimester) to the CC list to be in alignment with the other diagnosis codes describing intrahepatic cholestasis of pregnancy first trimester, second trimester, and third trimester (codes O26.641, O26.642, and O26.643, respectively) or to consider adding as a diagnosis subject to the “unspecified” code edit.

**Response:** We appreciate the commenters’ feedback. We are providing clarification that the Unspecified code edit is only applicable to diagnosis codes that are (1) defined as an unspecified code in the classification by the title description, (2) currently designated as a CC or MCC, and (3) able to be further specified by laterality (right, left, or bilateral) for the anatomic site by other codes in the code subcategory. Because the other intrahepatic cholestasis of pregnancy codes do not include laterality in their code title descriptions, and code O26.649 is not a CC or MCC, the intrahepatic cholestasis of pregnancy, unspecified trimester code (O26.649) is unable to be considered for addition to the Unspecified code edit. We also note that consistent with our established process, we considered the severity level for the predecessor code to determine the most appropriate severity level designation. The predecessor code for code O26.649 is diagnosis code O26.619 (Liver and biliary tract disorders in pregnancy, unspecified trimester), as reflected in the FY 2024 ICD–10–CM Conversion Table (available on the CMS web page at: https://www.cms.gov/medicare/icc-10/2024-icd-10-cm) and is designated as a NonCC. Therefore, consistent with the designation of that predecessor code, we proposed to designate code O26.649 as a NonCC.

**Comment:** A couple commenters requested that CMS change the MS–DRG assignment for new procedure codes X2H03R9 and X2H13R9 to MS–DRGs 266 and 267 and to monitor the costs of these procedures going forward to ensure appropriate assignment. Another commenter stated the TricValve® replaces the function of the tricuspid valve and should be described as a replacement procedure with assignment to MS–DRGs 266 and 267.

**Response:** We appreciate the commenters’ feedback. We note that as reflected in Table 6B.—New Procedure Codes, associated with the FY 2024 IPPS/LTCH PPS proposed rule, we finalized the two procedure codes (X2H03R9 and X2H13R9) after consideration of public comments from the September 13, 2022 ICD–10 Coordination and Maintenance (C&M) Committee meeting. We note that under the ICD–10–PCS classification, the root operation Replacement is defined as: Putting in or on biological or synthetic material that physically takes the place and/or function of all or a portion of a body part. As such, the TricValve® technology is not literally replacing the tricuspid valve as defined under ICD–10–PCS and the body part is not the tricuspid valve, rather, the site of the procedure is the superior vena cava (SVC) and inferior vena cava (IVC). Therefore, while the intent of the technology is to replace the function of the tricuspid valve, the procedure to place the bicaval valve system is not literally doing that and the native tricuspid valve is left in place. Using our established process, we proposed the Operating Room (O.R.) designations, MDC and MS–DRG assignments based on the predecessor code assignments. The predecessor code for procedure code X2H03R9 is procedure code 06H03DZ (Insertion of intraluminal device into inferior vena cava, percutaneous approach) and the
The Medicare Code Editor (MCE) is a software program that detects and reports errors in the coding of Medicare claims data. Patient diagnoses, procedure(s), and demographic information are entered into the Medicare claims processing systems and are subjected to a series of automated screens. The MCE screens are designed to identify cases that require further review before classification into an MS–DRG.

As discussed in the FY 2023 IPPS/ LTCH PPS final rule (87 FR 48874), we made available the FY 2022 ICD–10 MCE Version 40 manual file. The manual contains the definitions of the Medicare code edits, including a description of each coding edit with the corresponding diagnosis and procedure code edit lists. The link to this MCE manual file, along with the link to the mainframe and computer software for the MCE Version 41 (and ICD–10 MS–DRGs), are posted on the CMS website at: https://www.cms.gov/Medicare/Medicare-fee-for-service-payment/AcuteInpatientPPS/ICD-10-MS-DRGs-Edit-Software.

The MCE version 41 manual file contains the definitions of each new or modified diagnosis and procedure code edit. The manual also includes a description of the corresponding diagnosis and procedure code edit list. The link to this MCE manual file, along with the link to the mainframe and computer software for the MCE Version 41 (and ICD–10 MS–DRGs), are posted on the CMS website at: https://www.cms.gov/Medicare/Medicare-fee-for-service-payment/AcuteInpatientPPS/ICD-10-MS-DRGs-Edit-Software.

We also note that, as discussed in the CY 2024 Outpatient Prospective Payment System and Ambulatory Surgical Center (OPPS/ASC) proposed rule (88 FR 49552), we are making available the FY 2024 ICD–10 MCE Version 41 Manual file, along with the link to the mainframe and computer software for the MCE Version 41 (and ICD–10 MS–DRGs), on the CMS website at: https://www.cms.gov/Medicare/Medicare-fee-for-service-payment/AcuteInpatientPPS/ICD-10-MS-DRGs-Edit-Software.

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26755), we proposed to replace the sex conflict edit with the new and modified code updates approved after the annual spring 2023 ICD–10 Coordination and Maintenance Committee meeting. The new and modified code updates were approved after the annual spring 2023 ICD–10 Coordination and Maintenance Committee meeting. These changes are approved too late in the rulemaking schedule for inclusion in the proposed rule. Furthermore, although our MCE policies have been described in our proposed and final rules, we have not provided the detail of each new or modified diagnosis and procedure code edit in the final rule. However, we make available the finalized Definitions of Medicare Code Edits (MCE) file. Therefore, we are making available the FY 2023 ICD–10 MCE Version 40 Manual file, along with the link to the mainframe and computer software for the MCE Version 41 (and ICD–10 MS–DRGs), on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/ICD-10-MS-DRGs-Classifications-and-Software.

We also note that, as discussed in the CY 2024 Outpatient Prospective Payment System and Ambulatory Surgical Center (OPPS/ASC) proposed rule (88 FR 49552, July 31, 2023), consistent with the process that is used for updates to the “Integrated” Outpatient Code Editor (I/OCE) and other Medicare claims editing systems, we proposed to address any future revisions to the IPPS MCE, including any additions or deletions of claims edits, as well as the addition or deletion of ICD–10 diabetes and procedure codes to the applicable MCE edit code lists, outside of the annual IPPS rulemakings. As discussed in the CY 2024 OPPS/ASC proposed rule, we proposed to remove discussion of the IPPS MCE from the annual IPPS rulemakings, beginning with the CY 2025 rulemaking, and to generally address future changes or updates to the MCE through instruction to the Medicare administrative contractors (MACs).
the instructions provided in that proposed rule.

a. External Causes of Morbidity Codes as Principal Diagnosis

In the MCE, the external cause codes (V, W, X, or Y codes) describe the circumstance causing an injury, not the nature of the injury, and therefore should not be used as a principal diagnosis.

As discussed in section II.C.13. of the preamble of the proposed rule and this final rule, Table 6A.—New Diagnosis Codes, lists the diagnosis codes that have been approved to date which will be effective with discharges on and after October 1, 2023. We proposed to add the ICD–10–CM diagnosis codes shown in Table 6P.9a associated with the proposed rule and available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS to the edit code list for the External causes of morbidity codes as principal diagnosis edit.

**Comment:** Commenters agreed with CMS’ proposal to add the diagnosis codes listed in Table 6P.9a to the External causes of morbidity codes as principal diagnosis edit code list.

**Response:** We appreciate the commenters’ support.

After consideration of the public comments we received, we are finalizing our proposal to add the diagnosis codes listed in Table 6P.9a to the External causes of morbidity codes as principal diagnosis edit code list under the ICD–10 MCE Version 41, effective October 1, 2023.

b. Age Conflict Edit

In the MCE, the Age conflict edit exists to detect inconsistencies between a patient’s age and any diagnosis on the patient’s record; for example, a 5-year-old patient with benign prostatic hypertrophy or a 78-year-old patient coded with a delivery. In these cases, the diagnosis is clinically and virtually impossible for a patient of the stated age. Therefore, either the diagnosis or the age is presumed to be incorrect. Currently, in the MCE, the following four age diagnosis categories appear under the Age conflict edit and are listed in the manual and written in the software program:

- Perinatal/Newborn—Age 0 years only; a subset of diagnoses which will only occur during the perinatal or newborn period of age 0 (for example, tetanus neonatorum, health examination for newborn under 8 days old).
- Pediatric—Age is 0–17 years inclusive (for example, Reye’s syndrome, routine child health exam).
- Maternity—Age range is 9–64 years inclusive (for example, diabetes in pregnancy, antepartum pulmonary complication).
- Adult—Age range is 15–124 years inclusive (for example, senile delirium, mature cataract).

**Comment:** A commenter requested that we provide clarification regarding the overlapping age ranges (0 to 17 years and 15 to 124 years) in the Pediatric and Adult categories under the Age Conflict edit.

**Response:** As stated in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38045), the age ranges defined within the Age Conflict edits were established with the implementation of the IPPS. The adult age range includes the minimum age of 15 years to account for those patients who are declared emancipated minors.

(1) Perinatal/Newborn Diagnosis Category

Under the ICD–10 MCE, the Perinatal/Newborn diagnoses category for the Age conflict edit considers the age range of 0 years only. For that reason, the diagnosis codes on this Age conflict edit list would be expected to apply to conditions or disorders which will only occur during the perinatal or newborn period of age 0.

As discussed in section II.C.13. of the preamble of the proposed rule and this final rule, Table 6A.—New Diagnosis Codes, lists the diagnosis codes that have been approved to date which will be effective with discharges on and after October 1, 2023. We proposed to add new ICD–10–CM diagnosis codes Z05.81 (Observation and evaluation of newborn for suspected condition related to home physiologic monitoring device ruled out) and Z05.89 (Observation and evaluation of newborn for other specified suspected condition ruled out) to the edit code list for the Perinatal/Newborn diagnoses category under the Age conflict edit.

**Comment:** Commenters agreed with CMS’ proposal to add diagnosis codes Z05.81 and Z05.89 to the edit code list for the Perinatal/Newborn diagnoses category for the Age conflict edit.

**Response:** We appreciate the commenters’ support.

After consideration of the public comments we received, we are finalizing our proposal to add diagnosis codes Z05.81 and Z05.89 to the edit code list for the Perinatal/Newborn diagnoses category for the Age conflict edit. We proposed to add new ICD–10–CM diagnosis codes under the Age conflict edit for the ICD–10 MCE Version 41, effective October 1, 2023.

In addition, as discussed in section II.C.13. of the preamble of the proposed rule and this final rule, Table 6C.—Invalid Diagnosis Codes, lists the diagnosis codes that are no longer effective October 1, 2023. Included in this table is ICD–10–CM diagnosis code Z05.8 (Observation and evaluation of newborn for other specified suspected condition ruled out) that is currently listed on the edit code list for the Perinatal/Newborn diagnoses category under the Age conflict edit. We proposed to delete this code from the Perinatal/Newborn diagnoses edit code list.

**Comment:** Commenters agreed with CMS’ proposal to delete diagnosis code Z05.8 from the edit code list for the Perinatal/Newborn diagnoses category since it is no longer valid.

**Response:** We appreciate the commenters’ support.

After consideration of the public comments we received, we are finalizing our proposal to delete diagnosis code Z05.8 from the edit code list for the Perinatal/Newborn diagnoses category under the Age conflict edit for the ICD–10 MCE Version 41, effective October 1, 2023.

(2) Maternity Diagnoses

Under the ICD–10 MCE, the Maternity diagnoses category for the Age conflict edit considers the age range of 9 to 64 years inclusive. For that reason, the diagnosis codes on this Age conflict edit list would be expected to apply to conditions or disorders specific to that age group only.

As discussed in section II.C.13. of the preamble of the proposed rule, Table 6A.—New Diagnosis Codes, lists the diagnosis codes that have been approved to date which will be effective with discharges on and after October 1, 2023. We proposed to add new ICD–10–CM diagnosis codes under the Age conflict edit.

**Comment:** Commenters agreed with CMS’ proposal to add diagnosis codes under the Age conflict edit.

**Response:** We appreciate the commenters’ support.
<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>O26.641</td>
<td>Intrahepatic cholestasis of pregnancy, first trimester</td>
</tr>
<tr>
<td>O26.642</td>
<td>Intrahepatic cholestasis of pregnancy, second trimester</td>
</tr>
<tr>
<td>O26.643</td>
<td>Intrahepatic cholestasis of pregnancy, third trimester</td>
</tr>
<tr>
<td>O26.649</td>
<td>Intrahepatic cholestasis of pregnancy, unspecified trimester</td>
</tr>
<tr>
<td>O90.41</td>
<td>Hepatorenal syndrome following labor and delivery</td>
</tr>
<tr>
<td>O90.49</td>
<td>Other postpartum acute kidney failure</td>
</tr>
</tbody>
</table>

Comment: Commenters agreed with CMS’ proposal to add the diagnosis codes listed in the previous table to the Maternity diagnoses edit code list.

Response: We appreciate the commenters’ support.

After consideration of the public comments we received, we are finalizing our proposal to add the diagnosis codes listed in the previous table to the Maternity diagnoses edit code list under the Age conflict edit for the ICD–10 MCE Version 41, effective October 1, 2023.

In addition, as discussed in section II.C.13. of the preamble of the proposed rule and this final rule, Table 6C.—Invalid Diagnosis Codes, lists the diagnosis codes that are no longer effective October 1, 2023. Included in this table is ICD–10–CM diagnosis code O90.4 (Postpartum acute kidney failure) that is currently listed on the edit code list for the Maternity diagnoses category under the Age conflict edit. We proposed to delete this code from the Maternity diagnoses edit code list.

Comment: Commenters agreed with CMS’ proposal to remove diagnosis code O90.4 from the Maternity diagnoses edit code list since it is no longer valid.

Response: We appreciate the commenters’ support.

After consideration of the public comments we received, we are finalizing our proposal to remove diagnosis code O90.4 from the Maternity diagnoses edit code list under the Age conflict edit for the ICD–10 MCE Version 41, effective October 1, 2023.

(3) Adult Diagnoses

Under the ICD–10 MCE, the Adult diagnoses category for the Age conflict edit considers the age range of 15 to 124 years inclusive. For that reason, the diagnosis codes on this Age conflict edit list would be expected to apply to conditions or disorders specific to that age group only.

As discussed in section II.C.13. of the preamble of the proposed rule and this final rule, Table 6A.—New Diagnosis Codes, lists the diagnosis codes that have been approved to date which will be effective with discharges on and after October 1, 2023. We proposed to add the following new ICD–10–CM diagnosis codes to the edit code list for the Adult diagnoses category under the Age conflict edit.
Comment: Commenters agreed with CMS’ proposal to add the diagnosis codes listed in the previous table to the Adult diagnoses edit code list.

Response: We appreciate the commenters’ support.

After consideration of the public comments we received, we are finalizing our proposal to add the diagnosis codes listed in the previous table to the Adult diagnoses edit code list under the ICD–10 MCE Version 41, effective October 1, 2023.

c. Sex Conflict Edit

As discussed in the proposed rule, we received a request to reconsider sex conflict edits in connection with concerns related to claims processing for transgender individuals. The requestor raised concerns that the current edit is not clinically accurate and is inconsistent with equitable documentation of gender at the time of service. The requestor expressed concerns that automated systems are contributing to administrative burden for obstetrician-gynecologists because the sex conflict edit requires physicians to choose the sex assigned at birth only and that hospitals must include condition code 45 to override the edit for appropriate payment for certain

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>G93.44</td>
<td>Adult-onset leukodystrophy with axonal spheroids</td>
</tr>
<tr>
<td>M80.0B1A</td>
<td>Age-related osteoporosis with current pathological fracture, right pelvis, initial encounter for fracture</td>
</tr>
<tr>
<td>M80.0B1D</td>
<td>Age-related osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with routine healing</td>
</tr>
<tr>
<td>M80.0B1G</td>
<td>Age-related osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with delayed healing</td>
</tr>
<tr>
<td>M80.0B1K</td>
<td>Age-related osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with nonunion</td>
</tr>
<tr>
<td>M80.0B1P</td>
<td>Age-related osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with malunion</td>
</tr>
<tr>
<td>M80.0B1S</td>
<td>Age-related osteoporosis with current pathological fracture, right pelvis, sequela</td>
</tr>
<tr>
<td>M80.0B2A</td>
<td>Age-related osteoporosis with current pathological fracture, left pelvis, initial encounter for fracture</td>
</tr>
<tr>
<td>M80.0B2D</td>
<td>Age-related osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with routine healing</td>
</tr>
<tr>
<td>M80.0B2G</td>
<td>Age-related osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with delayed healing</td>
</tr>
<tr>
<td>M80.0B2K</td>
<td>Age-related osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with nonunion</td>
</tr>
<tr>
<td>M80.0B2P</td>
<td>Age-related osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with malunion</td>
</tr>
<tr>
<td>M80.0B2S</td>
<td>Age-related osteoporosis with current pathological fracture, left pelvis, sequela</td>
</tr>
<tr>
<td>M80.0B9A</td>
<td>Age-related osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture</td>
</tr>
<tr>
<td>M80.0B9D</td>
<td>Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with routine healing</td>
</tr>
<tr>
<td>M80.0B9G</td>
<td>Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with delayed healing</td>
</tr>
<tr>
<td>M80.0B9K</td>
<td>Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with nonunion</td>
</tr>
<tr>
<td>M80.0B9P</td>
<td>Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with malunion</td>
</tr>
<tr>
<td>M80.0B9S</td>
<td>Age-related osteoporosis with current pathological fracture, unspecified pelvis, sequela</td>
</tr>
</tbody>
</table>
surgical procedures or procedures. The requestor described that claims are inappropriately denied due to the edit singling out transgender individuals, contributing to continued alienation of transgender patients. The requestor further shared that obstetrician-gynecologists have indicated that to provide high-quality, patient-centered care, they need to be able to document a patient’s gender identity along with their sex.18 We note that the requestor raises a number of issues that are related to multiple prospective payment systems and broader aspects of health care, such as the electronic health record.

We share the requestor’s concern that the original design of the sex conflict edits is descriptive of a patient’s sex assigned at birth as submitted on a claim, which may not be fully reflective of the practice of medicine and patient-doctor interactions, as well as that CMS policy and communications about the use of condition code 45 for institutional claims has not been re-examined in some time. As we state in the CMS Framework for Health Equity, 2022–2032,19 we strive to identify and remedy systemic barriers to equity so that every one of the people we serve has a fair and just opportunity to attain their optimal health regardless of race, ethnicity, disability, sexual orientation, gender identity, socioeconomic status, geography, preferred language, or other factors that affect access to care and health outcomes. CMS is committed to looking holistically at the concerns raised by the commenter across settings of care and will consider how to address for future rulemaking or guidance, and we thank the commenter for continuing to share firsthand experiences.

**Comment:** Commenters expressed their appreciation that CMS stated it is committed to looking holistically at the concerns raised with respect to the sex conflict edit and claims processing of transgender individuals across settings of care. A commenter who expressed support for the continued application of the sex conflict edit stated that while the edit plays an important role in coding error detection and condition code 45 is intended to ensure claims submission accuracy, coding and MS-DRG assignment remain challenging as a result of the edit.

**Response:** We appreciate the commenters’ feedback. We also note that following publication of the FY 2024 IPPS/LTCI PPS proposed rule, in further consideration of the concerns expressed by the requestor and recognizing that communication about the use of condition code 45 for institutional claims had not been re-examined in some time, we issued guidance via a Medicare Learning Network® (MLN Connects) article on June 8, 2023 that is intended to provide clarification on the proper billing and usage of condition code 45 and modifier KX. This guidance also informed providers that effective July 1, 2023, the National Uniform Billing Committee (NUBC) revised the terminology and definition for Condition Code 45 to Gender Incongruence, defined as “characterized by a marked and persistent incongruence between an individual’s experienced gender and sex at birth.” We refer the reader to the CMS website at: https://www.cms.gov/outreach-and-education/outreach/ffsprovpartprog/provider-partnership-email-archive/2023-06-08-mlnc for additional information regarding this guidance.

d. Manifestation Code as Principal Diagnosis Edit

In the ICD–10–CM classification system, manifestation codes describe the manifestation of an underlying disease, not the disease itself, and therefore should not be used as a principal diagnosis.

As discussed in section II.C.13. of the preamble of the proposed rule and this final rule, Table 6A.—New Diagnosis Codes, lists the new diagnosis codes that have been approved to date which will be effective with discharges on and after October 1, 2023. Included in this table are the following new ICD–10–CM diagnosis codes that we proposed to add to the edit code list for the Manifestation code as principal diagnosis edit, because the disease itself would be required to be reported first.

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E20.811</td>
<td>Secondary hypoparathyroidism in diseases classified elsewhere</td>
</tr>
<tr>
<td>H36.89</td>
<td>Other retinal disorders in diseases classified elsewhere</td>
</tr>
</tbody>
</table>

**Comment:** Commenters agreed with CMS’ proposal to add the diagnosis codes listed in the previous table to the Manifestation code as principal diagnosis edit code list.

**Response:** We appreciate the commenters’ support.

After consideration of the public comments we received, we are finalizing our proposal to add the diagnosis codes listed in the previous table to the Manifestation code as principal diagnosis edit code list under the ICD–10 MCE Version 41, effective October 1, 2023.

In addition, as discussed in section II.C.13. of the preamble of the proposed rule and this final rule, Table 6C.—Invalid Diagnosis Codes, lists the diagnosis codes that are no longer effective October 1, 2023. Included in this table is ICD–10–CM diagnosis code H36 (Retinal disorders in diseases classified elsewhere) that is currently listed on the edit code list for the Manifestation code as principal diagnosis edit. We propose to delete this code from the Manifestation code as principal diagnosis edit code list.

**Comment:** Commenters agreed with CMS’ proposal to remove diagnosis code H36 from the Manifestation code as principal diagnosis edit code list since it is no longer valid.

**Response:** We appreciate the commenters’ support.

The requester was referring to “sex assigned at birth” in this context.

---

18 We note that the requestor used the phrase “gender identity along with their sex”. We believe...
unacceptable as a principal diagnosis. In limited situations, there are a few codes on the MCE Unacceptable Principal Diagnosis edit code list that are considered “acceptable” when a specified secondary diagnosis is also coded and reported on the claim.

As discussed in section II.C.13. of the preamble of the proposed rule and this final rule, Table 6A.—New Diagnosis Codes, lists the new diagnosis codes that have been approved to date which will be effective with discharges on and after October 1, 2023. We proposed to add the following new ICD–10–CM diagnosis codes to the Unacceptable Principal Diagnosis edit code list.
<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>B96.83</td>
<td>Acinetobacter baumannii as the cause of diseases classified elsewhere</td>
</tr>
<tr>
<td>E88.A</td>
<td>Wasting disease (syndrome) due to underlying condition</td>
</tr>
<tr>
<td>H36.811</td>
<td>Nonproliferative sickle-cell retinopathy, right eye</td>
</tr>
<tr>
<td>H36.812</td>
<td>Nonproliferative sickle-cell retinopathy, left eye</td>
</tr>
<tr>
<td>H36.813</td>
<td>Nonproliferative sickle-cell retinopathy, bilateral</td>
</tr>
<tr>
<td>H36.819</td>
<td>Nonproliferative sickle-cell retinopathy, unspecified eye</td>
</tr>
<tr>
<td>H36.821</td>
<td>Proliferative sickle-cell retinopathy, right eye</td>
</tr>
<tr>
<td>H36.822</td>
<td>Proliferative sickle-cell retinopathy, left eye</td>
</tr>
<tr>
<td>H36.823</td>
<td>Proliferative sickle-cell retinopathy, bilateral</td>
</tr>
<tr>
<td>H36.829</td>
<td>Proliferative sickle-cell retinopathy, unspecified eye</td>
</tr>
<tr>
<td>R40.2A</td>
<td>Nontraumatic coma due to underlying condition</td>
</tr>
<tr>
<td>Z02.84</td>
<td>Encounter for child welfare exam</td>
</tr>
<tr>
<td>Z16.13</td>
<td>Resistance to carbapenem</td>
</tr>
<tr>
<td>Z22.340</td>
<td>Carrier of carbapenem-resistant Acinetobacter baumannii</td>
</tr>
<tr>
<td>Z22.341</td>
<td>Carrier of carbapenem-sensitive Acinetobacter baumannii</td>
</tr>
<tr>
<td>Z22.349</td>
<td>Carrier of Acinetobacter baumannii, unspecified</td>
</tr>
<tr>
<td>Z22.350</td>
<td>Carrier of carbapenem-resistant Enterobacterales</td>
</tr>
<tr>
<td>Z22.358</td>
<td>Carrier of other Enterobacterales</td>
</tr>
<tr>
<td>Z22.359</td>
<td>Carrier of Enterobacterales, unspecified</td>
</tr>
<tr>
<td>Z29.81</td>
<td>Encounter for HIV pre-exposure prophylaxis</td>
</tr>
<tr>
<td>Z29.89</td>
<td>Encounter for other specified prophylactic measures</td>
</tr>
<tr>
<td>Z62.23</td>
<td>Child in custody of non-parental relative</td>
</tr>
<tr>
<td>Z62.24</td>
<td>Child in custody of non-relative guardian</td>
</tr>
<tr>
<td>Z62.823</td>
<td>Parent-step child conflict</td>
</tr>
<tr>
<td>Z62.831</td>
<td>Non-parental relative-child conflict</td>
</tr>
<tr>
<td>Z62.832</td>
<td>Non-relative guardian-child conflict</td>
</tr>
<tr>
<td>Z62.833</td>
<td>Group home staff-child conflict</td>
</tr>
<tr>
<td>Z62.892</td>
<td>Runaway [from current living environment]</td>
</tr>
<tr>
<td>Z83.710</td>
<td>Family history of adenomatous and serrated polyps</td>
</tr>
<tr>
<td>Z83.711</td>
<td>Family history of hyperplastic colon polyps</td>
</tr>
<tr>
<td>Z83.718</td>
<td>Other family history of colon polyps</td>
</tr>
<tr>
<td>Z83.719</td>
<td>Family history of colon polyps, unspecified</td>
</tr>
<tr>
<td>Z91.A41</td>
<td>Caregiver’s other noncompliance with patient’s medication regimen due to financial hardship</td>
</tr>
<tr>
<td>Z91.A48</td>
<td>Caregiver's other noncompliance with patient’s medication regimen for other reason</td>
</tr>
<tr>
<td>Z91.A51</td>
<td>Caregiver's noncompliance with patient’s renal dialysis due to financial hardship</td>
</tr>
<tr>
<td>Z91.A58</td>
<td>Caregiver's noncompliance with patient’s renal dialysis for other reason</td>
</tr>
<tr>
<td>Z91.A91</td>
<td>Caregiver's noncompliance with patient’s other medical treatment and regimen due to financial hardship</td>
</tr>
<tr>
<td>Z91.A98</td>
<td>Caregiver's noncompliance with patient’s other medical treatment and regimen for other reason</td>
</tr>
<tr>
<td>Z91.85</td>
<td>Personal history of military service</td>
</tr>
</tbody>
</table>

*Comment:* Commenters agreed with our proposal to add the diagnosis codes listed in the previous table to the Unacceptable Principal Diagnosis edit code list.
Response: We appreciate the commenters’ support. After consideration of the public comments we received, we are finalizing our proposal to add the diagnosis codes listed in the previous table to the Unacceptable Principal Diagnosis edit code list under the ICD–10 MCE Version 41, effective October 1, 2023.

In addition, as discussed in section II.C.13. of the preamble of the proposed rule and this final rule, Table 6C.—Invalid Diagnosis Codes, lists the diagnosis codes that are no longer effective October 1, 2023. Included in this table are the following ICD–10–CM diagnosis codes that are currently listed on the Unacceptable Principal Diagnosis edit code list. We propose to delete these codes from the Unacceptable Principal Diagnosis edit code list.

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z29.8</td>
<td>Encounter for other specified prophylactic measures</td>
</tr>
<tr>
<td>Z83.71</td>
<td>Family history of colonic polyps</td>
</tr>
<tr>
<td>Z91.A4</td>
<td>Caregiver’s other noncompliance with patient’s medication regimen</td>
</tr>
<tr>
<td>Z91.A5</td>
<td>Caregiver’s noncompliance with patient’s renal dialysis</td>
</tr>
<tr>
<td>Z91.A9</td>
<td>Caregiver’s noncompliance with patient’s other medical treatment and regimen</td>
</tr>
</tbody>
</table>

Comment: Commenters agreed with CMS’ proposal to remove the diagnosis codes listed in the previous table from the Unacceptable principal diagnosis edit code list since they are no longer valid.

Response: We appreciate the commenters’ support. After consideration of the public comments we received, we are finalizing our proposal to remove the diagnosis codes listed in the previous table from the Unacceptable Principal Diagnosis edit code list under the ICD–10 MCE Version 41, effective October 1, 2023.

f. Unspecified Code

In the FY 2022 IPPS/LTCH PPS final rule (86 FR 44940 through 44943), we finalized the implementation of a new Unspecified code edit, effective with discharges on and after April 1, 2022. Unspecified codes exist in the ICD–10–CM classification for circumstances when documentation in the medical record does not provide the level of detail needed to support reporting a more specific code. However, in the inpatient setting, there should generally be very limited and rare circumstances for which the laterality (right, left, bilateral) of a condition is unable to be documented and reported.

As discussed in section II.C.13. of the preamble of the proposed rule and this final rule, Table 6A.—New Diagnosis Codes, lists the new diagnosis codes that have been approved to date which will be effective with discharges on and after October 1, 2023. We propose to add the following new ICD–10–CM diagnosis codes to the Unspecified code edit list.
Comment: Commenters agreed with our proposal to add the diagnosis codes listed in the previous table to the Unspecified code edit code list.

Response: We thank the commenters for their support. We also note that we erroneously included the following diagnosis codes in our proposal that are not designated as a CC or MCC, and are therefore excluded from being subject to the Unspecified code edit. Specifically, Table 6A, associated with the proposed rule and this final rule lists the severity level designation for these six new diagnosis codes as NonCC.

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>M80.0B9A</td>
<td>Age-related osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture</td>
</tr>
<tr>
<td>M80.0B9D</td>
<td>Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with routine healing</td>
</tr>
<tr>
<td>M80.0B9G</td>
<td>Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with delayed healing</td>
</tr>
<tr>
<td>M80.0B9K</td>
<td>Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with nonunion</td>
</tr>
<tr>
<td>M80.0B9P</td>
<td>Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with malunion</td>
</tr>
<tr>
<td>M80.0B9S</td>
<td>Age-related osteoporosis with current pathological fracture, unspecified pelvis, sequela</td>
</tr>
<tr>
<td>M80.8B9A</td>
<td>Other osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture</td>
</tr>
<tr>
<td>M80.8B9D</td>
<td>Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with routine healing</td>
</tr>
<tr>
<td>M80.8B9G</td>
<td>Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with delayed healing</td>
</tr>
<tr>
<td>M80.8B9K</td>
<td>Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with nonunion</td>
</tr>
<tr>
<td>M80.8B9P</td>
<td>Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with malunion</td>
</tr>
<tr>
<td>M80.8B9S</td>
<td>Other osteoporosis with current pathological fracture, unspecified pelvis, sequela</td>
</tr>
</tbody>
</table>
After consideration of the public comments we received, we are finalizing our proposal to add the following diagnosis codes that are designated as CC to the Unspecified code edit code list under the ICD–10 MCE Version 41, effective October 1, 2023.

In addition, as stated in the proposed rule, we identified four diagnosis codes that were inadvertently omitted from the Unspecified code edit list effective with discharges on and after April 1, 2022. We therefore proposed to also add the following ICD–10–CM diagnosis codes to the Unspecified code edit list effective with discharges on and after October 1, 2023.

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>M80.0B9A</td>
<td>Age-related osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture</td>
</tr>
<tr>
<td>M80.0B9K</td>
<td>Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with nonunion</td>
</tr>
<tr>
<td>M80.0B9P</td>
<td>Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with malunion</td>
</tr>
<tr>
<td>M80.8B9A</td>
<td>Other osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture</td>
</tr>
<tr>
<td>M80.8B9K</td>
<td>Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with nonunion</td>
</tr>
<tr>
<td>M80.8B9P</td>
<td>Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with malunion</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>L89.103</td>
<td>Pressure ulcer of unspecified part of back, stage 3</td>
</tr>
<tr>
<td>L89.104</td>
<td>Pressure ulcer of unspecified part of back, stage 4</td>
</tr>
<tr>
<td>L89.93</td>
<td>Pressure ulcer of unspecified site, stage 3</td>
</tr>
<tr>
<td>L89.94</td>
<td>Pressure ulcer of unspecified site, stage 4</td>
</tr>
</tbody>
</table>

Comment: Commenters agreed with our proposal to add the diagnosis codes listed in the previous table to the Unspecified code edit code list. Response: We thank the commenters for their support. After consideration of the public comments we received, we are finalizing our proposal to add the previously listed diagnosis codes that are designated as MCC to the Unspecified code edit code list under the ICD–10 MCE Version 41, effective October 1, 2023.

g. Future Enhancement

As discussed previously in this section of this final rule, we have continued to evaluate the purpose and function of the MCE with respect to ICD–10, and encouraged public input for future discussion. As we have also discussed in prior rulemaking, we recognize a need to further examine the current list of edits and the definitions of those edits. We refer the reader to our discussion in the CY 2024 Outpatient Prospective Payment System and Ambulatory Surgical Center (OPPS/ASC) proposed rule (88 FR 49552, July 31, 2023), where we proposed to address any future revisions to the IPPS MCE, including any additions or deletions of claims edits, as well as the addition or deletion of ICD–10 diagnosis and procedure codes to the applicable MCE edit code lists, outside of the annual IPPS rulemakings.

We continue to encourage public comments on whether there are additional concerns with the current edits, including specific edits or language that should be removed or revised, edits that should be combined, or new edits that should be added to assist in detecting errors or inaccuracies in the coded data. Comments should be directed to the new electronic intake system, Medicare Electronic Application Request Information System (MEARIS™), discussed in section II.C.1.b. of the preamble of the proposed rule and this final rule, at: https://mearis.cms.gov/public/home by October 20, 2023.

15. Changes to Surgical Hierarchies

Some inpatient stays entail multiple surgical procedures, each one of which, occurring by itself, could result in assignment of the case to a different MS–DRG within the MDC to which the principal diagnosis is assigned. Therefore, it is necessary to have a decision rule within the GROUPER by which these cases are assigned to a single MS–DRG. The surgical hierarchy, an ordering of surgical classes from most resource-intensive to least resource-intensive, performs that function. Application of this hierarchy ensures that cases involving multiple surgical procedures are assigned to the MS–DRG associated with the most resource-intensive surgical class.
A surgical class can be composed of one or more MS–DRGs. For example, in MDC 11, the surgical class “knee transplant” consists of a single MS–DRG (MS–DRG 652) and the class “major bladder procedures” consists of three MS–DRGs (MS–DRGs 653, 654, and 655).

Consequently, in many cases, the surgical hierarchy has an impact on more than one MS–DRG. The methodology for determining the most resource-intensive surgical class involves weighting the average resource utilization for each MS–DRG by frequency to determine the weighted average resources for each surgical class. For example, assume surgical class A includes MS–DRGs 001 and 002 and surgical class B includes MS–DRGs 003, 004, and 005. Assume also that the average costs of MS–DRG 001 are higher than that of MS–DRG 003, but the average costs of MS–DRGs 004 and 005 are higher than the average costs of MS–DRG 002. To determine whether surgical class A should be higher or lower than surgical class B in the surgical hierarchy, we would weigh the average costs of each MS–DRG in the class by frequency (that is, by the number of cases in the MS–DRG) to determine average resource consumption for the surgical class. The surgical classes would then be ordered from the class with the highest average resource utilization to that with the lowest, with the exception of “other O.R. procedures” as discussed in this final rule.

This methodology may occasionally result in assignment of a case involving multiple procedures to the lower-weighted MS–DRG (in the highest, most resource-intensive surgical class) of the available alternatives. However, given that the logic underlying the surgical hierarchy provides that the GROUPER search for the procedure in the most resource-intensive surgical class, in cases involving multiple procedures, this result is sometimes unavoidable. We note that, notwithstanding the foregoing discussion, there are a few instances when a surgical class with a lower average cost is ordered above a surgical class with a higher average cost. For example, the “other O.R. procedures” surgical class is uniformly ordered last in the surgical hierarchy of each MDC in which it occurs, regardless of the fact that the average costs for the MS–DRG or MS–DRGs in that surgical class may be higher than those for other surgical classes in the MDC. The “other O.R. procedures” class is a group of procedures only infrequently related to the diagnoses in the MDC but are still occasionally performed on patients with cases assigned to the MDC with these diagnoses. Therefore, assignment to these surgical classes should only occur if no other surgical class more closely related to the diagnoses in the MDC is appropriate.

A second example occurs when the difference between the average costs for two surgical classes is very small. We have found that small differences generally do not warrant reordering of the hierarchy because, as a result of reassigning cases on the basis of the hierarchy change, the average costs are likely to shift such that the higher-ordered surgical class has lower average costs than the class ordered below it.

Based on the changes that we proposed to make for FY 2024, as discussed in section II.C. of the preamble of the proposed rule and this final rule, we proposed to modify the existing surgical hierarchy for FY 2024 as follows.

We proposed to revise the surgical hierarchy for the MDC 04 (Diseases and Disorders of the Respiratory System) MS–DRGs as follows: In the MDC 04 MS–DRGs, we proposed to sequence proposed new MS–DRG 173 (Ultrasound Accelerated and Other Thrombolysis with Principal Diagnosis Pulmonary Embolism) above MDC 04 MS–DRGs 166, 167, and 168 (Other Respiratory System O.R. Procedures with MCC, with CC, and without CC/ MCC, respectively) and below MS–DRGs 163, 164, and 165 (Major Chest Procedures with MCC, with CC, and without CC/MCC, respectively).

As discussed in section II.C.2.b. of the preamble of the proposed rule and this final rule, we proposed to revise the surgical hierarchy for the MDC 05 (Diseases and Disorders of the Circulatory System) MS–DRGs as follows: In the MDC 05 MS–DRGs, we proposed to sequence proposed new MS–DRG 212 (Concomitant Aortic and Mitral Valve Procedures) above MS–DRGs 216, 217, 218, 219, 220, and 221 (Cardiac Valve & Other Major Cardiothoracic Procedure with and without Cardiac Catheterization, with MCC, with CC, without CC/MCC, respectively) and below MS–DRG 215 (Other Heart Assist System Implant). As discussed in section II.C.4. of the preamble of the proposed rule and this final rule, we proposed to delete MS–DRGs 222, 223, 224, 225, 226, and 227 (Cardiac Defibrillator Implant with and without Cardiac Catheterization with and without AMI/HF/Shock with and without MCC, respectively).

We proposed to sequence proposed new MS–DRG 275 (Cardiac Defibrillator Implant with Cardiac Catheterization and MCC) above proposed new MS–DRG 276 (Cardiac Defibrillator Implant with MCC) and below MS–DRGs 231, 232, 233, 234, 235, and 236 (Coronary Bypass with or without PTCA, with or without Cardiac Catheterization or Open Ablation, with and without MCC, respectively). We proposed to sequence proposed new MS–DRG 276 (Cardiac Defibrillator Implant with MCC) above proposed new MS–DRG 277 (Cardiac Defibrillator Implant without MCC) and below proposed new MS–DRG 275 (Cardiac Defibrillator Implant with Cardiac Catheterization and MCC).

We proposed to sequence proposed new MS–DRG 277 (Cardiac Defibrillator Implant without MCC) above MS–DRGs 266 and 267 (Endovascular Cardiac Valve Replacement and Supplement Procedures with MCC and without MCC, respectively) and below proposed new MS–DRG 276 (Cardiac Defibrillator Implant with MCC).

As discussed in section II.C.4. of the preamble of the proposed rule and this final rule, we proposed to delete MDC 05 MS–DRGs 246 and 247 (Percutaneous Cardiovascular Procedures with Drug-Eluting Stent with MCC or 4+ Arteries or Stents and without MCC, respectively). We also proposed to delete MDC 05 MS–DRGs 248 and 249 (Percutaneous Cardiovascular Procedures with Non-Drug-Eluting Stent with MCC or 4+ Arteries or Stents and without MCC, respectively). We proposed to revise the titles for MS–DRGs 250 and 251 from “Percutaneous Cardiovascular Procedures without Coronary Artery Stent with MCC and without MCC, respectively” to “Percutaneous Cardiovascular Procedures without Intraluminal Device with MCC and without MCC, respectively.” Based on the changes we proposed to make for those MS–DRGs in MDC 05, we proposed to sequence proposed new MS–DRGs 323 and 324 (Coronary Intravascular Lithotripsy with Intraluminal Device with MCC and without MCC, respectively) above proposed new MS–DRG 325 (Coronary Intravascular Lithotripsy without Intraluminal Device) and below MS–DRGs 273 and 274 (Percutaneous and Other Intracardiac Procedures with MCC and without MCC, respectively).

We proposed to sequence proposed new MS–DRG 325 (Coronary Intravascular Lithotripsy without Intraluminal Device) above proposed new MS–DRGs 321 and 322 (Percutaneous Cardiovascular Procedures with Intraluminal Device, with MCC or 4+ Arteries/Intraluminal Devices and
without MCC, respectively) and below proposed new MS–DRGs 323 and 324 (Coronary Intravascular Lithotripsy with Intraluminal Device with MCC and without MCC, respectively). We proposed to sequence proposed new MS–DRGs 321 and 322 (Percutaneous Cardiovascular Procedures with Intraluminal Device with MCC or 4+ Arteries/Intraluminal Devices and without MCC, respectively), above MS–DRGs 250 and 251 (Percutaneous Cardiovascular Procedures without Intraluminal Device with MCC and without MCC, respectively) and below proposed new MS–DRG 325 (Coronary Intravascular Lithotripsy without Intraluminal Device).

In addition, based on the changes that we proposed to make as discussed in section II.C.8.a. of the preamble of the proposed rule and this final rule, we also proposed to sequence proposed new MDC 05 MS–DRGs 278 and 279 (Ultrasound Accelerated and Other Thrombolysis of Peripheral Vascular Structures with MCC and without MCC, respectively) above MDC 05 MS–DRGs 252, 253, and 254 (Other Vascular Procedures with MCC, with CC, and without CC/MCC, respectively) and below MS–DRGs 250 and 251 (Percutaneous Cardiovascular Procedures without Intraluminal Device with and without MCC, respectively).

As discussed in section II.C.4. of the preamble of the proposed rule and this final rule, we proposed to delete MS–DRGs 338, 339, and 340 (Appendectomy with Complicated Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively) and MS–DRGs 341, 342, and 343 (Appendectomy without Complicated Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively). Based on the changes we proposed to make for those MS–DRGs in MDC 06 (Diseases and Disorders of the Digestive System), we proposed to revise the surgical hierarchy for MDC 06 as follows: In MDC 06, we proposed to sequence proposed new MS–DRGs 397, 398, and 399 (Appendix Procedures with MCC, with CC, and without CC/MCC, respectively) above MDC 05 MS–DRGs 344, 345, and 346 (Minor Small and Large Bowel Procedures with MCC, with CC, and without CC/MCC, respectively) and below MS–DRGs 335, 336, and 337 (Peritoneal Adhesiolysis with MCC, with CC, and without CC/MCC, respectively).

Lastly, as discussed in section II.C.2.b. of the preamble of the proposed rule and this final rule, we proposed to revise the title for MDC 16 (Diseases and Disorders of Blood, Blood Forming Organs and Immunologic Disorders) MS–DRGs 799, 800, and 801 from “Splenectomy with MCC, with CC, and without CC/MCC, respectively” to “Splenectomy with MCC, with CC, and without CC/MCC, respectively.”

Our proposal for Appendix D MS–DRG Surgical Hierarchy by MDC and MS–DRG of the ICD–10 MS–DRG Definitions Manual Version 41 is illustrated in the following tables.
Commenters supported the proposed additions, deletions, and sequencing for the surgical hierarchy under MDCs 04, 05, 06, and 16. In response to the changes we proposed to make for MS-DRGs in MDC 05, a commenter stated this hierarchy is the most logical order given the clinical complexity associated with cases.
requiring coronary intravascular lithotripsy followed by the MS–DRGs for percutaneous cardiovascular procedures with or without intraluminal device.

We received a few public comments recommending that CMS consider an alternate option for the surgical hierarchy in MDC 05. Specifically, these commenters requested CMS consider switching—

- MS–DRGs 270, 271, and 272 and MS–DRG 319 and 320 in the surgical hierarchy so that MS–DRGs 270, 271, and 272 are sequenced before MS–DRGs 319 and 320;
- MS–DRG 245 with MS–DRGs 266 and 267 so that MS–DRG 245 is sequenced before MS–DRGs 266 and 267; and
- MS–DRGs 323, 324, and 325 to be sequenced after MS–DRGs 319 and 320 after these MS–DRGs are sequenced after MS–DRGs 270, 271, and 272 as shown in the following table.

<table>
<thead>
<tr>
<th>MS–DRGs 270-272</th>
<th>Other Major Cardiovascular Procedures</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS–DRGs 319-320</td>
<td>Other Endovascular Cardiac Valve Procedures</td>
</tr>
<tr>
<td>Proposed New MS–DRGs 323-324</td>
<td>Coronary Intravascular Lithotripsy with Intraluminal Device</td>
</tr>
<tr>
<td>Proposed New MS–DRG 325</td>
<td>Coronary Intravascular Lithotripsy without Intraluminal Device</td>
</tr>
</tbody>
</table>

A commenter displayed the proposed relative weights of MS–DRGs 245, MS–DRGs 266–267, MS–DRGs 270–272, MS–DRGs 319–320, proposed new MS–DRGs 323–324 and proposed new MS–DRG 325 from Table 5.—List of Medicare Severity Diagnosis-Related Groups (MS–DRGs), Relative Weighting Factors, and Geometric and Arithmetic Mean Length of Stay—FY 2024, associated with the proposed rule, in listing this alternative option. However, these commenters did not provide any rationale for their alternate recommendations.

Response: We appreciate the commenters’ support of our proposal. We also thank the commenters for their feedback. In response to the commenters that provided an alternate recommendation for the surgical hierarchy for MDC 05, we reviewed the suggestions from the commenters. In the absence of additional information to support the suggested modifications to our proposal, we continue to believe our proposed revisions to the surgical hierarchy account for the resources expended to address these complex procedures and do not believe any modifications are warranted at this time. We believe sequencing as discussed in the proposed rule more appropriately reflects resource utilization when the assigned cardiac procedures are performed and will result in the most suitable MS–DRG assignments. We will continue to review the surgical hierarchy, consistent with our annual rulemaking, to determine if other modifications are warranted in the future.

Therefore, after consideration of the public comments we received, and based on the changes that we are finalizing for FY 2024, as discussed in section II.C. of the preamble of the proposed rule and this final rule, we are finalizing our proposals to modify the existing surgical hierarchy, effective with the ICD–10 MS–DRGs Version 41, without modification.

For issues pertaining to the surgical hierarchy, as with other MS–DRG related requests, we encourage interested parties to submit comments no later than October 20, 2023 via the new electronic intake system, Medicare Electronic Application Request Information System™ (MEARIS™) at https://mearis.cms.gov/public/home so that they can be considered for possible inclusion in the annual proposed rule. We will consider these public comments for possible proposals in future rulemaking as part of our annual review process.


In September 1985, the ICD–9–CM Coordination and Maintenance Committee was formed. This is a Federal interdepartmental committee, co-chaired by the Centers for Disease Control and Prevention’s (CDC) National Center for Health Statistics (NCHS) and CMS, charged with maintaining and updating the ICD–9–CM system. The final update to ICD–9–CM codes was made on October 1, 2013. Thereafter, the name of the Committee was changed to the ICD–10 Coordination and Maintenance Committee, effective with the March 19–20, 2014, meeting. The ICD–10 Coordination and Maintenance Committee addresses updates to the ICD–10–CM and ICD–10–PCS coding systems. The Committee is jointly responsible for approving coding changes, and developing errata, addenda, and other modifications to the coding systems to reflect newly developed procedures and technologies and newly identified diseases. The Committee is also responsible for promoting the use of Federal and non-Federal educational programs and other communication techniques with a view toward standardizing coding applications and upgrading the quality of the classification system.

The official list of ICD–9–CM diagnosis and procedure codes by fiscal year can be found on the CMS website at: https://www.cms.gov/ICD9ProviderDiagnosisCodes/codes.html. The official list of ICD–10–CM and ICD–10–PCS codes can be found on the CMS website at: https://www.cms.gov/ICD10/index.html.

The NCHS has lead responsibility for the ICD–10–CM and ICD–9–CM diagnosis codes included in the Tabular List and Alphabetic Index for Diseases, while CMS has lead responsibility for the ICD–10–PCS and ICD–9–CM procedure codes included in the Tabular List and Alphabetic Index for Procedures.

The ICD–10 Coordination and Maintenance Committee holds its meetings in the spring and fall to update the codes and the applicable payment and reporting systems by October 1 or April 1 of each year. Items are placed on the agenda for the Committee meeting if the request is received at least 3 months prior to the meeting. This requirement allows time for staff to review and research the coding issues and prepare material for discussion at the meeting. It also allows time for the topic to be publicized in meeting announcements in the Federal Register as well as on the CMS website.

The Committee encourages participation in the previously mentioned process by health-related organizations and other interested parties. In this regard, the Committee holds public meetings for discussion of educational issues and proposed coding changes. These meetings provide an opportunity for representatives of recognized organizations in the coding field, such as the American Health Information Management Association (AHIMA), the American Hospital Association (AHA), and various
physician specialty groups, as well as
individual physicians, health
information management professionals,
and other members of the public, to
contribute ideas on coding matters.
After considering the opinions
expressed during the public meetings
and in writing, the Committee
formulates recommendations, which
then must be approved by the agencies.
A complete addendum describing
details of all diagnosis and procedure
coding changes, both tabular and index,
is published on the CMS and NCHS
websites in June of each year. Publishers
of coding books and software use this
information to modify their products
that are used by health care providers.
The Committee presented proposals
for coding changes for implementation
in FY 2024 at a public meeting held on
September 13–14, 2022, and finalized
the coding changes after consideration
of comments received at the meetings
and in writing by November 14, 2022.
The Committee held its 2023 meeting
on March 7–8, 2023. The deadline for
submitting comments on these code
proposals was April 7, 2023. It was
announced at this meeting that any new
diagnosis and procedure codes for
which there was consensus of public
support and for which complete tabular
and indexing changes would be made by
June 2023 would be included in the
October 1, 2023, update to the ICD–10–
CM diagnosis and ICD–10–PCS
procedure code sets.
As discussed in earlier sections of the
preamble of this final rule, there are
new, revised, and deleted ICD–10–CM
diagnosis codes and ICD–10–PCS
procedure codes that are captured in
Table 6A.—New Diagnosis Codes, Table
6B.—New Procedure Codes, Table 6C.—
Invalid Diagnosis Codes, Table 6D.—
Invalid Procedure Codes, Table 6E.—
Revised Diagnosis Code Titles and Table
6F.—Revised Procedure Code Titles for
this final rule, which are available on
the CMS website at: https://
www.cms.gov/medicare/medicare-fee-
for-service-payment/acuteinpatientpps.
The code titles are adopted as part of the
ICD–10 Coordination and Maintenance
Committee process. Therefore, although
we make the code titles available in
these tables for the IPPS proposed and
final rules, they are not subject to
comment in the proposed or final rule.
Because of the length of these tables,
they are not published in the
Addendum to the proposed or final rule.
Rather, they are available via the CMS
website as discussed in section VI. of
the Addendum to the proposed rule and
this final rule.
Recordings for the virtual meeting
discussions of the procedure codes at
the Committee’s September 13–14,
2022, meeting and the March 7–8, 2023,
meeting can be obtained from the CMS
website at: https://www.cms.gov/
Medicare/Coding/ICD10/C-and-M-
Meeting-Materials. The materials for the
discussions relating to diagnosis codes
at the September 13–14, 2022, meeting
and March 7–8, 2023, meeting can be
found at: http://www.cdc.gov/nchs/icd/
icd10cm_maintenance.html. These
websites also provide detailed
information about the Committee,
including information on requesting a
new code, participating in a Committee
meeting, timeline requirements and
meeting dates.
We encourage commenters to submit
questions and comments on coding
issues involving diagnosis codes via
Email to: nchsicd10cm@cdc.gov.
Questions and comments concerning
the procedure codes should be
submitted via Email to:
ICDProcedureCodeRequest@
cms.hhs.gov.
We stated in the proposed rule that in
an effort to better enable the collection
of health-related social needs (HRSNs),
defined as individual-level, adverse
social conditions that negatively impact
a person’s health or healthcare, are
significant risk factors associated with
worse health outcomes as well as
increased healthcare utilization, the
Centers for Disease Control and
Prevention’s (CDC) National Center for
Health Statistics (NCHS) implemented
42 new diagnosis codes into the ICD–
10–CM classification, for reporting
effective April 1, 2023. The diagnosis
codes are as follows:
We refer the reader to the CDC web page at https://www.cdc.gov/nchs/icd/Comprehensive-Listing-of-ICD-10-CM-Files.htm for additional details regarding the implementation of these new diagnosis codes.

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>T74.A1XA</td>
<td>Adult financial abuse, confirmed, initial encounter</td>
</tr>
<tr>
<td>T74.A1XD</td>
<td>Adult financial abuse, confirmed, subsequent encounter</td>
</tr>
<tr>
<td>T74.A1XS</td>
<td>Adult financial abuse, confirmed, sequela</td>
</tr>
<tr>
<td>T74.A2XA</td>
<td>Child financial abuse, confirmed, initial encounter</td>
</tr>
<tr>
<td>T74.A2XD</td>
<td>Child financial abuse, confirmed, subsequent encounter</td>
</tr>
<tr>
<td>T74.A2XS</td>
<td>Child financial abuse, confirmed, sequela</td>
</tr>
<tr>
<td>T76.A1XA</td>
<td>Adult financial abuse, suspected, initial encounter</td>
</tr>
<tr>
<td>T76.A1XD</td>
<td>Adult financial abuse, suspected, subsequent encounter</td>
</tr>
<tr>
<td>T76.A1XS</td>
<td>Adult financial abuse, suspected, sequela</td>
</tr>
<tr>
<td>T76.A2XA</td>
<td>Child financial abuse, suspected, initial encounter</td>
</tr>
<tr>
<td>T76.A2XD</td>
<td>Child financial abuse, suspected, subsequent encounter</td>
</tr>
<tr>
<td>T76.A2XS</td>
<td>Child financial abuse, suspected, sequela</td>
</tr>
<tr>
<td>Y07.010</td>
<td>Husband, current, perpetrator of maltreatment and neglect</td>
</tr>
<tr>
<td>Y07.011</td>
<td>Husband, former, perpetrator of maltreatment and neglect</td>
</tr>
<tr>
<td>Y07.020</td>
<td>Wife, current, perpetrator of maltreatment and neglect</td>
</tr>
<tr>
<td>Y07.021</td>
<td>Wife, former, perpetrator of maltreatment and neglect</td>
</tr>
<tr>
<td>Y07.030</td>
<td>Male partner, current, perpetrator of maltreatment and neglect</td>
</tr>
<tr>
<td>Y07.031</td>
<td>Male partner, former, perpetrator of maltreatment and neglect</td>
</tr>
<tr>
<td>Y07.040</td>
<td>Female partner, current, perpetrator of maltreatment and neglect</td>
</tr>
<tr>
<td>Y07.041</td>
<td>Female partner, former, perpetrator of maltreatment and neglect</td>
</tr>
<tr>
<td>Y07.050</td>
<td>Non-binary partner, current, perpetrator of maltreatment and neglect</td>
</tr>
<tr>
<td>Y07.051</td>
<td>Non-binary partner, former, perpetrator of maltreatment and neglect</td>
</tr>
<tr>
<td>Y07.44</td>
<td>Child, perpetrator of maltreatment and neglect</td>
</tr>
<tr>
<td>Y07.45</td>
<td>Grandchild, perpetrator of maltreatment and neglect</td>
</tr>
<tr>
<td>Y07.46</td>
<td>Grandparent, perpetrator of maltreatment and neglect</td>
</tr>
<tr>
<td>Y07.47</td>
<td>Parental sibling, perpetrator of maltreatment and neglect</td>
</tr>
<tr>
<td>Y07.54</td>
<td>Acquaintance or friend, perpetrator of maltreatment and neglect</td>
</tr>
<tr>
<td>Z55.6</td>
<td>Problems related to health literacy</td>
</tr>
<tr>
<td>Z58.81</td>
<td>Basic services unavailable in physical environment</td>
</tr>
<tr>
<td>Z58.89</td>
<td>Other problems related to physical environment</td>
</tr>
<tr>
<td>Z59.10</td>
<td>Inadequate housing, unspecified</td>
</tr>
<tr>
<td>Z59.11</td>
<td>Inadequate housing environmental temperature</td>
</tr>
<tr>
<td>Z59.12</td>
<td>Inadequate housing utilities</td>
</tr>
<tr>
<td>Z59.19</td>
<td>Other inadequate housing</td>
</tr>
<tr>
<td>Z62.814</td>
<td>Personal history of child financial abuse</td>
</tr>
<tr>
<td>Z62.815</td>
<td>Personal history of intimate partner abuse in childhood</td>
</tr>
<tr>
<td>Z91.141</td>
<td>Patient's other noncompliance with medication regimen due to financial hardship</td>
</tr>
<tr>
<td>Z91.148</td>
<td>Patient's other noncompliance with medication regimen for other reason</td>
</tr>
<tr>
<td>Z91.151</td>
<td>Patient's noncompliance with renal dialysis due to financial hardship</td>
</tr>
<tr>
<td>Z91.158</td>
<td>Patient's noncompliance with renal dialysis for other reason</td>
</tr>
<tr>
<td>Z91.413</td>
<td>Personal history of adult financial abuse</td>
</tr>
<tr>
<td>Z91.414</td>
<td>Personal history of adult intimate partner abuse</td>
</tr>
</tbody>
</table>

As discussed in the proposed rule, we provided the MS-DRG assignments for the 42 diagnosis codes effective with...
discharges on and after April 1, 2023, consistent with our established process for assigning new diagnosis codes. Specifically, we review the predecessor diagnosis code and MS–DRG assignment most closely associated with the new diagnosis code and consider other factors that may be relevant to the MS–DRG assignment, including the severity of illness, treatment difficulty, and the resources utilized for the specific condition/diagnosis. We note that this process does not automatically result in the new diagnosis code being assigned to the same MS–DRG as the predecessor code. The assignments for the previously listed diagnosis codes are reflected in Table 6A—New Diagnosis Codes associated with the proposed rule and available on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS. As with the other new diagnosis codes and MS–DRG assignments included in Table 6A in association with the proposed rule, we solicited public comments on the most appropriate MDC, MS–DRG, and severity level assignments for these codes for FY 2024, as well as any other options for the GROUPER logic.

We did not receive any comments opposing the MDC, MS–DRG, and severity level assignments for the listed codes and are therefore, finalizing, without modification, the assignments as reflected in Table 6A—New Diagnosis Codes in association with this final rule.

In addition, we noted in the proposed rule that CMS implemented 34 new procedure codes including laser interstitial thermal therapy (LITT) of various vertebral body sites, bone marrow transfusions, and the introduction or infusion of therapeutics, into the ICD–10–PCS classification effective with discharges on and after April 1, 2023. The procedure codes are as follows:
<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Description</th>
<th>O.R.</th>
<th>MDC</th>
<th>MS-DRG</th>
</tr>
</thead>
<tbody>
<tr>
<td>02LW0DJ</td>
<td>Occlusion of thoracic aorta, descending with intraluminal device, temporary, open approach</td>
<td>Y</td>
<td>05</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>04L00DJ</td>
<td>Occlusion of abdominal aorta with intraluminal device, temporary, open approach</td>
<td>Y</td>
<td>05</td>
<td>06</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0P530Z3</td>
<td>Destruction of cervical vertebra using laser interstitial thermal therapy, open approach</td>
<td>Y</td>
<td>03</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0P533Z3</td>
<td>Destruction of cervical vertebra using laser interstitial thermal therapy, percutaneous approach</td>
<td>Y</td>
<td>03</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0P534Z3</td>
<td>Destruction of cervical vertebra using laser interstitial thermal therapy, percutaneous endoscopic approach</td>
<td>Y</td>
<td>03</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0P540Z3</td>
<td>Destruction of thoracic vertebra using laser interstitial thermal therapy, open approach</td>
<td>Y</td>
<td>08</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0P543Z3</td>
<td>Destruction of thoracic vertebra using laser interstitial thermal therapy, percutaneous approach</td>
<td>Y</td>
<td>08</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0P544Z3</td>
<td>Destruction of thoracic vertebra using laser interstitial thermal therapy, percutaneous endoscopic approach</td>
<td>Y</td>
<td>08</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0Q500Z3</td>
<td>Destruction of lumbar vertebra using laser interstitial thermal therapy, open approach</td>
<td>Y</td>
<td>08</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0Q503Z3</td>
<td>Destruction of lumbar vertebra using laser interstitial thermal therapy, percutaneous approach</td>
<td>Y</td>
<td>08</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0Q504Z3</td>
<td>Destruction of lumbar vertebra using laser interstitial thermal therapy, percutaneous endoscopic approach</td>
<td>Y</td>
<td>08</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0Q510Z3</td>
<td>Destruction of sacrum using laser interstitial thermal therapy, open approach</td>
<td>Y</td>
<td>08</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0Q513Z3</td>
<td>Destruction of sacrum using laser interstitial thermal therapy, percutaneous approach</td>
<td>Y</td>
<td>08</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0Q514Z3</td>
<td>Destruction of sacrum using laser interstitial thermal therapy, percutaneous endoscopic approach</td>
<td>Y</td>
<td>08</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>302A3H0*</td>
<td>Transfusion of autologous whole blood into bone marrow, percutaneous approach</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>302A3H1*</td>
<td>Transfusion of nonautologous whole blood into bone marrow, percutaneous approach</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>302A3J0*</td>
<td>Transfusion of autologous serum albumin into bone marrow, percutaneous approach</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procedure Code</td>
<td>Description</td>
<td>O.R.</td>
<td>MDC</td>
<td>MS-DRG</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>------</td>
<td>-----</td>
<td>--------</td>
</tr>
<tr>
<td>302A3J1*</td>
<td>Transfusion of nonautologous serum albumin into bone marrow, percutaneous approach</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>302A3K0*</td>
<td>Transfusion of autologous frozen plasma into bone marrow, percutaneous approach</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>302A3K1*</td>
<td>Transfusion of nonautologous frozen plasma into bone marrow, percutaneous approach</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>302A3L0*</td>
<td>Transfusion of autologous fresh plasma into bone marrow, percutaneous approach</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>302A3L1*</td>
<td>Transfusion of nonautologous fresh plasma into bone marrow, percutaneous approach</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>302A3N0*</td>
<td>Transfusion of autologous red blood cells into bone marrow, percutaneous approach</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>302A3N1*</td>
<td>Transfusion of nonautologous red blood cells into bone marrow, percutaneous approach</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>302A3P0*</td>
<td>Transfusion of autologous frozen red blood cells into bone marrow, percutaneous approach</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>302A3P1*</td>
<td>Transfusion of nonautologous frozen red blood cells into bone marrow, percutaneous approach</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>302A3R0*</td>
<td>Transfusion of autologous platelets into bone marrow, percutaneous approach</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>302A3R1*</td>
<td>Transfusion of nonautologous platelets into bone marrow, percutaneous approach</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XW013G6*</td>
<td>Introduction of regn-cov2 monoclonal antibody into subcutaneous tissue, percutaneous approach, new technology group 6</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XW0DXK8*</td>
<td>Introduction of sabizabulin into mouth and pharynx, external approach, new technology group 8</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XW0G7K8*</td>
<td>Introduction of sabizabulin into upper GI, via natural or artificial opening, new technology group 8</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XW0H7K8*</td>
<td>Introduction of sabizabulin into lower GI, via natural or artificial opening, new technology group 8</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XW133J8</td>
<td>Transfusion of exagmogene autotemcel into peripheral vein, percutaneous approach, new technology group 8</td>
<td>N**</td>
<td>Pre-MDC</td>
<td>016-017</td>
</tr>
<tr>
<td>XW143J8</td>
<td>Transfusion of exagmogene autotemcel into central vein, percutaneous approach, new technology group 8</td>
<td>N**</td>
<td>Pre-MDC</td>
<td>016-017</td>
</tr>
</tbody>
</table>

* As the procedure codes are designated as non-O.R. procedures, there is no assigned MDC or MS-DRG. The ICD-10 MS-DRG assignment is dependent on the reported principal diagnosis, any secondary diagnoses defined as a complication or comorbidity (CC) or major complication or comorbidity (MCC), procedures or services performed, age, sex, and discharge status.

** NonOR affecting MS-DRG assignment.
AcuteInpatientPPS. As with the other new procedure codes and MS–DRG assignments included in Table 6B in association with the proposed rule, we solicited public comments on the most appropriate MDC, MS–DRG, and operating room status assignments for these codes for FY 2024, as well as any other options for the GROUPER logic. We did not receive any comments opposing the MDC, MS–DRG, and operating room status assignments for the listed codes and are therefore, finalizing, without modification, the assignments as reflected in Table 6B.—New Procedure Codes in association with this final rule.

In the proposed rule, we also noted that Change Request (CR) 13034, Transmittal 11746, titled “April 2023 Update to the Medicare Severity—Diagnosis Related Group (MS–DRG) Grouper and Medicare Code Editor (MCE) Version 40.1 for the International Classification of Diseases, Tenth Revision (ICD–10) Diagnosis Codes for Collection of Health-Related Social Needs (HRSNs) and New ICD–10 Procedure Coding System (PCS) Codes”, was issued on December 15, 2022 (available on the CMS website at: https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Transmittals/r11746cp), regarding the release of an updated version of the ICD–10 MS–DRG GROUPEr and Medicare Code Editor software, Version 40.1, effective with discharges on and after April 1, 2023, reflecting the new diagnosis and procedure codes. The updated GROUPEr and Medicare Code Editor software, Version 40.1, effective with discharges on and after April 1, 2023, reflecting the new diagnosis and procedure codes.

In the FY 2005 IPPS final rule, we implemented section 1886(d)(5)(K)(vii) of the Act, as added by section 503(a) of Public Law 108–173, by developing a mechanism for approving, in time for the April update, diagnosis and procedure code revisions needed to describe new technologies and medical services for purposes of the new technology add-on payment process. We also established the following process for making these determinations. Topics considered during the Fall ICD–10 (previously ICD–9–CM) Coordination and Maintenance Committee meeting were considered for an April 1 update if a strong and convincing case was made by the requestor during the Committee’s public meeting. The request needed to identify the reason why a new code was needed in April for purposes of the new technology process. Meeting participants and those reviewing the Committee meeting materials were provided the opportunity to comment on the expedited code request. We refer the reader to the FY 2022 IPPS/ LTCH PPS final rule (86 FR 44950) for further discussion of the implementation of this prior April 1 update for purposes of the new technology add-on payment process.

As discussed in the FY 2022 IPPS/LTCH PPS final rule, consistent with the process we outlined for the April 1 implementation date, we announced the new codes in November 2022 and provided the updated code files and ICD–10–CM Official Guidelines for Coding and Reporting in January 2023. On January 30, 2023, the Federal Register (88 FR 5882) notice for the March 7–8, 2023 ICD–10 Coordination and Maintenance Committee Meeting was published that includes the tentative agenda and identifies which topics are related to a new technology add-on payment application. By February 1, 2023, we made available the updated V40.1 ICD–10–MS–DRG GROUPEr software and related materials on the CMS web page at: https://www.cms.gov/Medicare/Medicare-fee-For-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software.

containing all ICD–10–CM and ICD–10–PCS coding changes to its Medicare contractors for use in updating their systems and providing education to providers. Information on ICD–10–CM diagnosis codes, along with the Official ICD–10–CM Coding Guidelines, can be found on the CDC website at https://www.cdc.gov/nchs/icd/Comprehensive-Listing-of-ICD-10-CM-Files.htm. Additionally, information on new, revised, and deleted ICD–10–CM diagnosis and ICD–10–PCS procedure codes is provided to the AHA for publication in the Coding Clinic for ICD–10. The AHA also distributes coding update information to publishers and software vendors.

In the proposed rule, we noted that for FY 2023, there are currently 73,674 diagnosis codes and 78,530 procedure codes. We also noted that as displayed in Table 6A.—New Diagnosis Codes and in Table 6B.—New Procedure Codes associated with the proposed rule (and available on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS), there are 395 new diagnosis codes and 10 new procedure codes that had been finalized for FY 2024 at the time of the development of the proposed rule. As discussed in section II.C.13 of the preamble of this final rule, we are making Table 6A.—New Diagnosis Codes, Table 6B.—New Procedure Codes, Table 6C.—Invalid Diagnosis Codes, Table 6D.—Invalid Procedure Codes, Table 6E.—Revised Diagnosis Code Titles and Table 6F.—Revised Procedure Code Titles available on the CMS website at: https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps in association with this final rule. As shown in Table 6B.—New Procedure Codes, there were procedure codes discussed at the March 7–8, 2023 ICD–10 Coordination and Maintenance Committee meeting that were not finalized in time to include in the proposed rule and are identified with an asterisk. We refer the reader to Table 6B.—New Procedure Codes associated with this final rule and available on the CMS website at: https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps for the detailed list of these additional 68 new procedure codes. The addition of these 68 new procedure codes to the 10 procedure codes that had been finalized at the time of the development of the proposed rule results in a total of 78 (10 + 68 = 78) new procedure codes for FY 2024.

We also note, as reflected in Table 6C.—Invalid Diagnosis Codes and in Table 6D.—Invalid Procedure Codes, there are a total of 25 diagnosis codes and 5 procedure codes that will become invalid effective October 1, 2023. Based on these code updates, effective October 1, 2023, there are a total of 74,044 ICD–10–CM diagnosis codes and 78,603 ICD–10–PCS procedure codes for FY 2024 as shown in the following table.

<table>
<thead>
<tr>
<th>FY 2023 ICD-10-CM</th>
<th>73,674 total codes</th>
<th>FY 2023 ICD-10-PCS</th>
<th>78,530 total codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2024 ICD-10-CM</td>
<td>395 additions</td>
<td>FY 2024 ICD-10-PCS</td>
<td>78 additions</td>
</tr>
<tr>
<td>FY 2024 ICD-10-CM</td>
<td>25 deletions</td>
<td>FY 2024 ICD-10-PCS</td>
<td>5 deletions</td>
</tr>
<tr>
<td>FY 2024 ICD-10-CM</td>
<td>74,044 total codes</td>
<td>FY 2024 ICD-10-PCS</td>
<td>78,603 total codes</td>
</tr>
</tbody>
</table>

As stated previously, the public is provided the opportunity to comment on any requests for new diagnosis or procedure codes discussed at the ICD–10 Coordination and Maintenance Committee meeting. The code titles are adopted as part of the ICD–10 Coordination and Maintenance Committee process. Thus, although we publish the code titles in the IPPS proposed and final rules, they are not subject to comment in the proposed or final rules.

17. Replaced Devices Offered Without Cost or With a Credit
   a. Background

In the FY 2008 IPPS final rule with comment period (72 FR 47246 through 47251), we discussed the topic of Medicare payment for devices that are replaced without cost or where credit for a replaced device is furnished to the hospital. We implemented a policy to reduce a hospital’s IPPS payment for certain MS–DRGs where the implantation of a device that subsequently failed or was recalled determined the base MS–DRG assignment. At that time, we specified that we will reduce a hospital’s IPPS payment for those MS–DRGs where the hospital received a credit for a replaced device equal to 50 percent or more of the cost of the device.

In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51556 through 51557), we clarified this policy to state that the policy applies if the hospital received a credit equal to 50 percent or more of the cost of the replacement device and issued instructions to hospitals accordingly.

b. Changes for FY 2024

As discussed in section II.C.5. of the preamble of the proposed rule and this final rule, for FY 2024, we proposed to delete MS–DRGs 222, 223, 224, 225, 226, and 227, add new MS–DRG 275 (Cardiac Defibrillator Implant with Cardiac Catheterization and MCC) and new MS–DRGs 276 and 277 (Cardiac Defibrillator Implant with MCC, and without MCC, respectively), and to reassign a subset of the procedures currently assigned to MS–DRGs 222 through 227 to proposed new MS–DRGs 275, 276, and 277. Therefore, we proposed that if the applicable proposed MS–DRG changes are finalized, we also would add proposed new MS–DRGs 275, 276, and 277 to the list of MS–DRGs subject to the policy. We also proposed to continue to include the existing MS–DRGs currently subject to the policy.

As discussed in section II.C.5. of the preamble of this final rule, we are finalizing our proposal to delete MS–DRGs 222, 223, 224, 225, 226, and 227. Additionally, we are finalizing our proposal to create new MS–DRG 275 (Cardiac Defibrillator Implant with Cardiac Catheterization and MCC) and new MS–DRGs 276 and 277 (Cardiac Defibrillator Implant with MCC, and without MCC, respectively), and to reassign a subset of the procedures currently assigned to MS–DRGs 222
through 227 to proposed new MS–DRGs 275, 276, and 277. We did not receive any public comments opposing our proposal to delete MS–DRGs 222, 223, 224, 225, 226, and 227 from the list of MS–DRGs that will be subject to the replaced devices offered without cost or with a credit policy effective October 1, 2023. Additionally, we did not receive any public comments opposing our proposal to add MS–DRGs 275, 276, and 277 to the list of MS–DRGs that will be subject to the policy for replaced devices offered without cost or with credit or to continue to include the existing MS–DRGs currently subject to the policy. Therefore, we are finalizing the list of MS–DRGs in the following table that will be subject to the replaced devices offered without cost or with a credit policy effective October 1, 2023.

<table>
<thead>
<tr>
<th>MDC</th>
<th>MS-DRG</th>
<th>MS-DRG Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-MDC</td>
<td>001</td>
<td>Heart Transplant or Implant of Heart Assist System with MCC</td>
</tr>
<tr>
<td>Pre-MDC</td>
<td>002</td>
<td>Heart Transplant or Implant of Heart Assist System without MCC</td>
</tr>
<tr>
<td>01</td>
<td>023</td>
<td>Craniotomy with Major Device Implant or Acute Complex CNS Principal Diagnosis with MCC or Chemotherapy Implant or Epilepsy with Neurostimulator</td>
</tr>
<tr>
<td>01</td>
<td>024</td>
<td>Craniotomy with Major Device Implant or Acute Complex CNS Principal Diagnosis without MCC</td>
</tr>
<tr>
<td>01</td>
<td>025</td>
<td>Craniotomy and Endovascular Intracranial Procedures with MCC</td>
</tr>
<tr>
<td>01</td>
<td>026</td>
<td>Craniotomy and Endovascular Intracranial Procedures with CC</td>
</tr>
<tr>
<td>01</td>
<td>027</td>
<td>Craniotomy and Endovascular Intracranial Procedures without CC/MCC</td>
</tr>
<tr>
<td>01</td>
<td>040</td>
<td>Peripheral, Cranial Nerve and Other Nervous System Procedures with MCC</td>
</tr>
<tr>
<td>01</td>
<td>041</td>
<td>Peripheral, Cranial Nerve and Other Nervous System Procedures with CC or Peripheral Neurostimulator</td>
</tr>
<tr>
<td>01</td>
<td>042</td>
<td>Peripheral, Cranial Nerve and Other Nervous System Procedures without CC/MCC</td>
</tr>
<tr>
<td>03</td>
<td>140</td>
<td>Major Head and Neck Procedures with MCC</td>
</tr>
<tr>
<td>03</td>
<td>141</td>
<td>Major Head and Neck Procedures with CC</td>
</tr>
<tr>
<td>03</td>
<td>142</td>
<td>Major Head and Neck Procedures without CC/MCC</td>
</tr>
<tr>
<td>05</td>
<td>215</td>
<td>Other Heart Assist System Implant</td>
</tr>
</tbody>
</table>
The final list of MS–DRGs subject to the IPPS policy for replaced devices offered without cost or with a credit will be issued to providers in the form of a Change Request (CR).

We received public comments on MS–DRG related issues that were outside the scope of the proposals included in the FY 2024 IPPS/LTCH PPS proposed rule. Because we consider these public comments to be outside the scope of the proposed rule, we are not addressing them in this final rule. As stated in

<table>
<thead>
<tr>
<th>MDC</th>
<th>MS-DRG</th>
<th>MS-DRG Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>05</td>
<td>216</td>
<td>Cardiac Valve and Other Major Cardiothoracic Procedure with Cardiac Catheterization with MCC</td>
</tr>
<tr>
<td>05</td>
<td>217</td>
<td>Cardiac Valve and Other Major Cardiothoracic Procedure with Cardiac Catheterization with CC</td>
</tr>
<tr>
<td>05</td>
<td>218</td>
<td>Cardiac Valve and Other Major Cardiothoracic Procedure with Cardiac Catheterization without CC/MCC</td>
</tr>
<tr>
<td>05</td>
<td>219</td>
<td>Cardiac Valve and Other Major Cardiothoracic Procedure without Cardiac Catheterization with MCC</td>
</tr>
<tr>
<td>05</td>
<td>220</td>
<td>Cardiac Valve and Other Major Cardiothoracic Procedure without Cardiac Catheterization with CC</td>
</tr>
<tr>
<td>05</td>
<td>221</td>
<td>Cardiac Valve and Other Major Cardiothoracic Procedure without Cardiac Catheterization without CC/MCC</td>
</tr>
<tr>
<td>05</td>
<td>242</td>
<td>Permanent Cardiac Pacemaker Implant with MCC</td>
</tr>
<tr>
<td>05</td>
<td>243</td>
<td>Permanent Cardiac Pacemaker Implant with CC</td>
</tr>
<tr>
<td>05</td>
<td>244</td>
<td>Permanent Cardiac Pacemaker Implant without CC/MCC</td>
</tr>
<tr>
<td>05</td>
<td>245</td>
<td>AICD Generator Procedures</td>
</tr>
<tr>
<td>05</td>
<td>258</td>
<td>Cardiac Pacemaker Device Replacement with MCC</td>
</tr>
<tr>
<td>05</td>
<td>259</td>
<td>Cardiac Pacemaker Device Replacement without MCC</td>
</tr>
<tr>
<td>05</td>
<td>260</td>
<td>Cardiac Pacemaker Revision Except Device Replacement with MCC</td>
</tr>
<tr>
<td>05</td>
<td>261</td>
<td>Cardiac Pacemaker Revision Except Device Replacement with CC</td>
</tr>
<tr>
<td>05</td>
<td>262</td>
<td>Cardiac Pacemaker Revision Except Device Replacement without CC/MCC</td>
</tr>
<tr>
<td>05</td>
<td>265</td>
<td>AICD Lead Procedures</td>
</tr>
<tr>
<td>05</td>
<td>266</td>
<td>Endovascular Cardiac Valve Replacement and Supplement Procedures with MCC</td>
</tr>
<tr>
<td>05</td>
<td>267</td>
<td>Endovascular Cardiac Valve Replacement and Supplement Procedures without MCC</td>
</tr>
<tr>
<td>05</td>
<td>268</td>
<td>Aortic and Heart Assist Procedures Except Pulsation Balloon with MCC</td>
</tr>
<tr>
<td>05</td>
<td>269</td>
<td>Aortic and Heart Assist Procedures Except Pulsation Balloon without MCC</td>
</tr>
<tr>
<td>05</td>
<td>270</td>
<td>Other Major Cardiovascular Procedures with MCC</td>
</tr>
<tr>
<td>05</td>
<td>271</td>
<td>Other Major Cardiovascular Procedures with CC</td>
</tr>
<tr>
<td>05</td>
<td>272</td>
<td>Other Major Cardiovascular Procedures without CC/MCC</td>
</tr>
<tr>
<td>05</td>
<td>275</td>
<td>Cardiac Defibrillator Implant with Cardiac Catheterization and MCC</td>
</tr>
<tr>
<td>05</td>
<td>276</td>
<td>Cardiac Defibrillator Implant with MCC</td>
</tr>
<tr>
<td>05</td>
<td>277</td>
<td>Cardiac Defibrillator Implant without MCC</td>
</tr>
<tr>
<td>05</td>
<td>319</td>
<td>Other Endovascular Cardiac Valve Procedures with MCC</td>
</tr>
<tr>
<td>05</td>
<td>320</td>
<td>Other Endovascular Cardiac Valve Procedures without MCC</td>
</tr>
<tr>
<td>08</td>
<td>461</td>
<td>Bilateral or Multiple Major Joint Procedures of Lower Extremity with MCC</td>
</tr>
<tr>
<td>08</td>
<td>462</td>
<td>Bilateral or Multiple Major Joint Procedures of Lower Extremity without MCC</td>
</tr>
<tr>
<td>08</td>
<td>466</td>
<td>Revision of Hip or Knee Replacement with MCC</td>
</tr>
<tr>
<td>08</td>
<td>467</td>
<td>Revision of Hip or Knee Replacement with CC</td>
</tr>
<tr>
<td>08</td>
<td>468</td>
<td>Revision of Hip or Knee Replacement without CC/MCC</td>
</tr>
<tr>
<td>08</td>
<td>469</td>
<td>Major Hip and Knee Joint Replacement or Reattachment of Lower Extremity with MCC or Total Ankle Replacement</td>
</tr>
<tr>
<td>08</td>
<td>470</td>
<td>Major Hip and Knee Joint Replacement or Reattachment of Lower Extremity without MCC</td>
</tr>
<tr>
<td>08</td>
<td>521</td>
<td>Hip Replacement with Principal Diagnosis of Hip Fracture with MCC</td>
</tr>
<tr>
<td>08</td>
<td>522</td>
<td>Hip Replacement with Principal Diagnosis of Hip Fracture without MCC</td>
</tr>
</tbody>
</table>
section II.D.1.b. of the preamble of this final rule, we encourage individuals with comments about MS–DRG classifications to submit these comments no later than October 20, 2023, via the new electronic intake system, Medicare Electronic Application Request Information System™ (MEARISTM) at: https://mearis.cms.gov/public/home, so that they can be considered for possible inclusion in the annual proposed rule. We will consider these public comments for possible proposals in future rulemaking as part of our annual review process.

D. Recalibration of the FY 2024 MS–DRG Relative Weights

1. Data Sources for Developing the Relative Weights

   Consistent with our established policy, in developing the MS–DRG relative weights for FY 2024, we proposed to use two data sources: claims data and cost report data. The claims data source is the MedPAR file, which includes fully coded diagnostic and procedure data for all Medicare inpatient hospital bills. The FY 2022 MedPAR data used in this final rule include discharges occurring on October 1, 2021, through September 30, 2022, based on bills received by CMS through March 31, 2023, from all hospitals subject to the IPPS and short-term, acute care hospitals in Maryland (which at that time were under a waiver from the IPPS).

   The FY 2022 MedPAR file used in calculating the relative weights includes data for approximately 6,991,373 Medicare discharges from IPPS providers. Discharges for Medicare beneficiaries enrolled in a Medicare Advantage managed care plan are excluded from this analysis. These discharges are excluded when the MedPAR “GHO Paid” indicator field on the claim record is equal to “1” or when the MedPAR DRG payment field, which represents the total payment for the claim, is equal to the MedPAR “Indirect Medical Education (IME)” payment field, indicating that the claim was an “IME only” claim submitted by a teaching hospital on behalf of a beneficiary enrolled in a Medicare Advantage managed care plan. In addition, the December 2022 update of the FY 2022 MedPAR file complies with version 5010 of the X12 HIPAA Transaction and Code Set Standards, and includes a variable called “claim type.” Claim type “60” indicates that the claim was an inpatient claim paid as fee-for-service. Claim types “61,” “62,” “63,” and “64” relate to encounter claims, Medicare Advantage IME claims, and HMO no-pay claims. Therefore, the calculation of the relative weights for FY 2024 also excludes claims with claim type values not equal to “60.” The data exclude CAHs, including hospitals that subsequently became CAHs after the period from which the data were taken. We note that the FY 2024 relative weights are based on the ICD–10–CM diagnosis codes and ICD–10–PCS procedure codes from the FY 2022 MedPAR claims data, grouped through the ICD–10 version of the FY 2024 Grouper (Version 41).

   The second data source used in the cost-based relative weighting methodology is the Medicare cost report data files from the HCRIS. In general, we use the HCRIS dataset that is 3 years prior to the IPPS fiscal year. Specifically, for this final rule, we used the March 2023 update of the FY 2021 HCRIS for calculating the FY 2024 cost-based relative weights. Consistent with our historical practice, for this FY 2024 final rule, we are providing the version of the HCRIS from which we calculated these 19 CCRs on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS. Click on the link on the left side of the screen titled “FY 2024 IPPS Proposed Rule Home Page” or “Acute Inpatient Files for Download.”

2. Methodology for Calculation of the Relative Weights

a. General

   We calculated the FY 2024 relative weights based on 19 CCRs. The methodology we proposed to use to calculate the FY 2024 MS–DRG cost-based relative weights was based on claims data in the FY 2022 MedPAR file and data from the FY 2021 Medicare cost reports is as follows:

   • To the extent possible, all the claims were regrouped using the FY 2024 MS–DRG classifications discussed in sections II.B. and II.C. of the preamble of this final rule.

   • The transplant cases that were used to establish the relative weights for heart and heart-lung, liver and/or intestinal, and lung transplants were limited to those Medicare-approved transplant centers that have cases in the FY 2022 MedPAR file. (Medicare coverage for heart, heart-lung, liver and/or intestinal, and lung transplants is limited to those facilities that have received approval from CMS as transplant centers.)

   • Organ acquisition costs for kidney, heart, heart-lung, liver, lung, pancreas, and intestinal (or multivisceral organs) transplants continue to be paid on a reasonable cost basis.

   Because these acquisition costs are paid separately from the prospective payment rate, it is necessary to subtract the acquisition charges from the total charges on each transplant bill that showed acquisition charges before computing the average cost for each MS–DRG and before eliminating statistical outliers.

   Section 108 of the Further Consolidated Appropriations Act, 2020 provides that, for cost reporting periods beginning on or after October 1, 2020, related to hematopoietic stem cell acquisition for the purpose of an allogeneic hematopoietic stem cell transplant shall be paid on a reasonable cost basis. We refer the reader to the FY 2021 IPPS/LTC PPS final rule for further discussion of the reasonable cost basis payment for cost reporting periods beginning on or after October 1, 2020 (85 FR 58935 through 58942). For FY 2022 and subsequent years, we subtract the hematopoietic stem cell acquisition charges from the total charges on each transplant bill that showed hematopoietic stem cell acquisition charges before computing the average cost for each MS–DRG and before eliminating statistical outliers.

   • Claims with total charges or total lengths of stay less than or equal to zero were deleted. Claims that had an amount in the total charge field that differed by more than $30.00 from the sum of the routine day charges, intensive care charges, pharmacy charges, implantable devices charges, supplies and equipment charges, therapy services charges, operating room charges, cardiology charges, laboratory charges, radiology charges, other service charges, labor and delivery charges, inhalation therapy charges, emergency room charges, blood and blood products charges, anesthesia charges, cardiac catheterization charges, computed tomography (CT) scan charges, and magnetic resonance imaging (MRI) charges were also deleted.

   • At least 92.6 percent of the providers in the MedPAR file had charges for 14 of the 19 cost centers. All claims of providers that did not have charges greater than zero for at least 14 of the 19 cost centers were deleted. In other words, a provider must have no more than five blank cost centers. If a provider did not have charges greater than zero in more than five cost centers, the claims for the provider were deleted.

   • Statistical outliers were eliminated by removing all cases that were beyond 3.0 standard deviations from the
geometric mean of the log distribution of both the total charges per case and the total charges per day for each MS–DRG.

- Effective October 1, 2008, because hospital inpatient claims include a POA indicator field for each diagnosis present on the claim, only for purposes of relative weight-setting, the POA indicator field was reset to “Y” for “Yes” for all claims that otherwise have an “N” (No) or a “U” (documentation insufficient to determine if the condition was present at the time of inpatient admission) in the POA field. Under current payment policy, the presence of specific HAC codes, as indicated by the POA field values, can generate a lower payment for the claim. Specifically, if the particular condition is present on admission (that is, a “Y” indicator is associated with the diagnosis on the claim), it is not a HAC, and the hospital is paid for the higher severity (and, therefore, the higher weighted MS–DRG). If the particular condition is present on admission (that is, a “N” indicator is associated with the diagnosis on the claim) and there are no other complicating conditions, the DRG GROUPER assigns the claim to a lower severity (and, therefore, the lower weighted MS–DRG) as a penalty for allowing a Medicare inpatient to contract a HAC. While the POA reporting meets policy goals of encouraging quality care and generates program savings, it presents an issue for the relative weight-setting process. Because cases identified as HACs are likely to be more complex than similar cases that are not identified as HACs, the charges associated with HAC cases are likely to be higher as well. Therefore, if the higher charges of these HAC claims are grouped into lower severity MS–DRGs prior to the relative weight-setting process, the relative weights of these particular MS–DRGs would become artificially inflated, potentially skewing the relative weights.

In addition, the FY 2013 IPPS/LTCH PPS final rule, for FY 2013 and subsequent fiscal years, we finalized a policy to treat hospitals that participate in the Bundled Payments for Care Improvement (BPCI) initiative the same as prior fiscal years for the IPPS payment modeling and ratesetting process without regard to hospitals’ participation within these bundled payment models (77 FR 53341 through 53343). Specifically, because acute care hospitals participating in the BPCI initiative still receive IPPS payments under section 1886(d) of the Act, we include all applicable data from these subsection (d) hospitals in our IPPS payment modeling and ratesetting calculations as if the hospitals were not participating in those models under the BPCI initiative. We refer readers to the FY 2013 IPPS/LTCH PPS final rule for a complete discussion on our final policy for the treatment of hospitals participating in the BPCI initiative in our ratesetting process. For additional information on the BPCI initiative, we refer readers to the CMS’ Center for Medicare and Medicaid Innovation’s website at https://innovation.cms.gov/initiatives/Bundled-Payments/index.html and to section IV.H.4. of the preamble of the FY 2013 IPPS/LTCH PPS final rule (77 FR 53341 through 53343).

The participation of hospitals in the BPCI initiative concluded on September 30, 2018. The participation of hospitals in the BPCI Advanced model started on October 1, 2018. The BPCI Advanced model, tested under the authority of section 1115A of the Act, is comprised of a single payment and risk track, which bundles payments for multiple services beneficiaries receive during a Clinical Episode. Acute care hospitals may participate in BPCI Advanced in one of two capacities: as a model Participant or as a downstream Episode Initiator. Regardless of the capacity in which they participate in the BPCI Advanced model, participating acute care hospitals will continue to receive IPPS payments under section 1886(d) of the Act. Acute care hospitals that are Participants also assume financial and quality performance accountability for Clinical Episodes in the form of a reconciliation payment. For additional information on the BPCI Advanced model, we refer readers to the BPCI Advanced web page on the CMS Center for Medicare and Medicaid Innovation’s website at https://innovation.cms.gov/initiatives/bpci-advanced/. Consistent with our policy for FY 2023, and consistent with how we have treated hospitals that participated in the BPCI Initiative, for FY 2024, we continue to believe it is appropriate to include all applicable data from the subsection (d) hospitals participating in the BPCI Advanced model in our IPPS payment modeling and ratesetting calculations because, as noted previously, these hospitals are still receiving IPPS payments under section 1886(d) of the Act. Consistent with the FY 2023 IPPS/LTCH PPS final rule, we also proposed to include all applicable data from subsection (d) hospitals participating in the Comprehensive Care for Joint Replacement (CJR) Model in our IPPS payment modeling and ratesetting calculations.

The charges for each of the 19 cost groups for each claim were standardized to remove the effects of differences in area wage levels, IME, and DSH payments, and for hospitals located in Alaska and Hawaii, the applicable cost-of-living adjustment. We also proposed to include charges for both operating and capital costs, we standardized total charges to remove the effects of differences in geographic adjustment factors, cost-of-living adjustments, and DSH payments under the capital IPPS as well. Charges were then summed by MS–DRG for each of the 19 cost groups so that each MS–DRG had 19 standardized charge totals. Statistical outliers were then removed. These charges were then adjusted to reflect the proposed national average CCRs developed from the FY 2021 cost report data.

The 19 cost centers that we used in the relative weight calculation are shown in a supplemental data file, Cost Center HCRIS Lines Supplemental Data File, posted via the internet on the CMS website for this final rule and available at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS. The supplemental data file shows the lines on the cost report and the corresponding revenue codes that we used to create the 19 national cost center CCRs. We stated in the proposed rule that if we receive comments about the groupings in this supplemental data file, we may consider these comments as we finalize our policy. However, we did not receive any comments on the groupings in this table, and therefore, we are finalizing the groupings as proposed.

Consistent with historical practice, we account for rare situations of non-monotonicity in a base MS–DRG and its severity levels, where the mean cost in the higher severity level is less than the
mean cost in the lower severity level, in
determining the relative weights for the
different severity levels. If there are
initially non-monotonic relative weights
in the same base DRG and its severity
levels, then we combine the cases that
group to the specific non-monotonic
MS–DRGs for purposes of relative
weight calculations. For example, if
there are two non-monotonic MS–DRGs,
combining the cases across those two
MS–DRGs results in the same relative
weight for both MS–DRGs. The relative
weight calculated using the combined
cases for those severity levels is
monotonic, effectively removing any
non-monotonicity with the base DRG
and its severity levels. For the FY 2024
proposed rule, this calculation was
applied to address non-monotonicity for
cases that grouped to MS–DRG 016 and
MS–DRG 017. In the supplemental file
titled AOR/BOR File associated with the
proposed rule, we included statistics for
the affected MS–DRGs both separately
and with cases combined.

We invited public comments on our
proposals related to recalibration of the
proposed FY 2024 relative weights and
the changes in relative weights from FY
2023.

Comment: A commenter stated that
CMS erred in calculating the relative
weights for MS–DRG 016 and MS–DRG
017. The commenter stated that if the
relative weight is going to be kept the
same, the MS–DRGs should be
combined, as they are for allogenic bone
marrow transplants.

Response: As discussed in the
proposed rule, we intentionally
combined the cases across the two MS–
DRGs because the mean cost in the
higher severity level is less than the
mean cost in the lower severity level,
consistent with our historical practice
for accounting for situations of non-
monotonicity in a base MS–DRG and its
severity levels. We may consider the
suggestion to combine these two MS–
DRGs for future rulemaking.

Accordingly, for this FY 2024 final
rule, this calculation was applied to
address non-monotonicity for cases that
grouped to MS–DRG 016 and MS–DRG
017. In the supplemental file titled
AOR/BOR File associated with this final
rule, we include statistics for the
affected MS–DRGs both separately and
with cases combined.

Comment: A commenter requested that
CMS implement an edit for claims that
group to MS–DRG 014, that would
reject claims when an inpatient type of
bill 11X claim is received without
charges mapped to revenue code 0815.
The commenter stated that this edit
would help ensure accurate claims
reporting, ensure the accuracy of CMS’
budget neutrality calculations, and help
ensure that CMS does not
inappropriately generate outlier
payment on MS–DRG 014 claims (given
that CMS removes costs associated with
revenue code 0815 from its outlier
calculation).

Response: We expect providers to
appropriately report charges associated
with revenue code 0815 and do not
believe that a novel claims processing
edit such as this is necessary at this
time. We may consider provider
education materials regarding reporting
Allogeneic Stem Cell Acquisition/Donor
Services in the future.

After consideration of the comments
received, we are finalizing our proposals
related to the recalibration of the FY
2024 relative weights. We summarize
and respond to comments relating to the
methodology for calculating the relative
weight for MS–DRG 018 in the next
section of this final rule.

b. Relative Weight Calculation for MS–
DRG 018

In the FY 2021 IPPS/LTCH PPS final
rule (85 FR 58451 through 58453), we
created MS–DRG 018 for cases that
include procedures describing Chimeric
Antigen Receptor (CAR) T-cell
therapies. We also finalized our
proposal to modify our existing relative
weight methodology to ensure that the
relative weight for MS–DRG 018
appropriately reflects the relative
resources required for providing CAR T-
cell therapy outside of a clinical trial,
while still accounting for the clinical
trial cases in the overall average cost for
all MS–DRGs (85 FR 58599 through
58600). Specifically, we stated that
clinical trial claims that group to new
MS–DRG 018 will not be included when
calculating the average cost for MS–DRG
018 that is used to calculate the relative
weight for this MS–DRG, so that the
relative weight reflects the costs of the
CAR T-cell therapy drug. We stated that
we identified clinical trial claims as
claims that contain CPT–10–CM
diagnosis code Z00.6 or contain
standardized drug charges of less than
$373,000, which was the average sales
price of KYMRIAH and YESCARTA, the
two CAR T-cell biological products
licensed to treat relapsed/refractory
large B-cell lymphoma as of the time of
the development of the FY 2021 final
rule. In addition, we stated that: (a)
when the CAR T-cell therapy product is
purchased in the usual manner, but the
case involves a clinical trial of a
different product, the claim will be
included when calculating the average
cost for new MS–DRG 018 to the extent
such cases can be identified in the
historical data, and (b) when there is
expanded access use of immunotherapy,
these cases will not be included when
calculating the average cost for new
MS–DRG 018 to the extent such cases
can be identified in the historical data.

We also finalized our proposal to
calculate an adjustment to account for
the CAR T-cell therapy cases identified
as clinical trial cases in calculating the
national average standardized cost per
case that is used to calculate the relative
weights for all MS–DRGs and for
purposes of budget neutrality and
outlier simulations. We calculate this
adjustor by dividing the average cost for
cases that we identify as clinical trial
cases by the average cost for cases that
we identify as non-clinical trial cases,
with the additional refinements that (a)
when the CAR T-cell therapy product is
purchased in the usual manner, but the
case involves a clinical trial of a
different product, the claim will be
included when calculating the average
cost for cases not determined to be
clinical trial cases to the extent such
cases can be identified in the historical
data, and (b) when there is expanded
access use of immunotherapy, these
cases will be included when calculating
the average cost for cases determined to
be clinical trial cases to the extent such
cases can be identified in the historical
data. We stated that to the best of our
knowledge, there were no claims in the
historical data used in the calculation of
this adjustment for cases involving a
clinical trial of a different product, and
to the extent the historical data contain
claims for cases involving expanded
access use of immunotherapy, we
believe those claims would have drug
charges less than $373,000.

In the FY 2021 IPPS/LTCH PPS final
rule (85 FR 58842), we also finalized an
adjustment to the payment amount for
applicable clinical trial and expanded
access use immunotherapy cases that
group to MS–DRG 018, and indicated
that we would provide instructions for
identifying these claims in separate
guidance. Following the issuance of the
FY 2021 IPPS/LTCH PPS final rule, we
issued guidance20 stating that providers
may enter a Billing Note NTE02
“Expand Acc Use” on the electronic
claim B37I or a remark “Expand Acc
Use” on a paper claim to notify the
Medicare administrative contractor
(MAC) of expanded access use of CAR
T-cell therapy. In this case, the MAC
would add payer-only condition code
“ZB” so that Pricer will apply the
payment adjustment in calculating
payment for the case. In cases when the
CAR T-cell therapy product is

r1607tcp.pdf.
purchased in the usual manner, but the case involves a clinical trial of a different product, the provider may enter a Billing Note NTE02 "Diff Prod Clin Trial" on the electronic claim 837I or a remark “Diff Prod Clin Trial” on a paper claim. In this case, the MAC would add payer-only condition code “ZC” so that the Pricer will not apply the payment adjustment in calculating payment for the case.

In the FY 2022 IPPS/LTCH PPS final rule, we revised MS–DRG 018 to include cases that report the procedure codes for CAR T-cell and non-CAR T-cell therapies and other immunotherapies (86 FR 44798 through 44806). We also finalized our proposal to continue to use the proxy of standardized drug charges of less than $373,000 (86 FR 44965) to identify clinical trial claims.

In the FY 2023 IPPS/LTCH PPS final rule (87 FR 48894), we once again finalized our policy to use a proxy of standardized drug charges of less than $373,000 to identify clinical trial claims and expanded access use cases under our special methodology for the calculation of the relative weight for MS–DRG 018 to date, we believe that because we calculated those have occurred since CMS initially adopted this policy, it may no longer be necessary to apply this proxy to identify these claims. In the FY 2021 IPPS/LTCH PPS final rule, we stated that because ICD–10–CM diagnosis code Z00.6 is required to be included with clinical trial cases, we expect hospitals to include this code for such cases grouping to MS–DRG 018 for FY 2021 and all subsequent years, and we believe that providers have continued to gain experience with the use of ICD–10–CM diagnosis code Z00.6 to report CAR T-cell therapy. This is supported by our observation that the percentage of claims reporting standardized drug charges of less than $373,000 that do not report ICD–10–CM code Z00.6 relative to all claims that group to MS–DRG 018 fell significantly from the FY 2019 data (used in the FY 2021 ratesetting) to the FY 2022 data (used in the FY 2024 ratesetting). For example, in the FY 2021 MedPAR data used for the FY 2021 IPPS/LTCH PPS final rule, cases that we identified as clinical trial cases (using our proxy of standardized drug charges of less than $373,000) that did not contain ICD–10–CM diagnosis code Z00.6 comprised 18 percent of all cases that grouped to MS–DRG 018. First, we proposed to exclude claims with the presence of condition code “90” (or, for FY 2024 ratesetting, which is based on the FY 2022 MedPAR data, the presence of condition code “ZB”) and claims that contain ICD–10–CM diagnosis code Z00.6 without payer-only code “ZC” that group to MS–DRG 018 when calculating the average cost for MS–DRG 018. Second, for the reasons described previously, we proposed to no longer use the proxy of standardized drug charges of less than $373,000 to identify clinical trial claims and expanded access use claims in MS–DRG 018. Therefore, in the FY 2024 IPPS/LTCH PPS proposed rule, we proposed to no longer use the proxy of standardized drug charges of less than $373,000 to identify clinical trial claims and expanded access use claims in MS–DRG 018.

Therefore, in the FY 2024 IPPS/LTCH PPS proposed rule, we proposed to no longer use the proxy of standardized drug charges of less than $373,000 to identify clinical trial claims and expanded access use claims in MS–DRG 018.

Following the issuance of the FY 2023 IPPS/LTCH PPS final rule, we issued guidance stating where there is an expanded access use of immunotherapy, the provider may submit condition code “90” on the claim so that Pricer will apply the payment adjustment in calculating payment for the case. We stated that MACs would no longer append Condition Code ‘ZB’ to inpatient claims reporting Billing Note NTE02 “Expand Acc Use” on the electronic claim 837I or a remark “Expand Acc Use” on a paper claim, effective for claims for discharges that occur on or after October 1, 2022.

We stated in the proposed rule that while we have applied a proxy of standardized drug charges of less than $373,000 to identify clinical trial claims and expanded access use cases under our special methodology for the calculation of the relative weight for MS–DRG 018 to date, we believe that because of changes that have occurred since CMS initially adopted this policy, it may no longer be necessary to apply this proxy to identify these claims. In the FY 2021 IPPS/LTCH PPS final rule, we stated that because ICD–10–CM diagnosis code Z00.6 is required to be included with clinical trial cases, we expect hospitals to include this code for such cases grouping to MS–DRG 018 for FY 2021 and all subsequent years, and we believe that providers have continued to gain experience with the use of ICD–10–CM diagnosis code Z00.6 to report CAR T-cell therapy. This is supported by our observation that the percentage of claims reporting standardized drug charges of less than $373,000 that do not report ICD–10–CM code Z00.6 relative to all claims that group to MS–DRG 018 fell significantly from the FY 2019 data (used in the FY 2021 ratesetting) to the FY 2022 data (used in the FY 2024 ratesetting). For example, in the FY 2021 MedPAR data used for the FY 2021 IPPS/LTCH PPS final rule, cases that we identified as clinical trial cases (using our proxy of standardized drug charges of less than $373,000) that did not contain ICD–10–CM diagnosis code Z00.6 comprised 18 percent of all cases that grouped to MS–DRG 018. First, we proposed to exclude claims with the presence of condition code “90” (or, for FY 2024 ratesetting, which is based on the FY 2022 MedPAR data, the presence of condition code “ZB”) and claims that contain ICD–10–CM diagnosis code Z00.6 without payer-only code “ZC” that group to MS–DRG 018 when calculating the average cost for MS–DRG 018. Second, for the reasons described previously, we proposed to no longer use the proxy of standardized drug charges of less than $373,000 to identify clinical trial claims and expanded access use claims in MS–DRG 018. Therefore, in the FY 2024 IPPS/LTCH PPS proposed rule, we proposed to no longer use the proxy of standardized drug charges of less than $373,000 to identify clinical trial claims and expanded access use claims in MS–DRG 018.
“ZB” (or, for subsequent fiscal years, condition code “90”) would be excluded from the calculation of the average cost for MS–DRG 018.

Consistent with this proposal, we also proposed to modify our calculation of the adjustment to account for the CAR T-cell therapy cases identified as clinical trial cases in calculating the national average standardized cost per case that is used to calculate the relative weights for all MS–DRGs:

• Calculate the average cost for cases assigned to MS–DRG 018 that either—
  (a) contain ICD–10–CM diagnosis code Z00.6 and do not contain condition code “ZC” or (b) contain condition code 90 (or, for FY 2024 ratessetting, condition code “ZB”).
• Calculate the average cost for all other cases assigned to MS–DRG 018.
• Calculate an adjustor by dividing the average cost calculated in step 1 by the average cost calculated in step 2.
• Apply the adjustor calculated in step 3 to the cases identified in step 1 as applicable clinical trial or expanded access use cases, then add this adjusted case count to the non-clinical trial case count prior to calculating the average cost across all MS–DRGs.

Applying this proposed methodology, based on the December 2022 update of the FY 2022 MedPAR file used for the proposed rule, we estimated that the average costs of cases assigned to MS–DRG 018 that are identified as clinical trial cases ($89,379) were 28 percent of the average costs of the cases assigned to MS–DRG 018 that are identified as nonclinical trial cases ($323,903). Accordingly, as we did for FY 2023, we proposed to adjust the transfer-adjusted case count for MS–DRG 018 by applying the proposed adjustor of 0.28 to the applicable clinical trial and expanded access use immunotherapy cases, and to use this adjusted case count for MS–DRG 018 in calculating the national average cost per case, which is used in the calculation of the relative weights.

Therefore, in calculating the national average cost per case for purposes of the proposed rule, each case identified as an applicable clinical trial or expanded access use immunotherapy case was adjusted by 0.28. As we did for FY 2023, we are applying this same adjustor for the applicable cases that group to MS–DRG 018 for purposes of budget neutrality and outlier simulations. We also proposed to update the value of the adjustor based on more recent data for the final rule.

Comment: Some commenters supported our proposal to remove the use of this proxy, and applying the adjustor to cases with standardized drug charges of less than $373,000, stating that it is consistent with existing hospital billing practices and would simplify the reimbursement for chimeric antigen receptor therapy (CAR–T) services. Many commenters opposed our proposal, stating that it was premature to remove this trim. While these commenters stated that provider charging practices are improving, they expressed concern that some providers have limited experience properly reporting claims for clinical trial and expanded access use cases and some providers do not appear to have fully complied with CMS guidance. A commenter requested that CMS maintain this trim for at least one additional fiscal year.

A commenter also requested that CMS publish information on cases included in the rate-setting methodology that are below the $373,000 threshold in the interest of transparency given the likely impact of those cases on the base DRG payment. A commenter expressed concern that 4 percent of cases are still reporting standardized drug charges of less than $373,000, given the relatively low volume of cases assigned to MS–DRG 018. A commenter stated that the inclusion of the 4 percent of cases would result in a potentially meaningful reduction in the base DRG payment for CAR–T cases. Another commenter modeled the inclusion of the 4 percent of cases and indicated that excluding them resulted in a $3,100 reduction in the base payment for MS–DRG 018. Commenters recommended that CMS monitor the impact of including these cases in ratessetting to ensure base payment for DRG 018 remain stable prior to removing the $373,000 low-cost threshold.

Response: We agree that removing the trim of excluding cases with standardized drug charges of less than $373,000 would be consistent with existing hospital billing practices. As discussed in the proposed rule, we believe providers have continued to gain experience with the use of ICD–10–CM diagnosis code Z00.6 to report cases involving a clinical trial of CAR T-cell therapy, as well as coding of expanded access use immunotherapy cases. This is supported by our observation that the percentage of claims reporting standardized drug charges of less than $373,000 that do not report ICD–10–CM code Z00.6 relative to all claims that group to MS–DRG 018 fell significantly from the FY 2019 data (used in the FY 2021 ratessetting) to the FY 2022 data (used in the FY 2024 ratessetting). While there continue to be a small percentage of claims that report standardized drug charges of less than $373,000 and do not report ICD–10–CM code Z00.6, we do not believe it is necessary to continue to use the proxy until the number of these claims reaches zero. We note that there is now only a very small percentage variation in the relative weight with and without this proxy, unlike in prior years. The $3,100 reduction referenced by the commenter in the range of 1 percent of the base DRG payment. With respect to the commenter who requested that CMS publish the details regarding specific cases, we note that information on obtaining the MedPAR Limited Data Set is available on the CMS website, at https://www.cms.gov/Research-Statistics-Data-and-Systems/Files-for-Order/LimitedDataSets/MEDPARDLHOSPIITALNATIONAL.

After consideration of the public comments we received, we are finalizing our proposals regarding the calculation of the relative weight for MS–DRG 018. Applying this finalized methodology, based on the March 2023 update of the FY 2022 MedPAR file used for this final rule, we estimated that the average costs of cases assigned to MS–DRG 018 that are identified as clinical trial cases ($84,883) were 27 percent of the average costs of the cases assigned to MS–DRG 018 that are identified as non-clinical trial cases ($314,862). Accordingly, as we did for FY 2023, we are finalizing our proposal to adjust the transfer-adjusted case count for MS–DRG 018 by applying the adjustor of 0.27 to the applicable clinical trial and expanded access use immunotherapy cases, and to use this adjusted case count for MS–DRG 018 in calculating the national average cost per case, which is used in the calculation of the relative weights. Therefore, in calculating the national average cost per case for purposes of this final rule, each case identified as an applicable clinical trial or expanded access use immunotherapy case was adjusted by 0.27. As we did for FY 2023, we are applying this same adjustor for the applicable cases that group to MS–DRG 018 for purposes of budget neutrality and outlier simulations.

c. Cap for Relative Weight Reductions

In the FY 2023 IPPS/LTCH PPS final rule, we finalized a permanent 10–percent cap on the reduction in an MS–DRG’s relative weight in a given fiscal year, beginning in FY 2023. We also finalized a budget neutrality adjustment to the standardized amount for all hospitals to ensure that application of the permanent 10-percent cap does not result in an increase or decrease of estimated aggregate payments. We refer the reader to the FY 2023 IPPS/LTCH PPS final rule for discussion of this policy. In the Addendum to this IPPS/LTCH PPS final rule, we present...
the budget neutrality adjustment for reclassification and recalibration of the FY 2024 MS–DRG relative weights with application of this cap. Table 5 contains the FY 2024 MS–DRG relative weights with and without the application of this cap. For a further discussion of the budget neutrality adjustment for FY 2024, we refer readers to the Addendum of this final rule.

3. Development of National Average CCRs

We developed the national average CCRs as follows:

Using the FY 2021 cost report data, we removed CAHs, Indian Health Service hospitals, all-inclusive rate hospitals, and cost reports that represented time periods of less than 1 year (365 days). We included hospitals located in Maryland because we include their charges in our claims database. Then we created CCRs for each provider for each cost center (see the supplemental data file for line items used in the calculations) and removed any CCRs that were greater than 10 or less than 0.01. We normalized the departmental CCRs by dividing the CCR for each department by the total CCR for the hospital for the purpose of trimming the data. Then we took the logs of the normalized cost center CCRs and removed any cost center CCRs where the log of the cost center CCR was greater or less than the mean log plus/minus 3 times the standard deviation for the log of that cost center CCR. Once the cost report data were trimmed, we calculated a Medicare-specific CCR. The Medicare-specific CCR was determined by taking the Medicare charges for each line item from Worksheet D–3 and deriving the Medicare-specific costs by applying the hospital-specific departmental CCRs to the Medicare-specific charges for each line item from Worksheet D–3. Once each hospital’s Medicare-specific costs were established, we summed the total Medicare-specific costs and divided by the sum of the total Medicare-specific charges to produce national average, charge-weighted CCRs.

After we multiplied the total charges for each MS–DRG in each of the 19 cost centers by the corresponding national average CCR, we summed the 19 “costs” across each MS–DRG to produce a total standardized cost for the MS–DRG. The average standardized cost for each MS–DRG was then computed as the total standardized cost for the MS–DRG divided by the transfer-adjusted case count for the MS–DRG. The average cost for each MS–DRG was then divided by the national average standardized cost per case to determine the relative weight. The FY 2024 cost-based relative weights were then normalized by an adjustment factor of 1.941198 so that the average case weight after recalibration was equal to the average case weight before recalibration. The normalization adjustment is intended to ensure that recalibration by itself neither increases nor decreases total payments under the IPPS, as required by section 1886(d)(4)(C)(iii) of the Act. We then applied the permanent 10-percent cap on the reduction in a MS–DRG’s relative weight in a given fiscal year; specifically for those MS–DRGs for which the relative weight otherwise would have declined by more than 10 percent from the FY 2023 relative weight, we set the FY 2024 relative weight equal to 90 percent of the FY 2023 relative weight. The relative weights for FY 2024 as set forth in Table 5 associated with this final rule and available on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS reflect the application of this cap.

The 19 national average CCRs for FY 2024 are as follows:

<table>
<thead>
<tr>
<th>Group</th>
<th>CCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routine Days</td>
<td>0.417</td>
</tr>
<tr>
<td>Intensive Days</td>
<td>0.351</td>
</tr>
<tr>
<td>Drugs</td>
<td>0.18</td>
</tr>
<tr>
<td>Supplies &amp; Equipment</td>
<td>0.303</td>
</tr>
<tr>
<td>Implantable Devices</td>
<td>0.269</td>
</tr>
<tr>
<td>Inhalation Therapy</td>
<td>0.153</td>
</tr>
<tr>
<td>Therapy Services</td>
<td>0.268</td>
</tr>
<tr>
<td>Anesthesia</td>
<td>0.072</td>
</tr>
<tr>
<td>Labor &amp; Delivery</td>
<td>0.416</td>
</tr>
<tr>
<td>Operating Room</td>
<td>0.16</td>
</tr>
<tr>
<td>Cardiology</td>
<td>0.086</td>
</tr>
<tr>
<td>Cardiac Catheterization</td>
<td>0.102</td>
</tr>
<tr>
<td>Laboratory</td>
<td>0.102</td>
</tr>
<tr>
<td>Radiology</td>
<td>0.128</td>
</tr>
<tr>
<td>MRIs</td>
<td>0.067</td>
</tr>
<tr>
<td>CT Scans</td>
<td>0.033</td>
</tr>
<tr>
<td>Emergency Room</td>
<td>0.153</td>
</tr>
<tr>
<td>Blood and Blood Products</td>
<td>0.245</td>
</tr>
<tr>
<td>Other Services</td>
<td>0.34</td>
</tr>
</tbody>
</table>

Since FY 2009, the relative weights have been based on 100 percent cost weights based on our MS–DRG grouping system. When we recalibrated the DRG weights for previous years, we set a
threshold of 10 cases as the minimum number of cases required to compute a reasonable weight. We proposed to use that same case threshold in recalibrating the proposed MS–DRG relative weights for FY 2024. Using data from the FY 2022 MedPAR file, there were 7 MS–DRGs that contain fewer than 10 cases. For FY 2024, because we do not have sufficient MedPAR data to set accurate and stable cost relative weights for these low-volume MS–DRGs, we proposed to compute relative weights for the low-volume MS–DRGs by adjusting their final FY 2023 relative weights by the percentage change in the average weight of the cases in other MS–DRGs from FY 2023 to FY 2024. The crosswalk table is as follows.

<table>
<thead>
<tr>
<th>Low-Volume MS-DRG</th>
<th>MS-DRG Title</th>
<th>Crosswalk to MS-DRG</th>
</tr>
</thead>
<tbody>
<tr>
<td>789</td>
<td>Neonates, Died or Transferred to Another Acute Care Facility</td>
<td>Final FY 2023 relative weight (adjusted by percent change in average weight of the cases in other MS-DRGs)</td>
</tr>
<tr>
<td>790</td>
<td>Extreme Immaturity or Respiratory Distress Syndrome, Neonate</td>
<td>Final FY 2023 relative weight (adjusted by percent change in average weight of the cases in other MS-DRGs)</td>
</tr>
<tr>
<td>791</td>
<td>Prematurity with Major Problems</td>
<td>Final FY 2023 relative weight (adjusted by percent change in average weight of the cases in other MS-DRGs)</td>
</tr>
<tr>
<td>792</td>
<td>Prematurity without Major Problems</td>
<td>Final FY 2023 relative weight (adjusted by percent change in average weight of the cases in other MS-DRGs)</td>
</tr>
<tr>
<td>793</td>
<td>Full-Term Neonate with Major Problems</td>
<td>Final FY 2023 relative weight (adjusted by percent change in average weight of the cases in other MS-DRGs)</td>
</tr>
<tr>
<td>794</td>
<td>Neonate with Other Significant Problems</td>
<td>Final FY 2023 relative weight (adjusted by percent change in average weight of the cases in other MS-DRGs)</td>
</tr>
<tr>
<td>795</td>
<td>Normal Newborn</td>
<td>Final FY 2023 relative weight (adjusted by percent change in average weight of the cases in other MS-DRGs)</td>
</tr>
</tbody>
</table>

BILLING CODE 4120–01–C

Comment: A commenter requested that CMS utilize the “other” CCR for CAR–T product charges associated with revenue code 0891 to mitigate charge compression problems until CMS data is available for cost center 0078. The commenter stated that this would result in a more appropriate case cost and a higher relative weight for MS–DRG 018.

Response: We do not believe it would be appropriate to utilize the “other” CCR for CAR product charges associated with revenue code 0891. The categories assigned to the “other” cost center are categorically not described by another cost center. This is not the case for CAR–T product charges, as the drug cost center describes the same type of product. Therefore, we do not believe it is necessary to make changes to the CCR used for CAR–T-cell product charges.

After consideration of the public comments we received, we are finalizing our proposals without modification.

E. Add-On Payments for New Services and Technologies for FY 2024

1. Background

Sections 1886(d)(5)[K] and (L) of the Act establish a process of identifying and ensuring adequate payment for new medical services and technologies (sometimes collectively referred to in this section as “new technologies”) under the IPPS. Section 1886(d)(5)[K](vi) of the Act specifies that a medical service or technology will be considered new if it meets criteria established by the Secretary after notice and opportunity for public comment. Section 1886(d)(5)[K](iii)(I) of the Act specifies that a new medical service or technology may be considered for new technology add-on payment if, based on the estimated costs incurred with respect to discharges involving such service or technology, the DRG prospective payment rate otherwise applicable to such discharges under this subsection is inadequate. The regulations at 42 CFR 412.87 implement these provisions and §412.87(b) specifies three criteria for a new medical service or technology to receive the additional payment: (1) The medical service or technology must be new; (2) the medical service or technology must be costly such that the DRG rate otherwise applicable to discharges involving the medical service or technology is determined to be inadequate; and (3) the service or technology must demonstrate a substantial clinical improvement over existing services or technologies. In addition, certain transformative new devices and antimicrobial products may qualify under an alternative inpatient new technology add-on payment pathway, as set forth in the regulations at §412.87(c) and (d).

We note that section 1886(d)(5)[K](i) of the Act requires that the Secretary establish a mechanism to recognize the costs of new medical services and technologies under the payment system established under that subsection, which establishes the system for paying for the operating costs of inpatient hospital services. The system of payment for capital costs is established under section 1886(g) of the Act. Therefore, as discussed in prior rulemaking (72 FR 47307 through 47308), we do not include capital costs in the add-on payments for a new medical service or technology or make new technology add-on payments under the IPPS for capital-related costs.

In this rule, we highlight some of the major statutory and regulatory provisions relevant to the new technology add-on payment criteria, as well as other information. For further discussion on the new technology add-on payment criteria, we refer readers to the FY 2012 IPPS/LTC PPS final rule (76 FR 51572 through 51574), the FY 2020 IPPS/LTC PPS final rule (84 FR 42288 through 42300), and the FY 2021 IPPS/LTC PPS final rule (85 FR 58736 through 58742).

a. New Technology Add-on Payment Criteria

(1) Newness Criterion

Under the first criterion, as reflected in §412.87(b)(2), a specific medical service or technology will no longer be considered “new” for purposes of new medical service or technology add-on payments after CMS has recalibrated the MS–DRGs, based on available data, to
reflect the cost of the technology. We note that we do not consider a service or technology to be new if it is substantially similar to one or more existing technologies. That is, even if a medical product receives a new FDA approval or clearance, it may not necessarily be considered “new” for purposes of new technology add-on payments if it is “substantially similar” to another medical product that was approved or cleared by FDA and has been on the market for more than 2 to 3 years. In the FY 2010 IPPS/RY 2010 LTCH PPS final rule (74 FR 43813 through 43814), we established criteria for evaluating whether a new technology is substantially similar to an existing technology, specifically whether: (1) a product uses the same or a similar mechanism of action to achieve a therapeutic outcome; (2) a product is assigned to the same or a different MS–DRG; and (3) the new use of the technology involves the treatment of the same or similar type of disease and the same or similar patient population. If a technology meets all three of these criteria, it would be considered substantially similar to an existing technology and would not be considered “new” for purposes of new technology add-on payments. For a detailed discussion of the criteria for substantial similarity, we refer readers to the FY 2006 IPPS final rule (70 FR 47351 through 47352) and the FY 2010 IPPS/LTCH PPS final rule (74 FR 43813 through 43814).

(2) Cost Criterion

Under the second criterion, § 412.87(b)(3) further provides that, to be eligible for the add-on payment for new medical services or technologies, the MS–DRG prospective payment rate otherwise applicable to discharges involving the new medical service or technology must be assessed for adequacy. Under the cost criterion, consistent with the formula specified in section 1886(d)(5)(K)(ii)(I) of the Act, to assess the adequacy of payment for a new technology paid under the applicable MS–DRG prospective payment rate, we evaluate whether the charges of the cases involving a new medical service or technology will exceed a threshold amount that is the lesser of 75 percent of the standardized amount (increased to reflect the difference between cost and charges) or 75 percent of one standard deviation beyond the geometric mean standardized charge for all cases in the MS–DRG to which the new medical service or technology is assigned (or the case-weighted average of all relevant MS–DRGs if the new medical service or technology occurs in many different MS–DRGs). The MS–DRG threshold amounts generally used in evaluating new technology add-on payment applications for FY 2024 are presented in a data file that is available, along with the other data files associated with the FY 2023 IPPS/LTCH PPS final rule and correction notification, on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.

We note that, under the policy established in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58603 through 58605), beginning with FY 2022, we use the proposed threshold values associated with the proposed rule for that fiscal year to evaluate the cost criterion for all applications for new technology add-on payments and previously approved technologies that may continue to receive new technology add-on payments, if those technologies would be assigned to a proposed new MS–DRG for that same fiscal year. As finalized in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41275), beginning with FY 2020, we include the thresholds applicable to the next fiscal year (previously included in Table 10 of the annual IPPS/LTCH PPS proposed and final rules) in the data files associated with the prior fiscal year. Accordingly, the proposed thresholds for applications for new technology add-on payments for FY 2025 were presented in a data file that is available on the CMS website, along with the other data files associated with the FY 2024 proposed rule, by clicking on the FY 2024 IPPS Proposed Rule Home Page at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index. We noted that, for the reasons discussed in section I.F. of the preamble of the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26777) and this final rule, we proposed to use the FY 2022 MedPAR claims data for FY 2024 ratesetting. Consistent with this proposal, for the FY 2025 proposed threshold values, we proposed to use the FY 2022 claims data to set the proposed thresholds for applications for new technology add-on payments for FY 2025.

As discussed in section I.E. of the preamble of this final rule, we are finalizing our proposal to use the FY 2022 MedPAR claims data for FY 2024 ratesetting. Accordingly, in this final rule, we are finalizing that we will use FY 2022 claims data to set the thresholds for applications for new technology add-on payments for FY 2025. The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries. In the FY 2020 IPPS/LTCH PPS final rule (84 FR 42288 through 42292), we prospectively codified in our regulations at § 412.87(b) the following aspects of how we evaluate substantial clinical improvement for purposes of new technology add-on payments under the IPPS:

- A determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
- The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
- The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
- The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
- The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
- The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
- The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
- The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
- The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
- The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
- The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
- The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
- The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
- The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
- The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
- The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
- The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
- The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
- The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
- The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
- The totality of the circumstances is considered when making a determination that a new medical service or technology represents an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of Medicare beneficiaries.
The new medical service or technology offers the ability to diagnose a medical condition in a patient population where that medical condition is currently undetectable, or offers the ability to diagnose a medical condition earlier in a patient population than allowed by currently available methods, and there must also be evidence that use of the new medical service or technology to make a diagnosis affects the management of the patient;

The use of the new medical service or technology significantly improves clinical outcomes relative to services or technologies previously available as demonstrated by one or more of the following: a reduction in at least one clinically significant adverse event, including a reduction in mortality or a clinically significant complication; a decreased rate of at least one subsequent diagnostic or therapeutic intervention; a decreased number of future hospitalizations or physician visits; a more rapid resolution of the disease process treatment including, but not limited to, a reduced length of stay or recovery time; an improvement in one or more activities of daily living; an improved quality of life; or a demonstrated greater medication adherence or compliance; or

The totality of the circumstances otherwise demonstrates that the new medical service or technology substantially improves, relative to technologies previously available, the diagnosis or treatment of Medicare beneficiaries;

Evidence from the following published or unpublished information sources from within the United States or elsewhere may be sufficient to establish that a new medical service or technology represents an advance that substantially improves, relative to technologies previously available, the diagnosis or treatment of Medicare beneficiaries:

• Evidence from the following clinical studies, peer reviewed journal articles; study results; meta-analyses; consensus statements; white papers; patient surveys; case studies; reports; systematic literature reviews; letters from major healthcare associations; editorials and letters to the editor; and public comments. Other appropriate information sources may be considered.

• The medical condition diagnosed or treated by the new medical service or technology may have a low prevalence among Medicare beneficiaries.

• The new medical service or technology may represent an advance that substantially improves, relative to services or technologies previously available, the diagnosis or treatment of a subpopulation of patients with the medical condition diagnosed or treated by the new medical service or technology.

We refer the reader to the FY 2020 IPPS/LTCH PPS final rule (84 FR 42288 through 42290) for additional discussion of the evaluation of substantial clinical improvement for purposes of new technology add-on payments under the IPPSs.

We note, consistent with the discussion in the FY 2020 IPPS final rule (67 FR 50015), that while FDA has regulatory responsibility for decisions related to marketing authorization (for example, approval, clearance, etc.), we do not rely upon FDA criteria in our evaluation of substantial clinical improvement for purposes of determining what services and technologies qualify for new technology add-on payments under Medicare. This criterion does not depend on the standard of safety and effectiveness on which FDA relies but on a determination of substantial clinical improvement in the Medicare population.

b. Alternative Inpatient New Technology Add-on Payment Pathway

Beginning with applications for FY 2021 new technology add-on payments, under the regulations at §412.87(c), a medical device that is part of FDA’s Breakthrough Devices Program may qualify for the technology add-on payment under an alternative pathway. Additionally, under the regulations at §412.87(d) for certain antimicrobial products, beginning with FY 2021, a drug that is designated by FDA as a Qualified Infectious Disease Product (QIDP), and, beginning with FY 2022, a drug that is approved by FDA under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD), may also qualify for the new technology add-on payment under an alternative pathway. We refer the reader to the FY 2020 IPPS/LTCH PPS final rule (84 FR 42292 through 42297) and the FY 2021 IPPS/LTCH PPS final rule (85 FR 58737 through 58739) for further discussion on this policy. We note that a technology is not required to have the specified FDA designation at the time the new technology add-on payment application is submitted. CMS reviews the application based on the information provided by the applicant only under the alternative pathway specified by the applicant at the time of application submission. However, to receive approval for the new technology add-on payment under that alternative pathway, the technology must have the applicable FDA designation and meet all other requirements in the regulations in §412.87(c) and (d), as applicable.

(1) Alternative Pathway for Certain Transformative New Devices

For applications received for new technology add-on payments for FY 2021 and subsequent fiscal years, a medical device designated under FDA’s Breakthrough Devices Program that has received FDA marketing authorization will be considered not substantially similar to an existing technology for purposes of the new technology add-on payment under the IPPSs, and will not need to meet the requirement under §412.87(b)(1) that it represent an advance that substantially improves, relative to technologies previously available, the diagnosis or treatment of Medicare beneficiaries. Under this alternative pathway, a medical device that has received FDA marketing authorization (that is, has been approved or cleared by, or had a De Novo classification request granted by, FDA) as a Breakthrough Device for the indication covered by the Breakthrough Device designation, will need to meet the requirements of §412.87(c). We note that in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58734 through 58736), we clarified our policy that a new medical device under this alternative pathway must receive marketing authorization for the indication covered by the Breakthrough Devices Program designation. We refer the reader to the §412.87(b)(1) of the FY 2021 IPPS/LTCH PPS final rule (85 FR 58734 through 58736) for further discussion regarding this clarification.

(2) Alternative Pathway for Certain Antimicrobial Products

For applications received for new technology add-on payments for certain antimicrobial products, beginning with FY 2021, if a technology is designated by FDA as a QIDP and received FDA marketing authorization, and, beginning with FY 2022, if a drug is approved under FDA’s LPAD pathway and used for the indication approved under the LPAD pathway, it will be considered not substantially similar to an existing technology for purposes of new technology add-on payments and will not need to meet the requirement that it represent an advance that substantially improves, relative to technologies previously available, the diagnosis or treatment of Medicare beneficiaries. Under this alternative pathway for QIDPs and LPADs, a medical product that has received FDA marketing authorization and is designated by FDA as a QIDP or LPAD under the LPAD pathway will need to meet the requirements of §412.87(d).
the reader to the FY 2020 IPPS/LTCH PPS final rule (84 FR 42297 through 42297) and FY 2021 IPPS/LTCH PPS final rule (85 FR 58737 through 58739) for further discussion on this policy.

We note that, in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58737 through 58739), we clarified that a new medical product seeking approval for the new technology add-on payment under the alternative pathway for QIDPs must receive FDA marketing authorization for the indication covered by the QIDP designation. We also finalized our policy to expand our alternative new technology add-on payment pathway for certain antimicrobial products to include products approved under the LPAD pathway and used for the indication approved under the LPAD pathway.

c. Additional Payment for New Medical Service or Technology

The new medical service or technology add-on payment policy under the IPPS provides additional payments for cases with relatively high costs involving eligible new medical services or technologies, while preserving some of the incentives inherent under an average-based prospective payment system. The payment mechanism is based on the cost to hospitals for the new medical service or technology. As noted previously, we do not include capital costs in the add-on payments for a new medical service or technology or make new technology add-on payments under the IPPS for capital-related costs (72 FR 47307 through 47308).

For discharges occurring before October 1, 2019, under §412.88, if the costs of the discharge (determined by applying cost-to-charge ratios (CCRs) as described in §412.84(h)) exceed the full DRG payment (including payments for IME and DSH, but excluding outlier payments), Medicare will make an add-on payment equal to the lesser of: (1) 65 percent of the costs of the new medical service or technology; or (2) 65 percent of the amount by which the costs of the case exceed the standard DRG payment.

For a new technology that is a medical product approved under FDA’s LPAD pathway, beginning with discharges on or after October 1, 2019, if the costs of a discharge involving a new technology (determined by applying CCRs as described in §412.84(h)) exceed the full DRG payment (including payments for IME and DSH, but excluding outlier payments), Medicare will make an add-on payment equal to the lesser of: (1) 75 percent of the costs of the new medical service or technology; or (2) 75 percent of the amount by which the costs of the case exceed the standard DRG payment.

For a new technology that is a medical product approved under FDA’s LPAD pathway, beginning with discharges on or after October 1, 2019, if the costs of a discharge involving a new technology (determined by applying CCRs as described in §412.84(h)) exceed the full DRG payment (including payments for IME and DSH, but excluding outlier payments), Medicare will make an add-on payment equal to the lesser of: (1) 75 percent of the costs of the new medical service or technology; or (2) 75 percent of the amount by which the costs of the case exceed the standard DRG payment.

Beginning with discharges on or after October 1, 2019, we do not include capital costs in the add-on payments for a new medical service or technology or make new technology add-on payments under the IPPS for capital-related costs (72 FR 47307 through 47308). For discharges occurring before October 1, 2019, under §412.88, if the costs of the discharge (determined by applying operating cost-to-charge ratios (CCRs) as described in §412.84(h)) exceed the full DRG payment (including payments for IME and DSH, but excluding outlier payments), CMS made an add-on payment equal to the lesser of: (1) 50 percent of the costs of the new medical service or technology; or (2) 50 percent of the amount by which the costs of the case exceed the standard DRG payment.

Beginning with discharges on or after October 1, 2019, for the reasons discussed in the FY 2020 IPPS/LTCH PPS final rule (84 FR 42297 through 42300), we finalized an increase in the new technology add-on payment percentage, as reflected at §412.88(a)(2)(ii). Specifically, for a new technology other than a medical product designated by FDA as a QIDP, beginning with discharges on or after October 1, 2019, if the costs of a discharge involving a new technology (determined by applying CCRs as described in §412.84(h)) exceed the full DRG payment (including payments for IME and DSH, but excluding outlier payments), Medicare will make an add-on payment equal to the lesser of: (1) 65 percent of the costs of the new medical service or technology; or (2) 65 percent of the amount by which the costs of the case exceed the standard DRG payment.

For a new technology that is a medical product approved under FDA’s QIDP pathway, beginning with discharges on or after October 1, 2019, if the costs of a discharge involving a new technology (determined by applying CCRs as described in §412.84(h)) exceed the full DRG payment (including payments for IME and DSH, but excluding outlier payments), Medicare will make an add-on payment equal to the lesser of: (1) 75 percent of the costs of the new medical service or technology; or (2) 75 percent of the amount by which the costs of the case exceed the standard DRG payment.

We note that, consistent with the prospective nature of the IPPS, we finalize the new technology add-on payment amount for technologies approved or conditionally approved for new technology add-on payments in the final rule for each fiscal year and do not make mid-year changes to new technology add-on payment amounts.

Updated cost information may be submitted and included in rulemaking for the following fiscal year.

Section 503(d)(2) of Public Law 108–173 provides that there shall be no reduction or adjustment in aggregate payments under the IPPS due to add-on payments for new medical services and technologies. Therefore, in accordance with section 503(d)(2) of Public Law 108–173, add-on payments for new medical services or technologies for FY 2005 and subsequent years have not been subjected to budget neutrality.

d. Evaluation of Eligibility Criteria for New Medical Service or Technology Applications

In the FY 2009 IPPS final rule (73 FR 48561 through 48563), we modified our regulation at §412.87 to codify our longstanding practice of how CMS evaluates the eligibility criteria for new medical service or technology add-on payment applications. That is, we first determine whether a medical service or technology meets the newness criterion, and only if so, do we then make a determination as to whether the technology meets the cost threshold and represents a substantial clinical improvement over existing medical services or technologies. We specified that all applicants for new technology add-on payments must have FDA approval or clearance by July 1 of the year prior to the beginning of the fiscal year for which the application is being considered. In the FY 2021 IPPS/LTCH PPS final rule, to more precisely describe the various types of FDA approvals, clearances and classifications that we consider under our new technology add-on payment policy, we finalized a technical clarification to the regulation to indicate that new technologies must receive FDA marketing authorization (such as pre-market approval (PMA); 510(k) clearance; the granting of a De Novo classification request, or approval of a New Drug Application (NDA)) by July 1 of the year prior to the beginning of the fiscal year for which the application is being considered. Consistent with our longstanding policy, we consider FDA marketing authorization as representing that a product has received FDA approval or clearance when considering eligibility for the new technology add-on payment under §412.87(e)(2) (85 FR 58742).

Additionally, in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58739 through 58742), we finalized our proposal to provide conditional approval for new technology add-on payment for a technology for which an application is submitted under the alternative pathway for certain antimicrobial products at §412.87(d) that does not receive FDA marketing authorization by the July 1 deadline specified in §412.87(e)(2), provided that
the technology otherwise meets the applicable add-on payment criteria. Under this policy, cases involving eligible antimicrobial products would begin receiving the new technology add-on payment sooner, effective for discharges the quarter after the date of FDA marketing authorization provided that the technology receives FDA marketing authorization by July 1 of the particular fiscal year for which the applicant applied for new technology add-on payments.

As discussed in more detail in section I.E.9 of the preamble of this final rule, in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26779 through 26780), beginning with the new technology add-on payment applications for FY 2025, we proposed, for technologies that are not already FDA market authorized, to require applicants to have a complete and active FDA market authorization request at the time of application submission, and to provide documentation of FDA acceptance or filing to CMS at the time of application submission. We also proposed that, beginning with FY 2025 applications, in order to be eligible for consideration for the new technology add-on payment for the upcoming fiscal year, an applicant for new technology add-on payments must have received FDA approval or clearance by May 1 rather than July 1 of the year prior to the beginning of the fiscal year for which the application is being considered (except for an application that is submitted under the alternative pathway for certain antimicrobial products). Please refer to section I.E.9 of the preamble of this final rule for a full discussion of these proposals, the comments we received on these proposals, and our final policies.

e. New Technology Liaisons

Many interested parties (including device/biologic/drug developers or manufacturers, industry consultants, others) engage CMS for coverage, coding, and payment questions or concerns. In order to streamline engagement by centralizing the different innovation pathways within CMS including new technology add-on payments, CMS has established a team of new technology liaisons that can serve as an initial resource for interested parties. This team is available to assist with all of the following:

• Help to point interested parties to or provide information and resources where possible regarding process, requirements, and timelines.

• Coordinate and facilitate opportunities for interested parties to engage with various CMS components.

• Serve as a primary point of contact for interested parties and provide updates on developments where possible or appropriate.

We receive many questions from parties interested in pursuing new technology add-on payments who may not be entirely familiar with working with CMS. While we encourage interested parties to first review our resources available at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/newtech, we know that there may be additional questions about the application process. Interested parties with further questions about Medicare’s coverage, coding, and payment processes, and about how they can navigate these processes, whether for new technology add-on payments or otherwise, can contact the new technology liaison team at MedicareInnovation@cms.hhs.gov.

f. Application Information for New Medical Services or Technologies

Applicants for add-on payments for new medical services or technologies for FY 2025 must submit a formal request, including a full description of the clinical applications of the medical service or technology and the results of any clinical evaluations demonstrating that the new medical service or technology represents a substantial clinical improvement (unless the application is under one of the alternative pathways as previously described), along with a significant sample of data to demonstrate that the medical service or technology meets the high-cost threshold. CMS will review the application based on the information provided by the applicant under the pathway specified by the applicant at the time of application submission. Complete application information, along with final deadlines for submitting a full application, will be posted as it becomes available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/newtech.html.

To allow interested parties to identify the new medical services or technologies under review before the publication of the proposed rule for FY 2025, once the application deadline has closed, CMS will post on its website a list of the applications submitted, along with a brief description of each technology as provided by the applicant.

As discussed in the FY 2023 IPPS/LTCH PPS final rule (87 FR 48986 through 48990), we finalized our proposal to publicly post online new technology add-on payment applications, including the completed application forms, certain related materials, and any additional updated application information submitted subsequent to the initial application submission (except certain volume, cost and other information identified by the applicant as confidential), beginning with the application cycle for FY 2024, at the time the proposed rule is published. We also finalized that with the exception of information included in a confidential information section of the application, cost and volume information, and materials identified by the applicant as copyrighted and/or not otherwise releasable to the public, the contents of the application and related materials may be posted publicly, and that we will not post applications that are withdrawn prior to publication of the proposed rule. We refer the reader to the FY 2023 IPPS/LTCH PPS final rule (87 FR 48986 through 48990) for further information regarding this policy.

We note that the burden associated with this information collection requirement is the time and effort required to collect and submit the data in the formal request for add-on payments for new medical services and technologies to CMS. The aforementioned burden is subject to the PRA and approved under OMB control number 0938–1347, and has an expiration date of November 30, 2023.

2. Public Input Before Publication of a Notice of Proposed Rulemaking on Add-On Payments

Section 1886(d)(5)(K)(viii) of the Act, as amended by section 503(b)(2) of Public Law 106–173, provides for a mechanism for public input before publication of a notice of proposed rulemaking regarding whether a new medical service or technology represents a substantial clinical improvement. The process for evaluating new medical service and technology applications requires the Secretary to do all of the following:

• Provide, before publication of a proposed rule, for public input regarding whether a new service or technology represents an advance in medical technology that substantially improves the diagnosis or treatment of Medicare beneficiaries.

• Make public and periodically update a list of the services and technologies for which applications for add-on payments are pending.

• Accept comments, recommendations, and data from the public regarding whether a service or
technology represents a substantial clinical improvement.

• Provide, before publication of a proposed rule, for a meeting at which organizations representing hospitals, physicians, manufacturers, and any other interested party may present comments, recommendations, and data regarding whether a new medical service or technology represents a substantial clinical improvement to the clinical staff of CMS.

In order to provide an opportunity for public input regarding add-on payments for new medical services and technologies for FY 2024 prior to publication of the FY 2024 IPPS/LTCH PPS proposed rule, we published a notice in the Federal Register on October 3, 2022 (87 FR 59793), and held a virtual town hall meeting on December 14, 2022. In the announcement notice for the meeting, we stated that the opinions and presentations provided during the meeting would assist us in our evaluations by allowing public discussion of the substantial clinical improvement criterion for the FY 2024 new medical service and technology add-on payment applications before the publication of the FY 2024 IPPS/LTCH IPPS proposed rule.

Approximately 180 individuals registered to attend the virtual town hall meeting. We posted the recordings of the virtual town hall on the CMS website at: https://www.cms.gov/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/newtech.

We considered each applicant’s presentation made at the town hall meeting, as well as written comments received by the December 22, 2022, deadline, in our evaluation of the new technology add-on payment applications for FY 2024 in the development of the FY 2024 IPPS/LTCH PPS proposed rule. In response to the published notice and the December 14, 2022 New Technology Town Hall meeting, we received written comments regarding the applications for FY 2024 new technology add-on payments. As explained earlier and in the Federal Register notice announcing the New Technology Town Hall meeting (87 FR 59793 through 59795), the purpose of the meeting was specifically to discuss the substantial clinical improvement criterion with regard to pending new technology add-on payment applications for FY 2024. Therefore, we did not summarize any written comments in the proposed rule that were unrelated to the substantial clinical improvement criterion. In section II.E.6. of the preamble of the proposed rule, we summarized comments regarding individual applications, or, if applicable, indicating that there were no comments received in response to the New Technology Town Hall meeting notice or New Technology Town Hall meeting, at the end of each discussion of the individual applications.

3. ICD–10–PCS Section “X” Codes for Certain New Medical Services and Technologies

As discussed in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49434), the ICD–10–PCS includes a new section containing the new Section “X” codes, which began being used with discharges occurring on or after October 1, 2015. Decisions regarding changes to ICD–10–PCS Section “X” codes will be handled in the same manner as the decisions for all of the other ICD–10–PCS code changes. That is, proposals to create, delete, or revise Section “X” codes under the ICD–10–PCS structure will be referred to the ICD–10 Coordination and Maintenance Committee. In addition, several of the new medical services and technologies that have been, or may be, approved for new technology add-on payments may now, and in the future, be assigned a Section “X” code within the structure of the ICD–10–PCS. We posted ICD–10–PCS Guidelines on the CMS website at: https://www.cms.gov/Medicare/Coding/ICD10, including guidelines for ICD–10–PCS Section “X” codes. We encourage providers to view the material provided on ICD–10–PCS Section “X” codes.

4. New COVID–19 Treatments Add-On Payment (NCTAP)

In response to the COVID–19 public health emergency (PHE), we established the New COVID–19 Treatments Add-On Payment (NCTAP) under the IPPS for COVID–19 cases that meet certain criteria (85 FR 71157 through 71158). We believe that as drugs and biological products are authorized for emergency use or approved by FDA for the treatment of COVID–19 in the inpatient setting, it is appropriate to increase the current IPPS payment amounts to mitigate any potential financial disincentives for hospitals to provide new COVID–19 treatments during the PHE. Therefore, effective for discharges occurring on or after November 2, 2020 and until the end of the PHE for COVID–19, we established the NCTAP to pay hospitals the lesser of (1) 65 percent of the operating outlier threshold for the claim or (2) 65 percent of the amount by which the costs of the case exceed the standard DRG payment, including the adjustment to the relative weight under section 3710 of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, for certain cases that include the use of a drug or biological product currently authorized for emergency use or approved for treating COVID–19.

In the FY 2022 IPPS/LTCH PPS final rule, we finalized a change to our policy to extend NCTAP through the end of the FY in which the PHE ends for all eligible products in order to continue to mitigate potential financial disincentives for hospitals to provide these new treatments, and to minimize any potential payment disruption immediately following the end of the PHE. We also finalized that, for a drug or biological product eligible for NCTAP that is also approved for new technology add-on payments, we will reduce the NCTAP for an eligible case by the amount of any new technology add-on payments so that we do not create a financial disincentive between technologies eligible for both the new technology add-on payment and NCTAP compared to technologies eligible for NCTAP only (86 FR 45162). As the PHE ended on May 11, 2023, as planned by the Department of Health and Human Services (HHS), discharges involving products recommended to the ICD–10 Coordination and Maintenance Committee. In addition, several of the new medical services and technologies that have been, or may be, approved for new technology add-on payments may now, and in the future, be assigned a Section “X” code within the structure of the ICD–10–PCS. We posted ICD–10–PCS Guidelines on the CMS website at: https://www.cms.gov/Medicare/Coding/ICD10, including guidelines for ICD–10–PCS Section “X” codes. We encourage providers to view the material provided on ICD–10–PCS Section “X” codes.

Further information about NCTAP, including updates and a list of currently eligible drugs and biologicals, is available on the CMS website at https://www.cms.gov/Medicare/Coding/covid-19-new-covid-19-treatments-add-payment-nctap.

Comment: We received public comments related to NCTAP. A commenter expressed appreciation for continued NCTAP through Sept. 30, 2023. A few commenters recommended that CMS continue NCTAP, including a commenter who recommended that CMS continue NCTAP through December 31, 2023, in order to provide financial assistance for COVID–19 treatments as hospitals navigate the public health emergency (PHE) unwinding. A commenter also recommended that when NCTAP does end, that CMS automatically add any newly developed COVID–19 treatments to the new technology add-on payment list without application. Some

commenters recommended that CMS monitor Medicare beneficiaries’ access to COVID–19 treatments in the hospital inpatient setting after NCTAP expires to determine whether there is a reduction in beneficiaries’ access to treatment, with a commenter further recommending that CMS take steps to minimize any barriers that could restrict the ability of Medicare beneficiaries to receive lifesaving treatments after the sunsetting of the NCTAP and other COVID–19 payment adjustments.

Response: We thank the commenters for their input. In the FY 2022 IPPS/LTCH PPS final rule, we finalized a change to our policy to extend NCTAP through the end of the FY in which the PHE ends for all eligible products in order to continue to mitigate potential financial disincentives for hospitals to provide these new treatments, and to minimize any potential payment disruption immediately following the end of the PHE. We did not make any proposals to extend or modify NCTAP in this year’s proposed rule, and NCTAP will end on September 30, 2023, as previously finalized in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45160 through 45162). Further information about NCTAP, including updates and a list of currently eligible drugs and biologicals, is available on the CMS website at https://www.cms.gov/medicare/covid-19/new-covid-19-treatments-add-payment-nctap.

5. FY 2024 Status of Technologies Receiving New Technology Add-On Payments for FY 2023

In this section of the final rule, we discuss the FY 2024 status of 24 technologies approved for FY 2023 new technology add-on payments, as set forth in the tables that follow. In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26781 through 26785) we presented our proposals to continue the new technology add-on payments for FY 2024 for those technologies that were approved for the new technology add-on payment for FY 2023 and which would still be considered “new” for purposes of new technology add-on payments for FY 2024. We also presented our proposals to discontinue new technology add-on payments for FY 2024 for those technologies that were approved for the new technology add-on payment for FY 2023 and which would no longer be considered “new” for purposes of new technology add-on payments for FY 2024.

Additionally, we noted that we conditionally approved DefenCath™ (a formulation of taurolidine/heparin) for FY 2023 new technology add-on payments under the alternative pathway for certain antimicrobial products (87 FR 26955 through 26957), subject to the technology receiving FDA marketing authorization by July 1, 2023. In the FY 2024 IPPS/LTCH PPS proposed rule, we proposed that if DefenCath™ receives FDA marketing authorization before July 1, 2023, we would continue making new technology add-on payments for DefenCath™ for FY 2024. We proposed that if DefenCath™ does not receive FDA marketing authorization by July 1, 2023, then it would not be eligible for new technology add-on payments for FY 2023, and therefore would not be eligible for the continuation of new technology add-on payments for FY 2024. Because DefenCath™ did not receive FDA approval by July 1, 2023, no new technology add-on payments will be made for cases involving the use of DefenCath™ for FY 2023, and DefenCath™ is therefore not eligible for the continuation of new technology add-on payments for FY 2024. We note that the applicant for DefenCath™ also submitted an application for new technology add-on payments for FY 2024 under the name taurolidine/heparin, and we refer the reader to section II.E.7.b.(1) of the preamble of this final rule for discussion of our conditional approval of the FY 2024 application for new technology add on payments for taurolidine/heparin.

Our policy is that a medical service or technology may continue to be considered “new” for purposes of new technology add-on payments within 2 or 3 years after the point at which data begin to become available reflecting the inpatient hospital code assigned to the new service or technology. Our practice has been to begin and end new technology add-on payments on the basis of a fiscal year, and we have generally followed a guideline that uses a 6-month window before and after the start of the fiscal year to determine whether to extend the new technology add-on payment for an additional fiscal year. In general, we extend new technology add-on payments for an additional year only if the 3-year anniversary date of the product’s entry onto the U.S. market, relevant final rule citations from prior fiscal years, proposed maximum add-on payment amount, and coding assignments for each technology. We referred readers to the cited final rules in the following table for a complete discussion of the new technology add-on payment application, coding and payment amount for these technologies, including the applicable indications and discussion of the newness start date.

We invited public comments on our proposals to continue new technology add-on payments for FY 2024 for the technologies listed in the table in the proposed rule.

Comment: We received multiple comments in support of our proposed continuation of new technology add-on payments for FY 2024 for those technologies that were approved for the new technology add-on payment for FY 2023 and which would still be considered “new” for purposes of new technology add-on payments for FY 2024.

Response: We appreciate the commenters’ support.

After consideration of the public comments we received, we are finalizing our proposals to continue new technology add-on payments for FY 2024 for the technologies that were approved for new technology add-on payment for FY 2023 and which would still be considered “new” for purposes of new technology add-on payments for FY 2024, as listed in the proposed rule and in the following Table II.F.-01 in this section of this final rule.

Table II.F.-01 in this final rule presents the newness start date, new technology add-on payment start date, 3-year anniversary date of the product’s entry onto the U.S. market, relevant final rule citations from prior fiscal years, maximum add-on payment amount, and coding assignments. We refer readers to the final rules cited in the following table for a complete discussion of the new technology add-on payment application, coding and payment amount for these technologies, including the applicable indications and discussion of the newness start date.

BILLING CODE 4120–01–P
In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26785), we provided Table II.P-02 listing the technologies for which we proposed to discontinue making new technology add-on payments for FY 2024 because 3-year anniversary date will occur on or after April 1, 2024.

<table>
<thead>
<tr>
<th>Technology</th>
<th>Newness Start Date</th>
<th>NTAP Start Date</th>
<th>3-year Anniversary Date of Entry onto U.S. Market</th>
<th>Previous Final Rule Citations</th>
<th>Maximum NTAP Amount for FY 2024</th>
<th>Coding Used to Identify Cases Eligible for NTAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Intercept® (PRCF)</td>
<td>05/05/2021</td>
<td>10/1/2021</td>
<td>5/05/2024</td>
<td>86 FR 45149 through 45150 86 FR 67875 87 FR 48913</td>
<td>$2,535.00</td>
<td>30233D1 or 30243D1 in combination with one of the following D62, D65, D68.2, D68.4 or D68.9</td>
</tr>
<tr>
<td>2 Rybrevant™</td>
<td>05/21/2021</td>
<td>10/1/2021</td>
<td>05/21/2024</td>
<td>86 FR 44988 through 44996 87 FR 48913</td>
<td>$6,405.89</td>
<td>XW033B7 or XW043B7</td>
</tr>
<tr>
<td>3 StrataGraft®</td>
<td>06/15/2021</td>
<td>10/1/2021</td>
<td>06/15/2024</td>
<td>86 FR 45079 through 45090 87 FR 48913</td>
<td>$44,200.00</td>
<td>XHRPKF7</td>
</tr>
<tr>
<td>4 aprevo® Intervertebral Body Fusion Device</td>
<td>6/30/2021 (TLIF)</td>
<td>10/1/2021</td>
<td>6/30/2024 (TLIF)</td>
<td>86 FR 45127 through 45133 86 FR 67874 through 67876 87 FR 48913</td>
<td>$40,950.00</td>
<td>XRG0AR7 or XRGAR7 orXRGAR4R7 or XRGB0R7 or XRGB3R7 or XRGB4R7 or XRGCC7R7 or XRGCC7R7 or XRGCG7R7 or XRGCF7R7 or XRGDR7R7 or XRGDP3R7 or XRGDP4R7</td>
</tr>
<tr>
<td>5 Hemolung Respiratory Assist System (RAS)</td>
<td>11/15/2021 (other)</td>
<td>10/1/2022</td>
<td>11/15/2024 (other)</td>
<td>87 FR 48937 through 48948</td>
<td>$6,500.00</td>
<td>5AO920Z without U07.1*</td>
</tr>
<tr>
<td>6 Liventec™</td>
<td>12/2/2021</td>
<td>10/1/2022</td>
<td>12/2/2024</td>
<td>87 FR 48948 through 48954</td>
<td>$32,500.00</td>
<td>XWDX38 or XWG7338 or XWOH738</td>
</tr>
<tr>
<td>7 Thoraflex Hybrid Device</td>
<td>04/19/2022</td>
<td>10/1/2022</td>
<td>04/19/2025</td>
<td>87 FR 48974 through 48975</td>
<td>$22,750.00</td>
<td>X2RX0N7 in combination with X2QW0N7</td>
</tr>
<tr>
<td>8 ViviStim</td>
<td>04/29/2022</td>
<td>10/1/2022</td>
<td>04/29/2025</td>
<td>87 FR 48975 through 48977</td>
<td>$23,400.00</td>
<td>X0HQ3R8</td>
</tr>
<tr>
<td>9 GORE TAG Thoracic Branch Endoprosthesis</td>
<td>05/13/2022</td>
<td>10/1/2022</td>
<td>05/13/2025</td>
<td>87 FR 48966 through 48969</td>
<td>$27,807.00</td>
<td>02VW3D2 in combination with 02VX3EZ</td>
</tr>
<tr>
<td>10 Cerament® G</td>
<td>05/17/2022</td>
<td>10/1/2022</td>
<td>05/17/2025</td>
<td>87 FR 48961 through 48966</td>
<td>$4,918.55</td>
<td>XW0V0P7</td>
</tr>
<tr>
<td>11 iFuse Bedrock Granite Implant System</td>
<td>05/26/2022</td>
<td>10/1/2022</td>
<td>05/26/2025</td>
<td>87 FR 48969 through 48974</td>
<td>$9,828.00</td>
<td>XNH6058 or XNH6358 or XNH7058 or XNH7358 or XRG0E58 or XRG0E68 or XRG0F58 or XRG0F358</td>
</tr>
</tbody>
</table>

*As discussed in the following section, we are finalizing our proposal to discontinue new technology add-on payments for COVID-19 Hemolung RAS cases.
they are no longer “new” for purposes of new technology add-on payments. This table also presented the newness start date, new technology add-on payment start date, the 3-year anniversary date of the product’s entry onto the U.S. market, and relevant final rule citations from prior fiscal years. We referred readers to the cited final rules in the table for a complete discussion of each new technology add-on payment application and the coding and payment amount for these technologies, including the applicable indications and discussion of the newness start date.

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26784), we noted, as discussed in the FY 2023 IPPS/LTCH PPS final rule (87 FR 48939) and in previous rulemaking, the intent of section 1886(d)(5)(K) of the Act and regulations under § 412.87(b)(2) is to pay for new medical services and technologies for the first 2 to 3 years that a product comes on the market, during the period when the costs of the new technology are not yet fully reflected in the MS–DRG weights (69 FR 49002). While our policy is, generally, to begin the newness period on the date of FDA approval or clearance or, if later, the date of availability of the product on the U.S. market, as discussed in prior rulemaking (77 FR 53348), we have noted that data reflecting the costs of products that have received an emergency use authorization (EUA) could become available as soon as the date of the EUA issuance and prior to receiving FDA approval or clearance (86 FR 45159). With respect to the Hemolung RAS, which received an EUA on April 22, 2020, when used for patients with COVID–19, we discussed whether the newness period for the use of the Hemolung RAS for patients with COVID–19 should begin on the date of its EUA (April 22, 2020), when the product became available on the market for this indication. We described a public comment submitted by the applicant for Hemolung RAS which stated that the newness period for COVID–19 Hemolung RAS cases should begin on November 15, 2021 (the date of commercial availability of the De Novo classified device), instead of April 22, 2020 (the date of the Hemolung RAS EUA). The applicant indicated that it provided the Hemolung RAS to hospitals free or at cost to swiftly respond to the global pandemic, and that it did not profit from EUA therapies. The applicant stated that additionally, during the EUA period, hospitals receiving payment for Hemolung RAS therapy. The applicant stated that, therefore, cost data collected during the EUA period and prior to FDA clearance do not accurately reflect the added cost of Hemolung RAS therapy. In our response, we noted that, while the commenter stated that it provided the Hemolung RAS to hospitals free or at cost, and that hospitals were not seeking payment for the Hemolung RAS therapy during the EUA period, additional information regarding whether hospitals charged for use of the Hemolung RAS therapy between the date of its EUA and the date of commercial availability of the De Novo classified device, and how it impacts whether use of the technology may be reflected in the data, would be helpful in determining that data reflecting the cost of the product did not become available until the date of commercial availability of the De Novo classified device.

We stated in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26784), that in the absence of additional information to support a conclusion that data reflecting the cost of the Hemolung RAS when used for patients with COVID–19 did not begin to become available as of the issuance of the EUA on April 22, 2020, we were proposing to discontinue new technology add-on payments for FY 2024 for Hemolung RAS patients with hypercapnic respiratory failure related to COVID–19, as the technology will no longer be considered new for this indication. We further stated that, as discussed in the FY 2023 IPPS/LTCH PPS final rule, we continued to welcome additional information regarding whether hospitals charged for use of the Hemolung RAS therapy between the date of its EUA and the date of commercial availability of the De Novo classified device, and how it impacts whether use of the technology may be reflected in the data. We further noted, as set forth in Table II.P.-01 of the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26783), that we were proposing to continue new technology add-on payment in FY 2024 for the use of the Hemolung RAS for patients with other causes of hypercapnic respiratory failure unrelated to COVID–19, for which we considered the beginning of the newness period to commence on the date of commercial availability of the De Novo classified device (November 15, 2021), as discussed in the FY 2023 IPPS/LTCH PPS final rule (87 FR 48939). In order to identify use of Hemolung RAS unrelated to COVID–19, we proposed to identify cases eligible for new technology add-on payment with ICD–10–PCS code 5A0920Z without ICD–10–CM diagnosis code U07.1 (COVID–19).

We invited public comments on our proposals to discontinue new technology add-on payments for FY 2024 for the technologies listed in Table II.P.-02 in the proposed rule.

Comment: A commenter disagreed with defining the newness start date as the date of commercial availability/FDA approval date for cell and gene therapies, and requested that CMS extend new technology add-on payments into FY 2024 for both ABECMA® and CARVYKTI™ as the newness start date being utilized is extremely close to the mid-year benchmark and also likely to be functionally inaccurate. The commenter stated that while it does not have sales or ordering information for ABECMA® and CARVYKTI™, it believes that it is likely that the first commercial shipment of ABECMA® took place weeks after FDA approval (which occurred March 26, 2021) and would have crossed the April 1 threshold date, enabling these technologies to be eligible for a third year of add-on payments. The commenter explained that this delay is due to the fact that CAR T-cell products take weeks to manufacture, in addition to the certification of treatment sites as required under a product’s REMS. The commenter stated that it is far more logical to use the definition of “market date” described in the May 2023 Medicaid proposed rule with regard to covered outpatient drugs, which is the date on which the drug was first sold (88 FR 34257), for cell and gene therapies due to the unique manufacturing parameters. The commenter also requested that CMS consider a standard third-year extension of new technology add-on payments for cell and gene therapies in general, due to the unique manufacturing process and low volume nature of the diseases treated.

Response: We thank the commenter for its input. We note that the timeframe that a new technology can be eligible to receive new technology add-on payments begins when data become available (69 FR 49003, 85 FR 58610). Consistent with the statute, a technology no longer qualifies as “new” once it is more than 2 to 3 years old, irrespective of how frequently it has been used in the Medicare population. Therefore, if a product is more than 2 to 3 years old, we consider its costs to be included in the MS–DRG relative weights whether its use in the Medicare population has been frequent or infrequent. In addition, while CMS may consider a documented delay in the technology’s market availability in our determination of newness, our policy for determining
whether to extend new technology add-on payments for an additional year generally applies regardless of the volume of claims for the technology after the beginning of the newness period (83 FR 41280). We do not consider the date of first sale of a product, or first shipment of a product, as an indicator of the entry of a product onto the U.S. market; neither of these dates indicate when a technology in fact became available for sale. Similarly, our policy for determining whether to extend new technology add-on payments for a third year generally applies regardless of the claims volume for the technology after the start of the newness period (85 FR 58610). We further note that, as discussed in the FY 2023 IPPS/LTCH PPS final rule (87 FR 48911), in response to a comment from the applicant for Abecma® stating that the date of first sale for this technology was May 10, 2021, and that add-on payments for Abecma® should therefore extend past FY 2023, we requested additional information from the applicant for Abecma® on when the technology first became available for sale. We stated that, absent such additional information from the applicant, we cannot determine a newness date based on a documented delay in the technology’s availability on the U.S. market. The applicant did not submit further information related to the availability of Abecma® for this final rule, nor did the commenter provide such information. Accordingly, we are finalizing that we consider March 26, 2021, to be the date the technology became available on the market and the beginning of its newness period. As discussed in the FY 2023 IPPS/LTCH PPS final rule (87 FR 48925), because we determined that CARVYKTI™ is substantially similar to ABECMA®, we consider the beginning of the newness period for CARVYKTI™ to be March 26, 2021 as well.

Comment: A commenter requested that CMS consider at least another year of new technology add-on payments for aprevo™, which has a newness start date of December 3, 2020 for its ALIF and LLIF indications, as many surgeries were not performed in 2020 due to the COVID–19 pandemic. The commenter stated that with hospital revenue trending negatively, this is an opportunity for hospitals to provide exceptional care with appropriate reimbursement due to the clinical benefits of this technology.

Response: We thank the commenter for its input. Consistent with the statute and our implementing regulations, a technology is no longer considered as "new" once it is more than 2 to 3 years old, irrespective of how frequently the medical service or technology has been used in the Medicare population (70 FR 47349, 85 FR 58610). As such, once a technology has been available on the U.S. market for more than 2 to 3 years, we consider the costs to be included in the MS–DRG relative weights regardless of whether the technology’s use in the Medicare population has been frequent or infrequent. We further note that we are renewing the TLIF indication for aprevo™, which has a newness start date of June 30, 2021, for FY 2024 as noted in the previous table, as this indication will still be considered “new”.

After consideration of the public comments we received, we are finalizing our proposal to discontinue new technology add-on payments for the technologies as listed in the proposed rule and in the following Table II.F.-02 of this final rule for FY 2024 because they are no longer “new” for purposes of new technology add-on payments. This table also presents the newness start date, new technology add-on payment start date, the 3-year anniversary date of the product’s entry onto the U.S. market, and relevant final rule citations from prior fiscal years. We also refer readers to the final rules cited in the following table for a complete discussion of the new technology add-on payment application, coding and payment amount for these technologies, including the applicable indications and discussion of the newness start dates.
<table>
<thead>
<tr>
<th>Technology</th>
<th>Newness Start Date</th>
<th>NTAP Start Date</th>
<th>3-year Anniversary Date of Entry onto U.S. Market</th>
<th>Previous Final Rule Citations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>87 FR 48913</td>
</tr>
<tr>
<td>VEKLURY**</td>
<td>7/1/2020*</td>
<td>10/1/2021</td>
<td>7/1/2023</td>
<td>86 FR 45104 through 45116</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>87 FR 48909 through 48914</td>
</tr>
<tr>
<td>Zepezela™</td>
<td>6/15/2020</td>
<td>10/1/2021</td>
<td>6/15/2023</td>
<td>86 FR 45116 through 45126</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>87 FR 48912 through 48913</td>
</tr>
<tr>
<td>aScope® Duodeno</td>
<td>7/17/2020</td>
<td>10/1/2021</td>
<td>7/17/2023</td>
<td>86 FR 45133 through 45135</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>87 FR 48912 through 48916</td>
</tr>
<tr>
<td>Caption Guidance™</td>
<td>9/15/2020</td>
<td>10/1/2021</td>
<td>9/15/2023</td>
<td>86 FR 45135 through 45138</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>87 FR 48911 through 48913</td>
</tr>
<tr>
<td>aprevo® Intervertebral Body Fusion Device</td>
<td>12/3/2020 (ALIF and LLIF)</td>
<td>10/1/2021</td>
<td>12/3/2023 (ALIF and LLIF)</td>
<td>86 FR 45127 through 45133</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>86 FR 67874 through 67876</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>87 FR 48913</td>
</tr>
<tr>
<td>Cosela™</td>
<td>2/12/2021</td>
<td>10/1/2021</td>
<td>2/12/2024</td>
<td>86 FR 45008 through 45017</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>87 FR 48912 through 48913</td>
</tr>
<tr>
<td>ShockWave C2 Intravascular Lithotripsy (IVL) System</td>
<td>2/12/2021</td>
<td>10/1/2021</td>
<td>2/12/2024</td>
<td>86 FR 45151 through 45153</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>87 FR 48913</td>
</tr>
<tr>
<td>ABECMA®</td>
<td>3/26/2021</td>
<td>10/1/2021</td>
<td>3/26/2024</td>
<td>86 FR 45028 through 45035</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>87 FR 48911 through 48925</td>
</tr>
<tr>
<td>Harmony™ Transcatheter Pulmonary Valve (TPV) System</td>
<td>03/26/2021</td>
<td>10/1/2021</td>
<td>3/26/2024</td>
<td>86 FR 45146 through 45149</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>87 FR 48913</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>86 FR 67874 through 67876</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>87 FR 48914</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>86 FR 67876 through 67876</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>87 FR 48913</td>
</tr>
<tr>
<td>DARZALEX FASPRO®</td>
<td>01/15/2021</td>
<td>10/1/2022</td>
<td>01/15/2024</td>
<td>87 FR 48925 through 48937</td>
</tr>
<tr>
<td>CARVYKTR™</td>
<td>03/26/2021**</td>
<td>10/1/2022</td>
<td>03/26/2024</td>
<td>87 FR 48920 through 48925</td>
</tr>
<tr>
<td>Hemolung Respiratory Assist System (RAS)</td>
<td>04/22/2020 (COVID-19)</td>
<td>10/1/2022</td>
<td>04/22/2023 (COVID-19)</td>
<td>87 FR 48937 through 48948</td>
</tr>
</tbody>
</table>

*See discussion in the FY 2023 IPPS/LTCH PPS final rule (87 FR 48909 through 48914).

** As discussed in the FY 2023 IPPS/LTCH PPS final rule, because we determined that CARVYKTR™ is substantially similar to ABECMA®, we consider the beginning of the newness period for CARVYKTR™ to be March 26, 2021, which is the date that ABECMA® received FDA marketing authorization (87 FR 48925).
6. FY 2024 Applications for New Technology Add-On Payments (Traditional Pathway)

As discussed previously, in the FY 2023 IPPS/LTCH PPS final rule, we finalized our policy to publicly post online applications for new technology add-on payment beginning with FY 2024 applications (87 FR 48986 through 48990). As noted in the FY 2023 IPPS/LTCH PPS final rule, we stated in the proposed rule that we are continuing to summarize each application in the proposed rule. However, we stated that while we are continuing to provide discussion of the concerns or issues we identified with respect to applications submitted under the traditional pathway, we are providing more succinct information as part of the summaries in the proposed and final rules regarding the applicant’s assertions as to how the medical service or technology meets the newness, cost, and substantial clinical improvement criteria. We refer readers to https://mearis.cms.gov/public/publications/ntap for the publicly posted FY 2024 new technology add-on payment applications and supporting information (with the exception of certain cost and volume information, and information or materials identified by the applicant as confidential or copyrighted). In addition, we noted that we made available separate tables listing the ICD–10–CM codes, ICD–10–PCS codes, and/or MS–DRGs related to the analyses of the cost criterion for certain technologies for the FY 2024 new technology add-on payment applications in Table 10 associated with the FY 2024 IPPS/LTCH PPS proposed rule, available via the internet on the CMS website at https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientppps. Click on the link on the left side of the screen titled “FY 2024 IPPS Proposed Rule Home Page” or “Acute Inpatient—Files for Download.” Please see section VI of the Addendum of the proposed rule for additional information regarding tables associated with the proposed rule.

We received 27 applications for new technology add-on payments for FY 2024 under the traditional new technology add-on payment pathway. In accordance with the regulations under 412.87(e), applicants for new technology add-on payments must have received FDA approval or clearance by July 1 of the year prior to the beginning of the fiscal year for which the application is being considered. Eight applicants submitted their applications prior to the issuance of the proposed rule. Subsequently, four applicants withdrew their respective applications for sabizabulin, DuraGraft, VEST, and omidubicel prior to the issuance of this FY 2024 IPPS/LTCH PPS final rule. In addition, two applicants, Daiichi Sankyo and Pfizer, for Vanflyta and elranatamab respectively, did not receive FDA approval for their technologies by July 1, 2023. Therefore, Vanflyta and elranatamab are not eligible for consideration for new technology add-on payments for FY 2024. Consistent with our standard approach, we are not including in this final rule the description and discussion of applications that were withdrawn or that are ineligible for consideration for FY 2024 due to not meeting the July 1 deadline, described previously, which were included in the FY 2024 IPPS/LTCH PPS proposed rule. We are also not summarizing nor responding to public comments received regarding these withdrawn or ineligible applications in this final rule. Of the remaining 13 applications, we are not approving the applications for NexoBrid®, SeptiCyte® RAPID, and XENOVIEW® for the reasons discussed in the following sections. We are approving the remaining 10 applications, with 4 of the applications considered as 2 technologies due to substantial similarity, for a total of 8 new approvals for new technology add-on payments for FY 2024. A discussion of these 13 applications is presented in the following sections.

a. CYTALUX® (Pafolacianine), First Indication

On Target Laboratories submitted an application for new technology add-on payments for CYTALUX® for use in ovarian cancer for FY 2024. The applicant stated that CYTALUX® is the first targeted intraoperative molecular imaging agent that illuminates ovarian cancer in real time, enabling the detection of more cancer for resection. CYTALUX® is an optical imaging agent comprised of a folic acid analog conjugated with a fluorescent dye which binds to folate receptor positive cancer cells and illuminates malignant lesions during surgery. Per the applicant, CYTALUX® is used in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions. CYTALUX® is to be used with a near-infrared imaging system (NIR) cleared by the FDA for specific use with CYTALUX®. We note that On Target Laboratories also submitted a second application for new technology add-on payments for CYTALUX® for FY 2024 for use in lung cancer, as discussed separately in this section. Please refer to the online application posting for CYTALUX®, available at https://mearis.cms.gov/public/publications/ntap/NTP221017X8NAN, for additional detail describing the technology and the disease treated by the technology.

With respect to the newness criterion, the applicant stated that a new drug application (NDA) for CYTALUX® was approved by FDA on November 29, 2021, as an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions. According to the applicant, CYTALUX® had market availability delayed until April 15, 2022, due to supply/product availability. The recommended dose of CYTALUX® is a single intravenous infusion of 0.025 mg/kg diluted in 250 mL of 5% Dextrose Injection, administered prior to surgery over 60 minutes using a dedicated infusion line.

The applicant submitted a request for a unique ICD–10–PCS procedure code for CYTALUX® and was granted approval to use the following procedure codes effective October 1, 2023: 8E0U0EN (Fluorescence guided procedure of female reproductive system using pafolacianine, open approach), 8E0U3EN (Fluorescence guided procedure of female reproductive system using pafolacianine, percutaneous approach), 8E0U4EN (Fluorescence guided procedure of female reproductive system using pafolacianine, percutaneous endoscopic approach), 8E0U7EN (Fluorescence guided procedure of female reproductive system using pafolacianine, via natural or artificial opening), and 8E0U8EN (Fluorescence guided procedure of female reproductive system using pafolacianine, via natural or artificial opening endoscopic). The applicant provided a list of diagnosis codes that may be used to currently identify this indication for CYTALUX®, and differentiate it from the lung cancer indication, under the ICD–10–CM coding system. Please refer to the online application posting for the complete list of ICD–10–CM codes provided by the applicant.

As previously discussed, if a technology meets all three of the substantial similarity criteria under the newness criterion, it would be considered substantially similar to an existing technology and would not be considered “new” for the purpose of new technology add-on payments.

With respect to the substantial similarity criteria, the applicant believed that CYTALUX® is not substantially similar to other currently
available technologies because there are no other optical imaging agents with the same active ingredient, nor the same mechanism of action for the same indication of ovarian cancer, and that therefore, the technology meets the newness criterion. The following table summarizes the applicant’s assertions regarding the substantial similarity criteria. Please see the online application posting for CYTALUX® for the applicant’s complete statements in support of its assertion that CYTALUX® is not substantially similar to other currently available technologies.

<table>
<thead>
<tr>
<th>Substantial Similarity Criteria</th>
<th>Applicant Response</th>
<th>Applicant Assertions Regarding this Criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does the technology use the same or similar mechanism of action to achieve a therapeutic outcome?</td>
<td>No</td>
<td>There are no existing drugs/biological products that are used as an adjunct for intraoperative identification of malignant lesions in adults with ovarian cancer other than CYTALUX®. Furthermore, there is no other drug marketed under the same active ingredient category or generic name, nor which have the same mechanism of action to target the folate receptor to illuminate cancerous lesions.</td>
</tr>
<tr>
<td>Is the technology assigned to the same MS-DRG as existing technologies?</td>
<td>No</td>
<td>There are no existing drugs/biological products that are used as an adjunct for intraoperative identification of malignant lesions in adult ovarian cancer other than CYTALUX®. Furthermore, there is no other drug marketed under the same active ingredient category or generic name.</td>
</tr>
<tr>
<td>Does new use of the technology involve the treatment of the same/similar type of disease and the same/similar patient population when compared to an existing technology?</td>
<td>No</td>
<td>There are no existing drugs/biological products that are used as an adjunct for intraoperative identification of malignant lesions in adults with ovarian cancer other than CYTALUX®. Furthermore, there is no other drug marketed under the same active ingredient category or generic name.</td>
</tr>
</tbody>
</table>

We invited public comments on whether CYTALUX® is substantially similar to existing technologies and whether CYTALUX® meets the newness criterion.

Comment: The applicant reiterated that there are no existing FDA-approved drugs/biological products that are used as an adjunct for intraoperative identification of malignant lesions in adults with ovarian cancer other than CYTALUX®. The applicant also reiterated that there is no other drug marketed under the same active ingredient category or generic name, nor which has the same mechanism of action to target the folate receptor to illuminate cancerous lesions. In terms of newness, the applicant asserted that the appropriate newness date for CYTALUX® for ovarian cancer is April 15, 2022, the date on which a supply of CYTALUX® was first made available for sale. The applicant stated that CYTALUX® was approved for ovarian cancer in November 2021 but experienced a delay in commercialization primarily due to external circumstances. The applicant further explained that as CYTALUX® was not available before April 15, 2022, and there were no clinical uses of CYTALUX® between the date of FDA approval and its market entry, the newness period for the technology should begin on April 15, 2022.

In addition, the applicant noted that initial clinical use of CYTALUX® involved 20 cases that were performed at only three select centers between May and June 2022 during a small commercial pilot with remaining product lots manufactured specifically to support planned clinical development. The applicant explained that the batch of CYTALUX® expired at the end of June 2022, thereby rendering it impossible to perform additional cases. The applicant further explained that due to the removal of the FDA cleared imaging system for use with CYTALUX® from the market, a commercial lot was not initiated again until there was strong confidence that the FDA would approve CYTALUX® for lung cancer, and that therefore, the first full commercial lot was released in June 2023, coinciding with the newness date for CYTALUX® for lung cancer, as discussed separately in this section.

Response: We thank the applicant for its comment. Based on our review of comments received and information submitted by the applicant as part of its FY 2024 new technology add-on payment application for CYTALUX®, we agree with the applicant that CYTALUX® is the only adjunct for intraoperative identification of malignant lesions in adults with ovarian cancer with a mechanism of action to target the folate receptor to illuminate cancerous lesions. Therefore, we believe that CYTALUX® is not substantially similar to existing treatment options and meets the newness criterion. We consider the beginning of the newness period to commence when CYTALUX® became commercially available on April 15, 2022.

With respect to the cost criterion, to identify potential cases representing patients who may be eligible for CYTALUX®, the applicant searched the FY 2021 Inpatient Standard Analytic File (IPSAF) for cases reporting a combination of ICD–10–CM/PCS codes for ovarian cancer that may require an adjunct for intraoperative identification of malignant lesions. Using the inclusion/exclusion criteria described in the following table, the applicant identified 3,281 claims mapping to five MS–DRGs. The applicant noted that it limited its search to these five MS–DRGs as 99 percent of cases map to these MS–DRGs. Please see Table 10.8.A.—CYTALUX® (ovarian) Codes—FY 2024 associated with the proposed rule for the complete list of codes that the applicant indicated were included in its cost analysis. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $133,657, which exceeded the average case-weighted threshold amount of $93,649. Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount, the
applicant asserted that CYTALUX® meets the cost criterion.

<table>
<thead>
<tr>
<th>Data Source and Time Period</th>
<th>FY 2021 Inpatient Standard Analytic Files</th>
</tr>
</thead>
<tbody>
<tr>
<td>List of ICD-10-CM codes</td>
<td>Please see Table 10.8.A. – CYTALUX® (ovarian) Codes – FY 2024 associated with the proposed rule for the complete list of ICD-10-CM codes included in the cost analysis.</td>
</tr>
<tr>
<td>List of ICD-10-PCS codes</td>
<td>Please see Table 10.8.A. – CYTALUX® (ovarian) Codes – FY 2024 associated with the proposed rule for the complete list of ICD-10-PCS codes included in the cost analysis.</td>
</tr>
<tr>
<td>List of MS-DRGs</td>
<td>736 (Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy with MCC) 737 (Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy with CC) 738 (Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy without CC/MCC) 739 (Uterine, Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with MCC) 740 (Uterine, Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with CC)</td>
</tr>
<tr>
<td>Inclusion/exclusion criteria</td>
<td>The applicant searched for cases reporting a combination of ICD-10-CM/PCS codes for ovarian cancer that may require an adjunct for intraoperative identification of malignant lesions as listed in Table 10.8.A. – CYTALUX® (ovarian) Codes – FY 2024 associated with the proposed rule that mapped to MS-DRG 736-740. The applicant limited its search to these five MS-DRGs as 99% of cases map to these MS-DRGs. The applicant calculated the average unstandardized charge per case for each MS-DRG. Hospitals with less than 11 admissions had their volume data hidden.</td>
</tr>
<tr>
<td>Charges removed for prior technology</td>
<td>Per the applicant, CYTALUX® does not completely replace any current technology so no direct or indirect charges were removed.</td>
</tr>
<tr>
<td>Standardized charges</td>
<td>The applicant used the standardization formula provided in Technical Appendix A of the FY 2024 application. The applicant used all relevant values reported in the impact file and the standardization file posted with the FY 2023 IPPS/LTCH PPS final rule. Hospitals were removed from this calculation if they were not present within the FY 2023 Standardizing File provided by CMS.</td>
</tr>
<tr>
<td>Inflation factor</td>
<td>The applicant applied an inflation factor of 20.47% to the standardized charges, which is based on the inflation factor used to calculate outlier threshold charges in the FY 2023 IPPS/LTCH PPS final rule.</td>
</tr>
<tr>
<td>Charges added for the new technology</td>
<td>CYTALUX® is supplied as a single dose vial for IV administration and one vial is used per patient. The applicant added charges for the new technology by dividing the cost of the new technology by the national average cost-to-charge ratio of 0.184 for drugs from the FY 2023 IPPS/LTCH PPS final rule. The applicant did not add indirect charges related to the new technology.</td>
</tr>
</tbody>
</table>

We invited public comments on whether CYTALUX® meets the cost criterion.

Comment: The applicant submitted a public comment reiterating that because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount, CYTALUX® meets the cost criterion.

Response: We thank the applicant for its comment. We agree that the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount. Therefore, CYTALUX® meets the cost criterion.

With regard to the substantial clinical improvement criterion, the applicant asserted that CYTALUX® represents a substantial clinical improvement over existing technologies because CYTALUX® enables the surgeon to identify cancer intraoperatively in real time that otherwise would have been missed, enabling the surgeon to achieve more complete resection in cytoreductive surgery for ovarian cancer. Per the applicant, the results of the Phase 3 study confirm that CYTALUX® serves as an adjunct to the surgeon, helping them to identify additional cancer which otherwise would not have been identified, enabling the surgeon to achieve more complete resection, which is the goal of cytoreductive surgery. The applicant provided two studies to support these claims as well as 11 background articles. The background articles included studies to demonstrate the importance of removing all residual disease (lesions) to improve patients’ survival; studies that showed that lesions can be diffuse and numerous, of various sizes, and often not readily visible in the surgical field; a study that showed, when CYTALUX® was used in a murine tumor model and in early clinical studies, that it enabled identifying occult tumor nodules and showed potential to eliminate positive tumor margins; a study demonstrating the folate receptor was expressed in most ovarian cancers; and a study and a review supporting the use of fluorescence in real-time to improve cancer surgery. The following table summarizes the applicant’s assertions regarding the substantial clinical improvement criterion. Please see the online posting for CYTALUX® for the applicant’s complete statements regarding the substantial clinical improvement criterion and the supporting evidence provided.

23 Background articles are not included in the following table but can be accessed via the online posting for the technology.
<table>
<thead>
<tr>
<th>Applicant Statements in Support</th>
<th>Supporting Evidence Provided by the Applicant</th>
<th>Outcome(s) or Findings Cited by the Applicant from Supporting Evidence to Support its Statements</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CYTALUX</strong> Substantial Clinical Improvement supportive ovarian cancer data: The goal of cytoreductive surgery for ovarian cancer is to safely remove all cancer, to minimize recurrence, and improve survival rates</td>
<td>The applicant provided background information to support this claim, which can be accessed via the online posting for the technology.</td>
<td></td>
</tr>
<tr>
<td><strong>CYTALUX</strong> Substantial Clinical Improvement supportive ovarian cancer data: Optimal or complete cytoreduction relies on accurate detection and successful surgical resection of all lesions.</td>
<td>The applicant provided background information to support this claim, which can be accessed via the online posting for the technology.</td>
<td></td>
</tr>
<tr>
<td><strong>CYTALUX</strong> aided the surgeon by identifying additional cancer intraoperatively, in real time, enabling the surgeon to achieve a more complete resection in cytoreductive surgery for ovarian cancer.</td>
<td>Tanyi JL, Randall LM, Chambers SK, Butler KA, Winer IS, Langstraat CL, Han ES, Vahrmeijer AL, Chon HS, Morgan MA, Powell MA, Tseng JH, Lopez A, Wenham RM. A Randomized Phase 3 Study of Paclitaxel Injection (OTL38) for Intraoperative Imaging of Folate Receptor Positive Ovarian Cancer. J Clin Oncol. 2022. doi:10.1200/JCO.22.00291.</td>
<td>In 33.0% of patients (95% CI, 24.3 to 42.7; P &lt; .001), paclitaxel with near-infrared imaging identified additional cancer on tissue not planned for resection and not detected by white light assessment and palpation, exceeding the prespecified threshold of 10%. Paclitaxel, to the authors’ knowledge, is the first of a new class of intraoperative fluorescent imaging agents to improve detection of malignant lesions during surgery. The accumulation of evidence through the clinical development supports the introduction of targeted fluorescent imaging into the surgical theater to enhance completeness of surgical resection with the goal of improving survival.</td>
</tr>
<tr>
<td><strong>CYTALUX</strong> Substantial Clinical Improvement supportive ovarian cancer data: Targeted fluorescent</td>
<td>The applicant provided background information to support this claim, which can be accessed via the online posting for the technology.</td>
<td></td>
</tr>
</tbody>
</table>
### Substantial Clinical Improvement Assertion #1: This technology significantly improves clinical outcomes relative to services or technologies previously available.

<table>
<thead>
<tr>
<th>Applicant Statements in Support</th>
<th>Supporting Evidence Provided by the Applicant</th>
<th>Outcome(s) or Findings Cited by the Applicant from Supporting Evidence to Support its Statements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imaging agents have potential to enable surgeons to identify malignant lesions intraoperatively during interval debulking surgery after chemotherapy, CYTALUX® aided the surgeon by identifying additional cancer intraoperatively, in real time, enabling the surgeon to achieve more complete resection.</td>
<td>Randall LM, Wenham RM, Low PS, Dowdy SC, Tanyi JL. A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer. Gynecol Oncol. 2019 Oct;155(1):63-68. doi: 10.1016/j.ygyno.2019.07.010. Epub 2019 Jul 27. PMID: 31362825. Brief study description: A phase II, multicenter, open-label trial of OTL38 (a folate-indole-cyanine green-like conjugate to folate receptor alpha (FRA)) injection to assess the safety and efficacy (sensitivity and positive predictive value (PPV)) of OTL38 for intraoperative imaging during epithelial ovarian cancer surgery.</td>
<td>The proportion of women receiving neoadjuvant chemotherapy (NACT) prior to surgery has significantly increased from 8.6% to 22.6% between the years of 2004 and 2013 (p &lt; 0.001), and adoption of this treatment modality occurred primarily after 2007 (95%CI 2006–2009; p = 0.001).</td>
</tr>
<tr>
<td></td>
<td>Among patients who underwent interval debulking surgery, the rate was 39.7% (95% CI, 27.0 to 53.4; P &lt; .001).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pafolacianine, to the authors’ knowledge, is the first of a new class of intraoperative fluorescent imaging agents for improving detection of malignant lesions during surgery. The accumulation of evidence through the clinical development supports the introduction of targeted fluorescent imaging into the surgical theater to enhance completeness of surgical resection with the goal of improving survival.</td>
<td></td>
</tr>
</tbody>
</table>

---


---

In the FY 2024 IPPS/LTCH proposed rule (88 FR 26789 through 26790), after review of the information provided by the applicant, we stated we had the following concerns regarding whether CYTALUX® meets the substantial clinical improvement criterion. We noted that CYTALUX® showed a false positive rate of 24.8 percent that led to resections in the Phase 3, randomized, multicenter, single-dose, open-label study of this technology.24 While the applicant submitted a separate comment stating there was no worsening in the safety profile for patients with false positive results, we continued to question the impact on patient outcomes when taking additional tissues that were false positives. In addition, while the applicant provided background citations to support the assertion that optimal or improved cytoreduction of tumor results in improved survival in ovarian adenocarcinoma, we noted that the Phase 3 study of CYTALUX® appears to have been designed to assess the efficacy of the technology rather than clinical outcomes such as survival, recurrence, or rate of additional procedures. We noted that we would be interested in additional or longer-term data demonstrating that CYTALUX® results in improved outcomes such as improved survival or a reduced rate of recurrence to support an assessment of whether CYTALUX® represents a substantial clinical improvement.

Comment: Several commenters supported the application for CYTALUX®. A commenter explained that ovarian cancer remains the most lethal gynecologic cancer, and that complete surgical cytoreduction is the single most important prognostic indicator for survival. The commenter explained that although bulky disease can be easily recognized, sub-centimeter implants are often difficult to discriminate from adjacent normal tissue and may not be recognized and...
resected. The commenter further noted that intraoperatively, a surgeon has only two tools to improve the outcome of the tumor resections: visual inspection and palpation, and thus, surgeons need tools to augment these approaches. The commenter explained that the Phase 3 study of CYTALUX® demonstrates that the technology provides an important real-time adjunct to current surgical approaches for ovarian cancer, identifying malignant lesions that would not have been resected without CYTALUX®.

Another commenter stated that CYTALUX® allowed discovery of more lesions which were not seen with the naked eye and these lesions were removed safely to achieve the surgical goal of removal of all visible tumor. The commenter asserted that during interval debulking surgery after chemotherapy, as CYTALUX® improved detection of viable tumor from scar tissue, lesions were removed and sent for quick pathology evaluation, leading to an increase of surgical margins. The commenter stated that additional removal of lesions discovered by CYTALUX® use did not lead to an increase of surgical morbidities.

Response: We thank the commenters for their input and have taken it into consideration in determining whether CYTALUX® meets the substantial clinical improvement criterion, discussed later in this section.

Comment: The applicant submitted a public comment regarding the substantial clinical improvement criterion, and provided responses to concerns raised by CMS in the proposed rule. In response to concerns on how CYTALUX® improves health outcomes and changes patient management, the applicant asserted that CYTALUX® helps surgeons detect ovarian cancer that is currently undetectable during surgery, allowing them to diagnose and treat additional cancer lesions earlier. The applicant stated that in the CYTALUX® Phase 3 trial, the use of CYTALUX® identified additional ovarian cancer on tissue that was not part of the preoperative surgical plan and not otherwise planned for resection in 27 percent of imaged patients. The applicant stated that the surgeons involved in the Phase 3 study responded that use of CYTALUX® led to a revision in their surgical plan for 56 percent of patients and more complete debulking was achieved in 51 percent of patients. The applicant stated that identifying additional cancer on tissue not planned for resection in the preoperative plan led to a change in the management of the patient, allowing the surgeon to treat additional cancer which otherwise would have been left behind and may not have been discovered and treated until the patient presented with a recurrence. Therefore, the applicant believes that CYTALUX® not only allowed identification of cancerous lesions that would have otherwise remained undetected, but that it also may potentially shorten the amount of treatment time for a given patient by potentially reducing the risk of recurrence of ovarian cancer. The applicant asserted that CYTALUX® improves health outcomes through the more complete resection of residual disease. The applicant added that, consistent with the goal of achieving R0 (no remaining visible disease after surgery), following what surgeons deemed to be complete (R0) resection with conventional methods of identifying cancer during surgery, the surgeons indicated that intraoperative imaging with CYTALUX® enabled them to achieve “R(1)-” having found additional disease that they otherwise would not have found.

In addition, the applicant asserted that CYTALUX® improves health outcomes through the more complete resections of residual disease, which is supported by a wealth of peer-reviewed literature and longstanding bedrock principles relating to the treatment of cancer. The applicant stated that in the CYTALUX® Phase 3 trial, in 70 percent of patients in which additional ovarian cancer was detected by CYTALUX® and not by white light palpation, the specimen size of malignant lesions plus the tissue margin was greater than 1cm. The applicant stated that in its Phase 3 trial, CYTALUX® demonstrated the ability to aid surgeons by identifying additional cancer intraoperatively otherwise the surgeon and on tissue not planned for resection, in real time, enabling the surgeon to achieve a more complete resection in cytoreductive surgery for ovarian cancer and therefore improving clinical outcomes for these patients. According to the applicant, substantial clinical literature demonstrates that complete resections are associated with improved survival in ovarian cancer, with a steep drop in survival with residual tumors greater than 1 cm remaining following cytoreductive surgery. The applicant asserted that CYTALUX® is not a therapeutic agent, and stated that it therefore believes that long-term survival studies are not necessary to prove the clinical improvement CYTALUX® can add to help surgeons identify and diagnose additional cancer they may have otherwise missed, thus supporting them in achieving the surgical goal.

With regard to the false positive rates, the applicant asserted that CYTALUX®’s false positive rates do not meaningfully alter CYTALUX®’s significant clinical improvement analysis. The applicant conducted an analysis to compare false positives under white light palpation and CYTALUX® with NIR imaging. The applicant stated that rates and specimen size of false positives are comparable between those identified and removed by the surgeon under standard methods of white light and palpation and those identified and removed by the surgeon under NIR imaging with CYTALUX®.

The applicant stated that, for CYTALUX®, the presence of false positive results did not cause negative patient outcomes or additional unnecessary treatments as the removal of benign tissue is often a consequence of standard surgical resection. Additionally, the applicant stated that the false positive results after use of CYTALUX® were comparable to those following standard treatment; and the false positive results from use of CYTALUX® led to only a small amount of noncancerous tissue being removed.

Response: We thank the applicant for its comment and the additional information provided regarding the substantial clinical improvement criterion.

Based on the additional information received, we agree with the applicant and commenters that CYTALUX® represents a substantial clinical improvement over existing technology because CYTALUX® can detect ovarian cancer that is currently undetectable during surgery, which enables the surgeon to diagnose and treat additional cancer earlier, and affects the management of the patient by identifying additional ovarian cancer not otherwise planned for resection, leading to revisions in the surgical plan that result in more complete resection of the cancer.

After consideration of the information included in the applicant’s new technology add-on payment application
and the comments received, we have determined that CYTALUX® meets the criteria for approval for new technology add-on payment. Therefore, we are approving new technology add-on payments for this technology for FY 2024. Cases involving the use of CYTALUX® that are eligible for new technology add-on payments will be identified by ICD–10–PCS codes: 8E0U0EN (Fluorescence guided procedure of female reproductive system using paflacianine, open approach), 8E0U3EN (Fluorescence guided procedure of female reproductive system using paflacianine, percutaneous approach), 8E0U4EN (Fluorescence guided procedure of female reproductive system using paflacianine, Percutaneous endoscopic approach), 8E0U7EN (Fluorescence guided procedure of female reproductive system using paflacianine, via natural or artificial opening), or 8E0U8EN (Fluorescence guided procedure of female reproductive system using paflacianine, via natural or artificial opening endoscopic).

In its application, the applicant estimated that the cost of CYTALUX® is $4,250 per single-use vial (one vial is used per patient). Under § 412.86(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, the maximum new technology add-on payment for a case involving the use of CYTALUX® is $2,762.50 for FY 2024.

b. CYTALUX® (Paflacianine), Second Indication

On Target Laboratories submitted an application for new technology add-on payments for CYTALUX® for use in lung cancer for FY 2024. The applicant stated that CYTALUX® is the first targeted intraoperative molecular imaging agent that illuminates lung cancer in real time, enabling the detection of more cancer for resection. CYTALUX® is an optical imaging agent comprised of a folic acid analog conjugated with a fluorescent dye which binds to folate receptor positive cancer cells and illuminates malignant lesions during surgery. Per the applicant, CYTALUX® is used in adult patients with known or suspected cancer in the lung as an adjunct for intraoperative identification of pulmonary lesions. CYTALUX® is to be used with a NIR cleared by the FDA for specific use with CYTALUX®. CYTALUX® is used by surgeons to illuminate cancer in real time during surgery. We note that On Target Laboratories also submitted a separate application for new technology add-on payments for CYTALUX® for FY 2024 for use in ovarian cancer, as discussed previously in this section.

Please refer to the online application posting for CYTALUX®, available at https://mearis.cms.gov/public/publications/ntap/NTP221017ED6BY, for additional detail describing the technology and the disease treated by the technology.

With respect to the newness criterion, the applicant stated that CYTALUX® received FDA approval in a supplemental new drug application (sNDA), effective December 16, 2022, to include an additional indication for lung cancer, following approval of the original NDA for use in ovarian cancer. CYTALUX® is indicated as an adjunct for intraoperative identification of malignant and non-malignant pulmonary lesions in adult patient with known or suspected cancer in the lung. According to the applicant, CYTALUX® will have market availability delayed until approximately the middle of 2023 due to supply/product availability. The recommended dose of CYTALUX® is a single intravenous infusion of 0.025 mg/kg diluted in 250 mL of 5% Dextrose Injection, administered prior to surgery over 60 minutes using a dedicated infusion line. We noted that, as discussed previously, the applicant stated that CYTALUX® for ovarian cancer became commercially available on April 15, 2022. We were interested in additional information regarding whether the versions or formulations for CYTALUX® for use in lung cancer and ovarian cancer are different, or further explanation regarding the longer delay for the market availability for CYTALUX® for lung cancer.

The applicant submitted a request for unique ICD–10–PCS procedure codes for CYTALUX® and was granted approval to use the following procedure codes effective October 1, 2023: 8E0W0EN (Fluorescence guided procedure of trunk region using paflacianine, open approach), 8E0W3EN (Fluorescence guided procedure of trunk region using paflacianine, percutaneous approach), 8E0W4EN (Fluorescence guided procedure of trunk region using paflacianine, Percutaneous endoscopic approach), 8E0W7EN (Fluorescence guided procedure of trunk region using paflacianine, via natural or artificial opening), and 8E0W8EN (Fluorescence guided procedure of trunk region using paflacianine, via natural or artificial opening endoscopic). The applicant provided a list of diagnosis codes that may be used to currently identify this indication for CYTALUX®, and differentiate it from the ovarian cancer indication, under the ICD–10–CM coding system. Please refer to the online application posting for the complete list of ICD–10–CM codes provided by the applicant.

As previously discussed, if a technology meets all three of the substantial similarity criteria under the newness criterion, it would be considered substantially similar to an existing technology and would not be considered “new” for the purpose of new technology add-on payments.

With respect to the substantial similarity criteria, the applicant believed that CYTALUX® is not substantially similar to other currently available technologies because there are no other optical imaging agents with the same active ingredient, nor same mechanism of action, for the same indication, and that therefore, the technology meets the newness criterion. The following table summarizes the applicant’s assertions regarding the substantial similarity criteria. Please see the online application posting for CYTALUX® for the applicant’s complete statements in support of its assertion that CYTALUX® is not substantially similar to other currently available technologies.

BILLING CODE 4120–01–P
We invited public comments on whether CYTALUX® is substantially similar to existing technologies and whether CYTALUX® meets the newness criterion.

Comment: The applicant submitted a public comment regarding the newness criterion. The applicant reiterated that there are no existing FDA approved drugs/biological products that are used as an adjunct for intraoperative identification of malignant and non-malignant pulmonary lesions in adult patients with known or suspected cancer in the lung other than CYTALUX®. The applicant also reiterated that there is no other drug marketed under the same active ingredient category or generic name, nor which has the same mechanism of action to target the folate receptor to illuminate cancerous lesions in the lung. In terms of newness, the applicant asserted that the appropriate newness date for CYTALUX® for lung cancer is June 5, 2023, the date CYTALUX® became available for purchase. The applicant explained that while CYTALUX® was approved in December 2022 to assist surgeons in identifying lung lesions in adult patients with known or suspected lung cancer, the product has never been sold or made available to the market after its approval for use in lung cancer. As discussed previously in this section, the applicant explained that although the use of CYTALUX® for ovarian cancer was briefly available on the market for a small limited pilot of 20 cases from April through June 2022 at three select centers, the technology was subsequently taken off the market due to the market withdrawal of the necessary imaging system, and therefore a commercial lot of CYTALUX® was not initiated again until there was strong confidence that the FDA would approve CYTALUX® for use in lung cancer. The applicant further stated that on June 5, 2023, the first commercial lot of CYTALUX® became available for use in lung cancer. The applicant asserted that therefore, because CYTALUX® was not available on the market following FDA approval of CYTALUX® for lung cancer, the appropriate newness date for CYTALUX® for lung cancer would be June 5, 2023, the market availability of the product.

Response: We thank the applicant for its comments. Based on our review of comments received and information submitted by the applicant as part of its FY 2024 new technology add-on payment application for CYTALUX®, we agree with the applicant that CYTALUX® is the only adjunct for intraoperative identification of malignant and non-malignant pulmonary lesions in adult patients with known or suspected cancer in the lung with a mechanism of action to target the folate receptor to illuminate cancerous lesions in the lung. Therefore, we believe that CYTALUX® is not substantially similar to existing treatment options and meets the newness criterion. We consider the beginning of the newness period to commence when CYTALUX® became commercially available on June 5, 2023.

With respect to the cost criterion, to identify potential cases representing patients who may be eligible for CYTALUX®, the applicant searched the FY 2021 IPSAF for cases reporting a combination of ICD–10–CM/PCS codes for malignant or suspected lung lesions. Using the inclusion/exclusion criteria described in the following table, the applicant identified 15,033 claims mapping to three MS–DRGs. The applicant noted that it limited its search to these three MS–DRGs as 99 percent of cases map to these MS–DRGs. Please see Table 10.9.A.—CYTALUX® (lung) Codes—FY 2024 associated with the proposed rule for the complete list of codes that the applicant included in its cost analysis. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $122,700, which exceeded the average case-weighted threshold amount of $101,584. Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount, the applicant asserted that CYTALUX® meets the cost criterion.
**CYTALUX® COST ANALYSIS**

<table>
<thead>
<tr>
<th>Data Source and Time Period</th>
<th>FY 2021 Inpatient Standard Analytic Files</th>
</tr>
</thead>
<tbody>
<tr>
<td>List of ICD-10-CM codes</td>
<td>Please see Table 10.9.A. – CYTALUX® (lung) Codes – FY 2024 associated with the proposed rule for the complete list of ICD-10-CM codes included in the cost analysis.</td>
</tr>
<tr>
<td>List of ICD-10-PCS codes</td>
<td>Please see Table 10.9.A. – CYTALUX® (lung) Codes – FY 2024 associated with the proposed rule for the complete list of ICD-10-PCS codes included in the cost analysis.</td>
</tr>
<tr>
<td>List of MS-DRGs</td>
<td>163 (Major Chest Procedures with MCC) 164 (Major Chest Procedures with CC) 165 (Major Chest Procedures without CC MCC)</td>
</tr>
<tr>
<td>Inclusion/exclusion criteria</td>
<td>The applicant searched for cases reporting a combination of ICD-10-CM/PCS codes for malignant or suspected lung lesions as listed in Table 10.9.A. – CYTALUX® (lung) Codes – FY 2024 associated with the proposed rule that mapped to MS-DRG 163-165. The applicant limited its search to these three MS-DRGs as 99% of cases map to these MS-DRGs. The applicant calculated the average unstandardized charge per case for each MS-DRG. Hospitals with less than 11 admissions had their volume data hidden.</td>
</tr>
<tr>
<td>Charges removed for prior technology</td>
<td>Per the applicant, CYTALUX® does not replace any current technology so no direct or indirect charges were removed.</td>
</tr>
<tr>
<td>Standardized charges</td>
<td>The applicant used the standardization formula provided in Technical Appendix A of the FY 2024 application. The applicant used all relevant values reported in the impact file and the standardization file posted with the FY 2023 IPPS/L.TCH PPS final rule. Hospitals were removed from this calculation if they were not present within the FY 2023 Standardizing File provided by CMS.</td>
</tr>
<tr>
<td>Inflation factor</td>
<td>The applicant applied an inflation factor of 20.47% to the standardized charges, which is based on the inflation factor used to calculate outlier threshold charges in the FY 2023 IPPS/L.TCH PPS final rule.</td>
</tr>
<tr>
<td>Charges added for the new technology</td>
<td>CYTALUX® is supplied as a single dose vial for IV administration and one vial is used per patient. The applicant added charges for the new technology by dividing the cost of the new technology by the national average cost-to-charge ratio of 0.184 for drugs from the FY 2023 IPPS/L.TCH PPS final rule. The applicant did not add indirect charges related to the new technology.</td>
</tr>
</tbody>
</table>

We invited public comments on whether CYTALUX® meets the cost criterion.

**Comment:** The applicant submitted a comment reiterating that because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount, CYTALUX® meets the cost criterion.

**Response:** We thank the applicant for its comment. We agree that the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount. Therefore, CYTALUX® meets the cost criterion.

With regard to the substantial clinical improvement criterion, the applicant asserted that CYTALUX® represents a substantial clinical improvement over existing technologies because CYTALUX® enables the surgeon to visualize cancer intraoperatively, in real time, that otherwise may have gone undetected. Per the applicant, the use of the CYTALUX® during pulmonary resection for lung cancer represents a significant potential advancement over current standards of surgery by enhancing the intraoperative localization of pulmonary nodules, improving the ability to remove them with clean margins, and reducing the probability of leaving otherwise undetected malignant synchronous lesions behind. The applicant provided six studies to support these claims and nine background articles. The background articles included studies about the importance of complete cancer tissue resection to overall survival, the limitations of thoracoscopic surgery by localizing the exact location of a pulmonary nodule for resection, the low 5-year survival for lung cancer patients, and the high rates of local recurrence after lung cancer surgery; one study demonstrating that contrasted chest computed tomography (CT) scan is not sufficient to identify pulmonary nodules that need resection; one study supporting the need for cleaner margins during resection to reduce local recurrence of lung cancer; one study supporting the use of the folate receptor as an appropriate tumor specific marker; one study indicating that folate-targeted agents may have a place in cancer treatment before, as well as, after chemotherapy; and a study showing that the folate receptor is expressed in the majority of lung cancers and that CYTALUX® targets and binds to folate receptors and thus the mechanism of action is a viable target for lung cancer.27 The following table summarizes the applicant’s assertions regarding the substantial clinical improvement criterion. Please see the online posting for CYTALUX® for the applicant’s complete statements regarding the substantial clinical improvement criterion and the supporting evidence provided.

---

27 Background articles are not included in the following table but can be accessed via the online posting for the technology.
**Substantial Clinical Improvement Assertion #1:** This technology significantly improves clinical outcomes relative to services or technologies previously available.

<table>
<thead>
<tr>
<th>Applicant Statements in Support</th>
<th>Supporting Evidence Provided by the Applicant</th>
<th>Outcome(s) or Findings Cited by the Applicant from Supporting Evidence to Support its Statements</th>
</tr>
</thead>
<tbody>
<tr>
<td>In 29% of subjects, CYTALUX® impacted the overall scope of the surgical procedure.</td>
<td>Singhal S, Martin L, Rice D, Blackmon S, Murthy S, Gangadharan S, Reddy R, Sarkaria I. Randomized, Multi Center Phase 3 Trial of Paflolanine during Intraoperative Molecular Imaging of Cancer in the Lung: Results of the ELUCIDATE Trial. AATS 102nd Annual Meeting. Boston MA. May 2022. Brief study description: A prospective study with 112 patients to evaluate the efficacy and safety of CYTALUX®.</td>
<td>The investigators indicated a change in scope in the surgical procedure based on IMI with paflolanine for 29% (22% increase, 7% decrease) of the patients. In the group randomized to IMI paflolanine, there were 8/78 (10%) NSCLC patients whose stage was changed due to the CSE. Study CSEs were counted as: IMI with paflolanine (i) localized the index lung nodule that could not be located by white light, (ii) identified a synchronous malignant lesion, or (iii) identified a close surgical margin (&lt;= 10mm).</td>
</tr>
</tbody>
</table>

**CYTALUX® Substantial Clinical Improvement supportive lung cancer data: High rates of recurrence/poor survival in part due to incomplete resection of disease**

The applicant provided background information to support this claim, which can be accessed via the online posting for the technology.

**Clinically Significant Events (CSE) occurred in 54% of**

Manuscript in preparation on the ELUCIDATE trial. Brief study description:

One or more clinically significant events (CSE) occurred in 53% of evaluated participants compared to a prespecified
| Patients with the use of CYTALUX<sup>®</sup>. | A Phase III, 12-center trial with 112 patients to determine the clinical utility of paclitaxel, a folate receptor (FR)-targeted fluorescent agent, in revealing by intraoperative molecular imaging (IMI) FRα positive cancers in the lung and narrow surgical margins that may otherwise be undetected with conventional visualization. Limit of 10% (p < 0.0001). In 38 participants, at least one was a margin ≤10 mm from the resected primary nodule (38%, 95% CI 28.5 – 48.3), 32 being confirmed by histopathology. In 19 subjects (19%, 95% CI 11.8 – 28.1), IMI located the primary nodule that the surgeon could not locate with white light and palpation. IMI revealed 10 occult synchronous malignant lesions in 8 subjects (8%, 95% CI 3.5 – 15.2) undetected using white light. Most (73%) IMI-discovered synchronous malignant lesions were outside the planned resection field. A change in the overall scope of surgical procedure occurred for 29 of the subjects (22 increase, 7 decrease). |
| CYTALUX<sup>®</sup> Substantial Clinical Improvement Supportive Lung Cancer Data: The Folate Receptor (FR) is an appropriate tumor specific marker for Non-Small Cell Lung Cancer (NSCLC) | The applicant provided background information to support this claim, which can be accessed via the online posting for the technology. |
| In 9% of subjects, surgeons identified a synchronous lesion with CYTALUX<sup>®</sup> that was not identified with conventional methods. | Singhal S, Martin L, Rice D, Blackmon S, Murthy S, Gangadharan S, Reddy R, Sarkaria I. Randomized, Multi Center Phase 3 Trial of Paclitaxel during Intraoperative Molecular Imaging of Cancer in the Lung: Results of the ELUCIDATE Trial. AATS 102nd Annual Meeting. Boston MA. May 2022. See prior study description |
| In 9% of subjects, surgeons identified a synchronous lesion with CYTALUX<sup>®</sup> that was not identified with conventional methods. | IMI with paclitaxel identified occult synchronous malignant lesions in nine patients (9%, 95% CI 4.2 – 16.4). Most (73%) IMI-identified synchronous malignant lesions were outside the planned field of resection. |
| In 38% of the subjects, a close surgical resection margin was detected with CYTALUX<sup>®</sup>. | Brief study description: A study with 50 patients with pulmonary nodules to examine whether IMI with a folate receptor targeted near-infrared contrast agent (OTL38<sup>®</sup>) can improve malignant pulmonary nodule identification when combined with PET. In this study, CYTALUX<sup>®</sup> identified 56 of 59 (94.9%) malignant pulmonary nodules identified by preoperative imaging. CYTALUX<sup>®</sup> located an additional 9 malignant lesions not identified preoperatively. Nodules only detected by CYTALUX<sup>®</sup> were smaller than nodules detected preoperatively (0.5 vs 2.4 cm; P < 0.01) but displayed similar fluorescence (tumor-to-background ratio 3.3 and 3.1; P = 0.50). Sensitivity of IMI and PET were 95.6% and 73.5% (P < 0.001), respectively; and positive predictive values were 94.2% and 89.3%, respectively (P > 0.05). Additionally, utilization of IMI clinically upstaged 6 (12%) subjects and improved management of 15 (30%) subjects. These data suggest that combining CYTALUX<sup>®</sup> with PET may provide superior oncologic outcomes for patients with resectable lung cancer. |
| In 38% of the subjects, a close surgical resection margin was detected with CYTALUX<sup>®</sup>. | Per the applicant, IMI with CYTALUX<sup>®</sup> found 38 patients with close margins ≤10 mm (38%, 95% CI 28.5 – 48.3). See prior study description |
In the FY 2024 IPPS/LTCH proposed rule (88 FR 26795), after review of the information provided by the applicant, we stated we had the following concerns regarding whether CYTALUX® meets the substantial clinical improvement criterion. We noted that CYTALUX® showed a false positive rate

<table>
<thead>
<tr>
<th>In 19% of subjects, surgeons localized primary lesions with CYTALUX® that otherwise were undetected by conventional methods.</th>
<th>The results of this study demonstrated that CYTALUX® is reliable for intraoperative lesion localization and margin identification. In 40 patients, conventional surgical methods localized 22 of 40 lesions (55%), while CYTALUX® localized 36 of 40 (90%). Of 18 nonpalpable lesions, CYTALUX® identified 15 (83.3%). Both palpable and nonpalpable lesions demonstrated mean signal-to-background ratio more than 2. A CYTALUX® margin was able to be calculated for 39 of 40 patients (95%). CYTALUX® margins were nearly identical to margins reported on final pathology (R2 = 0.9593), with median (interquartile range) difference of 1.3 (0.7-2.0) mm. CYTALUX® detected 2 margins in nonpalpable tumors that were clinically unacceptable and would have had a high probability of recurrence.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Predina JD, Newton A, Corbett C, Xia L, Sulyok LF, Shin M, Deshpande C, Litzky L, Barbosa E, Low PS, Kucharzczuk JC, Singhal S. Localization of Pulmonary Ground-Glass Opacities with Folate Receptor-Targeted Intraoperative Molecular Imaging. J Thorac Oncol. 2018 Jul;13(7):1028-1036. Doi: 10.1016/j.jtho.2018.03.023. Epub 2018 Apr 4. PMID: 29626619. PMCID: PMC6015787. Brief study description: A clinical trial exploring an alternative method involving near-infrared molecular imaging with a folate receptor–targeted agent, OTL38, to improve localization of GGOs and confirmation of resection margins.</td>
<td>The study demonstrated that of the 21 GGOs, 20 accumulated CYTALUX® and displayed fluorescence upon in situ or back table evaluation. Intraoperatively, near-infrared imaging localized 15 of 21 lesions whereas standard methods localized 10 of 21 (p = 0.05). The addition of molecular imaging affected care of nine (9) of 21 subjects by improving intraoperative localization (n = 6) and identifying close margins (n = 3).</td>
</tr>
<tr>
<td>Kennedy GT, Azari FS, Bernstein E, Marfatia I, Din A, Deshpande C, Galvis N, Sorger J, Kucharzczuk JC, Singhal S. First-in-human results of targeted intraoperative molecular imaging for visualization of ground glass opacities during robotic pulmonary resection. Transl Lung Cancer Res. 2022 Aug;11(8):1567-1577. doi: 10.21037/tlcr-21-1004. PMID: 36090642. PMCID: PMC9459620. Brief study description: A pilot study to determine whether IMI during RATS (RIMI) can localize GGOs.</td>
<td>As lung cancer screening rates rise, GGOs are becoming increasingly common. These types of lesions are particularly challenging to localize during surgery because they are not fully solid, and thus difficult to palpate. This paper demonstrated that CYTALUX® identified tumor-specific fluorescence in 100% (10/10) subjects in the study, whereas traditional methods identified the nodule in 70% (7/10) subjects.</td>
</tr>
</tbody>
</table>
of 25.8 percent that led to resections in the Phase 3, multicenter study of this technology.29 While the applicant submitted a separate comment stating there was no worsening in the safety profile for patients with false positive results, we continued to question the impact on patient outcomes when taking additional tissues that were false positive. We noted that the authors discussed in the results of the Phase 3 trial that there was a decreased rate of subsequent diagnostic intervention. We questioned if they were referring to fewer resections in future surgical procedures, and/or if this also implied a subsequent positive outcome of reduced mortality. While the studies provided in support of CYTALUX® measure identification of lesions and changes in the scope of the surgical procedure, we noted that the applicant did not provide data indicating that these endpoints directly lead to improved clinical outcomes (for example, reduction in mortality, hospitalizations, subsequent procedures, and/or rate of recurrence) based on use of CYTALUX®. Rather, we stated that improved outcomes were inferred by relying on the assumption that increased or decreased scope of resection results in better outcomes. We noted that we were interested in additional information or long-term data measuring the impact of the technology on treatment outcomes or the management of the patient to support that CYTALUX® results in an improvement over the standard of care.

We invited public comments on whether CYTALUX® meets the substantial clinical improvement criterion.

Comment: The applicant submitted a public comment regarding the substantial clinical improvement criterion and provided responses to CMS’s concerns from the proposed rule. With regard to improvement of patient management, the applicant asserted that CYTALUX® objectively improves surgeons’ management of the patient through enabling use of tissue-sparing procedures and by helping surgeons to identify and more completely resect undetected cancerous lesions during surgery. The applicant stated that as demonstrated in the Phase 3 ELUCIDATE trial, use of CYTALUX® allowed surgeons to localize the primary lesion in 19 percent of patients whose lesion could not be seen by white light and otherwise localized by the surgeon using standard techniques and a positive/close margin (<10mm from the resection line) in 38 percent of patients.29

In addition, the applicant asserted that the surgeon was able to identify the lesion more quickly with CYTALUX® as compared to preoperative localization techniques, thus improving the management of the patient through reducing the amount of time the patient is under anesthesia. The applicant stated that in the Phase 3 ELUCIDATE trial, the median time to localize the primary nodule was 1 minute (range <1–23), compared with another study showing that the mean procedural time for robotic navigational bronchoscopy, which is a preferred method for preoperative localization, was 67 minutes (range 37–97).30 Moreover, the applicant asserted that CYTALUX® aids surgeons’ ability to perform tissue-sparing procedures by providing visualization of the precise location and borders of the tumor, which helps surgeons determine where to resect tissue while ensuring a proper margin. The applicant stated that results from the Phase 3 ELUCIDATE trial indicated the maximum depth of lesions detected by CYTALUX® alone was 27.9mm increasing to 37.7mm with both CYTALUX® and white light while the minimum size of lesions identified by CYTALUX® and not by standard white light was as small as 2mm for synchronous lesions and 5mm for primary lesions.31 The applicant stated that Phase 2 and Phase 2 clinical trial data showed CYTALUX® increased the surgeon’s ability to detect the primary lesion intraoperatively from 72 percent to 94 percent of patients. The applicant stated that across all lesions in the Phase 2 and Phase 3 trials, 94 percent were folate receptor alpha or beta positive, demonstrating the efficacy of CYTALUX®’s mechanism of action across a multitude of cancer histologies in both primary lung cancer and metastatic disease.

Additionally, the applicant asserted that appropriate staging is a critical area to guide long-term treatment plans adjuvant to surgery, since correct staging ensures improved patient care, enabling earlier notification of the extent of disease and faster time to optimal treatment. According to the applicant, in clinical trials, CYTALUX® detected additional synchronous malignant lesions which were not identified on preoperative imaging. The applicant stated that one trial, the detection of 9 synchronous lesions in 8 percent of patients (n = 7 out of 92) resulted in each of the 7 patients being upstaged, enabling alterations to adjuvant treatment plans to reflect the greater extent of disease.32 The applicant stated that in the Phase 3 ELUCIDATE trial, CYTALUX® allowed the surgeon to identify one more or additional synchronous malignant lesions that were previously undetected on preoperative scans or intraoperatively in 8 percent of patients, with the majority outside the planned field of resection.33 In response to concerns on improvement of patient outcomes, the applicant claimed that CYTALUX® improves health outcomes through the more complete resection of otherwise undetected cancer, which is supported by substantial peer-reviewed literature and longstanding bedrock principles relating to the treatment of cancer. According to the applicant, CYTALUX® improves surgeons’ ability to treat the disease more completely via resection, which thereby may reduce the risk of recurrence and has the potential to increase the likelihood of patient survival by assisting the surgeon to overcome each of these established surgical challenges. The applicant stated that among the Phase 3 ELUCIDATE participants, 53 percent had a clinically significant event from use of CYTALUX®: in 19 percent of patients, CYTALUX® was able to localize the primary lesion otherwise not found by the surgeon using standard techniques; in 8 percent of patients, CYTALUX® identified an unknown occult synchronous lesions; and in 36 percent...


of patients, CYTALUX® was able to identify a close resection margin less than or equal to 10 mm. The applicant stated that use of CYTALUX® led to a change in the overall scope of surgical procedure for 29 percent of patients. In response to CMS’s questioning if the noted CYTALUX® “decreased rate of subsequent diagnostic intervention” refers to “fewer resections in future surgical procedure, and/or if this also implies a subsequent positive outcome of reduced mortality”, the applicant stated that the ELUCIDATE trial was not designed to follow patients long term to determine reduction in additional procedures, oncologic outcomes, nor mortality rates. According to the applicant, considering existing preoperative procedures commonly utilized today to provide localization aides to surgeons, CYTALUX® has the potential to reduce preoperative localization procedures, including endobronchial dye marking, microcoil placement, fiducial marker placement, and transbronchial percutaneous hook wire placement. The applicant stated that the ELUCIDATE phase 3 trial demonstrated that, without the use of CYTALUX, synchronous malignant lesions would have been left behind in 8 percent of patients, confirming similar findings from the phase 2 trial. The applicant stated that as the synchronous lesions increased in size, they would have been identified on follow up scans, and additional surgeries are likely to have been required to remove these lesions increasing the risk of complication and mortality in these patients. The applicant stated that the ability to perform a more complete resection during the initial procedure using a targeted imaging agent has the potential to reduce the need for future intervention (for example, additional surgery) and the associated morbidity risks thus addressing the goal of the surgeon and patients.

With regards to CMS’s concerns about false positives, the applicant stated that false positive rates for CYTALUX® do not meaningfully alter the substantial clinical improvement analysis presented in the application. The applicant stated that in the Phase 3 trial, the false positive rate for primary lesions in patients with confirmed cancer was low, at 1.4 percent, demonstrating the ability of CYTALUX® to correctly identify malignant lesions with multiple histologies in the lung, and that in patients with suspected or confirmed cancer in the lung, the false positive rate was 12.7 percent. Per the applicant, the difference between 1.4 percent and the 12.7 percent accounts for situations in which the patient did not have a confirmed diagnosis prior to surgery. Additionally, the applicant stated that clinical trial results across 769 patients from multiple clinical trials with CYTALUX® showed there were no drug-related serious adverse events among participants. The applicant stated that patients who had false positive lesions removed showed no associated increase in respiratory or pulmonary adverse events as compared to events occurring during standard care resections. The applicant also asserted that the presence of false positive results did not cause negative patient outcomes. The applicant stated that additionally, the false-positive results after use of CYTALUX® were comparable to those following standard treatment without CYTALUX®.

We also received several additional comments in support of the application for CYTALUX®, stating that the technology represents a substantial clinical improvement over existing technologies. These commenters stated that the Phase 3 trial presented in the application for CYTALUX® highlighted key challenges in the operative landscape namely localization of lesions, margin control and occult synchronous lesions. Commenters stated that CYTALUX® facilitates minimally invasive lung cancer surgery, improves the ability to detect smaller than 1 cm tumors and otherwise undetectable lesions without unreliable procedurally placed surrogates (for example, percutaneous wires, dye-marking, or coils) or larger procedures to locate lesions. Commenters asserted that CYTALUX® is easy for patients because they just undergo intravenous safe infusion of a medication preoperatively. Commenters asserted that CYTALUX® demonstrated a better option to visualize results directly compared to advanced imaging or standard visualization techniques that fail to reveal occult lesions during initial operative intervention. Commenters stated that CYTALUX® allowed the discovery of synchronous adenocarcinomas that were not identified by standard CT scan procedures, aided in confirming the location of a metastatic renal cell carcinoma lesion in the lung of a patient and allowed more precise detection and localization of lesions both for primary lung cancer and metastatic disease to the lung (pancreatic adenocarcinoma and pleomorphic liposarcoma). Commenters stated that CYTALUX® provided surgeons the ability to visually assess margin distance to ensure an adequate margin was obtained in real time. A commenter asserted that CYTALUX® allows the surgeon to see the tumor during staple firing to visualize the margin prior to a point that could leave an inadequate margin or require moving to a full lobectomy procedure. Commenters believed that CYTALUX® can transform surgical techniques, increase operative efficiency, and decrease risk for local recurrence or inaccurate staging. Commenters believed that CYTALUX® offers the possibility to improve cancer surgery outcomes by enabling surgeons to better identify primary tumors, detect occult synchronous lesions, ensure adequate margins of resection, and ensure resection of a related lesion that will upstage the cancer and likely necessitate adjuvant systemic therapy. A commenter stated that CYTALUX® will impact patient outcomes now that more sublobar resections are occurring as a result of earlier diagnosis of lung lesions. Another commenter encouraged CMS to assign new technology add-on payment status for new technologies like CYTALUX® supporting personalized medicine; stating this will remove barriers to accessing innovative tools that advance this approach to care. Another commenter believed that false positives are not significantly impactful, as very little tissue is removed to determine histology, and added that as more experience is gained with CYTALUX®, surgeons will learn how to better interpret the intraoperative imaging. Response: We thank the applicant and other commenters for their comments regarding the substantial clinical improvement criterion.

Based on the additional information received, we agree with the applicant that CYTALUX® represents a substantial clinical improvement over existing technology because CYTALUX® can identify lung cancer that is otherwise undetectable using standard methods, which enables more precise removal of
the cancer by the surgeon and affects patient management, as the detection of synchronous lesions using CYTALUX® results in the upstaging of patient care, enabling alterations to adjuvant treatment plans to reflect the greater extent of disease.

After consideration of the information included in the applicant’s new technology add-on payment application, we have determined that CYTALUX® meets the criteria for approval for new technology add-on payment. Therefore, we are approving new technology add-on payments for this technology for FY 2024. Cases involving the use of CYTALUX® that are eligible for new technology add-on payments will be identified by ICD–10–PCS codes: 8E0W0EN (Fluorescence guided procedure of trunk region using pafolacianine, open approach), 8E0W3EN (Fluorescence guided procedure of trunk region using pafolacianine, percutaneous approach), 8E0W4EN (Fluorescence guided procedure of trunk region using pafolacianine, percutaneous endoscopic approach), 8E0W7EN (Fluorescence guided procedure of trunk region using pafolacianine, via natural or artificial opening), or 8E0W8EN (Fluorescence guided procedure of trunk region using pafolacianine, via natural or artificial opening endoscopic).

In its application, the applicant estimated that the cost of CYTALUX® is $4,250 per single-use vial (one vial is used per patient). Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, the maximum new technology add-on payment for a case involving the use of CYTALUX® is $2,762.50 for FY 2024.

c. EPKINLY™ (Epcoritamab-bysp) and COLUMVTM (Glofitamab-gxbm)

Two manufacturers, Genmab US and Genentech, Inc., submitted separate applications for new technology add-on payments for FY 2024 for EPKINLY™ (epcoritamab-bysp) and COLUMVTM (glofitamab-gxbm), respectively. We note that we discussed both of these technologies in the proposed rule at 88 FR 26809 and 26816 using their generic names, epcoritamab and glofitamab, respectively, which received FDA Marketing Authorization after the proposed rule and are updated to EPKINLY™ (epcoritamab-bysp) and COLUMVTM (glofitamab-gxbm), respectively in this final rule. Both of these technologies are bispecific antibodies used for the treatment of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after two or more prior therapies, with COLUMVTM specifically targeting the largest subset of LBCL, diffuse LBCL (DLBCL). The bispecific antibodies directly bind two types of clusters of differentiation CD simultaneously, CD20 expressing B-cells and CD3 expressing T-cells, to induce activation, proliferation and cytotoxic activity of the T-cells against the malignant B-cells. In the FY 2024 IPPS/LTCPPS proposed rule we discussed these applications as two separate technologies. After further consideration and as discussed later in this section, we believe EPKINLY™ and COLUMVTM are substantially similar to each other and that it is appropriate to evaluate both technologies as one application for new technology add-on payments under the IPPS. We refer the reader below for a complete discussion regarding our analysis of the substantial similarity of EPKINLY™ and COLUMVTM.


With respect to the newness criterion, the applicant for EPKINLY™ stated that it was seeking Biologic License Application (BLA) approval from FDA for the treatment of adult patients with R/R LBCL after two or more lines of systemic therapy. The applicant for EPKINLY™ stated that EPKINLY™ is intended for subcutaneous administration with patients receiving 0.16 milligram (mg) priming and 0.87 mg intermediate dose before the first full dose of 48 mg. This is administered weekly in cycles one through three, every 2 weeks in cycles four through nine, and every 4 weeks in cycles 10 and onward until disease progression. According to the applicant, in the EPCORE NHL–1 study, all patients were required per protocol to be hospitalized for 24 hours on the third dose, which was the first full dose of 48 mg. According to the applicant, the mean per patient dose, including when provided during or related to inpatient stays across all 28 injection visits, is 44.61 mg. The applicant subsequently received BLA approval from FDA for EPKINLY™ on May 19, 2023, for the indication of treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.

With regard to COLUMVTM, the applicant received BLA approval from FDA on June 15, 2023, for the indication of treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma after two or more lines of systemic therapy. The applicant for COLUMVTM stated that COLUMVTM is administered as an intravenous infusion through a dedicated infusion line according to a dose step-up schedule leading to the recommended dosage of 30 mg, after completion of pre-treatment with obinutuzumab on cycle day 1, where each cycle is 21 days. The applicant recommends treatment for a maximum of 12 cycles or until the disease progresses to unmanageable toxicity. According to the applicant, the administration of COLUMVTM will be treated as part of an inpatient stay and reimbursed through the DRG: when a patient is admitted within 72 hours of the outpatient administration to treat a condition that results from the administration such as developing grade two or higher cytokine release syndrome (CRS). The applicant stated that, in clinical trials, when Grade 2, 3, or 4 CRS developed, 69 percent of the time it occurred after a 2.5 mg dose, 27 percent of the time it developed after a 10 mg dose, and 4 percent after a 30 mg dose. Therefore, according to the applicant, the expected average dose of COLUMVTM associated with an inpatient hospital stay is (2.5 mg * 0.69) + (10 mg * 0.27) + (30 mg * 0.04)) = 5.625 mg.

The applicant for EPKINLY™ submitted a request for a unique ICD–10–PCS code for EPKINLY™ beginning in FY 2024 and was granted approval for the following procedure code effective October 1, 2023: XW013S9 (Introduction of epcoritamab monoclonal antibody into subcutaneous tissue, percutaneous approach, new technology group 9). The applicant for COLUMVTM submitted a request for a unique ICD–10–PCS code for COLUMVTM beginning in FY 2024 and was granted approval for the following procedure code effective October 1, 2023: XW033P9 (Introduction of glofitamab antineoplastic into peripheral vein, percutaneous approach, new technology group 9 and XW043P9 (Introduction of glofitamab antineoplastic into central vein, percutaneous approach, new technology group 9). The applicants provided lists of diagnosis codes that may be used to
currently identify the indication for EPKINLY™ and COLUMVI™ under the ICD–10–CM coding system. Please refer to the online application postings for the complete list of ICD–10–CM codes provided by each applicant.

As stated earlier and for the reasons discussed further later in this section, we believe that EPKINLY™ and COLUMVI™ are substantially similar to each other such that it is appropriate to analyze these two applications as one technology for purposes of new technology add-on payments, in accordance with our policy. We discuss the information provided by the applicants, as summarized in the proposed rule, regarding whether EPKINLY™ and COLUMVI™ are substantially similar to existing technologies prior to their approval by the FDA and their release onto the U.S. market. As discussed earlier, if a technology meets all three of the substantial similarity criteria, it would be considered substantially similar to an existing technology and would not be considered “new” for purposes of new technology add-on payments.

With respect to the substantial similarity criteria, whether a product uses the same or a similar mechanism of action to achieve a therapeutic outcome, the applicant for EPKINLY™ asserted that the mechanism of action of EPKINLY™ is not the same as or similar to an existing technology. The applicant described EPKINLY™ as an anti-CD3xCD20 bispecific antibody with a unique mechanism of action that will be the first of its kind for the treatment of R/R LBCL. The following table summarizes the applicant’s assertions regarding the substantial similarity criteria. Please see the online application posting for EPKINLY™ for the applicant’s complete statements in support of its assertion that EPKINLY™ is not substantially similar to other currently available technologies.

<table>
<thead>
<tr>
<th>Substantial Similarity Criteria</th>
<th>Applicant Response</th>
<th>Applicant’s assertions regarding this criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does the technology use the same or similar mechanism of action to achieve a therapeutic outcome?</td>
<td>No</td>
<td>EPKINLY™ has a novel mechanism of action compared to any approved therapy for R/R LBCL. Currently, there are no approved anti-CD3xCD20 bispecific antibodies. In the non-immune activating class of LBCL therapies, EPKINLY™ shares the mechanism of targeting lymphoma cells through binding of antibodies with the monoclonal antibodies (mAbs). POLIVY™ and ZYNLONTA™ are both antibody drug conjugates (ADC), relying on the internalization and release of a cytotoxic agent to induce cell death. Moreover, POLIVY™ targets CD79b and ZYNLONTA™ targets CD19. Small molecule chemotherapies are the largest class of therapies for LBCL. While being non-immune activating therapies, they are defined as small molecules compared to the biologic, EPKINLY™.</td>
</tr>
</tbody>
</table>

1. Non-Immune Activating Therapies

1.A. Small molecule chemotherapies include REVIMID®, XPOVIO®, cyclophosphamide, doxorubicin, vincristine, prednisone, gemcitabine, bendamustine, oxaliplatim, and etopoide. Small molecule chemotherapies inhibit critical cellular functions associated with cell division, inducing cell death.

1.B. mAbs

1.B.i. POLIVY™ is an anti-CD79b antibody conjugated to the cytotoxic agent MMAE. Upon binding CD79b, POLIVY™ releases MMAE and induces cell death.

1.B. ii. ZYNLONTA™ is an anti-CD19 antibody conjugated to the cytotoxic agent PBD. After binding CD19, ZYNLONTA™ releases PBD and induces cell death. EPKINLY™ is an immune activating LBCL therapy within the class of CD19 and CD20 therapies. CD19 therapies include CAR T-cell therapy and Monjuvi™, both of which have a wholly different mechanism of action compared to epcritamab. Within the immune
<table>
<thead>
<tr>
<th>Substantial Similarity Criteria</th>
<th>Applicant Response</th>
<th>Applicant’s assertions regarding this criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>activating CD20, only rituximab is approved for LBCL. Rituximab is a mAb, while epocitamab is a CD3xCD20 bispecific antibody.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2. Immune Activating Therapies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.A. CD-19 Therapies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.A.i. CAR T-cell Therapies: YESCARTA™, KYMRIAH™, and Breyanzi™ are genetically modified autologous T-cell therapies that express an anti-CD19 extracellular domain to enable thetargeting and binding of cytotoxic T-cells to the surface of CD19 expressing B-cells, killing CD19 expressing B-cells.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.A. ii. Anti-CD19 Antibodies: Monjuvi™ is an anti-CD19 mAb that binds to CD19, which is highly expressed in malignant B-cells. After binding CD19, Monjuvi™ stimulates cytotoxicity of CD19 expressing cells.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.B. CD-20 Therapies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.B.i. Rituximab is an anti-CD20 mAb that binds to CD20, which is expressed on mature B-cells, including malignant B-cells. After binding, rituximab stimulates cytotoxicity through direct binding and CD20 inhibition and through Natural Killer (NK) cells and T-cell mediated cytotoxicity or macrophage phagocytosis.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.B. ii. EPKINLY™ is an anti-CD3xCD20 bispecific antibody enabling the simultaneous binding of a CD3 T-cell and a CD20 B-cell, thereby inducing T-cell activation and cytotoxic activity. Only National Comprehensive Cancer Network (NCCN) recommended therapies were included.</td>
</tr>
<tr>
<td>Is the technology assigned to the same MS-DRG as existing technologies?</td>
<td>Yes</td>
<td>Potential cases of patients who may be eligible for EPKINLY™ treatment would be assigned to the same MS-DRGs as cases representing patients who currently receive FDA-approved therapies.</td>
</tr>
<tr>
<td>Does new use of the technology involve the treatment of the same/similar type of disease and the same/similar patient population when compared to an existing technology?</td>
<td>Yes</td>
<td>EPKINLY™ will be for the treatment of R/R LBCL patients, including diffuse large B-cell lymphoma (DLBCL), HGBCL, PMBC, and G3B FL who have failed at least two previous treatments. Standard of care (SOC) for the treatment of these patients is chemoimmunotherapy regimen, however, 20-50% of patients are refractory or will relapse, and these patients consistently have poor clinical outcomes. While there are existing therapies approved for 3L+ LBCL patients (summarized in Substantial Clinical Improvement section), the unmet need for this population is quite high as a significant number of patients are unresponsive to currently available treatments. EPKINLY™ is poised to address this high unmet need by providing a safe and effective treatment option for a highly refractory patient population. See Substantial Clinical Improvement section for more info. Only NCCN recommended therapies are included here. Three FDA approved CAR T therapies are currently indicated for the treatment of 3L+ R/R LBCL:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1) Breyanzi™ — Indicated for adults with LBCL, including DLBCL not otherwise specified (NOS) &amp; DLBCL arising from indolent lymphoma, HGBCL, PMBC, and G3b FL, refractory to 1L chemotherapy or that relapses within 12 months of chemotherapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2) KYMRIAH™ — Indicated for adult patients with R/R LBCL after two or more lines of systemic therapies, including DLBCL NOS, HGBCL, and DLBCL arising from FL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3) YESCARTA™ — Indicated for adults with LBCL refractory to 1L chemotherapy or relapse within 12 months of chemotherapy, R/R LBCL after two or more systemic therapies, including DLBCL NOS, PMBC, HGBCL, and DLBCL arising from FL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other currently approved drugs for patients who have failed at least two therapies (that is, 3L+ therapies) are POLIVY™, XPOVIO™, and ZYNLONTA™:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1) POLIVY™ — Indicated for adults with R/R DLBCL NOS, including DLBCL arising from FL after at least two lines of systemic therapies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2) XPOVIO™ — Indicated for adults with R/R DLBCL NOS, including DLBCL arising from FL after at least two lines of systemic therapies</td>
</tr>
</tbody>
</table>
The applicant for COLUMVI™ asserted that COLUMVI™ offers a novel mechanism of action for the treatment of R/R DLBCL with two or more prior lines of therapy patients and is not substantially similar to other currently available technologies because the mechanism of action of COLUMVI™ is distinct from other available DLBCL therapies because COLUMVI™ does not treat the same or similar type of disease or patient population, and that therefore, the technology meets the newness criterion. The applicant’s assertions regarding substantial similarity are summarized briefly in the following table. Please see the online application posting for COLUMVI™ for the applicant’s complete statements in support of its assertion that COLUMVI™ is not substantially similar to other currently available technologies.

<table>
<thead>
<tr>
<th>Substantial Similarity Criteria</th>
<th>Applicant Response</th>
<th>Applicant’s assertions regarding this criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does the technology use the same or similar mechanism of action to achieve a therapeutic outcome?</td>
<td>No</td>
<td>COLUMVI™ has a mechanism of action that involves binding simultaneously to the target B-cell (via CD20 which are expressed on the cell surface of B-cells) and an effector T-cell (via CD3, expressed on the surface of T-cells). Upon binding to both cells, the T-cell is activated to kill the bound B-cell. At least two other investigational bispecific antibodies have similar mechanisms of action. However, to date, there have been no other bispecific antibody approved for the treatment of DLBCL. So, to date, COLUMVI™ mechanism of action does not resemble that of any approved therapy in the treatment of DLBCL. COLUMVI™ is the only anti-CD20/CD3 bispecific antibody that has a 2:1 structural configuration. This means that there are two CD20 binding domains on the COLUMVI™ Fab region and one CD3 binding domain and its binding to CD20 is bivalent. This is in contrast to traditional bispecific antibodies which have a 1:1 configuration. The unique structure of COLUMVI™ and its high avidity to CD20 contribute to its activity in vitro (up to 40x potency in cell killing compared to traditional bispecific antibodies with 1:1 configuration) and the structure may also contribute to its clinical characteristics in terms of efficacy, safety and combinability with other anti-CD20 molecules. COLUMVI™ is distinct from the BITE molecules (such as blinatumomab) because, unlike the BITEs (which are protein fragments), COLUMVI™ is a full-length antibody molecule, which contributes to the stability of the COLUMVI™ molecule in vivo and allows for a once-every-21-day dosing schedule. Blinatumomab (anti-CD19, CD3 bispecific BITE) requires continuous dosing. To date, there have been no BITE molecules that are indicated for the treatment of patients with DLBCL. Chimeric antigen receptor (CAR)-T therapies are live-cell therapies that also engage T-cells in their mechanism of action. In contrast to CAR T-cell therapy, COLUMVI™ does not entail a weeks-long manufacturing turn-around time, and physicians can readily access COLUMVI™ for their patients “off-the-shelf,” which is particularly beneficial for patients with aggressive disease who need treatment immediately. In addition, because COLUMVI™ is not manufactured for an individual patient, product manufacture and supply can be consistent.</td>
</tr>
</tbody>
</table>
In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26811 and 88 FR 26817), we noted that EPKINLY™ and COLUMVI™ may have a similar mechanism of action, for the treatment of adult patients with R/R LBCL/DLBCL after three or more prior lines of therapy. We noted that COLUMVI™’s mechanism of action is described as bivalent binding of CD20 on malignant B-cells and CD3 on T-cells, bringing them into close proximity inducing proliferation and targeted killing of B-cells. According to COLUMVI™’s application, the 2:1 structure of COLUMVI™ enables high-avidity, bivalent binding to CD20 that can result in activity against malignant B-cells even under low effector-to-target cells. Because of the potential similarity with the mechanism of binding of the CD3xCD20 bispecific antibody and other actions, we stated our belief that COLUMVI™’s mechanism of action may be the same or similar to that of COLUMVI™. While the applicant for COLUMVI™ stated that the use of COLUMVI™ does not involve treatment of the same or similar patient population when compared to existing technology, there are existing therapies approved for LBCL/DLBCL patients with three or more lines of therapy including CAR-T-cell therapies and others such as POLIVY®, XPOVIO®, and ZYNLONTA®. We therefore stated our belief that COLUMVI™ may treat the same or similar patient population as these existing FDA-approved treatments.

We further stated our belief that EPKINLY™ and COLUMVI™ may treat the same or similar disease (LBCL/DLBCL) in the same or similar patient population (R/R patients who have previously received two or more lines of therapy), which is also the same disease and population as existing treatments for R/R LBCL. Accordingly, we stated that as it appears that EPKINLY™ and COLUMVI™ are purposed to achieve the same therapeutic outcome using the same or similar mechanism of action and would be assigned to the same MS-DRG, we believed that these technologies may be substantially similar to each other and therefore should be considered as a single application for purposes of new technology add-on payments.

We invited public comment on whether EPKINLY™ and COLUMVI™ meet the newness criterion, including whether EPKINLY™ and COLUMVI™ are substantially similar to each other and therefore should be evaluated as a single technology for purposes of new technology add-on payments.

Comment: The applicant for EPKINLY™ submitted a letter maintaining that EPKINLY™ meets the newness criterion, including whether EPKINLY™ and COLUMVI™ are substantially similar to each other and therefore should be considered as a single application for purposes of new technology add-on payments. We were interested in information on how these two technologies may differ from each other with respect to the substantial similarity criteria and newness criterion, to inform our analysis of whether EPKINLY™ and COLUMVI™ are substantially similar to each other and therefore should be considered as a single application for purposes of new technology add-on payments.

### Substantial Similarity Criteria

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Applicant Response</th>
<th>Applicant assertions regarding this criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is the technology assigned to the same MS-DRG as existing technologies?</td>
<td>Yes</td>
<td>COLUMVI™ and existing therapies for 3L+ DLBCL could be assigned to the same MS-DRGs.</td>
</tr>
<tr>
<td>Does new use of the technology involve the treatment of the same/similar type of disease and the same/similar patient population when compared to an existing technology?</td>
<td>No</td>
<td>COLUMVI™ will fill an unmet need left by other 3L+ DLBCL approved therapies. Therefore, the use of COLUMVI™ in 3L+ R/R DLBCL does not involve the treatment of the same or a similar type of disease or the same or similar patient population when compared to an existing technology. Although there are approved therapies for treatment of R/R DLBCL, there is no standard of care. The prognosis of patients with R/R disease is poor, with overall survival being less than 10-12 months. The median age at diagnosis of DLBCL is 66 years, an age in which a significant number of patients have a history of other malignancies and comorbidities. In general, this is a difficult to treat patient population. Additionally, by the time patients reach 3L+, they have had multiple prior therapies, are frequently relapsed after or are refractory to chemoimmunotherapy (CIT), anti-CD20s, ASCt, and CAR T-cell therapy. The patient population in the pivotal NCT03075696 study demonstrated the efficacy of COLUMVI™ in heavily pretreated and highly refractory patients, a cohort that reflects patients requiring 3L+ treatment in the real world. The median age of patients enrolled in the NCT03075696 study was 66 years (range 21-90); 54% were aged ≥65 years. All patients had prior anti-CD20 therapy (100%), 96.8% had anthracycline (CIT), 33% had CAR T-cell therapy, and 18.2% had a prior autologous stem cell transplantation (ASCT). Most patients were refractory to the last prior therapy (85.7%), with 29.9% refractory to prior CAR T-cell therapy. Furthermore 58.4% were refractory to 1L therapy, a historically hard-to-treat patient population with poor outcomes. Responses to COLUMVI™ treatment were achieved across all patient subpopulations.</td>
</tr>
</tbody>
</table>
therapies primarily affect either cellular processes or functions of rapidly dividing cells through interference with DNA, RNA, or protein synthesis. We note that the applicant did not discuss whether it believed EPKINLY™ is substantially similar to COLUMVI™ in its comment.

The applicant for COLUMVI™ submitted a letter maintaining that COLUMVI™ meets the newness criterion. With respect to whether COLUMVI™ uses the same or a similar mechanism or action when compared to an existing technology, the applicant commented that COLUMVI™ is a novel bispecific antibody that binds to the target B-cell antigen CD20 bivalently, eliciting a complete response in heavily pre-treated patients with R/R DLBCL in the third line setting.

With respect to the request for comment on whether COLUMVI™ is substantially similar to EPKINLY™ and whether these technologies should be evaluated as a single technology for the purposes of new technology add-on payments, the applicant for COLUMVI™, while recognizing the COLUMVI™ and EPKINLY™ have similarities, stated that there are key distinctions between the two bispecific antibodies and compared the two CD20 binding domains in COLUMVI™ as substantially different than a single CD20 binding domain in EPKINLY™. Specifically, the applicant for COLUMVI™ stated that COLUMVI™ is a bispecific antibody with a unique 2:1 configuration, which enables bivalent binding of CD20 on B cells and a monovalent binding of CD3 on T cells, making COLUMVI™ the only bivalent bispecific antibody available for patients with R/R DLBCL, whereas EPKINLY™ includes a 1:1 configuration with monovalent binding of CD20 and CD3, a configuration common to other bispecific antibodies. Furthermore, the applicant for COLUMVI™ stated that COLUMVI™ elicits complete responses (CRs) faster than EPKINLY™ (citing a median of 1.4 months to CR versus 2.7 months) and is administered with a dosing schedule that requires fewer total treatment visits for patients compared with EPKINLY™. The applicant for COLUMVI™ also stated that COLUMVI™ is administered as a fixed-duration treatment, allowing patients the benefit of time off therapy while EPKINLY™ requires continuous administration until disease progression or intolerability.

With respect to CMS’s concern regarding existing FDA-approved therapies which are used to treat R/R DLBCL patients with 3 or more lines of therapy including CAR T-cell therapies, POLIVY®, XPOVIO®, and ZYNLONTA®, the applicant stated that there are significant limitations that render patients ineligible for or unable to benefit from these therapies. For CAR T-cell therapy, the applicant stated that despite promising response rates, they have adverse effect profiles that may not be manageable for some patients with R/R DLBCL, especially those with comorbidities and who are older. For POLIVY®, the applicant stated that limitations include serious adverse effects, such as peripheral neuropathy (40% all grades and 2.3% grades 3 or higher), which is reflected in the 31 percent discontinuation rate reported in the U.S. prescribing information. For XPOVIO®, the applicant stated that XPOVIO® has shown low responses (29% ORR and 13% CR) and high toxicity rates, including 80 percent patients that experienced any-grade gastrointestinal events (13% grade 3 or higher). Lastly, for ZYNLONTA®, the applicant stated that challenges with ZYNLONTA® include a low CR rate in patients (24%) and limited durability in responses (median duration of response was 10.3 months). Additionally, the applicant stated that the CD19-targeting MOA of ZYNLONTA® may impact how the treatment is sequenced for patients considering CAR T-cell therapy or who have relapsed after treatment. Lastly, the applicant stated that ZYNLONTA® has adverse effects of edema and skin reactions (including grade 3 or higher).

Response: We thank the applicants for their comments. After consideration of the public comments we received, although we recognize that there may be slight molecular differences, we believe EPKINLY™ and COLUMVI™ both fall into the same class of IG1 bispecific antibodies and are therefore substantially similar to each other. While COLUMVI™ has bivalent binding domains as opposed to monovalent binding domains for EPKINLY™, we do not believe number of domains meaningfully differentiate the mechanism of action, as discussed in prior rulemaking (87 FR 48924), and we instead believe that the technologies are purposed to achieve the same therapeutic outcome using the same or similar mechanism of action using bispecific CD20 and CD3 binding antibodies. Further, while COLUMVI™ may have a different administration schedule, we do not believe the administration schedule affects or substantiates a new mechanism of action. In addition, while COLUMVI™ may elicit a longer time to CR in comparison to EPKINLY™, we believe these differences relate to an assessment of whether the technologies meet the substantial clinical improvement criterion, rather than the newness criterion. For these reasons, while the applicant for COLUMVI™ highlighted differences between COLUMVI™ and EPKINLY™, we are not convinced that these differences result in the use of a different mechanism of action, therefore, we believe that the two technologies’ mechanisms of action are the same. Furthermore, we believe that EPKINLY™ and COLUMVI™ are substantially similar to one another because the technologies are intended to treat the same or similar disease in the same or similar patient population—patients with R/R LBCL/DLBCL with two or more prior lines of therapy, and that potential cases representing patients who may be eligible for treatment would be assigned to the same MS–DRGs.

We also believe EPKINLY™ and COLUMVI™ are not substantially similar to any other existing technologies because, as both applicants asserted in their FY 2024 new technology add-on payment applications and in their comments that they are anti-CD3xCD20 bispecific antibodies with a unique mechanism of action that will be the first of its kind for the treatment of R/R DLBCL after two or more lines of prior therapy, the technologies do not use the same or similar mechanism of action to achieve a therapeutic outcome as any other existing drug or therapy assigned to the same or different MS–DRGs. Based on the information described in this section, we believe EPKINLY™ and COLUMVI™ meet the newness criterion.

Based on the previous discussion, we are making one determination regarding approval for new technology add-on payments that will apply to both applications, and in accordance with our policy, we use the earliest market availability date submitted as the beginning of the newness period for both EPKINLY™ and COLUMVI™.

We believe our current policy for evaluating new technology payment applications for two technologies that are substantially similar to each other is consistent with the authority and criteria in section 1886(d)(5)(K) of the Act. We note that CMS is authorized by the Act to develop criteria for the purposes of evaluating new technology add-on payment applications. For the purposes of new technology add-on payments, when technologies are substantially similar to each other, we believe it is appropriate to evaluate both technologies as one application for new
If substantially similar technologies are submitted for review in different (and subsequent) years, rather than the same year, we evaluate and make a determination on the first application and apply that same determination to the second application. However, because the technologies have been submitted for review in the same year, and because we believe they are substantially similar to each other, we consider both sets of cost data and clinical data in making a determination, and we do not believe that it is possible to choose one set of data over another set of data in an objective manner.

With respect to the cost criterion, the applicant for EPKINLY™ provided multiple analyses to demonstrate that it meets the cost criterion. For each analysis, the applicant searched the FY 2021 MedPAR file using different ICD–10–CM codes to identify potential cases representing patients who may be eligible for EPKINLY™. Each analysis followed the order of operations described in the following table.

For the first analysis, the applicant searched for cases that represent potential patients who are being treated for CRS arising from the administration of EPKINLY™ with a diagnosis code for DLBCL. The applicant used the inclusion/exclusion criteria described in the following table. Under this analysis, the applicant identified 33 claims mapping to two MS–DRGs. The applicant calculated a final inflated average case-weighted standardized charge per case of $114,027, which exceeded the average case-weighted threshold amount of $59,550.

For the second analysis, the applicant searched for cases reporting diagnosis codes for CRS. The applicant used the inclusion/exclusion criteria described in the following table. Under this analysis, the applicant identified 101 claims mapping to three MS–DRGs. The applicant calculated a final inflated average case-weighted standardized charge per case of $88,482, which exceeded the average case-weighted threshold amount of $56,682. Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount in both scenarios, the applicant maintained that EPKINLY™ meets the cost criterion.
With respect to the cost criterion, the COLUMVITM applicant searched the FY 2021 MedPAR file for potential cases representing patients who may be eligible for COLUMVITM, defining two cohorts of patients who may be eligible for treatment and merging the cases for the cost criterion analysis.

For the first cohort, the applicant searched for cases representing potential patients who, as a result of developing CRS following outpatient administration of COLUMVITM, require an inpatient admission within the 3-day payment window following the outpatient treatment. The applicant then identified cases within the 3-day window that were associated with CRS and mapped these cases to the appropriate MS-DRGs. The applicant calculated the average unstandardized charge per case for each MS-DRG.

For the second cohort, the applicant searched for cases representing potential patients who developed CRS as a result of their condition being diagnosed after discharge from hospitalization. The applicant then identified cases within the 3-day window that were associated with CRS and mapped these cases to the appropriate MS-DRGs. The applicant calculated the average unstandardized charge per case for each MS-DRG.

### List of ICD-10-CM codes

<table>
<thead>
<tr>
<th>Scenario 1</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>T80.89XA</td>
<td>Other complications following infusion, transfusion, and therapeutic injection</td>
</tr>
<tr>
<td>C83.30</td>
<td>Diffuse large B-cell lymphoma, unspecified site</td>
</tr>
<tr>
<td>C83.31</td>
<td>Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck</td>
</tr>
<tr>
<td>C83.32</td>
<td>Diffuse large B-cell lymphoma, intrathoracic lymph nodes</td>
</tr>
<tr>
<td>C83.33</td>
<td>Diffuse large B-cell lymphoma, intra-abdominal lymph nodes</td>
</tr>
<tr>
<td>C83.34</td>
<td>Diffuse large B-cell lymphoma, lymph nodes of axilla and upper limb</td>
</tr>
<tr>
<td>C83.35</td>
<td>Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb</td>
</tr>
<tr>
<td>C83.36</td>
<td>Diffuse large B-cell lymphoma, intrapelvic lymph nodes</td>
</tr>
<tr>
<td>C83.37</td>
<td>Diffuse large B-cell lymphoma, spleen</td>
</tr>
<tr>
<td>C83.38</td>
<td>Diffuse large B-cell lymphoma, lymph nodes of multiple sites</td>
</tr>
<tr>
<td>C83.39</td>
<td>Diffuse large B-cell lymphoma, extranodal and solid organ sites</td>
</tr>
</tbody>
</table>

### List of MS-DRGs

<table>
<thead>
<tr>
<th>Scenario 1:</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>814</td>
<td>Reticuloendothelial and Immunity Disorders with MCC</td>
</tr>
<tr>
<td>815</td>
<td>Reticuloendothelial and Immunity Disorders with CC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scenario 2:</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>814</td>
<td>Reticuloendothelial and Immunity Disorders with MCC</td>
</tr>
<tr>
<td>815</td>
<td>Reticuloendothelial and Immunity Disorders with CC</td>
</tr>
<tr>
<td>816</td>
<td>Reticuloendothelial and Immunity Disorders without CC/MCC</td>
</tr>
</tbody>
</table>

### Inclusion/exclusion criteria

Scenario 1: The applicant selected claims with an ICD-10-CM principal diagnosis code of T80.89XA in combination with one of the remaining ICD-10-CM diagnosis codes listed for scenario 1. The applicant believes that cases reporting this combination of codes represent potential patients who are being treated for CRS arising from the administration of EPKINLYTM with a diagnosis code for DLBCL. The applicant included 100% of the cases identified. The applicant then trimmed cases that were mapped to low volume MS-DRGs (<11 cases). The applicant calculated the average unstandardized charge per case for each MS-DRG.

Scenario 2: The applicant selected claims with an ICD-10-CM principal diagnosis code of T80.89XA in combination with one of the remaining ICD-10-CM diagnosis codes listed for scenario 2 for Cytokine Release Syndrome. The applicant included 100% of the cases identified. The applicant then trimmed cases that were mapped to low volume MS-DRGs (<11 cases). The applicant calculated the average unstandardized charge per case for each MS-DRG.

### Charges removed for prior technology

Per the applicant, use of EPKINLYTM would not replace any current therapies. The applicant did not remove any direct or indirect charges from the identified cases.

### Standardized charges

The applicant used the standardization formula provided in Technical Appendix A of the FY 2024 application. The applicant used all relevant values reported in the Standardizing File posted with the FY 2021 IPPS/LTCH PPS final rule.

### Inflation factor

The applicant applied an inflation factor of 13.2% to the standardized charges, based on the inflation factor used to calculate outlier threshold charges in the FY 2023 IPPS/LTCH PPS final rule.

### Charges added for the new technology

Per the applicant they have not yet established the price of EPKINLYTM. The applicant stated that it will provide CMS with EPKINLYTM pricing information by June 30, 2023, subject to FDA approval. Therefore, the applicant stated charges for EPKINLYTM were not incorporated because the price has not yet been finalized. However, once the price is finalized, the applicant stated that this analysis will be updated to incorporate those charges.
administration. Using the inclusion/exclusion criteria described in the following table, the applicant identified 101 claims mapping to 3 MS–DRGs.

For the second cohort, the applicant searched for cases representing a potential subset of patients who are admitted as inpatients for the purposes of being administered COLUMVITM based on the clinical judgment of their provider. Using the inclusion/exclusion criteria described in the following table, the applicant identified 4,705 claims mapping to 9 MS–DRGs.

The applicant combined these two cohorts as there was no overlap between the MS–DRGs of the two cohorts (see the table that follows for a list of MS–DRGs for each cohort). The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $134,690 which exceeded the average case-weighted threshold amount of $96,417. Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount, the applicant asserted that COLUMVITM meets the cost criterion.

### COLUMVITM COST ANALYSIS

<table>
<thead>
<tr>
<th>Data Source and Time Period</th>
<th>FY 2021 MedPAR file</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>List of ICD-10-CM codes</strong></td>
<td></td>
</tr>
<tr>
<td>Cohort 1</td>
<td>T80.89XA (Other complications following infusion, transfusion and therapeutic injection, initial encounter) as principal diagnosis and D89.31 (Cytokine Release Syndrome, grade 1), as secondary or additional diagnosis, or D89.32 (Cytokine Release Syndrome, Grade 2), as secondary or additional diagnosis, or D89.833 (Cytokine Release Syndrome, Grade 3), as secondary or additional diagnosis, or D89.834 (Cytokine Release Syndrome, Grade 4), as secondary or additional diagnosis, or D89.835 (Cytokine Release Syndrome, Grade 5), as secondary or additional diagnosis, or D89.839 (Cytokine Release Syndrome, Grade unspecified), as secondary or additional diagnosis.</td>
</tr>
<tr>
<td>Cohort 2</td>
<td>C83.38 (Diffuse Large B-cell Lymphoma, Lymph Nodes of Multiple Sites) as principal diagnosis code</td>
</tr>
<tr>
<td><strong>List of MS-DRGs</strong></td>
<td></td>
</tr>
<tr>
<td>Cohort 1</td>
<td>814 (Reticuloendothelial and Immunity Disorders with MCC), 815 (Reticuloendothelial and Immunity Disorders without CC/MCC)</td>
</tr>
<tr>
<td>Cohort 2</td>
<td>820 (Lymphoma and Leukemia with Major O.R. Procedures with MCC) 823 (Lymphoma and Non-Acute Leukemia with Other Procedures with MCC) 824 (Lymphoma and Non-Acute Leukemia with Other Procedures with CC) 840 (Lymphoma and Non-Acute Leukemia with MCC) 841 (Lymphoma and Non-Acute Leukemia with CC)</td>
</tr>
<tr>
<td><strong>Inclusion/exclusion criteria</strong></td>
<td></td>
</tr>
<tr>
<td>Cohort 1</td>
<td>The applicant searched for cases representing potential patients who, as a result of developing CRS following outpatient administration of COLUMVITM, require an inpatient admission within the three-day payment window following the outpatient administration. The applicant identified these cases by searching for claims reporting an ICD-10-CM principal diagnosis code of T80.89XA in combination with one of the remaining ICD-10-CM diagnosis codes listed previously in this table for Cohort 1.</td>
</tr>
<tr>
<td>Cohort 2</td>
<td>The applicant searched for cases representing a potential subset of patients who are admitted as inpatients for the purposes of being administered COLUMVITM based on the clinical judgment of their provider. The applicant identified these cases by searching for claims reporting an ICD-10-CM diagnosis code of C83.38 as listed previously in this table.</td>
</tr>
<tr>
<td><strong>Charges removed for prior technology</strong></td>
<td>Per the applicant, use of COLUMVITM would not replace any other treatments. The applicant did not remove any direct or indirect charges from the identified cases.</td>
</tr>
<tr>
<td><strong>Standardized charges</strong></td>
<td>The applicant used the standardization formula provided in Technical Appendix A of the FY 2024 application. The applicant used all relevant values reported in the IPPS impact file posted with the FY 2023 IPPS/LTCH PPS final rule.</td>
</tr>
<tr>
<td><strong>Inflation factor</strong></td>
<td>The applicant applied an inflation factor of 13.2% to the standardized charges, based on the inflation factor used to calculate outlier threshold charges in the FY 2023 IPPS/LTCH PPS final rule.</td>
</tr>
<tr>
<td><strong>Charges added for the new technology</strong></td>
<td>The applicant stated that the average sales price of the technology has yet to be determined, and that when the price is available, a revised cost analysis will be provided that includes estimated hospital charges for the technology.</td>
</tr>
</tbody>
</table>
We invited public comment on whether EPKINLY\textsuperscript{TM} or COLUMVI\textsuperscript{TM} meet the cost criterion.

Comment: The applicant for EPKINLY\textsuperscript{TM} submitted a comment referring to the two cost analyses submitted with the application; one scenario using DLBCL diagnosis codes for patients who are being treated for cytokine release syndrome arising from the outpatient administration of EPKINLY\textsuperscript{TM} that would require inpatient admission within the 3-day payment window and the other scenario of cases reporting diagnosis codes for cytokine release syndrome. Given the availability of the wholesale acquisition cost (WAC) of EPINKLY, the applicant re-calculated the cost threshold analyses using the cost of $11,463.61 ($317.20/ mg \times 36.14$ mg) for EPKINLY\textsuperscript{TM} per patient to the hospital. The applicant reiterated that EPKINLY\textsuperscript{TM} meets the cost criterion under both scenarios where the final inflated case weighted standardized charge per case of $176,329 exceeds the case weighted threshold of $59,550 by $116,779 in the first scenario and where the final inflated case weighted standardized charge per case of $150,780 exceeds the case weighted threshold of $56,682 by $94,103 in the second scenario.

The applicant for COLUMVI\textsuperscript{TM} submitted a comment reiterating that COLUMVI\textsuperscript{TM} meets the cost criterion because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount in the cost criterion analysis submitted in its new technology add-on payment application.

Response: We thank the applicants for their comments. We agree that the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount for both technologies. Therefore, both EPKINLY\textsuperscript{TM} and COLUMVI\textsuperscript{TM} meet the cost criterion.

With regard to the substantial clinical improvement criterion, the applicant asserted that EPKINLY\textsuperscript{TM} represents a substantial clinical improvement over existing technologies because it offers a treatment option with improved efficacy and safety for R/R LBCL patients unresponsive to currently available treatments (for example, CAR T-cell therapies such as KYMRIAH\textsuperscript{®}, YESCARTA\textsuperscript{®}, and Breyanzi\textsuperscript{®}, and non-CAR T-cell therapies such as POLIVY\textsuperscript{®}, ADCETRIS\textsuperscript{®}, XPOVIO\textsuperscript{®}, and ZYNLONTA\textsuperscript{®}); and it significantly improves clinical outcomes among R/R LBCL patients as they progress through lines of therapy. The applicant provided two studies to support these claims, and nine background articles about other treatments available for R/R DLBCL patients and clinical outcomes for patients treated with other therapies such as Breyanzi\textsuperscript{®}, ZYNLONTA\textsuperscript{®}, YESCARTA\textsuperscript{®}, XPOVIO\textsuperscript{®}, KYMRIAH\textsuperscript{®}, and POLIVY\textsuperscript{®}.\textsuperscript{37} The following table summarizes the applicant’s assertions regarding the substantial clinical improvement criterion.

\textsuperscript{37} Background articles are not included in the following table but can be accessed via the online posting for the technology.
<table>
<thead>
<tr>
<th>Substantial Clinical Improvement Assertion #1: The technology offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Applicant statements in support</strong></td>
</tr>
<tr>
<td>R/R LBCL patients have increasingly worse prognosis as they progress through lines of therapy</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Substantial Clinical Improvement Assertion #2: The technology significantly improves clinical outcomes relative to services or technologies previously available</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Applicant statements in support</strong></td>
</tr>
<tr>
<td>Eporcitamab has the potential to substantially improve both the efficacy and safety outcomes of 3L+ R/R LBCA patients compared to non-CAR T-cell therapies</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26816), after review of the information provided by the applicant, we had the following concerns regarding whether EPKINLY™ meets the substantial clinical improvement criterion. With respect to whether the technology offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments, the applicant described EPKINLY™ as having stronger efficacy data in comparison to other 3L+ treatment options available. We noted that the applicant provided many background studies regarding R/R DLBCL treatment options. However, they were unable to provide the complete study of EPKINLY™ (EPCORE NHL-1) in support of its claim of EPKINLY™’s stronger efficacy data in comparison to other 3L+ treatment options, providing only the presentation of partial results used for the European Hematology Association meeting of 2022. Therefore, we stated we were limited in our ability to fully evaluate and assess the supporting evidence for this claim. Furthermore, we noted that there may be other available treatments for this specific population, including CAR T-cell therapies. We also noted that it is unclear which patient population is ineligible for these available treatment options. With respect to whether the technology improves clinical outcomes relative to services or technologies previously available, the applicant described EPKINLY™ as having better safety profiles and efficacy than existing treatments. However, the comparisons are not matched cases within a comparative study, and we questioned whether there are differences between the trials, such as differences in the patient populations included and the way outcomes are defined, that should be considered in assessing the comparison of clinical outcomes across these studies. We were interested in additional information to demonstrate that EPKINLY™ has significantly better efficacy and safety profiles than other available treatments.

With regard to the substantial clinical improvement criterion, the applicant asserted that COLUMVI™ represents a substantial clinical improvement over existing technologies because it offers a treatment option for R/R DLBCL patients who have progressed after three or more lines of therapy that engages T-cells in its mechanism of action with off-the-shelf access and a fixed-treatment duration; and it significantly improves clinical outcomes among R/R DLBCL patients with three or more lines of therapy as compared to placebo. The applicant provided two studies to support these claims, as well as 41 background articles about current therapies for R/R DLBCL patients including access and clinical outcomes for this patient population. The following table summarizes the applicant’s assertions regarding the substantial clinical improvement. Please see the online posting for COLUMVI™ for the applicant’s complete statements regarding the substantial clinical improvement criterion and the supporting evidence provided.

<table>
<thead>
<tr>
<th>Epocritamab has the potential to substantially improve the safety outcomes of 3L+ R/R LBL patients compared to CAR T-cell therapies</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thieblemont, C., Phillips, T., Ghesquieres, H., et al. (2022, June). Subcutaneous Epcritamab in Patients with Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study. 2022 European Hematology Association</strong></td>
</tr>
<tr>
<td><strong>See prior study description</strong></td>
</tr>
<tr>
<td>The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Epcritamab has the potential to substantially improve the safety outcomes of 3L+ R/R LBL patients compared to CAR T-cell therapies</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thieblemont, C., Phillips, T., Ghesquieres, H., et al. (2022, June). Subcutaneous Epcritamab in Patients with Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study. 2022 European Hematology Association</strong></td>
</tr>
<tr>
<td><strong>See prior study description</strong></td>
</tr>
<tr>
<td>The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology.</td>
</tr>
</tbody>
</table>

38 Background articles are not included in the following table but can be accessed via the online posting for the technology.
<table>
<thead>
<tr>
<th>Applicant statements in support</th>
<th>Supporting evidence provided by the applicant</th>
<th>Outcome(s) or findings cited by the applicant from supporting evidence to support its statements</th>
</tr>
</thead>
</table>
Brief study description: a phase I/II, multicenter, open-label, dose escalation and dose expansion study of COLUMVI™. | ORR n (%): 80 (51.6%); CR rate, n (%): 61 (39.4).  
Median PFS, months (95% CI): 4.9 (3.4, 8.1),  
Median OS, months (95% CI): 11.5 (7.9, 15.7). |
| **COLUMVI™ reduced mortality of patients who had progressed after ASCT or CAR T-cell therapy — a population for whom there are few successful treatment options** | Dickinson M, et al. N Engl J Med 2022; 387:2220-2231.  
See prior study description | The median overall survival months: (95% CI): 11.5 (7.9, 15.7) |
Brief study description: Phase I, multicenter, open-label, dose escalation, and dose-expansion study to evaluate safety and efficacy of COLUMVI™ in R/R B-cell NHL with obinutuzumab pretreatment (Gpt). | 7 days before the first dose of COLUMVI™, all patients received 1,000 mg Gpt, to deplete peripheral and tissue-based B-cells and mitigate serious CRS. Obinutuzumab was chosen as pretreatment because of its deeper clearance of peripheral and tissue-based B-cells compared with rituximab. COLUMVI™ was given as an initial 4 hour IV infusion, reduced to 2 hours once a prior infusion had occurred without complications. COLUMVI™ was given in 14- or 21-day cycles. Details of premedication, infusion time, and scheduling are provided in the supplementary material. A Bayesian-modified continuous reassessment method with overdose control based on emerging toxicity data guided the dose escalation. |
| **COLUMVI™ is a therapy that can be made available across various geographies for patients with DLBCL** | The applicant provided background information to support this claim, which can be accessed via the online posting for the technology. | The applicant provided background information to support this claim, which can be accessed via the online posting for the technology. |
| **COLUMVI™ is expected to be an efficacious option for patients who are ineligible for ASCT or CAR T-cell therapies,** | Dickinson M, et al. N Engl J Med 2022; 387:2220-2231.  
See prior study description | Median OS, months (95% CI): 11.5 (7.9, 15.7) |
### Substantial Clinical Improvement Assertion #1: The technology offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments

<table>
<thead>
<tr>
<th>Applicant statements in support</th>
<th>Supporting evidence provided by the applicant</th>
<th>Outcome(s) or findings cited by the applicant from supporting evidence to support its statements</th>
</tr>
</thead>
<tbody>
<tr>
<td>expanding access to treatment for these patients</td>
<td>Hutchings M, et al. J Clin Oncol. 2021; 39(18):1959-1970.</td>
<td>Key inclusion criteria were patients age ≥18 years with histologically confirmed B-NHL expected to express CD20; ≥1 prior lymphoma treatment, with no available life-extending treatment options; and who had &gt;1 measurable target lesion &gt;1.5 cm. Key exclusion criteria were a history of CNS lymphoma or other CNS pathology, anticancer therapy within 4 weeks or five half-lives of the drug or ASCT within 100 days before Gpt, or prior allogeneic stem-cell transplantation. Phase I study enrolling patients to be treated with COLUMVI™ based on age ≥18 years, histologically confirmed disease, and expression of CD20. No exclusions for chemosensitivity, T-cell number, or disease progression.</td>
</tr>
</tbody>
</table>

The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology.

### Substantial Clinical Improvement Assertion #2: The technology significantly improves clinical outcomes relative to services or technologies previously available

<table>
<thead>
<tr>
<th>Applicant statements in support</th>
<th>Supporting evidence that the applicant provided</th>
<th>Outcome(s) or findings cited by the applicant from supporting evidence to support its statements</th>
</tr>
</thead>
<tbody>
<tr>
<td>COLUMVI™ demonstrated efficacy, durable remissions, and a manageable safety profile with a fixed treatment duration</td>
<td>Dickinson M, et al. N Engl J Med 2022; 387:2220-2231.</td>
<td>Baseline characteristics: Median no of prior lines, n (range): 3 (2-7) -3 prior lines 92 (59.7%). ORR n (%): 80 (51.6%) - CR rate, n (%): 61 (39.4). Median duration of response (DoR): 18.4 mo (95% CI: 13.7, NE). Adverse events (AE) leading to treatment discontinuation, n (%): 14 (9.1)</td>
</tr>
</tbody>
</table>

The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology.

| COLUMVI™ has a manageable safety profile and had a low rate of treatment discontinuation in heavily pretreated and refractory patient populations. | Dickinson M, et al. N Engl J Med 2022; 387:2220-2231. | Median no of prior lines, n (range): -2 prior lines 62 (40.3) -3 prior lines 92 (59.7) - Refractory to any prior lines 139 (90.3). Complete response rates by IRC in pre-specified group, Table: Prior CAR-T therapy CR (95% CI): -Yes 35% (22%, 49%) - No 42% (32%, 52%). Other adverse events of interest, AE leading to treatment discontinuation, n (%): 14 (9.1). Infections (all grade), n (%): 59 (38.3) |

The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology.

| COLUMVI™ has a durable response and low rates of peripheral neuropathy | Dickinson M, et al. N Engl J Med 2022; 387:2220-2231. | Median DoR: 18.4 months (95% CI: 13.7, NE). AE leading to treatment discontinuation, n (%): 14 (9.1) -Peripheral neuropathy was not noted in any of the tables |

The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology.

| COLUMVI™ demonstrated efficacy with a manageable safety profile in heavily pretreated and refractory populations | Dickinson M, et al. N Engl J Med 2022; 387:2220-2231. | Median no of prior lines, n (range): 3 (2-7) -3 prior lines 92 (59.7%). ORR n (%): 80 (51.6%) CR rate, n (%): 61 (39.4). Median DoR: 18.4 month (95% CI: 13.7, NE). Median OS, months (95% CI): 11.5 (7.9, 15.7). AE leading to treatment discontinuation, n (%): 14 (9.1) |

The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology.
## Substantial Clinical Improvement Assertion #1: The technology offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments

<table>
<thead>
<tr>
<th>Applicant statements in support</th>
<th>Supporting evidence provided by the applicant</th>
<th>Outcome(s) or findings cited by the applicant from supporting evidence to support its statements</th>
</tr>
</thead>
<tbody>
<tr>
<td>COLUMVI™ is associated with a manageable safety profile.</td>
<td>Dickinson M, et al. N Engl J Med 2022; 387:2220-2231.</td>
<td>CRS (any grade), n (%): 97 (63.0); CRS (Grade 3): 4 (2.6); CRS (Grade 4): 2 (1.3). Neurologic AEs (all grade), n (%): 59 (38.3), Grade ≥3: 5 (3.2); ICANS (all grade), n (%): 12 (7.8); Grade ≥3: 4 (2.6); Infections (all grade), n (%): 59 (38.3); Grade ≥3: 23 (14.9).</td>
</tr>
</tbody>
</table>

**Technology.** With respect to the applicant’s claims that COLUMVI™ is an off-the-shelf therapy without any delay due to personalized manufacturing, such as CAR T-cell therapy, and that COLUMVI™ can be made available across various geographies for patients with DLBCL, we questioned whether other available therapies, such as POLIVY®, XPOVIO®, and ZYNLONTA®, that may be used to treat patients with multiple relapses or who are refractory to other therapies, also would not have those limitations.

With respect to the applicant’s claim that COLUMVI™ improves outcomes as compared to existing treatments, including safety and rate of treatment discontinuations, we noted that only one single arm trial with no comparators was provided in support of this claim. We further noted that the comparisons of the supporting evidence provided for other existing technologies to the main COLUMVI™ study are not matched cases; for example, the studies do not adjust for type and severity of AEs. Therefore, we questioned whether these comparisons can be used to demonstrate a significant difference in safety or efficacy.

With respect to the applicant’s claim that COLUMVI™ is a fixed-treatment duration therapy, providing patients with time off treatment and the potential to improve patient quality of life, we noted that this appears to be an inference, as the applicant did not provide any evidence that a fixed-treatment improves quality of life. According to the applicant, during the first cycle (each cycle is 21 days), the patient is required to receive the drug infusion once a week. After cycle 1, the frequency of infusion is reduced to once a month. While COLUMVI™ provides a fixed-treatment, it requires weekly up to monthly infusions in comparison to CAR–T cell therapy, which is a one-time treatment. We were interested in additional information regarding the association between treatment type and duration and quality of life, particularly how COLUMVI™’s treatment type and duration results in higher quality of life as compared to the treatment type and duration of existing technologies.

We invited public comments on whether EPKINLY™ or COLUMVI™ meet the substantial clinical improvement criterion.

**Comment:** The applicant for EPKINLY™ submitted a comment regarding the substantial improvement criterion and provided responses to concerns raised by CMS in the proposed rule. In response to CMS’s request for additional support of the claim that EPKINLY™ has stronger efficacy in comparison to other 3L+ treatment options available, the applicant for EPKINLY™ stated EPKINLY™ was shown to have significantly better clinical outcomes compared to chemoimmunotherapy in two indirect treatment comparisons. The applicant stated that R/R DLBCL patients face significant disease burden and poor clinical outcomes. The applicant further stated that for patients who have Failed two or more prior lines of therapy (LOT), there is no standard of care; although chemoimmunotherapy (CIT) regimens are commonly used, they do not provide optimal outcomes. The applicant also stated that while direct

---

44. MONJUVI® (tafasitamab) [prescribing information], Boston, MA: Morphosys US Inc.; June 2021.
CAR T-cell therapy in patients with standard of care has not been these patients, who relapse or who are never respond to treatment with a T-cell therapy, analysis of patients who received CAR and subsequent lines of therapy. The applicant indicated that access to CAR T-cell therapy is limited due to its availability only at approximately 200 centers in specialized medical centers to which older adults may be unable to travel to. In addition, the applicant indicated that an estimated 35 percent to 50 percent of patients would not be eligible for second line CAR T-cell therapy and that this number likely increases in third and subsequent lines of therapy. The applicant stated that in a real-world analysis of patients who received CAR T-cell therapy, ~60 percent of patients never respond to treatment with a median failure of only 49 days. For these patients, who relapse or who are refractory to CAR T-cell therapy, a standard of care has not been established. The applicant concluded that EPKINLY™ would be effective for those patients who are either ineligible or have progressed from CAR T-cell therapy, and that because EPKINLY™ is an off-the-shelf therapy, it is not constrained by the same individualized manufacturing timelines and associated challenges that can delay patient starts on CAR T-cell therapy.

Another commenter submitted a comment in support of the approval of the new technology add-on payment application for EPKINLY™, citing its efficacy in the third line setting in patients with R/R LBCL with an overall response rate of 63.1 percent and a complete response rate of 39 percent based on Lugano criteria and a manageable safety profile. Furthermore, the commenter stated that despite recent approval and expanded utilization of CAR T-cell therapy, there remains no clear standard of care for treatment of many patients with R/R LBCL due to issues surrounding access. The commenter stated that CAR T-cell therapy is offered at only ~210 centers in the U.S., often concentrated in major metropolitan areas, creating significant barriers for patients living in remote or rural areas. The commenter further stated that even when CAR T-cell therapy is accessible, CAR T-cell therapy poses several challenges for patients, starting with the potentially lengthy manufacturing process that includes pre-treatment procedures like leukapheresis, to collect T-cells, and then genetically modifying T-cells to express CARs, which can take up to several weeks. Lastly, the commenter stated that approximately 40 percent of DLBCL patients were ineligible for CAR T-cell therapy due to factors such as organ dysfunction, active infections or prior stem cell transplantation, while around 18–20 percent of those that were eligible underwent leukapheresis but did not receive CAR T-cells due to disease progression, adverse events, or clinical deterioration. The commenter concluded that, in summary, the significant challenges associated with CAR T-cell therapy including limited access, lengthy manufacturing processes, eligibility restrictions, and risk of treatment failure, underscore the need for effective treatments with comparable clinical benefits and broader patient reach.

The applicant for COLUMVI™ submitted comments in response to CMS’s concerns in the FY 2024 IPPS/ LTCH PPS proposed rule regarding whether COLUMVI™ meets the substantial clinical improvement criterion. The applicant reiterated its support for COLUMVI™ stating that COLUMVI™ significantly improves clinical outcomes of patients with R/R DLBCL after at least two prior systemic therapies.

With respect to CMS’s concern that the existence of other technologies and treatments approved for the R/R DLBCL patients with two or more lines of therapy made it unclear that this would represent a patient population unresponsive to or ineligible for currently available treatments, the applicant stated that COLUMVI™ expands treatment options for the key subsets of patients in the R/R DLBCL setting receiving and inadequately treated by existing therapies, including: patients who are ineligible for or who cannot access ASCT or CAR T-cell therapy, patients who have progressed after ASCT or CAR T-cell therapy, and patients who have progressed after two or more lines of approved therapies. The applicant stated that COLUMVI™ is a treatment option for patients who are ineligible for or cannot access ASCT or CAR T-cell therapy, indicating that about half of patients with R/R DLBCL with three or more lines of therapies are ineligible for ASCT or CAR T-cell therapies because of treatment-related toxicities. The applicant stated that this patient population is further vulnerable to accessing ASCT or CAR T-cell therapy as there are limited treatment sites and manufacturing delays. The applicant cited a retrospective study which showed that in patients with R/R DLBCL receiving three or more lines of treatment (3L) post CAR T-cell therapy approval, less than 20 percent of patients received CAR T-cell therapy in 3L between October 2017 and March 2020. The applicant further stated that COLUMVI™ is a new option for patients who have progressed after ASCT or CAR T-cell therapy, stating that about two-thirds of patients with R/ R DLBCL relapse after ASCT, and about half of patients receiving CAR T-cell therapies experience disease.
progression.\textsuperscript{55,56} The applicant stated that many patients in the 3L+ setting have low response rates to available therapies, and that tolerability of approved treatments can be poor with a range of potential adverse events (AEs) associated with these therapies. The applicant stated that tolerability of COLUMVIT\textsuperscript{TM} was demonstrated by low rates of treatment discontinuation and an overall favorable safety profile with AEs that are more tolerable than those associated with other treatment options in the 3L+ setting.

With respect to CMS’s concern that the applicant provided several background studies regarding other existing treatments for R/R DLBCL as well as the main COLUMVIT\textsuperscript{TM} study to support the applicant’s claim that COLUMVIT\textsuperscript{TM} reduces mortality of patients who had progressed after ASCT or CAR T-cell therapy, the applicant for COLUMVIT\textsuperscript{TM} stated that while ASCT can produce long-term remissions in about one-third of patients who undergo the procedure, the remaining patients who experience disease progression have poor outcomes. The applicant stated that effective treatments for patients who progress after ASCT is an unmet need in R/R DLBCL and cited the CORAL\textsuperscript{57} study where patients who relapsed after ASCT had a median overall survival (OS) of 10 months and an estimated 1-year OS of 39 percent whereas for patients who relapse within 6 months the median OS was 5.7 months. The applicant further stated that about half of patients receiving CAR T-cell therapy experience disease progression with 48 percent of patients who receive CAR T-cell therapy in 3L began a 4L treatment within 4 months. The applicant stated there is limited data on how patients progress after CAR T-cell therapy progression and patient response to salvage treatment given the recent introduction of commercial CAR T-cell therapy. The applicant indicated the outcomes from limited data are poor and cited a recent analysis of 298 patients who received CAR T-cells in the United Kingdom, 54 percent experienced disease with a median of 2.4 months to progression and had a median OS of 4.4 months.\textsuperscript{58} The applicant further stated that patients who went on to additional therapies had a median OS of 8.8 months with only 22 percent achieving a CR whereas patients who did not receive further treatment had a median OS of 1.7 months.\textsuperscript{59} The applicant stated that among currently approved 3L+ options, there is either no data or a lack of efficacy for patients after CAR T-cell therapy, indicating that in a trial of one therapy, enrolled patients with prior ASCT and CAR T-cell therapy 29 percent and 15 percent respectively achieved CRs.\textsuperscript{60} The applicant indicated that COLUMVIT\textsuperscript{TM} study patients with prior ASCT and CAR T-cell therapy achieved CRs at rates of 67 percent and 35 percent respectively indicating that this is a substantial clinical improvement for a patient population with an unmet need.

With respect to CMS’s concerns as to whether other available therapies, such as POLIVY\textsuperscript{®}, XPOVIO\textsuperscript{®}, and ZYNLONTA\textsuperscript{®}, may be used to treat patients with multiple relapses and do not require personalized manufacturing such as CAR T-cell therapy, the applicant for COLUMVIT\textsuperscript{TM} stated that although these therapies are available off the shelf, COLUMVIT\textsuperscript{TM} is an off-the-shelf therapy that provides a substantial clinical improvement via efficacy, durability, and low toxicity in a heavily pretreated, highly refractory patient population.

With respect to CMS’s concerns as to whether COLUMVIT\textsuperscript{TM} improves outcomes as compared to existing treatments, including safety and rate of treatment discontinuations, the applicant for COLUMVIT\textsuperscript{TM} stated that head-to-head data of therapies in 3L+ are not available and that while direct comparisons across different trials are subject to confounding and bias because of systematic differences, consideration of outcomes in clinical trials for currently approved therapies indicate the outcomes are in line with historical rates of response in the 3L+ setting where typically less than half of patients respond to conventional 3L therapies and the median OS of patients in the 3L setting is 4–10 months.\textsuperscript{61,62,63} The applicant further stated that single-arm studies are an important mechanism to facilitate faster access to novel therapies, particularly for patients who have exhausted other approved options. With respect to our request for additional information regarding the association between treatment type and the applicant for COLUMVIT\textsuperscript{TM}’s claim that COLUMVIT\textsuperscript{TM} is a fixed-treatment duration therapy that provides patients with time off treatment and the potential to improve patient quality of life, the applicant responded that while there is no data available on this subject in 3L+ DLBCLs yet, fixed-duration versus continuous therapy have been studied in other therapeutic areas and a range of benefits have been associated with fixed-duration therapies. The applicant indicated that the time off treatment may be associated with improvement in quality of life based on a nonrandomized study of patients with chronic myeloid leukemia whose patient-reported outcomes included improvement in treatment-related adverse effects when discontinuing a tyrosine kinase inhibitor treatment.\textsuperscript{64} The applicant indicated that patients prefer fixed-duration therapies to continuous therapies citing surveys of patients with chronic lymphocytic leukemia and Waldenstrom’s macroglobulinemia identified fixed duration therapy as a positive attribute when compared to continuous therapy.\textsuperscript{65,66} The applicant for COLUMVIT\textsuperscript{TM} further stated that fixed-duration therapy can reduce costs as compared to continuous treatment options.

**Response:** We thank the commentators for their comments regarding the


substantial clinical improvement criterion. Based on the additional information received, we agree that EPKINLY™ and COLUMVI™ represent a substantial clinical improvement over existing technologies because these technologies offer treatment options for patients with R/R DLBCL after two or more prior therapies who are unresponsive to, or ineligible for, currently available treatments, who are ineligible due to factors such as organ dysfunction, active infection, or prior stem cell transplantation, or for whom CAR T-cell therapy is not an available treatment option.

After consideration of the public comments we received, and the information included in both the applicants’ new technology add-on payment applications, we have determined that EPKINLY™ and COLUMVI™ meet all of the criteria for approval of new technology add-on payments. Therefore, we are approving new technology add-on payments for EPKINLY™ and COLUMVI™ for FY 2024. As previously stated, cases involving EPKINLY™ that are eligible for new technology add-on payments will be identified by ICD–10–PCS procedure code XW013S9 (Introduction of epcotitamab monoclonal antibody into subcutaneous tissue, percutaneous approach, new technology group 9). Cases involving COLUMVI™ that are eligible for new technology add-on payments will be identified by ICD–10–PCS procedure code XW033P9 (Introduction of glofitamab antineoplastic into peripheral vein, percutaneous approach, new technology group 9) or XW043P9 (Introduction of glofitamab antineoplastic into central vein, percutaneous approach, new technology group 9).

Each of the applicants submitted cost information for its application. The manufacturer of EPKINLY™ stated that the cost of its technology is $11,463.61 per patient. The applicant projected that 117 cases will involve the use of EPKINLY™ in FY 2024. The manufacturer of COLUMVI™ stated that the cost of its technology is $5,748.53. The applicant projected that 40 cases will involve the use of COLUMVI™ in FY 2024. Because the technologies are substantially similar to each other, we believe using a single cost for purposes of determining the new technology add-on payment amount is appropriate for EPKINLY™ and COLUMVI™ even though each applicant has its own set of codes. We also believe using a single cost provides predictability regarding the add on payment when using EPKINLY™ or COLUMVI™ for the treatment of patients with R/R DLBCL. As such, consistent with prior rulemaking (85 FR 58684), we believe that the use of a weighted average of the cost of EPKINLY™ and COLUMVI™ based on the projected number of cases involving each technology to determine the maximum new technology add-on payment would be most appropriate. To compute the weighted cost average, we summed the total number of projected cases for each of the applicants, which equaled 157 cases (117 plus 40). We then divided the number of projected cases for each of the applicants by the total number of cases, which resulted in the following case-weighted percentages: 74.5 percent for EPKINLY™ and 25.5 percent for COLUMVI™. We then multiplied the cost per case for the manufacturer specific drug by the case-weighted percentage (0.745 * $11,463.61 = $8,540.39 for EPKINLY™ and 0.255 * $5,748.53 = $1,465.87 for COLUMVI™). This resulted in a case-weighted average cost of $10,006.26 for the technology.

We then multiplied the cost per case for the manufacturer specific drug by the case-weighted percentage (0.745 * $11,463.61 = $8,540.39 for EPKINLY™ and 0.255 * $5,748.53 = $1,465.87 for COLUMVI™). This resulted in a case-weighted average cost of $10,006.26 for the technology. Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, the maximum new technology add-on payment for a case involving the use of EPKINLY™ or COLUMVI™ is $6,504.07 for FY 2024.

d. Lunsumio™ (Mosunetuzumab)

Genentech, Inc. submitted an application for new technology add-on payments for Lunsumio™ for FY 2024. The applicant, Lunsumio™ is a novel, full-length, humanized, immunoglobulin G1 (IgG1) bispecific antibody that is designed to concomitantly bind CD3 on T cells and CD20 on B cells, in the treatment of adults with relapsed/refractory (R/R) follicular lymphoma (FL) who have received at least 2 (≥2) prior systemic therapies (also referred to herein as 3L+FL). The applicant further stated that target B cell killing occurs only upon simultaneous binding to both targets, as it is a conditional agonist. We note that Genentech, Inc submitted an application for new technology add-on payments for Lunsumio™ for FY 2023 under the name mosunetuzumab, as summarized in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28261 through 28274), that it withdrew prior to the issuance of the FY 2023 IPPS/LTCH PPS final rule (87 FR 48920).

Please refer to the online application posting for Lunsumio™, available at https://mearis.cms.gov/public/publications/ntap/NTP2210171JLDM, for additional detail describing the drug and the disease treated by the technology.

With respect to the newness criterion, Lunsumio™ was granted accelerated approval of its BLA from FDA on December 22, 2022, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. According to the applicant, Lunsumio™ was made available for sale after the new year with the first order occurring on January 6, 2023, due to a companywide holiday shutdown and to provide manufacturing time. We noted in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26824), for the purposes of new technology add-on payments, we do not consider the date of first sale as an indicator of the entry of a product onto the U.S. market. According to the applicant, Lunsumio™ is sold in a 1 mg and 30 mg single dose vial and is administered for eight cycles according to the dosage schedule in the following table unless patients experience unacceptable toxicity or disease progression. Per the applicant, most of the inpatient usage of Lunsumio™ will occur as the result of adverse events, mainly CRS, that develop after outpatient administration of the drug. The applicant stated that clinical protocols require that inpatient hospitalization occur for most Grade 2 CRS patients, and for all patients with Grade 3 or 4 CRS. In clinical trials, when Grade 2, 3, or 4 CRS developed, 75 percent of the time it occurred after a 60 mg dose, 20 percent of the time it developed after a 1 mg dose, and 5 percent after a 2 mg dose. Based on this information, it seems that the weighted average inpatient dose would be 45.3 mg.
According to the applicant, effective October 1, 2022, the following ICD–10–PCS procedure codes may be used to distinctly identify administration of Lunsumio™: XW03358 (Introduction of mosunetuzumab antineoplastic into peripheral vein, percutaneous approach, new technology group 8) or XW04358 (Introduction of mosunetuzumab antineoplastic into central vein, percutaneous approach, new technology group 8). The applicant stated that diagnosis code C82 (Follicular lymphoma) may be used to currently identify the indication for Lunsumio™ under the ICD–10–CM coding system.

As previously discussed, if a technology meets all three of the substantial similarity criteria under the newness criterion, it would be considered substantially similar to an existing technology and would not be considered "new" for the purpose of new technology add-on payments.

With respect to the substantial similarity criteria, the applicant asserted that Lunsumio™ is not substantially similar to other currently available technologies because it does not use the same or a similar mechanism of action compared to any existing technology approved for treatment of 3L+ FL and because the use of Lunsumio™ in 3L+ FL does not involve the treatment of the same or a similar type of disease or the same or similar patient population when compared to an existing technology. The following table summarizes the applicant’s assertions regarding the substantial similarity criteria. Please see the online application posting for Lunsumio™ for the applicant’s complete statements in support of its assertion that Lunsumio™ is not substantially similar to other currently available technologies.

<table>
<thead>
<tr>
<th>Day of Treatment</th>
<th>Dosage</th>
<th>Rate of Infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cycle 1</td>
<td>Day 1</td>
<td>1 mg</td>
</tr>
<tr>
<td></td>
<td>Day 8</td>
<td>2 mg</td>
</tr>
<tr>
<td></td>
<td>Day 15</td>
<td>60 mg</td>
</tr>
<tr>
<td>Cycle 3</td>
<td>Day 1</td>
<td>60 mg</td>
</tr>
<tr>
<td>Cycle 3 +</td>
<td>Day 1</td>
<td>30 mg</td>
</tr>
</tbody>
</table>
In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26825), we stated that while the applicant indicated that the technology does not involve the treatment of the same or similar patient population as compared to existing technology, we noted that FL in 3L+ settings is not a new population because there are FDA approved therapies indicated in the treatment of patients with R/R FL after two or more lines of systemic therapy. We stated our belief that Lunsumio™ would be used for the same disease and patient population when compared to other therapies approved to treat FL in 3L+ settings.

We invited public comments on whether Lunsumio™ is substantially similar to existing technologies and whether Lunsumio™ meets the newness criterion.

<table>
<thead>
<tr>
<th>Substantial Similarity Criteria</th>
<th>Applicant Response</th>
<th>Applicant assertions regarding this criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does the technology use the same or similar mechanism of action to achieve a therapeutic outcome?</td>
<td>No</td>
<td>Lunsumio™ does not use the same or a similar mechanism of action compared to any existing technology approved for treatment of 3L+ R/R FL. As the first and only CD20xCD3 bispecific monoclonal antibody for the treatment of 3L+ FL, Lunsumio™ has a mechanism of action that is unique and different from that of existing technologies in this indication. Lunsumio™ binds CD20 on the surface of B cells and CD3 on T cells, allowing T cells to attack cancerous B cells. CD20 has been previously validated as a therapeutic target for the treatment of B-cell cancers such as FL, but Lunsumio™ is the only treatment for 3L+ FL that concomitantly targets both CD20 and CD3 at the same time. None of the available treatments for 3L+ FL uses the same mechanism of action; none are CD20xCD3 bispecific antibodies.</td>
</tr>
<tr>
<td>Is the technology assigned to the same MS-DRG as existing technologies?</td>
<td>Yes</td>
<td>Lunsumio™ might be assigned to the same MS-DRG as existing technologies.</td>
</tr>
<tr>
<td>Does new use of the technology involve the treatment of the same/similar type of disease and the same/similar patient population when compared to an existing technology?</td>
<td>No</td>
<td>Genentech Inc is seeking approval for Lunsumio™ as a 3L+ therapy for a heavily pretreated and highly refractory patient population. There is no standard of care for 3L+FL patients who have received two or more prior therapies. The heterogeneity of FL and transformation of disease over time are challenges for later lines of treatment. Additionally, there is continued unmet need, even with currently available 3L+ therapies due to high-risk features such as refractoriness to prior therapy, double refractoriness to prior alkylator and anti-CD20 monoclonal antibody therapy, POD24, FLIPI score of 3-5, or older age. The prognosis for patients with R/R FL who have received two or more prior therapies is poor and OS diminishes with each subsequent line of therapy. Lunsumio™’s clinical trial program is inclusive of patients reflecting a real-world FL patient population seeking 3L+ therapy. The patient population in the pivotal GO29781 study demonstrated the efficacy of Lunsumio™ in heavily pretreated, highly refractory, and older (&gt;65) patients. These patients have characteristics that reflect those in the real world requiring 3L+ FL treatment. The median age of patients enrolled in the study was 60 (range 53-67); 33.3% were aged ≥65 years. Most patients (71%) had FLIPI scores of ≥2, and 52% were POD24. All patients had prior alkylator therapy (100%) and anti-CD20 therapy (100%); 98% had anti-CD20 plus alkylator or anthracycline; 82% had anthracyclines; 19% had phosphoinositide 3-kinase (PI3K) inhibitors; 14% had immunomodulatory drugs; and 3% had chimeric antigen receptor (CAR) T-cell therapy. Most patients were refractory to the last prior therapy (69%). Responses to Lunsumio™ treatment were achieved across all patient subpopulations. Lunsumio™ is a fixed-treatment duration therapy that will be widely accessible to patients with R/R FL who have received two or more prior therapies. Currently, there is no approved fixed-treatment duration option for patients with 3L+ FL that is widely accessible across multiple treatment settings. Copanlisib and tazemetostat are indicated for continuous treatment until disease progression or unacceptable toxicity. Accessibility of axicabtagene ciloleucel and tisagenlecleucel are limited due to eligibility requirements, manufacturing slots, and geographic isolation. Finally, all currently approved therapies have limitations, including high toxicity or increased risk of high toxicity with ongoing exposures, limited utility in patients without cytogenetic mutation, and lower rates of CR. Lunsumio™ is a novel agent with a fixed-treatment duration that has shown efficacy (80% overall response rates and 60% CR).</td>
</tr>
</tbody>
</table>
Comment: The applicant submitted a public comment regarding the newness criterion. In response to CMS’s questions related to newness, the applicant stated that although several treatment regimens have been developed and approved for R/R FL in the U.S., there are no preferred treatment options for patients in the 3L+ setting. The applicant further stated that although currently available therapies for patients with R/R FL who have had two or more prior therapies may be appropriate for certain patients, substantial clinical factors impact whether a patient can benefit from these 3L+ treatment options (for example, copanlisib, tazemetostat, axicabtagene ciloleucel, and tisagenlecleucel). The applicant noted these include high-risk features such as refractoriness to prior therapy, double refractoriness to prior alkylator and anti-CD20 monoclonal antibody therapy, POD24 of 1L chemoimmunotherapy, FLIPI score of 3–5, or older age. The applicant further stated that certain treatment options for patients with R/R FL who have had two or more prior therapies have their own limitations that may restrict the eligible patient population. The applicant used copanlisib, tazemetostat, and CAR T-cell therapy as examples. According to the applicant, copanlisib is associated with severe toxicities and suboptimal responses that limit its use in patients with R/R FL who have received 2+ prior systemic therapies. With regard to tazemetostat, the applicant stated that it offers limited efficacy to patients with R/R FL who have received ≥2 prior systemic therapies and do not have an EZH2 mutation. The applicant stated that while tazemetostat is still approved for patients with wildtype EZH2, the label includes language that tazemetostat is indicated for the treatment of “Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options,” and that because EZH2 mutations are found in less than 30 percent of FL cases, 70 percent of the patients who progress after 2+ prior systemic treatments can benefit from additional options. With regard to CAR T-cell therapy, the applicant maintained that benefits of this treatment in patients with R/R FL who have received 2+ prior systemic therapies are limited by tolerability and accessibility. The applicant stated that patients aged 65 years or older make up about 35 percent of CAR T-cell recipients (25%–41%) and may experience rates of CRS and neurological AEs than patients under 65 years of age, and that unlike treatment-emergent AEs with other therapies, CAR T cells cannot be dose-reduced or delayed managing these AEs, nor can treatment be discontinued once administered.

According to the applicant, additional treatment options are needed for patients who may not be candidates for CAR T-cell therapies or who cannot access the therapy. The applicant argued that even for patients who are fit enough to tolerate CAR T-cell therapy toxicities, access to treatment remains a significant barrier. The applicant noted that twelve states currently have no available CAR T-cell therapy sites. The applicant stated that even for those with access to a treatment center, additional barriers limit the number of patients who can access CAR T-cell therapy, such as with ensuring that a manufacturing slot is available when a patient’s cells are collected (if frozen cells are not an option), or obtaining necessary reagents.

The applicant asserted that LunsumioTM is efficacious in patients with R/R FL who have received 2+ lines of systemic therapy. According to the applicant, LunsumioTM is efficacious across all subgroups, including those who are heavily pretreated and highly refractory, and those who aged 65 years or older, and has a generally manageable safety profile. In addition, the applicant maintained that the tolerability of LunsumioTM compared with currently approved 3L+ treatment options is a substantial clinical improvement. Per the applicant, LunsumioTM is anticipated to be an actionable treatment option for patients who have progressed after CAR T-cell therapy, substantially improving access to 3L+ treatment for these patients. According to the applicant, as an off-the-shelf therapy that does not require patient-specific manufacturing, LunsumioTM will be widely available at hospitals and clinics across the country, substantially improving access to treatment compared with CAR T-cell therapies. The applicant expected that LunsumioTM will fill an unmet need left by other approved 3L+ therapies and therefore does not treat the same or similar type of disease in the same or similar patient population when compared with existing technologies.

Another commenter submitted a public comment supporting the newness of LunsumioTM in the treatment of multiply relapsed FL, as the first approved CD20xCD3 bispecific monoclonal antibody. According to the commenter, while there are other agents approved for the treatment of multiply relapsed FL, they have clinical limitations that significantly constrain their utility, such as lower response rates, inferior durability of response, treatment schedules that limit routine use, and key toxicities. The commenter also explained that the use of CAR–T cell therapies for FL are limited by toxicity and by access to centers of excellence with the resources to administer such treatment. The commenter asserted that LunsumioTM represents a critical innovation for patients with multiply relapsed FL, offers a potent immunotherapy appropriate for outpatient and community-based use, and has a new and unique mechanism of action.

Response: We thank the applicant and commenter for their comments.

We disagree with the commenter and continue to believe that LunsumioTM would be used for the same disease in a similar patient population when compared to other therapies approved to treat FL in 3L+ settings. We note that according to the applicant, treatment options are available for R/R FL patients, though limitations impact which patients can benefit from these available 3L+ treatment options. However, we believe that these limitations relate to an assessment of whether the technology meets the substantial clinical improvement criterion rather than the newness criterion. As a result, we believe that LunsumioTM treats the same or similar disease in the same or similar patient population when compared to existing treatments for FL in 3L+ settings. Based on our review of the comments received and information submitted by the applicant as part of its FY 2024 new technology add-on payment application for LunsumioTM, we agree with the applicant that LunsumioTM has a unique mechanism of action as a CD20xCD3 bispecific monoclonal antibody for the treatment of 3L+ FL. Therefore, we believe that LunsumioTM is not substantially similar to existing treatment options and meets the newness criterion. As we have discussed in prior rulemaking (77 FR 53348), generally, our policy is to begin the newness period on the date of FDA approval or clearance or, if later, the date of availability of the product on the U.S. market. The applicant stated that LunsumioTM was FDA approved for 3L+ treatment of adult patients with R/R FL on December 22, 2022, and became available for sale after the new year with a date of first sale on January 6, 2023. However, it is unclear from the information provided whether the technology would have been available for sale prior to January 6, 2023. Nonetheless, we note that using either
the FDA approval date of December 22, 2022, or the date suggested by manufacturer of January 6, 2023, Lunsumio™ is still new for FY 2024 because the 3-year anniversary date (December 22, 2025, or January 6, 2026, respectively) would occur after FY 2024. Because we did not receive any additional information about whether the technology was available for sale before January 6, 2023, we therefore consider the beginning of the newness period to commence on December 22, 2022.

With respect to the cost criterion, the applicant provided multiple analyses to demonstrate that it meets the cost criterion. For each analysis, the applicant searched the FY 2021 MedPAR file using different ICD–10–CM codes to identify potential cases representing patients who may be eligible for Lunsumio™. The applicant explained that it used different codes to identify different cohorts that may be eligible for the technology. Each analysis followed the order of operations described in the following table.

For the first analysis, the applicant searched for cases reporting ICD–10–CM diagnosis codes for follicular lymphoma without a corresponding chemotherapy administration code. The applicant used the inclusion/exclusion criteria described in the following table. Under this analysis, the applicant identified 704 claims mapping to 12 MS–DRGs. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $104,824, which exceeded the average case-weighted threshold amount of $96,820.

For the second analysis, the applicant searched for cases reporting ICD–10–CM diagnosis codes for follicular lymphoma excluding follicular lymphoma grade 3B (FL3B) without a corresponding chemotherapy administration code. The applicant used the inclusion/exclusion criteria described in the following table. Under this analysis, the applicant identified 687 claims mapping to 12 MS–DRGs. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $103,171, which exceeded the average case-weighted threshold amount of $96,578.

For the third analysis, the applicant searched for cases reporting ICD–10–CM diagnosis codes for follicular lymphoma with accompanying chemotherapy administration codes. The applicant used the inclusion/exclusion criteria described in the following table. Under this analysis, the applicant identified 844 claims mapping to 13 MS–DRGs. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $101,992, which exceeded the average case-weighted threshold amount of $98,198.

For the fourth analysis, the applicant searched for cases reporting ICD–10–CM diagnosis codes for follicular lymphoma excluding FL3B with accompanying chemotherapy administration codes. The applicant used the inclusion/exclusion criteria described in the following table. Under this analysis, the applicant identified 813 claims mapping to 13 MS–DRGs. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $99,322, which exceeded the average case-weighted threshold amount of $97,505.
We invited public comments on whether Lunsumio™ meets the cost criterion.

Comment: The applicant submitted a comment that summarized the results of the four analyses discussed in the proposed rule, and reiterated that regardless of the criteria for selecting the cases for the analysis, the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount. Therefore, Lunsumio™ meets the cost criterion.

With regard to the substantial clinical improvement criterion, the applicant asserted that Lunsumio™ represents a substantial clinical improvement over existing technologies because it will expand access to patients for whom existing therapies are not adequate and because it offers patients with 3L+ FL multiple substantial clinical benefits, including high efficacy with significant tolerability; broad efficacy across patients with 3L+; and the opportunity to achieve sustained remission without continuous treatment. The applicant provided 13 studies to support these claims as well as 34 background articles. The following table summarizes the applicant’s assertions regarding the substantial clinical improvement criterion. Please see the online posting for Lunsumio™ for the applicant’s complete statements regarding the substantial clinical improvement criterion and the supporting evidence provided.

### LUNSUMIO™ COST ANALYSIS

<table>
<thead>
<tr>
<th>Data Source and Time Period</th>
<th>FY 2021 MedPAR file</th>
</tr>
</thead>
<tbody>
<tr>
<td>List of ICD-10-CM codes</td>
<td>Scenarios 1-4: Please see Table 10.14.A - Lunsumio™ Codes - FY 2024 associated with the proposed rule for the complete list of ICD-10-CM codes included in the cost analysis.</td>
</tr>
<tr>
<td>List of ICD-10-PCS codes</td>
<td>Scenarios 1-4: Please see Table 10.14.A - Lunsumio™ Codes - FY 2024 associated with the proposed rule for the complete list of ICD-10-PCS codes included in the cost analysis.</td>
</tr>
<tr>
<td>List of MS-DRGs</td>
<td>Scenarios 1-4: Please see Table 10.14.A - Lunsumio™ Codes - FY 2024 associated with the proposed rule for the complete list of MS-DRGs included in the cost analysis.</td>
</tr>
<tr>
<td>Inclusion/exclusion criteria</td>
<td>Scenario 1: The applicant required the presence of a follicular lymphoma ICD-10-CM code from C82.00 to C82.99 as listed in Table 10.14.A - Lunsumio™ Codes - FY 2024 associated with the proposed rule as it believes these codes represent indications for Lunsumio™. As a potential patient would need to fail an established prior therapy and not be engaged in active treatment, the applicant then removed all claims with a diagnosis code listed in Table 10.14.A - Lunsumio™ Codes - FY 2024 associated with the proposed rule that suggested the patient was still actively in the bone marrow transplant process and would not receive Lunsumio™. Additionally, cases that had at least one chemotherapy administration-related ICD-10-PCS code from Table 10.14.A - Lunsumio™ Codes - FY 2024 associated with the proposed rule were removed.</td>
</tr>
<tr>
<td></td>
<td>Scenario 2: The applicant selected claims based on scenario 1, except that cases with ICD-10-CM codes listed in Table 10.14.A - Lunsumio™ Codes - FY 2024 associated with the proposed rule for FL3B patients were excluded to align with one portion of the clinical trial.</td>
</tr>
<tr>
<td></td>
<td>Scenario 3: The applicant selected claims based on scenario 1, except that cases with ICD-10-CM codes listed in Table 10.14.A - Lunsumio™ Codes - FY 2024 associated with the proposed rule with chemotherapy administration-related codes were included in the analysis.</td>
</tr>
<tr>
<td></td>
<td>Scenario 4: The applicant selected claims based on scenario 3, except cases that had at least one chemotherapy administration-related ICD-10-PCS code listed in Table 10.14.A - Lunsumio™ Codes - FY 2024 associated with the proposed rule for FL3B patients were removed.</td>
</tr>
<tr>
<td></td>
<td>Only claims that would be used for Medicare IPPS rate setting were included (fee-for-service IPPS discharges, plus Maryland hospital discharges). All case counts less than 11 were imputed to have 11 cases. The applicant excluded all cases from PPS-exempt hospitals in its cost criterion analysis and calculated the average unstandardized charge per case for each MS-DRG.</td>
</tr>
<tr>
<td>Charges removed for prior technology</td>
<td>No charges were removed because the applicant stated that patients receiving Lunsumio™ would benefit from pain and inflammation relief included in the charges on the claim. The applicant did not remove indirect charges related to the prior technology.</td>
</tr>
<tr>
<td>Standardized charges</td>
<td>The applicant used the standardization formula provided in Technical Appendix A of the application. The applicant used all relevant values reported in the impact file posted with the FY 2023 IPPS/LTCH PPS final rule.</td>
</tr>
<tr>
<td>Inflation factor</td>
<td>The applicant applied an inflation factor of 13.2% to the standardized charges, based on the inflation factor used to calculate outlier threshold charges in the FY 2023 IPPS/LTCH PPS final rule.</td>
</tr>
<tr>
<td>Charges added for the new technology</td>
<td>The applicant did not include charges for Lunsumio™.</td>
</tr>
<tr>
<td>Substantial Clinical Improvement Assertion #1: The technology offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments.</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>Applicant statements in support</strong></td>
<td><strong>Supporting evidence provided by the applicant</strong></td>
</tr>
<tr>
<td>Increases treatment options for patients who do not have an EZH2 mutation and provides an additional option for patients who do have the mutation</td>
<td>Budde LE, et al. Lancet Oncol. 2022; Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicenter, phase 2 study. 23(8):P1055-P1065, <a href="https://doi.org/10.1016/">https://doi.org/10.1016/</a></td>
</tr>
<tr>
<td>Efficacy in patients with prior CAR T-cell treatment (100% ORR, 33% CR)</td>
<td>Budde LE, et al. (2022) op.cit. See prior study description</td>
</tr>
<tr>
<td>Low frequency and severity of CRS</td>
<td>Budde, LE, et al. (2022) op.cit. See prior study description</td>
</tr>
<tr>
<td>Is an off-the-shelf therapy that does not require personalized manufacturing</td>
<td>Budde LE, et al. (2022) op.cit., See prior study description</td>
</tr>
<tr>
<td>Will increase treatment options for patients who</td>
<td>Budde LE, et al. (2022). op.cit.</td>
</tr>
</tbody>
</table>

The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology.
<table>
<thead>
<tr>
<th>Have a higher risk of TEAEs and neurological AE$\text{s}$.</th>
<th>See prior study description</th>
<th>3% of 90; grade 1–2, disturbance in attention (one [1%]; grade 1), and cognitive disorder (one [1%]; grade 1). All events resolved. Neurological events consistent with ICANS: 5 events All events resolved. Any treatment-emergent adverse events (TEAE): 92.2% Grade 3/4 TEAE: 51.1%. The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Will be widely available to patients, substantially improving access to 3L treatment as an off-the-shelf therapy</td>
<td>Budde LE, et al. (2022) op.cit. See prior study description</td>
<td>A single-arm, multicenter, phase II study was conducted at 49 centers in seven countries (Australia, Canada, Germany, South Korea, Spain, UK, and USA). The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology.</td>
</tr>
<tr>
<td><strong>Substantial Clinical Improvement Assertion 2: Use of the new medical service or technology significantly improves clinical outcomes relative to services or technologies previously available.</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Fixed-treatment duration allows patients to have time off treatment without exhausting the drug class and the potential for retreatment with Lunsumio™</strong></td>
<td>Budde LE, et al. (2022) op.cit. See prior study description</td>
<td>Patients who reached a complete response completed treatment after cycle 8. Patients who reached a partial response or had stable disease after cycle 8 continued treatment for up to 17 cycles. Retreatment was allowed in complete responders who progressed after completion of initial treatment.</td>
</tr>
<tr>
<td>Cheah, Y.C., M.L. Bartlett, S. Assouline, et al. (2022) Mosunetuzumab treatment is effective and well-tolerated in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. 2022 European Hematology Association Annual Meeting, poster 1124. Brief study description: Poster presentation of single-arm trial of Lunsumio</td>
<td></td>
<td>Patients with relapsed or refractory follicular lymphoma (FL) (n=9) Observed response: 6 (66.7%); median duration of response (mDOR), months: 5.4–20.7. Complete response (CR): 4 (44.4%); mDOR, months: 8.3–20.7. Of 9 patients with FL who were retreated with Lunsumio™, 6 had second responses (4 CR and 2 Partial response (PR)). Any grade AE related to Lunsumio™: Initial treatment phase (N=15) 100%; Retreatment phase (N=15) 86.7% -Grade 3/4 AE related to Lunsumio™: Initial treatment phase (N=15) 60%; Retreatment phase (N=15) 46.7% -CRS any grade: Initial treatment phase (N=15) 26.7%; Retreatment phase (N=15) 33.3%. Our results show that IV Lunsumio™ monotherapy retreatment was efficacious in heavily pretreated patients with R/R NHL who initially achieved a CR with Lunsumio™ treatment, but subsequently developed progressive disease (PD), indicating treatment activity through multiple lines of therapy. Lunsumio™ retreatment had a manageable safety profile, consistent with that observed with initial treatment.</td>
</tr>
<tr>
<td><strong>Fixed-treatment duration therapy provides patients with time off treatment and the potential to increase patient quality of life (QOL)</strong></td>
<td>Budde LE, et al. (2022) op.cit. See prior study description</td>
<td>The proportion of patients who achieved an objective response according to IRC assessment was 80.0% (95% CI 70.3–87.7; 72 of 90 patients) and the proportion with a complete response was 60.0% (49.1–70.2; 54 of 90 patients). The median number of cycles of Lunsumio™ received was eight (IQR 8–8). Median duration of response per IRC was 22.8 months (95% CI 9.7–not reached). mDOR: 22.8 months. Notably, adverse events leading to Lunsumio™ discontinuation were rare and occurred in only four patients (4 of 90 patients = 4.4%). The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology.</td>
</tr>
<tr>
<td>Lunsumio™ is efficacious in all subgroups investigated including heavily pretreated, highly refractory patients and those aged ≥65 years</td>
<td>Budde LE, et al. (2022) op.cit. See prior study description</td>
<td>The proportion of patients who achieved an objective response according to IRC assessment was 80.0% (95% CI 70.3–87.7; 72 of 90 patients) and the proportion with a complete response was 60.0% (49.1–70.2; 54 of 90 patients). Forest plot of ORR and CR rate by IRC in pre-specified patient subgroups. Lunsumio™ (N=90) 2 therapies (N=34) CR: 74% ORR: 85% ±3 therapies (N=56) CR: 52% ORR: 77% POD24 Yes (N=47) CR: 57% ORR: 85% POD24 No (N=43) CR: 63% ORR: 74% Refractory to last prior therapy Yes (N=62) CR: 52% ORR: 77% Refractory to last prior therapy No (N=28) CR: 79% ORR: 86% Refractory to any prior anti-CD20 and an alkylating agent (double refractory) Yes (N=48) CR: 50% ORR: 71% Refractory to any prior anti-CD20 and an alkylating agent (double refractory) No (N=42) CR: 71% ORR: 90% &lt;65 years (N=60) CR: 55% ORR: 77% ≥65 years (N=30) CR: 70% ORR: 87%.</td>
</tr>
</tbody>
</table>
In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26830), after review of the information provided by the applicant, we stated that we had the following concerns regarding whether Lunsumio™ meets the substantial clinical improvement criterion. We noted that the applicant provided a single-arm, phase II trial of 90 patients, sub-study analysis, and another single-arm phase I/II trial of 15 patients to support its claims of substantial clinical improvement. As noted in the previous table, the studies evaluated complete response rates or indicators of safety, but did not evaluate survival as a primary outcome. They were also single-arm, without comparison to other existing treatments for the patient population. The applicant compared outcomes of the phase II trial with Lunsumio™ to outcomes, including QOL and AE from background studies of other technologies. However, we noted limitations in comparing to rates found in other clinical trials that were conducted in earlier time periods and under different circumstances of patient enrollment and treatment options. Additionally, the historical rates were compared directly to those from Lunsumio™ without more detailed adjustment for patient characteristics. Without a direct comparison of outcomes between these therapies, we were concerned as to whether the differences in outcomes identified by the applicant translate to clinically meaningful differences or improvements for patients treated with Lunsumio™ as compared to historical rates for other treatments.

We invited public comments on whether Lunsumio™ meets the substantial clinical improvement criterion.

Comment: The applicant submitted a public comment in response to CMS’s concerns regarding substantial clinical improvement. In response to the issue of study design, the applicant responded that there are benefits and limitations to single-arm studies in the 3L+ FL setting. The applicant noted that single-arm studies are an important mechanism to facilitate faster access to novel therapies, especially for patients who have exhausted other approved options. According to the applicant, investigating Lunsumio™ for patients in the 3L+ FL setting is an example of using a single-arm clinical trial strategy to bring a novel treatment to patients who have an unmet need. Other benefits of single-arm trials are smaller sample size requirements, shorter completion time, and the ability to identify signs of efficacy early in drug development. At the same time, the applicant acknowledged that single-arm studies are most appropriate for assessing response rates and since they lack a comparator arm, time-to-event endpoints, such as progression-free survival and overall survival, can only be understood in the context of a historical control. The applicant also noted that evaluation of safety outcomes is likewise limited by a lack of a comparator arm. Nonetheless, the applicant maintained that despite these limitations, single-arm trials are a valuable tool for drug discovery.

With regard to the use of historical control without adjusting for potential confounders, the applicant stated that...
The applicant asserted that therefore, the criteria used to assess response in patients with R/R FL who had 2+ prior systemic therapies across all pivotal trials reflects a similar approach to assessing antitumor activity for each therapeutic option.

In addition, the applicant included results of an updated analysis of the pivotal Lunsumio™ study (that is, Budde et al. 2022) in their comments. According to the applicant, the median duration of complete response (DOCR) was not reached (median time on study was 28.6 months). The 24-month DOCR rate after first CR was 65 percent (95% CI, 39–90). Also, the applicant stated that median Physician Fee Schedule (PFS) was not reached; 24-month PFS rate was 77 percent (95% CI, 63–91). Per the applicant, two years after the end of fixed-duration treatment, 67 percent of these 49 patients remained free of progressive disease or death. The applicant maintained that these outcomes approached the best ORRs and CRs reported with axicabtagene ciloleucel and tisagenlecleucel (ORRs of 91% and 86% and CRs of 60% and 68%, respectively) and were substantially better than the best outcomes with copanlisib (ORR of 50% and CR 14%) and tazemetostat (mutant EZH2 was 69% ORR and 12% CR; wild-type EZH2 was 34% ORR and 4% CR). The applicant stated that in addition, at 22.8 months, the median DOR with Lunsumio™ was longer than both copanlisib (DOR: 12.2 months) and tazemetostat (mutant EZH2 DOR of 10.9 months, wild-type EZH2 was 10.9 months).

Response: We thank the applicant for their comment regarding the substantial clinical improvement criterion. Based on the additional information received, we agree that Lunsumio™ represents a substantial clinical improvement over existing technologies for the treatment of patients with 3L+FL because Lunsumio™ offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments, in particular: R/R FL patients who have undergone 2+ prior treatments, but cannot access any of the four PI3K inhibitors or EZH2 inhibitor approved by FDA for 3L+ treatment of R/R FL; patients with EZH2 mutation, who are contra-indicated for tazemetostat, an EZH2 inhibitor approved for R/R FL; and patients who were unable to tolerate CAR T-cell therapy.

After consideration of the public comments received and the information included in the applicant’s new technology add-on payment application, we have determined that Lunsumio™ meets the criteria for approval for new technology add-on payment. Therefore, we are approving new technology add-on payments for this technology for FY 2024. Cases involving the use of Lunsumio™ that are eligible for new technology add-on payments will be identified by ICD–10–PCS codes: XW03358 (Introduction of mosunetuzumab antineoplastic into peripheral vein, percutaneous approach, new technology group 8), or XW04358 (Introduction of mosunetuzumab antineoplastic into central vein, percutaneous approach, new technology group 8).

Per the applicant, the WAC of Lunsumio™ is $594.06 for a 1 mg single dose vial. As stated previously, according to the applicant, Lunsumio™ is sold in a 1 mg and 30 mg single dose vial (we note, a 30 mg single dose vial is priced at the 1 mg single dose vial × 30 = $17,821.80). According to the applicant, most of the inpatient usage would occur as the result of adverse events, mainly CRS, that develop after outpatient administration of the drug, and that in clinical trials, when Grade 2, 3, or 4 CRS developed, 75 percent of the time it occurred after a 60 mg dose, 20 percent of the time it developed after a 1 mg dose, and 5 percent after a 2 mg dose. Based on this information, we determined a weighted average inpatient dose of 45.3 mg. Therefore, the average cost per patient for Lunsumio™ is $26,910.92 (45.3 mg * $594.06 per 1 mg vial). Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, the maximum new technology add-on payment for a
case involving the use of Lunsumio™ is $17,492.10 for FY 2024.

e. NexoBrid™ (Anacaulase-bcdb)

Vericel Corporation submitted an application for new technology add-on payments for NexoBrid™ for FY 2024. According to the applicant, NexoBrid™ is a novel, non-surgical option for eschar removal (debridement) in adult patients with deep partial thickness (DPT) and/or full thickness (FT) thermal burns. Per the applicant, NexoBrid™ is a botanical and biologic product for topical use consisting of a concentrate of proteolytic enzymes enriched in bromelain extracted from pineapple stems. We note that Vericel Corporation submitted an application for new technology add-on payments for NexoBrid™ for FY 2022, as summarized in the FY 2022 IPPS/LTCH PPS proposed rule (86 FR 25286 through 25291), that it withdrew prior to the issuance of the FY 2022 IPPS/LTCH PPS final rule (86 FR 44774).

Please refer to the online application posting for NexoBrid™, available at https://mearis.cms.gov/public/publications/ntap/NTP21017WGWT, for additional detail describing the technology and the condition treated by the technology.

With respect to the newness criterion, according to the applicant, NexoBrid™ was granted BLA approval from FDA on December 28, 2022, for eschar removal (debridement) in adults with DPT and/or FT thermal burns. According to the applicant, NexoBrid™ is expected to be commercially available the end of June or beginning of July 2023 in the U.S. market as manufacturing preparations are currently underway. NexoBrid™ is applied topically to the wound at 2-gram lyophilized powder with 20-gram gel vehicle per 1% total body surface area (TBSA), or 5-gram lyophilized powder with 50-gram gel vehicle per 2.5% TBSA, up to an area of up to 15% TBSA in one application. The applicant estimated that the average U.S. patient will receive approximately 2.8 5-gram packs of NexoBrid™ per inpatient stay, based upon the average NexoBrid™-treated area of 6.28% TBSA in the DETECT clinical trial with an expected wastage assumption of approximately 10 percent, as well as commercial use of the technology in Europe.

The applicant stated that effective October 1, 2021, the following ICD–10–PCS codes may be used to uniquely describe procedures involving the use of NexoBrid™: XW00X27 (Introduction of bromelain-enriched proteolytic enzyme into skin, external approach, new technology group 7) and XW01X27 (Introduction of bromelain-enriched proteolytic enzyme into subcutaneous tissue, external approach, new technology group 7).

As previously discussed, if a technology meets all three of the substantial similarity criteria under the newness criterion, it would be considered substantially similar to an existing technology and would not be considered “new” for the purpose of new technology add-on payments.

With respect to the substantial similarity criteria, the applicant asserted that NexoBrid™ is not substantially similar to other currently available technologies because NexoBrid™ has a novel mechanism of action and is the first enzymatic technology to achieve rapid, consistent eschar removal; the applicant further asserted that the active ingredient in NexoBrid™ has never been approved in any application under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) of 1938 or section 351(a) of the Public Health Service (PHS) Act; and no existing technology under the existing burn DRGs is similar to NexoBrid™, and that therefore, the technology meets the newness criterion. The following table summarizes the applicant’s assertions regarding the substantial similarity criteria. Please see the online application posting for NexoBrid™ for the applicant’s complete statements in support of its assertion that NexoBrid™ is not substantially similar to other currently available technologies.
However, we had the following concerns with regard to the newness criterion. We noted in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26831) that as discussed in the FY 2022 IPPS/LTCH PPS proposed rule (86 FR 25288), while the applicant discussed the differences between NexoBrid™ and collagenase-based products, we did not receive enough information regarding the specific composition of the proteolytic enzymes used within the NexoBrid™ active pharmaceutical ingredient and its mechanism of action. Specifically, it was unclear whether the proteolytic enzymes act similarly to existing collagenase-based enzymatic debridement products since the applicant claimed that NexoBrid™ debrides denatured collagen in the wound. We also noted that the applicant asserted that NexoBrid™ is not assigned to the same MS–DRGs as existing technologies used for burns, although it seemed that NexoBrid™ would be assigned to the same burn MS–DRGs as other enzymatic and surgical debridement technologies.

We invited public comments on whether NexoBrid™ is substantially similar to existing technologies and whether NexoBrid™ meets the newness criterion.

**Comment:** A commenter stated that NexoBrid™ does not meet the newness criterion because it has been commercially available in the European Union for a decade. Additionally, the commenter noted fruit-based enzymatic debridement products have been utilized for decades and marketed under various trade names, including Accuzyme®, Allanzyme, Ethenzym, Gladase™, Kovie, and Panafil. The commenter explained that these enzymatic debridement products utilize papain extract from papaya fruit (Carica papaya) and exhibit identical activation catalytic mechanisms as NexoBrid™’s pineapple-derived enzymes. The commenter further explained that papain and bromelain are fruit-derived cysteine proteases, also known as thiol proteases, with non-specific degradation profiles and proteolytic mechanisms of action. The commenter added that in addition to the fruit-based enzymatic debridement products mentioned, SANTYL® Collagenase Ointment is an enzymatic debridement product that has been commercially available since its approval in 1965 and is utilized to treat chronic dermal ulcers and severe burns.

**Response:** We thank the commenter and have taken it into consideration in determining whether NexoBrid™ meets the newness criterion, discussed later in this section.

<table>
<thead>
<tr>
<th>Substantial Similarity Criteria</th>
<th>Applicant Response</th>
<th>Applicant assertions regarding this criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does the technology use the same or similar mechanism of action to achieve a therapeutic outcome?</td>
<td>No</td>
<td>Collagenase-based technologies (that is, C.O), the comparator products presently on the market for burns, are generally considered inefficient, can result in a lengthy sloughing period, and have the potential for development of granulation tissue and increased infection and scarring. These products are all based on Clostridial collagenase, a bacterial enzyme that breaks down collagen in damaged tissue and helps healthy tissue to grow. Such products only have one major mode of action: proteolysis of a single substrate, resulting in cleavage of necrotic tissue at seven specific sites along the denatured collagen strand. In contrast, NexoBrid™ has a novel mechanism of action and is the first enzymatic technology to achieve rapid, consistent eschar removal. NexoBrid™ contains a concentrate of proteolytic enzymes enriched in bromelain extracted from pineapple stems (Ananas comosus L. Merr.) These pineapple stems are obtained from distinct pineapple cultivars, and they are processed using Bromelain Special Production (BSP), a proprietary method, from which the NexoBrid™ drug substance and drug product are produced. By design, NexoBrid™ is a combination of different thiol endopeptidases and other components such as phosphatases, glucosidases, peroxidases, cellulases and escharase. Because it is a natural product with a mixture of components, it has complex and varied modes of action, and thus it is an improvement on a single mode of action product such as a collagenase. The major mechanism of action of NexoBrid™ on wound healing is mediated by the proteolytic activity of its enzymes. It is associated selective degradation of eschar and denatured collagen while sparing healthy tissue.</td>
</tr>
<tr>
<td>Is the technology assigned to the same MS–DRG as existing technologies?</td>
<td>No</td>
<td>No existing technology used now (or previously) to treat patients under the existing burn DRGs (for example, 927, 928, 929, 933, 934, 935) is similar to NexoBrid™. As described previously, existing technologies for eschar removal are either surgical in nature or, if enzymatic, rely on collagenase (and not bromelain).</td>
</tr>
<tr>
<td>Does new use of the technology involve the treatment of the same/similar type of disease and the same/similar patient population when compared to an existing technology?</td>
<td>Yes</td>
<td>NexoBrid™ does treat the same patient population as existing approaches to eschar removal.</td>
</tr>
</tbody>
</table>
Comment: The applicant submitted a comment reiterating its assertion that NexoBrid™ has a novel mechanism of action that satisfies the newness criterion. The applicant stated that the active pharmaceutical ingredient in NexoBrid™, anacaulase-bcbd, is a mixture of proteolytic enzymes extracted from the stems of pineapple plants and is composed mainly (80% to 95% weight by weight [w/w]) of stem bromelain, ananain, jacalin-like lectin, bromelin inhibitors, phytocystatin inhibitor, small molecule metabolites, and saccharides, as both free monosaccharides and the N-linked glycan of stem bromelain. The applicant further explained that bromelain is a combination of thiol endopeptidases and other components, such as phosphatases, glucosidases, peroxidases, cellulases, glycoproteins, carbohydrates, and several protease inhibitors.

In response to CMS's concern regarding NexoBrid™'s mechanism of action, the applicant stated that NexoBrid™ degrades collagen by bromelain via a combination of endopeptidases and other enzymes. The applicant further explained that this degradation by bromelain results in a wide range of reactions beyond hydrolysis, such as peroxidases catalyze oxidation reactions, and acts on a group of substrates, including gelatin, chromogenic triptides, and casein. Additionally, the applicant noted, in the context of eschar removal, it has been hypothesized that the presence of multiple proteolytic enzymes likely results in the degradation of multiple substrates contained within the eschar in addition to denatured collagen. The applicant stated that NexoBrid™'s combination of enzymes is unique and distinct from collagenase-based debridement agents, which are primarily composed of collagenase derived from Clostridium histolyticum in petrolatum USP. The applicant explained that clostridial collagenase-based debridement agents are based on proteolysis of a collagen substrate through hydrolysis reactions and result in cleavage of necrotic tissue at seven specific sites along the denatured collagen strand.

The applicant also asserted that since the mechanism of action of NexoBrid™ differs significantly from collagenase-based debridement agents, the dosage and administration, as well as resulting clinical outcome, is also different. The applicant explained that NexoBrid™ is applied to the burn wound once (in some cases twice, for a four-hour period) and was shown in clinical studies to achieve complete eschar removal (295% eschar removal) in 93 percent of patients, while on the other hand, collagenase-based debridement agents are typically used daily, as a continuous application for multiple days with varying results.

In response to CMS's concern regarding the MS–DRG assignment for procedures in which NexoBrid™ is administered, the applicant stated that it may be appropriate for NexoBrid™ administration to be assigned to existing burn MS–DRGs (for example, 927, 928, 929, 933, 934, 935); however, the payment associated with these MS–DRGs would not adequately account for NexoBrid™'s cost. Response: We appreciate the additional information from the applicant and commenters with respect to whether NexoBrid™ is substantially similar to existing technologies. As stated in the preamble of this section, a specific medical service or technology will no longer be considered "new" for purposes of new medical service or technology add-on payments after CMS has recalibrated the MS–DRGs based on available data, to reflect the cost of the technology. Therefore, we disagree with the commenter that NexoBrid™ would not be considered new because it was launched a decade ago in the European Union, as the available data to reflect the cost of the technology would not have been available for CMS to recalibrate the MS–DRGs for those administrations.

We also disagree with the commenter that fruit-based enzymatic debridement products that have not received FDA marketing authorization are appropriate existing technology comparators for evaluating whether a new technology is substantially similar to an existing technology. As stated in the preamble of this section, even if a medical product receives a new FDA approval or clearance, it may not necessarily be considered "new" for purposes of new technology add-on payments if it is "substantially similar" to another medical product that was approved or cleared by FDA and has been on the market for more than 2 to 3 years. We believe that technologies that receive FDA marketing authorization have met regulatory standards that provide a reasonable assurance of safety and efficacy. We maintain that our intent in requiring applicants to receive FDA marketing authorization was to exclude technologies that lack FDA marketing authorization. Therefore, we do not believe that medical products that have not received FDA marketing authorization are appropriate comparators for evaluating if a new technology is "substantially similar" to another medical product that was approved or cleared by FDA and has been on the market for more than 2 to 3 years.

2
2 Regarding the first criterion, whether a technology uses the same or similar mechanism of action to achieve a therapeutic outcome, we agree with the commenter that there is an existing enzymatic debrider, the SANTYL Collagenase Ointment, that is commercially available for the treatment of burn and chronic wounds. We note that the applicant asserted that NexoBrid™ has a novel composition because it contains a unique pharmaceutical ingredient derived from pineapple and therefore has a unique combination of proteolytic enzymes as compared to collagenase-based debridement agents that are derived from Clostridium histolyticum. However, we note that the composition/ingredients of a technology does not represent the mechanism of action. Further, while the applicant asserted that NexoBrid™ degrades collagen via multiple reactions beyond hydrolysis, while clostridial collagenase degradation is based on hydrolysis reactions, we note that the applicant hypothesizes, but does not demonstrate that the presence of multiple proteolytic...
enzymes by Nexobrid™ results in the degradation of multiple substrates contained within the eschar in addition to denatured collagen. In addition, although we recognize that Nexobrid™ has a different use case than collagenase-based debridement agents with respect to the dosage and administration, these differences do not result in a substantially different therapeutic mechanism of action, and in our view, any differences in the resulting clinical outcome relate to an assessment of whether Nexobrid™ meets the substantial clinical improvement criterion. Therefore, even though there may be differences in composition between bromelain and clotridial collagenase, resulting in collagen degradation through hydrolysis and other reactions, these two technologies use a similar mechanism of action to achieve the same therapeutic outcome: the enzymatic degradation of collagen to debride eschar for the treatment of burns.

In regard to the second criterion, whether a technology is assigned to the same or a different MS–DRG; we note that the applicant acknowledged that the use of Nexobrid™ may be assigned under the existing MS–DRGs (for example, 927, 928, 929, 933, 934, 935), but stated the payment associated with these MS–DRGs does not adequately account for the cost of Nexobrid™. We agree with the applicant that Nexobrid™ would be assigned to these same burn MS–DRGs as other enzymatic and surgical debridement technologies used in the treatment of burns. However, we believe that inadequate payment for the technology associated with these MS–DRGs relates to an assessment of whether Nexobrid™ meets the cost criterion, rather than an assessment of substantial similarity.

In regard to the third criterion, whether a technology treats the same or similar type of disease and patient populations, we agree with the applicant’s assertion in its application that use of the technology would involve the treatment of burns. However, we believe that inadequate payment for the technology associated with these MS–DRGs relates to an assessment of whether Nexobrid™ meets the cost criterion, rather than an assessment of substantial similarity.

Because Nexobrid™ meets all three of the substantial similarity criteria, we believe the Nexobrid™ is substantially similar to an existing collagenase-based debridement agent, SANTYL Collagenase Ointment. Therefore, we consider the beginning of the newness period for Nexobrid™ to begin on the date on which SANTYL Collagenase Ointment received FDA approval for the treatment of burns. Since SANTYL Collagenase Ointment has been on the U.S. market for many years, the 3-year anniversary date of its entry onto the market occurred prior to FY 2024, 93 and therefore, Nexobrid™ does not meet the newness criterion and is not eligible for new technology add-on payments for FY 2024. We note that we received public comments with regard to the cost and substantial clinical improvement criterion for this technology, but because we have determined that the technology does not meet the newness criterion and therefore is not eligible for approval for new technology add-on payments for FY 2024, we are not summarizing comments received or making a determination on those criteria in this final rule.

f. REBYOTA™ (Fecal Microbiota, Live-jslm) and VOWST™ (Fecal Microbiota Spores, Live-brpk)

Two manufacturers, Ferring Pharmaceuticals, Inc., an affiliate of the manufacturer, Rebiotix Inc., and Seres Therapeutics, Inc., submitted separate applications for new technology add-on payments for FY 2024 for REBYOTA™ (focal microbiota, live-jslm, referred to as ‘RBX2660’ in the proposed rule) and VOWST™ (focal microbiota spores, live-brpk, referred to as ‘SER–109’ in the proposed rule), respectively. Both of these technologies are microbiota-based treatments indicated for the reduction or prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI (rCDI). In the FY 2024 IPPS/LTCF PPS proposed rule, we discussed these applications as two separate technologies. After further consideration, and as discussed elsewhere, we believe REBYOTA™ and VOWST™ are substantially similar to each other and that it is appropriate to evaluate both technologies as one application for new technology add-on payments under the IPPS. We refer the reader elsewhere for a complete discussion regarding our analysis of the substantial similarity of REBYOTA™ and VOWST™.


With respect to the newness criterion, the applicant for REBYOTA™ received BLA approval from FDA on November 30, 2022, for the prevention of rCDI in individuals 18 years of age and older, following antibiotic treatment for rCDI. According to the applicant, REBYOTA™ is a broad consortium microbiota-based live biotherapeutic suspension indicated for the prevention of recurrence of CDI in individuals 18 years of age and older, following antibiotic treatment for rCDI. Per the applicant, REBYOTA™ is administered rectally, 24 to approximately 72 hours after the last dose of antibiotics for CDI. The applicant stated that each 150mL dose of REBYOTA™ contains between 1x10^8 and 5x10^10 colony forming units (CFU) per mL of fecal microbes including more than 1x10^5 CFU/mL of Bacteroides and contains not greater than 5.97 grams of PEG3350 in saline. Per the applicant, REBYOTA™ first became commercially available on January 23, 2023, as the process to create packaging components and then start the packaging process could not start until FDA approval was received. The applicant stated that it received BLA approval from FDA on April 26, 2023, for the prevention of the recurrence of CDI in individuals 18 years of age and older following antibacterial treatment for rCDI. The applicant stated that the dose is four capsules taken orally once daily on an empty stomach before the first meal of the day for 3 consecutive days. The applicant stated that VOWST™ is an oral microbiome therapeutic administered to reduce CDI recurrence as part of a two-pronged treatment approach of (1) antibiotics to kill vegetative C. diff bacteria, followed by (2) VOWST™ to repair the microbiome to manage CDI and prevent its recurrence. According to the applicant, VOWST™ is a consortium of purified Firmicutes bacteria spores collected from healthy stool donors. The applicant stated that engraftment of spore producing Firmicutes bacteria is a necessary first step in microbiome repair, as Firmicutes bacteria produce metabolites, such as secondary bile acids, which inhibit C. diff spore germination and vegetative growth.

The applicant for REBYOTA™ stated that, effective October 1, 2022, the following ICD–10–PCS code may be used to uniquely describe procedures involving the use of REBYOTA™: WX0H7X8 (Introduction of broad consortium microbiota-based live biotherapeutic suspension into lower GI, via natural or artificial opening, new tech. group B). The applicant for VOWST™ submitted a request for approval for a unique ICD–10–PCS code for VOWST™ beginning in FY 2024 and
was granted approval for the following ICD–10–PCS procedure code, effective October 1, 2023: XW0DXN9 (Introduction of SER–109 into mouth and pharynx, external approach, new technology group 9). Both applicants stated that diagnosis codes A04.71 (Enterocolitis due to Clostridium difficile, recurrent) and A04.72 (Enterocolitis due to Clostridium difficile, not otherwise specified as recurrent) may be used to currently identify the indication for their technologies under the ICD–10–CM coding system.

As stated earlier and for the reasons discussed later in this section, we believe that REBYOTA™ and VOWST™ are substantially similar to each other such that it is appropriate to analyze these two applications as one technology for the purposes of new technology add-on payments, in accordance with our policy. We discuss the information provided by the applicants, as summarized in the FY 2024 IPPS/LTCH PPS proposed rule, regarding whether REBYOTA™ and VOWST™ are substantially similar to existing technologies. As discussed earlier, if a technology meets all three of the substantial similarity criteria, it would be considered substantially similar to an existing technology and would not be considered “new” for purposes of new technology add-on payments.

With respect to the substantial similarity criteria, whether a product uses the same or a similar mechanism of action to achieve a therapeutic outcome, in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26853 through 26854), the applicant for REBYOTA™ stated that REBYOTA™ is not substantially similar to other currently available technologies to reduce rCDI because REBYOTA™ has a new mechanism of action and is approved to treat a broader patient population than existing therapies (including standard of care antibiotics (for example, DIFICID®, FIRVANQ®), Fecal Microbiota Transplantation (FMT), and ZINPLAVA™), and that therefore, the technology meets the newness criterion. The following table summarizes the applicant’s assertions regarding the substantial similarity criteria. Please see the online application posting for REBYOTA™ for the applicant’s complete statements in support of its assertion that REBYOTA™ is not substantially similar to other currently available technologies.
In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26854), we noted the following concern with regard to the newness criterion for REBYOTA™. We noted that the applicant stated that ZINPLAVA™ is restricted to high-risk patients, and we questioned whether these high-risk patients were the same or a similar patient population as that treated with REBYOTA™, which is indicated for patients who have already had at least one recurrence of rCDI. In addition, we noted that the indication for ZINPLAVA™ does not exclude patients with a history of CHF and the labeling has no listed contraindications. Therefore, we sought clarification from the applicant regarding the differences in patient populations for ZINPLAVA™ and REBYOTA™.

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26874 through 26875), according to the applicant for VOWST™, VOWST™ is not substantially similar to other currently available technologies because VOWST™ does not have the same or a similar mechanism of action as any currently FDA-approved CDI treatment and does not involve treatment of the same or similar type of disease or patient population as there are currently no approved therapies indicated to repair a disrupted microbiome as a treatment intervention to prevent recurrence in patients with rCDI. Therefore, the applicant asserted that VOWST™ meets the newness criterion. The following table summarizes the applicant’s assertions regarding the substantial similarity criteria. Please see the online application posting for

<table>
<thead>
<tr>
<th>Substantial Similarity Criteria</th>
<th>Applicant Response</th>
<th>Applicant assertions regarding this criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does the technology use the same or similar mechanism of action to achieve a therapeutic outcome?</td>
<td>No</td>
<td>There are no existing technologies with the same or similar mechanism of action as REBYOTA™ currently approved by the FDA to achieve a therapeutic outcome. While the exact mechanism of action for REBYOTA™ has not been established, in studies, REBYOTA™-treated responders experienced clinically significant change in their gut microbiome, with a shift in gut bile acid predominance, which has been associated with suppression of C. difficile outgrowth. DIFCIT™ (fidaxomicin) is a macrolide antibacterial that is bactericidal against C. difficile in vitro, inhibiting ribonucleic acid (RNA) synthesis by RNA polymerases. FIRVANQ™ (vancomycin hydrochloride) is a glycopeptide antibacterial whose bactericidal action results primarily from inhibition of cell-wall biosynthesis. ZINPLAVA™ (bezlotoxumab) is a human monoclonal antibody that binds C. difficile toxin B. FMT is an investigational and non-standardized treatment that has not been approved by the FDA and its mechanism of action and the extent to which it may affect dysbiosis are not fully understood.</td>
</tr>
<tr>
<td>Is the technology assigned to the same MS-DRG as existing technologies?</td>
<td>Yes</td>
<td>Patients who may be eligible for treatment with REBYOTA™ could have their hospital stays assigned to the same MS-DRGs as patients who receive antibiotics, ZINPLAVA™, or FMT to reduce rCDI.</td>
</tr>
<tr>
<td>Does new use of the technology, involve the treatment of the same/similar type of disease and the same/similar patient population when compared to an existing technology?</td>
<td>No</td>
<td>There are differences in the type of disease and potential patient population for REBYOTA™ compared to existing technologies. Antibiotic treatments are currently recommended as standard-of-care therapy for CDI, an initial rCDI episode, and sometimes for later rCDI episodes. However, CDI-targeted antibiotics maintain and exacerbate a low-diversity microbiome (that is dysbiosis), while microbiome recovery is essential for durable clinical resolution of rCDI. REBYOTA™ is a treatment option that may help patients in reducing rCDI where standard-of-care antibiotics have fallen short. ZINPLAVA™ is indicated to reduce recurrence of CDI in adults who are receiving antibacterial drug treatment of CDI and who are at a high risk for CDI recurrence. The FDA has advised that ZINPLAVA™ should be used with caution—when the benefits outweigh the risks—in patients with a history of congestive heart failure (CHF). REBYOTA™’s use is not restricted to high-risk patients nor is there evidence of increased safety concerns in patients with a history of congestive heart failure CHF. FMT is a non-standardized therapy with limited clinical data that include considerable heterogeneity and variability. The lack of robust clinical data and serious safety concerns make understanding the exact patient population for FMT difficult to identify. REBYOTA™ is an FDA approved treatment alternative that addresses the safety and standardization concerns of FMT for rCDI patients. REBYOTA™ is a readily available, pathogen-tested, pharmaceutical-grade product that, unlike FMT, would not require healthcare providers to perform independent screening of donors or donor specimens.</td>
</tr>
</tbody>
</table>
VOWST™ for the applicant’s complete statements in support of its assertion that VOWST™ is not substantially similar to other currently available technologies.

<table>
<thead>
<tr>
<th>Substantial Similarity Criteria</th>
<th>Applicant Response</th>
<th>Applicant assertions regarding this criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does the technology use the same or similar mechanism of action to achieve a therapeutic outcome?</td>
<td>No</td>
<td>VOWST™ does not have the same or similar mechanism of action as any currently approved treatment for CDI. The two categories of approved therapies for CDI include antibiotics and ZINPLAVATM. Antibiotics function by killing the toxin-producing C. diff bacteria. However, antibiotics also kill beneficial flora, including Firmicutes bacteria, and do not kill dormant C. diff spores. After treatment discontinuation, these spores germinate into toxin-producing vegetative bacteria, which thrive in an environment depleted of Firmicutes bacteria, thereby causing recurrent infections. The symptoms caused by C. diff are caused primarily by the production of an enterotoxin (Toxin A) and/or a cytotoxin (Toxin B), which bind to the surface of endothelial cell receptors in the large intestine and damage the cells lining the intestinal wall. ZINPLAVATM is used concomitantly with standard of care antibiotics and neutralizes Toxin B sites, preventing Toxin B from binding to the host cell. This provides passive immunity against Toxin B; however, ZINPLAVATM does not act to restore the patient’s native gastrointestinal flora. Unlike antibiotics and ZINPLAVATM, VOWST™ prevents rCDI by repairing the microbiome. While the specific mechanism of action of VOWST™ is still under investigation, findings from the ECOSPOR III clinical trial indicate that VOWST™ results in more rapid and durable engraftment of the Firmicute bacteria relative to placebo, producing bile-acid profiles that are known to inhibit C. diff spore germination, and thus reduce rates of recurrent infection.</td>
</tr>
<tr>
<td>Is the technology assigned to the same MS-DRG as existing technologies?</td>
<td>Yes</td>
<td>The MS-DRGs to which cases for VOWST™ administration will be assigned will be the same as compared to the MS-DRGs assigned to an existing technology.</td>
</tr>
<tr>
<td>Does new use of the technology involve the treatment of the same/similar type of disease and the same/similar patient population when compared to an existing technology?</td>
<td>No</td>
<td>There are currently no approved therapies indicated to treat a disrupted microbiome in patients with rCDI. Antibacterial drug treatment to kill vegetative C. diff remains a cornerstone of CDI treatment. However, antibiotics alone are often not adequate for patients diagnosed with rCDI. Even when treatment with an antibacterial drug is successful in treating the initial occurrence of CDI, recurrence of CDI occurs in 40% to 60% of patients who had prior infections, with most occurrences after 3 weeks of antibiotic discontinuation. This recurrence stems from the microbiome disturbance often caused by the antibiotic treatment itself or prior exposure to broad-spectrum antibiotics, combined with persistence of C. diff spores not killed by antibiotic treatment. When germination of these C. diff spores overtake the re-establishment of intestinal microbiota, CDI reemerges together with the need for subsequent treatment. VOWST™ treats rCDI using a two-pronged approach: when followed by antibiotics, which kill the active C. diff infection, VOWST™ prevents the infection from recurring by repairing the microbiome. Thus, unlike antibiotics and ZINPLAVATM, VOWST™ is intended to treat rCDI specifically by reestablishing the microbiome necessary to prevent reinfection. VOWST™ also provides treatment options for patients who cannot currently access other therapies that might be used to treat CDI. In particular, VOWST™ can be administered to patients with a history of congestive heart failure (CHF) where use of ZINPLAVATM should be reserved per the product prescribing information.</td>
</tr>
</tbody>
</table>

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26875 through 26876), we noted the following concern with regard to the newness criterion for VOWST™. The applicant asserted that VOWST™ can be administered to patients with CHF and stated that the use of ZINPLAVATM (bezlotoxumab) should be reserved in this patient population. We noted that the indication for ZINPLAVATM does not exclude patients with a history of CHF.
and the labeling has no listed contraindications. We sought clarification from the applicant regarding the differences in patient populations for ZINPLAVATM and VOWSTTM.

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26854 through 26855 and 26875 through 26876), we noted that REBYOTA™ and VOWST™ may have similar mechanism of actions, and both are microbiome therapeutic agents for which we received an application for new technology add-on payments for FY 2024 to reduce the recurrence of rCDI in adults following antibiotic treatment for rCDI, inclusive of the first recurrence. We stated that notably, the exact mechanism of action for each biological product was not yet known; however, both appeared to act on the gut microbiome to suppress C.diff. and thereby prevent rCDI. Both REBYOTA™ and VOWST™ appeared to lead to compositional changes in the gastrointestinal microbiome that restore the diversity of gut flora which enabled each of these therapeutics to suppress outgrowth of C.diff. and rCDI, following the same or similar disease (rCDI) in the same MS–DRG, as each other and as existing technologies, and to treat the same or similar disease (rCDI) in the same or similar patient population (patients who have previously received standard-of-care antibiotics for CDI or rCDI). Accordingly, since it appeared that REBYOTA™ and VOWST™ were purposed to achieve the same therapeutic outcome using a similar mechanism of action and would be assigned to the same MS–DRG, we stated that these technologies may be substantially similar to each other such that they should be considered as a single application for purposes of new technology add-on payments.

We stated that we believe that if these technologies are substantially similar to each other, it is appropriate to use the earliest market availability date submitted as the beginning of the newness period for both technologies (83 FR 41286 through 41287). Therefore, with regard to both technologies, we believed that the beginning of the newness period would be the date on which REBYOTA™ became commercially available, January 23, 2023. We noted that although our policy is generally to begin the newness period on the date of FDA approval or clearance, we may consider a documented delay in the technology’s market availability in our determination of newness (87 FR 48977 and 77 FR 53348).

We invited public comment on whether REBYOTA™ or VOWST™ is substantially similar to existing technologies and whether it meets the newness criterion, including whether REBYOTA™ and VOWST™ are substantially similar to each other and therefore should be evaluated as a single technology for purposes of new technology add-on payments.

Comment: The applicant for REBYOTA™ submitted a comment in response to our question as to whether REBYOTA™ is substantially similar to VOWSTTM. The applicant stated that VOWST™ is an oral microbiome therapeutic consisting of gram-positive Firmicutes, and that administration of VOWST™ cannot begin until at least 8 hours after bowel prep and after 2 to 4 days of completing antibacterial treatment for rCDI. The applicant also noted that administration requirements may be burdensome on both patients and hospitals. The patient must take 4 capsules daily on an empty stomach prior to the first meal of the day for 3 consecutive days, and that oral administration issues should be a consideration in older patients. The applicant stated that in comparison, REBYOTA™ is a microbiota suspension that is delivered via rectal administration, contains both gram-positive and gram-negative bacteria, can be administered 24 to 72 hours following the last dose of antibiotics for recurrent CDI, and does not have pre-treatment requirements. The applicant also noted that REBYOTA™ studies reported safety and efficacy in older adult (age ≥65 years) patients with comorbid conditions, such as CHF, and that therefore, REBYOTA™ is safe and effective for a broader population of patients.

The applicant for REBYOTA™ also stated that REBYOTA™ is not substantially similar to ZINPLAVA™ because it is available to a broader patient population than those considered high risk for recurrence of CDI, as unlike ZINPLAVA™, REBYOTA™ use is not restricted to high-risk patients and can be administered after the first recurrence of CDI. The applicant noted the different mechanism of action of ZINPLAVA™, which is a human monoclonal antibody that is administered through intravenous infusion and that neutralizes the effect of the C.diff. toxin by binding to it. The applicant also acknowledged that although the mechanism of action of REBYOTA™ has not been established, in comparison, REBYOTA™ consists of live fecal microbes, including Bacteroidia and Clostridia classes, which in studies, results in clinically significant changes in patients’ gut microbiome associated with restorative microbiome changes that may help resist C. diff colonization and recurrence.

The applicant for VOWSTTM also submitted a comment maintaining that CMS should not evaluate VOWST™ and REBYOTA™ as a single applicant because the technologies are not substantially similar, arguing that since the mechanism of action for both therapies is unknown, it is not possible to state that the mechanism for both products is the same. The applicant for VOWSTTM argued that there is reason to believe its mechanism of action differs from REBYOTA™s in terms of therapeutic composition, manufacturing process, route of administration, dosage, and storage, stating that in contrast to REBYOTA™, VOWST™ has a low pill burden, containing ~1 percent residual mass comprised of defined consortia of Firmicutes bacterial spores recovered from healthy donor stool. The applicant further stated that the manufacturing process mitigates risk of transmission of agents of infection by including ethanolic inactivation of potential pathogens and removal of non-spore biomass. The applicant also provided an overview of the clinical and scientific evidence for VOWST™, noting differences in effectiveness, safety, and patient care in contrast to REBYOTA™.

The applicant for VOWSTTM also stated that VOWST™ is substantially similar to ZINPLAVA™ because the FDA labeling for VOWST™ does not include a warning or precaution for heart failure, nor a contraindication for any patient population; and in contrast, the FDA-approved labeling for ZINPLAVA™ concludes that, in patients with a history of CHF, ZINPLAVA™ “should be reserved for use when the benefit outweighs the risk.”

Response: We appreciate the additional information from both applicants with respect to whether their products are substantially similar to one another or to existing technologies. After consideration of the public comments we received, although we recognize that the exact mechanism of action for each technology is not fully defined, and that the technologies may not be completely the same in terms of their manufacturing process, route of administration, dosage, and storage, we are not convinced that these differences result in a substantially different therapeutic mechanism of action. Both applicants provide sufficient data to
suggest that their mechanisms of action relate to repopulation of the gastrointestinal microbiome. We believe that differences in the clinical and scientific evidence on effectiveness, safety, tolerability, and patient care between REBYOTATM and VOWSTTM relate to an assessment of whether the technologies meet the substantial clinical improvement criterion rather than the newness criterion.

With regard to the commenters noting differences in therapeutic composition, as both technologies are derived from donor human stool, where REBYOTATM contains both gram-positive and gram-negative bacteria including Bacteroidia and Clostridia classes, and VOWSTTM consists of a defined consortia of gram-positive Firmicutes bacteria, we also believe that there is, in fact, an overlap, and that the Firmicutes contained in VOWSTTM would also exist in the broad consortium of microorganisms contained in the REBYOTATM suspension. Although there might be slight differences in their proportional contributions to specific downstream molecular pathways, we believe that these two technologies achieve the same therapeutic outcome and overall clinical mechanism of action, as each restores the gut microbiome and resolves dysbiosis to prevent the recurrence of CDI in patients following antibiotic treatment for rCDI by restoring the diversity and composition to one that resembles a healthy microbiome.

Furthermore, we believe REBYOTATM and VOWSTTM are substantially similar to one another because the technologies are intended to treat the same or similar disease in the same or similar patient population—indicated for individuals 18 years of age and older, for the prevention of recurrence of CDI, following antibiotic treatment for rCDI, and that potential cases representing patients who may be eligible for treatment would be assigned to the same MS–DRG.

We also believe REBYOTATM and VOWSTTM are not substantially similar to any other existing technologies because, as both applicants asserted in their FY 2024 new technology add-on payment applications and in their comments, the technologies do not use the same or similar mechanism of action to achieve a therapeutic outcome as any other existing drug or therapy assigned to the same or different MS–DRG. Based on the information described in this section, we believe REBYOTATM and VOWSTTM meet the newness criterion.

Based on the previous discussion, we are making one determination regarding approval for new technology add-on payments that will apply to both applications, and in accordance with our policy, we use the earliest market availability date submitted as the beginning of the newness period for both REBYOTATM and VOWSTTM.

We believe our current policy for evaluating new technology payment applications for two technologies that are substantially similar to each other is consistent with the authority and criteria in section 1886(d)(5)(K) of the Act. We note that CMS is authorized by the Act to develop criteria for the purposes of evaluating new technology add-on payment applications. For the purposes of new technology add-on payments, when technologies are substantially similar to each other, we believe it is appropriate to evaluate both technologies as one application for new technology add-on payments under the IPPS, for the reasons we discussed previously and consistent with our evaluation of substantially similar technologies in prior rulemaking (85 FR 58679 and 82 FR 38120).

With respect to the newness criterion, as previously stated, REBYOTATM received BLA approval from FDA on November 30, 2022, and became commercially available on January 23, 2023. VOWSTTM received BLA approval from FDA on April 26, 2023. In accordance with our policy, because these technologies are substantially similar to each other, we use the earliest market availability date submitted as the beginning of the newness period for both technologies. Therefore, with regard to both technologies, we believe that the beginning of the newness period would be the date on which REBYOTATM became commercially available: January 23, 2023. We note that although our policy is generally to begin the newness period on the date of FDA approval or clearance, we may consider a documented delay in the technology’s market availability in our determination of newness (87 FR 48977 and 77 FR 53348).

The applicants submitted separate cost and clinical data, and in the proposed rule, we reviewed and discussed each set of data separately. However, as stated previously, for this final rule, we will make one determination regarding new technology add-on payments that will apply to both applications. We believe that this is consistent with our policy statements in the past regarding substantial similarity (85 FR 58679).

If substantially similar technologies are submitted for review in different (and subsequent) years, rather than the same year, we evaluate and make a determination on the first application and apply that same determination to the second application. However, because these technologies have been submitted for review in the same year, and because we believe they are substantially similar to each other, we consider both sets of cost data and clinical data in making a determination, and we do not believe that it is possible to choose one set of data over another set of data in an objective manner. As we discussed in the proposed rule and as stated previously, each applicant submitted separate analyses regarding the cost criterion for each of their products, and both applicants maintained that their product meets the cost criterion.

With respect to the cost criterion, to identify cases that may be eligible for REBYOTATM, the applicant searched the FY 2021 MedPAR file for claims using ICD–10–CM code A04.71 (Enterocolitis due to Clostridium difficile, recurrent). Using the inclusion/exclusion criteria described in the following table, the applicant identified 14,653 claims mapping to 398 MS–DRGs. Please see Table 10.17.A.—REBYOTATM Codes—FY 2024 associated with the proposed rule for the complete list of MS–DRGs that the applicant indicated were included in its cost analysis. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $156,292, which exceeded the average case-weighted threshold amount of $71,397. Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount, the applicant asserted that REBYOTATM meets the cost criterion.
With respect to the cost criterion, the applicant for VOWST™ conducted the following analysis to demonstrate that VOWST™ meets the cost criterion. To identify cases that may be eligible for the use of VOWST™, the applicant searched the FY 2021 MedPAR file for cases reporting ICD–10–CM code A04.71 (Enterocolitis due to Clostridium difficile, recurrent). Using the inclusion/exclusion criteria described in the following table, the applicant identified 14,497 claims mapping to 392 MS–DRGs. Please see Table 10.17.A.-REBYOTA™ Codes - FY 2024 associated with the proposed rule for the complete list of MS–DRGs identified in its cost analysis. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $175,157, which exceeded the average case-weighted threshold amount of $69,830. Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount, the applicant maintained that VOWST™ meets the cost criterion.

### REBYOTA™ COST ANALYSIS

<table>
<thead>
<tr>
<th>Data Source and Time Period</th>
<th>FY 2021 MedPAR file</th>
</tr>
</thead>
<tbody>
<tr>
<td>List of ICD-10-CM codes</td>
<td>A04.71 (Enterocolitis due to Clostridium difficile, recurrent)</td>
</tr>
<tr>
<td>List of MS-DRGs</td>
<td>Please see Table 10.17.A.- REBYOTA™ Codes - FY 2024 associated with the proposed rule for the complete list of MS-DRGs included in the cost analysis.</td>
</tr>
</tbody>
</table>

**Inclusion/exclusion criteria**

The applicant identified cases with the ICD-10-CM diagnosis code listed in this table. The applicant included only inpatient discharges paid as fee-for-service - claim type ‘’60.’’ Medicare Advantage discharges were excluded. These discharges are excluded when the MedPAR “GHO Paid” indicator field on the claim record is equal to “1” or when the MedPAR DRG payment field, which represents the total payment for the claim, is equal to the MedPAR “Indirect Medical Education (IME)” payment field.

The applicant used claims from the FY 2021 MedPAR with MS-DRG assignments based on ICD-10 MS-DRG GROUPER Software, Version 40. The applicant calculated the average unstandardized charge per case for each MS-DRG. Cases were excluded if a standardized charge could not be calculated. Any MS-DRG with a total discharge count less than 11 was imputed with a count of 11.

**Charges removed for prior technology**

The applicant did not remove direct or indirect charges related to the prior technology as REBYOTA™ does not replace prior technologies.

**Standardized charges**

The applicant used the standardization formula provided in Technical Appendix A of the application. The applicant used all relevant values reported in the impact file posted with the FY 2021 IPPS/LTCH PPS final rule.

**Inflation factor**

The applicant applied an inflation factor of 0.4686% to the standardized charges based on the inflation factor used to calculate outlier threshold charges in the FY 2023 IPPS/LTCH PPS final rule.

**Charges added for the new technology**

The applicant added charges for the new technology by dividing the cost of the new technology by the national average cost-to-charge ratio of 0.184 for drugs from the FY 2023 IPPS/LTCH PPS final rule.

The cost of the technology per patient is for a single-use dose bag and is based on its wholesale acquisition cost (WAC). The applicant did not add indirect charges related to the new technology.
We invited public comment on whether VOWST™ or REBYOTA™ meet the cost criterion.

**Comment:** The applicant for REBYOTA™ submitted a comment regarding an updated cost analysis utilizing its updated final wholesale acquisition cost (WAC). The applicant stated that in the new cost analysis, the final inflated case-weighted average standardized charge per case of $153,574 exceeded the case-weighted threshold of $71,397, demonstrating that the applicant continued to meet the cost criterion.

The applicant for VOWST™ submitted a comment regarding an updated cost analysis utilizing its updated final WAC to confirm their belief that VOWST™ meets the cost criterion because cost threshold analysis demonstrated the final inflated case-weighted standardized charge per case of $329,947 exceeded the case-weighted threshold of $95,859, therefore the applicant met the cost criterion.

**Response:** We thank the applicants for their comments and appreciate the updated cost analyses. We agree that the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount for both REBYOTA™ and VOWST™. Therefore, both REBYOTA™ and VOWST™ meet the cost criterion.

With respect to the substantial clinical improvement criterion, the applicant for REBYOTA™ asserted that REBYOTA™ represents a substantial clinical improvement over existing technologies because it offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments, and because the use of REBYOTA™ significantly improves clinical outcomes relative to the treatment options previously available. The applicant provided eight studies to support these claims, as well as background articles about occurrence and treatment of CDI and rCDI. The following table summarizes the applicant’s assertions regarding the substantial clinical improvement criterion. Please see the online posting for REBYOTA™ for the applicant’s complete statements regarding the substantial clinical improvement criterion and the supporting evidence provided.

---

**VOWST™ COST ANALYSIS**

<table>
<thead>
<tr>
<th>Data Source and Time Period</th>
<th>FY 2021 MedPAR file</th>
</tr>
</thead>
<tbody>
<tr>
<td>List of ICD-10-CM codes</td>
<td>A04.71 (Enterocolitis due to Clostridium difficile, recurrent)</td>
</tr>
<tr>
<td>List of MS-DRGs</td>
<td>Please see Table 10.22.A. - SER-109 Codes - FY 2024 associated with the proposed rule for the complete list of MS-DRGs included in the cost analysis.</td>
</tr>
<tr>
<td>Inclusion/exclusion criteria</td>
<td>The applicant identified cases reporting ICD-10-CM code A04.71 (Enterocolitis due to Clostridium difficile, recurrent). Only claims that are used for Medicare IPPS rate setting were included: fee-for-service IPPS discharges, plus Maryland hospital discharges. Any MS-DRG with a total discharge count less than 11 was imputed with a count of 11. The applicant calculated the average unstandardized charge per case for each MS-DRG.</td>
</tr>
<tr>
<td>Charges removed for prior technology</td>
<td>No charges were removed because VOWST™ would not replace other treatments.</td>
</tr>
<tr>
<td>Standardized charges</td>
<td>The applicant used the standardization formula provided in the application. The applicant used all relevant values reported in the impact file posted with the FY 2023 IPPS/LTCH PPS final rule.</td>
</tr>
<tr>
<td>Inflation factor</td>
<td>The applicant applied an inflation factor of 13.2% to the standardized charges, based on the inflation factor used to calculate outlier threshold charges in the FY 2023 IPPS/LTCH PPS final rule.</td>
</tr>
<tr>
<td>Charges added for the new technology</td>
<td>The applicant has not yet established the price of VOWST™ or the per-patient cost of the technology to hospitals. However, for the purposes of this analysis, the applicant approximated the per-patient cost related to the technology. The applicant added charges for the new technology by dividing the cost of the new technology by the national average cost-to-charge ratio of 0.184 for drugs from the FY 2023 IPPS/LTCH PPS final rule.</td>
</tr>
</tbody>
</table>

---

94 Background articles are not included in the table in this section but can be accessed via the online posting for the technology.
<table>
<thead>
<tr>
<th>Applicant statements in support</th>
<th>Supporting evidence provided by the applicant</th>
<th>Outcome(s) or findings cited by the applicant from supporting evidence to support its statements</th>
</tr>
</thead>
</table>
| **REBYOTA™ is an FDA-approved treatment option that addresses the inconsistent safety and efficacy results for FMT.** | The applicant provided background information to online posting for the technology. | **60% (50/83) of patients who received ≥1 dose of REBYOTA™ achieved treatment success vs 43% (19/44) of patients who received placebo.**  
The overall gut composition was significantly different between placebo responders and REBYOTA™ responders 60 days after treatment (P=0.02; Wald-type test), confirming that REBYOTA™ treatment is more effective at shifting the microbiome composition. |
Brief study description:  
A randomized, double-blinded placebo-controlled phase 2B trial. | **REBYOTA™ induced significant shifts to the intestinal microbiota of treatment-responsive participants. Changes among REBYOTA™-treated responders were significantly different than among placebo-treated responders (P<0.001).**  
**REBYOTA™-treated responders demonstrated more rapid and more extensive recovery of Bacteroidia and decreased Gammaproteobacteria relative to placebo-treated responders.**  
**Among PUNCH CD3 clinical responders, REBYOTA™ significantly increased taxa associated with health and decreased taxa associated with C. difficile pathology, and these shifts were durable to at least 6 months.** |
Brief study description:  
Results from the PUNCH CD3 study, a Phase 3 randomized, double-blinded, placebo controlled (2:1) study of REBYOTA™ versus placebo to reduce rCDI. | **Commensals (for example, Clostridia and Bacteroidia) in the colon convert primary Bile Acids (BAs) into secondary BAs, contributing to suppression of C. difficile outgrowth in a healthy gut, measured by a high secondary-BA-to-primary-BA (S:P) fecal concentration ratio.**  
Treatment responders (both those treated with REBYOTA™ and placebo) had a higher S:P ratio; treatment failure was associated with a lower S:P ratio. The S:P ratio in responders (REBYOTA™-treated and placebo) was significantly different than in non-responders (REBYOTA™-treated and placebo) (P=0.00033). |
Brief study description:  
See PUNCH CD3 study description as previously detailed. This analysis included 487 longitudinal stool samples from 192 participants. | The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology. |
Brief study description:  
A summary of REBYOTA™ efficacy in treating rCDI using data from five prospective clinical studies, two phase 3 RCTs (PUNCH CD3, PUNCH CD3-OLS ad hoc analysis), and three phase 2 open label studies (PUNCH CD, PUNCH CD2, PUNCH CD Open Label). | Across 5 trials with consistent investigational product and clinical endpoints, REBYOTA™ consistently reduced rCDI within 8 weeks after treatment. |
<table>
<thead>
<tr>
<th>REBYOTA™ is an FDA-approved therapeutic option for some patients who may not be eligible for treatment with ZINPLAVATM</th>
<th>The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feuerstadt P, Harvey A, Bancke I. REBYOTA™, an investigational live microbiota-based biotherapeutic, improves outcomes of Clostridiodes difficile infection in a real-world population: a retrospective study of use under an FDA enforcement discretion. Abstract for ACG2021. Brief study description: A retrospective analysis of a primary safety set (PSS) population who had not previously been treated with REBYOTA™. Braun T, Guthmueller B, Harvey A. Safety of investigational microbiota-based live biotherapeutic REBYOTA™ in individuals with recurrent Clostridiodes difficile infection: data from five prospective clinical studies. Abstract presented at: 10th Annual IDWeek; September 29, 2021 Brief study description: Poster presentation pooling the safety data from five prospective studies (three Phase 2 and two Phase 3). REBYOTA™ has been studied in a broad patient population, with no significant differences in safety and efficacy outcomes among subgroups including age, gender, race, number of previous cases of rCDI, or presence of certain common comorbid conditions, such as IBS. Among 832 clinical trial participants who received ≥1 treatment with REBYOTA™ or placebo, 571 (68.6%) experienced ≥1 treatment emergent adverse events (TEAEs). In all treatment groups, most TEAEs were mild or moderate in severity, with most being GI-related. No potentially life-threatening TEAEs were considered related to REBYOTA™. REBYOTA™ was well-tolerated, with low incidence of discontinuation in REBYOTA™-treated participants: &lt;1% (7/749) vs 0% (0/83) for placebo. Overall, study participants treated with REBYOTA™ were older and had more previous CDI recurrences than placebo-treated patients.</td>
<td>The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology.</td>
</tr>
</tbody>
</table>

### Substantial Clinical Improvement Assertion #2: The technology significantly improves clinical outcomes relative to services or technologies previously available.

<table>
<thead>
<tr>
<th>Applicant statements in support</th>
<th>Supporting evidence provided by the applicant</th>
<th>Outcome(s) or findings cited by the applicant from supporting evidence to support its statements</th>
</tr>
</thead>
<tbody>
<tr>
<td>REBYOTA™ offers a sustained clinical response</td>
<td>Orenstein R, Mische S, Blount D, et al. A long-time coming: final 2-year analysis of efficacy, durability, and microbiome changes in a controlled open-label trial of investigational microbiota-based drug REBYOTA™ for recurrent Clostridiodes difficile infections. IDWeek 2019 late breaker oral abstract LB5. Open Forum InfectDis. 2019;6(Suppl 2):S994-S995. Brief study description: A 2-year analysis that studied the clinical safety, efficacy, and durability of REBYOTA™ in a Phase 2 open-label trial.</td>
<td>Among REBYOTA™-treated participants, 79% (112/142) were recurrence-free at 8 weeks after treatment. At 6 months, 97% of evaluable primary REBYOTA™ responders (104/107) remained infection-free. At 12 months, 95% of evaluable primary REBYOTA™ responders (98/103) remained infection-free. At 24 months, 91% of evaluable primary REBYOTA™ responders (87/95) remained infection-free.</td>
</tr>
</tbody>
</table>

### Fewer serious adverse events related to the administration and use of REBYOTA™ than FMT

The applicant provided background information to support this claim, which can be accessed via the online posting for the technology.
<p>| Fewer serious adverse events with REBOTO\textsuperscript{TM} than with ZINPLAVA\textsuperscript{TM} | Braun T, Guthmueller B, Harvey A. Safety of investigational microbiota-based live biotherapeutic REBOTO\textsuperscript{TM} in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical studies. Abstract presented at: 10th Annual IDWeek; September 29, 2021.&lt;br&gt;See prior study description. | Among 832 clinical trial participants who received \geq 1 treatment with REBOTO\textsuperscript{TM} or placebo, 571 (68.6%) experienced \geq 1 treatment emergent adverse events (TEAEs). In all treatment groups, most TEAEs were mild or moderate in severity, with most being GI-related. No potentially life-threatening treatment-emergent AEs were considered related to REBOTO\textsuperscript{TM}.&lt;br&gt;REBOTO\textsuperscript{TM} was well-tolerated, with low incidence of discontinuation in REBOTO\textsuperscript{TM}-treated participants: &lt;1% (7/749) vs 0% (0/83) for placebo.&lt;br&gt;One TEAE-related death occurred within 30 days of treatment. This death was assessed as possibly related to REBOTO\textsuperscript{TM} or its administration procedure and related to CDI and a preexisting condition.&lt;br&gt;Overall, study participants treated with REBOTO\textsuperscript{TM} were older and had more previous CDI recurrences than placebo-treated patients. |
| REBOTO\textsuperscript{TM} is indicated for a broader patient population than either FMT or ZINPLAVA\textsuperscript{TM} | Feuerstadt P, Harvey A, Bancke L. REBOTO\textsuperscript{TM}, an investigational live microbiota-based biotherapeutic, improves outcomes of Clostridioides difficile infection in a real-world population: a retrospective study of use under an FDA enforcement discretion. Abstract for ACG2021.&lt;br&gt;Brief study description: See prior study description. | REBOTO\textsuperscript{TM} has been studied in a broad patient population, with no significant differences in safety and efficacy outcomes among subgroups including age, gender, race, number of previous cases of rCDI, or presence of certain common comorbid conditions, such as IBS. |
| REBOTO\textsuperscript{TM} is the only FDA-approved therapy indicated for reduction of rCDI that addresses dysbiosis | Papazyan R, Ferdyan N, Gonzalez C, et al. Rapid restoration of bile acid compositions after treatment with REBOTO\textsuperscript{TM} for recurrent Clostridioides difficile infection—results from the PUNCH CD3 phase 3 trial. Abstract presented at: 10th Annual IDWeek; September 29, 2021.&lt;br&gt;See prior study description. | In clinical responders, REBOTO\textsuperscript{TM} significantly restored bile acids (BA) toward healthier compositions. Significant and durable BA changes occur as early as 1-week post-treatment with REBOTO\textsuperscript{TM}. These clinically correlated BA shifts are highly consistent with results from a prior trial of REBOTO\textsuperscript{TM}. |
| Garcia-Diaz J, Jones C, Karathia H, Fanelli B, Hasan NA, Blount K. Response to microbiota-based drug REBOTO\textsuperscript{TM} is associated with reduction in antimicrobial resistance genes in patients with recurrent Clostridioides difficile infections. Presented at: ASM Microbe 2019; June 20-24, 2019; San Francisco, CA.&lt;br&gt;Brief study description: PUNCH Open Label: a prospective, multicenter, open label Phase 2 study assessing the efficacy and safety of REBOTO\textsuperscript{TM} treatment of CDI in patients with multi rCDI (\geq 2 recurrent episodes at enrollment). | Participants were dysbiotic at study entry, with decreased Bacteroidia and Clostridia and overabundance of Gammaproteobacteria and Bacilli. Bacteroidia and Clostridia increased, while Gammaproteobacteria and Bacilli decreased after treatment. Changes were durable to 6 months after treatment. |</p>
<table>
<thead>
<tr>
<th>Study</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blount KF, Shannon WD, Deych E, Jones C.</td>
<td>Exposure to broad-spectrum antibiotics is an important risk factor for recurrent CDI and rCDI. In a randomized double-blind placebo-controlled phase 2B trial, participants who received ≥1 dose of REBYOTA™ had fewer CDI recurrences than placebo-treated participants 8 weeks after treatment. The overall composition was significantly different between placebo responders and REBYOTA™ responders 60 days after treatment (P=0.02; Wald-type test), confirming that REBYOTA™ treatment is more effective at shifting the microbiome composition.</td>
</tr>
<tr>
<td>Blount, Walsh D, Gonzalez C, et al.</td>
<td>REBYOTA™ induced significant shifts to the intestinal microbiota of treatment-responsive participants. Changes among REBYOTA™-treated responders were significantly different than among placebo-treated responders (P&lt;0.001). REBYOTA™-treated responders demonstrated more rapid and more extensive recovery of Bacteroidia and decreased Gammaproteobacteria relative to placebo-treated responders. Among PUNCH CD3 clinical responders, REBYOTA™ significantly increased taxa associated with health and decreased taxa associated with C. difficile. REBYOTA™-treated subjects showed more rapid and extensive recovery of Bacteroidia and decreased Gammaproteobacteria relative to placebo-treated subjects, and the effects lasted for at least 6 months post-treatment.</td>
</tr>
<tr>
<td>Orenstein R, Mische S, Blount D, et al.</td>
<td>At 6 months, 97% of the evaluable primary REBYOTA™ responders (104/107) remained infection-free, while 95% of evaluable primary REBYOTA™ responders (98/103) were infection-free at 12 months. The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology.</td>
</tr>
</tbody>
</table>

### Efficacy of REBYOTA™

<table>
<thead>
<tr>
<th>Study</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bancke L, Su X.</td>
<td>In a phase 2 RCT, 60% (50/83) of patients who received ≥1 dose of REBYOTA™ achieved treatment success vs 43% (19/44) of patients who received placebo. REBYOTA™ is manufactured through a consistent quality-controlled process to minimize variation.</td>
</tr>
<tr>
<td></td>
<td>Overall, the majority of primary REBYOTA™ responders remained CDI-free to 6 months and up to 24 months post-treatment, with success rates in the phase 3 program ranging from 82.0% to 92.1%. Separation in treatment success between REBYOTA™ and placebo was durable through 6 months. There was a higher recurrence rate in the placebo-treated patients. Across 5 trials with consistent investigational product and clinical endpoints, REBYOTA™ consistently reduced rCDI within 8 weeks after treatment.</td>
</tr>
</tbody>
</table>
In the FY 2024 IPPS/LTCF PPS proposed rule (88 FR 26859 through 26860), we stated that we had the following concerns regarding whether REBYOTA™ meets the substantial clinical improvement criterion. Regarding the assertion that REBYOTA™ is an FDA-approved therapeutic option for some patients who may not be eligible for treatment with ZINPLAVA™ due to patient population restrictions (for example, high-risk patients) or contraindications (for example, history of congestive heart failure [CHF]), and that there is no evidence that REBYOTA™ poses an increased risk of serious AEs in patients with a history of CHF, the applicant cited a retrospective study of REBYOTA™ reported by Feuerstadt et al.95 in which 94 participants with comorbid conditions commonly found in people with rCDI were treated with REBYOTA™. The analysis showed a treatment success rate of 82.6 percent, with no observable difference between participants who received one dose (83.3%) vs. two doses (82.5%). We noted that the comorbid conditions represented in this population included: gastroesophageal reflux disease (47.9%); irritable bowel syndrome (17%); gastritis (11.7%); constipation (8.5%); microscopic colitis (7.4%); diverticulitis (6.4%); Crohn’s disease (5.3%); and ulcerative colitis (4.3%) but did not include patients with CHF as a comorbidity. We believed additional information regarding whether REBYOTA™ was tested in patients with CHF to determine clinical outcomes would be helpful to evaluate the applicant’s assertion. The applicant also referenced a poster presentation by Braun et al.96 that presents the safety data from five prospective studies in which 749 pooled participants received at least one dose of REBYOTA™, and 83 participants received placebo only to support its assertion. We stated that additional information demonstrating whether REBYOTA™ is safe for the patient population with CHF would help inform our assessment of whether REBYOTA™ demonstrates substantial clinical improvement over existing technologies.

Regarding the claim of sustained clinical response, the applicant referenced an abstract of an open-label trial of REBYOTA™ by Orenstein et al. This trial was a Phase 2 open-label trial where participants with multiple rCDI received two doses of REBYOTA™ administered 7 + 2 days apart. Researchers conducted a 2-year analysis of the clinical safety, efficacy, and durability of REBYOTA™. The absence of rCDI was compared between the REBYOTA™ and a historical control cohort that received standard-of-care antibiotic therapy. Durability was defined as continued absence of CDI episodes beyond 8 weeks, and was assessed at 3, 6, 12, and 24 months by assessing changes in stool samples. While the applicant submitted results from both a phase 2 trial of REBYOTA™,97 and the PUNCH CD3 phase 3 trial,98 to demonstrate the superiority of REBYOTA™ over placebo, we questioned whether other treatment options indicated to prevent rCDI, such as ZINPLAVA™, would be a more appropriate comparator. We noted that additional information regarding clinical outcomes as a result of treatment with REBYOTA™ compared to ZINPLAVA™ would be helpful to assess the substantial clinical improvement criterion. In summary, while we understood that there were no head-to-head trials comparing REBYOTA™ to ZINPLAVA™, we indicated that additional information would help inform our assessment of whether REBYOTA™ demonstrated a substantial clinical improvement over existing technologies.

With regard to the substantial clinical improvement criterion, the applicant for VOWST™ asserted that VOWST™ represents a substantial clinical improvement over existing technologies because VOWST™ treats patients unresponsive to antibiotic treatment for rCDI and can be used in patients ineligible for ZINPLAVA™ due to CHF. The applicant also asserted that it improves clinical outcomes by reducing rCDI, increasing resolution of the disease process by expediting microbiome repair, and reducing carriage of antimicrobial resistance genes. The applicant provided five studies to support these claims, as well as 11 background articles about CDI recurrence and risks of increased exposure to antibiotic therapies in a hospital setting for rCDI and cardiac risk of prescribing existing treatments, such as ZINPLAVA™, to patients with pre-existing heart failure.99 The following table summarizes the applicant’s assertions regarding the substantial clinical improvement criterion. Please see the online posting for VOWST™ for the applicant’s complete statements regarding the substantial clinical improvement criterion and the supporting evidence provided.

### Table

<table>
<thead>
<tr>
<th>Study Description</th>
<th>Comparison</th>
<th>Clinical Improvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feuerstadt et al.95</td>
<td>REBYOTA™ vs. placebo</td>
<td>Sustained</td>
</tr>
<tr>
<td>Braun et al.96</td>
<td>REBYOTA™ vs. historical control</td>
<td>Sustained</td>
</tr>
<tr>
<td>Orenstein et al.</td>
<td>REBYOTA™ vs. standard-of-care</td>
<td>Sustained</td>
</tr>
<tr>
<td>VOWST™ assertions</td>
<td>VOWST™ vs. existing technologies</td>
<td>Sustained</td>
</tr>
</tbody>
</table>

---


99 Background articles are not included in the following table but can be accessed via the online posting for the technology.
<table>
<thead>
<tr>
<th>Applicant statements in support</th>
<th>Supporting evidence provided by the applicant</th>
<th>Outcome(s) or findings cited by the applicant from supporting evidence to support its statements</th>
</tr>
</thead>
</table>
Brief study description:  
Multi-center, randomized, double-blind placebo-controlled phase 2 clinical trial that evaluated the safety and efficacy of VOWST™ (SER-109) versus placebo to reduce rCDI. | VOWST™ (SER-109) was generally well tolerated among subjects. Adverse events (Aes) occurred in 76.7% (46/60) subjects given VOWST™ (SER-109) and 20 of 29 (69.0%) subjects on the placebo. Aes were generally mild to moderate in severity.  
Six subjects (10.0%) on VOWST™ (SER-109) experienced a severe AE; none of these severe Aes were considered related to the study drug. These did not differ by treatment arm (55.0% VOWST™ (SER-109) vs 44.8% placebo; P = .44.  
Overall, 16.9% of subjects experienced an AE that the investigator considered to be related or possibly related to the study drug, including 18.3% on VOWST™ (SER-109) and 13.8% on placebo.  
13.5% (12/89) subjects experienced a serious AE: 15.0% (9/60) subjects who received VOWST™ (SER-109) and 10.3% (3/29) who received placebo. None of the serious Aes were considered treatment-related. |
Brief study description:  
Phase 3, open label, single-arm study. Following standard-of-care antibiotics with vancomycin or fidaxomicin. | VOWST™ (SER-109) was well-tolerated. Overall, 137 subjects (52.1%) experienced treatment-emergent adverse events (TEAEs) through week 8; the majority were mild to moderate in intensity and gastrointestinal. There were 6 deaths (2.3%) and 20 subjects (7.6%) had serious TEAEs, none of which were deemed treatment-related.  
The only reported SAE for worsening of CHF was among the placebo group; no such SAEs were reported among the VOWST™ (SER-109) test group. |
Brief study description:  
Double-blind, placebo-controlled trial to show superiority of VOWST™ (SER-109) as compared to placebo in reducing the risk of C. diff infection recurrence up to 8 weeks after treatment. | The only reported SAE for worsening of CHF was among the placebo group; no such SAEs were reported among the VOWST™ (SER-109) test group. |
Brief study description:  
This study provides 24-week follow-up data for the Phase III study (VOWST™ (SER-109), an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection ("ECOSPOR III"). | The only reported SAE for worsening of CHF was among the placebo group; no such SAEs were reported among the VOWST™ (SER-109) test group. |

The only reported SAE for worsening of CHF was among the placebo group; no such SAEs were reported among the VOWST™ (SER-109) test group.
<table>
<thead>
<tr>
<th><strong>VOWST™ (SER-109)</strong> treats patients who have been unresponsive to antibiotics, as evidenced by their rCDI, by reducing rates of CDI recurrence.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ECOSPOR III</strong> was a double-blind, randomized, multicenter trial with patients randomized to receive VOWST™ (SER-109) or matching placebo administered as 4 capsules daily for 3 days. Endpoints of adverse events (Aes) and duration of response through 24 weeks and time to recurrence. After 24 weeks, 63 of 182 participants had recurring CDI (19 in the VOWST™ (SER-109) group, compared to 44 in placebo). At 4, 8, 12, and 24 weeks, a significantly lower proportion of patients given VOWST™ (SER-109) experienced recurrence, compared to placebo. Serious Aes occurred in 15 patients given VOWST™ (SER-109) and 19 in placebo; none were considered drug-related. Overall, VOWST™ (SER-109) durably reduced rates of recurring CDI and was well-tolerated through 24 weeks in patients with prevalent comorbidities. The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology.</td>
</tr>
<tr>
<td><strong>Khanna S, Feuerstadt P, Huang E, et al.</strong> An open-label study (ECOSPOR IV) to evaluate the safety, efficacy, and durability of SER-109 in adults with recurrent Clostridioides difficile infection (rCDI). Am College Gastroenterol 2022 Annual Scientific Meeting. Charlotte, NC. Abstract 63. See prior study description</td>
</tr>
<tr>
<td>Among patients treated with VOWST™ (SER-109), the rate of CDI recurrence was low through week 8, which is consistent with results in the Phase 3 randomized controlled trial (ECOSPOR III). At week 8, 23 of 263 (8.7%) participants had recurring CDI: the rate of recurrence among patients with one recurring CDI episode was 6.5% (5/77), and 9.7% (18/186) among those with at least two recurrent episodes. CDI rates remained low through 24 weeks: 13.7% (36/263 participants).</td>
</tr>
<tr>
<td>In the overall population, there was no significant difference in CDI recurrence rates between VOWST™ (SER-109) or placebo subjects (44.1% vs 53.3%; RR, 0.1; 95% CI, 0.8–1.9). However, the primary endpoint by age stratum showed that VOWST™ (SER-109) significantly reduced recurrence, compared with placebo, among those aged 65 years or older (45.2% vs 80%, respectively; RR, 1.8; 95% CI, 1.1–2.8).</td>
</tr>
</tbody>
</table>
| VOWST™ (SER-109) was found to be superior to the placebo in reducing risk of CDI recurrence: The percentage of patients with recurrence was significantly lower in the VOWST™ (SER-109) group than in the placebo group (12% and 40%, respectively; relative risk, 0.32; 95% confidence interval [CI], 0.18 to 0.58; P=0.001 for both hypotheses tested). In the analysis of the alternative metric of sustained clinical response, 88% of the VOWST™ (SER-109) recipients were found to have a sustained clinical response, as compared with 60% of the placebo recipients VOWST™ (SER-109) also led to lower percentages of patients with C. difficile infection recurrence than did placebo in the age-stratified analysis (relative risk, 0.24 [95% CI, 0.07 to 0.78] among patients <65 years of age and 0.36 [95% CI, 0.18 to 0.72] among those ≥65 years of age) and in the antibiotic-stratified analysis (relative risk, 0.41 [95% CI, 0.22 to 0.79] among patients who took vancomycin and 0.09 [95% CI, 0.01 to 0.63] among those who took fidaxomicin). However, more patients were treated with vancomycin than with fidaxomicin.” (Efficacy pg. 224, para 1-2) Further, study results showed the benefit of VOWST™ (SER-109) as compared with placebo (that is, antibiotics alone) in patients with recurrent disease was also observed among age- and antibiotic-stratified groups. Additionally, although fidaxomicin is
viewed as less disruptive than vancomycin to microbial communities, the higher percentages of recurrence in the fidaxomicin-placebo subgroup highlight the paradox of treating an antibiotic-associated disease, rooted in microbiome disruption, with antibiotics alone.


See prior study description

This study provides 24-week follow-up data for the Phase III study, “ECOSPOR III” and supplement. Benefit from VOWST™ (SER-109) was evident at week 2 and durable through 24 weeks. After 24 weeks, 63 of 182 participants had recurring CDI (19 in the VOWST™ (SER-109) group, compared to 44 in placebo). At 4, 8, 12, and 24 weeks, a significantly lower proportion of patients given VOWST™ (SER-109) experienced recurrence, compared to placebo. Serious AEs occurred in 15 patients given VOWST™ (SER-109) and 19 in placebo; none were considered drug-related. Overall, VOWST™ (SER-109) durably reduced rates of recurring CDI and was well-tolerated through 24 weeks in patients with prevalent comorbidities.

The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology.

### Substantial Clinical Improvement Criterion Assertion #2: The technology significantly improves clinical outcomes relative to services or technologies previously available.

<table>
<thead>
<tr>
<th>Applicant statements in support</th>
<th>Supporting evidence provided by the applicant</th>
<th>Outcome(s) or findings cited by the applicant from supporting evidence to support its statements</th>
</tr>
</thead>
</table>


The study assessed engraftment by comparing the number of dose-species in stool samples at 3 time points. Minimal VOWST™ (SER-109) dose-species were detected at baseline (that is, following cessation of antibiotic) in either treatment arm. As early as week 1 following dosing, subjects receiving VOWST™ (SER-109) had significantly more dose-species than those on placebo; this response was durable through 8 weeks (P <0.001 for all comparisons; MannWhitney U test)” (P 2135, par 4).

The study evaluated whether the degree of engraftment differed by clinical outcome. Since 50% of recurrences were observed by day 11, the study compared dose-species diversity at baseline and week 1 by clinical outcome. Before VOWST™ (SER-109) treatment, dose-species diversity was not associated with outcome in either treatment group (Mann-Whitney U test). At week 1, VOWST™ (SER-109)–treated subjects with non-recurrence had significantly more dose-species than those who did experience a recurrence (P <0.05, Mann-Whitney U test). This association was not observed in placebo recipients at week 1. Although VOWST™ (SER-109) was associated with a significant reduction in recurrence among
<table>
<thead>
<tr>
<th>VOWST™ (SER-109)</th>
<th><strong>May reduce the number of future hospitalizations or physician visits for patients diagnosed with rCDI.</strong></th>
</tr>
</thead>
</table>

| Khanna S, Feuerstadt P, Huang E, et al. | Earlier intervention with VOWST™ (SER-109) in first recurrence may reduce morbidity associated with rCDI. In study participants evaluated following first recurrence of C. difficile infection, 5/77 (6.5%) had a recurrent event compared with 18/186 (9.7%) of participants who entered the study with two or more prior recurrences. This reduction in recurrent infections eliminates the need for subsequent treatment interventions in those individuals who respond to VOWST™ (SER-109) after a first recurrence. Such earlier intervention (that is, after the first recurrence) with VOWST™ (SER-109) may reduce the healthcare burden of further CDI episodes. |

| Cohen, Stuart H., Louie, Thomas J., et al. | This study provides 24-week follow-up data for the Phase III study, “ECOSPOR III” and supplement. Benefit from VOWST™ (SER-109) was evident at week 2 and durable through 24 weeks. After 24 weeks, 63 of 182 participants had recurring CDI (19 in the VOWST™ (SER-109) group, compared to 44 in placebo). At 4, 8, 12, and 24 weeks, a significantly lower proportion of patients given VOWST™ (SER-109) experienced recurrence, compared to placebo. Serious AEs occurred in 15 patients given VOWST™ (SER-109) and 19 in placebo; none were considered drug-related. Overall, VOWST™ (SER-109) durably reduced rates of recurring CDI and was well-tolerated through 24 weeks in patients with prevalent comorbidities. |

| Feuerstadt P, Stong L, Dahdal D, et al., Healthcare resource utilization and direct medical costs associated with index and recurrent Clostridioides difficile infection: a real-world data analysis, J Med Econ 2020;23:603–609, DOI: 10.1080/13696998.2020.1724117 | The mean time from one CDI episode to another recurrence was approximately 1 month regardless of number of prior recurrences. In the 12-month follow-up period, those with no recurrence had 1.4 inpatient visits per person and those with 3 or more recurrences had 5.8 inpatient visits per person. Most patients who had 3 or more recurrences had 2 or more hospital admissions. The mean annual, total all-cause direct medical costs per patient were $71,980 for those with no recurrence and rose (by $59,973) to a total of $131,953 for first recurrence, a total of $180,574 from the first to second recurrence, and a total of $207,733 for those with three or more recurrences. |

| Brief study description: Retrospective analysis of commercial claims data from the IQVIA PharMetrics Plus database for patients ages 18–64 with CDI episodes requiring inpatient stay with CDI diagnosis code or an | subjects aged 65 years or older, age had no impact on the magnitude of engraftment. (P 2136, par 1) |

To understand the association of VOWST™ (SER-109) engraftment with non-recurrence, study evaluated the relationship between engraftment and the abundance of secondary bile acids (BAs), previously shown to inhibit C. difficile germination. At week 1, there was a significant positive correlation between the number of VOWST™ (SER-109) species and the abundance of secondary BAs lithocholic acid (LCA) and deoxycholic acid (DCA), as shown in Fig. 5 (Spearman correlation, P <0.0001 for both comparisons). In subjects receiving VOWST™ (SER-109), DCA and LCA levels were higher in subjects with nonrecurrent CDI compared with subjects who experienced recurrence before week 8; however, these observations were not significant (P = 0.08 and 0.10, respectively; Mann Whitney U test). |

<p>| See prior study description | |</p>
<table>
<thead>
<tr>
<th>Study Title</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>outpatient medical claim for CDI plus a CDI treatment. Index CDI episodes</td>
<td>recurrences. The study found that inpatient costs were the key cost driver, accounting for 61–70% of the total costs across the study cohorts. Furthermore, HRU was high for all patients with an index CDI, with the highest utilization for those with 3 or more CDI recurrences.</td>
</tr>
<tr>
<td>Feuerstadt P, Louie TJ, Lashner B, et al., SER-109, an oral microbiome</td>
<td>The benefit of VOWST™ (SER-109) as compared with placebo (that is, antibiotics alone) in patients with recurrent disease was also observed among age- . . . -stratified groups. As demonstrated in the ECOSPOR III study, VOWST™ (SER-109) reduced CDI reinfection among Medicare-eligible patients (those ≥65 years of age), compared to those taking a placebo, 17% vs 46% (absolute difference, − 29%), respectively, [relative risk, 0.36; 95% CI, 0.18 to 0.72]. A reduction in the risk of recurrence among patients 65 years of age or older is clinically important, since patients in this age group are at increased risk for recurrent disease and hospital readmission.</td>
</tr>
<tr>
<td>therapy for recurrent Clostridiodes difficile infection. N Engl J Med</td>
<td></td>
</tr>
<tr>
<td>2022;386:220-9. DOI: 10.1056/NEJMoa2106516</td>
<td>See prior study description</td>
</tr>
<tr>
<td>See prior study description</td>
<td></td>
</tr>
<tr>
<td>Cohen, Stuart H., Louie, Thomas J., et al. Extended Follow-up of</td>
<td>This study provides 24-week follow-up data for the Phase III study, &quot;ECOSPOR III&quot; and supplement. Benefit from VOWST™ (SER-109) was evident at week 2 and durable through 24 weeks. After 24 weeks, 63 of 182 participants had recurring CDI (19 in the VOWST™ (SER-109) group, compared to 44 in placebo). At 4, 8, 12, and 24 weeks, a significantly lower proportion of patients given VOWST™ (SER-109) experienced recurrence, compared to placebo. Serious AEs occurred in 15 patients given VOWST™ (SER-109) and 19 in placebo; none were considered drug-related. Overall, VOWST™ (SER-109) durably reduced rates of recurring CDI and was well-tolerated through 24 weeks in patients with prevalent comorbidities.</td>
</tr>
<tr>
<td>Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridiodes</td>
<td></td>
</tr>
<tr>
<td>difficile Infection in a Randomized Clinical Trial. JAMA. Published Online:</td>
<td></td>
</tr>
<tr>
<td>See prior study description</td>
<td></td>
</tr>
<tr>
<td>VOWST™ (SER-109) is well-tolerated and mitigates the safety concerns of</td>
<td>The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology.</td>
</tr>
<tr>
<td>other alternative therapies.</td>
<td></td>
</tr>
<tr>
<td>Feuerstadt P, Louie TJ, Lashner B, et al., SER-109, an oral microbiome</td>
<td></td>
</tr>
<tr>
<td>therapy for recurrent Clostridiodes difficile infection. N Engl J Med</td>
<td></td>
</tr>
<tr>
<td>2022;386:220-9. DOI: 10.1056/NEJMoa2106516</td>
<td>See prior study description</td>
</tr>
<tr>
<td>See prior study description</td>
<td></td>
</tr>
<tr>
<td>Khanna S, Feuerstadt P, Huang E, et al. An open-label study (ECOSPOR IV)</td>
<td>No serious adverse events that were assessed by the site investigator as being related to VOWST™ (SER-109) were observed through week 8. Adverse events that were related or possibly related to VOWST™ (SER-109) or placebo occurred in slightly more than half of the patients in each group. The most common adverse events were gastrointestinal disorders, the majority of which were mild to moderate in nature. Three deaths occurred in the VOWST™ (SER-109) group, none of which were deemed by the investigators, who were unaware of the trial-group assignments, to be drug-related.</td>
</tr>
<tr>
<td>to evaluate the safety, efficacy, and durability of SER-109 in adults with</td>
<td></td>
</tr>
<tr>
<td>recurrent Clostridiodes difficile infection (rCDI). Am College</td>
<td></td>
</tr>
<tr>
<td>Gastroenterol 2022 Annual Scientific Meeting. Charlotte, NC. Abstract</td>
<td>See study outcomes previously described</td>
</tr>
<tr>
<td>63.</td>
<td></td>
</tr>
<tr>
<td>See prior study description</td>
<td></td>
</tr>
<tr>
<td>McGovern et al., SER-109, an Investigational Microbiome Drug to Reduce</td>
<td>See study outcomes previously described</td>
</tr>
<tr>
<td>Recurrence After Clostridiodes</td>
<td></td>
</tr>
</tbody>
</table>
In the FY 2024 IPPS/LTCH proposed rule (88 FR 26881 through 26882), after reviewing the information provided by the applicant, we noted that we had the following concerns regarding whether VOWST™ (SER-109) meets the substantial clinical improvement criterion. We stated that to demonstrate that VOWST™ reduces rates of CDI recurrence compared to standard of care therapies, the application primarily cited the ECOSPOR phase II trial and ECOSPOR phase III trial. The application also cited an abstract of the open-label single-arm ECOSPOR IV trial which did not appear to provide a comparison against currently available therapies. We stated that the major limitation of these data was that patients who received ZINPLAVA™ in the prior 3 months were excluded. We stated that while the study provided data comparing the effectiveness of VOWST™ to antibiotics alone, no data comparing the treatment of rCDI utilizing antibiotics plus ZINPLAVA™, as was recommended for rCDI, against antibiotics plus VOWST™ (with or without ZINPLAVA™) was provided. Without a comparison against such currently available therapies, we

<table>
<thead>
<tr>
<th>Unlike antibiotics, VOWST™ (SER-109) reduces carriage of antimicrobial resistance genes (ARGs) along with associated antibiotic resistance bacteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brief study description: Double-blind Phase 3 trial of rCDI patients (ECOSPOR III), VOWST™ (SER-109), an orally formulated consortia of purified Firmicutes spores</td>
</tr>
<tr>
<td>rCDI patients in the ECOSPOR-III study had an abundance of ARGs providing resistance against multiple drug classes after completion of standard of care antibiotics, which is not surprising since patients with CDI usually have a history of antibiotic exposure prior to clinical onset of CDI. Treatment with VOWST™ (SER-109) led to a significant decrease in ARG abundance vs. placebo, which was both rapid and sustained through week 8. Further studies will be needed to determine if the significant reduction of ARGs is associated with prevention of subsequent infections with drug resistant bacteria in patients with CDI.</td>
</tr>
<tr>
<td>For recurrent CDI patients (ECOSPOR III), VOWST™ (SER-109), was superior to placebo in reducing CDI recurrence at week 8 post clinical resolution on standard-of-care (SoC) antibiotics. Overall, recurrence rates were lower in VOWST™ (SER-109) (n=89) vs placebo (n=93) (12.4% vs 39.8%, respectively) relative risk, 0.32 (95% CI, 0.18-0.58; p&lt;0.001 for RR&lt;1.0; p&lt;0.001 for RR&lt;0.833). This is a post-hoc analysis examining the impact of VOWST™ (SER-109) on antimicrobial resistance genes (ARGs) abundance in the intestinal microbiota compared to placebo at weeks 1, 2, and 8.</td>
</tr>
</tbody>
</table>
questioned whether the information provided by the applicant was sufficient to support the applicant’s statements that VOWSTM is well-tolerated and mitigates the safety concerns of other alternative therapies, and that VOWSTM can be used in patients ineligible for ZINPLAVATM due to diagnosis of CHF.

With regard to the claim that VOWSTM can be used safely in patients with CHF, the cited trials either did not identify or document effects on patients with comorbid CHF to support this conclusion. The ECOSPOR trial specifically excluded patients with poor concurrent medical risks or clinically significant co-morbid disease such that, in the opinion of the investigator, the subject should not be enrolled. We stated that it was not clear whether this criterion necessarily excluded individuals with known pre-existing CHF from the study group and that it was also not clear how many individuals diagnosed with CHF prior to or during the study were identified in the study populations. We considered whether a lack of participants with CHF could potentially account for the low incidence of adverse effects, rather than being attributable to the safety of VOWSTM relative to ZINPLAVATM for patients with CHF. Absent additional information, we stated that it was difficult to confirm that VOWSTM offers a treatment option for patients ineligible for ZINPLAVATM due to CHF.

The applicant stated that there is an increased resolution of the disease process because VOWSTM expedites microbiome repair during the window of vulnerability, identified as 1–4 weeks after antibiotic discontinuation, by ensuring more rapid engraftment of beneficial Firmicutes bacteria needed to decrease germination of C. diff. spores and prevent recurrence. For this claim, the applicant cited three articles: two randomized controlled trials and one unpublished abstract. While the results of the Phase III randomized controlled trial demonstrated the superiority of VOWSTM over placebo, we questioned whether other treatment options indicated to prevent rCDI, such as ZINPLAVATM, would have been a more appropriate comparator. We stated that additional information regarding clinical outcomes as a result of treatment with VOWSTM compared to such treatment options, instead of placebo, would have been helpful in our assessment of the substantial clinical improvement criterion. With respect to the applicant’s claim that VOWSTM may reduce the number of future hospitalizations or physician visits for patients diagnosed with rCDI, the applicant cited the Feuerstadt study to suggest that reduced rates of rCDI shown in Phase III clinical trials would likely lead to fewer days in hospital. However, we stated that the study did not address this measure directly; rather, this was an inference by the applicant. We welcomed additional data to support the claim VOWSTM may reduce the number of future hospitalizations or physician visits for patients with rCDI.

With respect to the claim that VOWSTM reduces the abundance of antimicrobial resistance genes (ARGs) and associated taxa compared to placebo, which accelerates microbiome recovery from antibiotics, we stated that the applicant cited one unpublished study showing treatment with VOWSTM led to a significant decrease in ARG abundance versus placebo, which was both rapid and sustained through week eight. However, the authors stated that further studies were needed to determine if the significant reduction of ARGs is associated with prevention of subsequent infections with drug resistant bacteria in CDI patients.

We invited public comments on whether REBYOTA TM or VOWSTM meet the substantial clinical improvement criterion.

Comment: The applicants for REBYOTA TM and VOWSTM each submitted comments in response to CMS’s concerns in the FY 2024 IPPS/LTCH PPS proposed rule regarding whether REBYOTA TM and VOWSTM meet the substantial clinical improvement criterion.

In the applicant for VOWSTM’s comment regarding substantial clinical improvement, it asserted that VOWSTM significantly improves clinical outcomes relative to services or technologies previously available as most CDI recurrences occur within 2 weeks of antibiotic discontinuation, and VOWSTM expedites microbiome repair during the “window of vulnerability.” The applicant further stated that reduction of CDI recurrence as a result of VOWSTM may potentially lessen future healthcare costs, morbidity, and rCDI-related hospitalizations. The applicant also asserted that VOWSTM offers a therapeutic option to a patient population with a suboptimal response to, or ineligible for, currently available treatments. Demonstrating the superiority of REBYOTA TM in the patient population with CHF, the applicant presented...
results from a post hoc subgroup analysis of the PUNCH CD3 trial by Tillotson et al.\textsuperscript{101} that was published in January 2023. The applicant stated that the subgroup of patients with cardiac disorders included patients with CHF, described as “Cardiac failure congestive.” Per the applicant, results from the Tillotson et al. subgroup analysis showed that REBYOTA\textsuperscript{TM} treatment success was better than placebo in older adults with cardiac disorders (69\% [n = 25/36]), and that overall treatment success of older adults with comorbidities was similar to the total REBYOTA\textsuperscript{TM}-treated population (70.6\%). The applicant also stated that the subgroup analysis of adverse events further supports REBYOTA\textsuperscript{TM} is safe for CHF patients, and that, unlike the CHF warning included with ZINPLAVA\textsuperscript{®}, the FDA did not issue a warning about CHF on the approved label for REBYOTA\textsuperscript{TM}.

The applicant for REBYOTA\textsuperscript{TM} also provided additional details regarding the absence of comparative data using ZINPLAVA\textsuperscript{®}. The applicant stated that due to the limited use of ZINPLAVA\textsuperscript{TM} in real-world practice, it was not considered in a recent cost-effective analysis comparing REBYOTA\textsuperscript{TM} with standard-of-care. The applicant also noted that the different routes of administration for each of ZINPLAVA\textsuperscript{TM} (given by IV infusion) and REBYOTA\textsuperscript{TM} (via rectal administration) would make it difficult to blind the study and would require that the study sites be equipped to accommodate infusion administration, in addition to being overly burdensome to the study participants.

Response: We thank the applicants for their comments regarding the substantial clinical improvement criterion. After consideration of the information previously submitted in the applications for REBYOTA\textsuperscript{TM} and VOWST\textsuperscript{TM} and summarized in this final rule, and after review of the comments we received, we agree that both REBYOTA\textsuperscript{TM} and VOWST\textsuperscript{TM} represent a substantial clinical improvement over existing technologies because the technologies improve clinical outcomes by increasing resolution of the disease process over placebo without serious adverse effects for patients who have previously received standard of care antibiotics for rCDI. We believe that these two technologies restore the gut microbiome and resolve dysbiosis to prevent the recurrence of CDI in patients following antibacterial treatment for rCDI. In summary, we have determined that REBYOTA\textsuperscript{TM} and VOWST\textsuperscript{TM} meet all of the criteria for approval of new technology add-on payments. Therefore, we are approving new technology add-on payments for REBYOTA\textsuperscript{TM} and VOWST\textsuperscript{TM} for FY 2024. As previously stated, cases involving REBYOTA\textsuperscript{TM} that are eligible for new technology add-on payments will be identified by ICD–10–PCS procedure code WX0H7X6 (Introduction of broad consortium microbiota-based live biotherapeutic suspension into lower GI, via natural or artificial opening, new technology group 8). Cases involving VOWST\textsuperscript{TM} that are eligible for new technology add-on payments will be identified by ICD–10–PCS procedure code WX0DXX9 (Introduction of SER–109 into mouth and pharynx, external approach, new technology group 9).

Each of the applicants submitted cost information for its technology. The applicant for REBYOTA\textsuperscript{TM} stated that the cost of its technology is $9,000.00 per patient, and projected that 2,180 cases will involve the use of REBYOTA\textsuperscript{TM} in FY 2024. The manufacturer of VOWST\textsuperscript{TM} stated that the cost of its technology is $17,500.00 and projected that 448 cases will involve the use of VOWST\textsuperscript{TM} in FY 2024. Because the technologies are substantially similar to each other, we believe using a single cost for purposes of determining the new technology add-on payment amount is appropriate for REBYOTA\textsuperscript{TM} and VOWST\textsuperscript{TM} even though each applicant has its own set of codes. We also believe using a single cost provides predictability regarding the add-on payment when using REBYOTA\textsuperscript{TM} or VOWST\textsuperscript{TM} for the prevention of recurrence of CDI following antibiotic treatment for rCDI. As such, consistent with prior rulemaking (85 FR 58664), we believe that the use of a weighted average of the cost of REBYOTA\textsuperscript{TM} and VOWST\textsuperscript{TM} based on the projected number of cases involving each technology to determine the maximum new technology add-on payment would be most appropriate. To compute the weighted cost average, we summed the total number of projected cases for each of the applicants, which equaled 2,628 cases (2,180 plus 448). We then divided the number of projected cases for each of the applicants by the total number of cases, which resulted in the following case-weighted percentages: 83 percent for REBYOTA\textsuperscript{TM} and 17 percent for VOWST\textsuperscript{TM}. We then multiplied the cost per case for the specific drug by the case-weighted percentage (0.83 * $9,000 = $7,470 for REBYOTA\textsuperscript{TM} and 0.17 * $17,500 = $2,975 for VOWST\textsuperscript{TM}). This resulted in a case-weighted average cost of $10,445 for the technology. Under §412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, the maximum new technology add-on payment for a case involving the use of REBYOTA\textsuperscript{TM} or VOWST\textsuperscript{TM} is $6,789.25 for FY 2024.

g. SeptiCyte\textsuperscript{®} RAPID

Immunexpress, Inc. submitted an application for new technology add-on payments for SeptiCyte\textsuperscript{®} RAPID for FY 2024. Per the applicant, SeptiCyte\textsuperscript{®} RAPID is a gene expression assay used in conjunction with clinical assessments and other laboratory findings as an aid to differentiate infection-positive (sepsis) from infection-negative cases of systemic inflammatory response syndrome (SIRS) in patients suspected of sepsis on their first day of intensive care unit (ICU) admission. According to the applicant, the test is performed in a fully integrated cartridge, which runs on the Biocarts Idylla system, with sample to answer turnaround time of approximately 60 minutes. The applicant stated that SeptiCyte\textsuperscript{®} RAPID generates a score (SeptiScore\textsuperscript{®}) ranging from 0 to 15 that falls within one of four discrete Interpretation Bands based on the increasing likelihood of infection-positive systemic inflammation, also known as sepsis.

Please refer to the online application posting for SeptiCyte\textsuperscript{®} RAPID, available at https://mearis.cms.gov/public/publications/ntap/NTP2210170WWBT, for additional detail describing the technology and diagnostic indications.

With respect to the newness criterion, according to the applicant, SeptiCyte\textsuperscript{®} RAPID received 510(k) clearance (K203748) from FDA on November 29, 2021, for the following indication: SeptiCyte\textsuperscript{®} RAPID is indicated as a gene expression assay using reverse transcription polymerase chain reaction to quantify the relative expression levels of host response genes isolated from whole blood collected in the PAXgene\textsuperscript{®} Blood RNA Tube. The SeptiCyte\textsuperscript{®} RAPID test is used in conjunction with clinical assessments and other laboratory findings as an aid to differentiate infection-positive (sepsis) from infection-negative systemic inflammation in patients suspected of sepsis on their first day of ICU admission. The SeptiCyte\textsuperscript{®} RAPID test

\textsuperscript{101}Glenn Tillotson et. al.; Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities, Open Forum Infectious Diseases, Volume 10, Issue 1, January 2023, ofac703, https://doi.org/10.1093/ofid/ofac703.
generates a score (SeptiScore®) that falls within one of four discrete Interpretation Bands based on the increasing likelihood of infection-positive systematic inflammation. SeptiCyte® RAPID is intended for in-vitro diagnostic use on the Biocartis Idylla™ System. The applicant stated the SeptiCyte® RAPID was commercially available immediately after FDA clearance. Per the applicant, SeptiCyte® RAPID was cleared based on substantial equivalency to the predicate device SeptiCyte® LAB (K163260), which received 510(k) clearance from the FDA on April 6, 2017.

The applicant described differences between the two versions of the technology including: the automatic extraction of material from SeptiCyte® RAPID versus the manual extraction for SeptiCyte® LAB; reverse transcription polymerase chain reaction (RT–PCR) and dry format for SeptiCyte® RAPID versus reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and wet format for SeptiCyte® LAB; use of the Biocartis Idylla™ System for SeptiCyte® RAPID versus ABI 7500 Fast Dx for SeptiCyte® LAB; different fluorescent probes and quenchers between SeptiCyte® RAPID and SeptiCyte® LAB; and use of MS2 phage internal sample processing control for SeptiCyte® RAPID versus three external controls for SeptiCyte® LAB.

The applicant stated that effective October 1, 2022, the following ICD–10–PCS code may be used to uniquely describe procedures involving the use of SeptiCyte® RAPID: XXE5X38 (Measurement of infection, whole blood nucleic acid-base microbial detection, new technology group 5). We note that the correct descriptor for this code appears to be (Measurement of infection, whole blood reverse transcription and quantitative real-time polymerase chain reaction, new technology group 8).

As previously discussed, if a technology meets all three of the substantial similarity criteria under the newness criterion, it would be considered substantially similar to an existing technology and would not be considered “new” for the purpose of new technology add-on payments.

With respect to the substantial similarity criteria, the applicant asserted that SeptiCyte® RAPID is not substantially similar to other currently available technologies because SeptiCyte® RAPID differs in mechanism, performance, and turnaround time from all current sepsis diagnostic tools by leveraging the host’s immune response to systemic inflammation of infectious origin via measurement of the gene expression ratio between upregulated and downregulated genes, and therefore, the technology meets the newness criterion. The following table summarizes the applicant’s assertions regarding the substantial similarity criteria. Please see the online application posting for SeptiCyte® RAPID for the applicant’s complete statements in support of its assertion that SeptiCyte® RAPID is not substantially similar to other currently available technologies.

<table>
<thead>
<tr>
<th>Substantial Similarity Criteria</th>
<th>Applicant Response</th>
<th>Applicant assertions regarding this criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does the technology use the same or similar mechanism of action to achieve a therapeutic outcome?</td>
<td>No</td>
<td>SeptiCyte® RAPID uses a unique and novel technology which detects the host’s immune response to systemic inflammation of infectious origin via measurement of gene expression. It is the ratio between the upregulated gene PLAC8 and down regulated gene PLA2G7, that is measured and translated into a sepsis probability score, or SeptiScore®, ranging between 0 – 15 with a higher score correlating with higher likelihood of sepsis. Although many biomarkers are used in sepsis diagnosis, none have sufficient specificity or sensitivity to accurately differentiate sepsis versus SIRS. Consequently, they have limited value in assessing if the systemic inflammation has pathogenic origin, requiring antibiotics, or if there is some other etiology. A major factor limiting their use is the complex and heterogeneity of the immune response to sepsis. SeptiCyte® RAPID is the first and only host response gene expression assay to be clinically validated and FDA-cleared for use in conjunction with clinical assessments, vital signs, and laboratory findings to differentiate infection-positive (sepsis) from infection-negative systemic inflammation in patients suspected of sepsis on their first day of ICU admission.</td>
</tr>
<tr>
<td>Is the technology assigned to the same MS-DRG as existing technologies?</td>
<td>Yes</td>
<td>SeptiCyte® RAPID would most likely be grouped into the same MS-DRG for sepsis.</td>
</tr>
<tr>
<td>Does new use of the technology involve the treatment of the same/similar type of disease and the same/similar patient population when compared to an existing technology?</td>
<td>No</td>
<td>This technology is unique to aid in the early diagnosis of sepsis and guide treatment decisions for suspected sepsis patients. It accomplishes this primarily by providing a sepsis probability with high accuracy, differentiating sepsis versus non-infectious systemic inflammation, generating results in one hour to aid in guiding prompt and appropriate intervention. There is no other technology that can accomplish this with such a high level of accuracy and in such a timely manner. It can be used on any adult patient population where a patient is suspected of sepsis with SIRS criteria, such as critically ill patients, patient’s post-operative, trauma, or burn patients etc.</td>
</tr>
</tbody>
</table>

We invited public comments on whether Septicyte® RAPID is substantially similar to existing technologies and whether Septicyte® RAPID meets the newness criterion.

**Comment:** The applicant submitted a comment in response to CMS’s concerns pertaining to the newness criterion. Regarding our concern whether Septicyte® RAPID uses the same or similar mechanism of action as existing technology, the applicant clarified that Septicyte® LAB, the predicate device to Septicyte® RAPID, was never manufactured, commercialized, or sold in the U.S. The applicant stated that it does not believe Septicyte® RAPID is substantially similar to Septicyte® LAB, because Septicyte® RAPID applies the technology to an improved, streamlined methodology consisting of fewer steps that result in a 1-hour turnaround time. However, the applicant also noted that Septicyte® RAPID demonstrates a high correlation (r² = 0.94) to Septicyte® LAB, which were developed and validated using the same underlying polymerase chain technology.

The applicant stated its belief that even if CMS considers Septicyte® RAPID to be substantially similar to Septicyte® LAB, Septicyte® RAPID should be considered new because Septicyte® LAB was never commercially available in the U.S. The applicant explained that FDA cleared Septicyte® LAB on April 6, 2017, but Immunexpress Inc. never manufactured or sold the device in the U.S. due to the market access impediment of a 6-hour test turnaround time, when clinical management of sepsis needs to meet a 3-hour sepsis bundle of care, according to the CMS Severe Sepsis and Septic Shock Management Bundle core measure. The applicant stated that while FDA subsequently granted 510(k) clearance to Septicyte® RAPID on November 29, 2021, it believes the newness date for Septicyte® RAPID should begin on the date of the device’s first sale, which was April 20, 2022. The applicant noted that it provided Septicyte® RAPID free of charge for evaluations and quality improvement initiatives between its FDA clearance on November 29, 2021, and April 20, 2022, the date of first sale. The applicant stated its belief because the date of first sale occurred after a substantial delay from the date of FDA clearance.

Regarding our concern whether Septicyte® RAPID targets the same disease or patient population compared to existing sepsis diagnostic testing. Instead, the applicant stated that Septicyte® RAPID does not diagnose the same patient population compared to existing technology, because it allows for early diagnosis, guides treatment decisions, and has high accuracy. While this may be relevant to the assessment of substantial clinical improvement, it did not appear to be related to newness, and it was unclear how the patient population tested with Septicyte® RAPID differs from other patients tested for sepsis, including those tested with Septicyte® LAB. As the applicant stated that Septicyte® RAPID maps to the same MS–DRG as existing technologies, and it appears to have a similar mechanism of action and is used in the same patient population as Septicyte® LAB, we stated our belief these technologies may be substantially similar to each other. We noted that if Septicyte® RAPID is substantially similar to Septicyte® LAB, we believe the newness period for this technology would begin on April 6, 2017, with the 510(k) clearance date for Septicyte® LAB and, therefore, because the 3-year anniversary date of the technology’s entry onto the U.S. market (April 6, 2020) occurred in FY 2020, the technology would no longer be considered new and would not be eligible for new technology add-on payments for FY 2024.

Response: We thank the applicant for its comment and the additional information provided.

Based on our review of comments received and information submitted by the applicant as part of its FY 2024 new technology add-on payment application for Septicyte® RAPID, we agree with the applicant that Septicyte® RAPID has a unique mechanism of action as the first commercially available gene expression assay using reverse transcription polymerase chain reaction to aid in differentiating infection-positive (sepsis) from infection-negative systemic inflammation. Therefore, we believe that Septicyte® RAPID is not substantially similar to existing diagnostic options and meets the newness criterion.

In regard to the first criterion, whether a technology uses the same or similar mechanism of action to achieve a therapeutic outcome, we continue to believe that Septicyte® RAPID uses the same or similar mechanism of action as the predicate device, Septicyte® LAB, as gene expression assays using reverse transcription polymerase chain reaction to aid in differentiating infection-positive (sepsis) from infection-negative systemic inflammation. Although the applicant states that Septicyte® RAPID applies the technology to an improved methodology, which impacts clinical utility for rapid results to aid the clinician in suspected sepsis, we believe that improvements in clinical utility do not result in a substantially different mechanism of action, and these differences instead relate to an assessment of whether Septicyte® RAPID meets the substantial clinical improvement criterion. We also believe that regardless of whether the procedural steps have changed, the manner in which Septicyte® RAPID functions is unchanged from Septicyte® LAB. For example, we note that the analytes assessed by Septicyte® RAPID (PLAC8; PLA2G7) are a subset of those assessed by Septicyte® LAB (PLAC8; PLA2G7; LAMP1; CEACAM4); and as noted previously, studies conducted using Septicyte® LAB were used to demonstrate substantial clinical improvement for Septicyte® RAPID. Therefore, we believe that the SeptiScore® results target the same population. The applicant stated that no existing diagnostic technology can accurately or rapidly differentiate sepsis from non-infectious systemic inflammation as Septicyte® RAPID does.
obtained by SeptiCyte® RAPID are the same or similar as to those that would have been obtained with SeptiCyte® LAB, and that differences in methodology between the two technologies do not represent a new mechanism of action.

Furthermore, we agree with the applicant that the two versions of the technology map to the same MS–DRGs and are intended to treat the same or similar disease in the same or similar patient population—patients tested for sepsis to differentiate sepsis from infection-negative systemic inflammation. Because SeptiCyte® RAPID meets all three of the substantial similarity criteria, we believe SeptiCyte® RAPID is substantially similar to the predicate technology, SeptiCyte® LAB.

In accordance with our policy, because these technologies are substantially similar to each other, we use the earliest market availability date submitted as the beginning of the newness period for both technologies. However, we note that the applicant stated that SeptiCyte® LAB, although FDA cleared, was never manufactured, commercialized or sold in the U.S. market due to the market access impediment of a 6-hour test turnaround time. As we have discussed in prior rulemaking, generally, our policy is to begin the newness period on the date of FDA approval or clearance or, if later, the date of availability of the product on the U.S. market, and we may consider a documented delay in the technology’s market availability in our determination of newness (77 FR 53348 and 70 FR 47341). Since SeptiCyte® LAB has not been available for sale on the U.S. market, we are unable to establish the beginning of the newness period for SeptiCyte® LAB. Therefore, we believe it is appropriate to use the earliest market availability date submitted for SeptiCyte® RAPID as the beginning of the newness period for both technologies.

We note that, as stated previously, while CMS may consider a documented delay in the technology’s market availability in our determination of newness, our policy for determining whether to extend new technology add-on payments for an additional year generally applies regardless of the volume of claims for the technology after the beginning of the newness period (83 FR 41280). We do not consider the date of first sale of a product as an indicator of its entry onto the U.S. market. The applicant stated that the date of first sale of SeptiCyte® RAPID was April 20, 2022, but it is unclear from the information provided when the technology first became available for sale and, absent additional information from the applicant, we cannot determine a newness date based on a documented delay in the technology’s availability on the U.S. market. Therefore, we consider the beginning of the newness period for SeptiCyte® RAPID to commence on November 29, 2021, when SeptiCyte® RAPID received FDA marketing authorization.

With respect to the cost criterion, the applicant searched the FY 2021 MedPAR file for potential cases representing patients who may be eligible for SeptiCyte® RAPID. The applicant identified three different types of patient cases where SeptiCyte® RAPID could be used: patients with sepsis as an admission diagnosis; patients who develop sepsis after hospital admission; and patients with symptoms similar to sepsis patients. To identify these patients, the applicant used MS–DRGs and ICD–10–CM codes. These three groups were combined into one analysis with no overlap in cases between the three groups. Please see Table 10.21.A.—SeptiCyte® RAPID Codes—FY 2024 associated with the proposed rule for the complete list of MS–DRGs and codes provided by the applicant. Using the inclusion/exclusion criteria described in the following table, the applicant identified 3,460,256 claims mapping to 691 MS–DRGs. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $88,326, which exceeded the average case-weighted threshold amount of $72,992. Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount, the applicant maintained that SeptiCyte® RAPID meets the cost criterion.
We invited public comments on whether SeptiCyte® RAPID meets the cost criterion.

Comment: The applicant submitted a comment reiterating that SeptiCyte® RAPID meets the cost criterion because the inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount.

Response: We thank the applicant for its comment. We agree the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount. Therefore, SeptiCyte® RAPID meets the cost criterion.

With regard to the substantial clinical improvement criterion, the applicant asserted that SeptiCyte® RAPID represents a substantial clinical improvement over existing technologies because SeptiCyte® RAPID is the only technology to accurately differentiate sepsis versus non-infectious systemic inflammation in 1 hour, allowing for early, appropriate intervention in suspected sepsis patients and driving prompt source control investigation, while outperforming currently used sepsis diagnostic tools. The applicant asserted that for these reasons, SeptiCyte® RAPID offers the ability to diagnose sepsis earlier than allowed by currently available diagnostic methods and significantly improves clinical outcomes relative to current technologies. The applicant provided eight studies to support these claims, as well as 12 background articles about sepsis clinical guidelines, screening criteria, and treatment. The following table summarizes the applicant’s assertions regarding the substantial clinical improvement criterion. Please see the online posting for SeptiCyte® RAPID for the applicant’s complete statements regarding the substantial clinical improvement criterion and the supporting evidence provided.

### SeptiCyte® RAPID COST ANALYSIS

<table>
<thead>
<tr>
<th>Data Source and Time Period</th>
<th>FY 2021 MedPAR file</th>
</tr>
</thead>
<tbody>
<tr>
<td>List of ICD-10-CM codes</td>
<td>Please see Table 10.21.A. - SeptiCyte® RAPID Codes - FY 2024 associated with the proposed rule for the complete list of ICD-10-CM codes provided by the applicant.</td>
</tr>
<tr>
<td>List of MS-DRGs</td>
<td>Please see Table 10.21.A. - SeptiCyte® RAPID Codes - FY 2024 associated with the proposed rule for the complete list of MS-DRGs provided by the applicant.</td>
</tr>
</tbody>
</table>

#### Inclusion/exclusion criteria

The applicant identified and included three types of patients in its analysis:
- Group 1 - Patients with sepsis as an admission diagnosis: The applicant identified three MS-DRGs (870-872) related to sepsis or septicemia and included all the cases in these MS-DRGs in its analysis.
- Group 2 - Patients who develop sepsis after hospital admission: The applicant identified cases using ICD-10-CM diagnosis codes related to sepsis or septicemia.
- Group 3 - Patients with symptoms similar to sepsis patients: A clinical expert identified ICD-10-CM diagnosis codes where symptoms would potentially be similar to sepsis patients and MS-DRGs for the treatment of conditions that could present similarly to sepsis. For this group, the applicant also required the presence of emergency department charges, to signify that the patient presented initially in the emergency department, where SeptiCyte® RAPID would be used to aid in diagnosis and treatment planning.

Note: These three groups were combined into one analysis with no overlap in cases between the three groups.

Any MS-DRG with a total discharge count less than 11 was imputed with a count of 11. The applicant excluded claims that would not be used for Medicare IPPS rate setting. The applicant calculated the average unstandardized charge per case for each MS-DRG.

#### Charges removed for prior technology

The applicant did not remove any direct or indirect charges related to the prior technology, because SeptiCyte® RAPID would not replace any prior technology.

#### Standardized charges

The applicant used the standardization formula provided in the application. The applicant used all relevant values reported in the impact file posted with the FY 2023 IPPS/LTCH PPS final rule.

#### Inflation factor

The applicant applied an inflation factor of 13.2% to the standardized charges, based on the inflation factor used to calculate outlier threshold charges in the FY 2023 IPPS/LTCH PPS final rule.

#### Charges added for the new technology

The applicant stated that it is expected the hospital would use one SeptiCyte® RAPID test per patient, per hospitalization. The applicant added charges for the new technology by dividing the cost of the new technology by the national average cost-to-charge ratio of 0.107 for laboratories from the FY 2023 IPPS/LTCH PPS final rule. The applicant did not add indirect charges related to the new technology.

---

104 Background articles are not included in the following table but can be accessed via the online posting for the technology.
**Substantial Clinical Improvement Assertion #1:** The technology offers the ability to diagnose a medical condition in a patient population where that medical condition is currently undetectable or offers the ability to diagnose a medical condition earlier in a patient population than allowed by currently available methods.

<table>
<thead>
<tr>
<th>Applicant statements in support</th>
<th>Supporting evidence provided by the applicant</th>
<th>Outcomes or findings cited by the applicant from supporting evidence to support its statements</th>
</tr>
</thead>
<tbody>
<tr>
<td>SeptiCyte® RAPID is the Only Technology to Provide Early Differentiation Between Sepsis from Non-Infectious Systemic Inflammation (SIRS).</td>
<td>Hassan, E., David, R., Sampson, D., &amp; Miller, R. (2021). Comparison of lactate, procalcitonin and a gene signature assay alone or in combination to differentiate sepsis from non-infectious systemic inflammation in ICU patients. Infectious Disease Society of America IDWeek, A 994.</td>
<td>AUROC (area under the receiver operator curve) to Differentiate Sepsis from SIRS Lactate Alone: 0.56 PCT Alone: 0.76 PCT + Lactate: 0.76 SeptiCyte® Alone: 0.85 SeptiCyte® + Lactate 0.85 SeptiCyte® + PCT 0.86 SeptiCyte® + PCT + Lactate 0.86</td>
</tr>
<tr>
<td></td>
<td>Brief study description: Evaluate the use of lactate, PCT or SeptiCyte® either alone or in combination in differentiating sepsis from SIRS.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Balk, R., Esper, A.M., Martin, G.S., Miller III, R.R., Lopansri, B.K., et al. (2022). Validation of SeptiCyte RAPID SeptiCyte® RAPID to discriminate sepsis from non-infectious systemic inflammation. Submitted for review and publication September 2022. <a href="https://doi.org/10.1101/2022.07.20.22277648">https://doi.org/10.1101/2022.07.20.22277648</a>.</td>
<td>Correlation between SeptiCyte® Lab (4 biometric assay) to SeptiCyte® RAPID (2 biometric assay): R = 0.88, P &lt;0.001. Page 14, Figure 5 Probability of Sepsis SeptiCyte® Band 1: 9.4% SeptiCyte® Band 2: 20.7% SeptiCyte® Band 3: 42.3% SeptiCyte® Band 4: 80.7%</td>
</tr>
<tr>
<td></td>
<td>Brief study description: Validation and clinical performance of SeptiCyte® RAPID, 2 biomarker assay to distinguish between sepsis and non-infectious systemic inflammation (SIRS).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Miller III, R.R., Lopansri, B.K., Burke, J.P., Levy, M., Opal, S., et al. (2018). Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU. American Journal of Respiratory and Critical Care Medicine, 198(7), 903-913. <a href="https://doi.org/10.1164/rcrm.201712-2472oc">https://doi.org/10.1164/rcrm.201712-2472oc</a>.</td>
<td>In the absence of a gold standard, a panel of experts (PRD) reached unanimous decision on sepsis vs SIRS to generate these results: Page 907, Table 2 Sepsis (n=180) SIRS (n=230) SeptiCyte® Band 1, % (10 (5.6) 79 (34.3) SeptiCyte® Band 2, n (6% (11.1) 82 (35.6) SeptiCyte® Band 3, n (4%) 45 (25.0) 49 (21.3) SeptiCyte® Band 4, n (105 (58.3) 20 (8.7) Page 909, Table 3 Unanimous expert panel agreement: AUROC = 0.89 Sensitivity = 0.97 Specificity = 0.34 NPV = 0.94 PPV = 0.51 NB. Table 3 per Erratum (Erratum: Validation of a Host Response Assay, SeptiCyte® LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU. [No authors listed] Am J Respir Crit Care Med. 2020 Jul 1;202(1):155. doi: 10.1164/rcrm.v202erratum2. PMID: 32609017) Unanimous expert panel agreement: AUROC = 0.89 Sensitivity = 0.97 Specificity = 0.33 NPV = 0.93 PPV = 0.50.</td>
</tr>
<tr>
<td></td>
<td>Brief study description: Can SeptiCyte® distinguish between sepsis and non-infectious systemic inflammation (SIRS). Combination of 3) separate prospective, observational studies on the clinical performance of SeptiCyte®. Adult pts with two (2) or more SIRS findings upon ICU admission. SeptiCyte® sample obtained within 24 hours of ICU admission.</td>
<td></td>
</tr>
</tbody>
</table>

The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology.
<p>| SeptiCyte® RAPID Outperforms Current Sepsis Diagnostic Tools When Used Alone or in Combination | Balk, R., Esper, A.M., Martin, G.S., Miller III, R.R., Lopansri, B.K., et al. (2022). Validation of SeptiCyte® RAPID to discriminate sepsis from non-infectious systemic inflammation. Submitted for review and publication September 2022. <a href="https://doi.org/10.1101/2022.07.20.22277648">https://doi.org/10.1101/2022.07.20.22277648</a>. AUROC of 32,767 possible logistic combinations of 14 variables (SeptiCyte®, PCT, Lactate, various laboratories, minimum and maximum vital signs, demographics. For discrimination between sepsis and SIRS. Approximate AUROC: Clinical Variables Only (without SeptiCyte® or PCT): 0.68 PCT alone: 0.77 PCT with Clinical Variables, without SeptiCyte®: 0.80 SeptiCyte® Alone: 0.84 SeptiCyte® with PCT and Clinical Variables: 0.87. | See prior study description |
| SeptiCyte® RAPID Results Can Aid in Improving Diagnostic Stewardship Practices. | The applicant provided background information to support this claim, which can be accessed via the online posting for the technology. |
| SeptiCyte® RAPID provides Clinicians with Actionable Results Sooner than Pathogen Detection Systems | Balk, R., et al. (2022). Validation of SeptiCyte® RAPID to discriminate sepsis from non-infectious systemic inflammation. Submitted for review and publication September 2022. <a href="https://doi.org/10.1101/2022.07.20.22277648">https://doi.org/10.1101/2022.07.20.22277648</a>. The test has a hands-on time of “two (2) min and a turnaround time of “one (1) hour. SeptiCyte® RAPID scores were verified to be independent of the white blood cell (WBC) count across an input range of 25 to 25,000 WBC/ul. | See prior study description |
| The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology. |</p>
<table>
<thead>
<tr>
<th>Septicyte® RAPID Effectively Differentiates Sepsis from Infection Negative Systemic Inflammation (SIRS) in Various Clinical Conditions.</th>
<th>Davis, R.F., Navalkar, K.A., van der Poll, T., Schultz, M.J., Cremer, O.L., Bonten, M., &amp; Zimmerman, J.J. (2021). Septicyte® RAPID in sepsis cases with malignancy or treated with antineoplastic or immunosuppressants. Poster presentation for the 50th Critical Care Conference. Brief study description: Evaluate the clinical performance of Septicyte® RAPID in sepsis patients with systemic inflammation and a hematologic or metastatic malignancy or those being treated with immunosuppressant or antineoplastic agents.</th>
<th>AUROC for various Sepsis vs SIRS Comparisons Sepsis cases treated or with Malignancy vs SIRS cases: 0.83 – 0.97 Sepsis cases NOT treated or with Malignancy vs SIRS cases: 0.85 – 0.89.</th>
</tr>
</thead>
</table>

**Substantial Clinical Improvement Assertion #2:** The technology significantly improves clinical outcomes relative to services or technologies previously available.

<table>
<thead>
<tr>
<th>Applicant statements in support</th>
<th>Supporting evidence provided by the applicant</th>
<th>Outcomes or findings cited by the applicant from supporting evidence to support its statements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Septicyte® RAPID 1 Hour Turn Around Time Allows for Prompt Attention to Infection Source Control.</td>
<td>The applicant provided background information to support this claim, which can be accessed via the online posting for the technology.</td>
<td>Change in Initial Diagnosis with Septicyte® over Standard of Care True Negatives: Increase 9.4% False Positives: Decrease 4.5% Indeterminate, sepsis presumed decrease 9.4%</td>
</tr>
</tbody>
</table>

See prior study description


Brief study description: Evaluate and compare clinician’s perceptions of SeptiCyte® RAPID score as an addition to the clinicians clinical assessment of sepsis.

The applicant also provided background information to support this claim, which can be accessed via the online posting for the technology.

SeptiCyte® RAPID Aids Sepsis Antibiotic Initiation Consistent with Current Consensus Guidelines.


See prior study description

BILLING CODE 4120–01–C

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26873), after reviewing the information provided by the applicant, we stated that we had the following concerns regarding whether SeptiCyte® RAPID meets the substantial clinical improvement criterion. First, we noted that the applicant submitted two studies of SeptiCyte® LAB, the predicate device, to support its assertions as to why SeptiCyte® RAPID represents a substantial clinical improvement. The applicant did not present any clinical data to compare SeptiCyte® RAPID to SeptiCyte® LAB. Second, the studies provided showed that SeptiCyte® RAPID is not a definitive test and that resulting SeptiScores® in Bands 2 and 3 are inconclusive. We noted that the applicant stated that SeptiCyte® RAPID should be used in conjunction with clinical assessments and other laboratory findings. If additional diagnostic tests are needed in conjunction with SeptiCyte® RAPID to determine a diagnosis of sepsis or SIRS, we questioned whether SeptiCyte® RAPID can provide an earlier diagnosis and affect the management of the patient. In addition, we stated that the applicant did not provide evidence for this claim other than the 1-hour turnaround time for SeptiCyte® RAPID to provide test results. Additionally, we noted that the applicant did not provide any clinical data demonstrating that the SeptiCyte® RAPID affects the management of the patient, or that it improves clinical outcomes.

We invited public comments on whether SeptiCyte® RAPID meets the substantial clinical improvement criterion.

Comment: We received several comments in support of new technology add-on payments for SeptiCyte® RAPID. A few of the commenters stated their belief that SeptiCyte® RAPID has the potential to greatly improve patient care because of its high level of sensitivity, short turnaround time, and advantages over existing sepsis diagnostic tools. A commenter who recently evaluated SeptiCyte® RAPID’s impact on sepsis bundle compliance at their community hospital emergency department stated they had very encouraging findings and believe SeptiCyte® RAPID has the potential for clinical utility in the care of its sepsis patients, as well as the potential for improved antibiotic stewardship and reduced costs. A few commenters also explained that SeptiCyte® RAPID provides clinicians with the probability of sepsis to facilitate real-time decision making in patients with suspected sepsis. One commenter noted that SeptiCyte® RAPID has the potential to impact the morbidity and mortality of critically ill patients. A few commenters stated their support for approval of SeptiCyte® RAPID's new technology add-on payment application because approval for the payments would encourage adoption of the technology by hospitals and health systems who may otherwise delay usage of SeptiCyte® RAPID.


Response: We thank the commenters for their input and have taken it into consideration in our determination of whether SeptiCyte® RAPID meets the substantial clinical improvement criterion, discussed later in this section.

Comment: The applicant submitted a public comment regarding the substantial clinical improvement criterion and provided responses to concerns raised in the proposed rule. With respect to whether studies of SeptiCyte® LAB accurately represent clinical data from SeptiCyte® RAPID, the applicant stated that SeptiCyte® RAPID was compared to SeptiCyte® LAB and the two devices had a high correlation (r = 0.94), which measured the linear association between the two tests.

With respect to CMS’s concern about whether SeptiCyte® RAPID is a definitive test and that SeptiScores® in Bands 2 and 3 are inconclusive, the applicant stated that SeptiCyte® RAPID scores indicate the sepsis likelihood ratios based upon its four bands with high specificity and sensitivity for 80 percent of all patients. The applicant explained that for the remaining 20 percent of patients, whose SeptiScores® fall into Band 3, probability can be derived in conjunction with other lab variables. The applicant further explained that the high sensitivity of Band 1 and the high specificity of the test in Band 4 provides clinicians with rule-in or rule-out information, which is strong patient management information that is unavailable with current technologies.

With respect to whether SeptiCyte® RAPID should be used in conjunction with clinical assessments and other laboratory findings, the applicant stated that with the lack of a “Gold Standard” to effectively define sepsis, currently available diagnostic tools for suspected sepsis are inadequate, with high false positivity rates due to limited specificity (for example, C-reactive protein (CRP)), lengthy turnaround time for actionable results, and low sensitivity (for example, blood cultures). The applicant further stated that when used in conjunction with clinical assessments, vital signs, and laboratory findings, SeptiCyte® RAPID alone, or in combination with typically used biomarkers, is superior to existing technologies in differentiating sepsis from non-infectious systemic inflammation.108 The applicant also asserted that SeptiCyte® RAPID significantly differentiated between sepsis and non-infectious systemic inflammation in 143 patients where an expert panel of sepsis physicians was unable to retroactively diagnose sepsis or non-infectious systemic inflammation. In addition, the applicant noted that SeptiCyte® RAPID has been independently clinically validated for its role in triage and risk stratification of patients with severe COVID, which according to the applicant is a proxy for sepsis.

With respect to whether SeptiCyte® RAPID can provide an earlier diagnosis and affect the management of the patient, the applicant reasserted that SeptiCyte® RAPID allows for earlier differentiation of sepsis from non-infectious systemic inflammation, thereby impacting the management of patients by allowing for earlier therapeutic intervention as well as antibiotic and diagnostic stewardship. The applicant stated that literature provides well documented evidence that patient management aligned with Surviving Sepsis Campaign guidelines and meeting CMS quality metrics of 1- or 3-hour bundles improves care and clinical outcomes for sepsis patients. The applicant explained that this evidence supports its belief that the 1-hour turnaround time and significant likelihood ratios of SeptiCyte® RAPID for differentiating sepsis versus non-infectious systemic inflammation can impact sepsis bundle compliance and clinical outcomes.

With respect to CMS’s concern about the absence of clinical data demonstrating that the SeptiCyte® RAPID affects the management of the patient or that it improves clinical outcomes, the applicant reiterated its belief that by providing early and accurate differentiation between sepsis and non-infectious systemic inflammation, SeptiCyte® can decrease the time to diagnoses and treat sepsis resulting in improved outcomes and reduced mortality. To support this claim, the applicant included eight case studies which they stated demonstrate SeptiCyte® RAPID’s impact on the care process, antibiotic stewardship, and diagnostic stewardship. More specifically, the applicant provided a case study to demonstrate SeptiCyte® RAPID’s utility in each of the following: (1) monitoring patients post-operatively for secondary hospital acquired sepsis; (2) monitoring severe burn patients to differentiate infection negative systemic inflammation from infection positive systemic inflammation and sepsis; (3) diagnosing sepsis in an immunocompromised patient admitted with neutropenia and a recurrence of cancer who received chemotherapy; (4) confirming the presence of sepsis despite negative blood cultures; (5) evaluating the probability of sepsis in a patient with a change in clinical status and determining whether a de-escalation of antibiotics was appropriate; (6) differentiating infection negative systemic inflammation from infection positive systemic inflammation and sepsis; and (7/8) aiding the diagnosis of secondary sepsis following a central nervous system bleed and surgical procedure.

The first case study provided by the applicant pertains to a 64-year-old female admitted for a right hemi hepatectomy for hepatobiliary carcinoma. After 19 days in the hospital, the patient exhibited clinical deterioration and an altered mental status. The patient was transferred to the intensive care unit (ICU), where the patient underwent blood cultures, SeptiCyte® RAPID, and an abdominal computed (CT) scan. The SeptiScore® was 7.5, within Band 4, indicating a high probability of sepsis. The CT showed a peripheal abscess, which was drained, and the fluid was cultured. As a result of these tests, the patient started antibiotics. After 24 hours, SeptiCyte® RAPID showed a SeptiScore® of 8.8, within Band 4, and blood cultures showed Escherichia coli and Candida, confirming sepsis. The patient received treatment for 7 days and was transferred from the ICU to the ward with a SeptiScore® of 7.1, within Band 3, indicating an intermediate risk of sepsis. The applicant stated that the patient developed a post-operative infection and an abscess, and SeptiCyte® RAPID was used to confirm sepsis and to monitor the patient for evidence of secondary hospital acquired sepsis.

The second case study included in the applicant’s comment pertains to a 40-year-old male admitted to the burn unit with thermal burns covering 30 percent of his total body surface area (TBSA), with 10 percent of his TBSA deeply burned. At admission, SeptiCyte® RAPID was administered showing a SeptiScore® of 4, within Band 1, indicating a low probability of sepsis. During day 3 of admittance, the patient developed increased respiratory distress and another SeptiCyte® RAPID was administered. The SeptiScore® was


12.8, within Band 4, indicating a high probability of sepsis. The patient's sputum sample showed growth of Haemophilus influenzae and blood cultures were negative. As a result, the patient started antibiotics. On day 10, the patient developed fever, tachycardia, and leukocytosis. As a result, blood, urine, and cutaneous cultures were drawn and SeptiCyte® RAPID was administered. The SeptiScore® was 10.1, within Band 4, indicating a high probability of sepsis. The cutaneous cultures showed Enterococcus faecalis and Pseudomonas aeruginosa. The patient received antibiotics. The applicant stated that severe burn patients frequently develop an inflammatory response due to repeated surgeries, debridement, thrombotic complications, and other treatments. The applicant also stated that this case study demonstrates the use of SeptiCyte® RAPID to monitor the patient following a baseline low SeptiScore® on admission and repeating the SeptiCyte® RAPID test at the time of developing SIRS and possible infection. The applicant explained that the high SeptiScore® in the presence of SIRS supports the early diagnosis of a hospital-acquired infection and sepsis.

The applicant stated that the third case study is intended to demonstrate the role of SeptiCyte® RAPID in the diagnosis of sepsis in an immunocompromised patient with neutropenia and recurrence of cancer who was receiving chemotherapy. A 47-year-old patient with a history of cervical cancer considered to be in remission was admitted with a hemorrhagic stroke. An examination revealed recurrence of the cancer with hepatic and cerebral metastatic lesions. As a result, the patient began chemotherapy. On day 7, the patient developed a fever and had an absolute neutrophil count of 200 per microliter. Blood and urine cultures were negative, and the patient was treated with antibiotics for seven days, after which chemotherapy was restarted. On day 30, the patient developed fever, tachycardia, anuria, and hypotension. The patient received blood tests and a clinical assessment that showed a decrease in neutrophils to 0 per microliter, down from 170 two days prior; a c-reactive protein of 166 mg/L; and a blood pressure of 70/50 mmHg. The patient was admitted to the ICU where volume and vasopressors were started, and blood and urine cultures obtained. In addition, the patient’s SeptiScore® was 9, within Band 4, representing a high probability of sepsis. These clinical tests also showed growth of Enterococcus faecalis in the urine, and the patient started triple antibiotics and discontinued chemotherapy. The applicant stated that this case demonstrates SeptiCyte® RAPID's diagnostic capability of detecting sepsis much earlier in a patient with severe neutropenia and immunosuppression, confirming sepsis and prompting initiation of antibiotics and cessation of chemotherapeutics.

The applicant explained that the fourth case study represented an example of how SeptiCyte® RAPID is used to confirm the presence of sepsis despite negative blood cultures. A 79-year-old male with diabetes mellitus and chronic obstructive pulmonary disease was admitted for endoscopic devolulosis of a sigmoid volvulus. The patient developed dyspnea and productive cough with decreasing consciousness and increasing work of breathing. The patient was intubated and admitted to the ICU where he was placed on vasopressors and intermittent mandatory ventilation. The patient had a Sequential Organ Failure Assessment (SOFA) score of 9, a white blood cell count of 14,000, a lactate of 1.6 mm/L, a negative urine antigen test, and a chest x-ray that showed diffuse bilateral infiltrates. The patient's SeptiScore® was 7.7, within Band 4, indicating a high probability of sepsis. Blood and urine cultures were also obtained. The patient started triple antibiotics. The applicant stated that the SeptiScore® confirmed a high probability of sepsis resulting in early initiation of appropriate antimicrobials and early source investigation and control.

The applicant explained that the fifth case study is an example of how SeptiCyte® RAPID was used to evaluate an in-hospital change in clinical status and de-escalation of antibiotic therapy. A 63-year-old male with a history of diabetes mellitus and non-dialysis chronic renal failure was admitted to the ICU with bilateral SARS-CoV-2 pneumonia and respiratory failure. The patient's 78-day stay in the ICU included mechanical ventilation, tracheostomy, dialysis for acute renal failure, ventilator-associated pneumonia from Enterobacter cloacae, and two episodes of hospital-acquired bacteremia with Enterococcus faecalis and Staphylococcus aureus. Once the patient was transferred to the ward, his tracheostomy was removed, and dialysis was discontinued. Five days later, the patient presented a low-grade fever, shortness of breath, purulent sputum, and tachypnea and was readmitted to the ICU with hypoxic respiratory failure and intubated. At this time, the patient had a blood pressure of 70/50 mmHg, a SOFA score of 8, a white blood cell count of 9,800 with 89 percent neutrophils, and a chest x-ray that showed bilateral infiltrates and pulmonary edema. Blood and sputum cultures were also obtained, and the patient began antibiotics. The patient's SeptiScore® was 3.7, within Band 1, representing a low probability of sepsis. Considering prompt clinical improvement with ventilation and diuresis, no culture growth after 24 hours, and a SeptiScore® of 3.7, antibiotics were discontinued. The applicant explained that this case study shows how SeptiCyte® RAPID confirms low probability of sepsis in the presence of negative cultures and clinical improvement allowed for the appropriate discontinuation of antibiotics, driving antibiotic stewardship and de-escalation of unnecessary therapy.

The applicant described in the sixth case study how SeptiCyte® RAPID was used to differentiate infection negative systemic inflammation from infection positive systemic inflammation or sepsis in a 74-year-old patient with deteriorating mental status, loss of consciousness and tachypnea. The patient had normal initial diagnostic and laboratory studies and blood, sputum, urine cultures were ordered, and results were pending. The patient had SeptiCyte® RAPID which showed a SeptiScore® of 5, Band 1 which is a low risk of sepsis. The care team discontinued antibiotics due to SeptiCyte® RAPID in conjunction with negative cultures after 3 days. Further evaluation showed mass in left upper lobe of the lung with metastases in adrenal gland.

The applicant stated that, in the seventh and eighth case studies, SeptiCyte® RAPID aided in the diagnosis of sepsis after CNS bleed and surgical procedure. There were two patients who were both admitted to the ICU post subarachnoid hemorrhage with complicating secondary hydrocephalus requiring external ventricular drain placement. During the ICU stay, both patients developed fever and delirium, and both received CSF analysis with results that came back after 3 hours that showed high WBC count and protein but was gram stain negative. The patients received SeptiCyte® RAPID SeptiScore®’s of 8.8 and 7, respectively, both elevated with high probability of sepsis with a 1-hour turnaround. The CSF culture grew Klebsiella pneumoniae 24 hours after collection.
early appropriate antibiotic therapy pending bacterial confirmation and sensitivity testing.

Response: We thank the applicant and other commenters for their input. After further review, we continue to have concerns as to whether SeptiCyte® RAPID meets the substantial clinical improvement criterion to be approved for new technology add-on payments. Based on the additional information we received, we remain unclear whether SeptiCyte® RAPID offers the ability to diagnose a medical condition earlier in a patient population than allowed by currently available methods or that it changes the management of patients. While the applicant asserted that the technology allows for earlier differentiation of sepsis from SIRS, and thereby impacts the management of patients, it has not demonstrated that SeptiCyte® RAPID actually leads to changes in the management of patients such as initiating or discontinuing antibiotics. We note that the applicant stated it believes that the 1-hour time to results with SeptiCyte® RAPID can impact sepsis bundle compliance, and cited literature that meeting sepsis guidelines and quality metrics improves outcomes for sepsis patients. However, no evidence was presented to demonstrate that the technology improves compliance with guidelines or improves outcomes; this is only inferred. Although the applicant asserted that SeptiCyte® RAPID was independently clinically validated for its role in triage and risk stratification of patients with severe COVID–19, we could not determine that this is a proxy for sepsis. The applicant included case studies in support of SeptiCyte® RAPID’s ability to improve monitoring of patients at risk of sepsis, or as a confirmation test, and a diagnostic aid. We are unable to determine, based on these case studies, that the clinical data demonstrates that SeptiCyte® RAPID itself directly affects management of patients or improves clinical outcomes. For example, we believe that in the clinical scenarios presented, antibiotics would have been started or stopped based on clinical presentation alone in some cases, and with the additional diagnostic tests in other cases. The case studies did not describe when SeptiCyte® RAPID was performed or when results were received in relation to the other tests performed, and also did not describe at what point during the timeline of tests the antibiotics were started/discontinued (that is, before or after the results of the SeptiCyte® RAPID test or other tests were received. Therefore, it did not appear that any change in management was initiated directly as a result of receiving the SeptiCyte® RAPID test results in any of the scenarios, despite the 1-hour turnaround time. Instead, it appears that, in these scenarios, SeptiCyte® RAPID was used to confirm results from standard of care procedures, rather than providing actionable results resulting in a change in patient antibiotic use before blood culture or molecular pathogen detection results. For example, with regards to Case Study #1, it appears that patient clinical deterioration and altered mental status following high risk abdominal surgery prompted standard of care procedures, and that antibiotics were started after an abdominal CT noted a perihepatic abscess, with results confirmed by blood and abscess cultures and SeptiCyte® RAPID results. Further, it is unclear how substantial clinical improvement based on these scenarios can be demonstrated without a comparison to diagnosis and management of these patients using standard of care (SOC) methods alone. While other commenters stated that SeptiCyte® RAPID has the potential to improve health outcomes and patient management, clinical evidence to support those statements was not provided.

After review of the information submitted by the applicant as part of its FY 2024 new technology add-on payment application for SeptiCyte® RAPID and consideration of the comments received, we are unable to determine that SeptiCyte® RAPID meets the substantial clinical improvement criteria for the reasons discussed in the proposed rule and in this final rule, and therefore we are not approving new technology add-on payments for SeptiCyte® RAPID for FY 2024.

h. SPEVIGO® (Spesolimab)

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI), submitted an application for new technology add-on payments for SPEVIGO® for FY 2024. SPEVIGO® is a humanized antagonistic monoclonal immunoglobulin G1 antibody blocking human IL36R signaling for the treatment of flares in adult patients with generalized pustular psoriasis (GPP). We noted that the applicant submitted an application for new technology add-on payments for SPEVIGO® for FY 2023, under the name spesolimab, as summarized in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28108 through 28746), but the technology did not meet the deadline of July 1, 2022, for FDA approval or clearance of the technology and, therefore, was not eligible for consideration for new technology add-on payments for FY 2023 (87 FR 40920).

Please refer to the online application posting for SPEVIGO®, available at https://mearis.cms.gov/public/publications/ntap/NTP22110146275W, for additional detail describing the technology and the disease treated by the technology.

With respect to the newness criterion, according to the applicant, the BLA for SPEVIGO® was approved by FDA on September 1, 2022, for the treatment of GPP flares in adults. According to the applicant, SPEVIGO® is administered as a single 900 mg (2 × 450 mg/7.5 mL vials) intravenous infusion over 90 minutes, and an additional intravenous 900 mg dose may be administered 1 week after the initial dose if flare symptoms persist. The applicant indicated that, while there may be cases where a second dose is needed, there is insufficient frequency to impact the reported weighted average of one dose per patient.

The applicant stated that effective October 1, 2022, the following ICD–10–PCS code may be used to uniquely describe procedures involving the use of SPEVIGO®: XW03308 (Introduction of spesolimab monoclonal antibody into peripheral vein, percutaneous approach, new technology group 8). The applicant stated that L40.1 (Generalized pustular psoriasis) may be used to currently identify the indication for SPEVIGO® under the ICD–10–CM coding system.

As previously discussed, if a technology meets all three of the substantial similarity criteria under the newness criterion, it would be considered substantially similar to an existing technology and would not be considered “new” for the purposes of new technology add-on payments.
With respect to the substantial similarity criteria, the applicant asserted that SPEVIGO® is not substantially similar to other currently available technologies because, in the absence of an FDA-approved therapy specifically indicated for GPP, immunomodulatory therapies, including biologic products, are used in the treatment of GPP despite these medications being approved for plaque psoriasis, which is a different subtype of psoriasis. Additionally, there is limited evidence on the efficacy and safety of these therapies in the treatment of GPP. Due to the rarity of the disease, there are no high-quality clinical trials providing evidence for treatment options in GPP. Therefore, the applicant asserts that the technology meets the newness criterion. The following table summarizes the applicant’s assertions regarding the substantial similarity criteria. Please see the online application posting for SPEVIGO® for the applicant’s complete statements in support of its assertion that SPEVIGO® is not substantially similar to other currently available technologies.

<table>
<thead>
<tr>
<th>Substantial Similarity Criteria</th>
<th>Applicant Response</th>
<th>Applicant assertions regarding this criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does the technology use the same or similar mechanism of action to achieve a therapeutic outcome?</td>
<td>No</td>
<td>SPEVIGO® inhibits IL-36R signaling which is differentiated from TNF-α, integrin and IL-23 inhibitory pathways by directly and simultaneously blocking both inflammatory and pro-fibrotic pathways.</td>
</tr>
<tr>
<td>Is the technology assigned to the same MS-DRG as existing technologies?</td>
<td>No</td>
<td>There is no MS-DRG for SPEVIGO®</td>
</tr>
<tr>
<td>Does new use of the technology involve the treatment of the same/similar type of disease and the same/similar patient population when compared to an existing technology?</td>
<td>No</td>
<td>The clinical, pathological, and genetic features associated with GPP establish it as a distinct disease entity from plaque psoriasis that is being managed with existing therapies. There are no other FDA approved therapies to treat GPP.</td>
</tr>
</tbody>
</table>

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26882), we stated the following concerns with regard to the newness criterion, similar to concerns raised in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 26828). First, we noted that, when describing current treatments for the disease, the applicant stated that there are no FDA-approved therapies specifically indicated for GPP. However, we questioned whether there are any treatments that may be indicated for psoriasis generally that may therefore be considered an on-label use for subtypes of psoriasis such as GPP, and requested additional information on any such treatments and how they compare to SPEVIGO® with regard to substantial similarity. We also noted that while the applicant stated that SPEVIGO® has no DRG to which it maps, the applicant also provided a list of four MS–DRGs that cases eligible for the use of the technology would map to, and we believed these are the same MS–DRGs to which other treatments for GPP would map.

We invited public comments on whether SPEVIGO® is substantially similar to existing technologies and whether SPEVIGO® meets the newness criterion.

Comment: The applicant submitted a comment to address CMS’s concerns regarding the newness criterion. With respect to the request for additional information on currently available treatments and how they compare to SPEVIGO®, the applicant stated that SPEVIGO® is the only FDA approved therapy for the treatment of GPP flares in adults. The applicant noted that prior to SPEVIGO®, there was no consensus standard of care for GPP flares. Per the applicant, due to historical lack of robust clinical trial evidence or previously approved therapies for GPP flares, systemic agents were experimented with clinically in patients with GPP flares, based mainly on clinical experience in patients with plaque psoriasis (PSO). The applicant stated that even with treatment with these agents, many patients still had residual symptoms. Patients with GPP report a poorer quality of life compared with those with PSO, with greater severity of itch, pain, and fatigue, and a greater impact on work and daily activities. Per the applicant, treatments approved for PSO, including oral systemic therapies and biologic products, may have a slow time to response in patients with GPP flares. Regarding currently available treatments indicated for PSO and their on-label use for GPP, the applicant stated that aside from SPEVIGO®, there are no FDA-approved therapies indicated for the treatment of GPP flares in adults. The applicant noted that GPP flares have acute systemic presentation, with unpredictable and rapid periods of worsening disease and complications resulting from systemic inflammation and neutrophilic influx, often requiring hospitalization; PSO, on the other hand, is a chronic disease affecting mainly the skin, and is typically managed in an outpatient setting. The applicant noted that although historically considered a variant of PSO, GPP is a phenotypically, genetically, and histopathologically distinct entity from PSO.109 110 111 According to the applicant, GPP is characterized clinically by widespread eruption of neutrophilic, non-infectious pustules, while PSO is characterized by localized discrete plaques with excess scale resulting from abnormal differentiation of keratinocytes.112 The applicant stated that the pathways driving GPP and PSO are distinct. This is relevant to specifically targeting GPP. Specifically, GPP results from dysregulation of the innate immune system involving disruption of the interleukin IL–36 signaling pathway leading to uncontrolled systemic inflammation and a large influx of...
neutrophils. On the other hand, PSO is driven by the adaptive immune system, with dysregulation of the IL-17/IL-23 pathway being a key characteristic, leading to an inflammatory impact that is mainly observed on the skin. The applicant maintained that because of its extreme systemic impact, PSO has a considerable clinical burden, and symptoms related to PSO have not been reported to affect everyday tasks such as walking and sleeping. Patients with GPP report a poorer quality of life compared with patients with PSO with greater severity of itch, pain, and fatigue, and a greater impact on work and daily activities. The applicant, without a consensus standard of care for GPP flares (prior to SPEVIGO), various off-label PSO treatments have been used in an attempt to control flare symptoms. Due to the historical lack of robust clinical trial evidence and no previously approved therapies for GPP flares, systemic agents have been experimented with clinically in patients with GPP flares, based mainly on clinical experience in patients with PSO. According to the applicant, an important result of this is that, even with treatment with these agents, many patients still have residual symptoms. Treatments approved for PSO, including oral systemic therapies and biologic products, may have a slow time to response in patients with GPP flares. The applicant stated that in a recently published consensus panel, a network of international dermatology experts agreed that rapid response was critical to alleviate systemic and potentially life-threatening symptoms of GPP flares. In addition, there are well-documented safety concerns with long-term use of some of these systemic agents, making them inappropriate for continuous use. To name a few examples, retinoids are associated with teratogenic effects, liver toxicity, and skeletal abnormalities; cyclosporine has been associated with systemic hypertension and nephrotoxicity; and respiratory complications, myelosuppression, and hepatic impairment have been reported with methotrexate. The applicant noted that with respect to biologic products used for treating PSO, many are specifically indicated for and tested in randomized, controlled trials of patients with PSO; however, there have been no results from randomized, placebo-controlled trials of any agent other than SPEVIGO® in patients with GPP flares; therefore, comparisons (even cross-trial) cannot be made, nor can assumptions that PSO agents would benefit patients with GPP flares. For the applicant, some of these agents approved for the treatment of PSO have been studied in patients with GPP in Japan; however, none of the studies were randomized, controlled trials, most of the patient populations were mixed and included a small number of patients with GPP, and all of the trials used endpoints that were not specific to GPP. The applicant also stated that no study, aside from those of SPEVIGO®, has specifically reported the outcome of pustular clearance, and there are limited data on systemic improvements with these agents. With regard to whether SPEVIGO® may be mapped to the same MS–DRGs as other current treatments for GPP, the applicant maintained that since SPEVIGO® is the only FDA approved treatment for GPP flares, it would be the only therapy to be mapped for patients with GPP flares. The applicant also argued that once approved, other off-label therapies would not be expected to be used for treating GPP flares.

Response: We thank the applicant for its comment regarding the newness criterion. Based on our review of comments received and information submitted by the applicant as part of its FY 2024 new technology add-on payment application for SPEVIGO®, we agree with the applicant that SPEVIGO® has a new mechanism of action because it is a humanized anti-interleukin-36 (IL-36) receptor monoclonal antibody that targets the IL-36 pathogenic pathway in the treatment of GPP. Therefore, we agree with the applicant that SPEVIGO® is not substantially similar to existing treatment options and meets the newness criterion. We consider the beginning of the newness period to commence on September 1, 2022, when SPEVIGO® was FDA approved for the treatment of GPP flares in adults.

With respect to the cost criterion, to identify potential cases representing patients who may be eligible for SPEVIGO®, the applicant searched the FY 2021 MedPAR file for cases reporting ICD–10–CM diagnosis code L40.1 (Generalized pustular psoriasis). Using the inclusion/exclusion criteria described in the following table, the applicant identified 64 cases mapping to 4 MS–DRGs listed in the table in this section. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $387,414, which exceeded the average case-weighted threshold amount of $368,149.
$46,244. Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount, the applicant asserted that SPEVIGO® meets the cost criterion.

<table>
<thead>
<tr>
<th>SPEVIGO® COST ANALYSIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data Source and Time Period</td>
</tr>
<tr>
<td>List of ICD-10-CM codes</td>
</tr>
</tbody>
</table>
| List of MS-DRGs | 603 (Cellulitis without MCC)  
| | 607 (Minor Skin Disorders without MCC)  
| | 871 (Septicemia or Severe Sepsis without MV >96 hours with MCC)  
| | 872 (Septicemia or Severe Sepsis without MV >96 hours without MCC) |
| Inclusion/exclusion criteria | The applicant identified cases by using the ICD-10-CM diagnosis code L40.1 (Generalized pustular psoriasis) and limited the data to PPS hospitals by identifying claims with a claim type code of 60. The analysis was limited to DRGs with a case count of 11 or greater. The applicant also removed Medicare Advantage cases, cases with total charges or covered charges less than zero, and cases with a length of stay of zero. The applicant calculated the average unstandardized charge per case for each MS-DRG. |
| Charges removed for prior technology | The applicant did not remove any charges for prior technology because no FDA approved treatments for GPP existed prior to the FDA approval of SPEVIGO®. The applicant also did not remove any indirect charges related to prior technologies. |
| Standardized charges | The applicant used the standardization formula provided in Technical Appendix A of the application. The applicant used all relevant values reported in the standardizing file posted with the FY 2023 IPPS/LTC PPS final rule. |
| Inflation factor | The applicant applied the four-year inflation rate of 1.28134 to the standardized charges, based on the inflation factor used to calculate outlier threshold charges in the FY 2023 IPPS/LTC PPS final rule. |
| Charges added for the new technology | The charges added for the new technology were for the cost of SPEVIGO®, based on the WAC price. The applicant added charges for the new technology by dividing the cost of SPEVIGO® by the national average CCR for drugs which is 0.184 from the FY 2023 IPPS/LTC PPS final rule. |

In the FY 2024 IPPS/LTC PPS proposed rule (88 FR 26825), we noted the applicant stated that removing charges for prior technology was not applicable to SPEVIGO®; however, to the extent patients were treated with other treatments before SPEVIGO®, we questioned whether it may be appropriate to remove some portion of these charges to avoid inappropriately inflating the average charge per case. We invited public comments on whether it may be appropriate to remove charges for the prior technology and whether SPEVIGO® meets the cost criterion.

Comment: The applicant submitted a comment in response to our concerns pertaining to cost criterion. With respect to the appropriateness of not removing charges for prior technologies SPEVIGO®, the applicant responded that because there are no approved therapies specifically indicated for the treatment of GPP flares, and due to the severe condition of patients with GPP flares, off-label treatments may be experimented with, including those indicated for PSO. As a result, patients receiving SPEVIGO® may have altered utilization of the first- or second-line off-label therapies historically used to treat GPP flares. The applicant maintained that SPEVIGO® will replace the off-label PSO treatments as the primary standard of care based on the substantial clinical improvement demonstrated by SPEVIGO® in a robust clinical trial. The applicant stated that while removal of charges can be difficult with no consensus off-label standard of care previously, they provided an updated cost analysis in which they have removed all drug cost center charges (one of the 19 cost centers defined by CMS as part of the relative weight calculation process) to avoid any concern of costs from prior off-label therapies. According to the applicant’s updated cost analysis, the final inflated case-weighted average standardized charge per case of $361,189 exceeded the case-weighted threshold of $46,244, and the applicant therefore maintained that SPEVIGO® meets the cost criterion.

Response: We thank the applicant for the updated cost analysis. Based on the additional information received, we agree that the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount. Therefore, SPEVIGO® meets the cost criterion.

With regard to the substantial clinical improvement criterion, the applicant asserted that SPEVIGO® represents a substantial clinical improvement over existing technologies by being the first FDA approved drug for GPP, and existing treatments were associated with slow resolution of GPP flares and complete clearance of pustules and skin was not always achieved. The applicant further stated that in clinical trials, SPEVIGO® was associated with clinically significant improvements in patient-reported psoriasis symptoms, including fatigue, and significant decreases in markers of systemic inflammation. The applicant provided one study to support these claims. The following table summarizes the applicant’s assertions regarding the substantial clinical improvement criterion. Please see the online posting for SPEVIGO® for the applicant’s complete statements regarding the substantial clinical improvement criterion and the supporting evidence provided.
**Substantial Clinical Improvement Assertion #1:** The technology offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments.

<table>
<thead>
<tr>
<th>Applicant statements in support</th>
<th>Supporting evidence provided by the applicant</th>
<th>Outcome(s) or findings cited by the applicant from supporting evidence to support its statements</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPEVIGO® is a treatment specifically indicated for GPP</td>
<td>Bachelez H et al. N Engl J Med 2021;385:2431-40. Brief study description: Effisayil-1 Phase II trial randomized 2:1 spesolimab vs placebo (n=53)</td>
<td>A total of 52 of the 53 enrolled patients completed the first week of the trial. Data for 1 patient in the spesolimab group were missing for the primary and key secondary end points and were imputed as no response. At day 8, a total of 12 patients (34%) in the spesolimab group and 15 patients (83%) in the placebo group received an open-label dose of spesolimab. After day 8, a total of 32 patients (91%) who were randomly assigned to receive spesolimab and 17 patients (94%) who were randomly assigned to receive placebo completed the 12-week follow-up period, during which 4 and 2 patients, respectively, received rescue treatment with spesolimab. After completing 12 weeks of treatment, 39 patients were enrolled in the open-label extension trial. Efficacy - Primary and Key Secondary Efficacy End Points At the end of week 1, a total of 19 of the 35 patients (54%) who were assigned to the spesolimab group and 1 of the 18 patients (6%) who were assigned to the placebo group had a GPPGA psoriasis subscore of 0 (no visible pustules) (difference, 49 percentage points; 95% confidence interval [CI], 21 to 67; P&lt;0.001) (Table 2). A total of 15 patients (43%) who were assigned to the spesolimab group and 2 patients (11%) who were assigned to the placebo group had a GPPGA total score of 0 or 1 (clear or almost clear skin) (difference, 32 percentage points; 95% CI, 2 to 53; P=0.02). The results of the post hoc sensitivity analyses of the primary and key secondary end points to adjust for the observed baseline imbalances in sex, race, and GPPASI score were consistent with the results of the primary analysis.</td>
</tr>
</tbody>
</table>

**Substantial Clinical Improvement Assertion #2:** The technology significantly improves clinical outcomes relative to services or technologies previously available.

<table>
<thead>
<tr>
<th>Applicant statements in support</th>
<th>Supporting evidence provided by the applicant</th>
<th>Outcome(s) or findings cited by the applicant from supporting evidence to support its statements</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPEVIGO® is associated with improved psoriasis symptom scale, functional assessment, and reduced markers of inflammation</td>
<td>Bachelez H et al. N Engl J Med 2021;385:2431-40., phase II randomized trial See prior study description</td>
<td>At baseline, 46% of the patients in the spesolimab group and 39% of those in the placebo group had a GPPGA psoriasis subscore of 3, and 37% and 33%, respectively, had a psoriasis subscore of 4. At the end of week 1, a total of 19 of 35 patients (54%) in the spesolimab group had a postsubscore of 0, as compared with 1 of 18 patients (6%) in the placebo group (difference, 49 percentage points; 95% confidence interval [CI], 21 to 67; P&lt;0.001). A total of 15 of 35 patients (43%) had a GPPGA total score of 0 or 1, as compared with 2 of 18 patients (11%) in the placebo group (difference, 32 percentage points; 95% CI, 2 to 53; P=0.02). Drug reactions were reported in 2 patients who received spesolimab, in 1 of them concurrently with a drug-induced hepatic injury. Among patients assigned to the spesolimab group, infections occurred in 6 of 35 (17%) through the first week; among patients who received spesolimab at any time in the trial, infections had occurred in 24 of 51 (47%) at week 12. Antidrug antibodies were detected in 23 of 50 patients (46%) who received at least one dose of spesolimab.</td>
</tr>
</tbody>
</table>

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26886), after review of the information provided by the applicant, we stated that we had the following concerns regarding whether SPEVIGO® meets the substantial clinical improvement criterion. With regard to the Effisayil-1 study, we noted that it is not designed to compare SPEVIGO® to current treatment options. While the applicant stated that SPEVIGO® will be the first GPP treatment targeting the IL-36 pathway, we noted that per the applicant, other treatments are available, and we therefore questioned whether placebo was the most appropriate comparator. In particular, we noted that the Effisayil-1 trial primarily assessed clearance of skin manifestations, not systemic symptoms which the applicant noted differentiates GPP from other forms of psoriasis. We noted the applicant has stated in its application that existing treatments for
GPP are not specifically indicated for GPP and that it would not be appropriate to consider these treatments on-label for GPP. However, we noted that there are treatments that are indicated for psoriasis generally, such as methotrexate\textsuperscript{127} or retinoids,\textsuperscript{128} which may be considered an on-label use for subtypes of psoriasis such as GPP. Therefore, it was unclear whether there is a patient population ineligible for or unresponsive to existing technologies that could be treated with SPEVIGO\textsuperscript{®}. In addition, although the applicant stated that SPEVIGO\textsuperscript{®} represents a substantial clinical improvement over existing technologies where complete clearances were not always achieved, it seemed that complete clearance is also not always achieved with SPEVIGO\textsuperscript{®}. As demonstrated in the Effisayil-1 study cited by the applicant, 54.3 percent of the patients achieved complete pustular clearance in the SPEVIGO\textsuperscript{®} arm. We noted that GPP occurs most frequently between the ages of 15–20 years with a smaller peak occurring at 55–60 years.\textsuperscript{129} The mean age in the Effisayil-1 study was 43.2 years for the SPEVIGO\textsuperscript{®} arm and 42.6 years for the placebo group. Given the age range of patients, we questioned the generalizability of the outcomes demonstrated in a study of otherwise generally healthy patients with GPP to patients with GPP in the Medicare population who would likely be eligible for Medicare based on disabilities that could potentially present comorbidities for which SPEVIGO\textsuperscript{®} would not be appropriate or effective. In addition, the study administered SPEVIGO\textsuperscript{®} to the placebo group after one week, after which only outcomes with SPEVIGO\textsuperscript{®} were assessed, and the study concluded at 12 weeks. Given that the applicant did not provide any comparative data on existing technologies to demonstrate improved outcomes with SPEVIGO\textsuperscript{®}, in addition to the short duration of the single study provided and the often variable, remitting, and intermittent course of the disease in which most flares last between 2 and 5 weeks, we questioned whether the information we had supported a finding of substantial clinical improvement. We stated that additional information would support the applicant’s assertion of superiority over existing technologies would be helpful in better informing our assessment of this criterion.\textsuperscript{130,131}

We invited public comments on whether SPEVIGO\textsuperscript{®} meets the substantial clinical improvement criterion.

\textbf{Comment:} The applicant submitted a comment in response to CMS’s concerns pertaining to the substantial clinical improvement criterion. With respect to the appropriateness of comparing SPEVIGO\textsuperscript{®} to placebo instead of other current treatment options and of the sparsity of systemic end points, the applicant maintained that because there has been no established standard of care for GPP flares prior to the approval of SPEVIGO\textsuperscript{®}, numerous biologic and oral systemic agents indicated for PSO have been used anecdotally in clinical practice in attempts to treat GPP flares. The applicant stated that no other treatment approved for PSO has been tested in a randomized controlled trial in GPP flares, and evidence for these treatments come from small, single-arm, uncontrolled studies of mixed patient populations that did not evaluate clinically robust endpoints specific to GPP. The applicant further noted that because these treatments have variable efficacy and safety profiles, it becomes challenging to propose one of them as an active comparator for a trial in GPP flares. According to the applicant, due to the lack of FDA-approved treatments as well as consensus on standard of care for GPP flares, placebo can be considered an appropriate comparator. Per the applicant, FDA also considered placebo to be appropriate and requested the inclusion of the placebo arm for a robust and well controlled study. Regarding the selection of endpoints, the applicant mentioned that while the primary endpoint of the Effisayil-1 trial was complete pustular clearance, the trial also examined the impact of SPEVIGO\textsuperscript{®} on additional endpoints, including measures of systemic inflammation like C-reactive protein (CRP) levels and neutrophil count over time. Per the applicant, both the CRP levels and neutrophil count over time were shown, in conjunction with skin clearance, to improve to normal levels in the trial and were maintained throughout the course of the trial. With regard to whether there is a patient population ineligible for or responsive to existing technologies that could be treated with SPEVIGO\textsuperscript{®}, the applicant noted that there are distinct differences in the dysregulation of IL pathways between GPP and PSO. As the only GPP-indicated therapy, SPEVIGO\textsuperscript{®} offers patients an effective therapy targeting the GPP-specific IL-36 pathway. According to the applicant, it has been well-documented that GPP and psoriasis vulgaris (PV, also called plaque psoriasis) are separate clinical conditions, requiring specific treatment approaches.\textsuperscript{132} The applicant cited a recent longitudinal case series of patients with GPP as an example of the limited efficacy of the nontargeted immunomodulatory therapies (for example, methotrexate, retinoids) to treat GPP flares.\textsuperscript{133} Per the applicant, the result of these studies showed that despite the use of methotrexate and retinoids, which were among the most frequently used agents for treating GPP flares, the rates of emergency department visits and hospitalizations among GPP patients during the follow-up period remained at approximately 40 percent. Per the applicant, this suggested that these systemic agents are inadequate for controlling GPP flares. With regard to the result of the Effisayil-1 study that 54.3 percent of the patients achieved complete pustular clearance in the SPEVIGO\textsuperscript{®} arm, the applicant cited recent guidance, based on global expert consensus, that the goals of treatment of GPP flares are to achieve rapid and sustained clearance of pustules, inflammatory erythema, scaling, crust, and skin lesions; and to rapidly alleviate systemic symptoms and reduce pain while maintaining a favorable safety profile.\textsuperscript{134} According to the applicant, the primary endpoint was a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of zero at week 1, a highly stringent endpoint, according to many international dermatology experts. According to the applicant, 54.3 percent of the patients from the Effisayil-1 study achieved the GPPGA pustulation subscore of zero (complete pustular clearance) in the SPEVIGO\textsuperscript{®} arm after one dose. Moreover, in patients who received up to 2 doses of SPEVIGO\textsuperscript{®}, 66 percent achieved a GPPGA pustulation subscore of zero at week 2. The applicant added that of the patients randomized to placebo and who received a dose of SPEVIGO\textsuperscript{®} at week 1, 73 percent had a GPPGA pustulation score of zero at week 2 (one week after receiving their first dose of SPEVIGO\textsuperscript{®}) and 60 percent of patients maintained a GPPGA pustulation subscore of 0 out to week 12. The applicant asserted that...

\textsuperscript{127} https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/008085Orig1s071lbl.pdf.
\textsuperscript{128} https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019821s028lbl.pdf.
\textsuperscript{130} Krueger et al. Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol 2022;23(suppl 1):51–64.
\textsuperscript{132} Bacchi et al. 2022, op.cit.
\textsuperscript{133} Noe et al. (2022), op.cit.
\textsuperscript{134} Bacchi et al. (2022), op.cit.
treatment after prolonged GPP flare symptoms. **Response:** We thank the applicant for their comments regarding the substantial clinical improvement criterion. Based on the additional information received, we agree that SPEVIGO® represents a substantial clinical improvement because the technology offers a treatment option for generalized pustular psoriasis (GPP) flares in adults, for which it is the first FDA approved treatment.

After consideration of the public comments, we have determined that SPEVIGO® meets the criteria for approval for new technology add-on payment. Therefore, we are approving new technology add-on payments for this technology for FY 2024. Cases involving the use of SPEVIGO® that are eligible for new technology add-on payments will be identified by ICD–10–PCS code XW03308 (Introduction of spesolimab monoclonal antibody into peripheral vein, percutaneous approach, new technology group 8). In its application, the applicant estimated that the average inpatient cost of SPEVIGO® is $51,133 for one 900 mg dose, comprised of two 450 mg/7.5 mL (60 mg/mL) vials. Therefore, the average cost per patient for SPEVIGO® is $51,133. Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, the maximum new technology add-on payment for a case involving the use of SPEVIGO® is $33,236.45 for FY 2024.

i. **TECVAYLI®** (Teclistamab-cqys)

Johnson & Johnson Health Care Systems, Inc. submitted an application for new technology add-on payments for TECVAYLI® for FY 2024. According to the applicant, TECVAYLI® is the only bispecific antibody approved for the treatment of multiple myeloma (MM), specifically adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. According to the application, the product became commercially available on November 9, 2022. Commercial availability was delayed because of the need to complete final supply chain readiness activities. Per the applicant, patients in the hospital for their initial TECVAYLI® treatment will receive three doses subcutaneously—a 0.06 mg/kg loading dose, a 0.30 mg/kg loading dose, and the first 1.5 mg/kg treatment dose during their hospitalization. Patients over 102 kg will use two 30 mg and one 153 mg vials during their hospitalization. Patients over 102 kg will use three 30 mg and two 153 mg vials during their hospitalization. According to real world evidence and clinical studies, 89 percent of TECVAYLI® patients will be less than 102 kg. Due to the risk of CRS and neurologic toxicity, patients should be hospitalized for 48 hours after administration of all doses within the step-up dosing schedule. Therefore, according to the applicant, all three doses will be administered in a single inpatient hospitalization.

The applicant stated that effective October 1, 2022, the following ICD–10–PCS code may be used to uniquely describe procedures involving the use of TECVAYLI®: XW01348 (Introduction of teclistamab antineoplastic into subcutaneous tissue, percutaneous approach, new technology group 8).

As previously discussed, if a technology meets all three of the substantial similarity criteria under the newness criterion, it would be considered substantially similar to an existing technology and would not be considered “new” for the purpose of new technology add-on payments. With respect to the substantial similarity criteria, the applicant asserted that TECVAYLI® is not substantially
similar to other currently available technologies because it has a distinct mechanism of action, with a novel approach to engage a patient’s own T-cells to generate a myeloma-specific immune response and is the first therapy of its type for the treatment of RRMM, and therefore meets the newness criterion. The following table summarizes the applicant’s assertions regarding the substantial similarity criteria. Please see the online application posting for TECVAYLI™ for the applicant’s complete statements in support of its assertion that TECVAYLI™ is not substantially similar to other currently available technologies.

<table>
<thead>
<tr>
<th>Substantial Similarity Criteria</th>
<th>Applicant Response</th>
<th>Applicant assertions regarding this criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does the technology use the same or similar mechanism of action to achieve a therapeutic outcome?</td>
<td>No</td>
<td>TECVAYLI™ has a unique mechanism of action with a full-sized antibody containing 2 distinct binding domains that simultaneously bind the BCMA target on tumor cells and the CD3 T-cell receptor. Unlike ide-cel and cilta-cel, it engages the patient’s existing immune system without the requirement for cell extraction and engineering. TECVAYLI™ is the only commercially available bispecific antibody for MM. It is a novel and distinct molecule from the only other approved bispecific antibodies: blinatumomab and amivantamab. Blinatumomab is a bispecific T-cell engager (BiTE) targeting CD3 and CD19 and is approved only for pre-B-cell acute lymphoblastic lymphoma. The structure is different from TECVAYLI™ in that it is not a full-sized antibody but rather two Fab fragments held together by a chemical linker. Amivantamab, while also a bispecific antibody that targets two antigens, epidermal growth factor (EGF) and MET receptors, is specific to lung cancer cells. It does not induce T-cell redirection as its mechanism of action, as it does not contain a CD3-binding domain. In summary, TECVAYLI™ is a bispecific T-cell engaging antibody therapy that uses the patient’s own T-cells re-directed to BCMA expressing T-cells using a full-sized IgG antibody with bispecificity for BCMA and CD3 (the main T-cell receptor). TECVAYLI™ is not substantially similar to other existing bispecific antibodies like 1) blinatumomab or 2) amivantamab due to its 1) Duobody structure (versus BiTEs as previously discussed) and targeting of BCMA versus CD19 and 2) targeting of CD3 and BCMA versus the lung cancer antigens, cMET and EGFR. Because TECVAYLI™ has a novel structure and unique mechanism of action, it is unlike any existing technology utilized to treat MM.</td>
</tr>
<tr>
<td>Is the technology assigned to the same MS-DRG as existing technologies?</td>
<td>Yes</td>
<td>The use of TECVAYLI™ in treating a patient’s MM is not expected to change the DRG assignment of the case.</td>
</tr>
<tr>
<td>Does the technology involve the treatment of the same/similar type of disease and the same/similar patient population when compared to an existing technology?</td>
<td>Yes</td>
<td>TECVAYLI™’s indication is for the treatment of adult patients with RRMM who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This indication is similar to approved therapies for MM patients who have failed four prior therapies or lines of therapy.</td>
</tr>
</tbody>
</table>

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26887), we noted that TECVAYLI™ may have a similar mechanism of action to that of elranatamab, for which we received an application for new technology add-on payments for FY 2024 for the treatment of adult patients with relapsed or refractory multiple myeloma after three or more prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Per the application for elranatamab, elranatamab is substantially similar to TECVAYLI™. Elranatamab’s mechanism of action is described as a bispecific antibody, meaning it has two parts, one that recognizes the cancer cell and one that recognizes and engages the T-cell, and brings them together to facilitate T-cell killing of the MM cell. For elranatamab, the two targets are barcoded medication administration (BCMA) (which has high specific expression on normal plasma cells and on MM cells) and CD3 (which is expressed on T-cells). Elranatamab binds to the CD3 on the T-cells and binds to the BCMA on the MM cells thereby bringing the cells in close proximity. The engagement of the CD3 on the T-cell activates the T-cell, leading to the T-cells releasing cytokines that result in the killing of the close-proximity MM cell. Because of the apparent similarity with the bispecific antibody that uses binding domains that simultaneously bind the BCMA target on tumor cells and the CD3 T-cell receptor, we believed that the mechanism of action for TECVAYLI™ may be the same or similar to that of elranatamab.

We believed that TECVAYLI™ and elranatamab may also treat the same or similar disease (RRMM) in the same or similar patient population (patients who have previously received a proteasome inhibitor [PI], an immunomodulatory agent [IMiD], and an anti-CD38 antibody). Accordingly, as it appears
that TECVAYLI™ and elranatamab are purposefully to achieve the same therapeutic outcome using the same or similar mechanism of action and would be assigned to the same MS–DRG. We believed these technologies may be substantially similar to each other such that they should be considered as a single application for purposes of new technology add-on payments if elranatamab receives FDA approval by July 1, 2023. We stated that we were interested in information on how these two technologies may differ from each other with respect to the substantial similarity criteria and newness criterion, to inform our analysis of whether TECVAYLI™ and elranatamab are substantially similar to each other and therefore should be considered as a single application for purposes of new technology add-on payments.

We invited public comment on whether TECVAYLI™ meets the newness criterion, including whether TECVAYLI™ is substantially similar to elranatamab and whether these technologies should be evaluated as a single technology for purposes of new technology add-on payments.

Comment: The applicant submitted a comment regarding the newness criterion, reiterating that TECVAYLI® meets the overall requirements of the newness criterion as it does not meet all three criteria required to be deemed substantially similar to existing technology. With regard to whether TECVAYLI™ and elranatamab are substantially similar and should be considered as a single technology for the purposes of new technology add-on payments, the applicant stated that while elranatamab and TECVAYLI™ are both bispecific antibodies, the antibody for each product is meaningfully different, and therefore the mechanism of action for these two products should be considered distinct. The applicant explained that TECVAYLI™ is a humanized IgG4 antibody, whereas elranatamab is a humanized IgG2a antibody, and IgG4 antibodies have a high affinity for Fc gamma receptor subtype I (FcγRI) but weak affinities for all other Fc gamma receptor subtypes and are poor inducers of Fcγ-mediated effector functions, while IgG2 antibodies have a high affinity for the H131 form of Fc gamma receptor subtype IIA (FcγRIIA) but no measurable or weak affinity for FcγRI and all other Fc gamma receptors. The applicant agreed that both TECVAYLI™ and elranatamab are bispecific T-cell engaging antibodies that exert their efficacy primarily by re-directing the patient’s own T-cells to BCMA-expressing multiple myeloma cells, but stated they are distinctly and importantly different in regards to the whether the binding of the bispecific antibodies to Fc gamma receptors may activate immune effector cells that may lead to a pro-inflammatory state and contribute to cytokine release syndrome and other toxicities. The applicant asserted that the biological difference between TECVAYLI™ and elranatamab may result in meaningful clinical differences, and that therefore, CMS should consider these technologies separately for new technology add-on payments. The applicant added that elranatamab is not yet FDA-approved and therefore should not be considered as an existing technology for inclusion in meeting the substantial similarity criteria.

Another commenter, the manufacturer for elranatamab, stated that it believed that TECVAYLI™ and elranatamab are substantially similar and should be considered under a single application on the basis of (1) the mechanism of action (BCMA-directed bispecific antibody), (2) the patient population and disease intended to be treated (RRM in patients who have received four or more prior lines of therapy including a proteasome inhibitor (PI), immunomodulatory drug (IMiD), and anti-CD38 monoclonal antibody), and (3) MS–DRG assignment.

Response: We thank the applicant and other commenter for their comments regarding newness. As discussed previously, elranatamab has not been FDA approved as of the July 1 deadline and is therefore no longer eligible for consideration for new technology add-on payments for FY 2024, and we further note that the technology has not yet been FDA approved as of the time of the development of this final rule. Therefore, we agree with the applicant that elranatamab is not considered an existing technology for the purposes of the substantial similarity determination at this time.

Based on our review of comments received and information submitted by the applicant as part of its FY 2024 new technology add-on payment application for TECVAYLI™, we agree with the applicant that TECVAYLI™ has a unique mechanism of action as a bispecific antibody containing 2 distinct binding domains that simultaneously bind the BCMA target on myeloma cells and the CD3 T-cell receptor to treat RRMM. Therefore, we believe that TECVAYLI™ is not substantially similar to existing treatment options and meets the newness criterion. We consider the beginning of the newness period to commence on the date the product became commercially available, on November 9, 2022.

With respect to the cost criterion, to identify potential cases representing patients who may be eligible for TECVAYLI™, the applicant searched the FY 2021 MedPAR file for cases reporting one of the following ICD–10–CM codes in one of the first five diagnosis code positions: C90.00 (Multiple myeloma not having achieved remission), C90.01 (Multiple myeloma in remission), or C90.02 (Multiple myeloma in relapse). The applicant provided calculations for 2 cohorts. Based on the clinical advice of experts, for the first cohort, the applicant limited the analysis to cases assigned to MS–DRGs 846 (Chemotherapy Without Acute Leukemia as Secondary Diagnosis with MCC), 847 (Chemotherapy Without Acute Leukemia as Secondary Diagnosis with CC) and 848 (Chemotherapy Without Acute Leukemia as Secondary Diagnosis without CC/MCC), because the experts believed that TECVAYLI™ would mostly likely be administered in cases assigned to these MS–DRGs. This analysis was completed prior to the drug being available. Based on additional information gathered since TECVAYLI™ was FDA approved, the applicant included in the second cohort the following MS–DRGs in addition to the MS–DRGs included in the first cohort: 840 (Lymphoma and Non-Acute Leukemia with MCC), 841 (Lymphoma and Non-Acute Leukemia with CC), and 842 (Lymphoma and Non-Acute Leukemia without CC/MCC). For both cohorts, no cases were identified for MS–DRG 848 (Chemotherapy Without Acute Leukemia as Secondary Diagnosis without CC/MCC). Using the inclusion/exclusion criteria described in the following table, the applicant identified 600 claims for cohort 1 and 4,335 claims for cohort 2. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $119,279 for cohort 1 and $145,374 for cohort 2, both of which exceeded the average case-weighted threshold amount of $58,291 and $73,551, respectively. Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount in both scenarios, the applicant asserted that TECVAYLI™ meets the cost criterion.
### TECVAYLI™ Cost Analysis

<table>
<thead>
<tr>
<th>Data Source and Time Period</th>
<th>FY 2021 MedPAR file</th>
</tr>
</thead>
</table>

#### List of ICD-10-PCS Codes

- Cohort 1 and 2
  - C90.00 (Multiple myeloma not having achieved remission)
  - C90.01 (Multiple myeloma in remission)
  - C90.02 (Multiple myeloma in relapse)

- Cohort 1:
  - 846 (Chemotherapy without Acute Leukemia as Secondary Diagnosis with MCC),
  - 847 (Chemotherapy without Acute Leukemia as Secondary Diagnosis with CC),
  - 848 (Chemotherapy without Acute Leukemia as Secondary Diagnosis without CC/MCC)

- Cohort 2:
  - 840 (Lymphoma and Non-Acute Leukemia with MCC),
  - 841 (Lymphoma and Non-Acute Leukemia with CC),
  - 842 (Lymphoma and Non-Acute Leukemia without CC/MCC),
  - 846 (Chemotherapy without Acute Leukemia as Secondary Diagnosis with MCC),
  - 847 (Chemotherapy without Acute Leukemia as Secondary Diagnosis with CC),
  - 848 (Chemotherapy Without Acute Leukemia as Secondary Diagnosis without CC/MCC)

#### Inclusion/exclusion criteria

The applicant required the presence of a diagnosis code in this table in one of the first five diagnosis code positions. For cohort 1, the MS-DRGs were limited based on the clinical advice of experts. For cohort 2, the MS-DRGs were broadened based on additional information since FDA approval.

#### Charges removed for prior technology

Per the applicant, patients receiving TECVAYLI™ would receive three doses of the drug during their inpatient stay. This would replace other drug therapies. Because it is generally not possible to differentiate between different drugs on inpatient claims, the applicant removed all charges in the drug cost center.

#### Standardized charges

The applicant used the standardization formula provided in Technical Appendix A of the application. The applicant used all relevant values reported in the impact file posted with the FY 2023 IPPS/LTCH PPS final rule.

#### Inflation factor

The applicant applied the two-year inflation rate of 1.13218 to the standardized charges, based on the inflation factor used to calculate outlier threshold charges in the FY 2023 IPPS/LTCH PPS final rule.

#### Charges added for the new technology

Per the applicant, patients in the hospital for their initial TECVAYLI™ treatment will receive three doses subcutaneously—a 0.06 mg/kg loading dose, a 0.30 mg/kg loading dose, and the first 1.5 mg/kg treatment dose—during the hospital stay. Due to the risk of CRS and neurologic toxicity patients should be hospitalized for 48 hours after administration of all doses within the step-up dosing schedule. Therefore, all three doses will be administered in a single inpatient hospitalization. TECVAYLI™ is provided in two different dosage vials—a 30 mg/3 mL vial and a 153 mg/mL vial. Patients who are under 102 kgs will use two 30 mg/3 mL and one 153 mg/mL vials during their hospitalization. Patients over 102 kg will use three 30 mg and two 153 mg vials during their hospitalization. According to real world evidence and clinical studies, 89% of TECVAYLI™ patients will be less than 102 kg. Therefore, the applicant weighted the average cost per patient.

The applicant added charges for the new technology by dividing the cost of the new technology by the national average cost-to-charge ratio of 0.184 for drugs from the FY 2023 IPPS/LTCH PPS final rule. The applicant did not add indirect charges related to the new technology.

---

We invited public comments on whether TECVAYLI™ meets the cost criterion.

**Comment:** The applicant submitted a comment describing the analyses provided in the proposed rule and reiterating that, because the average charge per case for cases eligible for TECVAYLI® exceeded the threshold in both analyses, TECVAYLI® meets the cost criterion.

**Response:** We thank the applicant for its comment. We agree that the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount. Therefore, TECVAYLI™ meets the cost criterion.

With regard to the substantial clinical improvement criterion, the applicant asserted that TECVAYLI™ represents a substantial clinical improvement over existing technologies because its indication is less restrictive than some other treatments, making it available to patients who do not qualify for the other drugs that treat RRMM. In addition, the applicant stated that TECVAYLI™ may be more immediately accessible than the BCMA CAR T-cell therapies due to restrictions in site of care, manufacturing complexities, and other concerns with respect to the BCMA CAR T-cell therapies. Finally, the applicant stated that TECVAYLI™ improves clinical outcomes and results in less serious side effects than other off the shelf RRMM therapies. The applicant provided one study to support those
135 Background articles are not included in the following table but can be accessed via the online posting for the technology.

## Substantial Clinical Improvement Assertion #1: The technology offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments.

<table>
<thead>
<tr>
<th>Applicant statements in support</th>
<th>Supporting evidence provided by the applicant</th>
<th>Outcome(s) or finding(s) cited by the applicant from supporting evidence to support its statements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other therapies have indications and side effects that restrict the treatment population. TECVAYLI™ is available to some of these restricted patient populations.</td>
<td>Moreau P, Garfall AL, van de Donk NWCI, et al. Teclistamab in relapsed or refractory multiple myeloma. NEJM, 2022; 387(6): 495-505. Brief study description: Multi-center, Phase 1-2 MajesTEC-1 study of 165 adult patients with RRMM.</td>
<td>Two out of 165 patients discontinued teclistamab because of adverse events (grade 3 adenoviral pneumonia and grade 4 progressive multifocal leukoencephalopathy). One patient had a dose reduction during cycle 21 because of recurrent neutropenia, and 104 patients (63.0%) skipped a dose because of adverse events. No patients discontinued teclistamab owing to the development of cytokine release syndrome. No patients discontinued therapy because of neurotoxic events. The applicant provided additional background information to support this claim, which can be accessed via the online posting for the technology.</td>
</tr>
<tr>
<td>TECVAYLI™ may be a preferred treatment for patients unable to access CAR T-cell therapy.</td>
<td>The applicant provided background information to support this claim, which can be accessed via the online posting for the technology.</td>
<td></td>
</tr>
</tbody>
</table>

## Substantial Clinical Improvement Assertion #2: The technology significantly improves clinical outcomes relative to services or technologies previously available.

<table>
<thead>
<tr>
<th>Applicant statements in support</th>
<th>Supporting evidence provided by the applicant</th>
<th>Outcome(s) or finding(s) cited by the applicant from supporting evidence to support its statements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytokine Release Syndrome (CRS) is less serious and less frequent for patients treated with TECVAYLI™ than with BCMA CAR T-cells</td>
<td>Moreau P, Garfall AL, van de Donk NWCI, et al. Teclistamab in relapsed or refractory multiple myeloma. NEJM, 2022; 387(6): 495-505. See prior study description.</td>
<td>Most events of CRS were grade 1 or 2 in severity and fully resolved, except for one grade 3 event, the median time until the onset of CRS was 2 days (range, 1 to 6) after the most recent dose, and the median duration was 2 days (range, 1 to 9). The applicant provided additional background information to support this claim, which can be accessed via the online posting for the technology.</td>
</tr>
<tr>
<td>TECVAYLI™ improves clinical outcomes relative to other off-the-shelf therapies</td>
<td>Moreau P, Garfall AL, van de Donk NWCI, et al. Teclistamab in relapsed or refractory multiple myeloma. NEJM, 2022; 387(6): 495-505. See prior study description.</td>
<td>At the median follow-up of 14.1 months (range 0.3 to 24.2), responses occurred in 104 of 165 patient for an overall response rate of 63% (95% CI 55.2 to 70.4) with 58.8% achieving a very good partial response or better. The applicant provided additional background information to support this claim, which can be accessed via the online posting for the technology.</td>
</tr>
</tbody>
</table>

With regard to the claim that TECVAYLI™ may be a preferred treatment for patients unable to access CAR T-cell therapy, the applicant provided data on the number of patients who received CAR T-cell therapy from studies for CD19 CAR T-cell therapies used for B-cell lymphomas. For example, the applicant provided data from a survey of CAR T-cell treatment centers across the U.S. indicating only 25 percent of potential patients were reported to receive CD19 CAR T-cell treatments.
therapy, with a median wait time of 6 months.136 The applicant noted that the data was for CAR T-cell therapy used to treat B-cell lymphoma, because these treatments were approved prior to approvals for CAR T-cell therapies for MM, so there is more accumulated evidence for the former. However, given that B-cell lymphoma is a different disease than MM and the T-cell therapies used to treat these two diseases are different, we questioned whether the evidence related to B-cell lymphoma is applicable to T-cell therapies used to treat MM.

The applicant claimed that CRS is less serious and less frequent for patients treated with TECVAYLI™ than with BCMA CAR T-cell therapies. Notably, the applicant compared data from separate, single-arm, open-label studies of these technologies.137, 138, 139 In review, CRS occurrence rates were 72.1 percent, 95 percent and 84 percent for TECVAYLI™, ciltaclabtagene autoleucel, and idecabtagene vicleucel, respectively. In addition, only 0.6 percent of the CRS events for TECVAYLI™ were of grade 3 or higher, compared to 4 percent for ciltaclabtagene autoleucel and 5 percent for idecabtagene vicleucel. This improved safety claim, however, focused on only a single metric in the studies’ overall assessment of the safety and efficacy of these three drugs. The overall response rates reported in the studies were 63 percent, 97 percent and 73 percent for TECVAYLI™, ciltaclabtagene autoleucel, and idecabtagene vicleucel, respectively. When comparing across studies, other metrics of efficacy noted in these studies also appeared to support a superiority of the CAR T-cell therapies compared to TECVAYLI™ in the treatment of patients with RRMM. However, we also noted these comparisons are not matched cases within a comparative study. Therefore, we questioned the conclusions drawn by the applicant regarding the relative efficacy and safety profiles across these studies.

The applicant claimed that TECVAYLI™ improves clinical outcomes relative to other off-the-shelf therapies. The applicant stated the overall response rate (ORR) for XPOVIO® and BLENREP were 25 percent and 31 percent, while the ORR for TECVAYLI™ was 63 percent. However, this claim did not consider the higher ORR for CAR T-cell therapies compared to TECVAYLI™ when comparing across studies, as previously mentioned. While this claim compared TECVAYLI™ only to other off-the-shelf therapies, which would not include CAR T-cell therapies, we questioned whether there is significant clinical improvement compared to existing therapies, which include CAR T-cell therapies.

We invited public comments on whether TECVAYLI™ meets the substantial clinical improvement criterion.

Comment: We received a public comment stating that BCMA-directed bispecific antibody therapies indicated for the treatment of RRMM represent a substantial clinical improvement over existing treatment options. Specifically, the commenter stated while XPOVIO® may be an option for late-line patients with RRMM who are ineligible for or unable to access CAR T-cell therapies, they are unlikely to be treated with XPOVIO® due to the unfavorable benefit/risk ratio. Additionally, the commenter pointed out that BLENREP is no longer available on the U.S. market and is therefore not a treatment option for these patients. Furthermore, the commenter stated many patients do not have access to CAR T-cell therapies because of general access issues or because the disease is progressing quickly, and they are unable to wait for CAR T-cell therapy. Thus, the commenter continued that for nearly all RRMM patients, the choice will not be CAR T-cell therapy or a BCMA-directed bispecific antibody therapy or potentially nothing.

Response: We thank the commenter for its input and have taken it into consideration in our determination of whether TECVAYLI™ meets the substantial clinical improvement criterion, discussed later in this section.

Comment: The applicant submitted a comment reiterating that TECVAYLI™ meets the substantial clinical improvement criterion because the technology demonstrates improved clinical outcomes with RRMM and plays an important role in addressing an unmet need for patients, including Medicare beneficiaries, who are otherwise ineligible for, or unable to access, other treatments for RRMM. The applicant also responded to the concerns raised by CMS in the proposed rule. With respect to whether CAR T-cell therapies are also options for patients ineligible for XPOVIO® and BLENREP, the applicant claimed certain beneficiaries are ineligible to receive CAR T-cell therapies based on their clinical profile. Specifically, the applicant stated beneficiaries that are not clinically fit, including those with poor performance status and inadequate organ function, are not always appropriate candidates for CAR T-cell therapy and its related safety profile. Based on CAR T-cell therapy clinical trials and their labeling, the applicant noted that some of the medically significant factors that might limit a patient’s ability to receive a BCMA CAR T-cell therapy include any cardiac conditions (that is, upper limit of normal and left ventricular ejection fraction <45%), pre-existing cytopenias prior to the start of therapy (that is, absolute neutrophil count <1000 cells/mm3 and platelet count <50,000/mm3), or impaired renal function (that is, creatinine clearance <40–45 mL/min).

With respect to whether CAR T-cell therapy availability data was in reference to B-cell lymphoma, the applicant stated, in contrast with TECVAYLI™, even with very strong CAR T-cell therapy patient support programs, the requirements on the patient and their family can be both financially and logistically challenging. For example, the applicant stated patients are required to have a personal caregiver present for several weeks following dosing, and such caregiver requirements may not be possible for some beneficiaries. The applicant added, unlike TECVAYLI™, CAR T-cell therapies require a specialized healthcare setting certification necessary for the collection and handling of patient cells prior to and after the engineering of the product. The applicant stated while steadily increasing, only a limited number of institutions in the U.S. have the necessary requirements to obtain this certification, and it will take time for additional centers to ramp up, therefore limiting the availability of CAR T-cell therapies to those patients who can access the certified centers. The applicant noted this growth has increased demand for certified CAR T-cell therapy centers and has further compounded the access issues, with the certified CAR T-cell therapy centers experiencing limited availability and

138 Munshi NC, Anderson LD, Jr., Shah N, Madduri D, Berdeja J et al. (2021). Idecabtagene vicleucel manufacturing access. TECVAYLI™, ciltacabtagene autoleucel, and idecabtagene vicleucel, respectively.
waitlists. Since the approvals of the CAR T-cell technologies in the MM space, the applicant stated studies have highlighted the lack of accessibility of CAR T-cell products to MM patients. The applicant specified one study published this year showed that out of 20 centers with MM CAR T-cell therapies that were surveyed, 17 have a median allotment of one patient slot per month (per center), and the median number of patients per center on the waitlist since the FDA’s approval of idecabbtagene vilcucel (ABECMA®) is 20 (range, 5 to 100). Furthermore, the applicant noted patients remain on the waitlist for a median of six months (range, 2 to 8 months) prior to leukapheresis, which is the first step in the CAR T-cell manufacturing process, and the centers participating in the study estimated that only 25 percent of waitlisted patients eventually receive a slot for commercial CAR T-cell therapy, approximately 25 percent die or enroll in hospice, and the remaining 50 percent of patients are enrolled in clinical trials. According to the applicant, certain patients do not have a realistic chance of receiving a CAR T-cell product, and a percentage of these patients may not have access to an appropriate clinical trial due to eligibility criteria or distance from a large academic center with available studies, whereas these beneficiaries are eligible for TECVAYLI™. The applicant asserted for these patients starting their fifth line of therapy who may be on waitlists or otherwise unable to access CAR T-cell therapy, TECVAYLI™ provides a more readily available option that does not require the complex T-cell collection, genetic engineering, and cell manufacturing, or lymphodepleting chemotherapy prior to administration of therapy.

In response to CMS’s concerns pertaining to the lack of comparative safety data with CAR T-cell therapies, the applicant stated that there is not direct comparison data available, but that TECVAYLI™ has a strong safety profile concerning cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) compared with the BCMA CAR T-cell products. The applicant stated in the pivotal study of TECVAYLI™, CRS occurred in 72 percent of patients, including 50 percent in Grade 1, 21 percent in Grade 2, and 0.6 percent in Grade 3. ICANS occurred in 6 percent of patients. CRS occurred in 85 percent (108/127) of patients receiving ABECMA® Grade 3 or higher CRS (Lee grading system 1) occurred in 9 percent (12/127) of patients, with Grade 5 CRS reported in one (0.8%) patient. The applicant added that CAR T-cell-associated neurotoxicity occurred in 28 percent (36/127) of patients receiving ABECMA®, including Grade 3 in 4 percent (5/127) of patients. CARVYKTI® was associated with CRS in 95 percent of patients, including 5 percent Grade 3–5 CRS and 1 percent Grade 5 CRS. ICANS occurred in 23 percent of patients, including Grade 3⁄4 ICANS in 3 percent of all patients, whereas these beneficiaries are eligible for TECVAYLI™. The applicant stated fewer than 1 percent of TECVAYLI™ patients discontinued therapy due to adverse events, while this was 27 percent of selinexor patients. The applicant claimed TECVAYLI™ is an important treatment alternative to CAR T-cell therapies, with a median DOR of 21.6 months (ABECMA® is 11.0 months, and CARVYKTI® is 21.8 months). Additionally, the applicant stated the incidence and severity of both CRS and ICANS are less for TECVAYLI™ compared to the BCMA CAR T-cell products, and severe and potentially fatal HLH/MAS was not observed in the pivotal study of TECVAYLI™.

Response: We thank the applicant and commenters for their statements regarding the substantial clinical improvement criterion. Based on the additional information received and the information submitted in the application, we agree with the applicant that TECVAYLI™ represents a substantial clinical improvement over existing technologies because TECVAYLI™ offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments. We agreed with the commenters that TECVAYLI™ offers a treatment option for patients ineligible for CAR T-cell therapy or for who CAR T-cell therapy is not an available therapy and who are ineligible for XPOVIO®.

After consideration of the public comments we received, and the information included in the applicant’s new technology add-on payment application, we have determined that TECVAYLI™ meets the criteria for approval for new technology add-on payment. Therefore, we are approving new technology add-on payments for this technology for FY 2024. Cases involving the use of TECVAYLI™ that are eligible for new technology add-on payments will be identified by ICD–10–PCS code XW01348.

In its application, the applicant estimated that the cost of TECVAYLI is $13,754.67 per patient, as discussed previously. Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, the maximum new technology add-on payment for a case involving the use of TECVAYLI™ is $8,940.54 for FY 2024.

j. TERLIVAZ® (Terlipressin)

Mallickrodt Hospital Products, Inc. submitted an application for new technology add-on payments for TERLIVAZ® for FY 2024. Per the applicant, TERLIVAZ® is a pharmacologic therapy administered via IV bolus for the treatment of hepatoportal syndrome (HRS) with rapid reduction in kidney function. The applicant stated that TERLIVAZ® is a V1-receptor synthetic vasopressin analogue that acts as a pro-drug of lysine-vasopressin and has pharmacologic activity on its own. According to the applicant, TERLIVAZ® is the first and only FDA-approved treatment indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. We note that Mallickrodt Hospital Products, Inc. submitted an application for new technology add-on payments for TERLIVAZ® for FY 2022 under the name Mallinckrodt Pharmaceuticals, as summarized in the FY 2022 IPPS/LTCH PPS proposed rule (86 FR 25339 through 25344), that it withdrew prior to the issuance of the FY 2022 IPPS/LTCH PPS final rule (86 FR 44979). We note that the applicant also submitted an application for new technology add-on payments for FY 2023 under the name Mallinckrodt Pharmaceuticals, as summarized in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28287 through 28296), that it withdrew prior to the issuance of the FY 2023 IPPS/LTCH PPS final rule (87 FR 48920).

141 https://www.fda.gov/media/147055/download
[Review: FDA-2023-00053-D001] Division of Hematology and Oncology/Center for Drug Evaluation and Research/Center for Biologics Evaluation and Research (CDE; CBER).
Please refer to the online application posting for TERLIVAZ®, available at https://mearis.cms.gov/public/publications/ntap/NTP221014UR3R2, for additional detail describing the technology and the disease treated by the technology.

With respect to the newness criterion, according to the applicant, TERLIVAZ®’s NDA was approved by FDA on September 14, 2022, for the improvement of kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. According to the applicant, TERLIVAZ® became commercially available on October 14, 2022. Per the applicant, there was a delay in market availability because TERLIVAZ® received FDA approval three months earlier than expected, and the company needed additional time to conduct market commercialization, including labeling and packaging. Per the applicant, TERLIVAZ® is administered as an IV bolus injection. The applicant stated that for the first 3 days, the recommended dosage is 0.85 mg (1 vial) TERLIVAZ® every 6 hours by slow IV bolus injection. The applicant stated that on day 4, the serum creatinine level is assessed against the baseline level obtained prior to initiating the treatment. The applicant noted that if the serum creatinine has decreased by 30 percent or more from the baseline, then 0.85 mg TERLIVAZ® can continue to be administered every 6 hours. The applicant stated that if the serum creatinine has decreased by less than 30 percent from the baseline, then TERLIVAZ® may be increased to 1.7 mg (2 vials) every 6 hours. According to the applicant, TERLIVAZ® can continue to be administered until 24 hours after the patient achieves a second consecutive serum creatinine value of ≤1.5mg/dL at least 2 hours apart or for a maximum of 14 days. The applicant also stated that if, on day 4, serum creatine is at or above the baseline serum creatinine level, then TERLIVAZ® should be discontinued. According to the applicant, the mean treatment duration with TERLIVAZ® in the CONFIRM trial was 6.2 days, using 27 vials.

The applicant stated that, effective October 1, 2021, the following ICD–10–PCS codes may be used to uniquely describe procedures involving the administration of TERLIVAZ®: XW03367 (Introduction of terlipressin into peripheral vein, percutaneous approach, new technology group 7), or XW04367 (Introduction of terlipressin into central vein, percutaneous approach, new technology group 7). The applicant stated that diagnosis code K76.7 (Hepatorenal syndrome) may be used to currently identify the indication for TERLIVAZ® under the ICD–10–CM coding system.

As previously discussed, if a technology meets all three of the substantial similarity criteria under the newness criterion, it would be considered substantially similar to an existing technology and would not be considered “new” for the purpose of new technology add-on payments.

With respect to the substantial similarity criteria, the applicant asserted that TERLIVAZ® is not substantially similar to other currently available technologies because it offers a novel mechanism of action that allows for selective vasoconstrictive effects on the splanchnic vasculature via activation of V1 vasopressin receptors. The applicant also stated that TERLIVAZ® is the first and only FDA-approved pharmacologic therapy to satisfactorily treat patients with HRS and offers efficacy among patients who fail previous treatment. Therefore, the applicant asserted that the technology meets the newness criterion. The following table summarizes the applicant’s assertions regarding the substantial similarity criteria. Please see the online application posting for TERLIVAZ® for the applicant’s complete statements in support of its assertion that TERLIVAZ® is not substantially similar to other currently available technologies.
Similar to our discussion in the FY 2022 IPPS/LTCH PPS proposed rule (86 FR 25340), and the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28290), in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26892) we noted that while TERLIVAZ® may address an unmet need because it is the first treatment indicated specifically for the treatment of HRS, the applicant’s assertion that TERLIVAZ® does not involve the treatment of the same/similar type of disease and the same/similar patient population when compared to an existing technology, on the basis that there is a subset of patients for whom current treatments are ineffective and for whom TERLIVAZ® will offer a new treatment option, did not necessarily speak to the treatment of a new patient population for HRS.

We invited public comments on whether TERLIVAZ® is substantially similar to existing technologies and whether TERLIVAZ® meets the newness criterion. With regard to whether TERLIVAZ® involves treatment of the same/similar type of disease and the same/similar type of patient population when compared to an existing technology, the applicant stated that TERLIVAZ® offers an effective treatment for patients with HRS with rapid reduction in kidney function who are unresponsive to existing off-label therapies. The applicant further stated that in this subgroup of patients, treatment with TERLIVAZ® was associated with a greater rate of verified HRS reversal compared to placebo.

<table>
<thead>
<tr>
<th>Substantial Similarity Criteria</th>
<th>Applicant Response</th>
<th>Applicant assertions regarding this criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does the technology use the same or similar mechanism of action to achieve a therapeutic outcome?</td>
<td>No</td>
<td>TERLIVAZ® is the first and only FDA-approved treatment indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function, so no other therapies exist that FDA has found to be safe and effective. With this understanding, midodrine in combination with octreotide and norepinephrine have both been used off-label to treat HRS prior to the FDA approval of TERLIVAZ®. TERLIVAZ® offers a unique mechanism of action compared to these other treatments that allows for targeting of the splanchnic vasculature, rather than affecting the systemic circulation. Midodrine and norepinephrine both act as sympathomimetic alpha-adrenergic agonists that bind to alpha-1 adrenoceptors on peripheral vascular smooth muscle to promote smooth muscle contraction. Octreotide is a sympathomimetic somatostatin analogue that binds to somatostatin receptors and works in combination with midodrine to activate alpha-1 adrenergic receptors of arteriolar and venous vasculature, resulting in an increase in vascular tone and elevation in blood pressure. In contrast, TERLIVAZ® is a non-sympathomimetic, long-acting vasopressin analogue with selective affinity for the V1 vasopressin receptors that are predominantly located in the smooth muscle of arterial vasculature in the splanchnic region. In this way, TERLIVAZ® provides selective and potent vasoconstrictor and antidiuretic properties to elevate arterial pressure, leading to improved renal perfusion.</td>
</tr>
<tr>
<td>Is the technology assigned to the same MS-DRG as existing technologies?</td>
<td>No</td>
<td>There is no FDA approved technology for adults with HRS with rapid reduction in kidney function prior to the approval of TERLIVAZ®.</td>
</tr>
<tr>
<td>Does new use of the technology involve the treatment of the same/similar type of disease and the same/similar patient population when compared to an existing technology?</td>
<td>No</td>
<td>TERLIVAZ® is the first and only FDA-approved treatment for HRS with rapid reduction in kidney function, so there are no existing therapies with established efficacy and safety to treat this patient population. While midodrine, octreotide, and norepinephrine may be indicated and used in other disease states, clinical trials have not sufficiently supported their effective use in the HRS patient population. In the patient population that does not respond to first-line treatment with these therapies, TERLIVAZ® offers a new treatment option. Per the applicant, in the CONFIRM trial, 61% of TERLIVAZ®-treated patients had received prior treatment with midodrine and octreotide and 72.9% had received treatment with any vasopressor. Among patients who had received prior midodrine and octreotide, verified HRS reversal was achieved in 31.4% of patients in the TERLIVAZ® group vs 16.4% of patients in the placebo group. This demonstrates that TERLIVAZ® can be an effective treatment in patients who failed previous therapies.</td>
</tr>
</tbody>
</table>
leading to improved renal function in a population who did not respond to existing standard of care. The applicant also stated that TERLIVAZ® is listed as the preferred therapy for HRS by several U.S. and international guidelines, and these clinical recommendations provide greater support for the use of TERLIVAZ® compared to existing off-label therapies, suggesting that TERLIVAZ® may offer a treatment option for patients who would not respond to other available treatments.145 146 147 148

Response: We thank the applicant for its comment. Based on our review of comments, we agree with the applicant and commenters that TERLIVAZ® has a unique mechanism of action for selective vasoconstrictive effects on the splanchnic vasculature via activation of V1 vasopressin receptors as the first and only FDA-approved treatment for HRS. Therefore, we believe that TERLIVAZ® is not substantially similar to existing treatment options and meets the newness criterion. We consider the beginning of the newness period to commence on the date TERLIVAZ® became commercially available: October 14, 2022.

With respect to the cost criterion, the applicant provided multiple analyses to demonstrate that it meets the cost criterion. To identify potential cases representing patients who may be eligible for TERLIVAZ®, the applicant searched the FY 2021 MedPAR file for cases reporting ICD–10–CM code K76.7 (Hepatorenal syndrome). The applicant used the inclusion/exclusion criteria described in the following table. Each analysis differed with respect to the position of the ICD–10–CM code on the claim (that is, whether the ICD–10–CM code was the primary and/or admitting diagnosis code, or was in any position on the claim). Each analysis also differed with respect to requirements for the presence or absence of ICU-related charges (identified with the ICU indicator in the MedPAR with each analysis either including claims with ICU charges or claims without ICU charges), or whether ICU usage was not a consideration (the analysis included both claims with and without ICU charges). The applicant then presented six defined cohort analyses, and used the factors in the following table to define the cohorts. Please see Table 10.24.A.—TERLIVAZ® Codes (Analyses 1–6)—FY 2024 associated with the proposed rule for the complete list of MS–DRGs that the applicant included in its cost analysis for each cohort. The applicant followed the order of operations described in the following table.

For the first cohort analysis, the applicant identified 471 claims mapping to nine MS–DRGs. The applicant calculated a final inflated average case-weighted standardized charge per case of $279,135, which exceeded the average case-weighted threshold amount of $77,358.

For the second cohort analysis, the applicant identified 7,273 claims mapping to 183 MS–DRGs. The applicant then calculated a final inflated average case-weighted standardized charge per case of $319,685, which exceeded the average case-weighted threshold amount of $90,714.

For the third cohort analysis, the applicant identified 480 claims mapping to five MS–DRGs. The applicant then calculated a final inflated average case-weighted standardized charge per case of $189,783, which exceeded the average case-weighted threshold amount of $66,195.

For the fourth cohort analysis, the applicant identified 6,497 claims mapping to 173 MS–DRGs. The applicant then calculated a final inflated average case-weighted standardized charge per case of $211,960, which exceeded the average case-weighted threshold amount of $76,483.

For the fifth cohort analysis, the applicant identified 918 claims mapping to nine MS–DRGs. The applicant then calculated a final inflated average case-weighted standardized charge per case of $233,361, which exceeded the average case-weighted threshold amount of $69,919.

For the sixth cohort analysis, the applicant identified 12,801 claims mapping to 217 MS–DRGs. The applicant then calculated a final inflated average case-weighted standardized charge per case of $265,448, which exceeded the average case-weighted threshold amount of $81,949.

Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount for all scenarios, the applicant asserted that TERLIVAZ® meets the cost criterion.
We are invited public comments on whether TERLIVAZ® meets the cost criterion. We did not receive any comments on whether TERLIVAZ® meets cost criterion. Based on the information submitted by the applicant as part of its FY 2024 new technology add-on payment application for TERLIVAZ®, as previously summarized, the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount. Therefore, TERLIVAZ® meets the cost criterion.

With regard to the substantial clinical improvement criterion, the applicant asserted that TERLIVAZ® represents a substantial clinical improvement over existing technologies because among HRS patients who failed previous therapy with available off-label treatments, TERLIVAZ® has been shown

<table>
<thead>
<tr>
<th>TERLIVAZ® COST ANALYSIS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Data Source and Time Period</strong></td>
</tr>
<tr>
<td><strong>List of ICD-10-CM codes</strong></td>
</tr>
<tr>
<td><strong>List of MS-DRGs</strong></td>
</tr>
</tbody>
</table>
| **Inclusion/exclusion criteria** | Scenario 1: For the first scenario, the applicant included cases with the ICD-10-CM code, as previously listed, in the primary/admitting position, with ICU indicators (ICU charges reported on the claim), and stays of 2+ days only.  
Scenario 2: For the second scenario, the applicant included cases with the ICD-10-CM code, as previously listed, in any position, with ICU indicators (ICU charges reported on the claim), and stays of 2+ days only.  
Scenario 3: For the third scenario, the applicant included cases with the ICD-10-CM code, as previously listed, in the primary/admitting position, with no ICU indicators (no ICU charges reported on the claim), and stays of 2+ days only.  
Scenario 4: For the fourth scenario, the applicant included cases with the ICD-10-CM code, as previously listed, in any position, with no ICU indicators (no ICU charges reported on the claim), and stays of 2+ days only.  
Scenario 5: For the fifth scenario, the applicant included cases with the ICD-10-CM code, as previously listed, in the primary/admitting position, without requirements regarding ICU usage (claims with or without ICU charges reported on the claim), and stays of 2+ days only.  
Scenario 6: For the sixth scenario, the applicant included cases with the ICD-10-CM code, as previously listed, in any position, without requirements regarding ICU usage (claims with or without ICU charges reported on the claim), and stays of 2+ days only.  
For all scenarios, after case selection, data were trimmed to include only claims that would be used for Medicare IPPS rate setting (fee-for-service IPPS discharges, plus Maryland hospital discharges). Case counts less than 11 were imputed to have 11 claims. The applicant then calculated the average unstandardized charge per case for each MS-DRG. |
| **Charges removed for prior technology** | The applicant converted the costs of HRS-1 dosing regimens for norepinephrine (AnalySource 2018 U.S. Pricing) to charges dividing by the national average drug CCR of 0.184. These charges were removed in all cases with ICU usage. The applicant converted the costs of HRS-1 dosing regimens for midodrine plus octreotide (AnalySource 2018 U.S. Pricing) dividing by the national average drug CCR of 0.184. The applicant then removed these charges in all cases where there was no ICU usage. In some situations, the charges removed were larger than the total charges on the claim. In these situations, according to the applicant, it is clear that the charges replaced by TERLIVAZ® were overestimated. However, the applicant stated that TERLIVAZ® still meets the cost threshold in all scenarios. The applicant did not remove indirect charges related to the prior technology. |
| **Standardized charges** | The applicant used the standardization formula provided in Technical Appendix A of the application. The applicant used all relevant values reported in the impact file posted with the FY 2023 IPPS/LTCH PPS final rule. |
| **Inflation factor** | The applicant applied the two-year inflation rate of 1.13218 to the standardized charges, based on the inflation factor used to calculate outlier threshold charges in the FY 2023 IPPS/LTCH PPS final rule. |
| **Charges added for the new technology** | The applicant assumed a mean duration of treatment of 6.2 days, using 27 vials, based on the results of the clinical trial of the technology. Using the wholesale acquisition cost (WAC) per vial of TERLIVAZ®, the applicant calculated an average cost for TERLIVAZ®. The applicant added charges for the new technology by dividing the cost of the new technology by the national average cost-to-charge ratio of 0.184 for drugs from the FY 2023 IPPS/LTCH PPS final rule. The applicant did not add indirect charges related to the new technology. |
to significantly improve renal function. Additionally, the applicant stated that TERLIVAZ® remains the preferred treatment for HRS-acute kidney injury (AKI) according to several guidelines and guidance based on its significant efficacy, as shown by randomized clinical trials. The applicant asserted that for these reasons TERLIVAZ® offers a treatment option for HRS patients unresponsive to currently available treatments (for example, norepinephrine, midodrine, and octreotide), and it significantly improves clinical outcomes among HRS patients as compared to placebo as well as currently available treatments (for example, norepinephrine, midodrine and octreotide). The applicant provided 14 studies to support these claims. The following table summarizes the applicant’s assertions regarding the substantial clinical improvement criterion. Please see the online posting for TERLIVAZ® for the applicant’s complete statements regarding the substantial clinical improvement criterion and the supporting evidence provided.

<table>
<thead>
<tr>
<th>Applicant statements in support</th>
<th>Supporting evidence provided by the applicant</th>
<th>Outcome(s) or findings cited by the applicant from supporting evidence to support its statements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients in the CONFIRM trial with systemic inflammatory response syndrome (SIRS) at baseline achieved significant improvements</td>
<td>Wong F, Pappas SC, Curry MP, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021;384(9):818-828.</td>
<td>Primary endpoint was verified reversal of HRS, defined as two consecutive serum creatinine (SCr) measurements of ≤1.5 mg/dL at least 2 hours apart up to Day 14 and survival without renal replacement therapy (RRT) for at least an additional 10</td>
</tr>
<tr>
<td>Substantial Clinical Improvement Assertion #1: The technology offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>in renal function with TERLVAZ® treatment compared to placebo.</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Brief study description:</strong> Randomized, double-blind, placebo-controlled, multi-center U.S. Phase 3 trial. The purpose of the study was to evaluate efficacy and safety of terlipressin plus albumin in adults with HRS-1.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>days. Four secondary efficacy endpoints were adjusted for multiple comparisons: HRS reversal; durability of HRS reversal, defined as HRS reversal without RRT at Day 30; HRS reversal among patients with SIRS; and verified HRS reversal without recurrence of HRS by Day 30. HRS reversal in SIRS patients was noted in 31 patients (37%) with TERLVAZ® and 3 patients (6%) with placebo (P&lt;0.001).</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>The primary endpoint of CONFIRM, verified HRS reversal, is a clinically significant and appropriate measure of improvement in renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Data on File. Mallinckrodt Pharmaceuticals.</strong></td>
</tr>
<tr>
<td><strong>Brief study description:</strong> This is a copy of data on file from the CONFIRM trial clinical study report. The purpose of the CONFIRM study was to evaluate efficacy and safety of terlipressin plus albumin in adults with HRS-1.</td>
</tr>
<tr>
<td><strong>The primary endpoint, verified HRS reversal, was defined as the percentage of patients with two consecutive Scr values ≤1.5 mg/dL, obtained at least 2 hours apart while on treatment by Day 14 or discharge, and alive without RRT (eg, dialysis) for at least an additional 10 days. This was achieved in 29.1% of TERLVAZ® patients and 15.8% of placebo patients (P&lt;0.012). This endpoint demonstrates a robust and clinically significant improvement in renal function, emphasizes the durability of this improvement in renal function, and establishes the effect of treatment on a key clinical outcome of short-term survival. Combined, the three components of verified HRS reversal provide a strong, clinically meaningful measure of efficacy in the setting of multiple competing comorbidities.</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TERLVAZ®, Prescribing information. Mallinckrodt Hospital Products Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Brief study description:</strong> This is the TERLVAZ® U.S. prescribing information. TERLVAZ® is the first and only FDA-approved treatment indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.</td>
</tr>
<tr>
<td><strong>The efficacy of TERLVAZ® was evaluated in patients with cirrhosis, ascites, and a diagnosis of HRS-1 with a rapidly progressive worsening in renal function to a Scr of ≥2.25 mg/dL. A total of 300 patients were enrolled, with the primary endpoint of verified HRS reversal, defined as the percentage of patients with two consecutive Scr values ≤1.5 mg/dL, obtained at least 2 hours apart while on treatment by Day 14 or discharge. This endpoint was achieved in 29.1% of patients with TERLVAZ® vs placebo group of 15.8% (P&lt;0.012).</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Among patients in the CONFIRM trial, the majority failed prior therapy with available options, yet this subgroup achieved a statistically significant improvement in renal function with TERLVAZ®.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Data on File. Mallinckrodt Pharmaceuticals.</strong></td>
</tr>
<tr>
<td><strong>See prior description.</strong></td>
</tr>
<tr>
<td><strong>The primary endpoint, verified HRS reversal, was defined as the percentage of patients with two consecutive Scr values ≤1.5 mg/dL, obtained at least 2 hours apart while on treatment by Day 14 or discharge, and alive without RRT (eg, dialysis) for at least an additional 10 days. In the subgroup of patients who received prior midodrine and octreotide therapy, 31.4% vs 16.4% (P=0.030) achieved verified HRS reversal with TERLVAZ® vs placebo, respectively, and 38.8% vs 18.0% (P&lt;0.004) achieved HRS reversal with TERLVAZ® vs placebo, respectively. In the study intention-to-treat (ITT) population, of which 72.9% received prior vasopressor therapy, the primary endpoint of verified</strong></td>
</tr>
<tr>
<td>Substantial Clinical Improvement Assertion #1: The technology offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments.</td>
</tr>
<tr>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td>Patients in the CONFIRM trial with alcoholic hepatitis at baseline achieved improvements in renal function with TRLIVAZ treatment compared to placebo.</td>
</tr>
<tr>
<td>Data on File. Mallinckrodt Pharmaceuticals.</td>
</tr>
<tr>
<td>See prior description.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Verified HRS reversal has been accepted by multiple professional societies as a clinically significant measure of treatment efficacy for HRS patients.</th>
</tr>
</thead>
<tbody>
<tr>
<td>European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460.</td>
</tr>
<tr>
<td>Brief study description: EASL’s most recently published clinical practice guidelines regarding management of patients with decompensated cirrhosis define HRS as a functional renal failure caused by intrarenal vasoconstriction, which occurs in patients with end-stage liver disease, as well as patients with acute liver failure or alcoholic hepatitis. These guidelines recommend terlipressin as the first-line therapeutic option for patients diagnosed with HRS-AKI.</td>
</tr>
<tr>
<td>This recommendation was based on results from the CONFIRM trial, in which TRLIVAZ treatment resulted in a higher likelihood of HRS reversal and 10-day survival without RRT (29.1% vs 15.8% (P=0.012)). Additionally, the guidance notes that vasoconstrictors, including TRLIVAZ and norepinephrine, have demonstrated response rates of between 20% and 80%, with an average around 50%.</td>
</tr>
<tr>
<td>Brief study description: A comprehensive guidance on the diagnosis, evaluation, and management of ascites and HRS in patients with chronic liver disease. The treatment of choice in this guidance for HRS-AKI is vasoconstrictor drugs in combination with albumin. The preferred drug is terlipressin, administered as either IV bolus or continuous IV infusion.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Substantial Clinical Improvement Assertion #2: The technology significantly improves clinical outcomes relative to services or technologies previously available.</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRLIVAZ is listed by the 2021 AASLD guidance as the preferred therapy for HRS-AKI.</td>
</tr>
<tr>
<td>Brief study description: A comprehensive guidance on the diagnosis, evaluation, and management of ascites and HRS in patients with chronic liver disease.</td>
</tr>
</tbody>
</table>

| In an ex-U.S. head-to-head, randomized clinical trial comparing TRLIVAZ to | The primary endpoint of the study was complete response at completion of treatment. A significantly higher rate of |
|-------------------------------------------------|
| Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of | |
| |

| Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of | |
|-------------------------------------------------|
| | |
### Substantial Clinical Improvement Assertion #1: The technology offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments.

<table>
<thead>
<tr>
<th>midodrine and octreotide for HRS, TELIVAZ® treatment resulted in significantly greater rates of response.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatorenal syndrome: a randomized trial.</td>
</tr>
<tr>
<td>Brief study description: Randomized, controlled trial in Italy. The purpose of this study was to compare the effectiveness of TELIVAZ® plus albumin vs midodrine and octreotide plus albumin in the treatment of HRS.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Among patients aged ≥65 years and older, TELIVAZ® has been associated with increased rates of verified HRS reversal, durable HRS reversal, and verified HRS reversal without recurrence.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mujtaba M, Gamilla-Cruda AK, Merwat S, et al. Terlipressin, in combination with albumin, is an effective therapy for hepatorenal syndrome type 1 in patients aged ≥65 years. Poster presented at: KLF Spring Clinical Meeting, April 6-10, 2022; Boston, MA.</td>
</tr>
<tr>
<td>Brief study description: Oral presentation of pivotal data from CONFIRM (NCT02770716), a randomized, double-blind, placebo-controlled, multi-center U.S. Phase 3 trial. The purpose of this subgroup analysis was to evaluate the efficacy and safety of TELIVAZ® as a treatment for HRS in patients aged ≥65 years using data from the CONFIRM trial.</td>
</tr>
</tbody>
</table>
| The primary endpoint was verified HRS reversal, defined as the percentage of patients with two consecutive SCR values ≤1.5 mg/dL, obtained at least 2 hours apart while on treatment by Day 14 or discharge, and alive without RRT (eg, dialysis) for at least an additional 10 days. This was achieved in 31.4% of TELIVAZ® patients and 11.1% of placebo patients (P=0.177). Secondary endpoints and results are as follows: HRS reversal (34.3% vs 16.7%; P=0.225), durable HRS reversal (31.4% vs 16.7%; P=0.333) and verified HRS reversal without recurrence by Day 30 (31.4% vs 11.1%; P=0.177) in the TELIVAZ® vs placebo groups, respectively. Mean length of study site hospital stay was recorded: 21.7 days in the TELIVAZ® groups and 31.6 days in the placebo group. RRT requirements through 90 days were reported in TELIVAZ® and placebo groups, respectively: 20.8% vs 41.2% (P=0.158) at Day 14, 23.8% vs 46.2% (P=0.076) at Day 30, 22.2% vs 54.5% (P=0.114) at Day 60, 29.4% vs 66.7% (P=0.067) at Day 90, and
<table>
<thead>
<tr>
<th>Substantial Clinical Improvement Assertion #1: The technology offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments.</th>
<th>0% vs 83.3% (P=0.003) post-liver transplant (Figure 3).</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TERLIVAZ® treatment has been shown to improve outcomes in HRS patients who receive a liver transplant, as shown by a reduction in RRT requirements both pre- and post-transplant vs placebo.</strong></td>
<td>In CONFIRM, 34.8% of transplanted patients treated with TERLIVAZ® required RRT prior to transplant vs 62.1% of the placebo group. The P value for these data was not provided. In addition, the rate of RRT after transplant was significantly reduced with TERLIVAZ® treatment, with 19.6% of the TERLIVAZ® group vs 44.8% of the placebo group requiring RRT (P=0.036).</td>
</tr>
<tr>
<td>Data on File. Mallinckrodt Pharmaceuticals. Brief study description: See prior study description</td>
<td></td>
</tr>
<tr>
<td><strong>In an ex-U.S. open-label, randomized clinical trial, TERLIVAZ® demonstrated significant improvements in HRS reversal rate, response rate, and RRT requirements compared to norepinephrine.</strong></td>
<td>Compared to norepinephrine, TERLIVAZ® achieved greater response at Day 4 (26.1% vs 11.7%; P=0.03) and Day 7 (41.7% vs 20%; P=0.01). Reversal of HRS was also greater in the TERLIVAZ® group (40% vs 16.7%; P=0.004), with a significant reduction in RRT (56.6% vs 80%; P=0.006) and improved 28-day survival (48.3% vs 20%; P=0.001). As mentioned in previous comments related to the design of the Arora et al. study, an open-label study design was used; however, there is a paucity of data directly comparing TERLIVAZ® and norepinephrine for the treatment of HRS. To date, there are no large, high-quality, double-blind studies to compare TERLIVAZ® with either norepinephrine or midodrine/octreotide, or simply to support the efficacy and safety of either of these current therapies for HRS. In contrast, the safety and efficacy of TERLIVAZ® is supported by multiple large, double-blind, randomized, placebo-controlled trials. It is for this reason that the American Association for the Study of Liver Diseases (AASLD) guidance, American College of Gastroenterology (ACG) guidelines, American Gastroenterological Association (AGA) clinical practice update, and EASL guidelines all offer higher level recommendations for the use of TERLIVAZ® as the preferred treatment for HRS-AKI compared to norepinephrine.</td>
</tr>
<tr>
<td>Arora V, Maiwall R, Rajan V, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology. 2019;71(2):600-610. Brief study description: An open-label, randomized controlled trial (RCT) in a single center in India The purpose of the study was to compare norepinephrine and TERLIVAZ® for treatment of Acute on chronic liver failure (Aclf) patients with HRS-AKI. The primary endpoint was noted as reversal of HRS-AKI at Day 14, and secondary endpoints were to compare early response to norepinephrine and TERLIVAZ® at Days 4 and 5 and assess 28-day survival.</td>
<td></td>
</tr>
<tr>
<td><strong>Treatment with TERLIVAZ® has been associated with reductions in RRT requirements.</strong></td>
<td>Results show the rates of RRT in TERLIVAZ® vs placebo groups, respectively, at the following time points: Day 14 was 23% vs 35%, Day 30 was 26% vs 36%, Day 60 was 28% vs 38%, and Day 90 was 29% vs 39%. P values were not provided for these data.</td>
</tr>
<tr>
<td><strong>The newly published AGA clinical practice update also lists terlipressin as the preferred option for treatment of HRS-AKI.</strong></td>
<td>The recommended medication for the management of patients with cirrhosis and AKI is TERLIVAZ®. Should TERLIVAZ® not be available, either a combination therapy of octreotide and midodrine or norepinephrine could be used. Therapy is continued until 24 hours following return of SCR to within 0.3 mg/dl of baseline for</td>
</tr>
<tr>
<td><strong>Substantial Clinical Improvement Assertion #1:</strong> The technology offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments.</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td></td>
</tr>
<tr>
<td>This update from the AGA pertains to management of patients with cirrhosis and AKI and was based on best available published evidence.</td>
<td>2 consecutive days or for a total of 14 days of therapy. This guideline cited four randomized controlled trials, one in Europe and three in North America, totaling 646 patients and compared the efficacy of TERLIVAZ® combined with albumin vs placebo for reversing HRS. Of note, there was no difference in overall survival or transplant-free survival between TERLIVAZ® or placebo. In the most recent study carried out in the U.S. and Canada, 29% of patients reversed their HRS and survived for an additional 10 days after completion of treatment without needing RRT, which may allow for more time for liver transplantation.</td>
</tr>
<tr>
<td><strong>TERLIVAZ® has been associated with significant improvements in sustained renal function improvement to Day 30.</strong></td>
<td>TERLIVAZ®. Prescribing information. Mallinckrodt Hospital Products Inc. See prior study description. The efficacy of TERLIVAZ® was evaluated in patients with cirrhosis, ascites, and a diagnosis of HRS-1 with a rapidly progressive worsening in renal function to a SCr ≥ 2.25 mg/dL in the CONFIRM trial. A total of 300 patients were enrolled, with 199 randomized to TERLIVAZ® and 101 randomized to placebo. One of the secondary endpoints was durability of HRS reversal, which was measured as the percentage of patients with a SCr value ≤ 1.5 mg/dL while on treatment, by Day 14, or discharge, and who did not require RRT by Day 30. This was achieved in 31.7% in the TERLIVAZ® group and 15.8% in the placebo group (P=0.003).</td>
</tr>
<tr>
<td><strong>International guidelines also list TERLIVAZ® in combination with albumin as one of the first-line therapeutic options for the treatment of HRS-AKI.</strong></td>
<td>European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. See prior study description. TERLIVAZ® is the most commonly used therapy for HRS in Europe and has had efficacy proven in many studies. The total rates of response in recent studies (complete or partial response) range from 64% to 76%, and complete response from 46% to 56%. Alternatives to TERLIVAZ® have limited study information available, mainly norepinephrine and midodrine plus octreotide.</td>
</tr>
<tr>
<td>Xu X, Duan Z, Ding H, et al. Chinese guidelines on the management of ascites and its related complications in cirrhosis. Hepatol Int. 2019;13:1-21. Brief study summary: The Chinese Society of Hepatology invited experts in hepatology, gastroenterology, infectious disease, clinical pharmacology, and methodology to develop guideline recommendations for the appropriate diagnosis, treatment, and prevention of ascites and related complications.</td>
<td>These guidelines recommend vasoconstrictors as drug therapy for HRS patients to help improve hyperdynamic circulation and increase peripheral arterial pressure to increase renal blood flow. The vasoconstrictors listed are TERLIVAZ®, midodrine, norepinephrine, and octreotide. The guidelines state that studies of TERLIVAZ® have shown improvements in renal function, with efficacy rates of approximately 40%-50%.</td>
</tr>
<tr>
<td>Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients</td>
<td>These guidelines recommend that patients who meet diagnostic criteria for</td>
</tr>
<tr>
<td>Substantial Clinical Improvement Assertion #1: The technology offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments.</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td></td>
</tr>
<tr>
<td><strong>with cirrhosis:</strong> revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;82:968-974.</td>
<td></td>
</tr>
<tr>
<td><strong>Brief study summary:</strong> The ICA clinical practice guidelines provide updated consensus recommendations for the diagnosis and treatment of AKI in patients with cirrhosis.</td>
<td></td>
</tr>
<tr>
<td><strong>HRS should be treated with vasoconstrictors plus albumin. The guidelines do not provide a specific recommendation for use of one vasoconstrictor over another, but they do state that TERLIVAZ® in combination with albumin is the most investigated and effective treatment for HRS-1.</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Treatment with TERLIVAZ® has been associated with a significantly greater response rate compared to placebo.**

<table>
<thead>
<tr>
<th>Data on File. Mallinckrodt Pharmaceuticals.</th>
</tr>
</thead>
<tbody>
<tr>
<td>See prior study description</td>
</tr>
<tr>
<td>Complete response was defined as return of Scr to a value within 0.3 mg/dL above the baseline value, while partial response was defined as regression of AKI stage with a reduction of Scr to at least 0.3 mg/dL above baseline. In this population, combined rates of complete and partial response were 46.8% (30.7% complete response and 16.1% partial response) in the TERLIVAZ® group and 22.8% (9.5% complete response and 12.9% partial response) in the placebo group (P&lt;0.001). Baseline characteristics of the study population are included in the tables on pages 2 and 3.</td>
</tr>
</tbody>
</table>

**TERLIVAZ® has been associated with significant improvements in renal function, as measured by HRS reversal rate.**

<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>See prior study description</td>
</tr>
<tr>
<td>The secondary endpoint of HRS reversal was defined as any Scr level of ≤1.5 mg/dL while receiving TERLIVAZ® or placebo, and it was achieved in 39% of the TERLIVAZ® group vs 18% of the placebo group (P&lt;0.001).</td>
</tr>
</tbody>
</table>

**TERLIVAZ® is the first and only FDA-approved treatment for HRS because it has been associated with significant improvements in renal function, as measured by verified HRS reversal rate.**

<table>
<thead>
<tr>
<th>TERLIVAZ®. Prescribing information. Mallinckrodt Hospital Products Inc; 2022.</th>
</tr>
</thead>
<tbody>
<tr>
<td>See prior study description</td>
</tr>
<tr>
<td>The efficacy of TERLIVAZ® was evaluated in patients with cirrhosis, ascites, and a diagnosis of HRS-1 with a rapidly progressive worsening in renal function to a Scr of ≥2.25 mg/dL. A total of 300 patients were enrolled, with the primary endpoint of verified HRS reversal, defined as the percentage of patients with 2 consecutive Scr values ≤1.5 mg/dL, obtained at least 2 hours apart while on treatment by Day 14 or discharge. This endpoint was achieved in 29.1% of patients with TERLIVAZ® vs placebo group of 15.8% (P=0.012).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Data on File. Mallinckrodt Pharmaceuticals.</th>
</tr>
</thead>
<tbody>
<tr>
<td>See prior study description</td>
</tr>
</tbody>
</table>
| The primary endpoint, verified HRS reversal, was defined as the percentage of patients with two consecutive Scr values ≤1.5 mg/dL, obtained at least 2 hours apart while on treatment by Day 14 or discharge, and alive without RRT (for example, dialysis) for at least an additional 10 days. This was achieved in 29.1% of TERLIVAZ® patients and 15.8% of placebo patients (P=0.012) (Section 11.4.1/P3). This endpoint demonstrates a robust and clinically significant improvement in renal function, emphasizes the durability of this improvement in renal function, and establishes the effect of treatment on a key clinical outcome of short-term
Substantial Clinical Improvement Assertion #1: The technology offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments.

<table>
<thead>
<tr>
<th>The overall rates of adverse events (AEs) and serious adverse events (SAEs) were similar between TELIVAZ\textsuperscript{®} and placebo groups in the CONFIRM trial.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data on File. Mallinckrodt Pharmaceuticals.</td>
</tr>
</tbody>
</table>

See prior study description

The rates of AEs were 88.0% in the TELIVAZ\textsuperscript{®} group vs 89.9% in the placebo group, while the rates of SAEs were 65.0% in the TELIVAZ\textsuperscript{®} group vs 60.6% in the placebo group. In general, for statistical reasons, P values are not calculated for safety endpoints, so a statistically significant difference between groups cannot be determined.

**TERLIVAZ\textsuperscript{®} is also listed for the treatment of HRS-AKI, with higher quality evidence compared to norepinephrine in the 2022 ACG guidelines.**


Brief study summary:
The purpose of this guideline was to synthesize the current and emerging data on ACLF as a major entity in patients with chronic liver disease.

This guideline defined ACLF as a potentially reversible condition in patients with chronic liver disease with or without cirrhosis that is associated with the potential for multiple organ failure and mortality within 3 months of absence of treatment of the underlying liver condition. Furthermore, kidney failure is the most common organ failure in patients with ACLF, no matter how it is defined. In hospitalized patients with cirrhosis and HRS-AKI without high-grade ACLF or disease, these guidelines suggest TELIVAZ\textsuperscript{®} (moderate quality, conditional recommendation) or norepinephrine (low quality, conditional recommendation) to improve the renal function. The most commonly used vasoconstrictor worldwide for HRS-AKI/HRS-1 is TELIVAZ\textsuperscript{®}, which is associated with a response rate of up to 44%. This guideline was developed prior to FDA approval of TELIVAZ\textsuperscript{®}.

**In a study of real-world practice patterns, current standard of care in the U.S. is not adequately treating HRS patients, as response rates are low.**


Brief study summary: Oral presentation of retrospective chart review data from 11 U.S. tertiary care hospitals.
The purpose of the study was to describe characteristics of HRS-AKI patients in the U.S. and assess real-world treatment patterns and clinical outcomes based on disease severity.

Endpoints and results in the standard vs severe groups, respectively, are as follows: mean change in SCR from baseline to Day 14 was -0.2 mg/dL vs +0.7 mg/dL (P=0.006), overall response rates were 23.0% vs 34.3% (P=0.3), median time from initiation of vasoressors to response was 14 days in both groups, and median overall survival was 1.5 months vs 0.6 months. All results described can be found in the Clinical Outcomes and Survival sections of the poster.

**Among HRS patients aged 65 years and older, TELIVAZ\textsuperscript{®} has been associated with reduced hospital length of stay and RRT requirements vs placebo.**

Mujtaba M, Gamilla-Cruza AK, Merwat S, et al. Terlipressin, in combination with albumin, is an effective therapy for hepatorenal syndrome type 1 in patients aged ≥65 years. Poster presented at: NKF Spring Clinical Meeting, April 6-10, 2022; Boston, MA.

See prior study description

The primary endpoint was verified HRS reversal, defined as the percentage of patients with 2 consecutive SCR values ≤1.5 mg/dL, obtained at least 2 hours apart while on treatment by Day 14 or discharge, and alive without RRT (for example, dialysis) for at least an additional 10 days. This was achieved in 31.4% of TELIVAZ\textsuperscript{®} patients and 11.1% of...
**Substantial Clinical Improvement Assertion #1: The technology offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments.**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>placebo patients ((P=0.177)). Secondary endpoints and results are as follows: HRS reversal (34.3% vs 16.7%; (P=0.225)), durable HRS reversal (31.4% vs 16.7%; (P=0.333)), and verified HRS reversal without recurrence by Day 30 (31.4% vs 11.1%; (P=0.177)) in the TERLIVAZ® vs placebo groups, respectively. Mean length of study site hospital stay was recorded: 21.7 days in the TERLIVAZ® groups and 31.6 days in the placebo group. RRT requirements through 90 days were reported in TERLIVAZ® and placebo groups, respectively: 20.8% vs 41.2% ((P=0.158)) at Day 14, 23.8% vs 46.2% ((P=0.176)) at Day 30, 22.2% vs 54.5% ((P=0.114)) at Day 60, 29.4% vs 66.7% ((P=0.067)) at Day 90, and 0% vs 83.3% ((P=0.003)) post-liver transplant (Figure 3).</td>
<td></td>
</tr>
</tbody>
</table>

We also noted that the poster presentation of Mujtaba et al. is a post-hoc analysis of a subpopulation of patients aged ≥65 years from the CONFIRM study that appear to consist of post-hoc analyses of patient subgroups, for example, improvement in renal function for patients with alcoholic hepatitis at baseline, and reduction in RRT requirements in patients who received a liver transplant. Similar to our earlier concern, we questioned if we were able to draw conclusions from these post-hoc analyses alone without additional outcome data.

We also noted that the placebo patients (\(P=0.177\)). Secondary endpoints and results are as follows: HRS reversal (34.3% vs 16.7%; \(P=0.225\)), durable HRS reversal (31.4% vs 16.7%; \(P=0.333\)), and verified HRS reversal without recurrence by Day 30 (31.4% vs 11.1%; \(P=0.177\)) in the TERLIVAZ® vs placebo groups, respectively. Mean length of study site hospital stay was recorded: 21.7 days in the TERLIVAZ® groups and 31.6 days in the placebo group. RRT requirements through 90 days were reported in TERLIVAZ® and placebo groups, respectively: 20.8% vs 41.2% (\(P=0.158\)) at Day 14, 23.8% vs 46.2% (\(P=0.176\)) at Day 30, 22.2% vs 54.5% (\(P=0.114\)) at Day 60, 29.4% vs 66.7% (\(P=0.067\)) at Day 90, and 0% vs 83.3% (\(P=0.003\)) post-liver transplant (Figure 3).

We also noted that the primary endpoint of the CONFIRM trial, verified HRS reversal, is a clinically significant and appropriate measure of improvement in renal function. However, as we noted in the FY 2022 IPPS/LTCH PPS proposed rule (86 FR 25344) and FY 2023 IPPS/LTCH proposed rule (87 FR 28296), in the CONFIRM trial, while the proportion of patients with verified HRS reversal without HRS recurrence by Day 30 was numerically greater in the TERLIVAZ® group than placebo, the difference between groups was not statistically significant (26% vs 17%, \(p=0.08\)).\(^{149}\) We also noted that the potential for HRS recurrence among patients treated with TERLIVAZ® after 30 days is unclear. We questioned whether a statistically significant difference in verified HRS reversal in the TERLIVAZ® group at 14 days was sufficient to provide evidence of the durability of improvement in renal function.

With respect to the applicant’s assertion that TERLIVAZ® significantly improves clinical outcomes, we noted that the applicant provided evidence from data on file for the clinical study report of the CONFIRM trial that appear to consist of post-hoc analyses of patient subgroups, for example, improvement in renal function for patients with alcoholic hepatitis at baseline, and reduction in RRT requirements in patients who received a liver transplant. Similar to our earlier concern, we questioned if we were able to draw conclusions from these post-hoc analyses alone without additional outcome data.

We also noted that the poster presentation of Mujtaba et al. is a post-hoc analysis of a subpopulation of patients aged ≥65 years from the CONFIRM study, which was not powered to assess differences in clinical outcomes between the TERLIVAZ® and placebo groups in this subpopulation. As such, we noted that differences between the TERLIVAZ® and placebo groups in verified HRS reversal, HRS reversal, durability of HRS reversal, verified HRS reversal without HRS recurrence by Day 30, and length of study site hospital stay in days were not statistically significant. We also noted that the difference in RRT requirements through 90 days in the CONFIRM study among surviving patients aged ≥65 years was not statistically significant. Although the results numerically favored the TERLIVAZ® group, for those reasons, we questioned whether this analysis provided sufficient evidence of improved clinical outcomes in the Medicare population.

Finally, regarding the study conducted by Arora et al., we noted in the FY 2022 IPPS/LTCH PPS (86 FR 25344) and FY 2023 IPPS/LTCH PPS (87 FR 28296) proposed rules that this study included patients with a diagnosis of ACLF as well as HRS—AKI, which may have contributed to the differences observed between the TERLIVAZ® arm and the norepinephrine arm in this study.\(^{150}\)

We invited public comments on whether TERLIVAZ® meets the substantial clinical improvement criterion.

*Comment:* We received several comments in support of new technology add-on payments for TERLIVAZ®. The commenters supported the substantial clinical improvement assertions for TERLIVAZ®, and described high mortality and significant rates of HRS–related readmissions in this patient population.


population. Commenters cited the results of randomized, placebo-controlled trials where the use of TERLIVAZ® was associated with a reduced rate of mortality and more rapid resolution of the disease process as compared to the placebo.

Furthermore, commenters indicated that the CONFIRM trial demonstrated the substantial clinical improvement of TERLIVAZ® as compared with placebo on multiple outcomes, including: verified HRS reversal, verified HRS reversal in patients with prior midodrine and octreotide use, durability of HRS reversal, HRS reversal in the systemic inflammatory response syndrome subgroup, decreased incidence of RRT through Day 14, and decreased incidence of RRT after liver transplant. Several commenters noted that the HRS–1 patient population has substantial need for an effective treatment for this disease, and that outcomes have not improved for these patients since 2002.151 Additionally, several commenters indicated the clinical guidelines recommend using vasoconstrictors in combination with albumin as the first-line treatment to counteract splanchnic arterial vasodilation and that TERLIVAZ® is considered the first line treatment of choice in treating HRS–1 patients in European and Asian countries.152 153 A commenter further stated that the CONFIRM study demonstrated that TERLIVAZ® has an acceptable safety profile for this high-morbidity patient population.

Response: We thank the commenters for their input and have taken it into consideration in our determination regarding substantial clinical improvement, discussed later in this section.

Comment: The applicant submitted public comments regarding the substantial clinical improvement criterion, in response to CMS’s concerns raised in the proposed rule. With respect to CMS’s concern that the applicant provide evidence that TERLIVAZ® offers a treatment option for a patient population unresponsive to currently available treatments from a post-hoc analysis of the trial from which we were cautious about drawing conclusions without additional outcome data, the applicant indicated that although these were findings from a post hoc analysis, the data was derived from the largest multicenter, double-blind, randomized, placebo-controlled clinical trial of TERLIVAZ® to date. The applicant further stated the study of a prospective, randomized, head-to-head trial by Cavallin et al. (2015), in which patients with HRS receiving TERLIVAZ® were compared against patients receiving combination midodrine and octreotide demonstrated that TERLIVAZ®-treated patients attained complete response (decrease in serum creatinine to ≤1.5 mg/dL) at significantly higher rates (55.5%) than midodrine and octreotide-treated patients (4.8%; p < 0.001).154 providing greater confidence in the post hoc results from the CONFIRM trial. The applicant also noted that guidance and international guidelines stated that the efficacy of midodrine and octreotide is lower than that of TERLIVAZ®, and should only be used if TERLIVAZ® is unavailable or contraindicated. The applicant noted that these recommendations were further supported by real-world efficacy data from the United Kingdom demonstrating that TERLIVAZ® addresses an unmet need and may offer a treatment option for patients who do not respond to existing therapies.

In response to CMS’s concern that in the CONFIRM trial, while the proportion of patients with verified HRS reversal without HRS recurrence by Day 30 was numerically greater in the TERLIVAZ® group than placebo, the difference between groups was not statistically significant, and that the potential for HRS recurrence after 30 days was unclear, the applicant stated that verified HRS reversal was the primary endpoint of the CONFIRM trial, and based on study timing, was likely measured beyond Day 14 in most patients. The applicant stated that furthermore, although verified HRS reversal without recurrence was achieved in approximately 50 percent more patients treated with TERLIVAZ® compared to placebo, this endpoint was reported inconsistently, as recurrence was based on investigator judgment. The applicant stated that the endpoint of durability of HRS reversal was a more objective measure of sustained improvements in renal function than verified HRS reversal without HRS recurrence, and reached statistical significance in the CONFIRM trial. In addition, the applicant explained that regarding the potential for HRS recurrence beyond 30 days, HRS develops due to the hemodynamic alterations that occur from portal hypertension and cirrhosis and that TERLIVAZ® is not intended to resolve these complications. The applicant noted that patients whose underlying advanced liver disease is not corrected via transplant may develop HRS again if there is a new precipitating event, and that ultimately, the rate of HRS recurrence beyond 30 days would not be a reflection of TERLIVAZ® efficacy, but an effect of patients’ underlying liver disease.

With respect to CMS’s request for additional outcome data to support post hoc analyses of patient subgroups, the applicant stated that although the data was derived from post hoc analyses, the CONFIRM trial is the largest multicenter, double-blind, randomized, placebo-controlled clinical trial of TERLIVAZ® to date, and that the incidence of RRT through Day 90 was a prespecified endpoint for the full trial population. The applicant further stated that overall, data from the full intention-to-treat (ITT) population of the CONFIRM trial; data from the pooled analysis of the CONFIRM, REVERSE, and OT–0401 trials; and pre-transplant and long-term data from the subgroup of patients in the CONFIRM trial who received a liver transplant all consistently support that treatment with TERLIVAZ® reduced the incidence of RRT compared to placebo. Thus, TERLIVAZ® treatment offers significant clinical efficacy by helping patients avoid RRT, and has been associated with significant reductions in intensive care unit (ICU) length of stay because it can be administered on the general medicine floor. The applicant further stated that in the subgroup analysis of patients with alcoholic hepatitis, post hoc data from CONFIRM was consistent with published pooled data from all 3 trials, CONFIRM, REVERSE, and OT–0401, and showed that TERLIVAZ® led to significant improvements in renal function compared to placebo.156 The


156Sigal SH, Sanyal AJ, Frederick RT, Weinberg EM, Pappas SC, Jamil K. Terlipressin treatment is associated with reversal of hepatorenal syndrome in...
applicant further stated that there was a significant improvement in renal function in the pooled population subgroup, with 38.0 percent of the TERLIVAZ® group vs 13.1 percent of the placebo group achieving HRS reversal (p<0.001). Additionally, the applicant noted that significantly more patients were alive without RRT and maintained HRS reversal to Day 30 in the TERLIVAZ® group (33.9% vs 10.7%; p<0.001), consistently demonstrating that TERLIVAZ® treatment led to significant improvements in renal function among patients with alcoholic hepatitis.

With respect to whether the analysis submitted by the applicant provides sufficient evidence of improved clinical outcomes in the Medicare population given that the CONFIRM trial was not powered to assess differences in clinical outcomes in the subpopulation of patients aged ≥65 years, the applicant stated that HRS is a rare disease, and that therefore, it is difficult to enroll an adequate sample size to conduct large clinical trials that are powered to achieve statistical significance among specific subgroups. The applicant further stated that while the CONFIRM trial was not powered to detect a difference between therapies in patients aged 65 years and older, the mean age in the CONFIRM trial was 54 years, and approximately 18 percent of patients in each treatment group were aged 65 years and older. The applicant further stated that although the endpoints shown in the poster by Mujtaba et al.157 did not reach statistical significance based on the small sample size, each endpoint trended toward improvement in the TERLIVAZ® group compared to placebo and that as a result treatment with TERLIVAZ® in patients aged ≥65 years has shown efficacy results consistent with those of the larger CONFIRM population, and that available pharmacokinetic data does not suggest an older population would have a poorer response or tolerance to TERLIVAZ®. In a separate comment, the applicant also shared a manuscript, with data previously reported in the poster by Mujtaba et al.158 in abstract form, that had been accepted for publication in Annals of Hepatology.159

The applicant stated that the manuscript consisted of a pooled analysis of the CONFIRM, REVERSE, and OR-0401 trials that revealed positive results in patients aged 65 years or older with HRS, indicating that treatment with TERLIVAZ® and albumin was associated with clinical improvements for patients aged 65 years and older, and that no new safety signals were revealed in this analysis.

With respect to CMS’s concern that the study by Arora et al. included patients with a diagnosis of ACLF as well as HRS–AKI, which may have contributed to the differences observed between the TERLIVAZ® arm and the norepinephrine arm, the applicant responded that ACLF and HRS are often comorbid conditions and both were seen in all patients included in the CONFIRM trial.160 The applicant further specified that though it was not specifically required in the inclusion criteria, every patient enrolled in the CONFIRM trial had at least ACLF grade 1 at study entry. The applicant conclude that the patient population studied in the Arora et al. was similar to that of the CONFIRM trial and can be used to demonstrate that the improved outcomes seen with TERLIVAZ® compared to norepinephrine is expected in patients with HRS who meet ACLF criteria.

Response: We thank the applicant for its comments and the additional information provided regarding the substantial clinical improvement criterion. Based on the comments and additional information received, we agree that TERLIVAZ® represents a substantial clinical improvement over existing technologies because it is the only FDA-approved treatment for HRS patients, and significantly improves clinical outcomes among HRS patients by improving renal function, compared to placebo as well as currently available treatments, as demonstrated by statistically significant differences in HRS reversal rates, resulting in reduced RRT requirements and hospital length of stay.

After consideration of the public comments we received and the information included in the applicant’s new technology add-on payment application, we have determined that TERLIVAZ® meets the criteria for approval for new technology add-on payment. Therefore, we are approving new technology add-on payments for this technology for FY 2024. Cases involving the use of TERLIVAZ® that are eligible for new technology add-on payments will be identified by ICD–10–PCS codes: XW03367 (Introduction of terlipressin into peripheral vein, percutaneous approach, new technology group 7) or XW04367 (Introduction of terlipressin into central vein, percutaneous approach, new technology group 7).

Per the applicant, the WAC of TERLIVAZ® is $950 per vial, and the mean treatment duration with TERLIVAZ® in the CONFIRM trial was 6.2 days, using 27 vials. In its application, the applicant estimated that the average cost of therapy for TERLIVAZ® is $25,650 per patient ($950 × 27 vials). Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, the maximum new technology add-on payment for a case involving the use of TERLIVAZ® is $16,672.50 for FY 2024.

k. XENOVIEW® (Xenon Xe 129 Hyperpolarized)

Polarean, Inc. and The Institute for Quality Resource Management (collectively referred to as “applicant”) submitted an application for new technology add-on payments for XENOVIEW® (xenon Xe 129 hyperpolarized) for FY 2024. Per the applicant, XENOVIEW® is prepared using an FDA approved hyperpolarization process from a dose of Xenon 129/Xe Gas Blend. The applicant stated that the imaging signal is specifically created to address the unmet needs to quantitively diagnose early pulmonary oxygen deficiency, at the level of the alveoli oxygen exchange, without exposing the patient to ionizing radiation to inform management of patients with diseases manifested by diminished lung function. The applicant explained that after inhalation, HP 129/Xe freely diffuses from the airspace through alveolar-capillary barrier (comprised of alveolar epithelial cells, interstitial tissues, and capillary endothelial cells) and subsequently into the red blood cells (RBCs). The applicant noted that HP 129/Xe exhibits distinct magnetic resonance (MR) frequency shifts in the airspace, barrier, and RBCs, allowing the spatial imaging of its distribution in all three compartments, and that such imaging...
has been used to spatially characterize disease burden across a range of pulmonary disorders (for example, chronic obstructive pulmonary disease (COPD) and asthma). We note that the applicant submitted an application for new technology add-on payments for XENOVIEW™ for FY 2023, as summarized in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28307 through 28317), that it withdrew prior to the issuance of the FY 2023 IPPS/LTCH PPS final rule (87 FR 48920).

Please refer to the online application posting for XENOVIEW™ available at https://mearis.cms.gov/public/publications/ntap/NTP221017PBF9L, for additional detail describing the technology and the diseases diagnosed by the technology.

With respect to the newness criterion, according to the applicant, XENOVIEW™ was granted NDA approval from FDA on December 23, 2022, for the use of XENOVIEW™ (xenon Xe 129 hyperpolarized) with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older. According to the applicant, XENOVIEW™ was commercially available immediately following the NDA approval. The applicant stated that the dose for patients 12 years and older is 75 mL to 100 mL dose equivalent (DE, where DE = [total volume Xe gas] × [129Xe isotopic enrichment] × [polarized percent]) of HP 129Xe by oral inhalation of the entire contents of one XENOVIEW™ Dose Delivery Bag. The applicant explained that each bag contains at least 75 mL DE with a recommended target DE range of 75 mL to 100 mL in a volume of 250 mL to 750 mL total xenon with additional nitrogen, National Formulary (NF) (99.999% purity) added to reach a total volume of 1,000 mL measured 5 minutes before inhalation.

The applicant stated that effective October 1, 2022, the following ICD–10–PCS procedure code may be used to uniquely describe procedures involving the use of XENOVIEW™: BB34Z3Z (Magnetic resonance imaging (MRI) of bilateral lungs using hyperpolarized xenon 129 (Xe–129)).

As previously discussed, if a technology meets all three of the substantial similarity criteria under the newness criterion, it would be considered substantially similar to an existing technology and would not be considered “new” for the purpose of new technology add-on payments.

With respect to the substantial similarity criteria, the applicant asserted that XENOVIEW™ is not substantially similar to other currently available technologies because HP 129Xe, a new chemical entity, and new lung MRI signaling agent, is created on-site following an FDA approved method, for oral inhalation. The applicant explained that absent ionizing radiation, XENOVIEW™ identifies lung abnormalities reporting ventilation defect percent (VDP) diagnosing early deteriorating lung function to inform, guide and monitor therapy. The applicant explained that XENOVIEW™’s properties cause diffusion through the lung and distal alveoli, and that novelty mechanistically lies in the gas preparation, where HP creates a quantitative distinct volume DE for the patient’s anatomy. Therefore, the applicant asserted that the technology meets the newness criterion. The following table summarizes the applicant’s assertions regarding the substantial similarity criteria. Please see the online application posting for XENOVIEW™ for the applicant’s complete statements in support of its assertion that XENOVIEW™ is not substantially similar to other currently available technologies.
Similar to our discussion in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28308), we noted in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26917 through 26918) that although the applicant states that XENOVIEW™ has not been assigned to an MS–DRG and cannot be compared to an existing technology, we believed that based on its indication, cases involving the use of XENOVIEW™ would be assigned to the same MS–DRGs as cases involving the use of other MRIs and imaging modalities for pulmonary function and imaging of the lungs.

We invited public comments on whether XENOVIEW™ is substantially similar to existing technologies and whether XENOVIEW™ meets the newness criterion.

Comment: The applicant submitted a comment maintaining that XENOVIEW™ is substantially similar to existing technologies and whether XENOVIEW™ meets the newness criterion.

<table>
<thead>
<tr>
<th>Substantial Similarity Criteria</th>
<th>Applicant Response</th>
<th>Applicant assertions regarding this criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does the technology use the same or similar mechanism of action to achieve a therapeutic outcome?</td>
<td>No</td>
<td>HP $^{129}$Xe is a new chemical entity performing as a signaling agent when used in chest MRI to evaluate lung function throughout the lung, including the pulmonary vascular capillary network. There are no other imaging modalities that can visualize functional gas exchange in the smallest airways, known to be the nexus of disease. Furthermore, the unique properties of $^{129}$Xe (as compared to other noble gas isotopes $^{135}$Xe or $^3$He), including a difference resonance frequency in the airspace, lung barrier tissue, or in association with red blood cells, allows quantitative functional imaging of each of these 3 compartments at the level of the alveoli. No other signaling agent can achieve direct imaging of lung function at this level of specificity as the unique inhaled drug $^{129}$Xe, and no other imaging modality can do it with the benign safety profile of the MRI. As such, the combination of this new chemical entity and its application in MRI represents a completely new imaging modality.</td>
</tr>
<tr>
<td>Is the technology assigned to the same MS-DRG as existing technologies?</td>
<td>No</td>
<td>Lung imaging ICD-10-PCS codes do not determine the MS-DRG assignment upon discharge. The set of imaging ICD-10-PCS codes related to lung or pulmonary imaging are not assigned to any specific MS-DRG. For patients with lung disease that may be prescribed an HP $^{129}$Xe MRI, the resulting MS-DRGs are determined by the patient’s diagnosis codes, not the XENOVIEW™ MRI or any other lung imaging. Using the FY 2022 Optum 360 DRG Expert publication it was verified these ICD-10-PCS codes did not determine or cause assignment of any MS-DRG during an inpatient admission, and certainly not MS-DRG 190, 191, 192, 202 and 203 related to the population of patients who may require a medically necessary XENOVIEW™ MRI. XENOVIEW™ MRI is medically necessary to verify a patient’s exact lung ventilation defect percentage (VDP) to aid treatment planning and to monitor the patient for response to pharmacologic options. While the MS-DRGs for a patient population with lung disease represent the likely patients to be recommended a XENOVIEW™ MRI, this is a novel diagnostic, using a completely different chemical entity with a mechanism of action to enable regional VDP measurements to aid patient treatment. For patients with lung disease that may be prescribed an XENOVIEW™ MRI the resulting MS-DRGs are determined by the patient’s diagnosis codes, not the XENOVIEW™ MRI or any other lung imaging.</td>
</tr>
<tr>
<td>Does new use of the technology involve the treatment of the same/similar type of disease and the same/similar patient population when compared to an existing technology?</td>
<td>Yes</td>
<td>However, the new information opens treatment options because the pulmonologist receives information from the radiologist that they cannot otherwise obtain today. Existing technologies to measure pulmonary function cannot achieve the region specific quantified VDP. HP $^{129}$Xe MRI is reported to detect oxygen deficient regions of the lung better than pulmonary function tests (PFTs). Conventional MRI, CT, or VQ scintigraphy would not be ordered to measure oxygen exchange of the lung tissue. These modalities cannot provide such an image. Therefore, from the use of an ICD-10-CMS diagnosis coding perspective, the patient populations with disease that may benefit from a XENOVIEW™ MRI are different than those using conventional modalities. Patients with early disease can now be identified and physicians can obtain information to enhance their patients’ treatment to live a higher quality of life.</td>
</tr>
</tbody>
</table>
lungs using hyperpolarized xenon 129 (Xe–129) is used. The applicant explained that within Major Diagnostic Category (MDC) 004—Diseases & Disorders of the Respiratory System, 0.12 percent of cases included lung or pulmonary ICD–10–PCS codes for CT, MRI, or nuclear imaging, and that these imaging services are not ordered to report quantitative lung ventilation, therefore the ICD–10–CM diagnosis code of patients who benefit from XENOVIEW™ are different from those with diagnosis codes where conventional CT, MRI, or nuclear imaging would be ordered. The applicant explained that XENOVIEW™ is ordered for patients with respiratory disease, using the VDP as new information to guide treatment decisions and improve patient outcomes.

Response: We thank the applicant for the clarification regarding MS–DRG assignment for XENOVIEW™. Based on our review of comments received and information submitted by the applicant as part of its FY 2024 new technology add-on payment application for XENOVIEW™, we disagree with the applicant that XENOVIEW™ would not be assigned to the same MS–DRGs as cases involving the use of other MRIs or advanced imaging because medical necessity, images, spatial anatomy, and information obtained from the XENOVIEW™ MRI are different from the information from a conventional MRI, CT, and nuclear medicine lung imaging. The applicant further stated a patient’s principal diagnosis (specifically asthma, COPD, interstitial lung disease, Bronchiolitis Obliterans, cystic fibrosis, or complication post lung transplant), underlying comorbidities, and surgical procedures drive the MS–DRG assignment at the time of discharge, and creation of a new MS–DRG is not required. The applicant stated that XENOVIEW™ would be assigned within MS–DRGs 190–192, 196–198, 202–206 and 951 when ICD–10–PCS code BB34Z3Z (Magnetic resonance imaging (MRI) of bilateral lungs using hyperpolarized xenon 129 (Xe–129)) is used. However, we agree with the applicant that XENOVIEW™ uses a new mechanism of action for the diagnosis of respiratory conditions when compared to existing diagnostics because there are currently no FDA-approved or cleared technologies that use imaging with an inhaled hyperpolarized contrast agent that reports VDP quantitatively to provide a detailed, quantifiable image of gas distribution in regions of the lung. Therefore, we believe that XENOVIEW™ is not substantially similar to existing diagnostic options and meets the newness criterion. We consider the newness period to begin on December 23, 2022, when XENOVIEW™ was approved by FDA for the evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.

With respect to the cost criterion, the applicant searched the FY 2021 MedPAR file for potential cases representing patients who may be eligible for XENOVIEW™. The applicant limited its analysis to eight MS–DRGs, listed in the following table, as it believes these MS–DRGs represent patients most likely eligible for treatment with XENOVIEW™ (that is, patients with lung and pulmonary challenges, confirmed pulmonary disease, asthma, and COPD). Using the inclusion/exclusion criteria described in the following table, the applicant identified 87,801 claims mapping to these eight MS–DRGs. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $55,652, which exceeded the average case-weighted threshold amount of $46,624. Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount, the applicant asserted that XENOVIEW™ meets the cost criterion.
In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26918) we noted that the applicant limited its analysis to eight MS–DRGs. We were interested in information as to whether the technology would map to other MS–DRGs, such as other MS–DRGs under Major Diagnostic Category 004—Diseases & Disorders of the Respiratory System, as the indication for the technology regarding lung ventilation seems very broad. We invited public comments on whether XENOVIEW™ meets the cost criterion.

Comment: With respect to whether XENOVIEW™ would map to other MS–DRGs under Major Diagnostic Category 004—Diseases & Disorders of the Respiratory System, as the indication for the technology regarding lung ventilation seems very broad. We invited public comments on whether XENOVIEW™ meets the cost criterion.

Response: We thank the applicant for their revised cost analysis with the addition of MS–DRGs 204–206. We agree the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount, and therefore XENOVIEW™ meets the cost criterion.

With regard to the substantial clinical improvement criterion, the applicant asserted that XENOVIEW™ represents a substantial clinical improvement over existing technologies because HP 129Xe gas for oral inhalation with MRI offers an effective option for patients with pulmonary challenges to obtain quantitative information regarding their lung ventilation as it relates to their progression of disease without subjecting the patient to ionizing
radiation or the half-life of nuclear imaging agents. The applicant further stated that HP $^{129}$Xe MRI images are sharp and discrete, providing visual evidence of oxygen impairment across the barrier tissues leading to a quantifiable metric to follow patients’ treatment. The applicant asserted that XENOVIEW™ offers the ability to diagnose a medical condition in a patient population where that medical condition is currently undetectable or offers the ability to diagnose a medical condition earlier in a patient population than allowed by currently available methods. The applicant provided 10 studies to support these claims. The following table summarizes the applicant’s assertions regarding the substantial clinical improvement criterion.

Please see the online posting for XENOVIEW™ for additional details on the applicant’s statements regarding the substantial clinical improvement criterion and the supporting evidence provided.

<table>
<thead>
<tr>
<th>Applicant statements in support</th>
<th>Supporting evidence provided by the applicant</th>
<th>Outcome(s) or findings cited by the applicant from supporting evidence to support its statements</th>
</tr>
</thead>
</table>
| In patients with idiopathic pulmonary fibrosis (IPF), HP $^{129}$Xe MRI can predict disease progression in patient population where fibrosis is not detectable by traditional CT. | Hahn, AD, Carey KJ, Barton GP, Torres, LA, Kammerman J, et al. Hyperpolarized $^{129}$Xe MR Spectroscopy in the Lung Shows 1-year Reduced Function in Idiopathic Pulmonary Fibrosis. Radiology 2022; 000:1–9.  
Brief study description:  
Participants with IPF were followed up with forced vital capacity percent predicted (FVC%), diffusing capacity of the lungs for carbon monoxide percent predicted (DLco%), and clinical outcome at 1 year. IPF progression was defined as reduction in FVC% by at least 10%, reduction in DLco% by at least 15%, or admission to hospice care. CT and MRI were spatially coregistered and a measure of pulmonary gas transfer (red blood cell [RBC]-to-barrier ratio) and high-ventilation percentage of lung volume were compared across groups and across fibrotic versus normal-appearing regions at CT by using Wilcoxon signed rank tests. | HP $^{129}$Xe MRI, red blood cell (RBC)-to-barrier ratio (measure of gas exchange) and high-ventilation percent were reduced at baseline in participants with IPF who progressed in the year after imaging. The results also suggested that HP $^{129}$Xe MRI helps to detect reduced RBC-to-barrier ratio in participants with IPF progression compared with participants without progression in nonfibrotic lung, despite both groups showing the expected lower overall RBC-to-barrier ratio in fibrotic lung compared with nonfibrotic lung. This study demonstrates that functional measures of gas exchange and ventilation measured at HP $^{129}$Xe MRI and the extent of fibrotic structure at CT are associated with disease progression in IPF at 1 year later. |
Brief study description:  
This editorial comments on the importance of the Hahn 2022 study\(^{153}\) to provide information to aid use of HP $^{129}$Xe MRI into clinical practice, particularly to use the information to aid diagnoses of the image and the functional information simultaneously obtained. | Until recently, treatment options for non-IPF interstitial lung disease were limited to immunosuppressive agents that, in the case of predominantly fibrotic rather than cellular disease (such as in chronic hypersensitivity pneumonitis), had a limited evidence base and for many came with considerable long-term side effects. Evidence from Hahn suggests that Xe MRI can aid in understanding if patients on new therapies are progressing or not to... |
<table>
<thead>
<tr>
<th><strong>Substantial Clinical Improvement Assertion #1:</strong> The technology offers the ability to diagnose a medical condition in a patient population where that medical condition is currently undetectable or offers the ability to diagnose a medical condition earlier in a patient population than allowed by currently available methods.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>advance treatment effectiveness as a means of ensuring that treatment is prescribed appropriately to patients. The absence of radiation, ease of use, and rapid clearance from the body allows Xe MRI to advance a quantitative MR imaging approach to validate response to expensive treatment in time to make clinical effective treatment decisions.</strong></td>
</tr>
<tr>
<td><strong>In patients with Long-COVID, HP 129Xe MRI identifies patients with gas exchange abnormalities that are undetectable by standard CT.</strong></td>
</tr>
<tr>
<td><strong>In a prospective study with a total of 23 participants, there were significant differences in mean red blood cell tissue plasma between healthy controls (13) and post-hospitalized COVID (0.46 ± 0.07, [0.43-0.47] vs (0.31 ± 0.10, [0.24-0.37], respectively, p = 0.02) and between healthy controls and non-hospitalized long COVID participants (0.37 ± 0.10, [0.31-0.44], p = 0.03; see page 9), indicating differences in lung function. Non-hospitalized long COVID participants had near-normal CT scores, and DLco (%) was significantly lower between NHLC and PHC participants (76 ± 8%, [73-83] vs 86 ± 8%, [80-91] respectively, p = 0.04), potentially indicating a decrease in lung function but not structure.</strong> Fig 2 pg.17, Fig 4 pg.19, Fig 5 pg.20.</td>
</tr>
<tr>
<td><strong>HP 129Xe MRI revealed a significant difference in RBC:TP ratio between COVID-19 patients and healthy subjects (0.3 ± 0.1 vs. 0.5 ± 0.1, respectively; p = 0.001; effect size = 1.36). Furthermore, there was a significant difference in full width at half maximum during the RBC and gas phases (median ± range: 567 ± 1 Hz vs. 507 ± 81 Hz [p = 0.002] and 104 ± 2 Hz vs. 122 ± 17 Hz [p = 0.004]), but not in the tissue phase (420 ± 2 Hz vs. 418 ± 57 Hz; p = 0.72). Both COVID-19 patients and healthy subjects recorded high intraclass correlation coefficients (0.82 and 0.88, respectively). There were no significant correlations between the RBC:TP ratio and DLCO, age, D-dimer, hemoglobin, forced expiratory volume, or forced vital capacity, nor between the gas phase full width at half maximum and the tissue phase full width at half maximum, but there was a significantly strong correlation between the gas and RBC phase full width at half maximum (R² = 0.99; p = 0.04) and between the gas phase full width at half maximum and DLCO (R² = 0.94; p = 0.04).</strong></td>
</tr>
<tr>
<td><strong>The editorial described study results of significantly lower HP 129Xe MRI RBC-to-barrier ratio in never-hospitalized and previously hospitalized subgroups.</strong></td>
</tr>
<tr>
<td>Substantial Clinical Improvement Assertion #1: The technology offers the ability to diagnose a medical condition in a patient population where that medical condition is currently undetectable or offers the ability to diagnose a medical condition earlier in a patient population than allowed by currently available methods.</td>
</tr>
<tr>
<td>---</td>
</tr>
</tbody>
</table>
| **Brief study description:**
This editorial reviewed a study (Grist et al., 2022)\(^{162}\) that used HP \(^{129}\)Xe MRI to better understand the underlying cause of post-COVID-19 symptoms and limitations in recently discharged patients with COVID-19. Compared to the healthy group and no difference between measurements in the two COVID-19 subgroups. There were also no significant differences in spirometry measurements between the two subgroups, but mean DLCO was significantly lower in the never-hospitalized subgroup than the previously hospitalized subgroup despite still being normal. Chest CT imaging results of all patients were normal or near-normal. The editorial also noted a potential relationship between HP \(^ {129}\)Xe MRI RBC-to-barrier ratio and dyspnea score (p = 0.06–0.08). |
| **In patients with severe asthma and/or COPD, HP \(^{129}\)Xe MRI can identify an early treatment effect not possible with CT due to repeat imaging without repeated radiation exposure.** |
| **Brief study description:**
This study abstract compared metrics from HP \(^{129}\)Xe MRI, pulmonary function tests, and oximetry in 18 patients with severe asthma before and after application of bronchodilator at baseline and 28 days post-benzalizumab injection (and at 14 days post-benzalizumab injection for 6 patients). Results for ventilation defect percent (VDP) from HP \(^{129}\)Xe MRI, forced expiratory volume per one second (FEV1) from pulmonary function tests, oximetry, lung clearance index, and questionnaires were obtained. **Post-bronchodilator VDP improved significantly between baseline and 28 days post-benzalizumab injection (p = 0.03) whereas FEV1 did not. Of the 6 patients assessed at 14 days post-benzalizumab injection, 4 patients reported VDP improvement ≥M/CID at 14 days and 28 days post-benzalizumab injection and 2 patients reported a ≥100 mL FEV1 improvement at 14 days post-benzalizumab injection.** |
| **Brief study description:**
This prospective study aimed to assess treatment-related changes in HP \(^{129}\)Xe gas transfer function following administration of an inhaled long-acting beta agonist/long-acting muscarinic receptor antagonist (LABA/LAMA) bronchodilator. This prospective cohort study of 17 COPD (GOLD II/III classification per Global Initiative for Chronic Obstructive Lung Disease criteria) were imaged before and after 2 weeks of LABA/LAMA therapy. **HP \(^{129}\)Xe MRI recorded a significant decrease in ventilation defect percent and the percentage of voxels in the lowest or next lowest classification bins (vei\(\text{fracflow}\)) (57.8 ± 8.4% to 52.5 ± 10.6%; p < 0.05) and ventilation defect percent (33.7 ± 8.9% vs. 29.5 ± 11.4%, p < 0.05) in subjects with chronic obstructive pulmonary disorder before and after bronchodilator therapy, which was consistent with improved spirometry measurements (p < 0.05 for forced expiratory volume over one second [FEV1] and forced vital capacity [FVC]). Although no significant changes were found for barrier uptake (p=0.23), red blood cell transfer (p=0.21), dissolving capacity of the lung for carbon monoxide (DLCO) (p=0.80), total lung capacity (p=0.16), or residual volume (p=0.24). Improved ventilation after bronchodilator therapy was correlated** |

Substantial Clinical Improvement Assertion #1: The technology offers the ability to diagnose a medical condition in a patient population where that medical condition is currently undetectable or offers the ability to diagnose a medical condition earlier in a patient population than allowed by currently available methods.

| patients with cystic fibrosis, HP 129Xe MRI was a more sensitive measure than spirometry to identify patients with mild/early disease. | Thomen RP, Walkup LL, Roach DJ, Cleveland ZJ, Clancy JP, Woods JC. Hyperpolarized 129Xe for investigation of mild cystic fibrosis lung disease in pediatric patients. J Cyst Fibros 2016;16(2):275–282. Brief study description: This study compared the ventilation defect percent (VDP) determined by HP-129Xe MRI and forced expiratory volume per one second (FEV1) scores from pulmonary function tests between 11 healthy patients and 11 patients with cystic fibrosis (age 8–16 years; 9 of which had normal FEV1 scores [>85%]). FEV1 was not significantly different between healthy patients (100.3 ± 8.5%) and cystic fibrosis patients (97.9 ± 16.0%, p = 0.672; pg. 279). VDP was significantly different between healthy patients (6.4 ± 2.7%) and cystic fibrosis patients (18.3 ± 8.6%, p < 0.001), even when only cystic fibrosis patients with ‘normal’ FEV1 values (> 85%) were considered (FEV1: 103.1 ± 12.3%, p = 0.57; VDP: 15.4 ± 6.3%, p = 0.002; pg. 279). |
| In patients with COPD, HP 129Xe MRI provides a higher degree of diagnostic information that is undetectable by spirometry. | Labaki WW, Han MK. State of the Art Improving Detection of Early Chronic Obstructive Pulmonary Disease. Dec. 2018. Ann Am Thorac Soc Vol 15, Supplement 4, pp S243–S248. Brief study description: This state-of-the-art paper is seeking a method to accurately diagnose the underlying phenotypes to aid in prognostication and treatment for COPD, particularly of those who may rapidly progress, where a monitored intervention may be most effective. 33% -50% of individuals with chronic airway obstruction carry a formal diagnosis of COPD. To decrease the impact of COPD on healthcare costs and patient morbidity early detection is needed. Labaki (2018) does not discuss 129Xe MRI, yet defines a desired optimal method that is noninvasive, non-radioactive, non-effort dependent, laying a path for 129Xe MRI. Methods to measure regions of lung tissue not imaged by CT, nor measured by pulmonary function tests (PFT) are discussed, requesting a need for a reliable measure to identify patients that will rapidly progress to COPD and of those who may be monitored for treatment. |
| Mummy DG, Coleman M, Wang Z, Bier EA, Lu J, Driehuys D, Huang YC. J. Regional Gas Exchange Measured by 129Xe Magnetic Resonance Imaging Before and After Combination Bronchodilators Treatment in Chronic Obstructive Pulmonary Disease. J Magn Reson Imaging 54(3): 964–974. DOI: 10.1002/jmri.27662. See prior study description. Mummy’s prospective study of patients with COPD receiving treatment compared to healthy controls reveals the accuracy of 129Xe MRI to detect tissue changes indicative of alveolar damage to inform selection of treatment. Reduced 129Xe barrier signal and DLCO are both consistent with an emphysema-predominant COPD phenotype in which the alveolar septa have been destroyed. This reduces the alveolar surface area available for gas diffusion into the blood and leads to airway collapse. PFT FEV1 did not identify this patient set. Conversely, patients with relatively preserved measures of barrier uptake and DLCO may have airway obstruction that is caused by a bronchitis-predominant phenotype. It is this subset who appeared more likely to respond to the LABA/LAMA treatment as measured by 129Xe ventilation MRI. This is further supported by the observation that mean barrier uptake increased after treatment, suggesting that newly exposed regions of |
### Substantial Clinical Improvement Assertion #1: The technology offers the ability to diagnose a medical condition in a patient population where that medical condition is currently undetectable or offers the ability to diagnose a medical condition earlier in a patient population than allowed by currently available methods.

| In patients with asthma and/or COPD, HP $^{129}$Xe MRI identified patients with unique disease characteristics despite normal PFTs. | Marshall H, Smith LJ, Biancardi A, Collier GJ, Chan HF, et al. $^{129}$Xe MRI Patterns of lung function in patients with asthma and/or COPD in the NOVELTY study. Proc. Intl. Soc. Mag. Reson. Med. 30 2022. Brief study description: 164 patients were recruited from primary care and assessed with asthma and/or COPD to take part in the NOVELTY study. Metrics attained were ventilation defect percent (VDP), coefficient of variation of signal intensity (CV), mean diffusive length scale ($L_m$), alveolar surface area to volume ratio ($SA/V$), ratio of HP $^{129}$Xe dissolved in blood to gaseous HP $^{129}$Xe in the airspaces ($RBC/gas$), ratio of HP $^{129}$Xe dissolved in lung tissue and plasma to gaseous HP $^{129}$Xe in the airspaces ($TP/gas$), and $RBC/TP$ (a measure of alveolar gas exchange). The patients underwent spirometry and were divided into three groups based on physician-assigned diagnosis: asthma, COPD, or asthma+COPD. | In patients with normal FEV1, when imaged with HP $^{129}$Xe MRI ventilation defects were prevalent and ventilation MRI metrics showed significant differences between asthma ($n = 78$) and asthma+COPD ($n = 37$), and between asthma and COPD ($n = 10$). Patients with COPD or asthma+COPD had significantly higher VDP, CV, and $L_m$ and significantly lower $SA/V$, $RBC/TP$, $RBC/gas$, and $TP/gas$ than patients with asthma (all $p < 0.05$; see Fig. 2, pg. 5). Patients with only COPD also had significantly higher $L_m$ and significantly lower $RBC/gas$ and $TP/gas$ than patients with asthma+COPD (all $p < 0.05$). COPD patients had significantly lower $L_m$ in the lower-upper, mid-upper, and anterior-posterior regions compared to patients with asthma and significantly lower $L_m$ in the anterior-posterior region compared to patients with asthma+COPD (all $p < 0.05$). Patients with asthma had significantly higher $RBC/TP$ in the proximal-peripheral region compared to patients with COPD and significantly lower $TP/gas$ in the anterior-posterior region compared to patients with either asthma+COPD or only COPD (all $p < 0.05$). |

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26923 through 26924), after reviewing the information the applicant provided, we stated we had the following concerns regarding whether XENOVIEW™ meets the substantial clinical improvement criterion. We noted that, similar to our discussion in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28312), with respect to the evidence provided by the applicant to support its assertion that XENOVIEW™ is able to diagnose a medical condition in a patient population where the medical condition is currently undetectable and diagnose a medical condition earlier than currently available methods, the studies do not appear to demonstrate that subsequently, treatment planning or disease management was affected.

For example, we noted that studies were designed to assess the ability of XENOVIEW™ to detect changes in lung function before and after treatment in comparison to other technologies, rather than a change in patient management. For example, in the Mummy et al. (2021) study, $^{163}$ HP $^{129}$Xe MRI was used to observe treatment effects in COPD patients before and after receiving biologic therapy. Even though the study demonstrated that XENOVIEW™ may have more sensitivity in providing measurements of lung functioning in structurally normal areas of the lung, there were no additional follow-ups on patients who appeared to be non-responsive to therapy based on HP $^{129}$Xe MRI imaging. Without this information, it was difficult to determine whether using XENOVIEW™ to observe the effects of treatment has an impact on clinical decision-making for patients with COPD. Similarly, although the study abstract for McIntosh et al. (2020) $^{164}$ noted that clinically relevant VDP improvements were observed 14-days post-benralizumab in patients with minimal response detected using spirometry, it was not clear from the study abstract if the use of XENOVIEW™ to observe the effects of treatment impacted the clinical decision-making for these patients. In addition, we questioned the clinical significance of the findings in the Hahn et al. (2022) study $^{165}$ to support the applicant’s statement that in patients with IPF, HP $^{129}$Xe MRI can predict disease progression in patient...
population where fibrosis is not detectable by traditional CT, as the study authors suggested that findings need to be verified in a longitudinal multicenter study with more rigorous testing of the repeatability of the MRI-based measurements of gas exchange and ventilation in a larger sample of participants with IPF.

Furthermore, although the applicant stated that HP $^{129}$Xe MRI could be used to quantify abnormalities across three compartments of alveolar gas-exchange (in the airspaces (ventilation), barrier tissue of the lung parenchyma, and transfer to red blood cells (RBCs)), we questioned whether the detection of such abnormalities allows for a specific diagnosis of disease. For example, in the Grist et al. (2022) study, a follow-up to the Grist et al. (2021) study, the authors noted that the relationship of the HP $^{129}$Xe MRI abnormalities detected and the breathlessness experienced by the wider population of post-COVID–19 condition participants was unclear. The authors stated that caution is necessary in the use of HP $^{129}$Xe MRI for the detection of disease, as it was unknown whether participants with other respiratory tract infections, such as flu, had abnormal HP $^{129}$Xe MRI gas transfer months after infection. The authors also stated that it was not known whether the abnormalities detected were of clinical importance. The authors of the Mummy et al. (2021) study also indicated that HP $^{129}$Xe MRI ventilation measurements in COPD had not been well characterized, which limited the authors’ ability to determine a clinically meaningful change in ventilation metrics. In addition, we noted that the Thomen et al. (2016) study provided by the applicant consists of a pediatric population, and we questioned whether such detection of ventilation abnormalities by XENOVIEW™ would be generalizable to a Medicare population.

In summary, we questioned whether the evidence provided demonstrates that earlier detection of alveolar gas-exchange defects using XENOVIEW™ results in earlier diagnosis and subsequent changes to clinical decision-making following an earlier diagnosis. As such, we were interested in additional evidence to support the applicant’s assertion that use of XENOVIEW™ to make a diagnosis affects the management of the patient. We invited public comments on whether XENOVIEW™ meets the substantial clinical improvement criterion.

Comment: We received several comments in support of new technology add-on payments for XENOVIEW™, including one from the applicant, in response to CMS’s concerns in the FY 2024 IPPS/LTCF PPS proposed rule regarding whether XENOVIEW™ meets the substantial clinical improvement criterion.

The applicant asserted that the technology informs on spatial lung ventilation defects, leading to treatment decisions that positively impact patient outcomes. The applicant stated that VDP is able to provide quantitative information about a patient’s specific region of ventilation and oxygen defect across all functional regions of the lung, unlike conventional chest CT, MRI, nuclear imaging, or pulmonary function tests (PFTs), and therefore can be used to identify treatment effects of drug therapy and guide physicians in making adjustments. The applicant explained that, as a diagnostic test, XENOVIEW™ MRI would not be expected to directly change health outcomes; rather, a diagnostic test affects health outcomes through changes in disease management, and that the usefulness of a test result is constrained by the available treatment options. The applicant also noted that XENOVIEW™ is not effort dependent, unlike for patients who have difficulty with spirometry or PFTs. The applicant further asserted that XENOVIEW™ provides an objective quantified measure specific to the individual patient, which removes health disparities and improves equality in healthcare outcomes of chronic diseases where marginalized populations have few options for unbiased lung ventilation evaluation.

The applicant stated that outcomes of interest for the technology as a diagnostic test include beneficial or adverse clinical effects, such as changes in management due to test findings or preferably, improved health outcomes for Medicare beneficiaries. The applicant asserted that results from XENOVIEW™ MRI lead physicians to prescribe different and better treatments, and that those patients whose treatments are changed by test results remain on the regimen and achieve better long-term lung disease control. The applicant asserted that the evidence provided demonstrates the utility of the technology to accurately identify those patients who will, if untreated with improved treatment protocols, suffer the morbidity and mortality of lung disease. The applicant explained that peer-reviewed publications across patients with asthma, COPD, and asthma plus COPD with underlying risk factors demonstrated a reliable measurement of VDP with XENOVIEW™ proprietary software. The applicant stated that XENOVIEW™ VDP is an unbiased, quantitative measure compared to the patient’s own lung, rather than a population-based standard as in PFTs, and can detect subtle differences that cannot be captured by spirometry for PFTs. The applicant explained that higher rates of COPD diagnoses in non-Hispanic whites lends credibility to the inequity and bias in understanding and managing this disease, and asserted that XENOVIEW™ MRI can be used to reduce disparities in healthcare and improve management of chronic disease.

The applicant asserted that XENOVIEW™ MRI could be used to inform treatment outcomes to make changes as needed. The applicant referenced the Hahn et al. (2022) study, and explained that the study identified patients where VDP could explain the patient symptoms that were unable to be diagnosed by conventional spirometry or lung CT imaging. The applicant also referenced the study abstract for McIntosh et al. (2020), stating that the results support practical clinical use of VDP to inform treatment change, as it allowed for the differentiation between non-responders from responders to benralizumab therapy in patients with severe asthma. The applicant stated that the study provided evidence that the technology effectively measures gas exchange and functional ventilation in a population of asthma patients, and

---

allows clinically meaningful longitudinal follow-up. The applicant also referenced the Mummy et al. (2021) study, and stated it provided further evidence of treatment effect as VDP significantly improved in subjects with COPD before and after bronchodilator therapy. The applicant also asserted that without VDP measurements, physicians prescribe drugs without quantitative measures to document the treatment effect, and referenced a study by Hall et al. (2021).\(^{172}\) The applicant explained that the use of bronchial thermoplasty (BT) in severe asthma has been limited by peri-procedure adverse events, therefore VDP offers physicians an option to guide treatment to the specific region that will benefit. The applicant explained that the Hall et al. (2021)\(^{173}\) study randomly assigned 30 patients to BT treatment of the six most involved Airways in the first session (XENOVIEW™ MRI VDP guided group) or a standard three-session BT (unguided group). The applicant stated that statistically significant findings in XENOVIEW™ MRI guided BT patients resulted in actionable changes in the patient’s management, and that VDP guided patients experienced a better outcome with fewer adverse asthmatic events. The applicant stated although there were no significant difference in quality of life after one guided BT compared with three unguided BTs (guided = 0.91 [95% confidence interval, 0.28–1.53]; unguided = 1.49 [95% confidence interval, 0.84–2.14]; P = 0.201); VDP guided patients, however, had a statistically significant greater reduction in the percentage of poorly and nonventilated lung from baseline when compared with unguided BT treatments (217.2%; \(p = 0.009\)). The applicant further noted that 33 percent of patients experienced asthma exacerbations after one guided BT compared with 73 percent after three unguided BTs (\(p = 0.028\)).

Additional commenters supported the use of XENOVIEW™ MRI to aid in the characterization of the individual patient’s disease and impact clinical decision-making in patient management. One commenter suggested XENOVIEW™ may help characterize an individual’s disease and inform treatment decisions in an inpatient setting as it provides information about lung disease severity and activity beyond what is available with conventional PFTs. The commenter added that they foresaw Xenon MRI playing an important role in: (1) patients with respiratory symptoms but normal spirometry or PFTs to assess for lung disease; (2) patients undergoing bronchoscopic treatment of lung disease to guide regional treatments; (3) patients with lung disease who are not responding to treatment to quantify response to treatment or determine if a different treatment was required; and (4) patients with respiratory symptoms but a confusing clinical picture. The commenter stated that hyperpolarized gas MRI is more sensitive than the spirometry or pulmonary function testing in detecting mild or early disease and changes with treatment; has no ionizing radiation compared to CT; and can be used to identify regional lung function defects not seen with other modalities. The commenter stated they envisioned using XENOVIEW™ in longitudinal assessment of a patient’s response to therapy to stop or intensify treatments, and/or serve as an adherence tool to show patients their positive response to therapy and motivate continued compliance. The commenter explained that quantitative measures of VDP and the apparent diffusion coefficient [ADC] can be safely obtained with hyperpolarized Xe MRI. The commenter also explained that hyperpolarized gas MRI is advantageous compared to spirometry because each patient serves as their own normative value, and may be particularly helpful in populations that struggle with spirometry maneuvers.

Another commenter also asserted that XENOVIEW™ fills the current clinical gaps for the diagnosis and management of pulmonary diseases. The commenter stated that there are no clinical tests that can assess regional lung function with high resolution as PFT measures global lung function, while a CT scan provides structural detail, but not direct functional measurement, and has a radiation risk. The commenter stated that ventilation/perfusion scans lack the resolution for diagnosing lung disease, except pulmonary embolism. The commenter stated that XENOVIEW™ is non-invasive, is sensitive to changes in ventilation abnormalities, and provides novel information on VDP and the apparent diffusion coefficient-based emphysema index (ADC), which would allow clinicians to develop personalized care for patients to increase patient’s compliance with medications and decrease the need for unnecessary testing. The commenter described four common pulmonary conditions where XENOVIEW™ would be useful. The commenter suggested XENOVIEW™ could provide an early triage point in the clinical pathway for patients with unexplained dyspnea on exertion (DOE). The commenter provided a clinical scenario of a patient with DOE, and stated that if XENOVIEW™ had been available, they would have ordered the technology, which would have likely revealed ventilation defects that would have helped them diagnose small airflow disease asthma with more confidence and chose the appropriate medications. The commenter stated that chronic cough with failed treatments was another common pulmonary condition, which may be a result of cough-variant asthma that is difficult to diagnose with current clinical tests, and that if XENOVIEW™ were available, it would assist with disease diagnosis and treatment. The commenter further suggested the use of XENOVIEW™ in patients with COPD to differentiate between two clinical phenotypes, chronic bronchitis and emphysema. The commenter noted that patients with ventilation patterns more consistent with chronic bronchitis tended to respond better to LABA/LAMA, even if there was minimal response in PFT, and that this information would help clinicians change medications earlier in the “non-responders”. Finally, the commenter noted that patients with asthma may have a normal PFTs and other test results, while remaining symptomatic. The commenter referenced two studies using \(^{129}\)Xe MRI that had shown the presence of ventilation defects in asthma patients even if PFT was normal, and ventilation defects improved after treatment.\(^{175}\) 176 The commenter explained that ventilation defects on XENOVIEW™ could alert clinicians that the asthma may not have been well controlled.

An additional commenter affirmed that XENOVIEW™, when available in the clinical setting, would inform and/or change their treatment decisions due


\(^{173}\) Ibid


\(^{175}\)Serajeddini H, Eddy RL, Licskai G, McCormack DG, Paragha F. GEV1 and MRI ventilation defect reversibility in asthma and COPD. The European respiratory journal 2020; 55(3).

to knowledge of the underlying respiratory defect in a variety of clinical settings, and could serve as an adherence tool to motivate continued compliance. The commenter stated that children born prematurely have complex respiratory phenotypes, and that hyperpolarized Xe would allow simultaneous investigation of those phenotypes, and allow for targeted therapeutics. The commenter also stated that the technology could be used to detect, and therefore allow for treatment of, early onset obliterative bronchiolitis. The commenter noted that Xe MRI offered an alternative to assess lung function for children who were unable to cooperate with PFTs. The commenter stated that PFTs are insensitive to evaluate regional changes in lung function, and that XENOVIEW™ MRI can be used to identify regions of the lung with poor ventilation, changes in alveolar size, and gas exchange abnormalities to inform treatment options. The commenter stated that the technology would be able to image pulmonary anatomy not imaged by CT, while avoiding ionizing radiation, which would be particularly critical in children.

With respect to CMS’s question as to whether the detection of ventilation abnormalities by XENOVIEW™ in a study consisting of a pediatric population would be generalizable to a Medicare population, the applicant asserted that it would be because each XENOVIEW™ VDP measure is unique to individual patients across all ages, as it is compared to their own lung and not a contrived calculation as with PFTs. The applicant explained that as each XENOVIEW™ MRI is patient specific, the VDP relationship with poor regions of lung ventilation would be correctly identified in an adult when applying studies from patients under 18 years of age. The applicant stated that clinical trial evidence from studies of patients with cystic fibrosis could be related to an adult population. The applicant stated that approximately 14 percent of patients with cystic fibrosis have Medicare, and that therefore, data for this population is relevant to CMS beneficiaries.

In response to the same concern, a commenter stated they had performed hyperpolarized gas MRI in patients ranging from infants to those 80+ years, and asserted that results of research studies in lung diseases in the pediatric population are applicable to these diseases in the adult population since the underlying disease processes are the same. The commenter stated that their group had successfully and safely implemented Xe MRI throughout childhood from birth through adolescence to gather clinically applicable information, highlighting the ability of hyperpolarized Xe technology to influence care across the lifespan.

Response: We thank the applicant and other commenters for their comments. Based on our review of comments received and additional information submitted by the applicant as part of its FY 2024 new technology add-on payment application for XENOVIEW™, we continue to have concerns as to whether XENOVIEW™ meets the substantial clinical improvement criterion to be approved for new technology add-on payments. In particular, we remain concerned that although XENOVIEW™ may be able to diagnose pulmonary conditions, it remains unclear that the use of the technology to make a diagnosis affected the management of patients. Although commenters provided statements as to how they believed XENOVIEW™ could be used in clinical settings to impact patient management, we note that these testimonials appear to consist of hypothetical use cases, and we are uncertain if these testimonials would reflect the actual use of XENOVIEW™ in the inpatient Medicare population.

In particular, we note that neither the applicant nor the other commenters submitted evidence that demonstrated the use of XENOVIEW™ MRI to actually affect the management of patients, such as a change in diagnosis, a change in treatment planning, or discontinuation of or intensification of treatment regimens. For example, the study by Ebner et al. (2017) assessed the correlation between VDP and PFTs in asthmatic patients versus healthy controls, but did not describe changes in patient management due to VDP findings. In addition, we note that the study by Serajeddini et al. (2020) was a retrospective evaluation of spirometry and hyperpolarized 3He MRI measurements, and as such, does not appear to speak to the use of XENOVIEW™.

As described in the FY 2024 IPPS/LTC IPPS proposed rule (88 FR 26923 and 26924), we continue to have concerns about the Hahn et al. (2022), McIntosh et al. (2020), and Mummy et al. (2021) studies described in the applicant’s comment, and to continue to believe that these studies assess the ability of XENOVIEW™ to detect changes in lung function before and after treatment in comparison to other technologies, rather than a change in patient management. For the same reason, we have concerns that the Thomen et al. (2016) study does not demonstrate a change in patient management, as the study assessed the feasibility of 129Xe MRI usage and if usage would demonstrate ventilation defects in mild CF with greater sensitivity than FEV1. Therefore, we note the technology was not used to diagnose CF in the study, as patients were known to be either healthy control volunteers or cystic fibrosis patients, nor was there a change in diagnosis or treatment due to 129Xe MRI usage. In addition, we continue to have concerns with the preliminary results presented in the Grist et al. (2021) study referenced by commenters, as it was aimed to determine if hyperpolarized 129Xe MRI imaging could identify the possible cause of breathlessness in patients after hospital discharge following COVID–19 infection, and did not assess for changes in patient management due to those findings.

Furthermore, although the applicant shared a study of Xe-MRI VDP guided bronchial thermoplasty (BT) treatment compared to standard of care, with statistically significant findings reporting that Xe-MRI guided BT patients resulted in actionable changes in the patient’s management due to VDP measure of lung ventilation, we note that the study provided, associated with clinical trial number NCT01832363, utilized the MagniXene® technology by Xemed LLC. We note that it is unclear if the XENOVIEW™ technology from Polarean, Inc. is the same as the MagniXene® technology from Xemed LLC, or what differences may exist between the technologies. Therefore, we are unable to conclude that use of the XENOVIEW™ technology affects the management of the patient.

After review of the information submitted by the applicant as part of its FY 2024 new technology add-on payment application for XENOVIEW™ and consideration of the comments received, we are unable to determine that XENOVIEW™ meets the substantial clinical improvement criterion for the reasons discussed in the FY 2024 IPPS/LTCH PPS proposed rule and in this final rule, and therefore we are not approving new technology add-on payments for XENOVIEW™ for FY 2024.


As discussed previously, beginning with applications for FY 2021, a medical device designated under FDA’s Breakthrough Devices Program that has received marketing authorization as a Breakthrough Device, for the indication covered by the Breakthrough Device designation, may qualify for the new technology add-on payment under an alternative pathway. Additionally, beginning with FY 2021, a medical product that is designated by the FDA as a Qualified Infectious Disease Product (QIDP) and has received marketing authorization for the indication covered by the QIDP designation, and, beginning with FY 2022, a medical product that is a new medical product approved under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) and used for the indication approved under the LPAD pathway, may also qualify for the new technology add-on payment under an alternative pathway. Under an alternative pathway, a technology will be considered not substantially similar to an existing technology for purposes of the new technology add-on payment under the IPPS and will not need to meet the requirement that it represents an advance that substantially improves, relative to technologies previously available, the diagnosis or treatment of Medicare beneficiaries. These technologies must still be within the 2- to 3-year newness period to be considered “new,” and must also still meet the cost criterion.

As discussed previously, in the FY 2023 IPPS/LTCH PPS final rule, we finalized our proposal to publicly post online applications for new technology add-on payment beginning with FY 2024 applications (87 FR 48986 through 48990). As noted in the FY 2023 IPPS/LTCH PPS final rule, we stated in the proposed rule that we are continuing to summarize each application in the proposed rule. However, we stated that while we are continuing to provide discussion of the concerns or issues we identified with respect to applications submitted under the alternative pathway, we are providing more succinct information as part of the summaries in the proposed and final rules regarding the applicant’s assertions as to how the medical service or technology meets the applicable new technology add-on payment criteria. We refer readers to https://mearis.cms.gov/public/publications/ntap for the publicly posted FY 2024 new technology add-on payment applications and supporting information (with the exception of certain cost and volume information, and information or materials identified by the applicant as confidential or copyrighted). In addition, we noted that we made available separate tables listing the ICD-10-CM codes, ICD-10-PCS codes, and/or MS–DRGs related to the analyses of the cost criterion for certain technologies for the FY 2024 new technology add-on payment applications in Table 10 associated with the proposed rule, available via the internet on the CMS website at https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps. Click on the link on the left side of the screen titled “FY 2024 IPPS Proposed Rule Home Page” or “Acute Inpatient—Files for Download”. Please see section VI of the Addendum of the proposed rule for additional information regarding tables associated with the proposed rule.

We received 27 applications for new technology add-on payments for FY 2024 under the new technology add-on payment alternative pathway. Seven applicants withdrew applications prior to the issuance of the proposed rule. Subsequently, prior to the issuance of this final rule, seven additional applicants withdrew their respective applications for Selux NGP System, Total Ankle Talar Replacement, Transdental GFR Measurement System utilizing Lumitrace, Corbell Delirium Monitor, NUSurface, 4WEB Ankle Truss System, and the Nelli® Seizure Monitoring System. One applicant, LimFlow (the applicant for the LimFlow System), did not meet the July 1 deadline for FDA approval or clearance of the technology and, therefore, the technology is not eligible for consideration for new technology add-on payments for FY 2024. Of the remaining 12 applications, we are approving 11 and conditionally approving 1 for new technology add-on payments for FY 2024. A discussion of these 12 applications is presented in this final rule, including 9 technologies that have received a Breakthrough Device designation from FDA and 3 that were designated as a QIDP by FDA.

In accordance with the regulations under § 412.87(e)(2), applicants for new technology add-on payments for FY 2024, including Breakthrough Devices, must have FDA marketing authorization by July 1 of the year prior to the beginning of the fiscal year for which the application is being considered. Under the policy finalized in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58742), we revised the regulations at § 412.87 by adding a new paragraph (e)(3) which provides for conditional approval for a technology for which an application is submitted under the alternative pathway for certain antimicrobial products (QIDPs and LPADs) at § 412.87(d) that does not receive FDA marketing authorization by the July 1 deadline specified in § 412.87(e)(2), provided that the technology receives FDA marketing authorization by July 1 of the particular fiscal year for which the applicant applied for new technology add-on payments. We refer the reader to the FY 2021 IPPS/LTCH final rule for a complete discussion of this policy (85 FR 58737 through 58742).

As we did in the FY 2023 IPPS/LTCH PPS proposed rule, for applications under the alternative new technology add-on payment pathway, in the FY 2024 IPPS/LTCH PPS proposed rule we proposed to approve or disapprove each of these 12 applications for FY 2024 new technology add-on payments. Therefore, in this section of the preamble of this final rule, we provide background information on each of the remaining 12 alternative pathway applications and our determinations as to whether each technology is eligible for new technology add-on payments for FY 2024 or not. Consistent with our standard approach, we are not including in this final rule the description and discussion of applications that were withdrawn or that are ineligible for consideration for FY 2024 due to not meeting the July 1 deadline, described previously, which were included in the FY 2024 IPPS/LTCH PPS proposed rule. We are also not summarizing nor responding to public comments received regarding these withdrawn or ineligible applications in this final rule.

a. Alternative Pathway for Breakthrough Devices

(1) Aveir™ AR Leadless Pacemaker

Abbott Cardiac Rhythm Management submitted an application for new technology add-on payments for the
Aveir™ AR Leadless Pacemaker for FY 2024. Per the applicant, the Aveir™ AR Leadless Pacemaker is a programmable system comprised of a single leadless pacemaker implanted into the right atrium that provides single-chamber pacing therapy without the need for traditional “wired” leads. According to the applicant, this technology contains both the generator and electrodes within the device and is anticipated to be indicated for one or more of the following permanent conditions: syncope, presyncope, fatigue, disorientation due to arrhythmia/bradycardia, or any combination of those symptoms. We note that the applicant also submitted an application for new technology add-on payments for FY 2024 for the Aveir™ Leadless Pacemaker (herein referred to as the Aveir™ Dual-Chamber Leadless Pacemaker), discussed separately in the following section.

Please refer to the online application posting for Aveir™ AR Leadless Pacemaker, available at https://meaars.cms.gov/public/publications/ntap/NTP221017A7H7C, for additional detail describing the technology and the disease treated by the technology. According to the applicant, Aveir™ AR Leadless Pacemaker received Breakthrough Device designation from FDA on March 27, 2020, under the Breakthrough Device designation for the Leadless Dual Chamber System for the following proposed indication: Pacemaker implantation is indicated in one or more of the following permanent conditions: syncope, presyncope, fatigue, disorientation due to arrhythmia/bradycardia, or any combination of those symptoms. The proposed indications for the use of the Leadless Dual Chamber System included all four of the following: (1) Rate-Modulated Pacing is indicated for patients with chronotropic incompetence, and for those who would benefit from increased stimulation rates concurrent with physical activity. Chronotropic incompetence has not been rigorously defined. A conservative approach, supported by the literature, defines chronotropic incompetence as the failure to achieve an intrinsic heart rate of 70 percent of the age-predicted maximum heart rate or 120 bpm during exercise testing, whichever is less, where the age-predicted heart rate is calculated as 197 – (0.56 x age). (2) Dual-Chamber Pacing is indicated for those patients exhibiting: sick sinus syndrome; chronic, symptomatic second- and third-degree AV block; recurrent severe Stokes syndrome; symptomatic bilateral bundle branch block when tachyarrhythmia and other causes have been ruled out. (3) Atrial Pacing is indicated for patients with sinus node dysfunction and normal AV and intraventricular conduction systems. (4) Ventricular Pacing is indicated for patients with significant bradycardia and normal sinus rhythm with only rare episodes of AV block or sinus arrest; chronic atrial fibrillation; severe physical disability.

According to the applicant, the relevant indications for single-chamber atrial leadless pacing are the first and third indications, Rate-Modulated Pacing and Atrial Pacing. The applicant further stated that the Breakthrough Device designation applies to two clinical scenarios: a de novo system where a patient receives the Aveir™ Dual-Chamber Leadless Pacemaker (that is, both the Aveir™ AR Leadless Pacemaker and the Aveir™ VR Leadless Pacemaker are implanted within the same procedure), or an upgrade system where a patient already has a ventricular leadless pacemaker and is upgraded to the Aveir™ Dual-Chamber Leadless Pacemaker by receiving the Aveir™ AR Leadless Pacemaker. The applicant stated that it received FDA premarket approval for both the atrial leadless pacemaker (Aveir™ AR Leadless Pacemaker) and the dual chamber leadless pacemaker (Aveir™ Dual-Chamber Leadless Pacemaker) on June 29, 2023, for the same indications. We stated in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26927) that while the intended indications for the Aveir™ AR Leadless Pacemaker would appear to match sections of the Breakthrough Device designation, the Breakthrough Device designation provided by the applicant is for the Leadless Dual Chamber System, rather than the Aveir™ Dual-Chamber Leadless Pacemaker. Therefore, although the Aveir™ AR Leadless Pacemaker may be one component of the system, it appeared that the Aveir™ AR Leadless Pacemaker on its own is not the subject of the Breakthrough Device designation and would not be considered a Breakthrough Device once FDA approved. As discussed, a device must be designated under FDA’s Breakthrough Devices Program to be eligible under the alternative pathway. Accordingly, because the Aveir™ AR Leadless Pacemaker appeared to only be eligible under the alternative pathway for procedures involving the full dual-chamber system (that is, where patients are upgraded to the Aveir™ Dual-Chamber Leadless Pacemaker), we stated in the proposed rule that we believe any eligible use of the Aveir™ AR Leadless Pacemaker would be included under the new technology add-on payment application for the Aveir™ Dual-Chamber Leadless Pacemaker. We invited public comment on the eligibility of the Aveir™ AR Leadless Pacemaker under the alternative pathway.

Comment: The applicant submitted a comment regarding the eligibility of the Aveir™ AR Leadless Pacemaker for new technology add-on payments. The applicant asserted that FDA granted Breakthrough Device designation to the modular Leadless Dual Chamber System, which consists of the Aveir™ VR (ventricular leadless pacemaker) and the Aveir™ AR (atrial leadless pacemaker). The applicant stated it developed the modular Leadless Dual Chamber System with bidirectional implant-to-implant (i2i) communication to accommodate all pacing indications. According to the applicant, the i2i technology provides beat-to-beat communication and synchrony between two leadless pacemakers, a necessary foundation of dual-chamber leadless pacing therapy. The applicant stated that this system allows the two devices to communicate with each other—sensing for delayed or missed heartbeat and then pacing the appropriate chamber of the heart. According to the applicant, the Aveir™ system is modular, such that a single device can be implanted in a heart chamber initially, and the second pacemaker added to the other heart chamber in the future should the clinical need arise. The applicant asserted that the Aveir™ AR Leadless Pacemaker specifically corresponds to the Atrial Pacing configuration listed by FDA in the Breakthrough Device designation, which is distinct from Ventricular Pacing and Dual-Chamber Pacing. The applicant asserted that it would be incongruous for Aveir™ AR Leadless Pacemaker not to be a Breakthrough Device since it is the precise device that provides Atrial Pacing. The applicant stated that new technology add-on payment designation for the standalone Aveir™ AR Leadless Pacemaker would enable CMS to recognize that the costs to hospitals are different when a single leadless pacemaker is implanted in the right atrium compared with implantation of both a leadless ventricular pacemaker and atrial leadless pacemaker in the same procedure. The applicant commented that the Aveir™ AR Leadless Pacemaker with i2i technology also enables physician to implant for single chamber pacing indications and adapt treatment if symptoms progress.
and the patient requires dual-chamber pacing.

Response: We appreciate the information submitted by the applicant regarding the eligibility of the Aveir™ AR Leadless Pacemaker. However, we still note that Breakthrough Device designation was granted for the combination product. We agree with the applicant that the bidirectional i2i communication and synchrony between two leadless pacemakers is distinct from what is offered on implantation of the either the Aveir™ AR or the Aveir™ VR leadless pacemakers individually. While we understand that implantation of the Aveir™ AR Leadless Pacemaker alone during a procedure could be included under the Breakthrough Device designation, it is our understanding that that would only be the case with a prior implanted Aveir™ VR Pacemaker to trigger the i2i communication, and not with a future implant. Therefore, we believe that eligible uses of the Aveir™ AR Leadless Pacemaker would be procedures that result in a dual-chamber leadless system (whether as part of an initial dual-chamber insertion procedure or as part of an upgrade procedure to a dual-chamber device, as described previously). Since the Aveir™ AR Leadless Pacemaker on its own was not granted Breakthrough Device designation, it is therefore not eligible for consideration under the alternative pathway for Breakthrough Devices as a standalone device.

Comment: The applicant provided a list of clinical scenarios and procedure codes for which it believed either the Aveir™ AR Leadless Pacemaker or the Aveir™ Dual-Chamber Leadless Pacemaker qualified for the Breakthrough Device designation. The applicant asserted: (1) X2H63V9 and X2HK3V9 (Insertion of dual-chamber intracardiac pacemaker into right atrium, percutaneous approach, new technology group 9, Insertion of dual-chamber intracardiac pacemaker into right atrium, percutaneous approach, new technology group 9) could be used for de novo insertion, or removal and replacement of the dual chamber leadless system; (2) the procedure code X2H63V9 could be used for upgrading to dual chamber leadless system (Aveir™ AR insertion when patient has existing Aveir™ VR), or removal and replacement of right atrial component of dual chamber leadless system (Aveir™ AR removal and replacement); and (3) the procedure code X2H63V9 could be used for de novo insertion of atrial only single chamber leadless pacemaker, or removal and replacement of right atrial single chamber leadless pacemaker.

Another commenter requested that CMS clarify in the final rule the clinical scenarios to which the new technology add-on payment would apply if approved and provide guidance on appropriate coding to facilitate claims processing to ensure the new technology add-on payment is triggered only in cases that meet the alternative pathway requirements.

Response: We thank the commenters for the comments. As discussed previously, only use of the Aveir™ AR Leadless Pacemaker as part of an upgrade procedure to dual chamber pacemaker, or as part of a De Novo insertion of a dual chamber pacemaker (discussed in further detail in the following section for Aveir™ Dual Chamber Leadless Pacemaker), are relevant for the purposes of new technology add-on payments. As noted later in this section, the Aveir™ AR Leadless Pacemaker was granted approval for the following procedure code effective October 1, 2023: X2H63V9 (Insertion of dual-chamber intracardiac pacemaker into right atrium, percutaneous approach, new technology group 9), which describes upgrade procedures to dual-chamber pacing by implanting a leadless pacemaker into the atrium only where the patient already has a ventricular leadless pacemaker. We do not believe it would be appropriate to utilize X2H63V9 for a procedure that does not result in a dual-chamber pacemaker (such as implantation of an atrial-only pacemaker). We further note that single-chamber pacing is not intended to be captured by the new code, and additional codes are utilized for removal/replacement procedures in addition to insertion codes.

The applicant stated that the following ICD–10–PCS code may be used to uniquely describe procedures involving the use of Aveir™ AR Leadless Pacemaker effective beginning FY 2017: 02H63NZ (Insertion of intracardiac pacemaker into right atrium, percutaneous approach). The applicant also submitted a request for approval for a unique ICD–10–PCS code for the Aveir™ AR Leadless Pacemaker beginning in FY 2024 and was granted approval for the following procedure code effective October 1, 2023: X2H63V9 (Insertion of dual-chamber intracardiac pacemaker into right atrium, percutaneous approach, new technology group 9). The applicant stated that I49.9 (Cardiac arrhythmia, unspecified) may be used to currently identify the proposed indication for Aveir™ AR Leadless Pacemaker under the ICD–10–CM coding system.

With respect to the cost criterion, to identify potential cases representing patients who may be eligible for the Aveir™ AR Leadless Pacemaker, the applicant searched the FY 2021 MedPAR file for cases reporting ICD–10–PCS code 02H63NZ (Insertion of intracardiac pacemaker into right atrium, percutaneous approach). Using the inclusion/exclusion criteria described in the following table, the applicant identified 1,186 claims mapping to 43 MS–DRGs. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $207,890, which exceeded the average case-weighted threshold amount of $158,574. Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount, the applicant asserted that the Aveir™ AR Leadless Pacemaker meets the cost criterion.
In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26928), we stated that we have the following concerns regarding the cost criterion. As summarized in the following section, the applicant stated that the Aveir™ Dual-Chamber Leadless Pacemaker is identified using both ICD–10–PCS code 02H63NZ (used for the cost analysis for the Aveir™ AR Leadless Pacemaker) and ICD–10–PCS code 02HK3NZ (Insertion of Intracardiac Pacemaker into Right Ventricle, Percutaneous Approach). We questioned whether, by not excluding cases reporting ICD–10–PCS code 02HK3NZ as part of the case selection for the cost analysis for the Aveir™ AR Leadless Pacemaker, cases involving use of the dual chamber system could have been included as part of this analysis. Also, while it was our understanding that procedure code 02H63NZ was approved to describe procedures involving the use of intracardiac atrial pacemakers effective beginning FY 2017, the applicant stated that there are no technologies on the market eligible to be coded with procedure code 02H63NZ as the Aveir™ AR Leadless Pacemaker will be the first atrial leadless pacemaker, if approved. Therefore, we were unsure why the applicant searched for cases reporting procedure code 02H63NZ within the FY 2021 MedPAR file if there should not be any technologies coded with procedure code 02H63NZ until FY 2022 (when the applicant stated clinical trials for the Aveir™ AR Leadless Pacemaker began). We further questioned in the proposed rule which technology the cases identified in the MedPAR data represent. We questioned whether searching for cases utilizing standard pacemakers instead of leadless pacemakers (with relevant adjustments to remove/add charges as necessary) would better reflect the technology that the applicant anticipates Aveir™ AR Leadless Pacemaker will be replacing. Subject to the applicant adequately addressing these concerns, in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26928), we agreed that the technology meets the cost criterion and proposed to approve the Aveir™ AR Dual-Chamber Leadless Pacemaker for new technology add-on payments for FY 2024, subject to the technology receiving Breakthrough Device designation and FDA marketing authorization as a Breakthrough Device for the indication corresponding to the Breakthrough Device designation by July 1, 2023.

Subject to the applicant adequately addressing these concerns, in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26928), we agreed that the technology meets the cost criterion and proposed to approve the Aveir™ AR Dual-Chamber Leadless Pacemaker for new technology add-on payments for FY 2024, subject to the technology receiving Breakthrough Device designation and FDA marketing authorization as a Breakthrough Device for the indication corresponding to the Breakthrough Device designation by July 1, 2023.

The applicant had not provided an estimate for the cost of the Aveir™ AR Leadless Pacemaker at the time of the proposed rule. We stated in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26928) that we expected the applicant to submit cost information prior to the final rule, and that we would provide an update regarding the new technology add-on payment amount for the technology, if approved, in the final rule. We stated that any new technology add-on payment for the Aveir™ AR Dual-Chamber Leadless Pacemaker would be subject to our policy under § 412.88(a)(2) where we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case.

We invited public comments on whether the Aveir™ AR Leadless Pacemaker meets the cost criterion and our proposal to approve new technology add-on payments for the Aveir™ AR Dual-Chamber Leadless Pacemaker for FY 2024 subject to the technology receiving Breakthrough Device designation and FDA marketing authorization as a Breakthrough Device for the indication corresponding to the Breakthrough Device designation by July 1, 2023.

Comment: We received a comment in support of our proposal to approve new technology add-on payments for the Aveir™ AR Leadless Pacemaker. The commenter stated that the Aveir™ AR Leadless Pacemaker allows for mapping prior to fixation and reduces the number of repositioning attempts. According to the commenter, positioning capabilities may result in better long-term outcomes for patients, and in addition to an increased battery life—twice the battery life of other leadless pacemakers—it may lead to fewer procedures and reduce patient risk.

Response: We thank the commenter for the comments.

Comment: The applicant submitted a comment regarding the cost criterion and provided an alternate cost analysis in response to CMS’s concerns identified in the proposed rule regarding whether cases utilizing standard pacemakers instead of leadless pacemakers would better reflect the technology that the applicant anticipates Aveir™ AR Leadless Pacemaker will be replacing. In the updated analysis, the applicant searched for cases using a combination of ICD–10–PCS codes for implanting a standard dual-chamber pacemaker plus the insertion of the additional lead in the right atrium (rather than codes for leadless pacemakers) based on the assertion that this would appropriately describe patients who already have a leadless right ventricle pacemaker who are implanted with the Aveir™ AR Leadless Pacemaker. The applicant removed 100 percent of the charges from revenue centers 0275, 0278, 0279, and 0624 from the 1,317 identified discharges to be as conservative as possible. Because the final inflated average case-weighted standardized charge per case of $252,073 for a device upgrade exceeded the average case-
weighted threshold amount of $122,326 in the updated cost analysis, the applicant asserted that the Aveir™ AR Leadless Pacemaker met the cost criterion.

With respect to CMS’s question why the applicant searched for cases reporting procedure code 02H63NZ, the applicant stated that it included those cases in the original analysis with the expectation that CMS would seek that data because it is a code specific to a leadless pacemaker, notwithstanding that its technology was not reported until FY 2022. The applicant noted that it updated the analysis using traditional transvenous pacemaker codes and omitted this code, based on CMS’s suggestion, and as described previously.

In addition, the applicant provided an additional cost analysis for insertion of atrial only single chamber pacemaker in the right atrium to complement the prior analysis and other clinical scenarios, as it stated that Aveir AR™ Leadless Pacemaker with 12t technology also enables the implant for single chamber pacing indications and adapt treatment if symptoms progress and the patient requires dual-chamber pacing. In the new cost analysis, because the final inflated average case-weighted standardized charge per case of $276,818 for an atrial-only pacemaker exceeded the average case-weighted threshold amount of $137,401, the applicant maintained that the device meets the cost criterion.

Response: We thank the applicant for its comments and appreciate the updated and additional cost analyses. We agree that the technology meets the cost criterion based on the first updated analysis where the applicant searched for cases utilizing standard pacemakers and implanting an atrial lead during insertion of a dual-chamber system. As previously stated, the Breakthrough Device designation was granted for the dual-chamber product and not for the Aveir™ AR Leadless Pacemaker, and therefore eligible uses of the Aveir™ AR Leadless Pacemaker would be procedures that result in the insertion of a dual-chamber system, and it is not eligible for consideration under the alternative pathway for Breakthrough Devices as a standalone device.

Based on the information provided in the application for new technology add-on payments, and after consideration of the public comments we received, we believe Aveir™ AR Leadless Pacemaker meets the cost criterion. The technology received FDA premarket approval on June 29, 2023, as a Breakthrough Device where it is a Dual-Chamber system, with an indication for one or more of the following permanent conditions: syncope, presyncope, fatigue, disorientation due to arrhythmia/bradycardia, or any combination of those symptoms. Therefore, we are finalizing our proposal to approve new technology add-on payments for Aveir™ AR Leadless Pacemaker for FY 2024. We note, as discussed previously, that only the use of the technology resulting in the insertion of a dual-chamber system is relevant for the purposes of new technology add-on payments. We consider the beginning of the newness period to commence on June 29, 2023, the date on which technology received FDA marketing authorization for the indication covered by its Breakthrough Device designation.

Based on the information available at the time of this final rule, the cost per case of Aveir™ AR Leadless Pacemaker is $16,500, including one Aveir™ AR atrial leadless pacemaker, one delivery catheter, and one introducer. Under §412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, we are finalizing that the maximum new technology add-on payment for a case involving the use of Aveir™ AR Leadless Pacemaker is $10,725 for FY 2024 (that is, 65 percent of the average cost of the technology). Cases involving the use of Aveir™ AR Leadless Pacemaker that are eligible for new technology add-on payments will be identified by ICD–10–PCS procedure code 2H63V9 (Insertion of dual-chamber intracardiac pacemaker into right atrium, percutaneous approach, new technology group 9).

(2) Aveir™ Leadless Pacemaker (Dual-Chamber)

Abbott Cardiac Rhythm Management submitted an application for new technology add-on payments for the Aveir™ Leadless Pacemaker (herein referred to as the Aveir™ Dual-Chamber Leadless Pacemaker) for FY 2024. According to the applicant, the Aveir™ Dual-Chamber Leadless Pacemaker is a modular programmable system comprised of two implanted leadless pacemakers that provide dual-chamber pacing therapy: a ventricular leadless pacemaker intended for direct implantation into the right ventricle, and an atrial leadless pacemaker intended for direct implantation into the right atrium. The applicant stated that the Aveir™ Dual-Chamber Leadless Pacemaker has built-in power supply and electrodes, is designed to be retrievable by a dedicated retrieval catheter, and enables two separate pacemakers to function as one dual-chamber pacing system. The applicant stated that pacemaker implantation is generally indicated in one or more of the following permanent conditions: syncope, presyncope, fatigue, disorientation due to arrhythmia/bradycardia, or any combination of those symptoms. As discussed separately in the previous section, the applicant also submitted an application for FY 2024 new technology add-on payments for the Aveir™ AR Leadless Pacemaker, which provides atrial pacing.

Please refer to the online application posting for the Aveir™ Dual-Chamber Leadless Pacemaker, available at https://mearis.cms.gov/public/publications/ntap/NTP221017AJNQH, for additional detail describing the technology and the disease treated by the technology.

According to the applicant, the Aveir™ Dual-Chamber Leadless Pacemaker was granted Breakthrough Device designation from FDA on March 27, 2020, under the Breakthrough Device designation for the Leadless Dual Chamber System for the following proposed indication: Pacemaker implantation is indicated in one or more of the following permanent conditions: syncope, presyncope, fatigue, disorientation due to arrhythmia/bradycardia, or any combination of those symptoms. The proposed indications for use of the Leadless Dual Chamber System include all four of the following: (1) Rate-Modulated Pacing is indicated for patients with chronotropic incompetence, and for those who would benefit from increased stimulation rates concurrent with physical activity. Chronotropic incompetence has not been rigorously defined. A conservative approach, supported by the literature, defines chronotropic incompetence as the failure to achieve an intrinsic heart rate of 70 percent of the age-predicted maximum heart rate or 120 bpm during exercise testing, whichever is less, where the age-predicted heart rate is calculated as 197 – (0.56 × age); (2) Dual-Chamber Pacing is indicated for those patients exhibiting: sick sinus syndrome; chronic, symptomatic second- and third-degree AV block; recurrent Adams-Stokes syndrome; symptomatic bilateral bundle branch block when tachyarrhythmia and other causes have been ruled out; (3) Atrial Pacing is indicated for patients with: sinus node dysfunction and normal AV and intraventricular conduction systems; (4) Ventricular Pacing is indicated for patients with significant bradycardia and normal sinus rhythm with only rare episodes of AV block or
The applicant further stated that the Breakthrough Device designation applies to two clinical scenarios: a de novo system where a patient receives the Aveir™ Dual-Chamber Leadless Pacemaker, or an upgrade system where a patient already has a ventricular leadless pacemaker and is upgraded to the Aveir™ Dual-Chamber Leadless Pacemaker by receiving the Aveir™ AR Leadless Pacemaker. The applicant stated that it received FDA premarket approval for the Aveir™ Dual-Chamber Leadless Pacemaker on June 29, 2023, for the same indications.

According to the applicant, the following ICD–10–PCS procedure codes can currently be used to distinctly identify the Aveir™ Dual-Chamber Leadless Pacemaker effective beginning FY 2017: 02H63NZ (Insertion of intracardiac pacemaker into right atrium, percutaneous approach) and 02HK3NZ (Insertion of intracardiac pacemaker into right ventricle, percutaneous approach). The applicant stated that there are other systems also in development that will use this combination of ICD–10–PCS codes but that the Aveir™ Dual-Chamber Leadless Pacemaker will be the first dual chamber leadless pacemaker system on the market. The applicant also submitted a request for approval for a unique ICD–10–PCS code for the Aveir™ Dual-Chamber Leadless Pacemaker beginning in FY 2024 and was granted approval for the following procedure code combination effective October 1, 2023: X2H63V9 (Insertion of dual-chamber intracardiac pacemaker into right atrium, percutaneous approach, new technology group 9) and X2HK3V9 (Insertion of dual-chamber intracardiac pacemaker into right ventricle, percutaneous approach, new technology group). Both codes would be reported for this procedure to identify the percutaneous insertion of a dual-chamber leadless cardiac pacemaker system. The applicant stated that diagnosis code I49.9 (Cardiac arrhythmia, unspecified) may be used to currently identify the proposed indication for Aveir™ Dual-Chamber Leadless Pacemaker under the ICD–10–CM coding system.

With respect to the cost criterion, to identify potential cases representing patients who may be eligible for the Aveir™ Dual-Chamber Leadless Pacemaker, the applicant searched the FY 2021 MedPAR file for cases reporting ICD–10–PCS code 02H63NZ (Insertion of intracardiac pacemaker into right atrium, percutaneous approach) in combination with ICD–10–PCS code 02HK3NZ (Insertion of intracardiac pacemaker into right ventricle, percutaneous approach). Using the inclusion/exclusion criteria described in the following table, the applicant identified 991 claims mapping to 38 MS–DRGs. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $206,636, which exceeded the average case-weighted threshold amount of $159,357. Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount, the applicant asserted that the Aveir™ Dual-Chamber Leadless Pacemaker meets the cost criterion.

<table>
<thead>
<tr>
<th>AVEIR™ DUAL-CHAMBER LEADLESS PACEMAKER COST ANALYSIS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Data Source and Time Period</strong></td>
</tr>
<tr>
<td><strong>List of ICD-10-PCS Codes</strong></td>
</tr>
<tr>
<td><strong>List of MS-DRGs</strong></td>
</tr>
<tr>
<td><strong>Inclusion/Exclusion Criteria</strong></td>
</tr>
<tr>
<td><strong>Charges Removed for Prior Technology</strong></td>
</tr>
<tr>
<td><strong>Standardized Charges</strong></td>
</tr>
<tr>
<td><strong>Inflation Factor</strong></td>
</tr>
<tr>
<td><strong>Charges Added for the New Technology</strong></td>
</tr>
</tbody>
</table>

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26930), we stated that we have the following concern regarding the cost criterion. It was our understanding that procedure codes 02H63NZ and 02HK3NZ were approved for use in describing procedures involving intracardiac pacemakers effective beginning FY 2017. The applicant stated that there are no technologies on the market eligible to be coded with procedure code 02H63NZ as the Aveir™ AR Leadless Pacemaker will be the first atrial leadless pacemaker, if approved, and there are no dual-chamber leadless pacemakers currently available. Therefore, we were unsure why the applicant searched for cases reporting procedure code 02H63NZ within the FY 2021 MedPAR file if there should not be any technologies coded with 02H63NZ until FY 2022 (when the applicant stated clinical trials for the Aveir™ AR and Dual-Chamber Leadless Pacemaker began). We further questioned in the proposed rule which technology the cases identified in the MedPAR data represent. We questioned whether searching for cases utilizing standard...
pacing systems instead of leadless pacing systems (with relevant adjustments to remove/add charges as necessary) would better reflect the technology that the applicant anticipates Aveir™ Dual-Chamber Leadless Pacemaker will be replacing.

Subject to the applicant adequately addressing this concern, in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26930), we agreed with the applicant that the technology meets the cost criterion and therefore proposed to approve the Aveir™ Dual-Chamber Leadless Pacemaker for new technology add-on payments for FY 2024, subject to the technology receiving FDA marketing authorization as a Breakthrough Device for the indication corresponding to the Breakthrough Device designation by July 1, 2023.

The applicant had not provided an estimate for the cost of the Aveir™ Dual-Chamber Leadless Pacemaker at the time of the proposed rule. We stated in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26930) that we expected the applicant to submit cost information prior to the final rule, and that we would provide an update regarding the new technology add-on payment amount for the technology, if approved, in the final rule. We stated that any new technology add-on payment for the Aveir™ Dual-Chamber Leadless Pacemaker would be subject to our policy under § 412.88(a)(2) where we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case.

We invited public comments on whether the Aveir™ Dual-Chamber Leadless Pacemaker meets the cost criterion and our proposal to approve new technology add-on payments for the Aveir™ Dual-Chamber Leadless Pacemaker for FY 2024 subject to the technology receiving FDA marketing authorization as a Breakthrough Device for the indication corresponding to the Breakthrough Device designation by July 1, 2023.

Comment: The applicant submitted an alternate cost analysis in response to CMS’s concerns identified in the proposed rule whether cases utilizing standard double-chamber pacemakers instead of leadless pacemakers would be more representative of the discharges Aveir™ Dual-Chamber Leadless Pacemaker would be replacing. The applicant asserted that the cases selected in the updated cost analysis appropriately describe traditional transcatheter double-chamber de novo implant procedures and provide a good comparator for procedures it anticipates would be replaced with Aveir™ Dual-Chamber Leadless Pacemaker. The applicant removed 100 percent of the charges from revenue centers 0275, 0276, 0279, and 0624 from the 47,425 identified discharges to be as conservative as possible. In the updated cost analysis, because the final inflated average case-weighted standardized charge per case of $201,227 still exceeded the average case-weighted threshold amount of $115,421, the applicant asserted that Aveir™ Dual-Chamber Leadless Pacemaker meets the cost criterion.

With respect to CMS’s concern that whether cases coded with 02HK3NZ should be included in the analysis, the applicant stated that its original analysis included cases reporting 02H63NZ for purposes of completeness and in expectation that CMS would seek data on codes specific to a leadless pacemaker, notwithstanding that its specific technology was not reported until FY 2022. According to the applicant, the updated analysis used only the traditional transvenous pacemaker codes listed previously based on the CMS’s suggestion and omitted 02H63NZ.

Response: We thank the applicant for the comments and the alternate cost analysis.

Based on the information provided in the application for new technology add-on payments, and after consideration of the public comments we received, we believe Aveir™ Dual-Chamber Leadless Pacemaker meets the cost criterion. The technology received FDA premarket approval on June 29, 2023, as a Breakthrough Device, with an indication for one or more of the following permanent conditions: syncope, presyncope, fatigue, disorientation due to arrhythmia/bradycardia, or any combination of those symptoms. Therefore, we are finalizing our proposal to approve new technology add-on payments for Aveir™ Dual-Chamber Leadless Pacemaker for FY 2024. We consider the beginning of the newness period to commence on June 29, 2023, the date on which technology received FDA marketing authorization for the indication covered by its Breakthrough Device designation.

Based on the information available at the time of this final rule, the cost per case of Aveir™ Dual-Chamber Leadless Pacemaker is $24,000, including two leadless pacemakers (Aveir™ AR atrial leadless pacemaker and Aveir™ VR ventricular leadless pacemaker), two delivery catheters (one for each leadless pacemaker), and one introducer. Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, we are finalizing that the maximum new technology add-on payment for a case involving the use of Aveir™ Leadless Pacemaker is $15,600 for FY 2024 (that is, 65 percent of the average cost of the technology). Cases involving the use of Aveir™ Leadless Pacemaker that are eligible for new technology add-on payments will be identified by ICD–10–PCS procedure codes X2H63V9 (Insertion of dual-chamber intracardiac pacemaker into right atrium, percutaneous approach, new technology group 9) in combination with X2HK3V9 (Insertion of dual-chamber intracardiac pacemaker into right ventricle, percutaneous approach, new technology group). We note that both codes would be reported for this procedure to identify the percutaneous insertion of a dual-chamber leadless cardiac pacemaker system relevant for new technology add-on payments.

(3) Canary Tibial Extension (CTE) With Canary Health Implanted Reporting Processor (CHIRP) System

Zimmer Biomet submitted an application for new technology add-on payments for the Canary Tibial Extension (CTE) with Canary Health Implanted Reporting Processor (CHIRP) System for FY 2024. Per the application, the CTE with CHIRP System is a tibial extension implant containing electronics and software, used with the Zimmer Persona Personalized Knee System. According to the applicant, the CTE with CHIRP System collects kinematic data pertaining to a patient’s gait and activity level following total knee arthroplasty (TKA) surgery using internal motion sensors (3-D accelerometers and 3-D gyroscopes). Please refer to the online application posting for the CTE with CHIRP System, available at https://mearis.cms.gov/public/publications/ntap/NTP221014KYL1, for additional detail describing the technology and its intended use.

According to the applicant, the CTE with CHIRP System received Breakthrough Device designation from FDA on October 24, 2019, for the following proposed indication: for use with the Zimmer Persona Personalized Knee System (K113369) for TKA. The CTE with CHIRP System is intended to provide objective kinematic data from the implanted medical device to assist the patient and clinician during a patient’s TKA post-surgical care. The kinematic data is intended as an adjunct to standard of care and physiological parameter measurement tools applied or
utilized by the physician during the course of patient monitoring and treatment post-surgery. FDA granted De Novo classification to the CTE with CHIRP System on August 27, 2021, for the following indication: to provide objective kinematic data from the implanted medical device during a patient’s TKA post-surgical care. The kinematic data is an adjunct to other physiological parameter measurement tools applied or utilized by the physician during the course of patient monitoring and treatment post-surgery.

The device is indicated for use in patients undergoing a cemented TKA procedure that are normally indicated for at least a 58 mm sized tibial stem extension. The applicant stated that the technology was not immediately available for sale due to production delays related to COVID–19 and because of the need to negotiate data agreements with customer hospitals, but it became commercially available on October 4, 2021.

The applicant submitted a request for approval for a unique ICD–10–PCS procedure code for the CTE with CHIRP System beginning in FY 2024 and was granted approval for the following procedure code(s) effective October 1, 2023: XNHG0F9 (Insertion of tibial extension with motion sensors into right tibia, open approach, new technology group 9), or XNHH0F9 (Insertion of tibial extension with motion sensors into left tibia, open approach, new technology group 9).

With respect to the cost criterion, the applicant provided the following analysis to demonstrate that it meets the cost criterion. To identify potential cases representing patients who may be eligible for the CTE with CHIRP System, the applicant searched the FY 2021 MedPAR file for cases reporting the ICD–10–PCS codes describing cemented replacement of the knee joint with a synthetic device via an open approach, as listed in the following table. Using the inclusion/exclusion criteria described in the following table, the applicant identified 74,654 claims mapping to 60 MS–DRGs. See Table 10.5.A.—CTE with CHIRP System Codes—FY 2024 associated with the proposed rule for the complete list of MS–DRGs provided by the applicant. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $90,599, which exceeded the average case-weighted threshold amount of $84,613. Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount, the applicant asserted that the CTE with CHIRP System meets the cost criterion.

<table>
<thead>
<tr>
<th>Data Source and Time Period</th>
<th>FY 2021 MedPAR file</th>
</tr>
</thead>
<tbody>
<tr>
<td>List of ICD-10-PCS Codes</td>
<td>OSRO0F9 (Replacement of right knee joint with synthetic substitute, cemented, open approach)</td>
</tr>
<tr>
<td></td>
<td>OSRO1Z (Replacement of right knee joint with synthetic substitute, open approach)</td>
</tr>
<tr>
<td></td>
<td>OSRD0F9 (Replacement of left knee joint with synthetic substitute, cemented, open approach)</td>
</tr>
<tr>
<td></td>
<td>OSRD0Z (Replacement of left knee joint with synthetic substitute, open approach)</td>
</tr>
<tr>
<td>List of MS-DRGs</td>
<td>Please see Table 10.5.A - CTE with CHIRP System Codes - FY 2024 associated with the proposed rule for the complete list of MS-DRGs provided by the applicant.</td>
</tr>
<tr>
<td>Inclusion/Exclusion Criteria</td>
<td>The applicant identified cases reporting one of the four ICD-10-PCS procedure codes previously listed. The sample was limited to IPPS cases that would be used in rate-setting following the CMS methodology. Any MS-DRG with a total discharge count less than 11 was omitted with a count of 11. The applicant calculated the average unstandardized charge per case for each MS-DRG.</td>
</tr>
<tr>
<td>Charges Removed for Prior Technology</td>
<td>The applicant removed 25% of charges associated with Medical/Surgical Supplies and Devices (revenue centers 027X, and 0624). The applicant stated that the use of the CTE with CHIRP System is expected to replace minimal devices utilized in these cases. The applicant did not remove indirect charges related to the prior technology.</td>
</tr>
<tr>
<td>Standardized Charges</td>
<td>The applicant used the standardization formula provided in Technical Appendix A of the application. The applicant used all relevant values reported in the standardizing file posted with the FY 2021 IPPS/LTCH PPS final rule.</td>
</tr>
<tr>
<td>Inflation Factor</td>
<td>The applicant applied an inflation factor of 20.5% to the standardized charges based on the inflation factor used to calculate outlier threshold charges in the FY 2023 IPPS/LTCH PPS final rule.</td>
</tr>
<tr>
<td>Charges Added for the New Technology</td>
<td>The applicant added charges for the new technology by dividing the cost of the new technology by the national average cost-to-charge ratio of 0.281 for Implantable Devices from the FY 2023 IPPS/LTCH PPS final rule.</td>
</tr>
</tbody>
</table>

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26931), we agreed with the applicant that the technology meets the cost criterion and therefore proposed to approve the CTE with CHIRP System for new technology add-on payments for FY 2024 for the indication to provide objective kinematic data from the implanted medical device during a patient’s TKA post-surgical care. The kinematic data is an adjunct to other physiological parameter measurement tools applied or utilized by the physician during the course of patient monitoring and treatment post-surgery. The device is indicated for use in patients undergoing a cemented TKA procedure that are normally indicated for at least a 58 mm sized tibial stem extension.

Based on preliminary information from the applicant at the time of the proposed rule, the total cost of the CTE with CHIRP System to the hospital was approximately $1,654 per knee. This included $1,309 for the CTE and $345 for the Canary Medical Home Base Station. We noted that per the applicant, the Home Base Station System is intended for use in the patient’s home environment and is used to query the CTE while the patient is asleep. We further noted that the Home Base Station provided to the patient to set up and connect to their home Wi-Fi prior to surgery. We therefore stated that we believe the relevant inpatient costs for the add-on payment would include only the cost of the CTE. We noted that the cost information for this technology would be updated in the final rule based on revised or additional information CMS received prior to the final rule.

Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, we proposed that the maximum new technology add-on payment for a case involving the use of the CTE with CHIRP System would be $850.85 for one knee (or $1,701.70 for two knees) for FY 2024 (that is, 65

https://canarymedical.com/clinicians/additional-information-for-clinicians/.
percent of the average cost of the technology).

We invited public comments on whether the CTE with CHIRP System meets the cost criterion and our proposal to approve new technology add-on payments for the CTE with CHIRP System for the indication to provide objective kinematic data from the implanted medical device during a patient’s TKA post-surgical care.

Comment: The applicant submitted a comment regarding the cost of the technology relevant for add-on payments. Per the applicant, while they agreed that the home base station is used in the patient’s home, the CTE with CHIRP is a system requiring both the CTE and the home base station components for the system to function. The applicant noted that the home base station is necessary for the communication of data to an external server, is paired to only one patient (that is, it is not reusable), and though it is paid for by the facility, it becomes the property of the patient. Thus, it is not a piece of equipment, an instrument, apparatus, implement or item for which depreciation and financing expenses are recovered by the hospital. The applicant maintained that the home base station is different from the operating room base station, which they agreed is not applicable to the new technology add-on payment calculation and was not included in their application because it is given to the hospital, and remains with the hospital, to be used intraoperatively to activate the CHIRP System in multiple patients. The applicant requested that CMS recognize that the CTE with CHIRP is one system and include the $345 cost of the home base station in the new technology add-on payment calculation to bring the maximum new technology add-on payment to $1,075.10 per knee ($1,654 x 65%).

Response: We thank the applicant for its input. However, as stated in the proposed rule, we are concerned that that the Home Base Station is provided to the patient to set up and connect to their home Wi-Fi prior to surgery. The Home Base Station is not an item administered to the patient during the hospital that leaves the hospital with the patient upon discharge. While the applicant states that the Home Base Station is not a piece of equipment, an instrument, apparatus, implement or item for which depreciation and financing expenses are recovered by the hospital, we still are unclear if the Home Base Station is billable in the inpatient setting. Therefore, for this final rule we are excluding the Home Base Station from the add on payment and the relevant inpatient costs for the add-on payment would include only the cost of the CTE. We welcome additional information from the applicant in the future on whether the Home Base Station should be included in the add on payment.

Comment: Another commenter submitted a comment stating that the kinematic data generated by the CTE with CHIRP System has not demonstrated any clinical benefits or outcomes and is not intended to be utilized for clinical decision-making, and raised questions regarding how the technology would be used.

Response: We thank the commenter for its comment. We note, as discussed previously, that a technology that applies under an alternative pathway does not need to meet the requirement that it represents an advance that substantially improves, relative to technologies previously available, the diagnosis or treatment of Medicare beneficiaries. We refer the reader to the FY 2023 OPPS/LTCH PPS final rule for a discussion of the development of these alternative pathways (84 FR 42292 through 42297).

Based on the information provided in the application for new technology add-on payments, and after consideration of the public comment we received, we believe the CTE with CHIRP System meets the cost criterion. The technology received De Novo classification on August 27, 2021, as a Breakthrough Device for the following indication which is covered by its Breakthrough Device designation: to provide objective kinematic data from the implanted medical device during a patient’s total knee arthroplasty (TKA) post-surgical care. The device is indicated for use in patients undergoing a cemented TKA procedure that are normally indicated for at least a 58 mm sized tibial stem extension. Therefore, we are finalizing our proposal to approve new technology add-on payments for CTE with CHIRP for FY 2024. We consider the beginning of the newness period to commence on October 4, 2021, the date on which the technology became commercially available for the indication covered by its Breakthrough Device designation.

Based on the information available at the time of this final rule, as stated previously, the relevant inpatient costs for the add-on payment would include only the cost of the CTE. The cost per case of the CTE with CHIRP System is $1,309 per knee. Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, we are finalizing that the maximum new technology add-on payment for a case involving the use of the CTE with CHIRP System is $850.85 for one knee (or $1,701.70 for two knees) for FY 2024 (that is, 65 percent of the average cost of the technology). Cases involving the use of the CTE with CHIRP System that are eligible for new technology add-on payments will be identified by ICD–10–PCS procedure codes XNHH0D9 (Insertion of tibial extension with motion sensors into right tibia, open approach, new technology group 9) or XNHH0D9 (Insertion of tibial extension with motion sensors into left tibia, open approach, new technology group 9).

(4) Ceribell Status Epilepticus Monitor
Cerbell, Inc. submitted an application for new technology add-on payments for the Cerbell Status Epilepticus Monitor for FY 2024. According to the applicant, the Cerbell Status Epilepticus Monitor is a medical device system comprised of proprietary software and two cleared, premarketed components: a ready-to-use signal acquisition headband (the Cerbell EEG Headband) and a recorder (the Cerbell Pocket EEG). Per the applicant, the software utilizes a machine learning model to analyze EEG signals to detect features indicative of electrographic status epilepticus (ESE) to provide more effective diagnosis of ESE.


The applicant stated that the Cerbell Status Epilepticus Monitor received Breakthrough Device designation from FDA on October 25, 2022, for the following proposed indication: the Cerbell Status Epilepticus Monitor software is intended for the diagnosis of ESE in adult patients at risk for seizure. The Cerbell Status Epilepticus Monitor software analyzes EEG waveforms and identifies patterns consistent with ESE as defined in the American Clinical Neurophysiology Society’s Guideline 14. The applicant stated that the technology received 510(k) clearance from FDA on May 23, 2023, for the same indication. In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26933), we noted that the Cerbell EEG Headband and Cerbell Pocket EEG were not included on the Breakthrough Device designation, and it therefore appeared that only the software would be designated as the Breakthrough Device once market authorized, such that only the software would be eligible for new technology add-on payments under the alternative pathway. We note that the
510k clearance for the technology provided by the applicant was also for the software only.

The applicant submitted a request for approval for a unique ICD–10–PCS procedure code for the Ceribell Status Epilepticus Monitor beginning in FY 2024 and was granted approval for the following procedure code effective October 1, 2023: XX20X89 (Monitoring of brain electrical activity, computer-aided detection and notification, new technology group 9).

With respect to the cost criterion, the applicant provided multiple updated analyses to demonstrate that it meets the cost criterion. For the first two analyses, to identify potential cases representing patients who may be eligible for treatment involving the Ceribell Status Epilepticus Monitor, the applicant searched the FY 2021 MedPAR file for cases reporting charges in the revenue codes 020X (Intensive Care Unit) and 021X (Coronary Care Unit) as this is where the technology is expected to be utilized based on the expected FDA label of the technology. The first analysis used 100 percent of all cases within the revenue code categories because these cases could be monitored for Status Epilepticus, and the second analysis used 75 percent of these cases. The applicant also provided sensitivity analyses limited to cases reporting the diagnosis codes that were believed to identify cases with the highest risk of Status Epilepticus. The third analysis used 100 percent of these cases and the fourth analysis used 75 percent of these cases. The applicant followed the order of operations described in the following table.

Under the first analysis (100 percent of all cases within the revenue code categories), the applicant identified 2,985,030 claims mapping to 754 MS–DRGs (see Table 10.7.A.—Ceribell Status Epilepticus Monitor Codes (Analyses 1–2)—FY 2024 associated with the proposed rule for a complete list of MS–DRGs provided by the applicant) and calculated a final inflated average case-weighted standardized charge per case of $114,238, which exceeded the average case-weighted threshold amount of $85,765.

Under the second analysis (75 percent of all cases within the revenue code categories), the applicant identified 2,243,140 claims mapping to 92 MS–DRGs (see Table 10.7.B.—Ceribell Status Epilepticus Monitor Codes (Analyses 1–2)—FY 2024 associated with the proposed rule for a complete list of MS–DRGs provided by the applicant) and calculated a final inflated average case-weighted standardized charge per case of $110,949, which exceeded the average case-weighted threshold amount of $85,280.

Under the third analysis, in addition to searching for cases reporting charges in the two revenue code categories listed previously, the applicant limited the cases by selecting claims reporting diagnosis codes that it believed reflected the cases for patients age 65 or older with the highest risk of Status Epilepticus (see Table 10.7.B.—Ceribell Status Epilepticus Monitor Codes (Analyses 3–4)—FY 2024 associated with the proposed rule for a complete list of MS–DRGs provided by the applicant) and calculated a final inflated average case-weighted standardized charge per case of $127,942, which exceeded the average case-weighted threshold amount of $89,219.

Under the fourth analysis, using 75 percent of all cases reporting the diagnosis codes used in scenario 3, the applicant identified 734,908 claims mapping to 59 MS–DRGs (see Table 10.7.B.—Ceribell Status Epilepticus Monitor Codes (Analyses 3–4)—FY 2024 associated with the proposed rule for a complete list of MS–DRGs provided by the applicant) and calculated a final inflated average case-weighted standardized charge per case of $123,446, which exceeded the average case-weighted threshold amount of $88,063.

Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount in all scenarios, the applicant asserted that the Ceribell Status Epilepticus Monitor meets the cost criterion.
In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26934), we agreed that the technology meets the cost criterion and therefore proposed to approve the Ceribell Status Epilepticus Monitor for new technology add-on payments for FY 2024 subject to the technology receiving FDA marketing authorization as a Breakthrough Device for the indication corresponding to the Breakthrough Device designation by July 1, 2023.

Based on preliminary information from the applicant at the time of the proposed rule, the applicant anticipated the total cost of the Ceribell Status Epilepticus Monitor to the hospital to be $2,600 per patient (comprised of $1,800 for the software and $800 for the required headband). We stated in the proposed rule, however, that as discussed previously, it seemed that only the software would be eligible for the new technology add-on payment under the alternative pathway as it was the subject of the Breakthrough Device designation. We further noted that the Ceribell EEG headband appeared to have been 510(k)-cleared by FDA since August 2017 and was therefore no longer new. Therefore, it appeared any add-on payment for the Ceribell Status Epilepticus Monitor would include only the cost of the software ($1,800). We welcomed comment on including only the cost of the software in determining the add-on payment amount for the Ceribell Status Epilepticus Monitor. We noted that the cost information for this technology may be updated in the final rule based on revised or additional information CMS received prior to the final rule. Under §412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, we proposed that the maximum new technology add-on payment for a case involving the use of the Ceribell Status Epilepticus Monitor would be $1,170 ($1,800 × 0.65) for FY 2024 (that is, 65 percent of the average cost of the technology for the software).

We invited public comments on whether the Ceribell Status Epilepticus Monitor meets the cost criterion and our proposal to approve new technology add-on payments for the Ceribell Status Epilepticus Monitor for FY 2024 for the diagnosis of ESE in adult patients at risk for status epilepticus.

Comment: The applicant submitted a comment and a revised cost analysis. In its comment, the applicant noted that they have updated their pricing structure to commercialize the Status Epilepticus Monitor software through a subscription-based pricing model. Under this model, a hospital will pay a fixed monthly subscription fee for use of the software that allows the hospital to utilize the technology without limitations on volume. Per the applicant, their rationale for charging hospitals a monthly subscription fee is based on prior experience using a similar charge structure for launching their current EEG technology in 2020. The applicant noted that because they anticipated a lot of overlap in the use of their current EEG technology and the anticipated use of the Status Epilepticus Monitor, they plan to also commercialize the Status Epilepticus Monitor using a subscription-based pricing model. According to the applicant, their rationale for charging hospitals a monthly subscription fee is based on prior experience using a similar charge structure for launching their current EEG technology in 2020. The applicant noted that because they anticipated a lot of overlap in the use of their current EEG technology and the anticipated use of the Status Epilepticus Monitor, they plan to also commercialize the Status Epilepticus Monitor through a subscription-based pricing model. According to the applicant, their rationale for charging hospitals a monthly subscription fee is based on prior experience using a similar charge structure for launching their current EEG technology in 2020. The applicant noted that because they anticipated a lot of overlap in the use of their current EEG technology and the anticipated use of the Status Epilepticus Monitor, they plan to also commercialize the Status Epilepticus Monitor through a subscription-based pricing model.
the projected monthly subscription cost. According to the applicant, it arrived at an estimated annual utilization of the Status Epilepticus Monitor per hospital based on the median annual utilization of their customers’ existing EEG system over the three-year timeframe of 2020, 2021, and 2022. This resulted in a per case charge of $1,406 (instead of $1,800 in the proposed rule); the cost of the headband was unchanged at $800. Thus, the updated per patient cost is $2,206, per the applicant.

Using the new per patient cost, the applicant updated its cost analyses. According to the applicant, the updated analysis was consistent with what they had provided in the past, with the cost per patient as the only change. In their revised first analysis, in which the applicant used 100 percent of all cases within the revenue code categories, the final inflated average case-weighted standardized charge per case was $113,082, which exceeded the average cost-weighted threshold amount of $85,765. In the revised second analysis, the applicant used 75 percent of all cases within the revenue code categories, the final inflated average case-weighted standardized charge per case was $109,784, which exceeded the average case-weighted threshold amount of $85,280. In the revised third analyses, in which the applicant provided sensitivity analyses limited to 100 percent of all the cases with the highest risk of Status Epilepticus, the inflated average case-weighted standardized charge per case was $125,611, which exceeded the average case-weighted threshold amount of $88,778. In their revised fourth analysis, in which the applicant provided sensitivity analyses limited to 75 percent of all the cases with the highest risk of Status Epilepticus, the final inflated average case-weighted standardized charge per case was $121,188, which exceeded the average case-weighted threshold amount of $87,583. Per the applicant, all the revised cost analyses have demonstrated that the technology still meets cost criterion.

Response: We thank the applicant for their comments. We note that, under the eligibility criteria for approval under the alternative pathway for certain transformative new devices, only the use of the Ceribell Status Epilepticus Monitor software is relevant for purposes of the new technology add-on payment application for FY 2024. Since only the software was designated as a Breakthrough Device by FDA, the Ceribell EEG Headband is not eligible to be included in the Ceribell Status Epilepticus Monitor software.

Based on the information provided in the application for new technology add-on payments, and after consideration of the public comments we received, we believe the Ceribell Status Epilepticus Monitor meets the cost criterion. The Ceribell Status Epilepticus Monitor System received 510(k) clearance from FDA on May 23, 2023, for the diagnosis of Electrogrographic Status Epilepticus in adult patients at risk for seizure, which is covered by its Breakthrough Device designation. We consider the beginning of the newness period to commence on May 23, 2023, the date on which Ceribell Status Epilepticus Monitor was 510(k)—cleared by FDA for the indication covered in its Breakthrough Device designation.

As noted earlier, the applicant updated their pricing structure to commercialize the Status Epilepticus Monitor software through a subscription-based pricing model. Based on the information available at the time of this final rule, the cost per case of the Ceribell Status Epilepticus Monitor (using the per discharge amount based on a subscription-based pricing model) is $1,406, based on the cost per patient of the software only. Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the new technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, we are finalizing that the maximum new technology add-on payment for a case involving the use of the Ceribell Status Epilepticus Monitor is $913.90 for FY 2024 (that is, 65 percent of the average cost of the technology). Cases involving the use of the Ceribell Status Epilepticus Monitor that are eligible for new technology add-on payments will be identified by ICD–10–PCS procedure code XX20X89 (Monitoring of brain electrical activity, computer-aided detection and notification, new technology group 9).

(5) DETOUR System

Endologix, Inc., submitted an application for new technology add-on payments for the DETOUR System for FY 2024. According to the applicant, the DETOUR System is a percutaneous approach to femoral-popliteal bypass. Per the applicant, under fluoroscopic guidance, a proprietary TORUS Stent Graft System is deployed from the popliteal artery into the femoral vein, and from the femoral vein into the superficial femoral artery (SFA) in a continuous, overlapping fashion through two independent anastomoses. The applicant stated that the intended result is a large lumen endograft bypass, that delivers unobstructed, pulsatile flow from the SFA ostium to the popliteal artery.

Please refer to the online application posting for the DETOUR System, available at https://mearis.cms.gov/public/publications/ntap/NTP2210149Y5M6, for additional detail describing the technology and the disease treated by the technology.

According to the applicant, the DETOUR System received Breakthrough Device designation from FDA on September 2, 2020, for percutaneous revascularization of symptomatic femoropopliteal lesions 200mm to 460mm with a chronic total occlusion 100mm to 425mm, and/or moderate-to-severe calcification, and/or in-stent-restenosis in patients with severe peripheral arterial disease. The applicant received FDA premarket approval on June 7, 2023, for the same indication. According to the applicant, the device became available on the market immediately upon FDA approval.

The applicant submitted a request for approval for a unique ICD–10–PCS procedure code for DETOUR System beginning in FY 2024 and was granted.
approval for the following procedure codes effective October 1, 2023: X2KH3D9 (Bypass right femoral artery using conduit through femoral vein to superficial femoral artery, percutaneous approach, new technology group 9), X2KH3E9 (Bypass right femoral artery using conduit through femoral vein to popliteal artery, percutaneous approach, new technology group 9), X2KJ3D9 (Bypass left femoral artery using conduit through femoral vein to superficial femoral artery, percutaneous approach, new technology group 9), or X2KJ3E9 (Bypass left femoral artery using conduit through femoral vein to popliteal artery, percutaneous approach, new technology group 9). Per the applicant, diagnosis codes 170.92 (Chronic total occlusion of artery of the extremities), 170.2XX (Atherosclerosis of native arteries of the extremities), and 173.9 (Peripheral vascular disease, unspecified) may be used to currently identify the indication for the DETOUR System under the ICD–10–CM system.

With respect to the cost criterion, the applicant provided two analyses to demonstrate that it meets the cost criterion. For both analyses, the applicant searched the FY 2021 MedPAR file for potential cases representing patients who may be eligible for the DETOUR System femoral-popliteal bypass procedures using either a synthetic substitute or an autologous venous tissue graft. Under the first analysis, the applicant searched the FY 2021 MedPAR file for cases reporting one of the ICD–10–PCS codes listed in the following table and included 100 percent of the cases identified. Using the inclusion/exclusion criteria described in the following table, the applicant identified 3,110 cases mapping to 63 MS–DRGs. Please see Table 10.25.A.—The DETOUR System Codes—FY 2024 associated with the proposed rule for the complete list of MS–DRGs that the applicant indicated were included in its cost analysis. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $146,323, which exceeded the average case-weighted threshold amount of $106,123.

Under the second analysis, the applicant searched the FY 2021 MedPAR file for cases reporting one of the ICD–10–PCS codes listed in the table that follows and included 67.3 percent of the cases identified. Using the inclusion/exclusion criteria described in the following table, the applicant limited the search to the top three MS–DRGs as listed in the table and identified 2,094 cases. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $111,332, which exceeded the average case-weighted threshold amount of $96,526. Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount in both analyses, the applicant asserted that the DETOUR System meets the cost criterion.

<table>
<thead>
<tr>
<th>Data Source and Time Period</th>
<th>FY 2021 MedPAR File</th>
</tr>
</thead>
<tbody>
<tr>
<td>List of ICD-10-PCS Codes</td>
<td></td>
</tr>
<tr>
<td>04IK09L (Bypass right femoral artery to popliteal artery with autologous venous tissue, open approach)</td>
<td></td>
</tr>
<tr>
<td>041H09L (Bypass left femoral artery to popliteal artery with autologous venous tissue, open approach)</td>
<td></td>
</tr>
<tr>
<td>04IK3JQ (Bypass right femoral artery to lower extremity artery with synthetic substitute, percutaneous approach)</td>
<td></td>
</tr>
<tr>
<td>041H3JQ (Bypass left femoral artery to lower extremity artery with synthetic substitute, percutaneous approach)</td>
<td></td>
</tr>
<tr>
<td>List of MS-DRGs</td>
<td>Scenario 1: Please see Table 10.25.A. - The DETOUR System Codes - FY 2024 associated with the proposed rule for the complete list of MS-DRGs included in the cost analysis. Scenario 2: The applicant also identified the three MS-DRGs with the highest volume of cases: 252 (Other vascular procedures with MCC), 253 (Other vascular procedures with CC), and 254 (Other vascular procedures without CC/MCC)</td>
</tr>
<tr>
<td>Inclusion/Exclusion Criteria</td>
<td>Scenario 1: 100% of cases reporting the previously listed ICD-10-PCS codes. Any MS-DRG with a total discharge count less than 11 was imputed with a count of 11. Scenario 2: 67.3% of cases reporting the previously listed ICD-10-PCS codes.</td>
</tr>
<tr>
<td>The applicant limited the cases in both analyses to IPPS cases that would be used in ratesetting following the CMS methodology.</td>
<td></td>
</tr>
<tr>
<td>Charges Removed for Prior Technology</td>
<td>To provide a conservative estimate of the charges, the applicant removed 100% of charges associated with Medical/Surgical Supplies and Devices (revenue centers 027x, and 0624).</td>
</tr>
<tr>
<td>Standardized Charges</td>
<td>The applicant used the standardization formula provided in Technical Appendix A of the application. The applicant used all relevant values reported in the standardizing file posted with the FY 2021 IPPS/LTCH PPS correction notice.</td>
</tr>
<tr>
<td>Inflation Factor</td>
<td>The applicant applied an inflation factor of 20.4686% to the standardized charges based on the inflation factor used to calculate outlier threshold charges in the FY 2023 IPPS final rule.</td>
</tr>
<tr>
<td>Charges Added for the New Technology</td>
<td>The applicant stated that the average sales price of the technology has yet to be determined, and that when the price is available, a revised cost analysis will be provided that includes estimated hospital charges for the technology.</td>
</tr>
</tbody>
</table>

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26950), we agreed with the applicant that the DETOUR System meets the cost criterion and proposed to approve the DETOUR System for new technology add-on payments for FY 2024, subject to the technology receiving FDA marketing authorization as a Breakthrough Device for the indication corresponding to the Breakthrough Device designation by July 1, 2023. We stated in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26950) that we expected the applicant to submit cost information prior to the final rule, and we would provide an update regarding the new technology add-on payment amount for the technology, if approved, in the final rule. Any new technology add-on payment for the DETOUR System would be subject to our policy under §412.88(a)(2) where we limit new technology add-on payments to the lesser of 65 percent of
the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case.

We invited public comments on whether the DETOUR System meets the cost criterion and our proposal to approve new technology add-on payments for the DETOUR System for FY 2024 subject to the technology receiving FDA marketing authorization as a Breakthrough Device for the indication corresponding to the Breakthrough Device designation by July 1, 2023.

Comment: We received a comment from the applicant in support of CMS's proposal to approve the technology for new technology add-on payments. The applicant stated that the DETOUR System provides a transformative approach for the treatment of individuals with complex peripheral artery disease (PAD) through a novel, minimally invasive procedure referred to as percutaneous transmural arterial bypass (PTAB). We thank the commenter for its support.

Based on the information provided in the application for new technology add-on payments, we believe the DETOUR System meets the cost criterion. The technology received FDA marketing authorization on June 7, 2023, as a Breakthrough Device with an indication for percutaneous revascularization of symptomatic femoropopliteal lesions 200mm to 460mm with a chronic total occlusion 100mm to 425mm, and/or moderate-to-severe calcification, and/or in-stent-restenosis in patients with severe peripheral arterial disease, which is covered by its Breakthrough Device designation. Therefore, we are finalizing our proposal to approve new technology add-on payments for the DETOUR System for FY 2024. We consider the beginning of the newness period to commence on June 7, 2023, the date on which the technology became commercially available for the indication covered by its Breakthrough Device designation.

Based on the information available at the time of this final rule, the cost per case of the DETOUR System is $25,000 for the single-use system comprised of the TORUS Stent Graft(s) and the ENDOCROSS device. Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, we are finalizing that the maximum new technology add-on payment for a case involving the use of the DETOUR System is 65 percent of $16,250 for FY 2024 (that is, 65 percent of the average cost of the technology). Cases involving the use of the DETOUR System that are eligible for new technology add-on payments will be identified by one of the following ICD–10–PCS procedure codes: X2KH3D9 (Bypass right femoral artery using conduit through femoral vein to superficial femoral artery, percutaneous approach, new technology group 9), X2K3E9 (Bypass right femoral artery using conduit through femoral vein to popliteal artery, percutaneous approach, new technology group 9), X2K3D9 (Bypass left femoral artery using conduit through femoral vein to superficial femoral artery, percutaneous approach, new technology group 9), or X2K3E9 (Bypass left femoral artery using conduit through femoral vein to popliteal artery, percutaneous approach, new technology group 9).

(6) EchoGo Heart Failure 1.0

Ultromics Limited submitted an application for EchoGo Heart Failure 1.0 for FY 2024. Based on the information included in the application, EchoGo Heart Failure 1.0 is an automated machine learning-based decision support system, indicated as a diagnostic aid for patients undergoing routine functional cardiovascular assessment using echocardiography. Per the applicant, when utilized by an interpreting physician, this device provides information that may be useful in detecting heart failure with preserved ejection fraction (HFpEF).

Please refer to the online application posting for EchoGo Heart Failure 1.0, available at https://mearis.cms.gov/public/publications/ntap/NTP210172L1H4N, for additional detail describing the technology and the medical condition the technology is intended for.

According to the applicant, EchoGo Heart Failure 1.0 received Breakthrough Device designation from FDA on February 24, 2022, as an automated machine learning-based decision support system, indicated as a diagnostic aid for patients undergoing routine functional cardiovascular assessment using echocardiography. When utilized by an interpreting clinician, this device provides information that may be useful in detecting heart failure with preserved ejection fraction (HFpEF). EchoGo Heart Failure 1.0 is indicated in adult populations over 25 years of age. Patient management decisions should not be made solely on the results of the EchoGo Heart Failure 1.0 analysis.

EchoGo Heart Failure 1.0 takes as input an apical 4-chamber view of the heart that has been captured and assessed to have an ejection fraction 25 percent.

The applicant received FDA 510(k) clearance on November 23, 2022, for the same indication.

The applicant submitted a request for approval for a unique ICD–10–PCS procedure code for EchoGo Heart Failure 1.0 beginning in FY 2024 and was granted approval for the following procedure code effective October 1, 2023: XXE2X19 (Measurement of cardiac output, computer-aided assessment, new technology group 9).

The applicant provided a list of diagnosis codes that may be used to currently identify the indication for EchoGo Heart Failure 1.0 under the ICD–10–CM coding system. Please refer to the online application posting for the complete list of ICD–10–CM codes provided by the applicant.

With respect to the cost criterion, the applicant provided multiple analyses to demonstrate that it meets the cost criterion. For each analysis, the applicant searched the FY 2021 MedPAR file using a combination of MS–DRGs and ICD–10–CM codes to identify potential cases representing patients who may be eligible for EchoGo Heart Failure 1.0. The applicant explained that it ran eight additional simulations as a sensitivity analysis, in which the applicant used combinations of MS–DRGs and/or ICD–10–CM codes to identify potential cases. Each analysis followed the order of operations described in the following table.

For the first analysis, the applicant searched for specific ICD–10–CM codes in the primary diagnosis position mapped to specific MS–DRGs representing patients likely to undergo routine functional cardiovascular assessment using echocardiography and likely to use EchoGo Heart Failure 1.0 to detect HFpEF. Please see Table 10.12.A.—EchoGo Heart Failure 1.0 Codes (Analyses 1–5)—FY 2024 associated with the proposed rule for the complete list of ICD–10–CM codes and MS–DRGs that the applicant indicated were included in its cost analysis. Using the inclusion/exclusion criteria described in the following table, the applicant identified 407,813 claims mapping to 17 MS–DRGs. The applicant calculated a final inflated average case-weighted standardized charge per case of $66,144, which exceeded the average case-weighted threshold amount of $52,548.

For the second analysis, the applicant searched for cases that had a primary diagnosis from the applicant’s ICD–10–CM list, in any MS–DRG. Please see Table 10.12.A.—EchoGo Heart Failure 1.0 Codes (Analyses 1–5)—FY 2024 associated with the proposed rule for the complete lists of ICD–10–CM codes.
and MS–DRGs that the applicant indicated were included in its cost analysis 2. The applicant used the inclusion/exclusion criteria described in the following table. Under this analysis, the applicant identified 497,879 claims mapping to 92 MS–DRGs. The applicant calculated a final inflated average case-weighted standardized charge per case of $72,813. The applicant's ICD–10–CM codes list, in any MS–DRG. Please see Table 10.12.A.—EchoGo Heart Failure 1.0 Codes (Analyses 1–5)–FY 2024 associated with the proposed rule for the complete list of ICD–10–CM codes and MS–DRGs that the applicant indicated were included in its cost analysis 2. The applicant used the inclusion/exclusion criteria described in the following table. Under this analysis, the applicant identified 2,277,736 claims mapping to 746 MS–DRGs, with none exceeding more than 15 percent of the total identified cases. The applicant calculated a final inflated average case-weighted standardized charge per case of $107,796, which exceeded the average case-weighted threshold amount of $76,632.

For the fifth analysis, the applicant searched for any case with a primary or secondary diagnosis from the applicant's ICD–10–CM codes list, in any MS–DRG. Please see Table 10.12.A.—EchoGo Heart Failure 1.0 Codes (Analyses 1–5)–FY 2024 associated with the proposed rule for the complete list of ICD–10–CM codes and MS–DRGs that the applicant indicated were included in its cost analysis 5. The applicant used the inclusion/exclusion criteria described in the following table. Under this analysis, the applicant identified 244,399 claims mapping to 20 MS–DRGs. The applicant calculated a final inflated average case-weighted standardized charge per case of $69,126, which exceeded the average case-weighted threshold amount of $54,038.

For the fourth analysis, the applicant searched for any Medicare fee-for-service (FFS) case with an admitting diagnosis from the applicant's ICD–10–CM codes list, in any MS–DRG. Please see Table 10.12.A.—EchoGo Heart Failure 1.0 Codes (Analyses 1–5)–FY 2024 associated with the proposed rule for the complete lists of ICD–10–CM codes and MS–DRGs that the applicant indicated were included in its cost analysis 4. The applicant used the inclusion/exclusion criteria described in the following table. Under this analysis, the applicant identified 267,378 claims mapping to 493 MS–DRGs. The applicant calculated a final inflated average case-weighted standardized charge per case of $97,027, which exceeded the average case-weighted threshold amount of $72,813.

For the fifth analysis, the applicant searched for any case with a primary or secondary diagnosis from the applicant's ICD–10–CM codes list, in any MS–DRG. Please see Table 10.12.A.—EchoGo Heart Failure 1.0 Codes (Analyses 1–5)–FY 2024 associated with the proposed rule for the complete list of ICD–10–CM codes and MS–DRGs that the applicant indicated were included in its cost analysis 5. The applicant used the inclusion/exclusion criteria described in the following table. Under this analysis, the applicant identified 2,277,736 claims mapping to 746 MS–DRGs, with none exceeding more than 15 percent of the total identified cases. The applicant calculated a final inflated average case-weighted standardized charge per case of $107,796, which exceeded the average case-weighted threshold amount of $76,632.

According to the applicant, the ICD–10–CM codes for systolic HF were included in the initial cost criterion analysis as the provider may not know if the patient has either systolic or diastolic HF unless the provider has ordered an echo and subsequently EchoGo Heart Failure 1.0. Symptoms are often identical, and systolic HF is defined by low ejection fraction which the applicant stated is an incredibly variable measurement. In addition, in acute decompensated HF, these patients can present as HFpEF and transition to systolic HF or vice versa within a single inpatient stay. As such, the applicant asserted that ordering EchoGo Heart Failure 1.0 would be appropriate. To understand the impact of removing the cases where the only inclusion criteria met was one of the ICD–10–CM codes for systolic HF, the applicant conducted additional analyses six through nine, removing ICD–10–CM codes for systolic heart failure: I50.20 (Unspecified systolic (congestive) heart failure), I50.21 (Acute systolic (congestive) heart failure), I50.22 (Chronic systolic (congestive) heart failure), and I50.23 (Acute on chronic systolic (congestive) heart failure). Please see Table 10.12.B.—EchoGo Heart Failure 1.0 Codes (Analyses 6–9)–FY 2024 associated with the proposed rule for the complete list of ICD–10–CM codes and MS–DRGs that the applicant indicated were included in its cost analyses 6–9. Inclusion/exclusion criteria for analyses six through nine are detailed in the table that follows.

The sixth analysis mirrored the first analysis, except that cases with ICD–10–CM systolic heart failure codes were excluded. Under this analysis, the applicant identified 398,398 claims mapping to 17 MS–DRGs. The applicant calculated a final inflated average case-weighted standardized charge per case of $66,245, which exceeded the average case-weighted threshold amount of $52,651.

The seventh analysis mirrored the second analysis, except that cases with systolic heart failure ICD–10–CM codes were excluded. Under this analysis, the applicant identified 485,027 claims mapping to 92 MS–DRGs. The applicant calculated a final inflated average case-weighted standardized charge per case of $88,149, which exceeded the average case-weighted threshold amount of $66,991.

The eighth analysis mirrored the fourth analysis, except that cases with ICD–10–CM systolic heart failure codes were excluded. Under this analysis, the applicant identified 244,399 claims mapping to 491 MS–DRGs. The applicant calculated a final inflated average case-weighted standardized charge per case of $97,453, which exceeded the average case-weighted threshold amount of $72,735.

The ninth analysis mirrored the fifth analysis, except that cases with ICD–10–CM systolic heart failure codes were excluded. Under this analysis, the applicant identified 2,214,393 claims mapping to 746 MS–DRGs. The applicant calculated a final inflated average case-weighted standardized charge per case of $107,201, which exceeded the average case-weighted threshold amount of $76,389.

Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount in all scenarios, the applicant asserted that the EchoGo Heart Failure 1.0 meets the cost criterion.

BILLING CODE 4120–01–P
<table>
<thead>
<tr>
<th>Data Source and Time Period</th>
<th>FY 2021 MedPAR file</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analysis 1-5: Please see Table 10.12.A. - EchoGo Heart Failure 1.0 Codes (Analyses 1-5) – FY 2024 associated with the proposed rule for the complete list of codes that the applicant indicated were included in its cost analyses 1-5.</td>
<td></td>
</tr>
<tr>
<td>Analysis 6-9: Please see Table 10.12.B. EchoGo Heart Failure 1.0 Codes (Analyses 6-9) – FY 2024 associated with the proposed rule for the complete lists of codes that the applicant indicated were included in its cost analyses 6-9.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>List of ICD-10-CM Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>The ICD-10-CM code list for analyses 6-9 mirrors the list for analysis 1-5, but with the exclusion of the following systolic ICD-10-CM codes: 150.20 (Unspecified systolic (congestive) heart failure); 150.21 (Acute systolic (congestive) heart failure); 150.22 (Chronic systolic (congestive) heart failure); and 150.23 (Acute on chronic systolic (congestive) heart failure).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>List of MS-DRG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analyses 1 and 3 searched the applicant’s predetermined list of MS-DRGs, while analysis 2, 4, and 5 resulted in lists of MS-DRGs based on the search of ICD-10-CM codes. Please see Table 10.12.A. - EchoGo Heart Failure 1.0 Codes (Analyses 1-5) – FY 2024 associated with the proposed rule for the complete lists of MS-DRGs that the applicant indicated were included in its cost analyses 1-5.</td>
</tr>
<tr>
<td>Analysis 6 searched the applicant’s predetermined list of MS-DRGs, while analysis 7, 8, and 9 resulted in lists of MS-DRGs. Please see Table 10.12.B. - EchoGo Heart Failure 1.0 Codes (Analyses 6-9) – FY 2024 associated with the proposed rule for the complete lists of MS-DRGs that the applicant indicated were included in its cost analyses 6-9.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Inclusion/Exclusion Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analysis 1: The applicant identified cases by using any ICD-10-CM code listed in Table 10.12.A. - EchoGo Heart Failure 1.0 Codes (Analyses 1-5) – FY 2024 associated with the proposed rule in the primary diagnosis position, and a MS-DRG from the applicant’s predetermined MS-DRG list, which can also be found in the same table.</td>
</tr>
<tr>
<td>Analysis 2: The applicant identified cases using any ICD-10-CM code listed in Table 10.12.A. - EchoGo Heart Failure 1.0 Codes (Analyses 1-5) – FY 2024 associated with the proposed rule in the primary diagnosis position, in any MS-DRG.</td>
</tr>
<tr>
<td>Analysis 3: The applicant identified all cases in any of the applicant’s predetermined MS-DRGs listed in Table 10.12.A. - EchoGo Heart Failure 1.0 Codes (Analyses 1-5) – FY 2024 associated with the proposed rule.</td>
</tr>
<tr>
<td>Analysis 4: The applicant identified any case with an admitting diagnosis from the ICD-10-CM list in Table 10.12.A. - EchoGo Heart Failure 1.0 Codes (Analyses 1-5) – FY 2024 associated with the proposed rule, in any MS-DRG.</td>
</tr>
<tr>
<td>Analysis 5: The applicant identified any cases with a primary or secondary diagnosis from the ICD-10-CM codes listed in Table 10.12.A. - EchoGo Heart Failure 1.0 Codes (Analyses 1-5) – FY 2024 associated with the proposed rule, in any MS-DRG.</td>
</tr>
<tr>
<td>Analysis 6: The applicant used the same inclusion/exclusion criteria from Analysis 1, but with ICD-10-CM systolic heart failure codes excluded from the list of ICD-10-CM codes used for analyses 1-5.</td>
</tr>
<tr>
<td>Analysis 7: The applicant used the same inclusion/exclusion criteria from Analysis 2, but with ICD-10-CM systolic heart failure codes excluded from the list of ICD-10-CM codes used for analyses 1-5.</td>
</tr>
<tr>
<td>Analysis 8: The applicant used the same inclusion/exclusion criteria from Analysis 4, but with ICD-10-CM systolic heart failure codes excluded from the list of ICD-10-CM codes used for analyses 1-5.</td>
</tr>
<tr>
<td>Analysis 9: The applicant used the same inclusion/exclusion criteria from Analysis 5, but with ICD-10-CM systolic heart failure codes excluded from the list of ICD-10-CM codes used for analyses 1-5.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Charges Removed for Prior Technology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per the applicant, EchoGo Heart Failure 1.0 is not expected to replace prior technologies or replace the costs associated with prior technologies. Therefore, no costs associated with prior technologies were removed.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Standardized Charges</th>
</tr>
</thead>
<tbody>
<tr>
<td>The applicant used the standardization formula provided in Technical Appendix A of the application. The applicant used all relevant values reported in the standardizing file posted with the FY 2023 IPPS/LTCH PPS final rule.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Inflation Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>The applicant applied an inflation factor of 20.4686% to the standardized charges, which is based on the inflation factor used to calculate outlier threshold charges in the FY 2023 IPPS/LTCH PPS final rule.</td>
</tr>
</tbody>
</table>
In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26937), we agreed with the applicant that EchoGo Heart Failure 1.0 meets the cost criterion and therefore proposed to approve EchoGo Heart Failure 1.0 for new technology add-on payments for FY 2024.

Based on preliminary information from the applicant at the time of the proposed rule, the applicant’s anticipated cost per patient for EchoGo Heart Failure 1.0 was $1,575. According to the applicant, the EchoGo Heart Failure 1.0 is charged on a per patient basis with no monthly subscription to the hospital. We noted that the cost information for this technology may be updated in the final rule based on revised or additional information CMS received prior to the final rule. Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, we proposed that the maximum new technology add-on payment for a case involving the use of EchoGo Heart Failure 1.0 would be $1,023.75 for FY 2024 (that is, 65 percent of the average cost of the technology).

We invited public comments on whether EchoGo Heart Failure 1.0 meets the cost criterion and our proposal to approve new technology add-on payments for EchoGo Heart Failure 1.0 for FY 2024 for the indication as an automated machine learning-based decision support system, indicated as a diagnostic aid for patients undergoing routine functional cardiovascular assessment using echocardiography.

According to the applicant, the Phagenyx® System for FY 2022 and 2023, as summarized in the FY 2022 and 2023 IPPS/LTCH PPS proposed rules (86 FR 25382 through 25384 and 87 FR 28342 through 28344), but the technology did not meet the deadline of July 1, 2021/2022 for FDA approval or clearance of the technology and, therefore, was not eligible for consideration for new technology add-on payments for the FY 2022 or 2023 IPPS/LTCH PPS final rules (86 FR 45126 through 45127 and 87 FR 48780).

Please refer to the online application posting for the Phagenyx® System, available at https://mearis.cms.gov/public/publications/ntap/NTP221013D2MDC, for additional detail describing the technology and the disorder treated by the technology.

According to the applicant, the Phagenyx® System was granted De Novo Classification from FDA on September 16, 2022, as a neuromusculoskeletal device delivering electrical stimulation to the oropharynx, to be used in addition to standard dysphagia care, as an aid to improve swallowing in patients with severe dysphagia post stroke. In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26943) we noted that since the indication for which the applicant received 510(k) clearance is included within the scope of the Breakthrough Device designation, and FDA considers this marketing authorization to be the Breakthrough Device, it appears that the 510(k) indication is appropriate for consideration for new technology add-on payment under the alternative pathway criteria.

According to the applicant, Phagenesis Ltd is based in Manchester,
United Kingdom and currently setting up business operations infrastructure to commercially market and sell Phagenyx. This includes but is not limited to establishing an importing agent, third party warehousing and logistics, tax IDs in all states, a corporate office, and hiring staff. The applicant stated that for these reasons, April 1, 2023, was the expected commercial availability date for the Phagenyx® System.

The applicant stated that, effective October 1, 2021, the ICD–10–PCS code XWHD7Q7 (Insertion of neurostimulator lead into mouth and pharynx, via natural or artificial opening, new technology group 7) may be used to uniquely describe procedures involving the use of the Phagenyx® System. The applicant provided a list of diagnosis codes that may be used to currently identify the indication for the Phagenyx® System under the ICD–10–CM coding system. Please refer to the online application posting for the complete list of ICD–10–CM codes provided by the applicant.

With respect to the cost criterion, the applicant searched the FY 2021 MedPAR file for potential cases representing patients who may be eligible for the Phagenyx® System to demonstrate that it meets the cost criterion. The applicant searched for cases reporting a combination of the ICD–10–CM codes that may be used to currently identify the indication for the Phagenyx® System under the ICD–10–CM coding systems. Please see the following table for the complete list of ICD–10–CM codes provided by the applicant. Using the inclusion/exclusion criteria described in the following table, the applicant identified 79,056 claims mapping to 551 MS–DRGs (see Table 10.16.A.—Phagenyx® System Codes—FY 2024 associated with the proposed rule for a list of MS–DRGs that the applicant indicated were included in its cost analysis). The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $130,440, which exceeded the average case-weighted threshold amount of $82,183. Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount, the applicant asserted that the Phagenyx® System meets the cost criterion.

<table>
<thead>
<tr>
<th>Data Source and Time Period</th>
<th>FY 2021 MedPAR File</th>
</tr>
</thead>
<tbody>
<tr>
<td>List of ICD-10-CM Codes</td>
<td></td>
</tr>
<tr>
<td>ICD-10-CM codes for dysphagia:</td>
<td>R13.10 (Dysphagia unspecified)</td>
</tr>
<tr>
<td></td>
<td>R13.12 (Dysphagia oropharyngeal phase)</td>
</tr>
<tr>
<td></td>
<td>R13.13 (Dysphagia pharyngeal phase)</td>
</tr>
<tr>
<td></td>
<td>R13.14 (Dysphagia pharyngoesophageal phase)</td>
</tr>
<tr>
<td></td>
<td>R13.19 (Other dysphagia)</td>
</tr>
<tr>
<td>ICD-10-CM codes for stroke:</td>
<td>I60x (Nontraumatic subarachnoid hemorrhage)</td>
</tr>
<tr>
<td></td>
<td>I61x (Nontraumatic intracerebral hemorrhage)</td>
</tr>
<tr>
<td></td>
<td>I62x (Other and unspecified nontraumatic intracranial hemorrhage)</td>
</tr>
<tr>
<td></td>
<td>I63x (Cerebral infarction)</td>
</tr>
<tr>
<td>Dysphagia sequela codes:</td>
<td>I69.091 (Dysphagia following nontraumatic subarachnoid hemorrhage)</td>
</tr>
<tr>
<td></td>
<td>I69.191 (Dysphagia following nontraumatic intracerebral hemorrhage)</td>
</tr>
<tr>
<td></td>
<td>I69.291 (Dysphagia following other nontraumatic intracranial hemorrhage)</td>
</tr>
<tr>
<td></td>
<td>I69.391 (Dysphagia following cerebral infarction)</td>
</tr>
<tr>
<td>List of MS-DRGs</td>
<td>See Table 10.16.A. - Phagenyx® System Codes – FY 2024 associated with the proposed rule for a list of the MS-DRGs that the applicant indicated were included in its cost analysis.</td>
</tr>
</tbody>
</table>

**Phagenyx® System COST ANALYSIS**

**Inclusion/Exclusion Criteria**

Using the ICD-10-CM codes listed in this table, the applicant identified all discharges with any of the ICD-10-CM codes for dysphagia and an ICD-10-CM code for stroke. In addition to cases identified with both a dysphagia code and a stroke code, the applicant included discharges with one of the four dysphagia sequela codes. The applicant included only inpatient discharges paid as fee-for-service claim type “60.” Medicare Advantage discharges were excluded. The applicant excluded discharges where the MedPAR “GHO Paid” indicator field on the claim record is equal to “1” or when the MedPAR DRG payment field, which represents the total payment for the claim, is equal to the MedPAR “Indirect Medical Education (IME)” payment field. The applicant used MS-DRG grouper version 40 to identify the MS-DRG distribution. The applicant excluded cases where a standardized charge could not be calculated.

**Charges Removed for Prior Technology**

The applicant stated that the Phagenyx® System does not replace any prior technologies, and therefore they did not remove any prior or related technology charges.

**Standardized Charges**

The applicant used the standardization formula provided in Technical Appendix A of the application. The applicant used all relevant values reported in the impact file posted with the FY 2021 IPPS/LTCPPS correction notice.

**Inflation Factor**

The applicant applied the 3-year rate of inflation factor of 20.4686% to the standardized charges based on the inflation factor used to calculate outlier threshold charges in the FY 2023 IPPS/LTCPPS final rule.

**Charges Added for the New Technology**

The applicant added charges for the new technology by dividing the cost of the new technology’s single use, per patient catheter ($5,000) by the national average cost-to-charge ratio of 0.311 for supplies & equipment from the FY 2023 IPPS/LTCPPS final rule. The applicant did not add indirect charges related to the new technology.
In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26944), we agreed with the applicant that the Phagenyx® System meets the cost criterion and therefore proposed to approve the Phagenyx® System for new technology add-on payments for FY 2024.

Based on preliminary information from the applicant at the time of the proposed rule, the applicant anticipated the cost to the hospital for the Phagenyx® System to be $5,000, which is the price of the single use, per patient catheter. We noted that the cost information for this technology may be updated in the final rule based on revised or additional information CMS receives prior to the final rule. Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case.

As a result, we proposed that the maximum new technology add-on payment for a case involving the use of the Phagenyx® System would be $3,250 for FY 2024 (that is, 65 percent of the average cost of the technology). We invited public comments on whether the Phagenyx® System meets the cost criterion and our proposal to approve new technology add-on payments for the Phagenyx® System for FY 2024 as a neurostimulation device delivering electrical stimulation to the oropharynx, to be used in addition to standard dysphagia care, as an aid to improve swallowing in patients with severe dysphagia post stroke, which corresponds to the Breakthrough Device designation. Therefore, we are finalizing our proposal to approve new technology add-on payments for the Phagenyx® System for FY 2024. We consider the beginning of the newness period to commence on April 12, 2023, the date that the technology became commercially available for the indication covered by its Breakthrough Device designation.

Based on the information available at the time of this final rule, the cost per case of the Phagenyx® System is $5,000. Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, we are finalizing that the maximum new technology add-on payment for a case involving the use of the Phagenyx® System is $3,250 for FY 2024 (that is, 65 percent of the average cost of the technology). Cases involving the use of the Phagenyx® System that are eligible for new technology add-on payments will be identified by ICD–10–PCS procedure code XWHD7Q7 (Insertion of neurostimulator lead into mouth and pharynx, via natural or artificial opening, new technology group 7).

(8) SAINT Neuromodulation System

Magnus Medical, Inc. submitted an application for new technology add-on payments for the SAINT Neuromodulation System for FY 2023. We consider the beginning of the newness period to commence on April 12, 2023, the date that the technology became commercially available for the indication covered by its Breakthrough Device designation.

Comment: The applicant submitted a public comment expressing support for the approval of the Phagenyx® System for the new technology add-on payment for FY 2024. The applicant reiterated that the Phagenyx® System meets the cost criterion and confirmed the proposed cost of the Phagenyx® System. The applicant also restated that the ICD–10–PCS code XWHD7Q7 (Insertion of neurostimulator lead into mouth and pharynx, via natural or artificial opening, new technology group 7) must be used to appropriately describe the procedure. The applicant provided an update on the availability of the device, stating the actual commercial availability of the device was established when FDA cleared the product from U.S. customs on April 12, 2023.

Response: Based on the information provided in the application for new technology add-on payments, and after considering public comments we received, we believe the Phagenyx® System meets the cost criterion. The technology was granted FDA marketing authorization on September 16, 2022, as a Breakthrough Device with an indication as a neurostimulation device delivering electrical stimulation to the oropharynx, to be used in addition to standard dysphagia care, as an aid to improve swallowing in patients with severe dysphagia post stroke, which corresponds to the Breakthrough Device designation. Therefore, we are finalizing our proposal to approve new technology add-on payments for the Phagenyx® System for FY 2024. We consider the beginning of the newness period to commence on April 12, 2023, the date that the technology became commercially available for the indication covered by its Breakthrough Device designation.

The technology is covered when the SAINT Neuromodulation System is used to deliver SAINT Therapy to a targeted area within the left dorsolateral prefrontal cortex (L–DLPFC) to treat Major Depressive Disorder (MDD) in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. According to the applicant, the Magnus Neuromodulation System (SAINT Neuromodulation System) received 510(k) clearance from FDA on September 1, 2022, for the treatment of MDD in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. According to the applicant, the Magnus Neuromodulation System (SAINT Neuromodulation System) is the price of the single use, per patient catheter. We noted that the cost information for this technology may be updated in the final rule based on revised or additional information CMS receives prior to the final rule. Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, we are finalizing that the maximum new technology add-on payment for a case involving the use of the Phagenyx® System is $3,250 for FY 2024 (that is, 65 percent of the average cost of the technology). Cases involving the use of the Phagenyx® System that are eligible for new technology add-on payments will be identified by ICD–10–PCS procedure code XWHD7Q7 (Insertion of neurostimulator lead into mouth and pharynx, via natural or artificial opening, new technology group 7).
transcranial magnetic stimulation of prefrontal cortex, new technology group 8) may be used to uniquely describe procedures involving the use of the SAINT Neuromodulation System, effective October 1, 2022. The applicant stated that ICD–10–CM codes F32.2 (Major depressive disorder, single episode, severe without psychotic features) and F33.2 (Major depressive disorder, recurrent severe without psychotic features) may be used to currently identify the indication for the SAINT Neuromodulation System under the ICD–10–CM coding system.

With respect to the cost criterion, the applicant provided the following analysis to demonstrate that it meets the cost criterion. To identify potential cases representing patients who may be eligible for the SAINT Neuromodulation System, the applicant searched the FY 2021 MedPAR file for cases reporting one of the following ICD–10–CM codes: F32.2 (Major depressive disorder, single episode, severe without psychotic features) and F33.2 (Major depressive disorder, recurrent severe without psychotic features). Only MS–DRG 885 (Psychoses) had significant volume; all other MS–DRGs accounted for 1 percent or less of cases by volume. Using the inclusion/exclusion criteria described in the following table, the applicant identified 19,181 claims mapping to MS–DRG 885 (Psychoses). The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $94,697, which exceeded the average case-weighted threshold amount of $39,071. Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount, the applicant asserted that the SAINT Neuromodulation System meets the cost criterion.

<table>
<thead>
<tr>
<th>Data Source and Time Period</th>
<th>FY 2021 MedPAR file</th>
</tr>
</thead>
<tbody>
<tr>
<td>List of ICD-10-CM Codes</td>
<td>F32.2 (Major depressive disorder, single episode, severe without psychotic features) and F33.2 (Major depressive disorder, recurrent severe without psychotic features)</td>
</tr>
<tr>
<td>List of MS-DRGs</td>
<td>MS-DRG 885 (Psychoses)</td>
</tr>
<tr>
<td>Inclusion/Exclusion Criteria</td>
<td>The applicant searched for cases with ICD-10-CM diagnosis code F32.2 (Major depressive disorder, single episode, severe without psychotic features) or F33.2 (Major depressive disorder, recurrent severe without psychotic features). Only approved charges were used in the calculation of charges. Hospitals were removed from the calculation of charges if they were identified within the MedPAR data but not present within the FY 2023 Standardizing File provided by CMS.</td>
</tr>
<tr>
<td>Charges Removed for Prior Technology</td>
<td>The applicant stated that there are no charges for the prior technology, or the technology being replaced as analogous technologies are currently performed almost exclusively on an outpatient basis. Similarly, the applicant did not remove indirect charges related to the prior technology.</td>
</tr>
<tr>
<td>Standardized Charges</td>
<td>The applicant used the standardization formula provided in Technical Appendix A of the application. The applicant used all relevant values reported in the standardizing and impact files posted with the FY 2023 IPPS/LTCH PPS final rule and/or correction notice.</td>
</tr>
<tr>
<td>Inflation Factor</td>
<td>The applicant applied an inflation factor of 20.47% to the standardized charges, based on the inflation factor used to calculate outlier threshold charges in the FY 2023 IPPS final rule.</td>
</tr>
<tr>
<td>Charges Added for the New Technology</td>
<td>The applicant added charges for the new technology by dividing the $19,500.00 cost of the new technology by the national average cost-to-charge ratio of 0.359 for the Other Services from the FY 2023 IPPS/LTCH PPS final rule. The applicant did not add indirect charges related to the new technology.</td>
</tr>
</tbody>
</table>

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26946), we agreed with the applicant that SAINT Neuromodulation System meets the cost criterion and therefore proposed to approve SAINT Neuromodulation System for new technology add-on payments for FY 2024 for the treatment of MDD in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

Based on preliminary information from the applicant at the time of the proposed rule, the applicant anticipated the total cost of the SAINT Neuromodulation System to the hospital to be $19,500.00 per patient, including personalized target identification using the SAINT software, neuro-navigation, and treatment for 50 sessions over 5 days. We noted that the cost information for this technology may be updated in the final rule based on revised or additional information CMS receives prior to the final rule. Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, we proposed that the maximum new technology add-on payment for a case involving the use of the SAINT Neuromodulation System would be $12,675.00 for FY 2024 (that is, 65 percent of the average cost of the technology).

We invited public comments on whether the SAINT Neuromodulation System meets the cost criterion and our proposal to approve new technology add-on payments for the SAINT Neuromodulation System for FY 2024 for the treatment of MDD in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode, which corresponds to the Breakthrough Device designation. Comment: Several commenters expressed support for our proposal to approve new technology add-on payments for the SAINT Neuromodulation System. Many commenters shared anecdotal experiences with transcranial magnetic stimulation (TMS) and advocated for implementing the SAINT Neuromodulation System in the inpatient setting. Some commenters emphasized the importance of the inpatient schedule of treatment. Many commenters stated that this technology will not be available to Medicare patients without a new technology add-on payment. There were a multitude of comments directly from people who participated in trials of the SAINT...
Neuromodulation System who were supportive of CMS’s proposal to approve new technology add-on payments and attributed significant and remarkable relief from depression resulting from use of the SAINT Neuromodulation System.

Response: We thank the commenters for their support and feedback.

Comment: Several commenters asserted that the SAINT Neuromodulation System meets the cost criterion and supported the applicant’s use of MS–DRG 885 (Psychoses), and ICD–10–CM codes F32.2 (Major depressive disorder, single episode, severe without psychotic features) and F33.2 (Major depressive disorder, recurrent severe without psychotic features) in their analyses.

Response: We thank the commenters for their input.

Comment: A couple of commenters urged CMS to consider a higher reimbursement rate than what was proposed, noting that neuro-navigated TMS costs significantly more in the outpatient setting, than that of the SAINT Neuromodulation System’s $19,500 inpatient technology cost.

Comment: Several commenters noted that patients could resort to hospitalization to save on procedure costs, as a result. The commenters advocated for an increased rate of payment.

Response: It is unclear what the commenters are referring to by advocating for an increased rate of payment. The cost of the technology of $19,500 is based on information directly from the manufacturer. While the commenter may have concerns with regard to reimbursement in the outpatient setting, we believe the information for the cost per case of the SAINT Neuromodulation System in this final rule for the inpatient setting is accurate for the purposes of new technology add-on payments. We also rely on clinicians to determine whether to treat a patient in the inpatient or outpatient setting.

Comment: The applicant submitted a public comment in support of our proposal to approve new technology add-on payments for FY 2024 for the SAINT Neuromodulation System. The applicant reiterated that the SAINT Neuromodulation System meets the cost criterion, and reaffirmed the selection of codes and the MS–DRG used in the cost analysis, as discussed in the proposed rule. The applicant confirmed the proposed cost of the SAINT Neuromodulation System to the hospital of $19,500.00 per patient, including personalized target identification using the SAINT software, neuro-navigation, and treatment for 50 sessions over 5 days. The applicant also stated that they will commercially launch the SAINT Neuromodulation System, which is the subject of the Breakthrough Device designation (BDD) and is currently cleared by the FDA (510k number K220177, obtained September 1, 2022), on April 15, 2024. The applicant explained that the interval between the 510(k) clearance and the April 2024 launch date represents the time necessary to manufacture an adequate supply of SAINT Neuromodulation Systems and prepare for commercial launch. The applicant also stated that the company is also continuing to develop future versions of the technology but intends that any future modifications to the hardware system will be substantially equivalent to the hardware components in the current system, and that no changes to the BDD SAINT treatment are contemplated.

Response: We thank the applicant for this information and support to approve new technology add-on payments for the SAINT Neuromodulation System. As we have in prior rulemaking (86 FR 45132; 77 FR 53348), generally, our policy is to begin the newness period on the date of FDA approval or clearance or, if later, the date of availability of the product on the U.S. market. The applicant states that the SAINT Neuromodulation System will be commercially available on April 15, 2024, but it is unclear whether the technology would be available for sale, prior to that date. At this time, we cannot determine a definitive, future newness date based on a documented delay in the technology’s availability on the U.S. market. Absent additional information, we therefore consider the newness date for this technology to be September 1, 2022. We welcome updates from the applicant once the technology becomes commercially available for future rulemaking.

Comment: A comment was submitted on behalf of the applicant, Magnus Medical, stating that if the manufacturer makes changes to the SAINT Hardware System to integrate certain components but retains the same indication for use and intended patient population, the new version will continue to be recognized under the SAINT Neuromodulation System’s existing Breakthrough Device designation (BDD). The commenter further requested general confirmation that new technology add-on payment eligibility for devices qualified under the alternative pathway for transformative new devices will continue to apply to a future iteration of the device as long as: (1) FDA determines the device versions to be substantially equivalent via the 510(k) review and clearance process; and (2) the new version continues to meet the requirements of the new technology add-on payment program (for example, the indication for the new 510(k) is the indication covered by the Breakthrough Device designation).

Response: We thank the commenter for its comment. As discussed previously, eligible devices under the alternative pathway for Breakthrough Devices are devices that are designated and market authorized by FDA as a Breakthrough Device for the indication covered by the Breakthrough Device designation. We understand that Magnus has outreached FDA on whether a subsequent cleared version of a device would still be considered a Breakthrough Device. We appreciate updates as they become available.

Based on the information provided in the application for new technology add-on payments, and after consideration of the public comments we received, we believe the SAINT Neuromodulation System meets the cost criterion. The technology was granted FDA marketing authorization on September 1, 2022, as a Breakthrough Device for the treatment of MDD in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. Therefore, we are finalizing our proposal to approve new technology add-on payments for the SAINT Neuromodulation System for FY 2024. Absent additional information from the applicant, we consider the beginning of the newness period to commence on September 1, 2022, the date of FDA marketing authorization for the indication covered by its Breakthrough Device designation.

Based on the information available at the time of this final rule, the cost per case of the SAINT Neuromodulation System is $19,500.00. Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, we are finalizing that the maximum new technology add-on payment for a case involving the use of the SAINT Neuromodulation System is $12,675.00 for FY 2024 (that is, 65 percent of the average cost of the technology). Cases involving the use of the SAINT Neuromodulation System that are eligible for new technology add-on payments will be identified by ICD–10–PCS procedure code X020X18 (Computer-assisted transcranial magnetic stimulation of prefrontal cortex, new technology group 8).
(9) **TOPSTM System**

Premia Spine, Inc. submitted an application for new technology add-on payments for the TOPSTM System for FY 2024. According to the applicant, the TOPSTM System is a motion preserving device inserted and affixed during spinal surgery to allow for controlled decompression to preserve normal spinal motion and provide stabilization of the lumbar intervertebral segment. The applicant stated that the TOPSTM System replaces anatomical structures, such as the lamina and the facet joints, which are removed during spinal decompression treatment to alleviate pain. We note that Premia Spine, Inc. submitted an application for new technology add-on payments for the TOPSTM System for FY 2023, as summarized in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28346), that it withdrew prior to the issuance of the FY 2023 IPPS/LTCH PPS final rule (87 FR 48960).


According to the applicant, the TOPSTM System received Breakthrough Device designation from FDA on October 26, 2020, for patients between 35 and 80 years of age suffering from degenerative spondylolisthesis up to Grade I with moderate to severe lumbar spinal stenosis and either the thickening of the ligamentum flavum or scarring of the facet joint capsule at one level from L2 to L5. The applicant stated that it was seeking premarket approval from FDA for the following indication: for patients between the ages 35 and 80 years suffering from degenerative spondylolisthesis up to Grade I with moderate to severe lumbar spinal stenosis and either the thickening of the ligamentum flavum or scarring facet joint capsule at one level from L2 to L5. We noted in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26950) that the proposed premarket approval indication did not include limitation to neurogenic claudication as noted in the Breakthrough Device designation. We noted that, as previously stated, under the alternative pathway for certain transformative devices, only the use of the technology for the indication that corresponds to the technology’s Breakthrough Device designation would be eligible for the new technology add-on payment for FY 2024. The applicant subsequently received premarket approval from FDA on June 15, 2023, for patients between 35 and 80 years of age with symptomatic degenerative spondylolisthesis up to Grade I, with moderate to severe lumbar spinal stenosis and either the thickening of the ligamentum flavum and/or scarring of the facet joint capsule at one level from L3 to L5.

The applicant stated that effective October 1, 2021, the following ICD–10–PCS procedure code may be used to uniquely describe procedures involving the use of TOPSTM System: XRHB018 (Insertion of posterior spinal motion preservation device into lumbar vertebral joint, open approach, new technology group 8). The applicant stated that ICD–10–CM codes M43.16 (Spondylolisthesis, lumbar region), M48.061 (Spinal stenosis, lumbar region, without neurogenic claudication) and M48.062 (Spinal stenosis, lumbar region, with neurogenic claudication) may be used to currently identify the indication for the TOPSTM System under the ICD–10–CM coding system. We noted that ICD–10–CM code M48.061 was not relevant for identification of the indication under Breakthrough Device designation.

With respect to the cost criterion, the applicant provided the following analysis to demonstrate that it meets the cost criterion. To identify potential cases representing patients who may be eligible for the TOPSTM System, the applicant searched the FY 2021 MedPAR file for cases reporting one of the ICD–10–PCS codes listed in table 10.2.A.—TOPSTM System Codes—FY 2024 associated with the proposed rule. Using the inclusion/exclusion criteria described in the following table, the applicant identified 669 claims mapping to MS–DRG 518. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $175,574, which exceeded the average case-weighted threshold amount of $123,029. Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount, the applicant asserted that the TOPSTM System meets the cost criterion.
In the FY 2024 IPPS/LTC PPS proposed rule (88 FR 26951), we agreed with the applicant that the TOPSTM System meets the cost criterion and therefore proposed to approve the TOPSTM System for new technology add-on payments for FY 2024, subject to the technology receiving FDA marketing authorization as a Breakthrough Device for the indication corresponding to the Breakthrough Device designation by July 1, 2023.

Based on preliminary information from the applicant at the time of the proposed rule, the applicant anticipated the total cost of the TOPSTM System to the hospital to be $17,500 for a single level construct. Per the applicant, as the TOPSTM System is anticipated to only be implanted at one level, the per-patient anticipated cost to the hospital is $17,500. We noted that the cost information for this technology may be updated in the final rule based on revised or additional information CMS receives prior to the final rule. Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS–DRG payment for the case. As a result, we will not replace all devices, nor any medical supplies required to perform the procedure. However, an estimate of the percentage of these total charges for devices that would have been replaced could not be determined. To be as conservative as possible, the analysis removed 100% of charges associated with Medical/Surgical Supplies and Devices (revenue centers 027x, and 0624). According to the applicant, the financial impact of utilizing the TOPSTM System on hospital resources compared to prior technologies is minimal. The applicant did not remove indirect charges related to the prior technology.

We invited public comments on whether the TOPSTM System meets the cost criterion and our proposal to approve new technology add-on payments for the TOPSTM System for FY 2024 subject to the technology receiving FDA marketing authorization as a Breakthrough Device for the indication corresponding to the Breakthrough Device designation by July 1, 2023.

We did not receive any comments on the TOPSTM System. Based on the information provided in the application for new technology add-on payments, we believe the TOPSTM System meets the cost criterion. The technology received FDA premarket approval on June 15, 2023 as a Breakthrough Device, with an indication for patients between 35 and 80 years of age with symptomatic degenerative spondylolisthesis up to Grade I, with moderate to severe lumbar spinal stenosis and either the thickening of the ligamentum flavum and/or scarring of the facet joint capsule at one level from L3 to L5, which is covered by its Breakthrough Device designation. Therefore, we are finalizing our proposal to approve new technology add-on payments for the TOPSTM System for FY 2024.

We consider the beginning of the newness period to commence on June 15, 2023, the date on which technology received FDA marketing authorization for the indication covered by its Breakthrough Device designation. We note that, under the eligibility criteria for approval under the alternative pathway for certain transformative new devices, only the use of TOPSTM for patients suffering from neurogenic claudication resulting from degenerative spondylolisthesis, and the FDA Breakthrough Device designation it received for that use, are relevant for purposes of the new technology add-on payment application for FY 2024. Since the Breakthrough Device designation is limited to patients with neurogenic claudication specifically, as opposed to the PMA indication for patients with symptomatic disease, only use of the technology for patients with neurogenic claudication is relevant for new technology add-on payment purposes.

Based on the information available at the time of this final rule, the cost per case of the TOPSTM System is $17,500 for a single level construct. Per the applicant, as the TOPSTM System is anticipated to only be implanted at one level, the per-patient anticipated cost to the hospital is $17,500. As a result, we are finalizing that the maximum new technology add-on payment for a case involving the use of the TOPSTM System is $11,375 for FY 2024 (that is, 65 percent of the average cost of the technology).
vertebral joint, open approach, new technology group 8) in combination with ICD–10–CM code M48.062 (Spinal stenosis, lumbar region, with neurogenic claudication).

b. Alternative Pathways for Qualified Infectious Disease Products (QIDPs)

(1) taurolidine/heparin

CorMedix Inc. submitted an application for new technology add-on payments for taurolidine/heparin for FY 2024. Per the applicant, taurolidine/heparin is a proprietary formulation of taurolidine, a thiadiazinane antimicrobial, and heparin, an anticoagulant, that is under development for use as catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections (CRBSI) from in-dwelling catheters in patients undergoing hemodialysis (HD) through a central venous catheter (CVC). We note that CorMedix Inc. submitted an application for new technology add-on payments for taurolidine/heparin for FY 2023 under the name DefenCath™ and received conditional approval for new technology add-on payments for FY 2023, subject to DefenCath™ receiving FDA marketing authorization before July 1, 2023. (87 FR 48978 through 48982). In the proposed rule, we explained that if DefenCath™ receives FDA marketing authorization before July 1, 2023, the new technology add-on payment for cases involving the use of this technology would be made effective for discharges beginning in the first quarter after FDA marketing authorization is granted. We stated that if the FDA marketing authorization is received on or after July 1, 2023, no new technology add-on payments would be made for cases involving the use of DefenCath™ for FY 2023. We noted that the applicant stated that it submitted this second new technology add-on payment application for FY 2024 in the event it does not obtain FDA approval prior to July 1, 2023. We further noted that in the event DefenCath™ does receive FDA marketing authorization before July 1, 2023, evaluation of this FY 2024 application would no longer be necessary, and we would propose to instead continue the new technology add-on payment for DefenCath™ for FY 2024. We note that DefenCath™ did not receive FDA marketing authorization by July 1, 2023, and therefore no add-on payments will be made for this technology for FY 2023, and we are instead making a determination regarding this application for FY 2024.

Please refer to the online application posting for taurolidine/heparin, available at https://mearis.cms.gov/public/publications/ntap/NTP221014U889C, for additional detail describing the technology and the disease treated by the technology.

According to the applicant, taurolidine/heparin received QIDP designation from FDA in 2015 for the prevention of CRBSI in patients with end-stage renal disease (ESRD) receiving HD through a CVC and has been granted FDA Fast Track status. The applicant indicated that it was pursuing an NDA under FDA’s LPAD for the same indication. The applicant noted that FDA issued a Complete Response Letter, and the NDA is pending resubmission.

The applicant stated that effective October 1, 2022, the following ICD–10–PCS code may be used to uniquely describe procedures involving the use of taurolidine/heparin: XY0YX28 (Extracorporeal introduction of taurolidine anti-infective and heparin anticoagulant, new technology group 8).

With respect to the cost criterion, the applicant provided two analyses to demonstrate that it meets the cost criterion. For each analysis, the applicant searched the FY 2021 MedPAR file using a different combination of codes to identify potential cases representing patients who may be eligible for taurolidine/heparin.

Per the applicant, taurolidine/heparin will be used for patients receiving HD through a CVC. The applicant stated that coding to identify this population is difficult because the available CVC codes only describe the insertion of a CVC. The applicant asserted that it is not possible to identify in the MedPAR file those patients who had previously received a CVC and are now hospitalized and receiving HD. Therefore, the applicant developed two sets of selection criteria. Analysis A searched for claims with presence of a diagnosis code for ESRD, chronic kidney disease (CKD), AKI, or ATN in combination with diagnosis and procedure codes for HD. Analysis B searched for claims with presence of a diagnosis code for ESRD, CKD, AKI, or ATN with codes for both HD (diagnosis and procedure codes) and CVC (procedure codes). The applicant explained that Analysis A overstates the population of patients eligible for taurolidine/heparin because it includes any patient receiving HD, regardless of whether a central venous catheter is used. The applicant further explained that Analysis B undercounts the potential cases because CVC codes are not always available on inpatient claims. Please see Table 10.10.A Taurolidine/Heparin Codes—FY 2024 associated with the proposed rule for a complete list of ICD–10–CM and ICD–10–PCS codes provided by the applicant.

Under Analysis A, using the inclusion/exclusion criteria described in the following table, the applicant identified 412,436 claims mapping to 494 MS–DRGs. Please see Table 10.10.A.—Taurolidine/Heparin Codes—FY 2024 associated with the proposed rule for a complete list of MS–DRGs provided by the applicant. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $313,587, which exceeded the average case-weighted threshold amount of $141,035.

Under Analysis B, using the inclusion/exclusion criteria described in the following table, the applicant identified 66,861 claims mapping to 410 MS–DRGs. Please see Table 10.10.A.—Taurolidine/Heparin Codes—FY 2024 associated with the proposed rule for a complete list of MS–DRGs provided by the applicant. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $230,720, which exceeded the average case-weighted threshold amount of $201,755.

Because the final inflated average case-weighted standardized charge per case exceeded the average case-weighted threshold amount in all scenarios, the applicant asserted that taurolidine/heparin meets the cost criterion.
In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26957), we agreed with the applicant that taurolidine/heparin meets the cost criterion based on the analysis presented. We also welcomed additional information on using additional codes and/or criteria to better target cases of taurolidine/heparin for the cost criterion.

We stated that therefore, if taurolidine/heparin does not receive FDA approval by July 1, 2023, to receive new technology add-on payments beginning with FY 2023, per § 412.87(e)(3), we proposed to conditionally approve taurolidine/heparin for new technology add-on payments for FY 2024, subject to the technology receiving FDA marketing authorization by July 1, 2024. If taurolidine/heparin receives FDA marketing authorization before July 1, 2024, the new technology add-on payment for cases involving the use of this technology would be made effective in the first quarter after FDA marketing authorization is granted. If FDA marketing authorization is received on or after July 1, 2024, no new technology add-on payments will be made for cases involving the use of taurolidine/heparin for FY 2024. If taurolidine/heparin receives FDA marketing authorization prior to July 1, 2023, we proposed to continue making new technology add-on payments for taurolidine/heparin in FY 2024.

Based on preliminary information from the applicant at the time of the proposed rule, the applicant stated the Wholesale Acquisition Cost of taurolidine/heparin is $1,170 per three milliliter vial taurolidine/heparin. The cost for one vial of taurolidine/heparin (one vial for each lumen) will be used for each HD session and that while HD typically occurs three times/week for patients in the outpatient setting, inpatients may receive HD daily or every other day, depending on the severity of their disease. According to the applicant, on average, patients would receive 9.75 HD treatments per inpatient stay based upon the average length of stay of 13.3 days, which would require 19.5 vials of taurolidine/heparin. Thus, the applicant anticipated the cost of taurolidine/heparin to the hospital per patient to be $22,815. We stated in the FY 2024 IPPS/LTCH PPS proposed rule that we were interested in additional information as to how the length of stay for patients on HD and the estimation of daily or every other day dialysis were determined for purposes of estimating the anticipated average cost. We also noted that the cost information for this technology may be updated in the final rule based on revised or additional information CMS receives prior to the final rule. Under § 412.88(a)(2), we limit new technology add-on payments for QIDPs to the lesser of 75 percent of the average cost of the technology, or 75 percent of the costs in excess of the MS–DRG payment for the case. As a result, we proposed that the maximum new technology add-on payment for a case involving the use of taurolidine/heparin for FY 2024 would be $17,111.25 (that is, 75 percent of the average cost of the technology).

We invited public comments on whether taurolidine/heparin meets the cost criterion and our proposal to approve new technology add-on payments for taurolidine/heparin for FY 2024 for the prevention of CRBSI in patients with ESRD receiving HD through a CVC.

Comment: A commenter submitted a comment in support of the implementation of add-on payments for taurolidine/heparin for the treatment of CRBSI from in-dwelling catheters in ESRD patients undergoing HD through a CVC as well CMS’s proposal for conditional approval.

Response: We thank the commenter for its support.

<table>
<thead>
<tr>
<th>Data Source and Time Period</th>
<th>FY 2021 MedPAR File</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICD-10-CM Codes</td>
<td>Analysis A and B</td>
</tr>
<tr>
<td></td>
<td>N17.0 Acute kidney failure with tubular necrosis</td>
</tr>
<tr>
<td></td>
<td>N17.9 Acute kidney failure, unspecified</td>
</tr>
<tr>
<td></td>
<td>N18.1 Chronic kidney disease, stage 1</td>
</tr>
<tr>
<td></td>
<td>N18.2 Chronic kidney disease, stage 2 (mild)</td>
</tr>
<tr>
<td></td>
<td>N18.30 Chronic kidney disease, stage 3 unspecified</td>
</tr>
<tr>
<td></td>
<td>N18.31 Chronic kidney disease, stage 3a</td>
</tr>
<tr>
<td></td>
<td>N18.32 Chronic kidney disease, stage 3b</td>
</tr>
<tr>
<td></td>
<td>N18.4 Chronic kidney disease, stage 4</td>
</tr>
<tr>
<td></td>
<td>N18.5 Chronic kidney disease, stage 5</td>
</tr>
<tr>
<td></td>
<td>N18.6 End stage renal disease</td>
</tr>
<tr>
<td></td>
<td>N18.9 Chronic kidney disease, unspecified</td>
</tr>
<tr>
<td>ICD-10-PCS Codes</td>
<td>Analysis A and B; Please see Table 10.10.A - Taurolidine/Heparin Codes - FY 2024 associated with the proposed rule for a complete list of ICD-10-PCS codes included in the cost analysis.</td>
</tr>
<tr>
<td>List of MS-DRGs</td>
<td>Analysis A and B; Please see Table 10.10.A - Taurolidine/Heparin Codes - FY 2024 associated with the proposed rule for a complete list of MS-DRGs included in the cost analysis.</td>
</tr>
<tr>
<td>Inclusion/Exclusion Criteria</td>
<td>The applicant stated that it imputed a case count of 11 to any MS-DRG with fewer than 11 cases. Data were trimmed to include only claims that would be used for Medicare IPPS rate setting (fee-for-service IPPS discharges, plus Maryland hospital discharges).</td>
</tr>
<tr>
<td>Charges Removed for Prior Technology</td>
<td>The applicant stated that taurolidine/heparin does not replace any prior technologies, and therefore they did not remove any prior or related technology charges.</td>
</tr>
<tr>
<td>Standardized Charges</td>
<td>The applicant used the standardization formula provided in Technical Appendix A of the application. The applicant used all relevant values reported in the impact file posted with the FY 2023 IPPS/LTCH PPS final rule.</td>
</tr>
<tr>
<td>Inflation Factor</td>
<td>The applicant applied the 2-year inflation factor of 13.2% to the standardized charges (to inflate the data from 2021 to 2024), based on the inflation factor used to calculate outlier threshold charges in the FY 2023 IPPS/LTCH PPS final rule.</td>
</tr>
<tr>
<td>Charges Added for the New Technology</td>
<td>The applicant stated that the average per patient cost of the taurolidine/heparin to the hospital will be $22,815. The applicant added charges for the new technology by dividing the cost of the new technology by the national average cost-to-charge ratio (CCR) of 0.184 for drugs from the FY 2023 IPPS/LTCH PPS final rule. The applicant did not add indirect charges related to the new technology.</td>
</tr>
</tbody>
</table>
Based on the information provided in the application for new technology add-on payments, and after consideration of the public comment we received, we believe taurolidine/heparin meets the cost criterion. Therefore, we are granting conditional approval for taurolidine/heparin for new technology add-on payments for FY 2024, subject to the technology receiving FDA marketing authorization by July 1, 2024 (that is, by July 1 of the fiscal year for which the applicant applied for new technology add-on payments (2024)). In the proposed rule we stated that as an application submitted under the alternative pathway for certain antimicrobial products at § 412.87(d), taurolidine/heparin is eligible for conditional approval for new technology add-on payments if it does not receive FDA marketing authorization by the July 1 deadline specified in § 412.87(e)(2), provided that the technology receives FDA marketing authorization by July 1 of the particular fiscal year for which the applicant applied for new technology add-on payments (that is, July 1, 2024) (88 FR 26956 to 26957). If taurolidine/heparin receives FDA marketing authorization before July 1, 2024, the new technology add-on payment for cases involving the use of this technology would be made effective for discharges beginning in the first quarter after FDA marketing authorization is granted. If FDA marketing authorization is received on or after July 1, 2024, no new technology add-on payments will be made for cases involving the use of taurolidine/heparin for FY 2024.

Based on the information available at the time of this final rule, the cost per case of taurolidine/heparin is $22,815. Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 75 percent of the average cost of the technology, or 75 percent of the costs in excess of the MS–DRG payment for the case. As a result, we are finalizing that the maximum new technology add-on payment for a case involving the use of taurolidine/heparin is $17,111.25 for FY 2024 (that is, 75 percent of the average case-weighted cost of the technology). Cases involving the use of taurolidine/heparin that are eligible for new technology add-on payments will be identified by ICD–10–PCS procedure code XY0YX28 (Extracorporeal introduction of taurolidine anti-infective and heparin anticoagulant, new technology group 8).

(2) REZZAYO™ (Rezafungin for Injection)

Cidara Therapeutics submitted an application for new technology add-on payments for REZZAYO™ (rezafungin for injection) for FY 2024. According to the applicant, REZZAYO™ is an echinocandin antifungal drug for the treatment of candidemia and invasive candidiasis in patients 18 years of age or older. Please refer to the online application posting for REZZAYO™, available at https://mearis.cms.gov/public/publications/ntap/ntap221017057WN, for additional detail describing the technology and the disease treated by the technology.

According to the applicant, REZZAYO™ received QIDP designation from FDA on June 27, 2017, for treatment of candidemia and/or invasive candidiasis. The applicant stated that the NDA for REZZAYO™ was approved on March 22, 2023, for use in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data for REZZAYO™. The applicant stated that REZZAYO™ would not be commercially available until July 2023, but we note that a rationale for the delay in market availability was not provided. Due to the timing of receipt of FDA approval, we stated in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26958) that we were interested in additional information on whether the technology is considered a QIDP under this NDA.

The applicant submitted a request for approval for a unique ICD–10–PCS procedure code for REZZAYO™ beginning in FY 2024 and was granted approval for the following procedure codes effective October 1, 2023: XW033R9 (Introduction of rezafungin into peripheral vein, percutaneous approach, new technology group 9) and XW043R9 (Introduction of rezafungin into central vein, percutaneous approach, new technology group 9).

With respect to the cost criterion, to identify potential cases representing patients who may be eligible for REZZAYO™, the applicant searched the FY 2021 MedPAR file for cases reporting one of the ICD–10–CM diagnosis codes for candidemia or invasive candidiasis (in any position) listed in the table in this section. Using the inclusion/exclusion criteria described in the following table, the applicant identified 50,939 claims mapping to 540 MS–DRGs. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $177,099.74, which exceeded the average case-weighted threshold amount of $97,375.67. Because the final inflated average case-weighted standardized charge exceeded the average case-weighted threshold amount, the applicant asserted that REZZAYO™ meets the cost criterion.
In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26958), we agreed with the applicant that REZZAYO™ meets the cost criterion and therefore proposed to approve REZZAYO™ for new technology add-on payments for FY 2024 for use in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.

The applicant had not provided an estimate for the cost of REZZAYO™ at the time of the proposed rule. According to the applicant, REZZAYO™ is to be administered once weekly by intravenous infusion, with an initial loading dose of 400 mg and followed by a 200 mg dose once weekly thereafter. According to the applicant, in the pivotal trial, on average patients received 14 days of IV treatment and that data also showed that patients stay in the hospital after being diagnosed with invasive candidiasis for 14 days. Therefore, the applicant estimated the average dose of medication during an inpatient stay to be 600 mg, given the initial 400 mg dose plus one 200 mg maintenance dose prior to discharge from the hospital. We stated that we expected the applicant to submit cost information prior to the final rule, and we would provide an update regarding the new technology add-on payment amount for the technology, if approved, in the final rule. Any new technology add-on payment for REZZAYO™ would be subject to our policy under §412.88(a)(2) where we limit new technology add-on payments for QIDPs to the lesser of 75 percent of the average cost of the technology, or 75 percent of the costs in excess of the MS–DRG payment for the case.

We invited public comments on whether REZZAYO™ meets the cost criterion and our proposal to approve new technology add-on payments for REZZAYO™ for FY 2024 for use in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.

Comment: The applicant submitted a public comment urging CMS to finalize its proposal to approve REZZAYO™ for new technology add-on payments and reiterating that REZZAYO™ meets the criteria for approval. The applicant also stated that the wholesale acquisition cost of REZZAYO™ will be $1,950 per 200 mg vial. Per the applicant, as discussed in the proposed rule, the estimated average dose during an inpatient stay is 600mg and therefore the average cost of the technology would be $5,850 per inpatient stay. The applicant recommended a maximum add-on payment of $4,387.50 or 75 percent of the average cost of REZZAYO™ of $5,850.

Response: We thank the applicant for its support and the additional information.

Based on the information provided in the application for new technology add-on payments, and after consideration of the public comment we received, we believe REZZAYO™ meets the cost criterion. The technology was granted FDA marketing authorization on March 22, 2023, with an indication for use in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis, which is covered by its QIDP designation. Therefore, we are finalizing our proposal to approve new technology add-on payments for REZZAYO™ for FY 2024. The applicant has stated that the technology is not yet available for sale but has not provided information regarding a documented delay in market availability. Absent additional information, we therefore consider the newness period to commence on the date of marketing authorization, March 22, 2023.

Based on the information available at the time of this final rule, the cost per case of REZZAYO™ is $5,850. Under §412.88(a)(2), we limit new technology add-on payments to the lesser of 75 percent of the average cost of the technology, or 75 percent of the costs in excess of the MS–DRG payment for the case. As a result, we are finalizing that...
the maximum new technology add-on payment for a case involving the use of REZZAYO™ is $4,387.50 for FY 2024 (that is, 75 percent of the average cost of the technology). Cases involving the use of REZZAYO™ that are eligible for new technology add-on payments will be identified by ICD–10–PCS procedure codes: XW033R9 (Introduction of rezafungin into peripheral vein, percutaneous approach, new technology group 9) or XW043R9 (Introduction of rezafungin into central vein, percutaneous approach, new technology group 9).

(3) XACDURO® (Sulbactam/Durlobactam)

Entasis Therapeutics, Inc. submitted an application for new technology add-on payments for XACDURO® (sulbactam/durlobactam, referred to as “SUL–DUR” in the proposed rule) for FY 2024. According to the applicant, XACDURO® is a penicillin derivative and classified as a β-lactamase inhibitor but also has intrinsic antibacterial activity against Acinetobacter baumannii and other members of the Acinetobacter baumanii-calcoaceticus complex (ABC). According to the applicant, sulbactam, in combination with durlobactam, will be used for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and bloodstream infections (BSI) due to Acinetobacter baumannii.

Please refer to the online application posting for XACDURO®, available at https://mears.cms.gov/public/publications/ntap/NTP221017F5WKE, for additional detail describing the technology and the disease treated by the technology.

According to the applicant, XACDURO® received QIDP designation for the treatment of HABP/VABP and bloodstream infections due to Acinetobacter baumannii. The applicant stated that it was seeking approval of a broader NDA from FDA for the treatment of adults with infections due to Acinetobacter baumanii-calcoaceticus complex organisms, including multidrug-resistant and carbapenem-resistant strains. According to the applicant, patients are expected to receive 1 to 1.5 grams sulbactam and 1 to 1.5 grams durlobactam every 6 hours for an average of 10 days. In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26959), we noted that, under the eligibility criteria for approval under the alternative pathway for certain antimicrobial products, only the use of XACDURO® for the treatment of HABP/VABP and bloodstream infections due to Acinetobacter baumannii, and the FDA QIDP designation it received for that use, were relevant for purposes of the new technology add-on payment application for FY 2024. We also noted that, as an application submitted under the alternative pathway for certain antimicrobial products at §412.87(d), XACDURO® was eligible for conditional approval for new technology add-on payments if it did not receive FDA marketing authorization by the July 1 deadline specified in §412.87(e)(2), provided that the technology receives FDA marketing authorization by July 1 of the particular fiscal year for which the applicant applied for new technology add-on payments (that is, July 1, 2024). The applicant stated that XACDURO® received FDA approval on May 23, 2023, with an indication for use in patients 18 years of age and older for the treatment of HABP/VABP, caused by susceptible isolates of Acinetobacter baumanii-calcoaceticus complex since the indication for which the technology received FDA approval is included within the scope of the QIDP designation, it appears that the proposed FDA indication is appropriate for new technology add-on payment under the alternative pathway criteria.

The applicant submitted a request for approval for a unique ICD–10–PCS procedure code for XACDURO® beginning in FY 2024 and was granted approval for the following procedure codes effective October 1, 2023: XW033K9 (Introduction of sulbactam–durlobactam into peripheral vein, percutaneous approach, new technology group 9) and XW043K9 (Introduction of sulbactam–durlobactam into central vein, percutaneous approach, new technology group 9). The applicant provided a list of diagnosis codes that may be used to currently identify the indication for XACDURO® under the ICD–10–CM coding system. Please refer to the online application posting for the complete list of ICD–10–CM codes provided by the applicant. We noted that the applicant included ICD–10–CM codes that correspond to the broader anticipated NDA indication. As previously noted, only use of the technology for the indications corresponding to the QIDP designation would be relevant for new technology add-on payment purposes. We believed the relevant ICD–10–CM codes to identify the QIDP-designated indications were: Y95 and J15.6 (describing HABP due to Acinetobacter baumannii); or J95.851 and B96.89 (describing VABP due to Acinetobacter baumannii); or A41.59 (Other Gram-negative sepsis) for bloodstream infection due to Acinetobacter baumannii. We note that since the approved NDA indication is limited to HABP and VABP due to Acinetobacter baumannii and does not include bloodstream infections, we believe ICD–10–CM code A41.59 is no longer is relevant to describe the indication relevant for new technology add-on payment purposes.

With respect to the cost criterion, the applicant provided two analyses to demonstrate that it meets the cost criterion. For each analysis, the application searched the FY 2021 MedPAR file using a different combination of codes to identify potential cases representing patients who may be eligible for XACDURO®. The applicant explained that it used different codes to demonstrate different cohorts that may be eligible for the technology. Each analysis followed the order of operations described in the following table.

According to the applicant, XACDURO® was anticipated to be indicated in adults for the treatment of infections due to ABC complex including multi-drug resistant and carbapenem-resistant strains upon FDA approval. Therefore, in the first analysis, the applicant identified ICD–10–CM codes that reflect the anticipated FDA indication. According to the QIDP designation, XACDURO® was designated for the treatment of HABP/VABP and bloodstream infections due to Acinetobacter baumannii. Therefore, in the second analysis, the applicant identified ICD–10–CM codes that reflect the QIDP-designated indications. Please see Table 10.23.A.—XACDURO® Codes—FY 2024 associated with the proposed rule for the complete list of codes provided by the applicant.

For Analysis 1, using the inclusion/exclusion criteria described in the following table, the applicant identified 440,756 cases mapping to 452 MS–DRGs. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $182,533, which exceeded the average case-weighted threshold amount of $76,364.

For Analysis 2, using the inclusion/exclusion criteria described in the following table, the applicant identified 214,694 claims mapping to 330 MS–DRGs. The applicant followed the order of operations described in the following table and calculated a final inflated average case-weighted standardized charge per case of $202,171, which exceeded the average case-weighted threshold amount of $85,665.

Because the final inflated average case-weighted standardized charge per
In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26960), we agreed with the applicant that XACDURO® meets the cost criterion and therefore proposed to approve XACDURO® for new technology add-on payments for FY 2024 for the treatment of HABP/VABP and bloodstream infections due to Acinetobacter baumannii, subject to the technology receiving FDA marketing authorization for the indication corresponding to the QIDP designation by July 1, 2023. We stated that as an application submitted under the alternative pathway for certain antimicrobial products at §412.87(d), XACDURO® was eligible for conditional approval for new technology add-on payments if it did not receive FDA marketing authorization by the July 1 deadline specified in §412.87(e)(2), provided that the technology received FDA marketing authorization by July 1 of the particular fiscal year for which the application applied for new technology add-on payments (that is, July 1, 2024). If XACDURO® received FDA marketing authorization before July 1, 2024, the new technology add-on payment for cases involving the use of this technology would be made effective for discharges beginning in the first quarter after FDA marketing authorization is granted. If FDA marketing authorization was received on or after July 1, 2024, no new technology add-on payments would be made for cases involving the use of XACDURO® for FY 2024.

Based on preliminary information from the applicant at the time of the proposed rule, the applicant stated that the anticipated cost of XACDURO® was $15,000 per stay based upon the expectation that patients would receive 1 to 1.5 grams sulbactam and 1 to 1.5 grams durlobactam every 6 hours for an average of 10 days. The applicant did not provide the cost per vial and did not supply supporting information with regard to the average of 10 days. Therefore, we stated in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26960) that we were interested in information regarding the cost per vial and the average of 10 days to support the anticipated average cost of $15,000 provided by the applicant. We noted that the cost information for this technology may be updated in the final rule based on revised or additional information CMS received prior to the final rule. Under §412.88(a)(2), we limit new technology add-on payments for QIDPs to the lesser of 75 percent of the average cost of the technology, or 75 percent of the costs in excess of the MS–DRG payment for the case. As a result, we proposed that the maximum new technology add-on payment for a case involving the use of XACDURO® when used for the treatment of HABP/VABP and bloodstream infections due to Acinetobacter baumannii would be $11,250 for FY 2024 (that is, 75 percent of the average cost of the technology).

We invited public comments on whether XACDURO® meets the cost criterion and our proposal to approve new technology add-on payments for XACDURO® for FY 2024 for the treatment of HABP/VABP and bloodstream infections due to Acinetobacter baumannii subject to the technology receiving marketing authorization consistent with its QIDP designation by July 1, 2023.

Comment: The applicant submitted a public comment in support of its application and responding to questions raised by CMS in the proposed rule.
regarding the cost information. In its comment letter, the applicant stated that XACDURO™ for injection is supplied as a kit containing 3 single-dose vials. Per the applicant, one vial contains sulbactam 1g and 2 vials each contains durlobactam 0.5g. The applicant stated that the expected dosing schedule for XACDURO varies, but most patients will receive one infusion every 6 hours, for a total of 4 kits per 24-hour period. The applicant provided the following table showing the dosage of XACDURO™ based on renal function.

<table>
<thead>
<tr>
<th>Dose of Sulbactam and Durlobactam (g)</th>
<th>Estimated CLcr (mL/min)</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sulbactam 1g and Durlobactam 1g</td>
<td>Greater than or equal to 130</td>
<td>Every 4 hours</td>
</tr>
<tr>
<td></td>
<td>45 to 129</td>
<td>Every 6 hours</td>
</tr>
<tr>
<td></td>
<td>30 to 44</td>
<td>Every 8 hours</td>
</tr>
<tr>
<td></td>
<td>15 to 29</td>
<td>Every 12 hours</td>
</tr>
<tr>
<td></td>
<td>Less than 15</td>
<td>For patients initiating XACDURO™: every 12 hours for the first 3 doses (0, 12, and 24 hours) followed by every 24 hours after the third dose. For patients currently receiving XACDURO™ whose CLcr declines to less than 15 mL/min: every 24 hours</td>
</tr>
</tbody>
</table>

BILLING CODE 4120–01–C

The applicant stated that the recommended duration of treatment is 7 to 14 days and should be guided by the severity and site of infection and the patient’s clinical and bacteriological progress.

Per the applicant, the claims data analysis would not allow for identifying XACDURO™ dosing based on creatinine clearance utilizing ICD–10–CM, HCPCS Level I (CPT) and HCPCS Level II codes. Therefore, the applicant was unable to determine any XACDURO™ dosing adjustments of different time intervals based on the coding in claims data.

In response to CMS questions regarding cost and duration of treatment, the applicant submitted a change to the proposed average days of treatment from 10 days to 9.6 days. The applicant calculated a weighted average duration of treatment (in days) across the treatment arms in the trial. In Part A of the study, there were 91 patients with an average of 9.3 days of treatment duration. In Part B, there were 28 patients with an average treatment duration of 10.6 days. The weighted average days of treatment across both groups is 9.6 days. Based on an average estimated length of stay of 9.6 days, the applicant submitted a change to the expected cost for treatment per stay to be $18,240.

Based on the revised expected cost of treatment per stay, the applicant provided an updated analysis for the second analysis which matches the final approved indication and cost. The revised final inflated average case-weighted standardized charge per case was $219,780, which exceeded the average case-weighted threshold amount of $85,665. The applicant asserted that XACDURO™ still met the cost criterion threshold.

Response: We thank the applicant for its comments and the additional information.

Based on the information provided in the application for new technology add-on payments, and after consideration of the public comment we received, we believe XACDURO™ meets the cost criterion. The technology was granted FDA marketing authorization on May 23, 2023, for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii-calcoaceticus complex, for patients 18 years of age and older, which is covered by its QIDP designation. Therefore, we are finalizing our proposal to approve new technology add-on payments for XACDURO™ for FY 2024. We consider the beginning of the newness period to commence on May 23, 2023, the date on which the technology received FDA market authorization for the indication covered by its QIDP designation.

Based on the information available at the time of this final rule, the average cost per case of XACDURO™ is $18,240. Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 75 percent of the average cost of the technology, or 75 percent of the costs in excess of the MS–DRG payment for the case. As a result, we are finalizing that the maximum new technology add-on payment for a case involving the use of XACDURO™ is $13,680 for FY 2024 (that is, 75 percent of the average cost of the technology). Cases involving the use of XACDURO™ that are eligible for new technology add-on payments will be identified by ICD–10–PCS procedure codes WX033K9 (Introduction of sulbactam-durlobactam into peripheral vein, percutaneous approach, new technology group 9) or WX043K9 (Introduction of sulbactam-durlobactam into central vein, percutaneous approach, new technology group 9) in combination with one of the following ICD–10–CM codes: Y95 and J15.6 (describing HABP due to Acinetobacter baumannii); or J95.851 and B96.89 (describing VABP due to Acinetobacter baumannii).

8. Other Comments

We received several public comments requesting changes to the new technology add-on payment policies, such as increasing the add-on payment amount to 85 percent or more, creating new alternative pathway categories for different FDA designations or types of treatments, and expanding the conditional approval process to additional types of technologies or designations, that were outside the scope of the proposals included in the FY 2024 IPPS/LTCH PPS proposed rule and we are therefore not addressing them in this final rule. We appreciate these comments and may consider them for possible proposals in future rulemaking.

9. Modification of New Technology Add-On Payment Application Eligibility Requirements Related to FDA Application Status and Moving the Deadline for FDA Marketing Authorization from July 1 to May 1 for Technologies that Are Not Already FDA Market Authorized

As noted in section I.E.1.f. of this final rule, applicants for new technology add-on payments for new medical
services or technologies must submit to CMS a formal request, including a full description of the clinical applications of the medical service or technology and the results of any clinical evaluations demonstrating that the new medical service or technology represents a substantial clinical improvement (unless the application is under one of the alternative pathways). In addition, as reflected in the application, applicants must submit information about the technology’s FDA marketing authorization status and the status of any relevant designations required for new technology add-on payment eligibility.

As set forth in 42 CFR 412.87(e)(1), CMS considers whether a technology meets the criteria for the new technology add-on payment and announces the results as part of its annual updates and changes to the IPPS. Accordingly, in drafting the proposed rule, CMS Reviews each new technology add on payment application it receives under the pathway specified by the applicant at the time of application submission, along with any supplemental information obtained from the applicant, information provided at the Town Hall meeting, and comments received in response to the Town Hall meeting. As part of the new technology add-on payment application process, CMS summarizes in the IPPS/ LTCH PPS proposed rule the information submitted as part of each new technology add-on payment application. This generally includes summarizing and/or providing the public with information on the applicant’s explanation of what the technology does, background on the disease process, status of FDA approval or clearance, and the applicant’s assertions and supporting data on how the technology meets the new technology add-on payment criteria under § 412.87. As discussed in prior rulemaking, our goal is to ensure that the public has sufficient information to facilitate public comment on whether the medical service or technology meets the new technology add-on payment criteria.

In the FY 2023 IPPS/LTCH PPS final rule, to increase transparency, enable increased stakeholder engagement, and improve streamline our new technology add-on payment review process, we finalized a policy that, beginning with FY 2024, new technology add-on payment applications and certain related materials would be publicly posted online (87 FR 48986 through 48990). We noted that we believed making this information publicly available may help to further engage the public and foster greater input and insights through public comments on the new medical services and technologies presented annually for consideration for new technology add-on payments. Consistent with this finalized policy, the FY 2024 applications for new technology add-on payments are available at https://mearis.cms.gov/public/publications/ntap.

Building on our efforts to further increase transparency, facilitate public input, and improve the review process, we are finalizing as proposed modifications to both the new technology add-on payment application eligibility requirements and the date by which applicants must receive FDA marketing authorization in order to be eligible for consideration. Specifically, we are finalizing our proposed policies to modify the new technology add-on payment application eligibility requirements for technologies that are not already FDA market authorized to require such applicants to have a complete and active FDA marketing authorization request at the time of new technology add-on payment application submission, and to move the FDA marketing authorization deadline from July 1 to May 1, beginning with applications for FY 2025. As we discuss in further detail later in this section, we believe these changes will significantly improve our ability to evaluate whether a technology is eligible for new technology add-on payment.

We accept new technology add-on payment applications annually, each fall. As previously discussed, CMS considers whether the technology meets the criteria for the new technology add-on payment and announces the results as part of the annual IPPS rulemaking. To provide maximum flexibility for applicants for new technology add-on payments, we have not historically specified how complete an application must be at the time of its submission. This has resulted in a significant number of applicants submitting new technology add-on payment applications that lack critical information that is needed to evaluate whether the technology meets the eligibility criteria at § 412.87(b), (c), or (d), particularly with regard to having information available for the proposed rule and during the comment period. Specifically, many applicants submit new technology add-on payment applications prior to submitting a request to FDA for the necessary marketing authorization, and applicants have stated that information missing from their applications, which is needed to evaluate the technology for the add-on payment, will not become available until after submission to FDA. With regard to the alternative pathways, such applications may also be missing information that would help inform understanding of the details and interrelationship between the intended indication and FDA Breakthrough Device or QIDP designation, which is the basis for a product’s eligibility for the alternative pathway.

Ultimately, it is difficult for CMS to review and for interested parties to comment on a product that has not yet been submitted to FDA, as multiple sections of the new technology add-on payment applications lack preliminary information that is more likely to be available after an FDA submission. Public input is an important part of our assessment of whether a technology meets the new technology add-on payment criteria, particularly as the number of applicants submitting new technology add-on payments is increasing over time. By requiring applicants to submit their FDA marketing authorization requests prior to submitting an application for new technology add-on payments, the public and the agency will be able to more knowledgeably analyze the new technology add-on payment applications and supporting data and evidence to inform an assessment of the technology’s eligibility for the add-on payment.

Therefore, we proposed that beginning with the new technology add-on payment applications for FY 2025, to be eligible for consideration for the new technology add-on payment, an applicant must have already submitted an FDA marketing authorization request before submitting an application for new technology add-on payments. We proposed that, for the purposes of this policy, submission of a request for marketing authorization by FDA would mean that the applicant has submitted a complete application to FDA, and that the application has an active status with FDA (such as not in a Hold status or having received a Complete Response Letter). An applicant will provide documentation of the marketing authorization request at the time of submission of its new technology add-
on payment application to CMS. We stated our belief that requiring an FDA acceptance or filing letter would provide the clearest and most effective means of documenting that the applicant has submitted a complete request to FDA and therefore proposed to require this approach to documentation. We proposed that the applicant would also indicate on the new technology add-on payment application whether the FDA request has an active status with FDA. We noted that applicants for technologies that have already received FDA marketing authorization for the indication for which they are applying for new technology add-on payments would not be required to submit an FDA acceptance or filing letter and would continue to be eligible for consideration for new technology add-on payments. We proposed to amend 42 CFR 412.87 to reflect this proposal by redesignating current paragraph (e) as paragraph (f) and adding a new provision at 42 CFR 412.87(e) to state that CMS will only consider, for add-on payments for a particular fiscal year, an application for which the medical service or technology is either FDA market authorized for the indication that is the subject of the new technology add-on payment application or for which the medical service or technology is the subject of a complete and active FDA marketing authorization request and documentation of FDA acceptance or filing is provided to CMS at the time of new technology add-on payment application submission.

In the FY 2009 IPPS/LTCH PPS final rule (74 FR 48563), we finalized our proposal to set July 1 of each year as the deadline by which IPPS new technology add-on payment applications must receive FDA marketing authorization. We noted that while we prefer that technologies have FDA approval or clearance at the time of application, this may not always be feasible. At that time, we believed that the July 1 deadline would provide an appropriate balance between the necessity for adequate time to fully evaluate the applications, the requirement that IPPS follow the IPPS final rule by August 1 of each year, and addressing commenters’ concerns that potential new technology applicants have some flexibility with respect to when their technology receives FDA approval or clearance.

However, with the increased complexity and volume of applications for new technology add-on payments since finalization of this policy in the FY 2009 IPPS/LTCH PPS final rule, we believe the July 1 deadline may no longer provide sufficient time to fully evaluate the new technology applications in advance of the issuance of the final rule, including information that does not become available until FDA approval or clearance. The technologies that are the subject of new technology add-on payment applications are increasingly complex, such as fourth- and fifth-line therapies and devices utilizing artificial intelligence algorithms. The volume of new technology add-on payment applications has also risen substantially. In the first 20 years of the new technology add-on payment program, CMS received on average 2-10 applications per year. Applications have risen by 200 percent from FY 2020 to FY 2024 alone.

The increased volume and complexity of applications makes it more challenging to mitigate information gaps in advance of the final rule, particularly with regard to analysis and validation of information necessary to make determinations regarding whether technologies meet the add-on payment criteria. For traditional pathway applications, this may involve submission of new clinical studies and/or a different final indication, which can change the relevant comparators for consideration. For alternative pathway applications, CMS must assess the relevant designations in connection with the applicable indications and how the necessary marketing authorization relates to the designated technology, which often necessitates coordination with FDA and other components of HHS. As new technology continues to be developed, we expect both the complexity and the number of applications to increase, further increasing the need for additional time to fully evaluate the applications in advance of the final rule. We also believe that providing the opportunity for interested parties to review the FDA approved indications and the clinical data that often only becomes available after receiving, and may only be available in, FDA marketing authorization will strengthen the quality of the public comments and allow for more informed decision-making in the final rule.

Accordingly, to allow adequate time to fully evaluate the new technology add-on payment criteria for FDA-authorized technologies in advance of the final rule, and to further facilitate and inform public comment, we proposed requiring applicants to receive FDA approval or clearance by May 1 in order to be eligible for consideration for the new technology add-on payment for the upcoming fiscal year. We said we believed that this May 1 deadline would strike a balance between providing adequate time to fully evaluate the applications while also continuing to preserve flexibility for manufacturers. We proposed to amend proposed redesignated § 412.87(f)(2) to reflect this proposed change by revising the date by which new medical services or technologies must receive FDA marketing authorization from July 1 to May 1 and making other conforming changes to the regulatory text.

Consistent with our current approach, we will not include in the final rule the description and discussion of new technology add-on payment applications which were included in the proposed rule that were withdrawn or that were ineligible for consideration for the upcoming fiscal year due to not meeting the proposed May 1 deadline. We will also neither summarize nor respond to public comments received regarding these withdrawn or ineligible applications in the final rule.

We noted that we were not proposing to change the July 1 deadline for technologies for which an application is submitted under the alternative pathway for certain antimicrobial products because they would continue to be eligible for conditional approval under § 412.87(e)(3) (to be redesignated as § 412.87(f)(3)), as finalized in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58740). However, we proposed to amend the redesignated § 412.87(f)(3) to revise the current cross-reference to § 412.87(e)(2) in light of the previously discussed amendments being proposed. We sought public comment on our proposal to modify the new technology add-on payment application eligibility requirements for technologies that are not already FDA market authorized to require such applicants to have a complete and active FDA marketing authorization request at the time of new technology add-on payment application submission, to provide documentation of FDA acceptance or filing to CMS at the time of application submission, and to move the FDA marketing authorization deadline from July 1 to May 1, beginning with applications for FY 2025.

Comment: We received several public comments regarding the stated policy goals behind our proposal of promoting transparency, facilitating public input, and improving the review process. As part of improving the new technology add-on payment review process, we stated that as new technologies continue to be developed, we expect both the complexity and the number of applications to increase, further increasing the need for additional information earlier in the new technology add-on payment review
process in order to fully evaluate the applications. As discussed further in this section, many commenters stated that they understood our policy goals but provided alternatives as to how to achieve those goals or asked for a delay in implementation. We discuss the specific comments concerning alternatives to our proposal and asking for a delay in implementation later in this section.

Other commenters stated that it is unclear how the proposal would improve transparency, facilitate public input, and improve the review process, or disagreed that it would do so. One commenter specifically stated that it did not understand how our proposal would further facilitate and inform public comment, as the proposed rule is released in April and the information from the full FDA approval would not be available in the proposed rule at that time. A number of commenters asserted that the intent of these policies is to reduce the number of applications or decrease CMS’s workload, and some of these expressed the view that the proposal is unlikely to address the increasing volume and complexity of applications or reduce CMS’s review time. Commenters also stated that they did not believe the volume of applications would decline because they believe that applicants will likely continue to pursue a new technology add-on payment application as a “just in case” strategy, or to solicit information on what concerns CMS may have with a future application, even if they are unlikely to receive FDA approval until well after the proposed May 1 deadline. One commenter noted that even those with Priority Review status may not receive FDA approval until after May 1, and that technologies subject to the standard review timeline may not receive approval until late fall.

A few of the commenters noted that applicants who do not receive new technology add-on payment approval due to missing the marketing authorization deadline would likely apply again during the following application cycle and CMS would have to repeat this process the following year, resulting in a greater burden on both manufacturers and CMS. A few of these commenters also disagreed that our proposal would improve transparency nor materially impact the volume or complexity of applications, specifically for technologies with Breakthrough Device designations for which the new technology add-on payment applications only contain limited information as compared to traditional pathway applications that contain newness and SCI information.

One commenter stated that complete new technology add-on payment applications should provide CMS with sufficient information to assess the medical technology in question regardless of whether the FDA application has been formally submitted, and another commenter stated that CMS currently has the discretion not to approve applications that are missing data, regardless of the status of the FDA marketing authorization application.

Response: We thank commenters for their comments. While a number of commenters noted their belief that the intent of these policies is to reduce the number of applications or decrease CMS’s workload, the intent of our proposal is instead to address the ever-increasing complexity and number of applications lacking critical information that is needed to evaluate whether the technology meets the eligibility criteria at § 412.87(b), (c), or (d), by enhancing transparency and improving the evaluation process, as described in the proposed rule. Specifically, applications for technologies that have not yet received FDA marketing authorization often have incomplete information about the indication, lack cost information, and provide limited clinical information and supporting data (where applicable), all of which are necessary for a thorough analysis of new technology add-on payment criteria. Thus, the application summaries and lists of relevant CMS concerns in the proposed rule may be limited and the public may not have all of the necessary information on the new technology being considered for new technology add-on payment. Public commenters in previous final rules have noted that they cannot meaningfully comment on a product that has not yet been FDA approved because multiple sections of the new technology add-on payment applications are informed by the marketing authorization approval process. Public input on the new technology add-on payments is highly valued and an important consideration in our assessment of whether a new technology add-on payment application meets the eligibility criteria. This is especially important given that new technology applications are more complex and specialized and the volume of applications for new technology add-on payments is increasing.

Therefore, we believe more comprehensive applications at the time of submission will allow CMS to better identify critical questions in the proposed rule and will enable more comprehensive evaluation by commenters during the public comment process. In summary, the goal of the proposal is to increase the quality of the information contained in the application to allow the public and the agency to more knowledgeably review and analyze the applications, supporting data, and evidence to inform an assessment of a technology’s eligibility for the new technology add-on payment.

Although a commenter stated that complete new technology add-on payment applications should provide CMS with sufficient information to assess the medical technology in question regardless of whether an application has been formally submitted to FDA, as noted previously, applications for technologies that have not yet received FDA marketing authorization often have incomplete information about the indication, lack cost information, and provide limited clinical information and supporting data (where applicable). In addition, in regard to the commenter that stated CMS has the discretion not to approve applications that are missing data, this does not address our intent to increase the quality of the information contained in the application, as previously described.

CMS recognizes that some applicants who submit new technology add-on payment applications prior to submitting applications for FDA marketing authorization may be doing so strategically to identify information regarding concerns CMS may have with new technology that is the subject of the new technology add-on payment application as early as possible, as described by a commenter. While we acknowledge that it could be advantageous for an applicant to learn of CMS’s concerns regarding eligibility of its product for new technology add-on payments, we do not believe it is an appropriate use of resources to evaluate applications for technologies that will not be eligible in time for that particular rulemaking cycle. In addition, over the last 4 years, 50 to 75 percent of applications (depending on the fiscal year) did not meet the July 1 deadline for obtaining FDA marketing authorization. We believe that this proposal will serve to mitigate these practices to some extent, though this is

185 A priority review designation means FDA’s goal is to take action on the marketing application within 6 months of receipt (compared with 10 months under standard review). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics.
not the goal behind the proposal, as described previously.

Regarding the comments that stated that applicants who miss the marketing authorization deadline would likely apply again during the following application cycle, resulting in a greater burden on both manufacturers and CMS, we note that this would not be a change from our current policy. As noted previously, even with a July 1 deadline, 50–75 percent of applications do not meet the deadline and many reapply the following year. As described later in this section, we believe requiring technologies to have submitted FDA marketing authorization requests prior to submitting applications for new technology add-on payments would mitigate this issue, as we believe applications for which a “complete and active” FDA application has been accepted or filed have a greater chance of meeting the deadline for FDA marketing authorization for new technology add-on payment eligibility purposes.

Additionally, with regard to commenters’ assertion that our proposal would not improve transparency and materially impact the volume or complexity of Breakthrough Device applications, we believe that requiring a FDA marketing authorization request to have been submitted and in an active status at the time of application for technologies with Breakthrough Device designations will lead to applicants submitting information in their new technology add-on payments application that address the criteria needed to determine eligibility, such as the marketing authorization indication and other information that would help inform understanding of the details and interrelationship between the intended indication and FDA Breakthrough Device designation, which is the basis for a product’s eligibility for the alternative pathway, and whether the device that is the subject of the application is the same device designated as a Breakthrough Device. We note, as we have gained more experience with applications for technologies with Breakthrough Device designations, these applications are increasingly complex and involve many considerations and nuances across multiple aspects of the application, not just the cost criterion. This requirement will enhance the quality of information CMS receives at the time of application for all application pathways, making more information available to the public and providing CMS with more robust information to evaluate the application. Although a commenter mentioned that the proposed rule is released in April and therefore, information from the full FDA approval would not be available in the proposed rule, we note that a May 1 deadline allows for information necessary to determine whether a technology meets the requirements for new technology add-on payment eligibility, such as the full FDA marketing authorization indication and information for which release is dependent on that approval, to be publicly available during the comment period in time for consideration by the public and the agency, since this deadline would generally occur approximately 30 days before the public comment period closes. A technology’s FDA marketing authorization may differ from the proposed indication, which may require additional consideration when contemplating new technology add-on payment eligibility; for example, with respect to how the final marketing authorization indication compares to an alternative pathway designation, or what would be the appropriate comparators for newness and substantial clinical improvement for traditional pathway applications. Access to this information will enhance the quality of the review process and improve transparency for the public prior to the final rule.

Comment: One commenter was fully supportive of our proposal and agreed that increasing transparency is critical for the new technology add-on payment process. The commenter stated applications that lack information at the time of submission make it difficult for CMS and the public to assess whether the technology meets the new technology add-on payment criteria. The commenter believed that the vast majority of applicants, if not virtually all, who apply for new technology add-on payments before they are ready to submit an application for marketing authorization to FDA, do not end up receiving FDA approval in time for the new technology add-on payment determination, which leads to a tremendous use of resources to review technologies and put them through the proposed rule and comment period, just to have the applications be withdrawn from new technology add-on payment consideration at the last minute. The commenter further asserted that due to the increased volume and complexity of applications over the years, these issues may have been compounded. The commenter noted that spreading limited resources over a large number of applications with an extremely short deadline to review the applications could result in a less than thorough review process.

Response: We thank the commenter who was supportive of the proposal and agree that the policy will increase our stated goals of transparency, facilitating public input, and improving the review process.

Comment: Many commenters who opposed our proposal stated that one or both aspects of the proposal would create a barrier to beneficiary and provider access to innovative technologies. A few commenters recommended that CMS analyze the proposal’s impact on beneficiary access. Some of the commenters explained that the proposal would impact the timeliness of reimbursement for the new technology. One commenter stated that new technology add-on payments are often not in place until more than a year after a product receives marketing authorization from FDA and that the proposal would further delay that payment. Another commenter encouraged CMS to maintain the existing timelines as reducing the duration of the new technology add-on payment could reduce patient access to therapies like CAR T-cell therapy. One commenter raised concerns about the proposal having a negative effect on applicants that rely on new technology add-on payments to sustain a viable market entry point.

Several commenters noted that the proposal would worsen the lag time between FDA marketing authorization and new technology add-on payments and create disruptions, and thus delay beneficiary access to new technologies, which would be the opposite of the intent of the new technology add-on payment process. A few commenters stated that this proposal would negatively affect therapies intended to treat serious conditions and address unmet needs, and one commenter raised several concerns about timing for new technology add-on payment approvals for, and patient access to, certain types of newly approved FDA therapies, such as cell and gene therapies and therapies treating orphan conditions and rare diseases. One commenter stated that there is risk that the policies would have a disproportionately negative effect on drugs that utilize the FDA “rolling review” process, delaying patient access to these drugs.

186 Rolling Review means that a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track.
Response: We thank the commenters for sharing their concerns. CMS shares the goal of ensuring Medicare beneficiaries and their providers have access to new technologies. However, as described in the FY 2005 final rule (69 FR 49003 and 49009), patient access to these technologies should not be adversely affected if a technology does not qualify to receive new technology add-on payments, as CMS continues to pay for new technologies through the regular payment mechanism established by the MS–DRG methodology. We further note that whether a technology receives new technology add-on payments or not does not affect coverage of the technology or the ability for hospitals to provide a technology to patients where appropriate.

Comment: Many commenters raised concerns that our proposals to require a complete and active FDA marketing authorization request at the time of submission of the new technology add-on payment application and to move the FDA approval deadline from July 1 to May 1, for technologies to receive FDA marketing authorization would adversely impact their ability to enjoy maximum flexibility with respect to when to apply to FDA and when they apply for new technology add-on payment.

One commenter stated that the proposal could discourage applicants from applying for a new technology add-on payment. Another commenter noted a manufacturer could be working closely and actively with FDA through the FDA’s voluntary pre-submission process, which is intended to improve the quality of subsequent submissions, shorten total review times, and facilitate the development process for new devices. The commenter explained that the proposal would discourage industry collaboration with FDA in its voluntary pre-submission process since the policy could potentially delay eligibility for a new technology add-on payment by a full year. A commenter stated that CMS should consider a flexible approach for submitting additional documentation on a rolling basis that corresponds with the type of technology’s FDA review process to account for the variation in FDA review processes across new technologies and avoid creating new burdens on FDA.

One commenter noted that manufacturers’ timelines are driven primarily by trial enrollment so they may not be able to submit a BLA prior to the new technology add-on payment application submission or get approved by the July 1 deadline. A few commenters asserted that the proposal would jeopardize the ability of manufacturers to submit applications within the window of time necessary to be eligible to receive new technology add-on payments, leading to fewer products being eligible for approval each year.

A few commenters noted how the proposal does not reflect the variations in FDA processes and timelines for different types of new technologies, whereas the new technology add-on payment designation is the same and only occurs once a year. Additionally, commenters noted that the FDA provides estimates of timeline, but it does not provide applicants with definitive timelines of when the product will be approved or provide feedback on what is needed. A few commenters raised concerns about how the FDA submission process can be impacted by several factors, including timing of interactions with the FDA and manufacturing readiness. One commenter noted that there are examples of technologies receiving FDA clearance after submitting their new technology add-on payment application and meeting the new-technology add-on payment criteria, and that as long as new technology add-on payments can only be awarded annually, applicants should be able to apply for new technology add-on payments as long as there is potential for FDA clearance prior to the July 1 deadline.

Response: We understand the commenters’ concerns with regard to the impact of having maximum flexibility with respect to when they apply for FDA marketing authorization and when they apply for new technology add-on payments. We believe the new technology add-on payment application timeline with the same deadline for submission of a request for FDA marketing authorization is appropriate regardless of how long it takes for a technology to receive FDA approval. To date, we have not specified how complete an application for new technology add-on payments must be at the time of its submission, and used a late deadline for the requirement for FDA approval, in order to maximize flexibility for applicants. But as noted earlier, currently, many applicants submit new technology add-on payment applications prior to submitting a request to FDA for marketing authorization, and applicants have stated that information missing from their applications, which is needed to evaluate the eligibility of the technology for the add-on payment, will not become available until after submission to FDA. Our policy will further increase transparency and improve the evaluation process, including enabling CMS to identify critical questions regarding the technology’s eligibility for add-on payments in the proposed rule. It will also reduce the number of applications that CMS receives that contain limited information.

We further note that even under the current policy with the flexibilities mentioned by the commenters, most applicants do not receive FDA marketing authorization by the July 1 deadline. As noted previously, over the last 4 years, more than 50 percent of applications each year did not receive FDA marketing authorization by the July 1 deadline and were therefore ineligible for new technology add-on payments for the fiscal year for which they applied. As the commenters noted, there are many factors (including timing of interactions with FDA and manufacturing readiness) that can impact a technology’s approval or clearance by FDA, despite expected FDA timelines based on review time or submission planning. This is true regardless of whether the deadline for FDA approval is May 1 or July 1.

We note that this policy does not eliminate flexibilities built into the new technology add-on payment process, as FDA marketing authorization is not required at the time of application, and applicants can continue to provide information as it becomes available according to our standard processes (such as the December supplemental deadline and the public comment period). We believe in providing maximum flexibility to applicants where feasible, but due to the increasing complexity and volume of applications lacking critical information that is needed to evaluate whether the technology meets the eligibility criteria at § 412.87(b), (c), or (d), as we have noted previously, we will require information related to FDA submission at the time of application beginning with applications for FY 2025. We do not anticipate that the policy of requiring an applicant to have already submitted its marketing authorization application to FDA will discourage applicants from applying for new technology add-on payments, since they would be able to reasonably provide sufficient information at the time of application in order for CMS to identify critical questions regarding the technology’s eligibility for add-on payments and to allow the public to assess the relevant new technology evaluation criteria in the proposed rule. In addition, the extent to which an applicant decides to work with FDA is independent from the application process for new technology
add-on payment, and the applicants retain the autonomy to decide if, when, and how to collaborate with the FDA. Applicants are not precluded from continuing to work with FDA as appropriate, and can continue to submit applications to FDA based on their individual readiness and internal timelines.

Comment: Many commenters expressed specific concerns regarding moving the FDA approval deadline to May 1 and how it would impact how long technologies may be eligible for a new technology add-on payment. Several of the commenters asserted that this policy change would prevent a 3-year new technology add-on payment duration for almost all applicants, as only those technologies that receive FDA marketing authorization in April would get 3 years of new technology add-on payments, shortening the window from 3 months under the current policy to just 1 month (April 1 until July 1, vs April 1 until May 1).167 One commenter stated that few new technology add-on payment applications have a full three-year duration of add-on payments under existing policy, potentially limiting Medicare beneficiary access, and this new policy would exacerbate the issue. Further, another commenter provided an example of the potential impact of this policy by referring to Table II.P.–01 in the proposed rule that details the technologies that are scheduled to continue new technology add-on payments in FY 2024. The commenter noted that of the 11 technologies listed, seven (64%) received FDA approval/clearance between May 5 and June 30, and stated that if this policy had been in place at the time these technologies received add-on payments applications were evaluated, each of these would not have been granted new technology add-on payments the following October, representing a delay of 12 months.

Some commenters recommended that if CMS finalizes the aspect of its proposal to move the FDA approval date to May 1, it also adjust its regulations to provide that all devices that receive approval for a new technology add-on payment be granted 3 fiscal years of reimbursement from the time of approval for the new technology add-on payment, independent of the timing of the FDA approval. A few commenters noted that the shortened period resulting from decreasing the window for 3 years of payment for new technology add-on payments to 1 month (April 1 until May 1) would mean CMS would have less claims data available to determine the MS–DRG payment rate.

Several commenters believed our proposal would worsen lag times between FDA approval and the new technology add-on payment designation, resulting in an FDA-approved product being on the market for up to 17–18 months without being approved to receive new technology add-on payments and reducing the potential length of new technology add-on payment eligibility from a possible 3-year period to a 2-year period.

Some commenters performed analyses to demonstrate the potential impact of the proposed May 1 deadline policy: one commenter noted that if the policy were currently in effect then new technology add-on payments would have been denied to 9 out of the 25 technologies that received approval between 2019 and 2023; another noted that if this policy had already been implemented, then 9 out of the current 19 traditional applications would be disqualified for consideration for the FY 2024 rule; and another commenter noted that almost all renewals proposed for FY 2024 would have had new technology add-on payments delayed by a year as their newness periods begin in May/June. One commenter noted that 20 percent of FY 2022 approved technologies and 30 percent of FY 2023 approved technologies had FDA approval dates between May 2 and July 1, and that based on this data, the commenter estimated the proposed May 1 deadline would delay access by a full year for between one-in-three and one-in-five therapies. Another commenter cited a study finding that, historically, over 25 percent of new technology add-on payment denials were due to applicants being unable to meet the existing July 1 deadline, stating that the May 1 deadline would result in even more products experiencing delays in new technology add-on payments.

Response: We thank the commenters for their feedback. We note that it appears that commenters’ analyses may have conflated FDA approval dates with newness period start dates. For example, with respect to the commenter that referred to Table II.P.–01 in the proposed rule, we note that this table does not provide FDA approval/clearance dates, but rather the newness period start dates for these technologies. Furthermore, the commenters’ analyses of technologies in previous fiscal years that received approvals for new technology add-on payments with newness period start dates between May 2 and July 1 do not necessarily indicate that these technologies would have received a denial for new technology add-on payments for those respective fiscal years. In certain circumstances, the newness start date may occur after the FDA marketing authorization date. Applicants may have also applied for new technology add-on payments after receiving FDA marketing authorization. It is also possible that some of these manufacturers may have delayed their submission of their FDA marketing authorization application in an attempt to align that approval as much as possible with the existing new technology add-on payment timelines, rather than applying at a sooner time that could have resulted in an FDA marketing authorization date prior to May 1. With regard to the commenter that stated that 9 out of the current 19 traditional applications would be disqualified for consideration for the FY 2024 rule if CMS had already implemented an FDA marketing authorization deadline of May 1st, we note that of those 9 applications, 7 withdrew or were ineligible for new technology add-on payments.

We also note that even under the current policy with the flexibilities mentioned by the commenters, not all applicants receive the full three years of new technology add-on payments. As the commenters noted, there are many factors (including time of interactions with the FDA and manufacturing readiness) that can delay a technology’s approval by the FDA that would disrupt a technologies ability to receive the full three years of payment.

We note that our data analysis of applications over the last 3 years demonstrates that nearly all applicants who submit new technology add-on payment applications prior to FDA submission in fact do not receive FDA approval by the July 1 deadline. Between FY 2021 and FY 2023, only 3.7 percent of applicants that applied for a new technology add-on payment prior to having submitted its marketing authorization application to FDA received FDA marketing authorization prior to the July 1 deadline. We believe this may result in part from strategically planning the timing of application submission to FDA, as noted by commenters. However, while we expect that applicants are applying for new technology add-on payments with the expectation that they will receive FDA marketing authorization by the deadline, we agree that this choice to

167 We have generally followed a guideline that uses a 6-month window before and after the start of the fiscal year to determine whether to extend the add-on payment for an additional year. In general, we extend new technology add-on payments for an additional year only if the 3-year anniversary date of the product’s entry onto the U.S. market occurs in the latter half of the fiscal year (70 FR 47962).
“time” an application submission to FDA by applicants may not change with implementation of this policy. As stated previously, the goals of this policy are to increase transparency, facilitate public input, and improve the review process, and we believe that by receiving relevant information earlier (both in terms of the time of application and in terms of final FDA marketing authorization prior to the close of the comment period), these goals will be fostered and advanced. We further note that between FY 2021 and FY 2023, only 4 applications out of 187 received FDA marketing authorization between May 1 and July 1 and were approved for new technology add-on payments. Based on this analysis, however, we note that it appears that changing the FDA approval date from July 1 to May 1 would still have affected only a small percentage of new technology add-on payment applications.

We further note that section 1886(d)(5)(K)(ii) of the Act establishes a period of not less than two years and not more than three years for the collection of data with respect to the costs of new services or technologies; a full 3 years is not required. As previously stated, consistent with the statute and our implementing regulations, a technology is no longer considered “new” once it is more than 2 to 3 years old, irrespective of how frequently the medical service or technology has been used in the Medicare population (70 FR 47349). As such, once a technology has been available on the U.S. market for more than 2 to 3 years, we consider the costs to be included in the MS–DRG relative weights regardless of whether the technology’s use in the Medicare population has been frequent or infrequent. Therefore, we do not believe that 2 years’ worth of data would be insufficient to inform rate-setting for the inpatient setting.

However, we have noted commenters’ concerns regarding the possibility that moving the FDA approval deadline from July 1 to May 1 may limit the ability of new technology add-on payment recipients to receive three years of add-on payments, due to the shortened time period between April 1 and May 1. We note that we anticipate considering for future rulemaking changes to how we assess new technology add-on payment eligibility in the third year of newness, such as consideration of adjusting the April 1 cut-off to allow for a longer window of eligibility.

Comment: One commenter supported this aspect of the proposal, agreeing that moving the deadline to May 1 would allow interested parties to review the FDA-approved indications and clinical data that often becomes available only after receiving FDA marketing authorization, and would strengthen the quality of the public comments, allowing for a more informed decision-making process in the final rule.

Response: We thank the commenter and agree that the policy will increase our stated goals of transparency, facilitating public input, and improving the review process.

Comment: Commenters asked for clarifications or raised concerns with the terminology used in the proposal regarding the requirement for a complete and active FDA marketing authorization request at the time of new technology add-on payment application submission and providing documentation of FDA acceptance or filing to CMS at the time of application submission.

Some commenters requested that CMS clarify what constitutes a “complete and active FDA marketing authorization request.” Some of these commenters stated it was unclear what the terms “complete and active FDA marketing authorization” means, as they are not defined in statute, regulation, or guidance, or adequately defined in the proposed rule. A few commenters noted that these terms do not correlate with the terms used by the FDA and that there is currently no certification provided by the FDA indicating such a status. Some commenters suggested this would create further confusion between the FDA, CMS, and interested parties.

A few commenters noted the FDA application status at the time of the new technology add-on payment application submission is not always an accurate representation of the maturity of the FDA application. A few commenters stated that the FDA application process is dynamic and could switch from “active” to “on hold” at any time for various reasons including temporary pauses for minor questions or the request of supplemental materials, and noted that a temporary hold may be lifted with submission of supplemental materials.

Some commenters raised concerns about what documentation is sufficient to demonstrate that a product was submitted to FDA for approval or review at the time of submission of the new technology add-on payment application and requested additional clarification from CMS. One commenter recommended that CMS accept a copy of the first page of the marketing authorization request cover letter submitted to the FDA as sufficient documentation. Another commenter raised concerns that this would increase the burden on the FDA to provide applicants with proof of a “complete and active” application status.

One commenter requested clarification about whether a “Refuse to File” letter from the FDA would prevent an applicant from applying for new technology add-on payments, recommending that a “Refuse to File” letter should not preclude an applicant from applying for new technology add-on payments because the applicant could correct the filing error and resubmit their NDA or BLA and still meet the current July 1 FDA marketing authorization deadline.

Response: We thank the commenters for the feedback and sharing their concerns. We note that we collaborated with the FDA in developing the terminology used in this proposal, and the intent behind using the terms we did was to ensure that the requirement could apply to and be inclusive of the different types of FDA applications for different types of drugs and devices. Many of the commenters were only referenced terms used for either drugs or for devices, and because a variety of types of technologies, with different FDA marketing authorization application requirements, can be eligible for new technology add-on payment, we are not using terms defined in statute or existing regulations or terms defined by FDA.

We consider, for the purposes of new technology add-on payment applications, an FDA marketing authorization application to be “complete” when the full application has been submitted to FDA. Specifically, for relevant FDA application types, a full application includes all modules or all information following a rolling review or Real-Time Oncology Review (RTOR). We will only accept new technology add-on payment applications once FDA has received all of the information to determine whether it will accept (such as in the case of a 510k application or De Novo Classification request) or file (such as in the case of a FMA, NDA, or BLA) the application as demonstrated by the acceptance/filing letter that is already provided by FDA to indicate that FDA has determined that the application is sufficiently complete to allow for substantive review by FDA. Additionally, for the purposes of new technology add-on payment applications, we consider an FDA marketing authorization application to be in an “active” status when the application has been determined by

FDA application has an “active status” at the time of new technology add-on payment application submission. As described previously, the intent of this requirement is to ensure that applicants are far enough along in the FDA review process that applicants would be able to reasonably provide sufficient information at the time of application for CMS to identify critical questions regarding the technology’s eligibility for add-on payments and to allow the public to assess the relevant new technology evaluation criteria in the proposed rule. Regarding the documentation that would suffice for the purposes of this policy, as described previously, we are requiring the documentation provided to applicants by FDA after FDA concludes that the application is sufficiently complete to permit a substantive review. We note that when FDA instead provides applicants with a “Refuse to File” (RTF) or “Refusal to Accept” (RTA) letter, this specifically indicates that FDA has determined the application is not complete and therefore those applicants that have received an RTF or RTA letter will not be eligible to apply for new technology add-on payment until the application is resubmitted to FDA and an acceptance/filing letter is received. Comment: A few commenters requested exceptions for QIDPs and LPADs to one or both aspects of the proposal. The commenters stated that since applications for these technologies only require the cost criterion, they should be exempt from the proposal, as the proposal could delay access to QIDPs and LPADs.

Response: We thank commenters for their feedback. We note that we did not propose to change the July 1 deadline for technologies for which an application is submitted under the alternative pathway for certain antimicrobial products because they would continue to be eligible for conditional approval under § 412.87(e)(3) (as finalized in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58740)). However, we do not believe it is appropriate to exempt any technology from the requirement to request FDA marketing authorization prior to applying for new technology add-on payments. As discussed previously, this proposal is intended to increase transparency for the proposed rule, and as such, receiving the most information possible at the time of application would result in robust analysis and discussion for the proposed rule to maximize transparency. Furthermore, as discussed previously, with regard to the alternative pathways, such applications may also be missing information that would help inform understanding of the details and interrelationship between the intended indication and FDA QIDP (or Breakthrough Device) designation, which is the basis for a product’s eligibility for the relevant alternative pathway.

Comment: Several commenters requested that if CMS finalizes its proposal, it should delay implementing until after FY 2025. The commenters recommended that CMS provide more notice to manufacturers and delay implementation of the proposed new policies until FY 2026 or later to provide more time for manufacturers to adjust their development processes. Some commenters raised concerns that planning for the FY 2025 cycle is already underway and if these policy changes are implemented in this final rule, they would no longer be able to apply for a new technology add-on payment in the next cycle as they anticipated, which raises the risk that Medicare beneficiaries would not have reliable access to these new technologies for more than a year after FDA approval. One commenter also noted that it takes about 6–10 months from the initial FDA application request to receive an approval decision, and that by the time the final rule releases in August, if the policy is finalized, it may be too late for manufacturers to apply and receive FDA approval before the May 1 deadline. Other commenters specifically noted that this could require Breakthrough Devices/510k applications to submit an application to FDA earlier, such as 4–6 months sooner (since their FDA timeline is shorter), which would mean a year delay in add-on payments if the deadline is missed, since they can currently apply to FDA as late as April and still anticipate approval by July 1.

Response: We thank the commenters for their recommendations regarding delay of implementation of the proposal. It seems that commenters are suggesting that manufacturers may strategically time the submission of an application to the FDA to align an expected decision by the FDA with the timelines for new technology add-on payment eligibility. We encourage manufacturers to pursue the appropriate regulatory processes to bring new products to market as soon as practical. While FDA reviews often have standard estimated timeframes from application to approval, we understand that there can be many variables in the review, including FDA seeking new or additional information, that may result in a longer or shorter timeframe to approval than estimated. We further note that CMS continues to pay for new...
For an October 1 add-on payment start date, new technology add-on payment applications could have a deadline of April 1, with a public meeting in early/mid-May, with new technology add-on payment proposals issued in early/mid-June allowing for a 30-day comment period leading to final new technology add-on payment decisions in late August with an effective date of October 1; the second cycle would follow a similar timeline with a new technology add-on payment application deadline of October 1 and April 1 add-on payment start date. This commenter stated that this proposed timeline would be consistent with the statute and would allow for more new technology add-on payment determinations, which would, in theory, enhance the quantity and quality of claims data used for ratesetting. Other commenters also noted that biannual new technology add-on payment reviews could also theoretically result in more claims data to analyze in the next fiscal year.

Another commenter asserted that section 1886(d)(5)(K)(vi) of the Act does not prevent the agency from approving new technology add-on payment applications more than once a year, but mandates only that the Secretary provide the addition of new diagnosis and procedure codes on April 1, while giving the Secretary discretion to adjust the payment. One commenter proposed that the 60-day comment period could be avoided by CMS going through rulemaking to establish the substantive legal standards used to determine whether a product qualifies for new technology add-on payment, as well as the process, including the opportunity for public comment, for applying those standards. The commenter noted precedent for similar approaches under the Medicare program, including the Clinical Laboratory Fee Schedule rate setting process and the process for approving applications for transitional pass-through payment under the Outpatient Prospective Payment System. Another commenter stated that the statute does not prevent CMS from considering applications prior to the required public meeting, and accordingly supported a quarterly review process.

A few commenters suggested that more frequent reviews could help address patient access challenges, reduce the volume of applications per application cycle, provide CMS with additional time to fully review and analyze applications and reduce the administrative burden on the agency, and ensure timely reimbursement for new technologies. Other commenters recommended that CMS consider expanding alternative pathways and conditional approvals to more types of technologies, for example, products designated as Breakthrough Therapies and Regenerative Medicine Advanced Therapies (RMAT) by the FDA, innovative therapies, cell and gene therapies, in-vitro diagnostics, etc., to reduce workload and accelerate review timelines. Some commenters recommended that CMS expand the new technology add-on payment conditional approval pathway to include all technologies approved or cleared by the FDA through the Breakthrough Device Program to reduce workload and improve access.

One commenter stated that CMS should consider more frequent application cycles or other mechanisms that allow for faster NTAP eligibility, and indicated that certain technologies, such as antimicrobial products, have unique characteristics or policy needs recognized by CMS that warrant bespoke new technology add-on payment policies. The commenter stated that CMS should consider adopting a similar mechanism in other contexts to allow a new technology add-on payment to be implemented on a rolling or quarterly basis, especially in situations where there is a heightened policy need to facilitate new technology add-on payment availability.

A number of commenters suggested that CMS not finalize these policies and instead gather additional input from interested parties to assist with finding alternative policies, such as convening various interested parties to discuss potential alternatives or issuing a separate request for information (RFI) related to the new technology add-on payment applications process. One commenter stated that a 200 percent increase in new technology add-on payment applications would require additional resources but recommended that CMS work with interested parties to explore other options before finalizing any policy and ensure that any future changes to the new technology add-on payment process maintain transparency into the agency’s decisions and provide applicants and the public the opportunity to provide comments.

A few commenters recommended that instead of requiring proof of active FDA review by the application deadline, CMS should require that proof by the December supplemental information deadline. They stated that this could account for the lag between FDA submission and the acknowledgment letter CMS is proposing to require, and
this modification to the proposed policy would enable CMS to achieve the stated intent of striking a balance between being able to fully evaluate applications and preserving flexibility for manufacturers.

**Response:** We thank the commenters for their suggestions and recommendations. We believe at the heart of these comments is a shared interest among commenters and CMS in the goal of the new technology add-on payment program, which is to facilitate access to innovative new technologies for Medicare beneficiaries. We understand that the goals of other new technology payment pathways, such as transitional pass-through payments under the OPPS, may be similar.

However, there are a number of complexities, both legal and operational, that CMS would need to consider before proposing and finalizing an increase in the frequency of new technology add-on payment application review cycles, and not all of these complexities are the same in other new technology payment programs, such as transitional pass-through payment under the Outpatient Prospective Payment System. For example, the assessment of whether new technology add-on payment applicants meet the newness criterion intersects with other requirements associated with MS–DRG development and assessment, which is tied to fiscal year rulemaking and ratesetting. We note that we did not propose increasing the frequency of the new technology add-on payment application cycle, and as such, we believe it is most appropriate to consider the feasibility of taking such steps in future years, so that we could solicit public comment through a full notice-and-comment rulemaking cycle.

Regarding the comments that recommended CMS should require proof of active FDA review by the December supplemental information deadline instead of the new technology add-on payment application deadline, as stated previously, we believe the new technology add-on payment application timeline with a simultaneous deadline for submission of a request for FDA marketing authorization is appropriate because when applicants submit new technology add-on payment applications prior to submitting a request to FDA for marketing authorization, missing information from their applications, which is needed to evaluate the eligibility of the technology for the add-on payment, will not become available until after submission to FDA.

With regard to expanding conditional approvals to other types of technologies, we note that we only recently established the pathway of conditional approvals. To date, no application that has gone through the conditional approval pathway has received FDA approval after being granted conditional new technology add-on payment approval and we therefore do not yet have sufficient experience with the conditional approval process. We do not currently have any reasonable expectation that expansion of eligibility for conditional approvals would advance our policy goals of promoting transparency, facilitating public input, and improving the review/evaluation process, or lead to additional technologies being granted conditional approval based on other new technology add-on payment criteria that we are required to assess. In addition, we have stated in prior rulemaking that we do not believe it is appropriate for CMS to determine whether a medical service or technology represents a substantial clinical improvement over existing technologies before FDA makes a determination as to whether the medical service or technology is safe and effective, and therefore we are unable to extend conditional approval to traditional applications (86 FR 45049).

With regard to expanding alternative pathways, we will continue to consider these issues for future rulemaking, including suggestions previously made by commenters to develop other ways pursuant to which a technology could qualify for new technology add-on payments, such as technologies that are designated for an FDA expedited program for drugs or devices (85 FR 58432).

We appreciate all the comments and various suggested alternatives to our proposal, as well as the recognition of our efforts toward greater transparency, public input, and streamlining of the new technology add-on payment application process. We acknowledge the concerns raised by commenters regarding flexibility and clarification of our policy. While commenters were concerned about our proposal, they did not address our concerns with regard to transparency. However, after having reviewed and carefully considered the comments and suggestions we received, we have determined that the additional information that will be made available by requiring a complete and active FDA marketing authorization application prior to submission of a new technology add-on payment application, and the increased time for final review of such application made available by changing the FDA authorization deadline from July 1 to May 1, supports our decision to finalize these policy changes in this final rule.

We have also further clarified the requirements for documentation and the meaning of “complete and active” under this policy, as described previously.

Therefore, for the reasons discussed previously and in the FY 2024 IPPS/LTCH proposed rule, we are finalizing our proposal to require applications to have a complete and active FDA marketing authorization request at the time of the new technology add-on payment application submission, and to move up the FDA marketing authorization deadline from July 1 to May 1, beginning with applications for FY 2025. As stated previously, we have noted commenters’ concern regarding the potential impact of the shortened time period between April 1 and May 1, and we anticipate considering potential changes to the April 1 cut-off for future rulemaking. As previously noted, we are not making changes to the July 1 deadline for applications submitted under the alternative pathway for certain antimicrobial products because they would continue to be eligible for conditional approval under § 412.87(e)(3) (redesignated as § 412.87(f)(3)) in this final rule, as finalized in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58740). We are also finalizing our proposal to redesignate § 412.87(e)(3) as § 412.87(f)(3), and to amend the redesignated § 412.87(f)(3) to revise the current cross-reference to § 412.87(e)(2), in light of the previously discussed proposed amendments.

### III. Changes to the Hospital Wage Index for Acute Care Hospitals

#### A. Background

1. **Legislative Authority**

   Section 1886(d)(3)(E) of the Act requires that, as part of the methodology for determining prospective payments to hospitals, the Secretary adjust the standardized amounts for area differences in hospital wage levels by a factor (established by the Secretary) reflecting the relative hospital wage level in the geographic area of the hospital compared to the national average hospital wage level. We currently define hospital labor market areas based on the delineations of statistical areas established by the Office of Management and Budget (OMB). A discussion of the FY 2024 hospital wage index based on the statistical areas appears under section III.A.2. of the preamble of this final rule.

   Section 1886(d)(3)(E) of the Act requires the Secretary to update the wage index annually and to base the update on a survey of wages and wage-
related costs of short-term, acute care hospitals. CMS collects these data on the Medicare cost report, CMS Form 2552–10, Worksheet S–3, Parts II, III, IV. The OMB control number for this information collection request is 0938–0050, which expires on September 30, 2025. Section 1886(d)(3)(E) of the Act also requires that any updates or adjustments to the wage index be made in a manner that ensures that aggregate payments to hospitals are not affected by the change in the wage index. The adjustment for FY 2024 is discussed in section II.B. of the Addendum to this final rule.

As discussed in section III.I. of the preamble of this final rule, we also take into account the geographic reclassification of hospitals in accordance with sections 1886(d)(8)(B) and 1886(d)(10) of the Act when calculating IPPS payment amounts. Under section 1886(d)(8)(D) of the Act, the Secretary is required to adjust the standardized amounts so as to ensure that aggregate payments under the IPPS after implementation of the provisions, of sections 1886(d)(8)(B), 1886(d)(8)(C), and 1886(d)(10) of the Act are equal to the aggregate prospective payments that would have been made absent these provisions. The budget neutrality adjustment for FY 2024 is discussed in section II.A.4.b. of the Addendum to this final rule.

Section 1886(d)(3)(E) of the Act also provides for the collection of data every 3 years on the occupational mix of employees for short-term, acute care hospitals participating in the Medicare program, in order to construct an occupational mix adjustment to the wage index. (The OMB control number for approved collection of this information is 0938–0907, which expires on January 31, 2026.) A discussion of the occupational mix adjustment that we are applying to the FY 2024 wage index appears under sections III.E. and F. of the preamble of this final rule.

2. Core-Based Statistical Areas (CBSAs) for the FY 2024 Hospital Wage Index

The wage index is calculated and assigned to hospitals on the basis of the labor market area in which the hospital is located. Under section 1886(d)(3)(E) of the Act, beginning with FY 2005, we delineate hospital labor market areas based on OMB-established Core-Based Statistical Areas (CBSAs). The current statistical areas (which were implemented beginning with FY 2015) are based on revised OMB delineations issued on August 30, 2013, in OMB Bulletin No. 13–01. OMB Bulletin No. 13–01 established revised delineations for Metropolitan Statistical Areas, Micropolitan Statistical Areas, and Combined Statistical Areas in the United States and Puerto Rico based on the 2010 Census, and provided guidance on the use of the delineations of these statistical areas using standards published in the June 28, 2010, Federal Register (75 FR 37246 through 37252). We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 48895 through 49963 and 49973 through 49982) for a full discussion of our implementation of the OMB statistical area delineations beginning with the FY 2015 wage index.

Generally, OMB issues major revisions to statistical areas every 10 years, based on the results of the decennial census. However, OMB occasionally issues minor updates and revisions to statistical areas in the years between the decennial censuses through OMB Bulletins. On July 15, 2015, OMB issued OMB Bulletin No. 15–01, which provided updates to and superseded OMB Bulletin No. 13–01 that was issued on February 28, 2013. The attachment to OMB Bulletin No. 15–01 provided detailed information on the update to statistical areas since February 28, 2013. The updates provided in OMB Bulletin No. 15–01 were based on the implementation of the 2010 Standards for Delineating Metropolitan and Micropolitan Statistical Areas to Census Bureau population estimates for July 1, 2012, and July 1, 2013. In the FY 2017 IPPS/LTCH PPS final rule (81 FR 56913), we adopted the updates set forth in OMB Bulletin No. 15–01 effective October 1, 2016, beginning with the FY 2017 wage index. For a complete discussion of the adoption of the updates set forth in OMB Bulletin No. 15–01, we refer readers to the FY 2017 IPPS/LTCH PPS final rule (81 FR 56913).

In the FY 2018 IPPS/LTCH PPS final rule (82 FR 38130), we continued to use the OMB delineations that were adopted beginning with FY 2015 to calculate the area wage indexes, with updates as reflected in OMB Bulletin No. 15–01 and 0050, which expires on September 30, 2018. The updates provided in OMB Bulletin No. 15–01 provided detailed information on the update to statistical areas since July 1, 2014. In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41362 through 41363), we adopted the updates set forth in OMB Bulletin No. 17–01 effective October 1, 2018, beginning with the FY 2019 wage index. For a complete discussion of the adoption of the updates set forth in OMB Bulletin No. 17–01, we refer readers to the FY 2019 IPPS/LTCH PPS final rule. In the FY 2020 IPPS/LTCH PPS final rule (84 FR 42300 through 42301), we continued to use the OMB delineations that were adopted beginning with FY 2015 (based on the revised delineations issued in OMB Bulletin No. 13–01) to calculate the area wage indexes, with updates as reflected in OMB Bulletin Nos. 15–01 and 17–01.

On April 10, 2018 OMB issued OMB Bulletin No. 18–03 which superseded OMB Bulletin No. 17–01 (August 15, 2017). On September 14, 2018, OMB issued OMB Bulletin No. 18–04 which superseded OMB Bulletin No. 18–03 (April 10, 2018). Historically OMB bulletins issued between decennial censuses have only contained minor modifications to CBSA delineations based on changes in population counts. However, OMB’s 2010 Standards for Delineating Metropolitan and Micropolitan Statistical Areas to Census Bureau population estimates created a larger mid-decade redelineation that takes into account commuting data from the American Commuting Survey. As a result, OMB Bulletin No. 18–04 (September 14, 2018) included more modifications to the CBSAs than are typical for OMB bulletins issued between decennial censuses.

In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58743 through 58755) we adopted the updates set forth in OMB Bulletin No. 18–04 effective October 1, 2020, beginning with the FY 2021 wage index. For a complete discussion of the adoption of the updates set forth in OMB Bulletin No. 18–04, we refer readers to the FY 2021 IPPS/LTCH PPS final rule. In the FY 2022 IPPS/LTCH PPS final rule (87 FR 54449 through 54460), we adopted the updates set forth in OMB Bulletin No. 19–01 effective October 1, 2022, beginning with the FY 2022 wage index. For a complete discussion of the adoption of the updates set forth in OMB Bulletin No. 19–01, we refer readers to the FY 2022 IPPS/LTCH PPS final rule. In the FY 2023 IPPS/LTCH PPS final rule (88 FR 73866 through 73885), we adopted the updates set forth in OMB Bulletin No. 20–01 effective October 1, 2023, beginning with the FY 2023 wage index. For a complete discussion of the adoption of the updates set forth in OMB Bulletin No. 20–01, we refer readers to the FY 2023 IPPS/LTCH PPS final rule. In the FY 2024 IPPS/LTCH PPS final rule (89 FR 73797 through 73803), we adopted the updates set forth in OMB Bulletin No. 21–01 effective October 1, 2024, beginning with the FY 2024 wage index. For a complete discussion of the adoption of the updates set forth in OMB Bulletin No. 21–01, we refer readers to the FY 2024 IPPS/LTCH PPS final rule. In the FY 2025 IPPS/LTCH PPS final rule (90 FR 73893 through 73900), we adopted the updates set forth in OMB Bulletin No. 22–01 effective October 1, 2025, beginning with the FY 2025 wage index. For a complete discussion of the adoption of the updates set forth in OMB Bulletin No. 22–01, we refer readers to the FY 2025 IPPS/LTCH PPS final rule.
index for FY 2022. While we adopted the updates set forth in OMB Bulletin No. 20–01 in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45163 through 45164) consistent with our general policy of adopting OMB delineation updates, we also noted that specific wage index updates would not be necessary for FY 2022 as a result of adopting these updates. In other words, the updates set forth in OMB Bulletin No. 20–01 would not affect any hospital’s geographic area for purposes of the wage index calculation for FY 2022. For a complete discussion of the adoption of the updates set forth in OMB Bulletin No. 20–01, we refer readers to the FY 2022 IPPS/LTCH PPS final rule (86 FR 45163 through 45164).

For FY 2024, we will continue to use the OMB delineations that were adopted beginning with FY 2015 (based on the revised delineations issued in OMB Bulletin No. 13–01) to calculate the area wage indexes, with updates as reflected in OMB Bulletin Nos. 15–01, 17–01, 18–04 and 20–01.

3. Codes for Constituent Counties in CBSAs

CBSAs are made up of one or more constituent counties. Each CBSA and constituent county has its own unique identifying codes. There are two different lists of codes associated with counties: Social Security Administration (SSA) codes and Federal Information Processing Standard (FIPS) codes. Historically, CMS has listed and used SSA and FIPS county codes to identify and crosswalk counties to CBSA codes for purposes of the hospital wage index. As we discussed in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38129 through 38130), we have learned that SSA county codes are no longer being maintained and updated. However, the FIPS codes continue to be maintained by the U.S. Census Bureau. We believe that using the latest FIPS codes will allow us to maintain a more accurate and up-to-date payment system that reflects the reality of population shifts and labor market conditions.

The Census Bureau’s most current statistical area information is derived from ongoing census data received since 2010; the most recent data are from 2020. The Census Bureau maintains a complete list of changes to counties or county equivalent entities on the website at https://www.census.gov/programs-surveys/geography/technical-documentation/county-changes.html. We believe that it is important to use the latest counties or county equivalent entities in order to properly crosswalk hospitals from a county to a CBSA for purposes of the hospital wage index used under the IPPS. Per the schedule published in a July 16, 2021 OMB Notice of Decision, we expect revised delineations based on the 2020 decennial census data to be available in July 2023 (86 FR 37775). We intend to address these revisions in future rulemaking.

In the FY 2018 IPPS/LTCH PPS final rule (82 FR 38129 through 38130), we adopted a policy to discontinue the use of the SSA county codes and began using only the FIPS county codes for purposes of cross walking counties to CBSAs. In addition, in the same rule, we implemented the latest FIPS code updates, which were effective October 1, 2017, beginning with the FY 2018 wage indexes. These updates have been used to calculate the wage indexes in a manner generally consistent with the CBSA-based methodologies finalized in the FY 2005 IPPS final rule and the FY 2015 IPPS/LTCH PPS final rule. We refer the reader to the FY 2018 IPPS/LTCH PPS final rule (82 FR 38129 through 38130) for a complete discussion of our adoption of FIPS county codes.

For FY 2024, we are continuing to use only the FIPS county codes for purposes of crosswalking counties to CBSAs. For FY 2024, Tables 2 and 3 associated with this final rule and the County to CBSA Crosswalk File and Urban CBSAs and Constituent Counties for Acute Care Hospitals File posted on the CMS website reflect the latest FIPS code updates.

B. Worksheet S–3 Wage Data for the FY 2024 Wage Index

The FY 2024 wage index values are based on the data collected from the Medicare cost reports submitted by hospitals for cost reporting periods beginning in FY 2020 (the FY 2023 wage indexes were based on data from cost reporting periods beginning during FY 2019).

1. Included Categories of Costs

The FY 2024 wage index includes all of the following categories of data associated with costs paid under the IPPS (as well as outpatient costs):

- Salaries and hours from short-term, acute care hospitals (including paid lunch hours and hours associated with military leave and jury duty).
- Home office costs and hours.
- Certain contract labor costs and hours, which include direct patient care, certain top management, pharmacy, laboratory, and nonteaching physician crosswalk and certain contract indirect patient care services (as discussed in the FY 2008 final rule with comment period (72 FR 47315 through 47317)).
- Wage-related costs, including pension costs (based on policies adopted in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51586 through 51590) and modified in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49505 through 49508)) and other deferred compensation costs.

2. Excluded Categories of Costs

Consistent with the wage index methodology for FY 2023, the wage index for FY 2024 also excludes the direct and overhead salaries and hours for services not subject to IPPS payment, such as skilled nursing facility (SNF) services, home health services, costs related to GME (teaching physicians and residents) and certified registered nurse anesthetists (CRNAs), and other subprovider components that are not paid under the IPPS. The FY 2024 wage index also excludes the salaries, hours, and wage-related costs of hospital-based rural health clinics (RHCs), and Federally Qualified Health Centers (FQHCs) because Medicare pays for these costs outside of the IPPS (68 FR 45395). In addition, salaries, hours, and wage-related costs of CAHs are excluded from the wage index for the reasons explained in the FY 2004 IPPS final rule (68 FR 45397 through 45398). For FY 2020 and subsequent years, other wage-related costs are also excluded from the calculation of the wage index. As discussed in the FY 2019 IPPS/LTCH final rule (83 FR 41365 through 41369), other wage-related costs reported on Worksheet S–3, Part II, Line 18 and Worksheet S–3, Part IV, Line 25 and subscripts, as well as all other wage-related costs, such as contract labor costs, are excluded from the calculation of the wage index.

3. Use of Wage Index Data by Suppliers and Providers Other Than Acute Care Hospitals Under the IPPS

Data collected for the IPPS wage index also are currently used to calculate wage indexes applicable to suppliers and other providers, such as SNFs, home health agencies (HHAs), ambulatory surgical centers (ASCs), and hospices. In addition, they are used for prospective payments to IRFs, IPPs, and LTCHs, and for hospital outpatient services. We note that, in the IPPS rules, we do not address comments pertaining to the wage indexes of any supplier or provider except IPPS providers and LTCHs. Such comments should be made in response to separate proposed rules for those suppliers and providers. We did not receive any comments on the discussion in this section.
G. Verification of Worksheet S–3 Wage Data

The wage data for the FY 2024 wage index were obtained from Worksheet S–3, Parts II, III and IV of the Medicare cost report, CMS Form 2552–10 (OMB Control Number 0938–0050 with an expiration date September 30, 2025) for cost reporting periods beginning on or after October 1, 2019, and before October 1, 2020. For wage index purposes, we refer to cost reports beginning on or after October 1, 2019, and before October 1, 2020, as the “FY 2020 cost report,” the “FY 2020 wage data,” or the “FY 2020 data.” Instructions for completing the wage index sections of Worksheet S–3 are included in the Provider Reimbursement Manual (PRM), Part 2 (Pub. 15–2), Chapter 40, sections 4005.2 through 4005.4. The data file used to construct the FY 2024 wage index includes FY 2020 data submitted to us as of June 2023. As in past years, we performed an extensive review of the wage data, mostly through the use of edits designed to identify aberrant data.

Consistent with the IPPS and LTCH PPS ratesettings, our policy principles with regard to the wage index include generally using the most current data and information available which is usually data on a 4-year lag (for example, for the FY 2022 wage index we used cost report data from FY 2018). We stated in the FY 2023 IPPS/LTCH PPS final rule (87 FR 48994) that we will be looking at the differential effects of the COVID–19 PHE on the audited wage data in future fiscal years. We also stated we plan to review the audited wage data, and the impacts of the COVID–19 PHE on such data and evaluate these data for future rulemaking. For the FY 2024 wage index, the best available data typically would be from the FY 2020 wage data.

In the proposed rule we stated that based on pre reclassified wage data, the changes in the wage data from FY 2019 to FY 2020 show the following compared to the annual changes for the most recent 3 fiscal years (that is, FY 2016 to FY 2017, FY 2017 to FY 2018 and FY 2018 to FY 2019):

- Approximately 85 percent of hospitals have an increase in their average hourly wage (AHW) from FY 2019 to FY 2020 compared to a range of 76–77 percent of hospitals for the most recent 3 year periods.
- Approximately 81 percent of all CBSA AHWs increased from FY 2019 to FY 2020 compared to a range of 73–75 percent of all CBSAs for the most recent 3 year periods.
- Approximately 36 percent of all urban areas have an increase in their area wage index from FY 2019 to FY 2020 compared to a range of 41–43 percent of all urban areas for the most recent 3 year periods.
- Approximately 2.8 percent of all rural areas have an increase in their area wage index from FY 2019 to FY 2020 compared to a range of 4–6 percent of all rural areas for the most recent 3 year periods.
- The unadjusted national average hourly wage increased by a range of 2.4–2.8 percent per year from FY 2016 to FY 2019. For FY 2020, the unadjusted national average hourly increased by 5.3 percent from FY 2019.

Even if the comparison with the historical trends had indicated greater differences at a national level in this context, we stated it is not apparent whether any changes due to the COVID–19 PHE differentially impacted the wages paid by individual hospitals. Furthermore, even if hypothetically changes due to the COVID–19 PHE did differentially impact the wages paid by individual hospitals over time, we further stated that it is not clear how those changes could be isolated from changes due to other reasons and what an appropriate potential methodology might be to adjust the data.

Lastly, we also noted that we did not identify any significant issues with the FY 2020 wage data itself in terms of our audits of this data. As usual, the data was audited by the MACs, and there were no significant issues reported across the data for all hospitals. Taking all of these factors into account, we stated that we believe the FY 2020 wage data is the best available wage data to use for FY 2024. Therefore, we propose to use the FY 2020 wage data for FY 2024.

We also noted that AHW data by provider and CBSA, including the data upon which the comparisons as previously described are based, is available in our Public Use Files released with each proposed and final rule each fiscal year. The Public Use Files for the respective FY Wage Index Home Page can be found on the Wage Index Files web page at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Wage-Index-Files.

Comment: One commenter stated that CMS should not be utilizing any data from FY 2020 due to the impacts of COVID–19.

Another commenter stated that based on the agency’s description of the proposed rule, the specifics of the analysis above are unclear, as the agency does not reference specific tables or files for the public to review to confirm the agency’s conclusion. The commenter further stated that while CMS states that the data does not show a significant discrepancy from prior years’ data, when compared to trends from the previous three fiscal years, the FY 2020 data does not follow the same trends. Also, the commenter noted that the extent of the wage increases is important to consider, not just the percentage of hospitals that saw an hourly wage increase. The commenter stated that without knowing what other sources of data are available for future wage index calculations or evaluating a comparison of other data sources to identify any potential discrepancies, the commenter is concerned that the impact of the COVID–19 PHE may not be easily parsed out of future years’ data.

The commenter also commented that while CMS states that it does not believe the PHE alone is responsible for these changes, and that it is difficult to parse out what impact the PHE had versus other factors that may be driving up wages, the commenter is concerned that the agency does not provide alternate methods for calculating the wage index to try account for the impact of COVID–19. Although the impact of the PHE may not have been apparent on wage data until partially through FY 2020, the commenter believes that CMS should consider approaches to best account for the wage spikes and changes that are a result of the pandemic. The commenter cited data from Vizient’s May 2023 Workforce Intelligence Report that contract labor rates are expected to stay 15% above pre-pandemic levels due to inflation and other external economic factors. The commenter also noted that numerous nursing workforce trends changed once the pandemic began in 2020, including those related to nursing overtime hours as a percentage of hours work, burnout, and turnover and asserted that these trends are not sustainable. The commenter also stated that if hospitals were to adopt and use strategies to address staffing challenges (e.g., ensure nurses are practicing at the top of their license, plan ahead for seasonable contract labor use, using technology as an enabler but not a standalone solution) they would impact the wage index and such trends are not considered by CMS. The commenter encouraged CMS to share additional information regarding its analysis and other information the agency needs so stakeholders can better understand the
agency’s position and respond accordingly. The commenter further encouraged CMS to begin exploring alternate data sources and analyses to better understand how to account for the impact of the pandemic in the wage index given enduring employment trends that were triggered by the pandemic. The commenter concluded that CMS should work with stakeholders on further developing or refining such an approach to promote stability and accuracy.

Response: We are unsure what the commenter means when it states that the agency does not reference specific tables or files for the public to review to confirm the agency’s conclusion. As stated above, AHW data by provider and CBSA, including the data upon which the comparisons, as previously described are based, is available in our Public Use Files released with each proposed and final rule each fiscal year. The Public Use Files for the respective FY Wage Index Home Page can be found on the Wage Index Files web page at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Wage-Index-Files. Therefore, any comparisons that CMS made within the current year data and prior year data can easily be replicated by the public by utilizing standard, commonly known statistical methods.

Also, the commenter states that the FY 2020 data does not follow the same trends as prior years. However, as stated earlier, for the reasons described above (it is not apparent whether any changes due to the COVID–19 PHE differentially impacted the wages paid by individual hospitals; even if hypothetically changes due to the COVID–19 PHE did differentially impact the wages paid by individual hospitals over time, we further stated that it is not clear how those changes could be isolated from changes due to other reasons and what an appropriate potential methodology might be to adjust the data; we did not identify any significant issues with the FY 2020 wage data itself in terms of our audits of this data), we continue to believe the FY 2020 wage data is the best available wage data to use for FY 2024.

With regard to the use of alternative data, as stated above, we did not identify any significant issues with the FY 2020 wage data itself in terms of our audits of this data. As usual, the data was audited by the MACs, and there were no significant issues reported across the data for all hospitals. Also, as stated above, it is not apparent whether any changes due to the COVID–19 PHE differentially impacted the wages paid by individual hospitals. Furthermore, the commenters did not present any data from the actual wage data demonstrating the need to use alternative data. The commenter cited outside data sources with no actual data from our public use files. Additionally, the commenter is asking CMS to project potential changes hospitals may make to address potential staffing shortages without any supporting data. Also, if hospital workforce trends changed uniformly once the pandemic began in 2020 or if hospitals adopted strategies to address staffing shortages uniformly, then this would be reflected uniformly across the salaries and hours for all hospitals and areas (which is used to calculate an area’s AHW) which would lead to a commensurate change to the national AHW and not the wage index itself. Therefore, we continue to believe the FY 2020 wage data is the best available wage data to use for FY 2024.

Comment: One commenter stated that as a result of high COVID–19 patient volume for more than two years and subsequent healthcare staff departures during the pandemic, hospitals are in the midst of a national staffing shortage. The commenter continued that inflation is simultaneously driving up healthcare costs during this workforce shortage. The commenter believes CMS should offer short-term assistance to the hospital community, considering inflationary updates to the wage index as necessary to preserve current service levels, which is a particular risk point for underserved populations. The commenter recommended a more time-sensitive and layered approach to wage index updates to account for excess labor costs driven by increased contract labor and reimbursement rates to preserve critical national hospital system infrastructure. The commenter stated that CMS could accomplish this by leveraging current Medicare surveys and reporting to develop a wage adjustment until the labor market stabilizes. The commenter concluded that this approach would account for regional disparities and impact, use known and accepted survey data, create a standardized and auditable system, and support hospitals without disrupting the baseline Medicare wage index.

Response: The commenter mentions that CMS could leverage current Medicare surveys and reporting to develop a wage adjustment until the labor market stabilizes. It is not clear what the commenter is requesting. As stated above, the latest audited wage data is from FY 2020. We do not possess audited wage data from a more recent period. We also are unsure what type of adjustment the commenter is requesting and how this adjustment would account for regional adjustments. Without additional information we are unable to respond directly to the comment. Also, as previously noted, section 1886(d)(3)(E) of the Act requires that, as part of the methodology for determining prospective payments to hospitals, the Secretary adjust the standardized amounts for area differences in hospital wage levels by a factor (established by the Secretary) reflecting the relative hospital wage level in the geographic area of the hospital compared to the national average hospital wage level. If the commenter is requesting a uniform adjustment to the salaries and hours then uniformly adjusting the salaries and hours for all areas (which is used to calculate an areas AHW) would lead to a commensurate change to the national AHW and not the wage index itself. This is because the wage index is required to be a relative measure.

Comment: One commenter urged CMS to reconsider using FY 2020 cost report data to calculate the wage index. The commenter explained that CMS has stated that FY 2020 cost reports contained data that was significantly impacted by the COVID–19 PHE, which will disproportionately impact reimbursements for Massachusetts hospitals and cause these hospitals to be underpaid because of the “Nantucket effect.” That is, the commenter noted that, in general, Massachusetts hospitals saw heightened levels of COVID–19 patients in FY 2020, while one hospital located on the island of Nantucket saw almost no COVID–19 patients because the island was able to isolate from the rest of the state. As a result of this effect, the commenter contended that the Nantucket hospital’s FY 2020 cost report is not reflective of the COVID burden experienced by other hospitals in the state. The commenter recommended that CMS use the FY 2022 cost reports, which better reflects its labor market.

Response: We believe the commenter is referring to provider number 220110, Nantucket Cottage Hospital, as this is the only hospital from Nantucket included in the wage data. Within the wage data each fiscal year, there are hospitals that have different hiring practices and experiences. For example, some hospitals may be smaller than others and not provide the same complex services as another hospital in the area. Or one hospital may have more contracted workers compared to another hospital in the same area that has no contracted workers. Perhaps that hospital is focused on cancer patients compared to another hospital that tries
to provide all types of services. But these are not reasons that would make a hospital’s data aberrant. This simply means that hospitals provide different care, have different hiring practices or have different case mixes and are different from each other; but it does not make the wage data aberrant or not reflective of the area. Similarly, a hospital that may have had a different experience with COVID does not mean the wage data of that hospital is aberrant or not reflective of the area. Also, we are unsure what issue the commenter is referring to with regard to including this hospital in its area as Nantucket Cottage Hospital is the only hospital located in rural Massachusetts. Finally, the data for the FY 2024 wage index uses FY 2020 cost report data which was audited by the MACs, and there were no significant issues reported across the data for all hospitals. Additionally, CMS used the most recent audited surveys and data to develop the FY 2024 wage index. Audited cost report data from FY 2022 will be used for FY 2026 and is not available at the time of this final rule. Therefore, we do not have any audited data from the FY 2022 cost reports available for use at the time of this final rule. We continue to believe the FY 2020 wage data is the best available wage data to use for FY 2024.

For the FY 2025 wage index, as in the past two fiscal years, we plan to review the audited wage data, and the impacts of the COVID–19 PHE on such data and evaluate these data for future rulemaking.

Section 1886(d)(3)(E) of the Act requires the Secretary to adjust the proportion of hospitals’ costs attributable to wages and wage-related costs for area differences reflecting the relative hospital wage level in the geographic area of the hospital compared to the national average hospital wage level. In response to public comments, as previously stated in past final rules (the FY 2016 IPPS/LTCH PPS final rule (80 FR 49490 through 49491), the FY 2022 IPPS/LTCH PPS final rule (86 FR 45168 through 45169), and the FY 2023 IPPS/LTCH PPS final rule (87 FR 48996 through 48997)), we believe that, under this section of the Act, we have discretion to exclude aberrant hospital data from the wage index public use files (PUFs) to help ensure that the costs attributable to wages and wage-related costs in fact reflect the relative hospital wage level in the hospitals’ geographic area. We refer the reader to our previous responses to comments at the Federal Register pages cited earlier with regard to the exclusion of hospitals’ wage data from the wage index.

Comment: Commenters opposed the exclusion of audited hospitals’ wage data which they contended was arbitrarily excluded from the proposed rule wage data. These commenters stated that excluding accurate and verified data is inconsistent with the extensive process established by CMS to ensure the accuracy and reliability of hospital wage index data. Commenters also stated the following concerns about the lawfulness of excluding wage data for these hospitals:

- Nothing in the applicable statute, section 1886(d)(3)(E), permits CMS to exclude general acute care hospitals from the wage index data simply because those hospitals’ wages are higher than the wages of other hospitals in their area. Rather, as indicated by CMS in past rulemakings, the wages of all short-term acute care hospitals must be included unless such data are incomplete or inaccurate.
- Even if CMS had the authority to exclude certain hospitals despite the wage data were accurate and verifiable (which is the case with these hospitals), the exclusion of these hospitals would be arbitrary and capricious, as CMS has promulgated no standards to govern the exercise of its discretion. CMS has established an extensive process to ensure the accuracy and reliability of hospital wage data, which the excluded hospitals have been subjected to. Yet, where the agency does not like the result, it has decided to deviate from this process by arbitrarily excluding hospitals with accurate data.
- CMS’ exclusion of these hospitals is procedurally improper, as CMS has failed to promulgate a rule in accordance with the Administrative Procedures Act (APA) and section 2886 of the Social Security Act that would define what constitutes aberrant data or authorize excluding hospitals with verifiable data from the Medicare wage index.
- CMS has failed to consider the relevant factors and has relied on factors that are not relevant under the applicable statute. As a result, its action is arbitrary and capricious. The commenter explained that because CMS has not conducted notice-and-comment rulemaking to establish standards for excluding hospitals from the wage index, it is unknown what factors CMS considered. Further, since CMS has not proposed any ascertainable standards, the public has no meaningful opportunity to comment on the factors that should be considered.
- The proposed exclusions for FFY 2024 would not harm to not only IPPS hospitals, but also inpatient psychiatric hospitals, SNFs, inpatient rehabilitation hospitals (IRFs), and many others. The consequence of these exclusions negatively impacting more than the IPPS hospitals appear to be unintended by CMS, as it failed to even consider them in its regulatory fiscal impact analysis in the proposed rule, which it is legally required to do. Thus, the exclusions are legally impermissible.

Response: As discussed above, we responded to similar comments in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49490 through 49491) and the FY 2022 IPPS/LTCH PPS final rule (86 FR 45168 through 45169). We provide summary responses below based on our responses to similar comments from previous rulemaking. However, we refer commenters to the Federal Register pages cited earlier for our complete response to similar comments with regard to the exclusion of hospitals’ wage data from the wage index.

Section 1886(d)(3)(E) of the Act requires the Secretary to adjust the proportion of hospital costs attributable to wages and wage-related costs for area differences reflecting the relative hospital wage level in the geographic area of the hospital compared to the national average hospital wage level. As previously stated in those final rules, we believe that, under this section of the Act, we have discretion to exclude aberrant hospital data from the wage index PUFs to help ensure that the costs attributable to wages and wage-related costs in fact reflect the relative hospital wage level in the hospitals’ geographic area.

Also, as discussed in response to comments in prior rules (80 FR 49490 and 86 FR 45168), as a standard part of the refinement of the annual wage index, CMS evaluates the wage data for both accuracy and reasonableness to ensure that the wage index is a relative measure of the labor value provided to a typical hospital in a particular labor market area. We have also previously stated that a hospital is included in the wage index if its data are reasonable, regardless of whether the hospital is open or whether it has terminated after the relevant past period, because the wage index is constructed to represent the relative average hourly wage for each labor market area in that past period. Thus, reasonableness and relativity to each area’s average hourly wages have been longstanding tenets of the wage index development process that CMS has articulated in rulemaking.

We acknowledge the commenters’ suggestions for increased transparency and disclosure of hospital’s exclusion. We believe performing an analysis of hospitals’ wage data quality
We do not believe that the average hourly wage of this particular hospital accurately reflects the economic conditions in its labor market area during the FY 2018 cost reporting period. Therefore, its inclusion in the wage index would not ensure that the FY 2024 wage index represents the labor market area’s current wages as compared to the national average of wages. Rather, its inclusion would distort the average hourly wage of its labor market area. Accordingly, we have exercised our discretion to remove this hospital’s wage data from the FY 2024 wage index.

With regard to the impact on facilities paid under other PPSs, we refer commenters to the rulemaking of those PPSs for comments on the wage index. We requested that our MACs revise or verify data elements that result in specific edit failures. For the proposed FY 2024 wage index, we identified and excluded 88 providers with aberrant data that should not be included in the wage index. However, we stated that if data elements for some of these providers are corrected, we intended to include data from those providers in the final FY 2024 wage index. We also adjusted certain aberrant data and included these data in the wage index. For example, in situations where a hospital did not have documentable salaries, wages, and hours for housekeeping and dietary services, we imputed estimates, in accordance with policies established in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49965 through 49967). We instructed MACs to complete their data verification of questionable data elements and to transmit any changes to the wage data no later than March 20, 2023. For the final FY 2024 wage index, we restored the data of 27 hospitals to the wage index, because their data was either verified or improved. Thus, 61 hospitals with aberrant data remain excluded from the FY 2024 wage index (88 – 27 = 61).

In constructing the proposed FY 2024 wage index, we included the wage data for facilities that were IPPS hospitals in FY 2020, inclusive of those facilities that have since terminated their participation in the program as hospitals, as long as those data did not fail any of our edits for reasonableness. We stated in the proposed rule (88 FR 26965 through 26967) that we believe that including the wage data for these hospitals is, in general, appropriate to reflect the economic conditions in the various labor market areas during the relevant past period and to ensure that the current wage index represents the labor market area’s current wages as compared to the national average of wages. However, we excluded the wage data for CAHs as discussed in the FY 2004 IPPS final rule (68 FR 45397 through 45398); that is, any hospital that is designated as a CAH by 7 days prior to the publication of the preliminary wage index public use file (PUF) is excluded from the calculation of the wage index. For the proposed FY 2024 wage index, we removed 1 hospital that converted to CAH status on or after January 22, 2022, the cut-off date for CAH exclusion from the FY 2023 wage index, and through and including January 23, 2023, the cut-off date for CAH exclusion from the FY 2024 wage index. Since the proposed rule, we learned of 1 more hospital that converted to CAH status on or after January 22, 2022, and through and including January 23, 2023, the cut-off date for CAH exclusion from the FY 2024 wage index, for a total of 2 hospital that were removed from the FY 2024 wage index due to conversion to CAH status. In summary, we calculated the FY 2024 wage index using the Worksheet S–3, Parts II and III wage data for 3,129 hospitals.

For the FY 2024 wage index, we allotted the wages and hours data for a multicampus hospital among the different labor market areas where its campuses are located using campus full-time equivalent (FTE) percentages as originally finalized in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51591). Table 2, which contains the FY 2024 wage index associated with this final rule (available via the internet on the CMS website), includes separate wage data for the campuses of 28 multicampus hospitals. The following chart lists the multicampus hospitals by core service area (CSA) certification number (CCN) and the FTE percentages on which the wages and hours of each campus were allotted to their respective labor market areas:
<table>
<thead>
<tr>
<th>CCN of Main Campus of Multicampus Hospital</th>
<th>Full-Time Equivalent Percentage of Main Campus</th>
<th>CCN of Sub Campus of Multicampus Hospital</th>
<th>Full-Time Equivalent Percentage of Sub Campus</th>
</tr>
</thead>
<tbody>
<tr>
<td>050121</td>
<td>0.86</td>
<td>05B121</td>
<td>0.14</td>
</tr>
<tr>
<td>070010</td>
<td>0.87</td>
<td>07B010</td>
<td>0.13</td>
</tr>
<tr>
<td>070022</td>
<td>0.99</td>
<td>07B022</td>
<td>0.01</td>
</tr>
<tr>
<td>070033</td>
<td>0.93</td>
<td>07B033</td>
<td>0.07</td>
</tr>
<tr>
<td>100029</td>
<td>0.51</td>
<td>10B029</td>
<td>0.49</td>
</tr>
<tr>
<td>100167</td>
<td>0.66</td>
<td>10B167</td>
<td>0.34</td>
</tr>
<tr>
<td>140010</td>
<td>0.83</td>
<td>14B010</td>
<td>0.17</td>
</tr>
<tr>
<td>220074</td>
<td>0.89</td>
<td>22B074</td>
<td>0.11</td>
</tr>
<tr>
<td>310069</td>
<td>0.80</td>
<td>31B069</td>
<td>0.20</td>
</tr>
<tr>
<td>330103</td>
<td>0.64</td>
<td>33B103</td>
<td>0.36</td>
</tr>
<tr>
<td>330195</td>
<td>0.89</td>
<td>33B195</td>
<td>0.11</td>
</tr>
<tr>
<td>330214</td>
<td>0.76</td>
<td>33B214</td>
<td>0.24</td>
</tr>
<tr>
<td>330234</td>
<td>0.79</td>
<td>33B234</td>
<td>0.21</td>
</tr>
<tr>
<td>340115</td>
<td>0.95</td>
<td>34B115</td>
<td>0.05</td>
</tr>
<tr>
<td>360020</td>
<td>0.97</td>
<td>36B020</td>
<td>0.03</td>
</tr>
<tr>
<td>390006</td>
<td>0.96</td>
<td>39B006</td>
<td>0.04</td>
</tr>
<tr>
<td>390115</td>
<td>0.84</td>
<td>39B115</td>
<td>0.16</td>
</tr>
<tr>
<td>390142</td>
<td>0.84</td>
<td>39B142</td>
<td>0.16</td>
</tr>
<tr>
<td>450033</td>
<td>0.99</td>
<td>45B033</td>
<td>0.01</td>
</tr>
<tr>
<td>450107</td>
<td>0.50</td>
<td>45B107</td>
<td>0.50</td>
</tr>
<tr>
<td>450330</td>
<td>0.98</td>
<td>45B330</td>
<td>0.02</td>
</tr>
<tr>
<td>460051</td>
<td>0.78</td>
<td>46B051</td>
<td>0.22</td>
</tr>
<tr>
<td>510022</td>
<td>0.94</td>
<td>51B022</td>
<td>0.06</td>
</tr>
<tr>
<td>520009</td>
<td>0.70</td>
<td>52B009</td>
<td>0.30</td>
</tr>
<tr>
<td>520030</td>
<td>0.95</td>
<td>52B030</td>
<td>0.05</td>
</tr>
<tr>
<td>670062</td>
<td>0.69</td>
<td>67B062</td>
<td>0.31</td>
</tr>
<tr>
<td>670107</td>
<td>0.69</td>
<td>67B107</td>
<td>0.31</td>
</tr>
</tbody>
</table>

We note that, in past years, in Table 2, we have placed a “B” to designate the subordinate campus in the fourth position of the hospital CCN. However, for the FY 2019 IPPS/LTCH PPS proposed and final rules and subsequent rules, we have moved the “B” to the third position of the CCN. Because all IPPS hospitals have a “0” in the third position of the CCN, we believe that placement of the “B” in this third position, instead of the “0” for the subordinate campus, is the most efficient method of identification and interferes the least with the other, variable, digits in the CCN.

### D. Method for Computing the FY 2024 Unadjusted Wage Index

As stated in the proposed rule (88 FR 26967 through 26970), the method used to compute the FY 2024 wage index without an occupational mix adjustment follows the same methodology that we used to compute the wage indexes without an occupational mix adjustment in the FY 2021 IPPS/LTCH PPS final rule (see 85 FR 58758 through 58761, September 18, 2020), and we did not propose any changes to this methodology. We have restated our methodology in this section of this rule.

Step 1.—We gathered data from each of the non-Federal, short-term, acute care hospitals for which data were reported on the Worksheet S–3, Parts II and III of the Medicare cost report for the hospital’s cost reporting period relevant to the wage index (in this case, for FY 2024, these were data from cost reports for cost reporting periods beginning on or after October 1, 2019, and before October 1, 2020). In addition, we included data from some hospitals...
that had cost reporting periods beginning before October 2019 and reported a cost reporting period covering all of FY 2020. These data were included because no other data from these hospitals would be available for the cost reporting period as previously described, and because particular labor market areas might be affected due to the omission of these hospitals. However, we generally describe these wage data as FY 2020 data. We note that, if a hospital had more than one cost reporting period beginning during FY 2020 (for example, a hospital had two short cost reporting periods beginning on or after October 1, 2019, and before October 1, 2020), we include wage data from only one of the cost reporting periods, the longer, in the wage index calculation. If there was more than one cost reporting period and the periods were equal in length, we included the wage data from the later period in the wage index calculation.

Step 2.—Salaries.—The method used to compute a hospital’s average hourly wage excludes certain costs that are not paid under the IPPS. We note that, beginning with FY 2008 (72 FR 47315), we included what were then Lines 22, 01, 26.01, and 27.01 of Worksheet S–3, Part II of CMS Form 2552–96 for overhead salaries and home office salaries for which no corresponding hours are reported are not included, wage-related costs for nonteaching physician Part A services (Lines 11, 12 and 13), home office salaries and wage-related costs reported by the hospital on Lines 14.01, 14.02, and 15, and nonexcluded area wage-related costs (Lines 17, 22, 25.50, 25.51, and 25.52). We note that contract labor and home office salaries for which no corresponding hours are reported are not included, wage-related costs for nonteaching physician Part A employees (Line 22) are excluded if no corresponding salaries are reported for those employees on Line 4. The formula for Total Salaries plus Wage-Related Costs (from Worksheet S–3, Part II) is the following:

$$\frac{(\text{Line 1} + \text{Line 28} + \text{Line 33} + \text{Line 35})}{\text{Line 1} + \text{Lines 28, 33, and 35}}$$

Step 3.—Hours.—With the exception of wage-related costs, for which there are no associated hours, we compute total hours using the same methods as described for salaries in Step 2. The formula for Total Hours (from Worksheet S–3, Part II) is the following:

$$\frac{(\text{Line 1} + \text{Line 28} + \text{Line 33} + \text{Line 35})}{\text{Line 1} + \text{Lines 28, 33, and 35}}$$

Step 4.—For each hospital reporting both total overhead salaries and total overhead hours greater than zero, we then allocate overhead costs to areas of the hospital excluded from the wage index calculation. First, we determine the “excluded rate”, which is the ratio of excluded area hours to Revised Total Hours (from Worksheet S–3, Part II) with the following formula:

$$\text{Line 9 + Line 10}/(\text{Line 1} + \text{Line 28} + \text{Line 33} + \text{Line 35})$$

We then compute the amounts of overhead salaries and hours to be allocated to the excluded areas by multiplying the previously discussed ratio by the total overhead salaries and hours reported on Lines 26 through 43 of Worksheet S–3, Part II. Next, we compute the amounts of overhead wage-related costs to be allocated to the excluded areas using three steps:

- We determine the “overhead rate” (from Worksheet S–3, Part II), which is the ratio of overhead hours (Lines 26 through 43 minus the sum of Lines 28, 33, and 35) to revised hours excluding the sum of Lines 28, 33, and 35 (Line 1 minus the sum of Lines 2, 3, 4.01, 5, 6, 7, 7.01, 8, 9, 10, 28, 33, and 35). We note that, for the FY 2008 and subsequent wage index calculations, we have been excluding the overhead contract labor (Lines 28, 33, and 35) from the determination of the ratio of overhead hours to revised hours because hospitals typically do not provide fringe benefits (wage-related costs) to contract personnel. Therefore, it is not necessary for the wage index calculation to exclude overhead wage-related costs for contract personnel. Further, if a hospital does contribute to wage-related costs for contracted personnel, the instructions for Lines 28, 33, and 35 require that associated wage-related costs be combined with wages on the respective contract labor lines. The formula for the Overhead Rate (from Worksheet S–3, Part II) is the following:

$$(\text{Lines 26 through 43} - \text{Lines 28, 33 and 35})/(((\text{Line 1} + \text{Line 28}, 33, 35) - \text{Lines 2, 3, 4.01, 5, 6, 7, 7.01, 8, and 26 through 43}) - \text{Line 9 and 10}) + (\text{Lines 26 through 43} - \text{Lines 28, 33, and 35}))$$

- We compute overhead wage-related costs by multiplying the overhead hours ratio by wage-related costs reported on Part II, Lines 17, 22, 25.50, 25.51, and 25.52.

- We multiply the computed overhead wage-related costs by the previously described excluded area hours ratio.

Finally, we subtract the computed overhead salaries, wage-related costs, and hours associated with excluded areas from the total salaries (plus wage-related costs) and hours derived in Steps 2 and 3.

Step 5.—For each hospital, we adjust the total salaries plus wage-related costs to a common period to determine total adjusted salaries plus wage-related costs. To make the wage adjustment, we estimate the percentage change in the employment cost index (ECI) for compensation for each 30-day increment from October 14, 2019, through April 15, 2021, for private industry hospital workers from the Bureau of Labor Statistics’ (BLS’) National Compensation Survey. We use the ECI because it reflects the price
increase associated with total compensation (salaries plus fringe) rather than just the increase in salaries. In addition, the ECI includes managers as well as other hospital workers. This methodology to compute the monthly update factors uses actual quarterly ECI data and assures that the update factors match the actual quarterly and annual percent changes. We also note that, since April 2006 with the publication of March 2006 data, the BLS’ ECI uses a different classification system, the North American Industrial Classification System (NAICS), instead of the Standard Industrial Codes (SICs), which no longer exist. We have consistently used the ECI as the data source for our wages and salaries and other price proxies in the IPPS market basket, and we did not propose to make any changes to the usage of the ECI for FY 2024. The factors used to adjust the hospital’s data are based on the midpoint of the cost reporting period, as indicated in this rule.

Step 6.—Each hospital is assigned to its appropriate urban or rural labor market area before any reclassifications under section 1886(d)(6)(B), 1886(d)(6)(E), or 1886(d)(10) of the Act. Within each urban or rural labor market area, we add the total adjusted salaries plus wage-related costs obtained in Step 5 for all hospitals in that area to determine the total adjusted salaries plus wage-related costs for the labor market area.

Step 7.—We divide the total adjusted salaries plus wage-related costs obtained under Step 6 by the sum of the corresponding total hours (from Step 4) for all hospitals in each labor market area to determine an average hourly wage.

Step 8.—We add the total adjusted salaries plus wage-related costs obtained in Step 5 for all hospitals in the nation and then divide the sum by the national sum of total hours from Step 4 to arrive at a national average hourly wage.

Step 9.—For each urban or rural labor market area, we calculate the hospital wage index value, unadjusted for occupational mix, by dividing the area average hourly wage obtained in Step 7 by the national average hourly wage computed in Step 8.

Step 10.—For each urban labor market area for which we do not have any hospital wage data (either because there are no IPPS hospitals in that labor market area, or there are IPPS hospitals in that area but their data are either too new to be reflected in the current year’s wage index calculation, or their data are aberrant and are deleted from the wage index), we finalized in the FY 2020 IPPS/LTCH PPS final rule (84 FR 42305) that, for FY 2020 and subsequent years’ wage index calculations, such CBSA’s wage index would be equal to total urban salaries plus wage-related costs (from Step 5) in the State, divided by the total urban hours (from Step 4) in the State, divided by the national average hourly wage from Step 8 (see 84 FR 42305 and 42306, August 16, 2019). We stated that we believe that, in the absence of wage data for an urban labor market area, it is reasonable to use a statewide urban average, which is based on actual, acceptable wage data of hospitals in that State, rather than impute some other type of value using a different methodology. For calculation of the FY 2024 wage index, we note there is one urban CBSAs for which we do not have IPPS hospital wage data. In Table 3 (which is available via the internet on the CMS website) which contains the area wage indexes, we include a footnote to indicate to which CBSAs this policy applies. These CBSA’s wage indexes would be equal to total urban salaries plus wage-related costs (from Step 5) in the respective State, divided by the total urban hours (from Step 4) in the respective State, divided by the national average hourly wage (from Step 8) (see 84 FR 42305 and 42306, August 16, 2019). Under this step, we also apply our policy with regard to how dollar amounts, hours, and other numerical values in the wage index calculations are rounded, as discussed in this section of this rule. We refer readers to section II. of appendix A of this final rule for the policy regarding rural areas that do not have IPPS hospitals.

Step 11.—Section 4410 of Public Law 105–33 provides that, for discharges on or after October 1, 1997, the area wage index applicable to any hospital that is located in an urban area of a State may not be less than the area wage index applicable to hospitals located in rural areas in that State. The areas affected by this provision are identified in Table 2 listed in section VI. of the Addendum to the final rule and available via the internet on the CMS website.

The following is our policy with regard to rounding of the wage data (dollar amounts, hours, and other numerical values) in the calculation of the unadjusted and adjusted wage index, as finalized in the FY 2020 IPPS/LTCH PPS final rule (84 FR 42306, August 16, 2019). For data that we consider to be “raw data,” such as the cost report data on Worksheets S–3, Parts II and III, and the occupational mix survey data, we use such data “as is,” and do not round any of the individual line items or fields. However, for any dollar amounts within the wage index calculations, including any type of summed wage amount, average hourly wages, and the national average hourly wage (both the unadjusted and adjusted for occupational mix), we round the dollar amounts to 2 decimals. For any hour amounts within the wage index calculations, we round such hour amounts to the nearest whole number. For any numbers not expressed as dollars or hours within the wage index calculations, which could include ratios, percentages, or inflation factors, we round such numbers to 5 decimals. However, we continue rounding the actual unadjusted and adjusted wage indexes to 4 decimals, as we have done historically.

As discussed in the FY 2012 IPPS/LTCH PPS final rule, in “Step 5,” for each hospital, we adjust the total salaries plus wage-related costs to a common period to determine total adjusted salaries plus wage-related costs. To make the wage adjustment, we estimate the percentage change in the employment cost index (ECI) for compensation for each 30-day increment from October 14, 2019, through April 15, 2021, for private industry hospital workers from the BLS’ National Compensation Survey. We have consistently used the ECI as the data source for our wages and salaries and other price proxies in the IPPS market basket, and we did not propose any changes to the usage of the ECI for FY 2024. The factors used to adjust the hospital’s data are based on the midpoint of the cost reporting period, as indicated in the following table.
For example, the midpoint of a cost reporting period beginning January 1, 2020, and ending December 31, 2020, is June 30, 2020. An adjustment factor of 1.01923 was applied to the wages of a hospital with such a cost reporting period.

Previously, we also would provide a Puerto Rico overall average hourly wage. As discussed in the FY 2017 IPPS/LTCH PPS final rule (81 FR 56915), prior to January 1, 2016, Puerto Rico hospitals were paid based on 75 percent of the national standardized amount and 25 percent of the Puerto Rico-specific standardized amount. As a result, we calculated a Puerto Rico specific wage index that was applied to the labor-related share of the Puerto Rico-specific standardized amount. As we stated in the FY 2017 IPPS/LTCH PPS final rule (81 FR 56915 through 56916), because Puerto Rico hospitals are no longer paid with a Puerto Rico specific standardized amount as of January 1, 2016, under section 1886(d)(9)(E) of the Act, as amended by section 601 of the Consolidated Appropriations Act, 2016, there is no longer a need to calculate a Puerto Rico specific average hourly wage and wage index. Hospitals in Puerto Rico are now paid 100 percent of the national standardized amount and, therefore, are subject to the national average hourly wage (unadjusted for occupational mix) and the national wage index, which is applied to the national labor-related share of the national standardized amount.

Based on the previously discussed methodology, we stated in the proposed rule (88 FR 26970) that the proposed FY 2024 unadjusted national average hourly wage was $50.33.

We did not receive any comments regarding the discussion of our method for computing the FY 2024 unadjusted national average hourly wage. Based on the previously described methodology, the final FY 2024 unadjusted national average hourly wage is the following:

| Final FY 2024 Unadjusted National Average Hourly Wage | $50.39 |

### E. Occupational Mix Adjustment to the FY 2024 Wage Index

As stated earlier, section 1886(d)(3)(E) of the Act provides for the collection of data every 3 years on the occupational mix of employees for each short-term, acute care hospital participating in the Medicare program, in order to construct an occupational mix adjustment to the wage index, for application beginning October 1, 2004 (the FY 2005 wage index). The purpose of the occupational mix adjustment is to control for the effect of hospitals’ employment choices on the wage index. For example, hospitals may choose to employ different combinations of registered nurses, licensed practical nurses, nursing aides, and medical assistants for the purpose of providing nursing care to their patients. The varying labor costs associated with these choices reflect hospital management decisions rather than geographic differences in the costs of labor.

<table>
<thead>
<tr>
<th>After</th>
<th>Before</th>
<th>Adjustment Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/14/2019</td>
<td>11/15/2019</td>
<td>1.03524</td>
</tr>
<tr>
<td>11/14/2019</td>
<td>12/15/2019</td>
<td>1.03312</td>
</tr>
<tr>
<td>12/14/2019</td>
<td>01/15/2019</td>
<td>1.03102</td>
</tr>
<tr>
<td>01/14/2020</td>
<td>02/15/2020</td>
<td>1.02896</td>
</tr>
<tr>
<td>02/14/2020</td>
<td>03/15/2020</td>
<td>1.02694</td>
</tr>
<tr>
<td>03/14/2020</td>
<td>04/15/2020</td>
<td>1.02497</td>
</tr>
<tr>
<td>04/14/2020</td>
<td>05/15/2020</td>
<td>1.02305</td>
</tr>
<tr>
<td>05/14/2020</td>
<td>06/15/2020</td>
<td>1.02119</td>
</tr>
<tr>
<td>06/14/2020</td>
<td>07/15/2020</td>
<td>1.01923</td>
</tr>
<tr>
<td>07/14/2020</td>
<td>08/15/2020</td>
<td>1.01705</td>
</tr>
<tr>
<td>08/14/2020</td>
<td>09/15/2020</td>
<td>1.01465</td>
</tr>
<tr>
<td>09/14/2020</td>
<td>10/15/2020</td>
<td>1.01219</td>
</tr>
<tr>
<td>10/14/2020</td>
<td>11/15/2020</td>
<td>1.00987</td>
</tr>
<tr>
<td>11/14/2020</td>
<td>12/15/2020</td>
<td>1.00767</td>
</tr>
<tr>
<td>12/14/2020</td>
<td>01/15/2021</td>
<td>1.00540</td>
</tr>
<tr>
<td>01/14/2021</td>
<td>02/15/2021</td>
<td>1.00284</td>
</tr>
<tr>
<td>02/14/2021</td>
<td>03/15/2021</td>
<td>1.00000</td>
</tr>
<tr>
<td>03/14/2021</td>
<td>04/15/2021</td>
<td>0.99686</td>
</tr>
</tbody>
</table>
1. Use of 2019 Medicare Wage Index Occupational Mix Survey for the FY 2024 Wage Index

Section 304(c) of the Consolidated Appropriations Act, 2001 (Pub. L. 106–554) amended section 1886(d)(3)(E) of the Act to require CMS to collect data every 3 years on the occupational mix of employees for each short-term, acute care hospital participating in the Medicare program. As discussed in the FY 2022 IPPS/LTCH PPS proposed rule (86 FR 25402 through 25403) and final rule (86 FR 45173), we collected data in 2019 to compute the occupational mix adjustment for the FY 2022, FY 2023, and FY 2024 wage indexes. The FY 2024 occupational mix adjustment is based on the calendar year (CY) 2019 survey. Hospitals were required to submit their completed 2019 surveys (Form CMS–10079, OMB Number 0938–0907, expiration date January 31, 2026) to their MACs by September 3, 2021. The preliminary, unaudited CY 2019 survey data were posted on the CMS website on September 8, 2020. As with the Worksheet S–3, Parts II and III cost report wage data, as part of the FY 2022 desk review process, the MACs revised or verified data elements in hospitals’ occupational mix surveys that resulted in certain edit failures.

2. Calculation of the Occupational Mix Adjustment for FY 2024

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26971), for FY 2024, we proposed to calculate the occupational mix adjustment factor using the same methodology that we have used since the FY 2012 wage index (76 FR 51582 through 51586) and to apply the occupational mix adjustment to 100 percent of the FY 2024 wage index. In the FY 2020 IPPS/LTCH PPS final rule (84 FR 42308), we modified our methodology with regard to how dollar amounts, hours, and other numerical values in the unadjusted and adjusted wage index calculation are rounded, in order to ensure consistency in the calculation. According to the policy finalized in the FY 2020 IPPS/LTCH PPS final rule (84 FR 42308 and 42309), for data that we consider to be “raw data,” such as the cost report data on Worksheets S–3, Parts II and III, and the occupational mix survey data, we continue to use these data “as is”, and not round any of the individual line items or fields. However, for any dollar amounts within the wage index calculations, including any type of summed wage amount, average hourly wages, and the national average hourly wage (both the unadjusted and adjusted for occupational mix), we round such dollar amounts to 2 decimals. We round any hour amounts within the wage index calculations to the nearest whole number. We round any numbers not expressed as dollars or hours in the wage index calculations, which could include ratios, percentages, or inflation factors, to 5 decimals. However, we continue rounding the actual unadjusted and adjusted wage indexes to 4 decimals, as we have done historically.

Similar to the method we use for the calculation of the wage index without occupational mix, salaries and hours for a multicampus hospital are allotted among the different labor market areas where its campuses are located. Table 2 associated with this final rule (which is available via the internet on the CMS website), which contains the final FY 2024 occupational mix adjusted wage index, includes separate wage data for the campuses of multicampus hospitals. We refer readers to section III.C. of the preamble of this final rule for a chart listing the multicampus hospitals and the FTE percentages used to allot their occupational mix data.

Because the statute requires that the Secretary measure the earnings and paid hours of employment by occupational category not less than once every 3 years, all hospitals that are subject to payments under the IPPS, or any hospital that would be subject to the IPPS if not granted a waiver, must complete the occupational mix survey, unless the hospital has no associated cost report wage data that are included in the FY 2024 wage index. For the proposed FY 2024 wage index, we used the Worksheet S–3, Parts II and III wage data of 3,103 hospitals, and we used the occupational mix surveys of 3,007 hospitals for which we also had Worksheet S–3 wage data, which represented a “response” rate of 97 percent (3,007/3,103). For the proposed FY 2024 wage index, we applied proxy data for noncompliant hospitals, new hospitals, or hospitals that submitted erroneous or aberrant data in the same manner that we applied proxy data for such hospitals in the FY 2012 wage index occupational mix adjustment (76 FR 51586). As a result of applying this methodology, the final FY 2024 occupational mix adjusted national average hourly wage was $50.27.

For the final FY 2024 wage index, we are using the Worksheet S3, Parts II and III wage data of 3,129 hospitals, and we are using the occupational mix surveys of 3,031 hospitals for which we also have Worksheet S–3 wage data, which is a “response” rate of 97 percent (3,031/3,129). For the final FY 2024 wage index, we are applying proxy data for noncompliant hospitals, new hospitals, or hospitals that submitted erroneous or aberrant data in the same manner that we applied proxy data for such hospitals in the FY 2012 wage index occupational mix adjustment (76 FR 51586). As a result of applying this methodology, the final FY 2024 occupational mix adjusted national average hourly wage is the following:

| FY 2024 Occupational Mix Adjusted National Average Hourly Wage | $50.34 |

3. Deadline for Submitting the 2022 Medicare Wage Index Occupational Survey for Use Beginning With the FY 2025 Wage Index

A new measurement of occupational mix is required for FY 2025. The FY 2025 occupational mix adjustment will be based on a new calendar year (CY) 2022 survey. The CY 2022 survey (Form CMS–10079, OMB Number 0938–0907, expiration date January 31, 2026) received OMB approval on January 3, 2023. The final CY 2022 Occupational Mix Survey Hospital Reporting Form is available on the CMS website at: https://www.cms.gov/medicare/medicare-fee-service-payment/acuteinpatientpps/wage-index-files/2022-occupational-mix-survey-hospital. Hospitals were required to submit their completed 2022 surveys to their MACs (not directly to CMS) by June 30, 2023. The preliminary, unaudited CY 2022 survey data was posted on the CMS website in mid-July 2023. As with the Worksheet S–3, Parts II and III cost report wage data, as part of the FY 2025 desk review process, the MACs will revise or verify data elements in hospitals’ occupational mix surveys that result in certain edit failures.

Comment: We received comments with regard to the CY 2022 Occupational Mix Survey data. One commenter had concerns that the data may be skewed due to the PHE. Another commenter stated that CMS must ensure it is including all of the available data, including the data that were submitted.
to the agency, when it constructs an occupational mix adjustment to the wage index. In addition, the commenter stated CMS must ensure that such data is corrected after the initial submission deadline.

Response: CMS has yet to audit and review the CY 2022 Occupational Mix Survey data. We plan to assess the CY 2022 Occupational Mix Survey data in the FY 2025 IPPS proposed rule. Additionally, per the FY 2025 wage index development timetable on the web at https://www.cms.gov/files/document/fy2025-hospital-wage-index-development-timetable.pdf, providers have until September 1, 2023, to request revisions to their Worksheet S–3 wage data and CY 2022 occupational mix data as included in the wage and occupational mix preliminary public use files. We refer the reader to the FY 2025 wage index development timetable for complete details.

F. Analysis and Implementation of the Occupational Mix Adjustment and the FY 2024 Occupational Mix Adjusted Wage Index

As discussed in section III.E. of the preamble of this final rule, for FY 2024, we are applying the occupational mix adjustment to 100 percent of the FY 2024 wage index. We calculated the occupational mix adjustment using data from the 2019 occupational mix survey data, using the methodology described in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51582 through 51586).

The FY 2024 national average hourly wages for each occupational mix nursing subcategory as calculated in Step 2 of the occupational mix calculation are as follows:

<table>
<thead>
<tr>
<th>Occupational Mix Nursing Subcategory</th>
<th>Average Hourly Wage</th>
</tr>
</thead>
<tbody>
<tr>
<td>National RN</td>
<td>$44.42</td>
</tr>
<tr>
<td>National LPN and Surgical Technician</td>
<td>$26.85</td>
</tr>
<tr>
<td>National Nurse Aide, Orderly, and Attendant</td>
<td>$18.53</td>
</tr>
<tr>
<td>National Medical Assistant</td>
<td>$19.51</td>
</tr>
<tr>
<td>National Nurse Category</td>
<td>$37.35</td>
</tr>
</tbody>
</table>

The national average hourly wage for the entire nurse category is computed in Step 5 of the occupational mix calculation. Hospitals with a nurse category average hourly wage (as calculated in Step 4) of greater than the national nurse category average hourly wage receive an occupational mix adjustment factor (as calculated in Step 6) of less than 1.0. Hospitals with a nurse category average hourly wage (as calculated in Step 4) of less than the national nurse category average hourly wage receive an occupational mix adjustment factor (as calculated in Step 6) of greater than 1.0.

Based on the 2019 occupational mix survey data, we determined (in Step 7 of the occupational mix calculation) the following:

| National Percentage of Hospital Employees in the Nurse Category | 42% |
| National Percentage of Hospital Employees in the All Other Occupations Category | 58% |
| Range of Percentage of Hospital Employees in the Nurse Category (CBSA Level) | Low of 20 Percent in one CBSA to a high of 68 percent in another CBSA |

We compared the FY 2024 occupational mix adjusted wage indexes for each CBSA to the unadjusted wage indexes for each CBSA. Applying the occupational mix adjustment to the wage data resulted in the following:

<table>
<thead>
<tr>
<th>Comparison of the FY 2024 Occupational Mix Adjusted Wage Indexes to the Unadjusted Wage Indexes by CBSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Urban Areas Wage Index Increasing</td>
</tr>
<tr>
<td>Number of Rural Areas Wage Index Increasing</td>
</tr>
<tr>
<td>Number of Urban Areas Wage Index Increasing by Greater Than or Equal to 1 Percent But Less Than 5 Percent</td>
</tr>
<tr>
<td>Number of Urban Areas Wage Index Increasing by 5 percent or More</td>
</tr>
<tr>
<td>Number of Rural Areas Wage Index Increasing by Greater Than or Equal to 1 Percent But Less Than 5 Percent</td>
</tr>
<tr>
<td>Number of Rural Areas Wage Index Increasing by 5 percent or More</td>
</tr>
<tr>
<td>Number of Urban Areas Wage Index Decreasing</td>
</tr>
<tr>
<td>Number of Rural Areas Wage Index Decreasing</td>
</tr>
<tr>
<td>Number of Urban Areas Wage Index Decreasing by Greater Than or Equal to 1 Percent But Less Than 5 Percent</td>
</tr>
<tr>
<td>Number of Urban Areas Wage Index Decreasing by 5 percent or More</td>
</tr>
<tr>
<td>Number of Rural Areas Wage Index Decreasing by Greater Than or Equal to 1 Percent But Less Than 5 Percent</td>
</tr>
<tr>
<td>Number of Rural Areas Wage Index Decreasing by 5 percent or More</td>
</tr>
<tr>
<td>Largest Positive Impact for an Urban Area</td>
</tr>
<tr>
<td>Largest Positive Impact for a Rural Area</td>
</tr>
<tr>
<td>Largest Negative Impact for an Urban Area</td>
</tr>
<tr>
<td>Largest Negative Impact for a Rural Area</td>
</tr>
<tr>
<td>Urban Areas Unchanged by Application of the Occupational Mix Adjustment</td>
</tr>
<tr>
<td>Rural Areas Unchanged by Application of the Occupational Mix Adjustment</td>
</tr>
</tbody>
</table>
G. Application of the Rural Floor, Application of the Imputed Floor, Application of the State Frontier Floor, Continuation of the Low Wage Index Hospital Policy, and Permanent Cap on Wage Index Decreases

1. Application of the Rural Floor

Section 4410(a) of the Balanced Budget Act of 1997 (Pub. L. 105–33) provides that, for discharges on or after October 1, 1997, the area wage index applicable to any hospital that is located in an urban area of a State may not be less than the area wage index applicable to hospitals located in rural areas in that State. This provision is referred to as the rural floor. Section 3141 of the Patient Protection and Affordable Care Act (Pub. L. 111–148) also requires that a national budget neutrality adjustment be applied in implementing the rural floor.

Based on the FY 2024 wage index associated with this final rule (which is available via the internet on the CMS website) and based on the calculation of the rural floor in using the wage data of hospitals that have reclassified as rural under §412.103 (as discussed in section III.K. of the preamble of this final rule), we estimate that 646 hospitals will receive the rural floor in FY 2024. The budget neutrality impact of the proposed application of the rural floor is discussed in section II.A.4.e. of the Addendum of this final rule.

a. Treatment of Hospitals Reclassified as Rural Under §412.103 for the Rural Wage Index and Rural Floor Calculation

Section 1886(d)(8)(E)(i) of the Act, implemented at 42 CFR 412.103, requires that not later than 60 days after the receipt of an application (in a form and manner determined by the Secretary) from a subsection (d) hospital that satisfies certain criteria, the Secretary shall treat the hospital as being located in the rural area (as defined in paragraph (2)(D)) of the State in which the hospital is located.

In recent years, CMS’s wage index and floor policies involving the treatment of §412.103 hospitals has been the subject of frequent litigation. Courts have repeatedly held unlawful CMS wage index and floor policies that do not treat §412.103 hospitals the same as geographically rural hospitals based on section 1886(d)(8)(E)(i) of the Act, which requires that “the Secretary shall treat the §412.103 hospital as being located in the rural area.”

For example, on July 23, 2015, the U.S. Court of Appeals for the Third Circuit issued a decision in Geisinger Community Medical Center v. Secretary, United States Department of Health and Human Services, 794 F.3d 383 (3d Cir. 2015). Geisinger challenged as unlawful a CMS regulation prohibiting hospitals with an active §412.103 rural reclassification from applying for an additional reclassification for wage index purposes through the MGCRB. A divided panel of the Court of Appeals for the Third Circuit held that section 1886(d)(8)(E)(i) of the Act required the Secretary to treat §412.103 hospitals the same as geographically rural hospitals for the purposes of MGCRB reclassification. Because geographically rural hospitals were eligible for MGCRB reclassification, the court held CMS’s regulation prohibiting §412.103 hospitals from seeking MGCRB reclassification was unlawful.

On February 4, 2016, the U.S. Court of Appeals for the Second Circuit issued its decision in Lawrence + Memorial Hospital v. Burwell, 812 F.3d 257 (2d Cir. 2016), agreeing with the Third Circuit’s conclusion in Geisinger. The Second Circuit disagreed with CMS’s argument that the impact of these decisions—allowing §412.103 hospitals to be urban for wage index purposes and rural for others—was “‘absurd’”:

“[T]his is simply a function of the many different roles that hospitals play and the many different contexts in which they operate . . . Section 401 simply increases the number of situations in which hospitals can be treated as rural for some purposes and urban for others, but there is nothing ‘absurd’ about such a measured approach.” Id. At 267.

As a consequence of the Geisinger and Lawrence + Memorial decisions, CMS published an interim final rule with comment period (IFC) on April 21, 2016 (81 FR 23428 through 23438), revising the regulations to allow hospitals to hold simultaneous §412.103 and MGCRB reclassifications, consistent with the courts’ decisions. But commenters have since argued that CMS continued to treat §412.103 hospitals differently from geographically rural hospitals in two respects. First, CMS only allowed MGCRB reclassifications for §412.103 hospitals when the hospital’s wages are at least 106 percent of the urban area in which it was geographically located, rather than the rural area to which it was reclassified under §412.103. They also applied for rural reclassification under the Act to reclassify through the MGCRB but not under §412.103. They also applied for reclassification under the MGCRB but were denied because their wages were not at least 106 percent of the geographic urban area in which the hospitals were located. Each of the hospitals’ average hourly wages were at least 106 percent of the 3-year average hourly wage of all other hospitals in the rural area of the state in which the hospitals were located. The Court agreed with the Plaintiffs that section 1886(d)(8)(E)(i) of Act requires that CMS consider the rural area to be the area in which a §412.103 hospital is located for the wage comparisons required for MGCRB reclassifications.

CMS did not appeal this decision, and in the May 10, 2021 Federal Register (86 FR 24735), concurrent with the FY 2022 IPPS/LTCH PPS proposed rule, we published an interim final rule with comment period that amended our regulations to allow hospitals that received a rural reclassification under the Act to reclassify through the MGCRB using the rural reclassified area as the geographic area in which the hospital is located. We stated that these changes implemented the Bates Court’s interpretation of the requirement at section 1886(d)(8)(E)(i) of the Act that “the Secretary shall treat the hospital as being located in the rural area,” for all purposes of MGCRB reclassification, including the average hourly wage comparisons required by §412.230(a)(5)(i) and (d)(1)(iii)(C).

The second policy was recently challenged in Deaconess Hospital Inc. v. Becerra, No. 1:22–cv–03136 (D.D.C. Oct. 14, 2022) and Robert Packer v. Becerra, No. 1:22–cv–03196 (D.D.C. Oct. 19, 2022). Specifically, plaintiffs in Deaconess and Robert Packer contend that CMS must include §412.103 hospitals reclassified to another wage area under the MGCRB in the rural wage index and rural wage floor under the “hold harmless” provision in section 1886(d)(8)(C)(ii) of Act. That provision provides that if an MGCRB decision “reduces the wage index for that rural area (as applied under this subsection), the Secretary shall calculate and apply such wage index under this subsection as if the hospitals so treated had not been excluded from calculation of the wage index for that rural area.”

The treatment of §412.103 hospitals was again the subject of litigation in a recent case contesting our FY 2020 rural floor policy, under which we calculated the rural floor and the related budget neutrality adjustment without including
data from hospitals that reclassified from urban to rural (84 FR 42332 through 42336). On April 8, 2022, the district court in Citrus HMA, LLC, d/b/a Seven Rivers Regional Medical Center v. Becerra, No. 1:20-cv-00707 (D.D.C.) (Citrus) found that the Secretary did not have authority under section 4410(a) of the Balanced Budget Act of 1997 to establish a rural floor different from the rural wage index for a state.

Following our review of the Citrus decision (which we did not appeal) and the comments we received on the FY 2023 IPPS/LTCH PPS proposed rule, in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49002 through 49004), we finalized a policy that calculates the rural floor as it was calculated before FY 2020. We stated that we understand that our policy of setting a rural floor lower than the rural wage index for a state was inconsistent with the district court’s decision in Citrus. For FY 2023 and subsequent years, our policy is to include the wage data of hospitals that have reclassified from urban to rural under section 1886(d)(8)(C)(ii) of the Act (as implemented in the regulations at § 412.103) and have no MGCRB reclassification in the calculation of the rural floor, and to include the wage data of such hospitals in the calculation of “the wage index for rural areas in the State in which the county is located” as referred to in section 1886(d)(8)(C)(iii) of the Act.191 We stated that we will apply the same policy as prior to the FY 2020 final rule for calculating the rural floor, in which the rural wage index sets the rural floor.

In addition to the litigation, as previously described, CMS has received numerous public comments in recent years urging CMS to treat § 412.103 hospitals the same as geographically rural hospitals for the rural wage index calculation (87 FR 49002). Spurred by the aforementioned district court’s decision in Citrus, we stated that we now agree—for the reasons expressed by the U.S. Courts of Appeals for the Second and Third Circuits, as well as the U.S. District Court for the District of Columbia—that the best reading of section 1886(d)(8)(E)’s text that CMS “shall treat the § 412.103 hospital as being located in the rural area”, is that it instructs CMS to treat § 412.103 hospitals the same as geographically rural hospitals for the wage index calculation. We stated that while CMS has previously treated section 1886(d)(8)(E) reclassifications as one among many reclassifications provided for under section 1886(d) of the Act and so limited its scope in several ways, we now read it to provide that a § 412.103 reclassification functions the same as if the reclassifying hospital had physically relocated into a geographically rural area. We explained in the proposed rule that we are influenced by the fact that courts have largely adopted this interpretation of section 1886(d)(8)(E) of the Act, and that it requires considerable resources to unwind a wage index policy after adverse judicial decisions—often requiring an IFC outside the usual IPPS rulemaking schedule. We further note that such unwindings may have budget neutrality implications. Cf. Amgen, Inc. v. Smith, 357 F.3d 101, 112 (D.D.C. 2004) (collecting cases “not[ing] the havoc that piecemeal review of OPPS payments could bring about” in light of statutory budget neutrality requirements).

We acknowledged that this interpretation of section 1886(d)(8)(E) of the Act can lead to significant financial consequences. Many hospitals eligible for § 412.103 reclassifications have paired that reclassification with a MGCRB wage index reclassification to escalate their wage index beyond what would be otherwise available to them under the law. Section 1886(d)(3)(E)(j) of the Act states that any adjustments or updates made under subparagraph (E) for a fiscal year shall be made in a manner that assures that the aggregate payments Medicare makes to other hospitals. But, as the Second Circuit explained (Lawrence + Memorial Hospital v. HHS, 871 F.3d 451, 457 (2d Cir. 2017) (collecting cases “not[ing] the havoc that piecemeal review of OPPS payments could bring about” in light of statutory budget neutrality requirements).
Hospital, 812 F.3d at 267), these payment consequences are “a function of the many different roles that hospitals play and the many different contexts in which they operate.” We solicited comments on our proposed interpretation of sections 1886(d)(8)(E) and 1886(d)(3)(E)(i) of the Act.

As additionally previously discussed, pending litigation and public comments in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45181 and 45182) have raised concerns that there is an additional wage index policy under which CMS does not treat § 412.103 hospitals the same as geographically rural hospitals: its policy of CMS excluding data from § 412.103 hospitals that are reclassified to an urban area by the MGCRB for wage index purposes when calculating the rural wage index for that state. We proposed to change that policy, consistent with our new proposed interpretation of section 1886(d)(8)(E) of the Act, as described in this section of this rule. Under the policy changes adopted in the FY 2023 IPPS/LTCH PPS final rule under which the rural floor is the same as the rural wage index (87 FR 49002 through 49004), we believe that this change to the wage index policy will also resolve the concerns about the rural floor raised in comments discussed previously. As far as we are aware, these are the only policies that our reinterpretation of section 1886(d)(8)(E) of the Act requires us to change, but we solicited comments on whether there are any remaining policies that CMS should reexamine in light of our proposed reinterpretation of section 1886(d)(8)(E) of the Act.

b. Current Calculation of the Rural Wage Index and Application of Various Hold Harmless Policies

Sections 1886(d)(8)(C)(ii) and (iii) of the Act are “hold harmless” provisions that may affect the wage index calculation when hospitals reclassify out of a state’s rural area into another area. Section 1886(d)(8)(C)(ii) of the Act provides that if the application of section 1886(d)(8)(B) of the Act (“Lugar” status) or a decision of the MGCRB or the Secretary under section 1886(d)(10) of the Act, by treating hospitals located in a rural county or counties as not being located in the rural area in a state, reduces the wage index for that rural area, the Secretary shall calculate and apply such wage index as if the hospitals so treated had not been excluded from calculation of the wage index for that rural area. Section 1886(d)(8)(C)(iii) of the Act provides that the application of section 1886(d)(8)(B) of the Act (“Lugar” status) or a decision of the MGCRB or the Secretary under section 1886(d)(10) of the Act may not result in the reduction of any county’s wage index to a level below the wage index for rural areas in the state in which the county is located.

In the FY 2006 IPPS final rule (70 FR 47378 and 47379), we adopted a regulatory hold harmless policy for situations where hospitals reclassify into a state’s rural area under section 1886(d)(8)(E) of the Act. We stated that the wage data of an urban hospital reclassifying into the rural area are included in the rural area’s wage index, if including the urban hospital’s data increases the wage index of the rural area. Otherwise, the wage data are excluded. It has been CMS’s policy since then to include hospitals with state-to-state MGCRB reclassifications to a nearby state’s rural area along with hospitals reclassified under section 1886(d)(8)(E) of the Act in this regulatory hold harmless policy.

In the FY 2010 IPPS/LTCH PPS final rule (74 FR 43837 and 43838), as part of a summary of reclassification policies we had adopted, we stated that in cases where hospitals have reclassified to rural areas, such as urban hospitals reclassifying to rural areas under 42 CFR 412.103, the hospital’s wage data are: (a) included in the rural wage index calculation, unless doing so would reduce the rural wage index; and (b) included in the urban area where the hospital is physically located. We further stated that the effect of this policy, in combination with the statutory requirement at section 1886(d)(8)(C)(ii) of the Act, is that rural areas may receive a wage index based upon the highest of: (1) wage data from hospitals geographically located in the rural area (calculation 1 in the table in this section of this rule); (2) wage data from hospitals geographically located in the rural area, but excluding all data associated with hospitals reclassifying out of the rural area under section 1886(d)(8)(B) or section 1886(d)(10) of the Act (calculation 2 in the table in this section of this rule); or (3) wage data associated with hospitals geographically located in the area plus all hospitals reclassified into the rural area (calculation 3 in the table in this section of this rule).

In the April 21, 2016 IFC (81 FR 23428 through 23438), referenced earlier in section III.G.1.a. of the preamble of this final rule, as a result of the Geisinger decision, we adopted a policy allowing hospitals to hold simultaneous § 412.103 and MGCRB reclassifications. In our wage index development process, we refer to these hospitals as having “dual reclass” status. We further stated in the IFC that we will exclude hospitals with § 412.103 reclassifications from the calculation of the reclassified rural wage index if they also have an active MGCRB reclassification to another area (81 FR 23434).

We also clarified in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25070) that if a hospital qualified for “Lugar” status and obtained § 412.103 rural status, we would apply the urban “Lugar” status for wage index purposes only. These geographically rural hospitals would be included in the rural wage index calculation in accordance with the previously described hold harmless policy.

The following chart summarizes the current calculation of the rural wage index algebraically and in accordance with the statutes and policies previously described:

<table>
<thead>
<tr>
<th>Hospital Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>A=Geographically rural hospitals</td>
</tr>
<tr>
<td>A1=Subset of geographically rural hospitals with MGCRB or “Lugar” reclassification</td>
</tr>
<tr>
<td>B=Geographically urban hospitals with § 412.103 rural reclassification</td>
</tr>
<tr>
<td>B1=Subset of geographically urban hospitals with § 412.103 rural reclassification and MGCRB reclassification (“dual reclass” hospitals)</td>
</tr>
<tr>
<td>C=Cross-State MGCRB reclassification to rural area</td>
</tr>
</tbody>
</table>
c. Modification to the Rural Wage Index Calculation Methodology

In the FY 2022 IPPS/LTCH PPS final rule (86 FR 45181 and 45182), we responded to a comment disagreeing with our treatment of “dual reclass” hospitals when calculating the rural floor. The commenter stated that CMS’s policy of considering the hospital’s geographic CBSA and the urban CBSA to which the hospital is reclassified under the MGCRB for the wage index calculation violates the statutory requirement to treat § 412.103 hospitals the same as hospitals geographically located in the rural area of the state. The commenter requested that CMS include the wages of § 412.103 hospitals that also have an active MGCRB reclassification in calculating the rural wage of the state if not doing so would reduce the wage index for that area, in the same manner that geographically rural hospitals with a MGCRB reclassification are treated according to section 1886(d)(8)(C)(ii) of the Act.

We responded that we did not propose the policy the commenter suggested, and noted that it would constitute a significant change with numerous and potentially negative effects on the IPPS wage index. We stated that we did not believe it would be appropriate to adopt such a policy without describing it in a proposed rule and obtaining public comments. Therefore, we did not adopt the policy the commenter suggested, but we stated that we would consider further addressing the issue in future rulemaking. We also received and responded to a similar comment in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49003). After further consideration of these comments and our proposed reinterpretation of section 1886(d)(8)(E) of the Act discussed earlier in this section, we proposed changing the rural wage index calculation methodology consistent with that proposed reinterpretation. We acknowledged the ongoing risk of the pending lawsuits cited previously, and recognized the challenge should we need to implement any future remedy in a budget neutral manner.

Beginning with FY 2024, we proposed to include hospitals with § 412.103 reclassification along with geographically rural hospitals in all rural wage index calculations, and to exclude “dual reclass” hospitals (hospitals with simultaneous § 412.103 and MGCRB reclassifications) implicated by the hold harmless provision at section 1886(d)(8)(C)(ii) of the Act. The following chart summarizes the current (as described in the table earlier in this section) and proposed rural wage index calculation algebraically:

<table>
<thead>
<tr>
<th>Calculation 1</th>
<th>Current Calculation: Rural Wage Index is The Highest Of</th>
<th>Proposed Calculation: Rural Wage Index is The Highest Of</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calculation 2</td>
<td>A - A1</td>
<td>A + (B - B1) + C</td>
</tr>
<tr>
<td>Calculation 3</td>
<td>A + (B - B1) + C</td>
<td>A + B + C</td>
</tr>
</tbody>
</table>

As shown in the current calculation policy, as previously described, § 412.103 hospitals enter the rural wage index calculation in calculation 3, which reflects the regulatory hold harmless policy described in the FY 2006 IPPS final rule (70 FR 47378 and 47379) and previously referenced, preventing reclassification into a state’s rural area from reducing the rural wage index. That is, we determine the effects for outbound reclassification (from the rural area to another area) and inbound reclassification (from another area into the rural area) separately when determining the highest rural wage index value. Under our proposal, as shown in the proposed calculation policy, as previously described, § 412.103 hospitals will no longer be treated as an inbound reclassification (calculation 3 of the current policy), but will instead be included in all calculations in which geographically rural hospitals are included (calculations 1–3 of the proposed policy). “Dual reclass” hospitals will be excluded (calculation 2 of the proposed policy) in accordance with the hold harmless provision at section 1886(d)(8)(C)(ii) of the Act, along with other geographically rural hospitals with MGCRB or “Lugar” reclassification status.

As discussed earlier in section III.G.1.a. of the preamble of this final rule, in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49004), we stated that we will apply the same policy as prior to the FY 2020 IPPS/LTCH PPS final rule for calculating the rural floor, in which the rural wage index sets the
rural floor. For FY 2023 and subsequent years, our current policy is to include the wage data of §412.103 hospitals that have no MGCRRB reclassification in the calculation of the rural floor, and to include the wage data of such hospitals in the calculation of “the wage index for rural areas in the State in which the county is located” as referred to in section 1886(d)(8)(C)(iii) of the Act. Consistent with the previously discussed proposal, beginning with FY 2024 we proposed to include the data of all §412.103 hospitals (including those that have an MGCRRB reclassification) in the calculation of the rural floor and the calculation of “the wage index for rural areas in the State in which the county is located” as referred to in section 1886(d)(8)(C)(iii) of the Act.

We acknowledged that these proposals will have significant effects on wage index values. As discussed in prior rulemaking (72 FR 47371 through 47373, 84 FR 42332, 85 FR 58788) and in this rule, CMS has expressed concern with hospitals’ use of §412.103 reclassifications to increase the rural wage index and rural floor. However, as already mentioned, “this is simply a function of the many different roles that hospitals play and the many different contexts in which they operate,” Lawrence + Mem’l Hosp., 812 F.3d at 267, and follows from our proposed interpretation of section 1886(d)(8)(E) of the Act—which encompasses the calculation of the State’s rural wage index. We discuss the overall impact of these proposed changes on the rural wage index calculation methodology in detail in section II.A.4. of appendix A of this final rule.

As discussed in the previous section, in the FY 2006 IPPS final rule (70 FR 47378 and 47379), we adopted a regulatory hold harmless policy for situations where hospitals reclassify into a state’s rural area. Hospitals reclassified under §412.103 will no longer be affected by this policy, as we proposed to include them in the rural wage index calculation in the same manner as geographically rural hospitals. Therefore, only the effects of hospitals with state-to-state MGCRRB reclassifications to a nearby state’s rural area will be addressed by this policy. It has been CMS’s longstanding policy that hospitals with state-to-state MGCRRB reclassifications to a nearby state’s rural area receive a “combined” wage index (calculation 3 of the current rural wage index calculation, as previously detailed in the chart) that includes the wage data for geographically rural hospitals and all hospitals reclassified into that rural area. Given our longstanding goal to mitigate potential negative impacts on rural hospitals, we proposed to continue the part of our hold harmless policy that excludes the data of hospitals reclassifying into a state’s rural area if doing so would reduce that state’s rural wage index. We proposed that these reclassified hospitals be assigned the “combined” wage index (calculation 3 of the proposed rural wage index calculation as previously detailed in the chart) that includes the wage data for geographically rural hospitals and all hospitals reclassified into that rural area (subject to any additional wage index adjustment policies for which those reclassified hospitals may be eligible).

Finally, we proposed to continue the policy to apply the deemed urban wage index value for §412.103 hospitals that also qualify as “Lugar” under section 1886(d)(8)(B) of the Act. Prior to Geisinger, since section 1886(d)(8)(E) of the Act requires CMS to treat a reclassified hospital as being located in the rural area of the state, and section 1886(d)(8)(B) of the Act requires CMS to treat a rural hospital as being located in an urban area, our policy was that hospitals reclassified into a state’s rural area if obtaining §412.103 status would effectively waive a hospital’s deemed urban “Lugar” status. We discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25070) that if a hospital qualified for “Lugar” status and obtained §412.103 rural status, our policy is to apply the urban “Lugar” status for wage index purposes only.

Comment: Commenters strongly supported CMS’s proposal to revise the rural wage index and rural floor calculation. Specifically, commenters supported CMS’s proposed treatment of a §412.103 hospital in the calculation of the rural wage index of its state even when the hospital has an MGCRRB reclassification to another area.

Commenters stated that the inclusion of §412.103 hospitals in this manner represents a straightforward interpretation of the regulations and faithfully executes Congressional intent by treating §412.103 hospitals “as being located in the rural area” as required by section 1886(d)(8)(B) of the Act. Commenters also supported CMS’s proposed treatment of §412.103 hospitals for the calculation at section 1886(d)(8)(C)(ii) of the Act, stating that they believe that treating §412.103 hospitals the same as geographically rural hospitals is the only lawful interpretation of the Act. A commenter stated that the proposed changes in response to the court cases illustrate the complexity, inconsistency, and even irrationality of the wage index system. Commenters encouraged CMS to continue the policy of setting a state’s rural floor equal to its rural wage index as part of coherent and consistent treatment of §412.103 hospitals.

Numerous commenters stressed the positive payment impact of these proposals on many hospitals. Similarly, a commenter noted that the proposed change to the calculation of the rural wage index and rural floor would help further reduce the disparity between high and low wage index hospitals due to its larger impact on hospitals with wage index values at or below the 25th percentile. This commenter provided its own wage index analysis in support of this finding.

Multiple commenters expressed concern regarding the increased rural floor budget neutrality factor due to the proposed changes. While some commenters acknowledged CMS’s statutory budget neutrality requirement, another commenter requested that CMS not apply the rural floor budget neutrality factor to urban hospitals paid at the rural floor and to rural hospitals, stating that it was Congress’s intent that these providers be excluded from this factor. Another commenter requested CMS provide a more complete summary of the specific impact of the proposed changes to the rural wage index calculation.

Response: We appreciate the commenters’ support for our proposal. We reviewed the analysis a commenter provided that suggests the proposed change to the rural wage index calculation methodology would reduce the total level of adjustments made under the low wage policy, by raising the wage index of hospitals with wage index values currently at or below the 25th percentile. As proposed, nearly half of all IPPS hospitals will be assigned their State’s rural wage index value at or below the 25th percentile. A commenter noted that the proposed change to the rural floor weighted by the proposed changes. We expect that this number will increase in future years as hospitals adjust to the policy and as the relative value of States’ rural wage index values increase due to the strategic inclusion of hospitals that obtain §412.103 reclassification. An outcome of this trend would be that the majority of hospitals (if not all) will be assigned identical wage index values as all other hospitals within their states. This would greatly reduce wage index variations within a State but might dramatically increase wage index differentials between States.

We understand the other commenters’ concern regarding the effect that the
proposed modification of the rural wage index calculation has on the rural floor budget neutrality factor. This policy will result in the rural wage index being greater than the wage index of most or all urban areas in that State. This will result in substantially more hospitals receiving the rural floor (and the section 1886(d)(8)(C)(iii) reclassification hold-harmless floor), and a consequently greater budget neutrality impact. We acknowledge tension between hospitals receiving identical wage index values and the broader structure of a national wage index to reflect relative differences in regional labor market costs. However, we believe this result would be unavoidable given the requirement of section 1886(d)(8)(E) of the Act to treat § 412.103 hospitals ‘as being located in the rural area’ of the state.

With regard to the commenter’s assertion that urban hospitals paid at the rural floor and rural hospitals should be excluded from the application of the rural floor budget neutrality factor, we believe we have applied the rural floor budget neutrality adjustment correctly. Section 3141 of the Patient Protection and Affordable Care Act (Pub. L. 111–148) requires that a national budget neutrality adjustment be applied in implementing the rural floor. There is a statutory requirement for budget neutrality, and the statute does not express intent to exempt certain hospitals as the commenter claims. Consistent with our longstanding methodology for implementing rural floor budget neutrality, we believe it is appropriate to continue to apply a budget neutrality adjustment to all hospitals’ wage indexes so that the rural floor is implemented in a budget neutral manner.

With regard to the commenter requesting a summary of the specific impact of the changes to the rural wage index calculation, we refer the commenter to section II.A.4.e. of the Addendum of this final rule for a complete discussion of the budget neutrality impact of the application of the rural floor. 

Comment: Several commenters expressed concern with the timing of our proposed policy as it relates to Medicare Advantage (MA) reimbursement funding for MA plans. Commenters cited locations that would have significant, sudden increases in hospital payment rates due to the proposed change in the calculation of the rural wage index values and cited potential severe financial hardships (including increased insurance rates) if such changes were not granted adequate time to transition and adjust to the implications of the policy change.

Another commenter stated that while budget neutrality may mitigate the impact of CMS’s rural wage index adjustments overall, it does not prevent significant regional impacts. The commenter stated that MA organizations have limited mechanisms to account for any increased costs given that they must pay the FFS rate for non-contracted providers. The negative impacts would be greater on small, regional plans that do not provide services across a broad enough area to mitigate the effects. Commenters requested CMS delay changes to the rural wage index or implement a companion policy to counterbalance the effects of the policy.

Response: After reviewing the concerns submitted by commenters regarding the potential impact this policy would have on MA plan payments, we are not convinced that the impact of this specific policy is exceptionally unique (in either form or magnitude) from other policy proposals made in past cycles. That is, we note that any change in policy that has the effect of increasing the wage index of an area will always result in an increase in MA payment rates to non-contracted hospital providers in that area. It would be out of the scope of this rulemaking to implement any change in MA payment policy (for example, raising benchmark rates) and outside of our authority to change the statutory bidding deadline for MA organizations (the first Monday in June of the year preceding the payment and coverage year), and given the broad general support we received from other commenters, we find the benefits of the proposed policy outweigh the possible repercussions highlighted by the commenter. Further, MA rates (that is, the bidding benchmarks) are set, in part, using projections of national FFS per capita costs for the payment year combined with a localized cost index, or the average geographic adjustment (AGA). The AGA is based on the most recent five-years of historical FFS experience. The IPPS claims supporting the AGAs are repriced using the most recent available wage index, which is FY 2023 for the 2024 MA rates. These projections are subject to specific statutory exclusions of certain costs that are explained in the annual Rate Announcement.

In response to the specific request to delay IPPS payment changes because of non-contract MA claims, for the reason cited in the proposed rule (83 FR 26976 through 26977), we believe that any delay to the proposed changes to the rural wage index calculation would be detrimental to hospitals and would result in additional litigation. Consistent with sections 1852(a)(2), 1852(k)(1), and 1866(a)(1)(O) of the Act, non-contract providers must accept as payment in full payment amounts applicable in Original Medicare. We will take these comments regarding MA payment implications into consideration for future rulemaking.

Comment: A commenter requested that CMS provide clarification on how its proposed interpretation of § 412.103 impacts the distance and proximity requirements for MGCRB reclassification. The commenter specifically asked if a § 412.103 redesignated hospital can seek MGCRB reclassification to any CBSA within 35 miles of any point of the State’s rural area or to any CBSA adjacent to the rural area.

Response: We believe the commenter is misunderstanding the current MGCRB reclassification rules. Hospitals with a § 412.103 reclassification will continue to use the 35-mile rural proximity criterion at § 412.290(b)(1). All reclassification provisions that use mileage begin the measurement at the hospital’s geographic address and end at the nearest point in the requested CBSA area.

After consideration of public comments received, we are adopting the proposed changes to the rural wage index calculations as described in the proposed rule. Specifically, we are adopting without change our proposed interpretation of section 1886(d)(8)(E) of the Act. Accordingly, we are finalizing our proposal to include hospitals with § 412.103 reclassification along with geographically rural hospitals in all rural wage index calculations, and to exclude “dual reclass” hospitals (hospitals with simultaneous § 412.103 and MGCRB reclassifications) implicated by the hold harmless provision at section 1886(d)(8)(C)(iii) of the Act. We are also finalizing the proposed policy that hospitals with state-to-state MGCRB reclassifications to a nearby state’s rural area receive a “combined” wage index (calculation 3 of the rural wage index calculation as previously detailed in the chart) that includes the wage data for geographically rural hospitals and all hospitals reclassified into that rural area (subject to any additional wage index adjustment policies for which those reclassified hospitals may be eligible).

Finally, we are finalizing our policy to continue to apply the deemed urban wage index value for § 412.103 hospitals that also qualify as “Lugar” under section 1886(d)(8)(B) of the Act, for wage index purposes only.
being finalized regarding our treatment of hospitals reclassified under § 412.103 is that a hospital with a § 412.103 reclassification should be considered as being located in its State’s rural area for the purposes of applying the hold harmless provision under section 1886(d)(8)(C)(iii) of the Act. This would prevent the rare situation where § 412.103 hospitals with the state-to-state rural MGCRB reclassification would be assigned a lower wage index than geographically rural hospitals with the same state-to-state rural MGCRB reclassification.

We note that this policy implication would not alter any wage index values for any hospital or CBSA for this FY 2024 rule, but will have some minor underlying budget neutrality implications, as several additional hospitals will be assigned their State’s rural wage index prior to the application of the “rural floor” provision (insofar as CMS applies a budget neutrality adjustment in implementing the “rural floor”).

2. Imputed Floor

In the FY 2005 IPPS final rule (69 FR 49109 through 49111), we adopted the imputed floor policy as a temporary 3-year regulatory measure to address concerns from hospitals in all urban States that have stated that they are disadvantaged by the absence of rural hospitals to set a wage index floor for those States. We extended the imputed floor policy eight times since its initial implementation, the last of which was adopted in the FY 2018 IPPS/LTCH PPS final rule and expired on September 30, 2018. We refer readers to further discussions of the imputed floor in the IPPS/LTCH PPS final rules from FYS 2014 through 2019 (78 FR 50589 through 50590, 79 FR 49969 through 49971, 80 FR 49497 through 49498, 81 FR 56921 through 56922, 82 FR 38138 through 38142, and 83 FR 41376 through 41380, respectively) and to the regulations at 42 CFR 412.64(m) and to 42 CFR 412.64(e)(1) and (4) and (h)(4) and (5) of the Act to establish a minimum area wage index for hospitals in all-urban States for discharges occurring on or after October 1, 2021. Specifically, section 1886(d)(3)(E)(iv)(II) and (III) of the Act provides that for discharges occurring on or after October 1, 2021, the area wage index applicable to any hospital in an all-urban State may not be less than the minimum area wage index for the fiscal year for hospitals in that State established using the methodology described in § 412.64(h)(4)(vi) as in effect for FY 2018. Unlike the imputed floor that was in effect from FYs 2005 through 2018, section 1886(d)(3)(E)(iv)(I) of the Act provides that the imputed floor wage index shall not be applied in a budget neutral manner. Section 1886(d)(3)(E)(iv)(IV) of the Act provides that, for purposes of the imputed floor wage index under clause (iv), the term all-urban State means a State in which there are no rural areas (as defined in section 1886(d)(2)(D) of the Act) or a State in which there are no hospitals classified as rural under section 1886 of the Act. Under this definition, given that it applies for purposes of the imputed floor wage index, we consider a hospital to be classified as rural under section 1886 of the Act if it is assigned the State’s rural area wage index value.

Effective beginning October 1, 2021 (FY 2022), section 1886(d)(3)(E)(iv) of the Act reinstates the imputed floor wage index policy for all-urban States, with no expiration date, using the methodology described in 42 CFR 412.64(h)(4)(vi) as in effect for FY 2018. We refer readers to the FY 2022 IPPS/LTCH PPS final rule (86 FR 45176 through 45178) for further discussion of the original imputed floor calculation methodology implemented in FY 2005 and the alternative methodology implemented in FY 2013.

Based on data available for this final rule, States that will be all-urban States as defined in section 1886(d)(3)(E)(iv)(IV) of the Act, and thus hospitals in such States that will be eligible to receive an increase in their wage index due to application of the imputed floor for FY 2024, are identified in Table 3 associated with this final rule, which is available via the internet on the CMS website.

3. State Frontier Floor for FY 2024

The regulations at section 412.64(e)(1) and (4) and (h)(4) and (5) implement the imputed floor required by section 1886(d)(3)(E)(iv) of the Act for discharges occurring on or after October 1, 2021. The imputed floor will continue to be applied for FY 2024 in accordance with the policies adopted in the FY 2022 IPPS/LTCH PPS final rule. For more information regarding our implementation of the imputed floor requirement, readers to the discussion in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45176 through 45178).

In the FY 2020 IPPS/LTCH PPS final rule (84 FR 42325 through 42339), we finalized a policy to address the artificial magnification of wage index disparities, based in part on comments received in response to our request for information included in our FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20372 through 20377). In the FY 2020 IPPS/LTCH PPS final rule, based on those public comments and the growing disparities between wage index values for high- and low-wage-index hospitals, we explained that those growing disparities are likely caused by the use of historical wage data to prospectively set hospitals’ wage indexes. That lag creates barriers to hospitals with low wage index values from being able to increase employee compensation, because those hospitals will not receive corresponding increases in their Medicare payment for several years (84 FR 42327). Accordingly, we finalized a policy that provided certain low wage index hospitals with an opportunity to
increase employee compensation without the usual lag in those increases being reflected in the calculation of the wage index.\textsuperscript{193} We accomplished this by temporarily increasing the wage index values for certain hospitals with low wage index values and doing so in a budget neutral manner through an adjustment applied to the standardized amounts for all hospitals, as well as by changing the calculation of the rural floor. As explained in the FY 2020 IPPS/LTCH proposed rule (84 FR 19396) and final rule (84 FR 42329), we indicated that the Secretary has authority to implement the lowest quartile wage index proposal under both section 1886(d)(3)(E) of the Act and under his exceptions and adjustments authority under section 1886(d)(5)(I) of the Act.

We increase the wage index for hospitals with a wage index value below the 25th percentile wage index value for a fiscal year by half the difference between the otherwise applicable final wage index value for a year for that hospital and the 25th percentile wage index value for that year across all hospitals (the low wage index hospital policy). We stated in the FY 2020 IPPS/LTCH PPS final rule (84 FR 42326 through 42328) our intention that it would be in effect for at least 4 fiscal years beginning October 1, 2019. We stated we intended to revisit the issue of the duration of this policy in future rulemaking as we gained experience under the policy. At this time, we only have one year of relevant data (from FY 2020) that we could use to evaluate any potential impacts of this policy. As discussed in section III.B. of the preamble of this final rule, consistent with the IPPS and LTCH PPS rate settings, our policy principles with regard to the wage index include generally using the most current data and information available, which is usually data on a 4-year lag (for example, for the FY 2023 wage index we used cost report data from FY 2019). Given our current lack of sufficient data with which to evaluate the low wage index hospital policy, we believe it is necessary to wait until we have useable data from additional fiscal years before making any decision to modify or discontinue the policy. Therefore, for FY 2024, we proposed to continue the low wage index hospital policy and the related budget neutrality adjustment (discussed in this section of this rule).

In order to offset the estimated increase in IPPS payments to hospitals with wage index values below the 25th percentile wage index value, for FY 2024 and for subsequent fiscal years during which the low wage index hospital policy is in effect, we proposed to apply a budget neutrality adjustment in the same manner as we applied it since FY 2020 as a uniform budget neutrality factor applied to the standardized amount. We refer readers to section II.A.4.f. of the Addendum to this final rule for further discussion of the budget neutrality adjustment for FY 2024. For purposes of the low wage index hospital policy, based on the data for this final rule, the table displays the 25th percentile wage index value across all hospitals for FY 2024.

<table>
<thead>
<tr>
<th>FY 2024 25th Percentile Wage Index Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.8667</td>
</tr>
</tbody>
</table>

\textsuperscript{193}In the FY 2020 IPPS/LTCH proposed rule, we agreed with respondents to a request for information who indicated that some current wage index policies create barriers to hospitals with low wage index values from being able to increase employee compensation due to the lag between 4 years of wage data gathered should be post-COVID–19 wage data in part due to ongoing workforce shortages and regional impacts as a result of the COVID–19 public health emergency (PHE). Specifically, one commenter explained that CMS should not be utilizing any data from FY 2020 due to the impacts of the PHE and other commenters urged CMS to continue the low wage index policy at least through FY 2030 in order to collect wage data outside of the PHE.

Some commenters asked that CMS provide clarification on its plans for this low-wage hospital policy moving forward, urging CMS to specify how many years of data it expects to need in order to evaluate whether the policy has increased wages for low-wage hospitals. Commenters also urged CMS to describe how it will account for the dramatic shifts in wage costs during the COVID–19 PHE, while explaining that doing so will help provide clarity and predictability to the field, especially during the current financial climate in which hospitals are operating.

A commenter explained that regardless of whether the low-wage hospital policy had its intended effect, CMS should now enter the evaluation phase, ending the artificial increase in the low quartile hospitals’ wage indices after four years. According to the commenter, if CMS disagrees that four

wait for comprehensive wage index reform given the growing disparities between low and high wage index hospitals, including rural hospitals that may be in financial distress and facing potential closure (84 FR 19394 and 19395).
years of the policy is sufficient, it should better justify continuing the policy and lay out its criteria for evaluating the policy’s potential success and at what point it should be terminated.

Response: We thank the many commenters expressing their support of the low wage index hospital policy and the continued feedback regarding achievement of the intended policy goal. We appreciate the commenters’ requests to consider the impacts of COVID–19, to extend this policy beyond four years due to COVID–19, and to extend the policy until the intended goals of the policy are reached. We appreciate commenters’ suggestions on how we might evaluate the effectiveness of the policy and may consider those suggestions in future rulemaking.

Regarding the comments requesting clarity about how many years of data are needed in order to evaluate whether the policy has increased wages for low-wage hospitals, as noted in the proposed rule and discussed in this section of the final rule, in the FY 2020 IPPS/LTCH PPS final rule (84 FR 42326 through 42328) we stated our intention that this policy will be effective for at least 4 years, until the policy’s effects could be reflected in the wage index data. As discussed in section III.B. of the preamble of this final rule, consistent with the IPPS and LTCH PPS rate settings, our policy principles with regard to the wage index include generally using the most current data and information available, which is usually data on a 4-year lag (for example, with the FY 2023 wage index we used cost report data from FY 2019). At this time, we only have one year of relevant data (from FY 2020) that we could use to evaluate any potential impacts of this policy. Again, as described earlier in this section, when this policy was finalized in the FY 2020 IPPS/LTCH PPS final rule, it was our intention that it would be effective for at least 4 years, until the policy’s effects could be reflected in the wage index data. Given our current lack of sufficient data with which to evaluate the low wage index hospital policy, currently having access to only one year of relevant data at this time due to the 4-year data lag also as described earlier in this section, we believe it is necessary to wait until we have usable data from additional fiscal years before making any decision to modify or discontinue the policy.

Comment: Several commenters expressed their support for the continued implementation of wage index payment increases for low-wage hospitals but urged CMS to do so in a non-budget-neutral manner.

Commenters stated that implementing the policy with a budget neutrality adjustment merely redistributes funds from one hospital to another, arbitrarily causing some hospitals to experience a payment decrease and others an increase. One commenter stated that those hospitals that fall between approximately the 22nd and 25th percentile are receiving a reduction to the wage adjusted standardized rate because the amount of benefit received is less than the cost to fund the benefit. This commenter suggested holding hospitals under the 25th percentile harmless. Commenters also provided other suggestions for data and alternative methodologies to include: reducing the wage index for hospitals with values above the 75th percentile; working with Congress on a more permanent fix to address the disparities in the wage index by establishing a national floor for all hospitals; and seeking input from the hospital community on best overall reform options that will better avoid downstream consequences from wage index policy changes.

Response: We disagree with the commenters that the low wage index hospital policy should be implemented in a non-budget neutral manner. As we stated in response to similar comments in the FY 2020 IPPS/LTCH PPS final rule (84 FR 42331 and 42332), the FY 2022 IPPS/LTCH PPS final rule (86 FR 45180), and the FY 2023 IPPS/LTCH PPS final rule (87 FR 49007), under section 1886(d)(3)(E) of the Act, the wage index value is required to be implemented in a budget neutral manner. However, even if the wage index were not required to be budget neutral under section 1886(d)(3)(E) of the Act, we would consider it inappropriate to use the wage index to increase or decrease overall IPPS spending. As we stated in the FY 2020 IPPS/LTCH PPS final rule (84 FR 42331), the wage index is not a policy tool but rather a technical adjustment designed to be a relative measure of the wages and wage-related costs of subsection (d) hospitals. As a result, as we explained in the FY 2020 IPPS/LTCH PPS final rule, if it were determined that section 1886(d)(3)(E) of the Act does not require the wage index to be budget neutral, we invoke our authority at section 1886(d)(5)(I) of the Act in support of such a budget neutrality adjustment.

With regard to the commenter’s concern that application of the low wage index policy may result in a reduction to overall payment if the amount of benefit received from the wage index boost is less than the reduction to the standardized amount, we believe we have applied both the quartile policy and the budget neutrality policy appropriately. As we explained most recently in response to comments in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49007), the quartile adjustment is applied to the wage index, which results in an increase to the wage index for hospitals below the 25th percentile. The budget neutrality adjustment is applied to the standardized amount in order to ensure that the low wage index hospital policy is implemented in a budget neutral manner. Thus, consistent with our current methodology for implementing wage index budget neutrality under section 1886(d)(3)(E) of the Act and with how we implemented budget neutrality for the low wage index hospital policy in FY 2020, we believe it is appropriate to continue to apply a budget neutrality adjustment to the national standardized amount for all hospitals so that the low wage index hospital policy is implemented in a budget neutral manner for FY 2024.

Regarding the comment about reducing the wage index for hospitals with values above the 75th percentile, in the FY 2020 IPPS/LTCH final rule (84 FR 42329), we discussed that we originally proposed to reduce the wage index values for high wage index hospitals using a methodology analogous to the methodology used to increase the wage index values for low wage index hospitals described in section III.N.3.a. of the preamble of the proposed rule; that is, we proposed to decrease the wage index values for high wage index hospitals by a uniform factor of the distance between the hospital’s otherwise applicable wage index and the 75th percentile wage index value for a fiscal year across all hospitals. In response to comments we received (84 FR 42329 and 42330), we acknowledged that some commenters presented reasonable changes, and we stated in response to similar comments in the FY 2020 IPPS/LTCH final rule (87 FR 49007), under section 1886(d)(3)(E) of the Act, the wage index value is required to be implemented in a budget neutral manner. However, even if the wage index were not required to be budget neutral under section 1886(d)(3)(E) of the Act, we would consider it inappropriate to use the wage index to increase or decrease overall IPPS spending. As we stated in the FY 2020 IPPS/LTCH PPS final rule (84 FR 42331), the wage index is not a policy tool but rather a technical adjustment designed to be a relative measure of the wages and wage-related costs of subsection (d) hospitals. As a result, as we explained in the FY 2020 IPPS/LTCH PPS final rule, if it were determined that section 1886(d)(3)(E) of the Act does not require the wage index to be budget neutral, we invoke our authority at section 1886(d)(5)(I) of the Act in support of such a budget neutrality adjustment.

With regard to the commenter’s concern that application of the low wage index policy may result in a reduction to overall payment if the amount of benefit received from the wage index boost is less than the reduction to the standardized amount, we believe we have applied both the quartile policy and the budget neutrality policy appropriately. As we explained most recently in response to comments in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49007), the quartile adjustment is applied to the wage index, which results in an increase to the wage index for hospitals below the 25th percentile. The budget neutrality adjustment is applied to the standardized amount in order to ensure that the low wage index hospital policy is implemented in a budget neutral manner. Thus, consistent with our current methodology for implementing wage index budget neutrality under section 1886(d)(3)(E) of the Act and with how we implemented budget neutrality for the low wage index hospital policy in FY 2020, we believe it is appropriate to continue to apply a budget neutrality adjustment to the national standardized amount for all hospitals so that the low wage index hospital policy is implemented in a budget neutral manner for FY 2024.
do not have evidence a national rural labor market exists or would be created if we were to adopt this alternative, this alternative would not increase the accuracy of the wage index. Also, we believe we have applied both the quartile policy and the budget neutrality policy appropriately, as we explained in response to comments in the FYs 2021 and 2022 IPPS/LTCH PPS final rules and most recently FY 2023 IPPS/LTCH PPS final rule (87 FR 49007). The quartile adjustment is applied to the wage index, which resulted in an increase to the wage index for hospitals below the 25th percentile. The budget neutrality adjustment is applied to the standardized amount in order to ensure that the low wage index hospital policy is implemented in a budget neutral manner.

Comment: Several commenters opposed the low wage index hospital policy, stating that it is inappropriately redistributive, ineffective, and outside the agency’s statutory authority under section 1886(d)(3)(E) of the Act. Specifically, some commenters stated that although the policy is intended to help rural hospitals, some rural hospitals in certain states do not benefit from this policy. Furthermore, a commenter stated that the policy undermines the intent of the wage index by not recognizing real differences in labor costs.

Response: We believe we addressed the stated concerns in our responses to comments when we first finalized the policy and the related budget neutrality adjustment in the FY 2020 IPPS/LTCH PPS final rule (84 FR 42325 through 42332). Concerning the policy’s redistributive effect, we refer readers to our response to the previous comments about budget neutrality. With regard to the policy’s effectiveness, we continue to believe that the comments in support of the policy, specifically comments from relatively low-wage hospitals stating that the increased payments under the policy have allowed them to raise compensation for their workers, indicate that many low-wage hospitals are benefiting from this policy.

Furthermore, we stated in the FY 2020 IPPS/LTCH PPS final rule (84 FR 42326 through 42328) our intention that this policy will be effective for at least 4 years, until the policy’s effects could be reflected in the wage index data. Regarding the policy’s effect on rural hospitals, as we stated FY 2020 IPPS/LTCH PPS final rule (84 FR 42328), the wage index is a technical payment adjustment. The intent of the low wage hospital policy is to increase the accuracy of the wage index as a technical adjustment, and not to use the wage index as a policy tool to address non-wage issues related to rural hospitals, or the laudable goals of the overall financial health of hospitals in low wage areas or broader wage index reform. The low wage hospital policy aims to increase the accuracy of the wage index as a relative measure because it allows low wage index hospitals to increase their employee compensation in ways that we would expect if there were no lag between the time a hospital increases employee compensation and the time these increases are reflected in the wage index, and allows those increases to be more timely reflected in the wage index. While one effect of the policy may be to improve the overall well-being of low wage hospitals, and we would welcome that effect, that is not the primary rationale for our policy.

In response to comments stating the policy exceeds CMS’s statutory authority, we refer the commenters to our prior discussion of the authority for the policy in the FY 2020 IPPS/LTCH PPS final rule (84 FR 42326 through 42332).

In response to the assertion that the low wage index hospital policy does not recognize real differences in labor costs, we continue to believe, for the reasons stated in the FY 2020 IPPS/LTCH PPS final rule (84 FR 42327 and 42328), that by preserving the rank order in wage index values, our policy continues to reflect meaningful distinctions between the employee compensation costs faced by hospitals in different geographic areas. Thus, under the low wage index hospital policy, we believe the wage index for low wage index hospitals appropriately reflects the relative hospital wage level in those areas compared to the national average hospital wage level.

Comment: Many commenters noted that the low wage index hospital policy is currently the subject of pending litigation in Bridgeport. A few commenters urged CMS not to finalize the policy for FY 2024, or to wait until a final court decision is reached. One such commenter suggested CMS should eliminate the budget neutrality adjustments for FYs 2020, 2021, 2022 and 2023 in light of Bridgeport. Many commenters applauded CMS’s decision to appeal the district court’s decision in Bridgeport. These commenters stated that the consequences of halting the policy would be dire.

Response: We appreciate the commenters’ input. As noted previously, the FY 2020 low wage index hospital policy and the related budget neutrality adjustment are the subject of pending litigation, including in Bridgeport Hospital, et al. v. Becerra, No. 1:20–cv–01574 (D.D.C.) (hereafter referred to as Bridgeport). The district court in Bridgeport found that the Secretary did not have authority under section 1886(d)(3)(E) or 1886(d)(5)(I)(i) of the Act to adopt the low wage index hospital policy for FY 2020 and remanded the policy to the agency without vacatur. We have appealed the court’s decision.

After consideration of the comments we received, and for the reasons stated previously and in the proposed rule, we are finalizing as proposed to continue the low wage index hospital policy and the related budget neutrality adjustment for FY 2024.

5. Permanent Cap on Wage Index Decreases and Budget Neutrality Adjustment

In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49018 through 49021), we finalized a wage index cap policy and associated budget neutrality adjustment for FY 2023 and subsequent fiscal years. Under this policy, we apply a 5-percent cap on any decrease to a hospital’s wage index from its wage index in the prior FY, regardless of the circumstances causing the decline. A hospital’s wage index will not be less than 95 percent of its final wage index for the prior FY. If a hospital’s prior FY wage index is calculated with the application of the 5-percent cap, the following year’s wage index will not be less than 95 percent of the hospital’s capped wage index in the prior FY. Except for newly opened hospitals, we apply the cap for a FY using the final wage index applicable to the hospital on the last day of the prior FY. A newly opened hospital will be paid the wage index for the area in which it is geographically located for its first full or partial fiscal year, and it will not receive a cap for that first year, because it will not have been assigned a wage index in the prior year. The wage index cap policy is reflected at 42 CFR 412.64(h)(7). We apply the cap in a budget neutral manner through a national adjustment to the standardized amount each fiscal year. For more information about the wage index cap policy and associated budget neutrality adjustment, we refer readers to the discussion in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49018 through 49021).

Although we did not propose changes to the policy to apply a permanent cap on wage index decreases, we received comments which are summarized and responded to as follows.
LTCH PPS final rule (87 FR 49018 through 49021), to limit any decrease in a hospital’s wage index value to be no greater than 5 percent as compared to the hospital’s wage index value for the prior fiscal year, regardless of the circumstances causing the decline. According to commenters, the policy helps maintain stability and predictability to current and future payments under the IPPS by preventing abrupt variation in year-to-year wage data for affected hospitals, much of which may be beyond a hospital’s control.

Response: We appreciate the support from commenters.

Comment: Several commenters that supported the policy to apply a permanent cap on wage index decreases, explained that CMS is not bound by statute to make the policy budget neutral and urged CMS to revisit how the policy is funded in order to implement the policy in a non-budget neutral manner. According to these commenters, the budget neutral aspect of the policy causes unintended consequences as payment rates are redistributed and undermines the intended benefit of the policy. Commenters asked CMS to examine alternatives to fund this policy so that the policy is funded using separate and additional funds, rather than in a budget neutral way that reduces the wage indexes of other hospitals. Furthermore, commenters explained that implementing this policy in a non-budget neutral manner would both stabilize payments in the future and avoid further unexpected reductions for other providers. Finally, commenters encouraged CMS to continue working with stakeholders and Congress to address the need for more comprehensive reforms.

Response: We thank the commenters for their input regarding the policy to apply a permanent cap on wage index decreases. As discussed in our response to comments in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49020), the budget neutrality adjustment associated with the permanent cap on wage index decreases policy is implemented through our authority under sections 1886(d)(3)(E) and (d)(5)(I)(i) of the Act. Section 1886(d)(3)(E) gives the Secretary broad authority to adjust for area differences in hospital wage levels by a factor (established by the Secretary) reflecting the relative hospital wage level in the geographic area of the hospital compared to the national average hospital wage level, and requires that adjustments to be applied in a budget neutral manner. However, even if the wage index were not required to be budget neutral under section 1886(d)(3)(E) of the Act, we would not consider it an appropriate alternative to use the wage index and the proposed permanent cap on wage index decreases to increase or decrease overall IPPS spending. The wage index is not a policy tool but rather a technical adjustment designed to be a relative measure of the wages and wage-related costs of subsection (d) hospitals in the United States. Furthermore, our past policies involving a 5 percent cap on wage index decreases implemented in a budget neutral manner did not result in wage index volatility, and we expect the same for the overall budget neutrality adjustments associated with the permanent cap policy. For more information about the wage index cap policy and associated budget neutrality adjustment finalized in FY 2023 for FY 2023 and subsequent years, we refer readers to the discussion in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49018 through 49021). For FY 2024, we will apply the wage index cap and associated budget neutrality adjustment in accordance with the policies adopted in the FY 2023 IPPS/LTCH PPS final rule. We note that the budget neutrality adjustment will be updated, as appropriate, based on the final rule data. We refer readers to the Addendum of this final rule for further information regarding the budget neutrality calculations.

H. FY 2023 Wage Index Tables

In this FY 2024 IPPS/LTCH PPS final rule, we have included the following wage index tables: Table 2 titled “Case-Mix Index and Wage Index Table by CCN”; Table 3 titled “Wage Index Table by CBSA”; Table 4A titled “List of Counties Eligible for the Out-Migration Adjustment under Section 1886(d)(13) of the Act”; and Table 4B titled “Counties redesignated under section 1886(d)(8)(B) of the Act (Lugar Counties).” We refer readers to section VI. of the Addendum to this final rule for a discussion of the wage index tables for FY 2024.

I. Revisions to the Wage Index Based on Hospital Redesignations and Reclassifications

1. General Policies and Effects of Reclassification and Redesignation

Under section 1886(d)(10) of the Act, the Medicare Geographic Classification Review Board (MGCRB) considers applications by hospitals for geographic reclassification for purposes of payment under the IPPS. Hospitals must apply to the MGCRB to reclassify not later than 13 months prior to the start of the fiscal year for which reclassification is sought (usually by September 1). Generally, hospitals must be proximate to the labor market area to which they are seeking reclassification and must demonstrate characteristics similar to hospitals located in that area. The MGCRB issues its decisions by the end of February for reclassifications that become effective for the following fiscal year (beginning October 1). The regulations applicable to reclassifications by the MGCRB are located in 42 CFR 412.230 through 412.280. (We refer readers to a discussion in the FY 2002 IPPS final rule (66 FR 39874 and 39875) regarding how the MGCRB defines mileage for purposes of the proximity requirements.) The general policies for reclassifications and redesignations and the policies for the effects of hospitals’ reclassifications and redesignations on the wage index are discussed in the FY 2012 IPPS/LTCH PPS final rule for the FY 2012 final wage index (76 FR 51595 and 51596).

In addition, in the FY 2012 IPPS/LTCH PPS final rule, we discussed the effects on the wage index of urban hospitals reclassifying to rural areas under 42 CFR 412.103. In the FY 2020 IPPS/LTCH PPS final rule (84 FR 42332 through 42336), we finalized a policy to exclude the wage data of urban hospitals reclassifying to rural areas under 42 CFR 412.103 from the calculation of the rural floor, but we reverted back to the pre-FY 2020 policy in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49002 through 49004). Hospitals that are geographically located in States without any rural areas are ineligible to apply for rural reclassification in accordance with the provisions of 42 CFR 412.103.

On April 21, 2016, we published an interim final rule with comment period (IFC) in the Federal Register (81 FR 23428 through 23438) that included provisions amending our regulations to allow hospitals nationwide to have simultaneous §412.103 and MGCRB reclassifications. For reclassifications effective beginning October 1, a hospital may acquire rural status under §412.103 and subsequently apply for a reclassification under the MGCRB using distance and average hourly wage criteria designated for rural hospitals. In addition, we provided that a hospital that has an active MGCRB reclassification and is then approved for redesignation under §412.103 will not lose its MGCRB reclassification; such a hospital receives a reclassified urban wage index during the years of its active reclassification and then reclassifies to the considered rural under section 1886(d) of the Act and for other purposes.
We discussed that when there is both a § 412.103 redesignation and an MGCRB reclassification, the MGCRB reclassification controls for wage index calculation and payment purposes. Prior to FY 2024, we excluded hospitals with § 412.103 redesignations from the calculation of the reclassified rural wage index if they also have an active MGCRB reclassification to another area. That is, if an application for urban reclassification through the MGCRB is approved, and is not withdrawn or terminated by the hospital within the established timelines, we consider the hospital’s geographic CBSA and the urban CBSA to which the hospital is reclassified under the MGCRB for the wage index calculation. We refer readers to the April 21, 2016 IFC (81 FR 23428 through 23438) and the FY 2017 IPPS/ LTCH PPS final rule (81 FR 56922 through 56990), in which we finalized the April 21, 2016 IFC, for a full discussion of the effect of simultaneous reclassifications under both the § 412.103 and the MGCRB processes on wage index calculations. For FY 2024 and subsequent years, we refer readers to section III.G.1 of the preamble of this final rule for discussion of our proposal to include hospitals with a § 412.103 redesignation that also have an active MGCRB reclassification to another area in the calculation of the reclassified rural wage index.

On May 10, 2021, we published an interim final rule with comment period [IFC] in the Federal Register (86 FR 24735 through 24739) that included provisions amending our regulations to allow hospitals with a rural redesignation to reclassify through the MGCRB using the rural reclassified area as the geographic area in which the hospital is located. We revised our regulation so that the redesignated rural area, and not the hospital’s geographic urban area, is considered the area a § 412.103 hospital is located in for purposes of meeting MGCRB reclassification criteria, including the average hourly wage comparisons required by § 412.230(a)(5)(i) and (d)(1)(iii)(C). Similarly, we revised the regulations to consider the redesignated rural area, and not the geographic urban area, as the area a § 412.103 hospital is located in for purposes of meeting MGCRB reclassification beginning in FY 2023, a § 412.103 hospital could apply for a reclassification under the MGCRB using the State’s rural area as the area in which the hospital is located. We refer readers to the May 10, 2021 IFC (86 FR 24735 through 24739) and the FY 2022 IPPS/LTCH PPS final rule (86 FR 45187 through 45190), in which we finalized the May 10, 2021 IFC, for a full discussion of these policies.

2. MGCRB Reclassification and Redesignation Issues for FY 2024
   a. FY 2024 Reclassification Application Requirements and Approvals

As previously stated, under section 1886(d)(10) of the Act, the MGCRB considers applications by hospitals for geographic reclassification for purposes of payment under the IPPS. The specific procedures and rules that apply to the geographic reclassification process are outlined in regulations under 42 CFR 412.230 through 412.280. There are 466 hospitals approved for wage index reclassifications by the MGCRB starting in FY 2024. Because MGCRB wage index reclassifications are effective for 3 years, for FY 2024, hospitals reclassified beginning in FY 2022 or FY 2023 are eligible to continue to be reclassified to a particular labor market area based on such prior reclassifications for the remainder of their 3-year period. There were 271 hospitals approved for wage index reclassifications in FY 2022 that will continue for FY 2024, and 325 hospitals approved for wage index reclassifications in FY 2023 that will continue for FY 2024. Of all the hospitals approved for reclassification for FY 2022, FY 2023, and FY 2024, 1062 (approximately 30 percent) hospitals are in a MGCRB reclassification status for FY 2024 (with 187 of these hospitals reclassified back to their geographic location).

Under the regulations at 42 CFR 412.273, hospitals that have been reclassified by the MGCRB are permitted to withdraw their applications if the request for withdrawal is received by the MGCRB any time before the MGCRB issues a decision on the application, or after the MGCRB issues a decision, provided the request for withdrawal is received by the MGCRB within 45 days of the date that CMS’s annual notice of proposed rulemaking is issued in the Federal Register concerning changes to the inpatient hospital prospective payment system and proposed payment rates for the fiscal year for which the application has been filed. For information about withdrawing, terminating, or canceling a previous withdrawal or termination of a 3-year reclassification for wage index purposes, we refer readers to § 412.273, as well as the FY 2002 IPPS final rule (66 FR 39887 through 39888) and the FY 2003 IPPS final rule (67 FR 50065 through 50066). Additional discussion on withdrawals and terminations, and clarifications regarding reinstating reclassifications and “fallback” reclassifications were included in the FY 2008 IPPS final rule (72 FR 47333) and the FY 2018 IPPS/LTCH PPS final rule (82 FR 38148 through 38150).

We note that in the FY 2021 IPPS/ LTCH final rule (85 FR 58771 through 58778), CMS finalized an assignment policy for hospitals reclassified to CBSAs from which one or more counties moved to a new or different urban CBSA under the revised OMB delineations based on OMB Bulletin 18–04. We provided a table in that rule (85 FR 58777 and 58778) which described the assigned CBSA for all the MGCRB cases subject to this policy. For such reclassifications that continue to be active or are reinstated for FY 2024, the CBSAs assigned in the FY 2021 IPPS/ LTCH final rule continue to be in effect. Applications for FY 2025 reclassifications are due to the MGCRB by September 1, 2023. We note that this is also the deadline for canceling a previous wage index reclassification withdrawal or termination under 42 CFR 412.273(d). Applications and other information about MGCRB reclassifications may be obtained beginning in mid-July 2023 via the internet on the CMS website at https://www.cms.gov/Regulations- andGuidance/Review-Boards/MGCRB/index.html. This collection of information was previously approved under OMB Control Number 0938–0573 which expired on January 31, 2021. A reinstatement of this PRA package is currently being developed. The public will have an opportunity to review and submit comments regarding the reinstatement of this PRA package through a public notice and comment period separate from this rulemaking.

Comment: A commenter noted that the MGCRB issued determinations for FY 2024 on January 31, 2023. The commenter stated that this was earlier than in the past, when the MGCRB typically issued determinations mid-February, to meet the statutory requirement for decisions to be issued by the end of February. The commenter requested that CMS limit the MGCRB from issuing decisions prior to the first week of February to allow hospitals ample time to submit documentation of rural reclassification, SCH and RRC status to the Board or to submit a request to withdraw a decision based on review of the January PUF. The commenter stated that without a
more definitive timeline, hospitals face uncertainty if their documentation will be accepted by the MGCRB and could be adversely affected by an early decision being issued by the Board.

Response: We disagree with the commenter that hospitals are disadvantaged by earlier issuance of MGCRB decisions. First, we believe hospitals should submit applications complete with supporting documentation at the time MGCRB applications are due. Hospitals taking advantage of the MGCRB’s practice of accepting supporting documentation to supplement applications until the date of the MGCRB’s review are aware that the review is not held on the same date annually. In fact, the MGCRB even issued determinations for FY 2024 on a later date in January than it issued determinations for FY 2023 (January 31, 2023, versus January 24, 2022).

Furthermore, rural reclassification may be obtained at any time, and hospitals seeking benefits of rural status for MGCRB reclassification should plan accordingly. Finally, we note that hospitals dissatisfied with the MGCRB’s decision may request the Administrator’s review under § 412.278. To ensure proper accounting, we request hospitals to include their CCN, and either “waive Lugar” or “reinstated Lugar”, in the subject line of these requests.

3. Redesignations Under Section 1886(d)(8)(B) of the Act (Lugar Status Determinations)

In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51599 through 51600), we adopted the policy that, beginning with FY 2012, an eligible hospital that waives its Lugar status in order to receive the out-migration adjustment has effectively waived its deemed urban status and, thus, is rural for all purposes under the IPPS effective for the fiscal year in which the hospital receives the out-migration adjustment. In addition, in that rule, we adopted a minor procedural change that allows a Lugar hospital to request and accepts the out-migration adjustment (through written notification to CMS within 45 days from the publication of the proposed rule) to waive its urban status for the full 3-year period for which its out-migration adjustment is effective. By doing so, such a Lugar hospital will no longer be required during the second and third years of eligibility for the out-migration adjustment to advise us annually that it prefers to continue being treated as rural and receive the out-migration adjustment. In the FY 2017 IPPS/LTCH PPS final rule (81 FR 56930), we further clarified that if a hospital wishes to reinstates its urban status for any fiscal year within this 3-year period, it must send a request to CMS within 45 days of publication of the proposed rule for that particular fiscal year. We indicated that such reinstatement requests may be sent electronically to wageindex@cms.hhs.gov. In the FY 2018 IPPS/LTCH PPS final rule (82 FR 38147 through 38148), we clarified that both requests to waive and to reinstate “Lugar” status may be sent to wageindex@cms.hhs.gov. To ensure proper accounting, we request hospitals to include their CCN, and either “waive Lugar” or “restate Lugar”, in the subject line of these requests.

In the FY 2020 IPPS/LTCH PPS final rule (84 FR 42314 and 42315), we clarified that in circumstances where an eligible hospital elects to receive the out-migration adjustment within 45 days of the public display date of the proposed rule at the Office of the Federal Register in lieu of its Lugar wage index reclassification, and the county in which the hospital is located would no longer qualify for an out-migration adjustment when the final rule (or a subsequent correction notice) wage index calculations are completed, the hospital’s request to accept the out-migration adjustment will be denied, and the hospital will be automatically assigned to its deemed urban status under section 1886(d)(8)(B) of the Act. We stated that final rule wage index values will be recalculated to reflect reclassification. In some instances, after taking into account this reclassification, the out-migration adjustment for the county in question could be restored in the final rule. However, as the hospital is assigned a Lugar reclassification under section 1886(d)(8)(B) of the Act, it would be ineligible to receive the county out-migration adjustment under section 1886(d)(13)(G) of the Act.

We received three timely requests in wageindex@cms.hhs.gov mailbox from CCN 230005 (located in Lenawee County, PA), and CCNs 390183 and 390332 (located in Schuykill County, PA) to waive “Lugar” reclassification status to accept the county out-migration adjustment (OMA). These requests are approved. All three hospitals have current § 412.103 rural reclassifications. Per the regulation at § 412.103(g)(5), the rural reclassification status will be terminated, effective October 1, 2023. The status of these requests will be listed in Table 2 in the addendum of this final rule.

We received one request from CCN 150076 on June 13, 2023. The deadline to file a request to waive “Lugar” reclassification status to accept its county OMA was May 25, 2023; 45 days from the date of public display (April 10, 2023) of the proposed rule at the Office of the Federal Register. This request is therefore denied.

J. Out-Migration Adjustment Based on Commuting Patterns of Hospital Employees

In accordance with section 1886(d)(13) of the Act, as added by section 505 of Public Law 108–173, beginning with FY 2005, we established a process to make adjustments to the hospital wage index based on commuting patterns of hospital employees (the “out-migration” adjustment or OMA). The process, outlined in the FY 2005 IPPS final rule (69 FR 49061), provides for an increase in the wage index for hospitals located in certain counties that have a relatively high percentage of hospital employees who reside in the county but work in a different county (or counties) with a higher wage index. Section 1886(d)(13) of the Act requires the Secretary to use data the Secretary determines to be appropriate to establish the qualifying counties.

When the provision of section 1886(d)(13) of the Act was implemented for the FY 2005 wage index, we analyzed commuting data compiled by the U.S. Census Bureau that were derived from a special tabulation of the 2000 Census journey-to-work data for all industries (CMS extracted data applicable to hospitals). These data were compiled from responses to the “long-form” survey, which the Census
hospitals in the wage index calculation methodology, a § 412.103 hospital without an MCCRB or “Lugar” designation should be eligible to receive its county’s calculated OMA.

Response: We disagree that a hospital with an active § 412.103 rural reclassification is eligible to receive an OMA. Section 1886(d)(13)(G) of the Act states that a hospital that receives an OMA is not eligible for reclassification under section 1886(d)(8) or 1886(d)(10) of the Act. Section 1886(d)(6) of the Act describes both deemed urban status under section 1886(d)(6)(B) (“Lugar”, reclassification) and obtaining rural status under section 1886(d)(8)(E) of the Act (implemented by § 412.103). By voluntarily applying for a § 412.103 rural reclassification, a hospital is therefore waiving the application of the OMA, as described as section 1886(d)(13)(F) of the Act. Therefore, for the reasons set forth in this final rule and in the FY 2024 IPPS/LTCH PPS proposed rule, for FY 2024, we are finalizing our proposal, without modification, to continue using the same policies, procedures, and computations that were used for the FY 2012 out-migration adjustment and that were applicable for FYs 2016 through 2023.

Table 2 associated with this final rule (which is available via the CMS website) includes the proposed out-migration adjustments for the FY 2024 wage index. In addition, Table 4A associated with this final rule, “List of Counties Eligible for the Out-Migration Adjustment under Section 1886(d)(13) of the Act” (also available via the internet on the CMS website), consists of the following: A list of counties that are eligible for the out-migration adjustment for FY 2024 identified by FIPS county code, the proposed FY 2024 out-migration adjustment, and the number of years the adjustment will be in effect. We refer readers to section V.I. of the Addendum of this final rule for instructions on accessing IPPS tables that are posted on the CMS websites identified in this final rule.

K. Reclassification From Urban to Rural Under Section 1886(d)(8)(E) of the Act Implemented at 42 CFR 412.103

Under section 1886(d)(8)(E) of the Act, a qualifying prospective payment hospital located in an urban area may apply for rural status for payment purposes separate from reclassification through the MGCRB. Specifically, section 1886(d)(8)(E) of the Act provides that, not later than 60 days after the receipt of an application (in a form and manner determined by the Secretary) from a subsection (d) hospital that satisfies certain criteria, the Secretary shall treat the hospital as being located in the rural area (as defined in paragraph (2)(D)) of the State in which the hospital is located. We refer readers to the regulations at 42 CFR 412.103 for the general criteria and application requirements for a subsection (d) hospital to reclassify from urban to rural status in accordance with section 1886(d)(8)(E) of the Act. The FY 2012 IPPS/LTCH PPS final rule (76 FR 51595 through 51596) includes our policies regarding the effect of wage data from reclassified or redesignated hospitals. We refer readers to the FY 2023 IPPS/LTCH PPS final rule (87 FR 49004) for a discussion of our current policy to calculate the rural floor with the wage data of urban hospitals reclassifying to rural areas under 42 CFR 412.103. We also refer readers to section III.G.1. of the preamble of this final rule with regard to our proposal to modify how we calculate the rural wage index and its implications for the rural floor.

In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41369 through 41374), we codified certain policies regarding multicampus hospitals in the regulations at 42 CFR 412.92, 412.96, 412.103, and 412.108. We stated that reclassifications from urban to rural under 42 CFR 412.103 apply to the entire hospital (that is, the main campus and its remote location(s)). We also stated that a main campus of a hospital cannot obtain an SCH, RRC, or MDH status, or rural reclassification under 42 CFR 412.103, independently or separately from its remote location(s), and vice versa. In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49012 and 49013), we added 42 CFR 412.103(a)(8) to clarify that for a multicampus hospital, approved rural reclassification status applies to the main campus and any remote location located in an urban area, including a main campus or any remote location deemed urban under section 1886(d)(8)(B) of the Act. If a remote location of a hospital is located in a different CBSA than the main campus of the hospital, it is CMS’s longstanding policy to assign that remote location a wage index based on its own geographic area in order to comply with the statutory requirement to adjust for geographic differences in hospital wage levels (section 1886(d)(3)(E) of the Act). Hospitals are required to identify and allocate wages and hours based on FTEs for remote locations located in different CBSAs on Worksheet 5–2, Part I, Lines 165 and 166 of form CMS–2552–10. In calculating wage index values, CMS identifies the allocated wage data for
these remote locations in Table 2 with a "B" in the 3rd position of the CCN. These remote locations of hospitals with 42 CFR 412.103 rural reclassification status in a different CBSA are identified in Table 2, and hospitals should evaluate potential wage index outcomes for its remote location(s) when withdrawing or terminating MGCRB reclassification, or canceling § 412.103 rural reclassification status.

Finally, in section V.C.2. of the preamble of this final rule, we are changing the effective date of rural reclassification for a hospital qualifying for rural reclassification under § 412.103(a)(3) by meeting the criteria for SCH status (other than being located in a rural area), and also applying to obtain SCH status under § 412.92, where eligibility for SCH classification depends on a hospital merger.

Specifically, we are finalizing that in these circumstances, and subject to the requirements set forth at new § 412.92(b)(2)(vi), the effective date for rural reclassification will be as of the effective date set forth in new § 412.92(b)(2)(vi).

Also, in section V.C.2 of the preamble of this final rule, we are making a conforming change to the regulations at § 412.103(d) to modify the effective date of rural reclassification for a hospital qualifying for rural reclassification under § 412.103(a)(3) by meeting the criteria for SCH status (other than being located in a rural area), and also applying to obtain SCH status under § 412.92 where eligibility for SCH classification depends on a hospital merger. We are amending § 412.103(d)(1) and to add new paragraph § 412.103(d)(3) to provide that, subject to the hospital meeting the requirements set forth at new § 412.92(b)(2)(vi), the effective date for rural reclassification for such hospital will be as of the effective date determined under § 412.92(b)(2)(vi).

We refer the reader to section V.C.2. of the preamble of this final rule for complete details on these policies.

L. Process for Requests for Wage Index Data Corrections

1. Process for Hospitals To Request Wage Index Data Corrections

The preliminary, unaudited Worksheet S–3 wage data files and the CY 2019 occupational mix data files for the proposed FY 2024 wage index were made available on May 23, 2022. After reviewing requested changes submitted by hospitals, MACs were required to transmit to CMS any additional revisions resulting from the hospitals’ reconsideration requests by March 20, 2023. Under our current policy as adopted in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38153), the deadline for a hospital to request CMS intervention in cases where a hospital disagreed with a MAC’s handling of wage data on any basis (including a policy, factual, or other dispute) was March 20, 2023. Under our current policy as adopted in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38153), the deadline for a hospital to request CMS intervention in cases where a hospital disagreed with a MAC’s handling of wage data on any basis (including a policy, factual, or other dispute) was April 3, 2023. Data that were incorrect in the preliminary or January 30, 2023, wage index data PUFs, but for which no correction request was received by the May 23, 2022, deadline and of all other deadlines and requirements, including the requirement to review and verify their data as posted in the preliminary wage index data files on the internet, through the letters sent to them by their MACs.

On January 30, 2023, we posted a public use file (PUF) at https://www.cms.gov/medicare/medicare-fee-service-payment/acuteinpatientppswage-index-files/fy-2024-wage-index-home-page containing FY 2024 wage index data available as of January 30, 2023. This PUF contains a tab with the Worksheet S–3 wage data (which includes Worksheet S–3, Parts II and III wage data from cost reporting periods beginning on or after 2019 through September 30, 2020) and a tab with the occupational mix data (which includes data from the CY 2019 occupational mix survey. Form CMS–10079), a tab containing the Worksheet S–3 wage data of hospitals deleted from the January 30, 2023, wage data PUF, and a tab containing the CY 2019 occupational mix data of the hospitals deleted from the January 30, 2023, occupational mix PUF. In a memorandum dated January 31, 2023, we instructed all MACs to inform the IPPS hospitals that they service of the availability of the January 30, 2023, wage index data PUFs, and the process and timeframe for requesting revisions in accordance with the FY 2024 Hospital Wage Index Development Time Table available at https://www.cms.gov/files/document/fy-2024hospital-wage-index-development-time-table.pdf.

In the interest of meeting the data needs of the public, beginning with the proposed FY 2009 wage index, we post an additional PUF on the CMS website that reflects the actual data that are used in computing the proposed wage index. The release of this file does not alter the current wage index process or schedule. We notify the hospital community of the availability of these data as we do with the current public use wage data files through our Hospital Open Door Forum. We encourage hospitals to sign up for automatic notifications of information about hospital issues and the dates of the Hospital Open Door Forums at the CMS website at https://www.cms.gov/Outreach-and-Education/Outreach/OpenDoorForums.

In a memorandum dated May 3, 2022, we instructed all MACs to inform the IPPS hospitals that they service of the availability of the preliminary wage index data files and the CY 2019 occupational mix survey data files posted on May 23, 2022, and the process and timeframe for requesting revisions. If a hospital wished to request a change to its data as shown in the May 23, 2022, preliminary wage data files and occupational mix data files, the hospital had 90 days (by the April deadline (that is, by April 3, 2023, for the FY 2024 wage index) to provide supporting documentation along with complete, detailed supporting documentation to its MAC so that the MAC received them by September 2, 2022. Hospitals were notified of these deadlines and of all other deadlines and requirements, including the requirement to review and verify their data as posted in the preliminary wage index data files on the internet, through the letters sent to them by their MACs.

November 4, 2022, was the date by which MACs notified State hospital associations regarding hospitals that failed to respond to issues raised during the desk reviews. Additional revisions made by the MACs were transmitted to CMS throughout January 2023. CMS published the wage index PUFs that included hospitals’ revised wage index data on January 30, 2023. Hospitals had until February 15, 2023, to submit requests to the MACs to correct errors in the January 30, 2023, PUF due to CMS or MAC mishandling of the wage index data, or to revise desk review adjustments to their wage index data as included in the January 30, 2023, PUF. Hospitals also were required to submit sufficient documentation to support their requests. Hospital’s requests and supporting documentation must be received by the MAC by the February deadline (that is, by February 15, 2023, for the FY 2024 wage index).

After reviewing requested changes submitted by hospitals, MACs were required to transmit to CMS any additional revisions resulting from the hospitals’ reconsideration requests by March 20, 2023. Under our current policy as adopted in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38153), the deadline for a hospital to request CMS intervention in cases where a hospital disagreed with a MAC’s handling of wage data on any basis (including a policy, factual, or other dispute) was April 3, 2023. Data that were incorrect in the preliminary or January 30, 2023, wage index data PUFs, but for which no correction request was received by the February 15, 2023, deadline, are not considered for correction at this stage. In addition, April 3, 2023, was the final date for hospitals to dispute data corrections made by CMS. If a hospital was notified after the January 30, 2023, PUF and at least 14 calendar days prior to April 3, 2023 (that is, March 20, 2023), that do not arise from circumstances, and subject to the requirements set forth at new § 412.92(b)(2)(vi), the effective date for rural reclassification will be as of the effective date set forth in new § 412.92(b)(2)(vi).
opportunity to notify both its MAC and CMS regarding why the hospital believes an error exists and provide all supporting information, including relevant dates (for example, when it first became aware of the error). The hospital was required to send its request to CMS and to the MAC so that it was received no later than May 26, 2023. May 26, 2023, was also the deadline for hospitals to dispute data corrections made by CMS of which the hospital was notified on or after 13 calendar days prior to April 1, 2023 (that is, March 19, 2023), and at least 14 calendar days prior to May 26, 2023 (that is, May 12, 2023), that did not arise from a hospital’s request for revisions. (Data corrections made by CMS of which a hospital was notified on or after 13 calendar days prior to May 26, 2023 (that is, May 13, 2023), may be appealed to the Provider Reimbursement Review Board (PRRB)). In accordance with the FY 2024 Hospital Wage Index Development Time Table posted on the CMS website at https://www.cms.gov/files/document/fy-2024-hospital-wage-index-development-time-table.pdf, the May appeals were required to be sent via mail and email to CMS and the MACs. We refer readers to the FY 2024 Hospital Wage Index Development Time Table for complete details.

Verified corrections to the wage index data received timely (that is, by May 26, 2023) by CMS and the MACs were incorporated into the final FY 2024 wage index, which will be effective October 1, 2023. We created the processes previously described to resolve all substantive wage index data correction disputes before we finalize the wage and occupational mix data for the FY 2024 payment rates. Accordingly, hospitals that do not meet the procedural deadlines set forth earlier will not be afforded a later opportunity to submit wage index data corrections or to dispute the MAC’s decision with respect to requested changes. Specifically, our policy is that hospitals that do not meet the procedural deadlines as previously set forth (requiring requests to MACs by the specified date in February and, where such requests are unsuccessful, requests for intervention by CMS by the specified date in April) will not be permitted to challenge later, before the PRRB, the failure of CMS to make a requested data revision. We refer readers also to the FY 2000 IPPS final rule (64 FR 41513) for a discussion of the parameters for appeals to the PRRB for wage index data corrections. As finalized in the FY 2018 IPPS/CHPPS final rule (82 FR 38154 through 38156), this policy also applies to a hospital disputing corrections made by CMS that do not arise from a hospital’s request for a wage index data revision. That is, a hospital disputing an adjustment made by CMS that did not arise from a hospital’s request for a wage index data correction is required to request a correction by the first applicable deadline. Hospitals that do not meet the procedural deadlines set forth earlier will not be afforded a later opportunity to submit wage index data corrections or to dispute CMS’ decision with respect to changes.

We believe the wage index data correction process described earlier provides hospitals with sufficient opportunity to bring errors in their wage and occupational mix data to the MAC’s attention. Moreover, because hospitals that did not have access to the final wage index data PUFs by late April 2023, they have an opportunity to detect any data entry or tabulation errors made by the MAC or CMS before the development and publication of the final FY 2024 wage index by August 2023, and the implementation of the FY 2024 wage index on October 1, 2023. Given these processes, the wage index implemented on October 1 should be accurate. Nevertheless, in the event that errors are identified by hospitals and brought to our attention after May 26, 2023, we retain the right to make midyear changes to the wage index under very limited circumstances.

Specifically, in accordance with 42 CFR 412.64(k)(1) of our regulations, we make midyear corrections to the wage index for an area only if a hospital can show that: (1) The MAC or CMS made an error in tabulating its data; and (2) the requesting hospital could not have known about the error or did not have an opportunity to correct the error, before the beginning of the fiscal year. For purposes of this provision, “before the beginning of the fiscal year” means by the May deadline for making corrections to the wage data for the following fiscal year’s wage index (for example, May 26, 2023, for the FY 2024 wage index). This process is not available to a hospital seeking to revise another hospital’s data that may be affecting the requesting hospital's wage index for the labor market area. As indicated earlier, because CMS makes the wage index data available to hospitals on the CMS website prior to publishing both the proposed and final IPPS rules, and the MACs notify hospitals directly of any wage index data changes after completing their desk reviews, we do not expect that midyear corrections will be necessary; however, under our current policy, if the correction of a data error changes the
wage index value for an area, the revised wage index value will be effective prospectively from the date the correction is made.

In the FY 2006 IPPS final rule (70 FR 47385 through 47387 and 47485), we revised 42 CFR 412.64(k)(2) to specify that, effective on October 1, 2005, that is, beginning with the FY 2006 wage index, a change to the wage index can be made retroactive to the beginning of the Federal fiscal year only when CMS determines all of the following: (1) The MAC or CMS made an error in tabulating data used for the wage index calculation; (2) the hospital knew about the error and requested that the MAC and CMS correct the error using the established process and within the established schedule for requesting corrections to the wage index data, before the beginning of the fiscal year for the applicable IPPS update (that is, by the May 26, 2023, deadline for the FY 2024 wage index); and (3) CMS agreed before October 1 that the MAC or CMS made an error in tabulating the hospital’s wage index data and the wage index should be corrected.

In those circumstances where a hospital requested a correction to its wage index data before CMS calculated the final wage index (that is, by the May 26, 2023, deadline for the FY 2024 wage index), and CMS acknowledges that the error in the hospital’s wage index data was caused by CMS’s or the MAC’s mishandling of the data, we believe that the hospital should not be penalized by our delay in publishing or implementing the correction. As with our current policy, we indicated that the provision is not available to a hospital seeking to revise another hospital’s data. In addition, the provision cannot be used to correct prior years’ wage index data; it can only be used for the current Federal fiscal year. In situations where our policies would allow midyear corrections other than those specified in 42 CFR 412.64(k)(2)(ii), we continue to believe that it is appropriate to make prospective-only corrections to the wage index.

We note that, as with prospective changes to the wage index, the final retroactive correction will be made irrespective of whether the change increases or decreases a hospital’s payment rate. In addition, we note that the policy of retroactive adjustment will still apply in those instances where a final judicial decision reverses a CMS denial of a hospital’s wage index data revision request.

2. Process for Data Corrections by CMS

The process set forth with the wage index timetable discussed in section III.I.1. of the preamble of this final rule allows hospitals to request corrections to their wage index data within prescribed timeframes. In addition to hospitals’ opportunity to request corrections of wage index data errors or MACs’ mishandling of data, CMS has the authority under section 1886(d)(3)(E) of the Act to make corrections to hospital wage index and occupational mix data in order to ensure the accuracy of the wage index. As we explained in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49490 through 49491) and the FY 2017 IPPS/LTCH PPS final rule (81 FR 51414), section 1886(d)(3)(E) of the Act requires the Secretary to adjust the proportion of hospitals’ costs attributable to wages and wage-related costs for area differences reflecting the relative hospital wage level in the geographic areas of the hospital compared to the national average hospital wage level. We believe that, under section 1886(d)(3)(E) of the Act, we have discretion to make corrections to hospitals’ data to help ensure that the costs attributable to wages and wage-related costs in fact accurately reflect the relative hospital wage level in the hospitals’ geographic areas.

We have an established multistep, 15-month process for the review and correction of the hospital wage data that is used to create the IPPS wage index for the upcoming fiscal year. Since the origin of the IPPS, the wage index has been subject to its own annual review process, first by the MACs, and then by CMS. As a standard practice, after each annual desk review, CMS reviews the results of the MACs’ desk reviews and focuses on items flagged during the desk review, requiring that, if necessary, hospitals provide additional documentation, adjustments, or corrections to the data. This ongoing communication with hospitals about their wage data may result in the discovery by CMS of additional items that were reported incorrectly or other data errors, even after the posting of the January 30 PUF, and throughout the remainder of the wage index development process. In addition, the fact that CMS analyzes the data from a regional and even national level, unlike the review performed by the MACs that review a limited subset of hospitals, can facilitate additional editing of the data that may not be readily apparent to the MACs. In these occasional instances, an error may be of sufficient magnitude that the wage index of an entire CBSA is affected. Accordingly, CMS uses its authority to ensure that the wage index accurately reflects the relative hospital wage level in the geographic area of the hospital compared to the national average hospital wage level, by continuing to make corrections to hospital wage data upon discovering incorrect wage data, distinct from instances in which hospitals request data revisions.

We note that CMS corrects errors to hospital wage data as appropriate, regardless of whether that correction will raise or lower a hospital’s average hourly wage. For example, as discussed in section III.C. of the preamble of the FY 2019 IPPS/LTCH PPS final rule (83 FR 41364), in situations where a hospital did not have documentable salaries, wages, and hours for housekeeping and dietary services, we imputed estimates, in accordance with policies established in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49965 through 49967). Furthermore, if CMS discovers after conclusion of the desk review, for example, that a MAC inadvertently failed to incorporate positive adjustments resulting from a prior year’s wage index appeal of a hospital’s wage-related costs such as pension, CMS would correct that data error, and the hospital’s average hourly wage would likely increase as a result.

While we maintain CMS’ authority to conduct additional review and make resulting corrections at any time during the wage index development process, in accordance with the policy finalized in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38154 through 38156) and as first implemented with the FY 2019 wage index (83 FR 41389), hospitals are able to request further review of a correction made by CMS that did not arise from a hospital’s request for a wage index data correction. Instances where CMS makes a correction to a hospital’s data after the January 30 PUF based on a different understanding than the hospital about certain reported costs, for example, could potentially be resolved using this process before the final wage index is calculated. We believe this process and the timeline for requesting review of such corrections (as described earlier and in the FY 2018 IPPS/LTCH PPS final rule) promote additional transparency to instances where CMS makes data corrections after the January 30 PUF and provide opportunities for hospitals to request further review of CMS changes in time for the most accurate data to be factored into the final wage index calculations. These additional appeals opportunities are
described earlier and in the FY 2024 Hospital Wage Index Development Time Table, as well as in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38154 through 38156).

M. Labor-Related Share for the FY 2023 Wage Index

Section 1886(d)(3)(E) of the Act directs the Secretary to adjust the proportion of the national prospective payment system base payment rates that are attributable to wages and wage-related costs by a factor that reflects the relative differences in labor costs among geographic areas. It also directs the Secretary to estimate from time to time the proportion of hospital costs that are labor-related and to adjust the proportion (as estimated by the Secretary from time to time) of hospitals’ costs that are attributable to wages and wage-related costs of the DRG prospective payment rates. We refer to the portion of hospital costs attributable to wages and wage-related costs that is allocated share. The labor-related share of the prospective payment rate is adjusted by an index of relative labor costs, which is referred to as the wage index.

Section 403 of Public Law 108–173 amended section 1886(d)(3)(E) of the Act to provide that the Secretary must employ 62 percent as the labor-related share unless this would result in lower payments to a hospital than would otherwise be made. However, this provision of Public Law 108–173 did not change the legal requirement that the Secretary estimate from time to time the proportion of hospitals’ costs that are attributable to wages and wage-related costs. Thus, hospitals receive payment based on either a 62-percent labor-related share, or the labor-related share estimated from time to time by the Secretary, depending on which labor-related share resulted in a higher payment.

In the FY 2022 IPPS/LTCH PPS final rule (86 FR 45194 through 45208), we rebased and revised the hospital market basket. We established a 2018-based IPPS hospital market basket to replace the FY 2014-based IPPS hospital market basket, effective October 1, 2021. Using the 2018-based IPPS market basket, we finalized a labor-related share of 67.6 percent for discharges occurring on or after October 1, 2021. In addition, in FY 2022, we implemented this revised and rebased labor-related share in a budget neutral manner (86 FR 45193, 45529, and 45530). However, consistent with section 1886(d)(3)(E) of the Act, we did not take into account the additional payments that would be made as a result of hospitals with a wage index less than or equal to 1.0000 being paid using a labor-related share lower than the labor-related share of hospitals with a wage index greater than 1.0000.

The labor-related share is used to determine the proportion of the national IPPS base payment rate to which the area wage index is applied. We include a cost category in the labor-related share if the costs are labor intensive and vary with the local labor market. In the FY 2022 IPPS/LTCH PPS final rule (86 FR 45204 through 45207), we included in the labor-related share the national average proportion of operating costs that are attributable to the following cost categories in the 2018-based IPPS market basket: Wages and Salaries; Employee Benefits; Professional Fees: Labor-Related; Administrative and Facilities Support Services; Installation, Maintenance, and Repair Services; and All Other: Labor-Related Services. In the proposed rule, for FY 2024, we did not propose to make any further changes to the labor-related share. For FY 2024, we are finalizing the policy to continue to use a labor-related share of 67.6 percent for discharges occurring on or after October 1, 2023.

As discussed in section V.B. of the preamble of this final rule, prior to January 1, 2016, Puerto Rico hospitals were paid based on 75 percent of the national standardized amount and 25 percent of the Puerto Rico-specific standardized amount. As a result, we applied the Puerto Rico-specific labor-related share percentage and nonlabor-related share percentage to the Puerto Rico-specific standardized amount. Section 601 of the Consolidated Appropriations Act, 2016 (Pub. L. 114–113) amended section 1886(d)(9)(E) of the Act to specify that the payment calculation with respect to operating costs of inpatient hospital services of a subsection (d) Puerto Rico hospital for inpatient hospital discharges on or after January 1, 2016, shall use 100 percent of the national standardized amount. Because Puerto Rico hospitals are no longer paid with a Puerto Rico-specific standardized amount as of January 1, 2016, under section 1886(d)(9)(E) of the Act as amended by section 601 of the Consolidated Appropriations Act, 2016, there is no longer a need for us to calculate a Puerto Rico-specific labor-related share percentage and nonlabor-related share percentage for application to the Puerto Rico-specific standardized amount. Hospitals in Puerto Rico are now paid 100 percent of the national standardized amount and, therefore, are subject to the national labor-related share and nonlabor-related share percentages that are applied to the national standardized amount.

Accordingly, for FY 2024, we did not propose a Puerto Rico-specific labor-related share percentage or a nonlabor-related share percentage.

Tables 1A and 1B, which are published in section VI of the Addendum to this FY 2024 IPPS/LTCH PPS final rule and available via the internet on the CMS website, reflect the national labor-related share. Table 1C, in section VI of the Addendum to this FY 2024 IPPS/LTCH PPS final rule and available via the internet on the CMS website, reflects the national labor-related share for hospitals located in Puerto Rico. For FY 2024, for all IPPS hospitals (including Puerto Rico hospitals) whose wage indexes are less than or equal to 1.0000, we are applying the wage index to a labor-related share of 62 percent of the national standardized amount. For all IPPS hospitals (including Puerto Rico hospitals) whose wage indexes are greater than 1.0000, for FY 2024, we are applying the wage index to a labor-related share of 67.6 percent of the national standardized amount.

Comment: A commenter requested that CMS maintain the labor-related share from FY 2023 for FY 2024.

Response: We did not propose to make any further changes to the labor-related share for FY 2024. As discussed earlier, for FY 2024, we are continuing to use a labor-related share of 67.6 percent for discharges occurring on or after October 1, 2023.

IV. Payment Adjustment for Medicare Disproportionate Share Hospitals (DSHs) for FY 2024 (§ 412.106)

A. General Discussion

Section 1886(d)(5)(F) of the Act provides for additional Medicare payments to subsection (d) hospitals that serve a significantly disproportionate number of low-income patients. The Act specifies two methods by which a hospital may qualify for the Medicare disproportionate share hospital (DSH) adjustment. Under the first method, hospitals that are located in an urban area and have 100 or more beds may receive a Medicare DSH payment adjustment if the hospital can demonstrate that, during its cost reporting period, more than 30 percent of its net inpatient care revenues are derived from State and local government payments for care furnished to patients with low incomes. This method is commonly referred to as the “Pickle method.” The second method for qualifying for the DSH payment adjustment, which is the more common method, is based on a complex statutory formula under which the DSH payment
adjustment is based on the hospital's geographic designation, the number of beds in the hospital, and the level of the hospital's disproportionate patient percentage (DPP).

A hospital's DPP is the sum of two fractions: the "Medicare fraction" and the "Medicaid fraction." The Medicare fraction (also known as the "SSI fraction" or "SSI ratio") is computed by dividing the number of the hospital's inpatient days that are furnished to patients who were entitled to both Medicare Part A and Supplemental Security Income (SSI) benefits by the hospital's total number of patient days furnished to patients entitled to benefits under Medicare Part A. The Medicaid fraction is computed by dividing the hospital's number of inpatient days furnished to patients who, for such days, were eligible for Medicaid, but were not entitled to benefits under Medicare Part A, by the hospital's total number of inpatient days in the same period.

<table>
<thead>
<tr>
<th>DSH Eligibility</th>
<th>Qualifying Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statutory Formula</td>
<td>A hospital that has a DPP equal to or exceeding 15 percent may qualify for the Medicare DSH adjustment. We refer readers to 42 CFR 412.106 for the specific eligibility criteria and payment formulas.</td>
</tr>
<tr>
<td>&quot;Pickle Method&quot;</td>
<td>A hospital that is located in an urban area and has 100 or more beds may qualify to receive a Medicare DSH payment adjustment if the hospital can demonstrate that, during its cost reporting period, more than 30 percent of its net inpatient care revenues are derived from State and local government payments for care furnished to patients with low incomes.</td>
</tr>
</tbody>
</table>

Because the DSH payment adjustment is part of the IPPS, the statutory references to "days" in section 1886(d)(5)(F) of the Act have been interpreted to apply only to hospital acute care inpatient days. Regulations located at 42 CFR 412.106 govern the Medicare DSH payment adjustment and specify how the DPP is calculated as well as how beds and patient days are counted in determining the Medicare DSH payment adjustment. Under § 412.106(a)(1)(ii), the number of beds for the Medicare DSH payment adjustment is determined in accordance with bed counting rules for the IME adjustment under § 412.105(b).

Section 3133 of the Patient Protection and Affordable Care Act (Pub. L. 111–148), as amended by section 10316 of the same Act and section 1104 of the Health Care and Education Reconciliation Act (Pub. L. 111–152), added a section 1886(r) to the Act that modifies the methodology for computing the Medicare DSH payment adjustment. We refer to these provisions collectively as section 3133 of the Affordable Care Act. Beginning with discharges in FY 2014, hospitals that qualify for Medicare DSH payments under section 1886(d)(5)(F) of the Act receive 25 percent of the amount they previously would have received under the statutory formula for Medicare DSH payments. This provision applies equally to hospitals that qualify for DSH payments under section 1886(d)(5)(F)(I) of the Act and hospitals that qualify under the Pickle method under section 1886(d)(5)(F)(II) of the Act.

The remaining amount, equal to an estimate of 75 percent of what otherwise would have been paid as Medicare DSH payments, reduced to reflect changes in the percentage of individuals who are uninsured, is available to make additional payments to each hospital that qualifies for Medicare DSH payments and that has provided uncompensated care. These additional payments to each hospital for a fiscal year are based on the hospital’s amount of uncompensated care for a given time period relative to the total amount of uncompensated care for that same time period reported by all hospitals that receive Medicare DSH payments for that fiscal year.

In summary, since FY 2014, section 1886(r) of the Act has required that hospitals that are eligible for DSH payments under section 1886(d)(5)(F) of the Act receive two separately calculated payments:

<table>
<thead>
<tr>
<th>Medicare DSH Payment</th>
<th>An empirically justified DSH payment equal to 25% of the amount determined under the statutory formula in section 1886(d)(5)(F) of the Act.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicare DSH Uncompensated Care Payment</td>
<td>An uncompensated care payment determined as the product of 3 factors, as discussed in this section.</td>
</tr>
</tbody>
</table>

Specifically, section 1886(r)(1) of the Act provides that the Secretary shall pay to such subsection (d) hospital 25 percent of the amount the hospital would have received under section 1886(d)(5)(F) of the Act for DSH payments, which represents the empirically justified amount for such payment, as determined by the MedPAC in its March 2007 Report to Congress.194 We refer to this payment as the "empirically justified Medicare DSH payment."

In addition to this empirically justified Medicare DSH payment, section 1886(r)(2) of the Act provides that, for FY 2014 and each subsequent fiscal year, the Secretary shall pay to such subsection (d) hospital an additional amount equal to the product of three factors. The first factor is the difference between the aggregate amount of payments that would be made to subsection (d) hospitals under section 1886(d)(5)(F) of the Act if subsection (r) did not apply and the aggregate amount of payments that are made to subsection (d) hospitals under section 1886(r)(1) of the Act for such fiscal year. Therefore, this factor amounts to 75 percent of the payments that would otherwise be made under section 1886(d)(5)(F) of the Act.

The second factor is, for FY 2018 and subsequent fiscal years, equal to 1 minus the percent change in the percent of individuals who are uninsured. For purposes of calculating this factor, the Secretary determines the percent change in the percent of individuals who are uninsured by comparing the percent of individuals who were uninsured in 2013 (as estimated by the Secretary

Section 1886(r) of the Act applies to FY 2014 and each subsequent fiscal year. In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50620 through 50647) and the FY 2014 IPPS interim final rule with comment period (78 FR 61191 through 61197), we set forth our policies for implementing the required changes to the Medicare DSH payment methodology made by section 3133 of the Affordable Care Act beginning in FY 2014. In those rules, we noted that, because section 1886(r) of the Act modifies the payment required under section 1886(d)(5)(F) of the Act, it affects only the DSH payment under the operating IPPS. It does not revise or replace the capital IPPS DSH payment provided under 42 CFR part 412, subpart M, which was established through the exercise of the Secretary’s discretion in implementing the capital IPPS under section 1886(g)(1)(A) of the Act.

Finally, section 1886(r)(3) of the Act provides that there shall be no administrative or judicial review under section 1869, section 1878, or otherwise of any estimate of the Secretary for purposes of determining the factors described in section 1886(r)(2) of the Act or of any period selected by the Secretary for the purpose of determining those factors. Therefore, there is no administrative or judicial review of the estimates developed for purposes of applying the three factors used to determine uncompensated care payments, or the periods selected to develop such estimates.

**B. Eligibility for Empirically Justified Medicare DSH Payments and Uncompensated Care Payments**

As explained earlier, the payment methodology under section 3133 of the Affordable Care Act applies to “subsection (d) hospitals” that would otherwise receive a DSH payment made under section 1886(d)(5)(F) of the Act. In addition, section 1886(r) of the Act states that hospitals must receive empirically justified Medicare DSH payments in a fiscal year to receive an additional Medicare uncompensated care payment for that year. Specifically, section 1886(r)(2) of the Act provides that, in addition to the empirically justified Medicare DSH payment made to a subsection (d) hospital under section 1886(r)(1), the Secretary will pay to “such subsection (d) hospitals” the uncompensated care payment. Section 1886(r)(2)’s reference to “such subsection (d) hospitals” refers to hospitals that receive empirically justified Medicare DSH payments under Section 1886(r)(1). Therefore, the uncompensated care payment provided for in Section 1886(r)(2) is limited to those hospitals that receive empirically justified Medicare DSH payments.

Accordingly, in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50622) and the FY 2014 IPPS interim final rule with comment period (78 FR 61193), we explained that hospitals that are not eligible to receive empirically justified Medicare DSH payments in a fiscal year will not receive uncompensated care payments for that year. We also specified that we would make a determination concerning eligibility for interim uncompensated care payments based on each hospital’s estimated DSH status for the applicable fiscal year (using the most recent data that are available). In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26988), we stated that we would estimate DSH status for all hospitals using the most recent available SSI ratios and information from the most recent available Provider Specific File. We noted that FY 2020 SSI ratios available on the CMS website were the most recent available SSI ratios at the time of developing the proposed rule. We stated that if more recent data on DSH eligibility become available before the final rule, we would use such data in the final rule. The FY 2020 SSI ratios were the most recent data available at the time of developing this FY 2024 IPPS/LTCH PPS final rule.

Our final determination of a hospital’s eligibility for uncompensated care payments will be based on the hospital’s actual DSH status at cost report settlement for FY 2024.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50622) and in the rulemaking for subsequent fiscal years, we specified our policies regarding the eligibility of several specific classes of hospitals to receive empirically justified Medicare DSH payments and uncompensated care payments under section 1886(r) of the Act.

195 For more information on interim uncompensated care payments, we refer readers to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50624 through 50625).
196 The file contains information about the facts specific to the provider that affect computations for the IPPS.
197 https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/dsh.

---

| Factor 1 | 75% of the total amount of DSH payments that would otherwise be made under section 1886(d)(5)(F) of the Act. |
| Factor 2 | 1 minus the percent change in the percent of individuals who are uninsured (minus 0.2 percentage point for FYs 2018 and 2019). For FY 2020 and after, there is no additional reduction. |
| Factor 3 | The hospital’s uncompensated care amount relative to the uncompensated care amount for all DSH hospitals expressed as a percentage. |
Eligible hospitals include the following:

- Subsection (d) Puerto Rico hospitals that are eligible for DSH payments also are eligible to receive empirically justified Medicare DSH payments and uncompensated care payments under section 1886(r) of the Act (78 FR 50623 and 79 FR 50006).
- Sole community hospitals (SCHs) that are paid under the IPPS Federal rate receive interim payments based on what we estimate and project their DSH status to be prior to the beginning of the Federal fiscal year (based on the best available data at that time) subject to settlement through the cost report. If an SCH receives interim empirically justified Medicare DSH payments in a fiscal year, it also will receive interim uncompensated care payments for that fiscal year on a per discharge basis, subject to settlement through the cost report. Final eligibility determinations will be made at the end of the cost reporting period at settlement, and both interim and final Medicare DSH payments and uncompensated care payments will be adjusted accordingly (78 FR 50624 and 79 FR 50007).
- Medicare-dependent, small rural hospitals (MDHs) are paid based on the IPPS Federal rate or, if higher, the IPPS Federal rate plus 75 percent of the amount by which the updated hospital-specific rate from certain specified base years (76 FR 51684) exceeds the Federal rate. The IPPS Federal rate that is used in the MDH payment methodology is the same IPPS Federal rate that is used in the SCH payment methodology. Because MDHs are paid based on the IPPS Federal rate, they continue to be eligible to receive empirically justified Medicare DSH payments and uncompensated care payments if their DPP is at least 15 percent, and we apply the same process to determine MDHs’ eligibility for interim empirically justified Medicare DSH and interim uncompensated care payments as we do for all other IPPS hospitals. Legislation has extended the MDH program into FY 2024. The MDH program was initially extended through December 17, 2022, by section 102 of the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (Pub. L. 117–180), and through December 24, 2022, by section 102 of the Further Continuing Appropriations and Extensions Act, 2023 (Pub. L. 117–229). Section 4102 of the Continuing Appropriations Act, 2023 (Pub. L. 117–328) amended sections 1886(d)(5)(ii) and 1886(d)(5)(ii)(II) of the Act to provide extension of the MDH program through October 1, 2024 (that is, for discharges occurring on or before September 30, 2024). We refer readers to section V.F. of the preamble of this final rule for further discussion of the MDH program. We continue to make determinations concerning an MDH’s eligibility for interim uncompensated care payments based on the hospital’s estimated DSH status for the applicable fiscal year.
- IPPS hospitals that elect to participate in the Bundled Payments for Care Improvement Advanced (BPCI Advanced) model, which started October 1, 2018, will continue to be paid under the IPPS and, therefore, are eligible to receive empirically justified Medicare DSH payments and uncompensated care payments. On October 13, 2022, CMS announced that the BPCI Advanced Model would be extended for two years. Accordingly, the Model’s final performance year will end on December 31, 2025. For further information regarding the BPCI Advanced Model, we refer readers to the CMS website at https://innovation.cms.gov/innovation-models/bpci-advanced.
- IPPS hospitals that participate in the Comprehensive Care for Joint Replacement Model (80 FR 73300) continue to be paid under the IPPS and, therefore, are eligible to receive empirically justified Medicare DSH payments and uncompensated care payments. We refer the reader to the interim final rule with request for comments that appeared in the November 6, 2020 Federal Register for a discussion of the Model (85 FR 71167 through 71173). In that interim final rule, we extended the Model’s Performance Year 5 to September 30, 2021. In a subsequent final rule that appeared in the May 3, 2021 Federal Register (86 FR 23496), we further extended the Model for an additional three performance years. The Model’s Performance Year 8 will end on December 31, 2024.
- Ineligible hospitals include the following:
- Maryland hospitals are not eligible to receive empirically justified Medicare DSH payments and uncompensated care payments under the payment methodology of section 1886(r) of the Act because they are not paid under the IPPS. As discussed in the FY 2019 IPPS/ LTCH PPS final rule (83 FR 41402 through 41403), CMS and the State have entered into an agreement to govern payments to Maryland hospitals under a new payment model, the Maryland Total Cost of Care (TCOC) Model. Under this Model, which began on January 1, 2019, and concluded on December 31, 2026, Maryland hospitals are not paid under the IPPS and are ineligible to receive empirically justified Medicare DSH payments and uncompensated care payments under section 1886(r) of the Act.
- SCHs that are paid under their hospital-specific rate are not eligible for Medicare DSH and uncompensated care payments. (See 78 FR 50623 and 50624.)
- Hospitals participating in the Rural Community Hospital Demonstration Program are not eligible to receive empirically justified Medicare DSH payments and uncompensated care payments under section 1886(r) of the Act because they are not paid under the IPPS (78 FR 50625 and 79 FR 50008). The Rural Community Hospital Demonstration Program was originally authorized for a 5-year period by section 410A of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) (Pub. L. 108–173), and extended for another 5-year period by sections 3123 and 10313 of the Affordable Care Act (Pub. L. 111–148). The period of performance for this 5-year extension period (in place of the 5-year extension required by the Affordable Care Act), therefore requiring an additional 5-year participation period for the demonstration program. Section 15003 of Public Law 114–255 also required a solicitation for applications for additional hospitals to participate in the demonstration program. The period of performance for this second 5-year extension period ended December 31, 2021. The Consolidated Appropriations Act, 2021 (Pub. L. 116–260) amended section 410A of Public Law 108–173 to require a 10-year extension period (in place of the 5-year extension required by the Affordable Care Act), therefore requiring an additional 5-year participation period for the demonstration program. The period of performance for this 5-year extension period ended December 31, 2021. The Consolidated Appropriations Act, 2021 (Pub. L. 116–260) amended section 410A of Public Law 108–173 to extend the Rural Community Hospital Demonstration Program for an additional 5-year period. The period of participation for the last hospital in the demonstration under this most recent legislative authorization will end on June 30, 2028. Under the payment methodology that applies during the third 5-year extension period for the demonstration program, participating hospitals do not receive empirically justified Medicare DSH payments, and they are excluded from receiving interim and final uncompensated care payments. At the time of development of this final rule, we expect 26 hospitals may participate in the demonstration program at the start of FY 2024.
- We received a comment that was outside the scope of the proposed rule. The comment related to the eligibility of SCHs paid under hospital-specific rate and MDHs to receive DSH payments.
Because we consider this public comment to be outside the scope of the proposed rule, we are not addressing the comment in this final rule.

C. Empirically Justified Medicare DSH Payments

As we discussed earlier, section 1886(r)(1) of the Act requires the Secretary to pay 25 percent of the amount of the Medicare DSH payment that would otherwise be made under section 1886(d)(5)(F) of the Act to a subsection (d) hospital. Because section 1886(r)(1) of the Act merely requires the Medicare program to pay a designated percentage of these payments and does not revise the criteria governing eligibility for DSH payments or the underlying payment methodology, we stated in the FY 2014 IPPS/LTCH PPS final rule that we had determined that it was unnecessary to develop new operational mechanisms for making empirically justified DSH payments under section 1886(r)(1). Therefore, in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50626), we implemented section 1886(r)(1) of the Act by advising Medicare Administrative Contractors (MACs) to simply adjust subsection (d) hospitals’ interim claim payments to an amount equal to 25 percent of what would have been paid if section 1886(r) of the Act did not apply. We also made corresponding changes to the hospital cost report so that the empirically justified Medicare DSH payments can be settled at the appropriate level at the time of cost report settlement. We provided more detailed operational instructions and cost report instructions following issuance of the FY 2014 IPPS/LTCH PPS final rule, which are available on the CMS website at https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2014-Transmittals-Items/R3P240.html.

D. Supplemental Payment for Indian Health Service (IHS) and Tribal Hospitals and Puerto Rico Hospitals

In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49047 through 49051), we established a new supplemental payment for IHS/Tribal hospitals and hospitals located in Puerto Rico for FY 2023 and subsequent fiscal years. This payment was established to help to mitigate the impact of the decision to discontinue the use of low-income insured days as proxy for uncompensated care costs for these hospitals and to prevent undue long-term financial disruption for these providers. The regulations located at 42 CFR 412.106(g) govern the supplemental payment. In brief, the supplemental payment for a fiscal year is determined as the difference between the hospital’s base year amount and its uncompensated care payment for the applicable fiscal year as determined under § 412.106(g)(1). The base year amount is the hospital’s FY 2022 uncompensated care payment adjusted by one plus the percent change in the total uncompensated care amount between the applicable fiscal year (that is, FY 2024 for purposes of this rulemaking) and FY 2022, where the total uncompensated care amount for a year is determined as the product of Factor 1 and Factor 2 for that year. If the base year amount is equal to or lower than the hospital’s uncompensated care payment for the current fiscal year, then the hospital would not receive a supplemental payment because the hospital would not be experiencing financial disruption in that year as a result of the use of uncompensated care data from the Worksheet S–10 in determining Factor 3 of the uncompensated care payment methodology.

As discussed in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49048 and 49049), the eligibility and payment processes for the supplemental payment are consistent with the processes for determining eligibility to receive interim and final uncompensated care payments adopted in FY 2014 IPPS/LTCH final rule. We note that the MAC will make a final determination with respect to a hospital’s eligibility to receive the supplemental payment for a fiscal year, in conjunction with its final determination of the hospital’s eligibility for DSH payments and uncompensated care payments for that fiscal year.

Comment: Two commenters expressed continued support for these supplemental payments to lessen the impact of discontinuing the use of low-income patient days to calculate uncompensated care payments for IHS/Tribal hospitals in Puerto Rico. Specifically, a commenter noted that the permanent supplemental payments will mitigate the undue long-term financial disruption that would have occurred due to the discontinuance of the previous methodology for calculating uncompensated care costs.

Many commenters reiterated their recommendations that were submitted in response to the proposal to establish these supplemental payments in last year’s proposed rule. Specifically, these commenters recommended that CMS calculate the supplemental payment for Puerto Rico hospitals using a base year amount determined from Medicaid days and an SSI days proxy of at least 40 percent of the hospital’s Medicaid days, instead of the proxy that applied from FY 2017 through FY 2022, consisting of 14 percent of the hospital’s Medicaid days, and was developed based on national data regarding the relationship between Medicare SSI days and Medicaid days. In addition, these commenters requested that CMS make all acute care hospitals in Puerto Rico eligible to receive uncompensated care payments, including those that do not qualify for empirically justified DSH payments, which the commenters believe would be consistent with statutory language. As an alternative, these commenters requested that CMS determine a hospital’s eligibility to receive uncompensated care payments and supplemental payments using the suggested proxy for Medicare SSI days of 40 percent of the hospital’s Medicaid days. These commenters contend that hospitals that fail to qualify for empirically justified DSH payments might still qualify for uncompensated care payments by using the 40 percent metric.

Another commenter requested that CMS evaluate alternatives to the supplemental payment that would better support hospitals in Puerto Rico in instances of increasing uninsured days. This commenter argued that the supplemental payment only mitigates the anticipated impact of the changes to the uncompensated care payment methodology starting in FY 2023 relative to these hospitals’ 2022 uncompensated care payment levels. However, the commenter further stated that this approach is not helpful if uninsured patient volumes rise above the 2022 levels. The same commenter further expressed that they would alternatively support a return to the prior method of using a proxy to determine uninsured days for hospitals in Puerto Rico given the challenges around the collection of Worksheet S–10 data.

The Medicare Payment Advisory Commission (MedPAC) recommended that CMS alter its methodology for making interim supplemental payments as an add-on payment to the IPPS payment rates for Puerto Rico hospitals to avoid distorting Medicare Advantage (MA) benchmarks. MedPAC argued that the $80 million in supplemental payments to Puerto Rico hospitals in 2023 would inappropriately boost payments to MA plans operating in Puerto Rico by almost $1 billion per year.

Response: We appreciate the concerns and input raised by commenters regarding the supplemental payment for hospitals in Puerto Rico and IHS and Tribal hospitals that was established in
the FY 2023 IPPS/LTCH PPS final rule. We continue to recognize the unique financial circumstances and challenges faced by Puerto Rico hospitals and IHS and Tribal hospitals related to uncompensated care cost reporting on Worksheet S–10, with respect to uncompensated care due to structural differences in health care delivery and financing in these areas compared to the rest of the country (87 FR 49047). With respect to comments regarding SSI proxy recommendations, we refer readers to our response to a similar comment in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49049 and 49050).

Regarding the commenter’s request that all acute care hospitals in Puerto Rico receive uncompensated care payments regardless of DSH eligibility, we refer readers to the policy initially adopted in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50622 and 50623), which explains that hospitals, including Puerto Rico hospitals, must be eligible to receive empirically justified Medicare DSH payments to receive an additional Medicare uncompensated care payment for that year. As discussed in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49048 and 49049), the processes for determining eligibility for the supplemental payment and making interim and final payments are consistent with the processes for determining eligibility to receive interim and final uncompensated care payments adopted in FY 2014 IPPS/LTCH final rule and the approach used to make interim uncompensated care payments on a per discharge basis.

With respect to the comments recommending that CMS determine eligibility to receive empirically justified DSH payments using the suggested proxy for SSI days of 40 percent of Medicaid days, we note that in the FY 2024 IPPS/LTCH PPS proposed rule, we did not propose to adopt a proxy for Puerto Rico hospitals’ SSI days for use in determining eligibility to receive empirically justified Medicare DSH payments or the amount of such payments. Therefore, these comments are considered to be outside the scope of the FY 2024 proposed rule. However, we note that as discussed in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49050), section 1886(d)(5)(F)(vi) of the Act prescribes the disproportionate patient percentage used to determine empirically justified Medicare DSH payments, and it specifically calls for the use of SSI days in the Medicare fraction and does not allow the use of alternative data. Therefore, we continue to disagree with the commenter’s assertion that there is legal support for CMS to use a proxy for Puerto Rico hospitals’ SSI days in the calculation of the empirically justified Medicare DSH payment or in the eligibility determination for this payment.

Regarding the comments encouraging CMS to evaluate alternatives to supplemental payments to support Puerto Rico hospitals in the case of increasing uninsured days, we note that prior to FY 2023, we used low-income insured days as a proxy for uncompensated care costs. In contrast, we have never directly considered fluctuations in uninsured days in the calculation of uncompensated care payments. Therefore, we continue to believe that the supplemental payments, which are based on the FY 2022 uncompensated care payments calculated for Puerto Rico hospitals, are the appropriate approach to address the difficulties for Puerto Rico hospitals.

In response to MedPAC’s comment, we continue to believe the combined amount of empirically justified DSH payments, uncompensated care payments, and supplemental payments to IHS/Tribal hospitals and Puerto Rico hospitals will be comparable to the amount these hospitals would have received if CMS had continued to use the low-income days proxy to determine Factor 3 of the uncompensated care payment methodology. As a result, the supplemental payments are expected to have no significant impact on MA benchmarks in Puerto Rico. We also note that for the past several years, the MA benchmark rates in Puerto Rico hospitals have declined beneficiaries with coverage for only Medicare Part A or only Medicare Part B. For calendar years 2020 and 2021, about 70 percent of uncompensated care payments represented in Puerto Rico claim records were associated with Part A-only beneficiaries and thus excluded from the MA ratebook calculation. Accordingly, about 70 percent of supplemental payments to Puerto Rico hospitals would be excluded from the MA ratebook development.

E. Uncompensated Care Payments

As we discussed earlier, section 1886(r)(2) of the Act provides that, for each eligible hospital in FY 2014 and subsequent years, the uncompensated care payment is the product of our estimate of three factors: (1) 75 percent of the amount of Medicare DSH payments that would be made to subsection (d) hospitals under section 1886(d)(5)(F) of the Act if subsection (r) did not apply; (2) 1 minus the percent change in the national rate of uninsurance compared to the rate of uninsurance in 2013; and (3) each eligible hospital’s estimated uncompensated care amount relative to the estimated uncompensated care amount for all eligible hospitals. In this section of this final rule, we discuss the data sources and methodologies for computing each of these factors, our final policies for FYs 2014 through 2023, and our final policies for FY 2024.

1. Calculation of Factor 1 for FY 2024

Section 1886(r)(2)(A) of the Act establishes Factor 1 in the calculation of the uncompensated care payment. Section 1886(r)(2)(A) of the Act states that this factor is equal to the difference between: (1) the aggregate amount of payments that would be made to subsection (d) hospitals under section 1886(d)(5)(F) of the Act if section 1886(r) of the Act did not apply for such fiscal year (as estimated by the Secretary); and (2) the aggregate amount of payments that are made to subsection (d) hospitals under section 1886(r)(1) of the Act for such fiscal year (as so estimated). Therefore, section 1886(r)(2)(A)(i) of the Act represents the estimated Medicare DSH payments that would have been made under section 1886(d)(5)(F) of the Act if section 1886(r) of the Act did not apply for such fiscal year. Under a prospective payment system, we would not know the aggregate Medicare DSH payment amount that would be paid for a Federal fiscal year until cost report settlement for all IPPS hospitals is completed, which occurs several years after the end of the Federal fiscal year. Therefore, section 1886(r)(2)(A)(i) of the Act provides authority to estimate this amount, by specifying that, for each fiscal year to which the provision applies, such amount is to be estimated by the Secretary. Similarly, section 1886(r)(2)(A)(ii) of the Act represents the estimated empirically justified Medicare DSH payments to be made in a fiscal year, as prescribed under section 1886(r)(1) of the Act. Again, section 1886(r)(2)(A)(ii) of the Act provides authority to estimate this amount.

Therefore, Factor 1 is the difference between our estimates of: (1) the amount that would have been paid in Medicare DSH payments for the fiscal year in the absence of section 1886(r) of the Act; and (2) the amount of empirically justified Medicare DSH payments that are made for the fiscal year. The second element of Factor 1 reflects the statutory requirement to pay to subsection (d) hospitals 25 percent of what would have otherwise been paid under section
In the FY 2024 IPPS/LTCH PPS proposed rule, we proposed that to determine Factor 1 in the uncompensated care payment formula for FY 2024, we would continue the policy established in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50628 through 50630) and in the FY 2014 IPPS interim final rule with comment period (78 FR 61194). Accordingly, we proposed to determine Factor 1 by developing estimates of both the aggregate amount of Medicare DSH payments that would be made for FY 2024 in the absence of section 1886(r)(1) of the Act and the aggregate amount of empirically justified Medicare DSH payments to hospitals under section 1886(r)(1) of the Act. Consistent with the policy that we have applied in previous years, these estimates are not revised or updated subsequent to the publication of our final projections in this FY 2024 IPPS/LTCH PPS final rule.

Thus, in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26989 through 26992), we proposed that to determine the two elements of proposed Factor 1 for FY 2024, we would use the most recent available projections of Medicare DSH payments for the fiscal year, as calculated by CMS’ Office of the Actuary (OACT) using the most recently filed Medicare hospital cost reports with Medicare DSH payment information and the most recent Medicare DSH patient percentages and Medicare DSH payment adjustments provided in the FY 2023 IPPS/LTCH PPS final rule’s Impact File. The determination of the amount of DSH payments is partially based on OACT’s Part A benefits projection model. One of the components of this model is inpatient hospital spending. Projections of DSH payments require projections for expected increases in utilization and case-mix. The assumptions that were used in making these projections and the resulting estimates of DSH payments for FY 2021 through FY 2024 are discussed in the table titled “Factors Applied for FY 2021 through FY 2024 to Estimate Medicare DSH Expenditures Using File” (88 FR 26991).

For purposes of calculating the proposed Factor 1 and modeling the impact of the FY 2024 IPPS/LTCH PPS proposed rule, we used OACT’s January 2023 Medicare DSH estimates, which were based on data from the September 2022 update to the Medicare Hospital Cost Report Information System (HCRIS) and the FY 2023 IPPS/LTCH PPS final rule IPPS Impact File, published in conjunction with the FY 2023 IPPS/LTCH PPS final rule. Because SCHs that are projected to be paid under their hospital-specific rate are ineligible for empirically justified Medicare DSH payments and uncompensated care payments, they were excluded from the January 2023 Medicare DSH estimates. Furthermore, because Maryland hospitals are not paid under the IPPS, they are also ineligible for empirically justified Medicare DSH payments and uncompensated care payments and were also excluded from the OACT’s January 2023 Medicare DSH estimates. Finally, the 26 hospitals that CMS anticipates may participate in the Rural Community Hospital Demonstration Program in FY 2024 were excluded from these estimates because these hospitals are not eligible to receive empirically justified Medicare DSH payments or uncompensated care payments under the payment methodology that applies under the demonstration.

Using the data sources as previously discussed, OACT’s January 2023 estimate of Medicare DSH payments for FY 2024 without regard to the application of section 1886(r)(1) of the Act was approximately $13.621 billion, as explained in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26990). Therefore, based on that January 2023 estimate, the estimate of empirically justified Medicare DSH payments for FY 2024, with the application of section 1886(r)(1) of the Act, was approximately $3.405 billion (or 25 percent of the total amount of estimated Medicare DSH payments for FY 2024). Under §412.106(g)(1)(i), Factor 1 is the difference between these two OACT estimates. Thus, in the FY 2024 IPPS/LTCH PPS proposed rule, we proposed that Factor 1 for FY 2024 would be $13.621 billion minus $3.405 billion. In the FY 2024 IPPS/LTCH PPS proposed rule, we noted that, consistent with our approach in previous rulemakings, OACT would use more recent data to project the final Factor 1 estimates for the FY 2024 IPPS/LTCH PPS final rule if such data became available prior to the development of the final rule.

In the FY 2024 IPPS/LTCH PPS proposed rule, we noted that the Factor 1 estimates for proposed rules are generally consistent with the economic assumptions and actuarial analysis used to develop the President’s Budget estimates under current law, and that Factor 1 estimates for the final rules are generally consistent with those used for the Midsession Review of the President’s Budget (88 FR 26990). For additional information on the development of the President’s Budget, we refer readers to the Office of Management and Budget website at https://www.whitehouse.gov/omb/budget. Consistent with historical practice, we indicated in the proposed rule that we expected that the Midsession Review would have updated economic assumptions and actuarial analysis, which we would use to develop Factor 1 estimates in the FY 2024 final rule.

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26990), we referred readers to the “2022 Annual Report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds,” available on the CMS website at https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/reports/trustfunds under “Downloads” for a general overview of the principal steps involved in projecting future inpatient costs and utilization. We also noted that the annual reports of the Medicare Boards of Trustees to Congress represent the Federal Government’s official evaluation of the financial status of the Medicare Program. The actuarial projections contained in these reports are based on numerous assumptions regarding future trends in program enrollment, utilization and costs of health care services covered by Medicare, as well as other factors affecting program expenditures. In addition, although the methods used to estimate future costs based on these assumptions are complex, they are subject to periodic review by independent experts to ensure their validity and reasonableness. We also referred readers to the 2018 Actuarial Report on the Financial Outlook for Medicaid for a discussion of general issues regarding Medicaid projections (available at https://www.cms.gov/Research-Statistics-data-and-Systems/Research/ActuarialStudies/MedicaidReport).
Comment: Some commenters requested greater transparency in the methodology used by CMS and OACT to calculate Factor 1. Several commenters specifically requested that a detailed description of the methodology and the data behind the assumptions be made public. Specifically, commenters requested more detail from CMS on the “Other” component. A few commenters emphasized their inability to replicate CMS’ calculations and requested that the agency clarify how the effects of the COVID–19 Public Health Emergency (PHE) were accounted for in the “Other” factor. Some commenters suggested that CMS address this issue by disaggregating the variables that contribute to the “Other” factor and then demonstrating the impact of each of those variables on the final value, while a few other commenters requested that CMS publish a detailed methodology of its “Other” calculation, including how all the components contribute to its estimates from year to year. A couple of commenters requested that CMS clarify why the “Other” factor frequently varies in successive rulemaking cycles. Commenters requested that this information be provided in advance of the publication of the final rule and in the IPPS proposed rule each year going forward, so that the data is available to replicate CMS’ DSH calculation and comment sufficiently in future years.

Additionally, a few commenters asserted that the lack of opportunity afforded to hospitals to review the data used in the methodology is in violation of the Administrative Procedure Act. These commenters expressed concerns about the lack of transparency in how Factor 1 is calculated, arguing that hospitals cannot meaningfully comment on the methodology given the lack of details. In particular, these commenters asserted that the proposed rule provided neither sufficient details nor an explanation of the treatment of Medicaid expansions in the calculation for Factor 1.

Response: We thank the commenters for their input. We disagree with commenters’ assertion regarding the lack of transparency with respect to the methodology and assumptions used in the calculation of Factor 1. As explained in the FY 2024 IPPS/LTCH PPS proposed rule and in this section of this final rule, we have been and continue to be transparent about the methodology and data used to estimate Factor 1. Regarding the commenters who reference the Administrative Procedure Act, we note that under the Administrative Procedure Act, a proposed rule is required to include either the terms or substance of the proposed rule or a description of the subjects and issues involved. In this case, the FY 2024 IPPS/LTCH PPS proposed rule included a detailed discussion of our proposed Factor 1 methodology and the data sources that would be used in making our final estimate. See 88 FR 26989 through 26992. Accordingly, commenters had sufficient information to meaningfully comment on our proposed estimate of Factor 1.

To provide additional context, we note that Factor 1 is not estimated in isolation from other projections made by OACT. As we explained in the FY 2024 IPPS/LTCH PPS proposed rule and in other previous rulemakings, Factor 1 estimates used in our proposed rules are generally consistent with the economic assumptions and actuarial analyses used to develop the President’s Budget estimates under current law, which are publicly available, and the Factor 1 estimates used in our final rules are generally consistent with the economic assumptions and actuarial analyses used for the Midsession Review of the President’s Budget. As we have in the past, we refer readers to the Midsession Review of the President’s FY 2024 Budget” for additional information on the development of the President’s Budget and the specific economic assumptions used in the Midsession Review of the President’s FY 2024 Budget, forthcoming on the Office of Management and Budget website at https://www.whitehouse.gov/omb/budget. We recognize that our reliance on economic assumptions and actuarial analyses used to develop the President’s Budget and the Midsession Review of the President’s Budget in estimating Factor 1 has an impact on hospitals, health systems, and other impacted parties who wish to replicate the Factor 1 calculation, such as modeling the relevant Medicare Part A portion of the budget. Yet, commenters are able to meaningfully comment on our proposed estimate of Factor 1 without replicating the budget. For a general overview of the principal steps involved in projecting future inpatient costs and utilization, we refer readers to the “2023 Annual Report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds,” available under “Downloads” on the CMS website at: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/ReportsTrustFunds/index.html. We note that the annual reports of the Medicare Boards of Trustees to Congress represent the Federal Government’s official evaluation of the financial status of the Medicare Program. The actuarial projections contained in these reports are based on numerous assumptions regarding future trends in program enrollment, utilization and costs of health care services covered by Medicare, as well as other factors affecting program expenditures. In addition, although the methods used to estimate future costs based on these assumptions are complex, they are subject to periodic review by independent experts to ensure their validity and reasonableness.

As described in more detail later in this section, in the FY 2024 IPPS/LTCH PPS proposed rule, we included information regarding the data sources, methods, and assumptions employed by the actuaries to determine OACT’s estimate of Factor 1 (88 FR 26989 through FR 26992). We explained that the most recent Medicare DSH payment adjustments provided in the IPPS Impact File were used, and we provided the components of all update factors that were applied to the historical data to estimate the Medicare DSH payments for the upcoming fiscal year, along with the associated rationale and assumptions. This discussion also included a description of the “Other” and “Discharges” assumptions, as well as additional information regarding how we address the Medicaid and CHIP expansion.

For additional context, the “Other” factor column reflects the expectation that DSH payments will grow faster than IPPS payments in 2023. This expectation is based on the 2023 IPPS Impact File, which reflects the change in the mix of cases between 2019 and 2021. The “Other” factor varies in rulemaking cycles due to changing growth patterns for DSH payments and Medicaid enrollment. The impact of...
Medicaid enrollment is captured in the “Other” column. For further information on our assumptions regarding Medicaid expansion in the Factor 1 calculation, later in this section, we provide a discussion of more recent estimates and assumptions regarding Medicaid expansion as part of the discussion of the final Factor 1 for FY 2024. This discussion also incorporates the estimated impact of the COVID–19 PHE.

Comment: Many commenters questioned the proposed rule’s estimate of the “Discharges” component of the Factor 1 calculation. Some commenters requested that CMS align the discharge volume estimates in Factor 1 with the forecasted estimates for Federal fiscal year 2022 through Federal fiscal year 2024 cited in the March 2023 Medicare Trustee Report. Other commenters recommended that CMS use more recent data to reflect the changes in discharge volumes. Some commenters noted that the current assumptions of discharge volume estimate the growth in utilization in the Medicare fee-for-service (FFS) population. Four hospital associations questioned CMS’ discharge factor for FY 2024 based on “the assumption of recent trends recovering back to the long-term trend and the assumption related to how many beneficiaries will be enrolled in Medicare Advantage (MA) plans.” These commenters noted that they expect that the discharge factor will continue to decrease, as half of Medicare beneficiaries are now enrolled in MA plans. These commenters further expressed concern about the effect of this decreasing trend on hospitals serving a disproportionate share of lower-income beneficiaries. The same commenters requested that CMS provide detailed calculations of the discharge estimates in the proposed rule each year going forward and welcomed the opportunity to work with CMS to examine the impacts of MA enrollment on FFS inpatient hospital payments. One commenter recommended that CMS exclude FY 2021 and FY 2022 discharges from the FY 2024 Factor 1 calculation, as data from those years include atypical trends in Medicare discharges resulting from the COVID–19 PHE.

Some commenters also raised concerns about the “Case Mix” update factor used in the proposed FY 2024 Factor 1 calculation. Commenters stated that the proposed “Case Mix” update factor underestimates the complexity of patients seeking care following the postponement or deferral of care during the COVID–19 PHE. Some commenters requested that CMS consider the impact of Medicaid disenrollment, which may inhibit care access and lead to worse outcomes, resulting in more complex cases and higher hospitalization rates. One commenter requested that CMS include an acuity factor to reflect the fact that COVID–19 patients have longer lengths of stay and higher acuity than the typical patient population. Some commenters requested that CMS increase the FY 2022 market basket in the Factor 1 update factor by three percentage points to align with the “trued up” market basket cited in the March 2023 MedPAC report to Congress.200 Some of these commenters further recommended that CMS apply the recommendation from MedPAC to increase the FY 2024 market basket in the Factor 1 update factor by an additional percentage point.

Response: We thank the commenters for their input on the impact the COVID–19 PHE may have had on the factors used to estimate DSH payments for FY 2024. In updating our estimate of Factor 1 for this final rule, we considered, as appropriate, the same set of factors that we used in the proposed rule using the most recent available data at the time of developing this final rule. The “Discharges” and “Case Mix” factors incorporate the latest estimates of the COVID–19 PHE’s impact on the Medicare program. The “Case Mix” factor is specific for Medicare inpatient claims. In 2020, the COVID–19 PHE had a significant impact on the “Case Mix” factor, however its impact has lessened in subsequent years. The impact of COVID–19 discharges is captured in the 2021 and 2022 experience, which is the basis for the projections. The number of COVID–19 cases has dropped significantly since 2020, therefore we believe a separate acuity factor would not be necessary. We provide further details on the updated Factor 1 estimate and data sources as part of the discussion of the final Factor 1 estimate for FY 2024 in this section of the rule.

Regarding the comments requesting that we exclude FY 2021 and FY 2022 discharges due to the impacts of the COVID–19 PHE when estimating Factor 1 for FY 2024, we note that section 1886(r)(2)(A) of the Act specifies that Factor 1 is based on the amount of disproportionate share payments that would otherwise be made to subsection (d) hospitals for the fiscal year. As discussed further in this section, OACT’s estimates of Medicare DSH payments used in the development of Factor 1 reflect the estimated impact of the COVID–19 PHE on DSH payments. Excluding data from certain periods is not necessary to estimate DSH payments during FY 2024 for purposes of the Factor 1 calculation. To reasonably make projections for FY 2024, the FY 2021 and FY 2022 claims data experience is necessary to inform trends. The FY 2021 and FY 2022 claims are not atypical, in contrast to FY 2020 claims. Furthermore, the FY 2021 claims data are used for the FY 2023 Impact File, which make it consistent and reliable to use in making projections of the amount of DSH payments in FY 2024.

Regarding the comments on the impacts of MA enrollment on the Medicare FFS discharge volume, we believe the “Discharge” factor is a reasonable projection for purposes of Factor 1 estimates using the latest available data. For a discussion on trends in MA enrollment, we refer readers to the 2023 Annual Report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds, which contains actuarial projections and assumptions regarding future trends in program enrollment, utilization and costs of health care services covered by Medicare, as well as other factors affecting program expenditures. We also note that the estimates for the “Discharges” factor used to estimate Medicare DSH expenditures incorporate OACT’s analyses of “Discharges” using only claims from the Medicare FFS program rather than claims from the MA program.

In response to commenters who requested that CMS align the discharge volume estimates in Factor 1 with the estimates in the March 2023 Medicare Trustee Report and that CMS consider using more recent data to reflect the changes in discharge volume, we have determined that the use of the most recent available data to calculate Factor 1 at proposed and final rulemaking is appropriate and consistent with our approach in previous rulemakings and will produce results that are generally consistent with the Medicare Trustee Report. In this final rule, OACT has updated the estimate of Factor 1 with more recent economic assumptions and actuarial analyses.

Regarding comments about the inpatient hospital update and the FY 2024 update factor in the Factor 1 estimate, we refer readers to the discussion in the section V.B. of the preamble of this final rule. Consistent with the inpatient hospital update discussion in section V.B. of the rule, OACT is using the most recent available

Factors Applied for FY 2021 through FY 2024 to Estimate Medicare DSH Expenditures Using FY 2020 Baseline

<table>
<thead>
<tr>
<th>FY</th>
<th>Update</th>
<th>Discharges</th>
<th>Case-Mix</th>
<th>Other</th>
<th>Total</th>
<th>Estimated DSH Payment (in billions)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>1.029</td>
<td>0.940</td>
<td>1.029</td>
<td>0.9963</td>
<td>0.9919</td>
<td>13.150</td>
</tr>
<tr>
<td>2022</td>
<td>1.025</td>
<td>0.941</td>
<td>0.997</td>
<td>0.9939</td>
<td>0.9558</td>
<td>12.568</td>
</tr>
<tr>
<td>2023</td>
<td>1.043</td>
<td>0.959</td>
<td>1.005</td>
<td>1.0347</td>
<td>1.0398</td>
<td>13.068</td>
</tr>
<tr>
<td>2024</td>
<td>1.031</td>
<td>0.982</td>
<td>1.005</td>
<td>1.0043</td>
<td>1.0219</td>
<td>13.354</td>
</tr>
</tbody>
</table>

*Rounded.

In this table, the discharges column shows the changes in the number of Medicare FFS inpatient hospital discharges. The discharge figures for FY 2021 and FY 2022 are based on Medicare claims data that have been adjusted by a completion factor to account for incomplete claims data. We note that these claims data reflect the impact of the COVID–19 pandemic. The discharge figure for FY 2023 is based on preliminary data. The discharge figure for FY 2024 is an assumption based on recent historical experience and an assumed partial return to pre-COVID-19 trends. In addition, this column reflects a decrease in FFS enrollment, as a growing share of beneficiaries have moved into MA Plans. The discharge figures for FY 2021 to FY 2024 incorporate the actual impact and estimated future impact from the COVID–19 pandemic. The case-mix column shows the estimated change in case-mix for IPPS hospitals. The case-mix figures for FY 2021 and FY 2022 are based on actual claims data adjusted by a completion factor. We note that these claims data reflect the impact of the COVID–19 pandemic. The case-mix figure for FY 2023 is based on preliminary data, and the case-mix figure for FY 2024 is an assumption based on the recommendation of the 2010–2011 Medicare Technical Review Panel. Accordingly, the case-mix factor figures for FY 2021 to FY 2024 incorporate the actual impact and estimated future impact from the COVID–19 pandemic.

The “Other” column reflects the change in other factors that contribute to the Medicare DSH estimates. These factors include the difference between the total inpatient hospital discharges and the IPPS discharges and various adjustments to the payment rates that have been included over the years but are not reflected in the other columns (such as the 20 percent add-on for COVID–19 discharges). In addition, the “Other” column includes a factor for the estimated changes in Medicaid enrollment. We note that this factor also includes the estimated impacts on Medicaid enrollment from the COVID–19 pandemic and the end of the PHE declaration. On May 11, 2023, the Biden Administration ended the national emergency declaration and PHE declaration.

Based on the most recent available data, Medicaid enrollment is estimated to change as follows: 12.3 percent in FY 2021, 8.2 percent in FY 2022, 4.2 percent in FY 2023, and —11.6 percent in FY 2024. In the future, the assumptions regarding Medicaid enrollment may change based on actual enrollment in the States.

We note that, in developing their estimates of the effect of Medicaid expansion on Medicare DSH expenditures, our actuaries have assumed that the new Medicaid enrollees are healthier than the average Medicaid recipient and, therefore, receive fewer hospital services. Specifically, based on the most recent available data at the time of developing the proposed rule, OACT assumed per capita spending for Medicaid beneficiaries who enrolled due to the expansion to be approximately 80 percent of the average per capita expenditures for a pre-expansion Medicaid beneficiary, due to the better health of these beneficiaries. The same assumption was used for the new Medicaid beneficiaries who enrolled in 2020 and thereafter due to the COVID–19 pandemic. This assumption is consistent with recent internal estimates of Medicaid per capita spending pre-
expansion and post-expansion. In the future, the assumption about the average per-capita expenditures of Medicaid beneficiaries who enrolled due to the COVID–19 pandemic may change.

The following table shows the factors that are included in the “Update” column of the previous table:

<table>
<thead>
<tr>
<th>FY</th>
<th>Market Basket Percentage</th>
<th>Productivity Adjustment</th>
<th>Documentation and Coding</th>
<th>Total Update Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>2.4</td>
<td>0.0</td>
<td>0.5</td>
<td>2.9</td>
</tr>
<tr>
<td>2022</td>
<td>2.7</td>
<td>-0.7</td>
<td>0.5</td>
<td>2.5</td>
</tr>
<tr>
<td>2023</td>
<td>4.1</td>
<td>-0.3</td>
<td>0.5</td>
<td>4.3</td>
</tr>
<tr>
<td>2024</td>
<td>3.3</td>
<td>-0.2</td>
<td>0.0</td>
<td>3.1</td>
</tr>
</tbody>
</table>

Note: All numbers are the final inpatient hospital updates for the applicable year. We refer readers to section V.B. of the preamble of this final rule for a complete discussion of the changes in the inpatient hospital update for FY 2024.

2. Calculation of Factor 2 for FY 2024

a. Background

Section 1886(r)(2)(B) of the Act establishes Factor 2 in the calculation of the uncompensated care payment. Section 1886(r)(2)(B)(ii) of the Act provides that, for FY 2018 and subsequent fiscal years, the second factor is 1 minus the percent change in the percent of individuals who are uninsured, as determined by comparing the percent of individuals who were uninsured in 2013 (as estimated by the Secretary, based on data from the Census Bureau or other sources the Secretary determines appropriate and certified by the Chief Actuary of CMS) and the percent of individuals who were uninsured in the most recent period for which data are available (as so estimated and certified). We note that, unlike section 1886(r)(2)(B)(i) of the Act, which governed the calculation of Factor 2 for FYs 2014, 2015, 2016, and 2017, section 1886(r)(2)(B)(ii) of the Act permits the use of a data source other than the Congressional Budget Office (CBO) estimates to determine the percent change in the rate of uninsurance beginning in FY 2018, provided the Secretary determines that the data source is appropriate and the Chief Actuary of CMS certifies it. In addition, for FY 2018 and subsequent years, the statute does not require that the estimate of the percent of individuals who are uninsured be limited to individuals who are under 65 years of age. In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26992), we proposed to continue to use a methodology similar to the one that was used in FY 2018 through FY 2023 to determine Factor 2 for FY 2024.

In the FY 2018 IPPS/LTCH PPS final rule (82 FR 38197 and 38198), we explained that we determined the data source for the rate of uninsurance that, on balance, best meets all of our considerations and is consistent with the statutory requirement that the estimate of the rate of uninsurance be based on data from the Census Bureau or other sources the Secretary determines appropriate, is the uninsured estimates produced by OACT as part of the development of the National Health Expenditure Accounts (NHEA). The NHEA are the Federal Government’s official estimates of economic activity (spending) within the health sector. The information contained in the NHEA are used to study numerous topics related to the health care sector, including the following topics: changes in the amount and cost of health services purchased and the payers or programs that provide or purchase these services; the economic causal factors at work in the health sector; the impact of policy changes, including major health reform, on health care spending; and comparison of U.S. health care spending to other countries’ health care spending.

Of relevance to the determination of Factor 2 is that the comprehensive and integrated structure of the NHEA creates an ideal tool for evaluating changes to the health care system, such as the mix of the insured and uninsured, because this information is integral to the well-established NHEA methodology. A full description of the methodology used to develop the NHEA is available on the CMS website at https://www.cms.gov/files/document/definitions-sources-and-methods.pdf. We note that the NHEA estimates of uninsurance are for the total resident-based U.S. population, including all people who usually reside in the 50 States or the District of Columbia, but excluding individuals living in Puerto Rico and areas under U.S. sovereignty, members of the U.S. Armed Forces overseas, and U.S. citizens whose usual place of residence is outside the U.S., plus a small (typically less than 0.2 percent of population) adjustment to reflect Census undercounts. Thus, the NHEA estimates of uninsurance account for U.S. residents of all ages and are not limited to a specific age cohort, such as the population under the age of 65. As we explained in the FY 2018 IPPS/LTCH PPS proposed and final rules, we believe it is appropriate to use an estimate that reflects the rate of uninsurance in the U.S. across all age groups. In addition, our view continues to be that a resident-based population estimate more fully reflects the levels of uninsurance in the U.S. than influence uncompensated care for hospitals than an estimate that reflects only legal residents.

The NHEA includes comprehensive enrollment estimates for total private health insurance (PHI) (including direct and employer-sponsored plans), Medicare, Medicaid, the Children’s Health Insurance Program (CHIP), and other public programs, and estimates of the number of individuals who are uninsured. Estimates of total PHI enrollment are available for 1960 through 2021, estimates of Medicaid, Medicare, and CHIP enrollment are available for the length of the respective programs, and all other estimates (including the more detailed estimates of direct-purchased and employer-sponsored insurance) are available for 1987 through 2021. The NHEA data are publicly available on the CMS website at https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/index.html.

To compute Factor 2, the first metric that is needed is the proportion of the total U.S. population that was uninsured in 2013. In developing the estimates for the NHEA, OACT’s methodology included using the number of uninsured individuals for 1987 through 2009 based on the enhanced Current Population Survey.
(CPS) from the State Health Access Data Assistance Center (SHADAC). The CPS, sponsored jointly by the U.S. Census Bureau and the U.S. Bureau of Labor Statistics (BLS), is the primary source of labor force statistics for the U.S. population. (We refer readers to the website at https://www.census.gov/programs-surveys/cps/html.) The enhanced CPS, available from SHADAC (available at https://datacenter.shadac.org) accounts for changes in the CPS methodology over time. OACT further adjusts the enhanced CPS for an estimate of the undercount of Medicaid enrollees (a population that is often not fully captured in surveys that include Medicaid enrollees due to a perceived stigma associated with being enrolled in the Medicaid program or confusion about the source of their health insurance).

To estimate the number of uninsured individuals for 2010 through 2018, OACT extrapolates from the 2009 CPS data through 2018 using data from the National Health Interview Survey (NHIS), which is one of the major data collection programs of the National Center for Health Statistics (NCHS), which is part of the Centers for Disease Control and Prevention (CDC). The estimate of the number of uninsured individuals in 2019 was extrapolated using the 2019/2018 trend from the American Community Survey (ACS). Because the 2020 ACS data were not available, the ACS data were not used for purposes of estimating the number of uninsured individuals for 2020. Rather, the 2020 estimate was extrapolated using the 2020/2018 trend from the CPS as published by the Census Bureau. The 2021 estimate was based on the population share of the uninsured from the NHIS. The U.S. Census Bureau is the data collection agent for the NHIS, the ACS, and the CPS. The results from these data sources have been instrumental over the years in providing data to track health status, health care access, and progress toward achieving national health objectives. For further information regarding the NHIS, we refer readers to the CDC website at https://www.cdc.gov/nchs/nhis/index.htm. For further information regarding the ACS, we refer readers to the Census Bureau’s website at https://www.census.gov/programs-surveys/acs/.

The next metrics needed to compute Factor 2 for FY 2024 are projections of the rates of uninsurance in CY 2023 and CY 2024. On an annual basis, OACT projects enrollment and spending trends for the coming 10-year period. The projections for the rates of uninsurance in the FY 2024 IPPS/LTCH PPS proposed rule were derived using the most recent NHEA projections that were available at the time the proposed rule was developed (published March 28, 2022, with historical data through 2021). The NHEA projection methodology accounts for expected changes in enrollment across all the categories of insurance coverage previously listed. The projected growth rates in enrollment for Medicare, Medicaid, and CHIP are developed to be consistent with the 2022 Medicare Trustees Report,203 updated where possible with more recent data. Projected rates of growth in enrollment for private health insurance and the uninsured are based largely on OACT’s econometric models, which rely on a set of macroeconomic assumptions that are generally based on the 2022 Medicare Trustees Report. Greater detail on these projected rates of growth in enrollment for private health insurance and the uninsured can be found in OACT’s report titled “Projections of National Health Expenditure and Health Insurance Enrollment: Methodology and Model Specification,” which is available on the CMS website at https://www.cms.gov/Research-Statistics-Data- and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/ProjectionsMethodology.pdf.

b. Factor 2 for FY 2024

Using these data sources and the previously described methodologies in section IV.E.2.a., at the time of developing the proposed rule, OACT had estimated that the uninsured rate for the historical, baseline year of 2013 was 14 percent, while the estimated rates of uninsurance for CYs 2023 and 2024 were 9.3 percent and 9.2 percent, respectively. As required by section 1886(r)(2)[B][ii] of the Act, the Chief Actuary of CMS certified these estimates. We refer readers to OACT’s Memorandum on Certification of Rates of Uninsured prepared for the FY 2024 IPPS/LTCH PPS proposed rule for further details on the methodology and assumptions that were used in the projection of these rates of uninsurance for the proposed rule.204

As with the CBO estimates on which we based Factor 2 for fiscal years before FY 2018, the NHEA estimates are for a calendar year. Under the approach originally adopted in the FY 2014 IPPS/LTCH PPS final rule, we have used a weighted average approach to project the rate of uninsurance for each fiscal year. We continue to believe that, to estimate the rate of uninsurance during a fiscal year accurately, Factor 2 should reflect the estimated rate of uninsurance that hospitals will experience during the fiscal year, rather than the rate of uninsurance during only one of the calendar years that the fiscal year spans. Accordingly, in the FY 2024 IPPS/LTCH PPS proposed rule, we proposed to continue to apply the weighted average approach used in past fiscal years to estimate the rate of uninsurance for FY 2024.

OACT certified the estimate of the rate of uninsurance for FY 2024 determined using this weighted average approach to be reasonable and appropriate for purposes of section 1886(r)(2)[B][ii] of the Act. In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26993), we noted that we might also consider the use of more recent data that may become available for purposes of estimating the rates of uninsurance used in the calculation of the final Factor 2 for FY 2024. We noted the following examples of more up-to-date data that may become available for use in calculating Factor 2 for FY 2024: (1) data regarding the impacts of the expiration of the Families First Coronavirus Response Act’s continuous enrollment provision for Medicaid, which permits states to actively begin disenrolling beneficiaries no longer eligible for the program starting on April 1, 2023; (2) data on the impact of the Inflation Reduction Act’s extension of enhanced Marketplace premium tax credits through 2025; and (3) data on the impacts associated with the Internal Revenue Service’s amended regulations that expanded eligibility for Marketplace subsidies by revising the affordability test of employer coverage for family members of employees (87 FR 61979 and 62003).

In the proposed rule, we outlined the calculation of the proposed Factor 2 for FY 2024 as follows:

Percent of individuals without insurance for CY 2013: 14 percent.

Percent of individuals without insurance for CY 2023: 9.3 percent.

Percent of individuals without insurance for CY 2024: 9.2 percent.

203 For information regarding the data collection issues regarding the 2020 ACS, we refer readers to the Census Bureau’s website at https://www.census.gov/newsroom/blogs/random-samplings/2021/10/pandemic-impact-on-2020-acs-1-year-data.html.

We invited public comments on our proposed Factor 2 for FY 2024.

**Comment:** Most commenters discussed Factor 2 in the context of the impact of the temporary COVID–19 PHE provisions on the uninsured rate, such as expiration of the Families First Coronavirus Response Act’s Medicaid continuous coverage requirement and extension of the American Rescue Plan’s Marketplace enhanced premium tax credits. Large and small healthcare organizations and associations opposed the proposed Factor 2 and the estimated FY 2024 uninsured rate and urged OACT to update its estimate of Factor 2 to account for the projected increases in the number of uninsured individuals as the COVID–19 PHE Medicaid continuous enrollment provisions expire.

Many commenters also indicated that they expect increases in the uninsured rates in their communities. To that end, these commenters urged CMS to use more recent and accurate data sources to account for the anticipated increases in the uninsured population, citing CMS’ statement in the proposed rule that the agency may consider more recent data that may become available for the calculation of Factor 2 for the FY 2024 final rule. Some of these commenters urged CMS to monitor the forthcoming data to ensure that Factor 2 reflects the current coverage landscape considering the expiring COVID–19 PHE provisions.

A few commenters expressed their concern that the NHEA data that CMS proposed to use for Factor 2 do not reflect current trends in the uninsured rate as the COVID–19 PHE ends, as they appear to be the same data utilized in the FY 2023 IPPS/LTCH PPS final rule. These commenters requested that CMS consider applying a one-time increase in Factor 2 to account for the data lag and the anticipated increase in the uninsured population in FY 2024 following the expiration of the Medicaid continuous enrollment provisions, if the agency chooses to continue with its proposal of utilizing the same NHEA data used in the FY 2023 rule. In addition, one commenter stated as an example that an additional 0.7 percentage point increase in the uninsured rate for FY 2024 (9.9 percent uninsured, reflecting a projection of approximately 2.4 million additional uninsured individuals) would increase the proposed uncompensated care payment amount by about $511 million compared to the proposed rule’s uncompensated care amount.

Several commenters referenced various data sources and analyses that project between 3–18 million individuals will lose their Medicaid coverage in FY 2024, such as analyses by the Kaiser Family Foundation; the Congressional Budget Office; the Urban Institute; NORC at the University of Chicago; and HHS’ Assistant Secretary for Planning and Evaluation (ASPE). Accordingly, these commenters requested that CMS increase Factor 2 to reflect the anticipated increase in the uninsured population.

A few commenters requested CMS maintain the same level of total uncompensated care payments as in the FY 2023 IPPS/LTCH PPS final rule. Several other commenters opposed the proposed decrease in the total uncompensated care payments from the level in FY 2023. These commenters noted that the proposed decrease would disproportionately impact safety-net hospitals and negatively impact vulnerable patients and hospitals that are already financially strained.

**Response:** We thank the commenters for their input regarding the estimate of proposed Factor 2 discussed in the proposed rule. In the FY 2024 IPPS/ LTCH PPS proposed rule we used the most recent available estimates from the NHEA at that time, and we refer readers to OACT’s Memorandum on Certification of Rates of Uninsured prepared for the proposed rule for further details on the methodology and assumptions used in the calculation of the proposed rule’s projection of the uninsured rate.

We indicated that our projection of the rates of uninsurance for CY 2023 and CY 2024 were from the latest NHEA historical data available and accounted for expected changes in enrollment across all categories of insurance coverage. As detailed in the proposed rule, we believe that the most recently updated NHEA data, on balance, best meet all our considerations for ensuring that the data source used to estimate the rate of uninsurance meets the statutory requirement that the estimate be based on data from the Census Bureau, or other sources the Secretary determines appropriate, and will provide reasonable estimates for the rate of uninsurance that are available in conjunction with the IPPS rulemaking cycle.

For the final rule, we are using the NHEA data for the Factor 2 calculation because we continue to believe that it is the most appropriate measure of changes in the rate of uninsurance.

In response to the comments concerning the data sources used for calculating Factor 2, in this final rule we are updating Factor 2 using the most recently updated NHEA projections that were released in June 2023, which reflect the most recent historical data and updated expectations for the uninsurance rate. We also refer readers to the OACT memo that accompanies this final rule, which provides additional information regarding the development of the uninsurance rate projection.

Regarding the comments requesting that CMS maintain total uncompensated care payments at the FY 2023 level or delay any proposed changes to mitigate the impact on safety-net hospitals and vulnerable patients, we believe estimating Factor 2 based on the best available data is appropriate and consistent with the requirements of section 1886(r)(2)(B)(ii) of the Act.

**Comment:** Several commenters urged CMS to be transparent regarding the development of Factor 2 and how it accounts for the expiring COVID–19 PHE Medicaid continuous enrollment provisions.

**Response:** In response to the comments concerning transparency, we note that the accompanying OACT memo contains additional background describing the methods used to derive the FY 2024 rate of uninsured for this final rule. For purposes of this final

We indicated that our projection of the rates of uninsurance for CY 2023 and CY 2024 were from the latest NHEA historical data available and accounted for expected changes in enrollment across all categories of insurance coverage. As detailed in the proposed rule, we believe that the most recently updated NHEA data, on balance, best meet all our considerations for ensuring that the data source used to estimate the rate of uninsurance meets the statutory requirement that the estimate be based on data from the Census Bureau, or other sources the Secretary determines appropriate, and will provide reasonable estimates for the rate of uninsurance that are available in conjunction with the IPPS rulemaking cycle.

For the final rule, we are using the NHEA data for the Factor 2 calculation because we continue to believe that it is the most appropriate measure of changes in the rate of uninsurance.

In response to the comments concerning the data sources used for calculating Factor 2, in this final rule we are updating Factor 2 using the most recently updated NHEA projections that were released in June 2023, which reflect the most recent historical data and updated expectations for the uninsurance rate. We also refer readers to the OACT memo that accompanies this final rule, which provides additional information regarding the development of the uninsurance rate projection.

Regarding the comments requesting that CMS maintain total uncompensated care payments at the FY 2023 level or delay any proposed changes to mitigate the impact on safety-net hospitals and vulnerable patients, we believe estimating Factor 2 based on the best available data is appropriate and consistent with the requirements of section 1886(r)(2)(B)(ii) of the Act.

**Comment:** Several commenters urged CMS to be transparent regarding the development of Factor 2 and how it accounts for the expiring COVID–19 PHE Medicaid continuous enrollment provisions.

**Response:** In response to the comments concerning transparency, we note that the accompanying OACT memo contains additional background describing the methods used to derive the FY 2024 rate of uninsured for this final rule. For purposes of this final

We indicated that our projection of the rates of uninsurance for CY 2023 and CY 2024 were from the latest NHEA historical data available and accounted for expected changes in enrollment across all categories of insurance coverage. As detailed in the proposed rule, we believe that the most recently updated NHEA data, on balance, best meet all our considerations for ensuring that the data source used to estimate the rate of uninsurance meets the statutory requirement that the estimate be based on data from the Census Bureau, or other sources the Secretary determines appropriate, and will provide reasonable estimates for the rate of uninsurance that are available in conjunction with the IPPS rulemaking cycle.

For the final rule, we are using the NHEA data for the Factor 2 calculation because we continue to believe that it is the most appropriate measure of changes in the rate of uninsurance.

In response to the comments concerning the data sources used for calculating Factor 2, in this final rule we are updating Factor 2 using the most recently updated NHEA projections that were released in June 2023, which reflect the most recent historical data and updated expectations for the uninsurance rate. We also refer readers to the OACT memo that accompanies this final rule, which provides additional information regarding the development of the uninsurance rate projection.

Regarding the comments requesting that CMS maintain total uncompensated care payments at the FY 2023 level or delay any proposed changes to mitigate the impact on safety-net hospitals and vulnerable patients, we believe estimating Factor 2 based on the best available data is appropriate and consistent with the requirements of section 1886(r)(2)(B)(ii) of the Act.

**Comment:** Several commenters urged CMS to be transparent regarding the development of Factor 2 and how it accounts for the expiring COVID–19 PHE Medicaid continuous enrollment provisions.

**Response:** In response to the comments concerning transparency, we note that the accompanying OACT memo contains additional background describing the methods used to derive the FY 2024 rate of uninsured for this final rule. For purposes of this final

We indicated that our projection of the rates of uninsurance for CY 2023 and CY 2024 were from the latest NHEA historical data available and accounted for expected changes in enrollment across all categories of insurance coverage. As detailed in the proposed rule, we believe that the most recently updated NHEA data, on balance, best meet all our considerations for ensuring that the data source used to estimate the rate of uninsurance meets the statutory requirement that the estimate be based on data from the Census Bureau, or other sources the Secretary determines appropriate, and will provide reasonable estimates for the rate of uninsurance that are available in conjunction with the IPPS rulemaking cycle.

For the final rule, we are using the NHEA data for the Factor 2 calculation because we continue to believe that it is the most appropriate measure of changes in the rate of uninsurance.

In response to the comments concerning the data sources used for calculating Factor 2, in this final rule we are updating Factor 2 using the most recently updated NHEA projections that were released in June 2023, which reflect the most recent historical data and updated expectations for the uninsurance rate. We also refer readers to the OACT memo that accompanies this final rule, which provides additional information regarding the development of the uninsurance rate projection.

Regarding the comments requesting that CMS maintain total uncompensated care payments at the FY 2023 level or delay any proposed changes to mitigate the impact on safety-net hospitals and vulnerable patients, we believe estimating Factor 2 based on the best available data is appropriate and consistent with the requirements of section 1886(r)(2)(B)(ii) of the Act.

**Comment:** Several commenters urged CMS to be transparent regarding the development of Factor 2 and how it accounts for the expiring COVID–19 PHE Medicaid continuous enrollment provisions.

**Response:** In response to the comments concerning transparency, we note that the accompanying OACT memo contains additional background describing the methods used to derive the FY 2024 rate of uninsured for this final rule. For purposes of this final

We indicated that our projection of the rates of uninsurance for CY 2023 and CY 2024 were from the latest NHEA historical data available and accounted for expected changes in enrollment across all categories of insurance coverage. As detailed in the proposed rule, we believe that the most recently updated NHEA data, on balance, best meet all our considerations for ensuring that the data source used to estimate the rate of uninsurance meets the statutory requirement that the estimate be based on data from the Census Bureau, or other sources the Secretary determines appropriate, and will provide reasonable estimates for the rate of uninsurance that are available in conjunction with the IPPS rulemaking cycle.

For the final rule, we are using the NHEA data for the Factor 2 calculation because we continue to believe that it is the most appropriate measure of changes in the rate of uninsurance.

In response to the comments concerning the data sources used for calculating Factor 2, in this final rule we are updating Factor 2 using the most recently updated NHEA projections that were released in June 2023, which reflect the most recent historical data and updated expectations for the uninsurance rate. We also refer readers to the OACT memo that accompanies this final rule, which provides additional information regarding the development of the uninsurance rate projection.

Regarding the comments requesting that CMS maintain total uncompensated care payments at the FY 2023 level or delay any proposed changes to mitigate the impact on safety-net hospitals and vulnerable patients, we believe estimating Factor 2 based on the best available data is appropriate and consistent with the requirements of section 1886(r)(2)(B)(ii) of the Act.
rule, we are using the most recent NHEA estimates for the rate of uninsurance, which account for the legislative impacts from the expiration of the Families First Coronavirus Response Act’s Medicaid continuous coverage requirement and extension of the American Rescue Plan’s Marketplace enhanced premium tax credits and effects of the COVID–19 PHE on insurance coverage. Although Medicaid enrollment is expected to decrease significantly, the insured share of the population is only expected to decline in CY 2024 to 91.5 percent (from 92.3 percent in CY 2023), as many individuals who were not disenrolled from Medicaid during the public health emergency already had comprehensive coverage from another source (such as through an employer) and thus remain insured even when disenrolled from Medicaid. We note that the most recent NHEA projections are that the uninsured population will change from 25.7 million in CY 2023 to 28.6 million in CY 2024 and increase to 29.8 million in CY 2025. For more information about the methodology and data used to estimate Factor 2, we refer readers to NHEA’s “Health Insurance Enrollment and Enrollment Growth Rates” table.206

Section 1886(r)(2)(B)(ii) of the Act permits us to use a data source other than CBO estimates to determine the percent change in the rate of uninsurance beginning in FY 2018. The NHEA data and methodology that were used to estimate Factor 2 for this final rule are transparent and best meet all of our considerations for ensuring reasonable estimates for the rate of uninsurance that are available in conjunction with the IPPS rulemaking cycle. We have concluded it is appropriate to update the projection of the FY 2024 rate of uninsurance using the most recent NHEA data.

After consideration of the public comments we received, we are updating the calculation of Factor 2 for FY 2024 using more recent data from NHEA. The final estimates of the percent of uninsured individuals have been certified by the Chief Actuary of CMS. The calculation of the final Factor 2 for FY 2024 using a weighted average of OACT’s updated projections for CY 2023 and CY 2024 is as follows:

- Percent of individuals without insurance for CY 2013: 14 percent.
- Percent of individuals without insurance for CY 2023: 7.7 percent.
- Percent of individuals without insurance for CY 2024: 8.5 percent.

- Percent of individuals without insurance for FY 2024 (0.25 times 0.077) + (0.75 times 0.085): 8.3 percent.
- 1 – [(0.14 – 0.083)/0.14] = 1 – 0.4071 = 0.5929 (59.29 percent).

Therefore, the final Factor 2 for FY 2024 is 59.29 percent. The final FY 2024 uncompensated care amount is $10,015,191,021.88 * 0.5929 = $5,938,006,756.87.

### Final FY 2024 Uncompensated Care Amount

| $5,938,006,756.87 |

---

more accurate and consistent data through this reporting mechanism. In the FY 2018 IPPS/LTCH PPS final rule (82 FR 38202), we stated that we could no longer conclude that alternative data to the Worksheet S–10 are available for FY 2014 that are a better proxy for the costs of subsection (d) hospitals for treating individuals who are uninsured. Hospitals were on notice as of FY 2014 that Worksheet S–10 could eventually become the data source for CMS to calculate uncompensated care payments. Furthermore, hospitals’ cost reports from FY 2014 had been publicly available for some time, and CMS had analyses of Worksheet S–10, conducted both internally and by stakeholders, demonstrating that Worksheet S–10 accuracy had improved over time. In the FY 2018 IPPS/LTCH PPS final rule, we finalized a methodology under which we calculated Factor 3 for all eligible hospitals, with the exception of Puerto Rico hospitals and Indian Health Service (IHS) and Tribal hospitals, using Worksheet S–10 data from FY 2014 cost reports in conjunction with low-income insured days proxy data based on Medicaid days and SSI days. The time period for the Medicaid days data was FY 2012 and FY 2013 cost reports, which reflected the most recent available information regarding these hospitals’ low-income insured days before any expansion of Medicaid. We refer readers to the FY 2018 IPPS/LTCH PPS final rule (82 FR 38208 through 38212) for a further discussion of the methodology used to determine Factor 3 for FY 2018.

In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41414), we stated that with the additional steps we had taken to ensure the accuracy and consistency of the data reported on Worksheet S–10 since the publication of the FY 2018 IPPS/LTCH PPS final rule, we continued to believe that we could no longer conclude that alternative data to the Worksheet S–10 were available for FY 2014 or FY 2015 that would be a better proxy for the costs of subsection (d) hospitals for treating individuals who are uninsured. In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41428), we advanced the time period of the data used in the calculation of Factor 3 forward by one year and used Worksheet S–10 data from FY 2014 and FY 2015 cost reports in combination with the low-income insured days proxy for FY 2013 to determine Factor 3 for FY 2019. We note that, as discussed in the FY 2020 IPPS/LTCH PPS final rule (84 FR 42368), we received overwhelming feedback from commenters emphasizing the importance of audits in ensuring the accuracy and consistency of data reported on the Worksheet S–10. We began auditing the Worksheet S–10 data for selected hospitals in the fall of 2018 so that the audited uncompensated care data from these hospitals would be available in time for use in the FY 2020 IPPS/LTCH PPS proposed rule.

In the FY 2020 IPPS/LTCH PPS final rule (84 FR 42368), we finalized our proposal to use a single year of audited Worksheet S–10 cost report data from FY 2015 in the methodology for determining Factor 3 for FY 2020. Some commenters expressed support for the alternative policy of using the more recent FY 2017 Worksheet S–10 data to determine each hospital’s share of uncompensated care in FY 2020. However, given the feedback from commenters in response to both the FY 2019 and FY 2020 IPPS/LTCH PPS proposed rules emphasizing the importance of audits in ensuring the accuracy and consistency of data reported on the Worksheet S–10, we concluded that the FY 2015 Worksheet S–10 data were the best available audited data to be used in determining Factor 3 for FY 2020. In the FY 2020 IPPS/LTCH PPS final rule (84 FR 42369), we also noted that we had begun auditing the FY 2017 data in July 2019, with the goal of having the FY 2017 audited data available for future rulemaking.

In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58823 through 58825), we finalized our proposal to use the most recent available single year of audited Worksheet S–10 data to determine Factor 3 for FY 2021 and subsequent fiscal years. We explained our belief that using the most recent audited data available before the applicable Federal fiscal year (FY) would more accurately reflect a hospital’s uncompensated care costs, as opposed to averaging multiple years of unaudited and audited data. We explained that mixing audited and unaudited data for individual hospitals by averaging multiple years of data could potentially lead to a less smooth result. We also noted that if a hospital has relatively different data between cost report years, we potentially would be diluting the effect of our considerable auditing efforts and introducing unacceptable error in the calculation if we were to use multiple years of data to calculate Factor 3.

Therefore, we also believed using a single year of audited cost report data would be an appropriate methodology to determine Factor 3 for FY 2021 and subsequent years, except for IHS and Tribal hospitals and hospitals located in Puerto Rico. In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58825), we finalized the use of a low-income insured days proxy to determine Factor 3 for FY 2021 for IHS and Tribal hospitals and Puerto Rico hospitals.

In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58825 through 58828), we also finalized the definition of “uncompensated care” for FY 2021 and subsequent fiscal years, for purposes of determining uncompensated care costs and calculating Factor 3. Specifically, “uncompensated care” is defined as the amount on Line 30 of Worksheet S–10, which is the cost of charity care (Line 23) and the cost of non-Medicare bad debt and non-reimbursable Medicare bad debt (Line 29). This is the same definition that we initially adopted in the FY 2018 IPPS/LTCH PPS final rule. We refer readers to the FY 2021 IPPS/LTCH PPS final rule (85 FR 58825 through 58828) for a discussion of additional topics related to the definition of uncompensated care.

In the FY 2022 IPPS/LTCH PPS final rule (86 FR 45236 through 45243), consistent with the policy adopted in the FY 2021 IPPS/LTCH PPS final rule, we used a single year of Worksheet S–10 data from FY 2018 cost reports to calculate Factor 3 for FY 2022 for all eligible hospitals with the exception of IHS and Tribal hospitals and Puerto Rico hospitals that have a cost report for 2013. We continued to use the low-income insured days proxy to calculate Factor 3 for these IHS and Tribal hospitals and Puerto Rico hospitals for FY 2022.

b. Background on the Methodology Used To Calculate Factor 3 for FY 2023 and Subsequent Years

Section 1886(r)(2)(C) of the Act both governs the selection of the data to be used in calculating Factor 3 and allows the Secretary the discretion to determine the time periods from which we will derive the data to estimate the numerator and the denominator of the Factor 3 quotient. Specifically, section 1886(r)(2)(C)(i) of the Act defines the numerator of the quotient as the amount of uncompensated care for a subsection (d) hospital for a period selected by the Secretary. Section 1886(r)(2)(C)(ii) of the Act defines the denominator as the aggregate amount of uncompensated care for all subsection (d) hospitals that receive a payment under section 1886(r) of the Act for such period. In the FY...
Accordingly, for FY 2024 and subsequent fiscal years, we finalized a policy of using a 3-year average of the uncompensated care data from the most recent fiscal years for which audited data are available to determine Factor 3. Consistent with the approach that we followed when multiple years of data were previously used in the Factor 3 methodology, if a hospital does not have data for all 3 years used in the Factor 3 calculation, we will determine Factor 3 based on an average of the hospital’s available data. We also discontinued the use of the low-income days proxy to determine Factor 3 for IHS and Tribal hospitals and Puerto Rico hospitals and instead finalized use of the same multi-year average of Worksheet S–10 data to determine Factor 3 for FY 2023 and subsequent fiscal years, as is used to determine Factor 3 for all other DSH-eligible hospitals.

Because we finalized our proposal to use multiple years of cost reports to determine Factor 3 starting in FY 2023, we determined that it would also be necessary to make a further modification to the policy regarding cost reports that start in one fiscal year and span the entirety of the following fiscal year. Specifically, in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49041), we explained that in the rare cases when we use a cost report that starts in one fiscal year and spans the entirety of the subsequent Federal fiscal year to determine uncompensated care costs for the subsequent Federal fiscal year, we would not use the same cost report to determine uncompensated care costs for the earlier fiscal year. We explained that using the same cost report to determine uncompensated care costs for both fiscal years would not be consistent with our intent to smooth year-to-year variation in uncompensated care costs. As an alternative, we finalized our proposal to use the hospital’s most recent prior cost report, if that cost report spans the applicable period. In other words, in determining Factor 3 for FY 2023, we did not use the same cost report to determine the hospital’s uncompensated care costs for the earlier fiscal year. We explained that using the same cost report to determine uncompensated care costs for both fiscal years would not be consistent with our intent to smooth year-to-year variation in uncompensated care costs. As an alternative, we finalized our proposal to use the hospital’s most recent prior cost report, if that cost report spans the applicable period. In other words, in determining Factor 3 for FY 2023, we did not use the same cost report to determine the hospital’s uncompensated care costs for both FY 2018 and FY 2019. Rather, we used the cost report that spans the entirety of FY 2019 to determine uncompensated care costs for FY 2019 and we used the hospital’s most recent prior cost report to determine its uncompensated care costs for FY 2018, provided that cost report spans some portion of Federal fiscal year 2018.

(1) Scaling Factor
To address the effects of calculating Factor 3 using data from multiple fiscal years, in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49042) we finalized a policy under which we apply a scaling factor to the Factor 3 values calculated for all DSH eligible hospitals so that total uncompensated care payments to hospitals that are projected to be eligible for DSH for a fiscal year will be consistent with the estimated amount available to make uncompensated care payments for that fiscal year. Specifically, we adopted a policy under which we divide 1 (the expected sum of all DSH eligible hospitals’ Factor 3 values) by the actual sum of all DSH eligible hospitals’ Factor 3 values and then multiply the quotient by the uncompensated care payment determined for each DSH eligible hospital to obtain a scaled uncompensated care payment amount for each hospital. This process is designed to ensure that the sum of the scaled uncompensated care payments for all hospitals that are projected to be DSH eligible is consistent with the estimate of the total amount available to make uncompensated care payments for the applicable fiscal year. We noted that a similar scaling factor methodology was previously used in both FY 2018 (82 FR 38214 and 38215) and FY 2019 (83 FR 41414), when the Factor 3 calculation also included multiple years of data.

(2) New Hospital Policy for Purposes of Factor 3
In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49042), we modified the new hospital policy that was initially adopted in the FY 2020 IPPS/LTCH PPS final rule to determine Factor 3 for new hospitals. Consistent with our policy of using multiple years of cost reports to determine Factor 3, we defined new hospitals as hospitals that do not have cost report data for the most recent year of data being used in the Factor 3 calculation. Under this definition, the cut-off date for the new hospital policy is the beginning of the Federal fiscal year after the most recent year for which audits of the Worksheet S–10 data have been conducted. For FY 2023, the FY 2019 cost reports were the most recent year of cost reports for which audits of Worksheet S–10 data had been conducted. Thus, hospitals with CCNs (CMS Certification Numbers) established on or after October 1, 2019, were subject to the new hospital policy for FY 2023.

Under this modification to the new hospital policy, we continued the policy established in the FY 2020 IPPS/LTCH PPS final rule (84 FR 42370) that if a new hospital has a preliminary projection of being eligible for DSH payments based on its most recent
available disproportionate patient percentage, it may receive interim empirically justified DSH payments. However, new hospitals will not receive interim uncompensated care payments because we would have no uncompensated care data from which to determine what those interim payments should be. The MAC will make a final determination concerning whether the hospital is eligible to receive Medicare DSH payments at cost report settlement. In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49042), we also modified the methodology used to calculate Factor 3 for new hospitals. Specifically, while we continued to determine the numerator of the Factor 3 calculation using the new hospital’s uncompensated care costs reported on Worksheet S–10 of the hospital’s cost report for the current fiscal year, we adopted an approach under which we determine Factor 3 for new hospitals using a denominator based solely on uncompensated care costs from cost reports for the most recent fiscal year for which audits have been conducted. In addition, we applied a scaling factor to the Factor 3 calculation for a new hospital. We explained our belief that applying the scaling factor is appropriate for purposes of calculating Factor 3 for all hospitals, including new hospitals and hospitals that are treated as new hospitals, in order to improve consistency and predictability across all hospitals.

(3) Newly Merged Hospital Policy

In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49042 and 49043), we stated that we would continue to treat hospitals that merge after the development of the final rule for the applicable fiscal year similar to new hospitals. As explained in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50021), for these newly merged hospitals, we do not have data currently available to calculate a Factor 3 amount that accounts for the merged hospital’s uncompensated care burden. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50021 and 50022), we finalized a policy under which Factor 3 for hospitals that we do not identify as undergoing a merger until after the public comment period and additional review period following the publication of the final rule or that undergo a merger during the fiscal year will be recalculated similar to new hospitals.

Consistent with the policy adopted in the FY 2015 IPPS/LTCH PPS final rule, in the FY 2023 IPPS/LTCH PPS final rule, we stated that we would continue to treat newly merged hospitals in a similar manner to new hospitals, such that the newly merged hospital’s final uncompensated care payment will be determined at cost report settlement where the numerator of the newly merged hospital’s Factor 3 will be based on the cost report of only the surviving hospital (that is, the newly merged hospital’s cost report) for the current fiscal year. However, if the hospital’s cost reporting period includes less than 12 months of data, the data from the newly merged hospital’s cost report will be annualized for purposes of the Factor 3 calculation. Consistent with the modification to the methodology used to determine Factor 3 for new hospitals described previously, we finalized a policy for determining Factor 3 for newly merged hospitals using a denominator that is the sum of the uncompensated care costs for all DSH-eligible hospitals, as reported on Worksheet S–10 of their cost reports for the most recent fiscal year for which audits have been conducted. In addition, we apply a scaling factor, as discussed previously, to the Factor 3 calculation for a newly merged hospital. We stated our belief that applying the scaling factor is appropriate for purposes of calculating Factor 3 for all hospitals, including new hospitals and hospitals that are treated as new hospitals, in order to improve consistency and predictability across all hospitals. We also explained that consistent with past policy, interim uncompensated care payments for the newly merged hospital will be based only on the data for the surviving hospital’s CCN available at the time of the development of the final rule.

(4) CCR Trim Methodology

The calculation of a hospital’s total uncompensated care costs on Worksheet S–10 requires the use of the hospital’s cost to charge ratio (CCR). In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49043), we adopted a process for trimming CCRs under which we apply the following steps to determine the applicable CCR separately for each fiscal year that is included as part of the multi-year average used to determine Factor 3:

Step 1: Remove Maryland hospitals. In addition, we will remove all-inclusive rate providers because their CCRs are not comparable to the CCRs calculated for other IPPS hospitals.

Step 2: Calculate a CCR “ceiling” for the applicable fiscal year with the following data: for each IPPS hospital that was not removed in Step 1 (including non-DSH eligible hospitals), we use cost report data to calculate a CCR by dividing the total costs on Worksheet C, Part I, Line 202, Column 3 by the charges reported on Worksheet C, Part I, Line 202, Column 8. (Combining data from multiple cost reports from the same fiscal year is not necessary, as the longer cost report will be selected.) The ceiling is calculated as 3 standard deviations above the national geometric mean CCR for the applicable fiscal year. This approach is consistent with the methodology for calculating the CCR ceiling used for high-cost outliers. Remove all hospitals that exceed the ceiling so that these aberrant CCRs do not skew the calculation of the statewide average CCR.

Step 3: Using the CCRs for the remaining hospitals in Step 2, determine the urban and rural statewide average CCRs for the applicable fiscal year for hospitals within each State (including non-DSH eligible hospitals), weighted by the sum of total hospital discharges from Worksheet S–3, Part I, Line 14, Column 13.

Step 4: Assign the appropriate statewide average CCR (urban or rural) calculated in Step 3 to all hospitals, excluding all-inclusive rate providers, with a CCR for the applicable fiscal year greater than 3 standard deviations above the national geometric mean for that fiscal year (that is, the CCR “ceiling”).

Step 5: For hospitals that did not report a CCR on Worksheet S–10, Line 1, we assign them the statewide average CCR for the applicable fiscal year as determined in Step 3.

After completing the previously described steps, we re-calculate the hospital’s uncompensated care costs (Line 30) for the applicable fiscal year using the trimmed CCR (the statewide average CCR (urban or rural, as applicable)).

(5) Uncompensated Care Data Trim Methodology

After applying the CCR trim methodology, there are rare situations where a hospital has potentially aberrant uncompensated care data for a fiscal year that are unrelated to its CCR. Therefore, under the trim methodology for potentially aberrant uncompensated care costs (UCC) that was included as part of the methodology for purposes of determining Factor 3 in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58832), if the hospital’s uncompensated care costs for any fiscal year that is included as a part of the multi-year average are an extremely high ratio (greater than 50 percent) of its total operating costs from another available cost report, and apply that ratio to the total operating expenses
for the potentially aberrant fiscal year to determine an adjusted amount of uncompensated care costs for the applicable fiscal year. For example, if a hospital’s FY 2018 cost report is determined to include potentially aberrant data, data from its FY 2019 cost report would be used for the ratio calculation.

However, we note that we have audited the Worksheet S–10 data that will be used in the Factor 3 calculation for a number of hospitals. Because the UCC data for these hospitals have been subject to audit, we believe that there is increased confidence that if high uncompensated care costs are reported by these audited hospitals, the information is accurate. Therefore, consistent with the policy that was adopted in the FY 2021 IPPS/LTCH PPS final rule, it is unnecessary to apply the trim methodology for a fiscal year for which a hospital’s UCC data have been audited.

In rare cases, hospitals that are not currently projected to be DSH eligible and that do not have audited Worksheet S–10 data may have a potentially aberrant amount of insured patients’ charity care costs (line 23 column 2). According to the FY 2023 IPPS/LTCH PPS final rule (87 FR 49044), we stated that in addition to the UCC trim methodology, we will continue to apply a trim specific to certain hospitals that do not have audited Worksheet S–10 data for one or more of the fiscal years that are used in the Factor 3 calculation. For FY 2023 and subsequent fiscal years, in the rare case that a hospital’s ‘insured patients’ charity care costs for a fiscal year are greater than $7 million and the ratio of the hospital’s cost of insured patient charity care (line 23 column 2) to total uncompensated care costs (line 30) is greater than 60 percent, we will exclude the hospital from the prospective Factor 3 calculation. This trim will only impact hospitals that are not currently projected to be DSH-eligible and, therefore, are not part of the calculation of the denominator of Factor 3, which includes only uncompensated care costs for projected DSH-eligible hospitals. Consistent with the approach adopted in the FY 2022 IPPS/LTCH PPS final rule, if a hospital would be trimmed under both the UCC trim methodology and this alternative trim, we will apply this trim in place of the existing UCC trim methodology. We continue to believe this alternative trim more appropriately addresses potentially aberrant insured patient charity care costs compared to the UCC trim methodology because the UCC trim is based solely on the ratio of total uncompensated care costs to total operating costs and does not consider the level of insured patients’ charity care costs.

Similar to the approach initially adopted in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45245 and 45246), in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49044), we also stated that we would continue to use a threshold of 3 standard deviations from the mean ratio of insured patients’ charity care costs to total uncompensated care costs (line 23 column 2 divided by line 30) and a dollar threshold that is the median total uncompensated care cost reported on the most recent audited cost reports for hospitals that are projected to be DSH-eligible. We stated that we continued to believe these thresholds were appropriate in order to address potentially aberrant data. However, we modified the calculation to include Worksheet S–10 data from IHS/Tribal hospitals and Puerto Rico hospitals consistent with our final policy decision to begin using Worksheet S–10 data to determine Factor 3 for these hospitals. In addition, we continue a policy of applying the same threshold amounts originally calculated for the FY 2018 reports to identify potentially aberrant data for FY 2023 and subsequent fiscal years in order to facilitate transparency and predictability. If a hospital subject to this trim is determined to be DSH-eligible at cost report settlement, the MAC will calculate the hospital’s Factor 3 using the same methodology used to calculate Factor 3 for new hospitals.

c. Methodology for Calculating Factor 3 for FY 2024

For FY 2024, we proposed to follow the same methodology as applied in FY 2023 and that is described in section IV.E.3.b. of the preamble of this final rule to determine Factor 3 using the most recent 3 years of audited cost reports from FY 2018, FY 2019, and 2020. For purposes of the FY 2024 IPPS/LTCH PPS proposed rule, we used reports from the December 2022 Healthcare Cost Report Information System (HCRIS) extract to calculate Factor 3. We noted that we intended to use the March 2023 update of HCRIS to calculate the final Factor 3 for the FY 2024 IPPS/LTCH PPS final rule.

In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49051), we finalized our proposal to determine Factor 3 for IHS and Tribal hospitals and Puerto Rico hospitals based on uncompensated care data reported on Worksheet S–10, and we discontinued the use of low-income insured days as a proxy for the uncompensated care costs of these hospitals. Beginning in FY 2023, we established a new supplemental payment for IHS/Tribal hospitals and Puerto Rico hospitals, because we recognized that discontinuing the use of the low-income insured days proxy and relying solely on Worksheet S–10 data to calculate Factor 3 of the uncompensated care payment methodology for IHS/Tribal hospitals and Puerto Rico hospitals could result in significant financial disruption for these hospitals. We refer readers to section IV.D of this final rule for a further discussion of these payments.

We note that in the FY 2024 IPPS/LTCH PPS proposed rule, we did not propose any changes to the methodology for determining supplemental payments, and we will calculate the supplemental payments to eligible IHS/Tribal and Puerto Rico hospitals for FY 2024 consistent with the methodology described in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49047 through 49051) and in the regulations at § 412.106(h).

Consistent with the policy adopted in the FY 2023 IPPS/LTCH PPS final rule and codified in the regulations at § 412.106(g)(1)(iii)(C)(11), for FY 2024 and subsequent fiscal years, we will use 3 years of audited Worksheet S–10 data to calculate Factor 3 for all eligible hospitals, including IHS and Tribal hospitals and Puerto Rico hospitals that have a cost report for 2013.

Step 1: Select the hospital’s longest cost report for each of the most recent 3 years of Federal fiscal year audited cost reports (FY 2018, FY 2019, and FY 2020). (Alternatively, in the rare case when the hospital has no cost report for a particular year because the cost report for the previous Federal fiscal year spanned the more recent Federal fiscal year, the previous Federal fiscal year cost report would be used in this step. In the rare case that using a previous Federal fiscal year cost report results in a period without a report, we would use the prior year report, if that cost report spanned the applicable period. For example, if a hospital does not have a FY 2019 cost report because the hospital’s FY 2018 cost report spanned the FY 2019 time period, then we would use the FY 2018 cost report that spanned the FY 2019 time period for this step. Using the same example, where the hospital’s FY 2018 report is used for the FY 2019 time period, then we would use the hospital’s FY 2017 report if it spans some of the FY 2018 time period. In other words, we would not use the same cost report for both the FY 2019 and the FY 2018 time periods.)

In general, we note that, for purposes of the Factor 3 methodology, references to a fiscal year cost report are to the cost
report that spans the relevant Federal fiscal year period.

Step 2: Annualize the UCC from Worksheet S–10 Line 30, if a cost report is more than or less than 12 months. (If applicable, use the statewide average CCR (urban or rural) to calculate uncompensated care costs.)

Step 3: Combine adjusted and/or annualized uncompensated care costs for hospitals that merged using the merger policy.

Step 4: Calculate Factor 3 for all DSH-eligible hospitals using annualized uncompensated care costs (Worksheet S–10 Line 30) based on cost report data from the most recent 3 years of audited cost reports (from Step 1, 2, or 3). New hospitals and other hospitals that are treated as if they are new hospitals for purposes of Factor 3 are excluded from this calculation.

Step 5: Average the Factor 3 values from Step 4; that is, add the Factor 3 values, and divide that amount by the number of reporting periods with data to compute an average Factor 3 for the hospital. Multiply the result by a scaling factor.

We received comments regarding the uncompensated care costs definition, Worksheet S–10 cost report audits, and Factor 3 calculation instructions.

Comment: Several commenters expressed their support for CMS’ proposal in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26997 and 26999) to calculate Factor 3 for FY 2024 based on a three-year average of audited FY 2018, FY 2019, and FY 2020 Worksheet S–10 data, and the policy finalized in the FY 2023 IPPS/LTCH PPS final rule to implement a three-year average based on the most recent available audited data for subsequent fiscal years. Supporters of this proposal specified several benefits to the use of a multi-year average of Worksheet S–10 data, such as minimizing year-to-year volatility, promoting accuracy, and ensuring stability in future uncompensated care payments. One commenter noted their long-standing support for using audited Worksheet S–10 data to promote an accurate and consistent calculation of uncompensated care costs.

Notably, none of the commenters expressed opposition to using a three-year average of Worksheet S–10 data to calculate uncompensated care payments moving forward.

Response: We appreciate the commenters’ support for our proposal to use a three-year average of audited FY 2018, FY 2019, and FY 2020 Worksheet S–10 data to determining each hospital’s share of uncompensated care costs in FY 2024. As explained in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26995), we believe that using a multi-year average of Worksheet S–10 data will provide assurance that hospitals’ uncompensated care payments remain stable and predictable and will not be subject to unpredictable swings and anomalies in a hospital’s uncompensated care costs.

Comment: A few commenters suggested approaches to mitigating the impact of the COVID–19 PHE on the three-year average of Worksheet S–10 data. One commenter recommended that CMS exclude FY 2020 data entirely from FY 2024 DSH calculations, because the commenter believes the data are flawed due to COVID–19 PHE impacts. Another recommended that CMS hold the evaluation period of Worksheet S–10 data constant until data free of the impacts of the COVID–19 PHE are available. One commenter encouraged CMS to review the impact of the COVID–19 PHE may have on accurately capturing uncompensated care as the three-year average range includes more years with COVID–19 repercussions, while another recommended that CMS mitigate the effect of anomalies in FYs 2020–2022 report data that may adversely impact DSH payments in future years.

Response: Regarding requests that CMS account for the impact of the COVID–19 PHE on the three-year average of Worksheet S–10 data, we note that we will continue to use the three-year average of the most recently audited cost report data for FY 2024 and subsequent years, as finalized in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49038). In response to the comments requesting that we exclude FY 2020 data or hold data constant, we continue to believe using the three-year average will smooth the variation in year-to-year uncompensated care payments and lessen the impacts of the COVID–19 PHE and future unforeseen events. Further, we anticipate that there will be less fluctuation in cost report data as the PHE disruptions on healthcare utilization recover. We will continue to monitor the impacts of the PHE and will consider this issue further in future rulemaking, as appropriate.

Comment: Some commenters suggested alternative approaches to the uncompensated care payment calculation unrelated to methodological concepts concerning the blending of historical Worksheet S–10 data. Such recommendations included that CMS should consider the impact of the healthcare labor shortage on uncompensated care payments. One commenter recommended that CMS protect essential hospitals from fluctuations and cuts to uncompensated care payments, without reducing the payments to other DSH-eligible hospitals.

Another commenter requested that CMS modify the FY 2024 methodology to compensate safety-net hospitals for any decrease in FY 2020 uncompensated care payments inadvertently caused by the Factor 3 policies from the FY 2020 IPPS/LTCH PPS final rule. Specifically, this commenter’s recommendation was that CMS should account for FY 2015 uncompensated care costs from reopened FY 2015 Worksheet S–10 on a one-time basis to calculate Factor 3 for FY 2024.

Further, a handful of commenters expressed concern about the proposed reduction in uncompensated care payments. These commenters indicated that the proposed decrease in payments in addition to the inadequate payment update would be insufficient for these hospitals in the current financial environment.

Response: With regard to commenters’ concerns and suggestions unrelated to the previously discussed methodological concepts for the blending of historical Worksheet S–10 data, we consider these public comments to be outside the scope of the proposed rule, we are not addressing them in this final rule. However, we appreciate commenters’ input and note that we may address these and other considerations in future rulemaking.

Concerning the commenter’s suggestion to modify uncompensated care payments to account for payments from a previous year we are continuing to use Worksheet S–10 data from multiple years to mitigate fluctuations in the data and smooth variations in year-to-year uncompensated care payments. Regarding the commenter’s suggestion to account for FY 2015 uncompensated care costs from reopened Worksheet S–10, we are not considering re-using FY 2015 cost reports or supplementing the FY 2024 uncompensated care payments with information from FY 2015. As explained in the FY 2024 IPPS/LTCH PPS proposed rule, we believe that using a multi-year average of the most recent audited Worksheet S–10 data will reflect the most recent available information regarding a hospital’s uncompensated care costs. We note that MACs will continue to have discretion to determine if a provider revision may be accepted for amended or reopened cost reports, per 42 CFR 405.1885.
half a billion dollars from FY 2023 will have a disparate impact on DSH hospitals as they continue to face financial challenges related to the COVID–19 PHE. These challenges include increasing labor and supply costs, increasing inflation, and potential Medicare sequestration cuts. One commenter noted that any payment reduction during a time of increased operating costs for hospitals could hinder progress in areas that are top priorities for hospitals. These areas include investments in value-based payment models, climate policies, and data collection that are needed to build a foundation for improving health equity.

Response: We thank the commenters for their feedback. We agree that the COVID–19 PHE presents unique challenges to hospitals’ finances. Regarding the commenters’ concerns regarding changes to the amount available to make uncompensated care payments in this rulemaking, we note that, as described in the FY 2024 IPPS/LTCH PPS proposed rule, the statute instructs the Secretary to estimate the amounts of uncompensated care for a period based on appropriate data, which for FY 2024 include data that reflect the COVID–19 PHE’s effect on hospitals.

Comment: Some commenters proposed changes to the definition of uncompensated care and requested that CMS ensure its methodology accurately captures the full range of uncompensated care costs that hospitals incur in their provision of care for disadvantaged patient types. One commenter urged CMS to include all patient care costs in the CCR, including those for teaching and providing physician and other professional services, to ensure an accurate distribution of uncompensated care payments to hospitals with the highest levels of uncompensated care. This commenter stated that doing so should include Graduate Medical Education (GME) costs, which are disproportionately detrimental to teaching hospitals. The commenter further suggested that CMS revise the data collected on Medicaid shortfalls to better capture actual shortfalls incurred by hospitals by allowing hospitals to include unpaid coinsurance and deductibles on Worksheet S–10. Another commenter suggested treating the unreimbursed portion of state or local indigent care as charity care.

Response: We appreciate commenters’ suggestions for revisions and/or modifications to Worksheet S–10. We will consider modifications as necessary to further improve and refine the information that is reported on Worksheet S–10 to support collection of the information regarding uncompensated care costs.

Regarding the request to include costs for teaching and providing physician and other professional services, including GME costs when calculating the CCR, we note that because the CCR on Line 1 of Worksheet S–10 is obtained from Worksheet C, Part I, and is also used in other IPPS rate setting contexts (such as high-cost outliers and the calculation of the MS–DRG relative weights) from which it is appropriate to exclude the costs associated with supporting physician and professional services and GME costs, we remain reluctant to adjust CCRs in the narrower context of calculating uncompensated care costs. Therefore, as stated in past final rules, including the FY 2022 IPPS/LTCH PPS final rule (86 FR 45241 and 45242), we continue to believe that it is not appropriate to modify the calculation of the CCR on Line 1 of Worksheet S–10 to include any additional costs in the numerator of the CCR calculation. In response to the comments requesting that payment shortfalls from Medicaid and State and local indigent care programs be included in uncompensated care cost calculations, we have consistently stated in past final rules (85 FR 58826; 86 FR 45238; and 87 FR 49039) in response to similar comments that we believe there are compelling arguments for excluding such shortfalls from the definition of uncompensated care. We refer readers to those prior rules for further discussion.

Comment: Commenters expressed concern that the reductions in uncompensated care payments do not align with the Federal Government’s focus on equity. One commenter stated that safety-net hospitals provide eight times more uncompensated care than other hospital types, which disproportionately impacts safety-net hospitals’ payments. Another commenter requested that CMS revise the current payment policy to account for the proportion of low-income discharges for each hospital and the capacity of a hospital to absorb uncompensated care costs. This commenter recommended changing the uncompensated care payment calculation to be based on each hospital’s uncompensated care and disproportionate share percentage.

Response: We thank commenters for their continued concern regarding the distribution of uncompensated care payments and the impact of uncompensated care payments on safety-net hospitals. We have consistently stated in past final rules (88 FR 27187 through 27190), we included a Request for Information (RFI) that sought public feedback on the challenges faced by safety-net hospitals and potential approaches to help safety-net hospitals meet those challenges. We are in the process of reviewing the comments received in response to the RFI. Regarding the commenter noted that the distribution of uncompensated care payments on Worksheet S–10 data, one commenter requested that CMS regularly review Worksheet S–10 cost reports for any irregular trends in the data.

Response: The use of the three-year average of the most recently audited cost report data for FY 2024 and subsequent years will smooth the variation in year-to-year uncompensated care payments and lessen the impacts of future unforeseen events, such as the COVID–19 PHE. Further, we anticipate that there will be less fluctuation in cost report data as the PHE has ended. We note that the audit process for Worksheet S–10 cost reports will continue to be an important part of identifying potential irregularities in the data.

Comment: One commenter commended CMS for the agency’s efforts to develop and improve the audit process for Worksheet S–10 data. Existing concerns expressed in previous years, other commenters encouraged CMS to work with MACs to make the audit process clearer, more consistent, and more complete. The same commenters recommended that CMS establish a standardized process across auditors and make audit instructions publicly available. A few commenters cited the Medicare wage index audit as a model that CMS could use to clarify the timeline and process for Worksheet S–10 revisions. Like in the wage index audit process, these commenters recommended that CMS utilize a public use file, rather than the HCRIS data file, which would make the audit process more transparent. One commenter suggested that CMS ensure that Worksheet S–10 audits impose minimal burden and are equitable and uniform across hospitals. The same commenter also suggested CMS consider making the audit process more transparent by disclosing criteria used to identify hospitals for audits and publishing audit protocols in advance to allow hospitals time and opportunity to respond to audits and address findings through notice and comment rulemaking.
Worksheet S–10 audits, one commenter recommended that CMS select a discrete number of hospitals to audit every year. For example, in the case that CMS audits one third of DSH hospitals per year, every hospital would be audited once per 3-year cycle. Finally, this commenter also requested that CMS implement an informal, fast-track review process for audit appeals similar to the audit criteria the agency uses for retrospective DSH reimbursement, such that hospitals have the same protections afforded by the appeal rights for retrospective DSH reimbursement.

One commenter expressed concern with the handling of Health Resources & Services Administration’s (HRSA) COVID–19 claims and argued that claims not paid for by HRSA funds, but which are covered under the hospital’s financial assistance policy (FAP), should be included on Worksheet S–10.

Response: We thank commenters for their feedback on the audits of the FY 2020 Worksheet S–10 data and their recommendations for future audits. As we have stated previously in response to comments regarding audit protocols, they are provided to the MACs in advance of the audit to assure consistency and timeliness in the audit process. CMS began auditing the FY 2020 Worksheet S–10 data for selected hospitals last year so that the audited uncompensated care data for these hospitals would be available in time for use in the FY 2024 IPPS/LTCH PPS proposed rule. We chose to focus the audit on the FY 2020 cost reports in order to maximize the available audit resources. We also note that FY 2020 data are the most recent year of audited data.

We appreciate commenters’ input and recommendations on how to improve our audit process and reiterate our commitment to continue working with MACs and providers on audit improvements, which include making changes to increase the efficiency of the audit process, building on the lessons learned in previous audit years.

Regarding commenters’ requests for a standard audit timeline, we do not intend to establish a fixed timeline for audits across MACs at this time, to ensure we can retain the flexibility to use our limited audit resources to address and prioritize audit needs across all CMS programs each year. We note that MACs collaborate with providers regarding scheduling dates during the Worksheet S–10 audit process. We also note that MACs work closely with providers to balance the time needed to complete the Worksheet S–10 audits and to minimize the burden on providers and will continue to do so.

Regarding commenters’ requests that CMS make public the audit instructions and criteria, as we previously stated in the FY 2021 IPPS/LTCH PPS final rule and prior rules (81 FR 56964; 84 FR 42368; 85 FR 58822), we do not make review protocols public as CMS desk review and audit protocols are confidential and are for CMS and MAC use only. Concerning the request to promulgate the Worksheet S–10 audit policy and protocols, there is no requirement under either the Administrative Procedure Act or the Medicare statute that CMS adopt the audit protocols through notice and comment rulemaking. As previously discussed in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58822), at this point, to maximize our limited audit resources, we do not plan on introducing an audit appeals process.

Regarding commenters’ recommendations that we establish a similar process to that used for the wage index audits, at this point we do not plan to introduce an audit process with such a structure in order to maximize limited audit resources.

We also note that the quarterly HCRIS data is published as a public use file, available at https://www.cms.gov/research-statistics-data-and-systems/downloadable-public-use-files/cost-reports/cost-reports-by-fiscal-year. The December HCRIS extract is available for providers to review at the time the IPPS/LTCH PPS proposed rule is issued and the March HCRIS is generally available during the comment period.

Regarding comments on the handling of claims under the HRSA-administered COVID–19 Uninsured Program and the audits of Worksheet S–10, providers should discuss with their MAC during the Worksheet S–10 audit process if they encounter issues. In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58827), we noted that one term and condition of the HRSA Uninsured Program states as follows: “The Recipient will not include costs for which Payment was received in cost reports or otherwise seek uncompensated care reimbursement through federal or state programs for items or services for which Payment was received.”

Comment: One commenter commended CMS for its efforts to provide clearer instructions for Worksheet S–10. Three commenters requested that CMS clarify whether Worksheet S–10 Part I or Part II should be utilized to calculate Factor 3. A few commenters recommended that CMS allow Worksheet S–10 corrections following the March 2023 HCRIS deadline. These commenters noted that they were not aware of the March deadline until the publishing of the proposed rule. In addition, one commenter requested that CMS clarify the “normal timeline” MACs follow for allowing providers to amend or reopen previously audited Worksheet S–10 data used to calculate Factor 3. One commenter requested that CMS clarify inconsistent Worksheet S–10 instructions so that non-Medicare bad debt is not multiplied by CCR. This commenter stated that CMS’ revised instructions indicated that non-reimbursed Medicare bad debt is not reduced by the CCR, but that cost report instructions state that non-Medicare bad debt is multiplied by the CCR. This commenter indicated that such a practice is inconsistent with the way non-reimbursable Medicare bad debt is treated. The commenter also noted that CMS should provide opportunities for stakeholder feedback on Worksheet S–10 as well as additional educational outreach on revisions, extended submission deadlines, and training to hospital staff on accurately reporting data. Finally, one commenter proposed that CMS create a working group with industry and government stakeholders to develop standard specifications for the data fields and formats used for Worksheet S–10 cost reporting of uncompensated care, empirical DSH, and Medicare bad debt reimbursement.

Response: We appreciate commenters’ concerns regarding the need for clarification of the Worksheet S–10 instructions, as well as their suggestions for form revision to improve reporting. We reiterate our commitment to continuing to work with impacted parties to address their concerns regarding Worksheet S–10 instructions and reporting through provider education and further refinement of the instructions as appropriate. We also encourage providers to share with their respective MAC any questions regarding clarifications of instructions, reporting, and submission deadlines.

We continue to believe that our efforts to refine the instructions and guidance have improved provider understanding of the Worksheet S–10 and added clarity to the instructions. We also recognize that there are continuing opportunities to further improve the accuracy and consistency of the information that is reported on the Worksheet S–10, and to the extent that commenters have raised new questions and concerns regarding the reporting requirements, we will attempt to address them through future rulemaking and/or sub-regulatory guidance and sub-regulatory outreach. However, as stated in previous rules, we continue to believe that the Worksheet
S–10 instructions are sufficiently clear and continue to allow hospitals to accurately complete Worksheet S–10. Regarding commenters’ requests for clarification on whether Worksheet S–10 Part I or Part II is used for the Factor 3 calculation for “new” hospital and “newly merged” hospitals, we would use information reported on the hospital’s Worksheet S–10, Part I to determine Factor 3 if the hospital is determined to be DSH eligible at cost report settlement.

Concerning commenters’ requests to submit Worksheet S–10 corrections after the March 2023 HCRIS, we note that the December HCRIS extract is publicly available for providers to review on the CMS website at the time of the publishing of the IPPS/LTCH PPS proposed rule. The March update of HCRIS is generally available during the comment period to the proposed rule. We are continuing to use the March HCRIS extract, which is the latest data available during this final rule’s development and calculation.

Concerning commenters’ request that CMS clarify the timeline and procedures MACs follow to amend or reopen previously audited Worksheet S–10 data, we note that MACs will continue to have discretion to determine if a provider’s report may be accepted. We also note that MACs will not reject requests related to Worksheet S–10 revisions solely due to the direct reimbursement not meeting current year amended cost report or reopening thresholds. For hospital-requested revisions to Worksheet S–10, MACs make a determination to accept or reject the amended cost report or cost report reopening consistent with the current instructions at CMS Pub. 100–06, Chapter 8, available at www.cms.gov/regulations-and-guidance/guidance/manuals/internet-only-manuals-ions-items/cms019018.

Regarding the commenters’ request that CMS clarify whether non-Medicare bad debt is multiplied by CCR, we believe that the Worksheet S–10 instructions are clear and indicate that the CCR will not be applied to the deductible and coinsurance amounts for insured patients approved for charity care and non-reimbursed Medicare bad debt.

Regarding the comments requesting changes to Worksheet S–10 and/or further clarification of the reporting instructions, we note that these comments fall outside the scope of this final rule.

As discussed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26998), for purposes of identifying new hospitals, for FY 2024, the FY 2020 cost reports are the most recent year of cost reports for which audits of Worksheet S–10 data have been conducted. Thus, hospitals with CCNs established on or after October 1, 2020, would be subject to the new hospital policy in FY 2024. If a new hospital is ultimately determined to be eligible for Medicare DSH payments for FY 2024, the hospital would receive an uncompensated care payment calculated using a Factor 3, where the numerator is the uncompensated care costs reported on Worksheet S–10 of the hospital’s FY 2024 cost report, and the denominator is the sum of the uncompensated care costs reported on Worksheet S–10 of the FY 2020 cost reports for all DSH-eligible hospitals. In addition, we would apply a scaling factor, as discussed previously, to the Factor 3 calculation for a new hospital. As we explained in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49042), we believe applying the scaling factor is appropriate for purposes of calculating Factor 3 for all hospitals, including new hospitals and hospitals that are treated as new hospitals, in order to improve consistency and predictability across all hospitals.

In the proposed rule, we stated that for FY 2024, the eligibility of a newly merged hospital to receive interim uncompensated care payments and the amount of any interim uncompensated care payments, would be based on the uncompensated care costs from the FY 2018, FY 2019, and FY 2020 cost reports available for the surviving CCN at the time this final rule is developed. However, at cost report settlement, we would determine the newly merged hospital’s final uncompensated care payment based on the uncompensated care costs reported on its FY 2024 cost report. That is, we would revise the numerator of Factor 3 for the newly merged hospital to reflect the uncompensated care costs reported on the newly merged hospital’s FY 2024 cost report. The denominator would be the sum of the uncompensated care costs reported on Worksheet S–10 of the FY 2020 cost reports for all DSH-eligible hospitals, which is the most recent fiscal year for which audits have been conducted. We would also apply a scaling factor, as described previously.

Comment: A couple of commenters expressed support for the policy currently in place for newly merged hospitals. This policy states that uncompensated care payments for a merged hospital will be based on the surviving hospital’s cost report for the current fiscal year, and that the final uncompensated care payments for these hospitals will be determined during cost report settlement. These commenters also indicated support for the policy in place for new hospitals, which states that MACs will make the final determination concerning whether hospitals are eligible to receive DSH payments at cost report settlement based on the new hospital’s cost report.

Response: We appreciate the support for our policies for new and newly merged hospitals.

As we explained in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26998), for a hospital that is subject to the trim for potentially aberrant data and is ultimately determined to be DSH-eligible at cost report settlement, its uncompensated care payment should be calculated only after the hospital’s reporting of insured charity care costs on its FY 2024 Worksheet S–10 has been reviewed. Accordingly, the MAC would calculate a Factor 3 for the hospital only after reviewing the uncompensated care information reported on Worksheet S–10 of the hospital’s FY 2024 cost report. Then we would calculate Factor 3 for a hospital subject to the trim using the same methodology used to determine Factor 3 for new hospitals. Specifically, the numerator would reflect the uncompensated care costs reported on the hospital’s FY 2024 cost report, while the denominator would reflect the sum of the uncompensated care costs reported on Worksheet S–10 of the FY 2020 cost reports of all DSH-eligible hospitals. In addition, we would apply a scaling factor, as discussed previously, to the Factor 3 calculation for the hospital. We stated that we continue to believe applying the scaling factor is appropriate for purposes of calculating Factor 3 for all hospitals, including new hospitals and hospitals that are treated as new hospitals, in order to improve consistency and predictability across all hospitals.

We did not receive any comments on the discussion of CCR trim methodology or the UCC trim methodology.

For purposes of this final rule, the statewide average CCR was applied to 7 hospitals’ FY 2018 reports, of which 3 hospitals had FY 2018 Worksheet S–10 data. The statewide average CCR was applied to 13 hospitals’ FY 2019 reports, of which 6 hospitals had FY 2019 Worksheet S–10 data. The statewide average CCR was applied to 10 hospitals’ FY 2020 reports, of which 3 hospitals had FY 2020 Worksheet S–10 data.

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26998), we stated that for purposes of this FY 2024 IPPS/LTCH PPS final rule, we intended to use the March 2023 HCRIS extract to calculate Factor 3. We explained that the March HCRIS extract would be the
latest quarterly HCRIS extract that would be publicly available at the time of the development of this final rule.

Regarding requests from providers to amend and/or reopen previously audited Worksheet S–10 data for the most recent 3 cost reporting years that are used in the methodology for calculating Factor 3, we noted that MACs follow normal timelines and procedures. We explained that for purposes of the Factor 3 calculation for FY 2024, any amended reports and/or reopened reports would need to have completed the amended report and/or reopened report submission processes by the end of March 2023. In other words, if the amended report and/or reopened report was not available for the March HCRIS extract, then that amended and/or reopened report data would not be a part of the FY 2024 IPPS/LTCH PPS final rule’s Factor 3 calculation. We noted that the March HCRIS data extract would be available during the comment period for the proposed rule if providers want to verify that their amended and/or reopened data is reflected in the March HCRIS extract.

Comment: One commenter commended CMS for using the latest available data (i.e., the December 2022 HCRIS data) for determining DSH eligibility for the proposed rule and encouraged CMS to use the latest data that may become available prior to the development of the final rule (i.e., the March 2023 HCRIS update as indicated in the proposed rule) to ensure the proper allocation of uncompensated care payments.

Response: We appreciate the commenter’s support for our use of a later HCRIS extract for calculating Factor 3 for FY 2024. We are using the March HCRIS extract to calculate Factor 3 for this FY 2024 IPPS/LTCH PPS final rule. We believe on balance this is the best available data for the purposes of calculating Factor 3 for FY 2024. We also intend to continue utilizing the most recent data available for the applicable rulemaking, which generally means the December HCRIS extract for purposes of Factor 3 calculations in future proposed rules. Furthermore, as noted in the FY 2024 IPPS/LTCH PPS proposed rule, we continue to intend to use the respective March HCRIS extract for future final rules.

d. Per Discharge Amount of Interim Uncompensated Care Payments

Since FY 2014, we have made interim uncompensated care payments during the fiscal year on a per discharge basis. Typically, we use a 3-year average of the number of discharges for a hospital to produce an estimate of the amount of the hospital’s uncompensated care payment per discharge. Specifically, the hospital’s total uncompensated care payment amount for the applicable fiscal year is divided by the hospital’s historical 3-year average of discharges computed using the most recent available data to determine the uncompensated care payment per discharge for that fiscal year.

In the FY 2022 IPPS/LTCH PPS final rule (86 FR 45247 and 45248), we modified this calculation for FY 2022 to be based on an average of FY 2018 and FY 2019 historical discharge data, rather than a 3-year average that included data from FY 2018, FY 2019, and FY 2020. We explained our belief that computing a 3-year average with the FY 2020 discharge data would underestimate discharges, due to the decrease in discharges during the COVID–19 pandemic. In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49045), we calculated interim uncompensated care payment based on the 3-year average of discharges from FY 2018, FY 2019, and FY 2021. Consistent with the approach adopted in the FY 2023 IPPS/LTCH PPS final rule, for FY 2024, we proposed to calculate the average of FY 2019, FY 2021, and FY 2022 historical discharge data, rather than a 3-year average of the most recent 3 years of discharge data from FY 2020, FY 2021, and FY 2022. We stated that we continued to believe that computing a 3-year average using the most recent 3 years of discharge data would potentially underestimate the number of discharges for FY 2024, due to the effects of the COVID–19 pandemic during FY 2020, which was the first year of the COVID–19 pandemic. Therefore, as explained in the FY 2024 IPPS/LTCH IPPS proposed rule (88 FR 26999), we believed that our proposed approach may result in a better estimate of the number of discharges during FY 2024, for purposes of the interim uncompensated care payment calculation. In addition, we noted that including discharge data from FY 2022 to compute this 3-year average would be consistent with the proposal to use FY 2022 Medicare claims in the IPPS rate-setting, as discussed in section I.E. of the preamble of this FY 2024 IPPS/LTCH PPS final rule. As discussed in the proposed rule, we would use the resulting 3-year average of the number of discharges to calculate a per discharge payment amount that would be used to make interim uncompensated care payments to each projected DSH-eligible hospital during FY 2024. The interim uncompensated care payments made to a hospital during the fiscal year would be reconciled following the end of the year to ensure that the final payment amount is consistent with the hospital’s prospectively determined uncompensated care payment for the FY 2024.

We requested comments on our proposal to use data from FY 2019, FY 2021, and FY 2022 to compute a 3-year average of the number of discharges in order to calculate the per discharge amount for purposes of making interim uncompensated care payments to projected DSH eligible hospitals during FY 2024.

Comment: Several commenters supported CMS’ proposal to exclude FY 2020 data from the per-discharge amount calculation for interim uncompensated care payments. In contrast, one commenter noted that the use of FY 2019, FY 2021, and FY 2022 data would overestimate the discharge volume and decrease interim uncompensated care payments in FY 2024. The same commenter recommended alternative approaches, such as using the average of the two most recent years (FY 2020 and FY 2021) and applying a national adjustment factor to normalize the data based on projected discharge trends.

Response: We agree with the commenter that using FY 2019 data to calculate the per-discharge amount for interim uncompensated care payments may overestimate the discharge volume, in general. For example, the updated claims data used to estimate the FY 2024 discharges in the Factor 1 calculation indicate that discharge volumes are not expected to return to pre-pandemic levels during FY 2024; therefore, we believe omitting FY 2019 data from the per-discharge amount calculation for interim uncompensated care payments may more accurately estimate FY 2024 discharges. However, we note that we continue to believe the FY 2020 discharge data would underestimate discharges due to the effects of the COVID–19 PHE in FY 2020. Accordingly, to address these concerns regarding the use of FY 2019 discharge data, we are finalizing our proposal with modification, and will calculate the per-discharge amount of uncompensated care payments using FY 2021 and FY 2022 discharge data.

As we explained in the FY 2024 IPPS/LTCH PPS proposed rule, we finalized a voluntary process in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58833 and 58834), through which a hospital may submit a request via its MAC for a lower per discharge interim uncompensated care payment amount,
including a reduction to zero, once before the beginning of the Federal fiscal year and/or once during the Federal fiscal year. In conjunction with this request, the hospital must provide supporting documentation demonstrating that there would likely be a significant recoupment (for example, 10 percent or more of the hospital’s total uncompensated care payment or at least $100,000) at cost report settlement if the per discharge amount is not lowered. For example, a hospital might submit documentation showing a large projected increase in discharges during the fiscal year to support reduction of its per discharge uncompensated care payment amount. As another example, a hospital might request that its per discharge uncompensated care payment amount be reduced to zero midyear if the hospital’s interim uncompensated care payments during the year have already surpassed the total uncompensated care payment calculated for the hospital.

Under the policy we finalized in the FY 2021 IPPS/LTCH PPS final rule, the hospital’s MAC will evaluate these requests and the supporting documentation before the beginning of the Federal fiscal year and/or with midyear requests when the historical average number of discharges is lower than the hospital’s projected discharges for the current fiscal year. If following review of the request and the supporting documentation, the MAC agrees that there likely would be significant recoupment of the hospital’s interim Medicare uncompensated care payments at cost report settlement, the only change that will be made is to lower the per discharge amount either to the amount requested by the hospital or another amount determined by the MAC to be appropriate to reduce the likelihood of a substantial recoupment at cost report settlement. If the MAC determines it would be appropriate to reduce the interim Medicare uncompensated care payment per discharge amount, that updated amount will be used for purposes of the outlier payment calculation for the remainder of the Federal fiscal year. We refer readers to the Addendum in this FY 2024 IPPS/LTCH PPS final rule for the steps for determining the operating and capital Federal payment rate and the outlier payment calculation. No change would be made to the total uncompensated care payment amount determined for the hospital on the basis of its Factor 3. In other words, any change to the per discharge uncompensated care payment amount would not change the total uncompensated care payment amount will be reconciled at cost report settlement.

We received comments related to the uncompensated care payment reconciliation process. Comment: A couple of commenters recommended that CMS use the traditional payment reconciliation process to calculate final uncompensated care payments pursuant to section 1886(o)(2) of the Act. These commenters did not object to CMS using prospective estimates, derived from the best data available, to calculate interim payments for uncompensated care costs. However, the commenters stated that interim payments should be subject to later reconciliation based on estimates derived from actual data from the applicable Federal fiscal year. These same commenters noted that CMS’ failure to provide meaningful explanations for uncompensated care payment calculations is in violation of the Administrative Procedure Act. Commenters also recommended that CMS satisfy its legal obligation by providing hospitals the opportunity to review and comment on the more recent data used in rulemaking before the agency publishes the final rule.

Response: Consistent with the position that we have taken in past rulemaking, we continue to believe that applying our best estimates of the three factors used in the calculation of uncompensated care payments to determine payments prospectively is most conducive to administrative efficiency, finality, and predictability in payments (78 FR 50628; 79 FR 50010; 80 FR 49518; 81 FR 56949; 82 FR 38195; 84 FR 42373; 85 FR 58833; 86 FR 45246; and 87 FR 49046). We continue to believe that, in adhering the Secretary’s discretion to estimate the three factors used to determine uncompensated care payments and by including a prohibition against administrative and judicial review of those estimates in section 1886(o)(3) of the Act, Congress recognized the importance of finality and predictability under a prospective payment system. As a result, we do not agree with the commenter’s suggestion that we should establish a process for reconciling our estimates of uncompensated care payments, which would be contrary to the notion of a prospective payment system. Furthermore, we note that this rulemaking has been conducted consistent with the requirements of the Administrative Procedure Act and Title XVIII of the Act. Under the Administrative Procedure Act, a proposed rule is required to include either the terms or substance of the proposed rule, or a description of the subjects and issues involved. In this case, the FY 2024 IPPS/LTCH PPS proposed rule included a detailed discussion of our proposed methodology for calculating Factor 3 and the data that would be used. We made public the best data available at the time of the proposed rule to allow hospitals to understand the anticipated impact of the proposed methodology and submit comments, and we have considered those comments in determining our final policies for FY 2024.

After consideration of the comments received, we are finalizing our proposal to follow the same methodology used in the FY 2023 IPPS/LTCH PPS final rule to calculate Factor 3 for FY 2024 using data from the most recent 3 years of audited cost reports from FY 2018, FY 2019, and 2020, based on the March 2023 HCRIS extract. In addition, we are finalizing our proposal for determining the per-discharge amount of interim uncompensated care payments with modification. Specifically, for this FY2024 IPPS/LTCH PPS final rule, we calculated the per-discharge amount of interim uncompensated care payments using the FY 2021 and FY 2022 discharge data.

e. Process for Notifying CMS of Merger Updates and To Report Upload Issues

As we have done for every proposed and final rule beginning in FY 2014, in conjunction with this final rule, we will publish on the CMS website a table listing Factor 3 for hospitals that we estimate will receive empirically justified Medicare DSH payments in FY 2024 (that is, those hospitals that will receive interim uncompensated care payments during the fiscal year), and for the remaining subsection (d) hospitals and subsection (d) Puerto Rico hospitals that have the potential of receiving an uncompensated care payment in the event that they receive an empirically justified Medicare DSH payment for the fiscal year as determined at cost report settlement. However, we note that a Factor 3 will not be published for new hospitals and hospitals that are subject to the alternative trim for hospitals with potentially aberrant data that are not projected to be DSH-eligible. We also will publish a supplemental data file containing a list of the mergers that we are aware of and the computed uncompensated care payment for each merged hospital. In the DSH uncompensated care supplemental data file, we list new hospitals and the 11 hospitals that would be subject to the alternative trim for hospitals with potentially aberrant data that are not
projected to be DSH-eligible, with a N/A in the Factor 3 column.

Hospitals had 60 days from the date of public display of the FY 2024 IPPS/LTCH PPS proposed rule in the Federal Register to review the table and supplemental data file published on the CMS website in conjunction with the proposed rule and to notify CMS in writing of issues related to mergers and/or to report potential upload discrepancies due to MAC mishandling of Worksheet S–10 data during the report submission process (for example, reporting upload discrepancies due to MAC mishandling, or most recent report differs from previously accepted amended report due to MAC mishandling). In the proposed rule, we stated that comments raising issues or concerns that are specific to the table and supplemental data file should be submitted by email to the CMS inbox at Section3133DSH@cms.hhs.gov. We indicated that we would address comments related to mergers and/or reporting upload discrepancies submitted to the CMS DSH inbox as appropriate in the table and the supplemental data file that we publish on the CMS website in conjunction with the publication of the FY 2024 IPPS/LTCH PPS final rule. We also stated that all other comments submitted in response to our proposed policies for FY 2024 must be submitted in one of the three ways found in the Addresses section of the proposed rule before the close of the comment period in order to be assured consideration. In addition, we noted that the CMS DSH inbox is not intended for Worksheet S–10 audit process related emails, which should be directed to the MACs.

Hospitals had 15 business days from the date of public display of the FY 2023 IPPS/LTCH PPS final rule to review and submit via email any updated information on mergers and/or to report upload discrepancies (87 FR 49047). We did not receive comments during this notification period regarding mergers or data upload issues. In the FY 2024 IPPS/LTCH PPS final rule, we also noted that historical cost reports are publicly available on a quarterly basis on the CMS website for analysis and additional review of cost report data, separate from the supplemental data file published with the annual final rule.

As we have stated in previous rulemaking [see, for example, 87 FR 49046 and 86 FR 45249], in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27000), we stated our belief that hospitals have sufficient opportunity during the comment period for the proposed rule to provide information about recent and/or pending mergers and/or to report upload discrepancies. Hospitals do not enter into mergers without advanced planning. A hospital can inform CMS during the comment period for the proposed rule regarding any merger activity not reflected in supplemental file published in conjunction with the proposed rule. Therefore, for FY 2024 and subsequent fiscal years, we proposed to discontinue the 15 business day period after display of the final rule for hospitals to submit any updated information on mergers and/or to report upload discrepancies, because there will have been sufficient opportunity for hospitals to provide information on these issues during the comment period for the proposed rule. We invited public comments on this proposal.

Comment: One commenter expressed disagreement with the proposal to discontinue the 15-day period for hospitals to notify CMS of any data discrepancies after display of the final rule. This commenter asserted that the proposal affects all hospitals, not only those with recent or pending mergers. The commenter stated that the time period after the final rule is an important opportunity to address errors and/or verify the final rule’s DSH Supplemental File.

Response: We appreciate this commenter sharing their concerns regarding the proposal to discontinue the 15-day period following the final rule. However, we believe the opportunity for providers to notify CMS of discrepancies during the comment period on the proposed rule affords a sufficient opportunity to address data discrepancies and mergers. In addition, we note there is a policy for determining Factor 3 for hospitals that merge after the final rule’s Factor 3 calculation (i.e., newly merged hospitals during FY 2024). Accordingly, we are finalizing our proposal to discontinue the notification period following display of the final rule as proposed.

F. Counting Certain Days Associated With Section 1115 Demonstration in the Medicaid Fraction

1. Background

Section 1886(d)(5)(F) of the Social Security Act (the Act) provides for additional Medicare inpatient prospective payment system (IPPS) payments to subsection (d) hospitals that serve a significantly disproportionate number of low-income patients. These payments are known as the Medicare disproportionate share hospital (DSH) adjustment, and the statute specifies two methods by which a hospital may qualify for the DSH payment adjustment.

• Under the first method, hospitals that are located in an urban area and have 100 or more beds may receive a DSH payment adjustment if the hospital can demonstrate that, during its cost reporting period, more than 30 percent of its net inpatient care revenues are derived from State and local government payments for care furnished to patients with low incomes. This method is commonly referred to as the “Pickle method.”

• The second method for qualifying for the DSH payment adjustment, which is the most common method, is based on a complex statutory formula under which the DSH payment adjustment is based on the hospital’s geographic designation, the number of beds in the hospital, and the level of the hospital’s disproportionate patient percentage (DPP). A hospital’s DPP is the sum of two fractions: the “Medicare fraction” and the “Medicaid fraction.” The Medicare fraction (also known as the “SSI fraction” or “SSI ratio”) is computed by dividing the number of the hospital’s inpatient days that are furnished to patients who were entitled to both Medicare Part A and Supplemental Security Income (SSI) benefits by the hospital’s total number of patient days furnished to patients entitled to benefits under Medicare Part A. The Medicaid fraction is computed by dividing the hospital’s number of inpatient days furnished to patients who, for such days, were eligible for Medicaid but were not entitled to benefits under Medicare Part A, by the hospital’s total number of inpatient days in the same period.

Because the DSH payment adjustment is part of the IPPS, the statutory references to “days” in section 1886(d)(5)(F) of the Act have been interpreted to apply only to hospital acute care inpatient days. Regulations located at 42 CFR 412.106 govern the Medicare DSH payment adjustment and specify how the DPP is calculated as well as how beds and patient days are counted in determining the Medicare DSH payment adjustment. Under §412.106(a)(1)(i), the number of beds for the Medicare DSH payment adjustment is determined in accordance with bed counting rules for the Indirect Medical Education (IME) adjustment under §412.105(b).

Section 1115(a) of the Act gives the Secretary the authority to approve a demonstration requested by a State which, “in the judgment of the Secretary, is likely to assist in
promoting the objectives of [Medicaid.]” In approving a section 1115 demonstration, the Secretary may waive compliance with any Medicaid State plan requirement under section 1902 of the Act to the extent and for the period he finds necessary to enable the State to carry out such project. The costs of such project that would not otherwise be included as Medicaid expenditures eligible for Federal matching under section 1903 of the Act may be regarded as such federally matchable expenditures to the extent and for the period prescribed by the Secretary. States use section 1115(a) demonstrations to test changes to their Medicaid programs that generally cannot be made using other Medicaid authorities, including to provide health insurance to groups that generally could not or have not been made “eligible for medical assistance under a State plan approved under title XIX” (Medicaid benefits). These groups, commonly referred to as expansion populations or expansion waiver groups, are specific, finite groups of people defined in the demonstration approval letter and special terms and conditions for each demonstration. (We note in the discussion that follows, we use the term “demonstration” rather than “project” and/or “waiver” and the term “groups” instead of “populations,” as this terminology is generally more consistent with the implementation of the provisions of section 1115 of the Act. Therefore, we refer in what follows to groups extended health insurance through a demonstration as “demonstration expansion groups.”)

2. History of 42 CFR 412.106(b)(4) and the Deficit Reduction Act of 2005

Prior to 2000, some States had chosen to only cover Medicaid populations under their State plans when State plan coverage was mandatory under the statute, and they did not provide State plan coverage for populations for whom the statute made State plan coverage optional. Instead, coverage for these optional State plan coverage groups (as well as groups not eligible for even optional coverage) could be provided through demonstrations approved under section 1115 of the Act. We referred to these demonstration groups that could have been covered under optional State plan coverage as “hypothetical” groups—consisting of patients that could have been but were not covered under a State plan, but that received the same or very similar package of insurance benefits under a demonstration as individuals eligible for those benefits under the State plan. Many other States, however, still elected to cover optional State plan coverage groups under their Medicaid State plans instead of through a demonstration. In order to avoid disadvantaging hospitals in States that covered such optional State plan coverage groups under a demonstration, CMS developed a policy of counting such hypothetical group patients in the numerator of the Medicaid fraction of the Medicare DSH calculation (hereinafter, the DPP Medicaid fraction numerator) as if those patients were eligible for Medicaid.

Such demonstrations could also include individuals who could not have been covered under a State plan, such as childless adults for whom, at the time, State plan coverage was not mandatory under the statute, nor was optional State plan coverage available. We refer to these groups as “expansion” groups. Prior to 2000, CMS did not include expansion groups in the DPP Medicaid fraction numerator, even if individuals in that group received the same package of hospital insurance benefits under a demonstration as hypothetical groups and those eligible for Medicaid under the State plan.

On January 20, 2000, we issued an interim final rule with comment period (65 FR 3136) (hereinafter, January 2000 interim final rule), followed by a final rule issued on August 1, 2000 (65 FR 47086 through 47087), that changed the Secretary’s policy on how to treat the patient days of expansion groups that received Medicaid-like benefits under a section 1115 demonstration in calculating the Medicare DSH adjustment. The policy adopted in the January 2000 interim final rule (65 FR 3136) permitted hospitals to include in the DPP Medicaid fraction numerator all patient days of groups made eligible for title XIX matching payments through a section 1115 demonstration, whether or not those individuals were, or could be, made, eligible for Medicaid under a State plan (assuming they were not also entitled to benefits under Medicare Part A). Speaking literally, neither expansion groups nor hypothetical groups were in fact “eligible for medical assistance under a State plan”—meaning neither group was eligible for Medicaid benefits. But, in CMS’ view, certain section 1115 demonstrations introduced an ambiguity into the DSH statute (section 1886(d)(5)(F)(vi) of the Act) that justified including both hypothetical and expansion groups in the DPP Medicaid fraction numerator.

Specifically, CMS thought it appropriate to count the days of individuals in these demonstration groups because the demonstrations provided them the same or very similar benefits as the benefits provided to Medicaid beneficiaries under the State plan. As we explained in that rule (65 FR 3137), allowing hospitals to include patient days for section 1115 demonstration expansion groups in the DPP Medicaid fraction numerator is fully consistent with the Congressional goals of the Medicare DSH payment adjustment to recognize the higher costs to hospitals of treating low-income individuals covered under Medicaid. This policy was effective for discharges occurring on or after January 20, 2000.

In the FY 2004 IPPS final rule (68 FR 45420 and 45421), we further revised our regulations to limit the types of section 1115 demonstrations for which patient days could be counted in the DPP Medicaid fraction numerator. We explained that in allowing hospitals, in our 2000 rulemaking, to include patient days of section 1115 demonstration expansion groups, our intention was to include patient days of those groups who under a demonstration receive benefits, including inpatient hospital benefits, that are similar to the benefits provided to Medicaid beneficiaries under a State plan. But within a few years, we had become aware that certain section 1115 demonstrations provided some expansion groups with benefit packages so limited that the benefits were unlike the relatively expansive health insurance (including insurance for inpatient hospital services) provided to beneficiaries under a Medicaid State plan. Thus, we explained in the FY 2004 IPPS final rule that these limited section 1115 demonstrations extend benefits only for specific services and do not include similarly expansive benefits.

In the FY 2004 IPPS final rule we specifically discussed family planning benefits offered through a section 1115 demonstration as an example of the kind of demonstration days that should not be counted in the DPP Medicaid fraction numerator because the benefits granted to the expansion group are too limited, and therefore, unlike the package of benefits received as Medicaid benefits under a State plan. Our intention in discussing family planning benefits provided under a section 1115 demonstration was not to single out family planning benefits, but instead to provide a concrete example of how the changes being made in the FY 2004 IPPS final rule would refine the Secretary’s prior policy set forth in the January 2000 interim final rule (65 FR 3136). This refinement was to allow only the days of those demonstration expansion groups who are provided these benefits, and specifically inpatient hospital benefits, equivalent to the
health care insurance that Medicaid beneficiaries receive under a State plan, to be included in the DPP Medicaid fraction numerator. Moreover, this example was intended to illustrate the kind of benefits offered through a section 1115 demonstration that are so limited that the patients receiving them should not be considered eligible for Medicaid for purposes of the DSH calculation.

Because of the limited nature of the Medicaid benefits provided to expansion groups under some demonstrations, as compared to the benefits provided to the Medicaid population under a State plan, we determined it was appropriate to exclude the patient days of patients provided limited benefits under a section 1115 demonstration from the determination of Medicaid days for purposes of the DSH calculation. Therefore, in the FY 2004 IPPS final rule (68 FR 45420 and 45421), we revised the language of § 412.106(b)(4)(ii) to provide that for purposes of the demonstration, the DPP Medicaid fraction numerator, a patient is deemed eligible for Medicaid on a given day only if the patient is eligible for inpatient hospital services under an approved State Medicaid plan or under a section 1115 demonstration. Thus, under our current regulations, hospitals are allowed to count patient days in the DPP Medicaid fraction numerator only if they are days of patients made eligible for inpatient hospital services under either a State Medicaid plan or a section 1115 demonstration, and who are not also entitled to benefits under Medicare Part A.

In 2005, the United States Court of Appeals for the Ninth Circuit held that demonstration expansion groups receive care “under the State plan” and that, accordingly, our pre-2000 practice of excluding them from the DPP Medicaid fraction numerator was contrary to the plain language of the Act. Subsequently, the United States District Court for the District of Columbia reached the same conclusion, reasoning that if our policy after 2000 of counting the days of demonstration expansion groups was correct, then patients in demonstration expansion groups were necessarily “eligible for medical assistance under a State plan” (that is, eligible for Medicaid), and the Act had always required including their days in the Medicaid fraction.

Shortly after these court decisions, in early 2006, Congress enacted the Deficit Reduction Act of 2005 (the DRA) (Pub. L. 109–171, February 8, 2006). Section 5002 of the DRA amended section 1886(d)(5)(F)(vi) of the Act to clarify the Secretary’s discretion to regard as eligible for Medicaid those not so eligible and to include in or exclude from the DPP Medicaid fraction numerator demonstration days of patients regarded as eligible for Medicaid. First, by distinguishing between “patients who . . . were eligible for medical assistance under a State plan approved under subchapter XIX” (that is, Medicaid) and “patients not so eligible but who are regarded as such because they receive benefits under a demonstration project,” section 5002(a) of the DRA clarified that groups that receive benefits through a section 1115 demonstration are not “eligible for medical assistance under a State plan approved under title XIX.” This provision effectively overruled the earlier court decisions that held that expansion groups were made eligible for Medicaid under a State plan. Second, the DRA stated “the Secretary may, to the extent and for the period the Secretary determines appropriate, include patient days of patients not so eligible but who are regarded as such because they receive benefits under a demonstration project approved under title XI.” Thus, the statute provides the Secretary the discretion to determine “the extent to which patients not so eligible for Medicaid benefits “may” be regarded as” eligible “because they receive benefits under a demonstration project approved under title XI.” Third, this same language provides the Secretary with further authority to determine the days of which patients regarded as being eligible for Medicaid under the DPP Medicaid fraction numerator and for how long.

Having provided the Secretary with the discretion to decide whether and to what extent to include patients who receive benefits under a demonstration project, Congress expressly ratified in section 5002(b) of the DRA our prior and then-current policies on counting demonstration days in the Medicaid fraction. As stated before, our pre-2000 policy was not to include in the DPP Medicaid fraction numerator days of section 1115 demonstration expansion groups unless those patients could have been made eligible for Medicaid under a State plan (the “hypothetical” groups). We changed that policy in 2000 to include in the DPP Medicaid fraction numerator all patient days of demonstration expansion groups made eligible for matching payments under title XIX, regardless of whether they could have been made eligible for Medicaid under a State plan. And for FY 2004, before the DRA was enacted, CMS had further refined this policy and included in the DPP Medicaid fraction numerator the days of only a small subset of demonstration expansion group patients regarded as eligible for Medicaid: those that were eligible to receive inpatient hospital insurance benefits under the terms of a section 1115 demonstration. Thus, by ratifying the Secretary’s pre-2000 policy, the January 2000 interim final rule, and the FY 2004 IPPS final rule, the DRA further established that the Secretary had always had the discretion to determine which demonstration expansion group patients to regard as eligible for Medicaid and whether or not to include any of their days in the DPP Medicaid fraction numerator.

Because at the time the DRA was passed the language of § 412.106(b)(4) already addressed the treatment of section 1115 days to exclude some expansion populations that received limited health insurance benefits through the demonstration, we did not believe it was necessary to update our regulations after the DRA explicitly granted us the discretion to include or exclude section 1115 days from the Medicaid fraction of the DSH calculation. We believed instead that the language of § 412.106(b)(4) reflected our view that only those eligible to receive inpatient hospital insurance benefits under a demonstration project could be “regarded as” “eligible for medical assistance” under Medicaid. Thus, considering this history and the text of the DRA, we understand the Secretary to have broad discretion to decide (1) whether the extent to which to “regard as” eligible for Medicaid because they receive benefits under a demonstration those patients “not so eligible” under the State plan, and (2) of such patients regarded as Medicaid eligible, the days of which types of these patients to count in the DPP Medicaid fraction numerator and for what period of time to do so.

We do not believe that either the statute or the DRA permit or require the Secretary to count in the DPP Medicaid fraction numerator days of any patient who is in any way related to a section 1115 demonstration. Rather, section 1886(d)(5)(F)(vi) of the Act limits including days of expansion group patients to those who may be “regarded as” “eligible for medical assistance under a State plan approved under title XIX.”

3. Uncompensated/Undercompensated Care Funding Pools Authorized Through Section 1115 Demonstrations

CMS’s overall policy for including section 1115 demonstration days in the DPP Medicaid fraction numerator has
rested on the presumption that the demonstration provided a package of health insurance benefits that were essentially the same as what a State provided to its Medicaid population. More recently, however, section 1115 demonstrations have been used to authorize funding a limited and narrowly circumscribed set of payments to hospitals. For example, some section 1115 demonstrations include funding for uncompensated/undercompensated care pools that help to offset hospitals’ costs for treating uninsured and underinsured individuals. These pools do not extend health insurance to such individuals nor are they similar to the package of health insurance benefits provided to participants in a State’s Medicaid program under the State plan. Rather, such funding pools “promote the objectives of Medicaid” as required under section 1115 of the Act, but they do so by providing funds directly to hospitals, rather than providing health insurance to patients. These pools help hospitals that treat the uninsured and underinsured stay financially viable so they can treat Medicaid patients.

By providing hospitals payment based on their uncompensated care costs, the pools directly benefit those providers, and, in turn, albeit less directly, the patients they serve. Unlike demonstrations that expand the group of people who receive health insurance beyond those groups eligible under the State plan and unlike Medicaid itself, however, uncompensated/undercompensated care pools do not provide inpatient health insurance to patients or, like insurance, make payments on behalf of specific, covered individuals.209 In these ways, payments to hospitals meant to subsidize the cost of treating uninsured and low-income patients and that do not provide health insurance to individuals, such as uncompensated/undercompensated care pools for providers.

4. Recent Court Decisions and Rulemaking Proposals on the Treatment of 1115 Days in the Medicare DSH Payment Adjustment Calculation

Several hospitals challenged our policy of excluding uncompensated/undercompensated care days and premium assistance days from the DPP Medicaid fraction numerator, which the courts have recently decided in a series of cases.210 These decisions held that the current language of the regulation at §412.106(b)(4) requires CMS to count in the DPP Medicaid fraction numerator patient days for which hospitals have received payment from an uncompensated/undercompensated care pool authorized by a section 1115 demonstration, as well as days of patients who received premium assistance under a section 1115 demonstration. Interpreting this regulatory language, which was adopted before the DRA was enacted, two courts concluded that if a hospital received payment for a patient’s otherwise uncompensated inpatient hospital treatment, that patient is “eligible for inpatient hospital services” within the meaning of the current regulation, and therefore, their patient day must be included in the DPP Medicaid fraction. Likewise, a court concluded that patients who receive premium assistance to pay for private insurance that covers inpatient hospital services are “eligible for inpatient hospital services” within the meaning of the current regulation, and those patient days must be counted.

As discussed previously, it was never our intent when we adopted the current language of the regulation to include in the DPP Medicaid fraction numerator days of patients that benefitted so indirectly from a demonstration. In the FY 2022 IPPS/LTC PPS proposed rule (86 FR 25459) (hereinafter, the FY 2022 proposed rule), we stated that we continued to believe, as we have consistently believed since at least 2000, that it is not appropriate to include patient days associated with funding pools and premium assistance authorized by section 1115 demonstrations in the DPP Medicaid fraction numerator because the benefits provided patients under such demonstrations are not similar to Medicaid benefits provided beneficiaries under a State plan and may offset costs that hospitals incur when treating uninsured and underinsured individuals. In the FY 2022 proposed rule, we proposed to revise our regulations to more clearly state that in order for an inpatient day to be counted in the DPP Medicaid fraction numerator, the section 1115 demonstration must provide inpatient hospital insurance benefits directly to the individual whose day is being considered for inclusion. We specifically discussed that, under the proposed change, days of patients who receive premium assistance through a section 1115 demonstration and the days of patients for which hospitals receive payments from an uncompensated/undercompensated care pool created by a section 1115 demonstration would not be included in the DPP Medicaid fraction numerator. Because neither premium assistance nor uncompensated/undercompensated care pools are inpatient hospital insurance benefits directly provided to individuals, nor are they comparable to the breadth of benefits available under a Medicaid State plan, we stated that individuals associated with such assistance and pools should not be “regarded as” “eligible for medical assistance under a State plan.”

Commenters generally disagreed with our proposal, arguing that both premium assistance programs and uncompensated/undercompensated care pools are used to provide individuals with inpatient hospital services, either by reimbursing hospitals for the same services as the Medicaid program in the case of uncompensated/undercompensated care pools or by allowing individuals to purchase insurance with benefits similar to Medicaid benefits offered under a State plan in the case of premium assistance. Thus, they argued, those types of days should be included in the DPP Medicaid fraction numerator. Following review of these comments, in the final rule with comment period that appeared in the December 27, 2021 Federal Register, which finalized certain provisions of the

209 For more information on this distinction, as upheld by courts, we refer readers to Adena Regional Medical Center v. Leavitt, 527 F.3d 176 (D.C. Cir. 2008); Owensboro Health, Inc. v. HHS, 832 F.3d 615 (6th Cir. 2016).

210 Bethesda Health, Inc. v. Azar, 980 F.3d 121 (D.C. Cir. 2020); Forrest General Hospital v. Azar, 926 F.3d 221 (5th Cir. 2019); HealthAlliance Hospitals, Inc. v. Azar, 346 F. Supp. 2d 43 (D.D.C. 2018).
FY 2022 proposed rule related to Medicare graduate medical education payments for teaching and Medicare organ acquisition payment, we stated that after further consideration of the issue we had determined not to move forward with our proposal and planned to revisit the issue of section 1115 demonstration days in future rulemaking (86 FR 73418).

After considering the comments we received in response to the FY 2022 proposed rule, in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28398) (hereinafter, the FY 2023 proposed rule), we proposed to revise our regulation to explicitly reflect our interpretation of the language “regarded as” “eligible for medical assistance under a State plan approved under title XIX” in section 1886(d)(5)(F)(vi) of the Act to mean patients who (1) receive health insurance authorized by a section 1115 demonstration or (2) patients who pay for all or substantially all of the cost of health insurance with premium assistance authorized by a section 1115 demonstration, where the State expenditures to provide the health insurance or premium assistance may be matched with funds from title XIX. Moreover, of the groups we proposed as Medicaid eligible, we proposed to use our discretion under the Act to include in the DPP Medicaid fraction numerator only (1) the days of those patients who obtained health insurance directly or with premium assistance that provides essential health benefits (EHB) as set forth in 42 CFR part 440, subpart C, for an Alternative Benefit Plan (ABP), and (2) for patients obtaining premium assistance, only the days of those patients for which the premium assistance is equal to or greater than 90 percent of the cost of the health insurance, provided in either case that the patient is not also entitled to Medicare Part A (87 FR 28398 through 28402).

In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49051), we noted that the agency received numerous, detailed comments on our proposal. We indicated that due to the number and nature of the comments that we received, and after further consideration of the issue, we had determined not to move forward with the FY 2023 proposal. We stated that we expected to revisit the treatment of section 1115 demonstration days for purposes of the DSH adjustment in future rulemaking (87 FR 49051).

In a proposed rule published in the Federal Register on February 28, 2023 (88 FR 12623), we indicated that due to the number and nature of the comments that we received, and after further consideration of the issue, we had determined not to move forward with the FY 2023 proposal. We proposed revisions to our regulations on the counting of days associated with individuals eligible for certain benefits provided by section 1115 demonstrations in the Medicaid fraction of a hospital’s disproportionate patient percentage, as discussed in greater detail below. We proposed the revised regulation would be effective for discharges occurring on or after October 1, 2023.

5. Amendment to 42 CFR 412.106(b)(4)

Consistent with our interpretation of the Medicare DSH statute over more than two decades and the history of our policy on counting section 1115 demonstration days in the DPP Medicaid fraction numerator set forth in our regulations, considering the series of adverse cases interpreting the current regulation, in light of what we proposed in the FY 2022 and FY 2023 proposed rules and our consideration of the comments we received thereon, and considering the comments we received on the February 2023 proposed rule (86 FR 12623), we are amending the regulation at § 412.106(b)(4) as proposed. In order for days associated with section 1115 demonstrations to be counted in the DPP Medicaid fraction numerator, the statute requires those days to be of patients who can be “regarded as” eligible for Medicaid. Accordingly, and consistent with the proposed approach set forth in the FY 2023 proposed rule and with our longstanding interpretation of the statute and as amended by the DRA, and with the current language of § 412.106(b)(4), we are modifying our regulations to explicitly state our long-held view that only patients who receive health insurance through a section 1115 demonstration where State expenditures to provide the insurance may be matched with funds from title XIX can be “regarded as” eligible for Medicaid.

Similar to our statements in the FY 2023 and February 2023 proposed rules, and in further considering the comments received regarding the treatment of the days of patients provided premium assistance through a section 1115 demonstration to buy health insurance, we are finalizing our proposal that such patients can also be regarded as eligible for Medicaid under section 1886(d)(5)(F)(vi) of the Act. Therefore, we are finalizing our proposal for purposes of the Medicare DSH calculation in section 1886(d)(5)(F)(vi) of the Act to “regard as” “eligible for medical assistance under a State plan approved under title XIX” patients who receive health insurance authorized by a section 1115 demonstration or (2) buy health insurance with premium assistance provided to them under a section 1115 demonstration, where State expenditures to provide the health insurance or premium assistance is matched with funds from title XIX. Furthermore, of these expansion groups we proposed to regard as eligible for Medicaid, we are finalizing our proposal to include in the DPP Medicaid fraction numerator only the days of those patients who receive from the demonstration (1) health insurance that covers inpatient hospital services or (2) premium assistance that covers 100 percent of the premium cost to the patient, which the patient uses to buy health insurance that covers inpatient hospital services, provided in either case that the patient is also entitled to Medicare Part A.

Finally, we are finalizing our proposed amendment of the regulation to state specifically that patients whose inpatient hospital costs are paid for with funds from an uncompensated care pool authorized by a section 1115 demonstration are not patients “regarded as” eligible for Medicaid, and the days of such patients may not be included in the DPP Medicaid fraction numerator. As discussed previously, we continue to believe it is not appropriate to include in the DPP Medicaid fraction numerator days of all patients who may benefit in some way from a section 1115 demonstration. First, we do not believe the statute permits everyone receiving a benefit from a section 1115 demonstration to be “regarded as” “eligible for medical assistance under a State plan approved under title XIX” merely because they receive a limited benefit. Second, even if the statute were so to permit, as discussed herein, the Secretary believes the DRA provides him with discretion to determine which patients “not so eligible” for Medicaid under a State plan may be “regarded as” eligible. Thus, the Secretary is regarding as Medicaid eligible only those patients who receive as “benefits” from a demonstration health insurance or premium assistance to buy health insurance, because—at root—“medical assistance under a State plan approved under title XIX” provides Medicaid beneficiaries with health insurance, not simply medical care. Third, the DRA also gives the Secretary the authority to decide which days of patients “regarded as” Medicaid eligible to include in the DPP Medicaid fraction numerator. Using this discretion, we are including only the days of those patients who receive from a demonstration health insurance that covers inpatient hospital services or (2) premium assistance that...
covers 100 percent of the premium cost to the patient, which the patient uses to buy health insurance that covers inpatient hospital services, provided in either case that the patient is not also entitled to Medicare Part A.

We note this policy is a change from the proposal included in the FY 2023 proposed rule, which would have required that the insurance provide EHB and the premium assistance cover at least 90 percent of the cost of the insurance. The feedback we received on that proposal from interested parties included concerns regarding, among other issues, the burden associated with verifying whether a particular insurance program in which an individual was enrolled provided EHB, how to determine whether a particular premium assistance program covered at least 90 percent of the cost of the insurance, and the difficulty in receiving accurate information on those issues in a timely manner. In light of this feedback, the rule we proposed in February 2023 and are now finalizing maintains the policy established in the regulations at least as far back as FY 2004 that days associated with individuals who obtain health insurance from a demonstration that covers inpatient hospital services be included in the DPP Medicaid fraction numerator. We do not believe that it would be unduly difficult for providers to verify that a particular insurance program includes inpatient benefits. (We refer readers to section XII.B.2. of this final rule for more information on the burden estimate associated with this final rule.) For those individuals who buy health insurance covering inpatient hospital services using premium assistance received from a demonstration, we proposed and are finalizing that the premium assistance cover 100 percent of the individual’s cost of the premium to be included in the DPP Medicaid fraction numerator. Indeed, it may be difficult to distinguish between patients who, on the one hand, receive through a demonstration health insurance for inpatient hospital services or 100 percent premium assistance to purchase health insurance and patients who, on the other hand, are eligible for medical assistance under the State plan: all patients receive health insurance paid for with title XIX funds, and all may be enrolled in a Medicaid managed care plan. In the proposal, we stated that we also do not believe that it will be difficult for providers to verify that a particular demonstration covers 100 percent of the premium cost to the patient, as it is our understanding that all premium assistance demonstrations currently meet that standard. In other words, as a practical matter, if a hospital is able to document that a patient is in a demonstration that explicitly provides premium assistance, then that documentation would also document that a patient is in a demonstration that covers 100 percent of the individual’s costs of the premium. We also stated in the proposal that we believe our proposed standard of 100 percent of the premium cost to the beneficiary is appropriate because it encapsulates all current demonstrations as a practical matter. We also said that if in the future there is a demonstration that explicitly provides premium assistance that does not cover 100 percent of the individual’s costs for the premium, we may revisit this issue in future rulemaking.

As we have consistently stated, individuals eligible for medical assistance under title XIX are eligible for, among other things, specific benefits related to the provision of inpatient hospital services in the form of inpatient hospital insurance. Because funding pool payments to hospitals authorized by a section 1115 demonstration do not provide health insurance to any patient, nor do the payments inure to any specific individual, uninsured patients whose costs are subsidized by uncompensated/undercompensated care pool payments to hospitals do not receive benefits to the extent that or in a manner similar to the full equivalent of “medical assistance” available to those eligible under a Medicaid State plan. Uninsured or underinsured individuals, whether or not they benefit from uncompensated/undercompensated care pool payments to hospitals, do not have health insurance provided by the Medicaid program. Thus, we continue to believe that patients whose costs are associated with uncompensated/undercompensated care pools may not be “regarded as” Medicaid-eligible, and we are using the Secretary’s discretion to not regard them as such. Even if they could be so regarded and irrespective of whether the Secretary has the discretion to not regard them as such, the Secretary also is using his authority to not include the days of such patients in the DPP Medicaid fraction numerator. Such patients have not obtained insurance under the demonstration, and including all uninsured patients associated with uncompensated/undercompensated care pools could distort the Medicaid proxy in the Medicare DSH calculation that is used to determine the low-income, non-senior population a hospital serves.

An uninsured patient who does not pay their hospital bill (thereby creating uncompensated care for the hospital) is not necessarily a low-income patient.

Accordingly, in this rule, we are finalizing our proposal to revise our regulations at § 412.106(b)(4) to explicitly reflect our interpretation of the language “regarded as” “eligible for medical assistance under a State plan approved under title XIX” “because they receive benefits under a demonstration project approved under title XI” in section 1886(d)(5)(F)(vi) of the Act to mean patients provided health insurance benefits by a section 1115 demonstration. Specifically, we are finalizing our proposal to regard as Medicaid eligible for purposes of the Medicare DSH payment adjustment patients (1) who receive health insurance through a section 1115 demonstration itself or (2) who purchase health insurance with the use of premium assistance provided by a section 1115 demonstration, where State expenditures to provide the insurance or premium assistance is matchable with funds from title XIX. In addition, even if the statute would permit a broader reading, the Secretary is exercising his discretion under section 1886(d)(5)(F)(vi) of the Act to “regard as” Medicaid eligible only those patients. Furthermore, whether or not the Secretary has discretion to determine who is “regarded as” Medicaid eligible, we are using the authority provided the Secretary to limit the days of those section 1115 demonstration patients included in the DPP Medicaid fraction numerator to only those of individuals who receive from the demonstration (1) health insurance that covers inpatient hospital services or (2) premium assistance that covers 100 percent of the premium cost to the patient, which the patient uses to buy health insurance that covers inpatient hospital services, provided in either case that the patient is not also entitled to Medicare Part A. And we are finalizing our proposal to explicitly exclude from the DPP Medicaid fraction numerator the days of patients with uncompensated care costs for which a hospital is paid from a funding pool authorized by a section 1115 demonstration project.

Finally, we are finalizing as proposed that our revised regulation would be effective for discharges occurring on or after October 1, 2023. As has been our practice for more than two decades, we...
have made our periodic revisions to the counting of certain section 1115 patient days in the Medicare DSH calculation effective based on patient discharge dates. Doing so again here treats all providers similarly and does not impact providers differently depending on their cost reporting periods.

In developing the proposal we are finalizing, we considered counting the days of patients in the DPP Medicaid fraction numerator whose inpatient hospital costs are paid for with funds from an uncompensated/undercompensated care pool authorized by a section 1115 demonstration. However, after consideration, as discussed in the proposal and in greater detail herein, because of the Secretary’s interpretation of the statute and electing to exercise his discretion for policy reasons, we did not propose to include counting in the DPP Medicaid fraction numerator the days of patients whose inpatient hospital costs are paid for with funds from an uncompensated/undercompensated care pool authorized by a section 1115 demonstration. We invited public comments with regard to our statutory interpretation and our election to exercise the Secretary’s authority discussed above, as well as our proposal not to count in the DPP Medicaid fraction numerator days of patients whose inpatient hospital costs are paid to hospitals from uncompensated/undercompensated care pool funds authorized by a section 1115 demonstration.

6. Responses to Comments on CMS 1788–P

In section II.E. of the February 2023 proposed rule (88 FR 12629–12632), we addressed relevant comments the agency received on the proposed rules for FY 2022 and FY 2023 on the treatment of certain 1115 days in the Medicare DSH payment adjustment calculation (86 FR 25459 and 87 FR 28398). We directed the reader to section II.E. of the February 2023 proposed rule to review those comments and responses.

The agency received several timely comments on the February 2023 proposed rule. Many commenters submitted comments similar or identical to those that were submitted on the FY 2022 and FY 2023 proposals. Some of the comments we received on the February 2023 proposed rule were out of scope of the proposal. We will keep these comments in mind for future rulemaking.

Comment: Several commenters argued that CMS is prohibited from finalizing our proposed revisions with respect to days associated with 1115 demonstrations. Many of these commenters argued that section 1886(d)(5)[F](vi) of the Act prohibits the Secretary from distinguishing days of patients that receive any benefit at all under a demonstration from patients made eligible under a demonstration for health insurance coverage that includes inpatient hospital services. In addition, many of these commenters also argued that two Federal appeals courts have held that the statute requires all patients who are “capable of receiving a demonstration project’s helpful or useful effect by reason of a demonstration project’s authority” be counted in the Medicare DSH DPP Medicaid numerator, citing Forrest General Hospital v. Azar, 926 F.3d 221 (5th Cir. 2019), and Bethesda Health, Inc. v. Azar, 980 F.3d 121 (D.C. Cir. 2020). Some commenters argued that CMS was prohibited from revising our regulations in light of these court decisions and the decision in HealthAlliance Hospitals, Inc. v. Azar, 346 F. Supp. 3d 43 (D.D.C. 2018). Response: We thank commenters for their input but we continue to believe that the language “regarded as” “eligible for medical assistance under a State plan approved under title XIX” “because they receive benefits under a demonstration project approved under title XI,” in section 1886(d)(5)[F](vi) of the Act, as amended by the Deficit Reduction Act of 2005, Public Law 109–171, 120 Stat. 4, 31 (Feb. 6, 2006) (“DRA”) sec. 5002, means patients provided health insurance by a section 1115 demonstration that the Secretary determines meets health insurance is what patients covered under a Medicaid State plan receive under title XIX.

As we explained in the FY 2023 proposed rule (87 FR 28108 and 28400) and reiterated again in the February 2023 proposed rule (88 FR 12623), we believe the statutory phrase “regarded as” “regarding as such” refers to patients who are regarded as eligible for medical assistance under a State plan approved under title XIX, and therefore, should be understood to refer to patients who receive benefits that are most like those that Medicaid-eligible patients get. Patients covered by a Medicaid State plan receive a guarantee of payment for an extensive list of medical services paid for with Medicaid funds — effectively health insurance. In other words, for the purposes of Medicare DSH, patients “regarded as” Medicaid-eligible under a demonstration are people the Medicaid program treats as if they are eligible for Medicaid because a demonstration approved under title XI provides them the same or very similar benefits that Medicaid beneficiaries receive under the State plan, and which are paid for with Medicaid funds. Patients who do not receive the same or very similar benefits, but who might receive from a demonstration a benefit that is not effectively health insurance (such as receiving treatment at a hospital) are not “regarded as” Medicaid-eligible.

Moreover, we believe the DSH statute also provides the Secretary the discretion to determine which patients to “regard[ as]” “eligible for medical assistance under a State plan approved under title XIX” and to further determine, of those “regarded as” Medicaid-eligible, which patient days to include in the Medicare DSH DPP Medicaid fraction numerator. Therefore, under the Secretary’s discretion, we are including in the DPP Medicaid fraction numerator only patients regarded as eligible for Medicaid who are provided by a section 1115 demonstration (1) health insurance that covers inpatient hospital services or (2) premium assistance that covers 100 percent of the premium cost to the patient, which the patient uses to buy health insurance that covers inpatient hospital services, provided in either case that the patient is not also entitled to Medicare Part A.

In amending the DSH statute in 2006, Congress in section 5002 of the DRA provided the Secretary with: (1) authority to determine which types of patients extended benefits through a section 1115 demonstration to regard as eligible for Medicaid; and (2) discretion to count or not count in the DPP Medicaid fraction numerator days of patients regarded as Medicaid-eligible. We know this because, as discussed above, DRA section 5002(a) confirmed that (1) groups that receive benefits through a section 1115 demonstration are not Medicaid-eligible (meaning they do not receive benefits under a State plan), and (2) the Secretary’s pre-2000 policy of excluding expansion populations from the DPP (like patients in Portland Adventist and Cookville who received the same benefits as Medicaid beneficiaries, only under a demonstration] was proper under the DSH statute at the time (i.e., pre-DRA amendments). Thus, section 5002(a) of the DRA effectively overturned the Portland Adventist and Cookville cases that had held demonstration expansion groups received Medicaid benefits under a State plan. And by ratifying in DRA section 5002(b) the separate policies adopted in rulemaking in

January 2000 and for FY 2004, in which the Secretary first included in the DSH calculation all days of expansion groups and then later limited the inclusion to only the days of expansion group patients receiving coverage of inpatient hospital services, Congress affirmed that the Secretary could determine the contours and limits of what it meant under the amended statute for patients to be “regarded as [Medicaid-eligible] because they receive benefits under a demonstration project” and the “extent” to which to include the days of those patients in the DPP Medicaid fraction numerator.

In light of this history, we believe that commenters’ reliance on the quotation from Portland Adventist, to say CMS “has refused to implement the DSH provision in conformity with the intent behind the statute” does not reflect the statute as amended and is therefore incorrect. In amending the DSH statute in the DRA, Congress effectively overturned Portland Adventist and clearly stated the authority the Secretary has, and has always had, to determine whether a recipient of benefits under a section 1115 demonstration may be regarded as Medicaid-eligible and, if so, that the Secretary may decide whether to include such patient day in the DPP Medicaid fraction numerator.

As earlier noted, Section 5002(b) of the DRA ratified CMS’ January 2000 policy of including all demonstration expansion group days in the DPP Medicaid fraction numerator as those that the Secretary regarded as days of Medicaid-eligible patients. But Congress also ratified CMS’ FY 2004 policy that narrowed the type of expansion days included in the DPP Medicaid fraction numerator to only those of patients receiving coverage of inpatient hospital services. In revising the DSH regulation (42 CFR 412.106(b)(4)) for FY 2004, the agency noted that hospitals were claiming days of patients in the DPP Medicaid fraction numerator who were extended only limited benefits (like coverage for family planning services) by a section 1115 demonstration. Thus, in amending the DSH regulation for FY 2004 under the pre-DRA DSH statute, the Secretary affirmed his view that a patient receiving such limited benefits from a demonstration was not similar enough to a patient eligible for Medicaid under a State plan to include the demonstration patient’s day in the DPP Medicaid fraction numerator. In other words, the FY 2004 rule—the current regulation we are amending in this rule—underscored the Secretary’s belief that patients receiving only some benefit provided by a demonstration, but not the more comprehensive coverage provided under a Medicaid State plan, was not enough to regard such patient as Medicaid-eligible and to count their patient days as Medicaid days for purposes of the DSH calculation.

Moreover, by amending the DSH statute in DRA section 5002(a) to explicitly permit the Secretary to consider certain demonstration days as Medicaid days and include them in the DSH calculation, and by ratifying in section 5002(b) the Secretary’s policy of including only demonstration days of patients provided select benefits (coverage of inpatient hospital services), we disagree that the DSH statute requires counting as Medicaid days in the DPP Medicaid fraction numerator all days of patients merely “considered or accounted to be capable of receiving a demonstration project’s helpful or useful effects,” as some commenters assert. Rather, the DSH statute, as amended by the DRA, permits demonstration expansion groups to be “regarded as” Medicaid-eligible only when they get benefits similar to those of Medicaid, and makes clear that the Secretary with discretion to determine, in the context of Medicare DSH calculations, whether populations that receive benefits under a section 1115 demonstration are “regarded as” eligible for Medicaid; and likewise provides the Secretary further discretion to determine “the extent” to which the days of those regarded as Medicaid-eligible may be included in the Medicare DSH DPP Medicaid fraction numerator. Therefore, considering our prior rulemakings on this subject and Congress’ intent in enacting section 5002 of the DRA, we disagree with commenters who read section 1886(d)(5)(F)(vi) of the Act to mandate that all days of patients who may benefit in any way from a section 1115 demonstration must be included in the DSH DPP Medicaid fraction numerator.

The text of the statute also confirms the Secretary’s authority in these respects. The statute clearly uses discretionary language. It specifies that “the Secretary may, to the extent and for the period the Secretary determines appropriate, include patient days of patients not so eligible but who are regarded as such because they receive benefits under a demonstration project approved under title XI.” As the Supreme Court recently explained, “may” is quintessentially discretionary language and has repeatedly emphasized that the use of “may” in a statute is intended to confer discretion rather than establish a requirement.213

---

213 See Opati v. Republic of Sudan, 140 S. Ct. 1601, 1609 (2020) (The Court has “repeatedly observed” that “the word ‘may’ clearly connotes discretion.”). See also, for example, Weyerhaeuser Co. v. United States Fish & Wildlife Serv., 139 S. Ct. 361, 371 (2018); Jama v. Immigration & Customs Enforcement, 543 U.S. 335, 346 (2005).
interpreted the regulation we are replacing with the rule we are finalizing in that manner, we note that the current regulation was drafted prior to the enactment of DRA section 5002 and, therefore, the regulation does not interpret the language the DRA added to the Medicare statute, which, as we explain above and previously, gives the Secretary wide discretion whether to consider demonstration days as Medicaid-eligible days and whether to count them in the Medicaid fraction. Our revised regulation uses the authority granted to the Secretary under the DRA to not regard as eligible for Medicaid-eligible days and whether to consider demonstration days as Medicaid-eligible days and whether to count them in the Medicaid fraction. The revised regulation uses the authority granted the Secretary under the DRA to not count their days in the Medicaid fraction numerator. We are finalizing the proposed changes to the regulation in this rule to clarify who, under 1886(d)(5)(F)(vi) of the Act, as amended, the Secretary regards as eligible for Medicaid because of benefits provided by a section 1115 demonstration and which patient days the Secretary will and will not include in the Medicare DSH DPP Medicaid fraction numerator. We believe that our revisions are consistent with the statute and our statutory authority and are not precluded by the court decisions cited by the commenters.

Comment: Some commenters argued that our proposal violated the Administrative Procedure Act because it is arbitrary and capricious and irrationally overbroad. We believe that our proposal conforms with the DSH statute, as amended, and the authority given to the Secretary under the Act as it relates to calculating a hospital’s disproportionate patient percentage.

Response: For reasons we articulated both in the February 2023 proposed rule and above, we do not believe our proposal is arbitrary, capricious or irrationally overbroad. We believe that our proposal conforms with the DSH statute, as amended, and the authority given to the Secretary under the Act as it relates to calculating a hospital’s disproportionate patient percentage.

Comment: Several commenters specifically objected to our proposal to exclude from counting in the DPP Medicaid fraction numerator days associated with uncompensated/undercompensated care funding pools authorized by section 1115 demonstrations. These commenters argued that patients whose hospital costs were paid for by a section 1115 funding pool must be “regarded as” Medicaid-eligible under the statute because such patients “effectively” receive insurance paid for with Medicaid funds under section 1115 demonstrations. Thus, they assert, these uninsured patients cannot reasonably be distinguished from patients who receive insurance from the Medicaid program. Commenters also asserted that the vein that uninsured patients receive as benefits from a demonstration’s uncompensated/undercompensated funding pool program inpatient hospital services that are the same inpatient benefits that Medicaid beneficiaries receive because the inpatient care they receive from hospitals is the same.

Response: Several commenters for their input, however we respectfully disagree with the factual predicates and the legal conclusions of these assertions. First, we disagree with the proposition that uninsured patients whose costs may be partially paid to hospitals by uncompensated/undercompensated care pools effectively have insurance which includes inpatient hospital benefits. Therefore, we do not believe that these patients are indistinguishable from Medicaid beneficiaries and expansion group patients who receive health insurance under the State plan or demonstration, respectively, and whose days the Secretary includes in the DPP Medicaid fraction numerator. Uninsured patients, unlike Medicaid or expansion group patients, do not have health insurance.

It is clear, insurance is beneficial to specific patients in ways that uncompensated/undercompensated care pool payments to hospitals are not or could not possibly be to such patients. Medicaid and other forms of health insurance are not merely mechanisms of payment to providers for costs of patient care: Health insurance provides a reasonable expectation on the part of the insurance holder that they can seek treatment without the risk of financial ruin. On the other hand, hospitals may bill uninsured patients for the full cost of their care and refer their medical debts to collection agencies when they are unable to pay, even if some of their medical treatment costs may be paid to the provider by an uncompensated/undercompensated care pool. Thus, it remains the case that uninsured patients may avoid treatment for fear of being unable to pay for it. For example, if two patients receive identical care from a hospital that accepts government-funded insurance, but one of them has insurance as a Medicaid beneficiary or receives insurance through a section 1115 demonstration and, therefore, is financially protected, while the other patient is uninsured and spends years struggling to pay their hospital bill—even if the hospital receives partial payment from a demonstration-authorized uncompensated/undercompensated care pool for that patient’s treatment—the two patients have not received the same “benefit” from the government or one that could

214 See Health Insurance Coverage and Health—What the Recent Evidence Tells Us (https://www.nejm.org/doi/pdf/10.1056/nejmsbh1706645); Economic and Employment Effects of Medicaid Expansion Under ARP v Commonwealth Fund (https://www.commonwealthfund.org/publications/issue-briefs/2021/may/economic-employment-effects-medicaid-expansion-under-arp). To be clear, we mention these studies only in support of our assertion that having health insurance is fundamentally different than not having insurance.
reasonably be “regarded as” comparable. This distinction between insured and uninsured patients is meaningful in this context, and we believe it is a sound basis on which to distinguish the treatment of patient days in the DSH calculation of uninsured patients who may in some way benefit from a section 1115 demonstration-authorized uncompensated/undercompensated care pool and the days of patients provided health insurance as a Medicaid beneficiary under a State plan or through a demonstration as part of an expansion group.

Second, we also respectfully disagree with commenters who have stated that uninsured patients whose costs may be paid to hospitals by an uncompensated/undercompensated care pool receive the same benefits as patients eligible for Medicaid because the inpatient hospital care is likely the same for both groups. As stated above, within the meaning of section 1886(d)(5)(F)(vi) of the Act, the “benefits” provided to the individual by Medicaid and other forms of insurance a patient receives is the promise of a payment made on behalf of a specific patient to a provider of care for providing the care, not the care itself the hospital provides. The provision of inpatient hospital services and payment for such services are two distinct issues, and because a hospital treats a patient presenting a need for medical care does not indicate anything about whether or how the hospital may be paid for providing that care. And, similarly, the fact that a demonstration provides pool funding from which hospitals may be paid in no way creates an obligation under the demonstration to provide inpatient hospital care to any individual, nor does it create a reasonable expectation on behalf of a specific individual that a hospital must treat them or that such treatment will be paid for under the demonstration. Thus, the similarity of care a patient may receive and for which a hospital may receive some payment from a demonstration’s uncompensated/undercompensated care fund is irrelevant to the question of whether the “benefits” provided a patient “because” of a demonstration may be “regarded as” something akin to “medical assistance under a State plan approved under title XIX” such that the Secretary has to count patients’ days in the DPP Medicaid fraction numerator.

And even if hospitals that receive some Medicaid funds to provide similar treated uninsured patients permits or requires the Secretary to regard those patients as Medicaid-eligible for DSH calculation purposes, the Secretary has still reasonably distinguished such patients from Medicaid-eligible patients and is choosing not to count them in the DPP Medicaid fraction numerator.

Comment: Some commenters argued that because partial payment of costs by a demonstration’s uncompensated/undercompensated care fund to hospitals for the cost of treating uninsured/underinsured patients may be “medical assistance” within the meaning of the Medicaid statute, that the Medicare DSH statute requires the uninsured/underinsured patient to be “regarded as” eligible for Medicaid and their patient days included in the DPP Medicaid fraction numerator.

Response: We disagree with the conclusion that individuals who may benefit from a demonstration’s uncompensated/undercompensated care pool payments to hospitals must be “regarded as” eligible for Medicaid because those payments may be considered “medical assistance” under the Medicaid statute. We believe that their patient days must be included in the DPP Medicaid fraction numerator. We believe this conclusion is precluded in light of Congress’ amendment of the DSH statute and its ratification of the then-existing DSH regulation, which we are amending through this rule.

As discussed above, Congress ratified the Secretary’s FY 2004 regulation, which limited the agency’s prior DSH policy of including in the DPP Medicaid fraction all expansion days authorized by a section 1115 demonstration. In limiting the January 2000 regulation, the agency determined a demonstration needed to extend coverage for inpatient hospital services, one form of “medical assistance” (under SSA section 1905(a)(1)), to individuals to include the days of such patients in the DPP Medicaid fraction numerator. As an example of the limitation promulgated in the FY 2004 rule, no longer would the Secretary consider a demonstration’s provision of coverage only for family planning services sufficiently similar to the comprehensive coverage Medicaid beneficiaries receive under a State plan. Thus, despite family planning services being “medical assistance” under section 1905(a)(4)(C) of the Act, the FY 2004 rulemaking precluded including in the DPP Medicaid fraction numerator the days of patients receiving only that limited “medical assistance” under a demonstration because it was not similar enough to the medical assistance benefits Medicaid-eligible patients receive, even those expansion group patients who only received coverage of this particular type of medical assistance (family planning services) were no longer included in the DSH DPP Medicaid fraction. Congress ratified the FY 2004 regulation, thereby confirming that not every provision of “medical assistance” through a section 1115 demonstration constitutes a “benefit” under the DSH statute that requires the Secretary to regard the recipient as Medicaid-eligible and to include the patient day in the DSH DPP Medicaid fraction. Thus, even if the “benefit” an uninsured patient receives because a hospital is paid something under a section 1115 demonstration for providing that patient inpatient services could be considered “medical assistance,” the Secretary need not regard that patient as Medicaid-eligible for DSH purposes or include their patient day in the DPP Medicaid fraction numerator.

In keeping with this view, we continue to disagree with commenters that our prior discussions of court cases like Adena Regional Medical Center v. Leavitt, 527 F.3d 176 (D.C. Cir. 2008), and Owensboro Health, Inc. v. HHS, 832 F.3d 615 (6th Cir. 2016), are irrelevant to this discussion because those cases did not involve section 1115 demonstrations. We rely on these cases to refute the idea that the provision of something beneficial—like the provision of inpatient hospital services to the uninsured—even when paid for with Medicaid funds, transforms those things into “medical assistance” or makes the recipient of them “eligible for medical assistance” as those phrases are used in the Medicaid statute. The Medicaid program can subsidize the treatment of low-income uninsured patients without making those individuals eligible for “medical assistance.” The phrase, “eligible for medical assistance under a state plan approved under title XIX” is a term of art that Congress uses to identify patients that are eligible for Medicaid. As the D.C. Circuit put the point: “Congress has throughout the various Medicare and Medicaid statutory provisions, consistently used the words ‘eligible’ to refer to potential Medicaid beneficiaries and ‘entitled’ to refer to potential Medicare beneficiaries.” Northeast Hospital Corp. v. Sebelius, 657 F.3d 1, 12, (D.C. Cir. 2011). Congress simply followed suit when referring to the two programs in the Medicare DSH DPP provisions.

Response: We disagree with the commenters.

Comment: Owensboro Health, Inc. v. HHS, 832 F.3d 615 (6th Cir. 2016), is relevant to this discussion because those cases did not involve section 1115 demonstrations. We rely on these cases to refute the idea that the provision of something beneficial—like the provision of inpatient hospital services to the uninsured—even when paid for with Medicaid funds, transforms those things into “medical assistance” or makes the recipient of them “eligible for medical assistance” as those phrases are used in the Medicaid statute. The Medicaid program can subsidize the treatment of low-income uninsured patients without making those individuals eligible for “medical assistance.” The phrase, “eligible for medical assistance under a state plan approved under title XIX” is a term of art that Congress uses to identify patients that are eligible for Medicaid. As the D.C. Circuit put the point: “Congress has throughout the various Medicare and Medicaid statutory provisions, consistently used the words ‘eligible’ to refer to potential Medicaid beneficiaries and ‘entitled’ to refer to potential Medicare beneficiaries.” Northeast Hospital Corp. v. Sebelius, 657 F.3d 1, 12, (D.C. Cir. 2011). Congress simply followed suit when referring to the two programs in the Medicare DSH DPP provisions.

Response: We disagree with the commenters.

Comment: Owensboro Health, Inc. v. HHS, 832 F.3d 615 (6th Cir. 2016), is relevant to this discussion because those cases did not involve section 1115 demonstrations. We rely on these cases to refute the idea that the provision of something beneficial—like the provision of inpatient hospital services to the uninsured—even when paid for with Medicaid funds, transforms those things into “medical assistance” or makes the recipient of them “eligible for medical assistance” as those phrases are used in the Medicaid statute. The Medicaid program can subsidize the treatment of low-income uninsured patients without making those individuals eligible for “medical assistance.” The phrase, “eligible for medical assistance under a state plan approved under title XIX” is a term of art that Congress uses to identify patients that are eligible for Medicaid. As the D.C. Circuit put the point: “Congress has throughout the various Medicare and Medicaid statutory provisions, consistently used the words ‘eligible’ to refer to potential Medicaid beneficiaries and ‘entitled’ to refer to potential Medicare beneficiaries.” Northeast Hospital Corp. v. Sebelius, 657 F.3d 1, 12, (D.C. Cir. 2011). Congress simply followed suit when referring to the two programs in the Medicare DSH DPP provisions.

Response: We disagree with the commenters.
individuals eligible for “medical assistance” as that phrase is used in the Medicaid statute. The Courts of Appeals have repeatedly rejected lawsuits that presented some variation of the argument that when hospitals received Medicaid DSH payments—i.e., payments funded by title XIX—because they incurred costs treating low-income uninsured patients, it meant that the uninsured patients treated were thereby rendered eligible for Medicaid (or received “medical assistance”). They were not. Likewise here, a subsidy approved under section 1115 to hospitals for costs they incur in treating un- and under-insured patients—i.e., in the form of title XIX payments from a section 1115-approved uncompensated care fund—does not render the patients whose cost may be covered in part by those payments eligible for “medical assistance.” We therefore disagree with comments suggesting that patients whose costs may be offset by demonstration-authorized pool funding to hospitals receive “medical assistance” within the meaning of the Medicare DSH provision at section 1886(d)(5)(F)(vi) of the Act that would require the Secretary to regard such patients as eligible for Medicaid and that those patients days must be included in the DPP Medicaid fraction numerator.

Furthermore, even if uninsured patients could be regarded as eligible for Medicaid, we would not include them in the DPP Medicaid fraction numerator for policy reasons. The DPP is intended to be a proxy calculation for the percentage of low-income patients a hospital treats. Congress has defined the proxy to count in the Medicare fraction the days of patients entitled to Medicare Part A and SSI: the days of patients not entitled to Medicare but eligible for Medicaid are counted in the Medicaid fraction. Thus, because Medicaid has never covered everyone that could be considered low-income—for instance, it generally did not cover low-income, childless adults before passage of the Affordable Care Act—therefore not every low-income patient was ever necessarily accounted for in the DPP Medicaid proxy. If we counted all uninsured patients who could be said to have benefited from an uncompensated/undercompensated care pool (whether low income patients or not, because one need not be low-income to be uninsured and leave a hospital bill unpaid), we could potentially include in the DPP proxy not just all low-income patients in States run uncompensated/undercompensated care pools, including those who have never been, and in our view should not be accounted for int the DPP Medicaid proxy, but also patients who are not low-income but who do not have insurance and did not pay their hospital bill, who we also believe should not be included in the DPP Medicaid fraction numerator. This would be a distortion from how Congress intended the DSH calculation to work, where the DPP is a proxy for the percentage of low-income patients that hospitals serve based on patients covered by Medicare or Medicaid. We note that in contrast to an individual who could afford but elects not to buy insurance and lets bills go unpaid, an individual who receives insurance coverage under Medicaid or a section 1115 demonstration, by definition, must meet low-income standards.

Comment: Some commenters pointed out that in the recently approved Texas demonstration, the Special Terms and Conditions of that program only permit payment from the approved uncompensated/undercompensated care pool for providing medical services to uninsured individuals as “charity care” and thus only the hospitals’ costs of patients “who demonstrated financial need according to the provider’s charity care policy” could be paid from such fund. They assert that this undercuts the above rationale for exercising the Secretary’s discretion to exclude uncompensated/undercompensated care days from inclusion in the DPP Medicaid fraction numerator. Response: We respectfully disagree that the provision in the Texas program undercuts our rationale. As stated above, we think the fact that an individual is provided health insurance through Medicaid or a demonstration is a salient and rational basis for distinguishing individuals that should and should not count in the low-income proxy that is the DPP Medicaid fraction numerator. Moreover, a policy that incentivizes states to expand Medicaid eligibility by including in the DPP Medicaid fraction numerator only the days of patients made eligible for health insurance under a State plan or section 1115 demonstration is sound policy. And while recognizing that the objectives of the Medicaid program can be advanced through the approval of uncompensated/undercompensated care pools in section 1115 demonstration programs because they help keep hospitals financially viable to provide services to Medicaid patients, these funding pools do not provide individuals with a right to seek medical care or any guarantee that the cost of any care will be made on their behalf.

Thus, we continue to believe that there is a rational basis to distinguish for Medicare payment purposes days of uninsured patients from those who receive health insurance coverage under a Medicaid State plan or section 1115 demonstration.

Also, counting all patients that may be “capable of receiving a demonstration project’s helpful or useful effect by reason of a demonstration project’s authority” in States with uncompensated/undercompensated care pools could drastically and unfairly increase DSH payments to hospitals located in States with those programs in comparison to hospitals in States without them, even though the cost burden on hospitals of treating low-income, uninsured patients might be higher in States without uncompensated/undercompensated care pools, precisely because they do not have uncompensated/undercompensated care pools. The purpose “of the DSH provisions is not to pay hospitals the most money possible; it is instead to compensate hospitals for serving a disproportionate share of low-income patients.”215 We do not believe that purpose would be furthered by regarding uninsured patients associated with uncompensated/undercompensated care pools as if they were patients eligible for Medicaid or counting them in the DPP Medicaid fraction numerator.

Thus, while we continue to believe that the statute does not permit patients who might indirectly benefit from uncompensated/undercompensated care pool funding to be “regarded as” eligible for Medicaid, if the statute permits us to regard such patients as eligible for medical assistance under title XIX, the statute also provides the Secretary with the discretion to determine whether to do so. We are electing to exercise the Secretary’s discretion not to regard as eligible for Medicaid patients that may indirectly benefit from uncompensated/undercompensated funding pools. In any event, we believe the statute also expressly provides the Secretary with the authority to determine whether to include patient days of patients regarded as eligible for Medicaid in the DPP Medicaid fraction numerator “to the extent and for the period” that the Secretary deems appropriate. Thus, we are also exercising the Secretary’s discretion not to include in the DPP Medicaid fraction numerator patient days of patients associated with

215 Becerra v. Empire Health Found., 142 S. Ct. 2354, 2367 (2022) [emphasis added].
uncompensated/undercompensated care pool payments.

Comment: Some commenters stated that because CMS does not have evidence that uncompensated/undercompensated care pools are improperly used, we lack the authority to exclude days associated with those programs from the numerator of the Medicaid fraction.

Response: Our interpretation of the DSH statute and policy choices we are finalizing in this rule to exclude counting patient days for which hospitals are paid from demonstration-approved uncompensated/undercompensated care pools is not based on any conclusion that such funding mechanisms are being improperly used; and for the reasons previously stated, we believe we have the authority to do so. To the extent approved by a section 1115 demonstration, funding pools can play a proper role in paying hospitals with title XIX funds for uncompensated costs they incur treating un- and under-insured patients. In doing so, these funding pools can further the objectives of the Medicaid program, as required by section 1115 of the Act, by helping to financially stabilize hospitals that serve Medicaid beneficiaries. We do not, however, agree that the fact that demonstration funding pools can be used properly under section 1115 of the Act requires us, under section 1886(d)(5)(F)(vi) of the Act, to count days associated with them in the DPP Medicaid fraction numerator. As we have stated, individuals who have the cost of their care partially offset through the use of uncompensated/undercompensated care pools do not receive “medical assistance” that is sufficiently similar to the benefits individuals eligible for Medicaid receive under title XIX for us to regard them as eligible for Medicaid for the purposes of Medicare DSH or to count them in the DPP Medicaid fraction numerator, even if they could be regarded as Medicaid eligible under the Medicare statute.

Comment: Many commenters objected to our proposal to exercise the Secretary’s discretion to limit including in the DPP Medicaid fraction numerator days of patients who receive premium assistance under a section 1115 demonstration to only the days of those patients receiving such assistance that covers 100 percent of the premium cost to the patient and that are used to buy health insurance for inpatient hospital services. Some of these commenters stated that they believe CMS has ignored the burden of this proposal on hospitals.

Response: As we explained both herein and in our proposal, we believe that premium assistance that covers 100 percent of the costs of the premium to the patient, used to purchase health insurance coverage of inpatient hospital services is the level and type of benefit that is most similar to the benefits provided by the Medicaid program under title XIX of the Act—namely, health insurance that covers inpatient hospital services. Therefore, because this threshold of premium assistance to buy health insurance covering inpatient services provides the same benefit to individuals as Medicaid beneficiaries receive, albeit obtained through a slightly different mechanism, we believe it is an appropriate threshold to distinguish between individuals we will count for the purposes of calculating Medicare DSH and those we will not. Thus, we are choosing to not include in the DPP Medicaid fraction numerator the days of patients who buy insurance with demonstration-authorized premium assistance that accounts for less than 100 percent of their premium costs because the benefit the government is providing is not similar enough to that which Medicaid-eligible beneficiaries receive. Additionally, we disagree with the commenters who believe that we have ignored the burden of this proposal on providers. In our February 2023 proposal, we stated that it was our understanding that all states with current 1115 premium assistance demonstration programs provide 100 percent premium assistance to individuals; and based on this understanding we quantified as best we could that it would cost 310 hospitals a total of approximately $18,350,169 annually to determine whether a patient received under a demonstration’s premium assistance program 100 percent of the cost of their premium for inpatient hospital services coverage (88 FR 12632). While commenters may disagree as to the accuracy of our estimate, we believe that our estimate was reasonable and demonstrates that the burden to providers was not ignored.

We are unsure why some commenters have significant concerns with verifying an individual’s section 1115 eligibility and the amount of premium assistance when hospitals are already communicating with their state Medicaid office to verify an individual’s eligibility. We do not understand why it is unclear who would furnish this data to hospitals or how hospitals would obtain the patient-specific data that they would need to prove eligibility for each patient under the proposed premium assistance rule. The states have this information as part of the section 1115 demonstration requirements. Finally, as a commenter recognizes, it remains the hospitals’ burden to furnish data adequate to prove eligibility for each Medicaid patient day it claims in the DPP Medicaid fraction numerator, and we believe that the states will continue to be able to furnish hospitals with the eligibility data necessary for the hospitals to do so.

We note, as discussed below, since our proposal it has come to our attention that, in addition to the current
1115 demonstrations that all provide 100 percent premium assistance to at least some individuals, at least one demonstration—Massachusetts’ discussed in more detail below—also provides a sliding scale of premium assistance to other individuals, dependent on their income levels. Therefore, we are revising our burden estimate accordingly, as discussed in more detail below in section XII.B.2. of this final rule.

Comment: One commenter stated that the proposed requirement that premium assistance fund 100 percent of an individual’s health insurance premium to have that patient’s inpatient hospital day included in the DPP Medicaid fraction numerator “will complicate and negate the counting of certain Medicaid patients.” This commentator asserts that the Massachusetts 1115 demonstration provides premium assistance to enrollees in the state’s Medicaid program (MassHealth), including those who have access to employer-sponsored health insurance (ESI), and to other non-Medicaid-eligible residents who purchase health insurance in the state’s health insurance exchange (Health Connector). They claim setting the threshold at 100 percent of the patient’s premium costs may cause an increased burden on Massachusetts and the state’s providers to determine which patients receive 100 percent premium assistance.

Response: We acknowledge the commenter appears concerned that, by finalizing the premium assistance proposal, Medicaid enrollees made to participate in MassHealth premium assistance program, where some enrollees may be responsible for paying a small portion of premiums, would not be counted in the DPP Medicaid fraction numerator. We believe, however, that concern is unfounded. Under our proposal, the days of such Medicaid enrollees would be counted in the DPP Medicaid fraction numerator (assuming such enrollees are not also entitled to Medicare Part A), notwithstanding some small premium cost sharing required of the enrollees. As described by the commenter, these individuals are Medicaid enrollees under the State plan; the fact that the Secretary has approved section 1115 demonstration for Massachusetts to leverage available ESI with premium assistance does not change the nature of an individual’s status as a Medicaid enrollee under the State plan, and their Medicaid patient days, as they have always been, will continue to be included in the DPP Medicaid fraction numerator as a Medicaid enrollee. Assuming these enrollees are not also entitled to Medicare Part A. The requirement that the demonstration cover 100 percent of the cost of the premium to the patient only applies to individuals who are not eligible for Medicaid under the State plan.

We also disagree that our premium assistance proposal will unreasonably burden hospitals or the state in determining which days of patients who receive premium assistance through an 1115 demonstration may properly be included in the DPP Medicaid fraction numerator. To the extent a hospital seeks to include a day in the DPP Medicaid fraction of a Medicaid enrollee who receives premium assistance to purchase ESI, we are not aware why the hospital would bear any greater burden to determine such patient’s Medicaid-enrollee status than if such patient did not receive premium assistance. These patients are entitled to Medicaid under the State plan and should therefore be identifiable in any Medicaid eligibility system a state already maintains. Nothing in the comments we received suggests otherwise.

This commenter also notes that Massachusetts’s section 1115 demonstration provides premium assistance to other, non-Medicaid-eligible individuals, and that while the premium assistance covers 100 percent of the patient’s premium costs for some low-income individuals, others must contribute to the cost of their premiums depending on their income level and health plan choice. The commenter is concerned because they do not believe that current eligibility systems would inform hospitals whether an enrollee in the state’s health exchange had their premium entirely covered or only partially covered with premium assistance provided through the demonstration, and thus, hospitals would be burdened with attempting to obtain this information, which may not be possible unless the state were to modify its own systems that communicate with providers.

While we acknowledge that the premium assistance policy we are finalizing will lead to an increased burden on Massachusetts and providers in that state to identify which non-Medicaid-eligible patients have received premium assistance that covers 100 percent of their premium costs for that patient day to be included in the DPP Medicaid fraction, we do not believe that the burden involved is unreasonable. The commenters did not provide any supporting information as to the extent of the burden or why they believe it is unreasonable for Massachusetts or hospitals in that state to bear such burden.

While one commenter did point to a quotation in our proposed rule to support the difficulty in obtaining the required information, we believe that this quote has been misunderstood by the commenter. The commenter quotes our proposal as “CMS notes it may be difficult for hospitals to distinguish between patients with premium assistance paid for by Medicaid from patients who are otherwise covered by Medicaid through fee-for-service or managed care.” In the proposal (88 FR 12628), we stated in the context of acknowledging a change in our premium assistance proposal from the FY 2023 proposed rule, which would have required premium assistance that covered at least 90 percent of the cost of the patient’s premium for EHB coverage to be included in the DPP Medicaid fraction numerator, that the February 2023 proposal would require premium assistance to cover 100 percent of the patient’s premium cost for inpatient hospital coverage to count. As a basis for changing our proposal, we said, “Indeed, it may be difficult to distinguish between patients who, on the one hand, receive through a demonstration health insurance for inpatient hospital services or 100 percent premium assistance to purchase health insurance and patients who, on the other hand, are eligible for medical assistance under the State plan: all patients receive health insurance paid for with title XIX funds, and all may be enrolled in a Medicaid managed care plan.” Our point here was to show that those patients who receive under a demonstration 100 percent premium assistance to buy health insurance that provides inpatient hospital coverage look very similar to patients who receive health insurance under either a demonstration or a Medicaid State plan, thereby establishing why we have chosen to “regard as” Medicaid-eligible such premium assistance recipients and to count their patient days in the Medicare DSH DPP Medicaid numerator fraction. The proposal language the commenter noted was not a statement about the ease or difficulty a hospital may have in determining which patients receive—either under a State plan or 1115 demonstration—health insurance or premium assistance that covers 100 percent of a patient’s premium costs for insurance coverage of inpatient hospital services.

We do not believe it will be unreasonably difficult for providers to obtain the state information on whether certain non-Medicaid-eligible patients qualify through the demonstration to receive premium.
assistance that covers 100 percent of the cost of their premium for insurance that covers inpatient hospital services. The current Massachusetts section 1115 demonstration provides premium assistance of 100 percent of the cost of premiums to individuals making 150 percent or less of the Federal Poverty Level (FPL), and it provides a sliding scale of premium assistance to non-Medicaid-eligible residents whose income levels range from above 150 percent to over 1,000 percent FPL. (See MassHealth Medicaid and CHIP Section 1115 Demonstration [Project Number 11–W–00030/1 and 21–00071/1], Special Terms and Conditions (STCs), attachment C (Cost Sharing), https://www.masshealth.gov/the-commonwealth-masshealth-ca-demstrtn-aprvl-05192023.pdf.) As stated in the September 28, 2022 Massachusetts Demonstration Extension Approval Letter, “to evaluate the impact of the premium policy, the Commonwealth must continue to assess beneficiary access to and utilization of health care services, enrollment continuity, number and frequency of coverage gaps, and beneficiary experiences with care.” Therefore, to comply with the terms of the section 1115 demonstration, Massachusetts can reasonably be expected to have information on the patients extended premium assistance through the demonstration, including patients’ income levels relative to FPL and thus the level of premium assistance each patient receives, and to be able to provide that information to hospitals. See https://www.masshealth.gov/the-commonwealth-masshealth-ca-demstrtn-aprvl-05192023.pdf, page 14. We believe that, because the state already collects the information hospitals would need to determine which individuals receive 100 percent premium assistance for insurance coverage of inpatient hospital services, there should be no significant hurdle to hospitals obtaining this information from the state.

Comment: One commenter noted that in the proposal, CMS listed a number of states the agency believed to have a section 1115 demonstration that may be affected by the premium assistance proposal, and that this list did not include Indiana. The commenter agreed that Indiana is not among those states that operate such a demonstration. Another commenter noted that Connecticut was not among the states listed as having a section 1115 premium assistance program and requested clarification that the Connecticut program would qualify.

Response: We appreciate the commenter’s thoughts on Indiana’s 1115 premium assistance demonstration as it might relate to the proposal we are finalizing; we agree with the commenter that Indiana does not currently operate a section 1115 premium assistance demonstration that would be affected by the rule we proposed and are finalizing.

With respect to Connecticut, we agree with the commenter that individuals eligible for premium assistance under the current demonstration (which was approved subsequent to the issuance of the NPRM) would be “regarded as” eligible for Medicaid under the revisions to our regulations and included in the DPP Medicaid numerator (if not also entitled to Medicare Part A) because the demonstration covers 100 percent of the costs of the premium to individuals eligible for it. We note, however, that should the Connecticut program, or any other currently approved premium assistance program authorized under section 1115 of the Act, be revised or approved in the future so that premium assistance under the demonstration does not cover 100 percent of the costs of the premium to the individual or does not cover 100 percent of the costs of the premium for all individuals eligible for it, only the days of those individuals for whom the demonstration covers 100 percent of the cost of the premium to the individuals may be included in the DPP Medicaid fraction numerator under our revised regulations. We have added Connecticut to the list of states in the final rule that currently operate premium assistance programs authorized by section 1115 of the Act.

Comment: Some commenters suggested that the Secretary cannot finalize either the uncompensated/undercompensated care days policy or the premium assistance policy we proposed and apply them to currently approved demonstrations because of providers’ reliance interests. They argue once the Secretary approves a section 1115 demonstration “for purposes of the Medicaid program” it cannot exclude patient days attributable to such demonstration “for purposes of the Medicare DSH patient percentage.” They argue for the Secretary to do so would constitute a “take back” and has no basis in the text of the Medicare statute. In the alternative, some commenters stated that even if CMS had the authority to finalize the proposal with respect to currently approved demonstrations, we should not or specifically requested that we not.

Response: We respectfully disagree with the commenters’ interpretation of the statute and the effects of finalizing this rule. As stated above, we believe the Medicare statute provides the Secretary with the discretion to determine what patients may be “regarded as” Medicaid-eligible for purposes of being counted in the Medicare DSH DPP Medicaid fraction numerator and whether to include therein any or which days of patients so regarded. The Medicaid statute, section 1115(a) of the Act, separately provides the Secretary with the authority to authorize Medicaid demonstrations that waive Medicaid requirements and provide expenditure authority to states to incur costs not permitted under a State plan so that states may experiment with ways of using Medicaid funds to “assist in promoting the objective of” the Medicaid program. Thus, the Medicare DSH policies finalized here will not change the terms of any current demonstration or the calculations of Medicaid payments made thereunder. Therefore, by going through this notice and comment rulemaking to clarify our Medicare regulations (42 CFR 412.106(b)(4)) on the treatment of section 1115 patient days in the calculation of Medicare DSH payment adjustments, the Secretary is not “taking back” any Medicaid payments that hospitals or states might otherwise be entitled to under an approved Medicaid section 1115 demonstration. Nor does finalizing this prospective rule unsettle any legitimate reliance interest the hospitals may otherwise have in future Medicare DSH payment adjustments. With respect to the argument that CMS should not finalize the proposal with respect to currently approved demonstrations, for the reasons explained more fully in our February 2023 proposed rule and herein, we believe that, assuming CMS has the discretion to “regard” uninsured individuals as eligible for Medicaid (which we do not believe we can), we believe that the better policy is to exclude their days from the DPP Medicaid fraction numerator and to also exclude days of those receiving premium assistance that is less than 100 percent of the cost of their premiums for inpatient health insurance.

Comment: Some commenters state the proposed changes will have serious financial ramifications for hospitals at a time the hospitals can least afford it. Specifically, commenters raised the financial hardships hospitals have been experiencing over the last few years due to the Covid–19 pandemic, recent inflationary cost pressures, and other causes of financial strain. They suggest that reductions in DSH payments that may result from finalizing this proposal are...
“reason alone” the proposal should be withdrawn. Some of these commenters expressed concern that the proposal would have a negative effect on health equity in general and safety net hospitals specifically. Other commenters expressed concern that the proposed changes to our regulations would make it more difficult for hospitals to participate in the 340B Program.

Response: We appreciate the points the commenters raise and are sympathetic to the financial hardships faced by many hospitals and acknowledge that the proposed revisions to the regulations affect the calculation of the disproportionate patient percentage, which in turn affects the DSH adjustment, and that a certain DSH adjustment threshold is statutorily required for participation in the 340B Program as well as the unique concerns of safety net hospitals, and health equity remains an important goal of the Secretary. We note, however, as described above, that the Secretary is constrained by the statute as to which patients can be regarded as eligible for Medicaid under a demonstration, even though they are not actually Medicaid-eligible, and therefore whether such patient days may be included in the DPP Medicaid fraction numerator in calculating any DSH payment adjustment. And even if the statute does not require the Secretary to exclude from the DPP Medicaid fraction days of uninsured patients whose hospital care is paid to hospitals from uncompensated/undercompensated care pools or days of patients who receive less in premium assistance than 100 percent of their premium costs to purchase health insurance that covers inpatient hospital care, the Secretary believes that these parameters best further the goals of the Medicare DSH payment adjustment, which is to pay hospitals extra for treating a 

disproportionate share of low income patients. Additionally, maximizing the size of Factor 1 or the number of hospitals that qualify for HRSA’s 340B Program is required by the Medicare statute nor an appropriate policy goal of Medicare DSH policy. As the Supreme Court recently said, the purpose “of the DSH provisions is not to pay hospitals the most money possible; it is instead to compensate hospitals for serving a disproportionate share of low-income patients.”

To the extent hospitals may be suffering financially because of the COVID–19 pandemic, recent inflationary cost pressures, and other causes of financial strain, the commenters have not demonstrated whether or how such strains have had the effect of causing hospitals to treat a disproportionate share of low-income patients, and therefore it is beyond the boundaries of this rule to address such financial strain.

By using our discretion to regard as Medicaid eligible for purposes of the DPP Medicaid fraction numerator only the days of demonstration patients for which the demonstration provides health insurance or premium assistance to purchase health insurance, and to only include the days of those patients that receive from a demonstration health insurance for inpatient hospital services or premium assistance to buy inpatient hospital insurance, where the premium assistance accounts for 100 percent of the premium cost to the patient, we believe we are acting in accordance with Congress’ intent to count some, but not necessarily all, low-income patients in the proxy.

For the reasons stated previously, the DRA’s ratification of the Secretary’s prior regulations on including or excluding demonstration group patient days from the DPP Medicaid numerator also supports the Secretary having the discretion to exclude days of uninsured patients and patients that do not receive health insurance for inpatient hospital services, and for those receiving premium assistance, where the assistance is less than 100 percent of the premium cost to the patient. By ratifying the Secretary’s prior regulation that explicitly stated that our intent was to include in the fraction only the days of those most looked like Medicaid-eligible patients, the limits we are proposing here fully align with Congress’s amendment of the statute.

In summary, we proposed to revise our regulations at § 412.106(b)(4) to explicitly reflect our interpretation of the language “regarded as” “eligible for medical assistance under a State plan approved under title XIX” “because they receive benefits under a demonstration project approved under title XI” in section 1886(d)(5)(F)(vi) of the Act to mean patients (1) who receive health insurance through a section 1115 demonstration-authorized uncompensated/undercompensated care pools; or (2) who purchase health insurance through a section 1115 demonstration or (2) who purchase health insurance with the use of premium assistance provided by a section 1115 demonstration, where State expenditures to provide the insurance or premium assistance may be matched with funds from title XIX. Alternatively, we proposed exercising the discretion the statute provides the Secretary to limit to those two groups the patients the Secretary “regard[s] as” “eligible for medical assistance under a State plan” “because they receive benefits under a demonstration.” Moreover, using the Secretary’s authority to determine the days of which demonstration groups “regarded as” Medicaid eligible to include in the DPP Medicaid fraction numerator, we proposed that only the days of those patients who receive from the demonstration (1) health insurance that covers inpatient hospital services or (2) premium assistance that covers 100 percent of the premium cost to the patient, which the patient uses to buy health insurance that covers inpatient hospital services, are to be included, provided in either case that the patient is not also entitled to Medicare Part A. Finally, we proposed exercising the Secretary’s discretion to not regard as Medicaid-eligible patients whose costs are paid to hospitals from uncompensated/undercompensated care pool funds authorized by a section 1115 demonstration; and we similarly proposed exercising the Secretary’s authority to exclude the days of such patients from being counted in the DPP Medicaid fraction numerator, even if those patients could be “regarded as” “eligible for medical assistance under a State plan authorized by title XIX.” Thus, we proposed explicitly excluding from counting in the DPP Medicaid fraction numerator any days of patients for which hospitals are paid from demonstration-authorized uncompensated/undercompensated care pools.

Finally, we proposed our revised regulation would be effective for discharges occurring on or after October 1, 2023. As has been our practice for more than two decades, we have made our periodic revisions to the counting of certain section 1115 patient days in the Medicare DSH calculation effective based on patient discharge dates. Doing so again here treats all providers similarly and does not impact providers differently depending on their cost reporting periods.

For all the reasons stated in the February 2023 proposal and herein, after considering the comments received on this proposal, we are finalizing the rule as proposed. We are making some minor formatting changes to the regulation text to conform to the Office of Federal Register Document Drafting Handbook. See regulations text which appears at the end of this of final rule.
V. Other Decisions and Changes to the IPPS for Operating System

A. Changes to MS–DRGs Subject to Postacute Care Transfer Policy and MS–DRG Special Payments Policies (§ 412.4)

1. Background

Existing regulations at 42 CFR 412.4(a) define discharges under the IPPS as situations in which a patient is formally released from an acute care hospital or dies in the hospital. Section 412.4(b) defines acute care transfers, and § 412.4(c) defines postacute care transfers. Our policy set forth in § 412.4(f) provides that when a patient is transferred and his or her length of stay is less than the geometric mean length of stay for the MS–DRG to which the case is assigned, the transferring hospital is generally paid based on a graduated per diem rate for each day of stay, not to exceed the full MS–DRG payment that would have been made if the patient had been discharged without being transferred.

The per diem rate paid to a transferring hospital is calculated by dividing the full MS–DRG payment by the geometric mean length of stay for the MS–DRG. Based on an analysis that showed that the first day of hospitalization is the most expensive (60 FR 45804), our policy generally provides for payment that is twice the per diem amount for the first day, with each subsequent day paid at the per diem amount up to the full MS–DRG payment (§ 412.4(f)(1)). Transfer cases also are eligible for outlier payments. In general, the outlier threshold for transfer cases, as described in § 412.4(b), is equal to the fixed–loss outlier threshold for nontransfer cases (adjusted for geographic variations in costs), divided by the geometric mean length of stay for the MS–DRG, and multiplied by the length of stay for the case, plus 1 day.

We established the criteria set forth in § 412.4(d) for determining which DRGs qualify for postacute care transfer payments in the FY 2006 IPPS final rule (70 FR 47419 through 47420). The determination of whether a DRG is subject to the postacute care transfer policy was initially based on the Medicare Version 23.0 GROUPER (FY 2006) and data from the FY 2004 MedPAR file. However, if a DRG did not exist in Version 23.0 or a DRG included in Version 23.0 is revised, we use the current version of the Medicare GROUPER and the most recent complete year of MedPAR data to determine if the DRG is subject to the postacute care transfer policy. Specifically, if the MS–DRG’s total number of discharges to postacute care equals or exceeds the 55th percentile for all MS–DRGs and the proportion of short–stay discharges to postacute care to total discharges in the MS–DRG exceeds the 55th percentile for all MS–DRGs, CMS will apply the postacute care transfer policy to that MS–DRG and to any other MS–DRG that shares the same base MS–DRG. The statute at subparagraph 1886(d)(5)(J)(i) to the Act directs CMS to identify MS–DRGs based on a high volume of discharges to postacute care facilities and a disproportionate use of postacute care services. As discussed in the FY 2006 IPPS final rule (70 FR 47416), we determined that the 55th percentile is an appropriate level at which to establish these thresholds. In that same final rule (70 FR 47419), we stated that we will not revise the list of DRGs subject to the postacute care transfer policy annually unless we are making a change to a specific MS–DRG.

To account for MS–DRGs subject to the postacute care policy that exhibit exceptionally higher shares of costs very early in the hospital stay, § 412.4(f) also includes a special payment methodology. For these MS–DRGs, hospitals receive 50 percent of the full MS–DRG payment, plus the single per diem payment, for the first day of the stay, as well as a per diem payment for subsequent days (up to the full MS–DRG payment (§ 412.4(f)(1))). For an MS–DRG to qualify for the special payment methodology, the geometric mean length of stay must be greater than 4 days, and the average charges of 1–day discharge cases in the MS–DRG must be at least 50 percent of the average charges for all cases within the MS–DRG. MS–DRGs that are part of an MS–DRG severity level group will qualify under the MS–DRG special payment methodology policy if any one of the MS–DRGs that share that same base MS–DRG qualifies (§ 412.4(f)(6)). Prior to the enactment of the Bipartisan Budget Act of 2018 (Pub. L. 115–123), under section 1886(d)(5)(J)(i) of the Act, a discharge was deemed a “qualified discharge” if the individual was discharged to one of the following postacute care settings:

• A hospital or hospital unit that is not a subsection (d) hospital.
• A skilled nursing facility.
• Related home health services provided by a home health agency provided within a timeframe established by the Secretary (beginning within 3 days after the date of discharge).

Section 53109 of the Bipartisan Budget Act of 2018 amended section 1886(d)(5)(J)(ii) of the Act to also include discharges to hospice care provided by a hospice program as a qualified discharge, effective for discharges occurring on or after October 1, 2018. In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41394), we made conforming amendments to § 412.4(c) of the regulation to include discharges to hospice care occurring on or after October 1, 2018, as qualified discharges.

We specified that hospital bills with a Patient Discharge Status code of 50 (Discharged/Transferred to Hospice—Routine or Continuous Home Care) or 51 (Discharged/Transferred to Hospice, General Inpatient Care or Inpatient Respite) are subject to the postacute care transfer policy in accordance with this statutory amendment.

2. Changes for FY 2024

As discussed in section II.C. of the preamble of the proposed rule and this final rule, based on our analysis of FY 2022 MedPAR claims data, we proposed to make changes to a number of MS–DRGs, effective for FY 2024. Specifically, we proposed to do the following:

• Reassign procedures describing thrombolysis when performed for pulmonary embolism from MS–DRGs 166, 167, and 168 (Other Respiratory System O.R. Procedures with MCC, with CC, and without CC/MCC, respectively) to proposed new MS–DRG 173 (Ultrasound Accelerated and Other Thrombolysis for Pulmonary Embolism).
• Create proposed new base MS–DRG 212 (Concomitant Aortic and Mitral Valve Procedures) for cases reporting an aortic valve repair or replacement procedure and a mitral valve repair or replacement procedure in addition to another concomitant cardiovascular procedure.

• Reassign the procedures involving cardiac defibrillator implants by deleting MS–DRGs 222 through 227 (Cardiac Defibrillator Implant, with and without Cardiac Catheterization, with and without AMI/HF/shock, with and without MCC, respectively) and create proposed new MS–DRG 275 (Cardiac Defibrillator Implant with Cardiac Catheterization and MCC) for cases reporting cardiac defibrillator implant with cardiac catheterization with MCC, and proposed new MS–DRGs 276 and 277 (Cardiac Defibrillator Implant with MCC and without MCC, respectively) for cases reporting cardiac defibrillator implant.

• Reassign procedures describing thrombolysis performed on peripheral vascular structures from MS–DRGs 252, 253, and 254 (Other Vascular Procedures with MCC, with CC, and without CC/MCC, respectively) to proposed new MS–DRG 278 (Ultrasound Accelerated and Other...
Thrombolysis of Peripheral Vascular Structures with MCC) and proposed new MS–DRG 279 (Ultrasound Accelerated and Other Thrombolysis of Peripheral Vascular Structures without MCC).

- Create proposed MS–DRGs 323 and 324 (Coronary Intravascular Lithotripsy with Intraluminal Device with MCC and without MCC, respectively) for cases reporting C–IVL with placement of an intraluminal device, create proposed new base MS–DRG 325 (Coronary Intravascular Lithotripsy without Intraluminal Device) for cases reporting C–IVL without the placement of an intraluminal device, delete MS–DRG 246 (Percutaneous Cardiovascular Procedures with Drug-Eluting Stent with MCC or +4 Arteries or Stents), MS–DRG 247 (Percutaneous Cardiovascular Procedures with Drug-Eluting Stent without MCC), MS–DRG 248 (Percutaneous Cardiovascular Procedures with Non-Drug-Eluting Stent with MCC or +4 Arteries or Stents) and MS–DRG 249 (Percutaneous Cardiovascular Procedures with Non-Drug-Eluting Stent without MCC) and create proposed new MS–DRG 321 (Percutaneous Cardiovascular Procedures with Intraluminal Device with MCC or +4 Arteries/Intraluminal Devices) and proposed new MS–DRG 322 (Percutaneous Cardiovascular Procedures with Intraluminal Device without MCC).

- Delete MS–DRGs 338 through 340 (Appendectomy with Complicated Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively) and MS–DRGs 341 through 343 (Appendectomy without Complicated Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively) describing appendectomy with and without a complicated principal diagnosis and create proposed new MS–DRGs 397, 398, and 399 (Appendix Procedures with MCC, with CC, and without CC/MCC, respectively).

As discussed in the proposed rule, in light of the proposed changes to the MS–DRGs for FY 2024, according to the regulations under § 412.4(d), we evaluated the MS–DRGs using the general postacute care transfer policy criteria and data from the December 2022 update of the FY 2022 MedPAR file. If an MS–DRG qualified for the postacute care transfer policy, we also evaluated that MS–DRG under the special payment methodology criteria according to regulations at § 412.4(f)(6).

We continue to believe it is appropriate to assess new MS–DRGs and reassess revised MS–DRGs when proposing reassignment of procedure codes or diagnosis codes that would result in material changes to an MS–DRG. We noted that CMS proposed the reassignment of procedure codes from MS–DRGs 252, 253, and 254 to proposed new MS–DRGs 278 and 279, we do not consider the proposed revision to constitute a material change that would warrant reevaluation of the postacute care status of MS–DRGs 252, 253, and 254. We noted this base MS–DRG (MS–DRG 252) does not currently qualify for postacute care transfer status. CMS may further evaluate what degree of shifts in cases for existing MS–DRGs warrant consideration for the review of postacute care transfer and special payment policy status in future rulemaking.

We stated that proposed new MS–DRG 276 would qualify to be included on the list of MS–DRGs that are subject to the postacute care transfer policy. As described in the regulations at § 412.4(d)(3)(ii)(D), MS–DRGs that share the same base MS–DRG will all qualify under the postacute care transfer policy if any one of the MS–DRGs that share that same base MS–DRG qualifies. We therefore proposed to add proposed new MS–DRGs 276 and 277 to the list of MS–DRGs that are subject to the postacute care transfer policy. MS–DRGs 166, 167, and 168 are currently subject to the postacute care transfer policy. As a result of our review, these MS–DRGs, as proposed to be revised, would continue to qualify to be included on the list of MS–DRGs that are subject to the postacute care transfer policy. We note that, as discussed in section II. of this final rule, we are finalizing these proposed changes to the MS–DRGs.

CMS has updated its analysis using the March 2023 update of the FY 2022 MedPAR file, and has developed the following chart which sets forth the analysis of the postacute care transfer policy criteria completed for this final rule with respect to each of these new or revised MS–DRGs. We note that this chart is updated from the MedPAR file used in the proposed rule (the December 2022 update of the FY 2022 MedPAR file).
## LIST OF NEW OR REVISED MS–DRGs SUBJECT TO REVIEW OF POSTACUTE CARE TRANSFER POLICY STATUS FOR FY 2024

<table>
<thead>
<tr>
<th>New or Revised MS–DRG</th>
<th>MS–DRG Title</th>
<th>Total Cases</th>
<th>Postacute Care Transfers (55th percentile: 1.045)</th>
<th>Short-Stay Postacute Care Transfers</th>
<th>Percent of Short-Stay Postacute Care Transfers to all Cases (55th percentile: 10.5086%)</th>
<th>FY 2023 Postacute Transfer Policy Status</th>
<th>Postacute Care Transfer Policy Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>166</td>
<td>OTHER RESPIRATORY SYSTEM O.R. PROCEDURES WITH MCC</td>
<td>7,802</td>
<td>4,100</td>
<td>1,301</td>
<td>16.68%</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>167</td>
<td>OTHER RESPIRATORY SYSTEM O.R. PROCEDURES WITH CC</td>
<td>4,226</td>
<td>1,362</td>
<td>253</td>
<td>5.99%</td>
<td>Yes</td>
<td>Yes**</td>
</tr>
<tr>
<td>168</td>
<td>OTHER RESPIRATORY SYSTEM O.R. PROCEDURES WITHOUT CC/MCC</td>
<td>1,464</td>
<td>204</td>
<td>0</td>
<td>0.00%</td>
<td>Yes</td>
<td>Yes**</td>
</tr>
<tr>
<td>173</td>
<td>ULTRASOUND ACCELERATED AND OTHER THROMBOLYSIS WITH PRINCIPAL DIAGNOSIS PULMONARY EMBOLISM</td>
<td>1,542</td>
<td>555</td>
<td>30</td>
<td>1.95%</td>
<td>New</td>
<td>No</td>
</tr>
<tr>
<td>212</td>
<td>CONCOMITANT AORTIC AND MITRAL VALVE PROCEduRES</td>
<td>900</td>
<td>621</td>
<td>238</td>
<td>26.44%</td>
<td>New</td>
<td>No</td>
</tr>
<tr>
<td>275</td>
<td>CARDIAC DEFIBRILLATOR IMPLANT WITH CARDIAC CATHETERIZATION AND MCC</td>
<td>3,488</td>
<td>1,635</td>
<td>291</td>
<td>8.34%</td>
<td>New</td>
<td>No</td>
</tr>
<tr>
<td>276</td>
<td>CARDIAC DEFIBRILLATOR IMPLANT WITH MCC</td>
<td>3,848</td>
<td>1,781</td>
<td>411</td>
<td>10.68%</td>
<td>New</td>
<td>Yes</td>
</tr>
<tr>
<td>277</td>
<td>CARDIAC DEFIBRILLATOR IMPLANT WITHOUT MCC</td>
<td>517</td>
<td>280</td>
<td>65</td>
<td>12.57%</td>
<td>New</td>
<td>Yes**</td>
</tr>
<tr>
<td>278</td>
<td>ULTRASOUND ACCELERATED AND OTHER THROMBLYSIS OF PERIPHERAL VASCULAR STRUCTURES WITH MCC</td>
<td>4,141</td>
<td>911</td>
<td>143</td>
<td>3.45%</td>
<td>New</td>
<td>No</td>
</tr>
<tr>
<td>279</td>
<td>ULTRASOUND ACCELERATED AND OTHER THROMBOLYSIS OF PERIPHERAL VASCULAR STRUCTURES WITHOUT MCC</td>
<td>977</td>
<td>298</td>
<td>42</td>
<td>4.30%</td>
<td>New</td>
<td>No</td>
</tr>
<tr>
<td>321</td>
<td>PERCUTANEOUS CARDIOVASCULAR PROCEDURES WITH INTRALUMINAL DEVICE WITH MCC OR 4+ ARTERIES/INTRALUMINAL DEVICES</td>
<td>40,910</td>
<td>11,829</td>
<td>1,073</td>
<td>2.62%</td>
<td>New</td>
<td>No</td>
</tr>
<tr>
<td>322</td>
<td>PERCUTANEOUS CARDIOVASCULAR PROCEDURES WITH INTRALUMINAL DEVICE WITHOUT MCC</td>
<td>56,912</td>
<td>5,335</td>
<td>566</td>
<td>0.99%</td>
<td>New</td>
<td>No</td>
</tr>
<tr>
<td>323</td>
<td>CORONARY INTRAVASCULAR LITHOTRIPSY WITH INTRALUMINAL DEVICE WITH MCC</td>
<td>2,109</td>
<td>713</td>
<td>107</td>
<td>5.07%</td>
<td>New</td>
<td>No</td>
</tr>
<tr>
<td>324</td>
<td>CORONARY INTRAVASCULAR LITHOTRIPSY WITH INTRALUMINAL DEVICE WITHOUT MCC</td>
<td>2,188</td>
<td>283</td>
<td>19</td>
<td>0.87%</td>
<td>New</td>
<td>No</td>
</tr>
<tr>
<td>325</td>
<td>CORONARY INTRAVASCULAR LITHOTRIPSY WITHOUT INTRALUMINAL DEVICE</td>
<td>410</td>
<td>64</td>
<td>3</td>
<td>0.73%</td>
<td>New</td>
<td>No</td>
</tr>
<tr>
<td>397</td>
<td>APPENDIX PROCEDURES WITH MCC</td>
<td>1,186</td>
<td>402</td>
<td>45</td>
<td>3.79%</td>
<td>New</td>
<td>No</td>
</tr>
<tr>
<td>398</td>
<td>APPENDIX PROCEDURES WITH CC</td>
<td>3,838</td>
<td>701</td>
<td>112</td>
<td>2.92%</td>
<td>New</td>
<td>No</td>
</tr>
<tr>
<td>399</td>
<td>APPENDIX PROCEDURES WITHOUT CC/MCC</td>
<td>3,094</td>
<td>223</td>
<td>0</td>
<td>0.00%</td>
<td>New</td>
<td>No</td>
</tr>
</tbody>
</table>

* Indicates a current postacute care transfer policy criterion that the MS–DRG did not meet.  
** As described in the policy at 42 CFR 412.4(i)(3)(ii)(D), MS–DRGs that share the same base MS–DRG will all qualify under the postacute care transfer policy if any one of the MS–DRGs that share that same base MS–DRG qualifies.
MS–DRGs subject to the postacute care transfer policy for FY 2024 to determine if any of these MS–DRGs would also be subject to the special payment methodology policy for FY 2024. Based on our analysis of proposed changes to MS–DRGs included in the proposed rule, we determined that proposed new MS–DRG 276 meets the criteria for the MS–DRG special payment methodology. As described in the regulations at §412.4(f)(6)(iv), MS–DRGs that share the same base MS–DRG will all qualify under the MS–DRG special payment policy if any one of the MS–DRGs that share that same base MS–DRG qualifies. Therefore, we proposed that proposed new MS–DRG 277 also would be subject to the MS–DRG special payment methodology, effective for FY 2024. For this FY 2024 final rule, we updated this analysis using data from the March 2023 update of the FY 2022 MedPAR file.

<table>
<thead>
<tr>
<th>New or Revised MS–DRG</th>
<th>Geometric Mean Length of Stay</th>
<th>Average Charges of 1-Day Discharges</th>
<th>FY 2023 Special Payment Policy Status</th>
<th>Special Payment Policy Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>166</td>
<td>8.385896</td>
<td>$39,911</td>
<td>$84,881</td>
<td>No</td>
</tr>
<tr>
<td>167</td>
<td>3.460597</td>
<td>$47,236</td>
<td>$41,988</td>
<td>No</td>
</tr>
<tr>
<td>168</td>
<td>1.837013</td>
<td>$45,547</td>
<td>$32,813</td>
<td>No</td>
</tr>
<tr>
<td>276</td>
<td>6.296602</td>
<td>$182,624</td>
<td>$132.97</td>
<td>2</td>
</tr>
<tr>
<td>277</td>
<td>3.326289</td>
<td>$186,031</td>
<td>$106.85</td>
<td>5</td>
</tr>
</tbody>
</table>

* As described in the policy at 42 CFR 412.4(f)(6)(iv), MS–DRGs that share the same base MS–DRG will all qualify under the special payment transfer policy if any one of the MS–DRGs that share that same base MS–DRG qualifies.

Comment: One commenter, citing extremely high early stay costs, expressed concern about adding MS–DRGs 276 and 277 to the post-acute transfer policy unless the full cost of the cardiac defibrillator and the cost to implant is covered. The commenter stated that payment to the transferring hospital for these MS–DRGs would be twice the per-diem amount the first day and with each subsequent day paid at the per-diem amount up until the full MS–DRG payment.

Response: The commenter described the payment methodology under the post-acute care transfer policy. However, CMS proposed that these MS–DRGs also be added to the list of MS–DRGs subject to the special payment policy. Under this policy, the transferring hospital would receive 50 percent of the full MS–DRG payment, plus a single per diem payment, for the first day of the stay, as well as a per diem payment for subsequent days (up to the full MS–DRG payment). The intent of the special payment policy is specifically to address MS–DRGs with high initial costs, such as the one-time cost of surgically implanted devices. We believe the proposed addition of MS–DRGs 276 and 277 to the special payment policy adequately addresses the specific concerns expressed by the commenter.

After consideration of public comments we received, we are finalizing our proposal to add new MS–DRGs 276 and 277 to the list of MS–DRGs that are subject to the postacute care transfer policy and the MS–DRG special payment methodology for FY 2024.

The postacute care transfer and special payment policy status of these MS–DRGs is reflected in Table 5 associated with this final rule, which is listed in section VI. of the Addendum to this final rule and available on the CMS website.

B. Changes in the Inpatient Hospital Update for FY 2024 (§ 412.64(d))

1. FY 2024 Inpatient Hospital Update

In accordance with section 1886(b)(3)(B)(i) of the Act, each year we update the national standardized amount for inpatient hospital operating costs by a factor called the “applicable percentage increase.” For FY 2024, we stated in the proposed rule that we are setting the applicable percentage increase by applying the adjustments listed in this section in the same sequence as we did for FY 2023. (We note that section 1886(b)(3)(B)(xii) of the Act required an additional reduction each year only for FY’s 2010 through 2019.) Specifically, consistent with section 1886(b)(3)(B) of the Act, as amended by sections 3401(a) and 10319(a) of the Affordable Care Act, we stated that we are setting the applicable percentage increase by applying the following adjustments in the following sequence. The applicable percentage increase under the IPPS for FY 2024 is equal to the rate-of-increase in the hospital market basket for IPPS hospitals in all areas, subject to all of the following:

- A reduction of one-quarter of the applicable percentage increase (prior to the application of other statutory adjustments; also referred to as the market basket update or rate-of-increase (with no adjustments)) for hospitals that fail to submit quality information under rules established by the Secretary in accordance with section 1886(b)(3)(B)(viii) of the Act.
- A reduction of three-quarters of the applicable percentage increase (prior to the application of other statutory adjustments; also referred to as the market basket update or rate-of-increase (with no adjustments)) for hospitals not considered to be meaningful EHR users in accordance with section 1886(b)(3)(B)(ix) of the Act.
- An adjustment based on changes in economy-wide multifactor productivity (MFP) (the productivity adjustment). Section 1886(b)(3)(B)(xi) of the Act, as added by section 3401(a) of the
Affordable Care Act, states that application of the productivity adjustment may result in the applicable percentage increase being less than zero. We note, in compliance with section 404 of the MMA, in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45194 through 45204), we replaced the 2014-based IPPS operating and capital market baskets with the rebased and revised 2018-based IPPS operating and capital market baskets beginning in FY 2022. We proposed to base the FY 2024 market basket update used to determine the applicable percentage increase for the IPPS on IHS Global Inc.’s (IGI’s) fourth quarter 2022 forecast of the 2018-based IPPS market basket rate-of-increase with historical data through third quarter 2022, which was estimated to be 3.0 percent. We also proposed that if more recent data subsequently became available (for example, a more recent estimate of the market basket update), we would use such data, if appropriate, to determine the FY 2024 market basket update in the final rule.

Comment: Several commenters stated that hospitals continue to face significant inflationary pressures. Commenters specifically expressed concern that the proposed hospital IPPS payment update for FY 2024 does not adequately consider the cost growth that hospitals have faced over the last few years, noting cost increases related to workforce (including contract labor), drugs, medical supplies, personal protective equipment (PPE), and capital investment. The commenters stated that the significant inflation over the past several years has not been fully captured by the IPPS payment updates during the COVID years.

Several commenters requested that CMS use its exceptions and adjustments authority to increase the FY 2024 IPPS hospital market basket update higher than proposed. One commenter urged CMS to review the hospital cost data and the margin on Medicare reimbursement and readjust payment rates based on the new baseline cost of care that has resulted from supply shocks and labor shortages. A few commenters suggested CMS apply a market basket increase of at least 3.8 percent, reflecting MedPAC’s March 2023 Report to Congress recommending a one-percent increase to the FY 2024 market basket and requested that CMS consider a FY 2024 market basket that more accurately represents inflation on hospital expenses. One commenter supported a higher market basket payment update under the IPPS to reflect the effects of inflation on hospital operating costs and endorsed an annual inflation-based payment update based on the full Medicare Economic Index (MEI) while one commenter requested CMS use its authority to increase the FY 2024 IPPS hospital payment update to at least 5 percent.

Many commenters stated that they have experienced their lowest margins in decades and anticipated additional worse operating losses in at least the next two fiscal years. One commenter stated that in its March 2023 report to Congress, MedPAC reported overall Medicare hospital margins were negative 6.2 percent in 2021 (after accounting for temporary COVID–19 relief funds). Moreover, the commenter stated that MedPAC also projected hospitals’ Medicare margins in 2023 to be lower than in 2021, driven in part by the growth in hospitals’ input costs, which exceeded the forecasts CMS used to set Medicare payment rate updates, and in part by the expected expiration of Federal relief funds and temporary Medicare payment increases related to the public health emergency. The commenter stated that MedPAC also projects that even “relatively efficient” hospitals’ Medicare margins will fall below break-even in 2023.

One commenter stated that while the 2022 market basket increase of 4 percent provided some relief from the additional costs of COVID–19 for 2023, the proposed FY 2024 market basket update would not carry these elevated costs associated with COVID–19 forward into 2024 even though the commenter stated that additional costs of COVID–19 still exist. The commenter noted that hospitals are now faced with rebuilding long-term funds, paying longer-term inflated costs of supplies and equipment and high wages due to the lack of staffing that still exists as a result of COVID burn out. Several commenters stated that this year’s proposed update is inadequate and requested that CMS address the market basket update in the final rule.

One commenter noted that CMS proposed “that if more recent data subsequently become available, we would use such data, if appropriate, to determine the FY 2024 market basket update in the final rule.” The commenter urged CMS to use more recent data that include the recent inflationary increases in cost; and in the absence of such data urged CMS to consider an alternative approach to better align the market basket increases with increases in cost to treat patients. A few commenters appreciated the proposed payment increase but also stated alignment with other commenters that the proposed increase is inadequate given inflation and labor and supply pressures that hospitals, particularly rural hospitals, have been facing and continue to face. Many commenters had significant concerns that the proposed IPPS payment update does not adequately reflect labor costs. Commenters stated the significant increases in labor expenses over the last couple of years have been largely driven by increased utilization of contract staff (due to workforce shortages) and growth in employee salaries. One commenter cited their own analysis of payroll data to calculate the increased cost of labor, which it stated was significantly higher than the annual increases for compensation prices that CMS finalized over the last several years. Given what they stated was the significant difference between the increased cost of labor versus what CMS estimates using the ECIs, the commenters stated they had significant concerns that CMS’ data source for estimating the cost of labor does not capture current market dynamics and underestimates the actual cost of healthcare labor. Many commenters cited analysis that nursing staff shortages are predicted to continue for the next several years. Specifically, commenters raised concerns about the CMS use of the Bureau of Labor Statistics’ Employment Cost Index (ECI) in the IPPS market basket. Commenters stated they believe the BLS’ ECI does not accurately reflect the shift from salaried employees to contract labor since the ECI does not collect data for contract staff, and thus does not capture extraordinary labor cost growth associated with hospitals’ increased reliance on clinicians contracted through staffing agencies in response to supply shortages. One commenter highlighted their belief that a closely related measure—the Employer Costs for Employee Compensation (ECEC)—may be a better and more timely data source for growth in hospital compensation costs compared to the ECI. The commenter claimed that all else equal, if the hospital ECEC growth had matched the hospital ECEC growth, this would have meant an additional three percentage point increase in the IPPS hospital market basket over the 2019 to 2022 time period. Several commenters recommended that CMS use its exceptions and adjustments authority to adopt new or supplemental data sources such as commercial databases on hospital payrolls, to ensure labor costs are adequately reflected in the FY 2024 payment update in the final rule.

One commenter also requested CMS identify more accurate data inputs and use its existing authority to calculate the
final rule “base” (before additional adjustments) market basket update with data that better reflect the rapidly increasing input prices facing hospitals. The commenter suggested that CMS should consider using the average growth rate in allowable Medicare costs per risk adjusted discharge for IPPS hospitals between FY 2019 and FY 2021 to calculate the FY 2024 final rule market basket update rather than using the growth in the ECI as the price proxy for compensation in the IPPS market basket. The commenter requested using Medicare cost report data from Worksheets D–1, Part II, Lines 48 and 49 and S–3, Part 1, Column 13 to determine the Medicare costs per discharge. The commenter stated that this growth rate will capture the increased cost of contract labor, unlike the ECI. Based on their analysis of Medicare cost report data, they found that this methodology would yield an adjusted market basket update of 4.39 percent for FY 2024 rather than the 2.8 percent net market basket update proposed by CMS. The commenter also stated that Medicare margins have declined over the last 20 years and believes this is due to persistently inadequate Medicare market basket updates. They further stated that hospitals’ financial situations are so precarious that MedPAC recommended to Congress that it increase IPPS and OPPS payments over current law to preserve access.

Response: We acknowledge commenters’ concerns regarding recent trends in inflation. Section 1886(b)(3)(B)(iii) of the Act states the Secretary shall update IPPS payments based on a market basket percentage increase based on an index of appropriately weighted indicators of changes in wages and prices that are representative of the mix of goods and services included in such inpatient hospital services. The 2018-based IPPS market basket is a fixed-weight, Laspeyres-type price index that measures the change in price, over time, of the same mix of goods and services purchased by hospitals in the base period. As we discussed in response to similar comments in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49053), the IPPS market basket increase would reflect the prospective price pressures described by the commenters as increasing during a high inflation period (such as faster wage price growth or higher energy prices), but would inherently not reflect other factors that might increase the level of costs, such as the use of labor or any shifts between contract and staff nurses (which would be reflected in the Medicare cost report data). We disagree that costs as reported on the Medicare cost report are a suitable data source for determining the trend in compensation prices for the market basket update. The Medicare cost report data also reflects factors that are beyond those that impact wage or price growth. For instance, overall Medicare costs per discharge as reported by hospitals on the Medicare cost report would also reflect observed IPPS case-mix (and associated higher payments to hospitals), which from 2019 to 2022 has increased faster than in prior years and would be associated with the use of more skilled care and medical/drug supplies needed to provide these services.

Regarding commenters’ request that CMS consider other methods and data sources to calculate the final rule market basket update, we believe that the 2018-based IPPS market basket continues to appropriately reflect IPPS cost structures and we believe the price proxies used (such as those from BLS that reflect wage and benefit price growth) are an appropriate representation of price changes for the inputs used by hospitals in providing services. As discussed in appendix B of this final rule, in its March report, MedPAC recommended that the Congress update the inpatient hospital rate by the amount specified in current law plus one percent. Given that we believe the 2018-based IPPS market basket reflects an index of appropriately weighted indicators of changes in wages and prices that are representative of the mix of goods and services included in such inpatient hospital services and the percentage change of the 2018-based IPPS market basket is based on IGI’s more recent forecast reflecting the prospective price pressures for FY 2024, we do not believe it would be appropriate to use our exceptions and adjustment authority to create a separate payment that would have the effect of modifying the current law update. The ECI (published by the BLS) measures the change in the hourly labor cost to employers, independent of the influence of employment shifts among occupations and industry categories. We acknowledge that the ECI measures only reflect price changes and does not capture changes in quantity or mix of labor such as increased utilization of contract staff as noted by the commenter. We believe that the ECI for hospital workers is accurately reflecting the price change associated with the labor used to provide hospital care and appropriately does not reflect other factors that might affect labor costs (such as a shift in occupations that may occur due to increases in case-mix). The ECEC data cited by the commenter is limited in its usefulness in the market basket because it reflects averages across all employees (similar to another BLS wage series, Average Hourly Earnings, available from the Current Employment Statistics program). According to BLS documentation, the ECEC reflects average compensation in the economy at a point in time, including both changes in compensation and changes in employment. The wage measure in the market basket should not reflect changes in employment to be consistent with the statute that the market basket percentage increase be based on an index of appropriately weighted indicators of changes in wages and prices. The ECEC, an indicator that also includes changes in employment, is not as appropriate to use as the ECI in the IPPS market basket. For these reasons, we believe the ECI continues to be an appropriate measure to use in the IPPS market basket. We note that the Medicare cost report data shows contract labor hours account for about 4 percent of total compensation hours (reflecting employed and contract labor staff) for IPPS hospitals in 2021. Therefore, while we acknowledge that the ECI measures only reflect price changes for employed staff, we believe that the ECI for hospital workers is accurately reflecting the price change associated with the labor used to provide hospital care (as employed workers’ hours account for 96 percent of hospital compensation hours). Therefore, we believe it continues to be an appropriate measure to use in the IPPS market basket. We also note that when developing its forecast for the ECI for hospital workers, IGI considers overall labor market conditions (including rise in contract labor employment due to tight labor market conditions) as well as trends in contract labor wages, which both have an impact on wage pressures for workers employed directly by the hospital.

We would highlight that the market basket percentage increase is a forecast of the price pressures that are expected to be faced in 2024. As projected by IGI (a nationally recognized economic and financial forecasting firm with which CMS contracts to forecast the price proxies of the market baskets) and upward price pressures are expected to slow in FY 2024 relative to FY 2022 and FY 2023. As is our general practice, we proposed that if more recent data became available, we would use such data, if appropriate, to derive the final FY 2024 IPPS market basket update for the final rule. We appreciate the commenter’s concern regarding inflationary pressure and the request to use more recent data to determine the
FY 2024 IPPS market basket update. For this final rule, we are incorporating a projection of the 2018-based IPPS market basket that is based on the most recent forecast from IHS Global Inc. For this final rule, based on the more recent IGI second quarter 2023 forecast with historical data through the first quarter of 2023, the projected 2018-based IPPS market basket increase factor for FY 2024 is 3.3 percent, which is 0.3 percentage point higher than the projected FY 2024 market basket increase factor in the proposed rule based on IGI’s fourth quarter 2022 forecast, and reflects a projected increase in compensation prices of 4.3 percent. We would note that the 10-year historical average (2013–2022) growth rate of the 2018-based IPPS market basket is 2.5 percent reflecting a 10-year historical average (2013–2022) growth rate compensation prices equal to 2.4 percent.

Comment: One commenter recommended that CMS reevaluate the data sources it uses for rebasing its market basket and calculating the annual market basket update, including labor costs. They strongly encouraged CMS to adopt new or supplemental data sources in future rulemaking that more accurately reflect the costs to hospitals, such as through use of more real time data from the hospital community. They stated that they believe that the current market basket does not account for the higher costs of contract labor, which has become more common in hospitals in an era of clinical labor shortages. One commenter stated that CMS rebase the market baskets more frequently and at least every three years to ensure the market basket reflects the appropriate mix of services provided to Medicare beneficiaries.

Response: CMS appreciates the commenter’s request to rebase more frequently. Section 404 of Public Law 108–173 states the Secretary shall establish a frequency for revising the cost weights of the IPPS market basket more frequently than once every 5 years. As published in the FY 2006 IPPS final rule (70 FR 47403), we established a rebasing frequency of every four years, in part because the cost weights obtained from the Medicare cost reports do not indicate much of a change in the weights from year to year. The most recent rebasing of the IPPS market basket was for the FY 2022 payment update and reflected a base year of 2018 costs. Given recent concerns raised by commenters regarding changes in costs as a result of recent inflation and the COVID–19 pandemic, we also have been regularly monitoring the Medicare cost report data to assess whether a rebasing is technically appropriate, and we will continue to do so in the future. Based on a preliminary analysis of the Medicare cost report data for IPPS hospitals for 2021 that became available for this final rule, the IPPS compensation cost weight for 2021 is estimated to be about 1 percentage point lower than the 2018-based IPPS market basket compensation cost weight of 53.0 percent, and reflects a combined decrease in the salary and benefit cost weights that is larger than the increase in the contract labor cost weight. The major cost categories that preliminarily show an increase in the cost weight over this period are pharmaceuticals (proxied by the PPI—Commodity—Special Index—Pharmaceuticals for human use, prescription) and home office contract labor compensation costs (which would be proxied by the ECI for Professional and Related workers). We plan to review the 2021 Medicare cost report data in more detail as well as 2022 Medicare cost report data as soon as complete information is available and evaluate these data for future rebasing of the IPPS market basket.

Regarding the comment about using new or supplemental data sources in future rulemaking, we believe the Medicare cost report data is the most complete, timely and relevant data source for the development of the cost weights. We also welcome feedback on alternative publicly available data sources that could be used to evaluate the cost conditions facing hospitals and the subsequent derivation of the market basket cost weights.

Comment: Several commenters, including many associations, urged CMS to use its special exceptions and adjustments authority under section 1886(d)(5)(i)(I) of the Act to implement a retrospective adjustment for FY 2024 to account for the difference between the market basket update that was implemented for FY 2022 and what the currently projected market basket is for FY 2022. Commenters stated this is, in large part, because the market basket is a time-lagged estimate that cannot fully account for unexpected changes that occur, such as historic inflation and increased labor and supply costs. They stated this is exactly what occurred at the end of the calendar year 2021 into calendar year 2022, which resulted in a large forecast error in the FY 2022 market basket update. Commenters stated the IPPS reimbursement has failed to keep pace with inflation as costs for drugs, supplies, insurance premiums, and labor have increased. They recommended that CMS utilize the FY 2024 update to include a retrospective adjustment and methodology change to make the FY 2022 actual 5.7 percent market basket percentage increase to be more reflective of the costs hospitals face, including the true impact of inflation. One commenter also urged CMS to reflect the forecast error in FY 2022 as well as an additional 1.0 percent on top of the proposed FY 2024 market basket increase. One commenter requested that CMS use its special exceptions and adjustment authority to make a one-time retrospective adjustment of 10–15 percent to the market basket to account for what it stated hospitals should have received in 2022 when accounting for inflation, while another commenter stated that at a minimum, CMS should address what it stated was the gross underpayment that occurred in FY 2022 via a one-time adjustment of at least 3 percent.

One commenter urged CMS to use its exceptions and adjustments authority to apply a one-time adjustment to course correct for its significantly lower estimates of costs for FY 2021 through 2023. The commenter stated that because the annual payment update builds on the prior year’s payment rate, failing to correct what it described as CMS’ gross underestimation of the payment updates during the pandemic will further perpetuate inaccuracies in the payment rate moving forward, resulting in a permanent cut to hospital payments. Similarly, another commenter stated that in three of the last five years for which they had data to compare, they observed that the forecasted hospital market basket data used to set IPPS payment rates has fallen short of actual market basket data. They estimated, based on actual expenditure data from the 2023 Medicare Trustees Report, that in 2021 hospitals may have lost nearly $1 billion and in 2022 hospitals may have lost more than $4 billion as a result of the forecast error assumptions.

Several commenters suggested CMS should consider implementing a market basket forecast error adjustment within the methodology for calculating the annual IPPS payment update. One commenter stated that this change would reduce the risk hospitals face when rapid inflation causes CMS’s forecasted hospital market basket percentage increase to be out of alignment with the actual hospital market basket percentage increase. One commenter stated that CMS should do so if forecast error is more than 0.5 percentage point while another commenter recommended a threshold of 0.5 percentage points. One commenter stated that unlike other industries, hospitals cannot simply raise prices to
bring in additional revenue, but rather can only bring in additional revenue by renegotiating higher payments with employers and health insurers, something that is increasingly difficult in the current fiscal environment. They stated that if hospitals are unable to grow revenue from other sources, they must make cuts to important service lines just like any other business to remain financially viable.

One commenter also noted that for both the SNF PPS and the capital IPPS, CMS is making the forecast error adjustments based on a threshold level of difference between the update and the market basket that was adopted through rulemaking in prior years.

Response: While the projected IPPS hospital market basket updates for FY 2021 and FY 2022 were under forecast (actual increases less forecasted increases were positive), this was largely due to unanticipated inflationary and labor market pressures as the economy emerged from the COVID–19 PHE. Analysis of the forecast error of the IPPS market basket over a longer period of time shows the forecast error has been both positive and negative. For example, the 10-year cumulative forecast error showed a negative forecast error (that is, forecasted increases were greater than actual increases) of 1.1 percentage points (2013 through 2022). In addition, for each year from 2012 through 2020, the forecasted FY hospital market basket update implemented in the final rule was higher than the actual hospital market basket update when historical data were available, with 7 out of the 9 years having a negative forecast error greater than 0.5 percentage point (in absolute terms). Only considering the forecast error for years when the final hospital market basket update was lower than the actual market basket update does not consider the numerous years that providers benefited from the forecast error. Relatedly, the capital PPS and SNF PPS forecast error adjustments were adopted very early in both payment systems and, unlike what commenters are requesting here for the IPPS, forecast errors over many years have been consistently addressed within each of the Capital PPS and SNF PPS.

For these reasons, we do not believe it is appropriate to include adjustments to the market basket update for future years based on the difference between the actual and forecasted market basket increase in prior years. We thank the commenters for their comments. After consideration of the comments received and consistent with our proposal, we are finalizing to use more recent data to determine the FY 2024 market basket update for the final rule. Specifically, based on more recent data available, we determined final applicable percentage increases to the standardized amount for FY 2024, as specified in the table that appears later in this section.

In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51689 through 51692), we finalized our methodology for calculating and applying the productivity adjustment. As we explained in that rule, section 1886(b)(3)(B)(xi)(II) of the Act, as added by section 3401(a) of the Affordable Care Act, defines this productivity adjustment as equal to the 10-year moving average of changes in annual economy-wide, private nonfarm business MFP (as projected by the Secretary for the 10-year period ending with the applicable fiscal year, year, cost reporting period, or other annual period). The U.S. Department of Labor’s Bureau of Labor Statistics (BLS) publishes the official measures of private nonfarm business productivity for the U.S. economy. We note that previously the productivity measure referenced in section 1886(b)(3)(B)(xi)(II) was published by BLS as private nonfarm business multifactor productivity. Beginning with the November 18, 2021, release of productivity data, BLS replaced the term multifactor productivity (MFP) with total factor productivity (TFP). BLS noted that this is a change in terminology only and will not affect the data or methodology. As a result of the BLS name change, the productivity measure referenced in section 1886(b)(3)(B)(xi)(II) is now published by BLS as private nonfarm business total factor productivity. However, as mentioned, the data and methods are unchanged. Please see www.bls.gov for the BLS historical published TFP data. A complete description of IGI’s TFP projection methodology is available on the CMS website at https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareProgramRatesStats/MarketBasketResearch. In addition, we note that beginning with the FY 2022 IPPS/LTCH PPS final rule, we refer to this adjustment as the productivity adjustment rather than the MFP adjustment to more closely track the statutory language in section 1886(b)(3)(B)(xi)(III) of the Act. We note that the adjustment continues to rely on the same underlying data and methodology.

For FY 2024, we proposed a productivity adjustment of 0.2 percent. Similar to the proposed market basket update, for the proposed rule, the estimate of the proposed FY 2024 productivity adjustment was based on IGI’s second quarter 2022 forecast. As noted previously, we proposed that if more recent data subsequently became available, we would use such data, if appropriate, to determine the FY 2024 productivity adjustment for the final rule.

Comment: Several commenters expressed concern about the application of the productivity adjustment, stating that the PHE has had unimaginable impacts on hospital productivity. They state that even before the PHE, OACT indicated that hospital productivity will be less than the general economy-wide productivity, which is the measure that is required by law to be used to derive the productivity adjustment. Given that CMS is required by statute to implement a productivity adjustment to the market basket update, commenters asked the agency to work with Congress to permanently eliminate what they stated is an unjustified reduction to hospital payments. Further, they asked CMS to use its “exceptions and adjustments” authority to remove the productivity adjustment for any fiscal year that was covered under PHE determination (i.e., 2020 (0.4 percent), 2021 (0.0 percent), 2022 (0.7 percent), and 2023 (0.3 percent) from the calculation of the market basket update for FY 2024 and any year thereafter. A few commenters expressed concerns about the proposed productivity adjustment given the extreme and uncertain circumstances under which hospitals and health systems are currently operating and until CMS to eliminate the productivity cut for FY 2024.

Response: While we appreciate the commenters’ concerns, section 1886(b)(3)(B)(xi) of the Act requires the application of the productivity adjustment. As required by statute, the FY 2024 productivity adjustment is derived based on the 10-year moving average growth in economy-wide productivity for the period ending FY 2024.

We thank the commenters for their comments. After consideration of the comments received and consistent with our proposal, we are finalizing as proposed to use more recent data to determine the FY 2024 productivity adjustment for the final rule. Based on more recent data available for this FY 2024 IPPS/LTCH PPS final rule (that is, IGI’s second quarter 2023 forecast of the 2018-based IPPS market basket rate-of-increase with historical data through the first quarter of 2023), we estimate that the FY 2024 market basket update used to determine the applicable percentage increase for the IPPS is 3.3 percent. Based on more
recent data available for this FY 2024 IPPS/LTCH PPS final rule (that is, IGI’s second quarter 2023 forecast of the productivity adjustment), the current estimate of the productivity adjustment for FY 2024 is 0.2 percentage point.

As previously discussed, based on the more recent data available, for this final rule, we have determined four final applicable percentage increases to the standardized amount for FY 2024. For FY 2024, depending on whether a hospital submits quality data under the rules established in accordance with section 1886(b)(3)(B)(viii) of the Act (hereafter referred to as a hospital that submits quality data) and is a meaningful EHR user; and is a meaningful EHR user), there are four possible applicable percentage increases that can be applied to the standardized amount, as specified in this table.

**FY 2024 APPLICABLE PERCENTAGE INCREASES FOR THE IPPS**

<table>
<thead>
<tr>
<th>FY 2024</th>
<th>Hospital Submitted Quality Data and is a Meaningful EHR User</th>
<th>Hospital Submitted Quality Data and is NOT a Meaningful EHR User</th>
<th>Hospital Did NOT Submit Quality Data and is a Meaningful EHR User</th>
<th>Hospital Did NOT Submit Quality Data and is NOT a Meaningful EHR User</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Market Basket Rate-of-Increase</strong></td>
<td>3.3</td>
<td>3.3</td>
<td>3.3</td>
<td>3.3</td>
</tr>
<tr>
<td><strong>Adjustment for Failure to Submit Quality Data under Section 1886(b)(3)(B)(viii) of the Act</strong></td>
<td>0.0</td>
<td>0.0</td>
<td>-0.825</td>
<td>-0.825</td>
</tr>
<tr>
<td><strong>Adjustment for Failure to be a Meaningful EHR User under Section 1886(b)(3)(B)(ix) of the Act</strong></td>
<td>0.0</td>
<td>-2.475</td>
<td>0.0</td>
<td>-2.475</td>
</tr>
<tr>
<td><strong>Productivity Adjustment under Section 1886(b)(3)(B)(xii) of the Act</strong></td>
<td>-0.2</td>
<td>-0.2</td>
<td>-0.2</td>
<td>-0.2</td>
</tr>
<tr>
<td><strong>Applicable Percentage Increase Applied to Standardized Amount</strong></td>
<td>3.1</td>
<td>0.625</td>
<td>2.275</td>
<td>-0.2</td>
</tr>
</tbody>
</table>

In the FY 2020 IPPS/LTCH PPS final rule (84 FR 42344), we revised our regulations at 42 CFR 412.64(d) to reflect the current law for the update for FY 2020 and subsequent fiscal years. Specifically, in accordance with section 1886(b)(3)(B) of the Act, we added paragraph (d)(1)(viii) to § 412.64 to set forth the applicable percentage increase to the operating standardized amount for FY 2020 and subsequent fiscal years as the percentage increase in the market basket index, subject to the reductions specified under § 412.64(d)(2) for a hospital that does not submit quality data and § 412.64(d)(3) for a hospital that is not a meaningful EHR user, less a productivity adjustment. (As previously noted, section 1886(b)(3)(B)(iv) of the Act requires an additional reduction each year only for FY’s 2010 through 2019.)

Section 1886(b)(3)(B)(iv) of the Act provides that the applicable percentage increase to the hospital-specific rates for SCHs and MDHs equals the applicable percentage increase set forth in section 1886(b)(3)(B)(i) of the Act (that is, the same update factor as for all other hospitals subject to the IPPS). Therefore, the update to the hospital-specific rates for SCHs and MDHs also is subject to section 1886(b)(3)(B)(i) of the Act, as amended by sections 3401(a) and 10319(a) of the Affordable Care Act. As discussed in section V.F. of the preamble of this final rule, section 4102 of the Consolidated Appropriations Act, 2023 (Public Law 117–328), enacted on December 29, 2022, extended the MDH program through FY 2024 (that is, for discharges occurring on or before September 30, 2024). We refer readers to section V.F. of the preamble of this final rule for further discussion of the MDH program.

For FY 2024, we proposed the following updates to the hospital-specific rates applicable to SCHs and MDHs: A proposed update of 2.8 percent for a hospital that submits quality data and is a meaningful EHR user; a proposed update of 0.55 percent for a hospital that submits quality data and is not a meaningful EHR user; a proposed update of 2.05 percent for a hospital that fails to submit quality data and is a meaningful EHR user; and a proposed update of −0.2 percent for a hospital that fails to submit quality data and is not a meaningful EHR user.

We proposed that if more recent data subsequently became available (for example, a more recent estimate of the market basket update and the productivity adjustment), we would use such data, if appropriate, to determine the update in the final rule.

We did not receive any public comments on our proposed updates to hospital-specific rates applicable to SCHs and MDHs. The general comments we received on the proposed FY 2024 update (including the proposed market basket update and productivity adjustment) are discussed earlier in this section. For FY 2024, we are finalizing the proposal to determine the update to the hospital specific rates for SCHs and MDHs in this final rule using the more recent available data, as previously discussed.

For this final rule, based on more recent available data we are finalizing the following updates to the hospital specific rates applicable to SCHs and MDHs (the same update factor as for all other hospitals subject to the IPPS, consistent with the applicable percentage increases for the IPPS): An update of 3.1 percent for a hospital that submits quality data and is a meaningful EHR user; an update of 0.625 percent for a hospital that submits quality data and is not a meaningful EHR user; an update of 2.275 percent for a hospital that fails to submit quality data and is a meaningful EHR user; and an update of −0.2 percent for a hospital that fails to submit quality data and is not a meaningful EHR user.

2. **FY 2024 Puerto Rico Hospital Update**

Section 602 of Public Law 114–113 amended section 1886(n)(6)(B) of the Act to specify that subsection (d) Puerto Rico hospitals are eligible for incentive payments for the meaningful use of certified EHR technology, effective beginning FY 2016. In addition, section 1886(n)(6)(B) of the Act was amended to specify that the adjustments to the applicable percentage increase under section 1886(b)(3)(B)(ix) of the Act...
apply to subsection (d) Puerto Rico hospitals that are not meaningful EHR users, effective beginning FY 2022. Accordingly, for FY 2022, section 1886(b)(3)(B)(ix) of the Act in conjunction with section 602(d) of Public Law 114–113 requires that any subsection (d) Puerto Rico hospital that is not a meaningful EHR user as defined in section 1886(n)(3) of the Act and not subject to an exception under section 1886(b)(3)(B)(ix) of the Act will have “three-quarters” of the applicable percentage increase (prior to the application of other statutory adjustments), or three-quarters of the applicable market basket rate-of-increase, reduced by 33⅓ percent. The reduction to three-quarters of the applicable percentage increase for subsection (d) Puerto Rico hospitals that are not meaningful EHR users increases to 66⅔ percent for FY 2023, and, for FY 2024 and subsequent fiscal years, to 100 percent. (We note that section 1886(b)(3)(B)(viii) of the Act, which specifies the adjustment to the applicable percentage increase for “subsection (d)” hospitals that do not submit quality data under the rules established by the Secretary, is not applicable to hospitals located in Puerto Rico.) The regulations at 42 CFR 412.64(d)(3)(ii) reflect the current law for the update for subsection (d) Puerto Rico hospitals for FY 2022 and subsequent fiscal years. In the FY 2019 IPPS/LTCH PPS final rule, we finalized the payment reductions (83 FR 41674).

For FY 2024, consistent with section 1886(b)(3)(B) of the Act, as amended by section 602 of Public Law 114–113, we are setting the applicable percentage increase for Puerto Rico hospitals by applying the following adjustments in the following sequence. Specifically, the applicable percentage increase under the IPPS for Puerto Rico hospitals will be equal to the rate of-increase in the hospital market basket for IPPS hospitals in all areas, subject to a reduction of three-quarters of the applicable percentage increase (prior to the application of other statutory adjustments; also referred to as the market basket update or rate-of-increase (with no adjustments)) for Puerto Rico hospitals not considered to be meaningful EHR users in accordance with section 1886(b)(3)(B)(ix) of the Act, and then subject to the productivity adjustment at section 1886(b)(3)(B)(xi) of the Act. As noted previously, section 1886(b)(3)(B)(xii) of the Act states that application of the productivity adjustment may result in the applicable percentage increase being less than zero.

Based on IGI’s fourth quarter 2022 forecast of the 2018-based IPPS market basket update with historical data through third quarter 2022, in the FY 2024 IPPS/LTCH PPS proposed rule, in accordance with section 1886(b)(3)(B) of the Act, as discussed previously, for Puerto Rico hospitals we proposed a market basket update of 3.0 percent less a productivity adjustment of 0.2 percentage point. Therefore, for FY 2024, depending on whether a Puerto Rico hospital is a meaningful EHR user, we stated there would be two possible applicable percentage increases that could be applied to the standardized amount. Based on these data, we determined the following proposed applicable percentage increases to the standardized amount for FY 2024 for Puerto Rico hospitals:

- For a Puerto Rico hospital that is a meaningful EHR user, we proposed a FY 2024 applicable percentage increase to the operating standardized amount of 2.8 percent (that is, the FY 2024 estimate of the proposed market basket rate-of-increase of 3.0 percent less 0.2 percentage point for the proposed productivity adjustment).

- For a Puerto Rico hospital that is not a meaningful EHR user, an applicable percentage increase to the operating standardized amount of 0.55 percent (that is, the FY 2024 estimate of the proposed market basket rate-of-increase of 3.0 percent, less an adjustment of 2.25 percentage point (the proposed market basket rate-of-increase of 3.0 percent × 0.75 for failure to be a meaningful EHR user), and less 0.2 percentage point for the productivity adjustment).

As noted previously, we proposed that if more recent data subsequently became available, we would use such data, if appropriate, to determine the FY 2024 market basket update and the productivity adjustment for the FY 2024 IPPS/LTCH PPS final rule.

We did not receive any public comments on our proposed updates to the standardized amount for FY 2024 for Puerto Rico hospitals. The general comments we received on the proposed FY 2024 update (including the proposed market basket update and productivity adjustment) are discussed in greater detail earlier in this section. For FY 2024, we are finalizing the proposal to determine the update to the standardized amount for FY 2024 for Puerto Rico hospitals in this final rule using the more recent available data, as previously discussed.

As previously discussed in section V.A.1, based on more recent data available for this final rule (that is, IGI’s second quarter 2023 forecast of the 2018-based IPPS market basket rate-of-increase with historical data through the first quarter of 2023), we estimate that the FY 2024 market basket update used to determine the applicable percentage increase for the IPPS is 3.3 percent and the productivity adjustment is 0.2 percent. For FY 2024, depending on whether a Puerto Rico hospital is a meaningful EHR user, there are two possible applicable percentage increases that can be applied to the standardized amount. Based on these data, in accordance with section 1886(b)(3)(B) of the Act, we determined the following applicable percentage increases to the standardized amount for FY 2024 for Puerto Rico hospitals:

- For a Puerto Rico hospital that is a meaningful EHR user, an applicable percentage increase to the operating standardized amount of 3.1 percent (that is, the FY 2024 estimate of the market basket rate-of-increase of 3.3 percent less an adjustment of 0.2 percentage point for the productivity adjustment).

- For a Puerto Rico hospital that is not a meaningful EHR user, an applicable percentage increase to the operating standardized amount of 0.625 percent (that is, the FY 2024 estimate of the market basket rate-of-increase of 3.3 percent, less an adjustment of 2.475 percentage point (the market basket rate-of-increase of 3.3 percent × 0.75 for failure to be a meaningful EHR user), and less an adjustment of 0.2 percentage point for the productivity adjustment).
FY 2024 APPLICABLE PERCENTAGE INCREASES FOR PUERTO RICO HOSPITALS UNDER THE IPPS

<table>
<thead>
<tr>
<th>FY 2024</th>
<th>Hospital is a Meaningful EHR User</th>
<th>Hospital is NOT a Meaningful EHR User</th>
</tr>
</thead>
<tbody>
<tr>
<td>Market Basket Rate-of-Increase</td>
<td>3.3</td>
<td>3.3</td>
</tr>
<tr>
<td>Adjustment for Failure to be a Meaningful EHR User under Section 1886(b)(3)(B)(ix) of the Act</td>
<td>0.0</td>
<td>-2.475</td>
</tr>
<tr>
<td>Productivity Adjustment under Section 1886(b)(3)(B)(xi) of the Act</td>
<td>-0.2</td>
<td>-0.2</td>
</tr>
<tr>
<td>Applicable Percentage Increase Applied to Standardized Amount</td>
<td>3.1</td>
<td>0.625</td>
</tr>
</tbody>
</table>

C. Sole Community Hospitals (SCHs) (§ 412.92)

1. Background

Section 1886(d)(5)(D) of the Act provides special payment protections under the IPPS to sole community hospitals (SCHs). Section 1886(d)(5)(D)(iii) of the Act defines an SCH in part as a hospital that the Secretary determines is located more than 35 road miles from another hospital or that, by reason of factors such as isolated location, weather conditions, travel conditions, or absence of other like hospitals, is the sole source of inpatient hospital services reasonably available to Medicare beneficiaries. The regulations at 42 CFR 412.92 set forth the criteria that a hospital must meet to be classified as an SCH. For more information on SCHs, we refer readers to the FY 2009 IPPS/LTCH PPS final rule (74 FR 43894 through 43897).

In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41430), effective for SCH applications received on or after October 1, 2018, we modified the effective date of SCH classification from 30 days after the date of CMS’s written notification of approval to the date that the MAC receives the complete SCH application. As we explained in that final rule, section 401 of the Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act (BBRA) of 1999 (Pub. L. 106–113, Appendix F) amended section 1886(d)(8) of the Act to add paragraph (E) which authorizes reclassification of certain urban hospitals as rural if the hospital applies for such status and meets certain criteria. The effective date for rural reclassification status under section 1886(d)(8)(E) of the Act is set forth at 42 CFR 412.103(d)(1) as the filing date, which is the date CMS receives the reclassification application (§ 412.103(b)(3)). One way that an urban hospital can reclassify as rural under § 412.103 is if the hospital would qualify as a rural referral center (RRC) as set forth in § 412.96, or as an SCH as set forth in § 412.92, if the hospital were located in a rural area. A geographically urban hospital may simultaneously apply for reclassification as rural under § 412.103(a)(3) by meeting the criteria for SCH status (other than being located in a rural area), and apply to obtain SCH status under § 412.92 based on that acquired rural reclassification. However, as we explained in the FY 2019 final rule, the rural reclassification is effective as of the filing date, whereas under our policy at that time, the SCH status was effective 30 days after approval. In addition, while § 412.103(c) states that the CMS Regional Office will review the application and notify the hospital of its approval or disapproval of the request within 60 days of the filing date, the regulations do not set a timeframe by which CMS must decide on an SCH request. We stated that therefore, geographically urban hospitals that obtain rural reclassification under § 412.103 for the purposes of obtaining SCH status may face a payment disadvantage because, under the policy at that time, they are paid as rural until the SCH application is approved and the SCH classification and payment adjustment become effective 30 days after approval.

In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41430), to minimize the lag between the effective date of rural reclassification under § 412.103 and the effective date for SCH status, we revised our policy so that the effective date for SCH classification and for the payment adjustment would be the date that the MAC receives the complete SCH application, effective for SCH applications received on or after October 1, 2018, as reflected in § 412.92(b)(3)(i) and (iv). We stated that a complete application includes a request and all supporting documentation needed to demonstrate that the hospital meets criteria for SCH status as of the date of application. We also stated that for an application to be complete, all criteria must be met as of the date the MAC receives the SCH application. Further, we stated that for an application to be complete, all criteria must be met as of the date the MAC receives the SCH application. As we explained in the FY 2019 IPPS/LTCH PPS final rule, we believed that updating the regulations at § 412.92 to provide an effective date for SCH status that is consistent with the effective date for rural reclassification under § 412.103 would benefit hospitals by minimizing any payment disadvantage caused by the lag between the effective date of rural reclassification and the effective date of SCH status. We also stated that we believe that aligning the SCH effective date with the § 412.103 effective date supports agency efforts to reduce regulatory burden because it would provide for a more uniform policy.

In addition, we made parallel changes to the effective date for a Medicare dependent hospital (MDH) status determination under § 412.108(b)(4) such that for applications received on or after October 1, 2018, a determination of MDH status would be effective as of the date that the MAC receives the complete application, rather than the prior effective date of 30 days after the date the MAC provides written notification to the hospital. Similar to applications for SCH status, we stated that a complete application includes a request and all supporting documentation needed to demonstrate that the hospital meets criteria for MDH status as of the date of application. We further stated that for an application to be complete, all criteria must be met as of the date the MAC receives the MDH application. For example, a cost report must be settled at
the time of application for a hospital to use that cost report as one of the cost reports required in § 412.108(a)(1)(iv)(C).

We refer the reader to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41430) for further discussion of these changes to the effective dates of SCH and MDH status beginning with applications received on or after October 1, 2018.

As explained in the FY 2019 IPPS/LTCH PPS final rule, we specifically modified the effective date for SCH status for consistency with the effective date for rural reclassification in order to minimize any payment disadvantage caused by the lag between the effective date of rural reclassification and the effective date of SCH status for hospitals applying for both rural reclassification under § 412.103(a)(3) by meeting the criteria for SCH status (other than being located in a rural area), and applying to obtain SCH status under § 412.92 based on that acquired rural reclassification. As previously discussed, by meeting the criteria for SCH status (other than being located in a rural area), a hospital can qualify for rural reclassification per the regulations at § 412.103(a)(3), which then allows it to meet all the criteria for SCH status—including the rural requirement at § 412.92(a).

2. Change of Effective Date for SCH Status in the Case of a Merger

For some hospitals, eligibility for SCH classification may depend on the hospital’s merger with a nearby “like hospital” as defined in § 412.92(c)(2) and meeting other criteria at § 412.92(a). The merger allows the two hospitals involved to operate under a single provider agreement. The regulations at § 412.92(c)(2) define a like hospital as a nearby hospital that furnishes short-term acute care and whose total inpatient days attributable to units of the nearby hospital that provide a level of care characteristic of the level of care payable under the acute care hospital prospective payment system are greater than 8 percent of the similarly calculated total inpatient days of the hospital seeking SCH designation. In this scenario, prior to the merger, the applicant hospital was not eligible for SCH classification due to its proximity to a nearby like hospital. When the applicant hospital subsequently merges with the nearby like hospital, it is potentially eligible for SCH classification.

If an SCH application is approved, under current policy, the effective date of the SCH classification is the date the MAC receives the complete application. In situations where SCH classification is contingent on a merger, a hospital is not considered to have submitted a complete application to the MAC unless the application contains the notification that the merger was approved. We have heard concerns that in these situations the time difference between the effective date of the hospital merger, which may be retroactive, and the effective date of the SCH status, which is based on the date the complete application is received by the MAC, including the merger approval, may be problematic for hospitals because they cannot benefit from the special payment protections that are afforded to SCHs until the effective date of the SCH classification. We have also heard concerns that different merger requirements across states could potentially introduce an uneven playing field for providers seeking SCH classification because the timeframe for a merger approval could vary from one state or region to another.

Therefore, in an effort to address these concerns and in light of our continuing experience in applying these policies, in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27007), we proposed to revise § 412.92(b)(2) so that for SCH applications received on or after October 1, 2023, where (1) a hospital’s SCH approval is dependent on its merger with another nearby hospital, and (2) the hospital meets the other SCH classification requirements, the SCH classification and payment adjustment would be effective as of the effective date of the approved merger if the MAC receives the complete application within 90 days of CMS’ written notification to the hospital of the approval of the merger. We explained that this 90-day timeframe would provide sufficient time for a hospital to submit a complete SCH application, while addressing the concerns, as previously discussed, that merger approval may be delayed for reasons beyond a hospital’s control. Under this proposal, if the MAC does not receive the complete application within 90 days of CMS’ notification of the merger approval, SCH classification would be effective as of the day the MAC receives the complete application, including documentation of the merger approval, and in accordance with the regulations at § 412.92(b)(2)(i).

In connection with this proposal, we also proposed to change the effective date of rural reclassification for a hospital qualifying for rural reclassification under § 412.103(a)(3) by meeting the criteria for SCH status (other than being located in a rural area), and also applying to obtain SCH status under § 412.92, where eligibility for SCH classification depends on a hospital merger. Specifically, we proposed that in these circumstances, and subject to the requirements set forth at proposed new § 412.92(b)(2)(vi), the effective date for rural reclassification would be as of the effective date set forth in proposed new § 412.92(b)(2)(vi).

We note that we did not propose to modify any SCH classification requirements or what constitutes a “complete application”. The SCH application must, therefore, include all required documentation that would constitute a “complete application” including documentation of the hospital’s merger approval. We also note that we did not propose any change to the effective date for an SCH application that does not involve a merger.

In the proposed rule, we stated that we continue to believe that our current approach in determining the effective date for SCH classification where the SCH application is contingent on a hospital merger is reasonable. However, in light of our experience in applying these policies and the concerns we have heard about the timeframes involved, we believe that our proposed revision to the effective date for hospitals applying for SCH classification where that classification is dependent on a merger is also reasonable and appropriate and would benefit hospitals by minimizing the time difference between the effective date of the merger and the effective date of SCH status. We noted that we did not propose a parallel change to the effective date policy for MDH classification because eligibility for MDH classification is not dependent on proximity to nearby providers and, therefore, MDH classification would generally not be contingent on a merger taking place. However, we sought comment on the need for such a proposal, which we would consider for future rulemaking as appropriate.

*Comment: Commenters supported CMS’ proposed change to the effective date for SCH status for SCH applications received on or after October 1, 2023, in the case of a merger where eligibility for SCH classification depends on a hospital merger. Commenters also supported the proposed conforming change to the effective date of rural classification.*

327 42 CFR 412.92(c)(2): Like hospital means a hospital furnishing short-term, acute care, Effective with cost reporting periods beginning on or after October 1, 2002, for purposes of a hospital seeking sole community hospital designation, CMS will not consider the nearby hospital to be a like hospital if the total inpatient days attributable to units of the nearby hospital that provides a level of care characteristic of the level of care payable under the acute care hospital inpatient prospective payment system are less than or equal to 8 percent of the similarly calculated total inpatient days of the hospital seeking sole community hospital designation.
pends administrative appeal. We believe that following our usual approach and adopting the new effective date policies for SCH and rural reclassification applications where SCH eligibility is dependent on a hospital merger that are received on or after October 1, 2023 will allow for the most equitable application among all IPPS providers seeking to qualify for SCH classification and rural reclassification (as applicable). For these reasons, we are finalizing, without modification, that our proposed changes to the SCH and rural reclassification effective dates will apply prospectively for applications received on or after October 1, 2023.

Response: Several commenters requested that CMS clarify its current policy definition of a "complete application" for cases contingent on a merger.

Response: As stated in the FY 2024 IPPS/LTC/PS proposed rule (88 FR 27000), we did not propose to modify any SCH classification requirements or what constitutes a "complete application". We refer the commenters to the Chapter 28 of the Provider Reimbursement Manual (PRM), section 2810. B. (https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/p151_28.zip), for a list of documentation that must be included with its request for SCH classification. In addition to the documentation list in the PRM, for an SCH application where eligibility for SCH classification is dependent on a hospital merger, that documentation must include confirmation that the merger has been approved by CMS (for example, a CMS tie-in notice recognizing the two CCNs as merged). We note that we intend to update the list of required documentation in the PRM to include documentation indicating that the merger has been approved by CMS for SCH classification requests that are dependent on a hospital merger.

After consideration of the public comments we received, we are finalizing our policies as proposed, without modification. Specifically, we are finalizing our proposal to revise §412.92 by adding a new paragraph (b)(2)(vi) to specify that for applications received on or after October 1, 2023, where eligibility for SCH classification is dependent on a merger, the effective date of the SCH classification will be as of the effective date of the approved merger if the MAC receives the complete application within 90 days of CMS' written notification of the merger approval. SCH classification will be effective as of the date the MAC receives the complete application in accordance with the regulations at §412.92(b)(2)(i). We are also finalizing our proposal to make conforming changes to the existing regulations at §412.92(b)(ii) by adding an exception referencing paragraph §412.92(b)(2)(vi) to the language describing the effective date for applications received on or after October 1, 2018 at §412.92(b)(2)(i), and by revising and streamlining the language at §412.92(b)(2)(ii)(C) and (b)(2)(iv) to reference §412.92(b)(2)(i) as the effective date policy in effect for applications received on or after October 1, 2018. In addition, we are finalizing our proposed technical correction to paragraph (b)(1)(v) by revising the word "forward" to "subsequent".

We are also finalizing our proposal to make a conforming change to the regulations at §412.103(d) by modifying the effective date of rural reclassification for a hospital qualifying for rural reclassification under §412.103(a)(3) by meeting the criteria for SCH status (other than being located in a rural area), and also applying to obtain SCH status under §412.92 where eligibility for SCH classification depends on a hospital merger. We are finalizing our proposed amendment to §412.103(d)(1) and the proposed addition of new §412.103(d)(3) to provide that, subject to the hospital meeting the requirements set forth at §412.92(b)(2)(vi), the effective date for rural reclassification for such hospital will be as of the effective date determined under §412.92(b)(2)(vi).

D. Rural Referral Centers (RRCs) Annual Updates to Case-Mix Index (CMI) and Discharge Criteria (§412.96)

Under the authority of section 1886(d)(5)(C)(i) of the Act, the regulations at §412.96 set forth the criteria that a hospital must meet in order to qualify under the IPPS as a rural referral center (RRC). RRCs receive special treatment under both the DSH payment adjustment and the criteria for geographic reclassification.

Section 402 of Public Law 108–173 raised the DSH payment adjustment for RRCs such that they are not subject to the 12-percent cap on DSH payments that is applicable to other rural hospitals. RRCs also are not subject to the proximity criteria when applying for geographic reclassification. In addition, RRCs have the requirement that a hospital's average hourly wage must exceed, by a certain
percentage, the average hourly wage of the labor market area in which the hospital is located.

Section 4202(b) of Public Law 105–33 states, in part, that any hospital classified as an RRC by the Secretary for FY 1991 shall be classified as such an RRC for FY 1998 and each subsequent fiscal year. In the August 29, 1997, IPPS final rule with comment period (62 FR 45999), we reinstated RRC status for all hospitals that lost that status due to triennial review or MGCRB reclassification. However, we did not reinstate the status of hospitals that lost RRC status because they were now urban for all purposes because of the OMB designation of their geographic area as urban. Subsequently, in the August 1, 2000 IPPS final rule (65 FR 47089), we indicated that we were revisiting that decision. Specifically, we stated that we will permit hospitals that previously qualified as an RRC and lost their status due to OMB redesignation of the county in which they are located from rural to urban, to be reinstated as an RRC. Otherwise, a hospital seeking RRC status must satisfy all of the other applicable criteria. We use the definitions of “urban” and “rural” specified in subpart D of 42 CFR part 412. One of the criteria under which a hospital may qualify as an RRC is to have 275 or more beds available for use (§412.96(b)(1)(ii)). A rural hospital that does not meet the bed size requirement can qualify as an RRC if the hospital meets two mandatory prerequisites (a minimum case-mix index (CMI) and a minimum number of discharges), and at least one of three optional criteria (relating to specialty composition of medical staff, source of inpatients, or referral volume). (We refer readers to §412.96(c)(1) through (5) and the September 30, 1988, Federal Register (53 FR 38513) for additional discussion.) With respect to the two mandatory prerequisites, a hospital may be classified as an RRC if the hospital's—

- CMI is at least equal to the lower of the median CMI for urban hospitals in its census region, excluding hospitals with approved teaching programs, or the median CMI for all urban hospitals nationally; and
- Number of discharges is at least 5,000 per year, or, if fewer, the median number of discharges for urban hospitals in the census region in which the hospital is located. The number of discharges criterion for an osteopathic hospital is at least 3,000 discharges per year, as specified in section 1886(d)(5)(C)(i) of the Act.

In the FY 2022 final rule (86 FR 45217), in light of the COVID–19 PHE, we amended the regulations at §412.96(b)(1) to provide for the use of the best available data rather than the latest available data in calculating the national and regional CMI criteria. We also amended the regulations at §412.96(c)(1) to indicate that the individual hospital’s CMI value for discharges during the same Federal fiscal year used to compute the national and regional CMI values is used for purposes of determining whether a hospital qualifies for RRC classification. We also amended the regulations §412.96(i)(1) and (2), which describe the methodology for calculating the number of discharges criteria, to provide for the use of the best available data rather than the latest available or most recent data when calculating the regional discharges for RRC classification.

1. Case-Mix Index (CMI)

Section 412.96(c)(1) provides that CMS establish updated national and regional CMI values in each year’s annual notice of prospective payment rates for purposes of determining RRC status. The methodology we used to determine the national and regional CMI values is set forth in the regulations at §412.96(c)(1)(ii). The national median CMI value for FY 2024 is based on the CMI values of all urban hospitals nationwide, and the regional median CMI values for FY 2024 are based on the CMI values of all urban hospitals within each census region, excluding those hospitals with approved teaching programs that is, those hospitals that train residents in an approved GME program as provided in §413.75. These values are based on discharges occurring during FY 2022 (October 1, 2021 through September 30, 2022), and include bills posted to CMS’ records through March 2023. Because this is the latest available data, we believe that it is the best available data for use in calculating the national and regional median CMI values and is consistent with our proposal to use the FY 2022 MedPAR claims data for FY 2024 ratsetting.

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27009), we proposed that, in addition to meeting other criteria, if rural hospitals with fewer than 275 beds are to qualify for initial RRC status for cost reporting periods beginning on or after October 1, 2023, they must have a CMI value for FY 2022 that is at least—

- 1.8067 (national—all urban); or
- The median CMI value (not transfer-adjusted) for urban hospitals (excluding hospitals with approved teaching programs as identified in §413.75) calculated by CMS for the census region in which the hospital is located.

The proposed median CMI values by region were set forth in the table in the proposed rule (88 FR 27010). We stated in the proposed rule that we intended to update the proposed CMI values in the FY 2024 final rule to reflect the updated FY 2022 MedPAR file, which will contain data from additional bills received through March 2023.

Comment: Commenters supported our proposal to use FY 2022 data to calculate the national and regional median CMI values for FY 2024.

Response: We appreciate the commenters’ support.

Therefore, based on the best available data (FY 2022 bills received through March 2023), in addition to meeting other criteria, if rural hospitals with fewer than 275 beds are to qualify for initial RRC status for cost reporting periods beginning on or after October 1, 2023, they must have a CMI value for FY 2022 that is at least:

- 1.80655 (national—all urban); or
- The median CMI value (not transfer-adjusted) for urban hospitals (excluding hospitals with approved teaching programs as identified in §413.75) calculated by CMS for the census region in which the hospital is located.

The final CMI values by region are set forth in the following table.

<table>
<thead>
<tr>
<th>Region</th>
<th>CMI Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>National</td>
<td>1.80655</td>
</tr>
<tr>
<td>Urban</td>
<td>1.80655</td>
</tr>
</tbody>
</table>

Fiscal year FY 2023 includes the period beginning on or after October 1, 2022, and ending March 31, 2023.
A hospital seeking to qualify as an RRC should obtain its hospital-specific CMI value (not transfer-adjusted) from its MAC. Data are available on the Provider Statistical and Reimbursement (PS&R) System. In keeping with our policy on discharges, the CMI values are computed based on all Medicare patient discharges subject to the IPPS MS–DRG-based payment.

3. Discharges

Section 412.96(c)(2)(i) provides that CMS set forth the national and regional numbers of discharges criteria in each year's annual notice of prospective payment rates for purposes of determining RRC status. As specified in section 1886(d)(5)(C)(ii) of the Act, the national standard is set at 5,000 discharges. In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27010), for FY 2024, we proposed to update the regional standards based on discharges for urban hospitals’ cost reporting periods that began during FY 2021 (that is, October 1, 2020, through September 30, 2021). Because this is the latest available cost reporting data, we believe that it is the best available data for use in calculating the proposed median number of discharges by region and is consistent with our data proposal to use cost report data from cost reporting periods beginning during FY 2021 for FY 2024 rate setting.

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27010), we proposed that, in addition to meeting other criteria, a hospital, if it is to qualify for initial RRC status for cost reporting periods beginning on or after October 1, 2023, must have, as the number of discharges for its cost reporting period that began during FY 2021, at least—

- 5,000 (3,000 for an osteopathic hospital); or
- If less, the median number of discharges for urban hospitals in the census region in which the hospital is located. (We refer readers to the table set forth in the FY 2023 IPPS/LTCH PPS proposed rule at 88 FR 27010).

In the proposed rule, we stated that we intended to update to update these numbers in the FY 2024 final rule based on the latest available cost report data.

Comment: Commenters supported our proposal to use FY 2021 data to calculate median number of discharges by region for FY 2024.

Response: We appreciate the commenters’ support.

Therefore, based on the best available discharge data at this time, that is, for cost reporting periods that began during FY 2021, the final median number of discharges for urban hospitals by census region are set forth in the following table.

<table>
<thead>
<tr>
<th>Region</th>
<th>Proposed Number of Discharges</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. New England (CT, ME, MA, NH, RI, VT)</td>
<td>8,497</td>
</tr>
<tr>
<td>2. Middle Atlantic (PA, NJ, NY)</td>
<td>9,251</td>
</tr>
<tr>
<td>3. East North Central (IL, IN, MI, OH, WI)</td>
<td>7,798</td>
</tr>
<tr>
<td>4. West North Central (IA, KS, MN, MO, NE, ND, SD)</td>
<td>6,678</td>
</tr>
<tr>
<td>5. South Atlantic (DE, DC, FL, GA, MD, NC, SC, VA, WV)</td>
<td>10,125</td>
</tr>
<tr>
<td>6. East South Central (AL, KY, MS, TN)</td>
<td>8,672</td>
</tr>
<tr>
<td>7. West South Central (AR, LA, OK, TX)</td>
<td>5,831</td>
</tr>
<tr>
<td>8. Mountain (AZ, CO, ID, MT, NV, NM, UT, WY)</td>
<td>8,031</td>
</tr>
<tr>
<td>9. Pacific (AK, CA, HI, OR, WA)</td>
<td>8,455</td>
</tr>
</tbody>
</table>

We note that because the median number of discharges for hospitals in each census region is greater than the national standard of 5,000 discharges, under this final rule, 5,000 discharges is the minimum criterion for all hospitals, except for osteopathic hospitals for which the minimum criterion is 3,000 discharges.

E. Payment Adjustment for Low-Volume Hospitals (§ 412.101)

Section 1886(d)(12) of the Act provides for an additional payment to each qualifying low-volume hospital under the IPPS beginning in FY 2005. The low-volume hospital payment adjustment is implemented in the regulations at 42 CFR 412.101. The additional payment adjustment to a low-volume hospital provided for under section 1886(d)(12) of the Act is in
addition to any payment calculated under section 1886 of the Act. Therefore, the additional payment adjustment is based on the per discharge amount paid to the qualifying hospital under section 1886 of the Act. In other words, the low-volume hospital payment adjustment is based on total per discharge payments made under section 1886 of the Act, including capital, DSH, IME, and outlier payments. For SCFs and MDHs, the low-volume hospital payment adjustment is based in part on either the Federal rate or the hospital-specific rate, whichever results in a greater operating IPPS payment.

1. Recent Legislation

As discussed in the FY 2019 IPPS/LTCH PPS final rule, beginning with FY 2023, the low-volume hospital qualifying criteria and payment adjustment were set to revert to the statutory requirements that were in effect prior to FY 2011 (87 FR 49060). Subsequent legislation extended, for FYs 2023 and 2024, the temporary changes to the low-volume hospital qualifying criteria and payment adjustment originally provided for by section 50204 of the Bipartisan Budget Act of 2018 for FYs 2019 through 2022 as follows:


We discuss the extension of these temporary changes for FY 2023 and FY 2024 in greater detail in this section of this rule and in the FY 2024 IPPS/LTCH proposed rule (88 FR 27010 through 27011). Beginning in FY 2025, the low-volume hospital definition and payment adjustment methodology will revert back to the statutory requirements that were in effect prior to the amendments made by the Affordable Care Act, which were extended and modified through subsequent legislation.

2. Extension of the Temporary Changes to the Low-Volume Hospital Definition and Payment Adjustment Methodology for FYs 2023 and 2024

As discussed in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41398 through 41399), section 50204 of the Bipartisan Budget Act of 2018 (Pub. L. 115–123) modified the definition of a low-volume hospital and the methodology for calculating the payment adjustment for low-volume hospitals for FYs 2019 through 2022. Specifically, the qualifying criteria for low-volume hospitals under section 1886(d)(12)(C)(i) of the Act were amended to specify that, for FYs 2019 through 2022, a subsection (d) hospital qualifies as a low-volume hospital if it is more than 15 road miles from another subsection (d) hospital and has less than 3,800 total discharges during the fiscal year. Section 1886(d)(12)(D) of the Act was also amended to provide that, for discharges occurring in FYs 2019 through 2022, the Secretary determines the applicable percentage increase using a continuous, linear sliding scale ranging from an additional 25 percent payment adjustment for low-volume hospitals with 500 or fewer discharges to a zero percent additional payment for low-volume hospitals with more than 3,800 discharges in the fiscal year. Consistent with the requirements of section 1886(d)(12)(C)(i) and (D) of the Act, the term “discharge” for purposes of these provisions refers to total discharges, regardless of payer (that is, Medicare and non-Medicare discharges).

In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41399), to implement this requirement, we specified a continuous, linear sliding scale formula to determine the low-volume hospital payment adjustment for FYs 2019 through FY 2022 that is similar to the continuous, linear sliding scale formula used to determine the low-volume hospital payment adjustment originally established by the Affordable Care Act and implemented in the regulations at §412.101(c)(2)(ii) in the FY 2011 IPPS/LTCH PPS final rule (75 FR 50240 through 50241). Consistent with the statute, we provided that qualifying hospitals with 500 or fewer total discharges will receive a low-volume hospital payment adjustment of 25 percent. For qualifying hospitals with fewer than 3,800 discharges but more than 500 discharges, the low-volume payment adjustment is calculated by subtracting from 25 percent the proportion of payments associated with the discharges in excess of 500. As such, for qualifying hospitals with fewer than 3,800 total discharges but more than 500 total discharges, the low volume hospital payment adjustment for FYs 2019 through FY 2022 was calculated using the following formula:

\[
\text{Low-Volume Hospital Payment Adjustment} = 0.25 - \left[\frac{0.25}{3300}\right] \times (\text{number of total discharges} - 500) = \left(\frac{95}{330}\right) - (\text{number of total discharges}) \times \frac{1}{13,200}
\]

For this purpose, we specified that the “number of total discharges” is determined as total discharges, which includes Medicare and non-Medicare discharges during the fiscal year, based on the hospital’s most recently submitted cost report. The low-volume hospital payment adjustment for FYs 2019 through 2022 is set forth in the regulations at §412.101(c)(3).

As described previously, recent legislation extended through FY 2024 the definition of a low-volume hospital and the methodology for calculating the payment adjustment for low-volume hospitals in effect for FYs 2019 through FY 2022 pursuant to the Bipartisan Budget Act of 2018. Specifically, under sections 1886(d)(12)(C)(i) and 1886(d)(12)(C)(i)(III) of the Act, as amended, for FY 2023 and FY 2024, a low-volume hospital must be more than 15 road miles from another subsection (d) hospital and have less than 3,800 discharges during the fiscal year.

In addition, under section 1886(d)(12)(D)(ii) of the Act, as amended, for FY 2023 and FY 2024, the low-volume hospital payment adjustment is determined using a continuous linear sliding scale ranging from 25 percent for low-volume hospitals with 500 or fewer discharges to 0 percent for low-volume hospitals with greater than 3,800 discharges.
Based on the current law, beginning with FY 2025, the low-volume hospital qualifying criteria and payment adjustment will revert to the statutory requirements that were in effect prior to FY 2011. Section 1886(d)(12)(C)(i) of the Act, as amended, defines a low-volume hospital, for FYs 2005 through 2010 and FY 2025 and subsequent years, as a subsection (d) hospital that the Secretary determines is located more than 25 road miles from another subsection (d) hospital and that has less than 800 discharges during the fiscal year. As previously noted, section 1886(d)(12)(C)(ii) of the Act further stipulates that the term “discharge” means an inpatient acute care discharge of an individual, regardless of whether the individual is entitled to benefits under Medicare Part A (except with respect to FYs 2011 through 2018). Therefore, for FYs 2005 through 2010 and FY 2019 and subsequent years, the term “discharge” refers to total discharges, regardless of payer (that is, Medicare and non-Medicare discharges). Furthermore, as amended, section 1886(d)(12)(B) of the Act requires, for discharges occurring in FYs 2005 through 2010 and FY 2025 and subsequent years, that the Secretary determine an applicable percentage increase for these low-volume hospitals based on the “empirical relationship” between the standardized cost-per-case for such hospitals and the total number of discharges of such hospitals and the amount of the additional incremental costs (if any) that are associated with such number of discharges. The statute thus mandates that the Secretary develop an empirically justifiable adjustment based on the relationship between costs and discharges for these low-volume hospitals. Section 1886(d)(12)(B)(iii) of the Act limits the applicable percentage increase adjustment to no more than 25 percent. Based on an analysis we conducted for the FY 2005 IPPS final rule (69 FR 49099 through 49102), a 25-percent low-volume adjustment to all qualifying hospitals with less than 200 discharges was found to be most consistent with the statutory requirement to provide relief to low-volume hospitals where there is empirical evidence that higher incremental costs are associated with low numbers of total discharges. In the FY 2006 IPPS final rule (70 FR 47432 through 47434), we stated that multivariate analyses supported the existing low-volume adjustment implemented in FY 2005. Therefore, in order for a hospital to continue to qualify as a low-volume hospital on or after October 1, 2024, it must have fewer than 200 total discharges during the fiscal year and be located more than 25 road miles from the nearest “subsection (d)” hospital (see §412.101(b)(2)(i)). We refer readers to the FY 2023 IPPS/LTCH PPS final rule for further discussion.

As discussed in section V.E.4. of the preamble of this final rule, we proposed to make conforming changes to the regulation text in §412.101 to reflect the extension of the changes to the qualifying criteria and the payment adjustment methodology for low-volume hospitals through FY 2024.

Comment: Many commenters supported the extension of the changes to the low-volume hospital qualifying criteria and payment adjustment methodology for FYs 2023 and 2024.

Response: We appreciate the commenters sharing their support for the extension of the temporary changes to the low-volume hospital payment adjustment FYs 2023 and 2024. As discussed later in the section, we are finalizing our proposals without modification on the extension of the changes to the qualifying criteria and the payment adjustment methodology for low-volume hospitals through FY 2024, after consideration of the public comments.

3. Extension of the Temporary Changes to the Low-Volume Hospital Definition and Payment Adjustment Methodology for FY 2023

Prior to the enactment of Public Law 117–180, the temporary changes to the low-volume hospital qualifying criteria and payment adjustment originally provided by section 50204 of the Bipartisan Budget Act of 2018 were set to expire October 1, 2022. As previously discussed, these temporary changes to the low-volume hospital payment policy were extended through December 16, 2022 by section 101 of Public Law 117–180, through December 23, 2022 by section 101 of Public Law 117–229, and through September 30, 2024 by section 4101 of Public Law 117–328.

Based on an analysis we conducted for the FY 2005 IPPS final rule (69 FR 49099 through 49102), a 25-percent low-volume adjustment to all qualifying hospitals with less than 200 discharges was found to be most consistent with the statutory requirement to provide relief to low-volume hospitals where there is empirical evidence that higher incremental costs are associated with low numbers of total discharges. In the FY 2006 IPPS final rule (70 FR 47432 through 47434), we stated that multivariate analyses supported the existing low-volume adjustment implemented in FY 2005. Therefore, in order for a hospital to continue to qualify as a low-volume hospital on or after October 1, 2024, it must have fewer than 200 total discharges during the fiscal year and be located more than 25 road miles from the nearest “subsection (d)” hospital (see §412.101(b)(2)(i)). We refer readers to the FY 2023 IPPS/LTCH PPS final rule for further discussion.

As discussed in section V.E.4. of the preamble of this final rule, we proposed to make conforming changes to the regulation text in §412.101 to reflect the extension of the changes to the qualifying criteria and the payment adjustment methodology for low-volume hospitals through FY 2024.

Comment: Many commenters supported the extension of the changes to the low-volume hospital qualifying criteria and payment adjustment methodology for FYs 2023 and 2024.

Response: We appreciate the commenters sharing their support for the extension of the temporary changes to the low-volume hospital payment adjustment FYs 2023 and 2024. As discussed later in the section, we are finalizing our proposals without modification on the extension of the changes to the qualifying criteria and the payment adjustment methodology for low-volume hospitals through FY 2024, after consideration of the public comments.

3. Extension of the Temporary Changes to the Low-Volume Hospital Definition and Payment Adjustment Methodology for FY 2023

Prior to the enactment of Public Law 117–180, the temporary changes to the low-volume hospital qualifying criteria and payment adjustment originally provided by section 50204 of the Bipartisan Budget Act of 2018 were set to expire October 1, 2022. As previously discussed, these temporary changes to the low-volume hospital payment policy were extended through December 16, 2022 by section 101 of Public Law 117–180, through December 23, 2022 by section 101 of Public Law 117–229, and through September 30, 2024 by section 4101 of Public Law 117–328.

3. Extension of the Temporary Changes to the Low-Volume Hospital Definition and Payment Adjustment Methodology for FY 2023

Prior to the enactment of Public Law 117–180, the temporary changes to the low-volume hospital qualifying criteria and payment adjustment originally provided by section 50204 of the Bipartisan Budget Act of 2018 were set to expire October 1, 2022. As previously discussed, these temporary changes to the low-volume hospital payment policy were extended through December 16, 2022 by section 101 of Public Law 117–180, through December 23, 2022 by section 101 of Public Law 117–229, and through September 30, 2024 by section 4101 of Public Law 117–328. In accordance with section 1886(d)(12)(C)(i) of the Act, as amended, for FY 2023 a low-volume hospital must be more than 15 road miles from another subsection (d) hospital and must have less than 3,800 discharges during the fiscal year.

We addressed the extension provided by section 101 of the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (Pub. L. 117–180) for the portion of FY 2023 beginning on October 1, 2022, and ending on December 16, 2022 (in other words, occurring before December 17, 2022) in Change Request 12970 (Transmittal 117400), issued December 9, 2022. For additional information on this extension, please refer to the transmittal https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Transmittals/r11740otn.

We subsequently addressed the additional extensions of these provisions for FY 2023, specifically, through December 23, 2022, as provided by section 101 of the Further Continuing Appropriations and Extensions Act, 2023 (Pub. L. 117–229) and through September 30, 2023, as provided by section 4101 of the CAA 2023 (Pub. L. 117–328) in Change Request 13103 (Transmittal 11878), issued February 23, 2023. For additional information on this extension, please refer to the transmittal https://www.cms.gov/files/document/r11878otn.pdf.

We proposed to make conforming changes to the regulations text in §412.101 to codify these extensions for...
FY 2023 as discussed in section V.E.4. of the preamble of this final rule.

**Comment:** Many commenters supported the extension of the definition and payment of the low-volume hospital payment adjustment for FY 2023. A commenter urged CMS to expeditiously process claims and provide instructions to MACs for extensions, especially in instances when extensions are made retroactively. The commenter indicated seamless transition of these payments are crucial for rural providers.

**Response:** We appreciate the commenters sharing their support for legislative action of the extension. As we have said in the past, we will make every effort to implement any extension of the low-volume payment policy as expeditiously as possible.

After consideration of the public comments we received regarding the temporary changes to the qualifying criteria and the payment adjustment methodology for low-volume hospitals through FY 2023, we are finalizing our proposal without modification for the FY 2023 extensions.

4. Payment Adjustment for FY 2024 and Conforming Changes to Regulations

As discussed earlier, section 4101 of the CAA 2023 extended through FY 2024 the modified definition of a low-volume hospital and the methodology for calculating the payment adjustment for low-volume hospitals through FY 2023. Specifically, under section 1886(d)(12)(C)(ii) of the Act, as amended, for FYs 2019 through 2024, a subsection (d) hospital qualifies as a low-volume hospital if it is more than 15 road miles from another subsection (d) hospital and has less than 3,800 total discharges during the fiscal year. Under section 1886(d)(12)(D) of the Act, as amended, for discharges occurring in FYs 2019 through 2024, the Secretary determines the applicable percentage increase using a continuous, linear sliding scale ranging from an additional 25 percent payment adjustment for low-volume hospitals with 500 or fewer discharges to a zero percent additional payment for low-volume hospitals with more than 3,800 discharges in the fiscal year. Consistent with the requirements of section 1886(d)(12)(C)(i) of the Act, the term “discharge” for purposes of these provisions refers to total discharges, regardless of payer (that is, Medicare and non-Medicare discharges).

As previously discussed, in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41398), we proposed to make conforming changes to paragraphs (b)(2)(ii) and (c)(1) of §412.101 to reflect the low-volume hospital payment adjustment policy in effect for those years is the same the low-volume hospital payment adjustment policy in effect for FYs 2005 through 2010, as described previously.

**Comment:** In addition to expressing support for FY 2023, many commenters supported the extension to the FY 2024 definition and payment of the low-volume hospital payment adjustment.

**Response:** We appreciate the commenters sharing their support for the extension of the low-volume hospital definition and payment adjustment for FY 2024, and for legislative action for the permanent modification of the low-volume hospital payment policy.

For this purpose, the “number of total discharges” is determined as total discharges, which includes Medicare and non-Medicare discharges during the fiscal year, based on the hospital’s most recently submitted cost report, as explained previously.

Consistent with the extension of the methodology for calculating the payment adjustment for low-volume hospitals through FY 2024, we proposed to continue using the previously specified continuous, linear sliding scale formula to determine the low-volume hospital payment adjustment forFY 2024. We also proposed to make conforming changes to the regulation text in §412.101 to reflect the extensions of the changes to the qualifying criteria and the payment adjustment methodology for low-volume hospitals in accordance with the statute only extends the temporary changes to the definition of a low-volume hospital and the methodology for calculating the payment adjustment for low-volume hospitals for FY 2024 and subsequent years. Commenters stated that not continuing these temporary changes would result in significant reductions in payment that could impede the services hospitals, including those in rural communities, provide in the communities they serve.

**Response:** We appreciate the feedback from comments urging CMS to explore ways to continue the enhanced low-volume hospital payment policy for FY 2024 and subsequent years, we note that the statute only extends the temporary changes to the low-volume hospital policy for FYs 2023 and 2024. Therefore, beginning with FY 2025, the low-volume hospital qualifying criteria and the amount of the payment adjustment to such hospitals will revert back to those policies that were in effect prior to the amendments made by recent legislation.

After consideration of the public comments on the payment adjustment methodology for low-volume hospitals through FY 2024, we are finalizing our proposal to codify these extensions to the regulation text in §412.101 without modification.

5. Process for Requesting and Obtaining the Low-Volume Hospital Payment Adjustment for FY 2024

In the FY 2011 IPPS/LTCH PPS final rule (75 FR 50238 through 50275 and 50414) and subsequent rulemaking,
most recently in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49062 through 49063), we discussed the process for requesting and obtaining the low-volume hospital payment adjustment. Under this previously established process, a hospital makes a written request for the low-volume payment adjustment under §412.101 to its MAC. This request must contain sufficient documentation to establish that the hospital meets the applicable mileage and discharge criteria. The MAC will determine if the hospital qualifies as a low-volume hospital by reviewing the data the hospital submits with its request for low-volume hospital status in addition to other available data. Under this approach, a hospital will know in advance whether or not it will receive a payment adjustment under the low-volume hospital policy. The MAC and CMS may review available data such as the number of discharges, in addition to the data the hospital submits with its request for low-volume hospital status, to determine whether or not the hospital meets the qualifying criteria. (For additional information on our existing process for requesting the low-volume hospital payment adjustment, we refer readers to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41399 through 41401).)

As explained earlier, for FY 2019 and subsequent fiscal years, the discharge determination is made based on the hospital’s number of total discharges, which is, Medicare and non-Medicare discharges, as was the case for FYs 2005 through 2016. Under the revised §412.101(b)(2)(i) and (iii), a hospital’s most recently submitted cost report is used to determine if the hospital meets the discharge criterion to receive the low-volume payment adjustment in the current year. As discussed in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41399 and 41400), we use cost report data to determine if a hospital meets the discharge criterion because this is the best available data source that includes information on both Medicare and non-Medicare discharges. (For FY’s 2011 through 2016, the most recently available MedPAR data were used to determine the hospital’s Medicare discharge because non-Medicare discharges were not used to determine if a hospital met the discharge criterion for those years.) Therefore, a hospital must refer to its most recently submitted cost report for total discharges (Medicare and non-Medicare) to decide whether or not to apply for low-volume hospital status for a particular fiscal year. As also discussed earlier, in addition to the discharge criterion, for FY 2019 and subsequent fiscal years, eligibility for the low-volume hospital payment adjustment is also dependent upon the hospital meeting the applicable mileage criterion specified in the revised §412.101(b)(2)(i) or (iii) for the fiscal year. Specifically, to meet the mileage criterion for FY 2024, as noted earlier, a hospital must be located more than 15 road miles from the nearest subsection (d) hospital, as was the case for FYs 2019 through 2023. (We define in §412.101(a) the term “road miles” to mean “miles” as defined in §412.92(c)(1) (75 FR 50238 through 50275 and 50414)). For establishing that the hospital meets the applicable mileage criterion, the use of a web-based mapping tool as part of the documentation is acceptable. The MAC will determine if the information submitted by the hospital, such as the name and street address of the nearest hospitals, location on a map, and distance from the hospital requesting low-volume hospital status, is sufficient to document that it meets the mileage criterion. If not, the MAC will follow up with the hospital to obtain additional necessary information to determine whether or not the hospital meets the applicable mileage criterion. In accordance with our previously established process, a hospital must make a written request for low-volume hospital status that is received by its MAC no later than September 1, 2023, in order for the low-volume, add-on payment adjustment to be applied to payments for its discharges beginning on or after October 1, 2023. If a hospital’s written request for low-volume hospital status for FY 2024 is received after September 1, 2023, and if the MAC determines the hospital meets the criteria to qualify as a low-volume hospital, the MAC would apply the low-volume hospital payment adjustment to determine the payment for the hospital’s FY 2024 discharges, effective prospectively within 30 days of the date of the MAC’s low-volume hospital status determination.

Under this process, a hospital that qualified for the low-volume hospital payment adjustment for FY 2023 may continue to receive a low-volume hospital payment adjustment for FY 2024 without reapplying if it continues to meet both the discharge and the mileage criteria (which, as discussed previously, are the same qualifying criteria that apply for FY 2023). In this case, a hospital’s request can include a verification statement that it continues to meet the mileage criterion applicable for FY 2023. (Determination of meeting the discharge criterion is discussed earlier in this section.) We note that a hospital must continue to meet the applicable qualifying criteria as a low-volume hospital (that is, the hospital must meet the applicable discharge criterion and mileage criterion for the fiscal year) to receive the payment adjustment in that fiscal year; that is, low-volume hospital status is not based on a “one-time” qualification (75 FR 50238 through 50275). Consistent with historical policy, a hospital must submit its request, including this written verification, for each fiscal year for which it seeks to receive the low-volume hospital payment adjustment, and in accordance with the timeline described earlier.

We did not receive any comments on our process for requesting and obtaining the low-volume payment adjustment for FY 2024. For the reasons discussed in this final rule and in the FY 2024 IPPS/LTCH PPS proposed rule, we are finalizing our proposal, without modification.

F. Medicare-Dependent, Small Rural Hospital (MDH) Program (§ 412.108)

1. Background

Section 1886(d)(5)(G) of the Act provides special payment protections, under the IPPS, to a Medicare-dependent, small rural hospital (MDH). Section 1886(d)(5)(C)(iv) of the Act defines a MDH as a hospital that is
located in a rural area, or is located in an all-urban State but meets one of the specified statutory criteria for rural reclassification (as added by section 50205 of the Bipartisan Budget Act of 2018, Pub. L. 115–123), has not more than 100 beds, is not an sole community hospital (SCH), and has a high percentage of Medicare discharges (that is, not less than 60 percent of its inpatient days or discharges during the cost reporting period beginning in FY 1987 or two of the three most recently audited cost reporting periods for which the Secretary has a settled cost report were attributable to inpatients entitled to benefits under Part A). The regulations at 42 CFR 412.108 set forth the criteria that a hospital must meet to be classified as an MDH. (For additional information on the MDH program and the payment methodology, we refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51683 through 51684).)

2. Implementation of Legislative Extension of MDH Program

Since the extension of the MDH program through FY 2012 provided by section 3124 of the Affordable Care Act, the MDH program has been extended multiple times by subsequent legislation, most recently for FYs 2023 through 2024, as discussed further in this section (that is, for discharges occurring before October 1, 2024.) (Additional information on the extensions of the MDH program after FY 2012 and through FY 2022 can be found in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49064).) As discussed in the FY 2023 IPPS/LTCH PPS final rule, the MDH program provisions at section 1886(d)(5)(G) of the Act were set to expire at the end of FY 2022 (87 FR 49064). Subsequently, the MDH program was extended by additional legislation as follows:

- Division D, Section 102 of the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (Public Law 117–180, enacted on September 30, 2022, amended sections 1886(d)(5)(G)(i) and 1886(d)(5)(G)(ii)(I) of the Act to provide for an extension of the MDH program through December 16, 2022.
- Division FF, Section 4102 of the Consolidated Appropriations Act, 2023 (Pub. L. 117–328, enacted on December 29, 2022, amended sections 1886(d)(5)(G)(i) and 1886(d)(5)(G)(ii)(I) of the Act to provide for an extension of the MDH program through FY 2024 (that is, for discharges occurring on or before September 30, 2024).

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27014), we proposed to make conforming changes to the regulations governing the MDH program at § 412.108(a)(1) and (c)(2)(iii) and the general payment rules at § 412.90(j) to reflect the extension of the MDH program through FY 2024. We note that the legislative extensions of the MDH program provided by section 102 of Pub. L. 117–180 and section 102 of Public Law 117–229, which collectively extended the program through December 23, 2022, were signed into law prior to a statutory expiration of the MDH program.

Generally, as a result of these extensions, a provider that was classified as an MDH as of September 30, 2022, continued to be classified as an MDH as of October 1, 2022, with no need to reapply for MDH classification. (For more information on the MDH extensions through December 23, 2022, see Change Request 12970 and Change Request 13103, which are available online at https://www.cms.gov/files/document/R11740RTF.pdf and https://www.cms.gov/files/document/R11780TDF.pdf, respectively.) In contrast, the legislative extension provided by section 102 of Public Law 117–328 was signed into law on December 29, 2022, after the December 24, 2022, expiration of the MDH program. Generally, as a result of this extension and consistent with previous extensions of the MDH program, a provider that was classified as an MDH as of December 23, 2022, was reinstated as a MDH effective December 24, 2022, with no need to reapply for MDH classification.

The regulations at § 412.92(b)(2)(v) allow MDHs to apply for classification as a SCH 30 days prior to the anticipated expiration of the MDH program, and if approved, to be granted such status effective with the expiration of the MDH program. As discussed in Change Requests 12970 and 13103, because the MDH program did not, in fact, expire as of the anticipated October 1, 2022, or December 17, 2022, expiration dates, any MDH that applied for SCH classification per the regulations at § 412.92(b)(2)(v) in anticipation of either of those expiration dates would not have been classified as a SCH as of October 1, 2022, or December 17, 2022, as applicable. Furthermore, we are not aware of any hospitals with MDH status applying for SCH classification in this manner in advance of the December 24, 2022, expiration of the MDH program. However, as discussed in Change Request 13103, if there are any such hospitals and those hospitals are unsure about their MDH status, those hospitals should contact their MACs. We note that in accordance with Change Request 13103, a provider affected by the MDH program extension that also applied for SCH classification per the regulations at § 412.92(b)(2)(v) or cancelled its rural reclassification under § 412.103 in anticipation of the expiration of the MDH program will receive a notice from its MAC detailing its status in light of the MDH program extension.

Therefore, as collectively provided by division D, section 102 of the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023, division C, section 102 of the Further Continuing Appropriations and Extensions Act, 2023, and division FF, section 4102 of the Consolidated Appropriations Act, 2023, providers that were classified as MDHs as of September 30, 2022, generally continue to be classified as MDHs as of October 1, 2022, with no need to reapply for MDH classification. However, as discussed in Change Requests 12970 and 13103, if a MDH cancelled its rural classification under § 412.103(g) effective on or after October 1, 2022, its MDH status may not be applied continuously or automatically reinstated, as applicable (and as described previously). In order to meet the criteria to become an MDH, generally a hospital must be located in a rural area. To qualify for MDH status, some MDHs may have reclassified as rural under the regulations at § 412.103. With the anticipated expiration of the MDH provision, some of these providers may have requested a cancellation of their rural classification. Therefore, in order to qualify for MDH status, these providers must request to be reclassified as rural under 42 CFR 412.103(b) and reapply for MDH classification in accordance with the regulations at 42 CFR 412.108(b). As discussed, all other hospitals with MDH status as of September 30, 2022, continued to be classified as MDHs effective October 1, 2022. We refer readers to Change Requests 12970 and 13103 for further discussion on the extensions of the MDH program through FY 2023.

Comment: Commenters supported our proposals to make conforming changes to the regulations to reflect the legislation extending the MDH provision. Commenters also urged CMS to expeditiously process claims and provide instructions to MACs during program extensions, especially in instances when extensions are made.
retroactively. They noted that seamless transition of programmatic support are crucial life lines for rural providers.

Response: We appreciate the commenters’ support and their concern for the legislative interruption of Medicare programs that support rural providers. We note that in response to the multiple legislative extensions since the September 1, 2022, expiration (listed previously), CMS has issued multiple program instructions as expeditiously as possible to the MACs so that rural providers could benefit from the special payment protections afforded to MDHs.

After consideration of the public comments we received, we are adopting as final the proposed conforming changes to the regulations text at §§ 412.90 and 412.108 to reflect the extension of the MDH program through FY 2024 in accordance with division FF, section 4102 of the Consolidated Appropriations Act, 2023 (Pub. L. 117–328). We are finalizing the proposed changes in paragraphs (a)(1) and (c)(2)(iii) of § 412.108 and paragraph (j) of § 412.90 without modification.

G. Payment for Indirect and Direct Graduate Medical Education Costs (§§ 412.105 and 413.75 Through 413.83)

1. Background

Section 1886(h) of the Act, as added by section 9202 of the Consolidated Omnibus Budget Reconciliation Act (COBRA) of 1985 (Pub. L. 99–272) and as currently implemented in the regulations at 42 CFR 413.75 through 413.83, establishes a methodology for determining payments to hospitals for the direct costs of approved graduate medical education (GME) programs. Section 1886(h)(2) of the Act sets forth a methodology for the determination of a hospital-specific base-period per resident amount (PRA) that is calculated by dividing a hospital’s allowable direct costs of GME in a base period by its number of full-time equivalent (FTE) residents in the base period. The base period is, for most hospitals, the hospital’s cost reporting period beginning in FY 1984 (that is, October 1, 1983, through September 30, 1984). The base year PRA is updated annually for inflation. In general, Medicare direct GME payments are calculated by multiplying the hospital’s updated PRA by the weighted number of FTE residents working in all areas of the hospital complex (and at nonprovider sites, when applicable), and the hospital’s Medicare share of total inpatient days.

Section 1886(d)(5)(B) of the Act provides for a payment adjustment known as the indirect medical education (IME) adjustment under the IPPS for hospitals that have residents in an approved GME program, to account for the higher indirect patient care costs of teaching hospitals relative to nonteaching hospitals. The regulations regarding the calculation of this additional payment are located at 42 CFR 412.105. The hospital’s IME adjustment applied to the DRG payments is calculated based on the ratio of the hospital’s number of FTE residents training in either the inpatient or outpatient departments of the IPPS hospital (and, for discharges occurring on or after October 1, 1997, at non-provider sites, when applicable) to the number of inpatient hospital beds.

The calculation of both direct GME payments and the IME payment adjustment is affected by the number of FTE residents that a hospital is allowed to count. Generally, the greater the number of FTE residents a hospital counts, the greater the amount of Medicare direct GME and IME payments the hospital will receive. In an attempt to end the incentive for hospitals to increase the number of FTE residents, Congress, through the Balanced Budget Act of 1997 (Pub. L. 105–33), established a limit on the number of allopathic and osteopathic residents that a hospital could include in its FTE resident count for direct GME and IME payment purposes. Under section 1886(h)(4)(F) of the Act, for cost reporting periods beginning on or after October 1, 1997, a hospital’s unweighted FTE count of residents for purposes of direct GME may not exceed the hospital’s unweighted FTE count for direct GME in its most recent cost reporting period ending on or before December 31, 1996. Under section 1886(d)(5)(B)(v) of the Act, a similar limit based on the FTE count for IME during that same cost reporting period is applied, effective for discharges occurring on or after October 1, 1997. Dental and podiatric residents are not included in this statutorily mandated cap.

2. Calculation of Prior Year IME Resident to Bed Ratio When There Is a Medicare GME Affiliation Agreement

Section 1886(d)(5)(B) of the Act provides that IPPS hospitals that have residents in an approved graduate medical education (GME) program receive an additional payment to reflect the higher indirect patient care costs of teaching hospitals relative to nonteaching hospitals. The regulations regarding the calculation of this additional payment, known as the indirect medical education (IME) adjustment, are located at § 412.105.

The IME adjustment factor is calculated using a hospital’s ratio of residents to beds, which is represented as r, and a statutorily set multiplier, which is represented as c, in the following equation: c × [(1 + r)^0.405 – 1]. Section 1886(d)(5)(B)(ii)(XII) of the Act provides that, for discharges occurring during FY 2008 and fiscal years thereafter, the IME formula multiplier is 1.35. Thus, for FY 2024, the IME multiplier is 1.35. The formula is traditionally described in terms of a certain percentage increase in payment for every 10-percent increase in the resident-to-bed ratio. We refer readers to the FY 2012 IPPS/LTC PPS final rule (76 FR 51680) for a full discussion of the IME adjustment and IME adjustment factor.

Section 4621(b)(1) of the Balanced Budget Act of 1997 (Pub. L. 105–33) amended section 1886(d)(5)(B) of the Act by adding a clause (vi) to provide that, effective for cost reporting periods beginning on or after October 1, 1997, the resident-to-bed ratio may not exceed the ratio calculated during the prior cost reporting period (after accounting for the cap on the hospital’s number of full-time equivalent (FTE) residents). We implemented this policy in the August 29, 1997, final rule with comment period (62 FR 46003) and the May 12, 1998 final rule (63 FR 26323) under regulations at § 412.105(a)(1). In general, the resident-to-bed ratio from the prior cost reporting period, which is to be used as the cap on the resident-to-bed ratio for the current cost reporting period, should reflect the prior year FTE count subject to the FTE cap on the number of allopathic and osteopathic residents, but not subject to the three-year rolling average. We note that the resident-to-bed ratio cap is a cap on the resident-to-bed ratio calculated for all residents, including allopathic, osteopathic, dental, and podiatry residents (63 FR 26324, May 12, 1998). However, as described in existing § 412.105(a)(1), the numerator of the resident-to-bed ratio cap may be adjusted to reflect an increase in the current cost reporting period’s resident-to-bed ratio due to residents in a new GME program or new Rural Track Program, a Medicare GME affiliation agreement, or due to residents displaced by the closure of a hospital or a residency program. Under other circumstances where the exception does not apply, such as an increase in the number of podiatry or dentistry residents or a decrease in the number of beds (that is, the denominator of the resident-to-bed ratio), the ratio can increase after a 1-year delay. The law requires a hospital’s IME payment to be
determined based on the lower of the two ratios (see section 1886(d)(5)(B)(vi) of the Act and regulations at 42 CFR 412.105(a)(1)(i)). An increase in the current cost reporting period’s ratio (subject to the FTE cap on the overall number of allopathic and osteopathic residents) thereby establishes a higher cap for the following cost reporting period.

Sections 1886(h)(4)(F) and 1886(d)(5)(B)(v) of the Act established limits on the number of allopathic and osteopathic residents that hospitals may count for purposes of calculating direct GME payments and the IME adjustment, respectively, thereby establishing hospital specific direct GME and IME full-time equivalent (FTE) resident caps. However, under the authority granted by section 1886(h)(4)(H)(ii) of the Act, the Secretary may issue rules to allow institutions that are members of the same affiliated group to apply their direct GME and IME FTE resident caps on an aggregate basis through a Medicare GME affiliation agreement. The Secretary’s regulations permit hospitals, through a Medicare GME affiliation agreement, to increase or decrease their IME and direct GME FTE resident caps to reflect the rotation of residents among affiliated hospitals for agreed-upon academic years. Consistent with the broad authority conferred by the statute, we established criteria for defining an “affiliated group” and an “affiliation agreement” in both the August 29, 1997, final rule (62 FR 45966, 46006) and the May 12, 1998, final rule (63 FR 26318). In the August 1, 2002, IPPS final rule (67 FR 50069), we amended our regulations to require that each Medicare GME affiliation agreement must have a shared rotational arrangement. The regulations for “Medicare GME affiliation agreements” are at 42 CFR 413.75(b) and (f). In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49075, August 10, 2022), we expanded the regulations regarding Medicare GME affiliation agreements to permit urban and rural hospitals that participate in the same separately accredited family medicine Rural Track Program (RTP) and have rural track FTE limitations to enter into “Rural Track Medicare GME Affiliation Agreements”.

As previously mentioned, as described in existing § 412.105(a)(1)(i), the numerator of the prior year resident-to-bed ratio may be adjusted to reflect an increase in the current cost reporting period’s resident-to-bed ratio due to residents in a Medicare GME affiliation agreement (among other limited reasons). As discussed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27016), we have occasionally received inquiries related to adjusting the prior year numerator when the hospital is training more residents in the current year as a result of an IME FTE cap increase under the terms of a Medicare GME affiliation agreement. A hospital can train more residents in the current year versus the prior year under the terms of a Medicare GME affiliation agreement as a result of several scenarios. As an example, Hospital A and Hospital B participate in a Medicare GME affiliation agreement over a period of several years, and generally, under the terms of the agreement, Hospital A is giving IME FTE cap slots to Hospital B:

Example of Medicare GME Affiliations:

<table>
<thead>
<tr>
<th>HOSPITAL A IME CAP</th>
<th>HOSPITAL B IME CAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>-5 (decrease of 5)</td>
</tr>
<tr>
<td>2021</td>
<td>-6 (net decrease of 1 compared to prior year)</td>
</tr>
<tr>
<td>2022</td>
<td>-5 (net increase of 1, as Hospital A is giving away 1 less FTE this year compared to prior year)</td>
</tr>
</tbody>
</table>

In this example, we see that Hospital B’s IME cap increases from 2019 to 2020 and again from 2020 to 2021 because it receives cap slots from Hospital A. However, we also see that Hospital A experiences a net increase in its FTE cap from 2021 to 2022, even though it continues to loan IME slots to Hospital B. This is because, under the terms of the Medicare GME affiliation agreement, Hospital A loans one less IME FTE to Hospital B in 2022 than it did in 2021. In the FY 2024 IPPS/LTCH PPS proposed rule, we proposed to clarify how to determine the net increase in FTEs in the current year numerator as compared to the prior year numerator as a result of the terms of a Medicare GME affiliation agreement. We explained that to determine this change accurately, we need to isolate only changes resulting from the Medicare GME affiliation agreement, and not, for example, an increase in the resident-bed ratio due to participation in new programs, or due to a change in the number of beds in the denominator. Under the current cost report instructions (Transmittal 20 on Form CMS-2552-10, Worksheet E, Part A line 20, regarding the determination the prior year IRB ratio, states:

**Line 20—**In general, enter from the prior year cost report the intern and resident to bed ratio by dividing line 12 by line 4 (divide line 3,14 by line 3 if the prior year cost report was the Form CMS-2552-96). However, if the provider is participating in training residents in a new medical residency training program(s) under 42 CFR 413.79(e) for a new program started prior to October 1, 2012, add to the numerator of the prior year intern and resident to bed ratio (that is, line 12 of the prior cost report, which might be zero), if applicable, the number of FTE residents in the current cost reporting period that are in the initial period of years of a new program (line 16) (that is, the period of years is the minimum accredited length of the program).

For a new program started prior to October 1, 2012, contact your contractor for instructions on how to complete this line if you have a new program for which the period of years is less than or more than three years.

For urban hospitals that began participating in training residents in a new program for the first time on or after October 1, 2012, under 42 CFR 413.79(e)(1), if this cost reporting period is prior to the cost reporting period that coincides with or follows the start of the sixth program year of the first new program started, then divide line 16 of this cost report by line 4 of the prior year cost report (see 79 FR 50110 (August 22, 2014)). For rural hospitals participating in a new program on or after October 1, 2012, under 42 CFR 413.79(e)(3), for each new program started, if this cost reporting period is prior to the cost reporting period that coincides with or follows the start of the sixth program year of each particular new program, then add the amount from line 12 of the prior year (if greater than zero) and line 16 of this cost report, and divide the sum by line 4 of the prior year’s cost report (see 79 FR 50110 (August 12, 2014)). If the provider is participating in a Medicare GME affiliation agreement or rural track Medicare GME affiliation agreement under 42 CFR 413.79(f), and the provider increased its current year FTE cap and current year FTE count due to this affiliation agreement, identify the lower of (a) the difference between the current year numerator and the prior year numerator, and
the number by which the FTE cap increased per the affiliation agreement, and add the lower of these two numbers to the prior year’s numerator (see 42 CFR 412.105(a)(1)(ii)). If the hospital is participating in a valid emergency Medicare GME affiliation agreement under § 1125 waiver, and a portion of this cost report falls within the time frame covered by that emergency affiliation agreement, then, effective on and after October 1, 2008, enter the current year resident-to-bed ratio from line 19 (see 73 FR 48649 (August 19, 2008) and 42 CFR 412.105(f)(1)(iv)). Effective for cost reporting periods beginning on or after October 1, 2002, if the hospital is training FTE residents in the current year that were displaced by the closure of another hospital or program, also adjust the numerator of the prior year ratio for the number of current year FTE residents that were displaced by hospital or program closure (see 42 CFR 412.105(a)(1)(iii)). The amount added to the prior year’s numerator is the displaced resident FTE amount that you would not be able to count without a temporary cap adjustment. This is the same amount of displaced resident FTEs entered on line 17. For cost reporting periods beginning on or after October 1, 2022, for urban and rural hospitals participating in a rural track program(s), adjust the numerator by adding to the amount on Worksheet E, Part A, line 12, of the prior year cost report (if greater than zero) the FTEs in the rural track program(s) on line 16 of this worksheet, if this cost report is prior to the cost reporting period that coincides with or follows the start of the sixth program year of that rural track program (italics emphasis added).

Our proposed clarification focused on the italicized text as previously detailed:

If the provider is participating in a Medicare GME affiliation agreement or rural track Medicare GME affiliation agreement under 42 CFR 413.79(f), and the provider increased its current year FTE cap and current year FTE count due to this affiliation agreement, identify the lower of: (a) the difference between the current year numerator and the prior year numerator, and (b) the number by which the FTE cap increased per the affiliation agreement, and add the lower of these two numbers to the prior year’s numerator (emphasis added).

We have been asked by teaching hospitals to clarify what lines on the cost report to use to determine the provider “increased its current year FTE cap,” and that the provider increased its “current year FTE count” due to the affiliation agreement. We have also been asked to clarify what line on the cost report represents the “current year numerator,” specifically, whether this value refers to current year line 12, or line 15, or line 18.

Line 8 states: Enter the adjustment (increase or decrease) to the FTE count for allopathic and osteopathic programs for affiliated programs in accordance with 42 CFR 413.75(b), 413.79(c)(2)(iv)

and 63 FR 26340 (May 12, 1998), and 67 FR 50069 (August 1, 2002).

Line 10 states: Enter the FTE count for allopathic and osteopathic programs in the current year from your records. Do not include residents in the initial years of the new program.

Line 12 states: Enter the result of the lesser of line 9, or line 10 added to line 11.

Line 15 states: Enter the sum of lines 12 and 14 divided by three.

Line 18 states: Enter the sum of lines 15, 16 and 17.

Line 19 states: Enter the current year resident to bed ratio by dividing line 18 by line 4 (beds).

As discussed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27017 through 27018), if the provider is participating in a Medicare GME affiliation agreement (or rural track Medicare GME affiliation agreement under 42 CFR 413.75(b)), the provider first has to make sure that in fact, it increased the current year FTE cap, and second, that it increased its current year allowable FTE count. We proposed to clarify that, to determine if there is an increase in the current year FTE cap “due to this affiliation agreement,” the provider would check if the difference of current year line 8 minus prior year line 8 is positive. If yes, the provider would determine if the difference of current year allowable allopathic and osteopathic FTE count line 12 minus prior year allowable allopathic and osteopathic FTE count line 12 is positive. The provider would determine the difference between current year line 12 and prior year line 12 by first excluding any dental and podiatry FTEs on line 11 of both years, if applicable. If negative, then the provider did not increase its current year allowable allopathic and osteopathic FTE count due to the affiliation agreement, and there is no adjustment made to the prior year IRB ratio. If positive, the provider would proceed with the next part of the determination to “identify the lower of: (a) the difference between the current year numerator and the prior year numerator, and (b) the number by which the FTE cap increased per the affiliation agreement, and add the lower of these two numbers to the prior year’s numerator.”

“Further we proposed to clarify that the “current year numerator” referred to in the excerpt from Worksheet E, Part A line 20 is line 15; that is, the current year numerator before making any adjustments for new programs, new RTPs, or displaced residents, but including residents counted under the terms of a Medicare GME affiliation agreement, and subject to the three-year rolling average. We explained the reasons for this in detail and restate the explanation in this section of this final rule. We also acknowledged that the phrase “current year numerator” in the context of line 20 must refer to a different value than the numerator of the “current year resident to bed ratio” in line 19, which states, “Enter the current year resident to bed ratio by dividing line 18 by line 4.” In the context of Medicare GME affiliation agreements in line 20, the current year numerator cannot refer to line 18, as line 18 represents the current year IRB ratio with various adjustments, including the FTEs in new programs from line 16, and FTEs displaced by hospital or program closure on line 17.

As previously stated, we need to isolate only changes associated with the Medicare GME affiliation agreement, and including FTEs associated with new programs or closed programs on line 18 would introduce extraneous variables into the equation.

Next, we noted that the “current year numerator” is not line 12. Line 12 is the current year allowable FTE count; that is, the lower of the current year FTE count or the adjusted FTE cap, which reflects the FTE adjustment under the terms of the Medicare GME affiliation agreement. The current year allowable FTE count on line 12 is used in the 3-year rolling average calculation on line 15, which sums the current year allowable FTE count, the prior year allowable FTE count, and the penultimate year FTE count, and divides the result by 3. While it may seem that averaging the current year FTEs with FTEs from prior years interferes with determining only changes to the current year FTEs under an affiliation agreement, the law and regulations require that additional FTEs added due to a Medicare GME affiliation agreement are subject to the 3-year rolling average (see section 1866(d)(5)(B)(vii) of the Act and 42 CFR 413.79(f), regarding a Medicare GME affiliated group, which provides that a hospital may receive a temporary adjustment to its FTE cap, which is subject to the averaging rules under § 413.79(d), to reflect residents added or subtracted because the hospital is participating in a Medicare GME affiliation agreement (as defined under § 413.75(b)). Because any additional FTEs due to participation in a Medicare GME affiliation agreement must be included in the rolling average on line 15, we stated that we believe that the “current year numerator” referred to on Worksheet E, Part A line 20 is line 15,
not line 12. This contrasts with the “prior year numerator,” which we note is line 12, as the instructions for line 20 state: “In general, enter from the prior year cost report the intern and resident to bed ratio by dividing line 12 by line 4.” (See 42 CFR 412.105(a)(1)(i), which states “this ratio may not exceed the ratio for the hospital’s most recent prior cost reporting period after accounting for the cap on the number of allopathic and osteopathic full-time equivalent residents as described in paragraph (f)(1)(iv) of this section.” This regulation does not require accounting for the 3-year rolling average.) Therefore, we propose to clarify the instructions on Worksheet E, Part A line 20 as follows, in italics:

If the provider is participating in a Medicare GME affiliation agreement or rural track Medicare GME affiliation agreement under 42 CFR 413.79(f), and the provider increased its current year FTE cap (difference of current year line 8 and prior year line 8 is positive) and increased its current year allowable FTE count (difference of current year line 12 (excluding current year dental and podiatry from line 11) and prior year line 12 (excluding current year dental and podiatry from line 11)) and prior year line 12 (excluding prior year dental and podiatry from line 11) is positive) due to this affiliation agreement, identify the lower of: a) the difference between the current year numerator line 15 and the prior year numerator line 12 of the prior year cost report, and b) the number by which the FTE cap increased per the affiliation agreement (difference of current year line 8 and prior year line 8), and add the lower of these two numbers to the prior year’s numerator line 12 of the prior year cost report.

Comment: Several commenters appreciated CMS’s proposed clarification to the IME worksheet on the Medicare cost report when hospitals enter into a Medicare GME affiliation agreement, stating it will assist hospitals in ensuring that they complete the worksheet and report FTE counts in the proper manner. A commenter supported CMS’s clarification efforts and another asked CMS to continue listening to teaching hospitals when specific policies are unclear.

Other commenters disagreed with aspects of CMS’s proposed clarification. Another commenter noted that CMS’s proposed clarification involves a comparison of the total allowable FTEs from the prior year and the current year as reported on line 12 (“. . . the provider . . . increased its current year allowable FTE count (difference of current year line 12 (excluding current year dental and podiatry from line 11) and prior year line 12 (excluding prior year dental and podiatry from line 11)) is positive) due to this affiliation agreement . . . ”) (88 FR 27017–27018, emphasis added). The commenter noted that the total allowable FTE count on line 12 is subject to the FTE cap, and since there are many hospitals that have IME FTE counts limited by their FTE caps, utilizing this line may not be the most accurate reflection of an actual increase or decrease in FTEs between years. The commenter suggested that a better reflection of an increase/decrease between years would be to compare the actual current year FTEs from line 10 between years before any FTE cap limits are applied.

Two commenters that opposed CMS’s proposed clarification focused on another part of the clarification, where CMS proposed to compare current year line 15 and prior year line 12 (“. . . identify the lower of: (a) the difference between the current year numerator line 15 and the prior year numerator line 12 of the prior year cost report . . . ”) (88 FR 27018). The commenters provided two examples where they believed the prior year numerator would not be sufficiently increased as a result of this proposed clarification. In the first example, a hospital experiences a decrease in its three-year rolling average FTE count in the current year as a result of a decrease in its number of dental and pediatric FTEs, even though its allopathic and osteopathic FTE count and its FTE cap increase under the terms of a Medicare GME affiliation agreement. In the second example, a hospital’s allopathic and osteopathic FTE count and cap similarly increase in the current year as a result of a Medicare GME affiliation agreement, but the hospital’s three-year rolling average FTE count is nevertheless lower than the prior-year allowable FTE count as a result of a significantly lower FTE count in the penultimate year. Furthermore, the commenters noted that in these examples CMS’s proposed clarification would result in an inappropriate reduction to the numerator of the prior-year IRB ratio, since subtracting prior year line 12 from current year line 15 would result in a negative number. In addition, these commenters argued that CMS’s proposed language does not account for rural track FTE affiliation agreements.

Response: We appreciate commenters’ support of our proposed clarification and the careful review from those who raised concerns about it. Specifically, we proposed to add the following italicized language to Worksheet E, Part A, line 20 of CMS-Form-2552–10:

If the provider is participating in a Medicare GME affiliation agreement or rural track Medicare GME affiliation agreement under 42 CFR 413.79(f), and the provider increased its current year FTE cap (difference of current year line 8 and prior year line 8 is positive) and increased its current year allowable FTE count (difference of current year line 8 and prior year line 8 (excluding current year dental and podiatry from line 11) is positive) due to this affiliation agreement, identification of the lower of: (a) the difference between the current year numerator line 15 and the prior year numerator line 12 of the prior year cost report, and (b) the number by which the FTE cap increased per the affiliation agreement (difference of current year line 8 and prior year line 8), and add the lower of these two numbers to the prior year’s numerator line 12 of the prior year cost report (88 FR 27018).

We do not concur with the commenters who disagreed with certain aspects of the proposed clarification, because we believe the commenters overlooked key portions of the law and regulations in drawing their conclusions. First, we reiterate the point of permitting the numerator of the prior year IRB ratio to be adjusted due to the exceptions listed at 42 CFR 412.105(a)(1)(i) (for example, a new GME program or new Rural Track Program, a Medicare GME affiliation agreement, or due to residents displaced by the closure of a hospital or a residency program) is to more equitably compute a hospital’s IME payment in certain situations where the IME cap increases year-over-year, so that the hospital is not held to a lower IME payment based on the prior year’s FTE cap. Second, once the appropriate adjustments are made to the numerator of the prior year IRB ratio, the law at section 1886(d)(5)(B)(vi) of the Act requires that for actual payment, we take the lower of the current year IRB ratio or the prior year IRB ratio. That is, line 21 on Worksheet E, Part A states, “Enter the lesser of line 19 or 20.” It appears that the commenters disregarded this key point.

In the examples the commenters provided, they argued that under CMS’s proposed clarification, the prior year IRB ratio is not sufficiently increased, and that the comparison of current year line 15 to prior year line 12 distorts the calculation of the IRB ratio. However, we have reviewed the examples and the adjustments that commenters suggested, and the result is that even if the prior year numerator were increased in the manner requested by commenters, this would not increase a hospital’s IME payment, since doing so would have no effect on the value of the current year numerator: in both examples, the current year IRB ratio on line 19 would still be lower than the prior year IRB ratio on line 20, so that the current year IRB ratio would still be reported on line 21. This demonstrates that there is no need to increase the prior year numerator.
above the current year numerator; it is only necessary to ensure that the prior year numerator is adjusted to accommodate the additional FTEs counted as a result of certain increases to a hospital’s IME FTE cap.

In this way we also address the commenters’ concern that the proposed clarification distorts the calculation of the IRB ratio, and their contention that a hospital is harmed if its current year three-year average FTE count is less than its prior year total allowable FTE count, either through a decrease in dental or podiatry FTEs or because of a low FTE count in the penultimate year. Since the law requires IME payment to be based on the lesser of the current year IRB ratio or the prior year IRB ratio, if a hospital’s current year FTE count goes down, then payment would logically be made based on the current year’s lower IRB ratio; payment based on last year’s higher ratio would result in an overpayment in the current year. Thus, if a hospital increases its cap through a Medicare GME affiliation agreement, but, for whatever reason, its three-year average FTE count is less than the prior year total allowable FTE count, then an adjustment to the prior year numerator will make no difference, as the law requires that the hospital use the lower of the current year IRB ratio or prior year IRB ratio for IME payment.

Similarly, we do not believe it is appropriate to compare line 10 of the current year to line 10 of the prior year, as a commenter suggested. First, the FTEs used in the IRB ratio are subject to a hospital’s IME FTE cap, which applies to line 12 but not to line 10. Second, the following fairly common scenario demonstrates how comparing line 10 to line 10 may lead to unfair results. Assume a hospital is training FTEs significantly over its FTE cap, and even though it has increased its FTE cap via a Medicare GME affiliation agreement, it is still training FTEs in excess of that affiliated cap. However, this hospital’s current year FTE count on line 10 is somewhat less than the prior year FTE count on line 10. Specifically, assume that in 2020, Hospital A has an FTE cap of 100 (line 9 = 100) and trains 200 allopathic and osteopathic FTE residents (line 10 = 200); further assume that Hospital A does not train any dental or podiatry residents (line 11 = 0; line 12 = 100). In 2021, Hospital A has difficulty filling positions in a certain program, and therefore, it experiences a reduction in its FTE count and trains 190 allopathic and osteopathic residents (line 10 = 190). However, under the terms of a Medicare GME affiliation agreement, Hospital A increases its FTE cap by 10 to 110 (line 8 = 10; line 9 = 110; line 12 = 110). Thus, the hospital’s total FTE count decreased from 200 to 190, but because its FTE cap increased from 100 to 110 under the Medicare GME affiliation agreement, its allowable FTE count actually increased by 10, from 100 to 110. If we were to take the difference between the current year line 10 (190 FTEs) and prior year line 10 (200 FTEs), the result would be a negative number (−10), and there would be no adjustment to the prior year numerator, since the FTE count decreased in the current year. But under CMS’s proposed clarification, the hospital increased its allowable FTE count, and when we determine the difference between current year line 12 (110) and prior year line 12 (100), the result is a positive difference of 10, allowing the hospital to adjust the prior year numerator by +10. In this manner, the hospital’s IME payment will reflect the fact that its current year allowable FTE count increased by 10 relative to the prior year allowable FTE count. That is also why we proposed to clarify the language on line 20 to require that the hospital increase its allowable FTE count, as follows:
If the provider is participating in a Medicare GME affiliation agreement or rural track Medicare GME affiliation agreement under 42 CFR 413.79(f), and the provider increased its current year FTE cap (difference of current year line 8 and prior year line 8 is positive) and increased its current year allowable FTE count (difference of current year line 12 (excluding current year dental and podiatry from line 11) and prior year line 12 (excluding prior year dental and podiatry from line 11) is positive) due to this affiliation agreement . . . (88 FR 27018, bolded emphasis added).

As noted previously, commenters pointed out that under certain circumstances, instead of making a positive adjustment to the prior year numerator, CMS’s proposed instructions would direct the hospital to make an improper negative adjustment to the prior year numerator. In one of the commenters’ examples, even though a hospital’s current year line 8 increased by 8 FTEs due to an affiliation agreement, and the current year FTE count also increased by 8 FTEs, the hospital would receive a negative adjustment to its IRB ratio under CMS’s proposed clarification because the difference between the current year numerator line 15 (that is, 90.67) and the prior-year numerator line 12 of the prior year cost report (that is, 92) is -1.33. Since CMS’s proposed instructions say to “add the lower of these two numbers to the prior year’s numerator line 12 of the prior year cost report,” the result would be that the hospital would have to subtract 1.33 from prior year line 12 amount of 92 (92 - 1.33 = 90.67). The commenters believe it would be inappropriate to decrease the prior year numerator in the case where the current year FTE cap and FTE counts both increased. We agree with the commenters that the hospital should not “add” the lower of the two amounts to the prior year numerator if the lower amount is a negative number, as that would be a reduction to the prior year numerator. In this final rule, we are revising that portion of the instructions to line 20 to state: “. . . add the lower of these two numbers to the prior year’s numerator line 12 of the prior year cost report. If the lower of these two numbers is a negative number, do not adjust the prior year numerator line 12” (bolded language is new).
If the provider is participating in a Medicare GME affiliation agreement or rural track Medicare GME affiliation agreement under 42 CFR 413.79(f), and the provider increased its current year FTE cap (difference of the sum of current year line 8 and line 7.02, and sum of prior year line 8 and line 7.02 is positive) and increased its current year allowable FTE count (difference of current year line 12 (excluding current year dental and podiatry from line 11) and prior year line 12 (excluding prior year dental and podiatry from line 11) is positive) due to this affiliation agreement, identify the lower of: (a) the difference between the current year numerator line 15 and the prior year numerator line 12 of the prior year cost report, and (b) the number by which the FTE cap increased per the affiliation agreement (difference of sum of current year line 8 and line 7.02, and sum of prior year line 8 and line 7.02), and add the lower of these two numbers to the prior year’s numerator line 12 of the prior year cost report. If the lower of these two numbers is a negative number, do not adjust the prior year numerator line 12.

We did not propose any changes to the regulation text at 42 CFR 412.105, as we believe the appropriate regulations text already exists at 42 CFR 412.105(a)(1)(i) and 413.79(f), indicating that an adjustment may be made to the prior year numerator due to an increase in the Medicare GME affiliated cap, that the lower of the current or prior year IRB ratio is used for payment, and that FTE residents added under a Medicare GME affiliation agreement are subject to the rolling average. Rather, as we stated, we proposed to clarify the Medicare cost report instructions Form CMS-2552–10 Worksheet E, Part A, line 20 to more clearly indicate how these calculations are performed. We intend to insert the finalized clarification into the next update of the Medicare cost report instructions Form CMS-2552–10 Worksheet E, Part A, line 20.

3. Training in New REH Facility Type

In the Hospital Outpatient Prospective Payment System CY 2023 final rule with comment (87 FR 44502) CMS finalized certain payment policies and conditions of participation (CoPs) with respect to rural emergency hospitals (REHs). Section 125 of Division CC of the Consolidated Appropriations Act, 2021 (CAA) added a new section 1861(kkk) of the Act to establish REHs as a new Medicare provider type, effective January 1, 2023. REHs are facilities that convert from either a critical access hospital (CAH) or a rural hospital (or one treated as such under section 1886(d)(8)(E) of the Act) with not more than 50 beds, and that do not provide acute care inpatient services with the exception of post-hospital extended care services furnished in a unit of the facility that is a distinct part licensed as a skilled nursing facility. By statute, REH services include emergency department services and observation care and, at the election of the REH, other outpatient medical and health services furnished on an outpatient basis, as specified by the Secretary through rulemaking. REHs are a new provider type established by the CAA, 2021 to address the growing concern over closures of rural hospitals. Similar to CAHs, REHs are intended to provide much needed healthcare services, often times as the initial and only accessible point of care for individuals living in rural underserved areas.

As part of the comments received in response to the CY 2023 Outpatient Prospective Payment System (OPPS) proposed rule (87 FR 44502) and the proposed rule establishing REH CoPs (87 FR 40350), CMS received the request to designate REHs and GME eligible facilities similar to the GME designation for CAHs (87 FR 72164). CMS’ current policy with respect to CAHs and GME is discussed in the August 16, 2019 Federal Register (84 FR 42411). In that rule CMS finalized the policy that effective with portions of cost reporting periods beginning on or after October 1, 2019, a hospital may include FTE residents training at a CAH in its direct GME and IME FTE counts as long as it meets the nonprovider setting requirements currently included at 42 CFR 412.105(f)(1)(ii)(E) and 413.78(g).

We stated that while a CAH is considered a hospital along with the fact that a CAH is a facility primarily engaged in furnishing patient care and, at the election of the REH, the term “nonprovider” and a definitive determination as to whether a CAH is a hospital along with the fact that a CAH is a facility primarily engaged in furnishing patient care and, at the election of the REH, the term “nonprovider” and a definitive determination as to whether a CAH is considered a hospital along with the fact that a CAH is a facility primarily engaged in furnishing patient care (see the previous discussion of 1886(h)(5)(K)), we believe that statutory ambiguity of CAHs. We stated that the lack of both an explicit statutory definition of “nonprovider” and a definitive determination as to whether a CAH is considered a hospital along with the fact that a CAH is a facility primarily engaged in furnishing patient care (see the previous discussion of 1886(h)(5)(K)), we believe that statutory ambiguity of CAHs.

Section 125(a)(1)(A) of the CAA, 2021, amended section 1861(e) of the Social Security Act by inserting the phrase “or a rural emergency hospital (as defined in subsection (kkk)(2))”, such that the language now states that the term “hospital” does not include, unless the context otherwise requires, a critical access hospital (as defined in section 1861(mm)(1) of the Act), underscores the sometimes ambiguous status of CAHs. We stated that a CAH is a facility primarily engaged in patient care (see the previous discussion of 1886(h)(5)(K)), we believe that statutory ambiguity of CAHs.

In the Hospital Outpatient Prospective Payment System CY 2023 final rule with comment (87 FR 71741) CMS finalized the policy that effective with portions of cost reporting periods beginning on or after October 1, 2019, a hospital may include FTE residents training at a CAH in its direct GME and IME FTE counts as long as it meets the nonprovider setting requirements currently included at 42 CFR 412.105(f)(1)(ii)(E) and 413.78(g). We stated that while a CAH is considered a “provider of services” under section 1861(u) of the Act, the term “nonprovider” is not explicitly defined in the statute. Furthermore, section 1861(e) of the Act, which states that the term “does not include, unless the context otherwise requires, a critical access hospital (as defined in section 1861(mm)(1) of the Act), underscores the sometimes ambiguous status of CAHs.

In addition, facilities currently designated as CAHs, which do not qualify as hospitals, may choose to convert to REH status to be able to continue to provide healthcare
services within their communities. We believe that increasing access to physicians in rural areas can be supported by a flexible policy which would allow for residency training to continue at these former CAHs and begin at other newly designated REHs, which may have not previously trained residents. Therefore, we proposed to add a new paragraph (d) at 42 CFR 419.92 to state that effective for portions of cost reporting periods beginning on or after October 1, 2023, a hospital may include FTE residents training at an REH in its direct GME and IME FTE counts as long as it meets the nonprovider setting requirements included at 42 CFR 412.105(f)(1)(ii)(E) and 413.78(g) and any succeeding regulations. Consistent with our policy regarding residency training at CAHs during a hospital’s cap building period (84 FR 42415), if a hospital is at some point in its 5-year cap-building period as of October 1, 2023, and as of that date is sending residents in a new program to train at a REH, assuming the regulations governing nonprovider site training are met, the time spent by FTE residents training at the REH on or after October 1, 2023, will be included in the hospital’s FTE cap calculation.

As an alternative to being considered a nonprovider site, we stated in the August 16, 2019 Federal Register (84 FR 42415), that a CAH may decide to continue to incur the costs of training residents in an approved residency training program(s) and receive payment based on 101 percent of the reasonable costs for those training costs. In this situation no hospital can include the residents training at the CAH in its direct GME and IME FTE counts. We believe REHs may make a similar decision to incur residency training costs directly consistent with the statutory language at section 1866(k)(2)(D) of the Act, which refers to nonhospital providers, and the aforementioned flexibility provided under 1861(e) of the Act. Specifically, we proposed under the authority of section 1886(k)(2)(D) of the Act to add a new paragraph (d) at 42 CFR 419.92 indicating that effective for portions of cost reporting periods beginning on or after October 1, 2023, REHs may decide to incur the costs of training residents in an approved residency training program(s) and receive payment based on 100 percent of the reasonable costs for those training costs, consistent with the reasonable cost principles at section 1861(v)(1)(A) of the Act. As is the case when CAHs incur GME costs directly, no hospital can include the residents training at the REH in its direct GME and IME FTE counts when the REH chooses to be paid for direct GME costs instead of functioning as a nonprovider site and as such, residency training in this instance is not limited by FTE resident caps.

In summary, we proposed that effective for portions of cost reporting periods beginning on or after October 1, 2023, an REH may decide to be a nonprovider site such that if the requirements at 42 CFR 412.105(f)(1)(ii)(E) and 413.78(g) are met, a hospital can include the FTE residents training at the REH in its direct GME and IME FTE counts for Medicare payment purposes, or, the REH may decide to incur direct GME costs and be paid based on reasonable costs for those training costs. We proposed to add a new paragraph (d) at 42 CFR 419.92 to implement these provisions.

Comment: Commenters supported the proposal to treat REHs similar to CAHs for Medicare GME payment purposes such that an REH may choose to function as a nonprovider setting consistent with 42 CFR 412.105(f)(1)(ii)(E) and 413.78(g) or choose to be paid based on reasonable costs for the GME training costs that it incurs.

Many commenters stated that allowing REHs to be GME eligible facilities will help promote greater physician participation in rural healthcare thereby improving workforce shortages in rural areas and in turn improve patient access to care in underserved areas. Commenters noted the correlation between where residents train and where they practice such that increasing residency training in rural areas has a positive impact on physician supply and interest in serving in rural areas. A commenter noted that while the proposal is not a complete solution to oncology workforce challenges in rural areas, they support it as an initial step toward improving access to cancer care in rural communities. The commenter encouraged CMS to consider future policies to retain practitioners of various specialties, including oncology, in rural and underserved settings. A few commenters stated that family physicians are an essential source of emergency care in rural areas and are uniquely suited to work in REHs. The commenters stated that multiple studies have demonstrated that, while many family physicians provide emergency care in urban and suburban communities, rural family physicians are more likely to work in emergency departments. Commenters stated that The Accreditation Council for Graduate Medical Education (ACGME) requirements for family medicine residents include several proficiencies important for providing emergency care and that in addition to emergency services, REHs can offer other outpatient services like pregnancy and delivery care, behavioral health services, and primary care, all of which are within family physicians’ scope of training. The commenters therefore believe that REHs would be a valuable training site for family medicine residents. A commenter stated that it is critically important that REHs be adequately staffed, considering the important role that they play in rural communities. The commenter stated that as long as the rotations at REHs meet the requirements set out by the ACGME, thereby ensuring that residents are still receiving the high-quality education they deserve, they support the expansion of considering REHs as nonprovider sites for purposes of GME training and payment. A commenter expressed support for the proposal and noted that a large part of their state is designated as a Health Professional Shortage Area and reimbursement for GME training programs is an important piece to sustain and hopefully grow healthcare in these areas. Another commenter stated that allowing REHs to attract, educate, and be reimbursed for training additional healthcare workforce will help sustain these critical healthcare access points across rural parts of their state. A commenter stated they anticipate the proposed policy will be favorable to rural communities and REHs as it would provide for continued training of residents in rural areas. A few commenters noted that converting CAHs and offer the opportunity for additional rural training of residents that might not otherwise be viable in the absence of the proposal.

Response: We appreciate the commenters’ support. After consideration of the public comments received, we are finalizing our proposal that effective for portions of cost reporting periods beginning on or after October 1, 2023, an REH may decide to be a non-provider site. If the requirements at 42 CFR 412.105(f)(1)(ii)(E) and 413.78(g) and any succeeding regulations are met, a hospital can include the FTE residents training at the REH in its direct GME and IME FTE counts for Medicare payment purposes. In the alternative, the REH may decide to incur direct GME costs and be paid based on reasonable costs for those training costs. We are finalizing our proposed regulation text to include these provisions at 42 CFR 419.92(d).

Comment: A commenter stated that the designation of REHs as GME-eligible
facilities is a perfect example of how a flexible policy can increase access to physicians in rural areas. The commenter stated that the proposed policy reduces barriers to Tribal facilities that may be considering redesignation to an REH by eliminating one of the cons from the equation, that is, deciding whether it can cut its training program and continue providing adequate care to its patient populations. The commenter stated as this new provider type rolls out, CMS must continue to address the concerns that come up from Tribal facilities to ensure that the REH program operates as intended, to best serve folks in rural areas. One of these identified concerns is that the REH payment structure does not include the all-inclusive encounter rate, so the new provider type is not as attractive as it could be to Indian Health Care Providers (IHCPs). These are the kinds of issues that come up and can be addressed when CMS engages with Tribes.

Response: We appreciate hearing that the proposed policy may help alleviate concerns related to REH designation for Tribal facilities. Regarding the REH payment structure, while the proposed policy discussed in this section is not related to general REH payment policies, we appreciate hearing the concerns brought up by Tribal facilities regarding the REH program and look forward to continued discussions with Tribes to address these concerns.

Comment: Several commenters stated that the proposed policy to consider REHs as GME eligible training sites will allow small rural teaching hospitals and CAHs that convert to REHs to minimize unnecessary financial burdens when they convert and choose to continue their educational mission. The commenters stated that the REH program should provide stability in health care delivery systems for communities that would otherwise experience the closure of a hospital and that the proposal helps limit the financial barriers for any REH with the capacity to operate as a rural training site. Another commenter stated that their concern lies principally in the financial viability of the REH model, given the prohibition on providing inpatient services, and therefore the commenter’s advocacy focuses on ensuring that REHs retain every opportunity to participate fully in Medicare as permitted by Congress in the CAA, 2021. The commenters thanked CMS for the proposal to incorporate REHs into the GME program via the “nonprovider” designation and permit REHs the same opportunities as CAHs to receive reimbursement for the costs incurred in training residents. However, some commenters expressed concern over the proposed payment methodology should an REH choose to be reimbursed directly for training costs. Several commenters asked that CMS adopt cost-based reimbursement at 101 percent for REHs that choose to incur direct GME costs since CAHs currently receive reimbursement at 101 percent of reasonable costs for residency training and therefore CMS should maintain consistency for CAHs that convert to REHs. The commenters stated that hospitals that choose to convert to REHs do not make the decision lightly and are more likely to be independent CAHs, have a three-year negative operating margin, and have a relatively low average daily census. The commenters stated that hospitals that convert to REHs and decide to train residents are doing so while in a precarious financial position and thus should receive higher reimbursement. The commenters stated that aligning the REH GME policy with the policy applicable to CAHs is consistent with CMS’ approach in other areas of law for REHs, such as mirroring many CAH conditions of participation for REHs. A few commenters stated that the REH provider type was created with the express goal of enabling CAHs to transition into REHs to keep their doors open amid financial challenges. The commenters stated that they do not believe REHs should be penalized in their GME payments when transitioning from a CAH to an REH. Another commenter requested that CMS pay for residency training at CAHs at 101 percent of the reasonable cost under section 1861(v) of the Social Security Act, which would align with CAH payments based on reasonable cost principals. Response: We appreciate the comments indicating that allowing REHs to be GME eligible facilities will reduce financial barriers to REH conversion and aid in supporting the financial viability of REHs. We understand the commenters’ request to reimburse REHs based on 101 percent of reasonable costs when they choose to be paid for the direct costs of training residents as is the case for CAHs. However, there is no statutory basis for reimbursing REHs for the direct costs of GME at 101 percent of reasonable costs. Whereas the statutory language for CAH inpatient and outpatient reimbursement at sections 1814(l) and 1834(g) of the Act specifically refers to 101 percent of reasonable costs (27019), if an REH chooses to be reimbursed for its direct GME costs, it will be reimbursed based on 100 percent of reasonable costs. As stated in the proposed rule (88 FR 27019), if an REH chooses to be reimbursed for the direct costs of residency training, it is not limited by FTE residency caps. Therefore, training at REHs that choose to be reimbursed directly are Medicare GME payments that are made above the statutorily mandated caps and thus provide for additional funding supporting training in rural areas despite payment at 100 percent of reasonable costs as opposed to 101 percent of reasonable costs.

Comment: Several commenters submitted comments specific to REHs and rural track programs (RTPs). Commenters stated that the size of REH facilities and training requirements from the ACGME will likely limit the number of residents who train at these sites, but with new opportunities for hospitals to expand training through RTPs, REH GME has the potential to create training partnerships in rural areas with larger academic medical centers. The commenters stated that the learning experience provided to trainees in rural areas is unique and additional resources like REH GME may have positive patient care outcomes in these underserved areas. A commenter stated that as evidenced by their strong advocacy for RTPs (formerly rural training tracks) and the inclusion of hospitals located in rural areas among the beneficiaries of resident cap relief legislation, they support innovative strategies that will incentivize bringing physician services to those living in rural areas. Another commenter stated that they expect the proposed policy will enable REHs to serve sites for RTPs, which would enhance resident training in rural areas and potentially improve timely access to care in areas with an REH. The commenter specifically requested CMS clarify in the final rule that REHs will be able to serve as rotator sites in RTPs. Response: We appreciate the comments noting that training at REHs may help to expand RTPs. Since we are finalizing a policy to treat REHs similar to CAHs for Medicare payment purposes, REHs can serve as a rural training site in an RTP in the same manner as CAHs.
manner as a CAH would. Note that if an REH has reclassified as rural under 42 CFR 412.103 (section 1886(d)(6)(E) of the Act), it would only be considered rural for IME payment purposes in the event it is serving as a non-provider site. We refer readers to the current policies concerning RTPs as discussed in the December 27, 2021 Federal Register, which implements section 127 of the CAA, 2021 (86 FR 73445).

Comment: A commenter stated that as the REH model evolves, it would be helpful for CMS to evaluate and request feedback from participating facilities to help guide future policy. The commenter encouraged CMS to continue working collaboratively to provide support for facilities converting, or considering converting, to the new REH status, as well as provide clarity and support for those considering participating as a GME training facility.

Response: We appreciate the commenter’s recommendation to continue collaborative efforts that will support facilities interested in REH status. We encourage individuals to contact CMS or their Medicare Administrative Contractor (MAC) should they have any questions on specific policies concerning REHs and Medicare GME payments.

Comment: A commenter stated that to further alleviate workforce shortages and address the needs of rural and medically underserved communities, they urge CMS to work with members of the United States Senate Committee on Health, Education, Labor, and Pensions (HELP). The commenter stated that the Senate HELP Committee recently sought feedback from the public on healthcare workforce shortages, and provided several recommendations to reduce barriers to care, diversify the healthcare workforce, increase funding for GME programs specifically designated for mental health and substance use disorder providers, and advance technology solutions to reduce administrative friction and workforce burnout. The commenter stated by working together, CMS and the Senate HELP Committee can effectively address workforce shortages, increase community resources, and mitigate closures of rural hospitals. The commenter stated they welcome the opportunity to discuss their investments and recommendations with CMS and also encouraged CMS to work with Congress on additional policy changes and investments that support the healthcare workforce and rural and medically underserved communities.

A third that they support other initiatives to transform physician training programs from urban settings, currently representing the majority of programs, and having more robust training options in rural communities. The commenter recommended that the financial support and resources for such training programs be sustainable and allow residents to fully complete their training without the concern of funding gaps. The commenter stated that they aim to ensure continuous financial support for training programs, avoiding any interruptions or breaks in funding. The commenter noted that since most rural hospitals are unable to financially support residency training positions independently, they rely on federally funded GME resources. A commenter requested that similar to the GME designation for CAHs, REHs also include advanced practice nursing education. The commenter stated that this designation is essential, especially since 221 clinical sites for nurse anesthesia have been designated as having CAH status and are eligible to convert to REH status. The commenter stated that certified registered nurse anesthetists (CRNAs) predominate in rural hospitals, and it is critical that these educational opportunities are available for CRNAs and other advanced practice registered nurses. The commenter stated that in some states, CRNAs are the sole anesthesia providers in nearly 100 percent of rural hospitals, affording these medical facilities obstetrical, surgical, trauma stabilization, and pain management capabilities. The commenter stated that the importance of CRNA services in rural areas was highlighted in a recent study which examined the relationship between socioeconomic factors related to geography, insurance type, and the distribution of anesthesia provider type. The study correlated CRNAs with lower income populations and correlated anesthesiologist services with higher-income populations. The commenter stated that particular importance to the implementation of public benefit programs in the U.S., the study showed that compared with anesthesiologists, CRNAs are more likely to work in areas with lower median incomes and larger populations of citizens who are unemployed, uninsured, and/or Medicaid beneficiaries.

Response: The policy finalized in this rule relates specifically to Medicare GME payments made to REH facilities. These payments are made only for the training of medical, dental, and podiatry residents. Because Medicare GME payments do not include payments for training CRNAs and because the policy finalized in this rule is limited in scope to residency training at REHs, we consider these comments to be out of scope and are not responding to them in this final rule.

H. Reasonable Cost Payment for Nursing and Allied Health Education Programs (§§ 413.85 and 413.87)

1. General

Under section 1861(v) of the Act, Medicare has historically paid providers for Medicare’s share of the costs that providers incur in connection with approved educational activities. Approved nursing and allied health (NAH) education programs are those that are, in part, operated by a provider, and meet State licensure requirements, or are recognized by a national accrediting body. The costs of these programs are excluded from the definition of “inpatient hospital operating costs” and are not included in the calculation of payment rates for hospitals or hospital units paid under the IPPS, IRF PPS, or IPF PPS, and are excluded from the rate-of-increase ceiling for certain facilities not paid on a PPS. These costs are separately identified and “passed through” (that is, paid separately on a reasonable cost basis). Existing regulations on NAH education program costs are located at 42 CFR 413.85. The most recent substantive rulemakings on these regulations were in the January 12, 2001 final rule (66 FR 3358 through 3374), and in the August 1, 2003 final rule (68 FR 45423 and 45434).

b. Medicare Advantage Nursing and Allied Health Education Payments

Section 541 of the Balanced Budget Refinement Act (BBRA) of 1999 provides for additional payments to hospitals for costs of nursing and allied health education associated with services to Medicare+Choice (now called Medicare Advantage (MA)) enrollees. Hospitals that operate approved nursing or allied health education programs and receive Medicare reasonable cost reimbursement for these programs would receive additional payments from MA organizations. Section 541 of the BBRA limits total spending under the provision to no more than $60 million in any calendar year (CY). (In this document, we refer to the total amount of $60 million or less as the payment “pool”.) Section 541 of the BBRA also provides that direct graduate medical education (GME) payments for Medicare+Choice utilization are reduced to the extent that these additional payments are made for nursing and allied health education programs. This provision was effective for portions of cost reporting periods
Section 512 of the Benefits Improvement and Protection Act (BIPA) of 2000 changed the formula for determining the additional amounts to be paid to hospitals for MA nursing and allied health costs. Under section 541 of the BBRA, the additional payment amount was determined based on the proportion of each individual hospital’s nursing and allied health education payment to total nursing and allied health education payments made to all hospitals. However, this formula did not account for a hospital’s specific MA utilization. Section 512 of the BIPA revised this payment formula to specifically account for each hospital’s MA utilization. This provision was effective for portions of cost reporting periods occurring in a calendar year, beginning with CY 2001, and was implemented in the August 1, 2001 IFC (66 FR 39909 and 39910).

The regulations at 42 CFR 413.87 codified both statutory provisions. We first implemented the BBRA NAH MA provision in the August 1, 2000 IPPS interim final rule with comment period (IFC) (65 FR 47036 through 47039). In that IFC, we outlined the qualifying conditions for a hospital to receive the NAH MA payment, how we would calculate the NAH MA payment pool, and how a qualifying hospital would calculate its “share” of payment from that pool. Determining a hospital’s NAH MA payment essentially involves applying a ratio of the hospital-specific NAH Part A payments, total inpatient days, and MA inpatient days, to national totals of those same amounts, from cost reporting periods ending in the fiscal year that is 2 years prior to the current calendar year. The formula is as follows:

\[
\text{((Hospital NAH pass-through payment/ Hospital Part A Inpatient Days) \times (Hospital MA Inpatient Days)/ (National NAH pass-through payment/National Part A Inpatient Days) \times (National MA Inpatient Days)) \times \text{Current Year Payment Pool}}
\]

With regard to determining the total national amounts for NAH pass-through payment, Part A inpatient days, and MA inpatient days, we note that section 1886(l) of the Act, as added by section 541 of the BBRA, gives the Secretary the discretion to “estimate” the national components of the formula noted previously. For example, section 1886(l)(2)(A) of the Act states that the Secretary would estimate the ratio of payments for all hospitals for portions of cost reporting periods occurring in the year under subsection 1886(h)(3)(D) to total direct GME payments estimated for the same portions of periods under section 1886(h)(3) of the Act. Accordingly, we stated in the August 1, 2000 IFC (65 FR 47038) that each year, we would determine and publish in a final rule the total amount of nursing and allied health education payments made across all hospitals during the fiscal year 2 years prior to the current calendar year. We would use the best available cost reporting data for the applicable hospitals from the Hospital Cost Report Information System (HCRIS) for cost reporting periods in the fiscal year that is 2 years prior to the current calendar year (65 FR 47038).

To calculate the pool, in accordance with section 1886(l) of the Act, we would “estimate” a total amount for each calendar year, not to exceed $60 million (65 FR 47038). To calculate the proportional reduction to Medicare+Choice (now MA) Direct GME payments, we stated that the percentage is estimated by calculating the ratio of the Medicare+Choice nursing and allied health payment “pool” for the current calendar year to the projected total Medicare+Choice direct GME payments made across all hospitals for the current calendar year. We stated that the projections of Medicare+Choice direct GME and Part A direct GME are based on the best available cost report data from the HCRIS (for example, for calendar year 2000, the projections are based on the best available cost report data from HCRIS 1998), and these payment amounts were increased using the increases allowed by section 1886(h) of the Act for these services (using the percentage applicable for the current calendar year for Medicare+Choice direct GME and the Consumer Price Index (CPI–U) increases for Part A direct GME). We also stated that we would publish the applicable percentage reduction each year in the IPPS proposed and final rules (65 FR 47038). Thus, in the August 1, 2000 IFC, we described our policy regarding the timing and source of the national data components for the NAH MA add-on payment and the percent reduction to the direct GME MA payments, and we stated that we would publish the rates for each calendar year in the IPPS proposed and final rules. While the rates for CY 2000 were published in the August 1, 2000, IFC (see 65 FR 47038 and 47039), the rates for subsequent CYs were only issued through Change Requests (CRs) (CR 2692, CR 11642, CR 12407). After recent issuance of the CY 2019 rates in CR 12407 on August 19, 2021, we reviewed our update procedures, and were reminded that the August 1, 2000 IFC states that we would publish the NAH MA rates and direct GME percent reduction every year in the IPPS rules. Accordingly, for CY 2020 and CY 2021, we proposed and finalized the NAH MA add-on rates in the FY 2023 IPPS/LTCH PPS proposed and final rules. We stated that for CYs 2022 and after, we would similarly propose and finalize their respective NAH MA rates and direct GME percent reductions in subsequent IPPS/LTCH PPS rulemakings (see 87 FR 49073, August 10, 2022).

In the FY 2024 IPPS/LTCH PPS proposed rule, we proposed the rates forCY 2022. Consistent with the use of HCRIS data for past calendar years, we proposed to use data from cost reports ending in FY 2020 HCRIS (the fiscal year that is 2 years prior to CY 2022) to compile these national amounts: NAH pass-through payment, Part A inpatient Days, MA inpatient Days.

For the proposed rule, we accessed the FY 2020 HCRIS data from the fourth quarterly HCRIS update of 2022. However, to calculate the “pool” and the direct GME MA percent reduction, we “project” Part A direct GME payments and MA direct GME payments for the current calendar year, which in the proposed rule and in this final rule, is CY 2022, based on the “best available cost report data from the HCRIS” (65 FR 47038). Next, consistent with the method we described previously from the August 1, 2000 IFC, we increased these payment amounts from midpoint to midpoint of the appropriate calendar year using the increases allowed by section 1886(h) of the Act for these services (using the percentage applicable for the current calendar year for Medicare+Choice direct GME and the Consumer Price Index Urban (CPI–U) increases for Part A direct GME). For CY 2022, the direct GME projections are based on the fourth quarterly update of CY 2020 HCRIS, adjusted for the CPI–U and for increasing MA enrollment.

For CY 2022, the proposed national rates and percentages, and their data sources are set forth in this table. We stated in the proposed rule that we intend to update these numbers in the FY 2024 final rule based on the latest available cost report data.
We did not receive any comments on the proposed national NAH MA rates and percentages.

For this final rule, consistent with the use of HCRIS data for past calendar years, for CY 2022, we use data from cost reports ending in FY 2020 HCRIS (the fiscal year that is 2 years prior to CY 2022) to compile these national amounts: NAH pass-through payment, Part A Inpatient Days, MA Inpatient Days. For this final rule, we accessed the HCRIS data from the first quarterly HCRIS update of 2023. However, to calculate the “pool” and the direct GME MA percent reduction, we project Part A direct GME payments and MA direct GME payments for the current calendar year, which in this final rule, is CY 2022 as the best available cost report data. Next, consistent with the method we described previously from the August 1, 2000 IFC, we increased these payment amounts from midpoint to midpoint of the appropriate calendar year using the increases allowed by section 1886(h) of the Act for these services (using the percentage applicable for the current calendar year for MA direct GME, and the Consumer Price Index—Urban (CPI–U) increases for Part A direct GME). For CY 2022, the direct GME projections are based on FY 2020 HCRIS, and the final national rates and percentages, and their data sources are set forth in this table.

In summary, we are finalizing our proposal to use NAH MA add-on rates as well as the direct GME MA percent reductions for CY 2022, based on sufficient HCRIS data to develop the rates for these years. We expect to propose to issue the rates for CY 2023 in the FY 2025 IPPS/LTCH PPS proposed rule, when sufficient HCRIS data is available to develop the rates for CY 2023.

Section 4143 of the CAA 2023 (enacted December 29, 2022), called “Waiver of Cap on Annual Payments for Nursing and Allied Health Education Payments,” amends section 1886(l)(2)(B) of the Act to state that for portions of cost reporting periods occurring in each of CYs 2010 through 2019, the $60 million payment limit, or payment “pool,” shall not apply to the total amount of additional payments for nursing and allied health education to be distributed to hospitals that, as of the date of enactment of this clause, are operating a school of nursing, a school of allied health, or a school of nursing and allied health. As noted previously, section 541 of the BBRA 1999 also provides that direct GME payments for MA utilization will be reduced to the extent that these additional payments are made for nursing and allied health education programs. However, section 4143 of the CAA 2023 also provides that in not applying the $60 million limit for each of 2010 through 2019, the Secretary shall not take into account any increase in the total amount of such additional payment amounts for such nursing and allied health education for portions of cost reporting periods occurring in the year. In the proposed rule, we proposed to interpret this to mean that, pursuant to the requirement set out at section 4143(b) of CAA 2023, MACs shall not change the DGME MA percent reduction amounts specified in CR 11642 for CYs 2010 through 2018, and CR 12407 for CY 2019 (and CR 12596 which corrected the DGME MA percent reduction related to CY 2018 specified in CR 11642).

The following table shows the recalculated pool amounts for CYs 2010 through 2019. We proposed that MACs would first determine whether hospitals that received revised payments under CR 11642 were still receiving NAH MA payments on an interim basis as of December 29, 2022. For example, if a hospital’s payments for a NAH program(s) were adjusted under CR 11642, but that hospital since closed all of its NAH programs, that hospital would not be eligible under section 4143 to receive adjusted payments for CYs 2010 through 2019, even if the hospital itself has remained operational.

Second, we proposed that MACs would use the table in this section of this rule to recalculate an eligible hospital’s NAH MA payment for portions of cost reporting periods occurring in CY 2010 through CY 2019 that are still within the 3-year reopening period. The formula is specified previously in this section.

Third, we proposed that the MACs would subtract the payment amount determined under CR 11642 (or CR 12596 or CR 12407 as applicable) for a
CALCULATION TABLE FOR SECTION 4143 OF CAA OF 2023

| CY 2010 | $62,997,033 | $213,862,393 | 45,409,814 | 3,114,194 | $41,665,871 | 9.77% | $17,615,494 | $18,983,667 | 7.16% | $22,071,952 | 6.41% | $24,484,107 | 5.86% | $26,432,967 | 5.32% | $28,986,630 | 4.99% | $30,838,548 | 4.44% | $34,584,457 | 4.12% | $35,475,490 | 4.07% |
| CY 2012 | $76,035,672 | $240,958,503 | 55,551,047 | 4,376,532 | $18,983,667 | 7.16% | $22,071,952 | 6.41% | $24,484,107 | 5.86% | $26,432,967 | 5.32% | $28,986,630 | 4.99% | $30,838,548 | 4.44% | $34,584,457 | 4.12% | $35,475,490 | 4.07% |
| CY 2013 | $84,767,178 | $245,294,317 | 54,965,956 | 4,945,724 | $22,071,952 | 9.77% | $24,484,107 | 5.86% | $26,432,967 | 5.32% | $28,986,630 | 4.99% | $30,838,548 | 4.44% | $34,584,457 | 4.12% | $35,475,490 | 4.07% |
| CY 2014 | $93,598,893 | $248,506,989 | 54,405,730 | 5,360,315 | $24,484,107 | 5.86% | $26,432,967 | 5.32% | $28,986,630 | 4.99% | $30,838,548 | 4.44% | $34,584,457 | 4.12% | $35,475,490 | 4.07% |
| CY 2015 | $102,448,386 | $247,076,161 | 55,223,064 | 5,907,933 | $26,432,967 | 5.32% | $28,986,630 | 4.99% | $30,838,548 | 4.44% | $34,584,457 | 4.12% | $35,475,490 | 4.07% |
| CY 2016 | $110,412,962 | $253,272,740 | 55,717,901 | 6,376,818 | $28,986,630 | 4.99% | $30,838,548 | 4.44% | $34,584,457 | 4.12% | $35,475,490 | 4.07% |
| CY 2017 | $119,165,456 | $249,546,528 | 58,599,068 | 7,241,576 | $30,838,548 | 4.44% | $34,584,457 | 4.12% | $35,475,490 | 4.07% |
| CY 2018 | $130,335,289 | $267,714,849 | 61,066,487 | 7,888,809 | $34,584,457 | 4.12% |

Response: As commenters are aware, in the proposed rule, we noted that the provision applies to “each of 2010 through 2019,” and included a table called CALCULATION TABLE FOR SECTION 4143 OF CAA OF 2023 that includes revised Section 4143 Pool amounts for each of CYs 2010 through 2019. That is, we provided revised payment rates for as far back as 2010, thereby conforming with the retroactive aspect of this provision. However, we proposed that MACs would use the table to recalculate an eligible hospital’s NAH MA payment only for portions of cost reporting periods occurring in CY 2010 through CY 2019 that are still within the three-year reopening period. We have reviewed the comments and the language in section 4143, subsection (c) regarding “Retroactive Application,” and we do not believe that language overrides CMS’s existing reopening regulations. Rather, we believe the statute indicates that Congress instructed us to ensure that necessary payments “apply” retroactively. We note that any recoupments under CR 11642 (or CR 12596 or CR 12407 as applicable) occurred during the last three years, and thus we can reverse the recoupments by reopening cost reports affected by those CRs consistent with the reopening regulations. Further, because those CRs and the recoupments conducted under them are the source of the underpayments corrected by Section 4143 and this implementing rule, we do not believe it is necessary to reopen other cost reports to “apply” the
amendments made under Section 4143.” In addition, we do not understand the commenter’s concern that the proposal would only permit corrections to cost reports within the three-year reopening time period “as of 12/29/2022”; nowhere in the proposal did we specify such a requirement. On the contrary, we point out that generally, there should be no concern that a cost report reopening timeframe would expire since the time that the cost report was adjusted under CR 11642. We note that CR 11642 states that “MACs shall not make recalculation of cost or the MACs were relying on the instructions contained in CR 2692, which CMS had issued in 2003. Under these instructions, NAH MA payments were calculated on the basis of aggregate data that had not been updated since CY 2001, when total MA patient days were still relatively low, and the size of the calculated NAH MA payment pool was $43,663,043 (refer to CR 2692, Transmittal A–03–043, https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/a03043.pdf). Over the course of those years from 2003 through 2020, MACs were calculating NAH MA payments to individual hospitals using contemporaneous hospital-specific data, which, as the years passed, reflected the significant increase in MA patient days during this period. Because hospital-specific MA patient days are one of the factors used in the calculation of the hospital’s NAH MA payments in a calendar year (see §413.87(e)(1)(iii)), the interaction of the aggregate data that had not been updated since 2001 and the contemporaneous hospital-specific data for each calendar year resulted in significant empirical overpayments to hospitals.

Under CR 11642, CMS instructed MACs to recalculate historical payments to hospitals consistent with the $60 million limit per calendar year (applicable as of CY 2010 and after), and use updated national data and make applicable adjustments to NAH MA payments. Under our proposal for the implementation of section 4143, the amounts previously recouped under CR 11642 (or CR 12596 or CR 12407 as applicable) will be returned to hospitals, and recoupments that would have occurred under CR 11642 (or CR 12596 or CR 12407 as applicable) if not for the enactment of section 4143 of theCAA 2023 will not occur. In other words, CMS only imposed the $60 million cap that section 4143(a)(2)(ii) stated “shall not apply [for 2010–2019] to those hospitals that, as of [December 29, 2022], are operating a school of nursing, a school of allied health, or a school of nursing and allied health” via the previously described CRs, and all cost reports affected by those CRs are within the three-year reopening window. We believe we can fulfill Congress’s instruction to apply section 4143 retroactively without creating an exception to our reopening regulations.

For the reasons stated previously, we do not believe an override or exception to the reopening regulations is required, and we are finalizing our proposal to recalculate an eligible hospital’s NAH MA payment only for portions of cost reporting periods occurring in CY 2010 through CY 2019 that are still within the 3-year reopening period.

Comment: Some commenters disagreed with CMS’s proposal that MACs would first determine whether hospitals that received revised payments under CR 11642 were still receiving NAH MA payments on an interim basis of as of December 29, 2022. One commenter stated that there is nothing in the statute that suggests a hospital must receive payments on an interim basis, only that a nursing and allied health program “was operating” on December 29, 2022. This commenter asked that CMS eliminate the reference to payments on an interim basis and indicate that all hospitals operating a nursing and allied health program as of December 29, 2022, are eligible under section 4143 to receive adjusted nursing and allied health MA payments for CYs 2010 through 2019. Other commenters recommended that instead of interim rates, the MACs should apply Section 4143 to hospitals that file pass-through costs for NAH programs on their cost reports, because these hospitals still have their NAH programs even though the MAC disallowed their pass-through costs as a result of audits. Another commenter stated that some hospitals may have closed their NAH programs because the MACs disallowed payment. This commenter asserted that regardless of why a NAH program may have closed prior to December 29, 2022, it seems unfair not to provide the same relief for underpayments they received in the past when they were operating those programs. In cases where the MACs disallowed payment, and the hospitals are appealing those determinations, the commenters argued that, even though the hospitals were not receiving interim payments as of December 29, 2022, they were still operating their programs, and they expect their NAH payments to be recognized after a successful appeal.

Response: We understand that there may be a few possible reasons why a hospital may not have been receiving NAH MA payments on an interim basis as of December 29, 2022, even though the hospital had not formally closed its NAH program(s). For example, the hospital’s NAH pass-through amount may be too small to qualify for interim payments. Also, as the commenter described, the MACs have disallowed the hospital’s pass-through payments, and the hospital might currently be in...
the process of appealing that determination. Alternatively, a hospital may have several years of cost reports that it filed with NAH costs, but those cost reports may not yet be settled, and thus, the MAC has not yet made a determination as to the allowability of the NAH pass-through costs with regard to interim payments. In the first case, where the NAH pass-through amount is too small to qualify for interim payments, if the hospital’s NAH pass-through would otherwise qualify for interim payments as of December 29, 2022, if the amount had been large enough, then for the purpose of implementing Section 4143, we would treat the hospital as though it was receiving interim payments as of December 29, 2022. With regard to multiple cost reporting years that have not yet been settled, it may be that CR 11642 was not yet applied to those cost reports, in which case there would be no need for reversal of a recoupment upon eventual settlement of those cost reports. However, regarding the situation where the MAC has disallowed the NAH payment, we understand that in many cases the MACs have found that hospitals are not “operating” the NAH program(s) consistent with the regulations at 42 CFR 413.85, although hospitals may believe that “as of the date of enactment” of section 4143, the hospitals “are operating” a school of nursing and/or allied health. Where the MACs have disallowed the NAH payment, settled the cost report(s), and the hospitals are appealing the disallowance, then we believe the normal appeals process should be followed, and NAH payments, under section 4143 or otherwise, are held in abeyance pending the outcome of the appeals. Thus, we proposed to use receipt of interim payments as of December 29, 2022 as an indicator of eligibility of NAH pass-through payments; lack of such pass-through payment could indicate a MAC disallowance, which should be adjudicated through the normal appeals process. If the hospitals should be successful in their appeals to restore NAH pass-through payment, then for the purpose of implementing section 4143, we would treat the hospitals as though they were receiving interim payments as of December 29, 2022. If, on the other hand, a hospital closed its NAH program(s), whether the closure was allegedly a result of MAC disallowances or due to some other reason, we do believe that section 4143 applies in those cases, because section 4143 clearly states that payments should only be made to “those hospitals that, as of the date of enactment, are operating a school of nursing, a school of allied health, or a school of nursing and allied health (emphasis added).” Thus, in this final rule, we are still requiring that MACs first determine whether hospitals that received revised payments under CR 11642 were still receiving NAH MA payments on an interim basis as of December 29, 2022, with the exception of hospitals whose NAH pass-through payment would otherwise qualify for interim payments as of December 29, 2022, if the amount had been large enough, and hospitals that will be successful in their appeals to restore NAH pass-through payment.

Comment: One commenter believed that no money should be siphoned away from DGME funding to pay for nonphysician training. Though the commenter appreciates the role that nonphysician providers play, the commenter believed that there should be a funding source separate from GME funding. This commenter also expressed concern that the rule does not contain proposals to ensure that in the future, too much MA DGME would not be removed from GME funding, and recommended that CMS put robust guardrails in place to ensure that GME funding updates are made accurately every year moving forward.

Response: This comment is generally out of the scope of the proposals made in the FY 2024 IPPS/LTCH PPS proposed rule; therefore, we are not responding to it directly at this time. However, with regard to ensuring accurate (and timely) payment rate updates, we note that starting with the rates for CY 2020 and CY 2021, we proposed and finalized the NAH MA add-on rates in the FY 2023 IPPS/LTCH PPS proposed and final rules. We stated that for CYs 2022 and after, we would similarly propose and finalize their respective NAH MA rates and direct GME percent reductions in subsequent IPPS/LTCH PPS rulemakings (see 87 FR 49073 (August 10, 2022). In the FY 2024 IPPS/LTCH PPS proposed rule, we proposed the rates for CY 2022, and we are finalizing the CY 2022 rates in this final rule. Accordingly, we have established an annual process to ensure issuance of updated NAH MA and DGME MA rates that are as updated and accurate as possible.

In summary, after consideration of the public comments received, we are finalizing the proposed methodology for the implementation of section 4143, such that the amounts previously recouped under CR 11642 (or CR 12596 or CR 12407 as applicable) will be returned to hospitals, and recoupments that would have occurred under CR 11642 (or CR 12596 or CR 12407 as applicable) if not for the enactment of section 4143 of the CAA 2023 will not occur. After issuance of this final rule, we will issue another CR to reflect this finalized methodology.

I. Payment Adjustment for Certain Clinical Trial and Expanded Access Use Immunotherapy Cases (§§ 412.85 and 412.312)

Effective for FY 2021, we created MS–DRG 018 for cases that include procedures describing CAR T-cell therapies, which were reported using ICD–10–PCS procedure codes WX033C3 or WX043C3 (85 FR 58599 through 58600). Effective for FY 2022, we revised MS–DRG 018 to include cases that report the procedure codes for CAR T-cell and non-CAR T-cell therapies and other immunotherapies (86 FR 44798 through 448106).

Effective for FY 2021, we modified our relative weight methodology for MS–DRG 018 to develop a relative weight that is reflective of the typical costs of providing CAR T-cell therapies relative to other IPPS services. Specifically, under our finalized policy we do not include claims determined to be clinical trial claims that group to MS–DRG 018 when calculating the average cost for MS–DRG 018 that is used to calculate the relative weight for this MS–DRG, with the additional refinements that: (a) when the CAR T-cell therapy product is purchased in the usual manner, but the case involves a clinical trial of a different product, the claim will be included when calculating the average cost for MS–DRG 018 to the extent such claims can be identified in the historical data; and (b) when there is expanded access use of immunotherapy, these cases will not be included when calculating the average cost for MS–DRG 018 to the extent such claims can be identified in the historical data (85 FR 58600). The term “expanded access” (sometimes called “compassionate use”) is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when, among other criteria, there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat...
the disease or condition (21 CFR 312.305). Effective FY 2021, we also finalized an adjustment to the payment amount for applicable clinical trial and expanded access immunotherapy cases that group to MS–DRG 018 using the same methodology that we used to adjust the case count for purposes of the relative weight calculations (85 FR 58842 through 58844). (As previously noted, effective beginning FY 2022, we revised MS–DRG 018 to include cases that report the procedure codes for CAR T-cell and non-CAR T-cell therapies and other immunotherapies (86 FR 44798 through 448106).) Specifically, under our finalized policy we apply a payment adjustment to claims that group to MS–DRG 018 and include ICD–10–CM diagnosis code Z00.6, with the modification that when the CAR T-cell, non-CAR T-cell, or other immunotherapy product is purchased in the usual manner, but the case involves a clinical trial of a different product, the payment adjustment will not be applied in calculating the payment for the case. We also finalized that when there is expanded access use of immunotherapy, the payment adjustment will be applied in calculating the payment for the case. This payment adjustment is codified at 42 CFR 412.85 (for operating IPPS payments) and 412.312 (for capital IPPS payments), for claims appropriately containing Z00.6, as described previously, and reflects that the adjustment is also applied for cases involving expanded access use immunotherapy, and that the payment adjustment only applies to applicable clinical trial cases; that is, the adjustment is not applicable to cases where the CAR T-cell, non-CAR T-cell, or other immunotherapy product is purchased in the usual manner, but the case involves a clinical trial of a different product. The regulations at 42 CFR 412.85(c) also specify that the adjustment factor will reflect the average cost for cases to be assigned to MS–DRG 018 that involve expanded access use of immunotherapy or are part of an applicable clinical trial to the average cost for cases to be assigned to MS–DRG 018 that do not involve expanded access use of immunotherapy and are not part of a clinical trial (85 FR 58844).

For FY 2024, we proposed to continue to apply an adjustment to the payment amount for expanded access use of immunotherapy and applicable clinical trial cases that would group to MS–DRG 018, as calculated using the same proposed modifications to our existing methodology, as adopted in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58842), that we proposed to use to adjust the case count for purposes of the relative weight calculations, as described in section II.D. of the preamble of the proposed rule and this final rule. As discussed in that section, the December update of the FY 2022 MedPAR claims data now includes a field that identifies whether or not the claim involves expanded access use of immunotherapy. For the FY 2022 MedPAR claims data, this field identifies whether or not the claim includes condition code ZB. For the FY 2023 MedPAR data and for subsequent years, this field will identify whether or not the claim includes condition code 90. The MedPAR files now also include information for claims with the payer-only condition code “ZC”, which is used by the IPPS Pricer to identify a case where the CAR T-cell, non-CAR T-cell, or other immunotherapy product is purchased in the usual manner, but the case involves a clinical trial of a different product so that the payment adjustment is not applied in calculating the payment for the case (for example, see Change Request 11879, available at https://www.cms.gov/files/document/r10571cp.pdf). We refer the readers to II.D. of the preamble of the proposed rule and this final rule for further discussion of our proposed changes to our methodology for identifying clinical trial claims and expanded access use claims in MS–DRG 018 and our proposed modifications to the methodology used to adjust the case count for purposes of the relative weight calculations.

Consistent with these proposals, and using the same methodology that we proposed to use to adjust the case count for purposes of the relative weight calculations, we proposed to calculate the adjustment to the payment amount for expanded access use of immunotherapy and applicable clinical trial cases as follows:

1. Calculate the average cost for cases assigned to MS–DRG 018 that involve a clinical trial of a different product so that the payment adjustment is not applied in calculating the payment for the case where the CAR T-cell, non-CAR T-cell, or other immunotherapy product is purchased in the usual manner, but the case involves a clinical trial of a different product that the payment adjustment is not applied in calculating the payment for the case (for example, see Change Request 11879, available at https://www.cms.gov/files/document/r10571cp.pdf). We refer the readers to section II.D. of the preamble of the proposed rule and this final rule for further discussion of our proposed changes to our methodology for identifying clinical trial claims and expanded access use claims in MS–DRG 018 and our proposed modifications to the methodology used to adjust the case count for purposes of the relative weight calculations.

2. Calculate the average case cost for all other cases assigned to MS–DRG 018.

3. Calculate an adjustor based on the most recent data for FY 2024.

4. Apply the adjustor to calculate payments for expanded access use of immunotherapy and applicable clinical trial cases that group to MS–DRG 018 by multiplying the relative weight for MS–DRG 018 by the adjustor. We refer the readers to section II.D. of the preamble of the proposed rule and this final rule for further discussion of these proposed methodology changes.

Consistent with our calculation of the proposed adjustor for the relative weight calculations, for the proposed rule we proposed to calculate this adjustor based on the December 2022 update of the FY 2022 MedPAR file for purposes of establishing the FY 2024 payment amount. Specifically, in accordance with 42 CFR 412.85 (for operating IPPS payments) and 412.312 (for capital IPPS payments), we proposed to multiply the FY 2024 relative weight for MS–DRG 018 by a proposed adjustor of 0.28 as part of the calculation of the payment for claims determined to be applicable clinical trial or expanded access use immunotherapy claims that group to MS–DRG 018, which includes CAR T-cell and non-CAR T-cell therapies and other immunotherapies. We also proposed to update the value of the adjustor based on more recent data for the final rule.

We did not receive any comments specifically relating to the proposed payment adjustment for applicable clinical trial and expanded access use immunotherapy cases and are therefore finalizing our proposal without modification. We are also finalizing our proposal to update the value of this adjustor based on more recent data for this final rule. Therefore, using the March 2023 update of the FY 2022 MedPAR data, we are finalizing an adjustor of 0.27 for FY 2024, which will be multiplied by the final FY 2024 relative weight for MS–DRG 018 as part of the calculation of the payment for claims determined to be applicable clinical trial or expanded access use immunotherapy claims that group to MS–DRG 018.

J. Hospital Readmissions Reduction Program

1. Statutory Basis for the Hospital Readmissions Reduction Program

Section 1886(q) of the Act established the Hospital Readmissions Reduction Program. We refer readers to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49530 through 49531) and the FY 2018 IPPS/LTCH PPS final rule (82 FR 38221 through 38240) for a detailed discussion of and additional information on the statutory history of the Hospital Readmissions Reduction Program.
2. Regulatory Background

We refer readers to the following final rules for detailed discussions of the regulatory background and descriptions of the current policies for the Hospital Readmissions Reduction Program:

- **FY 2012 IPPS/LTCH PPS final rule** (76 FR 51660 through 51676);
- **FY 2013 IPPS/LTCH PPS final rule** (77 FR 53374 through 53401);
- **FY 2014 IPPS/LTCH PPS final rule** (78 FR 50649 through 50676);
- **FY 2015 IPPS/LTCH PPS final rule** (79 FR 50024 through 50048);
- **FY 2016 IPPS/LTCH PPS final rule** (80 FR 49530 through 49543);
- **FY 2017 IPPS/LTCH PPS final rule** (81 FR 56973 through 56979);
- **FY 2018 IPPS/LTCH PPS final rule** (82 FR 38221 through 38240);
- **FY 2019 IPPS/LTCH PPS final rule** (83 FR 41431 through 41439);
- **FY 2020 IPPS/LTCH PPS final rule** (84 FR 42380 through 42390);
- **FY 2021 IPPS/LTCH PPS final rule** (85 FR 58844 through 58847);
- **FY 2022 IPPS/LTCH PPS final rule** (86 FR 45249 through 45266);
- **FY 2023 IPPS/LTCH PPS final rule** (87 FR 49081 through 49094).

We have also codified certain requirements of the Hospital Readmissions Reduction Program at 42 CFR 412.152 through 412.154.

3. Current Measures

The Hospital Readmissions Reduction Program currently includes six applicable conditions/procedures: Acute myocardial infarction (AMI); heart failure (HF); pneumonia (PN); elective primary total hip arthroplasty/total knee arthroplasty (THA/TKA); chronic obstructive pulmonary disease (COPD); and coronary artery bypass graft (CABG) surgery.

We did not make any proposals or updates in the FY 2024 IPPS/LTCH PPS proposed rule (86 FR 27024) for the Hospital Readmissions Reduction Program. We refer readers to section V.G.5. of the preamble for an updated slope of the linear exchange function to translate this estimated amount available into a value-based incentive payment percentage for each hospital, based on its Total Performance Score (TPS). We published proxy value-based incentive payment adjustment factors in Table 16 associated with the proposed rule (which is available via CMS website).

We are publishing updated proxy value-based incentive payment adjustment factors in Table 16A associated with this final rule (which is available via the CMS website). We note that these proxy adjustment factors will not be used to adjust hospital payments for FY 2024 as they were calculated using the historical baseline and performance periods for the FY 2023 Hospital VBP Program.

These updated proxy factors were calculated using the March 2023 update to the FY 2022 MedPAR file. The updated slope of the linear exchange function used to calculate these proxy factors was 2.6517299103, and the estimated amount available for value-based incentive payments to hospitals for FY 2024 is approximately $1.7 billion. We will add Table 16B to display the actual value-based incentive payment adjustment factors, exchange function slope, and estimated amount available for the FY 2024 Hospital VBP Program. We expect that Table 16B will be posted in Fall 2023.

2. Retention and Removal of Quality Measures

a. Retention of Previously Adopted Hospital VBP Program Measures and Relationship Between the Hospital IQR and Hospital VBP Program Measure Sets

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53592), we finalized a policy to retain measures from prior program years for each successive program year, unless otherwise proposed and finalized. In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41440 through 41441), we finalized a revision to our regulations at 42 CFR 412.164(a) to clarify that once we have complied with the statutory prerequisites for adopting a measure for the Hospital VBP Program (that is, we have selected the measure from the Hospital IQR Program measure set and included data on that measure on Hospital Compare for at least one year prior to its inclusion in a Hospital VBP Program performance period), the Hospital VBP Program statute does not require that the measure continue to remain in the Hospital IQR Program.

We did not propose any changes to these policies in the FY 2024 IPPS/LTCH PPS proposed rule.
b. Codification of the Current Hospital VBP Program Measure Removal Factors

In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41441 through 41446), we finalized eight measure removal factors for the Hospital VBP Program, and we refer readers to that final rule for details.

In the FY 2024 IPPS/LTCH PPS proposed rule, we proposed to codify at 42 CFR 412.164(c) of our regulations these eight measure removal factors as well as the policies for updating measure specifications and retaining measures (88 FR 27025). We believe that this codification will make it easier for interested parties to find these policies and will further align the Hospital VBP Program regulations with the regulations we have codified for other quality reporting programs.

We invited public comment on this proposal.

We did not receive any comments on this proposal and are finalizing this proposal as proposed with minor technical modifications to regulation text at 42 CFR 412.164(c).

c. Substantive Measure Modifications

(1) Adoption of Substantive Measure Updates to the Medicare Spending per Beneficiary (MSPB)—Hospital Measure (CBE #2158) Beginning With the FY 2028 Program Year

In the FY 2024 IPPS/LTCH PPS proposed rule, we proposed to adopt substantive measure updates to the MSPB Hospital measure (CBE #2158) in the Hospital VBP Program beginning with the FY 2028 program year (88 FR 27025 through 27026). We adopted the MSPB Hospital measure in the Hospital VBP Program in the FY 2012 IPPS/LTCH PPS final rule beginning with the FY 2014 program year (76 FR 51654 through 51658). We continue to believe that the MSPB Hospital measure provides important data on resource use (addressing the Meaningful Measures Framework priority of making care affordable), which is why we proposed substantive updates to the MSPB Hospital measure in the Hospital VBP Program under the Efficiency/Cost Domain. We refer readers to the FY 2019 IPPS/LTCH PPS final rule for a broader discussion of the Meaningful Measures Framework (83 FR 41147).

We previously adopted the same substantive updates to the MSPB Hospital measure for use in the Hospital IQR Program in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49257 through 49260). The substantive updates to the MSPB Hospital measure are three refinements to ensure a more comprehensive and consistent assessment of hospital performance by capturing more episodes and adjusting the measure calculation:

- An update to allow readmissions to trigger new episodes to account for episodes and costs that are currently not included in the measure but that could be within the hospital’s reasonable influence;
- A new indicator variable in the risk adjustment model for whether there was an inpatient stay in the 30 days prior to episode start date; and
- An updated MSPB amount calculation methodology to change one step in the measure calculation from the sum of observed costs divided by the sum of expected costs (ratio of sums) to the mean of observed costs divided by expected costs (mean of ratios).

These refinements also appear in a summary of the measure re-evaluation on the CMS QualityNet website posted in July 2020.

We presented the three substantive updates to the MSPB Hospital measure (CBE #2158) to the consensus-based entity (CBE) in the Fall 2020 cycle for measure re-endorsement. During the Fall 2020 11-month endorsement cycle, the re-evaluated MSPB Hospital measure was reviewed by the Scientific Methods Panel (SMP), Cost and Efficiency Standing Committee, and Consensus Standards Approval Committee (CSAC). The re-evaluated measure passed on the reliability and validity criteria when reviewed by the SMP. The Cost and Efficiency Standing Committee reviewed each aspect of the re-evaluated measure in detail across three meetings. The CSAC approved the Standing Committee’s endorsement recommendation unanimously and re-endorsed the MSPB Hospital measure (CBE #2158) in June 2021 with the three refinements. Following re-endorsement, we included the updated measure in CMS’s “List of Measures Under Consideration (MUC)” for December 1, 2021. 

For the purpose of continuing to assess hospitals’ efficiency and resource use and to meet statutory requirements under section 1886(o)(2)(B)(ii) of the Act, we proposed to adopt the substantive updates to the MSPB Hospital measure in the Hospital VBP Program under the Efficiency and Cost Reduction Domain. As previously stated, we previously adopted the same substantive updates to the measure in the Hospital IQR Program (87 FR 49257 through 49263), and we intend to begin posting the updated measure data on Care Compare beginning in January 2024, which will enable us to post data on the substantive updates to the measure for at least one year before the proposed beginning of the performance period for the FY 2028 program year (discharges beginning January 1, 2026).

We proposed to adopt the substantive updates to the MSPB Hospital measure (CBE #2158) in the Hospital VBP Program beginning with the FY 2028 program year. We refer readers to section V.K.4.c of the preamble of this final rule where we discuss our defined baseline and performance periods for this updated measure under the Hospital VBP Program. We also proposed that the performance standards calculation methodology for the updated MSPB Hospital measure will be the same as that which we currently use for the measure. The performance standards for the updated measure for the FY 2028 program year are not yet available.

We invited public comment on this proposal.

Interested parties convened by the consensus-based entity will provide input and recommendations on the measures under Consideration (MUC) list as part of the pre-rulemaking process required by section 1890A of the Act. We refer readers to https://qif4dm.org/PRMR-MSR for more information.


Comment: Many commenters supported the proposal to implement the substantive updates to the MSPB Hospital measure in Hospital VBP Program. Several commenters commended CMS for its alignment with the Hospital IQR Program. A commenter cited the updates to readmission terminology as a significant factor in their support.

Response: We thank commenters for their support, and we aim to maintain alignment with the Hospital IQR Program in line with our statutory requirements and to update our existing measures when possible.

Comment: A few commenters did not support the proposal and expressed concern that allowing readmissions to trigger new episodes could lead to the same costs being attributed to hospitals twice and provide a misleading portrayal of hospital performance.

Response: As previously stated in the FY 2023 IPPS/LTC PPS final rule (87 FR 49257 through 49263) where we adopted the MSPB re-evaluated measure in the Hospital IQR Program, the refinement allows readmissions to trigger new episodes which will result in some services being assigned to multiple episodes. These services, however, will only be counted once per episode, so the cost of these services will not be counted twice within the same episode. Additionally, the presence of an inpatient admission within 30 days before the start date of an episode based on a readmission is controlled for in the risk adjustment model to account for the additional complexity that readmissions may entail.226 Further, the inclusion of episodes triggered by readmissions does not necessarily result in a worse measure score for the provider. Such episodes still use the observed over expected cost ratios, where it is possible for the observed cost to be lower than expected cost, if the hospital performed better on the episode than expected.

Comment: A few commenters did not support the proposal to adopt the re-evaluated MSPB Hospital measure citing concern that hospitals have not had enough time to understand how the updates impacted hospital performance in the Hospital IQR Program, including allowing hospitals to see performance metrics, prior to implementation in the Hospital VBP Program. A commenter requested to see the calculations and impact changes before being able to appropriately comment, and a commenter recommended delaying adoption for one year to allow for more robust feedback. Additionally, a few commenters expressed concern that the measure will increase the burden on hospitals because they will have to monitor and validate two different performance rates using two different measure specifications. A few commenters also expressed concern that the policy will result in two slightly different measure specifications being used simultaneously in the two different programs which they believe could yield different results and make it more difficult to interpret results.

Response: We appreciate the commenters’ concerns. As we have previously stated in the FY 2024 IPPS/LTC PPS proposed rule (88 FR 27025 through 27026), we adopted the re-evaluated version of the MSPB Hospital measure into the Hospital IQR Program to accommodate the statutory and regulatory requirements as well as to provide interested parties with an opportunity to become familiar with the new version of the measure and provide feedback. We staged our proposals across the Hospital IQR Program and Hospital VBP Program to accommodate statutory and regulatory requirements, as further discussed later in this section. We refer readers to the FY 2023 IPPS/LTC PPS final rule (87 FR 49257 through 49263) for more information on the policy to adopt the substantive updates to MSPB Hospital measure in the Hospital IQR Program, which provided interested parties with an opportunity to become familiar with the new version of the measure and provide feedback prior to our proposal to adopt the measure updates in the Hospital VBP Program. It should be noted that for the re-evaluated MSPB Hospital measure in the Hospital IQR Program, we will make sure it is clear which location through the policy to adopt the substantive updates to MSPB Hospital measure in the Hospital IQR Program, which provided interested parties with an opportunity to become familiar with the new version of the measure and provide feedback prior to our proposal to adopt the measure updates in the Hospital VBP Program. It should be noted that for the re-evaluated MSPB Hospital measure in the Hospital IQR Program, which provided interested parties with an opportunity to become familiar with the new version of the measure and provide feedback prior to our proposal to adopt the measure updates in the Hospital VBP Program.

Comment: A few commenters did not support the proposal to adopt the re-evaluated MSPB Hospital measure because they believed that the measure was not adequately tested and adjusted for social risk factors. A commenter believed that measure scores shifted when social risk factors were applied within the risk model. A commenter recommended implementing a social risk factor adjustment in calculating measure performance because they believed that it will improve measure reliability. A commenter specifically stated that they believed the endorsement review suggested low reliability and validity. Another commenter expressed concern about the scientific acceptability of the measure, and a commenter believed that there would be a potential inverse relationship between outcomes, adjustment for social risk factors, and medical complexities due to vulnerable patient groups driving performance differences.

Response: We respectfully disagree with the commenters that the re-evaluated MSPB Hospital measure has low reliability and validity. The CBE rated the measure’s reliability as high.
when endorsing the measure. The average reliability score of hospitals with at least 25 episodes was .92,\textsuperscript{227} which far exceeds the standard generally considered as 'high' reliability. The CBE rated the measure’s validity as moderate when endorsing the measure.\textsuperscript{228} Further, as part of the CBE endorsement submission we assessed the impact of social risk factors on the measure, conducting testing based on CBE precedents, as well as supplemented with novel testing and in response to specific stakeholder feedback. Specifically, we tested whether the inclusion of sex, dual eligibility status, race/ethnicity, the AHRQ socioeconomic status (SES) index, components of the AHRQ SES index, and the Area Deprivation Index could meaningfully be incorporated into the measure’s risk adjustment model so as not to penalize the hospital for the patients they treat, while also not setting a lower standard of care for hospitals with patients who have social risk factors. Results showed that the inclusion of these social risk factors in the risk model had a limited and inconsistent effect on measure scores, and some of the variation that was captured by tested covariates was attributable to the hospital in which the episodes were initiated. The CBE’s Scientific Methods Panel carefully reviewed the testing results on the impacts of social risk factors on the measure and our recommendation to continue not including them in the measure’s risk adjustment model and passed the measure on the validity criterion. While social risk factors continue to not be included in the measure’s risk adjustment model, we plan to continue to conduct testing and monitoring of the impact of social risk factors on the measure as part of normal measure maintenance.

**Comment:** Several commenters expressed concerns about the re-evaluated MSPB Hospital measure, including their beliefs that the measure does not inform performance by condition, there could be an increased number of episodes included in the measure that could impact performance, and the explanation of how services are allocated to an episode is unclear on how this would not penalize a hospital twice.

**Response:** Regarding the commenter’s concern about hospitals being penalized twice, this refinement will not result in hospitals being penalized twice because the re-evaluated MSPB Hospital measure, whether used in the Hospital IQR Program or Hospital VBP Program, and the condition- and procedure-specific readmission measures used in the Hospital Readmissions Reduction Program assess readmissions for different purposes. The re-evaluated MSPB Hospital measure assesses hospitals’ cost efficiency on readmissions and other costs for both the hospital and patient, while the condition- and procedure-specific measures in the Hospital Readmissions Reduction Program are intended to reduce avoidable readmissions.

We respectfully disagree that there could be an increased number of episodes included in the measure and thus impact performance due to readmissions triggering new episodes. The inclusion of episodes triggered by readmissions does not necessarily result in a worse measure score for the provider. Such episodes still use the observed over expected cost ratios, where it is possible for the observed cost to be lower than expected cost, if the hospital performed better on the episode than expected. Additionally, allowing readmissions to trigger new MSPB Hospital episodes does not impact a hospital’s readmissions rates, given that it merely captures episodes that are based on existing readmissions so that those episodes can be used to assess hospital performance.

**Comment:** A commenter requested additional clarification around what is a hospital’s reasonable influence for a readmission. They expressed concern that it may be difficult for hospitals to track readmissions without understanding what CMS considers to be reasonable influence and recommended providing additional information on Care Compare prior to FY 2028.

**Response:** We interpret “reasonable influence” in the comment to mean the appropriateness to hold the hospital accountable for the costs associated with the readmissions if they are influenced not only by the hospital’s care decisions but also other factors that the hospital may not have influence over (for example, a patient’s age, comorbidities, or other risk factors). The Technical Expert Panel (TEP) that provided feedback to the measure developer on the re-evaluated MSPB Hospital measure agreed that readmissions should not trigger MSPB episodes to capture costs in the subsequent 30 days post-discharge for the readmissions because they believed that it is clinically appropriate to hold a hospital responsible for these costs.\textsuperscript{229} Allowing readmissions to trigger new episodes (i) encourages hospitals to provide cost efficient care and improve care coordination not only during initial hospitalizations, but also during readmissions, (ii) increases the number of episodes for which a clinician can be scored, and (iii) captures potentially high-cost services that are otherwise excluded. Additionally, allowing readmissions to trigger new MSPB Hospital episodes does not impact a hospital’s readmissions rates, given that it merely captures episodes that are based on existing readmissions so that those episodes can be used to assess hospital performance. Furthermore, readmissions trigger an episode similarly to how initial admissions trigger in an episode, in that the episode window starts three days prior to the inpatient stay (whether it’s an initial admission or readmission) and ends 30 days after discharge—thus, this refinement to measure construction will not result in any additional burden for hospitals to track.

We provide clarification on (i) how readmissions trigger an episode, and (ii) the impact of the re-evaluated MSPB Hospital measure as follows. An episode is opened, or triggered, by an initial admission to an inpatient hospital, and the episode window starts three days prior to this index admission and ends 30 days after discharge. If a readmission for the same patient occurs within the 30-day post-discharge of the first episode, then the readmission triggers a new episode. This new episode’s window starts three days prior to the readmission and ends 30 days after discharge from the readmission. The hospital managing the readmission is now being measured under similar cost efficiency incentives by the new episode. Specifically, the new episode includes the costs in the post-discharge period of the readmission not previously captured. The refinement to allow readmissions to trigger a new episode will result in some services being assigned to multiple episodes. These services, however, are counted only once per episode (that is, cost will not be double-counted). The revised measure calculation compares each hospital’s observed episode costs to predicted episode costs among their peers for patients with the same

\textsuperscript{227}The submission materials, including the testing results, are available at: https://mmshub.cms.gov/sites/default/files/cost-and-efficiency-final-report-fall-2020.pdf.

\textsuperscript{228}The submission materials, including the testing results, are available at: https://mmshub.cms.gov/sites/default/files/cost-and-efficiency-final-report-fall-2020.pdf.

observable characteristics, rather than to a pre-defined standard. By comparing hospitals to other hospitals that are all attributed in the same way, we expect this comparison to be fair. This helps maintain care coordination incentives of the re-evaluated MSPB Hospital measure. Further, the inclusion of episodes triggered by readmissions does not necessarily result in a worse measure score for the provider—such episodes still use the observed over expected cost ratios, where it is possible for the observed cost to be lower than expected cost if the hospital performed better on the episode than expected. Additionally, the prior inpatient admission characteristic is controlled for in the risk adjustment model to avoid unfairly penalizing the hospital attributed to the newly triggered episode. An illustration of this refinement is available in Appendix B of the Measure Information Form (MIF) document available at: https://qualitynet.cms.gov/files/6478ba16/d77520013c7e032?filename=2023_HIQR_Re-eval_MSPB-%20MIF.pdf.

We also wish to note that because the updated version of this measure was adopted in the Hospital IQR Program in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49257 through 49263), hospitals will receive hospital-specific reports for the re-evaluated MSPB Hospital measure on an annual basis, which include patient-level episode information, prior to public display on the Compare tool. In addition, hospitals receive hospital-specific reports for seven readmission measures used in the Hospital IQR and Hospital Readmissions Reduction Programs that provide patient-level readmissions information.

Comment: A few commenters had recommendations for the re-evaluated MSPB Hospital measure including ensuring that the re-evaluated MSPB Hospital measure is reliable and valid for efficiency and cost reduction and exploring whether adding a new variable indicating a patient had an inpatient stay in the 30 days prior to an episode may unfairly disadvantage hospitals that frequently provide care to patients with a high case mix index.

Response: As discussed earlier, the re-evaluated MSPB Hospital measure rate high for reliability and moderate for validity during the CBE endorsement process. As part of the CBE endorsement submission, we undertook three approaches to empirically examine the extent to which the re-evaluated MSPB Hospital measure captures what it intends to capture. Firstly, we examined the relationship between risk adjusted episode cost ratios and episodes with and without post-admission events that are known indicators of high cost or intensive care. Secondly, we examined the relationship between a hospital’s average expected episode cost and average episode rates of several service use categories, to test whether the risk adjustment model can predict patient need for certain services. Thirdly, we examined the relationship between the re-evaluated MSPB Hospital measure and other cost-specific measures, efficiency-related measures, and measures in other Hospital VBP Program domains. For all three types of validity testing, we observed results that were in line with our expectations, demonstrating that the measure is functioning as intended.

We thank the commenter for their feedback regarding performance of hospitals with high case mix index. There has been extensive testing done on the measure to demonstrate the validity of its risk adjustment model. In general, the re-evaluated MSPB Hospital measure’s risk adjustment methodology accounts for patient case-mix and other factors by adjustment for patient age and severity of illness. Specifically, the risk adjustment methodology includes 12 age categorical variables, 79 hierarchical condition category (HCC) indicators, status indicator variables for whether the beneficiary qualifies for Medicare through disability or age and End-Stage Renal Disease (ESRD), indicators to account for disease interactions, an indicator of whether the beneficiary recently required long-term care, and the Medicare Severity-Diagnosis Related Group (MS–DRG) of the index hospitalization. We believe that this provides adequate adjustment for patient acuity. For the re-evaluated MSPB Hospital measure specifically, a variable indicator showing whether there was an inpatient stay in the 30 days prior to an episode start date is added to the risk adjustment model to account for differences in expected cost for episodes that are triggered by readmissions. This prior inpatient admission characteristic is controlled for in the risk adjustment model to ensure that the hospital attributed to the newly triggered episode from a readmission is not unfairly penalized for providing care to the patient during the episode that could be higher cost due to the readmission status. This refinement was supported by the TEP. As part of routine measure maintenance, we plan to continue to conduct testing and monitor the impact of risk factors on the measure.

After consideration of the public comments we received, we are finalizing this policy as proposed.

(2) Adoption of Substantive Measure Updates to the Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA) (CBE #1550) Measure Beginning With the FY 2030 Program Year

In the FY 2024 IPPS/LTCH PPS proposed rule, we proposed to adopt substantive measure updates to the Hospital-level Risk-Standardized Complication Rate (RSCR) Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA) (CBE #1550) measure, beginning with the FY 2030 program year (88 FR 27026). We adopted the THA/TKA Complication measure in the FY 2015 IPPS/LTCH PPS final rule beginning with the FY 2019 program year for use in the Hospital VBP Program (79 FR 50062 through 50063). We continue to consider the clinical outcomes of the THA/TKA Complication measure a high priority, and we believe that this measure provides important data on resource use (addressing the Meaningful Measures Framework priority of making care affordable), which is why we proposed to adopt substantive updates to the THA/TKA Complication measure under the Clinical Outcomes Domain.

We previously adopted the same substantive updates to the THA/TKA Complication measure for use in the Hospital IQR Program as a re-evaluated measure in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49257 through 49263). We also listed the re-evaluated THA/TKA Complication measure in the publicly available document entitled “List of Measures Under Consideration for December 1, 2021,” with identification number MUC2021–118. The MAP reviewed the re-evaluated the measure and voted to conditionally support the measure for rulemaking for use pending CBE review and endorsement of the measure update. The MAP Rural Health Advisory Group reviewed this re-evaluated measure on December 8, 2021, and agreed that the measure was suitable for use with rural providers given that there would be no undue consequences for rural hospitals. The CBE re-endorsed the
original measure in July of 2021.\textsuperscript{232} and we intend to submit the re-evaluated measure to the CBE for endorsement in Fall 2024. The substantive updates to the THA/TKA Complication measure are the inclusion of index admission diagnoses and in-hospital comorbidity data from Medicare Part A claims. Additional comorbidities prior to the index admission are assessed using Part A inpatient, outpatient, and Part B office visit Medicare claims in the 12 months prior to index (initial) admission. As a claims-based measure, hospitals will not be required to submit additional data for calculating the updated measure. We refer readers to the FY 2023 IPPS/LTCH PPS final rule (87 FR 49263 through 49267), which describes the same updates we proposed to apply to the THA/TKA Complication measure in the Hospital VBP Program, including updates to the risk adjustment and measure calculations.

Adopting these substantive measure updates into the Hospital VBP Program will expand the measure outcome to include 26 additional mechanical complication ICD–10 codes. The additional ICD–10 codes capture the following diagnoses: fracture following insertion of orthopedic implant, joint prosthesis, or bone plate of the pelvis, femur, tibia or fibula, and periprosthetic fracture around internal prosthetic hip, hip joint, knee, knee joint, and other or unspecified internal prosthetic joint. We refer readers to FY 2023 IPPS/LTCH PPS final rule (87 FR 49264) for further information. The additional included ICD–10 codes that are included in the updated measure as adopted for the Hospital IQR Program. Section 1886(o)(2)(A) of the Act requires the Hospital VBP Program to select measures that have been specified for the Hospital IQR Program. We note that although section 1886(b)(3)(B)(viii)(IX)(aa) of the Act generally requires measures specified by the Secretary in the Hospital IQR Program be endorsed by the entity with a contract under section 1890(a) of the Act, the Secretary may specify a measure that is not endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary. We reviewed CBE-endorsed measures and were unable to identify any other CBE-endorsed measures on this topic, and, therefore, we believe that the exception in section 1886 6(b)(3)(B)(viii)(IX)(bb) of the Act applies. We note that we intend to submit the re-evaluated measure to the CBE for endorsement in Fall 2024.

For the purpose of continuing to assess clinical outcomes, we proposed to adopt the substantive measure updates to the THA/TKA Complication measure (CBE #1550) in the Hospital VBP Program under the Clinical Domain beginning with the FY 2030 program year. As previously stated, we previously adopted the same substantive updates to the measure in the Hospital IQR Program (87 49257 through 49263), and we intend to begin posting the updated measure data on Care Compare beginning in July 2023, which will enable us to post data on the substantive updates to the measure for at least one year before the proposed beginning of the FY 2030 performance period, April 1, 2025, through March 31, 2028.

We proposed to adopt the substantive updates to THA/TKA Complications measure (CBE #1550) in the Hospital VBP Program beginning with the FY 2030 program year. We refer readers to section V.K.4.c of the preamble of this final rule where we discuss our defined baseline and performance periods for this updated measure under the Hospital VBP Program. We also proposed that the performance standards calculation methodology for the updated THA/TKA Complications measure will be the same as that which we currently use for the measure. The performance standards for the updated measure for FY 2030 are not yet available.

We invited public comment on this proposal.

Comment: Many commenters supported the proposal to implement the re-evaluated THA/TKA Complications measure in Hospital VBP Program, with a commenter noting they believed that it is important to ensure measure specifications align across programs. A commenter believed the measure updates will reduce duplicative reporting requirements for hospitals. In both programs, increase accountability for hospitals by rewarding hospitals with lower complication rates, and provide patients with information to guide their choices regarding where to seek care. The commenter also believed that the measure updates have the potential to lower healthcare costs by decreasing the likelihood of costly readmissions. A commenter noted that they believed that the expansion of the numerator events for this measure provides a more comprehensive picture of hospital performance for hip and knee arthroplasty procedures. A few commenters indicated their support of the inclusion of the 26 additional mechanical complication ICD–10 codes because the codes are clinically appropriate to be paired with arthroplasty and will improve the measure’s accuracy. A commenter specifically mentioned the measure cohort expansion to include admission diagnoses and in-hospital comorbidity data in their support because they believed that it enables the inclusion of the 26 additional mechanical complication ICD–10 codes.

Response: We thank commenters for their support. We agree that it is important to align measures across programs where possible and that the 26 additional mechanical complication ICD–10 codes are clinically appropriate. A few commenters did not support the substantive updates to the THA/TKA Complications measure citing concerns with the length of the delay in implementation, the inability to assess impact prior to implementation and ability to appropriately comment, and public confusion with the measure currently in the Hospital IQR Program. A commenter noted that they believe that the proposal does not provide enough information to demonstrate the anticipated improvements once implemented.

Comment: Section 1886(o)(2)(C)(i) of the Act and 42 CFR 412.164(b) state that measures must be publicly reported for one year in the Hospital IQR Program prior to the beginning of the performance period in the Hospital VBP Program. As we stated in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27026), we previously adopted the re-evaluated THA/TKA Complication measure into the Hospital IQR Program to accommodate these statutory and regulatory requirements. We staged our proposals across the Hospital IQR Program and Hospital VBP Program to accommodate the statutory requirement. Therefore, we do not want to alter the public reporting timeline of the measures. Hospital–specific reports for the re-evaluated THA/TKA Complications measure in the Hospital IQR Program were released to hospitals...

\textsuperscript{232}CMS Measure Inventory Tool. (2023) Hospital-level risk-standardized complication rate (RSCR) following elective primary total hip arthroplasty (THA) and/or total knee arthroplasty (TKA) Measure Specifications. Available at: https://cmit. cms.gov/cmit/#/MeasureView/VariantId=11547& sectionNumber=1.
in May 2023. Additionally, hospitals will be able to see their performance in the Hospital IQR Program for 6 years prior to measure implementation in the Hospital VBP Program beginning with the FY 2030 program year. Further, like the re-evaluated MSPB Hospital measure, we will make sure it is clear which version of the measure is being publicly displayed in which location through outreach and education efforts.

**Comment:** A few commenters expressed concern that the measure will increase burden on hospitals because they will have to monitor and validate two different performance rates, with a commenter expressing concern regarding the number of hospitals that participate in the Hospital VBP Program versus the Hospital IQR Program. The commenter recommended monitoring reporting rates to make sure no reporting gaps occur when the measure is removed from the Hospital IQR Program.

**Response:** We acknowledge the commenters’ concerns regarding burden of reporting two slightly different versions of the measure in the Hospital IQR and Hospital VBP Programs simultaneously. However, we respectfully disagree that the proposed transition of the re-evaluated THA/TKA Complication measure from the Hospital IQR Program to the Hospital VBP Program will cause significant data collection burden. Hospitals will not be required to submit additional data for calculating the measure as it is a claims-based measure.Section 1886(o) of the Act and at 42 CFR 412.164(b) of our regulations state that measures must be publicly reported for one year in the Hospital IQR Program prior to the beginning of the performance period in the Hospital VBP Program. As we have previously stated in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27026 through 27027), we adopted the revised version of the THA/TKA Complication measure into the Hospital IQR Program first to accommodate the statutory and regulatory requirements. The benefits of keeping the original THA/TKA Complications measure until the statutory timeframe for the updated measure has been met outweighs the burden of reporting two measures. We refer readers to FY 2023 IPPS/LTCH PPS final rule (87 FR 49263 through 49267), which provided interested parties with an opportunity to become familiar with the new version of the measure and provide feedback prior to our proposed adoption of that revised measure in the Hospital VBP Program.

**Comment:** Several commenters recommended that CMS consider modifying the measure to capture both inpatient and outpatient procedures in the case that the shift of procedures from an inpatient setting to an outpatient setting alters the measure validity and reliability or impacts performance.

**Response:** We thank the commenters for their feedback. We are monitoring the shifts of THA/TKA from the inpatient to outpatient setting as well as the potential impacts on this inpatient only measure. The proposed re-evaluated THA/TKA Complication measure is case mix adjusted for patient comorbidities and is a relative performance measure for hospitals performing these elective THA/TKA procedures. As such, we believe that this measure accurately reflects hospital performance even if patients receiving these procedures in the inpatient setting tend to be sicker, on average, than those treated in an outpatient setting. We also refer readers to section XIV.B.3.b of the CY 2024 OPPS proposed rule for a proposal to adopt the THA/TKA Patient-Reported Outcome-based Performance Measure (PRO-FM) in the Hospital Outpatient Quality Reporting (OQR) Program.

**Comment:** A few commenters expressed concerns about the inclusion of the additional ICD–10 codes, including that the feedback from subject matter experts have not been reviewed or endorsed by the CBE and that the additional codes will negatively impact patients and clinicians in small community hospitals.

**Response:** As stated in the proposed rule (88 FR 27026), the re-evaluated measure was conditionally supported by the MAP in December of 2021. The CBE re-endorsed the original measure in July of 2021, and we intend to submit the re-evaluated measure to the CBE for endorsement in the fall of 2024. Additionally, the MAP Rural Health Advisory Group reviewed this re-evaluated measure on December 8, 2021, and agreed that the measure was suitable for use with rural providers given that there would be no undue consequences for rural hospitals. We also note while conducting internal analyses, orthopedic surgeons and clinical coding experts vetted the additional 26 mechanical complication ICD–10 codes and agreed they should be included.

**Comment:** A commenter recommended suppressing one set of measure results from public reporting to reduce potential confusion, while another commenter recommended reviewing the changes to makes sure reliability and validity of the measure were not impacted. Additional recommendations included allowing hospitals to have the ability to see the performance metrics to have a better understanding of the impacts of the modifications and publicly reporting the risk-adjusted, one-year mortality and revision rates on the Care Compare website.

**Response:** We thank the commenters for their feedback on the re-evaluated THA/TKA measure. We will work to clearly identify the version of the measure when publicly reporting the re-evaluated THA/TKA Complications measure and help address any potential confusion. Data for this measure will continue to be posted to the Care Compare website.

**Comment:** A few commenters made recommendations about including adjustments around socioeconomic and SDOH considerations, including expanding the claims lines from 25 to a number that allows for the capture of mechanical complication codes along with SDOH diagnosis codes that could also impact the outcome of an elective THA or TKA, and creating a socioeconomic status risk-adjustment that stratifies by dual eligibility populations. A few commenters stated that they believe hospitals taking care of the most complex patients may be unfairly penalized and recommend exploring an alternative risk adjustment.

**Response:** We are committed to measuring and improving health equity and addressing social risk factors in quality measurement. During the last CBE endorsement maintenance submission for the THA/TKA Complication measure prior to 2022, comprehensive testing was completed which included an assessment of the impact of social risk as captured by dual eligibility and the AHRQ SES Index. The AHRQ SES index score considers aspects of socioeconomic status and is computed using US census data and considers factors including median household income, percentage of persons below the Federal poverty line, unemployment, education, property value, and percentage of persons in crowded households at the 9-digit zip

233 For more detailed measure specifications, we refer readers to the “2022 Procedure-Specific Complication Measure Updates and Specifications: THA/TKA” at the QualityNet website at: https://qualitynet.cms.gov/inpatient/measures/complication/methodology.

code level. We found wide variation in the prevalence of the two social risk factors we examined, with a large proportion of hospitals treating zero patients with these risk factors. We also found that both had some association with complication risk. However, adjustment for these factors did not have a material impact on hospital RSCRs. Our decisions about which risk factors should be included in each measure’s risk-adjustment model are based on whether inclusion of such variables is likely to make the measures more successful at illuminating quality differences and motivating quality improvement. Given these empiric findings and program considerations, we chose not to include these two social risk factors in the final risk model. In presenting these results and interpretation, the CBE re-endoered the original measure (CBE #1550) in June of 2021 without adjustment for patient-level social risk factors. We acknowledge the importance of balancing these competing considerations and we plan to continue to reevaluate the risk adjustment model and available risk factors on an ongoing basis as part of routine measure maintenance, with the goal of producing the most accurate and fair risk adjustment models for assessing provider performance. Further details related to social risk testing for this measure can be found from downloading the measure specifications from the National Quality Forum (NQF)”s Surgery Fall Cycle 2020 project here: https://nqfappservicesstorage.blob.core.windows.net/proddocs/22/Fall/2020/measures/1550/shared/1550.zip.

After consideration of the public comments we received, we are finalizing our policy as proposed.

3. New Measure for the Hospital VBP Program Set

We consider measures for adoption based on the statutory requirements, including specification under the Hospital IQR Program, posting measures on the Care Compare website, and our priorities for quality improvement as outlined in the CMS National Quality Strategy, available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Value-Based-Programs/CMS-Quality-Strategy. We also refer readers to the FY 2019 IPPS/LTC PPS final rule (83 FR 41447 through 41448), in which we describe the Meaningful Measures Framework, our objectives under this Framework for quality measurement, and the quality topics that we have identified as high-impact measurement areas that are relevant and meaningful to both patients and providers. Due to the time necessary to adopt measures, we often adopt policies for the Hospital VBP Program well in advance of the program year for which they will be applicable.

a. New Measure Adoption Beginning With the FY 2026 Program Year: Severe Sepsis and Septic Shock: Management Bundle (CBE #0500)

(1) Background

Sepsis, severe sepsis, and septic shock can arise from simple infections, such as a pneumonia or urinary tract infection. Although it can affect anyone at any age, sepsis is more common in infants, the elderly, and patients with chronic health conditions such as diabetes and immunosuppressive disorders. A 2021 report by the Healthcare Cost and Utilization Project on the most frequent principal diagnoses among non-maternal, non-neonatal inpatient stays using the 2018 National Inpatient Sample revealed septicemia as the most frequent principal diagnosis with over 2.2 million hospital stays. The CDC reported a pneumonia or urinary tract infection. The Burdens of Sepsis, 2012–2018. Crit Care Med. 48(3):276–286. doi: 10.1097/CCM.0000000000003342.


January 1, 2021, through December 31, 2021. Performance rates for the top 10 percent of hospitals have averaged 80 percent since we began public reporting with performance data from October 1, 2017, through September 30, 2018. We believe that additional incentives will support continued improvement in measure performance. The Sepsis and Septic Shock: Management Bundle measure (CBE #0500) was initially endorsed by the CBE in 2008 for the hospital/acute care facility setting, and underwent maintenance review and endorsement renewal in June 2013, November 2014, July 2017, and December 2021. The Sepsis and Septic Shock: Management Bundle measure supports the efficient, effective, and timely delivery of high-quality sepsis care. The Sepsis and Septic Shock: Management Bundle provides a standard operating procedure for the early risk stratification and management of a patient with severe infection. When the care interventions in the Sepsis and Septic Shock: Management Bundle measure are provided as a composite, there have been significant reductions observed in hospital length of stay, re-admission rates and mortality.  

Additional information about this measure is available on the CMS Measures Inventory Tool (CMIT) website.  

We believe that the adoption of this measure aligns with the core principles outlined in the HHS National Healthcare System Action Alliance to Advance Patient Safety, including the focus on demonstrating and fostering commitments to safety as a core value and the promotion of the development of safety cultures.  

We also believe that the adoption of the Sepsis and Septic Shock: Management Bundle measure will contribute toward CMS’ goal of advancing health equity, as outlined in the CMS National Quality Strategy.  

Research on in-hospital sepsis mortality between 2004–2013 showed that there is a higher rate of sepsis mortality for Black and Hispanic patients, compared with White patients. Further, this research showed that disparities in outcomes disappeared when results were adjusted for hospital characteristics which highlights the need for improved septic management in hospitals that are treating a high proportion of Black and Hispanic patients. Another study of 249 academic medical centers found that for patients with a diagnosis of sepsis, Black patients exhibited lower adjusted sepsis mortality than White patients. While the results of research in the field are varied, we believe that this measure, which outlines standardized protocols, could mitigate potential biases held by individuals and systems that lead to such variation in outcomes.

The measure was submitted to the MAP for the Hospital VBP Program for the 2022–2023 pre-rulemaking cycle and received conditional support for rulemaking pending the measure developer providing clarity about the differences between the measure specifications submitted to the MUC list in May 2022 and reviewed by MAP and the current measure specifications published in December 2022 which include abstraction guidance updates related to crystalloid fluid administration volumes. During the public comment period for the MUC list, we received comments that were both supportive and not supportive of the inclusion of the measure in the Hospital VBP Program. Public comments supportive of including the measure in the Hospital VBP Program noted the measure is CBE endorsed and that it encourages hospitals to follow published international guidelines for the early identification and management of severe sepsis and septic shock.

Public comments not supportive of including the measure in the Hospital VBP Program centered around two main themes. The first group of commenters were concerned that the adoption of the Sepsis and Septic Shock: Management Bundle measure could result in the overuse of antibiotics, more specifically, that adherence to the Sepsis and Septic Shock: Management Bundle measure includes administering antibiotic therapy to all patients with possible sepsis, regardless of severity-of-illness, which commenters believed could risk excessive and unwarranted antibiotic administration. The antibiotic requirements and timing for the measure are consistent with antimicrobial recommendations Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2021.

We believe that there is enough flexibility to incorporate clinician judgment in the measure as there are several opportunities for abstractors to disregard Systemic Inflammatory Response Syndrome (SIRS) criteria or signs of organ dysfunction if there is physician, advance practice nurse, or physician assistant documentation that SIRS criteria or signs of organ dysfunction are due to a chronic condition, medication, or a non-infectious source.

Second, some commenters had concerns around the burden associated with the data abstraction of the measure and staying up to date with changes to the data abstraction. We note that adding the measure to the Hospital VBP Program will not create a new burden for hospitals because they are already required to report data on the measure under the Hospital IQR Program. With regard to concerns about the overall burden of collecting these data in the Hospital IQR Program, we note that we are currently developing a sepsis outcome electronic clinical quality measure (eCQM) that, if adopted for that program, would not be as burdensome
for hospitals to report. However, in light of our high priority to address patient safety, in the FY 2024 IPPS/LTPP PPS proposed rule, we proceeded with the proposal to adopt the Severe Sepsis and Septic Shock: Management Bundle measure (88 FR 27027 through 27029). The specifications for the proposed measure are listed in v5.14 of the CMS Specifications Manual for National Hospital Inpatient Quality Measures, and those specifications apply to patients discharged from July 1, 2023, through December 31, 2023.254 The proposed measure specifications for v5.14 include minor technical updates to the data abstraction guidance and review for consistency with recent published literature. The minor technical updates were made to address hospital abstractor and clinician feedback received via the QualityNet Question and Answer Tool from hospital medical record abstractors and clinicians about the documentation required for fluid resuscitation within three hours of tissue hypoperfusion presentation. We routinely make these minor, technical updates based on feedback we receive from abstractors and clinicians to improve the data abstraction of the measure. The measure is in alignment with the Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2021 which suggest administering at least 30 mL/kg of intravenous (IV) crystalloid fluids within the first three hours of resuscitation noting that timely, effective fluid resuscitation is critical to stabilize patients with sepsis-induced tissue hypoperfusion. The guidelines noted that there are no prospective interventional studies comparing various crystalloid fluid volumes for initial resuscitation but reference observational studies and a retrospective study that demonstrated not administering 30 mL/kg of crystalloid fluids within three hours of sepsis identification was associated with higher mortality regardless of comorbidities such as end-stage renal disease and heart failure. With this in mind, the guidelines suggest that fluid administration should be guided by careful assessment of responsiveness to avoid over- and under-resuscitation. The measure requires starting crystalloid fluids within three hours of recognition of tissue hypoperfusion but does not require fluids for resuscitation be completely infused within three hours. This is in part due to recognition of various factors that can contribute to complete fluid infusion potentially taking longer. The measure establishes 30 mL/kg of crystalloid fluids as the default volume for fluid resuscitation but does allow for lesser volumes ordered by a clinician and accompanied by documentation of a reason for administering a lesser volume in recognition that some patients may not tolerate 30 mL/kg and that others may respond adequately to a lesser volume.

We have made technical updates to the measure specifications since we adopted this measure in the Hospital IQR Program, and we proposed to adopt the measure, as updated, for the Hospital VBP Program. The data submission requirements, Specifications Manual, and submission deadlines are posted on the QualityNet website at: https://qualitynet.cms.gov (or other successor CMS designated websites).

(3) Overview of the Measure Specifications

a. Numerator

Patients who received all of the following interventions for which they qualify:

<table>
<thead>
<tr>
<th>Time frame</th>
<th>Intervention</th>
</tr>
</thead>
</table>
| Within 3 hours of presentation of severe sepsis | • Initial lactate level measurement  
• Broad spectrum or other antibiotics administered  
• Blood cultures drawn prior to antibiotics |
| AND | |
| Within 6 hours of presentation of severe sepsis, ONLY if the initial lactate is elevated | • Repeat lactate level measurement |
| AND | |
| Within 3 hours of initial hypotension, OR Within 3 hours of septic shock | • Resuscitation with 30 mL/kg crystalloid fluids |
| AND | |
| Within 6 hours of septic shock presentation, ONLY if hypotension persists after fluid administration | • Vasopressors are administered |
| AND | |
| Within 6 hours of septic shock presentation, if hypotension persists after fluid administration, or initial lactate >= 4 mmol/L | • Repeat volume status and tissue perfusion assessment is performed |

b. Denominator

The denominator is patients 18 years of age and older with an ICD–10–CM Principal or Other Diagnosis Code for sepsis, severe sepsis without septic shock, or severe sepsis with septic shock, and without an ICD–10–CM Principal or Other Diagnosis Code of U07.1 (COVID–19).

Patients who are admitted as a transfer from an inpatient, outpatient, or emergency/observation department of another hospital or an ambulatory surgical center, or who are enrolled in a clinical trial associated with treatment of patients with sepsis, are excluded from the denominator. The denominator is further refined as the number of patients confirmed with severe sepsis or septic shock through medical record review for the presence of a suspected infection, two or more SIRS criteria, and a sign of organ dysfunction that are all documented within 6 hours of each other. Additional exclusions are for patients:

- With advanced directives for comfort care or palliative care;
- Who or for whom a surrogate decision maker declines or is unwilling to consent to interventions required to meet the numerator;
- With severe sepsis or septic shock who are discharged within six hours of presentation; or
- Who received IV antibiotics for more than 24 hours prior to severe sepsis presentation.

We proposed to adopt the Severe Sepsis and Septic Shock: Management Bundle measure in the Hospital VBP Program under the Safety Domain beginning with the FY 2026 program year. The proposed measure fulfills all the statutory requirements for the Hospital VBP Program based on our adoption of the measure in the Hospital IQR Program. We refer readers to section V.K.4.c of the preamble of this final rule where we discussed our proposed baseline periods and performance periods for this measure if adopted for the Hospital VBP Program.

We invited public comment on this proposal.

Comment: Many commenters supported the Severe Sepsis and Septic Shock Management Bundle measure proposal, agreeing that the severity of the diagnoses warrants the implementation of the measure, that the measure will not create additional burden, and that the measure is in alignment with the Surviving Sepsis Campaign International Guidelines for Management of Severe Sepsis and Septic Shock. A commenter supported that the measure is kept up to date by incorporating Version 5.14 and that the review period includes updates between May 2022 and December 2022. A commenter supported the measure proposal but recommended delaying implementation until streamlining and standardization of the severe sepsis and septic shock definition is completed by the Federal Sepsis Task Force.

Several commenters supported the Severe Sepsis and Septic Shock: Management Bundle proposal because they believed that it will benefit clinicians and patients, including allowing flexibilities for clinician judgment in prescribing therapies and driving enhanced quality of care for the Medicare patient population. A commenter noted the clinician benefit of initial and serial procalcitonin monitoring that complements and enhances compliance with Severe Sepsis and Septic Shock: Management Bundle. A commenter recommended future modifications to better tailor individual patients’ care.

Response: We thank the commenters for their support of our proposal to adopt the Severe Sepsis and Septic Shock: Management Bundle (CBE #0500) measure for the Hospital VBP Program beginning with the FY 2026 program year. We appreciate the commenters’ recognition that the measure is in alignment with the most recent Surviving Sepsis Campaign International Guidelines for Management of Severe Sepsis and Septic Shock. We recognize the importance of making sure the measure is maintained and consistent with the most recent guidelines and best practice published evidence. We understand and respect the need to harmonize with sepsis definitions and measures used by other Federal agencies, such as the Centers for Disease Control and Prevention (CDC) Adult Sepsis Event (ASE) definition.255 We will apply the severe sepsis and septic shock screening criteria that the measure currently uses because those criteria are consistent with previous iterations of the measure and are an established, tested method for early identification of sepsis. We will reevaluate this as newer methods and definitions are finalized.

We believe that recent updates to the measure that incorporate options that acknowledge clinician judgment and enable greater assessment and prescribing flexibility consistent with clinical practice guidelines and recent literature will be beneficial. We thank commenters for their feedback on the use of serial procalcitonin and recommendation for future modifications to better account for individual patient care needs. We will take these into consideration for future program years.

Comment: Several commenters supported the Severe Sepsis and Septic Shock: Management Bundle proposal in the Hospital VBP Program because they believed that it incentivizes hospitals to increase the quality and timeliness of care which result in better patient outcomes.

A few commenters supported the Severe Sepsis and Septic Shock: Management Bundle measure proposal because they believed in the importance of evidence-based correlation to outcomes. A commenter also supported the Severe Sepsis and Septic Shock: Management Bundle measure proposal because it promotes health equity.

Response: We agree that additional incentivization will lead to continued improvements in the quality and timeliness of care leading to better patient outcomes. We thank commenters for their support of our proposal to adopt the Severe Sepsis and Septic Shock: Management Bundle measure for the Hospital VBP Program and continue to strive to develop measures that support improving outcomes for patients with severe sepsis and septic while minimizing reporting burden. We also continue to take updated published guidelines and evidence-based literature that demonstrates correlations between processes of care and improved outcomes into consideration for measures.

We agree that efforts to support equity in the provision of health care are important to improving outcomes for all patients with severe sepsis and septic shock. As noted in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27028), and in section V.K.3(2) of this final rule, we believe that the adoption of the Sepsis and Septic Shock: Management Bundle measure will contribute toward CMS’ goal of advancing health equity, as outlined in the CMS National Quality

---


Variables, 2004–2013. Crit Care Med. 45(12):e1209-

Mortality: Using a Broad Case Capture Method and
Racial Disparities in Sepsis-Related In-Hospital
Patient-Assessment-Instruments/Value-Based-
Management Bundle measure because they believed
that there will continue to be frequent updates to the measure that make it
more difficult to implement the measure and educate staff. A few commenters
cited concerns around the baseline
periods noting that given the frequent
updates, it is unclear how CMS will
establish accurate baselines for
evaluating hospitals’ performance over
time and that the comparison of the
baseline period to the performance
period would not be equal because of
the measure updates every 6 months. A
few commenters expressed that the
continual shifts in the measure
specifications have led to inconsistent
interpretation across facilities. A
 commenter expressed concern that the
measure is still not stable if it is
undergoing changes with each manual
release every 6 months. A commenter
noted that frequent updates to the
measure leads to increased
documentation burden.

Response: We acknowledge the
commenters’ concerns that the Severe
Sepsis and Septic Shock: Management Bundle measure has subject to
frequent updates in response to changes
in the published evidence and feedback
from medical record abstractors and
clinicians. However, we respectfully
disagree that the updates will impact
performance. We wish to emphasize
that, as noted in the FY 2024 IPPS/
LTCH PPS proposed rule (88 FR 27028),
the updates made to Severe Sepsis and
Septic Shock: Management Bundle are
minor technical updates that are
incorporated for consistency with recent
published literature and to address
hospital abstractor and clinician
feedback received via the QualityNet
Question and Answer Tool from
hospital medical record abstractors
and clinicians that do not impact
performance. For example, in v5.13 of
the Hospital IQR measure specifications
manual, we added guidance about the
use of documentation of severe sepsis
and septic shock with a footnote in the
EHR identifying the time based on
question and comments from
abstractors. We also added examples to
the Crystalloid Fluid Administration
data element based upon documentation
scenarios provided by abstractors, and

258 Ibid.

DOI: 10.1007/CCM.00000000000320.


not necessary for the management of some patients with sepsis and oral therapy is quicker. A few commenters recommended minimizing the potential for antibiotic overuse. A commenter recommended excluding patients with unconfirmed sepsis who do not have shock from the bundle, as the data supporting immediate antibiotics are weak, and a commenter recommended that Severe Sepsis and Septic Shock: Management Bundle be modified so that there is additional time permitted to confirm an infection prior to providing antibiotics.

Response: We appreciate the commenters’ concern and will continue to monitor the literature for signs of antibiotic overuse associated with the measure. While we agree with the importance of antimicrobial stewardship, we are not aware of published literature that demonstrates an association between the implementation of the measure and antibiotic overutilization. In the largest study to address sepsis and antibiotic use to date which includes 701,055 patients, Anderson et al. found that among the subgroup of ten hospitals with complete microbiology data and specifically assessing patients with suspected sepsis (31,013 patients), antibiotic utilization was unchanged during the 12 months prior to measure implementation on October 1, 2015, and declined one percent each month during the 12 months after implementation of the measure in the Hospital IQR Program period from November 1, 2015, through October 31, 2016.261 We are not aware of any published information that reports a non-discriminatory increase in antibiotic administration associated with implementation of the Severe Sepsis and Septic Shock: Management Bundle measure. The measure screening criteria and construct focuses on patients with a high likelihood for sepsis or septic shock which is consistent with the Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021 recommendation for the immediate administration of antibiotics to patients with septic shock or a high likelihood for sepsis. We wish to clarify that the Severe Sepsis and Septic Shock: Management Bundle measure does not require that patients receive antibiotics within one hour of presentation. The measure requirements are for antibiotic administration within three hours of severe sepsis presentation time. We are not aware of any evidence that oral antimicrobial therapy is quicker or more effective than parenteral therapy. We refer to the Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021 recommendations for further information on recommendations for the delivery of antibiotics. We also wish to clarify that the measure does allow for exclusion of patients if there is clinician documentation indicating the patient does not have severe sepsis or an infection within six hours following clinical criteria being met thereby preserving clinical judgement and clinical decision making. In addition, patients presenting with sepsis of a viral etiology are excluded from the measure because antibiotics are typically not warranted. We also wish to note that the measure is meant to complement clinical judgement in the best interest of the patient.

Comment: Several commenters did not support the Severe Sepsis and Septic Shock: Management Bundle measure because of the level of detail required of the measure, noting that the measure is too nuanced which makes it challenging to determine whether a hospital is providing quality care because the measure is all-or-nothing. A few commenters also noted that the Severe Sepsis and Septic Shock: Management Bundle measure is very complex in terms of data elements, calculations, and measurements.

Response: We appreciate the commenters’ concern about the complexity of the measure. However, the complexity of this measure is commensurate with the complexity of sepsis and septic shock and with the severity of the consequences for patients if sepsis and septic shock are not detected and managed in a timely manner. All components of this measure ensure that timely and optimal care is delivered for patients with sepsis and septic shock. We are assuming that by “all-or-nothing” the commenter is referring to the fact that hospitals do not get partial credit for completing some of the protocols laid out in the Severe Sepsis and Septic Shock Management Bundle measure. In regards to the commenter’s concern that the all-or-nothing nature of the measure makes it challenging to determine whether a hospital is providing quality care, we note that performance data for the Severe Sepsis and Septic Shock: Management Bundle measure is reported at a more granular level on a CMS-designated website, currently Care.

Comment: Many commenters did not support the adoption of Severe Sepsis and Septic Shock: Management Bundle measure due to concerns around the burden of chart abstraction, citing that the measure is time and resource intensive and that the value of the measure is not worth the challenges. A few commenters noted that chart abstraction is labor intensive, given that determining eligibility for the measure can take upwards of 45 minutes, which they did not believe is in line with the CMS Burden Reduction efforts, and that even highly experienced teams spend 1–4 hours reviewing each sepsis core measure chart which is challenging and costly. A few commenters believed that adding a manual chart abstracted measure is not in line with CMS’ focus on transitioning to digital quality measures. A few commenters noted that the nuances of the measure make it challenging to develop a standard approach to abstraction, and that the complicated abstraction guidance leads to incorrect measure outcomes which affects performance. Many commenters recommended delaying adoption of a sepsis measure in the Hospital VBP Program until the development of sepsis outcome eCQM is available because they believed that an outcome eCQM measure is in alignment with the focus to reduce reporting burden, promotes unity in Federal measures, and emphasizes outcome measures. A commenter believed that the measure does not measure quality of care but rather quality of documentation. A commenter also recommended developing a risk standardized sepsis mortality measure, and another commenter recommended that the development of an eCQM include removing the SIRS criteria and diagnosis codes to simplify implementation and decrease variability between hospitals.

Response: We respectfully disagree with commenters who believe the burden of the Severe Sepsis and Septic Shock: Management Bundle measure outweighs the benefits. We believe that the impact of this measure on patient care and improved outcomes for patients with severe sepsis and septic shock outweighs the abstraction burden. In a recent study that used chart-abstracted data for the Severe Sepsis and Septic Shock: Management Bundle measure submitted to CMS for over 1.3 million patients, Townsend et al. found that compliance with the measure was associated with a reduction in 30-day mortality. In that same study, Townsend et al. noted that based on published average medical record abstraction times of 30 to 120 minutes per case and assuming that a hospital had 300 sepsis cases per quarter, less than one-quarter of a full-time employee would be required to perform medical record abstraction. In a study by Buchman et al., the costs of sepsis inpatient admissions and subsequent skilled nursing facility care to Medicare was estimated to exceed $41.5 billion annually with 6-month mortality rates for Medicare fee-for-service beneficiaries of approximately 60 percent for septic shock and 36 percent for severe sepsis. Adding the measure to the Hospital VBP Program will not create a new burden for hospitals because they are already required to report data on the measure under the Hospital IQR Program. We will continue with plans for transitioning to digital quality measures and are currently developing a sepsis outcome eCQM that will reduce unnecessary burden for hospitals to report. However, when the measure is fully developed, we remain committed to patient safety as a high priority and believe that the adoption of the Severe Sepsis and Septic Shock: Management Bundle measure aligns with the core principles outlined in the HHS National Healthcare System Action Alliance to Advance Patient Safety and is consistent with this commitment.

Response: We respectfully disagree with commenters who believe the measurement of the Severe Sepsis and Septic Shock: Management Bundle measure may be contraindicated but are not excluded. A commenter stated that the measure does not allow exceptions for providers to treat patients using their discretion specifically regarding crystalloid fluids and vasopressors. A commenter noted that the bundled nature of the measure does not help hospitals target specific areas for improvement. The Severe Sepsis and Septic Shock: Management Bundle measure includes flexibility for clinician judgment by providing multiple opportunities for exclusion of patients from the measure based on clinician documentation such as notations within six hours following clinical criteria being met that severe sepsis or an infection is not present or that SIRS criteria or signs of organ dysfunction are due to a chronic condition, medication, or a non-infectious source. This measure is meant to complement clinical judgment in the best interest of the patient. We wish to clarify that the measure does include allowances for fluid volumes less than 30 mL/kg with documentation of a reason for a lesser volume. We appreciate the commenter’s concern about the bundled nature of the measure. With respect to the concern that the bundled nature of the measure does not help hospitals target specific areas for improvement, we note that performance data for the Severe Sepsis and Septic Shock: Management Bundle measure is reported at a more granular level on a CMS-designated website, currently Care Compare, at the national, state, and hospital level for measure performance overall and by the four measure bundles, severe sepsis 3-hour, severe sepsis 6-hour, septic shock 3-hour, and septic shock 6-hour bundles at [https://data.cms.gov/provider-data/search?fulltext=timely%20and%20effective%20and%20category%3B%20care%20and%20theme%3B%20Hospitals](https://data.cms.gov/provider-data/search?fulltext=timely%20and%20effective%20and%20category%3B%20care%20and%20theme%3B%20Hospitals). This enables hospitals to view their performance for each bundle as well as their results overall and compare them to other hospitals, their state, and national average and top performing hospital results. We will take these comments into consideration as we evaluate updates for future program years.

Response: We respectfully disagree with commenters who believe the measure does not help hospitals target specific areas for improvement and does not allow exceptions for providers to treat patients using their discretion specifically regarding crystalloid fluids and vasopressors. A commenter noted that the bundled nature of the measure does not help hospitals target specific areas for improvement. Response: The Severe Sepsis and Septic Shock: Management Bundle measure includes flexibility for clinician judgment by providing multiple opportunities for exclusion of patients from the measure based on clinician documentation such as notations within six hours following clinical criteria being met that severe sepsis or an infection is not present or that SIRS criteria or signs of organ dysfunction are due to a chronic condition, medication, or a non-infectious source. This measure is meant to complement clinical judgment in the best interest of the patient. We wish to clarify that the measure does include allowances for fluid volumes less than 30 mL/kg with documentation of a reason for a lesser volume. We appreciate the commenter’s concern about the bundled nature of the measure. With respect to the concern that the bundled nature of the measure does not help hospitals target specific areas for improvement, we note that performance data for the Severe Sepsis and Septic Shock: Management Bundle measure is reported at a more granular level on a CMS-designated website, currently Care Compare, at the national, state, and hospital level for measure performance overall and by the four measure bundles, severe sepsis 3-hour, severe sepsis 6-hour, septic shock 3-hour, and septic shock 6-hour bundles at [https://data.cms.gov/provider-data/search?fulltext=timely%20and%20effective%20and%20category%3B%20care%20and%20theme%3B%20Hospitals](https://data.cms.gov/provider-data/search?fulltext=timely%20and%20effective%20and%20category%3B%20care%20and%20theme%3B%20Hospitals). This enables hospitals to view their performance for each bundle as well as their results overall and compare them to other hospitals, their state, and national average and top performing hospital results. Additionally, there are categories by bundle that providers can use for quality improvement information beyond seeing their performance rates.

Response: Many commenters did not support the adoption of the Severe Sepsis and Septic Shock: Management Bundle measure because they believed that the measure lacks evidence for improving patient outcomes and does...
not provide any benefit to patient care. Several commentators cited that compliance with the measure does not reflect the care provided to sepsis patients. Several commentators noted that survival rates were not significantly improved, and sepsis mortality rates have not lowered under the measure. A few commenters believed that the measure incorrectly assumes all patients have similar characteristics and does not consider significant clinical variation. A few commenters cited potential harms and worsened outcomes in patients from the measure and noted that the risks of the measure outweigh the benefits. A few commentators recommended that CMS focus on evidence-based measures that improve outcomes for patients with sepsis. A commenter expressed concern that the measure may create unintended threats to the health of those with sepsis or other conditions that can mimic sepsis. A commenter believed that the measure lumps together septic shock and non-shock patients and it may not be appropriate for all patients to receive each of the bundle elements. A commenter noted that the requirement of universal blood cultures prior to antimicrobial therapy worsens outcomes by adding to episode cost and length of stay.

Response: As referenced in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27028), there is evidence of an association between the elements of the Severe Sepsis and Septic Shock: Management Bundle measure and improved patient outcomes. A study by Townsend et al of over 1.3 million patients that used chart-abstracted data for the Severe Sepsis and Septic Shock: Management Bundle measure found that compliance with the measure was associated with a reduction in 30-day mortality. The Severe Sepsis and Septic Shock: Management Bundle measure was designed based on evidence based relevant literature and clinical practice guidelines and is intended to measure appropriate care as it applies to the majority of the patient population represented in the measure. As noted in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27027 through 27029), the measure is CBE-endorsed and follows published international guidelines for the early identification and management of severe sepsis and septic shock, which reflects that the measure is evidence-based and has undergone rigorous processes in measure development and maintenance. We appreciate and recognize that some patients may present with clinical characteristics and response to care that varies from the majority of patients with the same condition. We agree that in some cases the best outcome for the patient may be dependent upon clinician judgement that varies from guideline recommendations for care. We wish to emphasize that the measure is not intended to replace clinician judgement or to treat every patient identically; rather, complement clinical judgement in the best interest of the individual patient. With this in mind, we do not expect 100 percent performance for the measure with every patient. Recent data indicates that mean performance on this measure is less than 60% and thus there is still substantial room for improvement on sepsis care. Measure design and recent updates to the measure allow for some variations in care by allowing flexibility in crystalloid fluid administration volumes and exclusions for some groups of patients based on clinician documentation. We are not aware of published literature that makes an association between the measure and patient harm. We agree that all patients will not qualify for all of the bundle elements in the measure. While the measure performance results are reported as an overall score, the measure incorporates exclusion criteria for those patients who do qualify for specific elements of care. As referenced in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27027 through 27029), there is evidence of an association between the elements of the Severe Sepsis and Septic Shock: Management Bundle measure and improved patient outcomes. A 2022 study by Townsend et al. of over 1.3 million patients that used chart-abstracted data for the Severe Sepsis and Septic Shock: Management Bundle measure found that compliance with the measure was associated with a reduction in 30-day mortality. In 2019, Kahn et al. published the results of a study of over 325,786 sepsis admissions to 163 hospitals in New York State and the impact that mandated public reporting of sepsis had on mortality. The requirement for


265 Kahn JM, Davis BS, Yabes JG, et al. (2019) Association Between State-Mandated Protocolized Sepsis Care and In-hospital Mortality Among

protocolized sepsis care, consistent with the Severe Sepsis and Septic Shock: Management Bundle measure, was associated with a statistically significant reduction in risk-adjusted mortality. To address concerns about potential unintended consequences of protocol administration the authors also studied intensive care unit (ICU) admission rates, as an indicator of intensity of health care; hospital length of stay, as a reflection of resource utilization; central venous catheter use, to measure impact on invasive monitoring; and Clostridium difficile infection rates, as sign of potential antibiotic overuse. The study found no change in ICU admission, minimal impact on length of stay, a trend toward lower use of central venous catheters and a significant reduction in Clostridium difficile infection rates. With regard to the commenter’s concern about other conditions that can mimic sepsis, the Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021 recommends that clinicians perform a rapid assessment for the possibility of infectious versus non-infectious causes and recommend this assessment be completed, whenever possible, within three hours of symptom presentation to expedite clinical decision making. The Severe Sepsis and Septic Shock: Management Bundle measure requirements are consistent with these guideline recommendations in that the time frame for antibiotic administration is within three hours of severe sepsis presentation. The guidelines note that it is best practice to continually reassess the patient to determine whether diagnoses other than sepsis are possible to facilitate treatment adjustments as needed. The measure allows for exclusion of patients from the measure if there is clinician documentation indicating that severe sepsis or septic shock is not present within six hours after severe sepsis or septic shock presentation. Additionally, in regard to the commenter’s concern about universal blood cultures, we are not aware of any published information demonstrating a significant increase in costs or hospital length of stay directly associated with obtaining blood cultures. The measure’s requirement for obtaining blood cultures prior to antibiotic administration is consistent with the guideline recommendation to obtain routine microbiologic cultures (including blood) before starting antibiotic treatment in patients with

suspected sepsis and septic shock. Blood cultures are important to help optimize antibiotic coverage and assist with antibiotic de-escalation.

Comment: A few commenters did not support the adoption of Severe Sepsis and Septic Shock: Management Bundle measure because the measure does not include any risk stratification or stratification by race or other patient risk factors. A commenter noted that stratification would help advance health equity and is more appropriate for a claims-based measure.

Response: We appreciate the commenters’ feedback and recommendations regarding risk stratification and stratification by race or other patient factors. The Severe Sepsis and Septic Shock: Management Bundle measure provides a standard operating procedure for early risk stratification and management of a patient with severe infection by identifying patient risk levels relating to sepsis care needs. As we take these recommendations into consideration, we will carefully weigh the potential extra burden that collection of additional clinical information necessary for risk stratification of chart abstracted measures may impose upon hospitals. We are in the process of developing a methodology for stratifying measures by sex, race, ethnicity, and other social determinants of health.

Comment: Several commenters did not support the adoption of this measure because they believed the difficulty of capturing a diagnostic start time creates challenges for all components of the bundle and creates challenges for clinicians. A few commenters noted that the criteria in the sepsis bundle are different from care teams’ diagnostic criteria. A commenter believed that the complexity of the current time zero definition contributes to variability in abstraction and undermines the measure. A commenter believed that the measure is flawed because it is based on discharge diagnoses and retrospectively identifies a start time based on abnormal vital signs. A commenter recommended defining the inconsistent definition of time zero. A commenter noted that the Severe Sepsis and Septic Shock: Management Bundle measure’s focus is only on the initial 6 hours of care which the commenter believed oversimplifies the complexity of comprehensive sepsis care.

Response: We appreciate the commenters’ concerns about the challenges with identifying the severe sepsis presentation time and will take this under consideration as future methods and tools for early identification of severe sepsis and septic shock become available and are tested. We recognize there is variation in screening tools and criteria used at the bedside for identification of severe sepsis and septic shock and wish to clarify that the measure does not dictate nor limit the severe sepsis and septic shock screening criteria that clinicians use at the bedside. While the measure uses ICD–10–CM diagnosis codes to identify the initial patient population, clinical criteria are used to confirm the presence of severe sepsis and septic shock and allow for exclusion of patients who do not meet the clinical criteria. The intent of the measure is to confirm care and interventions provided upon early identification of the presence of severe sepsis and septic shock. The clinical criteria used by the measure provides a well-established common set of criteria, identified by Waligora et al. as having high sensitivity for early identification of sepsis (72%–94.5%), that abstracts from all hospitals across the U.S. to determine which patients from their initial populations remain in the measure. We agree that focusing on early therapies is not the only strategy important for sepsis care and improved outcomes but suggest that it is the predominate opportunity in the largest number of cases. The Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021, note that early identification of sepsis and timely appropriate management in the initial hours is associated with improved outcomes. The guidelines specifically note early administration of antibiotics as is one of the most effective interventions associated with reducing mortality and that fluid therapy is a crucial part of sepsis and septic shock resuscitation.

Comment: Many commenters did not support the adoption of this measure because of concerns around tying the Severe Sepsis and Septic Shock: Management Bundle measure to hospital performance and payment given that high performance is not related to improved outcomes and bundle scoring makes it difficult for hospitals to achieve high scores. A few commenters expressed concern that there will be a disproportionate impact to safety-net healthcare systems if the measure is included in a pay-for-performance program and that financially strapped organizations will struggle to implement the full-scale interventions of the Severe Sepsis and Septic Shock: Management Bundle measure. A commenter conducted their own calculations that showed that 66% of the hospitals that were scored on improvement under the Severe Sepsis and Septic Shock: Management Bundle measure had a score of zero, meaning that the hospital did not improve or improved minimally.

Response: We appreciate the commenters’ concern regarding the association between measure performance and patient outcomes. In a study by Townsend et al of over 1.3 million patients that used chart-abstracted data for the Severe Sepsis and Septic Shock: Management Bundle measure the authors found that compliance with the measure was associated with a reduction in 30-day mortality. We recognize that achieving high scores on a bundled measure is challenging since all bundle elements for which a patient is eligible must be met for the patient case to meet the measure. However, we believe that all the bundle elements are needed because the complete bundle impacts patient outcomes. As we noted in the proposed rule, performance rates for the top 10 percent of hospitals have averaged 80 percent since we began public reporting with performance data from October 1, 2017, through September 30, 2018. We wish to emphasize that under the Hospital VBP Program’s scoring methodology, the highest performing hospitals will receive achievement points, even if the highest performing hospitals are not performing at 100%. Additionally, we note that this measure will be added to the Safety domain which currently has 5 other measures and is weighted at 25% of the TPS.

We acknowledge commenters’ concern about potential impact on safety-net healthcare systems. We note eligible hospitals have successfully reported on the measure in the Hospital IQR Program since October 1, 2015, including smaller community and rural hospitals. Additionally, we wish to note that smaller hospitals have performed better than large hospitals, on average, for the Severe Sepsis and Septic Shock: Management Bundle measure. Regarding a commenter’s concern about sampling, sampling is a statistically valid method to estimate a hospital’s performance, and we have allowed sampling for many chart-abstracted measures including the Severe Sepsis and Septic Shock: Management Bundle measure to help reduce the abstraction burden. We refer commenters to the Population and Sampling Specifications.
in the Hospital Inpatient Specifications Manual located on QualityNet at https://qualitynet.cms.gov/inpatient/specifications-manuals for more information about case sampling for this measure.

Comment: Several commenters did not support the adoption of this measure over concerns that the Severe Sepsis and Septic Shock: Management Bundle measure is not aligned with scientific criteria used at the bedside for identification of severe sepsis and septic shock and for other purposes. We emphasize the Severe Sepsis and Septic Shock: Management Bundle measure is in alignment with the Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021 that recommended against using quick sequential organ failure assessment (qSOFA) compared with SIRS or other screening tools.\(^{269}\) In addition, antibiotic requirements and time measurement of lactate, administration of crystalloid fluids, monitoring response to fluid administration, and use of vasopressors for the measure are consistent with recommendations in the guidelines. We will continue to monitor the evidence and standards for sepsis care as they evolve and consider revisions as warranted for future program years. We also wish to clarify the concerns around the SEP–3 definitions. The SEP–3 definition, introduced in The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis–3) published in February 2016, uses the Sequential Organ Failure Assessment (SOFA), which has been well-validated association with mortality risk and the simplified quick SOFA (qSOFA).\(^{270}\) The SIRS based criteria used in the Severe Sepsis and Septic Shock: Management Bundle measure, were identified in a structured literature review by Waligora et al. as having a high sensitivity for early identification of sepsis (72%–94.5%) and as providing abstractors with a standard tool for confirmation of the presence of severe sepsis and septic shock.\(^{271}\) We wish to note that the criteria used by the measure is intended to provide abstractors with a standard tool for confirmation of the presence of severe sepsis and septic shock to help ensure the same criteria are used for all hospitals to determine which patients remain in the measure and which ones are excluded. The measure does not dictate nor limit the severe sepsis and septic shock screening criteria that clinicians use at the bedside.

Response: Sampling is a statistically valid method to estimate a hospital’s performance and we have allowed sampling for many chart-abstracted measures including the Severe Sepsis and Septic Shock: Management Bundle measure to help reduce the abstraction burden. We refer commenters to the Population and Sampling Specifications in the Hospital Inpatient Specifications Manual located on QualityNet at https://qualitynet.cms.gov/inpatient/specifications-manuals for more information about case sampling for this measure. The Severe Sepsis and Septic Shock: Management Bundle measure has been in the Hospital IQR Program since October 1, 2015, and eligible hospitals, including smaller community and rural hospitals, have successfully reported on the measure. We are aware that many hospitals already choose to oversample due to the relatively high case exclusion rate associated with the measure. Sepsis is associated with patient deaths, hospital readmissions, and increased length of hospital stays. This measure fills an important measure gap and will positively impact patient care. We believe that these benefits outweigh data collection burdens. We also do not believe this measure will be more burdensome than other measures for hospitals, because the measure data may be collected concurrently, retrospectively, or a combination of both. As we noted in the proposed rule,
adopting the measure into the Hospital VBP Program does not result in a change to measure data collection requirements and burden since hospitals are already required to report data on the measure under the Hospital IQR Program.

Comment: Several commenters recommended changes to the documentation requirements associated with the Severe Sepsis and Septic Shock: Management Bundle measure, including a commenter who recommended removing some of the documentation rules because they believed that it would make the measure less cumbersome, and a commenter who recommended making changes to allow providers to document rationale for why fluid bolus was not indicated.

Response: We note the measure specifications do allow providers to document rationale for why fluid bolus was not indicated; specifically, recent updates to crystalloid fluid administration guidance allow for the administration of fluid volumes of less than 30 mL/kg, and in specific situations, no fluid administration with supporting documentation. We will take other recommendations regarding documentation into consideration for refinements to the measure.

Comment: Several commenters recommended focusing solely on septic shock. A few commenters believed that focusing on septic shock would simplify data abstraction and a few commenters cited evidence supporting the benefits of immediate intervention with the subset of patients experiencing septic shock. A commenter believed that focusing on septic shock would minimize antibiotic overuse and eliminate bundle elements that do not contribute to improved patient outcomes. A commenter expressed concern that the measure is not supported by compelling evidence.

Response: We respectfully disagree with the commenters’ recommendations regarding focusing the measure only on septic shock. Early identification and treatment of patients with severe sepsis is essential and, in many cases, can prevent further clinical progression to septic shock. The Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021 includes a strong recommendation for the immediate administration of antibiotics to patients with septic shock or a high likelihood for sepsis. The measure is consistent with these guidelines since the measure screening criteria focus on patients with a high likelihood for sepsis or septic shock. We are not aware of literature that demonstrates an association between the implementation of the measure and antibiotic overutilization. We appreciate the commenter’s concerns about measure alignment with published evidence; however, we disagree. The Severe Sepsis and Septic Shock: Management Bundle measure is in alignment with the Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021 recommendations about use of screening tools, antibiotic requirements and timing, measurement of lactate, administration of crystalloid fluids, monitoring response to fluid administration, and use of vasopressors. We will continue to monitor the evidence and standards for sepsis care as the evolve and consider revisions as warranted for future program years.

Comment: Several commenters recommended that the focus should be on improving patient outcomes with a commenter recommending elimination of bundle elements that do not contribute to improved patient outcomes, such as lactate testing. A few commenters expressed concern that the time-zero definition does not reflect excellent care and that the focus on the initial hours of care takes away incentive to optimize subsequent care for patients. A commenter expressed their belief that shifting to this measure amidst clinical disagreement on measure specifications and abstraction issues will bring no additional benefit to patients.

Response: We appreciate the commenters’ recommendations regarding measure focus. We note that providing patients with evidence-based care such as that included in the Surviving Sepsis Campaign: Management Bundle measure has been associated with improved outcomes. We refer commenters to the results of the study of over 1.3 million patients by Townsend et al that utilized chart-abstracted data for the Severe Sepsis and Septic Shock: Management Bundle measure from October 1, 2015, to March 31, 2017, in which the authors found that compliance with the measure was associated with a reduction in 30-day mortality.273 We recognize that some elements of care may have a greater impact on outcomes and will take the commenter’s recommendations into consideration for future program years. We also wish to note that while focusing on early therapies is not the only area of opportunity for sepsis care improvement, it is the predominant opportunity in the majority of cases as subsequent care needs are often dependent on the early care that is provided. We also emphasize that the measure is in alignment with the Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021 recommendations about use of screening tools, antibiotic requirements and timing, measurement of lactate, administration of crystalloid fluids, monitoring response to fluid administration, and use of vasopressors. The guidelines note that the presence of an elevated lactate level in patients with suspected sepsis is associated with an increased likelihood of a final diagnosis of sepsis and that there is a well-established association between lactate levels and mortality in patients with suspected infection and sepsis. In a recent study that used chart-abstracted data for the Severe Sepsis and Septic Shock: Management Bundle measure submitted to CMS for over 1.3 million patients, Townsend et al. found that compliance with obtaining an initial lactate level was associated with decreased adjusted mortality.273

Comment: Several commenters expressed concerns about the flexibility of the measure or recommended that the measure be made more flexible. A commenter cited the challenge of a one-size-fits-all measure given the continuously evolving definition and best practices of sepsis. A commenter recommended that physicians should be able to opt out of blood cultures and parenteral therapy. A commenter also expressed concern that the all-or-nothing measure does not allow credit for timely and appropriate resuscitation efforts. A commenter recommended that the measure provide flexibility in a way that hospitals can receive support from CMS for quality improvement efforts to improve performance on the measure.

Response: The measure includes flexibility for clinician judgment by providing multiple opportunities for exclusion of patients from the measure based on clinician documentation such as notations within six hours following clinical criteria being met that severe sepsis or an infection is not present or that SIRS criteria or signs of organ dysfunction are due to a chronic condition, medication, or a non-infectious source. The measure also includes allowances for fluid volumes less than 30 mL/kg with documentation of a reason for a lesser volume. The measure is in alignment with the Surviving Sepsis Campaign: International Guidelines for...

and benchmark should be reversed. The achievement threshold for the Severe Sepsis and Septic Shock: Management Bundle measure as done in the measurement and reporting of other respiratory diseases, especially COVID–19, is in alignment with the previously finalized baseline periods for the Safety, Patient and Community Engagement, and Cost and Efficiency Domains for the FY 2026 program year (87 FR 49114). As discussed in the FY 2023 IPPS/LTCH PPS final rule we believe that using CY 2022 data is appropriate given the widespread availability of COVID–19 vaccines in CY 2022 and subsequent years (87 FR 49105 through 49106).

Comment: A few commenters recommended providing additional clarity on how CMS will establish an appropriate baseline and account for changes in measurement between the baseline and performance periods given frequent updates to the measure.

Response: We thank the commenters for their feedback. As we noted in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27028), the updates made to the Severe Sepsis and Septic Shock: Management Bundle measure, as reflected in the specification’s manual, are minor technical updates that do not impact performance. We, therefore, believe that the baseline and performance periods are appropriate as proposed because the updates to the measure specifications are not substantive and therefore do not require modifications to the baseline and performance periods.

After consideration of the public comments we received, we are finalizing our proposal as proposed.

b. Summary of Previously Adopted Measures for the FY 2024 and FY 2025 Program Years, and Previously Adopted Measures and Newly Adopted Measures Beginning With the FY 2026 Program Year

We refer readers to the FY 2022 IPPS/LTCH PPS final rule (86 FR 45281 through 45284) for summaries of previously adopted measures for the FY 2024 and FY 2025 program years, and to the FY 2023 IPPS/LTCH PPS final rule (87 FR 49110 through 49111) for summaries of previously adopted measures for the FY 2024, FY 2025, and FY 2026 program years. In the FY 2024 IPPS/LTCH PPS proposed rule, we did not propose any changes to the FY 2024 and FY 2025 measure sets (88 FR 27029 through 27030). The Hospital VBP Program measure set for the FY 2024 and FY 2025 years will contain the following measures:

Response: We interpret the commenter’s recommendation as suggesting to remove the exclusion of patients with suspected or confirmed COVID–19 from the measure. We added this exclusion because COVID–19 is viral, and the measure excludes cases of severe sepsis and septic shock with a viral etiology since antibiotics are generally not required unless there is also an underlying bacterial infection. In addition, early evidence suggested a conservative fluid resuscitation approach for patients with COVID–19 associated septic shock. As a result, patients with COVID–19 will have a higher likelihood of not meeting the measure numerator requirements.

Comment: A few commenters recommended that CMS obtain input and support from all interested parties for intended changes and recommended that CMS work with interested parties to develop digital quality measurement that is outcome-based and a true metric of sepsis care.

Response: We appreciate the commenters’ recommendations. We consider input from multiple interested parties and resources when determining whether to implement measure updates and will continue to do so. For example, we have previously collaborated with clinician representatives from organizations such as the California Maternal Quality Care Collaborative (CMQCC), Infectious Disease Society of America (IDSA), and Society for Healthcare Epidemiology of America (SHEA), and from clinical specialties such as emergency medicine, critical care medicine, internal medicine, and infectious disease. We also convene an Expert Work Group (EWG) with critical care medicine, emergency care medicine, infectious disease, pharmacy, performance improvement and patient representation as needed to provide feedback on the clinical aspects of measure maintenance. We also wish to note that the Sepsis Technical Expert Panel (TEP) which provides guidance on the development of the sepsis outcome electronic clinical quality measure (eCQM) includes clinicians representing emergency medicine, critical care medicine, internal medicine, infectious disease, as well as patients and caregivers.

Comment: A commenter did not support converting the Severe Sepsis and Septic Shock: Management Bundle measure to an eCQM in the future.

Response: We thank the commenter for their feedback and note that the sepsis eCQM we are currently developing in collaboration with the CDC is an outcome measure and not a direct conversion of the current measure to an eCQM.
In the FY 2024 IPPS/LTCH PPS proposed rule, we proposed substantive measure updates to the MSPB and THA/TKA Complication measures (88 FR 27030 through 27031). We also proposed to adopt the Severe Sepsis and Septic Shock: Management Bundle. Table V.K.–02 summarizes the previously adopted and newly adopted Hospital VBP Program measures for the FY 2026 through FY 2030 program years:

### Table V.K.–02: Summary of Previously Adopted Measures for the FY 2024 and FY 2025 Program Years

<table>
<thead>
<tr>
<th>Measure Short Name</th>
<th>Domain/Measure Name</th>
<th>CBE #</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Person and Community Engagement Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCAHPS</td>
<td>Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) (including Care Transition measure)</td>
<td>0166 (0228)</td>
</tr>
<tr>
<td><strong>Safety Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAUTI</td>
<td>National Healthcare Safety Network (NHSN) Catheter Associated Urinary Tract Infection (CAUTI) Outcome Measure</td>
<td>0138</td>
</tr>
<tr>
<td>CLABSI</td>
<td>National Healthcare Safety Network (NHSN) Central Line Associated Bloodstream Infection (CLABSI) Outcome Measure</td>
<td>0139</td>
</tr>
<tr>
<td>Colon and Abdominal Hysterectomy SSI</td>
<td>American College of Surgeons Centers for Disease Control and Prevention (ACS-CDC) Harmonized Procedure Specific Surgical Site Infection (SSI) Outcome Measure</td>
<td>0753</td>
</tr>
<tr>
<td>MRSA Bacteremia</td>
<td>National Healthcare Safety Network (NHSN) Facility wide Inpatient Hospital onset Methicillin-resistant Staphylococcus aureus (MRSA) Bacteremia Outcome Measure</td>
<td>1716</td>
</tr>
<tr>
<td>CDI</td>
<td>National Healthcare Safety Network (NHSN) Facility wide Inpatient Hospital onset Clostridiodes difficile Infection (CDI) Outcome Measure</td>
<td>1717</td>
</tr>
<tr>
<td><strong>Clinical Outcomes Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MORT-30-AMI</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Acute Myocardial Infarction (AMI) Hospitalization</td>
<td>0230</td>
</tr>
<tr>
<td>MORT-30-HF</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Heart Failure (HF) Hospitalization</td>
<td>0229</td>
</tr>
<tr>
<td>MORT-30-PN (updated cohort)</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Pneumonia Hospitalization</td>
<td>0468</td>
</tr>
<tr>
<td>MORT-30-COPD</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Chronic Obstructive Pulmonary Disease (COPD) Hospitalization</td>
<td>1893</td>
</tr>
<tr>
<td>MORT-30-CABG</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Coronary Artery Bypass Graft (CABG) Surgery</td>
<td>2558</td>
</tr>
<tr>
<td>COMP-HIP-KNEE</td>
<td>Hospital Level Risk-Standardized Complication Rate Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA)</td>
<td>1550</td>
</tr>
<tr>
<td><strong>Efficiency and Cost Reduction Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSPB</td>
<td>Medicare Spending Per Beneficiary (MSPB) Hospital</td>
<td>2158</td>
</tr>
</tbody>
</table>
We refer readers to section IX.C.10.h of this final rule where the Hospital IQR Program proposed to make updates to the administration and submission requirements of the HCAHPS Survey measure beginning with the FY 2027 payment determination. We also proposed to make the same updates to the form and manner of the administration of the HCAHPS Survey measure under the Hospital VBP Program. These changes are—

- Adding three new modes of survey administration (Web-Mail mode, Web-Phone mode, and Web-Mail-Phone mode) in addition to the current Mail Only, Telephone Only, and Mail-Phone modes, beginning with January 2025 discharges, because in the 2021 HCAHPS mode experiment, adding an initial web component to the three current HCAHPS modes of survey administration resulted in increased response rates;
- Removing the requirement that only the patient may respond to the survey to thus allow a patient’s proxy to...
respond to the survey, beginning with January 2025 discharges:

- Extending the data collection period for the HCAHPS Survey from 42 to 49 days, beginning with January 2025 discharges;
- Limiting the number of supplemental items to 12 to align with other CMS CAHPS surveys;
- Requiring hospitals to collect information about the language that the patient speaks while in the hospital (whether English, Spanish, or another language) and requiring the official CMS Spanish translation of the HCAHPS Survey be administered to all patients who prefer Spanish, beginning with January 2025 discharges; and
- Removing two currently available options for administration of the HCAHPS Survey that are not used by participating hospitals, beginning in January 2023:
  ++ The Active Interactive Voice Response (IVR) survey mode, also known as touch-tone IVR, which has not been employed by any hospital since 2016 and has never been widely used for the HCAHPS Survey, and
  ++ The “Hospitals Administering HCAHPS for Multiple Sites” option for HCAHPS Survey administration which has not been utilized by any hospitals since 2019 and has never been widely used.

We stated in the proposed rule that data collection and administration of the HCAHPS Survey measure would remain the same, except for the proposed changes described in section V.K.3.c of this final rule. We also stated that there would be no changes to the HCAHPS Survey measure patient eligibility or exclusion criteria. We noted that adopting these changes in the Hospital VBP Program would not create a new burden for hospitals because they are already required to report the measure under the Hospital VBP Program. Therefore, we stated that this proposal to adopt technical changes would not require hospitals to submit any additional information. Detailed information on the HCAHPS Survey measure data collection protocols can be found in the current HCAHPS Quality Assurance Guidelines, located at: [https://www.hcahpsonline.org/en/quality-assurance/](https://www.hcahpsonline.org/en/quality-assurance/).

We invited public comment on this proposal.

**Comment:** Many commenters stated their support of the proposed HCAHPS changes because they increase response rates, modernize and improve accessibility of the survey, advance health equity, and improve representation of different populations.

A commenter recommended testing the impact on performance measures derived from HCAHPS data before publicly reporting results or using results for payment purposes.

**Response:** We thank the commenters for their support. We refer the commenter who recommended testing changes to the Hospital IQR Program’s section of the FY 2024 IPPS/LTCH PPS proposed rule, where we discussed a large-scale mode experiment that we conducted to test adding the web mode and other updates to the form, manner, and timing of HCAHPS Survey data collection and reporting (88 FR 27112 through 27113). We also note that because these changes are only being made to the form and manner of the administration of the survey, we do not believe that there will be substantive impacts to hospitals’ performance.

**Comment:** Many commenters supported allowing the survey to be administered in Spanish because they believed that it will improve response rates and adequacy by ensuring that language does not hinder the quality or experience of care. A few commenters made recommendations to expand the requirement to other languages in the future, specifically the seven other languages that the survey is available in.

**Response:** We appreciate the commenters support and agree that these changes will encourage improved response rates from a wider pool of patients in HCAHPS responses. We thank the commenters for their recommendations regarding future translations of HCAHPS for the seven other languages that the survey is available in (Chinese, Russian, Vietnamese, Portuguese, German, Tagalog, and Arabic) and further validation of existing translated versions, and we will take these recommendations into consideration for future program years.

**Comment:** A commenter recommended using a separate patient experience survey that addresses psychiatric care rather than the traditional HCAHPS survey.

**Response:** We thank the commenter for the recommendation and we refer the commenter to the FY 2024 IPPS/LTCH PPS (88 FR 27114) proposed rule in which the Hospital IQR Program solicited feedback on the potential addition of patients with a primary psychiatric diagnosis to the HCAHPS Survey measure. After consideration of the public comments we received, we are finalizing this policy as proposed.

4. Previously Adopted and Newly Adopted Baseline and Performance Periods

a. Background

Section 1886(o)(4) of the Act requires the Secretary to establish a performance period for the Hospital VBP Program that begins and ends prior to the beginning of such fiscal year. We refer readers to the FY 2017 IPPS/LTCH PPS final rule (81 FR 56998 through 57003) for a previously finalized schedule for all future baseline and performance periods for previously adopted measures. We refer readers to the FY 2018 IPPS/LTCH PPS final rule (82 FR 38256 through 38261), the FY 2019 IPPS/LTCH PPS final rule (83 FR 41466 through 41469), the FY 2020 IPPS/LTCH...
PPS final rule (84 FR 42393 through 42396), the FY 2021 IPPS/LTCH PPS final rule (85 FR 58850 through 58854), the FY 2022 IPPS/LTCH PPS final rule (86 FR 45284 through 45290), and the FY 2023 IPPS/LTCH PPS final rule (87 FR 49111 through 49115) for additional previously adopted baseline and performance periods for the FY 2025 and subsequent program years.

b. Baseline and Performance Period for the Severe Sepsis and Septic Shock: Management Bundle Beginning With the FY 2026 Program Year

As discussed in section V.K.3.a of this final rule, we are finalizing the Severe and Septic Shock: Management Bundle measure beginning with the FY 2026 program year. In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27032), we proposed to adopt a 12-month baseline period and a 12-month performance period for that measure. Therefore, for the FY 2026 program year, we proposed to adopt a 12-month performance period that runs from January 1, 2024 to December 31, 2024 and a baseline period that runs from January 1, 2022 to December 31, 2022. We also proposed to use 12-month baseline and performance periods in subsequent program years, beginning with January 1st and ending with December 31st of a given year. Section V.K.3.a of this final rule describes the comments we received regarding the baseline and performance periods and our responses. We display these finalized baseline and performance periods in Table V.K.–04.

c. Summary of Previously Adopted Baseline and Performance Periods for the FY 2025 Program Year and Previously Adopted and Newly Adopted Baseline and Performance Periods Beginning With the FY 2026 Program Year

Tables V.K.–03, V.K.–04, V.K.–05, V.K.–06, and V.K.–07 summarize the baseline and performance periods that we have previously adopted and those that we are newly adopting in this final rule.

### TABLE V.K.–03: PREVIOUSLY ADOPTED BASELINE AND PERFORMANCE PERIODS FOR THE FY 2025 PROGRAM YEAR

<table>
<thead>
<tr>
<th>Measures</th>
<th>Baseline Period</th>
<th>Performance Period</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Person and Community Engagement Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCAHPS</td>
<td>January 1, 2019 – December 31, 2019*</td>
<td>January 1, 2023 – December 31, 2023</td>
</tr>
<tr>
<td><strong>Clinical Outcomes Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COMP-HIP-KNEE</td>
<td>April 1, 2015 – March 31, 2018</td>
<td>July 1, 2020 – March 31, 2023**</td>
</tr>
<tr>
<td><strong>Safety Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NHSN measures (CAUTI, CLABSI, Colon and Abdominal Hysterectomy SSI, CDI, MRSA Bacteremia)</td>
<td>January 1, 2019 – December 31, 2019*</td>
<td>January 1, 2023 – December 31, 2023</td>
</tr>
<tr>
<td><strong>Efficiency and Cost Reduction Domain</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*In the FY 2023 IPPS/LTCH PPS final rule, we finalized that these baseline periods would be January 1, 2019, through
### TABLE V.K.-04: PREVIOUSLY ADOPTED AND NEWLY ADOPTED BASELINE AND PERFORMANCE PERIODS FOR THE FY 2026 PROGRAM YEAR

<table>
<thead>
<tr>
<th>Measures</th>
<th>Baseline Period</th>
<th>Performance Period</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Person and Community Engagement Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCAHPS</td>
<td>January 1, 2022 – December 31, 2022</td>
<td>January 1, 2024 – December 31, 2024</td>
</tr>
<tr>
<td><strong>Clinical Outcomes Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COMP-HIP-KNEE</td>
<td>April 1, 2016 – March 31, 2019</td>
<td>April 1, 2021 – March 31, 2024</td>
</tr>
<tr>
<td><strong>Safety Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NHSN measures (CAUTI, CLABSI, Colon and Abdominal Hysterectomy SSI, CDI, MRSA Bacteremia)</td>
<td>January 1, 2022 – December 31, 2022</td>
<td>January 1, 2024 – December 31, 2024</td>
</tr>
<tr>
<td><strong>Efficiency and Cost Reduction Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSPB</td>
<td>January 1, 2022 – December 31, 2022</td>
<td>January 1, 2024 – December 31, 2024</td>
</tr>
</tbody>
</table>

* We are finalizing adoption of the Severe Sepsis and Septic Shock: Management Bundle measure beginning with the FY 2026 program year, as discussed in section XXX of this final rule.

### TABLE V.K.-05: PREVIOUSLY ADOPTED AND NEWLY ADOPTED BASELINE AND PERFORMANCE PERIODS FOR THE FY 2027 PROGRAM YEAR

<table>
<thead>
<tr>
<th>Measures</th>
<th>Baseline Period</th>
<th>Performance Period</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Person and Community Engagement Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCAHPS</td>
<td>January 1, 2023 – December 31, 2023</td>
<td>January 1, 2025 – December 31, 2025</td>
</tr>
<tr>
<td><strong>Clinical Outcomes Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COMP-HIP-KNEE</td>
<td>April 1, 2017 – March 31, 2020*</td>
<td>April 1, 2022 – March 31, 2025</td>
</tr>
<tr>
<td><strong>Safety Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NHSN measures (CAUTI, CLABSI, Colon and Abdominal Hysterectomy SSI, CDI, MRSA Bacteremia)</td>
<td>January 1, 2023 – December 31, 2023</td>
<td>January 1, 2025 – December 31, 2025</td>
</tr>
<tr>
<td>SEP-1</td>
<td>January 1, 2023 – December 31, 2023</td>
<td>January 1, 2025 – December 31, 2025</td>
</tr>
<tr>
<td><strong>Efficiency and Cost Reduction Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSPB</td>
<td>January 1, 2023 – December 31, 2023</td>
<td>January 1, 2025 – December 31, 2025</td>
</tr>
</tbody>
</table>

*These baseline periods are impacted by the ECE granted by CMS on March 22, 2020. Qualifying claims will be excluded from the measure calculations for January 1, 2020–March 31, 2020 (Q1 2020), and April 1, 2020–June 30, 2020 (Q2 2020), from the claims-based complication and mortality measures. For more detailed information, we refer readers to the FY 2022 IPPS/LTCH PPS final rule (86 FR 45297 through 45299).
**TABLE V.K.-06: PREVIOUSLY ADOPTED AND NEWLY ADOPTED BASELINE AND PERFORMANCE PERIODS FOR THE FY 2028 PROGRAM YEAR**

<table>
<thead>
<tr>
<th>Measures</th>
<th>Baseline Period</th>
<th>Performance Period</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Person and Community Engagement Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICAHPS</td>
<td>January 1, 2024 – December 31, 2024</td>
<td>January 1, 2026 – December 31, 2026</td>
</tr>
<tr>
<td><strong>Clinical Outcomes Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mortality measures (MORT-30-AMI, MORT-30-HF, MORT3-0-COPD, MORT-30-CABG, MORT-30-PN (updated cohort))</td>
<td>July 1, 2018 – June 30, 2021**</td>
<td>July 1, 2023 – June 30, 2026</td>
</tr>
<tr>
<td>COMP-HIP-KNEE</td>
<td>April 1, 2018 – March 31, 2021**</td>
<td>April 1, 2023 – March 31, 2026</td>
</tr>
<tr>
<td><strong>Safety Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NHSN measures (CAUTI, CLABSI, Colon and Abdominal Hysterectomy SSI, CDI, MRSA Bacteremia)</td>
<td>January 1, 2024 – December 31, 2024</td>
<td>January 1, 2026 – December 31, 2026</td>
</tr>
<tr>
<td>SEP-I</td>
<td>January 1, 2024 – December 31, 2024</td>
<td>January 1, 2026 – December 31, 2026</td>
</tr>
</tbody>
</table>

**Efficiency and Cost Reduction Domain**

<table>
<thead>
<tr>
<th>Measures</th>
<th>Baseline Period</th>
<th>Performance Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSPB</td>
<td>January 1, 2024 – December 31, 2024</td>
<td>January 1, 2026 – December 31, 2026</td>
</tr>
</tbody>
</table>

* We are finalizing substantive updates to the MSPB measure beginning with the FY 2028 program year, as discussed in section XXX of this final rule.

**These baseline periods are impacted by the ECE granted by CMS on March 22, 2020. Qualifying claims will be excluded from the measure calculations for January 1, 2020–March 31, 2020 (Q1 2020), and April 1, 2020–June 30, 2020 (Q2 2020), from the claims-based complication and mortality measures. For more detailed information, we refer readers to the FY 2022 IPPS/LTCH PPS final rule (86 FR 45297 through 45299).

**TABLE V.K.-07: NEWLY ADOPTED BASELINE AND PERFORMANCE PERIODS FOR THE FY 2029 PROGRAM YEAR**

<table>
<thead>
<tr>
<th>Measures</th>
<th>Baseline Period</th>
<th>Performance Period</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Person and Community Engagement Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICAHPS</td>
<td>January 1, 2025 – December 31, 2025</td>
<td>January 1, 2027 – December 31, 2027</td>
</tr>
<tr>
<td><strong>Clinical Outcomes Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mortality measures (MOR-T30-AMI, MORT-30-HF, MORT-30-COPD, MORT-30-CABG, MORT-30-PN (updated cohort))</td>
<td>July 1, 2019 – June 30, 2022*</td>
<td>July 1, 2024 – June 30, 2027</td>
</tr>
<tr>
<td>COMP-HIP-KNEE</td>
<td>April 1, 2019 – March 31, 2022*</td>
<td>April 1, 2024 – March 31, 2027</td>
</tr>
<tr>
<td><strong>Safety Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NHSN measures (CAUTI, CLABSI, Colon and Abdominal Hysterectomy SSI, CDI, MRSA Bacteremia)</td>
<td>January 1, 2025 – December 31, 2025</td>
<td>January 1, 2027 – December 31, 2027</td>
</tr>
<tr>
<td>SEP-I</td>
<td>January 1, 2025 – December 31, 2025</td>
<td>January 1, 2027 – December 31, 2027</td>
</tr>
<tr>
<td><strong>Efficiency and Cost Reduction Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSPB</td>
<td>January 1, 2025 – December 31, 2025</td>
<td>January 1, 2027 – December 31, 2027</td>
</tr>
</tbody>
</table>

*These baseline periods are impacted by the ECE granted by CMS on March 22, 2020. Qualifying claims will be excluded from the measure calculations for January 1, 2020–March 31, 2020 (Q1 2020), and April 1, 2020–June 30, 2020 (Q2 2020), from the claims-based complication and mortality measures. For more detailed information, we refer readers to the FY 2022 IPPS/LTCH PPS final rule (86 FR 45297 through 45299).

** We are finalizing substantive updates to the THA/TKA Complications measure beginning with the FY 2030 program year, as discussed in section XXX of this final rule.
5. Performance Standards for the Hospital VBP Program

a. Background

We refer readers to sections 1886(o)(3)(A) through 1886(o)(3)(D) of the Act for the statutory provisions governing performance standards under the Hospital VBP Program. We refer readers to the Hospital Inpatient VBP Program final rule (76 FR 26511 through 26513) for further discussion of achievement and improvement standards under the Hospital VBP Program. We refer readers to the FY 2013 IPPS/LTCH PPS final rule, the FY 2014 IPPS/LTCH PPS final rule, and the FY 2015 IPPS/LTCH PPS final rule (77 FR 53599 through 53605; 78 FR 50694 through 50699; and 79 FR 50077 through 50081, respectively) for a more detailed discussion of the general scoring methodology used in the Hospital VBP Program.

We refer readers to the FY 2022 IPPS/LTCH PPS final rule (86 FR 45290 through 45292) for previously established performance standards for the FY 2024 program year. We also refer readers to the FY 2023 IPPS/LTCH PPS final rule (87 FR 49115 through 49118) for the previously established performance standards for the FY 2025 program year. We refer readers to the FY 2021 IPPS/LTCH PPS final rule for further discussion on performance standards for which the measures are calculated with lower values representing better performance (85 FR 58855).

b. Technical Corrections

(1) Background

After publication of the FY 2023 IPPS/LTCH PPS final rule, we determined there was a display error in the performance standards for the FY 2025 program year and an incorrectly labeled title for the FY 2028 program year. In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27035 through 27036), we announced technical corrections in accordance with 42 CFR 412.160 of our regulations that allows for updates to a performance standard if making a single correction for calculation errors or other problems that would significantly change the performance standards. Technical corrections were issued for these performance standards tables to ensure that hospitals have the correct performance standards for the applicable performance periods. The corrected performance standards are displayed in sections V.K.5.b.(2) and V.K.5.b.(3) of this final rule.

(2) Technical Correction to the Performance Standards for the FY 2025 Program Year

In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49115 through 49116), we established performance standards for the measures in the FY 2025 program year in Table V.I–09. In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27035), we issued a correction to display the correct performance standards for the Safety domain measures using CY 2019 data for the FY 2025 program year. The previously established and newly corrected performance standards for the measures in the FY 2025 program year have been updated and are set out in Table V.K–08. All other performance standards for the FY 2025 program year, including the HCAHPS Performance Standards for the Person and Community Engagement domain, were correctly displayed in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49115 through 49117).

### TABLE V.K–08: PREVIOUSLY ESTABLISHED PERFORMANCE STANDARDS FOR THE FY 2025 PROGRAM YEAR

<table>
<thead>
<tr>
<th>Measure Short Name</th>
<th>Achievement Threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Safety Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAUTI*</td>
<td>0.650</td>
<td>0</td>
</tr>
<tr>
<td>CLABSI*</td>
<td>0.589</td>
<td>0</td>
</tr>
<tr>
<td>CDI*</td>
<td>0.520</td>
<td>0.014</td>
</tr>
<tr>
<td>MRSA Bacteremia*</td>
<td>0.726</td>
<td>0</td>
</tr>
<tr>
<td>Colon and Abdominal Hysterectomy SSI*</td>
<td>0.717</td>
<td>0</td>
</tr>
<tr>
<td>Colon and Abdominal Hysterectomy SSI*</td>
<td>0.738</td>
<td>0</td>
</tr>
<tr>
<td><strong>Clinical Outcomes Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MORT-30-AMI*</td>
<td>0.872624</td>
<td>0.889994</td>
</tr>
<tr>
<td>MORT-30-HF*</td>
<td>0.883990</td>
<td>0.910344</td>
</tr>
<tr>
<td>MORT-30-PN (updated cohort)*</td>
<td>0.841475</td>
<td>0.874425</td>
</tr>
<tr>
<td>MORT-30-COPD*</td>
<td>0.915127</td>
<td>0.932236</td>
</tr>
<tr>
<td>MORT-30-CABG*</td>
<td>0.970100</td>
<td>0.979775</td>
</tr>
<tr>
<td>COMP-HIP-KNEE*</td>
<td>0.025332</td>
<td>0.017946</td>
</tr>
<tr>
<td><strong>Efficiency and Cost Reduction Domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSPB*</td>
<td>Median Medicare Spending per Beneficiary ratio across all hospitals during the performance period.</td>
<td>Mean of the lowest decile Medicare Spending per Beneficiary ratios across all hospitals during the performance period.</td>
</tr>
</tbody>
</table>

* Lower values represent better performance.

# Previously established performance standards.
(3) Technical Correction to the Performance Standards for Certain Measures for the FY 2028 Program Year

In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49118), we established the performance standards for certain measures for the FY 2028 program in Table V.I.–13. The title of Table V.I.–13 incorrectly labeled the program year as FY 2027. In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27036), we issued a correction to display the title of the table as, Newly Established Performance Standards for the FY 2028 Program Year. The performance standards for the measures in the FY 2028 program year were correctly displayed and remain as finalized in the FY 2023 IPPS/LTCH PPS final rule and are set out in section V.K.5.e and Table V.K.–12 of this final rule.

c. Previously and Newly Established Performance Standards for the FY 2026 Program Year

In the FY 2021 IPPS/LTCH PPS final rule (84 FR 42398 through 42399), we established performance standards for the FY 2026 program year for the Clinical Outcomes domain measures (MORT–30–AMI, MORT–30–HF, MORT–30–PN (updated cohort), MORT–30–COPD, MORT–30–CABG, and COMP–HIP–KNEE) and for the Efficiency and Cost Reduction domain measure (MSPB Hospital). We note that the performance standards for the MSPB Hospital measure are based on performance period data. Therefore, we are unable to provide numerical equivalents for the standards at this time. As discussed in section V.K.3.a of this final rule, we are finalizing the Severe and Septic Shock: Management Bundle measure beginning with the FY 2026 program year. The previously established and newly established performance standards for the measures in the FY 2026 program year are set out in Tables V.K.–09 and V.K.–10.

<table>
<thead>
<tr>
<th>Measure Short Name</th>
<th>Achievemenit Threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAUTI**</td>
<td>0.615</td>
<td>0</td>
</tr>
<tr>
<td>CLABSI**</td>
<td>0.76</td>
<td>0</td>
</tr>
<tr>
<td>CDI*</td>
<td>0.423</td>
<td>0</td>
</tr>
<tr>
<td>MRSA Bacteremia*</td>
<td>0.793</td>
<td>0</td>
</tr>
<tr>
<td>Colon and Abdominal Hysterectomy SSI*</td>
<td>0.747</td>
<td>0.763</td>
</tr>
<tr>
<td>SEP-1***</td>
<td>0.597482</td>
<td>0.843620</td>
</tr>
</tbody>
</table>

Clinical Outcomes Domain

<table>
<thead>
<tr>
<th>Measure Short Name</th>
<th>Achievement Threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>MORT–30-AMI</td>
<td>0.874426</td>
<td>0.890687</td>
</tr>
<tr>
<td>MORT–30-HF</td>
<td>0.885949</td>
<td>0.912874</td>
</tr>
<tr>
<td>MORT–30-PN (updated cohort)</td>
<td>0.843369</td>
<td>0.877097</td>
</tr>
<tr>
<td>MORT–30-COPD</td>
<td>0.914691</td>
<td>0.932157</td>
</tr>
<tr>
<td>MORT–30-CABG</td>
<td>0.970568</td>
<td>0.980473</td>
</tr>
<tr>
<td>MSPB*</td>
<td>0.024019</td>
<td>0.016873</td>
</tr>
</tbody>
</table>

Efficiency and Cost Reduction Domain

<table>
<thead>
<tr>
<th>Measure Short Name</th>
<th>Achievement Threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median Medicare Spending per Beneficiary ratio across all hospitals during the performance period.</td>
<td>Median of the lowest decile Medicare Spending per Beneficiary ratios across all hospitals during the performance period.</td>
<td></td>
</tr>
</tbody>
</table>

* Lower values represent better performance.

** We note that the numerical values for the performance standards for the HAI measures in this final rule represent estimates based on the most recently available data. These estimates are based on CY 2022 data.

*** We note that the numerical values for the performance standards for the SEP-1 measure displayed in this final rule represent estimates based on the most recently available data. These estimates are based on CY 2022 data.

After publication of the FY 2024 IPPS/LTCH PPS proposed rule, we determined there was a display error in the performance standards for this measure. Specifically, the Achievement Threshold and Benchmark values, accurate, were presented in the wrong categories. We corrected this issue in the FY 2024 IPPS/LTCH PPS final rule and the correct performance standards are displayed in the table.

The HCAHPS Base Score is calculated using the eight dimensions of the HCAHPS measure. For each of the eight dimensions, Achievement Points (0–10 points) and Improvement Points (0–9 points) are calculated, the larger of which is then summed across the eight dimensions to create the HCAHPS Base Score (0–80 points). Each of the eight dimensions is of equal weight; therefore, the HCAHPS Base Score ranges from 0 to 80 points. HCAHPS Consistency Points are then calculated, which range from 0 to 20 points. The Consistency Points take into consideration the scores of all eight Person and Community Engagement dimensions. The final element of the scoring formula is the summation of the HCAHPS Base Score and the HCAHPS Consistency Points, which results in the Person and Community Engagement domain score that ranges from 0 to 100 points.
d. Previously Established Performance Standards for Certain Measures for the FY 2027 Program Year

We have adopted certain measures for the Safety domain, Clinical Outcomes domain, and the Efficiency and Cost Reduction domain for future program years to ensure that we can adopt baseline and performance periods of sufficient length for performance scoring purposes. In the FY 2022 IPPS/LTCH PPS final rule (86 FR 45294 through 45295), we established performance standards for the FY 2027 program year for the Clinical Outcomes domain measures (MORT–30–AMI, MORT–30–HF, MORT–30–PN (updated cohort), MORT–30–COPD, MORT–30–CABG, and COMP–HIP–KNEE) and the Efficiency and Cost Reduction domain measure (MSPB). We note that the performance standards for the MSPB measure are based on performance period data. Therefore, we are unable to provide numerical equivalents for the standards at this time. We also note that the performance standard calculation methodology for the substantive updates to the MSPB Hospital measure, discussed in section XXX of this final rule, will not change with the adoption of the substantive measure updates. The updated performance standards for the substantive measure updates to the MSPB measure are not yet available for FY 2028. The previously established performance standards for these measures are set out in Table V.K.–11.

<table>
<thead>
<tr>
<th>HCAHPS Survey Dimension*</th>
<th>Achievement Threshold (50th percentile)</th>
<th>Benchmark (mean of top decile)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Communication with Nurses</td>
<td>55.23</td>
<td>76.41</td>
</tr>
<tr>
<td>Communication with Doctors</td>
<td>58.04</td>
<td>76.83</td>
</tr>
<tr>
<td>Responsiveness of Hospital Staff</td>
<td>36.52</td>
<td>59.56</td>
</tr>
<tr>
<td>Communication about Medicines</td>
<td>39.27</td>
<td>58.06</td>
</tr>
<tr>
<td>Hospital Cleanliness &amp; Quietness</td>
<td>38.59</td>
<td>62.61</td>
</tr>
<tr>
<td>Discharge Information</td>
<td>63.22</td>
<td>85.54</td>
</tr>
<tr>
<td>Care Transition</td>
<td>19.98</td>
<td>48.55</td>
</tr>
<tr>
<td>Overall Rating of Hospital</td>
<td>31.58</td>
<td>67.59</td>
</tr>
</tbody>
</table>

* The newly established performance standards displayed in this table were calculated using CY 2022 data. Data includes IPPS hospitals with 100+ completed surveys from patients discharged between January 2022 and December 2022.

e. Previously Established Performance Standards for Certain Measures for the FY 2028 Program Year

We have adopted certain measures for the Safety domain, Clinical Outcomes domain, and the Efficiency and Cost Reduction domain for future program years to ensure that we can adopt baseline and performance periods of sufficient length for performance scoring purposes. In the FY 2023 IPPS/LTCH PPS final rule (86 FR 49118), we established performance standards for the FY 2028 program year for the Clinical Outcomes domain measures (MORT–30–AMI, MORT–30–HF, MORT–30–PN (updated cohort), MORT–30–COPD, MORT–30–CABG, and COMP–HIP–KNEE) and the Efficiency and Cost Reduction domain measure (MSPB Hospital). As discussed in section V.K.5.b.(3) of this final rule, in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27038), we issued a technical correction with respect to the title of Table V.I.–13 in the FY 2023 IPPS/LTCH PPS final rule. We note that the performance standards for the MSPB Hospital measure are based on performance period data. Therefore, we are unable to provide numerical equivalents for the standards at this time. The previously established performance standards for these measures are set out in Table V.K.–12.

<table>
<thead>
<tr>
<th>Measure Short Name</th>
<th>Achievement Threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>MORT–30–AMI</td>
<td>0.877824</td>
<td>0.893133</td>
</tr>
<tr>
<td>MORT–30–HF</td>
<td>0.887571</td>
<td>0.913388</td>
</tr>
<tr>
<td>MORT–30–PN (updated cohort)</td>
<td>0.844826</td>
<td>0.877204</td>
</tr>
<tr>
<td>MORT–30–COPD</td>
<td>0.917395</td>
<td>0.932640</td>
</tr>
<tr>
<td>MORT–30–CABG</td>
<td>0.971149</td>
<td>0.980752</td>
</tr>
<tr>
<td>COMP–HIP–KNEE*</td>
<td>0.023322</td>
<td>0.017018</td>
</tr>
</tbody>
</table>

** As discussed in the FY 2022 IPPS/LTCH PPS final rule (86 FR 5297 through 45299), we did not include data from Q1 and Q2 of CY 2020 in the calculation of these performance standards.
f. Newly Established Performance Standards for Certain Measures for the FY 2029 Program Year

As discussed previously, we have adopted certain measures for the Clinical Outcomes domain (MORT–30–AMI, MORT–30–HF, MORT–30–PN (updated cohort), MORT–30–COPD, MORT–30–CABG, and COMP–HIP–KNEE) and the Efficiency and Cost Reduction domain (MSPB Hospital) for future program years to ensure that we can adopt baseline and performance periods of sufficient length for performance scoring purposes. In accordance with our methodology for calculating performance standards discussed more fully in the Hospital Inpatient VBP Program final rule (76 FR 26511 through 26513), which is codified at 42 CFR 412.160, we are establishing the following performance standards for the FY 2029 program year for the Clinical Outcomes domain and the Efficiency and Cost Reduction domain. We note that the performance standards for the MSPB Hospital measure are based on performance period data. Therefore, we are unable to provide numerical equivalents for the standards at this time. The newly established performance standards for these measures are set out in Table V.K.–13.

<table>
<thead>
<tr>
<th>Measure Short Name</th>
<th>Achievement Threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>MORT–30–AMI</td>
<td>0.877260</td>
<td>0.893229</td>
</tr>
<tr>
<td>MORT–30–HF</td>
<td>0.885427</td>
<td>0.910649</td>
</tr>
<tr>
<td>MORT–30–PN (updated cohort)</td>
<td>0.831776</td>
<td>0.866166</td>
</tr>
<tr>
<td>MORT–30–COPD</td>
<td>0.913752</td>
<td>0.929652</td>
</tr>
<tr>
<td>MORT–30–CABG</td>
<td>0.971052</td>
<td>0.980570</td>
</tr>
<tr>
<td>COMP–HIP–KNEE</td>
<td>0.029758</td>
<td>0.022002</td>
</tr>
</tbody>
</table>

Efficiency and Cost Reduction Domain

<table>
<thead>
<tr>
<th>Measure Short Name</th>
<th>Achievement Threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSPB*</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Lower values represent better performance.
** We note that these performance standards are calculated using some data from CY 2020 and CY 2021, which are included in the COVID-19 PHE. However, these performance standards have been calculated using the updated technical specifications described in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49106 through 49110), which excludes patients diagnosed with COVID-19 and risk-adjusts for history of COVID-19 for these measures.

TABLE V.K.12: PREVIOUSLY AND NEWLY ESTABLISHED PERFORMANCE STANDARDS FOR THE FY 2028 PROGRAM YEAR
TABLE V.K.13: NEWLY ESTABLISHED PERFORMANCE STANDARDS FOR THE FY 2029
PROGRAM YEAR

<table>
<thead>
<tr>
<th>Measure Short Name</th>
<th>Achievement Threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>MORT-30-AMI</td>
<td>0.874856</td>
<td>0.893101</td>
</tr>
<tr>
<td>MORT-30-HF</td>
<td>0.880089</td>
<td>0.9072</td>
</tr>
<tr>
<td>MORT-30-PN</td>
<td>0.814736</td>
<td>0.853996</td>
</tr>
<tr>
<td></td>
<td>(updated cohort)</td>
<td></td>
</tr>
<tr>
<td>MORT-30-COPD</td>
<td>0.905916</td>
<td>0.924829</td>
</tr>
<tr>
<td>MORT-30-CABG</td>
<td>0.971027</td>
<td>0.979822</td>
</tr>
<tr>
<td>COMP-HIP-KNEE*</td>
<td>0.025024</td>
<td>0.018708</td>
</tr>
</tbody>
</table>

Efficiency and Cost Reduction Domain

<table>
<thead>
<tr>
<th>Measure Short Name</th>
<th>Median Medicare Spending per Beneficiary ratio across all hospitals during the performance period.</th>
<th>Mean of the lowest decile Medicare Spending per Beneficiary ratios across all hospitals during the performance period.</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSPB*</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Lower values represent better performance.
** We note that these performance standards are calculated using some data from CY 2020 and CY 2021, which are included the COVID-19 PHE. However, these performance standards have been calculated using the updated technical specifications described in sections V.1.3.c. and V.1.3.d. of this final rule, which excludes patients diagnosed with COVID-19 and risk adjusts for history of COVID-19 for these measures.

6. Change to the Scoring Methodology

a. Background

In the Hospital Inpatient VBP Program final rule, we adopted a methodology for scoring clinical process of care, patient experience of care, and outcome measures (76 FR 26513 through 26531). We also refer readers to our codified requirements for performance scoring under the Hospital VBP Program at 42 CFR 412.165. In the FY 2024 IPPS/LTCPPS proposed rule, we proposed modifications to the existing scoring methodology to reward excellent care in underserved populations.

b. Revision of the Hospital VBP Program Scoring Methodology To Add a New Adjustment That Rewards Hospitals Based on Their Performance and the Proportion of Their Patients Who Are Dually Eligible for Medicare and Medicaid

1) Background and Overview

Healthcare disparities exist among patients throughout the United States, and certain patient characteristics such as socioeconomic status are associated with worse health outcomes.\textsuperscript{274} \textsuperscript{275}

Research shows that patients experiencing worse health outcomes often face barriers to accessing health care services and have access to fewer healthcare providers.\textsuperscript{276} \textsuperscript{277} In leveraging our VBP programs to improve the quality of care and access to that care, we are interested in utilizing health equity-focused scoring modifications to create better health outcomes for all populations in these programs. The Office of the Assistant Secretary for Planning and Education’s (ASPE) March 2020 Report to Congress: Social Risk Factors and Performance in Medicare’s Value-Based Purchasing Program, provides insight into whether and how value-based programs should account for social risk factors such as income, housing, transportation, and nutrition, that might adversely affect access to health care services or health outcomes.\textsuperscript{278} A key finding was that dual enrollment status (that is, enrollment in both Medicare and Medicaid) is a strong predictor of poorer healthcare outcomes in Medicare’s VBP programs, even when accounting for other social and functional risk factors. Dual enrollment status, an indicator at the individual level, also represents one way to capture common socioeconomic challenges that could affect an individual’s ability to access care.

In the 2016 Report to Congress on Social Risk Factors and Performance in Medicare’s Value-Based Purchasing Program, ASPE reported that beneficiaries with social risk factors, including dual enrollment in Medicare and Medicaid as a marker for low income, residence in a low-income area, Black race, Hispanic ethnicity, disability, and residence in a rural area, had worse outcomes and were more likely to be cared for by lower quality providers.\textsuperscript{279} Patients with dual


\textsuperscript{279} Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health & Human Services. First Report to Congress on Social Risk Factors and Performance in Medicare’s Value-Based Purchasing Program. 2016. Available at:
eligibility status (DES), those who qualify for both Medicare and Medicaid coverage, are particularly vulnerable and experience significant disparities. Patients with DES are more likely to be disabled or functionally impaired, more likely to be medically complex, and have greater social needs compared to other beneficiaries. Patients with DES are one of the most vulnerable populations. Despite the multitude of indicators available for assessing vulnerability and health risks, dual eligibility remains the strongest predictor of negative health outcomes.

Executive Order 13985 of January 20, 2021 on Advancing Racial Equity and Support for Underserved Communities Through the Federal Government, defines “equity” as the consistent and systematic fair, just, and impartial treatment of all individuals, including individuals who belong to underserved communities that have been denied such treatment, such as Black, Latino, and Indigenous and Native American persons, LGBTQpersons, African Americans and Pacific Islanders and other persons of color; members of religious minorities; lesbian, gay, bisexual, transgender, and queer (LGBTQII[A]+) persons; persons with disabilities; persons who live in rural areas; and persons otherwise adversely affected by persistent poverty or inequality (86 FR 7009).

CMS defines “health equity” as the attainment of the highest level of health for all people, where everyone has a fair and just opportunity to attain their optimal health regardless of race, ethnicity, disability, sexual orientation, gender identity, socioeconomic status, geography, preferred language, or other factors that affect access to care and health outcomes. To achieve this vision, we are working to advance health equity by designing, implementing, and operationalizing policies and programs that support health for all individuals served by our programs, reducing avoidable differences in health outcomes experienced by people who are disadvantaged or underserved, and providing the care and support that our enrollees need to thrive.

Achieving health equity, addressing health disparities, and closing the performance gap in the quality of care provided to populations that have been disadvantaged, marginalized, and/or underserved by the healthcare system continue to be priorities for CMS as outlined in the CMS National Quality Strategy. The Hospital IQR Program adopted three new health-equity focused quality measures in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49191 through 49220). To further align with our goals to achieve health equity, address health disparities, and close the performance gap on the quality of care, in the FY 2024 IPPS/LTCH PPS proposed rule, we proposed to add Health Equity Adjustment bonus points to a hospital’s Total Performance Score (TPS) that will be calculated using a methodology that incorporates a hospital’s performance across all four domains for the program year and its proportion of patients with DES (88 FR 7039 through 7049).

We proposed to define the points that a hospital can earn based on its performance and proportion of patients with DES as the Health Equity Adjustment (HEA) bonus points. We believe that the awarding of these HEA bonus points is consistent with our strategy to advance health equity and will incentivize high-quality care across all hospitals.

We proposed to define the term “measure performance scaler” as the sum of the points awarded to a hospital for each domain based on the hospital’s performance on the measures in that domain. The number of points that we award to a hospital for each domain will be 4, 2, or 0, based on whether the hospital’s performance is in the top third, middle third, and bottom third of performance, respectively, of all hospitals for the domain. Specifically, a hospital will receive 4 points if its performance falls in the top third, 2 points if it falls in the middle third, or 0 points if its performance falls in the bottom third of performance of all hospitals for the domain. Hospitals could thus receive a maximum of 16 measure performance scaler points for being a top performer across all four domains.

We proposed to define the term “underserved multiplier” as the number of inpatient stays for patients with DES out of the total number of inpatient Medicare stays during the calendar year two years before the start of the respective program year. For example, for the FY 2026 program year, we will use the total number of inpatient stays from January 1, 2024 through December 31, 2024. A logistic exchange function will be then applied to the number of patients with DES. Data on DES is sourced from the State Medicare Modernization Act (MMA) file of dual eligible beneficiaries, which each of the 50 States and the District of Columbia submit to CMS at least monthly. This file is utilized to deem individuals with DES automatically eligible for the Medicare Part D Low Income Subsidy, as well as other CMS program needs and thus can be considered the gold standard for determining DES. We note that this is the same file used for determining DES in the Hospital Readmissions Reduction Program. More detail on this file can be found on the CMS website at https://www.cms.gov/Medicare-Medicaid-Coordination/Medicare-and-Medicaid-Coordination/OFFICE/STATISTICALRESOURCES/STATEMMAFILE and at the Research Data Assistance Center website at https://resdac.org/cms-data/variables/monthly-medicare-medicaid-dual-eligibility-code-january.

We proposed that the HEA bonus points will be calculated as the product of the measure performance scaler and the underserved multiplier. The HEA bonus points are designed to award higher points for hospitals that (1) serve Medicare%2C%20Medicaid%2C%20Marketplace%20coverage%2C%20Medicaid%2C%20Medicare...
greater percentages of underserved populations, which are defined here for the purpose of this proposal as hospital patients with DES who receive inpatient services, and (2) have higher quality performance.

The methodology for the calculation of the HEA bonus points is described in sections V.K.6.b.(3) and V.K.6.b.(4) of this final rule. By providing HEA bonus points to hospitals that serve higher proportions of patients with DES and perform well on quality measures, we believe that we can begin to bridge performance gaps and better address the social needs of patients, in alignment with our National Quality Strategy.288 We are committed to achieving health equity for hospitalized patients by supporting hospitals in quality improvement activities to reduce health disparities, enabling patients and their family members and caregivers to make more informed decisions, and promoting provider accountability for health care disparities. We believe that this scoring methodology update will continue to align with the CMS health equity goals to close gaps in health care quality and promote the highest quality outcomes for all people.289

We proposed to adopt this adjustment to the Hospital VBP Program scoring methodology beginning with the FY 2026 program year.

We note that the Shared Savings Program recently adopted a health equity adjustment for Accountable Care Organizations that report all-payer electronic clinical quality measures (eCQMs)/Merit-based Incentive Payment System CQMs, are high-performing on quality, and serve a large proportion of underserved beneficiaries, as defined by dual-eligibility, enrollment in the Medicare Part D low income subsidy (LIS) (meaning the individual is enrolled in a Part D plan and receives LIS) and an Area Deprivation Index (ADI) score of 85 or above, as detailed in the CY 2023 Physician Fee Schedule final rule (87 FR 69838 through 69857). The proposed definitions and calculations in this final rule are similar to the health equity adjustment finalized in the Shared Savings Program.

Additionally, a similar health equity adjustment was proposed in the FY 2024 Skilled Nursing Facility (SNF) Prospective Payment System (PPS) proposed rule for the SNP Value-Based Purchasing (VBP) Program (88 FR 21383 through 21393).

(2) Determining the Underserved Multiplier and Measure Performance Scaler

At this time, for purposes of the Hospital VBP Program’s health equity adjustment policy, we are unable to obtain patients’ neighborhood-level data necessary to incorporate the ADI under all of the Hospital VBP Program measures as currently specified. We note that the use of the LIS designation and DES could be preferable to using DES alone, as doing so reduces variability because of the differences in Medicaid eligibility across States; however, given that the DES data are readily available and already used in the Hospital Readmissions Reduction Program, we proposed to only use DES data at this time. As DES is a strong indicator of poorer healthcare outcomes in Medicare’s VBP programs,290 we believe that it can serve as an appropriate underserved multiplier on its own in the Hospital VBP Program.

We will continue to consider whether to incorporate the LIS, ADI, and other indicators for underserved populations in future health equity adjustment proposals for the Hospital VBP Program. We sought comment on the use of these additional indicators in the FY 2024 IPPS/LTCCH PPS proposed rule (88 FR 27049) and summarized the comments we received in section V.K.6.b.(7) of this final rule.

The measure performance scaler points will be available to all hospitals that exhibit high quality care across the entire patient population. Each domain will be assessed independently such that a hospital that performs in the top or middle third of performance for one domain will be eligible for measure performance scaler points even if it does not perform in the top or middle third of performance for any other domain. Similarly, if a hospital performs in the top third of performance for all domains, they will receive measure performance scaler points for all domains. Alternatively, a hospital which is in the bottom third of performance for all four domains will not receive any performance scaler points. A hospital’s performance is relative to the performance of all other hospitals in the Hospital VBP Program, and this measure performance scaler methodology is further defined in section V.K.6.b.(3) of this final rule.

The underserved multiplier will be calculated using a similar approach as the Hospital Readmissions Reduction Program’s dual proportion calculation, which identifies patients with DES based on the dual-eligibility codes in the Medicare Beneficiary Summary File.291 These data will provide us with the number of inpatient stays for patients with DES out of the total number of inpatient Medicare stays, which is all Medicare FFS and Medicare Advantage stays. A stay is identified as being dually eligible if it is for a patient with Medicare and full Medicaid benefits for the month the patient was discharged from the hospital, unless the patient died in the month of discharge, in which case DES is determined using the previous month. We proposed that the dual proportion is calculated with stays that occurred during the calendar year two years before the start of the respective program year. A logistic exchange function will then be applied to this dual proportion. We will then multiply this underserved multiplier by the aforementioned measure performance scaler to determine the hospital’s HEA bonus points. This methodology is described further in section V.K.6.b.(3) of this final rule.

Unlike the Shared Savings Program’s policy, we note that we did not propose a minimum percent of patients with DES that a hospital must treat, such that a hospital serving one percent of patients with DES and a hospital serving 80 percent of patients with DES are both eligible for HEA bonus points to give every hospital an opportunity to participate in this final scoring change.

Through the availability of HEA bonus points, we seek to improve outcomes by providing incentives to hospitals to strive for high performance.


290 Assistant Secretary for Planning and Evaluation. (2020) Social Risk and Performance in Medicare’s Value-Based Purchasing Programs. Available at: https://aspe.hhs.gov/sites/default/files/medicare-medicaid-dual-eligibility-code-january.

across the domains as well as to care for a high proportion of underserved populations, as defined by dual eligibility status for the purposes of this final rule. While we recognize and discuss in this final rule that there are many different indicators that could be used to measure underserved populations, we note that we are referring to patients with DES when we use the term “underserved population” throughout this final rule. As noted in section V.K.6.b.(1), DES is a good indicator of socioeconomic disadvantage, as dual eligibility is associated with a patient’s inability to access care.

The HEA bonus point calculation is purposefully designed to not reward poor quality. Likewise, if the underserved population represents only a small proportion of a hospital’s total population, such as a hospital only serving five percent of patients with DES, then the health equity adjustment will be lower because the bonus points are not designed to reward hospitals that serve a low number of underserved patients. Instead, the health equity adjustment is intended to incentivize hospitals to improve their overall quality of care across the entire hospital’s population by bridging performance gaps and improving overall health outcomes for patients while reducing the unintended risk of decreased access to care for underserved patients. As described more fully in this section of the final rule, the combination of the measure performance scaler and the underserved multiplier will result in a range of possible HEA bonus points that is designed to give the highest rewards to hospitals caring for a larger percentage of underserved individuals and delivering high quality care.

We also proposed to codify at 42 CFR 412.160 of our regulations the definitions of these new scoring methodology terms, and we proposed to codify at 42 CFR 412.165(b) of our regulations the updates to the steps for performance scoring with the incorporated health equity scoring adjustments.

(3) Application of Health Equity Adjustment

After considering how to modify the existing quality performance scoring in the Hospital VBP Program to more fully assess the quality of care provided by hospitals that serve a high proportion of underserved patients, we proposed to adjust the sum of an individual hospital’s domain scores based on their overall performance within each domain, with a maximum potential of 16 measure performance scaler points across the four domains. For hospitals that only get three domain scores because they do not meet measure minimums for all four domains, the maximum number of measure performance scaler points that a hospital could earn will be 12.

We proposed to calculate a hospital’s HEA bonus points by multiplying the measure performance scaler by the hospital’s underserved multiplier. As explained more fully in this section, the number of HEA bonus points that could then be added to a hospital’s TPS for a program year will be capped at 10. We believe that capping the total number of potential HEA bonus points at 10 recognizes the effort hospitals put forth to serve large populations of patients with DES, while not overly inflating TPSs. We believe that limiting the number of HEA bonus points that a hospital is eligible to receive to a maximum of 10 points creates a balanced incentive that increases a hospital’s TPS without dominating the score and creating unintended incentives. Additionally, the maximum of 10 HEA bonus points aligns with the magnitude of points we award for a given measure in the existing Hospital VBP Program’s scoring methodology. Therefore, the maximum number of HEA bonus points that could be added to the TPS would be 10 points. In the FY 2024 IPPS/LTCH PPS proposed rule, we proposed that no hospital could earn more than a 110 maximum final TPS that includes the HEA bonus points (88 FR 27049). We refer readers to section V.K.6.b.(6) of this final rule where we have finalized this proposal as proposed and our newly-adopted regulations at 42 CFR 412.160 where we modify the TPS maximum to 110. This final maximum at 110 will ensure that the application of the health equity adjustment allows for a hospital that receives the maximum number of points in weighted domain scores to still have the opportunity to receive the additional 10 HEA bonus points.

(4) Calculation Steps and Examples

In this section and in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27042 through 27045), we outline the calculation steps and provide examples of the determination of health equity adjustment bonus points and the application of these bonus points to a hospital’s TPS. These example calculations illustrate possible health equity adjustment bonus points resulting from the proposed approach, which accounts for both a hospital’s quality performance and a logistic exchange function applied to its proportion of patients with DES. For each hospital, the bonus will be calculated according to the following formula:

\[
\text{Health Equity Adjustment (HEA) bonus points} = \text{measure performance scaler} \times \text{underserved multiplier}
\]

The proposed calculation of the HEA bonus points will be as follows:

Step One—Calculate the Number of Measure Performance Scaler Points for Each Hospital

We proposed to first assign a measure performance scaler to each domain based on a hospital’s domain level scores. We will assign point values to hospitals for each domain based on their performance on the measures in that domain. A hospital will receive 4, 2, or 0 points for top third, middle third, or bottom third of performance, respectively, on each domain such that a hospital could receive a maximum of 16 measure performance scaler points for being in the top third of performance for all of the four domains, as depicted in this sample equation and in Table V.K.–13. We note that if a hospital performs in the bottom third of performance in all four domains, that hospital would receive a total of 0 out of 16 measure performance scaler points. Additionally, hospitals that can be scored in only three domains could receive a maximum of 12 measure performance scaler points for being in the top third of performance for each domain.

Hospital 1 (High Performance):
4 pts in Clinical Domain + 4 pts in Cost & Efficiency Domain + 4 pts in Safety Domain + 4 pts in Person & Community Engagement Domain = 16 total performance scaler points for Hospital 1

Hospital 2 (Medium Performance):
4 pts in Clinical Domain + 2 pts in Cost & Efficiency Domain + 2 pts in Safety Domain + 4 pts in Person & Community Engagement Domain = 10 total performance scaler points for Hospital 2

Hospital 3 (Low Performance):
0 pts in Clinical Domain + 0 pts in Cost & Efficiency Domain + 2 pts in Safety Domain + 0 pts in Person & Community Engagement Domain = 2 total performance scaler points for Hospital 3

Table V.K.–13 displays the measure performance scaler that three example hospitals will receive for each domain based on their performance.

**TABLE V.K.-13: EXAMPLE OF THE MEASURE PERFORMANCE SCALER ASSIGNED TO HOSPITAL BASED ON PERFORMANCE BY DOMAIN**

<table>
<thead>
<tr>
<th>Domain</th>
<th>Hospital 1 – High Performance</th>
<th>Hospital 2 - Middle performance</th>
<th>Hospital 3 - Low performance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Performance Group</td>
<td>Value</td>
<td>Performance Group</td>
</tr>
<tr>
<td>Clinical</td>
<td>Top third</td>
<td>4</td>
<td>Top Third</td>
</tr>
<tr>
<td>Cost &amp; Efficiency</td>
<td>Top third</td>
<td>4</td>
<td>Middle Third</td>
</tr>
<tr>
<td>Safety</td>
<td>Top third</td>
<td>4</td>
<td>Middle Third</td>
</tr>
<tr>
<td>Person and Community Engagement</td>
<td>Top third</td>
<td>4</td>
<td>Bottom Third</td>
</tr>
<tr>
<td>Total Measure Performance Scaler Value</td>
<td>16</td>
<td></td>
<td>Total Measure Performance Scaler Value</td>
</tr>
</tbody>
</table>

**Step Two—Calculate the Underserved Multiplier**

Second, we proposed to calculate an underserved multiplier for each hospital, which we proposed to define as the logistic function applied to the proportion of inpatient stays for patients with DES during the calendar year two years before the applicable program year divided by the total number of inpatient Medicare stays, which is all Medicare FFS and Medicare Advantage stays, at each hospital. For example, for the FY 2026 program year, we will use the total number of inpatient stays from January 1, 2024, through December 31, 2024. The primary goal of the underserved multiplier is to appropriately reward hospitals that are able to overcome the challenges of caring for high proportions of patients with DES. By utilizing a logistic exchange function to calculate the underserved multiplier, hospitals who care for the highest proportions of patients with DES will have the opportunity for the most HEA bonus points. Thus, we proposed to utilize a logistic exchange function to calculate the underserved multiplier for scoring hospitals such that there will be a lower rate of increase at the beginning and the end of the curve.

The underserved multiplier calculation will thus be:

\[
\text{Underserved Multiplier} = \frac{1}{1 + e^{-\frac{\text{Dual Rank} - \text{Max Dual Rank}}{5 + 10\%}}}
\]

To determine the proportion of the number of inpatient stays for patients with DES, we proposed to use patient level data on the proportion of all Medicare FFS and Medicare Advantage inpatient stays in a hospital in which the patient was dually eligible for Medicare and full Medicaid benefits. For the HEA adjustment, the dual proportion is calculated with stays that occurred during the calendar year two years before the applicable program year, and then a logistic exchange function is applied to that proportion. For example, for the FY 2026 program year, the dual proportion data will be calculated using stays from January 1, 2024, through December 31, 2024. In alignment with the Hospital Readmissions Reduction Program approach to determine the dual proportion, a stay is identified as being dually eligible if it is for a patient with Medicare and full Medicaid benefits for the month the patient was discharged from the hospital, unless the patient died in the month of discharge, in which case DES is determined using the previous month. Using the proportion of DES patients calculated among both Medicare FFS and Medicare Advantage patients more accurately represents the proportion of patients with DES served by the hospital compared to only using the proportion of Medicare FFS stays as well as that DES data for Medicare Advantage patients are readily available. This is the approach finalized by the Hospital Readmissions Reduction Program to determine the dual proportion in the FY 2018 IPPS/LTCPPS final rule (82 FR 38228 through 38229).

We proposed to utilize a logistic exchange function to calculate the underserved multiplier for scoring hospitals such that there will be a lower rate of increase at the beginning and the end of the curve. A logistic exchange function assumes a large difference between hospitals treating the most and fewest patients with DES and produces a large score difference between the groups, but less difference within the groups. This will ensure that there will be very few differences in the points awarded between hospitals with similar proportions of patients served. For example, there will be little difference in the points awarded to a hospital serving 59 percent of individuals with DES and a hospital serving 61 percent of individuals with DES. Utilizing a logistic function allows for hospitals in the middle third of performance to have a strong association between an increase in HEA bonus points based on proportion of patients with DES served. We note that there is no minimum or maximum threshold on the percentage of individuals with DES that a hospital serves for the calculation of HEA bonus...
points. We believe that this gives all hospitals an opportunity and incentive to serve a percentage of patients with DES. We also considered linear and actual scoring alternatives to calculate the underserved multiplier, as displayed in Figure V.K.–01, but we believe that the logistic function scoring applied to the proportion of patients with DES (dotted line in Figure V.K.–01) provides the best opportunity for hospitals serving large proportions of patients with DES to receive HEA bonus points. We note that a scoring approach using actual proportion of patients with DES, as depicted by the dashed line in Figure V.K.–01, assumes that a hospital’s treatment of patients with DES is reflected simply in their actual share in the patient population. A linear scoring approach, as depicted by the solid line in Figure V.K.–01, assumes that a hospital’s treatment of patients with DES is correlated by rank.

Figure V.K.–01

Step Three—Calculate the Health Equity Adjustment Bonus Points

We proposed to calculate the HEA bonus points that apply to a hospital for a program year by multiplying the measure performance scaler total by the underserved multiplier. We believe that combining the measure performance scaler and the underserved multiplier to calculate the HEA bonus points allows for us to reward those hospitals with high quality performance across the four domains that are also serving high populations of patients with DES. This approach also incentivizes other hospitals to improve their performance (by a higher measure performance scaler) and serve more patients with DES (by a higher underserved multiplier) to earn greater HEA bonus points. The product of the measure performance scaler points and the underserved multiplier proportion results is the HEA bonus point total capped at 10 points. Table V.K.–14 displays the HEA bonus points that six example hospitals would receive based on their measure performance scaler and underserved multiplier, with the cap of 10 total possible HEA bonus points. For example, Hospital 1 in Table V.K.–14 that has performed in the top third of performance in all four of the domains and whose population of patients with DES is 80 percent after applying the logistic function will earn 16 measure performance scaler points, which will then be multiplied by an underserved multiplier of 0.8, resulting in 12.8 HEA bonus points that would then be reduced to 10 HEA bonus points per the 10 HEA bonus point cap.
Step Four—Add Health Equity Adjustment Bonus Points to the Total of the Weighted Domain Scores To Calculate the TPS

Health Equity Adjustment (HEA) bonus points = Performance Scaler × Underserved Multiplier

<table>
<thead>
<tr>
<th>Hospital</th>
<th>Measure Performance Scaler</th>
<th>Underserved Multiplier</th>
<th>Health Equity Adjustment bonus points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital 1</td>
<td>16</td>
<td>0.8</td>
<td>10</td>
</tr>
<tr>
<td>Hospital 2</td>
<td>16</td>
<td>0.2</td>
<td>3.2</td>
</tr>
<tr>
<td>Hospital 3</td>
<td>8</td>
<td>0.3</td>
<td>2.4</td>
</tr>
<tr>
<td>Hospital 4</td>
<td>8</td>
<td>0.1</td>
<td>0.8</td>
</tr>
<tr>
<td>Hospital 5</td>
<td>2</td>
<td>0.8</td>
<td>1.6</td>
</tr>
<tr>
<td>Hospital 6</td>
<td>2</td>
<td>0.2</td>
<td>0.4</td>
</tr>
</tbody>
</table>

Finally, we proposed that we will add a hospital’s HEA bonus points as calculated in Step Three of this section to the total of the four weighted domain scores that we sum to calculate the hospital’s TPS. The sum of the weighted domain scores, which will remain as outlined in our regulations at 42 CFR 412.165(b)(4), and the HEA bonus points will be the hospital’s TPS for the program year. We did not propose to revise the process for converting the TPS into the incentive payment adjustment percentage. As established in our regulations at 42 CFR 412.162(b)(3), the value-based incentive payment percentage is calculated as the product of: the applicable percent as defined in 42 CFR 412.160, the hospital’s TPS, and the linear exchange function slope. We proposed to modify the definition of TPS in our regulations at 42 CFR 412.160 to align with the proposal to modify the TPS range to be 0–110 beginning with the FY 2026 program year as discussed in section V.K.6.b.5 of this final rule. Table V.K.–15 displays the HEA bonus points and TPSs awarded to the six example hospitals from Table V.K.–14.

Health equity adjustment bonus points + Total of Weighted Domain Scores = Total Performance Score

<table>
<thead>
<tr>
<th>Hospital</th>
<th>Total of Weighted Domain Scores</th>
<th>Health Equity Adjustment bonus points</th>
<th>TPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital 1</td>
<td>100</td>
<td>10</td>
<td>110</td>
</tr>
<tr>
<td>Hospital 2</td>
<td>90</td>
<td>3.2</td>
<td>93.2</td>
</tr>
<tr>
<td>Hospital 3</td>
<td>48</td>
<td>2.4</td>
<td>50.4</td>
</tr>
<tr>
<td>Hospital 4</td>
<td>47.2</td>
<td>0.8</td>
<td>48.8</td>
</tr>
<tr>
<td>Hospital 5</td>
<td>20</td>
<td>1.6</td>
<td>21.6</td>
</tr>
<tr>
<td>Hospital 6</td>
<td>20</td>
<td>0.4</td>
<td>20.4</td>
</tr>
</tbody>
</table>

By adding these HEA bonus points to the total of each hospital’s weighted domain scores, hospitals can be rewarded for delivering excellent care to large proportions of underserved populations. We believe that a scoring adjustment designed to advance health equity through the Hospital VBP Program is consistent with CMS’s goal to advance health equity by providing an incentive for hospitals to care for underserved populations and to provide high quality care to all of the populations they serve.

We invited public comment on this scoring change, which we also proposed to codify in our regulations at 42 CFR 412.160 and 412.165(b).

Comment: Many commenters supported the adoption of a Health Equity Adjustment for the Hospital VBP Program. Many commenters supported the Health Equity Adjustment because they believed that it would promote high quality care for underserved populations and incentivize hospitals to focus on reducing disparities. A commenter believed that it would encourage hospitals to reach additional underserved patients in the healthcare system. Many commenters supported the Health Equity Adjustment because they believed that the scoring would in turn support providers treating greater proportions of patients in underserved communities with higher payments. A
commenter stated that the scoring revision would account for the additional challenges hospitals overcome to achieve high standards for all their patients. Several commenters supported the Health Equity Adjustment because they believed that the revision aligns with goals, initiatives, and programs across CMS, such as the goal to advance health equity and CMS’s Health Equity Strategy and Roadmap. A few commenters stated how the proposal creates similarities in health equity adjustment policies across payment programs of CMS. A few commenters also supported the Health Equity Adjustment because it aligns with the health equity goals of their programs. A few commenters believed that this would allow for hospitals that care for patients from underserved communities with fewer resources to be fairly assessed and not heavily penalized. A few commenters supported the Health Equity Adjustment because it recognizes challenges that patients face and factors beyond a hospital’s control that may impact performance. In addition to the support, a few commenters recommended improvements to the methodology such as considering alternative approaches to identifying hospitals that disproportionately serve marginalized patient populations.

Response: We thank the commenters for their support of our proposal to adopt a Health Equity Adjustment. We agree that this adjustment will promote high quality care for underserved populations, incentivize addressing disparities, and recognize challenges hospitals overcome to achieve high standards for all their patients. We also agree that the adjustment recognizes structural challenges that patients with DES face and hospitals have to overcome to provide excellent care. We will take into consideration for future years the recommendations of assessing alternative approaches to identifying hospitals that disproportionately serve marginalized patient populations.

Comment: Several commenters supported the initial use of DES with a few commenters noting the alignment with the Hospital Readmissions Reduction Program. A few commenters recommended considering alternate indicators and sources of social risk factor data in the future as Medicaid eligibility varies by state.

Response: We thank commenters for their support of the initial use of DES and their recommendations to consider alternate approaches for capturing social risk. We will take this into consideration in future years. We also refer readers to section V.K.6.b.(7) of this final rule where we summarized additional comments we received in response to a request for information on additional indicators besides DES for the health equity adjustment. We remain committed to refining this health equity scoring methodology, as determined appropriate, in the future.

Comment: A few commenters supported the use of the logistic exchange function for calculating the underserved multiplier.

Response: We thank commenters for their support of using the logistic exchange function for calculating the underserved multiplier.

Comment: A few commenters supported structuring the Health Equity Adjustment as a form of bonus points as opposed to an addition to the base TPS because the financial incentive would help offset costs associated with addressing the social needs of underserved patient populations. A few commenters supported that the bonus points from the Health Equity Adjustment would be available to those in the top two thirds of each domain performance rather than only those in the top third. A commenter also supported the threshold methodology of three levels because it is consistent with health equity calculations in other payment programs.

Response: We thank the commenters for their support of the threshold methodology and how the Health Equity Adjustment is available as bonus points to the top two thirds of each domain performance.

Comment: A commenter supported beginning the adjustment in the FY 2026 program year to allow for an evaluation and adjustment period before it impacts hospital payments.

Response: We appreciate the commenter’s support. We note that for the FY 2026 program year, the dual proportion data will be calculated using stays from January 1, 2024, through December 31, 2024. We also refer readers to Table V.K.–04 in section V.K.4.c of this final rule that displays the baseline and performance periods for the FY 2026 program year. We anticipate hospitals will receive their confidential Percentage Payment Summary Reports with their FY 2026 program year results to review by no later than August 1, 2025.

Comment: A commenter did not support the alternate methodology in which hospitals must be in the top third of all performers in the measure domain to receive bonus points because it would create performance cliffs.

Response: We appreciate the commenter’s feedback and agree that awarding measure performance scaler points to the top two thirds of all performers instead of the top third of all performers for each domain would lessen the potential impact of performance cliffs. We are finalizing the proposed methodology as opposed to the alternate methodology.

Comment: Several commenters did not support the use of DES as an indicator for the Health Equity Adjustment. Several commenters expressed concern around the challenges of using DES because dual eligible beneficiary percentages vary across states and that the proportion of patients with DES varies over time within a hospital. A few commenters believed that DES provides an incomplete picture of health equity. A commenter recommended replacing the underserved multiplier with direct billing for case management. A few commenters did not support the use of ADI because they believe it is highly correlated across domains which may lead to the overstating of aspects of social risk, and it is incapable of accurately reflecting neighborhood deprivation in high-cost areas. A commenter also did not support the use of Part D LIS alone because it is not a reasonable proxy for social risk. A commenter also expressed concern over the inconsistent definition of “underserved” across CMS programs. The commenter cited the Medicare Shared Savings Program (MSSP), which uses DES along with ADI and the Part D LIS, and the Center for Medicare & Medicaid Innovation (CMMI) ACO REACH model, which uses DES and ADI.

Response: We appreciate the commentators’ concern regarding the use of DES and agree that by itself DES does not capture all aspects of social risk for health inequities. However, we believe that use of DES data is an important first step to introducing a health equity adjustment in the Hospital VBP Program, as well as being a readily available data source. As ASPE noted in its 2020 report to Congress, DES is a strong indicator of poorer healthcare...
outcomes in Medicare’s VBP programs. Regarding its availability, as mentioned in the FY 2024 IPPS/LTCH PPS proposed rule, we are able to capture the proportion of patients with DES served by a hospital by using patient level data on the proportion of Medicare FFS and Medicare Advantage stays within the defined performance period of two years prior to the program year (88 FR 27043). We will consider alternative approaches in future years and will take the concerns around the ADI into consideration at that time. We appreciate the support for Underserved Communities Through the Federal Government, which provides examples of individuals who belong to underserved communities, such as Black, Latino, and Indigenous and Native American persons, Asian Americans and Pacific Islanders and other persons of color; members of religious minorities; lesbian, gay, bisexual, transgender, and queer (LGBTQ[IA]+) persons; persons with disabilities; persons who live in rural areas; and persons otherwise adversely affected by persistent poverty or inequality (86 FR 7009). We believe that our definition of underserved, as defined by patients with DES for the purposes of this health equity adjustment, is in line with this definition, particularly with regards to persons otherwise adversely affected by persistent poverty or inequality. Additionally, we specified in the FY 2024 IPPS/LTCH PPS proposed rule that the term “underserved” for purposes of discussing the health equity adjustment in the Hospital VBP Program refers to hospital patients with DES who receive inpatient services (88 FR 27040).

Comment: A few commenters recommended focusing exclusively on rewards as opposed to rewards and penalties. A commenter recommended guaranteeing that non-participation or poor performance does not result in negative repercussions.

Response: We wish to clarify that the program is statutorily structured to withhold 2% from all hospitals and then distribute value-based incentive payments based on performance. However, all hospitals are still eligible to earn HEA bonus points. As noted in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27045 through 27046), under the health equity adjustment, even if a hospital receives a penalty, that hospital can still gain from the health equity adjustment, if the penalty is smaller after the health equity adjustment. The health equity adjustment thus offers every hospital an opportunity to earn HEA bonus points regardless of whether they receive a bonus or penalty under the Hospital VBP Program. In addition, we reiterate the budget neutral structure of the Hospital Value-Based Purchasing (HVBP) Program, as the HEA bonus points are added before the TPS is calculated. This would only result in changes to the hospital’s relative position to other hospitals as opposed to the distribution of bonuses and penalties. With regard to the concern of non-participation, we note that subsection (d) hospitals cannot opt-out of this proposal.

Comment: Several commenters recommended working with the hospital community to fine-tune the methodology for identifying underserved populations and to determine how they may impact hospitals across a diverse set of marginalized communities. A few commenters recommended working with relevant interested parties to create a standard framework and to implement consistent methodologies and risk factors for health equity adjustments across programs. A few commenters recommended that the HEA be utilized as a pilot before full implementation as it would allow for understanding potential impacts and identifying potential issues or challenges before going into full effect. A commenter recommended continuing to work to further optimize the use of reporting requirements and incentives to promote health equity.

Response: We thank commenters for their feedback. We note that the Hospital VBP Program’s proposed methodology is similar to the Shared Savings Program’s health equity adjustment and to the SNF VBP Program’s health equity adjustment proposal. While some differences exist between these programs’ methodologies due to the data available to each program and the structure of each program as dictated by their respective statutes, across all of these programs we have aimed to apply the same conceptual framework of rewarding excellent care in underserved populations, with an upside-only incentive approach to the greatest extent feasible for the applicable program, be it in terms of bonus points like the Hospital VBP Program or both bonus points and additional payments like the Shared Savings Program and proposal for the SNF VBP Program.

In regards to comments suggesting the health equity adjustment be implemented as a pilot, we refer readers to the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27045 through 27046) and section V.K.6.b.(5) of this final rule, where we presented the results of an impact analysis that simulated the proposed scoring methodology and provided an understanding of how hospitals will be impacted by the scoring change, as well as to show that the scoring change is feasible to implement across all hospitals participating in the Hospital VBP Program. Additionally, as noted in the proposed rule, this is a first step, and we expect the early years of this policy to effectively serve the purpose of piloting future health equity efforts in the program. We also note that we will monitor the impact of the adjustment and may, as necessary, consider modifications to the design of the adjustment through future notice and comment rulemaking. We agree with the commenter who recommended continuing to leverage reporting requirements and incentives to promote health equity. For example, in the FY 2023 IPPS/LTCH PPS final rule, we adopted the Screening for Social Drivers of Health measure in the Hospital IQR Program (87 FR 49202 through 49215). We welcome continued engagement with all interested parties on these efforts.

Comment: A commenter recommended focusing on a specific population for the performance evaluation in the future because evaluating performance only across dual eligible beneficiaries ensures that improvement efforts are focused on the population with the greatest risk factors.

Response: We thank the commenter for the feedback and will consider additional indicators for the underserved population in the future.
We believe that as a first step to incorporating a health equity adjustment in the Hospital VBP Program, the underserved multiplier adequately accounts for the patients with DES while the measure performance scaler accounts for overall quality such that if a large proportion of a hospital’s patients with DES population is receiving low quality of care, then the health equity adjustment bonus points will appropriately decrease. The health equity adjustment was purposefully designed to not reward poor quality. Likewise, if the quality of care received by a hospital’s underserved population is high, but the patients with DES represent only a small proportion of a hospital’s total population, then the health equity adjustment will be lower.

Comment: A commenter recommended incentivizing primary care or ambulatory services as an equity lever as they believed that those settings would be better for prevention and management of chronic conditions.

Response: We agree on the importance of incentivizing health equity in not only the acute care setting, but also primary care and other ambulatory care settings. For example, the Shared Savings Program’s Accountable Care Organizations are groups of doctors, hospitals, and other health care providers who collaborate to give coordinated high-quality care to people with Medicare. The Shared Savings Program recently adopted a health equity adjustment for Accountable Care Organizations that report all-payer electronic clinical quality measures (eCQMs)/Merit-based Incentive Payment System eCQMs, are high-performing on quality, and serve a large proportion of underserved beneficiaries, as defined by dual-eligibility, enrollment in the Medicare Part D low income subsidy (LIS) (meaning the individual is enrolled in a Part D plan and receives LIS) and an ADI score of 85 or above, as detailed in the CY 2023 Physician Fee Schedule final rule (87 FR 69838 through 69857).

In addition, in the CY 2023 Physician Fee Schedule final rule, the Merit-Based Incentive Payment System (MIPS) included four new health equity-related improvement activities (87 FR 70059 through 70060), expanded the definition of “high priority measure” in the Quality category to include health equity measures (87 FR 70047 through 70048), and added a new Quality measure called Screening for Social Drivers of Health (87 FR 70054 through 70055). We note that as outlined in section 1886(o)(1)(C)(i) of the Act, the Hospital VBP Program only applies to acute care hospitals that are paid under the IPPS.

Comment: A few commenters expressed concern around potential negative impacts including that a commenter believed that the proposed logistic multiplier will inadvertently negatively affect safety net and rural hospitals while inadvertently rewarding urban and non-safety net hospitals that were not receiving an incentive prior to the adjustment. A commenter expressed concern that the HEA may result in harm through reduced incentive payments to high-performing hospitals that do not serve high proportions of underserved patient populations.

Response: We do not believe that the logistic multiplier will negatively affect safety-net and rural hospitals given the results of the simulated impact analyses in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27045 through 27046) and in this final rule, which demonstrates that the increase in the number of hospitals receiving a bonus occurs primarily in safety net hospitals compared to non-safety net and resulted in the greatest gains among safety net hospitals and rural hospitals. Lastly, we do not believe that the scoring adjustment will result in harm to high-performing hospitals. The intent of the HEA is to incentivize high quality care among all patients in the hospital and to recognize the additional resources required to care for patients with DES.

Comment: A commenter expressed concern with utilizing overly complex scoring methods because they have been a challenge in getting hospitals to embrace data quality measurements in the past.

Response: We recognize that there is some inherent complexity in developing a new health equity scoring adjustment, however, we believe that hospitals will have time to adapt to the methodology given that the scoring change will not go into effect until the FY 2026 program year. As stated in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27042 through 27045) and this final rule, if a hospital, relative to other hospitals, is in the top or middle third of performance for any domain, they are eligible for measure performance scalar points. Additionally, if a hospital serves any proportion of patients with DES, they are eligible for the underserved multiplier. The HEA bonus points are then the product of the measure performance scalar and the underserved multiplier. The HEA bonus points are added to the total of hospital’s four weighted domain scores before the TPS is calculated. A hospital that knows that they provide care for high proportions of patients with DES and performs well on any domains may anticipate a higher adjustment due to this addition to the program. We also reiterate that the HEA is intended to reward high quality performance and not solely adjust for a greater underserved patient population, which may leave lower performing hospitals with high proportions of patients with DES without any HEA bonus points. We do not intend to reward lower quality performance, and we believe that the current HEA incentivizes lower performing facilities to improve their quality scores. We will continue to provide regular outreach and education on the QualityNet website about this scoring methodology.

Comment: A commenter expressed concern that the Health Equity Adjustment points will not be true bonus points as they will be added to the existing points and contribute to how the pool is distributed.

Response: We disagree that the HEA points are not a true bonus because, as noted in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27045) and this final rule, we proposed to add the HEA bonus points before the TPS is calculated. Therefore, the bonus points can change the relative position of the hospital compared to other hospitals.

Comment: A commenter did not support the proposed HEA as they believed that it may result in having to calculate a new linear exchange function to determine the minimum TPS at which a hospital begins to earn a bonus. A few commenters requested clarification around the linear exchange function slope and whether it would be adjusted by the HEA bonus points.

Response: As noted in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27045) and this final rule, we proposed to add the HEA bonus points before the TPS is calculated. Therefore, the linear exchange function slope remains unchanged and the Hospital VBP Program remains budget neutral because the bonus points are added to the total of the four weighted domain scores that we then sum to calculate the hospital’s TPS.

Comment: Many commenters provided recommendations around the scoring methodology. Many commenters recommended sharing information on potential new indicators, such as geographic or socioeconomic indicators, and moving away from DES. A few commenters recommended exploring the interaction between DES, ADI, and LIS variables as CMS continues to refine the HEA. Several commenters...
recommended that CMS provide the logistic exchange function for the underserved multiplier. Several commenters recommended that CMS convene a technical expert panel from the hospital community to fine-tune the health equity adjustment methodology.

Response: We thank commenters for their recommendation. At this time, we believe that using DES data is an important first step for the health equity adjustment in the Hospital VBP Program, but we will consider these alternative indicators in future years. We have added the logistic exchange function used for calculating the underserved multiplier to this final rule in section V.K.6.b.(4). We appreciate this feedback from commenters, and we will explore convening a technical expert panel in future years.

Comment: Several commenters recommended that CMS provide additional information such as detailed specifications for proposed HEA bonus points, how payments will be redistributlized once the HEA is accounted for, and how hospitals would perform on the HEA through confidential reports.

Response: We thank the commenters for their recommendations. We wish to clarify that the methodology for distributing payments will remain the same. As noted in the FY 2024 IPPS/LTC PPS proposed rule (88 FR 27045) and in this final rule, the HEA bonus points will be added before the TPS is calculated, and the linear exchange function slope remains unchanged.

Comment: A commenter recommended that the HEA be applied across the care delivery spectrum to ensure continuity of high-quality care. A commenter also recommended being consistent in the application of the HEA term and methodology, particularly for the use of indicators for underserved.

Response: We thank the commenters for their feedback, and we will explore avenues to increase consistency across programs in future years. We also wish to note that the Hospital VBP Program’s proposed methodology is similar to the Shared Savings Program’s health equity adjustment and to the SNF VBP Program’s health equity adjustment proposal. The differences that exist between these programs’ methodologies are due to the data available to each program and the structure of each program, which prevents further consistency across programs at this time.

Comment: A few commenters recommended accounting for different hospitals’ experience such as in budget and location, considering the realities that smaller health systems in rural areas face. A commenter expressed concern that the HEA may result in harm to high performing hospitals that do not serve a high proportion of the underserved patient population.

Response: We thank commenters for their recommendations. We reiterate that, on average, the HEA would not negatively impact safety net and rural hospitals. As discussed in the FY 2024 IPPS/LTC PPS proposed rule (88 FR 27045 through 27046b) and in this final rule, the impact analysis demonstrates that the increase in the number of hospitals receiving a bonus occurs primarily among safety net hospitals compared to non-safety net and that the greatest gains resulted among safety net hospitals and rural hospitals. We will consider additional ways to support smaller hospitals in rural areas, but we believe that this policy is a crucial first step in providing more opportunities to smaller and rural hospitals. With regard to high performance, on average, the HEA would similarly not negatively impact high-performing hospitals. The intent of the HEA is to incentivize high quality care among all patients in the hospital and to recognize the additional resources required to care for patients with DES. Additionally, hospitals that are high performing have other opportunities to be rewarded for their quality care under the Hospital VBP Program’s existing scoring methodology.

Comment: A commenter also recommended that CMS consider a peer grouping approach with regards to impacts on payments for providers with different shares of DES patients.

Response: We will take a peer grouping approach into consideration in future program years.

Comment: A commenter recommended that the measure performance scaler points to the hospitals in the top third of performance for each domain, while hospitals in the middle and bottom third of performance received 0 measure performance scaler points. We modeled this alternative methodology to contextualize the request for additional information in section V.K.6.b.(7) of this final rule. The proposal and alternative method both included HEA bonus points comprised of the measure performance scaler and the underserved multiplier based on the hospital’s proportion of patients who are dually eligible and their performance on existing Hospital VBP Program measures. For purposes of this simulation, we used the dual proportion data that were calculated using Medicare inpatient stays for the Hospital Readmissions Reduction Program FY 2023 performance period which included stays between June 1, 2018, to December 1, 2019, and July 1, 2020, to June 30, 2021.259 A logistic

---

259 We note that this calculation excludes Q1 and Q2 2020 data based on the ECE granted in response to the COVID–19 PHE and the policies finalized in the September 2, 2020 interim final rule with comment titled “Medicare and Medicaid Programs, Clinical Laboratory Improvement Amendments (CLIA), and Patient Protection and Affordable Care Act; Additional Policy and Regulatory Revisions in Response to the COVID–19 Public Health Emergency” (85 FR 54820). We will exclude qualifying claims data from measure calculations for the following quarters: January 1, 2020, through March 31, 2020 (Q1 2020), and April 1, 2020, through June 30, 2020 (Q2 2020), that was
The exchange function was then applied to the dual proportion. This analysis also used one-year base operating DRG payments for FY 2021 from October 1, 2020, to September 30, 2021, to calculate the bonus payments and penalties. Additionally, the TPS and quality domain scores data used in this analysis were calculated for the FY 2023 Hospital VBP Program. The proposal and alternative method both include a cap of 10 possible HEA bonus points.

We note that while this simulation uses multi-year Hospital Readmissions Reduction Program data for the calculation of the dual proportion, we proposed to use dual proportion data from the calendar year two years ahead of the program year, as discussed in section V.K.6.b(2) of this final rule. The results of these analyses are outlined in this section and described further in Tables V.K.–16 and V.K.–17. Based on this initial modeling, the average TPS will increase with the addition of the HEA bonus points.

Our analysis finds that both the proposed and alternative HEA scoring options increase the number of hospitals getting a bonus compared to the existing scoring methodology. We note that these analyses show the percentage of hospitals gaining from the proposed health equity scoring change. Through these analyses, we found that the hospital-weighted average payment adjustment is positive even though the Hospital VBP Program remains budget neutral. The increase in the number of hospitals receiving a bonus occurs primarily among safety net hospitals compared to non-safety net. A hospital was considered a safety net hospital if it was in the top Disproportionate Share Hospital (DSH) quintile.

Table V.K.–16 provides the number of hospitals that received a bonus or penalty, respectively, along with the size of these bonuses and penalties. The third column in Table V.K.–16 shows the estimated impact of our proposed scoring methodology changes. Based on the analyses, the proposed methodology resulted in the greatest gains among safety net hospitals and rural hospitals, on average. The proposed methodology resulted in the largest percent of hospitals gaining from the HEA bonus overall, where gains are indicated by both greater bonus payments and smaller penalty payments, compared to the existing methodology. The mean payment adjustment was 0.20 percent compared to 0.18 percent.

The fourth column in Table V.K.–16 shows the estimated impact of an alternative method in which we only award 4 measure performance scaler points to the hospitals in the top third of performance for each domain, while hospitals in the middle and bottom third of performance received 0 measure performance scaler points. This produced the smallest number of hospitals gaining from the alternative health equity scoring adjustment among rural hospitals and among safety net hospitals. This produced a smaller number of hospitals gaining from the alternative health equity scoring adjustment among rural hospitals, among large hospitals, and among safety net hospitals relative to the proposed approach. This alternative method resulted in a similar mean payment adjustment of 0.20 percent as the proposed approach, while the program remains revenue neutral. For both the proposed and alternative approaches, the mean payment adjustment, as shown in Table V.K.–16, is larger than the mean payment adjustment for the existing scoring methodology.

Table V.K.–17 shows the percentage of hospitals who gained under the proposed and alternative methodologies. For purposes of discussion in this final rule and Table V.K.–17, “Gaining” is defined as receiving a larger bonus or smaller penalty under the proposed health equity adjustment compared to their bonus or penalty under the original methodology. In Table V.K.–17, we note that the percentage of hospitals that gain may be different than the percentage of hospitals that receive a bonus. This is because hospitals, even if they receive a penalty, can still gain from the health equity adjustment, if the penalty is smaller after the health equity adjustment.

We sought feedback on the alternative scoring method in section V.K.6.b.(7) of this final rule for future consideration.
Based on the results of these analyses, we proposed to change the scoring methodology to award HEA bonus points (with a measure performance scaler of 0, 2, and 4 points) because this option allows more hospitals treating a large share of patients with DES to gain from the HEA bonus, particularly safety net hospitals. We believe that these bonuses offer an important first step in addressing the health equity within the Hospital VBP Program. Safety net hospitals serve large proportions of patients with DES, and patients living in rural areas tend to experience worse health outcomes. Therefore, we believe that our proposal ensures that we are addressing performance gaps and incentivizing high-quality care in underserved populations compared to the existing scoring methodology.

In developing this scoring methodology change, we also explored alternative indicators for the underserved variable, such as an Area Deprivation Index (ADI) of 85 or greater, and enrollment in LIS. Identifying and prioritizing social risk or demographic variables to consider for measuring equity can be challenging. This is due to the high number of variables that have been identified in the literature as risk factors for poorer health outcomes and the limited availability of much of

---


---

### TABLE V.K.-16 ESTIMATED BONUSES AND PENALTIES PER YEAR RESULTING FROM SCORING OPTIONS

<table>
<thead>
<tr>
<th>Performance scoring methodology features</th>
<th>Existing scoring methodology</th>
<th>Proposal: HEA bonus points with performance scaler (0,2,4) and underserved multiplier</th>
<th>Alternative: HEA bonus points with performance scaler (0,0,4) and underserved multiplier*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Underserved multiplier</td>
<td>N/A</td>
<td>Logistic</td>
<td>Logistic</td>
</tr>
<tr>
<td>Capped</td>
<td>NA</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Average Bonus</td>
<td>$3,738</td>
<td>$3,724</td>
<td>$3,886</td>
</tr>
<tr>
<td>Average Penalty</td>
<td>($3,980)</td>
<td>($4,246)</td>
<td>($4,424)</td>
</tr>
<tr>
<td>Bonus Hospitals (Count)</td>
<td>1,299</td>
<td>1,342</td>
<td>1,341</td>
</tr>
<tr>
<td>Safety net hospitals</td>
<td>195</td>
<td>241</td>
<td>232</td>
</tr>
<tr>
<td>Non-safety net</td>
<td>1,104</td>
<td>1,101</td>
<td>1,109</td>
</tr>
<tr>
<td>Urban</td>
<td>956</td>
<td>977</td>
<td>985</td>
</tr>
<tr>
<td>Rural</td>
<td>343</td>
<td>365</td>
<td>356</td>
</tr>
<tr>
<td>Penalty Hospitals (Count)</td>
<td>1,220</td>
<td>1,177</td>
<td>1,178</td>
</tr>
<tr>
<td>Safety net hospitals</td>
<td>285</td>
<td>239</td>
<td>248</td>
</tr>
<tr>
<td>Non-safety net</td>
<td>935</td>
<td>938</td>
<td>930</td>
</tr>
<tr>
<td>Urban</td>
<td>1,016</td>
<td>995</td>
<td>987</td>
</tr>
<tr>
<td>Rural</td>
<td>204</td>
<td>182</td>
<td>191</td>
</tr>
<tr>
<td>Average Payment Adjustment %</td>
<td>0.18%</td>
<td>0.20%</td>
<td>0.20%</td>
</tr>
</tbody>
</table>

* We are requesting feedback on the alternative scoring method in section V.K.6.b.(7) of this final rule.

### TABLE V.K.-17 ESTIMATED HOSPITALS GAINING FROM THE HEA BONUS POINTS

<table>
<thead>
<tr>
<th>Performance scoring features</th>
<th>Proposal: HEA bonus points with performance scaler (0,2,4) and underserved multiplier</th>
<th>Alternative: HEA bonus points with performance scaler (0,0,4) and underserved multiplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Underserved multiplier</td>
<td>Logistic</td>
<td>Logistic</td>
</tr>
<tr>
<td>Capped</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>All hospitals</td>
<td>50.18%</td>
<td>41.37%</td>
</tr>
<tr>
<td>Location</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban</td>
<td>45.59%</td>
<td>36.00%</td>
</tr>
<tr>
<td>Rural</td>
<td>66.73%</td>
<td>60.69%</td>
</tr>
<tr>
<td>Bed size</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bed size&lt; 100</td>
<td>47.71%</td>
<td>49.36%</td>
</tr>
<tr>
<td>Bed size 100 – 499</td>
<td>51.72%</td>
<td>40.75%</td>
</tr>
<tr>
<td>Bed size 500+</td>
<td>46.76%</td>
<td>31.47%</td>
</tr>
<tr>
<td>Safety net status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety net hospitals</td>
<td>86.88%</td>
<td>64.58%</td>
</tr>
<tr>
<td>Non-safety net</td>
<td>41.54%</td>
<td>35.90%</td>
</tr>
</tbody>
</table>


this data. Each source of data has advantages and disadvantages for identifying the most vulnerable populations to assess disparities. Income-based indicators are the most frequently used measures of vulnerability, but other indicators such as neighborhood-level indicators can also provide important insights and are becoming more common in quality programs. There is research to support that geographic, neighborhood-level factors are associated with worse health outcomes for affected residents. The ADI is a demonstrated tool for assessing socioeconomic conditions based on geographic, neighborhood-level disadvantage. Specifically, living in an area with an ADI score of 85 or above is shown to be a predictor of 30-day rehospitalization rates, lower rates of cancer survival, poor end-of-life care for patients with heart failure, and longer lengths of stay and fewer home discharges post-knee surgery even after accounting for individual social and economic risk factors.

Many rural areas also have relatively high levels of neighborhood disadvantage and high ADI levels. We believe that dual Medicare and Medicaid eligibility and ADI scores are both good indicators of patients with high needs. Dual eligibility, an indicator at the beneficiary level, is intended to capture socioeconomic challenges that could affect a patient’s ability to access care, while ADI, a neighborhood-level indicator, is intended to capture local socioeconomic factors correlated with medical disparities and underservice. However, the ADI data are updated infrequently. Additionally, to date, the ADI has not been extensively studied or widely used in value-based purchasing programs, and we do not collect patient level demographic level data for all measures that would allow us to use a neighborhood-level factors such as ADI in the Hospital VBP Program. However, we are considering using the ADI in the Hospital VBP Program in future years as data becomes more readily available through new measures in the Program to better align with other CMS programs such as the Shared Savings Program. ASPE recently conducted an environmental scan and concluded that while area-level indices can be beneficial, none of the existing area-level indices are ideal and should only be implemented in very specific circumstances. Finally, as compared to DES, use of the proportion of patients that receive LIS under the Medicare Part D prescription drug program may capture a more consistent group of low-income patients as the eligibility criteria for LIS do not vary by state. However, we note that Part D LIS has certain limitations as well. For example, individuals with DES or who receive Supplemental Security Income (SSI) automatically receive the LIS designation in CMS data systems. LIS designation means that the individual is enrolled in a Medicare Part D plan and receives the low-income subsidy. Individuals without DES or SSI status, but whose income is lower than 150 percent of the Federal poverty level and whose resources are limited, can qualify for LIS, but not D-SNAP. Additionally, LIS is not available in the U.S. territories. Most Medicare beneficiaries with the LIS designation are those who automatically receive this designation, rather than those who applied for the benefit and were approved. Nonetheless, despite this limitation, we agree that the use of the LIS designation, in addition to DES, is preferable to using DES alone, as doing so reduces variability across States. However, LIS is not available in the U.S. territories. Ultimately, we believe that using DES data is an important first step to introducing health equity adjustment bonus points in the Hospital VBP Program and will consider other indicators for the underscored multiplier in the future.

Comment: A commenter expressed concern that the impact analysis does not make a compelling case to indicate that the alternative methodology would be superior to what is proposed and recommended finalizing a methodology that is not overly complex and allows hospitals to have every opportunity to receive the maximum number of points.

Response: We thank the commenter for the feedback. We will not be finalizing the alternative methodology, and we believe that the proposed methodology that we are finalizing allows every hospital an opportunity to receive HEA bonus points. We recognize a level complexity with the methodology being adopted in this final rule and we will address this with education and outreach.

Comment: A commenter recommended that the average bonus under the proposed methodology should be higher than the stated amount because it is lower than the average under the existing methodology.

Response: We appreciate the commenter’s concern. As noted in the FY 2024 IPPS/LTC PPS proposed rule (88 FR 27045 through 27048), the proposed methodology that we are finalizing resulted in the largest percent of hospitals gaining from the HEA bonus overall, where gains are indicated by both greater bonus payments and smaller penalty payments, compared to the existing methodology. We wish to clarify that although the percent of hospitals gaining is higher under the proposed methodology, the average bonus under the proposed methodology is lower than the average under the existing methodology because the hospitals that are not benefitting from the bonus are larger and are fewer in number, and thus have a greater impact on the average payments. The change in average bonuses and penalties is based on the changes in how many hospitals receive a bonus or penalty, the size of the bonus or penalty, and the size of the hospital. The impact analysis showed that the proposed methodology spreads...
the bonuses among more hospitals, with the largest hospitals having the lowest proportion of gaining compared to medium- and smaller-sized hospitals. The result is thus a lower average bonus under the proposed methodology despite that the percent of hospitals gaining is higher.

(6) Modification of the Total Performance Score (TPS) Maximum

The Hospital Inpatient VBP Program final rule finalized a methodology for assessing the total performance of each hospital based on its performance under the Hospital VBP Program with respect to a fiscal year (76 FR 26493 through 26494). Additionally, section 1886(o)(5)(A) of the Act provides the Secretary with the discretion to adopt a performance scoring methodology. Currently, the TPS is defined in our regulations as a numeric score ranging from 0 to 100. In the FY 2024 IPPS/LTCH PPS proposed rule, we proposed to modify the Total Performance Score (TPS) maximum to be 110, resulting in numeric score range of 0 to 110, beginning with the FY 2026 program year (FR 88 27049). A TPS maximum of 110 will allow for hospitals that have achieved top performance across all four domains to still be eligible to earn HEA bonus points. For example, if a hospital obtains a summed total of 100 weighted domain score points, that hospital could still receive up to 10 HEA bonus points, resulting in a maximum TPS of 110. We believe that modifying the TPS range will afford even top-performing hospitals the opportunity to receive up to an additional 10 HEA bonus points.

We also proposed to codify at 42 CFR 412.160, 412.162(b)(3), and 412.165(b)(6) of our regulations the new TPS numeric score range of 0 to 110. We believe that this policy will make it easier for interested parties to find these updated policies.

We invited public comment on this proposal.

Comment: Several commenters expressed their support for the proposal to modify the TPS numeric score range to be 0 to 110 because it allows for high performing hospitals to be eligible to earn HEA bonus points.

Response: We thank the commenters for their support and agree that the modification of the TPS range will allow high performing hospitals to be eligible to earn the HEA bonus points.

After consideration of the public comments we received, we are finalizing our policy as proposed with minor technical modifications at 42 CFR 412.160, 412.162(b)(3), and 412.165(b)(6).

(7) Request for Information on Potential Additional Changes to the Hospital VBP Program That Would Address Health Equity

As noted in the CMS National Quality Strategy, we are committed to addressing the disparities that underlie our health system, both within and across settings, to ensure equitable access and care for all.\textsuperscript{307} We believe that the proposed scoring methodology embodies this commitment, but recognize it is only a first step.

Therefore, we welcomed public comment on the following:

- Should we consider using any of the previously detailed variables, ADI of greater than or equal to 85 and Medicare Part D LIS, in combination with or instead of DES? For example, should we use the higher of a few selected factors based on a hospital’s inpatient population in a given program year, including: (1) the proportion of the hospital’s patient population residing in a census block group with an ADI national percentile rank of at least 85 (or another threshold); (2) the proportion of the hospital’s patients that are dually eligible for Medicare and Medicaid; or (3) the proportion of the hospital’s patients receiving LIS? Should we consider patients with partial-dual eligibility in addition to full-dual eligibility? Are there additional variables we should consider using to identify populations that have been disadvantaged, marginalized, and/or underserved by the healthcare system?
- Should we consider other thresholds for scoring, such as using a quintile-based scoring approach whereby hospitals are awarded measure performance scaler points based on 5 levels of performance rather than 3? This would include awarding 0, 1, 2, 3, and 4, measure performance scaler points across the 5 levels from bottom to top performance, respectively, to allow for more nuance in the distribution of performance across each of the current four domains.
- In the future, we are considering further refining this scoring methodology change to only look at a hospital’s quality performance on patients in the focus population (for example, patients with DES). We believe that this future potential refinement would more specifically address disparities in performance, and in turn, close equity gaps which would ultimately result in greater overall improvement for the entire hospital patient population. At this time, we collect patient-level data on the claims measures in the clinical domain and the MSPB measure, but not on all other measures in the Hospital VBP Program. Because we do not collect patient level demographic level data for all measures, it is difficult to use neighborhood-level indicators, such as the ADI, the measure level at this time. Therefore, we are instead proposing to use performance on existing measures for all eligible patients and thus welcome stakeholder feedback on for the Hospital VBP Program to assess patient-level data in the future.
- Should we use a linear scoring function or actual scoring for calculating the underserved multiplier instead of the proposed logistic exchange function as depicted in Figure V.K.–01 instead?
- Are there other approaches that the Hospital VBP Program could propose to adopt to effectively address healthcare disparities and advance health equity, such as the alternative methodology simulated in the analysis displayed in Tables V.K.–16 and V.K.–17? For example, should we only award measure performance scaler points to the top third of performance whereby a hospital in the middle and bottom thirds of performance would receive 0 performance scaler points, as simulated in the analysis? Alternatively, should we only provide measure performance scaler points to the Clinical, Safety, and Patient and Community Engagement Domains, excluding the Cost and Effectiveness Domain from performance scaler points?

We received many comments on this request for information, which are summarized in this section of this document:

Comment: Many commenters provided feedback on alternative underserved multiplier variables. Several commenters recommended incorporating the ADI or LIS alongside the proposed use of patients with DES because there are multiple ways to recognize the structural challenges that patients and hospitals face and a combination of these will be the most sensitive to capturing at-risk beneficiaries. A commenter noted that the concerns of administrative complexity relating to using more than one variable are outweighed by the potential to draw on multiple sources of information. Another commenter also recommended incorporating partial-dual eligible patients. Another commenter recommended that CMS continue to consider variables that are not double counted and redundancies within social risk indices as the ADI are
accounted for. A commenter recommended considering the impact of states’ decisions for Medicaid expansion versus non-expansion because states without expansion will have higher rates of uninsured individuals, anticipated delays in access to care, and higher healthcare costs over time.

A few commenters expressed concerns around the underserved multiplier alternatives including concerns that ignoring race or ethnicity underestimates adverse local factors and that only focusing on DES is problematic because of the differential expansion of Medicaid. A few commenters expressed concern around the ADI including that it is unclear how CMS would ensure a patient residence on file is accurate if incorporating the ADI into the calculation and that the ADI is heavily weighted towards income and home values with little contribution from other variables which masks inequities and underestimates vulnerabilities of neighborhoods. A commenter expressed concern that CMS is not considering other potential indices that would be better indicators of social needs.

Several commenters recommended underserved multiplier variables beyond ADI, DES, and LIS, including such alternatives as, a socioeconomic index, a formal designation for essential hospitals that could be applied to the HEA adjustment to more accurately identify hospitals serving marginalized populations, a stratification by patients’ HRSN, an index using regression that is tuned for predictive strength, the social screening measure results from IQR, and a more tailored individual level health related social needs predictor that assesses the availability of ICD–10 Z-codes and may document individual social need factors. A commenter recommended that any social risk indices be weighted appropriately given that social risk has varying degrees of association with adverse events, and a commenter recommended aligning SDOH data items across care settings when future health equity quality measures are developed.

A few commenters also provided feedback on alternative thresholds for scoring including a few commenters recommending using quartiles or quintiles for performance scaler points to allow for greater diversity in the bonus points awarded to facilities. A commenter recommended considering whether institutions make improvement relative to where they started rather than where they are, that is, they are in by giving greater weight for improvement starting from a lower quintile than a similar improvement starting from a higher quintile.

Many commenters offered recommendations for alternative scoring methodologies. A commenter recommended excluding the Cost and Effectiveness Domain from the measure performance scaler because the data is not actionable. A few commenters made recommended stratification including stratifying results and prioritizing disparities in treatment rendered and stratifying results in a way that reflects both “within-provider” and “across-provider” assessments of the level of disparities in clinical processes and outcomes. Several commenters made additional recommendations including measuring performance of different measures within a domain as separate scores rather than a composite score for the domain, incorporating measure performance scaler points that incentivize hospitals to initiate service connections when a patient screens positive for HRSN, assigning greater weight to a local socioeconomic index and amount of uninsured care, capturing indicators among beneficiaries for which there are currently limited person-level data available, and considering the portion of behavioral health patients suffering from behavioral health issues represent some of the most vulnerable beneficiaries.

Several commenters made recommendations around improving data collection including creating a robust data collection system that identifies the social risk factors faced by patient populations, collecting demographic data, investing in strategies to improve more robust self-reporting of race and ethnicity data at point of service, working with the Office of the National Coordinator for Health Information Technology (ONC) to establish data exchange policies and infrastructure that allows access to electronic health record (EHR) data because private sector EHRs are successfully collecting demographic data with high volume and high levels of accuracy, and leveraging race and ethnicity data collected by NHIS, MEPS, and the 2020 Census to address gaps in the current data pool.

Several commenters made other recommendations including adopting health equity standards that could be used across medicine, aligning with the Hospital IQR Program’s health equity measure, working with hospital stakeholders to better understand how hospitals are identifying health inequities in their communities to better inform agency’s approach, prioritizing existing quality measures with identified disparity in treatment or outcomes, providing more staff education to increase awareness and understanding of social risk factors including better documentation of Z-codes, and continuously evaluating and adapting to reduce disparities and improve health equity. Several commenters recommended other considerations such as exploring if social risk factors should be added to the measures used in HVBP, including public reporting of stratified measure alongside overall measures in a meaningful and transparent way, considering hospital characteristics for equity in hospital scoring, considering various dimensions that influence inequities, and exploring new incentives to encourage providers to work with non-traditional healthcare workers to help address SDOH.

A few commenters made recommendations around the clarity of the scoring calculations, recommending transparent and interpretable definitions and algorithms with an opportunity for patients and communities to understand how it is impacting their care.

Response: We appreciate the comments and suggestions we have received. While we will not be responding to specific comments submitted in response to this request for information, we believe that this input is valuable in our efforts to continue to promote health equity in the Hospital VBP Program. We may consider these suggestions in future rulemaking.

c. Domain Weighting for Hospitals That Receive a Score on All Domains

In the FY 2018 IPPS/LTCH PPS final rule (82 FR 38265 through 38266), we finalized our proposal to retain the equal weight of 25 percent for each of the four domains in the Hospital VBP Program for the FY 2020 program year and subsequent years for hospitals that receive a score in all domains.

In the FY 2024 IPPS/LTCH PPS proposed rule, we did not propose any changes to these domain weights (88 FR 27050).

d. Domain Weighting for Hospitals Receiving Scores on Fewer Than Four Domains

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50084 through 50085), we adopted a policy that hospitals must receive domain scores on at least three of four quality domains to receive a TPS, for the FY 2017 program year and subsequent years. Hospitals with sufficient data on only two domains will have their TPSs proportionately
In the FY 2024 IPPS/LTCP PPS proposed rule, we did not propose any changes to these domain weights (88 FR 27050).

e. Minimum Numbers of Measures for Hospital VBP Program Domains

We refer readers to the FY 2018 IPPS/LTCPPS final rule (82 FR 38266) for our previously finalized requirements for the minimum numbers of measures for hospitals to receive domain scores.

In the FY 2024 IPPS/LTCP PPS proposed rule, we did not propose any changes to these policies (88 FR 27050).

f. Minimum Numbers of Cases for Hospital VBP Program Measures

1. Background

Section 1886(o)(1)(C)(ii)(IV) of the Act requires the Secretary to exclude for the fiscal year hospitals that do not report a minimum number (as determined by the Secretary) of cases for the measures that apply to the hospital for the performance period for the fiscal year. For additional discussion of the previously finalized minimum numbers of cases for measures under the Hospital VBP Program, we refer readers to the Hospital Inpatient VBP Program final rule (76 FR 26527 through 26531); the CY 2012 OPPS/ASC final rule (76 FR 74532 through 74534); the FY 2013 IPPS/LTCP PPS final rule (77 FR 53608 through 53610); the FY 2015 IPPS/LTCP PPS final rule (79 FR 50085 through 50086); the FY 2016 IPPS/LTCP PPS final rule (80 FR 49570); and the FY 2018 IPPS/LTCP PPS final rule (82 FR 38266 through 38267).

(2) Summary of Previously Adopted and Newly Established Minimum Numbers of Cases

The previously adopted minimum numbers of cases for the Hospital VBP Program measures are set forth in Table V.K–18. Table V.K–18 also sets forth the proposed minimum number of cases for the proposed Severe Sepsis and Septic Shock: Management Bundle measure beginning with the FY 2026 program year. For the proposed updates to MSPB Hospital measure and the proposed THA/TKA Complications measure, we proposed to maintain the same minimum number of cases as the current measures.

We invited comment on these proposals.

We received no comments on this proposal and are finalizing this provision without modification.

7. Extraordinary Circumstance Exception (ECE) Policy for the Hospital VBP Program

We refer readers to the FY 2022 IPPS/LTCP PPS final rule (86 FR 45298 through 45299) and 42 CFR 412.165(c) for additional details related to the Hospital VBP Program ECE policy.

We refer readers to the FY 2022 IPPS/LTCP PPS proposed rule, we did not propose any changes to the Hospital VBP Program ECE policy (88 FR 27051).

L. Hospital-Acquired Condition (HAC) Reduction Program

1. Regulatory Background

We refer readers to the FY 2014 IPPS/LTCP PPS final rule (78 FR 50707 through 50708) for a general overview of the HAC Reduction Program and to the same final rule (78 FR 50708 through 50709) for a detailed discussion of the statutory basis for the Program. For additional descriptions of our previously finalized policies for the HAC Reduction Program, we also refer readers to the following final rules:

- The FY 2014 IPPS/LTCP PPS final rule (78 FR 50707 through 50729).
- The FY 2015 IPPS/LTCP PPS final rule (79 FR 50087 through 50104).
- The FY 2016 IPPS/LTCP PPS final rule (80 FR 49570 through 49581).
- The FY 2017 IPPS/LTCP PPS final rule (81 FR 57011 through 57026).
- The FY 2018 IPPS/LTCP PPS final rule (82 FR 38269 through 38278).
- The FY 2019 IPPS/LTCP PPS final rule (83 FR 41472 through 41492).
- The FY 2020 IPPS/LTCP PPS final rule (84 FR 42402 through 42411).

---

**TABLE V.K–18: PREVIOUSLY ADOPTED AND NEWLY ESTABLISHED MINIMUM CASE NUMBER REQUIREMENTS FOR HOSPITAL VBP PROGRAM**

<table>
<thead>
<tr>
<th>Measure Short Name</th>
<th>Minimum Number of Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCAHPS</td>
<td>Hospitals must report a minimum number of 100 completed HCAHPS surveys.</td>
</tr>
<tr>
<td><strong>Clinical Outcomes Domain</strong></td>
<td></td>
</tr>
<tr>
<td>MORT-30-AMI</td>
<td>Hospitals must report a minimum number of 25 cases.</td>
</tr>
<tr>
<td>MORT-30-HF</td>
<td>Hospitals must report a minimum number of 25 cases.</td>
</tr>
<tr>
<td>MORT-30-PN (updated cohort)</td>
<td>Hospitals must report a minimum number of 25 cases.</td>
</tr>
<tr>
<td>MORT-30-COPD</td>
<td>Hospitals must report a minimum number of 25 cases.</td>
</tr>
<tr>
<td>MORT-30-CABG</td>
<td>Hospitals must report a minimum number of 25 cases.</td>
</tr>
<tr>
<td>COMP-HIP-KNEE</td>
<td>Hospitals must report a minimum number of 25 cases.</td>
</tr>
<tr>
<td><strong>Safety Domain</strong></td>
<td></td>
</tr>
<tr>
<td>CAUTI</td>
<td>Hospitals have a minimum of 1,000 predicted infections as calculated by the CDC.</td>
</tr>
<tr>
<td>CLABSI</td>
<td>Hospitals have a minimum of 1,000 predicted infections as calculated by the CDC.</td>
</tr>
<tr>
<td>Colon and Abdominal Hysterectomy SSI</td>
<td>Hospitals have a minimum of 1,000 predicted infections as calculated by the CDC.</td>
</tr>
<tr>
<td>MRSA Bacteremia</td>
<td>Hospitals have a minimum of 1,000 predicted infections as calculated by the CDC.</td>
</tr>
<tr>
<td>CDI</td>
<td>Hospitals have a minimum of 1,000 predicted infections as calculated by the CDC.</td>
</tr>
<tr>
<td>SEP-1*</td>
<td>Hospitals must report a minimum number of 25 cases.</td>
</tr>
<tr>
<td><strong>Efficiency and Cost Reduction Domain</strong></td>
<td></td>
</tr>
<tr>
<td>MSPB</td>
<td>Hospitals must report a minimum number of 25 cases.</td>
</tr>
</tbody>
</table>

*In section V.K.3.a of the preamble of this final rule, we proposed to adopt the Severe Sepsis and Septic Shock: Management Bundle measure beginning with the FY 2026 program year.*
• The FY 2021 IPPS/LTCH PPS final rule (85 FR 58860 through 58865).
• The FY 2022 IPPS/LTCH PPS final rule (86 FR 45300 through 45310).
• The FY 2023 IPPS/LTCH PPS final rule (87 FR 49120 through 49138).
  
We have also codified certain requirements of the HAC Reduction Program at 42 CFR 412.170 through 412.172.

2. Measures for FY 2024 and Subsequent Years in the HAC Reduction Program

We refer readers to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41472 through 41474) for more information about how the HAC Reduction Program supports our goal of bringing quality measurement, transparency, and improvement together with value-based purchasing to the hospital inpatient care setting through the Meaningful Measures Framework and Meaningful Measures 2.0.\footnote{Centers for Medicare & Medicaid Services. (2022) Meaningful Measures 2.0: Moving from Measure Reduction to Modernization. Available at: https://www.cms.gov/medicare/meaningful-measures-framework/meaningful-measures-20-moving-measure-reduction-modernization.}

a. Current Measures

The HAC Reduction Program has adopted six measures to date. In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50717), we finalized the use of the following Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) hospital-associated infection (HAI) measures:

1. Catheter-associated Urinary Tract Infection (CAUTI) Outcome Measure; (2) Facility-wide Inpatient Hospital-onset Clostridium difficile Infection (CDI) Outcome Measure; (3) Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure; (4) Colon and Abdominal Hysterectomy Surgical Site Infection (SSI) Outcome Measure; and (5) Facility-wide Inpatient Hospital-onset Methicillin-resistant F;\textit{Staphylococcus aureus} (MRSA) bacteremia Outcome Measure. In the FY 2017 IPPS/LTCH PPS final rule (81 FR 57041), we finalized the use of the CMS PSI 90 measure. These previously finalized measures are shown in table IX.L.–01.\footnote{In previous years, we referred to the consensus-based entity by corporate name. We have updated this language to refer to the consensus-based entity more generally.}

We did not propose any measure removal and retention factor policy changes.

b. Measure Removal Factors Policy

We refer readers to the FY 2020 IPPS/LTCH PPS final rule (84 FR 42404 through 42406) for information about our measure removal and retention factors for the HAC Reduction Program.

We did not propose any measure removal and retention factor policy changes.

3. Maintenance of Technical Specifications for Quality Measures in the HAC Reduction Program

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50100 through 50101), we adopted a process that allows us to expeditiously incorporate technical measure specification updates while preserving the public’s ability to comment upon updates that fundamentally change a measure. In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49133 through 49134), we adjusted the minimum threshold criteria for the CMS PSI 90 measure beginning in the FY 2023 program year, requiring hospitals to have one or more component PSI measures with at least 25 eligible discharges and seven or more component PSI measures with at least three eligible discharges to receive a CMS PSI 90 composite score. We also announced a technical measure specification update to the CMS PSI 90 software to include COVID–19 diagnosis as a risk adjustment parameter beginning with the FY 2024 program year, to address the impact of COVID–19 hospitalized individuals on the CMS PSI 90 measure. We note the COVID–19 public health emergency ended on May 11, 2023.\footnote{The White House. (2023) Notice of the Continuation of the National Emergency Concerning the Coronavirus Disease 2019 (COVID–19) Pandemic. Available at: https://www.whitehouse.gov/briefing-room/presidential-actions/2023/02/10/notice-on-the-continuation-of-the-national-emergency-concerning-the-coronavirus-disease-2019-covid-19-pandemic-3/}

We did not propose any changes to these policies.

4. Advancing Patient Safety in the HAC Reduction Program—Request for Comment

As discussed in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50708), the intent of the HAC Reduction Program is to encourage all hospitals to reduce the incidence of hospital-acquired conditions. According to the CDC 2021 National and State Healthcare-Associated Infection Progress Report, rates of CLABSI, CAUTI, and MRSA bacteremia increased between 2020 and

Technical specifications for the CMS PSI 90 measure can be found on the QualityNet website available at: https://qualitynet.cms.gov/inpatient/measures/psi/resources. Technical specifications for the CDC NHSN HAI measures can be found at the CDC’s NHSN website at https://www.cdc.gov/nhsn/acute-care-hospital/index.html and on the QualityNet website available at: https://qualitynet.cms.gov/inpatient/measures/haï/resources. These three web pages provide measure updates and other information necessary to guide hospitals participating in the collection of HAC Reduction Program data.

We did not propose to add or remove any measures from the HAC Reduction Program.

\begin{table}[h]
\centering
\caption{HAC Reduction Program Measures for FY 2024 and Subsequent Years}
\begin{tabular}{|l|l|l|}
\hline
\textbf{Short Name} & \textbf{Measure Name} & \textbf{CRF}\footnote{In previous years, we referred to the consensus-based entity by corporate name. We have updated this language to refer to the consensus-based entity more generally.} \\ 
\hline
CMS PSI 90 & CMS Patient Safety and Adverse Events Composite (CMS PSI 90) & 0531 \\
CAUTI & CDC NHSN Catheter-associated Urinary Tract Infection (CAUTI) Outcome Measure & 0138 \\
CDI & CDC NHSN Facility-wide Inpatient Hospital-onset \textit{Clostridium difficile} Infection (CDI) Outcome Measure & 1717 \\
CLABSI & CDC NHSN Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure & 0139 \\
Colon and Abdominal Hysterectomy SSI & American College of Surgeons – Centers for Disease Control and Prevention (ACS-CDC) Harmonized Procedure Specific Surgical Site Infection (SSI) Outcome Measure & 0753 \\
MRSA Bacteremia & CDC NHSN Facility-wide Inpatient Hospital-onset Methicillin-resistant \textit{Staphylococcus aureus} (MRSA) Bacteremia Outcome Measure & 1716 \\
\hline
\end{tabular}
\end{table}


2021, by 7 percent, 5 percent, and 14 percent respectively. HAI standard infection rates for these three measures were notably higher than pre-COVID–19 pandemic levels, indicating continued room for improvement to reduce the incidence of hospital-acquired conditions nationwide. The HAC Reduction Program’s efforts to reduce hospital-acquired conditions are vital to improving patients’ quality of care and reducing complications and mortality, while simultaneously decreasing costs. The reduction of hospital-acquired conditions is an important marker of quality of care and has a positive impact on both patient outcomes and cost of care. Moreover, the HAC Reduction Program has an opportunity to advance both healthcare safety and equity by encouraging participating hospitals to further focus their improvement efforts on eliminating disparities that exist in the rate and severity of hospital-acquired conditions among different patient populations. According to a 2021 study conducted by the Urban Institute, Black patients experienced worse quality of care in 6 out of 11 patient safety indicators relative to White patients in 2017 across 26 states. We aim to have the HAC Reduction Program advance the CMS National Quality Strategy goals of improving health equity by addressing underlying disparities in our health system and promoting safety by preventing harm or death from healthcare errors. Further, we also seek to align with the HHS-led National Healthcare System Action Alliance to Advance Patient Safety and its priority of establishing and sustaining a strong culture of safety in a way that is equitable and engaging of patients, families, care partners, and the health care workforce.

We are conducting a review of the patient safety and healthcare-associated infection measures and the scoring and weighting methodology, as part of our ongoing efforts to evaluate and strengthen the HAC Reduction Program. As we did in the FY 2018 IPPS/LTCH PPS proposed rule (82 FR 19986 through 19990), the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20437), and the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28452), we sought input from interested parties on the addition of new program measures. We seek to adopt patient safety focused electronic clinical quality measures (eCQMs) to strengthen the growing portfolio of eCQMs and promote further alignment across quality reporting and value-based purchasing programs.

Adoption of eCQMs in the HAC Reduction Program supports the CMS Meaningful Measures 2.0 priority to move fully to digital quality measurement. In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49136), we described the Request for Comment (RFC) on the potential future adoption of the digital NHSN Healthcare-associated Clostridioides difficile Infection Outcome measure and the digital NHSN Hospital-Onset Bacteremia (HOB) & Funemia Outcome measure. We received public input in support of the adoption of these two eCQMs. However, a few commenters stated concern regarding baseline data testing, measure definitions, and the risk adjustment methodology for both eCQMs. In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27052), we sought feedback on potentially adopting patient safety related eCQMs which are currently used in the Hospital Inpatient Quality Reporting (IQR) Program, including: Hospital Harm—Opioid-Related Adverse Events eCQM, Hospital Harm-Severe Hypoglycemia eCQM, and Hospital Harm-Severe Hyperglycemia eCQM. In the FY 2023 IPPS/LTCH PPS final rule (87 FR 40223), the Hospital IQR Program adopted the Hospital Harm—Opioid-Related Adverse Events eCQM and in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45382), the Hospital IQR Program adopted the Hospital Harm-Severe Hypoglycemia eCQM and Hospital Harm-Severe Hyperglycemia eCQM. In sections IX.C.5.a and IX.C.5.b of this final rule, the Hospital IQR Program is finalizing the adoption of three additional eCQMs, which we sought input on for inclusion in the HAC Reduction Program, including: Hospital Harm-Acute Kidney Injury eCQM, Hospital Harm-Pressure Injury eCQM, and Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computer Tomography in Adults eCQM. We believe adoption of hospital harm eCQMs would address two high priority areas including patient safety and adopting outcome eCQMs. In addition, as part of our commitment to patient safety, we are developing new digital quality measures that use data from hospital electronic health records that would assess various aspects of patient safety in the inpatient care setting. We invited public comment on the adoption of these six eCQMs in the HAC Reduction Program.

Our longstanding policy is that, to the extent practicable, HAC Reduction Program measures should be nationally endorsed by a multi-stakeholder organization. Measures should be aligned with best practices among other payers and the needs of the end users of the measures. Measures should consider widely accepted criteria established in medical literature.

We invited public comment on potential future measures as well as on how the HAC Reduction Program can further promote patient safety. Specifically, we invited comment on:

- What measures should be introduced in the HAC Reduction Program to address emerging high priority patient harm events and healthcare-associated infections?
- What measures should be introduced in the HAC Reduction Program to address equity gaps in the rate and severity of patient harm events and healthcare-associated infections?
- How can weighting and scoring methods be improved to better assess hospital performance and promote equity in the HAC Reduction Program?
- How can the HAC Reduction Program be strengthened to encourage patient safety best practices, which also prioritize the delivery of equitable care, in inpatient facilities?

Comment: Several commenters recommended that new measures be introduced in the HAC Reduction Program that address medication safety related adverse events, procedure or surgery related adverse events, and SSIs. Many commenters supported the adoption of a hospital-onset COVID–19 measure in the HAC Reduction Program,
defined as infections diagnosed after five days of admission or greater. Several commenters also recommended the adoption of a HOB measure with a blood culture contamination benchmark of less than one percent. Many commenters expressed support for the potential future adoption in the HAC Reduction Program of the three hospital harm and patient safety eCQMs that are currently in the Hospital IQR Program—Opioid-Related Adverse Events, Severe Hypoglycemia, and Severe Hyperglycemia eCQMs—and the three patient safety related eCQMs that were proposed in the Hospital IQR Program in the FY 2024 IPPS/LTCH PPS proposed rule—Acute Kidney Injury, Pressure Injury, and Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computer Tomography in Adults eCQMs—for the HAC Reduction Program.

Many commenters did not support the future adoption of the Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computer Tomography in Adults eCQM expressing concern about the metrics, calculation methods, and software used for the measure. Many commenters did not support the addition of new measures, specifically eCQMs, and expressed concern about receiving timely, actionable performance feedback and stated concern about the burden and cost associated with implementing eCQMs. Several commenters recommended CMS thoroughly review, test, and first adopt eCQMs in the Hospital IQR Program before adoption in the HAC Reduction Program. Several commenters recommended standardizing the health equity methods across quality reporting and value-based purchasing programs and to adjust measures for patients who are dually eligible for Medicare and Medicaid. A few commenters recommended peer grouping hospitals by size and hospital characteristics for better performance comparisons. Several commenters recommended stratifying measures by Medicaid eligibility and social risk factors for equitable comparisons and to mitigate overly penalizing hospitals that serve disproportionately impacted populations.

Response: We thank commenters for their feedback on the potential future measures to include in the HAC Reduction Program. We also appreciate commenters’ feedback on potential program modifications to encourage equitable care, reduce administrative and provider burden, and promote patient safety. We will consider all input and note that any future proposal to implement a new measure or program modification would be announced through future notice-and-comment rulemaking.

5. HAC Reduction Program Scoring Methodology and Scoring Review and Corrections Period

In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41484), we clarified the Scoring Calculations Review and Correction Period for the HAC Reduction Program. Hospitals must register and submit quality data through the Hospital Quality Reporting (HQR) System (previously referred to as the QualityNet Secure Portal) in order to access their annual hospital-specific reports. The HQR System is safeguarded in accordance with the HIPAA Privacy and Security Rules to protect submitted patient information. See 45 CFR parts 160 and 164, subparts A, C, and E.

We did not propose any changes to the Scoring Calculations Review and Correction Period process.

6. Validation of HAC Reduction Program Data

We previously adopted data validation policies for the CDC NHSN HAI measures in the HAC Reduction Program in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41478 through 41484). Since then, we have continued to update the validation policies. We refer readers to the FY 2020 IPPS/LTCH PPS final rule (84 FR 42406 through 42410), the FY 2021 IPPS/LTCH PPS final rule (85 FR 58862 through 58865), and the FY 2023 IPPS/LTCH PPS final rule (87 FR 49137 through 49138) for detailed information on the HAC Reduction Program data validation processes.

a. Validation Reconsideration Beginning With the FY 2023 Program Year

(1) Background

In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41480) and FY 2020 IPPS/LTCH final rule (84 FR 42407), we finalized annual random selection of up to 200 hospitals for inpatient validation, and the annual targeted selection of up to 200 hospitals using the following targeting criteria:

• Any hospital that failed validation the previous year;
• Any hospital that submits data to NHSN after the HAC Reduction Program data submission deadline has passed;
• Any hospital that has not been randomly selected for validation in the past 3 years;
• Any hospital that passed validation in the previous year, but had a two-tailed confidence interval that included 75 percent; and
• Any hospital which failed to report to NHSN at least half of actual HAI events detected as determined during the previous year’s validation effort.

As discussed in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41480), under the current policies, once we validate all quarters of the relevant fiscal year, we calculate a total score reflecting a hospital’s reporting accuracy for the HAI measures used within the HAC Reduction Program. The calculated total score is then utilized to compute a confidence interval with the consideration of the results from the educational review process. If the estimated reliability upper bound (ERUB) of the confidence interval is 75 percent or higher, the hospital will pass the HAC Reduction Program validation requirement; if the ERUB is below 75 percent, the hospital will fail the HAC Reduction Program validation requirement.

As described in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41481 through 41482), a hospital that fails validation (that is, their ERUB is below the 75 percent threshold) is identified and the maximum Winsorized z-scores only for the set of measures validated. For example, if a hospital were selected on CLABSI, CAUTI, and SSI, and failed validation, that hospital would receive the maximum Winsorized z-scores (that is, the worst score) for CLABSI, CAUTI, and SSI. We did not propose any changes to these processes.

(2) Adopt a Validation Reconsideration Process

In the FY 2024 IPPS/LTCH PPS proposed rule, we proposed to add a validation reconsideration process to the HAC Reduction Program, giving hospitals the opportunity to request reconsideration of their final validation scores (88 FR 27054 through 27055). Prior to establishing administrative policies for the HAC Reduction Program to collect, validate, and publicly report quality measure data independently instead of conducting these activities through the Hospital IQR Program, as finalized in FY 2019 IPPS/LTCH PPS final rule (83 FR 41475 through 41484), hospitals that failed their Annual Payment Update (APU) requirement related to validation of certain Hospital IQR Program measures, which included but was not limited to HAI measures, had the opportunity to request reconsideration of their final validation scores for the HAI measures. We intend for the HAC Reduction Program’s reconsideration processes to be similar to the current validation reconsideration processes of the Hospital IQR Program, which hospitals are familiar with. We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51650 through...
51651) for further detail on the Hospital IQR Program validation reconsideration process. Beginning with the FY 2025 program year (affecting calendar year 2022 discharges), we proposed to allow hospitals that fail validation to request reconsideration of their validation results before use in HAC Reduction Program scoring calculations. The validation reconsideration process will be conducted once per program year after the validation of HAIs for all four quarters of the relevant fiscal year’s data period and after the confidence interval has been calculated.317

The process will complement the quarterly educational reviews that are currently available to hospitals. The adoption of a reconsideration process for the HAC Reduction Program aligns data validation processes with the Hospital IQR Program reconsideration process, which hospitals are familiar with. We refer readers to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41480 through 41481) for more details on the HAC Reduction Program educational review process.

(a) Notification of Validation Results and Request for Reconsideration Process

Once we calculate the confidence intervals for validation total scores, we proposed to notify a hospital that failed the HAC Reduction Program validation requirement for the CDC NHSN HAI measures via a notification letter sent by certified mail. The letter will instruct a hospital on how to submit a request for reconsideration to CMS. A hospital requesting validation reconsideration must submit a reconsideration request form within 30 days from the date stated on the notification letter. The form for submitting a reconsideration request and a detailed description of the reconsideration process will be available on the QualityNet website. A hospital’s request for validation reconsideration must include, among other things:

- Basis for requesting reconsideration—identifying specific reason(s) for why the hospital believes it met the HAC Reduction Program validation requirements.
- All documentation and evidence that supports the hospital’s request for reconsideration.

We will provide hospitals an email acknowledgement, following receipt of a request for validation reconsideration, using the contact information provided in the validation reconsideration request. We will also provide written notification of the formal decision regarding the reconsideration request to the hospital contact(s) listed on the validation reconsideration form. We anticipate that the reconsideration process may take approximately 90 days from the receipt of the reconsideration request.

Only hospitals that fail to meet the passing threshold for the end-of-year confidence interval calculation will receive an opportunity to request reconsideration of their validation results. The scope of the proposed reconsideration parallels the scope used within the Hospital IQR Program reconsideration process:

- If the hospital requests reconsideration for CMS contractor-abstracted data elements classified as mismatches affecting validation scores, hospitals must submit a copy of the entire requested medical record to CMS during the initial validation process (not during reconsideration) by the 30-day deadline date indicated on the notification letter for the requested case to be eligible to be reconsidered on the basis of mismatched data elements.
- On occasion, a hospital requests reconsideration for medical record copies submitted during the initial validation process and classified as invalid record selections. Such invalid record selections are defined as medical records submitted by hospitals during the initial validation process that do not match the patient’s episode of care information as determined by CMS (in other words, CMS determines that the hospital returned a medical record that is different from that which was requested). For more information about inpatient validation case statuses, we refer readers to the CMS Inpatient Data Validation Case Status Details for Validated Results on the QualityNet website available at https://qualitynet.cms.gov/inpatient/data-management/data-validation/resources. If we determine that the hospital has submitted an invalid record selection case, it will be awarded a zero validation score for the case because the hospital did not submit the entire copy of the medical record for that requested case. During the reconsideration process, our review of invalid record selections would be limited to determining whether the record submitted was actually an entire copy of the requested medical record. If we determine during reconsideration that the hospital did submit the entire copy of the requested medical record, then we would re-abstract data elements from the medical record submitted by the hospital.

- If the hospital requests reconsideration for medical records not submitted within the 30-day deadline of the initial validation process, our review would initially be limited to determining whether we received the requested record within 30 calendar days of the initial validation process. If we determined during reconsideration that we did receive a copy of the requested medical record within 30 calendar days, then we will abstract data elements from the medical record submitted by the hospital. This proposed policy is also designed to address those instances where the hospital’s request is based on invalid record selections, which are defined as medical records submitted during the initial validation process that do not match the patient’s episode of care information as determined by CMS, as previously discussed.

In summary, similar to the validation reconsideration process under the Hospital IQR Program, we will limit the scope of our HAC Reduction Program data validation reconsideration reviews to information already submitted by the hospital during the initial validation process, and we will not abstract medical records that were not submitted during the initial validation process. We will expand the scope of our review only if we found during the review that the hospital correctly and timely submitted the requested medical records. In that case, we will abstract data elements from the medical record submitted by the hospital as part of our review of its reconsideration request. After the reconsideration process is complete, we will re-calculate a hospital’s confidence interval based on the results of the reconsideration of the hospital’s cases and determine whether the hospital passed or failed validation requirements for the HAC Reduction Program. Those results will then be used for HAC Reduction Program scoring, as detailed in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41485 through 41489). The updated validation results could impact a hospital’s payment adjustments. If a hospital still fails validation after receiving updated validation results, we will assign the maximum Winsorized z-score for the three measures CMS validated. If a hospital passes validation after the reconsideration process, their SIRs for the measures validated will be their measure results in the HAC Reduction Program scoring calculations process. As described in § 412.172(b) and (e)(2), hospitals in the worst performing quartile, that is the 25 percent of hospitals with the highest Total HAC

317To clarify, the validation reconsideration process would be conducted after validation of HAIs for all four quarters of the first year of the program’s performance period and after the confidence interval has been calculated.
Scores, are subject to a 1-percent payment reduction under the HAC Reduction Program. We noted in the proposed rule that the HAC Reduction Program reconsideration process would be limited to reconsideration as to the data validation requirements of the program. We did not propose a reconsideration process as to any other program requirements, including measure calculations, scoring, or determination of payment reductions not related to data validation. We refer readers to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41464) where we discuss our policies related to the Scoring Review and Corrections Period for hospitals that may have questions about their Total HAC Score calculations.

We invited public comment on this proposal.

Comment: Several commenters supported the proposal to establish a reconsideration process for data validation. A few commenters supported the proposal because it would provide hospitals an opportunity to request further review of mismatches between reported data and medical record information that were identified during the validation process and that may result in failing data validation and receiving the worst possible scores for the measures validated.

Response: We thank the commenters for their support.

Comment: A commenter questioned whether a hospital could file an appeal with the Provider Reimbursement Review Board (PRRB) and the potential options if it is dissatisfied with the reconsideration determination.

Response: We appreciate the commenter’s question on the options for hospitals to appeal their validation results. Hospitals will not have the option to file an appeal with the PRRB if it is dissatisfied with the reconsideration determination. We refer the commenter to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41480) where we finalized the Educational Review Process in which hospitals selected for validation would have a 30-day period following the receipt of quarterly validation results to seek educational review. During this 30-day period, hospitals may review, seek clarification, and potentially identify a CMS validation error. Additionally, hospitals may request reconsideration of their validation results as described in section X.X. of this final rule. We believe that both the educational review and the reconsideration processes provide hospitals with multiple avenues to request review of their validation results.

After consideration of the public comments we received, we are finalizing our proposal to establish a validation reconsideration process in the HAC Reduction Program beginning with the FY 2025 program year as proposed.

(3) Update the Targeting Criteria for Hospitals Granted an Extraordinary Circumstances Exception (ECE)

As proposed in the Hospital IQR Program as discussed in section IX.C.11.b of this final rule, we proposed to update our targeting criteria for validation of hospitals granted an extraordinary circumstances exception (ECE) in the HAC Reduction Program (88 FR 27055). Specifically, we proposed to modify the validation targeting criteria to include any hospital with a ERUB of the two-tailed confidence interval that is less than 75 percent and received an extraordinary circumstances exception (ECE) for one or more quarters beginning with the FY 2022 program year, affecting validation of calendar year 2024 discharges.

We proposed to add a new criterion to the five established targeting criteria used to select the up to 200 additional hospitals. We proposed that a hospital subject to validation that received an extraordinary circumstances exception (ECE) for one or more quarters for the data period validated and has a ERUB of the two-tailed confidence interval that is less than 75 percent would be targeted for validation in the subsequent validation year and would not fail data validation in the HAC Reduction Program. The hospital will not receive the penalty of the maximum Winsorized z-scores, the worst scores, for measures validated. This exception will not except a hospital from participation in the HAC Reduction Program, and the hospital will still receive a Total HAC Score. We refer readers to the previously established program scoring methodology in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41485). We believe this additional criterion will promote alignment with the Hospital IQR Program. Hospitals that meet this criterion will be required to submit medical records to CMS within 30 days of the date identified on the written request as finalized in the Hospital IQR Program in FY 2017 IPPS/LTCH PPS final rule (81 FR 57179 and 57180) and in the HAC Reduction Program in FY 2019 Rule IPPS/LTCH PPS final rule (83 FR 41482).

It is important to clarify that, consistent with our previously finalized policies, this exception does not apply to both the maximum Winsorized z-scores penalty and targeting for validation in the subsequent year if it does not have an ECE for one or more quarters and does not meet the 75 percent threshold.

Specifically, we proposed to add the following criterion for targeting up to 200 additional hospitals for validation: any hospital with a two-tailed confidence interval that is less than 75 percent, and received an ECE for one or more quarters for the data period validated.

This modification to the targeting criteria aligns across the HAC Reduction, Hospital IQR and Hospital OQR Programs. In the CY 2023 OPPS/ASC final rule, we finalized the addition of this criterion to the Hospital OQR Program’s targeting criteria for validation selection beginning with validations affecting the CY 2023 reporting period/CY 2025 payment determination (87 FR 72115 and 72116). We discussed in the proposed rule that this policy would also allow us to appropriately address instances in which hospitals, with an ECE for one or more quarters for the data period validated, will receive the maximum Winsorized z-scores penalty and thus be more likely to be subject to the payment reduction under the current validation policies.

We invited public comment on this proposal.

Comment: A few commenters supported the modification to the data validation targeting criteria. A commenter expressed support for the proposal because it would align with other quality reporting programs and ensure hospitals granted an ECE are not penalized for failing to meet the validation requirement during an unforeseen circumstances.

Response: We appreciate the commenters for their support of the proposal. We agree that the modification of the targeting criteria will further align the HAC Reduction Program with the Hospital IQR and Hospital OQR Programs. We agree that the addition of the criterion will appropriately address instances in which hospitals with an ECE for one or more quarters for the data period validated fail validation, and will prevent a hospital from receiving the maximum Winsorized z-scores based on data representing a period during an extraordinary event.

After consideration of the public comments we received, we are finalizing, as proposed, to modify the HAC Reduction Program data validation targeting criteria to include any hospital with a two-tailed confidence interval that is less than 75 percent, and received an ECE for one or more quarters for the data period validated beginning with the FY 2027 program year.
year, affecting validation of calendar year 2024 discharges.

K. Rural Community Hospital Demonstration Program

1. Introduction

The Rural Community Hospital Demonstration was originally authorized by section 410A of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) (Pub. L. 108–173). The demonstration has been extended three times since the original 5-year period mandated by the MMA, each time for an additional 5 years. These extensions were authorized by sections 3123 and 10313 of the Affordable Care Act (Pub. L. 111–143), section 15003 of the 21st Century Cures Act (Pub. L. 114–255) (Cures Act) enacted in 2016, and most recently, by section 128 of the Consolidated Appropriations Act of 2021 (Pub. L. 116–260). In this final rule, we summarize the status of the demonstration program, and the current methodologies for implementation and calculating budget neutrality.

We are finalizing the amount to be applied to the national IPPS payment rates to account for the costs of the demonstration in FY 2024, and, in addition, we are including the reconciled amount of demonstration costs for FY 2018 in the FY 2024 IPPS/LTCH final rule, based on the finalized cost reports for this earlier year.

2. Background

Section 410A(a) of Public Law 108–173 required the Secretary to establish a demonstration program to test the feasibility and advisability of establishing rural community hospitals to furnish covered inpatient hospital services to Medicare beneficiaries. The demonstration pays rural community hospitals under a reasonable cost-based methodology for Medicare payment purposes for covered inpatient hospital services furnished to Medicare beneficiaries. A rural community hospital, as defined in section 410A(1)(1), is a hospital that—

- Is located in a rural area (as defined in section 1866(a)(2)(D) of the Act) or is treated as being located in a rural area under section 1886(d)(3)(e) of the Act;
- Has fewer than 51 beds (excluding beds in a distinct part psychiatric or rehabilitation unit) as reported in its most recent cost report;
- Provides 24-hour emergency care services; and
- Is not designated or eligible for designation as a CAH under section 1822 of the Act.

Our policy for implementing the 5-year extension period authorized by Public Law 116–260 (the Consolidated Appropriations Act, 2021) follows upon the previous extensions under the ACA (Pub. L. 111–148) and the Cures Act (Pub. L. 114–255). Section 410A of Pub. L. 108–173 (MMA) initially required a 5-year period of performance. Subsequently, sections 3123 and 10313 of Public Law 111–148 required the Secretary to conduct the demonstration program for an additional 5-year period, to begin on the date immediately following the last day of the initial 5-year period. In addition, Public Law 111–148 limited the number of hospitals participating to no more than 30. Section 15003 of the Cures Act required a 10-year extension period in place of the 5-year extension period under the ACA, thereby extending the demonstration for another 5 years. Section 128 of Public Law 116–260, in turn, revised the statute to indicate a 15-year extension period, instead of the 10-year extension period mandated by the Public Law 114–159 (Cures Act). Please refer to the FY 2023 IPPS proposed and final rules (87 FR 28454 through 28458 and 87 FR 49138 through 49142, respectively) for an account of hospitals entering into and withdrawing from the demonstration with these re-authorizations. There are currently 26 hospitals participating in the demonstration.  

2. Budget Neutrality

a. Statutory Budget Neutrality Requirement

Section 410A(c)(2) of Public Law 108–173 requires that, in conducting the demonstration program under this section, the Secretary shall ensure that the aggregate payments made by the Secretary do not exceed the amount that the Secretary would have paid if the demonstration program under this section was not implemented. This requirement is commonly referred to as “budget neutrality.” Generally, when we implement demonstration programs on a budget neutral basis, the demonstration program is budget neutral on its own terms; in other words, the aggregate payments to the participating hospitals do not exceed the amount that would be paid to those same hospitals in the absence of the demonstration program. We note that the payment methodology for this demonstration, that is, cost-based payments to participating small rural hospitals, makes it unlikely that increased Medicare outlays will produce an offsetting reduction to Medicare expenditures elsewhere. Therefore, in the IPPS final rules spanning the period from FY 2005 through FY 2016, we adjusted the national inpatient PPS rates by an amount sufficient to account for the added costs of this demonstration program, thus applying budget neutrality across the payment system as a whole rather than merely across the participants in the demonstration program. (We applied a different methodology for FY 2017, with the demonstration expected to end prior to the Cures Act extension.) As we discussed in the FYs 2005 through 2017 IPPS/LTCH PPS final rules (69 FR 49183; 70 FR 47462; 71 FR 48100; 72 FR 47392; 73 FR 48670; 74 FR 43922, 75 FR 50343; 76 FR 51698, 77 FR 53449, 78 FR 50740, 77 FR 50145; 80 FR 49583; and 81 FR 57034, respectively), we believe that the statutory language of the budget neutrality requirements permits the agency to implement the budget neutrality provision in this manner.

We resumed this methodology of offsetting demonstration costs against the national payment rates in the IPPS final rules from FY 2018 through FY 2023. Please see the FY 2023 IPPS final rule for an account of how we applied the budget neutrality requirement for these fiscal years (87 FR 49140 through 49142).

b. General Budget Neutrality Methodology

We have generally incorporated two components into the budget neutrality offset amounts identified in the final IPPS rules in previous years. First, we have estimated the costs of the demonstration for the upcoming fiscal year, generally determined from historical, “as submitted” cost reports for the hospitals participating in that year. Update factors representing nationwide trends in cost and volume increases have been incorporated into these estimates, as specified in the methodology described in the final rule for each fiscal year. Second, as finalized cost reports became available, we determined the amount by which the actual costs of the demonstration for an earlier, given year differed from the estimated costs for the demonstration set forth in the final IPPS rule for the corresponding fiscal year, and incorporated that amount into the budget neutrality offset amount for the upcoming fiscal year. If the actual costs for the demonstration for the earlier fiscal year exceeded the estimated costs of the demonstration identified in the final rule for that year, this difference was added to the estimated costs of the demonstration for the upcoming fiscal year when determining the budget neutrality adjustment for the upcoming fiscal year. Conversely, if the estimated
costs of the demonstration set forth in the final rule for a prior fiscal year exceeded the actual costs of the demonstration for that year, this difference was subtracted from the estimated cost of the demonstration for the upcoming fiscal year when determining the budget neutrality adjustment for the upcoming fiscal year.

We note that we have calculated this difference for FYs 2005 through 2017 between the actual costs of the demonstration as determined from finalized cost reports once available, and estimated costs of the demonstration as identified in the applicable IPPS final rules for these years.

c. Budget Neutrality Methodology for the Extension Period Authorized by Public Law 116–159

For the most recently enacted extension period, under the Consolidated Appropriations Act, 2021, we have continued upon the general budget neutrality methodology used in previous years, as described above in the citations to earlier IPPS final rules. In this final rule, we outline the methodology for determining the offset to the national IPPS payment rates for FY 2024.

(1) Methodology for Estimating Demonstration Costs for FY 2024

Consistent with the general methodology from previous years, we estimate the costs of the demonstration for the upcoming fiscal year, and incorporate this estimate into the budget neutrality offset amount to be applied to the national IPPS rates for the upcoming fiscal year, that is, FY 2024. We are conducting this estimate for FY 2024 based on the 26 currently participating hospitals. The methodology for calculating this amount for FY 2024 proceeds according to the following steps:

Step 1: For each of these 26 hospitals, we identify the reasonable cost amount calculated under the reasonable cost-based methodology for covered inpatient hospital services, including swing beds, as indicated on the “as submitted” cost report for the most recent cost reporting period available. For each of these hospitals, the “as submitted” cost report is that with cost report period end date in CY 2021. We sum these hospital-specific amounts to arrive at a total general amount representing the costs for covered inpatient hospital services, including swing beds, across the total 26 hospitals eligible to participate during FY 2024. Then we multiply this amount by the FYs 2022, 2023, and 2024 IPPS market basket percentage increases, which are calculated by the CMS Office of the Actuary. (We are using the market basket percentage increase for FY 2024 IPPS final rule, which can be found at section V.B. of the preamble to this final rule.) The result for the 26 hospitals is the general estimated reasonable cost amount for covered inpatient hospital services for FY 2024.

Consistent with our methods in previous years for formulating this estimate, we are applying the IPPS market basket percentage increases for FYs 2022 through 2024 to the applicable estimated reasonable cost amount (previously described) to model the estimated FY 2024 reasonable cost amount under the demonstration. We believe that the IPPS market basket percentage increases appropriately indicate the trend of increase in inpatient hospital operating costs under the reasonable cost methodology for the years involved.

Step 2: For each of the participating hospitals, we identify the estimated amount that would otherwise be paid in FY 2024 under applicable Medicare payment methodologies for covered inpatient hospital services, including swing beds (as indicated on the same set of “as submitted” cost reports as in Step 1), if the demonstration were not implemented. We sum these hospital-specific amounts, and, in turn, multiply this sum by the FYs 2022, 2023, and 2024 IPPS applicable percentage increases. (For FY 2024, we are using the applicable percentage increase amount identified in section V.B. of the preamble of this final rule.) This methodology differs from Step 1, in which we apply the market basket percentage increases to the hospitals’ applicable estimated reasonable cost amount for covered inpatient hospital services. We believe that the IPPS applicable percentage increases are appropriate factors to update the estimated amounts that generally would otherwise be paid without the demonstration. This is because IPPS payments constitute the majority of payments that would otherwise be made without the demonstration and the applicable percentage increase is the factor used under the IPPS to update the inpatient hospital payment rates.

Step 3: We subtract the amount derived in Step 2 from the amount derived in Step 1. According to our methodology, the resulting amount indicates the total difference for the 26 hospitals (for covered inpatient hospital services, including swing beds), which will be the general estimated amount of the costs of the demonstration for FY 2024.

For this final rule, the resulting amount is $37,766,716, to be incorporated into the budget neutrality offset adjustment for FY 2024. This estimated amount is based on the specific assumptions regarding the data sources used, that is, recently available “as submitted” cost reports and historical update factors for cost and payment. We note that in this final rule we are using revised update factors as compared to the proposed rule, to estimate the costs for the demonstration program for FY 2024 in accordance with our methodology for determining the budget neutrality estimate.

(2) Reconciling Actual and Estimated Costs of the Demonstration for Previous Years

As described earlier, we have calculated the difference for FYs 2005 through 2017 between the actual costs of the demonstration, as determined from finalized cost reports once available, and estimated costs of the demonstration as identified in the applicable IPPS final rules for these years.

At this time, for the FY 2024 final rule, all of the finalized cost reports have become available for the 29 hospitals that completed cost report periods beginning in FY 2018 under the demonstration payment methodology. Thus, as we described in the proposed rule, we are including the difference between the actual cost of the demonstration for FY 2018 as determined from finalized cost reports and the estimated amount for the fiscal year within the budget neutrality offset amount in the FY 2024 final rule.

The actual costs of the demonstration for FY 2018, as determined from the finalized cost reports for the 29 hospitals that completed cost report periods beginning in FY 2018 under the demonstration payment methodology, is $46,745,899. This amount exceeds the amount that was estimated for FY 2018 in the FY 2019 IPPS final rule ($31,070,880) by $15,675,019. (Following upon the selection of new hospitals for the demonstration in 2017, the estimated costs of the demonstration for FYs 2018 and 2019 were included in the FY 2019 IPPS final rule. (83 FR 41054). Thus, keeping with past practice, we are adding this difference to the estimated cost for FY 2024 in determining the budget neutrality offset amount for the FY 2024 IPPS final rule.

(3) Total Budget Neutrality Offset Amount for FY 2024

Therefore, for this FY 2024 IPPS/LTCH PPS final rule, the budget
neutrality offset amount for FY 2024 is the sum of two amounts:

(i) the amount determined under section X.2.c.(1), of the preamble of this final rule, representing the difference applicable to FY 2024 between the sum of the estimated reasonable cost amounts that would be paid under the demonstration for covered inpatient services to the 26 hospitals eligible to participate in the fiscal year and the sum of the estimated amounts that would generally be paid if the demonstration had not been implemented. This estimated amount is $37,766,716.

(ii) the amount determined under section X.2.c.(2), which represents the difference between the actual costs of the demonstration for FY 2018, as determined from the finalized cost reports for the 29 hospitals with cost reporting periods under the demonstration payment methodology that began in that fiscal year, and the earlier estimated cost of the demonstration for the fiscal year. This amount is $15,675,019.

Thus, the total budget neutrality offset amount for the FY 2024 IPPS final rule is $53,441,735. This amount will be subtracted from the national IPPS payment rates for FY 2024.

Comment: The parent company for two of the participating hospitals expressed support for the continuation of the Rural Community Hospital Demonstration program, but noted that it does not offer long-term financial stability needed to maintain health care access in rural areas. The commenter requests that the demonstration be made a permanent program, and, in addition, that CMS institute an application process to ensure the demonstration meets program capacity. Furthermore, the commenter requests several technical adjustments to the administration of the demonstration that may enhance stability in the payment to the participating hospitals.

Response: We appreciate the comments. We have conducted the demonstration program in accordance with Congressional mandates. Title XVIII does not extend authority to make the demonstration a permanent program. With regard to any further actions, we intend to work with the commenter and other rural stakeholders to examine the issues involved.

VI. Changes to the IPPS for Capital Related Costs

A. Overview

Section 1886(g) of the Act requires the Secretary to pay for the capital-related costs of inpatient acute hospital services in accordance with a prospective payment system established by the Secretary. Under the statute, the Secretary has broad authority in establishing and implementing the IPPS for acute care hospital inpatient capital-related costs. We initially implemented the IPPS for capital-related costs in the FY 1992 IPPS final rule (56 FR 43358).

In that final rule, we established a 10-year transition period to change the payment methodology for Medicare hospital inpatient capital-related costs from a reasonable cost-based payment methodology to a prospective payment methodology (based fully on the Federal rate).

FY 2001 was the last year of the 10-year transition period that was established to phase in the IPPS for hospital inpatient capital-related costs. For cost reporting periods beginning in FY 2002, capital IPPS payments are based solely on the Federal rate for almost all acute care hospitals (other than hospitals receiving certain exception payments and certain new hospitals). (We refer readers to the FY 2002 IPPS final rule (66 FR 39910 through 39914) for additional information on the methodology used to determine capital IPPS payments to hospitals both during and after the transition period.)

The basic methodology for determining capital prospective payments using the Federal rate is set forth in the regulations at 42 CFR 412.312. For the purpose of calculating capital payments for each discharge, the standard Federal rate is adjusted as follows:

\[(\text{Standard Federal Rate}) \times (\text{DRG Weight}) \times (\text{Geographic Adjustment Factor (GAF)}) \times (\text{COLA for hospitals located in Alaska and Hawaii}) \times (1 + \text{Capital DSH Adjustment Factor} + \text{Capital IME Adjustment Factor, if applicable})\]

In addition, under §412.312(c), hospitals also may receive outlier payments under the capital IPPS for extraordinarily high-cost cases that qualify under the thresholds established for each fiscal year.

B. Additional Provisions

1. Exception Payments

The regulations at 42 CFR 412.348 provide for certain exception payments under the capital IPPS. The regular exception payments provided under §412.348(b) through (e) were available only during the 10-year transition period. For a certain period after the transition period, eligible hospitals may have received additional payments under the special exceptions provisions at §412.348(g). However, FY 2012 was the final year hospitals could receive special exception payments. For additional details regarding these exceptions policies, we refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51725).

Under §412.348(f), a hospital may request an additional payment if the hospital incurs unanticipated capital expenditures in excess of $5 million due to extraordinary circumstances beyond the hospital’s control. Additional information on the exception payment for extraordinary circumstances in §412.348(f) can be found in the FY 2005 IPPS final rule (69 FR 49185 and 49186).

2. New Hospitals

Under the capital IPPS, the regulations at 42 CFR 412.300(b) define a new hospital as a hospital that has operated (under previous or current ownership) for less than 2 years and lists examples of hospitals that are not considered new hospitals. In accordance with §412.304(c)(2), under the capital IPPS, a new hospital is paid 85 percent of its allowable Medicare inpatient hospital capital related costs through its first 2 years of operation, unless the new hospital elects to receive full prospective payment based on 100 percent of the Federal rate. We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51725) for additional information on payments to new hospitals under the capital IPPS.

3. Payments for Hospitals Located in Puerto Rico

In the FY 2017 IPPS/LTCH PPS final rule (81 FR 57061), we revised the regulations at 42 CFR 412.374 relating to the calculation of capital IPPS payments to hospitals located in Puerto Rico beginning in FY 2017 to parallel the change in the statutory calculation of operating IPPS payments to hospitals located in Puerto Rico, for discharges occurring on or after January 1, 2016, made by section 601 of the Consolidated Appropriations Act, 2016 (Pub. L. 114–113). Section 601 of Public Law 114–113 increased the applicable Federal percentage of the operating IPPS payment for hospitals located in Puerto Rico from 75 percent to 100 percent and decreased the applicable Puerto Rico percentage of the operating IPPS payments for hospitals located in Puerto Rico from 25 percent to zero percent, applicable to discharges occurring on or after January 1, 2016. As such, under revised §412.374, for discharges occurring on or after October 1, 2016, capital IPPS payments to hospitals located in Puerto Rico are based on 100 percent of the capital Federal rate.
C. Annual Update for FY 2024

The annual update to the national capital Federal rate, as provided for in § 412.308(c), for FY 2024 is discussed in section III. of the Addendum to this FY 2024 IPPS/LTCH PPS final rule.

D. Treatment of Rural Reclassifications for Capital DSH Payments

Section 1886(d)(2)(E)(i) of the Act, implemented at § 412.103, specifies for a hospital that meets certain requirements and criteria, the Secretary shall treat the hospital as being located in the rural area of the State in which the hospital is located for purposes of section 1886(d) of the Act. In the FY 2007 IPPS/LTCH PPS final rule (71 FR 48104), we codified at § 412.320(a)(1)(iiii) that hospitals reclassified as rural under § 412.103 also are considered rural under the capital IPPS for purposes of determining eligibility for capital DSH payments. Under the capital IPPS, as set forth in § 412.320(a), only urban hospitals with 100 or more beds are eligible for capital DSH payments. Therefore, under the current regulations, hospitals reclassified as rural under § 412.103 are not eligible to receive capital DSH payments. On September 30, 2021, in Toledo Hospital v. Becerra, the U.S. District Court for the District of Columbia issued a decision that the FY 2007 final rule codifying CMS’s policy of not providing capital DSH payments to urban hospitals that are reclassified as rural under § 412.103 was arbitrary and capricious because, the court concluded, the record did not demonstrate that CMS took relative costs into account when considering the rule and the policy at issue.

We do not necessarily agree with the court’s conclusions but nevertheless in light of the decision, in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27058 through 27059), we proposed to revise the capital DSH regulations in response to this court ruling.

Specifically, we proposed that effective for discharges occurring on or after October 1, 2023, hospitals reclassified as rural under § 412.103 will no longer be considered rural for purposes of determining eligibility for capital DSH payments. We proposed to codify this change by amending existing § 412.320(a)(1)(iiii) to specify that the exception for a rural hospital present in § 412.103 is effective for discharges occurring on or after October 1, 2006, and before October 1, 2023. That is, for discharges occurring on or after October 1, 2023, for purposes of § 412.320, the geographic classifications specified under § 412.64 would apply with no exceptions.

Comment: Commenters were generally supportive of our proposal to no longer consider hospitals reclassified as rural under § 412.103 as rural for purposes of determining eligibility for capital DSH payments and some emphasized their belief that capital costs of reclassified rural providers under § 412.103 are more equivalent to other urban providers as opposed to geographically rural providers. Some commenters expressed concern that CMS did not propose to apply this change in policy retroactively. These commenters disagree that the exception codified at § 412.320(a)(1)(iiii) should remain effective for discharges occurring on or after October 1, 2006, and before October 1, 2023. These commenters believe that this exception remaining effective for this period is inconsistent with the court’s decision and also inconsistent with the proposal that the exception will no longer apply for discharges occurring on or after October 1, 2023. Some of these commenters believe at a minimum CMS should allow hospitals reclassified as rural under § 412.103 to receive capital DSH payments for any open or reopenable cost reports between FY 2007 and FY 2023.

Response: We thank commenters for their support of our proposal. We do not agree with commenters that believe our proposal should be applied retroactively. The IPPS is a prospective system, and therefore we generally make changes to IPPS regulations effective prospectively based on the date of discharge or the start of a cost reporting period within a certain Federal fiscal year.

Comment: A commenter encouraged CMS to also expand capital DSH eligibility to geographically rural hospitals. The commenter believes this would bolster the rural health care safety net. The commenter cited negative capital margins at geographically rural hospitals, low occupancy rates in geographically rural hospitals, as well as recent closure of geographically rural hospitals as reasons why expanding capital DSH eligibility to geographically rural hospitals would be justified.

Response: We believe this comment is out of scope of this rulemaking. We thank the commenter for this suggestion and may consider it in future rulemaking. We note that the capital DSH payment adjustments were finalized in the FY 1992 IPPS final rule (56 FR 43377 through 43379) based on a cost regression analysis.

After consideration of the public comments we received, we are finalizing as proposed, that effective for discharges occurring on or after October 1, 2023, hospitals reclassified as rural under § 412.103 will no longer be considered rural for purposes of determining eligibility for capital DSH payments. We also are finalizing our proposal to amend existing § 412.320(a)(1)(iiii) to specify that the exception for an urban hospital that is reclassified as rural as set forth in § 412.103 is effective for discharges occurring on or after October 1, 2006, and before October 1, 2023. That is, for discharges occurring on or after October 1, 2023, for purposes of § 412.320, the geographic classifications specified under § 412.64 will apply with no exceptions.

VII. Changes for Hospitals Excluded From the IPPS

A. Rate-of-Increase in Payments to Excluded Hospitals for FY 2024

Certain hospitals excluded from a prospective payment system, including children’s hospitals, 11 cancer hospitals, and hospitals located outside the 50 States, the District of Columbia, and Puerto Rico (that is, hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa) receive payment for inpatient hospital services they furnish on the basis of reasonable costs, subject to a rate-of-increase ceiling. A per discharge limit (the target amount, as defined in § 413.40(a) of the regulations) is set for each hospital based on the hospital’s own cost experience in its base year, and updated annually by a rate-of-increase percentage. For each cost reporting period, the updated target amount is multiplied by total Medicare discharges during that period and applied as an aggregate upper limit (the ceiling as defined in § 413.40(a)) of Medicare reimbursement for total inpatient operating costs for a hospital’s cost reporting period. In accordance with § 403.752(a) of the regulations, religious nonmedical health care institutions (RNHCIs) also are subject to the rate-of-increase limits established under § 413.40 of the regulations discussed previously. Furthermore, in accordance with § 412.526(c)(3) of the regulations, extended neonatal disease care hospitals also are subject to the rate-of-increase limits established under § 413.40 of the regulations discussed previously.

As explained in the FY 2006 IPPS final rule (70 FR 47396 through 47398), beginning with FY 2006, we have used...
the percentage increase in the IPPS operating market basket to update the target amounts for children’s hospitals, the 11 cancer hospitals, and RNHCIs. Consistent with the regulations at §§ 412.23(g) and 413.40(a)(2)(ii)(A) and (c)(3)(viii), we also have used the percentage increase in the IPPS operating market basket to update target amounts for short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa. In the FY 2018 IPPS/LTCH PPS final rule, we rebased and revised the IPPS operating market basket to a 2014 base year, effective for FY 2018 and subsequent fiscal years (82 FR 38158 through 2022 and subsequent fiscal years.

For the FY 2024 IPPS/LTCH PPS proposed rule, based on IGI’s 2022 fourth quarter forecast, we estimated that the 2018-based IPPS operating market basket percentage increase for FY 2024 would be 3.0 percent (that is, the estimate of the market basket rate-of-increase). However, we proposed that if more recent data became available for the FY 2024 IPPS/LTCH PPS final rule, we would use such data, if appropriate, to calculate the IPPS operating market basket rate of increase for FY 2024. For this FY 2024 IPPS/LTCH PPS final rule, based on IGI’s 2023 second quarter forecast, we estimate that the 2018-based IPPS operating market basket update for FY 2024 is 3.3 percent.

We received no comments on this proposal and therefore are finalizing this provision without modification. Incorporating more recent data available for this final rule, as we proposed, we are adopting a 3.3 percent update for FY 2024.

B. Report on Adjustment (Exception) Payments

Section 4419(b) of Public Law 105–33 requires the Secretary to publish annually in the Federal Register a report describing the total amount of adjustment payments made to excluded hospitals and hospital units by reason of section 1886(b)(4) of the Act during the previous fiscal year. The process of requesting, reviewing, and awarding an adjustment payment is likely to occur over a 2-year period or longer. First, generally, an excluded hospital must file its cost report for the fiscal year in accordance with § 413.24(f)(2) of the regulations. The MAC reviews the cost report and issues a notice of provider reimbursement (NPR). Once the hospital receives the NPR, if its operating costs are in excess of the ceiling, the hospital may file a request for an adjustment payment. After the MAC receives the hospital’s request in accordance with applicable regulations, the MAC or CMS, depending on the type of adjustment requested, reviews the request, and determines if an adjustment payment is warranted. This determination is sometimes not made until more than 180 days after the date the request is filed because there are times when the request applications are incomplete and additional information must be requested to have a completed request application. However, in an attempt to provide interested parties with data on the most recent adjustment payments for which we have data, we are publishing data on adjustment payments that were processed by the MAC or CMS during FY 2022.

The table that follows includes the most recent data available from the MACs and CMS on adjustment payments that were adjudicated during FY 2022. As indicated previously, the adjustments made during FY 2022 only pertain to cost reporting periods ending in years prior to FY 2022. Total adjustment payments to IPPS-excluded hospitals during FY 2022 are $4,338,890. The table depicts for each
class of hospitals, in the aggregate, the number of adjustment requests adjudicated, the excess operating costs over the ceiling, and the amount of the adjustment payments.

<table>
<thead>
<tr>
<th>Class of Hospital</th>
<th>Number</th>
<th>Excess Cost Over Ceiling</th>
<th>Adjustment Payments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer Hospitals</td>
<td>2</td>
<td>$11,974,166</td>
<td>$3,645,981</td>
</tr>
<tr>
<td>Children’s Hospitals</td>
<td>5</td>
<td>$1,038,797</td>
<td>$625,277</td>
</tr>
<tr>
<td>RNHCIs</td>
<td>1</td>
<td>$160,881</td>
<td>$67,632</td>
</tr>
<tr>
<td>Total</td>
<td>8</td>
<td>$13,173,844</td>
<td>$4,338,890</td>
</tr>
</tbody>
</table>

B. Critical Access Hospitals (CAHs)

1. Background

Section 1820 of the Act provides for the establishment of Medicare Rural Hospital Flexibility Programs (MRHFPs), under which individual States may designate certain facilities as critical access hospitals (CAHs). Facilities that are so designated and meet the CAH conditions of participation under 42 CFR part 485, subpart F, will be certified as CAHs by CMS. Regulations governing payments to CAHs for services to Medicare beneficiaries are located in 42 CFR part 413.

2. Frontier Community Health Integration Project Demonstration

a. Introduction

The Frontier Community Health Integration Project Demonstration was originally authorized by section 123 of the Medicare Improvements for Patients and Providers Act of 2008 (Pub. L. 110–275). The demonstration has been extended by section 129 of the Consolidated Appropriations Act, 2021 (Pub. L. 116–260) for an additional 5 years. In this final rule, we are summarizing the status of the demonstration program, and the ongoing methodologies for implementation and budget neutrality for the demonstration extension period.

b. Background and Overview

As discussed in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49144 through 49147), section 123 of the Medicare Improvements for Patients and Providers Act of 2008, as amended by section 3126 of the Affordable Care Act, authorized a demonstration project to allow eligible entities to develop and test new models for the delivery of health care services in eligible counties in order to improve access to and better integrate the delivery of acute care, extended care and other health care services to Medicare beneficiaries. The demonstration was titled “Demonstration Project on Community Health Integration Models in Certain Rural Counties,” and commonly known as the Frontier Community Health Integration Project (FCHIP) Demonstration.

The authorizing statute stated the eligibility criteria for entities to be able to participate in the demonstration. An eligible entity, as defined in section 123(d)(1)(B) of Public Law 110–275, as amended, is a Medicare Rural Hospital Flexibility Program (MRHFP) grantee under section 1820(g) of the Act (that is, a CAH); and is located in a state in which at least 65 percent of the counties in the state are counties that have 6 or less residents per square mile.

The authorizing statute stipulated several other requirements for the demonstration. In addition, section 123(g)(1)(B) of Public Law 110–275 required that the demonstration be budget neutral. Specifically, this provision stated that, in conducting the demonstration project, the Secretary shall ensure that the aggregate payments made by the Secretary do not exceed the amount which the Secretary estimates would have been paid if the demonstration project under the section were not implemented. Furthermore, section 123(i) of Public Law 110–275 stated that the Secretary may waive such requirements of titles XVII and XIX of the Act as may be necessary and appropriate for the purpose of carrying out the demonstration project, thus allowing the waiver of Medicare payment rules encompassed in the demonstration. CMS selected CAHs to participate in four interventions, under which specific waivers of Medicare payment rules would allow for enhanced payment for telehealth, skilled nursing facility/nursing facility beds, ambulance services, and home health services. These waivers were formulated with the goal of increasing access to care with no net increase in costs.

Section 123 of Public Law 110–275 initially required a 3-year period of performance. The FCHIP Demonstration began on August 1, 2016, and concluded on July 31, 2019 (referred to in this section of the final rule as the “initial period”). Subsequently, section 129 of the Consolidated Appropriations Act, 2021 (Pub. L. 116–260) extended the demonstration by 5 years (referred to in this section of the final rule as the “extension period”). The Secretary is required to conduct the demonstration for an additional 5-year period. CAHs participating in the demonstration project during the extension period began such participation in their cost reporting year that began on or after January 1, 2022.

As described in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49144 through 49147), 10 CAHs were selected for participation in the demonstration initial period. The selected CAHs were located in three states—Montana, Nevada, and North Dakota—and participated in three of the four interventions identified in the FY 2023 IPPS/LTCH PPS final rule. Each CAH was allowed to participate in more than one of the interventions. None of the selected CAHs were participants in the home health intervention, which was the fourth intervention.

In the FY 2022 IPPS/LTCH PPS final rule (86 FR 45323 through 45328), CMS concluded that the initial period of the FCHIP Demonstration (covering the performance period of August 1, 2016, to July 31, 2019) had satisfied the budget neutrality requirement described in section 123(g)(1)(B) of Public Law 110–275. Therefore, CMS did not apply a budget neutrality payment offset policy for the initial period of the demonstration.

Section 129 of Public Law 116–260, stipulates that only the 10 CAHs that participated in the initial period of the FCHIP Demonstration are eligible to participate during the extension period. Among the eligible CAHs, five have elected to participate in the extension period. The selected CAHs are located in two states—Montana and North Dakota—and are implementing three of the four interventions. The eligible CAH participants elected to change the number of interventions and payment waivers they would participate in during the extension period. CMS accepted and approved the CAHs intervention and payment waiver updates. For the extension period, four
CAHs are participants in the telehealth intervention, three CAHs are participants in the skilled nursing facility/nursing facility bed intervention, and three CAHs are participants in the ambulance services intervention. As with the initial period, each CAH was allowed to participate in more than one of the interventions during the extension period. None of the selected CAHs are participants in the home health intervention, which was the fourth intervention.

c. Intervention Payment and Payment Waivers

As described in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49144 through 49147), CMS waived certain Medicare rules for CAHs participating in the demonstration initial period to allow for alternative reasonable cost-based payment methods in the three distinct intervention service areas: telehealth services, ambulance services, and skilled nursing facility/nursing facility (SNF/NF) beds expansion. The payments and payment waiver provisions only apply if the CAH is a participant in the associated intervention. CMS Intervention Payment and Payment Waivers for the demonstration extension period consist of the following:

(1) Telehealth Services Intervention Payments

CMS waives section 1834(m)(2)(B) of the Act, which specifies the facility fee to the originating site for Medicare telehealth services. CMS modifies the facility fee payment specified under section 1834(m)(2)(B) of the Act to make reasonable cost-based reimbursement to the participating CAH where the participating CAH serves as the originating site for a telehealth service furnished to an eligible telehealth recipient, as defined in section 1834(m)(4)(B) of the Act. CMS reimburses the participating CAH serving as the originating site at 101 percent of its reasonable costs for overhead, salaries and fringe benefits associated with telehealth services at the participating CAH. CMS does not fund or provide reimbursement to the participating CAH for the purchase of new telehealth equipment.

CMS waives section 1834(m)(2)(A) of the Act, which specifies that the payment for a telehealth service furnished by a distant site practitioner is the same as it would be if the service had been furnished in-person. CMS modifies the payment amount specified for telehealth services under section 1834(m)(2)(A) of the Act to make reasonable cost-based reimbursement to the participating CAH for telehealth services furnished by a physician or practitioner located at distant site that is a participating CAH that is billing for the physician or practitioner professional services. Whether the participating CAH has or has not elected Optional Payment Method II for outpatient services, CMS would pay the participating CAH 101 percent of reasonable costs for telehealth services when a physician or practitioner has reassigned their billing rights to the participating CAH and furnishes telehealth services from the participating CAH as a distant site practitioner. This means that participating CAHs that are billing under the Standard Method on behalf of employees who are physicians or practitioners (as defined in section 1834(m)(4)(D) and (E) of the Act, respectively) would be eligible to bill for distant site telehealth services furnished by these physicians and practitioners. Additionally, CAHs billing under the Optional Method would be reimbursed based on 101 percent of reasonable costs, rather than paid based on the Medicare physician fee schedule, for the distant site telehealth services furnished by physicians and practitioners who have reassigned their billing rights to the CAH. For distant site telehealth services furnished by physicians or practitioners who have not reassigned billing rights to a participating CAH, payment to the distant site physician or practitioner would continue to be made as usual under the Medicare physician fee schedule. Except as described herein, CMS does not waive any other provisions of section 1834(m) of the Act for purposes of the telehealth services intervention payments, including the scope of Medicare telehealth services as established under section 1834(m)(4)(F) of the Act.

(2) Ambulance Services Intervention Payments

CMS waives 42 CFR 413.70(b)(5)(i)(D) and section and 1834(l)(6) of the Act, which provides that payment for ambulance services furnished by a CAH, or an entity owned and operated by a CAH, is 101 percent of the reasonable costs of the ambulance services, but only if the CAH or the entity is the only provider or supplier of ambulance services located within a 35-mile drive of the CAH, excluding ambulance providers or suppliers that are not legally authorized to furnish ambulance services to transport individuals to or from the CAH. The participating CAH would be paid 101 percent of reasonable costs for its ambulance services regardless of whether there is any provider or supplier of ambulance services located within a 35-mile drive of the participating CAH or participating CAH-owned and operated entity. CMS would not make cost-based payment to the participating CAH for any new capital (for example, vehicles) associated with ambulance services. This waiver does not modify any other Medicare rules regarding or affecting the provision of ambulance services.

(3) SNF/NF Beds Expansion Intervention Payments

CMS waives 42 CFR 485.620(a) and 485.645(a)(2) and section 1820(c)(2)(B)(iii) of the Act which limit CAHs to maintaining no more than 25 inpatient beds, including beds available for acute inpatient or swing bed services. CMS waives 1820(f) of the Act permitting designating or certifying a facility as a critical access hospital for which the facility at any time is furnishing inpatient beds which exceed more than 25 beds. Under this waiver, if the participating CAH has received swing bed approval from CMS, the participating CAH may maintain up to ten additional beds (for a total of 35 beds) available for acute inpatient or swing bed services; however, the participating CAH may only use these 10 additional beds for nursing facility or skilled nursing facility level of care. CMS would pay the participating CAH 101 percent of reasonable costs for its SNF/NF services furnished in the 10 additional beds.

d. Budget Neutrality

(1) Budget Neutrality Requirement

In the FY 2022 IPPS/LTCH PPS final rule (86 FR 45323 through 45328), we finalized a policy to address the budget neutrality requirement for the demonstration initial period. As explained in the FY 2022 IPPS/LTCH PPS final rule, we based our selection of CAHs for participation in the demonstration with the goal of maintaining the budget neutrality of the demonstration on its own terms meaning that the demonstration would produce savings from reduced transfers and admissions to other health care providers, offsetting any increase in Medicare payments as a result of the demonstration. However, because of the small size of the demonstration and uncertainty associated with the projected Medicare utilization and costs, the policy we finalized for the demonstration initial period of performance in the FY 2022 IPPS/LTCH PPS final rule provides a contingency plan to ensure that the budget neutrality...
requirement in section 123 of Public Law 110–275 is met.

In the FY 2023 IPPS/LTCH PPS final rule, we adopted the same budget neutrality policy contingency plan used during the demonstration initial period to ensure that the budget neutrality requirement in section 123 of Public Law 110–275 is met during the demonstration extension period. If analysis of claims data for Medicare beneficiaries receiving services at each of the participating CAHs, as well as from other data sources, including cost reports for the participating CAHs, shows that increases in Medicare payments under the demonstration during the 5-year extension period are not sufficiently offset by reductions elsewhere, we would recoup the additional expenditures attributable to the demonstration through a reduction in payments to all CAHs nationwide.

As explained in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49144 through 49147), because of the small scale of the demonstration, we indicated that we did not believe it would be feasible to implement budget neutrality for the demonstration extension period by reducing payments to only the participating CAHs. Therefore, in the event that this demonstration extension period is found to result in aggregate payments in excess of the amount that would have been paid if this demonstration extension period were not implemented, CMS policy is to comply with the budget neutrality requirement finalized in the FY 2023 IPPS/LTCH PPS final rule, by reducing payments to all CAHs, not just those participating in the demonstration extension period.

In the FY 2023 IPPS/LTCH PPS final rule, we stated that we believe it is appropriate to make any payment reductions across all CAHs because the F CHIP Demonstration was specifically designed to test innovations that affect delivery of services by the CAH provider category. We explained our belief that the language of the statutory budget neutrality requirement at section 123(g)(1)(B) of Public Law 110–275 permits the agency to implement the budget neutrality provision in this manner. The statutory language merely refers to ensuring that aggregate payments made by the Secretary do not exceed the amount which the Secretary estimates would have been paid if the demonstration project was not implemented, and does not identify the range across which aggregate payments must be held equal.

In the FY 2023 IPPS/LTCH PPS final rule, we finalized a policy that in the event the demonstration extension period is found not to have been budget neutral, any excess costs would be recouped within one fiscal year. We explained our belief that this policy is a more efficient timeframe for the government to conclude the demonstration operational requirements (such as analyzing claims data, cost report data or other data sources) to adjudicate the budget neutrality payment recoupment process due to any excess cost that occurred as result of the demonstration extension period.

(2) FCHIP Budget Neutrality Methodology and Analytical Approach

As explained in the FY 2022 IPPS/LTCH PPS final rule, we finalized a policy to address the demonstration budget neutrality methodology and analytical approach for the initial period of the demonstration. In the FY 2023 IPPS/LTCH PPS final rule, we finalized a policy to adopt the budget neutrality methodology and analytical approach used during the demonstration initial period to ensure budget neutrality for the extension period. The analysis of budget neutrality during the initial period of the demonstration identified both the costs related to providing the intervention services under the FCHIP Demonstration and any potential downstream effects of the intervention-related services, including any savings that may have accrued.

The budget neutrality analytical approach for the demonstration initial period incorporated two major data components: (1) Medicare cost reports; and (2) Medicare administrative claims. As described in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45323 through 45328), CMS computed the cost of the demonstration for each fiscal year of the demonstration initial period using Medicare cost reports for the participating CAHs, and Medicare administrative claims and enrollment data for beneficiaries who received demonstration intervention services.

In addition, in order to capture the full impact of the interventions, CMS developed a statistical modeling, Difference-in-Difference (DiD) regression analysis to estimate demonstration expenditures and compute the impact of expenditures on the intervention services by comparing cost data for the demonstration and non-demonstration groups using Medicare administrative claims across the demonstration period of performance under the initial period of the demonstration. The DiD regression analysis would compare the direct cost and potential downstream effects of intervention services, including any savings that may have accrued, during the baseline and performance period for both the demonstration and comparison groups.

Second, the Medicare administrative claims analysis would be reconciled using data obtained from auditing the participating CAHs’ Medicare cost reports. We would estimate the costs of the demonstration using “as submitted” cost reports for each hospital’s financial fiscal year participation within each of the demonstration extension period performance years. Each CAH has its own Medicare cost report end date applicable to the 5-year period of performance for the demonstration extension period. The cost report is structured to gather costs, revenues and statistical data on the provider’s financial fiscal period. As a result, we finalized a policy in the FY 2023 IPPS/LTCH PPS final rule that we would determine the final budget neutrality results for the demonstration extension once complete data is available for each CAH for the demonstration extension period.


As stated in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49144 through 49147), our policy for implementing the 5-year extension period for section 129 of Public Law 116–260 follows same budget neutrality methodology and analytical approach as the demonstration initial period methodology. While we expect to use the same methodology that was used to assess the budget neutrality of the FCHIP Demonstration during initial period of the demonstration to assess the financial impact of the demonstration during this extension period, upon receiving data for the extension period, we may update and/or modify the FCHIP budget neutrality methodology and analytical approach to ensure that the full impact of the demonstration is appropriately captured.

f. Total Budget Neutrality Offset Amount for FY 2024

At this time, for the FY 2024 IPPS/LTCH PPS final rule, while this discussion represents our anticipated approach to assessing the financial impact of the demonstration extension period based on upon receiving data for the full demonstration extension period, we may update and/or modify the FCHIP Demonstration budget neutrality methodology and analytical approach to ensure that the full impact of the
demonstration is appropriately captured.

We received no comments on our proposal not to apply a budget neutrality payment offset to payments to CAHs in FY 2024. Therefore, we are finalizing this provision without modification. This policy will have no impact for any national payment system for FY 2024.

VIII. Changes to the Long-Term Care Hospital Prospective Payment System (LTCH PPS) for FY 2024

A. Background of the LTCH PPS

1. Legislative and Regulatory Authority

Section 123 of the Medicare, Medicaid, and SCHIP (State Children’s Health Insurance Program) Balanced Budget Refinement Act of 1999 (BBRA) (Pub. L. 106–113), as amended by section 307(b) of the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 (BIPA) (Pub. L. 106–554), provides for payment for both the operating and capital-related costs of hospital inpatient stays in long-term care hospitals (LTCHs) under Medicare Part A based on prospectively set rates. The Medicare prospective payment system (PPS) for LTCHs applies to hospitals that are described in section 1886(d)(1)(B)(iv) of the Act, effective for cost reporting periods beginning on or after October 1, 2002.

Section 1886(d)(1)(B)(iv)(I) of the Act originally defined an LTCH as a hospital that has an average inpatient length of stay (as determined by the Secretary) of greater than 25 days. Section 1886(d)(1)(B)(iv)(II) of the Act also provided an alternative definition of LTCHs (“subclause II” LTCHs).

However, section 15008 of the 21st Century Cures Act (Pub. L. 114–255) amended section 1886 of the Act to exclude former “subclause II” LTCHs from being paid under the LTCH PPS and created a new category of IPPS-excluded hospitals, which we refer to as “extended neonatal intensive care hospitals,” to be paid as hospitals that were formerly classified as “subclause (II)” LTCHs (82 FR 38298).

Section 123 of the BBRA requires the PPS for LTCHs to be a “per discharge” system with a diagnosis-related group (DRG) based patient classification system that reflects the differences in patient resource use and costs in LTCHs.

Section 307(b)(1) of the BIPA, among other things, mandates that the Secretary shall examine, and may petition for, payments under the LTCH PPS, including adjustments to DRG weights, area wage adjustments, geographic reclassification, outliers, updates, and a disproportionate share adjustment.

In the August 30, 2002 Federal Register, we issued a final rule that implemented the LTCH PPS authorized under the BBRA and BIPA (67 FR 55954). For the initial implementation of the LTCH PPS (FYs 2003 through 2007), the system used information from LTCH patient records to classify patients into distinct long-term care-diagnosis-related groups (LTCDRGs) based on clinical characteristics and expected resource needs. Beginning in FY 2008, we adopted the Medicare severity-long-term care-diagnosis related groups (MS–LTC–DRGs) as the patient classification system used under the LTCH PPS. Payments are calculated for each MS–LTC–DRG and provisions are made for appropriate payment adjustments. Payment rates under the LTCH PPS are updated annually and published in the Federal Register.

The LTCH PPS replaced the reasonable cost payment system under the Tax Equity and Fiscal Responsibility Act of 1982 (TEFRA) (Pub. L. 97–248) for payments for inpatient services provided by an LTCH with a cost reporting period beginning on or after October 1, 2002. (The regulations implementing the TEFRA reasonable-cost-based payment provisions were located at 42 CFR part 413.) With the implementation of the PPS for acute care hospitals authorized by the Social Security Amendments of 1983 (Pub. L. 98–21), which added section 1886(d) to the Act, certain hospitals, including LTCHs, were excluded from the PPS for acute care hospitals and paid their reasonable costs for inpatient services subject to a per discharge limitation or target amount under the TEFRA system. For each cost reporting period, a hospital specific ceiling on payments was determined by multiplying the hospital’s updated target amount by the number of total current year Medicare discharges. (Generally, in this section of the preamble of this final rule, when we refer to discharges, we describe Medicare discharges.) The August 30, 2002 final rule further details the payment policy under the TEFRA system (67 FR 55954).

In the August 30, 2002 final rule, we provided for a 5-year transition period from payments under the TEFRA system to payments under the LTCH PPS. During this 5-year transition period, an LTCH’s total payment under the PPS was based on an increasing percentage of the LTCH’s total payment under the Federal rate. Beginning with LTCHs’ cost reporting periods beginning on or after October 1, 2006, total LTCH PPS payments are based on 100 percent of the Federal rate.

In addition, in the August 30, 2002 final rule, we presented an in-depth discussion of the LTCH PPS, including the patient classification system, relative weights, payment rates, additional payments, and the budget neutrality requirements mandated by section 123 of the BBRA. The same final rule that established regulations for the LTCH PPS under 42 CFR part 412, subpart O, also contained LTCH provisions related to covered inpatient services, limitation on charges to beneficiaries, medical review requirements, furnishing of inpatient hospital services directly or under arrangement, and reporting and recordkeeping requirements. We refer readers to the August 30, 2002 final rule for a comprehensive discussion of the research and data that supported the establishment of the LTCH PPS (67 FR 55954).

In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49601 through 49623), we implemented the provisions of the Pathway for Sustainable Growth Rate (SGR) Reform Act of 2013 (Pub. L. 113–67), which mandated the application of the “site neutral” payment rate under the LTCH PPS for discharges that do not meet the statutory criteria for exclusion beginning in FY 2016. For cost reporting periods beginning on or after October 1, 2015, discharges that do not meet certain statutory criteria for exclusion are paid based on the site neutral payment rate. Discharges that do meet the statutory criteria continue to receive payment based on the LTCH PPS standard Federal payment rate. For more information on the statutory requirements of the Pathway for SGR Reform Act of 2013, we refer readers to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49601 through 49623) and the FY 2017 IPPS/LTCH PPS final rule (81 FR 57068 through 57075).

In the FY 2018 IPPS/LTCH PPS final rule, we implemented several provisions of the 21st Century Cures Act (“the Cures Act”) (Pub. L. 114–255) that affected the LTCH PPS. (For more information on these provisions, we refer readers to 82 FR 38299.)

In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41529), we made conforming changes to our regulations implementing the provisions of section 51005 of the Bipartisan Budget Act of 2018 (Pub. L. 115–123), which extended reasonable cost concepts, unless an LTCH made a one-time election to be paid based on 100 percent of the Federal rate. Beginning with LTCHs’ cost reporting periods beginning on or after October 1, 2006, total LTCH PPS payments are based on 100 percent of the Federal rate.
the transitional blended payment rate for site neutral payment rate cases for an additional 2 years. We refer readers to section VII.C. of the preamble of the FY 2019 IPPS/LTCH PPS final rule for a discussion of our final policy. In addition, in the FY 2019 IPPS/LTCH PPS final rule, we removed the 25-percent threshold policy under 42 CFR 412.538, which was a payment adjustment that was applied to payments for Medicare patient LTCH discharges when the number of such patients originating from any single referring hospital was in excess of the applicable threshold for given cost reporting period.

In the FY 2020 IPPS/LTCH PPS final rule (84 FR 42439), we further revised our regulations to implement the provisions of the Pathway for SGR Reform Act of 2013 (Pub. L. 113–67) that relate to the payment adjustment for discharges from LTCHs that do not maintain the requisite discharge payment percentage and the process by which such LTCHs may have the payment adjustment discontinued.

2. Criteria for Classification as an LTCH

a. Classification as an LTCH

Under the regulations at § 412.23(e)(1), to qualify to be paid under the LTCH PPS, a hospital must have a provider agreement with Medicare. Furthermore, § 412.23(e)(2)(i), which implements section 1886(d)(1)(B)(iv) of the Act, requires that a hospital have an average Medicare inpatient length of stay of greater than 25 days to be paid under the LTCH PPS. In accordance with section 1206(a)(3) of the Pathway for SGR Reform Act of 2013 (Pub. L. 113–67), as amended by section 15007 of Public Law 114–255, we amended our regulations to specify that Medicare Advantage plans’ and site neutral payment rate discharges are excluded from the calculation of the average length of stay for all LTCHs, for discharges occurring in cost reporting periods beginning on or after October 1, 2015.

b. Hospitals Excluded From the LTCH PPS

The following hospitals are paid under special payment provisions, as described in § 412.22(c) and, therefore, are not subject to the LTCH PPS rules:

• Veterans Administration hospitals.

• Hospitals that are reimbursed under State cost control systems approved under 42 CFR part 403.

• Hospitals that are reimbursed in accordance with demonstration projects authorized under section 402(a) of the Social Security Amendments of 1967 (Pub. L. 90–248) (42 U.S.C. 1395b-1), section 222(a) of the Social Security Amendments of 1972 (Pub. L. 92–603) (42 U.S.C. 1395b1 (note)) (Statewide-all payer systems, subject to the rate-of increase test at section 1814(b) of the Act), or section 3201 of the Patient Protection and Affordable Care Act (Pub. L. 111–148) (42 U.S.C. 1315a).

• Nonparticipating hospitals furnishing emergency services to Medicare beneficiaries.

3. Limitation on Charges to Beneficiaries

In the August 30, 2002 final rule, we presented an in-depth discussion of beneficiary liability under the LTCH PPS (67 FR 55974 through 55975). This discussion was further clarified in the RY 2005 LTCH PPS final rule (69 FR 25676). In keeping with those discussions, if the Medicare payment to the LTCH is the full LTC–DRG payment amount, consistent with other established hospital prospective payment systems, § 412.507 currently provides that an LTCH may not bill a Medicare beneficiary for more than the deductible and coinsurance amounts as specified under §§ 409.82, 409.83, and 409.87, and for items and services specified under § 489.30(a). However, under the LTCH PPS, Medicare will only pay for services furnished during the days for which the beneficiary has coverage until the short-stay outlier (SSO) threshold is exceeded. If the Medicare payment was for a SSO case (in accordance with § 412.529), and that payment was less than the full LTC–DRG payment amount because the beneficiary had insufficient coverage as a result of the remaining Medicare days, the LTCH also is currently permitted to charge the beneficiary for services delivered on those uncovered days (in accordance with § 412.507). In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49623), we amended our regulations to expressly limit the charges that may be imposed upon beneficiaries whose LTCHs’ discharges are paid at the site neutral payment rate under the LTCH PPS. In the FY 2017 IPPS/LTCH PPS final rule (81 FR 57102), we amended the regulations under § 412.507 to clarify our existing policy that blended payments made to an LTCH during its transitional period (that is, an LTCH’s payment for discharges occurring in cost reporting periods beginning in FYs 2016 through 2019) are considered to be site neutral payment rate payments.

4. Best Available Data

We refer readers to section I.E. of the preamble of this final rule for our discussion on our use of the most recent data available for the FY 2024 LTCH PPS ratesetting, including the FY 2022 MedPAR claims and FY 2021 cost report data.

Comment: We received several comments unrelated to LTCH PPS proposals included in the proposed rule. For example, some commenters requested changes to the structure of the site neutral payment policy or the calculation of the average length of stay.

Response: We appreciate the commenters’ feedback and will keep these comments in mind for future rulemaking.

B. Medicare Severity Long-Term Care Diagnosis-Related Group (MS–LTC–DRG) Classifications and Relative Weights for FY 2024

1. Background

Section 123 of the BBRA required that the Secretary implement a PPS for LTCHs to replace the cost-based payment system under TEFRA. Section 307(b)(1) of the BIPA modified the requirements of section 123 of the BBRA by requiring that the Secretary examine the feasibility and the impact of basing payment under the LTCH PPS on the use of existing (or refined) hospital DRGs that have been modified to account for different resource use of LTCH patients.

Under both the IPPS and the LTCH PPS, the DRG-based classification system uses information on the claims for inpatient discharges to classify patients into distinct groups (for example, DRGs) based on clinical characteristics and expected resource needs. When the LTCH PPS was implemented for cost reporting periods beginning on or after October 1, 2002, we adopted the same DRG patient classification system utilized at that time under the IPPS. We referred to this patient classification system as the “long-term care diagnosis-related groups (LTC–DRGs).” As part of our efforts to better recognize severity of illness among patients, in the FY 2008 IPPS final rule with comment period (72 FR 47130), we adopted the MS–DRGs and the Medicare severity long-term care diagnosis-related groups (MS–LTC–DRGs) under the IPPS and the LTCH PPS, respectively, effective beginning October 1, 2007 (FY 2008). For a full description of the development, implementation, and rationale for the use of the MS–DRGs and MS–LTC–DRGs, we refer readers to the FY 2008 IPPS final rule with comment period (72 FR 47141 through 47175 and 47277 through 47299). (We note that, in that same final rule, we revised the regulations at § 412.503 to specify that for LTCH discharges occurring on
after October 1, 2007, when applying the provisions of 42 CFR part 412, subpart Q, applicable to LTCHs for policy descriptions and payment calculations, all references to LTC–
DRGs would be considered a reference to MS–LTC–DRGs. For the remainder of this section, we present the discussion in terms of the current MS–LTC–DRG patient classification system unless specifically referring to the previous
LTC–DRG patient classification system that was in effect before October 1, 2007.)

Consistent with section 123 of the BBRA, as amended by section 307(b)(1) of the BIPA, and §412.515 of the
regulations, we use information derived from LTCH PPS patient records to classify LTCH discharges into distinct
MS–LTC–DRGs based on clinical characteristics and estimated resource needs. As noted previously, we adopted
the same DRG patient classification system utilized at that time under the
IPPS. The MS–DRG classifications are updated annually, which has resulted in the
number of MS–DRGs changing over time. For FY 2024, there will be 766
MS–DRG, and by extension, MS–LTC–
DRG, groupings based on the changes,
as discussed in section II.E. of the preamble of this final rule.

Although the patient classification system used under both the LTCH PPS and the IPPS are the same, the relative
weights are different. The established relative weight methodology and data
used under the LTCH PPS result in relative weights under the LTCH PPS that reflect the differences in patient
resource use of LTCH patients, consistent with section 123(a)(1) of the
BBRA. That is, we assign an appropriate weight to the MS–LTC–DRGs to account for the differences in resource use by patients exhibiting the case complexity and multiple medical problems characteristic of LTCH patients.

2. Patient Classifications Into MS–LTC–
DRGs
a. Background

The MS–DRGs (used under the IPPS) and the MS–LTC–DRGs (used under the
LTCH PPS) are based on the CMS DRG structure. As noted previously in this
section, we refer to the DRGs under the
LTCH PPS as MS–LTC–DRGs although they are structurally identical to the
MS–DRGs used under the IPPS.

The MS–DRGs are organized into 25 major diagnostic categories (MDCs),
most of which are based on a particular organ system of the body: the remainder
involve multiple organ systems (such as MDC 22, Burns). Within most MDCs,
cases are then divided into surgical

DRGs and medical DRGs. Surgical DRGs are assigned based on a surgical
hierarchy that orders operating room (O.R.) procedures or groups of O.R.
procedures by resource intensity. The GROUPER software program does not
recognize all ICD–10–PCS procedure codes as procedures affecting DRG
assignment. That is, procedures that are not surgical (for example, EKGs) or are
minor surgical procedures (for example, a biopsy of skin and subcutaneous
tissue (procedure code 0JBH3ZX)) do not affect the MS–LTC–DRG assignment
based on their presence on the claim.

Generally, under the LTCH PPS, a Medicare payment is made at a
predetermined specific rate for each discharge that varies based on the MS–
LTC–DRG to which a beneficiary’s discharge is assigned. Cases are
classified into MS–LTC–DRGs for payment based on the following six data elements:

- Principal diagnosis.
- Additional or secondary diagnoses. Surgical procedures.
- Age.
- Sex.
- Discharge status of the patient. Currently, for claims submitted using the
version ASC X12 5010 standard, up to 25 diagnosis codes and 25 procedure
codes are considered for an MS–DRG assignment. This includes one principal
diagnosis and up to 24 secondary diagnoses for severity of illness
determinations. (For additional information on the processing of up to 25
diagnosis codes and 25 procedure codes on hospital inpatient claims, we refer
readers to section II.G.11.c. of the preamble of the FY 2011 IPPS/LTCH PPS
final rule (75 FR 50127).)

Under the HIPAA transactions and code sets regulations at 45 CFR parts
160 and 162, covered entities must comply with the adopted transaction
standards and operating rules specified in subparts I through S of part 162.
Among other requirements, on or after January 1, 2012, covered entities are
required to use the ASC X12 Standards for Electronic Data Interchange
Technical Report Type 3—Health Care Claim: Institutional (837), May 2006,
ASC X12N/005010X223, and Type 1
Errata to Health Care Claim: Institutional (837) ASC X12 Standards for
Electronic Data Interchange Technical Report Type 3, October 2007,
ASC X12N/005010X233A1 for the
health care claims or equivalent encounter information transaction (45 CFR 162.1102(c)).

HIPAA requires covered entities to use the appropriate medical data code sets when conducting HIPAA
transactions (45 CFR 162.1000).

Currently, upon the discharge of the patient, the LTCH must assign
appropriate diagnosis and procedure codes from the International
Classification of Diseases, 10th
Revision, Clinical Modification (ICD–
10–CM) for diagnosis coding and the
International Classification of Diseases, 10th
Revision, Procedure Coding System (ICD–10–PCS) for inpatient
hospital procedure coding, both of
which were required to be implemented
October 1, 2015 (45 CFR 162.1002(c)(2)
and (3)). For additional information on the implementation of the ICD–10
coding system, we refer readers to
section II.F.1. of the preamble of the FY
2017 IPPS/LTCH PPS final rule (81 FR
56787 through 56790) and section II.E.1.
of the preamble of this final rule.

Additional coding instructions and examples are published in the AHA’s
Coding Clinic for ICD–10–CM/PCS.

To create the MS–DRGs (and by
extension, the MS–LTC–DRGs), base
DRGs were subdivided according to the
presence of specific secondary
diagnoses designated as complications or comorbidities (CCs) into one, two, or
three levels of severity, depending on the impact of the CCs on resources used
for those cases. Specifically, there are sets of MS–DRGs that are split into 2 or
3 subgroups based on the presence or absence of a CC or a major complication
or comorbidity (MCC). We refer readers to
section II.D. of the preamble of the FY
2008 IPPS final rule with comment
period for a detailed discussion about the
creation of MS–DRGs based on
severity of illness levels (72 FR 47141
through 47175).

Medicare Administrative Contractors
(MACs) enter the clinical and
demographic information submitted by
LTCHs into their claims processing
systems and subject this information to
a series of automated screening
processes called the Medicare Code
Editor (MCE). These screens are
designed to identify cases that require
further review before assignment into a
MS–LTC–DRG can be made. During this
process, certain types of cases are
selected for further explanation (74 FR
43949).

After screening through the MCE,
each claim is classified into the
appropriate MS–LTC–DRG by the
Medicare LTCH GROUPER software on
the basis of diagnosis and procedure
codes and other demographic
information (age, sex, and discharge
status). The GROUPER software used
under the LTCH PPS is the same
GROUPER software program used under
the IPPS. Following the MS–LTC–
DRG assignment, the MAC determines the
prospective payment amount by using
the Medicare PRI CER program, which accounts for hospital-specific adjustments. Under the LTCH PPS, we provide an opportunity for LTCHs to review the MS–LTC–DRG assignments made by the MAC and to submit additional information within a specified timeframe as provided in § 412.513(c).

The GROUPER software is used both to classify past cases to measure relative hospital resource consumption to establish the MS–LTC–DRG relative weights and to classify current cases for purposes of determining payment. The records for all Medicare hospital inpatient discharges are maintained in the MedPAR file. The data in this file are used to evaluate possible MS–DRG and MS–LTC–DRG classification changes and to recalibrate the MS–DRG and MS–LTC–DRG relative weights during our annual update under both the IPPS (§ 412.60(e)) and the LTCH PPS (§ 412.517), respectively.

b. Changes to the MS–LTC–DRGs for FY 2024

As specified by our regulations at § 412.517(a), which require that the MS–LTC–DRG classifications and relative weights be updated annually, and consistent with our historical practice of using the same patient classification system under the LTCH PPS as is used under the IPPS, in this final rule, as proposed, we updated the MS–LTC–DRG classifications effective October 1, 2023 through September 30, 2024 (FY 2024) consistent with changes to specific MS–DRG classifications presented in section II.F. of the preamble of this final rule. Accordingly, the MS–LTC–DRGs for FY 2024 are the same as the MS–DRGs being used under the IPPS for FY 2024. In addition, because the MS–LTC–DRGs for FY 2024 are the same as the MS–DRGs for FY 2024, the other changes that affect MS–DRG (and by extension MS–LTC–DRG) assignments under GROUPER Version 41, as discussed in section II.E. of the preamble of this final rule, including the changes to the MCE software and the ICD–10–CM/PCS coding system, are also applicable under the LTCH PPS for FY 2024.

3. Development of the FY 2024 MS–LTC–DRG Relative Weights

a. General Overview of the MS–LTC–DRG Relative Weights

One of the primary goals for the implementation of the LTCH PPS is to pay each LTCH an appropriate amount for the delivery of medical care to Medicare patients. The system must be able to account adequately for each LTCH’s case-mix to ensure both fair distribution of Medicare payments and access to adequate care for those Medicare patients whose care is costlier (67 FR 55984). To accomplish these goals, we have annually adjusted the LTCH PPS standard Federal prospective payment rate by the applicable relative weight in determining payment to LTCHs for each case. Under the LTCH PPS, relative weights for each MS–LTC–DRG are a primary element used to account for the variations in cost per discharge and resource utilization among the payment groups (§ 412.515). To ensure that Medicare patients classified to each MS–LTC–DRG have access to an appropriate level of services and to encourage efficiency, we calculate a relative weight for each MS–LTC–DRG that represents the resources needed by an average inpatient LTCH case in that MS–LTC–DRG. For example, cases in an MS–LTC–DRG with a relative weight of 2 would, on average, cost twice as much to treat as cases in an MS–LTC–DRG with a relative weight of 1.

The established methodology to develop the MS–LTC–DRG relative weights is generally consistent with the methodology established when the LTCH PPS was implemented in the August 30, 2002 LTCH PPS final rule (67 FR 55089 through 55991). However, there have been some modifications of our historical procedures for assigning relative weights in cases of zero volume or nonmonotonicity or both resulting from the adoption of the MS–LTC–DRGs. We also made a modification in conjunction with the implementation of the dual rate LTCH PPS payment structure beginning in FY 2016 to use LTCH claims data from only LTCH PPS standard Federal payment rate cases (or LTCH PPS cases that would have qualified for payment under the LTCH PPS standard Federal payment rate if the dual rate LTCH PPS payment structure had been in effect at the time of the discharge). We also adopted, beginning in FY 2023, a 10-percent cap policy on the reduction in a MS–LTC–DRG’s relative weight in a given year. (For details on the modifications to our historical procedures for assigning relative weights in cases of zero volume and nonmonotonicity or both, we refer readers to the FY 2008 IPPS/LTCH PPS final rule with comment period (72 FR 47289 through 47295) and the FY 2009 IPPS final rule (73 FR 48542 through 48550).) For details on our adoption of the 10-percent cap policy, we refer readers to the FY 2023 IPPS/LTCH PPS final rule (87 FR 49152 through 49154).

For purposes of determining the MS–LTC–DRG relative weights, under our historical methodology, there are three different categories of MS–LTC–DRGs based on volume of cases within specific MS–LTC–DRGs: (1) MS–LTC–DRGs with at least 25 applicable LTCH cases in the data used to calculate the relative weight, which are each assigned a unique relative weight; (2) low-volume MS–LTC–DRGs (that is, MS–LTC–DRGs that contain between 1 and 24 applicable LTCH cases that are grouped into quintiles); and (3) no-volume MS–LTC–DRGs that are cross-walked to other MS–LTC–DRGs based on the clinical similarities and assigned the relative weight of the cross-walked MS–LTC–DRG (as described later in this section in Step 3 of our methodology) and assigned the relative weight of the quintile; and (3) no-volume MS–LTC–DRGs that are cross-walked to other MS–LTC–DRGs based on the clinical similarities and assigned the relative weight of the cross-walked MS–LTC–DRG (as described later in this section in Step 8 of our methodology). For FY 2024, we are continuing to use applicable LTCH cases to establish the same volume-based categories to calculate the FY 2024 MS–LTC–DRG relative weights.

b. Development of the MS–LTC–DRG Relative Weights for FY 2024

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27064 through 27073), we presented our proposed methodology for determining the MS–LTC–DRG relative weights for FY 2024. In this section, we first respond to the public comments received regarding the proposed methodology and the proposed MS–LTC–DRG relative weights for FY 2024. As discussed in Section I.E., of the preamble to this final rule, we received several comments on our proposal to use FY 2022 data for purposes of the FY 2024 LTCH PPS ratessetting. While the comments were nearly all focused on the specific use of FY 2022 data when determining the FY 2024 outlier fixed-loss amount for LTCH PPS standard Federal payment rate cases, some commenters did state that CMS should not use FY 2022 data to calculate the MS–LTC–DRG relative weights without also modifying our proposed MS–LTC–DRG relative weight methodology. The commenters did not provide specific suggestions on what modifications CMS should make to the FY 2024 MS–LTC–DRG relative weight
methodology, but did express that modifications are necessary due to the impact of the COVID–19 PHE on the FY 2022 data. Since these comments were nearly all focused on the specific use of FY 2022 data when determining the FY 2024 outlier fixed-loss amount for LTCH PPS standard Federal payment rate cases, we have fully summarized and responded to all comments on the use of FY 2022 data for purposes of the FY 2024 LTCH PPS ratesetting in section V.D.3. of the Addendum to this final rule. For the reasons discussed in that section, we are finalizing our proposal to use FY 2022 data for purposes of the FY 2024 IPPS and LTCH PPS ratesetting. We also are finalizing, without modification, our proposed methodology for determining the FY 2024 MS–LTC–DRG relative weights.

Comment: A commenter stated that the proposed MS–LTC–DRG relative weights would have a negative impact on Virginia hospitals. The commenter asked that CMS readdress the proposed MS–LTC–DRG weight methodology, stating that it appears to be flawed due to the cases used in the calculations. The commenter did not specify what cases they believe make the methodology flawed or provide a specific suggestion on what modifications CMS should make to our proposed methodology.

Response: We thank the commenter for this suggestion to further study these MS–LTC–DRGs. We may consider this suggestion for future rulemaking.

Comment: A commenter objected to our proposal to continue to apply a budget neutrality adjustment to the MS–LTC–DRG relative weights so that the 10-percent cap on relative weight reductions is implemented in a budget neutral manner. This commenter urged CMS to fund this policy for FY 2024 with additional new funds rather than through a budget-neutrality reduction.

Response: We thank the commenter for this comment. However, we continue to believe it is appropriate to apply this policy in a budget neutral manner, consistent with the existing budget neutrality requirement for annual MS–LTC–DRG reclassification and recalibration, which we adopted to mitigate estimated fluctuations in estimated aggregate LTCH PPS payments (72 FR 26881 through 26882).

After consideration of the comments we received, we are finalizing, without modification, our proposed methodology for determining the MS–LTC–DRG relative weights for FY 2024. In the remainder of this section, we present our finalized methodology. We first list and provide a brief description of our steps for determining the FY 2024 MS–LTC–DRG relative weights. We then, later in this section, discuss in greater detail each step. (We note for FY 2023, to account for the impact of COVID–19 on the ratesetting data, we finalized a temporary modification to our relative weights methodology that established the FY 2023 MS–LTC–DRG relative weights as an average of the relative weights calculated both including and excluding COVID–19 cases. For FY 2024, as we proposed, we are returning to our historical relative weight methodology as described in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58908 through 58907), subject to a ten percent cap as described in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49162). For this reason, the steps presented in this section differ from those presented in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49155 through 49162).)

1. Prepare data for MS–LTC–DRG relative weight calculation. In this step, we select and group the applicable claims data used in the development of the MS–LTC–DRG relative weights.

• Step 1—Prepare data for MS–LTC–DRG relative weight calculation. In this step, we select and group the applicable claims data used in the development of the MS–LTC–DRG relative weights.
trim the applicable claims data to remove cases with a length of stay of 7 days or less.

- **Step 3—Establish low-volume MS–LTC–DRG quintiles.** In this step, we employ our established quintile methodology for low-volume MS–LTC–DRGs (that is, MS–LTC–DRGs with less than 25 cases).

- **Step 4—Remove statistical outliers.** In this step, we trim the applicable claims data to remove statistical outlier cases.

- **Step 5—Adjust charges for the effects of Short Stay Outliers (SSOs).** In this step, we adjust the number of applicable cases in each MS–LTC–DRG (or low-volume quintile) for the effect of SSO cases.

- **Step 6—Calculate the relative weights on an iterative basis using the hospital-specific relative weights methodology.** In this step, we use our established hospital-specific relative value (HSRV) methodology, which is an iterative process, to calculate the relative weights.

- **Step 7—Adjust the relative weights to account for nonmonotonically increasing relative weights.** In this step, we make adjustments that ensure that within each base MS–LTC–DRG, the relative weights increase by MS–LTC–DRG severity.

- **Step 8—Determine a relative weight for MS–LTC–DRGs with no applicable LTCH cases.** In this step, we cross-walk each no-volume MS–LTC–DRG to another MS–LTC–DRG for which we calculated a relative weight.

- **Step 9—Budget neutralize the uncapped relative weights.** In this step, to ensure budget neutrality in the annual update to the MS–LTC–DRG classifications and relative weights, we adjust the relative weights by a normalization factor and a budget neutrality factor that ensures estimated aggregate LTCH PPS payments will be unaffected by the updates to the MS–LTC–DRG classifications and relative weights.

- **Step 10—Apply the 10-percent cap to decreases in MS–LTC–DRG relative weights.** In this step, we limit the reduction of the relative weight for a MS–LTC–DRG to 10 percent of its prior year value. This 10-percent cap does not apply to zero-volume MS–LTC–DRGs or low-volume MS–LTC–DRGs.

- **Step 11—Budget neutralize the application of the 10-percent cap policy.** In this step, to ensure budget neutrality in the application of the MS–LTC–DRG cap policy, we adjust the relative weights by a budget neutrality factor that ensures estimated aggregate LTCH PPS payments will be unaffected by our application of the cap to the MS–LTC–DRG relative weights.

We next describe each of the 11 proposed steps for calculating the proposed FY 2024 MS–LTC–DRG relative weights in greater detail.

**Step 1—Prepare data for MS–LTC–DRG relative weight calculation.**

For the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27067), consistent with our proposal in section I.E. of the preamble of the proposed rule to use FY 2022 data for the FY 2023 LTCH PPS ratsetting, we obtained total charges from FY 2022 Medicare LTCH claims data from the December 2022 update of the FY 2022 MedPAR file and used proposed Version 41 of the GROUPER to classify LTCH cases. Consistent with our historical practice, we proposed that if better data become available, we would use those data and the finalized Version 41 of the GROUPER in establishing the FY 2024 MS–LTC–DRG relative weights in the final rule. Accordingly, in this final rule, we are establishing the FY 2024 MS–LTC–DRG relative weights based on updated FY 2022 Medicare LTCH claims data from the March 2023 update of the FY 2022 MedPAR file, which is the best available data at the time of development of this final rule, and the finalized Version 41 of the GROUPER to classify LTCH cases. To calculate the FY 2024 MS–LTC–DRG relative weights under the dual rate LTCH PPS payment structure, as we proposed, we continue to use applicable LTCH data, which includes our policy of only using cases that meet the criteria for exclusion from the site neutral payment rate (or would have met the criteria had they been in effect at the time of the discharge) (80 FR 40624).

Specifically, we began by first evaluating the LTCH claims data in the March 2023 update of the FY 2022 MedPAR file to determine which LTCH cases would meet the criteria for exclusion from the site neutral payment rate under § 412.522(b) or had the dual rate LTCH PPS payment structure applied to those cases at the time of discharge. We identified the FY 2022 LTCH cases that were not assigned to MS–LTC–DRGs 876, 880, 881, 882, 883, 884, 885, 886, 887, 894, 895, 896, 897, 945, and 946, which identify LTCH cases that do not have a principal diagnosis relating to a psychiatric diagnosis or to rehabilitation; and that either—

- The admission to the LTCH was "immediately preceded" by discharge from a subsection (d) hospital and the claim for the LTCH discharge includes the applicable procedure code that indicates at least 96 hours of ventilator services were provided during the LTCH stay, as we define under the ventilator criterion. Claims data from the FY 2022 MedPAR file that reported ICD–10–PCS procedure code S5A19S5Z were used to identify cases involving at least 96 hours of ventilator services in accordance with the ventilator criterion.

We note that section 3711(b)(2) of the CARES Act, which provided a waiver of the application of the site neutral payment rate for LTCH cases admitted during the COVID–19 PHE period, was in effect for the entirety of FY 2022. Therefore, all LTCH PPS cases in FY 2022 were paid the LTCH PPS standard Federal rate regardless of whether the discharge met the statutory patient criteria. However, for purposes of setting rates for LTCH PPS standard Federal rate cases for FY 2024 (including MS–LTC–DRG relative weights), we used FY 2022 cases that meet the statutory patient criteria without consideration to how those cases were paid in FY 2022.

Furthermore, consistent with our historical methodology, we excluded any claims in the resulting data set that were submitted by LTCHs that were all-inclusive rate providers and LTCHs that are paid in accordance with demonstration projects authorized under section 402(a) of Public Law 90–248 or section 222(a) of Public Law 92–603. In addition, consistent with our historical practice and our policies, we excluded any Medicare Advantage (Part C) claims in the resulting data. Such claims were identified based on the presence of a GHO Paid indicator value of “1” in the MedPAR files.

In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49448), we discussed an LTCH (CCN 312024) whose abnormal charging practices in FY 2021 led to the LTCH receiving an excessive amount of high cost outlier payments. In that rule, we stated our belief, based on information we received from the provider, that these abnormal charging practices would not persist into FY 2023. Therefore, we did not include their cases in our model for determining the FY 2023 outlier fixed-loss amount.

The FY 2022 MedPAR claims also reflect the abnormal charging practices of this LTCH. In the March 2023 update of the FY 2022 MedPAR file, we identified 166 LTCH PPS standard Federal rate cases for this LTCH. Of these 166 cases, 118 of the cases had charges that were exactly or
within ten dollars of $10 million. Since the majority of this LTCH’s FY 2022 claims reflect very little variation in charges, we do not believe they are an accurate reflection of relative resources used and therefore it would not be appropriate to use these claims in determining the FY 2024 MS–LTC–DRG relative weights. Therefore, as we proposed, we removed claims from CCN 312024 when determining the FY 2024 MS–LTC–DRG relative weights. We note, as discussed in section V of the addendum to this final rule, we also are removing this LTCH from all other FY 2024 ratesetting calculations, including the calculation of the area wage level adjustment budget neutrality factor and the fixed-loss amount for LTCH PPS standard Federal payment rate cases.

In summary, in general, we identified the claims data used in the development of the FY 2024 MS–LTC–DRG relative weights in this final rule by trimming claims data that would have been paid the site neutral payment rate had the provisions of the CARES Act not been in effect. We trimmed the claims data of all-inclusive rate providers reported in the March 2023 update of the FY 2022 MedPAR file and any Medicare Advantage claims data. There were no data from any LTCHs that are paid in accordance with a demonstration project reported in the March 2023 update of the FY 2022 MedPAR file, but had there been any, we would have trimmed the claims data from those LTCHs as well, in accordance with our established policy. We also removed all claims from CCN 312024.

We used the remaining data (that is, the applicable LTCH data) in the subsequent steps to calculate the MS–LTC–DRG relative weights for FY 2024.

Step 2—Remove cases with a length of stay of 7 days or less.

The next step in our calculation of the FY 2024 MS–LTC–DRG relative weights is to remove cases with a length of stay of 7 days or less. The MS–LTC–DRG relative weights reflect the average of resources used on representative cases of a specific type. Generally, cases with a length of stay of 7 days or less do not belong in an LTCH because these stays do not fully receive or benefit from treatment that is typical in an LTCH stay, and full resources are often not used in the earlier stages of admission to an LTCH. If we were to include stays of 7 days or less in the computation of the FY 2024 MS–LTC–DRG relative weights, the value of many relative weights would decrease and, therefore, payments would decrease to a level that may not be appropriate. We do not believe that it would be appropriate to compromise the integrity of the payment determination for those LTCH cases that actually benefit from and receive a full course of treatment at an LTCH by including data from these very short stays. Therefore, as we proposed, consistent with our existing relative weight methodology, in determining the FY 2024 MS–LTC–DRG relative weights, we removed LTCH cases with a length of stay of 7 days or less from applicable LTCH cases. (For additional information on what is removed in this step of the relative weight methodology, we refer readers to 67 FR 55989 and 74 FR 43959.)

Step 3—Establish low-volume MS–LTC–DRG quintiles.

To account for MS–LTC–DRGs with low-volume (that is, with fewer than 25 applicable LTCH cases), consistent with our existing methodology, as we proposed, we are continuing to employ the quintile methodology for low-volume MS–LTC–DRGs, such that we grouped the “low-volume MS–LTC–DRGs” (that is, MS–LTC–DRGs that contain between 1 and 24 applicable LTCH cases into one of five categories (quintiles) based on average charges (67 FR 55984 through 55995; 72 FR 47283 through 47288; and 81 FR 25148).

In this final rule, based on the best available data (that is, the March 2023 update of the FY 2022 MedPAR file), we identified 236 MS–LTC–DRGs that contained between 1 and 24 applicable LTCH cases. This list of MS–LTC–DRGs was then divided into 1 of the 5 low-volume quintiles. We assigned the low-volume MS–LTC–DRGs to specific low-volume quintiles by sorting the low-volume MS–LTC–DRGs in ascending order by average charge in accordance with our established methodology. Based on the data available for this final rule, the number of MS–LTC–DRGs with less than 25 applicable LTCH cases was not evenly divisible by 5. The quintiles each contained at least 47 MS–LTC–DRGs (236/5 = 47 with a remainder of 1). As we proposed, we employed our historical methodology of assigning each remainder low-volume MS–LTC–DRG to the low-volume quintile that contains an MS–LTC–DRG with an average charge closest to that of the remainder low-volume MS–LTC–DRG. In cases where these initial assignments of low-volume MS–LTC–DRGs to quintiles results in nonmonotonicity within a base-DRG, as we proposed, we adjusted the resulting low-volume MS–LTC–DRGs to preserve monotonicity, as discussed in Step 7 of our methodology.

To determine the FY 2024 relative weights for the low-volume MS–LTC–DRGs, however, as in historical practice, we used the five low-volume quintiles described previously. We determined a relative weight and (geometric) average length of stay for each of the five low-volume quintiles using the methodology described in Step 6 of our methodology. We assigned the same relative weight and average length of stay to each of the low-volume MS–LTC–DRGs that make up an individual low-volume quintile. We note that, as this system is dynamic, it is possible that the number and specific type of MS–LTC–DRGs with a low-volume of applicable LTCH cases would vary in the future. Furthermore, we note that we continue to monitor the volume (that is, the number of applicable LTCH cases) in the low-volume quintiles to ensure that our quintile assignments used in determining the MS–LTC–DRG relative weights result in appropriate payment for LTCH cases grouped to low-volume MS–LTC–DRGs and do not result in an unintended financial incentive for LTCHs to inappropriately admit these types of cases.

For this final rule, we are providing the list of the composition of the low-volume MS–LTC–DRGs in a supplemental data file for public use posted via the internet on the CMS website for this final rule at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html to streamline the information made available to the public that is used in the annual development of Table 11.

Step 4—Remove statistical outliers.

The next step in our calculation of the FY 2024 MS–LTC–DRG relative weights is to remove statistical outlier cases from the LTCH cases with a length of stay of at least 8 days. Consistent with our existing relative weight methodology, as we proposed, we are continuing to define statistical outliers as cases that are outside of 3.0 standard deviations from the mean of the log distribution of both charges per case and the charges per day for each MS–LTC–DRG. These statistical outliers are removed prior to calculating the relative weights because we believe that they may represent aberrations in the data that distort the measure of average resource use. Including those LTCH cases in the calculation of the relative weights could result in an inaccurate relative weight that does not truly reflect relative resource use among those MS–LTC–DRGs. (For additional information on what is removed in this step of the relative weight methodology, we refer readers to 67 FR 55989 and 74 FR 43959.) After removing cases with a length of stay of 7 days or less and statistical outliers, if at all claims, we were left with applicable LTCH cases that have a length of stay greater...
than or equal to 8 days. In this final rule, we refer to these cases as “trimmed applicable LTCH cases.”

Step 5—Adjust charges for the effects of Short Stay Outliers (SSOs).

As the next step in the calculation of the FY 2024 MS–LTC–DRG relative weights, consistent with our historical approach, as we proposed, we adjusted each LTCH’s charges per discharge for those remaining cases (that is, trimmed applicable LTCH cases) for the effects of SSOs (as defined in § 412.529(a) in conjunction with § 412.509). Specifically, as we proposed, we made this adjustment by counting an SSO case as a fraction of a discharge based on the ratio of the length of stay of the case to the average length of stay of all cases grouped to the MS–LTC–DRG. This has the effect of proportionately reducing the impact of the lower charges for the SSO cases in calculating the average charge for the MS–LTC–DRG. This process produces the same result as if the actual charges per discharge of an SSO case were adjusted to what they would have been had the patient’s length of stay been equal to the average length of stay of the MS–LTC–DRG.

Counting SSO cases as full LTCH cases with no adjustment in determining the FY 2024 MS–LTC–DRG relative weights would lower the relative weight for affected MS–LTC–DRGs because the relatively lower charges of the SSO cases would bring down the average charge for all cases within a MS–LTC–DRG. This would result in an “underpayment” for non-SSO cases and an “overpayment” for SSO cases. Therefore, we are continuing to adjust for SSO cases under § 412.529 in this manner because it would result in more appropriate payments for all LTCH PPS standard Federal payment rate cases. (For additional information on this step of the relative weight methodology, we refer readers to 67 FR 55989 and 74 FR 43959.)

Step 6—Calculate the relative weights on an iterative basis using the hospital-specific relative value methodology.

By nature, LTCHs often specialize in certain areas, such as ventilator-dependent patients. Some case types (MS–LTC–DRGs) may be treated, to a large extent, in hospitals that have, from a perspective of charges, relatively high (or low) charges. This nonrandom distribution of cases with relatively high (or low) charges in specific MS–LTC–DRGs has the potential to inappropriately distort the measure of average charges. To account for the fact that charges are randomly distributed across LTCHs, consistent with the methodology we have used since the implementation of the LTCH PPS, in this FY 2024 IPPS/LTCH PPS final rule, as we proposed, we are continuing to use a hospital-specific relative value (HSRV) methodology to calculate the MS–LTC–DRG relative weights for FY 2024. We believe that this method removes this hospital-specific source of bias in measuring LTCH average charges (67 FR 55985). Specifically, under this methodology, we reduced the impact of the variation in charges across providers on any particular MS–LTC–DRG relative weight by converting each LTCH’s charge for an applicable LTCH case to a relative value based on that LTCH’s average charge for such cases.

Under the HSRV methodology, we standardize charges for each LTCH by converting its charges for each applicable LTCH case to hospital-specific relative charge values and then adjusting those values for the LTCH’s case-mix. The adjustment for case-mix is needed to rescale the hospital-specific relative charge values (which, by definition, average 1.0 for each LTCH). The average relative weight for an LTCH is its case-mix; therefore, it is reasonable to scale each LTCH’s average relative charge value by its case-mix. In this way, each LTCH’s relative charge value is adjusted by its case-mix to an average that reflects the complexity of the applicable LTCH cases it treats relative to the complexity of the applicable LTCH cases treated by all other LTCHs (the average LTCH PPS case-mix of all applicable LTCH cases across all LTCHs). In other words, by multiplying an LTCH’s relative charge values by the LTCH’s case-mix index, we account for the fact that the same relative charges are given greater weight at an LTCH with higher average costs than they would at an LTCH with low average costs, which is needed to adjust each LTCH’s relative charge value to reflect its case-mix relative to the average case-mix for all LTCHs. By standardizing charges in this manner, we count charges for a Medicare patient at an LTCH with high average charges as less resource-intensive than they would be at an LTCH with low average charges. For example, a $10,000 charge for a case at an LTCH with an average adjusted charge of $17,500 reflects a higher level of relative resource usage than a $10,000 charge for a case at an LTCH with the same case-mix, but an average adjusted charge of $35,000. We believe that the adjusted charge of an individual case more accurately reflects actual resource use for an individual LTCH because the variation in charges due to systematic differences in the markup of charges among LTCHs is taken into account.

Consistent with our historical relative weight methodology, as we proposed, we calculated the FY 2024 MS–LTC–DRG relative weights using the HSRV methodology, which is an iterative process. Therefore, in accordance with our established methodology, for FY 2024, we continued to standardize charges for each applicable LTCH case by first dividing the adjusted charge for the case (adjusted for SSOs under § 412.529 as described in Step 5 of our methodology) by the average adjusted charge for all applicable LTCH cases at the LTCH in which the case was treated. The average adjusted charge reflects the average intensity of the health care services delivered by a particular LTCH and the average cost level of that LTCH. The average adjusted charge is then multiplied by the LTCH’s case-mix index to produce an adjusted hospital-specific relative charge value for the case. We used an initial case-mix index value of 1.0 for each MS–LTC–DRG, we calculated the FY 2024 relative weight by dividing the SSO-adjusted average of the hospital-specific relative charge values for applicable LTCH cases for the MS–LTC–DRG (that is, the sum of the hospital-specific relative charge value, as previously stated, divided by the sum of equivalent cases from Step 5 for each MS–LTC–DRG) by the overall SSO-adjusted average hospital-specific relative charge value across all applicable LTCH cases for all LTCHs (that is, the sum of the hospital-specific relative charge value, as previously stated, divided by the sum of equivalent applicable LTCH cases from Step 5 for each MS–LTC–DRG). Using these recalculated MS–LTC–DRG relative weights, each LTCH’s average relative weight for all of its SSO-adjusted trimmed applicable LTCH cases (that is, its case-mix) was calculated by dividing the sum of all the LTCH’s MS–LTC–DRG relative weights by its total number of SSO-adjusted trimmed applicable LTCH cases. The LTCHs’ hospital-specific relative charge values (from previous) are then multiplied by the hospital-specific case-mix indexes. The hospital-specific case-mix adjusted relative charge values are then used to calculate a new set of MS–LTC–DRG relative weights across all LTCHs. This iterative process continued until there was convergence between the relative weights produced at adjacent steps, for example, when the maximum difference was less than 0.0001.

Step 7—Adjust the relative weights to account for nonmonotonically increasing relative weights.
The MS–DRGs contain base DRGs that have been subdivided into one, two, or three severity of illness levels. Where there are three severity levels, the most severe level has at least one secondary diagnosis code that is referred to as an MCC (that is, major complication or comorbidity). The next lower severity level contains cases with at least one secondary diagnosis code that is a CC (that is, complication or comorbidity). Those cases without an MCC or a CC are referred to as "without CC/MCC." When data do not support the creation of three severity levels, the base MS–DRG is subdivided into either two levels or the base MS–DRG is not subdivided. The two-level subdivisions may consist of the MS–DRG with CC/MCC and the MS–DRG without CC/MCC. Alternatively, the other type of two-level subdivision may consist of the MS–DRG with MCC and the MS–DRG without MCC.

In those base MS–LTC–DRGs that are split into either two or three severity levels, cases classified into the "without CC/MCC" MS–LTC–DRG are expected to have a lower resource use (and lower costs) than the "with CC/MCC" MS–LTC–DRG (in the case of a two-level split) or both the "with CC" and the "with MCC" MS–LTC–DRGs (in the case of a three-level split). That is, theoretically, cases that are more severe typically require greater expenditure of medical care resources and would result in higher average charges. Therefore, in the three severity levels, relative weights should increase by severity, from lowest to highest. If the relative weights decrease as severity increases (that is, if within a base MS–LTC–DRG, an MS–LTC–DRG with CC has a higher relative weight than one with MCC, or the MS–LTC–DRG "without CC/MCC" has a higher relative weight than either of the others), they are nonmonotonic. We continue to believe that utilizing nonmonotonic relative weights would result in inappropriate payments because the payment for the cases in the higher severity level in a base MS–LTC–DRG (which are generally expected to have higher resource use and costs) would be lower than the payment for cases in a lower severity level within the same base MS–LTC–DRG (which are generally expected to have lower resource use and costs). Therefore, in determining the FY 2024 MS–LTC–DRG relative weights, consistent with our historical methodology, as we proposed, we continued to combine MS–LTC–DRG severity levels within a base MS–LTC–DRG for the purpose of computing a relative weight when necessary to ensure that monotonicity is maintained. For a comprehensive description of our existing methodology to adjust for nonmonotonicity, we refer readers to the FY 2010 IPPS/RY 2010 LTCH PPS final rule (74 FR 43964 through 43966).

Any adjustments for nonmonotonicity that were made in determining the FY 2024 MS–LTC–DRG relative weights by applying this methodology are denoted in Table 11, which is listed in section VI. of the Addendum to this final rule and is available via the internet on the CMS website.

Step 8—Determine a relative weight for MS–LTC–DRGs with no applicable LTCH cases.

Using the trimmed applicable LTCH cases, consistent with our historical methodology, we identified the MS–LTC–DRGs for which there were no claims in the March 2023 update of the FY 2022 MedPAR file and, therefore, for which no charge data was available for these MS–LTC–DRGs. Because patients with a number of the diagnoses under these MS–LTC–DRGs may be treated at LTCHs, consistent with our historical methodology, we generally assign a relative weight to each of the no-volume MS–LTC–DRGs based on clinical similarity and relative costliness (with the exception of "transplant" MS–LTC–DRGs, "error" MS–LTC–DRGs, and MS–LTC–DRGs that indicate a principal diagnosis related to a psychiatric diagnosis or rehabilitation (referred to as the "psychiatric or rehabilitation" MS–LTC–DRGs), as discussed later in this section of this final rule). For additional information on this step of the relative weight methodology, we refer readers to 67 FR 55991 and 74 FR 43959 through 43960.

Consistent with our existing methodology, as we proposed, we crosswalked each non-volume MS–LTC–DRG to another MS–LTC–DRG for which we calculated a relative weight (determined in accordance with the methodology as previously described). Then, the "no-volume" MS–LTC–DRG is assigned the same relative weight (and average length of stay) of the MS–LTC–DRG to which it was crosswalked (as described in greater detail in this section of this final rule).

Of the 766 MS–LTC–DRGs for FY 2024, we identified 429 MS–LTC–DRGs for which there were no trimmed applicable LTCH cases. The 429 MS LTC DRGs for which there were no trimmed applicable LTCH cases includes the 11 "transplant" MS–LTC–DRGs, the 2 "error" MS–LTC–DRGs, and the 15 "psychiatric or rehabilitation" MS–LTC–DRGs, which are discussed in this section of this rule, such that we identified 401 MS–LTC–DRGs that for which, we assigned a relative weight using our existing "no-volume" MS–LTC–DRG methodology (that is, 429 – 11 – 2 – 15 = 401). As we proposed, we assigned relative weights to each of the 401 no-volume MS–LTC–DRGs based on clinical similarity and relative costliness to 1 of the remaining 337 (766 – 429 = 337) MS–LTC–DRGs for which we calculated relative weights based on the trimmed applicable LTCH cases in the FY 2022 MedPAR file data using the steps described previously. For the remainder of this discussion, we refer to the "cross-walked" MS–LTC–DRGs as one of the 337 MS–LTC–DRGs to which we cross-walked each of the 401 "no-volume" MS–LTC–DRGs. Then, in general, we assigned the 401 no-volume MS–LTC–DRGs the relative weight of the cross-walked MS–LTC–DRG (when necessary, we made adjustments to account for nonmonotonicity).

We cross-walked the no-volume MS–LTC–DRG to a MS–LTC–DRG for which we calculated relative weights based on the March 2023 update of the FY 2022 MedPAR file, and to which it is similar clinically in intensity of use of resources and relative costliness as determined by criteria such as care provided during the period of time surrounding surgery, surgical approach (if applicable), length of time of surgical procedure, postoperative care, and length of stay. (For more details on our process for evaluating relative costliness, we refer readers to the FY 2010 IPPS/RY 2010 LTCH PPS final rule (73 FR 48543).) We believe in the rare event that there would be a few LTCH cases grouped to one of the no-volume MS–LTC–DRGs in FY 2024, the relative weights assigned based on the cross-walked MS–LTC–DRGs would result in an appropriate LTCH PPS payment because the crosswalks, which are based on clinical similarity and relative costliness, would be expected to generally require equivalent relative resource use.

Then we assigned the relative weight of the cross-walked MS–LTC–DRG as the relative weight for the no-volume MS–LTC–DRGs such that both of these MS–LTC–DRGs (that is, the no-volume MS–LTC–DRG and the cross-walked MS–LTC–DRG) have the same relative weight (and average length of stay) for FY 2024. We note that, if the crosswalked MS–LTC–DRG had 25 applicable LTCH cases or more, its relative weight (calculated using the methodology as previously described in Steps 1 through 4) is assigned to the no-volume MS–LTC–DRG as well. Similarly, if the MS–LTC–DRG to which the no-volume MS–LTC–DRG was crosswalked had 24 or less cases and,
therefore, was designated to 1 of the low-volume quintiles for purposes of determining the relative weights, we assigned the relative weight of the applicable low-volume quintile to the no-volume MS–LTC–DRG such that both of these MS–LTC–DRGs (that is, the no-volume MS–LTC–DRG and the cross-walked MS–LTC–DRG) have the same relative weight for FY 2024. As we noted previously, in the infrequent case where nonmonotonicity involving a no-volume MS–LTC–DRG resulted, additional adjustments are required to maintain monotonically increasing relative weights. 

For this final rule, we are providing the list of the no-volume MS–LTC–DRGs and the MS–LTC–DRGs to which each was cross-walked (that is, the cross-walked MS–LTC–DRGs) for FY 2024 in a supplemental data file for public use posted via the internet on the CMS website for this final rule at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html to streamline the information made available to the public that is used in the annual development of Table 11.

To illustrate this methodology for determining the relative weights for the FY 2024 MS–LTC–DRGs with no applicable LTCH cases, we are providing the following example. 

**Example:** There were no trimmed applicable LTCH cases in the FY 2022 MedPAR file that we are using for this final rule for MS–LTC–DRG 061 (Ischemic stroke, precerebral occlusion or transient ischemia with thrombolytic agent with MCC). We determined that MS–LTC–DRG 064 (Intracranial hemorrhage or cerebral infarction with MCC) is similar clinically and based on resource use to MS–LTC–DRG 061. Therefore, we assigned the same relative weight (and average length of stay) of MS–LTC–DRG 064 of 1.4532 for FY 2024 to MS–LTC–DRG 061 (we refer readers to Table 11, which is listed in section VI. of the Addendum to this final rule and is available via the internet on the CMS website).

Again, we note that, as this system is dynamic, it is entirely possible that the number of MS–LTC–DRGs with no volume would vary in the future. Consistent with our historical practice, as we proposed, we used the best available claims data to identify the trimmed applicable LTCH cases from which we determined the relative weights in the final rule.

For FY 2024, consistent with our historical relative weight methodology, as we proposed, we established a relative weight of 0.0000 for the following transplant MS–LTC–DRGs:

- Heart Transplant or Implant of Heart Assist System with MCC (MS–LTC–DRG 001); Heart Transplant or Implant of Heart Assist System without MCC (MS–LTC–DRG 002); Liver Transplant with MCC or Intestinal Transplant (MS–LTC–DRG 005); Liver Transplant without MCC (MS–LTC–DRG 006); Lung Transplant (MS–LTC–DRG 007); Simultaneous Pancreas/Kidney Transplant (MS–LTC–DRG 008); Simultaneous Pancreas/Kidney Transplant with Hemodialysis (MS–LTC–DRG 019); Pancreas Transplant (MS–LTC–DRG 010); Kidney Transplant (MS–LTC–DRG 652); Kidney Transplant with Hemodialysis with MCC (MS–LTC–DRG 650), and Kidney Transplant with Hemodialysis without MCC (MS LTC DRG 651).

This is because Medicare only covers these procedures if they are performed at a hospital that has been certified for the specific procedures by Medicare and presently no LTCH has been so certified. At the present time, we include these 11 transplant MS–LTC–DRGs in the GROUPER program for administrative purposes only. Because we use the same GROUPER program for LTCHs as is used under the IPPS, removing these MS–LTC–DRGs would be administratively burdensome. (For additional information regarding our treatment of transplant MS–LTC–DRGs, we refer readers to the FY 2010 LTCH PPS final rule (74 FR 43964).) In addition, consistent with our historical policy, we are establishing a relative weight of 0.0000 for the 2 “error” MS–LTC–DRGs (that is, MS–LTC–DRG 998 (Principal Diagnosis Invalid as Discharge Diagnosis) and MS–LTC–DRG 999 (Unigroupable)) because applicable LTCH cases grouped to these MS–LTC–DRGs cannot be properly assigned to an MS–LTC–DRG according to the grouping logic.

Additionally, we are establishing a relative weight of 0.0000 for the following “psychiatric or rehabilitation” MS–LTC–DRGs: MS–LTC–DRG 876 (O.R. Procedure with Principal Diagnoses of Mental Illness); MS–LTC–DRG 880 (Acute Adjustment Reaction & Psychosocial Dysfunction); MS–LTC–DRG 881 (Depressive Neuroses); MS–LTC–DRG 882 (Neuroses Except Depressive); MS–LTC–DRG 883 (Disorders of Personality & Impulse Control); MS–LTC–DRG 884 (Organic Disturbances & Mental Retardation); MS–LTC–DRG 885 (Psychoses); MS–LTC–DRG 886 (Behavioral & Developmental Disorders); MS–LTC–DRG 887 (Other Mental Disorder Diagnoses); MS–LTC–DRG 894 (Alcohol/Drug Abuse or Dependence, Left Ama); MS–LTC–DRG 895 (Alcohol/Drug Abuse or Dependence, with Rehabilitation Therapy); MS–LTC–DRG 896 (Alcohol/Drug Abuse or Dependence, without Rehabilitation Therapy with MCC); MS–LTC–DRG 897 (Alcohol/Drug Abuse or Dependence, without Rehabilitation Therapy without MCC); MS–LTC–DRG 945 (Rehabilitation with CC/MCC); and MS–LTC–DRG 946 (Rehabilitation without CC/MCC). We are establishing a relative weight of 0.0000 for these 15 “psychiatric or rehabilitation” MS–LTC–DRGs because the blended payment rate and temporary exceptions to the site neutral payment rate would not be applicable for any LTCH discharges occurring in FY 2024, and as such payment under the LTCH PPS would be no longer be made in part based on the LTCH PPS standard Federal payment rate for any discharges assigned to those MS–LTC–DRGs.

**Step 9—Budget neutralize the uncapped relative weights.**

In accordance with the regulations at § 412.517(b) (in conjunction with § 412.503), the annual update to the MS–LTC–DRG classifications and relative weights is done in a budget neutral manner such that estimated aggregate LTCH PPS payments would be unaffected, that is, would be neither greater than nor less than the estimated aggregate LTCH PPS payments that would have been made without the MS–LTC–DRG classification and relative weight changes. (For a detailed discussion on the establishment of the budget neutrality requirement for the annual update of the MS–LTC–DRG classifications and relative weights, we refer readers to the FY 2008 LTCH PPS final rule (72 FR 26881 and 26882).

To achieve budget neutrality under the requirement at § 412.517(b), under our established methodology, for each annual update the MS–LTC–DRG relative weights are uniformly adjusted to ensure that estimated aggregate payments under the LTCH PPS would not be affected (that is, decreased or increased). Consistent with that provision, as we proposed, we continued to apply budget neutrality adjustments in determining the FY 2024 MS–LTC–DRG relative weights so that our update of the MS–LTC–DRG classifications and relative weights for FY 2024 are made in a budget neutral manner. For FY 2024, as we proposed, we applied two budget neutrality factors to determine the MS–LTC–DRG relative weights. In this step, we describe the determination of the budget neutrality adjustment that applies to the update of the MS–LTC–DRG classifications and relative weights prior to the application...
of the ten-percent cap. In steps 10 and 11, we describe the application of the 10-percent cap policy (step 10) and the determination of the budget neutrality factor that accounts for the application of the 10-percent cap policy (step 11).

In this final rule, to ensure budget neutrality for the update to the MS–LTC–DRG classifications and relative weights prior to the application of the 10-percent cap (that is, uncapped relative weights), under § 412.517(b), we continued to use our established two-step budget neutrality methodology. Therefore, in the first step of our MS–LTC–DRG update budget neutrality methodology, for FY 2024, we calculated and applied a normalization factor to the recalibrated relative weights (the result of Steps 1 through 8 discussed previously) to ensure that estimated payments are not affected by changes in the composition of case types or the changes to the classification system. That is, the normalization adjustment is intended to ensure that the recalibration of the MS–LTC–DRG relative weights (that is, the process itself) neither increases nor decreases the average case-mix index.

To calculate the normalization factor for FY 2024, we used the following three steps: (1.a.) use the applicable LTHC cases from the best available data (that is, LTCH discharges from the FY 2022 MedPAR file) and group them using the FY 2024 GROUPER (that is, Version 41 for FY 2024) and the recalibrated FY 2024 MS–LTC–DRG uncapped relative weights (determined in Steps 1 through 8 discussed previously) to calculate the average case-mix index; (1.b.) group the same applicable LTCH cases (as are used in Step 1.a.) using the FY 2023 GROUPER (Version 40) and FY 2023 MS–LTC–DRG relative weights and calculate the average case-mix index; and (1.c.) compute the ratio of these average case-mix indexes by dividing the average case-mix index for FY 2024 (determined in Step 1.b.) by the average case-mix index for FY 2024 (determined in Step 1.a.). As a result, in determining the MS–LTC–DRG relative weights for FY 2024, each recalibrated MS–LTC–DRG uncapped relative weight is multiplied by the normalization factor of 1.31064 (determined in Step 1.c.) in the first step of the budget neutrality methodology, which produces “normalized relative weights.”

In the second step of our MS–LTC–DRG update budget neutrality methodology, we calculated a budget neutrality adjustment factor consisting of the estimated aggregate FY 2024 LTCH PPS standard Federal payment rate payments for applicable LTCH cases before reclassification and recalibration to estimated aggregate payments for FY 2024 LTCH PPS standard Federal payment rate payments for applicable LTCH cases after reclassification and recalibration. That is, for this final rule, for FY 2024, we determined the budget neutrality adjustment factor using the following three steps: (2.a.) simulate estimated total FY 2024 LTCH PPS standard Federal payment rate payments for applicable LTCH cases using the uncapped normalized relative weights for FY 2024 and GROUPER Version 41; (2.b.) simulate estimated total FY 2024 LTCH PPS standard Federal payment rate payments for applicable LTCH cases using the uncapped normalized relative weights for FY 2024 and GROUPER Version 41; (2.c.) calculate the ratio of these estimated total payments by dividing the value determined in Step 2.b. by the value determined in Step 2.a. In determining the FY 2024 MS–LTC–DRG relative weights, each uncapped normalized relative weight is then multiplied by a budget neutrality factor of 0.9964763 (the value determined in Step 2.c.) in the second step of the budget neutrality methodology.

Step 10—Apply the 10-percent cap to decreases in MS–LTC–DRG relative weights.

To mitigate the financial impacts of significant year-to-year reductions in MS–LTC–DRGs relative weights, beginning in FY 2023, we adopted a policy that applies, in a budget neutral manner, a 10-percent cap on annual relative weight decreases for MS–LTC–DRGs with at least 25 applicable LTCH cases (§ 412.515(b)). Under this policy, in cases where CMS creates new MS–LTC–DRGs or modifies the MS–LTC–DRGs as part of its annual reclassifications resulting in renumbering of one or more MS–LTC–DRGs, the 10-percent cap does not apply to the relative weight for any new or renumbered MS–LTC–DRGs for the fiscal year. See section VIII.B.3.b. of the preamble of the FY 2023 IPPS/LTCH PPS final rule with comment period for a detailed discussion on the adoption of the 10-percent cap policy (87 FR 49152 through 49154).

Applying the 10-percent cap to MS–LTC–DRGs with 25 or more applicable LTCH cases using the capped relative weights for FY 2024 (determined in Step 10) and GROUPER Version 41; (b) simulate estimated total FY 2024 LTCH PPS standard Federal payment rate payments for applicable LTCH cases using the capped relative weights for FY 2024 (determined in Step 9) and GROUPER Version 41; and (c) calculate
the ratio of these estimated total payments by dividing the value determined in step (b) by the value determined in step (a). In determining the FY 2024 MS–LTC–DRG relative weights, each capped relative weight is then multiplied by a budget neutrality factor of 0.9984221 (the value determined in step (c)) to achieve the budget neutrality requirement.

Table 11, which is listed in section VI. of the Addendum to this final rule and is available via the internet on the CMS website, lists the MS–LTC–DRGs and their respective relative weights, geometric mean length of stay, and five-sixths of the geometric mean length of stay (used to identify SSO cases under § 412.529(a)) for FY 2024. We also are making available on the website the MS–LTC–DRG relative weights prior to the application of the 10 percent cap on MS–LTC–DRG relative weight reductions and corresponding cap budget neutrality factor.

C. Changes to the LTCH PPS Payment Rates and Other Changes to the LTCH PPS for FY 2024

1. Overview of Development of the LTCH PPS Standard Federal Payment Rates

The basic methodology for determining LTCH PPS standard Federal payment rates is currently set forth at 42 CFR 412.535 through 412.533 and 412.535. In this section, we discuss the factors that we use to update the LTCH PPS standard Federal payment rate for FY 2024, that is, effective for LTCH discharges occurring on or after October 1, 2023, through September 30, 2024. Under the dual rate LTCH PPS payment structure required by statute, beginning with discharges in cost reporting periods beginning in FY 2016, only LTCH discharges that meet the criteria for exclusion from the site neutral payment rate are paid based on the LTCH PPS standard Federal payment rate specified at 42 CFR 412.523. (For additional details on our finalized policies related to the dual rate LTCH PPS payment structure required by statute, we refer readers to the August 30, 2002 LTCH PPS final rule (67 FR 56027 through 56037). For subsequent updates to the standard Federal rate from FYs 2003 through 2015, and LTCH PPS standard Federal payment rate from FY 2016 through present, as implemented under 42 CFR 412.523(c)(3), we refer readers to the FY 2020 IPPS/LTCH PPS final rule (84 FR 42445 through 42446).

In this FY 2024 IPPS/LTCH PPS final rule, we present our policies related to the annual update to the LTCH PPS standard Federal payment rate for FY 2024.

The update to the LTCH PPS standard Federal payment rate for FY 2024 is presented in section V.A. of the Addendum to this final rule. The components of the annual update to the LTCH PPS standard Federal payment rate for FY 2024 are discussed in this section, including the statutory reduction to the annual update for LTCHs that fail to submit quality reporting data for FY 2024 as required by the statute (as discussed in section VIII.C.2.c. of the preamble of this final rule). As we proposed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27073), we also made an adjustment to the LTCH PPS standard Federal payment rate to account for the estimated effect of the changes to the area wage level for FY 2024 on estimated aggregate LTCH PPS payments, in accordance with 42 CFR 412.523(d)(4) (as discussed in section V.B. of the Addendum to this final rule).

2. FY 2024 LTCH PPS Standard Federal Payment Rate Annual Market Basket Update

a. Overview

Historically, the Medicare program has used a market basket to account for input price increases in the services furnished by providers. The market basket used for the LTCH PPS includes both operating and capital-related costs of LTCHs because the LTCH PPS uses a single payment rate for both operating and capital-related costs. We adopted the 2017-based LTCH market basket for use under the LTCH PPS beginning in FY 2021. The 2017-based LTCH market basket is primarily based on the Medicare cost report data submitted by LTCHs and, therefore, specifically reflects the cost structures of only LTCHs. For additional details on the development of the 2017-based LTCH market basket, we refer readers to the FY 2021 IPPS/LTCH PPS final rule (85 FR 58909 through 58926). We continue to believe that the 2017-based LTCH market basket appropriately reflects the cost structure of LTCHs for the reasons discussed when we adopted its use in the FY 2021 IPPS/LTCH PPS final rule. Therefore, in this final rule, as we proposed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27073), we use the 2017-based LTCH market basket to update the LTCH PPS standard Federal payment rate for FY 2024.

Section 3401(c) of the Affordable Care Act provides for certain adjustments to any annual update to the LTCH PPS standard Federal payment rate and refers to the timeframes associated with such adjustments as a “rate year.” We note that, because the annual update to the LTCH PPS policies, rates, and factors now occurs on October 1, we adopted the term “fiscal year” (FY) rather than “rate year” (RY) under the LTCH PPS beginning October 1, 2010, to conform with the standard definition of the Federal fiscal year (October 1 through September 30) used by other PPSSs, such as the IPPS (75 FR 50396 through 50397). Although the language of sections 3004(a), 3401(c), 10319, and 1105(b) of the Affordable Care Act refers to years 2010 and thereafter under the LTCH PPS as “rate year,” consistent with our change in the terminology used under the LTCH PPS from “rate year” to “fiscal year,” for purposes of clarity, when discussing the annual update for the LTCH PPS standard Federal payment rate, including the provisions of the Affordable Care Act, we use “fiscal year” rather than “rate year” for 2011 and subsequent years.

b. Annual Update to the LTCH PPS Standard Federal Payment Rate for FY 2024

As previously noted, we adopted the 2017-based LTCH market basket for use under the LTCH PPS beginning in FY 2021. The 2017-based LTCH market basket is primarily based on the Medicare cost report data submitted by LTCHs and, therefore, specifically reflects the cost structures of only LTCHs. For additional details on the development of the 2017-based LTCH market basket, we refer readers to the FY 2021 IPPS/LTCH PPS final rule (85 FR 58909 through 58926). We continue to believe that the 2017-based LTCH market basket appropriately reflects the cost structure of LTCHs for the reasons discussed when we adopted its use in the FY 2021 IPPS/LTCH PPS final rule. Therefore, in this final rule, as we proposed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27073), we use the 2017-based LTCH market basket to update the LTCH PPS standard Federal payment rate for FY 2024.

Section 1886(m)(3)(A) of the Act provides that, beginning in FY 2010, any annual update to the LTCH PPS standard Federal payment rate is reduced by the adjustments specified in clauses (i) and (ii) of subparagraph (A), as applicable. Clause (i) of section 1886(m)(3)(A) of the Act provides for a productivity adjustment for FY 2012 and each subsequent rate year, by “the productivity adjustment” described in
section 1886(b)(3)(B)(xi)(II) of the Act. Clause (ii) of section 1886(m)(3)(A) of the Act provided for a reduction, for each of FYS 2010 through 2019, by the “other adjustment” described in section 1886(m)(4)(F) of the Act; therefore, it is not applicable for FY 2024.

Section 1886(m)(3)(B) of the Act provides that the application of the adjustment described in paragraph (3) of section 1886(m) of the Act may result in the annual update being less than zero for a rate year, and may result in payment rates for a rate year being less than such payment rates for the preceding rate year.

c. Adjustment to the LTCH PPS Standard Federal Payment Rate Under the Long-Term Care Hospital Quality Reporting Program (LTCH QRP)

In accordance with section 1886(m)(5) of the Act, the Secretary established the Long-Term Care Hospital Quality Reporting Program (LTCH QRP). The reduction in the annual update to the LTCH PPS standard Federal payment rate for failure to report quality data under the LTCH QRP for FY 2014 and subsequent fiscal years is codified under 42 CFR 412.523(c)(4). The LTCH QRP, as required for FY 2014 and subsequent fiscal years by section 1886(m)(5)(A)(i) of the Act, requires that a 2.0 percentage points reduction be applied to any update under 42 CFR 412.523(c)(3) for an LTCH that does not submit quality reporting data to the Secretary in accordance with section 1886(m)(5)(C) of the Act with respect to such a year (that is, in the form and manner and at the time specified by the Secretary under the LTCH QRP) (42 CFR 412.523(c)(4)(i)). Section 1886(m)(5)(A)(ii) of the Act provides that the application of the 2.0 percentage points reduction may result in an annual update that is less than 0.0 for a year, and may result in LTCH PPS payment rates for a year being less than such LTCH PPS payment rates for the preceding year. Furthermore, section 1886(m)(5)(B) of the Act specifies that the 2.0 percentage points reduction is applied in a noncumulative manner, such that any reduction made under section 1886(m)(5)(A) of the Act shall apply only with respect to the year involved, and shall not be taken into account in computing the LTCH PPS payment amount for a subsequent year. These requirements are codified in the regulations at 42 CFR 412.523(c)(4). (For additional information on the history of the LTCH QRP, including the statutory authority and the selected measures, we refer readers to section VIII.C. of the preamble of this final rule.)

d. Annual Market Basket Update Under the LTCH PPS for FY 2024

Consistent with our historical practice, we estimate the market basket percentage increase and the productivity adjustment based on IHS Global Inc.’s (IGI’s) forecast using the most recent available data. Based on IGI’s fourth quarter 2022 forecast, the proposed FY 2024 market basket percentage increase for the LTCH PPS using the 2017-based LTCH market basket was 3.1 percent. The proposed productivity adjustment for FY 2024 based on IGI’s fourth quarter 2022 forecast was 0.2 percentage point.

For FY 2024, section 1886(m)(3)(A)(i) of the Act requires that any annual update to the LTCH PPS standard Federal payment rate be reduced by the productivity adjustment, described in section 1886(b)(3)(B)(xi)(II) of the Act. Consistent with the statute, we proposed in the FY 2024 IPPS/LTCH PPS proposed rule (86 FR 27074) to reduce the FY 2024 market basket percentage increase by the FY 2024 productivity adjustment. To determine the proposed market basket update for LTCHs for FY 2024 we subtracted the proposed FY 2024 productivity adjustment from the proposed FY 2024 market basket percentage increase. (For additional details on our established methodology for adjusting the market basket percentage increase by the productivity adjustment, we refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51771.) In addition, for FY 2024, section 1886(m)(5) of the Act requires that, for LTCHs that do not submit quality reporting data as required under the LTCH QRP, any annual update to an LTCH PPS standard Federal payment rate, after application of the adjustments required by section 1886(m)(3) of the Act, shall be further reduced by 2.0 percentage points.

In the FY 2024 IPPS/LTCH PPS proposed rule, in accordance with the statute, we proposed to reduce the proposed FY 2024 market basket percentage increase of 3.1 percent (based on IGI’s fourth quarter 2022 forecast of the 2017-based LTCH market basket) by the proposed FY 2024 productivity adjustment of 0.2 percentage point (based on IGI’s fourth quarter 2022 forecast). Therefore, under the authority of section 123 of the BBRA as amended by section 307(b) of the BIPA, consistent with 42 CFR 412.523(c)(3)(xvii), we proposed to establish an annual market basket update to the LTCH PPS standard Federal payment rate for FY 2024 of 2.9 percent (that is, the LTCH PPS market basket increase of 3.1 percent less the productivity adjustment of 0.2 percentage point). For LTCHs that fail to submit quality reporting data under the LTCH QRP, under 42 CFR 412.523(c)(3)(xvii) in conjunction with 42 CFR 412.523(c)(4), we proposed to further reduce the annual update to the LTCH PPS standard Federal payment rate by 2.0 percentage points, in accordance with section 1886(m)(5) of the Act. Accordingly, we proposed to establish an annual update to the LTCH PPS standard Federal payment rate of 0.9 percent (that is, 2.9 percent minus 2.0 percentage points) for FY 2024 for LTCHs that fail to submit quality reporting data as required under the LTCH QRP.

Consistent with our historical practice, we proposed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27074) to use a more recent estimate of the market basket and the productivity adjustment, if appropriate, in the final rule to establish an annual update to the LTCH PPS standard Federal payment rate for FY 2024. We note that, consistent with historical practice, we also proposed to adjust the FY 2024 LTCH PPS standard Federal payment rate by an area wage level budget neutrality factor in accordance with 42 CFR 412.523(d)(4) (as discussed in section V.B.5. of the Addendum to the proposed rule).

Comment: Many commenters expressed concern that the proposed 3.1 percent market basket update and the 0.4 percentage point increase to the labor-related share do not sufficiently account for the dramatic increases in labor costs that LTCHs are incurring. They stated labor costs, especially for clinicians, are increasing faster than what CMS factored into the market basket for this FY 2024 update. Some of the commenters cited their own analysis of labor costs and many referenced the analysis from the American Hospital Association (AHA). Commenters also noted that medical supply costs had also increased significantly in recent years and are expected to continue to rise in FY 2024. Commenters stated that the rising labor and supply costs have resulted in nearly half of hospitals having negative profit margins for 2022, according to a Kauffman Hall analysis. Several commenters also stated that the proposed increase is inadequate noting the unprecedented inflationary environment that LTCHs are experiencing. Several commenters further stated that it is incorrect for CMS to argue that the market basket update appropriately accounts for provider costs when the projection used in the final rule has severely underestimated
LTCH costs in the recent annual updates.

Commenters requested that CMS implement a temporary payment adjustment increase or add-on payment to increase LTCH payments to account for higher labor and supply costs. A commenter requested that the Secretary consider using his “special adjustment authority” to increase the market basket update to 10 percent to reflect the actual increases in costs over the last year. A few commenters requested that CMS modify the market basket update to provide an additional payment increase to help offset the unprecedented inflation currently faced by LTCHs and other providers.

Several of the commenters indicated that a temporary payment adjustment should be applied to Medicare payments to LTCHs at least until CMS rebases the LTCH PPS market basket. A commenter noted that CMS did not propose to rebase and revise the 2017-based LTCH market basket despite CMS proposing the IRF and IPF market baskets for FY 2024. The commenter noted that CMS stated in the FY 2024 IRF PPS proposed rule that commenters in prior years reported significantly higher IRF labor and other costs due to the COVID–19 PHE and inflation and therefore, CMS determined that it was appropriate to rebase and revise the IRF PPS market basket using a 2021 base year. The commenter stated that LTCHs are similarly affected by increased costs attributable to COVID–19 and inflation, including labor and supply costs. CMS did not propose to rebase and revise the LTCH PPS market basket.

A commenter stated that CMS clearly has the authority to implement this type of payment adjustment for the LTCH PPS in FY 2024 using its “broad authority under section 123 of the BBRA as amended by section 307(b)(1) of the BIPA to determine appropriate adjustments under the LTCH PPS, including whether (and how) to provide for adjustments to reflect variations in the necessary costs of treatment among LTCHs,” noting CMS has used this authority to establish other payment adjustment policies in the LTCH PPS. The commenter requested that if CMS does not apply a temporary payment increase or add-on payment then it should rebase and revise the 2017-based LTCH market basket for FY 2024 using the most recent LTCH cost report data available to account for the drastic increase in labor costs.

Response: CMS has historically used a market basket to account for input price increases in the services furnished by fee-for-service providers. Since the inception of the LTCH PPS, the LTCH PPS standard Federal payment rates (with the exception of statutorily mandated updates) have been updated based on a projection of a market basket percentage increase. The LTCH market basket (as well as other CMS market baskets) is a fixed-weight, Laspeyres-type index that measures price changes over time and would not reflect increases in costs associated with changes in the volume or intensity of input goods and services. As such, the LTCH market basket update would reflect the most recent Medicare prices described by the commenters as increasing during a high inflation period (such as faster wage growth or higher energy prices), but would inherently not reflect other factors that might increase the level of costs, such as the quantity of labor used. Changes in quantity or use of services would be captured when the market basket is rebased.

While we did not propose to rebase the LTCH market basket in the FY 2024 IPPS/LTCH proposed rule, we did revise the Medicare cost report data for FY 2021 Medicare cost report data available for LTCHs. At the time of the FY 2024 proposed rulemaking, the latest complete Medicare cost report data for LTCHs was for 2020. The latest 2020 Medicare cost report data showed a compensation cost weight of 52.1 percent compared to the 2017-based LTCH market basket compensation cost weight of 53.2 percent. As part of our review of the latest available Medicare cost report data, we found that about 50 percent of LTCHs have a Medicare cost reporting period that begins on or after July 1st of the current year and therefore complete 2021 Medicare cost report data for LTCHs was not available in time to analyze for the FY 2024 rulemaking cycle. Over the next year, we plan to analyze the submitted Medicare cost report data for LTCHs and assess whether a proposal to rebase and revise the LTCH market basket would be appropriate for FY 2025.

We appreciate the commenters’ concern regarding inflationary pressure, including labor and supply costs, encountered by LTCHs. We note that the market basket percentage increase is a forecast of the price pressures that LTCHs are expected to face in FY 2024, and the final FY 2024 LTCH market basket percentage increase reflects IGI’s (a nationally recognized economic and financial forecasting firm with which CMS contracts to forecast the price proxies of the market baskets) projected inflation and overall economic outlook. As projected by IGI and other independent forecasters, compensation growth and upward price pressures are expected to slow in FY 2024 relative to FY 2022 and FY 2023. As is our general practice, we proposed that if more recent data became available, we would use such data, if appropriate, to derive the final FY 2024 LTCH market basket update for the final rule. For this final rule, we now have an updated forecast of the price proxies underlying the market basket that incorporates more recent historical data. Based on IGI’s second quarter 2023 forecast with historical data through the first quarter of 2023, the projected 2017-based LTCH market basket percentage increase factor for FY 2024 is 3.5 percent, which is 0.4 percentage point higher than the projected FY 2024 LTCH market basket percentage increase factor in the proposed rule, and reflects a projected increase in compensation prices of 4.3 percent. We note that the 10-year historical average (2013–2022) growth rate of the 2017-based LTCH market basket is 2.4 percent with the historical average growth rate of compensation prices equal to 2.5 percent.

As discussed earlier, we believe the LTCH market basket percentage increase appropriately reflects the input price growth (including compensation price growth) that LTCHs incur in providing medical services. As also described earlier, we are using an updated forecast of the price proxies underlying the market basket that incorporates more recent historical data. For these reasons, as discussed previously, we believe the LTCH market basket is methodologically sound and is using the best available data for FY 2024. The commenter does not agree with the commenters that CMS should apply a temporary payment adjustment, add-on payment or additional payment increase to the LTCH PPS to account for or offset higher labor and supply costs or unprecedented inflation.

Comment: Many commenters stated that the existing market basket methodology has failed to properly account for inflation in recent annual updates, particularly in FY 2021 and FY 2022. They stated that in FY 2022, CMS implemented a 2.6 percent LTCH market basket update, and in contrast, the actual increase according to IGI data was 5.5 percent. Many commenters urged CMS to use its authority to implement an adjustment for FY 2024 to account for the difference between the market basket update that was implemented for FY 2022 and what the market basket is currently projected to be for FY 2022.

Commenters pointed out that there are bipartisan coalitions in both the Senate and House of Representatives sending letters to CMS, calling on the agency to use its broad authority to
reevaluate the hospital market basket update and implement a retrospective payment adjustment to account for the difference between the projected market basket update for FY 2022 and the actual market basket in FY 2022. These commenters stated that although these letters specify the IPPS, LTCH PPS payments are based on the same DRGs and LTCH site neutral payments are equivalent to IPPS payments; therefore, the commenters requested that CMS make the same types of changes to the LTCH PPS.

Response: In responding to similar comments in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49165), we explained that under the law, the LTCH PPS is a per-discharge prospective payment system that uses a market basket percentage increase to set the annual update prospectively. This means that the update relies on a mix of both historical data for part of the period for which the update is calculated and forecasted data for the remainder. (For instance, the 2017-based LTCH market basket growth rate for FY 2024 in this final rule is based on IGI’s second quarter 2023 forecast with historical data through the first quarter of 2023.) While there is currently no mechanism to adjust for market basket forecast error in the LTCH payment update, the forecast error for a market basket update is equal to the actual market basket percentage increase for a given year less the forecasted market basket percentage increase. Due to the uncertainty regarding future price trends, forecast errors can be both positive and negative.

While the projected LTCH market basket updates for FY 2021 and FY 2022 were underforecast (actual increases less forecasted increases were positive), this was largely due to unanticipated inflation and labor market pressures as the economy emerged from the COVID–19 pandemic. However, an analysis of the forecast error of the LTCH market basket over a longer period of time shows the forecast error has been both positive and negative. For example, for each fiscal year from 2012 through 2020, the forecasted LTCH market basket update implemented in the final rule was shown to be higher than the actual LTCH market basket update once historical data were available. Only considering the forecast error for years when the final LTCH market basket update is lower than the actual LTCH market basket update addresses only one direction of a forecast error that can be either positive or negative. For these reasons, we are not adopting the commenters’ request to implement an adjustment for FY 2024 to account for the difference between the actual and forecasted FY 2022 LTCH market basket update.

Comment: A commenter believes that the IGI data does not conform with CMS’s assumption about COVID–19 related costs. The commenter stated that the reduction in the proposed FY 2024 market basket update relative to the FY 2023 market basket update is likely due to the IGI projecting a decrease in COVID–19 cases, hospitalizations, and costs for providers. The commenter further states that CMS proposed to establish the outlier fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2024 using FY 2022 claims because CMS expects LTCH hospitalization rates and cases to be similar in these two fiscal years. The commenter therefore believes that CMS has taken inconsistent positions with respect to projected costs in FY 2024, and that this highlights the need for CMS to provide an adjustment to the FY 2024 market basket update.

Response: The FY 2024 LTCH market basket update is derived using IGI’s independent projections of price, wage, and economic expectations. These projections are not based on similar considerations as those used to derive the outlier fixed-loss amount for LTCH PPS standard Federal payment rate cases. However, we note that after consideration of comments received, as discussed in section V.D.3. of the addendum to this final rule, we are modifying our proposed methodology for establishing the FY 2024 outlier fixed-loss amount for LTCH PPS standard Federal payment rate cases. These modifications include changes to the proposed charge inflation factor and cost-to-charge ratio adjustment factor, which when used to estimate the cost of each claim reflects a projected increase in the cost of FY 2024 LTCH PPS standard Federal payment rate cases that more closely aligns with the FY 2024 market basket update.

Comment: Several commenters expressed concerns about the proposed productivity adjustment and requested that CMS use its existing authority to eliminate the adjustment for FY 2024. Several commenters requested that CMS at least temporarily (if not permanently) suspend the productivity adjustment due to recent declines in hospital productivity. A commenter noted that the private nonfarm business economy experienced a rapid increase in output and productivity gains when communities began emerging from COVID–19 lockdowns in late 2021, but that this does not refute the need for hospital services. The commenter stated that generally, hospital services have not recovered to pre-pandemic levels, and it is highly unlikely that hospitals have achieved the significant productivity gains incorporated into the proposed FY 2024 payment update. The commenter stated that CMS research indicates that hospitals can only achieve a productivity gain that is one-third of the gains seen in the private nonfarm business sector and using the private nonfarm business sector total factor productivity to adjust the market basket exacerbates Medicare underpayments to hospitals.

Response: As required by statute and as discussed in greater detail in section V.B.1. of this preamble, the FY 2024 productivity adjustment is derived based on the 10-year moving average growth in economy-wide productivity for the period ending in FY 2024. We recognize the concerns of the commenters regarding the appropriateness of the productivity adjustment; however, as we explained in response to similar comments in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49165), we are required pursuant to section 1886(m)(3)(A)(i) of the Act to apply the specific productivity adjustment described in section 1886(b)(3)(B)(xi) of the Act; therefore, we do not have the authority to eliminate the productivity adjustment. For this final rule, based on IGI’s second quarter 2023 forecast, we are updating the productivity adjustment to reflect more recent historical data as published by BLS for 2022 as well as a revised economic outlook for FY 2023 and FY 2024. Using this forecast, the FY 2024 productivity adjustment based on the 10-year moving average growth in economy-wide total factor productivity for the period ending FY 2024 is 0.2 percentage point, which is lower than the productivity adjustments applied for FY 2022 and FY 2023.

Comment: A commenter cited a 2022 AHA report that stated that contract nurses continue to account for an outsized portion of hospitals’ labor costs. The commenter noted that this is important for two reasons: first, because of the increased expense and second, because the Employment Cost Index (ECI) used by CMS to calculate the market basket update includes only hospital-employed staff and not the contract staffing that hospitals have been forced to rely on more than ever in recent years. The commenter urged CMS to use its broad authority to provide a more accurate payment update. The commenter recognized that CMS has an established methodology for calculating rate increases and that CMS relies on a specific source of data for those calculations, however, in the
commenter’s view, that data source is failing to produce an appropriate update that reflects actual increases in healthcare costs. The commenter stated that CMS has the authority to change its methodology and encouraged CMS to do so.

Response: As previously discussed, the 2017-based LTCH market basket is a fixed-weight, Laspeyres-type price index that measures the change in price, over time, of the same mix of goods and services purchased in the base period. Any changes in the quantity or mix of goods and services (that is, intensity) purchased over time relative to a base period are not measured.

For the compensation cost weight in the 2017-based LTCH market basket (which includes salaried and contract labor employees), we use the ECI for wages and salaries and benefits for all civilian workers in hospitals to proxy the price increases of labor for LTCHs (there is not a publicly available data source for LTCH workers only). We note that the 2017-based LTCH market basket cost weights show that contract labor costs account for about 8 percent of total compensation costs (reflecting employed and contract labor staff) for LTCHs in 2017 and we found a similar proportion based on 2020 Medicare cost report data. As mentioned previously, we will analyze more recent Medicare cost report data as they become available. The ECI (published by the BLS) measures the change in the hourly labor cost to employers, independent of the influence of employment shifts among occupations and industry categories. An analysis of Medicare cost report data for LTCHs that reported contract labor hours on Worksheet S–3 part II shows that contract labor hours accounted for about 4 percent of total compensation hours (reflecting employed and contract labor staff) in 2020. The proportion found for IPPS hospitals was similar. Therefore, while we acknowledge that the ECI measures only reflect price changes for employed staff, we believe that the ECI for hospital workers accurately reflects the price change associated with the labor used to provide hospital care (as employed workers’ hours account for 96 percent of hospital compensation hours). For these reasons, we believe it continues to be an appropriate measure to use in the LTCH market basket. Therefore, we are not adopting commenters’ request to make an adjustment to the FY 2024 payment update. As discussed earlier, we plan to analyze the Medicare cost report data for LTCHs and assess whether a proposal to rebase and revise the LTCH market basket is appropriate for FY 2025.

After consideration of public comments, we are finalizing the LTCH payment update using the most recent forecast of the 2017-based LTCH market basket percentage increase and productivity adjustment. As such, based on IGI’s second quarter 2023 forecast, the FY 2024 market basket update for the LTCH PPS using the 2017-based LTCH market basket is 3.5 percent. The current estimate of the productivity adjustment for FY 2024 based on IGI’s second quarter 2023 forecast is 0.2 percentage point. Therefore, under the authority of section 123 of the BBRA as amended by section 307(b) of the BIPA, consistent with 42 CFR 412.523(c)(3)(xviii), we are establishing an annual market basket update to the LTCH PPS standard Federal payment rate for FY 2024 of 3.3 percent (that is, the most recent estimate of the LTCH market basket percentage increase of 3.5 percent less the productivity adjustment of 0.2 percentage point).

For LTCHs that fail to submit quality reporting data under the LTCH QRP, under § 412.523(c)(3)(xvii) in conjunction with 42 CFR 412.523(c)(4), as we proposed, we further reduced the annual update to the LTCH PPS standard Federal payment rate by 2.0 percentage points, in accordance with section 1886(m)(5) of the Act. Accordingly, we are establishing an annual update to the LTCH PPS standard Federal payment rate of 1.3 percent (that is, 3.3 percent minus 2.0 percentage points) for FY 2024 for LTCHs that fail to submit quality reporting data as required under the LTCH QRP.

IX. Quality Data Reporting Requirements for Specific Providers

A. Overview

In section IX of the preamble of the proposed rule (88 FR 27074 through 27173), we sought comment on and proposed changes to the following Medicare quality reporting programs:

• In section IX.B., Proposal to Modify the COVID–19 Vaccination Coverage Among Healthcare Personnel Measure in the Hospital IQR Program, PCHQR Program, and LTCH QRP.
  • In section IX.C., the Hospital IQR Program.
  • In section IX.F., the PCHQR Program.
  • In section IX.G., the LTCH QRP.
  • In section IX.H. the Medicare Promoting Interoperability Program for Eligible Hospitals and Critical Access Hospitals (CAHs) (previously known as the Medicare EHR Incentive Program).

We respond to public comments on each of these sections below.

B. Modification of the COVID–19 Vaccination Coverage Among Healthcare Personnel Measure for the Hospital Inpatient Quality Reporting, Long-Term Care Hospital Quality Reporting, and PPS-Exempt Cancer Hospital Quality Reporting Programs

(1) Background

On January 31, 2020, the Secretary of the Department of Health and Human Services declared a public health emergency (PHE) for the United States in response to the global outbreak of SARS–CoV–2, a novel (new) coronavirus that causes a disease named “coronavirus disease 2019” (COVID–19). Subsequently, the measure was adopted across multiple quality reporting programs including the Hospital Inpatient Quality Reporting Program (86 FR 45374), the Inpatient Psychiatric Facility Quality Reporting Program (86 FR 42633 through 42640), the Hospital Outpatient Quality Reporting Program (86 FR 63824 through 63833), the PPS-Exempt Cancer Hospital Quality Reporting Program (86 FR 45428 through 45434), the Ambulatory Surgical Center Quality Reporting Program (86 FR 45385), the Skilled Nursing Facility Quality Reporting Program (86 FR 42480 through 42489), the End-Stage Renal Disease Quality Incentive Program (87 FR 67244 through 67248), and the Inpatient Rehabilitation Facility Quality Reporting Program (86 FR 42385 through 42396). COVID–19 has continued to spread domestically and around the world with more than 103.9 million cases and 1.13 million deaths in the United States as of June 19, 2023. In recognition of the ongoing significance and complexity of COVID–19, the Secretary renewed the PHE on April 21, 2020, July 23, 2020, October 2, 2020, January 7, 2021, April 15, 2021, July 19, 2021, October 15, 2021, January 14, 2022, April 12, 2022, July 15, 2022, October 13, 2022, January 11, 2023, and February 9, 2023.319
While the PHE status expired on May 11, 2023, HHS stated that the public health response to COVID–19 remains a public health priority with a whole of government approach to combating the virus, including through vaccination efforts.321

As we stated in the FY 2022 IPPS/LTC PP final rule (Hospital IQR Program (86 FR 45375), PCHQR Program (86 FR 45428), and LTCQ QRP (86 FR 45436)) and in our Revised Guidance for Staff Vaccination Requirements,322 vaccination is a critical part of the nation’s strategy to effectively counter the spread of COVID–19. We continue to believe it is important to incentivize and track HCP vaccination through quality measurement across care settings, including the inpatient, long-term care, and cancer hospital settings to protect healthcare workers, patients, and caregivers, and to help sustain the ability of HCP in each of these care settings to continue serving their communities throughout the PHE and beyond. At the time we issued the FY 2022 IPPS/LTC PP final rule, the Food and Drug Administration (FDA) had issued emergency use authorizations (EUAs) COVID–19 vaccines for adults manufactured by Pfizer-BioNTech,323 Moderna,324 and Janssen.325 The populations for which all three vaccines were authorized at that time included individuals 18 years of age and older, and the Pfizer-BioNTech vaccine was authorized for ages 12 and older. Shortly following the publication of that final rule, on August 23, 2021, the FDA issued an approval for the Pfizer-BioNTech vaccine, marketed as Comirnaty.326 The FDA issued approval for the Moderna vaccine, marketed as Spikevax, on January 31, 2022,327 and an EUA for the Novavax adjuvanted vaccine on July 13, 2022.328 The FDA also issued EUAs for single booster doses of the then authorized COVID–19 vaccines. As of November 19, 2021,329 330 331 a single booster dose of each COVID–19 vaccine was authorized for all eligible individuals 18 years of age and older. EUAs were subsequently issued for a second booster dose of the Pfizer-BioNTech and Moderna vaccines in certain populations in March 2022.332 FDA first authorized the use of a booster dose of bivalent or “updated” COVID–19 vaccines from Pfizer-BioNTech and Moderna in August 2022.333 We stated at the time of publication of the FY 2022 IPPS/LTC PP final rule that data on the effectiveness of COVID–19 vaccines to prevent asymptomatic infection or transmission of SARS–CoV–2 were limited (Hospital IQR Program (86 FR 45375) and PCHQR Program (86 FR 45430)). While the impact of COVID–19 vaccines on asymptomatic infection and transmission is not yet fully known, there is now robust data available on COVID–19 vaccine effectiveness across multiple populations against symptomatic infection, hospitalization, and death. Two-dose COVID–19 vaccines from Pfizer-BioNTech and Moderna were found to be 88 percent and 93 percent effective against hospitalization for COVID–19, respectively, over six months for adults over age 18 without immunocompromising conditions.334 During a SARS–CoV–2 surge in the spring and summer of 2021, 92 percent of COVID–19 hospitalizations and 91 percent of COVID–19–associated deaths were reported among persons not fully vaccinated.335 Real-world studies of population-level vaccine effectiveness indicated similarly high rates of effectiveness in preventing SARS–CoV–2 infection among frontline workers in multiple industries, with a 90 percent effectiveness in preventing symptomatic and asymptomatic infection from December 2020 through August 2021.336 Vaccines have also been highly effective in real-world conditions preventing COVID–19 in HCP with up to 96 percent effectiveness for fully vaccinated HCP, including those at risk for severe infection and those in racial and ethnic groups disproportionately affected by COVID–19.337


community prevalence of COVID–19, residents of nursing homes with low staff vaccination coverage had bad cases of COVID–19 related deaths 195 percent higher than those among residents of nursing homes with high staff vaccination coverage. Overall, data demonstrate that COVID–19 vaccines are effective and prevent severe disease, including hospitalization and death.

As SARS–CoV–2 persists and evolves, our COVID–19 vaccination strategy must remain responsive. When we finalized adoption of the COVID–19 Vaccination Coverage among HCP measure in the FY 2022 IPPS/LTCH PPS final rule, we stated that the need for booster doses of COVID–19 vaccines had not been established and no additional doses had been recommended (Hospital IQR Program (86 FR 45378), PCHQR Program (86 FR 45432), and LTCH QRP (86 FR 45444)). We also stated that we believed the numerator was sufficiently broad to include potential future boosters as part of a “complete vaccination course” and that the measure was sufficiently specified to address boosters (Hospital IQR Program (86 FR 45378), PCHQR Program (86 FR 45432), and LTCH QRP (86 FR 45444)). Since we finalized the COVID–19 Vaccination Coverage among HCP measure in the FY 2022 IPPS/LTCH PPS final rule, new variants of SARS–CoV–2 have emerged around the world and within the United States. Specifically, the Omicron variant (and its related subvariants) is listed as a variant of concern by the CDC because it spreads more easily than earlier variants. Vaccine manufacturers have responded to the Omicron variant by developing bivalent COVID–19 vaccines, which include a component of the original virus strain to provide broad protection against COVID–19 and a component of the Omicron variant to provide better protection against COVID–19 caused by the Omicron variant.
of getting adequate documentation and emphasized the goal to ensure the measure does not present a burden on the provider. The developer also noted that the model used for this measure is based on the Influenza Vaccination Coverage among HCP measure (CBE #0431), and it intends to utilize a similar approach to the modified COVID–19 Vaccination Coverage among HCP measure if vaccination strategy becomes seasonal. The revised measure received conditional support for rulemaking from both MAP workgroups pending testing indicating the measure is reliable and valid, and endorsement by the consensus-based entity (CBE). The MAP noted that the previous version of the measure received endorsement from the CBE (CBE #3636) and that the CDC intends to submit the updated measure for endorsement.

(a) Measure Specifications
This measure includes at least one week of data collection a month for each of the three months in a quarter. The denominator is the number of HCP eligible to work in the facility for at least one day during the reporting period, excluding persons with contraindications to COVID–19 vaccination that are described by the CDC. Facilities report the following four categories of HCP to NHSN:354

1. Employees: includes all persons who receive a direct paycheck from the reporting facility (that is, on the facility’s payroll), regardless of clinical responsibility or patient contact.

2. Licensed independent practitioners (LIPs): This includes physicians (MD, DO), advanced practice nurses, and physician assistants only who are affiliated with the reporting facility, but not directly employed by it (that is, they do not receive a direct paycheck from the reporting facility), regardless of clinical responsibility or patient contact. Post-residency fellows are also included in this category if they are not on the facility’s payroll.

3. Adult students/trainees and volunteers: This includes all medical, nursing, or other health professional students, interns, medical residents, and volunteers aged 18 or over who are affiliated with the healthcare facility but are not directly employed by it (that is, they do not receive a direct paycheck from the facility), regardless of clinical responsibility or patient contact.

4. Other contract personnel: Contract personnel are defined as persons providing care, treatment, or services at the facility through contract who do not fall into any of the previously discussed denominator categories. This also includes vendors providing care, treatment, or services at the facility who may or may not be paid through a contract. Facilities are required to enter data on other contract personnel for submission in the NHSN application, but data for this category are not included in the COVID–19 Vaccination Coverage among HCP measure.

The denominator excludes other contract personnel with contraindications as defined by the CDC.355 There are no changes to the denominator exclusions.

The numerator will be the cumulative number of HCP in the denominator population who are considered up to date with CDC recommended COVID–19 vaccines. Providers should refer to the definition of up to date as of the first day of the applicable reporting quarter, which can be found at: https://www.cdc.gov/nhsn/pdfs/hps/covidvax/UpToDateGuidance-508.pdf. In the proposed rule we provided the example that HCP would have been considered up to date during the Quarter 4 CY 2022 reporting period for the Hospital IQR Program, PCHQR Program, and the LTCH QRP if they met one of the following criteria:

1. Individuals who received an updated bivalent356 booster dose, or
2a. Individuals who received their last booster dose less than 2 months ago, or
2b. Individuals who completed their primary series357 less than 2 months ago.

We note that since publication of the proposed rule, CDC’s definition for up to date vaccination has evolved. HCP who would be considered up to date in the Quarter 3 CY 2023 reporting period for the Hospital IQR Program, PCHQR Program, and the LTCH QRP if they met the following criteria:


1. Individuals who received an updated bivalent booster dose. We refer readers to https://www.cdc.gov/hnhs/pdfs/ngf/covid-vax-hcpcoverage-rev-2023-508.pdf for more details on the measure specifications.

We proposed that public reporting of the modified version of the COVID–19 Vaccination Coverage among HCP measure will begin with the October 2024 Care Compare refresh or as soon as technically feasible after then, for the Hospital IQR Program, PCHQR Program, and LTCH QRP.

(b) CBE Endorsement

The current version of the measure in the Hospital IQR Program, PCHQR Program, and LTCH QRP received CBE endorsement (CBE #3636, “Quarterly Reporting of COVID–19 Vaccination Coverage among Healthcare Personnel”) on July 26, 2022. The applicable authorities of the Hospital IQR Program, PCHQR Program, and LTCH QRP generally require that measures specified by the Secretary for use in these programs be endorsed by the CBE with a contract under section 1886(m)(5)(D)(ii) of the Act for the LTCH QRP.

(c) Bivalent mRNA COVID–19 Vaccines

We invited public comment on this proposal. Many commenters supported the proposed modification to the COVID–19 Vaccination Coverage among HCP measure. A few commenters noted the importance of vaccination in preventing greater spread of COVID–19 and the potential for continued vaccination to prevent future large-scale outbreaks.

Response: We thank the commenters for their support. We agree that vaccination plays a critical part of the Nation’s strategy to effectively counter the spread of COVID–19. We continue to believe it is important to incentivize and track HCP vaccination through quality measurement across care settings, including the inpatient, long-term care, and cancer hospital settings to protect healthcare workers, patients, and caregivers, and to help sustain the ability of HCP in each of these care settings to continue serving their communities.

Comment: Many commenters did not support updating the specifications for the COVID–19 Vaccination Coverage among HCP measure because the PHE has expired and the CoPs for hospitals have been revised to no longer require reporting of these data. Several commenters expressed concern that retaining measurement of COVID–19 vaccination coverage among HCP after the vaccination requirement has been removed from CoPs sends an inconsistent message regarding CMS’s priorities and increases the burden required to continue to collect and report these data. A commenter observed that the end of other Federal vaccination requirements creates challenges for justifying continued data collection for this measure, particularly in states where vaccination requirements have been contentious.

Response: Since publication of the FY 2024 IPPS/LTCH PPS proposed rule, the COVID–19 PHE expired on May 11, 2023. We acknowledge that some state and Federal requirements regarding COVID–19 vaccination have since changed. CMS requirements for Medicare and Medicaid-certified providers and suppliers to ensure that their staff were fully vaccinated for COVID–19 have ended with the expiration of the COVID–19 PHE (88 FR 36448). Nevertheless, we revised the hospital and critical access hospitals (CAHs) infection prevention and control CoP so that hospitals and CAHs will continue to report on a reduced number of COVID–19 data elements after the conclusion of the COVID–19 PHE until April 30, 2024, unless the Secretary
establishes an earlier end date. While these changes may impact certain aspects of facility reporting on COVID–19 data, we note that the reporting requirements of the Hospital IQR, PCHQR, and LTCH QRPs are distinct from those related to the expiration of the PHE and facilities participating in these programs are required to report the COVID–19 Vaccination Coverage among HCP measure. We further note that in our final rule removing staff vaccination requirements, we clarified that we were aligning our approach with that for other infectious diseases, specifically influenza, and that we would encourage ongoing COVID–19 vaccination through our quality reporting and value-based incentive programs (88 FR 38446).

This measure continues to align with our goals to promote wellness and disease prevention. Under CMS’ Meaningful Measures Framework 2.0, the COVID–19 Vaccination Coverage among HCP measure addresses the quality priorities of “Immunizations” and “Public Health,” through the Meaningful Measures Area of “Wellness and Prevention.” Under the National Quality Strategy, the measure addresses the goal of Safety under the priority area Safety and Resiliency. Our continued response to COVID–19 is not fully dependent on the emergency declaration for the COVID–19 PHE and, beyond the end of the COVID–19 PHE, we continue to work to protect individuals and communities from the virus and its worst impacts by supporting access to COVID–19 vaccines and tests.

Comment: Many commenters did not support updating the COVID–19 Vaccination Coverage among HCP measure because of concerns that the frequency of changes to the CDC’s definition of up to date combined with the uncertainty around future vaccination schedules creates unnecessary burden for facilities. Many commenters expressed concern that changing definitions and guidance exacerbates staffing and resource challenges and requires updates to facility or system-level vaccination policies, adding burden and confusion. Some of these commenters recommended maintaining current measure requirements to collect only primary vaccination series to reduce this burden or to remove the measure entirely.

Response: Since the adoption of the current version of the COVID–19 Vaccination Coverage among HCP measure, the public health response to COVID–19 has necessarily adapted to respond to the changing nature of the virus’s transmission and community spread. When we finalized the adoption of the COVID–19 Vaccination Coverage among HCP measure in the FY 2022 IPPS/LTC PPS final rule (Hospital IQR Program, 86 FR 45374; PCHQR Program, 86 FR 45428; LTCH QRP, 86 FR 45438), we received several comments encouraging us to continue to update the measure as new evidence on COVID–19 continues to arise and we stated our intention to continue to work with partners including the FDA and CDC to consider any updates to the measure in future rulemaking as appropriate. We recognize commenters’ recommendations to limit reporting to primary series or remove the measure to reduce burden but disagree with these suggestions given the ongoing circulation of SARS–CoV–2. The measure modification aligns with the CDC’s responsive approach to COVID–19 and will continue to support vaccination as the most effective means to prevent the worst consequences of COVID–19, including severe illness, hospitalization, and death.

Comment: Many commenters did not support the measure modification and recommended that we reduce the required reporting frequency to quarterly or annually to reduce reporting burden for facilities. Some of these commenters observed that annual reporting would mirror the reporting schedule for the Influenza Vaccination Coverage among HCP measure, which is in some quality reporting programs. A couple of commenters observed that the COVID–19 Vaccination Coverage among HCP measure is significantly more burdensome than the Influenza Vaccination Coverage among HCP measure, which is a “yes” or “no” attestation. Others believed that annual reporting would not improve patient understanding of publicly reported measure data, which they considered as out of date at the time of display and therefore not accurately reflective of facility HCP vaccination levels. A couple of commenters stated that there is variation between states and facilities in what information can be requested of staff and under which conditions of employment, which may also impact the accuracy of public reporting and could increase the burden of reporting depending on a facility’s location. A few commenters believed that the requirements to report vaccination status for all personnel, including contract personnel, students, volunteers, and independent contractors, is particularly burdensome and requires multiple applications and processes. Several commenters believed that, in addition to reducing reporting frequency, any future reporting of the measure should be voluntary. A commenter recommended collecting data only for HCP who have been vaccinated within the prior six months to reduce burden and increase data accuracy. Another commenter observed that, in addition to reduced reporting frequency, an alternate data collection option, such as collection of information at the location where the vaccinations occurred, would be less burdensome for small, rural, and underserved facilities.

Response: As we stated in the FY 2024 IPPS/LTC PPS proposed rule (88 FR 27077), the measure developer noted that the model used for this measure is based on the Influenza Vaccination Coverage among HCP measure (CBE #0431), which is reported annually, and it intends to utilize a similar approach to the modified COVID–19 Vaccination Coverage among HCP measure if vaccination strategy becomes seasonal. While monitoring and surveillance are ongoing, we do not currently have data demonstrating seasonal trends in the circulation of SARS–CoV–2 and therefore at this time, reporting at least one self-selected week during each month of the reporting quarter remains appropriate. Additionally, while the measure developer noted that the model used for this measure is based on the Influenza Vaccination Coverage among HCP measure (CBE #0431), these are different public health initiatives, and different vaccines, and therefore the measure specifications are not in complete alignment (86 FR 45379). Further, as the continued circulation of the SARS–CoV–2 virus in the United States, we do not believe it...
is appropriate to propose voluntary reporting or reduce the population of HCP reported for the measure at this time. We agree with commenters who observe that there is a delay between data collection and public reporting for this measure and note that such a delay exists for all measures in the Hospital IQR, PCHQR, and LTCH Quality Reporting Programs. However, the data will provide meaningful information to consumers in making healthcare decisions because the data will be able to reflect differences between facilities in COVID–19 vaccination coverage of their workforce even if the data do not reflect immediate vaccination rates. While we recognize the commenter suggestion to limit data collection to those HCP vaccinated in the prior six months, we disagree that this would reduce burden for reporting facilities and would not improve data accuracy as reporting facilities may be required to revise reporting processes.

We also recognize the commenter concerns about reporting burden, we note that for purposes of NHSN surveillance, the CDC began using the same definition of up to date reflected in the measure modification beginning with the Quarter 3 2023 surveillance period (June 26, 2023–September 24, 2023). Additionally, facilities have been reporting the COVID–19 Vaccination Coverage among HCP measure since October 1, 2021 and there has been sufficient time to allocate the necessary resources required to report the measure. We recognize the unique challenges of small and rural facilities but note that NHSN reporting does not permit data collection from the site of vaccination at this time. We continue to monitor COVID–19 as part of our public health response and will consider data as well as commenters’ feedback to inform any future rulemaking.

Comment: Several commenters expressed concern that the COVID–19 Vaccination Coverage among HCP measure has not been endorsed by the CBE.

Response: The current version of the measure received CBE endorsement (CBE #3636, “Quarterly Reporting of COVID–19 Vaccination Coverage among Healthcare Personnel”) on July 26, 2022. As we stated in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27078), in the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed by the entity with a contract under section 1890(a) of the Act, the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary. For this FY 2024 IPPS/LTCH PPS rule cycle, we reviewed CBE-endorsed measures. While the current, CBE-endorsed version of the measure is available, the modified version of the measure more completely accounts for the availability of booster and bivalent doses which were not yet developed when the current version of the measure was adopted. Because the modified version of the measure is more comprehensive than the current version, the exception for non-CBE-endorsed measures applies. The measure steward, CDC, has submitted the modified measure to the CBE for endorsement and it is currently under review.372

Comment: Some commenters recommended that we include an exclusion for sincerely held religious beliefs to adhere to HHS Office of Civil Rights Guidance. Some of these commenters also requested the measure be updated to track the number of HCP who decline vaccination. Several commenters observed that there are many factors beyond a facility’s control (such as weather, holidays, state or local regulations, etc.) that may affect performance on this measure.

Response: We recognize that there are many reasons, including religious objections or concerns regarding an individual HCP’s specific health status that may lead individual HCP to decline vaccination. The CDC’s NHSN tool allows facilities to report on the number of HCP who decline vaccination. Several commenters observed that there are many factors beyond a facility’s control (such as weather, holidays, state or local regulations, etc.) that may affect performance on this measure.

Comment: We thank the commenters for their questions. We are aware that some facilities may have experienced issues with reporting weeks that crossed between two months, whereafter the reporting is not properly received and the facility appears non-compliant. Another commenter requested clarification whether NHSN data submission for the measure meets all requirements for the measure under the Hospital IQR Program.

Response: We thank the commenters for their questions. We are aware that some facilities may have experienced issues with reporting weeks that crossed between two months. CDC has clarified that a week is designated as belonging to the month of the week-end date. For example, reporting data for the week of September 27 through October 3 is


373 Weekly Healthcare Personnel Influenza Vaccination Summary for Non-Long-Term Care Facilities-HCP (cdc.gov).
considered as submitting data for a week in October. More information is available in the NHSN Manual for COVID–19 Vaccination Reporting and through CDC Frequently Asked Questions on COVID–19 Hospital Data Reporting. We also wish to clarify that NHSN data submission for the measure does meet requirements under the Hospital IQR Program for participating facilities.

After consideration of the public comments we received, we are finalizing the proposal as proposed.

C. Changes to the Hospital Inpatient Quality Reporting (IQR) Program

1. Background and History of the Hospital IQR Program

Through the Hospital IQR Program, we strive to ensure that patients, along with their clinicians, can use information from meaningful quality measures to make better decisions about their health care. We support technology that reduces burden and allows clinicians to focus on providing high-quality healthcare for their patients. We also support innovative approaches to improve quality, accessibility, affordability, and equity of care while paying particular attention to improving clinicians’ and beneficiaries’ experiences when interacting with CMS programs. In combination with other efforts across HHS, we believe the Hospital IQR Program incentivizes hospitals to improve healthcare quality and value, while giving patients the tools and information needed to make the best decisions for themselves.

We seek to promote higher quality, equitable, and more efficient healthcare for Medicare beneficiaries. The adoption of widely agreed upon quality and cost measures supports this effort. We work with relevant interested parties to define measures in almost every care setting and currently measure many aspects of care for almost all Medicare beneficiaries. These measures assess clinical processes and outcomes, patient safety and adverse events, patient experiences with care, care coordination, and cost of care. We have implemented quality measure reporting programs for multiple settings of care. To measure the quality of hospital inpatient services, we implemented the Hospital IQR Program. We refer readers to the following final rules for detailed discussions of the history of the Hospital IQR Program, including statutory history, and for the measures we have previously adopted for the Hospital IQR Program measure set:

- The FY 2010 IPPS/LTCH PPS final rule (74 FR 43860 through 43861);
- The FY 2011 IPPS/LTCH PPS final rule (75 FR 50180 through 50181);
- The FY 2012 IPPS/LTCH PPS final rule (76 FR 51605 through 61653);
- The FY 2013 IPPS/LTCH PPS final rule (77 FR 53503 through 53555);
- The FY 2014 IPPS/LTCH PPS final rule (78 FR 50775 through 50837);
- The FY 2015 IPPS/LTCH PPS final rule (79 FR 50217 through 50249);
- The FY 2016 IPPS/LTCH PPS final rule (80 FR 49660 through 49692);
- The FY 2017 IPPS/LTCH PPS final rule (81 FR 57148 through 57150);
- The FY 2018 IPPS/LTCH PPS final rule (82 FR 38326 through 38328 and 38348);
- The FY 2019 IPPS/LTCH PPS final rule (83 FR 41538 through 41609);
- The FY 2020 IPPS/LTCH PPS final rule (84 FR 42448 through 42509);
- The FY 2021 IPPS/LTCH PPS final rule (85 FR 58926 through 58959);
- The FY 2022 IPPS/LTCH PPS final rule (86 FR 45360 through 45426); and
- The FY 2023 IPPS/LTCH PPS final rule (87 FR 49190 through 49310).

We also refer readers to 42 CFR 412.140 for Hospital IQR Program regulations.

2. Retention of Previously Adopted Hospital IQR Program Measures for Subsequent Payment Determinations

We refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53512 and 53513) for our finalized measure retention policy. Pursuant to this policy, when we adopt measures for the Hospital IQR Program beginning with a particular payment determination, we automatically readopt these measures for all subsequent payment determinations unless a different or more limited period is proposed and finalized. Measures are also retained unless we propose to remove, suspend, or replace the measures. We did not propose any changes to these policies in the proposed rule.

3. Removal Factors for Hospital IQR Program Measures

We refer readers to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41540 through 41544) for a summary of the Hospital IQR Program’s removal factors. We did not propose any changes to these policies in the proposed rule. However, as discussed in section IX.C.7.d. of this final rule, we are codifying our measure retention and removal policies in our regulations at § 412.140.

4. Considerations in Expanding and Updating Quality Measures

We refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53510 through 53512) for a discussion of the previous considerations we have used to expand and update quality measures under the Hospital IQR Program. We also refer readers to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41147 and 41148), in which we describe the Meaningful Measures Framework. In 2021, we launched Meaningful Measures 2.0 to promote innovation and modernization of all aspects of quality, and to address a wide variety of settings, interested parties, and measure requirements.

We also refer readers to the CMS National Quality Strategy that we launched on April 12, 2022, with the aims of promoting the highest quality outcomes and safest care for all individuals.

We did not propose any changes to these policies in the proposed rule.

5. Proposed New Measures for the Hospital IQR Program Measure Set

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27079 through 27084), we proposed to adopt three new measures, all of which are electronic clinical quality measures (eCQMs): (1) Hospital Harm—Pressure Injury eCQM, with inclusion in the eCQM measure set beginning with the CY 2025 reporting period/FY 2027 payment determination and for subsequent years; (2) Hospital Harm—Acute Kidney Injury eCQM, with inclusion in the eCQM measure set beginning with the CY 2025 reporting period/FY 2027 payment determination and for subsequent years; and (3) Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography (CT) in Adults (Hospital Level—Inpatient) eCQM, with inclusion in the eCQM measure set beginning with the CY 2025 reporting period/FY 2027 payment determination and for subsequent years.

We discuss each of these measures, along with the public comments that we received on them, in subsequent sections.


a. Adoption of Hospital Harm—Pressure Injury eCQM, Beginning With the CY 2025 Reporting Period/FY 2027 Payment Determination and for Subsequent Years

(1) Background

Hospital-acquired pressure injuries are serious events and one of the most common patient harms. The incidence of pressure injuries in hospitalized patients has been estimated at 5.4 per 10,000 patient-days and the rate of hospital-acquired pressure injuries has been estimated at 8.4 percent for inpatients.379 Pressure injuries commonly lead to further patient harm, including local infection, osteomyelitis, anemia, and sepsis.380 In addition to causing pain and discomfort to patients,381 Development of a pressure injury can increase the length of a patient’s hospital stay by an average of four days.382 Hospital-acquired pressure injuries are associated with 1.5 to 2.0 times greater risk of 30, 60, and 90-day readmissions.383 Any stage 3, stage 4, or unstageable pressure ulcer acquired after admission/presentation to a healthcare setting is considered a serious reportable event by the Agency for Healthcare Research and Quality (AHRQ).384 The risk of developing a pressure injury can be reduced through best practices including risk assessment, assessment of skin and tissue, preventive skin care, and reducing progression through treatment of pressure injuries, including nutrition.385

Prior studies also confirm that significant variation in rates of hospital-acquired pressure injuries exists between hospitals and show a higher prevalence of pressure injuries in patients with darker skin tones.386-387 These findings suggest that current skin assessment protocols could be less effective at assessing lower stage pressure injuries for people with darker skin tones and indicate an opportunity for improvement.

(2) Overview of Measure

The Hospital Harm-Pressure Injury measure is an outcome eCQM that assesses the proportion of inpatient hospitalizations for patients 18 years and older who suffer the harm of developing a new stage 2, stage 3, stage 4, deep tissue, or unstageable pressure injury. The intent of this measure is to incentivize greater achievements in reducing harms and to enhance hospital performance on patient safety outcomes. Systematically assessing patients who develop new pressure injuries while in the hospital setting will provide hospitals with a reliable and timely measurement of harm reduction efforts and the ability to modify their improvement efforts in near real-time.

This measure was previously described in the FY 2020 IPPS/LTCH PPS proposed rule (84 FR 19489 through 19491) to solicit public comment on potential future inclusion in the Hospital IQR Program. The measure developer has since revised the measure specifications in response to public comments and feedback. Specifically, the measure developer:

- Expanded the value set to improve capture of pressure injuries;
- Incorporated a present on admission indicator for ICD–10–CM diagnoses;
- Incorporated a denominator exclusion for pressure injuries present on admission;
- Incorporated a 24-hour time window for accurate and timely identification of stage 2, 3, 4, or unstageable pressure injury present on admission; and
- Incorporated a 72-hour time window for accurate and timely identification of deep tissue pressure injury (DTPI) because early diagnosis of DTPI allows prompt identification of possible causes, initiation of treatment, and implementation of preventive strategies. Up to 72 hours can lapse between the precipitating pressure event and the onset of purple or maroon skin, so a longer time window is needed to exclude cases when the precipitating event occurred before the patient’s admission.388

The measure was re-tested in 18 hospitals (test sites) with two different electronic health record (EHR) vendors (Epic and Cerner) with varying bed size, geographic location, teaching status, and urban/rural status. Test results indicated strong measure reliability (0.97 signal-to-noise ratio and 0.916 intra-class correlation coefficient using the split-half sample) and validity (strong concordance and inter-rater agreement between data exported from the EHR and data in the patient chart).389

An older version of this measure was reviewed by the consensus-based entity (CBE) convened Measure Applications Partnership (MAP)390 for the Hospital IQR Program and Medicare Promoting Interoperability Program during the 2017–2018 pre-rulemaking cycle. The measure received a recommendation of conditional support for rulemaking pending review and endorsement by the CBE once the measure was fully tested. This measure was subsequently reviewed by the CBE during the Spring 2019 cycle but withdrawn due to anticipated substantive changes in measure specifications, described in the Measure Overview section of the proposed rule and this final rule. The revised measure was re-submitted to the MAP for the 2022–2023 pre-rulemaking cycle and received conditional support for rulemaking pending endorsement by the CBE.391 During its review, the MAP expressed concern about the measure specifications and cautioned about potential bias against facilities that do not have the expertise needed to accurately stage pressure injuries (for example, certified wound care nurses).


382 Bauer K, Rock K, Nazzal M, Jones O, Qu W. (2021). Incorporating the 24-hour time window for accurate and timely identification of stage 2, 3, 4, or unstageable pressure injury present on admission; and

383 Prior studies also confirm that significant variation in rates of hospital-acquired pressure injuries exists between hospitals and show a higher prevalence of pressure injuries in patients with darker skin tones.386-387 These findings suggest that current skin assessment protocols could be less effective at assessing lower stage pressure injuries for people with darker skin tones and indicate an opportunity for improvement. Three studies have been reported that support these findings.


386 Interested parties convened by the consensus-based entity provide input and recommendations on the Measures under Consideration (MUC) list as part of the pre-rulemaking process required by section 1890A of the Act. We refer readers to https://p4qm.org/FRM/ for more information.

The MAP noted that risk adjustment may be necessary to ensure the measure does not disproportionately penalize facilities that may treat more complex patients (for example, academic medical centers or safety net providers). The MAP stated that the measure has several benefits as an eCQM in the Hospital IQR Program, including that hospitals can receive reliable and timely information on pressure injury rates and noted that hospital-acquired pressure injuries are one of the most common patient harms. Weighing these factors, the MAP ultimately offered its conditional support for rulemaking.392

The Hospital Harm-Pressure Injury measure was submitted to the CBE for endorsement review in the Fall 2022 cycle (CBE #3498e). Although section 1886(b)(3)(B)(viii)(IX)(aa) of the Act generally requires that measures specified by the Secretary for use in the Hospital IQR Program be endorsed by the entity with a contract under section 1890(a) of the Act, section 1886(b)(3)(B)(viii)(IX)(bb) of the Act states that in the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed by the entity with a contract under section 1890(a) of the Act, the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary. We reviewed CBE-endorsed measures and were unable to identify any other CBE-endorsed measures on this topic, and, therefore, we believe the exception in section 1886(b)(3)(B)(viii)(IX)(bb) of the Act applies.

(3) Measure Specifications
The numerator is inpatient hospitalizations for patients with a new DTPI or stage 2, 3, 4, or unstageable pressure injury, as evidenced by any of the following: (1) a diagnosis of DTPI with the DTPI not present on admission; (2) a diagnosis of stage 2, 3, 4 or unstageable pressure injury with the pressure injury diagnosis not present on admission; (3) a DTPI found on exam greater than 72 hours after the start of the encounter; (4) a stage 2, 3, 4 or unstageable pressure injury found on exam greater than 24 hours after the start of the encounter. The denominator is inpatient hospitalizations for patients with a DTPI or stage 2, 3, 4 or unstageable pressure injury diagnosis present on admission, (2) inpatient hospitalizations for patients with a DTPI found on exam within 72 hours of the encounter start, (3) inpatient hospitalizations for patients with a stage 2, 3, 4, or unstageable pressure injury found on exam within 24 hours of the encounter start, or (4) inpatient hospitalizations for patients with diagnosis of a COVID–19 infection during the encounter. Importantly, at the time of development and testing, the literature highlights a wide variety of skin manifestations of COVID–19 which hospitals have been confusing with pressure injury and sometimes report as pressure injury in the absence of clear coding guidance and clear evidence regarding the pathophysiology of COVID–19–related lesions.393 394 395 396 397

Based on recommendations from the Technical Expert Panel (TEP), the exclusion for COVID–19 is included as transitional with the intention to be removed in the future (during the routine eCQM Annual Update process) when the field develops a better consensus about what is COVID–19–related tissue breakdown versus what is pressure injury. We refer readers to the eCQM Resource Center (https://ecqi.healthit.gov/eh-cah?qt-tabs_eh=1) for more details on the measure specifications.

(4) Data Source and Reporting
This eCQM uses data collected through hospitals’ EHRs. The measure is designed to be calculated by the hospitals’ certified electronic health record technology (CEHRT) using the patient-level data and then submitted by hospitals to CMS. As with all quality measures we develop, testing was performed to confirm the feasibility of the measure, data elements, and validity of the numerator, using clinical adjudicators who validated the EHR data compared with medical chart-abstracted data. Testing demonstrated that all critical data elements were reliably and consistently captured in patient EHRs and measure implementation is feasible.

We proposed the adoption of the Hospital Harm-Pressure Injury eCQM as part of the eCQM measure set, from which hospitals can self-select measures to report to meet the eCQM requirement, beginning with the CY 2025 reporting period/FY 2027 payment determination and for subsequent years. We refer readers to section IX.C.10.e. of the preamble of this final rule for a discussion of our previously finalized eCQM reporting and submission policies. Additionally, we refer readers to section IX.F. of the preamble of this final rule for a discussion of a similar policy to adopt this measure in the Medicare Promoting Interoperability Program.

We invited public comment on this proposal. Comment: Many commenters supported the proposal to add the Hospital Harm-Pressure Injury eCQM (CBE #3498e) in the Hospital IQR Program. Many commenters noted that adoption of the measure would create valuable public transparency for hospitals and patients on the prevalence of pressure injuries and drive care improvements by encouraging the adoption of patient safety best practices, thereby reducing the risk for patient harm. A few commenters noted their appreciation for CMS expanding the list of available eCQMs within the Hospital IQR Program. A commenter suggested that the measure trigger an automatic mandatory submission of the Global Malnutrition Composite Score eCQM to strengthen the HAC Reduction Program by encouraging best practices for patient safety in inpatient facilities. A few commenters believed the measure should be incorporated into a value-based payment program to incentivize hospitals to adopt best practices. A few commenters appreciated the measure updates that exclude pressure injuries present on admission or that develop in a time window where the cause is unlikely to be tied to quality of care at the admitting hospital.

Response: We thank commenters for their support and input on the inclusion of Hospital Harm-Pressure Injury eCQM (CBE #3498e) in the Hospital IQR Program measure set, along with the CY 2025 reporting period/FY 2027 payment determination. Regarding

---

392 Ibid.

Note: The numbers 393, 394, 395, 396, and 397 correspond to references in the text.
commenters’ suggestion on mandatory reporting and use in a value-based payment program, we highlight that the Hospital Harm-Pressure Injury eCQM was proposed for the Hospital IQR Program and CMS separately makes decisions about inclusion of measures in value-based payment programs such as the HAC Reduction Program. However, in alignment with our goal of transitioning to a fully digital quality measurement landscape, we envision the potential future use of patient safety eCQMs in pay-for-performance programs such as the HAC Reduction Program.

Comment: A few commenters questioned whether 0.00 percent to 2.02 percent variation in performance rates among 18 hospital test sites is a sufficient performance gap to allow users to distinguish meaningful differences in performance. A commenter requested CMS weigh the performance gap of this measure against its other existing and potential new measures of patient safety to ensure this measure merits use in a CMS program. Others were supportive of addressing important patient safety concerns with the measure, but requested additional testing in a broader set of EHRs and hospitals.

Response: We acknowledge that some commenters have expressed concern regarding the magnitude of the performance gap, which they perceive to be small. We highlight that this measure was tested in 18 hospital test sites with varying bed size, geographic location, teaching status, urbanicity, and two different EHR systems. While it is true that measure scores among the hospitals tested ranged from 0.00 percent to 2.02 percent, regression results demonstrated that the measure detects clinically meaningful differences in pressure injuries across hospitals.

During testing, several hospitals’ performance rates were consistently below the system-wide average while a few others were above that mean, indicating room for quality improvement in the inpatient setting.

We will monitor the performance gap as hospitals begin to report this measure.

Comment: Several commenters requested CMS delay adoption of the measure until it was reviewed and endorsed by the CBE.

Response: We thank commenters for their feedback. As mentioned previously, although section 1886(b)(3)(B)(viii)(IX)(aa) of the Act generally requires that measures specified by the Secretary for use in the Hospital IQR Program be endorsed by the entity with a contract under section 1890(a) of the Act, section 1886(b)(3)(B)(viii)(IX)(bb) of the Act states that in the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed by the entity with a contract under section 1890(a) of the Act, the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary. The Hospital Harm-Pressure Injury measure was submitted to the CBE for endorsement review in the Fall 2022 cycle (CBE #3498e). The Patient Safety Standing Committee reviewed the measure at the measure evaluation meeting on February 9, 2023. The measure received high passing scores on all measure criterion (100% pass for evidence, reliability, validity, feasibility, usability and 92.9% pass for performance gap and use) and the committee passed the measure unanimously (14/0) with a feasibility and usability rating of 0/0 for endorsement.

CMS expects final measure endorsement when the Consensus Standards Approval Committee (CSAC) meets on July 24, 2023.

Comment: Several commenters did not support the adoption of the measure, raising concerns about implementation burden. A commenter requested that CMS allow hospitals two years to implement measures after they are finalized as there is significant technology and information technology (IT) systems work required to get hospital systems up to speed. Another commenter requested to delay measure adoption to the CY 2026 reporting period as pressure injuries are not currently documented in discrete fields at their facility but rather through provider notes. A few commenters had concerns with competing Federal quality reporting and EHR-related mandates given limited hospital quality and health IT resources.

Response: We thank commenters for their input. We highlight that the addition of this eCQM further advances CMS’ goal of transitioning to a fully digital quality measurement landscape, promoting interoperability that will help decrease burden. Feasibility testing in 34 hospital inpatient acute care facilities (17 using Meditech EHRs and 17 using Cerner EHRs) showed that all data elements for this measure are in defined fields in electronic sources.

Further, this measure is able to capture the occurrence of pressure injuries through either clinical documentation or ICD–10–CM diagnosis codes, providing an alternative option for hospitals that do not yet use discrete fields for pressure injuries. This measure was proposed for inclusion beginning in the CY 2025 reporting period, which means it would first be reported to CMS in early March 2026. As hospitals will not be required to report on this eCQM, the selection of this measure in the Hospital IQR Program need not compete with other Federal quality reporting and EHR-related mandates for limited hospital quality and health IT resources. Rather, the measure will be included as one of the eCQMs that hospitals can self-select for reporting beginning with the CY 2025 reporting period/FY 2027 payment determination.

Comment: Several commenters did not support measure adoption, citing that there is already a claims-based pressure injury measure in the Hospital Acquired Condition (HAC) Reduction Program (CMS PSI–03 within the CMS PSI–90 composite). Commenters noted that this measure is duplicative and does not reduce reporting requirements or align measures across programs. A few commenters asked for a single measure to streamline data tracking and avoid duplication and redundancies. A few commenters asked clarifying questions on measure implementation. A commenter asked if the intent is to retire PSI–03 when the Hospital Harm-Pressure Injury eCQM is added to the Hospital IQR Program. Another commenter asked if a single submission of the Hospital Harm-Pressure Injury eCQM would meet requirements for the Hospital IQR, Promoting Interoperability, and HAC Reduction Programs.

We thank commenters for their input. We highlight that the addition of this eCQM further advances CMS’ goal of transitioning to a fully digital quality measurement landscape, promoting interoperability that will help decrease burden. Feasibility testing in 34 hospital inpatient acute care facilities (17 using Meditech EHRs and 17 using Cerner EHRs) showed that all data elements for this measure are in defined fields in electronic sources.

Further, this measure is able to capture the occurrence of pressure injuries through either clinical documentation or ICD–10–CM diagnosis codes, providing an alternative option for hospitals that do not yet use discrete fields for pressure injuries. This measure was proposed for inclusion beginning in the CY 2025 reporting period, which means it would first be reported to CMS in early March 2026. As hospitals will not be required to report on this eCQM, the selection of this measure in the Hospital IQR Program need not compete with other Federal quality reporting and EHR-related mandates for limited hospital quality and health IT resources. Rather, the measure will be included as one of the eCQMs that hospitals can self-select for reporting beginning with the CY 2025 reporting period/FY 2027 payment determination.

Comment: Several commenters did not support measure adoption, citing that there is already a claims-based pressure injury measure in the Hospital Acquired Condition (HAC) Reduction Program (CMS PSI–03 within the CMS PSI–90 composite). Commenters noted that this measure is duplicative and does not reduce reporting requirements or align measures across programs. A few commenters asked for a single measure to streamline data tracking and avoid duplication and redundancies. A few commenters asked clarifying questions on measure implementation. A commenter asked if the intent is to retire PSI–03 when the Hospital Harm-Pressure Injury eCQM is added to the Hospital IQR Program. Another commenter asked if a single submission of the Hospital Harm-Pressure Injury eCQM would meet requirements for the Hospital IQR, Promoting Interoperability, and HAC Reduction Programs.

We thank commenters for their input. We highlight that the addition of this eCQM further advances CMS’ goal of transitioning to a fully digital quality measurement landscape, promoting interoperability that will help decrease burden. Feasibility testing in 34 hospital inpatient acute care facilities (17 using Meditech EHRs and 17 using Cerner EHRs) showed that all data elements for this measure are in defined fields in electronic sources.

Further, this measure is able to capture the occurrence of pressure injuries through either clinical documentation or ICD–10–CM diagnosis codes, providing an alternative option for hospitals that do not yet use discrete fields for pressure injuries. This measure was proposed for inclusion beginning in the CY 2025 reporting period, which means it would first be reported to CMS in early March 2026. As hospitals will not be required to report on this eCQM, the selection of this measure in the Hospital IQR Program need not compete with other Federal quality reporting and EHR-related mandates for limited hospital quality and health IT resources. Rather, the measure will be included as one of the eCQMs that hospitals can self-select for reporting beginning with the CY 2025 reporting period/FY 2027 payment determination.

Comment: Several commenters did not support measure adoption, citing that there is already a claims-based pressure injury measure in the Hospital Acquired Condition (HAC) Reduction Program (CMS PSI–03 within the CMS PSI–90 composite). Commenters noted that this measure is duplicative and does not reduce reporting requirements or align measures across programs. A few commenters asked for a single measure to streamline data tracking and avoid duplication and redundancies. A few commenters asked clarifying questions on measure implementation. A commenter asked if the intent is to retire PSI–03 when the Hospital Harm-Pressure Injury eCQM is added to the Hospital IQR Program. Another commenter asked if a single submission of the Hospital Harm-Pressure Injury eCQM would meet requirements for the Hospital IQR, Promoting Interoperability, and HAC Reduction Programs.

We thank commenters for their input. We highlight that the addition of this eCQM further advances CMS’ goal of transitioning to a fully digital quality measurement landscape, promoting interoperability that will help decrease burden. Feasibility testing in 34 hospital inpatient acute care facilities (17 using Meditech EHRs and 17 using Cerner EHRs) showed that all data elements for this measure are in defined fields in electronic sources.

Further, this measure is able to capture the occurrence of pressure injuries through either clinical documentation or ICD–10–CM diagnosis codes, providing an alternative option for hospitals that do not yet use discrete fields for pressure injuries. This measure was proposed for inclusion beginning in the CY 2025 reporting period, which means it would first be reported to CMS in early March 2026. As hospitals will not be required to report on this eCQM, the selection of this measure in the Hospital IQR Program need not compete with other Federal quality reporting and EHR-related mandates for limited hospital quality and health IT resources. Rather, the measure will be included as one of the eCQMs that hospitals can self-select for reporting beginning with the CY 2025 reporting period/FY 2027 payment determination.

Comment: Several commenters did not support measure adoption, citing that there is already a claims-based pressure injury measure in the Hospital Acquired Condition (HAC) Reduction Program (CMS PSI–03 within the CMS PSI–90 composite). Commenters noted that this measure is duplicative and does not reduce reporting requirements or align measures across programs. A few commenters asked for a single measure to streamline data tracking and avoid duplication and redundancies. A few commenters asked clarifying questions on measure implementation. A commenter asked if the intent is to retire PSI–03 when the Hospital Harm-Pressure Injury eCQM is added to the Hospital IQR Program. Another commenter asked if a single submission of the Hospital Harm-Pressure Injury eCQM would meet requirements for the Hospital IQR, Promoting Interoperability, and HAC Reduction Programs.
Response: We appreciate commenters’ feedback regarding duplicative measures. Hospital-acquired pressure injuries are currently measured and publicly reported in the HAC Reduction Program as Patient Safety Indicator (PSI) 03, a component of the Patient Safety PSI 03 measure. However, PSI-03 does not include stage 2 pressure injuries in the outcome, uses claims as its sole data source, and is focused only on Medicare fee-for-service beneficiaries aged 18 years and older. The Hospital Harm-Pressure Injury eCQM is the only EHR-based measure intended for use in acute care hospitals related to pressure injuries. By comparison with PSI 03, this measure utilizes EHR clinical documentation to identify pressure injuries more accurately, allowing hospitals to track pressure injury events and enabling other interested parties to understand the incidence of these events in a broader adult, all-payer population.

In alignment with our goal of transitioning to a fully digital quality measurement landscape, we envision the potential future use of patient safety eCQMs not only in the Hospital IQR Program, but also pay-for-performance programs such as the HAC Reduction Program, including as a potential replacement for the claims-based PSI 90 measure. As discussed in section V.L.2.b.(4) of the proposed rule, we seek to adopt patient safety focused eCQMs to promote further alignment across quality reporting and value-based purchasing programs. However, until that time we intend to retain PSI 03 (within the PSI 90 composite) in the HAC Reduction Program as well as finalizing the Hospital Harm-Pressure Injury eCQM in the Hospital IQR Program. We also clarify that meeting the Hospital IQR Program eCQM requirement also satisfies the eCQM reporting requirement for the Medicare Promoting Interoperability Program for eligible hospitals and critical access hospitals (CAHs). However, HAC Reduction Program reporting requirements for PSI 90 are separate.

Comment: Several commenters provided feedback on the measure specifications and opportunities for improvement. A few commenters asked for additional population exclusions for patients in hospice, obstetrics, and behavioral health units. A commenter suggested exclusions for pressure injuries that reopen over scar tissue or are hypotensive at admission. Another commenter expressed concern that the two different time courses in the numerator and denominator (stage 2, 3, or 4 or unstable pressure injury greater than 24 hours after the start of the encounter and DTPI greater than 72 hours after the start of the encounter) adds to the complexity of the measure. A commenter had significant concerns about the potential for DTPI, which are often associated with incontinence-associated dermatitis, to be mistreated as stage 2 pressure injuries, stating their experience that wounds related to incontinence-associated dermatitis are often misidentified as stage 2 pressure injuries, resulting in inaccurate reporting and reimbursement. Another commenter recommended that the ‘encounter start’ begin when the patient is admitted to inpatient, as patients may unfortunately have long hold times in the emergency room, where the usual inpatient protocols for skin care cannot reliably be implemented. Another commenter advised CMS to consider any changes to measure exclusion criteria as substantive, requiring use of the rulemaking process.

Response: We thank commenters for their feedback on the measure specification. We clarify this measure captures the number of patients who experience a pressure injury of stage 2 or higher during an acute care hospitalization. Therefore, hospice and behavioral health encounters are indirectly excluded from the measure.

With regards to obstetrical patients, although the incidence is rare (<1%), patients receiving care in hospital labor and delivery units are still at risk of developing pressure injuries.405 Some reported risk factors including: immobility and unsuitable positions (especially with epidural use), excessive humidity (particularly after rupture of membranes), excess weight, dehydration, prolonged labor, lack of risk assessment and planning, and lack of bariatric and pressure-relieving equipment.406-407 The target population for this measure is inpatient hospital encounters, inclusive of obstetrical encounters, and does not apply to hospice encounters or behavioral health encounters.

In response to commenter feedback regarding the two different time courses in the numerator and denominator, the use of a 24-hour time window for accurate and timely identification of stage 2, 3, 4, or unstable pressure injury present on admission aligns with National Pressure Injury Advisory Panel (NPIAP) Clinical Practice Guidelines. The 72-hour time window for accurate and timely identification of DTPI was chosen because a longer time window is needed to exclude cases when the precipitating event occurred before the patient’s admission. The use of two different time windows is determined by the complexity of the clinical condition and current practice guidelines.

Regarding the inclusion of stage 2 pressure injuries, we highlight that over 50% of reported pressure injuries in hospitals are stage 2 or higher and new-onset pressure injuries of stage 2 or greater are widely considered to be potentially avoidable with best practices.408 The inclusion of stage 2 pressure injuries also harmonizes this measure with other National Database of Nursing Quality Indicators (NDNQI) measures, and CMS pressure injury measures used in the long-term care hospital, inpatient rehabilitation

facility, and home health care programs. CMS encourages hospitals to continue robust educational efforts to address knowledge gaps among health professionals, strengthen processes to avoid misidentification of pressure injuries, and ensure consistency in clinical documentation.

Regarding other recommendations to modify denominator exclusion criteria, CMS will continue to consider refinements as new information becomes available. Any proposed specification changes will be evaluated against CMS’ existing criteria for technical measure specifications changes to determine whether the rulemaking process or a sub-regulatory process for review is most appropriate. We refer readers to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41538) for more details on previously finalized policies regarding substantive vs. non-substantive changes.

As described in § 412.164(c)(1), CMS announces technical measure specification updates through the QualityNet website (https://qualitynet.cms.gov) and listserv announcements.

Finally, we appreciate the commenters’ recommendation to begin ‘encounter start’ upon admission to the acute unit (due to potentially long wait times and varying skin assessment protocols in the ED). However, as up to 40% of hospitalized patients are admitted through the emergency department annually, it is critical that pressure injury prevention begin at that point of entry to protect patients from avoidable harm.

Comment: A few commenters thought the measure would benefit from risk adjustment to ensure facilities treating patients with complex health conditions (such as safety net hospitals) or patient with higher illness acuity are not inadvertently penalized.

Response: We appreciate commenters’ feedback to consider risk adjusting this measure. New-onset pressure injuries of stage 2 or greater are widely considered to be potentially avoidable with appropriate identification and mitigation of risk factors. There are many actions hospitals can take to reduce risk, such as conducting a structured risk assessment to identify individuals at risk for pressure injury (as soon as possible upon arrival and at regular intervals thereafter), as well as

proper skin care, nutrition, and careful repositioning of patients. Although higher risk patients require more intervention to prevent pressure injuries, there is no empirically observed association between pre-existing risk and perceived avoidability. For these reasons, none of the existing CMS measures of pressure injury (for example, home health care, skilled nursing facilities, rehabilitation facilities, long-term acute care) are risk-adjusted.

Comment: A commenter requested clarification on whether diagnosis of a pressure ulcer as a numerator case will be determined based on physician or advanced practice provider documentation (for example, diagnoses in problem lists or discharge documentation).

Response: We thank the commenter for their feedback. The numerator is determined through either ICD–10 CM coded diagnoses or structured clinical documentation to support variances in hospital documentation workflows and practices.

Comment: A few commenters supported the inclusion of the measure and requested that CMS post the pressure injury rates for each hospital on a yearly basis, to allow the public to see improvements soon, and so that hospitals can assess their performance over time as they adopt new protocols and various innovative technologies to reduce pressure injuries.

Response: We thank commenters for their suggestion of annual reporting and overall support for the measure. Based on our previously finalized policy in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58954 through 58959), eCQM performance information is publicly displayed on a CMS-specified website (currently, data.cms.gov). For example, if a hospital chooses to self-select the Hospital Harm—Pressure Injury eCQM as one of their self-selected eCQMs to meet the eCQM requirement in the CY 2025 reporting period, results would be posted in the October 2026 release on data.cms.gov. During a 30-day preview period, hospitals can review their data before the data are displayed. We will announce the public display of eCQM data on Care Compare on a later date.

Comment: A few commenters stated the measure should be kept as optional, as there are several operational challenges hospitals would need to work through if the measure were to be made mandatory.

Response: As finalized in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49299 through 49302), hospitals must report on six total eCQMs beginning with the CY 2024 reporting period and subsequent years. Hospitals must report on three eCQMs chosen by CMS and then three additional eCQMs that are self-selected from the list of remaining eCQMs. We reiterate this measure will be included as one of the eCQMs hospitals have the option to self-select for reporting beginning with the CY 2025 reporting period/FY 2027 payment determination. Future changes to the eCQM reporting requirements, including any additional eCQMs for mandatory reporting, would go through notice-and-comment rulemaking.

After consideration of the public comments we received, we are finalizing our proposal as proposed. We also refer readers to section IX.H.10.a.2. of this final rule where we are finalizing the same eCQM for the Medicare Promoting Interoperability Program.

b. Adoption of Hospital Harm—Acute Kidney Injury eCQM, Beginning With the CY 2023 Reporting Period/FY 2027 Payment Determination and for Subsequent Years

(1) Background

Acute kidney injury (AKI) is a group of conditions characterized by a sudden decrease in glomerular filtration rate, as evidenced by an increase in serum creatinine concentration or oliguria, and classified by stage and cause. Published literature suggests that the incidence of AKI is 10–20 percent in general hospitalized patients and up to 45–50 percent among critically ill patients. Up to two thirds of intensive care patients will develop AKI, which may result in the need for dialysis and is associated with an increased risk of mortality. Both worsening renal function and injury requiring dialysis have lasting negative


impacts. AKI has also been associated with longer term harmful outcomes, such as increased odds of death, increased length of hospital stay, and an average of approximately $7,500 in excess hospital costs. Several studies have demonstrated the association of chronic kidney disease (CKD) development following AKI, and development of ESRD, which increases hospital admissions and long-term mortality. About 30 percent of patients with AKI may require ongoing dialysis in the outpatient setting after hospital discharge. Survivors of AKI also have significantly lower health-related quality of life (HRQOL) compared to the general population. HRQOL is a predictor of mortality among AKI survivors after adjusting for clinical risk variables. Not all AKI is avoidable, but a substantial proportion of AKI cases are preventable and/or treatable at an early stage to improve outcomes. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest careful management of hemodynamic status, fluids, and vasoactive medications for the prevention of AKI. Literature suggests early AKI treatment such as nephroprotective avoidance, drug dose adjustment, and attention to fluid balance are also effective preventive measures. Using EHR data from 20 hospitals in 2020, the measure developer found that hospital-level measure performance rates ranged from 0.76 percent to 4.43 percent, with a system-wide, weighted average rate equal to 1.52 percent. The wide variability indicates room for quality improvement in hospital inpatient settings, with several hospitals’ performance rates consistently below the overall mean. (2) Overview of Measure The Hospital Harm-Acute Kidney Injury measure is an outcome eCQM that assesses the proportion of inpatient hospitalizations for patients 18 years and older who have an AKI (stage 2 or greater) that occurred during the encounter. An AKI stage 2 or greater is defined as a substantial increase in serum creatinine value, or by the initiation of kidney dialysis (continuous renal replacement therapy [CRRT], hemodialysis or peritoneal dialysis). The goal of this measure is to improve patient safety and prevent patients from developing moderate-to-severe AKI (that is, stage 2 or greater) during their hospitalization. Early identification and management of at-risk patients is critical, as there is no specific treatment to reverse AKI. Accurately monitoring the rate at which AKI occurs in the hospital setting will allow hospitals to improve quality and reduce AKI harm rates. This measure was tested in 20 hospitals (test sites) with two different EHR vendors (Meditec and Cerner) with varying bed size, geographic location, teaching status, and urban/rural status. Testing results indicated strong measure reliability (0.91 for the signal-to-noise ratio and 0.79 for intra-class correlation coefficient using the split-half sample) and validity (strong concordance and inter-rater agreement between data exported from the EHR and data in the patient chart). The Hospital Harm-Acute Kidney Injury measure was submitted to the CBE-convened MAP for the 2022–2023 pre-rulemaking cycle and received conditional support for rulemaking pending endorsement by the CBE. During its review, MAP noted that the measure fills a gap in quality measurement and provides incentives for improvement since there is currently no AKI measure in the Hospital IQR Program. The MAP also acknowledged that the measure aligns with CMS’s goals for high-impact and outcome-based measures, as well as two high-priority areas for the Hospital IQR Program in safety and outcome eCQMs. This measure was submitted to the CBE for endorsement review in the Fall 2022 cycle (CBE #3713e). Although section 1886(b)(3)(B)(viii)(IX)(aa) of the Act requires that measures specified by the Secretary for use in the Hospital IQR Program be endorsed by the entity with a contract under section 1890(a) of the Act, section 1886(b)(3)(B)(viii)(IX)(bb) of the Act states that in the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed by the entity with a contract under section 1890(a) of the Act, the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary. We reviewed CBE-endorsed measures and were unable to identify any other CBE-endorsed measures on this topic, and, therefore, we believe the exception in section 1886(b)(3)(B)(viii)(IX)(bb) of the Act applies. (3) Measure Specifications The numerator is inpatient hospitalizations for patients 18 years and older who develop AKI (stage 2 or greater) during the encounter, as evidenced by: (1) a subsequent increase in the serum creatinine value at least 2
times higher than the lowest serum creatinine value, and the increased value is greater than the highest sex-specific normal value for serum creatinine or (2) kidney dialysis (hemodialysis or peritoneal dialysis) initiated 48 hours or more after the start of the encounter. The denominator is inpatient hospitalizations for patients 18 years and older without a diagnosis of obstetrics, with a length of stay of 48 hours or longer, and who had at least one serum creatinine value after 48 hours from the start of the encounter. The denominator excludes inpatient hospitalizations for patients who (1) are already in AKI at the start of the encounter, (2) have CKD stage 3A or greater, (3) have less than two serum creatinine results within 48 hours of the encounter start, (4) have kidney dialysis initiated within 48 hours of the encounter start, (5) have at least one specified diagnosis present on admission that puts them at extremely high risk for AKI, or (6) have at least one specified procedure during the encounter that puts them at extremely high risk for AKI. We refer readers to the eCQI Resource Center (https://ecqi.healthit.gov/ecqm?eh-cah?qt-tabs_eh=1) for more details on the measure specifications.

(4) Data Source and Reporting.

The Hospital Harm-Acute Kidney Injury eCQM uses data collected through hospitals’ EHRs. The measure is designed to be calculated by the hospitals’ CEHRT using the patient-level data and then submitted by hospitals to CMS. With patient data available from hospitals’ EHRs, we believe that hospitals could use confidential feedback reports for this measure to identify disparities in outcomes across different patient demographics, and potentially use that information to inform targeted quality improvement efforts. As with all quality measures we develop, testing was performed to confirm the feasibility of the measure, data elements, and validity of the numerators, using clinical adjudicators who validated the EHR data compared with medical chart-abstracted data. Feasibility testing in 34 inpatient acute care facilities showed that all critical data elements for this measure are defined in electronic fields.

We proposed the adoption of the Hospital Harm-Acute Kidney Injury eCQM as part of the eCQM measure set, from which hospitals can self-select measures to report to meet the eCQM requirement, beginning with the CY 2025 Medicare Promoting Interoperability Program. Results were consistently below the system-wide average while a few others were above that mean, indicating room for quality improvement in the inpatient setting. We will monitor the performance gap as hospitals begin to report this measure.

Comment: Several commenters urged CMS to delay adoption of the measure until it was reviewed and endorsed by the CBE.

Response: We thank commenters for their feedback to consider delaying adoption of Hospital Harm-Acute Kidney Injury measure until it has been endorsed by a CBE. This measure was submitted to the CBE for endorsement review in the Fall 2022 cycle (CBE #3498e). The Patient Safety Standing Committee reviewed the measure at the measure evaluation meeting on February 9, 2023. The measure received high passing scores on all measure criteria (100% pass for reliability, validity and performance gap, 92.9% pass for evidence, feasibility, and use, and 85.7% pass on usability) and the committee passed the measure almost unanimously (13/14) on suitability for endorsement. CMS expects final measure endorsement when the CSAC meets on July 24, 2023.

Comment: A few commenters were concerned that this measure is duplicative, citing that there is already a claims-based measure of Acute Kidney Injury in the HAC Reduction Program (PSI–10 Postoperative Acute Kidney Injury Requiring Dialysis Rate within the CMS PSI 90 composite). A few commenters were opposed to measure adoption as it would create instances of “double jeopardy” for the same patients or cases.

Response: We appreciate commenters’ feedback regarding duplicative measures. Patient Safety Indicator (PSI) 10: Postoperative Acute Kidney Injury
Requiring Dialysis Rate, a component of the CMS PSI 90 composite measure, only captures patients who develop postoperative kidney failure requiring renal replacement therapy, uses claims as its sole data source, and is focused only on Medicare fee-for-service beneficiaries aged 18 years and older. In comparison, the Hospital Harm-Acute Kidney Injury eCQM measures how often stage 2 or greater AKI occurs in the inpatient hospital setting, whether or not the patient received dialysis, and whether or not the patient had surgery before developing AKI. The new measure is developed as an eCQM for adult inpatients, regardless of payer, so it is the only EHR-based measure intended for use in acute care hospitals related to AKI.

We wish to clarify that we intend to retain PSI–10 (within the PSI 90 composite) in the HAC Reduction Program when this measure is implemented into the Hospital IQR Program. In alignment with our goal of transitioning to a fully digital quality measurement landscape, we envision the potential future use of patient safety eCQMs not only in the Hospital IQR Program, but also pay-for-performance programs such as the HAC Reduction Program, including as a potential replacement for the claims-based PSI 90 measure. As discussed in section V.L.2.b.(4) of the proposed rule, we seek to adopt patient safety focused eCQMs to promote further alignment across quality reporting and value-based purchasing programs. However, until that time we intend to retain PSI 10 (within the PSI 90 composite) in the HAC Reduction Program as well as finalizing the Hospital Harm-Acute Kidney Injury eCQM in the Hospital IQR Program.

Comment: Several commenters raised concerns about implementation burden. A few commenters highlighted that there is a substantial cost and time burden faced by hospitals when adopting new eCQMs. A few commenters stated the measure should be kept as optional and a commenter requested that CMS delay until the CY 2026 reporting period. A commenter requested that new eCQMs be delayed until formats are changed to Fast Healthcare Interoperability Resources (FHIR) standard to avoid unnecessary duplication of work.

Response: We thank commenters for their input. We reiterate this measure will be included as one of the eCQMs hospitals can self-select for reporting beginning with the CY 2025 reporting period/FY 2027 payment determination. We thank the commenters for their feedback on the measure. We envision the potential future use of patient safety eCQMs not only in the Hospital IQR Program, but also pay-for-performance programs such as the HAC Reduction Program, including as a potential replacement for the claims-based PSI 90 measure. As discussed in section V.L.2.b.(4) of the proposed rule, we seek to adopt patient safety focused eCQMs to promote further alignment across quality reporting and value-based purchasing programs. However, until that time we intend to retain PSI 10 (within the PSI 90 composite) in the HAC Reduction Program as well as finalizing the Hospital Harm-Acute Kidney Injury eCQM in the Hospital IQR Program.

Comment: Several commenters suggested alternative approaches to defining AKI, including measures of urine output or other biomarkers.

Response: This eCQM uses a seven-day rolling window to examine a rise in serum creatinine by 2.0 times or greater, based on the KDIGO stage 2 definition established in the 2012 KDIGO AKI clinical practice guidelines. CMS will continue to monitor developments in the field and incorporate professional consensus into future refinements.

Additionally, this measure excludes encounters that do not have at least two serum creatine values within 48 hours of arrival. Two values are needed within this timeframe to determine if the patient has AKI or moderate-to-severe kidney dysfunction on arrival. Encounters for patients with an increase in serum creatinine of at least 0.3 mg/dL between the index serum creatinine and any subsequent serum creatinine taken within 48 hours of the encounter start are excluded. Due to the variability of decimal precision within programming languages and calculation tools, the value of ≥0.3 is expressed in the logic as >0.299.

Comment: A few commenters provided feedback on measure exclusions. A commenter recommended excluding patients who have a co-diagnosis of volume overload as their lowest creatinine level may be a result of not being at their dry weight or euvolemic state. Another commenter suggested expanding the list of patients “at extremely high risk for AKI” to include sepsis, cardiac arrest, and acute myocardial infarction requiring urgent/emergent cardiac catheterization. Another commenter expressed that the current set of exclusions may not adequately address the delay in kidney injury seen in the setting of complicated medical conditions that require complex interventions or those receiving palliative care.

Response: We thank the commenters for their feedback on the measure denominator exclusions. Most of the suggested exclusions are already covered in the current measure specification, including:

- Inpatient hospitalizations for patients with an increase in serum creatinine value of at least 0.3 mg/dL between the index serum creatinine and a subsequent serum creatinine taken within 48 hours of the index serum creatinine. (This criterion excludes patients with AKI at presentation, including patients with sepsis, cardiogenic or traumatic shock, and other conditions that cause early-onset AKI.)
- Inpatient hospitalizations for patients with an eGFR value of <60 mL/min within 48 hours of the encounter start. (This criterion excludes patients with CKD stage 3a or greater at presentation as well as those with end stage kidney disease on dialysis.)
- Inpatient hospitalizations for patients who have kidney dialysis (CRRT, hemodialysis or peritoneal dialysis) initiated within 48 hours of the encounter start. (This criterion excludes patients who require early dialysis due to complete renal failure, acute volume overload, or toxic exposures at presentation.)
- Encounters that do not have at least two serum creatinine values within 48 hours of arrival. Two values are needed within this timeframe to determine if the patient has AKI or moderate-to-severe kidney dysfunction on arrival.

All of these denominator exclusions have been validated by manual review of medical records to ensure that
patients with conditions causing AKI at presentation to the hospital have been excluded. Regarding other recommendations to modify denominator exclusion criteria, we will continue to consider refinements as new information becomes available. Any proposed specification changes will be evaluated against our existing criteria for technical measure specifications changes to determine whether the rulemaking process or a sub-regulatory process for review is most appropriate. We refer readers to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41538) for more details on previously finalized policies regarding substantive vs. non-substantive changes. As described in § 412.164(c)(1), CMS announces technical measure specification updates through the QualityNet website (https://qualitynet.cms.gov) and listserv announcements.

Comment: A few commenters acknowledged that there are different methods of calculating eGFR values, the measure should use a standard calculation and utilize a non-racially based formula to calculate eGFR.

Response: The eGFR values are calculated using the CKD–EPI Creatinine Equation (2021), recommended by the National Kidney Foundation (NKF) and American Society of Nephrology (ASN). This is a gender-specific, race-neutral formula. This eCQM applies this formula to all reporting entities to eliminate variation in eGFR calculation methods across clinical laboratories.

Comment: A few commenters indicated concerns with the capture of acute dialysis treatment and that dialysis treatment can be used for non-AKI reasons.

Response: The measure has been carefully designed to exclude patients on chronic dialysis, including hospitalizations for patients who have kidney dialysis (CRRT, hemodialysis or peritoneal dialysis) initiated within 48 hours of the encounter start, hospitalizations for patients with stage 3a or greater CKD within 48 hours of the encounter start, and hospitalizations for patients whose serum creatinine rises by 0.3 mg/dL or more between the index serum creatinine and a subsequent serum creatinine taken within 48 hours of the index serum creatinine. The measure does not use diagnosis codes to identify patients on chronic dialysis; however, those patients would be captured by the previously noted exclusions. Although dialysis may be used for reasons other than AKI, these treatments are generally provided within 48 hours of the encounter start (for example, salicylate toxicity), or they employ other modalities such as isolated ultrafiltration (for example, heart failure with anasarca), which are not captured by the proposed measure.437 438

Comment: Several commenters did not support the measure due to concerns about false positives; they stated that serum creatinine levels can be influenced by various factors such as medications and underlying medical conditions such as sepsis. A commenter noted that aminoglycosides, cisplatin, and cyclosporin may cause reversible kidney injury, but are necessary for patient care and another commenter mentioned that trimethoprim-sulfamethoxazole (TMP–SMX), angiotensin-converting enzyme (ACE) inhibitors, and sodium-glucose cotransporter-2 (SGLT2) inhibitors cause an elevation in creatinine without kidney injury. A commenter noted that radiographic contrast can cause AKI, but may be essential for accurate diagnosis of a patient’s condition.

Response: We thank the commenters for their feedback on the use of serum creatinine as a marker for kidney function and diagnosis of AKI. We reiterate that KDIGO clinical practice guidelines for AKI cite serum creatinine as an acceptable and widely available proxy for defining and monitoring AKI and have provided detailed clinical guidelines to evaluate and monitor patients at-risk of kidney damage.439

While some instances of AKI may be due to natural progression of underlying illness or complication of a necessary treatment, a substantial proportion of AKI cases are preventable and treatable if detected at stage 1, with improved outcomes.440 441 Further, KDIGO guidelines suggest careful management of hemodynamic status, fluids, and vasoactive medications, along with avoidance of nephrotoxic exposure and drug dose adjustment, for the prevention of AKI and the progression of AKI once identified.442 443

We clarify that patients with an underlying medical condition such as sepsis are “designed out” of the measure specification in two ways. First, patients are excluded from the denominator if they have AKI when they present to the hospital or develop AKI (based on even the smallest meaningful bump in the serum creatinine, 0.3 mg/dL) within the first 48 hours of the encounter. Second, risk adjustment includes patient’s vital signs at presentation, thus accounting for patients presenting with systemic inflammatory response syndrome (SIRS), including sepsis. Validation testing confirmed that the first criterion excludes nearly all patients admitted with community-acquired sepsis. The medications to which the commenters refer (for example, aminoglycosides, ACE inhibitors, SGLT–2 inhibitors) generally cause modest increases in the serum creatinine, within the range of what is classified as stage 1 AKI (for example, 1.5–2.0 fold increase in serum creatinine).444 This measure’s numerator is restricted to stage 2 AKI, or “a subsequent increase in serum creatinine value at least 2 times higher than the lowest serum creatinine value, and the increased value is greater than the highest sex-specific normal value for that patient’s age and sex.” Recognizing stage 1 AKI will provide an opportunity for the clinician to discontinue or adjust the offending medication without penalty. Most of the drugs specified are not approved for the treatment of AKI.


nephrotic at the doses that are typically used, and with appropriate monitoring, significant increases in serum creatinine levels can be avoided.\textsuperscript{445} Risk-adjustment provides additional assurance that providers will not be penalized for appropriate care. Based on the risk-adjustment model, for example, patients with heart failure have about 70% higher odds of AKI than patients without heart failure. The risk model also includes pre-existing diabetes, hypertension, cancer, and obesity.\textsuperscript{446}

There has been extensive debate about whether contrast-induced nephropathy is a meaningful clinical entity.\textsuperscript{447} 448 449 For example, a recent systematic review and meta-analysis of 13 nonrandomized controlled studies involving over 25,000 patients found no increased AKI risk among patients who received intravenous contrast.\textsuperscript{450} Additionally, the risk of contrast-induced AKI is extremely low among patients with normal or minimally impaired kidney function at baseline, to which this measure is restricted.\textsuperscript{451} 452 453 Finally, the 2020 KDIGO conference directly addressed this question as follows: “recent evidence suggests that the risks associated with IV contrast are far fewer with modern agents and practice patterns, and significant kidney injury is unusual in patients with normal or mildly reduced baseline kidney function. IV contrast should not be withheld owing to concern for AKI in life-threatening conditions in which the information gained from the contrast study could have important therapeutic implications.”\textsuperscript{454} 455 It is generally within the provider’s control to determine if the benefits of the contrast study outweigh the risks, and to effectively mitigate those risks.\textsuperscript{455} 456

After consideration of the public comments we received, we are finalizing our proposal as proposed. We also refer readers to section IX.H.10.a.2. of this final rule where we are finalizing the same eCQM for the Medicare P romoting Interoperability Program.


1 Large body of research links CT scans to a higher risk of developing cancer.\textsuperscript{462} 463 464 465 466 One study found that patients who received CT scans had a 0.7 percent higher risk of developing cancer in their lifetime compared to the general U.S. population. The risk increased for patients who underwent multiple CT scans, ranging from 2.7 to 12 percent higher.\textsuperscript{467} While the

\textsuperscript{454} Ibid.

\textsuperscript{455} Ibid.

\textsuperscript{456} Ibid.


\textsuperscript{459} Mathews JD, Forsythe AV, Brady Z, Butler MW, Goergen SK, Byrnes GB, Giles GG, Wallace AB, Anderson PR, Guiver TA, McGale P, Cain TM, Dowty JG, Bickerstaffe AC, Darby SC. Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data from a large image study of 1.1 million patients. BMJ. 2013 May 21;346:f2360. Doi: 10.1136/bmj.f2360. PMID: 23694687; PMCID: PMC3660619.


\textsuperscript{462} Mathews JD, Forsythe AV, Brady Z, Butler MW, Goergen SK, Byrnes GB, Giles GG, Wallace AB, Anderson PR, Guiver TA, McGale P, Cain TM, Dowty JG, Bickerstaffe AC, Darby SC.
likelihood of developing cancer from a CT scan is small on an individual level, on a population level it can lead to many more cancer cases given the number of CT scans performed every year. One study estimated that the percentage of cancers in the U.S. attributable to CT scans may be as high as two percent. Therefore, it is critically important to ensure that patients are exposed to the lowest possible level of radiation while preserving image quality.

(2) Overview of Measure

The Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography (CT) in Adults (Hospital Level—Inpatient) eCQM (hereinafter referred to as the Excessive Radiation eCQM) provides a standardized method for monitoring the performance of diagnostic CT to discourage unnecessarily high radiation doses while preserving image quality. It is expressed as a percentage of eligible CT scans that are out-of-range based on having either excessive radiation dose or inadequate image quality, relative to evidence-based thresholds based on the clinical indication for the exam. This measure is not currently risk-adjusted. The purpose of this measure is to reduce unintentional harm to patients. Setting a standard for diagnostic CT scans to prevent unnecessarily high radiation doses while preserving image quality will provide hospitals with a reliable method to assess harm reduction efforts and modify their improvement efforts. This measure also addresses high priority areas as stated in our Meaningful Measures Framework, including the transition to digital quality measures and the adoption of high-quality measures that improve patient outcomes and safety.

We also proposed to adopt the Excessive Radiation eCQM to support the National Quality Strategy goal of promoting safety by reducing preventable harm to patients. The measure was developed according to evidence and consensus-based clinical guidelines for optimizing CT radiation doses. These include guidelines created by the American College of Radiology, The Society of Interventional Radiology, The Society of Cardiovascular CT, cardiovascular imaging societies, Image Wisely 2020, and the FDA. The measure was tested across 16 inpatient and outpatient hospitals and a large system of outpatient radiology practices. Measure testing revealed that availability, accuracy, validity and reproducibility were high for all of the measure’s required data elements and the variables that were calculated by the translation software. The measure developer further assessed the reporting burden by administering surveys to each of the participating hospitals and outpatient groups. They found that the burden was small to moderate, comparable to the burden of measure reporting for other measures and fell to information technology (IT) personnel rather than physicians.

Measure testing found that assessing radiation doses and providing audit feedback to radiologists resulted in significant reductions in excessive and unsafe dose levels. The testing sites also noted that the assessment of their doses as specified in the measure was helpful for identifying areas for quality improvement. Over 40 letters were submitted in support of the measure, including several from radiologists and medical physicists who serve as leaders of the testing sites, that confirmed it was feasible and data assembly would not pose a large burden.

(3) Data Sources

The Excessive Radiation eCQM uses hospitals’ EHR data and radiology electronic clinical data systems, including the Radiology Information System (RIS) and the Picture Archiving and Communication System (PACS). Medical imaging information such as Radiation Dose Structured Reports and image pixel data are stored according to the universally adopted Digital Imaging and Communications in Medicine (DICOM) standard. Currently, eCQMs cannot access and process data elements in their original DICOM formats. The measure developer has created software, called the Alara Imaging Software for CMS Measure Compliance, to address this gap. This software links primary data elements, assesses CT scans for eligibility for inclusion in the measure, and generates three data elements mapped to a clinical terminology for eCQM consumption: CT Dose and Image Quality Category, Calculated CT Size-Adjusted Dose, and Calculated CT Global Noise.

The Alara Imaging Software for CMS Measure Compliance will be available to all reporting entities free of charge and will be accessible by creating a secure account through the measure developer’s website. Education materials will provide step-by-step instructions on how hospitals can create an account and then link their EHR and PACS data to the software. Reporting entities and their vendors will be able to use the data elements created by this software to calculate the eCQM and to submit results to the Hospital IQR Program as they do for all other eCQMs.

(4) Measure Specifications

The measure numerator includes diagnostic CT scans that have a size-adjusted radiation dose greater than the

---


469 Ibid.


471 Centers for Medicare & Medicaid Services. (2021 cycle (CBE #3663e) and was endorsed on August 2, 2022. The Excessive Radiation eCQM (MUC2022–018) was submitted to the CBE-convened MAP for the 2022–2023 pre-rulemaking cycle and received support for rulemaking. The MAP noted that the Hospital IQR Program currently does not have any measures assessing the risk of radiation exposure from CT scans, and this measure will encourage shared decision-making between providers and patients.

472 Image Wisely 2020. Available at: https://www.imagewisely.org/.

threshold defined for the specific CT category. The threshold is determined by the body region being imaged and the reason for the exam, which affects the radiation dose and image quality required for that exam. The numerator also includes CT scans with a noise value greater than a threshold specific to the CT category.\(^{481}\)

The measure denominator is the number of all diagnostic CT scans performed on patients 18 years and older during the one-year measurement period which have an assigned CT category, a size-adjusted radiation dose value, and a global noise value.\(^{482}\)

The measure excludes CT scans that cannot be categorized by the area of the body being imaged or reason for imaging. These include scans that are simultaneous exams of multiple body regions outside of four commonly performed multiple region exams defined by the measure, or scans that cannot be classified based on diagnosis and procedure codes. Exams that cannot be classified are specified as Logical Observation Identifiers Names and Codes (LOINC) 96914–7, CT Dose and Image Quality Category, Full Body. The measure also has technical exclusions for CT scans missing information on the patient’s age, Calculated CT Size-Adjusted Dose, or Calculated CT Global Noise. We refer readers to the eCQI Resource Center (https://ecqi.healthit.gov/eh-cali?ttabs_eh=1&globalyearfilter=2024&global_measure_group=3726) for more details on the measure specifications.

(5) Data Submission and Reporting

We proposed the adoption of the Excessive Radiation eCQM as part of the Hospital IQR Program measure set, from which hospitals can self-select to report it to meet the eCQM requirement, beginning with the CY 2025 reporting period/FY 2027 payment determination. We refer readers to section IX.C.10.e. of the preamble of this final rule for a discussion of our previously finalized eCQM reporting and submission policies. We also refer readers to section IX.F. of the preamble of this final rule for more information on our proposal to adopt the Excessive Radiation eCQM in the Medicare Promoting Interoperability Program.

We invited public comment on this proposal.

Comment: Many commenters supported our proposal to adopt the Excessive Radiation eCQM into the Hospital IQR Program. Many commenters expressed their belief that the measure would improve patient safety by reducing unnecessary radiation exposure and risk of developing cancer for patients. Several commenters appreciated that this measure could help address a lack of oversight of CT scans, which has led to wide variation in the radiation doses administered. Many commenters noted their belief that adopting the measure would not compromise diagnostic image quality. Several commenters supported the measure proposal, citing the rigorous testing that the measure went through, which demonstrated that implementation was highly feasible and would not place a large reporting burden on clinicians. Several commenters also expressed support because the measure was endorsed by the CBE. Several commenters supported the adoption of the eCQM as an optional measure that hospitals can select to meet eCQM reporting requirements.

Response: We thank the commenters for their support. We agree that rigorous testing that the measure went through, which demonstrated that implementation was highly feasible and would not place a large reporting burden on clinicians. Several commenters also expressed support because the measure was endorsed by the CBE. Several commenters supported the adoption of the eCQM as an optional measure that hospitals can select to meet eCQM reporting requirements.

Comment: Many commenters recommended implementing this measure earlier than proposed, beginning as early as the CY 2024 reporting period. Many commenters urged CMS to make the measure mandatory to report for the Hospital IQR Program. Commenters expressed their belief that given the large number of exams performed annually, excessive radiation from CT scans is a major issue, and mandatory reporting of this measure would drive considerable improvements in safety.

Response: We appreciate commenters’ support for an earlier adoption date and for requiring reporting on the Excessive Radiation eCQM. When proposing this measure for adoption, we sought to balance quickly addressing the patient safety concerns presented by exposure to excessive radiation while still providing hospitals with enough time to implement the measure. To ensure this balance remains, we are not accelerating the adoption timeline. We will consider requiring reporting of this measure for future rulemaking.

Comment: Many commenters did not support adoption of the Excessive Radiation eCQM and raised concerns with the measure’s technical specifications. A few commenters stated their belief that the measure had not been adequately vetted by experts such as major radiology societies or standards organizations. Some commenters believed that some of the measure’s data elements lack scientific and practical validity. A few commenters recommended that CMS find an alternate approach for optimizing radiation doses while preserving diagnostic image quality, whether through existing standards or by working with the medical imaging community to develop new approaches.

Response: We thank the commenters for their input and feedback on this measure. We respectfully disagree that the measure has not been adequately tested. The data elements are scientifically and practically valid. The measure’s thresholds for noise and radiation dose were developed with close input from an experienced and diverse TEP, which included representation from radiologists and physicists in medicine and were informed by an image quality study.\(^{483}\) The measure also relies on evidence and consensus-based clinical guidelines for optimizing CT radiation doses. These include guidelines developed by the American College of Radiology,\(^{484}\) The Society of Interventional Radiology,\(^{485}\) The Society of Cardiovascular CT,\(^{486}\) cardiovascular imaging societies,\(^{487}\) Image Wisely\(^{2020,488}\) and the FDA.\(^{489}\) Measure testing by the measure developer across 16 inpatient and outpatient hospitals


\(^{488}\) Image Wisely 2020. Available at: https://www.imagewisely.org/.

showed that availability, accuracy, validity and reproducibility were high for all of the measure’s required data elements and the variables that were calculated by the translation software. The testing sites reported that the assessment of their radiation doses as specified in the measure was helpful for identifying areas for quality improvement, and the measure received support from radiologists and medical physicists who serve as leaders of the testing sites (88 FR 27084). We also reiterate that this measure was submitted to the CBE by the measure developer for endorsement review (CBE #3663c) and was endorsed on August 2, 2022. The Excessive Radiation eCQM (MUC2022–018) was submitted to the CBE-convened MAP for the 2022–2023 pre-rulemaking cycle and received support for rulemaking (88 FR 27083 and 27084).490

Comment: Some commenters stated their belief that the complex relationship between noise and radiation is oversimplified by the measure. Many commenters did not support the measure out of concern that the fixed limits for noise and dose may prevent CT scan operators from appropriately adjusting radiation doses when needed, resulting in incorrect radiation doses and potential misdiagnoses, particularly for patients of size.

Response: We thank the commenters for their feedback. We wish to clarify that the purpose of the Excessive Radiation eCQM is to ensure that radiation dose and image quality fall within thresholds that are safe and appropriate, and it is not intended to oversimplify the relationship between noise and radiation. The image quality component is included in the measure as a balancing component to the radiation dose thresholds, to ensure that CT image quality does not decrease as an unintended consequence of the measure.

We also acknowledge the commenters’ concerns about the fixed limits for noise and radiation dose. We reiterate that the thresholds for radiation doses are size-adjusted to accommodate patients of all sizes. We would like to further emphasize that hospitals should use the measure as a guideline for conducting CT scans while also adjusting noise and radiation doses when necessary to provide quality patient care in special circumstances. The measure seeks to reduce harm from excessive radiation for the vast majority of patients and should not replace appropriate clinical judgement if adjustments need to be made in select circumstances.

Comment: A few commenters stated that CMS did not adequately consider references that express concern with the measure’s benchmarking approach such as “Benchmarking CT Radiation Doses Based on Clinical Indications: Is Subjective Image Quality Enough?” by Mahadevappa Mahesh in Radiology (2022; 302:2, 390–391). Response: We acknowledge the commenters’ concern. We note that the measure developer reviewed the reference cited by the commenters and took its recommendations into account while developing the Excessive Radiation eCQM. The measure developer then rigorously tested the measure across 16 inpatient and outpatient hospitals and a large system of outpatient radiology practices (88 FR 27084).

Comment: Some commenters suggested that this measure is not suitable for eCQM reporting because the measure requires information from radiology data systems, as opposed to clinical information stored in an EHR system.

Response: This measure is suitable for eCQM reporting. As set forth in the eCQI Resource Center, we define an eCQM as a measure specified in a standard electronic format that uses data electronically extracted from EHRs and/or health IT systems to measure the quality of health care provided.491 By using patients’ radiology data that exist in a structured and standard electronic format that can be electronically extracted from radiology IT data systems, this measure meets the definition of an eCQM. And while radiology data are stored in health IT systems, we understand that for many hospitals the radiology data system may not be fully integrated or interoperable with the EHRs. To address this gap, the measure developer created the Alara Imaging Software for CMS Measure Compliance. This software links primary data elements, assesses CT scans for eligibility for inclusion in the measure, and generates three data elements mapped to a clinical terminology for eCQM consumption: CT Dose and Image Quality Category, Calculated CT Size-Adjusted Dose, and Calculated CT Global Noise (88 FR 27084).

Comment: Many commenters expressed concern that implementing this software may be additionally burdensome. Specifically, commenters were concerned that integrating proprietary software and securely deploying it within existing IT systems would place an administrative burden exceeding that of other measures. They stated this burden could include ensuring the compatibility of the software with their system IT networks. Commenters questioned how hospitals unable to use the software for any reason would be able to report this measure.

Other commenters believed that hospital staff would face additional burden in reporting the data. Commenters questioned how the software would integrate with certified EHR reporting technology. They believed that staff would need to manually enter data into the EHR and verify data accuracy across systems as part of the data submission processes. According to commenters, if the software integrates with the EHR, they believe staff time would also be required to build and maintain that integration. Commenters believed that EHR developers would face a burden in developing and configuring new software to support measure reporting. Multiple interfaces and third-party applications might need to be reconfigured and mapped to process radiology data.

Response: We thank the commenters for sharing their concerns about the Alara Imaging Software for CMS Measure Compliance. The software accepts a wide range of FHIR, HL7 formats for EHR data, and DICOM CT radiation dose and image data to decrease burden. Similar to other eCQMs, the measure has also been developed using proven formats: Quality Data Model (QDM) for immediate implementation and FHIR when adopted in the future, in accordance with our aim of encouraging interoperability based on the FHIR Application Programming Interface (API). Thus, the overall burden is comparable to that of existing eCQMs.

While the Alara Imaging Software for CMS Measure Compliance is proprietary, it will be available to all reporting entities free of charge and accessible by creating a secure account through the measure steward’s website. To clarify the reporting process, we note that a hospital can log in through the measure developer’s secure portal and run the Alara Imaging Software for CMS Measure Compliance inside the firewall. The software runs automatically to create the three intermediate data elements needed for the measure, CT Dose and Image Quality Category, Calculated CT Size-Adjusted Dose, and


Calculated CT Global Noise. Once the software finishes creating these intermediate variables, hospitals can send the data to its EHFR for measure calculation and reporting. The software allows additional options such as the ability to send the data to other business associates of the hospital if needed. No manual data entry is required.

We anticipate that some EHR vendors may develop solutions to ingest these calculated variables and calculate the eCQM, as they have done for other eCQMs. This burden to EHR developers should be similar to any other new eCQM adopted into the Hospital IQR Program.

We additionally note that the adoption timeline and option to self-select reporting on this measure should provide sufficient flexibility for those hospitals that may need time to integrate the software and implement this measure.

Comment: A few commenters requested that we release the complete specifications and guidance on implementing the software at least one year before adopting this measure.

Response: We note that measure details including the electronic specifications were posted on the eCQI Resource Center pre-rulemaking page at the time of publication of the proposed rule: https://ecqi.healthit.gov/ecqm/eh/pre-rulemaking/2024/cms1074v1. Education materials will provide step-by-step instructions for the creation of secure accounts and linking hospital EHRs and PACS data to the Alara Imaging Software for CMS Measure Compliance (88 FR 27084). Additional outreach and education will be provided through routine communication channels. This includes but is not limited to issuing memos, emails, and notices on the QualityNet and eCQI Resource Center websites. Therefore, hospitals should have sufficient guidance for implementing the software.

Comment: Some commenters worried about relying on the measure developer as the sole vendor of the translation software. They believed that hospitals could be left unable to report data should the measure developer or its software experience problems. A few commenters raised the concern that hospitals would have to agree to onerous licensing and data use conditions to use the software.

Commenters suggested that we allow other vendors to provide translation software to support reporting on this measure. Commenters expressed concern about potential data breaches and whether the measure developer and software have appropriate security protocols to safeguard sensitive patient information. Commenters also stated that hospitals would need to conduct a third-party risk management assessment prior to using the software. A commenter asked whether translation software is currently available for hospitals to integrate with their systems.

Response: We appreciate the commenters’ concerns. Hospitals are not required to use the Alara Imaging Software for CMS Measure Compliance. They may choose to use any software that performs the necessary functions to generate the same standardized data elements necessary to calculate the measure consistent with the measure’s specifications. The Alara Imaging Software for CMS Measure Compliance was created for this purpose under a CMS-funded grant. The software links primary data elements, assesses CT scans for eligibility for inclusion in the measure, and generates three data elements mapped to clinical terminology for EHR consumption (CT Dose and Image Quality Category, Calculated CT Size-Adapted Dose, and Calculated CT Global Noise). These calculations all occur within the hospital’s firewall to ensure data security. We also note that the measure has been extensively tested in a variety of inpatient and outpatient settings. The Alara Imaging Software for CMS Measure Compliance has security protocols to safeguard sensitive patient information. It is installed and computes the measure within a hospital’s firewall to be used for measure-related activities, including calculation, and reporting. The measure steward’s security aligns with industry standards, including HIPAA and Systems and Organization Controls (SOC) 2 certification verified via ongoing third-party audits. As noted previously, while the Alara Imaging Software for CMS Measure Compliance is proprietary, it will be available to all reporting entities free of charge and accessible by creating a secure account through the measure steward’s website.

Comment: Many commenters did not support the measure due to concerns about the measure developer’s relevant expertise and for-profit status, as well as the potential for a conflict of interest due to the measure developer also being the only vendor for the translation software required for the measure.

Response: We respectfully disagree with the commenters’ belief that the measure developer lacks the relevant expertise to steward the Excessive Radiation eCQM. The measure developer employs radiologists and medical imaging informaticians experienced in developing, testing, publishing, and maintaining national quality measures. Additionally, this measure has undergone rigorous testing and received endorsement from the CBE. We do not believe that Alara Imaging’s corporate status by itself automatically poses a conflict of interest.

Comment: We additionally note that the increase in radiation to patients during CT scans is a major patient safety issue. Over 80 million CT scans are performed each year in the United States, compared to only three million in 1980. As a result of the increased use of CT scans, it accounts for 24 percent of all radiation exposure for people in the U.S.

Response: We appreciate the commenters’ position. However, excessive radiation during CT scans is a major patient safety issue. Over 80 million CT scans are performed each year in the United States, compared to only three million in 1980. As a result of the increased use of CT scans, it accounts for 24 percent of all radiation exposure for people in the U.S. We reiterate that a large body of research links CT scans to a higher risk of developing cancer.

942 CY 2024 Outpatient Prospective Payment System (OPPS)/Ambulatory Surgical Center (ASC) Payment System proposed rule, 88 FR 49552, July 31, 2023.
946 Mathews JD, Forsythe AV, Brady Z, Butler MW, Goergen SK, Byrnes GL, Giles GG, Wallace...
study found that patients who received CT scans had a 0.7 percent higher risk of developing cancer in their lifetime compared to the general U.S. population. The risk increased for patients who underwent multiple CT scans, ranging from 2.7 to 12 percent higher.500

While the likelihood of developing cancer from a CT scan is small on an individual level, on a population level it can lead to many more cancer cases given the number of CT scans performed every year.500 One study estimated that the percentage of cancers in the U.S. attributable to CT scans may be as high as two percent. Ensuring that patients are exposed to the lowest possible level of radiation while preserving CT scan image quality therefore represents an opportunity to meaningfully reduce the incidence of cancer in the population (88 FR 27083).

While there are established regulations and programs to regulate radiation doses, radiation doses still vary greatly depending on where a patient goes for care.502 This is concerning because the risk of developing cancer increases with the dose administered to patients.503 The Excessive Radiation eCQM will address the problem by establishing a common standard for hospitals to follow and providing transparency in the public reporting of data.

Comment: Several commenters urged CMS not to require reporting of this measure. A few commenters recommended that CMS evaluate the feasibility and burden of measure implementation, as well as hospital performance, before considering requiring reporting or moving the measure to a pay-for-performance program.

Response: We appreciate the commenters’ input. We note that at this time, the measure is being finalized for addition to the list of eCQMs from which hospitals can self-select in the Hospital IQR Program and in the Medicare Promoting Interoperability Program as discussed in section IX.F. As finalized in the FY 2023 IPPS/LTCPPS final rule (87 FR 49299 through 49302), hospitals participating in the Hospital IQR Program must report on six total eCQMs beginning with the CY 2024 reporting period and subsequent years. Hospitals must report on three eCQMs chosen by CMS and then three additional eCQMs that are self-selected from the list of remaining eCQMs. We note that this eCQM is being added to the list of eCQMs from which a hospital can self-select to report and no hospital is required to select the Excessive Radiation eCQM to successfully meet the eCQM requirement in a given year.

There are also many ways to achieve this eCQM by aligning pay-for-performance programs at this time and any future adoption of the measure in pay-for-performance programs would first be proposed in notice and comment rulemaking.

Comment: Several commenters recommended that the adoption timeline be delayed to allow for additional measure testing and implementation of the measure. Specifically, a commenter suggested that the measure be tested in hospitals serving small or rural communities. Another commenter requested additional opportunities for consultation with hospitals for more testing and input prior to adoption. A commenter recommended starting with a voluntary reporting period for testing and validation before requiring the measure.

Response: We thank the commenters for sharing these suggestions. When considering this measure for adoption, we sought to balance quickly addressing the patient safety concerns presented by exposure to excessive radiation while still providing hospitals enough time to implement the measure. Indeed, as described earlier, many commenters requested that CMS adopt this measure earlier than proposed. The adoption timeline and option to self-select reporting on this measure provide sufficient flexibility for those hospitals that desire to report this measure but may need more time to integrate and implement this measure. Moreover, this measure is ready for adoption as proposed, as it has undergone rigorous testing and received endorsement from the CBE. The CBE endorsement process included review by the CBE-convened MAP Health Equity Advisory Group and Rural Health Advisory Group, which supported the measure. Therefore, the measure has received input from a variety of relevant parties including hospitals serving small or rural communities.

Comment: A few commenters did not support the Excessive Radiation eCQM’s adoption as proposed, citing the recent addition of many new measures to the Hospital IQR Program. They urged CMS to take a more gradual approach in changing reporting requirements, particularly noting the burden on hospitals to update their systems to report a new eCQM. One of these commenters further suggested that CMS delay adoption of new eCQMs until after hospitals have finished updating their systems to report in the FHIR-based format. A few commenters recommended that CMS instead consider adopting this measure as a dQM.

Response: We acknowledge the commenters’ concern over the rate that the Hospital IQR Program has been adopting new eCQMs during recent rulemaking, and emphasize that we are not changing the total number of eCQMs that a hospital must report in this final rule. This eCQM is being added to the list of eCQMs from which a hospital can self-select to report, which should provide hospitals with enough time to implement the measure should they choose to report it.

We also appreciate the commenters’ recommendation to adopt the measure as a dQM. An eCQM is a type of dQM. The addition of the Excessive Radiation eCQM further advances CMS’ goal of transitioning to a fully digital quality measurement landscape, which promotes interoperability that will decrease the burden of reporting quality measures. While our goal is to eventually move to the FHIR API (87 FR 49181), it is important to address excessive radiation exposure from CT

scans as soon as feasible to protect patients.

Comment: A few commenters encouraged CMS to obtain endorsement from the CBE before adopting this measure.

Response: We thank the commenters for their input. As we stated in the proposed rule (88 FR 27084), this measure has received endorsement from the CBE.

Comment: A commenter stated that using the term “Excessive Radiation” could deter patients from undergoing needed clinical care and suggested using more neutral terminology instead.

Response: We appreciate the commenter’s recommendation. The measure name is nonetheless appropriate because excessive radiation doses are an outcome that the eCQM measures. We further expect that rather than deterring patients from needed care, reporting on this measure will reassure patients that the CT scans they undergo are safe and will use an appropriate amount of radiation.

Comment: A commenter requested clarification regarding whether a facility choosing to report this measure would be able to use a single submission to meet requirements for the Hospital IQR, Promoting Interoperability, and HAC Reduction Programs. Another commenter stated that if the measure is also proposed for adoption in the Hospital OQR Program, CMS should streamline reporting and allow hospitals to report one set of data for both the Hospital IQR and Hospital OQR Programs.

Response: We thank the commenters for their suggestions and feedback and will take it under consideration for future rulemaking. Regarding reporting a measure for multiple programs, hospitals can report the same Excessive Radiation eCQM for both the Hospital IQR and Medicare Promoting Interoperability Programs. This measure was not proposed in the HAC Reduction Program. We note that the HAC Reduction Program does not currently include eCQMs but has requested feedback on the possibility of adopting eCQMs (such as the Excessive Radiation eCQM) in the future, as discussed in section V.I.4. of this final rule. The Hospital OQR Program has also proposed to adopt the Excessive Radiation eCQM in the CY 2024 OPPS/ASC proposed rule,506 which if adopted would require a separate submission to report. At this time, hospitals would not be able to report one set of data for both the Hospital IQR and Hospital OQR Programs because the two programs operate with respect to distinct patient populations. As we strive to increase electronic quality reporting, we will consider ways to improve cross-program reporting efficiencies.

Comment: A commenter stated that if the measure is adopted, CMS should develop a robust dissemination plan to inform patients and families of the measure’s existence.

Response: We appreciate this recommendation and will continue to share outreach and education about the measure when it is publicly reported.

Comment: A commenter encouraged CMS to make specifications for the Excessive Radiation eCQM available for 2025 in the eCQI Resource Center, to allow the commenter to evaluate the measure’s implementation.

Response: We appreciate the commenter’s input and will take it into account. The measure specifications were posted on the eCQI Resource Center at https://ecqi.healthit.gov/ecqm/eh/pre-rulemaking/2024/cms1074v1 at the time of the proposed rule. We will continue to update this page as more information becomes available. We will also provide information about the software’s specifications as it becomes available through routine communication channels to hospitals, vendors, and other interested parties, including but not limited to, issuing memos, emails, and notices on QualityNet and the eCQI Resource Center websites.

Comment: A commenter requested clarification on several aspects of the measure. The commenter asked how “good image quality” would be determined beyond noise and stated that there are other elements that should be taken into consideration such as contrast resolution, lesion detection ability, and physician preference. The commenter also requested greater transparency around the data inputs, algorithm, and how the software would classify individual cases. The commenter recommended that CMS specifically identify the threshold values, particularly for image quality, and provide additional information about how these values were derived. The commenter further encouraged CMS to be as transparent as possible about the cost and burden associated with the measure, including costs associated with hardware, application support, and software maintenance. The commenter further requested clarification on whether the one-year measurement period measures the cumulative dose for all patients or individual patients. The commenter also asked CMS to identify specific requirements for maintaining the data over time, such as where to store the information.

Response: We appreciate the commenter’s feedback. Regarding the commenter’s question about how good image quality would be determined beyond noise, we wish to clarify that the image quality component, as measured by noise, was included to ensure that CT image quality does not decrease as an unintended consequence of lowering radiation doses. Noise was selected as the metric for measuring image quality because it is the most widely used measure of image quality for CT. Because the image quality component is not meant to be a comprehensive measure of image quality that can assess nuanced differences in quality across all CT scans, it does not take into account variables beyond noise.

We also wish to clarify the data inputs, algorithm, and how the software would classify individual cases. The measure specifications are listed in measure submission materials to the NQF and on the eCQI Resource Center at https://ecqi.healthit.gov/ecqm/eh/pre-rulemaking/2024/cms1074v1. The framework for classifying CT scans into CT categories was published in “An Image Quality-Informed Framework for CT Characterization,” 506

Regarding the measure’s threshold values and approach for deriving them, this information can be found in the materials that the measure developer submitted to the NQF for endorsement review. 506 The thresholds were derived in part using data from the ACR Dose Index Registry and UCSF International CT Dose Registry.

We additionally thank the commenter for their encouragement to be as transparent as possible about the cost and burden associated with the measure. As discussed previously, to clarify the current reporting process, we note that a hospital would log in through the measure developer’s secure portal and run the Alara Imaging

506 Measure 3663e Information Form. Available at: https://www.qualityforum.org/ProjectMeasures.aspx?projectID=86057&cycleNo=2&cycleYear=2021.
508 Measure 3663e Information Form. Available at: https://www.qualityforum.org/ProjectMeasures.aspx?projectID=86057&cycleNo=2&cycleYear=2021.
Software for CMS Measure Compliance inside the firewall. The software runs automatically to create the three intermediate data elements needed for the measure: CT Dose and Image Quality Category, Calculated CT Size-Adjusted Dose, and Calculated CT Global Noise. Once the software finishes creating these intermediate variables, hospitals can send the data to its EHR for measure calculation and reporting. No additional hardware will be needed, nor any manual data entry.

With regard to the commenter’s question about what the one-year measurement period is measuring, each CT scan in the one-year period is evaluated against size-adjusted dose and permissible image noise thresholds set for each CT category. There is no assessment that combines dose across time and there are no cumulative dose calculations.

Additionally, regarding the question about requirements for data maintenance, the Excessive Radiation eCQM uses data from radiology electronic clinical data systems, including the Radiology Information System (RIS) and the Picture Archiving and Communication System (PACS), and these medical imaging information such as Radiation Dose Structured Reports and image pixel data are stored according to the universally adopted DICOM standard, as described in the proposed rule (88 FR 27084). These data will need to be available at the time the hospital and/or its vendor calculates the eCQM for quality improvement and monitoring purposes as well reporting to CMS.

After consideration of the public comments we received, we are finalizing our proposal as proposed.

6. Refinements to Current Measures in the Hospital IQR Program Measure Set

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27084 through 27088), we proposed refinements to three measures currently in the Hospital IQR Program measure set: (1) Hybrid Hospital-Wide All-Cause Risk Standardized Mortality (HWM) measure beginning with the FY 2027 payment determination; (2) Hybrid Hospital-Wide All-Cause Readmission (HWR) measure beginning with the FY 2027 payment determination; and (3) COVID-19 Vaccination Coverage among Healthcare Personnel (HCP) measure beginning with Quarter 4 CY 2023 reporting period/FY 2025 payment determination. We provide more details on these proposed refinements in the subsequent sections and for the modification of the COVID-19 Vaccination Coverage among HCP measure, as previously discussed in section IX.B. of this final rule.

a. Modification of Hybrid Hospital-Wide All-Cause Risk Standardized Mortality (HWM) Measure Beginning With the FY 2027 Payment Determination

(1) Background

Estimates suggest that more than 400,000 patients die each year from preventable harm in hospitals.510 Existing condition-specific mortality measures support targeted quality improvement work and may have contributed to national declines in hospital mortality rates for measured conditions and/or procedures.511 They do not, however, allow for measurement of a hospital’s broader performance, nor do they meaningfully capture performance for low-volume hospitals. While we do not ever expect mortality rates to be zero, studies have shown that, for selected conditions and diagnoses, mortality within 30 days of hospital admission is related to quality of care.512

In the FY 2022 IPPS/LTCH PPS final rule (86 FR 45365 through 45374), we adopted the Hybrid HWM measure into the Hospital IQR Program starting with one voluntary confidential reporting period beginning with performance data from July 1, 2022, through June 30, 2023, followed by mandatory data submission and public reporting in subsequent years. Specifically, hospitals are required to report the Hybrid HWM measure beginning with the performance data from July 1, 2023, through June 30, 2024, impacting the FY 2026 payment determination and subsequent years.513

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27085 through 27086), we proposed to modify the measure to expand the cohort of the Hybrid HWM measure from only Medicare fee-for-service (FFS) patients to a cohort which includes both FFS and Medicare Advantage (MA) patients 65 to 94 years old for the FY 2027 payment determination and subsequent years. The FY 2027 payment determination is associated with discharge data from July 1, 2024, through June 30, 2025. We proposed to expand the measure cohort to include MA patients because MA beneficiary enrollment has been rapidly increasing as a share of overall beneficiaries. In 2022, nearly half of Medicare beneficiaries—or over 28 million people—were enrolled in MA plans, and it is projected that enrollment will continue to grow.514 The Congressional Budget Office estimates that by 2030, 62 percent of beneficiaries will be covered by MA plans.515 MA coverage also varies across counties and states (ranging between one to 59 percent) with lower enrollment in rural states.516 Including MA beneficiaries in hospital outcome measures will help ensure that hospital quality is measured across all Medicare beneficiaries. We further believe that the addition of MA beneficiaries to FFS will significantly increase the size of the measure’s cohort, enhance the reliability of the measure scores, lead to more hospitals receiving results, and increase the chance of identifying meaningful differences in quality for some low-volume hospitals. Moreover, this update will address interested parties’ concerns about differences in quality for MA and FFS beneficiaries by ensuring hospital outcomes are measured across all Medicare beneficiaries.517

513 Subsequent reporting periods for the Hybrid HWM measure are from July 1, three years prior to the fiscal year in which the payment determination is applied and end on June 30, two years prior to the fiscal year in which the payment determination is applied.
515 Ibid.
516 Ibid.
(2) Overview of Measure

The Hybrid HWM measure is an outcome measure developed to capture the hospital-level, risk-standardized mortality within 30 days of hospital admission for most conditions or procedures. Hospitalizations are eligible for inclusion in the measure if the patient was hospitalized at a non-Federal, short-term acute care hospital. The measure is reported as a single summary score, derived from the results of risk-adjustment models for 15 mutually exclusive service-line divisions (categories of admissions grouped based on similar discharge diagnoses or procedures), with a separate risk model for each of the 15 service-line divisions. The 15 service-line divisions include nine non-surgical divisions and six surgical divisions. The non-surgical divisions are: cancer; cardia/cardiaco; gastrointestinal; infectious disease; neurology; orthopedics; pulmonary; renal; and other. The surgical divisions are: cancer; cardiothoracic; general; neurosurgery; orthopedics; and other. The focus population is Medicare FFS and proposed MA beneficiaries who are 65 to 94 years old and hospitalized in non-Federal hospitals.

To compare mortality performance across hospitals, the measure accounts for differences in patient characteristics (patient case mix), as well as differences in the medical services provided and procedures performed by hospitals (hospital service mix). In addition, the Hybrid HWM measure employs a combination of administrative claims data and clinical EHR data to enhance clinical case mix adjustment with additional clinical data. As described previously, the measure is reported as a single summary score, derived from the results of risk-adjustment models for 15 mutually exclusive service-line divisions.

(3) Measure Calculation

The current Hybrid HWM measure cohort consists of Medicare FFS beneficiaries, between 65 and 94 years old, discharged from a non-Federal, short-term acute care hospital, within the one-year measurement period (July 1 to June 30). The cohort definition attempts to capture as many admissions as possible for which survival will be a reasonable indicator of quality and for which adequate risk adjustment is possible. The outcome for this measure is all-cause 30-day mortality. We define all-cause mortality as death from any cause within 30 days of the index hospital admission date.\(^{519}\) The Hybrid HWM measure uses three main sources of data for the calculation of the measure: (1) Medicare Part A claims data; (2) a set of core clinical data elements from a hospital’s EHR; and (3) mortality status obtained from the Medicare Enrollment Database.

The proposed inclusion of MA beneficiaries has several important benefits for the reliability and validity of this hospital outcome measure. Using data from July 1, 2018 through June 30, 2019, we calculated results from the MA claims to compare to the FFS-only results. We assessed 6,883,980 unique admissions (2,466,453 MA and 4,417,527 FFS) extracted from the CMS Integrated Data Repository for FFS claims, hospital-submitted MA claims, and Medicare Advantage Organization (MAO)-submitted MA inpatient encounter claims. Due to the lack of available EHR data, we conducted testing of the combined cohort (MA and FFS) in a claims-only version of the HWM measure. The Hybrid HWM measure is identical to the claims-only version of the measure except for the addition of the core clinical data elements. When the Hybrid HWM measure was initially developed, results using the Medicare Claims Re-Specification Dataset were compared with the hybrid measure results. The measure scores based on the claims-only model in the hybrid data are highly correlated to the measure scores based on the hybrid model (correlation coefficient = 0.96). C-statistics from logistic regression models comparing the hybrid and claims-only models were very similar, with improvement in the C-statistics with the addition of the core clinical data elements found in the EHR.\(^{520}\)

With the inclusion of MA claims, 84 additional hospitals and 2,466,453 additional admissions were included in the Hybrid HWM measure cohort. When considering only hospitals with 25 or more eligible admissions, the cutoff used for public reporting of the HWM measure, the inclusion of MA data resulted in 62 additional hospitals in the measure. The observed (unadjusted) mortality rate was lower among MA admissions compared to FFS admissions (6.20 versus 6.36 percent). Additionally, the prevalence of comorbidities was generally lower among MA beneficiaries as compared to FFS. The mean hospital risk-standardized mortality rate was lower for the FFS and MA cohort compared to the FFS-only cohort (6.35 versus 6.39 percent for hospitals with 25 or more admissions). After the addition of MA admissions to the FFS-only HWM cohort and among hospitals with 25 or more FFS admissions, 70 percent of hospitals remained in the same risk standardized mortality rate (RSMR) quintile and 98 percent remained within one quintile. The correlation between hospital RSMRs was 0.90. Test-retest reliability for the combined FFS and MA cohort was higher than for the FFS-only cohort (0.736 versus 0.620 for hospitals with 25 or more admissions).

The only change to the current Hybrid HWM measure that we proposed is the addition of MA admissions into the cohort; all other specifications will remain the same.


The modified Hybrid HWM measure was re-submitted to the MAP for the 2022–2023 pre-rulemaking cycle and received conditional support for rulemaking, pending CBE endorsement. The Hybrid HWM measure received endorsement by the CBE on October 23, 2019.\(^{521}\) The modified measure with expanded cohort is expected to be submitted for CBE re-endorsement in Fall 2024.

(4) Data Submission and Reporting

We proposed that hospitals will use Quality Reporting Data Architecture (QRDA) Category I files to report core clinical data elements for each Medicare FFS and MA beneficiary who is 65 to 94 years old for data submission (86 FR 45370 and 45371). Submission of data to CMS using QRDA I files is the current EHR data and measure reporting standard adopted for eCQMs implemented in the Hospital IQR Program (84 FR 42506, 85 FR 58940 through 58942). These core clinical data elements are data that hospitals

\(^{519}\) https://cciui.healthit.gov/glossary.


\(^{521}\) Centers for Medicare & Medicaid Services Measures Inventory Tool (CMIT). Hybrid Hospital-Wide All-Cause Risk Standardized Mortality Measure with Claims and Electronic Health Record Data. Available at: https://cmit.cms.gov/cm/s/MeasureView?variantId=35409&sectionNumber=3.
routinely collect, that can be feasibly extracted from hospital EHRs, and that can be utilized as part of specific quality outcome measures.\(^{522}\) The data elements are the values for a set of vital signs and common laboratory tests collected at the time the patient initially presents to the hospital. They are used, in addition to claims data, for risk adjustment of patients’ severity of illness (for Medicare FFS beneficiaries who are between 65 and 94 years old).

To successfully submit the Hybrid HWM measure, hospitals will need to submit the core clinical data elements included in the Hybrid HWM measure, as described for measure calculation,\(^{523}\) for all Medicare FFS and MA beneficiaries between 65 to 94 years old discharged from an acute care hospitalization in the one-year measurement period. Hospitals will also be required to successfully submit six linking variables that are necessary to merge the core clinical data elements with the CMS claims data to calculate the measure. For more details on Hybrid HWM measure submission requirements, we refer readers to the FY 2022 IPPS/LTCF PPS final rule (86 FR 45368 through 45374).

The cohort expansion of the Hybrid HWM measure to include MA admissions was the only change to the Hybrid HWM measure that was proposed. We proposed to include MA admissions in the Hybrid HWM beginning with the admissions data from July 1, 2024 through June 30, 2025, which affects the FY 2027 payment determination, and for subsequent years.

We invited public comment on this proposal.

**Comment:** Many commenters supported our proposal to modify the Hybrid Hospital-Wide Mortality (Hybrid HWM) measure to include Medicare Advantage (MA) beneficiaries. A few commenters noted that MA enrollment is expected to surpass the Fee-for-Service (FFS) population by the time this modification is implemented, and therefore, will allow a more robust view of all Medicare beneficiaries. A few commenters stated that the inclusion of MA beneficiaries is aligned with CMS’ goal of providing more comprehensive information on the quality of care for all Medicare beneficiaries.

**Response:** We agree and thank the commenters for their support.

A few commenters shared a concern that some MA plans may manipulate risk scoring by selectively enrolling healthier patients, down coding diagnoses, or other risk-adjustment gaming behaviors, yet they applauded CMS for having implemented a number of programs and initiatives to address these practices, including risk adjustment data validation, medical record audits, and continued refinement of the Hierarchical Condition Categories (HCC) model.

We acknowledge the commenter’s concerns related to the inclusion of MA data. In regard to the gaming behaviors, we thank the commenter for the recognition of the number of programs implemented by CMS to protect against impermissible practices. The Medicare Payment Advisory Commission (MedPAC) notes that the CMS-HCC risk-adjustment model, combined with requirements for MA plans to enroll all eligible Medicare beneficiaries who elect a plan, have generally reduced favorable selection of healthier or less costly beneficiaries by MA plans.\(^{524}\) In addition, we note that prior research has found evidence of more intensive use of diagnosis codes leading to higher risk scores used for payment based on the HCCs for MA beneficiaries as compared to FFS.\(^{525}\) In contrast, the risk variables we use in the Hybrid HWM measure do not apply the hierarchical methodology for the condition categories; rather, they are based on clinically relevant condition categories and Agency for Healthcare Research and Quality (AHRQ) clinical classification software (CCS) condition groups for principal diagnoses. Based on the Hybrid HWM measure’s risk factors, we found the prevalence of comorbidities was slightly lower among MA beneficiaries. Additionally, as part of regular reevaluation efforts, we assess the need for measure modification annually. Modifications are informed by review of the most recent literature related to measure outcomes, feedback from interested parties, empirical analyses, and assessment of coding trends that reveal shifts in clinical practice or billing patterns.

A few commenters shared reliability concerns due to incomplete data for the MA population. A commenter recommended that CMS consider policies to ensure that MA plans provide complete encounter data that can be relied on for measurement, such as setting new data completeness requirements for plan payment and/or adopting sufficient penalties for plans that submit incomplete data. A commenter encouraged CMS to continue to explore different options to make data about MA beneficiary utilization and outcomes more available, particularly utility data at a procedure level across all care settings. A commenter suggested delaying the modification of the measure due to incomplete data for the MA population.

We respectfully disagree that the level of completeness of the MA data presents a significant issue with regards to measure reliability. We have been evaluating the data for trends in quality measurement since 2017 as discussed further in this section, and we note recent CMS policies have aimed to improve timeliness, completeness, and accuracy of MA data, thereby further enhancing its usability for hospital outcome measures.\(^{526}\)\(^{527}\) Hospital-submitted MA claims data are currently already in use for DSH and GME payment calculations and Medicare Advantage Organization (MAO)-submitted encounter data are currently already in use for calculating MA beneficiary risk scores.\(^{528}\) In calculating the Hybrid HWM measure, we clarify that for each MA admission, we would use either the hospital-submitted MA claim or the MAO-submitted MA encounter claim, whichever is available. If the MA admission information for a patient is available in both sources, we would use the hospital-submitted MA claim.


claim because it is timelier and already associated with the applicable hospital’s CCN.

More generally, we have found that incorporating data regarding MA patients into the Hybrid HWM measure improves reliability, narrows the confidence intervals of measure scores, and leads to more hospitals and beneficiaries being included in the measures. Based on internal analyses of MA data reported to CMS by hospitals and MAOs for the years 2017 through 2021, we determined that it is feasible to use MA admissions in CMS hospital outcome measures. Hospitals and MAOs submit the data on a schedule that allows for their use. National Provider Identifiers (NPIs) from inpatient MA claims in the Integrated Data Repository (IDR) can be matched to CMS Certification Numbers (CCNs) currently used to identify hospitals in the CMS outcome measures. A high percentage of MA claims were submitted within the three-month time frame needed for reporting hospital measures and has improved over time (90.3% in 2018 compared to 95.2% in 2021 for inpatient claims for acute care and critical access hospitals). Our internal analysis found a high rate of matching diagnoses between the MAO-submitted MA claims and the hospital-submitted MA claims, supporting the use of either data source for a given admission for measure calculation.

Comment: A commenter expressed that they believe MA plans are already including quality metrics tied to hospitals. A commenter suggested CMS places duplicative reporting burdens on requiring this reporting as part of the MA contracts, to incorporate MA enrollees into these measures, to avoid duplicate efforts and necessary changes to hospital reporting processes and systems.

Response: We disagree that reporting of the Hybrid HWM measure with the addition of MA beneficiaries creates significant burden for hospitals. This hybrid measure uses both claims-based data and EHR data, specifically, a set of core clinical data elements consisting of vital signs and laboratory test information and patient linking variables collected from hospitals’ EHR systems. We note that hospitals are responsible for combining the claims and EHR data to calculate the measure score as that is performed by CMS and the results are shared with hospitals in feedback reports. We refer readers to the Information Collection Requirements (ICR) section B.6.d within this final rule, for information regarding burden for the Hybrid HWM measure including MA beneficiaries.

The mandatory reporting requirement for the currently implemented version of the Hybrid HWM measure (FFS beneficiaries only) was finalized in the FY 2022 IPPS/LTC PPS final rule (86 FR 45365 through 45374). The implementation timeline started with one voluntary confidential reporting period beginning with performance data from July 1, 2022, through June 30, 2023, followed by mandatory data submission and public reporting in subsequent years. Specifically, hospitals are required to report the previously adopted version of the Hybrid HWM measure beginning with the performance data from July 1, 2023, through June 30, 2024, impacting the FY 2026 payment determination and subsequent years. The addition of the MA data to the cohort would not impact payment determinations until FY 2027 and subsequent years. The FY 2027 payment determination is associated with discharge data from July 1, 2024, through June 30, 2025. We proposed to expand the measure cohort to include MA patients because MA beneficiary enrollment has been rapidly increasing as a share of overall beneficiaries.529 Thus, it is important to avoid further delay of incorporating MA patients within the cohort of the currently implemented Hybrid HWM measure. There will be sufficient time to allow hospitals and their health IT vendors to familiarize themselves with the measure reporting process. We strongly encouraged hospitals to participate in the voluntary reporting periods as an opportunity to obtain detailed feedback on their performance on the measure, to provide us with additional feedback on the measure specifications and their implementation experience, to confirm mapping and extraction of data elements, to perform quality assurance, and to troubleshoot any problems during data submissions.

Comment: A few commenters suggested delaying implementation until the measure is endorsed by a consensus-based endorsement process. We note that the currently implemented version of the Hybrid HWM measure received endorsement on October 23, 2019.530 The modified measure with the addition of MA beneficiaries is expected to be submitted for CBE endorsement maintenance in Fall 2024. The re-endorsement process is expected to be completed prior to the FY 2027 payment determination. We believe the use of the updated measure is preferable to the existing, endorsed version of the

measure as the addition of MA beneficiaries to the cohort enhances the reliability and validity of the measure and all other fundamental elements of the endorsed measure remain unchanged.

Comment: A commenter requested CMS make available the specifications for the new proposed eCQM. A few commenters requested CMS share information about how the incorporation of MA data has affected the validity, accuracy, and reliability of the hybrid measure.

Response: Measure specifications for the Hybrid HWM measure with the inclusion of MA patients were posted on the eCQI Resource Center on the FY 2024 Pre-Rulemaking page at the time of publication of the proposed rule: https://ecqi.healthit.gov/eh-cah?qt-tabs_eh=1&globalyearfilter=2024&global_measure_group=3731. Measure specifications for the previously adopted Hybrid HWM measure are located in the Annual Update and Specifications (AUS) reports found at https://qualitynet.cms.gov/Inpatient/measures/hybrid/methodology. According to the eCQI Resource Center, an eCQM is a measure specified in a standard electronic format that uses data electronically extracted from EHRs and/or health IT systems to measure the quality of health care provided.531 Hybrid measures differ from eCQMs within the Hospital IQR Program because they merge EHR data elements, which are used for risk-adjustment, with claims data to calculate the risk-standardized mortality rates. We do consider this hybrid measure to be a digital quality measure (dQM), under our draft definition. The draft definition of dQM that we have published as part of strategic materials on the eCQI Resource Center states that in general, eCQMs are considered to be a subset of dQMs. This draft definition states that dQMs are quality measures that use standardized, digital data from one or more sources of health information that are captured and exchanged via interoperable systems; apply quality measures and algorithms that are standards-based and use code packages; and are computable in an integrated environment without additional effort. CMS’ definition of a dQM is available on the eCQI Resource Center at: https://ecqi.healthit.gov/dqm?qt-tabs_dqm=1.532

With regards to how expanding the measure cohort has affected the measures’ validity, reliability, and accuracy, as described in the proposed rule, the inclusion of MA beneficiaries has several important benefits for the hospital outcome measure. With the inclusion of MA claims, 84 additional hospitals and 2,466,453 additional admissions were included in the Hybrid HWM measure cohort. When considering only hospitals with 25 or more eligible admissions, the cutoff used for public reporting of the HWM measure, the inclusion of MA data resulted in 62 additional hospitals in the measure. The observed (unadjusted) mortality rate was lower among MA admissions compared to FFS admissions (6.20 versus 6.36 percent). Additionally, the prevalence of comorbidities was generally lower among MA beneficiaries as compared to FFS. The mean hospital risk-standardized mortality rate was lower for the FFS and MA cohort compared to the FFS-only cohort (6.35 versus 6.39 percent for hospitals with 25 or more admissions). After the addition of MA admissions to the FFS-only HWM cohort and among hospitals with 25 or more FFS admissions, 70 percent of hospitals remained in the same risk-standardized mortality rate (RSMR) quintile and 98 percent remained within one quintile. The correlation between hospital RSMRs was 0.90. Test-retest reliability for the combined FFS and MA cohort was higher than for the FFS-only cohort (0.736 versus 0.620 for hospitals with 25 or more admissions). We also refer readers to Appendix G in the Hospital-Wide (All-Condition, All-Procedur) Risk-Standardized Mortality Measure with Electronic Health Record Extracted Risk Factors Methodology Report (Version 2.1) revised March 2023 533 for detailed rationale and testing results of integrating MA beneficiaries in the Hybrid Hospital-Wide Mortality (HWM) measure.

Comment: A few commenters recommended that CMS publicly report the Hybrid HWM measure in aggregate, as in not separately by Medicare FFS and MA or by insurance type, as they state the measure was developed and tested to provide information on hospital performance and has not been tested at the health plan level of analysis.

Response: We plan to publicly report the Hybrid HWM measure as an aggregate, single summary score by each hospital’s CCN. The modification to the Hybrid HWM measure to add MA beneficiaries to the cohort will not affect the way this measure is publicly reported. The measure summary score is derived from the results of risk-adjustment models for 15 mutually exclusive service-line divisions (categories of admissions grouped based on similar discharge diagnoses or procedures), with a separate risk model for each of the 15 service-line divisions. In the future, we may consider public reporting of more granular measure performance information, and will take commenters’ feedback into consideration.

After consideration of the public comments we received, we are finalizing our proposal as proposed.

b. Modification of Hybrid Hospital-Wide All-Cause Readmission (HWR) Measure Beginning With the FY 2027 Payment Determination (1) Background

Hospital readmission rates are affected by complex and critical aspects of care such as communication between providers or between providers and patients; prevention of, and response to, complications; patient safety; and coordinated transitions to the outpatient environment.534 Some readmissions are unavoidable, for example, those that result from the inevitable progression of disease or worsening of chronic conditions. However, readmissions may also result from poor quality of care or inadequate transitional care.535 536 537 538

538 Koehler BE, Richter KM, Youngblood L, Cohen RA, Frenziger ID, Cheng D, et al. Reduction of 30-day post discharge hospital readmission or emergency department (ED) visit rates in high-risk elderly medical patients through delivery of a

Continued
For the July 1, 2020, through June 30, 2021, measurement period, the risk-standardized readmission rate from the hospital-wide population ranged from 9.9 to 22.5 percent, showing a performance gap across hospitals with wide variation and an opportunity to improve quality.539

In the FY 2020 IPPS/LTCH PPS final rule (84 FR 42465 through 42479), we adopted the Hybrid HWR measure into the Hospital IQR Program in a stepwise implementation timeline starting with two voluntary reporting periods, followed by mandatory data submission and public reporting. The first voluntary reporting period used performance period data from July 1, 2021, through June 30, 2022, and the second voluntary reporting period is July 1, 2022, through June 30, 2023. Hospitals are required to report the Hybrid HWR measure beginning with performance period data from July 1, 2023, through June 30, 2024, impacting the FY 2026 payment determination, and for subsequent years.540

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27086 through 27088), similar to our proposal for the Hybrid HWR measure, we proposed to expand the cohort of the Hybrid HWR measure from only Medicare FFS patients to a cohort which includes FFS and MA patients 65 years and older beginning with the FY 2027 payment determination.

We proposed to expand the measure cohort to include MA patients because MA beneficiary enrollment has been rapidly expanding as a share of Medicare beneficiaries. In 2022, nearly half of Medicare beneficiaries—or over 28 million people—were enrolled in MA plans, and it is projected that enrollment will continue to grow.541 The Congressional Budget Office projects that by 2030, 62 percent of beneficiaries will be covered by MA plans.542 MA coverage also varies across counties and states (ranging between one to 59 percent) with lower enrollment in rural states.543 Including MA beneficiaries in CMS hospital outcome measures will help ensure that hospital quality is measured across all Medicare beneficiaries and not just the FFS population. We also believe that the addition of MA beneficiaries to FFS will significantly increase the size of the measure’s cohort, enhance the reliability of the measure scores, lead to more hospitals receiving results, and increase the chance of identifying meaningful differences in quality for some low-volume hospitals. Moreover, this update will address stakeholder concerns about differences in quality for MA and FFS beneficiaries by ensuring hospital outcomes are measured across all Medicare beneficiaries.544 545

(2) Overview of Measure

The Hybrid HWR measure is an outcome measure that captures the hospital-level, risk-standardized readmission rate (RSRR) of unplanned, all-cause readmissions within 30 days of hospital discharge for any eligible condition. The measure reports a single summary RSRR, derived from the volume-weighted results of five different models, one for each of the following specialty cohorts based on groups of discharge condition categories or procedure categories: (1) Surgery/gynecology; (2) general medicine; (3) cardiorespiratory; (4) cardiovascular; and (5) neurology. The measure also indicates the hospital-level standardized readmission ratios (SRR) for each of these five specialty cohorts. The outcome is defined as unplanned readmission for any cause within 30 days of the discharge date for the index admission (the admission included in the measure cohort). A specified set of readmissions are planned and do not count in the readmission outcome. The focus population is Medicare FFS and proposed MA beneficiaries who are 65 years or older and hospitalized in non-Federal hospitals.

(3) Measure Calculation

The outcome of this measure is 30-day unplanned readmissions. For this measure, we define readmission as an inpatient admission for any cause, except for certain planned readmissions, within 30 days from the date of discharge from an eligible index admission. If a patient has more than one unplanned admission (for any reason) within 30 days after discharge from the index admission, only one is counted as a readmission. The current measure includes admissions for beneficiaries enrolled in Medicare FFS for the 12 months prior to the date of index admission, on the date of the index admission, and the 30 days following discharge of the index admission; 65 years old or over; discharged alive from a non-Federal short-term acute care hospital; and not transferred to another acute care facility.

We proposed to add MA beneficiaries 65 years and older to the existing cohort of Medicare FFS beneficiaries for the Hybrid HWR measure. Using HWR claims-only data from July 1, 2018—June 30, 2019, we calculated measure results for the combined FFS and MA admissions and compared them to the results for FFS-only admissions. We assessed 11,029,470 unique admissions (4,077,633 MA and 6,951,837 FFS) extracted from the CMS Integrated Data Repository for FFS claims, hospital-submitted MA claims, and Medicare Advantage Organization (MAO)-submitted MA inpatient encounter claims. Based on the lack of availability of EHR data, we conducted testing of the combined cohort (MA and FFS) in the claims-only version of the HWR measure. The Hybrid HWR measure is identical to the claims-only measure except for the addition of the clinical data elements. When the Hybrid HWR measure was initially developed, the original claims-only HWR measure was compared with the hybrid measure results. The measure scores based on the claims-only model in the hybrid data were highly correlated to the measure scores based on the hybrid model (correlation coefficient = 0.99). C-statistics from logistic regression models comparing the hybrid and claims-only models were very similar, with some improvements in the C-statistics with the addition of the core clinical data elements found in the EHR.546
Inclusion of MA beneficiaries has several important benefits for the reliability and validity of the Hybrid HWR measure. The inclusion of MA admissions added 127 hospitals and more than four million admissions to the HWR cohort during the data period tested. When considering only hospitals with 25 or more eligible admissions, the cutoff used for public reporting of the HWR measure, the inclusion of MA data resulted in 63 additional hospitals in the measure. Observed (unadjusted) readmission within 30 days was higher for MA-only admissions than for FFS-only admissions (15.72 versus 15.35 percent), with comorbidities generally lower among MA beneficiaries. The mean risk-standardized readmission rate was slightly higher for the combined FFS and MA cohort compared to the FFS-only cohort (15.48 versus 15.35 percent for hospitals with 25 or more admissions in each cohort). This trend was seen across all specialty cohorts. After the addition of MA admissions to the FFS-only HWR measure and among hospitals with 25 or more FFS admissions, about two thirds (67 percent) of hospitals remained in their same performance quintile, and 95 percent remained within one quintile. The correlation between hospital RSRRs was 0.92. Test-retest reliability for the combined FFS and MA cohort was higher than for the FFS-only cohort (0.780 versus 0.725 among hospitals with 25 or more admissions). The only change to the existing Hybrid HWR measure was the addition of MA admissions into the cohort; all other specifications remained the same. We refer readers to the Hybrid Hospital-Wide Readmission Measure with Expanded Cohort (HWR) as described for measure calculation,548

1886(b)(3)(B)(viii)(IX)(aa) of the Act generally requires that measures specified by the Secretary for use in the Hospital IQR Program be endorsed by the entity with a contract under section 1890(a) of the Act. Under section 1886(b)(3)(B)(viii)(IX)(bb) of the Act, in the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed by the entity with a contract under section 1890(a) of the Act, the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary. We reviewed CBE-endorsed measures and were unable to identify any other CBE-endorsed measures on this topic, and, therefore, we believe the exception in section 1886(b)(3)(B)(viii)(IX)(bb) of the Act applies.

(4) Data Submission and Reporting

Hospitals will use Quality Reporting Data Architecture (QRDA) Category I files for each Medicare FFS and MA beneficiary who is 65 years and older for data submission. Submission of data to CMS using QRDA I files is the current EHR data and measurement reporting standard adopted for eCQMs implemented in the Hospital IQR Program.84 FR 42469 and 42470, 85 FR 59890.

To successfully submit the Hybrid HWR measure, hospitals will need to submit the core clinical data elements included in the Hybrid HWR measure, as described for measure calculation,548 for all Medicare FFS and MA beneficiaries 65 years and older discharged from an acute care hospitalization in the one-year measurement period. These core clinical data elements are data that hospitals routinely collect, that can be feasibly extracted from hospital EHRs, and that can be utilized as part of specific quality outcome measures.549 The data elements are the values for a set of vital signs and common laboratory tests collected at the time the patient initially presents to the hospital. They are used, in addition to claims data, for risk adjustment of patients’ severity of illness (for Medicare FFS beneficiaries who are 65 years and older). Hospitals will also be required to successfully submit the six linking variables that are necessary to merge the core clinical data elements with the CMS claims data to calculate the measure. For more details on Hybrid HWR measure data submission requirements, we refer readers to the FY 2020 IPPS/LTCH PPS final rule (84 FR 42467 through 42470).

The cohort expansion of the Hybrid HWR measure to include MA admissions was the only proposed change to the Hybrid HWR measure. We proposed to include MA admissions in the Hybrid HWR cohort beginning with the discharge data from July 1, 2024 through June 30, 2025, which affects the FY 2027 payment determination, and for subsequent years.

We invited public comment on this proposal. Many commenters had the same comments about adding MA beneficiaries to the Hybrid HWR measure as they did for adding MA beneficiaries to the Hybrid HWM measure. We direct readers to section C.6.a. for the full discussion of these comments in the Hybrid HWM section. Comments specific to the Hybrid HWR measure are noted in the section.

Response: We agree and thank the commenters for their support.

Comment: A commenter questioned whether the Hybrid HWR measure may be a measure of care utilization instead of a measure of quality of care and suggested that smaller hospitals or health systems may be disadvantaged by this measure unless it is somehow adjusted to reflect the environment of care delivery.

Response: We acknowledge the commenters’ concern that the Hybrid HWR measure may be a measure of care utilization rather than a measure of quality of care. We disagree that the Hybrid HWR measure is a measure of care utilization and assert that it is a measure of quality of care. The goal of the Hybrid HWR measure is to improve patient outcomes by providing patients, clinicians, and hospitals with

547 Centers for Medicare & Medicaid Services Measures Inventory Tool (CMIT). Available at: https://cmit.cms.gov/cmit/#/MeasureView? variantId=45975&sectionNumber=3.


The Hybrid HWR measure provides an overall signal of quality for hospitals in contrast to current specific measures which provide more narrowly focused quality information. Both types of readmission measures provide beneficiaries and providers with useful information that allows them to improve patient outcomes.

After consideration of the public comments we received, we are finalizing our proposal as proposed.

7. Proposed Measure Removals for the Hospital IQR Program Measure Set and Proposed Codification of Measure Removal Factors

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27088 through 27093) we proposed to remove these measures: (1) Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA) measure beginning with the April 1, 2023 through March 31, 2028 reporting period/FY 2030 payment determination; (2) Medicare Spending Per Beneficiary (MSPB)—Hospital measure beginning with the CY 2026 reporting period/FY 2028 payment determination; and (3) Elective DeliveryPrior to 39 Completed Weeks Gestation: Percentage of Babies Electively Delivered Prior to 39 Completed Weeks Gestation (PC–01) measure beginning with the CY 2024 reporting period/FY 2026 payment determination.

We also proposed to codify the Measure Removal Factors that we have previously adopted for the Hospital IQR Program.

We provide more details on each of these proposals, as well as the public comments we received on them, in the subsequent sections.

a. Removal of Hospital-Level Risk-Standardized Complication Rate Following Elective Primary Total Hip Arthroplasty and/or Total Knee Arthroplasty Measure Beginning With the FY 2030 Payment Determination

We adopted the original Hospital-Level Risk-Standardized Complication Rate Following Elective Primary Total Hip Arthroplasty and/or Total Knee Arthroplasty measure (hereinafter referred to as the THA/TKA Complication measure) for use in the Hospital IQR Program in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53516 through 53518). In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50062 and 50063), we adopted the same measure for use in the Hospital Value-Based Purchasing (VBP) Program. In the FY 2019 IPPS/LTCH PPS final rule (83 FR 15528 and 41559), we finalized the removal of the measure from the Hospital IQR Program under measure removal factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program. The measure’s removal was part of agency-wide efforts to reduce provider burden since the measure is also being reported under the Hospital VBP Program.

After the measure was removed from the Hospital IQR Program, it was revised by the measure steward to include 26 additional mechanical complication ICD-10 codes, which were identified during measure maintenance. Our analyses showed the addition of these clinically relevant codes contributed to an increase in the THA/TKA national observed complication rate. Findings demonstrated an increase of approximately 0.5 percent (from 2.42 percent to 2.93 percent) in the THA/TKA national observed complication rate when evaluated for the FY 2021 performance period. These findings suggested that the expanded outcome will allow the updated THA/TKA Complication measure to capture a more complete outcome.

Therefore, in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49263 through 49267), we adopted the re-evaluated THA/TKA Complication measure with an expanded measure outcome, beginning with claims data with admission dates from April 1, 2019 through March 31, 2022 (excluding data from the period covered by the extraordinary circumstances exception (ECE) granted by CMS related to the COVID–19 Public Health Emergency (PHE)) that is associated with the FY 2024 payment determination. For measure specification details on the updated measure, we refer readers to the Hip and Knee Arthroplasty
Complications (ZIP) folder on the CMS.gov Measure Methodology website at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInitiatives/Measure-Methodology.

As stated in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49263), we adopted this measure into the Hospital IQR Program with the intention to propose the updated measure into the Hospital VBP Program after the required year of public reporting in Hospital IQR Program. As noted at 42 CFR 412.164(b), measures in the Hospital VBP Program must be publicly reported for one year prior to the beginning of the performance period.

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27089 through 27090), we proposed to remove the measure beginning with the April 1, 2025, through March 31, 2028, reporting period associated with the FY 2030 payment determination under measure removal factor 8, the costs associated with the measure outweigh the benefit of its continued use in the program. Concurrent to this proposal to remove the measure, the Hospital VBP Program proposed to adopt the re-evaluated measure to replace the original version of the measure that is in the Hospital VBP Program. Therefore, we proposed its removal from the Hospital IQR Program to prevent duplicative reporting of the measure in a quality reporting program and value-based program, and to simplify administration of both programs. This proposed removal is contingent on finalizing our proposal to adopt the re-evaluated measure in the Hospital VBP Program beginning with the FY 2030 program year. For example, we may modify the date on which we will remove the measure from the Hospital IQR Program to align with the date on which the Hospital VBP Program adopts the re-evaluated measure. We refer readers to section V.K. of this final rule for more information on the policy to adopt the re-evaluated measure in the Hospital VBP Program.

We believe that removing this measure from the Hospital IQR Program will eliminate the costs associated with implementing and maintaining the measure for the program if and when the re-evaluated THA/TKA Complication measure is adopted in that program.

We proposed to remove the THA/TKA Complication measure from the Hospital VBP Program beginning with the FY 2030 program year. We invited public comment on this proposal.

Response: We thank the commenters for their support. Results for the updated THA/TKA Complication measure being adopted into the Hospital VBP Program will continue to be publicly reported on Care Compare and data.cms.gov for the period of time in which hospitals report on the two versions of this measure.

Comment: A few commenters supported our proposal to remove the THA/TKA Complication measure because that health care providers would incur additional costs to monitor measure performance in multiple programs for internal quality improvement and financial planning purposes. Individuals may also find it confusing to see public reporting on the same measure in different programs. In addition, maintaining the specifications for the measure, as well as the tools we need to analyze and publicly report the measure data, results in costs to CMS. We believe the cost of maintaining the same measure in multiple programs, as previously discussed, outweigh the associated benefit to individuals of receiving the same information from multiple programs, because that information could be captured through inclusion of the re-evaluated version of this measure solely in the Hospital VBP Program if the re-evaluated form of the THA/TKA Complication measure is adopted in that program.

We seek to advance the Hospital IQR Program by maintaining a set of the most meaningful quality measures and recognizing the associated burden of reporting those measures. We believe the Hospital IQR Program continues to incentivize improvement in the quality of care provided to patients. We further believe that removing this measure from the Hospital IQR Program will help achieve that goal. We believe keeping this measure in both programs would be inconsistent with our goal of avoiding unnecessary complexity and cost with duplicative measures across programs. We continue to believe that this measure provides important data on patient outcomes following inpatient hospitalization (addressing Meaningful Measures 2.0’s priority of driving outcome improvement).551 which is why we proposed to adopt the updated measure in the Hospital VBP Program. Unlike the Hospital IQR Program, performance data on measures maintained in the Hospital VBP Program are used both to assess the quality and value of care provided at a hospital and to calculate incentive payment adjustments for a given year of the program based on performance. The Hospital VBP Program’s incentive payment structure ties hospitals’ payment adjustments on claims paid under the IPPS to their performance on selected quality measures, including the THA/TKA Complication measure, sufficiently incentivizing performance improvement on this measure among participating hospitals.

We proposed to remove the THA/TKA Complication measure from the Hospital IQR Program beginning with the FY 2030 payment determination. This proposal is contingent on finalizing our proposal to adopt the measure in the Hospital VBP Program beginning with the FY 2030 program year.

Comment: Many commenters supported the proposal to remove the THA/TKA Complication measure from the Hospital IQR Program. Specifically, some commenters appreciated the removal of the THA/TKA Complication measure from the Hospital IQR Program as it will reduce duplication. A few commenters supported the removal of THA/TKA Complication measure from the Hospital IQR Program provided it will continue to be reported on the Care Compare website.

Response: We thank the commenters for their support. Results for the updated THA/TKA Complication measure being adopted into the Hospital VBP Program will continue to be publicly reported on Care Compare and data.cms.gov for the period of time in which hospitals report on the two versions of this measure.

Comment: We respectfully disagree that the proposed transition of the THA/TKA Complication measure from the Hospital IQR Program to the Hospital VBP Program will cause significant data

collection burden. Hospitals will not be required to submit additional data for calculating the measure as it is a claims-based measure. Section 1886(o)(2)(C)(i) of the Act requires that a measure be publicly reported for one year in the Hospital IQR Program prior to the beginning of the applicable Hospital VBP Program performance period for the measure. As we have previously stated in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49263 through 49267), we adopted the revised version of the THA/TKA Complication measure into the Hospital IQR Program with the intention of eventually proposing the updated measure into the Hospital VBP Program with a performance period that starts after the required one year of public reporting in the Hospital IQR Program as well as to provide interested parties with an opportunity to become familiar with the new version of the measure and provide feedback. We refer readers to section V.K. of this final rule for more information on the policy to adopt the re-evaluated THA/TKA Complication measure in the Hospital VBP Program. We intend to continue publishing THA/TKA Complication measure data on the Care Compare site for the period of time in which this measure is reported in the Hospital IQR Program. In addition, we will make sure it is clear which version of the measure is being displayed in which location through outreach and education efforts.

After consideration of the public comments we received, we are finalizing our proposal as proposed.

b. Removal of Medicare Spending Per Beneficiary (MSPB)—Hospital Measure Beginning With the CY 2026 Reporting Period/FY 2028 Payment Determination

We adopted the original Medicare Spending Per Beneficiary (MSPB)—Hospital measure (CBE# 2158) (hereinafter referred to as the MSPB Hospital measure) for use in the Hospital IQR Program in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51618 through 51627). In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51654 through 51658) we adopted the same measure for use in the Hospital Value-Based Purchasing (VBP) Program. In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41559 and 41560), we removed the MSPB Hospital measure from the Hospital IQR Program beginning with the FY 2022 payment determination under measure removal factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program. We believed that removing the measure from the Hospital IQR Program would eliminate costs associated with implementing and maintaining the measure, and in particular, development and release of duplicative and potentially confusing confidential feedback reports provided to hospitals across multiple hospital quality and value-based purchasing programs. The original version of the MSPB Hospital measure that was removed from the Hospital IQR Program was identical to the version that was concurrently and continues to be used in the Hospital VBP Program.

To continue assessing hospitals’ efficiency and resource use and to meet statutory requirements under section 1886(o)(2)(B)(ii) of the Act, in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49257 through 49263), we adopted the re-evaluated version of the MSPB Hospital measure in the Hospital IQR Program. We noted our plans to subsequently propose this version of the measure for the Hospital VBP Program measure set after the required year of public reporting in Hospital IQR Program. As required by 42 CFR 412.164(b), measures in the Hospital VBP Program must be publicly reported for at least one year prior to the beginning of the performance period.

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27090 through 27091), we proposed to remove this measure beginning with the FY 2028 payment determination under measure removal factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program. This measure was proposed for adoption by the Hospital VBP Program in section V.K. of the proposed rule (88 FR 27025 through 27026), and we proposed its removal from the Hospital IQR Program to reduce the burden that would arise from duplicative reporting of the measure in a quality reporting program and value-based program, and to simplify administration of both programs. This proposed removal is contingent on finalizing our proposal to adopt the re-evaluated measure in the Hospital VBP Program beginning with the FY 2028 program year. For example, we may modify the date on which we will remove the measure from the Hospital IQR Program to align with the date on which the Hospital VBP Program adopts the re-evaluated measure. We refer readers to section V.K. of the preamble of this final rule for more information on the proposal to adopt the re-evaluated version of the MSPB Hospital measure in the Hospital VBP Program. We believe that removing this measure from the Hospital IQR Program will minimize the associated with implementing and maintaining the measure, and in particular, development and release of duplicative and potentially confusing confidential feedback reports provided to hospitals across multiple hospital quality and value-based purchasing programs. For example, it may be costly for health care providers to track confidential feedback, preview reports, and publicly reported information on this measure in both the Hospital IQR Program and in the Hospital VBP Program. We expect that health care providers would incur additional costs to monitor measure performance in multiple programs for internal quality improvement and financial planning purposes when measures are used across value-based purchasing programs. Individuals may also find it confusing to see public reporting on the same measure in different programs. In addition, maintaining the specifications for the measure, as well as the tools we need to analyze and publicly report the measure data, result in costs to CMS. We believe the cost of maintaining the same measure in multiple programs, as previously discussed, outweigh the associated benefit to individuals of receiving the same information from multiple programs, because that information could be captured through inclusion of the updated version of this measure solely in the Hospital VBP Program if the re-evaluated version of the MSPB Hospital measure is adopted in that program.

We sought to advance the Hospital IQR Program by maintaining a set of the most meaningful quality measures and recognizing the associated burden of reporting those measures. We believe the Hospital IQR Program continues to incentivize improvement in the quality of care provided to patients. We further believe that removing this measure from the Hospital IQR Program will help achieve that goal. As discussed in section V.K. of the preamble of this final rule, we believe keeping this measure in both programs would be inconsistent with our goal of avoiding unnecessary complexity or cost with duplicative measures across programs. We continue to believe this measure provides important data on resource use (addressing the Meaningful Measures Framework priority of making care affordable), which is why we proposed to adopt the updated measure in the Hospital VBP Program. Unlike the Hospital IQR Program, performance data on measures maintained in the Hospital VBP Program are used both to assess the quality and value of care provided at a hospital and to calculate incentive payment adjustments for a given year of the program based on performance. The
Hospital VBP Program’s incentive payment structure ties hospitals’ payment adjustments on claims paid under the IPPS to their performance on selected quality measures, including the MSPB Hospital measure, sufficiently incentivizing performance improvement on this measure among participating hospitals.

We proposed removal of the updated MSPB Hospital measure (CBI #2158) from the Hospital IQR Program beginning with the FY 2028 payment determination and for subsequent years, which is contingent on finalizing our proposal to adopt the updated MSPB Hospital measure in the Hospital VBP Program.

We invited public comment on this proposal.

Comment: Many commenters expressed their support of CMS' proposal to remove the MSPB Hospital measure from the Hospital IQR Program. Specifically, some commenters appreciated the removal of the MSPB Hospital measure from the Hospital IQR Program as it will reduce duplication. A few commenters supported the removal of MSPB Hospital measure from the Hospital IQR Program provided it will continue to be reported on the Care Compare website.

Response: We thank the commenters for their support. We intend to continue publicly reporting MSPB Hospital measure data on Care Compare for the period of time in which hospitals report on two version of the measure.

Comment: A few commenters supported our proposal to remove the MSPB Hospital measure but also shared concerns about the transition of the measure from the Hospital IQR Program to the Hospital VBP Program. Specifically, a few commenters identified concerns about reporting on two different versions of the measure for a single year and suggested that we adjust the removal and adoption timeline. Another commenter expressed concern about the public’s ability to interpret the data from the two versions of the measure and suggested that we suppress one set of results from public reporting. A commenter suggested we wait to transition the updated MSPB Hospital measure into the Hospital VBP Program until after the data had been available to hospitals.

Response: We thank the commenters for their support and raising these concerns. We acknowledge the commenters’ concerns that two slightly different versions of the measure would be in use across the Hospital IQR Program and Hospital VBP Programs simultaneously. Section 1886(o)(2)(C)(i) of the Act requires that a measure be publicly reported for one year in the Hospital IQR Program prior to the beginning of the applicable Hospital VBP Program performance period for the measure. As we have previously stated in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49257), we adopted the revised version of the MSPB Hospital measure into the Hospital IQR Program with the intention of eventually proposing the updated measure into the Hospital VBP Program after the required year of public reporting in the Hospital IQR Program as well as to provide interested parties with an opportunity to become familiar with the new version of the measure and provide feedback. We refer readers to section V.K. of this final rule for more information on the policy to adopt the re-evaluated MSPB Hospital measure in the Hospital VBP Program.

Additionally, by statute, the Hospital VBP Program must contain a cost measure. The MSPB Hospital measure, therefore, cannot be removed from the Hospital VBP Program, as it is the only cost measure under the Efficiency and Cost Reduction. Results for the MSPB Hospital measure currently implemented in the Hospital VBP Program will continue to be available on data.medicare.gov until it is removed under the finalized policy outlined in section X.k of the preamble this final rule. We intend to continue publishing MSPB Hospital measure data on Care Compare for the period of time in which this measure is reported in the Hospital IQR Program. In addition, we will make sure it is clear which version of the measure is being displayed in which location through outreach and education efforts.

Comment: A commenter requested clarification about whether removal of the MSPB Hospital measure in the Hospital IQR Program will impact the Merit-based Incentive Payment System (MIPS) and MIPS Value Pathways (MVPs) programs.

Response: We wish to clarify that the removal of MSPB Hospital measure from the Hospital IQR Program does not impact the MIPS and MVPs programs. MIPS eligible clinicians can continue to use their Hospital VBP Program Total Performance Score (TPS) for facility-based measurement. Facility-based measurement offers certain MIPS eligible clinicians and groups the opportunity to receive scores in traditional MIPS for the quality and cost performance categories based on their Hospital VBP Program TPS earned by their assigned facility.

After consideration of the public comments we received, we are finalizing our proposal as proposed.

c. Removal of Elective Delivery Prior to 39 Completed Weeks Gestation: Percentage of Babies Electively Delivered Prior to 39 Completed Weeks Gestation (PC–01) Measure Beginning With the CY 2024 Reporting Period/FY 2026 Payment Determination

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53528 through 53530), we adopted the Elective Delivery Prior to 39 Completed Weeks Gestation: Percentage of Babies Electively Delivered Prior to 39 Completed Weeks Gestation measure (PC–01) (herein after referred to as the Elective Delivery measure) as a chart-abstracted measure beginning with the FY 2015 payment determination and subsequent years.

Over the six most recent reporting periods, hospital performance on PC–01 has met the criteria for removal under measure removal factor 1: Measure performance is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (that is, “topped out”) with statistically indistinguishable performance at the 75th and 90th percentiles; and truncated coefficient of variation ≤0.10 (83 FR 41540 through 41544).
To address the ongoing maternal health crisis and reduce maternal morbidity and mortality, the Hospital IQR Program has continued to prioritize maternal health through quality measurement. In the FY 2022 IPPS/LTCH PPS final rule, we adopted the Maternal Morbidity Structural Measure beginning with the FY 2023 payment determination and for subsequent years (86 FR 45361 through 45365). In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49220 through 49233), we adopted the Severe Obstetric Complications eCQM and the Cesarean Birth eCQM as two of the eCQMs in the Hospital IQR Program measure set that hospitals can self-select to report for the CY 2023 reporting period/FY 2023 payment determination. We also finalized mandatory reporting of these two eCQMs beginning with the CY 2024 reporting period/FY 2026 payment determination and for subsequent years. Additionally, in the FY 2023 IPPS/LTCH PPS final rule, we adopted a Birthing-Friendly Hospital designation to capture the quality and safety of maternal health care (87 FR 49282 through 49288). In December 2022, HHS convened maternal health leaders across government and industry to unveil the logo for the Birthing-Friendly Hospital designation, which will be posted on CMS’ Care Compare website and on the websites of participating health plans, to indicate which facilities have received the Birthing-Friendly Hospital designation. HHS further announced that more than 25 health plans have committed to displaying the “Birthing-Friendly Hospital” designation on their provider directories when the designation goes live in Fall 2023, providing more than 150 million Americans with the opportunity to make informed decisions about their birth options for care.

We believe that the recent adoption of these measures highlights the importance of maternal health and provides hospitals with robust data to improve maternity care quality, safety, and equity, including through the reduction of early elective deliveries. Specifically, the Cesarean Birth eCQM is intended to facilitate safer patient care by assessing the rate of low-risk nulliparous, term, or singleton vertex (NTSV) C-sections to ultimately reduce the occurrence of non-medically indicated C-sections, promoting adherence to recommended clinical guidelines, and encouraging hospitals to track and improve their practices of appropriate monitoring and care management for pregnant and postpartum patients (87 FR 49222). While hospital performance on the Elective Delivery measure no longer provides meaningful distinctions and improvements to support its retention in the Hospital IQR Program measure set, we believe the prior adoption of the Cesarean Birth eCQM, along with the Maternal Morbidity Structural Measure, the Severe Obstetric Complications eCQM, and the Birthing-Friendly Hospital designation will provide hospitals with meaningful and actionable data to address rates of early elective delivery, among other factors that contribute to maternal morbidity and mortality as well as disparities in maternity care quality. We know that the Elective Delivery measure was used widely in quality measurement outside of CMS quality programs, and therefore we reached out to various other parts of the Department, including the Health Resources and Services Administration, National Institutes for Health, and the Centers for Disease Control and Prevention (CDC) in the development of this proposal. We reached consensus across these groups that while the measure is important, given the topped-out status and the availability of the two new eCQMs, it was appropriate to propose for removal at this time. We also refer readers to the FY 2023 IPPS/LTCH PPS final rule (87 FR 49282 through 49288) in which we announced the Birthing-Friendly Hospital designation and remind readers that, while we proposed to remove the Elective Delivery measure, we continue to assess whether the Cesarean Birth and Severe Obstetric Complications eCQMs are appropriate for inclusion in the Birthing-Friendly Hospital designation as part of our continued commitment to improve maternity care quality, safety and equity.

Therefore, we proposed to remove the Elective Delivery measure no longer providing meaningful distinctions and improvements to support its retention in the Hospital IQR Program measure set, and we will continue to assess whether the Cesarean Birth and Severe Obstetric Complications eCQMs are appropriate for inclusion in the Birthing-Friendly Hospital designation as part of our continued commitment to improve maternity care quality, safety and equity.

Comment: Many commenters supported the removal of the measure. Several commenters agreed that the topped-out measure is no longer meaningful for hospital quality improvement efforts, with a few noting that the opportunity for improvement is small. Several commenters stated their belief that the recent addition of more meaningful maternal health measures in the Hospital IQR Program will support maternal health outcomes and reduce redundancy. A few commenters recommended continued exploration and adoption of additional impactful maternity measures.

Response: We thank commenters for their support. We agree that the Elective...
Delivery measure is no longer meaningful for hospital quality improvement efforts because it has been consistently topped-out for six years. We believe this demonstrates that the standard of care has improved to the point where other measurements are necessary to further drive improvements in maternal care. However, we recognize that the rates of Cesarean delivery have continued to rise in the FY 2023 IPPS/LTC PPS final rule (87 FR 49220), we stated that there is a considerable amount of variation in the rates based on U.S. region, state, and healthcare institution as well as substantial variability across races and ethnicities.\textsuperscript{554} The Administration has prioritized the reduction of low-risk Cesarean deliveries as part of the HHS Initiative to Improve Maternal Health.\textsuperscript{556} Because the Elective Delivery measure has been consistently topped out and rates of Cesarean deliveries have not meaningfully decreased, there is still room for improvement and a need for more robust quality measurement on this topic. Therefore, we also agree with commenters that the prior adoption of the Cesarean Birth eCQM, along with the Maternal Morbidity Structural measure, the Severe Obstetric Complications eCQM, and the Birthing-Friendly Hospital designation will provide hospitals with meaningful and actionable data and play a key role as part of our continued commitment to improve maternity care quality, safety, and equity.

Specifically, the Cesarean Birth eCQM expands our measurement and quality improvement opportunities for non-medically indicated Cesarean deliveries by measuring all NTSV Cesarean births after 37 weeks currently measured by the Elective Delivery measure. The Cesarean Birth eCQM seeks to focus attention on the most variable portion of Cesarean births, the term labor Cesarean birth in nulliparous women, as more than 60 percent of the variation among hospitals can be attributed to first birth labor induction rates and first birth early labor admission rates.\textsuperscript{557} A reduction in primary Cesarean births will reduce the number of women having repeat Cesarean births as almost 90 percent of mothers who have a primary cesarean birth will have subsequent cesarean birth.\textsuperscript{559} As we stated in the FY 2023 IPPS/LTC PPS final rule when we adopted the measure (87 FR 49221), Cesarean deliveries have higher morbidity and mortality than vaginal deliveries, higher risk of subsequent miscarriage, placental abnormalities, and repeat Cesarean delivery for NTSV births, and higher rates of transfusions, ruptured uteri, unplanned hysterectomies, and intensive care unit (ICU) admissions for NTSV births across all races and ethnicities.\textsuperscript{560} We recognize that Cesarean births are not a never event and the rate of Cesarean birth will never be zero as Cesarean delivery can be medically indicated. However, continued quality improvement efforts to reduce non-medically indicated Cesarean birth rates are important for improving patient safety, decreasing maternal and neonatal morbidity and mortality, and reducing health care costs.\textsuperscript{561} While the Elective Delivery measure has established the importance of measuring non-medically indicated Cesarean deliveries and labor inductions, its topped-out status limits the utility of the measure moving forward. The addition of the Cesarean Birth eCQM, the Maternal Morbidity Structural measure, the Severe Obstetric Complications eCQM, and the Birthing-Friendly Hospital designation offers hospitals greater opportunities for more comprehensive maternal health quality improvement, and reaffirms our commitment to and continued prioritization of maternal health quality measurement in the Hospital IQR Program. We also note that in the future we are planning to provide confidential reporting on the two new eCQMs that stratifies results by race and ethnicity. Comment: Several commenters did not support measure removal because they did not believe the Hospital IQR Program measure set included a suitable alternative. A few commenters stated that maternal morbidity and mortality is an ongoing public health crisis and rates of maternal mortality have continued to rise despite topped-out performance of the measure. Some commenters expressed concern about unintended consequences from removing the measure, including neonatal and maternal complications resulting from increases in non-medically indicated labor inductions and Cesarean deliveries.

Response: We acknowledge commenters’ concerns and agree that the improvement of maternity care quality and safety is critically important. When we adopted the Cesarean Birth eCQM in the FY 2023 IPPS/LTC PPS final rule (87 FR 49222), we stated that the measure is intended to facilitate safer patient care by assessing the rate of low-risk NTSV C-sections to ultimately reduce the occurrence of non-medically indicated C-sections, promoting adherence to recommended clinical guidelines, and encouraging hospitals to track and improve their practices of appropriate monitoring and care management for pregnant and postpartum patients. The Cesarean Birth eCQM measures the rate of NTSV patients delivered by Cesarean section after 37 weeks, with the exclusion of patients with abnormal presentation or placenta previa during the encounter. The measure will assist health care organizations to track all NTSV patients delivering by Cesarean section after 37 weeks and will support hospitals in their goals to reduce non-medically indicated labor inductions and Cesarean deliveries by going beyond those deliveries prior to 39 weeks currently measured by the Elective Delivery measure. We reiterate that this measure, in combination with the Severe Obstetric Complications eCQM finalized in the FY 2023 IPPS/LTC PPS final rule (87 FR 49226 through 49233) and the Maternal Morbidity Structural measure finalized in the FY 2022 IPPS/LTC PPS final rule (86 FR 45361 through 45368), will provide hospitals with robust data to monitor and improve maternal safety.
morbidity and mortality, disparities in maternity care quality, and rates of early elective delivery to expand quality measurement within the Hospital IQR Program and reflect our commitment to maternal health. Regarding commenter concerns about unintended consequences of removing the Elective Delivery measure, we regularly monitor measure data and performance as part of the standard measure maintenance and will continue to do so with the Cesarean Birth and Severe Obstetric Complication eCQMs and the Maternal Morbidity Structural Measure. Finally, because the Cesarean Birth and Severe Obstetric Complications eCQMs will begin mandatory reporting in the CY 2024 reporting period/FY 2026 payment determination, there will be no gap in reporting on Cesarean births following the removal of the Elective Delivery measure, which will also be effective beginning with the CY 2024 reporting period/FY 2026 payment determination.

Comment: A few commenters expressed concern about the impact of removal on Medicaid programs and commercial payers that are still observing variation in rates and find value in the measure.

Response: In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27092), we acknowledged that the Elective Delivery measure was used widely in quality measurement outside of CMS quality programs, and therefore we reached out to various other parts of the Department, including the Health Resources and Services Administration, National Institutes for Health, and the Centers for Disease Control and Prevention (CDC) in the development of this proposal. We reached consensus across these groups that while the measure is important, it was appropriate to propose for removal at this time given its topped-out status and the availability of two new eCQMs to further drive improvements in maternal care. We also stated our belief that the prior adoption of the Cesarean Birth eCQM, along with the Maternal Morbidity Structural measure, the Severe Obstetric Complications eCQM, and the Birthing-Friendly Hospital designation will provide hospitals with meaningful and actionable data to address rates of early elective delivery. Regarding information available to commercial payers, we note that more than 25 health plans have committed to displaying the Birthing-Friendly Hospital designation on their provider directories when the designation goes live, which will share important maternal health quality information with more than 150 million enrollees in commercial plans. These additional maternal health measures will offer value to CMS quality reporting programs and other payers. While the Elective Delivery measure would no longer be included in the Hospital IQR Program, we expect that the improvements in reducing non-medically indicated labor inductions and Cesarean deliveries prior to 39 weeks that have been achieved outside of CMS quality reporting programs will remain because its removal would not prevent use of the measure outside of CMS quality programs and the measure continues to be maintained by The Joint Commission.

Comment: A commenter requested the eCQM version of the Elective Delivery measure be restored in place of the chart-abstracted measure to continue to prioritize low rates of non-medically indicated elective Cesarean births and reduce reporting burden.

Response: We appreciate the commenter’s suggestion. When we removed the eCQM version of the Elective Delivery measure in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41569), we stated that the chart-abstracted version of this measure were to be removed from the Hospital IQR Program, and hospitals could only elect to report the eCQM version of this measure, due to the low volume of patients relative to total adult hospital population, we would not receive enough data to produce meaningful analyses. Furthermore, the adoption of the Cesarean Birth eCQM, the Maternal Morbidity Structural measure, the Severe Obstetric Complications eCQM, and the Birthing-Friendly Hospital designation in the Hospital IQR Program continue to prioritize both a reduction of non-medically indicated elective Cesarean births and reporting burden for hospitals. Therefore, proposing to adopt the eCQM version of Elective Delivery for readoption would not be appropriate and would not reduce burden. After consideration of the public comments we received, we are finalizing our proposal as proposed.

Response: We acknowledged that the Elective Delivery measure was used widely in quality measurement outside of CMS quality programs, and therefore we reached out to various other parts of the Department, including the Health Resources and Services Administration, National Institutes for Health, and the Centers for Disease Control and Prevention (CDC) in the development of this proposal. We reached consensus across these groups that while the measure is important, it was appropriate to propose for removal at this time given its topped-out status and the availability of two new eCQMs to further drive improvements in maternal care. We also stated our belief that the prior adoption of the Cesarean Birth eCQM, along with the Maternal Morbidity Structural measure, the Severe Obstetric Complications eCQM, and the Birthing-Friendly Hospital designation will provide hospitals with meaningful and actionable data to address rates of early elective delivery. Regarding information available to commercial payers, we note that more than 25 health plans have committed to displaying the Birthing-Friendly Hospital designation on their provider directories when the designation goes live, which will share important maternal health quality information with more than 150 million enrollees in commercial plans. These additional maternal health measures will offer value to CMS quality reporting programs and other payers. While the Elective Delivery measure would no longer be included in the Hospital IQR Program, we expect that the improvements in reducing non-medically indicated labor inductions and Cesarean deliveries prior to 39 weeks that have been achieved outside of CMS quality reporting programs will remain because its removal would not prevent use of the measure outside of CMS quality programs and the measure continues to be maintained by The Joint Commission.

Comment: A commenter requested the eCQM version of the Elective Delivery measure be restored in place of the chart-abstracted measure to continue to prioritize low rates of non-medically indicated elective Cesarean births and reduce reporting burden.

Response: We appreciate the commenter’s suggestion. When we removed the eCQM version of the Elective Delivery measure in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41569), we stated that the chart-abstracted version of this measure were to be removed from the Hospital IQR Program, and hospitals could only elect to report the eCQM version of this measure, due to the low volume of patients relative to total adult hospital population, we would not receive enough data to produce meaningful analyses. Furthermore, the adoption of the Cesarean Birth eCQM, the Maternal Morbidity Structural measure, the Severe Obstetric Complications eCQM, and the Birthing-Friendly Hospital designation in the Hospital IQR Program continue to prioritize both a reduction of non-medically indicated elective Cesarean births and reporting burden for hospitals. Therefore, proposing to adopt the eCQM version of Elective Delivery for readoption would not be appropriate and would not reduce burden. After consideration of the public comments we received, we are finalizing our proposal as proposed.

Response: We acknowledged that the Elective Delivery measure was used widely in quality measurement outside of CMS quality programs, and therefore we reached out to various other parts of the Department, including the Health Resources and Services Administration, National Institutes for Health, and the Centers for Disease Control and Prevention (CDC) in the development of this proposal. We reached consensus across these groups that while the measure is important, it was appropriate to propose for removal at this time given its topped-out status and the availability of two new eCQMs to further drive improvements in maternal care. We also stated our belief that the prior adoption of the Cesarean Birth eCQM, along with the Maternal Morbidity Structural measure, the Severe Obstetric Complications eCQM, and the Birthing-Friendly Hospital designation will provide hospitals with meaningful and actionable data to address rates of early elective delivery. Regarding information available to commercial payers, we note that more than 25 health plans have committed to displaying the Birthing-Friendly Hospital designation on their provider directories when the designation goes live, which will share important maternal health quality information with more than 150 million enrollees in commercial plans. These additional maternal health measures will offer value to CMS quality reporting programs and other payers. While the Elective Delivery measure would no longer be included in the Hospital IQR Program, we expect that the improvements in reducing non-medically indicated labor inductions and Cesarean deliveries prior to 39 weeks that have been achieved outside of CMS quality reporting programs will remain because its removal would not prevent use of the measure outside of CMS quality programs and the measure continues to be maintained by The Joint Commission.

Comment: A commenter requested the eCQM version of the Elective Delivery measure be restored in place of the chart-abstracted measure to continue to prioritize low rates of non-medically indicated elective Cesarean births and reduce reporting burden.

Response: We appreciate the commenter’s suggestion. When we removed the eCQM version of the Elective Delivery measure in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41569), we stated that the chart-abstracted version of this measure were to be removed from the Hospital IQR Program, and hospitals could only elect to report the eCQM version of this measure, due to the low volume of patients relative to total adult hospital population, we would not receive enough data to produce meaningful analyses. Furthermore, the adoption of the Cesarean Birth eCQM, the Maternal Morbidity Structural measure, the Severe Obstetric Complications eCQM, and the Birthing-Friendly Hospital designation in the Hospital IQR Program continue to prioritize both a reduction of non-medically indicated elective Cesarean births and reporting burden for hospitals. Therefore, proposing to adopt the eCQM version of Elective Delivery for readoption would not be appropriate and would not reduce burden. After consideration of the public comments we received, we are finalizing our proposal as proposed.

Under our current policies, when we adopt a measure for the Hospital IQR Program beginning with a particular payment determination, we automatically readopt the measure for all subsequent payment determinations unless we proposed to remove, suspend, or replace the measure (77 FR 53512 and 53513).

We have also adopted Measure Removal Factors as considerations when evaluating measures for removal from the Hospital IQR Program measure set. We most recently updated our measure removal factors in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41540 through 41544). In that final rule, we adopted measure removal factor 8, the costs associated with measure removal factor 8 would not outweigh the benefit of its continued use in the program. The current list of Measure Removal Factors for the Hospital IQR Program is:

Factor 1. Measurement among hospitals is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made ("topped out" measure). For the purpose of this paragraph, a measure is topped out when the performance of subsection (d) hospitals on the measure is statistically indistinguishable performance at the 75th and 90th percentiles and the measure’s truncated coefficient of variation is less than or equal to 0.10;

Factor 2. A measure does not align with current clinical guidelines or practice;

Factor 3. The availability of a more broadly applicable measure (across settings or populations), or the availability of a measure that is more proximal in time to desired patient outcomes for the particular topic;

Factor 4. Performance improvement on a measure does not result in better patient outcomes;

Factor 5. The availability of a measure that is more strongly associated
with desired patient outcomes for the particular topic;

- **Factor 6.** Collection or public reporting of a measure leads to negative unintended consequences other than patient harm;

- **Factor 7.** It is not feasible to implement the measure specifications; and

- **Factor 8.** The costs associated with a measure outweigh the benefits of its continued use in the program.

We proposed to codify our existing measure retention and removal policies in our regulations at 42 CFR 412.140(g)(1) through (3).

We invited public comment on this proposal.

Comment: A few commenters expressed support for our proposal to codify our measure retention and removal policies.

Response: We thank the commenters for their support.

Comment: A commenter opposed our proposal to codify our measure removal and retention factors, stating that we should consider more carefully whether measures are important to beneficiaries’ or the public’s interests. The commenter also suggested removing “topped out” status under Factor 1 from our measure removal criteria because some Hospital IQR Program measures quantify so-called never events, the methodology comparing performance between the 75th and 90th percentiles is “problematic” and does not adequately consider variation between higher and lower performing hospitals, and many Hospital IQR Program measures only include patients covered by FFS Medicare and exclude the large and growing population of MA beneficiaries, which makes the determination of whether a measure is topped out incomplete and inaccurate. The commenter also requested that we provide more details on the costs and benefits of a measure that we consider under Factor 8.

Response: We thank the commenter for this feedback. We consider in detail and on a case-by-case basis how each measure in the Program affects clinical care, and the quality of care delivered to patients is of paramount importance to Medicare beneficiaries and the public. We respectfully disagree with the commenter’s suggestion of removing the topped out status as a removal criterion. Measures on which hospitals’ performance is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made does not provide useful information to Medicare beneficiaries or the public about the quality of care that they receive. For this reason, topped out status is an important removal factor for the program. Regarding removal factor 8, we note that we estimate the information collection costs and other effects associated with each quality measure we adopt in each rule. For example, in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27194 through 27196), we discussed the estimated changes in reporting costs for participating hospitals associated with the rule’s proposed changes to the Hospital IQR Program’s measure set. We also discuss in detail the benefits of the measure to patients and to the health care system when we propose it. For example, in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27079 through 27080), we discussed the problems presented by hospital-acquired pressure injuries as well as the details of the Hospital Harm—Pressure Injury measure and how it assesses that clinical topic. We will, nonetheless, take the commenter’s feedback into consideration for future potential refinements to the measure removal factors, as well as whether additional information on the costs and benefits beyond the discussion that we place in proposed rules would be helpful for the public.

After consideration of the public comments we received, we are finalizing the codification of this policy as proposed.

8. Summary of Previously Finalized and Newly Adopted Hospital IQR Program Measures

a. Summary of Previously Finalized and Newly Adopted Hospital IQR Program Measures for the FY 2025 Payment Determination

This table summarizes the previously finalized Hospital IQR Program measure set for the FY 2025 payment determination.
<table>
<thead>
<tr>
<th>Short Name</th>
<th>Measure Name</th>
<th>CBE #</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCP Influenza Vaccination</td>
<td>Influenza Vaccination Coverage among Healthcare Personnel</td>
<td>0431</td>
</tr>
<tr>
<td>HCP COVID-19 Vaccination*</td>
<td>COVID-19 Vaccination Coverage among Healthcare Personnel</td>
<td>3636</td>
</tr>
<tr>
<td>CMS PSI-04</td>
<td>Death Rate among Surgical Inpatients with Serious Treatable Complications (CMS Recalibrated Death Rate among Surgical Inpatients with Serious Treatable Complications)</td>
<td>0351</td>
</tr>
<tr>
<td>MORT-30-STK</td>
<td>Hospital 30-Day, All-Cause, Risk Standardized Mortality- Rate Following Acute Ischemic Stroke</td>
<td>N/A</td>
</tr>
<tr>
<td>COMP-HIP-KNEE</td>
<td>Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective Primary THA and/or TKA</td>
<td>1550</td>
</tr>
<tr>
<td>READM-30-HWR**</td>
<td>Hospital-Wide All-Cause Unplanned Readmission Measure (HWR)</td>
<td>1789</td>
</tr>
<tr>
<td>AMI Excess Days</td>
<td>Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction</td>
<td>2881</td>
</tr>
<tr>
<td>HF Excess Days</td>
<td>Excess Days in Acute Care after Hospitalization for Heart Failure</td>
<td>2880</td>
</tr>
<tr>
<td>PN Excess Days</td>
<td>Excess Days in Acute Care after Hospitalization for Pneumonia</td>
<td>2882</td>
</tr>
<tr>
<td>AMI Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care for Acute Myocardial Infarction (AMI)</td>
<td>2431</td>
</tr>
<tr>
<td>HF Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care For Heart Failure (HF)</td>
<td>2436</td>
</tr>
<tr>
<td>PN Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-day Episode-of-Care For Pneumonia</td>
<td>2579</td>
</tr>
<tr>
<td>THA/TKA Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with an Episode-of-Care for Primary Elective Total Hip Arthroplasty and/or Total Knee Arthroplasty</td>
<td>3474</td>
</tr>
<tr>
<td>MSPB</td>
<td>Medicare Spending Per Beneficiary (MSPB)—Hospital</td>
<td>2158</td>
</tr>
</tbody>
</table>

**Claims and Electronic Data Measures**
<table>
<thead>
<tr>
<th>Short Name</th>
<th>Measure Name</th>
<th>CBE #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hybrid HWR**</td>
<td>Hybrid Hospital-Wide All-Cause Readmission Measure (HWR)</td>
<td>2879</td>
</tr>
<tr>
<td>Hybrid HWM***</td>
<td>Hybrid Hospital-Wide All-Cause Risk Standardized Mortality Measure (HWM)</td>
<td>3502</td>
</tr>
</tbody>
</table>

**Chart-Abstracted Clinical Process of Care Measures**

<table>
<thead>
<tr>
<th>Measure Name</th>
<th>CBE #</th>
</tr>
</thead>
<tbody>
<tr>
<td>PC-01 Elective Delivery</td>
<td>0469</td>
</tr>
<tr>
<td>SEP-1 Severe Sepsis and Septic Shock: Management Bundle (Composite Measure)</td>
<td>0500</td>
</tr>
</tbody>
</table>

**Structural Measures**

<table>
<thead>
<tr>
<th>Measure Name</th>
<th>CBE #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal Morbidity</td>
<td>N/A</td>
</tr>
<tr>
<td>HCHE Hospital Commitment to Health Equity</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Electronic Clinical Quality Measures (eCQMs)**

<table>
<thead>
<tr>
<th>Measure Name</th>
<th>CBE #</th>
</tr>
</thead>
<tbody>
<tr>
<td>ED-2 Admit Decision Time to Emergency Department (ED) Departure Time for Admitted Patients</td>
<td>0497</td>
</tr>
<tr>
<td>PC-05 Exclusive Breast Milk Feeding</td>
<td>0480</td>
</tr>
<tr>
<td>Safe Use of Opioids Safe Use of Opioids – Concurrent Prescribing</td>
<td>3316e</td>
</tr>
<tr>
<td>STK-02 Discharged on Antithrombotic Therapy</td>
<td>0435</td>
</tr>
<tr>
<td>STK-03 Anticoagulation Therapy for Atrial Fibrillation/Flutter</td>
<td>0436</td>
</tr>
<tr>
<td>STK-05 Antithrombotic Therapy by the End of Hospital Day Two</td>
<td>0438</td>
</tr>
<tr>
<td>STK-06 Discharged on Statin Medication</td>
<td>0439</td>
</tr>
<tr>
<td>VTE-1 Venous Thromboembolism Prophylaxis</td>
<td>0371</td>
</tr>
<tr>
<td>VTE-2 Intensive Care Unit Venous Thromboembolism Prophylaxis</td>
<td>0372</td>
</tr>
<tr>
<td>HH-01 Hospital Harm—Severe Hypoglycemia Measure</td>
<td>3503e</td>
</tr>
<tr>
<td>HH-02 Hospital Harm—Severe Hyperglycemia Measure</td>
<td>3533e</td>
</tr>
<tr>
<td>ePC-02 Cesarean Birth</td>
<td>0471e</td>
</tr>
<tr>
<td>ePC-07/SMM Severe Obstetric Complications</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Patient Experience of Care Survey Measures**

<table>
<thead>
<tr>
<th>Measure Name</th>
<th>CBE #</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCAHPS Hospital Consumer Assessment of Healthcare Providers and Systems Survey (including Care Transition Measure)</td>
<td>0166 (0228)</td>
</tr>
</tbody>
</table>

**Process Measures**

<table>
<thead>
<tr>
<th>Measure Name</th>
<th>CBE #</th>
</tr>
</thead>
<tbody>
<tr>
<td>SDOH-1**** Screening for Social Drivers of Health</td>
<td>N/A</td>
</tr>
<tr>
<td>SDOH-2**** Screen Positive Rate for Social Drivers of Health</td>
<td>N/A</td>
</tr>
</tbody>
</table>

* In this final rule, we are finalizing refinements to the COVID-19 Vaccination Coverage among Healthcare Personnel (HCP) measure beginning with the FY 2025 payment determination and for subsequent years. We refer readers to section IX.B. for more detailed discussion.

** In the FY 2020 IPPS/LTCH PPS final rule, we finalized removal of the claims-only Hospital-Wide All-Cause Unplanned Readmission (HWR claims-only) measure (CBE #1779) and will replace it with the Hybrid HWR measure (CBE #2879), beginning with the FY 2026 payment determination (84 FR 42465 through 42481). In this final rule, we are finalizing refinements to these measures beginning with the FY 2027 payment determination. We refer readers to section IX.C.6.a. for more detailed discussion.

*** In the FY 2022 IPPS/LTCH PPS final rule, we finalized the adoption of the Hybrid Hospital-Wide All-Cause Risk Standardized Mortality (HWM) measure beginning with one voluntary reporting period (July 1, 2022-June 30, 2023), followed by mandatory reporting beginning with the July 1, 2023-June 30, 2024 reporting period, impacting the FY 2026 payment determination (86 FR 45365 through 45374). In this rule, we are finalizing refinements to this measure beginning with the FY 2027 payment determination. We refer readers to section IX.C.6.a. for more detailed discussion.

**** In the FY 2023 IPPS/LTCH PPS final rule, we finalized the adoption of the Screening for Social Drivers of Health measure and the Screen Positive Rate for Social Drivers of Health measure with voluntary data collection for the CY 2023 reporting period, and then mandatory reporting beginning with the CY 2024 reporting period/FY 2026 payment determination and subsequent years (87 FR 49201 through 49220).
b. Summary of Previously Finalized and Newly Adopted Hospital IQR Program Measures for the FY 2026 Payment Determinations

This table summarizes the previously finalized and newly finalized Hospital IQR Program measure set for the FY 2026 payment determination, including the removal of the Elective Delivery (PC–01) measure beginning with the FY 2026 payment determination:

<table>
<thead>
<tr>
<th>Short Name</th>
<th>Measure Name</th>
<th>CBE #</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCP Influenza Vaccination</td>
<td>Influenza Vaccination Coverage among Healthcare Personnel</td>
<td>0431</td>
</tr>
<tr>
<td>HCP COVID-19 Vaccination*</td>
<td>COVID-19 Vaccination Coverage among Healthcare Personnel</td>
<td>3636</td>
</tr>
<tr>
<td>CMS PSI-04</td>
<td>Death Rate among Surgical Inpatients with Serious Treatable Complications (CMS Recalibrated Death Rate among Surgical Inpatients with Serious Treatable Complications)</td>
<td>0351</td>
</tr>
<tr>
<td>MORT-30-STK</td>
<td>Hospital 30-Day, All-Cause, Risk Standardized Mortality-Rate Following Acute Ischemic Stroke</td>
<td>N/A</td>
</tr>
<tr>
<td>COMP-HIP-KNEE</td>
<td>Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective Primary THA and/or TKA</td>
<td>1550</td>
</tr>
<tr>
<td>AMI Excess Days</td>
<td>Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction</td>
<td>2881</td>
</tr>
<tr>
<td>HF Excess Days</td>
<td>Excess Days in Acute Care after Hospitalization for Heart Failure</td>
<td>2880</td>
</tr>
<tr>
<td>PN Excess Days</td>
<td>Excess Days in Acute Care after Hospitalization for Pneumonia</td>
<td>2882</td>
</tr>
<tr>
<td>AMI Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care for Acute Myocardial Infarction (AMI)</td>
<td>2431</td>
</tr>
<tr>
<td>HF Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care For Heart Failure (HF)</td>
<td>2436</td>
</tr>
<tr>
<td>PN Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-day Episode-of-Care For Pneumonia</td>
<td>2579</td>
</tr>
<tr>
<td>THA/TKA Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with an Episode-of-Care for Primary Elective Total Hip Arthroplasty and/or Total Knee Arthroplasty</td>
<td>3474</td>
</tr>
<tr>
<td>MSPB</td>
<td>Medicare Spending Per Beneficiary (MSPB)—Hospital</td>
<td>2158</td>
</tr>
<tr>
<td>Hybrid HWM**</td>
<td>Hybrid Hospital-Wide All-Cause Risk Standardized Mortality Measure (HWM)</td>
<td>3502</td>
</tr>
</tbody>
</table>

**Hybrid Measures**

<table>
<thead>
<tr>
<th>Short Name</th>
<th>Measure Name</th>
<th>CBE #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hybrid HWM**</td>
<td>Hybrid Hospital-Wide All-Cause Risk Standardized Mortality Measure (HWM)</td>
<td>3502</td>
</tr>
</tbody>
</table>
### Chart-Abstracted Clinical Process of Care Measures

<table>
<thead>
<tr>
<th>Short Name</th>
<th>Measure Name</th>
<th>CBE #</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEP-1</td>
<td>Severe Sepsis and Septic Shock: Management Bundle (Composite</td>
<td>0500</td>
</tr>
<tr>
<td></td>
<td>Measure)</td>
<td></td>
</tr>
</tbody>
</table>

### Structural Measures

<table>
<thead>
<tr>
<th>Measure Name</th>
<th>Measure Name</th>
<th>CBE #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal</td>
<td>Maternal Morbidity Structural Measure</td>
<td>N/A</td>
</tr>
<tr>
<td>Morbidity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCHE</td>
<td>Hospital Commitment to Health Equity</td>
<td>N/A</td>
</tr>
</tbody>
</table>

### Electronic Clinical Quality Measures (eCQMs)

<table>
<thead>
<tr>
<th>Safe Use of Opioids</th>
<th>Safe Use of Opioids – Concurrent Prescribing</th>
<th>3316e</th>
</tr>
</thead>
<tbody>
<tr>
<td>ePC-02</td>
<td>Cesarean Birth</td>
<td>0471e</td>
</tr>
<tr>
<td>ePC-07/SMM</td>
<td>Severe Obstetric Complications</td>
<td>N/A</td>
</tr>
<tr>
<td>STK-02</td>
<td>Discharged on Antithrombotic Therapy</td>
<td>0435</td>
</tr>
<tr>
<td>STK-03</td>
<td>Anticoagulation Therapy for Atrial Fibrillation/Flutter</td>
<td>0436</td>
</tr>
<tr>
<td>STK-05</td>
<td>Antithrombotic Therapy by the End of Hospital Day Two</td>
<td>0438</td>
</tr>
<tr>
<td>VTE-1</td>
<td>Venous Thromboembolism Prophylaxis</td>
<td>0371</td>
</tr>
<tr>
<td>VTE-2</td>
<td>Intensive Care Unit Venous Thromboembolism Prophylaxis</td>
<td>0372</td>
</tr>
<tr>
<td>HH-01</td>
<td>Hospital Harm—Severe Hypoglycemia Measure</td>
<td>3503e</td>
</tr>
<tr>
<td>HH-02</td>
<td>Hospital Harm—Severe Hyperglycemia Measure</td>
<td>3533e</td>
</tr>
<tr>
<td>HH-ORAE</td>
<td>Hospital Harm—Opioid Related Adverse Events</td>
<td>3501e</td>
</tr>
<tr>
<td>GMCS</td>
<td>Global Malnutrition Composite Score</td>
<td>3592e</td>
</tr>
</tbody>
</table>

### Patient Experience of Care Survey Measures

| HCAHPS | Hospital Consumer Assessment of Healthcare Providers and Systems Survey (including Care Transition Measure) | 0166   |
|        |                                                                                                           | (0228) |

### Patient-Reported Outcome Performance Measures

| THA/TKA PRO-PM | Hospital-Level Total Hip Arthroplasty and/or Total Knee Arthroplasty Patient-Reported Outcome-Based Performance Measure (PRO-PM) | 3559   |

### Process Measures

| SDOH-1 | Screening for Social Drivers of Health | N/A    |
| SDOH-2 | Screen Positive Rate for Social Drivers of Health | N/A    |

---

* In this final rule, we are finalizing refinements to the COVID-19 Vaccination Coverage among Healthcare Personnel (HCP) measure beginning with the FY 2025 payment determination and for subsequent years. We refer readers to section IX.B. for more detailed discussion.

** In the FY 2020 IPPS/LTCH PPS final rule, we finalized removal of the claims-only Hospital-Wide All-Cause Unplanned Readmission (HWR claims-only) measure (CBE #1789) and its replacement with the Hybrid HWR measure (CBE #2879), beginning with the FY 2026 payment determination (84 FR 42465 through 42481).

*** In the FY 2022 IPPS/LTCH PPS final rule, we finalized the adoption of the Hybrid Hospital-Wide All-Cause Risk Standardized Mortality (HWM) measure beginning with one voluntary reporting period (July 1, 2022-June 30, 2023), followed by mandatory reporting beginning with the July 1, 2023-June 30, 2024 reporting period, impacting the FY 2026 payment determination (86 FR 45365 through 45374).
c. Summary of Previously Finalized and Proposed Hospital IQR Program Measures for the FY 2027 Payment Determination

This table summarizes the previously finalized and newly finalized Hospital IQR Program measure set for the FY 2027 payment determination including the adoption of three new eCQMs beginning with the CY 2025 reporting period/FY 2027 payment determination:
### TABLE IX.C–04. MEASURES FOR THE FY 2027 PAYMENT DETERMINATION

<table>
<thead>
<tr>
<th>Short Name</th>
<th>Measure Name</th>
<th>CBE #</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>National Healthcare Safety Network Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCP Influenza Vaccination</td>
<td>Influenza Vaccination Coverage among Healthcare Personnel</td>
<td>0431</td>
</tr>
<tr>
<td>HCP COVID-19 Vaccination*</td>
<td>COVID-19 Vaccination Coverage among Healthcare Personnel</td>
<td>3636</td>
</tr>
<tr>
<td><strong>Claims-Based Patient Safety Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CMS PSI-04</td>
<td>Death Rate among Surgical Inpatients with Serious Treatable Complications (CMS Recalibrated Death Rate among Surgical Inpatients with Serious Treatable Complications)</td>
<td>0351</td>
</tr>
<tr>
<td><strong>Claims-Based Mortality/Complications Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MORT-30-STK</td>
<td>Hospital 30-Day, All-Cause, Risk Standardized Mortality- Rate Following Acute Ischemic Stroke</td>
<td>N/A</td>
</tr>
<tr>
<td>COMP-HIP-KNEE</td>
<td>Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective Primary THA and/or TKA</td>
<td>1550</td>
</tr>
<tr>
<td><strong>Claims-Based Coordination of Care Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMI Excess Days</td>
<td>Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction</td>
<td>2881</td>
</tr>
<tr>
<td>HF Excess Days</td>
<td>Excess Days in Acute Care after Hospitalization for Heart Failure</td>
<td>2880</td>
</tr>
<tr>
<td>PN Excess Days</td>
<td>Excess Days in Acute Care after Hospitalization for Pneumonia</td>
<td>2882</td>
</tr>
<tr>
<td><strong>Claims-Based Payment Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMI Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care for Acute Myocardial Infarction (AMI)</td>
<td>2431</td>
</tr>
<tr>
<td>HF Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care For Heart Failure (HF)</td>
<td>2436</td>
</tr>
<tr>
<td>PN Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-day Episode-of-Care For Pneumonia</td>
<td>2579</td>
</tr>
<tr>
<td>THA/TKA Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with an Episode-of-Care for Primary Elective Total Hip Arthroplasty and/or Total Knee Arthroplasty</td>
<td>3474</td>
</tr>
<tr>
<td>MSPB</td>
<td>Medicare Spending Per Beneficiary (MSPB)—Hospital</td>
<td>2158</td>
</tr>
<tr>
<td><strong>Hybrid Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hybrid HWM**</td>
<td>Hybrid Hospital-Wide All-Cause Risk Standardized Mortality Measure (HWM)</td>
<td>N/A</td>
</tr>
<tr>
<td>Hybrid HWR**</td>
<td>Hybrid Hospital-Wide All-Cause Readmission Measure (HWR)</td>
<td>2879</td>
</tr>
<tr>
<td><strong>Chart-Abstracted Clinical Process of Care Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SEP-1</td>
<td>Severe Sepsis and Septic Shock: Management Bundle (Composite Measure)</td>
<td>0500</td>
</tr>
<tr>
<td>Short Name</td>
<td>Measure Name</td>
<td>CBE #</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Maternal Morbidity</td>
<td>Maternal Morbidity Structural Measure</td>
<td>N/A</td>
</tr>
<tr>
<td>HCHE</td>
<td>Hospital Commitment to Health Equity</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Structural Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safe Use of Opioids</td>
<td>Safe Use of Opioids – Concurrent Prescribing</td>
<td>3316e</td>
</tr>
<tr>
<td>ePC-02</td>
<td>Cesarean Birth</td>
<td>N/A</td>
</tr>
<tr>
<td>ePC-07/SMM</td>
<td>Severe Obstetric Complications</td>
<td>N/A</td>
</tr>
<tr>
<td>STK-02</td>
<td>Discharged on Antithrombotic Therapy</td>
<td>0435</td>
</tr>
<tr>
<td>STK-03</td>
<td>Anticoagulation Therapy for Atrial Fibrillation/Flutter</td>
<td>0436</td>
</tr>
<tr>
<td>STK-05</td>
<td>Antithrombotic Therapy by the End of Hospital Day Two</td>
<td>0438</td>
</tr>
<tr>
<td>VTE-1</td>
<td>Venous Thromboembolism Prophylaxis</td>
<td>0371</td>
</tr>
<tr>
<td>VTE-2</td>
<td>Intensive Care Unit Venous Thromboembolism Prophylaxis</td>
<td>0372</td>
</tr>
<tr>
<td>HH-01</td>
<td>Hospital Harm—Severe Hypoglycemia Measure</td>
<td>3503e</td>
</tr>
<tr>
<td>HH-02</td>
<td>Hospital Harm—Severe Hyperglycemia Measure</td>
<td>3533e</td>
</tr>
<tr>
<td>HH-ORAE</td>
<td>Hospital Harm—Opioid Related Adverse Events</td>
<td>3501e</td>
</tr>
<tr>
<td>HH-PI***</td>
<td>Hospital Harm—Pressure Injury</td>
<td>3498e</td>
</tr>
<tr>
<td>HH-AKI****</td>
<td>Hospital Harm—Acute Kidney Injury</td>
<td>3713e</td>
</tr>
<tr>
<td>GMCS</td>
<td>Global Malnutrition Composite Score</td>
<td>3592e</td>
</tr>
<tr>
<td>ExRad*****</td>
<td>Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography (CT) in Adults</td>
<td>3663e</td>
</tr>
<tr>
<td><strong>Patient Experience of Care Survey Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCAHPS</td>
<td>Hospital Consumer Assessment of Healthcare Providers and Systems Survey (including Care Transition Measure)</td>
<td>0166</td>
</tr>
<tr>
<td><strong>0228</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Patient-Reported Outcome Performance Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>THA/TKA PRO-PM</td>
<td>Hospital-Level Total Hip Arthroplasty and/or Total Knee Arthroplasty Patient-Reported Outcome-Based Performance Measure (PRO-PM)</td>
<td>3559</td>
</tr>
<tr>
<td><strong>Process Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SDOH-1</td>
<td>Screening for Social Drivers of Health</td>
<td>N/A</td>
</tr>
<tr>
<td>SDOH-2</td>
<td>Screen Positive Rate for Social Drivers of Health</td>
<td>N/A</td>
</tr>
</tbody>
</table>

* In this final rule, we are finalizing refinements to the COVID-19 Vaccination Coverage among Healthcare Personnel (HCP) measure beginning with the FY 2025 payment determination and for subsequent years. We refer readers to section IX.B. for more detailed discussion.

** In this final rule, we are finalizing the refinements to two Hospital IQR Program measures-Hybrid Hospital-Wide All-Cause Risk Standardized Mortality Measure (HWM) and Hybrid Hospital-Wide All-Cause Readmission Measure (HWR)-beginning with the FY 2027 payment determination. We refer readers to sections IX.C.6.a. and IX.C.6.b., respectively, for more detailed discussion.

*** In this final rule, we are finalizing the adoption of the Hospital Harm—Pressure Injury eCQM beginning with the FY 2027 payment determination and for subsequent years. We refer readers to section IX.C.5.a. for more detailed discussion.

**** In this final rule, we are finalizing the adoption the Hospital Harm—Acute Kidney Injury eCQM beginning with the FY 2027 payment determination and for subsequent years. We refer readers to section IX.C.5.b. for more detailed discussion.

***** In this final rule, we proposed to adopt the Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography (CT) in Adults eCQM beginning with the FY 2027 payment determination and for subsequent years. We refer readers to section IX.C.5.c. for more detailed discussion.
This table summarizes the previously finalized and newly finalized Hospital IQR Program measure set for the FY 2028 payment determination, including the removal of the re-evaluated MSPB Hospital measure beginning with the CY 2026 reporting period/FY 2028 payment determination.
<table>
<thead>
<tr>
<th>Short Name</th>
<th>Measure Name</th>
<th>CBE #</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>National Healthcare Safety Network Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCP Influenza Vaccination</td>
<td>Influenza Vaccination Coverage among Healthcare Personnel</td>
<td>0431</td>
</tr>
<tr>
<td>HCP COVID-19 Vaccination*</td>
<td>COVID-19 Vaccination Coverage among Healthcare Personnel</td>
<td>3636</td>
</tr>
<tr>
<td><strong>Claims-Based Patient Safety Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CMS PSI-04</td>
<td>Death Rate among Surgical Inpatients with Serious Treatable Complications (CMS Recalibrated Death Rate among Surgical Inpatients with Serious Treatable Complications)</td>
<td>0351</td>
</tr>
<tr>
<td><strong>Claims-Based Mortality/Complications Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MORT-30-STK</td>
<td>Hospital 30-Day, All-Cause, Risk Standardized Mortality- Rate Following Acute Ischemic Stroke</td>
<td>N/A</td>
</tr>
<tr>
<td>COMP-HIP-KNEE**</td>
<td>Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective Primary THA and/or TKA</td>
<td>1550</td>
</tr>
<tr>
<td><strong>Claims-Based Coordination of Care Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMI Excess Days</td>
<td>Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction</td>
<td>2881</td>
</tr>
<tr>
<td>HF Excess Days</td>
<td>Excess Days in Acute Care after Hospitalization for Heart Failure</td>
<td>2880</td>
</tr>
<tr>
<td>PN Excess Days</td>
<td>Excess Days in Acute Care after Hospitalization for Pneumonia</td>
<td>2882</td>
</tr>
<tr>
<td><strong>Claims-Based Payment Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMI Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care for Acute Myocardial Infarction (AMI)</td>
<td>2431</td>
</tr>
<tr>
<td>HF Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care For Heart Failure (HF)</td>
<td>2436</td>
</tr>
<tr>
<td>PN Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-day Episode-of-Care For Pneumonia</td>
<td>2579</td>
</tr>
<tr>
<td>THA/TKA Payment</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with an Episode-of-Care for Primary Elective Total Hip Arthroplasty and/or Total Knee Arthroplasty</td>
<td>3474</td>
</tr>
<tr>
<td><strong>Hybrid Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hybrid HWM***</td>
<td>Hybrid Hospital-Wide All-Cause Risk Standardized Mortality Measure (HWM)</td>
<td>N/A</td>
</tr>
<tr>
<td>Hybrid HWR***</td>
<td>Hybrid Hospital-Wide All-Cause Readmission Measure (HWR)</td>
<td>2879</td>
</tr>
<tr>
<td><strong>Chart-Abstracted Clinical Process of Care Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SEP-1</td>
<td>Severe Sepsis and Septic Shock: Management Bundle (Composite Measure)</td>
<td>0500</td>
</tr>
<tr>
<td><strong>Structural Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maternal Morbidity</td>
<td>Maternal Morbidity Structural Measure</td>
<td>N/A</td>
</tr>
<tr>
<td>HCHE</td>
<td>Hospital Commitment to Health Equity</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Electronic Clinical Quality Measures (eCQMs)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safe Use of Opioids</td>
<td>Safe Use of Opioids – Concurrent Prescribing</td>
<td>3316e</td>
</tr>
<tr>
<td>ePC-02</td>
<td>Cesarean Birth</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Future Considerations

We seek to develop a comprehensive set of quality measures to be available for widespread use for informed decision-making and quality and cost improvements focused on the inpatient hospital setting. We have identified potential future measures, which we believe address areas that are important to interested parties, but which are not currently included in the Hospital IQR Program’s measure set. Therefore, in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27103 through 27109) we sought public feedback on these measures as we consider how best to develop the Hospital IQR Program’s measure set. These are discussed in more detail in this section.
a. Potential Future Inclusion of Two Geriatric Care Measures

(1) Background

The U.S. population is aging rapidly, with one in five Americans estimated to be over 65 years old in the next 10 years. By the year 2030, all baby boomers will be older than 65.567 The 65 and older population is expected to double in the U.S. by 2060, from an estimated 49 million in 2016 to an estimated 95 million people in 2060.568 Similarly, the number of people 85 years and older is expected to grow from 6.5 million to 11.8 million in 2035, and to triple by 2060 to an estimated 19 million people.569

As the population ages, care can become more complex,570 with patients often developing multiple chronic conditions. The CDC estimates that 68.4 percent of Medicare beneficiaries have two or more chronic conditions.571 Research on Medicare fee-for-service beneficiaries with 15 prevalent chronic conditions showed that 62 percent for those between 65–74 years old and 81.5 percent for those 85 years and older experience multiple chronic conditions.572

Hospitals are increasingly faced with treating older patients who have complex medical, behavioral, and psychosocial needs that are often inadequately addressed by the current healthcare infrastructure.573 Although existing Hospital IQR Program quality measures include patients who are 65 years and older, some of these measures may be narrow in scope and may not capture the full spectrum of geriatric care needs. Rather than addressing individual clinical issues in isolation, optimizing care for older patients with multiple co-morbidities will require a holistic approach that reimagines the entire care pathway to better serve the needs of this unique population. We believe an important part of what is needed in redesigning care for the older adult population is programmatic, facility-level geriatric assessment and management efforts.

Given these challenges, the American Geriatrics Society (AGS) developed guiding principles on the care of older adults with multiple chronic conditions using structured literature searches and consensus among clinicians.574 To translate these principles into action steps, the AGS convened a group of geriatricians, cardiologists, and generalists to identify a framework for decision-making for clinicians who provide care to older adults with multiple chronic conditions.575 This workgroup recommended three actions: (1) identify and communicate patients’ health priorities and health trajectory; (2) stop, start, or continue care based on health priorities, potential risks versus benefits, and health trajectories; and (3) align decisions and care among patients, caregivers, and other clinicians with patients’ health priorities and trajectories.

To address the challenges of delivering care to older adults with multiple chronic conditions from a health system perspective, multiple organizations including the American College of Surgeons (ACS), the Institute for Healthcare Improvement (IHI), and the American College of Emergency Physicians (ACEP) collaborated to identify clinical frameworks based on evidence-based best practices that provide goal-centered, clinically effective care for older patients. Together, these organizations have established an Age-Friendly Health System initiative. Age-friendly care is defined as: (1) following an essential set of evidence-based practices; (2) causing no harm; and (3) aligning with What Matters577 to the older adult and their family or other caregivers.578 The Age-Friendly Health System initiative has identified a framework comprised of a set of four evidence-based elements of high-quality care to older adults, called the “4 Ms”: What Matters, Medication, Mentation, and Mobility.579 These elements organize care for older adult wellness and apply regardless of the number of chronic conditions, a person’s culture, or their racial, ethnic, or religious background.580

The collective evidence provided by these research efforts demonstrates that patient-centered care for aging patient populations with multiple chronic conditions should be prioritized by hospitals. Therefore, we are considering two attestation-based structural measures, the Geriatric Hospital measure and the Geriatric Surgical measure, for the Hospital IQR Program. We also requested public comment on the potential future proposal for a hospital designation focused on hospitals that participate in patient-centered geriatric care system improvement initiatives.

These attestation-based structural measures apply evidence-based, concrete, actionable steps to improve patient-centered care in the hospital inpatient setting for older adults. The measures incentivize team-based care organized around the geriatric patient to meet their unique needs.581 A major challenge presented in the geriatric population is that care is not a single structural element or process.582 Within clinical domains of care such as geriatric care, there are crucial structures and processes, among these research efforts demonstrates that patient-centered care, that reach across multiple interactions and link the care team’s efforts together.583584 Orchestrating all

568 Ibid.
569 Ibid.
571 Lochner KA, Cox CS. Prevalence of Multiple Chronic Conditions Among Medicare Beneficiaries, United States, 2010. Prev Chronic Dis 2013;10:120137. DOI: https://dx.doi.org/10.5888/pcd10.120137
576 Ibid.
these elements results in better outcomes, and improving their implementation would be an essential first step to improve geriatric outcomes.585

Both structural measures are a collection of coordinated, team-based components across the continuum of care. Together, these represent patient-centered programs of care designed to improve surgical and general health outcomes for geriatric patients. When the components are properly tied together, complex care for this population is better coordinated and more reliably delivered, with harms minimized and outcomes optimized. The elements in these geriatric structural measures are focused on care delivery, coordination, data, and data-driven improvement activities.

The measure developer, ACS, designed these structural measures to assess geriatric care across various domains (see Table IX.C–06 and Table IX.C–07) using a suite of organizational competencies aimed at achieving patient-centered care for aging populations with multiple chronic conditions. We believe these measures would complement the current patient safety reporting, support hospitals in improving the quality of care for a complex patient population and could further our commitment to advancing health equity among the diverse communities served by participants in CMS programs.

These measures also align with our efforts under the Meaningful Measures Framework, which identifies high priority areas for quality measurement and improvement to assess core issues most critical to high-quality healthcare and improving patient outcomes.586 More specifically, the measures align with the Meaningful Measures Framework priority focus on patient-centered care.587 In 2021, we launched Meaningful Measures 2.0 to promote innovation and modernization of all aspects of quality and address a wide variety of settings, interested parties, and measure requirements. The Geriatric Hospital and Geriatric Surgical structural measures support the goal of “leverage[ing] quality measures to promote health equity and close gaps in care.”588 In addition, these measures align with CMS’s National Quality Strategy goal to “embed quality into the care journey,” by taking a person-centered approach to ensure a smoother care journey for a patient population that often has complex needs.589

The Geriatric Hospital (MUC2022–112) and Geriatric Surgical (MUC2022–032) measures were included in the publicly available “2022 Measures Under Consideration Spreadsheet” (MUC List), the list of measures under consideration for use in various Medicare programs.590 The MAP Rural Health Advisory Group reviewed the MUC List and the Geriatric Hospital (MUC2022–112) and Geriatric Surgical (MUC2022–032) measures in detail on December 8–9, 2022.591 The Rural Health Advisory Group agreed that both measures are important but had concerns regarding the limited resources that rural health providers face, including fewer clinicians and social services availability.592 The Rural Health Advisory Workgroup also had concerns related to the potential for public trust to be negatively impacted if these measures are publicly reported.593

On December 6–7, 2022, the MAP Health Equity Advisory Group met to review the 2022 MUC List and Geriatric Hospital (MUC2022–112) and Geriatric Surgical (MUC2022–032) measures.594 The MAP Health Equity Advisory Group was convened to provide input on the MUC List with the goal of reducing health disparities closely linked with social, economic, environmental and other systemic disadvantages. The Health Equity Advisory Group also requested that participants provide input on potential unintended consequences or measurement gap areas related to health disparities. The Health Equity Advisory Group agreed the geriatric measures are important measures, noting that geriatric patients are often more fragile and emphasized the importance of assessing their needs. The Health Equity Advisory Group had concerns related to implementation and to the limited evidence that attestation measures lead to improved health outcomes that further health equity.595

The MUC List, including Geriatric Hospital (MUC2022–112) and Geriatric Surgical (MUC2022–032) measures, were also reviewed by the MAP Hospital Workgroup on December 13–14, 2022.596 The MAP Hospital Workgroup discussed the overlap between the Geriatric Hospital measure (MUC2022–112) and Geriatric Surgical measure (MUC2022–032), noting that hospitals, particularly ones in rural settings, may find it burdensome to report both measures. The MAP Hospital Workgroup did not support the Geriatric Hospital measure (MUC2022–112) for rulemaking, with the potential for mitigation. The potential mitigation for this measure (MUC2022–112) is considered for combining the two geriatric care measures (MUC2022–112 and MUC2022–032) into a single measure that is less burdensome, or focusing on one of the two measures.597

The MAP Hospital Workgroup conditionally supported the Geriatric Surgical measure (MUC2022–032) for rulemaking pending additional revisions to reduce the number of elements included in the attestation and present information about gaps for the components.

The MAP Coordinating Committee convened on January 23–24, 2023, to review the MUC List, including Geriatric Hospital (MUC2022–112) and Geriatric Surgical (MUC2022–032) measures.598 The MAP Coordinating Committee similarly discussed the overlap between the Geriatric Hospital measure (MUC2022–112) and Geriatric Surgical measure (MUC2022–032), and agreed with the concerns noted by the MAP Hospital Workgroup that hospitals may find it burdensome to report both measures, particularly in rural settings. The MAP Coordinating Committee agreed with the decision to conditionally support the Geriatric Hospital measure (MUC2022–112) for rulemaking, pending CBE endorsement.


587 Ibid.


The MAP Coordinating Committee agreed the potential for mitigation for this measure should be to consider combining the two geriatric care measures (MUC2022–112 and MUC2022–032) into a single measure that is less burdensome, or focus on one measure.\textsuperscript{599} The MAP Coordinating Committee agreed with the MAP Hospital Workgroup’s decision to conditionally support the Geriatric Surgical measure (MUC2022–032) for rulemaking, pending CBE endorsement, further paring down elements included in the attestations, and providing further information on the gaps in the measure components.\textsuperscript{600} The MAP Coordinating Committee had concerns related to the subjectiveness of attestation based measures, noting a preference for outcome or process measures.\textsuperscript{601} The MAP Coordinating Committee supported the focus of the measure and noted that attestation measures can help build infrastructure for important topics such as this and that these measures fill a gap in care management among a vulnerable population.\textsuperscript{602}

\section*{(2) Potential Future Inclusion of a Geriatric Hospital Structural Measure}

\subsection*{(i) Measure Overview}

The Geriatric Hospital structural measure assesses hospital commitment to improving outcomes for patients 65 years or older through patient-centered competencies aimed at achieving quality of care and safety for all older patients. The measure includes 14 attestation-based questions across eight domains representing a comprehensive framework required for optimal care of older patients admitted to the hospital or being evaluated in the emergency department. Table IX.C–06 includes the eight attestation domains and 14 attestation statements which would be required to qualify for this measure.

\textsuperscript{599} Ibid.
\textsuperscript{600} Ibid.
\textsuperscript{601} Ibid.
\textsuperscript{602} Ibid.
### Table IX.C–06. The Geriatric Hospital Measure’s Eight Domain Attestations

<table>
<thead>
<tr>
<th>Attestation Domains</th>
<th>Attestation Statements: Select All That Apply</th>
</tr>
</thead>
</table>
| **Domain 1: Identifying Goals of Care**  | (1) **Advance Care Planning.** Please attest that your hospital provides education to patients and providers regarding advance care planning and ensures that advance care planning preferences are captured, updated, and available for review in the medical record.  
(2) **Patient Goals.** Please attest that your hospital provides education regarding goal concordant care and has established protocols for ensuring patient goals and decision making is documented in the medical record. |
| **Domain 2: Medication Management**      | (3) **Inappropriate Medications.** Please attest that your hospital flags medications that may be inappropriate for older patients and has established protocols for reviewing drug and non-drug alternatives to identified substances.  
(4) **Pain Management.** Please attest that your hospital employs opioid sparing multimodal pain management strategies where possible and has protocols for capturing these regimens in the medical record. |
| **Domain 3: Cognition and Delirium**     | (5) **Delirium and Cognition Screening.** Please attest that your hospital performs delirium and cognition screens and assessments and implements appropriate management plans for those with delirium. |
| **Domain 4: Preventing Delirium Related Events** | (6) **Delirium Prevention.** Please attest that your hospital establishes protocol for minimizing delirium for patients in the hospital through environment modifications, delirium screens, and timely discharge/transfer of patients. |
| **Domain 5: Function and Mobility**      | (7) **Function and Mobility Screening.** Please attest that your hospital performs function and mobility assessments and implements appropriate management plans to promote mobility.  
(8) **Assistance with Activities of Daily Living (ADLs) / Instrumental Activities of Daily Living (IADLs).** Please attest that your hospital screens older patients for ADL/IADL needs and establishes protocols for management of patients with identified deficiencies. |
| **Domain 6: Social Determinants of Health** | (9) **Social Determinants of Health.** Please attest that your hospital assesses patients for psychosocial risk factors and employs appropriate management plans.  
(10) **Elder Abuse, Neglect, and Exploitation.** Please attest that your hospital assesses older patient for potential abuse and has protocols for intervention for positive assessments including appropriate reporting and involvement of social services. |
| **Domain 7: Care Transitions**           | (11) **Identifying Needs at Hospital Discharge.** Please attest that your hospital elicits discussion between providers and patients regarding discharge care and establishes protocols to ensure that discharge summaries contain management plans for all identified post-discharge needs.  
(12) **Post-Acute Care.** Please attest that your hospital has protocols for establishing two-way communication between providers and post-acute care facilities and tracks the quality of care at post-acute care facilities upon discharge. |
<table>
<thead>
<tr>
<th>Attestation Domains</th>
<th>Attestation Statements: Select All That Apply</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(Note: Attestation of all statements would be required to qualify for the measure numerator)</td>
</tr>
</tbody>
</table>
| Domain 8: Ensuring Quality Care for High-Risk Patients | (13) Identification and Management of Seriously Ill Patients. Please attest that your hospital employs multidisciplinary evaluation of older patients and provides appropriate management, including the early utilization of palliative care consultations, for those with serious illness.  
(14) Geriatric Leader and Quality Framework. Please attest that your hospital designates a geriatric champion to oversee all aspects of this measure and establishes a framework for ongoing quality improvement regarding the care for older patients. |

Attestation of each statement within a domain would be required to qualify for the measure numerator. The denominator for each hospital is eight, which represents the total number of domain attestations. The measure would be calculated as the number of complete attestations divided by the total number of questions.  
A hospital would not be able to receive partial credit for a domain. For example, for Domain 1 (“Identifying Goals of Care”), a hospital would evaluate and determine whether their hospital processes meet each of the attestation statements described in (1) and (2) (see Table IX.C–06.). If the hospital’s processes meet both of these statements, the hospital would affirmatively attest to Domain 1 and would receive a point for that attestation domain.  
We invited public comment on the potential future use of this measure in the Hospital IQR Program.

We thank readers for their comments and have summarized all responses to this potential future measure after the potential geriatric hospital designation RFI in section IX.C.9.b.

(3) Potential Future Inclusion of the Geriatric Surgical Structural Measure

(i) Measure Overview

The Geriatric Surgical structural measure assesses hospital commitment to improving surgical outcomes for patients 65 years or older through patient-centered competencies aimed at achieving quality of care and safety for all older patients. The measure includes 11 attestation-based questions across seven domains (see Table IX.C–07.), representing a comprehensive framework required for optimal care of the older surgical patient.
### Table IX.C–07. The Geriatric Surgical Measure’s Seven Domain Attestations

<table>
<thead>
<tr>
<th>Attestation Domains</th>
<th>Attestation Statements: Select All That Apply</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(Note: Attestation of all statements discussed in the chart would be required to qualify for the measure numerator)</td>
</tr>
</tbody>
</table>
| **Domain 1: Identifying Goals of Care** | (1) **Advance Care Planning.** Please attest that your hospital provides education to patients and providers regarding advance care planning and ensures that advance care planning preferences are captured, updated, and available for review in the medical record.  
(2) **Patient Goals.** Please attest that your hospital provides education regarding goal concordant care and has established protocols for ensuring patient goals and decision making is documented in the medical record. |
| **Domain 2: Medication Management** | (3) **Inappropriate Medications.** Please attest that your hospital flags medications that may be inappropriate for older surgical patients and has established protocols for reviewing drug and non-drug alternatives to identified substances.  
(4) **Pain Management.** Please attest that your hospital employs opioid sparing multimodal pain management strategies where possible and has protocols for capturing these regimens in the medical record. |
| **Domain 3: Cognition and Delirium** | (5) **Delirium and Cognition Screening.** Please attest that your hospital performs delirium and cognition screens and implements protocols for flagging high risk patients and implementing appropriate management plans for those with positive screens. |
| **Domain 4: Function and Mobility** | (6) **Function and Mobility Screening.** Please attest that your hospital performs pre-operative function and mobility screens and implements protocols to flagging high risk patients and implementing appropriate management plans for those with positive screens. |
| **Domain 5: Social Determinants of Health** | (7) **Social Determinants of Health.** Please attest that your hospital performs preoperative screens for psychosocial risk factors and establishes protocols for identifying at risk patients and employing appropriate management plans. |
### Attestation Domains

<table>
<thead>
<tr>
<th>Domain 6: Care Transitions</th>
<th>Attestation Statements: Select All That Apply (Note: Attestation of all statements discussed in the chart would be required to qualify for the measure numerator)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(8) <strong>Identifying Needs at Hospital Discharge.</strong> Please attest that your hospital elicits discussion between providers and patients regarding discharge care and establishes protocols to ensure that discharge summaries contain management plans for all identified post-discharge needs.</td>
</tr>
<tr>
<td></td>
<td>(9) <strong>Post-Acute Care.</strong> Please attest that your hospital has protocols for establishing two-way communication between providers and post-acute care facilities and tracks the quality of care at post-acute care facilities upon discharge</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Domain 7: Ensuring Quality Care for High-Risk Patients</th>
<th>(10) <strong>Identification and Management of Seriously Ill Patients.</strong> Please attest that your hospital employs multidisciplinary evaluation of older patients and provides appropriate management, including the early utilization of palliative care consultations, for those with serious illness.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(11) <strong>Geriatric Leader and Quality Framework.</strong> Please attest that your hospital designates a geriatric surgery point person to oversee all aspects of this measure and establishes a framework for ongoing quality improvement regarding the care for patients.</td>
</tr>
</tbody>
</table>

---

**BILLING CODE 4120-01-C**

(ii) Measure Calculation

The Geriatric Surgical structural measure consists of seven domains. Each domain represents a separate domain commitment. A hospital would need to evaluate and determine whether it can affirmatively attest to each domain, some of which have multiple statements to which a hospital must attest.

To report on this measure, hospitals would respond to the seven domain attestations that encompass 11 corresponding statements. A hospital would receive one point for each domain where they attest to each of the corresponding statements (for a total of zero to seven points). For domain questions with multiple statements, positive attestation to each statement would be required to qualify for the corresponding domain attestation.

The numerator is the number of complete domain attestations. Attestation of each statement within a domain would be required to qualify for the measure numerator. The denominator for each hospital is seven, which represents the total number of domain attestations. The measure would be calculated as the number of complete attestation questions divided by the total number of domains.

A hospital would not be able to receive partial credit for a domain. For example, for Domain 1 ("Identifying Goals of Care"), a hospital would evaluate and determine whether their hospital processes meet each of the attestation statements described in (1) and (2) (see Table IX.C–07.). If the hospital’s processes meet both of these statements, the hospital would affirmatively attest to Domain 1 and would receive a point for that attestation domain.

We invited public comment on the potential use of this measure in the Hospital IQR Program.

We thank readers for their comments and have summarized all responses to this potential future measure after the potential geriatric hospital designation RFI in section IX.C.9.b.

b. Potential Establishment of a Publicly Reported Hospital Designation To Capture the Quality and Safety of Patient-Centered Geriatric Care

In alignment with the Geriatric Hospital and Geriatric Surgical structural measures discussed in section IX.C.9.a., we are considering a geriatric care hospital designation to be publicly reported on a CMS website. This designation could initially be based on data from hospitals reporting on both Geriatric Hospital and Geriatric Surgical structural measures if they are proposed and finalized in the future. If proposed for future rulemaking, we could develop a scoring methodology for granting the designation, such as recognizing those hospitals that affirmatively attest to all domains in the Geriatric Hospital and Geriatric Surgical structural measures. This designation could be similar to the Birthing-Friendly designation that was finalized in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49282 through 49292).

We are considering whether to propose in future notice-and-comment rulemaking a more robust set of metrics for awarding the designation that may include other geriatric care-related measures that may be finalized for the Hospital IQR Program measure set in the future. We believe adding this designation to a consumer-facing CMS website would allow patients and families to choose hospitals that have demonstrated a commitment to improving patient-centered geriatric care through their implementation of best practices that support delivery of safe, high-quality, patient-centered geriatric care. Therefore, we are also soliciting comment on additional measures to consider for incorporation in the designation for future years.

We invited public comment on the potential future hospital designation for geriatric care in addition to the following questions:

- What are some of the key barriers and challenges faced by rural providers in reporting the attestation measures discussed in section IX.C.9.a. of the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27103 through 27109)?
- What are the best practices for hospitals to actively engage with post-
acute care facilities? What barriers do providers face, especially rural providers, in establishing protocols for bi-directional communication?

- What are the best practices that hospitals are implementing to provide education for and conduct outreach to patients in underserved communities to increase access to timely geriatric care?
- Among rural providers, do hospitals face barriers when identifying care goals between patients and providers, establishing protocols for ensuring patients’ goals are met, and documenting the decision making process? Are there specific barriers to providing education regarding the coordination of care to meet the patient’s goals?
- Are there barriers to implementing protocols for delirium and cognition screenings to flag high risk patients among geriatric populations? What challenges do providers face when implementing care management plans for high-risk patients?
- What barriers do hospitals face when implementing multidisciplinary evaluations of older adults? Are there challenges hospitals face with the early utilization of palliative care consultations for older populations with serious illness?
- Are any of the proposed elements of these measures potentially duplicative of existing measures in the Hospital IQR Program?
- Family caregivers play an important role in providing informal, often unpaid, care to help loved ones, including aging family members on Medicare. It is critical, particularly during care transitions, that hospital procedures focus on the patient’s goals and preferences, and include family caregivers as active partners. How should the potential future hospital designation for geriatric care capture the role of family caregivers in hospital care delivery, care transitions and/or discharge planning?

We received comments on this topic. Comment: Many commenters supported a combined geriatric measure that consolidates the attestation domains of the geriatric hospital and geriatric surgical measures, that could potentially be the foundation of a geriatric hospital designation. Commenters believed these measures and designation will help a rapidly aging, vulnerable population find the care they need.

- Other commenters did not support the implementation of the geriatric attestation-based measures because they believed the burden would outweigh the potential benefits and would not add value to the patient or measure outcomes. Several commenters did not support adoption of either geriatric measure stating that there is no clear link between attestation and improving patient outcomes. A few commenters did not support geriatric measures due to concerns related to increased burden, particularly on rural hospitals, and concerns that the measures and potential hospital designation may not benefit hospitals and could confuse patients.

Commenters provided many recommendations for additional geriatric care considerations. These included recommendations regarding new attestations, the role of family caregivers, and clinical guidelines and screening tools. Additional recommendations focused on provider education regarding the specific needs of geriatric patients.

Commenters additionally recommended moving away from attestation measures and encouraging development of a more fulsome and streamlined set of measures that assess performance to support the geriatric hospital designation, including CBE-endorsed outcome-based measures for display on Care Compare. A few commenters recommended that the scoring methodology for a geriatric hospital designation be based on hospital performance and outcomes. Commenters recommended voluntary participation in a geriatric hospital designation and that only participating hospitals be impacted.

Response: We thank the commenters for their input and appreciate the many meaningful practices being utilized in hospitals across our nation and the commitment to improving geriatric care. We will consider these comments in any future rulemaking related to geriatric care in the Hospital IQR Program.

10. Form, Manner, and Timing of Quality Data Submission
   a. Background

   Section 1886(b)(3)(B)(i) and (ii) of the Act states that the applicable percentage increase for FY 2015 and each subsequent year shall be reduced by one-quarter of such applicable percentage increase (determined without regard to section 1886(b)(3)(B)(ix), (xi), or (xii) of the Act) for any subsection (d) hospital that does not submit data required to be submitted on measures specified by the Secretary in a form and manner, and at a time, specified by the Secretary. To successfully participate in the Hospital IQR Program, hospitals must meet specific procedural, data collection, submission, and validation requirements.

b. Maintenance of Technical Specifications for Quality Measures

For each Hospital IQR Program payment determination, we require that hospitals submit data on each specified measure in accordance with the measure’s specifications for a particular period. We refer readers to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41538), in which we proposed how the Hospital IQR Program maintains the technical measure specifications for quality measures and the subregulatory process for incorporation of nonsubstantive updates to the measure specifications to ensure that measures remain up to date.

The data submission requirements, specifications manual, measure methodology reports, and submission deadlines are posted. For example, for the CY 2023 reporting period/FY 2025 payment determination, hospitals are collecting and will submit eCQM data using the May 2022 Annual Update and any applicable addenda. The Annual Update contains updated measure specifications for the year prior to the reporting period. For example, for the CY 2023 reporting period/FY 2025 payment determination, hospitals are collecting and will submit eCQM data using the May 2022 Annual Update and any applicable addenda. The Annual Update contains updated measure specifications for the year prior to the reporting period. For example, for the CY 2023 reporting period/FY 2025 payment determination, hospitals are collecting and will submit eCQM data using the May 2022 Annual Update and any applicable addenda.
Chart-Abstracted Measures

d. Data Submission Requirements for Chart-Abstracted Measures

We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51640 through 51641), the FY 2013 IPPS/LTCH PPS final rule (77 FR 53536 through 53537), and the FY 2014 IPPS/LTCH PPS final rule (78 FR 50811) for details on the Hospital IQR Program data submission requirements for chart-abstracted measures.

We did not propose any changes to these policies in the proposed rule.

d. Data Submission Requirements for eCQMs

For a discussion of our previously finalized eCQMs and policies, we refer readers to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50807 through 50810; 50811 through 50819), the FY 2015 IPPS/LTCH PPS final rule (79 FR 50241 through 50253; 50256 through 50259; and 50273 through 50276), the FY 2016 IPPS/LTCH PPS final rule (80 FR 49692 through 49698; and 49704 through 49709), the FY 2017 IPPS/LTCH PPS final rule (81 FR 57150 through 57161; and 57169 through 57172), the FY 2018 IPPS/LTCH PPS final rule (82 FR 38355 through 38361; 38386 through 38394; 38474 through 38485; and 38487 through 38493), the FY 2019 IPPS/LTCH PPS final rule (83 FR 41567 through 41575; 83 FR 41602 through 41607), the FY 2020 IPPS/LTCH PPS final rule (84 FR 42501 through 42506), the FY 2021 IPPS/LTCH PPS final rule (85 FR 58932 through 58940), the FY 2022 IPPS/LTCH PPS final rule (86 FR 45417 through 45421), and the FY 2023 IPPS/LTCH PPS final rule (87 FR 49304).

In the FY 2018 IPPS/LTCH PPS final rule, we finalized eCQM reporting and submission requirements such that hospitals were required to report only one, self-selected, calendar quarter of data for four self-selected eCQMs for the CY 2018 reporting period/FY 2020 payment determination (82 FR 38358 through 38361). Those reporting requirements were extended to the CY 2019 reporting period/FY 2021 payment determination through the CY 2021 reporting year (86 FR 45418). We clarified in the FY 2022 IPPS/LTCH PPS final rule that until hospitals are required to report all four quarters of data beginning with the CY 2023 reporting period/FY 2025 payment determination, they may submit consecutive or non-consecutive self-selected quarters of data (85 FR 58939). In the FY 2022 IPPS/LTCH PPS final rule, we clarified that the self-selected eCQMs must be the same eCQMs across quarters in a given reporting year (86 FR 45418).

In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49299 through 49302), we finalized a policy to increase eCQM reporting requirements from four to six eCQMs beginning with the CY 2024 reporting period/FY 2026 payment determination and for subsequent years. Specifically, hospitals will be required to report four calendar quarters of data for each required eCQM: (1) Three self-selected eCQMs; (2) the Safe Use of Opioids—Concurrent Prescribing eCQM, for a total of four eCQMs (84 FR 42503 through 42505).

In the FY 2021 IPPS/LTCH PPS final rule, we finalized a progressive increase in the number of required reported quarters of eCQM data, from one self-selected quarter of data to four quarters of data over a three-year period (85 FR 58932 through 58939). Specifically, for the CY 2021 reporting period/FY 2023 payment determination, hospitals were required to report two self-selected calendar quarters of data for each of the four self-selected eCQMs (85 FR 58939). For the CY 2022 reporting period/FY 2024 payment determination, hospitals were required to report three self-selected calendar quarters of data for each eCQM: (a) Three self-selected eCQMs, and (b) the Safe Use of Opioids—Concurrent Prescribing eCQM (85 FR 58939). We clarified in the FY 2021 IPPS/LTCH PPS final rule that until hospitals are required to report all four quarters of data beginning with the CY 2023 reporting period/FY 2025 payment determination, they may submit consecutive or non-consecutive self-selected quarters of data (85 FR 58939). In the FY 2022 IPPS/LTCH PPS final rule, we clarified that the self-selected eCQMs must be the same eCQMs across quarters in a given reporting year (86 FR 45418).

In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49299 through 49302), we finalized a policy to increase eCQM reporting requirements from four to six eCQMs beginning with the CY 2024 reporting period/FY 2026 payment determination and for subsequent years. Specifically, hospitals will be required to report four calendar quarters of data for each required eCQM: (1) Three self-selected eCQMs; (2) the Safe Use of Opioids—Concurrent Prescribing eCQM; (3) the Cesarean Birth eCQM; and (4) the Severe Obstetric Complications eCQM; for a total of six eCQMs.

We did not propose any changes to these policies in the proposed rule.

The following Table IX.C–08 summarizes our finalized policies.
TABLE IX.C–08. eCQM REPORTING AND SUBMISSION REQUIREMENTS FOR THE CY 2022 REPORTING PERIOD/FY 2024 PAYMENT DETERMINATION AND FOR SUBSEQUENT YEARS

<table>
<thead>
<tr>
<th>Reporting Period/ Payment Determination</th>
<th>eCQM Data Publicly Reported</th>
<th>Total Number of eCQM Reports</th>
<th>eCQM’s Required to be Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>CY 2022/FY 2024</td>
<td>Three Quarters of Data</td>
<td>Four</td>
<td>Three self-selected eCQMs; and Safe Use of Opioids—Concurrent Prescribing eCQM</td>
</tr>
<tr>
<td>CY 2023/FY 2025</td>
<td>Four Quarters of Data</td>
<td>Four</td>
<td>Three self-selected eCQMs; and Safe Use of Opioids—Concurrent Prescribing eCQM</td>
</tr>
<tr>
<td>CY 2024/FY 2026 and for subsequent years</td>
<td>Four Quarters of Data</td>
<td>Six</td>
<td>Three self-selected eCQMs; and Safe Use of Opioids—Concurrent Prescribing eCQM; and Cesarean Birth eCQM; and Severe Obstetric Complications eCQM</td>
</tr>
</tbody>
</table>

(1) Continuation of Certification Requirements for eCQM Reporting

(a) Requiring Use of the 2015 Edition Cures Update Certification Criteria

In the FY 2022 IPPS/LTCH PPS final rule, beginning with the CY 2023 reporting period/FY 2025 payment determination and subsequent years, we finalized the requirement for hospitals to use only certified technology updated consistent with the 2015 Edition Cures Update to submit data for the Hospital IQR Program (86 FR 45418). We refer readers to the ONC 21st Century Cures Act final rule for additional information about the updates included in the 2015 Edition Cures Update (85 FR 25665).

We did not propose any changes to this policy in the proposed rule.

(b) Requiring EHR Technology to be Certified to all Available eCQMs

In the FY 2020 IPPS/LTCH PPS final rule (84 FR 42505 through 42506), we finalized the requirement that EHRs be certified to all available eCQMs used in the Hospital IQR Program for the CY 2020 reporting period/FY 2022 payment determination and subsequent years. In the FY 2022 IPPS/LTCH PPS final rule (86 FR 45418), we finalized the requirement for hospitals to use the 2015 Edition Cures Update beginning with the CY 2023 reporting period/FY 2025 payment determination; then all available eCQMs used in the Hospital IQR Program for the CY 2023 reporting period/FY 2025 payment determination and subsequent years would need to be reported using certified technology updated to the 2015 Edition Cures Update.

We did not propose any changes to this policy in the proposed rule.

(2) File Format for EHR Data, Zero Denominator Declarations, and Case Threshold Exemptions

We refer readers to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49705 through 49708) and the FY 2017 IPPS/LTCH PPS final rule (81 FR 57170) for our previously adopted eCQM file format requirements. Under these requirements, hospitals: (1) Must submit eCQM data via the Quality Reporting Document Architecture Category I (QRDA I) file format, (2) may use third parties to submit QRDA I files on their behalf, and (3) may either use abstraction or pull the data from non-certified sources to then input these data into certified EHR technology (CEHRT) for capture and reporting QRDA I. Hospitals can continue to meet the reporting requirements by submitting data via QRDA I files, zero denominator declaration, or case threshold exemption (82 FR 38387).

More specifically regarding the use of QRDA I files, we refer readers to the FY 2017 IPPS/LTCH PPS final rule (81 FR 57169 and 57170) and the FY 2020 IPPS/LTCH PPS final rule (85 FR 58940), in which we specified QRDA I file requirements. We also refer readers to the CMS Implementation Guide for the data and file requirements, which is published on the eCQI Resource Center website at: https://ecqi.healthit.gov/QRDA.

We did not propose any changes to this policy in the proposed rule.

(3) Submission Deadlines for eCQM Data

We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50256 through 50259), the FY 2016 IPPS/LTCH PPS final rule (80 FR 49705 through 49709), and the FY 2017 IPPS/LTCH PPS final rule (81 FR 57169 through 57172) for our previously adopted policies to align eCQM data reporting periods and submission deadlines for both the Hospital IQR Program and the Medicare Promoting Interoperability Program. In the FY 2017 IPPS/LTCH PPS final rule (81 FR 57172), we finalized the alignment of the Hospital IQR Program eCQM submission deadline with that of the Medicare Promoting Interoperability Program—the end of two months following the close of the calendar year—for the CY 2017 reporting period/FY 2019 payment determination and subsequent years. We note the submission deadline will be moved to the next business day if it falls on a weekend or Federal holiday.

We did not propose any changes to this policy in the proposed rule.

f. Data Submission and Reporting Requirements for Hybrid Measures

In the FY 2020 IPPS/LTCH PPS final rule, we finalized the adoption of the Hybrid HWR measure for the Hospital IQR Program (84 FR 42465 through 42481) such that, beginning with the CY 2026 reporting period/FY 2028 payment determination, hospitals are required to report on the Hybrid HWR measure (84 FR 42479). In the FY 2022 IPPS/LTCH PPS final rule, we also finalized the adoption of the Hybrid HWM measure in a stepwise fashion, beginning with a voluntary reporting
period from July 1, 2022, through June 30, 2023, and followed by mandatory reporting from July 1, 2023 through June 30, 2024, affecting the FY 2026 payment determination, and for subsequent years (86 FR 45365). We also finalized several requirements related to data submission and reporting requirements for hybrid measures under the Hospital IQR Program (84 FR 42506 through 42508).

We refer readers to the FY 2020 IPPS/LTCH PPS final rule (84 FR 19498 and 19499), the FY 2021 IPPS/LTCH PPS final rule (85 FR 59941), the CY 2021 PPS final rule (85 FR 84472), and the FY 2022 IPPS/LTCH PPS final rule (86 FR 45421) for our previously adopted policies regarding certification and file format requirements for hybrid measures in the Hospital IQR Program.

We refer readers to sections IX.C.6.a. and IX.C.6.b. of this final rule where we finalized refinements of the two hybrid measures in the Hospital IQR Program—the Hybrid Hospital-Wide All-Cause Risk Standardized Mortality measure and the Hybrid Hospital-Wide All-Cause Risk Standardized Readmission measure. In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49304), we finalized our proposal to remove zero denominator declarations and case threshold exemptions as an option for the reporting of hybrid measures beginning with the FY 2026 payment determination because we do not believe that these policies are applicable to hybrid measures due to the process of reporting the measure data since hybrid measures do not require that hospitals report a traditional denominator as is required for the submission of ECVMs (Id.). Instead, hybrid measures utilize the Initial Patient Population (IPP), as per their measure specifications, that identifies the patients for which hospitals need to extract the EHR data and annual claims data (Id.). We note that the FY 2026 payment determination is the first year for which hybrid measures, finalized as part of the Hospital IQR Program, will become mandatory for reporting.

We did not propose any changes to these policies in the proposed rule.

We refer readers to the FY 2021 IPPS/LTCH PPS final rule (75 FR 50220), the FY 2012 IPPS/LTCH PPS final rule (76 FR 51641 through 51643), the FY 2013 IPPS/LTCH PPS final rule (77 FR 53537 and 53538), and the FY 2014 IPPS/LTCH PPS final rule (78 FR 50819 and 50820) for details on previously adopted HCAHPS submission requirements. We also refer hospitals and HCAHPS Survey vendors to the official HCAHPS website at https://www.hcahpsonline.org for new information and program updates regarding the HCAHPS Survey, its administration, oversight, and data adjustments.

(1) Updates to the HCAHPS Survey Measure (CBE #0166) Beginning With the FY 2027 Payment Determination

(a) Background

We partnered with the Agency for Healthcare Research and Quality (AHRQ) to develop the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) patient experience of care survey (CBE #0166) (hereinafter referred to as the HCAPHS Survey). We adopted the HCAHPS Survey in the Hospital IQR Program in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68202 through 68204) beginning with the FY 2008 payment determination. We refer readers to the FY 2010 IPPS/LTCH PPS final rule (74 FY 43882), the FY 2011 IPPS/LTCH PPS final rule (75 FR 50220 through 50222), the FY 2012 IPPS/LTCH PPS final rule (76 FR 51641 through 51643), the FY 2013 IPPS/LTCH PPS final rule (77 FR 53537 and 53538), the FY 2014 IPPS/LTCH PPS final rule (78 FR 50819 and 50820), the FY 2018 IPPS/LTCH PPS final rule (82 Fr 38328 through 38342), and the CY 2019 OPPS/ASC final rule (83 Fr 59140 through 59149) for details on previously adopted HCAHPS Survey requirements.

The HCAHPS Survey (OMB control number 0938–0981) is the first national, standardized, publicly reported survey of patients’ experience of hospital care and asks eligible discharged patients 29 questions about their recent hospital stay. The HCAHPS Survey is administered to a random sample of adult patients who receive medical, surgical, or maternity care between 48 hours and six weeks (42 calendar days) after discharge and is not restricted to Medicare beneficiaries.603 Hospitals must survey patients throughout each month of the year.604 The HCAHPS Survey is available in official English, Spanish, Chinese, Russian, Vietnamese, Portuguese, German, Tagalog, and Arabic versions.

The HCAHPS Survey and its protocols for sampling, data collection and coding, and file submission can be found in the current HCAHPS Quality Assurance Guidelines, which is available on the official HCAHPS website at: https://www.hcahpsonline.org/quality-assurance/. AHRQ carried out a rigorous scientific process to develop and test the HCAHPS Survey instrument. This process entailed multiple steps, including: a public call for measures; literature reviews; cognitive interviews; consumer focus groups; multiple opportunities for additional stakeholder input; a three-state pilot test; small-scale field tests; and notice-and-comment rulemaking. The CBE first endorsed the revised HCAHPS Survey in 2005,605 and re-endorsed the measure in 2010, 2015, and 2019.606

In 2021, we conducted a large-scale mode experiment to test adding the web mode and other updates to the form, manner, and timing of HCAHPS Survey data collection and reporting. The 2021 mode experiment employed a nationwide random sample of short-term acute care hospitals that participate in the HCAHPS Survey, including those from each of CMS’s 10 geographic regions. Participating hospitals contributed patients discharged from April through September 2021. Within each hospital, patients were randomly assigned to each mode of survey administration. In total, we received responses to a revised version of the HCAHPS Survey from 36,001 patients in 46 hospitals. The design of the experiment was of sufficient scale to test survey items on new topics, revisions to existing survey items, and new and revised composite measures. It also enabled precise estimation of mode adjustments for current and new HCAHPS items for...

603 We refer readers to the CY 2019 OPPS/ASC final rule (83 Fr 59140 through 59149), the FY 2018 IPPS/LTCH PPS final rule (82 Fr 38328 through 38342, 38398), and to the official HCAHPS website at: https://www.hcahpsonline.org for details on HCAHPS requirements.

604 Ibid.

605 https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/HospitalHCAHPS.

three currently approved HCAHPS Survey mode protocols and an additional three web-based protocols. This mode experiment was designed to have the power and precision of adjustment estimates comparable to those that are used and have proven necessary for adjustment of previous HCAHPS data.

The 2021 HCAHPS mode experiment had four main goals: (1) test the large-scale feasibility of web-first sequential multimode survey administrations in an inpatient setting; (2) investigate whether mode effects significantly differ between individuals with email addresses available to the data collection vendor compared to individuals without email addresses available to the vendor; (3) develop mode adjustments to be used in future national implementation; and (4) test potential new survey items. This experiment included three currently approved mode protocols most commonly used by hospitals participating in HCAHPS: Mail Only, Phone Only, and Mail-Phone (mail with phone follow-up of non-responders). In this experiment, three additional mode protocols that added an initial Web phase to these current modes were considered: Web-Mail, Web-Phone, and Web-Mail-Phone. In addition, the mode experiment employed a 49-day data collection period for all six modes, which extended the standard HCAHPS data collection period by seven days. Doing so preserved the survey response period of the current survey while adding time for the Web phase. Unlike the current HCAHPS Survey, proxy respondents were not prohibited from completing the survey.

Another goal of the 2021 HCAHPS mode experiment was to test new survey content related to care coordination, discharge experience, communication with patients’ families, emotional support, sleep, and summoning help. We are using the mode experiment results to inform decisions about potential changes to administration protocols and survey content. Potential measure changes will be submitted to MUC List in 2023 and may be proposed in future rulemaking. We did not propose changes to the HCAHPS Survey’s content in this rule.

(b) Addition of Three New Modes of Survey Implementation

In the FY 2024 IPPS/LTC PPS proposed rule (88 FR 27713), we proposed to add three new modes of survey administration (Web-Mail mode, Web-Phone mode, and Web-Mail-Phone mode) in addition to the current Mail Only, Phone Only, and Mail-Phone modes, beginning with January 2025 discharges. We proposed this update because in the 2021 HCAHPS mode experiment, adding an initial web component to three current HCAHPS modes of survey administration resulted in increased response rates. Overall, 9,642 patients completed a survey, resulting in a 28 percent response rate. The response rate for Mail Only mode was 22 percent, compared to 29 percent for Web-Mail mode. The response rate for Phone Only mode was 23 percent, compared to 30 percent for Web-Phone mode. The response rate for Mail-Phone was 31 percent compared to 36 percent for Web-Mail-Phone mode.

Analysis of 2021 mode experiment data also revealed that patients who supplied an email address had a statistically significant higher response rate (31 percent) than patients without an email address (22 percent). The percentage of sampled patients with an email address varied by hospital, ranging from 11 percent to 94 percent. Overall 63 percent of patients supplied an email address. Evidence from this and previous HCAHPS mode experiments indicate that sequential mixed modes of survey administration (for example, web followed by mail, or phone, or both) result in overall higher response rates and better representation of younger, Spanish language-prefering, racial and ethnic minority, and maternity care patients.

We invited public comment on this proposed update. Comment: Many commenters expressed their support for the addition of three new modes of survey implementation and stated their belief that the additional modes of survey implementation would likely increase survey response rates. A few commenters believed that new modes of survey implementation would increase participation from more diverse and underserved patient populations. A commenter believed that the additional modes of survey implementation would streamline data collection and reduce the data management burden. Another commenter believed that the new modes of survey implementation will be more cost effective in the long run. A commenter recommended considering sending a second email survey to non-respondents.

Response: We thank the commenters for their support and agree that the addition of these three new modes of survey implementation will likely increase response rates for all patient populations. We also agree that these new modes of survey implementation have the potential to reduce the data collection and management burden while reducing survey administration costs in the long run. We will send a second and third email invitation in the Web-Mail and Web-Phone modes, and a second email invitation in the Web-Mail-Phone mode, to patients who did not respond to earlier email invitations. We note that procedures for survey administration will be clearly defined in the HCAHPS Quality Assurance Guidelines for all survey administration modes.

Comment: A commenter recommended that CMS ensure comparability of results across modalities and determine if adjustments are needed to ensure accuracy of results.

Response: We thank the commenter for their feedback and remind the commenter that per HCAHPS Quality Assurance Guidelines, all HCAHPS Survey results are adjusted for survey mode and patient-mix prior to public reporting and note that only adjusted results are publicly reported and considered the official HCAHPS results.

Comment: A commenter requested clarification on whether the telephone mode of administration included a text message option and a few commenters recommended that CMS explore the inclusion of text message-based modes of HCAHPS administration.

Response: We thank the commenters for their feedback. While the current telephone administration mode does not include a text message option, we will take these recommendations into consideration for future program years, taking into consideration the Telephone Consumer Protection Act requirements.

Comment: A commenter recommended that non-English translations of HCAHPS be made available for use in the new web modes and that vendors be allowed and encouraged to develop an option within the web survey interface to allow respondents to select their preferred language and choose the survey version that aligns with their language preference.

Response: We thank the commenter for their feedback and would like to note that official HCAHPS Survey translations (English, Spanish, Chinese, Russian, Vietnamese, Portuguese, German, Tagalog, and Arabic) will be available for use in the new modes of implementation.

Comment: A commenter requested clarification on whether the sequence of mixed survey modes would be determined by CMS or whether hospitals would be permitted to choose the sequence of outreach.

Response: We appreciate the commenter’s feedback and wish to clarify that much like the original mixed
mode survey which consisted of Mail combined with Telephone follow-up, the sequence for new modes of survey administration will be clearly defined in the HCAHPS Quality Assurance Guidelines which are updated regularly and can be found online at https://www.hcahpsonline.org/en/quality-assurance/.

After consideration of the public comments we received, we are finalizing this policy as proposed.

(c) Removal of Prohibition of Proxy Respondents to the HCAHPS Survey

In response to stakeholder feedback, and evidence that proxy response does occur in mail administration despite the current protocol that asks that only the patient complete the survey, the mode experiment assessed the impact of not excluding proxy respondents. We found that not excluding proxies did not impact HCAHPS measure scores and as such it is not necessary to control for completion of the survey by a proxy. Consequently, we proposed to remove the requirement that only the patient may respond to the survey and thus allow a patient’s proxy to respond to the survey, beginning with January 2025 discharges. We will, however, still encourage patients to respond to the survey rather than proxies.

We invited public comment on this update.

Comment: Many commenters supported removing the prohibition of proxy respondents to the HCAHPS Survey. Many commenters expressed their belief that this change would increase the overall response rate and several commenters noted that they believed the change would widen the diversity of experiences in responses.

Response: We thank the commenters for their support.

Comment: A commenter recommended that the new survey modes be implemented for one to two years to measure changes in response rates prior to removing the prohibition on proxy respondents.

Response: We thank the commenter for this recommendation and would refer readers to the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27112 through 72113) which discusses the 2021 Mode Experiment upon which our proposed changes were based. This experiment included the addition of the new survey modes while simultaneously removing the prohibition on proxy respondents and found that not excluding proxies did not impact measure scores and as such it is not necessary to control for completion of the survey by a proxy.

(d) Extension of the Data Collection Period

The 2021 mode experiment showed that extending the data collection period from 42 to 49 days allows time for respondents in the web-first modes to respond by email before contacting non-responders with the secondary mode of administration while still preserving adequate time for the secondary mode (either mail, phone, or mail followed by phone). Nearly 13 percent of respondents in the mode experiment completed the survey between days 43 and 49. Compared to the first 42 days, during days 43 to 49 there was a statistically significant increase in responses from patients who are typically under-represented in HCAHPS, including patients who speak Spanish at home, are Black, 25 to 34 years old, and with an 8th grade education or less. We therefore proposed to extend the data collection period for the HCAHPS Survey from 42 to 49 days, beginning with January 2025 discharges.

We invited public comment on the proposed change in the length of the data collection period.

Comment: Many commenters supported the proposed extension of the data collection period. Several commenters expressed their belief that the extension of the data collection period will likely increase overall response rates.

Response: We thank the commenters for their support and agree that the extended collection period will likely increase overall response rates.

Comment: A few commenters did not support our proposal to extend the data collection period, expressing concern that recall bias is already an issue with the current data collection period. A commenter suggested that we shorten the data collection period to address this challenge and expressed concern about the quality of responses that may be collected and whether these responses are fully reflective of patients’ actual experience. Another commenter recommended CMS allow hospitals to administer surveys as soon as a patient is discharged.

Response: We understand and appreciate the commenters’ concerns. Recall bias is a legitimate concern with survey responses, and we will continue to monitor results for potential recall bias effects, however, the benefits of extending the HCAHPS data collection period outweigh these concerns. Extending the data collection period will not delay the administration of the HCAHPS Survey, which may begin as soon as 48 hours after discharge. The proposed change will allow for more time for responses to be received. Through patient-mix adjustment we will continue to control for response percentile, which adjusts for when during the data collection period the respondent completes the survey. The 2021 Mode Experiment upon which our proposed changes were based demonstrated that within the extended period, there was a statistically significant increase in responses specifically in groups that are typically under-represented in HCAHPS and the increased representation among these populations will improve the extent to which HCAHPS results are reflective of the entire patient population experience.

We thank the commenter for their recommendation to allow hospitals to immediately administer surveys upon patient discharge however we refer readers to the HCAHPS Quality Assurance Guidelines which outlines that the delay in allowing hospitals to administer the surveys is designed to ensure patients have time to return home and feel settled after a hospital stay prior to being contacted by the HCAHPS administrator.

Comment: A commenter recommended that we delay extension of data collection period until CMS can first measure success of the new collection modes.

Response: We thank the commenter for this recommendation and refer readers to the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27112 through 72113) which discusses the 2021 Mode Experiment upon which our proposed changes were based. This experiment included the addition of the new survey modes while simultaneously extending the data collection period and resulted in a statistically significant increase in responses from patients who are typically under-represented in HCAHPS.

Comment: A commenter expressed concern that the extended data collection period would impact timelines for preview and publication of stars data.
Response: We appreciate the commenter’s concern, however we do not anticipate that the extension of the reporting period will result in a delay in the release of star ratings data. After consideration of the public comments we received, we are finalizing this policy as proposed.

(e) Limit on the Number of Supplemental HCAHPS Survey Items

Currently, we do not place a limit on the number of supplemental items that may be added to the HCAHPS Survey for quality improvement purposes. We are concerned that this policy has contributed to decline in the survey’s response rate. Other CMS CAHPS surveys limit the number of supplemental items that may be added to prevent the survey from becoming so long that the response rate is negatively impacted. For example, the Medicare Advantage and Prescription Drug Plan (MA & PDP) CAHPS Survey limits the number of supplemental items to a maximum of 12. Evidence from the 2016 HCAHPS mode experiment, as well as from the MA & PDP CAHPS Survey, strongly indicates that survey response rates decrease as the number of supplemental items increases. Analysis of the 2016 HCAHPS mode experiment data revealed that in the Mixed Mode (mail survey with phone follow-up of non-responders), 12 supplemental items would be expected to reduce HCAHPS response rates by 2.7 percentage points. An analysis of data from the MA & PDP CAHPS project found a 2.5 percentage point reduction in response rate associated with 12 supplemental items in Mixed Mode.607 This is particularly relevant because it includes both mail and phone, the two most commonly used survey modes for CAHPS. Declines of this magnitude represent a substantial loss in response rate. The proposed limit of 12 supplemental items aligns with other CMS CAHPS surveys.

We invited public comment on our proposal to limit the number of supplemental items. We welcomed suggestions for alternative limits below 12 supplemental items.

Comment: Many commenters supported limiting the number of supplemental survey items and several commenters noted they believe this would improve response rates.

Response: We thank the commenters for their support and agree that limiting supplemental items will likely increase response rates. Comment: A few commenters did not support the proposal to limit the number supplemental HCAHPS survey items. A commenter requested clarification on the rationale for limiting the number of supplemental items at 12 and another commenter expressed their belief that capping the number of supplemental items at 12 was arbitrary and would not meaningfully affect response rates. A few commenters recommended setting the limit on supplemental items at 15.

Response: We acknowledge the commenters’ concerns, and we refer readers to the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27113 through 27114) which outlines the data-based evidence that informed the proposal. This evidence demonstrates that additional supplemental questions reduce response rates and supports the decision to limit supplemental items to 12. Furthermore, the proposed limit of 12 supplemental items aligns with other CMS CAHPS surveys.

Comment: A few commenters expressed concern that specific hospital designations may require incorporation of specific supplemental HCAHPS questions, and a commenter noted that standardized CAHPS surveys include supplemental questions to address specific needs.

Response: We appreciate the commenters’ concerns regarding required supplemental HCAHPS questions for hospital designation statuses, and we refer readers to the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27113 through 27114) which outlines the data-based evidence that informed the proposal. This evidence demonstrates that additional supplemental questions reduce response rates. Given the demonstrated decline in response rates as the number of supplemental questions increases, the benefits of limiting the number supplemental questions outweigh the benefits of unlimited supplemental questions. We would also remind readers that hospitals will still be able to select supplemental questions that best align with their hospital’s unique needs.

After consideration of the public comments we received, we are finalizing this policy as proposed.

(f) Requirement to Use Official Spanish Translation for Spanish Language-Preferring Patients

We have created official translations of the HCAHPS Survey in eight languages in addition to English order to accommodate patient populations.608 Hospitals’ use of these translations, however, is voluntary. To ensure that all Spanish language-preferring patients, who constitute about four percent of HCAHPS respondents, have the opportunity to receive the Spanish translation of the HCAHPS Survey, we proposed that hospitals be required to collect information about the language that the patient speaks while in the hospital (whether English, Spanish, or another language), and that the official CMS Spanish translation of the HCAHPS Survey be administered to all patients who prefer Spanish, beginning with January 2025 discharges.

We invited public comment on the proposed requirement to administer the survey in Spanish. We also welcomed suggestions for additional translations beyond the existing translations in Spanish, Chinese, Russian, Vietnamese, Portuguese, German, Tagalog, and Arabic.

Comment: Many commenters expressed their support for the requirement to use official Spanish translation for Spanish Language-Preferring patients. Many commenters also expressed the belief that these requirements would improve health equity by allowing more patients an opportunity to provide feedback.

Response: We appreciate the commenters’ support and agree that these changes will encourage representation from a wider pool of patients in HCAHPS responses.

Comment: Several commenters recommended expanding the number of translations available in the survey. On commenter specifically recommended including the following languages in future HCAHPS language translations: Armenian, Cambodian, Simplified Chinese, Farsi, Hindi, Hmong, Japanese, Korean, and Ilocano. A commenter specifically requested a translation to Haitian Creole and another commenter requested that we ensure that the translated versions of the surveys are fully valid and reliable for all targeted languages.

Response: We thank the commenters for their recommendations regarding future translations of HCAHPS and further validation of existing translated versions and we will take these recommendations into consideration for future program years.

Comment: A commenter recommended that patients should be given the option of Spanish and English versions so that the patient can select

---


the version best aligning with their language preferences or those of their proxy.

Response: We refer readers to the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27114) where we proposed that hospitals be required to collect information about patient language preferences. This additional requirement will help to ensure that patients receive the version that best aligns with their language preferences.

Comment: A commenter requested clarification on whether the requirement for hospitals to collect information about the language spoken by patients during their hospital also applies to separate certified Electronic Health Record technology (CEHRT) requirements, and recommended CMS consider this extension.

Response: We wish to clarify that this proposal applied only to the HCAHPS Survey, however, we thank the commenter for their recommendation and will consider this in future program years.

Comment: A commenter recommended the survey administration process be updated to allow for both preferred reading languages and preferred speaking languages as these may differ for some patients.

Response: We thank the commenter for their suggestion and will take this into consideration for future program years. If a hospital collects detailed information about the language a patient prefers to read versus a language a patient prefers to speak, there is nothing in the HCAHPS protocols that would prevent the hospital from sharing this information with their survey vendor.

Comment: A commenter requested clarification on whether HCAHPS survey translations would be available in all survey modes.

Response: We thank the commenter for their concern and wish to clarify that language translations are available in additional modes for some but not all official HCAHPS translations. In the Web-Mail mode, the web survey will be available in all of the languages in which the Mail survey is available. In the Web-Phone mode, the web survey will be available in all of the languages in which the Phone survey is available. We would refer readers to the HCAHPS Quality Assurance Guidelines for further information on which HCAHPS translations are offered for additional survey modes.

After consideration of the public comments we received, we are finalizing this policy as proposed.

(g) Removal of Two Administration Methods

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27114), we proposed to remove two currently available options for administration of the HCAHPS Survey that are not used by participating hospitals. The Active Interactive Voice Response (IVR) survey mode, also known as touch-tone IVR, has not been employed by any hospital since 2016 and has never been widely used for the HCAHPS Survey. To streamline HCAHPS oversight and training, we proposed to discontinue IVR as an approved mode of survey administration beginning in January 2025. With the proposed addition of three new web-based modes in January 2023, hospitals will have the option to choose among six modes of survey administration: Mail Only, Phone Only, Mixed Mode (mail followed by phone), Web-Mail mode, Web-Phone mode, and Web-Mail-Phone mode (web followed by mail, followed by phone). To streamline HCAHPS oversight and training, we also proposed to discontinue “Hospitals Administering HCAHPS for Multiple Sites” as an option for HCAHPS Survey administration beginning in January 2023. The option for a hospital to administer the HCAHPS Survey for other hospitals, known as “Hospitals Administering HCAHPS for Multiple Sites”, has not been utilized by any hospitals since 2019 and has never been widely used. Hospitals will continue to have two options for HCAHPS Survey administration: either contracting with an approved HCAHPS survey vendor, currently utilized by about 3,112 hospitals (99 percent of IPPS hospitals); or self-administration of the HCAHPS Survey, currently utilized by fewer than 20 IPPS hospitals (less than one percent of IPPS hospitals).

In addition to the previous proposals, we encourage participating hospitals to carefully consider the impact of mode of survey administration on response rates and the representativeness of survey respondents. High response rates for all patient groups promote our health equity goals. Our research on the HCAHPS Survey indicates that there are pronounced differences in response rates by mode of survey administration for some patient characteristics. In particular, Black, Hispanic, Spanish language-prefering, younger, and maternity patients are more likely to respond to a telephone survey, while older patients are more likely to respond to a mail survey. Choosing a mode that is easily accessible to the diversity of a hospital’s patient population provides a more complete representation of patients’ care experiences. For more information, we refer hospitals to the podcast “Improving Representativeness of the HCAHPS Survey” on the HCAHPS website: https://hcahpsonline.org/en/podcasts/#ImprovingRepresentativeness.

We invited public comment on the proposed removal of two HCAHPS administration methods.

Comment: Many commenters expressed support for the removal of two HCAHPS administration methods.

Response: We thank the commenters for their support.

Comment: A few commenters recommended that CMS temporarily suspend the Active Interactive Voice Response (IVR) survey mode and conduct further research as to why this mode is not widely utilized rather than permanently remove this mode from HCAHPS.

Response: We thank the commenters for their recommendations. As noted in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27114), the touch-tone IVR survey mode has not been employed by any hospital since 2016. Given the addition of three new survey modes, further assessment of the touch-tone IVR survey mode would not represent a responsible use of resources. Furthermore, the removal of this underutilized survey mode is necessary to streamline HCAHPS oversight and training, and to reduce HCAHPS administration burden.

After consideration of the public comments we received, we are finalizing this policy as proposed.

(h) Data Collection

The HCAHPS Survey will be administered and data collected in exactly the same manner as the current HCAHPS Survey, except for the proposed changes described in this section of this final rule. There will be no changes to HCAHPS patient eligibility or exclusion criteria (we note that the immediately following section includes a request for information regarding patient eligibility). Detailed information on HCAHPS data collection protocols can be found in the current HCAHPS Quality Assurance Guidelines, located at: https://www.hcahpsonline.org/en/quality-assurance/.

We invited public comments on these proposals.

Comment: Many commenters expressed their support these proposed changes.

Response: We thank the commenters for their support.
After consideration of the public comments we received, we are finalizing this policy as proposed.

i. Request for Information on Potential Addition of Patients With a Primary Psychiatric Diagnosis to the HCAHPS Survey Measure

We solicited comments about the inclusion of patients with a primary psychiatric diagnosis in the HCAHPS Survey. The HCAHPS Survey was designed, tested, and validated for patients in the medical, surgical, and maternity service lines of short-term, acute care hospitals. Patients with a primary psychiatric diagnosis are currently eligible for this survey; patients with a secondary psychiatric diagnosis are currently eligible for the HCAHPS Survey.

We sought public input on the potential inclusion of patients with a primary psychiatric diagnosis who are admitted to short-term, acute care hospitals for the HCAHPS Survey. Specifically, we requested public comment on whether all patients in the psychiatric service line (that is, MS–DRG codes of 876, 880–887, 894–897) or particular sub-groups thereof should be included in the HCAHPS Survey; whether the current content of the HCAHPS Survey is appropriate for these patients; and whether the current HCAHPS Survey measure implementation procedures might face legal barriers or pose legal risks when applied to patients with primary psychiatric diagnoses. The HCAHPS Survey measure instrument can be found at https://hcahpsonline.org/en/survey-instruments/. HCAHPS Survey measure implementation procedures can be found in the HCAHPS Quality Assurance Guidelines, V18.0 at https://hcahpsonline.org/en/quality-assurance/.

We invited public comments on these topics.

Comment: We received many comments in support of the potential inclusion of patients with a primary psychiatric diagnosis in the HCAHPS Survey. Many of these commenters recommended that we conduct further testing within this population and engage hospitals and other interested parties in technical expert panels before proposing to include this group in the HCAHPS Survey population. Several commenters also recommended that we capture responses from patients with a primary psychiatric diagnosis who receive care in the Emergency Department. A commenter recommended adjusting the minimal sample size to ensure the psychiatric patient population is adequately represented in reporting.

Other commenters did not support the potential inclusion of patients with a primary psychiatric diagnosis in the HCAHPS Survey. Several of these commenters instead recommended that we conduct a separate survey for patients with a primary psychiatric diagnosis that could be used across all care settings. A few commenters highlighted concerns about the ability to reach patients with a primary psychiatric diagnosis for follow-up surveys given higher rates of housing insecurity within this patient population. A few commenters recommended survey administration at discharge for this patient population.

Response: We thank the commenters for their valuable input. We will consider their feedback if we make proposals on this subject in the future.

Comment: A commenter recommended using a separate patient experience survey that addresses psychiatric care rather than the traditional HCAHPS survey.

Response: We also wish to note that currently, the HCAHPS Survey excludes discharged patients with a primary diagnosis code related to psychiatric care (discharged patients who have a secondary diagnosis code related to psychiatric care are included). During the development of the HCAHPS Survey in the early 2000s, the exclusion of discharged patients with a primary diagnosis code related to psychiatric care occurred due to concerns about the sensitivity and privacy of such information and the possible risk of harm to the patient if the primary diagnosis was disclosed during survey administration. Because patients who receive psychiatric inpatient care were excluded from development of the survey, HCAHPS may not fully address aspects of their experiences that are associated with quality care.

The Agency for Healthcare Research and Quality (AHRQ) has funded a patient experience of care survey development project that is exploring issues regarding inpatient care and patients with a primary psychiatric diagnosis. They are exploring issues around patient privacy issues, safety, and differences in state requirements, as well as the relevance of HCAHPS survey items and potential additional items for this population. The research team is following a standardized and rigorous development and testing process, including conducting Technical Expert Panels (TEPs) with relevant stakeholders and field testing. CMS plans to monitor this work closely and use information gleaned from this work to determine the best way to add patients with a primary psychiatric diagnosis to CMS’s efforts to evaluate the patient experience of care in the inpatient acute care setting.

j. Data Submission and Reporting Requirements for Structural Measures

We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51643 and 51644) and the FY 2013 IPPS/LTCH PPS final rule (77 FR 53536 and 53539) for details on the data submission requirements for structural measures. Hospitals are required to submit information for structural measures once annually using a CMS-approved web-based data collection tool available within the HQR System. The data submission period for structural measures begins in April and has the same submission deadline as the fourth calendar quarter chart-abstracted measure deadline. For example, for the FY 2025 payment determination, hospitals will be required to submit the required information between April 1, 2024, and May 15, 2024, with respect to the measure reporting period of January 1, 2023, through December 31, 2023.

We did not propose any changes to these policies in the proposed rule.

k. Data Submission and Reporting Requirements for CDC NHSN Measures

For details on the data submission and reporting requirements for measures reported via the CDC’s National Healthcare Safety Network (NHSN), we refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51629 through 51644) and the FY 2013 IPPS/LTCH PPS final rule (77 FR 53536 and 53539), the FY 2014 IPPS/LTCH PPS final rule (78 FR 50821 and 50822), and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50259 through 50262). The data submission deadlines are posted on the QualityNet website at: https://qualitynet.cms.gov (or other successor CMS designated websites).

We did not propose any changes to these policies in the proposed rule.
I. Data Submission and Reporting Requirements for Patient-Reported Outcome-Based Performance Measures (PRO–PMs)

In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49246 through 49257), we finalized the adoption of the hospital-level THA/TKA PRO–PM into the Hospital IQR Program measure set. In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49305), we further finalized the reporting and submission requirements for PRO–PM measures as a new type of measure to the Hospital IQR Program (87 FR 49305 through 49308).

We did not propose any changes to these policies in the proposed rule.

11. Validation of Hospital IQR Program Data

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27115 through 27116), we proposed to update our targeting criteria for validation of hospitals granted an extraordinary circumstances exception (ECE).

Specifically, we proposed to modify the validation targeting criteria to include any hospital with a two-tailed confidence interval that is less than 75 percent and which submitted less than four quarters of data due to receiving an ECE for one or more quarters, beginning with the FY 2027 payment determination.

a. Background

We refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53539 through 53553), the FY 2014 IPPS/LTCH PPS final rule (78 FR 50822 through 50835), the FY 2015 IPPS/LTCH PPS final rule (79 FR 50262 through 50273), the FY 2016 IPPS/LTCH PPS final rule (80 FR 49710 through 49712), the FY 2017 IPPS/LTCH PPS final rule (81 FR 57173 through 57181), the FY 2018 IPPS/LTCH PPS final rule (82 FR 38398 through 38403), the FY 2019 IPPS/LTCH PPS final rule (83 FR 41607 and 41608), the FY 2020 IPPS/LTCH PPS final rule (84 FR 42509), the FY 2021 IPPS/LTCH PPS final rule (85 FR 58942 through 58953), the FY 2022 IPPS/LTCH PPS final rule (86 FR 45423 through 45426), and the FY 2023 IPPS/LTCH PPS final rule (87 FR 49308 through 49310) for detailed information on and previous changes to chart-abstracted and eCQM data validation requirements for the Hospital IQR Program.

In the FY 2021 IPPS/LTCH PPS final rule, we combined the validation processes for eCQMs and chart-abstracted measures. In that rule, we adopted a policy to remove the separate process for eCQM validation, beginning with the validation affecting the FY 2024 payment determination (for validation commencing in CY 2022 using data from the CY 2021 reporting period) (85 FR 58942 through 58953).

Beginning with validation affecting the FY 2024 payment determination and subsequent years, we finalized a policy to incorporate eCQMs into the existing validation process for chart-abstracted measures such that there will be one pool of hospitals selected through random selection and one pool of hospitals selected using targeting criteria, for both chart-abstracted measures and eCQMs (85 FR 58942 through 58953).

Under the aligned validation process, a single hospital could be selected for validation of both eCQMs and chart-abstracted measures and is expected to submit data for both chart-abstracted measures and eCQMs (85 FR 58942 through 58953).

We refer readers to the FY 2017 IPPS/LTCH PPS final rule (81 FR 57179 and 57180) for details on the Hospital IQR Program data submission requirements for chart-abstracted measures.

We select a random sample of up to 200 hospitals for validation purposes, and select up to 200 additional hospitals for validation purposes based on the following targeting criteria:

• Any hospital with abnormal or conflicting data patterns. One example of an abnormal data pattern would be if a hospital has extremely high or extremely low values for a particular measure. As described in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53552), we define an extremely high or low value as one that falls more than three standard deviations from the mean which is consistent with the Hospital Outpatient Quality Reporting (OQR) Program (76 FR 74485). An example of a conflicting data pattern would be if two records were identified for the same patient episode of care but the data elements were mismatched for primary diagnosis. Primary diagnosis is just one of many fields that should remain constant across measure sets for an episode of care. Other examples of fields that should remain constant across measure sets are patient age and sex. Any hospital not included in the base validation annual sample and with statistically significantly more abnormal or conflicting data patterns per record than would be expected based on chance alone (p < .05), would be included in the population of hospitals targeted in the supplemental sample.

• Any hospital with rapidly changing data patterns. For this targeting criterion, we define a rapidly changing data pattern which improves its quality for one or more measures by more than two standard deviations from one year to the next and has a statistically significant difference in improvement (one-tailed p < .05) (77 FR 53553).

Any hospital that submits data to NHSN after the Hospital IQR Program data submission deadline has passed.

Any hospital that joined the Hospital IQR Program within the previous three years, and which has not been previously validated.

Any hospital that has not been randomly selected for validation in any of the previous three years.

Any hospital that passed validation in the previous year, but had a two-tailed confidence interval that included 75 percent.

Any hospital which failed to report to NHSN at least half of actual HAI events detected as determined during the previous year's validation effort.

b. Addition of Targeting Criterion for Validation

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27115 through 27116), beginning with validations of CY 2024 reporting period data for the FY 2027 payment determination, we proposed to add a new criterion to the six established targeting criteria used to select up to 200 additional hospitals for validation. We proposed that a hospital with less than four quarters of data subject to validation due to receiving an ECE for one or more quarters and with a two-tailed confidence interval that is less than 75 percent would be targeted for validation in the subsequent validation year. These hospitals would not fail the validation-related requirements for the Annual Payment Update (APU) determination for the payment year for which an ECE provides hospitals with an exception from data reporting or validation requirements. These hospitals could be selected for validation in the following year. We proposed this additional criterion because such a hospital would have less than four quarters of data available for validation and its validation results could be considered inconclusive for a payment determination. Hospitals that meet this criterion will be required to submit medical records to the CDAC contractor within 30 days of the date identified on the written request as finalized in the FY 2017 IPPS/LTCH PPS final rule (81 FR 57179 and 57180).

It is important to clarify that, consistent with our previously finalized policy, a hospital is subject to both payment reduction and targeting for validation in the subsequent year if it either: (a) has less than four quarters of data, but does not have an ECE for one
more or more quarters and does not meet the 75 percent threshold; or (b) has four quarters of data subject to validation and does not meet the 75 percent threshold (77 FR 53539 through 53553).

Specifically, we proposed to add the following criterion for targeting up to 200 additional hospitals for validation:

• Any hospital with a two-tailed confidence interval that is less than 75 percent, and that had less than four quarters of data due to receiving an ECE for one or more quarters.

Our proposal was intended to allow us to appropriately address instances in which hospitals that submit fewer than four quarters of data due to receiving an ECE for one or more quarters might face payment reduction under the current validation policies. This proposal was also to align targeting criteria across the Hospital IQR and Hospital OQR Programs. In the CY 2023 OPPS/ASC final rule, we finalized the addition of this criterion to the Hospital OQR Program’s targeting criteria for validation selection beginning with validations affecting the CY 2023 reporting period/CY 2025 payment determination (87 FR 72115 and 72116).

We invited public comment on our proposal.

Comment: A few commenters supported the proposed update to the targeting criterion.

Response: We thank commenters for their support.

After consideration of the public comments we received, we are finalizing our proposal as proposed.

12. Data Accuracy and Completeness

Acknowledgement (DACA) Requirements

We refer readers to the FY 2013 IPPS/LTCPPS final rule (77 FR 53554) for previously adopted details on DACA requirements.

We did not propose any changes to this policy in the proposed rule.

13. Public Display Requirements

Section 1886(b)(3)(B)(vii)(VII) of the Act requires the Secretary to report quality measures of process, structure, outcome, patients’ perspectives on care, efficiency, and costs of care that relate to services furnished in inpatient settings in hospitals on the internet website of CMS. Section 1886(b)(3)(B)(vii)(VII) of the Act also requires that the Secretary establish procedures for making information regarding measures available to the public after ensuring that a hospital has the opportunity to review its data before they are made public. Our current policy is to report data from the Hospital IQR Program as soon as it is feasible on CMS websites such as the Compare tool hosted by HHS, currently available at: https://www.medicare.gov/care-compare, or its successor website, after a 30-day preview period (78 FR 50776 through 50778). We refer readers to the FY 2008 IPPS/LTCPPS final rule (72 FR 47364), the FY 2011 IPPS/LTCPPS final rule (75 FR 50230), the FY 2012 IPPS/LTCPPS final rule (76 FR 51650), the FY 2013 IPPS/LTCPPS final rule (77 FR 53554), the FY 2014 IPPS/LTCPPS final rule (78 FR 50836), the FY 2015 IPPS/LTCPPS final rule (79 FR 50277), the FY 2016 IPPS/LTCPPS final rule (80 FR 49712 and 49713), the FY 2017 IPPS/LTCPPS final rule (81 FR 57181), the FY 2018 IPPS/LTCPPS final rule (82 FR 38403 through 38409), the FY 2019 IPPS/LTCPPS final rule (83 FR 41538 and 41539), the FY 2020 IPPS/LTCPPS final rule (84 FR 42509), the FY 2021 IPPS/LTCPPS final rule (85 FR 58953), the FY 2022 IPPS/LTCPPS final rule (86 FR 45426), and the FY 2023 IPPS/LTCPPS final rule (87 FR 49310) for details on public display requirements.

We did not propose any changes to these policies in the proposed rule.

a. Public Reporting of eCQM Data

We refer readers to the FY 2021 IPPS/LTCPPS final rule (85 FR 58953 through 58959) where we finalized public reporting requirements of eCQM data reported by hospitals for the CY 2021 reporting period/FY 2023 payment determination and subsequent years.

In the FY 2023 IPPS/LTCPPS final rule, we finalized policies that further incrementally increases eCQM data that is publicly reported from four to six eCQMs for the CY 2024 reporting period/FY 2026 payment determination and subsequent years (87 FR 49298 through 49302). We refer readers to section IX.C.10.e. of the proposed rule (88 FR 27110 through 27112) for a discussion of our previously finalized eCQM reporting and submission policies.

We did not propose any changes to these policies in the proposed rule.

b. Overall Hospital Star Ratings

In the CY 2021 OPPS/ASC final rule with comment period and interim final rule with comment period (85 FR 86193 through 86236), we finalized a methodology to calculate the Overall Hospital Quality Star Rating (Overall Star Ratings). The Overall Star Ratings utilizes data collected on hospital inpatient and outpatient measures that are publicly reported on a CMS website, including data from the Hospital IQR Program. We refer readers to section XVI of the CY 2021 OPPS/ASC final rule with comment period for details (85 FR 86193 through 86236).

We did not propose any changes to these policies in the proposed rule.

14. Reconsideration and Appeal Procedures

We refer readers to the FY 2012 IPPS/LTCPPS final rule (76 FR 51650 and 51651), the FY 2014 IPPS/LTCPPS final rule (78 FR 50836 and 50837), and 42 CFR 412.140(e) for details on reconsideration and appeal procedures for the FY 2017 payment determination and subsequent years.

We did not propose any changes to these policies in the proposed rule.

15. Hospital IQR Program Extraordinary Circumstances Exceptions (ECE) Policy

We refer readers to the FY 2012 IPPS/LTCPPS final rule (76 FR 51650 and 51651), the FY 2014 IPPS/LTCPPS final rule (78 FR 50836 and 50837), the FY 2015 IPPS/LTCPPS final rule (79 FR 50277), the FY 2016 IPPS/LTCPPS final rule (80 FR 49713), the FY 2017 IPPS/LTCPPS final rule (81 FR 57181 and 57182), the FY 2018 IPPS/LTCPPS final rule (82 FR 38409 through 38411), and 42 CFR 412.140(c)(2) for details on the current Hospital IQR Program ECE policy. We also refer readers to the QualityNet website at: https://qualitynet.cms.gov for our current requirements for submission of a request for an exception.

We did not propose any changes to these policies in the proposed rule.

D. Updates to the PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program

1. Background

The PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program is authorized by section 1866(k) of the Act and applies to hospitals described in section 1886(d)(1)(B)(v) (referred to as “PPS-Exempt Cancer Hospitals” or “PCHs”). For additional background information, including previously finalized measures and other policies for the PCHQR Program, we refer readers to the following final rules:

• The FY 2013 IPPS/LTCPPS final rule (77 FR 53555 through 53567);
• The FY 2014 IPPS/LTCPPS final rule (78 FR 50837 through 50853);
• The FY 2015 IPPS/LTCPPS final rule (79 FR 50277 through 50286);
• The FY 2016 IPPS/LTCPPS final rule (80 FR 49713 through 49723);
• The FY 2017 IPPS/LTCPPS final rule (81 FR 57181 through 57193);
• The FY 2018 IPPS/LTCPPS final rule (82 FR 38411 through 38425);
2. Measure Retention and Removal Factors for the PCHQR Program

For a detailed discussion regarding our retention and removal factors, we refer readers to the FY 2017 IPPS/LTC PPS final rule (81 FR 57182 through 57183), where we adopted policies for measure retention and removal, the FY 2019 IPPS/LTC PPS final rule (83 FR 41609 through 41611), where we updated our measure retention factors, and the FY 2023 IPPS/LTC PPS final rule (87 FR 49311 through 49311), where we updated our measure removal policy. We did not propose any changes to our measure removal or retention policies.

We proposed to adopt four new measures for the PCHQR Program: (i) three health equity-focused measures: the Facility Commitment to Health Equity measure, the Screening for Social Drivers of Health measure, and the Preference-focused measure, the Drivers of Health measure, and (ii) a patient preference-focused measure, the Documentation of Goals of Care Discussions Among Cancer Patients measure (86 FR 27177 through 27178, 27178 through 27172 through 27130). We also referred readers to the proposed modifications of the COVID-19 Vaccination Coverage Among Healthcare Personnel (HCP) measure in the PCHQR, Hospital Inpatient Quality Reporting, and Long-Term Care Hospital Quality Reporting Programs and refer readers to section IX.B. of this final rule.

3. Adoption of the Facility Commitment to Health Equity Measure Beginning With the FY 2026 Program Year

a. Background

Significant and persistent disparities in healthcare outcomes exist in the U.S. For example, belonging to a racial or ethnic minority group, being a member of the lesbian, gay, bisexual, transgender, and queer (LGBTQ+) community, being a member of a religious minority, living in a rural area, being a person with a disability or


631 Additional inequities in the drivers of health affecting these groups, such as

poverty and healthcare access, are interrelated and influence a wide range of health and quality-of-life outcomes and risks.632

In the FY 2022 IPPS/LTC PPS proposed rule (86 FR 25601), the PCHQR Program requested information on our Equity Plan for Improving Quality in Medicare, which outlines our commitment to improved data collection to better measure and analyze disparities across programs and policies in order to close equity gaps. The request for information asked for public comment regarding the potential stratification of quality measure results by race and ethnicity and the potential creation of a hospital equity score in CMS quality reporting and value-based purchasing programs, including the PCHQR Program.

Additionally, we note that the Agency for Healthcare Research and Quality (AHRQ) and The Joint Commission identified that hospital leadership plays an important role in promoting a culture of quality and safety.633 634 635 AHRQ research shows that hospital boards can influence quality and safety in a variety of ways; not only through strategic initiatives, but also through more direct interactions with frontline workers.636 Because we are working toward the goal of all patients receiving high-quality healthcare, regardless of individual characteristics, we are committed to supporting healthcare organizations in building a culture of safety and equity that focuses on educating and empowering their workforce to recognize and eliminate health disparities. This includes patients receiving the right care, at the right time, in the right setting for their condition(s), regardless of those characteristics.

In alignment with the same measures adopted for the Hospital IQR Program, we believe that strong and committed leadership from PCH executives and board members is essential and can play a role in shifting organizational culture and advancing equity goals for PCHs. Studies demonstrate that hospital leadership can positively influence culture for better quality, patient outcomes, and experience of care.637 638 639 A systematic review of 122 published studies showed that strong leadership that prioritized safety, quality, and the setting of clear guidance with measurable goals for improvement resulted in a high-performing hospital with better patient outcomes.640 We believe leadership commitment to health equity will have a parallel effect in contributing to a reduction in health disparities.

The Institute for Healthcare Improvement’s (IHI’s) research of 23 health systems throughout the U.S. and Canada also shows that health equity must be a priority championed by leadership teams to improve both patient access to needed healthcare services and outcomes among populations that have been disadvantaged by the healthcare system.641 This IHI study specifically identified concrete actions to make advancing health equity a core strategy, including establishing this goal as a leader-driven priority alongside organizational development structures and processes.642 Based upon these findings, we believe that PCH leadership can be instrumental in setting specific, measurable, attainable, realistic, and time-based (SMART) goals to assess progress towards achieving equity goals and ensuring high-quality care is accessible to all. Therefore, we proposed to adopt an attestation-based structural measure, Facility Commitment to Health Equity, beginning with the FY 2026 program.

The first pillar of our strategic priorities643 reflects our deep commitment to improvements in health equity by addressing the health disparities that underly our health system. In line with this strategic pillar, we developed this structural measure to assess facility commitment to health equity across five domains (see Table IX.D–01) using a suite of organizational competencies aimed at achieving health equity for racial and ethnic minority groups, people with disabilities, members of the LGBTQ+ community, individuals with limited English proficiency, rural populations, religious minorities, and people facing socioeconomic challenges. We believe these elements are actionable focus areas and assessment of PCH leadership commitment to them is foundational.

We also believe this measure will incentivize PCHs to collect and utilize data to identify critical equity gaps, implement plans to address said gaps, and ensure that resources are dedicated toward addressing health equity initiatives. While many factors contribute to achieving health equity, we believe this measure is an important step toward assessing PCH leadership commitment, and a fundamental step toward closing the gap in equitable care for all populations. We note that this measure is not intended to encourage PCHs to act on any one data element or domain, but instead encourages PCHs to analyze their own findings to understand if there are any demographic factors (for example, race, national origin, primary language, and ethnicity), as well as social determinant of health information (for example, housing status and food security) associated with underlying inequities; and, in turn, develop solutions to deliver more equitable care. Thus, the measure aims to support PCHs in leveraging available data, pursuing focused quality improvement activities, and promoting efficient and effective use of resources.

The five questions of the structural measure are adapted from the CMS Office of Minority Health’s Building an
Organizational Response to Health Disparities framework, which focuses on data collection, data analysis, culture of equity, and quality improvement. The measure aligns with the measure previously adopted in the Hospital IQR Program, and we refer readers to the FY 2023 IPPS/LTCH PPS final rule (87 FR 49191 through 49201). This measure also aligns with our efforts under the Meaningful Measures Framework, which identifies high-priority areas for quality measurement and improvement to assess core issues most critical to high-quality healthcare and improving patient outcomes. In 2021, we launched Meaningful Measures 2.0 to promote innovation and modernization of all aspects of quality, and to address a wide variety of settings, stakeholders, and measure requirements. We are addressing healthcare priorities and gaps with Meaningful Measures 2.0 by leveraging quality measures to promote equity and close gaps in care. The Facility Commitment to Health Equity measure supports these efforts and is aligned with the Meaningful Measures Area of “Equity of Care” and the Meaningful Measures 2.0 goal to “Leverage Quality Measures to Promote Equity and Close Gaps in Care.” This measure also supports the Meaningful Measures 2.0 objective to “Commit to a patient-centered approach in quality measure and value-based incentives programs to ensure that quality and safety measures address healthcare equity.”

b. Overview of Measure

The Facility Commitment to Health Equity measure assesses PCH commitment to health equity using a suite of equity-focused organizational competencies aimed at achieving health equity for populations that have been disadvantaged, marginalized, and underserved by the healthcare system. As previously noted, this includes, but is not limited to racial and ethnic minority groups, people with disabilities, members of the LGBTQ+ community, individuals with limited English proficiency, rural populations, religious minorities, and people facing socioeconomic challenges. Table IX.D–01 includes the five attestation domains and the elements within each of those domains to which a PCH will affirmatively attest for the PCH to receive credit for that domain.

---


### TABLE IX.D.-01: THE FACILITY COMMITMENT TO HEALTH EQUITY MEASURE’S FIVE ATTESTATIONS*

<table>
<thead>
<tr>
<th>Attestation</th>
<th>Elements: Select all that apply</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Domain 1: Equity is a Strategic Priority</strong></td>
<td>(A) Our facility strategic plan identifies priority populations who currently experience health disparities.</td>
</tr>
<tr>
<td>Facility commitment to reducing healthcare disparities is strengthened</td>
<td>(B) Our facility strategic plan identifies health equity** goals and discrete action steps to achieving these goals.</td>
</tr>
<tr>
<td>when equity is a key organizational priority. Please attest that your hospital</td>
<td>(C) Our facility strategic plan outlines specific resources which have been dedicated to achieving our equity goals.</td>
</tr>
<tr>
<td>has a strategic plan for advancing health equity** and that it includes</td>
<td>(D) Our facility strategic plan describes our approach for engaging key stakeholders, such as community-based organizations.</td>
</tr>
<tr>
<td>all the following elements.</td>
<td></td>
</tr>
<tr>
<td><strong>Domain 2: Data Collection</strong></td>
<td>(A) Our facility collects demographic information, *** such as self-reported race, national origin, primary language, and ethnicity data) and/or social determinant of health information on the majority of our patients.</td>
</tr>
<tr>
<td>Collecting valid and reliable demographic and social determinant of health</td>
<td>(B) Our facility has training for staff in culturally sensitive collection of demographic and/or social determinant of health information.</td>
</tr>
<tr>
<td>data on patients served in a facility is an important step in identifying</td>
<td>(C) Our facility inputs demographic and/or social determinant of health information collected from patients into structured, interoperable data elements using certified EHR technology.</td>
</tr>
<tr>
<td>and eliminating health disparities. Please attest that your hospital</td>
<td></td>
</tr>
<tr>
<td>engages in the following activities.</td>
<td></td>
</tr>
<tr>
<td><strong>Domain 3: Data Analysis</strong></td>
<td>(A) Our facility stratifies key performance indicators by demographic and/or social determinants of health variables to identify equity gaps and includes this information on hospital performance dashboards.</td>
</tr>
<tr>
<td>Effective data analysis can provide insights into which factors contribute</td>
<td></td>
</tr>
<tr>
<td>to health disparities and how to respond. Please attest that your facility</td>
<td></td>
</tr>
<tr>
<td>engages in the following activities.</td>
<td></td>
</tr>
<tr>
<td><strong>Domain 4: Quality Improvement</strong></td>
<td>(A) Our facility participates in local, regional, or national quality improvement activities focused on reducing health disparities.</td>
</tr>
<tr>
<td>Health disparities are evidence that high-quality care has not been</td>
<td></td>
</tr>
<tr>
<td>delivered equitably to all patients. **** Engagement in quality improvement</td>
<td></td>
</tr>
<tr>
<td>activities can improve quality of care for all patients.</td>
<td></td>
</tr>
<tr>
<td><strong>Domain 5: Leadership Engagement</strong></td>
<td>(A) Our facility senior leadership, including chief executives and the entire facility board of trustees, annually reviews our strategic plan for achieving health equity.</td>
</tr>
<tr>
<td>Leaders and staff can improve their capacity to address disparities by</td>
<td>(B) Our facility senior leadership, including chief executives and the entire facility board of trustees, annually reviews key performance indicators stratified by demographic and/or social factors.</td>
</tr>
<tr>
<td>demonstrating routine and thorough attention to equity and setting an</td>
<td></td>
</tr>
<tr>
<td>organizational culture of equity. Please attest that your facility</td>
<td></td>
</tr>
<tr>
<td>engages in the following activities.</td>
<td></td>
</tr>
</tbody>
</table>
c. Measure Calculation

The Facility Commitment to Health Equity measure consists of five attestation-based questions, each representing a separate domain of commitment. Some of the domains have multiple elements to which a PCH will be required to attest. For a PCH to affirmatively attest "yes" to a domain, and receive credit for that domain, the PCH will evaluate and determine whether it engages in each of the sub-elements that comprise the domain. PCHs will only receive a point for each domain if they attest "yes" to all related sub-elements. There is no "partial credit" for sub-elements. Each of the domains will be represented in the denominator as a point, for a total of 5 points (one per domain).

For example, for Domain 1 ("Facility commitment to reducing healthcare disparities is strengthened when equity is a key organizational priority"), a PCH will evaluate and determine whether its strategic plan meets each of the elements described in (A) through (D) (see Table IX.D.-01). If the PCH's plan meets all four of these elements, the PCH will affirmatively attest to Domain 1 and receive one (1) point for that attestation. A PCH will not be able to receive partial credit for a domain. In other words, if a PCH's strategic plan meets elements (A) and (B) but not (C) and (D), the PCH will not be able to affirmatively attest to Domain 1 and will not receive a point for that attestation. The numerator will capture the total number of domain attestations to which the PCH is able to affirm. For example, a PCH that affirmatively attests each element of the 5 domains will receive the maximum 5 points.

Specifications for the measure are available on the CMS Measure Inventory page with the file name "Facility Commitment to Health Equity Measure Specifications" at: https://cmhit.cms.gov/cmit/#/.

d. Data Submission and Reporting

In the proposed rule, we proposed to require PCHs to submit information for the Facility Commitment to Health Equity measure once on an annual basis using a CMS-approved web-based data collection tool available within the Hospital Quality Reporting (HQR) System beginning with the FY 2026 program year. PCHs will follow the submission and reporting requirements for web-based measures for the PCHQR Program posted on the QualityNet website.

e. Review by the Measure Applications Partnership

The Facility Commitment to Health Equity measure was included for consideration in the PCHQR Program on the publicly available "List of Measures Under Consideration for December 1, 2022" (MUC List), a list of measures under consideration for use in various Medicare quality programs. The CBE-convened Measure Applications Partnership (MAP) Health Equity Advisory Group reviewed the MUC List and the Facility Commitment to Health Equity measure (MUC2022-027) in detail on December 6–7, 2022. The Health Equity Advisory Group expressed concerns that this is more of a "checklist" measure that may not directly address health inequities at a systemic level, but the advisory group generally agreed that a structural measure such as this one represents progress toward improving equitable care. In addition, on December 8–9, 2022, the MAP Rural Health Advisory Group reviewed the 2022 MUC List, and the MAP Hospital Workgroup reviewed the 2022 MUC List on December 13–14, 2022. The MAP recognized that reducing health care disparities would represent a substantial benefit to overall quality of care, but expressed reservations about the measure's link to clinical outcomes; the MAP Workgroup members voted to conditionally support the measure for rulemaking pending: (1) endorsement by a consensus-based entity (CBE); (2) committing to look at outcomes in the future; (3) providing more clarity on the measure; and (4) supplementing interpretations with results; and (4) verifying attestation provided by the accountable entities. Thereafter, the MAP Coordinating Committee deliberated on January 24–25, 2023, and ultimately voted to conditionally support the Facility Commitment to Health Equity measure for rulemaking with the same conditions.

We believe this measure establishes an important foundation to prioritize the achievement of health equity among PCHs. Our approach to developing equity-focused measures has been incremental to date, but we see inclusion of such measures in the PCHQR Program as informing efforts to advance and achieve health equity among PCHs by allowing for the recognition and tracking of disparities for the population served by PCHs. We additionally believe this measure to be a building block that lays the groundwork for a future meaningful suite of measures that could assess PCH progress in providing high-quality healthcare for all patients, regardless of social risk factors or demographic characteristics.
f. Consensus-Based Entity Endorsement

We have not submitted this measure for consensus-based entity (CBE) endorsement at this time. Although section 1866(k)(3)(A) of the Act generally requires that measures specified by the Secretary for use in the PCHQR Program be endorsed by the entity with a contract under section 1890(a) of the Act, section 1866(k)(3)(B) of the Act states that in the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed by the entity with a contract under section 1890(a) of the Act, the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary. We reviewed CBE-endorsed measures and were unable to identify any other CBE-endorsed measures on this topic, and, therefore, we believe the exception in section 1866(k)(3)(B) of the Act applies.

We invited public comment on this proposal.

Comment: Many commenters expressed support for the measure believing it promotes health equity. A commenter expressed support for the measure because the measure includes several important domains of health equity, requiring inclusion in strategic plans, assessment of a commitment to data collection and reporting, and stratification of data that will show whether there is improvement over time. Another commenter expressed its belief that the measure can incentivize hospitals to collect and use data to identify and address quality gaps. Another commenter expressed support for the measure believing it assesses important aspects of a hospital’s commitment to health equity including an organizational commitment to reducing health disparities, collecting demographic data, and training staff on best practices for data collection. Another commenter expressed its support for the measure believing it supports efforts to identify and track institutional biases in the reimbursement structure and healthcare system.

Response: We thank commenters for their support of our proposal to adopt the Facility Commitment to Health Equity measure. We agree that the measure assesses important aspects of a PCH’s commitment to health equity and will incentivize the collection and use of data by PCHs to address health equity to identify and address quality gaps and deliver equitable culturally competent care to all patients.

Comment: A few commenters expressed support for the measure with some concerns including that the measure should be monitored for unintended consequences and updating, that the data lack reliability or validity testing in the PCH setting, and that the measure may require data from outside of the hospital-setting. Another commenter recommended analyzing lessons learned from the Hospital IQR Program to inform implementation strategy.

Response: We appreciate the commenters’ support and recommendations. We also understand commenters’ concerns regarding the accuracy of provider self-reported data; however, while we do not have a specific means to validate PCHs’ attestation to this measure, we do require all PCHs participating in the PCHQR Program to complete the Data Accuracy and Completeness Acknowledgement (DACA) each year which requires attestation that the quality measure results and any and all data including numerator and denominator data provided are accurate and complete. For more information on the PCHQR Program’s DACA requirements, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53563). We also acknowledge commenters’ desire to be able to learn from the experiences of PCH reporting of this measure over time. We note that the Hospital IQR Program adopted the Facility Commitment to Health Equity measure last year and that hospitals participating in the Hospital IQR Program will have already reported data on this measure before the reporting of the Facility Commitment to Health Equity Measure for the PCHQR Program begins, so we believe PCHs will have the opportunity to learn from the experiences of hospitals when hospital data is publicly reported in addition to monitoring the experience of PCHs when data reporting is required.

Comment: A commenter expressed its belief that the data should be standardized and validated and collected in a way that minimizes burden. A commenter expressed concern that the measure may add burden without demonstrable benefits because it only requires attestation.

Response: We recognize the commenter’s concerns about burden of participating in the PCHQR Program and have aligned PCHQR Program measures with the Hospital IQR Program as appropriate, including the reporting of the Facility Commitment to Health Equity measure. We also believe the benefits of encouraging PCH commitment to health equity outweigh the burden of attestation under this measure.

Comment: A commenter recommended the measure be submitted for CBE review and endorsement.

Response: While we recognize the value of measures undergoing CBE endorsement review, measures of health equity are a priority for CMS, and we believe it is important to implement this measure as soon as possible. We note that under section 1886(s)(4)(D)(ii) of the Act the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary. We reviewed CBE-endorsed measures and were unable to identify any other CBE-endorsed measures on this topic, and, therefore, we believe the exception in section 1886(s)(4)(D)(ii) of the Act applies. We believe the Facility Commitment to Health Equity measure is sufficiently accurate and reliable without CBE endorsement, noting its adoption in the Hospital IQR Program, and that this measure establishes an important foundation to prioritize the achievement of health equity among PCHs.

Comment: A commenter expressed support and requested more data on how high- and low-quality care facilities will be differentiated and used for quality improvement versus penalties.
Response: We believe strong and committed leadership from PCH executives and board members is essential and can play a role in advancing equity goals for PCHs. The measure is intended to provide information to PCHs on the level of unmet need among their patients and potentially in the community and not for comparison between PCHs. We believe this measure is an important step toward assessing PCH leadership commitment and a fundamental step toward closing the gap in equitable care for all populations. The PCHQR Program does not include a financial incentive or penalty for PCHs, and we encourage providers to analyze their own data to understand the many factors, including race, ethnicity, and various drivers of health, such as housing stability and food security, to deliver more equitable care and, in turn, improve patient outcomes.

Comment: A commenter recommended CMS revisit the measure as more sophisticated measures are developed and assess outcomes. Another commenter recommended CMS consider measuring other concepts such as accessibility and appropriateness of services, forming the right community partnerships, and improving patient experiences by reducing discrimination and implicit bias.

Response: We appreciate the commenter’s recommendations and believe this measure to be a building block that lays the groundwork for a more comprehensive suite of measures that could assess progress in providing high-quality healthcare for all patients regardless of social risk factors or demographic characteristics. A more comprehensive suite of measures could potentially include health equity-related outcome measures.

Comment: A commenter recommended that CMS delay public reporting until the data's accuracy are verified. Another commenter recommended making reporting voluntary and not subject to public display for the first year of the measure in the program.

Response: We believe that adopting the Facility Commitment to Health Equity measure beginning with the CY 2026 program year and displaying the data publicly beginning July 2026 or as soon as feasible thereafter would allow PCHs the opportunity to review the accuracy of their data prior to public display and refer readers to Table IX.D.–04 for our finalized public display requirements.

Comment: A commenter did not support the measure believing it is built on the false premise not supported by evidence that medical institutions are mired by bigotry, racism, and discrimination. The commenter expressed its belief that disparate health outcomes should not be assumed to be a direct result of quality of care provided by a hospital. The commenter also expressed concerns that the proposal would force cancer hospitals to make a commitment to health equity beginning in FY 2026 with an adjustment to the funding formula.

Response: We believe this measure is an important foundational measure for improving health equity among those that have been disadvantaged or underserved by the healthcare system, and there is substantial research showing differences in care and experiences among these populations and refer readers to the literature discussed in this section. We encourage providers to analyze their own data to understand the many factors, including race, ethnicity, and various drivers of health, such as housing stability and food security, to deliver more equitable care and in turn improve patient outcomes for all patients. We also believe the public display of data provides the opportunity for CMS, patients, and other stakeholders to recognize PCHs that provide equitable health care and refer readers to Table IX.D.–04 for our finalized public display requirements.

After consideration of the public comments we received, we are finalizing this measure.

4. Adoption of the Screening for Social Drivers of Health Measure Beginning With Voluntary Reporting for the FY 2026 Program Year and Mandatory Reporting Beginning With the FY 2027 Program Year

Health-related social needs (HRSNs), which we define as individual-level, adverse social conditions that negatively impact a person's health or healthcare, are significant risk factors associated with worse health outcomes as well as increased healthcare utilization. We believe that consistently pursuing identification of HRSNs will have two significant benefits. First, these social risk factors disproportionately impact populations that have historically been underserved by the healthcare system and screening helps identify individuals who may have HRSNs.

Second, screening for social risk factors could support ongoing PCH quality improvement initiatives by providing data with which to stratify patient risk and organizational performance. Further, we believe collecting patient-level HRSN data through screening is essential for the long-term in encouraging meaningful collaboration between healthcare providers and community-based organizations, and in implementing and evaluating related innovations in health and social care delivery.

As a first step towards leveraging the opportunity to close equity gaps by identifying patients’ HRSNs, we finalized the adoption of two evidence-based measures in the Hospital IQR Program, the Screening for Social Drivers of Health measure and the Screen Positive Rate for Social Drivers of Health measure in the FY 2023 IPPS/ LTCH PPS final rule (FR 27726 through 49220). These two social drivers of health measures support identification of specific risk factors for inadequate healthcare access and adverse health outcomes among patients. These measures also enable systematic collection of HRSN data. This activity aligns with our other efforts beyond the acute care setting, including the CY 2023 Medicare Advantage and Part D final rule in which we finalized the policy requiring that all Special Needs Plans (SNPs) include one or more questions on housing stability, food security, and access to transportation in their Health Risk Assessment (HRA) using questions from a list of screening instruments specified in sub-regulatory guidance (87 FR 27726 through 27740), as well as the CY 2023 PFS final rule in which we adopted the Screening for Social Drivers of Health measure in the Merit-based Incentive Payment System (87 FR 70054 through 70055).

These measures will allow PCHs to identify patients with HRSNs, who are known to experience the greatest risk of poor health outcomes, thereby improving the accuracy of high-risk prediction calculations. Improvement in risk prediction has the potential to reduce healthcare access barriers, address the disproportionate expenditures attributed to populations with greatest risk, and improve the...
Further, these data could guide future public and private resource allocation to promote focused collaboration between PCHs, health systems, community-based organizations, and others in support of improving patient outcomes.

We provide further details on each measure in the subsequent discussion and section I.D.5. of the preamble of this final rule.

a. Background

Health disparities manifest primarily as worse health outcomes in population groups where access to care is inequitably,661 662 663 664 665 Such differences persist across geography and healthcare settings irrespective of improvements in quality of care over time.666 667 668 Assessment of HRSNs is an essential mechanism for capturing the interaction between social, community, and environmental factors associated with health status and health outcomes.669 670 671 Growing evidence demonstrates that specific social risk factors are directly associated with patient health outcomes as well as healthcare utilization, costs, and performance in quality reporting and payment programs.672 673 While widespread interest in addressing HRSNs exists, action is inconsistent, with 92 percent of hospitals screening for one or more live HRSNs—food insecurity, housing instability, transportation needs, utility difficulties, and interpersonal safety—specified in the Screening for Social Drivers of Health and the Screen Positive for Social Drivers of Health measures, but only 24 percent of hospitals screening for all five HRSNs.674

In 2017, CMS’s Center for Medicare and Medicaid Innovation launched the Accountable Health Communities (AHC) Model to test the impact of systematically identifying and addressing the HRSNs of community-dwelling Medicare and Medicaid beneficiaries (through screening, referral, and community navigation on their health outcomes and related healthcare utilization and costs).675 676 677 678 The AHC Model is one of the first Federal pilots to systematically test whether identifying and addressing core HRSNs improves healthcare costs, utilization, and outcomes of participating bridge organizations.679 680 The AHC Model had a 5-year period of performance that began in May 2017 and ended in April 2022, with beneficiary screening beginning in the summer of 2018.681 682 Evaluation of the AHC Model data is still underway.

While social risk factors account for 50 to 70 percent of health outcomes, the mechanisms by which this connection emerges are complex and multifaceted.683 684 685 686 The persistent

679 Khullar, D., MD. (2020, September 8). Association Between Patient Social Risk and Continued

We note that the model officially concluded in April 2022 but many awardees are continuing with no-cost extensions to continue utilizing unspent cooperative agreement funding and all awardees will conclude by April 2023.
681 Khullar, D., MD. (2020, September 8). Association Between Patient Social Risk and Continued


associations between disproportionate health risk, hospitalization, and adverse health outcomes have been highlighted and magnified by the COVID–19 pandemic.690,691

The following five core domains were selected to screen for HRSNs among Medicare and Medicaid beneficiaries under the AHC Model: (1) food insecurity; (2) housing instability; (3) transportation needs; (4) utility difficulties; and (5) interpersonal safety. These domains were chosen based upon literature review and expert consensus utilizing the following criteria: (1) availability of high-quality scientific evidence linking a given HRSN to adverse health outcomes and increased healthcare utilization, including hospitalizations and associated costs; (2) ability for a given HRSN to be screened and identified in the inpatient setting prior to hospital discharge, addressed by community-based services, and potentially improve health care outcomes, including reduced hospital re-admissions; and (3) evidence that a given HRSN is not systematically addressed by healthcare providers.692 In addition to established evidence of their association with health status, risk, and outcomes, these five domains were also selected because they can be assessed across the broadest spectrum of individuals in a variety of settings.693,694,695

These five evidence-based HRSN domains, which informed development of the two social drivers of health measures, are described in Table IX.D–02.


These five evidence-based HRSN domains, which informed development of the two social drivers of health measures, are described in Table IX.D–02.


### TABLE IX.D.-02: THE FIVE CORE HRSN DOMAINS TO SCREEN FOR SOCIAL DRIVERS OF HEALTH

<table>
<thead>
<tr>
<th>Domain</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Food Insecurity</td>
<td>Food insecurity is defined as limited or uncertain access to adequate quality and quantity of food at the household level. It is associated with diminished mental and physical health and increased risk for chronic conditions. Individuals experiencing food insecurity often have inadequate access to healthier food options which can impede self-management of chronic diseases like diabetes and heart disease, and require individuals to make personal trade-offs between food purchases and medical needs, including prescription medication refills and preventive health.</td>
</tr>
<tr>
<td>Housing Instability</td>
<td>Housing instability encompasses multiple conditions ranging from inability to pay rent or mortgage, frequent changes in residence including temporary stays with friends and relatives, living in crowded conditions, and actual lack of sheltered housing in which an individual does not have a personal residence. Population surveys consistently show that people from some racial and ethnic minority groups constitute the largest proportion of the U.S. population experiencing unstable housing. Housing instability is associated with higher rates of chronic illnesses, injuries, and complications and more frequent utilization of high-cost healthcare services.</td>
</tr>
<tr>
<td>Transportation Needs</td>
<td>Unmet transportation needs include limitations that impede transportation to destinations required for all aspects of daily living. Groups disproportionately affected include older adults (aged ≥65 years), people with lower incomes, people with impaired mobility, residents of rural areas, and people from some racial and ethnic minority groups. Transportation needs contribute to postponement of routine medical care and preventive services which ultimately lead to chronic illness exacerbation and more frequent utilization of high-cost healthcare services including emergency medical services, Eds, and hospitalizations.</td>
</tr>
<tr>
<td>Utility Difficulties</td>
<td>Inconsistent availability of electricity, water, oil, and gas services is directly associated with housing instability and food insecurity. Specifically, interventions that increase or maintain access to such services have been associated with individual and population-level health improvements.</td>
</tr>
<tr>
<td>Interpersonal Safety</td>
<td>Interpersonal safety affects individuals across the lifespan, from birth to old age, and is directly linked to mental and physical health. Assessment for this domain includes screening for exposure to intimate partner violence, child abuse, and elder abuse. Exposure to violence and social isolation are reflective of individual-level social relations and living conditions that are directly associated with injury, psychological distress, and death in all age groups.</td>
</tr>
</tbody>
</table>
Utilization of screening tools to identify the burden of unmet HRSNs


628 For data collection of this measure, PCHs can use a self-selected screening tool and collect these data in multiple ways, which can vary to accommodate the population they serve and their individual needs. For example, the AHC Model employed a 10-item AHC Health-Related Social Needs Screening Tool to enable providers to identify HRSNs in the five core domains (described in Table IX.D.—02) among community-dwelling Medicare, Medicaid, and dually eligible beneficiaries. The AHC Model was tested across varied care-delivery sites in diverse geographic locations across the U.S. We reviewed literature that shows the Tool was evaluated psychometrically and demonstrated evidence of both reliability and validity, including inter-rater reliability and concurrent and predictive validity. Moreover, the screening instrument can be implemented in a variety of places where patients seek healthcare, including cancer hospitals, for data collection of this measure, PCHs can use a self-selected screening tool and collect these data in multiple ways, which can vary to accommodate the population they serve and their individual needs.
The intent of this measure is to promote adoption of HRSN screening by PCHs. We encourage PCHs to use the screening as a basis for developing their own individual action plans (which could include navigation services and subsequent referral), as well as an opportunity to initiate and/or improve partnerships with community-based service providers. This effort will yield actionable information to close equity gaps by encouraging PCHs to identify HRSNs; with a reciprocal goal of strengthening linkages between PCHs and community-based partners so as to promptly connect patients and families to the support they need.

Under our Meaningful Measures Framework, the Screening for Social Drivers of Health measure discussed in section IX.D.5. of the preamble of this final rule, address the quality priority of “Work with Communities to Promote Best Practices of Healthy Living” through the Meaningful Measures Area of “Equity of Care.” Additionally, pursuant to Meaningful Measures 2.0, this measure addresses the “healthcare equity” priority area and aligns with our commitment to introduce plans to close health equity gaps and promote equity through quality measures, including to “develop and implement measures that reflect social and economic determinants.” Development and proposal of this measure also align with our strategic pillar to advance health equity by addressing the health disparities that underlie our health system.

In alignment with the measure’s adoption in the Hospital IQR Program in the FY 2023 IPPS/LTCH final rule (87 FR 49202 through 49215), the Screening for Social Drivers of Health measure (alongside the Screen Positive Rate for Social Drivers of Health measure described in section IX.D.5. of the preamble of this final rule) is the first patient-level measurement of social drivers of health in the PCHQR Program. We believe this measure is appropriate for the measurement of the quality of care furnished by PCHs. Screening will allow healthcare providers to identify and potentially help address HRSNs as part of discharge planning and contribute to long-term improvements in patient outcomes. This will have a direct and positive impact on cancer hospital quality performance. Moreover, collecting baseline data via this measure is crucial in informing design of future measures that can enable us to set appropriate performance targets for PCHs.

b. Overview of Measure

The Screening for Social Drivers of Health measure will assess whether a PCH implements screening for all patients who are 18 years or older at time of admission for food insecurity, housing instability, transportation needs, utility difficulties, and interpersonal safety. To report on this measure, PCHs will provide: (1) The number of patients admitted to the PCH who are 18 years or older at time of admission and who are screened for all of the five HRSNs: Food insecurity, housing instability, transportation needs, utility difficulties, and interpersonal safety; and (2) the total number of patients who are admitted to the PCH who are 18 years or older on the date they are admitted.

Measure specifications for this measure are currently available at: https://cmit.cms.gov/cmit/#/.

(g) Cohort

The Screening for Social Drivers of Health measure will assess the total number of patients, aged 18 years and older, screened for food insecurity, housing instability, transportation needs, utility difficulties, and interpersonal safety.

(2) Numerator

The numerator consists of the number of patients who are 18 years or older on the date of their PCH admission and are screened for all of the following five HRSNs: Food insecurity, housing instability, transportation needs, utility difficulties, and interpersonal safety.

(3) Denominator

The denominator consists of the number of patients who are admitted to a PCH and who are 18 years or older on the date of admission. The following patients will be excluded from the denominator: (1) Patients who opt-out of screening; and (2) patients who are themselves unable to complete the screening during their PCH stay and have no legal guardian or caregiver able to do so on the patient’s behalf during their PCH stay.

c. Measure Calculation

The Screening for Social Drivers of Health measure will be calculated as the number of patients admitted to a PCH stay who are 18 years or older on the date of admission screened for all five HRSNs (food insecurity, housing instability, transportation needs, utility difficulties, and interpersonal safety) divided by the total number of patients 18 years or older on the date of admission admitted to the PCH.

D. Data Submission and Reporting

In the proposed rule, we proposed to require PCHs to report this measure on an annual basis beginning with voluntary reporting in the FY 2026 program year and mandatory reporting in the FY 2027 program year. In alignment with the Hospital IQR Program, we will allow PCHs flexibility to select a tool or tools to screen patients for food insecurity, housing instability, transportation needs, utility difficulties, and interpersonal safety. Potential sources of these data for incorporation in a tool could include, for example, administrative claims data, electronic clinical data, standardized patient assessments, or patient-reported data and surveys. Additionally, multiple screening tools exist and are publicly available. PCHs could refer to evidence-based resources like the Social Interventions Research and Evaluation Network (SIREN) website, for example, for comprehensive information about the most widely used HRSN screening tools. SIREN contains descriptions of the content and characteristics of various tools, including information about intended populations, completion time, and number of questions. We encourage PCHs to implement digital standardized screening tools and refer readers to the FY 2023 IPPS/LTCH PPS final rule (87 FR 49207) where we noted that use of certified health IT can support capture and exchange of HRSN information in an interoperable fashion so that these data can be shared across communities.
the care continuum to support coordinated care.

PCHs will be required to submit information for the Screening for Social Drivers of Health measure once annually using a CMS-approved web-based data collection tool available within the Hospital Quality Reporting (HQR) System. PCHs will follow the established submission and reporting requirements for web-based measures for the PCHQR Program posted on the QualityNet website.

e. Review by the Measure Applications Partnership

The Screening for Social Drivers of Health measure was included for consideration in the PCHQR Program on the publicly available MUC List, a list of measures under consideration for use in various Medicare programs.734 The CBE-convened MAP Health Equity Advisory Group reviewed the MUC List and the Screening for Social Drivers of Health measure (MUC 2022–053) in detail and at the same time as the Screening Positive Rate for Social Drivers of Health measure on December 6–7, 2022.735 The Health Equity Advisory Group expressed support for the data collection related to social drivers of health, but raised concerns about public reporting of the data and redundancy in asking for the same information of patients. In addition, on December 8–9, 2022, the MAP Rural Health Advisory Group reviewed the 2022 MUC List and the MAP Hospital Workgroup did so on December 13–14, 2022.736 The Rural Health Advisory Group noted some potential reporting challenges including the potential masking of health disparities that are underrepresented in some areas and that sample size and populations served may be an issue, but expressed that the measure serves as a starting point to determine where screening is occurring. The MAP Hospital Workgroup expressed strong support for the measure but noted that interoperability will be important and cautioned about survey fatigue. The MAP Hospital Workgroup members conditionally supported the measure pending: (1) testing of the measure’s reliability and validity; (2) endorsement by a consensus-based entity (CBE); (3) additional details on how potential tools map to the individual drivers, as well as best practices; (4) what resources may be available to assist patients; and (5) alignment with data standards, particularly the GRAVITY project.737 Thereafter, the MAP Coordinating Committee deliberated on January 24–25, 2023, and ultimately voted to conditionally support the Screening for Social Drivers of Health measure for rulemaking with the same conditions.738

We believe this measure establishes an important foundation to prioritizing the achievement of health equity among PCHs. Our approach to developing health equity-focused measures is incremental, and we believe that health care equity outcomes in the PCHQR Program will inform future efforts to advance and achieve health care equity by PCHs. We additionally believe this measure to be a building block that lays the groundwork for a future meaningful suite of measures that could assess PCH progress in providing high-quality healthcare for all patients, regardless of social risk factors or demographic characteristics.

f. CBE Endorsement

We have not submitted this measure for CBE endorsement at this time. Although section 1866(k)(3)(A) of the Act generally requires that measures specified by the Secretary for use in the PCHQR Program be endorsed by the entity with a contract under section 1890(a) of the Act, section 1866(k)(3)(B) of the Act states that in the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed by the entity with a contract under section 1890(a) of the Act, the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary. We reviewed CBE-endorsed measures and were unable to identify any other CBE-endorsed measures on this topic, and, therefore, we believe the exception in section 1866(k)(3)(B) of the Act applies.

Public Display

In the proposed rule, we proposed to publicly display the PCH-specific results for the Social Drivers of Health measure and refer readers to Table IX.D–04 in the preamble of this final rule for the public display requirements.

Comment: Many commenters expressed support believing the measure improves health equity. A few commenters expressed support for the measure for encouraging attention and resources for social needs. A commenter expressed support for the measure believing it addresses structural inequities faced in rural and underserved communities. Another commenter expressed support for screening believing it is an opportunity to build trust between patients and providers. Another commenter expressed support for public reporting of facility specific results. Another commenter expressed support for the measure noting that the delayed date for mandatory reporting may assist with concerns about creating additional burden capturing the required data elements.

Response: We thank the commenters for their support.

Comment: A few commenters expressed support for the measure, but with recommendations including that data may be more appropriately reported at the system or regional level, economic insecurity should be added as a social risk factor for screening, and occupational therapists should be included in the list of professionals who gather data for this measure.

Response: We appreciate the commenters’ support and recommendations. We note that this measure is considered a building block and lays the groundwork for future measures that could consider additional factors such as economic insecurity. We note that the Screening for Social Drivers of Health measure requires data collection at the PCH level rather than the system or regional level that allows PCHs to identify patients with HRSNs who are known to experience the greatest risk of poor health outcomes thereby improving the accuracy of high-risk prediction outcomes. We will work with PCHs to monitor the data reported and for feedback on opportunities to improve the quality of the data or data collection and reporting processes.

Comment: A few commenters recommended minimizing burden including standardizing data collection and validation, revising the measure to not burden patients with repeated requests for information within a single hospital stay, and allowing for use of prior screening information to satisfy the measure.

Response: We recognize the concerns about burden of participating in the...
PCHQR Program and have aligned PCHQR Program measures with the Hospital IQR Program as appropriate. While we understand implementation of HRSN screening processes and reporting of the Social Drivers of Health measures is associated with some burden, as discussed in sections VI.B. and VI.A. of this final rule, we believe the benefits outweigh the burden as screening for and identifying patients’ HRSNs is a critical step towards treating the whole patient, improving clinical outcomes, and eliminating health disparities. We also note that hospitals participating in the Hospital IQR Program will have already reported data on this measure before the reporting of the Screening for Social Drivers of Health measure for the PCHQR Program begins, so we believe PCHs will have the opportunity to learn from the experiences of hospitals including processes for data collection.

Comment: A commenter recommended that CMS provide hospitals with additional flexibility to incorporate the patient screening for health-related social needs at the most appropriate care location, whether in inpatient hospital, outpatient, or physician office locations. Another commenter recommended technical assistance and funding pathways to support connecting patients to services. Another commenter recommended CMS provide financial support for connecting with community resources.

Response: While PCHs must meet the reporting requirements of the Screening for Social Drivers of Health measure for purposes of the PCHQR Program, we encourage PCHs to use the screening as a basis for developing their own individual action plans that could include additional settings other than the inpatient setting. For additional information on how to apply and report these screenings, we refer readers to the Hospital IQR Program’s Frequently Asked Questions document regarding this measure in the Hospital IQR Program, available at: https://www.qualityreportingcenter.com/globalAssets/sts/231/iqr/sdob-measure-faqs_vfinal_04012023508.pdf. We will develop a similar Frequently Asked Questions document for PCHs as part of providing educational and training materials; this document will be conveyed through routine communication channels to hospitals, vendors, and QIOs, including, but not limited to, issuing memos, emails, and notices on the QualityNet website. Regarding the comment about financial support, it is not available through the PCHQR Program. However, the intent of the two Social Drivers of Health measures is to promote adoption of screening patients for HRSNs by healthcare providers as well as taking action to connect patients who identify one or more HRSNs with available resources. Evaluation of the AHC Model concluded that universal screening may identify needs that would otherwise remain undetected. While broad availability of community-based resources that address patients’ health-related social needs would be ideal, we believe that one of the benefits of collecting data from screening for HRSNs will be identification of opportunities to enable meaningful action, including prioritizing and investing in such resources. Beginning to collect the data on patients’ HRSNs remains imperative and a crucial step in developing resources for advancing health equity. Such data collection has already allowed some entities to reallocate resources to address particular HRSNs that disproportionately affect a given patient population or geographic region, as noted in the FY 2023 IPFS/LTCH PPS final rule, in which the Hospital IQR Program adopted these measures (87 FR 49213).

Comment: A commenter recommended analyzing lessons learned from the Hospital IQR Program to inform best practices and to identify pitfalls for the implementation of health equity measures.

Response: We appreciate the recommendation and note that hospitals participating in the Hospital IQR Program will have already reported data on this measure. This commenter recommended the screening for Social Drivers of Health measure for the PCHQR Program begins allowing PCHs the opportunity to learn from the experiences of hospitals when hospital data are publicly reported.

Comment: A commenter recommended CMS revisit the topic as more sophisticated measures are developed to assess action by providers to address identified social needs.

Response: We believe this measure to be a building block that lays the groundwork for a more comprehensive suite of measures that could assess progress in providing high-quality healthcare for all patients regardless of social risk factors or demographic characteristics. This more comprehensive suite of measures could eventually include health equity related outcome measures.

Comment: A commenter supported the inclusion of this measure if sufficient time is allowed before implementation to develop the supporting infrastructure to train staff, develop documentation, and refine reporting.

Response: Given the urgency of achieving health equity, we believe it is important to implement this measure as soon as possible while balancing PCHs’ need for sufficient time to implement screening and data collection processes if not already implemented, which is why we proposed to adopt the measure beginning with voluntary reporting in the FY 2026 program year and mandatory reporting beginning with the FY 2027 program year.

Comment: A commenter expressed several concerns with the lack of alignment with other similar measures such as NCQA’s Social Need Screening and Intervention measure proposed for adoption in HEDIS and the Screening for Social Drivers of Health and Screen Positive Rate for Social Drivers of Health measures under review for the Medicaid Core Set. This commenter’s annual review believing the misalignment will cause confusion and waste resources. This commenter recommended that the Screening for Social Drivers of Health measure and the Screen Positive Rate for Social Drivers of Health measure align with the Gravity Project’s standards to lessen burden on patients and reduce missing data, and because the standards use interoperable data and are risk adjusted. This commenter also recommended CMS leveraged interoperability requirements and other ways to connect with a person’s record from their primary care provider to retrieve information. This commenter recommended CMS work with Core Quality Measures Collaborative (CQMC) and NCQA to harmonize the specifications of these measures through a multistakeholder process, such as the CBE endorsement process.

Response: The current Screening for Social Drivers of Health and Screen Positive Rate for Social Drivers of Health measures mirror the core domains of NCQA by including food insecurity, housing insecurity, and transportation insecurity. We commend additional stakeholder efforts currently underway to expand capabilities to capture drivers of health data elements using health IT standards, including the Gravity Project, a public-private collaborative focused on standard development for the collection, use, and exchange of data to address social determinants of health, referenced by a commenter. We have prioritized the five HRSN domains in the screening for Social Drivers of Health measure based on existing evidence from the AHC.
Model including recommendations from a Technical Expert Panel that informed the initial selection. We note that the five domains covered by the Screening for Social Drivers of Health measure are included within the “social risk domains” of the Gravity Project. We also note ongoing reevaluation efforts that aim to improve the Screening for Social Drivers of Health and Screen Positive Rate for Social Drivers of Health measures through the development of the Addressing Social Needs (ASN) electronic clinical quality measure (eCQM). We support harmonization of social risk factor data for interoperable electronic health information exchange and encourage use of tools that can enable interoperable exchange of this data. In addition, adoption of the Screening for Social Drivers of Health and Screen Positive Rate for Social Drivers of Health measures for the PCHQR Program aligns with other quality reporting and value-based purchasing programs; specifically, the Hospital IQR Program and the Merit-based Incentive Payment System (87 FR 70055) as well as the same measure proposals for the Inpatient Psychiatric Facility Quality Reporting Program in the FY 2024 IPF PPS proposed rule (88 FR 21280) and the End-Stage Renal Disease (ESRD) Quality Incentive Program in the CY 2024 ESRD PPS proposed rule (88 FR 42515). We appreciate commenter concern about the potential for misalignment with NCQA’s Social Need Screening and Intervention measure proposed for adoption in HEDIS and for Social Drivers of Health measures that could be included in the Medicaid Core Set; however, we wish to reiterate that our approach to developing health equity measures is incremental and will evolve over time to capture health equity outcomes in the PCHQR Program and we will continue to look for ways to minimize provider reporting burden. While we recognize the value of measures undergoing CBE endorsement review, given the urgency of achieving health equity, we believe it is important to implement the measure in the PCH setting as soon as possible.

Comment: A commenter recommended implementation of health equity measures over a longer period of time to ensure resource support patient outcomes and do not erode consumer trust.

Response: We believe that adopting the Screening for Social Drivers of Health measure beginning with voluntary reporting for the FY 2026 program year and mandatory reporting beginning with the FY 2027 program year will allow PCHs to have the time needed to prepare to collect these data if not already doing so and to identify community partners for connecting individuals to resources in their communities. However, we will continue to monitor implementation and consider feedback.

Comment: A commenter recommended the Screening for Social Drivers of Health and Screen Positive Rate for Social Drivers of Health measures be implemented consistently and allow fair comparisons across providers and regions citing concerns with resource differences between hospitals and the potential for inaccurate or biased results for indicators that may have small denominators.

Response: The Screening for Social Drivers of Health and Screen Positive Rate for Social Drivers of Health measures support the identification of specific risk factors for inadequate healthcare access and adverse health outcomes among patients. The Screening for Social Drivers of Health measure supports data collection for PCHs to inform more meaningful and sustainable solutions for closing equity gaps among the communities they serve. The Screen Positive Rate for Social Drivers of Health measure is intended to provide information to PCHs on the level of unmet need among their patients and potentially in the community while providing an opportunity to compare PCHs and to promote higher levels of screening. We believe public reporting of healthcare quality data promotes transparency in the delivery of care by increasing the involvement of leadership in healthcare quality improvement, creating a sense of accountability, helping to focus organizational priorities, and providing a means of delivering important healthcare information to consumers and patient advocates. To support patient and patient understanding and to minimize confusion, we intend to conduct outreach and education with providers and patients to share information about the two Social Drivers of Health measures in conjunction with public reporting.

Comment: A commenter recommended CMS ensure social needs screenings are done in a respectful and person-centered way that build trust consumers on why hospitals are collecting these data, how it will be used, how it will not be used, and how it will be protected.

Response: We agree with the commenter that it is important for the screening to be accomplished in a way that is respectful, person-centered, and engenders trust. We recommend that PCHs evaluate the requirements for administration (such as whether the screening instrument can be administered by peer support specialists) as part of their instrument selection process. We note that the AHC instrument described in this section of the preamble of the final rule allows administration by clinicians and staff and would allow administration by peer support specialists. We note that the data produced by these screenings are considered protected health information and are therefore covered by the HIPAA Privacy Rule. Therefore, PCHs are responsible for adopting reasonable safeguards to ensure that these data are not disclosed. We defer to PCHs to make the appropriate disclosures to their patients regarding how the collected data are used as well as ensuring that the patient and their caregiver(s) are informed of their option to opt-out of screening.

Comment: A commenter recommended that CMS address the technical challenges of this measure including working with ONC to standardize documentation across EHRs and add the capability to screen for social needs and document the results to the ONC Health IT Certification Program.

Response: We recognize that there are multiple sources for HRSN data that could be incorporated into a tool, such as administrative claims data, electronic clinical data, standardized patient assessments, patient-reported data and surveys, and multiple publicly available screening tools. We also recognize that this could present some technical challenges for PCHs. We encourage PCHs to implement digital standardized screening tools which conform to health IT vocabulary standards that enable interoperability of this data across systems. We note that the use of certified health IT can support the capture and exchange of HRSN information in an interoperable fashion so that these data can be shared across the care continuum to support coordinated care, for instance, through use of standards for SDOH Assessment data identified as part of the United States Core Data for Interoperability.741

Comment: A commenter expressed its belief that the measure is vague and recommended it be submitted for review and endorsement by a CBE to ensure feasibility and scientific acceptability.

Response: The two Social Drivers of Health measures are derived from

existing evidence from both the AHC Model\textsuperscript{742} and emerging evidence of correlations between the designated drivers of health and higher healthcare utilization of emergency departments and hospitals, worse health outcomes and/or drivers of health for which interventions have shown marked improvements in health outcomes and healthcare utilization. We disagree with the characterization of the measure as vague and refer to the measure specifications available at: https://innovation.cms.gov/cmit/#/. While we recognize the value of measures undergoing CBE endorsement review, given the urgency of achieving health equity, we believe it is important to implement this measure as soon as possible while balancing PCPs’ need for sufficient time to implement screening and data collection processes if not already implemented, which is why we proposed to adopt the measure beginning with voluntary reporting in the FY 2026 program year and mandatory reporting beginning with the FY 2027 program year. We note that under section 1886(s)(4)(D)(ii) of the Act the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary. We reviewed CBE-endorsed measures and were unable to identify any other CBE-endorsed measures on this topic, and therefore, we believe the exception in section 1886(s)(4)(D)(ii) of the Act applies.

Comment: A commenter recommended that the initiation of public display be contingent upon verification of accuracy of data reported.

Response: We believe that adopting the Screening for Social Drivers of Health measure beginning with voluntary reporting for the FY 2026 program year and mandatory reporting beginning with the FY 2027 program year and displaying the data publicly beginning July 2027 or as soon as feasible thereafter would allow PCPs the opportunity to review the accuracy of their data prior to public display.

After consideration of the public comments we received, we are finalizing this measure.

5. Adoption of the Screen Positive Rate for Social Drivers of Health Beginning With Voluntary Reporting for the FY 2026 Program Year and Mandatory Reporting Beginning With the FY 2027 Program Year

a. Background

The impact of social risk factors on health outcomes has been well-established in the literature.\textsuperscript{743,744,745,746,747} The Physicians Foundation reported that 73 percent of the physician respondents to their annual survey agreed that social risk factors such as housing instability and food insecurity would drive health services demand in 2021.\textsuperscript{748} Recognizing the need for a more comprehensive approach to closing equity gaps, we have prioritized quality measures that identify drivers of health among patients served in various care settings and, in turn, support providers in addressing the impact of these drivers on disparities in patient outcomes, healthcare utilization, and costs.\textsuperscript{749,750,751}

Specifically, in the inpatient setting, we aim to encourage systematic identification of patients’ HRSNs as part of discharge planning, with the intention of promoting linkages with relevant community-based services that address those needs and support sustainable improvements in health outcomes following discharge from the PCH.

While the Screening for Social Drivers of Health measure (discussed previously in section IX.D.4. of the preamble of this final rule) enables identification of individuals with HRSNs, the Screen Positive Rate for Social Drivers of Health measure would allow providers to capture the magnitude of these needs and even estimate the impact of individual-level HRSNs on healthcare utilization when evaluating quality of care.\textsuperscript{752,753,754} The Screen Positive Rate for Social Drivers of Health measure will require the reporting of the resulting screen positive rates for each domain. Reporting the screen positive rate for social drivers of health for each domain could inform actionable planning by PCHs towards closing equity gaps unique to the populations they serve and enable the development of individual patient action plans (including navigation and referral).

The Screen Positive Rate for Social Drivers of Health measure will assess the percent of patients admitted to the PCH who are 18 years or older at time of admission who were screened for HRSN and who screen positive for one or more of the core HRSNs, including food insecurity, housing instability, transportation needs, utility difficulties, or interpersonal safety (reported as five separate rates).\textsuperscript{755} We refer readers to


the discussion of the identification process resulting in the selection of these five domains in section IX.D.A. of the preamble of this final rule.

The COVID–19 pandemic underscored the overwhelming impact that these five core domains have on disparities in risk, healthcare access, and health outcomes, including premature mortality.\(^756\) Adoption of the Screen Positive Rate for Social Drivers of Health measure seeks to encourage PCHs to track the prevalence of specific HRSNs among patients over time and use the data to stratify risk as part of quality improvement efforts. This measure may also prove useful to patients by providing data transparency and signifying PCHs’ familiarity, expertise, and commitment regarding these issues. For example, evaluation of AHCC Model participation demonstrated positive feedback and enhanced trust among patients.\(^758\) This measure also has the potential to reduce healthcare provider burden and burnout by both acknowledging patients’ non-clinical needs that, nevertheless, greatly contribute to adverse clinical outcomes and linking providers with community-based organizations to enhance patient-centered treatment and discharge planning.\(^759\)\(^760\)\(^761\) Finally, we believe this measure has the potential to facilitate data-informed collaboration with community-based services and focused community investments, including the development of pathways and infrastructure to more seamlessly connect patients to local community resources.

Ultimately, we are focused on supporting effective and sustainable collaboration between healthcare delivery and community-based providers to meet the unmet needs of people they serve. Reporting data from both the Screening for Social Drivers of Health and Screen Positive Rate for Social Drivers of Health measures would enable both identification and quantification of HRSNs among communities served by PCHs. These measures harmonize, as it is important to know both if screening occurred and the results from the screening to develop sustainable solutions. As with the theory of change for the AHC Model, we also expect resultant clinical-community collaborations, and an associated increase in system capacity and community investments, to yield a net reduction in costly healthcare utilization by promoting more appropriate healthcare service consumption.\(^762\) Pursuant to the Meaningful Measures 2.0 Framework and in alignment with the measures previously adopted for hospitals participating in the Hospital IQR Program, this measure will address the “healthcare equity” priority area and align with our commitment to introduce plans to close health equity gaps and promote equity through quality measures, including to “develop and implement measures that reflect social and economic determinants.”\(^763\)

Under CMS’ Meaningful Measures Framework, the Screen Positive Rate for Social Drivers of Health measure will address the quality priority of “Work with Communities to Promote Best Practices of Healthy Living” through the Meaningful Measures Area of “Equity of Care.”\(^764\) Development of this measure also aligns with our strategic pillar to advance health equity by addressing the health disparities that underlie our health system.\(^765\)


\(^764\) [25x20]VerDate Sep<11>2014 23:04 Aug 25, 2023 Jkt 259001 PO 00000 Frm 00582 Fmt 4701 Sfmt 4700 E:\FR\Fm\28AUR2.SGM 28AUR2
denominator: (1) Patients who opt-out of screening; and (2) patients who are themselves unable to complete the screening during their inpatient stay and have no caregiver able to do so on the patient’s behalf during their inpatient stay.

c. Measure Calculation

The result of this measure will be calculated as five separate rates. Each rate is derived from the number of patients admitted for a PCH stay and who are 18 years or older on the date of admission, screened for an HRSN, and who screen positive for each of the five HRSNs—food insecurity, housing instability, transportation needs, utility difficulties, or interpersonal safety—divided by the number of patients 18 years or older on the date of admission screened for each of the five HRSNs.

d. Data Collection, Submission and Reporting

In the proposed rule, we proposed to require PCHs to submit information for this measure once annually using a CMS-approved web-based data collection tool available within the Hospital Quality Reporting (HQR) System beginning with voluntary reporting for the FY 2026 program year and mandatory reporting beginning with the FY 2027 program year. PCHs will follow the established submission and reporting requirements for web-based measures for the PCHQR Program posted on the QualityNet website.

e. Review by the Measure Applications Partnership

The Screen Positive Rate for Social Drivers of Health measure was included for consideration in the PCHQR Program on the publicly available MUC List, a list of measures under consideration for use in various Medicare programs. The CBE-convened MAP Health Equity Advisory Group reviewed the MUC List and the Screen Positive Rate for Social Drivers of Health measure (MUC 2022–050) in detail and at the same time as the Screening for Social Drivers of Health measure on December 6–7, 2022. The Health Equity Advisory Group expressed support for the collection of data related to social health drivers, but raised concerns regarding public reporting and the repetition of asking patients the same questions. In addition, on December 8–9, 2022, the MAP Rural Health Advisory Group reviewed the 2022 MUC List and was also reviewed by the MAP Hospital Workgroup on December 13–14, 2022. The Rural Health Advisory Group noted potential reporting challenges including the potential masking of health disparities that are underrepresented in some areas and that sample size and populations served may be an issue, but also expressed support that the measure seeks to advance the drivers of health and serves as a starting point to determine where screening is occurring. The MAP Hospital Workgroup recommended conditional support for the measure for rulemaking pending endorsement by a CBE to address reliability and validity concerns, attentiveness to how results are shared and contextualized for public reporting, and encouragement for CMS to examine any differences in reported rates by reporting process (to assess whether they are the same or different across PCHs). Thereafter, the MAP Coordinating Committee deliberated on January 24–25, 2023, and ultimately voted to conditionally support the Screen Positive Rate for Social Drivers of Health measure for rulemaking with the same conditions.

We agree with the MAP Coordinating Committee’s support for the Screen Positive Rate for Social Drivers of Health measure. We believe this measure establishes an important foundation to prioritizing the achievement of health equity among providers participating in a comprehensive quality reporting program. Our approach to developing health equity-focused measures is incremental, and we believe that health care equity outcomes in the PCHQR Program will inform future efforts to advance and achieve health care equity by PCHs. We additionally believe this measure to be a building block that lays the groundwork for a future meaningful suite of measures that could assess PCH progress in providing high-quality healthcare for all patients, regardless of social risk factors or demographic characteristics.

f. CBE Endorsement

We have not submitted this measure for CBE endorsement at this time. Although section 1866(k)(3)(A) of the Act generally requires that measures specified by the Secretary for use in the PCHQR Program be endorsed by the entity with a contract under section 1890(a) of the Act, section 1866(k)(3)(B) of the Act states that in the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed by the entity with a contract under section 1890(a) of the Act, the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary. We reviewed CBE-endorsed measures and were unable to identify any other CBE-endorsed measures on this topic, and, therefore, we believe the exception in section 1866(k)(3)(B) of the Act applies.

g. Public Display

In the proposed rule, we proposed to publicly display the PCH-specific results for the Screen Positive Rate for Social Drivers of Health measure and refer readers to Table IX.D–04 in the preamble of this final rule for the public display requirements.

We invited public comment on this proposal.

We note that we have addressed comments that broadly referred to both the Screening for Social Drivers of Health measure and the Screen Positive Rate for Social Drivers of Health measure in the previous section IX.D.4. of this final rule.

Comment: Many commenters expressed support for the measure to advance health equity. A few commenters expressed support for the measure as an important step in addressing equity through quality measurement. A commenter expressed support for the measure believing it will focus attention and resources on patient needs, address a measurement gap in CMS quality programs for hospitals, and help inform more comprehensive care and discharge planning. A commenter expressed support for the measure believing it is a positive first step toward considering and tracking SDOH.

Response: We thank the commenters for their support.

Comment: A few commenters expressed concern with how the results of the Screen Positive Rate for Social Drivers of Health measure would be communicated and displayed believing the results could be misunderstood by consumers.

Response: We appreciate the commenters’ concerns. As we discussed previously, the measure provides a means of delivering important...

767 Available at: https://mmshub.cms.gov/measure-lifecycle/measure-implementation/pre-rulemaking/lists-and-reports.
768 Available at: https://mmshub.cms.gov/measure-lifecycle/measure-implementation/pre-rulemaking/lists-and-reports.
769 Available at: https://mmshub.cms.gov/measure-lifecycle/measure-implementation/preview-rulemaking/lists-and-reports.
770 Available at: https://mmshub.cms.gov/measure-lifecycle/measure-implementation/pre-rulemaking/lists-and-reports.
771 Available at: https://mmshub.cms.gov/measure-lifecycle/measure-implementation/pre-rulemaking/lists-and-reports.
healthcare information to consumers and patient advocates on the level of unmet need among PCH patients and potentially in the community, and not for comparison between PCHs. We believe public reporting of healthcare quality data promotes transparency in the delivery of care by increasing the involvement of leadership in healthcare quality improvement, creating a sense of accountability, helping to focus organizational priorities, and providing a means of delivering important healthcare information to consumers and patient advocates. We intend to conduct outreach and education with providers and patients to share information about the two Social Drivers of Health measures in conjunction with public reporting.

After consideration of the public comments we received, we are finalizing this measure.

6. Adoption of the Documentation of Goals of Care Discussions Among Cancer Patients Measure Beginning With the FY 2026 Program Year

a. Background

Goals of care discussions are intended to inform future treatment decisions that account for and are responsive to the interests expressed by patients with advanced cancer and can also impact referrals to palliative care and end-of-life treatments. Goal of care discussions are discussions between the patient and the oncology team and the primary oncologist is responsible for ensuring documentation of these discussions.

While 99 percent of clinicians believe that serious illness conversations are important, only 29 percent of clinicians report having received serious illness communication training. One study found that Americans report having a serious illness conversation with their clinician only 11 percent of the time.

In the 2017 publication Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline, the American Society of Clinical Oncology (ASCO) recommended clinician training in communication skills and discussion of goals of care and prognosis, treatment selection, end-of-life care, and facilitating family involvement in care.

We believe the lack of these conversations creates a gap in the care delivered when the oncology team, including the oncologist, does not know their patients’ goals of care. While 92 percent of Americans say that they would be comfortable having these discussions with their clinicians, among seriously ill patients who prefer comfort care, only 41 percent report care consistent with their wishes. Care inconsistent with preferences is associated with a lower quality of care and higher medical costs.

Guidelines suggest that goal of care discussions should be conducted early for patients with metastatic cancer who have a life expectancy of less than one year. However, most oncology settings do not adequately support documentation that is most relevant to goals of cancer care. In 2020, the Alliance of Dedicated Cancer Centers (ADCC) initiated the Improving Goal Concordant Care (IGCC) to address system gaps and to establish new expectations for when and how goals-of-care conversations occur. The initiative places responsibility on the primary oncology team with the oncologist responsible for ensuring documentation of these discussions, for timely initiation and ongoing conversations regarding goals of care with their patients and recommends a structured goals-of-care documentation in electronic health records, including a minimum set of structured fields and functionality to promote access and retrieval across providers and settings.

Goals of care documentation should be discrete and structured whenever possible to both ease entry and to facilitate retrieval. We note that the oncology team, including the oncologist, is responsible for the goals of care discussion and the oncologist is responsible for ensuring documentation of these discussions. The ADCC made the following structure and functionality recommendations:

- Minimizing documentation burden is critical to support clinician workflow and promote efficiencies.
- Core documentation should be in a ‘single source of truth’ in one location in the EHR, reflecting conversations across time, settings, and providers.
- Designated, authorized members of the care team (which might include advanced practice providers, oncology nurses and social workers, as designated by the center) should be able to document appropriate fields related to goals of care communications.

We believe documentation of goals in structured fields prompts meaningful patient-centered discussions, enhances care quality and efficiency, promotes accessibility, and supports concordant care.

b. Overview of Measure

This measure assesses goals of care discussion documentation among patients with cancer who die while receiving care at the reporting PCH. On an annual basis, PCHs will report the percentage of cancer patients who died during the reporting period and had patients’ goals of care documented prior to death, beginning with the FY 2026 program year.

The Documentation of Goals of Care Discussions Among Cancer Patients measure is a process measure which focuses on the essential process of documenting goals of care conversations in the EHR by assessing the presence of this documentation in the medical record. The intent of this measure is for PCHs to track and improve this documentation to ensure that such conversations have taken place, have been properly documented in a manner that is retrievable by all members of the PCH healthcare team, and to facilitate the delivery of care that aligns with patients’ and families’ values and unique priorities.

This measure requires the use of both hospital administrative data (non-claims) for clinical information and discrete documentation in the EHR documenting the goals of care discussion. Measure specifications can be found here: https://cmit.cms.gov/cm#/

(1) Measure Population

The population is the number of patients who died in the measurement period, including patients participating in clinical trials, as long as these

patients meet the criteria for the measure’s population. This population is defined using PCH administrative data (non-claims) and discrete documentation in the electronic health record as follows:

- Patients who died at the PCH in the measurement period; and
- Who had a diagnosis of cancer; and
- Who had at least two eligible contacts at the PCH within the six months prior to their date of death. Eligible contacts are inpatient admissions and hematologic or oncology ambulatory visits at the reporting hospital.

(2) Denominator

The denominator is the number of patients meeting the criteria for inclusion in the measure’s population in the reporting period.

(3) Numerator

The numerator is the number of patients who were included in the denominator for whom a Goals of Care conversation was documented in a structured field in the medical record. The measure will require any documentation in one or more patient goals fields. To meet the requirements for inclusion in the numerator, the documentation in the EHR will be required to include either of the following:

- Any documentation in one or more patient goals fields in the electronic medical record, or
- Documentation that the patient opted not to have a goals of care discussion. Documentation may originate from any visit type or provider as permitted by the PCH. Any member of the PCH health care team could perform such documentation for purposes of the measure, but we strongly encourage a patient’s oncologist to ensure appropriate discussions of goals of care occur and to oversee the documentation of the goals of care discussion.

c. Calculation of Performance Score

Performance is reported as a proportion (percentage) determined by calculating ([Numerator ÷ Denominator]) x 100. A higher score is better.

d. Data Submission and Reporting

In the proposed rule, we proposed to require PCHs to submit information for this measure once annually using a CMS-approved web-based data collection tool available within the Hospital Quality Reporting (HQR) System (previously referred to as the QualityNet Secure Portal) beginning with the FY 2026 program year. PCHs will follow the submission and reporting requirements for web-based measures for the PCHQR Program posted on the QualityNet website.

e. Review by the Measure Applications Partnership

The Documentation of Goals of Care Discussions Among Cancer Patients measure was included in the publicly available MUC List, a list of measures under consideration for use in various Medicare quality programs. The CBE-convened MAP reviewed the MUC List and the Documentation of Goals of Care Discussions Among Cancer Patients measure (MUC 2022–120) in detail on December 6–7, 2022. In addition, on December 8–9, 2022, the MAP Rural Health Advisory Group reviewed the 2022 MUC List and the MAP Hospital Workgroup reviewed the measure on December 13–14, 2022. The Rural Health Advisory Group expressed strong support for the measure. The MAP Hospital Workgroup recommended conditional support for rulemaking pending testing indicating the measure is reliable and valid, and endorsement by a consensus-based entity (CBE). Thereafter, the MAP Coordinating Committee deliberated on January 24–25, 2023, and ultimately voted to conditionally support the Documentation of Goals of Care Discussions Among Cancer Patients measure for rulemaking with the same conditions.

We agree with the MAP that measuring documentation of goals of care discussions is an important step toward achieving the outcome of goal-concordant care and that documentation of goals in structured fields prompts discussions, enhances their quality and efficiency, and promotes accessibility. We also believe goals of care discussions with patients are associated with better patient and family outcomes.

f. CBE Endorsement

The measure has not been submitted by its steward, ADCC, for CBE endorsement at this time. Although section 1866(k)(3)(A) of the Act generally requires that measures specified by the Secretary for use in the PCHQR Program be endorsed by the entity with a contract under section 1890(a) of the Act, section 1866(k)(3)(B) of the Act states that in the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed by the entity with a contract under section 1890(a) of the Act, the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary. We reviewed CBE-endorsed measures and were unable to identify any other CBE-endorsed measures on this topic, and, therefore, we believe the exception in section 1866(k)(3)(B) of the Act applies.

g. Public Display

In the proposed rule, we proposed to publicly display the PCH-specific results for the Documentation of Goals of Care Discussion Among Cancer Patients measure and refer readers to Table IX.D.–04 in the preamble of this final rule for the public display requirements.

We invited public comment on this proposal.

Comment: Several commenters expressed support for the Documentation of Goals of Care Discussions Among Cancer Patients measure. A commenter believed the measure is an initial step toward person-centered cancer care. Another commenter supported the measure because it supports delivering concordant care to cancer patients, particularly for coordination with primary care settings in rural communities. A few commenters expressed support for future public display.

Response: We appreciate commenters’ support for the Documentation of Goals of Care Discussions Among Cancer Patients measure. We agree that this measure is an important step in alignment with our commitment to person centered care. We also agree that public display is an important part of quality improvement in cancer care.

Comment: A few commenters recommended CMS consider replacing the measure with a process or outcomes measure at a future point. A commenter recommended that occupational therapists should be added to the list of professionals who gather measure data citing their expertise gathering patient information and guiding patients through care plans. Another commenter recommended the measure should not include advance care
planning because it has not yet proven to have significant impact on end-of-life care.

Response: We thank the commenters for their recommendations. We will consider the potential role for occupational therapists in future rulemaking. We note the commenter’s concern about including advance care planning in the Documentation of Goals of Care Discussions Among Cancer Patients measure and will continue to work with PCHs for opportunities to improve the quality of data in the PCHQR Program.

Comment: Another commenter recommended delaying public reporting at least one year to allow verification of data accuracy.

Response: We appreciate the commenter’s recommendation; however, we believe that adopting the Documentation of Goals of Care Discussions Among Cancer Patients measure beginning with the FY 2026 program year and publicly displaying PCH-specific results in July 2026 or as soon as feasible thereafter would provide the time needed for PCHs to review data for accuracy. We refer readers to Table IX.D.–04 for previously finalized and newly finalized public display requirements.

After consideration of the public comments we received, we are finalizing this measure.

7. Summary of Previously Adopted and New PCHQR Program Measures for the FY 2026 Program Year and Subsequent Years

For ease of reference, Table IX.D.–03 summarizes the previously adopted and the newly finalized measures for the PCHQR Program measures for the FY 2026 program year and subsequent years.
### TABLE IX.D.-03: PREVIOUSLY ADOPTED MEASURES AND NEW MEASURES FOR THE PCHQR PROGRAM MEASURE SET FOR FY 2026 PROGRAM YEAR AND SUBSEQUENT YEARS

<table>
<thead>
<tr>
<th>Short Name</th>
<th>CBE Number</th>
<th>Measure Name</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Safety and Healthcare-Associated Infection (HAI) Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAUTI</td>
<td>0138</td>
<td>National Healthcare Safety Network (NHSN) Catheter-associated Urinary Tract Infection (CAUTI) Outcome Measure</td>
</tr>
<tr>
<td>CLABSI</td>
<td>0139</td>
<td>NHSN Central line-associated Bloodstream Infection (CLABSI) Outcome Measure</td>
</tr>
<tr>
<td>Flu HCP Vaccination</td>
<td>0431</td>
<td>Influenza Vaccination Coverage Among Healthcare Personnel (HCP)</td>
</tr>
<tr>
<td>COVID-19 HCP Vaccination</td>
<td>N/A</td>
<td>COVID-19 Vaccination Coverage Among HCP *</td>
</tr>
<tr>
<td>Colon and Abdominal Hysterectomy SSI</td>
<td>0753</td>
<td>American College of Surgeons – Centers for Disease Control and Prevention (ACS-CDC) Harmonized Procedure Specific Surgical Site Infection (SSI) Outcome Measure (currently includes SSIs following Colon Surgery and Abdominal Hysterectomy Surgery)</td>
</tr>
<tr>
<td>MRSA</td>
<td>1716</td>
<td>NHSN Facility-wide Inpatient Hospital-onset Methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) Bacteremia Outcome Measure</td>
</tr>
<tr>
<td>CDI</td>
<td>1717</td>
<td>NHSN Facility-wide Inpatient Hospital-onset <em>Clostridium difficile</em> Infection (CDI) Outcome Measure</td>
</tr>
<tr>
<td><strong>Clinical Process/Oncology Care Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EOL-Chemo</td>
<td>0210</td>
<td>Proportion of Patients Who Died from Cancer - Receiving Chemotherapy in the Last 14 Days of Life</td>
</tr>
<tr>
<td>EOL-Hospice</td>
<td>0215</td>
<td>Proportion of Patients Who Died from Cancer - Not Admitted to Hospice</td>
</tr>
<tr>
<td><strong>Intermediate Clinical Outcome Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EOL-ICU</td>
<td>0213</td>
<td>Proportion of Patients Who Died from Cancer - Admitted to the ICU in the Last 30 Days of Life</td>
</tr>
<tr>
<td>EOL-3DH</td>
<td>0216</td>
<td>Proportion of Patients Who Died from Cancer - Admitted to Hospice for Less Than Three Days</td>
</tr>
<tr>
<td><strong>Patient Engagement/Experience of Care Measure</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCAHPS</td>
<td>0166</td>
<td>Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Survey</td>
</tr>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>Documentation of Goals of Care Discussions Among</td>
</tr>
</tbody>
</table>
8. Maintenance of Technical Specifications for Quality Measures

We maintain and periodically update technical specifications for the PCHQR Program measures. The specifications may be found on the QualityNet website at https://qualitynet.cms.gov/pch. We also refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50281), where we adopted a policy to use a subregulatory process to make nonsubstantive updates to measures used for the PCHQR Program. We did not propose any changes to our processes for maintaining technical specifications for PCHQR Program measures.

9. Public Display Requirements

a. Background

Section 1866(k)(4) of the Act requires us to establish procedures for making the data submitted under the PCHQR Program available to the public. We refer readers to the FY 2017 IPPS/LTCH PPS final rule (81 FR 57191 through 57192) for a detailed discussion of our public display procedures. We did not propose any changes to our previously finalized public display requirements.

b. Public Display of the Surgical Treatment Complications for Localized Prostate Cancer Measure Beginning With the FY 2025 Program Year

In the FY 2020 IPPS/LTCH PPS final rule, we adopted the Surgical Treatment Complications for Localized Prostate Cancer Measure (PCH–37) for the PCHQR Program measure set beginning with the FY 2022 program year (84 FR 42514 through 42517). We also finalized that we would confidentially report PCH performance on this measure to individual PCHs and that we would propose to publicly display PCH performance on this measure in the future (84 FR 42517).

Under our current policy, the PCH–37 measure is calculated on an annual basis using a one-year reporting period that is based on data collected from July 1 of the year that is three years prior to the program year to June 30 of the year that is two years prior to the program year (84 FR 42515). For the FY 2023 program year data, we confidentially reported to PCHs their data and measure calculations on the PCH–37 measure in July of 2022 reflecting the July 1, 2019 to June 30, 2020 reporting period. Additionally, we will confidentially report this measure for the FY 2024 program year data in the summer of 2023, reflecting the July 1, 2020 to June 30, 2021 reporting period.

We believe that providing PCHs confidential facility specific reports for 2 years will allow us to assess and confirm the feasibility of PCHs providing statistically robust, reliable, and valid measure results for the PCH–37 measure. Therefore, we proposed to publicly display the PCH-specific results for the PCH–37 measure beginning with the FY 2025 program year data in the summer of 2024, which would reflect PCH performance for the July 1, 2021 through June 30, 2022 reporting period. We will make these data publicly available following a 30-day period in which PCHs would have an opportunity to review the data. We will announce the exact timeframe on a CMS website and our applicable listservs.

We invited public comment on the proposal.

Comment: Many commenters expressed support for the public reporting of the Surgical Treatment Complications for Localized Prostate Cancer measure. A commenter expressed support believing the two years of confidential data reporting prior to public display ensures data accuracy. Another commenter believed it is an important factor for patient choice of providers.

Response: We thank the commenters for their support. We agree that two years of confidential data reporting prior to public reporting gives sufficient time ensure data accuracy. We also agree that publicly reporting this data will provide beneficiaries with important information when considering choice of providers.

Comment: Another commenter expressed its belief that information gathered from the PCH–37 measure should be made available to the public; however, the commenter also expressed concerns with how the data for the PCHQR Program are displayed to patients believing it is difficult to find data that would help a patient identify a provider or facility that would meet their specific needs. This commenter recommended that the data should be made easier to find, understandable by patients at all levels of health literacy, and include a variety of elements related to patient care such as proximity to home, cultural competency of the
healthcare facility, quality of services, and communication protocols.

Response: We strive to ensure all publicly reported data are reported both accurately and in a way that can be accessed by all our beneficiaries. We thank the commenter for the suggestion and intend to review for opportunities to increase useability of the data.

After consideration of the public comments we received, we are finalizing this policy.

c. Summary of Previously Finalized and Newly Finalized Public Display Requirements for the PCHQR Program

Our previously finalized and newly finalized public display requirements for the PCHQR Program measures are shown in the following Table IX.D.–04:
### TABLE IX.D.-04: PREVIOUSLY FINALIZED AND NEWLY FINALIZED PUBLIC DISPLAY REQUIREMENTS FOR THE PCHQR PROGRAM

<table>
<thead>
<tr>
<th>Measures</th>
<th>Public Reporting</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCAHPS (CBE #0166)</td>
<td>2016 and subsequent years</td>
</tr>
<tr>
<td>American College of Surgeons – Centers for Disease Control and Prevention (ACS-CDC) Harmonized Procedure Specific Surgical Site Infection (SSI) Outcome Measure [currently includes SSIs following Colon Surgery and Abdominal Hysterectomy Surgery] (CBE #0753)</td>
<td>2019 and subsequent years</td>
</tr>
<tr>
<td>NHSN Facility-wide Inpatient Hospital-onset Methicillin-resistant <em>Staphylococcus aureus</em> Bacteremia Outcome Measure (CBE #1716)</td>
<td></td>
</tr>
<tr>
<td>NHSN Facility-wide Inpatient Hospital-onset <em>Clostridium difficile</em> Infection (CDI) Outcome Measure (CBE #1717)</td>
<td></td>
</tr>
<tr>
<td>NHSN Influenza Vaccination Coverage Among Healthcare Personnel (CBE #0431)</td>
<td></td>
</tr>
<tr>
<td>COVID-19 Vaccination Coverage Among Healthcare Personnel</td>
<td>October 2022 and subsequent years</td>
</tr>
<tr>
<td>Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy</td>
<td>April 2020 and subsequent years</td>
</tr>
<tr>
<td>CAUTI (CBE #0138)</td>
<td>October 2022 and subsequent years</td>
</tr>
<tr>
<td>CLABSI (CBE #0139)</td>
<td>October 2022 and subsequent years</td>
</tr>
<tr>
<td>Proportion of Patients Who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life (CBE #0210)</td>
<td>July 2024 or as soon as feasible thereafter</td>
</tr>
<tr>
<td>Proportion of Patients Who Died from Cancer Not Admitted to Hospice (CBE #0215)</td>
<td></td>
</tr>
<tr>
<td>Proportion of Patients Who Died from Cancer Admitted to the ICU in the Last 30 Days of Life (CBE #0213)</td>
<td></td>
</tr>
<tr>
<td>Proportion of Patients Who Died from Cancer Admitted to Hospice for Less Than Three Days (CBE #0216)</td>
<td></td>
</tr>
<tr>
<td>30-day Unplanned Readmissions for Cancer Patients (CBE #3188)</td>
<td>October 2023 or as soon as feasible thereafter</td>
</tr>
<tr>
<td>Surgical Treatment Complications for Localized Prostate Cancer Measure (PCH-37)*</td>
<td>July 2024 or as soon as feasible thereafter</td>
</tr>
<tr>
<td>Facility Commitment to Health Equity*</td>
<td>July 2026 or as soon as feasible thereafter</td>
</tr>
<tr>
<td>Screening for Social Drivers of Health*</td>
<td>July 2027 or as soon as feasible thereafter</td>
</tr>
<tr>
<td>Screen Positive Rate for Social Drivers of Health*</td>
<td>July 2027 or as soon as feasible thereafter</td>
</tr>
<tr>
<td>Documentation of Goals of Care Discussions Among Cancer Patients*</td>
<td>July 2026 or as soon as feasible thereafter</td>
</tr>
</tbody>
</table>

*Indicates policies finalized in this final rule.
10. Form, Manner, and Timing of Data Submissions

a. Background

We refer readers to the FY 2013 IPPS/LTCPPS final rule (77 FR 53563 through 53567); the FY 2014 IPPS/LTCPPS final rule (78 FR 50848 through 50853); the FY 2015 IPPS/LTCPPS final rule (79 FR 50282 through 50286); the FY 2016 IPPS/LTCPPS final rule (80 FR 49722 through 49723); the FY 2017 IPPS/LTCPPS final rule (FR); FY 2018 IPPS/LTCPPS final rule (82 FR 38424); the FY 2019 IPPS/LTCPPS final rule (83 FR 41623); FY 2020 IPPS/LTCPPS final rule (84 FR 42523 through 42524); and the FY 2022 IPPS/LTCPPS final rule (86 FR 45436) for our previously finalized procedural requirements for the PCHQR Program. Data submission requirements and deadlines for the PCHQR Program are posted on the QualityNet website.

b. Updates to the Data Submission and Reporting Requirements for the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Survey Measure (CBE #0166) Beginning with the FY 2027 Program Year

(1) Background

We partnered with the Agency for Healthcare Research and Quality (AHRQ) to develop the HCAHPS patient experience of care survey (CBE #0166) (hereinafter referred to as the HCAHPS Survey). We adopted the HCAHPS Survey in the PCHQR Program in the FY 2014 IPPS/LTCPPS final rule (78 FR 50852 through 50853) and refer readers to the FY 2016 IPPS/LTCPPS final rule (80 FR 49720 through 49722) and the FY 2020 IPPS/LTCPPS final rule (84 FR 42523 through 42524) for details on previously adopted HCAHPS Survey measure submission and reporting requirements. We also refer PCHs and HCAHPS Survey vendors to the official HCAHPS website at https://www.hcahpsonline.org for new information and program updates regarding the HCAHPS Survey, its administration, oversight, and data adjustments.

The HCAHPS Survey (OMB control number 0938–0981) is the first national, standardized, publicly reported survey of patients’ experience of hospital care and asks discharged patients 29 questions about their recent hospital stay. The HCAHPS Survey is administered to a random sample of adult patients who receive medical, surgical, or maternity care between 48 hours and six weeks (42 calendar days) after discharge and is not restricted to Medicare beneficiaries.783 Hospitals must survey patients throughout each month of the year.784 The HCAHPS Survey is available in official English, Spanish, Chinese, Russian, Vietnamese, Portuguese, German, Tagalog, and Arabic versions.

The HCAHPS Survey and its protocols for sampling, data collection and coding, and file submission can be found in the current HCAHPS Quality Assurance Guidelines, which is available on the official HCAHPS website at: https://www.hcahpsonline.org/en/quality-assurance/. A CBE first endorsed the HCAHPS Survey in 2005,785 and re-endorsed the measure in 2015, 2016, and 2018.786

In 2021, we conducted a large-scale mode experiment to test adding the web mode and other updates to the form, manner, and timing of HCAHPS Survey data collection and reporting. The 2021 mode experiment employed a nationwide random sample of short-term acute care hospitals that participate in the HCAHPS Survey, including those from each of CMS’s 10 geographic regions. Participating hospitals contributed discharged patients discharged from April through September 2021. Within each hospital, the patients were randomly assigned to each mode of survey administration. In total, we received responses to a revised version of the HCAHPS Survey from 36,001 patients in 46 hospitals. The design of the experiment was sufficient scale to test survey items on new topics, revisions to existing survey items, and new and revised composite measures. It also enabled precise estimation of mode adjustments for current and new HCAHPS items for three currently approved HCAHPS Survey mode protocols and an additional three web-based protocols.

This mode experiment was designed to have the power and precision of adjustment estimates comparable to those that are used and have proven necessary for adjustment of previous HCAHPS data.

The 2021 HCAHPS mode experiment had four main goals: (1) test the large-scale feasibility of web-first sequential multimode survey administrations in an inpatient setting; (2) investigate whether mode effects significantly differ between individuals with email addresses available to the data collection vendor compared to individuals without email addresses available to the vendor; (3) develop mode adjustments to be used in future national implementation; and, (4) test potential new survey items. This experiment included three currently approved mode protocols most commonly used by hospitals participating in HCAHPS: Mail Only, Phone Only, and Mail-Phone (mail with phone follow-up of non-responders). In this experiment, three additional mode protocols that added an initial Web phase to these current modes were considered: Web-Mail, Web-Phone, and Web-Mail-Phone. In addition, the mode experiment employed a 49-day data collection period for all six modes, which extended the standard HCAHPS data collection period by seven days. Doing so preserved the survey response period of the current survey while adding time for the Web phase. Unlike the current HCAHPS Survey, proxy respondents were not prohibited from completing the survey.

Another goal of the 2021 HCAHPS mode experiment was to test new survey content related to care coordination, discharge experience, communication with patient families, emotional support, sleep, and summoning help. We are using the mode experiment results to inform decisions about potential changes to administration protocols and survey content. Potential measure changes will be submitted to the MUC List in 2023 and may be proposed in future rulemaking. We did not propose changes to the HCAHPS Survey’s content.

(2) Addition of Three New Modes of Survey Implementation

We proposed to add three new modes of survey administration (Web-Mail mode, Web-Phone mode, and Web-Mail-Phone mode) in addition to the current Mail Only, Phone Only and Mail-Phone modes, beginning with January 2025 discharges. We noted that the 2021 HCAHPS mode experiment added an initial web component to three current HCAHPS modes of survey
administration resulting in increased response rates. Overall, 9,642 patients completed a survey, resulting in a 28 percent response rate. The response rate for Mail Only mode was 22 percent, compared to 29 percent for Web-Mail mode. The response rate for Phone Only mode was 23 percent compared to 30 percent through Web-Phone mode. The response rate for Mail-Phone was 31 percent compared to 36 percent for Web-Mail-Phone mode.

Analysis of 2021 mode experiment data also revealed that patients who supplied an email address had a statistically significant higher response rate (31 percent) than patients without an email address (22 percent). The percentage of sampled patients with an email address varied by hospital, ranging from 11 percent to 94 percent. Overall, 63 percent of patients supplied an email address. Evidence from this and previous HCAHPS mode experiments indicates that sequential mixed modes of survey administration (for example, web followed by mail, or phone or both) result in overall higher response rates and better representation of younger, Spanish-language preferring, racial and ethnic minority, and maternity care patients.

We invited public comment on this proposed update.

Comment: A commenter expressed support for proposed changes to the administration of HCAHPS.

Response: We thank the commenter for their support.

Comment: Several commenters supported the additional survey administration modes believing the changes reflect current communication preferences, will increase response rates, and increase patient satisfaction with the survey. A commenter expressed its belief that the expanded internet methods would increase the response rates overall and among younger, Spanish-language preferring, racial and ethnic minority, and maternity care patients. Another commenter believed the addition of the new modes would meaningfully aid in streamlining the data procurement and analysis process, substantially reduce data entry errors, enhance data security, and be cost effective.

Response: We thank the commenters for their support and agree that the addition of these three new modes of survey implementation will likely increase response rates for all patient populations. We also agree that these new modes of survey implementation have the potential to reduce the data collection and management burden while reducing survey administration costs in the long run. We will send a second and third email invitation in the Web-Mail and Web-Phone modes, and a second email invitation in the Web-Mail-Phone mode, to patients who did not respond to earlier email invitations. We note that procedures for survey administration will be clearly defined in the HCAHPS Quality Assurance Guidelines for all survey administration modes.

After consideration of the public comments we received, we are finalizing this policy.

(3) Removal of Prohibition of Proxy Respondents to the HCAHPS Survey

In response to stakeholder feedback, and evidence that proxy response does occur in mail administration despite the current protocol that asks that only the patient complete the survey, the mode experiment assessed the impact of not excluding proxy respondents. We found that not excluding proxies did not impact HCAHPS measure scores and, as such, it is not necessary to control for completion of the survey by a proxy in patient-mix adjustment. Consequently, we propose to remove the requirement that only the patient may respond to the survey and allow a patient’s proxy to respond to the survey, beginning with January 2025 discharges. We will, however, still encourage patients to respond to the survey rather than proxies.

We invited public comment on this proposed update.

Comment: Several commenters expressed support for the allowance of proxies believing it will increase response rates among certain hard to reach groups, provide valuable insight into care improvement, and that the risk of a proxy’s response not being reflective of a patient’s experience is outweighed by the need to attempt to capture the experiences of vulnerable patient populations. A commenter expressed support believing that proxy completion is critical to older patients with serious illness.

Response: We thank the commenters for their support.

After consideration of the public comments we received, we are finalizing this policy.

(4) Extension of the Data Collection Period

The 2021 mode experiment showed that extending the data collection period from 42 to 49 days allows time for respondents in the web-first modes to respond by email before contacting non-responders with the secondary mode of administration while also preserving adequate time for the secondary mode (either mail, phone, or mail followed by phone). Nearly 13 percent of respondents in the mode experiment completed the survey between days 43 and 49. Compared to the first 42 days, during days 43 to 49 there was a statistically significant increase in responses from patients typically under-represented in HCAHPS, including patients who speak Spanish at home, are Black, ages 25 to 34 years old, and with an 8th grade education or less. We therefore proposed to extend the data collection period for the HCAHPS Survey from 42 to 49 days, beginning with January 2025 discharge.

We invited public comment on the proposed change in the length of the data collection period.

Comment: A few commenters expressed support for the extension of the data collection period believing it will improve accessibility; increase engagement with disadvantaged groups and patients, including individuals recovering from an injury or illness; and allow for a more robust data set.

Response: We thank the commenters for their support.

After consideration of the public comments we received, we are finalizing this policy.

(5) Limit on the Number of Supplemental HCAHPS Survey Items

Currently, we do not place a limit on the number of supplemental items that may be added to the HCAHPS survey for quality improvement purposes. We are concerned that this policy has contributed to decline in the survey’s response rate. Other CMS CAHPS surveys limit the number of supplemental items that may be added to prevent the survey from becoming so long that the response rate is negatively impacted. For example, the Medicare Advantage and Prescription Drug Plan (MA & PDP) CAHPS survey limits the number of supplemental items to a maximum of 12. Evidence from the 2016 HCAHPS mode experiment, as well as from the MA & PDP CAHPS Survey, strongly indicates that survey response rates decrease as the number of supplemental items increases. Analysis of the 2016 HCAHPS mode experiment data revealed that in the Mixed Mode (mail survey with phone follow-up of non-responders) 12 supplemental items would be expected to reduce HCAHPS response rates by 2.7 percentage points. An analysis of data from the MA & PDP CAHPS project found a 2.5 percentage point reduction in response rate associated with 12 supplemental items in Mixed Mode.767 This is particularly


relevant because it includes both mail and phone, the two most commonly used survey modes for HCAHPS. Declines of this magnitude represent a substantial loss in response rate. The proposed limit of 12 supplemental items aligns with other CMS CAHPS surveys.

We invited public comment on our proposal to limit the number of supplemental items. We also welcomed suggestions for alternative limits below 12 supplemental items.

Comment: A few commenters expressed support for the proposed limit on the number of supplemental HCAHPS Survey items preferring shorter surveys.

Response: We thank the commenters for their support.

After consideration of the public comments we received, we are finalizing this policy.

(6) Requirement to Use Official Spanish Translation for Spanish-Language-Preferring Patients

We have created official translations of the HCAHPS Survey in eight languages in addition to English to accommodate patient populations.8788 PCHs’ use of these translations, however, is voluntary. To ensure that all Spanish-language-preferring patients, who constitute about four percent of HCAHPS respondents, have the opportunity to receive the Spanish translation of the HCAHPS Survey, we proposed that PCHs be required to collect information about the language that the patient speaks while in the PCH (whether English, Spanish, or another language), and that the official CMS Spanish translation of the HCAHPS Survey be administered to all patients who prefer Spanish, beginning with January 2025 discharges.

We invited public comment on the proposed requirement to administer the survey in Spanish. We also welcomed suggestions for additional translations beyond the existing translations in Spanish, Chinese, Russian, Vietnamese, Portuguese, German, Tagalog, and Arabic.

Comment: A few commenters expressed support believing the requirement will improve accessibility and engagement with patients and lead to better collection of preferred language at admission.

Response: We thank the commenters for their support.

10.1093/poq/nfw028

Comment: A few commenters made recommendations including that CMS expand the list of approved languages to include Haitian Creole and that CMS use the data from hospitals tracking languages spoken to make additional official translations available or mandated.

Response: We thank the commenters for their recommendations regarding future translations of HCAHPS and further validation of existing translated versions and we will take these recommendations into consideration for future program years.

Comment: A commenter expressed support for the proposal, but also expressed its belief that the proposal would require a patient that is a Spanish speaker to be provided the official CMS Spanish translation of the HCAHPS Survey and recommended the patient should be given the option of both versions.

Response: We appreciate the commenter’s support. We would also clarify that the proposal would not require that a Spanish speaker be provided the Spanish language version of the HCAHPS survey, but instead that the Spanish language version would be offered to patients who identify as Spanish-preferred, not all Spanish-speaking patients.

After consideration of the public comments we received, we are finalizing this policy.

(7) Removal of an Administration Method

We proposed to remove one of the currently available options for administration of the HCAHPS Survey that are not used by participating PCHs. The Active Interactive Voice Response (IVR) survey mode, also known as touch-tone IVR, has not been employed by any hospital since 2016 and has never been widely used for the HCAHPS Survey. To streamline HCAHPS oversight and training, we proposed to discontinue IVR as an approved mode of survey administration beginning in January 2025. With the addition of three new web-based modes in January 2025, PCHs will have the option to choose among six modes of survey administration: Mail Only, Phone Only, Mixed Mode (mail followed by phone), Web-Mail mode, Web-Phone mode, and Web-Mail-Phone mode (web followed by mail, followed by Phone).

In addition, we encouraged participating PCHs to carefully consider the impact of mode of survey administration on response rates and the representativeness of survey respondents. High response rates for all patient groups promote our health equity goals. Our research on the HCAHPS Survey indicates that there are pronounced differences in response rates by mode of survey administration for some patient characteristics. In particular, Black, Hispanic, Spanish language-prefering, younger, and maternity patients are more likely to respond to a phone survey, while older patients are more likely to respond to a mail survey. Choosing a mode that is easily accessible to the diversity of a PCH’s patient population provides a more complete representation of patients’ care experiences. For more information, we refer PCHs to the podcast, “Improving Representativeness of the HCAHPS Survey” on the HCAHPS website: https://hcahpsonline.org/en/podcasts/#ImprovingRepresentativeness.

Comment: Several commenters expressed support for the removal of an administration method that has not been used by hospitals.

Response: We thank the commenters for their support.

After consideration of the public comments we received, we are finalizing this policy.

(8) Data Collection

The HCAHPS Survey will be administered and data collected in exactly the same manner as the current HCAHPS Survey, except for the changes described in this section of the preamble of this final rule. There will be no changes to HCAHPS patient eligibility or exclusion criteria. Detailed information on HCAHPS data collection protocols can be found in the current HCAHPS Quality Assurance Guidelines, located at: https://www.hcahpsonline.org/en/quality-assurance/.

We invited public comments on these proposals.

Comment: A commenter expressed support for the update to data collection.

Response: We thank the commenter for their support.

After consideration of the public comments we received, we are finalizing this policy.

(9) Public Reporting

The scoring of the updated HCAHPS Survey will be the same as the current HCAHPS Survey. Detailed information on how the measure will be scored for purposes of public reporting can be found on the HCAHPS website at: https://hcahpsonline.org/en/hcahps-star-ratings/.

We invited public comments on these proposals.
We did not receive any public comments on this topic; therefore, we are finalizing this policy.

11. Extraordinary Circumstances Exceptions (ECE) Policy Under the PCHQR Program

We refer readers to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41623 through 41624), for a discussion of the Extraordinary Circumstances Exceptions (ECE) policy under the PCHQR Program. We did not propose any changes to this policy.

E. Long-Term Care Hospital Quality Reporting Program (LTCH QRP)

1. Background and Statutory Authority

The Long-Term Care Hospital Quality Reporting Program (LTCH QRP) is authorized by section 1886(m)(5) of the Act, and it applies to all hospitals certified by Medicare as Long-Term Care Hospitals (LTCHs). Section 1886(m)(5)(C) of the Act requires LTCHs to submit to the Secretary quality measure data specified under section 1886(m)(5)(D) in a form and manner, and at a time, specified by the Secretary. Under the LTCH QRP, the Secretary must reduce by 2 percentage points the annual update to the LTCH PPS standard Federal rate for discharges for an LTCH during a fiscal year (FY) if the LTCH has not complied with the LTCH QRP requirements specified for that FY. Section 1890A of the Act requires that the Secretary establish and follow a pre-rulemaking process, in coordination with the consensus-based entity (CBE) with a contract under section 1890(a) of the Act, to solicit input from certain groups regarding the selection of quality and efficiency measures for the LTCH QRP. We have codified our program requirements in our regulations at 42 CFR 412.560.

In the proposed rule, we proposed to modify one measure in the LTCH QRP as described in section IX.E. of the preamble of this final rule. Second, we proposed to adopt two new measures, and remove two existing measures. Third, we sought information on principles CMS could use to select and prioritize LTCH QRP quality measures in future years. Fourth, we provided an update on our efforts to close the health equity gap. Fifth, we proposed to change the LTCH QRP data completion thresholds. Finally, we proposed to begin public reporting of four measures.

2. General Considerations Used for the Selection of Quality Measures for the LTCH QRP

For a detailed discussion of the considerations we historically use for the selection of LTCH QRP quality, resource use, and other measures, we refer readers to the FY 2016 Inpatient Prospective Payment System (IPPS)/LTCH PPS final rule (80 FR 49728).

3. Quality Measures Currently Adopted for the FY 2024 LTCH QRP

The LTCH QRP currently has 18 measures for the FY 2024 LTCH QRP, which are set out in Table IX.E.–01. For a discussion of the factors used to evaluate whether a measure should be removed from the LTCH QRP, we refer readers to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41624 through 41654) and to the regulations at 42 CFR 412.560(b)(3).
Table IX.E.-01. Quality Measures Currently Adopted for the FY 2024 LTCH QRP

<table>
<thead>
<tr>
<th>Short Name</th>
<th>Measure Name &amp; Data Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>LTCH CARE Data Set</td>
<td></td>
</tr>
<tr>
<td>Pressure Ulcer/Injury</td>
<td>Changes in Skin Integrity Post-Acute Care: Pressure Ulcer/Injury</td>
</tr>
<tr>
<td>Application of Falls</td>
<td>Application of Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay)</td>
</tr>
<tr>
<td>Functional Assessment</td>
<td>Percent of Long-Term Care Hospital (LTCH) Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function</td>
</tr>
<tr>
<td>Application of Functional Assessment/Care Plan</td>
<td>Application of Percent of Long-Term Care Hospital (LTCH) Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function</td>
</tr>
<tr>
<td>Change in Mobility</td>
<td>Functional Outcome Measure: Change in Mobility Among Long-Term Care Hospital (LTCH) Patients Requiring Ventilator Support</td>
</tr>
<tr>
<td>DRR</td>
<td>Drug Regimen Review Conducted With Follow-Up for Identified Issues–Post Acute Care (PAC) Long-Term Care Hospital (LTCH) Quality Reporting Program (QRP)</td>
</tr>
<tr>
<td>Compliance with SBT</td>
<td>Compliance with Spontaneous Breathing Trial (SBT) by Day 2 of the LTCH Stay</td>
</tr>
<tr>
<td>Ventilator Liberation</td>
<td>Ventilator Liberation Rate</td>
</tr>
<tr>
<td>TOH–Provider</td>
<td>Transfer of Health Information to the Provider Post-Acute Care (PAC)</td>
</tr>
<tr>
<td>TOH–Patient</td>
<td>Transfer of Health Information to the Patient Post-Acute Care (PAC)</td>
</tr>
<tr>
<td>CAUTI</td>
<td>National Healthcare Safety Network (NHSN) Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure</td>
</tr>
<tr>
<td>CDI</td>
<td>National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset Clostridium difficile Infection (CDI) Outcome Measure</td>
</tr>
<tr>
<td>HCP Influenza Vaccine</td>
<td>Influenza Vaccination Coverage among Healthcare Personnel</td>
</tr>
<tr>
<td>HCP COVID-19 Vaccine</td>
<td>COVID-19 Vaccination Coverage among Healthcare Personnel</td>
</tr>
<tr>
<td>Claims-Based</td>
<td></td>
</tr>
<tr>
<td>MSPB LTCH</td>
<td>Medicare Spending Per Beneficiary (MSPB)–Post Acute Care (PAC) Long-Term Care Hospital (LTCH) Quality Reporting Program (QRP)</td>
</tr>
<tr>
<td>DTC</td>
<td>Discharge to Community (DTC)–Post Acute Care (PAC) Long-Term Care Hospital (LTCH) Quality Reporting Program (QRP)</td>
</tr>
<tr>
<td>PPR</td>
<td>Potentially Preventable 30-Day Post-Discharge Readmission Measure for Long-Term Care Hospital (LTCH) Quality Reporting Program (QRP)</td>
</tr>
</tbody>
</table>

4. Overview of LTCH QRP Quality Measures

In the proposed rule, we included LTCH QRP proposals for FY 2025 and FY 2026 LTCH QRP. Beginning with the FY 2025 LTCH QRP, we proposed to (1) modify the COVID–19 Vaccination Coverage among Healthcare Personnel (HCP) measure; (2) adopt the Discharge Function Score, which we are specifying under section 1886(m)(5)(F)(i) of the Act; and (3) remove two current measures: (i) the Application of Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function measure and (ii) the Percent of LTCH Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function measure.

Beginning with the FY 2026 LTCH QRP, we proposed to adopt the COVID–19 Vaccine: Percent of Patients/Residents Who Are Up to Date measure, which we are specifying under section 1899B(d)(1) of the Act.

a. Modification of the COVID–19 Vaccination Coverage Among Healthcare Personnel (HCP) Measure Beginning With the FY 2025 LTCH QRP

As we stated in the FY 2022 LTCH PPS final rule (86 FR 45375) and in the Guidance for Staff Vaccination Requirements, vaccination is a critical part of the Nation’s strategy to effectively counter the spread of COVID–19. While the PHE status ended on May 11, 2023, HHS has stated that the public health response to COVID–19 remains a public health priority with a whole of government approach to combatting the virus, including through vaccination efforts. We continue to

789 This measure was submitted to the Measures Under Consideration (MUC) List as the Cross-Setting Discharge Function Score. Subsequent to the MAP Workgroup meetings, the measure developer modified the name. Discharge Function Score for Long-Term Care Hospitals (LTCHs) Technical Report. https://www.cms.gov/files/document/ltch-discharge-function-score-technical-report-february-2023.pdf.


believe it is important to incentivize and track HCP vaccination in LTCHs through quality measurement in order to protect healthcare workers, patients, and caregivers, and to help sustain the ability of LTCHs to continue serving their communities throughout the public health emergency (PHE) and beyond. We proposed to modify the COVID–19 Vaccination Coverage among Healthcare Personnel (HCP) measure beginning with the FY 2025 LTCH QRP, to require that LTCHs track HCP vaccination in LTCHs, to utilize the term “up to date” in the HCP COVID–19 Vaccine measure beyond. We proposed to modify the COVID–19 Vaccination Coverage among Healthcare Personnel (HCP) measure beginning with the FY 2025 LTCH QRP, to require that LTCHs track HCP vaccination in LTCHs, to utilize the term “up to date” in the HCP COVID–19 Vaccine measure, including booster doses, beginning with the FY 2025 LTCH QRP.

The full proposal can be found in section IX.B. of this final rule. We invited public comment on our proposal to modify the COVID–19 Vaccination Coverage among Healthcare Personnel (HCP) measure beginning with the FY 2025 LTCH QRP. A summary of the comments we received on our proposal to modify the COVID–19 Vaccination Coverage among Healthcare Personnel (HCP) measure beginning with the FY 2025 LTCH QRP and our responses can be found in section IX.B. of this final rule.

b. Discharge Function Score Measure Beginning With The FY 2025 LTCH QRP

(1) Background

LTCHs provide medical care for clinically complex patients with multiple acute or chronic conditions, including patients requiring mechanical ventilation, and who require care for a relatively extended period of time. Many LTCH patients are at a high risk for profound debilitation due to functional limitations arising from their highly complex conditions and treatment requirements. Patients frequently have respiratory conditions, including pulmonary edema and respiratory failure and respiratory system diagnoses with ventilator support, septicemia, renal failure, heart failure, skin ulcers, infectious and parasitic disease, or diabetes. As a result of the COVID–19 PHE, post-COVID patients who required or still require ventilator support are often treated at LTCHs. For these patients, research has shown that addressing their functional deficits can improve patients’ mobility, their capabilities in daily life activities, and their participation in society, all of which can lead to an improved quality of life. Section 1886(m)(5)(F)(i) of the Act, cross-referencing subsections (b), (c), and (d) of section 1899B of the Act, requires CMS to develop and implement standardized quality measures from five quality measure domains, including the domain of functional status, cognitive function, and changes in function and cognitive function, across the post-acute care (PAC) settings, including LTCHs. To satisfy this requirement, CMS adopted the Application of Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (Application of Functional Assessment/Care Plan) measure, for the LTCH QRP in the FY 2015 IPPS/LTCH PPS final rule (80 FR 49739 through 49747). While that process measure allowed for the standardization of functional assessments across assessment instruments and facilitated cross-setting data collection, quality measurement, and interoperable data exchange, we believe it is now toppped out and proposed to remove it in section IX.E.4.c of the proposed rule. While there is an additional outcome measure addressing functional status that can reliably distinguish performance among providers in the LTCH QRP, that outcome measure only captures patients requiring ventilator support at admission. In contrast, a cross-setting functional outcome measure would include the LTCH population regardless of ventilation status. Moreover, the proposed measure specifications would be aligned across settings. Including the use of a common set of standardized functional assessment data elements.

(a) Measure Importance

Maintenance or improvement of physical function among older adults is increasingly an important focus of health care. Adults age 65 years and older constitute the most rapidly growing population in the United States, and functional capacity in physical (non-psychological) domains has been shown to decline with age. Moreover, impaired functional capacity is associated with poorer quality of life and an increased risk of all-cause mortality, postoperative complications, and cognitive impairment, the latter of which can complicate the return of a patient to the community from post-acute care.

Nonetheless, evidence suggests that physical functional abilities, including mobility and self-care, are modifiable predictors of patient outcomes across PAC settings, including functional recovery or decline after post-acute care.

798

PMCID: PMC3578448.


discharge to community, and falls. The implementation of interventions that improve patients’ functional outcomes and reduce the risks of associated undesirable outcomes as a part of a patient-centered care plan is essential to maximizing functional improvement. For many people, the overall goals of LTCH care may include optimizing functional improvement, returning to a previous level of independence, maintaining functional abilities, or avoiding institutionalization. Studies have suggested that rehabilitation services provided in LTCHs can improve patients’ motor function at discharge for geriatric patients and patients with various diagnoses, including dementia. Moreover, assessing functional status as a health outcome in LTCHs may provide valuable information in determining treatment decisions throughout the care continuum, such as the need for rehabilitation service and discharge planning, as well as provide information to consumers about the effectiveness of skilled nursing services and rehabilitation services delivered. Because evidence shows that older adults experience aging heterogeneously and require individualized and comprehensive health care, functional status can serve as a vital component in informing the provision of health care and thus indicate an LTCH’s quality of care.

We propose to adopt the Discharge Function Score (DC Function) measure in the LTCH QRP beginning with the FY 2025 LTCH QRP. This assessment-based outcome measure evaluates functional status by calculating the percentage of LTCH patients who meet or exceed an expected discharge function score. If finalized, this measure would replace the topped-out Application of Functional Assessment/Care Plan process measure. Like the cross-setting process measure we proposed to remove in section IX.E.4.c. of the preamble of the proposed rule, the DC Function measure would be calculated using standardized patient assessment data from the current LTCH assessment tool, the Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS).

The proposed DC Function measure supports current CMS priorities. Specifically, the measure aligns with the Streamline Quality Measurement domain in CMS’s Meaningful Measures 2.0 framework in two ways. First, the proposed outcome measure could further CMS’s objective to prioritize outcome measures by replacing the current cross-setting process measure (section IX.E.4.c. of the preamble of the proposed rule). Unlike the existing functional outcomes measures, the proposed DC Function measure uses a set of cross-setting assessment items which would facilitate data collection, quality measurement, outcome comparison, and interoperable data exchange among PAC settings. Second, this measure adds no additional provider burden since it would be calculated using data from the LCDS that are already reported to the Medicare program for payment and quality reporting purposes.

The proposed DC Function measure would also follow a calculation approach similar to the existing functional outcome measures, which are CBE endorsed, with some modifications. Specifically, the measure (1) considers two dimensions of function (self-care and mobility activities) and (2) accounts for missing data by using statistical imputation to improve the validity of measure performance. The statistical imputation method is explained in section IX.E.4.a. of the preamble of the proposed rule.
approach recodes missing functional status data to the most likely value had the status been assessed, whereas the current imputation approach implemented in existing functional outcome measures recodes missing data to the lowest functional status. A benefit of statistical imputation is that it uses patient characteristics to produce an unbiased estimate of the score on each item with a missing value. In contrast, the current approach treats patients with missing values and patients who were coded to the lowest functional status similarly, despite evidence suggesting varying measure performance between the two groups, which can lead to less accurate measure performances.

(b) Measure Testing
Measure testing using FY 2019 data was conducted on the DC Function measure to assess validity, reliability, and reportability, all of which informed interested parties’ feedback and Technical Expert Panel (TEP) input (see section IX.E.4.b.3. of the preamble of the proposed rule). Validity was assessed for the measure performance, the risk adjustment model, face validity, and statistical imputation models. Validity testing of measure performance entailed determining Spearman’s rank correlations between the proposed measure’s performance for providers with 20 or more stays and the performance of other publicly reported LTCH quality measures. Results indicated that the measure captures the intended outcome based on the directionality and strengths of correlation coefficients and are further detailed in Table IX.E.—02.

### TABLE IX.E.—02. SPEARMAN’S RANK CORRELATION RESULTS OF DC FUNCTION MEASURE WITH PUBLICLY REPORTED LTCH QUALITY MEASURES

<table>
<thead>
<tr>
<th>Measure – Long Name</th>
<th>Measure – Short Name</th>
<th>ρ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discharge to Community – PAC LTCH QRP</td>
<td>Discharge to Community</td>
<td>0.40</td>
</tr>
<tr>
<td>Potentially Preventable 30-Days Post-Discharge Readmission Measure for LTCH QRP</td>
<td>Potentially Preventable Readmissions within 30 Days Post-Discharge</td>
<td>-0.19</td>
</tr>
<tr>
<td>Medicare Spending Per Beneficiary – PAC LTCH QRP</td>
<td>Medicare Spending Per Beneficiary</td>
<td>-0.13</td>
</tr>
<tr>
<td>Functional Outcome Measure: Change in Mobility Among Long-Term Care Hospital Patients Requiring Ventilator Support</td>
<td>Change in Mobility</td>
<td>0.76</td>
</tr>
</tbody>
</table>

Validity testing of the risk adjustment model showed good model discrimination as the measure model has the predictive ability to distinguish patients with low expected functional capabilities from those with high expected functional capabilities. The ratios of observed-to-predicted discharge function score across eligible stays, by deciles of expected functional capabilities, ranged from 0.96 to 1.06. Both the Cross-Setting Discharge Function TEPs and patient-family feedback showed strong support for the face validity and importance of the proposed measure as an indicator of quality of care (see section IX.G.4.b.3 of the proposed rule). Lastly, validity testing of the measure’s statistical imputation models indicated that the models demonstrate good discrimination and produce more precise and accurate estimates of function scores for items with missing scores when compared to the current imputation approach implemented in the LTCH QRP functional outcome measure, Change in Mobility Among LTCH Patients Requiring Ventilator Support.

Reliability and reportability testing also yielded results that support the measure’s scientific acceptability. Split-half testing revealed the proposed measure’s excellent reliability, indicated by an intraclass correlation coefficient value of 0.94. Reportability testing indicated high reportability (97 percent) of providers meeting the public reporting threshold of 20 eligible stays. For additional measure testing details, we refer readers to the document titled Discharge Function Score for Long-Term Care Hospital (LTCHs) Technical Report.827

(2) Competing and Related Measures
Section 1899B(e)(2)(A) of the Act requires that, absent an exception under section 1899B(e)(2)(B) of the Act, measures specified under section 1899B of the Act be endorsed by the consensus-based entity (CBE) with a contract under section 1890(a). In the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed, section 1899B(e)(2)(B) permits the Secretary to specify a measure that is not so endorsed, as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary.

The proposed DC Function measure is not CBE endorsed, so we considered whether there are other available measures that (1) assess both functional domains of self-care and mobility in LTCHs and (2) satisfy the requirement of the Act to specify standardized quality measures with respect to functional status, cognitive function, and changes in function and cognitive function. While the Application of Functional Assessment/Care Plan measure assesses both functional domains and satisfies the Act’s requirement, this cross-setting process measure is not CBE endorsed and the performance on this measure among LTCHs is so high and unvarying across most LTCHs that the measure does not offer meaningful distinctions in performance. Additionally, after review of CBE-endorsed measures, we were unable to identify any CBE-endorsed measures for LTCHs that meet the aforementioned requirements. While the LTCH QRP includes a CBE endorsed outcome measure addressing functional status, the Change in Mobility measure, this measure assesses a single domain of function and captures only a subset of the assessed LTCH population.

826 “Expected functional capabilities” is defined as the predicted discharge function score.

Therefore, after consideration of other available measures, we found that the exception under section 1890B(e)(2)(B) of the Act applies and proposed to adopt the DC Function measure beginning with the FY 2025 LTCH QRP. We intend to submit the proposed measure to the CBE for consideration of endorsement when feasible.

(3) Interested Parties and Technical Expert Panel (TEP) Input

In our development and specification of this measure, we employed a transparent process in which we sought input from interested parties and national experts and engaged in a process that allowed for pre-rulemaking input, in accordance with section 1890A of the Act. To meet this requirement, we provided the following opportunities for interested parties’ input: a Patient and Family Engagement Listening Session, two TEPs, and public comments through a request for information (RFI).

First, the measure development contractor convened a Patient and Family Engagement Listening Session, during which patients and caregivers provided support for the proposed measure concept. Participants emphasized the importance of measuring functional outcomes and found self-care and mobility to be critical aspects of care. Additionally, they expressed a strong interest in metrics assessing the number of patients discharged from particular facilities with improvements in self-care and mobility, and their views of self-care and mobility aligned with the functional domains captured by the proposed measure. All feedback was used to inform measure development efforts.

The measure development contractor subsequently convened TEPs on July 14–15, 2021, and January 26–27, 2022, to obtain expert input on the development of a cross-setting function measure for use in the LTCH QRP. The TEPs consisted of interested parties with a diverse range of expertise, including LTCH and PAC subject matter knowledge, clinical expertise, patient andfamily perspectives, and measure development experience. The TEPs supported the proposed measure concept and provided the following substantive feedback regarding the measure’s specifications and measure testing data.

First, the TEP was asked whether they prefer a cross-setting measure that is modeled after measures currently adopted in the Inpatient Rehabilitation Facility (IRF) QRP and the Skilled Nursing Facility (SNF)/Nursing Facility (NF), and Home Health (HH) Function Measures Summary Report (July 2021 TEP)828 and Technical Expert Panel (TEP) for Cross-Setting Function Measure Development Summary Report (January 2022 TEP)829 are available on the CMS Measures Management System (MMS) Hub.

Finally, we solicited feedback from interested parties on the importance, relevance, and applicability of a cross-setting functional outcome measure for LTCHs through an RFI in the FY 2023 LTCH PPS proposed rule (87 FR 28568). Commenters were supportive of a cross-setting functional outcome measure that is inclusive of both self-care and mobility items, but also provided information related to potential risk adjustment methodologies as well as other measures that could be used to capture functional outcomes across PAC settings (87 FR 49316).

(4) Measure Application Partnership (MAP) Review

In accordance with section 1890A of the Act, our pre-rulemaking process includes making publicly available a list of quality and efficiency measures, called the Measures Under Consideration (MUC) List, that the Secretary is considering adopting for use in Medicare programs. This allows interested parties to provide recommendations to the Secretary on the measures included on the MUC list.

We included the DC Function measure under the LTCH QRP on the publicly available MUC List for December 1, 2022.830 After the MUC List was published, the CBE convened Measure Applications Partnership (MAP) received one comment supporting the DC Function measure for rulemaking. Shortly after, several CBE

828 Technical Expert Panel (TEP) for the Refinement of Long-Term Care Hospital (LTCH), Inpatient Rehabilitation Facility (IRF), Skilled Nursing Facility (SNF)/Nursing Facility (NF), and Home Health (HH) Function Measures.

convoked MAP workgroups met virtually to provide input on the measure. First, the MAP Health Equity Advisory Group convened on December 6–7, 2022. The Health Equity Advisory Group did not share any health equity concerns related to the implementation of the measure, and only asked for clarification regarding measure specifications from measure developers. The MAP Rural Health Advisory Group met on December 8–9, 2022, during which two members provided support for the DC Function measure and other Rural Health Advisory Group members did not express rural health concerns regarding the measure.

The MAP Post-Acute Care/Long-Term Care (PAC/LTC) workgroup met on December 12, 2022 and provided input on the DC Function measure. During this meeting, we were able to address several concerns raised by interested parties after the publication of the MUC List. Specifically, we clarified that the expected discharge scores are not calculated using self-reported functional goals, and are simply calculated by risk-adjusting the observed discharge scores (see section IV.E.4.b.5. of the preamble of the proposed rule). Therefore, we believe that these scores cannot be “gamed” by reporting less-ambitious functional goals. We also pointed out that the measure is highly usable as it is similar in design and complexity to existing function measures and that the data elements used in this measure are already in use. Lastly, we clarified that the DC Function measure is intended to supplement rather than replace the existing LTC Function measure for mobility, and implements improvements on the existing Application of Functional Assessment/Care Plan and Functional Assessment/Care Plan measures that make the measure more valid and harder to game.

The MAP PAC/LTC workgroup went on to discuss several concerns with the measure, including (1) whether the measure is truly cross-setting due to varying denominator populations across settings, (2) whether the measure would adequately represent the full picture of function, especially for patients who may have a limited potential for functional gain, and (3) that the range of expected scores was too large to offer a functional gain, and (4) that the range of observed scores is consistent with the range of observed scores. The PAC/LTC workgroup voted to support the staff recommendation of conditional support for rulemaking, with the condition that we seek CBE endorsement.

In response to the PAC/LTC workgroup’s preliminary recommendation, the CBE received two additional comments from interested parties supporting the PAC–LTC workgroup’s preliminary recommendation of conditional support for rulemaking. A commenter recommended the DC Function measure under the condition that it be reviewed and refined such that implementation would support patient autonomy and result in care that aligns with patients’ personal functional goals. The second commenter provided support for the measure under the condition that it produces statistically meaningful information that can inform improvements in care processes, while also expressing concern that the measure is not truly cross-setting because it utilizes different patient populations and risk-adjustment models with setting-specific covariates across settings. Additionally, this commenter noted that using a single set of cross-setting section GG items is not appropriate since the items may not be relevant across varying patient populations.

Finally, the MAP Coordinating Committee convened on January 24–25, 2023. CMS noted again that the TEP had reviewed the item set and determined that all the self-care and mobility items were suitable for all settings. Further, we clarified that, because the DC Function measure would assess whether a patient met or exceeded their expected discharge score, it accounts for patients who are not expected to improve. Lastly, we noted that the DC Function measure has a high degree of correlation with the existing function measures and that the range of expected scores is consistent with the range of observed scores. The PAC/LTC workgroup voted to support the recommendation of conditional support for rulemaking, with the condition that we seek CBE endorsement.

The proposed outcome measure estimates the percentage of LTCH patients who meet or exceed an expected discharge score during the reporting period. The proposed measure’s numerator is the number of LTCH stays with an observed discharge function score that is equal to or greater than the calculated expected discharge function score. The observed discharge function score is the sum of individual function item values at discharge. The expected discharge function score is computed by risk-adjusting the observed discharge function score for each LTCH stay. Risk adjustment controls for patient characteristics such as admission function score, age, and clinical conditions. The denominator is the total number of LTCH stays within an LCDS record in the measure target period (four rolling quarters) that do not meet the measure exclusion criteria. For additional details regarding the numerator, denominator, risk adjustment, and exclusion criteria, refer to the Discharge Function Score for Long Term Care Hospitals (LTCHs) Technical Report.

The proposed measure implements a statistical imputation approach for handling “missing” standardized functional assessment data elements. The coding guidance for standardized functional assessment data elements allows for using “Activity Not Attempted” (ANA) codes, resulting in “missing” information about a patient’s functional ability on at least some items, at admission and/or discharge, for a substantive portion of LTCH patients. Currently, the functional outcome measures in the LTCH QRP use a simple imputation method whereby all ANA codes or otherwise missing scores, on both admission and discharge records, are recoded to “1” or “0” for dependent.” Statistical imputation, on the other hand, replaces these missing values with a variable based on the values of other, non-missing variables in the assessment and on the values of other assessments which are otherwise similar to the assessment with a missing value. Specifically, in the proposed DC Function measure’s statistical imputation allows missing values (for example, the ANA codes) to be replaced

---


with any value from 1 to 6, based on a patient’s clinical characteristics and codes assigned on other standardized functional assessment data elements. The measure implements separate imputation models for each standardized functional assessment data element used in construction of the admission score and the discharge score. Relative to the current simple imputation method, this statistical imputation approach increases precision and accuracy and reduces the bias in estimates of missing item scores. We refer readers to the Discharge Function Score for Long Term Care Hospitals (LTCHs) Technical Report833 for measure specifications and additional details.

We invited public comment on our proposal to adopt the DC Function measure beginning with the FY 2025 LTCH QRP. The following is a summary of the comments we received on our proposal to adopt the DC Function measure, beginning with the FY 2025 LTCH QRP, and our responses.

Comment: Several commenters provided support for the DC Function measure. A commenter supported the proposed adoption of the DC Function measure, noting its importance as a patient-centered measure; however, this commenter strongly encouraged CMS to submit the measure for CBE endorsement.

Response: We thank the commenters for their support of the proposed measure. We intend to submit the proposed measure to the CBE for consideration of endorsement when feasible.

Comment: A commenter preferred separate quality measures for self-care and mobility to ensure each setting is able to capture items most relevant to its patient population needs and goals and use the measures to determine meaningful quality improvement activities. However, this commenter stated that if CMS uses one measure, then they would support the proposed measure since it does capture both self-care and mobility items, but encouraged the review and refinement of the measure as needed.

Response: We thank the commenter for their support and agree with the importance of capturing both self-care and mobility items in the proposed measure as well as capturing each dimension of function in separate measures, one of which is reflected in the Change in Mobility Score for Ventilator Patients measure in the LTCH QRP. As with all other measures, we will routinely monitor this measure to ensure the measure maintains strong scientific acceptability and utility to ensure it captures the relevant patient population needs and goals.

Comment: Several commenters opposed the proposed DC Function measure stating LTCH patients’ capabilities and goals differ from other post-acute care settings, making this measure inappropriate for LTCHs. Two of these commenters explained that improved function upon discharge is not the primary goal of critically ill LTCH patients. One of these two commenters expanded that the functional improvements LTCH patients likely experience would not be visible in the DC Function measure, and they are concerned with using the DC Function measure to assess quality or using it in public reporting since measure scores between LTCHs and other PAC settings may be inappropriately compared. Finally, another commenter believed that to see LTCH patients’ progression reflected in the proposed measure, LTCHs would be required to keep patients longer, causing financial burden for potential unpaid days.

Response: We acknowledge that different patient populations are served across the PAC settings, including LTCHs, and the capabilities and goals of these populations differ. However, measuring function is important in all PAC settings and is appropriate for LTCHs. The PFAs we engaged in the development of the DC Function measure supported this measure’s concept. We also understand that for many people, the overall goals of LTCH care may include maintaining functional abilities and avoiding institutionalization in addition to optimizing functional improvement and returning to a previous level of independence. We acknowledge that significant improvement may not be attainable in very low or high acuity patients. Because we recognized these cases, the proposed measure assesses whether a patient met or exceeded their expected discharge score and thus accounts for patients who are not expected to improve during their LTCH stay. For each stay included in the measure calculations, the observed function score is compared to the expected discharge score, which is adjusted to account for clinical characteristics, admission functional status, and demographic characteristics of the patient. Risk adjustment creates an individualized expectation for discharge function score for each stay that controls for these factors and ensures that each stay is measured against an expectation that is calibrated to the patient’s individual circumstances when determining the numerator for each discharge function score.

Because LTCHs determine when a patient is ready for discharge, keeping in mind the patient’s health and safety, and are responsible to have an effective discharge planning process that is consistent with the patient’s goals for care834 they coordinate the appropriate transition plan. Also, to clarify that cross-setting measures do not necessarily suggest that facilities can and should be compared across settings. Instead, these measures are intended to compare providers within a specific setting while standardizing measure specifications across settings. The proposed measure does just this, by aligning measure specifications across settings and using a common set of standardized functional assessment data elements.

Comment: A commenter believed that the Discharge to Community measure captures LTCH patient outcomes better than the DC Function measure.

Response: This commenter did not elaborate on why they believe the Discharge to Community (DTC) measure captures patient outcomes better, so we cannot address their point. However, we agree the DTC measure is an important measure for capturing LTCH patient outcomes. The DTC and DC Function measures have a correlation of 0.45, demonstrating that the proposed measure and the DTC measure each capture different aspects of care, with the proposed measure capturing functional status at discharge and the DTC measure capturing the successful discharge to the community after an LTCH stay. As such, each measure provides different insight into the quality of patient care and therefore, adds a different value to the LTCH QRP measure set.

Comment: Three commenters opposed the proposed DC Function measure because they believe the measure is not cross-setting. Two of these commenters stated that the measure is only “cross-setting” in name and that while the measure attempts to take into account the “myriad of differences” in the patient populations across settings, the DC Function measure is nevertheless four different measures across settings because the differences in patient populations alter


834Section 482.43, Condition of participation: Discharge planning.
the underlying calculation of the cross-setting measure.

Response: We acknowledge that different patient populations are served across the post-acute care settings and the capabilities and goals of these populations differ. However, we would like to clarify that cross-setting measures do not necessarily suggest that facilities can and should be compared across settings. Instead, these measures are intended to compare providers within a specific setting while standardizing measure specifications across settings. The proposed measure does just this by aligning measure specifications across settings and using a common set of standardized functional assessment data elements. This alignment satisfies the requirement of section 1886(m)(5) of the Act for a cross-setting measure in the functional status domain specified under section 1899B(c)(1) of the Act.

Comment: A commenter requested a rationale as to why confidence intervals were not calculated and reported for the expected function scores and utilized in determining meaningful differences between the observed and expected function score. This commenter also stated that the minimum clinical difference in discharge function scores that indicates a change is meaningful to patient progress has not been identified.

Response: The proposed DC function measure uses the same approach in determining whether an observed discharge score is different than its associated, expected discharge score as the currently adopted function measures that are CBE endorsed. Specifically, the DC Function measure reports the proportion of a given provider’s stays where observed discharge function matches or exceeds expected discharge function. The measure score is a continuous variable with values between 0 and 100, allowing for intuitive interpretation and comparisons. Our TEP supported that patients and families are more likely to understand a measure that expresses functional outcome as a simple proportion of patients who meet expectation for their discharge functional status, rather than units of change in a scoring system that is unfamiliar to most Care Compare website users (the primary audience for this measure). Measure scores based on statistical significance of differences between observed and expected values (based on confidence intervals) place providers in broad categories, such as “No different than national average,” which do not allow more granular provider comparisons for the public reviewing the measure’s data on Care Compare. Given the excellent reliability of the DC Function measure, reporting provider scores as broad categories is not warranted.

Comment: A commenter noted the variability in median scores and believed this range suggests the measure may not be valid, and that the variability may be problematic when making comparisons among providers.

Response: We would like to clarify that median scores are not used in the calculation of this measure. While we would require additional information regarding the median scores referenced in this comment to provide a more complete response, we acknowledge that the measure has a large range of average expected discharge scores, as calculated for each provider. This range is consistent with the range of observed discharge scores, indicating that the measure is capturing the range of patient’s functional abilities, and thus, in fact, supports the validity of the measure.

Comment: A commenter noted that intrinsic to the discharge scores are the associated admission scores, and suggested an analysis of this measure to assess the variability in initial admission function scores between hospitals for similar types of patients. Differences may account for the gaps in the observed discharge function scores.

Response: We acknowledge that the observed gap in discharge function scores may be due to variability in the initial admission function scores. The admission function scores are included as covariates in the risk adjustment model and thus are accounted for in the calculation of the expected discharge function scores.

Comment: A commenter questioned CMS’ characterization of the adjusted R-squared value of 0.65 for the proposed DC Function measure’s risk adjustment model. This commenter believed a 0.65 suggested moderate, rather than “good” model discrimination. This commenter suggested CMS should address the ability of the risk adjustment model to make predictions by comparing R-squared values of the “training” and “validation” sets and reporting “predicted R-squared” values.

Response: We want to clarify that the adjusted R-squared for the DC Function measure, as reported in the Discharge Function Score for Long-Term Care Hospitals (LTCHs) Technical Report, was 0.65. This value indicates “good” model discrimination and it is comparable to or greater than those of existing LTCH QRP measures, such as the Medicare Spending Per Beneficiary (0.45) and Change in Mobility for Ventilator Patients (0.16) measures. Additionally, because the measure model uses all available data, the concepts of ‘training’ and ‘validation’ sets (and any related ‘predicted R-squared’) are not applicable. Rather, adjusted R-squared values capture model fit for the risk-adjustment model.

Comment: Several commenters did not support the adoption of this proposed measure because it lacks CBE endorsement or has not undergone the CBE endorsement process. Three of these commenters noted that the CBE endorsement process provides information on whether the measure provides valuable information that can be used to inform improvements in care.

Response: We direct readers to section IX.E.4.b.1. of this final rule, where we discuss this topic in detail. Measures adopted in the LTCH QRP are not required to be CBE endorsed. Section 1899B(e)(2)(B) of the Act permits the Secretary to specify a measure that is not CBE endorsed, as long as due consideration is given to the measures that have been endorsed or adopted by a consensus organization identified by the Secretary. Despite the current absence of CBE endorsement for this measure, it is important to adopt the DC Function measure into the LTCH QRP because the DC Function measure relies on functional status data elements collected in all PAC settings. The measure also satisfies the requirement for a cross-setting quality measure as set forth in sections 1886(m)(5) and 1899B(c)(1)(A) of the Act, and assesses both domains of self-care and mobility. We also direct readers to section IX.E.4.b.2. of this final rule, where we discuss measurement gaps that the DC function measure fulfills in relation to competing and related measures. We also acknowledge the importance of the CBE endorsement process and plan to submit the proposed measure for CBE endorsement when feasible. We direct readers to section IX.E.4.b.1.b. of this final rule, and the technical report for detailed measures testing results demonstrating that the measure provides meaningful information which can be used to improve quality of care, and to the TEP report summaries.

836 Technical Expert Panel (TEP) for the Refinement of Long-Term Care Hospital (LTCH), Inpatient Rehabilitation Facility (IRF), Skilled Nursing Facility (SNF)/Nursing Facility (NF), and Home Health (HH) Function Measures Summary Report (July 2021 TEP) is available at https://mms-
which detail TEP support for the proposed measure concept.

Comment: Two commenters opposed the adoption of the DC Function measure because they do not believe it is appropriate or accurate for CMS to override the clinical judgement of the clinicians who are treating the patient by using statistical imputation to impute a value to a data element when an ANA (Activity Not Attempted) code is used. These commenters noted that the “Activity Not Attempted” codes allow clinicians to use their professional judgement when certain activities should not or could not be safely attempted by the patient, which may be due to medical reasons.

Response: We acknowledge that the “Activity Not Attempted” (ANA) codes allow clinicians to use their professional judgement when certain activities should not or could not be attempted safely by the patient and that there may be medical reasons that a patient cannot safely attempt a task. We note that we did not propose changes to the coding guidance for using ANA codes, and we would not expect LTCH coding practices to change. However, we want to clarify that utilizing statistical imputation to calculate a quality measure does not override the clinical judgement of clinicians who are expected to continue determining whether certain activities can be safely attempted by patients at the time of admission and discharge, and utilize that information to determine appropriate goals and treatment interventions for their LTCH patients. Rather, statistical imputation is a component in measure calculation of reported data and improves upon the current imputation approach in the currently adopted Change in Mobility Score for Ventilator Patients measure. In this currently adopted measure, ANA codes are always imputed to 1 (dependent) when calculating the measure scores, regardless of a patient’s own clinical and functional information. However, the imputation approach implemented in the proposed DC Function measure uses each patient’s available functional and clinical information to estimate each ANA value had the item been completed. Testing demonstrates that, relative to the current simple imputation method, the statistical imputation approach used in this DC Function measure increases precision and accuracy and reduces bias in estimates of ANA values.

Comment: Three commenters expressed concern about the calculation of expected scores. Two of these commenters believed that the proposed measure numerator is not wholly attributed to facility’s quality of care and that the calculation of the “expected” discharge score is opaque, resulting in difficulty for providers to determine the score that they’re striving for. These commenters further noted that functional goals are not based on statistical regression and are identified via individual-specific goals related to function, independence, and overall health. One of these commenters requested clarification about whether the expected scores are calculated by using patient admission goals or risk adjustment.

Response: We agree with the commenter that functional goals are identified for each patient as a result of an individual assessment and clinical decisions, rather than statistics. We want to remind commenters that the DC Function measure is not calculated using the goals identified in clinical process. The “expected” discharge score is calculated by risk-adjusting the observed discharge score (that is, the sum of individual function item values at discharge) for admission functional status, age, and clinical characteristics using an ordinary least squares linear regression model. To clarify, the model intercept and risk adjustor coefficients are determined by running the risk adjustment model on all eligible LTCH stays. For more detailed measure specifications, we direct readers to the document titled Discharge Function Score for Long-Term Care Hospitals (LTCHs) Technical Report.838 The risk-adjustment model for this measure controls for clinical, demographic, and function characteristics to ensure that the score fully reflects a facility’s quality of care.

Comment: A commenter suggested for CMS to be more involved with clinicians in discussions surrounding the assessment and coding of patients rather than using an imputation approach if there is concern that ANA codes are not truly reflective of patients’ function abilities.

Response: We have engaged with post-acute care providers on several occasions. As described in Section IX.E.4.b.3. of this final rule, our measure development contractor convened two TEPs to obtain expert clinician input on the development of the measure. The TEPs consisted of interested parties with a diverse range of expertise, including LTCH and other PAC subject matter expertise, clinical knowledge, and measure development experience. As described in the PAC QRP Functions TEP Summary Report—March 2022,839 panelists agreed that the recode approach used in the already adopted functional outcome measures could be improved upon and reiterated that not all ANAs reflect dependence on a function activity. Based on the extensive testing results presented to the TEP, a majority of panelists favored the statistical imputation over alternative methodologies and an imputation method that is more accurate over one that is simpler.

Comment: A commenter expressed concern with the proposed statistical imputation approach utilized in the DC Function measure, and suggested it might lead to this measure score varying significantly from the existing function outcome measure.

Response: It is important to capture both self-care and mobility items in the proposed measure as well as capturing each dimension of function in separate measures, which is reflected in the Change in Mobility Score for Ventilator Patients measure in the LTCH QRP. The DC Function measure captures information that is distinct from the Change in Mobility Score for Ventilator Patients measure. Specifically, the DC Function measure considers both dimensions of function (utilizing a subset of self-care and mobility GG items on the LCDS), controls for admission function levels, and applies to a much larger set of LTCH patients, while the Change in Mobility Score for Ventilator Patients measure considers one dimension of function (utilizing only mobility GG items), does not control for mobility at admission, and is only applied to a subset of patients (those requiring ventilator support). For these same reasons, we expect to see differences in outcome percentages among these two measures for reasons unrelated to the imputation approach used.

Comment: A commenter expressed that the adoption of the proposed measure would result in additional provider burden. This commenter explained that the measure would increase costs and administrative


burden due to the measure’s complexity.

Response: The adoption of the proposed measure would not result in additional burden because we are not proposing changes to the number of items required or the reporting frequency of the items reported. In fact, this measure requires the same set of data elements that are currently reported. Additionally, CMS calculates this measure for LTCHs, and provides LTCHs with various resources to review and monitor their own performance on this measure.

After careful consideration of the public comments we received, we are finalizing our proposal to adopt the DC Function measure as an assessment-based outcome measure beginning with the FY 2025 LTCH QRP as proposed.

c. Removal of the Application of Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Functional Measure. Beginning With the FY 2025 LTCH QRP

We proposed to remove the process measure, Application of Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Functional Measure. Beginning With the FY 2025 LTCH QRP.

We invited public comment on our proposal to remove the Application of Functional Assessment/Care Plan measure from the FY 2025 LTCH QRP. We received comments from several sources.

Several commenters supported the removal of the Application of Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Functional Measure. Beginning With the FY 2025 LTCH QRP. The following is a summary of the comments we received on our proposal to remove the Application of Functional Assessment/Care Plan measure from the FY 2025 LTCH QRP.

Comment: Several commenters expressed support for the removal of the Application of Functional Assessment/Care Plan measure. A commenter noted their support in conjunction with the adoption of the DC Function measure. Meanwhile, another commenter, supported the removal given that the value of the measure has remained consistent over the last few years. The commenter indicated that the potential for improvement is very limited and therefore, the measure represents little to no value to the LTCH QRP.

Additionally, the commenter recommends the immediate removal of data with respect to the domain of functional status, cognitive function, and changes in function and cognitive function. In light of this development, the process measure Application of Functional Assessment/Care Plan, which measures only whether a functional assessment is completed and a functional goal is included in the care plan, is no longer necessary, and can be replaced with a measure that evaluates the LTCH’s outcome of care on a patient’s function.

Because the Application of Functional Assessment/Care Plan measure meets measure removal factors one and six under § 412.560(b)(3), we proposed to remove it from the LTCH QRP beginning with the FY 2025 LTCH QRP. We also proposed that public reporting of the Application of Functional Assessment/Care Plan measure would end by the September 2024 Care Compare refresh or as soon as technically feasible when public reporting of the DC Function measure is proposed to begin (see section IX.E.9.b. of the preamble of this final rule).

Under our proposal, LTCHs would no longer be required to report a Self-Care Discharge Goal (that is, GG0130, Column 2) or a Mobility Discharge Goal (that is, GG0170, Column 2) for the purposes of the Application of Functional Assessment/Care Plan measure beginning with patients admitted on October 1, 2023. We would remove the items for Self-Care Discharge Goal (that is, GG0130, Column 2) and Mobility Discharge Goal (that is, GG0170, Column 2) with the next release of the LCDS.

We invited public comment on our proposal to remove the Application of Functional Assessment/Care Plan measure from the LTCH QRP beginning with the FY 2025 LTCH QRP. The following is a summary of the comments we received on our proposal to remove the Application of Functional Assessment/Care Plan measure from the FY 2025 LTCH QRP.

Response: The adoption of the proposed measure would not result in additional burden because we are not proposing changes to the number of items required or the reporting frequency of the items reported. In fact, this measure requires the same set of data elements that are currently reported. Additionally, CMS calculates this measure for LTCHs, and provides LTCHs with various resources to review and monitor their own performance on this measure.

After careful consideration of the public comments we received, we are finalizing our proposal to adopt the DC Function measure as an assessment-based outcome measure beginning with the FY 2025 LTCH QRP as proposed.

In regard to removal factor one, the Application of Functional Assessment/Care Plan measure has become topped out, with average performance rates reaching nearly 100 percent over the past three years (ranging from 99.4 percent to 99.6 percent during calendar years [CYs] 2019–2021).

For the 12-month period of Q3 2020 through Q2 2021 (7/1/2020 through 6/30/2021), LTCHs had an average score for this measure of 99.4 percent, with nearly 70 percent of LTCHs scoring 100 percent, and for CY 2021, LTCHs had an average score of 99.4 percent, with nearly 63 percent of LTCHs scoring 100 percent.

The proximity of these mean rates to the maximum score of 100 percent suggests a ceiling effect and a lack of variation that restricts distinction between facilities.

In regard to measure removal factor six, the proposed DC Function measure is more strongly associated with desired patient functional outcomes than the current Application of Functional Assessment/Care Plan measure. As described in section IX.E.9.b. of the preamble of this final rule, the proposed DC Function measure has the predictive ability to distinguish patients with low expected functional capabilities from those with high expected functional capabilities. CMS has been collecting standardized functional assessment elements across PAC settings since 2016, which has allowed for the development of the proposed DC Function measure and meets the requirements of the IMPACT Act to submit standardized patient assessment data and other necessary...
the Application of Functional Assessment/Care Plan measure from the LTCH QRP rather than waiting until FY 2025.

**Response:** We thank the commenters for their support and agree that the Application of Functional Assessment/Care Plan measure should be removed due to topped-out performance. With respect to the commenter’s request that the Application of Functional Assessment/Care Plan measure be removed immediately, we refer the commenter to section IX.E.4.c of this final rule where we proposed LTCHs would no longer be required to report a Self-Care Discharge Goal (that is, GG0130, Column 2) or a Mobility Discharge Goal (that is, GG0170, Column 2) for the purposes of the Application of Functional Assessment/Care Plan measure beginning with patients admitted on October 1, 2023. Data reported in quarter four of 2023 counts toward the FY 2025 QRP.

After consideration of the public comments, we are finalizing our proposal to remove the Application of Functional Assessment/Care Plan measure from the LTCH QRP beginning with the FY 2025 LTCH QRP as proposed.

d. Removal of the Percent of LTCH Patients With an Admission and Discharge Functional Assessment and a Care Plan Measure Beginning With the FY 2025 LTCH QRP

We proposed to remove the process measure, Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (Functional Assessment/Care Plan) measure from the LTCH QRP beginning with the FY 2025 LTCH QRP. We proposed this measure’s removal because the Functional Assessment/Care Plan measure satisfies factor one of our measure removal factors, as described at 42 CFR 412.530(b)(3)(i). measure performance among LTCHs is so high and unvarying that meaningful distinctions in improvements in performance can no longer be made.

In the FY 2015 IPPS/LTCPPPS final rule (79 FR 50291 through 50298), we adopted the Functional Assessment/Care Plan measure. This quality measure reports the percent of LTCH patients with both an admission and a discharge functional assessment and a care plan that addresses function. This process measure requires the collection of admission and discharge functional status data which assess specific functional activities such as self-care and mobility. The treatment goal provides documentation that care plan with a goal has been established for the patient.

Since its adoption into the LTCH QRP, the Functional Assessment/Care Plan measure has become topped out, with average performance rates reaching nearly 100 percent over the past three years (ranging from 99.3 percent to 99.5 percent during CYs 2019–2021). The proximity of these mean rates to the maximum score of 100 percent suggests a ceiling effect and a lack of variation that restricts distinction between facilities. Additionally, for the 12-month period of Q3 2020 through Q2 2021 (7/1/2020 through 6/30/2021), 67 percent of LTCHs scored 100 percent, and for CY 2021, 61 percent of LTCHs scored 100 percent.

Our proposal to remove this measure does not mean that CMS no longer considers functional assessment and functional outcomes in LTCH settings important. The functional status and outcomes of LTCH patients are represented in the LTCH QRP through the Functional Assessment/Care Plan measure: Change in Mobility Among Long-Term Care Hospital Patients Requiring Ventilator Support. In addition, the proposed DC Function measure would assess whether the LTCH has achieved expected discharge scores for all patients admitted to an LTCH. Therefore, we proposed to remove the Functional Assessment/Care Plan measure from the LTCH QRP beginning with the FY 2025 LTCH. If finalized as proposed, public reporting of the Functional Assessment/Care Plan measure would end by September 2024 or as soon as technically feasible.

If finalized as proposed, LTCHs would no longer be required to submit Admission Performance for Wash Upper Body, a Self-Care Discharge Goal, and a Mobility Discharge Goal for purposes of the Functional Assessment/Care Plan measure beginning with patients admitted on or after October 1, 2023. We would remove the items for Wash Upper Body, the Self-Care Discharge Goals, and the Mobility Discharge Goals with the next release of the LCDS.

We invited public comment on our proposal to remove the Functional Assessment/Care Plan That Addresses Function measure from the LTCH QRP beginning with the FY 2025 LTCH QRP. The following is a summary of the comments we received on our proposal to remove the Functional Assessment/Care Plan measure from the LTCH QRP beginning with the FY 2025 LTCH QRP and our responses.

**Comment:** Several commenters expressed support for the removal of the Functional Assessment/Care Plan Measure. A commenter noted their support in conjunction with the adoption of the DC Function measure.

**Response:** We thank the commenters for their support of the removal of this measure in conjunction with the adoption of the DC Function score measure. We agree the Functional Assessment/Care Plan measure should be removed due to topped-out performance.

After consideration of the public comments we received, we are finalizing our proposal to remove the Functional Assessment/Care Plan measure from the LTCH QRP beginning with the FY 2025 LTCH QRP as proposed.

e. COVID–19 Vaccine: Percent of Patients/Residents Who Are Up To Date Beginning With the FY 2026 LTCH QRP

(1) Background

COVID–19 has been and continues to be a major challenge for PAC facilities, including LTCHs. The Secretary first declared COVID–19 a PHE on January 31, 2020. As of June 19, 2023, the U.S. has reported 103.9 million cumulative cases of COVID–19, and 1.13 million deaths due to COVID–19 in the United States. Although all age groups are at risk of contracting COVID–19, older persons are at a significantly higher risk of mortality and severe disease following infection, with those over age 80 dying at five times the average

---


rate. Older adults, in general, are prone to both acute and chronic infections owing to reduced immunity, and are a high-risk population. Adult age 65 and older comprise over 75 percent of total COVID–19 deaths despite representing 13.2 percent of reported cases. COVID–19 has impacted older adults’ access to care, leading to poorer clinical outcomes, as well as taking a serious toll on their mental health and well-being due to social distancing.

Since the development of the vaccines to combat COVID–19, studies have shown they continue to provide strong protection against severe disease, hospitalization, and death in adults, including during the predominance of Omicron BA.4 and BA.5 variants. Initial studies showed the efficacy of FDA-approved or authorized COVID–19 vaccines preventing COVID–19. Prior to the emergence of the Delta variant of the virus, vaccine effectiveness against COVID–19-associated hospitalization among adults age 65 and older was 91 percent for those who were fully vaccinated with a mRNA vaccine (Pfizer-BioNTech or Moderna), and 84 percent for those receiving a viral vector vaccine (Janssen). Adults age 65 and older who were fully vaccinated with an mRNA COVID–19 vaccine had a 94 percent reduction in risk of COVID–19 hospitalization; those who were partially vaccinated had a 64 percent reduction in risk. Further, after the emergence of the Delta variant, vaccine effectiveness against COVID–19-associated hospitalization for adults who were fully vaccinated was 76 percent among adults age 75 and older.

More recently, since the emergence of the Omicron variant and availability of booster doses, multiple studies have shown that while vaccine effectiveness has waned, protection is higher among those receiving booster doses than among those only receiving the primary series. Centers for Disease Control and Prevention (CDC) data show that, among people age 50 and older, those who have received both a primary vaccination series and booster dose have a lower risk of hospitalization and dying from COVID–19 than their non-vaccinated counterparts. Additionally, a second vaccine booster dose has been shown to reduce risk of severe outcomes related to COVID–19, such as hospitalization or death. Early evidence also demonstrates that the bivalent boosters, specifically aimed to provide better protection against Omicron disease caused by the prevalent BA.4/BA.5 Omicron subvariants, have been quite effective, and underscores the role of up-to-date vaccination protocols in effectively countering the spread of COVID–19.

(a) Measure Importance

Despite the availability and demonstrated effectiveness of COVID–19 vaccinations, significant gaps continue to exist in vaccination rates. As of March 15, 2023, vaccination rates among people age 65 and older are generally high for the primary vaccination series (94.3 percent) but lower for the first booster (73.6 percent among those who received a primary series) and even lower for the second booster (59.9 percent among those who received a first booster). Additionally, though the uptake in boosters among people age 65 and older has been much higher than among people of other ages, booster uptake still remains relatively low compared to primary vaccination among older adults.

Variations are also present when examining vaccination rates by gender, and race.

For example, 66.2 percent of the Asian, non-Hispanic population have completed the primary series and 21.2 percent have received a bivalent booster dose, whereas 44.9 percent of the Black, non-Hispanic population have completed the primary series and only 8.9 percent have received a bivalent booster dose. Among Hispanic populations, 57.1 percent of the population have completed the primary


860 A person is fully vaccinated with an mRNA vaccine when they receive two doses of a primary series.

861 A person is fully vaccinated with a viral vector vaccine after receiving one dose of a primary series.

We proposed to adopt the COVID–19 Vaccine: Percent of Patients/Residents Who Are Up to Date (Patient/Resident COVID–19 Vaccine) measure for the LTCH QRP beginning with the FY 2026 LTCH QRP. The proposed measure has the potential to increase COVID–19 vaccination coverage of patients in LTCHs, as well as prevent the spread of COVID–19 within the LTCH patient population. This measure would also support the goal of the CMS Meaningful Measure Initiative 2.0 to “Empower consumers to make good health care choices through patient-directed quality measures and public transparency objectives.” The proposed Patient/Resident COVID–19 Vaccine measure would be reported on Care Compare and would provide patients and caregivers, including those who are at high risk for developing serious complications from COVID–19, with valuable information they can consider when choosing an LTCH. The proposed Patient/Resident COVID–19 Vaccine measure would facilitate patient care and care coordination during the hospital discharge planning process. Because this measure would be reported on Care Compare, a discharging acute care hospital, in collaboration with the patient and family, could use the information on Care Compare, to coordinate care and ensure patient preferences are considered in the discharge plan. Additionally, the measure would be an indirect measure of provider action. Since the patient’s vaccination status would be reported at discharge from the LTCH, if a patient is not up to date with their vaccine at the time of LTCH admission, the LTCH has the opportunity to educate the patient and provide information on why that patient should become up to date. LTCHs may also choose to administer the vaccine to the patient prior to discharge from the LTCH or coordinate a follow-up visit for the patient to obtain the vaccine at a physician’s office or local pharmacy.

(b) Item Testing

The measure development contractor conducted testing with LTCHs on the proposed standardized patient/resident COVID–19 vaccination coverage assessment item using patient scenarios and cognitive interviews to assess their comprehension of the item and the associated guidance. A team of clinical experts, assembled by CMS’s measure development contractor, developed patient scenarios to represent the most common scenarios LTCH providers would encounter. The results of the item testing demonstrated that LTCHs that used the guidance had a high percentage of accurate responses, supporting its reliability. The testing also provided information to improve the item itself, as well as the accompanying guidance.

(2) Competing and Related Measures

Section 1899B(e)(2)(A) of the Act requires that, absent an exception under section 1899B(e)(2)(B) of the Act, each measure specified under section 1899B of the Act be endorsed by a CBE with a contract under section 1890(a) of the Act be endorsed by a CBE with a contract under section 1890(a) of the Act. In the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed, section 1899B(e)(2)(B) of the Act permits the Secretary to specify a measure that is not so endorsed, as long as due consideration is given to the measures that have been endorsed or adopted by a consensus organization identified by the Secretary. The proposed Patient/Resident COVID–19 Vaccine measure is not CBE endorsed, and after review of other CBE-endorsed measures, we were unable to identify any CBE-endorsed measures for LTCHs focused on capturing COVID–19 vaccination coverage of LTCH patients. We found only one related measure addressing COVID–19 vaccination, the COVID–19 Vaccination Coverage among Healthcare Personnel (HCP) measure, adopted for the FY 2023 LTCH QRP (87 FR 45438 through 45446), which captures the percentage of HCPs who receive a complete COVID–19 vaccination course.

Therefore, after consideration of other available measures that assess COVID–19 vaccination rates, we believe the exception under section 1899B(e)(2)(B) of the Act applies. We intend to submit the proposed measure to the CBE for consideration of endorsement when feasible.

(3) Interested Parties and Technical Expert Panel (TEP) Input

First, the measure development contractor convened a focus group of patient and family/caregiver advocates (PFAs) to solicit input. The PFAs felt a measure capturing raw vaccination rate, irrespective of provider action, would be most helpful in decision making. Next, a TEP was held on November 19, 2021 and December 15, 2021 to solicit feedback on the development of patient/resident COVID–19 vaccination measures and assessment items for the PAC settings. The TEP panelists voiced their support for PAC patient/resident COVID–19 vaccination measures and agreed that developing a measure to report the rate of vaccination in an LTCH setting without denominator exclusions was an important goal. We considered all the TEP’s recommendations for developing vaccination-related measures, and applied those recommendations where technically feasible and appropriate. A summary of the TEP proceedings titled Technical Expert Panel (TEP) for the Development of Long-Term Care Hospital (LTCH), Inpatient Rehabilitation Facility (IRF), Skilled Nursing Facility (SNF)/Nursing Facility (NF), and Home Health (HH) COVID–19 Vaccination-Related Items and Measures Summary Report is available on the CMS Measures Management System (MMS) web page.


To seek input on the importance, relevance, and applicability of a patient/resident COVID–19 vaccination coverage measure, we solicited public comments in an RFI for publication in the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 47553). Commenters stated they understood why CMS was considering a measure addressing COVID–19 vaccination coverage among patients, but noted CMS should postpone considering this measure since the definition of “fully vaccinated” is evolving.

(4) Measure Applications Partnership (MAP) Review

We included the Patient/Resident COVID–19 Vaccine measure under the LTCH QRP on the publicly available “List of Measures Under Consideration for December 1, 2022” (MUC List), a list of quality and efficiency measures the Secretary is considering adopting for use in Medicare programs. The MUC List allows interested parties to provide recommendations to the Secretary on measures included on the MUC List. After the MUC List was published, the MAP received three comments from interested parties on the Patient/Resident COVID–19 Vaccine measure. Commenters were mostly supportive of the measure and recognized the importance of patient COVID–19 vaccination, and that measurement and reporting is one important method to help healthcare organizations assess their performance in achieving high rates of up-to-date vaccination. A commenter noted the benefit of less-specific criteria for inclusion in the numerator and denominator, which would provide flexibility for the measure to remain relevant to current circumstances, while others raised concerns over measure specifications, including the concept of “up to date” given the evolving definition of the term, the fact that patient refusals are not excluded, and the frequency of data submission. Two interested parties noted there could be unintended consequences to patient access if the measure was adopted.

Subsequently, several MAP workgroups met to provide input on the measure. First, the MAP Health Equity Advisory Group convened on December 6, 2022. One MAP member noted that the percentage of true contraindications for the COVID–19 vaccine is low, and the lack of exclusions on the measure makes sense to avoid varying interpretations of valid contraindications. Similarly, the MAP Rural Health Advisory Group met on December 8, 2022 and expressed that the measure is important for rural communities.

Next, the MAP Post-Acute Care/Long-Term Care (PAC/LTC) workgroup met on December 12, 2022, where the PAC/LTC workgroup members discussed their concerns about: (1) the evolving vaccine recommendations, (2) the lack of denominator exclusions, and (3) the reporting frequency for this measure. CMS noted that the Patient/Resident COVID–19 Vaccine measure does not have exclusions for patient refusals because the measure was intended to report raw rates of vaccination. CMS explained that raw rates of vaccination collected by the Patient/Resident COVID–19 vaccine measure are important for consumer choice and PAC providers, including LTCHs, are in a unique position to leverage their care processes to increase vaccination rates and in their settings to protect patients and prevent negative outcomes. CMS also clarified that the measure defines “up to date” in a manner that provides flexibility to reflect future changes in CDC guidance. Finally, CMS clarified that, like the existing COVID–19 HCP Vaccine measure, this measure would continue to be reported quarterly because the CDC has not yet determined that COVID–19 is seasonal. Ultimately, the PAC/LTC workgroup reached consensus on the vote, “Do not support for rulemaking,” for the Patient/Resident COVID–19 Vaccine measure.

The MAP received four comments by industry commenters in response to the PAC/LTC workgroup recommendations. The commenters generally understood the importance of COVID–19 vaccinations’ role in preventing the spread of COVID–19; however, most commenters did not recommend the inclusion of this measure for the LTCH QRP. Specifically, commenters were concerned about providers’ inability to influence results based on factors outside of their control, including COVID–19 vaccine hesitancy. Commenters also noted that the measure has not been fully tested and questioned whether the measure would produce meaningful results. Commenters also encouraged CMS to monitor the measure for unintended consequences. Another commenter supported the measure and recommended that CMS consider an exclusion for medical contraindications, and also seek CBE endorsements.

Finally, the MAP Coordinating Committee convened on January 24, 2023, and noted concerns previously discussed in the PAC/LTC workgroup, such as the lack of exclusions for medical contraindications and potential for patient selection bias based on patients’ vaccination status. CMS was able to clarify that this measure does not have exclusions for patient refusals since this is a process measure intended to report raw rates of vaccination, and is not intended to be a measure of LTCHs’ actions. CMS acknowledged that a measure accounting for variables, such as LTCHs’ actions to vaccinate patients, could be important, but CMS is focused on a measure which would provide and publicly report vaccination rates for consumers given the importance of this information to patients and their caregivers.

The MAP Coordinating Committee recommended three mitigation strategies for the Patient/Resident COVID–19 Vaccine measure: (1) reconsider exclusions for medical contraindications; (2) complete reliability and validity measure testing; and (3) seek CBE endorsement. The Coordinating Committee ultimately reached 90 percent consensus on the vote of “Do not support with potential for mitigation.” Despite the MAP Coordinating Committee’s vote, we believed it was still important to propose the Patient/Resident COVID–19 Vaccine measure for the LTCH QRP. As we stated in the FY 2024 PPS proposed rule (88 FR 27148), we did not include exclusions for medical contraindications because the PFAs we met with told us that a measure capturing raw vaccination rate, irrespective of any medical contraindications, would be most helpful in patient and family/caregiver decision-making. We do plan to conduct reliability and validity measure testing.
once we have collected enough data, and we intend to submit the proposed measure to the CBE for consideration of endorsement when feasible. We refer readers to the final MAP recommendations, titled 2022–2023 MAP Final Recommendations.

(5) Quality Measure Calculation

The proposed Patient/Resident COVID–19 Vaccine measure is a process measure that reports the percent of stays in which patients in an LTCH are up to date on their COVID–19 vaccinations per CDC’s latest guidance. This measure has no exclusions and is not risk adjusted.

The numerator for the measure would be the total number of LTCH stays in the denominator in which patients are up to date with the COVID–19 vaccine during the reporting period. The denominator for the measure would be the total number of LTCH stays discharged during the reporting period.

The data source for the proposed quality measure is the LCDS assessment instrument. For more information about the proposed data submission requirements, we refer readers to section VI.B.d. of the preamble of this final rule. For additional technical information about this final measure, we refer readers to the draft measure specifications document titled Patient-Resident-COVID-Vaccine-Draft-Specs.pdf on the LTCH QRP Measures Information web page.

We invited public comments on the proposal to adopt the Patient/Resident COVID–19 Vaccine measure beginning with the FY 2026 LTCH QRP. The following is a summary of the comments we received on our proposal to adopt the Patient/Resident COVID–19 Vaccine measure beginning with the FY 2026 LTCH QRP and our responses.

Comment: Four commenters supported the adoption of this measure into the LTCH QRP beginning FY2026. A commenter noted that COVID–19 pandemic has had a disproportionate and devastating impact on older adults, particularly those residing in long-term care and congregate care settings.

Response: We thank the commenters for their support.

A number of commenters did not support the proposal to adopt the Patient/Resident COVID–19 Vaccine measure to the IRF QRP for various reasons. The following is a summary of these public comments received on our proposal and our responses.

Comment: Several commenters did not support the proposal due to the measure not being fully tested for reliability and validity, and questioned whether it was feasible for LTCHs to collect the information and whether the measure would produce statistically meaningful information. Two of these commenters noted that CMS should validate the data collection tool used in the measure prior to adopting the measure. These commenters also suggested CMS “rushed through” the validation process to add the measure to the LTCH QRP as soon as possible, pointing to the fact that CMS did not provide support showing the measure is practical or feasible.

Response: We acknowledge the concerns raised by the commenters related to the measure testing. However, we have tested the item proposed for the LCDS to capture data for this measure and its feasibility and appropriateness. Since a COVID–19 vaccination item does not exist within the LCDS, we developed clinical vignettes to test item-level reliability of a draft Patient/Resident COVID–19 vaccination. The clinical vignettes were a proxy for patient records with the most common and challenging cases providers would encounter, similar to the approach that CMS uses to train providers on all new assessment items, and the results demonstrated strong agreement (that is, 80 percent).

Validity testing has not been completed yet, since a COVID–19 vaccination item does not currently exist on the LCDS. However, the Patient/Resident COVID–19 Vaccine measure was constructed based on prior use of similar items, such as the Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) for the IRF QRP and LTCH QRP. We have used these types of patient vaccination assessment items in the calculation of vaccination quality measures in our PAC QPRs and intend to conduct reliability and validity testing for this specific Patient/Resident COVID–19 Vaccine measure once a COVID–19 vaccination item has been added to the LCDS and we have collected sufficient data.

Additionally, we solicited feedback from our Technical Expert Panel (TEP) on the proposed assessment item and its feasibility. No concerns were raised by the TEP regarding obtaining information required to complete the new COVID–19 vaccination item.

Comment: A few commenters did not support the measure due to lack of support from the MAP and urged CMS to delay adoption of the measure until concerns raised by the MAP Coordinating Committee have been addressed. Specifically, they noted that the MAP is a multi-stakeholder panel of experts representing providers, patients and payers and they encouraged CMS to address the MAP’s recommendations for adding exclusions to the measure, conducting measure testing and submitting the measure for CBE endorsement. Several of these commenters specifically requested that exclusions for medical contraindications, religious beliefs, cultural norms, and patient refusals be added to the measure specifications, noting that without them the vaccination rates could be misleading.

Response: As part of the pre-rulemaking process, HHS takes into consideration the recommendations of the MAP in selecting candidate quality and efficiency measures. HHS selects candidate measures and publishes proposed rules in the Federal Register, which allows for public comment and further consideration before a final rule is issued. If the CMS CBE has not endorsed a candidate measure, then HHS must publish a rationale for the use of the measure described in section 1890(b)(7)(B) of the Act in the notice. We would like to reiterate that this measure is intended to promote transparency of raw data regarding COVID–19 vaccination rates for patients/caregivers to make informed decisions for selecting facilities, providing potential patients with an important piece of information regarding vaccination rates as part of their process of identifying providers they would want to seek care from. As we stated in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27148), we did not include exclusions for medical contraindications, religious beliefs, cultural norms, and patient refusals because the PFAs we met with told us that a measure capturing raw vaccination rate, irrespective of any medical contraindications, would be most helpful in patient and family/...
caregiver decision-making. Our TEP also agreed that developing a measure to report the rate of vaccination without denominator exclusions was an important goal.93 Based on this feedback, excluding patients/residents with contraindications from the measure would distort the intent of the measure of providing raw COVID–19 patient vaccination rates, while making the information more difficult for patients/caregivers to interpret, and therefore we did not include any exclusions. We also stated in the FY 2024 IPPS/LTCH proposed rule (88 FR 27149) that we intend to conduct measure testing once sufficient data on the COVID–19 vaccination item is collected through the LCDS and plan to submit the measure for CBE endorsement when it is technically feasible to do so.

Comment: A commenter noted that vaccination administration rates can ebb and flow significantly based on factors outside the control of LTCHs, including holidays, weather, vaccine/pharmaceutical supply chain management, staff availability and more. As a result, they do not believe the rates will accurately depict the vaccination rate of an LTCH’s patients.

Response: LTCHs will be able to administer the COVID–19 vaccine if a patient consents. This measure does not require LTCHs to administer the vaccine themselves. They could arrange for the patient to obtain the vaccine outside of their facility, or work with community pharmacies to obtain vaccines.

Comment: A few commenters opposed the measure because they believe vaccine uptake is subject to patient-level factors outside the control of the LTCH, including a patient’s transiting their vaccination status, and therefore the Patient/Resident COVID–19 Vaccine measure would not be a reflection of the actions or efforts taken by an LTCH to improve patient care. Three of these commenters referenced the MAP’s Health Equity Advisory Group who “expressed concerns about vaccine hesitancy due to cultural norms,” and they want to honor the choice of their patients once they have been offered clinical advice. Two of these commenters noted that disparities in vaccine uptake exist among racial and geographic categories because of differences deeply rooted in culture, religion, ethnicity, socioeconomic status, and are not related to the local LTCH’s efforts to vaccine their patients. A commenter noted that requiring vaccination data to be reported will not sway those individuals who are reluctant to continue receiving vaccines, while two other commenters noted that it is possible for an LTCH to encourage vaccination among their patients and still have a relatively low rate of vaccination.

Response: We appreciate providers’ commitment to ensuring that patients are educated and encouraged to receive vaccinations, and we acknowledge that individuals have a choice about whether to receive a COVID–19 vaccine or booster, despite an LTCH’s best efforts. However, it is also true that patients and family/caregivers have choices about selecting and LTCH, and it is our intention to empower them with the information they need to make an informed decision by publicly reporting the data we receive from LTCHs on this measure. We understand that there may be instances where a patient chooses not to be vaccinated, and we want to remind LTCHs that this measure does not mandate patients be up to date with their COVID–19 vaccination, only that the LTCH report on patients’ vaccination status. LTCHs are able to successfully report the measure, and comply with the LTCH QRP requirements, irrespective of the number of patients who have been vaccinated.

Comment: Two commenters believe it is often infeasible or inappropriate to offer vaccination for patients due to length of stay, ability to manage side effects and medical contraindications, or other logistical challenges to gathering information from a patient who may have received care from multiple proximal providers. Another commenter noted that patients admitted to an LTCH almost exclusively come from a general acute care hospital following a complex course of illness or a traumatic event, and it is not unusual for such complex and compromised patients to be inappropriate to receive immunizations. Two commenters raised concerns that CMS had not addressed how LTCHs should report vaccination data for patients that are on mechanical ventilators.

Response: We understand concerns about post-acute care length of stay, acuity of patient health, or effect of the vaccine on patient care. LTCHs should continue to use clinical judgement to determine if a patient is eligible to receive the vaccination, as well as when it is appropriate for a patient to receive vaccination, keeping in mind patient’s health and safety. Regarding the commenters’ concerns about reporting data for patients on mechanical ventilators, providers will be able to use multiple sources of information available to obtain the vaccination data, such as patient interviews, medical records, proxy response, and vaccination cards provided by the patient/caregivers. Therefore, coding of this item in the LCDS would not be limited by a patient’s ability to respond.

Comment: A commenter noted that sometimes patients may not have the opportunity to ‘shop’ for an LTCH outside of their region simply based on the COVID–19 vaccinations rates. They noted that insurance and proximity to loved ones are often the drivers for selecting an LTCH.

Response: We acknowledge that sometimes patients may not have access to as many LTCH choices as others. However, the information provided by this measure will still be valuable to potential LTCH patients and their caregivers who may have geographic limitations.

Comment: Several commenters opposed the Patient/Resident COVID–19 Vaccine measure because they believe it will have minimal impact on patient health while increasing administrative burden on LTCHs, including burden associated with data collection, education, and updates to IT systems. Two of these commenters noted that collecting this information would be especially burdensome in cases where patients are unable or unwilling to provide the necessary information.

Another commenter suggested that with extreme staffing shortages, the resources to spend additional time gathering COVID–19 vaccine data, administering the vaccine, or doing extensive education on vaccination are limited. A commenter was concerned that this would increase the burden associated with managing and updating IT system changes and re-training staff in data collection.

Response: We think the measure could have an impact on patient health. This measure will provide potential patients with an important piece of information regarding vaccination rates as part of their process of identifying providers they would want to seek care from, empowering them to make informed decisions about their health care. Additionally, as noted in the


COVID–19 Vaccine: Percent of Patients/Residents Who Are Up to Date Draft Measure Specifications. Providers will be able to use all sources of information available to obtain the vaccination data, such as patient interviews, medical records, proxy response, and vaccination cards provided by the patient/caregivers. Therefore, coding would not be limited to a patient response. Regarding the comment about the additional time LTCHs would have to spend gathering COVID–19 vaccine data, LTCHs should be assessing whether patients are up to date with COVID–19 vaccination as a part of their routine care and infection control processes. During our item testing, we heard from LTCHs that they are already routinely inquiring about COVID–19 vaccination status when admitting patients. Additionally, this measure does not require LTCHs to administer the vaccine themselves. They could arrange for the patient to obtain the vaccine outside of their facility, or work with community pharmacies to obtain vaccines. In response to the comment on the burden associated with managing and updating IT systems, we will be posting the Final Measure Specifications and Draft Data Submission Specifications for the Patient/Resident COVID–19 Vaccine measure in the Fall of 2023, and believe IT vendors will have enough time to update their software prior to October 1, 2024. The item and response options are not complex, and the item is only required at discharge. The time, form, and manner in which the LCDS will be submitted is not changing; rather, it is the addition of one item to be collected at one time point. Therefore, the implementation of this proposal should not require health IT vendors to completely rewrite their software. Finally, as with any new assessment item, we will provide free training and education to LTCHs as well as publish coding guidance and instructions for LTCHs to be prepared for data collection.

Comment: A commenter requested that CMS consider utilizing the short-stay hospital questionnaire on this metric as its base and not require the LTCH to also collect this information. They noted that if a patient comes to an LTCH without having a predecessor short-stay hospital stay, only then an LTCH should be required to submit that data.

Response: We are unable to determine what short-stay hospital questionnaire the commenter is referring to, and therefore are unable to respond.

Comment: Two commenters believed the adoption of a patient-level measure of COVID–19 vaccination status would face similar challenges to the Percent of Residents of Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (CBE #0680) that was retired in the FY 2019 IRF PPS final rule (83 FR 38514). They also stated that LTCH performance on this proposed measure will fail to show meaningful distinctions in improvements since 94.3 percent of the United States population at least 65 years of age had completed their primary series as of May 2023.

Response: We interpret the commenter to be referring to the Percent of Residents of Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (CBE #0680) that was removed from the LTCH QRP measure set in the FY 2018 LTCH PPS final rule (82 FR 38433 through 38439). However, we do not believe this measure is at risk of being retired early. The proposed Patient/Resident COVID–19 Vaccine measure reports the percentage of patients in an LTCH who are up to date on their COVID–19 vaccinations per the CDC’s latest guidance, rather than capturing the rates of primary vaccination series only. Because the measure reflects an “up to date” status, it minimizes the potential for topping out. We believe that continued monitoring of up to date vaccination will remain an important tool to minimize severe illness, hospitalization, and death in post-acute care facilities. Additionally, we find there is substantial room for improvement in measure performance. As of May 2023, while the vaccination rates among people 65 and older were high for the primary vaccination series (94.3 percent), the vaccination rates are lower for the first booster (73.9 percent among those who received a primary series) and even lower for the second booster dose (60.4 percent among those who received a first booster). However, we routinely monitor measures to determine if they meet any of the measure removal factors, set forth in § 412.560(b)(3), and if identified, we may remove the measure through the rulemaking process.

Comment: A commenter noted that CMS should not adopt this proposed measure due to the end of the PHE, and that CMS should eliminate any tracking of vaccines with the end of Federal vaccination mandates. Two commenters noted that adding a new quality measure to the LTCH QRP now for reporting patient COVID–19 vaccination status is inconsistent with the agency’s decision to remove the vaccination requirements for health care personnel from the hospital conditions of participation. These commenters said they found it confusing that CMS has proposed this new measure because it contradicts CMS’s statement to treat COVID–19 like other infectious diseases going forward, specifically influenza, and they point out that there is no existing measure in the LTCH QRP addressing patient influenza vaccination status.

Response: Despite the announcement of the end of the COVID–19 PHE, many people continue to be affected by COVID–19, particularly seniors, people who are immunocompromised, and people with disabilities. As mentioned in the End of COVID–19 Public Health Emergency Fact Sheet, our response to the spread of SARS-CoV–2, the virus that causes COVID–19, remains a public health priority. Even with the end of the COVID–19 PHE, we continue to work to protect Americans from the virus and its worst impacts by supporting access to COVID–19 vaccines, treatments, and tests, including for people without health insurance. Given the continued impacts of COVID–19, it is important to promote patient vaccination and education, which this measure aims to achieve. As mentioned previously, continued monitoring of up to date COVID–19 vaccination will remain an important tool to minimize severe illness, hospitalization, and death in LTCHs because, as stated earlier, there is substantial room for improvement in measure performance. As of May 2023, while the vaccination rates among people 65 and older were high for the primary vaccination series (94.3 percent), the vaccination rates are lower for the first booster (73.9 percent among those who received a primary series) and even lower for the second booster dose (60.4 percent among those who received a first booster).
We also want to note that the proposed Patient/Resident COVID–19 Vaccine measure is not associated with the Conditions of Participation. This measure is being proposed for the LTCH QRP to support the goal of the CMS Meaningful Measure Initiative 2.0 to “Empower consumers to make good health care choices through patient-directed quality measures and public transparency objectives,” which is consistent with previous vaccination measures.

**Comment:** A commenter noted that the NHSN measure reflecting all patients provides a better picture of each facility. Two commenters suggested that having a single yes or no item on the LCDS without any requirements for documentation or validation of vaccination status would amount to a mere checkmark in a box with no evidence that it leads to improved quality of care.

**Response:** Although some LTCHs may voluntarily submit patient-level COVID–19 vaccine data to the NHSN, we do not collect patient-level COVID vaccination data as part of the LTCH QRP. Therefore, adding an LCDS item for the purposes of collecting patient-level COVID vaccination data would be appropriate for data collection, similar to other assessment-based measures. As stated earlier in this section, assessment-based measures have several benefits, including patient-level data and a variety of reports LTCHs can use to assess performance, inform patient engagement and refine infection control processes. Additionally, this data will allow for granular analyses of vaccinations, including identification of potential disparities within the LTCH population.

**Comment:** A commenter noted that the CDC maintains different definitions of “up to date” and “fully vaccinated.” This commenter believed that the public has a limited appreciation for the differences in these definitions and could easily misreport their vaccination status to facility staff when asked, giving the public a misleading picture of the experience and patient satisfaction. Therefore, adding an LCDS item for the purposes of collecting patient-level COVID vaccination data would be appropriate for data collection, similar to other assessment-based measures. As stated earlier in this section, assessment-based measures have several benefits, including patient-level data and a variety of reports LTCHs can use to assess performance, inform patient engagement and refine infection control processes. Additionally, this data will allow for granular analyses of vaccinations, including identification of potential disparities within the LTCH population.

**Response:** We appreciate the input from the commenters. However, these alternate recommendations do not meet the intent of the measure, which is a raw rate of patient vaccinations, irrespective of LTCH actions. We will use this input to inform our future measure development efforts.

**After consideration of the public comments we received, we are finalizing our proposal to adopt the Patient/Resident COVID–19 Vaccine measure as an assessment-based measure beginning with the FY 2026 LTCH QRP as proposed.**

5. **Principles for Selecting and Prioritizing LTCH QRP Quality Measures and Concepts**

   **Under Consideration for Future Years: Request for Information (RFI)**

   **a. Solicitation of Comments**

   We solicited general comments on the principles for identifying LTCH QRP measures, as well as additional comments about measurement gaps, and suitable measures for filling these gaps. Specifically, we solicited comment on the following questions:

   - **Principles for Selecting and Prioritizing LTCH QRP Measures**
     
     **++ To what extent do you agree with the principles for selecting and prioritizing measures?**
     
     **++ Are there principles that you believe CMS should eliminate from the measure selection criteria?**
     
     **++ Are there principles that you believe CMS should add to the measure selection criteria?**

   - **LTCH QRP Measurement Gaps**
     
     **++ CMS requests input on the identified measurement gaps, including in the areas of cognitive function, behavioral and mental health, patient experience and patient satisfaction, and chronic conditions and pain management.**
     
     **++ Are there gaps in the LTCH QRP measures that have not been identified in this RFI?**
     
     **- Measures and Measure Concepts Recommended for Use in the LTCH QRP**
     
     **++ Are there measures that you believe are either currently available for use, or that could be adapted or developed for use in the LTCH QRP program to assess performance in the areas of: (1) cognitive functioning; (2) behavioral and mental health; (3) patient experience and patient satisfaction; (4) chronic conditions; (5) pain management; or (6) other areas not mentioned in this RFI?**

   CMS also sought input on data available to develop measures, approaches for data collection, perceived challenges or barriers, and approaches for addressing challenges.

   We received several comments in response to this RFI in the proposed rule, which are summarized later in this section.

   **Comments:** A commenter indicated that the principles for measure selection and prioritization identified by CMS in the RFI in the proposed rule are consistent with the principles inherent in the CMS Measure Management System (MMS), and recommended that MMS measure development principles be integrated into the LTCH QRP principles. The same commenter suggested that clearly delineated processes are required in order to guide the application of these principles. Two commenters expressed concern about the addition of measures to the QRP given the administrative burden associated with measure reporting. These commenters suggested that CMS’ guiding principles consider whether a measure is important, well-defined, has scientific merit, is feasible and useable, and does not duplicate existing measures. A commenter recommended that CMS support testing through the CBE.

   Although several commenters agreed with CMS on the presence of measurement gaps in the LTCH QRP, not all commenters thought that measures should be added to the LTCH QRP. A commenter recommended that CMS continually evaluate whether measures are necessary, and remove measures that are deemed unnecessary. Another commenter, who agreed with CMS on the need to fill measurement gaps in the areas identified in the RFI, encouraged CMS to utilize measures and/or assessment data already available (for example, claims data, LCDS, and NHSN) in order to reduce LTCH burden. This commenter further
suggested that CMS reduce administrative burden by streamlining LTCH data collection (for example, incorporating additional skip logic to bypass questions that are not relevant to an LTCH).

Three commenters recommended that CMS prioritize operational improvements to the LTCH QRP rather than the addition of new measures. Operational issues identified by the commenters included the lack of training on new instruments, time necessary to conduct patient assessments, and the need to remove “low-value” measures when new measures are added to the QRP. Another commenter urged CMS to ensure that reported measures account for LTCHs high-acuity patient population, and focus on topics that LTCHs are able to directly impact.

A couple of commenters agreed that the area of cognitive function was an important LTCH QRP measurement gap that needs to be filled. A commenter encouraged CMS to select measures of cognitive functioning that are reliable, feasible, valid, and that are, or could be, endorsed by a CBE. The other commenter expressed concern about the inability of cognitive function tools to identify mild and moderate cognitive impairment. A commenter acknowledged the prevalence of behavioral and mental health issues in the U.S. adult population and recommended that, given occupational therapists’ role in addressing behavioral and mental health issues, they be included in quality measures.

A commenter agreed that the area of chronic condition and pain management is an important LTCH QRP measurement gap that needed to be filled. The commenter encouraged CMS to select measures that are reliable, feasible, valid, and that are, or could be, endorsed by a CBE. Another commenter expressed support for assessments of pain and its effect on sleep, participation in therapy, and ability to perform activities of daily living. A few commenters indicated that measurement gaps exist in areas not identified in the RFI. A commenter recommended that measures focusing on care rendered to patients with chronic kidney disease (CKD) be included as part of the LTCH QRP measure set. The commenter urged CMS to consider a suite of measures that addressed kidney care. Among the recommended measures, the commenter identified the Kidney Health Evaluation for Patients with Diabetes (KED) in order to promote screening and monitoring of kidney health; patient reported outcome measures that address care planning and shared-decision making; measures of CKD patients that are on a cardio-renal protective agent; and post-discharge measures of care coordination and medication management.

Some commenters recommended that CMS incorporate measures of health equity in the LTCH QRP. Measures recommended for consideration included the Screening and Referral to Services for Social Needs, and the Screening for Social Drivers of Health. Two commenters further recommended that CMS report quality measures using stratification, such as race, socioeconomic status, dual eligibility status, disability status, sexual orientation and gender identity, to identify disparities in health outcomes. A commenter urged CMS to adopt measures of malnutrition in order to address health equity. Other measures and measurement concepts suggested by commenters included a measure of patients that are pharmaceutically restrained during an acute inpatient stay, and that are subsequently discharged to an LTCH to be titrated off their medications; measures associated with issues related to vents, wounds, nutrition, and dialysis; and an updated version of the NHSN healthcare associated clostridioides difficile infection outcome measure derived from EHR data and microbiologic evidence.

Response: We appreciate the input provided by commenters. While we will not be responding to specific comments submitted in response to this RFI in this final rule, we intend to use this input to inform our future measure development efforts.

6. Health Equity Update

a. Background

In the FY 2023 IPPS/LTCH PPS proposed rule (87 FR 28570 through 28576), we included an RFI entitled “Overarching Principles for Measuring Equity and Healthcare Quality Disparities Across CMS Quality Programs.” We define health equity as “the attainment of the highest level of health for all people, where everyone has a fair and just opportunity to attain their optimal health regardless of race, ethnicity, disability, sexual orientation, gender identity, socioeconomic status, geography, preferred language, or other factors that affect access to care and health outcomes.”

We are working to advance health equity by designing, implementing, and operationalizing policies and programs that support health for all the people served by our programs and models, eliminating avoidable differences in health outcomes experienced by people who are disadvantaged or underserved, and providing the care and support that our enrollees need to thrive. Our goals outlined in the CMS Framework for Health Equity 2022–2023 are in line with Executive Order 13985, “Advancing Racial Equity and Support for Underserved Communities Through the Federal Government.” The goals included in the CMS Framework for Health Equity serve to further advance health equity, expand coverage, and improve health outcomes for the more than 170 million individuals supported by our programs, and set a foundation and priorities for our work, including: strengthening our infrastructure for assessment, creating synergies across the health care system to drive structural change, and identifying and working to eliminate barriers to CMS-supported benefits, services, and coverage. The CMS Framework for Health Equity outlines the approach CMS will use to promote health equity for enrollees, mitigate health disparities, and prioritize CMS’s commitment to expanding the collection, reporting, and analysis of standardized data.

In addition to the CMS Framework for Health Equity, we seek to advance health equity and whole-person care as one of eight goals comprising the CMS National Quality Strategy (NQS). The NQS identifies a wide range of potential quality levers that can support our advancement of equity, including: (1) establishing a standardized approach for patient-reported data and stratification; (2) employing quality and value-based programs to address closing equity gaps; and (3) developing equity-focused data collections, analysis, regulations, and reports.


oversight strategies, and quality improvement initiatives.

A goal of this NQS is to address persistent disparities that underlie our healthcare system. Racial disparities in health, in particular, are estimated to cost the U.S. $93 billion in excess medical costs and $42 billion in lost productivity per year, in addition to economic losses due to premature deaths. At the same time, racial and ethnic diversity has increased in recent years with an increase in the percentage of people who identify as two or more races accounting for most of the change, rising from 2.9 percent to 10.2 percent between 2010 and 2020. Therefore, we need to consider ways to reduce disparities, achieve equity, and support our diverse beneficiary population through the way we measure quality and display the data.

We solicited public comments via the aforementioned RFI on changes that we should consider in order to advance health equity. We refer readers to the FY 2023 IPPS/LTCH PPS final rule (87 FR 49317 through 49319) for a summary of the public comments and suggestions we received in response to the health equity RFI. We will take these comments into account as we continue to work to develop policies, quality measures, and measurement strategies on this important topic.

b. Anticipated Future State

We are committed to developing approaches to meaningfully incorporate the advancement of health equity into the LTCH QRP. One option we are considering is including social determinants of health (SDOH) as part of new quality measures.

Social determinants of health are the conditions in the environments where people are born, live, learn, work, play, worship, and age that affect a wide range of health, functioning, and quality-of-life outcomes and risks. They may have a stronger influence on the population’s health and well-being than services delivered by practitioners and healthcare delivery organizations. Measure stratification by CMS is important for better understanding differences in health outcomes from across different patient population groups according to specific demographic and SDOH variables. For example, when “pediatric measures over the past two decades are stratified by race, ethnicity, and income, they show that outcomes for children in the lowest income households and for Black and Hispanic children have improved faster than outcomes for children in the highest income households or for White children, thus narrowing an important health disparity.” This analysis and comparison of the SDOH items in the assessment instruments support our desire to understand the benefits of measure stratification. Hospital providers receive such information in their confidential feedback reports (CFRs) and we think this learning opportunity would benefit post-acute care providers. The goals of the CFR are to provide LTCHs with their results so they can compare certain quality measures stratified by dual eligible status and race and ethnicity. The process is meant to increase provider’s awareness of their data. We will solicit feedback from LTCHs for future enhancements to the CF Rs.

In the proposed rule, we said that we are considering whether health equity measures we have adopted for other settings, such as hospitals, could be adopted in post-acute care settings. We are exploring ways to incorporate SDOH elements into the measure specifications. For example, we could consider a future health equity measure like screening for social needs and interventions using our current SDOH data items of preferred language, interpreter services, health literacy, transportation, and social isolation. With 30 percent to 55 percent of health outcomes attributed to SDOH, a measure capturing and addressing SDOH could encourage LTCHs to identify patients’ specific needs and connect them with the community resources necessary to overcome social barriers to their wellness. We could specify a health equity measure using the same SDOH data items that we currently collect as standardized patient assessment data elements under the LTCH. These SDOH data items assess health literacy, social isolation, transportation problems, and preferred language (including need or want of an interpreter). We also see value in aligning SDOH data items according to existing health information technology (IT) vocabulary and codes sets where applicable and appropriate such as those included in the Office of the National Coordinator for Health Information (ONC) United States Core Data for Interoperability (USCDI) across all care settings as we develop future health equity quality measures under our LTCH QRP statutory authority. This would further the NQS to align quality measures across our programs as part of the Universal Foundation.

Although we did not directly solicit feedback to our update, we did receive some public comments, which we summarize later in this section.

Comment: Commenters were overwhelmingly supportive of CMS’ efforts to develop ways to measure and mitigate health inequities. Four commenters applauded CMS’ continuing efforts to advance health equity and encouraged CMS to continue to develop and adopt measures of social determinants of health (SDOH) into the LTCH QRP. One of these commenters suggested that CMS should ensure any quality measure is feasible and would have an intended impact within the LTCH.

A commenter encouraged stratified reporting of all LTCH QRP quality measures by race, dual eligibility status, disability status, sexual orientation and gender identity, and socioeconomic status to provide visibility to clinicians and LTCHs as to where disparities exist within each measure. Another commenter believed collecting race and ethnicity information and other SDOH would provide LTCHs an opportunity to stratify their own data for patient populations to better plan for needed services; identify members of a target population to whom elements of an intervention would apply; understand potential patterns in access and outcomes for different segments of the patient population; and increase patient and provider understanding.

We also received two comments supporting the adoption of screening or structural measures in the LTCH QRP. Both of these commenters supported the Screening and Referral to Services for Social Needs measure and the Screening for Social Drivers of Health measure.
noting that both of these align with the CMS Universal Foundation Set for adults. One of these commenters also supported CMS’ structural measures. This commenter acknowledged that structural measures are not a complete solution, but believe they play an important role in achieving patient safety and health equity goals, and when combined with public reporting has the potential to focus the commitment of leaders and impact organizational cultures in LTCHs to address existing problems with both explicit and implicit bias.

We also received feedback on other ways to incorporate health equity into the LTCH QRP. A commenter pointed out that nutritional status, and hence malnutrition, is often influenced by a variety of SDOH domains and could result in certain populations, such as the elderly, disabled, and the poorest segments of society, having a higher degree of malnutrition. This commenter recommended CMS adopt a diagnosis of malnutrition as a measure to address health equity to ensure appropriate identification and nutritional management of malnourished patients. Another commenter strongly urged CMS to adopt IT standards and consistent guidance across programs for the collection of structured data that addresses the capture, use, and exchange of relevant health data. This commenter noted that SDOH is a data class in USCDI, and referenced the work of the Gravity Project on health equity, SDOH, and other health-related social needs (HRSN) data. Finally, a commenter who noted that the ability to collect and analyze data is crucial to advance health equity also cautioned that there may be significant operational challenges for entities either not using electronic health records or not using them with standardized data entry.

Response: We thank all the commenters for responding to our update on this important CMS priority. We will continue to prioritize our efforts to advance health equity by designing, implementing, and operationalizing policies and programs that support health for all people served by our program.

7. Form, Manner, and Timing of Data Submission Under the LTCH QRP

a. Background

We refer readers to the regulatory text at 42 CFR 412.560(b) for information regarding the current policies for reporting LTCH QRP data.

b. Reporting Schedule for the LCDS Assessment Data for the Discharge Function Score Measure Beginning With the FY 2025 LTCH QRP

As discussed in section IX.E.4.b. of the preamble of this final rule, we proposed to adopt the DC Function measure beginning with the FY 2025 LTCH QRP. We proposed that LTCHs would be required to report these LCDS assessment data beginning with patients admitted or discharged on October 1, 2023 for purposes of the FY 2025 LTCH QRP. Starting in CY 2024, LTCHs would be required to submit data for the entire calendar year beginning with the FY 2026 LTCH QRP. Because the DC Function quality measure is calculated based on data that are currently submitted to the Medicare program, there would be no new burden associated with data collection for this measure.

We invited public comments on this proposal. We did not receive public comments on this proposed provision, and therefore, we are finalizing as proposed.

c. Reporting Schedule for the LCDS Assessment Data for the COVID–19 Vaccine: Percent of Patients/Residents Who Are Up to Date Measure Beginning With the FY 2026 LTCH QRP

As discussed in section IX.E.4.e. of this final rule, we proposed to adopt the COVID–19 Vaccine: Percent of Patients/Residents Who Are Up to Date quality measure beginning with the FY 2026 LTCH QRP. We proposed that LTCHs would be required to report these LCDS assessment data beginning with patients discharged on October 1, 2024 for purposes of the FY 2026 LTCH QRP. Starting in CY 2025, LTCHs would be required to submit data for the entire calendar year beginning with the FY 2027 LTCH QRP.

We also proposed to add a new item to the LCDS in order for LTCHs to report the proposed measure. A new item would be added to the discharge item sets to collect information on whether a patient is up to date with their COVID–19 vaccine at the time of discharge. A draft of the new item is available in the COVID–19 Vaccine: Percent of Patients/Residents Who Are Up to Date Draft Measure Specifications. We invited public comments on this proposal. The following is a summary of the comments we received on our proposal to require LTCHs to report a new LCDS assessment data item for the Patient/Resident COVID–19 Vaccine measure beginning with patients discharged on October 1, 2024 and our responses.

Comment: Two commenters provided an alternate recommendation, encouraging CMS to explore other methods of collecting patient COVID–19 vaccine data rather than imposing new reporting requirements on providers. They cited a Washington Post article that found that only around 20 percent of healthcare facilities are “equipped to report disease cases electronically to state health departments.” These commenters stated CMS should therefore continue to explore improvements in gathering data through the states rather than imposing these burdensome reporting requirements on providers.

Response: We do not find this article to be applicable to the LTCH QRP, nor do we think this article is relevant to the proposed measure since the proposed Patient/Resident COVID–19 Vaccine measure reports vaccination status, and not a disease case. LTCHs have been successfully reporting disease cases to the NHSN since 2013 and currently report Catheter-Associated Urinary Tract Infection (CAUTI), Central Line-Associated Bloodstream Infection (CLABSI) and Clostridium difficile Infection (CDI) information to NHSN as part of the LTCH QRP. We find assessment-based measures like the Patient/Resident COVID–19 Vaccine measure have several benefits that are not provided by state reported data, such as patient-level data, a variety of reports LTCHs can use to assess performance, as well as public reporting of the data. This measure will be included in LTCH Review and Correct reports as well as QM patient and facility level confidential feedback reports. Additionally, this data will allow for granular analyses of vaccinations, including identification of potential disparities within the LTCH QRP.

After consideration of the public comments we received, we are finalizing our proposal to require LTCHs to report the new LCDS assessment data item for the Patient/Resident COVID–19 Vaccine measure beginning with patients discharged on October 1, 2024 for the FY 2026 LTCH QRP.

d. LTCH QRP Data Completion Thresholds for LCDS Data Items

Beginning With The FY 2026 Payment Determination

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50312 through 50315), we finalized that LTCHs would need to complete 100 percent of the data collected using the LCDS on at least 80 percent of the LCDS assessments they submit through the CMS-designated submission system in order to be considered in compliance with the LTCH QRP reporting requirements for the applicable program year. We established this data completion threshold in order to give LTCHs time to become familiar with quality reporting, and that their experience and understanding with respect to reporting quality data using a standardized data collection instrument, and thus their compliance, would increase over time. We also noted at that time our intent to raise the proposed 80 percent threshold in subsequent program years.912

We proposed that, beginning with the FY 2026 LTCH QRP, LTCHs would be required to report 100 percent of the required quality measures data and standardized patient assessment data collected using the LCDS on at least 90 percent of the assessments they submit through the CMS-designated submission system.

Complete data are needed to help ensure the validity and reliability of quality data items, including risk-adjustment models. The proposed threshold of 90 percent is based on the need for substantially complete records, which allows appropriate analysis of quality measure data for the purposes of updating quality measure specifications as they undergo yearly and triennial measure maintenance reviews with the CBE. CMS wants to ensure complete quality data from LTCHs, which will ultimately be reported to the public, allowing our beneficiaries to gain a more complete understanding of LTCH performance related to these quality metrics, and helping them to make informed healthcare choices. Finally, the proposal would contribute to further alignment of data completion thresholds across the PAC settings.

We believe LTCHs should be able to meet the proposed requirement for the LTCH QRP because our data shows that LTCHs are already in compliance with, or exceeding, the proposed threshold. The complete list of items required under the LTCH QRP is updated annually and posted on the LTCH QRP Measures Information page.913

We proposed that LTCHs would be required to comply with the proposed new completion threshold beginning with the FY 2026 LTCH QRP LTCH QRP. Starting in CY 2024, LTCHs would be required to report 100 percent of the required quality measures data and standardized patient assessment data collected using the LCDS on at least 90 percent of all assessments submitted January 1 through December 31 for that calendar year’s payment determination. We also proposed to update § 412.560(f)(1) of our regulations to reflect this new policy (see the regulation text in this final rule).

We invited public comment on the proposed schedule for the increase of LTCH QRP data completion thresholds for the LCDS Data Items beginning with the FY 2026 LTCH QRP. The following is a summary of the comments we received and our responses.

Comment: A commenter supported our proposal to increase the data compliance threshold for LCDS data items for the LTCH QRP.

Response: We thank the commenter for their support.

Comment: A number of commenters opposed the proposal to increase the data completion threshold for LCDS data items and referenced CMS’ statement in the proposed rule (88 FR 27154) that our data shows LTCHs are already in compliance with, or exceeding, the proposed threshold. They stated the existing 80 percent data completion threshold is a sufficient incentive for ensuring that CMS obtains the quality data it needs and the proposed higher threshold is unlikely to significantly increase the rate of complete LCDS assessments submitted by LTCHs, since many are already satisfying the 90 percent compliance threshold.

Three of these commenters suggested that the increased threshold would put unnecessary pressure on those who were achieving the minimum 80 percent threshold and potentially negatively affect the accuracy of the data. These commenters stated that increasing the data completion threshold from 80 percent to 90 percent would disadvantage LTCHs that care for the most vulnerable, highly complex patients while not providing any additional incentive for others to report better data.

Response: We acknowledge the commenters concerns but we still think increasing the threshold will result in a greater number of complete LCDS assessments submitted by LTCHs. While we acknowledge that patients in LTCHs can be complex and acutely ill, it is for those reasons that collection of more complete data is important. The LCDS is composed of data items designed to inform quality measure calculations, including risk-adjustment calculations. Increasing the data completion threshold will further inform our quality work at CMS, allowing for the continued improvement in quality of care. Additionally, having more complete information will ensure we recognize the acuity and complexity of these patients for LTCH measures’ risk adjustment, while also allowing our beneficiaries to gain a more complete understanding of LTCH performance related to LTCH QRP measures, and helping them to make informed healthcare choices.

Comment: Several commenters opposed the increase in data completion threshold stating that the buffer is necessary in order to accommodate those instances in which it is not possible to complete the assessment for clinical reasons, such as when patients are discharged or transferred to an acute care hospital under emergency circumstances. They believe that in these cases, it would be inappropriate to stop the emergency discharge or transfer process to undertake, for example, a skin assessment of the patient. They believe that for facilities who serve larger proportions of complex and/or acutely ill patients, these cases are more frequent and increasing the threshold to 90 percent would put these facilities that have otherwise been in compliance with the reporting requirements at a serious disadvantage. A commenter noted that they are concerned CMS will use the higher compliance threshold to impose the 2 percent LTCH QRP payment penalty on more LTCH providers for unplanned discharges. They referenced the LCDS Manual V5.0 that states CMS is aware that there are certain circumstances in which LTCHs may not be able to complete every item on the LCDS assessment.”

Two of these commenters suggested that CMS should not adopt the 90 percent data completion threshold until they also adopted an exclusion for unplanned discharges and hospital readmissions within 30 days of admission from the LTCH QRP data compliance calculation. They believe this exclusion is necessary because there are a significant number of unplanned or emergent discharges.

912 79 FR 50312 through 50313.

where it is impossible to fully complete all LCDS data items. Another commenter suggested removing the skin assessment from the unplanned discharge LCDS item set.

Response: We believe LTCHs consider patient care of paramount importance and should use clinical judgement when patients are discharged or transferred to an acute care hospital under emergency circumstances. The LCDS Manual V5.0 provides guidance on how to code LCDS items on discharge, and we encourage LTCHs to use the guidance as well as other QRP item sets. We also acknowledge the statement the commenters reference in the LCDS Manual V5.0 Chapter 2, and note that section of the manual goes on to say that we expect dash use to be a rare occurrence.914

We have considered emergent discharges as one reason that LTCHs may not meet data completion thresholds approaching 90 percent, but we believe the LTCH should be able to meet the proposed threshold of 90 percent and can confirm that the majority of LTCHs are meeting this threshold presently. Additionally, there is an LCDS item set specifically for unplanned discharges that contains a reduced set of data elements. The LCDS Version 5.0, Unplanned Discharge item set is 33 percent shorter than the LCDS Version 5.0, Planned Discharge item set, and has approximately 33 percent fewer items to complete. For each of the items on the Unplanned Discharge item set, the LCDS Guidance Manual provides instructions for how to code the item if the item does not apply to the patient or the patient is unable to respond. Selecting these responses when applicable counts toward the data completion threshold. Additionally, the assessments of the special services, treatments, and interventions with multiple responses are formatted as a “check all that apply” format. Therefore, when treatments do not apply, the assessor need only check one row for “None of the Above,” and the data completion requirement is met.

Regarding the commenters’ suggestion that we exclude unplanned discharges or discharges from the LTCH within 30 days of admission from the calculation of an LTCH’s data completion, we believe collecting quality data using the LCDS on these patients is just as important as data we collect on patients who have a planned discharge.

Comment: Several commenters expressed concern that if CMS were to raise the data completion threshold, it would be used to impose the 2 percent payment penalty on more LTCH providers for technical issues or system problems that LTCHs frequently experience with CDC’s National Healthcare Safety Network (NHSN) and CMS’s internet Quality Improvement and Evaluation System (iQIES) data submission systems. They believe that until CMS adopts safeguards against these technical non-compliance and system errors, it should not increase the LCDS data completion threshold because it would punish more providers that make unintentional technical errors, experience challenges outside of their control, or are attempting to report data timely in good faith.

Three of these commenters also request that CMS reconsider its position that only categorically and absolutely perfect quality data reporting is sufficient, without any leeway to correct clerical or administrative errors, or any grace period for inadvertently omitted data. They request CMS adopt a short grace period after each reporting deadline to allow LTCHs to correct with CMS, NHSN and iQIES staff to determine the specific data that was not properly submitted or received by CMS, and resolve the issue in a productive and collaborative way before the LTCH is penalized. Such a grace period would achieve the agency’s goal of increased compliance and data completion, and reduce unnecessary payment penalties on well-intentioned providers. They also noted concerns with NHSN data submission.

Response: Regarding the commenters’ concerns about the CDC’s NHSN, our proposal was specific to the data completion threshold for assessment-based data and therefore, we will not be responding to the comments about the NHSN.

We acknowledge that there are occasional technical issues with the iQIES data submission system. However, in CY 2022, all of the known issues posted on the iQIES website915 were corrected with ample time remaining in the data submission window for LTCHs to submit data. In the FY 2016 IPPS/LTCH final rule (80 FR 49751), we finalized data submission and correction timelines for LTCH QRP data. LTCHs have 4.5 months (approximately 135 days) from the end of a calendar year quarter to submit, review, and correct their quality data for that CY quarter. This timeline aligns with other quality reporting programs’ data submission and correction deadlines and meets the goal of providing a ‘grace period’ where LTCHs and CMS can resolve any issues.

We also want to remind providers that there are several reports available to providers to monitor their compliance with the QRP reporting requirements during the year. These reports are available within iQIES to providers, including the LTCH Final Validation Report (FVR) and the Provider Threshold Report (PTR). The LTCH FVR is automatically generated in iQIES within 24 hours of the submission of a file and placed in the provider’s My Reports folder. The FVR provides detailed information about the status of submission files, including warnings and fatal errors encountered. The PTR allows providers to monitor their compliance status regarding the required data submission for the LTCH QRP measures for the current Annual Payment Update (APU). It is a user requested and on-demand report, meaning that it can be pulled anytime by the LTCH. LTCHs can sign up to receive informational messages if you are not meeting the APU threshold. These are sent out on a quarterly basis ahead of each submission deadline.916

The iQIES Help Desk is also available to answer any questions related to data submission.917

Finally, if LTCHs believe they have received the QRP penalty unfairly, they can choose to use the LTCH QRP Reconsideration and Exception and Extension process. LTCHs may file for reconsideration if they believe the finding of non-compliance is an error, or they have evidence of the impact of extraordinary circumstances that prevented timely submission of data. LTCHs dissatisfied with the reconsideration ruling may file a claim under 42 CFR part 405, subpart R (a Provider Reimbursement Review Board [PRRB] appeal).918 Details are available on the PRRB Review Instructions web page. Alternatively, LTCHs can request an exception or extension from the program’s reporting requirements in the event they were unable to submit quality data due to extraordinary circumstances beyond their control, as


long as they submit the request within 90 days of the event. 

Comment: Two commenters believed that the statutory language Congress passed as part of the Patient Protection and Affordable Care Act (ACA) gives CMS the discretion to take a more flexible approach to the administration of the LTCH QRP. They point to paragraph (5) of the LTCH PPS statute at 42 U.S.C. 1395ww(m) that directs CMS to apply a 2 percent payment penalty when the LTCH does not submit data on quality measures in the form and manner required by CMS. However, they suggested that CMS’ interpretation of the statute is too strict since an LTCH must have essentially perfect compliance with the form, manner, and timing of its LTCH QRP data submissions to avoid the 2 percent payment penalty, and they believe there is no basis for this strict application.

Response: We strive to have a program that enables the submission of complete measure data which informs not only the public on the care received during an LTCH stay. The goal is always to have 100 percent of the data submission, rather than an expectation that LTCHs will meet the minimum threshold of the compliance required. However, we understand that at times data cannot be gathered or entered perfectly. We have accounted for this in a variety of ways through outreach, reports, our exception and extension process, as well as the ability to use the ‘dash’ within the assessment itself. We see this increase in the compliance threshold as moving the goal post to incentivize higher quality of care, rather than a punitive action. Currently, the threshold is set at 80 percent, and we proposed a 90 percent data submission threshold, which still allows a 10 percent buffer for LCDS assessments that fail to report 100 percent of the data required. 

We do not have the same interpretation of the statute. Our interpretation is based on the Affordable Care Act enacted by the 111th Congress, which stipulated that the Secretary of HHS set forth administration requirements for LTCH QRP. Specifically, section 1886(m)(5)(C) of the Act requires that, for the FY 2014 payment determination and subsequent years, each LTCH submit data on quality measures specified by the Secretary in a form and manner, and at a time, specified by the Secretary. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 28273 through 28275), we adopted specific LTCH QRP thresholds for completion of LTCH quality data beginning with data affecting the FY 2016 payment determination and subsequent years, and these are codified at § 412.560(f). We want to reiterate that CMS does not use the data completion thresholds as a punitive tool but rather a way to benchmark the quality of care using quality measures. We must adhere to the standards previously enacted through notice and comment rulemaking, and currently the standard is that LTCH’s must achieve at least 80 percent for completion of measures data and standardized patient assessment data submitted using the LCDS submitted through the CMS designated data submission system.

Comment: Several commenters opposed the proposal to increase the LTCH data completion thresholds for LCDS data items due to the burden associated with the increased number of items on the LCDS V5.0. Two of these commenters also related the burden to the ongoing workforce challenges, while two others related it to the complexity of their patients or the number of unplanned discharges they experience, both of which they stated are out of their control. Four of these commenters stated that before implementing any changes, CMS should do four things: (1) assess the actual burden of completing the LCDS; (2) gain an understanding of the data elements and factors driving below 90 percent response rates (for example, unplanned discharge assessments); (3) assess the quality of the information it has already collected; and (4) document how existing information is being used to improve patient outcomes.

Response: We have strived to balance the scope and level of detail of the data elements against the potential burden placed on LTCHs. We have provided multiple training resources and opportunities for LTCHs to take advantage of in order to become more familiar and proficient with completing the LCDS. These continue to be available to LTCHs on the LTCH QRP Training webpage so LTCHs can use them with new staff. While we acknowledge the impacts of the ongoing workforce challenges, these challenges also make it especially important now to monitor quality of care. We must maintain commitment to the quality of care for all patients, and we continue to believe that the collection of the standardized patient assessment data elements and other data elements on the LCDS will contribute to this effort. That includes staying committed to achieving health equity by improving data collection to better measure and analyze disparities across programs and policies and improving the quality of care in LTCHs through a reduction in preventable adverse events, such as emergent and unplanned discharges.

In response to the commenters’ four recommendations CMS should undertake before raising the threshold, we address each of those next. First, we do assess the burden of completing the LCDS. Prior to adding any new data element to the LCDS, we evaluate the need for the information collection and its usefulness to the LTCH QRP, as well as the quality, utility, and clarity of the information to be collected. We employ a transparent process to seek input from interested parties and national experts and engage in a process that allows for pre-rulemaking input on proposed data elements and consider all recommendations to minimize the information collection burden on LTCHs. The data elements are proposed in formal notice and comment rulemaking, so there is transparency for LTCHs in evaluating the proposal and the estimate of burden that accompanies it. Each time CMS has proposed adding a new item or items, we have followed this process.922

In response to the commenters’ recommendation that CMS gain an understanding of the specific data elements and factors that contribute to LTCHs failing to achieve the data completion threshold, we do routinely monitor the LTCH data to identify the process gaps and trends. At the end of each reporting period, CMS reviews the data submitted by LTCHs to understand which item(s) may have contributed to a provider(s) lower compliance threshold. We use this information to build our education and
outreach programs. In response to the recommendations that we assess the quality of the information we have collected and document how existing information is being used to improve patient outcomes, we already undertake these activities. For example, we assess the quality of the information we collect each quarter before we publicly report the data on Care Compare. We have an obligation to beneficiaries to ensure complete and accurate LTCH QRP measure data, which allows our beneficiaries to gain a more complete understanding of LTCH performance, helping them to make informed healthcare choices. We also routinely monitor the individual data elements and the quality measures they contribute to, in order to ensure they produce statistically meaningful information that can inform improvements in care processes.

In response to comments received, while still maintaining our goal of moving towards more complete data, we note that as part of this final rule, we are updating the proposed compliance threshold from 90 percent to 95 percent. This iterative approach will incentivize LTCHs to strive for more complete data submission at the same time they meet the compliance threshold of 95 percent. Consequently, LTCHs will be required to collect and report LCDS assessment data on at least 95 percent of all assessments beginning with FY 2026. CMS will closely monitor LTCH’s performance at this threshold. As we stated in previous rules, it was always our intent to raise the 80 percent threshold, and it is still our intent to raise this threshold in order to further align data completion thresholds across the PAC settings. Such revisions would be proposed through the notice and comment rulemaking process.

Comment: Three commenters suggested that if CMS finalizes the proposed increase to the LCDS data completion threshold it will still not improve the data available to CMS, but it would lead to more LTCHs receiving the 2 percent payment penalty even when reporting data timely in good faith. However, they request that if CMS does increase the LCDS data completion threshold to 95 percent, CMS should also set a uniform 90 percent threshold for the LTCH QRP by decreasing the NHSN compliance threshold from 100 percent to 90 percent. They believe the current 100 percent threshold for NHSN quality measures has a clear history of being used in a punitive way that frequently results in consequences for LTCHs that they believe are impacted by NHSN system issues or minor clerical errors LTCHs make.

Response: Increasing the LCDS data completion threshold will improve the data available to CMS and help ensure the validity and reliability of quality data items, including risk-adjustment models. As we stated in the FY 2024 IPPS/LTCH proposed rule (88 FR 27154), the increase in threshold percent is based on the need for substantially complete records and would contribute to further alignment of the data completion thresholds across the PAC settings. Regarding the commenters’ suggestion that CMS should lower the NHSN compliance threshold from 100 percent to 90 percent, we did not propose to modify the NHSN threshold and therefore we will not be responding to the comment.

Comment: Two commenters believe it is imperative that CMS address the calculation method of the LCDS data completion percentage. They do not believe CMS should treat a patient assessment where it omitted the same way a patient assessment missing 95 percent of the items is treated. As a result, they disagree that the proposed increase in the threshold from 80 percent to 90 percent ensures a significant increase in the patient assessment data CMS receives, but instead would result in 2 percent payment penalties to well-intentioned LTCHs that submit nearly flawless patient assessment.

Response: The LCDS data completion threshold was adopted in the FY 2015 IPPS/LTCH final rule (79 FR 50312–50313), and was based on the need for “complete” quality data, and therefore partial data submission cannot be considered to meet the quality standards. An LCDS is “complete” when the required data elements have actual patient data reported, as opposed to a non-informative response, such as a dash (-), that indicates the LTCH was unable to provide patient data. “Complete” LCDS data is needed to create complete records, which allows for appropriate analysis of quality measure data for the purposes of updating quality measure specifications as they undergo yearly and triennial measure maintenance reviews with the CBE. In addition, complete data is needed to understand the validity and reliability of quality data items, including risk-adjustment models. Finally, we want to ensure complete quality data from LTCHs, which will ultimately be reported to the public.

Comment: A commenter is especially concerned with the proposed increase in the data completion threshold because of the required Standardized Patient Assessment Data Elements (SPADEs) that they believe are neither used for quality reporting purposes nor proposed for use in any quality measure for the LTCH QRP. They state that CMS has not provided any additional information related to the intended use of many of the data elements other than the intent to levy payment penalties should the information not be collected. In addition, limited testing was conducted on the feasibility of collecting the new SPADEs and consideration was not given to whether these new data elements would differentiate patient characteristics or provider performance.

Response: The standardized patient assessment data elements adopted for the LTCH QRP underwent extensive testing over several years. The Improving Medicare Post-Acute Care Transformation Act of 2014 (the IMPACT Act) required the reporting of standardized patient assessment data with regard to quality measures and standardized patient assessment data elements. Development of the candidate standardized patient assessment data items began in 2015 and there were multiple opportunities for input and comment by interested parties through technical expert panels, listening sessions, townhalls, and requests for information in formal notice and comment rulemaking. We encourage the commenter to go to the IMPACT Act web page where these materials are available for review.

Comment: A commenter shared feedback on LCDS Version 5.0 (effective October 1, 2022) and the challenges that were created with the most recent data collection and submission requirements.

Response: Because we consider these public comments to be outside the scope of the proposed rule, we are not addressing them in this final rule.

After consideration of the public comments we received, we are finalizing our proposal with modification to require LTCHs to report 100 percent of the required quality measures data and standardized patient assessment data collected using the LCDS on at least 85 percent of all assessments submitted beginning with the FY 2026 payment determination and subsequent years.

9. Policies Regarding Public Display of Measure Data for the LTCH QRP

a. Background

Section 1886(m)(5)(E) of the Act requires the Secretary to establish procedures for making the LTCH QRP data available to the public after ensuring that LTCHs have the opportunity to review their data prior to public display.

b. Public Reporting of the Transfer of Health Information to the Patient Post-Acute Care and Transfer of Health Information to the Provider Post-Acute Care Measures Beginning with the FY 2025 LTCH QRP

We proposed to begin publicly displaying data for the measures: (1) Transfer of Health (TOH) Information to the Provider—Post-Acute Care (PAC) Measure (TOH-Provider) and (2) TOH Information to the Patient—PAC Measure (TOH-Patient) beginning with the September 2024 Care Compare refresh or as soon as technically feasible. We adopted these measures in the FY 2020 IPPS/LTCH PPS final rule (84 FR 42525 through 42535). In response to the COVID–19 PHE, we released an interim final rule (85 FR 27595 through 27597) which delayed the compliance date for the collection and reporting of the TOH-Provider and TOH-Patient measures to October 1 of the year that is at least one full FY after the end of the COVID–19 PHE. Subsequently, in the CY 2022 Home Health PPS Rate Update final rule (86 FR 62386 through 62390), the compliance date for the collection and reporting of the TOH-Provider and TOH-Patient measures was revised to October 1, 2022. Data collection for these two assessment-based measures began with patients admitted and discharged on or after October 1, 2022.

We proposed to publicly display data for these two assessment-based measures based on four rolling quarters, initially using discharges from January 1, 2023 through December 31, 2023 (Quarter 1 through Quarter 4 2023), and to begin publicly reporting these measures with the September 2024 refresh of Care Compare, or as soon as technically feasible. To ensure the statistical reliability of the data, we proposed that we would not publicly report an LTCH’s performance on a measure if the LTCH had fewer than 20 eligible cases in any four consecutive rolling quarters for that measure. LTCHs that have fewer than 20 eligible cases would be distinguished with a footnote that states: “The number of cases/patient stays is too small to publicly report.”

We invited public comment on our proposal for the public display of the (1) Transfer of Health (TOH) Information to the Provider—Post-Acute Care (PAC) Measure (TOH-Provider) and (2) Transfer of Health (TOH) Information to the Patient—Post-Acute Care (PAC) Measure (TOH-Patient) assessment-based measures. The following is a summary of the comments we received and our responses.

Comment: We received overwhelming support for the proposal to publicly report the Transfer of Health Information to the Provider-PAC Measure and the Transfer of Health Information to the Patient-PAC Measure beginning with the September 2024 Care Compare refresh or as soon as possible.

Response: We appreciate these commenters’ support for the proposed public reporting of these measures.

After consideration of the public comments we received, we are finalizing our proposal to begin publicly displaying data for the measures: (1) Transfer of Health (TOH) Information to the Provider—Post-Acute Care (PAC) Measure (TOH-Provider); and (2) TOH Information to the Patient—PAC Measure (TOH-Patient) beginning with the September 2024 Care Compare refresh or as soon as technically feasible.

c. Public Reporting of the Discharge Function Score Measure Beginning With the FY 2025 LTCH QRP

We proposed to begin publicly displaying data for the DC Function measure beginning with the September 2024 refresh of Care Compare, or as soon as technically feasible, using data collected from January 1, 2023, through December 31, 2023 (Quarter 1 2023 through Quarter 4 2023). We proposed that an LTCH’s DC Function score would be displayed based on four quarters of data. Provider preview reports would be distributed in June 2024, or as soon as technically feasible. Thereafter, an LTCH’s DC Function score would be displayed based on four quarters of data and updated quarterly. To ensure the statistical reliability of the data, we proposed that we would not publicly report an LTCH’s performance on the measure if the LTCH had fewer than 20 eligible cases in any quarter. LTCHs that have fewer than 20 eligible cases would be distinguished with a footnote that states: “The number of cases/patient stays is too small to publicly report.”

We invited public comment on the proposal for the public display of the DC Function measure. The following is a summary of the comments we received and our responses.

Comment: A commenter provided support to publicly report the DC Function measure.

Response: We thank the commenter for their support to publicly report the DC Function measure.

After consideration of the public comments we received, we are finalizing our proposal to begin publicly displaying data for the DC Function measure beginning with the September 2024 Care Compare refresh or as soon as technically feasible.

d. Public Reporting of the COVID–19 Vaccine: Percent of Patients/Residents Who Are Up to Date Measure Beginning With the FY 2026 LTCH QRP

We proposed to begin publicly displaying data for the COVID–19 Vaccine: Percent of Patients/Residents Who Are Up to Date measure beginning with the September 2025 refresh of Care Compare or as soon as technically feasible using data collected for Q4 2024 (October 1, 2024, through December 31, 2024). We proposed that an LTCH’s Patient/Resident level COVID–19 Vaccine percent of patients who are up to date would be displayed based on one quarter of data. Provider preview reports would be distributed in June 2025 for data collected in Q4 2024, or as soon as technically feasible.

Thereafter, the percent of LTCH patients who are up to date with their COVID–19 vaccinations would be publicly displayed based on one quarter of data and updated quarterly. To ensure the statistical reliability of the data, we proposed that we would not publicly report an LTCH’s performance on the measure if the LTCH had fewer than 20 eligible cases in any quarter. LTCHs that have fewer than 20 eligible cases would be distinguished with a footnote that states: “The number of cases/patient stays is too small to publicly report.”

We invited public comment on the proposal for the public display of the COVID–19 Vaccine: Percent of Patients/Residents Who Are Up to Date measure beginning with the September 2025 refresh of Care Compare, or as soon as technically feasible. The following is a summary of the comments we received and our responses.

Comment: Three commenters supported public reporting of this measure. One of the commenters noted their support stating this would help patients, caregivers and loved ones make informed decisions about LTCH choices that might best suit their individual health care needs, especially
if they are greater risk of serious complications from COVID–19.

Response: We thank the commenters for their support and agree this measure will provide potential patients with important information regarding COVID–19 vaccination rates as part of their process of identifying providers they would want to seek care from, in addition to other measures available on Care Compare.

After consideration of the public comments we received, we are finalizing our proposal to begin publically displaying data for the Patient/Resident COVID–19 measure beginning with the September 2025 Care Compare refresh or as soon as technically feasible.

F. Changes to the Medicare Promoting Interoperability Program

1. Statutory Authority for the Medicare Promoting Interoperability Program for Eligible Hospitals and Critical Access Hospitals (CAHs)

The Health Information Technology for Economic and Clinical Health Act (HITECH Act) (Title IV of Division B of the American Recovery and Reinvestment Act of 2009 (ARRA), together with Title XIII of Division A of the ARRA) authorized incentive payments under Medicare and Medicaid, as well as downward payment adjustments under Medicare, for the adoption and meaningful use of certified electronic health record technology (CEHRT). Incentive payments under Medicare were available to eligible hospitals and critical access hospitals (CAHs) for certain payment years (as authorized under sections 1886(n) and 1814(l)(3) of the Act, respectively) if they successfully demonstrated the meaningful use of CEHRT for an electronic health record (EHR) reporting period. In accordance with the timeframe set forth in the statute, these incentive payments under Medicare are no longer available. Sections 1886(b)(3)(B)(ix) and 1814(l)(4) of the Act authorize downward payment adjustments under Medicare, beginning with FY 2015 (and beginning with FY 2022 for subsection (d) Puerto Rico hospitals), for eligible hospitals and CAHs that do not successfully demonstrate meaningful use of CEHRT for an EHR reporting period for a payment adjustment year. For more information, we refer readers to the regulations at 42 CFR 412.64(d)(3) and (4) and 413.70(a)(5) and (6) and part 495.

2. EHR Reporting Periods

a. EHR Reporting Period in CY 2025 for Eligible Hospitals and CAHs

Under the definition of EHR reporting period for a payment adjustment year at 42 CFR 495.4, for eligible hospitals and CAHs that are new or returning participants in the Medicare Promoting Interoperability Program, the EHR reporting period in calendar year (CY) 2024 is a minimum of any continuous 180-day period within CY 2024, as finalized in the FY 2022 Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System (IPPS/LTCH PPS) final rule (86 FR 45460 through 45462). We believe that maintaining a 180-day EHR reporting period for an additional year will provide consistency with the prior years’ EHR reporting period and afford eligible hospitals and CAHs the flexibility to make any work with their chosen vendors on continuing to develop and update their CEHRT, as required. For eligible hospitals and CAHs that are new or returning participants in the Medicare Promoting Interoperability Program, we proposed in the FY 2024 IPPS/LTCH PPS proposed rule that the EHR reporting period in CY 2025 would continue to be a minimum of any continuous 180-day period within CY 2025 (86 FR 27155 through 27156). We described in the proposed rule that a 180-day EHR reporting period would be the minimum length, and eligible hospitals and CAHs would be encouraged to use longer periods, up to and including the full CY 2025. We proposed corresponding revisions to the definition of EHR reporting period for a payment adjustment year at § 495.4 (88 FR 27155 through 27156).

We invited public comment on this proposal.

Comment: Many commenters supported our proposal to maintain a 180-day EHR reporting period in CY 2025 for eligible hospitals and CAHs. One commenter specifically supported the proposal because they believed that vendors have consistently proven they are able to release software updates that can accommodate this length of a reporting period. Another commenter supported the proposal, while recommending CMS provide flexibility for hospitals that may switch EHRs within an EHR reporting period, and those that have an EHR vendor acquired or divested. A few commenters supported the proposal because they believed that it would maintain stability, flexibility, and consistency. One such commenter believed that program consistency has led to nearly universal EHR adoption among non-Federal acute care hospitals and use by most office-based physicians. Another such commenter believed that the 180-day EHR reporting period would allow hospitals to adequately account for system upgrades and other pertinent changes to their EHR technology, ensuring accurate and comprehensive reporting.

Response: We thank the commenters for their support. We agree that maintaining a minimum of 180-day EHR reporting period for an additional year will provide consistency with the prior years’ EHR reporting period and afford eligible hospitals and CAHs the flexibility they may need to work with their chosen vendors on continuing to develop and update their CEHRT, as required. For commenters asking for additional flexibility to account for a change in EHR vendor, we do not specify which 180-days must be chosen, only that the chosen 180-days are continuous. We recommend eligible hospitals and CAHs work with their chosen vendor on the timing of their system updates in advance.

Comment: Many commenters did not support our proposal to maintain a 180-day EHR reporting period in CY 2025 for eligible hospitals and CAHs. A few commenters believed that 180-days of continuous reporting would be difficult to achieve and would place more burden on providers. One such commenter expressed that annual releases for the Medicare Promoting Interoperability Program measure specifications are usually made available during the second quarter of the calendar year from EHR developers. This commenter believed that the program measures require significant time and resources to configure, validate, optimize, and implement in the EHR. This commenter further believed that a period of one year or less when a new measure is released to mandatory reporting would not be adequate for the necessary preparations to report in a 180-day reporting period. Several commenters wished to maintain a 90-day EHR reporting period for CY 2024 onwards. One of these commenters believed that a 90-day EHR reporting period would give providers flexibility to develop their reporting infrastructure and make necessary updates to their EHR systems to comply with the Merit-based Incentive Payment System (MIPS) Promoting Interoperability performance category requirements. This commenter also believed that a shorter reporting period would give hospitals time to adjust to these changes and make system changes necessitated by revised
measures or vendor changes and upgrades. A few commenters expressed a preference for a 90-day reporting period because they believed that EHRs are continually undergoing software upgrades, system downtime, expansions to other sites within a system, and a variety of other improvement and maintenance activities. A commenter believed that changing the reporting period to a continuous 180-day EHR reporting period would not produce a more comprehensive score card of reliable data.

Response: We thank the commenters for their feedback. We would like to remind commenters that under the definition of EHR reporting period for a payment adjustment year at § 495.4, for eligible hospitals and CAHs that are new or returning participants in the Medicare Promoting Interoperability Program, the EHR reporting period in calendar year (CY) 2024 is already a minimum of any continuous 180-day period within CY 2024, as previously finalized in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45460 through 45462). The proposal in the FY 2024 IPPS/LTCH PPS proposed rule was for a continuation of our existing 180-day EHR reporting period established for CY 2023. We disagree with commenters who believe that 180-days of continued reporting would be difficult to achieve and would place additional burden on health care providers. We believe that after finalizing the 180-day EHR reporting period for CY 2024 in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45460 through 45462), and proposing to continue with the 180-day EHR reporting period in CY 2025 (88 FR 27155 through 27156), eligible hospitals and CAHs will have had more than three years of advance planning with their vendors to build upon and utilize investments already made within their infrastructure to meet site-specific needs for implementation. We also note that the EHR reporting period has remained at 90-days since its adoption in 2011, where at that time, we indicated that we would continue to increase the number of days in an EHR reporting period (75 FR 44320). We believe that maintaining an EHR reporting period of 180 days for CY 2025 will not impact eligible hospitals’ and CAHs’ efforts to update, implement, and test the EHR systems to maintain effective use of CEHRT in furtherance of meaningful use.

Reporting on additional data will provide eligible hospitals and CAHs the opportunity to continuously monitor their process and identify areas that may require investigation and corrective action. Maintaining the 180-day EHR reporting period in CY 2025 is important for the continued improvement of interoperability and health information exchange by producing more comprehensive and reliable data for patients and providers, which are key goals of the Medicare Promoting Interoperability Program. In response to commenters requesting that the Medicare Promoting Interoperability Program maintain alignment with the MIPS Promoting Interoperability performance category, we refer readers to the CY 2024 PFS proposed rule (FR Doc. 2023–14624, publishing in the Federal Register on August 7, 2023; available at https://www.federalregister.gov/public-inspection/2023-14624/medicare-and-medicaid-programs-cy-2024-payment-policies-under-the-physician-fee-schedule-and-other), where we have proposed a minimum of a continuous 180-day performance period for MIPS eligible clinicians in CY 2024, in order to maintain alignment with the Medicare Promoting Interoperability Program’s 180-day EHR reporting period.

Comment: Several commenters did not support our proposal to maintain a 180-day EHR reporting period in CY 2025 for eligible hospitals and CAHs because they believed that vendors and providers need more time and additional resources. Several commenters believed that vendors need additional time to develop and deploy technology, understand CEHRT requirements, capabilities, and functionalities. Further, other commenters believed that eligible hospitals and CAHs need additional time to budget for the adoption and implementation of this requirement, and time to identify and resolve software issues. A few commenters believed that eligible hospitals, CAHs, and other health care organizations needed more time to recover from the financial, workforce, and operational challenges the COVID–19 pandemic placed on them, such as provider burnout, staffing shortages, and other burdens and disruptions. A commenter believed that eligible hospitals and CAHs need more time to return to the traditional reporting and regulatory landscape as they adjust clinical and administrative processes until all PHE flexibilities expire.

Response: We thank commenters for sharing their concerns. We believe that continuing the 180-day EHR reporting period in CY 2025 will not impact eligible hospitals’ and CAHs’ efforts to update and test their EHR systems to maintain effective use of CEHRT in furtherance of meaningful use. For commenters concerned with limited flexibility in choosing a 180-day EHR reporting period when considering general updates to health IT systems or transitions between health IT systems, we suggest early planning with vendors on the timing of routine system updates and downtimes to allow for maximum flexibility in choosing their 180-day EHR reporting period. Additionally, we would like to remind commenters that the Medicare Promoting Interoperability Program allows hardship exception applications for extreme and uncontrollable circumstances, including certain vendor issues, as permitted by section 1886(b)(3)(B)(ix)(II) of the Act.

Additional information on this process is available at: https://www.cms.gov/files/document/medicare-pi-program-hardship-exception-fact-sheet-2023-04-06.pdf. Moreover, we understand there are residual impacts of the COVID–19 public health emergency (PHE) on eligible hospitals and CAHs. We believe that the COVID–19 PHE highlighted areas where we can focus our efforts, to include allowing eligible hospitals and CAHs the opportunity to monitor their performance over a longer EHR reporting period, and to identify areas that may require investigation and corrective action. This is important for the continued improvement of interoperability and health information exchange, which are key goals of the Medicare Promoting Interoperability Program. For additional information on our proposal to increase the EHR reporting period from 90-days to 180-days in CY 2024, we refer readers to the discussion in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45461).

After consideration of the public comments we received, we are finalizing that the EHR reporting period in CY 2025 will be a minimum of any continuous 180-day period within CY 2025. We are also finalizing our proposal to revise the definition of EHR reporting period for a payment adjustment year at § 495.4.

b. Changes to the EHR Reporting Period for a Payment Adjustment Year for Eligible Hospitals

In the definition of EHR reporting period for a payment adjustment year, under paragraphs (2)(vii) and (viii) of § 495.4, we specify that the EHR reporting periods in CYs 2023 and 2024 that apply for purposes of determining whether an eligible hospital may be subject to a downward payment adjustment in a later year, read as follows:

For CY 2023: (A) If an eligible hospital has not successfully demonstrated it is a meaningful EHR
user in a prior year, the EHR reporting period is any continuous 90-day period within CY 2023 and applies for the FY 2024 and 2025 payment adjustment years. For the FY 2024 payment adjustment year, the EHR reporting period must end before, and the eligible hospital must successfully register for and attest to meaningful use no later than October 1, 2023. (B) If in a prior year an eligible hospital has successfully demonstrated it is a meaningful EHR user, the EHR reporting period is any continuous 90-day period within CY 2023 and applies for the FY 2025 payment adjustment year.

For CY 2024: (A) If an eligible hospital has not successfully demonstrated it is a meaningful EHR user in a prior year, the EHR reporting period is any continuous 180-day period within CY 2024 and applies for the FY 2025 and 2026 payment adjustment years. For the FY 2025 payment adjustment year, the EHR reporting period must end before and the eligible hospital must successfully register for and attest to meaningful use no later than October 1, 2024. (B) If in a prior year an eligible hospital has successfully demonstrated it is a meaningful EHR user, the EHR reporting period is any continuous 180-day period within CY 2024 and applies for the FY 2026 payment adjustment year.

Stated generally, the EHR reporting period occurs 2 years before the payment adjustment year, unless an eligible hospital is demonstrating meaningful use for the first time, in which case the EHR reporting period occurs one year before the payment adjustment year, subject to an October 1 deadline for registration and attestation. Beginning with the EHR reporting period in CY 2025, we proposed to change the rule for eligible hospitals that have not successfully demonstrated they are a meaningful EHR user in a prior year (88 FR 27156 through 27157).

We have made technological modifications to the data submission process for the Medicare Promoting Interoperability Program, including the registration and attestation processes. As a result of these modifications, an October 1 deadline is no longer feasible, as the submission period is only open during the 2 months following the close of the CY in which the EHR reporting period occurs (or a later date specified by CMS), annually. Eligible hospitals that have not successfully demonstrated meaningful use in a prior year and seek to attest by October 1 of CY 2023 or CY 2024 should contact the CCSQ help desk for assistance at QnetSupport@cms.hhs.gov or 1-866-288-8912 for instructions.

According to the ONC “‘National Trends in Hospital and Physician Adoption of Electronic Health Records,’” Health IT Quickstat #61, a majority (96%) of non-Federal acute care hospitals, most of which are eligible hospitals or CAHs, but which include pediatric and specialty cancer hospitals, have adopted CEHRT.925 We believe that few eligible hospitals or CAHs will be new participants in the Medicare Promoting Interoperability Program, and therefore, few eligible hospitals or CAHs are likely to be affected by this change. In the FY 2020 IPPS/LTC PPS final rule (84 FR 42591), we removed the October 1, 2019 deadline for eligible hospitals for the FY 2020 payment adjustment year. This policy was finalized in response to public comments that supported CMS eliminating the October 1, 2019 deadline for eligible hospitals that had not successfully demonstrated meaningful EHR use in a prior year. When we removed the October 1 deadline for the FY 2020 payment adjustment year, we did so with public support, and did not experience operational concerns related to its removal, so we believed that this proposal was feasible. Therefore, beginning with the EHR reporting period in CY 2025, we proposed in the FY 2024 IPPS/LTC PPS proposed rule to no longer differentiate between those eligible hospitals that have successfully demonstrated they are meaningful EHR users in a prior year and those that have not, with regard to the EHR reporting period that applies for purposes of a payment adjustment year (88 FR 27156 through 27157).

We also proposed that for all eligible hospitals (new and returning participants), the EHR reporting period in CY 2025 will apply for purposes of the FY 2027 payment adjustment year (88 FR 27156 through 27157). Eligible hospitals and CAHs will submit data during the 2 months following the close of the CY in which the EHR reporting period occurs, or by a later date specified by CMS. This will mean that for eligible hospitals that have not successfully demonstrated they are meaningful EHR users in a prior year, there will be a 2-year period between the EHR reporting period in CY 2025 and the FY 2027 payment adjustment year, which is the same submission timeframe that eligible hospitals that have previously demonstrated they are meaningful EHR users are currently required to meet. Therefore, beginning with the EHR reporting period in CY 2025, eligible hospitals that have not demonstrated they are meaningful EHR users in a prior year will not have to attest to meaningful use by October 1, 2025. Instead, similar to eligible hospitals that have demonstrated meaningful use, these eligible hospitals would attest during the same submission period that occurs during the 2 months following the close of the CY in which the EHR reporting period occurs, or by a later date specified by CMS, and, if applicable, a payment adjustment will be applied for the FY 2027 payment adjustment year. We proposed corresponding revisions to the definition of EHR reporting period for a payment adjustment year at § 495.4 (88 FR 27156 through 27157).

We invited comment on this proposal.

Comment: A few commenters supported our proposal to eliminate the requirement for eligible hospitals to attest to meaningful use by October 1 of the year prior to the payment adjustment year if they have not successfully demonstrated meaningful use in a prior year. A commenter believed that it will reduce confusion and level the playing field, as longer EHR reporting periods are now required. Another commenter appreciated our proposal to simplify the regulatory language at § 495.4. Another commenter believed that requiring first time attestors to attest prior to October 1 of the reporting year is unworkable with the 180-day reporting period, and that allowing first time attestors the ability to attest during the two months following the end of the reporting year is appropriate.

Response: We thank commenters for their support. We agree that eliminating the requirement for eligible hospitals to attest to meaningful use by October 1 (or by a later date specified by CMS) of the year prior to the payment adjustment year, and to allow first time attestors to attest during the two months following the end of the reporting year will level the playing field for new and returning eligible hospitals. We thank commenters for also supporting our proposal to make corresponding changes to the regulatory text.

After consideration of the public comments we received, we are finalizing our proposal that beginning with the EHR reporting period in CY 2025 for all eligible hospitals (new and returning participants), the EHR reporting period in CY 2025 will apply for purposes of the FY 2027 payment adjustment year, and we are finalizing...
our proposed changes to § 495.4, which reflect this proposal.

3. Safety Assurance Factors for EHR Resilience Guides (SAFER Guides)

a. Background

In the FY 2022 IPPS/LTCH PPS final rule (86 FR 45479 through 45481), we adopted the SAFER Guides measure under the Protect Patient Health Information Objective beginning with the EHR reporting period in CY 2022. Eligible hospitals and CAHs are required to attest to whether they have conducted an annual self-assessment using all nine SAFER Guides (https://www.healthit.gov/topic/safety/safer-guides), at any point during the calendar year in which the EHR reporting period occurs, with one “yes/no” attestation statement. Beginning in CY 2022, the attestation of this measure was required, but eligible hospitals and CAHs were not scored, and an attestation of “yes” or “no” were both acceptable answers without penalty. For additional information, please refer to the discussion of the SAFER Guides measure in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45479 through 45481).

b. Change to the SAFER Guides Measure

The SAFER Guides measure is intended to incentivize eligible hospitals and CAHs to use all nine SAFER Guides to: annually assess EHR implementation, safety and effectiveness; identify vulnerabilities; and develop a “culture of safety” within their organization. By implementing the SAFER Guides’ recommended practices, eligible hospitals and CAHs may be better positioned to operate CEHRT responsibly in care delivery, and able to make improvements to the safety and safe use of EHRs as necessary over time. The intent of the measure is for eligible hospitals and CAHs to regularly assess their progress and status on important facets of patient safety. Given our interest in more strongly promoting safety and the safe use of EHRs, we proposed to require eligible hospitals and CAHs to conduct the annual SAFER Guides self-assessments and attest a “yes” response accounting for a completion of the self-assessment for all nine guides. We stated that we believe this is feasible for eligible hospitals and CAHs, as they have had time to grow familiar with the use of the SAFER Guides by attesting either “yes” or “no” to conducting the self-assessment. We also noted the availability of resources to assist eligible hospitals and CAHs with completing the self-assessment as required by the SAFER Guides measure. One example of such resources is the SAFER Guides authors’ paper titled “Guidelines for US Hospitals and Clinicians on Assessment of Electronic Health Record Safety Using SAFER Guides,” available to download or use at https://jamanetwork.com/journals/jama/fullarticle/2788984.

In the FY 2024 IPPS/LTCH PPS proposed rule, we proposed to modify our requirements for the SAFER Guides measure beginning with the EHR reporting period in CY 2024 and continuing in subsequent years, to require eligible hospitals and CAHs to attest “yes” to having conducted an annual self-assessment using all nine SAFER Guides (available at https://www.healthit.gov/topic/safety/safer-guides), at any point during the calendar year in which the EHR reporting period occurs (88 FR 27157). Under this proposal, an attestation of “no” would result in the eligible hospital or CAH not meeting the measure requirements, and not satisfying the definition of a meaningful EHR user under § 495.4, which would subject the eligible hospital or CAH to a downward payment adjustment. We refer readers to Table IX.F.–03. in this final rule for a description of the measure.

We invited public comment on this proposal.

Comment: Many commenters expressed support for the proposal to require eligible hospitals and CAHs to attest “yes” to having conducted an annual self-assessment of all nine SAFER Guides. Several commenters expressed support because they believe that the self-assessment promotes patient safety and EHR system security and reliability.

Response: We appreciate the commenters’ support to require an annual self-assessment with all nine SAFER Guides. We agree that yearly self-assessments of all nine SAFER Guides supports EHR-related patient safety and security practices.

Comment: A commenter expressed support for the proposal to require an annual self-assessment with the SAFER Guides, but requested a delay of at least one additional year to ensure hospitals have had sufficient time for full adoption of the SAFER Guides’ recommended practices.

Response: We thank the commenter for their support and suggestion. We remind readers that the SAFER Guides measure only requires that eligible hospitals and CAHs attest “yes” to having conducted an annual self-assessment using all nine SAFER Guides at any point during the calendar year in which the EHR reporting period occurs. There is no requirement to implement any of the best practices identified while performing the self-assessment, and we defer to eligible hospitals and CAHs to identify an appropriate timeline and utility of adopting specific best practices contained within the SAFER Guides. We disagree that a delay in requiring an annual self-assessment would be helpful to prepare hospitals for full adoption, because implementation of SAFER Guides recommended practices is not required as part of the attestation.

Comment: A commenter supported the proposal but requested that CMS include detailed instructions for completing the self-assessment after the first year.

Response: We thank the commenter for their support and request for detailed instructions. As with other Medicare Promoting Interoperability Program measures, CMS will provide resources such as specification sheets, fact sheets, webinars, and public announcements to communicate details about the SAFER Guides measure requirements and how to fulfill them. CMS and ONC will continue to provide supporting material as necessary for the completion of the SAFER Guides self-assessment, and we will continue to obtain publicly available materials for participants. We remind readers to visit the CMS resource library website at https://www.cms.gov/regulations-guidance/promoting-interoperability/resource-library and the ONC website at https://www.healthit.gov/topic/safety/safer-guides for resources on the content and appropriate use of the SAFER Guides.

We expect that after the first year of conducting the initial SAFER Guides self-assessment, the answers to the assessment questions may not change significantly unless an eligible hospital or CAH has made significant system upgrades or transitions between systems or vendors. If there have been no significant intervening changes to a participant’s EHR system, vendor, or its relevant policies and procedures, then the participant’s responses can be held to remain valid and repeated after confirmation of that fact while completing their annual self-assessments. Our larger focus is for eligible hospitals and CAHs to regularly assess their progress and status on important facets of patient safety.

Comment: Many commenters did not support this proposal and expressed concerns regarding the perceived burden of requiring a “yes” attestation to having conducted an annual self-assessment using all nine SAFER Guides. While commenters acknowledged the importance of implementing safety practices for
planned or unplanned EHR downtime, many believed that that requiring an annual assessment of all nine guides would place significant burden on acute care hospitals and CAHs, particularly small, rural hospitals with limited resources. A few commenters stated that it would be challenging for both smaller hospitals and large organizations to gather the required documentation from various staff, partner organizations, and other vendors. A commenter cautioned CMS against inadvertently passing the burden down through implementation requirements. Another commenter believed that the annual cost was drastically different from the entirety of the proposed changes to the Hospital IQR Program. Another commenter recommended performing a one-time self-assessment instead of annual self-assessments.

Response: We thank commenters for sharing their feedback and concerns. We would like to clarify and emphasize that this proposal does not require eligible hospitals and CAHs to confirm that they have implemented any of the SAFER Guides practices. We are requiring eligible hospitals and CAHs to affirmatively attest that they have completed the self-assessment using each of the nine SAFER Guides. We believe that this requirement will incentivize hospitals and CAHs to conduct the annual self-assessment and assist them in actively understanding and addressing potential safety vulnerabilities routinely, which may significantly impact their organization’s safety posture in a timelier manner.

With regard to the estimated annual costs associated with the proposal, in section I.0. of appendix A we acknowledge that while an upfront investment of resources and staff time may be needed to conduct a SAFER Guides self-assessment, we believe the cost is outweighed by the potential for improved healthcare outcomes, increased efficiency, reduced risk of data breaches and ransomware attacks, and decreased malpractice premiums. Comment: A few commenters did not support this proposal because of their concerns about the time necessary to meet the requirement of this proposal. One vendor stated that they would not have time to provide any development or other software support to their clients given the current list of health IT requirements to meet in CY 2023. Another commenter stated that their organization does not have sufficient time by CY 2024 to operationalize these requirements. A few commenters recommended that CMS continue the existing requirement and delay implementation of a required “yes” attestation to a later year.

Response: We appreciate the commenters sharing their concerns. We recognize that conducting the SAFER Guides self-assessments may entail a time commitment for some eligible hospitals and CAHs. However, the benefits of ensuring EHR safety far outweigh the necessary investment of time. In addition, we would like to emphasize again that the measure only requires self-assessment using the SAFER Guides and does not require implementation of the practices described in the Guides. Furthermore, we expect that after the first year of conducting the initial SAFER Guides self-assessment, the answers to the assessment questions may not change significantly unless an eligible hospital or CAH has made significant system upgrades or transitions between systems or vendors. If there have been no significant intervening changes to a participant’s EHR system, vendor, or its relevant policies and procedures, then the participant’s responses can be held to remain valid and repeated after confirmation of that fact while completing their annual self-assessments. Eligible hospitals and CAHs may need to work together with health IT developers and other vendors to perform these self-assessments; however, the self-assessment requirement does not require any immediate updates or upgrades of their EHR systems. We believe that in conducting an annual self-assessment with the SAFER Guides promotes EHR-related safety practices, therefore we disagree with the recommendation to delay its requirement.

Comment: We thank the commenter for their feedback. We understand that the initial self-assessment is the most time-consuming, and self-assessments may be less burdensome in subsequent years. We offered eligible hospitals and CAHs a two year period to begin the process, without penalty for not being able to complete the self-assessments. Additionally, this two year period without penalty offered eligible hospitals and CAHs time to review available resources, work with staff and vendors on establishing an annual review process, where they would not be penalized for not having completed the self-assessments.

Response: We thank the commenter for their feedback. We understand that the initial self-assessment is the most time-consuming, and self-assessments may be less burdensome in subsequent years. We offered eligible hospitals and CAHs a two year period to begin the process, without penalty for not being able to complete the self-assessments. Additionally, this two year period without penalty offered eligible hospitals and CAHs time to review available resources, work with staff and vendors on establishing an annual review process, where they would not be penalized for not having completed the self-assessments.
incentive, and believed that it was counterintuitive to CMS’ stated intention for the SAFER Guides measure.

Response: We thank the commenters for sharing their concerns. The Medicare Promoting Interoperability Program uses both performance-based and attestation measures to assess the performance of eligible hospitals and CAHs, and potentially applies downward payment adjustments based on their performance scores and the results of their attestation measures as the financial consequence of not meeting the definition of a meaningful EHR user under § 495.4. As we discussed in the Stage 2 final rule when we adopted the Protect Patient Health Information objective (77 FR 54002 through 54003), it is essential to all aspects of meaningful use to ensure that patient health information is protected and secure. Under the Protect Patient Health Information objective, the SAFER Guides measure is one way that we encourage eligible hospitals and CAHs, and their vendors, to proactively assess their readiness for EHR safety. Therefore, we respectfully disagree with the commenters’ perspective.

Comment: A commenter did not support this proposal and expressed concerns that there are no scholarly articles, journals, or systematic research citing or indicating the guides can offer any of the “potential” CMS claims. Another commenter believed that ONC intended to use the SAFER Guides for informational purposes instead of legal compliance purposes. Another commenter believed that the SAFER Guides was a framework from a specific vendor instead of providing general standards.

Response: We thank the commenters for expressing their concerns. We note that the SAFER Guides are based on extensive research and input from various stakeholders in the healthcare industry, have been widely adopted in the industry, and are not specific to any one vendor. The SAFER Guides provide general guidance and best practices for enhancing the safety and resilience of an organization’s EHR system. Readers can visit the CMS resource library website at https://www.cms.gov/regulations-guidance/promoting-interoperability/resource-library and the ONC website at https://www.healthit.gov/topic/safety/safer-guides for resources on the content and appropriate use of the SAFER Guides. By providing practical guidance on enhancing security and resilience of EHR systems, the SAFER Guides meet the goal of the Medicare Promoting Interoperability Program to improve the safety, quality, and equity of healthcare systems.

The proposal to update the SAFER Guides measure in the Medicare Promoting Interoperability Program was developed in consultation with ONC. The SAFER Guides themselves are not intended to be used for legal compliance purposes, and implementation of a recommended practice does not guarantee compliance with HIPAA, the HIPAA Security Rule, Medicare or Medicaid Conditions of Participation, or any other laws or regulations. The SAFER Guides are for informational purposes only and are not intended to be an exhaustive or definitive source, nor do they constitute legal advice. Users of the SAFER Guides are encouraged to consult with their own legal counsel regarding compliance with Medicare or Medicaid program requirements, HIPAA, and any other laws. However, attesting “yes” to the SAFER Guides measure each year would be a requirement for an eligible hospital or CAH to avoid a downward payment adjustment in the Medicare Promoting Interoperability Program.

Comment: A commenter did not support this proposal and believed that the SAFER Guides were not applicable to every organization, which could cause extreme financial and workforce burden.

Response: We thank the commenters for expressing their concerns, and we will take them under consideration. We acknowledge that every organization faces unique circumstances and will implement a particular safety practice differently. As a result, some of the specific examples in the SAFER Guides for recommended practices may not be applicable to every organization. However, conducting the self-assessments using the nine SAFER Guides can be valuable for any organization that utilizes EHR systems. In addition, it is important for eligible hospitals and CAHs to perform the annual self-assessment required by the SAFER Guides measure to address vulnerabilities early on.

Comment: A few commenters requested clarification on what level of action is required to attest “yes” to having conducted the self-assessment with the SAFER Guides. Specifically, commenters wanted to know if implementation of recommended practices is a necessary requirement for a “yes” attestation.

Response: Only a review and annual self-assessment of each of the nine SAFER Guides is required for eligible hospitals and CAHs to attest “yes” to the SAFER Guides measure. Implementation of any of the recommended practices is not required as part of our proposal. We recognize that participants will have unique circumstances, priorities, and constraints that inform their decision-making regarding when and how to undertake EHR safety improvements that may be identified through the assessment process. The requirement for the measure is thus only that eligible hospitals and CAHs affirmatively attest to having conducted a review of their own EHR safety practices using all nine SAFER Guides, and we defer to eligible hospitals and CAHs to determine what improvements, if any, are needed in their EHR safety practices.

Comment: One commenter recommended that if CMS were to finalize the proposal, it should do so in a way where eligible hospitals and CAHs are able to complete self-assessments with minimal vendor support.

Response: We thank the commenter for their suggestion. We believe that although many SAFER Guides self-assessment questions can be addressed by a hospital’s clinical, administrative, and information technology staff, the SAFER Guides were intended to be best utilized by EHR users in collaboration with developers, and others who are concerned with optimizing the safe use of health IT. The appropriate configuration and maintenance of EHRs impacts patient safety and necessarily involves EHR vendors. Although eligible hospitals and CAHs have primary responsibility for performing the SAFER Guides self-assessment under this measure, participants may need to solicit information from their EHR vendors to understand how EHR vendor installation or configuration decisions impact patient safety.

Comment: A few commenters recommended that CMS and ONC update the SAFER Guides, citing that the SAFER Guides were last updated in 2016. These commenters questioned the relevancy of the SAFER Guides to patient safety in hospitals due to the rapid advancement of health IT. Two commenters suggested changing the guides to remove what they believe is redundant material between the nine guides, and a commenter suggested a more focused approach to address gap areas in EHR safety. Another commenter recommended convening technical experts to inform best practices in making updates to the SAFER Guides. Another commenter supported the proposal but encouraged CMS to work with ONC to update the SAFER Guides prior to requiring eligible hospitals and CAHs to report on all nine SAFER Guides, because they believed that ONC
and CMS should use current evidence and recommendations to update the guides and ensure that healthcare organizations have access to reliable and timely resources.

Response: We thank the commenters for their suggestions, and for expressing their concerns. The SAFER Guides have been widely used in the healthcare industry to enhance the safety and resilience of EHR systems. CMS will continue to work with ONC to consider whether updates to the Guides are needed, for instance, to reflect new research available. We will also work to ensure the relevance of the SAFER Guides’ content for eligible hospitals and CAHs specifically. However, we believe that the current SAFER Guides reflect relevant and valuable guidelines for safe practices with respect to current EHR systems. We do not believe that there is a safety benefit in delaying the requirement to conduct the self-assessment until after any future updates are made to the SAFER Guides, because the self-assessments themselves remain up to date and valuable as a means to promote EHR safety. In cases where a participant believes that a SAFER Guide question is redundant with one contained in another Guide, we expect that the additional burden of self-assessment would therefore be minimal, since the participant would have already answered it; however, we will continue to explore opportunities with ONC to identify these issues as part of future updates. We appreciate additional suggestions from commenters for consideration in any future updates to the Guides.

Comment: A few commenters recommended that, rather than requiring self-assessment with all nine SAFER Guides, CMS should require self-assessment using fewer guides, citing the belief that this would increase flexibility by invoking less burden while still promoting high-priority practices.

Response: Because each SAFER Guide addresses a different component of EHR safety, and each SAFER Guide contains recommended practices not addressed in other guides, we believe that the safety benefit of conducting a self-assessment using all nine Guides is a better approach to promoting EHR safety than requiring only a subset of SAFER Guides for review. We therefore believe that the safety benefit of self-assessment with all nine SAFER Guides outweighs its burden.

Comment: A few commenters requested additional educational resources to assist eligible hospitals and CAHs in completing all nine SAFER Guides. A commenter noted that a supporting resource (“Guidelines for US Hospitals and Clinicians on Assessment of Electronic Health Record Safety Using SAFER Guides,” accessible at https://jamanetwork.com/journals/jama/article-abstract/2788984) cited in the proposed rule is not freely available. Another commenter made a specific request for resources tailored to small and medium-sized health care organizations.

Response: We agree that eligible hospitals and CAHs should have the necessary resources available to successfully complete a self-assessment and attest “yes” to the SAFER Guides measure. As with other Medicare Promoting Interoperability Program measures, CMS will provide resources such as specification sheets, fact sheets, webinars, and events to communicate details about the SAFER Guides measure and its appropriate fulfillment. CMS and ONC will continue to provide supporting material as necessary for the completion of the SAFER Guides self-assessment, and we will work to obtain free access to available materials for participating hospitals.

Comment: Two commenters requested clarification on how eligible hospitals and CAHs will be alerted when there are any updates to the SAFER Guides.

Response: As with other Medicare Promoting Interoperability Program measures, we will provide resources such as specification sheets, fact sheets, webinars, and events to communicate details about the SAFER Guides measure. Updates to the SAFER Guides would be provided with accompanying educational and promotional materials to notify participants, in collaboration with ONC.

Comment: A commenter requested that CMS include detailed instructions for completing the self-assessment in subsequent years after having completed a first self-assessment.

Response: We expect that eligible hospitals and CAHs completing the SAFER Guides self-assessment will have a lower burden of completion after their first year conducting the self-assessment. For a given SAFER Guide Recommended Practice, within a given self-assessment, if there have been no significant intervening changes to a participant’s EHR system, vendor, or its relevant policies and procedures, then the participant’s responses can be held to remain valid and repeated on a subsequent self-assessment after confirmation of that fact. As with other Medicare Promoting Interoperability Program measures, we will provide resources such as specification sheets, fact sheets, webinars, and events to communicate details about the SAFER Guides measure.

Comment: A commenter recommended that CMS promote EHR safety in other ways such as promoting certain approaches or guidelines rather than using a measure in the Medicare Promoting Interoperability Program.

Response: We thank the commenter for their suggestion. Although CMS has other means available to disseminate best practices in EHR safety, we believe that the Medicare Promoting Interoperability Program is a very valuable means to promote the regular review of EHR-related safety practices by eligible hospitals and CAHs and using standard review criteria. Whereas the publication of guidelines alone is useful for proactive eligible hospitals and CAHs, the use of Medicare Promoting Interoperability Program measures incentivizes every eligible hospital and CAH to undertake a self-assessment of their EHR safety practices. As such, we believe that the Medicare Promoting Interoperability Program is the appropriate program to ensure broad attention to EHR safety in acute care hospitals.

After consideration of the public comments received, we are finalizing our proposal to modify our requirement for the SAFER Guides measure beginning with the EHR reporting period in CY 2024 and continuing in subsequent years, to require eligible hospitals and CAHs to attest “yes” to having conducted an annual self-assessment using all nine SAFER Guides, at any point during the calendar year in which the EHR reporting period occurs.

4. Scoring Methodology for the EHR Reporting Period in CY 2024

In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41636 through 41645), we adopted a new performance-based scoring methodology for eligible hospitals and CAHs attesting under the Medicare Promoting Interoperability Program beginning with the EHR reporting period in CY 2019, which included a minimum scoring threshold of a total score of 50 points or more, which eligible hospitals and CAHs must meet to satisfy the requirement to report on the objectives and measures of meaningful use under § 495.24. In the FY 2022 IPPS/LTCH PPS final rule (86 FR 45491 through 45492), we increased the minimum scoring threshold from 50 to 60 points beginning with the EHR reporting period in CY 2022. As shown in Table I.X–F–01., the points associated with the required measures sum to 100 points, and the optional measures may add additional bonus points. The scores for each of the measures are added together to calculate a total score of up
to 100 possible points for each eligible hospital or CAH (83 FR 41636 through 41645).
We did not propose any changes to the scoring methodology for the EHR reporting period in CY 2024. We refer readers to Table IX.F.–01. in this final rule, which reflects the objectives, measures, maximum points available, and whether a measure is required or optional for the EHR reporting period in CY 2024 based on our previously adopted policies.

### TABLE IX.F.–01.: PERFORMANCE-BASED SCORING METHODOLOGY FOR EHR REPORTING PERIODS IN CY 2024

<table>
<thead>
<tr>
<th>Objective</th>
<th>Measure</th>
<th>Maximum Points</th>
<th>Required/Optional</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic Prescribing</td>
<td>e-Prescribing</td>
<td>10 points</td>
<td>Required</td>
</tr>
<tr>
<td></td>
<td>Query of Prescription Drug Monitoring Program (PDMP)</td>
<td>10 points</td>
<td>Required</td>
</tr>
<tr>
<td>Health Information Exchange</td>
<td>Support Electronic Referral Loops by Sending Health Information</td>
<td>15 points</td>
<td>Required</td>
</tr>
<tr>
<td></td>
<td>-AND-</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Support Electronic Referral Loops by Receiving and Reconciling Health Information</td>
<td>15 points</td>
<td>Required (eligible hospitals and CAHs must choose one of the three reporting options)</td>
</tr>
<tr>
<td></td>
<td>-OR-</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Health Information Exchange Bi-Directional Exchange</td>
<td>30 points</td>
<td></td>
</tr>
<tr>
<td></td>
<td>-OR-</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enabling Exchange under the Trusted Exchange Framework and Common Agreement (TEFCA)</td>
<td>30 points</td>
<td></td>
</tr>
<tr>
<td>Provider to Patient Exchange</td>
<td>Provide Patients Electronic Access to Their Health Information</td>
<td>25 points</td>
<td>Required</td>
</tr>
<tr>
<td>Public Health and Clinical Data Exchange</td>
<td>Report the following five measures:</td>
<td>25 points</td>
<td>Required</td>
</tr>
<tr>
<td></td>
<td>- Syndromic Surveillance Reporting</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Immunization Registry Reporting</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Electronic Case Reporting</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Electronic Reportable Laboratory Result Reporting</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Antimicrobial Use and Resistance (AUR) Surveillance</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Report one of the following measures:</td>
<td>5 points (bonus)</td>
<td>Optional</td>
</tr>
<tr>
<td></td>
<td>- Public Health Registry Reporting</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Clinical Data Registry Reporting</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: The Security Risk Analysis measure, SAFER Guides measure, and attestations required by section 106(b)(2)(B) of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) are required but will not be scored. eCQM measures are required but will not be scored. Eligible hospitals and CAHs must also submit their level of active engagement for measures under the Public Health and Clinical Data Exchange objective. Participants may spend only one EHR reporting period at the Option 1: Pre-production and Validation level per measure and must progress to Option 2: Validated Data Production level for the next EHR reporting period. See FY 2023 IPPS/LTCH PPS final rule (87 FR 49337) for more details about active engagement.

The maximum points available in Table IX.F.–01. in this final rule do not include the points that would be redistributed in the event an exclusion is claimed for a given measure. We did not propose any changes to our policy.
for point redistribution in the event an exclusion is claimed for the EHR reporting period in CY 2024. We refer readers to Table IX.F.–02. in this final rule, which shows how points would be redistributed among the objectives and measures for the EHR reporting period in CY 2024, in the event an eligible hospital or CAH claims an exclusion.

**TABLE IX.F.–02.: EXCLUSION REDISTRIBUTION FOR EHR REPORTING PERIOD IN CY 2024**

<table>
<thead>
<tr>
<th>Objective</th>
<th>Measure</th>
<th>Redistribution if Exclusion is Claimed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic Prescribing</td>
<td>e-Prescribing</td>
<td>10 points to Health Information Exchange (HIE) Objective</td>
</tr>
<tr>
<td></td>
<td>Query of PDMP</td>
<td>10 points to e-Prescribing measure</td>
</tr>
<tr>
<td>Health Information Exchange</td>
<td>Support Electronic Referral Loops by Sending Health Information</td>
<td>No exclusion</td>
</tr>
<tr>
<td></td>
<td>-AND-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Support Electronic Referral Loops by Receiving and Reconciling Health Information</td>
<td>No exclusion</td>
</tr>
<tr>
<td></td>
<td>-OR-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Health Information Exchange Bi-Directional Exchange</td>
<td>No exclusion</td>
</tr>
<tr>
<td></td>
<td>-OR-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enabling Exchange under the Trusted Exchange Framework and Common Agreement (TEFCA)</td>
<td>No exclusion</td>
</tr>
<tr>
<td>Provider to Patient Exchange</td>
<td>Provide Patients Electronic Access to Their Health Information</td>
<td>No exclusion</td>
</tr>
<tr>
<td>Public Health and Clinical Data Exchange</td>
<td>Report the following five measures:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Syndromic Surveillance Reporting</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Immunization Registry Reporting</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Electronic Case Reporting</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Electronic Reportable Laboratory Result Reporting</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Antimicrobial Use and Resistance (AUR) Surveillance</td>
<td></td>
</tr>
<tr>
<td></td>
<td>If an exclusion is claimed for each of the five measures, 25 points are redistributed to the Provide Patients Electronic Access to their Health Information measure</td>
<td></td>
</tr>
</tbody>
</table>

5. Changes to Calculation Considerations Related To Counting Unique Patients or Actions

In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49349 through 49357), we included Table IX.H.–07. for ease of reference, which lists the objectives and measures for the EHR reporting period in CY 2023 as revised to reflect the final policies established in that final rule. Table IX.H.–07. includes a column titled Calculation Considerations Related to Counting Unique Patients or Actions (referred to as “calculation considerations”), and the information in that column was previously codified at § 495.24(e)(3). For more information regarding the previous codification of the objectives, measures, and other policies under § 495.24(e), we refer readers to the discussion in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49347 through 49350). The calculation considerations column of Table IX.H.–07. indicates whether the measures that count unique patients or actions may be calculated by reviewing only the actions for patients whose records are maintained using CEHRT or must be calculated by reviewing all patient records.

As we stated in the CY 2024 IPPS/LTCH PPS proposed rule (88 FR 27159 through 27160), we have reviewed the descriptions of the calculation considerations in Table IX.H.–07. and believe that some are not applicable to certain measures. We believe that the term “calculation considerations” is not applicable to all measures, as there are measures that require a “Yes/No” response instead of requiring numerators and denominators. We believe that the inclusion of the calculation considerations for these measures has the potential to cause confusion for eligible hospitals and CAHs attempting to report on the measures for the Medicare Promoting Interoperability Program.

Therefore, beginning with the EHR reporting period in CY 2024, we proposed to modify the way we refer to calculation considerations related to
unique patients or actions for measures for which there is no numerator and denominator, and for which unique patients or actions are not counted, to read “N/A (measure is Yes/No)” (88 FR 27159 through 27160). The following measures will be affected by this proposal because they do not have a numerator and denominator and they require a “Yes/No” response: Query of PDMP measure; HIE Bi-Directional Exchange measure; Immunization Registry Reporting measure; Syndromic Surveillance Reporting measure; Electronic Case Reporting measure; Electronic Reportable Laboratory (ELR) Result Reporting measure; Public Health Registry Reporting measure; Clinical Data Registry Reporting measure; Antimicrobial Use and Resistance (AUR) Surveillance measure; Security Risk Analysis measure; and the SAFER Guides measure. We stated that we believe this policy will reduce potential confusion regarding which measures require calculations related to unique patients or actions.

After consideration of the public comments we received, we are finalizing our proposal that beginning with the EHR reporting period in CY 2024, we will refer to calculation considerations related to unique patients or actions for measures for which there is no numerator and denominator, and for which unique patients or actions are not counted, to read “N/A (measure is Yes/No)”.

6. Overview of Objectives and Measures for the Medicare Promoting Interoperability Program for the EHR Reporting Period in CY 2024

In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49347 through 49349), we added a new paragraph (f) at § 495.24, regarding the Stage 3 objectives and measures for eligible hospitals and CAHs attesting to CMS in CY 2023 and subsequent years, which did not include the objectives and measures text for the Medicare Promoting Interoperability Program, such as that text found at § 495.24(e). We inadvertently neglected to make the associated changes to the demonstration of meaningful use criteria requirements at § 495.40(b)(2)(i), stating that for CY 2024 and subsequent years, an eligible hospital or CAH attesting to CMS would satisfy the required objectives and associated measures for meaningful use as defined by CMS. We proposed to update the regulatory text at § 495.40 to make it consistent with § 495.24(f) (88 FR 27160).

We invited public comment on this proposal.

Comment: A few commenters expressed support for our proposal to update the objectives and measures regulatory text at § 495.40 for consistency with § 495.24(f) for CY 2024 and subsequent years.

Response: We thank the commenters for their support. After consideration of the public comments we received, we are finalizing our proposal to update the regulatory text at § 495.40 to make it consistent with § 495.24(f).

For ease of reference, Table IX.F.–03. lists the objectives and measures for the Medicare Promoting Interoperability Program for the EHR reporting period in CY 2024 as revised to reflect the changes adopted in this final rule. Table IX.F.–04. lists the 2015 Edition certification criteria required to meet the objectives and measures.
<table>
<thead>
<tr>
<th>Objective</th>
<th>Measure</th>
<th>Numerator</th>
<th>Denominator</th>
<th>Exclusion</th>
<th>Calculation Considerations Related to Counting Unique Patients or Actions for CY 2024 and Subsequent Years*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic Prescribing</td>
<td>e-Prescribing:</td>
<td>The number of prescriptions in the denominator generated and transmitted electronically.</td>
<td>The number of new or changed prescriptions written for drugs requiring a prescription in order to be dispensed, other than controlled substances for patients discharged during the EHR reporting period.</td>
<td>Any eligible hospital or CAH that does not have an internal pharmacy that can accept electronic prescriptions, and there are no pharmacies that accept electronic prescriptions within 10 miles at the start of their EHR reporting period.</td>
<td>Measure may be calculated by reviewing only actions for patients whose records are maintained using CEHRT for which sufficient data were entered in the CEHRT to allow the record to be saved and not rejected due to incomplete data.</td>
</tr>
<tr>
<td>Electronic Prescribing</td>
<td>Query of PDMP:</td>
<td>N/A (measure is Y/N)</td>
<td>N/A (measure is Y/N)</td>
<td>(1) Any eligible hospital or CAH that does not have an internal pharmacy that can accept electronic prescriptions for controlled substances that include Schedule II, III and IV drugs and is not located within 10 miles of any pharmacy that accepts electronic prescriptions for controlled substances at the start of their EHR reporting period. (2) Any eligible hospital or CAH that could not report on this measure in accordance with applicable law.</td>
<td>N/A (measure is Y/N)*</td>
</tr>
<tr>
<td>Health Information Exchange</td>
<td>Support Electronic Referral Loops by Sending Health Information:</td>
<td>Number of transitions of care and referrals in the denominator where a summary of care record was created using CEHRT and exchanged electronically.</td>
<td>Number of transitions of care and referrals during the EHR reporting period for which the eligible hospital or CAH inpatient or emergency department (Place of Service [POS] 21 or 23) was the transitioning or referring provider.</td>
<td>None</td>
<td>Measure may be calculated by reviewing only actions for patients whose records are maintained using CEHRT for which sufficient data were entered in the CEHRT to allow the record to be saved and not rejected due to incomplete data.</td>
</tr>
<tr>
<td>Health Information Exchange</td>
<td>Support Electronic Referral Loops by Receiving and Reconciling Health Information: For at least one electronic summary of care record received using CEHRT for patient encounters during the EHR reporting period for which an eligible hospital or CAH was the receiving party of a transition of care or referral, or for patient encounters during the EHR reporting period in which the eligible hospital or CAH has never before encountered the patient, the eligible hospital or CAH conducts clinical information reconciliation for medication, medication allergy, and current problem list using CEHRT.</td>
<td>Number of electronic summary of care records in the denominator for which clinical information reconciliation is completed using CEHRT for the following three clinical information sets: (1) Medication – Review of the patient’s medication, including the name, dosage, frequency, and route of each medication; (2) Medication Allergy – Review of the patient’s known medication allergies; and (3) Current Problem List – Review of the patient’s current and active diagnoses.</td>
<td>None</td>
<td>Measure may be calculated by reviewing only actions for patients whose records are maintained using CEHRT for which sufficient data were entered in the CEHRT to allow the record to be saved and not rejected due to incomplete data.</td>
<td></td>
</tr>
<tr>
<td>Health Information Exchange</td>
<td>HIE Bi-Directional Exchange</td>
<td>(1) Participating in an HIE in order to enable secure, bi-directional exchange of information to occur for all unique patients discharged from the eligible hospital or CAH inpatient or emergency department (POS 21 or 23), and all unique patient records stored or maintained in the EHR for these departments, during the EHR reporting period in accordance with applicable law and policy.</td>
<td>N/A (measure is Y/N)</td>
<td>N/A (measure is Y/N)</td>
<td>None</td>
</tr>
<tr>
<td>Health Information Exchange</td>
<td>Enabling Exchange under TEFCA</td>
<td>N/A (measure is Y/N)</td>
<td>N/A (measure is Y/N)</td>
<td>None</td>
<td>N/A (measure is Y/N)*</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------------------------------</td>
<td>----------------------</td>
<td>----------------------</td>
<td>------</td>
<td>----------------------</td>
</tr>
<tr>
<td></td>
<td>The eligible hospital or CAH must attest to the following: (1) Participating as a signatory to a Framework Agreement (as that term is defined by the Common Agreement for Nationwide Health Information Interoperability as published in the <strong>Federal Register</strong> and on ONC’s website) in good standing (that is, not suspended) and enabling secure, bidirectional exchange of information to occur, in production, for all unique patients discharged from the eligible hospital or CAH inpatient or emergency department (POS 21 or 23), and all unique patient records stored or maintained in the EHR for these departments, during the EHR reporting period in accordance with applicable law and policy. (2) Using the functions of CEHRT to support bidirectional exchange of patient information, in production, under this Framework Agreement.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provider to Patient Exchange</td>
<td>Provide Patients Electronic Access to Their Health Information: For at least one unique patient discharged from the eligible hospital or CAH inpatient or emergency department (POS 21 or 23): (1) the patient (or patient-authorized representative) is provided timely access to view online, download, and transmit their health information; and (2) the eligible hospital or CAH ensures the patient's health information is available for the patient (or patient-authorized representative) to access using any application of their choice that is configured to meet the technical specifications of the application programming interface (API) in the eligible hospital's or CAH's CEHRT.</td>
<td>The number of patients in the denominator (or patient authorized representatives) who are provided timely access to health information to view online, download and transmit to a third party and to access using an application of their choice that is configured to meet the technical specifications of the API in the eligible hospital's or CAH's CEHRT.</td>
<td>None</td>
<td>Measure must be calculated by reviewing all patient records, not just those maintained using CEHRT.</td>
<td></td>
</tr>
<tr>
<td>Public Health and Clinical Data Exchange</td>
<td>Immunization Registry Reporting: The eligible hospital or CAH is in active engagement with a public health agency (PHA) to submit immunization data and receive immunization forecasts and histories from the public health immunization registry or immunization information system (IIS).</td>
<td>N/A (measure is Y/N)</td>
<td>N/A (measure is Y/N)</td>
<td>Any eligible hospital or CAH meeting one or more of the following criteria may be excluded from the immunization registry reporting measure if the eligible hospital or CAH: (1) Does not administer any immunizations to any of the populations for which data is collected by its jurisdiction’s immunization registry or IIS during the EHR reporting period; (2) Operates in a jurisdiction for which no immunization registry or IIS is capable of accepting the specific standards required to meet the CEHRT definition at the start of the EHR reporting period; or (3) Operates in a jurisdiction where no immunization registry or IIS has declared readiness to receive immunization data as of 6 months prior to the start of the EHR reporting period.</td>
<td>N/A (measure is Y/N)*</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Public Health and Clinical Data Exchange</td>
<td>Syndromic Surveillance Reporting: The eligible hospital or CAH is in active engagement with a PHA to submit syndromic surveillance data from an emergency department (POS 23).</td>
<td>N/A (measure is Y/N)</td>
<td>N/A (measure is Y/N)</td>
<td>Any eligible hospital or CAH meeting one or more of the following criteria may be excluded from the syndromic surveillance reporting measure if the eligible hospital or CAH: (1) Does not have an emergency department; (2) Operates in a jurisdiction for which no PHA is capable of receiving electronic syndromic surveillance data from eligible hospitals or CAHs in the specific standards required to meet the CEHRT definition at the start of the EHR reporting period; or (3) Operates in a jurisdiction where no PHA has declared readiness to receive syndromic surveillance data from eligible hospitals or CAHs as of 6 months prior to the start of the EHR reporting period.</td>
<td>N/A (measure is Y/N)*</td>
</tr>
<tr>
<td>Public Health and Clinical Data Exchange</td>
<td>Electronic Case Reporting: The eligible hospital or CAH is in active engagement with a PHA to submit case reporting of reportable conditions.</td>
<td>N/A (measure is Y/N)</td>
<td>N/A (measure is Y/N)</td>
<td>Any eligible hospital or CAH meeting one or more of the following criteria may be excluded from the case reporting measure if the eligible hospital or CAH: (1) Does not treat or diagnose any reportable diseases for which data is collected by its jurisdiction’s reportable disease system during the EHR reporting period; (2) Operates in a jurisdiction for which no PHA is capable of receiving electronic case reporting data in the specific standards required to meet the CEHRT definition at the start of the EHR reporting period; or (3) Operates in a jurisdiction where no PHA has declared readiness to receive electronic case reporting data as of 6 months prior to the start of the EHR reporting period.</td>
<td>N/A (measure is Y/N)*</td>
</tr>
<tr>
<td>Public Health and Clinical Data Exchange</td>
<td>Electronic Reportable Laboratory (ELR) Result Reporting: The eligible hospital or CAH is in active engagement with a PHA to submit ELR results.</td>
<td>N/A (measure is Y/N)</td>
<td>N/A (measure is Y/N)</td>
<td>Any eligible hospital or CAH meeting one or more of the following criteria may be excluded from the ELR result measure if the eligible hospital or CAH: (1) Does not perform or order laboratory tests that are reportable in its jurisdiction during the EHR reporting period; (2) Operates in a jurisdiction for which no PHA is capable of accepting the specific ELR standards required to meet the CEHRT definition at the start of the EHR reporting period; or (3) Operates in a jurisdiction where no PHA has declared readiness to receive ELR results from an eligible hospital or CAH as of 6 months prior to the start of the EHR reporting period.</td>
<td>N/A (measure is Y/N)*</td>
</tr>
<tr>
<td>Public Health and Clinical Data Exchange</td>
<td>AUR Surveillance: The eligible hospital or CAH is in active engagement with CDC’s National Healthcare Safety Network (NHSN) to submit antimicrobial use and resistance (AUR) data for the EHR reporting period and receives a report from NHSN indicating their successful submission of AUR data for the EHR reporting period.</td>
<td>N/A (measure is Y/N)</td>
<td>N/A (measure is Y/N)</td>
<td>Any eligible hospital or CAH meeting one or more of the following criteria may be excluded from the case reporting measure if the eligible hospital or CAH: (1) Does not have any patients in any patient care location for which data are collected by the NHSN during the EHR reporting period; (2) Does not have electronic medication administration records (eMAR)/barcoded medication administration (BCMA) records or electronic admission discharge transfer (ADT) system during the EHR reporting period; (3) Does not have an electronic laboratory information system or ADT system during the EHR reporting period.</td>
<td>N/A (measure is Y/N)*</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Public Health and Clinical Data Exchange</td>
<td>Public Health Registry Reporting: The eligible hospital or CAH is in active engagement with a PHA to submit data to public health registries.</td>
<td>N/A (measure is Y/N)</td>
<td>N/A (measure is Y/N)</td>
<td>None</td>
<td>N/A (measure is Y/N)*</td>
</tr>
<tr>
<td>Public Health and Clinical Data Exchange</td>
<td>Clinical Data Registry Reporting: The eligible hospital or CAH is in active engagement to submit data to a clinical data registry.</td>
<td>N/A (measure is Y/N)</td>
<td>N/A (measure is Y/N)</td>
<td>None</td>
<td>N/A (measure is Y/N)*</td>
</tr>
<tr>
<td>Protect Patient Health Information</td>
<td>Security Risk Analysis</td>
<td>N/A (measure is Y/N)</td>
<td>N/A (measure is Y/N)</td>
<td>None</td>
<td>N/A (measure is Y/N)*</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-----------------------</td>
<td>----------------------</td>
<td>----------------------</td>
<td>------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Protect Patient Health Information</td>
<td>SAFER Guides*</td>
<td>N/A (measure is Y/N)</td>
<td>N/A (measure is Y/N)</td>
<td>None</td>
<td>N/A (measure is Y/N)*</td>
</tr>
</tbody>
</table>

* Signifies a finalized proposal made in this FY 2024 IPPS/LTCH PPS final rule.
<table>
<thead>
<tr>
<th>Objective</th>
<th>Measure</th>
<th>2015 Edition (EHR Reporting Period in CY 2024)*/**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic Prescribing</td>
<td>e-Prescribing</td>
<td>§ 170.315(b)(3) Electronic prescribing</td>
</tr>
<tr>
<td>Support electronic referral loops by sending health information</td>
<td>Query of PDMP</td>
<td>§ 170.315(b)(3) Electronic prescribing</td>
</tr>
<tr>
<td>Health Information Exchange</td>
<td>Support electronic referral loops by receiving and reconciling health information</td>
<td>§ 170.315(b)(1) Transitions of care</td>
</tr>
<tr>
<td>Health Information Exchange (alternative)</td>
<td>Health Information Exchange (HIE) Bi-Directional Exchange</td>
<td>§ 170.315(b)(1) Transitions of care</td>
</tr>
<tr>
<td></td>
<td></td>
<td>§ 170.315(b)(2) Clinical information reconciliation and incorporation</td>
</tr>
<tr>
<td></td>
<td>Examples of certified health IT capabilities to support the actions of this measure may include but are not limited to technology certified to the following criteria:</td>
<td>§ 170.315(b)(7) Application access — patient selection</td>
</tr>
<tr>
<td></td>
<td></td>
<td>§ 170.315(g)(9) Application access — all data request</td>
</tr>
<tr>
<td></td>
<td></td>
<td>§ 170.315(g)(10) Application access — standardized API for patient and population services</td>
</tr>
<tr>
<td>Health Information Exchange (alternative)</td>
<td>Participation in TEFCA</td>
<td>§ 170.315(b)(1) Transitions of care</td>
</tr>
<tr>
<td></td>
<td></td>
<td>§ 170.315(b)(2) Clinical information reconciliation and incorporation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>§ 170.315(g)(7) Application access — patient selection</td>
</tr>
<tr>
<td></td>
<td></td>
<td>§ 170.315(g)(9) Application access — all data request</td>
</tr>
<tr>
<td></td>
<td></td>
<td>§ 170.315(g)(10) Application access — standardized API for patient and population services</td>
</tr>
<tr>
<td>Provider to Patient Exchange</td>
<td>Provide patients electronic access to their health information</td>
<td>§ 170.315(e)(1) View, download, and transmit to 3rd party</td>
</tr>
<tr>
<td></td>
<td></td>
<td>§ 170.315(g)(7) Application access — patient selection</td>
</tr>
<tr>
<td></td>
<td></td>
<td>§ 170.315(g)(9) Application access — all data request</td>
</tr>
<tr>
<td></td>
<td></td>
<td>§ 170.315(g)(10) Application access — standardized API for patient and population services</td>
</tr>
<tr>
<td>Public Health and Clinical Data Exchange</td>
<td>Immunization registry reporting</td>
<td>§ 170.315(f)(1) Transmission to immunization registries</td>
</tr>
<tr>
<td></td>
<td>Syndromic surveillance reporting</td>
<td>§ 170.315(f)(2) Transmission to public health agencies — syndromic surveillance</td>
</tr>
<tr>
<td></td>
<td>Electronic case reporting</td>
<td>§ 170.315(f)(5) Transmission to public health agencies — electronic case reporting</td>
</tr>
<tr>
<td></td>
<td>Public health registry reporting</td>
<td>§ 170.315(f)(6) Transmission to public health agencies — antimicrobial use and resistance reporting</td>
</tr>
<tr>
<td></td>
<td></td>
<td>§ 170.315(f)(7) Transmission to public health agencies — health care surveys</td>
</tr>
<tr>
<td></td>
<td>Clinical data registry reporting</td>
<td>No 2015 health IT certification criteria at this time.</td>
</tr>
<tr>
<td></td>
<td>Electronic reportable laboratory result reporting</td>
<td>§ 170.315(f)(3) Transmission to public health agencies — reportable laboratory tests and value/results</td>
</tr>
<tr>
<td></td>
<td>AUR Surveillance Reporting</td>
<td>§ 170.315(f)(6) Transmission to public health agencies — antimicrobial use and resistance reporting</td>
</tr>
<tr>
<td>Electronic Clinical Quality Measures (eCQMs)</td>
<td>eCQMs for eligible hospitals and CAHs</td>
<td>§ 170.315(c)(1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>§ 170.315(c)(2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>§ 170.315(c)(3)(i) and (ii)</td>
</tr>
<tr>
<td>Protect Patient Health Information</td>
<td>Security Risk Assessment</td>
<td>No 2015 health IT certification criteria at this time.</td>
</tr>
<tr>
<td>Safety Assurance Factors for EHR Resilience Guides (SAFER Guides)</td>
<td></td>
<td>No 2015 health IT certification criteria at this time.</td>
</tr>
</tbody>
</table>
BILLING CODE 4120–01–C

7. Clinical Quality Measurement for Eligible Hospitals and CAHs Participating in the Medicare Promoting Interoperability Program

a. Changes to Clinical Quality Measures in Alignment With the Hospital IQR Program

(1) Background

Under sections 1814(l)(3)(A) and 1886(n)(3)(A)(iii) of the Act, and the definition of “meaningful EHR user” under § 495.4, eligible hospitals and CAHs must report on clinical quality measures selected by CMS using CEHRT (also referred to as electronic clinical quality measures, or eCQMs), as part of being a meaningful EHR user under the Medicare Promoting Interoperability Program.

Tables IX.F.–05. and IX.F.–06. in this final rule summarize the previously finalized eCQMs available for eligible hospitals and CAHs to report under the Medicare Promoting Interoperability Program for the CY 2023 reporting period and the CY 2024 reporting period and subsequent years (87 FR 45360).

### TABLE IX.F.–05.: PREVIOUSLY FINALIZED ECQMS FOR ELIGIBLE HOSPITALS AND CAHs FOR THE CY 2023 REPORTING PERIOD

<table>
<thead>
<tr>
<th>Short Name</th>
<th>Measure Name</th>
<th>CBE^ No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ED-2 **</td>
<td>Admit Decision Time to ED Departure Time for Admitted Patients</td>
<td>0497</td>
</tr>
<tr>
<td>HH-01</td>
<td>Hospital Harm – Severe Hypoglycemia</td>
<td>3503e</td>
</tr>
<tr>
<td>HH-02</td>
<td>Hospital Harm – Severe Hyperglycemia</td>
<td>3533e</td>
</tr>
<tr>
<td>PC-05 **</td>
<td>Exclusive Breast Milk Feeding</td>
<td>0480</td>
</tr>
<tr>
<td>STK-02</td>
<td>Discharged on Antithrombotic Therapy</td>
<td>0435</td>
</tr>
<tr>
<td>STK-03</td>
<td>Anticoagulation Therapy for Atrial Fibrillation/Flutter</td>
<td>0436</td>
</tr>
<tr>
<td>STK-05</td>
<td>Antithrombotic Therapy by End of Hospital Day Two</td>
<td>0438</td>
</tr>
<tr>
<td>STK-06 **</td>
<td>Discharged on Statin Medication</td>
<td>0439</td>
</tr>
<tr>
<td>VTE-1</td>
<td>Venous Thromboembolism Prophylaxis</td>
<td>0371</td>
</tr>
<tr>
<td>VTE-2</td>
<td>Intensive Care Unit Venous Thromboembolism Prophylaxis</td>
<td>0372</td>
</tr>
<tr>
<td>ePC-07/SMM</td>
<td>Severe Obstetric Complications</td>
<td>N/A</td>
</tr>
<tr>
<td>ePC-02</td>
<td>Cesarean Birth</td>
<td>N/A</td>
</tr>
</tbody>
</table>

^ In previous years, we referred to the consensus-based entity by corporate name. We have updated this language to refer to the consensus-based entity more generally.

*Reporting the Safe Use of Opioids-Concurrent Prescribing eCQM is mandatory beginning with the CY 2022 reporting period.

**CY 2023 is the last year to report on Admit Decision Time to ED Departure Time for Admitted Patients, Exclusive Breast Milk Feeding, and Discharged on Statin Medication eCQMs as one of the self-selected eCQMs.
TABLE IX.F.-06.: PREVIOUSLY FINALIZED ECQMS FOR ELIGIBLE HOSPITALS AND CAHS FOR THE CY 2024 REPORTING PERIOD AND SUBSEQUENT YEARS

<table>
<thead>
<tr>
<th>Short Name</th>
<th>Measure Name</th>
<th>CBE No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safe Use of Opioids*</td>
<td>Safe Use of Opioids – Concurrent Prescribing</td>
<td>3316e</td>
</tr>
<tr>
<td>ePC-07/SMM**</td>
<td>Severe Obstetric Complications</td>
<td>N/A</td>
</tr>
<tr>
<td>ePC-02**</td>
<td>Cesarean Birth</td>
<td>N/A</td>
</tr>
<tr>
<td>HH-01</td>
<td>Hospital Harm – Severe Hypoglycemia</td>
<td>3503e</td>
</tr>
<tr>
<td>HH-02</td>
<td>Hospital Harm – Severe Hyperglycemia</td>
<td>3533e</td>
</tr>
<tr>
<td>HH-03</td>
<td>Hospital Harm – Opioid-Related Adverse Events</td>
<td>3501e</td>
</tr>
<tr>
<td>STK-02</td>
<td>Discharged on Antithrombotic Therapy</td>
<td>0435</td>
</tr>
<tr>
<td>STK-03</td>
<td>Anticoagulation Therapy for Atrial Fibrillation/Flutter</td>
<td>0436</td>
</tr>
<tr>
<td>STK-05</td>
<td>Antithrombotic Therapy by End of Hospital Day Two</td>
<td>0438</td>
</tr>
<tr>
<td>VTE-1</td>
<td>Venous Thromboembolism Prophylaxis</td>
<td>0371</td>
</tr>
<tr>
<td>VTE-2</td>
<td>Intensive Care Unit Venous Thromboembolism Prophylaxis</td>
<td>0372</td>
</tr>
<tr>
<td>GMCS</td>
<td>Global Malnutrition Composite Score</td>
<td>3592e</td>
</tr>
</tbody>
</table>

*Reporting the Safe Use of Opioids-Concurrent Prescribing eCQM is mandatory beginning with the CY 2022 reporting period.

**Reporting the Severe Obstetric Complications eCQM and Cesarean Birth eCQM are mandatory beginning with CY 2024 reporting period.

(2) eCQM Adoptions

As we stated in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38479), we intend to continue to align the eCQM reporting requirements for the Medicare Promoting Interoperability Program with similar requirements under the Hospital IQR Program to the extent feasible. Section 1886(m)(3)(B)(i)(I) of the Act provides, in part, that in selecting clinical quality measures for the Medicare Promoting Interoperability Program, the Secretary shall provide preference to such measures that have been selected for purposes of the Hospital IQR Program. In addition, section 1886(n)(3)(B)(viii) of the Act provides that in selecting clinical quality measures for the Medicare Promoting Interoperability Program, and in establishing the form and manner for reporting, the Secretary shall seek to avoid redundant or duplicative reporting with reporting otherwise required, including reporting under the Hospital IQR Program. To minimize redundant or duplicative reporting, while maintaining a set of meaningful clinical quality measures that continue to incentivize improvement in the quality of care provided to patients, and in alignment with proposals for the Hospital IQR Program eCQM measure set as discussed in section IX.C. of this final rule, we proposed to adopt three new eCQMs for the Medicare Promoting Interoperability Program, beginning with the CY 2025 reporting period (88 FR 27171 through 27173). Specifically, we proposed to add the following two eCQMs that address factors contributing to hospital harm to the Medicare Promoting Interoperability Program eCQM measure set on which hospitals can self-select to report, beginning with the CY 2025 reporting period: (1) the Hospital Harm—Pressure Injury eCQM (CBE #3408e); and (2) the Hospital Harm—Acute Kidney Injury eCQM (CBE #3713e). In addition, we proposed to add the Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography (CT) in Adults (Hospital Level—Inpatient) eCQM (CBE #3663e) to the Medicare Promoting Interoperability Program eCQM measure set on which hospitals can self-select to report, beginning with CY 2025 reporting period. We refer readers to the discussion of the proposals for the Hospital IQR Program in sections IX.C.5.a, IX.C.5.b., and IX.C.5.c. of the preamble of this final rule for more information about these three measures and our policy reasons for finalizing them. Table IX.F.–07. in this final rule summarizes previously finalized, and newly proposed, eCQMs in the Medicare Promoting Interoperability Program for the CY 2025 reporting period and subsequent years.
We invited public comment on these proposals.

Comment and Response: We received many comments about the Hospital Harm—Pressure Injury eCQM (CBE #3498e). To continue alignment of eCQM policies across the Medicare Promoting Interoperability Program and the Hospital IQR Program, we refer readers to section IX.C.5.a. of this final rule for a detailed summary of the comments received and our responses thereto.

Comment and Response: We received many comments about the Hospital Harm—Acute Kidney Injury eCQM (CBE #3713e). To continue alignment of eCQM policies across the Medicare Promoting Interoperability Program and the Hospital IQR Program, we refer readers to section IX.C.5.b. of this final rule for a detailed summary of the comments received and our responses thereto.

Comment and Response: We received many comments about the Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography (CT) in Adults (Hospital Level—Inpatient) eCQM. To continue alignment of eCQM policies across the Medicare Promoting Interoperability Program and the Hospital IQR Program, we refer readers to section IX.C.5.c. of this final rule for a detailed summary of the comments received and our responses thereto.

Comment: A commenter commended CMS’s continued effort to align quality measures across its public reporting programs.

Response: We thank the commenter for their support.

After consideration of the public comments we received, we are finalizing these policies as proposed for both the Medicare Promoting Interoperability Program and the Hospital IQR Program. We refer readers to the discussion of these same measures for the Hospital IQR Program in sections IX.C.5.a, IX.C.5.b, and IX.C.5.c. of the preamble of this final rule for more information about these finalized policies.

b. eCQM Reporting and Submission Requirements for the CY 2025 Reporting Period and Subsequent Years

Consistent with our goal to align the eCQM reporting periods and criteria in the Medicare Promoting Interoperability Program with the Hospital IQR Program, in the FY 2023 IPPS/LTCH PPS final rule, we finalized our policy to modify the eCQM reporting and submission requirements under the Medicare Promoting Interoperability Program for eligible hospitals and CAHs beginning with the CY 2024 reporting period (87 FR 49365 through 49367). Specifically, eligible hospitals and CAHs will be required to report four calendar quarters of data for each required eCQM: (1) Three self-selected eCQMs; (2) the Safe Use of Opioids—Concurrent Prescribing eCQM; (3) the Severe Obstetric Complications eCQM; and (4) the Cesarean Birth eCQM, for a total of six eCQMs, beginning with the CY 2024 reporting period and for subsequent years (87 FR 49365). Additionally, as finalized in the FY 2023 IPPS/LTCH PPS final rule, the Severe Obstetric Complications eCQM and the Cesarean Birth eCQM are available for eligible hospitals and CAHs to select as one of their three self-selected eCQMs for the CY 2023 reporting period, and then beginning with the CY 2024 reporting period and for subsequent years, all eligible hospitals and CAHs are required to report these two eCQMs.

We previously finalized our policy to eliminate attestation as a method for reporting CQMs for the Medicare Promoting Interoperability Program, and instead require all eligible hospitals and CAHs to submit their CQM data electronically through the reporting methods available for the Hospital IQR Program beginning with the reporting period in CY 2023. We did not propose any changes to the policy for CY 2024. For more information, we refer readers to the FY 2020 IPPS/LTCH PPS final rule (84 FR 42601 through 42602).

After consideration of the public comments we received, we are finalizing our proposal to adopt the Hospital Harm—Pressure Injury eCQM, the Hospital Harm—Acute Kidney Injury eCQM, and the Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography (CT) in Adults (Hospital Level—Inpatient) eCQM, as measures...
available for self-selection, in alignment with the Hospital IQR Program.

X. Other Provisions Included in This Final Rule

A. Medicare Program—Special Requirements for Rural Emergency Hospitals (REHs)

1. Background

This final rule would codify requirements for additional information that an eligible facility would be required to submit when applying for enrollment as a Rural Emergency Hospital (REH), as specified in the Consolidated Appropriations Act (CAA), 2021. Section 125 of Division CC of the CAA was signed into law on December 27, 2020 and establishes REHs as a new Medicare provider that will receive Medicare payment for services furnished on or after January 1, 2023. Section 125 of the CAA added section 1861(kkk) to the Act, which sets forth the requirements for REHs. The establishment of REHs as a Medicare provider is intended to promote equity in health care for those living in rural communities by facilitating access to needed services, such as emergency, urgent, and observation care services, as well as other additional outpatient medical and health services that an REH might elect to provide.

In the November 23, 2022 Federal Register (87 FR 71748), we published a final rule with comment period titled “Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Organ Acquisition; Rural Emergency Hospitals: Payment Policies, Conditions of Participation, Provider Enrollment, Physician Self-Referral; New Service Category for Hospital Outpatient Department Prior Authorization Process; Overall Hospital Quality Star Rating: COVID-19” (https://www.federalregister.gov/d/2022-23918). Included as part of this rule were the provider enrollment procedures for REHs, including that REHs: (1) must comply with all applicable provider enrollment provisions in 42 CFR part 424, subpart P, in order to enroll in Medicare; and (2) must submit a Form CMS–855A change of information application (rather than an initial enrollment application) to convert to an REH. These enrollment requirements became effective on January 1, 2023.

On January 26, 2023, CMS released QSO–23–07–REH (https://www.cms.gov/files/document/qso-23-07-reh.pdf) which provided the additional information requirements specified by section 1861(kkk)(4)[A](i)-(iv) of the Act as well as guidance regarding the process by which eligible facilities must submit the additional information detailed here. We proposed to codify these additional information requirements in this rule, and we have included a proposed Information Collection Requirement (ICR) in section B.10. of this rule for solicitation of public comments and for OMB approval of this ICR. We note that the processing of the REH enrollment applications (as those requirements were finalized in the November 23, 2022, rule) is not dependent on the finalization of the provisions of this final rule.

We also proposed to update certain definitions in the survey and certification regulations to address REHs. Specifically, we proposed the definition of a “Provider of services or provider” at 42 CFR 488.1 to include REHs as well as add REHs to the other applicable provisions contained in 42 CFR parts 488 and 489: §§ 488.2, “Statutory basis”; 488.18, “Documentation of findings”; and 489.102, “Requirements for providers.”

2. Proposed Revision to the Definition of “Provider of Services or Provider” (§ 488.1)

We proposed to revise the definition of “Provider of services or provider” at § 488.1. The proposed new definition of “provider of services or provider” would state that it refers to a hospital, critical access hospital, rural emergency hospital, skilled nursing facility, nursing facility, home health agency, hospice, comprehensive outpatient rehabilitation facility, or a clinic, rehabilitation agency or public health agency that furnishes outpatient physical therapy or speech pathology services.

3. Proposed Addition to the Statutory Basis for Part 488 (§ 488.2)

We proposed to add the statutory basis for REHs to the Statutory Basis section of part 488 at § 488.2. The proposed revision would add section 1861(kkk) of the Act, which sets forth the statutory basis for REHs.

4. Proposed Addition to the Section “Documentation of Findings” (§ 488.18(d))

We proposed to add REHs to the provider-types subject to the requirement at § 488.18(d). The proposed revision at § 488.18(d) would specify that if the State agency receives information to the effect that a hospital, critical access hospital (as defined in section 1861(mm)(3) of the Act) or a rural emergency hospital (as defined in section 1861(kkk)(2) of the Act) has violated § 489.24 (regarding compliance with EMTALA provisions), the State agency must report the information to CMS promptly.

We also announce in this final rule that OMB approved information collection requirements in § 488.18(d) that were published at 59 FR 32120, June 22, 1994, on January 30, 1995.

5. Proposed Special Requirements for REHs (§ 488.70)

We proposed to add new regulation text at § 488.70, so that an eligible facility that submits an application for enrollment as an REH under section 1866(j) of the Act must also submit additional information as specified in this final rule. In accordance with section 1861(kkk)[4][A](i) through (iv) of the Act, we specifically propose to add § 488.70(a) through (d), so that the provider must include an action plan containing: (1) a plan for initiating REH services (as those services are defined in 42 CFR 485.502, including mandatory provision of emergency department services and observation care); (2) a detailed transition plan that lists the specific services that the provider will retain, modify, add, and discontinue as an REH; (3) a detailed description of other outpatient medical and health services that it intends to furnish on an outpatient basis as an REH; and (4) information regarding how the provider intends to use the additional facility payment provided under section 1834(x)(2) of the Act, including a description of the services that the additional facility payment would be supporting, such as the operation and maintenance of the facility and the furnishing of covered services (for example, telehealth services and ambulance services). Although section 1861(kkk)[4][A](iv) of the Act gives us the authority to require such additional information as the Secretary may deem necessary, we did not propose any additional information submissions at this time.

6. Proposed Requirements for Providers (§ 489.102) (Advance Directives)

We proposed to add REHs to the applicable provisions at § 489.102(a) and add a new § 489.102(b)(5) to also include a provision for REHs.

Comment: We received comments on the proposed Special Requirements for Rural Emergency Hospitals at § 488.70 that expressed appreciation to CMS for providing additional clarity in the proposed rule on how hospitals might become REHs. However, one commenter was concerned that the proposed regulations could create barriers and burdens on rural hospitals seeking to
become REHs. The commenter recognized the value of having a detailed action plan, but noted that additional or burdensome paperwork could impact a rural hospital’s ability to transition to an REH. The commenter requested that CMS implement the final regulation with an understanding of the challenges rural hospitals and communities face while maintaining standards for safety and high-quality care. The commenter stated that CMS must balance the need for oversight while minimizing the administrative burden for rural hospitals with limited capacities.

Response: We appreciate the comments received on these requirements and recognize the need to minimize the burden of unnecessary paperwork requirements for rural hospitals and CAHs applying to become REHs. However, the proposed requirements at § 488.70 contain only those provisions that are required by statute. Our guidance for the requirements at § 488.70 (QSO–23–07–REH, issued January 26, 2023) provides details for rural hospitals and CAHs considering conversion to an REH and also provides flexibility in the process by allowing applicants to use either the model template attached to our memo or the facility’s own letterhead with a description of the action plan and additional information as required by the statute at section 1861(kkk) of the Act (https://www.cms.gov/medicare/provider-enrollment-and-certification/surveycertificationgeninfo/policy-and-memos-states/guidance-rural-emergency-hospital-provisions-conversion-process-and-conditions-participation).

Comment: A commenter thanked CMS for implementing Congressional intent in creating these hospitals and noted that they serve an important role in our health care system. The commenter also agreed with CMS’ proposed change to the definition of “provider of services” at § 488.1 to now include REHs. The commenter also requested CMS ensure that the submission of the action plan and additional information require adequate nurse staffing at REHs. Specifically, the commenter asked for CMS to ensure that appropriate nurse staffing is included in sections regarding transition plans for services maintained, added, or removed during the transition to an REH and that nursing is included in a detailed description of services that the REH intends to furnish.

Response: We appreciate the commenter’s support of the proposed changes and thank them for their recommendations regarding nurse staffing for REHs. Our guidance (QSO–23–07–REH) for these requirements specifically state that the action plan should include details regarding staffing provisions and the number and type of qualified staff for the provision of REH services. We expect that these staffing details would include the REH’s plans for nursing staffing as well as those for other qualified staff providing services to patients of the REH.

Comment: We received comments which expressed support for the special requirements for REHs and thanked CMS for codifying guidance on documentation for hospitals’ REH applications and enrollment procedures. One commenter also encouraged CMS to incentivize maternity care in REHs to expand access to care for this critical service and improve maternal health outcomes.

Response: We appreciate the commenter’s expressed concern regarding access to maternal health services in rural communities and the improvement of maternal health outcomes. Section 1861(kkk)(1)(A)(ii) of the Act allows REHs to provide additional outpatient medical and health services which may include maternal health services that are aligned with the health needs of the community served by the REH as required by § 485.524(a). This aligns with a priority of the Biden-Harris Administration to improve access to maternal health care services. Therefore, we expect that REHs will provide various outpatient services including, but not limited to services such as, low-risk labor and delivery supported by any emergency surgical procedures necessary if identified by a health needs assessment of their community and in accordance with the CoPs for additional outpatient medical and health services.

Comment: One commenter requests CMS clarification that a hospital may qualify for Rural Emergency Hospital status if the number of actual beds in use on December 27, 2020, was 50 beds or less as many hospitals report beds based on the licensed number of beds.

Response: We thank the commenter for expressing the need for clarification as it relates to the methodology used to determine if a rural hospital with not more than 50 beds meets the bed count requirement to seek REH designation. The final rule titled “Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Organ Acquisition; Rural Emergency Hospitals: Payment Policies, criteria for Participation, Provider Enrollment, Physician Self-Referral; New Service Category for Hospital Outpatient Department Prior Authorization Process: Overall Hospital Quality Star Rating; COVID–19” (https://www.federalregister.gov/documents/2022/11/23/2022-23918/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-pay) finalized the methodology used to determine if a rural hospital with not more than 50 beds meets the bed count requirement to seek REH designation. Based on the methodology finalized, this will be determined by calculating the number of available bed days during the most recent cost reporting period divided by the number of days in the most recent cost reporting period. We use this methodology to determine if Medicare-dependent small rural hospitals meet the required bed count for that program. We believe this is an appropriate methodology for determining if a rural hospital meets the bed count requirement to seek REH designation, as this is a known and existing methodology for small rural hospitals seeking to determine bed count for eligibility in Medicare programs.

After consideration of the public comments we received, we are finalizing the requirements as proposed.

B. Physician Self-Referral Law: Physician-Owned Hospitals

1. Background
   a. Statutory and Regulatory History: General

Section 1877 of the Act, also known as the physician self-referral law: (1) prohibits a physician from making referrals for certain designated health services payable by Medicare to an entity with which he or she (or an immediate family member) has a financial relationship, unless the requirements of an applicable exception are satisfied; and (2) prohibits the entity from filing claims with Medicare (or billing another individual, entity, or third-party payor) for any improperly referred designated health services. A financial relationship may be an ownership or investment interest in the entity or a compensation arrangement with the entity. The statute establishes a number of specific exceptions and grants the Secretary of the Department of Health and Human Services (the Secretary) the authority to create regulatory exceptions for financial relationships that do not pose a risk of program or patient abuse. Section 1903(s) of the Act extends aspects of the physician self-referral law’s prohibitions to Medicaid. (For additional information about section 1903(s) of the Act, see 66 FR 857 through 858.)
The following discussion provides a chronology of our more significant and comprehensive rulemakings; it is not an exhaustive list of all rulemakings related to the physician self-referral law. After the passage of section 1877 of the Act, we proposed rulemakings in 1992 (related only to referrals for clinical laboratory services) (57 FR 8588) (the 1992 proposed rule) and 1996 (addressing referrals for all designated health services) (63 FR 1659) (the 1998 proposed rule). We finalized the proposals from the 1992 proposed rule in 1995 (60 FR 41914) (the 1995 final rule) and issued final rules following the 1996 proposed rule in three stages. The first final rulemaking (Phase I) was a final rule with comment period that appeared in the January 4, 2001 Federal Register (66 FR 856). The second final rulemaking (Phase II) was an interim final rule with comment period that appeared in the March 26, 2004 Federal Register (69 FR 16054). Due to a printing error, a portion of the Phase II preamble was omitted from the March 26, 2004 Federal Register publication.

That portion of the preamble, which addressed reporting requirements and sanctions, appeared in the April 6, 2004 Federal Register (69 FR 17953). The third final rulemaking (Phase III) was a final rule that appeared in the September 5, 2007 Federal Register (72 FR 51012).

After passage of the Patient Protection and Affordable Care Act of 2010 (Pub. L. 111–148) (the Affordable Care Act), we issued final regulations in the CY 2011 PFS final rule with comment period that codified a disclosure requirement established by the Affordable Care Act for the in-office ancillary services exception (75 FR 73443). In the CY 2016 PFS final rule, we issued regulations to reduce burden and facilitate compliance (80 FR 71300 through 71341). In that rulemaking, we established two new exceptions to the physician self-referral law, clarified certain provisions of the physician self-referral regulations, updated regulations to reflect changes in terminology, and revised definitions related to hospitals with physician ownership or investment. A final rule entitled “Modernizing and Clarifying the Physician Self-Referral Regulations” (the MCR final rule) appeared in the December 2, 2020 Federal Register (85 FR 77492) and established three new exceptions to the physician self-referral law applicable to compensation arrangements that qualify as “value-based arrangements,” established exceptions for limited remuneration to a physician and the donation of cybersecurity technology and services, and revised or clarified several existing exceptions. The MCR final rule also provided guidance and updated or established regulations related to the fundamental terminology used in many provisions of the physician self-referral law. Most notably, we defined the term “commercially reasonable” in regulation, established an objective test for evaluating whether compensation is considered to take into account the volume or value of referrals or other business generated between the parties, and revised the definitions of “fair market value” and “general market value.” The MCR final rule also revised the definition of “indirect compensation arrangement,” which was further revised in the CY 2022 PFS final rule (86 FR 65343).

b. Statutory and Regulatory Background: Physician-Owned Hospitals

(1) Exceptions to the Physician Self-Referral Law for Ownership or Investment in a Hospital

Section 1877(d) of the Act sets forth exceptions related to ownership or investment interests held by a physician (or an immediate family member of a physician) in an entity that furnishes designated health services. Section 1877(d)(2) of the Act provides an exception for ownership or investment interests in rural providers (the “rural provider exception”). To use the rural provider exception, an entity must furnish substantially all of the designated health services that it furnishes to residents of a rural area (as defined in section 1886(d)(2) of the Act). To satisfy the requirements of the rural provider exception, the designated health services must be furnished in a rural area and, in the case where the entity is a hospital, the hospital must meet the requirements of section 1877(i)(1) of the Act no later than September 23, 2011. Section 1877(d)(3) of the Act provides an exception for ownership or investment interests in a hospital located outside of Puerto Rico (the “whole hospital exception”). To satisfy the requirements of the whole hospital exception, the referring physician must be authorized to perform services at the hospital, the ownership or investment interest must be in the hospital itself (and not merely in a subdivision of the hospital), and the hospital must meet the requirements of section 1877(i)(1) of the Act no later than September 23, 2011. These exceptions are codified in our regulations at § 411.356(c)(1) and (3), respectively.

In a series of reports reviewing the growth in specialty hospitals that are largely for-profit and owned, in part, by physicians, the United States Government Accountability Office (GAO) (formerly known as the United States General Accounting Office) found that these hospitals were much less likely to have emergency departments, treat smaller percentages of Medicaid patients, and derive a smaller share of their revenues from inpatient services. Following the issuance of these reports, the Congress held hearings and began to consider policies to limit the growth of these facilities. Section 6001(a) of the Affordable Care Act effectively eliminated the exceptions for physician ownership or investment in hospitals, although hospitals with physician ownership or investment and a Medicare provider agreement on December 31, 2010, are “grandfathered” to continue using the rural provider exception, if applicable, and the whole hospital exception.

(2) Prohibition on Facility Expansion

Section 6001(a)(3) of the Affordable Care Act amended the rural provider exception and the whole hospital exception to provide that a hospital with physician ownership or investment may not increase the number of operating rooms, procedure rooms, and beds beyond that for which the hospital was licensed on March 23, 2010 (or, in the case of a hospital that did not have a Medicare provider agreement in effect as of this date, but had a provider agreement in effect on December 31, 2010, the effective date of such provider agreement). However, the Secretary may grant an exception from the prohibition on facility expansion.

Section 6001(a)(3) of the Affordable Care Act added new section 1877(i)(3)(A)(i) of the Act, which required the Secretary to establish and implement a process under which a hospital that is an “applicable hospital” may apply for an exception from the prohibition on expansion of facility capacity. Section 1106 of the Health Care and Education Reconciliation Act

Sections 1877(i)(3)(A)(i) of the Act requires the establishment of a process under which an applicable hospital may apply for an exception from the prohibition on expansion of facility capacity (emphasis added). The Secretary’s authority to grant an expansion exception is limited by section 1877(i)(3)(C)(ii) of the Act, which states that the Secretary shall not permit an increase in the number of operating rooms, procedure rooms, and beds for which the hospital is licensed that results in a hospital’s facility capacity exceeding 200 percent of its baseline facility capacity (emphasis added). In addition, section 1877(i)(3)(H) of the Act requires the Secretary to publish in the Federal Register the final decision with respect to a hospital’s application (emphasis added). We interpret this statutory language to mean that, to request an expansion exception with respect to which CMS may issue a decision, a hospital must first establish

2. Proposals

a. Process for Requesting an Exception From the Prohibition on Expansion of Facility Capacity

To satisfy the requirements of the rural provider exception or the whole hospital exception, a hospital must comply with the requirements of section 1877(i) of the Act and existing § 411.362 of our regulations no later than September 23, 2011. Thus, the physician self-referral law prohibits a referral made on or after September 23, 2011, by a physician who has (or whose immediate family member has) an ownership or investment interest in the hospital if the number of operating rooms, procedure rooms, and beds for which the hospital is licensed (referred to in this final rule as “facility capacity”) at the time of the referral is greater than its baseline number of operating rooms, procedure rooms, and beds (as defined at existing § 411.362(a) and referred to in this final rule as “baseline facility capacity”), unless the hospital has been granted an exception from the prohibition on expansion of facility capacity (referred to in this final rule as an “expansion exception”). The regulations at existing § 411.362(c) set forth the current expansion exception process.

As stated in the proposed rule, we recently reviewed the expansion exception process, including a fresh examination of the statutory language and certain legislative history of the Affordable Care Act. Section 1877(i)(3)(A)(i) of the Act requires that CMS recently reviewed the expansion exception process (76 FR 74524). Citing alignment with the Patients over Paperwork initiative—a former initiative launched by CMS in 2017 to evaluate and streamline regulations with a goal to reduce unnecessary burden, increase efficiencies, and improve the beneficiary experience—in the CY 2021 OPPS/ASC final rule, we reversed this temporal program integrity requirement for high Medicaid facilities, noting that the plain language of the statute does not impose the same limitations on the expansion of high Medicaid facilities as it does on the expansion of applicable hospitals (85 FR 86257).
that it meets the criteria for an applicable hospital or a high Medicaid facility. We further interpret this statutory language to mean that CMS has discretion to approve or deny a request for an expansion exception even if the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility. Put another way, it is our position that, under section 1877(i)(3)(A)(ii) of the Act, meeting the criteria for an applicable hospital or a high Medicaid facility merely makes a hospital eligible to request an expansion exception, but it does not guarantee approval of such a request. We note that, for purposes of interpreting the statutory provisions, codification in our regulations, and discussion in our rulemakings, we use the term “request” in the same way as “apply” and “application,” and use the term “approve” in the same way as “grant.” (See 76 FR 74517 (when the statute refers to an “application,” we use the term “request”) and 79 FR 64801 and 64802 (“II. Exception Approval Process” and “decision to approve” a request, respectively).

Section 1877(i)(3)(A)(ii) of the Act requires that the expansion exception process shall provide for community input with respect to an expansion exception request. We have always interpreted the requirement to provide for community input “with respect to [an] application” to require CMS to permit any input with respect to the expansion exception request—not just input related to whether the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility. In the CY 2012 OPPS/ASC proposed and final rules, we noted examples of community input, such as documentation demonstrating that the requesting hospital does not satisfy one or more of the data criteria or that the requesting hospital discriminates against beneficiaries of Federal health programs; however, we stated that these are examples only and that we do not restrict the type of community input that may be submitted (76 FR 42332 and 74517). We noted that, if the Congress did not intend for the Secretary to have discretion to approve or deny an expansion exception request from a hospital that meets the criteria for an applicable hospital or a high Medicaid facility, the statutorily required community input would be limited to whether the hospital met such criteria. The plain language of the statute is not so limited.

To clarify our interpretation of the Secretary’s authority, ensure that approval of a request to expand a hospital’s facility capacity occurs only in appropriate circumstances, and facilitate compliance with the process for requesting an expansion exception, we proposed to modify and clarify our regulations at existing §411.362(c). Specifically, we proposed to revise the regulations that set forth the expansion exception process and separate them from the requirements that a hospital must satisfy under the rural provider exception and the whole hospital exception. We proposed to renumber existing §411.362(c), as well as certain related definitions in existing §411.362(a), at new §411.363, noting that having a separate regulation dedicated to the expansion exception process could provide greater transparency and facilitate compliance with the expansion exception process. To provide clarity and transparency for hospitals that wish to request an expansion exception and other interested parties, we proposed to revise our regulations to clarify that CMS will only consider expansion exception requests from eligible hospitals, clarify the data and information that must be included in an expansion exception request, identify factors that CMS will consider when making a decision on an expansion exception request, and revise certain aspects of the process for requesting an expansion exception.

(1) Relevant Definitions

We proposed to include at new §411.363(a) definitions for the terms “baseline number of operating rooms, procedure rooms, and beds,” “external data source,” “main campus of the hospital,” and “procedure room” for purposes of the expansion exception process set forth in proposed §411.363. These definitions are currently included in existing §411.362(a). Because the terms “baseline number of operating rooms, procedure rooms, and beds,” “external data source,” and “main campus of the hospital” are not used in §411.362 as it would be revised, we proposed to remove their definitions from §411.362(a). Because the term “procedure room” is used in both existing §411.362(a) and proposed §411.363, we proposed to define the term “procedure room,” for purposes of new §411.363(a) to have the meaning set forth at existing §411.362(a).

(2) CMS Consideration of an Expansion Exception Request and Publication in the Federal Register

We proposed to revise §411.362(c)(1) and renumber it at §411.363(b) to clarify that CMS will not consider an expansion exception request from a hospital that is not eligible to request an expansion exception. To be eligible to request an expansion exception, a hospital must first meet the criteria as an applicable hospital or a high Medicaid facility, which we proposed to renumber at §411.363(c) and (d), respectively. We proposed certain clarifying and other revisions to these regulations, which are discussed in sections X.B.2.a.(4) and (6), of the preamble in this final rule.

To facilitate the proposed reinstatement of the program integrity restriction regarding the maximum aggregate expansion of a hospital, we proposed at §411.363(b)(2)(i) that CMS would not consider an expansion exception request from a hospital for which CMS had previously approved an expansion exception that would allow the hospital’s facility capacity to reach 200 percent of its baseline facility capacity if the full expansion is utilized, even if the hospital met the criteria for an applicable hospital or a high Medicaid facility. We also proposed to apply this eligibility restriction to any hospital requesting an expansion exception. We illustrate this proposal with the following example. A hospital with a baseline facility capacity of 100 that was granted an expansion exception for 100 additional operating rooms, procedure rooms, and beds would have a potential facility capacity of 200, or 200 percent of its baseline number of operating rooms, procedure rooms, and beds. Consequently, the hospital would not be eligible to request another expansion exception. A hospital with a baseline facility capacity of 100 that was granted an expansion exception for 75 additional operating rooms, procedure rooms, and beds could request to further expand its facility capacity by no more than an additional 25 operating rooms, procedure rooms, and beds, because CMS would be prohibited under section 1877(i)(3)(C)(ii) of the Act from approving the subsequent expansion exception request if it would allow the hospital’s aggregate facility capacity to exceed 200 percent of its baseline facility capacity.

We proposed to implement section 1877(i)(3)(B) of the Act at proposed §411.363(b)(2)(ii), which permits an applicable hospital to request an expansion exception up to once every 2 years, and apply the limitation to any hospital requesting an expansion exception. In the proposed rule we noted that, after receiving no comments on our proposals in the CY 2012 OPPS/ASC final rule to allow an applicable hospital or high Medicaid facility to request an expansion exception up to once every 2 years from the date of a CMS decision on the hospital’s most
recent request, using our authority in sections 1871 and 1877 of the Act, we implemented section 1877(i)(3)(B) of the Act at existing § 411.362(c)(1) (76 FR 74525). In that final rule, we stated that we would consider the date of a CMS decision to be the date of the decision letter sent to the requesting party (76 FR 74525). However, as we noted in the proposed rule, in the CY 2021 OPPS/ASC final rule, we reversed the regulatory extension of statutory program integrity restrictions—including the restriction on frequency of expansion exception requests—for hospitals that meet the criteria for a high Medicaid facility (85 FR 86256). Therefore, since January 1, 2021, a high Medicaid facility has been permitted to request an expansion exception at any time, provided that it has not submitted another request for an expansion exception for which CMS has not issued a decision. In the proposed rule, we also noted that, even though we reversed the regulatory extension of the restriction on the frequency of expansion exception requests for hospitals that meet the criteria for a high Medicaid facility, in the CY 2021 OPPS/ASC final rule, we nonetheless limited a high Medicaid facility to applying for an expansion exception only when it does not have another expansion exception request pending with CMS. We reiterated that we did so to preserve CMS resources and continue to maintain an orderly and efficient expansion exception process (85 FR 86256), noting that, historically, CMS has worked with requesting hospitals for several weeks or months following the initial submission to complete the request so that CMS can publish notice of the request in the Federal Register. Depending on the amount of time from submission to publication of the notice of the request in the Federal Register, and given the timeframes under the expansion exception process for deeming a request complete, reviewing the request, and publishing CMS’s decision regarding a request, it could take well over a year to receive a CMS decision on an expansion exception request. We emphasized that we continue to believe that permitting a hospital to submit a subsequent request before CMS has made a decision on an earlier request would be an improper use of agency resources, could result in confusion to interested parties that wish to provide community input, and would unnecessarily complicate the expansion exception process. Therefore, we proposed § 411.363(b)(2)(ii) that CMS would not consider an expansion exception request from a hospital—even if it meets the criteria for an applicable hospital or a high Medicaid facility—if it has been less than 2 years from the date of the most recent decision by CMS approving or denying the hospital’s most recent (prior) request for an expansion exception.

Under the proposed regulations, CMS would consider an expansion exception request submitted by a hospital that meets the criteria for an applicable hospital or a high Medicaid facility and is otherwise eligible to request the expansion exception, provided that the request includes all information required under proposed § 411.363(e). In the proposed rule we stated that, in processing an expansion exception request, we would first determine whether the requesting hospital is eligible to request the expansion exception (that is, whether the hospital meets the criteria for an applicable hospital or a high Medicaid facility). This would include providing an opportunity for community input regarding whether the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility (depending on the specific request). If the hospital meets the criteria for an applicable hospital or a high Medicaid facility, and is not otherwise precluded from making an expansion exception request under proposed § 411.363(b)(2), we would then decide whether to approve or deny the request. This would include providing an opportunity for community input regarding, among other things, the factors that CMS will consider in deciding whether to approve or deny the hospital’s expansion exception request. Because community input would be relevant to both the determination that a requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility and our decision whether to approve or deny the expansion exception request, we stated that we anticipate publication in the Federal Register of any expansion exception request that a requesting hospital has not elected to withdraw following its initial submission, provided that the hospital is otherwise eligible to request an expansion exception. We noted that, in the Federal Register notice, we would seek community input on both whether the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility (depending on the specific request) and whether CMS should approve or deny the request. We believed it would be the most efficient use of CMS and governmental resources, as well as eliminate the duplication of efforts by individuals and entities in the community that wish to provide input on a hospital’s expansion exception request.

In the proposed rule, we stated that, following publication of the notice of the expansion exception request in the Federal Register, receipt of community input, if any, and receipt of the requesting hospital’s rebuttal notice, if any, CMS would first determine whether the hospital meets the criteria for an applicable hospital or a high Medicaid facility (depending on the specific request). We proposed to codify this part of the process at § 411.363(h). If CMS determines that the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility, CMS would then decide whether to approve or deny the expansion exception request. As previously explained, it is our position that the authority granted to the Secretary in section 1877(i) of the Act provides CMS discretion to approve or deny an expansion exception request. In making its decision whether to approve or deny an expansion exception request, CMS would consider data and information provided by the hospital in its request, included in the community input, if any, and provided by the hospital in its rebuttal statement, if any. CMS may also consider any other data and information relevant to its decision. We proposed to codify this part of the process at § 411.363(i)(1). Other data and information relevant to CMS’s decision may include, but is not limited to, data and information that is not publicly available, provided to CMS by the requesting hospital or interested parties in other contexts, or provided by CMS’ law enforcement partners and other government agencies (whether publicly available or not). For example, CMS may use the internet or other sources to perform an environmental scan of the geographic area of the country in which the requesting hospital is located, identify trends, recent events, or planned events (such as expected population growth or new employers entering the local market), or review information related to the quality of care at the requesting hospital and other hospitals in its community.

We also proposed a nonsubstantive revision to the introductory language at existing § 411.362(c)(2) and (3). The existing regulations state the criteria that an applicable hospital or a high Medicaid facility, respectively, must satisfy. To conform to our regulations in 42 CFR part 411, subpart J more closely, we proposed to use the word “satisfies” in place of “satisfies” in the introductory language of these regulations, which we
proposed would be renumbered at § 411.363(c) and (d).

(3) CMS Decision To Approve or Deny an Expansion Exception Request

In proposed § 411.363(i)(2), we identified factors that CMS would always consider when deciding whether to approve or deny an expansion exception request. As proposed, these factors include: (1) the specialty (for example, maternity, psychiatric, or substance use disorder care) of the hospital or the services furnished by or to be furnished by the hospital if CMS approves the request; (2) program integrity or quality of care concerns related to the hospital; (3) whether the hospital has a need for additional operating rooms, procedure rooms, or beds; and (4) whether there is a need for additional operating rooms, procedure rooms, or beds in the county in which the main campus of the hospital is located, in any county in which the hospital provides inpatient or outpatient hospital services; and (5) the date the hospital submits the expansion exception request, or in any county in which the hospital plans to provide inpatient or outpatient hospital services if CMS approves the request. We stated that we believe these factors are especially relevant to CMS’ decision whether to approve or deny an expansion exception request; however, proposed § 411.363(i)(2) did not limit CMS to the enumerated factors in making its decision. By way of example, we stated that CMS may also consider any other factors it deems relevant to its decision to approve or deny an expansion exception request, such as program integrity or quality concerns related to other hospitals in the requesting hospital’s community or their ability to serve a growing patient population in the community. As explained in section X.B.2.A.(8) of this final rule, we are not finalizing our proposal to require information regarding how or where a requesting hospital would use approved expansion facility capacity if its request is approved. Therefore, we are not finalizing our proposal to include as a factor for our consideration of an expansion exception request whether there is a need for additional operating rooms, procedure rooms, or beds in any county in which the hospital plans to provide inpatient or outpatient hospital services if CMS approves the request. In the proposed rule, we noted that expansion exception requests are now and would continue to be assessed on a case-by-case basis and CMS would base its decision to approve or deny an expansion exception request on the totality of the information available to the agency. Thus, decisions to approve or deny requests from hospitals that appear similar with respect to overall capacity to serve Medicaid and other underserved populations could differ based on factors such as planned expansion of needed psychiatric services instead of general acute care services or whether the requesting hospital seeks an expansion exception to replace operating rooms, procedure rooms, or beds that it has relocated (or intends to relocate) from its main campus to other areas in need of services.

As required in section 1877(i)(3)(I) of the Act, no later than 60 days after receiving a complete request, CMS will publish in the Federal Register its final decision with respect to a hospital’s expansion exception request. This requirement is codified in our regulations at existing § 411.362(c)(7), which we proposed to revise for clarity and renumber at § 411.363(k). In the proposed rule, we noted that, if CMS determines that the requesting hospital does not meet the criteria for an applicable hospital or a high Medicaid facility (depending on the specific request), under proposed § 411.363(b)(1), the hospital would not be eligible to request the expansion exception and CMS would not further consider the request. In that case, the required Federal Register notice would address only the determination that the requesting hospital does not meet the criteria for an applicable hospital or a high Medicaid facility. We noted further that, if CMS determines that the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility, as required by statute, CMS must decide whether to approve or deny the expansion exception request and publish its decision in the Federal Register. In that case, the required Federal Register notice would address both CMS’ determination that the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility (depending on the specific request) and CMS’ decision to approve or deny the request. Section 1877(i)(3)(I) of the Act and our regulation at existing § 411.362(c)(8) state that there shall be no administrative or judicial review under section 1869 of the Act, section 1878 of the Act, or otherwise of the expansion exception process (including the establishment of such process). We stated that we interpret the statute to mean that neither the process itself nor CMS’ decision whether to approve or deny an expansion exception request are subject to administrative or judicial review. Therefore, we proposed to revise the regulation to expressly state that the limitation on review of the expansion exception process under § 411.363 includes any CMS determination or decision under the process, noting that this would include determinations regarding whether a hospital meets the criteria for an applicable hospital or a high Medicaid facility and decisions regarding whether to approve or deny a hospital’s request. We also proposed to renumber the regulation at § 411.363(i).

(4) Required Information From a Requesting Hospital

Existing § 411.362(c)(4)(ii) sets forth information that must be included in an expansion exception request for CMS to consider the request. We proposed to revise the introductory language of this regulation and renumber it at § 411.363(e)(2) to clarify that inclusion of the required information is a prerequisite to consideration of the request by CMS. We did not propose any revisions to existing § 411.362(c)(4)(ii)(A), which requires that an expansion exception request must include the name, address, National Provider Identification number(s) (NPI), Tax Identification Number(s) (TIN), and CMS Certification Number(s) (CCN) of the hospital requesting the expansion exception; however, we proposed to renumber this regulation at § 411.363(e)(2)(i). We proposed to revise existing § 411.362(c)(4)(ii)(C), which requires that an expansion exception request must include the name, title, address, and daytime telephone number of a contact person who will be available to discuss the request with CMS on behalf of the requesting hospital, to clarify that the request must include an address for receipt of hard copy mail by the contact person. We also proposed to require an electronic mail address for correspondence with the contact person. Finally, we proposed to renumber this regulation at § 411.363(e)(2)(iii). We proposed to revise existing § 411.362(c)(4)(ii)(B) and renumber this regulation at § 411.363(e)(2)(ii). As proposed, an expansion exception request must include the name of the county in which the main campus of the requesting hospital is located and the names of any counties in which the hospital provides inpatient or outpatient hospital services or plans to provide inpatient or outpatient hospital services if CMS approves the request. We stated that it is important to our ability to properly consider an expansion exception request to understand where the expansion facility capacity would be
located. As explained in section X.B.2.a.(8) of this final rule, we are not finalizing our proposal to require a hospital to include in its expansion exception request the names of any counties in which the hospital plans to provide inpatient or outpatient hospital services if CMS approves the request.

Under existing § 411.362(c)(4)(ii)(D), an expansion exception request must include a statement identifying the hospital as an applicable hospital or a high Medicaid facility and a detailed explanation with supporting documentation regarding whether and how the hospital satisfies each of the criteria for applicable hospitals or a high Medicaid facility. In addition, the request must state that the requesting hospital does not discriminate against beneficiaries of Federal health care programs and does not permit physicians practicing at the hospital to discriminate against such beneficiaries. We proposed to bifurcate this regulation such that the first element of existing § 411.362(c)(4)(ii)(D) (identification as an applicable hospital or a high Medicaid facility and supporting documentation regarding satisfaction of the criteria for such) would be separate from the requirement for information regarding nondiscrimination against beneficiaries of Federal health care programs. We also proposed to renumber this regulation at § 411.363(e)(2)(iv) and replace the word “satisfies” with the word “meets” to conform to the conventions in our regulations.

We proposed to move the requirement regarding nondiscrimination to a separate regulation at proposed § 411.363(e)(2)(v) and revise this requirement to state that the expansion exception request must include a statement and, if available, supporting documentation regarding the hospital’s compliance with the requirement that it does not discriminate against beneficiaries of Federal health care programs and does not permit physicians practicing at the hospital to discriminate against such beneficiaries. The existing regulation requires only that the expansion exception request must “state” that the hospital does not discriminate against beneficiaries of Federal health care programs and does not permit physicians practicing at the hospital to discriminate against such beneficiaries. The existing regulation requires only that the expansion exception request must “state” that the hospital does not discriminate against beneficiaries of Federal health care programs and does not permit physicians practicing at the hospital to discriminate against such beneficiaries. In the proposed rule, we stated that, although we believe that most parties would understand that we require the requesting hospital to show that it meets this applicable hospitals (proposed § 411.363(c)(3)) and high Medicaid facilities (proposed § 411.363(d)(3)), for clarity, we proposed to revise the regulation to expressly require a statement that explains how the hospital meets the criterion (as opposed to merely stating that it meets the criterion).

In the proposed rule, we observed that the needs of all patients, but especially Medicaid beneficiaries and other underinsured or underserved populations, for specialty care—such as maternity, psychiatric, and substance use disorder care—often go unaddressed. Both the Department and CMS have prioritized improving access to maternal health services, psychiatric care, and substance use disorder treatment. (See, for example, the White House Blueprint for Addressing the Maternal Health Crisis, https://www.whitehouse.gov/wp-content/uploads/2022/06/Maternal-Health-Blueprint.pdf, and CMS Behavioral Health Strategy, https://www.cms.gov/cms-behavioral-health-strategy.) We explained that, in light of this, it is important to understand whether and how a hospital requesting an expansion exception could improve access for underserved populations to these critically necessary services for underserved populations if the request is approved. Therefore, we proposed to require that, in addition to the documentation supporting the hospital’s calculations of its baseline facility capacity, the hospital’s current facility capacity, and the number of operating rooms, procedure rooms, and beds by which the hospital is requesting to expand that is currently required at existing § 411.362(c)(4)(ii)(E), the expansion exception request must include information regarding whether and how the hospital has used any expansion facility capacity previously approved by CMS and whether it plans to use expansion facility capacity to provide specialty services if the request is approved. We proposed to include this revised requirement at § 411.363(e)(2)(vi) (renumbered from existing § 411.362(c)(4)(ii)(E)). After consideration of the comments and as described in section X.B.2.a.(8) of this final rule, we are not mandating the inclusion of this information in an expansion exception request.

Finally, we proposed to revise existing § 411.362(c)(4)(i)[j] and renumber it at § 411.363(e)(1)(viii) to require that the signed certification required under existing § 411.362(c)(4)(i)[j] be submitted electronically to CMS. Instead, all expansion exception requests would be submitted electronically to CMS according to the instructions specified on the CMS website. This is consistent with current agency practice with respect to other submissions, such as advisory opinion requests and submissions under the CMS Voluntary Self-Referral Disclosure Protocol (SRDP). Similarly, we proposed at § 411.363(e)(1) to require that the signed certification required under existing § 411.362(c)(4)(i)[j] and proposed § 411.363(e)(3) be submitted only in electronic form and according to the instructions specified on the CMS website. For consistency with the SRDP,
which also requires specific certifications related to submissions to CMS, we proposed to revise the definition of "authorized representative" at proposed § 411.363(e)(3) to mean the chief executive officer, chief financial officer, or other individual who is authorized by the hospital to make the request.

(5) Community Input

Existing § 411.362(c)(5) implements the mandate at section 1877(i)(3)(A)(ii) of the Act that the expansion exception process provides individuals and entities in the community in which the requesting hospital is located with the opportunity to provide input with respect to the request. As we stated in the proposed rule, we believe that the Congress intended for hospitals, patients, and others that are most likely to be affected by the expansion of the requesting hospital to have input in CMS' decision whether to approve or deny the request, as well as to provide information that may confirm or refute the requesting hospital's claim that it meets the criteria for an applicable hospital or a high Medicaid facility. We noted that our current regulations do not define the "community" in which the requesting hospital is located. To eliminate uncertainty, we proposed to define the requesting hospital's "community" at proposed § 411.363(f)(3)(ii) to include the geographic area served by the hospital, as defined at § 411.357(e)(2) of our regulations, and the counties in which the requesting hospital's main campus is located, the requesting hospital provides inpatient or outpatient hospital services as of the date the hospital submits the expansion exception request, and the requesting hospital plans to provide inpatient or outpatient hospital services if CMS approves the request. We highlighted that certain exceptions to the physician self-referral law's prohibitions identify the geographic area served by a hospital to define the location where specified activity may occur (for example, the location of a recruited physician's medical practice) and stated that we believe that it is desirable to employ a consistent approach to identifying a hospital's service area for purposes of our exceptions and identifying which individuals and entities are eligible to provide input related to an expansion exception request. As explained in section X.B.2.a.(8), of this final rule, we are not finalizing our proposal to include "community" the counties in which the requesting hospital plans to provide inpatient or outpatient hospital services as of the date the hospital submits the expansion exception request.

We also proposed at § 411.363(f)(2) that the requesting hospital must provide actual notification that it is requesting an expansion exception directly to hospitals whose data are part of the comparisons required to determine whether the hospital meets the criteria for an applicable hospital or a high Medicaid facility and to hospitals located in the requesting hospital's community. Thus, hospitals in the requesting hospital's community that wish to provide input related to the expansion exception request would be aware of the request. As explained in in section X.B.2.a.(8), of this final rule, we are not finalizing our proposal to require actual notification directly to any hospital whose data are not part of the comparisons required to determine whether the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility (depending on the specific request). In the proposed rule, we recognized that, by defining the requesting hospital's "community" input from individuals and entities that are not located in the defined areas could be excluded from consideration by CMS when reviewing a hospital's expansion exception request. We stated that, if this proposal was finalized, we would encourage parties that wish to have their input considered to address how they are part of the requesting hospital's community in their submissions.

In the proposed rule, we noted our existing policy that the type of community input that we will accept is not restricted in any way (76 FR 74522). To support the two-step process for first determining whether a requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility and, if so, deciding whether to approve or deny the request, we proposed to revise existing § 411.362(c)(5) and renumber it at § 411.363(f)(3)(i) to provide a 60-day period following the publication of the notice of the expansion exception request in the Federal Register for the submission of community input. We stated that we did not believe that an extension of the 30-day period for the requesting hospital to submit a rebuttal statement was necessary but sought comment regarding whether we should extend this timeframe to 60 days to provide the requesting hospital additional time to review and respond to any community input.

(6) Permissible Data Sources

When we first established the expansion exception process, we required the use of data from the Healthcare Cost Report Information System (HCRIS) to perform the calculations necessary to show that a hospital meets the criteria for an applicable hospital or a high Medicaid facility (76 FR 74518 through 74521). Following the implementation of the expansion exception process in 2012, hospitals and their representatives informed us of certain limitations regarding the required use of HCRIS data, and our own review confirmed that HCRIS was not sufficiently complete for all hospitals that wished to request an expansion exception to have access to the process because, at that time, HCRIS did not capture Medicaid managed care admissions or discharge data. We also recognized that, if all hospitals in the county in which the requesting hospital is located did not have Medicaid provider agreements during each of the years for which comparisons are required, the
requesting hospital would be unable to show that it met the statutory and regulatory criteria as an applicable hospital or a high Medicaid facility because HCRIS contains only the data of hospitals that participate in Medicare (79 FR 66988). To address the limitations regarding the required use of HCRIS data, in the CY 2015 OPPS/ASC final rule, we modified the expansion exception process to permit the use of external data sources for the calculations necessary to estimate inpatient Medicaid admissions (79 FR 66988 through 66993). Around the same time, CMS revised the hospital cost report to require reporting of Medicaid managed care discharges in addition to Medicaid fee-for-service discharges (79 FR 66990). In the CY 2015 OPPS/ASC final rule, we stated that, as a result of this revision, a correctly completed hospital cost report will include Medicaid managed care discharges; at some point in the future, HCRIS should be sufficiently complete to estimate the percentages of Medicaid inpatient admissions required under the statute and our regulations; and the limitations that led to permitting the use of external data sources will be resolved (Id.). Therefore, we modified our regulations at existing §411.362(c)(2)(ii) and (c)(3)(ii) to permit the use of external data sources only until such time that the Secretary determines that HCRIS contains sufficiently complete inpatient Medicaid discharge data.

In the proposed rule, we announced that HCRIS now contains sufficiently complete inpatient Medicaid discharge data to complete the calculations to estimate Medicaid inpatient admissions, both as currently required and as would be required if we finalized our proposals to revise the expansion exception process. Although the regulations at existing §411.362(c)(2)(ii) and (c)(3)(ii) do not require the Secretary to announce his determination that HCRIS contains sufficiently complete inpatient Medicaid discharge data through notice-and-comment rulemaking, we proposed at §411.363(c)(2) and (d)(2) to eliminate the use of external data sources for purposes of the expansion exception process with respect to requests submitted on or after the effective date of the revised regulations if our proposals were finalized. As we stated in the CY 2012 OPPS/ASC final rule, we believe that requiring the use of filed Medicare hospital cost report data from HCRIS for all expansion exception requests will result in the use of uniform and consistent data, which will minimize inconsistent application of the criteria for applicable hospitals and high Medicaid facilities (76 FR 74518).

We recognize that requiring the use of filed Medicare hospital cost report data from HCRIS for all expansion exception requests will not resolve every issue identified in the CY 2015 OPPS/ASC proposed and final rules (79 FR 66988). For example, all the hospitals to which the requesting hospital must compare itself (the comparison hospitals) may not have participated in Medicare in all years for which comparisons are required. As explained in the proposed rule (88 FR 27181 through 27182) and in this section X.2.B.a.(6), if Medicaid inpatient admissions data is not available for every hospital in a county for a particular comparison year, it would be impossible for any hospital in that county to meet the criteria for an applicable hospital or a high Medicaid facility under section 1877(i)(3)(E) or (F) of the Act, respectively, during the period when the use of data from that comparison year is required under the statute and our regulations. We do not believe that the Congress intended that a hospital that meets the criteria for an applicable hospital or a high Medicaid facility and is willing to expand in a community where there is a clear need for additional facility capacity would be foreclosed from doing so because one or more of the other hospitals in its community did not participate in Medicare (or if Medicaid inpatient admissions data was otherwise unavailable for all hospitals in the county in which the requesting hospital is located). Therefore, even though sections 1877(i)(3)(E)(ii) and (F)(ii) of the Act necessitate the use of data regarding Medicaid inpatient admissions for each hospital in the county in which the requesting hospital is located, using our authority at sections 1871 and 1877 of the Act, we proposed that the comparisons required to show that a hospital meets the Medicaid inpatient admissions criteria for an applicable hospital at proposed §411.363(c)(2) or a high Medicaid facility at proposed §411.363(d)(2) must be made using only data from those hospitals that have a Medicare participation agreement with CMS. In the proposed rule, we stated that we consider our proposal to align with the intent of the Congress in establishing the criteria for applicable hospitals and high Medicaid facilities and are confident that it would provide a robust comparison that allows CMS to be sure the requesting hospital has a history of providing Medicare beneficiaries, uninsured patients, and other underserved populations. We further stated that we believe that our proposal to permit only the use of filed Medicare hospital cost report data from HCRIS for purposes of the calculations required at proposed §411.363(c)(2) and (d)(2) while requiring comparisons only to hospitals that have a Medicare provider agreement with CMS strikes the appropriate balance between effectuating the intent of the statute and requiring strict compliance with the exact standards set forth in sections 1877(i)(3)(E)(ii) and (F)(ii) of the Act. As we stated in the proposed rule, we anticipate that requiring the use of filed Medicare hospital cost report data from HCRIS for all comparison calculations will have little practical impact on whether a requesting hospital meets the criteria for an applicable hospital or high Medicaid facility and that we do not believe that a requesting hospital would be prejudiced by this requirement.

We also proposed to revise the terminology used in our regulations to describe the comparisons that a hospital requesting an expansion exception must make to show that it is an applicable hospital or a high Medicaid facility. We did so solely for consistency in the terminology: we do not view this as a change to our interpretation of the statutory requirements for the comparisons. Section 1877(i)(3)(E) of the Act defines the term "applicable hospital" and section 1877(i)(3)(F) of the Act defines the term "high Medicaid facility." With respect to Medicaid inpatient admissions, an applicable hospital is a hospital whose annual percent of Medicaid inpatient admissions is equal to or greater than the average percent with respect to such admissions for "all" hospitals located in the county where the hospital is located, and a high Medicaid facility is a hospital that, with respect to each of the 3 most recent years for which data are available, has an annual percent of Medicaid inpatient admissions that is greater than the percent of such admissions for "any other" hospital in the county. Our existing regulations use the terms "all" hospitals (with respect to applicable hospitals) and "every" hospital (with respect to high Medicaid facilities). In setting forth the permissible data sources to be used for making the required comparisons, our existing regulations use the term "all" hospitals (with respect to applicable hospitals) and "every" hospital (with respect to high Medicaid facilities). We interpret the statute to mean that a hospital requesting an expansion exception as an applicable hospital must use data for itself and...
each of the other hospitals in the county in which it is located to determine the county average for Medicare inpatient admissions, and a hospital requesting an expansion exception as a high Medicaid facility must compare itself to each of the other hospitals in the county in which it is located. We do not view the term “any other”—as used in section 1877(i)(3)(F) of the Act—and the terms “each,” “every,” and “every other”—as used in our existing regulations—to have disparate meanings or refer to different subsets of comparison hospitals. However, for consistency and to eliminate any misinterpretation of the comparison requirements, we proposed to revise the references in our regulations to refer to “each” or “each other” hospital (where appropriate). We did not propose to revise the reference in existing § 411.362(c)(2)(ii) (with respect to applicable hospitals) to the average percent of Medicare inpatient admissions for “all” hospitals located in the county where the requesting hospital is located, as the existing language is consistent with the required comparison. However, for clarity, we proposed at renumbered § 411.363(c)(2) to expressly state that the requesting hospital’s percent of Medicare inpatient admissions must be included with the percent of Medicare inpatient admissions for each of the other hospitals in the county when determining the average percent of Medicare inpatient admissions for “all” hospitals in the county in which the requesting hospital is located.

Under proposed § 411.363(c)(2), to meet the Medicaid inpatient admissions criterion for an applicable hospital, the requesting hospital must have an annual percent of total inpatient admissions under Medicaid that is equal to or greater than the average percent with respect to such admissions for all hospitals (including the requesting hospital) that have a Medicare participation agreement with CMS and are located in the county in which the requesting hospital is located. The proposed regulation provided that the most recent 12-month period for which data are available means the most recent 12-month period for which the data source used contains all data from the requesting hospital and each other hospital that has a Medicare participation agreement with CMS and is located in the county in which the requesting hospital is located. We noted that, with respect to requests submitted on or after the effective date of the revised regulations if our proposals were finalized, a hospital may use only filed Medicare hospital cost report data from HCRIS to estimate its annual percent of total inpatient admissions under Medicaid and the average percent with respect to such admissions for all hospitals (including the requesting hospital) in the county in which the hospital is located. Under proposed § 411.363(d)(2), to meet the Medicaid inpatient admissions criterion for a high Medicaid facility, with respect to each of the three most recent 12-month periods for which data are available as of the date the hospital submits its request, the requesting hospital must have an annual percent of total inpatient admissions under Medicaid that is estimated to be greater than such percent with respect to such admissions for each other hospital that has a Medicare participation agreement with CMS and is located in the county in which the requesting hospital is located. The proposed regulation provided that the most recent 12-month period for which data are available means the most recent 12-month period for which the data source used contains all data from the requesting hospital and each other hospital that has a Medicare participation agreement with CMS and is located in the county in which the requesting hospital is located. We noted that, with respect to requests submitted on or after the effective date of the revised regulations if our proposals were finalized, a hospital may use only filed Medicare hospital cost report data from HCRIS to estimate its annual percent of total inpatient admissions under Medicaid and the average percent with respect to such admissions for all hospitals (including the requesting hospital) that have a Medicare participation agreement with CMS and are located in the county in which the requesting hospital is located.

In the proposed rule, we recognized that it is possible that a facility that is provider-based to a hospital is located in a county other than the county in which the main campus of the hospital is located. To provide clarity for purposes of completing the necessary calculations to demonstrate that a hospital meets the criteria for an applicable hospital or a high Medicaid facility, we proposed at § 411.363(c)(6) (for an applicable hospital) to consider the location of a hospital to be the county and State in which the main campus of the hospital is located and at § 411.363(d)(4) (for a high Medicaid facility) to consider the location of a hospital to be the county in which the main campus of the hospital is located. This would apply to the requesting hospital and any hospital to which the requesting hospital must compare itself for purposes of the calculations related to percentage increase in population, Medicare inpatient admissions, average bed capacity, and average bed occupancy rate.

(7) Timing of a Complete Request

In the CY 2015 OPPS/ASC final rule, in addition to expanding the permissible data sources a hospital may use to show that it meets the criteria for an applicable hospital or a high Medicaid facility, we also amended the expansion exception process to increase the period of time after which an expansion exception request will be deemed complete when an external data source is used by a requesting hospital or in the community input to determine whether a hospital meets the criteria for an applicable hospital or a high Medicaid facility, reasoning that it is possible (if not likely) that, when reviewing an expansion exception request, CMS would need to verify the data (and other information, if any) provided by the requesting hospital and any commenters, as well as consider the data in light of the information otherwise available to CMS (79 FR 66995). Because we proposed at § 411.363(c)(2) and (d)(2) that only filed Medicare hospital cost report data from HCRIS may be used to show that the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility, in the proposed rule, we stated that we did not believe that we would continue to need the full 180 days currently provided for at existing § 411.362(c)(5)(ii) to deem an expansion exception request complete. Therefore, we proposed to revise and renumber this regulation to deem an expansion exception request complete no later than 90 days after the end of the 60-day comment period if CMS does not receive written comments from the community, or no later than 90 days after the end of the rebuttal period, regardless of whether the requesting hospital submits a rebuttal statement, if CMS receives written comments from the community. We proposed that the regulation would be renumbered at § 411.363(g), which would also include other existing regulations related to the timing of a complete expansion exception request, amended to recognize the proposed increase to a 60-day period for community input. Because the data used for the Medicaid inpatient admissions comparisons, as well as the data for the other calculations required under the expansion exception process, would be
maintained by CMS, we stated that we believed that 90 days would be sufficient to review the data and information in the expansion exception request, community input (if any), and rebuttal statement (if any) regarding whether the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility and whether CMS should approve or deny the request. We also stated that our proposals would not affect expansion exception requests submitted before the effective date of the revised regulations if our proposals were finalized.

(8) Provisions of the Final Rule: Expansion Exception Process

We received comments both in support of and opposition to our proposals to modify and clarify the process for requesting an exception from the prohibition on facility expansion. Many of the assertions and suggestions made by commenters were founded on the commenter’s view of whether section 1877(i) of the Act authorizes the Secretary to deny an expansion exception request from a hospital that meets the criteria for an applicable hospital or a high Medicaid facility. Some commenters agreed with CMS that the statute confers discretion for CMS to deny a request for an expansion exception even if the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility. These commenters viewed our proposals to identify the information required from a requesting hospital and the factors that CMS will consider in deciding whether to approve or deny an expansion exception request as bringing transparency to the expansion exception process to ensure that all parties are treated comparably in the process. Other commenters interpreted the statute to mean that CMS may not prohibit a hospital from expanding if the hospital meets the statutory criteria for an applicable hospital or a high Medicaid facility and completes any procedural requirements established by CMS under section 1877(i) of the Act. Because of this foundational view, these commenters viewed our proposals as adding criteria to the definitions of “applicable hospital” and “high Medicaid facility.”

We are finalizing our proposals with modifications. Under the final rule, we are establishing a new § 411.363 that will include the expansion exception process and, therefore, removing existing § 411.362(c) from our regulations. At § 411.363(a), we are including for purposes of the expansion exception process. At § 411.363(b), we are finalizing our proposal to expressly state that CMS will not consider an expansion exception request from a hospital that is not eligible to request the exception. Under the final regulation, a hospital that meets the criteria for an applicable hospital or a high Medicaid facility is eligible to request an expansion exception, provided that: (i) the hospital has not already been approved by CMS for an expansion exception that would allow the hospital to reach 200 percent of its baseline facility capacity; and (ii) it has been at least 2 calendar years from the date of the most recent decision by CMS approving or denying the hospital’s most recent expansion exception. We note that, because section 1877(i)(3)(C)(ii) of the Act prohibits CMS from approving an increase in a hospital’s facility capacity to the extent such increase would result in the hospital’s facility capacity exceeding 200 percent of its baseline facility capacity, CMS could not approve further expansion of a hospital that CMS has already approved to expand to 200 percent of its baseline facility capacity. Therefore, under the final regulation at § 411.363(b)(2)(I), such a hospital would be ineligible to request an additional expansion exception. To consider an expansion exception request that CMS is prohibited to approve would not be an appropriate use of agency and other Federal resources.

Final § 411.363(c) states the criteria that a hospital must meet to be an applicable hospital. In addition to incorporating the existing criteria for an applicable hospital, the final regulation provides that, for purposes of the statute, CMS will require comparisons with respect to Medicaid inpatient admissions, the hospital need only compare itself to other hospitals that have a Medicare participation agreement with CMS and are located in the county in which the hospital is located. The final regulation also clarifies that a hospital is located in the county in which the main campus of the hospital is located. In addition, beginning with expansion exception requests submitted on or after October 1, 2023, the requesting hospital may use only filed Medicare cost report data from HCRIS to perform the required calculations. Final § 411.363(d) states the criteria that a hospital must meet to be a high Medicaid facility. In addition to incorporating the existing criteria for high Medicaid facilities, the final regulation provides that, for purposes of the statute, CMS will require comparisons with respect to Medicaid inpatient admissions, the hospital need only compare itself to other hospitals that have a Medicare participation agreement with CMS and are located in the county in which the hospital is located. The final regulation clarifies that a hospital is located in the county in which the main campus of the hospital is located. In addition, beginning with expansion exception requests submitted on or after October 1, 2023, the requesting hospital may use only filed Medicare cost report data from HCRIS to perform the required calculations.
expansion facility capacity to provide specialty services if the request is approved. Likewise, a hospital may, but is not required to, submit information regarding the current or future need for additional operating rooms, procedure rooms, or beds for itself, in the county where its main campus is located, or in any county where it provides inpatient or outpatient hospital services (that is, in any county in which one or more of its hospital-based facilities, if any, is located). We believe that the final regulations reduce the burden on a hospital that seeks approval for an expansion of its facility capacity while providing an opportunity to submit additional information that it wishes CMS to consider. We emphasize the fact that a hospital elects not to provide information beyond what is required under §411.363(e)(2) will not factor into CMS’ decision to approve or deny the request.

We are also finalizing our proposals regarding the community input that may be provided with respect to an expansion exception request. First, we are finalizing the definition of “community” at §411.363(f)(3)(ii) to mean all of the following: the geographic area served by the hospital (as defined at §411.357(e)(2) of our regulations); the county in which the requesting hospital’s main campus is located; and the counties in which the requesting hospital provides inpatient or outpatient hospital services as of the date that it submits its request. Final §411.363(f)(1) replicates our existing process by requiring that, upon submitting a request for an expansion exception and until the hospital receives a CMS decision on the request, the hospital must disclose on any public website for the hospital that it is requesting the expansion exception. However, we are making one notable modification in the final regulations. At §411.363(f)(2), we are requiring the hospital to request the expansion exception to provide actual notification of its request only to hospitals whose data are part of the comparisons required to show that it meets the criteria for an applicable hospital or a high Medicaid facility. The notice must be provided directly to these hospitals. We are not finalizing our proposal to require that the requesting hospital also provide actual notice directly to hospitals that are located in the remainder of the requesting hospital’s community (as defined at §411.363(f)(3)(ii)). Lastly, we are finalizing our proposal to extend the period for community input from the current 30 days to 60 days. Based on the comments received on this proposal, at §411.363(f)(3)(iv), we are also extending the period for the requesting hospital to submit a rebuttal statement from the current 30 days to 60 days.

We are finalizing our proposal that, no later than 60 days after an expansion exception request is deemed complete, CMS will publish its determination whether the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility and, if so, its decision whether to approve or deny the request. In keeping with final §411.363(f)(2)(ii) and (d)(2)(ii), which require the use of CMS-provided Medicare filed Medicare hospital cost report data from HCRIS for all expansion exception requests submitted on or after October 1, 2023, we are finalizing our proposal to deem a request complete no later than 90 days after the end of the comment period if we do not receive community input or, if we do receive community input, 90 days after the end of the rebuttal period, regardless of whether the requesting hospital submits a rebuttal statement. For expansion exception requests that are submitted prior to October 1, 2023, and include data from an external data source in the expansion exception request, community input, or the hospital’s rebuttal statement, the request will continue to be deemed complete no later than 180 days after the end of the comment period if we do not receive community input or, if we do receive community input, 180 days after the end of the rebuttal period, regardless of whether the requesting hospital submits a rebuttal statement. We are also finalizing the regulations at §411.363(h) and (i) to clarify that CMS will take a two-step approach to considering expansion exception requests. First, CMS will determine whether the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility using the information provided by the hospital in its expansion exception request and rebuttal statement, if any, and the community input, if any. Second, using data and information provided from these sources, as well as data and information that is otherwise available to CMS and relevant to its decision, CMS will decide whether to approve or deny the expansion exception request. Final §411.363(i)(2) identifies the factors that CMS will consider in deciding whether to approve or deny a hospital’s request for an expansion exception. These factors include: (i) the specialty of the requesting hospital or the services it desires to provide (if to be furnished by the hospital if CMS approves the expansion exception request; (ii) program integrity or quality of care concerns related to the hospital; (iii) whether the hospital has a need for additional operating rooms, procedure rooms, or beds; and (iv) whether there is a need for additional operating rooms, procedure rooms, or beds in the county in which the main campus of the hospital is located or in any county in which the hospital provides inpatient or outpatient hospital services as of the date the hospital submits the request. As §411.363(i)(2) expressly states, CMS is not limited to consideration of these factors in deciding whether to approve or deny a hospital’s expansion exception request.

At §411.363(k), we are finalizing our proposal regarding the information that will be published in the Federal Register following CMS’ consideration of an expansion exception request. Specifically, if CMS determines that the hospital does not meet the criteria for an applicable hospital or a high Medicaid facility, CMS will publish in the Federal Register notice of such determination. If CMS determines that the hospital meets the criteria for an applicable hospital or a high Medicaid facility, CMS will publish in the Federal Register notice of such determination and its decision regarding the hospital’s request for an expansion exception. At §411.363(l), we are finalizing our proposal to codify that, under section 1877(q)(3)(I) of the Act, there is no administrative or judicial review under section 1869 of the Act, section 1878 of the Act, or otherwise of the process under this section (including the establishment of such process and any CMS determination or decision under such process).

To facilitate readers’ understanding of our final policies, we provide here a high-level summary of the expansion exception process as finalized. Under the regulations finalized in this final rule, a hospital may submit its expansion exception request to CMS. CMS will confirm that the request includes all required information and that CMS is not proceeding considering the expansion exception request under final §411.363(b)(2)(i) or (ii). CMS will also confirm the accuracy of the required calculations as we do under the existing process. If the requesting hospital has performed the required calculations incorrectly, CMS will continue its current practice and inform the hospital of the error(s) and work with the hospital to ensure the required calculations are performed correctly. After these steps are completed, if the hospital does not withdraw the expansion exception request, CMS will publish notice of the
expansion exception request in the Federal Register. Community input may be submitted during the 60-day comment period as set forth at final § 411.363(f). If CMS receives community input on the expansion exception request, it will be provided to the requesting hospital. Under final § 411.363(f)(3)(iv), the hospital will have 60 days to submit a rebuttal statement if it chooses to do so. Following the receipt of community input (if any) and the hospital’s rebuttal statement (if any), CMS will determine whether the hospital meets the criteria for an applicable hospital or a high Medicaid facility. If the hospital meets the criteria for an applicable hospital or a high Medicaid facility, CMS will then consider the factors identified at § 411.363(i)(2) and decide whether to approve or deny the expansion exception request. CMS will publish notice of its determination whether the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility in the Federal Register. If CMS determines that the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility, CMS will also publish notice of its decision to approve or deny the expansion exception request in the same Federal Register notice.

We received the following comments on our proposals to revise and clarify the expansion exception process. Our responses follow.

Comment: We received comments regarding our interpretation of section 1877(i)(3) of the Act as affording the Secretary the discretion to approve or deny a hospital’s request for an expansion exception. Many commenters endorsed our interpretation of the statute, concurring that the language of section 1877(i)(3) of the Act provides CMS with discretion to consider and ultimately approve or deny requests for expansion exceptions, even if the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility. One of these commenters stressed that CMS’ interpretation of its authority is consistent with the statutory requirement for the Secretary to implement a process under which an applicable hospital or high Medicaid facility may “apply” for an exception from the prohibition on facility expansion and the statutory language referencing the “grant” of exceptions. Other commenters disagreed with our interpretation of the authority granted to the Secretary in section 1877(i)(3) of the Act. These commenters interpreted the statute as prohibiting the Secretary from denying a request for an expansion exception from a hospital that meets the criteria for an applicable hospital or a high Medicaid facility. One of these commenters described CMS’ assessment that the words “apply,” “granted,” “permit,” and “decision” support a statutory grant of authority to approve or deny an application (that is, request) for an expansion exception as a contrived contortion of the English language, and further described our interpretation of CMS’s authority as overriding an unambiguous statutory scheme in order to supersede it with the preferred policy of certain trade associations and competitors of physician-owned hospitals. This commenter interpreted the language of sections 1877(i)(3)(E) and (F) of the Act, which set forth the definitions of an “applicable hospital” and a “high Medicaid facility,” respectively, as establishing two expansion exceptions, which are automatically granted to any applicable hospital or high Medicaid facility that completes the procedural steps established by the Secretary under section 1877(i)(3)(A) of the Act. Another commenter asserted that nothing about establishing a process to grant expansion exceptions connotes discretion to approve or deny them. Both of these commenters asserted that, because section 1877(i)(3)(A)(i) of the Act directs the Secretary to establish and implement a process under which a hospital that meets the criteria for an applicable hospital or a high Medicaid facility “may” apply for an exception from the prohibition on facility expansion, the statute affords discretion to the requesting hospital (that is, discretion to apply or not to apply for an expansion exception) but not to the Secretary.

Response: We are not persuaded by the arguments of the commenters that disagree with our interpretation of the authority granted to the Secretary in section 1877(i)(3) of the Act or that our reading of the statute’s use of the terms “apply,” “granted,” “permit,” and “decision” is a contrived contortion of the English language. As we stated in the proposed rule, section 1877(i)(3)(A)(i) of the Act directs CMS to establish a process under which an applicable hospital or a high Medicaid facility may apply for an exception from the prohibition on facility expansion, and section 1877(i)(3)(C)(i) of the Act imposes certain program integrity restrictions on a hospital granted an exception under the process (emphasis added). The Secretary’s authority to grant an expansion exception is limited by section 1877(i)(3)(C)(ii) of the Act, which states that the Secretary shall not permit an increase in the number of operating rooms, procedure rooms, and beds for which the hospital is licensed that results in a hospital’s facility capacity exceeding 200 percent of its baseline facility capacity. In addition, section 1877(i)(3)(H) of the Act requires the Secretary to publish in the Federal Register the final decision with respect to a hospital’s application. The dictionary definition of the term “apply” in this context is “to make a formal request or petition, usually in writing, to a court, officer, board, or company, for the granting of some favor, or of some rule or order, which is within his or their power or discretion.” Further, Black’s Law Dictionary (2nd ed. 1910) defines the term “apply” to mean “to make an appeal or request, especially in the form of a written application.” As we noted in the proposed rule, we use the term “apply” in the same way as the term “request” (88 FR 27177), which is supported in these definitions.) It follows that, in the case of a submitted application, a decision to approve or deny the application would be expected from the party that holds the discretion to grant the requested action. The dictionary definition of the term “grant” in this context is “to give something that is asked for, especially formal or legal permission to do something” or “to permit as a right, privilege, or favor.” In addition, the dictionary definition of “permit” in this context is “to consent to, expressly or formally.” Essentially, the terms “grant” and “permit” are synonymous, and both require the action or decision of the party to whom the application or request is made. The dictionary definition of “decision” in this context is “a determined result arrived at after consideration.” Even though the terms “approve” and “deny” do not appear in the text of section 1877(i)(3) of the Act, the plain meanings of the terms that are used in section 1877(i)(3) of the Act are reasonably interpreted to confer discretion to approve or deny an expansion exception request made to CMS. We believe that this is the best interpretation of the statute. Accordingly, we also disagree with the
commenters that the definitions of the terms “applicable hospital” and “high Medicaid facility” in sections 1877(i)(3)(E) and (F) of the Act merely establish an automatic authorization to expand facility capacity for any hospital that meets the criteria of one of these sections, rendering the Secretary powerless to deny an expansion exception request from a hospital that completes any procedural steps set forth in our regulations.

We agree with the commenters that section 1877(i)(3)(A)(i) of the Act affords certain discretion to the requesting hospital (that is, discretion to apply or not to apply for an expansion exception). This provision clearly does not mandate that a hospital request an expansion exception at any given time or ever. However, we disagree that this is the only discretion that the statute affords. For the reasons discussed in this final rule, we interpret section 1877(i)(3) of the Act to also afford the Secretary discretion to approve or deny an expansion exception request made to CMS.

Comment: One commenter asserted that CMS had previously made clear that CMS may not consider criteria not in the statute when reviewing an expansion exception request and, therefore, may not finalize its proposals based on the interpretation of the Secretary’s statutory authority set forth in the proposed rule. The commenter cited a CMS 2015 statement that it cannot consider any concerns raised in the community input that are unrelated to the statutory eligibility criteria when determining whether to grant an exception to a requesting hospital (80 FR 55852). The commenter also cited CMS’ statement that, if a hospital qualifies as an applicable hospital or a high Medicaid facility, CMS does not have the discretion to grant less than the requested increase in facility capacity (Id.).

Response: The specific language cited by the commenter appeared in a decision notice published in the Federal Register announcing CMS’ approval of an expansion exception request. We understand the commenter to suggest that CMS is permanently bound by the statement in the 2015 notice. We disagree. An essential function of the agency is to implement the statute as enacted by the Congress. Assessing and, as necessary, reassessing the statutory authority granted to the Secretary is a critical step in implementing any statutory provision. As we stated in the proposed rule, we recently reviewed the expansion process, including a fresh examination of the statutory language and certain legislative history of the Affordable Care Act. The policies announced in this final rule supersede any prior statements regarding CMS’ authority to approve or deny an expansion exception request. For all expansion exception requests submitted on or after October 1, 2023, receiving approval for an exception from the prohibition on expansion of facility capacity at section 1877(i)(B) of the Act is a two-step process. Meeting the criteria for an applicable hospital or a high Medicaid facility is the first step and makes a hospital eligible to request an expansion exception, subject to the limitations of final § 411.363(b)(2). The second step for approval of an expansion exception request requires a decision by CMS after consideration of the data and information provided by the hospital in its request and rebuttal statement (if any), the community input (if any), and data and information otherwise available to CMS and relevant to its decision.

Comment: We received two comments asserting that the statutory criteria that a hospital must meet to be an applicable hospital or a high Medicaid facility are the same and only criteria that must be met for a hospital to be granted an expansion exception. One of these commenters further asserted that CMS previously acknowledged that it did not have authority to create additional criteria for classification as an applicable hospital or high Medicaid facility.

Response: We disagree with the commenters that a hospital is entitled to an expansion exception merely because it meets the definition of an “applicable hospital” or a “high Medicaid facility.” The plain language of section 1877(i)(3)(A) of the Act anticipates that an applicable hospital or a high Medicaid facility must apply for an expansion exception. It is our position that, when a hospital applies for an expansion exception request, it is making a request to CMS to grant permission for the hospital to expand its facility capacity without violating the prohibition set forth in section 1877(i)(1)(B) of the Act. We have considered the assertions of the commenters but are not persuaded to adopt their view that the use of the word “apply” in the statute is akin to exercising a right to an expansion exception for a hospital that meets the definition of an “applicable hospital” or a “high Medicaid facility.”

As we explained in the proposed rule and in section X.B.2.a. of this final rule, we interpret section 1877(i)(3) of the Act to mean that a hospital must first establish that it meets the criteria for an applicable hospital or a high Medicaid facility and, if it does, it may request—but is not guaranteed—an exception from the prohibition on facility expansion. With respect to the comment regarding authority to create additional criteria for classification as an applicable hospital or high Medicaid facility, we agree that sections 1877(i)(3)(E) and (F) of the Act define the terms “applicable hospital” and “high Medicaid facility,” respectively, do not authorize CMS to establish additional criteria in regulation that a hospital must meet to be an applicable hospital or high Medicaid facility. We did not propose to do so (88 FR 27178 through 27179), nor are we finalizing regulations that establish criteria beyond the statutory criteria for applicable hospitals and high Medicaid facilities. Rather, our proposals and final policies establish the sources of information and factors that CMS will consider when deciding whether to approve or deny an expansion exception request.

Comment: We received little comment on our proposal to permit only the use of filed Medicare hospital cost report data from HCRIS to show that a hospital meets the criteria for an applicable hospital or high Medicaid facility, although one commenter expressed support for the proposal as it would standardize data sources for all interested parties.

Response: In accordance with existing § 411.362(c)(2)(ii) and (c)(3)(ii), we announced in the proposed rule the Secretary’s determination that HCRIS now contains sufficiently complete inpatient Medicare discharge data to perform the calculations to estimate Medicare inpatient admissions as required under both our existing expansion exception process and under this final rule (88 FR 27182). For the reasons explained in the CY 2012 OPPS/ASC final rule—namely, that requiring the use of filed Medicare hospital cost report data from HCRIS for all expansion exceptions will result in the use of uniform and consistent data, which will minimize inconsistent application of the criteria for applicable hospitals and high Medicaid facilities—we are finalizing our proposal to require the use of filed Medicare hospital cost report data from HCRIS in all expansion exception requests submitted on or after October 1, 2023.

Comment: We received comments generally in support of our proposed clarification of and revisions to the expansion exception process, as well as comments either opposed to or in favor of changes to the regulations that set forth the expansion exception process or the
statutory prohibition on the expansion of facility capacity in general. The commenters in support of the clarification and revisions cited benefits such as transparency, clarity, and uniform application of the process and CMS’ decision making if we finalize our proposals. The commenters opposed to the proposals asserted that they represent an unfair departure from CMS’ previously neutral stance in the friction between hospitals that have physician ownership and those that do not, and emphasized that hospitals with physician ownership or investment provide high-quality care, have high patient satisfaction ratings, and promote competition among health care providers. These commenters also suggested that the proposals, if finalized, would create barriers to access to care and lengthen the process for an applicable hospital or a high Medicaid facility to expand its facility capacity.

Response: The prohibition on the expansion of a hospital’s facility capacity in the rural provider exception and the whole hospital exception is statutory and may not be rescinded through regulation. The prohibition applies equally to any hospital seeking to use the rural provider exception or the whole hospital exception, regardless of whether the hospital provides high quality care, has high patient satisfaction scores, or promotes competition among health care providers. We are aware of the studies highlighted by commenters both in support of and opposition to our proposals. The policies that we are finalizing in this rulemaking do not represent an assessment of the quality or cost of care provided by any hospital, whether invested in by physicians or not, or the impact of any hospital on its local community or economy. We are not taking sides in what the commenter referred to as the friction between hospitals that have physician ownership and those that do not. CMS is statutorily obligated to establish a process for requesting an expansion exception, and we believe that providing transparency is essential to its implementation.

Further, we are not persuaded (and the commenter provided no support for its suggestion) that ensuring transparency by refining the process for making, considering, and deciding an expansion exception request would harm access to care for Medicare or Medicaid beneficiaries, uninsured patients, or other underserved populations. Finally, because we are limiting the data that may be used in an expansion exception request submitted on or after October 1, 2023, to filed Medicare hospital cost report data from HCRIS, which CMS makes readily available on its website, we believe that the final regulations that update the expansion exception process may shorten the period from receipt of an expansion exception request until the issuance of CMS’ decision on the request.

Comment: Two commenters objected to the proposed requirement that a requesting hospital must identify where and how it plans to provide inpatient or outpatient hospital services if CMS approves its expansion exception request. One of the commenters noted that a hospital may not know at the time of its request what its future expansion plans may entail.

Response: As explained in section X.B.2.b. of this final rule, we are finalizing our proposal to reinstate the program integrity restriction regarding the location of permitted expansion facility capacity. Consequently, all approved expansion facility capacity under an expansion exception request that is submitted on or after October 1, 2023, will be restricted to the main campus of the requesting hospital. Thus, it is unnecessary to request information regarding the location of any planned CMS-approved expansion of operating rooms, procedure rooms, or beds. To address the commenters’ concerns regarding the potential that a hospital may not know how it will use expansion facility capacity if CMS approves its expansion exception request, we are removing from the list of required information at § 411.363(e)(2)(vi) information regarding whether the hospital plans to use expansion facility capacity to provide specialty services if the request is approved. Instead, under final § 411.363(e)(3), a hospital may—but is not required to—provide this information in its expansion exception request. Also, we are not requiring information regarding the hospital’s need for additional facility capacity to serve Medicaid, uninsured, and underserved populations, or the need for additional operating rooms, procedure rooms, and beds in the county in which the main campus of the hospital is located or any county in which the hospital provides inpatient or outpatient hospital services as of the date the hospital submits its expansion exception request. Like information regarding the hospital’s planned use of any approved expansion facility capacity, this information is optional and may be submitted at the requesting hospital’s election.

Even though we are not finalizing our proposal to require information from a requesting hospital regarding its plans for any potential approved expansion facility capacity or the need for such expansion facility capacity, we remind readers that, as we stated in the proposed rule and prior rules, we believe that an important purpose of authorizing the Secretary to approve expansion of a hospital’s facility capacity is to allow limited growth of grandfathered hospitals in cases of clear community need (88 FR 27180 and 76 FR 74524). And, because the statutory criteria for an applicable hospital and a high Medicaid facility focus on Medicaid inpatient admissions, we believe that approved expansion facility capacity should be used, at least in part, to address the need for services to Medicaid and other underserved populations in the hospital’s community (88 FR 27180). It remains relevant to our decision with respect to an expansion exception request to ascertain whether the approval of the request could improve access to specialty services for populations whose need for such services often goes unaddressed. To the extent a requesting hospital has information regarding the need for additional facility capacity or is aware of its future plans for any approved expansion facility capacity, we welcome such information, but we emphasize that the fact that a hospital elects not to provide information beyond what is required under § 411.363(e)(2) will not factor into CMS’ decision to approve or deny the request.

Comment: We received several comments from parties that viewed proposed § 411.363(e)(2)(vi) and (vii), which (as proposed) set forth the information required to be included in an expansion exception request, and proposed § 411.363(i)(2), which sets forth factors that CMS would consider in deciding whether to approve or deny a hospital’s request for an expansion exception, as resembling, if not establishing, a Federal certificate of need (CON) program. In other words, the commenters viewed the proposed information requirements and factors as minimum thresholds that a requesting hospital must meet to prove that it deserves approval of its expansion exception request. Many of these commenters described CON programs as anti-competitive, time-consuming, and ineffective. One of these commenters questioned why CMS would require a Federal CON in instances where a hospital has been approved for expansion through a state CON process, while another expressed concern that the proposed factors could result in fewer approvals of expansion exception...
requests and diminished competition among hospitals.

Response: CMS is obligated to follow the statutory provisions of section 1877(i)(3) of the Act. The regulations finalized in this rulemaking are intended to support the purpose of the expansion exception process, which, as we stated in the proposed rule and the CY 2012 OPPS/ASC final rule, is to provide the opportunity to expand in areas where a sufficient need for access is demonstrated (88 FR 27184 and 76 FR 74524). The proposed regulations were not designed to make it harder for a hospital to obtain approval of an expansion exception request. To be clear, the proposed regulations were not intended to establish an actual or de facto Federal CON program or to establish minimum thresholds that must be met or maximum thresholds that may not be exceeded by a hospital to establish a showing of need for additional facility capacity. As the other commenters correctly assessed, the required information and enumerated factors were (and, as finalized, are) intended to aid a requesting hospital and interested parties in providing useful information that could assist CMS in deciding whether to approve or deny an expansion exception request.

We emphasize that the final regulations do not establish an actual or de facto Federal CON program or establish minimum thresholds that must be met or maximum thresholds that may not be exceeded by a hospital to establish a showing of need for additional facility capacity. We encourage hospitals to include in their expansion exception requests information (beyond the data showing that they meet the criteria for an applicable hospital or a high Medicaid facility) to support that there is a need for additional operating rooms, procedure rooms, and beds for the hospital to serve Medicaid, uninsured, and underserved populations, or generally in the county in which the main campus of the hospital is located or any other county in which the hospital provides inpatient or outpatient hospital services as of the date it submits its expansion exception request. A hospital requesting an expansion exception may include any information it considers relevant or useful to support its request, and is not limited to specific data points, such as bed occupancy levels or expected population growth, to support that there is a need for additional facility capacity. We also remind parties that the statutory prohibition on expansion of facility capacity limits only the expansion of the hospital’s aggregate number of operating rooms, procedure rooms, and beds.

Comment: Some commenters viewed our proposals to identify the information required from a requesting hospital and the factors that CMS will consider in deciding whether to approve or deny an expansion exception request as a tool to facilitate the provision of useful information from the requesting hospital and in the community input with respect to an expansion exception request. These commenters expressed appreciation for the transparency and specificity of the information and factors that CMS will consider in deciding whether to approve or deny an expansion exception request. Other commenters asserted that CMS’ consideration of anything other than whether the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility is inappropriate, if not impermissible. Some of these commenters specifically objected to proposed § 411.363(i)(1), which describes the sources of the data and information that CMS will consider in reviewing an expansion exception request, and includes data and information provided by the hospital in its request, included in the community input (if any), and provided by the hospital in its rebuttal statement (if any), and makes clear that CMS may also consider any other data and information relevant to its decision. One of these commenters expressed concern that CMS’ ability to consider data and information not provided by the hospital or the community input could result in arbitrary decisions whether to approve or deny expansion exception requests.

Response: As a preliminary matter, we note that the comments addressing our proposals to require particular information in an expansion exception request and to identify the factors that CMS will consider in deciding whether to approve or deny a hospital’s request were generally derivative of the commenter’s view of CMS’ statutory authority to deny an expansion exception request from a hospital that meets the criteria for an applicable hospital or a high Medicaid facility. That is, commenters that interpreted section 1877(i)(3) of the Act to authorize the Secretary to decide whether or not to grant an exception from the prohibition on expansion of facility capacity at section 1877(i)(1)(B) of the Act viewed our proposals as modifications and clarifications of the expansion exception process.

Comment: Some commenters interpreted the statute as prohibiting the Secretary from denying a request for an expansion exception from a hospital that meets the criteria for an applicable hospital or a high Medicaid facility viewed our proposals as unauthorized additional criteria to qualify as an applicable hospital or a high Medicaid facility and secure a hospital’s guaranteed right to expand.

We are pleased that some commenters recognized our intention to bring transparency and uniformity to the expansion exception process. We agree that communicating the factors that CMS will consider in deciding whether to approve or deny a hospital’s expansion exception request should assist hospitals and interested in parties with the preparation and submission of expansion exception requests and community input. We do not agree that the expansion exception process, as finalized, will result in inconsistent outcomes or arbitrary decisions to approve or deny expansion exception requests. Rather, we anticipate that, because expansion exception requests submitted on or after October 1, 2023, should include similar information (or categories of information) linked to the factors enumerated in § 411.363(i)(2), the final regulations identifying the information that is pertinent to our consideration of an expansion exception request will be assessed on a case-by-case basis, and we will consider the totality of the information available to CMS in deciding whether to approve or deny an expansion exception request (88 FR 27179). For each expansion exception request, CMS will consider the factors set forth in final § 411.363(i)(2), as well as any other information provided by the requesting hospital or in the community input. No single factor, data point, or other piece of information is dispositive to a decision. Of course, a lack of information regarding a particular factor or factors could impact
CMS’ decision with respect to an expansion exception request. We disagree that this will result in arbitrary decisions with respect to expansion exception requests. As required in section 1877(i)(3)(H) of the Act, CMS will publish a notice of each decision to approve or deny an expansion exception request in the Federal Register, and we will explain in detail the rationale for the approval or denial of the request in that notice.

Under the final regulations, the information that must be included in a request is identical to that required under the historical expansion exception process, with two exceptions. First, we are requiring at §411.363(e)(2)(iii) that the hospital provide an address where hard copy mail may be sent to the contact person identified as available to discuss the request with CMS on behalf of the hospital. Second, final §411.363(e)(2)(vi) requires the requesting hospital to submit documentation supporting whether and how the hospital has used any available expansion facility capacity approved in a prior request because this information is relevant to our decision to approve or deny an expansion exception request.

Knowing whether the hospital has unused, previously approved expansion facility capacity (or has the ability to return to its baseline facility capacity if it has reduced its aggregate number of operating rooms, procedure rooms, and beds below the baseline prior to the date it submits its expansion exception request) will help us assess whether the hospital has a current or future need for additional facility capacity to serve Medicaid, uninsured, and underserved populations, as well as whether there is a need in the counties where the hospital’s main campus and hospital-based facilities, if any, are located. It is important to require this information, especially because we are not requiring the requesting hospital to provide information about the need for additional operating rooms, procedure rooms, or beds in counties where the hospital’s main campus and hospital-based facilities, if any, are located as of the date the hospital submits the request. Final §411.363(i)(2) also makes clear that CMS will consider factors other than those expressly stated in the regulation; for example, depending on the facts and circumstances of the particular expansion exception request, CMS may consider program integrity or quality concerns related to other hospitals in the requesting hospital’s community or their ability to serve a growing patient population in the community (88 FR 27179).

Final §411.363(i)(2)(i) includes the specialty (for example, maternity, psychiatric, or substance abuse disorder care) of the requesting hospital or the services furnished by or to be furnished by the hospital if CMS approves the request as a factor for CMS’ consideration. As we stated in the proposed rule, we believe it is important to understand whether and how any hospital requesting an expansion exception could improve access to specialty care, such as maternity, psychiatric, and substance use disorder care, the need for which often goes unaddressed, especially for Medicaid beneficiaries and other uninsured or underserved populations (88 FR 27180).

Although we understand that a hospital may not know at the time of its request what its future expansion plans may entail, it is still pertinent to our decision to understand how any hospital requesting an expansion exception request, indeed to our faithful implementation of the statutorily required expansion exception process, to understand how approved expansion facility capacity could address the need for specialty services for Medicaid and other underserved populations in the hospital’s community (see 88 FR 27180). Final §411.363(i)(2)(i) includes program integrity or quality of care concerns related to the requesting hospital as a factor for CMS’ consideration. Because the underlying purpose of the physician self-referral law is to protect against the abuse of the Medicare program and its beneficiaries, program integrity concerns or quality of care concerns related to the requesting hospital or, for that matter, any hospital in the counties where the hospital’s main campus and hospital-based facilities (if any) are located would be relevant to CMS’ decision whether to approve or deny an expansion exception request. The nature and extent of the program integrity or quality of care concerns, as well as whether they relate to the requesting hospital or another hospital in its community, are most pertinent to our consideration of this factor.

Final §411.363(i)(2)(iii) and (iv) list factors that relate to a community’s general need for additional operating rooms, procedure rooms, and beds as factors for CMS’ consideration. We are not prescribing the data points or other criteria that the requesting hospital or community input may use to support an assertion of the need for (or lack of need for) expansion facility capacity. Data and information that could relate to a hospital’s or community’s need for additional operating rooms, procedure rooms, and beds could include a number and variety of things, such as impediments to accessing timely care (for example, long wait times to schedule elective surgery), the closure of a hospital outside the community that could lead to increased utilization of the hospital and other services in the community, or information regarding population increase, bed occupancy, and bed capacity in the community, even with respect to expansion exception requests from high Medicaid facilities (which need not meet specific criteria related to these data points to qualify as a high Medicaid facility under section 1877(i)(3)(F) of the Act). We do not believe that a need for additional operating rooms, procedure rooms, and beds in a community is shown simply because the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility. For example, two of the criteria for an applicable hospital are that the hospital has an average bed occupancy rate that is higher than the average bed occupancy rate in the State in which it is located and that the State must have an average bed capacity that is less than the national bed capacity during the relevant time period. We do not see a clear or obvious indication of community need, for example, where a hospital that has a bed occupancy rate of only 60 percent is located in a State that has an average hospital bed capacity of 125 compared to the national average bed capacity of 126, both of which would meet the statutory criteria.

We have not assigned a weight to any of these factors or to any particular data point that may be provided to support the assertions of a hospital or in the community input regarding one or more of the factors. We acknowledge the unique characteristies and needs of each community to which an expansion exception request may relate. Because the CMS decision to approve or deny an
expansion exception request will be made on a case-by-case basis, the significance of each factor (and any other information that CMS may consider when making its decision) will vary among requests. However, all expansion exception requests will be treated the same in that all factors will be considered. As we noted in the proposed rule, decisions to approve or deny requests from hospitals that appear similar could differ because of factors such as planned expansion of needed psychiatric (or other specialty) services instead of general acute care services or whether the requesting hospital seeks an expansion exception to replace facility capacity on its main campus that it has relocated or intends to relocate to other areas in need of services. Other examples of information that could impact CMS’s decision include but are not limited to: an expected increase in the number of Medicaid beneficiaries or uninsured patients in the community; an expected change in the population (or portion of the population) in the community; program integrity, quality of care, or patient safety concerns with providers or suppliers of services in the community; and development or planned development of additional operating rooms, procedure rooms, or beds in the community. CMS will consider any data and information provided by the requesting hospital or in the community input related to impediments to accessing timely care. In all instances where CMS has determined that the requesting hospital has met the criteria for an applicable hospital or a high Medicaid facility, CMS will provide a detailed explanation of its decision and the rationale for approving or denying the hospital’s request in the Federal Register notice announcing the decision.

Comment: One commenter objected to our proposal to require a hospital requesting an expansion exception request to provide actual notice of its request directly to hospitals whose data are part of the comparisons required to show that the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility. As we explained in the CY 2015 OPPS/ASC proposed rule, the purpose of this requirement is to ensure that that comparison hospitals are aware of the opportunity to provide input. (At that time, we had not defined in regulation the requesting hospital’s “community” for purposes of the statutory requirement that individuals and entities in the requesting hospital’s community must have an opportunity to provide input with respect to the expansion exception request.) We are retaining this requirement at §411.363(f)(2).

As discussed in section X.B.2.a.(8) of this final rule, we are finalizing regulations at §411.363(e)(2)(vi) and (vii) and (i)(2) that set forth the information required to be included in an expansion exception request, information that may be included in an expansion exception request at the requesting hospital’s election, and factors that CMS will consider in deciding whether to approve or deny a hospital’s request for an expansion exception, respectively. Although we believe that hospitals located in the geographic area served by the requesting hospital (as defined at existing §411.357(e)(2)) or in the counties in which the requesting hospital provides inpatient or outpatient hospital services as of the date it submits its expansion exception request would likely have information relevant and useful to CMS’ decision to approve or deny a request, we are not finalizing our proposal to require actual notification of an expansion exception request to these hospitals. We do not believe that the incremental burden of providing actual notice to such hospitals, if any, outweighs the benefit of having the most comprehensive body of information for use in deciding whether to approve or deny a hospital’s expansion exception request. However, we recognize that multiple configurations of the geographic area served by a requesting hospital could exist at any single point in time, and the regulation as proposed does not provide sufficient clarity and direction to requesting hospitals regarding which hospitals (other than the comparison hospitals) must receive actual notification of the expansion exception request. Therefore, we are not finalizing the proposed regulation at §411.363(f)(2) which would have required actual notification by a hospital that it is requesting an exception, in either electronic or hard copy form, directly to hospitals located in the requesting hospital’s community (other than the comparison hospitals, which must receive actual notification). We are finalizing the regulation at §411.363(f)(1), which replicates our current requirement for disclosure on any public website for the hospital that it is requesting an exception from the prohibition on facility expansion.

We decline to expand the definition of “community” as suggested by the last commenter. Section 1877(i)(3)(A)(ii) of the Act identifies the individuals and entities entitled to an opportunity to provide input with respect to an expansion exception request as those that are located in the community in which the requesting hospital is located. We interpret this statutory provision as establishing a geographic nexus between the individual or entity providing the input and the hospital requesting the expansion exception. We are confident that our definition of “community” for purposes of final §411.363 will allow for robust input on an expansion exception request while ensuring this important nexus. As we did in the proposed rule (88 FR 27181), we encourage parties that wish to have their input considered to address how they are part of the requesting hospital’s community in their submissions.

Comment: Recognizing that our existing regulations permitting community input with respect to all expansion exception requests were established through notice-and-comment rulemaking, one commenter nonetheless requested that we not permit community input with respect to an expansion exception request made by a high Medicaid facility because the statute does not expressly require community input with respect to such hospitals. Other commenters suggested that we limit community input to whether the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility. One commenter objected to our proposal to require actual notice from the community in their submissions. This commenter suggested that, if we extend the period for community input, we should extend the period for the requesting hospital’s rebuttal statement from the current 30 days to 60 days. In contrast, some commenters highlighted our longstanding policy that community input is not confined to the narrow question of whether the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility and supported our position that
the Congress intended for hospitals, patients, and others that are most likely to be affected by the expansion of the requesting hospital to have input in CMS’ decision whether to approve or deny the request. One commenter asserted that broad community input on expansion exception requests will better enable CMS to provide case-by-case evaluation of requests and ensure that they are only approved where the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility and the totality of the information supports the appropriateness of the expansion.

Response: We decline to adopt the first commenter’s suggestion. We agree with the commenters on the proposed rule, as well as commenters on the CY 2021 OPPS/ASC proposed rule, of which supported proposals to eliminate the program integrity restrictions on high Medicaid facilities, that community input is a valuable part of the expansion exception process and that it was the Congress’ intent to include it (85 FR 86258). We also decline to limit community input to whether the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility. The plain language of section 1877(i)(3)(A)(ii) of the Act requires that the expansion exception process provide for community input “with respect to the application” (that is, the expansion exception request). It is our position that, by not limiting community input to whether the requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility, the Congress intended for CMS to obtain and consider community input on the entire application (or request) for an expansion exception. Moreover, our longstanding policy, established through notice-and-comment rulemaking, is not to restrict the types of community input that may be submitted (76 FR 74122). Finally, the final regulations should bring clarity regarding the factors that CMS will consider in deciding whether to approve or deny an expansion exception request and will likely result in the submission of more varied information than we have historically received from both requesting hospitals and parties that submit community input on their expansion exception requests. Therefore, we believe that extending the period for both community input and the requesting hospital’s rebuttal statement, if any, to 60 days is appropriate.

b. Program Integrity Restrictions on Approved Facility Expansion

As discussed in sections X.B.1.b. of this final rule, in the CY 2012 OPPS/ASC final rule, we issued regulations setting forth the expansion exception process at existing § 411.362(c) and related definitions at § 411.362(a) (76 FR 74122). Using our rulemaking authority in sections 1871 and 1877(i)(3) of the Act, we extended to high Medicaid facilities certain statutory program integrity restrictions related to the expansion of a hospital with physician ownership or investment and the process for requesting an exception from the prohibition on expansion of facility capacity that applied expressly by statute to applicable hospitals. In the CY 2021 OPPS/ASC final rule, we removed the regulatory program integrity restrictions on high Medicaid facilities. There, we stated that we continue to believe that our then-current regulations, for which the Secretary appropriately used his authority and which treat high Medicaid facilities the same as applicable hospitals, are consistent with the Congress’ intent to prohibit expansion of physician-owned hospitals generally (85 FR 86256).

Nevertheless, because the statute does not expressly apply to high Medicaid facilities the program integrity restrictions related to the frequency of permitted requests for exceptions to the prohibition on expansion of facility capacity, the total amount of permitted expansion of facility capacity, or the location of permitted expansion facility capacity, citing the former Patients over Paperwork initiative, we removed these restrictions from our regulations as they applied to high Medicaid facilities (Id.). We remain steadfast in our belief that the Secretary appropriately used his authority in the CY 2012 OPPS/ASC final rule in establishing an expansion exception process that treated high Medicaid facilities the same as applicable hospitals, and that such treatment is consistent with the Congress’ intent to generally prohibit expansion of hospitals with physician ownership or investment. As noted, the removal of the program integrity restrictions as they apply to high Medicaid facilities was not the result of a determination that they were unnecessary. Rather, the purpose of the regulatory change was to streamline regulations to eliminate potential burden under the former Patients over Paperwork initiative.

(1) Proposals

As we explained in the proposed rule, we recently reviewed the CY 2021 OPPS/ASC regulatory revisions, including the comments on our proposals in that rulemaking, and considered whether those revisions currently pose a risk of the types of program or patient abuse that the physician self-referral law is intended to thwart. Commenters opposed to our proposal in the CY 2021 OPPS/ASC proposed rule to remove the program integrity restrictions on high Medicaid facilities highlighted their concern that a hospital that meets the criteria for a high Medicaid facility could expand into markets without large Medicaid patient populations, creating additional campuses far away from the patients the expansion is intended to serve. In addition, commenters asserted that hospitals with physician ownership or investment present a risk of program or patient abuse through cherry-picking patients, avoiding Medicaid and uninsured patients, and treating fewer medically complex patients, and that unrestricted expansion of such hospitals could exacerbate the risk (85 FR 86256 through 86257). We also reviewed community input related generally to the expansion of hospitals with physician ownership or investment that we received in conjunction with an expansion exception request submitted after the effective date of the CY 2021 OPPS/ASC final rule. One of the comments included in the community input asserted that the removal of the program integrity restrictions on high Medicaid facilities posed grave risk to the stability and integrity of patient care, and another asserted that removal of the restrictions contravenes and undermines the Congress’ intent to strictly limit expansion of hospitals with physician ownership or investment.

We stated in the proposed rule that our position, following this recent review, is that not applying the program integrity restrictions regarding the frequency of expansion exception requests, maximum aggregate expansion of a hospital, and location of expansion facility capacity to high Medicaid facilities poses a significant risk of program or patient abuse. We noted that, although we are cognizant that the plain language of section 1877(i) of the Act does not expressly apply these program integrity restrictions to high Medicaid facilities in the same way that they pertain to applicable hospitals, we must balance the risk to patients and the Medicare program against any burden that the program integrity restrictions may impose on high Medicaid facilities. It is our position that protecting the Medicare program and its beneficiaries,
as well as Medicaid beneficiaries, uninsured patients, and other underserved populations, from harms such as overutilization, patient steering, cherry-picking, and lemon-dropping outweighs any perceived burden on high Medicaid facilities. In addition, as we stated in the proposed rule, we believe that treating all hospitals the same under the expansion exception process by applying the program integrity restrictions to both applicable hospitals and high Medicaid facilities will promote consistency among decisions to approve or deny expansion exception requests. For these reasons, we proposed to restate the program integrity restrictions regarding the frequency of expansion exception requests, maximum aggregate expansion of a hospital, and location of expansion facility capacity as they apply to high Medicaid facilities.

We proposed to revise existing §411.362(c)(6) to reinstate, with respect to high Medicaid facilities, the program integrity restrictions on the maximum aggregate expansion of a hospital and location of expansion facility capacity. We also proposed to renumber this regulation at §411.363(j). We noted that these program integrity restrictions would not apply to an increase in facility capacity approved by CMS with respect to an expansion exception request submitted by a high Medicaid facility between January 1, 2021, and the day before the effective date of the revised regulations if our proposals were finalized. We did not propose any change to program integrity restrictions affecting applicable hospitals, which have been subject to the same limitations on maximum aggregate expansion of facility capacity and location of expansion facility capacity under our regulations since January 1, 2012. In addition to the regulation at proposed §411.363(j), the restriction on the maximum aggregate expansion of a hospital is also implemented at proposed §411.363(b)(2)(i), which provides that CMS will not consider a request from a hospital if CMS has previously approved a request from the hospital that would allow the hospital’s facility capacity to reach 200 percent of its baseline facility capacity if the full expansion is utilized. We note that all but two of the expansion exception requests approved to date have permitted an increase in facility capacity that, if fully utilized, would allow the requesting hospital to reach 200 percent of its baseline number of operating rooms, procedure rooms, and beds. (See https://www.cms.gov/medicare/fraud-and-abuse/physicianselfreferral/physician_owned_hospitals.) Therefore, CMS would not consider a future expansion exception request from those hospitals on or after October 1, 2023. The two hospitals that were approved for expansion facility capacity less than their baseline number of operating rooms, procedure rooms, and beds would not be precluded from submitting a future expansion exception request if they are eligible to request another expansion exception request at §411.363(b) at the time of the request.

The program integrity restriction on the location of expansion facility capacity proposed at §411.363(j) requires that any approved expansion occur only on the main campus of the hospital. We noted in the proposed rule, however, that nothing in our existing physician self-referral regulations affects a hospital’s ability to relocate some or all of the “original” operating rooms, procedure rooms, or beds that are part of its baseline facility capacity. On April 18, 2019, we published on the CMS website a FAQ regarding this issue (https://www.cms.gov/Medicare/Fraud-and-Abuse/PhysicianSelfReferral/Downloads/FAQs-Physician-Self-Referral-Law.pdf). The FAQ states:

**Question:** Where the Secretary has granted a physician-owned hospital (“POH”) an exception to the prohibition on facility expansion under section 1877(i)(1) of the Social Security Act (the “Act”) and 42 CFR 411.362(c), does the physician self-referral law prohibit the POH from relocating operating rooms, procedure rooms, or beds that were licensed on March 23, 2010, from its main campus to a remote location of the POH before implementing the approved facility expansion on the POH’s main campus?

**Answer:** The physician self-referral law does not prohibit the relocation of operating rooms, procedure rooms, or beds that were licensed on March 23, 2010,934 from a POH’s main campus to a remote location. However, because the regulation at 42 CFR 411.362(c)(6) provides that any increase in the number of operating rooms, procedure rooms, or beds by the Secretary through an exception may occur only in facilities on the POH’s main campus, any operating rooms, procedure rooms, or beds added as a result of the Secretary’s approval can be located only on the main campus of the POH and may not subsequently be relocated from the main campus. We note that all hospitals must comply with applicable Federal and state laws and regulations regarding, among other things, the licensure, location, construction, and use of operating rooms, procedure rooms, and beds. These laws and regulations may impose additional requirements or limitations on a POH that wishes to relocate operating rooms, procedure rooms, or beds from its main campus.

In the proposed rule, we noted that our policy has not changed since the publication of the FAQ, and this continues to be the case. We reiterate that the physician self-referral law does not prohibit the relocation of “original” operating rooms, procedure rooms, or beds from a hospital’s main campus to a remote location, but note that a hospital that wishes to expand its service area by locating operating rooms, procedure rooms, or beds in a location beyond its main campus must comply with other Medicare, Federal, and State laws and regulations related to such expansion, which may require that actions occur in a particular sequential order. We also caution that, to avoid the physician self-referral law’s referral and billing prohibitions under the rural provider exception or the whole hospital exception, an ownership or investment exception may satisfy the requirements of the applicable exception at the time of the physician’s referral, and the hospital must meet the requirements of section 1877(i) of the Act and §411.362 no later than September 23, 2011. Section 1877(i)(1)(A) of the Act and §411.362(b)(1) require that the hospital had physician ownership or investment on December 31, 2010, and a provider agreement under section 1866 of the Act on that date. Put another way, for a hospital to bill Medicare (or another individual, entity, or third-party payor) for a designated health service furnished as a result of a physician owner’s referral following the relocation of “original” operating rooms, procedure rooms, or beds to a location other than the main campus of a hospital, the hospital (including all of its provider-based locations) must remain the **same hospital** that had both physician ownership or investment and a Medicare provider agreement on December 31, 2010. (See 87 FR 44798 for a complete discussion of this requirement.) Parties may request an advisory opinion from CMS regarding whether a hospital is (or would be) “the same hospital” for the relocation of “original” operating rooms, procedure rooms, or beds to a location.
other than the main campus of a hospital.

Finally, to ensure consistency in the application of the expansion exception process, as well as preserve CMS resources and maintain an orderly and efficient expansion exception process, we also proposed, with respect to high Medicaid facilities, to reinstate the program integrity restriction on the frequency of expansion exception requests as proposed at §411.363(b)(2)(ii). Specifically, we proposed that a hospital may not request an expansion exception unless it has been at least 2 calendar years from the date of the most recent decision by CMS approving or denying the hospital’s most recent request for an exception from the prohibition on facility expansion. As we noted in the proposed rule, applicable hospitals have been subject to this limitation under our regulations since the effective date of our CY 2012 OPPS/ASC final rule. We did not propose any substantive change to the application of the limitation on applicable hospitals. However, to slightly revise the language of existing §411.362(c)(1) and renumber it at §411.363(b)(2)(ii).

(2) Provisions of the Final Rule: Program Integrity Restrictions

We are finalizing our proposals to reinstate the limitations on high Medicaid facilities with respect to the maximum aggregate expansion of a hospital and location of expansion facility capacity. Specifically, final §411.363(j) provides that an increase in facility capacity approved by CMS may not result in the hospital’s aggregate facility capacity exceeding 200 percent of its baseline facility capacity and that the expansion facility capacity may occur only in facilities on the hospital’s main campus. With respect to applicable hospitals, these program integrity restrictions apply to all increases in facility capacity approved by CMS. With respect to high Medicaid facilities, these program integrity restrictions do not apply to an increase in facility capacity approved by CMS with respect to an expansion exception request submitted between January 1, 2021, and September 30, 2023. As discussed in section X.B.2.a.(8), of this final rule, under final §411.363(b)(2)(ii), a hospital may submit an expansion exception request, provided that it has been at least 2 calendar years from the date of the most recent decision by CMS approving or denying the hospital’s most recent expansion exception request.

We received the following comments on our proposals to reinstate certain program integrity restrictions on high Medicaid facilities and our responses follow.

Comment: We received comments in support of our proposals to reinstate, with respect to high Medicaid facilities, the program integrity restrictions on the maximum aggregate expansion of a hospital and the location of expansion facility capacity, as well as the limitation on the frequency of expansion exception requests. We also received comments that objected to these proposals. Commenters in support of finalizing the proposals identified benefits such as uniform application of the expansion exception process to both applicable hospitals and high Medicaid facilities and the appropriate use of agency resources. Importantly, these commenters asserted that finalizing these policies is necessary to protect the Medicare program and patients from abuses resulting when medical decision making is affected by a physician’s financial self-interest, such as an ownership or investment interest in a hospital to which the physician refers Medicare and other patients for designated health services. These commenters also asserted that preventing such abuses outweighs any perceived burden on high Medicaid facilities. One commenter expressed concern that it has seen and would continue to see expansion exception requests from hospitals seeking to bring physician ownership to entirely new markets previously barred by section 1877(i)(1)(B) of the Act and CMS regulations. Other commenters in support of our proposals stated that the application of the program integrity restrictions to all hospitals requesting an expansion exception will encourage a wider breadth of access and choice among Medicare beneficiaries. In contrast, commenters opposed to the application of program integrity restrictions to high Medicaid facilities variously asserted that, recognizing the need to increase access to health care for Medicaid beneficiaries, the Congress intentionally did not apply the program integrity restrictions to high Medicaid facilities and that the application of such restrictions would create barriers to care and exacerbate poor health outcomes for patients with lower incomes and socioeconomic disadvantages because high Medicaid facilities serve many patients in such categories. One of these commenters suggested that CMS should not impose these program restrictions on high Medicaid facilities in the absence of a showing of cherry-picking, lemon-dropping, and the other harms of self-referral. Another of these commenters maintained that, because there have been a limited number of expansion exception requests to date, there is no need for consistency in the treatment of applicable hospitals and high Medicaid facilities.

Response: As we stated in the proposed rule, we recently undertook a fresh review of the CY 2021 OPPS/ASC regulatory revisions, including the comments on our proposals in that rulemaking, and considered whether those revisions currently pose a risk of the types of programs or patient abuse that the physician self-referral law is intended to thwart. We also reviewed community input related generally to the expansion of hospitals with physician ownership or investment (not specifically related to an individual hospital that requested an expansion exception) that we received in conjunction with an expansion exception request submitted after the effective date of the CY 2021 OPPS/ASC final rule (86 FR 27185). Based on that review and the comments that we received on the FY 2024 IPPS proposed rule, we share many of the concerns expressed by commenters that support the application of the program integrity restrictions on all hospitals seeking an exception from the prohibition on expansion of facility capacity at section 1877(i)(1)(B) of the Act. As we have stated in previous rulemakings, we are concerned that, when physicians have a financial incentive to refer a patient to a particular entity, that incentive can affect utilization, patient choice, and competition. Physicians cannot overcharge by ordering items and services for patients that, absent a profit motive, they would not have ordered. A patient’s choice is diminished when physicians steer patients to less convenient, lower quality, or more expensive providers of health care just because the physicians are sharing profits with, or receiving remuneration from, the providers. And lastly, where referrals are controlled by those sharing profits or receiving remuneration, the medical marketplace suffers if new competitors cannot win business with superior quality, service, or price (80 FR 41926 and 81 FR 80533).

Section 1877 of the Act was enacted to combat the potential that financial self-interest would affect a physician’s medical decision making and ensure that patients have options for quality care. The law’s prohibitions were intended to prevent a patient from being referred for services that are not needed or steered to certain health care providers because the patient’s physician may improve their financial standing through those referrals. These
prohibitions also aim to prevent the steering of “desirable” Medicare beneficiaries (that is, those who may have few complicating or other medical conditions or are economically advantaged) to entities from which the referring physician may benefit financially. Importantly, they protect the Medicare program from increased costs from physician referrals that are influenced by financial self-interest. (See, for example, 85 FR 77493.) At their core, our regulations, including those that govern the process for requesting an exception from the prohibition on expansion of facility capacity, share a common purpose with the statutory prohibitions. Their primary objective is to protect against program or patient abuse, which may occur for any of the reasons noted. To protect the Medicare program and its beneficiaries, as well as Medicaid beneficiaries, uninsured patients, and other underserved populations from potential harms such as (but not limited to) overutilization, patient steering, cherry-picking, and lemon-dropping, we are finalizing our proposals to reinstate program integrity restrictions on high Medicaid facilities. Under final § 411.363(j) and (b)(2)(ii), with respect to expansion exception requests submitted on or after October 1, 2023, a high Medicaid facility may not expand beyond 200 percent of its baseline facility capacity, must locate all approved expansion facility capacity on its main campus, and may request an expansion exception no earlier than 2024 calendar years from the date of the most recent decision by CMS approving or denying the hospital’s most recent expansion exception request.

As we stated in the proposed rule, we believe that not applying the program integrity restrictions regarding the frequency of expansion exception requests, maximum aggregate expansion of a hospital, and location of expansion facility capacity to high Medicaid facilities poses a significant risk of program or patient abuse (88 FR 27185). Although we are cognizant that section 1877(f)(3) of the Act does not expressly apply these restrictions to high Medicaid facilities in the same way that they are applied to applicable hospitals, unlike the commenters opposed to our proposals, we see nothing in the plain language of the statute to indicate that this was intentional or that the Congress did not apply the restrictions to high Medicaid facilities because, as one commenter contended, it recognized the need to increase access to health care for Medicare beneficiaries and that the expansion of such hospitals would increase this access. In fact, the statutory criteria defining an applicable hospital and the statutory criteria defining a high Medicaid facility both include the hospital’s Medicaid inpatient admissions as a criterion, indicating that any hospital that may request an expansion exception must show that it provides a certain level of access to health care for Medicaid beneficiaries relative to the other hospitals in the county in which it is located. Moreover, we are not persuaded that reinstating the program integrity restrictions on high Medicaid facilities would result in barriers to care for Medicaid, uninsured, or other underserved populations. We acknowledge that some high Medicaid facilities may serve a large number of Medicaid beneficiaries but it is not true that—by definition—even high Medicaid facility serves a large (or even significant) number of Medicaid beneficiaries. Determining whether a hospital meets the criteria for a high Medicaid facility requires a relativity assessment. A hospital that meets the criteria for a high Medicaid facility need only have a higher annual percent of total inpatient admissions under Medicaid than each other hospital in the county that participates in the Medicare program for the relevant time period. For example, a hospital may have only 3 percent of its inpatient admissions under Medicaid and still be a high Medicaid facility if the each of the other Medicare-participating hospitals in the county have less than 3 percent of their inpatient admissions under Medicaid.

As we stated in the proposed rule, we must balance the risk to patients and the Medicare program against any burden that the program integrity restrictions may impose on high Medicaid facilities (88 FR 27185). It remains our position that protecting the Medicare program and its beneficiaries, as well as Medicaid beneficiaries, uninsured patients, and other underserved populations, from potential harms such as overutilization, patient steering, cherry-picking, and lemon-dropping outweighs any perceived burden on high Medicaid facilities. With respect to the commenter that suggested that CMS should not impose these program restrictions on high Medicaid facilities in the absence of a showing of cherry-picking, lemon-dropping, and the other harms of self-referral, we note that we have addressed similar comments in prior rulemakings. In the CY 2017 PFS final rule, we stated that an agency’s reasoned assessment of the potential for abuse inherent in a particular business arrangement justifies the issuance of a prophylactic rule and cited longstanding judicial holdings in support of our position (81 FR 80532). Our position has not changed.

Like the commenters that highlighted the benefits of uniform treatment of all hospitals requesting an expansion exception, we believe that treating all hospitals the same under the expansion exception process by applying the program integrity restrictions to both applicable hospitals and high Medicaid facilities will promote consistency among decisions to approve or deny expansion exception requests. Moreover, as these commenters asserted, doing so would be an appropriate use of (and may conserve) agency resources. As we stated in previous rulemaking—and commenters agreed—uniform treatment of all hospitals seeking an expansion exception balances the general ban on new or expanded hospitals with physician ownership or investment with the policy that allows limited growth of certain hospitals (76 FR 74523 through 74524). Finally, we are unclear regarding the basis of the last commenter’s assertion that, because there have been a limited number of expansion exception requests to date, there is no need for consistency in the treatment of applicable hospitals and high Medicaid facilities. As such, we are unable to respond to this comment.

Comment: Highlighting CMS’ statement in the proposed rule that the program integrity restrictions on high Medicaid facilities, if finalized, would apply prospectively only (88 FR 27185), one commenter agreed that they should not be applied to expansion exceptions already approved by CMS.

Response: Final § 411.363(j), which implements the program integrity restrictions on the maximum aggregate expansion of a hospital and location of expansion facility capacity, does not apply to an increase in facility capacity approved by CMS with respect to an expansion exception request submitted by a high Medicaid facility between January 1, 2021, and September 30, 2023. The final rule at § 411.363(j)(2) expressly states this limitation. Final § 411.363(b)(2), which implements the restriction on requesting an expansion exception more frequently than once every 2 calendar years, applies to all hospitals seeking an expansion exception request on or after the effective date of this final rule.

c. Technical and Grammatical Revisions

We proposed certain technical and grammatical revisions to our regulations setting forth the expansion exception process. First, we proposed to revise the reference at § 411.362(b)(2) to the
expansion exception process by substituting “§ 411.363” (the proposed location of the regulations setting forth the expansion exception process) for the current reference to “paragraph (c) of this section.” In addition, to conform the terminology regarding “approval” of a request to that used throughout our proposals, we also proposed to substitute the word “approved” for the reference to “granted” at § 411.362(b)(2). We proposed to use the same phrasing of “exception from the prohibition on facility expansion” wherever that language appears in the regulations. We proposed to use defined acronyms, such as HCRIS, where those terms appear following the initial designation of the acronym. In addition, we proposed to clarify that the references to section 1869 and 1878 in existing § 411.362(c)(8) (renumbered to at § 411.363(l) under this final rule) are references to the Social Security Act. For consistency with our regulations in this subpart J, we proposed to revise the term “Web site” to “website” wherever the term appears in existing § 411.362. We also proposed to change numbers to words and vice versa where those conventions are correct in the Code of Federal Regulations. Finally, we proposed minor changes to correct grammatically the wording of certain regulations. For example, we proposed to restate the regulation at existing § 411.362(c)(2)(iii) and renumber it at § 411.363(c)(3) to read “The hospital does not discriminate against beneficiaries of Federal health programs and does not permit physicians practicing at the hospital to discriminate against beneficiaries.” Currently, the regulation does not include the words “The hospital.” We received no comments on these proposals and are therefore finalizing them as proposed.

C. Technical Corrections to 42 CFR 411.353 and 411.357

On November 16, 2020, the Department issued a final rule titled “Regulatory Clean-up Initiative” (85 FR 72899) that contained multiple technical corrections to various regulations. Among the changes finalized in that rule was an amendment to 42 CFR 411.353(d) to reflect the prior regulatory text. There were also additional typographical errors in the text of 42 CFR 411.357(s) introduced in the MCR final rule. We proposed to correct these technical errors. Specifically, in § 411.353(d) we proposed to amend paragraph (d) by removing the parenthetical phrase “§ 1003.101 of this title.” and adding in its place “§ 1003.110 of this title.” We also proposed to amend § 411.357 as follows:

- In paragraph (s)(3) by removing the parenthetical phrase “governing body;” and adding in its place “governing body; and”.
- In paragraph (s)(4) by removing the parenthetical phrase “financial need;” and adding in its place “financial need.”

We received no comments on these proposals and are therefore finalizing them as proposed.

D. Safety Net Hospitals—Request for Information

1. Background

As discussed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27187 through 27190), consistent with President Biden’s Executive Order 13985 on “Advancing Racial Equity and Support for Underserved Communities Through the Federal Government,” 935 and Executive Order 14091 on “Further Advancing Racial Equity and Support for Underserved Communities Through the Federal Government,” 936 CMS has made advancing health equity the first pillar in its Strategic Plan. We define health equity as the attainment of the highest level of health for all people, where everyone has a fair and just opportunity to attain their optimal health regardless of race, ethnicity, disability, sexual orientation, gender identity, socioeconomic status, geography, preferred language, and other factors that affect access to care and health outcomes. CMS is working to advance health equity by designing, implementing, and operationalizing policies and programs that support health for all the people served by our programs, eliminating avoidable differences in health outcomes experienced by people who are disadvantaged or underserved, and providing the care and support that our beneficiaries need to thrive.937

Among the goals of CMS’s health equity pillar is to evaluate policies to determine how CMS can support safety-net providers, partner with providers in underserved communities, and ensure care is accessible to those who need it.938 In the FY 2024 IPPS/LTCH PPS proposed rule, we noted that, although various approaches exist to identifying “safety-net providers,” this term is commonly used to refer to healthcare providers that furnish a substantial share of services to uninsured and low-income patients.939 As such, safety-net providers, including acute care hospitals, play a crucial role in the advancement of health equity by making essential services available to the uninsured, underinsured, and other populations that face barriers to accessing health care, including people from racial and ethnic minority groups, the LGBTQ+ community, rural communities, and members of other historically disadvantaged groups. Whether located in urban centers or geographically isolated rural areas, safety-net hospitals are often the sole providers in their communities of specialized services such as burn and trauma units, neonatal care and inpatient psychiatric facilities.940 They also frequently partner with local health departments and other institutions to sponsor programs that address homelessness, food insecurity and other social determinants of health, and offer culturally and linguistically appropriate care to their patients. During the COVID–19 pandemic, safety-net hospitals provided emergency care to many of the country’s most at-risk patients and leveraged their position as trusted providers to drive vaccine uptake in their communities.941

In the proposed rule, we also noted that, because they serve many low-income and uninsured patients, safety-net hospitals may experience greater financial challenges compared to other hospitals. Among the factors that negatively impact safety-net hospital finances, MedPAC pointed specifically to the greater share of patients insured by public programs, which it stated typically pay lower rates for the same

940 https://www.ncbi.nlm.nih.gov/books/NBK224521/
services than commercial payers; the increased costs associated with treating low-income patients, whose conditions may be complicated by social determinants of health, such as homelessness and food insecurity; and the provision of higher levels of uncompensated care.\textsuperscript{942} Moreover, the financial pressures on many safety-net hospitals have been further exacerbated by the impacts of the COVID–19 pandemic.\textsuperscript{943} In response to the challenges posed by COVID–19, HHS had authorized several targeted distributions from the Provider Relief Fund to safety-net hospitals and other hospitals that serve vulnerable populations.\textsuperscript{944}

In its June 2022 Report to Congress, MedPAC expressed concern over the financial position of safety-net hospitals.\textsuperscript{945} The Commission noted that the limited resources of many safety-net hospitals may make it difficult for them to compete with other hospitals for labor and technology, and observed that “[i]t’s disadvantage, in turn, could lead to difficulty maintaining quality of care and even to hospital closure.”\textsuperscript{946} During the earlier phases of the COVID–19 pandemic, for example, studies showed higher rates of mortality among patients who received treatment at certain safety-net hospitals, with researchers citing understaffing and lack of access to advanced therapies as some of the factors that may have contributed to negative health outcomes.\textsuperscript{947} Other research shows that the closure of a safety-net hospital can have negative effects within the community, making it more difficult for disadvantaged patients to access care and shifting uncompensated care costs onto neighboring facilities.\textsuperscript{948 949}

As explained in the FY 2024 IPPS/LTCH PPS proposed rule, two of the ways the Medicare statute currently recognizes the additional costs of safety-net hospitals are through disproportionate share hospital (DSh) payments and uncompensated care payments. In its June 2022 Report, however, MedPAC raised concerns about whether these payments appropriately target safety-net hospitals.\textsuperscript{950} The Medicare statute also includes special payment provisions for other hospitals in underserved communities, including sole community hospitals, which are the sole source of care in their areas, as well as Critical Access Hospitals and Rural Emergency Hospitals.

In the proposed rule, we stated that given the critical importance of safety-net hospitals to the communities they serve, it is important to be able to identify these hospitals for policy purposes. We next discussed two potential approaches, as outlined in the following sections: the Safety-Net Index (SNI), which MedPAC has developed as a measure of the degree to which a hospital functions as a safety-net hospital, and area-level indices, which are intended to capture local socioeconomic factors correlated with medical disparities and underservice.

2. Methodological Considerations When Identifying Safety Net Hospitals Using the SNI

As explained in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27188), the SNI developed by MedPAC is calculated as the sum of—(1) the share of the hospital’s Medicare volume associated with low-income beneficiaries; (2) the share of its revenue spent on uncompensated care; and (3) an indicator of how dependent the hospital is on Medicare.

a. Medicare Low-Income Subsidy (LIS) Enrollment Ratio

For the share of the hospital’s Medicare volume associated with low-income beneficiaries, MedPAC’s definition of low-income beneficiaries includes all those who are dually eligible for full or partial Medicaid benefits, and those who do not qualify for Medicaid benefits in their states but who receive the Part D low-income subsidy (LIS) because they have limited assets and an income below 150 percent of the Federal poverty level. Collectively, MedPAC refers to this population as “LIS beneficiaries” because those who receive full or partial Medicaid benefits are automatically eligible to receive the LIS. MedPAC states that its intent in defining low-income beneficiaries in this manner is to reduce the effect of variation in states’ Medicaid policies on the share of beneficiaries whom MedPAC considers low-income, but to allow for appropriate variation across states based on the share of beneficiaries who are at or near the Federal poverty level.

In the FY 2024 IPPS/LTCH PPS proposed rule, we explained that to calculate the LIS ratio for a hospital for a fiscal year, we could use the number of inpatient discharges of Medicare beneficiaries who are also LIS beneficiaries during the month of discharge, divided by the total number of inpatient discharges of Medicare beneficiaries. In a similar manner to how we currently use the most recent fiscal year MedPAR claims for ratesetting purposes,\textsuperscript{951} we could use the most recent MedPAR claims for the discharge information needed to calculate the LIS ratio. We could merge onto this MedPAR data the LIS beneficiary information needed to calculate the LIS ratio.

c. Medicare Share of Total Inpatient Days

For the indicator of how dependent a hospital is on Medicare, MedPAC’s recommendation is to use one-half of the Medicare share of total inpatient days.\textsuperscript{952} Specifically, the ratio could be calculated as Worksheet S–10 column 1, line 30 (Total cost of uncompensated care) divided by Worksheet G–3 column 1, line 3 (Net patient revenues) using these existing lines from the most recent available audited cost report data.

948 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2677897.
950 The most recent fiscal year MedPAR data lag two years behind the rulemaking year (for example, FY 2022 MedPAR data are available for this FY 2024 final rule).
951 The most recent available cost report data for this purpose generally lags four years behind the rulemaking year (for example, FY 2020 cost report data were available for the FY 2024 proposed rule).
inpatient days for a hospital, the most recent available audited cost report data could be used. The numerator could be calculated from existing lines on the cost report as follows: the sum of Worksheet S–3 Part I, column 6, line 2 (MA days and days for individuals enrolled in Medicare cost plans); Worksheet S–3 Part I, column 6, line 14 (Medicare adult and pediatric hospital days excluding SNF and NF swing-bed, observation bed, and hospice days); Worksheet S–3 Part I, column 6, line 32 (total Medicare labor and delivery days); and subtracting Worksheet S–3 Part I, column 6, line 5 (total Medicare adult and pediatric NF swing-bed days) and Worksheet S–3 Part I, column 6, line 6 (total Medicare adult and pediatric NF swing-bed days).

The denominator could be calculated from existing lines on the cost report as follows: the sum of Worksheet S–3 Part I, column 6, line 30 (total all patients’ employee discount days); Worksheet S–3 Part I, column 8, line 5 (total all patients’ adult and pediatric hospital days excluding SNF and NF swing-bed, observation bed, and hospice days); Worksheet S–3 Part I, column 8, line 30 (total all patients’ labor room days); and subtracting Worksheet S–3 Part I, column 8, line 5 (total swing-beds SNF patient days) and Worksheet S–3 Part I, column 8, line 6 (total swing-beds NF patient days).

In the proposed rule, we also noted that, when calculating the SNI, the following circumstances may be encountered: new hospitals (for example, hospitals that begin participation in the Medicare program after the available audited cost report data), hospital mergers, hospitals with multiple cost reports and/or cost reporting periods that are shorter or longer than 365 days, cost reporting periods that span fiscal years, and potentially aberrant data. We solicited comments on how MedPAC’s SNI calculation should address these circumstances and whether the approaches used in the uncompensated care payment methodology might be appropriate. We discussed in section IV.E.3. of the preamble to the proposed rule how these circumstances are addressed in the uncompensated care payment methodology.

For MedPAC’s SNI calculation, we also solicited comments on whether a multi-year approach using the three most recently available years of data may be appropriate to increase the stability of the index, similar to the approach used in the uncompensated care payment methodology.

3. An Alternative Approach to Identifying Safety Net Hospitals—Area-level Indices

As discussed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27188 through 27190), an alternative to using an SNI approach could be to identify safety-net hospitals using area-level indices. This approach could potentially better target policies to address the social determinants of health as well as address the lack of community resources that may increase risk of poor health outcomes and risk of disease in the population. We noted that the Office of the Assistant Secretary for Planning and Evaluation (ASPE) had recently commissioned three environmental scans of: (1) area-level indices of social risk; (2) measures used in government programs that target areas, providers, or populations with social risk; and (3) existing payment models that incorporate measures of social risk. ASPE suggested that an area-level index could be used to prioritize communities for funding and other assistance to improve social determinants of health (SDOH)—such as affordable housing, availability of food stores, and transportation infrastructure. Although ASPE concluded that none of the existing area-level indices are ideal, they concluded that the area deprivation index (ADI) or the Social Deprivation Index (SDI) were the best available choices when selecting an index for addressing health-related social needs or social determinants of health.

The ADI was developed by researchers at the National Institutes of Health with the goal of quantifying and comparing social disadvantage across geographic neighborhoods. It is a composite measure derived through a combination of 17 input variables from census data. The ADI measure is intended to capture local socioeconomic factors correlated with medical disparities and underservice. Several peer reviewers and researchers have acknowledged that neighborhood-level factors for those residing in disadvantaged neighborhoods also have a relationship to worse health outcomes for these residents. Living in an area with an ADI score of 85 or above, a validated measure of neighborhood disadvantage, is shown to be a predictor of 30-day readmission rates, lower rates of cancer survival, poor end-of-life care for patients with heart failure, and longer lengths of stay and fewer home discharges post-knee surgery even after accounting for individual social and economic risk factors. Many rural areas also have relatively high levels of neighborhood disadvantage and high ADI levels.

In the FY 2024 IPPS/LTCH PPS proposed rule, we noted that Medicare already uses ADI to assess underserved beneficiary populations in the Shared Savings Program. In the CY 2023 PFS final rule, CMS adopted a policy to provide eligible Accountable Care Organizations (ACOs) the option to receive advanced investment payments (87 FR 69778). Advance investment payments are intended to encourage low-revenue ACOs that are inexperienced with risk to participate in the Shared Savings Program and to provide additional resources to such ACOs to support care improvement for underserved beneficiaries (87 FR 69845 through 69849).

Medicare uses ADI to calculate the amount of advance investment payments it will make on a quarterly basis to an ACO. There are two types of advance investment payments: a one-time payment of $250,000 and quarterly payments. When calculating the quarterly payments, CMS first determines the ACO’s assigned


959 Under 42 CFR 425.630(g)(1), CMS will recoup advance investment payments made to an ACO from any shared savings the ACO earns until CMS has recouped in full the amount of advance investment payments made to the ACO.
beneficiary population. CMS then assigns each beneficiary a risk factors-based score as follows: (A) the risk factors-based score will be set to 100 if the beneficiary is enrolled in the Medicare Part D LIS or is dually eligible for Medicare and Medicaid; (B) the risk factors-based score will be set to the ADI national percentile rank matched to the beneficiary’s mailing address if the beneficiary is not enrolled in the LIS or is not dually eligible for Medicare and Medicaid and sufficient data is available to match the beneficiary to an ADI national percentile rank; and (C) the risk factors-based score will be set to 50 if the beneficiary is not enrolled in the LIS or is not dually eligible for Medicare and Medicaid and sufficient data is not available to match the beneficiary to an ADI national percentile rank.

The risk-factors based scores assigned to the beneficiaries assigned to the ACO form the basis for determining the quarterly advanced investment payment to the ACO. For additional detail, please see the quarterly payment amount calculation methodology at 42 CFR 425.630(f)(2).

4. Request for Information

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27189 through 27190), we stated that we were interested in public feedback on the challenges faced by safety-net hospitals, and potential approaches to help safety-net hospitals meet those challenges. We welcomed all feedback on this issue and asked the following questions to help facilitate that feedback.

- How should safety-net hospitals be identified or defined?
- What factors should not be considered when identifying or defining a safety-net hospital and why?
- What are the different types of safety-net hospitals?
- What are the main challenges facing safety-net hospitals?
- What are particular challenges facing rural safety-net hospitals?
- What new approaches or modifications to existing approaches should be implemented or considered to address these challenges, either for safety-net hospitals in general, or for specific types of safety-net hospitals, including rural safety-net hospitals?
- How helpful is it to have multiple types or definitions of safety-net hospitals that may be used for different purposes or to help address specific challenges?
- For Medicare purposes, would these new or modified approaches require additional authority, or could they be accomplished using existing statutory authority? If there is existing statutory authority, we requested that commenters identify the existing statutory authority.
- Are there specific payment approaches either as previously described or otherwise to consider for rural safety-net hospitals, including acute care hospitals and CAHs, to address challenges?
- For any new or modified approaches, how can specific hospitals be identified as safety-net hospitals, or a type of safety-net hospital, using existing data sources? Are there new data sources that should be developed to better identify these hospitals?
- Is MedPAC’s SNI an appropriate basis for identifying safety-net hospitals for Medicare purposes?
- How might it be improved?
- Should there be a threshold for identifying safety net hospitals using the SNI?
- Should an area-level index, such as the ADI, be part of an appropriate basis for identifying safety-net hospitals?
- Would it be appropriate to adapt the risk-factors based scores used in the Shared Savings Program to the identification of safety-net hospitals?
- How might it be adapted?
- Are there social determinants data collected by hospitals that could be used to inform an approach to identify safety net hospitals? Are there HHS or CMS policies that could support that data collection?
- What challenges do safety-net hospitals face around investments in information technology infrastructure?
- What are ways that CMS policy could advance more robust investments in infrastructure for safety net hospitals?
- How could any potential payment adjustments be determined?
- Should safety-net hospitals’ reporting burden and compensation be different than other hospitals? If so, how?
- What are the patient demographics at safety-net hospitals? What challenges do patients of safety net hospitals face before and after receiving care at the hospital?
- Given Administration efforts to reduce the patient burden of medical debt, are there ways to develop payment approaches for safety net hospitals that would also support hospital patients that need financial assistance?

We greatly appreciate the many thoughtful and wide-ranging comments we received in response to this RFI, including comments from organizations representing safety-net hospitals, State hospital associations, industry trade groups, hospitals, and other interested parties. Our public collaboration on these issues has been and will continue to be critical in achieving our mutual goal of helping safety-net hospitals meet the unique challenges they face. We are expeditiously conducting an in-depth review of the comments we received, and this will help to inform and guide our future rulemaking and other actions in this area.

E. Disclosures of Ownership and Additional Disclosable Parties Information for Skilled Nursing Facilities and Nursing Facilities—Applicability to Other Providers and Suppliers

In the February 15, 2023 Federal Register (88 FR 9820), we published a proposed rule titled “Disclosures of Ownership and Additional Disclosable Parties Information for Skilled Nursing Facilities and Nursing Facilities” (hereinafter occasionally referred to as the first disclosures proposed rule). This proposed rule would implement portions of section 6101 of the Affordable Care Act, which require the disclosure of certain ownership, managerial, and other information regarding Medicare skilled nursing facilities (SNFs) and Medicaid nursing facilities. It also proposed definitions of the terms “private equity company” (PEC) and “real estate investment trust” (REIT) (88 FR 9829). Specifically, a private equity company would be defined in 42 CFR 424.502 as a publicly-traded or non-publicly traded company that collects capital investments from individuals or entities (that is, investors) and purchases an ownership share of a provider (for example, SNF, home health agency, etc.). A REIT would be defined in the same regulation as a publicly-traded or non-publicly traded company that owns part or all of the buildings or real estate in or on which the provider operates. The purpose of these definitions was to assist SNFs that complete the Form CMS–655A enrollment application (Medicare Enrollment Application—Institutional Providers; OMB Control No. 0938–0085) in determining whether an owning or managing entity reported in Section 5 of the application must be identified therein as a PEC and REIT.

We outlined in the first disclosures proposed rule our concerns about the quality of care furnished by PEC-owned and REIT-owned SNFs and the consequent need for transparency regarding such owners (88 FR 9822 and 9823). Yet these concerns about PEC and REIT ownership are not limited to SNFs but extend to other provider and supplier types. Given the concerns discussed in the first disclosures proposed rule between PEC and REIT...
ownership and a decline in nursing
home quality, we believed it was critical for us to collect this information from all providers and suppliers that complete the Form CMS–855A. Doing so would enable us to: (1) determine whether a similar connection exists with respect to non-SNF providers and suppliers; and (2) help us take measures to improve beneficiary quality of care to the extent such connections exist. Indeed, it was with this in mind that we proposed on December 15, 2022, to revise the Form CMS–855A application in a Paperwork Reduction Act submission (87 FR 76626) to require all owning and managing entities listed on any provider’s or supplier’s Form CMS–855A submission to disclose whether they are a PEC or a REIT.960

For the foregoing reasons and to assist these entities in completing the Form CMS–855A, we proposed in the May 1, 2023 IPPS/LTCH PPS proposed rule that the aforementioned definitions of PEC and REIT would apply to all providers and suppliers completing the Form CMS–855A enrollment application. The definitions would not be limited to SNFs. We solicited comment on the propriety of the PEC and REIT definitions first proposed in the February 15, 2023 proposed rule and welcomed suggested revisions. We also sought comment and feedback on whether: (1) our proposed PEC definition should include publicly-traded PECs; and (2) CMS should consider collecting information on other types of private ownership besides PECs and REITs.

We received approximately 10 sets of comments on our proposed application of the PEC and REIT definitions to all providers and suppliers that complete the Form CMS–855A application. As many of these comments closely aligned with those we received on the first disclosure proposed rule’s PEC and REIT provisions, we believe that addressing all of them at one time would facilitate consistency, clarity, and a more streamlined approach. Accordingly, we are not finalizing in this rule the PEC and REIT proposals (including the associated information collection estimates) we made in the May 1, 2023 proposed rule. They will instead be addressed as part of a final rule that we will publish at a later date that will also address the February 15, 2023 disclosures proposed rule.


XI. MedPAC Recommendations and Publicly Available Files

A. MedPAC Recommendations

Under section 1886(e)(4)(B) of the Act, the Secretary must consider MedPAC’s recommendations regarding hospital inpatient payments. Under section 1886(e)(5) of the Act, the Secretary must publish in the annual proposed and final IPPS rules the Secretary’s recommendations regarding MedPAC’s recommendations. We have reviewed MedPAC’s March 2023 “Report to the Congress: Medicare Payment Policy” and have given the recommendations in the report consideration in conjunction with the policies set forth in this final rule. MedPAC recommendations for the IPPS for FY 2024 are addressed in appendix B to this final rule.

For further information relating specifically to the MedPAC reports or to obtain a copy of the reports, contact MedPAC at (202) 653–7226, or visit MedPAC’s website at https://www.medpac.gov.

B. Publicly Available Files

IPPS-related data are available on the internet for public use. The data can be found on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index. We listed the data files available in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27190 through 27192).

Commenters interested in discussing any data files used in construction of this final rule should contact Michael Treitel at (410) 786–4532.

XII. Collection of Information Requirements

A. Statutory Requirement for Solicitation of Comments

Under the Paperwork Reduction Act (PRA) of 1995, we are required to provide 60-day notice in the Federal Register and solicit public comment before a collection of information requirement is submitted to the Office of Management and Budget (OMB) for review and approval. In order to fairly evaluate whether an information collection should be approved by OMB, section 3506(c)(2)(A) of the PRA of 1995 requires that we solicit comment on the following issues:

- The need for the information collection and its usefulness in carrying out the proper functions of our agency.
- The accuracy of our estimate of the information collection burden.
- The quality, utility, and clarity of the information to be collected.
- Recommendations to minimize the information collection burden on the affected public, including automated collection techniques.

In the FY 2024 IPPS/LTCH PPS proposed rule, we solicited public comment on each of these issues for the following sections of this document that contain information collection requirements (ICRs) except for the ICRs related to our proposal on counting certain days associated with section 1115 demonstrations in the Medicaid fraction, for which we solicited public comment in a proposed rule published in the Federal Register on February 28, 2023 (CMS–1788–P (88 FR 12623)). The following ICRs are listed in the order of appearance within the preamble (see sections II. through X. of the preamble of this final rule).

B. Collection of Information Requirements

1. ICRs for the Hospital Wage Index for Acute Care Hospitals

Section III.I.2.a. of the preamble of this final rule, FY 2023 Reclassification Application Requirements and Approvals, references the information collection request 0938–0573 which expired on January 31, 2021. A reinstatement of the information collection request (ICR) is currently being developed. The public will have an opportunity to review and submit comments regarding the reinstatement of this ICR through a public notice and comment period separate from this rulemaking.

2. ICR Relating to Counting Certain Days Associated With Section 1115 Demonstrations in the Medicaid Fraction

In February 2023, we issued a proposed rule (88 FR 12623) to revise our regulations on the counting of days associated with individuals eligible for certain benefits provided by section 1115 demonstrations in the Medicaid fraction of a hospital’s disproportionate patient percentage. In section IV.F. of the preamble of this final rule, we are revising the criteria for a hospital to count days associated with individuals eligible for certain benefits provided by section 1115 demonstrations in the Medicaid fraction of a hospital’s disproportionate patient percentage (DPP): for the patient days of individuals to be included in the DPP Medicaid fraction numerator (if they are not also entitled to Medicare Part A), the demonstration must provide those patients with insurance that includes coverage of inpatient hospital services, or the insurance the patient purchased...
with premium assistance provided by the demonstration must include coverage of inpatient hospital service; and that for days of patients who have bought health insurance that provides inpatient hospital benefits using premium assistance obtained through a section 1115 demonstration, that assistance must be equal to 100 percent of the premium cost to the patient.

In section IV.F. of the preamble of this final rule, we summarized and responded to a comment that Connecticut recently received approval for a premium assistance program under section 1115 that pays through the health insurance exchange 100 percent of the premium costs to cover low-income individuals ineligible for Medicaid under the State plan. For this final rule, we are including Connecticut in the list of states that have section 1115 demonstrations with premium assistance programs.

Overall, we estimate 340 hospitals will be affected by the requirement under our assistance policy, which is the total number of Medicare certified subsection (d) hospitals in the eight States (Arkansas, Connecticut, Massachusetts, Oklahoma, Rhode Island, Tennessee, Utah, and Vermont) that currently operate approved section 1115 demonstrations with premium assistance programs. This estimated total burden is $20,899,060 a year (1,978,141 inquiries a year \times 0.25 hours per inquiry \times \text{wages of $21.13/hour} \times 2 \text{ (fringe benefits)}) \approx 20,899,060/year). The number of inquiries is calculated by subtracting the total CY 2019 Medicare discharges from total CY 2019 discharges for all payers for all subsection (d) hospitals in each State with a currently approved premium assistance section 1115 demonstration. We used annualized discharges for both Medicare and all payer discharge figures rather than actual discharges, as some hospitals’ cost reports do not provide data for an entire calendar year. To determine whether a patient’s premiums for inpatient hospital services insurance are paid for by subsidies provided by a section 1115 demonstration, we believe hospitals would need to conduct inquiries for all patients with non-Medicare insurance for purposes of reporting on the Medicare cost report. The estimated difference between all payer annualized discharges and annualized Medicare discharges was 1,978,141 in CY 2019.

We estimate that hospitals will use their existing communication methods that are in place to verify insurance information when collecting the information under this ICR. We estimate that verifying whether a patient receives 100 percent of the cost of their premium as premium assistance authorized by a section 1115 demonstration will take 15 minutes per individual. We believe that information clerks will be making these inquiries. Based on the Bureau of Labor Statistics Occupational Employment Statistics data (May 2021) for Category 43–4199, information and record clerks, all other, the mean hourly wage for an information and record clerk is $21.13. We have added 100 percent for fringe and other indirect costs benefits which calculates to $42.26 per hour. We estimate this total annual cost is $20,899,060 (1,978,141 inquiries \times 0.25 hours per inquiry \times$42.26 per hour).

In addition, in section IV.F. of the preamble of this final rule, we summarized and responded to comments regarding Massachusetts’ premium assistance program authorized under section 1115. The commentator asserted that the Massachusetts 1115 demonstration provides premium assistance to Medicaid enrollees and other non-Medicare-eligible residents who purchase health insurance in the state’s health insurance exchange that supports low-income individuals enrolled in the Massachusetts Medicaid program who have access to employer-sponsored health insurance, and that this may cause an increased burden on Massachusetts and the providers in that state to determine which patients receive 100 percent premium assistance. In addition, the Massachusetts demonstration provides premium assistance to non-Medicare-eligible individuals at levels less than 100 percent of the individual’s premium cost.

In response to this comment, we stated that while it may be that the premium assistance policy proposed will lead to an increased burden on Massachusetts and providers in that state to identify which non-Medicare-eligible patients have received premium assistance that covers 100 percent of their costs for that patient day to be included in the DPP Medicaid fraction numerator, we do not believe that this burden is unreasonable. The commenters did not provide any information in support of their allegation as to the extent of the burden and why they believe it would be unreasonable.

We are providing an estimate of the increase in burden with regard to Massachusetts to identify whether any non-Medicare-eligible patients have received premium assistance that covers less than 100 percent of their costs for their patient day to be included in the DPP Medicaid fraction numerator. We estimate 56 hospitals will be affected by this requirement, which is the total number of Medicare certified subsection (d) hospitals in Massachusetts. This estimated total burden is $479,322 a year (453,689 inquiries \times 0.025 hours per inquiry \times $42.26 per hour).

To determine whether any non-Medicare-eligible patients have received premium assistance that covers less than 100 percent of their premium costs, we estimate that hospitals will use their existing communication methods. As discussed previously, we estimated that verifying whether a patient receives 100 percent of the cost of their premium as premium assistance authorized by a section 1115 demonstration will take 15 minutes per individual. We believe in many cases verifying whether a patient receives premium assistance under the demonstration that provides less than 100 percent of the individual’s premium cost can occur during that time 15 minutes. However, to account for circumstances where additional time may be needed, we estimated this additional verification will take 1.5 minutes (or 10 percent more time in addition to the time we have estimated it will take to determine whether any non-Medicare-eligible patients have received premium assistance that covers 100 percent of their premium costs).

Overall, we estimate the difference between all payer annualized discharges and annualized Medicare discharges for the 56 Massachusetts hospitals was 453,689 in CY 2019. Similar to the previous discussion, we believe that information clerks will be making these inquiries, and we have used the Bureau of Labor Statistics Occupational Employment Statistics data (May 2021) for Category 43–4199 information and record clerks, all other, the mean hourly wage for an information and record clerk of $21.13. We have added 100 percent for fringe and other indirect costs benefits, which calculates to $42.26 per hour. We estimate the total annual cost is $479,322 for this additional verification (453,689 inquiries \times 0.025 hours per inquiry \times $42.26 per hour).

In summary, we estimate that the total annual burden for Medicare certified subsection (d) hospitals in the eight states with currently approved premium assistance demonstrations to determine whether any non-Medicare-eligible patients have received premium assistance.
assistance from a section 1115 demonstration that covers 100 percent of their premium costs under this requirement is $21,386,382 ($20,899,060 + $479,322).

3. ICRs for Payments for Low-Volume Hospitals

As discussed in section V.E. of the preamble of this final rule, under section 1886(d)(12) of the Act, as amended, the low-volume hospital definition and payment adjustment methodology in effect for FYs 2019 through 2022 under section 50204 of the Bipartisan Budget Act of 2018 are extended through FY 2024. Therefore, for FYs 2019 through 2024, in order to qualify as a low-volume hospital, a subsection (d) hospital must be more than 15 road miles from another subsection (d) hospital and have less than 3,800 total discharges during the fiscal year. In section V.E. of the preamble of this final rule, we also discuss the process for requesting and obtaining the low-volume hospital payment adjustment under § 412.101. Under this previously established process, a hospital makes a written request to its MAC. This request must contain sufficient documentation to establish that the hospital meets the applicable mileage and discharge criteria. The MAC will determine if the hospital qualifies as a low-volume hospital by reviewing the data the hospital submits with its request for low-volume hospital status in addition to other available data. The MAC and CMS may review available data such as the number of discharges, in addition to the data the hospital submits with its request for low-volume hospital status, to determine whether or not the hospital meets the qualifying criteria. (For qualifying hospitals, MACs determine the applicable low-volume hospital payment amount, and no additional action is needed by the hospital.) The burden associated with this requirement is estimated to be 1 hour per hospital. The burden associated with these requests is the time and effort for the hospital to provide the MAC with evidence that it meets the specified mileage and discharge requirements. The burden associated with this requirement is estimated to be 1 hour per hospital. An accountant and auditor would perform this at the wage rate of $40.37. The wage would be doubled to include overhead. We estimate it would take 650 annual hours (1 hour × 650 hospitals seeking the low-volume payment adjustment). Therefore, the cost is $52,481 (650 hours × $80.74). The information collection request under OMB control number 0938–NEW will be submitted to OMB for approval. We did not receive comments regarding the ICRs for payments for low-volume hospitals.

4. ICRs Relating to the Hospital Readmissions Reduction Program

In section V.J. of the preamble of this final rule, we discuss requirements for the Hospital Readmissions Reduction Program. In the FY 2024 IPPS/LTCH PPS proposed rule, we did not propose any changes to the Hospital Readmissions Reduction Program for FY 2024 (88 FR 27024). All six of the current Hospital Readmissions Reduction Program’s measures are claims-based measures. We believe that continuing to use these claims-based measures will not create or reduce any information collection burden for hospitals because they will continue to be collected using Medicare FFS claims that hospitals are already submitting to the Medicare program for payment purposes.

5. ICRs for the Hospital Value-Based Purchasing (VBP) Program

In section V.K. of the preamble of this final rule, we discuss updates to the Hospital VBP Program. Specifically, in the FY 2024 IPPS/LTCH PPS proposed rule, we proposed to adopt substantial measure updates to the MSPB Hospital measure beginning with the FY 2028 program year and to the Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA) measure beginning with the FY 2030 program year (88 FR 27025 through 27026). We also proposed to adopt the Severe Sepsis and Septic Shock: Management Bundle measure beginning with the FY 2026 program year (88 FR 27027 through 27029). Additionally, we proposed to adopt technical changes to the form and manner of the administration of the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Survey measure (88 FR 27031 through 27032). We also proposed a scoring methodology change that adjusts for treating a high proportion of underserved patients, defined by dual eligibility, that rewards hospitals for providing excellent care to this population beginning with the FY 2026 program year (88 FR 27039 through 27049). We also requested feedback on potential additional changes to the Hospital VBP Program that would address health equity (88 FR 27049 through 27050). Lastly, we proposed to modify the Total Performance Score (TPS) maximum to be 110, resulting in numeric score range of 0 to 110 (88 FR 27049). In the FY 2024 IPPS/LTCH PPS proposed rule, we discussed collection of information burden for these proposals (88 FR 27193). In this final rule, we are finalizing all of the Hospital VBP’s Program’s proposals, as proposed. Data collections for the Hospital VBP Program are associated with the Hospital Inpatient Quality Reporting (IQR) Program under OMB control number 0938–1022, the National Healthcare Safety Network under OMB control number 0920–0666, and the HCAHPS survey under OMB control number 0938–0981. The Hospital VBP Program will use data that are also used to calculate quality measures in other programs and Medicare FFS claims data that hospitals are already submitting to CMS for payment purposes, so therefore the program does not estimate any change in burden associated with these finalized measures. There is also no change in burden due to the finalized scoring methodology change because the policy does not require hospitals to submit any additional information but instead changes how hospitals are scored based on the information already being submitted.

6. ICRs Relating to the Hospital-Acquired Condition (HAC) Reduction Program

OMB has currently approved 28,800 hours of burden and approximately $1.2 million under OMB control number 0938–1352 (expiration date November 30, 2025), accounting for information collection burden experienced by 400 subsection (d) hospitals selected for validation each year in the HAC Reduction Program. In the FY 2024 IPPS/LTCH PPS proposed rule, we did not propose to add or remove any measures from the HAC Reduction Program.

In the FY 2024 IPPS/LTCH PPS proposed rule, we proposed to provide hospitals the opportunity to request reconsideration of their final validation score prior to HAC Reduction Program scoring beginning with the FY 2025 program year and future years (88 FR 27054 through 27055). In section V.L. of the preamble of this final rule, we are finalizing this process. This reconsideration process will be conducted once per program fiscal year after validation of HAIs for all four quarters of the given fiscal year’s data period and after the confidence interval has been calculated. A hospital requesting HAC Reduction Program reconsideration must submit a reconsideration request form. As we previously finalized for purposes of the
In the FY 2024 IPPS/LTCH PPS proposed rule, we proposed to modify the validation targeting criteria to include any hospital with a ERUB of the two-tailed confidence interval that is less than 75 percent and received an extraordinary circumstances exception (ECE) for one or more quarters beginning with the FY 2027 program year (88 FR 27055). In section V.I. of the preamble of this final rule, we are finalizing this modification. Because we are neither modifying the number of hospitals that will be selected for validation nor the number of records each selected hospital is required to submit, we do not estimate any changes to our currently approved burden estimates as a result of this policy.

7. ICRs for the Hospital Inpatient Quality Reporting (IQR) Program
a. Background

Data collections for the Hospital IQR Program are associated with OMB control number 0938–1022. OMB has currently approved 1,772,318 hours of burden and approximately $72 million under OMB control number 0938–1022 (expiration date January 31, 2026), accounting for information collection burden experienced by approximately 3,150 IPPS hospitals and 1,350 non-IPPS hospitals for the FY 2025 payment determination. In the FY 2024 IPPS/LTCH PPS proposed rule, we described the burden changes regarding collection of information under OMB control number 0938–1022, for IPPS hospitals (88 FR 27194 through 27196).

For more detailed information on our finalized policies for the Hospital IQR Program, we refer readers to section IX.C. of the preamble of this final rule. In the FY 2024 IPPS/LTCH PPS proposed rule, we proposed to adopt three electronic clinical quality measures (eCQMs) beginning with the FY 2025 reporting period/FY 2027 payment determination: (1) Hospital Harm—Pressure Injury eCQM; (2) Hospital Harm—Acute Kidney Injury eCQM, and (3) Excessive Radiation eCQM (88 FR 27079 through 27084). We proposed to modify two measures within the Hospital IQR Program measure set beginning with the performance data from July 1, 2024 through June 30, 2025, impacting the FY 2027 payment determination: the (1) Hybrid Hospital-Wide All-Cause Risk Standardized Mortality measure and (2) the Hybrid Hospital-Wide All-Cause Risk Standardized Readmission measure (88 FR 27085 through 27088). We proposed to modify the COVID–19 Vaccination Coverage among Healthcare Personnel (HCP) measure beginning with the Q4 2023 reporting period/FY 2025 payment determination (88 FR 27074 through 27078). We proposed to remove the Elective Delivery measure beginning with the CY 2024 reporting period/FY 2026 payment determination (88 FR 27091 through 27093). We proposed to remove two Medicare FFS claims-based measures: the Hospital-Level RCSR Following Elective Primary THA and/or TKA measure beginning with the April 1, 2025 through March 31, 2028 reporting period impacting the FY 2030 payment determination, and the MSPB Hospital measure beginning with the CY 2026 reporting period/FY 2028 payment determination (88 FR 27089 through 27091). We proposed to modify the validation targeting criteria to include any hospital with a two-tailed confidence interval that is less than 75 percent and which submitted less than four quarters of data due to receiving an extraordinary circumstances exception (ECE) for one or more quarters beginning with the FY 2027 payment determination (88 FR 27116). Lastly, we proposed to modify data collection and reporting requirements for the HCAHPS survey measure beginning with the FY 2027 payment determination (88 FR 27112 through 27114). In this final rule, we are finalizing all of the Hospital IQR Program’s proposals, as proposed.

Our finalized policies to remove the Elective Delivery measure beginning with the CY 2024 reporting period/FY 2026 payment determination and to modify data collection and reporting requirements for the HCAHPS survey measure beginning with the FY 2027 payment determination result in changes of collection of information burden as detailed in this section. The remaining policies being finalized will not affect the information collection burden associated with the Hospital IQR Program.

The most recent data from the Bureau of Labor Statistics reflects a median hourly wage of $22.43 per hour for medical records specialists.664 We calculated the cost of overhead, including fringe benefits, at 100 percent of the median hourly wage, consistent with previous years. This is necessary to rough adjustment, both because fringe benefits and overhead costs vary significantly by employer and methods of estimating these costs vary widely in the literature. Nonetheless, we believe that doubling the hourly wage rate ($22.43 × 2 = $44.86) to estimate total cost is a reasonably accurate estimation method. Accordingly, unless otherwise specified, we will calculate cost burden to hospitals using a wage plus benefits estimate of $44.86 per hour throughout the discussion in this section of this rule for the Hospital IQR Program. In the FY 2023 IPPS/LTCH PPS final rule (86 FR 45507), our burden estimates were based on an assumption of approximately 3,150 IPPS hospitals. For this final rule, based on data from the FY 2023 Hospital IQR Program payment determination, which supports this assumption, we will continue to estimate that 3,150 IPPS hospitals will report data to the Hospital IQR Program.

b. Information Collection Burden Estimate for the Finalized Removal of the Elective Delivery Measure Beginning With the CY 2024 Reporting Period/FY 2026 Payment Determination

In section IX.C.7.e. of this final rule, we discuss the removal of the Elective Delivery measure beginning with the CY 2024 reporting period/FY 2026 payment determination. In the FY 2013 IPPS/LTCH PPS final rule, we finalized a burden of 10 minutes, or 0.167 hours, per record to report this measure (77 FR 53666). The currently approved burden estimate for this measure assumes each IPPS hospital will report 76 records quarterly for this measure. We estimate a total reduction in burden of 51 hours (0.167 hours/record × 76 records × 4 quarters) at a cost of $2,288 (51 hours × $44.86) per IPPS hospital associated with the removal of this measure. For the CY 2024 reporting period and subsequent years, we estimate a total burden decrease of 159,600 hours (51 hours × 3,150 hospitals) at a cost of $7,159,656 (159,600 hours × $44.86) related to this policy.

c. Information Collection Burden Estimate for the Finalized Adoption of Three eCQMs Beginning With the CY 2025 Reporting Period/FY 2027 Payment Determination: (1) Hospital Harm—Pressure Injury eCQM; (2) Hospital Harm—Acute Kidney Injury eCQM, and (3) Excessive Radiation eCQM

In sections IX.C.5.a., b., and c. of the preamble of this final rule, we are adopting three new eCQMs: (1) Hospital Harm—Pressure Injury eCQM; (2) Hospital Harm—Acute Kidney Injury eCQM; and (3) Excessive Radiation eCQM.

eCQM—beginning with the CY 2025 reporting period/FY 2027 payment determination. Under OMB control number 0938–1022 (expiration date January 31, 2026) and as finalized in the FY 2023 IPPS/LTCH PPS final rule, the currently approved burden estimate for reporting and submission of eCQM measures is one hour per IPPS hospital for all six required eCQM measures (87 FR 49387). The addition of these three eCQMs does not affect the information collection burden associated with submitting eCQM measure data under the Hospital IQR Program. As finalized in the FY 2023 IPPS/LTCH PPS final rule, current Hospital IQR Program policy requires hospitals to select six eCQMs from the eCQM measure set on which to report (87 FR 49299 through 49302). In other words, although these new eCQMs are being added to the eCQM measure set, hospitals are not required to report more than a total of six eCQMs.

For the Excessive Radiation eCQM, hospitals will also be required to log in through the measure developer’s secure portal and run the Alara Imaging Software for CMS Measure Compliance inside the firewall. The software runs automatically to create the three intermediate data elements needed for the measure. Once the software finishes creating these intermediate variables, hospitals can either: (1) send the data to a hospital’s EHR for reporting; (2) send the data to another vendor for reporting; or (3) have the measure developer submit the data on behalf of and at the behest of hospitals to CMS. No manual data entry is required. We estimate that each hospital will spend approximately 15 minutes (0.25 hours) annually to conduct these activities prior to data submission and therefore estimate a total annual burden of 788 hours (0.25 hours × 3,150 hospitals) at a cost of $35.327 (788 hours × $44.86/hour).

With respect to any costs/burdens unrelated to data submission, we refer readers to the Regulatory Impact Analysis (section II. of appendix A of this final rule).

d. Information Collection Burden Estimate for the Two Hybrid Measure Refinements

In sections IX.C.6.a. and b. of this final rule, we are modifying the: (1) Hybrid Hospital-Wide All-Cause Risk Standardized Mortality measure; and (2) Hybrid Hospital-Wide All-Cause Risk Standardized Readmission measure beginning with the performance data from July 1, 2024 through June 30, 2025, impacting the FY 2027 payment determination.

Although the finalized modifications of both measures will expand the measure cohort to include MA patients, the burden associated with submission of claims data continues to be accounted for under OMB control number 0938–1197 (expiration date October 31, 2023) and the burden associated with submission of eCQM data under OMB control number 0938–1022 (expiration date March 31, 2026) remains unchanged as hospitals will not be required to submit any additional data. Therefore, we are not finalizing any changes in burden associated with the finalized modifications of these measures.

e. Information Collection Burden for the Refinement of the COVID–19 Vaccination Coverage Among Healthcare Personnel (HCP) Measure Beginning With the Quarter 4 CY 2023 Reporting Period/FY 2025 Payment Determination

In the FY 2022 IPPS/LTCH PPS final rule, we finalized adoption of the COVID–19 Vaccination Coverage among HCP measure for the Hospital IQR Program (86 FR 45374 through 45382). In section IX.B. of this final rule, we are replacing the term “complete vaccination course” with the term “up to date” in the HCP vaccination definition and update the numerator to specify the time frames within which an HCP is considered up to date with recommended COVID–19 vaccines, including booster doses, beginning with the Quarter 4 CY 2023 reporting period/FY 2025 payment determination. We previously discussed information collection burden associated with this measure in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45509). We do not believe that the use of the term “up to date” or the update to the numerator will impact information collection or reporting burden because the modification changes neither the amount of data being submitted nor the frequency of data submission. Additionally, because we are not finalizing any updates to the form, manner, and timing of data submission for this measure, there will be no increase in burden associated with the proposal. Furthermore, the modified COVID–19 Vaccination Coverage among HCP measure will continue to be calculated using data submitted to the CDC under a separate OMB control number (0920–1317; expiration date March 31, 2026). However, the CDC currently has a PRA waiver for the collection and reporting of vaccination data under section 321 of the National Childhood Vaccine Injury Act of 1986 (Pub. L. 99–660, enacted on November 14, 1986).

f. Information Collection Burden for the Finalized Removal of Two Claims-Based Measures

In sections IX.C.7.a. and b. of the preamble of this final rule, we are removing two claims-based measures: the Hospital-Level RSCR Following Elective Primary THA/TKA and the MSPB Hospital measures. Because these measures are calculated using Medicare FFS claims that are already reported to the Medicare program for payment purposes, removing these measures will not result in a change to the burden estimates provided in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49384 through 49392).

g. Information Collection Burden for the Finalized Modification of Validation Targeting Criteria Beginning With the FY 2027 Payment Determination

In section IX.C.11.b. of the preamble of this final rule, we are modifying the validation targeting criteria to include any hospital with a two-tailed confidence interval that is less than 75 percent and which submitted less than four quarters of data due to receiving an ECE for one or more quarters beginning with the FY 2027 payment determination. Because we are neither modifying the number of IPPS hospitals that will be selected for validation nor the number of records each selected IPPS hospital will be required to submit, we are not finalizing any changes to our currently approved burden estimates as a result of this proposal.

h. Information Collection Burden for the Finalized Modified Data Collection and Reporting Requirements for the HCAHPS Survey Beginning With the CY 2025 Reporting Period/FY 2027 Payment Determination

In section IX.C.10.h. of the preamble of this final rule, we are finalizing updates to the data collection and reporting for the HCAHPS survey measure beginning with the CY 2025 reporting period/FY 2027 program year. Specifically, we are finalizing to: (1) add three new modes of survey administration (Web-Mail mode, Web-Phone mode, and Web-Mail-Phone mode) in addition to the current Mail Only, Telephone Only and Mail-Phone modes; (2) remove the rule that only the patient may respond to the survey and allow a patient’s proxy to respond to the survey; (3) extend the data collection period for the HCAHPS Survey from 42 to 49 days; (4) limit the number of supplemental items that may be added.
to the HCAHPS survey for quality improvement purposes to 12 items; (5) require hospitals to collect information about the language that the patient speaks while in the hospital (whether English, Spanish, or another language), and that the official Spanish translation of the HCAHPS Survey be administered to all patients who prefer Spanish; and (6) remove two currently available options for administration of the HCAHPS survey that are not used by participating hospitals (Active Interactive Voice Response and Hospitals Administering HCAHPS for Multiple Sites).

With the exception of the removal of two currently available options for administering the survey that are not in use, which CMS estimates to have no effect on the information collections, the remaining policies are estimated to result in a five percent increase from the 2,313,192 respondents who completed and submitted the HCAHPS survey as part of the Hospital IQR Program, which equates to 115,660 additional respondents (2,313,192 \times .05). We do not believe any of these proposals will affect the time required to complete the survey, which is estimated to be 7.25 minutes (0.120833 hours) per respondent, as currently approved under OMB control number 0938–0981 (expiration date September 30, 2024).

We believe that the cost for beneficiaries undertaking administrative and other tasks on their own time is a post-tax wage of $20.71/hr. The Valuing Time in U.S. Department of Health and Human Services Regulatory Impact Analyses: Conceptual Framework and Best Practices identifies the approach for valuing time when individuals undertake activities on their own time.\textsuperscript{965} To derive the costs for beneficiaries, a measurement of the usual weekly earnings of wage and salary workers of $998, divided by 40 hours to calculate an hourly pre-tax wage rate of $24.95/hr. This rate is adjusted downwards by an estimate of the effective tax rate for median income households of about 17 percent, resulting in the post-tax hourly wage rate of $20.71/hr. Unlike our State and private sector wage adjustments, we are not adjusting beneficiary wages for fringe benefits and other indirect costs since the individuals’ activities, if any, would occur outside the scope of their employment. We therefore estimate a burden increase of 13,976 hours (115,660 respondents \times 0.120833 hours) at a cost of $289,443 (13,976 hours \times $20.71).

We are not making any revisions to the information collection at this time; however, we will submit a revised information collection request to OMB for approval under OMB control number 0938–0981 as part of the FY 2025 IPPS/LTCH PPS rulemaking cycle.

### TABLE XII.B-01: SUMMARY OF HOSPITAL IQR PROGRAM ESTIMATED INFORMATION COLLECTION BURDEN CHANGE FOR THE CY 2024 REPORTING PERIOD/FY 2026 PAYMENT DETERMINATION

<table>
<thead>
<tr>
<th>Activity</th>
<th>Estimated time per record (minutes)</th>
<th>Number reporting quarters per year</th>
<th>Number of respondents reporting</th>
<th>Average number records per respondent per quarter</th>
<th>Annual burden (hours) per respondent</th>
<th>Finalized Annual burden (hours) across hospitals</th>
<th>Previously finalized annual burden (hours) across hospitals</th>
<th>Net difference in annual burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Removal of Elective Delivery (PC-01) measure</td>
<td>10</td>
<td>4</td>
<td>3,150</td>
<td>76</td>
<td>51</td>
<td>159,600</td>
<td>N/A</td>
<td>-159,600</td>
</tr>
<tr>
<td><strong>Total Change in Information Collection Burden Hours:</strong> -159,600</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total Cost Estimate:</strong> Updated Hourly Wage ($44.86) x Change in Burden Hours (-159,600) = -$7,159,656</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### TABLE XII.B-02: SUMMARY OF HOSPITAL IQR PROGRAM ESTIMATED INFORMATION COLLECTION BURDEN CHANGE FOR THE CY 2025 REPORTING PERIOD/FY 2027 PAYMENT DETERMINATION

<table>
<thead>
<tr>
<th>Activity</th>
<th>Estimated time per record (minutes)</th>
<th>Number reporting quarters per year</th>
<th>Number of respondents reporting</th>
<th>Average number records per respondent per quarter</th>
<th>Annual burden (hours) per respondent</th>
<th>Finalized Annual burden (hours) across hospitals</th>
<th>Previously finalized annual burden (hours) across hospitals</th>
<th>Net difference in annual burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adopt Excessive Radiation eCQM</td>
<td>15</td>
<td>1</td>
<td>3,150</td>
<td>1</td>
<td>0.25</td>
<td>788</td>
<td>0</td>
<td>+788</td>
</tr>
<tr>
<td>Adopt Updates to the Data Collection and Reporting of HCAHPS</td>
<td>7.25</td>
<td>1</td>
<td>2,428,852</td>
<td>1</td>
<td>0.120833</td>
<td>293,486</td>
<td>279,510</td>
<td>+13,976</td>
</tr>
</tbody>
</table>

**Total Change in Information Collection Burden Hours:** +14,764

**Total Cost Estimate:** Updated Hourly Wage (Varies) x Change in Burden Hours (+14,764) = $324,770
8. ICRs for PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program
OMB has currently approved 0 hours of burden under OMB control number 0938–1175 (expiration date January 31, 2025), accounting for the annual information collection requirements for 11 PCHs for the PCHQR Program for measures finalized through the CY 2023 IPPS/LTCH PPS final rule. The PCHQR program also includes measures that are calculated using data submitted via the National Healthcare Safety Network (NHSN) under OMB control number 0920–0666, claims data that is already reported to the Medicare program for payment purposes, and survey-based measures that are calculated using data collected via the HCAHPS survey under OMB control number 0938–0981. In this final rule, we describe the collection of information burden associated with the PCHQR Program. As discussed in the FY 2024 IPPS/LTCH PPS proposed rule, we proposed to modify the COVID–19 Vaccination Coverage among HCP measure with the FY 2025 Program Year (88 FR 27134). In this final rule, we are finalizing all of the PCHQR Program’s proposals as proposed.

The most recent data from the Bureau of Labor Statistics reflects a median hourly wage of $22.43 per hour for a medical records specialist. We calculated the cost of overhead, including fringe benefits, at 100 percent of the median hourly wage, consistent with previous years. This is necessarily a rough adjustment, both because fringe benefits and overhead costs vary significantly by employer and methods of estimating these costs vary widely in publicly available literature.

Nonetheless, we believe that doubling the hourly wage rate ($22.43 × 2 = $44.86) to estimate total cost is a reasonably accurate estimation method and is consistent with OMB guidance. Accordingly, we will calculate cost burden to PCHs using a wage plus benefits estimate of $44.86 per hour throughout the discussion in this section of this final rule for the PCHQR Program.

a. Information Collection Burden Estimate for the Documentation of Goals of Care Discussions Among Cancer Patients Measure Beginning With the FY 2026 Program Year

In section IX.D.6. of the preamble of this final rule, we are adopting the Documentation of Goals of Care Discussions Among Cancer Patients Measure Beginning With the FY 2026 Program Year. PCHs will report data through the Hospital Quality Reporting (HQR) System on annual basis during the submission period.

Similar to other measures reported via the HQR System for the PCHQR program, we estimate a burden of no more than 10 minutes per hospital per year, as each hospital will only be required to report one aggregate numerator and denominator for all patients. Using the estimate of 10 minutes (or 0.167 hours) per PCH per year, and the updated wage estimate as described previously, we estimate that this policy will result in a total annual burden of approximately 2 hours across all PCHs (0.167 hours × 11 PCHs) at a cost of $90 (2 hours × $44.86). With respect to any costs/burdens unrelated to data submission, we refer readers to the Regulatory Impact Analysis (section I.M. of appendix A of this final rule).

b. Information Collection Burden Estimate for the Facility Commitment to Health Equity Structural Measure Beginning With the FY 2026 Program Year

In section IX.D.3. of the preamble of this final rule, we are adopting the Facility Commitment to Health Equity Structural Measure beginning with the FY 2026 program year. This measure was previously adopted for the Hospital IQR Program in the FY 2023 IPPS/LTCH PPS final rule with an estimated burden of no more than 10 minutes per hospital per year, as it involves attesting to as many as five questions one time per year for a given reporting period (87 FR 49385). We believe the estimated burden will be the same for PCHs.

PCHs will report data through the HQR System on an annual basis during the submission period. Using the estimate of 10 minutes (or 0.167 hours) per PCH per year, and the updated wage estimate as described previously, we estimate that this policy will result in a total annual burden of approximately 2 hours across all PCHs (0.167 hours × 11 PCHs) at a cost of $90 (2 hours × $44.86). With respect to any costs/burdens unrelated to data submission, we refer readers to the Regulatory Impact Analysis (section I.M. of appendix A of this final rule).

c. Information Collection Burden for the Screening for Social Drivers of Health Measure Beginning With the FY 2026 Program Year

In section IX.D.4. of the preamble of this final rule, we are adopting the Screening for Social Drivers of Health measure beginning with voluntary reporting for the FY 2026 program year followed by mandatory reporting on an annual basis beginning with the FY 2027 program year. This measure was previously adopted for the Hospital IQR Program in the FY 2023 IPPS/LTCH PPS final rule with an estimated burden of 2 minutes (0.033 hours) per patient to conduct this screening and 10 minutes (0.167 hours) per hospital response to transmit the measure data (87 FR 49385 through 49386). We believe the estimated burden for both patient screening and data submission will be the same for PCHs. As discussed in the preamble of this final rule, PCHs will be able to collect data and report the measure via multiple methods. We believe that most PCHs will likely collect data through a screening tool incorporated into their electronic health record (EHR) or other patient intake process. For data submission, PCHs will report measure data through the HQR System annually.
We believe that the cost for beneficiaries undertaking administrative and other tasks on their own time is a post-tax wage of $20.71/hr. The Valuing Time in U.S. Department of Health and Human Services Regulatory Impact Analyses: Conceptual Framework and Best Practices identifies the approach for valuing time when individuals undertake activities on their own time. To derive the costs for beneficiaries, a measurement of the usual weekly earnings of wage and salary workers of $998, divided by 40 hours to calculate an hourly pre-tax wage rate of $24.95/hr. This rate is adjusted downwards by an estimate of the effective tax rate for median income households of about 17 percent, resulting in the post-tax hourly wage rate of $20.71/hr. Unlike our State and private sector wage adjustments, we are not adjusting beneficiary wages for fringe benefits and other indirect costs since the individuals’ activities, if any, would occur outside the scope of their employment. Based on the most recent patient data from PCHs, approximately 275 patients will be screened annually in each PCH, for a total of 3,025 patients across all 11 PCHs. Similar to our assumptions for the Hospital IQR Program, for the purposes of calculating burden for voluntary reporting in the FY 2026 program year, we assume 50 percent of PCHs will screen 50 percent of patients. For the FY 2027 program year, we assume 100 percent of PCHs will screen 100 percent of patients. For the FY 2026 program year, we estimate that 828 total patients will be screened (6 PCHs × 138 patients) for a total annual burden of patient screening of 28 hours (828 respondents × 0.033 hours) at a cost of $580 (28 hours × $20.71). For data submission for the FY 2026 program year, we estimate a burden of 1 hour (0.167 hours × 6 PCHs) at a cost of $45 (1 hour × $24.95/hour). For the FY 2027 program year, we estimate a total annual burden of patient screening of 101 hours (3,025 respondents × 0.033 hours) at a cost of $2,092 (101 hours × $20.71) across all PCHs. For data submission for the FY 2027 program year, we estimate a total annual burden of approximately 2 hours across all PCHs (0.167 hours × 11 PCHs) at a cost of $44.86 (2 hours × $22.43/hour).

With respect to any costs/burdens unrelated to data submission, we refer readers to the Regulatory Impact Analysis (section I.M. of appendix A of this final rule).

d. Information Collection Burden for the Screen Positive Rate for Social Drivers of Health Measure Beginning With the FY 2026 Program Year

In section IX.D.5. of the preamble of this final rule, we are adopting the Screen Positive Rate for Social Drivers of Health measure with voluntary reporting for the FY 2026 program year followed by mandatory reporting on an annual basis beginning with the FY 2027 program year. This measure was previously adopted for the Hospital IQR Program in the FY 2023 IPPS/LTC/PPS final rule with an estimated burden of 10 minutes (0.167 hours) per hospital response to transmit the measure data as we estimate only the additional burden for a hospital reporting via the HQR System since patients will not need to provide any additional information for this measure (87 FR 49385). We believe the estimated burden will be the same for PCHs. Similar to our assumptions for the Hospital IQR Program, for the purposes of calculating burden for voluntary reporting in the FY 2026 program year, we assume 50 percent of PCHs would transmit measure data. For the FY 2027 program year, we assume 100 percent of PCHs would transmit measure data.

We estimate a total burden in the FY 2026 program year of 1 hour (0.167 hours × 6 PCHs) at a cost of $45 (1 hour × $24.95/hour). We estimate a total annual burden beginning with the FY 2027 program year of 2 hours across all PCHs (0.167 hours × 11 PCHs) at a cost of $90 (2 hours × $44.86).

e. Information Collection Burden Estimate for the Updates to the Data Collection and Reporting for the HCAHPS Survey Measure (NQF #0166) Beginning With the FY 2027 Program Year

In section IX.D.10. of the preamble of this final rule, we are finalizing updates to the data collection and reporting for the HCAHPS survey measure beginning with the FY 2027 program year. Specifically, we are finalizing the following: (1) add three new modes of survey administration (Web-Mail mode, Web-Phone mode, and Web-Mail-Phone mode) in addition to the current Mail Only, Telephone Only and Mail-Phone modes; (2) remove the rule that only the patient may respond to the survey and allow a patient’s proxy to respond to the survey; (3) extend the data collection period for the HCAHPS Survey from 42 to 49 days; (4) limit the number of supplemental items that may be added to the HCAHPS survey for quality improvement purposes to 12 items; (5) require hospitals to collect information about the language that the patient speaks while in the hospital (whether English, Spanish, or another language), and that the official Spanish translation of the HCAHPS Survey be administered to all patients who prefer Spanish; and (6) remove two currently available options for administration of the HCAHPS Survey that are not used by participating hospitals (Active Interactive Voice Response and Hospitals Administering HCAHPS for Multiple Sites).

With the exception of the removal of two currently available options for administering the survey that are not in use, the remaining proposals are estimated to result in a 5 percent increase from the 13,064 respondents who completed and submitted the HCAHPS survey as part of the PCHQR program, which equates to 653 additional respondents (13,064 × 5 percent). We do not believe any of these proposals will affect the time required to complete the survey, which is estimated to be 7.25 minutes (0.120833 hours) per respondent, as currently approved under OMB control number 0938-0981 (expiration date September 30, 2024). We therefore estimate a burden increase of 79 hours (653 respondents × 0.120833 hours/ respondent) at a cost of $1,636 (79 hours × $20.71).

We are not making revisions to the information collection at this time; however, we will submit a revised information collection request to OMB for approval under OMB control number 0938-0981 as part of the FY 2025 IPPS rulemaking cycle.

f. Information Collection Burden Estimate for the Refinement of the COVID–19 Vaccination Coverage Among Healthcare Personnel (HCP) Measure Beginning With the FY 2025 Program Year

In the FY 2022 IPPS/LTC/PPS final rule, we adopted the COVID–19 Vaccination Coverage among HCP Measure for the PCHQR Program (86 FR 45428 through 45434). In section IX.B. of the preamble of this final rule, we are modifying the COVID–19 Vaccination Coverage among HCP Measure to replace the term “complete vaccination course” with the term “up to date” in the HCP vaccination definition and update the numerator to specify the time frames within which an HCP is considered up to date with recommended COVID–19 vaccines, including booster doses, beginning with the FY 2025 program year. We previously discussed information collection burden associated with this
measure in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45513).

We do not believe that the change in terminology to refer to “up to date” instead of “complete vaccination course” will impact information collection or reporting burden because the modification changes neither the amount of data being submitted nor the frequency of data submission. Furthermore, the COVID–19 Vaccination Coverage among HCP measure will be calculated using data submitted to the CDC under a separate OMB control number (0920–1317; expiration date January 31, 2024).

g. Information Collection Burden Estimate for the Policy to Begin Public Reporting of the Surgical Treatment Complications for Localized Prostate Cancer (PCH–37) Measure Beginning With the FY 2025 Program Year Data

In section IX.D.9.b. of the preamble of this final rule, we are finalizing that we will begin public reporting of the Surgical Treatment Complications for Localized Prostate Cancer (PCH–37) measure beginning with the FY 2025 program year data. Because this measure was previously finalized for inclusion in the PCHQR Program and we are not requiring PCHs to collect or submit any additional data, we do not estimate any change in information collection burden associated with this final rule.

h. Summary of Information Collection Burden Estimates for the PCHQR Program

In summary, under OMB control number 0938–1175 (expiration date January 31, 2025), we estimate that the policies promulgated in this final rule will result in a total increase of 109 hours at a cost of $2,452 annually for 11 PCHs from the FY 2026 program year through the FY 2027 program year. The subsequent tables summarize the total burden changes for each respective FY program year compared to our currently approved information collection burden estimates (the table for the FY 2027 program year reflects the total burden change associated with these policies). Under OMB control number 0938–0981 (expiration date September 30, 2024), we estimate that the policies promulgated in this final rule will result in a total increase of 79 hours at a cost of $1,636 annually for 11 PCHs beginning with the FY 2027 program year. The total increase in burden associated with this information collection is approximately 188 hours at a cost of $4,088. We will submit the revised information collection estimates to OMB for approval under OMB control number 0938–1175. The information collection request approved under OMB control number 0938–0981 will be revised and submitted to OMB as part of the FY 2025 IPPS rulemaking cycle.
<table>
<thead>
<tr>
<th>Activity</th>
<th>Estimated time per record (minutes)</th>
<th>Number reporting quarters per year</th>
<th>Number of respondents per quarter</th>
<th>Average number of records per respondent per quarter</th>
<th>Annual burden (hours) per respondent</th>
<th>Finalized annual burden (hours) across PCIs</th>
<th>Previously finalized annual burden (hours) across PCIs</th>
<th>Net difference in annual burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adopt Proposed Documentation of Goals of Care Discussions Among Cancer Patients Measure</td>
<td>10</td>
<td>1</td>
<td>11</td>
<td>1</td>
<td>167</td>
<td>2</td>
<td>N/A</td>
<td>+2</td>
</tr>
<tr>
<td>Adopt Proposed Facility Commitment to Health Equity Measure</td>
<td>10</td>
<td>1</td>
<td>11</td>
<td>1</td>
<td>167</td>
<td>2</td>
<td>N/A</td>
<td>+2</td>
</tr>
<tr>
<td>Adopt Proposed Screening for Social Drivers of Health Measure (Survey)</td>
<td>2</td>
<td>N/A</td>
<td>828</td>
<td>N/A</td>
<td>4.6</td>
<td>28</td>
<td>N/A</td>
<td>+28</td>
</tr>
<tr>
<td>Adopt Proposed Screening for Social Drivers of Health Measure (Reporting)</td>
<td>10</td>
<td>1</td>
<td>6</td>
<td>1</td>
<td>0.167</td>
<td>1</td>
<td>N/A</td>
<td>+1</td>
</tr>
<tr>
<td>Adopt Proposed Screen Positive Rate for Social Drivers of Health</td>
<td>10</td>
<td>1</td>
<td>11</td>
<td>1</td>
<td>0.167</td>
<td>2</td>
<td>N/A</td>
<td>+2</td>
</tr>
<tr>
<td><strong>Total Change in Information Collection Burden Hours:</strong> 35</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total Cost Estimate:</strong> Updated Hourly Wage (Varies) x Change in Burden Hours (+35) = $895</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### TABLE XII.B-04--SUMMARY OF PCHQR PROGRAM ESTIMATED INFORMATION COLLECTION BURDEN CHANGE FOR THE FY 2027 PROGRAM YEAR

<table>
<thead>
<tr>
<th>Activity</th>
<th>Estimated time per record (minutes)</th>
<th>Number reporting quarters per year</th>
<th>Number of respondents per year</th>
<th>Average number of respondents per quarter</th>
<th>Annual burden (hours) per respondent</th>
<th>Finalized Annual burden (hours) across PCHs</th>
<th>Previously finalized annual burden (hours) across PCHs</th>
<th>Net difference in annual burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adopt Proposed Documentation of Goals of Care Discussions Among Cancer Patients Measure</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>.167</td>
<td>2</td>
<td>N/A</td>
<td>+2</td>
</tr>
<tr>
<td>Adopt Proposed Facility Commitment to Health Equity Measure</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>.167</td>
<td>2</td>
<td>N/A</td>
<td>+2</td>
</tr>
<tr>
<td>Adopt Proposed Screening for Social Drivers of Health Measure (Survey)</td>
<td>2</td>
<td>N/A</td>
<td>3,025</td>
<td>N/A</td>
<td>9.167</td>
<td>101</td>
<td>N/A</td>
<td>+101</td>
</tr>
<tr>
<td>Adopt Proposed Screening for Social Drivers of Health Measure (Reporting)</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0.167</td>
<td>2</td>
<td>N/A</td>
<td>+2</td>
</tr>
<tr>
<td>Adopt Proposed Screen Positive Rate for Social Drivers of Health</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0.167</td>
<td>2</td>
<td>N/A</td>
<td>+2</td>
</tr>
</tbody>
</table>

**Total Change in Information Collection Burden Hours:** 109

**Total Cost Estimate:** Updated Hourly Wage (Varies) x Change in Burden Hours (+109) = $2,452
## Annual Recordkeeping and Reporting Requirements Under OMB Control Number 0938-0981 for the FY 2027 Program Year

<table>
<thead>
<tr>
<th>Activity</th>
<th>Estimated time per record (minutes)</th>
<th>Number reporting quarters per year</th>
<th>Number of respondents reporting</th>
<th>Average number records per respondent per quarter</th>
<th>Annual burden (hours) per respondent</th>
<th>Finalized Annual burden (hours) across PCHs</th>
<th>Previously finalized annual burden (hours) across PCHs</th>
<th>Net difference in annual burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adopt Proposed Updates to the Data Collection and Reporting of HCAHPS</td>
<td>7.25</td>
<td>1</td>
<td>15,717</td>
<td>1</td>
<td>0.120833</td>
<td>1,657.5</td>
<td>1,578.6</td>
<td>+79</td>
</tr>
</tbody>
</table>

**Total Change in Information Collection Burden Hours:** +79

**Total Cost Estimate:** Updated Hourly Wage (Varies) x Change in Burden Hours (+79) = $1,636
TABLE XII.B-05: U.S. BUREAU OF LABOR AND STATISTICS’ MAY 2021 NATIONAL OCCUPATIONAL EMPLOYMENT AND WAGE ESTIMATES

<table>
<thead>
<tr>
<th>Occupation Title</th>
<th>Occupation Code</th>
<th>Mean Hourly Wage ($/hr)</th>
<th>Overhead and Fringe Benefit ($/hr)</th>
<th>Adjusted Hourly Wage ($/hr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registered Nurse (RN)</td>
<td>29-1141</td>
<td>$39.78</td>
<td>$39.78</td>
<td>$79.56</td>
</tr>
<tr>
<td>Licensed Vocational Nurse (LVN)</td>
<td>29-2061</td>
<td>$24.93</td>
<td>$24.93</td>
<td>$49.86</td>
</tr>
<tr>
<td>Speech Language Pathologist (SLP)</td>
<td>29-1127</td>
<td>$41.26</td>
<td>$41.26</td>
<td>$82.52</td>
</tr>
<tr>
<td>Physical Therapist (PT)</td>
<td>29-1123</td>
<td>$44.67</td>
<td>$44.67</td>
<td>$89.34</td>
</tr>
<tr>
<td>Occupational Therapist (OT)</td>
<td>29-1122</td>
<td>$43.02</td>
<td>$43.02</td>
<td>$86.04</td>
</tr>
</tbody>
</table>

As a result of these two measure removal proposals, the estimated burden and cost for LTCHs for complying with requirements of the FY 2025 LTCH QRP will decrease. The removal of the measure will result in a decrease of 18 seconds (0.3 min or 0.005 hr) of clinical staff time at admission beginning with the FY 2025 LTCH QRP. The LCDS item affected by the proposed removal of the Application of Functional Assessment/Care Plan measure is completed by Occupational Therapists (OT), Physical Therapists (PT), Registered Nurses (RN), Licensed Practical and Licensed Vocational Nurses (LVN), Speech-Language Pathologists (SLP) depending on the functional goal selected. We identified the staff type per LCDS item based on past LCDS burden calculations. Our assumptions for staff type were based on the categories generally necessary to perform an assessment, however, individual LTCHs determine the staffing resources necessary. Therefore, we averaged BLS’ National Occupational Employment and Wage Estimates (see Table XII.B-05) for these labor types and established a composite cost estimate using our adjusted wage estimates. The composite estimate of $89.34/hr was calculated by weighting each hourly wage based on the following breakdown regarding provider types most likely to collect this data: OT 45 percent at $86.04/hr; PT 45 percent at $89.34/hr; RN 5 percent at

967 A correction to the FY 2024 IPPS/LTCH proposed rule is made. The proposed rule inadvertently referenced a decrease of 0.1 hour.

We invited public comments on the proposed information collection requirements.

The following is a summary of the public comment received on the proposed revisions and our responses:

**Comment:** A commenter suggested that CMS’ burden estimates underestimated the burden on providers to complete the assessments, including the time it takes to conduct an interview, obtain a patient response, and change workflows to accomplish the collection. They also point to the burden of educating personnel, the burden on informatics to update paper-based facility forms and EMR builds increase the cost significantly. This commenter stated that it currently takes its members a minimum of 30 minutes to complete each LCDS V5.0 on admission and on discharge. However, they report that other members have estimated that it takes between 100 and 110 minutes to complete a full patient assessment, which is nearly three times more than the time CMS has estimated it takes to complete an assessment. This commenter also believes the data may be duplicative of other data captured in the medical chart, as well as being rarely relevant for ongoing training needs and facility-wide improvement efforts, and therefore takes time away from actual patient care without contributing to improved quality.

**Response:** We appreciate the time and effort LTCHs invest in completing the LCDS. The LCDS is an evaluation and assessment tool and the data collected is directly relevant to patient care, such as hearing, speech, vision, cognition, mood and emotional function, bladder and bowel function, pain, swallowing, nutrition, skin integrity, high-risk medications, and SLP 2.5 percent at $82.52/hr. LVN 2.5 percent at $49.86/hr; RN 2.5 percent at $89.34 per hour, 0.03 minutes registered nurse time at $86.21 composite wage = $175,618.35) or $532.18 per LTCH annually ($175,618.35/330 LTCHs).

In section IX.E.8.a. of the preamble of the proposed rule, we proposed that beginning with the FY 2026 payment determination, LTCHs must report 100 percent of the required quality measures data and standardized patient assessment data collected using the LCDS on at least 90 percent of the assessments they submit through the CMS designated submission system. After consideration of the public comments we received, we are modifying our proposal and finalizing that LTCHs are required to report 100 percent of the required quality measures data and standardized patient assessment data collected using the LCDS on at least 85 percent of all assessments submitted beginning with the FY 2026 payment determination and subsequent years. Because LTCHs have been required to submit LCDS assessments in this manner since October 1, 2012, there will be no increase in burden to LTCH providers associated with this final rule.

In section IX.E.4.d. of the preamble of the proposed rule, we proposed to adopt the Patient/Resident COVID–19 Vaccine measure beginning with the FY 2026 LTCH QRP. The proposed measure will be collected using the LCDS. The LCDS V5.0 has been approved under OMB control number 0938–1163 (expiration date: 08/31/2025). One data element will be added to the LCDS in order to allow for collection of this measure and will result in an increase of 0.005 hours (0.3 minutes/60) of clinical staff time at discharge. Using data collected for CY 2021, we estimated a $148,965 total discharge (that is planned, unplanned, and expired) from 330 LTCHs annually. This equates to an increase of 744.825 hours for all LTCHs (148,965 × $79.56/hr and 111,251 planned discharges). We estimated the total cost will be increased by $146.05 per LTCH annually, or $48,197.63 for all LTCHs annually.

As described in following table, under OMB control number 0938–1163, we estimate that the policies finalized in this final rule for the LTCH QRP will result in an overall decrease of 1,292.31 hours annually for 330 LTCHs. The total cost decrease related to this information collection is approximately $127,420.728. The decrease in burden will be accounted for in a revised information collection request under OMB control number (0938–1163).

<table>
<thead>
<tr>
<th>Proposal</th>
<th>Per LTCH</th>
<th>All LTCHCs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in Burden associated with proposed removal of the Functional Assessment and Application of Functional Assessment/Care Plan measures beginning with the FY 2025 LTCH QRP</td>
<td>(6.17)</td>
<td>(532,1768)</td>
</tr>
<tr>
<td>Change in Burden associated with proposed Patient/Resident COVID-19 vaccine beginning with the FY 2026 LTCH QRP</td>
<td>2.26</td>
<td>146,0534</td>
</tr>
<tr>
<td>Total Change in Burden for the LTCH QRP associated with the proposed rule</td>
<td>(3.91)</td>
<td>(386,1234)</td>
</tr>
</tbody>
</table>
special treatments and procedures, and ventilator status. Each of these data elements contributes to the development of a patient-centered plan of care. We also would like to point out that LTCHs have been collecting the data elements in the LCDS V5.0 since October 1, 2022, and our proposal to increase the data completion threshold does not increase the number of items an LTCH must collect at admission or discharge.

As the commenter pointed out in their example, the patient must be assessed and information gathered. After the patient assessment is completed, the LCDS is coded with the information and submitted to iQES, and we want to remind LTCHs, that it is these steps (after the patient assessment) that the estimated burden and cost captures. The burden estimated is based on past LTCH burden calculations and represents the time it takes to encode the LCDS. Our assumptions for staff type were based on the categories generally necessary to perform an assessment, and subsequently encode it, which is consistent with past collection of information estimates. While we acknowledge that some LTCHs may train and utilize other personnel, our estimates are based on the categories of personnel necessary to complete the LCDS.

We continually look for opportunities to minimize burden associated with collection of the LCDS for information users through strategies that simplify collection and submission requirements. At the time we adopt new items, we ensure that all instructions and notices are written in plain language and provide step-by-step examples for completing the LCDS. We provide a dedicated help desk to support users and respond to questions about the data collection. Additionally, a dedicated LTCH QRP web page houses multiple modes of tools, such as instructional videos, case studies, user manuals, and frequently asked questions which support understanding of the items collected on the LCDS generally, and these can be used by current and assist new users of the LCDS. We utilize a listserv to facilitate outreach to users, such as communicating timely and important new material(s), and we continue to use those outreach resources when providing training and information. We create data collection specifications for LTCH electronic health record (EHR) software with ‘skip’ patterns associated with the items used for LTCH QRP compliance to ensure that the LCDS is limited to the minimum data required to meet quality reporting requirements. These specifications are available free of charge to all LTCHs and their technology partners. Further, these minimum requirements are standardized for all users of the LCDS assessment forms. Finally, we provide LTCHs with various resources to review and monitor their own performance on APU, and provide a free internet-based system through which users can access on-demand reports for feedback on the collection of the LCDS associated with their facility.

10. ICRs for the Medicare Promoting Interoperability Program

a. Historical Background

In section IX.F. of the preamble of this final rule, we discuss requirements for the Medicare Promoting Interoperability Program. OMB has currently approved 29,588 hours and approximately $1.3 million under OMB control number 0938–1278 (expiration date August 31, 2025), accounting for information collection burden experienced by approximately 3,150 eligible hospitals and 1,350 CAHs for the EHR reporting period in CY 2023. In the FY 2024 IPPS/LTCH PPS proposed rule, we described the burden changes regarding collection of information under OMB control number 0938–1278 for eligible hospitals and CAHs (88 FR 27204 through 27205). The collection of information burden analysis in this final rule focuses on all eligible hospitals and CAHs that could participate in the Medicare Promoting Interoperability Program and attest to the objectives and measures, and report eCQMs, under the Medicare Promoting Interoperability Program for the EHR reporting periods in CY 2024 and CY 2025.

For more detailed information on our finalized policies for the Medicare Promoting Interoperability Program, we refer readers to section IX.F. of the preamble of this final rule. In the FY 2024 IPPS/LTCH PPS proposed rule, we proposed several policies that will not affect the information collection burden associated with the Medicare Promoting Interoperability Program. We proposed to adopt three electronic clinical quality measures (eCQMs) beginning with the CY 2025 reporting period: (1) Hospital Harm—Pressure Injury eCQM, (2) Hospital Harm—Acute Kidney Injury eCQM, and (3) Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography (CT) in Adults (Hospital Level—Inpatient) eCQM.

In sections IX.F.7.a.(2), of the preamble of this final rule, we are adopting new eCQMs beginning with the CY 2025 reporting period: (1) Hospital Harm—Pressure Injury eCQM, (2) Hospital Harm—Acute Kidney Injury eCQM, and (3) Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography (CT)
in Adults (Hospital Level—Inpatient) eCQM.

The addition of these three eCQMs does not affect the information collection burden of submitting eCQMs under the Medicare Promoting Interoperability Program. Current policy requires eligible hospitals and CAHs to select three eCQMs from the eCQM measure set on which to report in addition to reporting three mandatory eCQMs for a total of six eCQMs (87 FR 49365 through 49367). In other words, although these new eCQMs are being added to the eCQM measure set, eligible hospitals and CAHs are not required to report more than a total of six eCQMs. The burden associated with the reporting of eCQM measures for 3,150 eligible hospitals and 1,350 CAHs as part of the Hospital Inpatient Quality Reporting program is included under OMB control number 0938–1022 (CAHs are referred to as non-IPPS hospitals under OMB 0938–1022).

With respect to any costs/burdens unrelated to data submission, we refer readers to the Regulatory Impact Analysis (section IO. of appendix A of this final rule).

c. Information Collection Burden Estimate for the Finalized Modification to the SAFER Guides Measure

In section IX.F.3. of the preamble of this final rule, we are modifying the SAFER Guides measure to require eligible hospitals and CAHs to submit a “yes” attestation to fulfill the measure beginning with the EHR reporting period in CY 2024. In the FY 2022 IPPS/LTCH PPS final rule, we adopted the SAFER Guides measure and required eligible hospitals and CAHs to attest “yes” or “no” as to whether they completed an annual self-assessment on each of the nine SAFER Guides at any point during the calendar year in which their EHR reporting period occurs (86 FR 45479 through 45481).

Because we are not modifying the information that eligible hospitals and CAHs will be required to submit but are instead requiring an attestation of “yes,” we are not finalizing any changes to our currently approved burden estimates as a result of this policy.

With respect to additional costs/burdens unrelated to data submission, we refer readers to the Regulatory Impact Analysis (section I.O. of appendix A of this final rule).

d. Information Collection Burden for the Establishment of an EHR Reporting Period of a Minimum of Any Continuous 180-Day Period in CY 2025

In section IX.F.2.a. of the preamble of this final rule, we are establishing an EHR reporting period of a minimum of any continuous 180-day period in CY 2025. Because we are not modifying the type or amount of data each eligible hospital and CAH will be required to submit, we are not finalizing any changes to our currently approved burden estimates as a result of this policy.

e. Summary of Estimates Used To Calculate the Collection of Information Burden

In summary, under OMB control number 0938–1278 (expiration date August 31, 2025), we estimate that the policies in this final rule will not result in a change in burden. We continue to estimate an annual burden of 6.6 hours per eligible.

f. Burden Associated With Submission of Additional Information on the Action and Transition Plans for Enrollment as an REH

An eligible facility that submits an application for enrollment as an REH under section 1861(k)(4)(A)(ii) through (iv) of the Act, we specifically require an eligible facility to submit additional information that must include an action plan containing: (1) a plan for initiating REH services (as those services are defined in 42 CFR 485.502, and which must include the provision of emergency department services and observation care); (2) a detailed transition plan that lists the specific services that the provider intends to use to either begin or expand services and ambulance services). We estimate that approximately 68 eligible facilities (that is, CAHs and small rural hospitals with not more than 50 beds) will elect to convert to REHS. This is the same estimate used in the final rule titled “Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Organ Acquisition; Rural Emergency Hospitals; Payment Policies, Conditions of Participation, Provider Enrollment, Physician Self-Referral; New Service Category for Hospital Outpatient Department Prior Authorization Process; Overall Hospital Quality Star Rating; COVID–19,” which was published in the November 23, 2022 Federal Register (87 FR 71748).

We estimate that it would take each CAH or small rural hospital 4 hours to prepare this action plan containing the four required elements specified previously. We further estimate that the annual time burden across all 68 facilities would be 272 hours (4 hours × 68 facilities).

We believe that the person at the facility who would perform this task would be the hospital administrator or CEO. This person would fall under the U.S. Bureau of Labor Statistics (BLS) to determine the mean hourly wage for the positions used in this analysis.970 For the total hourly wage, we doubled the mean hourly wage for a 100 percent increase to cover overhead and fringe benefits, according to standard HHS estimating procedures. If the total cost after doubling resulted in 0.50 or more, the cost was rounded up to the next dollar. If it was 0.49 or below, the total cost was rounded down to the next dollar. The total costs used in this analysis are indicated in Table 1.

b. Burden Associated With Submission of Additional Information on the Action and Transition Plans for Enrollment as an REH

We estimate that it would take each CAH or small rural hospital 4 hours to prepare this action plan containing the four required elements specified previously. We further estimate that the annual time burden across all 68 facilities would be 272 hours (4 hours × 68 facilities).

We believe that the person at the facility who would perform this task would be the hospital administrator or CEO. This person would fall under the U.S. Bureau of Labor Statistics’ job category of Medical and Health Services Manager. According the U.S. Bureau of Labor Statistics, the mean hourly wage for a Medical and Health Services Manager is $57.61.972 This wage,
adjusted for the employer’s fringe benefits and overhead would be $115.

We estimate that the cost burden to each facility for preparing the action plan containing the four required elements would be $460 (4 hours × $115). We further estimate that the cost burden across all CAHs and small rural hospitals converting to REHs would be $31,280 (272 hours × $115 per hour).

It is important to note that this is a one-time burden to the facility. After this task has been completed, this burden will be non-recurring. The information collection request under the OMB control number 0938–NEW will be sent to OMB for approval.

12. ICRs for Physician-Owned Hospitals

In section X.B. of the preamble of this final rule, we discuss our changes pertaining to the process for hospitals with physician ownership or investment that request an exception from the prohibition against facility expansion and program integrity restrictions on approved facility expansion.

Specifically, we are making certain technical and clarifying changes to the information that must be submitted for an expansion exception request. These changes include: (1) providing an email address as well as a hard copy mailing address for the contact person for the hospital; (2) providing the names of any counties in which the hospital provides inpatient or outpatient hospital services, in addition to the name of the county in which the main campus of the requesting hospital is located; (3) providing a statement and, if available, supporting documentation regarding the hospital’s compliance with the requirement that it does not discriminate against beneficiaries of Federal health care programs and does not permit physicians practicing at the hospital to discriminate against such beneficiaries (as opposed to merely stating that it complies with this criterion); and (4) providing information regarding whether another hospital the hospital has used any expansion facility capacity approved in a prior request. The final rule also identifies additional information that a requesting hospital may submit in support of its request for an exception from the prohibition on facility expansion, including, but not limited to, whether it plans to use expansion facility capacity to provide specialty services if the request is approved and information about the current or future need for additional operating rooms, procedure rooms, or beds to serve Medicaid, uninsured, and underserved populations in the county where its main campus is located or in any county where it provides inpatient or outpatient hospital services. In addition, we are requiring electronic submission of requests following instructions posted on the CMS website and eliminating both the option to mail hard copy requests and the requirement to mail an original hard copy of the signed certification statement to CMS. We are also eliminating the use of external data sources for determining whether a hospital meets the criteria for an applicable hospital or a high Medicaid facility. Finally, we are reinstating, with respect to high Medicaid facilities, the program integrity restrictions on the frequency of expansion exception requests at final §411.363(b)(2)(ii), which provides that CMS will not consider an expansion exception request unless the date of submission is at least 2 calendar years from the date of the most recent decision by CMS approving or denying the hospital’s most recent request for an exception from the prohibition on facility expansion.

As we stated in the proposed rule, we do not believe any of these revisions, as finalized, will result in any changes in burden under the PRA. The changes to the information required to be submitted under this final rule are primarily technical or clarifying in nature, and we do not anticipate that they will meaningfully affect the time needed to prepare and submit a request. In addition, we do not anticipate that the changes will affect the annual number of respondents. We did not propose any changes to the definitions of an applicable hospital or a high Medicaid facility, and we anticipate that requiring the use of HCRIS data for all comparison calculations will have little practical impact on whether a requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility. Also, although our regulations have permitted high Medicaid facilities to potentially request an exception to the prohibition on expansion of facility capacity more frequently than once every 2 years since January 1, 2021, no high Medicaid facility has made such request more frequently than every 2 years.

While information collection would normally be subject to the PRA, we continue to believe in this instance it is exempt. The universe of potential respondents is extremely small and represents a tiny fraction of the hospital industry. The expansion exception process is available only to “grandfathered” hospitals with physician ownership and a Medicare provider agreement on December 31, 2010 that also meet the criteria for an applicable hospital or a high Medicaid facility. As stated in the CY 2021 OPPS/ASC final rule (85 FR 86255), an applicable hospital means a hospital: (1) that is located in a county in which the percentage increase in the population during the most recent 5-year period (as of the date that the hospital submits its request for an exception to the prohibition on expansion of facility capacity) is at least 150 percent of the percentage increase in the population growth of the State in which the hospital is located during that period, as estimated by the Bureau of the Census; (2) whose annual percent of total inpatient admissions under Medicaid is equal to or greater than the average percent with respect to such admissions for all hospitals in the county in which the hospital is located during the most recent 12-month period for which data are available (as of the date that the hospital submits its request for an exception to the prohibition on expansion of facility capacity); (3) that does not discriminate against beneficiaries of Federal health care programs and does not permit physicians practicing at the hospital to discriminate against such beneficiaries; (4) that is located in a state in which the average bed capacity in the state is less than the national average bed capacity; and (5) that has an average bed occupancy rate that is greater than the average bed occupancy rate in the State in which the hospital is located. In the same final rule we stated that a high Medicaid facility means a hospital that: (1) is not the sole hospital in a county; (2) with respect to each of the three most recent 12-month periods for which data are available, has an annual percent of total inpatient admissions under Medicaid that is estimated to be greater than such percent with respect to such admissions for any other hospital located in the county in which the hospital is located; and (3) does not discriminate against beneficiaries of Federal health care programs and does not permit physicians practicing at the hospital to discriminate against such beneficiaries. These criteria greatly limit the universe of potential respondents. For example, hospitals that provide only specialized services often do not have the same or a higher percentage of Medicaid inpatient admissions as general acute care hospitals in the counties in which they are located and, thus, could not meet the threshold criteria to use the expansion exception process. The number of potential respondents is further reduced to include only those hospitals with the desire and resources to expand their facility capacity, and then limited to
those that can meet applicable state or local requirements for expansion (such as certificate of need). Given all of these factors, we continue to estimate that we would receive one expansion exception request per year. This estimate is consistent with our experience with the expansion exception process to date. Since January 1, 2012 (the effective date of the regulations setting forth the expansion exception process), on average, we have received approximately one expansion exception request per year. Therefore, in accordance with the implementing regulations of the PRA at 5 CFR 1320.3(c)(4), we believe that the information collection is exempt as it affects less than 10 entities in a 12-month period. Although we believe the information collection is exempt, we note that we estimate that it takes approximately 6 hours and 45 minutes to prepare an expansion exception request and that a request is prepared by a lawyer. To estimate the cost to prepare an expansion exception request, we use a 2021 wage rate of $71.17 for lawyers from the Bureau of Labor Statistics,973 and we double that wage to account for overhead and benefits. The total estimated annual cost is $960.79.

Comment: A commenter asserted that the solicitation of community input on expansion exception requests is subject to the PRA. The commenter stated that CMS did not propose an information collection process for the solicitation of community input, provide a burden estimate, or request public comment on the proposed collection of information associated with the solicitation of community input. The commenter further asserted that CMS did not request approval from OMB.

Response: We disagree that the solicitation of community input is subject to the PRA. For purposes of the PRA, “information” is defined at 5 CFR 1320.3(h); facts or opinions submitted in response to general solicitations of comments in the Federal Register or other publications do not constitute “information” subject to the requirements of the PRA. Further, as noted earlier in this section, we addressed the information collection requirements for our proposals in the proposed rule. The proposed rule, including the determination that the process for requesting an expansion exception is exempt from the PRA, was reviewed by OMB.

Chiquita Brooks-LaSure, Administrator of the Center for Medicare & Medicaid Services, approved this document on July 24, 2023.

List of Subjects
42 CFR Part 411
Diseases, Medicare, Reporting and recordkeeping requirements.

42 CFR Part 412
Administrative practice and procedure, Health facilities, Medicare, Puerto Rico, Reporting and recordkeeping requirements.

42 CFR Part 419
Hospitals, Medicare, Reporting and recordkeeping requirements.

42 CFR Part 488
Administrative practice and procedure, Health facilities, Health professions, Medicare, Reporting and recordkeeping requirements.

42 CFR Part 489
Health facilities, Medicare, Reporting and recordkeeping requirements.

42 CFR Part 495
Administrative practice and procedure, Health facilities, Health maintenance organizations (HMO), Health professions, Health records, Medicaid, Medicare, Penalties, Privacy, Reporting and recordkeeping requirements.

§ 411.353 [Amended]
1. The authority citation for part 411 continues to read as follows:

Authority: 42 U.S.C. 1302, 1395w–101 through 1395w–152, 1395hh, and 1395mm.

§ 411.353 [Amended] b. In paragraph (b)(2), removing the phrase “is granted pursuant to paragraph (c) of this section” and adding in its place the phrase “is approved under § 411.363”; and
c. Removing paragraph (c).
5. Section 411.363 is added to read as follows:

§ 411.363 Process for requesting an exception from the prohibition on facility expansion.

(a) Definitions. For purposes of this section—

Baseline number of operating rooms, procedure rooms, and beds means the number of operating rooms, procedure rooms, and beds for which the applicable hospital or high Medicaid facility is licensed as of March 23, 2010 (or, in the case of a hospital that did not have a provider agreement in effect as of March 23, 2010, but does have a provider agreement in effect on December 31, 2010, the date of effect of such agreement). For purposes of determining the number of beds in a hospital’s baseline number of operating rooms, procedure rooms, and beds, a bed is included if the bed is considered licensed for purposes of State licensure, regardless of the specific number of beds identified on the physical license issued to the hospital by the State.

External data source means a data source that—

(i) Is generated, maintained, or under the control of a State Medicaid agency;
(ii) Is reliable and transparent;
(iii) Maintains data that, for purposes of the process described in this section, are readily available and accessible to the requesting hospital, comparison hospitals, and CMS; and
(iv) Maintains or generates data that, for purposes of the process described in this section, are accurate, complete, and objectively verifiable.

Main campus of the hospital means “campus” as defined at § 413.65(a)(2) of this chapter.

Procedure room has the meaning set forth at § 411.362(a).

(b) CMS consideration of requests for an exception from the prohibition on facility expansion. (1) CMS will not consider a request for an exception from the prohibition on facility expansion from a hospital that is not eligible to request the exception. (2) A hospital that meets the criteria for an applicable hospital or a high Medicaid facility is eligible to request an exception from the prohibition on

facility expansion for consideration by CMS, provided that—

(i) CMS has not previously approved a request for an exception from the prohibition on facility expansion that would allow the hospital’s number of operating rooms, procedure rooms, and beds for which the hospital is licensed to reach 200 percent of the hospital’s baseline number of operating rooms, procedure rooms, and beds if the full expansion is utilized; and

(ii) It has been at least 2 calendar years from the date of the most recent decision by CMS approving or denying the hospital’s most recent request for an exception from the prohibition on facility expansion.

(c) **Criteria for an applicable hospital.** An applicable hospital is a hospital that meets the following criteria:

1. **Population increase.** The hospital is located in a county that has a percentage increase in population that is at least 150 percent of the percentage increase in population of the State in which the hospital is located during the most recent 5-year period for which data are available as of the date that the hospital submits its request. To calculate State and county population growth, a hospital must use Bureau of the Census estimates.

2. **Medicaid inpatient admissions.** The hospital has an annual percent of total inpatient admissions under Medicaid that is equal to or greater than the average percent with respect to such admissions for all hospitals (including the requesting hospital) that have Medicare participation agreements with CMS and are located in the county in which the hospital is located.

(i) With respect to requests submitted on or after October 1, 2023, a hospital may use only filed Medicare hospital cost report data from HCRIS to estimate its annual percent of total inpatient admissions under Medicaid and the average percent with respect to such admissions for all hospitals (including the requesting hospital) that have Medicare participation agreements with CMS and are located in the county in which the hospital is located.

(ii) CMS will provide on its website State average bed capacities and the national average bed capacity.

3. **Average bed capacity.** The hospital is located in a State in which the average bed capacity in the State is less than the national average bed capacity during the most recent fiscal year for which HCRIS, as of the date that the hospital submits its request, contains data from a sufficient number of hospitals to determine a State’s average bed capacity and the national average bed capacity.

4. **Average bed occupancy.** The hospital has an average bed occupancy rate that is greater than the average bed occupancy rate in the State in which the hospital is located during the most recent 12-month period for which data are available as of the date that the hospital submits its request. For purposes of this paragraph (c)(2), the most recent 12-month period for which data are available means the most recent 12-month period for which the data source used contains all data from the requesting hospital and each other hospital that has a Medicare participation agreement with CMS and is located in the county in which the hospital is located.

(i) With respect to requests submitted before October 1, 2023, a hospital may use filed Medicare hospital cost report data from HCRIS or data from an external data source (as defined in paragraph (a) of this section) to estimate its annual percent of total inpatient admissions under Medicaid and the average percent with respect to such admissions for all hospitals (including the requesting hospital) that have Medicare participation agreements with CMS and are located in the county in which the hospital is located.

(ii) For purposes of this paragraph (c)(4), sufficient number means the number of hospitals, as determined by CMS that would ensure that the determination under this paragraph (c)(4) would not materially change after additional hospital data are reported.

5. **Average bed occupancy.** The hospital has an average bed occupancy rate that is greater than the average bed occupancy rate in the State in which the hospital is located during the most recent 12-month period for which the hospital submits its request, contains data from a sufficient number of hospitals to determine the requesting hospital’s average bed occupancy rate and the relevant State’s average bed occupancy rate.

(i) A hospital must use filed hospital cost report data from HCRIS to determine its average bed occupancy rate.

(ii) CMS will provide on its website State average bed occupancy rates. For purposes of this paragraph (c)(5), sufficient number means the number of hospitals, as determined by CMS that would ensure that the determination under this paragraph (c)(5) would not materially change after additional hospital data are reported.

6. **Hospital location.** For purposes of this paragraph (c), a hospital is located in the county and State in which the main campus of the hospital is located.

(d) **Criteria for a high Medicaid facility.** A high Medicaid facility is a hospital that meets all of the following criteria:

1. Sole hospital. The hospital is not the sole hospital in the county in which the hospital is located.

2. Medicaid inpatient admissions. With respect to each of the three most recent 12-month periods for which data are available as of the date the hospital submits its request, the hospital has an annual percent of total inpatient admissions under Medicaid that is estimated to be greater than such percent with respect to such admissions for each other hospital that has a Medicare participation agreement with CMS and is located in the county in which the hospital is located. For purposes of this paragraph (d)(2), the most recent 12-month period for which data are available means the most recent 12-month period for which the data source used contains all data from the requesting hospital and each other hospital that has a Medicare participation agreement with CMS and is located in the county in which the hospital is located.

(i) With respect to requests submitted before October 1, 2023, a hospital may use filed Medicare hospital cost report data from HCRIS or data from an external data source (as defined in paragraph (a) of this section) to estimate its annual percent of total inpatient admissions under Medicaid and the annual percentages of total inpatient admissions under Medicaid for each other hospital that has a Medicare participation agreement with CMS and is located in the county in which the hospital is located.

(ii) With respect to requests submitted on or after October 1, 2023, a hospital must use filed Medicare hospital cost report data from HCRIS to estimate its annual percent of total inpatient admissions under Medicaid and the annual percentages of total inpatient admissions under Medicaid for each other hospital that has a Medicare participation agreement with CMS and is located in the county in which the hospital is located.

3. **Nondiscrimination.** The hospital does not discriminate against beneficiaries of Federal health care programs and does not permit physicians practicing at the hospital to discriminate against such beneficiaries.

4. **Hospital location.** For purposes of this paragraph (d), a hospital is located in the county in which the main campus of the hospital is located.
(e) Procedure for submitting a request for an exception from the prohibition on facility expansion. (1) A hospital must submit the request for an exception from the prohibition on facility expansion and the signed certification set forth in paragraph (e)(3) of this section electronically to CMS according to the instructions specified on the CMS website.

(2) For a hospital’s request for an exception from the prohibition on facility expansion to be considered by CMS, the request must include all of the following information:

(i) The name, address, national provider identification number(s) (NPI), tax identification number (TIN), and CMS certification number (CCN) for the hospital.

(ii) (A) The name of the county in which the main campus is located; and
(B) The names of any counties in which the hospital provides inpatient or outpatient hospital services.

(iii) The name, title, daytime telephone number, electronic mail address, and hard copy mail address for the contact person who will be available to discuss the request with CMS on behalf of the hospital.

(iv) (A) A statement identifying the hospital as an applicable hospital or high Medicaid facility; and
(B) A detailed explanation with supporting documentation regarding whether and how the hospital meets each of the criteria for an applicable hospital or high Medicaid facility.

(v) A statement and supporting documentation, if available, explaining how the hospital satisfies the criterion in paragraph (c)(3) or (d)(3) of this section that it does not discriminate against beneficiaries of Federal health care programs and does not permit physicians practicing at the hospital to discriminate against such beneficiaries.

(vi) Documentation supporting—
(A) The hospital’s calculations of its baseline number of operating rooms, procedure rooms, and beds;
(B) The number of operating rooms, procedure rooms, and beds for which the hospital is licensed as of the date that the hospital submits a request for an exception;
(C) Whether and how the hospital has used any expansion facility capacity approved in a prior request; and
(D) The additional number of operating rooms, procedure rooms, and beds by which the hospital requests to expand.

(2) A hospital may submit other information with respect to the request, including but not limited to information regarding—

(i) Whether the hospital plans to use expansion facility capacity to provide specialty services (for example, maternity, psychiatric services, or substance use disorder care) if the request is approved; and
(ii) The current or future need, if any, for additional operating rooms, procedure rooms, and beds—
(A) For the hospital to serve Medicaid, uninsured, and underserved populations;
(B) In the county in which the main campus of the hospital is located; and
(C) In any county in which the hospital provides inpatient or outpatient hospital services as of the date the hospital submits the request.

(3) A request for an exception from the prohibition on facility expansion must include the following certification signed by an authorized representative of the hospital: “With knowledge of the penalties for false statements provided by 18 U.S.C. 1001, I certify that all of the information provided in the request and all of the documentation provided with the request is true and correct to the best of my knowledge and belief.” An authorized representative is the chief executive officer, chief financial officer, or other individual who is authorized by the hospital to make the request.

(f) Community input. (1) Upon submitting a request for an exception from the prohibition on facility expansion and until the hospital receives a CMS decision on the request, the hospital must disclose on any public website for the hospital that it is requesting an exception from the prohibition on facility expansion.

(2) A hospital submitting a request for an exception from the prohibition on facility expansion must provide actual notification that it is requesting an exception, in either electronic or hard copy form, directly to hospitals whose data are part of the comparisons in paragraphs (c)(2) and (d)(2) of this section.

(3)(i) Individuals and entities in the hospital’s community may provide input with respect to the hospital’s request for an exception from the prohibition on facility expansion, including, but not limited to, input regarding whether the hospital meets the criteria for an applicable hospital or a high Medicaid facility and the factors listed in paragraph (i)(2) of this section that CMS will consider in deciding whether to approve or deny a hospital’s request.

(ii) The hospital’s community includes the geographic area served by the hospital (as defined at §411.357(e)(2)) and all of the following:

(A) The county in which the hospital’s main campus is located.
(B) The counties in which the hospital provides inpatient or outpatient hospital services as of the date the hospital submits the request.

(iii) Community input must be—
(A) In the form of written comments;
(B) Submitted according to the instructions in the Federal Register notice of the hospital’s request; and
(C) Received no later than 60 days after CMS publishes notice of the hospital’s request in the Federal Register.

(iv) If CMS receives written comments from the community, the hospital has 60 days after CMS notifies the hospital of the written comments to submit a rebuttal statement.

(g) Timing of complete request. (1) If only filed Medicare hospital cost report data from HCRIS are used in the hospital’s request for an exception from the prohibition on facility expansion, the written comments, and the hospital’s rebuttal statement, a request will be deemed complete no later than 90 days after the end of—

(i) The 60-day comment period if CMS does not receive written comments from the community.

(ii) The 60-day rebuttal period, regardless of whether the hospital submits a rebuttal statement, if CMS receives written comments from the community.

(2) If data from an external data source are used in the hospital’s request for an exception from the prohibition on facility expansion, the written comments, or the hospital’s rebuttal statement, a request will be deemed complete no later than 180 days after the end of—

(i) The 60-day comment period if CMS does not receive written comments from the community.

(ii) The 60-day rebuttal period, regardless of whether the hospital submits a rebuttal statement, if CMS receives written comments from the community.

(h) Determination that the hospital is an applicable hospital or a high Medicaid facility. Based on the information described in paragraph (e) of this section and the community input described in paragraph (f) of this section, if any, CMS will first determine whether the hospital meets the criteria for an applicable hospital or a high Medicaid facility.

(i) CMS decision to approve or deny a request for an exception from the prohibition on facility expansion—

(1) Data and information for consideration by CMS. In reviewing a request for an
exception from the prohibition on facility expansion. CMS—
(i) Will consider data and information provided by the hospital in its request, included in the community input, if any, and provided by the hospital in its rebuttal statement, if any; and
(ii) May also consider any other data and information relevant to its decision.
(2) Factors considered by CMS.
Factors that CMS will consider in deciding whether to approve or deny a hospital’s request for an exception from the prohibition on facility expansion include, but are not limited to the following:
(i) The specialty (for example, maternity, psychiatric, or substance use disorder care) of the hospital or the services furnished by or to be furnished by the hospital if CMS approves the request.
(ii) Program integrity or quality of care concerns related to the hospital.
(iii) Whether the hospital has a need for additional operating rooms, procedure rooms, or beds.
(iv) Whether there is a need for additional operating rooms, procedure rooms, or beds in the county in which the main campus of the hospital is located or in any county in which the hospital provides inpatient or outpatient hospital services as of the date the hospital submits the request.
(j) Permitted increase in facility capacity. (1) Except as provided in paragraph (j)(2) of this section, a permitted increase under this section—
(i) May not result in the number of operating rooms, procedure rooms, and beds for which the hospital is licensed exceeding 200 percent of the hospital’s baseline number of operating rooms, procedure rooms, and beds; and
(ii) May occur only in facilities on the hospital’s main campus.
(2) The limitations of paragraph (j)(1) of this section do not apply to an increase in facility capacity approved by CMS with respect to a request for an exception from the prohibition on facility expansion submitted by a high Medicaid facility between January 1, 2021, and September 30, 2023.
(k) Publication of final determination and decision. Not later than 60 days after receiving a complete request—
(1) If CMS determines that the hospital does not meet the criteria for an applicable hospital or a high Medicaid facility, CMS will publish in the Federal Register notice of such determination; or
(2) If CMS determines that the hospital meets the criteria for an applicable hospital or a high Medicaid facility, CMS will publish in the Federal Register notice of such determination and its decision regarding the hospital’s request for an exception from the prohibition on facility expansion.
(l) Limitation on review. There shall be no administrative or judicial review under section 1869 of the Act, section 1878 of the Act, or otherwise of the process under this section (including the establishment of such process and any CMS determination or decision under such process).

PART 412—PROSPECTIVE PAYMENT SYSTEMS FOR INPATIENT HOSPITAL SERVICES

§ 412.90 [Amended]
8. Section 412.90 is amended in paragraph (j) by removing the date “October 1, 2022” and adding in its place the date “October 1, 2024”.
9. Section 412.92 is amended by—
(a) In paragraph (b)(1)(v), removing the term “forwards” and adding the term “forwards” in its place;
(b) In paragraph (b)(2)(i), removing the second reference to “paragraph (b)(2)(v) of this section” and adding in its place the reference “paragraphs (b)(2)(v) and (vi) of this section”; and
(c) Revising paragraphs (b)(2)(ii) and (b)(2)(iv); and
(d) Adding paragraph (b)(2)(vi).
The revisions and addition read as follows:

§ 412.92 Special treatment: Sole community hospitals.

§ 412.87 Additional payment for new medical services and technologies: General provisions.

The addition reads as follows:

§ 412.87 Additional payment for new medical services and technologies: General provisions.

(iv) For applications received on or before September 30, 2018, a hospital classified as a sole community hospital receives a payment adjustment, as described in paragraph (d) of this section, effective with discharges occurring on or after 30 days after the date of CMS’ approval of the classification. For applications received on or after October 1, 2018, a hospital classified as a sole community hospital receives a payment adjustment, as described in paragraph (d) of this section, effective with discharges occurring on or after the effective date as provided in paragraph (b)(2)(ii) of this section.

(vi) For applications received on or after October 1, 2023, where eligibility for sole community hospital classification is dependent on the hospital’s merger with another hospital, sole community hospital status is effective as of the effective date of the approved merger if, and only if, the date that the Medicare administrative contractor (MAC) receives the complete application is within 90 days of CMS’ written notification to the hospital of the approval of the merger.

§ 412.90 [Amended]
§ 412.101 [Amended]

10. Section 412.101 is amended by—

(a) In paragraph (b)(2)(i), removing the phrase “FY 2010 and FY 2025 and subsequent”; and

(b) In paragraph (b)(2)(ii), removing the phrase “FY 2022” and adding in its place the phrase “For FY 2010 through FY 2024”;

(c) In paragraph (c)(1), removing the phrase “FY 2010, FY 2023, and FY 2025 and subsequent” and adding in its place the phrase “FY 2010 through FY 2024”;

(d) In paragraph (c)(3) introductory text, removing the phrase “For FY 2010 through FY 2022” and adding in its place the phrase “For FY 2010 through FY 2024”.

11. Section 412.103 is amended by—

(a) In paragraph (d)(1), removing the reference “paragraph (d)(2) of this section” and adding in its place the reference “paragraphs (d)(2) and (3) of this section”;

(b) Adding paragraph (d)(3).

The addition reads as follows:

§ 412.103 Special treatment: Hospitals located in urban areas and that apply for reclassification as rural.

(d) CMS will consider a hospital that satisfies the criteria set forth in paragraph (a)(3) of this section and which qualifies for sole community hospital status in accordance with the requirements of § 412.92(b)(2)(vi) as being located in the rural area of the State in which the hospital is located as of the effective date set forth in § 412.92(b)(2)(vi).

12. Section 412.106 is amended by—

(a) Revising paragraphs (b)(4) introductory text and (b)(4)(i) and (ii); and

(b) Redesignating paragraphs (b)(4)(iii) and (iv) as paragraphs (b)(4)(iv) and (v), respectively; and

(c) Adding a new paragraph (b)(4)(iii).

The revisions and addition read as follows:

§ 412.106 Special treatment: Hospitals that serve a disproportionate share of low-income patients.

(b) Second computation. The fiscal intermediary determines, for the same cost reporting period used for the first computation, the number of the hospital’s patient days of service for patients who were not entitled to Medicare Part A, and who were either eligible for Medicaid on such days as described in paragraph (b)(4)(i) of this section or who were regarded as eligible for Medicaid on such days and the Secretary has determined to include those days in this computation as described in paragraph (b)(4)(ii)(A) or (B) of this section. The fiscal intermediary then divides that number by the total number of patient days in the same period. For purposes of this second computation, the following requirements apply:

(i) For purposes of this computation, a patient is eligible for Medicaid on a given day if the patient is eligible on that day for inpatient hospital services under the State Medicaid plan approved under title XIX of the Act, regardless of whether particular items or services were covered or paid for on that day under the State plan.

(ii) For purposes of this computation, a patient is regarded as eligible for Medicaid on such days and the days of such patients may not be included in this second computation.

§ 412.108 [Amended]

13. Section 412.108 is amended by—

(a) In paragraph (a)(1) introductory text, removing the date “October 1, 2022” and adding in its place the date “October 1, 2024”;

(b) In paragraph (c)(2)(iii) introductory text, removing the date “October 1, 2022” and adding in its place the date “October 1, 2024”.

14. Section 412.140 is amended by adding paragraph (g) to read as follows:

§ 412.140 Participation, data submission, and validation requirements under the Hospital Inpatient Quality Reporting (IQR) Program.

(g) Retention and removal of quality measures under the Hospital IQR Program—(1) General rule for the retention of quality measures. Quality measures adopted for the Hospital IQR Program measure set for a previous payment determination year are retained for use in subsequent payment determination years, except when they are removed, suspended, or replaced as set forth in paragraphs (g)(2) and (3) of this section.

(2) Immediate measure removal. For cases in which CMS believes that the continued use of a measure raises specific patient safety concerns, CMS will immediately remove a quality measure from the Hospital IQR Program and will promptly notify hospitals and the public of the removal of the measure and the reasons for its removal through the Hospital IQR Program ListServ and the QualityNet website, as applicable.

(3) Measure removal, suspension, or replacement through the rulemaking process. Unless a measure raises specific safety concerns as set forth in paragraph (g)(2) of this section, CMS will use the regular rulemaking process to remove, suspend, or replace quality measures in the Hospital IQR Program to allow for public comment.

(i) Factors for consideration of removal of quality measures. CMS will weigh whether to remove a measure based on the following factors:

(A) Factor 1. Measure performance among hospitals is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (“topped out” measure).

(B) Factor 2. A measure does not align with current clinical guidelines or practice.
(C) Factor 3. The availability of a more broadly applicable measure (across settings or populations), or the availability of a measure that is more proximal in time to desired patient outcomes for the particular topic.

(D) Factor 4. Performance or improvement on a measure does not result in better patient outcomes.

(E) Factor 5. The availability of a measure that is more strongly associated with desired patient outcomes for the particular topic.

(F) Factor 6. Collection or public reporting of a measure leads to negative unintended consequences other than patient harm.

(G) Factor 7. It is not feasible to implement the measure specifications.

(H) Factor 8. The costs associated with a measure outweigh the benefit of its continued use in the program.

(iii) Application of measure removal factors. The benefits of removing a measure from the Hospital IQR Program will be assessed on a case-by-case basis.

16. Section 412.162 is amended by revising paragraph (b)(3) to read as follows:

§ 412.162 Process for reducing the base operating DRG payment amount and applying the value-based incentive payment amount adjustment under the Hospital Value-Based Purchasing (VBP) Program.

(b) * * * * * (3) Calculation of the value-based incentive payment percentage. The value-based incentive payment percentage is calculated as the product of all of the following:

(i) The applicable percent as defined in § 412.160.

(ii)(A) For fiscal years before FY 2026, the hospital’s Total Performance Score divided by 100; or

(B) Beginning with FY 2026, the hospital’s Total Performance Score divided by 110; and

(iii) The linear exchange function slope.

* * * * *

17. Section 412.164 is amended by—

(a) In paragraph (b), removing the phrase “. . . for at least” and adding in its place the phrase “. . . for least”; and

(b) Adding paragraph (c). The addition reads to read as follows:

§ 412.164 Measure selection under the Hospital Value-Based Purchasing (VBP) Program.

(c)(1) Updating of measure specifications. CMS uses rulemaking to make substantive updates to the specifications of measures used in the Hospital VBP Program. CMS announces technical measure specification updates through the QualityNet website (https://qualitynet.cms.gov) and listserv announcements.

(2) Measure retention. All measures selected under paragraph (a) of this section remain in the measure set unless CMS, through rulemaking, removes or replaces them.

(3) Measure removal factors—(i) General rule. CMS may remove or replace a measure based on one of the following factors:

(A) Factor 1. Measure performance among hospitals is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (“topped out” measures), defined as: statistically indistinguishable performance at the 75th and 90th percentiles; and truncated coefficient of variation ≤0.10.

(B) Factor 2. A measure does not align with current clinical guidelines or practice.

(C) Factor 3. The availability of a more broadly applicable measure (across settings or populations) or the availability of a measure that is more proximal in time to desired patient outcomes for the particular topic.

(D) Factor 4. Performance or improvement on a measure does not result in better patient outcomes.

(E) Factor 5. The availability of a measure that is more strongly associated with desired patient outcomes for the particular topic.

(F) Factor 6. Collection or public reporting of a measure leads to negative unintended consequences other than patient harm.

(G) Factor 7. It is not feasible to implement the measure specifications.

(H) Factor 8. The costs associated with a measure outweigh the benefit of its continued use in the program.

(ii) Application of measure removal factors. CMS assesses the benefits of removing a measure from the Hospital VBP Program on a case-by-case basis.

(iii) Patient safety exception. Upon a determination by CMS that the continued requirement for hospitals to submit data on a measure raises specific patient safety concerns, CMS may elect to immediately remove the measure from the Hospital VBP measure set. CMS will, upon removal of the measure—

(A) Provide notice to hospitals and the public at the time CMS removes the measure, along with a statement of the specific patient safety concerns that would be raised if hospitals continued to submit data on the measure; and

(B) Provide notice of the removal in the Federal Register.
a. In paragraph (a)(1), adding a sentence at the end of the paragraph followed by a table;

b. Redesignating paragraph (b)(5) as paragraph (b)(6);

c. Adding a new paragraph (b)(5); and

d. Revising newly redesignated paragraph (b)(6).

The additions and revision read as follows:

§ 412.165 Performance scoring under the Hospital Value-Based Purchasing (VBP) Program.

(a) * * *

(1) * * * The applicable minimum number of cases are set forth as follows:

<table>
<thead>
<tr>
<th>Measure short name</th>
<th>Minimum number of cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCAHPS</td>
<td>Hospitals must report a minimum number of 100 completed Hospital Consumer Assessment of Healthcare providers and Systems (HCAHPS) surveys.</td>
</tr>
<tr>
<td>MORT–30–AMI</td>
<td>Hospitals must report a minimum number of 25 cases.</td>
</tr>
<tr>
<td>MORT–30–HF</td>
<td>Hospitals must report a minimum number of 25 cases.</td>
</tr>
<tr>
<td>MORT–30–PN (updated cohort)</td>
<td>Hospitals must report a minimum number of 25 cases.</td>
</tr>
<tr>
<td>MORT–30–COPD</td>
<td>Hospitals must report a minimum number of 25 cases.</td>
</tr>
<tr>
<td>MORT–30–CABG</td>
<td>Hospitals must report a minimum number of 25 cases.</td>
</tr>
<tr>
<td>COMP–HIP–KNEE</td>
<td>Hospitals must report a minimum number of 25 cases.</td>
</tr>
<tr>
<td>CAUTI</td>
<td>Hospitals must report a minimum number of 25 cases.</td>
</tr>
<tr>
<td>CLABSI</td>
<td>Hospitals have a minimum of 1.000 predicted infections as calculated by the Centers for Disease Control and Prevention (CDC).</td>
</tr>
<tr>
<td>Colon and Abdominal Hysterectomy SSI.</td>
<td>Hospitals have a minimum of 1.000 predicted infections as calculated by the CDC.</td>
</tr>
<tr>
<td>MRSA Bacteremia</td>
<td>Hospitals have a minimum of 1.000 predicted infections as calculated by the CDC.</td>
</tr>
<tr>
<td>CDI</td>
<td>Hospitals must report a minimum number of 25 cases.</td>
</tr>
<tr>
<td>SEP–1</td>
<td>Hospitals must report a minimum number of 25 cases.</td>
</tr>
<tr>
<td>MSPB</td>
<td>Hospitals must report a minimum number of 25 cases.</td>
</tr>
</tbody>
</table>

(5) Beginning with FY 2026, CMS will calculate the number of health equity adjustment bonus points the hospital has earned for the fiscal year as follows:

- (a) Awarding 4 points where the hospital’s performance on the domain for the fiscal year meets or exceeds the top third of performance of all hospitals on the domain for the same fiscal year;
- (b) Awarding 2 points where the hospital’s performance on the domain for the fiscal year meets or exceeds the middle third of performance, but is less than the top third of performance, of all hospitals on the domain for the same fiscal year;
- (C) Awarding 0 points where the hospital’s performance on the domain is less than the middle third of performance of all hospitals on the domain for the fiscal year; and
- (D) Summing the points awarded under paragraph (b)(5)(i) of this section to calculate the measure performance scaler for the hospital.

(ii) Calculating the underserved multiplier for the hospital.

(iii) Multiplying the measure performance scaler calculated under paragraph (b)(5)(i) of this section by the underserved multiplier and, if the resulting product is greater than 10, capping that product at 10.

(6) The hospital’s Total Performance Score for the fiscal year is as follows:

- (i) For fiscal years before FY 2026, the sum of the weighted domain scores up to a maximum score of 100.
- (ii) Beginning with FY 2026, the sum of the weighted domain scores and the health equity adjustment bonus points up to a maximum score of 110.

§ 412.320 [Amended]

19. Section 412.320 is amended in paragraph (a)(1)(iii) by adding the phrase “and before October 1, 2023,” after “October 1, 2006,”.

20. Section 412.560 is amended by revising paragraph (f)(1) to read as follows:

§ 412.560 Requirements under the Long-Term Care Hospital Quality Reporting Program (LTCH QRP).

(f) * * *

(1) Long-term care hospitals must meet or exceed the following data completeness thresholds with respect to a fiscal year:

- (i) The threshold set at 100 percent completion of measures data and standardized patient assessment data collected using the LTCH Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) on at least 80 percent of the assessments LTCHs submit through the CMS designated data submission system for the FY 2014 through the FY 2025 LTCH QRP.
- (B) The threshold set at 100 percent completion of measures data and standardized patient assessment data collected using the LTCH Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) on at least 80 percent of the assessments LTCHs submit through the CMS designated data submission system for the FY 2014 through the FY 2025 LTCH QRP.

(ii) The threshold set at 100 percent for measures data collected and submitted using the Centers for Disease Control and Prevention’s (CDC) National Healthcare Safety Network (NHSN) for
FY 2014 and all subsequent payment
updates.

* * * * *

PART 419—PROSPECTIVE PAYMENT SYSTEMS FOR HOSPITAL
OUTPATIENT DEPARTMENT SERVICES

21. The authority citation for part 419 continues to read as follows:

Authority: 42 U.S.C. 1302, 1395(t), and
1395hh.

22. Section 419.92 is amended by adding paragraph (d) to read as follows:

§ 419.92 Payment to rural emergency
hospitals.

* * * * *

(d) REH payment for the costs of
graduate medical education. (1) For
portions of cost reporting periods
beginning on or after October 1, 2023,
an REH that incurs costs of training full-
time equivalent (FTE) residents that
rotate to the REH may receive direct
graduate medical education payments
for those costs.

(2) Payment is equal to the Medicare
reasonable costs that the REH incurs to
train the FTE residents that rotate to
the REH, as determined in accordance with
section 1861(v)(1)(A) of the Act and the
applicable principles of cost
reimbursement in part 413 of this
chapter, except that the following
payment principles are excluded:

(i) Lesser of cost or charges.

(ii) Ceilings on hospital operating
costs.

(3) An REH that does not incur costs
of training FTE residents that rotate to
the REH is considered a nonprovider
setting for purposes of graduate medical
education payments, consistent with
§§ 412.105(f)(1)(ii)(E) and 413.78(g)
of this chapter.

(4) Direct graduate medical education
payments to REHs made under this
section are made from the Federal
Hospital Insurance Trust Fund.

PART 488—SURVEY, CERTIFICATION,
AND ENFORCEMENT PROCEDURES

23. The authority citation for part 488 continues to read as follows:

Authority: 42 U.S.C. 1302 and 1395hh.

§ 488.1 [Amended]

24. Section 488.1 is amended in the
definition of “Provider of services or
provider” by adding the phrase “rural
emergency hospital,” after “critical
access hospital,”.

25. Section 488.2 is revised to read as
follows:

§ 488.2 Statutory basis.

This part is based on the indicated
provisions of the following sections of the Act:

TABLE 1 TO § 488.2

<table>
<thead>
<tr>
<th>Section</th>
<th>Subject</th>
</tr>
</thead>
<tbody>
<tr>
<td>1128</td>
<td>Exclusion of entities from participation in Medicare.</td>
</tr>
<tr>
<td>1128A</td>
<td>Civil money penalties.</td>
</tr>
<tr>
<td>1138(b)</td>
<td>Requirements for organ procurement organizations and organ procurement agencies.</td>
</tr>
<tr>
<td>1814</td>
<td>Conditions for, and limitations on, payment for Part A services.</td>
</tr>
<tr>
<td>1819</td>
<td>Requirements for skilled nursing facilities (SNFs).</td>
</tr>
<tr>
<td>1820</td>
<td>Requirements for critical access hospitals (CAHs).</td>
</tr>
<tr>
<td>1822</td>
<td>Hospice Program survey and enforcement procedures.</td>
</tr>
<tr>
<td>1832(a)(2)(C)</td>
<td>Requirements for Organizations that provide outpatient physical therapy and speech language pathology services.</td>
</tr>
<tr>
<td>1832(a)(2)(F)</td>
<td>Requirements for ambulatory surgical centers (ASCs).</td>
</tr>
<tr>
<td>1832(a)(2)(J)</td>
<td>Requirements for partial hospitalization services provided by community mental health centers (CMHCs).</td>
</tr>
<tr>
<td>1861(e)</td>
<td>Requirements for hospitals.</td>
</tr>
<tr>
<td>1861(f)</td>
<td>Requirements for psychiatric hospitals.</td>
</tr>
<tr>
<td>1861(m)</td>
<td>Requirements for Home Health Services.</td>
</tr>
<tr>
<td>1861(o)</td>
<td>Requirements for Home Health Agencies.</td>
</tr>
<tr>
<td>1861(p)(4)</td>
<td>Requirements for rehabilitation agencies.</td>
</tr>
<tr>
<td>1861(z)</td>
<td>Institutional planning standards that hospitals and SNFs must meet.</td>
</tr>
<tr>
<td>1861(aa)</td>
<td>Requirements for rural health clinics (RHCs) and federally qualified health centers (FQHCs).</td>
</tr>
<tr>
<td>1861(cc)(2)</td>
<td>Requirements for comprehensive outpatient rehabilitation facilities (CORFs).</td>
</tr>
<tr>
<td>1861(dd)</td>
<td>Requirements for hospices.</td>
</tr>
<tr>
<td>1861(ee)</td>
<td>Discharge planning guidelines for hospitals.</td>
</tr>
<tr>
<td>1861(ff)(3)(A)</td>
<td>Requirements for CMHCs.</td>
</tr>
<tr>
<td>1861(ss)(2)</td>
<td>Accreditation of religious nonmedical health care institutions.</td>
</tr>
<tr>
<td>1861(kkk)</td>
<td>Requirements for rural emergency hospitals (REHs).</td>
</tr>
<tr>
<td>1863</td>
<td>Consultation with state agencies, accrediting bodies, and other organizations to develop conditions of participation, conditions for coverage, conditions for certification, and requirements for providers or suppliers.</td>
</tr>
<tr>
<td>1864</td>
<td>Use of State survey agencies.</td>
</tr>
<tr>
<td>1865</td>
<td>Effect of accreditation.</td>
</tr>
<tr>
<td>1875(b)</td>
<td>Requirements for performance review of CMS-approved accreditation programs.</td>
</tr>
<tr>
<td>1880</td>
<td>Requirements for hospitals and SNFs of the Indian Health Service.</td>
</tr>
<tr>
<td>1881</td>
<td>Requirements for end stage renal disease (ESRD) facilities.</td>
</tr>
<tr>
<td>1883</td>
<td>Requirements for hospitals that furnish extended care services.</td>
</tr>
<tr>
<td>1891</td>
<td>Conditions of participation for home health agencies; home health quality.</td>
</tr>
<tr>
<td>1902</td>
<td>Requirements for participation in the Medicaid program.</td>
</tr>
<tr>
<td>1913</td>
<td>Medicaid requirements for hospitals that provide nursing facility (NF) care.</td>
</tr>
<tr>
<td>1919</td>
<td>Medicaid requirements for NFs.</td>
</tr>
</tbody>
</table>

§ 488.18 [Amended]

26. Section 488.18 is amended in
paragraph (d) by adding the phrase “or
a rural emergency hospital (as defined
in section 1861(kkk)(2) of the Act)” after
the parenthetical phrase “(as defined in
section 1861(mm)(1) of the Act)”.

27. Section 488.70 is added to read as
follows:
§ 489.70 Special requirements for rural emergency hospitals (REHs).

An eligible facility submitting an application for enrollment under section 1866(j) of the Act to become a rural emergency hospital (REH) (as defined in § 485.502 of this chapter) must also submit an action plan containing the following additional information:

(a) Plan for provision of services. The provider must submit an action plan for initiating rural emergency hospital (REH) services (as defined in § 485.502 of this chapter, and which must include the provision of emergency department services and observation care).

(b) Transition plan. The provider must submit a detailed transition plan that lists the specific services that the provider will retain, modify, add, and discontinue as an REH.

(c) Other outpatient medical and health services. The provider must submit a detailed description of the other medical and health services that it intends to furnish on an outpatient basis as an REH.

(d) Use of additional facility payment. The provider must submit information regarding how the provider intends to use the additional facility payment provided in accordance with section 1834(x)(2) of the Act, including a description of the services that the additional facility payment would be supporting, such as the operation and maintenance of the facility and the furnishing of covered services (for example, telehealth services, and ambulance services).

PART 495—STANDARDS FOR THE ELECTRONIC HEALTH RECORD TECHNOLOGY INCENTIVE PROGRAM

§ 495.54 Definitions.

EHR reporting period for a payment adjustment year. * * * *(2) * * *

(ix) For an eligible hospital in CY 2025, the EHR reporting period is any continuous 180-day period within CY 2025 and applies for the FY 2027 payment adjustment year.

* * * *

§ 495.40 Demonstration of meaningful use criteria.

* * * *

(b) * * *

(i) For CY 2024 and subsequent years, for an eligible hospital or CAH attesting to CMS, satisfied the required objectives and associated measures for meaningful use as defined by CMS.

* * * *

Dated: July 26, 2023.

Xavier Becerra,
Secretary, Department of Health and Human Services.

Note: The following addendum and appendices will not appear in the Code of Federal Regulations.

Addendum—Schedule of Standardized Amounts, Update Factors, Rate-of-Increase Percentages Effective With Cost Reporting Periods Beginning on or After October 1, 2023, and Payment Rates for LTCHs Effective for Discharges Occurring on or After October 1, 2023

I. Summary and Background

In this Addendum, we are setting forth a description of the methods and data we used to determine the prospective payment rates for Medicare hospital inpatient operating costs and Medicare hospital inpatient capital-related costs for FY 2024 for acute care hospitals. We also are setting forth the rate-of-increase percentage for updating the target amounts for certain hospitals excluded from the IPPS for FY 2024. We note that, because certain hospitals excluded from the IPPS are paid on a reasonable cost basis subject to a rate-of-increase ceiling (and not by the IPPS), these hospitals are not affected by the figures for the standardized amounts, offsets, and budget neutrality factors. Therefore, in this final rule, we are setting forth the rate-of-increase percentage for updating the target amounts for certain hospitals excluded from the IPPS that will be effective for cost reporting periods beginning on or after October 1, 2023.

In addition, we are setting forth a description of the methods and data we used to determine the LTCH PPS standard Federal payment rate that would be applicable to Medicare LTCHs for FY 2024.

In general, except for SCHs and MDHs, for FY 2024, each hospital’s payment per discharge under the IPPS is based on 100 percent of the Federal national rate, also known as the national adjusted standardized amount. This amount reflects the national average hospital cost per case from a base year, updated for inflation.

SCHs are paid based on whichever of the following rates yields the greatest aggregate payment: the Federal national rate (including, as discussed in section IV.G. of the preamble of this final rule, uncompensated care payments under section 1886(f)(2) of the Act); the updated hospital-specific rate based on FY 1982 costs per discharge; the updated hospital-specific rate based on FY 1987 costs per discharge; the updated hospital-specific rate based on FY 1996 costs per discharge; or the updated hospital-specific rate based on FY 2006 costs per discharge.

Under section 1886(d)(5) of the Act, MDHs historically were paid based on the Federal national rate or, if higher, the Federal national rate plus 50 percent of the difference between the Federal national rate and the updated hospital-specific rate based on FY 1982 or FY 1987 costs per discharge, whichever was higher. However, section 5003(a)(1) of Public Law 109–171 extended and modified the MDH special payment provision that was previously set to expire on October 1, 2006, to include discharges occurring on after October 1, 2006, but before October 1, 2011. Under section 5003(b) of Public Law 109–171, if the change results in an increase to an MDH’s target amount, we must rebase an MDH’s hospital specific rates based on its FY 2002 cost report.
Section 5003(c) of Public Law 109–171 further required that MDHs be paid based on the Federal national rate or, if higher, the Federal national rate plus 75 percent of the difference between the Federal national rate and the updated hospital specific rate. Further, based on the provisions of section 5003(d) of Public Law 109–171, MDHs are no longer subject to the 12-percent cap on their DSH payment adjustment factor. Under current law, the Medicare-dependent, small rural hospital (MDH) program is effective through FY 2024.

As discussed in section V.A.2. of the preamble of this final rule, section 1886(n)(6)(B) of the Act was amended to specify that the adjustments to the applicable percentage increase under section 1886(b)(3)(B)(i) of the Act apply to subsection (d) Puerto Rico hospitals that are not meaningful EHR users, effective beginning FY 2022. In general, Puerto Rico hospitals are paid 100 percent of the national standardized amount and are subject to the same national standardized amount as subsection (d) hospitals that receive the full update. Accordingly, our discussion later in this section does not include references to the Puerto Rico-specific wage index.

As discussed in section II. of this Addendum, we are making changes in the determination of the prospective payment rates for Medicare inpatient operating costs for acute care hospitals for FY 2024. In section III. of this Addendum, we discuss our policy changes for determining the prospective payment rates for Medicare inpatient capital-related costs for FY 2024. In section IV. of this Addendum, we are setting forth the rate-of-increase percentage for determining the rate-of-increase limits for certain hospitals excluded from the IPPS for FY 2024. In section V. of this Addendum, we discuss policy changes for determining the LTCH PPS standard Federal rate for LTCHs paid under the LTCH PPS for FY 2024. The tables to which we refer in the preamble of this final rule are listed in section VI. of this Addendum and are available via the internet on the CMS website.

II. Changes to Prospective Payment Rates for Hospital Inpatient Operating Costs for Acute Care Hospitals for FY 2024

The basic methodology for determining prospective payment rates for hospital inpatient operating costs for FY 2005 and subsequent fiscal years is set forth under §412.64. The basic methodology for determining the prospective payment rates for hospital inpatient operating costs for FY 2024 is set forth under §§412.211 and 412.212. In this section, we discuss the factors we are using for determining the prospective payment rates for FY 2024.

In summary, the standardized amounts set forth in Tables 1A, 1B, and 1C that are listed and published in section VI. of this Addendum (and available via the internet on the CMS website) reflect—

- Equalization of the standardized amounts for urban and other areas at the level computed for large urban hospitals during FY 2004 and onward, as provided for under section 1886(d)(3)(A)(iv)(II) of the Act.
- The labor-related share that is applied to the standardized amounts to give the hospital the highest payment, as provided for under sections 1886(d)(3)(E) and 1886(d)(9)(C)(iv) of the Act. For FY 2024, depending on whether a hospital submits quality data under the rules established in accordance with section 1886(b)(3)(B)(viii) of the Act (hereafter referred to as a hospital that submits quality data) and is a meaningful EHR user under section 1886(b)(3)(B)(ix) of the Act (hereafter referred to as a hospital that is a meaningful EHR user), there are four possible applicable percentage increases that can be applied to the national standardized amount.

We refer readers to section V.B. of the preamble of this final rule for a complete discussion on the FY 2024 inpatient hospital update. The table that follows shows these four scenarios:

<table>
<thead>
<tr>
<th>FY 2024</th>
<th>Hospital Submitted Quality Data and is a Meaningful EHR User</th>
<th>Hospital Submitted Quality Data and is NOT a Meaningful EHR User</th>
<th>Hospital Did NOT Submit Quality Data and is a Meaningful EHR User</th>
<th>Hospital Did NOT Submit Quality Data and is NOT a Meaningful EHR User</th>
</tr>
</thead>
<tbody>
<tr>
<td>Market Basket Rate-of-Increase</td>
<td>3.3</td>
<td>3.3</td>
<td>3.3</td>
<td>3.3</td>
</tr>
<tr>
<td>Adjustment for Failure to Submit Quality Data under Section 1886(b)(3)(B)(viii) of the Act</td>
<td>0</td>
<td>0</td>
<td>-0.825</td>
<td>-0.825</td>
</tr>
<tr>
<td>Adjustment for Failure to be a Meaningful EHR User under Section 1886(b)(3)(B)(ix) of the Act</td>
<td>0</td>
<td>-2.475</td>
<td>0</td>
<td>-2.475</td>
</tr>
<tr>
<td>Productivity Adjustment under Section 1886(b)(3)(B)(xi) of the Act</td>
<td>-0.2</td>
<td>-0.2</td>
<td>-0.2</td>
<td>-0.2</td>
</tr>
<tr>
<td>Applicable Percentage Increase Applied to Standardized Amount</td>
<td>3.1</td>
<td>0.625</td>
<td>2.275</td>
<td>-0.2</td>
</tr>
</tbody>
</table>

We note that section 1886(b)(3)(B)(viii) of the Act, which specifies the adjustment to the applicable percentage increase for “subsection (d)” hospitals that do not submit quality data under the rules established by the Secretary, is not applicable to hospitals located in Puerto Rico.

In addition, section 602 of Public Law 114–113 amended section 1886(n)(6)(B) of the Act to specify that Puerto Rico hospitals are eligible for incentive payments for the meaningful use of certified EHR technology, effective beginning FY 2016, and also to apply the adjustments to the applicable percentage increase under section 1886(b)(3)(B)(ix) of the Act to subsection (d) Puerto Rico hospitals that are not meaningful EHR users for FY 2024 and subsequent fiscal years is adjusted by the adjustment for failure to
be a meaningful EHR user under section 1886(b)(3)(B)(ix) of the Act. The regulations at 42 CFR 412.64(d)(3)(ii) reflect the current law for the update for subsection (d) Puerto Rico hospitals for FY 2022 and subsequent fiscal years.

- An adjustment to the standardized amount to ensure budget neutrality for DRG recalibration and reclassification, as provided for under section 1886(d)(4)(C)(iii) of the Act.
- An adjustment to the standardized amount to ensure budget neutrality for the permanent 10 percent cap on the reduction in a MS–DRG’s relative weight in a given fiscal year, as discussed in section II.D.2.c. of the preamble of this final rule, consistent with our current methodology for implementing DRG recalibration and reclassification budget neutrality under section 1886(d)(4)(C)(iii) of the Act.
- An adjustment to ensure the wage index and labor-related share changes (depending on the fiscal year) are budget neutral, as provided for under section 1886(d)(3)(E)(i) of the Act (as discussed in the FY 2006 IPPS final rule (70 FR 47395) and the FY 2010 IPPS final rule (74 FR 44005)). We note that section 1886(d)(3)(E)(i) of the Act requires that when we compute such budget neutrality, we assume that the provisions of section 1886(d)(3)(E)(ii) of the Act (requiring a 62-percent labor-related share in certain circumstances) had not been enacted.
- An adjustment to ensure the effects of geographic reclassification are budget neutral, as provided for under section 1886(d)(3)(E)(ii) of the Act, by removing the FY 2023 budget neutrality factor and applying a revised factor.
- An adjustment to the standardized amount to implement in a budget neutral manner the increase in the wage index values for hospitals with a wage index value below the 25th percentile wage index value across all hospitals (as described in section III.G.4 of the preamble of this final rule).
- An adjustment to the standardized amount to implement in a budget neutral manner the wage index cap policy (as described in section III.G.5. of the preamble of this final rule).
- An adjustment to ensure the effects of the Rural Community Hospital Demonstration program required under section 410A of Public Law 108–173 (as amended by sections 3123 and 10313 of Pub. L. 111–148, which extended the demonstration program for an additional 5 years and section 15003 of Pub. L. 114–255), are budget neutral as required under section 410A(c)(2) of Public Law 108–173.
- An adjustment to remove the FY 2023 outlier offset and apply an offset for FY 2024, as provided for in section 1886(d)(3)(B) of the Act.

For FY 2024, consistent with current law, we are applying the rural floor budget neutrality adjustment to hospital wage indexes. Also, consistent with section 3141 of the Affordable Care Act, instead of applying a State-level rural floor budget neutrality adjustment to the wage index, we are applying a uniform, national budget neutrality adjustment to the FY 2024 wage index for the rural floor.

For FY 2024, as we proposed, we are continuing to not remove the Stem Cell Acquisition Budget Neutrality Factor from the prior year’s standardized amount and to not apply a new factor. If we removed the prior year’s adjustment, we would not satisfy budget neutrality. We believe this approach ensures the effects of the reasonable cost-based payment for allogeneic hematopoietic stem cell acquisition costs under section 108 of the Further Consolidated Appropriations Act, 2020 (Pub. L. 116–94) are budget neutral as required under section 108 of Public Law 116–94. For a discussion of Stem Cell Acquisition Budget Neutrality Factor, we refer the reader to the FY 2021 IPPS/LTCH PPS final rule (85 FR 59032 and 59033).

Section 1886(d)(3)(E) of the Act, as proposed, we are using a labor-related share of 67.6 percent for the national standardized amounts for all IPPS hospitals (including hospitals in Puerto Rico) that have a wage index value that is greater than 1.0000. Consistent with section 1886(d)(3)(E) of the Act, as proposed, we are applying the wage index to a labor-related share of 62 percent of the national standardized amount for all IPPS hospitals (including hospitals in Puerto Rico) whose wage index values are less than or equal to 1.0000.

The standardized amounts for operating costs appear in Tables 1A, 1B, and 1C that are listed and published in section VI. of the Addendum to this final rule and are available via the internet on the CMS website.

2. Computing the National Average Standardized Amount

Section 1886(d)(3)(A)(iv)(II) of the Act requires that, beginning with FY 2004 and thereafter, an equal standardized amount be computed for all hospitals at the level computed for large urban hospitals during FY 2003, updated by the applicable percentage update. Accordingly, as proposed, we are calculating the FY 2024 national average standardized amount irrespective of whether a hospital is located in an urban or rural location.

3. Updating the National Average Standardized Amount

Section 1886(b)(3)(B) of the Act specifies the applicable percentage increase used to update the standardized amount for payment for inpatient hospital operating costs. We note that, in compliance with section 404 of the MMA, we are using the 2018-based IPPS operating and capital market baskets for FY 2024. As discussed in section IV.B. of the preamble of this final rule, in accordance with section 1886(b)(3)(B) of the Act, as amended by section 3401(a) of the Affordable Care Act, we are reducing the FY 2024
applicable percentage increase (which for this final rule is based on IGI’s second quarter 2023 forecast of the 2018-based IPPS market basket) by the productivity adjustment, as discussed elsewhere in this final rule. Based on IGI’s second quarter 2023 forecast (as discussed in appendix B of this final rule), the forecast of the hospital market basket percentage increase for FY 2024 for this final rule is 3.3 percent and the forecast of the productivity adjustment for FY 2024 for this final rule is 0.2 percent. As discussed earlier, for FY 2024, depending on whether a hospital submits quality data under the rules established in accordance with section 1886(b)(3)(B)(viii) of the Act and is a meaningful EHR user under section 1886(b)(3)(B)(ix) of the Act, there are four possible applicable percentage increases that can be applied to the standardized amount. We refer readers to section V.B. of the preamble of this final rule for a complete discussion on the FY 2024 inpatient hospital update to the standardized amount. We also refer readers to the previous table for the four possible applicable percentage increases that would be applied to update the national standardized amount. The standardized amounts shown in Tables 1A through 1C that are published in section VI. of this Addendum and that are available via the internet on the CMS website reflect these differential amounts.

Although the update factors for FY 2024 are set by law, we are required by section 1886(e)(6) of the Act to recommend, taking into account MedPAC’s recommendations, appropriate update factors for FY 2024 for both IPPS hospitals and hospitals and hospital units excluded from the IPPS. Section 1886(e)(5)(A) of the Act requires that we publish our recommendations in the Federal Register for public comment. Our recommendation on the update factors is set forth in appendix B of this final rule.

4. Methodology for Calculation of the Average Standardized Amount

The methodology we used to calculate the FY 2024 standardized amount is as follows:

- To ensure we are only including hospitals paid under the IPPS in the calculation of the standardized amount, we applied the following inclusion and exclusion criteria: include hospitals whose last four digits fall between 0001 and 0879 (section 2779A1 of Chapter 2 of the State Operations Manual on the CMS website at: https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/som107c02.pdf); exclude CAHs at the time of this final rule; exclude hospitals in Maryland (because these hospitals are paid under an all payer model under section 1115A of the Act); and remove PPS excluded—cancer hospitals that have a “V” in the fifth position of their provider number or a “E” or “F” in the sixth position.
- As in the past, we are adjusting the FY 2024 standardized amount to remove the effects of the FY 2023 geographic reclassifications and outlier payments before applying the FY 2024 updates. We then applied budget neutrality offsets for outliers and geographic reclassifications to the standardized amount based on FY 2024 payment policies.
- We do not remove the prior year’s budget neutrality adjustments for reclassification and recalibration of the DRG relative weights and for updated wage data because, in accordance with sections 1886(d)(4)(C)(iii) and 1886(d)(3)(E) of the Act, estimated aggregate payments after updates in the DRG relative weights and wage index should equal estimated aggregate payments prior to the changes. If we removed the prior year’s adjustment, we would not satisfy these conditions.

Budget neutrality is determined by comparing aggregate IPPS payments before and after making changes that are required to be budget neutral (for example, changes to MS–DRG classifications, recalibration of the MS–DRG relative weights, updates to the wage index, and different geographic reclassifications). We include outlier payments in the simulations because they may be affected by changes in these parameters.

- Consistent with our methodology established in the FY 2011 IPPS/LTCH PPS final rule (75 FR 50422 through 50433), because IME Medicare Advantage payments are made to IPPS hospitals under section 1886(d) of the Act, we believe these payments must be part of these budget neutrality calculations. However, we note that it is not necessary to include Medicare Advantage IME payments in the outlier threshold calculation or the outlier offset to the standardized amount because the statute requires that outlier payments be no less than 5 percent nor more than 6 percent of total “operating DRG payments,” which does not include IME and DSH payments. We refer readers to the FY 2011 IPPS/LTCH PPS final rule for a complete discussion on our methodology of identifying and adding the total Medicare Advantage IME payment amount to the budget neutrality adjustments.

- Consistent with the methodology in the FY 2012 IPPS/LTCH PPS final rule, to ensure that we capture only fee-for-service claims, we are only including claims with a “Claim Type” of 60 (which is a field on the MedPAR file that indicates a claim is an FFS claim).
- Consistent with our methodology established in the FY 2017 IPPS/LTCH PPS final rule (81 FR 57277), to further ensure that we capture only FFS claims, we are excluding claims with a “GHOPAID” indicator of 1 (which is a field on the MedPAR file that indicates a claim is not an FFS claim and is paid by a Group Health Organization).
- Consistent with our methodology established in the FY 2011 IPPS/LTCH PPS final rule (7 FR 50422 through 50443), we examine the MedPAR file and remove pharmacy charges for anti-hemophilic blood factor (which are paid separately under the IPPS) with an indicator of “3” for blood clotting with a revenue code of “0636” from the covered charge field for the budget neutrality adjustments for removing organ acquisition charges, except for cases that group to MS–DRG 018, from the covered charge field for the budget neutrality adjustments because organ acquisition is a pass-through payment not paid under the IPPS. Revenue centers 081X–089X are typically excluded from ratesetting; however, we are not removing revenue center 891 charges from MS–DRG 018 claims during ratesetting because those revenue 891 charges were included in the relative weight calculation for MS–DRG 018, which is consistent with the policy finalized in FY 2021 final rule (85 FR 58600). We note that a new MedPAR variable for revenue code 891 charges was introduced in April 2020.

- For FY 2024, we are continuing to remove allogeneic hematopoietic stem cell acquisition charges from the covered charge field for budget neutrality adjustments. As discussed in the FY 2021 IPPS/LTCH PPS final rule, payment for allogeneic hematopoietic stem cell acquisition costs is made on a reasonable cost basis for cost reporting periods beginning on or after October 1, 2020 (85 FR 58835 through 58842).
- The participation of hospitals under the BPCI (Bundled Payments for Care Improvement) Advanced model started on October 1, 2018. The BPCI Advanced model, tested under the authority of section 3021 of the Affordable Care Act (codified at section 1115A of the Act), is comprised of a single payment and risk track, which bundles payments for multiple services beneficiaries receive during a Clinical Episode. Blood cancer hospitals may participate in the BPCI Advanced model in one of two
In order to properly determine aggregate payments on each side of the comparison, consistent with the approach we have taken in prior years, for FY 2023 (as we did for FY 2024) we are including estimated empirically justified Medicare DSH payments that would be paid in accordance with section 1886(r)(1) of the Act and estimates of the additional uncompensated care payments made to hospitals receiving Medicare DSH payment adjustments as described by section 1886(c)(2) of the Act. That is, we considered estimated empirically justified Medicare DSH payments at 25 percent of what would otherwise have been paid, and also the estimated additional uncompensated care payments for hospitals receiving Medicare DSH payment adjustments on both sides of our comparison of aggregate payments when determining all budget neutrality factors described in section II.A.4. of this Addendum.

For FY 2024, consistent with how we treated hospitals that participated in the BPCI Advanced Model in the FY 2021 IPPS/LTCH PPS final rule (85 FR 59029 and 59030), as we proposed, we are including all applicable data from subsection (d) hospitals participating in the BPCI Advanced model in our IPPS payment modeling and ratesetting calculations. We believe it is appropriate to include all applicable data from the subsection (d) hospitals participating in the BPCI Advanced model in our IPPS payment modeling and ratesetting calculations because these hospitals are still receiving IPPS payments under section 1886(d) of the Act. For the same reasons, as we proposed, we included all applicable data from subsection (d) hospitals participating in the Comprehensive Care for Joint Replacement (CJR) Model in our IPPS payment modeling and ratesetting calculations.

• Consistent with our methodology established in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53687 through 53688), we believe that it is appropriate to include adjustments for the Hospital Readmissions Reduction Program and the Hospital VBP Program (established under the Affordable Care Act) within our budget neutrality calculations.

Both the hospital readmissions payment adjustment (reduction) and the hospital VBP payment adjustment (redistribution) are applied on a claim-by-claim basis by adjusting, as applicable, the base-operating DRG payment amount for individual subsection (d) hospitals, which affects the overall sum of aggregate payments on each side of the comparison within the budget neutrality calculations.

In order to properly determine aggregate payments on each side of the comparison, consistent with the approach we have taken in prior years, for FY 2024 this would be FY 2023 final adjustment factors from Table 15 of the FY 2023 IPPS/LTCH PPS final rule and the FY 2024 proposed hospital VBP payment adjustment on each side of the comparison (we note, generally, we use the prior year VBP factors. In the proposed rule, we used an adjustment factor of 1 to reflect our policy for the FY 2023 program year to suppress measures and award each hospital a value-based payment amount that matches the reduction to the base operating DRG payment amount. For this final rule, we used the FY 2024 proposed proxy VBP factors from Table 16A of the proposed rule), consistent with the methodology that we adopted in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53687 through 53688). That is, we are applying a proxy readmissions payment adjustment factor from the prior final rule and a proxy hospital VBP payment adjustment factor on both sides of our comparison of aggregate payments when determining all budget neutrality factors described in section II.A.4. of this Addendum. We refer the reader to section V.H. of the preamble of this final rule for a complete discussion on the Hospital Readmissions Reduction Program and section V.G. of the preamble of this final rule for a complete discussion on the Hospital VBP Program.

• The Affordable Care Act also established section 1886(e) of the Act, which modifies the methodology for computing the Medicare DSH payment adjustment beginning in FY 2014. Beginning in FY 2014, IPPS hospitals receiving Medicare DSH payment adjustments receive an empirically justified Medicare DSH payment equal to 25 percent of the amount that would previously have been received under the statutory formula set forth under section 1886(d)(5)(F) of the Act governing the Medicare DSH payment adjustment. In accordance with section 1886(e)(2) of the Act, the remaining amount, equal to an estimate of 75 percent of what otherwise would have been paid as Medicare DSH payments, reduced to reflect changes in the percentage of individuals who are uninsured and any additional statutory adjustment, is available to make additional payments to Medicare DSH hospitals based on their share of the total amount of uncompensated care reported by Medicare DSH hospitals for a given time period. To properly determine aggregate payments on each side of the comparison for budget neutrality, prior to FY 2014, we included estimated Medicare DSH payments on both sides of our comparison of aggregate payments when determining all budget neutrality factors described in section II.A.4. of this Addendum.

To do this for FY 2024 (as we did for the last 10 fiscal years), as we proposed, we are including estimated empirically justified Medicare DSH payments that would be paid in accordance with section 1886(r)(1) of the Act and estimates of the additional uncompensated care payments made to hospitals receiving Medicare DSH payment adjustments as described by section 1886(c)(2) of the Act. That is, we considered estimated empirically justified Medicare DSH payments at 25 percent of what would otherwise have been paid, and also the estimated additional uncompensated care payments for hospitals receiving Medicare DSH payment adjustments on both sides of our comparison of aggregate payments when determining all budget neutrality factors described in section II.A.4. of this Addendum.

• When calculating total payments for budget neutrality, to determine total payments for SCHs, we model total hospital-specific rate payments and total Federal rate payments and then include whichever one of the total payments is greater. As discussed in section IV.G. of the preamble to this final rule and later in this section, we are continuing to use the FY 2014 finalized methodology under which we take into consideration uncompensated care payments in the comparison of payments under the Federal rate and the hospital-specific rate for SCHs. Therefore, we are including estimated uncompensated care payments in this comparison.

Similarly, for MDHs, as discussed in section IV.G. of the preamble to this final rule, when computing payments under the Federal national rate plus 75 percent of the difference between the payments under the Federal national rate and the payments under the updated hospital-specific rate, we are continuing to take into consideration uncompensated care payments in the computation of payments under the Federal rate and the hospital-specific rate for MDHs.

• As we proposed, we included an adjustment to the standardized amount for those hospitals that are meaningful EHR users for modeling of aggregate payments for budget neutrality for FY 2024. Similar to FY
2023, we are including this adjustment based on data on the prior year's performance. Payments for hospitals would be estimated based on the applicable standardized amount in Tables 1A and 1B for discharges occurring in FY 2024.

- In our determination of all budget neutrality factors described in section II.A.4. of this Addendum, we used transfer-adjusted discharges.

We note, in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49414 through 49415), we finalized a change to the ordering of the budget neutrality factors in the calculation so that the RCH Demonstration budget neutrality factor is applied after all wage index and other budget neutrality factors. We refer the reader to the FY 2023 IPPS/LTCH PPS final rule for further discussion.

a. Reclassification and Recalibration of MS–DRG Relative Weights Before Cap

Section 1886(d)(4)(C)(iii) of the Act specifies that, beginning in FY 1991, the annual DRG reclassification and recalibration of the relative weights must be made in a manner that ensures that aggregate payments to hospitals are not affected. As discussed in section II.D. of the preamble of this final rule, we normalized the recalibrated MS–DRG relative weights by an adjustment factor so that the average case relative weight after recalibration is equal to the average case relative weight prior to recalibration. However, equating the average case relative weight after recalibration to the average case relative weight before recalibration does not necessarily achieve budget neutrality with respect to aggregate payments to hospitals because payments to hospitals are affected by factors other than average case relative weight. Therefore, as we have done in past years, we are making a budget neutrality adjustment to ensure that the requirement of section 1886(d)(4)(C)(iii) of the Act is met.

For this FY 2024 final rule, as we proposed, to comply with the requirement that MS–DRG reclassification and recalibration of the relative weights be budget neutral for the standardized amount and the hospital-specific rates, we used FY 2022 discharge data to simulate payments and compared the following:

- Aggregate payments using the FY 2023 labor-related share percentages, the FY 2024 relative weights before applying the 10 percent cap, and the FY 2023 pre-reclassified wage data, and applied the same proxy FY 2024 hospital readmissions payment adjustments and proxy FY 2024 hospital VBP payment adjustments applied previously.

Because this payment simulation uses the FY 2024 relative weights (before applying the 10 percent cap), consistent with our policy in section IV.I. of the preamble to this final rule, we applied the adjustor for certain cases that group to MS–DRG 018 in our simulation of these payments. We note that because the simulations of payments for all of the budget neutrality factors discussed in this section also use the FY 2024 relative weights, we are applying the adjustor for certain MS–DRG 018 (Chimeric Antigen Receptor (CAR) T-cell and other immunotherapies) cases in all simulations of payments for the budget neutrality factors discussed later in this section. We refer the reader to section IV.I. of the preamble of this final rule for a complete discussion on the adjustor for certain cases that group to MS–DRG 018 and to section II.D.2.b. of the preamble of this final rule, for a complete discussion of the adjustment to the FY 2024 relative weights to account for certain cases that group to MS–DRG 018.

Based on this comparison, we computed a budget neutrality adjustment factor and applied this factor to the standardized amount. As discussed in section IV. of this Addendum, as we proposed, we are applying the MS–DRG reclassification and recalibration budget neutrality factor to the hospital-specific rates that are effective for cost reporting periods beginning on or after October 1, 2023. Please see the table later in this section setting forth each of the FY 2024 budget neutrality factors.

b. Budget Neutrality Adjustment for Reclassification and Recalibration of MS–DRG Relative Weights With Cap

As discussed in section II.D.2.c of this final rule, in the FY 2023 IPPS/LTCH PPS final rule (87 FR 48897 through 48900), we finalized a permanent 10 percent cap on the reduction in an MS–DRG’s relative weight in a given fiscal year, beginning in FY 2023. As also discussed in section II.D.2.c of the preamble of this final rule, and consistent with our current methodology for implementing budget neutrality for MS–DRG reclassification and recalibration of the relative weights under section 1886(d)(3)(E)(i) of the Act, we apply a budget neutrality adjustment to the standardized amount for all hospitals so that this 10-percent cap on relative weight reductions does not increase estimated aggregate Medicare payments beyond the payments that would be made had we never applied this cap. We refer the reader to the FY 2023 IPPS/LTCH PPS final rule for further discussion.

To calculate this final budget neutrality adjustment factor for FY 2024, we used FY 2022 discharge data to simulate payments and compared the following:

- Aggregate payments using the FY 2023 labor-related share percentages, the FY 2024 relative weights before applying the 10-percent cap, and the FY 2023 pre-reclassified wage data, and applied the proxy FY 2024 hospital readmissions payment adjustments and the proxy FY 2024 hospital VBP payment adjustments.

Because this payment simulation uses the FY 2024 relative weights (after applying the 10 percent cap), consistent with our policy in section IV.I. of the preamble to this final rule and our historical policy, and as discussed in the preceding section, we applied the adjustor for certain cases that group to MS–DRG 018 in our simulation of these payments.

In addition, we applied the MS–DRG reclassification and recalibration budget neutrality adjustment factor before the cap (derived in the first step) to the payment rates that were used to simulate payments for this comparison of aggregate payments from FY 2023 to FY 2024. Based on this comparison, we computed a budget neutrality adjustment factor and applied this factor to the standardized amount.

As discussed in section IV. of this Addendum, as we proposed, we are applying this budget neutrality factor to the hospital-specific rates that are effective for cost reporting periods beginning on or after October 1, 2023. Please see the table later in this section setting forth each of the FY 2024 budget neutrality factors.

c. Updated Wage Index—Budget Neutrality Adjustment

Section 1886(d)(3)(E)(i) of the Act requires us to update the hospital wage index on an annual basis beginning October 1, 1993. This provision also requires us to make any updates or
adjustments to the wage index in a manner that ensures that aggregate payments to hospitals are not affected by the change in the wage index. Section 1886(d)(3)(E)(i) of the Act requires that we implement the wage index adjustment in a budget neutral manner. However, section 1886(d)(3)(E)(ii) of the Act sets the labor-related share at 62 percent for hospitals with a wage index less than or equal to 1.0000, and section 1886(d)(3)(E)(i) of the Act provides that the Secretary shall calculate the budget neutrality adjustment for the adjustments or updates made under that provision as if section 1886(d)(3)(E)(ii) of the Act had not been enacted. In other words, this section of the statute requires that we implement the updates to the wage index in a budget neutral manner, but that our budget neutrality adjustment should not take into account the requirement that we set the labor-related share for hospitals with wage indexes less than or equal to 1.0000 at the more advantageous level of 62 percent. Therefore, for purposes of this budget neutrality adjustment, section 1886(d)(3)(E)(i) of the Act prohibits us from taking into account the fact that hospitals with a wage index less than or equal to 1.0000 is paid using a labor-related share of 62 percent. Consistent with current policy, for FY 2024, as we proposed, we are adjusting 100 percent of the wage index factor for occupational mix. We describe the occupational mix adjustment in section III.E. of the preamble of this final rule.

To compute a budget neutrality adjustment factor for wage index and labor-related share percentage changes, we used FY 2022 discharge data to simulate payments and compared the following:

- Aggregate payments using the FY 2024 relative weights and the FY 2024 pre-reclassified wage indexes, applied the FY 2023 labor-related share of 67.6 percent to all hospitals (regardless of whether the hospital’s wage index was above or below 1.0000), and applied the proxy FY 2024 hospital readmissions payment adjustment and the proxy FY 2024 hospital VBP payment adjustment.

- Aggregate payments using the FY 2024 relative weights and the FY 2024 pre-reclassified wage indexes, applied the labor-related share for FY 2024 of 67.6 percent to all hospitals (regardless of whether the hospital’s wage index was above or below 1.0000), and applied the same proxy FY 2024 hospital readmissions payment adjustment and proxy FY 2024 hospital VBP payment adjustments.

In addition, we applied the MS–DRG recalculation and recalibration budget neutrality adjustment factor before the cap (derived in the first step) and the 10 percent cap on relative weight reductions adjustment factor (derived from the second step) to the payment rates that were used to simulate payments for this comparison of aggregate payments from FY 2023 to FY 2024. Based on this comparison, we computed a budget neutrality adjustment factor and applied this factor to the standardized amount for changes to the wage index. Please see the table later in this section for a summary of the FY 2024 budget neutrality factors.

d. Reclassified Hospitals—Budget Neutrality Adjustment

Section 1886(d)(8)(B) of the Act provides that certain rural hospitals are deemed urban. In addition, section 1886(d)(10) of the Act provides for the reclassification of hospitals based on determinations by the MGCRB. Under section 1886(d)(10) of the Act, a hospital may be reclassified for purposes of the wage index.

Under section 1886(d)(8)(D) of the Act, the Secretary is required to adjust the standardized amount to ensure that aggregate payments under the IPPS after implementation of the provisions of sections 1886(d)(8)(B) and (C) and 1886(d)(10) of the Act are equal to the aggregate prospective payments that would have been made absent these provisions. We note, as discussed in section III.G.1. of the preamble of this final rule, we are finalizing as proposed, beginning with FY 2024, to include hospitals with §412.103 reclassification along with geographically rural hospitals in all rural wage index calculations, and only exclude “dual reclass” hospitals (hospitals with simultaneous §412.103 and MGCRB reclassifications) in accordance with the hold harmless provision at section 1886(d)(8)(C)(ii) of the Act. Consistent with the previous policy, beginning with FY 2024, we will include the data of all §412.103 hospitals (including those that have an MGCRB reclassification) in the calculation of “the wage index for rural areas in the State in which the county is located” as referred to in section 1886(d)(8)(C)(iii) of the Act. As discussed in section III.G.1. of the preamble of this final rule, we acknowledge that this policy has significant effects on wage index values. In addition, as a result of this change, the geographic reclassification budget neutrality adjustment is significantly larger than in prior years. We refer the reader to the FY 2015 IPPS final rule (79 FR 50371 and 50372) for a complete discussion regarding the requirement of section 1886(d)(8)(C)(iii) of the Act. We further note that the wage index adjustments provided for under section 1886(d)(13) of the Act are not budget neutral. Section 1886(d)(13)(H) of the Act provides that any increase in a wage index under section 1886(d)(13) of the Act shall not be taken into account in applying any budget neutrality adjustment with respect to such index under section 1886(d)(8)(D) of the Act. To calculate the budget neutrality adjustment factor for FY 2024, we used FY 2022 discharge data to simulate payments and compared the following:

- Aggregate payments using the FY 2024 labor-related share percentage, the FY 2024 relative weights, and the FY 2024 wage data prior to aggregate payments under the IPPS after implementation of the provisions of sections 1886(d)(8)(B) and (C) and 1886(d)(10) of the Act, and applied the proxy FY 2024 hospital readmissions payment adjustments and the proxy FY 2024 hospital VBP payment adjustments.

- Aggregate payments using the FY 2024 labor-related share percentage, the FY 2024 relative weights, and the FY 2024 wage data after such reclassifications, and applied the same proxy FY 2024 hospital readmissions payment adjustments and the proxy FY 2024 hospital VBP payment adjustments applied previously.

We note that the reclassifications applied under the second simulation and comparison are those listed in Table 2 associated with this final rule, which is available via the internet on the CMS website. This table reflects reclassification crosswalks for FY 2024 and applies the policies explained in section III. of the preamble of this final rule. Based on this comparison, we computed a budget neutrality adjustment factor and applied this factor to the standardized amount to ensure that the effects of these provisions are budget neutral, consistent with the statute. Please see the table later in this section for a summary of the FY 2024 budget neutrality factors.

The FY 2024 budget neutrality adjustment factor was applied to the standardized amount after removing the effects of the FY 2023 budget neutrality adjustment factor. We note that the FY 2024 budget neutrality adjustment reflects FY 2024 wage index reclassifications approved by the MGCRB or the Administrator at the time of development of this final rule. We finally note, in the absence of the policies discussed in section III.G.1 of the final rule (to the hospitals with §412.103 reclassification along with geographically rural hospitals in all
rural wage index calculations, and to only exclude "dual reclass" hospitals (hospitals with simultaneous § 412.103 and MGCRB reclassifications) in accordance with the hold harmless provision at section 1886(d)(8)(C)(iii) of the Act, the reclassification budget neutrality factor would be 0.984000.

e. Rural Floor Budget Neutrality Adjustment

Under § 412.64(e)(4), we make an adjustment to the wage index to ensure that aggregate payments after implementation of the rural floor under section 4410 of the BBA (Pub. L. 105–33) are equal to the aggregate prospective payments that would have been made in the absence of this provision. Consistent with section 3141 of the Affordable Care Act and as discussed in section III.G. of the preamble of this final rule and codified at § 412.64(e)(4(ii), the budget neutrality adjustment for the rural floor is a national adjustment to the wage index.

Similar to our calculation in the FY 2015 IPPS/LTCPPS final rule (79 FR 50369 through 50370), for FY 2024, as we proposed, we calculated a national rural Puerto Rico wage index. Because there are no rural Puerto Rico hospitals with established wage data, our calculation of the FY 2024 rural Puerto Rico wage index is based on the policy adopted in the FY 2008 IPPS final rule with comment period (72 FR 47323). That is, we use the unweighted average of the wage indexes from all CBSSA urban areas) that are contiguous to (share a border with) the rural counties to compute the rural floor (72 FR 47323; 76 FR 51594). Under the OMB labor market area delineations, except for Arecibo, Puerto Rico (CBSA 11640), all other Puerto Rico urban areas are contiguous to a rural area. Therefore, based on our existing policy, the FY 2024 rural Puerto Rico wage index is calculated based on the average of the FY 2024 wage indexes for the following urban areas: Aguadilla-Isabela, PR (CBSA 10380); Guayama, PR (CBSA 25020); Mayaguez, PR (CBSA 32420); Ponce, PR (CBSA 38660); San German, PR (CBSA 41900); and San Juan-Carolina-Caguas, PR (CBSA 41980).

We note, as discussed in section III.G.1 of the preamble of this final rule, that these policies have significant effects on wage index values. In addition, as a result of this change, the rural floor budget neutrality adjustment is significantly larger than in prior years.

To calculate the national rural floor budget neutrality adjustment factor, we used FY 2022 discharge data to simulate payments, and the post-reclassified national wage indexes and compared the following:

- National simulated payments without the rural floor;
- National simulated payments with the rural floor.

Based on this comparison, we determined a national rural floor budget neutrality adjustment factor. The national adjustment was applied to the national wage indexes to produce rural floor budget neutral wage indexes. Please see the table later in this section for a complete discussion regarding the imputed floor.

f. Continuation of the Low Wage Index Hospital Policy—Budget Neutrality Adjustment

As discussed in section III.G.2. of the preamble of this final rule, we are continuing for FY 2024 the wage index policy finalized in the FY 2020 IPPS/LTCPPS final rule to address wage index disparities by increasing the wage index value for hospitals with a wage index value below the 25th percentile wage index value across all hospitals (the low wage index hospital policy). As discussed in section III.G.3. of this final rule, we are making a budget neutrality adjustment to the national standardized amount for all hospitals so that the increase in the wage index for hospitals with a wage index below the 25th percentile wage index, is implemented in a budget neutral manner.

To calculate this final budget neutrality adjustment factor for FY 2024, we used FY 2022 discharge data to simulate payments and compared the following:

- Aggregate payments using the FY 2024 labor-related share percentage, the FY 2024 relative weights, and the FY 2024 wage index for each hospital before adjusting the wage indexes under the low wage index hospital policy, and applied the proxy FY 2024 hospital readmissions payment adjustments and the proxy FY 2024 hospital VBP payment adjustments; and
- Aggregate payments using the FY 2024 labor-related share percentage, the FY 2024 relative weights, and the FY 2024 wage index for each hospital after adjusting the wage indexes under the low wage index hospital policy, and applied the same proxy FY 2024 hospital readmissions payment adjustments and the proxy FY 2024 hospital VBP payment adjustments; and
hospital VBP payment adjustments applied previously.

This final FY 2024 budget neutrality adjustment factor was applied to the standardized amount.

g. Permanent Cap Policy for Wage Index—Budget Neutrality Adjustment

As noted previously, in section III.N. of the preamble to this final rule, in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49018 through 49021) we finalized a policy to apply a 5-percent cap on any decrease to a hospital’s wage index from its wage index in the prior FY, regardless of the circumstances causing the decline. That is, a hospital’s wage index would not be less than 95 percent of its final wage index for the prior FY. We also finalized the application of this permanent cap policy in a budget neutral manner through an adjustment to the standardized amount to ensure that estimated aggregate payments under our wage index cap policy for hospitals that will have a decrease in their wage indexes for the upcoming fiscal year of more than 5 percent will equal what estimated aggregate payments would have been without the permanent cap policy.

To calculate a wage index cap budget neutrality adjustment factor for FY 2024, we used FY 2022 discharge data to simulate payments and compared the following:

- Aggregate payments without the 5-percent cap using the FY 2024 labor-related share percentages, the FY 2024 relative weights, the FY 2024 wage index for each hospital after adjusting the wage indexes under the low wage index hospital policy, and applied the same proxy FY 2024 hospital readmissions payment adjustments and the proxy FY 2024 hospital VBP payment adjustments applied previously.

We note, Table 2 associated with this final rule contains the wage index by provider before and after applying the low wage index hospital policy and the cap.

h. Rural Community Hospital Demonstration Program Adjustment

In section V.L. of the preamble of this final rule, we discuss the Rural Community Hospital (RCH) Demonstration program, which was originally authorized for a 5-year period by section 410A of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) (Pub. L. 108–173), and extended for another 5-year period by sections 3123 and 10313 of the Consolidated Appropriations Act of 2017 (Pub. L. 115–141). Subsequently, section 15003 of the 21st Century Cures Act (Pub. L. 114–255), enacted December 13, 2016, amended section 410A of Public Law 108–173 to require a 10-year extension period (in place of the 5-year extension required by the Affordable Care Act, as further discussed later in this section). Finally, Division CC, section 128(a) of the Consolidated Appropriations Act of 2021 (Pub. L. 116–260) again amended section 410A to require a 15-year extension period in place of the 10-year period. We make an adjustment to the standardized amount to ensure the effects of the RCH Demonstration program are budget neutral as required under section 410A(c)(2) of Public Law 108–173. For FY 2024, based on the most recent data available to account for the estimated costs of the demonstration program, for FY 2024, we computed a factor for the Rural Community Hospital Demonstration program that would be applied to the standardized amount.

The following table is a summary of the FY 2024 budget neutrality factors, as discussed in the previous sections.

<table>
<thead>
<tr>
<th>Summary of FY 2024 Budget Neutrality Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG Reclassification and Recalibration Budget Neutrality Factor</td>
</tr>
<tr>
<td>Cap Policy MS-DRG Weights Budget Neutrality Factor</td>
</tr>
<tr>
<td>Wage Index Budget Neutrality Factor</td>
</tr>
<tr>
<td>Reclassification Budget Neutrality Factor</td>
</tr>
<tr>
<td>*Rural Floor Budget Neutrality Factor</td>
</tr>
<tr>
<td>Low Wage Index Hospital Policy Budget Neutrality Factor</td>
</tr>
<tr>
<td>Cap Policy Wage Index Budget Neutrality Factor</td>
</tr>
<tr>
<td>Rural Demonstration Budget Neutrality Factor</td>
</tr>
</tbody>
</table>

*The rural floor budget neutrality factor is applied to the national wage indexes while the rest of the budget neutrality adjustments are applied to the standardized amounts.

i. Outlier Payments

Section 1886(d)(5)(A) of the Act provides for payments in addition to the basic prospective payments for “outlier” cases involving extraordinarily high costs. To qualify for outlier payments, a case must have costs greater than the sum of the prospective payment rate for the MS-DRG, any IME and DSH payments, uncompensated care payments, supplemental payment for eligible IHS/Tribal hospitals and Puerto Rico hospitals, any new technology add-on payments, and the “outlier
threshold” or “fixed-loss” amount (a dollar amount by which the costs of a case must exceed payments in order to qualify for an outlier payment). We refer to the sum of the prospective payment rate for the MS–DRG, any IME and DSH payments, uncompensated care payments, supplemental payment for eligible IHS/Tribal hospitals and Puerto Rico hospitals, any new technology add-on payments, and the outlier threshold as the outlier “fixed-loss cost threshold.” To determine whether the costs of a case exceed the fixed-loss cost threshold, a hospital’s CCR is applied to the total covered charges for the case to convert the charges to estimated costs. Payments for eligible cases are then made based on a marginal cost factor, which is a percentage of the estimated costs above the fixed-loss cost threshold. The marginal cost factor for FY 2024 is 80 percent, or 90 percent for burn MS–DRGs 927, 928, 929, 933, 934 and 935. We have used a marginal cost factor of 90 percent since FY 1989 (54 FR 36479 through 36480) for designated burn DRGs as well as a marginal cost factor of 80 percent for all other DRGs since FY 1995 (59 FR 45367).

In accordance with section 1886(d)(5)(A)(iv) of the Act, outlier payments for any year are projected to be not less than 5 percent nor more than 6 percent of total operating DRG payments (which does not include IME and DSH payments) plus outlier payments. When setting the outlier threshold, we compute the percent target by dividing the total operating outlier payments by the total operating DRG payments plus outlier payments. As discussed in the next section, for FY 2024, we are incorporating an estimate of outlier reconciliation when setting the outlier threshold. We do not include any other payments such as IME and DSH within the outlier target amount. Therefore, it is not necessary to include Medicare Advantage IME payments in the outlier threshold calculation.

Section 1886(d)(3)(B) of the Act requires the Secretary to reduce the average standardized amount by a factor to account for the unattributed proportion of total DRG payments made to outlier cases. More information on outlier payments may be found on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/outlier.htm.

(1) Methodology To Incorporate an Estimate of Outlier Reconciliation in the FY 2024 Outlier Fixed-Loss Cost Threshold

The regulations in 42 CFR 412.84(i)(4) state that any outlier reconciliation at cost report settlement will be based on operating and capital cost-to-charge ratios (CCRs) calculated based on a ratio of costs to charges computed from the relevant cost report and charge data determined at the time the cost report coinciding with the discharge is settled. We have instructed MACs to identify for CMS any instances where: (1) A hospital’s actual CCR for the cost reporting period fluctuates plus or minus 10 percentage points compared to the interim CCR used to calculate outlier payments when a bill is processed; and (2) the total outlier payments for the hospital exceeded $500,000.00 for that cost reporting period. If we determine that a hospital’s outlier payments should be reconciled, we reconcile both operating and capital outlier payments. We refer readers to section 20.1.2.5 of Chapter 3 of the Medicare Claims Processing Manual (available on the CMS website at: https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c03.pdf) for complete details regarding outlier reconciliation. The regulation at §412.84(m) further states that at the time of any outlier reconciliation under §412.84(i)(4), outlier payments may be adjusted to account for the time value of any underpayments or overpayments. Section 20.1.2.6 of Chapter 3 of the Medicare Claims Processing Manual contains instructions on how to assess the time value of money for reconciled outlier amounts.

If the operating CCR of a hospital subject to reconciliation is lower at cost report settlement compared to the operating CCR used for payment, the hospital would owe CMS money because it received an outlier overpayment at the time of claim payment. Conversely, if the operating CCR increases at cost report settlement compared to the operating CCR used for payment, CMS would owe the hospital money because the hospital outlier payments were underpaid.

In the FY 2020 IPPS/LTCH PPS final rule (84 FR 42623 through 42625), we finalized a methodology to incorporate reconciliation in the FY 2020 outlier fixed loss cost threshold. As discussed in the FY 2020 IPPS/LTCH PPS final rule, for FY 2020, we used the historical outlier reconciliation amounts from the FY 2014 cost reports (cost reports with a begin date on or after October 1, 2013, and on or before September 30, 2014), which we believed would provide the most recent and complete available data to project the estimate of outlier reconciliation. We refer the reader to the FY 2020 IPPS/LTCH PPS final rule (84 FR 42623 through 42625) for a discussion on the use of the FY 2014 cost report data for purposes of projecting outlier payment reconciliations for the FY 2020 outlier threshold calculation. For FY 2023, we applied the same methodology finalized in FY 2020, using the historical outlier reconciliation amounts from the FY 2017 cost reports (cost reports with a begin date on or after October 1, 2016, and on or before September 30, 2017).

Similar to the FY 2023 methodology, in this final rule, we are determining a projection of outlier payment reconciliations for the FY 2024 outlier threshold calculation, by advancing the methodology by 1 year. Specifically, we are using FY 2018 cost reports (cost reports with a begin date on or after October 1, 2017, and on or before September 30, 2018).

For FY 2024, as we proposed, we are using the same methodology from FY 2020 to incorporate a projection of operating outlier payment reconciliations for the FY 2024 outlier threshold calculation.

The following steps are the same as those finalized in the FY 2020 final rule but with updated data for FY 2024:

Step 1.—Use the Federal FY 2018 cost reports for hospitals paid under the IPPS from the most recent publicly available quarterly data set (or any other publicly available at the time of development of the proposed and final rules, and
exclude sole community hospitals (SCHs) that were paid under their hospital-specific rate (that is, if Worksheet E, Part A, Line 48 is greater than Line 47). We note that when there are multiple columns available for the lines of the cost report described in the following steps and the provider was paid under the IPPS for that period(s) of the cost report, then we believe it is appropriate to use multiple columns to fully represent the relevant IPPS payment amounts, consistent with our methodology for the FY 2020 final rule.

Step 2.—Calculate the aggregate amount of historical total of operating outlier reconciliation dollars (Worksheet E, Part A, Line 2.01) using the Federal FY 2018 cost reports from Step 1.

Step 3.—Calculate the aggregate amount of total Federal operating payments using the Federal FY 2018 cost reports from Step 1. The total Federal operating payments consist of the Federal payments (Worksheet E, Part A, Line 1.01 and Line 1.02, plus Line 1.03), outlier payments (Worksheet E, Part A, Line 2 and Line 2.02), and the outlier reconciliation payments (Worksheet E, Part A, Line 2.01). We note that a negative amount on Worksheet E, Part A, Line 2.01 for outlier reconciliation indicates an amount that was owed by the hospital, and a positive amount indicates this amount was paid to the hospital.

Step 4.—Divide the amount from Step 2 by the amount from Step 3 and multiply the resulting amount by 100 to produce the percentage of total operating outlier reconciliation dollars to total Federal operating payments for FY 2018. This percentage amount would be used to adjust the outlier target for FY 2023 as described in Step 5.

Step 5.—Because the outlier reconciliation dollars are only available on the cost reports, and not in the Medicare claims data in the MedPAR file used to model the outlier threshold, we are targeting 5.1 percent minus the percentage determined in Step 4 in determining the outlier threshold. Using the FY 2018 cost reports, because the aggregate outlier reconciliation dollars from Step 2 are negative, we are targeting an amount higher than 5.1 percent for outlier payments for FY 2024 under our methodology.

For the FY 2024 proposed rule, we used the December 2022 HCRIS extract of the cost report data to calculate the proposed percentage adjustment for outlier reconciliation. For the FY 2024 final rule, we proposed to use the latest quarterly HCRIS extract that is publicly available at the time of the development of that rule which, for FY 2024, would be the March 2023 extract. While in the past we have considered the use of more recent data that may become available for purposes of projecting the estimate of operating outlier reconciliation used in the calculation of the final outlier threshold, we have also noted that we generally expect historical cost reports for the applicable fiscal year to be available by March (84 FR 53609). Since the FY 2020 final rule we have worked with our Medicare Administrator Contractors (MACs) so that historical cost reports for the applicable fiscal year can be made available with the March HCRIS update for the final rule, which, as noted, would be the March 2023 HCRIS extract for purposes of projecting the estimate of operating outlier reconciliation used in the calculation of the FY 2024 outlier threshold for the final rule. Information on availability of the HCRIS cost report data can be found at https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/Cost-Reports.

In the FY 2024 proposed rule, based on the December 2022 HCRIS, 5 hospitals had an outlier reconciliation amount recorded on Worksheet E, Part A, Line 2.01 for total operating outlier reconciliation dollars of negative $6,925,967 (Step 2). The total Federal operating payments based on the December 2021 HCRIS was $88,729,603,026 (Step 3). The ratio (Step 4) is a negative 0.007806 percent, which, when rounded to the second digit, is -0.01 percent. Therefore, for FY 2024, we proposed to incorporate a projection of operating outlier reconciliation dollars by targeting an outlier threshold at 5.12 percent [5.1 percent – (−0.01 percent)]. When the percentage of operating outlier reconciliation dollars to total Federal operating payments rounds to a negative value (that is, when the aggregate amount of outlier reconciliation as a percent of total operating payments rounds to a negative percent), the effect is a decrease to the outlier threshold compared to an outlier threshold that is calculated without including this estimate of operating outlier reconciliation dollars. As explained in the FY 2020 IPPS/LTCH PPS proposed rule (84 FR 19593), we would continue to use a 5.1 percent target (or an outlier offset factor of 0.0490) in calculating the outlier offset to the standardized amount. Therefore, the proposed operating outlier offset to the standardized amount was 0.949 (1 – 0.051).

We invited public comment on our methodology for projecting an estimate of outlier reconciliation and incorporating that estimate into the modeling for the fixed-loss cost outlier threshold for FY 2024.

We did not receive any comments on the proposed methodology, and for the reasons discussed in the proposed rule and in this final rule, we are finalizing the methodology described previously for incorporating the outlier reconciliation in the outlier threshold calculation. Therefore, for this final rule we used the same steps described previously and in the proposed rule to incorporate a projection of operating outlier payment reconciliations for the calculation of the FY 2024 outlier threshold calculation.

Based on March 2023 HCRIS data, a total of 15 hospitals had an outlier reconciliation amount recorded on Worksheet E, Part A, Line 2.01 for total operating outlier reconciliation dollars of negative $15,014,533 (Step 2). The total Federal operating payments based on the March 2023 HCRIS is $88,747,588,563 (Step 3). The ratio (Step 4) is a negative 0.016918 percent, which, when rounded to the second digit, is negative 0.02 percent. Therefore, for FY 2024, using the finalized methodology, we incorporated a projection of operating IPPS outlier reconciliation dollars by targeting an outlier threshold at 5.12 percent [5.1 percent – (−0.02 percent)]. As noted previously, when the percentage of operating outlier reconciliation dollars to total Federal operating payments is negative (such is the case when the aggregate amount of outlier reconciliation is negative), the effect is a decrease to the outlier threshold compared to an outlier threshold that is calculated without including this estimate of operating outlier reconciliation dollars.

(b) Reduction to the FY 2024 Capital Standard Federal Rate by an Adjustment Factor To Account for the Projected Proportion of Capital IPPS Payments Paid as Outliers

We establish an outlier threshold that is applicable to both hospital inpatient operating costs and hospital inpatient capital related costs (56 FR 46348). Similar to the calculation of the adjustment to the standardized amount to account for the projected proportion of operating payments paid as outlier payments, as discussed in greater detail in section II.A.2. of the Addendum, we proposed to reduce the FY 2024 capital standard Federal rate by an adjustment
factor to account for the projected proportion of capital IPPS payments paid as outliers. The regulations in 42 CFR 412.84(f)(4) state that any outlier reconciliation at cost report settlement would be based on operating and capital CCRs calculated based on a ratio of costs to charges computed from the relevant cost report and charge data determined at the time the cost report coinciding with the discharge is settled. As such, any reconciliation also applies to capital outlier payments.

For FY 2024, we proposed to use the same methodology from FY 2020 to adjust the FY 2024 capital standard Federal rate by an adjustment factor to account for the projected proportion of capital IPPS payments paid as outliers. Similar to FY 2020, as part of our proposal for FY 2024 to incorporate into the outlier model the total outlier reconciliation dollars from the most recent and most complete fiscal year cost report data, we also proposed to adjust our estimate of FY 2024 capital outlier payments to incorporate a projection of capital outlier reconciliation payments when determining the adjustment factor to be applied to the capital standard Federal rate to account for the projected proportion of capital IPPS payments paid as outliers (that is, the capital outlier payment adjustment factor). To do so, we proposed to use the following methodology, which generally parallels the proposed methodology to incorporate a projection of operating outlier reconciliation payments for the FY 2024 outlier threshold calculation.

Step 1.—Use the Federal FY 2018 cost reports for hospitals paid under the IPPS from the most recent publicly available quarterly HCRIS extract available at the time of development of the proposed and final rules, and exclude SCHs that were paid under their hospital-specific rate (that is, if Worksheet E, Part A, Line 48 is greater than Line 47). We note that when there are multiple columns available for the lines of the cost report described in the following steps and the provider was paid under the IPPS for that period(s) of the cost report, then we believe it is appropriate to use multiple columns to fully represent the relevant IPPS payment amounts, consistent with our methodology for the FY 2020 final rule.

Step 2.—Calculate the aggregate amount of the historical total of capital outlier reconciliation dollars (Worksheet E, Part A, Line 93, Column 1) using the Federal FY 2018 cost reports from Step 1.

Step 3.—Calculate the aggregate amount of total capital Federal payments using the Federal FY 2018 cost reports from Step 1. The total capital Federal payments consist of the capital DRG payments, including capital indirect medical education (IME) and capital disproportionate share hospital (DSH) payments (Worksheet E, Part A, Line 50, Column 1) and the capital outlier reconciliation payments (Worksheet E, Part A, Line 93, Column 1). We note that a negative amount on Worksheet E, Part A, Line 93 for capital outlier reconciliation indicates an amount that was owed by the hospital, and a positive amount indicates this amount was paid to the hospital.

Step 4.—Divide the amount from Step 2 by the amount from Step 3 and multiply the resulting amount by 100 to produce the percentage of total capital outlier reconciliation dollars to total capital Federal payments for FY 2018. This percentage amount would be used to adjust the estimate of capital outlier payments for FY 2024 as described in Step 5.

Step 5.—Because the outlier reconciliation dollars are only available on the cost reports, and not in the specific Medicare claims data in the MedPAR file used to estimate outlier payments, we proposed that the estimate of capital outlier payments for FY 2024 would be determined by adding the percentage in Step 4 to the estimated percentage of capital outlier payments otherwise determined using the shared outlier threshold that is applicable to both hospital inpatient operating costs and hospital inpatient capital-related costs. (We note that this percentage is added for capital outlier payments but subtracted in the analogous step for operating outlier payments. We have a unified outlier payment methodology that uses a shared threshold to identify outlier cases for both operating and capital payments. The difference stems from the fact that operating outlier payments are determined by first setting a “target” percentage of operating outlier payments relative to aggregate operating payments which produces the outlier threshold. Once the shared threshold is set, it is used to estimate the percentage of capital outlier payments to total capital payments based on that threshold. Because the threshold is already set based on the operating target, rather than adjusting the threshold (or operating target), we adjust the percentage of capital outlier to total capital payments to account for the estimated effect of capital outlier reconciliation payments. This percentage is adjusted by adding the capital outlier reconciliation dollar amount from Step 5 to the estimate of the percentage of capital outlier payments to total capital payments based on the shared threshold.) We note, when the aggregate capital outlier reconciliation dollars from Step 2 are negative, the estimate of capital outlier payments for FY 2024 under our methodology would be lower than the percentage of capital outlier payments otherwise determined using the shared outlier threshold.

For the FY 2024 proposed rule, we used the December 2022 HCRIS extract of the cost report data to calculate the proposed percentage adjustment for outlier reconciliation. For this FY 2024 final rule, we proposed to use the latest quarterly HCRIS extract that is publicly available at the time of the development of that rule which, for FY 2024, would be the March 2023 extract. While in the past we have considered the use of more recent data that may become available for purposes of projecting the estimate of capital outlier reconciliation used in the calculation of the adjustment to the capital standard Federal rate for the final rule, we have also noted that we generally expect historical cost reports for the applicable fiscal year to be available by March (84 FR 53609). As noted previously, since the FY 2020 final rule we have worked with our Medicare Administrator Contractors (MACs) so that historical cost reports for the applicable fiscal year can be made available with the March HCRIS update for the final rule, which, as noted, would be the March 2023 HCRIS extract for purposes of projecting the estimate of capital outlier reconciliation used in the calculation of the FY 2024 adjustment to the FY 2024 capital standard Federal rate for the final rule.

For the FY 2024 proposed rule, the estimated percentage of FY 2024 capital outlier payments otherwise determined using the shared outlier threshold was 4.16 percent (estimated capital outlier payments of $280,666,342 divided by estimated capital outlier payments of $280,666,342 plus the estimated total capital Federal payment of $6,470,989,911)). The proposed ratio in step 4 above is a negative 0.00477 × (−383,169,827,006,104) × 100, which, when rounded to the second digit, is 0.00 percent. Therefore, for the FY 2024 proposed rule, we stated that taking into account projected capital outlier reconciliation payments under our proposed methodology, there would be no decrease to the estimated percentage of FY 2024 aggregate capital outlier payments.

As discussed in section III.A.2. of this Addendum, we proposed to incorporate the capital outlier reconciliation dollars from Step 5 when applying the outlier adjustment factor in determining the capital Federal rate based on the
estimated percentage of capital outlier payments to total capital Federal rate payments for FY 2024.

We invited public comment on our proposed methodology for projecting an estimate of capital outlier reconciliation and incorporating that estimate into the modeling of the estimate of FY 2024 capital outlier payments for purposes of determining the capital outlier adjustment factor.

We did not receive comments about the proposed capital outlier reconciliation methodology. For the reasons discussed earlier, we are finalizing the methodology for projecting an estimate of capital outlier reconciliation as previously described. Therefore, for this final rule, we used the same steps as described in the proposed rule and this final rule to reduce the FY 2024 capital standard Federal rate by an adjustment factor to account for the projected proportion of capital IPPS payments paid as outliers. For projecting the estimate of capital outlier reconciliation, similar to our projection of the estimate of operating outlier reconciliation, we are using cost report data from the March 2023 HCRIS. We note that a difference in the number of cost reports for the operating and capital outlier reconciliation projections is possible and may be due to new hospitals defined in the regulations at 42 CFR 412.300(b) that may receive capital cost-based payments (in lieu of Federal rate payments), and therefore would not receive capital outlier payments. As a result, capital outlier reconciliation is not applicable to such hospitals since there is no capital outlier payment.

Based on the March 2023 HCRIS data, 10 hospitals had an outlier reconciliation amount recorded on Worksheet E, Part A, Line 93 for total capital outlier reconciliation dollars of negative $1,494,671 (Step 2). The total Federal capital payments based on the March 2023 HCRIS is approximately $8,032,054,774 (Step 3). The ratio (Step 4) is a negative 0.018609 percent, which, when rounded to the second digit, is negative 0.02 percent (Step 4). Therefore, for FY 2024, taking into account projected capital outlier reconciliation payments under our methodology will decrease the estimated percentage of FY 2024 aggregate capital outlier payments by 0.02 percent.

(2) FY 2024 Outlier Fixed-Loss Cost Threshold

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50977 through 50983), in response to public comments on the FY 2013 IPPS/LTCH PPS proposed rule, we made changes to our methodology for projecting the outlier fixed-loss cost threshold for FY 2014. We refer readers to the FY 2014 IPPS/LTCH PPS final rule for a detailed discussion of the changes.

As we have done in the past, to calculate the FY 2024 outlier threshold, we simulated payments by applying FY 2024 payment rates and policies using cases from the FY 2022 MedPAR file. As noted in section II.C. of this Addendum, we specify the formula used for actual claim payment which is also used by CMS to project the outlier threshold for the upcoming fiscal year. The difference is the source of some of the variables in the formula. For example, operating and capital CCRs for actual claim payment are from the Provider-Specific File (PSF) while CMS uses an adjusted CCR (as described later in this section) to project the threshold for the upcoming fiscal year. In addition, charges for a claim payment are from the bill while charges to project the threshold are from the MedPAR data with an inflation factor applied to the charges (as described earlier).

To determine the FY 2024 outlier threshold, we inflated the charges on the MedPAR claims by 2 years, from FY 2022 to FY 2024. Consistent with the FY 2020 IPPS/LTCH PPS final rule (84 FR 42626 and 42627), we proposed to use the following methodology to calculate the charge inflation factor for FY 2024:

- Include hospitals whose last four digits fall between 0001 and 0899 (section 2779A1 of Chapter 2 of the State Operations Manual on the CMS website at https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/som107c02.pdf); include CAHs that were IPPS hospitals for the time period of the MedPAR data being used to calculate the charge inflation factor; include hospitals in Maryland; and remove PPS-excluded cancer hospitals that have a “V” in the fifth position of their provider number or a “E” or “F” in the sixth position.
- Include providers that are in both periods of charge data that are used to calculate the 1-year average annual rate-of-change in charges per case. We note this is consistent with the methodology used since FY 2014.
- We excluded Medicare Advantage IME claims for the reasons described in section I.A.4. of this Addendum. We refer readers to the FY 2011 IPPS/LTCH PPS final rule for a complete discussion on our methodology of identifying and adding the total Medicare Advantage IME payment amount to the budget neutrality adjustments.
- In order to determine that we capture only FFS claims, we included claims with a “Claim Type” of 60 (which is a field on the MedPAR file that indicates a claim is an FFS claim).
- In order to further ensure that we capture only FFS claims, we excluded claims with a “GHOPAID” indicator of 1 (which is a field on the MedPAR file that indicates a claim is not an FFS claim and is paid by a Group Health Organization).
- We examined the MedPAR file and removed pharmacy charges for anti-hemophilic blood factor (which are paid separately under the IPPS) with an indicator of “3” for blood clotting with a revenue code of “0636” from the covered charge field. We also removed organ acquisition charges from the covered charge field because organ acquisition is a pass-through payment not paid under the IPPS. As noted previously, we are removing allogeneic hematopoietic stem cell acquisition charges from the covered charge field for budget neutrality adjustments. As discussed in the FY 2021 IPPS/LTCH PPS final rule, payment for allogeneic hematopoietic stem cell acquisition costs is made on a reasonable cost basis for cost reporting periods beginning on or after October 1, 2020 (85 FR 56835 through 56842).
- Because this payment simulation uses the FY 2024 relative weights, consistent with our policy discussed in section IV.L. of the preamble to this final rule, we applied the adjustor for certain cases that group to MS–DRG 018 in our simulation of these payments.

In the FY 2023 IPPS/LTCH PPS final rule, due to the impact of the COVID–19 PHE on our ordinary ratesetting data, we finalized modifications to our usual ratesetting methodologies for FY 2023, including the methodology for calculating the FY 2023 outlier threshold. We refer the reader to the FY 2023 IPPS/LTCH PPS final rule (87 FR 49422 through 49428) for a discussion of the FY 2023 outlier threshold and the modifications made to our usual methodologies for calculating the outlier threshold. As discussed in section I.E. of the preamble to the proposed rule, based on the information available at the time, we stated that we do not believe there is a reasonable basis for us to assume that there will be a meaningful difference in the number of COVID–19 cases treated at IPPS hospitals and LTCHs in FY 2023 relative to FY 2022, such that modifications to our usual ratesetting methodologies (including the methodology for calculating the outlier threshold) would be warranted. Therefore, we proposed to calculate the FY 2024 outlier threshold consistent with our historic
methodologies, as described further in this section, without modifications.

Our general methodology to inflate the charges computes the 1-year average annual rate-of-change in charges per case which is then applied twice to inflate the charges on the MedPAR claims by 2 years since we typically use claims data for the fiscal year that is 2 years prior to the upcoming fiscal year.

In the FY 2020 IPPS/LTCH PPS final rule (84 FR 42627), we modified our charge inflation methodology. We stated that we believe balancing our preference to use the latest available data from the MedPAR files and stakeholders’ concerns about being able to use publicly available MedPAR files to review the charge inflation factor can be achieved by modifying our methodology to use the publicly available Federal fiscal year period (that is, for FY 2020, we used the charge data from Federal fiscal years 2017 and 2018), rather than the most recent data available to CMS which, under our prior methodology, was based on prior year data. We refer the reader to the FY 2020 IPPS/LTCH PPS final rule for a complete discussion regarding this change.

For the same reasons discussed in that rulemaking, for FY 2024, we proposed to use the same methodology as FY 2020 to determine the charge inflation factor. That is, for FY 2023, we proposed to use the MedPAR files for the two most recent available Federal fiscal year time periods to calculate the charge inflation factor, as we did for FY 2020. Specifically, for the proposed rule we used the December 2021 MedPAR file of FY 2021 (October 1, 2020 to September 30, 2021) charge data (released for the FY 2023 IPPS/LTCH PPS proposed rule) and the December 2022 MedPAR file of FY 2022 (October 1, 2021 to September 30, 2022) charge data (released for the FY 2024 IPPS/LTCH PPS proposed rule) to compute the proposed charge inflation factor. We proposed that for the FY 2024 final rule, we would use more recently updated data, that is the MedPAR files from March 2022 for the FY 2021 time period and March 2023 for the FY 2022 time period.

For FY 2024, under this methodology, to compute the 1-year average annual rate-of-change in charges per case, we computed the average covered charge per case of $70,089.49 ($579,065,304,520/7,415,406) from October 1, 2020 through September 30, 2021, to the average covered charge per case of $82,583.83 ($574,783,177,187 / 6,959,997) from October 1, 2021 through September 30, 2022. This rate-of-change was 11.8412 percent (1.118412) over 2 years. The billed charges are obtained from the claims from the MedPAR file and inflated by the inflation factor specified previously.

As we have done in the past, in the FY 2024 IPPS/LTCH PPS proposed rule, we proposed to establish the FY 2024 outlier threshold using hospital CCRs from the December 2022 update to the Provider-Specific File (PSF), the most recent available data at the time of the development of the proposed rule. We proposed to apply the following edits to providers’ CCRs in the PSF. We believe these edits are appropriate to accurately model the outlier threshold. We first search for Indian Health Service providers and those providers assigned the statewide average CCR from the current fiscal year. We then replace these CCRs with the statewide average CCR for the upcoming fiscal year. We also assign the statewide average CCR (for the upcoming fiscal year) to those providers that have no value in the CCR field in the PSF or whose CCRs exceed the ceilings described later in this section (3.0 standard deviations from the mean of the log distribution of CCRs for all hospitals). We do not apply the adjustment factors described later in this section to hospitals assigned the statewide average CCR. For FY 2024, we also proposed to continue to apply an adjustment factor to the CCRs to account for cost and charge inflation (as explained later in this section). We also proposed that, if more recent data become available, we would use that data to calculate the final FY 2024 outlier threshold.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50979), we adopted a new methodology to adjust the CCRs. Specifically, we finalized a policy to compare the national average case-weighted operating and capital CCR from the most recent update of the PSF to the national average case-weighted operating and capital CCR from the same period of the prior year. Therefore, as we have done in the past, we proposed to adjust the CCRs from the December 2022 update of the PSF by comparing the percentage change in the national average case-weighted operating CCR and capital CCR from the December 2021 update of the PSF to the national average case-weighted operating CCR and capital CCR from the December 2022 update of the PSF. We note that, in the proposed rule, we used total transfer-adjusted cases from FY 2022 to determine the national average case-weighted CCRs for both sides of the comparison. As stated in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50979), we believe that it is appropriate to use the same case count on both sides of the comparison because this will produce the true percentage change in the average case-weighted operating and capital CCR from one year to the next without any effect from a change in case count on different sides of the comparison.

Using the proposed methodology, for the proposed rule, we calculated a December 2021 operating national average case-weighted CCR of 0.253006 and a December 2022 operating national average case-weighted CCR of 0.247389. We then calculated the percentage change between the two national operating case-weighted CCRs by subtracting the December 2021 operating national average case-weighted CCR from the December 2022 operating national average case-weighted CCR and then dividing the result by the December 2021 national operating case-weighted CCR. This resulted in a proposed one-year national operating CCR adjustment factor of 0.977799.

We used this same proposed methodology to adjust the capital CCRs. Specifically, we calculated a December 2021 capital national average case-weighted CCR of 0.0202 and a December 2022 capital national average case-weighted CCR of 0.018054. We then calculated the percentage change between the two national capital case-weighted CCRs by subtracting the December 2021 capital national average case-weighted CCR from the December 2022 capital national average case-weighted CCR and then dividing the result by the December 2021 capital national average case-weighted CCR. This resulted in a proposed one-year national capital CCR adjustment factor of 0.893762.

For purposes of estimating the proposed outlier threshold for FY 2024, we used a wage index that reflects the policies discussed in the proposed rule. This includes the following:

—Application of the proposed rural and imputed floor adjustment
—The proposed frontier State floor adjustments in accordance with section 10324(a) of the Affordable Care Act.
—The proposed out-migration adjustment as added by section 505 of Public Law 108–173.
—Incorporating the proposed FY 2024 low wage index hospital policy (described in section III.G.4 of the preamble of this final rule) for hospitals with a wage index value below the 25th percentile, where the increase in the wage index value for these hospitals would be equal to half the difference between the otherwise applicable final wage index value for
a year for that hospital and the 25th percentile wage index value for that year across all hospitals.

—Incorporating our policy (described in section III.N. of the preamble of this final rule) to apply a 5-percent cap on any decrease to a hospital’s wage index from its wage index in the prior FY, regardless of the circumstances causing the decline.

As stated earlier, if we did not take the aforementioned into account, our estimate of total FY 2024 payments would be too low, and, as a result, our outlier threshold would be too high, such that estimated outlier payments would be less than our projected 5.1 percent of total payments (which includes outlier reconciliation).

As described in sections V.K. and V.L., respectively, of the preamble of this final rule, sections 1886(q) and 1886(o) of the Act establish the Hospital Readmissions Reduction Program and the Hospital VBP Program, respectively. We do not believe that it is appropriate to include the proposed hospital VBP payment adjustments and the hospital readmissions payment adjustments in the proposed outlier threshold calculation or the outlier offset to the standardized amount. Specifically, consistent with our definition of the base operating DRG payment amount for the Hospital Readmissions Reduction Program under § 412.152 and the Hospital VBP Program under § 412.160, outlier payments under section 1886(d)(5)(A) of the Act are not affected by these payment adjustments. Therefore, outlier payments would continue to be calculated based on the unadjusted base DRG payment amount (as opposed to using the base-operating DRG payment amount adjusted by the hospital readmissions payment adjustment and the hospital VBP payment adjustment). Consequently, we proposed to exclude the estimated hospital VBP payment adjustments and the estimated hospital readmissions payment adjustments from the calculation of the proposed outlier fixed-loss cost threshold.

We note that, to the extent section 1886(r) of the Act modifies the DSH payment methodology under section 1886(d)(5)(F) of the Act, the uncompensated care payment under section 1886(r)(2) of the Act, like the empirically justified Medicare DSH payment under section 1886(r)(1) of the Act, may be considered an amount payable under section 1886(d)(5)(F) of the Act such that it would be reasonable to incorporate in the outlier determination under section 1886(d)(5)(A) of the Act. As we have done since the implementation of uncompensated care payments in FY 2014, for FY 2024, we proposed to allocate an estimated per-discharge uncompensated care payment amount to all cases for the hospitals eligible to receive the uncompensated care payment amount in the calculation of the outlier fixed-loss cost threshold methodology. We continue to believe that allocating an eligible hospital’s estimated uncompensated care payment to all cases equally in the calculation of the outlier fixed-loss cost threshold would best approximate the amount we would pay in uncompensated care payments during the year because, when we make claim payments to a hospital eligible for such payments, we would be making estimated per-discharge uncompensated care payments to all cases equally.

Furthermore, we continue to believe that using the estimated per-claim uncompensated care payment amount to determine outlier estimates provides predictability as to the amount of uncompensated care payments included in the calculation of outlier payments. Therefore, consistent with the methodology used since FY 2014 to calculate the outlier fixed-loss cost threshold, for FY 2024, we proposed to include estimated FY 2024 uncompensated care payments in the computation of the proposed outlier fixed-loss cost threshold. Specifically, we proposed to use the estimated per-discharge uncompensated care payments to hospitals eligible for the uncompensated care payment for all cases in the calculation of the proposed outlier fixed-loss cost threshold methodology.

In addition, consistent with the methodology finalized in the FY 2023 final rule, we proposed to include the estimated supplemental payments for eligible IHS/tribal hospitals and Puerto Rico hospitals in the computation of the FY 2024 proposed outlier fixed-loss cost threshold. Specifically, we proposed to use the estimated per-discharge supplemental payments to hospitals eligible for the supplemental payment for all cases in the calculation of the proposed outlier fixed-loss cost threshold methodology.

Using this methodology, we used the formula described in section I.C.1. of this Addendum to simulate and calculate the Federal payment rate and outlier payments for all claims. In addition, as described in the earlier section to this Addendum, we proposed to incorporate an estimate of FY 2024 outlier reconciliation in the methodology for determining the outlier threshold. As noted previously, for the FY 2024 proposed rule, the ratio of outlier reconciliation dollars to total Federal Payments (Step 4) is a negative 0.007806 percent, which, when rounded to the second digit, is −0.01 percent. Therefore, for FY 2024, we proposed to incorporate a projection of outlier reconciliation dollars by targeting an outlier threshold at 5.11 percent. Under this proposed approach, we determined a proposed threshold of $40,732 and calculated total outlier payments of $4,259,029,890 and total operating Federal payments of $79,087,551,441. We then divided total outlier payments by total operating Federal payments plus total outlier payments and determined that this threshold matched with the 5.11 percent target, which reflected our proposal to incorporate an estimate of outlier reconciliation in the determination of the outlier threshold (as discussed in more detail in the previous section of this Addendum). We noted that, if calculated without applying our methodology for incorporating an estimate of outlier reconciliation in the determination of the outlier threshold, the proposed threshold would be $40,808. We proposed an outlier fixed-loss cost threshold for FY 2024 equal to the prospective payment rate for the MS–DRG, plus any IME, empirically justified Medicare DSH payments, estimated uncompensated care payment, estimated supplemental payment for eligible IHS/tribal hospitals and Puerto Rico hospitals, and any add-on payments for new technology, plus $40,732.

Comment: A commenter expressed appreciation for the stabilization of the outlier threshold. Another commenter stated that the fixed loss threshold remains significantly higher than the threshold prior to the COVID–19 PHE. The commenter stated that this represents a more than 55 percent increase over the PHE fixed loss threshold. The commenter stated that this suggests the data to establish the threshold is abnormal and that CMS needs to adjust its process further so that the threshold will be established at a level likely to result in total outlier payments of 5.1 percent. This commenter requested that CMS model a significant reduction in COVID–19 cases compared to the volume of cases in the FY 2022 claims data to better model estimated post-PHE outlier cases. The commenter noted that this has the impact of reducing the threshold by $700. Another commenter requested that CMS maintain the outlier threshold from FY 2023 given the large increase.
that took effect in FY 2023. Another commenter suggested that the increase to the fixed loss threshold should be limited to the 3 percent market basket update.

A commenter recommended suppressing COVID–19 cases from the FY 2022 MedPAR data for the first half of FY 2022 and duplicating the COVID–19 cases from the second half of the year, essentially applying an extrapolation methodology based on data from the second half of FY 2022 for COVID–19 cases. The commenter believes this approach is a rational and targeted strategy for adjusting the FY 2022 MedPAR data for use in estimating post-PHE outlier cases.

Another commenter urged CMS to undertake a thorough examination of the outlier methodology and consider further changes to address the persistent upward trend of the fixed loss threshold. Another commenter requested that CMS share more information regarding the factors driving the increase to the fixed-loss threshold to facilitate more informed comments.

A commenter stated that CMS did not explain why it is appropriate to use data from the PHE to calculate the CCR adjustment factor, and that the CCRs are expected to decrease even more than the adjustment factors included in the proposed rule.

Response: We thank the commenters for their feedback. To determine the applicable fixed-loss amount, we estimate outlier payments and total payments using claims data from the MedPAR files. As discussed in section I.E. of the preamble to this final rule, in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26670 through 26671), we proposed to use the FY 2022 MedPAR claims file and the FY 2021 HCRIS (which contains data from many cost reports ending in FY 2022 based on each hospital’s cost reporting period) for purposes of FY 2024 IPPS ratesetting without any modifications to our usual ratesetting methodologies to account for the impact of COVID–19 on the ratesetting data. One key component of our ratesetting methodologies is the determination of the outlier fixed-loss amount. In the proposed rule, we stated our belief that FY 2022 data, as the most recent available data, is the best available data for approximating the inpatient experience at both IPPS hospitals and LTCHs in FY 2024. We also stated that based on the information available at the time of the proposed rule, we believe there will continue to be COVID–19 cases treated at IPPS hospitals and LTCHs in FY 2024, such that it was appropriate to use the FY 2022 data, as the most recent available data, for purposes of the FY 2024 IPPS and LTCH PPS ratesetting. However, based on the information available at that time, we did not believe there is a reasonable basis for us to assume that there will be a meaningful difference in the number of COVID–19 cases treated at IPPS hospitals in FY 2024 relative to FY 2022, such that modifications to our usual ratesetting methodologies would be warranted. We acknowledge that COVID–19 hospitalizations have recently trended below FY 2022 levels. We believe there remains uncertainty regarding the impact that COVID–19 will have on IPPS in FY 2024 relative to FY 2022. For this final rule, for the reasons stated previously we continue to believe that the most recent available data is the best available data for approximating the inpatient experience for IPPS hospitals for FY 2024, including for purposes of determining the adjustment factors used in the outlier fixed-loss cost threshold methodology, without modifications to that methodology for COVID–19.

We also note that the final FY 2024 outlier fixed-loss cost threshold of $42,750 increased by 10 percent from the final FY 2023 outlier fixed-loss cost threshold of $38,859. This increase is in line with increases from one year to the next for fiscal years prior to the PHE. For example, the FY 2017 outlier fixed-loss cost threshold was $23,573 and increased 12.5 percent in FY 2018 to $26,537. Other prior FYs such as FY 2015 have also seen increases greater than 10 percent, therefore, with the increase in the threshold from FY 2023 to FY 2024 in line with prior fiscal years, we do not see the need to make an adjustment to the outlier fixed-loss cost threshold due to COVID–19 for FY 2024.

With respect to the commenter who stated that the increase over the pre-PHE fixed loss threshold suggests the data to establish the threshold is abnormal, while also noting that modeling a significant reduction to the COVID–19 cases would lower the threshold by $700, as stated earlier, we acknowledge that COVID–19 hospitalizations have recently trended below FY 2022 levels. We believe there remains uncertainty regarding the impact that COVID–19 will have on IPPS in FY 2024 relative to FY 2022. For this final rule, for the reasons stated previously we continue to believe that the most recent available data is the best available data for approximating the inpatient experience for IPPS hospitals for FY 2024, including for purposes of determining the adjustment factors used in the outlier fixed-loss cost threshold methodology, without modifications to that methodology for COVID–19. Also, with respect to commenters who suggested alternative fixed loss thresholds, we note that using these alternative thresholds would mean that the fixed loss threshold for FY 2024 would not meet the requirement that outlier payments result in 5.1 percent of total payments.

Regarding the comment that the CCRs are expected to decrease even more than the adjustment factors included in the proposed rule, the commenter did not provide any evidence or data as to why it believes the CCR adjustment factors are expected to decrease even more than the adjustment factors included in the proposed rule.

With regard to the commenters that urged CMS to undertake a thorough examination of the outlier methodology, consider further changes to address the persistent upward trend of the fixed loss threshold and share more information regarding the factors driving the increase, each year we provide the methodology to meet the statutory target. We believe we have thoroughly explained our proposed methodology so that commenters can review and provide meaningful comments. There are many factors that can drive the threshold to increase or decrease from one fiscal year to the next making it challenging to pinpoint which exact issue is causing the threshold to increase from one FY to the next.

We appreciate the comments and concerns from the commenters. However, after consideration of the comments received and for the reasons discussed, for FY 2024, we are finalizing to use the most recent available data without any adjustments to the outlier fixed-loss cost threshold methodology for COVID–19.

Comment: A commenter requested that CMS apply trims when calculating charge inflation as it does under the LTCH PPS to “remove all claims from providers whose growth in average charges was a statistical outlier”.

Response: With regard to the charge inflation methodology for the LTCH PPS, in section V.D.3 of this addendum, we stated that we remove all claims from providers whose growth in average charges was a statistical outlier. We further stated that we remove these statistical outliers prior to calculating the charge inflation factor because we believe they may represent aberrations in the data that would distort the measure of average charge growth. We note, in the FY 2024 LTCH PPS final rule impact file, there are 333 providers with approximately 61,000 claims. In the FY 2024 IPPS final rule impact file,
there are 3,199 providers with approximately 6.8 million claims. There are many more providers and claims under the IPPS compared to the LTCH PPS. When we analyzed the LTCH PPS claims data, a single LTCH provider had substantial increases in its charges with average charges per case of approximately $10 million which significantly influenced the charge inflation factor. Since there are fewer hospitals and claims under the LTCH PPS, the potential for a single provider to influence the charge inflation factor is much more significant. We are not aware of a similar situation with a hospital having such high average charges under the IPPS. Therefore, we believe it is not necessary to apply the same trim to hospitals included in the IPPS charge inflation factor.

Comment: A commenter stated that the growth in the fixed loss threshold is occurring because of inadequate IPPS payment rates. The commenter urged CMS to adopt a forecast error adjustment and apply a payment adjustment under section 7(b)(1)(B) of the TMA with a positive 0.9412 percent adjustment, both of which would lower the fixed loss threshold.

Response: We refer readers to section V.A of the preamble of this final rule for our response to comments about the market basket update.

Comment: A commenter requested that CMS consider whether it is appropriate to include extreme cases when calculating the threshold. This commenter explained that high charge cases have a significant impact on the threshold. The commenter stated that when it examined the data to understand the factors that drove an increase of over $15,000 between FY 2017 and FY 2023, and to propose to increase the threshold almost an additional $1,900 for FY 2024, and stated that it observed that the inclusion of extreme cases in the calculation of the threshold, the rate of which are increasing over time, significantly impacts CMS' determination of the fixed-loss threshold. If this trend continues (that is, if the number (and proportion) of extreme cases continues to increase each year), the commenter stated that the impact of this population of cases on the threshold will likewise increase. Thus, the commenter recommended that CMS carefully consider what is causing this trend, whether the inclusion of these cases in the calculation of the threshold is appropriate, or whether a separate outlier mechanism should apply to these cases that more closely hews outlier payments to marginal costs.

Response: As we explained when responding to a similar comment in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38526) and other prior rulemaking, the methodology used to calculate the outlier threshold includes all claims to account for all different types of cases, including high charge cases, to ensure that CMS meets the 5.1 percent target. As the commenter pointed out, the volume of these cases continues to rise, making their impact on the threshold significant. We believe excluding these cases would artificially lower the threshold. We believe it is important to include all cases in the calculation of the threshold no matter how high or low the charges. Including these cases with high charges lends more accuracy to the threshold, as these cases have an impact on the threshold and continue to rise in volume. Therefore, we believe the inclusion of the high-cost outlier cases in the calculation of the outlier threshold is appropriate. Also, in response to commenter recommending that CMS consider whether a separate outlier mechanism should apply to these cases that more closely hews outlier payments to marginal costs, we believe the current calculation of outlier payment meets these goals. If a case has high charges that once reduced to cost significantly exceed the payment plus the threshold, then the case will receive a larger outlier payment reflective of the higher costs. Therefore, we believe the current payment system provides such a mechanism.

Comment: A commenter stated that it believes that CMS should disclose all aspects of its edits to the most current data used for the proposed rule and commit to the same process and methods when it recalculates the threshold for purposes of the final rule. Additionally, the commenter stated CMS should commit to make public the data files it uses for the final rule, including all edits and calculations, when it publishes the final rule.

Response: We refer the reader to the FY 2022 IPPS/LTCH final rule (86 FR 45543) where we responded to a similar comment.

Comment: A commenter supported the inclusion of the impact of outlier reconciliation in setting the FY 2024 fixed-loss threshold and requested that CMS release information on the outlier reconciliation process and data showing the amounts recovered so that it can evaluate the impact of the reconciliation process on the outlier threshold.

Response: We appreciate the commenter’s support. We note that the quarterly HCRIS data contains the information the commenter is requesting and is published as a public use file, available at https://www.cms.gov/research-statistics-data-and-systems/downloadable-public-use-files/cost-reports/cost-reports-by-fiscal-year. For the annual proposed rule we use the December HCRIS and for the annual final rule we use the March HCRIS. Quarterly updates of HCRIS are generally available by the end of the month following the quarterly cutoff date. For example, the December 2022 HCRIS update used in the FY 2024 proposed rule would generally become available towards the end of January 2023. This final rule discusses the impact of incorporating the reconciliation amounts from March 2023 HCRIS reports.

Comment: A commenter noted the final fixed-loss threshold established by CMS has consistently been lower than the threshold set forth in the proposed rule, and the variance between the proposed and final thresholds has generally exceeded 4 percent. The commenter emphasized that this demonstrates that CMS must ordinarily use the most recent data to appropriately calculate the outlier threshold.

Response: We responded to similar comments in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50378 through 50379) and refer readers to that rule for our response. We reiterate that CMS’ historical policy is to use the best available data when setting the payment rates and factors in both the proposed and final rules. Sometimes there are variables that change between the proposed and final rule as result of the availability of more recent data, such as the charge inflation factor and the CCR adjustment factors that can cause fluctuations in the threshold amount. Other factors such as changes to the wage indexes and market basket increase can also cause the outlier fixed loss cost threshold to fluctuate between the proposed rule and the final rule each year. We use the latest data that is available at the time of the development of the proposed and final rules, such as the most recent update of MedPAR claims data and CCRs from the most recent update of the PSF.

After consideration of the public comments we received and for the reasons discussed, we are finalizing to use the same methodology we proposed, without modifications, to calculate the final outlier threshold for FY 2024.

For the FY 2024 final outlier threshold, we used the used the March 2022 MedPAR file of FY 2021 (October 1, 2020, through September 30, 2021) charge data (reconciled in conjunction with the FY 2023 IPPS/LTCH PPS final rule) and the March 2023 MedPAR file
of FY 2022 (October 1, 2021 through September 30, 2022) charge data (released in conjunction with this FY 2024 IPPS/LTCH PPS final rule) to determine the charge inflation factor. To compute the 1-year average annual rate-of-change in charges per case, we compared the average covered charge per case of $78,169.74 ($581,708,955,080/7,441,613 cases) from October 1, 2020, through September 31, 2021, to the average covered charge per case of $82,691.67 ($578,217,120,322/6,992,447 cases) from October 1, 2021, through September 31, 2022. This rate-of-change was 5.8 percent (1.05785) or 11.9 percent (1.11904) over 2 years. The billed charges are obtained from the claims from the MedPAR file and inflated by the inflation factor specified previously.

As we have done in the past, we are establishing the FY 2024 outlier threshold using hospital CCRs from the March 2023 update to the Provider-Specific File (PSF)—the most recent available data at the time of the development of the final rule. We applied the following edits to providers’ CCRs in the PSF. We believe these edits are appropriate to accurately model the outlier threshold. We first search for Indian Health Service providers and those providers assigned the statewide average CCR from the current fiscal year. We then replace these CCRs with the statewide average CCR for the upcoming fiscal year. We also assigned the statewide average CCR (for the upcoming fiscal year) to those providers that have a value in the CCR field in the PSF or whose CCRs exceed the ceilings described later in this section (3.0 standard deviations from the mean of the log distribution of CCRs for all hospitals). We did not apply the adjustment factors described later in this section to hospitals assigned the statewide average CCR. For FY 2024, we also are continuing to apply an adjustment factor to the CCRs to account for cost and charge inflation (as explained later in this section).

For this final rule, as we have done since FY 2014 (with the exception of FYs 2022 and 2023, as discussed in the FY 2022 and FY 2023 IPPS/LTCH PPS proposed and final rules), we are adjusting the CCRs from the March 2023 update of the PSF by comparing the percentage change in the national average case-weighted operating CCR and capital CCR from the March 2022 update of the PSF to the national average case-weighted operating CCR and capital CCR from the March 2023 update of the PSF. We note that we used total transfer-adjusted cases from FY 2022 to determine the national average case weighted CCRs for both sides of the comparison. As stated in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50979), we believe that it is appropriate to use the same case count on both sides of the comparison because this will produce the true percentage change in the average case-weighted operating and capital CCR from one year to the next without any effect from a change in case count on different sides of the comparison.

Using the methodology noted earlier, for this final rule, we calculated a March 2022 operating national average case-weighted CCR of 0.251181 and a March 2023 operating national average case-weighted CCR of 0.248881. We then calculated the percentage change between the two national operating case-weighted CCRs by subtracting the March 2022 operating national average case-weighted CCR from the March 2023 operating national average case-weighted CCR and then dividing the result by the March 2022 national operating average case-weighted CCR. This resulted in a national operating CCR adjustment factor of 0.990843.

We used the same methodology earlier to adjust the capital CCRs. Specifically, for this final rule, we calculated a March 2022 capital national average case-weighted CCR of 0.019678 and a March 2023 capital national average case-weighted CCR of 0.017779. We then calculated the percentage change between the two national capital case-weighted CCRs by subtracting the March 2022 capital national average case-weighted CCR from the March 2023 capital national average case-weighted CCR and then dividing the result by the March 2022 capital national average case-weighted CCR. This resulted in a national capital CCR adjustment factor of 0.904055.

As discussed previously, for purposes of estimating the final outlier threshold for FY 2024, we used a wage index that reflects the policies discussed in this final rule. This includes the following:

—Application of the rural imputed floor adjustment.
—The frontier State floor adjustments in accordance with section 10324(a) of the Affordable Care Act.
—The out-migration adjustment as added by section 505 of Public Law 108–173.
—Incorporating the FY 2024 low wage index hospital policy (described in section III.G.4 of the preamble of this final rule) for hospitals with a wage index value below the 25th percentile, wherein the increase in the wage index value for these hospitals would be equal to half the difference between the otherwise applicable final wage index value for a year for that hospital and the 25th percentile wage index value for that year across all hospitals.

—Incorporating our policy (described in section III.N. of the preamble of this final rule) to apply a 5-percent cap on any decrease to a hospital’s wage index from its wage index in the prior FY, regardless of the circumstances causing the decline.

As stated previously, if we did not take the previous into account, our estimate of total FY 2024 payments would be too low, and, as a result, our outlier threshold would be too high, such that estimated outlier payments would be less than our projected 5.12 percent of total payments (which reflects the estimate of outlier reconciliation calculated for this final rule).

—We excluded the hospital VBP payment adjustments and the hospital readmissions payment adjustments from the calculation of the outlier fixed-loss cost threshold.
—We used the estimated per-discharge uncompensated care payments to hospitals eligible for the uncompensated care payment for all cases in the calculation of the outlier fixed-loss cost threshold methodology.
—Based on the policy finalized, as previously described, we used the estimated per-discharge supplemental payments to hospitals eligible for the supplemental payment for all cases in the calculation of the outlier fixed-loss cost threshold methodology.

Using this methodology, we used the formula described in section I.C.1. of this Addendum to simulate and calculate the Federal payment rate and outlier payments for all claims. In addition, as described in the earlier section to this Addendum, we are finalizing to incorporate an estimate of FY 2024 outlier reconciliation in the methodology for determining the outlier threshold. As noted previously, for this final rule, the ratio of outlier reconciliation dollars to total Federal Payments (Step 4) is a negative 0.016918 percent, which, when rounded to the second digit, is –0.02 percent. Therefore, for FY 2024, we incorporated a projection of outlier reconciliation dollars by targeting an outlier threshold at 5.12 percent [5.1 percent – (—0.02 percent)]. Under this approach, we determined a threshold of $42,750 and calculated total outlier payments of $4,289,273,383 and total operating Federal payments of $79,484,223,474. We then divided total outlier payments by total operating Federal payments plus total outlier payments and
We are applying the outlier adjustment factors to the FY 2024 payment rates after removing the effects of the FY 2023 outlier adjustment factors on the standardized amount. To determine whether a case qualifies for outlier payments, we currently apply hospital-specific CCRs to the total covered charges for the case. Estimated operating and capital costs for the case are calculated separately by applying separate operating and capital CCRs. These costs are then combined and compared with the outlier fixed-loss cost threshold.

Under our current policy at § 412.84, we calculate operating and capital CCR ceilings and assign a statewide average CCR for hospitals whose CCRs exceed 3.0 standard deviations from the mean of the log distribution of CCRs for all hospitals. Based on this calculation, for hospitals for which the MAC computes operating CCRs greater than 1.209 or capital CCRs greater than 0.124 or hospitals for which the MAC is unable to calculate a CCR (as described under § 412.84(i)(3) of our regulations), statewide average CCRs are used to determine whether a hospital qualifies for outlier payments. Table 8A listed in section VI. of this Addendum (and available via the internet on the CMS website) contains the statewide average operating and/or capital CCRs for urban hospitals and for rural hospitals for which the MAC is unable to compute a hospital-specific CCR within the range previously specified. These statewide average ratios would be effective for discharges occurring on or after October 1, 2023, and would replace the statewide average ratios from the prior fiscal year. Table 8B listed in section VI. of this Addendum (and available via the internet on the CMS website) contains the comparable statewide average capital CCRs. As previously stated, the CCRs in Tables 8A and 8B would be used during FY 2024 when hospital-specific CCRs based on the latest settled cost report either are not available or are outside the range noted previously. Table 8C listed in section VI. of this Addendum (and available via the internet on the CMS website) contains the statewide average total CCRs used under the LTCH PPS as discussed in section V. of this Addendum.

We finally note that section 20.1.2 of chapter three of the Medicare Claims Processing Manual (on the internet at https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c03.pdf) covers an array of topics, including CCRs, reconciliation, and the time value of money. We encourage hospitals that are assigned the statewide average operating and/or capital CCRs to work with their MAC on a possible alternative operating and/or capital CCR as explained in the manual. Use of an alternative CCR developed by the hospital in conjunction with the MAC can avoid possible overpayments or underpayments at cost report settlement, thereby ensuring better accuracy when making outlier payments and negating the need for outlier reconciliation. We also note that a hospital may request an alternative operating or capital CCR at any time as long as the guidelines of the manual are followed. In addition, the manual outlines the outlier reconciliation process for hospitals and Medicare contractors. We refer hospitals to the manual instructions for complete details on outlier reconciliation.

(4) FY 2022 Outlier Payments

Our current estimate, using available FY 2022 claims data, is that actual outlier payments for FY 2022 were approximately 6.78 percent of actual total MS–DRG payments. Therefore, the data indicate that, for FY 2022, the percentage of actual outlier payments relative to actual total payments is higher than we projected for FY 2022. Consistent with the policy and statutory interpretation we have maintained since the inception of the IPPS, we do not make retroactive adjustments to outlier payments to ensure that total outlier payments for FY 2022 are equal to 5.1 percent of total MS–DRG payments. As explained in the FY 2003 Outlier final rule (68 FR 34502), if we were to make retroactive adjustments to all outlier payments to ensure total payments are 5.1 percent of MS–DRG payments (by retroactively adjusting outlier payments), we would be removing the important aspect of the prospective nature of the IPPS. Because such an
across-the-board adjustment would either lead to more or less outlier payments for all hospitals, hospitals would no longer be able to reliably approximate their payment for a patient while the patient is still hospitalized. We believe it would be neither necessary nor appropriate to make such an aggregate retroactive adjustment. Furthermore, we believe it is consistent with the statutory language at section 1886(d)(5)(A)(iv) of the Act not to make retroactive adjustments to outlier payments. This section states that outlier payments be equal to or greater than 5 percent and less than or equal to 6 percent of projected or estimated (not actual) MS–DRG payments. We believe that an important goal of a PPS is predictability. Therefore, we believe that the fixed-loss outlier threshold should be projected based on the best available historical data and should not be adjusted retroactively. A retroactive change to the fixed-loss outlier threshold would affect all hospitals subject to the IPPS, thereby undercutting the predictability of the system as a whole.

We note that, because the MedPAR claims data for the entire FY 2023 period would not be available until after September 30, 2023, we are unable to provide an estimate of actual outlier payments for FY 2023 based on FY 2023 claims data in this final rule. We will provide an estimate of actual FY 2023 outlier payments in the FY 2025 IPPS/LTCH PPS proposed rule.

5. FY 2024 Standardized Amount

The adjusted standardized amount is divided into labor-related and nonlabor-related portions. Tables 1A and 1B listed and published in section VI. of this Addendum (and available via the internet on the CMS website) contain the national standardized amounts that we are applying to all hospitals, except hospitals located in Puerto Rico, for FY 2024. The standardized amount for hospitals in Puerto Rico is shown in Table 1C listed and published in section VI. of this Addendum (and available via the internet on the CMS website). The amounts shown in Tables 1A and 1B differ only in that the labor-related share applied to the standardized amounts in Table 1A is 67.6 percent, and the labor-related share applied to the standardized amounts in Table 1B is 62 percent. In accordance with sections 1886(d)(3)(E) and 1886(d)(9)(C)(iv) of the Act, we are applying a labor-related share of 62 percent, unless application of that percentage would result in lower payments to a hospital than would otherwise be made. In effect, the statutory provision means that we would apply a labor-related share of 62 percent for all hospitals whose wage indexes are less than or equal to 1.0000.

In addition, Tables 1A and 1B include the standardized amounts reflecting the applicable percentage increases for FY 2024. The labor-related and nonlabor-related portions of the national average standardized amounts for Puerto Rico hospitals for FY 2024 are set forth in Table 1C listed and published in section VI. of this Addendum (and available via the internet on the CMS website). Similarly, section 1886(d)(9)(C)(iv) of the Act, as amended by section 403(b) of Public Law 108–173, provides that the labor-related share for hospitals located in Puerto Rico be 62 percent, unless the application of that percentage would result in lower payments to the hospital.

The following table illustrates the changes from the FY 2023 national standardized amounts to the FY 2024 national standardized amounts. The second through fifth columns display the changes from the FY 2023 standardized amounts for each applicable FY 2024 standardized amount. The first row of the table shows the updated (through FY 2023) average standardized amount after restoring the FY 2023 offsets for outlier payments, geographic reclassification, rural demonstration, lowest quartile, and wage index cap policy budget neutrality. The MS–DRG reclassification and recalibration wage index, and stem cell acquisition budget neutrality factors are cumulative (that is, we have not restored the offsets). Accordingly, those FY 2023 adjustment factors have not been removed from the base rate in the following table. Additionally, for FY 2024 we have applied the budget neutrality factors for the lowest quartile hospital policy, described previously.
### CHANGES FROM FY 2023 STANDARDIZED AMOUNTS TO THE FY 2024 STANDARDIZED AMOUNTS

<table>
<thead>
<tr>
<th></th>
<th>Hospital Submitted Quality Data and is a Meaningful EHR User</th>
<th>Hospital Submitted Quality Data and is NOT a Meaningful EHR User</th>
<th>Hospital Did NOT Submit Quality Data and is a Meaningful EHR User</th>
<th>Hospital Did NOT Submit Quality Data and is NOT a Meaningful EHR User</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2024 Base Rate after removing:</td>
<td>If Wage Index is Greater Than 1.0000: Labor (67.6%): $4,628.54 Nonlabor (32.4%): $2,218.41</td>
<td>If Wage Index is Greater Than 1.0000: Labor (67.6%): $4,628.54 Nonlabor (32.4%): $2,218.41</td>
<td>If Wage Index is Greater Than 1.0000: Labor (67.6%): $4,628.54 Nonlabor (32.4%): $2,218.41</td>
<td>If Wage Index is Greater Than 1.0000: Labor (67.6%): $4,628.54 Nonlabor (32.4%): $2,218.41</td>
</tr>
<tr>
<td>1. FY 2023 Geographic Reclassification Budget Neutrality Factor (0.984399 )</td>
<td>If Wage Index is less Than or Equal to 1.0000: Labor (62%): $4,245.11 Nonlabor (38%): $2,601.84</td>
<td>If Wage Index is less Than or Equal to 1.0000: Labor (62%): $4,245.11 Nonlabor (38%): $2,601.84</td>
<td>If Wage Index is less Than or Equal to 1.0000: Labor (62%): $4,245.11 Nonlabor (38%): $2,601.84</td>
<td>If Wage Index is less Than or Equal to 1.0000: Labor (62%): $4,245.11 Nonlabor (38%): $2,601.84</td>
</tr>
<tr>
<td>2. FY 2023 Operating Outlier Offset (0.949)</td>
<td>If Wage Index is less Than or Equal to 1.0000: Labor (62%): $4,245.11 Nonlabor (38%): $2,601.84</td>
<td>If Wage Index is less Than or Equal to 1.0000: Labor (62%): $4,245.11 Nonlabor (38%): $2,601.84</td>
<td>If Wage Index is less Than or Equal to 1.0000: Labor (62%): $4,245.11 Nonlabor (38%): $2,601.84</td>
<td>If Wage Index is less Than or Equal to 1.0000: Labor (62%): $4,245.11 Nonlabor (38%): $2,601.84</td>
</tr>
<tr>
<td>3. FY 2023 Rural Demonstration Budget Neutrality Factor (0.998935)</td>
<td>FY 2024 Update Factor 1.031 1.00625 1.02275 .998</td>
<td>FY 2024 MS-DRG Reclassification and Recalibration Budget Neutrality Factor Before Cap 1.001463 1.001463 1.001463 1.001463</td>
<td>FY 2024 Cap Policy MS-DRG Weight Budget Neutrality Factor 0.999928 0.999928 0.999928 0.999928</td>
<td>FY 2024 Wage Index Budget Neutrality Factor 0.971295 0.971295 0.971295 0.971295</td>
</tr>
<tr>
<td>4. FY 2023 Lowest Quartile Budget Neutrality Factor (0.998146)</td>
<td>FY 2024 Reclassification Budget Neutrality Factor 0.997402 0.997402 0.997402 0.997402</td>
<td>FY 2024 Lowest Quartile Budget Neutrality Factor 0.997402 0.997402 0.997402 0.997402</td>
<td>FY 2024 Cap Policy Wage Index Budget Neutrality Factor 0.999645 0.999645 0.999645 0.999645</td>
<td>FY 2024 RCH Demonstration Budget Neutrality Factor 0.999463 0.999463 0.999463 0.999463</td>
</tr>
<tr>
<td>5. FY 2023 Cap Policy Wage Index Budget Neutrality Factor (0.999689)</td>
<td>FY 2024 Operating Outlier Factor 0.949 0.949 0.949 0.949</td>
<td>National Standardized Amount for FY 2024 if Wage Index is Greater Than 1.0000; Labor/Non-Labor Share Percentage (67.6/32.4) Labor: $4,392.49 Nonlabor: $2,105.28</td>
<td>National Standardized Amount for FY 2024 if Wage Index is Less Than or Equal to 1.0000; Labor/Non-Labor Share Percentage (67.6/32.4) Labor: $4,287.05 Nonlabor: $2,054.74</td>
<td>National Standardized Amount for FY 2024 if Wage Index is Greater Than 1.0000; Labor/Non-Labor Share Percentage (67.6/32.4) Labor: $4,357.34 Nonlabor: $2,088.43</td>
</tr>
<tr>
<td></td>
<td>National Standardized Amount for FY 2024 if Wage Index is Less Than or Equal to 1.0000; Labor/Non-Labor Share Percentage (62.38%) Labor: $4,028.62 Nonlabor: $2,409.15</td>
<td>National Standardized Amount for FY 2024 if Wage Index is Less Than or Equal to 1.0000; Labor/Non-Labor Share Percentage (62.38%) Labor: $3,931.91 Nonlabor: $2,409.88</td>
<td>National Standardized Amount for FY 2024 if Wage Index is Greater Than 1.0000; Labor/Non-Labor Share Percentage (62.38%) Labor: $4,251.90 Nonlabor: $2,037.89</td>
<td>National Standardized Amount for FY 2024 if Wage Index is Less Than or Equal to 1.0000; Labor/Non-Labor Share Percentage (62.38%) Labor: $3,899.67 Nonlabor: $2,390.12</td>
</tr>
</tbody>
</table>
B. Adjustments for Area Wage Levels and Cost-of-Living

Tables 1A through 1C, as published in section VI. of this Addendum (and available via the internet on the CMS website), contain the labor-related and nonlabor-related shares that we are using to calculate the prospective payment rates for hospitals located in the 50 States, the District of Columbia, and Puerto Rico for FY 2024. This section addresses two types of adjustments to the standardized amounts that are made in determining the prospective payment rates as described in this Addendum.

1. Adjustment for Area Wage Levels

Sections 1886(d)(3)(E) and 1886(d)(9)(C)(iv) of the Act require that we make an adjustment to the labor-related portion of the national prospective payment rate to account for area differences in hospital wage levels. This adjustment is made by multiplying the labor-related portion of the adjusted standardized amounts by the appropriate wage index for the area in which the hospital is located. For FY 2024, as discussed in section IV.B.3. of the preamble of this final rule, we are applying a labor-related share of 67.6 percent for the national standardized amounts for all IPPS hospitals (including hospitals in Puerto Rico) that have a wage index value that is greater than 1.0000. Consistent with section 1886(d)(3)(E) of the Act, we are applying the wage index to a labor-related share of 62 percent of the national standardized amount for all IPPS hospitals (including hospitals in Puerto Rico) whose wage index values are less than or equal to 1.0000. In section III. of the preamble of this final rule, we discuss the data and methodology for the FY 2024 wage index.

2. Adjustment for Cost-of-Living in Alaska and Hawaii

Section 1886(d)(5)(H) of the Act provides discretionary authority to the Secretary to make adjustments as the Secretary deems appropriate to take into account the unique circumstances of hospitals located in Alaska and Hawaii. Higher labor-related costs for these two States are taken into account in the adjustment for area wages described previously. To account for higher non-labor-related costs for these two States, we multiply the nonlabor-related portion of the standardized amount for hospitals in Alaska and Hawaii by an adjustment factor.

In the FY 2013 IPPS/LTCH PPS final rule, we established a methodology to update the cost of living adjustment (COLA) factors for Alaska and Hawaii that were published by the U.S. Office of Personnel Management (OPM) every 4 years (coinciding with the update to the labor related share of the IPPS market basket), beginning in FY 2014. We refer readers to the FY 2013 IPPS/LTCH PPS proposed and final rules for additional background and a detailed description of this methodology (77 FR 28145 through 28146 and 77 FR 53700 through 53701, respectively). For FY 2022, in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45546 through 45547), we updated the COLA factors published by OPM for 2009 (as these are the last COLA factors OPM published prior to transitioning from COLAs to locality pay) using the methodology that we finalized in the FY 2013 IPPS/LTCH PPS final rule. Based on the policy finalized in the FY 2013 IPPS/LTCH PPS final rule, we are continuing to use the same COLA factors in FY 2024 that were used in FY 2023 to adjust the nonlabor-related portion of the standardized amount for hospitals located in Alaska and Hawaii. The following table lists the COLA factors for FY 2024.

| FY 2024 Cost-of-Living Adjustment Factors (COLA): Alaska and Hawaii Hospitals |
|-----------------|--------------------------|
| Area                        | FY 2022 through FY 2024 |
| Alaska:                |                          |
| City of Anchorage and 80-kilometer (50-mile) radius by road | 1.22 |
| City of Fairbanks and 80-kilometer (50-mile) radius by road | 1.22 |
| City of Juneau and 80-kilometer (50-mile) radius by road | 1.22 |
| Rest of Alaska | 1.24 |
| Hawaii:                   |                          |
| City and County of Honolulu | 1.25 |
| County of Hawaii          | 1.22 |
| County of Kauai           | 1.25 |
| County of Maui and County of Kalawao | 1.25 |

Lastly, as we finalized in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53700 and 53701), we intend to update the COLA factors based on our methodology every 4 years, at the same time as the update to the labor-related share of the IPPS market basket.

C. Calculation of the Prospective Payment Rates

1. General Formula for Calculation of the Prospective Payment Rates for FY 2024

In general, the operating prospective payment rate for all hospitals (including hospitals in Puerto Rico) paid under the IPPS, except SCHs and MDHs, for FY 2024 equals the Federal rate (which includes uncompensated care payments). Under current law, the MDH program is effective for discharges on or before September 30, 2024. SCHs are paid based on whichever of the following rates yields the greatest aggregate payment: the Federal national rate (which, as discussed in section VI.G. of the preamble of this final rule,
includes uncompensated care payments); the updated hospital-specific rate based on FY 1982 costs per discharge; the updated hospital-specific rate based on FY 1987 costs per discharge; the updated hospital-specific rate based on FY 2006 costs per discharge to determine the rate that yields the greatest aggregate payment.

The prospective payment rate for SCHs for FY 2024 equals the higher of the applicable Federal rate, or the hospital-specific rate as described later in this section. The prospective payment rate for MDHs for FY 2024 equals the higher of the Federal rate, or the Federal rate plus 75 percent of the difference between the Federal rate and the hospital-specific rate as described in this section. For MDHs, the updated hospital-specific rate is based on FY 1982, FY 1987, or FY 2002 costs per discharge, whichever yields the greatest aggregate payment.

2. Operating and Capital Federal Payment Rate and Outlier Payment Calculation

   a. Calculation of Hospital-Specific Rate

   Section 1886(b)(3)(C) of the Act provides that SCHs are paid based on whichever of the following rates yields the greatest aggregate payment: the Federal rate; the updated hospital-specific rate based on FY 1982 costs per discharge; the updated hospital-specific rate based on FY 1987 costs per discharge; the updated hospital-specific rate based on FY 1996 costs per discharge; or the updated hospital-specific rate based on FY 2006 costs per discharge to determine the rate that yields the greatest aggregate payment. Under current law, the MDH program has been extended for discharges occurring through September 30, 2024.

   For a more detailed discussion of the calculation of the hospital-specific rates, we refer readers to the FY 1984 IPPS interim final rule (48 FR 39772); the April 20, 1990 final rule with comment period (55 FR 15150); the FY 1991 IPPS final rule (55 FR 35994); and the FY 2001 IPPS final rule (65 FR 47082).

   b. Updating the FY 1982, FY 1987, FY 1996, FY 2002 and FY 2006 Hospital-Specific Rate for FY 2024

   Section 1886(b)(3)(B)(iv) of the Act provides that the applicable percentage increase applicable to the hospital-specific rates for SCHs and MDHs equals the applicable percentage increase set forth in section 1886(b)(3)(B)(i) of the Act (that is, the same update factor as for all other hospitals subject to the IPPS). Because the Act sets the update factor for SCHs and MDHs equal to the update factor for all other IPPS hospitals, the update to the hospital-specific rates for SCHs and MDHs is subject to the amendments to section 1886(b)(3)(B) of the Act made by sections 3401(a) and 10319(a) of the Affordable Care Act. Accordingly, the applicable percentage increases to the hospital-specific rates applicable to SCHs and MDHs are the following:

   - Federal Payment for Capital Costs = MS–DRG Relative Weight × Federal Capital Rate × Geographic Adjustment Fact × (1 + IME + DSH)
   - Step 4—Determine operating and capital costs:
     - Operating Costs = (Billed Charges × Operating CCR)
     - Capital Costs = (Billed Charges × Capital CCR).
   - Step 5—Compute operating and capital outlier threshold (CMS applies a geographic adjustment to the operating and capital outlier threshold to account for local cost variation):
     - Operating CCR to Total CCR = (Operating CCR)/(Operating CCR + Capital CCR)
     - Operating Outlier Threshold = [Fixed Loss Threshold × ((Labor-Related Portion × CBSA Wage Index) + Nonlabor-Related portion)] × Operating CCR to Total CCR + Federal Payment with IME, DSH + Uncompensated Care Payment + supplemental payment for eligible IHS/ Tribal hospitals and Puerto Rico hospitals + New Technology Add-On Payment Amount
     - Capital CCR to Total CCR = (Capital CCR)/(Capital CCR + Operating CCR)
     - Capital Outlier Threshold = (Fixed Loss Threshold × Geographic Adjustment Factor × Capital CCR to Total CCR) + Federal Payment with IME and DSH
   - Step 6—Compute operating and capital outlier payments:
     - Marginal Cost Factor = 0.80 or 0.90 (depending on the MS–DRG)
     - Operating Outlier Payment = (Operating Costs – Operating Outlier Threshold) × Marginal Cost Factor
     - Capital Outlier Payment = (Capital Costs – Capital Outlier Threshold) × Marginal Cost Factor
   - The payment rate may then be further adjusted for hospitals that qualify for a low-volume payment adjustment under section 1886(d)(12) of the Act and 42 CFR 412.101(b). The base-operating DRG payment amount may be further adjusted by the hospital readmissions payment adjustment and the hospital VBP payment adjustment as described under sections 1886(q) and 1886(o) of the Act, respectively. Payments also may be reduced by the 1-percent adjustment under the HAC Reduction Program as described in section 1886(p) of the Act. We also make new technology add-on payments in accordance with section 1886(d)(5)(K) and (L) of the Act. Finally, we add the uncompensated care payment and supplemental payment for eligible IHS/ Tribal hospitals for Puerto Rico to the total claim payment amount. As noted in the previous formula, we take uncompensated care payments, supplemental payments for eligible IHS/Tribal hospitals and Puerto Rico hospitals, and new technology add-on payments into consideration when calculating outlier payments.

   3. Hospital-Specific Rate (Applicable Only to SCHs and MDHs)

   a. Calculation of Hospital-Specific Rate

   Related Applicable Standardized Amount depending on
   whether the hospital submitted
   standardized amount depending on
   the ICD–10–CM diagnosis and ICD–10–PCS
   procedure codes on the claim.

   The formula specified in this section
   is used for actual claim payment and is also
   used by CMS to project the outlier threshold
   for the upcoming fiscal year. The difference
   is the source of some of the variables in the
   formula. For example, operating and capital
   CCRs for actual claim payment are from the
   PSF while CMS uses an adjusted CCR (as
   described previously) to project the threshold
   for the upcoming fiscal year. In addition,
   charges for a claim payment are from the bill
   while charges to project the threshold are
   from the MedPAR data with an inflation
   factor applied to the charges (as described
   earlier).

   Step 1—Determine the MS–DRG and
   MS–DRG relative weight (from Table 5)
   for each claim primarily based on the
   ICD–10–CM diagnosis and ICD–10–PCS
   procedure codes on the claim.

   Step 2—Select the applicable average
   standardized amount depending on
   whether the hospital submitted
   qualifying quality data and is a
   meaningful EHR user, as described
   previously.

   Step 3—Compute the operating and
   capital Federal payment rate:

   —Federal Payment Rate for Operating
     Costs = MS–DRG Relative Weight ×
     ([Labor-Related Applicable
     Standardized Amount × Applicable
     CBSA Wage Index] + [Nonlabor-
     Related Applicable Standardized
     Amount × Cost-of-Living
     Adjustment]) × (1 + IME + (DSH * 0.25))
III. Changes to Payment Rates for Acute Care Hospital Inpatient Capital-Related Costs for FY 2024

The PPS for acute care hospital inpatient capital-related costs was implemented for cost reporting periods beginning on or after October 1, 1991. The basic methodology for determining Federal capital prospective rates is set forth in the regulations at 42 CFR 412.308 through 412.352. In this section of this Addendum, we discuss the factors that we used to determine the capital Federal rate for FY 2024, which would be effective for discharges occurring on or after October 1, 2023.

All hospitals (except “new” hospitals under § 412.304(c)(2)) are paid based on the capital Federal rate. We annually update the capital standard Federal rate, as provided in § 412.308(c)(1), to account for capital input price increases and other factors. The regulations at § 412.308(c)(2) also provide that the capital Federal rate be adjusted annually by a factor equal to the estimated proportion of outlier payments under the capital Federal rate to total capital payments under the capital Federal rate. In addition, § 412.308(c)(3) requires that the capital Federal rate be reduced by an adjustment factor equal to the estimated proportion of payments for exceptions under § 412.348. (We note that, as discussed in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53705), there is generally no longer a need for an exceptions payment adjustment factor.)

In the discussion that follows, we explain the factors that we used to determine the capital Federal rate for FY 2024. In particular, we explain why the FY 2024 capital Federal rate would increase approximately 4.14 percent, compared to the FY 2023 capital Federal rate. As discussed in the impact analysis in appendix A to this final rule, we estimate that capital payments per discharge will increase approximately 6.6 percent during that same period. Because capital payments constitute approximately 10 percent of hospital payments, a 1-percent change in the capital Federal rate yields only approximately a 0.1 percent change in actual payments to hospitals.

1. Projected Capital Standard Federal Rate Update

Under § 412.308(c)(1), the capital standard Federal rate is updated on the basis of an analytical framework that takes into account changes in a capital input price index (CIPI) and several other policy adjustment factors. Specifically, we adjust the projected CIPI rate of change, as appropriate, each year for case-mix index-related changes, for intensity, and for errors in previous CIPI forecasts. The update factor for FY 2024 under that framework is 3.8 percent based on a projected 2.9 percent increase in the 2018-based CIPI, a 0.0 percentage point adjustment for intensity, a 0.0 percentage point adjustment for case-mix, a 0.0 percentage point adjustment for the
DRG reclassification and recalibration, and a forecast error correction of 0.9 percentage point. As discussed in section III.C. of this Addendum, we continue to believe that the CPI is the most appropriate input price index for capital costs to measure capital price changes in a given year. We also explain the basis for the FY 2024 CPII projection in that same section of this Addendum. In this final rule, we describe the policy adjustments that we applied in the update framework for FY 2024.

The case-mix index is the measure of the average DRG weight for cases paid under the IPPS. Because the DRG weight determines the prospective payment for each case, any percentage increase in the case-mix index corresponds to an equal percentage increase in hospital payments.

The case-mix index can change for any of several reasons—
- The average resource use of Medicare patient changes ("real" case-mix change);
- Changes in hospital documentation and coding of patient records result in higher-weighted DRG assignments ("coding effects"); or
- The annual DRG reclassification and recalibration changes may not be budget neutral ("reclassification effect").

We define real case-mix change as actual changes in the mix (and resource requirements) of Medicare patients, as opposed to changes in documentation and coding behavior that result in assignment of cases to higher-weighted DRGs, but do not reflect higher resource requirements. The capital update framework includes the same case-mix index adjustment used in the former operating IPPS update framework (as discussed in the May 18, 2004 IPPS proposed rule for FY 2005 (69 FR 28816)). (We no longer use an update framework to make a recommendation for updating the operating IPPS standardized amounts, as discussed in section II. of appendix B to the FY 2006 IPPS final rule (70 FR 47707).)

For FY 2024, we are projecting a 0.5 percent total increase in the case-mix index. We estimated that the real case-mix increase would equal 0.5 percent for FY 2024. The net adjustment for change in case-mix is the difference between the projected real increases in case mix and the projected total increase in case mix. Therefore, as proposed, the net adjustment for case-mix change in FY 2024 is 0.0 percentage point.

The capital update framework also contains an adjustment for the effects of DRG reclassification and recalibration. This adjustment is intended to remove the effect on total payments of prior year's changes to the DRG classifications and relative weights, to retain budget neutrality for all case-mix index-related changes other than those due to patient severity of illness. Due to the lag time in the availability of data, there is a 2-year lag in data used to determine the adjustment for the effects of DRG reclassification and recalibration. For example, for this final rule, we have the FY 2022 MedPAR claims data available to evaluate the effects of the FY 2022 DRG reclassification and recalibration as part of our update for FY 2024. We assume for purposes of this adjustment, that the estimate of FY 2022 DRG reclassification and recalibration would result in no change in the case-mix when compared with the case-mix index that would have resulted if we had not made the reclassification and recalibration changes to the DRGs.

Therefore, as proposed, we are making a 0.0 percentage point adjustment for reclassification and recalibration in the update framework for FY 2024.

The capital update framework also contains an adjustment for forecast error. The input price index forecast is based on historical trends and relationships ascertainable at the time the update factor is established for the upcoming year. In any given year, there may be unanticipated price fluctuations that may result in differences between the actual increase in prices and the forecast used in calculating the update factors. In setting a prospective payment rate under the framework, we make an adjustment for forecast error only if our estimate of the change in the capital input price index for any year is greater than 0.25 percentage point in absolute terms. There is a 2-year lag between the forecast and the availability of data to develop a measurement of the forecast error. Historically, when a forecast error of the CPI is greater than 0.25 percentage point in absolute terms, it is reflected in the update recommended under this framework. A forecast error of 0.9 percentage point was calculated for the FY 2022 update, for which there are historical data. That is, current historical data indicate that the forecasted FY 2022 CPI increase (1.1 percent) used in calculating the FY 2022 update factor is 0.9 percentage point lower than actual realized price increases (2.0 percent). As this exceeds the 0.25 percentage point threshold, we are making an adjustment of 0.9 percentage point for the FY 2022 forecast error in the update for FY 2024.

Under the capital IPPS update framework, we also make an adjustment for changes in intensity. Historically, we calculate this adjustment using the same methodology and data that were used in the past under the framework for operating IPPS. The intensity factor for the operating update framework reflects how hospital services are utilized to produce the final product, that is, the discharge. This component accounts for changes in the use of quality-enhancing services, for changes within DRG severity, and for expected modification of practice patterns to remove noncost-effective services. Our intensity measure is based on a 5-year average.

We calculate case-mix constant intensity as the change in total cost per discharge, adjusted for price level changes (the CPI for hospital and related services) and changes in real case-mix. Without reliable estimates of the proportions of the overall annual intensity changes that are due, respectively, to ineffective practice patterns and the combination of quality-enhancing new technologies and complexity within the DRG system, we assume that one-half of the annual change is due to each of these factors. Thus, the capital update framework provides an add-on to the input price index rate of increase of one-half of the estimated annual increase in intensity, to allow for increases within DRG severity and the adoption of quality-enhancing technology.

In this final rule, as proposed, we are continuing to use a Medicare-specific intensity measure that is based on a 5-year adjusted average of cost per discharge for FY 2024 (we refer readers to the FY 2011 IPPS/LTCH PPS final rule (75 FR 0436) for a full description of our Medicare-specific intensity measure). Specifically, for FY 2024, we are using an intensity measure that is based on an average of cost-per-discharge data from the 5-year period beginning with FY 2017 and extending through FY 2021. Based on these data, we estimated that case-mix constant intensity declined during FYs 2017 through 2021. In the past, when we found intensity to be declining, we believed a zero (rather than a negative) intensity adjustment was appropriate. Consistent with this approach, because we estimated that intensity would decline during that 5-year period, we believe it is appropriate to continue to apply a zero-intensity adjustment for FY 2024. Therefore, as proposed, we are making a 0.0 percentage point adjustment for intensity in the update for FY 2024.

Earlier, we described the basis of the components we used to develop the 3.8 percent capital update factor under the capital update framework for FY 2024, as shown in the following table.
2. Outlier Payment Adjustment Factor

Section 412.312(c) establishes a unified outlier payment methodology for inpatient operating and inpatient capital-related costs. A shared threshold is used to identify outlier cases for both inpatient operating and inpatient capital-related payments. Section 412.308(c)(2) provides that the standard Federal rate for inpatient capital-related costs be reduced by an adjustment factor equal to the estimated proportion of capital-related outlier payments to total inpatient capital-related PPS payments. The outlier threshold is set so that operating outlier payments are projected to be 5.1 percent of total operating IPPS DRG payments. For FY 2024, we have incorporated the estimated outlier reconciliation payment amounts into the outlier threshold model, as we did for FY 2023. (For more details on our incorporation of the estimated outlier reconciliation payment amounts into the outlier threshold model, please see section II.A. of this Addendum to this final rule.)

For FY 2024, we estimated that outlier payments for capital-related PPS payments would equal 5.51 percent of inpatient capital-related payments based on the capital Federal rate. Based on the threshold discussed in section II.A. of this Addendum, we estimate that prior to taking into account projected capital outlier reconciliation payments, outlier payments for capital-related costs will equal 4.04 percent of inpatient capital-related payments based on the capital Federal rate in FY 2024. Using the methodology outlined in section II.A. of this Addendum, we estimate that taking into account projected capital outlier reconciliation payments will decrease the estimated percentage of FY 2024 capital outlier payments by 0.02 percent. Therefore, accounting for estimated capital outlier reconciliation, the estimated outlier payments for capital-related payments would equal 4.02 percent (4.04 percent − 0.02 percent) of inpatient capital-related payments based on the capital Federal rate in FY 2024. Accordingly, we applied an outlier adjustment factor of 0.9598 in determining the capital Federal rate for FY 2024. Thus, we estimate that the percentage of capital outlier payments to total capital Federal rate payments for FY 2024 would be lower than the percentage for FY 2023.

The outlier reduction factors are not built permanently into the capital rates; that is, they are not applied cumulatively in determining the capital Federal rate. The FY 2024 outlier adjustment of 0.9598 is a 1.57 percent change from the FY 2023 outlier adjustment of 0.9449. Therefore, the net change in the outlier adjustment to the capital Federal rate for FY 2024 is 1.0157 (0.9598/0.9449) so that the outlier adjustment will increase the FY 2024 capital Federal rate by approximately 1.57 percent compared to the FY 2023 outlier adjustment.

3. Budget Neutrality Adjustment Factor for Changes in DRG Classifications and Weights and the GAF

Section 412.308(c)(4)(ii) requires that the capital Federal rate be adjusted so that aggregate payments for the fiscal year based on the capital Federal rate, after any changes resulting from the annual DRG reclassification and recalibration and changes in the GAF, are projected to equal aggregate payments that would have been made on the basis of the capital Federal rate without such changes.

As discussed in section III.G.3. of the preamble of this final rule in the FY 2020 IPPS/LTCH PPS final rule (84 FR 42325 through 42339), we finalized a policy to help reduce wage index disparities between high and low wage index hospitals by increasing the wage index values for hospitals with a wage index value below the 25th percentile wage index. We stated that this policy will be effective for at least 4 years, beginning in FY 2020. As discussed in section III.G.3. of the preamble of this final rule, this policy was applied in FYs 2020 through 2023, and will continue to apply in FY 2024 as we proposed. In addition, beginning in FY 2023, we finalized a permanent 5-percent cap on any decrease to a hospital’s wage index from its wage index in the prior FY regardless of the circumstances causing the decline. That is, under this policy, a hospital’s wage index value would not be less than 95 percent of its prior year value (87 FR 49018 through 49021).

We have established a 2-step methodology for computing the budget neutrality factor for changes in the GAFs in light of the effect of those wage index changes on the GAFs. In the first step, we first calculate a factor to ensure budget neutrality for changes to the GAFs due to the update to the wage data, wage index reclassifications and redesignations, and application of the rural floor policy, consistent with our historical GAF budget neutrality factor methodology. In the second step, we calculate a factor to ensure budget neutrality for changes to the GAFs due to our policy to increase the wage index for hospitals with a wage index value below the 25th percentile wage index, which we are finalizing to continue in FY 2024, and our policy to place a 5-percent cap on any decrease in a hospital’s wage index from the hospital’s final wage index in the prior fiscal year. In this section, we refer to the policy that we applied in FYs 2020 through FY 2023 and are finalizing to continue to apply in FY 2024, of increasing the wage index for hospitals with a wage index value below the 25th percentile wage index, as the lowest quartile hospital wage index adjustment (also known as low wage index hospital policy). We refer to our policy to place a 5-percent cap on any decrease in a hospital’s wage index from the hospital’s final wage index in the prior fiscal year as the 5-percent cap on wage index decreases policy.
The budget neutrality factors applied for changes to the GAFs due to the update to the wage data, wage index reclassifications and redesignations, and application of the rural floor policy are built permanently into the capital Federal rate; that is, they are applied cumulatively in determining the capital Federal rate. However, the budget neutrality factor for the lowest quartile hospital wage index adjustment and the 5-percent cap on wage index decreases policy is not permanently built into the capital Federal rate. This is because the GAFs with the lowest quartile hospital wage index adjustment and the 5-percent cap on wage index decreases policy applied from the previous year are not used in the budget neutrality factor calculations for the current year. Accordingly, and consistent with this approach, prior to calculating the GAF budget neutrality factors for FY 2024, we removed from the capital Federal rate the budget neutrality factor applied in FY 2023 for the lowest quartile hospital wage index adjustment and the 5-percent cap on wage index decreases policy. Specifically, we divided the capital Federal rate by the FY 2023 budget neutrality factor of 0.9972 (87 FR 49463). We refer the reader to the FY 2022 IPPS/LTCH PPS final rule (86 FR 45552) for additional discussion on our policy of removing the prior year budget neutrality factor for the lowest quartile hospital wage index adjustment and the 5-percent cap on wage index decreases from the capital Federal rate.

In light of the changes to the wage index and relative weights policies for FY 2024 discussed previously, which directly affect the GAF, we continue to compute a budget neutrality adjustment for changes in the GAFs in two steps. We discuss our 2-step calculation of the GAF budget neutrality factors for FY 2024 as follows.

To determine the GAF budget neutrality factors for FY 2024, we first compared estimated aggregate capital Federal rate payments based on the FY 2023 MS–DRG classifications and relative weights and the FY 2023 GAFs to estimated aggregate capital Federal rate payments based on the FY 2023 MS–DRG classifications and relative weights and the FY 2024 GAFs without incorporating the lowest quartile hospital wage index adjustment and the 5-percent cap on wage index decreases policy. To achieve budget neutrality for these changes in the GAFs, we calculated an incremental GAF budget neutrality adjustment factor of 0.9869 for FY 2024. Next, we compared estimated aggregate capital Federal rate payments based on the FY 2024 GAFs with and without the lowest quartile hospital wage index adjustment and the 5-percent cap on wage index decreases policy. For this calculation, estimated aggregate capital Federal rate payments were calculated using the FY 2024 MS–DRG classifications and relative weights (after application of the 10-percent cap discussed later in this section) and the FY 2024 GAFs (both with and without the lowest quartile hospital wage index adjustment and the 5-percent cap on wage index decreases policy). We note, for this calculation the GAFs included the imputed floor, out-migration, and Frontier state adjustments.) To achieve budget neutrality for the effects of the lowest quartile hospital wage index adjustment and the 5-percent cap on wage index decreases policy on the FY 2024 GAFs, we calculated an incremental GAF budget neutrality adjustment factor of 0.9964. As discussed earlier in this section, the budget neutrality factor for the lowest quartile hospital wage index adjustment factor and the 5-percent cap on wage index decreases policy is not permanently built into the capital Federal rate. Consistent with this, we present the budget neutrality factor for the lowest quartile hospital wage index adjustment and the 5-percent cap on wage index decreases policy. This is because the GAFs with the lowest quartile hospital wage index adjustment and the 5-percent cap on wage index decreases policy are not permanently built into the capital Federal rate. However, the budget neutrality factor to account for the application of the 10-percent cap on wage index decreases policy. The incremental adjustment factor for DRG classifications and changes in relative weights prior to the application of the 10-percent cap is 0.0107. Next, we compared estimated aggregate capital Federal rate payments based on the FY 2024 MS–DRG classifications and relative weights prior to the application of the 10-percent cap. For these calculations, estimated aggregate capital Federal rate payments were calculated using the FY 2024 GAFs without the lowest quartile hospital wage index adjustment and the 5-percent cap on wage index decreases policy. The incremental adjustment factor for DRG classifications and changes in relative weights prior to the application of the 10-percent cap is 0.0107. Next, we compared estimated aggregate capital Federal rate payments based on the FY 2024 MS–DRG classifications and relative weights prior to the application of the 10-percent cap. For these calculations, estimated aggregate capital Federal rate payments were calculated using the FY 2024 GAFs without the lowest quartile hospital wage index adjustment and the 5-percent cap on wage index decreases policy. The incremental adjustment factor for the application of the 10-percent cap on relative weight decreases is 0.0999. Therefore, to
achieve budget neutrality for the FY 2024 MS–DRG reclassification and recalibration (including the 10-percent cap), based on the calculations described previously, we are applying an incremental budget neutrality adjustment factor of 1.0016 (1.0017 × 0.9999) for FY 2024 to the capital Federal rate. We note that all the values are calculated with unrounded numbers.

The incremental adjustment factor for the FY 2024 MS–DRG reclassification and recalibration (1.0016) and for changes in the FY 2024 GAFs due to the update to the wage data, wage index reclassifications and redesignations, and application of the rural floor policy (0.9869) is 0.9885 (1.0016 × 0.9869). This incremental adjustment factor is built permanently into the capital Federal rates. To achieve budget neutrality for the effects of the lowest quartile hospital wage index adjustment and the 5-percent cap on wage index decreases policy on the FY 2024 GAFs, as described previously, we calculated a budget neutrality adjustment factor of 0.9964 for FY 2024. We refer to this budget neutrality factor for the remainder of this section as the lowest quartile/cap adjustment factor.

We applied the budget neutrality adjustment factors described previously to the capital Federal rate. This follows the requirement under § 412.308(c)(4)(ii) that estimated aggregate payments each year be no more or less than they would have been in the absence of the annual DRG reclassification and recalibration and changes in the GAFs.

The methodology used to determine the recalibration and geographic adjustment factor (GAF/DRG) budget neutrality adjustment is similar to the methodology used in establishing budget neutrality adjustments under the IPPS for operating costs. One difference is that, under the operating IPPS, the budget neutrality adjustments for the effect of updates to the wage data, wage index reclassifications and redesignations, and application of the rural floor policy are determined separately. Under the capital IPPS, there is a single budget neutrality adjustment factor for changes in the GAF that result from updates to the wage data, wage index reclassifications and redesignations, and application of the rural floor policy. In addition, there is no adjustment for the effects that geographic reclassification, the lowest quartile hospital wage index adjustment, or the 5-percent cap on wage index decreases policy described previously have on the other payment parameters, such as the payments for DSH or IME.

The incremental GAF/DRG adjustment factor of 0.9885 accounts for the MS–DRG reclassifications and recalibration (including application of the 10-percent cap on relative weight decreases) and for changes in the GAFs that result from updates to the wage data, the effects on the GAFs of FY 2024 geographic reclassification decisions made by the MGCRB compared to FY 2023 decisions, and the application of the rural floor policy. The lowest quartile/cap adjustment factor of 0.9964 accounts for changes in the GAFs that result from our policy to increase the wage index values for hospitals with a wage index value below the 25th percentile wage index and the 5-percent cap on wage index decreases policy described previously have on the other payment parameters, such as the payments for DSH or IME.

We are providing the following chart that shows how each of the factors and adjustments for FY 2024 affects the computation of the FY 2024 national capital Federal rate in comparison to the FY 2023 national capital Federal rate.

We are providing the following chart that shows how each of the factors and adjustments for FY 2024 affects the computation of the FY 2024 national capital Federal rate in comparison to the FY 2023 national capital Federal rate.

4. Capital Federal Rate for FY 2024

For FY 2023, we established a capital Federal rate of $483.79 (87 FR 49436, as corrected in 87 FR 66563). We are establishing an update of 3.8 percent in determining the FY 2024 capital Federal rate for all hospitals. As a result of this update and the budget neutrality factors discussed earlier, we are establishing a national capital Federal rate of $503.83 for FY 2024. The national capital Federal rate for FY 2024 was calculated as follows:

- The FY 2024 update factor is 1.0380; that is, the update is 3.8 percent.
- The FY 2024 GAF/DRG budget neutrality adjustment factor that is applied to the capital Federal rate for changes in the MS–DRG classifications and relative weights (including application of the 10-percent cap on relative weight decreases) and changes in the GAFs that result from updates to the wage data, wage index reclassifications and redesignations, and application of the rural floor policy is 0.9885.
- The FY 2024 lowest quartile/cap budget neutrality adjustment factor that is applied to the capital Federal rate for changes in the GAFs that result from our policy to increase the wage index values for hospitals with a wage index value below the 25th percentile wage index and the 5-percent cap on wage index decreases policy is 0.9964.
- The FY 2024 outlier adjustment factor is 0.9598.

We are providing the following chart that shows how each of the factors and adjustments for FY 2024 affects the computation of the FY 2024 national capital Federal rate in comparison to the FY 2023 national capital Federal rate.

The FY 2024 update factor has the effect of increasing the capital Federal rate by 3.8 percent compared to the FY 2023 capital Federal rate. The GAF/DRG budget neutrality adjustment factor has the effect of decreasing the capital Federal rate by 1.15 percent. The FY 2024 lowest quartile/cap budget neutrality adjustment factor has the effect of decreasing the capital Federal rate by 0.08 percent compared to the FY 2023 capital Federal rate. The FY 2024 outlier adjustment factor has the effect of increasing the capital Federal rate by 1.57 percent compared to the FY 2023 capital Federal rate. The combined effect of all the changes will increase the national capital Federal rate by approximately 4.14 percent, compared to the FY 2023 national capital Federal rate.
## COMPARISON OF FACTORS AND ADJUSTMENTS: FY 2023 CAPITAL FEDERAL RATE AND THE FY 2024 CAPITAL FEDERAL RATE

<table>
<thead>
<tr>
<th></th>
<th>FY 2023</th>
<th>FY 2024</th>
<th>Change</th>
<th>Percent Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Update Factor¹</td>
<td>1.0250</td>
<td>1.0380</td>
<td>0.0130</td>
<td>1.30%</td>
</tr>
<tr>
<td>GAF/DRG Adjustment Factor¹</td>
<td>1.0012</td>
<td>0.9885</td>
<td>-0.0127</td>
<td>-1.27%</td>
</tr>
<tr>
<td>Quartile/Cap Adjustment Factor²</td>
<td>0.9972</td>
<td>0.9964</td>
<td>-0.0008</td>
<td>-0.08%</td>
</tr>
<tr>
<td>Outlier Adjustment Factor³</td>
<td>0.9449</td>
<td>0.9598</td>
<td>0.0151</td>
<td>1.57%</td>
</tr>
<tr>
<td>Capital Federal Rate</td>
<td>$483.79</td>
<td>$503.83</td>
<td>1.414</td>
<td>1.41%</td>
</tr>
</tbody>
</table>

¹ The update factor and the GAF/DRG budget neutrality adjustment factors are built permanently into the capital Federal rate. Thus, for example, the incremental change from FY 2023 to FY 2024 resulting from the application of the 0.9885 GAF/DRG budget neutrality adjustment factor for FY 2024 is a net change of 0.9885 (or -1.15 percent).

² The lowest quartile/cap budget neutrality adjustment factor is not built permanently into the capital Federal rate; that is, the factor is not applied cumulatively in determining the capital Federal rate. Thus, for example, the net change resulting from the application of the FY 2024 lowest quartile/cap budget neutrality adjustment factor is 0.9964/0.9972 or 0.9992 (or -0.08 percent).

³ The outlier reduction factor is not built permanently into the capital Federal rate; that is, the factor is not applied cumulatively in determining the capital Federal rate. Thus, for example, the net change resulting from the application of the FY 2024 outlier adjustment factor is 0.9598/0.9449 or 1.0157 (or 1.57 percent).

¹ Percent change may not sum due to rounding.

### B. Calculation of the Inpatient Capital-Related Prospective Payments for FY 2024

For purposes of calculating payments for each discharge during FY 2024, the capital Federal rate is adjusted as follows: (Standard Federal Rate) × (DRG weight) × (GAF) × (COLA for hospitals located in Alaska and Hawaii) × (1 + DSH Adjustment Factor + IME Adjustment Factor, if applicable). The result is the adjusted capital Federal rate.

Hospitals also may receive outlier payments for those cases that qualify under the threshold established for each fiscal year. Section 412.312(c) provides for a shared threshold to identify outlier cases for both inpatient operating and inpatient capital-related payments. The outlier threshold for FY 2024 is in section II.A. of this Addendum. For FY 2024, a case will qualify as a cost outlier if the cost for the case is greater than the prospective payment rates for the MS–DRG plus IME and DSH payments (including the empirically justified Medicare DSH payment and the estimated uncompensated care payment), estimated supplemental payment for eligible IHS/ Tribal hospitals and Puerto Rico hospitals, and any add-on payments for new technology, plus the fixed-loss amount of $42,750.

Currently, as provided under §412.304(c)(2), we pay a new hospital 85 percent of its reasonable costs during the first 2 years of operation, unless it elects to receive payment based on 100 percent of the capital Federal rate.

Effective with the third year of operation, we pay the hospital based on 100 percent of the capital Federal rate (that is, the same methodology used to pay all other hospitals subject to the capital PPS).

### C. Capital Input Price Index

#### 1. Background

Like the operating input price index, the capital input price index (CIPI) is a fixed-weight price index that measures the price changes associated with capital costs during a given year. The CIPI differs from the operating input price index in one important aspect—the CIPI reflects the vintage nature of capital, which is the acquisition and use of capital over time. Capital expenses in any given year are determined by the stock of capital in that year (that is, capital that remains on hand from all current and prior capital acquisitions). An index measuring capital price changes needs to reflect this vintage nature of capital. Therefore, the CIPI was developed to capture the vintage nature of capital by using a weighted-average of past capital purchase prices up to and including the current year.

We periodically update the base year for the operating and capital input price indexes to reflect the changing composition of inputs for operating and capital expenses. For this final rule, we are using the IPPS operating and capital market baskets that reflect a 2018 base year. For a complete discussion of this rebasing, we refer readers to section IV. of the preamble of the FY 2022 IPPS/ LTCH PPS final rule (86 FR 45194 through 45213).

#### 2. Forecast of the CIPI for FY 2024

Based on IHS Global Inc.’s second quarter 2023 forecast, for this final rule, we are forecasting the 2018-based CIPI to increase 2.9 percent in FY 2024. This reflects a projected 3.4 percent increase in vintage-weighted depreciation prices (building and fixed equipment, and movable equipment), and a projected 5.4 percent increase in other capital expense prices in FY 2024, partially offset by a projected 1.6 percent decline in vintage-weighted interest expense prices in FY 2024. The weighted average of these three factors produces the forecasted 2.9 percent increase for the 2018-based CIPI in FY 2024. As proposed in the FY 2024 IPPS/LTCH proposed rule (88 FR 27232), we are using the more recent data available for this final rule to determine the FY 2024 increase in the 2018-based CIPI for this final rule.

### IV. Changes to Payment Rates for Excluded Hospitals: Rate-of-Increase Percentages for FY 2024

Payments for services furnished in children’s hospitals, 11 cancer hospitals, and hospitals located outside the 50 States, the District of Columbia and Puerto Rico (that is, short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa) that are excluded from the IPPS are paid on the basis of reasonable costs based on the hospital’s own historical cost experience, subject to a rate-of-increase ceiling. A per discharge limit (the target amount, as defined in §413.40(a) of the regulations) is set for each hospital, based on the hospital’s own cost experience in its base year, and updated annually by a rate-of-increase percentage specified in §413.40(c)(3). In addition, as specified in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38536), effective for cost reporting periods beginning during FY 2018, the annual update to the target amount for extended neoplastic disease care hospitals (hospitals described in §412.22(l) of the regulations) also is the...
rate-of-increase percentage specified in § 413.40(c)(3). (We note that, in accordance with § 403.752(a), religious nonmedical health care institutions (RNHCIs) are also subject to the rate-of-increase limits established under § 413.40 of the regulations.)

For the FY 2024 IPPS/LTCH PPS proposed rule, based on IGI’s 2022 fourth quarter forecast, we estimated that the 2018-based IPPS operating market basket percentage increase for FY 2024 would be 3.0 percent (that is, the estimate of the market basket rate-of-increase). However, we proposed that if more recent data became available for the FY 2024 IPPS/LTCH PPS final rule, we would use such data, if appropriate, to calculate the final IPPS operating market basket update for FY 2024. As proposed, we used more recent data for this FY 2024 IPPS/LTCH PPS final rule, based on IGI’s 2023 second quarter forecast, we estimate that the 2018-based IPPS operating market basket update for FY 2024 is 3.3 percent. Based on this estimate, the FY 2024 rate-of-increase percentage that will be applied to the FY 2023 target amounts in order to calculate the FY 2024 target amounts for children’s hospitals, the 11 cancer hospitals, RNHCIs, and short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa will be 3.3 percent, in accordance with the applicable regulations at 42 CFR 413.40.

IRFs and rehabilitation distinct part units, IPFs and psychiatric units, and LTCHs are excluded from the IPPS and paid under their respective PPSs. The IRF PPS, the IPF PPS, and the LTCH PPS are updated annually. We refer readers to section VIII. of the preamble and section V. of the Addendum of this final rule for the changes to the Federal payment rates for LTCHs under the LTCH PPS for FY 2024. The annual updates for the IRF PPS and the IPF PPS are issued by the agency in separate Federal Register documents.

V. Changes to the Payment Rates for the LTCH PPS for FY 2024

A. LTCH PPS Standard Federal Payment Rate for FY 2024

1. Overview

In section VIII. of the preamble of this final rule, we discuss our annual updates to the payment rates, factors, and specific policies under the LTCH PPS for FY 2024.

Under § 412.523(c)(3) of the regulations, for FY 2012 and subsequent years, we updated the standard Federal payment rate for LTCHs with the LTCH PPS. Therefore, in accordance with § 412.523(c)(3)(xvii), we are applying an update factor of 1.033 to the FY 2023 LTCH PPS standard Federal payment rate of $46,432.77 to determine the FY 2024 LTCH PPS standard Federal payment rate. Also, in accordance with § 412.523(c)(3)(xvii) and (c)(4), we are required to reduce the annual update to the LTCH PPS standard Federal payment rate by 2.0 percentage points for LTCHs that fail to submit the required quality reporting data for FY 2024 as required under the LTCH QRP. Therefore, for LTCHs that fail to submit quality reporting data under the LTCH QRP, we are establishing an annual update to the LTCH PPS standard Federal payment rate of 1.3 percent (or an update factor of 1.013). This update amount reflects the 0.2 percentage point productivity adjustment to the annual market basket update of 3.5 percent, as required by section 1886(m)(5)(B) of the Act.

Consistent with § 412.523(d)(4), we are applying an area wage level budget neutrality factor to the FY 2024 LTCH PPS standard Federal payment rate of 1.0031599, based on the best available data at this time, to ensure that any changes to the area wage level adjustment (that is, the annual update of the wage index (including application of the 5-percent cap on wage index decreases, discussed later in this section), and labor-related share) will not result in any change (increase or decrease) in estimated aggregate LTCH PPS standard Federal payment rate payments. Accordingly, we are establishing an LTCH PPS standard Federal payment rate of $48,116.62 (calculated as $46,432.77 × 1.033 × 1.0031599) for FY 2024. For LTCHs that fail to submit quality reporting data for FY 2024, in accordance with the requirements of the LTCH QRP under section 1866(m)(5) of the Act, we are establishing an LTCH PPS standard Federal payment rate of $47,185.03 (calculated as $46,432.77 × 1.013 × 1.0031599) for FY 2024.

B. Adjustment for Area Wage Levels Under the LTCH PPS for FY 2024

1. Background

Under the authority of section 123 of the BBRA, as amended by section 307(b) of the BIPA, we established an adjustment to the LTCH PPS standard
Federal payment rate to account for differences in LTCH area wage levels under § 412.525(c). The labor-related share of the LTCH PPS standard Federal payment rate is adjusted to account for geographic differences in area wage levels by applying the applicable LTCH PPS wage index. The applicable LTCH PPS wage index is computed using wage data from inpatient acute care hospitals without regard to reclassification under section 1886(d)(8) or section 1886(d)(10) of the Act.

The FY 2024 LTCH PPS standard Federal payment rate wage index values that will be applicable for LTCH PPS standard Federal payment rate discharges occurring on or after October 1, 2023, through September 30, 2024, are presented in Table 12A (for urban areas) and Table 12B (for rural areas), which are listed in section VI. of this Addendum and available via the internet on the CMS website.

2. Geographic Classifications (Labor Market Areas) for the LTCH PPS Standard Federal Payment Rate

In adjusting for the differences in area wage levels under the LTCH PPS, the labor-related portion of an LTCH’s Federal prospective payment is adjusted by using an appropriate area wage index based on the geographic classification (labor market area) in which the LTCH is located. Specifically, the application of the LTCH PPS area wage level adjustment under existing § 412.525(c) is made based on the location of the LTCH—either in an “urban area,” or a “rural area,” as defined in § 412.503. Under § 412.503, an “urban area” is defined as a Metropolitan Statistical Area (MSA) (which includes a Metropolitan division, where applicable), as defined by the Executive OMB, and a “rural area” is defined as any area outside of an urban area (75 FR 37246).

The geographic classifications (labor market area definitions) currently used under the LTCH PPS, effective for discharges occurring on or after October 1, 2014, are based on the Core Based Statistical Areas (CBSAs) established by OMB, which are based on the 2010 decennial census data. In general, the current statistical areas (which were implemented beginning with FY 2015) are based on revised OMB delineations issued on February 28, 2013, in OMB Bulletin No. 13–01. (We note we have adopted minor revisions and updates in the years between the decennial censuses.) We adopted these labor market area delineations because they were at that time based on the best available data that reflect the local economies and area wage levels of the hospitals that are currently located in these geographic areas. We also believed that these OMB delineations would ensure that the LTCH PPS area wage level adjustment most appropriately accounted for and reflected the relative hospital wage levels in the geographic area of the hospital as compared to the national average hospital wage level. We noted that this policy was consistent with the IPPS policy adopted in FY 2015 under § 412.64(b)(1)(ii)(D) [79 FR 49951 through 49963]. (For additional information on the CBSA-based labor market area (geographic classification) delineations currently used under the LTCH PPS and the history of the labor market area definitions used under the LTCH PPS, we refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50180 through 50185).)

In general, it is our historical practice to update the CBSA-based labor market area delineations annually based on the most recent updates issued by OMB. Generally, OMB issues major revisions to statistical areas every 10 years, based on the results of the decennial census. However, OMB occasionally issues minor updates and revisions to statistical areas in the years between the decennial censuses. OMB Bulletin No. 17–01, issued August 15, 2017, established the delineations for the Nation’s statistical areas, and the corresponding changes to the CBSA-based labor market areas were adopted in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41731). A copy of this bulletin may be obtained on the website at https://www.whitehouse.gov/wp-content/uploads/legacy_drupal_files/omb/bulletins/2017/b-17-01.pdf.

On April 10, 2018, OMB issued OMB Bulletin No. 18–03, which superseded OMB Bulletin No. 17–01 (August 15, 2017). On September 14, 2018, OMB issued OMB Bulletin No. 18–04, which superseded OMB Bulletin No. 18–03 (April 10, 2018). Historically OMB bulletins issued between decennial censuses have only contained minor modifications to CBSA delineations based on changes in population counts. However, OMB’s 2010 Standards for Delineating Metropolitan and Micropolitan Standards created a larger mid-decade redelineation that takes into account commuting data from the American Commuting Survey. As a result, OMB Bulletin No. 18–04 (September 14, 2018) included more modifications to the CBSAs than are typical for OMB bulletins issued between decennial censuses. We adopted the updates set forth in OMB Bulletin No. 18–04 in the FY 2021 IPPS/LTCH PPS final rule (85 FR 59050 through 59051). A copy of OMB Bulletin No. 18–04 (September 14, 2018) may be obtained at https://www.whitehouse.gov/wp-content/uploads/2018/09/Bulletin-18-04.pdf.

On March 6, 2020, OMB issued Bulletin No. 20–01, which provided updates to and superseded OMB Bulletin No. 18–04, which was issued on September 14, 2018. The attachments to OMB Bulletin No. 20–01 provided detailed information on the update to statistical areas since September 14, 2018. (For a copy of this bulletin, we refer readers to the following website: https://www.whitehouse.gov/wp-content/uploads/2020/03/Bulletin-20-01.pdf.) In OMB Bulletin No. 20–01, OMB announced one new Micropolitan Statistical Area and one new component of an existing Combined Statistical Area. After reviewing OMB Bulletin No. 20–01, we determined that the changes in OMB Bulletin 20–01 encompassed delineation changes that would not affect the CBSA-based labor market area delineations used under the LTCH PPS.

Therefore, we adopted the updates set forth in OMB Bulletin No. 20–01 in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45556 through 45557) consistent with our general policy of adopting OMB delineation updates; however, the LTCH PPS area wage level adjustment was not altered as a result of adopting the updates because the CBSA-based labor market area delineations were the same as the CBSA-based labor market area delineations adopted in the FY 2021 IPPS/LTCH PPS final rule based on OMB Bulletin No. 18–04 (85 FR 59050 through 59051).

We believe the CBSA-based labor market area delineations, as established in OMB Bulletin 20–01, ensure that the LTCH PPS area wage level adjustment most appropriately accounts for and reflects the relative hospital wage levels in the geographic area of the hospital as compared to the national average hospital wage level based on the best available data that reflect the local economies and area wage levels of the hospitals that are currently located in these geographic areas (81 FR 57298). Therefore, for FY 2024, we did not propose any changes to the CBSA-based labor market area delineations as established in OMB Bulletin 20–01 and adopted in the FY 2022 IPPS/LTCH final rule.

CBSAs are made up of one or more constituent counties. For FY 2024, we are continuing to use the Federal Information Processing Standard (FIPS) county codes, maintained by the U.S. Census Bureau, for purposes of the crosswalking counties to CBSAs. The current county-to-CBSA crosswalk was adopted under the LTCH PPS in the FY...
3. Labor-Related Share for the LTCH PPS Standard Federal Payment Rate

Under the payment adjustment for the differences in area wage levels under §412.525(c), the labor-related share of an LTCH’s standard Federal payment rate is adjusted by the applicable wage index for the labor market area in which the LTCH is located. The LTCH PPS labor-related share currently represents the sum of the labor-related portion of operating costs and a labor-related portion of capital costs using the applicable LTCH market basket. Additional background information on the historical development of the labor-related share under the LTCH PPS can be found in the FY 2007 LTCH PPS final rule (71 FR 27810 through 27817 and 27829 through 27830) and the FY 2012 IPPS/LTCH PPS final rule (76 FR 51769 through 51808).

For FY 2013, we rebased and revised the market basket used under the LTCH PPS by adopting a 2009-based LTCH market basket. In addition, for FY 2013 through FY 2016, we determined the labor-related share annually as the sum of the relative importance of each labor-related cost category of the 2009-based LTCH market basket for the respective fiscal year based on the best available data. (For more details, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53477 through 53479).) For FY 2017, we rebased and revised the 2009-based LTCH market basket to reflect a 2013 base year. In addition, for FY 2017 through FY 2020, we determined the labor-related share annually as the sum of the relative importance of each labor-related cost category of the 2013-based LTCH market basket for the respective fiscal year based on the best available data. (For more details, we refer readers to the FY 2017 IPPS/LTCH PPS final rule (81 FR 57085 through 57096).) Then, effective for FY 2021, we rebased and revised the 2013-based LTCH market basket to reflect a 2017 base year and determined the labor-related share annually as the sum of the relative importance of each labor-related cost category of the 2017-based LTCH market basket using the most recent available data. (For more details, we refer readers to the FY 2021 IPPS/LTCH PPS final rule (85 FR 58909 through 58926).)

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27235), consistent with our historical practice, we proposed that the LTCH PPS labor-related share for FY 2024 would be the sum of the FY 2024 relative importance of each labor-related cost category in the LTCH market basket using the most recent available data. Specifically, we proposed that the labor-related share for FY 2024 would continue to include the sum of the labor-related portion of operating costs from the 2017-based LTCH market basket (that is, the sum of the FY 2024 relative importance shares of Wages and Salaries; Employee Benefits; Professional Fees: Labor-Related; Administrative and Facilities Support Services; Installation, Maintenance, and Repair Services; All Other: Labor-Related Services) and a portion of the relative importance of Capital-Related cost weight from the 2017-based LTCH market basket. The relative importance reflects the different rates of price change for these cost categories between the base year (2017) and FY 2024. Based on IHS Global Inc.’s fourth quarter 2022 forecast of the 2017-based LTCH market basket, the sum of the FY 2024 relative importance for Wages and Salaries; Employee Benefits; Professional Fees: Labor-Related; Administrative and Facilities Support Services; Installation, Maintenance, & Repair Services; and All Other: Labor-Related Services was 64.2 percent. The portion of capital-related costs that is influenced by the local labor market is estimated to be 46 percent (that is, the same percentage applied to the 2009-based and 2013-based LTCH market basket capital-related costs relative importance). Since the FY 2024 relative importance for capital-related costs was 9.2 percent based on IHS Global Inc.’s fourth quarter 2022 forecast of the 2017-based LTCH market basket, we took 46 percent of 9.2 percent to determine the labor-related share for capital-related costs for FY 2024 of 4.2 percent. Therefore, in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27235), we proposed a total labor-related share for FY 2024 of 68.4 percent (the sum of 64.2 percent for the labor-related share of operating costs and 4.2 percent for the labor-related share of capital-related costs). We also proposed that if more recent data became available after the publication of the proposed rule and before the publication of the final rule (for example, a more recent estimate of the relative importance of each labor-related cost category of the 2017-based LTCH market basket), we would use such data, if appropriate, to determine the FY 2024 LTCH PPS labor-related share.

Comment: A commenter stated that they do not support the increase in the labor-related share from 68.0 percent in FY 2023 to 68.4 percent in FY 2024. They claimed that any increase to the labor-related share percentage penalizes any facility that has a wage index less than 1.0. They further stated that there is a growing disparity between high-wage and low-wage states that harms hospitals in many rural and underserved communities. The commenter stated that limiting the increase in the labor-related share helps mitigate that growing disparity.

Response: We appreciate the commenter’s concern over the proposed increase in the labor-related share and the impact to payments for facilities with a wage index less than 1.0; however, we believe it is technically accurate and appropriate to use the sum of the FY 2024 relative importance values for the labor-related cost categories, based on the most recent forecast of the 2017-based LTCH market basket, in order to determine the final labor-related share for FY 2024, as it accounts for more recent data regarding price pressures and cost structure of LTCHs. After consideration of public comments, we are finalizing the FY 2024 labor-related share using the most recently available data. Based on IHS Global Inc.’s second quarter 2023 forecast of the 2017-based LTCH market basket, the sum of the FY 2024 relative importance for Wages and Salaries; Employee Benefits; Professional Fees: Labor-Related; Administrative and Facilities Support Services; Installation, Maintenance, & Repair Services; and All Other: Labor-Related Services is 64.3 percent. The portion of capital-related costs that is influenced by the local labor market is estimated to be 46 percent (that is, the same percentage applied to the 2009-based and 2013-based LTCH market basket capital-related costs relative importance). Since the FY 2024 relative importance for capital-related costs is 9.2 percent based on IHS Global Inc.’s second quarter 2023 forecast of the 2017-based LTCH market basket, we took 46 percent of 9.2 percent to determine the labor-related share of capital-related costs for FY 2024 of 4.2 percent. Therefore, we are finalizing a total labor-related share for FY 2024 of 68.5 percent (the sum of 64.3 percent for the labor-related share of operating costs and 4.2 percent for the labor-related share of capital-related costs). We also proposed that if more recent data became available after the publication of the proposed rule and before the publication of the final rule (for example, a more recent estimate of the relative importance of each labor-related cost category of the 2017-based LTCH market basket), we would use such data, if appropriate, to determine the FY 2024 LTCH PPS labor-related share.
wage data without taking into account geographic reclassification under sections 1886(d)(8) and 1886(d)(10) of the Act (67 FR 56019). The area wage level adjustment established under the LTCH PPS is based on an LTCH’s actual location without regard to the “urban” or “rural” designation of any related or affiliated provider. As with the IPPS wage index, wage data for multicampus hospitals with campuses located in different labor market areas (CBSAs) are apportioned to each CBSA where the campus (or campuses) are located. We also employ a policy for determining area wage index values for areas where there are no IPPS wage data.

Consistent with our historical methodology, to determine the applicable area wage index values for the FY 2024 LTCH PPS standard Federal payment rate, under the broad authority of section 123 of the BBRA, as amended by section 307(b) of the BIPA, as we proposed, we are continuing to employ our historical practice of using the same data we used to compute the FY 2024 acute care hospital inpatient wage index, as discussed in section III. of the preamble of this final rule (that is, wage data collected from cost reports submitted by IPPS hospitals for cost reporting periods beginning during FY 2020) because these data are the most recent complete data available.

In addition, as we proposed, we computed the FY 2024 LTCH PPS standard Federal payment rate area wage index values consistent with the “urban” and “rural” geographic classifications that is, the proposed labor market area delineations as previously discussed in section V.B. of this Addendum and our historical policy of not taking into account IPPS geographic reclassifications under sections 1886(d)(8) and 1886(d)(10) of the Act in determining payments under the LTCH PPS. As we proposed, we also continued to apportion the wage data for multicampus hospitals with campuses located in different labor market areas to each CBSA where the campus or campuses are located, consistent with the IPPS policy. Lastly, consistent with our existing methodology for determining the LTCH PPS wage index values, for FY 2024, as we proposed, we continued to use our existing policy for determining area wage index values for areas where there are no IPPS wage data. Under our existing methodology, the LTCH PPS wage index value for urban CBSAs with no IPPS wage data is determined by using the unweighted average of the wage indices from all of the CBSAs that are contiguous to the rural counties of the State.

Based on the FY 2020 IPPS wage data that we used to determine the FY 2024 LTCH PPS area wage index values in this final rule, there are no IPPS wage data for the urban area of Hinesville, GA (CBSA 25980). Consistent with our existing methodology, we calculated the FY 2024 wage index value for CBSA 25980 as the average of the wage index values for all of the other urban areas within the State of Georgia (that is, CBSAs 10500, 12620, 12660, 12690, 15260, 16860, 17980, 19140, 23580, 31420, 40660, 42340, 46660 and 47580), as shown in Table 12A, which is listed in section VI. of this Addendum.

Based on the FY 2020 IPPS wage data that we used to determine the FY 2024 LTCH PPS standard Federal payment rate area wage index values in this final rule, there are no rural areas without IPPS hospital wage data. Therefore, it is not necessary to use our established methodology to calculate a LTCH PPS wage index value for rural areas with no IPPS wage data for FY 2024. We note that, as IPPS wage data are dynamic, it is possible that the number of rural areas without IPPS wage data will vary in the future.

5. Permanent Cap on Wage Index Decreases

a. Permanent Cap on LTCH PPS Wage Index Decreases

In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49440 through 49442), we finalized a policy that applies a permanent 5-percent cap on any decrease to an LTCH’s wage index from its wage index in the prior year. Consistent with the requirement at § 412.525(c)(2) that changes to area wage level adjustments are made in a budget neutral manner, we include the application of this policy in the determination of the area wage level budget neutrality factor that is applied to the standard Federal payment rate, as is discussed later in section V.B.6. of this Addendum.

Under this policy, an LTCH’s wage index will not be less than 95 percent of its wage index for the prior fiscal year. An LTCH’s wage index cap adjustment is determined based on the wage index value applicable to the LTCH on the last day of the prior Federal fiscal year. LTCHs that became operational during the prior Federal fiscal year are subject to the LTCH PPS wage index cap. Therefore, for newly opened LTCHs that become operational on or after the first day of the fiscal year to which this final rule would apply, these LTCHs are not subject to the LTCH PPS wage index cap since they were not paid under the LTCH PPS in the prior year. These LTCHs would receive the calculated wage index for the area in which they are geographically located, even if other LTCHs in the same geographic area are receiving a wage index cap. The cap on wage index decreases policy is reflected at § 412.525(c)(1).

For each LTCH we identify in our rulemaking data, we are including in a supplemental data file the wage index values from both fiscal years used in determining its capped wage index. This includes the LTCH’s final prior year wage index value, the LTCH’s uncapped current year wage index value, and the LTCH’s capped current year wage index value. Due to the lag in rulemaking data, a new LTCH may not be listed in this supplemental file for a few years. For this reason, a newly opened LTCH could contact their MAC to ensure that its wage index value is not less than 95 percent of the value paid to it for the prior Federal fiscal year. This supplemental data file for public use will be posted on the CMS website for this final rule at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/Acute InpatientPPS/index.html.

Comment: A commenter stated that while they support the permanent cap on LTCH PPS wage index decreases policy, they urge CMS to implement this policy in a non-budget-neutral manner. The commenter believes this would both stabilize provider reimbursement and avoid further unexpected reductions for other providers.

Response: Implementation of this policy in a budget neutral manner is consistent with the requirement at § 412.525(c)(2) that changes to area wage level adjustments are made in a budget neutral manner. Consistent with this requirement, we continue to believe that changes to area wage level adjustments, including the 5-percent cap on the decrease on an LTCH’s wage index, should not result in any change in estimated aggregate LTCH PPS payments. Furthermore, we anticipate that, in the absence of wage index policy changes beyond an annual update of the wage data, most LTCHs will experience year-to-year wage index declines less than 5 percent in any given year, and that the overall budget neutrality adjustments associated with the cap on wage index decreases will therefore be relatively small and will not create volatility in LTCH PPS payments.
b. Permanent Cap on IPPS Comparable Wage Index Decreases

Determining LTCH PPS payments for short-stay outlier cases (reflected in §412.529 and site neutral payment rate cases (reflected in §412.522(c)) requires calculating an “IPPS comparable amount.” For information on this “IPPS comparable amount,” we refer the reader to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49608 through 49610). Determining LTCH PPS payments for LTCHs that do not meet the applicable discharge payment percentage (reflected in §412.522(d)) requires calculating an “IPPS equivalent amount.” For information on this “IPPS equivalent amount,” we refer the reader to the FY 2020 IPPS/LTCH PPS final rule (84 FR 42439 through 42445).

Calculating both the “IPPS comparable amount” and the “IPPS equivalent amount” requires adjusting the IPPS operating and capital standardized amounts by the applicable IPPS wage index for nonreclassified IPPS hospitals. That is, the standardized amounts are adjusted by the IPPS wage index for nonreclassified IPPS hospitals located in the same geographic area as the LTCH. In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49442 through 49443), we finalized a policy that applies a permanent 5-percent cap on decreases in an LTCH’s applicable IPPS comparable wage index from its applicable IPPS comparable wage index in the prior year. Historically, we have not budget neutralized changes to LTCH PPS payments that result from the annual update of the IPPS wage index for nonreclassified IPPS hospitals. Consistent with this approach, the cap on decreases in an LTCH’s applicable IPPS comparable wage index is not applied in a budget neutral manner.

Under this policy, an LTCH’s applicable IPPS comparable wage index will not be less than 95 percent of its applicable IPPS comparable wage index for the prior fiscal year. An LTCH’s applicable IPPS comparable wage index cap adjustment is determined based on the wage index value applicable to the LTCH on the last day of the prior Federal fiscal year. LTCHs that became operational during the prior Federal fiscal year are subject to the applicable IPPS comparable wage index cap. However, for newly opened LTCHs that become operational on or after the first day of the fiscal year to which this final rule would apply, these LTCHs are not subject to the applicable IPPS comparable wage index cap since they were not paid under the LTCH PPS in the prior year. This means that these LTCHs would receive the calculated applicable IPPS comparable wage index for the area in which they are geographically located, even if other LTCHs in the same geographic area are receiving a wage cap. The cap on IPPS comparable wage index decreases policy is reflected at §412.529(d)(4)(ii)(B) and (d)(4)(iii)(B).

Similar to the information we are making available for the cap on the LTCH PPS wage index values (described previously), for each LTCH we identify in our rulemaking data, we are including in a supplemental data file the wage index values from both fiscal years used in determining its capped applicable IPPS comparable wage index. Due to the lag in rulemaking data, a new LTCH may not be listed in this supplemental file for a few years. For this reason, a newly opened LTCH could contact its MAC to ensure that its applicable IPPS comparable wage index value is not less than 95 percent of the value paid to them for the prior Federal fiscal year. This supplemental data file for public use will be posted on the CMS website for this final rule at: https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html.

6. Budget Neutrality Adjustments for Changes to the LTCH PPS Standard Federal Payment Rate Area Wage Level Adjustment

Historically, the LTCH PPS wage index and labor-related share are updated annually based on the latest available data. Under §412.525(c)(2), any changes to the area wage index values or labor-related share are to be made in a budget neutral manner such that estimated aggregate LTCH PPS payments are unaffected; that is, will be neither greater than nor less than estimated aggregate LTCH PPS payments without such changes to the area wage level adjustment. Under this policy, we determine an area wage level adjustment budget neutrality factor that is applied to the standard Federal payment rate to ensure that any changes to the area wage level adjustments are budget neutral such that any changes to the area wage index values or labor-related share would not result in any change (increase or decrease) in estimated aggregate LTCH PPS payments. Accordingly, under §412.523(d)(4), we have applied an area wage level adjustment budget neutrality factor in determining the standard Federal payment rate, and we also established a methodology for calculating the area wage level adjustment budget neutrality factor. (For additional information on the establishment of our budget neutrality policy for changes to the area wage level adjustment, we refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51771 through 51773 and 51809).)

For FY 2024, in accordance with §412.523(d)(4), we are applying an area wage level budget neutrality factor to adjust the LTCH PPS standard Federal payment rate to account for the estimated effect of the adjustments or updates to the area wage level adjustment under §412.525(c)(1) on estimated aggregate LTCH PPS payments, consistent with the methodology we established in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51773). As discussed in section V.B.6. of this Addendum, consistent with, §412.525(c)(2), we include the application of the 5-percent cap on wage index decreases in the determination of the area wage level budget neutrality factor. Specifically, as we proposed, we determined an area wage level adjustment budget neutrality factor that is applied to the LTCH PPS standard Federal payment rate payments using the FY 2024 wage index values and the FY 2023 labor-related share of 68.0 percent.

Step 2—Simulate estimated aggregate LTCH PPS standard Federal payment rate payments using the FY 2024 wage index values (including application of the 5 percent cap on wage index decreases) and the FY 2024 labor-related share of 68.5 percent. (As noted previously, the changes to the wage index values based on updated hospital wage data are discussed in section V.B.4. of this Addendum and the labor-related share is discussed in section V.B.3. of this Addendum.)

Step 3—Calculate the ratio of these estimated total LTCH PPS standard Federal payment rate payments by dividing the estimated total LTCH PPS standard Federal payment rate payments using the FY 2023 area wage level adjustments (calculated in Step 1) by the estimated total LTCH PPS standard Federal payment rate payments using the FY 2024 updates to the area wage level adjustment (calculated in Step 2) to determine the budget neutrality factor for updates to the area wage level adjustment for FY 2024 LTCH PPS standard Federal payment rate payments.

Step 4—Apply the FY 2024 updates to the area wage level adjustment budget neutrality factor for budget neutrality factor for the FY 2024 LTCH PPS standard Federal payment rate after the
application of the FY 2024 annual update.

In section I.E., of the preamble of this final rule, we finalized our proposal to use the most recent data available for the FY 2024 LTCH PPS ratesetting, including the FY 2022 MedPAR file. Therefore, we used claims from the FY 2022 MedPAR file in calculating the FY 2024 LTCH PPS standard Federal payment rate area wage level adjustment budget neutrality factor. We note that, because the area wage level adjustment under §412.525(c) is an adjustment to the LTCH PPS standard Federal payment rate, consistent with historical practice, we only used data from claims that qualified for payment at the LTCH PPS standard Federal payment rate under the dual rate LTCH PPS to calculate the FY 2024 LTCH PPS standard Federal payment rate area wage level adjustment budget neutrality factor.

In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49448), we discussed an LTCH (CCN 312012) whose abnormal charging practices in FY 2021 led to the LTCH receiving an excessive amount of high cost outlier payments. In that rule, we stated our belief, based on information we received from the provider, that these abnormal charging practices would not persist into FY 2023. Therefore, we did not include its cases in our model for determining the FY 2023 outlier fixed-loss amount. The FY 2022 MedPAR claims also reflect the abnormal charging practices of this LTCH. In the March 2023 update of the FY 2022 MedPAR file, we identified 166 LTCH PPS standard Federal payment rate cases for this LTCH. Of these 166 cases, 118 of the cases had charges that were exactly or within ten dollars of $10 million. We do not believe these abnormal charging practices will persist into FY 2024. As such, simulating FY 2023 and FY 2024 payments for this LTCH based on their FY 2022 claims results in simulated payment amounts that we do not believe are reasonable approximations of the payment amounts this LTCH will actually receive in FY 2023 and FY 2024. For this reason, we do not believe it would be appropriate to use these claims in determining the FY 2024 LTCH PPS standard Federal payment rate area wage level adjustment budget neutrality factor. Therefore, as we proposed, we removed claims from CCN 312012 when determining the FY 2024 LTCH PPS standard Federal payment rate area wage level adjustment budget neutrality factor.

For this final rule, using the steps in the methodology previously described, we determined a FY 2024 LTCH PPS standard Federal payment rate area wage level adjustment budget neutrality factor of 1.0031599. Accordingly, in section V.A. of this Addendum, we applied the area wage level adjustment budget neutrality factor of 1.0031599 to determine the FY 2024 LTCH PPS standard Federal payment rate, in accordance with §412.523(d)(4).

C. Cost-of-Living Adjustment (COLA) for LTCHs Located in Alaska and Hawaii

Under §412.525(b), a cost-of-living adjustment (COLA) is provided for LTCHs located in Alaska and Hawaii to account for the higher costs incurred in those States. Specifically, we apply a COLA to payments to LTCHs located in Alaska and Hawaii by multiplying the nonlabor-related portion of the standard Federal payment rate by the applicable COLA factors established annually by CMS. Higher labor-related costs for LTCHs located in Alaska and Hawaii are taken into account in the adjustment for area wage levels previously described. The methodology used to determine the COLA factors for Alaska and Hawaii is based on a comparison of the growth in the Consumer Price Indexes (CPIs) for Anchorage, Alaska, and Honolulu, Hawaii, relative to the growth in the CPI for the average U.S. city as published by the Bureau of Labor Statistics (BLS). It also includes a 25-percent cap on the CPI-updated COLA factors. Under our current policy, we have updated the COLA factors using the methodology as previously described every 4 years (at the same time as the update to the labor-related share of the IPPS market basket) and we last updated the COLA factors for Alaska and Hawaii published by OPM for 2009 in FY 2022 (86 FR 45559 through 45560).

We continue to believe that determining updated COLA factors using this methodology would appropriately adjust the nonlabor-related portion of the LTCH PPS standard Federal payment rate for LTCHs located in Alaska and Hawaii. Therefore, in this final rule, for FY 2024, under the broad authority conferred upon the Secretary by section 123 of the BBRA, as amended by section 307(b) of the BIPA, to determine appropriate payment adjustments under the LTCH PPS, as we proposed, we are continuing to use the COLA factors based on the 2009 OPM COLA factors updated through 2020 by the comparison of the growth in the CPIs for Anchorage, Alaska, and Honolulu, Hawaii, relative to the growth in the CPI for the average U.S. city as established in the FY 2022 IPPS/LTCH PPS final rule. (For additional details on our current methodology for updating the COLA factors for Alaska and Hawaii and for a discussion on the FY 2022 COLA factors, we refer readers to the FY 2022 IPPS/LTCH PPS final rule (86 FR 45559 through 45560).)
COST-OF-LIVING ADJUSTMENT FACTORS (COLA):
ALASKA AND HAWAII UNDER THE LTCH PPS FOR FY 2024

<table>
<thead>
<tr>
<th>Area</th>
<th>FY 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alaska:</td>
<td></td>
</tr>
<tr>
<td>City of Anchorage and 80-kilometer (50-mile) radius by road</td>
<td>1.22</td>
</tr>
<tr>
<td>City of Fairbanks and 80-kilometer (50-mile) radius by road</td>
<td>1.22</td>
</tr>
<tr>
<td>City of Juneau and 80-kilometer (50-mile) radius by road</td>
<td>1.22</td>
</tr>
<tr>
<td>Rest of Alaska</td>
<td>1.24</td>
</tr>
<tr>
<td>Hawaii:</td>
<td></td>
</tr>
<tr>
<td>City and County of Honolulu</td>
<td>1.25</td>
</tr>
<tr>
<td>County of Hawaii</td>
<td>1.22</td>
</tr>
<tr>
<td>County of Kauai</td>
<td>1.25</td>
</tr>
<tr>
<td>County of Maui and County of Kalawao</td>
<td>1.25</td>
</tr>
</tbody>
</table>

D. Adjustment for LTCH PPS High Cost Outlier (HCO) Cases

1. HCO Background

From the beginning of the LTCH PPS, we have included an adjustment to account for cases in which there are extraordinarily high costs relative to the costs of most discharges. Under this policy, additional payments are made based on the degree to which the estimated cost of a case (which is calculated by multiplying the Medicare allowable covered charge by the hospital’s overall hospital CCR) exceeds a fixed-loss amount. This policy results in greater payment accuracy under the LTCH PPS and the Medicare program, and the LTCH sharing the financial risk for the treatment of extraordinarily high-cost cases.

We retained the basic tenets of our HCO policy in FY 2016 when we implemented the dual rate LTCH PPS payment structure under section 1206 of Public Law 113–67. LTCH discharges that meet the criteria for exclusion from the site neutral payment rate (that is, LTCH PPS standard Federal payment rate cases) are paid at the LTCH PPS standard Federal payment rate, which includes, as applicable, HCO payments under § 412.522(c)(2)(i). LTCH discharges that do not meet the criteria for exclusion are paid at the site neutral payment rate, which includes, as applicable, HCO payments under § 412.522(c)(2)(ii). In the FY 2016 IPPS/LTCH PPS final rule, we established separate fixed-loss amounts and targets for the two different LTCH PPS payment rates. Under this bifurcated policy, the historic 8-percent HCO target was retained for LTCH PPS standard Federal payment rate cases, with the fixed-loss amount calculated using only data from LTCH cases that would have been paid at the LTCH PPS standard Federal payment rate if that rate had been in effect at the time of those discharges. For site neutral payment rate cases, we adopted the operating IPPS HCO target (currently 5.1 percent) and set the fixed-loss amount for site neutral payment rate cases at the value of the IPPS fixed-loss amount. Under the HCO policy for both payment rates, an LTCH receives 80 percent of the difference between the estimated cost of the case and the applicable HCO threshold, which is the sum of the LTCH PPS payment for the case and the applicable fixed-loss amount for such case.

To maintain budget neutrality, consistent with the budget neutrality requirement at § 412.523(d)(1) for HCO payments to LTCH PPS standard Federal rate payment cases, we also adopted a budget neutrality requirement for HCO payments to site neutral payment rate cases by applying a budget neutrality factor to the LTCH PPS payment for those site neutral payment rate cases. (We refer readers to § 412.522(c)(2)(ii) of the regulations for further details.) We note that, during the 4-year transitional period, the site neutral payment rate HCO budget neutrality factor did not apply to the LTCH PPS standard Federal payment rate portion of the blended payment rate at § 412.522(c)(3) payable to site neutral payment rate cases. (For additional details on the HCO policy adopted for site neutral payment rate cases under the dual rate LTCH PPS payment structure, including the budget neutrality adjustment for HCO payments to site neutral payment rate cases, we refer readers to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49617 through 49623).)
ceiling. Under our established policy, an LTCH with a calculated CCR in excess of the applicable maximum CCR threshold (that is, the LTCH total CCR ceiling, which is calculated as 3 standard deviations from the national geometric average CCR) is generally assigned the applicable statewide CCR. This policy is premised on a belief that calculated CCRs in excess of the LTCH total CCR ceiling are most likely due to faulty data reporting or entry, and CCRs based on erroneous data should not be used to identify and make payments for outlier cases.

b. LTCH Total CCR Ceiling

Consistent with our historical practice, as we proposed, we used the best available data to determine the LTCH total CCR ceiling for FY 2024 in this final rule. Specifically, in this final rule, we used our established methodology for determining the LTCH total CCR ceiling based on IPPS total CCR data from the March 2023 update of the Provider Specific File (PSF), which is the most recent data available. Accordingly, we are establishing an LTCH total CCR ceiling of 1.289 under the LTCH PPS for FY 2024 in accordance with § 412.525(a)(4)(iv)(C)(2) for HCO cases under either payment rate and § 412.522(c)(1)(iii) for the site neutral payment rate. (For additional information on our methodology for determining the LTCH total CCR ceiling, we refer readers to the FY 2007 IPPS final rule (71 FR 48117 through 48119).)

We did not receive any public comments on our proposals and are finalizing our proposals as described previously, without modification.

c. LTCH Statewide Average CCRs

Our general methodology for determining the statewide average CCRs used under the LTCH PPS is similar to our established methodology for determining the LTCH total CCR ceiling because it is based on “total” IPPS CCR data. (For additional information on our methodology for determining statewide average CCRs under the LTCH PPS, we refer readers to the FY 2007 IPPS final rule (71 FR 48119 through 48120)).

Under the LTCH PPS HCO policy at § 412.525(a)(4)(iv)(C), the SSO policy at § 412.529(f)(4)(iii), and the site neutral payment rate at § 412.522(c)(1)(iii), the MAC may use a statewide average CCR, which is established annually by CMS, if it is unable to determine an accurate CCR for an LTCH in one of the following circumstances: (1) New LTCHs that have not yet submitted their first Medicare cost report; (2) LTCHs that are defined as an entity that has not accepted assignment of an existing hospital’s provider agreement in accordance with § 489.18; (3) LTCHs whose calculated CCR is in excess of the LTCH total CCR ceiling; and (3) other LTCHs for whom data with which to calculate a CCR are not available (for example, missing or faulty data). (Other sources of data that the MAC may consider in determining an LTCH’s CCR include data from a different cost reporting period for the LTCH, data from the cost reporting period preceding the period in which the hospital began to be paid as an LTCH (that is, the period of at least 6 months that it was paid as a short-term, acute care hospital), or data from other comparable LTCHs, such as LTCHs in the same chain or in the same region.)

Consistent with our historical practice of using the best available data, in this final rule, as we proposed, we are using our established methodology for determining the LTCH PPS statewide average CCRs, based on the most recent complete IPPS “total CCR” data from the March 2023 update of the PSF. As we proposed, we are establishing LTCH PPS statewide average total CCRs for urban and rural hospitals that will be effective for discharges occurring on or after October 1, 2023, through September 30, 2024, in Table 8C listed in section VI. of this Addendum (and available via the internet on the CMS website).

Under the current LTCH PPS labor market areas, all areas in Delaware, the District of Columbia, New Jersey, and Rhode Island are classified as urban. Therefore, there are no rural statewide average total CCRs listed for those jurisdictions in Table 8C. This policy is consistent with the policy that we established when we revised our methodology for determining the applicable LTCH statewide average CCRs in the FY 2007 IPPS final rule (71 FR 48119 through 48121) and is the same as the policy applied under the IPPS. In addition, although Connecticut has areas that are designated as rural, in our calculation of the LTCH statewide average CCRs, there were no short-term, acute care IPPS hospitals classified as rural or LTCHs located in these rural areas as of March 2023. Therefore, consistent with our existing methodology, we used the national average total CCR for rural IPPS hospitals for rural Massachusetts in Table 8C. Furthermore, consistent with our existing methodology, in determining the urban and rural statewide average total CCRs for Maryland LTCHs paid under the LTCH PPS, as we proposed, we are continuing to use, as a proxy, the national average total CCR for urban IPPS hospitals and the national average total CCR for rural IPPS hospitals, respectively. We are using this proxy because we believe that the CCR data in the PSF for Maryland hospitals may not be entirely accurate (as discussed in greater detail in the FY 2007 IPPS final rule (71 FR 48120)).

We did not receive any public comments on our proposals. We are finalizing our proposals as described previously, without modification.

d. Reconciliation of HCO Payments

Under the HCO policy at § 412.525(a)(4)(iv)(D), the payments for HCO cases are subject to reconciliation (regardless of whether payment is based on the LTCH standard Federal payment rate or the site neutral payment rate). Specifically, any such payments are reconciled at settlement based on the CCR that was calculated based on the cost report coinciding with the discharge. For additional information on the reconciliation policy, we refer readers to sections 150.26 through 150.28 of the Medicare Claims Processing Manual (Pub. 100-4), as added by Change Request 7192 (Transmittal 2111; December 3, 2010), and the FY 2009 LTCH PPS final rule (73 FR 26820 through 26821).

3. High-Cost Outlier Payments for LTCH PPS Standard Federal Payment Rate Cases

a. High-Cost Outlier Payments for LTCH PPS Standard Federal Payment Rate Cases

Under the regulations at § 412.525(a)(2)(ii) and as required by section 1886(m)(7) of the Act, the fixed-loss amount for HCO payments is set each year so that the estimated aggregate HCO payments for LTCH PPS standard Federal payment rate cases are 99.6875 percent of 8 percent (that is, 7.975 percent) of estimated aggregate LTCH PPS payments for LTCH PPS standard Federal payment rate cases. (For more details on the requirements for high-cost outlier payments in FY 2018 and subsequent years under section 1886(m)(7) of the Act and additional information regarding high-cost outlier payments, we refer readers to the FY 2018 IPPS/LTCH PPS final rule (82 FR 38542 through 38544).)
b. Fixed-Loss Amount for LTCH PPS

Standard Federal Payment Rate Cases for FY 2024

To determine the applicable fixed-loss amount for LTCH PPS standard Federal payment rate cases, we estimate outlier payments and total LTCH PPS payments using claims data from the MedPAR files. As discussed in section I.E. of the preamble to this final rule, in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 26670 through 26671), we proposed to use the FY 2022 MedPAR claims file and the FY 2021 HCRIS (which contains data from many cost reports ending in FY 2022 based on each hospital’s cost reporting period) for purposes of the FY 2024 LTCH PPS ratesetting without any modifications to our usual ratesetting methodologies to account for the impact of COVID–19 ratesetting data. One key component of our LTCH ratesetting methodologies is the determination of the outlier fixed-loss amount for LTCH PPS standard Federal payment rate cases. In the proposed rule, we stated our belief that FY 2022 data, as the most recent available data, is the best available data for approximating the inpatient experience at both IPPS hospitals and LTCHs in FY 2024. We also stated that based on the information available at the time of the proposed rule, we believe there will continue to be COVID–19 cases treated at IPPS hospitals and LTCHs in FY 2024, such that it was appropriate to use the FY 2022 data, as the most recent available data, for purposes of the FY 2024 IPPS and LTCH PPS ratesetting. However, based on the information available at that time, we did not believe there was a reasonable basis for us to assume that there will be a meaningful difference in the number of COVID–19 cases treated at LTCHs in FY 2024 relative to FY 2022, such that modifications to our usual ratesetting methodologies would be warranted. We received several comments on our proposal to use FY 2022 data for purposes of the FY 2024 LTCH PPS ratesetting, nearly all focused on the specific use of FY 2022 MedPAR claims data when determining the FY 2024 outlier fixed-loss amount for LTCH PPS standard Federal payment rate cases. Therefore, we summarize and respond to all of these comments in this section. As discussed in greater detail later in this section, in addition to the claims data, the charge inflation factor and CCR adjustment factors are key components of our methodology for determining the outlier fixed-loss amount for LTCH PPS standard Federal payment rate cases. In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27240 through 27242), we presented our proposed methodology for determining the outlier fixed-loss amount for LTCH PPS standard Federal payment rate cases and proposed an outlier fixed-loss amount of $94,378. This proposed amount was significantly higher than the fixed-loss amount we finalized for FY 2023. For this reason, in the proposed rule (88 FR 27242), we solicited comments on our proposed methodology and the assumptions underlying it, and stated that we would consider these comments when finalizing our methodology in the final rule. As noted previously, we summarize and respond to the comments received in response to that solicitation later in this section. Later in this section of the Addendum, we present the detailed application of our finalized methodology based on consideration of the comments and our responses that are presented later in the section.

Comment: We received several comments expressing concern with our proposal to use FY 2022 data for purposes of the FY 2024 LTCH PPS ratesetting without any modifications to our usual ratesetting methodologies that would account for the impact of COVID–19 on the ratesetting data. Several commenters disagreed with our statement in the proposed rule that we do not believe there is a reasonable basis for us to assume that there will be a meaningful difference in the number of COVID–19 cases treated at LTCHs in FY 2024 relative to FY 2022, such that modifications to our usual ratesetting methodologies would be warranted. Some commenters found this statement to be unsupported by the most recent data on COVID–19 hospitalizations. These commenters found that FY 2022 was the “worst” year for COVID–19 hospitalizations, citing surges in hospitalizations that occurred in January 2022 and again during the summer of 2022. The commenters pointed out, however, that since FY 2022 there has been a sustained decline in COVID–19 hospitalizations. These commenters believe the most recent hospitalization data provide a reasonable basis to assume that the number of COVID–19 cases treated at LTCHs in FY 2024 will be lower relative to FY 2022. Some commenters also cited the CDC’s most recent monthly COVID–19 hospitalization forecast, which predicts that trends in numbers of future hospitalizations are uncertain or predicted to remain stable in all states and territories over the next four weeks, as evidence that the number of COVID–19 cases treated at LTCHs will be lower in FY 2024 relative to FY 2022. Some commenters stated that the U.S. population’s immunity to COVID–19 is higher than it was in FY 2022 due to increases in COVID–19 vaccination rates and increases in natural immunity from prior infection. These commenters believe this increase in immunity supports the assumption that there will be a decrease in the number of COVID–19 cases treated at LTCHs in FY 2024 relative to FY 2022. A few commenters stated that certain declarations (such as the World Health Organization (WHO) declaring an end to the COVID–19 global pandemic on May 5, 2023), certain measures (such as HHS allowing the COVID–19 PHE to expire on May 11, 2023), and other actions (such as the removal of the health care personnel vaccination requirements from the hospital conditions of participation), are inconsistent with CMS’s stated belief that there is not a reasonable basis to assume that there will be a meaningful difference in the number of COVID–19 cases treated at LTCHs in FY 2024 relative to FY 2022. Commenters cited several ways the COVID–19 PHE impacted the FY 2022 LTCH PPS data that we proposed to use for FY 2024 ratesetting. For example, some commenters discussed how they believe the FY 2022 claims data reflect the significant number of patients treated at LTCHs in FY 2022 who were positive with COVID–19 or were suffering from varying diseases that resulted from a previous COVID–19 infection. Other commenters stated that the case-mix index and average length of stay for LTCHs rose significantly during the COVID–19 PHE, which resulted in major cost anomalies in the FY 2022 data. Since these commenters believe that there will be a decrease in the number of COVID–19 cases treated at LTCHs in FY 2024 relative to FY 2022, they argue CMS must make modifications to our usual LTCH PPS ratesetting methodologies to account for the effect of the COVID–19 PHE on the FY 2022 data ratesetting data.

Some commenters suggested that CMS use FY 2019 LTCH PPS claims (the last fiscal year prior to the PHE) to determine the outlier fixed-loss amount. These commenters stated that given the COVID–19 impacts on hospitals and other providers have diminished and the PHE waivers have expired, it would be reasonable to assume that LTCH utilization in FY 2024 would more closely resemble pre-pandemic times. A commenter suggested blending FY 2019 and FY 2021 LTCH claims data for purposes of determining the outlier fixed-loss amount.

Several commenters expressed that during FY 2022, many IPPS hospitals...
were operating beyond capacity and could not always offer an ICU placement to critical patients for a full three days. Due to the CARES Act waiver of the site neutral payment rate, which was in effect for all of FY 2022 and expired on May 11, 2023, commenters stated that there was no financial disincentive to LTCHs for admitting these types of patients (that is, patients that did not meet the statutory patient criteria to be excluded from the site-neutral payment rate in section 1886(m)(6) of the Act). Commenters stated that CMS is treating these types of cases in the FY 2022 MedPAR as site neutral payment rate cases and excluding them from the calculations of the FY 2024 outlier fixed-loss amount. However, commenters believe that in the absence of the COVID–19 PHE and the CARES Act waiver, these types of cases would have met the statutory patient criteria to be paid the standard Federal payment rate. Commenters admitted that there is not an easy way to identify these types of cases in the FY 2022 MedPAR file. Therefore, for purposes of determining the FY 2024 outlier fixed-loss amount, commenters stated that CMS should use all FY 2022 cases regardless of whether the case would have met the statutory patient criteria to be excluded from the site-neutral payment rate. Some commenters urged CMS to exclude dialysis patients from the FY 2022 claims data when determining the outlier fixed-loss amount. Commenters discussed the rising cost of treating dialysis patients at LTCHs in FY 2022 and the difficulties LTCHs faced in discharging dialysis patients into outpatient dialysis or home care, which commenters stated led to longer lengths of stay and resulted in higher charges. In describing the challenges and increased costs faced by LTCHs in providing dialysis services, some commenters noted that they have made modifications to their procurement of dialysis services provided to their patients, such as updating their dialysis vendor contracts with third party companies, hiring additional clinical staff to be able to provide the service “in-house” rather than under arrangements by third party companies, and making capital investments to purchase the necessary equipment. Some commenters stated that these issues are abating in their justification for why it would be appropriate for CMS to exclude claims for dialysis patients when calculating the fixed-loss threshold for FY 2024.

Numerous commenters made specific suggestions for modifying the proposed methodology for determining the FY 2024 outlier fixed-loss amount for LTCH PPS standard Federal payment rate cases. Many of these comments objected to the charge inflation factor we proposed to apply under our methodology when determining the FY 2024 fixed-loss amount. Commenters stated that the proposed 1-year charge inflation factor of 13.56 percent was too high and is reflective of pandemic era inflationary trends. Some commenters stated the proposed charge inflation factor reflects the increase in patient complexity that occurred during the pandemic. Commenters believe it is unreasonable to assume that charges will continue to increase at this rate and therefore provided several modifications they believe CMS should adopt regarding the charge inflation factor.

A commenter stated that CMS should modify the statistical outlier trim used in our usual methodology for determining the charge inflation factor. The commenter believes that CMS should modify this trim by removing claims for providers with a calculated charge growth factor that exceeds 1 standard deviation from the mean provider charge growth factor during the FY 2021 and FY 2022 period. Some commenters requested that CMS exclude claims for dialysis patients from the calculation of the charge inflation factor.

Many commenters urged CMS to not base the charge inflation factor on the growth in charges that occurred from FY 2021 to FY 2022. Many commenters cited an AHA analysis that found that the average covered charge per case for LTCH PPS standard Federal payment rate cases during the first six months of FY 2023 only increased 2.5 percent compared to data from FY 2022. Many commenters supported setting the charge inflation factor based on this more recent data as they believe it would provide a more accurate indication of LTCH charges levels in FY 2024. Other commenters recommended that CMS return to the methodology employed prior to FY 2022 in which the charge inflation factor was set equal to the market basket update. A commenter suggested that CMS continue to use a charge inflation factor based on data prior to the COVID–19 PHE.

Response: We thank the commenters for their feedback. We acknowledge that COVID–19 hospitalizations have recently trended below FY 2022 levels, that a significant portion of the U.S. population has received at least one dose of the COVID–19 vaccination, and that certain COVID–19-related actions have subsequently been discontinued (such as the national COVID–19 PHE). We continue to believe there remains uncertainty regarding the impact that COVID–19 will have on LTCHs in FY 2024 relative to FY 2022.

We also acknowledge that it is likely that some LTCH cases in the FY 2022 MedPAR file would have met the site neutral exclusion criteria but for extenuating circumstances involving the COVID–19 PHE and the CARES Act waiver. However, we do not believe the number of these types of cases is significant enough to justify including all cases in our calculation of the outlier fixed-loss amount. In the FY 2022 MedPAR file, we found approximately 32 percent of cases did not meet the statutory patient criteria for exclusion from the site neutral payment rate (that is, were treated as site neutral payment rate cases for the FY 2024 ratesetting in the proposed rule). This percentage of cases is not significantly different than the percentage of a site neutral payment rate cases we identified in years prior to the PHE. For example, in the FY 2018 and FY 2019 MedPAR files, respectively, we found approximately 29 percent and 25 percent of cases did not meet the statutory patient criteria for exclusion from the site neutral payment rate. Furthermore, the commenters did not describe why these types of cases differ significantly enough from the cases we treat as standard payment rate cases for the FY 2024 ratesetting such that including them in the calculation of the outlier fixed-loss amount would have a material effect on the resulting outlier fixed-loss amount. For these reasons, we disagree with commenters that it would be appropriate to include all cases in the FY 2022 MedPAR claims data in the determination of the FY 2024 outlier fixed-loss amount.

We thank the commenters for the suggestion to exclude dialysis claims when calculating the fixed-loss threshold. However, as discussed in greater detail later in the section, we are required by section 1886(m)(7) of the Act to establish a fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2024 that would result in total estimated outlier payments being equal to 7.975 percent of projected total LTCH PPS payments for LTCH PPS standard Federal payment rate cases. We acknowledge that the factors that led to increased costs to treat dialysis patients in FY 2022 may be lessening for some LTCHs. However, we expect LTCHs will continue to treat such patients, and as such, those cases would continue to be eligible for high cost outlier payments. For example, some commenters stated that LTCHs are transitioning back to their prior admissions practices, and a commenter indicated that the “in-hospital” dialysis
issues that contributed to the increases in dialysis costs experienced in the last 2 years are not limited to COVID–19 surge periods. Although commenters provided evidence on why dialysis cases were costly in FY 2022, we do not believe the commenters provided sufficient evidence to support why costs for these types of patients would differ significantly from FY 2022 to FY 2024, such that it would be appropriate to exclude them from our calculations. Therefore, we believe it would not be appropriate to completely exclude certain high cost cases from our payment model for determining the outlier fixed-loss amount. For these reasons, we are not adopting commenters’ suggestion to exclude dialysis claims when calculating the fixed-loss threshold for FY 2024.

We appreciate feedback and suggestions commenters provided on the proposed charge inflation factor. In light of these comments, we examined the increase in LTCHs’ charges between FY 2022 and FY 2023 using the most recent available data for those years. Specifically, we calculated a charge inflation factor based on the average covered charge in the March 2023 update of the FY 2023 MedPAR claims compared to the average covered charge in the March 2022 update of the FY 2022 MedPAR claims using our established charge inflation methodology. Based on this analysis, we found that charges for LTCH PPS standard Federal payment rate cases have increased approximately 6 percent during the first six months of FY 2023 compared to the first six months of FY 2022. After reviewing this more recently available data on LTCH charges and considering the broader economic slowdown in inflation, we agree with commenters that it is not likely that charges will continue to increase at the rates observed during the FY 2021 to FY 2022 period. For this reason, in this final rule and under the broad authority of section 123(a)(1) of the BBRA and section 307(b)(1) of the BIPA, we are modifying our methodology for determining the charge inflation factor for FY 2024 by setting the charge inflation factor based on data prior to the COVID–19 PHE. As explained later in this section, our methodology for determining the outlier fixed-loss amount includes a charge inflation factor, and a CCR adjustment factor.) Therefore, under the broad authority of section 123(a)(1) of the BBRA and section 307(b)(1) of the BIPA, we are also modifying our methodology in this final rule to apply the same CCR adjustment factor that we utilized in both the FY 2022 final rule (86 FR 45565), and the FY 2023 final rule (87 FR 49447) to determine the FY 2024 outlier fixed-loss amount. This CCR adjustment factor of 0.961554 is based on the change in CCRs that occurred between the March 2019 PSF and the March 2020 PSF, which is the last 1-year period prior to the COVID–19 PHE. We note that this CCR adjustment factor is considerably lower than CCR adjustment factor of 0.996923 calculated using the most recently available data and our usual methodology. Therefore, in this final rule, after consideration of public comments and for the reasons discussed previously, we are using the FY 2022 MedPAR claims file and the FY 2021 HCRIS for purposes of the FY 2024 LTCH PPS ratesetting, as proposed. However, we are making modifications to our usual ratesetting methodology for determining the FY 2024 outlier fixed-loss amount for LTCH PPS standard Federal payment rate cases by modifying the charge inflation factor and the CCR adjustment factor (as described earlier). As stated previously, later in this section of the Addendum, we present the detailed application of our finalized methodology based on consideration of the comments and our responses.

Comment: Some commenters stated that CMS needs to better account for the impact of the dual rate payment structure on its methodology for determining the outlier fixed-loss amount for standard Federal rate cases. These commenters stated that the percentage increase in charges used in determining the fixed-loss amount has decreased since the implementation of the dual payment rate structure due to LTCH closures and because only standard Federal payment rate cases are used in the calculations. The commenter believes utilizing these relatively smaller datasets has led to fluctuations in the fixed-loss amount that CMS needs to address.

Some commenters also stated that the ICU criterion and ventilator criterion exceptions to site neutral payment rate have resulted in a high concentration of LTCH discharges assigned to only a few MS–LTC–DRGs. A commenter stated their belief that this concentration is one of the main factors causing the increase in the fixed-loss amount. The commenter explained that when there is a significant concentration of cases in an MS–LTC–DRG, there is a wider range of costs among the cases assigned to the MS–LTC–DRG. The commenter stated that when this occurs it is more likely that there will be high cost outlier cases in that MS–LTC–DRG. The commenter proposed a technically complex modification to the CMS methodology for determining the FY 2024 outlier fixed-loss amount that the commenter believes would address this. The modification involved regrouping cases with relatively long length of stays to a new temporary MS–LTC–DRG, calculating an alternative set of relative weights for all MS–LTC–DRGs using these regrouped cases, and then modelling payments for purposes of determining the high-cost outlier threshold using these alternative relative weights.

Response: We thank the commenters for this feedback. We note that comments did not provide specific recommendations on how CMS could address the decreasing number of cases available for LTCH PPS ratesetting or provide specific details on how CMS could develop a formula to adjust for the various factors noted. Without this information, we are unable to fully evaluate these suggested modifications to our methodology for this final rule; however, we may consider these comments for future rulemaking.

We also acknowledge the commenters’ concern regarding the potential impact that the high concentration of LTCH discharges in certain MS–LTC–DRGs may have on LTCH PPS outlier payments. We may also consider this issue for future rulemaking. With regards to the specific
modification presented by the commenter, we do not believe it would be appropriate to use an alternative set of relative weights for purposes of calculating the FY 2024 outlier fixed-loss amount that differ from the relative weights that will be used to make payments. We are required by statute to establish an outlier fixed-loss amount that we project will result in total estimated outlier payments being equal to 7.975 percent of projected total LTCH PPS payments for LTCH PPS standard Federal payment rate cases. We do not believe we can accurately model FY 2024 LTCH PPS payments without using the relative weights that we are finalizing for FY 2024.

Comment: Many commenters stated that the proposed increase to the outlier fixed-loss amount would have devastating financial impacts on LTCHs and lead to LTCH closures. Commenters also stated that the proposed outlier fixed-loss amount would lead to LTCHs avoiding high-cost cases and consequently creating an access barrier for the sickest of patients and leading to overcrowding at IPPS hospital ICUs. Some commenters stated that the proposed increase to the outlier fixed-loss amount violates CMS’s principle for stability and predictability in reimbursement rates. A commenter stated that to the extent increases in the fixed-loss threshold are necessary, they should be limited to no more than the market basket percent increase in any given year. Another commenter stated that CMS should use its regulatory authority to set the FY 2024 outlier fixed-loss amount equal to the FY 2023 outlier fixed-loss amount. Another commenter expressed that CMS should phase in the increase to the fixed-loss amount over a multi-year period.

Response: We thank the commenters for their feedback. We acknowledged in the proposed rule that the proposed increase to the fixed-loss amount was substantial and sought comments on our proposed methodology and the assumptions underlying it to take into consideration when finalizing our methodology in the final rule. However, we are required by section 1886(m)(7) of the Act to establish a fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2024 that would result in total estimated outlier payments being equal to 7.975 percent of projected total LTCH PPS payments for LTCH PPS standard Federal payment rate cases. Therefore, we do not agree with commenters that CMS should use its regulatory authority to establish an alternative outlier fixed-loss amount that would not be projected to result in total estimated outlier payments being equal to 7.975 percent of projected total LTCH PPS payments for LTCH PPS standard Federal payment rate cases. After consideration of all comments that discussed approaches that commenters believe would result in more accurate estimations of the total outlier payments and/or the total LTCH PPS payments for LTCH PPS standard Federal payment rate cases in FY 2024, as described in greater detail later in this section, we are finalizing a fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2024 that is notably lower than in the proposed rule. Although this fixed-loss amount for FY 2024 is still considerably higher than the current fixed-loss amount, we believe this increase will meet the 7.975 percent target required by section 1886(m)(7) of the Act. As we discussed in the IPPS/LTCH PPS proposed rule (88 FR 27242), we estimate that high cost outlier payments significantly exceeded the statutory 7.975 percent target in both FY 2021 and FY 2022. Using the FY 2021 and FY 2022 MedPAR files, we currently estimate that actual high cost outlier payments accounted for 11.1 and 11.9 percent of total LTCH PPS standard Federal payment rate payments in FY 2021 and FY 2022, respectively. We also currently project that in FY 2023, high cost outlier payments will be approximately 10.9 percent of the estimated total LTCH PPS standard Federal payment rate payments.

In summary, we are finalizing our proposed methodology for determining the fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2024, with modifications. In this section of this Addendum, we present the detailed application of our finalized methodology, including the modifications discussed earlier.

When we implemented the LTCH PPS, we established a fixed-loss amount so that total estimated outlier payments are projected to equal 7.975 percent of total estimated payments in LWPA cases (i.e., the target percentage) under the LTCH PPS (67 FR 560022 through 560262). When we implemented the dual rate LTCH PPS payment structure beginning in FY 2016, we established that, in general, the historical LTCH PPS HCO policy would continue to apply to LTCH PPS standard Federal payment rate cases. That is, the fixed-loss amount for LTCH PPS standard Federal payment rate cases would be determined using the LTCH PPS HCO policy adopted when the LTCH PPS was first implemented, but we limited the data used under that policy to LTCH cases that would have been LTCH PPS standard Federal payment rate cases if the statutory changes had been in effect at the time of those discharges.

To determine the applicable fixed-loss amount for LTCH PPS standard Federal payment rate cases, we estimate outlier payments and total LTCH PPS payments for each LTCH PPS standard Federal payment rate case (or for each case that would have been an LTCH PPS standard Federal payment rate case if the statutory changes had been in effect at the time of the discharge) using claims data from the MedPAR files. In accordance with §412.525(a)(2)(i), the applicable fixed-loss amount for LTCH PPS standard Federal payment rate cases results in estimated total outlier payments being projected to be equal to 7.975 percent of projected total LTCH PPS payments for LTCH PPS standard Federal payment rate cases.

In the FY 2023 IPPS/LTCH PPS final rule (87 FR 49448), we discussed an LTCH (CMS certification number (CCN) 312024) whose abnormal charging practices in FY 2021 led to the LTCH receiving an excessive amount of high cost outlier payments. In that rule, we stated our belief, based on information we received from the provider, that these abnormal charging practices would not persist into FY 2023. Therefore, we did not include its cases in our model for determining the FY 2023 outlier fixed-loss amount. The FY 2022 MedPAR claims also reflect the abnormal charging practices of this LTCH. In the March 2023 update of the FY 2022 MedPAR file, we identified 166 LTCH PPS standard Federal payment rate cases for this LTCH. Of these 166 cases, 118 of the cases had charges that were exactly or within ten dollars of $10 million. Due to the abnormal charges reflected in this LTCH’s FY 2022 claims, we do not believe it would be appropriate to use these claims in determining the fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2024. Therefore, as we proposed, we removed those cases from CCN 312024 when determining the fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2024.

(1) Charge Inflation Factor for Use in Determining the Fixed-Loss Amount for LTCH PPS Standard Federal Payment Rate Cases for FY 2024

Under the LTCH PPS, the cost of each claim is estimated by multiplying the charges on the claim by the provider’s CCR. Due to the lag time in the availability of claims data, when estimating costs for the upcoming payment year we typically inflate the charges from the claims data by a uniform factor.
For greater accuracy in calculating the fixed-loss amount, in the FY 2022 IPPS/ LTCH PPS final rule (86 FR 45562 through 45566), we finalized a technical change to our methodology for determining the charge inflation factor. Similar to the method used under the IPPS hospital payment methodology (as discussed in section II.A.4.i.(2). of this Addendum), our methodology determines the LTCH charge inflation factor based on the historical growth in charges for LTCH PPS standard Federal payment rate cases, calculated using historical MedPAR claims data. In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27240 through 27241) we described our methodology for computing the charge inflation factor in detail. Using this methodology and the most recently available data, we computed a proposed 2-year charge inflation factor of 1.289703. We proposed to inflate the billed charges obtained from the FY 2022 MedPAR file by this 2-year charge inflation factor of 1.289703 when determining the fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2024.

As we discussed earlier in this section, many commenters objected to this proposed charge inflation factor. After considering these comments, we are modifying our proposed methodology for determining the charge inflation factor by setting the charge inflation factor based on data prior to the COVID–19 PHE. Specifically, to determine the FY 2024 outlier fixed-loss amount we applied the same charge inflation factor determined in the FY 2022 IPPS/LTCH PPS final rule (86 FR 45565), which was based on the growth in charges that occurred between FY 2018 and FY 2019 (the last 1-year period prior to the COVID–19 PHE). The rate of LTCH charge growth determined in the FY 2022 IPPS/LTCH PPS final rule, based on the growth in charges that occurred between FY 2018 and FY 2019, was 6.0723 percent. This results in a 1-year charge inflation factor of 1.060723, and a 2-year charge inflation factor of 1.125133 (calculated by squaring the 1-year factor). Therefore, for this final rule, we inflated the billed charges obtained from the FY 2022 MedPAR file by this 2-year charge inflation factor of 1.125133 when determining the fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2024.

We note that, using data we would ordinarily use for purposes of determining the charge inflation factor for this final rule, which is FY 2021 MedPAR claims data from the March 2022 update and FY 2022 MedPAR claims data from the March 2023 update and FY 2022 MedPAR claims data from the March 2023 update, we calculated a 2-year charge inflation factor of 1.29349.

(2) CCRs for Use in Determining the Fixed-Loss Amount for LTCH PPS Standard Federal Payment Rate Cases for FY 2024

For greater accuracy in calculating the fixed-loss amount, in the FY 2022 IPPS/ LTCH PPS final rule (86 FR 45562 through 45566), we finalized a technical change to our methodology for determining the CCRs used to calculate the fixed-loss amount. Similar to the methodology used for IPPS hospitals (as discussed in section II.A.4.i.(2). of this Addendum), our methodology adjusts CCRs obtained from the best available PSF data by an adjustment factor that is calculated based on historical changes in the average case-weighted CCR for LTCHs. We believe these adjusted CCRs more accurately reflect CCR levels in the upcoming payment year because they account for historical changes in the relationship between costs and charges for LTCHs.

In the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27241 through 27242) we described our methodology for computing the CCR adjustment factor in detail. Using this methodology and the most recently available data, we computed a proposed 1-year national CCR adjustment factor of 0.975513. When calculating the proposed fixed-loss amount for FY 2024, we proposed to assign the statewide average CCR for the upcoming fiscal year to all providers who were assigned the statewide average in the December 2022 PSF or whose CCR was missing in the December 2022 PSF. For all other providers, we proposed to multiply their CCR from the December 2022 PSF by the proposed 1-year national CCR adjustment factor of 0.975513.

As we discussed earlier in this section, after consideration of comments received, we are modifying our methodology for determining the charge inflation factor for this final rule by setting the charge inflation factor based on data prior to the COVID–19 PHE. As discussed previously, to be consistent with this modification, we believe it is also appropriate to use a CCR adjustment factor based on data prior to the COVID–19 PHE. Therefore, we are modifying our methodology in this final rule to apply the same CCR adjustment factor that we utilized in both the FY 2022 final rule (86 FR 45565) and the FY 2023 final rule (87 FR 49447) to determine the FY 2024 outlier fixed-loss amount. This CCR adjustment factor of 0.961554 is based on the change in CCRs that occurred between the March 2019 PSF and the March 2020 PSF, which is the last 1-year period prior to the COVID–19 PHE.

Therefore, for this final rule, when calculating the fixed-loss amount for FY 2024, we assigned the statewide average CCR for the upcoming fiscal year to all providers who were assigned the statewide average in the March 2023 PSF or whose CCR was missing in the March 2023 PSF. For all other providers, we multiplied their CCR from the March 2023 PSF by the 1-year national CCR adjustment factor of 0.961554.

We note that, using the data we would ordinarily use for purposes of determining the CCR for this final rule, which is the March 2022 PSF and the March 2023 PSF, we calculated a 1-year national CCR adjustment factor of 0.996623.

(3) Fixed-Loss Amount for LTCH PPS Standard Federal Payment Rate Cases for FY 2024

In this final rule, for FY 2024, using the best available data and the steps described previously, we calculated a fixed-loss amount that would maintain estimated HCO payments at the projected 7.975 percent of total estimated LTCH PPS payments for LTCH PPS standard Federal payment rate cases as required by section 1886(m)(7) of the Act and in accordance with §412.525(a)(2)(ii) (based on the payment rates and policies for these cases presented in this final rule). Consistent with our historical practice, we use the best available LTCH claims data and CCR data, if applicable, when determining the fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2024 in the final rule. Therefore, based on LTCH claims data from the March 2023 update of the FY 2024 MedPAR file adjusted for charge inflation and adjusted CCRs from the March 2023 update of the PSF, under the broad authority of section 123(a)(1) of the BBRA and section 307(b)(1) of the BIPA, we are establishing a fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2024 of $59,873 that will result in estimated outlier payments projected to be equal to 7.975 percent of estimated FY 2024 payments for such cases. We are continuing, as proposed, to make an additional HCO payment for the cost of an LTCH PPS standard Federal payment rate case that exceeds the HCO threshold amount that is equal to 80 percent of the difference between the estimated cost of the case and the outlier threshold (the sum of the adjusted LTCH PPS standard Federal payment rate payment and the fixed-
loss amount for LTCH PPS standard Federal payment rate cases of $59,873).

4. High-Cost Outlier Payments for Site Neutral Payment Rate Cases

When we implemented the application of the site neutral payment rate in FY 2016, in examining the appropriate fixed-loss amount for site neutral payment rate cases issue, we considered how LTCH discharges based on historical claims data would have been classified under the dual rate LTCH PPS payment structure and the CMS’ Office of the Actuary projections regarding how LTCHs will likely respond to our implementation of policies resulting from the statutory payment changes. We again relied on these considerations and actuarial projections in FY 2017 and FY 2018 because the historical claims data available in each of these years were not all subject to the LTCH PPS dual rate payment system. Similar to, for FYs 2019 through 2023, we continued to rely on these considerations and actuarial projections because, due to the transitional blended payment policy for site neutral payment rate cases and the provisions of section 3711(b)(2) of the CARES Act, the historical claims data available in each of these years were not subject to the full effect of the site neutral payment rate.

For FYs 2016 through 2023, our actuaries projected that the proportion of cases that would qualify as LTCH PPS standard Federal payment rate cases versus site neutral payment rate cases under the statutory provisions would remain consistent with what is reflected in the historical LTCH PPS claims data. Although our actuaries did not project an immediate change in the proportions found in the historical data, they did project cost and resource changes to account for the lower payment rates. Our actuaries also projected that the costs and resource use for cases paid at the site neutral payment rate would likely be lower, on average, than the costs and resource use for cases paid at the LTCH PPS standard Federal payment rate and would likely mirror the costs and resource use for IPPS cases assigned to the same MS–DRG, regardless of whether the proportion of site neutral payment rate cases in the future remains similar to what is found based on the historical data. As discussed in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49619), this actuarial assumption is based on our expectation that site neutral payment rate cases would generally be paid based on an IPPS cost per diem amount under the statutory LTCH PPS payment changes that began in FY 2016, which, in the majority of cases, is much lower than the payment that would have been paid if those statutory changes were not enacted. In light of these projections and expectations, we discussed that we believed that the use of a single fixed-loss amount and HCO target for all LTCH PPS cases would be problematic. In addition, we discussed that we did not believe that it would be appropriate for comparable LTCH PPS site neutral payment rate cases to receive dramatically different HCO payments from those cases that would be paid under the IPPS (80 FR 49617 through 49619 and 81 FR 57305 through 57307). For those reasons, we stated that we believed that the most appropriate fixed-loss amount for site neutral payment rate cases for FYs 2016 through 2023 would be equal to the IPPS fixed-loss amount for that particular fiscal year. Therefore, we established the fixed-loss amount for site neutral payment rate cases as the corresponding IPPS fixed-loss amounts for FYs 2016 through 2023. In particular, in FY 2023, we established the fixed-loss amount for site neutral payment rate cases as the FY 2023 IPPS fixed-loss amount of $38,788 (87 FR 49450, as corrected in 87 FR 66564).

As discussed in section I.E. of the preamble of this final rule, we are finalizing our proposal to use FY 2022 data in the FY 2024 LTCH PPS ratesetting. Section 3711(b)(2) of the CARES Act, which provided a waiver of the application of the site neutral payment rate for LTCH cases admitted during the COVID–19 PHE period, was in effect for the entirety of FY 2022. Therefore, all LTCH PPS cases in FY 2022 were paid the LTCH PPS standard Federal rate regardless of whether the discharge met the statutory patient criteria. Because not all FY 2022 claims in the data used for this final rule were subject to the site neutral payment rate, we continue to rely on the same considerations and actuarial projections used in FYs 2016 through 2023 when developing a fixed-loss amount for site neutral payment rate cases for FY 2024. Our actuaries continue to project that the costs and resource use for FY 2024 cases paid at the site neutral payment rate would likely be lower, on average, than the costs and resource use for cases paid at the LTCH PPS standard Federal payment rate and will likely mirror the costs and resource use for IPPS cases assigned to the same MS–DRG, regardless of whether the proportion of site neutral payment rate cases in the future remains similar to what was found based on the historical data. (Based on the FY 2022 LTCH claims data used in the development of this final rule, if the provisions of the CARES Act had not been in effect, approximately 68 percent of LTCH cases would have been paid the LTCH PPS standard Federal payment rate and approximately 32 percent of LTCH cases would have been paid the site neutral payment rate for discharges occurring in FY 2022.)

For these reasons, we continue to believe that the most appropriate fixed-loss amount for site neutral payment rate cases for FY 2024 is the FY 2022 IPPS fixed-loss amount for FY 2024. Therefore, for FY 2024, as we proposed, we are establishing that the applicable HCO threshold for site neutral payment rate cases is the sum of the site neutral payment rate for the case and the IPPS fixed-loss amount. That is, we are establishing a fixed-loss amount for site neutral payment rate cases of $42,750, which is the same FY 2024 IPPS fixed-loss amount discussed in section II.A.4.(I) of this Addendum. Accordingly, under this policy, for FY 2024, we will calculate an HCO payment for site neutral payment rate cases with costs that exceed the HCO threshold amount that is equal to 80 percent of the difference between the estimated cost of the case and the outlier threshold (the sum of the site neutral payment rate payment and the fixed-loss amount for site neutral payment rate cases of $42,750).

In establishing an HCO policy for site neutral payment rate cases, we established a budget neutrality adjustment under § 412.522(c)(2)(i). We established this requirement because we believed, and continue to believe, that the HCO policy for site neutral payment rate cases should be budget neutral, just as the HCO policy for LTCH PPS standard Federal payment rate cases is budget neutral, meaning that estimated site neutral payment rate HCO payments should not result in any change in estimated aggregate LTCH PPS payments.

To ensure that estimated HCO payments payable to site neutral payment rate cases in FY 2024 would not result in any increase in estimated aggregate FY 2024 LTCH PPS payments, under the budget neutrality requirement at § 412.522(c)(2)(i), it is necessary to reduce site neutral payment rate payments by 5.1 percent to account for the estimated additional HCO payments payable to those cases in FY 2024.

Consistent with our historical practice, as we proposed, we are continuing this policy.

As discussed earlier, consistent with the IPPS HCO payment threshold, we estimate the fixed-loss threshold would
result in FY 2024 HCO payments for site neutral payment rate cases to equal 5.1 percent of the site neutral payment rate payments that are based on the IPPS comparable per diem amount. As such, to ensure estimated HCO payments payable for site neutral payment rate cases in FY 2024 would not result in any increase in estimated aggregate FY 2024 LTCH PPS payments, under the budget neutrality requirement at § 412.522(c)(2)(i), it is necessary to reduce the site neutral payment rate amount paid under § 412.522(c)(1)(i) by 5.1 percent to account for the estimated additional HCO payments payable for site neutral payment rate cases in FY 2024. To achieve this, for FY 2024, as we proposed, we are applying a budget neutrality factor of 0.949 (that is, the decimal equivalent of a 5.1 percent reduction, determined as 1.0 - 5.1/100 = 0.949) to the site neutral payment rate for those site neutral payment rate cases paid under § 412.522(c)(1)(i). We note that, consistent with our current policy, this HCO budget neutrality adjustment will not be applied to the HCO portion of the site neutral payment rate amount (81 FR 57309).

We did not receive any public comments on our proposals and are finalizing our proposals as described previously, without modification.

E. Update to the IPPS Comparable Amount to Reflect the Statutory Changes to the IPPS DSH Payment Adjustment Methodology

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50766), we established a policy to reflect the changes to the Medicare IPPS DSH payment adjustment methodology made by section 3133 of the Affordable Care Act in the calculation of the “IPPS comparable amount” under the SSO policy at § 412.529 and the “IPPS equivalent amount” under the site neutral payment rate at § 412.522.

Historically, the determination of both the “IPPS comparable amount” and the “IPPS equivalent amount” includes an amount for inpatient operating costs “for the costs of serving a disproportionate share of low-income patients.” Under the statutory changes to the Medicare DSH payment adjustment methodology that began in FY 2014, in general, eligible IPPS hospitals receive an empirically justified Medicare DSH payment equal to 25 percent of the amount they otherwise would have received under the statutory formula for Medicare DSH payments prior to the amendments made by the Affordable Care Act. The remaining amount, equal to an estimate of 75 percent of the amount that otherwise would have been paid as Medicare DSH payments, reduced to reflect changes in the percentage of individuals who are uninsured and any additional statutory adjustment, is made available to make additional payments to each hospital that qualifies for Medicare DSH payments and that has uncompensated care. The additional uncompensated care payments are based on the hospital’s amount of uncompensated care for a given time period relative to the total amount of uncompensated care for that same time period reported by all IPPS hospitals that receive Medicare DSH payments.

To reflect the Medicare DSH payment adjustment methodology statutory changes in section 3133 of the Affordable Care Act in the calculation of the “IPPS comparable amount” and the “IPPS equivalent amount” under the IPPS PPS, we stated in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50766) that we will include a reduced Medicare DSH payment amount that reflects the projected percentage of the payment amount calculated based on the statutory Medicare DSH payment formula prior to the amendments made by the Affordable Care Act that will be paid to eligible IPPS hospitals as empirically justified Medicare DSH payments and uncompensated care payments in that year (that is, a percentage of the operating Medicare DSH payment amount that has historically been reflected in the LTCH PPS payments that are based on IPPS rates). We also stated, in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50766), that the projected percentage will be updated annually, consistent with the annual determination of the amount of uncompensated care payments that will be made to eligible IPPS hospitals.

We believe that this approach results in appropriate payments under the LTCH PPS and is consistent with our intention that the “IPPS comparable amount” and the “IPPS equivalent amount” under the LTCH PPS closely resemble what an IPPS payment would have been for the same episode of care while recognizing that some features of the IPPS cannot be translated directly into the LTCH PPS (79 FR 50766 through 50767).

As discussed in the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27244), for FY 2024, based on the most recent data available at that time, we proposed to establish that the calculation of the “IPPS comparable amount” under § 412.529 would include an applicable operating Medicare DSH payment amount that is equal to 74.28 percent of the operating Medicare DSH payment amount that would have been paid based on the statutory Medicare DSH payment formula absent the amendments made by the Affordable Care Act. Moreover, consistent with our historical practice, we proposed that, if more recent data became available, we would use that data to determine the applicable operating Medicare DSH payment amount used to calculate the “IPPS comparable amount” in this final rule using more recent data. For FY 2024, as discussed in greater detail in section IV.E.2.b. of the preamble of this final rule, based on the most recent data available, our estimate of 75 percent of the amount that would otherwise have been paid as Medicare DSH payments (under the methodology outlined in section 1886(r)(2) of the Act) is adjusted to 59.29 percent of that amount to reflect the change in the percentage of individuals who are uninsured. The resulting amount is then used to determine the amount available to make uncompensated care payments to eligible IPPS hospitals in FY 2024.

In other words, the amount of the Medicare DSH payments that would have been made prior to the amendments made by the Affordable Care Act is adjusted to 44.47 percent (the product of 75 percent and 59.29 percent) and the resulting amount is used to calculate the uncompensated care payments to eligible hospitals. As a result, for FY 2024, we project that the reduction in the amount of Medicare DSH payments pursuant to section 1886(r)(2) of the Act, will result in overall Medicare DSH payments of 69.47 percent of the amount of Medicare DSH payments that would otherwise have been made in the absence of the amendments made by the Affordable Care Act (that is, 25 percent + 44.47 percent = 69.47 percent).

Therefore, for FY 2024, consistent with our proposal, we are establishing that the calculation of the “IPPS comparable amount” under § 412.529 will include an applicable operating Medicare DSH payment amount that is equal to 69.47 percent of the operating Medicare DSH payment amount that would have been paid based on the statutory Medicare DSH payment formula absent the amendments made by the Affordable Care Act.
F. Computing the Adjusted LTCH PPS Federal Prospective Payments for FY 2024

Section 412.525 sets forth the adjustments to the LTCH PPS standard Federal payment rate. Under the dual rate LTCH PPS payment structure, only LTCH PPS cases that meet the statutory criteria to be excluded from the site neutral payment rate are paid based on the LTCH PPS standard Federal payment rate. Under § 412.525(c), the LTCH PPS standard Federal payment rate is adjusted to account for differences in area wages by multiplying the labor-related share of the LTCH PPS standard Federal payment rate for a case by the applicable LTCH PPS wage index (the final FY 2024 values are shown in Tables 12A through 12B listed in section VI. of this Addendum and are available via the internet on the CMS website). The LTCH PPS standard Federal payment rate is also adjusted to account for the higher costs of LTCHs located in Alaska and Hawaii by the applicable COLA factors (the final FY 2024 factors are shown in the chart in section V.C. of this Addendum) in accordance with § 412.525(b). In this final rule, we are establishing an LTCH PPS standard Federal payment rate for FY 2024 of $48,116.62, as discussed in section V.A. of this Addendum. We illustrate the methodology to adjust the LTCH PPS standard Federal payment rate for FY 2024, applying our finalized LTCH PPS amounts for the standard Federal payment rate, MS–LTC–DRG relative weights, and wage index in the following example:

Example:

During FY 2024, a Medicare discharge that meets the criteria to be excluded from the site neutral payment rate, that is, an LTCH PPS standard Federal payment rate case, is from an LTCH that is located in CBSA 16984, which has a FY 2024 LTCH PPS wage index value of 1.0419 (as shown in Table 12A listed in section VI. of this Addendum). The Medicare patient case is classified into MS–LTC–DRG 189 (Pulmonary Edema & Respiratory Failure), which has a relative weight for FY 2024 of 0.9416 (as shown in Table 11 listed in section VI. of this Addendum). The LTCH submitted quality reporting data for FY 2024 in accordance with the LTCH QRP under section 1886(m)(5) of the Act.

To calculate the LTCH’s total adjusted Federal prospective payment for this Medicare patient case in FY 2024, we computed the wage-adjusted Federal prospective payment amount by multiplying the unadjusted FY 2024 LTCH PPS standard Federal payment rate ($48,116.62) by the labor-related share (68.5 percent) and the wage index value (1.0419). This wage-adjusted amount was then added to the nonlabor-related portion of the unadjusted LTCH PPS standard Federal payment rate (31.5 percent; adjusted for cost of living, if applicable) to determine the adjusted LTCH PPS standard Federal payment rate, which is then multiplied by the MS–LTC–DRG relative weight (0.9416) to calculate the total adjusted LTCH PPS standard Federal prospective payment for FY 2024 ($46,606.98). The table illustrates the components of the calculations in this example.

| Unadjusted LTCH PPS Standard Federal Prospective Payment Rate | $48,116.62 |
| Labor-Related Share | x 0.685 |
| Labor-Related Portion of the LTCH PPS Standard Federal Payment Rate | = $32,959.88 |
| Wage Index (CBSA 16984) | x 1.0419 |
| Wage-Adjusted Labor Share of the LTCH PPS Standard Federal Payment Rate | = $34,340.90 |
| Nonlabor-Related Portion of the LTCH PPS Standard Federal Payment Rate ($48,116.62 x 0.315) | + $15,156.74 |
| Adjusted LTCH PPS Standard Federal Payment Amount | = $49,497.64 |
| MS–LTC–DRG 189 Relative Weight | x 0.9416 |
| Total Adjusted LTCH PPS Standard Federal Prospective Payment | = $46,606.98 |

VI. Tables Referenced in This Final Rule Generally Available Through the internet on the CMS website

This section lists the tables referenced throughout the preamble of this final rule and in the Addendum. In the past, a majority of these tables were published in the Federal Register as part of the annual proposed and final rules. However, similar to FYs 2012 through 2023, for the FY 2024 rulemaking cycle, the IPPS and LTCH PPS tables will not be published in the Federal Register in the annual IPPS/ LTCH PPS proposed and final rules and will be on the CMS website. Specifically, all IPPS tables listed in the final rule, with the exception of IPPS Tables 1A, 1B, 1C, and 1D, and LTCH PPS Table 1E, will generally be available on the CMS website. IPPS Tables 1A, 1B, 1C, and 1D, and LTCH PPS Table 1E are displayed at the end of this section and will continue to be published in the Federal Register as part of the annual proposed and final rules. For additional discussion of the information included in the IPPS and LTCH PPS tables associated with the IPPS/LTCH PPS proposed and final rules, as well as prior changes to the information included in these tables, we refer readers to the FY 2023 IPPS/LTCH PPS final rule (87 FR 49451 through 49453).

Tables 7A and 7B historically contained the Medicare prospective payment system selected percentile lengths of stay for the MS–DRGs for the prior year and upcoming fiscal year. We note, in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49451 through 49453),

As discussed in section II.E. of the preamble to this final rule, we made available separate tables listing the ICD–10–CM codes, ICD–10–PCS codes, and/or MS–DRGs related to the analyses of the cost criterion for the FY 2024 new technology add-on payment applications in Table 10 associated with the proposed rule. For this final rule, we have not updated these tables and therefore are not issuing Table 10 with this final rule.

After hospitals have been given an opportunity to review and correct their calculations for FY 2024, we will post Table 15 (which will be available via the CMS website) to display the final FY 2024 readmissions payment adjustment factors that will be applicable to discharges occurring on or after October 1, 2023. We expect Table 15 will be posted on the CMS website in the Fall 2023.

Readers who experience any problems accessing any of the tables that are posted on the CMS websites identified
in this final rule should contact Michael Treitel at (410) 786–4552. The following IPPS tables for this final rule are generally available on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html. Click on the link on the left side of the screen titled “FY 2024 IPPS Final Rule Home Page” or “Acute Inpatient-Files-for Download.”

Table 2.—Case-Mix Index and Wage Index Table by CCN—FY 2024 Final Rule

Table 3.—Wage Index Table by CBSA—FY 2024 Final Rule

Table 4A.—List of Counties Eligible for the Out-Migration Adjustment under Section 1886(d)(13) of the Act—FY 2024 Final Rule

Table 4B.—Counties Redesignated under Section 1886(d)(8)(B) of the Act (LUGAR Counties)—FY 2024 Final Rule

Table 5.—List of Medicare Severity Diagnosis-Related Groups (MS–DRGs), Relative Weighting Factors, and Geometric and Arithmetic Mean Length of Stay—FY 2024 Final Rule

Table 6A.—New Diagnosis Codes—FY 2024

Table 6B.—New Procedure Codes—FY 2024

Table 6C.—Invalid Diagnosis Codes—FY 2024

Table 6D.—Invalid Procedure Codes—FY 2024

Table 6E.—Revised Diagnosis Code Titles—FY 2024

Table 6F.—Revised Procedure Code Titles—FY 2024

Table 6G.1.—Secondary Diagnosis Order Additions to the CC Exclusions List—FY 2024

Table 6G.2.—Principal Diagnosis Order Additions to the CC Exclusions List—FY 2024

Table 6H.1.—Secondary Diagnosis Order Deletions to the CC Exclusions List—FY 2024

Table 6H.2.—Principal Diagnosis Order Deletions to the CC Exclusions List—FY 2024

Table 6I.—Complete MCC List—FY 2024

Table 6I.1.—Additions to the MCC List—FY 2024

Table 6I.2.—Deletions to the MCC List—FY 2024

Table 6J.—Complete CC List—FY 2024

Table 6J.1.—Additions to the CC List—FY 2024

Table 6J.2.—Deletions to the CC List—FY 2024

Table 6K.—Complete List of CC Exclusions—FY 2024

Table 6L.—Final FY 2024 Statewide Average Operating Cost-to-Charge Ratios (CCRs) for Acute Care Hospitals

Table 6M.—Updated Proxy Hospital Value-Based Purchasing (VBP) Program Adjustment Factors for FY 2024

Table 6N.—FY 2024 Final Rule Medicare DSH Uncompensated Care Payment Factor 3 (Final Methodology)

The following LTCH PPS tables for this FY 2024 final rule are available through the internet on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/LongTermCareHospitalPPS/index.html under the list item for Regulation Number CMS–1785–F:

Table 8C.—Final FY 2024 Statewide Average Total Cost-to-Charge Ratios (CCRs) for LTCHs (Urban and Rural)

Table 10.—MS–LTC–DRGs, Relative Weights, Geometric Average Length of Stay, and Short-Stay Outlier (SSO) Threshold for LTCH PPS Discharges Occurring from October 1, 2023, through September 30, 2024

Table 12A.—LTCH PPS Wage Index for Urban Areas for Discharges Occurring from October 1, 2023, through September 30, 2024

Table 12B.—LTCH PPS Wage Index for Rural Areas for Discharges Occurring from October 1, 2023, through September 30, 2024

**TABLE 1A.—NATIONAL ADJUSTED OPERATING STANDARDIZED AMOUNTS, LABOR/NONLABOR (67.6 PERCENT LABOR SHARE/32.4 PERCENT NONLABOR SHARE IF WAGE INDEX IS GREATER THAN 1)—FY 2024**

<table>
<thead>
<tr>
<th>Hospital Submitted Quality Data and is a Meaningful EHR User (Update = 3.1 Percent)</th>
<th>Hospital Submitted Quality Data and is NOT a Meaningful EHR User (Update = 0.625 Percent)</th>
<th>Hospital Did NOT Submit Quality Data and is a Meaningful EHR User (Update = 2.275 Percent)</th>
<th>Hospital Did NOT Submit Quality Data and is NOT a Meaningful EHR User (Update = -0.2 Percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labor</td>
<td>Nonlabor</td>
<td>Labor</td>
<td>Nonlabor</td>
</tr>
<tr>
<td>$4,392.49</td>
<td>$2,105.28</td>
<td>$4,287.05</td>
<td>$2,054.74</td>
</tr>
</tbody>
</table>

**TABLE 1B.—NATIONAL ADJUSTED OPERATING STANDARDIZED AMOUNTS, LABOR/NONLABOR (62 PERCENT LABOR SHARE/38 PERCENT NONLABOR SHARE IF WAGE INDEX IS LESS THAN OR EQUAL TO 1)—FY 2024**

<table>
<thead>
<tr>
<th>Hospital Submitted Quality Data and is a Meaningful EHR User (Update = 3.1 Percent)</th>
<th>Hospital Submitted Quality Data and is NOT a Meaningful EHR User (Update = 0.625 Percent)</th>
<th>Hospital Did NOT Submit Quality Data and is a Meaningful EHR User (Update = 2.275 Percent)</th>
<th>Hospital Did NOT Submit Quality Data and is NOT a Meaningful EHR User (Update = -0.2 Percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labor</td>
<td>Nonlabor</td>
<td>Labor</td>
<td>Nonlabor</td>
</tr>
<tr>
<td>$4,028.62</td>
<td>$2,469.15</td>
<td>$3,931.91</td>
<td>$2,409.88</td>
</tr>
</tbody>
</table>
Appendix A—Economic Analyses

I. Regulatory Impact Analysis

A. Statement of Need

This final rule is necessary to make payment and policy changes under the IPPS for Medicare acute care hospital inpatient services for operating and capital-related costs as well as for certain hospitals and hospital units excluded from the IPPS. This final rule also is necessary to make payment and policy changes for Medicare hospitals under the LTCH PPS. Also, as we note later in this appendix, the primary objective of the IPPS and the LTCH PPS is to create incentives for hospitals to operate efficiently and minimize unnecessary costs, while at the same time ensuring that payments are sufficient to adequately compensate hospitals for their legitimate costs in delivering necessary care to Medicare beneficiaries. In addition, we share national goals of preserving the Medicare Hospital Insurance Trust Fund.

We believe that the changes in this final rule, such as the updates to the IPPS and LTCH PPS rates, and the final policies and discussions relating to applications for new technology add-on payments, are needed to further each of these goals while maintaining the financial viability of the hospital industry and ensuring access to high quality health care for Medicare beneficiaries.

We expect that these changes will ensure that the outcomes of the prospective payment systems are reasonable and provide equitable payments, while avoiding or minimizing unintended adverse consequences.

1. Acute Care Hospital Inpatient Prospective Payment System (IPPS)

a. Update to the IPPS Payment Rates

In accordance with section 1886(b)(3)(B) of the Act and as described in section V.B. of the preamble to this final rule, we are updating the national standardized amount for inpatient hospital operating costs by the applicable percentage increase of 3.1 percent (that is, a 3.3 percent market basket update with a reduction of 0.2 percentage point for the productivity adjustment). We are also applying the applicable percentage increase (including the market basket update and the productivity adjustment) to the hospital-specific rates.

Subsection (d) hospitals that do not submit quality information under rules established by the Secretary and that are meaningful EHR users under section 1886(b)(3)(B)(ix) of the Act will receive an applicable percentage increase of 2.275 percent. Hospitals that are identified as not meaningful EHR users and do not submit quality information under section 1886(b)(3)(B)(viii) of the Act will receive an applicable percentage increase of 0.625 percent.

Hospitals that are identified as not meaningful EHR users under section 1886(b)(3)(B)(ix) of the Act and also do not submit quality data under section 1886(b)(3)(B)(viii) of the Act will receive an applicable percentage increase of 0.2 percent, which reflects a one-quarter percent reduction of the market basket update for failure to submit quality data and a three-quarter percent reduction of the market basket update for being identified as not a meaningful EHR user.

b. Changes for the Add-On Payments for New Services and Technologies

Consistent with sections 1886(d)(5)(K) and (L) of the Act, we review applications for new technology add-on payments based on the eligibility criteria at 42 CFR 412.87. As set forth in 42 CFR 412.87(e)(1), we consider whether a technology meets the criteria for the new technology add-on payment and announce the results as part of the annual updates and changes to the IPPS.

As discussed in section ILE.9. of this final rule, beginning with new technology add-on payment applications for FY 2025, for technologies that are not already market authorized, we are finalizing our policy to require applicants to have a complete and active FDA market authorization request at the time of the new technology add-on payment application submission and to provide documentation of FDA acceptance or filing to CMS at the time of application submission. We are also finalizing our policy that, beginning with FY 2025 applications, to be eligible for consideration for the new technology add-on payment for the upcoming fiscal year, an applicant for new technology add-on payments must have received FDA marketing authorization by May 1 rather than July 1 of the year prior to the beginning of the fiscal year for which the application is being considered.

c. Continuation of the Low Wage Index Hospital Policy

To help mitigate wage index disparities between high wage and low wage hospitals, in the FY 2020 IPPS/LTCH PPS rule (84 FR 42326 through 42332), we adopted a policy to increase the wage index values for certain...
hospitals with low wage index values (the low wage index hospital policy). This policy was adopted in a budget neutral manner through an adjustment applied to the standardized amounts for all hospitals. We also indicated our intention that this policy would be effective for at least 4 years, beginning in FY 2020, to allow employee compensation increases implemented by these hospitals sufficient time to be reflected in the wage index calculation. As discussed in section III.G.4. of the preamble of this final rule, as well as in the relevant statutory language with regard to its policies involving the treatment of hospitals that have reclassified as rural under section 1886(d)(8)(E) of the Act, as implemented in the regulations under 42 CFR 412.103. After doing so, CMS now agrees that the best reading of section 1886(d)(8)(E) of the Act is that it instructs CMS to treat § 412.103 hospitals the same as geographically rural hospitals for the wage index calculation. Therefore, we believe it is proper to include these hospitals in all iterations of the rural wage index calculation methodology included in section 1886(d) of the Act, including all hold harmless calculations in that provision. Beginning with FY 2024, we are finalizing the proposal to include hospitals with § 412.103 reclassification along with geographically rural hospitals in all rural wage index calculations, and to exclude “dual reclass” hospitals (hospitals with simultaneous § 412.103 and MGCRB reclassifications) implicated by the hold harmless provision at section 1886(d)(8)(Cl)(ii) of the Act. Changes to the rural wage index which affect the rural floor would be implemented in a budget neutral manner.

e. Payment Adjustment for Medicare Disproportionate Share Hospitals (DSHS)

In this final rule, as required by section 1886(f)(2) of the Act, we are updating our estimates of the 3 factors used to determine uncompensated care payment methodology for FY 2024. Beginning with FY 2023, we adopted a multiyear averaging methodology to determine Factor 3 of the uncompensated care payment methodology, which will help to mitigate against large fluctuations in uncompensated care payments from year to year. Under this methodology, for FY 2024 and subsequent fiscal years, we will determine Factor 3 for all eligible hospitals using a 3-year average of the data on uncompensated care costs from Worksheet S–10 for the 3 most recent fiscal years for which audited data are available.

Specifically, we will use a 3-year average of audited data on uncompensated care costs from Worksheet S–10 from the FY 2018, FY 2019, and FY 2020 cost reports to calculate Factor 3 for FY 2024 for all eligible hospitals. Beginning with FY 2023, we established a supply chain and reporting for Long Term Care Hospitals, Services (LTCs), and Home Health Services (HHS) and Tribal hospitals and hospitals located in Puerto Rico to help prevent undue long-term financial disruption to these hospitals due to the discontinuation of the use of the low-income insured days proxy in the uncompensated care payment methodology for these providers.

In this final rule, beginning with FY 2024, we are revising our regulations governing the treatment of certain section 1115 demonstration data, the calculation of the Medicaid fraction in the Medicare DSH disproportionate patient percentage. Specifically, we are to revising our regulations at §412.106(b)(4) to explicitly reflect our interpretation of the language “regarded as” “because they receive medical assistance under a State plan approved under title XIX” “because they receive benefits under a demonstration project approved under title XI” in section 1886(d)(5)(f)(vi) of the Act to mean patients—(1) who receive health insurance through the 1115 demonstration itself; or (2) who purchase health insurance with the use of premium assistance provided by a section 1115 demonstration, where State expenditures to provide the insurance or premium assistance may be matched with funds from Title XIX and to explicitly state that we will not regard as Medicaid-eligible patients whose costs are paid to hospitals from uncompensated/undercompensated care pool funds authorized by a section 1115 demonstration; and we are similarly excluding the days of such patients from being counted in the DPP Medicaid fraction numerator. Thus, we are explicitly excluding from counting in the DPP Medicaid fraction numerator any days of patients for which hospitals are paid from demonstration-authorized uncompensated/undercompensated care pools. Our revised regulation will be effective for discharges occurring on or after October 1, 2023. As has been our practice for more than two decades, we have made our periodic revisions to the counting of certain section 1115 patient days in the Medicare DSH calculation effective based on patient discharge dates. Doing so again here treats all providers similarly and does not impact providers differently depending on their cost reporting periods.

f. Effects of Implementation of the Rural Community Hospital Demonstration Program in FY 2024

The Rural Community Hospital Demonstration (RCHD) was authorized originally for a 5-year period by section 410A of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) (Pub. L. 108–173), and it was extended for another 5-year period by section 3123 and 10313 of the Affordable Care Act (Pub. L. 111–148). Section 15003 of the 21st Century Cures Act (Cures Act) (Pub. L. 114–255) extended the demonstration for an additional 5-year period, and section 128 of the Consolidated Appropriations Act of 2021(Pub.L. L. 116–159) included an additional 5-year re-authorization. CMS has conducted the demonstration since 2004, which allows enhanced, cost-based payment for Medicare inpatient services for up to 30 small rural hospitals.

The authorizing legislation imposes a strict budget neutrality requirement. In the final rule, we summarize the status of the demonstration program, and the ongoing methodologies for implementation and budget neutrality.

2. Frontier Community Health Integration Project (FCHIP) Demonstration

The Frontier Community Health Integration Project (FCHIP) demonstration was authorized under section 123 of the Medicare Improvements for Patients and Providers Act of 2008 (Pub. L. 110–275), as amended by section 3126 of the Affordable Care Act of 2010 (Pub. L. 114–158), and most recently re-authorizated and extended by the Consolidated Appropriations Act of 2021 (Pub. L. 116–159). The legislation authorized a demonstration project to allow eligible entities to develop and test new models for the delivery of health care to improve access to and better integrate the delivery of acute care and extended care and other health care services to Medicare beneficiaries in certain rural areas. The FCHIP demonstration initial period was conducted in 10 critical access hospitals (CAHs) from August 1, 2016, to July 31, 2019, and the demonstration “extension period” began on January 1, 2022, to run through June 30, 2027.

The authorizing legislation requires the FCHIP demonstration to be budget neutral. In this final rule, we proposed to continue with the budget neutrality approach used in the demonstration initial period for the demonstration extension period—to offset payments across CAHs nationally—should the demonstration incur costs to Medicare.

3. Update to the LTCH PPS Payment Rates

As described in section VIII.C.2. of the preamble of this final rule, to update to LTCHs using the best available data, we are updating the LTCH PPS standard Federal payment rate by 3.3 percent (that is, a 3.5 percent market basket update with a reduction of 0.2 percentage point for the productivity adjustment, as required by section 1886(m)(3)(A)(i) of the Act). LTCHs that failed to submit quality data, as required by 1886(m)(3)(A)(i) of the Act and described in section VIII.C.2. of the preamble of this final rule, would receive an update of 1.3 percent, which reflects a 2.0 percentage point reduction for failure to submit quality data.

4. Hospital Quality Programs

Section 1886(b)(3)(B)(viii) of the Act requires subsection (d) hospitals to report data in accordance with the requirements of the Hospital IQR Program for purposes of measuring and making publicly available information on health care quality. This provision links the submission of quality data to the annual applicable percentage increase. Sections 1886(b)(3)(B)(ix), 1886(nn), and 1814(l) of the Act require eligible hospitals and CAHs to demonstrate they are meaningful users of certified EHR technology for purposes of electronic exchange of health information to improve the quality of health.
furnish on an outpatient basis as an REH; and (4) information regarding how the provider intends to use the additional facility payment provided under section 1834(x)(2) of the Act, including a description of the services that the additional facility payment would be supporting, such as the operation and maintenance of the facility and the furnishing of covered services (for example, telehealth services and ambulance services).

On January 26, 2023, CMS issued QSO-23-07–REH (https://www.cms.gov/files/document/qso-23-07-reh.pdf) that provided the additional information requirements specified by section 1861(zzz)(4)(A)(i) through (iv) as well as guidance regarding the REH enrollment and conversion process for eligible facilities. We proposed to codify those requirements at 42 CFR 488.70. We also proposed to update the definition of a “participating hospital” to include REHs, and to add REHs to the other applicable provisions contained in 42 CFR parts 488 and 489 (including definitions”;

488.2, “Statutory basis”;
488.18, “Documentation of findings”; and 489.102, “Requirements for providers.”

b. Physician-Owned Hospitals

As discussed in section X.B. of the preamble of this final rule, we recently reviewed the expansion exception process for hospitals that wish to expand beyond the number of operating rooms, procedure rooms, and beds for which they were licensed at the time of enactment of the Affordable Care Act (ACA). CMS’s interpretation of the statutory authority, ensure that approval of a request to expand a hospital’s facility capacity occurs only in appropriate circumstances, and provide transparency to facilitate compliance with the process for requesting an expansion exception, we are revising the regulations to consider expansion exception requests from eligible hospitals, clarify the data and information that must be included in an expansion exception request, identify factors that CMS will consider when making a decision on an expansion exception request, and revise certain aspects of the process for requesting an expansion exception.

Also, we recently reconsidered whether CY 2021 OPPS/ASC regulatory revisions that removed program integrity restrictions regarding the frequency of expansion exception requests, maximum aggregate expansion of a hospital, and location of expansion facility capacity for high Medicaid facilities currently present a risk of the types of program or patient abuse that the physician self-referral law is intended to thwart. Following this review, we believe that not applying these program integrity restrictions poses a significant risk of program or patient abuse. Therefore, we are reissuing, with respect to high Medicaid facilities, the program integrity restrictions on the frequency of expansion exception requests, maximum aggregate expansion of a hospital, and location of expansion facility capacity that were removed in the CY 2021 OPPS/ASC final rule.

B. Overall Impact

We have examined the impacts of this final rule as required by Executive Order 12866 on Regulatory Planning and Review (September 30, 1993), Executive Order 13563 on Improving Regulation and Regulatory Review (January 18, 2011), Executive Order 14094 on Modernizing Regulatory Review (April 6, 2023), the Regulatory Flexibility Act (RFA) (September 19, 1980, Pub. L. 96–354), section 1102(b) of the Act, section 202 of the Unfunded Mandates Reform Act of 1995 (March 22, 1995; Pub. L. 104–4), Executive Order 13132 on Federalism (April 4, 1999), and the Congressional Review Act (CRA) (5 U.S.C. 804(2)).

Executive Orders 12866 and 13563 direct agencies to assess all costs and benefits of available regulatory alternatives and, if regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety effects, distributive impacts, and equity). Executive Order 14094 amends section 3(f) of Executive Order 12866 to direct agencies to “seek to achieve the greatest potential for eliminating a significant regulatory action as an action that is likely to result in a rule: (1) having an annual effect on the economy of $200 million or more in any 1 year, or adversely affect in a material way the economy, productivity, competition, jobs, the competitive ability of United States businesses in national and world markets, or the proliferation of barriers to fair competition; (2) significantly or uniquely affecting one state, one sector of the economy, a category of small entities, or one geographic region, or the overall economy; (3) raising legal or procedural barriers to',[399x643]
to payments made in FY 2023. The impact analysis of the capital payments can be found in section I.I. of this appendix. In addition, as described in section I.J. of this appendix, LTCHs are expected to experience an increase in payments by approximately $6 million in FY 2024 relative to FY 2023.

Our operating payment impact estimate includes the 3.1 percent hospital update to the standardized amount (reflecting the 3.3 percent market basket update reduced by the 0.2 percent productivity adjustment). The estimates of IPPS operating payments to acute care hospitals do not reflect any changes in hospital admissions or real case-mix intensity, which will also affect overall payment changes.

The analysis in this appendix, in conjunction with the remainder of this document, demonstrates that this final rule is consistent with the regulatory philosophy and principles identified in Executive Orders 12866 and 13563, the RFA, and section 1102 of the Act. This final rule would affect payments to a substantial number of small rural hospitals, as well as other classes of hospitals, and the effects on some hospitals may be significant. Finally, in accordance with the provisions of Executive Order 12866, Office of Management and Budget has reviewed this final rule.

C. Objectives of the IPPS and the LTCH PPS

The primary objective of the IPPS and the LTCH PPS is to create incentives for hospitals to operate efficiently and minimize unnecessary costs, while at the same time ensuring that payments are sufficient to adequately compensate hospitals for their costs in delivering necessary care to Medicare beneficiaries. In addition, we share national goals of preserving the Medicare Hospital Insurance Trust Fund.

We believe that the changes in this final rule would further each of these goals while maintaining the financial viability of the hospital, ensuring access to high quality health care for Medicare beneficiaries. We expect that these changes would ensure that the outcomes of the prospective payment systems are reasonable and equitable, while avoiding or minimizing unintended adverse consequences.

Because this final rule contains a range of policies, we refer readers to the section of the final rule where each policy is discussed. These sections include the rationale for our decisions, including the need for the policy.

D. Limitations of Our Analysis

The following quantitative analysis presents the projected effects of our policy changes, as well as statutory changes effective for FY 2024, on various hospital groups. We estimate the effects of individual policy changes by estimating payments per case, while holding all other payment parameters constant. We use the best data available, but, generally unless specifically indicated, we do not attempt to make adjustments for future changes in such variables as admissions, lengths of stay, case mix, changes to the Medicare population, or incentives. In addition, we discuss limitations of our analysis for specific policies in the discussion of those policies as needed.

E. Hospitals Included in and Excluded From the IPPS

The prospective payment systems for hospital inpatient operating and capital related-costs of acute care hospitals encompass most general short-term, acute care hospitals that participate in the Medicare program. There were 24 Indian Health Service hospitals in our database, which we excluded from the analysis due to the special characteristics of the prospective payment methodology for these hospitals. Among other short term, acute care hospitals, hospitals in Maryland are paid in accordance with the Maryland Total Cost of Care Model, and hospitals located outside the 50 States, the District of Columbia, and Puerto Rico (that is, 6 short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa. Changes in the prospective payment systems for IPPS for FY 2024 are discussed in section I.J. of this appendix.

F. Quantitative Effects of the Policy Changes Under the IPPS for Operating Costs

1. Basis and Methodology of Estimates

In this final rule, we are announcing policy changes and payment rate updates for the IPPS for FY 2024 for operating costs of acute care hospitals. The FY 2024 updates to the capital payments to acute care hospitals are discussed in section I.I. of this appendix.

Based on the overall percentage change in payments per case estimated using our payment simulation model, we estimate that total FY 2024 operating payments would increase by 3.1 percent, compared to FY 2023. The impacts do not reflect changes in the number of hospital admissions or real case-mix intensity, which would also affect overall payment

We have prepared separate impact analyses of the changes to each system. This section deals with the changes to the operating inpatient prospective payment system for acute care hospitals. Our payment simulation model relies on the best available claims data to enable us to estimate the impacts on payments per case of certain changes in this final rule. As discussed in section I.E. of the preamble to this final rule, we believe that the FY 2022 claims data is the best available data for purposes of the FY 2024 rate-setting and this impact analysis reflects the use of that data. However, there are changes for which we do not have data available that would allow us to estimate the payment impacts using this model. For those changes, we have attempted to predict the payment impacts based upon our experience and other more limited data.

The data used in developing the quantitative analyses of changes in payments per case presented in this section are taken from the FY 2022 MedPAR file, as discussed previously in this final rule, and the most current Provider-Specific File (PSF) that is used for payment purposes. Although the analyses of the changes to the operating PPS do not incorporate cost data, data from the best available hospital sources are used to categorize hospitals, as also discussed previously in this final rule. Our analysis has several qualifications. First, in this analysis, we do not adjust for future changes in such variables as admissions, lengths of stay, or underlying growth in a hospital’s volume. Second, due to the interdependent nature of the IPPS payment components, it is very difficult to precisely quantify the impact associated with each change. Third, we use various data sources to categorize hospitals in the tables. In some cases, particularly the number of beds, there is a fair degree of variation in the data from the different sources. We have attempted to construct these variables with the best available source overall.

Using cases from the FY 2022 MedPAR file, we simulate payments under the operating IPPS given various combinations of payment parameters. As described previously, Indian Health Service hospitals and hospitals in Maryland are excluded from the simulations. The impact of payments under the capital IPPS, and the impact of payments for costs other than inpatient operating costs, are not analyzed in this section. Estimated payment impacts of the capital IPPS for FY 2024 are discussed in section I.I. of this appendix.

We discuss the following changes:

• The effects of the application of the applicable percentage increase of 3.1 percent (that is, a 3.3 percent market basket update with a reduction of 0.2 percentage point for the productivity adjustment), and the applicable percentage increase (including the market basket update and the productivity adjustment) to the hospital-specific rates.

• The effects of the changes to the relative weights and MS–DRG GROU/ER.

• The effects of the changes in hospitals’ wage index values reflecting updated wage data from hospitals’ cost reporting periods beginning during FY 2020, compared to the FY 2019 wage data, to calculate the FY 2024 wage index.

• The effects of the geographic reclassifications by the MGCRB (as of publication of this final rule) that will be effective for FY 2024.

• The effects of the rural floor with the application of the national budget neutrality
factor to the wage index and the change to the rural wage index and rural floor methodology.

- The effects of the imputed floor wage index adjustment. This provision is not budget neutral.
- The effects of the Frontier State wage index adjustment under the statutory provision that requires hospitals located in States that qualify as Frontier States to not have a wage index less than 1.0. This provision is not budget neutral.
- The effects of the implementation of section 1886(d)(13) of the Act, which provides for an increase in a hospital’s wage index if a threshold percentage of residents of the county where the hospital is located commute to work at hospitals in counties with higher wage indexes for FY 2024. This provision is not budget neutral.
- The total estimated change in payments based on the FY 2024 policies relative to payments based on FY 2023 policies.

To illustrate the impact of the FY 2024 changes, our analysis begins with a FY 2023 baseline simulation model using: the FY 2023 applicable percentage increase of 3.8 percent; the 0.5 percentage point adjustment required under section 414 of the MACRA applied to the IPPS standardized amount; the FY 2023 MS-DRG GROUPER (Version 40); the FY 2023 CBSA designations for hospitals based on the OMB definitions from the 2010 Census; the FY 2023 wage index; and no MGCRB reclassifications. Outlier payments are set at 5.1 percent of total operating MS-DRG and outlier payments for modeling purposes.

Section 1886(b)(3)(B)(viii) of the Act provides that, for FY 2007 and each subsequent year through FY 2014, the update factor will include a reduction of 2.0 percentage points for any subsection (d) hospital that does not submit data on measures in a form and manner, and at a time specified by the Secretary. Beginning in FY 2015, the reduction is one-quarter of such applicable percentage increase determined without regard to section 1886(b)(3)(B)(ix), (xi), or (xii) of the market basket rate-of-increase. Therefore, hospitals that do not submit quality information under rules established by the Secretary and that are meaningful EHR users under section 1886(b)(3)(B)(viii) of the Act would receive an applicable percentage increase of 0.625 percent. At the time this impact was prepared, 110 hospitals are estimated to not receive the full market basket rate-of-increase for FY 2024 because they are identified as not meaningful EHR users that do not submit quality information under section 1886(b)(3)(B)(viii) of the Act. For purposes of the simulations shown in this section, we modeled the payment changes for FY 2024 using a reduced update for these hospitals.

Hospitals that are identified as not meaningful EHR users under section 1886(b)(3)(B)(ix) of the Act and also do not submit quality data under section 1886(b)(3)(B)(viii) of the Act would receive a three-quarter reduction of the market basket rate-of-increase for failure to submit quality data and a three-quarter reduction of the market basket rate-of-increase for being identified as not a meaningful EHR user. At the time this impact was prepared, 31 hospitals are estimated to not receive the market basket rate-of-increase for FY 2024 because they are identified as not meaningful EHR users that do not submit quality data under section 1886(b)(3)(B)(viii) of the Act.

Each policy change, statutory or otherwise, is then added incrementally to this baseline, finally arriving at an FY 2024 model incorporating all of the changes. This simulation allows us to isolate the effects of each change.

Our comparison illustrates the percent change in payments per case from FY 2023 to FY 2024. Two factors not discussed separately have significant impacts here. The first factor is the update to the standardized amount. In accordance with section 1886(b)(3)(B)(i) of the Act, we are updating the standardized amounts for FY 2024 using an applicable percentage increase of 3.1 percent. This includes the FY 2024 IPPS operating hospital market basket increase of 3.3 percent with a 0.2 percentage point adjustment for the productivity adjustment. Hospitals that fail to comply with the quality data submission requirements and are meaningful EHR users would receive an update of 2.725 percent. This update includes a reduction of one-quarter of the market basket rate-of-increase for failure to submit these data. Hospitals that do comply with the quality data submission requirements but are not meaningful EHR users would receive an update of 0.625 percent, which includes a reduction of three-quarters of the market basket rate-of-increase. Furthermore, hospitals that do not comply with the quality data submission requirements and are not meaningful EHR users would receive an update of 0.2 percent. Under section 1886(b)(3)(B)(iv) of the Act, the update to the hospital-specific amount is equal to the applicable percentage increase, or 3.1 percent, if the hospital submits quality data and is a meaningful EHR user.

A second significant factor that affects the changes in hospitals’ payments per case from FY 2023 to FY 2024 is the change in hospitals’ geographic reclassification status from one year to the next. That is, payments may be reduced for hospitals reclassified in FY 2023 that are no longer reclassified in FY 2024. Conversely, payments may increase for hospitals not reclassified in FY 2023 that are reclassified in FY 2024.

2. Analysis of Table 1

Table 1 displays the results of our analysis of the changes for FY 2024. The table categorizes hospitals by various geographic and special payment consideration groups to illustrate the varying impacts on different types of hospitals. The top row of the table shows the overall impact on the 3,131 acute care hospitals included in the analysis. The next two rows of Table 1 contain hospitals categorized according to their geographic location: urban and rural. There are 2,416 hospitals located in urban areas and 715 hospitals in rural areas included in our analysis. The next two groupings are by bed-size categories, shown separately for urban and rural hospitals. The last groupings by geographic location are by census divisions, also shown separately for urban and rural hospitals.

The second part of Table 1 shows hospital groups based on hospitals’ FY 2024 payment classifications, including any reclassifications under section 1886(d)(10) of the Act. For example, the rows labeled urban and rural show that the numbers of hospitals paid based on these categorizations after consideration of geographic reclassifications (including reclassifications under sections 1886(d)(8)(B) and 1886(d)(8)(E) of the Act that have implications for capital payments) are 1,811 and 1,320, respectively.

The next three groupings examine the impacts of the changes on hospitals grouped by whether or not they have GME residency programs (teaching hospitals that receive an IME adjustment) or receive Medicare DSH payments, or some combination of these two adjustments. There are 1,900 nonteaching hospitals in our analysis, 30 teaching hospitals with fewer than 100 residents, and 278 teaching hospitals with 100 or more residents.

The next four rows examine the impacts of the changes on rural hospitals by special payment groups (SCFs, MDCs, and RRCs) and reclassification status from urban to rural in accordance with section 1886(d)(6)(E) of the Act. The hospitals that are not reclassified from urban to rural, there are 133 RRCs, 256 SCFs, 116 MDCs, 121 hospitals that are both SCFs and RRCs, and 18 hospitals that are both MDCs and RRCs. Of the hospitals that are reclassified from urban to rural, there are 491 RRCs, 116 MDCs, 121 hospitals that are both SCFs and RRCs, and 13 hospitals that are both MDCs and RRCs.

The next series of groupings are based on the type of ownership and the hospital’s Medicare and Medicaid utilization expressed as a percent of total inpatient days. These
<table>
<thead>
<tr>
<th>Number of Hospitals</th>
<th>Hospital Rate Update (1)</th>
<th>FY 2024 Weights and DRG Changes with Application of Budget Neutrality (2)</th>
<th>FY 2024 Wage Data with Application of Wage Budget Neutrality (3)</th>
<th>FY 2024 MGCRF Reclassifications (4)</th>
<th>FY 2024 Rural Floor with Application of National Rural Floor Budget Neutrality (5)</th>
<th>Application of the Imputed Floor, Frontier State Wage Index and Outmigration Adjustment (6)</th>
<th>All FY 2024 Changes (7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Hospitals</td>
<td>3,131</td>
<td>3.1</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.4</td>
</tr>
<tr>
<td><strong>By Geographic Location:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Urban hospitals</strong></td>
<td>2,416</td>
<td>3.1</td>
<td>0.0</td>
<td>-0.1</td>
<td>0.0</td>
<td>0.0</td>
<td>0.4</td>
</tr>
<tr>
<td>Rural hospitals</td>
<td>715</td>
<td>3.0</td>
<td>-0.2</td>
<td>-0.3</td>
<td>1.8</td>
<td>-0.6</td>
<td>0.1</td>
</tr>
<tr>
<td><strong>Bed Size (Urban):</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-99 beds</td>
<td>650</td>
<td>3.0</td>
<td>-0.2</td>
<td>-0.1</td>
<td>-1.6</td>
<td>0.9</td>
<td>0.5</td>
</tr>
<tr>
<td>100-199 beds</td>
<td>696</td>
<td>3.1</td>
<td>0.2</td>
<td>0.0</td>
<td>-0.6</td>
<td>0.8</td>
<td>0.4</td>
</tr>
<tr>
<td>200-299 beds</td>
<td>414</td>
<td>3.1</td>
<td>0.1</td>
<td>-0.1</td>
<td>0.5</td>
<td>0.5</td>
<td>0.3</td>
</tr>
<tr>
<td>300-499 beds</td>
<td>404</td>
<td>3.1</td>
<td>0.0</td>
<td>0.1</td>
<td>0.6</td>
<td>0.2</td>
<td>0.3</td>
</tr>
<tr>
<td>500 or more beds</td>
<td>250</td>
<td>3.0</td>
<td>-0.1</td>
<td>0.0</td>
<td>-0.3</td>
<td>-0.6</td>
<td>0.4</td>
</tr>
<tr>
<td><strong>Bed Size (Rural):</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-49 beds</td>
<td>363</td>
<td>2.9</td>
<td>0.1</td>
<td>-0.1</td>
<td>1.1</td>
<td>-0.5</td>
<td>0.2</td>
</tr>
<tr>
<td>50-99 beds</td>
<td>188</td>
<td>3.0</td>
<td>0.3</td>
<td>0.0</td>
<td>1.7</td>
<td>-0.4</td>
<td>0.1</td>
</tr>
<tr>
<td>100-149 beds</td>
<td>87</td>
<td>3.0</td>
<td>0.4</td>
<td>-0.2</td>
<td>2.0</td>
<td>-0.5</td>
<td>0.1</td>
</tr>
<tr>
<td>150-199 beds</td>
<td>46</td>
<td>3.1</td>
<td>0.2</td>
<td>-0.5</td>
<td>1.9</td>
<td>-0.7</td>
<td>0.0</td>
</tr>
<tr>
<td>200 or more beds</td>
<td>31</td>
<td>3.1</td>
<td>-0.7</td>
<td>2.5</td>
<td>-0.7</td>
<td>0.3</td>
<td>3.1</td>
</tr>
<tr>
<td><strong>Urban by Region:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New England</td>
<td>108</td>
<td>3.1</td>
<td>0.0</td>
<td>-0.5</td>
<td>4.0</td>
<td>0.0</td>
<td>0.6</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>292</td>
<td>3.1</td>
<td>0.1</td>
<td>0.9</td>
<td>-0.1</td>
<td>-0.5</td>
<td>1.0</td>
</tr>
<tr>
<td>East North Central</td>
<td>372</td>
<td>3.1</td>
<td>0.0</td>
<td>-0.6</td>
<td>-1.1</td>
<td>-1.0</td>
<td>0.1</td>
</tr>
<tr>
<td>West North Central</td>
<td>156</td>
<td>3.1</td>
<td>-0.2</td>
<td>-0.1</td>
<td>-1.4</td>
<td>-0.9</td>
<td>0.6</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>403</td>
<td>3.1</td>
<td>0.0</td>
<td>-0.6</td>
<td>-0.2</td>
<td>0.4</td>
<td>3.3</td>
</tr>
<tr>
<td>East South Central</td>
<td>138</td>
<td>3.1</td>
<td>0.0</td>
<td>-0.6</td>
<td>-0.2</td>
<td>0.4</td>
<td>3.4</td>
</tr>
<tr>
<td>West South Central</td>
<td>359</td>
<td>3.1</td>
<td>0.0</td>
<td>-0.6</td>
<td>-0.2</td>
<td>0.4</td>
<td>3.5</td>
</tr>
<tr>
<td>Mountain</td>
<td>177</td>
<td>3.1</td>
<td>-0.1</td>
<td>-0.4</td>
<td>0.5</td>
<td>1.4</td>
<td>0.4</td>
</tr>
<tr>
<td>Pacific</td>
<td>360</td>
<td>3.0</td>
<td>0.0</td>
<td>0.1</td>
<td>1.0</td>
<td>2.7</td>
<td>0.1</td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>51</td>
<td>3.0</td>
<td>-0.3</td>
<td>-1.9</td>
<td>-2.5</td>
<td>-0.2</td>
<td>0.1</td>
</tr>
<tr>
<td><strong>Rural by Region:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New England</td>
<td>19</td>
<td>3.1</td>
<td>0.0</td>
<td>-1.2</td>
<td>0.9</td>
<td>-0.7</td>
<td>0.1</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>47</td>
<td>3.1</td>
<td>0.2</td>
<td>-0.1</td>
<td>5.6</td>
<td>-0.8</td>
<td>0.4</td>
</tr>
<tr>
<td>East North Central</td>
<td>113</td>
<td>3.1</td>
<td>0.1</td>
<td>-0.3</td>
<td>1.1</td>
<td>-0.4</td>
<td>0.0</td>
</tr>
<tr>
<td>West North Central</td>
<td>84</td>
<td>3.0</td>
<td>0.2</td>
<td>-0.1</td>
<td>0.4</td>
<td>-0.3</td>
<td>0.3</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>108</td>
<td>3.1</td>
<td>0.4</td>
<td>-0.7</td>
<td>2.0</td>
<td>-0.7</td>
<td>0.1</td>
</tr>
<tr>
<td>East South Central</td>
<td>140</td>
<td>3.0</td>
<td>0.3</td>
<td>-0.7</td>
<td>1.9</td>
<td>-0.8</td>
<td>0.1</td>
</tr>
<tr>
<td>West South Central</td>
<td>134</td>
<td>3.0</td>
<td>0.2</td>
<td>-0.1</td>
<td>2.1</td>
<td>-0.7</td>
<td>0.0</td>
</tr>
<tr>
<td>Mountain</td>
<td>46</td>
<td>2.8</td>
<td>0.0</td>
<td>0.1</td>
<td>0.1</td>
<td>-0.2</td>
<td>0.8</td>
</tr>
<tr>
<td>Pacific</td>
<td>24</td>
<td>3.1</td>
<td>0.4</td>
<td>-0.2</td>
<td>3.6</td>
<td>-0.5</td>
<td>0.0</td>
</tr>
<tr>
<td><strong>By Payment Classification:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban hospitals</td>
<td>1,811</td>
<td>3.1</td>
<td>0.0</td>
<td>-1.8</td>
<td>1.1</td>
<td>0.6</td>
<td>0.6</td>
</tr>
<tr>
<td>Rural areas</td>
<td>1,320</td>
<td>3.1</td>
<td>0.0</td>
<td>1.8</td>
<td>-1.1</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Teaching Status:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonteaching</td>
<td>1,900</td>
<td>3.1</td>
<td>0.1</td>
<td>-0.1</td>
<td>-0.2</td>
<td>0.9</td>
<td>0.3</td>
</tr>
<tr>
<td></td>
<td>Number of Hospitals</td>
<td>Hospital Rate Update (1)</td>
<td>FY 2024 Weight and DRG Changes with Application of Budget Neutrality (2)</td>
<td>FY 2024 Wage Data with Application of Wage Budget Neutrality (3)</td>
<td>FY 2024 MGCRB Reclassifications (4)</td>
<td>Rural Floor with Application of National Rural Floor Budget Neutrality (5)</td>
<td>Application of the Imputed Floor, Frontier State Wage Index and Outmigration Adjustment (6)</td>
</tr>
<tr>
<td>------------------------------</td>
<td>---------------------</td>
<td>-------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------</td>
<td>------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Fewer than 100 residents</td>
<td>953</td>
<td>3.1</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.5</td>
</tr>
<tr>
<td>100 or more residents</td>
<td>278</td>
<td>3.0</td>
<td>0.0</td>
<td>0.1</td>
<td>0.1</td>
<td>-0.7</td>
<td>0.4</td>
</tr>
<tr>
<td><strong>Urban DSH:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-DSH</td>
<td>353</td>
<td>3.1</td>
<td>-0.4</td>
<td>0.2</td>
<td>-1.8</td>
<td>-0.2</td>
<td>0.9</td>
</tr>
<tr>
<td>100 or more beds</td>
<td>1,099</td>
<td>3.1</td>
<td>0.1</td>
<td>0.0</td>
<td>-1.8</td>
<td>1.2</td>
<td>0.6</td>
</tr>
<tr>
<td>Less than 100 beds</td>
<td>359</td>
<td>3.1</td>
<td>-0.1</td>
<td>0.1</td>
<td>-1.8</td>
<td>1.7</td>
<td>0.4</td>
</tr>
<tr>
<td><strong>Rural DSH:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-DSH</td>
<td>108</td>
<td>3.0</td>
<td>-0.3</td>
<td>0.1</td>
<td>2.6</td>
<td>-1.0</td>
<td>0.2</td>
</tr>
<tr>
<td>SCH</td>
<td>257</td>
<td>3.0</td>
<td>0.3</td>
<td>0.0</td>
<td>0.3</td>
<td>-0.1</td>
<td>0.0</td>
</tr>
<tr>
<td>RRC</td>
<td>712</td>
<td>3.1</td>
<td>0.0</td>
<td>-0.1</td>
<td>2.0</td>
<td>-1.1</td>
<td>0.1</td>
</tr>
<tr>
<td>100 or more beds</td>
<td>32</td>
<td>3.1</td>
<td>-0.2</td>
<td>0.5</td>
<td>-1.1</td>
<td>-1.2</td>
<td>0.1</td>
</tr>
<tr>
<td>Less than 100 beds</td>
<td>211</td>
<td>3.0</td>
<td>0.3</td>
<td>-0.1</td>
<td>1.9</td>
<td>-0.8</td>
<td>0.2</td>
</tr>
<tr>
<td><strong>Urban teaching and DSH:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Both teaching and DSH</td>
<td>637</td>
<td>3.1</td>
<td>0.1</td>
<td>0.1</td>
<td>-1.8</td>
<td>0.8</td>
<td>0.7</td>
</tr>
<tr>
<td>Teaching and no DSH</td>
<td>57</td>
<td>3.1</td>
<td>-0.3</td>
<td>0.6</td>
<td>-1.8</td>
<td>-0.5</td>
<td>1.1</td>
</tr>
<tr>
<td>No teaching and DSH</td>
<td>821</td>
<td>3.1</td>
<td>0.1</td>
<td>-0.1</td>
<td>-1.7</td>
<td>2.2</td>
<td>0.3</td>
</tr>
<tr>
<td>No teaching and no DSH</td>
<td>296</td>
<td>3.1</td>
<td>-0.4</td>
<td>-0.1</td>
<td>-1.7</td>
<td>-0.1</td>
<td>0.8</td>
</tr>
<tr>
<td><strong>Special Hospital Types:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RRC</td>
<td>133</td>
<td>3.2</td>
<td>0.0</td>
<td>-0.4</td>
<td>1.8</td>
<td>-0.3</td>
<td>0.4</td>
</tr>
<tr>
<td>RRC with Section 401 Rural Reclassification</td>
<td>491</td>
<td>3.1</td>
<td>-0.1</td>
<td>0.0</td>
<td>2.1</td>
<td>-1.3</td>
<td>0.1</td>
</tr>
<tr>
<td>SCH</td>
<td>256</td>
<td>3.0</td>
<td>0.2</td>
<td>0.0</td>
<td>0.3</td>
<td>-0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>SCH with Section 401 Rural Reclassification</td>
<td>45</td>
<td>3.1</td>
<td>0.3</td>
<td>0.0</td>
<td>0.1</td>
<td>-0.1</td>
<td>0.0</td>
</tr>
<tr>
<td>SCH and RRC</td>
<td>121</td>
<td>3.1</td>
<td>0.2</td>
<td>-0.2</td>
<td>0.9</td>
<td>-0.3</td>
<td>0.1</td>
</tr>
<tr>
<td>SCH and RRC with Section 401 Rural Reclassification</td>
<td>43</td>
<td>3.1</td>
<td>-0.1</td>
<td>0.0</td>
<td>0.3</td>
<td>-0.1</td>
<td>0.0</td>
</tr>
<tr>
<td>MDH</td>
<td>116</td>
<td>3.0</td>
<td>0.1</td>
<td>-0.2</td>
<td>1.3</td>
<td>-0.6</td>
<td>0.6</td>
</tr>
<tr>
<td>MDH with Section 401 Reclassification</td>
<td>30</td>
<td>3.1</td>
<td>0.3</td>
<td>-0.2</td>
<td>0.6</td>
<td>-0.3</td>
<td>0.0</td>
</tr>
<tr>
<td>MDH and RRC</td>
<td>18</td>
<td>3.0</td>
<td>0.3</td>
<td>0.0</td>
<td>1.2</td>
<td>-0.4</td>
<td>0.1</td>
</tr>
<tr>
<td>MDH and RRC with Section 401 Reclassification</td>
<td>13</td>
<td>3.1</td>
<td>0.3</td>
<td>-0.1</td>
<td>0.7</td>
<td>-0.3</td>
<td>0.0</td>
</tr>
<tr>
<td><strong>Type of Ownership:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Voluntary</td>
<td>1,920</td>
<td>3.1</td>
<td>0.0</td>
<td>0.0</td>
<td>0.2</td>
<td>-0.2</td>
<td>0.4</td>
</tr>
<tr>
<td>Proprietary</td>
<td>778</td>
<td>3.1</td>
<td>0.0</td>
<td>-0.2</td>
<td>-0.4</td>
<td>1.3</td>
<td>0.2</td>
</tr>
<tr>
<td>Government</td>
<td>432</td>
<td>3.0</td>
<td>0.1</td>
<td>0.0</td>
<td>-0.6</td>
<td>-0.1</td>
<td>0.1</td>
</tr>
<tr>
<td><strong>Medicare Utilization as a Percent of Inpatient Days:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-25</td>
<td>995</td>
<td>3.0</td>
<td>0.1</td>
<td>0.1</td>
<td>-0.5</td>
<td>0.3</td>
<td>0.2</td>
</tr>
<tr>
<td>25-50</td>
<td>1,945</td>
<td>3.1</td>
<td>0.0</td>
<td>-0.1</td>
<td>0.3</td>
<td>-0.2</td>
<td>0.5</td>
</tr>
<tr>
<td>50-65</td>
<td>138</td>
<td>3.0</td>
<td>0.1</td>
<td>0.1</td>
<td>-0.6</td>
<td>1.6</td>
<td>0.6</td>
</tr>
<tr>
<td>Over 65</td>
<td>25</td>
<td>2.7</td>
<td>0.7</td>
<td>0.3</td>
<td>0.3</td>
<td>-0.2</td>
<td>0.0</td>
</tr>
<tr>
<td><strong>Medicaid Utilization as a Percent of Inpatient Days:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-25</td>
<td>2,038</td>
<td>3.1</td>
<td>-0.1</td>
<td>0.0</td>
<td>0.1</td>
<td>-0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>25-50</td>
<td>974</td>
<td>3.1</td>
<td>0.1</td>
<td>0.0</td>
<td>-0.1</td>
<td>0.3</td>
<td>0.4</td>
</tr>
<tr>
<td>50-65</td>
<td>91</td>
<td>2.9</td>
<td>0.8</td>
<td>0.5</td>
<td>-0.7</td>
<td>2.7</td>
<td>0.1</td>
</tr>
<tr>
<td>Over 65</td>
<td>28</td>
<td>2.9</td>
<td>1.1</td>
<td>0.3</td>
<td>-1.9</td>
<td>7.6</td>
<td>0.0</td>
</tr>
<tr>
<td><strong>FY 2024 Reclassifications:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Reclassified Hospitals</td>
<td>1,054</td>
<td>3.1</td>
<td>0.0</td>
<td>0.0</td>
<td>1.9</td>
<td>-0.8</td>
<td>0.1</td>
</tr>
<tr>
<td>Non-Reclassified Hospitals</td>
<td>2,077</td>
<td>3.1</td>
<td>0.0</td>
<td>0.0</td>
<td>-2.0</td>
<td>0.8</td>
<td>0.6</td>
</tr>
<tr>
<td>Urban Hospitals Reclassified</td>
<td>869</td>
<td>3.1</td>
<td>-0.1</td>
<td>0.0</td>
<td>1.8</td>
<td>-0.8</td>
<td>0.2</td>
</tr>
<tr>
<td>Urban Non-Reclassified Hospitals</td>
<td>1,561</td>
<td>3.1</td>
<td>0.0</td>
<td>0.1</td>
<td>-2.4</td>
<td>1.0</td>
<td>0.7</td>
</tr>
<tr>
<td>Rural Hospitals Reclassified Full Year</td>
<td>298</td>
<td>3.1</td>
<td>0.3</td>
<td>-0.3</td>
<td>2.3</td>
<td>-0.6</td>
<td>0.0</td>
</tr>
<tr>
<td></td>
<td>Number of Hospitals¹</td>
<td>Hospital Rate Update (1)²</td>
<td>FY 2024 Weights and DRG Changes with Application of Budget Neutrality (2)³</td>
<td>FY 2024 Wage Data with Application of Wage Budget Neutrality (3)⁴</td>
<td>FY 2024 MGCRB Reclassifications (4)⁵</td>
<td>Rural Floor with Application of National Rural Floor Budget Neutrality (5)⁶</td>
<td>Application of the Imputed Floor, Frontier State Wage Index and Outmigration Adjustment (6)⁷</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>----------------------</td>
<td>---------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------</td>
<td>--------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Rural Non-Reclassified Hospitals Full Year</td>
<td>403</td>
<td>3.0</td>
<td>0.2</td>
<td>-0.3</td>
<td>1.0</td>
<td>-0.5</td>
<td>0.4</td>
</tr>
<tr>
<td>All Section 401 Rural Reclassified Hospitals</td>
<td>659</td>
<td>3.1</td>
<td>-0.1</td>
<td>0.0</td>
<td>1.8</td>
<td>-1.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Other Reclassified Hospitals (Section 1886(d)(8)(B))</td>
<td>54</td>
<td>3.1</td>
<td>0.2</td>
<td>-0.4</td>
<td>4.0</td>
<td>-0.9</td>
<td>0.0</td>
</tr>
</tbody>
</table>

¹ Because data necessary to classify some hospitals by category were missing, the total number of hospitals in each category may not equal the national total. Discharge data are from FY 2022, and hospital cost report data are from the latest available reporting periods.

² This column displays the payment impact of the hospital rate update, including the 3.1 percent update to the national standardized amount and the hospital-specific rate (the 3.3 percent market basket rate-of-increase reduced by 0.2 percentage point for the productivity adjustment).

³ This column displays the payment impact of the changes to the Version 41 GROUPER, the changes to the relative weights and the recalibration of the MS-DRG weights based on FY 2022 MedPAR data as the best available data, and the permanent 10-percent cap where the relative weight for a MS-DRG would decrease by more than ten percent in a given fiscal year. This column displays the application of the recalibration budget neutrality factors of 1.001463 and 0.999928.

⁴ This column displays the payment impact of the update to wage index data using FY 2020 cost report data and the OMB labor market area delineations based on 2010 Decennial Census data. This column displays the payment impact of the application of the wage budget neutrality factor. The wage budget neutrality factor is 1.000702.

⁵ Shown here are the effects of geographic reclassifications by the Medicare Geographic Classification Review Board (MGCRB). The effects demonstrate the FY 2024 payment impact of going from no reclassifications to the reclassifications scheduled to be in effect for FY 2024. Reclassification for prior years has no bearing on the payment impacts shown here. This column reflects the geographic budget neutrality factor of 0.971295.

⁶ This column displays the effects of the rural floor and the change to the rural wage index methodology. The Affordable Care Act requires the rural floor budget neutrality adjustment to be a 100 percent national level adjustment. The rural floor budget neutrality factor applied to the wage index is 0.978183.

⁷ This column shows the combined impact of (1) the imputed floor for all-urban states; (2) the policy that requires hospitals located in frontier States have a wage index no less than 1.0; and (3) the policy which provides for an increase in a hospital’s wage index if a threshold percentage of residents of the county where the hospital is located commute to work at hospitals in counties with higher wage indexes. These are not budget neutral policies.

⁸ This column shows the estimated change in payments from FY 2023 to FY 2024.
a. Effects of the Hospital Update (Column 1)
As discussed in section V.A. of the preamble of this final rule, this column includes the hospital update, including the 3.3 percent market basket rate-of-increase reduced by the 0.2 percentage point for the productivity adjustment. As a result, we are making a 3.1 percent update to the national standardized amount. This column also includes the update to the hospital-specific rates which includes the 3.3 percent market basket rate-of-increase reduced by 0.2 percentage point for the productivity adjustment. As a result, we are making a 3.1 percent update to the hospital-specific rates.

Overall, hospitals would experience a 3.1 percent increase in payments primarily due to the combined effects of the hospital update to the national standardized amount and the hospital update to the hospital-specific rate.

b. Effects of the Changes to the MS–DRG Reclassifications and Relative Cost-Based Weights With Recalibration Budget Neutrality (Column 2)
Column 2 shows the effects of the changes to the MS–DRGs and relative weights with the application of the recalibration budget neutrality factor to the standardized amounts. Section 1886(d)(4)(C)(i) of the Act requires us annually to make appropriate classification changes to reflect changes in treatment patterns, technology, and any other factors that may change the relative use of hospital resources. Consistent with section 1886(d)(4)(C)(iii) of the Act, we calculated a recalibration budget neutrality factor to account for the changes in MS–DRGs and relative weights to ensure that the overall payment impact is budget neutral. We also applied the permanent 10-percent cap on the reduction in a MS–DRG’s relative weight in a given year and an associated recalibration cap budget neutrality factor to account for the 10-percent cap on relative weight reductions to ensure that the overall payment impact is budget neutral.

As discussed in section II.D. of the preamble of this final rule, for FY 2024, we calculated the MS–DRG relative weights using the FY 2022 MedPAR data grouped to the Version 41 (FY 2024) MS–DRGs. The reclassification changes to the GROUPER are described in more detail in section II.C. of the preamble of this final rule.

The “All Hospitals” line in Column 2 indicates that changes due to the MS–DRGs and relative weights would result in a 0.0 percent change in payments with the application of the recalibration budget neutrality factor of 1.001463 and the recalibration cap budget neutrality factor of 0.9999280 the standardized amount.

c. Effects of the Wage Index Changes (Column 3)
Column 3 shows the impact of the updated wage data, with the application of the wage budget neutrality factor. The wage index is calculated and assigned to hospitals on the basis of the labor market area in which the hospital is located. Under section 1886(d)(3)(E) of the Act, beginning with FY 2005, we delineate hospital labor market areas based on the Core Based Statistical Areas (CBSAs) established by OMB. The current statistical standards (based on OMB standards) used in FY 2024 are discussed in section III.A.2. of the preamble of this final rule.

Section 1886(d)(3)(E) of the Act requires that, beginning October 1, 1993, we annually update the wage data used to calculate the wage index. In accordance with this requirement, the wage index for acute care hospitals for FY 2024 is based on data submitted for hospital cost reporting periods, beginning on or after October 1, 2019 and before October 1, 2020. The estimated impact of the updated wage data and the OMB labor market area delineations on hospital payments is isolated in Column 3 by holding the other payment parameters constant in this simulation. That is, Column 3 shows the percentage change in payments when going from a model using the FY 2023 wage index, the labor-related share of 67.6 percent, under the OMB delineations and having a 100-percent occupational mix adjustment applied, to a model using the FY 2024 pre-reclassification wage index with the labor-related share of 67.6 percent, under the OMB delineations, also having a 100-percent occupational mix adjustment applied, while holding other payment parameters, such as use of the Version 41 MS–DRG GROUPER constant. The FY 2024 occupational mix adjustment is based on the CY 2019 occupational mix survey.

In addition, the column shows the impact of the application of the wage budget neutrality to the national standardized amount. In FY 2010, we began calculating separate wage budget neutrality and recalibration budget neutrality factors, in accordance with section 1886(d)(3)(E) of the Act, which specifies that budget neutrality to account for wage index changes or updates made under that subparagraph must be made without regard to the 62 percent labor-related share guaranteed under section 1886(d)(3)(E)(ii) of the Act. Therefore, for FY 2024, we are calculating the wage budget neutrality factor to ensure that payments under updated wage data and the labor-related share of 67.6 percent are budget neutral, without regard to the lower labor-related share of 62 percent applied to hospitals with a wage index less than or equal to 1.0. In other words, the wage budget neutrality is calculated under the assumption that all hospitals receive the higher labor-related share of the standardized amount.
The FY 2024 wage budget neutrality factor is 1.000702 and the overall payment change is 0 percent.

Column 3 shows the impacts of updating the wage data. Overall, the new wage data and the labor-related share, combined with the wage budget neutrality adjustment, would lead to no change for all hospitals, as shown in Column 3.

In looking at the wage data itself, the national average hourly wage would increase 5.2 percent compared to FY 2023. Therefore, the only manner in which to maintain or exceed the previous year’s wage index was to match or exceed the 5.2 percent increase in the national average hourly wage.

The following chart compares the shifts in wage index values for hospitals due to changes in the average hourly wage data for FY 2024 relative to FY 2023. These figures reflect proposed changes in the “pre-reclassified, occupational mix-adjusted wage index,” that is, the wage index before the application of geographic reclassification, the rural floor, the out-migration adjustment, and other wage index exceptions and adjustments. We note that the "post-reclassified wage index" or "payment wage index," which is the wage index that includes all such exceptions and adjustments (as reflected in Tables 2 and 3 associated with this final rule) is used to adjust the labor-related share of a hospital’s standardized amount, either 67.6 percent (as proposed) or 62 percent, depending upon whether a hospital’s wage index is greater than 1.0 or less than or equal to 1.0.

Therefore, the pre-reclassified wage index figures in the following chart may illustrate a somewhat larger or smaller change than would occur in a hospital’s payment wage index and total payment.

The following chart shows the projected impact of changes in the area wage index values for urban and rural hospitals based on the wage data used for this final rule.

<table>
<thead>
<tr>
<th>FY 2024 Percentage Change in Area Wage Index Values</th>
<th>Number of Hospitals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase 10 percent or more</td>
<td>Urban 3</td>
</tr>
<tr>
<td>Increase greater than or equal to 5 percent and less than 10 percent</td>
<td>80</td>
</tr>
<tr>
<td>Increase or decrease less than 5 percent</td>
<td>2,226</td>
</tr>
<tr>
<td>Decrease greater than or equal to 5 percent and less than 10 percent</td>
<td>79</td>
</tr>
<tr>
<td>Decrease 10 percent or more</td>
<td>7</td>
</tr>
<tr>
<td>Unchanged</td>
<td>0</td>
</tr>
</tbody>
</table>
d. Effects of MGCRB Reclassifications (Column 4)

Our impact analysis to this point has assumed acute care hospitals are paid on the basis of their actual geographic location (with the exception of ongoing policies that provide that certain hospitals receive payments on bases other than where they are geographically located, such as hospitals with a § 412.103 reclassification). The changes in Column 4 reflect the per case payment impact of moving from this baseline to a simulation incorporating the MGCRB decisions for FY 2024.

By spring of each year, the MGCRB makes reclassification determinations that will be effective for the next fiscal year, which begins on October 1. The MGCRB may approve a hospital’s reclassification request for the purpose of using another area’s wage index value. Hospitals may appeal denials by the MGCRB of reclassification requests to the CMS Administrator. Further, hospitals have 45 days from the date the IPPS proposed rule is issued in the Federal Register to decide whether to withdraw or terminate an approved geographic reclassification for the following year.

As discussed in section III.G.1 of this final rule, this column also reflects the change to include hospitals with § 412.103 reclassification along with geographically rural hospitals in all wage index calculations, and to only exclude “dual reclass” hospitals (hospitals with simultaneous § 412.103 and MGCRB reclassifications) in accordance with the hold harmless provision at section 1886(d)(8)(C)(ii) of the Act. Consistent with this change, beginning with FY 2024, we are including the data of all § 412.103 hospitals (including those that have an MGCRB reclassification where appropriate) in the calculation of the “wage index for rural areas in the State in which the county is located,” as referred to in section 1886(d)(8)(C)(iii) of the Act.

The overall effect of geographic reclassification is required by section 1886(d)(8)(D) of the Act to be budget neutral. Therefore, for purposes of this impact analysis, we have used an adjustment of 0.971295 to ensure that the effects of the reclassifications under sections 1886(d)(8)(B) and (C) and 1886(d)(10) of the Act are budget neutral (section II.A. of the Addendum to this final rule).

Geographic reclassification generally benefits hospitals in rural areas. We estimate that the geographic reclassification would increase payments to rural hospitals by an average of 1.8 percent. By region, urban hospital categories would experience increases in payments due to MGCRB reclassifications.

Table 2 listed in section VI. of the Addendum to this final rule and available via the internet on the CMS website reflects the reclassifications for FY 2024.

e. Effects of the Rural Floor, Including Application of National Budget Neutrality (Column 5)

As discussed in section III.G.1. of the preamble of this FY 2024 IPPS/LTCH IPPS final rule, section 4410 of Pub. L. 105-33 established the rural floor by requiring that the wage index for a hospital in any urban area cannot be less than the wage index applicable to hospitals located in rural areas in the same state. We apply a uniform budget neutrality adjustment to the wage index. Column 5 shows the effects of the rural floor.

As discussed in section III.G.1 of this final rule, this column also reflects the change to include hospitals with § 412.103 reclassification along with geographically rural hospitals in all wage index calculations, and to only exclude “dual reclass” hospitals (hospitals with simultaneous § 412.103 and MGCRB reclassifications) in accordance with the hold harmless provision at section 1886(d)(8)(C)(ii) of the Act. Consistent with this change, beginning with FY 2024, we are including the data of all § 412.103 hospitals (including those that have an MGCRB reclassification where appropriate) in the calculation of the rural floor.

The Affordable Care Act requires that we apply one rural floor budget neutrality factor to the wage index nationally. We have calculated a FY 2024 rural floor budget neutrality factor to be applied to the wage index of 0.978183, which would reduce wage indexes by 2.2 percent compared to the rural floor provision not being in effect.

Column 5 shows the projected impact of the rural floor with the national rural floor budget neutrality factor applied to the wage index based on the OMB labor market area delineations and the projected impact of the change to the rural floor and rural wage index methodology. The column compares the post-reclassification FY 2024 wage index of providers before the rural floor adjustment and the post-reclassification FY 2024 wage index of providers with the rural floor adjustment based on the OMB labor market area delineations and with the change to the rural floor and the rural wage index methodology applied.

We estimate that 646 hospitals would receive the rural floor in FY 2024. All IPPS hospitals in our model would have their wage indexes reduced by the rural floor wage index neutrality adjustment of 0.978183. We project that, in aggregate, rural hospitals would experience a 0.6 percent decrease in payments as a result of the application of the rural floor budget neutrality adjustment because the rural hospitals do not benefit from the rural floor, but have their wage indexes downwardly adjusted to ensure that the application of the rural floor is budget neutral overall. We project that, in aggregate, hospitals located in urban areas would experience no change in payments, because increases in payments to hospitals benefitting from the rural floor offset decreases in payments to non-rural floor urban hospitals whose wage index is downwardly adjusted by the rural floor budget neutrality factor. Urban hospitals in the Pacific region would experience a 2.7 percent increase in payments primarily due to the application of the rural floor in California.

f. Effects of the Application of the Imputed Floor, Frontier State Wage Index and Out-Migration Adjustment (Column 6)

This column shows the combined effects of the application of the following: (1) the imputed floor used under section 1886(d)(3)(E)(iv)(I) and (II) of the Act, which provides for increases in payments occurring on or after October 1, 2021, to any rural hospital wage index applicable to any hospital in an all-urban State may not be less than the minimum area wage index for the fiscal year for hospitals in that State established using the methodology described in § 412.64(b)(4)(iv) in an effect for FY 2018; (2) section 10324(a) of the Affordable Care Act, which requires that we establish a minimum post-reclassified wage index of 1.00 for all hospitals located in “frontier States”; and (3) the effects of section 1886(d)(13) of the Act, which provides for an increase in the wage index for hospitals located in certain counties that have a relatively high percentage of hospital employees who reside in the county, but work in a different area with a higher wage index.

These three wage index provisions are not budget neutral and would increase payments overall by 0.4 percent compared to the provisions not being in effect.

Section 1886(d)(3)(E)(iv)(III) of the Act provides that the imputed floor wage index for all-urban States shall not be applied in a budget neutral manner. Therefore, the imputed floor adjustment is estimated to increase IPPS operating payments by approximately $230 million. There are an estimated 66 providers along with the imputed floor wage index of 1.0000. We note, the rural floor for Nevada exceeds the frontier state wage index of 1.00, and therefore no hospitals in Nevada receive the frontier state wage index. Overall, this provision is not budget neutral and is estimated to increase IPPS operating payments by approximately $60 million.

In addition, section 1886(d)(13) of the Act provides for an increase in the wage index for hospitals located in certain counties that have a relatively high percentage of hospital employees who reside in the county but work in a different area with a higher wage index. Hospitals located in counties that qualify for the payment adjustment would receive an increase in the wage index that is equal to a weighted average of the difference between the wage index of the hospital prior to post-reclassification and the higher wage index work area(s), weighted by the overall percentage of workers who are employed in an area with a higher wage index. There are an estimated 173 providers that would receive the out-migration wage adjustment in FY 2024. This out-migration wage adjustment
is not budget neutral, and we estimate the impact of these providers receiving the out-migration increase would be approximately $52 million.

g. Effects of All FY 2024 Changes (Column 7)

Column 7 shows our estimate of the changes in payments per discharge from FY 2023 and FY 2024, resulting from all changes reflected in this final rule for FY 2024. It includes combined effects of the year-to-year change of the previous columns in the table.

The average increase in payments under the IPPS for all hospitals is approximately 3.1 percent for FY 2024 relative to FY 2023 and for this row is primarily driven by the changes reflected in Column 1. Column 7 includes the annual hospital update of 3.1 percent to the national standardized amount. This annual hospital update includes the 3.3 percent market basket rate-of-increase reduced by the 0.2 percentage point productivity adjustment. Hospitals paid under the hospital-specific rate would receive a 3.1 percent hospital update. As described in Column 1, the annual hospital update for hospitals paid under the national standardized amount, combined with the annual hospital update for hospitals paid under the hospital-specific rates, combined with the other adjustments described previously and shown in Table I, would result in a 3.1 percent increase in payments in FY 2024 relative to FY 2023.

This column also reflects the estimated effect of outlier payments returning to their targeted levels in FY 2024 as compared to the estimated outlier payments for FY 2023 produced from our payment simulation model. As discussed in section II.A.4.j. of the Addendum to this final rule, the statute requires that outlier payments for any year are projected to be not less than 5 percent nor more than 6 percent of total operating DRG payments plus outlier payments, and also requires that the average standardized amount be reduced by a factor to account for the estimated proportion of total DRG payments made to outlier cases. We continue to use a 5.1 percent target (or an outlier offset factor of 0.949) in calculating the outlier offset to the standardized amount, just as we did for FY 2023. Therefore, our estimate of payments per discharge for FY 2024 from our payment simulation model reflects this 5.1 percent outlier payment target. Our payment simulation model shows that estimated outlier payments for FY 2023 exceed that target by approximately 0.3 percent. Therefore, our estimate of the changes in payments per discharge from FY 2023 and FY 2024 in Column 7 reflects the estimated – 0.3 percent change in outlier payments produced by our payment simulation model when returning to the 5.1 percent outlier target for FY 2024. There are also interactive effects among the various factors comprising the payment system that we are not able to isolate, which may contribute to our estimate of the changes in payments per discharge from FY 2023 and FY 2024 in Column 7.

Overall payments to hospitals paid under the IPPS due to the applicable percentage increase and changes to policies related to MS–DRGs, geographic adjustments, and outliers are estimated to increase by 3.1 percent for FY 2024. Hospitals in urban areas would experience a 3.1 percent increase in payments per discharge in FY 2024 compared to FY 2023. Hospital payments per discharge in rural areas are estimated to increase by 3.5 percent in FY 2024.

3. Impact Analysis of Table II

Table II presents the projected impact of the changes for FY 2024 for urban and rural hospitals and for the different categories of hospitals shown in Table I. It compares the estimated average payments per discharge for FY 2024 with the estimated average payments per discharge for FY 2023, as calculated under our models. Therefore, this table presents, in terms of the average dollar amounts paid per discharge, the combined effects of the changes presented in Table I. The estimated percentage changes shown in the last column of Table II equal the estimated percentage changes in average payments per discharge from Column 7 of Table I.
## TABLE II.--IMPACT ANALYSIS OF CHANGES FOR FY 2024 ACUTE CARE HOSPITAL OPERATING PROSPECTIVE PAYMENT SYSTEM (PAYMENTS PER DISCHARGE)

<table>
<thead>
<tr>
<th></th>
<th>Number of Hospitals (1)</th>
<th>Estimated Average FY 2023 Payment Per Discharge (2)</th>
<th>Estimated Average FY 2024 Payment Per Discharge (3)</th>
<th>FY 2024 Changes (4)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All Hospitals</strong></td>
<td>3,131</td>
<td>15,741</td>
<td>16,226</td>
<td>3.1</td>
</tr>
<tr>
<td><strong>By Geographic Location:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban hospitals</td>
<td>2,416</td>
<td>16,127</td>
<td>16,619</td>
<td>3.1</td>
</tr>
<tr>
<td>Rural hospitals</td>
<td>715</td>
<td>11,736</td>
<td>12,144</td>
<td>3.5</td>
</tr>
<tr>
<td><strong>Bed Size (Urban):</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-99 beds</td>
<td>650</td>
<td>12,051</td>
<td>12,355</td>
<td>2.5</td>
</tr>
<tr>
<td>100-199 beds</td>
<td>696</td>
<td>12,843</td>
<td>13,254</td>
<td>3.2</td>
</tr>
<tr>
<td>200-299 beds</td>
<td>414</td>
<td>14,388</td>
<td>14,871</td>
<td>3.4</td>
</tr>
<tr>
<td>300-499 beds</td>
<td>404</td>
<td>15,896</td>
<td>16,498</td>
<td>3.8</td>
</tr>
<tr>
<td>500 or more beds</td>
<td>250</td>
<td>20,094</td>
<td>20,578</td>
<td>2.4</td>
</tr>
<tr>
<td><strong>Bed Size (Rural):</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-99 beds</td>
<td>363</td>
<td>9,901</td>
<td>10,212</td>
<td>3.1</td>
</tr>
<tr>
<td>50-99 beds</td>
<td>188</td>
<td>11,569</td>
<td>12,030</td>
<td>4.0</td>
</tr>
<tr>
<td>100-149 beds</td>
<td>87</td>
<td>11,371</td>
<td>11,790</td>
<td>3.7</td>
</tr>
<tr>
<td>150-199 beds</td>
<td>46</td>
<td>12,690</td>
<td>13,096</td>
<td>3.2</td>
</tr>
<tr>
<td>200 or more beds</td>
<td>31</td>
<td>13,853</td>
<td>14,285</td>
<td>3.1</td>
</tr>
<tr>
<td><strong>Urban by Region:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New England</td>
<td>108</td>
<td>17,955</td>
<td>18,041</td>
<td>0.5</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>292</td>
<td>18,824</td>
<td>19,553</td>
<td>3.9</td>
</tr>
<tr>
<td>East North Central</td>
<td>372</td>
<td>15,377</td>
<td>15,560</td>
<td>1.2</td>
</tr>
<tr>
<td>West North Central</td>
<td>156</td>
<td>15,447</td>
<td>15,642</td>
<td>1.3</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>403</td>
<td>13,823</td>
<td>14,280</td>
<td>3.3</td>
</tr>
<tr>
<td>East South Central</td>
<td>138</td>
<td>13,363</td>
<td>13,657</td>
<td>2.2</td>
</tr>
<tr>
<td>West South Central</td>
<td>359</td>
<td>14,105</td>
<td>14,337</td>
<td>1.6</td>
</tr>
<tr>
<td>Mountain</td>
<td>177</td>
<td>16,223</td>
<td>16,729</td>
<td>3.1</td>
</tr>
<tr>
<td>Pacific</td>
<td>360</td>
<td>20,337</td>
<td>21,644</td>
<td>6.4</td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>51</td>
<td>9,146</td>
<td>9,318</td>
<td>1.9</td>
</tr>
<tr>
<td><strong>Rural by Region:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New England</td>
<td>19</td>
<td>17,495</td>
<td>17,840</td>
<td>2.0</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>47</td>
<td>11,703</td>
<td>12,551</td>
<td>7.2</td>
</tr>
<tr>
<td>Region</td>
<td>Number of Hospitals (1)</td>
<td>Estimated Average FY 2023 Payment Per Discharge (2)</td>
<td>Estimated Average FY 2024 Payment Per Discharge (3)</td>
<td>FY 2024 Changes (4)</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-------------------------</td>
<td>-----------------------------------------------------</td>
<td>-----------------------------------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>East North Central</td>
<td>113</td>
<td>11,904</td>
<td>12,250</td>
<td>2.9</td>
</tr>
<tr>
<td>West North Central</td>
<td>84</td>
<td>12,168</td>
<td>12,549</td>
<td>3.1</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>108</td>
<td>10,759</td>
<td>11,126</td>
<td>3.4</td>
</tr>
<tr>
<td>East South Central</td>
<td>140</td>
<td>10,501</td>
<td>10,830</td>
<td>3.1</td>
</tr>
<tr>
<td>West South Central</td>
<td>134</td>
<td>9,808</td>
<td>10,108</td>
<td>3.1</td>
</tr>
<tr>
<td>Mountain</td>
<td>46</td>
<td>13,806</td>
<td>14,160</td>
<td>2.6</td>
</tr>
<tr>
<td>Pacific</td>
<td>24</td>
<td>16,169</td>
<td>17,039</td>
<td>5.4</td>
</tr>
</tbody>
</table>

**By Payment Classification:**

<table>
<thead>
<tr>
<th></th>
<th>Number of Hospitals (1)</th>
<th>Estimated Average FY 2023 Payment Per Discharge (2)</th>
<th>Estimated Average FY 2024 Payment Per Discharge (3)</th>
<th>FY 2024 Changes (4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urban hospitals</td>
<td>1,811</td>
<td>14,687</td>
<td>15,176</td>
<td>3.3</td>
</tr>
<tr>
<td>Rural areas</td>
<td>1,320</td>
<td>16,977</td>
<td>17,456</td>
<td>2.8</td>
</tr>
</tbody>
</table>

**Teaching Status:**

<table>
<thead>
<tr>
<th></th>
<th>Number of Hospitals (1)</th>
<th>Estimated Average FY 2023 Payment Per Discharge (2)</th>
<th>Estimated Average FY 2024 Payment Per Discharge (3)</th>
<th>FY 2024 Changes (4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonteaching</td>
<td>1,900</td>
<td>12,201</td>
<td>12,633</td>
<td>3.5</td>
</tr>
<tr>
<td>Fewer than 100 residents</td>
<td>953</td>
<td>14,464</td>
<td>14,929</td>
<td>3.2</td>
</tr>
<tr>
<td>100 or more residents</td>
<td>278</td>
<td>23,163</td>
<td>23,757</td>
<td>2.6</td>
</tr>
</tbody>
</table>

**Urban DSH:**

<table>
<thead>
<tr>
<th></th>
<th>Number of Hospitals (1)</th>
<th>Estimated Average FY 2023 Payment Per Discharge (2)</th>
<th>Estimated Average FY 2024 Payment Per Discharge (3)</th>
<th>FY 2024 Changes (4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-DHS</td>
<td>355</td>
<td>12,630</td>
<td>12,886</td>
<td>2.0</td>
</tr>
<tr>
<td>100 or more beds</td>
<td>1,099</td>
<td>15,218</td>
<td>15,750</td>
<td>3.5</td>
</tr>
<tr>
<td>Less than 100 beds</td>
<td>359</td>
<td>11,052</td>
<td>11,393</td>
<td>3.1</td>
</tr>
</tbody>
</table>

**Rural DSH:**

<table>
<thead>
<tr>
<th></th>
<th>Number of Hospitals (1)</th>
<th>Estimated Average FY 2023 Payment Per Discharge (2)</th>
<th>Estimated Average FY 2024 Payment Per Discharge (3)</th>
<th>FY 2024 Changes (4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-DSH</td>
<td>108</td>
<td>15,340</td>
<td>15,687</td>
<td>2.3</td>
</tr>
<tr>
<td>SCH</td>
<td>257</td>
<td>12,903</td>
<td>13,345</td>
<td>3.4</td>
</tr>
<tr>
<td>RRC</td>
<td>712</td>
<td>17,607</td>
<td>18,093</td>
<td>2.8</td>
</tr>
<tr>
<td>100 or more beds</td>
<td>32</td>
<td>17,548</td>
<td>18,189</td>
<td>3.7</td>
</tr>
<tr>
<td>Less than 100 beds</td>
<td>211</td>
<td>9,629</td>
<td>10,000</td>
<td>3.9</td>
</tr>
</tbody>
</table>

**Urban teaching and DSH:**

<table>
<thead>
<tr>
<th></th>
<th>Number of Hospitals (1)</th>
<th>Estimated Average FY 2023 Payment Per Discharge (2)</th>
<th>Estimated Average FY 2024 Payment Per Discharge (3)</th>
<th>FY 2024 Changes (4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Both teaching and DSH</td>
<td>637</td>
<td>16,590</td>
<td>17,121</td>
<td>3.2</td>
</tr>
<tr>
<td>Teaching and no DSH</td>
<td>57</td>
<td>13,880</td>
<td>14,219</td>
<td>2.4</td>
</tr>
<tr>
<td>No teaching and DSH</td>
<td>821</td>
<td>12,258</td>
<td>12,859</td>
<td>4.1</td>
</tr>
<tr>
<td>No teaching and no DSH</td>
<td>296</td>
<td>11,947</td>
<td>12,157</td>
<td>1.8</td>
</tr>
</tbody>
</table>

**Special Hospital Types:**

<table>
<thead>
<tr>
<th></th>
<th>Number of Hospitals (1)</th>
<th>Estimated Average FY 2023 Payment Per Discharge (2)</th>
<th>Estimated Average FY 2024 Payment Per Discharge (3)</th>
<th>FY 2024 Changes (4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RRC</td>
<td>133</td>
<td>12,423</td>
<td>12,804</td>
<td>3.1</td>
</tr>
<tr>
<td>RRC with Section 401 Rural Reclassification</td>
<td>491</td>
<td>18,490</td>
<td>18,981</td>
<td>2.7</td>
</tr>
<tr>
<td>SCH</td>
<td>256</td>
<td>12,156</td>
<td>12,561</td>
<td>3.3</td>
</tr>
<tr>
<td>SCH with Section 401 Rural Reclassification</td>
<td>45</td>
<td>15,004</td>
<td>15,516</td>
<td>3.4</td>
</tr>
<tr>
<td>SCH and RRC</td>
<td>121</td>
<td>13,819</td>
<td>14,286</td>
<td>3.4</td>
</tr>
<tr>
<td>SCH and RRC with Section 401 Rural Reclassification</td>
<td>43</td>
<td>16,466</td>
<td>16,944</td>
<td>2.9</td>
</tr>
<tr>
<td>MDH</td>
<td>116</td>
<td>10,065</td>
<td>10,431</td>
<td>3.6</td>
</tr>
<tr>
<td>MDH with Section 401 Reclassification</td>
<td>30</td>
<td>12,929</td>
<td>13,410</td>
<td>3.7</td>
</tr>
<tr>
<td>MDH and RRC</td>
<td>18</td>
<td>11,080</td>
<td>11,469</td>
<td>3.5</td>
</tr>
<tr>
<td>MDH and RRC with Section 401 Reclassification</td>
<td>13</td>
<td>13,926</td>
<td>14,385</td>
<td>3.3</td>
</tr>
</tbody>
</table>

**Type of Ownership:**

<table>
<thead>
<tr>
<th></th>
<th>Number of Hospitals (1)</th>
<th>Estimated Average FY 2023 Payment Per Discharge (2)</th>
<th>Estimated Average FY 2024 Payment Per Discharge (3)</th>
<th>FY 2024 Changes (4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Voluntary</td>
<td>1,920</td>
<td>15,799</td>
<td>16,266</td>
<td>3.0</td>
</tr>
<tr>
<td>Proprietary</td>
<td>778</td>
<td>13,749</td>
<td>14,266</td>
<td>3.8</td>
</tr>
<tr>
<td>Government</td>
<td>452</td>
<td>18,052</td>
<td>18,602</td>
<td>3.0</td>
</tr>
</tbody>
</table>

**Medicare Utilization as a Percent of Inpatient Days:**

<table>
<thead>
<tr>
<th></th>
<th>Number of Hospitals (1)</th>
<th>Estimated Average FY 2023 Payment Per Discharge (2)</th>
<th>Estimated Average FY 2024 Payment Per Discharge (3)</th>
<th>FY 2024 Changes (4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-25</td>
<td>995</td>
<td>17,920</td>
<td>18,568</td>
<td>3.6</td>
</tr>
<tr>
<td>25-50</td>
<td>1,945</td>
<td>14,967</td>
<td>15,385</td>
<td>2.8</td>
</tr>
<tr>
<td>50-65</td>
<td>138</td>
<td>12,459</td>
<td>12,895</td>
<td>3.5</td>
</tr>
<tr>
<td>Over 65</td>
<td>25</td>
<td>8,593</td>
<td>8,950</td>
<td>4.1</td>
</tr>
</tbody>
</table>

**Medicaid Utilization as a Percent of Inpatient Days:**

<table>
<thead>
<tr>
<th></th>
<th>Number of Hospitals (1)</th>
<th>Estimated Average FY 2023 Payment Per Discharge (2)</th>
<th>Estimated Average FY 2024 Payment Per Discharge (3)</th>
<th>FY 2024 Changes (4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-25</td>
<td>2,038</td>
<td>14,256</td>
<td>14,635</td>
<td>2.7</td>
</tr>
<tr>
<td>25-50</td>
<td>974</td>
<td>18,011</td>
<td>18,629</td>
<td>3.4</td>
</tr>
<tr>
<td>50-65</td>
<td>91</td>
<td>21,156</td>
<td>22,514</td>
<td>6.4</td>
</tr>
<tr>
<td>Over 65</td>
<td>28</td>
<td>19,730</td>
<td>22,029</td>
<td>11.7</td>
</tr>
</tbody>
</table>

**FY 2024 Reclassifications:**

<table>
<thead>
<tr>
<th></th>
<th>Number of Hospitals (1)</th>
<th>Estimated Average FY 2023 Payment Per Discharge (2)</th>
<th>Estimated Average FY 2024 Payment Per Discharge (3)</th>
<th>FY 2024 Changes (4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Reclassified Hospitals</td>
<td>1,054</td>
<td>16,846</td>
<td>17,340</td>
<td>2.9</td>
</tr>
<tr>
<td>Non-Reclassified Hospitals</td>
<td>2,077</td>
<td>14,731</td>
<td>15,207</td>
<td>3.2</td>
</tr>
<tr>
<td>Urban Hospitals Reclassified</td>
<td>869</td>
<td>17,458</td>
<td>17,969</td>
<td>2.9</td>
</tr>
<tr>
<td>Urban Nonreclassified Hospitals</td>
<td>1,561</td>
<td>14,794</td>
<td>15,268</td>
<td>3.2</td>
</tr>
<tr>
<td>Rural Hospitals Reclassified Full Year</td>
<td>298</td>
<td>11,792</td>
<td>12,185</td>
<td>3.3</td>
</tr>
<tr>
<td>Rural Non-Reclassified Hospitals Full Year</td>
<td>403</td>
<td>11,652</td>
<td>12,085</td>
<td>3.7</td>
</tr>
<tr>
<td>All Section 401 Reclassified Hospitals</td>
<td>659</td>
<td>18,109</td>
<td>18,604</td>
<td>2.7</td>
</tr>
</tbody>
</table>
4. Impact Analysis of Table III: Provider Deciles by Beneficiary Characteristics

Advancing health equity is the first pillar of CMS’s 2022 Strategic Framework. To gain insight into how the IPPS policies could affect health equity, we have added Table III, Provider Deciles by Beneficiary Characteristics, for informational purposes.

Table III details providers in terms of the beneficiaries they serve, and shows differences in estimated average payments per case and changes in estimated average payments per case relative to other providers. As noted in Section I.C of this approach, this final rule contains a range of policies and there is a section of the final rule where each policy is discussed. Each section includes the rationale for our decisions, including the need for the final policy. The information contained in Table III is provided solely to demonstrate the quantitative effects of our policies across a number of health equity dimensions and does not form the basis or rationale for the policies.

Patient populations that have been disadvantaged or underserved by the healthcare system may include patients with the following characteristics, among others: members of racial and ethnic minorities; members of federally recognized Tribes, people with disabilities; members of the lesbian, gay, bisexual, transgender, and queer (LGBTQ+) community; individuals with limited English proficiency, members of rural communities, and persons otherwise adversely affected by persistent poverty or inequality. The CMS Framework for Health Equity was developed with particular attention to disparities in chronic and infectious diseases; as an example of a chronic disease associated with significant disparities, we therefore also detail providers in terms of the percentage of their claims for beneficiaries receiving ESRD Medicare coverage.

Because we do not have data for all characteristics that may identify disadvantaged or underserved patient populations, we use several proxies to capture these characteristics, based on claims data from the FY 2022 MedPAR file and Medicare enrollment data from Medicare’s Enrollment Database (EDB), including: race/ethnicity, dual eligibility for Medicaid and Medicare, Medicare low income subsidy (LIS) enrollment, a joint indicator for dual or LIS enrollment, presence of an ICD–10–CM Z code designation for ICD–10–CM diagnosis codes that capture screening and identification of patient-level, health-related social needs (MUC21–134 and MUC21–136) (see 87 FR 49201 through 49220). We also refer the reader to section II.C.12.c. of the preamble of this final rule, where we discuss our final policy to change the severity level designation for ICD–10–CM diagnosis codes Z59.00 (Homelessness or migration), Z59.01 (Sheltered homelessness) and Z59.02 (Unsheltered homelessness) from a non-CC to a CC for FY 2024.

A reader to section II.C.12.c. of the preamble of this final rule, where we discuss our final policy to change the severity level designation for ICD–10–CM diagnosis codes Z59.00 (Homelessness or migration), Z59.01 (Sheltered homelessness) and Z59.02 (Unsheltered homelessness) from a non-CC to a CC for FY 2024.

### Table III: Provider Deciles by Beneficiary Characteristics

<table>
<thead>
<tr>
<th>Number of Hospitals (1)</th>
<th>Estimated Average FY 2023 Payment Per Discharge (2)</th>
<th>Estimated Average FY 2024 Payment Per Discharge (3)</th>
<th>FY 2024 Changes (4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>54</td>
<td>11,086</td>
<td>11,518</td>
<td>3.9</td>
</tr>
</tbody>
</table>

Other Reclassified Hospitals (Section 1886(d)(8)(B))

living in an area with an area deprivation index (ADI) greater than or equal to 85. We refer to each of these proxies as characteristics in Table III and the discussion that follows.

- **Race**
  - The first health equity-relevant grouping presented in Table III is race/ethnicity. To assign the race/ethnicity variables used in Table III, we utilized the Medicare Bayesian Improved Surname Geocoding (MBISG) data in conjunction with the MedPAR data. The method used to develop the MBISG data involves estimating a set of six racial and ethnic probabilities (White, Black, Hispanic, American Indian or Alaskan Native, Asian or Pacific Islander, and multiracial) from the surname and address of beneficiaries by using previous self-reported data from a national survey of Medicare beneficiaries, post-stratified to CMS enrollment files. The MBISG method is used by the CMS Office of Minority Health in its reports analyzing Medicare Advantage plan performance on Healthcare Effectiveness Data and Information Set (HEDIS) measures, and is being considered by CMS for use in other CMS programs. To estimate the percentage of discharges for each specified racial/ethnic category for each hospital, the sum of the probabilities for that category for that hospital was divided by the hospital’s total number of discharges.

- **Income**
  - The two main proxies for income available in the Medicare claims and enrollment data are dual eligibility for Medicare and Medicaid and Medicare LIS status. Dual-enrollment status is a powerful predictor of poor outcomes on some quality and resource use measures even after accounting for additional social and functional risk factors. Medicare LIS enrollment refers to a beneficiary’s enrollment in the low-income subsidy program for the Part D prescription drug benefit. This program covers all or part of the Part D premium for qualifying Medicare beneficiaries and gives them access to reduced copays for Part D drugs. (We note that beginning on January 1, 2024, eligibility for the full low-income subsidy will be expanded to include individuals currently eligible for the partial low-income subsidy.) Because Medicare eligibility rules and benefits vary by state/territory, Medicare LIS enrollment identifies beneficiaries who are likely to have low income but may not be eligible for Medicaid. Not all beneficiaries who qualify for the duals or LIS programs actually enroll. Due to differences in the dual eligibility and LIS qualification criteria and less than complete participation in these programs, sometimes beneficiaries were flagged as dual but not LIS or vice versa. Hence this analysis also used a “dual or LIS” flag as a third proxy for low income. The dual and LIS flags were constructed based on enrollment/eligibility status in the EDB during the month of the hospital discharge.

- **Social Determinants of Health (SDOH)**
  - Social determinants of health (SDOH) are the conditions in the environments where people are born, live, learn, work, play, worship, and age that affect a wide range of health, functioning, and quality-of-life outcomes and risks. These circumstances or determinants influence an individual’s health status and can contribute to wide health disparities and inequities. ICD–10–CM contains Z-codes that describe a range of issues related—but not limited—to education and literacy, employment, housing, ability to obtain adequate amounts of food or safe drinking water, and occupational exposure to toxic agents, dust, or radiation. The presence of ICD–10–CM Z-codes in the range Z55–Z65 identifies beneficiaries with these SDOH characteristics. The SDOH flag used for this analysis was turned on if one of these Z-codes was recorded on the claim for the hospital stay itself (that is, the beneficiary’s prior claims were not examined for additional Z-codes). Since these codes are not required for Medicare FFS patients and do not currently impact payment under the IPPS, we believe they may be underreported in current claims data and not reflect the actual rates of SDOH. In 2019, 0.11% of all Medicare FFS claims were Z code claims and 1.59% of continuously enrolled Medicare FFS beneficiaries had claims with Z codes. However, we expect the reporting of Z codes on claims may increase over time, because of newer quality measures in the Hospital Inpatient Quality Reporting (IQR) Program that capture screening and identification of patient-level, health-related social needs (MUC21–134 and MUC21–136) (see 87 FR 49201 through 49220). We also refer the reader to section II.C.12.c. of the preamble of this final rule, where we discuss our final policy to change the severity level designation for ICD–10–CM diagnosis codes Z59.00 (Homelessness or migration), Z59.01 (Sheltered homelessness) and Z59.02 (Unsheltered homelessness) from a non-CC to a CC for FY 2024.

1 Available at: https://health.gov/healthypeople/priority-areas/social-determinants-health.
d. Behavioral Health

Beneficiaries with behavioral health diagnoses often face co-occurring physical illnesses, but often experience difficulty accessing care. The combination of physical and behavioral health conditions can exacerbate both conditions and result in poorer outcomes than one condition alone. Additionally, the intersection of behavioral health and health inequities is a core aspect of CMS’ Behavioral Health Strategy. We used the presence of one or more ICD–10–CM codes in the range of F01–F99 to identify beneficiaries with a behavioral health diagnosis.

f. ESRD

Beneficiaries with ESRD have high healthcare needs and high medical spending, and often experience comorbid conditions and poor mental health. Beneficiaries with ESRD also experience significant disparities, such as a limited life expectancy. Beneficiaries were classified as ESRD for the purposes of this analysis if they were receiving Medicare ESRD coverage during the month of the discharge; this information was obtained from Medicare’s EDB.

g. Geography

Beneficiaries in some geographic areas—particularly rural areas or areas with concentrated poverty—often have difficulty accessing care. For this impact analysis, beneficiaries were classified on two dimensions: from a rural area and from an area with an area deprivation index (ADI) greater than or equal to 85. Rural status is defined for purposes of this analysis using the primary Rural-Urban Community Area (RUMA) codes 4–10 (including micropolitan, small town, and rural areas) corresponding to each beneficiary’s zip code. RUCA codes are defined at the census tract level based on measures of population density, urbanization, crime, and housing. The ADI is obtained from a publicly available dataset designed to capture socioeconomic disadvantage at the neighborhood level. It utilizes data on income, education, employment, housing quality, and 13 other factors from the American Community Survey and combines them into a single raw score, which is then used to rank neighborhoods (defined at various levels), with higher scores reflecting greater deprivation. The version of the ADI used for this analysis is the Census Block Group level and the ADI corresponds to the Census Block Group’s percentile nationally. Living in an area with an ADI score of 85 or above, a validated measure of neighborhood disadvantage, is shown to be a predictor of 30-day readmissions, lower rates of colon cancer, poor end of life care for patients with heart failure, and longer lengths of stay and fewer home discharges post-knee surgery even after accounting for individual and economic risk factors.

For the purposes of this analysis, if their original reason for qualifying for Medicare was disability; this information was obtained from Medicare’s EDB. We note that this is unlikely to exaggerate the duration of disability because it does not account for beneficiaries who became disabled after becoming entitled to Medicare. This metric also does not capture all individuals who would be considered to have a disability under 29 U.S.C. 705(9)(B).


National Healthcare Quality and Disparities Report chartbook on rural health care. Rockville, MD: Agency for Healthcare Research and Quality; the MedPAR discharge data was linked to the RUCA using beneficiaries’ five-digit zip code and to the ADI data using beneficiaries’ 9-digit zip codes, both of which were derived from Common Medicare Enrollment (CME) files. Beneficiaries with no recorded zip code were treated as living from an urban area and as having an ADI less than 85. For each of these characteristics, the hospitals were classified into groups as follows. First, all discharges at IPPS hospitals (excluding Maryland and IHS hospitals) in the FY 2022 MedPAR file were flagged for the presence of the characteristic, with the exception of race/ethnicity, for which probabilities were assigned instead of binary flags, as described further in this section.

Second, the percentage of discharges at each hospital for the characteristic was calculated. Finally, the hospitals were divided into four groups based on the percentage of discharges for each characteristic: decile group 1 contains the 10% of hospitals with the lowest rate of discharges for that characteristic; decile group 2 to 5 contains the hospitals with less than or equal to the median rate of discharges for that characteristic, excluding those in decile group 1; decile group 6 to 9 contains the hospitals with greater than the median rate of discharges for that characteristic, excluding those in decile group 10; and decile group 10 contains the 10% of hospitals with the highest rate of discharges for that characteristic. These decile groups provide an overview of the ways in which the average estimated payments per discharge vary between the providers with the lowest and the highest percentages of discharges for each characteristic, as well as those above and below the median.

We note that a supplementary provider-level dataset containing the percentage of discharges at each hospital for each of the characteristics in Table III is available on our website.

Columns 1 of Table III specifies the beneficiary characteristic.

Column 2 specifies the decile group.

Column 3 specifies the percentiles covered by the decile grouping.

Column 4 specifies the percentage range of discharges for each decile group specified in the first column.

Columns 5 and 6 present the average estimated payments per discharge for FY 2023 and average estimated payments per discharge for FY 2024, respectively.

Column 7 shows the percentage difference between these averages. The average payment per discharge, as well as the percentage difference between the average payment per discharge in FY 2023 and FY 2024, can be compared across decile groups. For example, providers with the lowest decile of discharges for Dual(All) or LIS Enrolled beneficiaries have an average FY 2023 payment per discharge of $1,500.03, while providers with the highest decile of discharges for Dual(All) or LIS Enrolled beneficiaries have an average FY 2023 payment per discharge of $19,779.23.

This pattern is also seen in the average FY 2024 payment per discharge.

*Comment:* A few commenters supported the addition of the 15 new health equity hospital categorizations as presented in the proposed rule.

*Response:* We appreciate commenters’ support. We are providing an updated Table III using the more recent data available for this final rule.
<table>
<thead>
<tr>
<th>Beneficiary Characteristics</th>
<th>Decile Group*</th>
<th>Percentile Range of Group</th>
<th>Decile Value Range</th>
<th>Average Payment Per Discharge - FY 2023</th>
<th>Average Payment Per Discharge - FY 2024</th>
<th>Percent Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(1)</td>
<td>(2)</td>
<td>(3)</td>
<td>(4)</td>
<td>(5)</td>
<td>(6)</td>
</tr>
<tr>
<td>All Hospitals</td>
<td></td>
<td></td>
<td></td>
<td>15,741.05</td>
<td>16,225.71</td>
<td>3.1%</td>
</tr>
<tr>
<td>% Of Discharges for Beneficiaries Who Are American Indian or Alaska Native</td>
<td></td>
<td>1</td>
<td>0 to 10</td>
<td>0.1% - 0.2%</td>
<td>12,244.26</td>
<td>12,473.69</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 to 5</td>
<td>&gt;10 to 50</td>
<td>0.2% - 0.3%</td>
<td>15,144.88</td>
<td>15,519.39</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6 to 9</td>
<td>&gt;50 to 90</td>
<td>0.3% - 1.3%</td>
<td>17,095.17</td>
<td>17,754.18</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10</td>
<td>&gt;90 to 100</td>
<td>1.3% - 48.6%</td>
<td>15,487.81</td>
<td>15,974.98</td>
</tr>
<tr>
<td>% Of Discharges for Beneficiaries Who Are Asian or Pacific Islander</td>
<td></td>
<td>1</td>
<td>0 to 10</td>
<td>0.0% - 0.2%</td>
<td>10,391.59</td>
<td>10,687.12</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 to 5</td>
<td>&gt;10 to 50</td>
<td>0.2% - 0.8%</td>
<td>12,895.49</td>
<td>13,257.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6 to 9</td>
<td>&gt;50 to 90</td>
<td>0.8% - 4.9%</td>
<td>16,411.50</td>
<td>16,853.16</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10</td>
<td>&gt;90 to 100</td>
<td>4.9% - 95.1%</td>
<td>21,502.44</td>
<td>22,538.97</td>
</tr>
<tr>
<td>% Of Discharges for Beneficiaries Who Are Black</td>
<td></td>
<td>1</td>
<td>0 to 10</td>
<td>0.0% - 0.4%</td>
<td>13,055.75</td>
<td>13,376.97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 to 5</td>
<td>&gt;10 to 50</td>
<td>0.4% - 4.3%</td>
<td>14,424.23</td>
<td>14,891.48</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6 to 9</td>
<td>&gt;50 to 90</td>
<td>4.3% - 24.4%</td>
<td>16,460.05</td>
<td>16,972.70</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10</td>
<td>&gt;90 to 100</td>
<td>24.4% - 95.9%</td>
<td>18,430.40</td>
<td>18,895.95</td>
</tr>
<tr>
<td>% Of Discharges for Beneficiaries Who Are Hispanic</td>
<td></td>
<td>1</td>
<td>0 to 10</td>
<td>0.3% - 1.1%</td>
<td>12,163.17</td>
<td>12,515.36</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 to 5</td>
<td>&gt;10 to 50</td>
<td>1.1% - 2.6%</td>
<td>13,955.81</td>
<td>14,269.57</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6 to 9</td>
<td>&gt;50 to 90</td>
<td>2.6% - 21.0%</td>
<td>17,154.62</td>
<td>17,689.06</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10</td>
<td>&gt;90 to 100</td>
<td>21.0% - 98.5%</td>
<td>18,050.92</td>
<td>19,254.78</td>
</tr>
<tr>
<td>Beneficiary Characteristics (1)</td>
<td>Decile Group* (2)</td>
<td>Percentile Range of Group (3)</td>
<td>Decile Value Range (4)</td>
<td>Average Payment Per Discharge - FY 2023 (5)</td>
<td>Average Payment Per Discharge - FY 2024 (6)</td>
<td>Percent Change (7)</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-------------------</td>
<td>-----------------------------</td>
<td>------------------------</td>
<td>------------------------------------------</td>
<td>------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>% Of Discharges for Beneficiaries Who Are Multiracial</td>
<td>1</td>
<td>0 to 10</td>
<td>0.1% - 1.5%</td>
<td>13,462.81</td>
<td>13,909.00</td>
<td>3.3%</td>
</tr>
<tr>
<td></td>
<td>2 to 5</td>
<td>&gt;10 to 50</td>
<td>1.5% - 2.1%</td>
<td>15,229.28</td>
<td>15,669.77</td>
<td>2.9%</td>
</tr>
<tr>
<td></td>
<td>6 to 9</td>
<td>&gt;50 to 90</td>
<td>2.1% - 3.1%</td>
<td>16,460.05</td>
<td>16,981.96</td>
<td>3.2%</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>&gt;90 to 100</td>
<td>3.1% - 10.5%</td>
<td>16,923.21</td>
<td>17,499.33</td>
<td>3.4%</td>
</tr>
<tr>
<td>% Of Discharges for Beneficiaries Who Are White</td>
<td>1</td>
<td>0 to 10</td>
<td>0.1% - 45.9%</td>
<td>20,281.36</td>
<td>21,244.51</td>
<td>4.7%</td>
</tr>
<tr>
<td></td>
<td>2 to 5</td>
<td>&gt;10 to 50</td>
<td>45.9% - 84.8%</td>
<td>17,142.48</td>
<td>17,657.02</td>
<td>3.0%</td>
</tr>
<tr>
<td></td>
<td>6 to 9</td>
<td>&gt;50 to 90</td>
<td>84.8% - 95.0%</td>
<td>13,832.43</td>
<td>14,231.39</td>
<td>2.9%</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>&gt;90 to 100</td>
<td>95.0% - 98.2%</td>
<td>11,680.89</td>
<td>11,994.14</td>
<td>2.7%</td>
</tr>
<tr>
<td>% Of Discharges for Beneficiaries Who Are Dual(All) Enrolled During The Month Of Discharge</td>
<td>1</td>
<td>0 to 10</td>
<td>0.0% - 11.2%</td>
<td>13,498.58</td>
<td>13,767.90</td>
<td>2.0%</td>
</tr>
<tr>
<td></td>
<td>2 to 5</td>
<td>&gt;10 to 50</td>
<td>11.2% - 25.8%</td>
<td>14,551.16</td>
<td>14,899.75</td>
<td>2.4%</td>
</tr>
<tr>
<td></td>
<td>6 to 9</td>
<td>&gt;50 to 90</td>
<td>25.8% - 50.1%</td>
<td>17,042.97</td>
<td>17,633.84</td>
<td>3.5%</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>&gt;90 to 100</td>
<td>50.1% - 100.0%</td>
<td>20,031.32</td>
<td>21,241.33</td>
<td>6.0%</td>
</tr>
<tr>
<td>% Of Discharges for Beneficiaries Who Are LIS Enrolled During The Month Of Discharge</td>
<td>1</td>
<td>0 to 10</td>
<td>0.0% - 13.2%</td>
<td>13,514.17</td>
<td>13,801.82</td>
<td>2.1%</td>
</tr>
<tr>
<td></td>
<td>2 to 5</td>
<td>&gt;10 to 50</td>
<td>13.2% - 28.3%</td>
<td>14,669.68</td>
<td>15,022.90</td>
<td>2.4%</td>
</tr>
<tr>
<td></td>
<td>6 to 9</td>
<td>&gt;50 to 90</td>
<td>28.3% - 53.5%</td>
<td>17,011.32</td>
<td>17,611.03</td>
<td>3.5%</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>&gt;90 to 100</td>
<td>53.5% - 100.0%</td>
<td>19,776.30</td>
<td>20,944.75</td>
<td>5.9%</td>
</tr>
<tr>
<td>% Of Discharges for Beneficiaries Who Are Dual(All) or LIS Enrolled During The Month Of Discharge</td>
<td>1</td>
<td>0 to 10</td>
<td>0.0% - 13.2%</td>
<td>13,500.03</td>
<td>13,786.41</td>
<td>2.1%</td>
</tr>
<tr>
<td></td>
<td>2 to 5</td>
<td>&gt;10 to 50</td>
<td>13.2% - 28.3%</td>
<td>14,665.75</td>
<td>15,019.20</td>
<td>2.4%</td>
</tr>
<tr>
<td></td>
<td>6 to 9</td>
<td>&gt;50 to 90</td>
<td>28.3% - 53.5%</td>
<td>17,015.22</td>
<td>17,614.13</td>
<td>3.5%</td>
</tr>
<tr>
<td>Beneficiary Characteristics (1)</td>
<td>Decile Group* (2)</td>
<td>Percentile Range of Group (3)</td>
<td>Decile Value Range (4)</td>
<td>Average Payment Per Discharge - FY 2023 (5)</td>
<td>Average Payment Per Discharge - FY 2024 (6)</td>
<td>Percent Change (7)</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------</td>
<td>-------------------------------</td>
<td>------------------------</td>
<td>--------------------------------------------</td>
<td>--------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>&gt;90 to 100</td>
<td>53.5% - 100.0%</td>
<td>19,779.23</td>
<td>20,950.62</td>
<td>5.9%</td>
</tr>
<tr>
<td>% Of Discharges for Beneficiaries With a Z code reported related to SDOH **</td>
<td>1</td>
<td>0 to 10</td>
<td>0%</td>
<td>11,658.11</td>
<td>11,934.99</td>
<td>2.4%</td>
</tr>
<tr>
<td></td>
<td>2 to 5</td>
<td>&gt;10 to 50</td>
<td>0.0% - 1.2%</td>
<td>14,865.94</td>
<td>15,320.40</td>
<td>3.1%</td>
</tr>
<tr>
<td></td>
<td>6 to 9</td>
<td>&gt;50 to 90</td>
<td>1.2% - 4.7%</td>
<td>16,200.33</td>
<td>16,677.74</td>
<td>2.9%</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>&gt;90 to 100</td>
<td>4.7% - 59.5%</td>
<td>18,017.60</td>
<td>18,733.66</td>
<td>4.0%</td>
</tr>
<tr>
<td>% Of Discharges for Beneficiaries With a Behavioral Health Diagnosis</td>
<td>1</td>
<td>0 to 10</td>
<td>0.0% - 35.3%</td>
<td>18,016.70</td>
<td>18,607.22</td>
<td>3.3%</td>
</tr>
<tr>
<td></td>
<td>2 to 5</td>
<td>&gt;10 to 50</td>
<td>35.3% - 46.6%</td>
<td>16,533.82</td>
<td>17,059.74</td>
<td>3.2%</td>
</tr>
<tr>
<td></td>
<td>6 to 9</td>
<td>&gt;50 to 90</td>
<td>46.6% - 57.4%</td>
<td>14,743.11</td>
<td>15,138.56</td>
<td>2.7%</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>&gt;90 to 100</td>
<td>57.4% - 100.0%</td>
<td>13,943.19</td>
<td>14,675.89</td>
<td>5.3%</td>
</tr>
<tr>
<td>% Of Discharges for Beneficiaries who come from rural areas</td>
<td>1</td>
<td>0 to 10</td>
<td>0.0% - 0.8%</td>
<td>16,650.86</td>
<td>17,119.01</td>
<td>2.8%</td>
</tr>
<tr>
<td></td>
<td>2 to 5</td>
<td>&gt;10 to 50</td>
<td>0.8% - 14.0%</td>
<td>16,187.97</td>
<td>16,715.39</td>
<td>3.3%</td>
</tr>
<tr>
<td></td>
<td>6 to 9</td>
<td>&gt;50 to 90</td>
<td>14.0% - 93.9%</td>
<td>15,309.77</td>
<td>15,749.46</td>
<td>2.9%</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>&gt;90 to 100</td>
<td>93.9% - 100.0%</td>
<td>11,813.81</td>
<td>12,235.97</td>
<td>3.6%</td>
</tr>
<tr>
<td>% Of Discharges for Beneficiaries With ESRD coverage **</td>
<td>1</td>
<td>0 to 10</td>
<td>0%</td>
<td>11,124.30</td>
<td>11,388.98</td>
<td>2.4%</td>
</tr>
<tr>
<td></td>
<td>2 to 5</td>
<td>&gt;10 to 50</td>
<td>0.0% - 4.2%</td>
<td>13,179.54</td>
<td>13,552.31</td>
<td>2.8%</td>
</tr>
<tr>
<td></td>
<td>6 to 9</td>
<td>&gt;50 to 90</td>
<td>4.2% - 9.8%</td>
<td>16,290.82</td>
<td>16,769.89</td>
<td>2.9%</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>&gt;90 to 100</td>
<td>9.8% - 87.5%</td>
<td>19,906.33</td>
<td>20,735.97</td>
<td>4.2%</td>
</tr>
<tr>
<td>% Of Discharges for Beneficiaries who come from rural areas</td>
<td>1</td>
<td>0 to 10</td>
<td>0.0% - 17.0%</td>
<td>14,180.96</td>
<td>14,567.66</td>
<td>2.7%</td>
</tr>
<tr>
<td>Beneficiary Characteristics</td>
<td>Decile Group*</td>
<td>Percentile Range of Group</td>
<td>Decile Value Range</td>
<td>Average Payment Per Discharge - FY 2023 (5)</td>
<td>Average Payment Per Discharge - FY 2024 (6)</td>
<td>Percent Change (7)</td>
</tr>
<tr>
<td>------------------------------</td>
<td>--------------</td>
<td>---------------------------</td>
<td>-------------------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>% Of Discharges for Beneficiaries with Disability</td>
<td>2 to 5</td>
<td>&gt;10 to 50</td>
<td>17.0% - 27.4%</td>
<td>15,250.58</td>
<td>15,644.53</td>
<td>2.6%</td>
</tr>
<tr>
<td></td>
<td>6 to 9</td>
<td>&gt;50 to 90</td>
<td>27.4% - 39.7%</td>
<td>16,433.79</td>
<td>17,012.19</td>
<td>3.5%</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>&gt;90 to 100</td>
<td>39.7% - 100.0%</td>
<td>17,788.32</td>
<td>18,573.66</td>
<td>4.4%</td>
</tr>
<tr>
<td>% Of Discharges for Beneficiaries who live in an area with ADI &gt;= 85</td>
<td>1</td>
<td>0 to 10</td>
<td>0.0% - 0.6%</td>
<td>18,272.11</td>
<td>18,748.63</td>
<td>2.6%</td>
</tr>
<tr>
<td></td>
<td>2 to 5</td>
<td>&gt;10 to 50</td>
<td>0.6% - 12.4%</td>
<td>16,379.17</td>
<td>16,914.52</td>
<td>3.3%</td>
</tr>
<tr>
<td></td>
<td>6 to 9</td>
<td>&gt;50 to 90</td>
<td>12.4% - 45.8%</td>
<td>14,524.77</td>
<td>14,958.59</td>
<td>3.0%</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>&gt;90 to 100</td>
<td>45.8% - 100.0%</td>
<td>12,173.03</td>
<td>12,553.29</td>
<td>3.1%</td>
</tr>
</tbody>
</table>

* Decile group 1 contains the 10% of hospitals with the lowest rate of discharges for that characteristic; decile group 2 to 5 contains the hospitals with less than or equal to the median rate of discharges for that characteristic, excluding those in decile group 1; decile group 6 to 9 contains the hospitals with greater than the median rate of discharges for that characteristic, excluding those in group 10; and decile group 10 contains the 10% of hospitals with the highest rate of discharges for that characteristic.

** Greater than 10 percent of providers did not report discharges associated with this characteristic. Therefore, we have randomly allocated those providers to decile groups 1 and 2.
G. Effects of Other Policy Changes

In addition to those policy changes discussed previously that we can model using our IPPS payment simulation model, we are making various other changes in this final rule. As noted in section I.D. of this appendix, our payment simulation model uses the most recent available claims data to estimate the impacts on payments per case of certain changes in this final rule. Generally, we have limited or no specific data available with which to estimate the impacts of these changes using that payment simulation model. For these changes, we have attempted to predict the payment impacts based upon our experience and other more limited data. Our estimates of the likely impacts associated with these other changes are discussed in this section.

1. Effects of Policy Changes Relating to New Medical Service and Technology Add-On Payments

In addition to those proposed policy changes discussed previously that we are able to model using our IPPS payment simulation model, we are making various other changes in this final rule. As noted in section I.D. of this appendix, our payment simulation model uses the most recent available claims data to estimate the impacts on payments per case of certain changes in this final rule. Generally, we have limited or no specific data available with which to estimate the impacts of these changes using that payment simulation model. For those changes, we have attempted to predict the payment impacts based upon our experience and other more limited data. Our estimates of the likely impacts associated with these other changes are discussed in this section.

1. Effects of Policy Changes Relating to New Medical Service and Technology Add-On Payments

a. FY 2024 Status of Technologies Approved for FY 2023 New Technology Add-On Payments

As discussed in section II.E.5. of the preamble of this final rule, we are continuing new technology add-on payments in FY 2024 for 11 technologies that are still within their newness period. Under § 412.88(a)(2), the new technology add-on payment for each case involving use of an approved technology would be limited to the lesser of: (1) 65 percent of the costs of the new technology (or 75 percent of the costs for technologies designated as Qualified Infectious Disease Products (QIDPs) or approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) pathway); or (2) 65 percent of the amount by which the costs of the case exceed the standard MS–DRG payment for the case (or 75 percent of the amount for technologies designated as QIDPs or approved under the LPAD pathway). Because it is difficult to predict the actual new technology add-on payment for each case, the estimated total payments in this final rule are based on the applicant’s estimated cost and volume projections at the time they submitted their application (or based on updated figures provided during the public comment period) and the assumption that every claim that would qualify for a new technology add-on payment would receive the maximum add-on payment.

In the following table, we present estimated payment for the 11 technologies for which we are continuing to make new technology add-on payments in FY 2024:

<table>
<thead>
<tr>
<th>Technology Name</th>
<th>Estimated Cases</th>
<th>FY 2024 NTA Amount (65% or 75%)</th>
<th>Estimated Total FY 2024 Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept® (PRCFC)</td>
<td>2,296</td>
<td>$2,535.00</td>
<td>$5,820,360.00</td>
</tr>
<tr>
<td>Rybrevent™</td>
<td>349</td>
<td>$6,405.89</td>
<td>$2,235,655.61</td>
</tr>
<tr>
<td>StrataGraft®</td>
<td>261</td>
<td>$44,200.00</td>
<td>$11,536,200.00</td>
</tr>
<tr>
<td>Hemolung Respiratory Assist System (RAS)</td>
<td>161</td>
<td>$6,500.00</td>
<td>$1,046,500.00</td>
</tr>
<tr>
<td>aproo® Intervertebral Body Fusion Device (TLIF indication)</td>
<td>1,261</td>
<td>$40,950.00</td>
<td>$51,637,950.00</td>
</tr>
<tr>
<td>Liventivity™</td>
<td>129.5</td>
<td>$32,500.00</td>
<td>$4,208,750.00</td>
</tr>
<tr>
<td>Thoraflex Hybrid Device</td>
<td>800</td>
<td>$22,750.00</td>
<td>$18,200,000.00</td>
</tr>
<tr>
<td>ViviStim</td>
<td>135</td>
<td>$23,400.00</td>
<td>$3,159,000.00</td>
</tr>
<tr>
<td>GORE TAG Thoracic Branch Endoprosthesis</td>
<td>386</td>
<td>$27,807.00</td>
<td>$10,733,502.00</td>
</tr>
<tr>
<td>Cerament® G</td>
<td>1,610</td>
<td>$4,918.55</td>
<td>$7,918,865.50</td>
</tr>
<tr>
<td>iFusc Bedrock Granite Implant System</td>
<td>1,480</td>
<td>$9,828.00</td>
<td>$14,545,440.00</td>
</tr>
<tr>
<td>Aggregate Estimated Total FY 2024 Impact</td>
<td></td>
<td></td>
<td>$131,042,223.11</td>
</tr>
</tbody>
</table>

b. FY 2024 Applications for New Technology Add-On Payments

In sections II.E.6. and 7. of the preamble to this final rule, we discussed 25 technologies for which we received applications for add-on payments for new medical services and technologies for FY 2024. We noted that of the 54 applications (27 alternative and 27 traditional), 26 applicants withdrew their application (14 alternative and 12 traditional) prior to the issuance of this final rule, and 3 technologies (1 alternative and 2 traditional) did not meet the July 1 deadline for FDA approval or clearance of the technology and are therefore ineligible for consideration for new technology add-on payments for FY 2024. Of the 25 technologies discussed in the preamble of this final rule, we are not approving 3, and 4 other applications are considered as 2 technologies due to substantial similarity. This results in a total of 20 new approvals or conditional approvals (8 traditional and 12 alternative) for new technology add-on payments for FY 2024. As explained in the preamble to this final rule, add-on payments for new medical services and technologies under section 1886(d)(5)(K) of the Act are not required to be budget neutral.

As discussed in section II.E.7. of the preamble of this final rule, under the alternative pathway for new technology add-on payments, new technologies that are medical products with a QIDP designation, approved through the FDA LPAD pathway, or designated under the Breakthrough Device program will be considered not substantially similar to an existing technology for purposes of the new technology add-on payment under the IPPS, and will not need to demonstrate that the technology represents a substantial clinical improvement. These technologies must still be within the 2 to 3-year newness period, as discussed in section II.E.1.a.(1), of the preamble this final rule, and must also still meet the cost criterion.

As fully discussed in section II.E.7. of the preamble of this final rule, we are approving or conditionally approving 12 alternative pathway applications submitted for FY 2024 new technology add-on payments, including 9 technologies that received a Breakthrough Device designation from FDA and 3 that were designated as a QIDP by FDA. We did not receive any LPAD applications for add-on payments for new technologies for FY 2024.

Based on information from the applicants at the time of this final rule, we estimate that total payments for the 12 technologies approved under the alternative pathway will be approximately $205 million. Total estimated FY 2024 payments for new technologies that are designated as a QIDP are approximately $218 million, and the total estimated FY 2024 payments for new technologies that are part of the Breakthrough Device program are approximately $87 million.
In the following table, we present detailed estimates for the 12 technologies for which we are approving or conditionally approving new technology add-on payments under the alternative pathway in FY 2024:

<table>
<thead>
<tr>
<th>Technology Name</th>
<th>Pathway (QIDP, LPAD, or Breakthrough Device)</th>
<th>Estimated Cases</th>
<th>FY 2024 NTAP Amount (65 % or 75 %)</th>
<th>Estimated Total FY 2024 Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>taurolidine/heparin*</td>
<td>QIDP</td>
<td>12,000</td>
<td>$17,111.25</td>
<td>$205,335,000.00</td>
</tr>
<tr>
<td>REZZAYO™</td>
<td>QIDP</td>
<td>795</td>
<td>$4,387.50</td>
<td>$3,488,062.50</td>
</tr>
<tr>
<td>XACDUR®</td>
<td>QIDP</td>
<td>654</td>
<td>$13,680.00</td>
<td>$8,946,720.00</td>
</tr>
<tr>
<td>Aveir™ AR Leadless Pacemaker</td>
<td>Breakthrough Device</td>
<td>245</td>
<td>$10,725.00</td>
<td>$2,627,625.00</td>
</tr>
<tr>
<td>Aveir™ Leadless Pacemaker (Dual-Chamber)</td>
<td>Breakthrough Device</td>
<td>2,250</td>
<td>$15,600.00</td>
<td>$35,100,000.00</td>
</tr>
<tr>
<td>Canary Tibial Extension (CTE) with Canary Health Implanted Reporting Processor (CHIRP) System</td>
<td>Breakthrough Device</td>
<td>3,157</td>
<td>$850.85</td>
<td>$2,686,133.45</td>
</tr>
<tr>
<td>Cerillbell Status Epilepticus Monitor</td>
<td>Breakthrough Device</td>
<td>2,477</td>
<td>$913.90</td>
<td>$2,263,730.30</td>
</tr>
<tr>
<td>EchoGo Heart Failure 1.0</td>
<td>Breakthrough Device</td>
<td>19,656</td>
<td>$1,023.75</td>
<td>$20,123,830.00</td>
</tr>
<tr>
<td>Phagenyx® System</td>
<td>Breakthrough Device</td>
<td>294</td>
<td>$3,250.00</td>
<td>$955,300.00</td>
</tr>
<tr>
<td>SAIN™ Neuromodulation System</td>
<td>Breakthrough Device</td>
<td>25</td>
<td>$12,675.00</td>
<td>$316,875.00</td>
</tr>
<tr>
<td>DETOUR System</td>
<td>Breakthrough Device</td>
<td>600</td>
<td>$16,250.00</td>
<td>$9,750,000.00</td>
</tr>
<tr>
<td>TOPSTM System</td>
<td>Breakthrough Device</td>
<td>1,200</td>
<td>$11,375.00</td>
<td>$13,650,000.00</td>
</tr>
<tr>
<td>Estimated Total FY 2024 Impact</td>
<td></td>
<td></td>
<td></td>
<td>$305,242,476.25</td>
</tr>
</tbody>
</table>

*Conditional approval; Payments will only be made if the technology receives FDA approval, beginning the quarter after approval is received.

As fully discussed in section II.E.6. of the preamble of this final rule, we are approving 8 new technology add-on payments for 10 technologies that applied under the traditional pathway for new technology add-on payments for FY 2024. Based on information from the applicants at the time of rulemaking, we estimate that total payments for the technologies for which we are making new technology add-on payments is approximately $59 million for FY 2024.

In the following table, we present detailed estimates for the 10 technologies for which we are providing 8 new technology add-on payments under the traditional pathway in FY 2024:

<table>
<thead>
<tr>
<th>Technology Name</th>
<th>Estimated Cases</th>
<th>FY 2024 NTAP Amount (65 % or 75 %)</th>
<th>Estimated Total FY 2024 Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYTALUX® (lung)</td>
<td>300</td>
<td>$2,762.50</td>
<td>$828,750.00</td>
</tr>
<tr>
<td>CYTALUX® (ovarian)</td>
<td>50</td>
<td>$2,762.50</td>
<td>$138,125.00</td>
</tr>
<tr>
<td>EPKINLY™ and COLUMV</td>
<td>157</td>
<td>$6,504.07</td>
<td>$1,021,138.83</td>
</tr>
<tr>
<td>Lumsumio™</td>
<td>40</td>
<td>$17,492.10</td>
<td>$699,683.92</td>
</tr>
<tr>
<td>REBYOTA™ and VOWST™</td>
<td>2,628</td>
<td>$6,789.25</td>
<td>$17,842,149.00</td>
</tr>
<tr>
<td>SPEVIGO®</td>
<td>76</td>
<td>$33,233.45</td>
<td>$2,525,970.20</td>
</tr>
<tr>
<td>TECVAYLI™</td>
<td>1906</td>
<td>$8,940.54</td>
<td>$17,040,660.66</td>
</tr>
<tr>
<td>TERLIVAZ®</td>
<td>1146</td>
<td>$16,672.50</td>
<td>$19,106,685.00</td>
</tr>
<tr>
<td>Aggregate Estimated Total FY 2024 Impact</td>
<td></td>
<td></td>
<td>$59,203,162.61</td>
</tr>
</tbody>
</table>

* These two technologies were determined to be substantially similar to each other and were therefore evaluated as one application for new technology add-on payments under the IPPS.

c. Total Estimated Costs for NTAP in FY 2024

In the following table, we present summary estimates for all technologies approved for new technology add-on payments for FY 2024:
2. Effects of the Changes to Medicare DSH and Uncompensated Care Payments and Supplemental Payments for Indian Health Service Hospitals and Tribal Hospitals and Hospitals Located in Puerto Rico for FY 2024

a. Effects of the Changes to Medicare DSH Payments of Counting Certain Days Associated With Section 1115 Demonstrations in the Medicaid Fraction

In February 2023 we issued a proposed rule (88 FR 12623) to revise our regulations on the counting of days associated with individuals eligible for certain benefits provided by section 1115 demonstrations in the Medicaid fraction of a hospital’s disproportionate patient percentage (DPP). In section IV.F. of the preamble to this final rule, we discuss our finalized policies related to counting certain days associated with section 1115 demonstrations in the Medicaid fraction. Specifically, we are revising our regulations to explicitly reflect our interpretation of the statutory language “patients . . . regarded as” “eligible for medical assistance under a State plan approved under title XIX” “because they receive benefits under a demonstration project approved under title XI” in section 1886(d)(5)(F)(vi) of the Act to mean patients who receive health insurance authorized by a section 1115 demonstration or patients who pay for health insurance with premium assistance authorized by a section 1115 demonstration, where State expenditures to provide the health insurance or premium assistance may be matched with funds from title XIX. Alternatively, we are using the statutory discretion provided the Secretary to regard as eligible for Medicaid only these same groups of patients. Moreover, of individuals who are “regarded as” Medicaid eligible, the Secretary is exercising his discretion to include in the DPP Medicaid fraction numerator only the days of those patients who receive from a section 1115 demonstration (1) health insurance that covers inpatient hospital services, provided in either case that the patient is not also entitled to Medicare Part A.

Eight states currently have section 1115 demonstrations that explicitly include premium assistance programs that we believe include providing assistance that covers 100 percent of the premium cost to patients: Arkansas, Connecticut, Massachusetts, Oklahoma, Rhode Island, Tennessee, Utah, and Vermont. In the preamble of this final rule, we summarized a comment that Connecticut recently received demonstration approval for a premium assistance program that pays through the health insurance exchange to cover low-income individuals ineligible for Medicaid. For this final rule, we are including Connecticut in the list of states that have section 1115 waivers, bringing the total to eight from the seven we noted in the February 2023 proposal (88 FR 12634). We also summarized in the preamble of this final rule a comment that Massachusetts demonstrated, in addition to providing 100 percent premium assistance to some patients, also provides premium assistance to some Medicaid-ineligible patients at less than 100 percent of the premium cost to the patient. We note in the finalized policy in this final rule that patient days of patients receiving this type of premium assistance are not includable in the DPP Medicaid fraction numerator.

Hospitals in States that have section 1115 demonstrations that explicitly include premium assistance programs that provide 100 percent of the premium cost to the patient will be allowed to continue to include days of those patients receiving 100 percent premium assistance in the DPP Medicaid fraction numerator, provided the patient is also entitled to Medicare Part A. Therefore, there will be no change to these hospitals reporting these days as Medicaid days and no impact on their Medicaid fraction as a result of our revisions to the regulations regarding the counting of patient days associated with these section 1115 demonstrations. However, to the extent any state’s demonstration includes a premium assistance program that provides assistance that covers less than 100 percent of the premium cost to the patient (such as Massachusetts and only these same groups of patients), we do not currently possess data to estimate an impact of this aspect of our policy. For States that have section 1115 demonstrations that include uncompensated/undercompensated care pools, the patients whose care is subsidized by these section 1115 demonstration funding pools will not be “regarded as” “eligible for medical assistance under a State plan approved under title XIX” in section 1886(d)(5)(F)(vi) of the Act because the demonstration does not provide them with health insurance benefits. Even if they could be regarded as Medicaid eligible, the Secretary is using his authority to not so regard such patients and to exclude the days of those patients from being counted in the DPP Medicaid fraction numerator. Therefore, hospitals in the following six States can no longer report days of patients for which they receive payments from uncompensated/undercompensated care pools authorized by these section 1115 demonstration days as Medicaid days in the DPP Medicaid fraction numerator: Florida, Kansas, Massachusetts, New Mexico, Tennessee, and Texas.

As discussed in the February 2023 proposed rule (88 FR 12623) in section IV.F. of this final rule, to estimate the impact of the policy to exclude uncompensated/undercompensated care pool days, we would need to know the number of these section 1115 demonstration days per hospital for the hospitals potentially impacted. As described previously, we do not currently possess such data because the Medicare cost report does not include lines for section 1115 demonstration days to be reported separately from other types of days that providers report for Medicare payment purposes. Therefore, the number of demonstration-authorized uncompensated/undercompensated care pool days per hospital and the net overall savings of our proposal were (and continue to be) especially challenging to estimate.

However, in light of the public comments received in prior rulemakings recommending that we use plaintiff data to help inform this issue, in the February 2023 proposed rule, we examined the unaudited figures claimed by plaintiffs in the most recent of the series of court cases on this issue, Bethesda Health, Inc. v. Azar, 980 F.3d 121 (D.C. Cir. 2020), as reflected in the System for Tracking Audit and Reimbursement (STAR) or the STAR system as of the time of the development of the February 2023 proposed rule. (We note, there were no changes made to the STAR system at the time of this final rule.)
Of the Bethesda Health plaintiff data in the STAR system that listed reported uncompensated/undercompensated care pool days for purposes of implementing the judgment in that case, we used the reported unaudited amounts in controversy claimed by the plaintiffs for the more recent of their cost reports ending in FY 2016 or FY 2017 ($6,167,193). We then used the total number of beds (2,490) reported in the March 2022 Provider Specific File to determine the average unaudited amount in controversy per bed for these plaintiffs. Based on the data as shown in Table I.G.–1, the average unaudited amount in controversy per bed for these plaintiffs is $2,477 (= $6,167,193/2,490). We note that there are Bethesda Health plaintiffs that do not have section 1115 demonstration program days listed in STAR, and one plaintiff that has section 1115 demonstration program days listed in STAR, but the most recent cost report with this data ends in FY 2012; therefore, these plaintiffs are not included in the calculation reflected in Table I.G.–1.

### TABLE I.G.1: AVERAGE UNAUDITED AMOUNT IN CONTROVERSY PER BED (A/B)

<table>
<thead>
<tr>
<th>Unaudited Amount in Controversy by Plaintiff (A)</th>
<th>Beds (B)</th>
<th>Average unaudited amount in controversy per bed (A/B)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2,174,897</td>
<td>382</td>
<td></td>
</tr>
<tr>
<td>$1,342,081</td>
<td>512</td>
<td></td>
</tr>
<tr>
<td>$253,404</td>
<td>210</td>
<td></td>
</tr>
<tr>
<td>$1,301,024</td>
<td>717</td>
<td></td>
</tr>
<tr>
<td>$505,899</td>
<td>310</td>
<td></td>
</tr>
<tr>
<td>$318,984</td>
<td>181</td>
<td></td>
</tr>
<tr>
<td>$270,905</td>
<td>178</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong> $6,167,193</td>
<td><strong>Total 2,490</strong></td>
<td><strong>$2,477</strong></td>
</tr>
</tbody>
</table>

In Table I.G.–2, we used the number of beds in DSH eligible hospitals in the six States currently with section 1115 demonstration programs that include uncompensated/undercompensated care pools and the average unaudited per bed amount derived in Table I.G.–1 to extrapolate an unaudited amount in controversy for all DSH eligible hospitals in those States. The result is $348,749,215 (= 140,795 x $2,477).
TABLE I.G.-2: EXTRAPOLATED UNAUDITED AMOUNT IN CONTROVERSY

<table>
<thead>
<tr>
<th>State</th>
<th>DSH Hospital Beds (A)</th>
<th>Unaudited average amount in controversy per bed from Table 1 (B)</th>
<th>Extrapolated unaudited amount in controversy (A x B)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Florida</td>
<td>50,352</td>
<td>$2,477</td>
<td>$124,721,904</td>
</tr>
<tr>
<td>Kansas</td>
<td>5,881</td>
<td>$2,477</td>
<td>$14,567,237</td>
</tr>
<tr>
<td>Massachusetts</td>
<td>13,099</td>
<td>$2,477</td>
<td>$32,446,223</td>
</tr>
<tr>
<td>New Mexico</td>
<td>3,405</td>
<td>$2,477</td>
<td>$8,434,185</td>
</tr>
<tr>
<td>Tennessee</td>
<td>15,718</td>
<td>$2,477</td>
<td>$38,933,486</td>
</tr>
<tr>
<td>Texas</td>
<td>52,340</td>
<td>$2,477</td>
<td>$128,646,180</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>140,795</strong></td>
<td><strong>$2,477</strong></td>
<td><strong>$348,749,215</strong></td>
</tr>
</tbody>
</table>

Note, we caution against considering the extrapolated unaudited amount in controversy to be the estimated Trust Fund savings that would result from our proposal. As we explained in the February 2023 proposed rule, for the reasons described earlier, the savings from our proposal are highly uncertain. The savings may be higher or lower than the extrapolated amount. However, in the proposed rule we provided the transfer calculations earlier in response to the public comments received on prior rulemakings recommending that we utilize plaintiff data in some manner to help inform this issue.

Comment: A commenter noted that CMS stated in the regulatory impact analysis in the February 2023 proposed rule that "The financial viability of the hospital industry and access to high quality health care for Medicare beneficiaries will be maintained." The commenter asserted that the proposed rule provides no quantitative assurances or analyses to back up this assertion. If CMS were to finalize this proposal, the commenter stated that CMS must include a more detailed impact analysis that will help guarantee that the payment cuts do not contribute to even more hospital closures or reductions in critical, life-saving services.

Response: We do not believe our proposed and finalized policy would cause harm to hospitals, especially to the point that would cause hospital closures. We also disagree that we provided no quantitative analysis; we provided the analysis described earlier in Tables 1 and 2. While we do not provide a quantitative analysis beyond this due to the agency’s lack of data on the number of days for which hospitals receive payment from demonstration-approved uncompensated/undercompensated care pools and for which patients receive less than 100 percent of their premium cost in premium assistance from a demonstration, the extrapolated unaudited amount in controversy of $348,749,215 is approximately 0.3 percent (less than half of one percent) of total IPPS payments. Therefore, we continue to believe that the financial viability of the hospital industry and access to high quality health care for Medicare beneficiaries will be maintained in light of our proposed and final policy.

Comment: A commenter concluded that CMS identifies in the proposed rule the states that have currently approved 1115 demonstration projects that include uncompensated care pools or premium assistance programs, but they fall short in determining what the patient and hospital impacts would be for those hospitals in the affected states. The commenter further stated that for states with premium assistance programs, CMS makes a modest attempt to estimate hospital burden but does not estimate the potential loss of DSH payments, and for states with uncompensated care pools, CMS states that it cannot estimate the impact because the Medicare cost report does not have information on 1115 demonstration days by hospital. The commenter stated that, in reality, the impacts would be devastating to low-income individuals and the providers who care for them in many states. Another commenter was concerned that CMS remains unable to sufficiently account for the potential financial implications and burdens on hospitals by excluding these section 1115 demonstration days. The commenter believes that the estimates in the proposed rule vastly underestimate the likely financial impacts on hospitals, which the commenter believes would exceed $1 billion.

Response: We respectfully disagree that our proposal (80 FR 12629) is "fatally flawed" because it fails to consider the impact of its policy on low-income patients and the hospitals that care for them. The commenter explained that CMS states that CMS must include a more detailed impact analysis that will help guarantee that the payment cuts do not contribute to even more hospital closures or reductions in critical, life-saving services.

Comment: We do not believe our proposed and finalized policy would cause harm to hospitals, especially to the point that would cause hospital closures. We also disagree that we provided no quantitative analysis; we provided the analysis described earlier in Tables 1 and 2. While we do not provide a quantitative analysis beyond this due to the agency’s lack of data on the number of days for which hospitals receive payment from demonstration-approved uncompensated/undercompensated care pools and for which patients receive less than 100 percent of their premium cost in premium assistance from a demonstration, the extrapolated unaudited amount in controversy of $348,749,215 is approximately 0.3 percent (less than half of one percent) of total IPPS payments. Therefore, we continue to believe that the financial viability of the hospital industry and access to high quality health care for Medicare beneficiaries will be maintained in light of our proposed and final policy.

Comment: A commenter concluded that CMS states that CMS must include a more detailed impact analysis that will help guarantee that the payment cuts do not contribute to even more hospital closures or reductions in critical, life-saving services.

Response: We respectfully disagree that our proposal (80 FR 12629) is "fatally flawed" because it fails to consider the impact of its policy on low-income patients and the hospitals that care for them. The commenter explained that CMS identifies in the proposed rule the states that have currently approved 1115 demonstration projects that include uncompensated care pools or premium assistance programs, but they fall short in determining what the patient and hospital impacts would be for those hospitals in the affected states. The commenter further stated that for states with premium assistance programs, CMS makes a modest attempt to estimate hospital burden but does not estimate the potential loss of DSH payments, and for states with uncompensated care pools, CMS states that it cannot estimate the impact because the Medicare cost report does not have information on 1115 demonstration days by hospital. The commenter stated that, in reality, the impacts would be devastating to low-income individuals and the providers who care for them in many states. Another commenter was concerned that CMS remains unable to sufficiently account for the potential financial implications and burdens on hospitals by excluding these section 1115 demonstration days. The commenter believes that the estimates in the proposed rule vastly underestimate the likely financial impacts on hospitals, which the commenter believes would exceed $1 billion.

Response: We respectfully disagree that our proposal (80 FR 12629) is "fatally flawed" because it fails to consider the impact of its policy on low-income patients and the hospitals that care for them. The commenter explained that CMS identifies in the proposed rule the states that have currently approved 1115 demonstration projects that include uncompensated care pools or premium assistance programs, but they fall short in determining what the patient and hospital impacts would be for those hospitals in the affected states. The commenter further stated that for states with premium assistance programs, CMS makes a modest attempt to estimate hospital burden but does not estimate the potential loss of DSH payments, and for states with uncompensated care pools, CMS states that it cannot estimate the impact because the Medicare cost report does not have information on 1115 demonstration days by hospital. The commenter stated that, in reality, the impacts would be devastating to low-income individuals and the providers who care for them in many states. Another commenter was concerned that CMS remains unable to sufficiently account for the potential financial implications and burdens on hospitals by excluding these section 1115 demonstration days. The commenter believes that the estimates in the proposed rule vastly underestimate the likely financial impacts on hospitals, which the commenter believes would exceed $1 billion.
Commenters may not agree with CMS regarding the source of data used in the estimate or the total of the estimate, we believe the estimate we provided responds to commenters concerns on the impact of the proposal by using unaudited figures claimed by plaintiffs in the most recent of the series of court cases on this issue, which we believe is the best information currently available upon which to estimate the net overall savings of the proposal. With regard to hospital burden concerns, we note in response to similar comments in section IV.F. of the preamble of this final rule. In that section, in particular, we explain that we are unsure why some commenters have significant concerns with verifying an individual’s 1115 eligibility and premium assistance when hospitals are already communicating with their state Medicaid office to verify an individual’s eligibility. In addition, as we noted in the February 2023 proposed rule (88 FR 12634), there would be no change to how these hospitals report Medicare DSH payments under the 2000 DSH regulation and the DSH adjustment. It is problematic given the purpose of the 2000 DSH regulation and the DSH adjustment that the agency’s RFA assessment that the financial impact of the proposal would be “significant” if a proposal affects greater than five percent of providers in the amount of three to five percent or more of total revenue or total costs. We based our belief that the requirements in the proposed rule would not reach this threshold using data from the FY 2023 IPPS/LTPA final rule (87 FR 49051). We estimated that DSH payments were approximately 2.8 percent of all payments under the IPPS for FY 2023. Therefore, we cannot agree with the commenter’s claim that the impact of the February 2023 proposed rule, which we are finalizing here and could result in a reduction in total DSH payments to some hospitals, will not have a significant economic impact on a substantial number of small entities, which the Secretary considers the great majority of hospitals to be. (88 FR 12636)

Comment: Another commenter asserted that CMS’s estimate of the financial impact is arbitrary and capricious because the agency fails to consider other available sources of data in arriving at its estimate. The commenter explained that CMS does not take into account that many hospitals across the country have protested this issue on their cost reports or appealed the issue to the Provider Reimbursement Review Board and have submitted calculations of the protested amounts to the agency. The commenter believes that CMS could have collected the data that it needs to determine the true impact on those hospitals. The commenter asserted that the agency’s failure to do so renders the proposal arbitrary and capricious under the APA, and cited several court cases. Other commenters further asserted that CMS’s estimate is also arbitrary and unreasonable because the agency entirely failed to account for the adverse effect of its proposal on safety-net hospitals, in particular, which is problematic given the purpose of the 2000 DSH regulation and the DSH adjustment.

Response: We disagree that the agency has acted arbitrarily or capriciously in estimating the financial impact of the proposed rule by failing to consider other available sources of data in arriving at its estimate. As explained previously, the Medicare cost report does not provide a way for hospitals to indicate the number of days they want treated as Medicaid days in the DPP calculation because the DPP fraction numerator is not updated under the 2000 DSH regulation and the DSH adjustment.

Response: We disagree that the agency has acted arbitrarily or capriciously in estimating the financial impact of the proposed rule by failing to consider other available sources of data in arriving at its estimate. As explained previously, the Medicare cost report does not provide a way for hospitals to indicate the number of days they want treated as Medicaid days in the DPP calculation because the DPP fraction numerator is not updated under the 2000 DSH regulation and the DSH adjustment.

Response: We disagree that the agency has acted arbitrarily or capriciously in estimating the financial impact of the proposed rule by failing to consider other available sources of data in arriving at its estimate. As explained previously, the Medicare cost report does not provide a way for hospitals to indicate the number of days they want treated as Medicaid days in the DPP calculation because the DPP fraction numerator is not updated under the 2000 DSH regulation and the DSH adjustment.

Response: We disagree that the agency has acted arbitrarily or capriciously in estimating the financial impact of the proposed rule by failing to consider other available sources of data in arriving at its estimate. As explained previously, the Medicare cost report does not provide a way for hospitals to indicate the number of days they want treated as Medicaid days in the DPP calculation because the DPP fraction numerator is not updated under the 2000 DSH regulation and the DSH adjustment.

Response: We disagree that the agency has acted arbitrarily or capriciously in estimating the financial impact of the proposed rule by failing to consider other available sources of data in arriving at its estimate. As explained previously, the Medicare cost report does not provide a way for hospitals to indicate the number of days they want treated as Medicaid days in the DPP calculation because the DPP fraction numerator is not updated under the 2000 DSH regulation and the DSH adjustment.

Response: We disagree that the agency has acted arbitrarily or capriciously in estimating the financial impact of the proposed rule by failing to consider other available sources of data in arriving at its estimate. As explained previously, the Medicare cost report does not provide a way for hospitals to indicate the number of days they want treated as Medicaid days in the DPP calculation because the DPP fraction numerator is not updated under the 2000 DSH regulation and the DSH adjustment.

Response: We disagree that the agency has acted arbitrarily or capriciously in estimating the financial impact of the proposed rule by failing to consider other available sources of data in arriving at its estimate. As explained previously, the Medicare cost report does not provide a way for hospitals to indicate the number of days they want treated as Medicaid days in the DPP calculation because the DPP fraction numerator is not updated under the 2000 DSH regulation and the DSH adjustment.

Response: We disagree that the agency has acted arbitrarily or capriciously in estimating the financial impact of the proposed rule by failing to consider other available sources of data in arriving at its estimate. As explained previously, the Medicare cost report does not provide a way for hospitals to indicate the number of days they want treated as Medicaid days in the DPP calculation because the DPP fraction numerator is not updated under the 2000 DSH regulation and the DSH adjustment.
Response: As noted earlier, we disagree that we have failed to make a proper financial assessment of the proposed rule’s impact or that the agency has ignored the RFA. The commenter confuses the requirement of section 3(f) of Executive Order 12866, which defines a ‘significant regulatory action’ as an action that is likely to result in a rule having an annual effect on the economy of $100 million or more in any one year, with the RFA, which requires agencies to analyze options for regulatory relief of small entities if a rule has a significant impact on a substantial number of small entities. As discussed in the February 2023 proposed rule and reiterated earlier, HHS’s practice in interpreting the RFA is to consider the effects of a policy to be economically “significant” under the RFA if the policy affects greater than five percent of providers in the amount of three to five percent or more of total revenue or total costs. This methodology has been followed the regulators for each of these requirements (Executive Order 12866 and the RFA), estimating the overall impact under the Executive order, and determining under the separate RFA standard for what is “significant” that the agency did not need to analyze options for regulatory relief of small entities because the finalized rule will not have a significant impact on a substantial number of small entities.

Comment: One commenter noted that the agency bases its policy changes on the Federal fiscal year and not according to a hospital’s cost reporting year, making such changes administratively challenging for hospitals.

Response: As we stated in the February 2023 proposed rule and reiterated in the preamble to this final rule, as has been our practice for more than two decades, we have made our periodic revisions to the counting of certain section 1115 patient days in the Medicare DSH calculation effective based on patient discharge dates. Thus, doing so again here treats all providers similarly and does not impact hospitals differently depending on their cost reporting periods. All hospitals will equally be able to include or not include certain section 1115 demonstration days in the DPP Medicaid fraction numerator, as permitted under this final rule, based on discharge dates of October 1, 2023, or later. We therefore disagree that the changes being finalized here will present administrative challenges or administratively impact hospitals differently depending on their cost reporting year.

Comment: One commenter stated that the exclusion of uncompensated care pool patient days from the Medicaid fraction would significantly reduce hospitals’ empirical Medicare DSH payments in states that use an uncompensated care pool to cover inpatient hospital care under a section 1115 demonstration. The commenter also noted that the proposed policy would also have the follow-on effect of significantly reducing national Medicare uncompensated care payments under section 1886(r) of the Act, and that CMS’s cost estimate does not address or account for the impact of the proposed rule on Medicare uncompensated care payments. Therefore, the commenter stated that the February 2023 proposed rule’s estimated impact of approximately $350 million likely represents only a portion of the aggregate financial impact of the proposal on IPPS hospitals nationally.

Response: As stated in the proposed rule, to estimate the impact of the proposal to exclude uncompensated/undercompensated care pool days, we would need to know the number of these demonstration days per hospital for the hospitals potentially impacted. The commenter also indicates that such data because the Medicare cost report does not include lines for section 1115 demonstration days separately from other types of days. Therefore, the number of demonstration-authorized uncompensated/undercompensated care pool days per hospital and the net overall savings of this proposal are especially challenging to estimate. We did use extrapolated unalloyed amount in controversy data from plaintiffs to help inform this, but cautioned against considering the extrapolated amount in controversy to be the estimated Trust Fund savings that would result from our proposal (88 FR 12634 through 12635). Given this lack of data and level of uncertainty, we do not believe it would be appropriate to explicitly reduce Factor 1 of the FY 2024 Medicare uncompensated care payments by the extrapolated unalloyed amount in controversy and did not propose to do so, nor are we doing so in this final rule. Please see section I.V.E. of this final rule for a discussion of the components of Factor 1 for the FY 2024 Medicare uncompensated care payments. Therefore, our proposal had no impact on Factor 1 of the FY 2024 Medicare uncompensated care payments in the proposed rule and our final policy has no impact on Factor 1 of the FY 2024 Medicare uncompensated care payments in this final rule.

b. Medicare DSH Uncompensated Care Payments and Supplemental Payment for Indian Health Service Hospitals and Tribal Hospitals and Hospitals Located in Puerto Rico

As discussed in section I.V.E. of the preamble of this final rule, under section 3133 of the Affordable Care Act, hospitals that are eligible to receive Medicare DSH payments will receive 25 percent of the amount they previously would have received under the statutory formula for Medicare DSH payments under section 1886(d)(5)(F) of the Act. The remainder, equal to an estimate of 75 percent of what formerly would have been paid as Medicare DSH payments (Factor 1), reduced to reflect changes in the percentage of uninsured individuals (Factor 2), is available to individual payments to each hospital that qualifies for Medicare DSH payments and that has reported uncompensated care. Each hospital eligible for Medicare DSH payments will receive an additional payment based on its estimated share of the total amount of uncompensated care for all hospitals eligible for Medicare DSH payments. The uncompensated care payment methodology has redistributive effects based on the proportion of a hospital’s amount of uncompensated care relative to the aggregate amount of uncompensated care of all hospitals eligible for Medicare DSH payments (Factor 3). The change to Medicare DSH payments under section 3133 of the Affordable Care Act is not budget neutral.

In this final rule, we are establishing the amount to be distributed as uncompensated care payments (UCP) to eligible hospitals for FY 2024, which is $5,938,006,756.87. This figure represents 75 percent of the amount that otherwise would have been paid for Medicare DSH payment adjustments by a Factor 2 of 59.29 percent. For FY 2023, the amount available to be distributed for uncompensated care was $6,874,403,459.42 or 75 percent of the amount that otherwise would have been paid for Medicare DSH payment adjustments by a Factor 2 of 65.71 percent. In addition, eligible IHS/Tribal hospitals and hospitals located in Puerto Rico are estimated to receive approximately $83.2 million in supplemental payments in FY 2024, as determined based on the difference between each hospital’s FY 2022 UCP (reduced by the change between the FY 2024 total uncompensated care payment amount and the total uncompensated care payment amount for FY 2022) and its FY 2024 UCP as calculated using the methodology for FY 2024. If this difference is less than or equal to zero, the hospital will not receive a supplemental payment. For this final rule, the total uncompensated care payments and supplemental payments equal approximately $6.021 billion. For FY 2024, we are using 3 years of data on uncompensated care costs from Worksheet S–10 of the FYs 2018, 2019, and 2020 cost reports to calculate Factor 3 for all DSH-eligible hospitals, including IHS/Tribal hospitals and Puerto Rico hospitals. For a complete discussion regarding the methodology for calculating Factor 3 for FY 2024, we refer readers to section I.V.E. of the preamble of this final rule. For a discussion regarding the methodology for calculating the supplemental payments, we refer readers to section IV.D. of the preamble of this final rule.

To estimate the impact of the combined effect of the changes in Factors 1 and 2, as well as the changes to the data used in determining Factor 3, on the calculation of Medicare uncompensated care payments along with changes to supplemental payments for IHS/Tribal hospitals and hospitals located in Puerto Rico, we compared total uncompensated care payments and supplemental payments estimated in the FY 2023 IPPS/LTC PPS final rule to the combined total of the uncompensated care payments and the supplemental payments estimated in this FY 2024 IPPS/LTC PPS final rule. For FY 2023, we calculated 75 percent of the estimated amount that would be paid as Medicare DSH payments absent section 3133 of the Affordable Care Act, adjusted by a Factor 2 of 65.71 percent and multiplied by Factor 3 calculated using the methodology described in the FY 2023 IPPS/LTC PPS final rule. For FY 2024, we calculated 75 percent of the estimated amount that would be paid as Medicare DSH payments during FY 2024 absent section 3133 of the Affordable Care Act, adjusted by a Factor 2 of 59.29 percent.
of 59.29 percent and multiplied by a Factor 3 calculated using the methodology described previously. For this final rule, the supplemental payments for IHS/Tribal hospitals and Puerto Rico hospitals are calculated as the difference between the hospital’s adjusted base year amount (as determined based on the hospital’s FY 2022 uncompensated care payment) and the hospital’s FY 2024 uncompensated care payment.

Our analysis included 2,384 hospitals that are projected to be eligible for DSH in FY 2024. Our analysis did not include hospitals that had terminated their participation in the Medicare program as of June 13, 2023. Maryland hospitals, new hospitals, and SCHs that are expected to be paid based on their hospital-specific rates. The 26 hospitals that are anticipated to be participating in the Rural Community Hospital Demonstration Program were also excluded from this analysis, as participating hospitals are not eligible to receive empirically justified Medicare DSH payments and uncompensated care payments. In addition, the data from merged or acquired hospitals were combined under the surviving hospital’s CMS certification number (CCN), and the non-surviving CCN was excluded from the analysis. The estimated impact of the changes in Factors 1, 2, and 3 on uncompensated care payments and supplemental payments for eligible IHS/Tribal hospitals and Puerto Rico hospitals across all hospitals projected to be eligible for DSH payments in FY 2024, by hospital characteristic, is presented in the following table:

<table>
<thead>
<tr>
<th>MODELED UNCOMPENSATED CARE PAYMENTS* AND SUPPLEMENTAL PAYMENTS FOR ESTIMATED FY 2024 DSHS BY HOSPITAL TYPE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Estimated DSHs</td>
</tr>
<tr>
<td>(1)</td>
</tr>
<tr>
<td>--------</td>
</tr>
<tr>
<td>Total</td>
</tr>
<tr>
<td>By Geographic Location</td>
</tr>
<tr>
<td>Urban Hospitals</td>
</tr>
<tr>
<td>Large Urban Areas</td>
</tr>
<tr>
<td>Other Urban Areas</td>
</tr>
<tr>
<td>Rural Hospitals</td>
</tr>
<tr>
<td>Bed Size (Urban)</td>
</tr>
<tr>
<td>0 to 99 Beds</td>
</tr>
<tr>
<td>100 to 249 Beds</td>
</tr>
<tr>
<td>250+ Beds</td>
</tr>
<tr>
<td>Bed Size (Rural)</td>
</tr>
<tr>
<td>0 to 99 Beds</td>
</tr>
<tr>
<td>100 to 249 Beds</td>
</tr>
<tr>
<td>250+ Beds</td>
</tr>
<tr>
<td>Urban by Region</td>
</tr>
<tr>
<td>New England</td>
</tr>
<tr>
<td>Middle Atlantic</td>
</tr>
<tr>
<td>South Atlantic</td>
</tr>
<tr>
<td>East North Central</td>
</tr>
<tr>
<td>East South Central</td>
</tr>
<tr>
<td>West North Central</td>
</tr>
<tr>
<td>West South Central</td>
</tr>
<tr>
<td>Mountain</td>
</tr>
<tr>
<td>Pacific</td>
</tr>
<tr>
<td>Puerto Rico</td>
</tr>
<tr>
<td>Rural by Region</td>
</tr>
<tr>
<td>New England</td>
</tr>
<tr>
<td>Middle Atlantic</td>
</tr>
<tr>
<td>South Atlantic</td>
</tr>
<tr>
<td>East North Central</td>
</tr>
</tbody>
</table>
The changes in projected FY 2024 uncompensated care payments and supplemental payments compared to the total of uncompensated care payments and supplemental payments in FY 2023 are driven by decreases in Factor 1 and Factor 2. The final Factor 1 has decreased from the FY 2023 final rule’s Factor 1 of $10.461 billion to this final rule’s Factor 1 of $10.015 billion. The final Factor 2 has decreased from FY 2023 final rule’s Factor 2 of 65.71 percent to this final rule’s Factor 2 of 59.29 percent. In addition, we note that there is a slight increase in the number of projected DSH eligible hospitals to 2,384 at the time of the development for this final rule compared to the projected 2,368 DSHs in the FY 2023 IPPS/LTPP final rule (87 FR 49472). Based on the changes, the impact analysis found that, across all projected DSH eligible hospitals, FY 2024 uncompensated care payments and supplemental payments are estimated at approximately $6.021 billion, or

| Modeled Uncompensated Care Payments* and Supplemental Payments for Estimated FY 2024 DSHs by Hospital Type |
|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Number of Estimated DSHs (1) | FY 2023 Final Rule Estimated Uncompensated Care Payments and Supplemental Payments ($ in millions) (2) | FY 2024 Uncompensated Care Payments and Supplemental Payments** ($ in millions) (3) | Dollar Difference: FY 2023 - FY 2024 ($ in millions) (4) | Percent Change*** (5) |
| East South Central | 77 | 107 | 93 | -14 | -13.17 |
| West North Central | 116 | 81 | 68 | -13 | -16.20 |
| West South Central | 107 | 81 | 71 | -9 | -11.42 |
| Mountain | 20 | 14 | 10 | -3 | -24.31 |
| Pacfic | 6 | 6 | 5 | -1 | -17.17 |
| **By Payment Classification** | | | | | |
| Urban Hospitals | 1,422 | 4,038 | 3,499 | -539 | -13.34 |
| Large Urban Areas | 812 | 2,720 | 2,359 | -361 | -13.27 |
| Other Urban Areas | 610 | 1,317 | 1,140 | -178 | -13.49 |
| Rural Hospitals | 962 | 2,933 | 2,522 | -411 | -14.01 |
| **Teaching Status** | | | | | |
| Nonteaching | 1,311 | 1,824 | 1,598 | -225 | -12.35 |
| Fewer than 100 residents | 800 | 2,476 | 2,106 | -369 | -14.91 |
| 100 or more residents | 273 | 2,672 | 2,316 | -355 | -13.29 |
| **Type of Ownership** | | | | | |
| Voluntary | 1,499 | 4,015 | 3,452 | -563 | -14.02 |
| Proprietary | 528 | 1,005 | 878 | -127 | -12.66 |
| Government | 357 | 1,950 | 1,691 | -259 | -13.30 |
| **Medicare Utilization Percent*** | | | | | |
| 0 to 25 | 874 | 3,985 | 3,431 | -554 | -13.89 |
| 25 to 50 | 1,432 | 2,951 | 2,555 | -396 | -13.41 |
| 50 to 65 | 70 | 33 | 33 | 0 | -0.12 |
| Greater than 65 | 8 | 2 | 2 | | -11.92 |
| **Medicaid Utilization Percent*** | | | | | |
| 0 to 25 | 1,365 | 2,903 | 2,547 | -356 | -12.25 |
| 25 to 50 | 898 | 3,347 | 2,839 | -509 | -15.20 |
| 50 to 65 | 92 | 538 | 481 | -57 | -10.50 |
| Greater than 65 | 29 | 183 | 154 | -29 | -15.67 |

Source: Dobson | DaVanzo analysis of 2018, 2019, and 2020 Hospital Cost Reports.

* Dollar uncompensated care payments calculated by [0.75 * estimated section 1886(d)(5)(F) payments * Factor 2 * Factor 3]. When summed across all hospitals projected to receive DSH payments, uncompensated care payments and supplemental payments are estimated to be $6,971 million in FY 2023 and uncompensated care payments and supplemental payments are estimated to be $6,021 million in FY 2024.

** For IHS/Tribal hospitals and Puerto Rico hospitals, this impact table reflects the supplemental payments.

*** Percentage change is determined as the difference between Medicare uncompensated care payments and supplemental payments modeled for this FY 2024 IPPS/LTPP final rule (column 3) and Medicare uncompensated care payments and supplemental payments modeled for the FY 2023 IPPS/LTPP final rule correction notice (column 2) divided by Medicare uncompensated care payments and supplemental payments modeled for the FY 2023 IPPS/LTPP final rule correction notice (column 2) times 100 percent.

**** Hospitals with missing or unknown Medicare utilization or Medicaid utilization are not shown in the table.
a decrease of approximately 13.62 percent from FY 2023 uncompensated care payments and supplemental payments (approximately $6.971 billion). While the changes result in a net decrease in the total amount available to be distributed in uncompensated care payments and supplemental payments, the projected payment decreases vary by hospital type. This redistribution of payments is caused by changes in Factor 3 and the amount of the supplemental payment for DSH-eligible IHS/Tribal hospitals and Puerto Rico hospitals. As seen in the previous table, a percent change of less than negative 13.62 percent indicates that hospitals within the specified category are projected to experience a larger decrease in payments, on average, compared to the universe of projected FY 2024 DSH hospitals. Conversely, a percent change greater than negative 13.62 percent indicates that a hospital type is projected to have a smaller decrease compared to the overall average. The variation in the distribution of overall payments by hospital characteristics is dependent on a given hospital’s uncompensated care costs as reported on the Worksheet S–10 and used in the Factor 3 computation and whether the hospital is eligible to receive the supplemental payment.

Rural hospitals, in general, are projected to experience a slightly larger decrease in uncompensated care payments compared to the decrease their urban counterparts are projected to experience. Overall, rural hospitals are projected to receive a 13.65 percent decrease in payments, while urban hospitals are projected to receive a 13.5 percent decrease in payments, which is equal to the overall hospital average. By bed size, rural hospitals with 100 to 249 beds and rural hospitals with 250+ beds are projected to receive larger than average decreases of 15.21 percent and 15.38 percent, respectively, while rural hospitals with 0 to 99 beds are projected to receive a smaller than average decrease of 12.33 percent. Among urban hospitals, the largest urban hospitals, those with 250+ beds, are projected to experience a larger decrease in payments that is greater than the overall hospital average, at 14.01 percent. In contrast, smaller urban hospitals with 0–99 beds and urban hospitals with 100–249 beds are projected to receive a 11.06 and 12.81 percent decrease in payments, respectively.

By region, rural hospitals are projected to receive a varied range of payment changes. Rural hospitals in the New England, East North Central, West North Central, Mountain, and Pacific regions are projected to receive larger than average decreases in payments. Rural hospitals in the Middle Atlantic, South Atlantic, East South Central, and West South Central regions are projected to receive smaller than average decreases in payments. Urban hospitals in the Middle Atlantic, South Atlantic, East North Central, East South Central, West North Central, and Pacific regions are projected to receive larger than average decreases in payments, while urban hospitals in New England, West South Central, and Mountain regions, as well as hospitals in Puerto Rico, are projected to receive smaller than average decreases in payments.

By payment classification, although hospitals in urban payment areas overall are expected to see an increase in uncompensated care payments and supplemental payments, hospitals in large urban payment areas are projected to receive a decrease in payments of 13.27 percent. In contrast, hospitals in rural payment areas are projected to receive a larger than average decrease in payments of 14.01 percent. Teaching hospitals with fewer than 100 residents are projected to receive a larger than average payment decrease of 14.91 percent. Nonteaching hospitals and teaching hospitals with 100+ residents are projected to receive smaller than average payment decreases of 13.35 percent and 13.29 percent, respectively. Proprietary and government-owned hospitals are projected to receive smaller than average decreases of 12.86 and 13.36 percent, respectively. Rural hospitals are expected to receive a larger than average payment decrease of 14.02 percent. Hospitals with less than 25 percent Medicare utilization are projected to receive larger than average decreases of 13.89 percent, while hospitals with Medicare utilization of 25 percent or more are projected to receive smaller than average payment decreases.

Hospitals with less than 25 percent Medicaid utilization and those with 50–65 percent Medicaid utilization are projected to receive lower than average payments of 12.25 and 10.50 percent, respectively, while hospitals with 25–50 percent Medicaid utilization and those with greater than 65 percent Medicaid utilization are projected to receive a larger than average decrease of 15.20 percent and 15.67 percent, respectively.

The impact table reflects the modeled FY 2024 uncompensated care payments and supplemental payments for IHS/Tribal and Puerto Rico hospitals. We note that the supplemental payments for IHS and Tribal hospitals and Puerto Rico hospitals are estimated to be approximately $83.2 million in FY 2024.

3. Effects of the Changes to Indirect Medical Education and Direct Graduate Medical Education Payments

a. Calculation of Prior Year IME Resident to Bed Ratio When There Is a Medicare GME Affiliation Agreement

Under section V.G.2. of the preamble of this final rule, we are finalizing a proposed clarification to the Medicare cost report, CMS-Form-2552–10, Worksheet E, Part A, line 20, with regard to the IME calculation. As described in existing §412.105(a)(1)(i), the numerator of the prior year resident-to-bed ratio may be adjusted to reflect an increase in the current cost reporting period’s resident-to-bed ratio due to residents in a Medicare GME affiliation agreement (among other limited reasons). We explain how to measure the net increase in FTEs in the “current year numerator” as compared to the prior year’s numerator when there is a Medicare GME affiliation agreement. We are clarifying how to determine if the hospital increased its current year allowable FTE count, and are clarifying that the phrase “current year numerator” on Worksheet E, Part A line 20 refers to line 15 from Worksheet E, Part A. See section IL.F.2 of the preamble of this final rule for more details on this policy. An increase in the hospital’s FTE cap is offset by a decrease to another hospital’s FTE cap under the terms of a Medicare GME affiliation agreement. We estimate that there is no impact for this policy clarification, as there continues to be no change in the overall number of FTEs under the combined caps of the hospitals participating in the affiliation agreement.

b. Training in New REH Facility Type

As discussed in section V.G.3. of the preamble of this final rule, section 125 of Division CC of the Consolidated Appropriations Act, 2021 (CAA) added a new section 1861(kkk) of the Act to establish REHs as a new Medicare facility type, effective January 1, 2023. As part of the comments received in response to the CY 2023 OPPS proposed rule (87 FR 44502) and the proposed rule establishing REH CoPs (87 FR 40350), CMS received the request to designate REHs as graduate medical education (GME) eligible facilities similar to the GME designation for critical access hospitals (CAHs) (87 FR 72164).

As we note in this final rule, given the flexibility provided under section 1861(o) of the Act and the fact that an REH is a facility primarily engaged in patient care (see the definition of “nonprovider setting that is primarily engaged in furnishing patient care” at section 1886(h)(3)(K) of the Act), we believe that similarly to CAHs, statutory flexibility also exists for REHs to be considered nonprovider settings for GME payment purposes. We believe that increasing access to physicians in rural areas can be supported by a flexible policy which would allow for residency training to continue at CAHs that are not REHs and begin at other newly designated REHs, which may have not previously trained residents. Therefore, we proposed that effective for portions of cost reporting periods beginning on or after October 1, 2023, an REH may be considered a nonprovider site and a hospital may include FTEs residents training at an REH in its direct GME and IME FTE counts as long as it meets the nonprovider setting requirements included at 42 CFR 412.105(b)(1)(ii)(E) and 413.78(g) and any succeeding regulations. As an alternative to being considered a nonprovider site, we proposed under the authority of section 1886(k)(2)(D) of the Act, that REHs may decide to incur the costs of training residents in a hospital or CAH training program(s) and receive payment at 100 percent of the reasonable costs for those training costs consistent with section 1861(v)(1)(A) of the Act. In response to comments, we are finalizing these policies as proposed.
4. Effects of Changes for Reasonable Cost Payments for Nursing and Allied Health Programs

Under section V.H. of the preamble of this final rule, we finalize our proposal to implement section 4143 of the CAA 2023 (enacted December 29, 2022), called “Waiver of Cap on Annual Payments for Nursing and Allied Health Education Payments,” to state that for portions of cost reporting periods occurring in each of CYs 2010 through 2019, the $60 million payment limit, or payment “pool,” shall not apply to the “total amount of additional payments for nursing and allied health education to be distributed to hospitals” that, “as of the date of enactment of this clause, are operating a school of nursing, a school of allied health, or a school of nursing and allied health.” Section 4143 of the CAA 2023 also provides that in not applying the $60 million limit “for each of 2010 through 2019, the Secretary shall not take into account any increase in the total amount of such additional payment amounts for such nursing and allied health education for portions of cost reporting periods occurring in the year . . . .” We have estimated that the impact of this provision for FY 2024 to be approximately $1.8 billion.

5. Effects of Requirements Under the Hospital Readmissions Reduction Program for FY 2024

In section V.J. of the preamble of the FY 2024 IPPS/LTCH PPS proposed rule, we did not propose to add, modify, or remove any policies for the FY 2024 Hospital Readmissions Reduction Program (88 FR 27024); the policies finalized in FY 2023 IPPS/LTCH PPS final rule (87 FR 49081 through 49094) continue to apply. This program requires a reduction to a hospital’s base operating DRG payment to account for excess readmissions of selected applicable conditions and procedures. Table I.G.-01 and the analysis in this final rule illustrate the estimated financial impact of the Hospital Readmissions Reduction Program payment adjustment methodology by hospital characteristic for the FY 2024 program year. Hospitals are sorted into quintiles based on the proportion of dual-eligible stays among Medicare fee-for-service (FFS) and managed care stays between July 1, 2019, and June 30, 2022 (that is, the FY 2024 Hospital Readmissions Reduction Program’s applicable period).18 Hospitals’ excess readmission adjustment factor calculation to maintain Medicare budget neutrality. In this FY 2024 IPPS/LTCH PPS final rule, we are providing an updated estimate of the financial impact using the proportion of dual-eligible beneficiaries, ERRs, and aggregate payments for each condition/procedure and all discharges for applicable hospitals from the FY 2024 Hospital Readmissions Reduction Program applicable period.

The results in Table I.G.-03 include 2,855 non-Maryland hospitals estimated as eligible to receive a penalty during the performance period. Hospitals are eligible to receive a penalty if they have 25 or more eligible discharges for at least one measure during the FY 2024 applicable period. The second column in Table I.G.-01 indicates the total number of non-Maryland hospitals with available data for each characteristic that have an estimated payment adjustment factor calculation to maintain Medicare budget neutrality. In this FY 2024 IPPS/LTCH PPS final rule, we are providing an updated estimate of the financial impact using the proportion of dual-eligible beneficiaries, ERRs, and aggregate payments for each condition/procedure and all discharges for applicable hospitals from the FY 2024 Hospital Readmissions Reduction Program applicable period.

The results in Table I.G.-03 include 2,855 non-Maryland hospitals estimated as eligible to receive a penalty during the performance period. Hospitals are eligible to receive a penalty if they have 25 or more eligible discharges for at least one measure during the FY 2024 applicable period. The second column in Table I.G.-01 indicates the total number of non-Maryland hospitals with available data for each characteristic that have an estimated payment adjustment factor calculation to maintain Medicare budget neutrality. In this FY 2024 IPPS/LTCH PPS final rule, we are providing a penalty if they have 25 or more eligible discharges for at least one measure during the FY 2024 applicable period. The second column in Table I.G.-01 indicates the total number of non-Maryland hospitals with available data for each characteristic that have an estimated payment adjustment factor calculation to maintain Medicare budget neutrality. In this FY 2024 IPPS/LTCH PPS final rule, we are providing an updated estimate of the financial impact using the proportion of dual-eligible beneficiaries, ERRs, and aggregate payments for each condition/procedure and all discharges for applicable hospitals from the FY 2024 Hospital Readmissions Reduction Program applicable period.

18 Although the FY 2024 performance period is July 1, 2019, through June 30, 2022, we note that first and second quarter data from CY 2020 is excluded from program calculations due to the nationwide ECE that was granted in response to the COVID–19 PHE. Taking into consideration the 30-day window to identify readmissions, the period for calculating DRG payments will be adjusted to July 1, 2019, through December 1, 2019, and July 1, 2020, through June 30, 2022.
<table>
<thead>
<tr>
<th>Hospital Characteristic</th>
<th>Number of Eligible Hospitals</th>
<th>Number of Penalized Hospitals</th>
<th>Percentage of Hospitals Penalized (%)</th>
<th>Penalty as a Share of Payments (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Hospitals</td>
<td>2,855</td>
<td>2,356</td>
<td>82.52</td>
<td>0.44</td>
</tr>
<tr>
<td><strong>By Geographic Location (n= 2,852)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban hospitals</td>
<td>2,172</td>
<td>1,836</td>
<td>84.53</td>
<td>0.44</td>
</tr>
<tr>
<td>1-99 beds</td>
<td>499</td>
<td>329</td>
<td>65.93</td>
<td>0.45</td>
</tr>
<tr>
<td>100-199 beds</td>
<td>630</td>
<td>556</td>
<td>88.25</td>
<td>0.49</td>
</tr>
<tr>
<td>200-299 beds</td>
<td>394</td>
<td>359</td>
<td>91.12</td>
<td>0.49</td>
</tr>
<tr>
<td>300-399 beds</td>
<td>279</td>
<td>257</td>
<td>92.11</td>
<td>0.47</td>
</tr>
<tr>
<td>400-499 beds</td>
<td>118</td>
<td>105</td>
<td>88.98</td>
<td>0.49</td>
</tr>
<tr>
<td>500 or more beds</td>
<td>252</td>
<td>230</td>
<td>91.27</td>
<td>0.36</td>
</tr>
<tr>
<td><strong>Rural hospitals</strong></td>
<td>680</td>
<td>518</td>
<td>76.18</td>
<td>0.42</td>
</tr>
<tr>
<td>1-49 beds</td>
<td>325</td>
<td>225</td>
<td>69.23</td>
<td>0.30</td>
</tr>
<tr>
<td>50-99 beds</td>
<td>192</td>
<td>150</td>
<td>78.13</td>
<td>0.39</td>
</tr>
<tr>
<td>100-149 beds</td>
<td>85</td>
<td>73</td>
<td>85.88</td>
<td>0.50</td>
</tr>
<tr>
<td>150-199 beds</td>
<td>45</td>
<td>40</td>
<td>88.89</td>
<td>0.39</td>
</tr>
<tr>
<td>200 or more beds</td>
<td>33</td>
<td>30</td>
<td>90.91</td>
<td>0.51</td>
</tr>
<tr>
<td><strong>By Teaching Status (n= 2,852)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-teaching</td>
<td>1,677</td>
<td>1,317</td>
<td>78.53</td>
<td>0.49</td>
</tr>
<tr>
<td>Fewer than 100 residents</td>
<td>897</td>
<td>786</td>
<td>87.63</td>
<td>0.45</td>
</tr>
<tr>
<td>100 or more residents</td>
<td>278</td>
<td>251</td>
<td>90.29</td>
<td>0.39</td>
</tr>
<tr>
<td><strong>By Ownership Type (n= 2,852)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Government</td>
<td>399</td>
<td>313</td>
<td>78.45</td>
<td>0.33</td>
</tr>
<tr>
<td>Proprietary</td>
<td>663</td>
<td>527</td>
<td>79.49</td>
<td>0.55</td>
</tr>
<tr>
<td>Voluntary</td>
<td>1,790</td>
<td>1,514</td>
<td>84.58</td>
<td>0.44</td>
</tr>
<tr>
<td><strong>By Safety-net Status (n= 2,852)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety-net hospitals</td>
<td>557</td>
<td>469</td>
<td>84.20</td>
<td>0.37</td>
</tr>
<tr>
<td>Non-safety-net hospitals</td>
<td>2,295</td>
<td>1,885</td>
<td>82.14</td>
<td>0.46</td>
</tr>
<tr>
<td><strong>By Disproportionate Share Hospital (DSH) Patient Percentage (n= 2,852)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-24</td>
<td>1,148</td>
<td>901</td>
<td>78.48</td>
<td>0.52</td>
</tr>
<tr>
<td>25-49</td>
<td>1,412</td>
<td>1,208</td>
<td>85.55</td>
<td>0.41</td>
</tr>
<tr>
<td>50-64</td>
<td>182</td>
<td>157</td>
<td>86.26</td>
<td>0.31</td>
</tr>
<tr>
<td>65 and over</td>
<td>110</td>
<td>88</td>
<td>80.00</td>
<td>0.40</td>
</tr>
<tr>
<td><strong>By Medicare Cost Report (MCR) Percentage (n= 2,849)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-24</td>
<td>816</td>
<td>691</td>
<td>84.68</td>
<td>0.35</td>
</tr>
<tr>
<td>25-49</td>
<td>1,884</td>
<td>1,551</td>
<td>82.32</td>
<td>0.47</td>
</tr>
<tr>
<td>50-64</td>
<td>134</td>
<td>98</td>
<td>73.13</td>
<td>0.83</td>
</tr>
<tr>
<td>65 and over</td>
<td>15</td>
<td>12</td>
<td>80.00</td>
<td>0.27</td>
</tr>
</tbody>
</table>
6. Effects of Changes Under the Hospital Value-Based Purchasing (VBP) Program

a. Effects for the FY 2024 Program Year

In section V.K. of the preamble of this final rule, we discuss the Hospital VBP Program under which the Secretary makes value-based incentive payments to hospitals based on their performance on measures during the performance period with respect to a fiscal year. These incentive payments will be funded for FY 2024 through a reduction to the FY 2024 base operating DRG payment amount for hospital discharges for such fiscal year, as required by section 1886(o)(7)(B) of the Act. The applicable percentage for FY 2024 and subsequent years is 2 percent. The total amount available for value-based incentive payments must be equal to the total amount of reduced payments for all hospitals for the fiscal year, as estimated by the Secretary. In section V.K.1.b. of the preamble of this final rule, we estimate the available pool of funds for value-based incentive payments in the FY 2024 program year, which, in accordance with section 1886(o)(7)(C)(v) of the Act, will be 2.00 percent of base operating DRG payments, or a total of approximately $1.7 billion. This estimated available pool for FY 2024 is based on the historical pool of hospitals that were eligible to participate in the FY 2023 program year and the payment information from the March 2023 update to the FY 2022 MedPAR file. The proxy adjustment factors can be found in Table 16A associated with this final rule (available via the internet on the CMS website).

The impact analysis shows that, for the FY 2024 program year, the number of hospitals with a positive percent change in base operating DRG payments for the program year is lower than the number of hospitals with a negative percentage change. On average, urban hospitals in the West North Central region and rural hospitals in the East South Central region have the highest positive
percent change in base operating DRG. Urban hospitals in the New England, South Atlantic, East South Central, and Pacific regions and rural hospitals in the Middle Atlantic region experience an average negative percent change in base operating DRG. All other regions (both urban and rural) experience an average positive percent change in base operating DRG. With respect to hospitals’ Medicare utilization as a percent of inpatient days (MCR), as the MCR percent increases, the average percent change in base operating DRG generally increases, except for those hospitals of more than 50 percent MCR. As DSH percent increases, the average percent change in base operating DRG generally stays the same. On average, non-teaching hospitals have a lower percent change in base operating DRG compared to teaching hospitals; both non-teaching hospitals and teaching hospitals have a positive percent change in base operating DRG.

### TABLE I.G.-04 IMPACT ANALYSIS of BASE OPERATING DRG PAYMENT AMOUNTS RESULTING FROM THE FY 2024 HOSPITAL VBP PROGRAM

<table>
<thead>
<tr>
<th>BY GEOGRAPHIC LOCATION:</th>
<th>Number of Hospitals</th>
<th>Average Net Percentage Payment Adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Hospitals</td>
<td>2,523</td>
<td>0.025%</td>
</tr>
<tr>
<td>Urban Area</td>
<td>1,977</td>
<td>0.012%</td>
</tr>
<tr>
<td>Rural Area</td>
<td>546</td>
<td>0.073%</td>
</tr>
<tr>
<td>Missing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban Hospitals</td>
<td>1,977</td>
<td>0.012%</td>
</tr>
<tr>
<td>0-99 beds</td>
<td>344</td>
<td>0.036%</td>
</tr>
<tr>
<td>100-199 beds</td>
<td>617</td>
<td>0.010%</td>
</tr>
<tr>
<td>200-299 beds</td>
<td>396</td>
<td>0.017%</td>
</tr>
<tr>
<td>300-499 beds</td>
<td>381</td>
<td>0.032%</td>
</tr>
<tr>
<td>500 or more beds</td>
<td>239</td>
<td>-0.054%</td>
</tr>
<tr>
<td>Rural Hospitals</td>
<td>546</td>
<td>0.073%</td>
</tr>
<tr>
<td>0-49 beds</td>
<td>210</td>
<td>0.080%</td>
</tr>
<tr>
<td>50-99 beds</td>
<td>182</td>
<td>0.004%</td>
</tr>
<tr>
<td>100-149 beds</td>
<td>80</td>
<td>0.071%</td>
</tr>
<tr>
<td>150-199 beds</td>
<td>42</td>
<td>0.210%</td>
</tr>
<tr>
<td>200 or more beds</td>
<td>32</td>
<td>0.249%</td>
</tr>
</tbody>
</table>

### BY REGION:

| Urban By Region          | 1,977               | 0.012%                                    |
| New England              | 100                 | -0.006%                                   |
| Middle Atlantic          | 255                 | 0.015%                                    |
| South Atlantic           | 365                 | -0.080%                                   |
| East North Central       | 321                 | 0.060%                                    |
| East South Central       | 110                 | -0.008%                                   |
| West North Central       | 127                 | 0.178%                                    |
| West South Central       | 243                 | 0.030%                                    |
| Mountain                 | 148                 | 0.065%                                    |
| Pacific                  | 308                 | -0.025%                                   |

| Rural By Region          | 546                 | 0.073%                                    |
| New England              | 18                  | 0.113%                                    |
| Middle Atlantic          | 43                  | -0.075%                                   |
The actual FY 2024 program year’s TPSs will not be reviewed and corrected by hospitals until after the FY 2024 IPPS/LTCH PPS final rule has been published. Therefore, the same historical universe of eligible hospitals and corresponding TPSs from the FY 2023 program year have been used for the updated impact analysis in this final rule.

b. Estimated Effects for the FY 2026 Program Year Applying Finalized Scoring Methodology Change

The estimated effects of the finalized Health Equity Adjustment (HEA) bonus points include larger mean changes in payments for both hospitals that receive bonus payments and for those that incur penalties. In a simulated analysis of the impacts of HEA bonus points in the Hospital VBP Program using FY 2023 program year data, the average bonus payment with the HEA bonus points would be $3,724 and the average penalty would be $4,246. Our analysis finds that the finalized HEA scoring option increases the number of hospitals gaining compared to the existing scoring methodology. "Gaining" in this analysis means both those who are receiving a larger bonus and those who are receiving a smaller penalty under the health equity scoring change than they would receive in the existing scoring methodology. Through these analyses, we found that the average hospital-weighted payment adjustment is positive even though the Hospital VBP Program remains budget neutral. The increase in the number of hospitals gaining occurs primarily among safety net hospitals compared to non-safety net. Additionally, the distribution of TPSs would be higher after the HEA bonus points are incorporated. These impacts are described further in section V.K.6.b. of the preamble of this final rule.

7. Effects of Requirements Under the HAC Reduction Program for FY 2024

We are presenting the estimated impact of the FY 2024 Hospital-Acquired Condition (HAC) Reduction Program on hospitals by hospital characteristic based on previously adopted policies for the program. In the FY 2024 IPPS/LTCH PPS proposed rule, we did not propose to add or remove any measures from the HAC Reduction Program, nor did we propose any changes to reporting or submission requirements which would have any significant economic impact for the FY 2024 program year or future years. The table in this section presents the estimated proportion of hospitals in the worst-performing quartile of Total HAC Scores by hospital characteristic. Hospitals’ CMS Patient Safety and Adverse Events Composite (CMS PSI 90) measure results are based on Medicare fee-for-service (FFS) discharges from July 1, 2019, through December 31, 2019, and January 1, 2021, through June 30, 2021, and version 12.0 of the PSI software. Not all data from the FY 2024 HAC Reduction Program CMS PSI 90 performance period (January 1, 2021 through June 30, 2022) were available at the publication of the final rule. Hospitals’ measure results for Centers for Disease Control and Prevention (CDC) Central Line-Associated Bloodstream Infection (CLABSI), Catheter-Associated Urinary Tract Infection (CAUTI), Colon and Abdominal Hysterectomy Surgical Site Infection (SSI), Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, and Clostridium difficile Infection (CDI) are derived from standardized infection ratios (SIRs) calculated with hospital surveillance data reported to the CDC’s National Healthcare Safety Network (NHSN) for infections occurring between January 1, 2022, and December 31, 2022. Hospital characteristics are based on the FY 2024 IPPS Proposed Rule Impact File. We do not believe the proposals to establish a reconsideration process for data validation as discussed in section V.L.6.a.(2) of the preamble of the FY 2024 IPPS/LTCH PPS proposed rule (88 FR 27054 through 27055) and finalized in this rule will result in any significant economic impacts because the reconsideration request form will not be filled out by hospitals on a regular basis and information collection requirements imposed subsequent to an administrative action are not subject to the PRA under 5 CFR 1320.4(a)(2) (75 FR 50411). This form is intended to be submitted by a
hospital only in the event a hospital did not meet the HAC Reduction Program data validation requirement and seeks reconsideration from CMS on their data validation results for chart-abstracted measures. We anticipate receiving a small number of reconsideration requests annually as we expect very few, if any, hospitals selected for validation will not have their data successfully validated.

This table includes 2,997 non-Maryland hospitals with an estimated FY 2024 Total HAC Score. Maryland hospitals and hospitals without a Total HAC Score are excluded from the table. The first column presents a breakdown of each characteristic and the second column indicates the number of hospitals for the respective characteristic.

The third column in the table indicates the number of hospitals for each characteristic that would be in the worst-performing quartile of Total HAC Scores. These hospitals would receive a payment reduction under the FY 2024 HAC Reduction Program. For example, with regard to teaching status, 566 hospitals out of 1,767 hospitals characterized as non-teaching hospitals would be subject to a payment reduction. Among teaching hospitals, 123 out of 931 hospitals with fewer than 100 residents and 43 out of 279 hospitals with 100 or more residents would be subject to a payment reduction.

The fourth column in the table indicates the proportion of hospitals for each characteristic that would be in the worst performing quartile of Total HAC Scores and thus receive a payment reduction under the FY 2024 HAC Reduction Program. For example, 32.0 percent of the 1,767 hospitals characterized as non-teaching hospitals, 13.2 percent of the 931 teaching hospitals with fewer than 100 residents, and 15.4 percent of the 279 teaching hospitals with 100 or more residents would be subject to a payment reduction.
<table>
<thead>
<tr>
<th>Hospital Characteristic</th>
<th>Number of Hospitals</th>
<th>Number of Hospitals in the Worst-performing Quartile&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Percent of Hospitals in the Worst-Performing Quartile&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total&lt;sup&gt;c&lt;/sup&gt;</strong></td>
<td>2,997</td>
<td>749</td>
<td>25.0</td>
</tr>
<tr>
<td><strong>By Geographic Location (n = 2,977)&lt;sup&gt;d&lt;/sup&gt;</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban hospitals</td>
<td>2,295</td>
<td>450</td>
<td>19.6</td>
</tr>
<tr>
<td>1-99 beds</td>
<td>579</td>
<td>222</td>
<td>38.3</td>
</tr>
<tr>
<td>100-199 beds</td>
<td>655</td>
<td>121</td>
<td>18.5</td>
</tr>
<tr>
<td>200-299 beds</td>
<td>408</td>
<td>40</td>
<td>9.8</td>
</tr>
<tr>
<td>300-399 beds</td>
<td>282</td>
<td>23</td>
<td>8.2</td>
</tr>
<tr>
<td>400-499 beds</td>
<td>118</td>
<td>17</td>
<td>14.4</td>
</tr>
<tr>
<td>500 or more beds</td>
<td>253</td>
<td>27</td>
<td>10.7</td>
</tr>
<tr>
<td>Rural hospitals</td>
<td>682</td>
<td>282</td>
<td>41.3</td>
</tr>
<tr>
<td>1-49 beds</td>
<td>326</td>
<td>179</td>
<td>54.9</td>
</tr>
<tr>
<td>50-99 beds</td>
<td>193</td>
<td>71</td>
<td>36.8</td>
</tr>
<tr>
<td>100-149 beds</td>
<td>85</td>
<td>15</td>
<td>17.6</td>
</tr>
<tr>
<td>150-199 beds</td>
<td>45</td>
<td>11</td>
<td>24.4</td>
</tr>
<tr>
<td>200 or more beds</td>
<td>33</td>
<td>6</td>
<td>18.2</td>
</tr>
<tr>
<td><strong>By Safety-Net Status&lt;sup&gt;e&lt;/sup&gt; (n = 2,977)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-safety net</td>
<td>2,364</td>
<td>565</td>
<td>23.9</td>
</tr>
<tr>
<td>Safety-net</td>
<td>613</td>
<td>167</td>
<td>27.2</td>
</tr>
<tr>
<td><strong>By DSH Percent&lt;sup&gt;f&lt;/sup&gt; (n = 2,977)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-24</td>
<td>1,208</td>
<td>308</td>
<td>25.5</td>
</tr>
<tr>
<td>25-49</td>
<td>1,428</td>
<td>311</td>
<td>21.8</td>
</tr>
<tr>
<td>50-64</td>
<td>198</td>
<td>65</td>
<td>32.8</td>
</tr>
<tr>
<td>65 and over</td>
<td>143</td>
<td>48</td>
<td>33.6</td>
</tr>
<tr>
<td><strong>By Teaching Status&lt;sup&gt;g&lt;/sup&gt; (n =2,977)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-teaching</td>
<td>1,767</td>
<td>566</td>
<td>32.0</td>
</tr>
<tr>
<td>Fewer than 100 residents</td>
<td>931</td>
<td>123</td>
<td>13.2</td>
</tr>
<tr>
<td>100 or more residents</td>
<td>279</td>
<td>43</td>
<td>15.4</td>
</tr>
<tr>
<td><strong>By Ownership (n = 2,977)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Voluntary</td>
<td>1,843</td>
<td>377</td>
<td>20.5</td>
</tr>
<tr>
<td>Proprietary</td>
<td>716</td>
<td>187</td>
<td>26.1</td>
</tr>
<tr>
<td>Government</td>
<td>418</td>
<td>168</td>
<td>40.2</td>
</tr>
<tr>
<td><strong>By MCR Percent&lt;sup&gt;h&lt;/sup&gt; (n = 2,975)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-24</td>
<td>917</td>
<td>207</td>
<td>22.6</td>
</tr>
<tr>
<td>25-49</td>
<td>1,911</td>
<td>462</td>
<td>24.2</td>
</tr>
<tr>
<td>50-64</td>
<td>128</td>
<td>48</td>
<td>37.5</td>
</tr>
<tr>
<td>65 and over</td>
<td>19</td>
<td>13</td>
<td>68.4</td>
</tr>
<tr>
<td><strong>By Region&lt;sup&gt;i&lt;/sup&gt; (n= 2,997)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New England</td>
<td>129</td>
<td>27</td>
<td>20.9</td>
</tr>
<tr>
<td>Mid-Atlantic</td>
<td>323</td>
<td>73</td>
<td>22.6</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>496</td>
<td>99</td>
<td>20.0</td>
</tr>
<tr>
<td>East North Central</td>
<td>473</td>
<td>113</td>
<td>23.9</td>
</tr>
<tr>
<td>East South Central</td>
<td>260</td>
<td>90</td>
<td>34.6</td>
</tr>
<tr>
<td>West North Central</td>
<td>236</td>
<td>51</td>
<td>21.6</td>
</tr>
<tr>
<td>West South Central</td>
<td>473</td>
<td>155</td>
<td>32.8</td>
</tr>
<tr>
<td>Mountain</td>
<td>228</td>
<td>62</td>
<td>27.2</td>
</tr>
<tr>
<td>Pacific</td>
<td>379</td>
<td>79</td>
<td>20.8</td>
</tr>
</tbody>
</table>

Source: FY 2024 HAC Reduction Program estimated final rule results are based on CMS PSI 90 data from July 1, 2019, through December 31, 2019, and January 1, 2021, through June 30, 2021, and CDC NHSHN HAI results from January 1, 2022, through December 31, 2022. Hospital Characteristics are based on the FY 2024 IPPS Proposed Rule Impact File.
In section V.L.6.a.(3) of the preamble of the FY 2024 IPPS/LTCH PPS proposed rule, we proposed to update our targeting criteria for validation of hospitals granted an extraordinary circumstances exception (ECE) in the HAC Reduction Program (86 FR 27058). Specifically, we proposed to modify the validation targeting criteria to include any hospital with a two-tailed confidence interval that is less than 75 percent and received an ECE for one or more quarters beginning with the FY 2027 program year. In previous years, we have incorporated a second component into the budget neutrality offset methodology for these years.

For this final rule, we are finalizing this modification. We do not believe this modification of targeting criteria will have any economic impact on the hospitals selected for validation but will only increase the number of hospitals which are subject to being targeted for validation. Any increase will not exceed the total maximum number of hospitals that will be selected for targeted validation as previously finalized.

8. Effects of Implementation of the Rural Community Hospital Demonstration Program in FY 2024

In section V.K. of the preamble of this final rule for FY 2023, we discussed our implementation and budget neutrality methodology for section 410A of Public Law 108–173, as amended by sections 3123 and 10313 of Public Law 111–148, by section 15003 of Public Law 114–255, and most recently, by section 128 of Public Law 116–260, which requires the Secretary to conduct a demonstration that would modify payments for inpatient services for up to 30 rural hospitals.

Section 128 of Public Law 116–255 requires the Secretary to conduct the Rural Community Hospital Demonstration for a 15-year extension period (that is, for an additional 5 years beyond the previous extension period). In addition, the statute provides for continued participation for all hospitals participating in the demonstration program as of December 30, 2019.

Section 410A(c)(2) of Public Law 108–173 requires that in conducting the demonstration program under this section, the Secretary shall ensure that the aggregate payments made by the Secretary do not exceed the amount which the Secretary would have paid if the demonstration program under this section was not implemented (budget neutrality). We propose to adopt the general methodology used in previous years, whereby we estimated the additional payments made by the program for each of the participating hospitals as a result of the demonstration, and then adjusted the national IPPS rates by an amount sufficient to account for the additional costs of this demonstration. In other words, we have applied budget neutrality across the payment system as a whole rather than across the participants of this demonstration. The language of the statutory budget neutrality requirement permits the agency to implement the budget neutrality provision in this manner. The statutory language requires that aggregate payments made by the Secretary do not exceed the amount which the Secretary would have paid if the demonstration was not implemented, but does not identify the range across which aggregate payments must be held equal.

For this final rule, the resulting amount applicable to FY 2024 is $37,766,716, which we are including in the budget neutrality offset adjustment for FY 2024. This estimated amount is based on the specific assumptions regarding the data sources used, that is, recently available “as submitted” cost reports and historical and currently finalized update factors for cost and payment.

In previous years, we have incorporated a second component into the budget neutrality offset amounts identified in the final IPPS rules. As finalized cost reports became available, we determined the amount by which the actual costs of the demonstration for this fiscal year differed from the estimated costs for the demonstration set forth in the final IPPS rule for the corresponding fiscal year, and we incorporated that amount into the budget neutrality offset amount for the upcoming fiscal year. We have calculated this difference for FY 2005 through 2017 between the actual costs of the demonstration as determined from finalized cost reports once available, and estimated costs of the demonstration as identified in the applicable IPPS final rule for that fiscal year.

With the extension of the demonstration for another 5-year period, as authorized by section 128 of Public Law 116–260, we continue this general procedure. At this time, for the FY 2024 final rule, all of the finalized cost reports are available for the 20 hospitals that completed cost report periods beginning in FY 2019 under the demonstration payment methodology; these cost reports show the actual costs of the demonstration for this fiscal year to be $46,745,899. This amount exceeds the amount that was estimated for FY 2018 in the FY 2019 IPPS final rule ($31,070,880) by $15,675,019. (Following upon the selection of new hospitals for the demonstration in 2017, the estimated costs of the demonstration for FY 2018 and 2019 were included in the FY 2019 IPPS final rule). (83 FR 41054). Thus, keeping with past practice, we are adding this difference to the estimated cost for FY 2024 in determining the budget neutrality offset amount for the FY 2024 IPPS final rule.

Therefore, for this FY 2024 IPPS/LTCH PPS final rule, the budget neutrality offset amount for FY 2024 is based on the sum of two amounts:

- The amount representing the difference applicable to FY 2024 between the sum of the estimated reasonable cost amounts that would be paid under the demonstration for covered inpatient services to the 26 hospitals participating in the fiscal year and the sum of the estimated amounts that would generally be paid if the demonstration had not been implemented. This estimated amount is $37,766,716.

- The amount by which the actual costs of the demonstration in FY 2018 differ from the estimated costs for that fiscal year) differ from the amount determined for FY 2018. The amount of this difference is for FY 2018 is $15,675,019.

We are thus subtracting the sum of these amounts ($53,441,735) from the national IPPS rates for FY 2024.

9. Effects of Continued Implementation of the Frontier Community Health Integration Project (FCHIP) Demonstration

In section VII.B.2. of the preamble of this final rule, we discussed the implementation of the FCHIP Demonstration, which allows eligible entities to develop and test new models for the delivery of health care services in eligible counties to improve access to and integrate the delivery of acute care, extended care, and other health care services to Medicare beneficiaries in no more than four States. Section 123 of Public Law 110–275 initially required a 3-year period of performance. The FCHIP Demonstration began on August 1, 2016, and concluded on July 31, 2019 (referred to in
this section as the “initial period”). Section 129 of the Consolidated Appropriations Act (Pub. L. 116–159) extended the FCHIP Demonstration by 5 years (referred to in this section as the “extension period” of the demonstration). CAHs participating in the demonstration extension period during the extension period began such participation in their cost reporting year that began on or after January 1, 2022. Budget neutrality estimates for the demonstration described in the preamble of this final rule are based on the demonstration extension period.

As described in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49144 through 49147), CMS waived certain Medicare rules for CAHs participating in the demonstration extension period to allow for alternative reasonable cost-based payment methods in the three distinct intervention service areas: telehealth services, ambulance services, and skilled nursing facility/nursing facility services. These waivers were implemented with the goal of increasing access to care with no net increase in costs, as explained in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49144 through 49147), section 129 of Public Law 116–159 stipulates that only the 10 CAHs that participated in the initial period of the FCHIP Demonstration are eligible to participate during the extension period. Among the eligible CAHs, five elected to participate in the extension period. The selected CAHs are in two states—Montana and North Dakota—and are implementing the three intervention services.

As explained in the FY 2023 IPPS/LTCH PPS final rule, we based our selection of CAHs for participation in the demonstration with the goal of maintaining the budget neutrality of the demonstration on its own terms meaning that the demonstration would produce savings from reduced transfers and admissions to other health care providers, offsetting any increase in Medicare payments as a result of the demonstration. However, because of the small size of the demonstration and uncertainty associated with the projected Medicare utilization and costs, the policy we finalized for the demonstration extension period of performance in the FY 2023 IPPS/LTCH PPS final rule provides a contingency plan to ensure that the budget neutrality requirement in section 123 of Public Law 110–275 is met. In the FY 2023 IPPS/LTCH PPS final rule, we adopted the same budget neutrality policy contingency plan used during the demonstration initial period to ensure that the budget neutrality requirement in section 123 of Public Law 110–275 is met during the demonstration extension period. If analysis of claims data for Medicare beneficiaries receiving services at each of the participating CAHs, as well as from other data sources, including cost reports for the participating CAHs, shows that increases in Medicare payments under the demonstration during the 5-year period is not sufficiently offset by reductions elsewhere, we will recoup the additional expenditures attributable to the demonstration through a reduction in payments to all CAHs nationwide.

As explained in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49144 through 49147), because of the small scale of the demonstration, we indicated that we did not believe it would be feasible to implement budget neutrality for the demonstration extension period by reducing payments to only the participating CAHs. Therefore, in the event that this demonstration extension period is found to result in aggregate payments in excess of the amount that would have been paid if this demonstration extension period were not implemented, CMS policy is to comply with the budget neutrality requirement finalized in the FY 2023 IPPS/LTCH PPS final rule, by reducing payments to all CAHs, not just those participating in the demonstration extension period.

In the FY 2023 IPPS/LTCH PPS final rule, we stated that we believe it is appropriate to make any payment reductions across all CAHs because the FCHIP Demonstration was specifically designed to test innovations that affect delivery of services by the CAH provider category. As we explained in the FY 2023 IPPS/LTCH PPS final rule, we believe that the language of the statutory budget neutrality requirement at section 123(g)(1)(B) of Public Law 110–275 permits the agency to implement the budget neutrality provision in this manner. The statutory language merely refers to ensuring that aggregate payments made by the Secretary do not exceed the amount which the Secretary estimates would have been paid if the demonstration project was not implemented, and does not identify the range across which aggregate payments must be held equal.

In the FY 2022 IPPS/LTCH PPS final rule (86 FR 45323 through 45328), CMS concluded that the initial period of the FCHIP Demonstration had satisfied the budget neutrality requirement described in section 123(g)(1)(B) of Public Law 110–275. Therefore, CMS did not apply a budget neutrality payment offset policy for the initial period of the demonstration. As explained in the FY 2022 IPPS/LTCH PPS final rule, we finalized a policy to address the demonstration initial period methodology and analytical approach for the initial period of the demonstration. As stated in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49144 through 49147), our policy for implementing the 5-year extension period for the demonstration initial period methodology. While we expect to use the same methodology that was used to assess the budget neutrality of the FCHIP Demonstration during initial period of the demonstration to assess the financial impact of the demonstration during this extension period, upon receiving data for the extension period, we may modify the FCHIP budget neutrality methodology and analytical approach to ensure that the full impact of the demonstration is appropriately captured. Therefore, we did not propose to apply a budget neutrality payment offset to payments to CAHs in FY 2024. This policy will have no impact for any national payment system for FY 2024.

10. Effects of Changes for Rural Emergency Hospitals

Section X.A. of the preamble of this final rule would address the special requirements for REHs that would require an eligible facility (a CAH or a small rural hospital with not more than 50 beds) to submit additional information that must include an action plan containing four specific elements if the facility submits an application for enrollment as an REH. An eligible facility that submits an application for enrollment as an REH under section 1866(i) of the Act must also submit additional information as specified in this final rule. In accordance with paragraph 1861(kkk)(4)(A)(i) through (iv) of the Act, we specifically propose to require an eligible facility to submit additional information that must include an action plan containing: (1) a plan for initiating REH services (as those services are defined in 42 CFR 485.502, and which must include the provision of emergency department services and observation care); (2) a detailed transition plan that lists the specific services that the provider will retain, modify, add, and discontinue as an REH; (3) a detailed description of other outpatient medical and health services that it intends to furnish on an outpatient basis as an REH; and (4) information regarding how the provider intends to use the additional facility payment.

The RFA requires agencies to analyze options for regulatory relief of small entities, if a rule has a significant impact on a substantial number of small entities. For purposes of the RFA, small entities include small businesses, nonprofit organizations, and small governmental jurisdictions. Most hospitals and most other healthcare providers and suppliers are small entities, either by nonprofit status or by having revenues of less than $8.6 million to $41.5 million in any 1 year. Individuals and states are not included in the definition of a small entity. We estimate that almost all of the new REH facilities are or would be small entities based on legal status, revenues, or both. The North American Industry Classification System Code for the converting hospitals is 622110 (General Medical and Surgical Hospitals), and for the REHs to which they convert the closest Code is 621493 (Freestanding Ambulatory Surgical and Emergency Centers). HHS uses an increase in costs or decrease in revenues of more than 3 percent as its threshold for “significant economic impact”. Our collection of information (COI) estimate is that the 68 facilities converting to REH status would face a one-time cost of about $460 each (68 × $460 = $31,280 (COI burden estimate)). The North Carolina Rural Health Research Program estimated that the 68 hospitals it thought most likely to convert to REH status had average patient revenues of $7.3 million.19

19 "How Many Hospitals Might Convert to a Rural Emergency Hospital (REH)?" July 2021. Pink, GH et
For these facilities, the 3 percent threshold would be about $219,000, nearly 500 times our estimated cost of information collection. These relationships between revenues and costs would not be substantially different if the number of conversions was substantially fewer or substantially greater in number. More importantly, these facilities would be converting voluntarily to the new program. We expect that the costs any facility faces would be less than the anticipated gains of conversion, or it would not convert. For these reasons, an Initial Regulatory Flexibility Analysis is not required for the proposed Special Requirements for REHs.

11. Effects of Changes for Physician-Owned Hospitals

Provisions related to hospitals that have physician ownership or investment are discussed in section X.B. of the preamble of this final rule. Section X.B.2.a. of the preamble of this final rule describes our changes to the regulations to clarify that CMS will only consider an expansion exception requests from eligible hospitals, clarify the data and information that must be included in an expansion exception request and the information that a requesting hospital may submit at its option, identify factors that CMS will consider when deciding whether to approve or deny an expansion exception request, and revise certain aspects of the process for requesting an expansion exception. We expect that the clarifications and revisions, as finalized, along with the description of the factors we will consider when deciding whether to approve or deny an expansion exception request, will increase transparency, allow for greater community input, ensure that approval of a request to expand a hospital’s facility capacity occurs only in appropriate circumstances, and facilitate compliance with the process for requesting an expansion exception. The use of HCRIS data for all comparison calculations, as required under the final rule, will have little practical impact on whether a requesting hospital meets the criteria for an applicable hospital or a high Medicaid facility, nor will a requesting hospital be prejudiced by this requirement.

Section X.B.2.b. of the preamble of this final rule describes our reinstatement, with respect to high Medicaid facilities, of the program integrity restrictions on the frequency of expansion exception requests, maximum aggregate expansion of a hospital, and location of expansion capacity that were removed in the CY 2021 OPPS/ASC final rule. We believe that not applying these program integrity restrictions poses a significant risk of program or patient abuse that must be addressed despite any potential perceived burden on high Medicaid facilities. We anticipate that treating both applicable and high Medicaid hospitals the same will create consistency in the expansion exception process and protect the Medicare program and its beneficiaries, as well as Medicaid beneficiaries, uninsured patients, and other underserved populations, from harms such as overutilization, patient steering, cherry-picking, and lemon-dropping. More information on the comments received on the physician-owned hospital provisions can be found in section X.B. of the preamble of this final rule.

H. Effects on Hospitals and Hospital Units Excluded From the IPPS

As of July 2023, there were 91 children’s hospitals, 11 cancer hospitals, 6 short term acute care hospitals in the Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa, 1 extended neoplastic disease care hospital, and 9 RNHCIs being paid on a reasonable cost basis subject to the rate-of-increase ceiling under §413.40. (In accordance with §403.752(a) of the regulation, RNHCIs are paid under §413.40.) Among the remaining providers, the rehabilitation hospitals and units, and the LTCHs, are paid the Federal prospective payment rate and the rate-of-increase ceiling under §413.40. (For the LTCHs, respectively, and the psychiatric hospitals and units are paid the Federal per diem amount under the IPPS.) As stated previously, IRFs and IPFs are not affected by the rate updates discussed in this final rule. The impacts of the changes are discussed in section I.J. of this appendix. For the children’s hospitals, cancer hospitals, short-term acute care hospitals located in the Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa, the extended neoplastic disease care hospital, and RNHCIs, the update to the rate-of-increase limit for FY 2024 is as follows:

The impact of the update in the rate-of-increase limit for FY 2024 for excluded hospitals depends on the cumulative cost increases experienced by each excluded hospital since its applicable base period. For excluded hospitals that have maintained their cost increases at a level below the rate-of-increase limits since their base period, the major effect is the level of increase that the excluded hospitals receive. Conversely, for excluded hospitals with cost increases above the cumulative update in their rate-of-increase limits, the major effect is the amount of excess costs that would not be paid. We note that, under §413.40(j), an excluded hospital that continues to be paid under the TEFRa system and whose costs exceed 110 percent of its rate-of-increase limit receives its rate-of-increase limit plus the lesser of: (1) 50 percent of its reasonable costs in excess of 110 percent of the limit; or (2) 10 percent of its limit. In addition, under the various provisions set forth in §413.40, hospitals can obtain payment adjustments for justifiable increases in operating costs that exceed the limit.

I. Effects of Changes in the Capital IPPS

1. General Considerations

For the impact analysis presented in this section of this final rule, we used data from the March 2023 update of the FY 2022 MedPar file and the March 2023 update of the Provider-Specific File (PSF) that was used for payment purposes. Although the analyses of the changes to the capital prospective payment system do not incorporate cost data, we used the March 2023 update of the most recently available hospital cost report data to categorize hospitals. Our analysis has several qualifications and uses the best data available, as described later in this section of this final rule.

Due to the interdependent nature of the IPPS, it is very difficult to precisely quantify the impact associated with each change. In addition, we draw upon various sources for the data used to categorize hospitals in the tables. In some cases (for instance, the number of beds), there is a fair degree of variation in the data from different sources. We have attempted to construct these variables with the best available sources overall. However, it is possible that some individual hospitals are placed in the wrong category. Using cases from the March 2023 update of the FY 2022 MedPar file, we simulated payments under the capital IPPS for FY 2023 and the payments for FY 2024 for a comparison of total payments per case. Short-term, acute care hospitals not paid under the general IPPS (for example, hospitals in Maryland) are excluded from the simulations.

The methodology for determining a capital IPPS payment is set forth at §412.312. The basic methodology for calculating the capital IPPS payments in FY 2024 is as follows:

I. Cost-based Federal rate × (DRG weight) × (GAF) × (COLA for hospitals located in Alaska and Hawaii) × (1 + DSH adjustment factor + IME adjustment factor, if applicable).

In addition to the other adjustments, hospitals may receive outlier payments for those cases that qualify under the threshold established for each fiscal year. We modeled
payments for each hospital by multiplying the capital Federal rate by the geographic adjustment factor (GAF) and the hospital’s case-mix. Then we added estimated payments for indirect medical education, disproportionate share, and outliers, if applicable. For purposes of this impact analysis, the model includes the following assumptions:

- The capital Federal rate was updated, beginning in FY 1996, by an analytical framework that considers changes in the prices associated with capital-related costs and adjustments to the capital Federal rate. This framework allows for changes in the case-mix index, allow changes in intensity, and other factors. As discussed in section III.A.1. of the Addendum to this final rule, the update to the capital Federal rate is 3.8 percent for FY 2024.

- In addition to the FY 2024 update factor, the FY 2024 capital Federal rate was calculated based on a GAF/DRG budget neutrality adjustment factor of 0.9885, a budget neutrality adjustment factor for the lowest quartile hospital wage index adjustment and the 5-percent cap on wage index decreases policy of 0.9964, and an outlier adjustment factor of 0.9598.

2. Results

We used the payment simulation model previously described in section I.I. of appendix A of this final rule to estimate the potential impact of the changes for FY 2024 on total capital payments per case, using a universe of 3,131 hospitals. As previously described, the individual hospital payment parameters are taken from the best available data, including the March 2023 update of the FY 2022 MedPAR file, the March 2023 update to the PSF, and the most recent available cost report data from the March 2023 update of HCRIS. In Table III, we present a comparison of estimated total payments per case for FY 2023 and estimated total payments per case for FY 2024 based on the FY 2024 payment policies. Column 2 shows estimates of payments per case under our model for FY 2023. Column 3 shows estimates of payments per case under our model for FY 2024. Column 4 shows the total percentage change in payments from FY 2023 to FY 2024. The change represented in Column 4 includes the 3.80 percent update to the capital Federal rate and other changes in the hospital’s capital Federal rate. The comparisons are provided by: (1) geographic location; (2) region; and (3) payment classification. The simulation results show that, on average, capital payments per case in FY 2024 are expected to increase 6.6 percent compared to capital payments per case in FY 2023. This expected increase is primarily due to the 3.80 percent update to the capital Federal rate and an estimated increase in capital DSH payments. As discussed in section V.I.D. of the preamble to this final rule, we are finalizing that beginning in FY 2024, hospitals reclassified as rural under § 412.103 will no longer be considered rural for purposes of determining eligibility for capital DSH payments. As such, under this policy, geographically urban hospitals with 100 or more beds reclassified as rural under § 412.103 will be eligible for capital DSH payments beginning in FY 2024. The CMS’ Office of the Actuary estimates this change in policy will increase capital payments $170 million in FY 2024.

In general, regional variations in estimated capital payments per case in FY 2024 as compared to capital payments per case in FY 2023 are primarily due to the changes in the wage index (and policies affecting the wage index), as shown in Table I in our final rule to estimate the potential impact of the changes for FY 2024.

Meanwhile, the change in capital payments per case from FY 2023 to FY 2024 for rural areas range from a 2.4 percent increase for the New England rural region to a 16.8 percent increase for the Middle Atlantic region. These regional differences are primarily due to the changes in the GAFs, which reflect the changes to the rural wage index methodology. We note that the changes to the rural wage index methodology are significantly contributing to the lower than average increase in capital payments per case for the rural Middle Atlantic region.

The comparison by hospital type of ownership (Voluntary, Proprietary, and Government) shows that voluntary hospitals are expected to experience the highest increase in capital payments per case from FY 2023 to FY 2024 of 6.6 percent. Meanwhile, proprietary and government hospitals are expected to experience an increase in capital payments per case from FY 2023 to FY 2024 of 6.4 percent.

Section 1886(d)(10) of the Act established the MGCRB. Hospitals may apply for reclassification for purposes of the wage index for FY 2024. Reclassification for wage index purposes also affects the GAFs because that factor is constructed from the hospital wage index. To present the effects of the hospitals being reclassified as of the publication of this final rule for FY 2024, we show the average capital payments per case for reclassified hospitals compared to urban nonreclassified hospitals are expected to experience an increase in capital payments of 4.6 percent. The higher expected increase in payments for urban reclassified hospitals compared to urban nonreclassified hospitals is primarily due to an estimated increase in capital DSH payments to urban reclassified hospitals. As discussed previously, we are finalizing a change to our capital DSH policy under which geographically urban hospitals with 100 or more beds reclassified as rural under § 412.103 will be eligible for capital DSH payments beginning in FY 2024. Rural reclassified hospitals are expected to experience an increase in capital payments of 5.4 percent; rural nonreclassified hospitals are expected to experience an increase in capital payments of 6.6 percent.
### TABLE III.--COMPARISON OF TOTAL PAYMENTS PER CASE

<table>
<thead>
<tr>
<th>[FY 2023 PAYMENTS COMPARED TO FY 2024 PAYMENTS]</th>
<th>Number of Hospitals</th>
<th>Average FY 2023 Payments/Case</th>
<th>Average FY 2024 Payments/Case</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All Hospitals</strong></td>
<td>3,131</td>
<td>1,088</td>
<td>1,160</td>
<td>6.6</td>
</tr>
<tr>
<td><strong>By Geographic Location:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban hospitals</td>
<td>2,416</td>
<td>1,119</td>
<td>1,194</td>
<td>6.7</td>
</tr>
<tr>
<td>Rural hospitals</td>
<td>715</td>
<td>763</td>
<td>807</td>
<td>5.8</td>
</tr>
<tr>
<td><strong>Bed Size (Urban):</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-99 beds</td>
<td>650</td>
<td>881</td>
<td>912</td>
<td>3.5</td>
</tr>
<tr>
<td>100-199 beds</td>
<td>696</td>
<td>942</td>
<td>1,000</td>
<td>6.2</td>
</tr>
<tr>
<td>200-299 beds</td>
<td>414</td>
<td>1,030</td>
<td>1,102</td>
<td>7.0</td>
</tr>
<tr>
<td>300-499 beds</td>
<td>404</td>
<td>1,108</td>
<td>1,193</td>
<td>7.7</td>
</tr>
<tr>
<td>500 or more beds</td>
<td>250</td>
<td>1,332</td>
<td>1,416</td>
<td>6.3</td>
</tr>
<tr>
<td><strong>Bed Size (Rural):</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-49 beds</td>
<td>363</td>
<td>648</td>
<td>686</td>
<td>5.9</td>
</tr>
<tr>
<td>50-99 beds</td>
<td>188</td>
<td>734</td>
<td>786</td>
<td>7.1</td>
</tr>
<tr>
<td>100-149 beds</td>
<td>87</td>
<td>746</td>
<td>789</td>
<td>5.8</td>
</tr>
<tr>
<td>150-199 beds</td>
<td>46</td>
<td>838</td>
<td>882</td>
<td>5.3</td>
</tr>
<tr>
<td>200 or more beds</td>
<td>31</td>
<td>901</td>
<td>948</td>
<td>5.2</td>
</tr>
<tr>
<td><strong>Urban by Region:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New England</td>
<td>108</td>
<td>1,199</td>
<td>1,259</td>
<td>5.0</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>292</td>
<td>1,250</td>
<td>1,349</td>
<td>7.9</td>
</tr>
<tr>
<td>East North Central</td>
<td>372</td>
<td>1,048</td>
<td>1,101</td>
<td>5.1</td>
</tr>
<tr>
<td>West North Central</td>
<td>156</td>
<td>1,077</td>
<td>1,124</td>
<td>4.4</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>403</td>
<td>972</td>
<td>1,038</td>
<td>6.8</td>
</tr>
<tr>
<td>East South Central</td>
<td>138</td>
<td>944</td>
<td>993</td>
<td>5.2</td>
</tr>
<tr>
<td>West South Central</td>
<td>359</td>
<td>1,025</td>
<td>1,075</td>
<td>4.9</td>
</tr>
<tr>
<td>Mountain</td>
<td>177</td>
<td>1,131</td>
<td>1,208</td>
<td>6.8</td>
</tr>
<tr>
<td>Pacific</td>
<td>360</td>
<td>1,451</td>
<td>1,590</td>
<td>9.6</td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>51</td>
<td>606</td>
<td>627</td>
<td>3.5</td>
</tr>
<tr>
<td><strong>Rural by Region:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New England</td>
<td>19</td>
<td>1,051</td>
<td>1,076</td>
<td>2.4</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>47</td>
<td>744</td>
<td>869</td>
<td>16.8</td>
</tr>
<tr>
<td>East North Central</td>
<td>113</td>
<td>757</td>
<td>792</td>
<td>4.6</td>
</tr>
<tr>
<td>West North Central</td>
<td>84</td>
<td>774</td>
<td>810</td>
<td>4.7</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>108</td>
<td>705</td>
<td>747</td>
<td>6.0</td>
</tr>
<tr>
<td>East South Central</td>
<td>140</td>
<td>725</td>
<td>760</td>
<td>4.8</td>
</tr>
<tr>
<td>West South Central</td>
<td>134</td>
<td>684</td>
<td>717</td>
<td>4.8</td>
</tr>
<tr>
<td>Mountain</td>
<td>46</td>
<td>860</td>
<td>885</td>
<td>2.9</td>
</tr>
<tr>
<td>Pacific</td>
<td>24</td>
<td>982</td>
<td>1,084</td>
<td>10.4</td>
</tr>
</tbody>
</table>

**By Payment Classification:**
J. Effects of Payment Rate Changes and Policy Changes Under the LTCH PPS

1. Introduction and General Considerations

In section VII. of the preamble of this final rule and section V. of the Addendum to this final rule, we set forth the annual update to the payment rates for the LTCH PPS for FY 2024. In the preamble of this final rule, we specify the statutory authority for the provisions that are presented, identify the policies for FY 2024, and present rationales for our provisions as well as alternatives that were considered. In this section, we discuss the impact of the changes to the payment rate, factors, and other payment rate policies related to the LTCH PPS that are presented in the preamble of this final rule in terms of their estimated fiscal impact on the Medicare budget and on LTCHs.

There are 333 LTCHs included in this impact analysis. We note that, although there are currently approximately 341 LTCHs, for purposes of this impact analysis, we excluded the data of all-inclusive rate providers consistent with the development of the FY 2024 MS–LTC–DRG relative weights (discussed in section VII.B.3. of the preamble of this final rule). We have also excluded data for CCN 312024 from this impact analysis.
analysis due to their abnormal charging practices. We note this is consistent with our removal of this LTCH from the calculation of the FY 2024 MS–LTC–DRG relative weights, the area wage level adjustment budget neutrality factor, and the fixed-loss amount for LTCH PPS standard Federal payment rate cases (discussed in section VII.B.3. of the preamble of this final rule). Moreover, in the claims data used for this final rule, one of these 333 LTCHs only have claims for site neutral payment rate cases and, therefore, do not affect our impact analysis for LTCH PPS standard Federal payment rate cases.

In the impact analysis, we used the payment rate, factors, and policies presented in this final rule, the 3.3 percent annual update to the LTCH PPS standard Federal payment rate, the update to the MS–LTC–DRG classifications and relative weights, the update to the wage index values and labor-related share, and the best available claims and CCR data to estimate the change in payments for FY 2024.

Under the site neutral LTCH PPS payment structure, payment for LTCH discharges that meet the criteria for exclusion from the site neutral payment rate (that is, LTCH PPS standard Federal payment rate cases) is based on the LTCH PPS standard Federal payment rate. Consistent with the statute, the site neutral payment rate is the lower of the IPPS comparable per diem amount as determined under §412.529(d)(4), including any applicable outlier payments as specified in §412.525(a), reduced by 4.6 percent for FYs 2018 through 2026; or 100 percent of the estimated Medicare approved charges as determined under §412.529(d)(2). In addition, there are two separate high cost outlier targets—one for LTCH PPS standard Federal payment rate cases and one for site neutral payment rate cases. We note that section 3711(b)(2) of the CARES Act provided a waiver of the application of the site neutral payment rate for LTCH cases admitted during the COVID–19 PHE period. The COVID–19 PHE expired on May 11, 2023. As a result, all FY 2023 cases with admission dates on or before the PHE expiration date will be paid the LTCH PPS standard Federal payment rate regardless of whether the discharge meet the statutory patient criteria. However, all FY 2023 and FY 2024 cases with admission dates after the PHE expiration date (that is, admissions occurring on or after May 12, 2023) that do not meet the criteria for exclusion from the site neutral payment rate will be paid the site neutral payment rate determined under §412.522(c). For purposes of this impact analysis, estimates of total LTCH PPS payments for site neutral payment rate cases in FYs 2023 and 2024 were calculated using the site neutral payment rate determined under §412.522(c) for all cases and the provisions of the CARES Act were not considered.

Based on the best available data from the 333 LTCHs and data that were considered in the analyses used for this final rule, we estimate that overall LTCH PPS payments in FY 2024 will increase by approximately 0.2 percent (or approximately $6 million) based on the rates and factors presented in section VII. of the preamble and section V. of the Addendum to this final rule.

Based on the FY 2022 LTCH cases that were used for the analysis in this final rule, approximately 32 percent of those cases were classified as site neutral payment rate cases (that is, 32 percent of LTCH cases would not meet the statutory patient-level criteria for exclusion from the LTCH PPS standard payment rate). Our Office of the Actuary currently estimates that the percent of LTCH PPS cases that will be classified as site neutral payment rate cases in FY 2024 will not change significantly from the most recent historical data. When applicable, per diem amounts using the prior year’s IPPS rates and factors, updated to reflect estimated changes to the IPPS rates and payments finalized for FY 2024. Taking this into account along with other changes that will apply to the site neutral payment rate cases in FY 2024, we estimate that aggregate LTCH PPS payments for these site neutral payment rate cases will increase by approximately 3.2 percent (or approximately $10 million). This projected increase in payments to LTCH PPS site neutral payment rate cases is partly due to the finalized updates to the IPPS rates and payments reflected in our estimate of the IPPS comparable per diem amount. We note that we estimate payments to site neutral payment rate cases in FY 2024 will represent approximately 12 percent of estimated aggregate FY 2024 LTCH PPS payments.

Based on the FY 2022 LTCH cases that were used for the analysis in this final rule, approximately 68 percent of LTCH cases will meet the patient-level criteria for exclusion from the site neutral payment rate in FY 2023 and, as a result, the LTCH PPS standard Federal payment rate for the full year. We estimate that total LTCH PPS payments for these LTCH PPS standard Federal payment rate cases in FY 2024 will decrease approximately 0.2 percent (or approximately $4 million). This estimated decrease in LTCH PPS payments for LTCH PPS standard Federal payment rate cases in FY 2024 is primarily due to the projected 2.9 percent decrease in high cost outlier payments as a percentage of total LTCH PPS standard Federal payment rate payments, which is discussed later in this section of the final rule.

Based on the 333 LTCHs that were represented in the FY 2022 LTCH cases that were used for the analyses in this final rule presented in this appendix, we estimate that aggregate FY 2023 LTCH PPS payments will be approximately $2,603 billion, as compared to estimated aggregate FY 2024 LTCH PPS payments of approximately $2,609 billion, resulting in an estimated overall increase in LTCH PPS payments of approximately $6 million. We note that the estimated $6 million increase in LTCH PPS payments in FY 2024 does not reflect changes in LTCH admissions or case-mix intensity, which will also affect the overall payment effects of the policies in this final rule.

The LTCH PPS standard Federal payment rate for FY 2023 is $46,432.77. For FY 2024, we are establishing an LTCH PPS standard Federal payment rate of $48,116.62 which reflects the 3.3 percent annual update to the LTCH PPS standard Federal payment rate and the budget neutrality factor for updates to the area wage level adjustment of 1.0031599 (discussed in section V.B.6. of the Addendum to this final rule). For LTCHs that fail to submit data for the LTCH QRP, in accordance with section 1886(m)(5)(C) of the Act, we are establishing an LTCH PPS standard Federal payment rate of $47,185.03. This LTCH PPS standard Federal payment rate reflects the updates and factors previously described, as well as the required 2.0 percentage point reduction to the annual update for failure to submit data under the LTCH QRP.

Table IV shows the estimated impact for LTCH PPS standard Federal payment rate cases. The estimated change attributable solely to the annual update of 3.3 percent to the LTCH PPS standard Federal payment rate is projected to result in an increase of 3.2 percent in payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2023 to FY 2024, on average, for all LTCHs (Column 6). The estimated increase of 3.2 percent shown in Column 6 of Table IV also includes estimated payments for short-stay outlier (SSO) cases, which are not affected by the annual update to the LTCH PPS standard Federal payment rate, as well as the reduction that is applied to the annual update for LTCHs that do not submit the required LTCH QRP data. For most hospital categories, the projected increase in payments based on the LTCH PPS standard Federal payment rate to LTCH PPS standard Federal payment rate cases also rounds to approximately 3.2 percent.

For FY 2024, we are updating the wage index values based on the most recent available data (ICF’s second quarter 2023 forecast) of the relative importance of the labor-related share of operating and capital costs of the 2017-based LTCH market basket. We also are applying an area wage level budget neutrality factor of 1.0031599 to ensure that the changes result in any change in estimated aggregate LTCH PPS payments to LTCH PPS standard Federal payment rate cases.

For LTCH PPS standard Federal payment rate cases, we currently estimate high cost outlier payments as a percentage of total LTCH PPS standard Federal payment rate payments will decrease from FY 2023 to FY 2024. Based on the FY 2022 LTCH cases that were used for the analyses in this final rule, we estimate that the FY 2023 high cost outlier threshold of $38,518 (as established in the FY 2023 IPPS/LTCH PPS final rule) will result in estimated high cost outlier payments for LTCH PPS standard Federal payment rate cases in FY 2023 that are projected to exceed the 7.975 percent target. Specifically, we currently estimate that high cost outlier payments for LTCH PPS standard Federal payment rate cases will be approximately 10.9 percent of the estimated total LTCH PPS standard Federal payment rate payments in FY 2023. Combined with our estimate that FY 2024 high cost outlier payments for LTCH PPS standard Federal payment rate cases will be 7.975 percent of
estimated total LTCH PPS standard Federal payment rate payments in FY 2024, this will result in an estimated decrease in high cost outlier payments as a percentage of total LTCH PPS standard Federal payment rate payments of approximately 2.9 percent between FY 2023 and FY 2024. We note that, in calculating these estimated high cost outlier payments, we inflated charges reported on the FY 2022 claims by the charge inflation factor described in section V.D.3.b. of the Addendum to this final rule. We also note that, in calculating these estimated high cost outlier payments, we estimated the cost of each case by multiplying the inflated charges by the adjusted CCRs that we determined using our finalized methodology described in section V.D.3.b. of the Addendum to this final rule.

Table IV shows the estimated impact of the payment rate and policy changes on LTCH PPS payments for LTCH PPS standard Federal payment rate cases for FY 2024 by comparing estimated FY 2023 LTCH PPS payments and FY 2024 LTCH PPS payments. (As noted earlier, our analysis does not reflect changes in LTCH admissions or case-mix intensity.) We note that these impacts do not include LTCH PPS site neutral payment rate cases as discussed in section I.J.3. of this appendix.

Comment: We received comments expressing concern about the 2.5 percent decrease in payments to LTCH PPS standard Federal payment rate cases that we projected in the proposed rule. Some commenters stated that this decrease would jeopardize the ability of LTCHs to continue caring for their patients and would lead to LTCH closures. Some commenters stated that Medicare reimbursements already do not cover hospital costs and therefore they found the projected payment reduction especially concerning.

Response: We appreciate commenters’ concerns about the proposed 2.5 percent decrease in payments to LTCH PPS standard Federal payment rate cases. As explained in the proposed rule (88 FR 27286), that estimate was approximately 2.5 percent was primarily due to the projected decrease in high cost outlier payments. Specifically, we explained that we estimated high cost outlier payments in FY 2023 would account for approximately 12.7 percent of total LTCH PPS standard Federal payment rate payments. Because this exceeds the statutory 7.975 percent target, it resulted in an estimated decrease in high cost outlier payments as a percentage of total LTCH PPS standard Federal payment rate payments of approximately 4.7 percent between FY 2023 and FY 2024.

Based on the finalized payment rates and factors in this final rule, we now project a 0.2 percent decrease in payments to LTCH PPS standard Federal payment rate cases for FY 2024. This change in projected payments is primarily driven by a downward LTCH PPS revision in this final rule to our estimate of FY 2023 high cost outlier payments to LTCH PPS standard Federal payment rate cases. In this final rule, after incorporating into our payment model the modified charge inflation and CCR adjustment factors discussed in section V.D.3.b. of the Addendum to this final rule, we now estimate that high cost outlier payments for LTCH PPS standard Federal payment rate cases will be approximately 10.9 percent of the estimated total LTCH PPS standard Federal payment rate payments in FY 2023 (as compared to approximately 12.7 percent noted previously). In addition, this change in projected payments is partially being driven by the annual update factor of 3.3 percent (which is 0.4 percentage point higher than the proposed annual update factor). As discussed in section I.J.3. of the preamble to this final rule, we believe this LTCH market basket increase appropriately reflects the input price growth that LTCHs will incur providing medical services in FY 2024.

As we discuss in detail throughout this final rule, based on the best available data, we believe that the provisions of this final rule relating to the LTCH PPS, which are projected to result in an overall increase in estimated aggregate LTCH PPS payments (for both LTCH PPS standard Federal payment rate cases and site neutral payment rate cases), and the LTCH PPS payment amounts will result in appropriate Medicare payments that are consistent with the statute.

2. Impact on Rural Hospitals

For purposes of section 1102(b) of the Act, we define a small rural hospital as a hospital that is located outside of an urban area and has fewer than 100 beds. As shown in Table IV, we are projecting a 0.3 percent increase in estimated payments for LTCH PPS standard Federal payment rate cases for LTCHs located in a rural area. This estimated impact is based on the FY 2022 data for the 18 rural LTCHs (out of 333 LTCHs) that were used for the impact analyses shown in Table IV.

3. Anticipated Effects of the LTCH PPS Payment Rate Changes and Policy Changes

a. Budgetary Impact

Section 123(a)(1) of the BBRA requires that the PPS developed for LTCHs “maintain budget neutrality.” We believe that the statute’s mandate for budget neutrality applies only to the first year of the implementation of the LTCH PPS (that is, FY 2003). Therefore, in calculating the FY 2003 standard Federal payment rate under § 412.523(d)(2), we set total estimated payments for FY 2003 under the LTCH PPS structure for LTCH PPS standard Federal payment rate cases equal to the amount that would have been paid if the LTCH PPS had not been implemented. Section 1886(m)(6)(A) of the Act establishes a dual rate LTCH PPS payment structure with two distinct payment rates for LTCH discharges beginning in FY 2016. Under this statutory change, LTCH discharges that meet the patient-level criteria for exclusion from the site neutral payment rate (that is, LTCH PPS standard Federal payment rate cases) are paid based on the LTCH PPS standard Federal payment rate. LTCH discharges paid at the site neutral payment rate generally paid the lower of the IPPS comparable per diem amount, reduced by 4.6 percent for FYs 2018 through 2026, including any applicable high cost outlier (HCO) payments, or 100 percent of the estimated cost of the case, reduced by 4.6 percent.

As discussed in section I.J.1. of this appendix, we project an increase in aggregate LTCH PPS payments in FY 2024 of approximately $6 million. This estimated increase in payments reflects the projected decrease in payments to LTCH PPS standard Federal payment rate cases of approximately $4 million and the projected increase in payments to site neutral payment rate cases of approximately $10 million under the dual rate LTCH PPS payment structure established by the statute beginning in FY 2016.

As discussed in section V.D. of the Addendum to this final rule, our actuaries project cost and resource changes for site neutral payment rate cases due to the site neutral payment rates required under the statute. Specifically, our actuaries project that the costs and resource use for cases paid at the siteneutral payment rate will likely be lower, on average, than the costs and resource use for cases paid at the LTCH PPS standard Federal payment rate. This projected reduction in payments to site neutral payment rate cases will likely mirror the costs and resource use for IPPS cases assigned to the same MS–DRG.

While we are able to incorporate this projection using aggregate level data into our payment modeling, because the historical claims data that we are using in this final rule to project estimated FY 2024 LTCH PPS payments (that is, FY 2022 LTCH claims data) do not reflect this actuarial projection, we are unable to model the impact of the change in LTCH PPS payments for site neutral payment rate cases at the same level of detail with which we are able to model the impacts of the changes to LTCH PPS payments for LTCH PPS standard Federal payment rate cases. Therefore, Table IV only reflects changes in LTCH PPS payments for LTCH PPS standard Federal payment rate cases and, unless otherwise noted, the remaining discussion in section I.J.3. of this appendix refers only to the impact on LTCH PPS payments for LTCH PPS standard Federal payment rate cases. In the following section, we present our provider impact analysis for the changes that affect LTCH PPS payments for LTCH PPS standard Federal payment rate cases.

b. Impact on Providers

The basic methodology for determining a per discharge payment for LTCH PPS standard Federal payment rate cases is currently set forth at 42 U.S.C. § 1395mt through 42 U.S.C. § 1395mx. In addition to adjusting the LTCH PPS standard Federal payment rate by the MS–LTCH–DRG relative weight, we make adjustments to account for area wage levels and SSOs. LTCHs located in Alaska and Hawaii also have their payments adjusted by a COLA. Under our application of the dual rate LTCH PPS payment structure, the LTCH PPS standard Federal payment rate is generally only used to determine payments for LTCH PPS standard Federal payment rate cases that is, those LTCH discharges that meet the statutory criteria to be excluded from the site neutral payment rate. LTCH discharges that do not meet the patient-level criteria for exclusion are paid the site neutral payment rate, which we are calculating as the lower of the IPPS comparable per diem amount as determined under 412.529(d)(4).
been in effect at the time of discharge for all cases in the FY 2022 MedPAR files. For modeling FY 2023 LTCH PPS payments, we used the FY 2023 standard Federal payment rate of $46,432.77 (or $45,538.11 for LTCHs that failed to submit quality data as required under the requirements of the LTCH QRP). Similarly, for modeling FY 2024 LTCH PPS standard Federal payment rate, we used the finalized FY 2024 standard Federal payment rate of $48,116.62 (or $47,185.03 for LTCHs that failed to submit quality data as required under the requirements of the LTCH QRP). In each case, we applied the applicable adjustments for area wage levels and the COLA for LTCHs located in Alaska and Hawaii. Specifically, for modeling FY 2023 LTCH PPS payments, we used the current FY 2023 labor-related share (68.0 percent), the wage index values established in the Tables 12A and 12B listed in the Addendum to the FY 2023 IPPS/LTCH PPS final rule (which are available via the internet on the CMS website), the FY 2023 HCO fixed-loss amount for LTCH PPS standard Federal payment rate cases of $38,518 (as reflected in the FY 2023 IPPS/LTCH PPS final rule), and the FY 2023 COLA factors (shown in the table in section V.C. of the Addendum to that final rule) to adjust the FY 2024 nonlabor-related share (31.5 percent) for LTCHs located in Alaska and Hawaii. Similarly, for modeling FY 2024 LTCH PPS payments, we used the FY 2024 LTCH PPS labor-related share (68.5 percent), the FY 2024 wage index values from Tables 12A and 12B listed in section VI. of the Addendum to this final rule (which are available via the internet on the CMS website), the FY 2024 HCO fixed-loss amount for LTCH PPS standard Federal payment rate cases of $59,873 (as discussed in section V.C. of the Addendum to this final rule) to adjust the FY 2024 nonlabor-related share (31.5 percent) for LTCHs located in Alaska and Hawaii. We note that in modeling payments for HCO cases for LTCH PPS standard Federal payment rate cases, we inflated charges reported on the FY 2022 claims by the charge inflation factors in section V.D.3.b. of the Addendum to this final rule. We also note that in modeling payments for HCO cases for LTCH PPS standard Federal payment rate cases, we estimated the cost of each case by multiplying the inflated charges by the adjusted CCRs that we determined using our finalized methodology described in section V.D.3.b. of the Addendum to this final rule.

The impacts that follow reflect the estimated “losses” or “gains” among the various classifications of LTCHs from FY 2023 to FY 2024 based on the payment rates and policy changes applicable to LTCH PPS standard Federal payment rate cases presented in this final rule. Table IV illustrates the estimated aggregate impact of the change in LTCH PPS payments for LTCH PPS standard Federal payment rate cases among various classifications of LTCHs. (As discussed previously, these impacts do not include LTCH PPS site neutral payment rate cases.)

- The first column, LTCH Classification, identifies the type of LTCH.
- The second column lists the number of LTCHs of each classification type.
- The third column identifies the number of LTCH cases expected to meet the LTCH PPS standard Federal payment rate criteria.
- The fourth column shows the estimated FY 2023 payment per discharge for LTCH cases expected to meet the LTCH PPS standard Federal payment rate criteria (as described previously).
- The fifth column shows the estimated FY 2024 payment per discharge for LTCH cases expected to meet the LTCH PPS standard Federal payment rate criteria (as described previously).
- The sixth column shows the percentage change in estimated payments per discharge for LTCH cases expected to meet the LTCH PPS standard Federal payment rate criteria from FY 2023 to FY 2024 due to the annual update to the standard Federal rate (as discussed in section V.A.2. of the Addendum to this final rule).
- The seventh column shows the percentage change in estimated payments per discharge for LTCH cases expected to meet the LTCH PPS standard Federal payment rate cases from FY 2023 to FY 2024 for changes to the area wage level adjustment (that is, the updated hospital wage data and labor-related share) and the application of the corresponding budget neutrality factor (as discussed in section V.B.6. of the Addendum to this final rule).
- The eighth column shows the percentage change in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2023 (Column 4) to FY 2024 (Column 5) for all changes.

For the following analysis, we group hospitals based on characteristics provided in the OSCAR data, cost report data in HCRIIS, and PSF data. Hospital groups included the following:

- Location: large urban/other urban/rural.
- Participation date.
- Ownership control.
- Census region.
- Bed size.

c. Calculation of LTCH PPS Payments for LTCH PPS Standard Federal Payment Rate Cases

For purposes of this impact analysis, to estimate the per discharge payment effects of our policies on payments for LTCH PPS standard Federal payment rate cases, we simulated FY 2023 and FY 2024 payments on a case-by-case basis using historical LTCH claims from the FY 2022 MedPAR files that met or would have met the criteria to be paid at the LTCH PPS standard Federal payment rate if the statutory patient-level criteria had been in effect at the time of discharge for all
<table>
<thead>
<tr>
<th>LTCH Classification</th>
<th>No. of LTCHS</th>
<th>Number of LTCH PPS Standard Payment Rate Cases</th>
<th>Average FY 2023 LTCH PPS Payment Per Standard Payment Rate</th>
<th>Average FY 2024 LTCH PPS Payment Per Standard Payment Rate¹</th>
<th>Change Due to Change to the Annual Update to the Standard Federal Rate²</th>
<th>Percent Change Due to Changes to Area Wage Adjustment with Wage Budget Neutrality³</th>
<th>Percent Change Due to All Standard Payment Rate Changes⁴</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Providers</td>
<td>332</td>
<td>41,552</td>
<td>55,109</td>
<td>55,022</td>
<td>3.2</td>
<td>0.0</td>
<td>-0.2</td>
</tr>
<tr>
<td>By Location:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rural</td>
<td>18</td>
<td>1,550</td>
<td>43,038</td>
<td>43,157</td>
<td>3.1</td>
<td>-0.5</td>
<td>0.3</td>
</tr>
<tr>
<td>Urban</td>
<td>314</td>
<td>40,002</td>
<td>55,577</td>
<td>55,482</td>
<td>3.2</td>
<td>0.0</td>
<td>-0.2</td>
</tr>
<tr>
<td>By Participation Date:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Before Oct. 1983</td>
<td>10</td>
<td>889</td>
<td>51,487</td>
<td>50,344</td>
<td>3.3</td>
<td>0.0</td>
<td>-2.2</td>
</tr>
<tr>
<td>Oct. 1983 - Sept. 1993</td>
<td>36</td>
<td>5,180</td>
<td>63,155</td>
<td>63,317</td>
<td>3.1</td>
<td>0.4</td>
<td>0.3</td>
</tr>
<tr>
<td>Oct. 1993 - Sept. 2002</td>
<td>132</td>
<td>16,865</td>
<td>54,398</td>
<td>54,568</td>
<td>3.2</td>
<td>-0.1</td>
<td>-0.1</td>
</tr>
<tr>
<td>After October 2002</td>
<td>154</td>
<td>18,618</td>
<td>53,687</td>
<td>53,530</td>
<td>3.2</td>
<td>-0.1</td>
<td>-0.3</td>
</tr>
<tr>
<td>By Ownership Type:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Voluntary</td>
<td>54</td>
<td>4,738</td>
<td>58,953</td>
<td>57,920</td>
<td>3.2</td>
<td>0.1</td>
<td>-1.8</td>
</tr>
<tr>
<td>Proprietary</td>
<td>269</td>
<td>36,271</td>
<td>54,329</td>
<td>54,372</td>
<td>3.2</td>
<td>0.0</td>
<td>0.1</td>
</tr>
<tr>
<td>Government</td>
<td>9</td>
<td>543</td>
<td>73,665</td>
<td>73,126</td>
<td>3.1</td>
<td>1.2</td>
<td>-0.7</td>
</tr>
<tr>
<td>By Region:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New England</td>
<td>10</td>
<td>1,178</td>
<td>46,952</td>
<td>46,155</td>
<td>3.3</td>
<td>-0.1</td>
<td>-1.7</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>19</td>
<td>2,605</td>
<td>65,336</td>
<td>65,882</td>
<td>3.2</td>
<td>0.4</td>
<td>0.8</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>61</td>
<td>8,558</td>
<td>53,413</td>
<td>53,193</td>
<td>3.2</td>
<td>0.2</td>
<td>-0.4</td>
</tr>
<tr>
<td>East North Central</td>
<td>47</td>
<td>5,870</td>
<td>57,030</td>
<td>56,359</td>
<td>3.2</td>
<td>-0.4</td>
<td>-1.2</td>
</tr>
<tr>
<td>East South Central</td>
<td>31</td>
<td>3,071</td>
<td>50,921</td>
<td>50,560</td>
<td>3.2</td>
<td>-0.4</td>
<td>-0.7</td>
</tr>
<tr>
<td>West North Central</td>
<td>22</td>
<td>2,329</td>
<td>54,179</td>
<td>52,745</td>
<td>3.3</td>
<td>-0.2</td>
<td>-2.6</td>
</tr>
<tr>
<td>West South Central</td>
<td>92</td>
<td>10,635</td>
<td>46,573</td>
<td>46,938</td>
<td>3.2</td>
<td>0.2</td>
<td>0.8</td>
</tr>
<tr>
<td>Mountain</td>
<td>27</td>
<td>2,291</td>
<td>54,250</td>
<td>54,767</td>
<td>3.1</td>
<td>-0.7</td>
<td>1.0</td>
</tr>
<tr>
<td>Pacific</td>
<td>23</td>
<td>5,015</td>
<td>73,846</td>
<td>74,068</td>
<td>3.0</td>
<td>0.3</td>
<td>0.3</td>
</tr>
<tr>
<td>By Bed Size:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beds: 0-24</td>
<td>28</td>
<td>1,770</td>
<td>53,280</td>
<td>53,176</td>
<td>3.2</td>
<td>-0.1</td>
<td>-0.2</td>
</tr>
<tr>
<td>Beds: 25-49</td>
<td>162</td>
<td>16,088</td>
<td>50,021</td>
<td>50,060</td>
<td>3.2</td>
<td>-0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>Beds: 50-74</td>
<td>74</td>
<td>10,213</td>
<td>54,689</td>
<td>54,639</td>
<td>3.2</td>
<td>0.1</td>
<td>-0.1</td>
</tr>
<tr>
<td>Beds: 75-124</td>
<td>48</td>
<td>8,757</td>
<td>62,822</td>
<td>62,598</td>
<td>3.1</td>
<td>0.0</td>
<td>-0.4</td>
</tr>
<tr>
<td>Beds: 125-199</td>
<td>17</td>
<td>4,294</td>
<td>60,993</td>
<td>60,646</td>
<td>3.1</td>
<td>0.4</td>
<td>-0.6</td>
</tr>
<tr>
<td>Beds: 200+</td>
<td>3</td>
<td>430</td>
<td>47,123</td>
<td>46,882</td>
<td>3.2</td>
<td>-0.1</td>
<td>-0.5</td>
</tr>
</tbody>
</table>
1 Estimated FY 2024 LTCH PPS payments for LTCH PPS standard Federal payment rate criteria based on the finalized payment rate and factor changes applicable to such cases presented in the preamble of and the Addendum to this final rule.
2 Percent change in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2023 to FY 2024 for the annual update to the LTCH PPS standard Federal payment rate.
3 Percent change in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2023 to FY 2024 for changes due to the changes to the area wage level adjustment under § 412.525(c) (that is, updated hospital wage data and the labor related share).
4 Percent change in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2023 (shown in Column 4) to FY 2024 (shown in Column 5), including all of the changes to the rates and factors applicable to such cases presented in the preamble and the Addendum to this final rule. We note that this column, which shows the percent change in estimated payments per discharge for all changes, does not equal the sum of the percent changes in estimated payments per discharge for the annual update to the LTCH PPS standard Federal payment rate (Column 6) and the changes due to the changes to the area wage level adjustment with budget neutrality (Column 7) due to the effect of estimated changes in estimated payments to aggregate HCO payments for LTCH PPS standard Federal payment rate cases (as discussed in this impact analysis), as well as other interactive effects that cannot be isolated.
d. Results

Based on the FY 2023 LTCH cases (from 333 LTCHs) that were used for the analyses in this final rule, we have prepared the following summary of the impact (as shown in Table IV) of the LTCH PPS payment rate and policy changes for LTCH PPS standard Federal payment rate cases presented in this final rule. The impact analysis in Table IV shows that estimated payments per discharge for LTCH PPS standard Federal payment rate cases are projected to decrease 0.2 percent, on average, for all LTCHs from FY 2023 to FY 2024 as a result of the payment rate and policy changes applicable to LTCH PPS standard Federal payment rate cases presented in this final rule. This estimated 0.2 percent decrease in LTCH PPS payments per discharge was determined by comparing estimated FY 2024 LTCH PPS payments (using the finalized payment rates and factors discussed in this final rule) to estimated FY 2023 LTCH PPS payments for LTCH discharges which will be LTCH PPS standard Federal payment rate cases if the dual rate LTCH PPS payment structure was or had been in effect at the time of the discharge (as described in section I.J.3. of this appendix).

As stated previously, we are finalizing an annual update to the LTCH PPS standard Federal payment rate for FY 2024 of 3.3 percent. For LTCHs that fail to submit quality data under the requirements of the LTCH QRP, as required by section 1886(m)(5)(C) of the Act, a 2.0 percentage point reduction is applied to the annual update to the LTCH PPS standard Federal payment rate. Consistent with § 412.523(d)(4), we also are applying a budget neutrality factor for changes to the area wage level adjustment of 1.0031599 (discussed in section V.B.6. of the Addendum to this final rule), based on the best available data at this time, to ensure that any changes to the area wage level adjustment will not result in any change (increase or decrease) in estimated aggregate LTCH PPS standard Federal payment rate cases. As we also explained earlier in this section of the final rule, for most categories of LTCHs (as shown in Table IV, Column 6), the estimated payment increase due to the 3.3 percent annual update to the LTCH PPS standard Federal payment rate is projected to result in approximately a 3.2 percent increase in estimated payments per discharge for LTCH PPS standard Federal payment rate cases for all LTCHs from FY 2023 to FY 2024. We note our estimate of the changes in payments due to the update to the LTCH PPS standard Federal payment rate also includes estimated payments for short-stay outlier (SSO) cases, a portion of which are not affected by the annual update to the LTCH PPS standard Federal payment rate, as well as the reduction that is applied to the annual update for LTCHs that do not submit data under the requirements of the LTCH QRP.

(1) Location

Based on the most recent available data, the vast majority of LTCHs are located in urban areas. Only approximately 5 percent of the LTCHs are identified as being located in a rural area, and approximately 4 percent of all LTCH PPS standard Federal payment rate cases are expected to be treated in these rural hospitals. The impact analysis presented in Table IV shows that the overall average percent decrease in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2023 to FY 2024 for all hospitals is approximately 0.2 percent. Urban LTCHs are also projected to experience a decrease of 0.2 percent. Meanwhile, rural LTCHs are projected to experience an increase of 0.3 percent.

(2) Participation Date

LTCHs are grouped by participation date into four categories: (1) between October 1983; (2) between October 1983 and September 1993; (3) between October 1993 and September 2002; and (4) October 2002 and after. Based on the best available data, the categories of LTCHs with the largest expected percentage of LTCH PPS standard Federal payment rate cases (approximately 41 percent and 42 percent, respectively) are in LTCHs that began participating in the Medicare program between October 1993 and September 2002 and after October 2002. These LTCHs are expected to experience a decrease in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2023 to FY 2024 of 0.1 percent and 0.3 percent, respectively. LTCHs that began participating in the Medicare program between October 1983 and September 1993 are projected to experience an increase in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2023 to FY 2024 of 0.3 percent, as shown in Table IV. Approximately 3 percent of LTCHs began participating in the Medicare program before October 1983, and these LTCHs are projected to experience a decrease in estimated payments per discharge for LTCH PPS standard Federal payment rate cases of 0.6 percent.

(3) Ownership Control

LTCHs are grouped into three categories based on ownership control type: voluntary, proprietary, and government. Based on the best available data, approximately 16 percent of LTCHs are identified as voluntary (Table IV). The majority (approximately 81 percent) of LTCHs are identified as proprietary, while government owned and operated LTCHs represent approximately 3 percent of LTCHs. Based on ownership type, proprietary LTCHs are expected to experience an increase in estimated payments per discharge for LTCH PPS standard Federal payment rate cases of 0.1 percent. Voluntary LTCHs are expected to experience a decrease in payments to LTCH PPS standard Federal payment rate cases from FY 2023 to FY 2024 of 0.7 percent.

(4) Census Region

The comparisons by region show that the changes in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2023 to FY 2024 are projected to range from a decrease of 2.6 percent in the West North Central region to an increase of 1.0 percent in the Mountain region. These regional variations are primarily due to the changes to the area wage adjustment and estimated changes in outlier payments.

(5) Bed Size

LTCHs are grouped into six categories based on bed size: 0–24 beds; 25–49 beds; 50–74 beds; 75–124 beds; 125–199 beds; and greater than 200 beds. We project that LTCHs with 125–199 beds will experience a decrease in payments for LTCH PPS standard Federal payment rate cases of 0.6 percent. LTCHs with 25–49 beds are projected to experience an increase in payments of 0.1 percent. The remaining bed size categories are projected to experience a decrease in payments in the range of 0.1 to 0.5 percent.

5. Effect on the Medicare Program

As stated previously, we project that the provisions of this final rule will result in a decrease in estimated aggregate LTCH PPS payments to LTCH PPS standard Federal payment rate cases from FY 2023 to FY 2024 relative to FY 2023 of approximately $4 million (or approximately 0.2 percent) for the 333 LTCHs in our database. Although, as stated previously, the hospital-level impacts do not include LTCH PPS site neutral payment rate cases, we estimate that the provisions of this final rule will result in an increase in estimated aggregate LTCH PPS payments to site neutral payment rate cases in FY 2024 relative to FY 2023 of approximately $10 million (or approximately 0.3 percent) for the 333 LTCHs in our database. Therefore, we project that the provisions of this final rule will result in an increase in estimated aggregate LTCH PPS payments for all LTCH cases in FY 2024 relative to FY 2023 of approximately 6 million (or approximately 0.2 percent) for the 333 LTCHs in our database.

5. Effect on Medicare Beneficiaries

Under the LTCH PPS, hospitals receive payment based on the average resources consumed by patients admitted to the hospital. We do not expect any changes in the quality of care that is consumed in LTCHs. LTCHs are grouped into six categories based on bed size: 0–24 beds; 25–49 beds; 50–74 beds; 75–124 beds; 125–199 beds; and greater than 200 beds. The majority (approximately 81 percent) of LTCHs are identified as proprietary, while government owned and operated LTCHs represent approximately 3 percent of LTCHs. Based on ownership type, proprietary LTCHs are expected to experience an increase in estimated payments per discharge for LTCH PPS standard Federal payment rate cases of 0.1 percent. Voluntary LTCHs are expected to experience a decrease in payments to LTCH PPS standard Federal payment rate cases from FY 2023 to FY 2024 of 0.7 percent.
In this final rule, we are: (1) removing the Elective Delivery measure beginning with the CY 2024 reporting period/FY 2026 payment determination; (2) adopting the Hospital Harm-Pressure Injury electronic clinical quality measure (eCQM) beginning with the CY 2025 reporting period/FY 2027 payment determination; (3) adopting the Hospital Harm—Acute Kidney Injury eCQM beginning with the CY 2025 reporting period/FY 2027 payment determination; (4) adopting the Excessive Radiation eCQM beginning with CY 2025 reporting period/FY 2027 payment determination; (5) modifying the Hybrid Hospital-Wide All-Cause Risk Standardized Mortality measure beginning with the performance data from July 1, 2024 through June 30, 2025, impacting the FY 2027 payment determination; (6) modifying the Hybrid Hospital-Wide All-Cause Risk Standardized Readmission measure beginning with the performance data from July 1, 2024 through June 30, 2025, impacting the FY 2027 payment determination; (7) modifying the Risk-Standardized Complication Rate Following Elective Primary Total Hip Arthroplasty and/or Total Knee Arthroplasty measure beginning with the April 1, 2025 through March 31, 2028 reporting period impacting the FY 2030 payment determination; (8) removing the Medicare Beneficiary Hospital measure beginning with the CY 2024 reporting period/FY 2026 payment determination; (9) modifying the validation targeting criteria to include any hospital with a two-tailed confidence interval that is less than 75 percent and which submitted less than four quarters of data due to receiving an extraordinary circumstances exception (ECE) for one or more quarters beginning with the FY 2027 payment determination; and (11) modifying data collecting and reporting requirements for the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey beginning with the FY 2027 payment determination.

As shown in the summary tables in section XII.B.6. of the preamble of this final rule, we estimate a total information collection burden decrease for 3,150 IPPS hospitals of 144,836 hours at a savings of $6,834,886 annually associated with the policies we are finalizing across a 4-year period from the CY 2024 reporting period/FY 2026 payment determination through the CY 2028 reporting period/FY 2030 payment determination, compared to our currently approved information collection burden estimates.

We note that in sections IX.C.5.a., b., and c. of the preamble of this final rule, we are adopting three new eCQMs. Similar to the FY 2019 IPPS/LTCH PPS final rule regarding removing possible sources of added burden due to changes in information collection burden related to the finalized policies with regard to submission of measure data, we believe that costs associated with adopting three new eCQMs are multifaceted and include not only the burden associated with reporting, but also the costs associated with implementing and maintaining all of the eCQMs available for use in the Hospital IQR Program in hospitals’ EHR systems (83 FR 41771). For the Excessive Radiation eCQM, hospitals will be required to create a secure account through the measure developer’s website and link their EHR and PACS data to the Alara Imaging Software for CMS Measure Compliance. We estimate this one-time activity will require no more than one hour to complete and therefore estimate a total of 3,150 hours (1 hour × 3,150 hospitals) at a cost of $4.50 per hour × 3,150 hours = $13,925 for all IPPS hospitals.

In section IX.B. of this final rule, we are modifying the COVID–19 Vaccination Coverage among HCP measure to utilize the term “up to date” in the HCP vaccination definition and update the numerator to specify the time frames within which an HCP is considered up to date with recommended COVID–19 vaccines. Although we anticipate this modification may require some facilities to update IT systems or workflow related to maintaining accurate vaccination records for HCP, we assume the cost savings are within the estimated timeframe.

As shown in the summary table in section XII.B.6. of the preamble of this final rule, we estimate a total information collection burden increase for 11 PCHs of 188 hours at a cost of $4,088 annually associated with our finalized policies and updated burden estimates beginning with the FY 2027 program year compared to our currently approved information collection burden estimates. We refer readers to section XII.B.7. of the preamble of this final rule (Collection of Information) for a detailed discussion of the calculations estimating the changes to the information collection burden for submitting data to the PCHQR Program.

In section IX.D. of the preamble of this final rule, we are adopting the Documentation of Goals of Care Discussions Among Cancer Patients measure beginning with the FY 2026 program year; (2) adopting the Facility Commitment to Health Equity measure beginning with the FY 2026 program year; (3) adopting the Screening for Social Drivers of Health Measure with voluntary reporting for the FY 2025 program year and mandatory reporting beginning with the FY 2027 program year; (4) adopting the Screen Positive Rate for Social Drivers of Health measure with voluntary reporting for the FY 2025 program year and mandatory reporting beginning with the FY 2027 program year; (5) updating the data collection and reporting for the HCAHPS Survey Measure (NQF #0166) beginning with the FY 2027 program year; (6) modifying the COVID–19 Vaccination Coverage among Healthcare Personnel (HCP) measure beginning with the FY 2025 program year; and (7) beginning public reporting of the Surgical Treatment Complications for Localized Prostate Cancer (PCH–37) measure. As shown in the summary table in section XI.D.6. of the final rule, we estimate a total information collection burden increase for 11 PCHs of 188 hours at a cost of $4,088 annually associated with our finalized policies and updated burden estimates beginning with the FY 2027 program year compared to our currently approved information collection burden estimates.

In section IX.D. of the preamble of this final rule, we are adopting the Documentation of Goals of Care Discussions Among Cancer Patients measure beginning with the FY 2026 program year. This measure will focus on the essential process of documenting goals of care conversations in the EHR. The intent of this measure is for PCHs to track and improve this documentation to ensure that such conversations have taken place, have been properly documented in the patient record, and are retrievable by all members of the healthcare team, and to facilitate the delivery of care that aligns with patients’ and family’s values and unique priorities. Ideally, these conversations will occur with patients with serious illness, however, definitions of and the means of identifying serious illness may vary widely. This measure is intended to focus on cancer patients who died in the reporting PCH in the measurement period, had a diagnosis of cancer, and had at least 2 eligible contacts at the reporting hospital in the 6 months prior to death. Since we are unable to determine either an exact number of patients who meet these criteria or the extent to which the conversations currently take place, as a maximum, we estimate an average of 275 patients for each of the 11 PCHs, for a total of 3,025 patients for all PCHs. We estimate the time required for this discussion to be approximately 30 minutes (0.5 hours).

To estimate the cost per patient, we use the same methodology as in the Collection of Information section (section XII.B.7.c. of the preamble of this final rule) and estimate a
In section IX.G. of the preamble of this final rule, we proposed to modify one measure, adopt two measures and remove two measures from the LTCH QRP. Specifically, we proposed to modify the HCP COVID–19 Vaccine measure and adopt the DC Function measure beginning with the FY 2025 LTCH QRP, as well as the Patient/Resident COVID–19 Vaccine measure beginning with the FY 2026 LTCH QRP. We also proposed to remove two measures, the Application of Functional Assessment/Care Plan and the Functional Assessment/Care Plan measures beginning with the FY 2025 LTCH QRP. We proposed to begin publicly displaying data for the quality measures TOH–Patient, TOH–Provider, DC Function, and Patient/Resident COVID–19 Vaccine measures. We proposed to increase the LTCH QRP data completion thresholds for the LCD5 items beginning with the FY 2026 LTCH QRP. Finally, we sought information on principles for selecting and prioritizing LTCH QRP quality measures and concepts for measure development and provided an update on CMS continued efforts to close the health equity gap.

We note that the CDC would account for the burden associated with the COVID–19 Vaccination Coverage among HCP measure collection under OMB control number 0920–1317 (expiration January 31, 2024). Additionally, because we did not propose any updates to the form, manner, and timing of data submission for this measure, there will be no increase in burden associated with the proposal.

The effect of the remaining proposals for the LTCH QRP will be an overall decrease in burden for LTCHs participating in the LTCH QRP. As shown in Table XII.B.8–1 in section XII.B.8 of the preamble of this final rule, we estimate a total information collection burden decrease for 330 eligible LTCHs of 1,301 hours for a total cost reduction of $127,048 annually associated with our finalized policies with regard to submission of measure data, including costs associated with adoption of eCQMs. These associated with reporting, but also the costs associated with implementing and maintaining all of the eCQMs available for use in the Medicare Promoting Interoperability Program in hospitals’ and CAHs’ EHR systems (83 FR 41171).

In section IX.F.3. of the preamble of this final rule, we are modifying the SAFER Guides quality measures to require eligible hospitals and CAHs to submit a “yes” attestation to the SAFER Guides measure beginning with the CY 2024 reporting period in CY 2024. In the FY 2022 IPPS/LTCH PPS final rule, we adopted the SAFER Guides measure and required eligible hospitals and CAHs to attest “yes” or “no” as to whether they completed an annual self-assessment on each of the nine SAFER Guides during the calendar year in which their EHR reporting period occurs (86 FR 45479 through 45481). As a result of this finalized policy, eligible hospitals and CAHs will be required to complete an annual self-assessment on each of the nine SAFER Guides. Because each eligible hospital or CAH is unique and may conduct these self-assessments with varying degrees of rigor, we are unable to accurately estimate the time each eligible hospital or CAH will spend performing each self-assessment or the staff they would utilize. Therefore, we believe the time required to conduct each self-assessment will range from approximately 30 minutes per guide to approximately 20 minutes per recommendation.20

20 Toward More Proactive Approaches to Safety in the Electronic Health Record Era. Available at
nine SAFER Guides and 165 recommendations within them, the estimated time to complete all nine self-assessments will range from a minimum of 4.5 hours to a maximum of 55 hours. Based on the suggested sources of input provided in the SAFER Guides, we assume that eligible hospitals and CAHs will form multidisciplinary teams composed of 1.0 FTE of a clinical administrator and 0.75 FTE each of a clinician, support staff, EHR developer, and health IT support staff to conduct the self-assessments. The following table provides the detail of our calculated cost to conduct SAFER Guide self-assessments.

<table>
<thead>
<tr>
<th>Eligible Hospital/CAH Staff Title</th>
<th>BLS Labor Category (Occupation Code)</th>
<th>Wage Rate()</th>
<th>FTE</th>
<th>Labor Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinicians</td>
<td>Physicians</td>
<td>$242.76</td>
<td>0.75</td>
<td>$182.07</td>
</tr>
<tr>
<td>Support Staff</td>
<td>Medical Record Specialists</td>
<td>$44.86</td>
<td>0.75</td>
<td>$33.65</td>
</tr>
<tr>
<td>Clinical Administration</td>
<td>Medical and Health Services Managers</td>
<td>$97.44</td>
<td>1.0</td>
<td>$97.44</td>
</tr>
<tr>
<td>EHR Developer</td>
<td>Web Developers</td>
<td>$116.10</td>
<td>0.75</td>
<td>$87.08</td>
</tr>
<tr>
<td>Health IT Support Staff</td>
<td>Health Information Technologists and</td>
<td>$53.42</td>
<td>0.75</td>
<td>$40.07</td>
</tr>
<tr>
<td></td>
<td>Medical Registrars</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Cost Per Hour of Self-Assessment Team</td>
<td></td>
<td></td>
<td></td>
<td>$440.31</td>
</tr>
<tr>
<td>Minimum Cost to Conduct Self-Assessment (4.5 hours x $440.31/hour)</td>
<td></td>
<td></td>
<td></td>
<td>$1,981</td>
</tr>
<tr>
<td>Maximum Cost to Conduct Self-Assessment (55 hours x $440.31/hour)</td>
<td></td>
<td></td>
<td></td>
<td>$22,417</td>
</tr>
</tbody>
</table>

\* We calculated the cost of overhead, including fringe benefits, at 100 percent of the median hourly wage, consistent with previous years. This is necessarily a rough adjustment, both because fringe benefits and overhead costs vary significantly by employer and methods of estimating these costs vary widely in the literature. Nonetheless, we believe that doubling the hourly wage rate to estimate total cost is a reasonably accurate estimation method.

Using the cost to complete all nine self-assessments from Table XX, we estimate all 4,500 eligible hospitals and CAHs would require between 20,250 hours (4.5 hours per hospital/CAHs × 4,500 hospitals/CAHs) and 247,500 hours (55 hours per hospital/CAHs × 4,500 hospitals/CAHs) at a cost between $8,916,278 (20,250 hours × $440.31/hour) and $108,976,725 (247,500 hours × $440.31/hour) to attest “yes” to the measure. We did not receive any public comments regarding our assumptions or estimate of economic impact associated with the modification to the SAFER Guides measure.

While the cost to conduct a SAFER Guides self-assessment can be high, we believe the cost is outweighed by the potential for improved healthcare outcomes, increased efficiency, reduced risk of data breaches and ransomware attacks, and decreased malpractice premiums.\[22\]

O. Alternatives Considered

This final rule contains a range of policies. It also provides descriptions of the statutory provisions that are addressed, identifies the finalized policies, and presents rationales for our decisions and, where relevant, alternatives that were considered.

1. Alternatives Considered to the Hospital Wage Index Calculations

As discussed in section III.G.1. of the preamble of this final rule, we are finalizing our proposal to include hospitals with § 412.103-reclassification along with geographically rural hospitals in all rural wage index calculations, and to only exclude “dual reclass” hospitals (hospitals with simultaneous § 412.103 and MGCRB reclassifications) in accordance with the hold harmless provision at section 1886(d)(8)(C)(ii) of the Act. Consistent with the previous proposal, beginning with FY 2024 we are including the data of all § 412.103 hospitals (including those that have an MGCRB reclassification when appropriate) in the calculation of the rural floor and the calculation of “the wage index for rural areas in the State in which the county is located” as referred to in section 1886(d)(8)(C)(iii) of the Act. As also discussed in section III.G.1. of the preamble of this final rule, we acknowledge that these policies will have significant effects on wage index values. In addition, as a result of this change, both the geographic reclassification budget neutrality adjustment and the rural floor budget neutrality adjustment are significantly larger than in prior years.

Considering past concerns with hospitals’ use of § 412.103 reclassification to increase the rural wage index and rural floor (as discussed in prior rulemaking (72 FR 47371 through 47375, 84 FR 42332, and 85 FR 58788) and in this rule), as well as the significant redistributive effects, we therefore considered maintaining our current methodology for calculating the rural wage index, which would not require any modification to the rural floor or the calculation of “the wage index for rural areas in the State in which the county is located” as referred to in section 1886(d)(8)(C)(ii) of the Act. However, after revisiting the case law, prior public comments, and the relevant statutory language, along with public comments on the proposed rule, we now agree that the best reading of section 1886(d)(8)(E) of the Act is that it instructs CMS to treat § 412.103 hospitals the same as geographically rural hospitals for the wage index calculation. We are influenced by the fact that courts have largely adopted this interpretation of section 1886(d)(8)(E) of the Act, and that it requires considerable resources to unwind a wage index policy after adverse judicial decisions—often requiring an IFC outside the usual IPPS rulemaking schedule, and further note that such unwinding may have budget neutrality implications. Therefore, after consideration of public comments, we determined that it was necessary to finalize our proposal to include hospitals with § 412.103 reclassification along with geographically rural hospitals in all rural wage index calculations, and to exclude “dual reclass” hospitals (hospitals with simultaneous § 412.103 and MGCRB reclassifications) implicated by the hold harmless provision at section 1886(d)(8)(C)(ii) of the Act, with the resulting changes to the rural floor and the calculation of “the wage index for rural areas in the State in which the county is located” as referred to in section 1886(d)(8)(C)(iii) of the Act.

2. Alternatives Considered to the HCP COVID–19 Vaccine Measure

With regard to the proposal to modify the HCP COVID–19 Vaccine Measure to add the Patient/Resident COVID–19 Vaccine Measure to the LTCH QRP Program, the COVID–19 pandemic has exposed the importance of implementing infection prevention strategies, including the promotion of COVID–19 vaccination for healthcare personnel and patients. We believe this measure will encourage healthcare personnel to get up to date with the COVID–19 vaccine and increase vaccine uptake in patients/residents resulting in fewer cases, less hospitalizations, and lower mortality associated with the SARS–CoV–2 virus, but we were unable to identify any alternative methods for collecting the data. An overwhelming public need exists to target quality improvement among LTCHs, as well


as provide data to patients and caregivers through transparency of data. Therefore, these measures have the potential to generate actionable data on COVID–19 vaccination rates.

3. Alternatives Considered to the LTCH QRP Reporting Requirements

With regard to the proposal to increase the data completion threshold for LCDS data submitting to meet the LTCH QRP reporting requirements, the proposed threshold of 90 percent was based on the need for substantially complete records, which allows appropriate analysis of quality measure data for the purposes of updating quality measure specifications. This data is ultimately reported to the public, allowing our beneficiaries to gain a more complete understanding of LTCH performance related to these quality metrics, and helping them to make informed healthcare choices. We considered the alternative of not increasing the data completion threshold, but our data suggest that LTCHs are already in compliance with, or exceeding this proposed threshold. However, after consideration of the public comments we received, we are finalizing our proposal to require LTCHs to report 100 percent of the required quality measures and standardized patient assessment data collected using the LCDS on at least 85 percent of all assessments submitted beginning with the FY 2026 payment determination and subsequent years.

4. Alternatives Considered for the Replacement of the Application of Functional Assessment/Care Plan Process Measure

The proposal to replace the topped-out Application of Functional Assessment/Care Plan process measure with the proposed DC Function measure, which has strong scientific acceptability, satisfies the requirement that there be at least one cross-setting function measure in the Post-Acute Care (PAC) QRPs, including the IRF QRP, that uses standardized functional assessment data elements from standardized patient assessment instruments. We considered the alternative of delaying the proposal of adopting the DC Function measure. However, given the proposed DC Function measure’s strong scientific acceptability, the fact that it provides an opportunity to replace the current Application of Functional Assessment/Care Plan process measure, and uses standardized functional assessment data elements that are already collected, we believe further delay of the DC Function measure is unwarranted. Further, the proposed removal of the Application of Functional Assessment/Care Plan and Functional Assessment measures meets measure removal factors one and six, and no longer provide meaningful distinctions in improvements in performance. Therefore, no alternatives were considered.

As discussed previously, these changes to the LTCH QRP will result in an overall decrease in burden for LTCHs, and we believe the importance of the information necessitates these provisions.

P. Overall Conclusion

1. Acute Care Hospitals

Acute care hospitals are estimated to experience an increase of approximately $2.2 billion in FY 2024, including operating, capital, and new technology changes. The estimated change in operating payments is approximately $2.1 billion (discussed in section I.F. and I.G. of this appendix). The estimated change in capital payments is approximately $0.474 billion (discussed in section I.F. of this appendix). The estimated change in technology add-on payments is approximately $0.364 billion as discussed in section I.G. of this appendix. Total may differ from the sum of the components due to rounding.

The discussions presented in the previous pages, in combination with the remainder of this final rule, constitute a regulatory impact analysis.

2. LTCHs

Overall, LTCHs are projected to experience an increase in estimated payments in FY 2024. In the impact analysis, we are using the rates, factors, and policies presented in this final rule based on the best available claims and CCR data, and the estimated change in payments for the LTCH PPS for FY 2024. Accordingly, based on the best available data for the 333 LTCHs included in our analysis, we estimate that overall FY 2024 LTCH PPS payments would increase approximately $8 million relative to FY 2023, primarily due to the annual update to the LTCH PPS standard Federal rate offset by an estimated decrease in high cost outlier payments.

Q. Regulatory Review Cost Estimation

If regulations impose administrative costs on private entities, such as the time needed to read and interpret a rule, we should estimate the cost associated with regulatory review. Due to the uncertainty involved with accurately quantifying the number of entities that would review the final rule, we assumed that the total number of timely pieces of correspondence on this year’s proposed rule would be the number of reviewers of the final rule. We acknowledge that this assumption may undervalue or overstate the costs of reviewing the rule. It is possible that not all commenters reviewed this year’s rule in detail, and it is also possible that some reviewers chose not to comment on the proposed rule. For these reasons, we believe that the number of past commenters would be a fair estimate of the number of reviewers of the final rule. We recognize that different types of entities are in many cases affected by mutually exclusive sections of the rule. Thus, for the purposes of our estimate we assume that each reviewer reads approximately 50 percent of the proposed rule. Finally, in our estimates, we have used the 3.274 number of timely pieces of correspondence on the FY 2024 IPPS/LTCH PPS proposed rule as our estimate for the number of reviewers of the final rule. We continue to acknowledge the uncertainty involved with using this number, but we believe it is a fair estimate due to the variety of entities affected and the likelihood that some of them choose to rely (in full or in part) on press releases, newsletters, fact sheets, or other sources rather than the comprehensive review of preamble and regulatory text. Using the wage information from the BLS for medical and health service managers (Code 11–9111), we estimate that the cost of reviewing the final rule is $115.22 per hour, including overhead and fringe benefits (https://www.bls.gov/oes/current/oes_nat.htm). Assuming an average reading speed, we estimate that it would take approximately 24.35 hours for the staff to review half of this final rule. For each IPPS hospital or LTCH that reviews this final rule, the estimated cost is $2,805.61 (24.35 hours × $115.22). Therefore, we estimate that the total cost of reviewing this final rule is $9,185,567 ($2,805.61 × 3,274 reviewers).

II. Accounting Statements and Tables

A. Acute Care Hospitals

As required by OMB Circular A–4 (available at https://www.whitehouse.gov/wp-content/uploads/legacy_drupal_files/omb/circulars/A4/a-4.pdf), in Table V. of this appendix, we have prepared an accounting statement showing the expenditures associated with the provisions of this final rule as they relate to acute care hospitals. This table provides our best estimate of the change in Medicare payments to providers as a result of the changes to the IPPS presented in this final rule. All expenditures are classified as transfers to Medicare providers.

As shown in Table V. of this appendix, the net costs to the Federal Government associated with the policies in this final rule are estimated at $2.2 billion.
TABLE V.—ACCOUNTING STATEMENT: CLASSIFICATION OF ESTIMATED EXPENDITURES UNDER THE IPPS FROM FY 2023 TO FY 2024

<table>
<thead>
<tr>
<th>Category</th>
<th>Transfers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annualized Monetized Transfers</td>
<td>$2.2 billion</td>
</tr>
<tr>
<td>From Whom to Whom</td>
<td>Federal Government to IPPS Medicare Providers</td>
</tr>
</tbody>
</table>

Therefore, as required by OMB Circular A–4 (available at https://www.whitehouse.gov/wp-content/uploads/legacy_drupal_files/omb/circulars/Aa/a-4.pdf), in Table VI. of this appendix, we have prepared an accounting statement showing the classification of the expenditures associated with the provisions of this final rule as they relate to the changes to the LTCH PPS. Table VI. of this appendix provides our best estimate of the estimated change in Medicare payments under the LTCH PPS as a result of the payment rates and factors and other provisions presented in this final rule based on the data for the 333 LTCHs in our database. All expenditures are classified as transfers to Medicare providers (that is, LTCHs).

As shown in Table VI. of this appendix, the net cost to the Federal Government associated with the policies for LTCHs in this final rule are estimated at $6 million.

TABLE VI.—ACCOUNTING STATEMENT: CLASSIFICATION OF ESTIMATED EXPENDITURES FROM THE FY 2023 LTCH PPS TO THE FY 2024 LTCH PPS

<table>
<thead>
<tr>
<th>Category</th>
<th>Transfers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annualized Monetized Transfers</td>
<td>$6 million</td>
</tr>
<tr>
<td>From Whom to Whom</td>
<td>Federal Government to LTCH Medicare Providers</td>
</tr>
</tbody>
</table>

III. Regulatory Flexibility Act (RFA) Analysis

The RFA requires agencies to analyze options for regulatory relief of small entities. For purposes of the RFA, small entities include small businesses, nonprofit organizations, and small government jurisdictions. We estimate that most hospitals and most other providers and suppliers are small entities as that term is used in the RFA. The great majority of hospitals and most other health care providers and suppliers are small entities, either by being nonprofit organizations or by meeting the SBA definition of a small entity. MACs are not considered to be small entities because they do not meet the SBA definition of a small business.

HHS’s practice in interpreting the RFA is to consider effects economically “significant” if greater than 5 percent of providers reach a threshold of 3 to 5 percent or more of total revenue or total costs. We believe that the provisions of this final rule relating to IPPS hospitals would have an economically significant impact on small entities as explained in this appendix. Therefore, the Secretary has certified that this final rule would have a significant economic impact on a substantial number of small entities. For example, the majority of the 5,131 IPPS hospitals included in the impact analysis shown in “Table I.—Impact Analysis of Changes to the IPPS for Operating Costs for FY 2024,” on average are seen to see increases in the range of 3.1 percent, primarily due to the hospital rate update, as discussed in section I.G. of this appendix. On average, the rate update for these hospitals is estimated to be 3.1 percent.

The 333 LTCH PPS hospitals included in the impact analysis shown in “Table IV: Impact of Payment Rate and Policy Changes to LTCH PPS Payments for LTCH PPS Standard Federal Payment Rate Cases for FY 2024 (Estimated FY 2023 Payments Compared to Estimated FY 2024 Payments)” on average are expected to see a decrease of approximately 0.2 percent, primarily due to the 2.9 percent decrease in high cost outlier payments as a percentage of total LTCH PPS standard Federal payment rate payments, as discussed in section I.J. of this appendix.

This final rule contains a range of final policies. It provides descriptions of the statutory provisions that are addressed, identifies the finalized policies, and presents rationales for our decisions and, where relevant, alternatives that were considered. The analyses discussed in this appendix and throughout the preamble of this final rule constitutes our regulatory flexibility analysis. We solicited public comments on our estimates and analysis of the impact of our proposals on small entities.

IV. Impact on Small Rural Hospitals

Section 1102(b) of the Act requires us to prepare a regulatory impact analysis for any proposed or final rule that may have a significant impact on the operations of a substantial number of small rural hospitals. This analysis must conform to the provisions of section 604 of the RFA. With the exception of hospitals located in certain New England counties, for purposes of section 1102(b) of the Act, we define a small rural hospital as a hospital that is located outside of an urban area and has fewer than 100 beds. Section 601(g) of the Social Security Amendments of 1983 (Pub. L. 98–91) designated hospitals in certain New England counties as belonging to the adjacent urban area. Thus, for purposes of the IPPS and the LTCH PPS, we continue to classify these hospitals as urban hospitals.

As shown in Table I. in section I.G. of this appendix, rural IPPS hospitals with 0–49 beds (363 hospitals) and 50–99 beds (188 hospitals) are expected to experience an increase in payments from FY 2023 to FY 2024 of 3.1 percent and 4.0 percent, respectively, primarily driven by the hospital rate update and the change to the calculation of the rural wage index, as discussed in section I.G of this appendix. We refer readers to Table I. in section I.G. of this appendix for additional information on the quantitative effects of the policy changes under the IPPS for operating costs.

All rural LTCHs (18 hospitals) shown in Table IV. in section I.J. of this appendix have less than 100 beds. These hospitals are expected to experience an increase in payments from FY 2023 to FY 2024 of 3.3 percent. This increase is primarily due to the 3.3 percent annual update to the LTCH PPS standard Federal payment rate for FY 2024.

B. LTCHs

As discussed in section I.J. of this appendix, the impact analysis of the payment rates and factors presented in this final rule under the LTCH PPS is projected to result in an increase in estimated aggregate LTCH PPS payments in FY 2024 relative to FY 2023 of approximately $6 million based on the data for 333 LTCHs in our database that are subject to payment under the LTCH PPS.
and the projected 2.9 percent decrease in high cost outlier payments as a percentage of total LTCH PPS standard Federal payment rate payments, as discussed in section I.J. of this appendix.

V. Unfunded Mandates Reform Act Analysis

Section 202 of the Unfunded Mandates Reform Act of 1995 (Pub. L. 104–4) also requires that agencies assess anticipated costs and benefits before issuing any rule whose mandates require spending in any 1 year of $100 million in 1995 dollars, updated annually for inflation. In 2023, that threshold level is approximately $177 million. This final rule would not mandate any requirements that meet the threshold for State, local, or tribal governments, nor would it affect private sector costs.

VI. Executive Order 13132

Executive Order 13132 establishes certain requirements that an agency must meet when it promulgates a proposed rule (and subsequent final rule) that imposes substantial direct requirement costs on state and local governments, preempts state law, or otherwise has federalism implications. This final rule would not have a substantial direct effect on state or local governments, preempt states, or otherwise have a federalism implication.

VII. Executive Order 13175

Executive Order 13175 directs agencies to consult with Tribal officials prior to the formal promulgation of regulations having tribal implications. Section 1880(a) of the Act states that a hospital of the Indian Health Service, whether operated by such Service or by an Indian tribe or tribal organization, is eligible for Medicare payments so long as it meets all of the conditions and requirements for such payments which are applicable generally to hospitals. Consistent with section 1880(a) of the Act, this final rule contains general provisions also applicable to hospitals and facilities operated by the Indian Health Service or Tribes or Tribal organizations under the Indian Self-Determination and Education Assistance Act. We continue to engage in consultations with Tribal officials on IPPS issues of interest. We will use input received from these consultations, as well as the comments on the proposed rule, to inform this rulemaking.

VIII. Executive Order 12866

In accordance with the provisions of Executive Order 12866, the Office of Management and Budget reviewed this final rule.

Appendix B—Recommendation of Update Factors for Operating Cost Rates of Payment for Inpatient Hospital Services

I. Background

Section 1886(e)(4)(A) of the Act requires that the Secretary, taking into consideration the recommendations of MedPAC, recommend update factors for inpatient hospital services for each fiscal year that take into account the amounts necessary for the efficient and effective delivery of medically appropriate and necessary care of high quality. Under section 1886(e)(5) of the Act, we are required to publish update factors recommended by the Secretary in the proposed and final IPPS rules. Accordingly, this appendix provides the recommendations for the update factors for the IPPS national standardized amount, the hospital-specific rate for SCHs and MDHs, and the rate-of-increase limits for certain hospitals excluded from the IPPS, as well as LTCHs. In prior years, we made a recommendation in the IPPS proposed rule and final rule for the update factors for the payment rates for IRFs and IPPS. However, for FY 2024, consistent with our approach for FY 2023, we are including the Secretary’s recommendation for the update factors for IRFs and IPPS in separate Federal Register documents at the time that we announce the annual updates for IRFs and IPPS. We also discuss our response to MedPAC’s recommended update factors for inpatient hospital services.

II. Inpatient Hospital Update for FY 2024

A. FY 2024 Inpatient Hospital Update

As discussed in section IV.A. of the preamble to this final rule, for FY 2024, consistent with section 1886(b)(3)(B) of the Act, as amended by sections 3401(a) and 10319(a) of the Affordable Care Act, we are setting the applicable percentage increase by applying the following adjustments in the following sequence. Specifically, the applicable percentage increase under the IPPS is equal to the rate-of-increase in the hospital market basket for IPPS hospitals in all areas, subject to a reduction of one-quarter of the applicable percentage increase (prior to the application of other statutory adjustments; also referred to as the market basket update or rate-of-increase (with no adjustments)) for hospitals that fail to submit quality data under the rules established in section IV.B. of the preamble of the FY 2024 IPPS/LTCH PPS proposed rule, based on our approach for FY 2023, we proposed a productivity adjustment of 0.2 percentage point for FY 2024. We also proposed that if more recent data subsequently became available, we would use such data, if appropriate, to determine the FY 2024 market basket update and productivity adjustment for the FY 2024 IPPS/LTCH PPS final rule. In the FY 2024 IPPS/LTCH PPS proposed rule, based on IGI’s fourth quarter 2022 forecast of the 2018-based IPPS market basket rate-of-increase with historical data through third quarter 2022, which was estimated to be 3.0 percent. In accordance with section 1886(b)(3)(B) of the Act, as amended by section 3401(a) of the Affordable Care Act, in section IV.B. of the preamble of the FY 2024 IPPS/LTCH PPS proposed rule, based on IGI’s fourth quarter 2022 forecast, we proposed a productivity adjustment of 0.2 percentage point for FY 2024. We also proposed that if more recent data subsequently became available, we would use such data, if appropriate, to determine the FY 2024 market basket update and productivity adjustment for the FY 2024 IPPS/LTCH PPS final rule. In the FY 2024 IPPS/LTCH PPS proposed rule, based on IGI’s fourth quarter 2022 forecast of the 2018-based IPPS market basket update and the productivity adjustment, depending on whether a hospital submits quality data under the rules established in accordance with section 1886(b)(3)(B)(viii) of the Act (hereafter referred to as a hospital that submits quality data) and is a meaningful EHR user under section 1886(b)(3)(B)(ix) of the Act (hereafter referred to as a hospital that is a meaningful EHR user), we presented 4 possible applicable percentage increases that could be applied to the standardized amount.

In accordance with section 1886(b)(3)(B) of the Act, as amended by section 3401(a) of the Affordable Care Act, we are establishing the applicable percentages increase for the FY 2024 updates based on IGI’s second quarter 2023 forecast of the 2018-based IPPS market basket of 3.3 percent and the productivity adjustment of 0.2 percentage point, as discussed in section V.A of the preamble of this final rule, depending on whether a hospital submits quality data under the rules established in accordance with section 1886(b)(3)(B)(ix) of the Act, and then subject to an adjustment based on changes in economy-wide productivity (the productivity adjustment), Section 1886(b)(3)(B)(xi) of the Act, as added by section 3401(a) of the Affordable Care Act, states that application of the productivity adjustment may result in the applicable percentage increase being less than zero.
### B. FY 2024 SCH and MDH Update

Section 1866(b)(3)(B)(iv) of the Act provides that the FY 2024 applicable percentage increase in the hospital-specific rate for SCHs and MDHs equals the applicable percentage increase set forth in section 1886(b)(3)(B)(i) of the Act (that is, the same update factor as for all other hospitals subject to the IPPS).

Division FF, section 4102 of the Consolidated Appropriations Act, 2023 (Public Law 117–326), enacted on December 29, 2022, extended the MDH program through FY 2024 (that is, for discharges occurring on or before September 30, 2024).

We refer readers to section V.F. of the preamble of this final rule for further discussion of the MDH program.

As previously stated, the update to the hospital specific rate for SCHs and MDHs is subject to section 1886(b)(3)(B)(i) of the Act, as amended by sections 3401(a) and 10319(a) of the Affordable Care Act. Accordingly, depending on whether a hospital submits quality data and is a meaningful EHR user, we are establishing the same four possible applicable percentage increases in the previous table for the hospital-specific rate applicable to SCHs and MDHs.

### C. FY 2024 Puerto Rico Hospital Update

Because Puerto Rico hospitals are no longer paid with a Puerto Rico-specific standardized amount under the amendments to section 1886(d)(9)(E) of the Act, there is no longer a need for us to make an update to the Puerto Rico standardized amount. Hospitals in Puerto Rico are now paid 100 percent of the national standardized amount, and therefore, are subject to the same update to the national standardized amount discussed under section IV.A.1. of the preamble of this final rule.

In addition, as discussed in section IV.A.2. of the preamble of this final rule, section 602 of Public Law 114–133 amended section 1886(n)(6)(B) of the Act to specify that subsection (d) Puerto Rico hospitals are eligible for incentive payments for the meaningful use of certified EHR technology, effective beginning FY 2016. In addition, section 1886(n)(6)(B) of the Act was amended to specify that the adjustments to the applicable percentage increase under section 1886(b)(3)(B)(ix) of the Act apply to subsection (d) Puerto Rico hospitals that are not meaningful EHR users, effective beginning FY 2022.

Accordingly, section 1886(b)(3)(B)(ix) of the Act in conjunction with section 602(d) of Public Law 114–113 requires that for FY 2024 and subsequent fiscal years, any subsection (d) Puerto Rico hospital that is not a meaningful EHR user as defined in section 1886(n)(3) of the Act and not subject to an exception under section 1886(b)(3)(B)(ix) of the Act will have a reduction of three-quarters of the applicable percentage increase (prior to the application of other statutory adjustments).

Based on IGI’s fourth quarter 2022 forecast of the 2018-based IPPS market basket update with historical data through third quarter 2022, in the FY 2024 IPPS/LTCPPS proposed rule, in accordance with section 1886(b)(3)(B) of the Act, as previously discussed, for Puerto Rico hospitals, we proposed a market basket update of 3.0 percent and a productivity adjustment of 0.2 percentage point. Therefore, for FY 2024, depending on whether a Puerto Rico hospital is a meaningful EHR user, we stated that there are two possible applicable percentage increases that can be applied to the standardized amount. Based on these data, we determined the following applicable percentage increases to the standardized amount for FY 2024 for Puerto Rico hospitals:

- For a Puerto Rico hospital that is a meaningful EHR user, we proposed an applicable percentage increase to the FY 2024 operating standardized amount of 3.0 percent less an adjustment of 0.2 percentage point for the productivity adjustment.
- For a Puerto Rico hospital that is not a meaningful EHR user, we proposed an applicable percentage increase to the FY 2024 operating standardized amount of 3.0 percent less an adjustment of 0.2 percentage point for the productivity adjustment.

### D. Update for Hospitals Excluded From the IPPS for FY 2024

Section 1886(b)(3)(B)(ii) of the Act is used for purposes of determining the percentage increase in the rate-of-increase limits for children's hospitals, cancer hospitals, and hospitals located outside the 50 States, the District of Columbia, and Puerto Rico (that is, short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and America Samoa).
Section 1886(b)(3)(B)(ii) of the Act sets the percentage increase in the rate-of-increase limits equal to the market basket percentage increase. In accordance with §403.752(a) of the regulations, religious nonmedical health care institutions (RNHCIs) are paid under the provisions which also use section 1886(b)(3)(B)(ii) of the Act to update the percentage increase in the rate-of-increase limits.

Currently, children’s hospitals, PPS-excluded cancer hospitals, RNHCIs, and short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa are among the remaining types of hospitals still paid under the reasonable cost methodology, subject to the rate-of-increase limits. In addition, in accordance with §412.526(c)(3) of the regulations, extended neoplastic disease care hospitals (described in §412.221(i) of the regulations) also are subject to the rate-of-increase limits. As discussed in section VI. of the preamble of this final rule, we are finalizing our proposal to use the percentage increase in the 2018-based IPPS operating market basket to update the target amounts for children’s hospitals, PPS-excluded cancer hospitals, RNHCIs, short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa, and extended neoplastic disease care hospitals for FY 2024 and subsequent fiscal years. Accordingly, for FY 2024, the rate-of-increase percentage to be applied to the target amount for these children’s hospitals, cancer hospitals, RNHCIs, extended neoplastic disease care hospitals, and short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa is the FY 2024 percentage increase in the 2018-based IPPS operating market basket. For this final rule, the current estimate of the IPPS operating market basket percentage increase for FY 2024 is 3.3 percent.

E. Update for LTCHs for FY 2024

Section 123 of Public Law 106–113, as amended by section 1004(b) of Public Law 106–554 (and codified at section 1886(m)(1) of the Act), provides the statutory authority for updating payment rates under the LTCH PPS.

As discussed in section V.A. of the Addendum to this final rule, we are updating the LTCH PPS standard Federal payment rate for FY 2024 by 3.3 percent, consistent with section 1886(m)(3) of the Act which provides that any annual update be reduced by the productivity adjustment described in section 1886(b)(3)(B)(ii) of the Act (that is, the productivity adjustment). Furthermore, in accordance with the LTCH QR Program under section 1886(m)(5) of the Act, we are reducing the annual update to the LTCH PPS standard Federal rate by 2.0 percentage points for failure of a LTCH to submit the required quality data. Accordingly, we are establishing an update factor of 1.033 in determining the LTCH PPS standard Federal rate for FY 2024. For LTCHs that fail to submit quality data for FY 2024, we are establishing an annual update to the LTCH PPS standard Federal rate of 3.3 percent (that is, the annual update for FY 2024 for 3.3 percent less 2.0 percentage points for failure to submit the required quality data in accordance with section 1886(m)(5)(C) of the Act and our rules) by applying an update factor of 1.013 in determining the LTCH PPS standard Federal rate for FY 2024. (We note that, as discussed in section VII.D. of the preamble of this final rule, the update to the LTCH PPS standard Federal payment rate of 3.3 percent for FY 2024 does not reflect any budget neutrality factors.)

III. Secretary’s Recommendations

MedPAC is recommending inpatient hospital rates be updated by the amount specified in current law plus one percent. MedPAC’s rationale for this update recommendation is described in more detail in this section. As previously stated, section 1886(e)(4)(A) of the Act requires that the Secretary, taking into consideration the recommendations of MedPAC, recommend update factors for inpatient hospital services for each fiscal year that take into account the amounts necessary for the efficient and effective delivery of medically appropriate and necessary care of high quality. Consistent with current law, depending on whether a hospital submits quality data and is a meaningful EHR user, we are recommending the four applicable percentage increases to the standardized amount listed in the table under section II. of this appendix. We are recommending that the same applicable percentage increases apply to SCHs and MDHs.

In addition to making a recommendation for IPPS hospitals, in accordance with section 1886(e)(4)(A) of the Act, we are recommending update factors for certain other types of hospitals excluded from the IPPS. Consistent with our policies for these facilities, we are recommending an update to the target amounts for children’s hospitals, cancer hospitals, RNHCIs, short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa and extended neoplastic disease care hospitals of 3.3 percent.

For FY 2024, consistent with policy set forth in section VII. of the preamble of this final rule, for LTCHs that submit quality data, we are recommending an update of 3.3 percent to the LTCH PPS standard Federal rate. For LTCHs that fail to submit quality data for FY 2024, we are recommending an annual update to the LTCH PPS standard Federal rate of 1.3 percent.

IV. MedPAC Recommendation for Assessing Payment Adequacy and Updating Payments in Traditional Medicare

In its March 2023 Report to Congress, MedPAC assessed the adequacy of current payments and costs, and the relationship between payments and an appropriate cost base. MedPAC recommends that the Congress update the hospital payment rates by the amount specified in current law plus 1 percent. MedPAC anticipates that their recommendation to update the IPPS payment rate by the amount specified under current law plus 1 percent in 2024 would generally be adequate to maintain beneficiaries’ access to hospital inpatient and outpatient care and keep IPPS payment rates close to, if somewhat below, the cost of delivering high-quality care efficiently.

MedPAC stated that their recommended update to IPPS and OPPS payment rates of current law plus 1 percent may not be sufficient to ensure the financial viability of some Medicare safety-net hospitals with a poor payer mix. MedPAC recommends redistributing the current Medicare safety-net payments (disproportionate share hospital and uncompensated care payments) using the MedPAC-developed Medicare Safety-Net Index (MSNI) for hospitals. In addition, MedPAC recommends adding $2 billion to this MSNI pool of funds to help maintain the financial viability of Medicare safety-net hospitals and recommended to Congress transitional approaches for a MSNI policy.

We refer readers to the March 2023 MedPAC report, which is available for download at www.medpac.gov, for a complete discussion on these recommendations.

In light of these recommendations, and in particular those concerning safety net hospitals, we look forward to working with Congress and we sought comments on approaches CMS could take. We are establishing an applicable percentage increase for FY 2024 of 3.3 percent as described in section 1886(b)(3)(B) of the Act, provided the hospital submits quality data and is a meaningful EHR user consistent with these statutory requirements. We note that, because the operating and capital payments in the IPPS remain separate, we are continuing to use separate updates for operating and capital payments in the IPPS. The update to the capital rate is discussed in section III of the Addendum to this final rule.

With regard to MedPAC’s recommendation for a MSNI policy, we note that a discussion is in section X.C. of the preamble of this final rule. We note that section 1886(d)(5)(F) of the Act provides for additional Medicare payments, called Medicare disproportionate share hospital (DSH) payments, to subsection (d) hospitals that serve a significantly disproportionate number of low-income patients. Section 1886(r) of the Act provides that, for FY 2014 and each subsequent fiscal year, the Secretary shall pay each such subsection (d) hospital that is eligible for DSH an empirically justified DSH payment equal to 25 percent of the Medicare DSH adjustment they otherwise would have received. The remaining amount, equal to an estimate of 75 percent of what otherwise would have been paid as Medicare DSH payments, reduced to reflect changes in the percentage of individuals who are uninsured, is available to make additional payments to each hospital that qualifies for Medicare DSH payments and has uncompensated care. We refer readers to section IV. of this final rule for a further discussion of Medicare DSH and uncompensated care payments.

[FR Doc. 2023–16252 Filed 8–1–23; 4:15 pm]
BILLING CODE 4120–01–P